﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Awi, NJ
   Armon, S
   Peh, KB
   Peh, SC
   Teow, SY
AF Awi, Noel Jacques
   Armon, Subasri
   Peh, Kaik-Boo
   Peh, Suat-Cheng
   Teow, Sin-Yeang
TI High expression of LC3A, LC3B, and p62/SQSTM1 autophagic proteins in
   human colonic ganglion cells
SO MALAYSIAN JOURNAL OF PATHOLOGY
LA English
DT Article
DE autophagy; colorectal cancer; colon; ganglion cells; LC3A; LC3B;
   p62/SQSTM1; immunohistochemistry
AB Introduction: Autophagy is a mechanism that degrades large damaged organelles and misfolded proteins to maintain the homeostasis in all cells. It plays double-faceted roles in tumourigenesis and prevention of various cancers. In our side observation of investigating the prognostic value of autophagy in colorectal cancer (CRC), we found high expression of autophagy proteins (LC3A, LC3B, and p62/SQSTM1) in the colonic ganglion cells. To our best understanding, this is the first paper reporting such finding. Materials and Methods: Formalin- ixed paraffin-embedded (FFPE) CRC tissues blocks were retrieved and confirmed by haematoxylin & eosin (H&E) staining. Immunohistochemistry (IHC) targeting autophagy proteins (LC3A, LC3B, and p62/SQSTM1) was then performed followed by pathological examination. Results: All three autophagy proteins were present in both normal and tumour tissues of CRC patients. Interestingly, high expression of autophagy proteins in colonic ganglion cells was consistently seen regardless of tissue type (normal or cancer) or tumour site (caecum, ascending, transverse, descending, sigmoid colon and rectum). Conclusions: This work highlights the high autophagic activities in human colonic ganglion cells.
C1 [Awi, Noel Jacques; Peh, Suat-Cheng; Teow, Sin-Yeang] Sunway Univ, Sch Healthcare & Med Sci, Dept Med Sci, Jalan Univ, Subang Jaya 47500, Selangor Darul, Malaysia.
   [Armon, Subasri] Hosp Kuala Lumpur, Pathol Dept, Jalan Pahang, Kuala Lumpur 50586, Malaysia.
   [Peh, Kaik-Boo] Mahkota Med Ctr, Jalan Merdeka, Melaka 75000, Malaysia.
   [Peh, Suat-Cheng] Sunway Med Ctr, Jalan Lagoon Selatan, Subang Jaya 47500, Selangor Darul, Malaysia.
RP Teow, SY (corresponding author), Sunway Univ, Subang Jaya 47500, Selangor Darul, Malaysia.
EM ronaldt@sunway.edu.my
RI Teow, Sin-Yeang/J-2253-2019
OI Teow, Sin-Yeang/0000-0002-3824-0224
FU Sunway University [INT-2019-SHMS-DMS-01]; National Cancer Council
   Malaysia (MAKNA) Cancer Research Award (CRA) 2016
   [EXT-SIDS-SIHD-MAKNA-2017-01]; Sunway Medical Centre Research Funds
   [SRC/002/2017/FR, SRC/003/2017/FR]; Sunway University
FX This work was funded by Sunway University Internal Research Grant 2019
   (INT-2019-SHMS-DMS-01), National Cancer Council Malaysia (MAKNA) Cancer
   Research Award (CRA) 2016 (EXT-SIDS-SIHD-MAKNA-2017-01), and Sunway
   Medical Centre Research Funds (SRC/002/2017/FR and SRC/003/2017/FR).
   Noel Jacques Awi is the recipient of Sunway University Postgraduate
   Degree by Research Scholarship.
CR Boya P, 2017, EYE, V31, P185, DOI 10.1038/eye.2016.278
   Gil J, 2016, BIOMARK MED, V10, P1081, DOI 10.2217/bmm-2016-0083
   Kim SH, 2008, J NEUROSCI RES, V86, P2943, DOI 10.1002/jnr.21738
   Knoferle J, 2010, P NATL ACAD SCI USA, V107, P6064, DOI 10.1073/pnas.0909794107
   Lee K, 2016, CURR EYE RES, V41, P1367, DOI 10.3109/02713683.2015.1119856
   Li HY, 2019, CELL TRANSPLANT
   Lin WJ, 2014, AUTOPHAGY, V10, P1692, DOI 10.4161/auto.36076
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Pang SW, 2018, CELL CULTURE, P75
   Rodriguez-Muela N, 2012, AUTOPHAGY, V8, P286, DOI 10.4161/auto.8.2.18982
   Rubinsztein DC, 2011, CELL, V146, P682, DOI 10.1016/j.cell.2011.07.030
   Santana-Codina N, 2017, ANNU REV CANC BIOL, V1, P19, DOI 10.1146/annurev-cancerbio-041816-122338
   Sivridis E, 2010, AM J PATHOL, V176, P2477, DOI 10.2353/ajpath.2010.090049
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
NR 14
TC 0
Z9 0
U1 0
U2 1
PU MALAYSIAN JOURNAL PATHOLOGY
PI KUALA LUMPUR
PA UNIV MALAYSIA, FAC MEDICINE, DEPT PATHOLOGY, KUALA LUMPUR, 59100,
   MALAYSIA
SN 0126-8635
J9 MALAYS J PATHOL
JI Malay. J. Pathol.
PD APR
PY 2020
VL 42
IS 1
BP 85
EP 90
PG 6
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA LI9ZW
UT WOS:000529835400011
PM 32342935
DA 2022-04-25
ER

PT J
AU Wu, WKK
   Sung, JJY
   Wu, YC
   Li, HT
   Yu, L
   Li, ZJ
   Cho, CH
AF Wu, William Ka Kei
   Sung, Joseph Jao Yiu
   Wu, Ya Chun
   Li, Hai To
   Yu, Le
   Li, Zhi Jie
   Cho, Chi Hin
TI Inhibition of cyclooxygenase-1 lowers proliferation and induces
   macroautophagy in colon cancer cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Cyclooxygenase-1; Colon cancer; Proliferation; Cell cycle;
   Macroautophagy
ID FAMILIAL ADENOMATOUS POLYPOSIS; SELECTIVE INHIBITOR; CARCINOMA CELLS;
   RECTAL ADENOMAS; AUTOPHAGY; DEATH; SUPPRESSION; APOPTOSIS; CELECOXIB;
   MOFEZOLAC
AB Evolving evidence supports that cyclooxygenase-1 (COX-1) takes part in colon carcinogenesis. The effects of COX-1 inhibition on colon cancer cells, however, remains obscured. In this Study, we demonstrate that COX-1 inhibitor sc-560 inhibited colon cancer cell proliferation with concomitant G(0)/G(1)-phase cell cycle arrest. The anti-proliferative effect was associated with down-regulation of c-Fos, cyclin E-2 and E2F-1 and up-regulation of p21(Waf1/Cip1) and p27(Kip1). In addition, sc-560 induced macroautophagy, an emerging mechanism of tumor suppression, as evidenced by the formation of LC3(+) autophagic vacuoles, enhanced LC3 processing, and the accumulation of acidic vesicular organelles and autolysosomes. In this connection, 3-methyladenine, a Class III phosphoinositide 3-kinase inhibitor, significantly abolished the formation of LC3(+) autophagic vacuoles and the processing of LC3 induced by sc-560. To conclude, this study reveals the unreported relationship between COX-1 and proliferation/macroautophagy of colon cancer cells. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Wu, William Ka Kei; Sung, Joseph Jao Yiu; Yu, Le; Cho, Chi Hin] Chinese Univ Hong Kong, Inst Digest Dis, Fac Med, Hong Kong, Hong Kong, Peoples R China.
   [Wu, William Ka Kei; Sung, Joseph Jao Yiu] Chinese Univ Hong Kong, Dept Med & Therapeut, Fac Med, Hong Kong, Hong Kong, Peoples R China.
   [Wu, William Ka Kei; Wu, Ya Chun; Li, Hai To; Yu, Le; Li, Zhi Jie; Cho, Chi Hin] Chinese Univ Hong Kong, Dept Pharmacol, Shatin, Hong Kong, Peoples R China.
RP Sung, JJY (corresponding author), Prince Wales Hosp, Dept Med & Therapeut, 9-F Clin Sci Bldg, Shatin, Hong Kong, Peoples R China.
EM wukakei@cuhk.edu.hk; joesung@cuhk.edu.hk; chcho@cuhk.edu.hk
RI Sung, Joseph J. Y./R-3203-2018; Wu, William K.K./A-3277-2009; Cho, Chi
   Hin/C-6543-2014
OI Sung, Joseph J. Y./0000-0003-3125-5199; Wu, William
   K.K./0000-0002-5662-5240; Cho, Chi Hin/0000-0002-7658-3260
CR Akasu T, 2002, HEPATO-GASTROENTEROL, V49, P1259
   Arico S, 2002, J BIOL CHEM, V277, P27613, DOI 10.1074/jbc.M201119200
   Backer JM, 2008, BIOCHEM J, V410, P1, DOI 10.1042/BJ20071427
   Bialik S, 2008, ADV EXP MED BIOL, V615, P177, DOI 10.1007/978-1-4020-6554-5_9
   Chen Q, 2008, BLOOD, V111, P4690, DOI 10.1182/blood-2007-09-112904
   Chulada PC, 2000, CANCER RES, V60, P4705
   Dolara P, 1999, SCAND J GASTROENTERO, V34, P1168
   GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805
   Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kitamura T, 2002, CARCINOGENESIS, V23, P1463, DOI 10.1093/carcin/23.9.1463
   Martin S, 2005, CANCER RES, V65, P11447, DOI 10.1158/0008-5472.CAN-05-1494
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Munafo DB, 2001, J CELL SCI, V114, P3619
   Niho N, 2006, CANCER SCI, V97, P1011, DOI 10.1111/j.1349-7006.2006.00275.x
   Paglin S, 2001, CANCER RES, V61, P439
   Riehl TE, 2006, AM J PHYSIOL-GASTR L, V291, pG1062, DOI 10.1152/ajpgi.00129.2006
   Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272
   Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603
   Wang M, 2008, J BIOL CHEM, V283, P18678, DOI 10.1074/jbc.M801855200
   Wu WKK, 2008, BIOCHEM BIOPH RES CO, V374, P258, DOI 10.1016/j.bbrc.2008.07.031
   Yazbeck VY, 2008, EXP HEMATOL, V36, P443, DOI 10.1016/j.exphem.2007.12.008
   Zhang ZH, 2000, GASTROENTEROLOGY, V118, P1012, DOI 10.1016/S0016-5085(00)70352-0
NR 24
TC 9
Z9 9
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD APR 24
PY 2009
VL 382
IS 1
BP 79
EP 84
DI 10.1016/j.bbrc.2009.02.140
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 432HO
UT WOS:000265124300016
PM 19258012
DA 2022-04-25
ER

PT J
AU DiPrima, M
   Wang, DR
   Troster, A
   Maric, D
   Terrades-Garcia, N
   Ha, T
   Kwak, H
   Sanchez-Martin, D
   Kudlinzki, D
   Schwalbe, H
   Tosato, G
AF DiPrima, Michael
   Wang, Dunrui
   Troester, Alix
   Maric, Dragan
   Terrades-Garcia, Nekane
   Ha, Taekyu
   Kwak, Hyeongil
   Sanchez-Martin, David
   Kudlinzki, Denis
   Schwalbe, Harald
   Tosato, Giovanna
TI Identification of Eph receptor signaling as a regulator of autophagy and
   a therapeutic target in colorectal carcinoma
SO MOLECULAR ONCOLOGY
LA English
DT Article
DE cell death; colorectal cancer; Eph receptors; Ephrin ligand; tyrosine
   kinase signaling
ID STEM-CELLS; SMALL-INTESTINE; CANCER; EXPRESSION; COLON; PROLIFERATION;
   GENE; PROGRESSION; METASTASIS; PROMOTES
AB Advanced colorectal carcinoma is currently incurable, and new therapies are urgently needed. We report that phosphotyrosine-dependent Eph receptor signaling sustains colorectal carcinoma cell survival, thereby uncovering a survival pathway active in colorectal carcinoma cells. We find that genetic and biochemical inhibition of Eph tyrosine kinase activity or depletion of the Eph ligand EphrinB2 reproducibly induces colorectal carcinoma cell death by autophagy. Spautin and 3-methyladenine, inhibitors of early steps in the autophagic pathway, significantly reduce autophagy-mediated cell death that follows inhibition of phosphotyrosine-dependent Eph signaling in colorectal cancer cells. A small-molecule inhibitor of the Eph kinase, NVP-BHG712 or its regioisomer NVP-Iso, reduces human colorectal cancer cell growth in vitro and tumor growth in mice. Colorectal cancers express the EphrinB ligand and its Eph receptors at significantly higher levels than numerous other cancer types, supporting Eph signaling inhibition as a potential new strategy for the broad treatment of colorectal carcinoma.
C1 [DiPrima, Michael; Wang, Dunrui; Ha, Taekyu; Kwak, Hyeongil; Sanchez-Martin, David; Tosato, Giovanna] NCI, Lab Cellular Oncol, Ctr Canc Res, 37 Convent Dr,NIH Bethesda Campus,Bldg 37, Bethesda, MD 20892 USA.
   [Troester, Alix; Kudlinzki, Denis; Schwalbe, Harald] Goethe Univ Frankfurt, Ctr Biomol Magnet Resonance, Inst Organ Chem & Chem Biol, Frankfurt, Germany.
   [Maric, Dragan] NINDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
   [Terrades-Garcia, Nekane] Univ Barcelona, Hosp Clin, Dept Autoimmune Dis, Vasculitis Res Unit, Barcelona, Spain.
RP Tosato, G (corresponding author), NCI, Lab Cellular Oncol, Ctr Canc Res, 37 Convent Dr,NIH Bethesda Campus,Bldg 37, Bethesda, MD 20892 USA.
EM Tosatog@mail.nih.gov
RI Schwalbe, Harald/AAB-3143-2020; Schwalbe, Harald J/F-9023-2010; Sanchez
   Martin, David/C-9927-2013
OI Schwalbe, Harald/0000-0001-5693-7909; Schwalbe, Harald
   J/0000-0001-5693-7909; Tosato, Giovanna/0000-0003-1663-3227; DiPrima,
   Michael/0000-0001-9189-6049; Sanchez Martin, David/0000-0002-2712-4762
FU intramural research program of the CCR/NCI/NIH
FX We thank Dr Seth Steinberg, Biostatistics and Data Management Section,
   CCR, NCI for his assistance in the statistical analyses; Drs Alexey
   Nesvizhskii, Felipe Leprevost, and Hui-Yin Chang, Department of
   Computational Medicine & Bioinformatics, University of Michigan for
   MSfragger proteomics data analysis; Dr Douglas Lowy for intellectual
   input and review of the manuscript; Drs Lisa Jenkins, Hidetaka Ohnuki,
   Ombretta Salvucci, and Maria C. Cid for their help in various aspects of
   this work; the CCR animal facility personnel; Langston Lim for confocal
   imaging; Addgene for sharing pk-LC3 vector; and Dr Ira Daar for
   constructive suggestions. This work was supported by the intramural
   research program of the CCR/NCI/NIH.
CR Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196
   Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626
   Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2
   Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409
   Berg KCG, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0691-y
   Bochenek ML, 2010, J CELL SCI, V123, P1235, DOI 10.1242/jcs.061903
   Boyd AW, 2014, NAT REV DRUG DISCOV, V13, P39, DOI 10.1038/nrd4175
   CHEN Y, 2017, SEMIN CANCER BIOL, V56, P37
   Cortina C, 2007, NAT GENET, V39, P1376, DOI 10.1038/ng.2007.11
   Daar IO, 2012, SEMIN CELL DEV BIOL, V23, P65, DOI 10.1016/j.semcdb.2011.10.012
   Melo FDE, 2017, NATURE, V543, P676, DOI 10.1038/nature21713
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Fulda S, 2015, ONCOGENE, V34, P5105, DOI 10.1038/onc.2014.458
   Genander M, 2009, CELL, V139, P679, DOI 10.1016/j.cell.2009.08.048
   Harada K, 2011, EXP CELL RES, V317, P1701, DOI 10.1016/j.yexcr.2011.05.014
   Herath NI, 2012, EUR J CANCER, V48, P753, DOI 10.1016/j.ejca.2011.07.003
   Holmberg J, 2006, CELL, V125, P1151, DOI 10.1016/j.cell.2006.04.030
   Jagle S, 2014, P NATL ACAD SCI USA, V111, P4886, DOI 10.1073/pnas.1314523111
   Junttila MR, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac7433
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kadife E, 2018, ACTA ONCOL, V57, P1043, DOI 10.1080/0284186X.2018.1429650
   Kamentsky L, 2011, BIOINFORMATICS, V27, P1179, DOI 10.1093/bioinformatics/btr095
   Kania A, 2016, NAT REV MOL CELL BIO, V17, P240, DOI 10.1038/nrm.2015.16
   Karsli-Uzunbas G, 2014, CANCER DISCOV, V4, P914, DOI 10.1158/2159-8290.CD-14-0363
   Kong AT, 2017, NAT METHODS, V14, P513, DOI [10.1038/nmeth.4256, 10.1038/NMETH.4256]
   Kundu P, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010567
   Kwak H, 2016, J CLIN INVEST, V126, P4554, DOI 10.1172/JCI87848
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Linnekamp JF, 2018, CELL DEATH DIFFER, V25, P616, DOI 10.1038/s41418-017-0011-5
   Lv JH, 2016, EXP MOL PATHOL, V100, P402, DOI 10.1016/j.yexmp.2016.03.011
   Maddigan A, 2011, J IMMUNOL, V187, P5983, DOI 10.4049/jimmunol.1003482
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Martiny-Baron G, 2010, ANGIOGENESIS, V13, P259, DOI 10.1007/s10456-010-9183-z
   Mathot L, 2017, CANCER RES, V77, P1730, DOI 10.1158/0008-5472.CAN-16-1921
   Matos I, 2016, EXPERT OPIN EMERG DR, V21, P267, DOI 10.1080/14728214.2016.1220535
   McCall JL, 2016, MOL CELL BIOL, V36, P2246, DOI 10.1128/MCB.00087-16
   Noberini R, 2012, PHARMACOL RES, V66, P363, DOI 10.1016/j.phrs.2012.05.010
   Noberini R, 2012, CELL ADHES MIGR, V6, P102, DOI 10.4161/cam.19620
   Qin HN, 2010, J BIOL CHEM, V285, P644, DOI 10.1074/jbc.M109.064824
   Romano G, 2018, ONCOGENE, V37, P2481, DOI 10.1038/s41388-018-0155-x
   Salvucci O, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7576
   Schepers AG, 2012, SCIENCE, V337, P730, DOI 10.1126/science.1224676
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/nmeth.2019, 10.1038/NMETH.2019]
   Shimokawa M, 2017, NATURE, V545, P187, DOI 10.1038/nature22081
   Shoshkes-Carmel M, 2018, NATURE, V557, P242, DOI 10.1038/s41586-018-0084-4
   Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005
   Tian H, 2011, NATURE, V478, P255, DOI 10.1038/nature10408
   Troster A, 2018, CHEMMEDCHEM, V13, P1629, DOI 10.1002/cmdc.201800398
   van Es JH, 2012, NAT CELL BIOL, V14, P1099, DOI 10.1038/ncb2581
   Wei YJ, 2013, CELL, V154, P1269, DOI 10.1016/j.cell.2013.08.015
   Welch HG, 2016, NEW ENGL J MED, V374, P1605, DOI 10.1056/NEJMp1600448
   Yang NY, 2006, J BIOL CHEM, V281, P32574, DOI 10.1074/jbc.M604338200
NR 52
TC 4
Z9 5
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1574-7891
EI 1878-0261
J9 MOL ONCOL
JI Mol. Oncol.
PD NOV
PY 2019
VL 13
IS 11
BP 2441
EP 2459
DI 10.1002/1878-0261.12576
EA OCT 2019
PG 19
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA JU0OO
UT WOS:000491574000001
PM 31545551
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Ellington, AA
   Berhow, M
   Singletary, KW
AF Ellington, AA
   Berhow, M
   Singletary, KW
TI Induction of macroautophagy in human colon cancer cells by soybean
   B-group triterpenoid saponins
SO CARCINOGENESIS
LA English
DT Article
ID CARCINOMA CELLS; COLORECTAL-CANCER; TUMOR-SUPPRESSOR; DEATH; AUTOPHAGY;
   RISK; SOY; CONSUMPTION; DIVERSITY
AB The impact of triterpenoid saponins isolated from soybeans on suppression of colon cancer cell proliferation was evaluated. Experiments were conducted to determine the effects of a purified soybean B-group saponin extract on cell proliferation, cell-cycle distribution and programmed cell death in cultures of human HCT-15 colon adenocarcinoma cells. Treatment of cells with the soyasaponins at concentrations of 25-500 p.p.m. significantly reduced viable cell numbers after 24 and 48 h of exposure. Treatment of cells with 25 and 100 p.p.m. of saponins also resulted in a transient accumulation of cells in the S-phase of the cell cycle that was associated with a significant reduction of cyclin-dependant kinase-2 (CDK-2) activity. More striking was that, when examined by transmission electron microscopy, soyasaponin-treated cells exhibited an similar to4.5-fold increase in cell morphologies characteristic of Type II non-apoptotic programmed cell death (PCD) including numerous autophagic vacuoles, changes that collectively suggest autophagic cell death. In addition, the protein levels of microtubule-associated protein light chain 3 (LC-3), a specific marker of macroautophagy, increased substantially following soyasaponin treatment. Taken together these results thus indicate that soybean saponins, at physiologically relevant doses, can suppress HCT-15 colon cancer cell proliferation through S-phase cell-cycle delay, and can induce macroautophagy, the hallmark of Type II PCD. These findings suggest that B-group soyasaponins may be another colon-cancer suppressive component of soy that warrants further examination as a potential chemopreventive phytochemical.
C1 Dept Food Sci & Human Nutr, 905 S Goodwin Ave,467 Bevier Hall, Urbana, IL 61801 USA.
   Natl Ctr Agr Res Serv, Peoria, IL USA.
RP Singletary, KW (corresponding author), Dept Food Sci & Human Nutr, 905 S Goodwin Ave,467 Bevier Hall, Urbana, IL 61801 USA.
EM kws@uiuc.edu
OI Berhow, Mark/0000-0002-1278-4071
CR Bashir T, 2000, P NATL ACAD SCI USA, V97, P5522, DOI 10.1073/pnas.090485297
   Bennink MR, 2001, ADV EXP MED BIOL, V492, P11
   BERGMAN AS, 1994, BIOCHEM J, V298, P661, DOI 10.1042/bj2980661
   Berhow MA, 2002, PHYTOCHEM ANALYSIS, V13, P343, DOI 10.1002/pca.664
   BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3
   Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852
   Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595
   Butler R, 2000, CELL GROWTH DIFFER, V11, P49
   Byers T, 2002, CA-CANCER J CLIN, V52, P92, DOI 10.3322/canjclin.52.2.92
   Chiu BCH, 2003, CANCER EPIDEM BIOMAR, V12, P201
   CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615
   Coulonval K, 2003, J BIOL CHEM, V278, P52052, DOI 10.1074/jbc.M307012200
   DANLOY S, 1994, PLANTA MED, V60, P45, DOI 10.1055/s-2006-959406
   DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192
   Edinger AL, 2003, CANCER CELL, V4, P422, DOI 10.1016/S1535-6108(03)00306-4
   Franceschi S, 1997, INT J CANCER, V72, P56, DOI 10.1002/(SICI)1097-0215(19970703)72:1&lt;56::AID-IJC8&gt;3.0.CO;2-3
   Fung T, 2003, ARCH INTERN MED, V163, P309, DOI 10.1001/archinte.163.3.309
   GESTETNER B, 1968, J AGR FOOD CHEM, V16, P1031, DOI 10.1021/jf60160a025
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Greenwald P, 2001, EUR J CANCER, V37, P948, DOI 10.1016/S0959-8049(01)00070-3
   Gurfinkel DM, 2003, NUTR CANCER, V47, P24, DOI 10.1207/s15327914nc4701_3
   Hakkak R, 2001, CANCER LETT, V166, P27, DOI 10.1016/S0304-3835(01)00441-4
   Hu J, 2004, J AGR FOOD CHEM, V52, P2689, DOI 10.1021/jf035290s
   Hu J, 2004, J NUTR, V134, P1867, DOI 10.1093/jn/134.8.1867
   Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Komata T, 2003, BRIT J CANCER, V88, P1277, DOI 10.1038/sj.bjc.6600862
   Koratkar R, 1997, NUTR CANCER, V27, P206, DOI 10.1080/01635589709514526
   Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897
   MILGATE J, 1995, NUTR RES, V15, P1223, DOI 10.1016/0271-5317(95)00081-S
   Munafo DB, 2001, J CELL SCI, V114, P3619
   Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0
   Oh YJ, 2001, NUTR CANCER, V39, P132, DOI 10.1207/S15327914nc391_18
   Opipari AW, 2004, CANCER RES, V64, P696, DOI 10.1158/0008-5472.CAN-03-2404
   Petiot A, 2002, CELL STRUCT FUNCT, V27, P431, DOI 10.1247/csf.27.431
   Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143
   Rao A V, 2000, Drug Metabol Drug Interact, V17, P211
   Rowlands JC, 2002, FOOD CHEM TOXICOL, V40, P1767, DOI 10.1016/S0278-6915(02)00181-3
   SchulteHermann R, 1997, TOXICOL PATHOL, V25, P89, DOI 10.1177/019262339702500117
   SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509
   Singh PN, 1998, AM J EPIDEMIOL, V148, P761, DOI 10.1093/oxfordjournals.aje.a009697
   Spector D, 2003, NUTR CANCER, V47, P1, DOI 10.1207/s15327914nc4701_1
   SUNG MK, 1995, FOOD CHEM TOXICOL, V33, P357, DOI 10.1016/0278-6915(95)00007-O
   SUNG MK, 1995, NUTR CANCER, V23, P259, DOI 10.1080/01635589509514380
   Thiagarajan DG, 1998, AM J CLIN NUTR, V68, p1394S, DOI 10.1093/ajcn/68.6.1394S
   Yanamandra N, 2003, CLIN EXP METASTAS, V20, P375, DOI 10.1023/A:1024043104803
   Yew PR, 2001, J CELL PHYSIOL, V187, P1, DOI 10.1002/1097-4652(2001)9999:9999<1::AID-JCP1049>3.0.CO;2-O
   Yoshiki Y, 1998, BIOSCI BIOTECH BIOCH, V62, P2291, DOI 10.1271/bbb.62.2291
   Zheng L, 2001, EXP CELL RES, V264, P2, DOI 10.1006/excr.2000.5129
NR 50
TC 138
Z9 152
U1 2
U2 14
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD JAN
PY 2005
VL 26
IS 1
BP 159
EP 167
DI 10.1093/carcin/bgh297
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 885WB
UT WOS:000226186800019
PM 15471899
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Knaevelsrud, H
   Ahlquist, T
   Merok, MA
   Nesbakken, A
   Stenmark, H
   Lothe, RA
   Simonsen, A
AF Knaevelsrud, Helene
   Ahlquist, Terje
   Merok, Marianne A.
   Nesbakken, Arild
   Stenmark, Harald
   Lothe, Ragnhild A.
   Simonsen, Anne
TI UVRAG mutations associated with microsatellite unstable colon cancer do
   not affect autophagy
SO AUTOPHAGY
LA English
DT Article
DE UVRAG; Vps34/PI3K complex; microsatellite instability; colorectal
   neoplasm; survival; autophagy; tumor suppressor; tumorigenesis;
   frameshift mutation
ID PHOSPHATIDYLINOSITOL 3-KINASE COMPLEXES; MISMATCH REPAIR;
   COLORECTAL-CANCER; TUMOR-SUPPRESSOR; BECLIN 1; INSTABILITY; GENES;
   CELLS; TUMORIGENESIS; IDENTIFICATION
AB Reduced levels of autophagy correlate with tumorigenesis, and several inducers of autophagy have been found to be tumor suppressors. One such autophagic inducer is the Beclin 1 binding protein UVRAG, a positive regulator of the class III PI3K/Vps34 complex. UVRAG has been implicated in the formation and maturation of autophagosomes, as well as in endocytic trafficking and suppression of proliferation and in vivo tumorigenicity. In this study we show that approximately one-third of a large series of colon carcinomas with microsatellite instability (MSI) (n = 102) carry a monoallelic UVRAG mutation, leading to expression of a truncated protein, indicating that this event is involved in tumorigenesis. In order to investigate whether the high incidence of UVRAG mutation in MSI colorectal carcinomas is associated with dysfunctional autophagy we analyzed autophagy levels in several colon cancer cell lines that express wild-type or mutant UVRAG protein. No reduction in autophagy was detected in cell lines expressing mutant UVRAG. Consistent with this, depletion of UVRAG in HEK cells stably expressing GFP-LC3 did not inhibit autophagy, but did decrease epidermal growth factor receptor (EGFR) degradation. Overall our results show that there is no correlation between the presence of the monoallelic UVRAG mutation and inhibition of autophagy. Thus, our data indicate that mechanisms other than autophagy contribute to the tumorigenicity of microsatellite unstable colon carcinomas with monoallelic UVRAG mutation.
C1 [Knaevelsrud, Helene; Simonsen, Anne] Univ Oslo, Inst Basic Med Sci, Oslo, Norway.
   [Knaevelsrud, Helene; Ahlquist, Terje; Merok, Marianne A.; Nesbakken, Arild; Stenmark, Harald; Lothe, Ragnhild A.] Univ Oslo, Ctr Canc Biomed, Oslo, Norway.
   [Merok, Marianne A.; Nesbakken, Arild; Stenmark, Harald; Lothe, Ragnhild A.] Univ Oslo, Fac Med, Oslo, Norway.
   [Knaevelsrud, Helene; Stenmark, Harald] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Biochem, Oslo, Norway.
   [Ahlquist, Terje; Merok, Marianne A.; Lothe, Ragnhild A.] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Canc Prevent, Oslo, Norway.
   [Merok, Marianne A.; Nesbakken, Arild] Oslo Univ Hosp Aker, Dept Surg, Oslo, Norway.
RP Simonsen, A (corresponding author), Univ Oslo, Inst Basic Med Sci, Oslo, Norway.
EM anne.simonsen@medisin.uio.no
RI Knævelsrud, Helene/G-9302-2016; Stenmark, Harald/B-8868-2008;
   Knævelsrud, Helene/E-5279-2010
OI Knævelsrud, Helene/0000-0001-8848-8829; Lothe,
   Ragnhild/0000-0002-1693-1032; Simonsen, Anne/0000-0003-4711-7057
FU EMBIO, University of Oslo; Norwegian Cancer SocietyNorwegian Cancer
   Society; Research Council of NorwayResearch Council of Norway
FX We thank Sharon Tooze for the gift of the HEK CFP-LC3 cells. H.K. is
   supported by grants from EMBIO, University of Oslo. A.S. is supported by
   grants from the Norwegian Cancer Society and the Research Council of
   Norway.
CR Abdel-Rahman WM, 1999, ONCOGENE, V18, P2139, DOI 10.1038/sj.onc.1202589
   Boland CR, 1998, CANCER RES, V58, P5248
   Brech A, 2009, MOL ONCOL, V3, P366, DOI 10.1016/j.molonc.2009.05.007
   Chan EYW, 2007, J BIOL CHEM, V282, P25464, DOI 10.1074/jbc.M703663200
   Duval A, 2002, ANN GENET-PARIS, V45, P71, DOI 10.1016/S0003-3995(02)01115-2
   Duval A, 2002, ONCOGENE, V21, P8062, DOI 10.1038/sj.onc.1206013
   Duval A, 2001, HUM MOL GENET, V10, P513, DOI 10.1093/hmg/10.5.513
   Farre JC, 2010, AUTOPHAGY, V6, P86, DOI 10.4161/auto.6.1.10535
   Filimonenko M, 2007, J CELL BIOL, V179, P485, DOI 10.1083/jcb.200702115
   GUNN JM, 1977, NATURE, V266, P58, DOI 10.1038/266058a0
   Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178
   Itakura E, 2008, MOL BIOL CELL, V19, P5360, DOI 10.1091/mbc.E08-01-0080
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519
   Kim MS, 2008, HUM PATHOL, V39, P1059, DOI 10.1016/j.humpath.2007.11.013
   Kim NG, 2002, ONCOGENE, V21, P5081, DOI 10.1038/sj.onc.1205703
   KISEN GO, 1993, CARCINOGENESIS, V14, P2501, DOI 10.1093/carcin/14.12.2501
   Liang CY, 2008, NAT CELL BIOL, V10, P776, DOI 10.1038/ncb1740
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lindmo K, 2006, J CELL SCI, V119, P605, DOI 10.1242/jcs.02855
   LOTHE RA, 1993, CANCER RES, V53, P5849
   Maiuri MC, 2009, CELL DEATH DIFFER, V16, P87, DOI 10.1038/cdd.2008.131
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Matsunaga K, 2009, NAT CELL BIOL, V11, P385, DOI 10.1038/ncb1846
   Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204
   Raiborg C, 2008, EXP CELL RES, V314, P801, DOI 10.1016/j.yexcr.2007.10.014
   Royrvik Ellen C., 2007, Critical Reviews in Oncogenesis, V13, P229
   Sagona AP, 2010, NAT CELL BIOL, V12, P362, DOI 10.1038/ncb2036
   Sun QM, 2008, P NATL ACAD SCI USA, V105, P19211, DOI 10.1073/pnas.0810452105
   Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634
   TEITZ T, 1990, GENE, V87, P295, DOI 10.1016/0378-1119(90)90316-J
   Yamamoto H, 1998, CANCER RES, V58, P997
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zhong Y, 2009, NAT CELL BIOL, V11, P468, DOI 10.1038/ncb1854
NR 37
TC 49
Z9 50
U1 0
U2 5
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD OCT 1
PY 2010
VL 6
IS 7
BP 863
EP 870
DI 10.4161/auto.6.7.13033
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 661ED
UT WOS:000282705400004
PM 20724836
OA Bronze
DA 2022-04-25
ER

PT J
AU Sun, YZ
   Mironova, V
   Chen, Y
   Lundh, EPF
   Zhang, Q
   Cai, YP
   Vasiliou, V
   Zhang, YW
   Garcia-Milian, R
   Khan, SA
   Johnson, CH
AF Sun, Yazhi
   Mironova, Varvara
   Chen, Ying
   Lundh, Elliott P. F.
   Zhang, Qian
   Cai, Yuping
   Vasiliou, Vasilis
   Zhang, Yawei
   Garcia-Milian, Rolando
   Khan, Sajid A.
   Johnson, Caroline H.
TI Molecular Pathway Analysis Indicates a Distinct Metabolic Phenotype in
   Women With Right-Sided Colon Cancer
SO TRANSLATIONAL ONCOLOGY
LA English
DT Article
ID COLORECTAL-CANCER; DENDRITIC CELLS; TUMOR REJECTION; EXPRESSION;
   EPIDEMIOLOGY; VACCINATION; AUTOPHAGY; SATB2; LEADS
AB Colon cancer is the third most commonly diagnosed cancer in the United States. Recent reports have shown that the location of the primary tumor is of clinical importance. Patients with right-sided colon cancers (RCCs) (tumors arising between the cecum and proximal transverse colon) have poorer clinical outcomes than those with left-sided colon cancers (LCCs) (tumors arising between the distal transverse colon and sigmoid colon, excluding the rectum). Interestingly, women have a lower incidence of colon cancer than men, but have a higher propensity for RCC. The reason for this difference is not known; however, identification of sex-specific differences in gene expression by tumor anatomical location in the colon could provide further insight. Moreover, it could reveal important predictive markers for response to various treatments. This study provides a comprehensive bioinformatic analysis of various genes and molecular pathways that correlated with sex and anatomical location of colon cancers using four publicly available annotated data sets housed in the National Center for Biotechnology Information's Gene Expression Omnibus. We identified differentially expressed genes in tumor tissues from women with RCC, which showed attenuated energy and nutrient metabolism when compared with women with LCC. Specifically, we showed the downregulation of 5' AMP-activated protein kinase alpha subunit (AMPK alpha) and anti-tumor immune responses in women with RCC. This difference was not seen when comparing tumor tissues from men with RCC to men with LCC. Therefore, women with RCC may have a specific metabolic and immune phenotype which accounts for differences in prognosis and treatment response.
C1 [Sun, Yazhi; Mironova, Varvara; Chen, Ying; Lundh, Elliott P. F.; Zhang, Qian; Cai, Yuping; Vasiliou, Vasilis; Zhang, Yawei; Garcia-Milian, Rolando; Johnson, Caroline H.] Yale Univ, Yale Sch Publ Hlth, Dept Environm Hlth Sci, New Haven, CT 06520 USA.
   [Mironova, Varvara; Khan, Sajid A.] Yale Univ, Sch Med, Dept Surg, Sect Surg Oncol, New Haven, CT 06510 USA.
   [Zhang, Qian] Harbin Med Univ, Affiliated Hosp 2, Dept Colorectal Surg, Harbin, Heilongjiang, Peoples R China.
   [Zhang, Yawei] Yale Univ, Sch Med, Dept Surg, New Haven, CT 06510 USA.
   [Garcia-Milian, Rolando] Yale Sch Med, Cushing Whitney Med Lib, Bioinformat Support Program, New Haven, CT USA.
RP Johnson, CH (corresponding author), Yale Univ, Yale Sch Publ Hlth, Dept Environm Hlth Sci, New Haven, CT 06520 USA.
EM caroline.johnson@yale.edu
OI Garcia-Milian, Rolando/0000-0003-1557-566X; Johnson,
   Caroline/0000-0002-5298-1299
FU Women's Health Research at Yale; Yale Cancer Center; National Institutes
   of Health (NIH)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [1R21CA223686-01,
   5R24AA022057-08, 5R01AA021724-05, 5K01AA025093-04]; National Center for
   Advancing Translational Science (NCATS), components of the NIH [UL1
   TR001863]
FX The authors would like to thank Women's Health Research at Yale, and the
   Yale Cancer Center for funding this project (C.J., S.K., Y.Z.). They
   would also like to acknowledge funding from the National Institutes of
   Health (NIH); 1R21CA223686-01 (CJ, SJ), 5R24AA022057-08 (VV),
   5R01AA021724-05 (VV) and 5K01AA025093-04 (YC). This publication was also
   made possible by CTSA Grant Number UL1 TR001863 from the National Center
   for Advancing Translational Science (NCATS), components of the NIH, and
   NIH roadmap for Medical Research (SK). Its contents are solely the
   responsibility of the authors and do not necessarily represent the
   official view of the NIH.
CR Aran V, 2016, CLIN COLORECTAL CANC, V15, P195, DOI 10.1016/j.clcc.2016.02.008
   Bauer KM, 2012, MOL CARCINOGEN, V51, P411, DOI 10.1002/mc.20804
   Benedix F, 2010, DIS COLON RECTUM, V53, P57, DOI 10.1007/DCR.0b013e3181c703a4
   Chabanais J, 2018, CANCERS, V10, DOI 10.3390/cancers10110411
   Dai CP, 2017, ONCOTARGET, V8, P95810, DOI 10.18632/oncotarget.21336
   Gervaz P, 2004, J SURG ONCOL, V88, P261, DOI 10.1002/jso.20156
   Gervaz P, 2016, EJSO-EUR J SURG ONC, V42, P1343, DOI 10.1016/j.ejso.2016.04.002
   Gonzalez EC, 2001, DIS COLON RECTUM, V44, P251, DOI 10.1007/BF02234301
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Haggar Fatima A, 2009, Clin Colon Rectal Surg, V22, P191, DOI 10.1055/s-0029-1242458
   Hu WG, 2018, MOL CANCER RES, V16, P476, DOI 10.1158/1541-7786.MCR-17-0483
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Jagadish N, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2592-7
   Ji ML, 2016, ONCOTARGET, V7, P29216, DOI 10.18632/oncotarget.8703
   Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004
   Larsson SC, 2005, INT J CANCER, V113, P829, DOI 10.1002/ijc.20658
   Lee MS, 2017, J NATL COMPR CANC NE, V15, P411, DOI 10.6004/jnccn.2017.0038
   Loffler AS, 2011, AUTOPHAGY, V7, P696, DOI 10.4161/auto.7.7.15451
   Mansour MA, 2015, FEBS J, V282, P1394, DOI 10.1111/febs.13227
   Matsuyama T, 2010, INT J CANCER, V127, P2292, DOI 10.1002/ijc.25256
   Miyazaki M, 2005, CANCER SCI, V96, P695, DOI 10.1111/j.1349-7006.2005.00093.x
   Mohini L, AMPK PROMOTES NOTCH1
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Moore RL, 2012, J ENDOCRINOL, V213, P37, DOI 10.1530/JOE-11-0217
   Okuyama H, 2010, CANCER RES, V70, P10213, DOI 10.1158/0008-5472.CAN-10-2720
   Peng QL, 2018, ONCOTARGETS THER, V11, P609, DOI 10.2147/OTT.S154207
   Rabanal-Ruiz Y, 2017, ESSAYS BIOCHEM, V61, P565, DOI 10.1042/EBC20170027
   Ramachandran S, 2005, ONCOGENE, V24, P188, DOI 10.1038/sj.onc.1207906
   Rattray NJW, 2018, HUM GENOMICS, V12, DOI 10.1186/s40246-018-0134-x
   Rattray Nicholas J W, 2017, Curr Pharmacol Rep, V3, P114, DOI 10.1007/s40495-017-0088-z
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Song M, 2014, ANN SURG ONCOL, V21, pS481, DOI 10.1245/s10434-013-3435-2
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Suman S, 2014, CURR COLORECT CANC R, V10, P411, DOI 10.1007/s11888-014-0252-3
   Tsukahara T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081139
   Waly MI, 2018, BIOACTIVE COMPONENTS, P111
   Wang X, 2016, BMC CANC, V16
   Yokomine K, 2006, BIOCHEM BIOPH RES CO, V343, P269, DOI 10.1016/j.bbrc.2006.02.142
   Yokomine K, 2007, CANCER SCI, V98, P1930, DOI 10.1111/j.1349-7006.2007.00612.x
   Zhang YJ, 2018, EBIOMEDICINE, V28, P62, DOI 10.1016/j.ebiom.2018.01.001
   Zhou YF, 2012, CANCER RES, V72, P304, DOI 10.1158/0008-5472.CAN-11-1674
NR 41
TC 10
Z9 10
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1936-5233
J9 TRANSL ONCOL
JI Transl. Oncol.
PD JAN
PY 2020
VL 13
IS 1
BP 42
EP 56
DI 10.1016/j.tranon.2019.09.004
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA JW1MD
UT WOS:000502822300006
PM 31760268
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Wu, Q
   Deng, JJ
   Fan, DD
   Duan, ZG
   Zhu, CH
   Fu, RZ
   Wang, SS
AF Wu, Qian
   Deng, Jianjun
   Fan, Daidi
   Duan, Zhiguang
   Zhu, Chenhui
   Fu, Rongzhan
   Wang, Shanshan
TI Ginsenoside Rh4 induces apoptosis and autophagic cell death through
   activation of the ROS/JNK/p53 pathway in colorectal cancer cells
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Apoptosis; Autophagic cell death; Colorectal cancer; Ginsenoside Rh4;
   ROS/JNK/p53 pathway
ID CARCINOMA CELLS; DOWN-REGULATION; CYCLE; INDUCTION; SUPPRESSION;
   INHIBITION; EXPRESSION; CROSSTALK; ANTITUMOR; ROLES
AB The use of ginsenosides in cancer therapy has been intensively investigated. The ginsenoside Rh4 (Rh4), a rare saponin obtained from Panax notoginseng, dissolves in water more readily than total saponins, making this compound easier to use in anti-cancer pharmaceutics. Here, we investigated the antiproliferative activity and mechanisms of Rh4 in colorectal cancer, both in vivo and in vitro. A colorectal cancer xenograft model showed that Rh4 significantly inhibited tumor growth with few side effects. CCK-8 assays, flow cytometric analysis, Western blotting and immunohistochemistry revealed that Rh4 effectively suppressed colorectal cancer cell proliferation via inducing G(0)/G(1) phase arrest, caspase-dependent apoptosis and autophagic cell death but was not significantly cytotoxic to normal colon epithelial cells. Furthermore, apoptosis played a dominant role in Rh4-induced cell death, as the pan-caspase inhibitor Z-VAD-FMK blocked cell death to a greater extent than the autophagy inhibitor 3-methyladenine. Moreover, Rh4 increased reactive oxygen species (ROS) accumulation and subsequently activated the JNK-p53 pathway. An ROS scavenger and JNK and p53 inhibitors significantly attenuated Rh4-induced apoptosis and autophagy. Thus, the present study is the first to illustrate that Rh4 triggers apoptosis and autophagy via activating the ROS/JNK/p53 pathway in colorectal cancer cells, providing basic scientific evidence that Rh4 shows great potential as an anti-cancer agent. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Wu, Qian; Deng, Jianjun; Fan, Daidi; Duan, Zhiguang; Zhu, Chenhui; Fu, Rongzhan; Wang, Shanshan] Northwest Univ Xian, Sch Chem Engn, Shaanxi Key Lab Degradable Biomed Mat, 229 North Taibai Rd, Xian 710069, Shaanxi, Peoples R China.
   [Wu, Qian; Deng, Jianjun; Fan, Daidi; Duan, Zhiguang; Zhu, Chenhui; Fu, Rongzhan; Wang, Shanshan] Northwest Univ Xian, Sch Chem Engn, Shaanxi R&D Ctr Biomat & Fermentat Engn, 229 North Taibai Rd, Xian 710069, Shaanxi, Peoples R China.
RP Fan, DD (corresponding author), Northwest Univ Xian, Sch Chem Engn, Shaanxi Key Lab Degradable Biomed Mat, 229 North Taibai Rd, Xian 710069, Shaanxi, Peoples R China.
EM fandaidi@nwu.edu.cn
RI Jianjun, Deng/U-5306-2019
OI Jianjun, Deng/0000-0002-3057-6997
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [21476182, 21776227, 21776228, 21506171];
   Shaanxi Key Laboratory of Degradable Biomedical Materials Program
   [2014SZS07-K04, 2014SZS07-P05, 14JS104]; Shaanxi R&D Center of
   Biomaterials and Fermentation Engineering Program [2015HBGC-04]
FX The present study was financially supported by Grants from the National
   Natural Science Foundation of China (21476182, 21776227, 21776228, and
   21506171), the Shaanxi Key Laboratory of Degradable Biomedical Materials
   Program (2014SZS07-K04, 2014SZS07-P05, and 14JS104), and the Shaanxi R&D
   Center of Biomaterials and Fermentation Engineering Program
   (2015HBGC-04).
CR Attele AS, 1999, BIOCHEM PHARMACOL, V58, P1685, DOI 10.1016/S0006-2952(99)00212-9
   Baek NI, 1996, PLANTA MED, V62, P86, DOI 10.1055/s-2006-957816
   Booth LA, 2014, CELL SIGNAL, V26, P549, DOI 10.1016/j.cellsig.2013.11.028
   Broker LE, 2005, CLIN CANCER RES, V11, P3155, DOI 10.1158/1078-0432.CCR-04-2223
   Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852
   Chen F, 2017, J FUNCT FOODS, V32, P382, DOI 10.1016/j.jff.2017.03.013
   Chen F, 2015, FOOD FUNCT, V6, P3828, DOI [10.1039/c5fo00518c, 10.1039/C5FO00518C]
   Deng JJ, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00506
   Duan Z. G., 2017, FOOD FUNCT
   Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116
   Guo WJ, 2013, AUTOPHAGY, V9, P996, DOI 10.4161/auto.24407
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710
   Jeremic I, 2013, PLANTA MED, V79, P1516, DOI 10.1055/s-0033-1350809
   Joo EJ, 2015, CHEM-BIOL INTERACT, V233, P25, DOI 10.1016/j.cbi.2015.03.016
   Kachadourian R, 2010, TOXICOLOGY, V268, P176, DOI 10.1016/j.tox.2009.12.010
   Kim SJ, 2015, J GINSENG RES, V39, P125, DOI 10.1016/j.jgr.2014.09.003
   Kim YJ, 2008, BIOL PHARM BULL, V31, P826, DOI 10.1248/bpb.31.826
   Kim YJ, 2013, J AGR FOOD CHEM, V61, P9185, DOI 10.1021/jf402774d
   Lee CH, 2014, J GINSENG RES, V38, P161, DOI 10.1016/j.jgr.2014.03.001
   Li HY, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.543
   Li MM, 2015, APOPTOSIS, V20, P769, DOI 10.1007/s10495-015-1110-8
   LI Y, 1994, ONCOGENE, V9, P2261
   Li YB, 2013, MOL NEUROBIOL, V47, P1000, DOI 10.1007/s12035-013-8403-0
   Liao PY, 2008, J AGR FOOD CHEM, V56, P1751, DOI 10.1021/jf073000s
   Lim SH, 2013, DEVELOPMENT, V140, P3079, DOI 10.1242/dev.091744
   Liu Q, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/925625
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Markman M., 2002, J CLIN ONCOL, V20, P491
   Midgley A, 2011, LUPUS, V20, P71, DOI 10.1177/0961203310382128
   Obenauf AC, 2015, NATURE, V520, P368, DOI 10.1038/nature14336
   Park EJ, 2016, MOL NUTR FOOD RES, V60, P1482, DOI 10.1002/mnfr.201500977
   Quan K, 2015, SCI REP-UK, V5, DOI 10.1038/srep08598
   Ravindran J, 2011, APOPTOSIS, V16, P145, DOI 10.1007/s10495-010-0554-0
   Ryan KM, 2011, EUR J CANCER, V47, P44, DOI 10.1016/j.ejca.2010.10.020
   Scherz-Shouval R, 2011, TRENDS BIOCHEM SCI, V36, P30, DOI 10.1016/j.tibs.2010.07.007
   Schwartz GK, 2005, J CLIN ONCOL, V23, P9408, DOI 10.1200/JCO.2005.01.5594
   Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304
   Tang JJ, 2015, CANCER LETT, V363, P101, DOI 10.1016/j.canlet.2015.04.014
   Mai TT, 2012, CANCER LETT, V321, P144, DOI 10.1016/j.canlet.2012.01.045
   Wang GY, 2017, FREE RADICAL BIO MED, V106, P24, DOI 10.1016/j.freeradbiomed.2017.02.015
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Wong CH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009996
   Zalckvar E, 2009, EMBO REP, V10, P285, DOI 10.1038/embor.2008.246
   Zhao Y, 2010, CANCER LETT, V288, P42, DOI 10.1016/j.canlet.2009.06.021
NR 45
TC 73
Z9 79
U1 7
U2 89
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
EI 1873-2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD FEB
PY 2018
VL 148
BP 64
EP 74
DI 10.1016/j.bcp.2017.12.004
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA FX5SZ
UT WOS:000426141200006
PM 29225132
DA 2022-04-25
ER

PT J
AU Xie, CM
   Chan, WY
   Yu, S
   Zhao, J
   Cheng, CHK
AF Xie, Chuan-Ming
   Chan, Wood Yee
   Yu, Sidney
   Zhao, Jun
   Cheng, Christopher H. K.
TI Bufalin induces autophagy-mediated cell death in human colon cancer
   cells through reactive oxygen species generation and JNK activation
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Bufalin; Colon cancer; ROS; JNK; LC3; Apoptosis; Autophagy; Cell death;
   Cancer therapy
ID LEUKEMIA U937 CELLS; HEPATOCELLULAR-CARCINOMA; INDUCED APOPTOSIS;
   SIGNALING PATHWAYS; ARSENIC TRIOXIDE; UP-REGULATION; GLIOMA-CELLS;
   INHIBITION; PROTEIN; LC3
AB Colorectal cancer is the second most common cause of cancer death in the world and about half of the patients with colorectal cancer require adjuvant therapy after surgical resection. Therefore, the eradication of cancer cells via chemotherapy constitutes a viable approach to treating patients with colorectal cancer. In this study, the effects of bufalin isolated from a traditional Chinese medicine were evaluated and characterized in HT-29 and Caco-2 human colon cancer cells. Contrary to its well-documented apoptosis-promoting activity in other cancer cells, bufalin did not cause caspase-dependent cell death in colon cancer cells, as indicated by the absence of significant early apoptosis as well as poly(ADP-ribose) polymerase and caspase-3 cleavage. Instead, bufalin activated an autophagy pathway, as characterized by the accumulation of LC3-II and the stimulation of autophagic flux. The induction of autophagy by bufalin was linked to the generation of reactive oxygen species (ROS). ROS activated autophagy via the c-Jun NH(2)-terminal kinase (JNK). JNK activation increased expression of ATG5 and Beclin-1. ROS antioxidants (N-acetylcysteine and vitamin C), the JNK-specific inhibitor SP600125, and JNK2 siRNA attenuated bufalin-induced autophagy. Our findings unveil a novel mechanism of drug action by bufalin in colon cancer cells and open up the possibility of treating colorectal cancer through a ROS-dependent autophagy pathway. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Xie, Chuan-Ming; Chan, Wood Yee; Yu, Sidney; Cheng, Christopher H. K.] Chinese Univ Hong Kong, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China.
   [Zhao, Jun] Shanghai Normal Univ, Coll Life & Environm Sci, Shanghai 200234, Peoples R China.
   [Cheng, Christopher H. K.] Chinese Univ Hong Kong, Ctr Novel Funct Mol, Shatin, Hong Kong, Peoples R China.
RP Cheng, CHK (corresponding author), Chinese Univ Hong Kong, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China.
EM chkcheng@cuhk.edu.hk
RI CHENG, Ki Christopher/R-9641-2018; Bin Sidney Yu, Siu/R-4936-2018; Chan,
   Wood Yee/R-6692-2018; Xie, Chuan-Ming/AAT-9557-2021
OI CHENG, Ki Christopher/0000-0001-8970-9048; Bin Sidney Yu,
   Siu/0000-0001-9643-2729; Chan, Wood Yee/0000-0002-7114-1463; Xie,
   Chuan-Ming/0000-0003-4362-6612
FU Chinese University of Hong KongChinese University of Hong Kong
FX This work was supported by a Strategic Investments Scheme from the
   Chinese University of Hong Kong. The authors thank the Chinese
   University of Hong Kong for the provision of Direct Grants and graduate
   studentships. The authors also thank Jean Lai-Sin Kung and Cathy Yui
   Hung for their valuable technical assistance in transmission electron
   microscopy.
CR Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Borsello T, 2003, EUR J NEUROSCI, V18, P473, DOI 10.1046/j.1460-9568.2003.02757.x
   Byun JY, 2009, CARCINOGENESIS, V30, P1880, DOI 10.1093/carcin/bgp235
   Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78
   Chan WY, 2003, TOXICOLOGY, V186, P191, DOI 10.1016/S0300-483X(02)00746-1
   Chau I, 2006, ANN ONCOL, V17, P1347, DOI 10.1093/annonc/mdl029
   Chen QH, 2005, FREE RADICAL BIO MED, V38, P226, DOI 10.1016/j.freeradbiomed.2004.10.019
   Chen YQ, 2008, AUTOPHAGY, V4, P246, DOI 10.4161/auto.5432
   Chiu HW, 2009, AUTOPHAGY, V5, P472, DOI 10.4161/auto.5.4.7759
   Efferth T, 2002, BLOOD CELL MOL DIS, V28, P160, DOI 10.1006/bcmd.2002.0492
   Gao M, 2008, CANCER RES, V68, P9348, DOI 10.1158/0008-5472.CAN-08-1642
   Guzman M, 2006, BRIT J CANCER, V95, P197, DOI 10.1038/sj.bjc.6603236
   Han KQ, 2007, WORLD J GASTROENTERO, V13, P3374, DOI 10.3748/wjg.v13.i24.3374
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Huerta S, 2006, AM J SURG, V191, P517, DOI 10.1016/j.amjsurg.2005.11.009
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095
   Kawazoe N, 1999, ONCOGENE, V18, P2413, DOI 10.1038/sj.onc.1202555
   Kim DK, 2009, CANCER RES, V69, P923, DOI 10.1158/0008-5472.CAN-08-2115
   Kim MJ, 2011, J BIOL CHEM, V286, P12924, DOI 10.1074/jbc.M110.138958
   Li DD, 2009, ONCOGENE, V28, P886, DOI 10.1038/onc.2008.441
   Li D, 2009, ANTI-CANCER DRUG, V20, P59, DOI 10.1097/CAD.0b013e3283160fd6
   Liu XC, 2009, BIOL REPROD, V80, P1253, DOI 10.1095/biolreprod.108.070250
   Liu YL, 2010, AUTOPHAGY, V6, P1057, DOI 10.4161/auto.6.8.13365
   Marchetti S, 2007, BRIT J CANCER, V97, P577, DOI 10.1038/sj.bjc.6603925
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Meng ZQ, 2009, CANCER-AM CANCER SOC, V115, P5309, DOI 10.1002/cncr.24602
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Nahimana A, 2009, BLOOD, V113, P3276, DOI 10.1182/blood-2008-08-173369
   Newman RA, 2007, INTEGR CANCER THER, V6, P354, DOI 10.1177/1534735407309623
   Qin TJ, 2008, WORLD J GASTROENTERO, V14, P5210, DOI 10.3748/wjg.14.5210
   Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272
   Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Sivaprasad U, 2008, J CELL MOL MED, V12, P1265, DOI 10.1111/j.1582-4934.2008.00282.x
   [苏永华 Su Yonghua], 2003, [中成药, Chinese Traditional Patent Medicine], V25, P24
   Tan MJ, 2010, FREE RADICAL BIO MED, V49, P976, DOI 10.1016/j.freeradbiomed.2010.05.030
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Watabe M, 1996, J BIOL CHEM, V271, P14067, DOI 10.1074/jbc.271.24.14067
   Watabe M, 1998, ONCOGENE, V16, P779, DOI 10.1038/sj.onc.1201592
   Xu Y, 2006, J BIOL CHEM, V281, P19179, DOI 10.1074/jbc.M513377200
   Yeh JY, 2003, PROSTATE, V54, P112, DOI 10.1002/pros.10172
   Yin JQ, 2007, ACTA PHARMACOL SIN, V28, P712, DOI 10.1111/j.1745-7254.2007.00559.x
   Yu CH, 2008, CANCER SCI, V99, P2467, DOI 10.1111/j.1349-7006.2008.00966.x
   Yuk JM, 2010, AUTOPHAGY, V6, P46, DOI 10.4161/auto.6.1.10325
NR 45
TC 188
Z9 209
U1 0
U2 58
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD OCT 1
PY 2011
VL 51
IS 7
BP 1365
EP 1375
DI 10.1016/j.freeradbiomed.2011.06.016
PG 11
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 818GV
UT WOS:000294740700009
PM 21763418
DA 2022-04-25
ER

PT J
AU Li, SG
   Wang, XW
   Wang, G
   Shi, PY
   Lin, SL
   Xu, DF
   Chen, B
   Liu, AL
   Huang, LY
   Lin, XH
   Yao, H
AF Li, Shaoguang
   Wang, Xuewen
   Wang, Gang
   Shi, Peiying
   Lin, Shilan
   Xu, Dafen
   Chen, Bing
   Liu, Ailin
   Huang, Liying
   Lin, Xinhua
   Yao, Hong
TI Ethyl Acetate Extract of Selaginella doederleinii Hieron Induces Cell
   Autophagic Death and Apoptosis in Colorectal Cancer via PI3K-Akt-mTOR
   and AMPK alpha-Signaling Pathways
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE colorectal carcinoma; autophagy; apoptosis; Selaginella doederleinii
   Hieron ethyl acetate; antitumor mechanism
ID KAPPA-B ACTIVATION; LUNG-CANCER; CYCLE ARREST; AMENTOFLAVONE; A549;
   GROWTH; SUPPRESSION; INHIBITION; BIFLAVONES; FLAVONES
AB Colorectal cancer is one type of cancer with high incidence rate and high mortality worldwide. Thus, developing new chemotherapeutic drugs is important. The Selaginella doederleinii Hieron ethyl acetate (SDEA) extract showed good anti-colon cancer effect in vitro and in vivo, but its mechanism is unclear. This study aimed to further reveal the anti-colon cancer effect of SDEA and its possible mechanism. The effects on cell viability, apoptosis, autophagy, and cell cycle in colorectal cells (HT29 and HCT116) were studied using MTT assay, fluorescence microscopy, transmission electron microscopy, and flow cytometry. The mechanisms were further studied using cell transfection, Western blot, and real-time quantitative polymerase chain reaction assay. The effect of xenotransplantation in vivo was observed using immunohistochemistry. Results showed that SDEA inhibited cell proliferation and induced cell morphological changes, cell cycle arrest, autophagy, and apoptosis. It also induced loss of mitochondrial membrane potential, increased the autophagic flux, raised the ratio of Bax/Bcl-2, activated caspases, and inhibited PI3K-Akt-mTOR signaling pathways. Furthermore, SDEA inhibited the growth of xenograft tumors in a dose-dependent manner. Immunohistochemistry analysis confirmed the alteration of autophagy- and apoptosis-related proteins and immunohistochemical microvascular density in xenografts, which were consistent with the results in vitro. Therefore, SDEA is important for developing candidate drugs against colorectal cancers.
C1 [Li, Shaoguang; Wang, Xuewen; Wang, Gang; Lin, Shilan; Xu, Dafen; Chen, Bing; Liu, Ailin; Huang, Liying; Lin, Xinhua; Yao, Hong] Fujian Med Univ, Sch Pharm, Dept Pharmaceut Anal, Fuzhou, Peoples R China.
   [Li, Shaoguang; Wang, Xuewen; Wang, Gang; Lin, Shilan; Xu, Dafen; Chen, Bing; Liu, Ailin; Lin, Xinhua; Yao, Hong] Fujian Med Univ, Higher Educ Key Lab Nano Biomed Technol Fujian Pr, Fuzhou, Peoples R China.
   [Li, Shaoguang; Wang, Xuewen; Wang, Gang; Lin, Shilan; Xu, Dafen; Chen, Bing; Liu, Ailin; Lin, Xinhua; Yao, Hong] Fujian Med Univ, Nano Med Technol Res Inst, Fuzhou, Peoples R China.
   [Shi, Peiying] Fujian Agr & Forestry Univ, Dept Tradit Chinese Med Resource & Bee Prod, Bee Sci Coll, Fuzhou, Peoples R China.
   [Yao, Hong] Fujian Med Univ, Fujian Key Lab Drug Target Discovery & Struct & F, Fuzhou, Peoples R China.
RP Lin, XH; Yao, H (corresponding author), Fujian Med Univ, Sch Pharm, Dept Pharmaceut Anal, Fuzhou, Peoples R China.; Lin, XH; Yao, H (corresponding author), Fujian Med Univ, Higher Educ Key Lab Nano Biomed Technol Fujian Pr, Fuzhou, Peoples R China.; Lin, XH; Yao, H (corresponding author), Fujian Med Univ, Nano Med Technol Res Inst, Fuzhou, Peoples R China.; Yao, H (corresponding author), Fujian Med Univ, Fujian Key Lab Drug Target Discovery & Struct & F, Fuzhou, Peoples R China.
EM xhlin1963@sina.com; yauhung@126.com
OI Chen, Bing/0000-0002-0026-1249
FU National Nature Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [21775023, 81303298, 81973558]; Joint Funds
   for the Innovation of Science and Technology, Fujian Province
   [2017Y9118, 2017Y9123, 2017Y9124]; Fujian Provincial Natural Science
   Foundation [2018J01596]
FX The authors gratefully acknowledge the financial supports of the
   National Nature Science Foundation of China (grant numbers 21775023,
   81303298, and 81973558), the Joint Funds for the Innovation of Science
   and Technology, Fujian Province (grant numbers 2017Y9118, 2017Y9123, and
   2017Y9124), and the Fujian Provincial Natural Science Foundation (grant
   numbers 2018J01596).
CR Banerjee T, 2002, MOL CELL BIOCHEM, V238, P105, DOI 10.1023/A:1019963222510
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Cao Y, 2010, FITOTERAPIA, V81, P253, DOI 10.1016/j.fitote.2009.09.007
   Chen JH, 2015, ANTICANCER RES, V35, P6685
   Chen XM, 2019, FREE RADICAL BIO MED, V131, P225, DOI 10.1016/j.freeradbiomed.2018.12.008
   Ding Y, 2019, CANCER LETT, V467, P58, DOI 10.1016/j.canlet.2019.09.007
   Guruvayoorappan C, 2007, INTEGR CANCER THER, V6, P185, DOI 10.1177/1534735407302345
   Jin MY, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00369
   Jung HJ, 2020, PHYTOTHER RES, V34, P126, DOI 10.1002/ptr.6506
   Jung YJ, 2017, J ETHNOPHARMACOL, V202, P78, DOI 10.1016/j.jep.2017.03.010
   Kuete V, 2016, PHYTOMEDICINE, V23, P856, DOI 10.1016/j.phymed.2016.04.007
   Kukula-Koch W, 2018, PHYTOTHER RES, V32, P933, DOI 10.1002/ptr.6035
   Lee KC, 2018, IN VIVO, V32, P549, DOI 10.21873/invivo.11274
   Li SG, 2014, PHYTOCHEM ANALYSIS, V25, P127, DOI 10.1002/pca.2478
   Lian R, 2013, AFR J TRADIT COMPLEM, V10, P490, DOI 10.4314/ajtcam.v10i6.17
   Liu HH, 2011, J ETHNOPHARMACOL, V138, P184, DOI 10.1016/j.jep.2011.08.072
   Liu LH, 2020, NUTR CANCER, V72, P662, DOI 10.1080/01635581.2019.1650192
   Moosavi MA, 2018, CANCER LETT, V424, P46, DOI 10.1016/j.canlet.2018.02.030
   Pei JS, 2012, IN VIVO, V26, P963
   Sui YX, 2017, J MOL MED, V95, P311, DOI 10.1007/s00109-016-1487-z
   Sui YX, 2016, J ETHNOPHARMACOL, V190, P261, DOI 10.1016/j.jep.2016.06.029
   Tian XL, 2019, CANCER LETT, V448, P20, DOI 10.1016/j.canlet.2019.01.031
   Tsui KC, 2014, MOLECULES, V19, P17663, DOI 10.3390/molecules191117663
   Yao H, 2017, MOLECULES, V22, DOI 10.3390/molecules22020325
   Zhang LL, 2019, ADV CANCER RES, V142, P187, DOI 10.1016/bs.acr.2019.01.005
   Zhang YM, 2014, PHYTOCHEM LETT, V9, P82, DOI 10.1016/j.phytol.2014.04.015
   Zhao MM, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00223
   Zheng XK, 2016, MOLECULES, V21, DOI 10.3390/molecules21050624
NR 28
TC 4
Z9 5
U1 3
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD OCT 19
PY 2020
VL 11
AR 565090
DI 10.3389/fphar.2020.565090
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA OI5II
UT WOS:000583311600001
PM 33192508
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Peng, JQ
   Han, SM
   Chen, ZH
   Yang, J
   Pei, YQ
   Bao, C
   Qiao, L
   Chen, WQ
   Liu, B
AF Peng, Jie-qiong
   Han, Shu-mei
   Chen, Ze-hao
   Yang, Jing
   Pei, Yan-qing
   Bao, Cong
   Qiao, Lei
   Chen, Wen-qiang
   Liu, Bo
TI Chaperone-mediated autophagy regulates apoptosis and the proliferation
   of colon carcinoma cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Colorectal cancer; Chaperone-mediated autophagy; Apoptosis;
   Proliferation
ID TUMOR-SUPPRESSOR; DEGRADATION; CANCER; TUMORIGENESIS; PROTEINS; UNIQUE
AB Chaperone-mediated autophagy (CMA) is one of the three types of autophagy. In recent years, CMA has been shown to be associated with the pathogenesis of several types of cancer. However, whether CMA is involved in the pathogenesis of colorectal cancer (CRC) remains unclear. In this study, we investigated CMA activity in tissue specimens from CRC patients and mouse models of colitis-associated CRC (induced by administration of AOM plus DSS). In addition, we down-regulated CMA in CT26 colon carcinoma cells stably transfected with a vector expressing a siRNA targeting LAMP-2A, the limiting component in the CMA pathway, to explore the role of CMA in these cells. Apoptosis was detected using TUNEL assay, and the apoptosis-related proteins were detected using western blotting. Cell proliferation was assessed using MTT assay, Ki-67 labelling and western blotting for PCNA. We found that LAMP-2A expression was significantly increased in CRC patients and mouse models and varied according to the stage of the disease. Inhibition of CMA in CT26 cells facilitated apoptosis, as evidenced by increased TUNEL immunolabeling, increased expression of Bax and Bnip3, and decreased expression of Bcl-2. Cell proliferation assays showed that inhibition of CMA impeded the proliferation of CT26 cells. These data support the hypothesis that CMA is up-regulated in CRC, and inhibition of CMA may be a new therapeutic strategy for CRC patients. (C) 2019 Elsevier Inc. All rights reserved.
C1 [Peng, Jie-qiong] Univ Jinan, Sch Med & Life Sci, Shandong Acad Med Sci, Jinan, Peoples R China.
   [Peng, Jie-qiong; Han, Shu-mei; Yang, Jing; Pei, Yan-qing; Liu, Bo] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Oncol, Jinan, Peoples R China.
   [Qiao, Lei; Chen, Wen-qiang] Shandong Univ, Qilu Hosp, Key Lab Cardiovasc Remodeling & Funct Res, Chinese Minist Educ,Chinese Natl Hlth Commiss, 107 Wenhuaxi Rd, Jinan 250012, Peoples R China.
   [Qiao, Lei; Chen, Wen-qiang] Shandong Univ, Qilu Hosp, Chinese Acad Med Sci, State & Shandong Prov Joint Key Lab Translat Card, 107 Wenhuaxi Rd, Jinan 250012, Peoples R China.
   [Bao, Cong] Pingyi Cty Peoples Hosp, Dept Pathol, Linyi 273300, Shandong, Peoples R China.
   [Chen, Ze-hao] Shandong First Med Univ, Tai An, Shandong, Peoples R China.
RP Chen, WQ (corresponding author), Shandong Univ, Qilu Hosp, Key Lab Cardiovasc Remodeling & Funct Res, Chinese Minist Educ, 107 Wen Hua Xi Rd, Jinan 250012, Shandong, Peoples R China.; Chen, WQ (corresponding author), Shandong Univ, Qilu Hosp, Chinese Minist Hlth,Dept Cardiol, State & Shandong Prov Joint Key Lab Translat Card, 107 Wen Hua Xi Rd, Jinan 250012, Shandong, Peoples R China.; Liu, B (corresponding author), Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, 440 Jiyan Rd, Jinan 250117, Peoples R China.
EM 199262000802@sdu.edu.cn; 15553115688@163.com
OI Pei, Yanqing/0000-0003-0936-4049
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81770436]; National Key Project of Chronic
   Non-Communicable Diseases of China [2016 YFC1300403]
FX This work was supported by grants from the National Natural Science
   Foundation of China (81770436). This reserach was also supported by the
   National Key Project of Chronic Non-Communicable Diseases of China (No.
   2016 YFC1300403).
CR Cuervo AM, 2000, J CELL SCI, V113, P4441
   Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501
   DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8
   Du CZ, 2017, CANCER LETT, V400, P183, DOI 10.1016/j.canlet.2017.04.033
   Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kaushik S, 2008, MOL BIOL CELL, V19, P2179, DOI 10.1091/mbc.E07-11-1155
   Kaushik S, 2018, NAT REV MOL CELL BIO, V19, P365, DOI 10.1038/s41580-018-0001-6
   Kaushik S, 2012, TRENDS CELL BIOL, V22, P407, DOI 10.1016/j.tcb.2012.05.006
   Kon M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003182
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Liu DX, 2019, ONCOL LETT, V17, P323, DOI 10.3892/ol.2018.9584
   Massey AC, 2006, P NATL ACAD SCI USA, V103, P5805, DOI 10.1073/pnas.0507436103
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Neufert C, 2007, NAT PROTOC, V2, P1998, DOI 10.1038/nprot.2007.279
   Quintavalle C, 2014, J CELL PHYSIOL, V229, P1359, DOI 10.1002/jcp.24569
   Suzuki J, 2017, BIOCHEM BIOPH RES CO, V482, P1334, DOI 10.1016/j.bbrc.2016.12.037
   Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595
   Thorburn A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003390
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Wunderlich CM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03773-0
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yu C, 2018, CANCER MED-US, V7, P471, DOI 10.1002/cam4.1287
   Zhang SL, 2018, CANCER LETT, V419, P116, DOI 10.1016/j.canlet.2018.01.045
   Zhou JF, 2016, AUTOPHAGY, V12, P515, DOI 10.1080/15548627.2015.1136770
NR 25
TC 9
Z9 9
U1 3
U2 19
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD FEB 5
PY 2020
VL 522
IS 2
BP 348
EP 354
DI 10.1016/j.bbrc.2019.11.081
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA KC9LF
UT WOS:000507492100011
PM 31761324
DA 2022-04-25
ER

PT J
AU Ellington, AA
   Berhow, MA
   Singletary, KW
AF Ellington, AA
   Berhow, MA
   Singletary, KW
TI Inhibition of Akt signaling and enhanced ERK1/2 activity are involved in
   induction of macroautophagy by triterpenoid B-group soyasaponins in
   colon cancer cells
SO CARCINOGENESIS
LA English
DT Article
ID ALPHA-INTERACTING PROTEIN; SOYBEAN SAPONINS; CARCINOMA CELLS;
   COLORECTAL-CANCER; GROWTH-FACTOR; AMINO-ACIDS; KINASE-B; AUTOPHAGY;
   DEATH; RISK
AB Triterpenoid B-group soyasaponins have been found to induce macroautophagy in human colon cancer cells at concentrations obtainable through consumption of legume foodstuffs. In the present studies the mechanism(s) for this autophagy-inducing action of soyasaponins was evaluated by measuring changes in signal transduction pathways associated with autophagy. Specifically, inhibition of the Akt signaling pathway and enhanced activity of ERK1/2 have previously been implicated in controlling induction of macroautophagy in mammalian cancer cells. Here we show that these pathways are also involved in B-group soyasaponin-induced macroautophagy, as changes in enzyme activities preceded significant increases in autophagic activity. The autophagic capacity of HCT-15 cells was significantly increased by 6 h post-saponin exposure, which led us to measure alterations in signaling events that preceded this time point. We determined that exposure to B-group soyasaponins suppressed Akt activity maximally by 50%, which was associated with a reduction in the activating phosphorylation of the Akt-serine(473) residue. In addition, ERK1/2 activity was significantly increased by 60%, and was determined to be necessary for B-group soyasaponin-induced autophagy. The raf-1 kinase has been identified as a potential point of cross-talk between the Akt and ERK1/2 signaling cascades. Following B-group soyasaponin treatment activity of raf-1 was significantly increased by a maximal 200%, suggesting that this enzyme in part modulates the enhanced ERK1/2 activity. These results provide new insights into the signaling events that control induction of autophagy by B-group soyasaponins in human colon cancer cells and suggest that soyasaponins warrant further study as potential colon cancer chemopreventive agents.
C1 Univ Illinois, Dept Food Sci & Human Nutr, Urbana, IL 61801 USA.
   Natl Ctr Agr Res Serv, Peoria, IL 61601 USA.
RP Ellington, AA (corresponding author), Univ Illinois, Dept Food Sci & Human Nutr, 905 S Goodwin Ave,Bevier Hall, Urbana, IL 61801 USA.
EM kws@uiuc.edu
OI Berhow, Mark/0000-0002-1278-4071
CR Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200
   Bauvy C, 2001, EXP CELL RES, V268, P139, DOI 10.1006/excr.2001.5285
   Bennink MR, 2001, ADV EXP MED BIOL, V492, P11
   BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3
   Bondzi C, 2000, ONCOGENE, V19, P5030, DOI 10.1038/sj.onc.1203862
   Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595
   Byers T, 2002, CA-CANCER J CLIN, V52, P92, DOI 10.3322/canjclin.52.2.92
   Chiang Gary G, 2004, Methods Mol Biol, V281, P125
   Clark GJ, 2000, CANC DRUG DISC DEV, V5, P213
   CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615
   DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923
   DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935
   Ellington AA, 2005, CARCINOGENESIS, V26, P159, DOI 10.1093/carcin/bgh297
   Franceschi S, 1997, INT J CANCER, V72, P56, DOI 10.1002/(SICI)1097-0215(19970703)72:1&lt;56::AID-IJC8&gt;3.0.CO;2-3
   Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115
   Fung T, 2003, ARCH INTERN MED, V163, P309, DOI 10.1001/archinte.163.3.309
   GESTETNER B, 1968, J AGR FOOD CHEM, V16, P1031, DOI 10.1021/jf60160a025
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Greenwald P, 2001, EUR J CANCER, V37, P948, DOI 10.1016/S0959-8049(01)00070-3
   Gurfinkel DM, 2003, NUTR CANCER, V47, P24, DOI 10.1207/s15327914nc4701_3
   Hakkak R, 2001, CANCER LETT, V166, P27, DOI 10.1016/S0304-3835(01)00441-4
   Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009
   Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704
   Hu J, 2004, J AGR FOOD CHEM, V52, P2689, DOI 10.1021/jf035290s
   Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10
   Kanazawa T, 2004, J BIOL CHEM, V279, P8452, DOI 10.1074/jbc.M306337200
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Kim HY, 2004, CANCER LETT, V210, P1, DOI 10.1016/j.canlet.2004.01.009
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Koratkar R, 1997, NUTR CANCER, V27, P206, DOI 10.1080/01635589709514526
   Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3
   Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003
   Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231
   Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002
   Mochizuki T, 2002, J BIOL CHEM, V277, P2790, DOI 10.1074/jbc.M106361200
   Mordier S, 2000, J BIOL CHEM, V275, P29900, DOI 10.1074/jbc.M003633200
   Munafo DB, 2001, J CELL SCI, V114, P3619
   Murillo G, 2004, ANTICANCER RES, V24, P3049
   Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0
   Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200
   OGIERDENIS E, 1995, J BIOL CHEM, V270, P13, DOI 10.1074/jbc.270.1.13
   Oh YJ, 2001, NUTR CANCER, V39, P132, DOI 10.1207/S15327914nc391_18
   Opipari AW, 2004, CANCER RES, V64, P696, DOI 10.1158/0008-5472.CAN-03-2404
   Pattingre S, 2004, METHOD ENZYMOL, V390, P17
   Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200
   Pearl LH, 2002, CURR OPIN STRUC BIOL, V12, P761, DOI 10.1016/S0959-440X(02)00386-X
   Petiot A, 1999, BIOCHEM J, V337, P289, DOI 10.1042/0264-6021:3370289
   Rao A V, 2000, Drug Metabol Drug Interact, V17, P211
   Saeki K, 2003, J LEUKOCYTE BIOL, V74, P1108, DOI 10.1189/jlb.0503211
   Scarlatti F, 2004, J BIOL CHEM, V279, P18384, DOI 10.1074/jbc.M313561200
   SchulteHermann R, 1997, TOXICOL PATHOL, V25, P89, DOI 10.1177/019262339702500117
   Singh PN, 1998, AM J EPIDEMIOL, V148, P761, DOI 10.1093/oxfordjournals.aje.a009697
   Spector D, 2003, NUTR CANCER, V47, P1, DOI 10.1207/s15327914nc4701_1
   SUNG MK, 1995, FOOD CHEM TOXICOL, V33, P357, DOI 10.1016/0278-6915(95)00007-O
   SUNG MK, 1995, NUTR CANCER, V23, P259, DOI 10.1080/01635589509514380
   Takeuchi H, 2004, BRIT J CANCER, V90, P1069, DOI 10.1038/sj.bjc.6601605
   Tee AR, 2003, J BIOL CHEM, V278, P37288, DOI 10.1074/jbc.M303257200
   Thiagarajan DG, 1998, AM J CLIN NUTR, V68, p1394S, DOI 10.1093/ajcn/68.6.1394S
   VARA J, 2001, CANC TREAT REV, V30, P193
   Yao KC, 2003, J NEUROSURG, V98, P378, DOI 10.3171/jns.2003.98.2.0378
   Yoshiki Y, 1998, BIOSCI BIOTECH BIOCH, V62, P2291, DOI 10.1271/bbb.62.2291
   Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741
NR 62
TC 179
Z9 190
U1 2
U2 20
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD FEB
PY 2006
VL 27
IS 2
BP 298
EP 306
DI 10.1093/carcin/bgi214
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 004UU
UT WOS:000234778700015
PM 16113053
OA Bronze
DA 2022-04-25
ER

PT J
AU Elamin, KM
   Yamashita, Y
   Motoyama, K
   Higashi, T
   Arima, H
AF Elamin, Khaled M.
   Yamashita, Yuki
   Motoyama, Keiichi
   Higashi, Taishi
   Arima, Hidetoshi
TI Involvement of mitophagy-mediated cell death in colon cancer cells by
   folate-appended methyl-beta-cyclodextrin
SO JOURNAL OF INCLUSION PHENOMENA AND MACROCYCLIC CHEMISTRY
LA English
DT Article
DE Folate receptor; Methyl-beta-cyclodextrin; Colon cancer; Autophagy;
   Targeting
ID COLORECTAL-CANCER; DRUG-DELIVERY; MECHANISMS; AUTOPHAGY; PROGRESSION;
   PATHWAYS; SYSTEMS
AB In recent years, colorectal cancer has gained great attention among various types of cancers. We previously synthesized folate-appended methyl-beta-cyclodextrin (FA-M-beta-CyD) as a novel autophagic antitumor agent. In this study, to further elucidate the impact of FA-M-beta-CyD as an antitumor agent, we evaluated cytotoxic activity and the antiproliferative effect in colon cancer cells and colorectal cancer model mice, respectively. As a result, FA-M-beta-CyD showed potent cytotoxic activity in HCT116 cells, a human colon cancer cell line, through folate receptor-alpha (FR-alpha)-mediated cellular uptake. In addition, FA-M-beta-CyD elicited autophagosome formation and induced mitophagy in HCT116 cells. Importantly, FA-M-beta-CyD drastically reduced the number of tumor polyps in colorectal cancer model mice induced by azoxymethane/dextran sodium sulfate after intravenous injections once a week for 4 weeks. These results suggest that FA-M-beta-CyD has the antiproliferative effect in the colorectal cancer, due to the FR-alpha-mediated endocytosis and mitophagy induction.
C1 [Elamin, Khaled M.; Yamashita, Yuki; Motoyama, Keiichi; Higashi, Taishi; Arima, Hidetoshi] Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Phys Pharmaceut, Chuo Ku, 5-1 Oe Honmachi, Kumamoto 8620973, Japan.
   [Yamashita, Yuki; Arima, Hidetoshi] Kumamoto Univ, Program Leading Grad Sch, HIGO Hlth Life Sci Interdisciplinary & Glocal Ori, Kumamoto, Japan.
RP Arima, H (corresponding author), Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Phys Pharmaceut, Chuo Ku, 5-1 Oe Honmachi, Kumamoto 8620973, Japan.; Arima, H (corresponding author), Kumamoto Univ, Program Leading Grad Sch, HIGO Hlth Life Sci Interdisciplinary & Glocal Ori, Kumamoto, Japan.
EM arimah@gpo.kumamoto-u.ac.jp
FU Japan Society for the Promotion of ScienceMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science [16K08198]; Center for Clinical and
   Translational Research of Kyushu University; Ministry of Health, Labor,
   and WelfareMinistry of Health, Labour and Welfare, Japan [24100701]
FX This work was partially supported by a Grant-in-Aid for Scientific
   Research (C) from the Japan Society for the Promotion of Science
   (16K08198), Center for Clinical and Translational Research of Kyushu
   University, and a Ministry of Health, Labor, and Welfare Grant-in-Aid
   for Third Term Comprehensive Control Research for Cancer program
   (24100701).
CR Amankwatia EB, 2015, BRIT J CANCER, V112, P1480, DOI 10.1038/bjc.2015.125
   Barderas R, 2013, SCI REP-UK, V3, DOI 10.1038/srep02938
   Cheng Y, 2013, PHARMACOL REV, V65, P1162, DOI 10.1124/pr.112.007120
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Danhier F, 2010, J CONTROL RELEASE, V148, P135, DOI 10.1016/j.jconrel.2010.08.027
   De Robertis Mariangela, 2011, J Carcinog, V10, P9, DOI 10.4103/1477-3163.78279
   Doherty GJ, 2009, ANNU REV BIOCHEM, V78, P857, DOI 10.1146/annurev.biochem.78.081307.110540
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Grosse PY, 1998, BRIT J CANCER, V78, P1165, DOI 10.1038/bjc.1998.648
   Haggar Fatima A, 2009, Clin Colon Rectal Surg, V22, P191, DOI 10.1055/s-0029-1242458
   Kameyama K, 2017, INT J NANOMED, V12, P3433, DOI 10.2147/IJN.S133482
   Kelemen LE, 2006, INT J CANCER, V119, P243, DOI 10.1002/ijc.21712
   Kiss T, 2010, EUR J PHARM SCI, V40, P376, DOI 10.1016/j.ejps.2010.04.014
   Kurkov SV, 2013, INT J PHARMACEUT, V453, P167, DOI 10.1016/j.ijpharm.2012.06.055
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Mattar Mark C, 2011, Gastrointest Cancer Res, V4, P53
   Millimouno FM, 2014, CANCER PREV RES, V7, P1081, DOI 10.1158/1940-6207.CAPR-14-0136
   Motoyama K, 2015, BIOL PHARM BULL, V38, P374, DOI 10.1248/bpb.b14-00531
   Motoyama K, 2009, EUR J PHARM SCI, V38, P249, DOI 10.1016/j.ejps.2009.07.010
   Onodera R, 2014, SCI REP-UK, V4, DOI 10.1038/srep04417
   Onodera R, 2013, INT J PHARMACEUT, V452, P116, DOI 10.1016/j.ijpharm.2013.04.071
   Onodera R, 2013, SCI REP-UK, V3, DOI 10.1038/srep01104
   Onodera R, 2011, J INCL PHENOM MACRO, V70, P321, DOI 10.1007/s10847-010-9843-z
   Rajamanickam S, 2008, DRUG DEVELOP RES, V69, P460, DOI 10.1002/ddr.20276
   Ricci MS, 2006, ONCOLOGIST, V11, P342, DOI 10.1634/theoncologist.11-4-342
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Stein A, 2014, WORLD J GASTROENTERO, V20, P899, DOI 10.3748/wjg.v20.i4.899
   Szabo ZI, 2017, J INCL PHENOM MACRO, V88, P43, DOI 10.1007/s10847-017-0710-z
   Tan SJ, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9028435
   Tanaka T, 2012, INT J INFLAMM, V2012, DOI 10.1155/2012/658786
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yoshimi K, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-448
   Zhang JX, 2013, ADV DRUG DELIVER REV, V65, P1215, DOI 10.1016/j.addr.2013.05.001
NR 33
TC 3
Z9 3
U1 1
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388-3127
EI 1573-1111
J9 J INCL PHENOM MACRO
JI J. Incl. Phenom. Macrocycl. Chem.
PD DEC
PY 2017
VL 89
IS 3-4
BP 333
EP 342
DI 10.1007/s10847-017-0757-x
PG 10
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA FM0YL
UT WOS:000414694500011
DA 2022-04-25
ER

PT J
AU Yang, KZ
   Niu, T
   Luo, MY
   Tang, LH
   Kang, L
AF Yang Kaizhen
   Niu Ting
   Luo Mengyu
   Tang Lihua
   Kang Ling
TI Enhanced cytotoxicity and apoptosis through inhibiting autophagy in
   metastatic potential colon cancer SW620 cells treated with Chlorin e6
   photodynamic therapy
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE Autophagy; Apoptosis; Photodynamic therapy; Chlorin e6; Colorectal
   cancer
ID DEATH; PHOTOSENSITIZER; STATISTICS; PATHWAYS; ACTIVATION; GUIDELINES;
   PROTEINS; STRESS; FAMILY; ASSAYS
AB Photodynamic therapy (PDT) is a novel and non-invasive treatment that induces apoptosis and autophagy. Autophagy could play a pro-survival role, thus inhibiting autophagic activity might be a promising method to enhance the effectiveness of PDT for tumors. In the present study, photosensitizer Chlorin e6 (Ce6) was found to mainly locate in endoplasmic reticulum, and to a lesser extent in mitochondria and lysosome. Chlorin e6 photodynamic therapy (Ce6-PDT) could kill human colon cancer SW620 cells by inducing apoptotic cell death, and autophagy also induced by Ce6-PDT in colon cancer cells. More importantly, autophagy played a pro-survival role. Its inhibition enhanced Ce6-PDT-associated apoptotic cell death because cells pretreated with the typical autophagy inhibitor 3-methyladenine exhibited higher cytotoxicity and apoptotic cell death.
C1 [Yang Kaizhen; Tang Lihua] First Peoples Hosp Urumqi, Teaching & Res Dept, 1 Jiankang Rd, Urumqi, Xinjiang Uygur, Peoples R China.
   [Niu Ting; Luo Mengyu; Kang Ling] Xinjiang Med Univ, Sch Publ Hlth, 393 Xinyi Rd, Urumqi, Xinjiang Uygur, Peoples R China.
RP Kang, L (corresponding author), Xinjiang Med Univ, Sch Publ Hlth, 393 Xinyi Rd, Urumqi, Xinjiang Uygur, Peoples R China.
EM lingkang1220@sina.com
FU Xinjiang Uygur Autonomous Region Natural Science Foundation
   [2014211C003]
FX This study was supported by the Xinjiang Uygur Autonomous Region Natural
   Science Foundation (No. 2014211C003).
CR Agostinis P, 2011, CA-CANCER J CLIN, V61, P250, DOI 10.3322/caac.20114
   Ahn MY, 2013, J ORAL PATHOL MED, V42, P17, DOI 10.1111/j.1600-0714.2012.01187.x
   Allison RR, 2010, FUTURE ONCOL, V6, P929, DOI 10.2217/FON.10.51
   Aluigi A., 2016, RSC ADV, V10, P1
   Andrzejak M, 2011, AUTOPHAGY, V7, P979, DOI 10.4161/auto.7.9.15865
   Buytaert E, 2006, FASEB J, V20, P756, DOI 10.1096/fj.05-4305fje
   Cai Y, 2016, J CELL BIOL, V215, P245, DOI 10.1083/jcb.201605065
   Carew Jennifer S, 2012, Cancer Manag Res, V4, P357, DOI 10.2147/CMAR.S26133
   Du LH, 2014, J PHOTOCH PHOTOBIO B, V133, P1, DOI 10.1016/j.jphotobiol.2014.02.010
   Du X.X., 2014, J MODERN ONCOL, V1, P204
   Furre IE, 2006, APOPTOSIS, V11, P2031, DOI 10.1007/s10495-006-0190-x
   Gogvadze V, 2009, APOPTOSIS, V14, P624, DOI 10.1007/s10495-009-0323-0
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Granville DJ, 1998, FEBS LETT, V437, P5, DOI 10.1016/S0014-5793(98)01193-4
   Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Kessel D, 1997, PHOTOCHEM PHOTOBIOL, V65, P422, DOI 10.1111/j.1751-1097.1997.tb08581.x
   Kessel D, 2007, PHOTOCH PHOTOBIO SCI, V6, P1290, DOI 10.1039/b707953b
   Kessel D, 2018, PHOTOCHEM PHOTOBIOL, V94, P213, DOI 10.1111/php.12857
   Kessel DH, 2012, AUTOPHAGY, V8, P1333, DOI 10.4161/auto.20792
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Klionsky DJ, 2010, AUTOPHAGY, V6, P438, DOI 10.4161/auto.6.4.12244
   Lam M, 2001, J BIOL CHEM, V276, P47379, DOI 10.1074/jbc.M107678200
   Li B, 2012, ONCOL REP, V27, P1455, DOI 10.3892/or.2012.1656
   Li JZ, 2006, J BIOL CHEM, V281, P7260, DOI 10.1074/jbc.M509868200
   Li Q, 2014, ULTRASONICS, V54, P981, DOI 10.1016/j.ultras.2013.11.009
   Li YX, 2012, ULTRASONICS, V52, P490, DOI 10.1016/j.ultras.2011.10.013
   Loos B, 2013, AUTOPHAGY, V9, P1270, DOI 10.4161/auto.25560
   Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Ouyang GQ, 2018, PHOTODIAGN PHOTODYN, V21, P396, DOI 10.1016/j.pdpdt.2018.01.010
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   SPIKES JD, 1990, J PHOTOCH PHOTOBIO B, V6, P259, DOI 10.1016/1011-1344(90)85096-F
   STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463
   Tao XJ, 1997, J CLIN ENDOCR METAB, V82, P2738, DOI 10.1210/jc.82.8.2738
   Thome M. P., 2016, J CELL SCI, V14, P1
   Thorburn A, 2008, APOPTOSIS, V13, P1, DOI 10.1007/s10495-007-0154-9
   Tsai JC, 2005, LASER SURG MED, V36, P398, DOI 10.1002/lsm.20179
   VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X
   Whitacre CM, 2000, CLIN CANCER RES, V6, P2021
   Xu C. S., 2015, ULTRASONICS, V7, P1
   Xue LY, 2010, AUTOPHAGY, V6, P248, DOI 10.4161/auto.6.2.11077
   Yavari N, 2011, CAN J UROL, V18, P5778
NR 47
TC 14
Z9 15
U1 3
U2 24
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD DEC
PY 2018
VL 24
BP 332
EP 341
DI 10.1016/j.pdpdt.2018.10.012
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HE6FH
UT WOS:000453498200052
PM 30355513
DA 2022-04-25
ER

PT J
AU John, S
   Mls, J
   Cervinka, M
   Rudolf, E
AF John, Stanislav
   Mls, Jan
   Cervinka, Miroslav
   Rudolf, Emil
TI The Role of Autophagic Cell Death and Apoptosis in Irinotecan-treated
   p53 Null Colon Cancer Cells
SO ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
LA English
DT Article
DE Irinotecan; Colon cancer; Autophagy; p53; Chemotherapy; Autophagic cell
   death; Apoptosis; Bax; Lysosomes; Mitochondria
ID LYSOSOMAL MEMBRANE PERMEABILIZATION; COLORECTAL-CANCER; INVOLVEMENT;
   THERAPY
AB The roles of autophagic cell death and apoptosis induced by topoisomerase inhibitor irinotecan in colon cancer cells with deleted p53 were investigated during 48 h. We report that irinotecan-dependent cytotoxicity and proapoptotic activity were reduced in the present model while autophagy levels significantly increased. Upon p53 transfection, cell demise rates increased, with cells bearing the features of apoptosis and autophagic cell death. The subsequent studies into mechanisms of cell death process revealed the important role of Bax in mediating mitochondrial and lysosomal leakage which might serve as leading signals for both apoptosis and autophagic cell death. These results suggest that different modes of cell death in p53 null colon cancer cells treated with cytostatics (irinotecan) may be activated simultaneously. Moreover, their interactions possibly occur at several stages and aren't mutually exclusive. This might thus lead to a potential synergism with interesting therapeutic ramifications.
C1 [John, Stanislav; Mls, Jan; Cervinka, Miroslav; Rudolf, Emil] Charles Univ Prague, Fac Med Hradec Kralove, Dept Med Biol & Genet, Hradec Kralove 50038, Czech Republic.
RP Rudolf, E (corresponding author), Charles Univ Prague, Fac Med Hradec Kralove, Dept Med Biol & Genet, Simkova 870, Hradec Kralove 50038, Czech Republic.
EM rudolf@lfhk.cuni.cz
RI Cervinka, Miroslav/R-7387-2016; Rudolf, Emil/B-5956-2017
OI Cervinka, Miroslav/0000-0001-8602-4756; Rudolf, Emil/0000-0002-9526-3174
FU program PRVOUK [P37/01]
FX This work was supported by the program PRVOUK P37/01.
CR Bitomsky N, 2009, FEBS J, V276, P6074, DOI 10.1111/j.1742-4658.2009.07331.x
   Boya P, 2008, ONCOGENE, V27, P6434, DOI 10.1038/onc.2008.310
   Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497
   Das G., 2012, COLD SPRING HARB PER, V4, P25
   Gagne JF, 2002, MOL PHARMACOL, V62, P608, DOI 10.1124/mol.62.3.608
   Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899
   Humerickhouse R, 2000, CANCER RES, V60, P1189
   Kagedal K, 2005, INT J EXP PATHOL, V86, P309, DOI 10.1111/j.0959-9673.2005.00442.x
   Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054
   Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Li H, 2011, CANCER RES, V71, P3625, DOI 10.1158/0008-5472.CAN-10-4475
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001
   Morselli E, 2008, CELL CYCLE, V7, P3056, DOI 10.4161/cc.7.19.6751
   Nakatomi K, 2001, BIOCHEM BIOPH RES CO, V288, P827, DOI 10.1006/bbrc.2001.5850
   Ng G, 2005, MOL CARCINOGEN, V43, P183, DOI 10.1002/mc.20097
   O'Connell MJ, 2009, J CLIN ONCOL, V27, P3082, DOI 10.1200/JCO.2009.22.2919
   Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977
   Potter JD, 1999, JNCI-J NATL CANCER I, V91, P916, DOI 10.1093/jnci/91.11.916
   Pourahmad J, 2001, FREE RADICAL BIO MED, V30, P89, DOI 10.1016/S0891-5849(00)00450-0
   Roos WP, 2006, TRENDS MOL MED, V12, P440, DOI 10.1016/j.molmed.2006.07.007
   Rufini A, 2011, BIOCHEM BIOPH RES CO, V414, P445, DOI 10.1016/j.bbrc.2011.09.110
   Weekes J, 2009, WORLD J GASTROENTERO, V15, P3597, DOI 10.3748/wjg.15.3597
   Werneburg NW, 2007, J BIOL CHEM, V282, P28960, DOI 10.1074/jbc.M705671200
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Worthley DL, 2007, WORLD J GASTROENTERO, V13, P3784
NR 29
TC 4
Z9 5
U1 0
U2 21
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1871-5206
EI 1875-5992
J9 ANTI-CANCER AGENT ME
JI Anti-Cancer Agents Med. Chem.
PD JUN
PY 2013
VL 13
IS 5
BP 811
EP 820
DI 10.2174/1871520611313050015
PG 10
WC Oncology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 147TP
UT WOS:000319190500015
PM 22721392
DA 2022-04-25
ER

PT J
AU Shafabakhsh, R
   Arianfar, F
   Vosough, M
   Mirzaei, HR
   Mahjoubin-Tehran, M
   Khanbabaei, H
   Kowsari, H
   Shojaie, L
   Azar, MEF
   Hamblin, MR
   Mirzaei, H
AF Shafabakhsh, Rana
   Arianfar, Farzaneh
   Vosough, Massoud
   Mirzaei, Hamid Reza
   Mahjoubin-Tehran, Maryam
   Khanbabaei, Hashem
   Kowsari, Hamed
   Shojaie, Layla
   Azar, Maryam Ebadi Fard
   Hamblin, Michael R.
   Mirzaei, Hamed
TI Autophagy and gastrointestinal cancers: the behind the scenes role of
   long non-coding RNAs in initiation, progression, and treatment
   resistance
SO CANCER GENE THERAPY
LA English
DT Review
ID PROMOTES CELL-PROLIFERATION; COMPETING ENDOGENOUS RNA;
   HEPATOCELLULAR-CARCINOMA PROGRESSION; HNF1A-AS1 REGULATES PROLIFERATION;
   EPITHELIAL-MESENCHYMAL TRANSITION; ANTERIOR GRADIENT 2; GASTRIC-CANCER;
   COLORECTAL-CANCER; PANCREATIC-CANCER; POOR-PROGNOSIS
AB Gastrointestinal (GI) cancers comprise a heterogeneous group of complex disorders that affect different organs, including esophagus, stomach, gallbladder, liver, biliary tract, pancreas, small intestine, colon, rectum, and anus. Recently, an explosion in nucleic acid-based technologies has led to the discovery of long non-coding RNAs (lncRNAs) that have been found to possess unique regulatory functions. This class of RNAs is >200 nucleotides in length, and is characterized by their lack of protein coding. LncRNAs exert regulatory effects in GI cancer development by affecting different functions such as the proliferation and metastasis of cancer cells, apoptosis, glycolysis and angiogenesis. Over the past few decades, considerable evidence has revealed the important role of autophagy in both GI cancer progression and suppression. In addition, recent studies have confirmed a significant correlation between lncRNAs and the regulation of autophagy. In this review, we summarize how lncRNAs play a behind the scenes role in the pathogenesis of GI cancers through regulation of autophagy.
C1 [Shafabakhsh, Rana; Kowsari, Hamed; Mirzaei, Hamed] Kashan Univ Med Sci, Inst Basic Sci, Res Ctr Biochem & Nutr Metab Dis, Kashan, Iran.
   [Arianfar, Farzaneh] Shiraz Univ Med Sci, Sch Med, Dept Biochem, Shiraz, Iran.
   [Vosough, Massoud] ACECR, Royan Inst Stem Cell Biol & Technol, Cell Sci Res Ctr, Dept Stem Cells & Dev Biol, Tehran 1665659911, Iran.
   [Mirzaei, Hamid Reza] Univ Tehran Med Sci, Sch Med, Dept Med Immunol, Tehran, Iran.
   [Mahjoubin-Tehran, Maryam] Mashhad Univ Med Sci, Student Res Comm, Mashhad, Razavi Khorasan, Iran.
   [Mahjoubin-Tehran, Maryam] Mashhad Univ Med Sci, Fac Med, Dept Med Biotechnol, Mashhad, Razavi Khorasan, Iran.
   [Khanbabaei, Hashem] Ahvaz Jundishapur Univ Med Sci, Sch Med, Med Phys Dept, Ahvaz, Iran.
   [Shojaie, Layla] Univ Southern Calif, Keck Sch Med, Dept Med, Res Ctr Liver Dis, Los Angeles, CA 90007 USA.
   [Azar, Maryam Ebadi Fard] Iran Univ Med Sci, Student Res Comm, Tehran, Iran.
   [Hamblin, Michael R.] Univ Johannesburg, Fac Hlth Sci, Laser Res Ctr, ZA-2028 Doornfontein, South Africa.
RP Mirzaei, H (corresponding author), Kashan Univ Med Sci, Inst Basic Sci, Res Ctr Biochem & Nutr Metab Dis, Kashan, Iran.; Azar, MEF (corresponding author), Iran Univ Med Sci, Student Res Comm, Tehran, Iran.; Hamblin, MR (corresponding author), Univ Johannesburg, Fac Hlth Sci, Laser Res Ctr, ZA-2028 Doornfontein, South Africa.
EM maryam.e.f.azar@gmail.com; Hamblin.lab@gmail.com; mirzaei-h@kaums.ac.ir
RI Hamblin, Michael R/H-2758-2019; Vosough, Massoud/AAR-8970-2021; Mirzaei,
   Hamid Reza/I-4673-2019; Mirzaei, Hamed/X-2374-2018; Shojaie,
   Layla/AAV-8262-2020
OI Hamblin, Michael R/0000-0001-6431-4605; Vosough,
   Massoud/0000-0001-5924-4366; Mirzaei, Hamid Reza/0000-0002-3303-2565;
   Mirzaei, Hamed/0000-0002-9399-8281; Shojaie, Layla/0000-0002-5020-5181;
   Mahjoubin-Tehran, Maryam/0000-0001-5719-5345
CR Akerman I, 2017, CELL METAB, V25, P400, DOI 10.1016/j.cmet.2016.11.016
   Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Lizarbe MA, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/7354260
   Arab K, 2014, MOL CELL, V55, P604, DOI 10.1016/j.molcel.2014.06.031
   Arends JW, 2000, J PATHOL, V190, P412
   Avalos Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/603980
   Bai J, 2019, HUM CELL, V33, P1
   Bai YL, 2020, J CELL BIOCHEM, V121, P353, DOI 10.1002/jcb.29183
   Bao YJ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1925-2
   Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480
   Bermudez M, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01008
   Bester AC, 2018, CELL, V173, P649, DOI 10.1016/j.cell.2018.03.052
   Bhutia SK, 2013, ADV CANCER RES, V118, P61, DOI 10.1016/B978-0-12-407173-5.00003-0
   Bian ZH, 2016, SCI REP-UK, V6, DOI 10.1038/srep23892
   Blessing AM, 2017, AUTOPHAGY, V13, P506, DOI 10.1080/15548627.2016.1268300
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Bu Xiaoyun, 2019, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V44, P741, DOI 10.11817/j.issn.1672-7347.2019.190142
   Cai B, 2014, NEOPLASMA, V61, P379, DOI 10.4149/neo_2014_075
   Cao C, 2019, J CELL MOL MED, V23, P7342, DOI 10.1111/jcmm.14593
   Cao JN, 2014, BIOL PROCED ONLINE, V16, DOI 10.1186/1480-9222-16-11
   Cao SG, 2019, MOL THER-NUCL ACIDS, V17, P455, DOI 10.1016/j.omtn.2019.04.030
   Cao YJ, 2019, CLIN CHIM ACTA, V489, P10, DOI 10.1016/j.cca.2018.11.028
   Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10
   Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028
   Chang L, 2016, CANCER LETT, V383, P183, DOI 10.1016/j.canlet.2016.09.034
   Changyong E, 2019, CANCER MANAG RES, V11, P2871, DOI 10.2147/CMAR.S197979
   Chen CL, 2015, BIOMATERIALS, V44, P71, DOI 10.1016/j.biomaterials.2014.12.023
   Chen HY, 2011, CANCER PREV RES, V4, P973, DOI 10.1158/1940-6207.CAPR-10-0387
   Chen JF, 2018, MOL CANCER, V17, DOI 10.1186/s12943-017-0756-y
   Chen J, 2019, BIOMED PHARMACOTHER, V116, DOI 10.1016/j.biopha.2019.108966
   Chen Q, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1332-7
   Chen SY, 2019, BIOCHEM BIOPH RES CO, V519, P901, DOI 10.1016/j.bbrc.2019.09.091
   Chi JL, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109201
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Cicchini M, 2015, CLIN CANCER RES, V21, P498, DOI 10.1158/1078-0432.CCR-13-2438
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Coppola D, 2008, CANCER-AM CANCER SOC, V113, P2665, DOI 10.1002/cncr.23892
   CORY S, 1985, EMBO J, V4, P675, DOI 10.1002/j.1460-2075.1985.tb03682.x
   Cui K, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0922-y
   Cui M, 2015, CANCER RES, V75, P846, DOI 10.1158/0008-5472.CAN-14-1192
   Dahariya S, 2019, MOL IMMUNOL, V112, P82, DOI 10.1016/j.molimm.2019.04.011
   Dang Y, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0706-3
   Daskalaki I, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00104
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Deng PC, 2019, J CELL MOL MED, V23, P7222, DOI 10.1111/jcmm.14467
   Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111
   Dey BK, 2014, TRANSCR-AUSTIN, V5, DOI 10.4161/21541272.2014.944014
   Ding J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.328
   Dong SJ, 2019, BIOL OPEN, V8, DOI 10.1242/bio.041343
   Du YM, 2012, J BIOL CHEM, V287, P26302, DOI 10.1074/jbc.M112.342113
   Dumartin L, 2011, CANCER RES, V71, P7091, DOI 10.1158/0008-5472.CAN-11-1367
   Ebert MPA, 2012, NEW ENGL J MED, V366, P44, DOI 10.1056/NEJMoa1009473
   Faber C, 2009, VIRCHOWS ARCH, V454, P359, DOI 10.1007/s00428-009-0751-9
   Faghihi MA, 2009, NAT REV MOL CELL BIO, V10, P637, DOI 10.1038/nrm2738
   Fan JY, 2020, BIOCHEM BIOPH RES CO, V521, P196, DOI 10.1016/j.bbrc.2019.10.105
   Fan YH, 2017, CLIN CHIM ACTA, V466, P120, DOI 10.1016/j.cca.2017.01.016
   Fan Y, 2014, FEBS J, V281, P1750, DOI 10.1111/febs.12737
   Fang YW, 2016, GENOM PROTEOM BIOINF, V14, P42, DOI 10.1016/j.gpb.2015.09.006
   Fang Z, 2017, CANCER MED-US, V6, P2897, DOI 10.1002/cam4.1253
   Feng L, 2020, J CELL PHYSIOL, V235, P4388, DOI 10.1002/jcp.29315
   Fino KK, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07724-5
   Gan L, 2019, INT J ONCOL, V54, P2157, DOI 10.3892/ijo.2019.4773
   Gao H, 2019, CANCER BIOTHER RADIO, V34, P666, DOI 10.1089/cbr.2019.2904
   Gao JZ, 2016, ONCOL LETT, V11, P1791, DOI 10.3892/ol.2016.4130
   Gao Y, 2020, WORLD J GASTROENTERO, V26, P3401, DOI 10.3748/wjg.v26.i24.3401
   Ghiam AF, 2017, ONCOTARGET, V8, P4668, DOI 10.18632/oncotarget.13576
   Gu J, 2018, CANCER LETT, V434, P1, DOI 10.1016/j.canlet.2018.06.039
   Guo JB, 2019, J CELL BIOCHEM, V120, P17975, DOI 10.1002/jcb.29064
   Guo JB, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0879-x
   Guo YM, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109255
   Gupta PK, 2019, MAT SCI ENG C-MATER, V101, P448, DOI 10.1016/j.msec.2019.03.041
   Hammerle M, 2013, HEPATOLOGY, V58, P1703, DOI 10.1002/hep.26537
   Han P, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0583-1
   Han YY, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12678
   He SS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8839
   He XY, 2019, EUR REV MED PHARMACO, V23, P5762, DOI 10.26355/eurrev_201907_18314
   He XQ, 2017, ONCOTARGET, V8, P9451, DOI 10.18632/oncotarget.14276
   Hesari A, 2019, INT J CANCER, V144, P1215, DOI 10.1002/ijc.31947
   Higa A, 2011, J BIOL CHEM, V286, P44855, DOI 10.1074/jbc.M111.275529
   Hsu CL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03340-7
   Hu B, 2019, AM J TRANSL RES, V11, P3238
   Hu JH, 2019, ONCOTARGETS THER, V12, P7865, DOI 10.2147/OTT.S189471
   Hu XH, 2019, CANCER MANAG RES, V11, P8789, DOI 10.2147/CMAR.S216774
   Hu YR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0743-3
   Hu YJ, 2012, TUMOR BIOL, V33, P1863, DOI 10.1007/s13277-012-0446-8
   Hua YQ, 2019, AGING-US, V11, P8860, DOI 10.18632/aging.102307
   Huang C, 2015, MINERVA MED, V106, P143
   Huang F, 2018, WORLD J GASTROENTERO, V24, P4643, DOI 10.3748/wjg.v24.i41.4643
   Huang FT, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0845-6
   Huang HS, 2019, ONCOL LETT, V18, P3331, DOI 10.3892/ol.2019.10671
   Huang YK, 2015, WORLD J GASTROENTERO, V21, P9863, DOI 10.3748/wjg.v21.i34.9863
   Huang Z, 2016, INT J CANCER, V139, P23, DOI 10.1002/ijc.29990
   Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981
   Hurley JH, 2017, ANNU REV BIOCHEM, V86, P225, DOI 10.1146/annurev-biochem-061516-044820
   Ip JY, 2012, DEV GROWTH DIFFER, V54, P44, DOI 10.1111/j.1440-169X.2011.01303.x
   Islam F, 2017, EXP CELL RES, V357, P260, DOI 10.1016/j.yexcr.2017.05.021
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Jia M, 2016, HEPATOL RES, V46, P1137, DOI 10.1111/hepr.12659
   Jiang CM, 2018, BIOMED PHARMACOTHER, V97, P844, DOI 10.1016/j.biopha.2017.10.146
   Jiang H, 2019, ONCOTARGETS THER, V12, P7429, DOI 10.2147/OTT.S214336
   Jiang XJ, 2015, J CLIN INVEST, V125, P47, DOI 10.1172/JCI73942
   Jiao F, 2015, INT J MOL SCI, V16, P6677, DOI 10.3390/ijms16046677
   Jiao F, 2014, ONCOL REP, V32, P2485, DOI 10.3892/or.2014.3518
   Jiao JQ, 2019, MOL MED REP, V20, P2685, DOI 10.3892/mmr.2019.10515
   Jin X, 2019, ONCOL LETT, V18, P1218, DOI 10.3892/ol.2019.10416
   Jones DZ, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4258-0
   Kam Y, 2014, CANCER LETT, V352, P90, DOI 10.1016/j.canlet.2013.02.014
   Kardideh B, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-019-0327-6
   Katheder NS, 2017, NATURE, V541, P417, DOI 10.1038/nature20815
   Khan MZI, 2019, FRONT GENET, V9, DOI 10.3389/fgene.2018.00750
   Khorkova O, 2014, HUM MOL GENET, V23, pR54, DOI 10.1093/hmg/ddu207
   Kim K, 2013, ONCOGENE, V32, P1616, DOI 10.1038/onc.2012.193
   Kim KH, 2014, NAT REV ENDOCRINOL, V10, P322, DOI 10.1038/nrendo.2014.35
   Kim MS, 2008, HUM PATHOL, V39, P1059, DOI 10.1016/j.humpath.2007.11.013
   Kim SH, 2018, YONSEI MED J, V59, P588, DOI 10.3349/ymj.2018.59.5.588
   Kong R, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0355-8
   Krishna M, 2018, J CANC THERAPY, V9, P281, DOI [10.4236/jct.2018.93026, DOI 10.4236/JCT.2018.93026]
   Ktistakis NT, 2016, TRENDS CELL BIOL, V26, P624, DOI 10.1016/j.tcb.2016.03.006
   Kung CP, 2011, CRIT REV EUKAR GENE, V21, P71, DOI 10.1615/CritRevEukarGeneExpr.v21.i1.50
   Lan T, 2017, TUMOR BIOL, V39, P1, DOI 10.1177/1010428317705338
   Lee MS, 2018, MOL CELLS, V41, P1, DOI 10.14348/molcells.2018.0400
   Li CG, 2016, CANCER CHEMOTH PHARM, V78, P1199, DOI 10.1007/s00280-016-3178-4
   Li CY, 2019, CANCER MED-US, V8, P4428, DOI 10.1002/cam4.2165
   Li H, 2017, ONCOTARGET, V8, P39859, DOI 10.18632/oncotarget.16339
   Li JL, 2018, ARCH BIOCHEM BIOPHYS, V640, P53, DOI 10.1016/j.abb.2018.01.002
   Li L, 2019, HUM CELL, V32, P495, DOI 10.1007/s13577-019-00277-x
   Li MW, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.02420
   Li T, 2016, ONCOGENE, V35, P1575, DOI 10.1038/onc.2015.223
   Li XY, 2020, J CELL PHYSIOL, V235, P3402, DOI 10.1002/jcp.29230
   Li Y, 2018, LIFE SCI, V208, P295, DOI 10.1016/j.lfs.2018.07.032
   Li YF, 2019, J CELL BIOCHEM, V120, P19457, DOI 10.1002/jcb.29239
   Li ZM, 2018, CELL PHYSIOL BIOCHEM, V49, P463, DOI 10.1159/000492986
   Li ZK, 2014, CANCER SCI, V105, P951, DOI 10.1111/cas.12461
   Liang CJ, 2019, MOL THER-NUCL ACIDS, V18, P183, DOI 10.1016/j.omtn.2019.08.009
   Liang R, 2018, BIOMED PHARMACOTHER, V107, P1434, DOI 10.1016/j.biopha.2018.08.099
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Ling H, 2013, GENOME RES, V23, P1446, DOI 10.1101/gr.152942.112
   Ling J, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1174-3
   Lipinski MM, 2010, DEV CELL, V18, P1041, DOI 10.1016/j.devcel.2010.05.005
   Liu EY, 2012, J CELL SCI, V125, P2349, DOI 10.1242/jcs.093708
   Liu HY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168406
   Liu JH, 2014, ASIAN PAC J CANCER P, V15, P2971, DOI 10.7314/APJCP.2014.15.7.2971
   Liu LL, 2017, ONCOTARGET, V8, P13666, DOI 10.18632/oncotarget.14623
   Liu MJ, 2018, CANCER SCI, V109, P3055, DOI 10.1111/cas.13746
   Liu ML, 2018, WORLD J GASTROENTERO, V24, P1004, DOI 10.3748/wjg.v24.i9.1004
   Liu RT, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20160532
   Liu T, 2016, ONCOTARGETS THER, V9, P1437, DOI 10.2147/OTT.S98268
   Liu XW, 2016, NAT CELL BIOL, V18, P431, DOI 10.1038/ncb3328
   Liu YW, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.150
   Liu Y, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000041
   Liu Y, 2019, WORLD J GASTROENTERO, V25, P2763, DOI 10.3748/wjg.v25.i22.2763
   Liu Z, 2017, MOL NEUROBIOL, V54, P7762, DOI 10.1007/s12035-016-0249-9
   Liu Z, 2019, BRAZ J MED BIOL RES, V52, DOI [10.1590/1414-431X20198631, 10.1590/1414-431x20198631]
   Liu ZC, 2019, DNA CELL BIOL, V38, P1366, DOI 10.1089/dna.2019.4882
   Liu ZQ, 2016, BIOCHEM BIOPH RES CO, V473, P1268, DOI 10.1016/j.bbrc.2016.04.054
   Lou CJ, 2020, J CELL PHYSIOL, V235, P3928, DOI 10.1002/jcp.29288
   Lu ZP, 2016, ONCOTARGET, V7, P241, DOI 10.18632/oncotarget.6280
   Luo KL, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1263-3
   Luo T, 2016, AUTOPHAGY, V12, P1355, DOI 10.1080/15548627.2015.1034405
   Luo X, 2019, FEBS OPEN BIO, V9, P18, DOI 10.1002/2211-5463.12553
   Ma C, 2019, BIOCHEM BIOPH RES CO, V518, P325, DOI 10.1016/j.bbrc.2019.08.057
   Ma JX, 2019, EUR REV MED PHARMACO, V23, P4756, DOI 10.26355/eurrev_201906_18057
   Ma MZ, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.541
   Ma YL, 2016, GUT, V65, P1494, DOI 10.1136/gutjnl-2014-308392
   Ma YB, 2019, ANTI-CANCER DRUG, V30, P1013, DOI 10.1097/CAD.0000000000000807
   Ma Y, 2019, ONCOL LETT, V18, P2212, DOI 10.3892/ol.2019.10551
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Maes H, 2013, TRENDS MOL MED, V19, P428, DOI 10.1016/j.molmed.2013.04.005
   Malek E, 2014, ONCOTARGET, V5, P8027, DOI 10.18632/oncotarget.2469
   Mans LA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07116-9
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Matouk IJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000845
   Mei DY, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0709-2
   Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Mo YC, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317690999
   Mohtar MA, 2018, MOL CELL PROTEOMICS, V17, P737, DOI 10.1074/mcp.RA118.000573
   Moran I, 2012, CELL METAB, V16, P435, DOI 10.1016/j.cmet.2012.08.010
   Morlando M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020570
   Morselli E, 2009, BBA-MOL CELL RES, V1793, P1524, DOI 10.1016/j.bbamcr.2009.01.006
   Mowers EE, 2017, ONCOGENE, V36, P1619, DOI 10.1038/onc.2016.333
   Mowers EE, 2016, AUTOPHAGY, V12, P1679, DOI 10.1080/15548627.2016.1203487
   Muller S, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0358-5
   Naeli P, 2020, CRIT REV ONCOL HEMAT, V145, DOI 10.1016/j.critrevonc.2019.102854
   Nagar R, 2017, INDIAN J DERMATOL VE, V83, P290, DOI 10.4103/0378-6323.196320
   Nishida N, 2016, DIGEST DIS, V34, P708, DOI 10.1159/000448863
   Ouyang H, 2019, EXP THER MED, V18, P2547, DOI 10.3892/etm.2019.7850
   Ozes AR, 2016, ONCOGENE, V35, P5350, DOI 10.1038/onc.2016.75
   Pan B, 2018, EXP HEMATOL, V68, P80, DOI 10.1016/j.exphem.2018.09.001
   Pang EJ, 2015, TUMOR BIOL, V36, P2403, DOI 10.1007/s13277-014-2850-8
   Pang WF, 2019, CANCER MANAG RES, V11, P7263, DOI 10.2147/CMAR.S211856
   Paolini A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27429-7
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Peng Wei, 2019, Pathol Oncol Res, V25, P883, DOI 10.1007/s12253-017-0367-3
   Peng W, 2016, BIOMED PHARMACOTHER, V83, P450, DOI 10.1016/j.biopha.2016.06.056
   Peng XC, 2020, J CELL BIOCHEM, V121, P1953, DOI 10.1002/jcb.29430
   Peng YJ, 2019, BMC MICROBIOL, V19, DOI 10.1186/s12866-019-1491-x
   Du PD, 2019, J NANOMATER, V2019, DOI 10.1155/2019/6061275
   Pourhanifeh MH, 2014, NATURE, V513, P202, DOI [10.1038/nature13480, DOI 10.1038/NATURE13480]
   Pourhoseingholi Mohamad Amin, 2015, Gastroenterol Hepatol Bed Bench, V8, P19
   Pu J, 2019, AM J TRANSL RES, V11, P5897
   Qin Q., 2019, IEEE T SMART GRID, P1
   Qin Y, 2019, J CELL BIOCHEM, V120, P17926, DOI 10.1002/jcb.29060
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Ragusa M, 2015, WORLD J GASTROENTERO, V21, P11709, DOI 10.3748/wjg.v21.i41.11709
   Ramachandran V, 2008, CANCER RES, V68, P7811, DOI 10.1158/0008-5472.CAN-08-1320
   Rebucci M, 2013, BIOCHEM PHARMACOL, V85, P1219, DOI 10.1016/j.bcp.2013.02.017
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Rosenfeldt MT, 2011, CARCINOGENESIS, V32, P955, DOI 10.1093/carcin/bgr031
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014
   Samuels Y, 2004, CELL CYCLE, V3, P1221, DOI 10.4161/cc.3.10.1164
   Santana-Codina N, 2017, NAT REV CANCER, V7, P961
   Shabaninejad Z, 2019, J OVARIAN RES, V12, DOI 10.1186/s13048-019-0558-5
   Shabaninejad Z, 2019, ANAL BIOCHEM, V581, DOI 10.1016/j.ab.2019.113349
   Shah MA, 2015, J CLIN ONCOL, V33, P1760, DOI 10.1200/JCO.2014.60.1799
   Shan TD, 2016, ONCOTARGET, V7, P961, DOI 10.18632/oncotarget.5830
   Shan Y, 2019, YONSEI MED J, V60, P842, DOI 10.3349/ymj.2019.60.9.842
   Shen J, 2019, INT J BIOCHEM CELL B, V113, P17, DOI 10.1016/j.biocel.2019.05.021
   Shen Y, 2008, AUTOPHAGY, V4, P1067, DOI 10.4161/auto.6827
   Shi DB, 2017, BIOMED PHARMACOTHER, V85, P355, DOI 10.1016/j.biopha.2016.11.036
   Shi YY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122109
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Song FL, 2019, J CELL PHYSIOL, V234, P7420, DOI 10.1002/jcp.27500
   Song HJ, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-225
   Song W, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0857-3
   Song W, 2019, CELL CYCLE, V18, P3177, DOI 10.1080/15384101.2019.1671089
   Stratford JK, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000307
   Su DN, 2016, ONCOL LETT, V12, P4061, DOI 10.3892/ol.2016.5127
   Su M, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0663-8
   Su XH, 2019, ONCOTARGETS THER, V12, P8117, DOI 10.2147/OTT.S208133
   Su ZY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0321-5
   Sun JM, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190332
   Sun L, 2013, STEM CELLS, V31, P1454, DOI 10.1002/stem.1394
   Sun LT, 2019, ONCOL LETT, V17, P4957, DOI 10.3892/ol.2019.10176
   Sun M, 2016, CANCER RES, V76, P6299, DOI 10.1158/0008-5472.CAN-16-0356
   Sun Q, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12687
   Sun WL, 2016, ONCOL LETT, V12, P367, DOI 10.3892/ol.2016.4644
   Sun WL, 2013, TUMOR BIOL, V34, P2697, DOI 10.1007/s13277-013-0821-0
   Taby R, 2010, CA-CANCER J CLIN, V60, P376, DOI 10.3322/caac.20085
   Takahashi Y, 2014, Br J Cancer, V110, P164, DOI 10.1038/bjc.2013.698
   Takahashi Y, 2013, AUTOPHAGY, V9, P1107, DOI 10.4161/auto.24817
   Takahashi Y, 2013, BLOOD, V121, P1622, DOI 10.1182/blood-2012-10-459826
   Tan P, 2015, GASTROENTEROLOGY, V149, P1153, DOI 10.1053/j.gastro.2015.05.059
   Tang XH, 2019, YONSEI MED J, V60, P319, DOI 10.3349/ymj.2019.60.4.319
   Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986
   Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311
   Vafadar A, 2019, CURR PHARM DESIGN, V25, P3563, DOI 10.2174/1381612825666190830161528
   Wahlestedt C, 2013, NAT REV DRUG DISCOV, V12, P433, DOI 10.1038/nrd4018
   Wan WB, 2019, EUR REV MED PHARMACO, V23, P6453, DOI 10.26355/eurrev_201908_18528
   Wang AH, 2019, EUR REV MED PHARMACO, V23, P8310, DOI 10.26355/eurrev_201910_19142
   Wang CJ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1032-0
   Wang CY, 2015, INT J CLIN EXP PATHO, V8, P779
   Wang CZ, 2019, WORLD J GASTROENTERO, V25, P5310, DOI 10.3748/wjg.v25.i35.5310
   Wang CY, 2019, J CELL BIOCHEM, V120, P357, DOI 10.1002/jcb.27387
   Wang FZ, 2019, EUR REV MED PHARMACO, V23, P6899, DOI 10.26355/eurrev_201908_18729
   Wang F, 2014, HEPATOLOGY, V60, P1278, DOI 10.1002/hep.27239
   Wang FQ, 2016, CELL PHYSIOL BIOCHEM, V40, P287, DOI 10.1159/000452545
   Wang GC, 2015, AM J CANCER RES, V5, P3162
   Wang HY, 2019, AGING-US, V11, P6657, DOI 10.18632/aging.102164
   Wang HY, 2017, CELL PHYSIOL BIOCHEM, V41, P2221, DOI 10.1159/000475637
   Wang JL, 2019, IRAN J VET RES, V20, P199
   Wang JY, 2010, NUCLEIC ACIDS RES, V38, P5366, DOI 10.1093/nar/gkq285
   Wang J, 2015, INT J MOL SCI, V16, P19886, DOI 10.3390/ijms160819886
   Wang M, 2019, J CANCER, V10, P4603, DOI 10.7150/jca.32065
   Wang P, 2013, GASTROENTEROLOGY, V145, P1133, DOI 10.1053/j.gastro.2013.07.048
   Wang SH, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1220-2
   Wang SY, 2017, J PHARMACOL SCI, V134, P197, DOI 10.1016/j.jphs.2017.07.001
   Wang TH, 2016, ONCOTARGET, V7, P43588, DOI 10.18632/oncotarget.9635
   Wang W, 2019, WORLD J GASTROENTERO, V25, P3972, DOI 10.3748/wjg.v25.i29.3972
   Wang WL, 2019, AGING-US, V11, P2610, DOI 10.18632/aging.101933
   Wang WG, 2003, BMC BIOTECHNOL, V3, DOI 10.1186/1472-6750-3-13
   Wang X, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.26
   Wang XS, 2006, CLIN CANCER RES, V12, P4851, DOI 10.1158/1078-0432.CCR-06-0134
   Wang XK, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0951-6
   Wang XK, 2019, INT J MED SCI, V16, P51, DOI 10.7150/ijms.27359
   Wang Y, 2019, EUR REV MED PHARMACO, V23, P7350, DOI 10.26355/eurrev_201909_18841
   Wang YY, 2015, CELL STEM CELL, V16, P413, DOI 10.1016/j.stem.2015.03.003
   Wang YX, 2015, ONCOTARGET, V6, P35684, DOI 10.18632/oncotarget.5533
   Wang YJ, 2016, AM J CANCER RES, V6, P2651
   Wang YG, 2016, FASEB J, V30, P3133, DOI 10.1096/fj.201500058R
   Wang ZK, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414-431X20176793, 10.1590/1414-431x20176793]
   Wei HM, 2019, INT IMMUNOPHARMACOL, V73, P72, DOI 10.1016/j.intimp.2019.04.049
   Wei L, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01185-7
   Wen JJ, 2017, EUR REV MED PHARMACO, V21, P498
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Wolpin BM, 2014, NAT GENET, V46, P994, DOI 10.1038/ng.3052
   Wu H, 2017, TRENDS GENET, V33, P540, DOI 10.1016/j.tig.2017.05.004
   Wu W, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0059749, 10.1371/journal.pone.0059016]
   Wu XB, 2019, AM J TRANSL RES, V11, P5740
   Wu Y, 2015, ONCOTARGET, V6, P9160, DOI 10.18632/oncotarget.3247
   Xia TF, 2019, EUR REV MED PHARMACO, V23, P6914, DOI 10.26355/eurrev_201908_18731
   Xiao BX, 2013, TUMOR BIOL, V34, P3271, DOI 10.1007/s13277-013-0916-7
   Xiao HZ, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00321
   Xiao J, 2019, CANCER MED-US, V8, P6768, DOI 10.1002/cam4.1302
   Xie X, 2016, ONCOTARGET, V7, P5226, DOI 10.18632/oncotarget.6446
   Xin L, 2019, J CANCER RES CLIN, V145, P2507, DOI 10.1007/s00432-019-03015-w
   Xiong DM, 2016, ONCOTARGET, V7, P47593, DOI 10.18632/oncotarget.10250
   Xiong GB, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0777-7
   Xiong H, 2017, ONCOGENE, V36, P3528, DOI 10.1038/onc.2016.521
   Xiu YL, 2017, ONCOTARGET, V8, P31727, DOI 10.18632/oncotarget.15955
   Xu CG, 2016, EUR REV MED PHARMACO, V20, P4362
   Xu J, 2019, CANCER RES, V79, P4882, DOI 10.1158/0008-5472.CAN-18-3880
   Xu MD, 2017, CLIN CANCER RES, V23, P2071, DOI 10.1158/1078-0432.CCR-16-0742
   Xu MD, 2014, MODERN PATHOL, V27, P1310, DOI 10.1038/modpathol.2014.33
   Xu M, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-018-0690-5
   Xu ZJ, 2017, ONCOL REP, V37, P1359, DOI 10.3892/or.2017.5416
   Xuan Y, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1940-3
   Xue JF, 2018, CANCER BIOMARK, V21, P849, DOI 10.3233/CBM-170780
   Xue XF, 2018, CANCER LETT, V412, P170, DOI 10.1016/j.canlet.2017.10.024
   Yan K, 2017, CELL PHYSIOL BIOCHEM, V42, P999, DOI 10.1159/000478682
   Yan PH, 2019, EUR REV MED PHARMACO, V23, P8287, DOI 10.26355/eurrev_201910_19139
   Yang C, 2012, GENE, V496, P8, DOI 10.1016/j.gene.2012.01.012
   Yang F, 2013, J CANCER RES CLIN, V139, P437, DOI 10.1007/s00432-012-1324-x
   Yang F, 2012, FEBS J, V279, P3159, DOI 10.1111/j.1742-4658.2012.08694.x
   Yang H, 2013, BIOCHEM PHARMACOL, V85, P1761, DOI 10.1016/j.bcp.2013.04.020
   Yang JY, 2019, CANCER MANAG RES, V11, P4209, DOI 10.2147/CMAR.S194453
   Yang L, 2019, GENE, V697, P94, DOI 10.1016/j.gene.2019.02.036
   Yang L, 2016, MOL BIOSYST, V12, P2605, DOI 10.1039/c6mb00114a
   Yang LX, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.464
   Yang X, 2014, GUT, V63, P881, DOI 10.1136/gutjnl-2013-305266
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Ye LC, 2015, ONCOL LETT, V9, P1039, DOI 10.3892/ol.2015.2846
   Ying L, 2012, MOL BIOSYST, V8, P2289, DOI 10.1039/c2mb25070e
   Yoon JH, 2014, SEMIN CELL DEV BIOL, V34, P9, DOI 10.1016/j.semcdb.2014.05.015
   You L, 2011, BIOCHEM BIOPH RES CO, V407, P1, DOI 10.1016/j.bbrc.2011.02.027
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Yu Y, 2018, EUR REV MED PHARMACO, V22, P4812, DOI 10.26355/eurrev_201808_15616
   Yu ZY, 2018, ONCOL LETT, V15, P3127, DOI 10.3892/ol.2017.7677
   Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010
   Yuan ZX, 2016, INT J ONCOL, V48, P2675, DOI 10.3892/ijo.2016.3447
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
   Zeng T, 2015, FRONT BIOSCI-LANDMRK, V20, P1104, DOI 10.2741/4362
   Zeng X, 2019, CANCER MANAG RES, V11, P6981, DOI 10.2147/CMAR.S208983
   Zeng Z, 2019, THERANOSTICS, V9, P5298, DOI 10.7150/thno.34559
   Zhang C, 2019, ONCOTARGETS THER, V12, P7949, DOI 10.2147/OTT.S222903
   Zhang F, 2019, J CELL PHYSIOL, V234, P18626, DOI 10.1002/jcp.28501
   Zhang H, 2019, DNA CELL BIOL, V38, P857, DOI 10.1089/dna.2019.4770
   Zhang HW, 2019, AGING-US, V11, P9111, DOI 10.18632/aging.102378
   Zhang JJ, 2019, EUR REV MED PHARMACO, V23, P8321, DOI 10.26355/eurrev_201910_19143
   Zhang JY, 2016, INT J ONCOL, V48, P1590, DOI 10.3892/ijo.2016.3385
   Zhang L, 2016, J HAZARD MATER, V320, P187, DOI 10.1016/j.jhazmat.2016.08.020
   Zhang L, 2015, NATURE, V527, P100, DOI 10.1038/nature15376
   Zhang PG, 2020, HUM CELL, V33, P123, DOI 10.1007/s13577-019-00290-0
   Zhang W, 2018, BIOCHIMIE, V144, P21, DOI 10.1016/j.biochi.2017.10.002
   Zhang YF, 2019, CANCER SCI, V110, P2760, DOI 10.1111/cas.14136
   Zhang ZY, 2016, CANCER LETT, V376, P62, DOI 10.1016/j.canlet.2016.03.022
   Zhang ZY, 2018, ONCOL REP, V39, P2101, DOI 10.3892/or.2018.6296
   Zhao B, 2019, AM J TRANSL RES, V11, P5978
   Zhao HF, 2020, J CELL BIOCHEM, V121, P1690, DOI 10.1002/jcb.29404
   Zhao Q, 2019, TOHOKU J EXP MED, V249, P43, DOI 10.1620/tjem.249.43
   Zhao W, 2017, CLIN TRANSL ONCOL, V19, P735, DOI 10.1007/s12094-016-1597-7
   Zhao Y, 2014, ONCOL REP, V31, P358, DOI 10.3892/or.2013.2850
   Zheng J, 2019, ONCOGENE, V38, P7073, DOI 10.1038/s41388-019-0934-z
   Zheng SL, 2007, JNCI-J NATL CANCER I, V99, P1525, DOI 10.1093/jnci/djm169
   Zheng S, 2019, AM J TRANSL RES, V11, P5869
   Zhong YC, 2019, PHYSIOL GENOMICS, V51, P500, DOI 10.1152/physiolgenomics.00019.2019
   Zhou CH, 2019, CANCER BIOMARK, V26, P393, DOI 10.3233/CBM-190497
   Zhou HY, 2016, CANCER BIOMARK, V17, P1, DOI 10.3233/CBM-160613
   Zhou Q, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5936-2
   Zhou RJ, 2019, J CLIN LAB ANAL, V33, DOI 10.1002/jcla.22962
   Zhou TC, 2020, INT J BIOCHEM CELL B, V118, DOI 10.1016/j.biocel.2019.105637
   Zhou WY, 2019, J CELL PHYSIOL, V234, P23176, DOI 10.1002/jcp.28884
   Zhou WJ, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1126-1
   Zhu KX, 2019, ONCOL LETT, V17, P5335, DOI 10.3892/ol.2019.10253
   Zhu LY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1585-2
   Zhu Q, 2017, FEBS J, V284, P2856, DOI 10.1111/febs.14155
   Zhu XQ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0544-0
   Zhu YY, 2019, IEEE WRK SIG PRO SYS, P1, DOI 10.1109/SiPS47522.2019.9020522
   Zhuang LK, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.100
   Zhuo CJ, 2017, ONCOTARGET, V8, P1429, DOI 10.18632/oncotarget.13637
   Zong W, 2020, GASTRIC CANCER, V23, P228, DOI 10.1007/s10120-019-00998-w
NR 378
TC 18
Z9 18
U1 6
U2 8
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0929-1903
EI 1476-5500
J9 CANCER GENE THER
JI Cancer Gene Ther.
PD DEC
PY 2021
VL 28
IS 12
BP 1229
EP 1255
DI 10.1038/s41417-020-00272-7
EA JAN 2021
PG 27
WC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
   Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
   Research & Experimental Medicine
GA XG6LD
UT WOS:000607045900001
PM 33432087
OA hybrid
HC Y
HP N
DA 2022-04-25
ER

PT J
AU Zhang, SL
   Hu, B
   You, Y
   Yang, ZW
   Liu, LX
   Tang, HH
   Bao, WL
   Guan, YY
   Shen, XY
AF Zhang, Sulin
   Hu, Bin
   You, Yan
   Yang, Zhiwen
   Liu, Lixin
   Tang, Huanhuan
   Bao, Weilian
   Guan, Yunyun
   Shen, Xiaoyan
TI Sorting nexin 10 acts as a tumor suppressor in tumorigenesis and
   progression of colorectal cancer through regulating chaperone mediated
   autophagy degradation of p21(Cip1/WAF1)
SO CANCER LETTERS
LA English
DT Article
DE SNX10; Chaperone-mediated autophagy; Colorectal cancer; p21(Cip1/WAF1)
ID COLON-CANCER; LYSOSOME; CELLS; CARCINOGENESIS; INFLAMMATION; PREVENTION;
   PROTEINS; RECEPTOR; COLITIS; DISEASE
AB Chaperone-mediated autophagy (CMA) characterized by the selective degradation of target proteins has been linked with tumorigenesis in recent years. Here, we explored the function of sorting nexin 10 (SNX10), a protein involved in maintaining endosome/lysosome homeostasis, in mediating CMA activity and its impact on the progression of mouse inflammation-driven colorectal cancer. Our results revealed that SNX10 deficiency increased the activation of CMA by preventing the degradation of lysosomal LAMP-2A. In SNX10 KO cells, we disclosed that p21(Cip1/WAF1). a master effector in various tumor suppressor pathways, is a substrate of CMA, and decrease of p21(Cip1/WAF1) caused by SNX10-mediated CMA activation contributes to HCT116 cell proliferation and survival. Moreover, we found that SNX10 KO promoted tumorigenesis in the mouse colorectum which could be restored by SNX10 over-expression. Furthermore, SNX10 was remarkably down-regulated in. human CRC tissues which showed the increased activity of CMA and decreased expression of p21(Cip1/lWAF1). These findings suggest that SNX10 acts as a tumor suppressor in the mouse colorectum and drives inflammation-associated colorectal cancer by a chaperone-mediated autophagy mechanism. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Zhang, Sulin; Hu, Bin; You, Yan; Liu, Lixin; Tang, Huanhuan; Bao, Weilian; Guan, Yunyun; Shen, Xiaoyan] Fudan Univ, Sch Pharm, Dept Pharmacol, 826 Zhangheng Rd, Shanghai 201203, Peoples R China.
   [Yang, Zhiwen] Shanghai Jiao Tong Univ, Affiliated Shanghai Peoples Hosp 1, Songjiang Hosp, Dept Pharm, Shanghai, Peoples R China.
RP Shen, XY (corresponding author), Fudan Univ, Sch Pharm, Dept Pharmacol, 826 Zhangheng Rd, Shanghai 201203, Peoples R China.
EM shxiaoy@fudan.edu.cn
RI Bao, Weilian/AAU-5822-2021
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81773744, 81573441, 81371923, 81173056]
FX This study was supported by the National Natural Science Foundation of
   China (No. 81773744, 81573441, 81371923, and 81173056).
CR Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657
   Abdulamir A. S., 2008, AM J IMMUNOL, V4, P14
   ALI A, 2011, PLOS ONE, V0006
   Cervantes-Anaya N, 2017, TUMOR BIOL, V39, DOI [10.1177/1010428317695932, 10.1177/1010428317732181]
   Chen YQ, 2012, CELL RES, V22, P333, DOI 10.1038/cr.2011.134
   Ciechanover A, 2005, CELL DEATH DIFFER, V12, P1178, DOI 10.1038/sj.cdd.4401692
   Cuervo AM, 2000, TRAFFIC, V1, P570, DOI 10.1034/j.1600-0854.2000.010707.x
   Cuervo AM, 2003, EMBO J, V22, P47, DOI 10.1093/emboj/cdg002
   Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501
   Cullen PJ, 2012, NAT CELL BIOL, V14, P29, DOI 10.1038/ncb2374
   Dice JF, 2007, AUTOPHAGY, V3, P295, DOI 10.4161/auto.4144
   DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8
   Eskelinen Eeva-Liisa, 2006, Molecular Aspects of Medicine, V27, P495, DOI 10.1016/j.mam.2006.08.005
   Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235
   Gerber MM, 2015, INT J CANCER, V137, P2323, DOI 10.1002/ijc.29599
   Guo WJ, 2014, AUTOPHAGY, V10, P972, DOI 10.4161/auto.28374
   Jackson RJ, 2003, CANCER RES, V63, P3021
   Kaushik S, 2008, MOL BIOL CELL, V19, P2179, DOI 10.1091/mbc.E07-11-1155
   Kaushik S, 2012, TRENDS CELL BIOL, V22, P407, DOI 10.1016/j.tcb.2012.05.006
   Kon M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003182
   Kreis NN, 2015, ONCOGENE, V34, P1758, DOI 10.1038/onc.2014.133
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025
   Massey A, 2004, INT J BIOCHEM CELL B, V36, P2420, DOI 10.1016/j.biocel.2004.04.010
   Massey AC, 2006, P NATL ACAD SCI USA, V103, P5805, DOI 10.1073/pnas.0507436103
   Neufert C, 2007, NAT PROTOC, V2, P1998, DOI 10.1038/nprot.2007.279
   Pancione Massimo, 2012, Patholog Res Int, V2012, P509348, DOI 10.1155/2012/509348
   Qin BM, 2006, J BIOL CHEM, V281, P36891, DOI 10.1074/jbc.M608884200
   Quintavalle C, 2014, J CELL PHYSIOL, V229, P1359, DOI 10.1002/jcp.24569
   Saha T, 2012, AUTOPHAGY, V8, P1643, DOI 10.4161/auto.21654
   Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9
   Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003
   Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Triantafillidis JK, 2009, ANTICANCER RES, V29, P2727
   Warfel NA, 2013, CURR OPIN ONCOL, V25, P52, DOI 10.1097/CCO.0b013e32835b639e
   Worby CA, 2002, NAT REV MOL CELL BIO, V3, P919, DOI 10.1038/nrm974
   Ye L, 2013, IBMS BONEKEY, V2013, P421
   You Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep20630
   Zhou C, 2013, NEUROSCIENCE, V254, P361, DOI 10.1016/j.neuroscience.2013.09.045
   Zhou JF, 2016, AUTOPHAGY, V12, P515, DOI 10.1080/15548627.2015.1136770
NR 41
TC 18
Z9 18
U1 1
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PY 2018
VL 419
BP 116
EP 127
DI 10.1016/j.canlet.2018.01.045
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FY8GN
UT WOS:000427102300013
PM 29355659
DA 2022-04-25
ER

PT J
AU Yang, F
   Sun, SY
   Yang, F
AF Yang, Fan
   Sun, Siyu
   Yang, Fei
TI Prognostic and Predicted Significance of FENDRR in Colon and Rectum
   Adenocarcinoma
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE colon and rectum adenocarcinoma; LncRNA; FENDRR; TCGA database;
   biomarker
ID COLORECTAL-CANCER; LNCRNA
AB Background The role of fetal-lethal non-coding developmental regulatory RNA (FENDRR) has been explored in various cancers; however, its relationship with colon adenocarcinoma/rectum adenocarcinoma (COAD/READ) remains unclear. The objectives of this study were to identify and assess any associations between FENDRR and COAD/READ using The Cancer Genome Atlas (TCGA) database and the Genetic Data Commons (GDC) Data Portal.
   Methods The records of patients with COAD/READ were collected from the GDC Data Portal. After comparing the expression level of FENDRR in COAD/READ and healthy tissues, we evaluated the association of FENDRR with clinicopathological characters and the survival rate, the impact of FENDRR on prognosis, the biological function of FENDRR, and the relative abundance of tumor-infiltrating immune cells in patients with COAD/READ. Moreover, we aimed to construct a protein-protein interaction (PPI) network for selecting genes and a ceRNA network for presenting mRNA-miRNA-lncRNA interactions.
   Results In patients with COAD/READ, FENDRR expression could differentiate tumor tissues from the adjacent healthy tissues since it was significantly lower in the former than in the latter. High FENDRR expression was correlated with poorer survival and higher tumor stage, current tumor stage, and metastasis stage, and also exhibited high scores for apoptosis, autophagy, and senescence. Immune cell infiltration analysis showed that the high expression group had significantly lower immune and stromal scores. Low FENDRR expression was correlated with poor overall survival (OS), and thus, it could serve as an independent risk factor. The prognostic models constructed in the study performed well for the prediction of OS and disease-specific survival (DFS) using FENDRR expression. Gene set enrichment analysis revealed that vascular smooth muscle contraction, melanogenesis, basal cell carcinoma, and Hedgehog signaling pathways were significantly enriched in patients with high FENDRR expression. Eight hub genes, namely, PKM, ALDOA, PFKP, ALDOC, PYGL, CTNNB1, PSMA5, and WNT5A, were selected from the PPI network, and a ceRNA network was constructed based on the differentially expressed mRNAs, miRNAs, and lncRNAs to illustrate their regulatory relationships.
   Conclusion FENDRR may serve as a potential biomarker for the diagnosis and prognosis of COAD/READ.
C1 [Yang, Fan; Sun, Siyu; Yang, Fei] China Med Univ, Dept Gastroenterol, Sheng Jing Hosp, Shenyang, Peoples R China.
RP Sun, SY (corresponding author), China Med Univ, Dept Gastroenterol, Sheng Jing Hosp, Shenyang, Peoples R China.
EM sunsy@sj-hospital.org
FU China Postdoctoral Science FoundationChina Postdoctoral Science
   Foundation [2020M670101ZX]; Doctoral Scientific Research Foundation of
   Liaoning Province [2019-BS276]; Science and Technology Program of
   Shenyang [19-112-4-103]; Youth Support Foundation of China Medical
   University [QGZ2018058]; Scientific Fund of Shengjing Hospital [201801];
   345 Talent Project of Shengjing Hospital [52-30C]
FX This study was supported by the China Postdoctoral Science Foundation
   (Grant No. 2020M670101ZX), Doctoral Scientific Research Foundation of
   Liaoning Province (Grant No. 2019-BS276), Science and Technology Program
   of Shenyang (Grant No. 19-112-4-103), Youth Support Foundation of China
   Medical University (Grant No. QGZ2018058), Scientific Fund of Shengjing
   Hospital (Grant No. 201801), and 345 Talent Project of Shengjing
   Hospital (Grant No. 52-30C).
CR Aparicio T, 2018, J CLIN ONCOL, V36, P674, DOI 10.1200/JCO.2017.75.2931
   Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752-0509-8-S4-S11
   Dietrich CF, 2020, ENDOSC ULTRASOUND, V9, P284, DOI 10.4103/eus.eus_25_20
   Dietrich CF, 2019, ENDOSC ULTRASOUND, V8, P3, DOI 10.4103/eus.eus_54_18
   Fusaroli P, 2019, ENDOSC ULTRASOUND, V8, P329, DOI 10.4103/eus.eus_3_19
   Grote P, 2013, RNA BIOL, V10, P1579, DOI 10.4161/rna.26165
   Grote P, 2013, DEV CELL, V24, P206, DOI 10.1016/j.devcel.2012.12.012
   He W, 2019, ONCOL LETT, V17, P103, DOI 10.3892/ol.2018.9624
   He ZC, 2018, AM J TRANSL RES, V10, P3211
   Herrera-Merchan Antonio, 2020, Oncotarget, V11, P1172
   Lascorz J, 2012, BMC MED GENET, V13, DOI 10.1186/1471-2350-13-31
   Laurent C, 2011, CANCER RES, V71, P666, DOI 10.1158/0008-5472.CAN-10-0605
   Li Y, 2018, ONCOTARGETS THER, V11, P1403, DOI 10.2147/OTT.S149511
   Liang JY, 2019, J TRANSL INTERN MED, V7, P3, DOI 10.2478/jtim-2019-0002
   Liu JC, 2019, ONCOTARGETS THER, V12, P4287, DOI 10.2147/OTT.S195853
   Mauri G, 2019, MOL ONCOL, V13, P109, DOI 10.1002/1878-0261.12417
   Munteanu MC, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70633-7
   Nunes G, 2019, ENDOSC ULTRASOUND, V8, P211, DOI 10.4103/eus.eus_62_18
   Okugawa Y, 2015, GASTROENTEROLOGY, V149, P1204, DOI 10.1053/j.gastro.2015.07.011
   Qian GY, 2020, CANCER BIOTHER RADIO, V35, P629, DOI 10.1089/cbr.2019.3468
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77
   Sak K, 2019, J TRANSL INTERN MED, V7, P90, DOI 10.2478/jtim-2019-0020
   Scholer LV, 2017, CLIN CANCER RES, V23, P5437, DOI 10.1158/1078-0432.CCR-17-0510
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shen T, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0638-9
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P145, DOI 10.3322/caac.21601
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Wang B, 2019, BIOCHEM BIOPH RES CO, V509, P143, DOI 10.1016/j.bbrc.2018.12.091
   Wu CQ, 2017, ONCOTARGETS THER, V10, P3249, DOI 10.2147/OTT.S139639
   Xu TP, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0063-7
   Yang F, 2019, ENDOSC ULTRASOUND, V8, P73, DOI 10.4103/eus.eus_13_19
   Yin SL, 2020, J CELL BIOCHEM, V121, P3973, DOI 10.1002/jcb.29555
   Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Yu ZY, 2019, MOL THER-NUCL ACIDS, V17, P516, DOI 10.1016/j.omtn.2019.05.027
   Zhang GY, 2018, BIOMARKERS, V23, P435, DOI 10.1080/1354750X.2018.1443509
   Zhao DL, 2019, J CELL BIOCHEM, V120, P8160, DOI 10.1002/jcb.28097
   Zhu YH, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01223-w
NR 41
TC 0
Z9 0
U1 5
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD SEP 21
PY 2021
VL 11
AR 668595
DI 10.3389/fonc.2021.668595
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA WB3IT
UT WOS:000703470000001
PM 34621665
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Sakitani, K
   Hirata, Y
   Hikiba, Y
   Hayakawa, Y
   Ihara, S
   Suzuki, H
   Suzuki, N
   Serizawa, T
   Kinoshita, H
   Sakamoto, K
   Nakagawa, H
   Tateishi, K
   Maeda, S
   Ikenoue, T
   Kawazu, S
   Koike, K
AF Sakitani, Kosuke
   Hirata, Yoshihiro
   Hikiba, Yohko
   Hayakawa, Yoku
   Ihara, Sozaburo
   Suzuki, Hirobumi
   Suzuki, Nobumi
   Serizawa, Takako
   Kinoshita, Hiroto
   Sakamoto, Kei
   Nakagawa, Hayato
   Tateishi, Keisuke
   Maeda, Shin
   Ikenoue, Tsuneo
   Kawazu, Shoji
   Koike, Kazuhiko
TI Inhibition of autophagy exerts anti-colon cancer effects via apoptosis
   induced by p53 activation and ER stress
SO BMC CANCER
LA English
DT Article
DE Autophagy; Colon cancer; Apoptosis
ID ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; GENOME-WIDE
   ASSOCIATION; CROHN-DISEASE; EXPRESSION; MOUSE; CELLS; 5-FLUOROURACIL;
   INFLAMMATION; INVOLVEMENT
AB Background: Although some molecularly targeted drugs for colorectal cancer are used clinically and contribute to a better prognosis, the current median survival of advanced colorectal cancer patients is not sufficient. Autophagy, a basic cell survival mechanism mediated by recycling of cellular amino acids, plays an important role in cancer. Recently, autophagy has been highlighted as a promising new molecular target. The unfolded protein response (UPR) reportedly act in complementary fashion with autophagy in intestinal homeostasis. However, the roles of UPR in colon cancer under autophagic inhibition remain to be elucidated. We aim to clarify the inhibitory effect of autophagy on colon cancer.
   Methods: We crossed K19(CreERT) and Atg5(flox/flox) mice to generate Atg5(flox/flox)/K19(CreERT) mice. Atg5(flox/flox)/K19(CreERT) mice were first treated with azoxymethane/dextran sodium sulfate and then injected with tamoxifen to inhibit autophagy in CK19-positive epithelial cells. To examine the anti-cancer mechanisms of autophagic inhibition, we used colon cancer cell lines harboring different p53 gene statuses, as well as small interfering RNAs (siRNAs) targeting Atg5 and immunoglobulin heavy-chain binding protein (BiP), a chaperone to aid folding of unfolded proteins.
   Results: Colon tumors in Atg5(flox/flox)/K19(CreERT) mice showed loss of autophagic activity and decreased tumor size (the total tumor diameter was 28.1 mm in the control and 20.7 mm in Atg5(flox/flox)/K19(CreERT) mice, p = 0.036). We found that p53 and UPR/endoplasmic reticulum (ER) stress-related proteins, such as cleaved caspase 3, and CAAT/enhancer-binding protein homologous protein, are up-regulated in colon tumors of Atg5(flox/flox)/K19(CreERT) mice. Although Atg5 and BiP silencing, respectively, increased apoptosis in p53 wild type cells, Atg5 silencing alone did not show the same effect on apoptosis in p53 mutant cells. However, co-transfection of Atg5 and BiP siRNAs led to increased apoptosis in p53 mutant cells.
   Conclusions: Blocking autophagy has potential in the treatment of colon cancer by inducing apoptosis via p53 and ER stress, and suppressing the UPR pathway is a valid strategy to overcome resistance to autophagic inhibition.
C1 [Sakitani, Kosuke; Hikiba, Yohko; Sakamoto, Kei; Kawazu, Shoji] Asahi Life Fdn, Inst Adult Dis, Chuo Ku, Tokyo 1138655, Japan.
   [Sakitani, Kosuke; Hirata, Yoshihiro; Hayakawa, Yoku; Ihara, Sozaburo; Suzuki, Hirobumi; Suzuki, Nobumi; Serizawa, Takako; Kinoshita, Hiroto; Nakagawa, Hayato; Tateishi, Keisuke; Koike, Kazuhiko] Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Tokyo, Japan.
   [Maeda, Shin] Yokohama City Univ, Grad Sch Med, Gastroenterol Div, Yokohama, Kanagawa 232, Japan.
   [Ikenoue, Tsuneo] Univ Tokyo, Inst Med Sci, Div Clin Genome Res, Tokyo, Japan.
RP Sakitani, K (corresponding author), Asahi Life Fdn, Inst Adult Dis, Chuo Ku, 2-2-6 Bakuro Cho, Tokyo 1138655, Japan.
EM sakitani-tky@umin.ac.jp
RI Nakagawa, Hayato/I-2837-2012; Hayakawa, Yoku/AAI-8581-2020; Ihara,
   Sozaburo/ABF-5268-2021
OI Nakagawa, Hayato/0000-0002-6973-5094; Hayakawa,
   Yoku/0000-0002-3988-2499; Sakitani, Kosuke/0000-0002-4537-6023
FU JSPS KAKENHIMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT)Japan Society for the Promotion of
   ScienceGrants-in-Aid for Scientific Research (KAKENHI) [26860538]; Life
   Science Foundation of JapanLife Science Foundation of Japan; Kato
   Memorial Bioscience Foundation
FX This study was supported by grants from JSPS KAKENHI (Grant Number
   26860538), the Life Science Foundation of Japan, and the Kato Memorial
   Bioscience Foundation to K. Sakitani. The authors are grateful to Dr.
   Noboru Mizushima (The University of Tokyo) and Dr. Guoqiang Gu
   (Vanderbilt University) for providing the mice.
CR Adolph TE, 2013, NATURE, V503, P272, DOI 10.1038/nature12599
   Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35
   Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116
   Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057
   Benjamin JL, 2013, CELL HOST MICROBE, V13, P723, DOI 10.1016/j.chom.2013.05.004
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Conway KL, 2013, GASTROENTEROLOGY
   De Robertis Mariangela, 2011, J Carcinog, V10, P9, DOI 10.4103/1477-3163.78279
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Gulow K, 2002, J CELL SCI, V115, P2443
   Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954
   Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724
   Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI 10.3322/caac.20073
   Karin M, 2006, CELL, V124, P823, DOI 10.1016/j.cell.2006.02.016
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029
   Lee HK, 2010, IMMUNITY, V32, P227, DOI 10.1016/j.immuni.2009.12.006
   Lee IH, 2012, SCIENCE, V336, P225, DOI 10.1126/science.1218395
   Li DD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045058
   Li J, 2008, CELL DEATH DIFFER, V15, P1460, DOI 10.1038/cdd.2008.81
   Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760
   Matheu A, 2012, CANCER RES, V72, P1301, DOI 10.1158/0008-5472.CAN-11-3660
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001
   Means AL, 2008, GENESIS, V46, P318, DOI 10.1002/dvg.20397
   Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657
   MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7
   MULDER JWR, 1994, LANCET, V344, P1470, DOI 10.1016/S0140-6736(94)90290-9
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Nishida Y, 2009, NATURE, V461, P654, DOI 10.1038/nature08455
   Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954
   Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056
   Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865
   Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383
   Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Schleicher SM, 2010, DRUG RESIST UPDATE, V13, P79, DOI 10.1016/j.drup.2010.04.002
   Shimizu S, 2012, INT J CANCER, V131, P548, DOI 10.1002/ijc.26374
   Su YX, 2005, CLIN IMMUNOL, V116, P118, DOI 10.1016/j.clim.2005.04.004
   Suh DH, 2012, ANN NY ACAD SCI, V1271, P20, DOI 10.1111/j.1749-6632.2012.06739.x
   SUZUI M, 1995, MOL CARCINOGEN, V12, P193, DOI 10.1002/mc.2940120403
   Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Tanaka T, 2003, CANCER SCI, V94, P965, DOI 10.1111/j.1349-7006.2003.tb01386.x
   TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E
   VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901
   Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741
   Zeelenberg IS, 2003, CANCER RES, V63, P3833
NR 54
TC 23
Z9 24
U1 0
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD OCT 24
PY 2015
VL 15
AR 795
DI 10.1186/s12885-015-1789-5
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CU2TS
UT WOS:000363377100020
PM 26496833
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhu, J
   Zhao, BX
   Xiong, PG
   Wang, CY
   Zhang, JJ
   Tian, XH
   Huang, YH
AF Zhu, Jing
   Zhao, Bangxia
   Xiong, Pingan
   Wang, Chaoyun
   Zhang, Juanjuan
   Tian, Xiaohua
   Huang, Yinghui
TI Curcumin Induces Autophagy via Inhibition of Yes-Associated Protein
   (YAP) in Human Colon Cancer Cells
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Autophagy; Colonic Neoplasms; Curcumin
ID PROLIFERATION; DEGRADATION; ENCODES; KINASE
AB Background: Colon cancer is one of the most common cancers and it is the fourth leading cause of cancer-related deaths worldwide. YAP can promote cell proliferation and inhibit apoptosis, leading to loss of cell contact inhibition and promoting malignant cell transformation.
   Material/Methods: In this study we analyzed the effects of different curcumin concentrations on the proliferation of colon cancer cells using MTT and colony formation assays. Western blot detection was performed to confirm the YAP,LC3-II, and P62 expression.
   Results: Curcumin inhibited proliferation and promoted colon cancer cell autophagy. In addition, Western blot results indicated that curcumin suppressed YAP expression in colon cancer cells. To assess the mechanism, we treated the cell lines with curcumin and assessed YAP overexpression and YAP knockdown. The results revealed that curcumin inhibits the proliferation and promotes autophagy of these cell lines. Western blot results showed that curcumin reversed the effect of YAP in colon cancer cells.
   Conclusions: Our results suggest that YAP has great promise for treatment of colon cancer and that it might be a potential diagnostic marker for colon cancer.
C1 [Zhu, Jing; Huang, Yinghui] Beijing Univ Technol, Coll Life Sci & Bioengn, Lab Canc, Beijing, Peoples R China.
   [Zhu, Jing] Hubei Univ Med, Inst Basic Med Sci, Shiyan, Hubei, Peoples R China.
   [Zhao, Bangxia; Xiong, Pingan; Wang, Chaoyun; Zhang, Juanjuan; Tian, Xiaohua] Hubei Univ Med, Taihe Hosp, Reprod Med Ctr, Shiyan, Hubei, Peoples R China.
RP Zhu, J; Huang, YH (corresponding author), Beijing Univ Technol, Coll Life Sci & Bioengn, Lab Canc, Beijing, Peoples R China.; Zhu, J (corresponding author), Hubei Univ Med, Inst Basic Med Sci, Shiyan, Hubei, Peoples R China.
EM Jing_Zhu0719@163.com; yhuang@bjut.edu.en
OI Zhu, Jing/0000-0002-2860-3685
FU National Natural Technology Foundation of China [81428016]; Key Program
   for Science and Technology Development of Beijing [Z151100003915073]
FX This study was supported by the National Natural Technology Foundation
   of China (No. 81428016) and the Key Program for Science and Technology
   Development of Beijing (No. Z151100003915073)
CR Boehmer U, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004461
   Carvalho C, 2017, LANCET ONCOL, V18, pE354, DOI 10.1016/S1470-2045(17)30346-7
   Commandeur JNM, 1996, XENOBIOTICA, V26, P667, DOI 10.3109/00498259609046741
   Gao Y, 2014, INT J MOL SCI, V15, P15173, DOI 10.3390/ijms150915173
   Hewlings SJ, 2017, FOODS, V6, DOI 10.3390/foods6100092
   Huang F, 2017, AM J TRANSL RES, V9, P5538
   Jalili-Nik M, 2018, J CELL PHYSIOL, V233, P6337, DOI 10.1002/jcp.26368
   Jia YL, 2009, J ASIAN NAT PROD RES, V11, P918, DOI 10.1080/10286020903264077
   JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534
   Liu XW, 2017, ONCOL REP, V38, P271, DOI 10.3892/or.2017.5648
   Liu ZM, 2017, AM J TRANSL RES, V9, P3212
   Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876
   Petherick KJ, 2013, EMBO J, V32, P1903, DOI 10.1038/emboj.2013.123
   SUDOL M, 1994, ONCOGENE, V9, P2145
   Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055-9965.EPI-15-0578
   Wang SP, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.160119
   Wang YP, 2015, INT J CLIN EXP MED, V8, P1080
   XU TA, 1995, DEVELOPMENT, V121, P1053
   Zhou DW, 2011, P NATL ACAD SCI USA, V108, pE1312, DOI 10.1073/pnas.1110428108
   Zhou XX, 2016, ONCOTARGET, V7, P79062, DOI 10.18632/oncotarget.12596
   Zhuang WZ, 2012, CANCER SCI, V103, P684, DOI 10.1111/j.1349-7006.2011.02198.x
NR 21
TC 26
Z9 26
U1 0
U2 25
PU INT SCIENTIFIC LITERATURE, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
SN 1643-3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD OCT 3
PY 2018
VL 24
BP 7035
EP 7042
DI 10.12659/MSM.910650
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA GV5WK
UT WOS:000446175800003
PM 30281585
OA Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Yuk, JM
   Shin, DM
   Song, KS
   Lim, K
   Kim, KH
   Lee, SH
   Kim, JM
   Lee, JS
   Paik, TH
   Kim, JS
   Jo, EK
AF Yuk, Jae-Min
   Shin, Dong-Min
   Song, Kyoung-Sub
   Lim, Kyu
   Kim, Ki-Hye
   Lee, Sang-Hee
   Kim, Jin-Man
   Lee, Ji-Sook
   Paik, Tae-Hyun
   Kim, Jun-Sang
   Jo, Eun-Kyeong
TI Bacillus calmette-guerin cell wall cytoskeleton enhances colon cancer
   radiosensitivity through autophagy
SO AUTOPHAGY
LA English
DT Article
DE BCG cell wall skeleton; autophagy; radiosensitization; reactive oxygen
   species; JNK; toll-like receptor
ID RECTAL-CANCER; RADIATION-THERAPY; IMMUNE-RESPONSES; DENDRITIC CELLS;
   LUNG-CANCER; II TRIAL; SKELETON; DEATH; IMMUNOTHERAPY; ACTIVATION
AB The cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guerin (BCG/CWS) is an effective antitumor immunotherapy agent. Here, we demonstrate that BCG/CWS has a radiosensitizing effect on colon cancer cells through the induction of autophagic cell death. Exposure of HCT116 colon cancer cells to BCG/CWS before ionizing radiation (IR) resulted in increased cell death in a caspase-independent manner. Treatment with BCG/CWS plus IR resulted in the induction of autophagy in colon cancer cells. Either the autophagy inhibitor 3-methyladenine or knockdown of beclin 1 or Atg7 significantly reduced tumor cell death induced by BCG/CWS plus IR, whereas the caspase inhibitor z-VAD-fmk failed to do so. BCG/CWS plus IR-mediated autophagy and cell death was mediated predominantly by the generation of reactive oxygen species (ROS). The c-Jun NH2-terminal kinase pathway functioned upstream of ROS generation in the induction of autophagy and cell death in HCT116 cells after co-treatment with BCG/CWS and IR. Furthermore, toll-like receptor (TLR) 2, and in part, TLR4, were responsible for BCG/CWS-induced radiosensitization. In vivo studies revealed that BCG/ CWS-mediated radiosensitization of HCT116 xenograft growth is accompanied predominantly by autophagy. Our data suggest that BCG/CWS in combination with IR is a promising therapeutic strategy for enhancing radiation therapy in colon cancer cells through the induction of autophagy.
C1 [Kim, Jun-Sang] Chungnam Natl Univ Hosp, Taejon, South Korea.
   [Yuk, Jae-Min; Shin, Dong-Min; Kim, Ki-Hye; Jo, Eun-Kyeong] Chungnam Natl Univ, Coll Med, Dept Microbiol, Taejon, South Korea.
   [Song, Kyoung-Sub; Lim, Kyu] Chungnam Natl Univ, Coll Med, Dept Biochem, Taejon, South Korea.
   [Yuk, Jae-Min; Shin, Dong-Min; Lim, Kyu; Kim, Ki-Hye; Kim, Jin-Man; Lee, Ji-Sook; Paik, Tae-Hyun; Jo, Eun-Kyeong] Chungnam Natl Univ, Coll Med, Infect Signaling Network Res Ctr, Taejon, South Korea.
   [Kim, Jin-Man] Chungnam Natl Univ, Coll Med, Dept Pathol, Taejon, South Korea.
   [Lim, Kyu; Kim, Jin-Man; Kim, Jun-Sang] Chungnam Natl Univ, Canc Res Inst, Dept Pathol, Taejon, South Korea.
   [Jo, Eun-Kyeong] Chungnam Natl Univ, Res Inst Med Sci, Dept Pathol, Taejon, South Korea.
   [Lee, Sang-Hee] Korea Adv Inst Sci & Technol, Mol Genom Lab, Dept Biol Sci, Taejon 305701, South Korea.
RP Kim, JS (corresponding author), Chungnam Natl Univ Hosp, Taejon, South Korea.
EM k423j@cnu.ac.kr; hayoungj@cnu.ac.kr
OI KIM, JUN-SANG/0000-0002-5329-6605; Eun-Kyeong, Jo/0000-0001-7191-0587;
   Yuk, Jae-Min/0000-0002-0630-9194; KIM, JIN MAN/0000-0003-0905-9730
FU Korea Science & Engineering Foundation through the Infection Signaling
   Network Research CenterKorea Science and Engineering Foundation
   [R13-2007-020-01000-0]
FX We thank B. Vogelstein and J. W. Son for reagents; T. H. Paik for
   invaluable discussion and reagents; and H. H. Choi for technical
   support. This work was supported by the Korea Science & Engineering
   Foundation through the Infection Signaling Network Research Center
   (R13-2007-020-01000-0) at Chungnam National University. The authors have
   no financial conflict of interests.
CR AZUMA I, 1974, JNCI-J NATL CANCER I, V52, P95, DOI 10.1093/jnci/52.1.95
   Azuma I, 2001, INT IMMUNOPHARMACOL, V1, P1249, DOI 10.1016/S1567-5769(01)00055-8
   Bhardwaj N, 2007, J CLIN INVEST, V117, P1130, DOI 10.1172/JCI32136
   Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x
   Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233
   Chen YQ, 2008, AUTOPHAGY, V4, P246, DOI 10.4161/auto.5432
   Chen YQ, 2007, J CELL SCI, V120, P4155, DOI 10.1242/jcs.011163
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Daido S, 2005, CANCER RES, V65, P4368, DOI 10.1158/0008-5472.CAN-04-4202
   Freyer G, 2001, J CLIN ONCOL, V19, P2433, DOI 10.1200/JCO.2001.19.9.2433
   Galluzzi L, 2008, BIOCHEM SOC T, V36, P786, DOI 10.1042/BST0360786
   Gerard JP, 2003, J CLIN ONCOL, V21, P1119, DOI 10.1200/JCO.2003.10.045
   Golstein P, 2007, TRENDS BIOCHEM SCI, V32, P37, DOI 10.1016/j.tibs.2006.11.001
   Grauer OM, 2008, J IMMUNOL, V181, P6720, DOI 10.4049/jimmunol.181.10.6720
   Hayashi A, 1998, P JPN ACAD B-PHYS, V74, P50, DOI 10.2183/pjab.74.50
   Javvadi P, 2008, MOL PHARMACOL, V73, P1491, DOI 10.1124/mol.107.043554
   Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041
   Kim JS, 2002, INT J RADIAT ONCOL, V54, P403, DOI 10.1016/S0360-3016(02)02856-0
   Kim KW, 2006, J BIOL CHEM, V281, P36883, DOI 10.1074/jbc.M607094200
   Kishi K, 2000, CANCER RES, V60, P1326
   Kissova I, 2006, FREE RADICAL BIO MED, V41, P1655, DOI 10.1016/j.freeradbiomed.2006.08.012
   Kodama K, 2009, SURG TODAY, V39, P194, DOI 10.1007/s00595-008-3826-3
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kondo Y, 2006, AUTOPHAGY, V2, P85, DOI 10.4161/auto.2.2.2463
   Kroemer G, 2005, CELL DEATH DIFFER, V12, P1463, DOI 10.1038/sj.cdd.4401724
   Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005
   Lee SB, 2006, J BIOL CHEM, V281, P36228, DOI 10.1074/jbc.M606702200
   Li DD, 2009, ONCOGENE, V28, P886, DOI 10.1038/onc.2008.441
   Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   MAJANDER A, 1994, J BIOL CHEM, V269, P21037
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mauceri HJ, 1998, NATURE, V394, P287, DOI 10.1038/28412
   Mehta VK, 2003, INT J RADIAT ONCOL, V55, P132, DOI 10.1016/S0360-3016(02)03863-4
   Minsky BD, 1997, INT J RADIAT ONCOL, V37, P289, DOI 10.1016/S0360-3016(96)00487-7
   Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005
   Moretti L, 2007, AUTOPHAGY, V3, P142, DOI 10.4161/auto.3607
   Murata M, 2008, CANCER SCI, V99, P1435, DOI 10.1111/j.1349-7006.2008.00832.x
   Nakano H, 2006, CELL DEATH DIFFER, V13, P730, DOI 10.1038/sj.cdd.4401830
   OCONNELL M, 1994, NEW ENGL J MED, V331, P502, DOI 10.1056/NEJM199408253310803
   Paglin S, 2001, CANCER RES, V61, P439
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Pattingre S, 2009, J BIOL CHEM, V284, P2719, DOI 10.1074/jbc.M805920200
   Pyo JO, 2008, AUTOPHAGY, V4, P315, DOI 10.4161/auto.5525
   Rodel C, 2008, INT J RADIAT ONCOL, V70, P1081, DOI 10.1016/j.ijrobp.2007.07.2356
   Sauer R, 2004, NEW ENGL J MED, V351, P1731, DOI 10.1056/NEJMoa040694
   Schueneman AJ, 2003, CANCER RES, V63, P4009
   Seya T, 2002, MICROBES INFECT, V4, P955, DOI 10.1016/S1286-4579(02)01610-6
   Tal MC, 2009, P NATL ACAD SCI USA, V106, P2770, DOI 10.1073/pnas.0807694106
   Tasdemir Ezgi, 2008, V445, P29, DOI 10.1007/978-1-59745-157-4_3
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046
   Tsuji S, 2000, INFECT IMMUN, V68, P6883, DOI 10.1128/IAI.68.12.6883-6890.2000
   Udagawa M, 2006, CLIN CANCER RES, V12, P7465, DOI 10.1158/1078-0432.CCR-06-1840
   Uehori J, 2003, INFECT IMMUN, V71, P4238, DOI 10.1128/IAI.71.8.4238-4249.2003
   Ventura JJ, 2004, GENE DEV, V18, P2905, DOI 10.1101/gad.1223004
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   Xu Y, 2006, J BIOL CHEM, V281, P19179, DOI 10.1074/jbc.M513377200
   YAMAMURA Y, 1976, ANN NY ACAD SCI, V277, P209, DOI 10.1111/j.1749-6632.1976.tb41699.x
   Yang CS, 2009, J IMMUNOL, V182, P3696, DOI 10.4049/jimmunol.0802217
   YASUMOTO K, 1979, CANCER RES, V39, P3262
   Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103
   ZBAR B, 1974, J NATL CANCER I, V52, P1571, DOI 10.1093/jnci/52.5.1571
   Zois CE, 2009, AUTOPHAGY, V5, P442, DOI 10.4161/auto.5.4.7667
NR 64
TC 57
Z9 60
U1 0
U2 12
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD JAN 1
PY 2010
VL 6
IS 1
BP 46
EP 60
DI 10.4161/auto.6.1.10325
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 577CG
UT WOS:000276197900006
PM 19901560
OA hybrid
DA 2022-04-25
ER

PT S
AU Naji, M
   Soroudi, S
   Akaberi, M
   Sahebkar, A
   Emami, SA
AF Naji, Melika
   Soroudi, Setareh
   Akaberi, Maryam
   Sahebkar, Amirhossein
   Emami, Seyed Ahmad
BE Barreto, GE
   Sahebkar, A
TI Updated Review on the Role of Curcumin in Gastrointestinal Cancers
SO PHARMACOLOGICAL PROPERTIES OF PLANT-DERIVED NATURAL PRODUCTS AND
   IMPLICATIONS FOR HUMAN HEALTH
SE Advances in Experimental Medicine and Biology
LA English
DT Review; Book Chapter
DE Gastrointestinal; Cancer; Curcumin; Esophagus; Colon; Oral cavity
ID HUMAN COLORECTAL-CANCER; HUMAN COLON-CANCER; EPITHELIAL-MESENCHYMAL
   TRANSITION; SQUAMOUS-CELL CARCINOMA; GASTRIC-CANCER; ESOPHAGEAL CANCER;
   DOWN-REGULATION; ORAL-CANCER; SUPPRESSES PROLIFERATION; POLYMERIC
   NANOPARTICLES
AB Malignant conditions of the gastrointestinal tract and accessory organs of digestion, including the oral cavity, esophagus, stomach, biliary system, pancreas, small intestine, large intestine, rectum and anus, are referred to as gastrointestinal cancers. Curcumin is a natural compound derived from turmeric with a wide range of biological activities. Several in vitro and in vivo studies have investigated the effects of curcumin on gastrointestinal cancers. In the current review, we aimed to provide an updated summary on the recent findings regarding the beneficial effects of curcumin on different gastrointestinal cancers in the recent decade. For this purpose, ScienceDirect," "Google Scholar," "PubMed," "ISI Web of Knowledge," and "Wiley Online Library" databases were searched using "curcumin", "cancer", and "gastrointestinal organs" as keywords. In vitro studies performed on different gastrointestinal cancerous cell lines have shown that curcumin can inhibit cell growth through cycle arrest at the G2/M and G1 phases, as well as stimulated apoptosis and autophagy by interacting with multiple molecular targets. In vivo studies performed in various animal models have confirmed mainly the chemopreventive effects of curcumin. Several nano-formulations have been proposed to improve the bioavailability of curcumin and increase its absorption. Moreover, curcumin has been used in combinations with many anti-tumor drugs to increase their anticarcinogenic properties. Taken together, curcumin falls within the category of plant-derived substances capable of preventing or treating gastrointestinal cancers. Further studies, particularly clinical trials, on the efficacy and safety of curcumin are suggested in this regard.
C1 [Naji, Melika; Soroudi, Setareh; Akaberi, Maryam] Mashhad Univ Med Sci, Sch Pharm, Dept Pharmacognosy, Mashhad, Razavi Khorasan, Iran.
   [Sahebkar, Amirhossein] Mashhad Univ Med Sci, Appl Biomed Res Ctr, Mashhad, Razavi Khorasan, Iran.
   [Sahebkar, Amirhossein] Mashhad Univ Med Sci, Pharmaceut Technol Inst, Biotechnol Res Ctr, Mashhad, Razavi Khorasan, Iran.
   [Sahebkar, Amirhossein] Mashhad Univ Med Sci, Sch Pharm, Mashhad, Razavi Khorasan, Iran.
   [Sahebkar, Amirhossein] Polish Mothers Mem Hosp Res Inst PMMHRI, Lodz, Poland.
   [Emami, Seyed Ahmad] Mashhad Univ Med Sci, Sch Pharm, Dept Tradit Pharm, Mashhad, Razavi Khorasan, Iran.
RP Sahebkar, A (corresponding author), Mashhad Univ Med Sci, Appl Biomed Res Ctr, Mashhad, Razavi Khorasan, Iran.; Sahebkar, A (corresponding author), Mashhad Univ Med Sci, Pharmaceut Technol Inst, Biotechnol Res Ctr, Mashhad, Razavi Khorasan, Iran.; Sahebkar, A (corresponding author), Mashhad Univ Med Sci, Sch Pharm, Mashhad, Razavi Khorasan, Iran.; Sahebkar, A (corresponding author), Polish Mothers Mem Hosp Res Inst PMMHRI, Lodz, Poland.; Emami, SA (corresponding author), Mashhad Univ Med Sci, Sch Pharm, Dept Tradit Pharm, Mashhad, Razavi Khorasan, Iran.
EM sahebkara@mums.ac.ir; emamia@mums.ac.ir
FU Mashhad University of Medical Sciences (MUMS)
FX The authors are grateful to Mashhad University of Medical Sciences
   (MUMS) for the help and support.
CR AL-Ishaq RK, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10010105
   Alibeiki F, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02666-4
   Anchi P, 2018, J PHARM SCI-US, V107, P2869, DOI 10.1016/j.xphs.2018.07.009
   Bolat ZB, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00050
   Buyel JF, 2018, BIOTECHNOL ADV, V36, P506, DOI 10.1016/j.biotechadv.2018.02.002
   Cai XZ, 2013, PHYTOMEDICINE, V20, P495, DOI 10.1016/j.phymed.2012.12.007
   Cai XZ, 2009, CANCER BIOL THER, V8, P1360, DOI 10.4161/cbt.8.14.8720
   Calibasi-Kocal G, 2019, J BUON, V24, P1482
   Cavatorta Ottavia, 2018, Acta Biomed, V89, P82, DOI 10.23750/abm.v89i8-S.7966
   Chen D, 2016, MED SCI MONITOR, V22, P3215, DOI 10.12659/MSM.900802
   Chen GP, 2017, INT J CLIN EXP PATHO, V10, P11496
   Chen KH, 2010, TRANSPL P, V42, P744, DOI 10.1016/j.transproceed.2010.03.017
   Chen TK, 2020, FOOD CHEM TOXICOL, V137, DOI 10.1016/j.fct.2020.111131
   Chung Seyung S, 2019, Oncotarget, V10, P4516, DOI 10.18632/oncotarget.27000
   Da W, 2019, INT J IMMUNOPATH PH, V33, DOI 10.1177/2058738419861600
   Da W, 2015, TUMOR BIOL, V36, P5215, DOI 10.1007/s13277-015-3178-8
   Dai W, 2019, BRAZ J PHARM SCI, V55, DOI [10.1590/S2175--97902019000118276, DOI 10.1590/S2175--97902019000118276]
   Dhanavel S, 2020, POLYM BULL, V77, P213, DOI 10.1007/s00289-019-02734-x
   Dhivya R, 2017, MAT SCI ENG C-MATER, V80, P59, DOI 10.1016/j.msec.2017.05.128
   DiMarco-Crook C, 2020, J FOOD SCI, V85, P1292, DOI 10.1111/1750-3841.15073
   Donohoe CL, 2014, THER ADV GASTROENTER, V7, P38, DOI 10.1177/1756283X13501786
   Dou HQ, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00877
   Ebrahimifar Meysam, 2017, Asian Pac J Cancer Prev, V18, P65
   Epelbaum R, 2010, NUTR CANCER, V62, P1137, DOI 10.1080/01635581.2010.513802
   Fan YX, 2017, GENET MOL RES, V16, DOI 10.4238/gmr16029414
   Fu HB, 2018, J CELL PHYSIOL, V233, P4634, DOI 10.1002/jcp.26190
   Gallo KA, 2020, PHARMACOL THERAPEUT, V207, DOI 10.1016/j.pharmthera.2019.107457
   Gavrilas LI, 2019, FOOD FUNCT, V10, P3717, DOI [10.1039/C9FO01014A, 10.1039/c9fo01014a]
   Ghandadi M, 2017, CURR PHARM DESIGN, V23, P921, DOI 10.2174/1381612822666161006151605
   Goncalves VD, 2015, J CELL BIOCHEM, V116, P787, DOI 10.1002/jcb.25035
   Gupta SC, 2010, CANCER METAST REV, V29, P405, DOI 10.1007/s10555-010-9235-2
   He B, 2017, ONCOL LETT, V14, P3387, DOI 10.3892/ol.2017.6627
   He DL, 2016, Chin J Tissue Eng Res, V20, P4731, DOI 10.3969/J.ISSN.2095-4344.2016.32.003
   He GD, 2016, CANCER CHEMOTH PHARM, V78, P1151, DOI 10.1007/s00280-016-3172-x
   He WT, 2019, CHIN J INTEGR MED, V25, P416, DOI 10.1007/s11655-018-2997-z
   Hosseini S, 2018, REP BIOCHEM MOL BIOL, V6, P137
   Howells LM, 2019, J NUTR, V149, P1133, DOI 10.1093/jn/nxz029
   Hu H, 2010, J PRACT ONCOL, V25
   Hu YZ, 2020, INT J NANOMED, V15, P1239, DOI 10.2147/IJN.S232777
   Huang F, 2017, AM J TRANSL RES, V9, P5538
   Huang YT, 2016, J AGR FOOD CHEM, V64, P2247, DOI 10.1021/acs.jafc.5b05649
   Intaraphairot T, 2017, PHARM SCI-IRAN, V23, P112, DOI 10.15171/PS.2017.17
   Iranshahi M, 2009, EUR J CANCER PREV, V18, P412, DOI 10.1097/CEJ.0b013e32832c389e
   Jayaprakasha GK, 2016, EUR J PHARMACOL, V789, P291, DOI 10.1016/j.ejphar.2016.07.017
   Kanai M, 2013, CANCER CHEMOTH PHARM, V71, P1521, DOI 10.1007/s00280-013-2151-8
   Kanai M, 2011, CANCER CHEMOTH PHARM, V68, P157, DOI 10.1007/s00280-010-1470-2
   Kang YT, 2016, ONCOTARGETS THER, V9, P7373, DOI 10.2147/OTT.S118272
   Karunagaran D, 2005, CURR CANCER DRUG TAR, V5, P117, DOI 10.2174/1568009053202081
   Kim JY, 2012, ARCH ORAL BIOL, V57, P1018, DOI 10.1016/j.archoralbio.2012.04.005
   Kocaadam B, 2017, CRIT REV FOOD SCI, V57, P2889, DOI 10.1080/10408398.2015.1077195
   Kujundzic RN, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051180
   Kunnumakkara AB, 2017, CLIN SCI, V131, P1781, DOI 10.1042/CS20160935
   Kuriakose MA, 2016, CANCER PREV RES, V9, P683, DOI 10.1158/1940-6207.CAPR-15-0390
   Kuttan G, 2007, ADV EXP MED BIOL, V595, P173
   Kwiecien S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061477
   Lai KC, 2019, TOXICOL APPL PHARM, V382, DOI 10.1016/j.taap.2019.114734
   Lan YT, 2013, WORLD CHIN J DIGESTO, V21, P1522, DOI [10.11569/WCJD.V21.I16.1522, DOI 10.11569/WCJD.V21.I16.1522]
   Le TT, 2019, MAT SCI ENG C-MATER, V101, P464, DOI 10.1016/j.msec.2019.03.100
   Lee HM, 2016, PHYTOMEDICINE, V23, P1535, DOI 10.1016/j.phymed.2016.09.005
   Li W, 2017, Zhonghua Zhong Liu Za Zhi, V39, P490, DOI 10.3760/cma.j.issn.0253-3766.2017.07.003
   Li W, 2017, ONCOL REP, V37, P3459, DOI 10.3892/or.2017.5637
   Liang BX, 2017, EUR J PHARMACOL, V796, P139, DOI 10.1016/j.ejphar.2016.12.030
   Liang T, 2014, INT J MOL SCI, V15, P15754, DOI 10.3390/ijms150915754
   Liu G, 2016, ONCOL LETT, V12, P5156, DOI 10.3892/ol.2016.5354
   Liu GP, 2018, J PHARM PHARMACOL, V70, P1340, DOI 10.1111/jphp.12981
   Liu Wen-Hu, 2019, Zhongguo Zhong Yao Za Zhi, V44, P3107, DOI 10.19540/j.cnki.cjcmm.20190304.002
   Liu XH, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-389
   Liu Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0959-0
   Lotfi-Attari J, 2017, NUTR CANCER, V69, P1290, DOI 10.1080/01635581.2017.1367932
   Mahattanadul S, 2006, J NAT MED-TOKYO, V60, P198, DOI 10.1007/s11418-006-0036-4
   Malhotra M, 2020, WORLD J PHARM RES, P8, DOI [10.20959/WJPR201911--15870, DOI 10.20959/WJPR201911--15870]
   Man SM, 2018, NAT REV GASTRO HEPAT, V15, P721, DOI 10.1038/s41575-018-0054-1
   Marjaneh RM, 2018, J CELL PHYSIOL, V233, P6785, DOI 10.1002/jcp.26538
   Mazzarino L, 2015, J NANOSCI NANOTECHNO, V15, P781, DOI 10.1166/jnn.2015.9189
   Mishra A, 2015, ECANCERMEDICALSCIENC, V9, DOI 10.3332/ecancer.2015.525
   Mizumoto A, 2019, J GASTROENTEROL, V54, P687, DOI 10.1007/s00535-019-01549-x
   Mollazadeh H, 2019, CRIT REV FOOD SCI, V59, P89, DOI 10.1080/10408398.2017.1358139
   Momtazi AA, 2016, MOL DIAGN THER, V20, P335, DOI 10.1007/s40291-016-0202-7
   Montgomery A, 2016, J CANCER, V7, P1250, DOI 10.7150/jca.15690
   Mu JF, 2019, J CELL BIOCHEM, V120, P1011, DOI 10.1002/jcb.27542
   Nagaraju GP, 2019, INT J CANCER, V145, P10, DOI 10.1002/ijc.31867
   Naijil G, 2015, NUTR RES, V35, P823, DOI 10.1016/j.nutres.2015.06.011
   Nalini D, 2020, J CANCER RES CLIN, V146, P1, DOI 10.1007/s00432-019-03068-x
   Niu ShuRong, 2018, Tumor, V38, P526
   O'Sullivan-Coyne G, 2009, BRIT J CANCER, V101, P1585, DOI 10.1038/sj.bjc.6605308
   Panahi Y, 2018, J CELL PHYSIOL, V233, P141, DOI 10.1002/jcp.25756
   Pandey A, 2015, NUTR CANCER, V67, P1293, DOI 10.1080/01635581.2015.1085581
   Pastorelli D, 2018, PHARMACOL RES, V132, P72, DOI 10.1016/j.phrs.2018.03.013
   Paulraj F, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9070270
   Prakobwong S, 2011, CARCINOGENESIS, V32, P1372, DOI 10.1093/carcin/bgr032
   Pricci M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072364
   Qiang ZR, 2019, J INT MED RES, V47, P1288, DOI 10.1177/0300060518822213
   Rafiee P, 2009, AM J PHYSIOL-GASTR L, V296, pG388, DOI 10.1152/ajpgi.90428.2008
   Rahmani AH, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/761608
   Rajamanickam V, 2020, CANCER MANAG RES, V12, P247, DOI 10.2147/CMAR.S227415
   Rajitha B, 2017, MOL CARCINOGEN, V56, P288, DOI 10.1002/mc.22492
   Rajitha B, 2016, CANCER LETT, V373, P227, DOI 10.1016/j.canlet.2016.01.052
   Ravindranathan P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32267-8
   Rawla P, 2019, GASTROENTEROL REV, V14, P26, DOI 10.5114/pg.2018.80001
   Ren Hai-yu, 2018, Chinese Pharmacological Bulletin, V34, P1455, DOI 10.3969/j.issn.1001-1978.2018.10.025
   Rodrigues FC, 2019, EUR J MED CHEM, V177, P76, DOI 10.1016/j.ejmech.2019.04.058
   Roy PS, 2016, INDIAN J CANCER, V53, P441, DOI 10.4103/0019-509X.200658
   de Porras VR, 2016, SCI REP-UK, V6, DOI 10.1038/srep24675
   Sahebkar A, 2010, FERTIL STERIL, V94, pE75, DOI 10.1016/j.fertnstert.2010.07.1071
   Sankpal UT, 2016, ONCOTARGET, V7, P3186, DOI 10.18632/oncotarget.6553
   Sato T, 2017, ANTICANCER RES, V37, P4789, DOI 10.21873/anticanres.11885
   Selvam C, 2019, LIFE SCI, V239, DOI 10.1016/j.lfs.2019.117032
   Sesarman A, 2018, PHARMACOL REP, V70, P331, DOI 10.1016/j.pharep.2017.10.004
   Shin SA, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092651
   Siddappa G, 2017, MOL CARCINOGEN, V56, P2446, DOI 10.1002/mc.22692
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Silva G, 2018, MOLECULES, V23, DOI 10.3390/molecules23020279
   Singh Sarvjeet, 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P259, DOI 10.2174/187152006776930918
   Sintara K, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/915380
   Soleimani V, 2018, PHYTOTHER RES, V32, P985, DOI 10.1002/ptr.6054
   Srivastava S, 2018, J MAXILLOFAC ORAL SU, V17, P597, DOI 10.1007/s12663-018-1126-z
   Su PF, 2018, INT J ONCOL, V53, P1343, DOI 10.3892/ijo.2018.4461
   Subramaniam D, 2018, CURR MED CHEM, V25, P2585, DOI 10.2174/0929867324666170127095832
   Subramaniam D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030590
   Sun CL, 2019, CANCER BIOTHER RADIO, V34, P634, DOI 10.1089/cbr.2019.2874
   Sun QQ, 2016, TUMOR BIOL, V37, P13177, DOI 10.1007/s13277-016-5221-9
   Sun XiaoRan, 2016, Tumor, V36, P1312
   Tang J, 2019, TROP J PHARM RES, V18, P2531, DOI 10.4314/tjpr.v18i12.10
   Teymouri M, 2017, BIOFACTORS, V43, P331, DOI 10.1002/biof.1344
   Tong WH, 2016, ONCOL LETT, V12, P4139, DOI 10.3892/ol.2016.5148
   Udompornmongkol P, 2015, J BIOMATER APPL, V30, P537, DOI 10.1177/0885328215594479
   Umar SB, 2008, NAT CLIN PRACT GASTR, V5, P517, DOI 10.1038/ncpgasthep1223
   Walvekar M. V., 2016, IJPCR, V8, P1314
   Wang DZ, 2018, J CLIN INVEST, V128, P2732, DOI 10.1172/JCI97953
   Wang M, 2019, INT J BIOL SCI, V15, P1200, DOI 10.7150/ijbs.33710
   Wang Y, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00820
   Wang YJ, 2019, MOL MED REP, V20, P3027, DOI 10.3892/mmr.2019.10547
   Weng WH, 2022, SEMIN CANCER BIOL, V80, P73, DOI 10.1016/j.semcancer.2020.02.011
   Wongsirisin P, 2018, PHARMANUTRITION, V6, P100, DOI 10.1016/j.phanu.2018.05.003
   Xu B, 2017, AM J TRANSL RES, V9, P1866
   Xu H, 2019, TROP J PHARM RES, V18, P2355, DOI 10.4314/tjpr.v18i11.18
   Yang GG, 2018, ANTICANCER RES, V38, P131, DOI 10.21873/anticanres.12200
   Yang HR, 2017, J CANCER, V8, P3697, DOI 10.7150/jca.20196
   Ye CM, 2019, ONCOTARGETS THER, V12, P2259, DOI 10.2147/OTT.S196914
   Ye F, 2012, WORLD J GASTROENTERO, V18, P126, DOI 10.3748/wjg.v18.i2.126
   Yin JH, 2019, ONCOTARGETS THER, V12, P3893, DOI 10.2147/OTT.S199601
   Yu H, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819870781
   Yu LL, 2011, ONCOL REP, V26, P1197, DOI 10.3892/or.2011.1410
   Yue GGL, 2016, PHARMACOL RES, V111, P43, DOI 10.1016/j.phrs.2016.05.025
   Yulianty R, 2017, TROP J PHARM RES, V16, P2141, DOI 10.4314/tjpr.v16i9.14
   Yusefi Ali Reza, 2018, Asian Pac J Cancer Prev, V19, P591
   Zhang JY, 2015, MOLECULES, V20, P11524, DOI 10.3390/molecules200611524
   Zhang JR, 2017, AM J CANCER RES, V7, P275
   Zhang P, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0661-7
   Zhang ZW, 2016, ONCOL REP, V35, P2615, DOI 10.3892/or.2016.4669
   Zhao P, 2019, TROP J PHARM RES, V18, P1405, DOI 10.4314/tjpr.v18i7.6
   Zheng BZ, 2018, EUR REV MED PHARMACO, V22, P551, DOI 10.26355/eurrev_201801_14209
   Zhou SF, 2017, FEBS OPEN BIO, V7, P1078, DOI 10.1002/2211-5463.12237
   Zhou X, 2015, ONCOL RES, V23, P29, DOI 10.3727/096504015X14452563486011
   Zhu J, 2018, MED SCI MONITOR, V24, P7035, DOI 10.12659/MSM.910650
NR 155
TC 1
Z9 1
U1 2
U2 8
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 0065-2598
EI 2214-8019
BN 978-3-030-64872-5; 978-3-030-64871-8
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2021
VL 1308
BP 55
EP 89
DI 10.1007/978-3-030-64872-5_6
D2 10.1007/978-3-030-64872-5
PG 35
WC Chemistry, Medicinal; Medicine, Research & Experimental; Pharmacology &
   Pharmacy
WE Book Citation Index – Science (BKCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Research & Experimental Medicine
GA BR3MG
UT WOS:000647701200006
PM 33861437
DA 2022-04-25
ER

PT J
AU Efe, EY
   Mazumder, A
   Lee, JY
   Gaigneaux, A
   Radogna, F
   Nasim, MJ
   Christov, C
   Jacob, C
   Kim, KW
   Dicato, M
   Chaimbault, P
   Cerella, C
   Diederich, M
AF Efe, Esma Yagdi
   Mazumder, Aloran
   Lee, Jin-Young
   Gaigneaux, Anthoula
   Radogna, Flavia
   Nasim, Muhammad Jawad
   Christov, Christo
   Jacob, Claus
   Kim, Kyu-Won
   Dicato, Mario
   Chaimbault, Patrick
   Cerella, Claudia
   Diederich, Marc
TI Tubulin-binding anticancer polysulfides induce cell death via mitotic
   arrest and autophagic interference in colorectal cancer
SO CANCER LETTERS
LA English
DT Article
DE Diallyl sulfide; Mitotic arrest; Cell death; Autophagic flux; Zebrafish
   xenografts
ID HUMAN COLON; CARCINOMA CELLS; P-GLYCOPROTEIN; CYCLE ARREST; IN-VITRO;
   P62; APOPTOSIS; SURVIVAL; PROTEIN; PROLIFERATION
AB Polysulfanes show chemopreventive effects against gastrointestinal tumors. We identified diallyl tetra-sulfide and its derivative, dibenzyl tetrasulfide (DBTTS), to be mitotic inhibitors and apoptosis inducers. Here, we translate their application in colorectal cancer (CRC). MALDI-TOF-MS analysis identified both compounds as reversible tubulin binders, validated by in cellulo alpha-tubulin degradation. BRAF(V600E)mutated HT-29 cells were resistant to DBTTS, as evidenced by mitotic arrest for 48 h prior to apoptosis induction compared to KRAS(G12V)-mutated SW480/620 cells, which committed to death earlier. The prolonged mitotic block correlated with autophagy impairment and p62 protein accumulation in HT-29 but not in SW480/620 cells, whereas siRNA-mediated p62 inhibition sensitized HT 29 cells to death. In silico analysis with 484 colorectal cancer patients associated higher p62 expression and reduced autophagic flux with greater overall survival. Accordingly, we hypothesized that DB1TS targets CRC survival/death through autophagy interference in cell types with differential autophagic capacities. We confirmed the therapeutic potential of DBTTS by the inhibition of spheroid and colony formation capacities in CRC cells, as well as in HT-29 zebrafish xenografts in vivo. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Efe, Esma Yagdi; Gaigneaux, Anthoula; Radogna, Flavia; Dicato, Mario; Cerella, Claudia] Hop Kirchberg, Lab Biol Mol & Cellulaire Canc, 9 Rue Edward Steichen, L-2540 Luxembourg, Luxembourg.
   [Mazumder, Aloran; Lee, Jin-Young; Kim, Kyu-Won; Diederich, Marc] Seoul Natl Univ, Coll Pharm, Seoul 08826, South Korea.
   [Nasim, Muhammad Jawad; Jacob, Claus] Univ Saarland, Sch Pharm, Div Bioorgan Chem, Campus B 2-1, D-66123 Saarbrucken, Germany.
   [Christov, Christo] Univ Lorraine, Serv Commun Microscopie, Nancy, France.
   [Chaimbault, Patrick] Univ Lorraine, SRSMC, UMR7565, Metz, France.
RP Diederich, M (corresponding author), Seoul Natl Univ, Dept Pharm, Coll Pharm, Bldg 29 Room 233,1 Gwanak Ro, Seoul 08826, South Korea.
EM marcdiederich@snu.ac.kr
RI Radogna, Flavia/AAL-5698-2020; Diederich, Marc/O-7335-2015; Kim, Kyu
   Won/AAJ-7213-2020
OI Diederich, Marc/0000-0003-0115-4725; Cerella,
   Claudia/0000-0001-9308-8176; Radogna, Flavia/0000-0003-0385-3335;
   CHAIMBAULT, Patrick/0000-0001-7588-8751
FU Televie Luxembourg fellowship; "Recherche Cancer et Sang" Foundation;
   "Recherches Scientifiques Luxembourg" Association; "Een Faerz fir
   kriibskrank Kanner" Association; Action LIONS "Vaincre le Cancer"
   Association; NRF; MEST of KoreaMinistry of Education, Science and
   Technology, Republic of Korea [GCRC 2012-0001184]; Brain Korea (BK21)
   PLUS program; Televie Luxembourg
FX EY, CC, AG, and FR are recipients of a Televie Luxembourg fellowship.
   This work was supported by the "Recherche Cancer et Sang" Foundation,
   the "Recherches Scientifiques Luxembourg" Association, the "Een Faerz
   fir kriibskrank Kanner" Association, the Action LIONS "Vaincre le
   Cancer" Association, and by Televie Luxembourg. AM, JYL, and MD are
   supported by the NRF, the MEST of Korea for Tumor Microenvironment GCRC
   2012-0001184 grant, and by Brain Korea (BK21) PLUS program.
CR Arora A, 2004, CARCINOGENESIS, V25, P941, DOI 10.1093/carcin/bgh060
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4
   Cerella C, 2017, LEUKEMIA, V31, P755, DOI 10.1038/leu.2016.341
   Cerella C, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.134
   Cerella C, 2014, BIOTECHNOL ADV, V32, P1111, DOI 10.1016/j.biotechadv.2014.03.006
   Cerella C, 2009, APOPTOSIS, V14, P641, DOI 10.1007/s10495-009-0328-8
   Czepukojc B, 2014, FOOD CHEM TOXICOL, V64, P249, DOI 10.1016/j.fct.2013.10.020
   Donzelli M, 1999, ONCOGENE, V18, P439, DOI 10.1038/sj.onc.1202309
   Eggler AL, 2005, P NATL ACAD SCI USA, V102, P10070, DOI 10.1073/pnas.0502402102
   Foty R, 2011, JOVE-J VIS EXP, DOI 10.3791/2720
   Hannewald P, 2006, ANAL CHEM, V78, P4390, DOI 10.1021/ac0601462
   Hannewald P, 2008, ANAL BIOANAL CHEM, V392, P1335, DOI 10.1007/s00216-008-2409-x
   Jacobsen A., 2017, CGDSR R BASED API AC
   Kelkel M, 2012, CARCINOGENESIS, V33, P2162, DOI 10.1093/carcin/bgs240
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Liu WJ, 2016, CELL MOL BIOL LETT, V21, DOI 10.1186/s11658-016-0031-z
   Liu XL, 2011, AM J CLIN PATHOL, V135, P245, DOI 10.1309/AJCP7FO2VAXIVSTP
   Lobert S, 2000, METHOD ENZYMOL, V323, P77
   Luo F, 2016, ONCOTARGET, V7, P63937, DOI 10.18632/oncotarget.11570
   Mackeh R, 2013, J CELL SCI, V126, P1071, DOI 10.1242/jcs.115626
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   McCarthy DJ, 2009, BIOINFORMATICS, V25, P765, DOI 10.1093/bioinformatics/btp053
   Moscat J, 2012, TRENDS BIOCHEM SCI, V37, P230, DOI 10.1016/j.tibs.2012.02.008
   Mukhtar E, 2014, MOL CANCER THER, V13, P275, DOI 10.1158/1535-7163.MCT-13-0791
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Norman JM, 2010, AUTOPHAGY, V6, P1042, DOI 10.4161/auto.6.8.13337
   PAZDUR R, 1994, ANN ONCOL, V5, P468, DOI 10.1093/oxfordjournals.annonc.a058883
   Phipps AI, 2013, BRIT J CANCER, V108, P1757, DOI 10.1038/bjc.2013.118
   Pino MS, 2010, GASTROENTEROLOGY, V138, P2059, DOI 10.1053/j.gastro.2009.12.065
   Preto A, 2008, J PATHOL, V214, P320, DOI 10.1002/path.2295
   Puissant A, 2012, AM J CANCER RES, V2, P397
   R.C. Team, 2016, LANG ENV STAT COMP
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Schnekenburger M, 2011, BIOCHEM PHARMACOL, V81, P364, DOI 10.1016/j.bcp.2010.10.013
   Sean D, 2007, BIOINFORMATICS, V23, P1846, DOI 10.1093/bioinformatics/btm254
   Sparreboom A, 1997, P NATL ACAD SCI USA, V94, P2031, DOI 10.1073/pnas.94.5.2031
   Spitzner M, 2010, INT J RADIAT ONCOL, V78, P1184, DOI 10.1016/j.ijrobp.2010.06.023
   Therneau T.M., 2000, STAT BIOL HEALTH
   Therneau TM, 2015, A Package for Survival Analysis in S.
   Wei HJ, 2014, GENE DEV, V28, P1204, DOI 10.1101/gad.237354.113
   Yagdi E, 2016, FOOD CHEM TOXICOL, V95, P219, DOI 10.1016/j.fct.2016.07.016
   Zeng RX, 2014, CELL BIOL INT, V38, P1221, DOI 10.1002/cbin.10311
NR 45
TC 9
Z9 9
U1 1
U2 29
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD DEC 1
PY 2017
VL 410
BP 139
EP 157
DI 10.1016/j.canlet.2017.09.011
PG 19
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FN1VB
UT WOS:000415778200014
PM 28943451
DA 2022-04-25
ER

PT J
AU Wei, Y
   Huang, C
   Wu, HY
   Huang, J
AF Wei, Yong
   Huang, Can
   Wu, Haoyu
   Huang, Jian
TI Estrogen Receptor Beta (ER beta) Mediated-CyclinD1 Degradation via
   Autophagy Plays an Anti-Proliferation Role in Colon Cells
SO INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Article
DE ER beta; autophagy; colorectal cancer; mTOR; BNIP3; CyclinD1
ID COLORECTAL-CANCER; CYCLIN D1; DOWN-REGULATION; EXPRESSION; DEATH;
   ARREST; PROLIFERATION; PROGRESSION; ACTIVATION; PREVENTION
AB Dysfunction of autophagic degradation machinery causes tumorigenesis, including colorectal cancer (CRC). Overexpression of CyclinD1 in CRC has been reported. Recent evidence also suggests that ER beta deficiency is related to the pathogenesis of CRC. Very little is known, however, about the detailed molecular mechanisms underlying the relationship among ER beta, autophagy, and CyclinD1 in CRC. Here, results showed that ER beta played an anti-proliferation role in HCT116 through impairing cell cycle but not apoptosis. Additionally, CyclinD1 accumulation was increased in response to chloroquine (CQ) or in MEF Atg7 knockout cells. Further, ER beta could inhibit the mammalian target of rapamycin (mTOR) or activate Bcl-2/adenovirus E1 B 19-kDa-interacting protein 3 (BNIP3) to promote autophagy in HCT116. In summary, these results indicate that ER beta-mediated CyclinD1 degradation can inhibit colon cancer cell growth via autophagy.
C1 [Wei, Yong; Wu, Haoyu; Huang, Jian] Wuhan Univ, Coll Life Sci, Hubei Key Lab Cell Homeostasis, Wuhan, Hubei, Peoples R China.
   [Huang, Can] Wuhan Agr Inspect Ctr, Wuhan, Hubei, Peoples R China.
RP Huang, J (corresponding author), Wuhan Univ, Coll Life Sci, Room 5105, Wuhan 430072, Hubei, Peoples R China.
EM jianhuang@whu.edu.cn
OI Wei, Yong/0000-0002-3506-7921
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31870786, 31371331]; National Basic Research
   Program of China (973 Program)National Basic Research Program of China
   [2012CB720600]
FX We are grateful to Professor Michael Mancini, Professor LongPing Wen,
   Professor Xiaochun Bai and Professor Wei Ding for generously providing
   plasmids. We also thank Dr. Du and Dr. Li for providing the support of
   TEM (The Core Facility and Technical Support, Wuhan Institute of
   Virology). This study was supported by the National Natural Science
   Foundation of China (NO. 31870786 and 31371331) and The National Basic
   Research Program of China (973 Program, 2012CB720600). We thank Mr. Ryan
   Tames and Dr. Yujun Hou (National Institutes of Health) for critical
   reading of the manuscript.
CR Alao JP, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-8
   Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874
   Aryal P, 2014, FEBS J, V281, P4644, DOI 10.1111/febs.12969
   Caiazza F, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00019
   Campbell-Thompson M, 2001, CANCER RES, V61, P632
   Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002
   Chatterjee A, 2015, CANCER LETT, V360, P134, DOI 10.1016/j.canlet.2015.01.043
   Chlebowski RT, 2004, NEW ENGL J MED, V350, P991, DOI 10.1056/NEJMoa032071
   Cho DH, 2012, ANTICANCER RES, V32, P4091
   Choi JH, 2014, GASTROENT RES PRACT, V2014, DOI 10.1155/2014/179586
   Chung JH, 2006, HUM MOL GENET, V15, P2553, DOI 10.1093/hmg/ddl177
   Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004
   Garcia-Fernandez M, 2016, AUTOPHAGY, V12, P1776, DOI 10.1080/15548627.2016.1199301
   Guido C, 2012, CELL CYCLE, V11, P2911, DOI 10.4161/cc.21336
   Ichikawa M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129851
   Jin YP, 2016, FEBS LETT, V590, P672, DOI 10.1002/1873-3468.12090
   Jurikova M, 2016, ACTA HISTOCHEM, V118, P544, DOI 10.1016/j.acthis.2016.05.002
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Komatsu M, 2007, P NATL ACAD SCI USA, V104, P14489, DOI 10.1073/pnas.0701311104
   Komatsu M, 2010, FEBS LETT, V584, P1374, DOI 10.1016/j.febslet.2010.02.017
   Korolchuk VI, 2010, FEBS LETT, V584, P1393, DOI 10.1016/j.febslet.2009.12.047
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Labrie F, 2007, NAT CLIN PRACT ENDOC, V3, P584, DOI 10.1038/ncpendmet0559
   Levi Z, 2017, CANCER-AM CANCER SOC, V123, P4022, DOI 10.1002/cncr.30819
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Loukil A, 2014, J CELL SCI, V127, P2145, DOI 10.1242/jcs.139188
   Martineti V, 2005, ENDOCR-RELAT CANCER, V12, P455, DOI 10.1677/erc.1.00861
   Masamha CP, 2009, CANCER RES, V69, P6565, DOI 10.1158/0008-5472.CAN-09-0913
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Nakamura Y, 2013, PROSTATE, V73, P590, DOI 10.1002/pros.22599
   Paglin S, 2001, CANCER RES, V61, P439
   Paquette M, 2018, CANCERS, V10, DOI 10.3390/cancers10010018
   Porta C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00064
   Raven JF, 2008, J BIOL CHEM, V283, P3097, DOI 10.1074/jbc.M709677200
   Ruddy SC, 2014, MOL CANCER THER, V13, P1882, DOI 10.1158/1535-7163.MCT-13-1066
   Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Shimizu S, 2014, INT J MOL SCI, V15, P3145, DOI 10.3390/ijms15023145
   Shor B, 2009, CELL CYCLE, V8, P3831, DOI 10.4161/cc.8.23.10070
   Sobolewska A, 2009, EUR J CELL BIOL, V88, P117, DOI 10.1016/j.ejcb.2008.09.004
   Song HM, 2015, BIOMOL THER, V23, P339, DOI 10.4062/biomolther.2015.024
   Wang XW, 2014, WORLD J GASTROENTERO, V20, P4178, DOI 10.3748/wjg.v20.i15.4178
   Williams C, 2016, CANCER LETT, V372, P48, DOI 10.1016/j.canlet.2015.12.009
   Wu SY, 2018, HEPATOLOGY, V68, P141, DOI 10.1002/hep.29781
   Xiong HY, 2010, CANCER LETT, V288, P68, DOI 10.1016/j.canlet.2009.06.039
   2004, CANC RES, V64, P423
NR 50
TC 14
Z9 15
U1 4
U2 5
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449-2288
J9 INT J BIOL SCI
JI Int. J. Biol. Sci.
PY 2019
VL 15
IS 5
BP 942
EP 952
DI 10.7150/ijbs.30930
PG 11
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics
GA HX9PE
UT WOS:000467739600004
PM 31182915
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Lin, SC
   Yang, LY
   Shi, HY
   Du, WP
   Qi, YX
   Qiu, C
   Liang, X
   Shi, WB
   Liu, JW
AF Lin, Shengchao
   Yang, Liyan
   Shi, Haiyang
   Du, Wenpei
   Qi, Yingxue
   Qiu, Cen
   Liang, Xin
   Shi, Weibin
   Liu, Jianwen
TI Endoplasmic reticulum-targeting photosensitizer Hypericin confers
   chemosensitization towards oxaliplatin through inducing pro-death
   autophagy
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE Endoplasmic reticulum (ER); Photodynamic therapy (PDT); Autophagic cell
   death; Chemo-sensitization
ID MEDIATED PHOTODYNAMIC THERAPY; CELL-DEATH; CANCER-CELLS; ER STRESS;
   COLORECTAL-CANCER; CARCINOMA CELLS; BREAST-CANCER; GLIOMA-CELLS;
   ACTIVATION; PATHWAY
AB Hypericin is an endoplasmic reticulum (ER)-located photosensitizer, which causes oxidative damage to ER during photodynamic therapy (PDT). Hypericin-mediated PDT (HY-PDT) has been confirmed to enhance chemosensitivity of oxaliplatin (L-OHP) in colon cancer cells. The present study reveals that autophagy plays a key role in chemosensitization during HY-PDT. We proved pro-death autophagy was required for sensitization and HY-PDT/L-OHP antitumor synergism. High dosage of HY-PDT induced autophagic cell death; while low dose of HY-PDT predominantly triggered protective autophagy and promoted cell proliferation. Low dose of HY-PDT reduced the cytotoxicity of L-OHP in oxaliplatin-resistant colon cancer cells. Different level of autophagy therefore contributed to the opposite effect of HY-PDT on cell fate and chemo-sensitivity. Furthermore, we revealed the role of CHOP as a regulator connecting pro-survival and pro-death autophagy under ER damage. High dose of HY-PDT induced massive ROS generation and severe ER stress, which then led to induction of CHOP. CHOP thereby activated CHOP/TRIB3/Akt/mTOR cascade and triggered autophagic cell death. Additionally, when apoptotic pathway was blocked, cells treated with high dose of HY-PDT preferentially underwent death through autophagic pathway. On the other hand, suppression of autophagy made cells more vulnerable to apoptosis under low dose of HY-PDT. These results provided new evidences for the clinical application of ER-targeting PDT in modifying chemosensitivity of colorectal cancer therapy.
C1 [Lin, Shengchao; Yang, Liyan; Shi, Haiyang; Du, Wenpei; Qi, Yingxue; Qiu, Cen; Liang, Xin; Liu, Jianwen] East China Univ Sci & Technol, State Key Lab Bioreactor Engn, Sch Pharm, POB 268,130 Meilong Rd, Shanghai 200237, Peoples R China.
   [Lin, Shengchao; Yang, Liyan; Shi, Haiyang; Du, Wenpei; Qi, Yingxue; Qiu, Cen; Liang, Xin; Liu, Jianwen] East China Univ Sci & Technol, Shanghai Key Lab New Drug Design, Sch Pharm, POB 268,130 Meilong Rd, Shanghai 200237, Peoples R China.
   [Shi, Weibin] Shanghai Jiao Tong Univ, Dept Gen Surg, Xinhua Hosp, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China.
RP Liang, X; Liu, JW (corresponding author), East China Univ Sci & Technol, State Key Lab Bioreactor Engn, Sch Pharm, POB 268,130 Meilong Rd, Shanghai 200237, Peoples R China.; Liang, X; Liu, JW (corresponding author), East China Univ Sci & Technol, Shanghai Key Lab New Drug Design, Sch Pharm, POB 268,130 Meilong Rd, Shanghai 200237, Peoples R China.; Shi, WB (corresponding author), Shanghai Jiao Tong Univ, Dept Gen Surg, Xinhua Hosp, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China.
EM xin.liang@ecust.edu.cn; weibindr@aliyun.com; liujian@ecust.edu.cn
FU Shanghai Committee of Science and TechnologyShanghai Science &
   Technology Committee [11DZ2260600]; Shanghai Health and Family Planning
   Commission [201440495]
FX We are grateful to Prof. Feng Qian (Fudan University, Shanghai China)
   for providing the pCDNA3.1-GFP-LC3 plasmid. This work was supported by
   Shanghai Committee of Science and Technology [grant 11DZ2260600] and
   Program of Shanghai Health and Family Planning Commission (201440495).
CR B'chir W, 2014, CELL SIGNAL, V26, P1385, DOI 10.1016/j.cellsig.2014.03.009
   B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563
   Borowicz S, 2014, JOVE-J VIS EXP, DOI 10.3791/51998
   Buytaert E, 2008, ONCOGENE, V27, P1916, DOI 10.1038/sj.onc.1210825
   Buytaert E, 2006, AUTOPHAGY, V2, P238, DOI 10.4161/auto.2730
   Buytaert E, 2006, FASEB J, V20, P756, DOI 10.1096/fj.05-4305fje
   Byun YJ, 2009, NEUROSCI LETT, V461, P131, DOI 10.1016/j.neulet.2009.06.011
   Chen S, 2013, CLIN CANCER RES, V19, P6853, DOI 10.1158/1078-0432.CCR-13-1617
   Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233
   CHOU TC, 1983, TRENDS PHARMACOL SCI, V4, P450, DOI 10.1016/0165-6147(83)90490-X
   Cloonan SM, 2011, INT J CANCER, V128, P1712, DOI 10.1002/ijc.25477
   Davids LM, 2008, J PHOTOCH PHOTOBIO B, V91, P67, DOI 10.1016/j.jphotobiol.2008.01.011
   Dewaele M, 2011, J CELL MOL MED, V15, P1402, DOI 10.1111/j.1582-4934.2010.01118.x
   Ding ZB, 2011, CLIN CANCER RES, V17, P6229, DOI 10.1158/1078-0432.CCR-11-0816
   Donadelli M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.36
   Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817
   Ell C, 1998, GUT, V43, P345, DOI 10.1136/gut.43.3.345
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1
   Grothey A, 2010, ONCOLOGY-BASEL, V79, P389, DOI 10.1159/000323491
   Guo WJ, 2013, AUTOPHAGY, V9, P996, DOI 10.4161/auto.24407
   Hariharan N, 2011, ANTIOXID REDOX SIGN, V14, P2179, DOI 10.1089/ars.2010.3488
   Huang Z, 2005, TECHNOL CANCER RES T, V4, P283, DOI 10.1177/153303460500400308
   Jendzelovska Z, 2014, TOXICOL IN VITRO, V28, P1259, DOI 10.1016/j.tiv.2014.06.011
   Karioti A, 2010, INT J MOL SCI, V11, P562, DOI 10.3390/ijms11020562
   Kondo Y, 2006, AUTOPHAGY, V2, P85, DOI 10.4161/auto.2.2.2463
   Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984
   Krammer B, 2012, CURR MED CHEM, V19, P793, DOI 10.2174/092986712799034842
   Lee YJ, 2012, INT J MED SCI, V9, P881, DOI 10.7150/ijms.5011
   Leng SL, 2013, INT J CANCER, V133, P2781, DOI 10.1002/ijc.28301
   Li JR, 2013, TOXICOL LETT, V220, P267, DOI 10.1016/j.toxlet.2013.04.021
   Li TL, 2013, AUTOPHAGY, V9, P1057, DOI 10.4161/auto.24632
   Li YQ, 2012, J CELL BIOCHEM, V113, P3165, DOI 10.1002/jcb.24194
   Lin SC, 2016, INT J BIOCHEM CELL B, V71, P24, DOI 10.1016/j.biocel.2015.12.003
   Lin SC, 2014, CELL STRESS CHAPERON, V19, P927, DOI 10.1007/s12192-014-0517-4
   Liu W., 2015, MATH PROBL ENG, V2015, P1, DOI DOI 10.1007/S00382-015-2782-Z
   McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001
   Paba V, 2001, J PHOTOCH PHOTOBIO B, V60, P87, DOI 10.1016/S1011-1344(01)00125-7
   Panjehpour M, 2005, GASTROINTEST ENDOSC, V61, P13, DOI 10.1016/S0016-5107(04)02394-6
   Rashid HO, 2015, AUTOPHAGY, V11, P1956, DOI 10.1080/15548627.2015.1091141
   Reiners JJ, 2010, AUTOPHAGY, V6, P7, DOI 10.4161/auto.6.1.10220
   Ren SX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063641
   Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027
   Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948
   Schonthal AH, 2009, CANCER LETT, V275, P163, DOI 10.1016/j.canlet.2008.07.005
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Shi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051076
   Solar P., 2010, RADIAT RES, V175, P51, DOI DOI 10.1667/RR2276.1
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Tai WT, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.18
   Tang B, 2015, AUTOPHAGY, V11, P344, DOI 10.1080/15548627.2015.1023682
   Tasdemir Ezgi, 2008, V445, P29, DOI 10.1007/978-1-59745-157-4_3
   Torres S, 2011, MOL CANCER THER, V10, P90, DOI 10.1158/1535-7163.MCT-10-0688
   Vandenbogaerde AL, 1998, J PHOTOCH PHOTOBIO B, V45, P87, DOI 10.1016/S1011-1344(98)00163-8
   Vandenbogaerde AL, 1996, ANTICANCER RES, V16, P1619
   Verfaillie T., 2010, INT J CELL BIOL, V2010
   Wada Atsushi, 2002, Drug Metab Pharmacokinet, V17, P467, DOI 10.2133/dmpk.17.467
   Wang J, 2014, AUTOPHAGY, V10, P766, DOI 10.4161/auto.27954
   Wiedmann MW, 2004, CURR PHARM BIOTECHNO, V5, P397, DOI 10.2174/1389201043376805
   Yang HZ, 2015, CANCER LETT, V361, P128, DOI 10.1016/j.canlet.2015.02.045
   Zheng YH, 2015, J BIOL CHEM, V290, P8975, DOI 10.1074/jbc.M114.624965
   Zoepf T, 2008, HPB, V10, P161, DOI 10.1080/13651820801992625
NR 62
TC 26
Z9 27
U1 3
U2 35
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357-2725
EI 1878-5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD JUN
PY 2017
VL 87
BP 54
EP 68
DI 10.1016/j.biocel.2017.04.001
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA EX8VN
UT WOS:000403528400008
PM 28392376
DA 2022-04-25
ER

PT J
AU Mokarram, P
   Albokashy, M
   Zarghooni, M
   Moosavi, MA
   Sepehri, Z
   Chen, QM
   Hudecki, A
   Sargazi, A
   Alizadeh, J
   Moghadam, AR
   Hashemi, M
   Movassagh, H
   Klonisch, T
   Owji, AA
   Los, MJ
   Ghavami, S
AF Mokarram, Pooneh
   Albokashy, Mohammed
   Zarghooni, Maryam
   Moosavi, Mohammad Amin
   Sepehri, Zahra
   Chen, Qi Min
   Hudecki, Andrzej
   Sargazi, Aliyeh
   Alizadeh, Javad
   Moghadam, Adel Rezaei
   Hashemi, Mohammad
   Movassagh, Hesam
   Klonisch, Thomas
   Owji, Ali Akbar
   Los, Marek J.
   Ghavami, Saeid
TI New frontiers in the treatment of colorectal cancer: Autophagy and the
   unfolded protein response as promising targets
SO AUTOPHAGY
LA English
DT Review
DE autophagy; Beclin 1; cancer therapy; colorectal cancer; ER-stress;
   GRP78; unfolded protein response
ID ENDOPLASMIC-RETICULUM-STRESS; CHAPERONE-MEDIATED AUTOPHAGY; GENE COPY
   NUMBER; RANDOMIZED CONTROLLED-TRIAL; GENOME-WIDE ASSOCIATION; INDUCED
   COLON-CANCER; STEM-LIKE CELLS; GROWTH IN-VIVO; DENDRITIC CELLS;
   THYMIDYLATE SYNTHASE
AB Colorectal cancer (CRC), despite numerous therapeutic and screening attempts, still remains a major life-threatening malignancy. CRC etiology entails both genetic and environmental factors. Macroautophagy/autophagy and the unfolded protein response (UPR) are fundamental mechanisms involved in the regulation of cellular responses to environmental and genetic stresses. Both pathways are interconnected and regulate cellular responses to apoptotic stimuli. In this review, we address the epidemiology and risk factors of CRC, including genetic mutations leading to the occurrence of the disease. Next, we discuss mutations of genes related to autophagy and the UPR in CRC. Then, we discuss how autophagy and the UPR are involved in the regulation of CRC and how they associate with obesity and inflammatory responses in CRC. Finally, we provide perspectives for the modulation of autophagy and the UPR as new therapeutic options for CRC treatment.
C1 [Mokarram, Pooneh] Shiraz Univ Med Sci, Colorectal Res Ctr, Shiraz, Iran.
   [Mokarram, Pooneh] Shiraz Univ Med Sci, Dept Biochem, Sch Med, Shiraz, Iran.
   [Albokashy, Mohammed; Chen, Qi Min; Alizadeh, Javad; Moghadam, Adel Rezaei; Klonisch, Thomas; Ghavami, Saeid] Univ Manitoba, Max Rady Coll Med, Rady Fac Hlth Sci, Dept Human Anat & Cell Sci, Winnipeg, MB, Canada.
   [Zarghooni, Maryam; Sepehri, Zahra; Sargazi, Aliyeh] Zabol Univ Med Sci, Zabol, Iran.
   [Zarghooni, Maryam] Univ Toronto Alumni, Toronto, ON, Canada.
   [Moosavi, Mohammad Amin] Natl Inst Genet Engn & Biotechnol, Inst Med Biotechnol, Dept Mol Med, Tehran, Iran.
   [Hudecki, Andrzej] Inst Nonferrous Met, Gliwice, Poland.
   [Hashemi, Mohammad] Zahedan Univ Med Sci, Sch Med, Dept Clin Biochem, Zahedan, Iran.
   [Movassagh, Hesam] Univ Manitoba, Coll Med, Rady Fac Hlth Sci, Dept Immunol, Winnipeg, MB, Canada.
   [Owji, Ali Akbar] Shiraz Med Univ, Sch Med, Dept Clin Biochem, Shiraz, Iran.
   [Los, Marek J.] Jagiellonian Univ, Malopolska Ctr Biotechnol, Krakow, Poland.
   [Ghavami, Saeid] LinkoCare Life Sci AB, Mjardevi Sci Pk,Teknikringen 10,Floor 3, Linkoping, Sweden.
   [Ghavami, Saeid] Shiraz Univ Med Sci, Hlth Policy Res Ctr, Shiraz, Iran.
RP Los, MJ (corresponding author), LinkoCare Life Sci AB, Mjardevi Sci Pk,Teknikringen 10,Floor 3, Linkoping, Sweden.; Ghavami, S (corresponding author), Univ Manitoba, Coll Med, Fac Hlth Sci, Dept Human Anat & Cell Sci, Winnipeg, MB, Canada.
EM bioappl@gmail.com; saied.ghavami@umanitoba.ca
RI Klonisch, Thomas/W-9923-2019; Hashemi, Mohammad/H-2446-2016; Alizadeh,
   Javad/AAR-4824-2020; Moosavi, Mohammad Amin/AAK-3240-2020; Mokarram,
   Pooneh/E-1613-2012
OI Hashemi, Mohammad/0000-0002-6074-7101; Alizadeh,
   Javad/0000-0001-9082-3083; Mokarram, Pooneh/0000-0002-9717-0473;
   Ghavami, Saeid/0000-0001-5948-508X; ALBOKASHY,
   MOHAMMED/0000-0002-0933-9110; Sargazi, Aliyeh/0000-0002-9037-6639;
   Klonisch, Thomas/0000-0003-0448-6741
FU University of Manitoba; National Institute for Genetic Engineering and
   Biotechnology; Natural Sciences and Engineering Council of Canada
   (NSERC)Natural Sciences and Engineering Research Council of Canada
   (NSERC); MITACS; NCN [2016/21/B/NZ1/02812]; Manitoba Medical Service
   Foundation
FX SG acknowledges Manitoba Medical Service Foundation, and University of
   Manitoba Research Grant Program. AM acknowledges National Institute for
   Genetic Engineering and Biotechnology Research Grants. TK extends his
   gratitude to the Natural Sciences and Engineering Council of Canada
   (NSERC) for funding. MA was supported by MITACS Globalink award. MJL and
   AH kindly acknowledges the support from NCN grant #:
   2016/21/B/NZ1/02812.
CR Aarnio M, 1999, INT J CANCER, V81, P214, DOI 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.3.CO;2-C
   Abd-Elzaher MM, 2014, RES CHEM INTERMEDIAT, V40, P1923, DOI 10.1007/s11164-013-1090-7
   Abdallah EA, 2015, INT J CANCER, V137, P1397, DOI 10.1002/ijc.29495
   Adwan H, 2014, BIOTECHNOL ADV, V32, P1077, DOI 10.1016/j.biotechadv.2014.03.008
   Akbari-Birgani S, 2016, DRUG DISCOV TODAY, V21, P836, DOI 10.1016/j.drudis.2016.03.004
   Al-aidaroos AQO, 2013, J CLIN INVEST, V123, P3459, DOI 10.1172/JCI66824
   Allegra CJ, 2002, J CLIN ONCOL, V20, P1735, DOI 10.1200/JCO.2002.07.080
   Allen WL, 2012, MOL CANCER THER, V11, P119, DOI 10.1158/1535-7163.MCT-11-0510
   Amankwatia EB, 2015, BRIT J CANCER, V112, P1480, DOI 10.1038/bjc.2015.125
   Anderson JC, 2011, EXPERT REV GASTROENT, V5, P25, DOI 10.1586/EGH.10.86
   Andre T, 2013, CURR COLORECT CANC R, V9, P261, DOI 10.1007/s11888-013-0181-6
   Arcaroli JJ, 2012, MOL ONCOL, V6, P370, DOI 10.1016/j.molonc.2012.03.004
   Ashktorab H, 2012, DIGEST DIS SCI, V57, P905, DOI 10.1007/s10620-011-2026-y
   Banchereau J, 2005, NAT REV IMMUNOL, V5, P296, DOI 10.1038/nri1592
   Bao WH, 2016, MOL MED REP, V13, P796, DOI 10.3892/mmr.2015.4599
   Bennett MK, 2015, patent application publication, Patent No. [us2015/0004134A1, 20150004134]
   Berard F, 2000, J EXP MED, V192, P1535, DOI 10.1084/jem.192.11.1535
   Berindan-Neagoe I, 2013, J GASTROINTEST LIVER, V22, P37
   Bijnsdorp IV, 2010, INT J CANCER, V126, P2457, DOI 10.1002/ijc.24943
   Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4
   Bluemlein K, 2012, ONCOTARGET, V3, P1356
   Boelens J, 2007, IN VIVO, V21, P215
   Boidot R, 2016, INT J COLORECTAL DIS, V31, P1245, DOI 10.1007/s00384-015-2448-7
   Bondanese VP, 2016, METALLOMICS, V8, P1177, DOI 10.1039/c6mt00102e
   Bosset JF, 2006, NEW ENGL J MED, V355, P1114, DOI 10.1056/NEJMoa060829
   Bravo R, 2013, INT REV CEL MOL BIO, V301, P215, DOI 10.1016/B978-0-12-407704-1.00005-1
   Brech A, 2009, MOL ONCOL, V3, P366, DOI 10.1016/j.molonc.2009.05.007
   Brenner H, 2011, ANN INTERN MED, V154, P22, DOI 10.7326/0003-4819-154-1-201101040-00004
   Broaddus RR, 2004, MODERN PATHOL, V17, P981, DOI 10.1038/modpathol.3800150
   Buchanan JA, 2012, CURR OPIN HEMATOL, V19, P27, DOI 10.1097/MOH.0b013e32834da9ef
   Buhrmann C, 2015, BIOCHEM PHARMACOL, V98, P51, DOI 10.1016/j.bcp.2015.08.105
   Bultman SJ, 2016, SEMIN ONCOL, V43, P97, DOI 10.1053/j.seminoncol.2015.09.001
   Burt RW, 2000, GASTROENTEROLOGY, V119, P837, DOI 10.1053/gast.2000.16508
   Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416
   Canada CCSNCIo, 2008, CAN CANC STAT 2008
   Cao SS, 2012, CURR BIOL, V22, pR622, DOI 10.1016/j.cub.2012.07.004
   Caraglia M, 2005, CANCER BIOL THER, V4, P1159, DOI 10.4161/cbt.4.10.2206
   Carethers JM, 2015, GASTROENTEROLOGY, V149, P1177, DOI 10.1053/j.gastro.2015.06.047
   Caruso ME, 2008, MOL CELL BIOL, V28, P4261, DOI 10.1128/MCB.02252-07
   Castellarin M, 2012, GENOME RES, V22, P299, DOI 10.1101/gr.126516.111
   Cebola I, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0110-4
   Celluzzi CM, 1996, J EXP MED, V183, P283, DOI 10.1084/jem.183.1.283
   Center MM, 2009, CA-CANCER J CLIN, V59, P366, DOI 10.3322/caac.20038
   Chaabane W, 2014, NEOPLASIA, V16, P679, DOI 10.1016/j.neo.2014.08.001
   Chaniyara R, 2013, J MED CHEM, V56, P1544, DOI 10.1021/jm301788a
   Chaudhuri AR, 2012, NAT STRUCT MOL BIOL, V19, P417, DOI 10.1038/nsmb.2258
   Chekhonin VP, 2013, CURR CANCER DRUG TAR, V13, P423, DOI 10.2174/15680096113139990074
   Chen D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090607
   Chen N, 2010, FEBS LETT, V584, P1427, DOI 10.1016/j.febslet.2009.12.034
   Chen N, 2009, BBA-MOL CELL RES, V1793, P1516, DOI 10.1016/j.bbamcr.2008.12.013
   Chen ZH, 2013, DIGEST DIS SCI, V58, P2887, DOI 10.1007/s10620-013-2732-8
   Cherry Lorraine M, 2011, Proc (Bayl Univ Med Cent), V24, P139
   Chevet E, 2015, CANCER DISCOV, V5, P586, DOI 10.1158/2159-8290.CD-14-1490
   Chia WK, 2012, NAT REV CLIN ONCOL, V9, P561, DOI 10.1038/nrclinonc.2012.137
   Chiacchiera F, 2009, CELL DEATH DIFFER, V16, P1203, DOI 10.1038/cdd.2009.36
   Chiacchiera F, 2008, CANCER LETT, V265, P16, DOI 10.1016/j.canlet.2008.02.061
   Chiacchiera F, 2009, AUTOPHAGY, V5, P1030, DOI 10.4161/auto.5.7.9252
   Cho J, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-141
   Choi JH, 2014, GASTROENT RES PRACT, V2014, DOI 10.1155/2014/179586
   Cieslar-Pobuda A, 2014, CYTOM PART A, V85A, P628, DOI 10.1002/cyto.a.22437
   Coffee EM, 2013, CLIN CANCER RES, V19, P2688, DOI 10.1158/1078-0432.CCR-12-2556
   Collura A, 2014, GASTROENTEROLOGY, V146, P401, DOI 10.1053/j.gastro.2013.10.054
   Comes F, 2007, CELL DEATH DIFFER, V14, P693, DOI 10.1038/sj.cdd.4402076
   Coppola A, 2015, FRONT MED, V2, DOI 10.3389/fmed.2015.00033
   Coppola D, 2008, CANCER-AM CANCER SOC, V113, P2665, DOI 10.1002/cncr.23892
   Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471
   Cui XJ, 2016, J VIROL, V90, P486, DOI 10.1128/JVI.01263-15
   Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003
   Cushman SM, 2015, CLIN CANCER RES, V21, P1078, DOI 10.1158/1078-0432.CCR-14-2313
   Dalerba P, 2016, NEW ENGL J MED, V374, P211, DOI 10.1056/NEJMoa1506597
   Dang CV, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.297pe75
   de la Cruz-Morcillo MA, 2012, ONCOGENE, V31, P1073, DOI 10.1038/onc.2011.321
   De Pergola G, 2013, J OBES, V2013, DOI 10.1155/2013/291546
   De Roock W, 2010, JAMA-J AM MED ASSOC, V304, P1812, DOI 10.1001/jama.2010.1535
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Deegan S, 2013, CELL MOL LIFE SCI, V70, P2425, DOI 10.1007/s00018-012-1173-4
   Deenen MJ, 2011, CLIN CANCER RES, V17, P3455, DOI 10.1158/1078-0432.CCR-10-2209
   Delgado MA, 2009, CELL DEATH DIFFER, V16, P976, DOI 10.1038/cdd.2009.40
   Diaz-Algorri Y, 2015, J DIABETES COMPLICAT, V29, P502, DOI 10.1016/j.jdiacomp.2015.01.010
   Dikic I, 2010, CANCER RES, V70, P3431, DOI 10.1158/0008-5472.CAN-09-4027
   Din FVN, 2012, GASTROENTEROLOGY, V142, P1504, DOI 10.1053/j.gastro.2012.02.050
   Dolatkhah R, 2015, J CANCER EPIDEMIOL, V2015, DOI 10.1155/2015/643020
   Donohoe DR, 2011, CELL METAB, V13, P517, DOI 10.1016/j.cmet.2011.02.018
   Du HS, 2011, ONCOL REP, V26, P495, DOI 10.3892/or.2011.1297
   Elinav E, 2013, MUCOSAL IMMUNOL, V6, P4, DOI 10.1038/mi.2012.115
   Eskelinen EL, 2005, TRAFFIC, V6, P1058, DOI 10.1111/j.1600-0854.2005.00337.x
   Falchook GS, 2012, LANCET, V379, P1893, DOI 10.1016/S0140-6736(12)60398-5
   Farraye FA, 2010, GASTROENTEROLOGY, V138, P746, DOI [10.1053/j.gastro.2009.12.035, 10.1053/j.gastro.2009.12.037]
   Fasano E, 2012, BBA-MOL BASIS DIS, V1822, P1762, DOI 10.1016/j.bbadis.2012.08.003
   Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235
   Fels DR, 2008, CANCER RES, V68, P9323, DOI 10.1158/0008-5472.CAN-08-2873
   Fels DR, 2006, CANCER BIOL THER, V5, P723, DOI 10.4161/cbt.5.7.2967
   Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027
   Fiala O, 2013, CANCER GENET-NY, V206, P26, DOI 10.1016/j.cancergen.2012.12.003
   Flemer B, 2016, GUT
   Forman MS, 2003, TRENDS NEUROSCI, V26, P407, DOI 10.1016/S0166-2236(03)00197-8
   Francipane MG, 2013, ONCOTARGET, V4, P1948, DOI 10.18632/oncotarget.1310
   Fujimoto T, 2007, ANTICANCER RES, V27, P127
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Gandesiri M, 2012, APOPTOSIS, V17, P1300, DOI 10.1007/s10495-012-0757-7
   Gao C, 2010, NAT CELL BIOL, V12, P781, DOI 10.1038/ncb2082
   Garcia-Maurino S, 2012, CURR PHARM DESIGN, V18, P3853, DOI 10.2174/138161212802083653
   Gardella S, 2002, EMBO REP, V3, P995, DOI 10.1093/embo-reports/kvf198
   Garg AD, 2012, TRENDS MOL MED, V18, P589, DOI 10.1016/j.molmed.2012.06.010
   Garg AD, 2010, BBA-REV CANCER, V1805, P53, DOI 10.1016/j.bbcan.2009.08.003
   Ge RR, 2006, CLIN CANCER RES, V12, P4315, DOI 10.1158/1078-0432.CCR-06-0162
   Geva R, 2015, CANCER INVEST, V33, P89, DOI 10.3109/07357907.2014.998834
   Ghavami S., 2015, AUTOPHAGY CANC OTHER, V7, P91, DOI [10.1016/B978-0-12-801043-3.00005-4, DOI 10.1016/B978-0-12-801043-3.00005-4]
   Ghavami S, 2014, PROG NEUROBIOL, V112, P24, DOI 10.1016/j.pneurobio.2013.10.004
   Ghavami S, 2010, BBA-MOL CELL RES, V1803, P452, DOI 10.1016/j.bbamcr.2009.12.005
   Ghoshal K, 1997, BIOCHEM PHARMACOL, V53, P1569, DOI 10.1016/S0006-2952(97)00040-3
   Giovannetti E, 2005, MOL PHARMACOL, V68, P110, DOI 10.1124/mol.104.009373
   Goel A, 2010, NUTR CANCER, V62, P919, DOI 10.1080/01635581.2010.509835
   Gomes LC, 2014, MOL CELL, V54, P224, DOI 10.1016/j.molcel.2014.03.009
   Gong C, 2013, ONCOGENE, V32, P2261, DOI 10.1038/onc.2012.252
   Gonzalez G, 1998, ANN ONCOL, V9, P431, DOI 10.1023/A:1008261031034
   Gregory AD, 2011, CANCER RES, V71, P2411, DOI 10.1158/0008-5472.CAN-10-2583
   Grimm WA, 2015, GUT, V2, P2014
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Guichard C, 2006, CARCINOGENESIS, V27, P1812, DOI 10.1093/carcin/bgl009
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   Gurevich-Panigrahi T, 2009, CURR MED CHEM, V16, P506, DOI 10.2174/092986709787315568
   Gustavsson B, 2015, CLIN COLORECTAL CANC, V14, P1, DOI 10.1016/j.clcc.2014.11.002
   Habeeb BS, 2011, CANCER SCI, V102, P999, DOI 10.1111/j.1349-7006.2011.01902.x
   Haller DG, 2005, J CLIN ONCOL, V23, P8671, DOI 10.1200/JCO.2004.00.5686
   Hardcastle JD, 1996, LANCET, V348, P1472, DOI 10.1016/S0140-6736(96)03386-7
   Healy SJM, 2009, EUR J PHARMACOL, V625, P234, DOI 10.1016/j.ejphar.2009.06.064
   Hetz C, 2013, NAT REV DRUG DISCOV, V12, P703, DOI 10.1038/nrd3976
   Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270
   Hinnebusch BF, 2002, J NUTR, V132, P1012, DOI 10.1093/jn/132.5.1012
   Hiss DC, 2009, EXPERT OPIN DRUG DIS, V4, P907, DOI 10.1517/17460440903055032
   Hiss DC, 2009, EXPERT OPIN DRUG DIS, V4, P799, DOI 10.1517/17460440903052559
   Honeywell RJ, 2015, INT J BIOCHEM CELL B, V60, P73, DOI 10.1016/j.biocel.2014.12.010
   Hong Y, 2014, J PINEAL RES, V56, P264, DOI 10.1111/jpi.12119
   Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034
   Hotamisligil GS, 2008, NAT REV IMMUNOL, V8, P923, DOI 10.1038/nri2449
   Huo HZ, 2014, BIOCHEM BIOPH RES CO, V443, P406, DOI 10.1016/j.bbrc.2013.11.099
   Ieta K, 2009, INT J CANCER, V125, P926, DOI 10.1002/ijc.24453
   Innocenti F, 2012, CLIN CANCER RES, V18, P577, DOI 10.1158/1078-0432.CCR-11-1387
   Ioannou S, MEDIATORS INFLAMM
   Iranpour M, 2016, EXPERT REV MOL MED, V18, DOI 10.1017/erm.2015.19
   Ishtikhar M, 2016, J BIOMOL STRUCT DYN, V34, P1545, DOI 10.1080/07391102.2015.1082504
   Jain MV, 2016, ONCOTARGET, V7, P20953, DOI 10.18632/oncotarget.7996
   Jain MV, 2015, CELL CYCLE, V14, P2109, DOI 10.1080/15384101.2015.1041692
   Jakobsen CH, 2008, J LIPID RES, V49, P2089, DOI 10.1194/jlr.M700389-JLR200
   Jangamreddy JR, 2012, HEPAT MON, V12, DOI 10.5812/hepatmon.6159
   Jasperson KW, 2010, GASTROENTEROLOGY, V138, P2044, DOI 10.1053/j.gastro.2010.01.054
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Jin C, 2016, BIOCHEM BIOPH RES CO, V470, P75, DOI 10.1016/j.bbrc.2015.12.119
   Jin DP, 2015, CLIN THER, V37, P996, DOI 10.1016/j.clinthera.2015.04.004
   Jin HR, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.122
   Jin KT, 2010, CLIN TRANSL ONCOL, V12, P473, DOI 10.1007/s12094-010-0540-6
   Jo YK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052705
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kaczirek K, 2015, CLIN COLORECTAL CANC, V14, P91, DOI 10.1016/j.clcc.2014.12.003
   Kan S, 2012, ANTICANCER RES, V32, P5363
   Kandioler D, 2015, EBIOMEDICINE, V2, P825, DOI 10.1016/j.ebiom.2015.06.003
   Kaneko M, 2014, J CANCER RES CLIN, V140, P769, DOI 10.1007/s00432-014-1628-0
   Kantara C, 2014, CANCER RES, V74, P2487, DOI 10.1158/0008-5472.CAN-13-3536
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Kaufman RJ, 2004, TRENDS BIOCHEM SCI, V29, P152, DOI 10.1016/j.tibs.2004.01.004
   Kauntz H, 2011, APOPTOSIS, V16, P1042, DOI 10.1007/s10495-011-0631-z
   Kaushik S, 2008, MOL BIOL CELL, V19, P2179, DOI 10.1091/mbc.E07-11-1155
   Keku TO, 2015, AM J PHYSIOL-GASTR L, V308, P24
   Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167
   Khan O, 2012, IMMUNOL CELL BIOL, V90, P85, DOI 10.1038/icb.2011.100
   Khan S, 2015, CRIT REV ONCOL HEMAT, V15, P00091
   Kim JY, 2010, J CELL PHYSIOL, V224, P33, DOI 10.1002/jcp.22085
   Kim JH, 2011, AUTOPHAGY, V7, P1187, DOI 10.4161/auto.7.10.16643
   Kim SY, 2014, BIOCHEM PHARMACOL, V88, P178, DOI 10.1016/j.bcp.2014.01.027
   Kim YH, 2016, FEBS LETT, V590, P1365, DOI 10.1002/1873-3468.12172
   Kirchberger S, 2013, J EXP MED, V210, P917, DOI 10.1084/jem.20122308
   Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Knudsen Anne Lyster, 2003, Fam Cancer, V2, P43, DOI 10.1023/A:1023286520725
   Ko YH, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/329839
   Ko YS, 2016, APMIS, V124, P748, DOI 10.1111/apm.12569
   Koehler BC, 2014, WORLD J GASTROENTERO, V20, P1923, DOI 10.3748/wjg.v20.i8.1923
   Koido S, 2000, J IMMUNOL, V165, P5713, DOI 10.4049/jimmunol.165.10.5713
   Koido S, 2005, CLIN CANCER RES, V11, P7891, DOI 10.1158/1078-0432.CCR-05-1330
   Koido S, 2013, WORLD J GASTROENTERO, V19, P8531, DOI 10.3748/wjg.v19.i46.8531
   Koido S, 2012, IMMUNOTHERAPY-UK, V4, P5, DOI [10.2217/imt.11.150, 10.2217/IMT.11.150]
   Kon M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003182
   Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497
   Kostic AD, 2012, GENOME RES, V22, P292, DOI 10.1101/gr.126573.111
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Kourelis TV, 2012, MED ONCOL, V29, P1314, DOI 10.1007/s12032-011-9846-7
   Kozlenkov A, 2004, J BONE MINER RES, V19, P1862, DOI 10.1359/JBMR.040608
   Kuniyasu H, 2003, ONCOL REP, V10, P445
   Labianca R, 2010, ANN ONCOL, V21, pv70, DOI 10.1093/annonc/mdq168
   Latheef SAA, 2016, IMMUNOL LETT, V170, P37, DOI 10.1016/j.imlet.2015.12.008
   Lau T, 2013, CANCER RES, V73, P3132, DOI 10.1158/0008-5472.CAN-12-4562
   Le Grand JN, 2011, AUTOPHAGY, V7, P1098, DOI 10.4161/auto.7.10.15904
   Lee SJ, 2015, ONCOTARGET, V6, P39028, DOI 10.18632/oncotarget.5494
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Levy J, 2015, NAT CELL BIOL, V17, P1062, DOI 10.1038/ncb3206
   Li Sha, 2013, Acta Micropalaeontologica Sinica, V30, P1
   Li W, 2012, J CELL BIOL, V197, P27, DOI 10.1083/jcb.201111053
   Li XM, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756-8722-4-8
   Liang XY, 2012, CANCER RES, V72, P2791, DOI 10.1158/0008-5472.CAN-12-0320
   Liao VHC, 2010, CHEM RES TOXICOL, V23, P926, DOI 10.1021/tx100016e
   Liesenfeld DB, 2015, AM J CLIN NUTR, V102, P433, DOI 10.3945/ajcn.114.103804
   Likus W, 2016, ARCH IMMUNOL THER EX, V64, P241, DOI 10.1007/s00005-015-0373-7
   Likus W, 2016, DRUG RESIST UPDATE, V25, P13, DOI 10.1016/j.drup.2016.02.001
   Lin JH, 2007, SCIENCE, V318, P944, DOI 10.1126/science.1146361
   Liton PB, 2016, EXP EYE RES, V144, P29, DOI 10.1016/j.exer.2015.07.013
   Liu EY, 2012, J CELL SCI, V125, P2349, DOI 10.1242/jcs.093708
   Liu X, 2014, PHARMACOGENOMICS J, V14, P120, DOI 10.1038/tpj.2013.10
   Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Lopez P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078756
   Lorenzo G, 2015, MOL IMMUNOL, V66, P78, DOI 10.1016/j.molimm.2015.02.001
   Lourencao BC, 2016, SENSOR ACTUAT B-CHEM, V222, P181, DOI 10.1016/j.snb.2015.08.036
   Lu JJ, 2011, INVEST NEW DRUG, V29, P1276, DOI 10.1007/s10637-010-9481-8
   Lu M, 2015, CELL BIOCHEM BIOPHYS, V73, P137, DOI 10.1007/s12013-015-0643-3
   Lundemo AG, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-190
   Luo B, 2013, ONCOGENE, V32, P805, DOI 10.1038/onc.2012.130
   Luo Y, 2014, CANCER RES, V74, P330, DOI 10.1158/0008-5472.CAN-13-1052
   Luo Y, 2013, EUR J CANCER, V49, P741, DOI 10.1016/j.ejca.2012.09.016
   Lupini L, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1752-5
   Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242
   Ma YT, 2013, IMMUNITY, V39, P211, DOI 10.1016/j.immuni.2013.07.017
   Maclean DS, 2000, J MICROENCAPSUL, V17, P307
   Madia Federica, 2012, Cells, V1, P535, DOI 10.3390/cells1030535
   Mah LY, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008821
   Mandel JS, 2000, NEW ENGL J MED, V343, P1603, DOI 10.1056/NEJM200011303432203
   Marechal R, 2010, CANCER-AM CANCER SOC, V116, P5200, DOI 10.1002/cncr.25303
   Marin JJG, 2012, DRUG METAB REV, V44, P148, DOI 10.3109/03602532.2011.638303
   Marshall JL, 2005, J CLIN ONCOL, V23, P720, DOI 10.1200/JCO.2005.10.206
   Marzban H, 2015, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00450
   Mattar Mark C, 2011, Gastrointest Cancer Res, V4, P53
   Maude RJ, 2014, J INFECT DIS, V209, P120, DOI 10.1093/infdis/jit410
   McKnight Nicole C, 2013, Curr Pathobiol Rep, V1, P231
   McLeod HL, 1999, BRIT J CANCER, V79, P191, DOI 10.1038/sj.bjc.6690033
   McWilliams TG, 2016, J CELL BIOL, V214, P333, DOI 10.1083/jcb.201603039
   Mehta RS, 2015, GASTROENTEROLOGY, V149, P614, DOI 10.1053/j.gastro.2015.05.038
   Mhaidat NM, 2016, CYTOTECHNOLOGY, V68, P459, DOI 10.1007/s10616-014-9799-8
   Mhaidat NM, 2015, J CHEMOTHERAPY, V27, P167, DOI 10.1179/1973947815Y.0000000006
   Mhaidat NM, 2009, ANTI-CANCER DRUG, V20, P601, DOI 10.1097/CAD.0b013e32832e3120
   Modest DP, 2012, ONCOLOGY-BASEL, V83, P241, DOI 10.1159/000339534
   Moehler M, 2016, EUR J CANCER, V59, P160, DOI 10.1016/j.ejca.2016.02.020
   Moghadam AR, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0773-6
   Moh Saudi, 2013, HLTH AW CTR CANC INC
   Mokarram P, 2015, EPIGENETICS TERRITOR, P373
   Moretti L, 2007, DRUG RESIST UPDATE, V10, P135, DOI 10.1016/j.drup.2007.05.001
   Morselli E, 2009, BBA-MOL CELL RES, V1793, P1524, DOI 10.1016/j.bbamcr.2009.01.006
   MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4
   Nakatsu G, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9727
   Namba T, 2007, BIOCHEM BIOPH RES CO, V355, P543, DOI 10.1016/j.bbrc.2007.02.004
   Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328
   Nicoli ER, 2014, ROM J MORPHOL EMBRYO, V55, P57
   Nishida N, 2012, ANN SURG ONCOL, V19, P3065, DOI 10.1245/s10434-012-2246-1
   Nishikawa T, 2010, ANN SURG ONCOL, V17, P592, DOI 10.1245/s10434-009-0696-x
   Noguchi T, 2013, IMMUNOTHERAPY-UK, V5, P533, DOI [10.2217/IMT.13.35, 10.2217/imt.13.35]
   Nowak AK, 2003, CANCER RES, V63, P4490
   Nygard SB, 2014, SCAND J GASTROENTERO, V49, P84, DOI 10.3109/00365521.2013.856464
   O'Donnell PH, 2012, CANCER-AM CANCER SOC, V118, P4063, DOI 10.1002/cncr.26737
   Oguri T, 2013, INT J CLIN PHARM TH, V51, P475, DOI 10.5414/CP201851
   Ohmori H, 2011, EXPERT OPIN THER TAR, V15, P183, DOI 10.1517/14728222.2011.546785
   Ohmori H, 2010, PATHOBIOLOGY, V77, P210, DOI 10.1159/000296305
   Okamoto K, 2014, J CELL BIOL, V205, P435, DOI 10.1083/jcb.201402054
   Oliveira CS, 2015, CELL DEATH DIS, V18, P157
   Ouyang F, 2016, INT J MOL MED, V37, P679, DOI 10.3892/ijmm.2016.2474
   Paridaens A, 2014, LIVER INT, V34, pE10, DOI 10.1111/liv.12457
   Park HR, 2007, TOXICOLOGY, V229, P253, DOI 10.1016/j.tox.2006.11.049
   Park HR, 2004, JNCI-J NATL CANCER I, V96, P1300, DOI 10.1093/jnci/djh243
   Parkhurst MR, 2011, MOL THER, V19, P620, DOI 10.1038/mt.2010.272
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Paschall AV, 2015, J IMMUNOL, V195, P1868, DOI 10.4049/jimmunol.1402243
   Patil U.S., 2012, INT J PHARM PHARM SC, V4, P30, DOI DOI 10.5455/NJPPP.2017.7.0203808032017
   Paul B, 2016, IMMUNOTHERAPY-UK, V8, P693, DOI 10.2217/imt-2016-0013
   Paulsen JE, 2002, ANTICANCER RES, V22, P171
   Perego P, 2016, CANCER CHEMOTH PHARM, V77, P5, DOI 10.1007/s00280-015-2901-x
   Peters GJ, 2012, PHARMACOGENOMICS, V13, P1445, DOI [10.2217/PGS.12.134, 10.2217/pgs.12.134]
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   PETRELLI N, 1989, J CLIN ONCOL, V7, P1419, DOI 10.1200/JCO.1989.7.10.1419
   Pfalzer AC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135758
   Pietrzyk Lukasz, 2015, Asian Pac J Cancer Prev, V16, P4161
   Porcelli L, 2012, CURR MED CHEM, V19, P3858, DOI 10.2174/092986712802002563
   Pratt WB, 2010, EXP BIOL MED, V235, P278, DOI 10.1258/ebm.2009.009250
   Prummel MF, 2000, J CLIN ENDOCR METAB, V85, P4347, DOI 10.1210/jc.85.11.4347
   Qian QY, 2014, BIOCHEM BIOPH RES CO, V443, P1041, DOI 10.1016/j.bbrc.2013.12.090
   Rad R, 2013, CANCER CELL, V24, P15, DOI 10.1016/j.ccr.2013.05.014
   Ramsay RG, 2005, INT J BIOCHEM CELL B, V37, P1254, DOI 10.1016/j.biocel.2004.12.011
   Ren F, 2014, MOL CELL BIOCHEM, V385, P95, DOI 10.1007/s11010-013-1818-0
   Reyes-Gibby CC, 2015, BIODATA MIN, V8, DOI 10.1186/s13040-015-0058-0
   Rhodes JM, 2002, TRENDS MOL MED, V8, P10, DOI 10.1016/S1471-4914(01)02194-3
   Ricci MS, 2006, ONCOLOGIST, V11, P342, DOI 10.1634/theoncologist.11-4-342
   Roberts HR, 2011, CARCINOGENESIS, V32, P1741, DOI 10.1093/carcin/bgr210
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Rosell R, 2002, LUNG CANCER, V38, P217, DOI 10.1016/S0169-5002(02)00224-6
   Rosmarin D, 2015, GUT, V64, P111, DOI 10.1136/gutjnl-2013-306571
   Rothwell PM, 2010, LANCET, V376, P1741, DOI 10.1016/S0140-6736(10)61543-7
   Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027
   Roy S, 2010, SEMIN IMMUNOPATHOL, V32, P383, DOI 10.1007/s00281-010-0213-0
   Rustgi AK, 2007, GENE DEV, V21, P2525, DOI 10.1101/gad.1593107
   Saif MW, 2009, ONCOTARGETS THER, V2, P29
   Sakai H, 2013, J CLIN BIOCHEM NUTR, V52, P64, DOI 10.3164/jcbn.12-60
   Sakharkar Meena K, 2007, Curr Drug Discov Technol, V4, P48
   Sakurai H, 2013, MOL CELL PROTEOMICS, V12, P2313, DOI 10.1074/mcp.M112.023853
   Sanchez-Castanon M, 2016, CLIN CHIM ACTA, V460, P78, DOI 10.1016/j.cca.2016.06.027
   Sanchez-Martin FJ, 2016, CLIN CANCER RES, V22, P3260, DOI 10.1158/1078-0432.CCR-15-2400
   SANTI DV, 1974, BIOCHEMISTRY-US, V13, P471, DOI 10.1021/bi00700a012
   Sargent D, 2009, J CLIN ONCOL, V27, P872, DOI 10.1200/JCO.2008.19.5362
   Sartore-Bianchi A, 2009, CANCER RES, V69, P1851, DOI 10.1158/0008-5472.CAN-08-2466
   Sasaki K, 2012, ANTI-CANCER DRUG, V23, P675, DOI 10.1097/CAD.0b013e328353f8c7
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Sato M, 2016, GENES CELLS, V21, P861, DOI 10.1111/gtc.12390
   Sauer R, 2012, J CLIN ONCOL, V30, P1926, DOI 10.1200/JCO.2011.40.1836
   Savelyeva A, 2014, ADV EXP MED BIOL, V818, P197, DOI 10.1007/978-1-4471-6458-6_10
   Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858
   Scherz-Shouval R, 2010, P NATL ACAD SCI USA, V107, P18511, DOI 10.1073/pnas.1006124107
   Schleicher SM, 2010, DRUG RESIST UPDATE, V13, P79, DOI 10.1016/j.drup.2010.04.002
   Schmid D, 2015, ANN ONCOL, V26, P272, DOI 10.1093/annonc/mdu250
   Schonewolf CA, 2014, WORLD J GASTRO ONCOL, V6, P74, DOI 10.4251/wjgo.v6.i3.74
   Sebag-Montefiore D, 2009, LANCET, V373, P811, DOI 10.1016/S0140-6736(09)60484-0
   Shakeri R, 2015, INT J BIOL MACROMOL, V81, P370, DOI 10.1016/j.ijbiomac.2015.08.027
   Shen WD, 2014, CHINESE J CANCER RES, V26, P59, DOI 10.3978/j.issn.1000-9604.2014.01.10
   Shi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051076
   Siegelin MD, 2011, patent application publication, Patent No. [us20110268722A1, 20110268722]
   Simone C, 2007, AUTOPHAGY, V3, P468, DOI 10.4161/auto.4319
   Soda H, 1999, J SURG ONCOL, V72, P211, DOI 10.1002/(SICI)1096-9098(199912)72:4<211::AID-JSO6>3.0.CO;2-A
   Sou Y, 2006, J BIOL CHEM, V281, P3017, DOI 10.1074/jbc.M505888200
   Sovolyova N, 2014, BIOL CHEM, V395, P1, DOI 10.1515/hsz-2013-0174
   Speetjens FM, 2009, CLIN CANCER RES, V15, P1086, DOI 10.1158/1078-0432.CCR-08-2227
   Staab TA, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003354
   Stranks AJ, 2015, J INNATE IMMUN, V7, P375, DOI 10.1159/000370112
   Suh DH, 2012, ANN NY ACAD SCI, V1271, P20, DOI 10.1111/j.1749-6632.2012.06739.x
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Sui XB, 2014, SCI REP-UK, V4, DOI 10.1038/srep04694
   Sun Z, 2015, CLIN TRANSL ONCOL, V17, P876, DOI 10.1007/s12094-015-1318-7
   Sutherland A, 2010, GENES NUTR, V5, P215, DOI 10.1007/s12263-010-0176-8
   Symonds EL, 2013, BRIT J NUTR, V109, P2117, DOI 10.1017/S0007114512004333
   Szokalska A, 2009, CANCER RES, V69, P4235, DOI 10.1158/0008-5472.CAN-08-3439
   Tae CH, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-811
   Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626
   Tai CJ, 2013, EVID-BASED COMPL ALT, V2013, P12
   Talero E, 2012, CURR PHARM DESIGN, V18, P3939, DOI 10.2174/138161212802083725
   Tanaka Y, 2015, BRIT J CANCER, V113, P669, DOI 10.1038/bjc.2015.263
   Tang D, 2010, ONCOGENE, V29, P5299, DOI 10.1038/onc.2010.261
   Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078
   Tanida I, 2004, J BIOL CHEM, V279, P36268, DOI 10.1074/jbc.M401461200
   Taniguchi K, 2015, CANCER LETT, V363, P17, DOI 10.1016/j.canlet.2015.03.026
   Lopez PJT, 2014, CLIN MED INSIGHTS-GA, V7, P33, DOI 10.4137/CGast.S14039
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Thornton M, 2013, INT J CANCER, V133, P1408, DOI 10.1002/ijc.28137
   Tian L, 2014, ANTI-CANCER DRUG, V25, P1175, DOI 10.1097/CAD.0000000000000151
   Tjalsma H, 2012, NAT REV MICROBIOL, V10, P575, DOI 10.1038/nrmicro2819
   Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113
   Trondl R, 2014, MOL PHARMACOL, V85, P451, DOI 10.1124/mol.113.090605
   Trusevych EH, 2015, CURR PHARM DESIGN, V21, P2983, DOI 10.2174/1381612821666150514104800
   Tsai WT, 2016, J BIOL CHEM, V291, P19299, DOI 10.1074/jbc.M115.686683
   Tsai Yien Che, 2010, Genes Cancer, V1, P764
   Tsoi KKF, 2009, CLIN GASTROENTEROL H, V7, P682, DOI 10.1016/j.cgh.2009.02.016
   Vakifahmetoglu-Norberg H, 2016, GENE DEV, V30, P870, DOI 10.1101/gad.280453.116
   Vakifahmetoglu-Norberg H, 2013, GENE DEV, V27, P1718, DOI 10.1101/gad.220897.113
   Van Cutsem E, 2015, J CLIN ONCOL, V33, P692, DOI 10.1200/JCO.2014.59.4812
   Vanio H, 2002, IARC HDB CANC PREV, V6
   Vasen HFA, 2008, GUT, V57, DOI 10.1136/gut.2007.136127
   Verfaillie T, 2013, CANCER LETT, V332, P249, DOI 10.1016/j.canlet.2010.07.016
   Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038
   Wang D, 2015, GASTROENTEROLOGY, V7, P01097
   Wang KP, 2014, IMMUNITY, V41, P1052, DOI 10.1016/j.immuni.2014.11.009
   Wasik AM, 2014, INT REV CEL MOL BIO, V308, P167, DOI 10.1016/B978-0-12-800097-7.00005-1
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   Weijenberg Matty P, 2013, Curr Nutr Rep, V2, P19
   Wen X, 2016, AUTOPHAGY, V12, P617, DOI 10.1080/15548627.2016.1158373
   Whitlock EP, 2008, 080505124EF1 AG HEAL
   Wiersma VR, 2015, AUTOPHAGY, V11, P1373, DOI 10.1080/15548627.2015.1063767
   Wirth MD, 2015, BRIT J NUTR, V113, P1819, DOI 10.1017/S000711451500104X
   Won HH, 2012, CANCER-AM CANCER SOC, V118, P2828, DOI 10.1002/cncr.26614
   Won SJ, 2015, J CELL PHYSIOL, V230, P930, DOI 10.1002/jcp.24825
   Wu CW, 2013, CHIN CLIN ONCOL, V2, DOI 10.3978/j.issn.2304-3865.2012.11.07
   Wu SH, 2015, INT J CLIN EXP PATHO, V8, P3882
   Wu XY, 2013, TUMOR BIOL, V34, P713, DOI 10.1007/s13277-012-0599-5
   Wu YN, 2013, INT J NANOMED, V8, P3321, DOI 10.2147/IJN.S47742
   Wyatt MD, 2009, CELL MOL LIFE SCI, V66, P788, DOI 10.1007/s00018-008-8557-5
   Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016
   Xie XL, 2013, PATHOL RES PRACT, V209, P237, DOI 10.1016/j.prp.2013.02.007
   Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779
   Yang C, 2016, ONCOL LETT, V11, P1549, DOI 10.3892/ol.2016.4097
   Yang PM, 2013, SCI REP-UK, V3, DOI 10.1038/srep03219
   Yang WL, 2012, J SURG ONCOL, V106, P680, DOI 10.1002/jso.23184
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yang ZL, 2015, CLIN RES HEPATOL GAS, V39, P98, DOI 10.1016/j.clinre.2014.06.014
   Yeganeh B, 2015, AM J PHYSIOL-LUNG C, V308, pL270, DOI 10.1152/ajplung.00011.2014
   Yeganeh B, 2013, IRAN J ALLERGY ASTHM, V12, P1, DOI 012.01/ijaai.117
   Yu CH, 2015, J GINSENG RES, V39, P230, DOI 10.1016/j.jgr.2014.12.004
   Yuk JM, 2010, AUTOPHAGY, V6, P46, DOI 10.4161/auto.6.1.10325
   Yusof AS, 2012, ASIAN PAC J CANCER P, V13, P4713, DOI 10.7314/APJCP.2012.13.9.4713
   Zackular JP, 2013, MBIO, V4, DOI 10.1128/mBio.00692-13
   Zarzynska JM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/710345
   Zaytseva YY, 2015, ONCOTARGET, V6, P18891, DOI 10.18632/oncotarget.3783
   Zeindl-Eberhart E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087386
   Zeki AA, 2016, ALLERGY, V71, P5, DOI 10.1111/all.12761
   Zhai HY, 2015, ONCOTARGET, V6, P19735, DOI 10.18632/oncotarget.3771
   Zhang GY, 2015, ONCOL REP, V33, P1147, DOI 10.3892/or.2014.3702
   Zhang JCL, 2001, MOL CELL BIOL, V21, P1336, DOI 10.1128/MCB.2001.21.4.1336-1344.2001
   Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203
   Zhang SZ, 2006, CANCER RES, V66, P8847, DOI 10.1158/0008-5472.CAN-06-0769
   Zhang TM, 2016, J BIOL CHEM, V291, P21616, DOI 10.1074/jbc.M116.733410
   Zhang XB, 2013, CANCER PREV RES, V6, P1337, DOI 10.1158/1940-6207.CAPR-13-0220
   Zhang XT, 2006, ONCOL REP, V16, P563
   Zheng YZ, 2009, CANCER INVEST, V27, P286, DOI 10.1080/07357900802427927
   Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051
   Zhou HY, 2016, CANCER BIOMARK, V17, P1, DOI 10.3233/CBM-160613
   Zhou JF, 2016, AUTOPHAGY, V12, P515, DOI 10.1080/15548627.2015.1136770
   Zhou X, 2015, ONCOL RES, V23, P29, DOI 10.3727/096504015X14452563486011
   Zhou YT, 2016, ACTA BIOCH BIOPH SIN, V48, P60, DOI 10.1093/abbs/gmv119
   Zhu L, 2016, NEUROSCIENCE, V315, P286, DOI 10.1016/j.neuroscience.2015.12.020
   Zorbas M, 1999, ONCOGENE, V18, P5821, DOI 10.1038/sj.onc.1202971
NR 413
TC 91
Z9 93
U1 0
U2 24
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PY 2017
VL 13
IS 5
BP 781
EP 819
DI 10.1080/15548627.2017.1290751
PG 39
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EV4CZ
UT WOS:000401707200002
PM 28358273
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Kantara, C
   O'Connell, M
   Sarkar, S
   Moya, S
   Ullrich, R
   Singh, P
AF Kantara, Carla
   O'Connell, Malaney
   Sarkar, Shubhashish
   Moya, Stephanie
   Ullrich, Robert
   Singh, Pomila
TI Curcumin Promotes Autophagic Survival of a Subset of Colon Cancer Stem
   Cells, Which Are Ablated by DCLK1-siRNA
SO CANCER RESEARCH
LA English
DT Article
ID NF-KAPPA-B; SIGNALING PATHWAYS; BETA-CATENIN; PROGASTRIN; APOPTOSIS;
   GROWTH; DOUBLECORTIN; RADIATION; MICE; DIFFERENTIATION
AB Curcumin is known to induce apoptosis of cancer cells by different mechanisms, but its effects on cancer stem cells (CSC) have been less investigated. Here, we report that curcumin promotes the survival of DCLK1-positive colon CSCs, potentially confounding application of its anticancer properties. At optimal concentrations, curcumin greatly reduced expression levels of stem cell markers (DCLK1/CD44/ALDHA1/Lgr5/Nanog) in three-dimensional spheroid cultures and tumor xenografts derived from colon cancer cells. However, curcumin unexpectedly induced proliferation and autophagic survival of a subset of DCLK1-positive CSCs. Spheroid cultures were disintegrated by curcumin in vitro but regrew within 30 to 40 days of treatment, suggesting a survival benefit from autophagy, permitting long-term persistence of colorectal cancer. Notably, RNA interference-mediated silencing of DCLK1 triggered apoptotic cell death of colon cancer cells in vitro and in vivo, and abolished colorectal cancer survival in response to curcumin; combination of DCLK1-siRNA and curcumin dramatically reversed CSC phenotype, contributing to attenuation of the growth of spheroid cultures and tumor xenografts. Taken together, our findings confirm a role of DCLK1 in colon CSCs and highlight DCLK1 as a target to enhance antitumor properties of curcumin.
C1 [Kantara, Carla; O'Connell, Malaney; Sarkar, Shubhashish; Moya, Stephanie; Singh, Pomila] Univ Texas Med Branch, Dept Cell Biol & Neurosci, Galveston, TX 77555 USA.
   [Kantara, Carla; Ullrich, Robert; Singh, Pomila] Univ Texas Med Branch Hlth, Sealy Canc Ctr, Galveston, TX 77555 USA.
RP Singh, P (corresponding author), Univ Texas Med Branch, Dept Cell Biol & Neurosci, 10-104 Med Res Bldg,301 Univ Blvd,Route 1043, Galveston, TX 77555 USA.
EM posingh@utmb.edu
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [CA97959, CA114264]; NASANational
   Aeronautics & Space Administration (NASA) [NNX09AM08G, NNJ04HD83G];
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R01CA114264, R01CA097959] Funding Source: NIH RePORTER
FX This work was supported by NIH grants CA97959 and CA114264 to P. Singh
   and NASA grants NNX09AM08G and NNJ04HD83G to R. Ullrich.
CR Almanaa TN, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-195
   Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167
   Bailey JM, 2014, GASTROENTEROLOGY, V146, P245, DOI 10.1053/j.gastro.2013.09.050
   Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196
   Basile V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053664
   Gupta SC, 2011, NAT PROD REP, V28, P1937, DOI 10.1039/c1np00051a
   Hatcher H, 2008, CELL MOL LIFE SCI, V65, P1631, DOI 10.1007/s00018-008-7452-4
   He CC, 2010, CURR OPIN CELL BIOL, V22, P140, DOI 10.1016/j.ceb.2010.01.001
   Helson L, 2012, ANTICANCER RES, V32, P4365
   Kemper K, 2012, STEM CELLS, V30, P2378, DOI 10.1002/stem.1233
   Kim JY, 2012, ARCH ORAL BIOL, V57, P1018, DOI 10.1016/j.archoralbio.2012.04.005
   Li B, 2013, INT J GYNECOL CANCER, V23, P803, DOI 10.1097/IGC.0b013e31828c9581
   Lin L, 2011, BRIT J CANCER, V105, P212, DOI 10.1038/bjc.2011.200
   Liu JS, 2012, MOL CELL, V47, P707, DOI 10.1016/j.molcel.2012.06.025
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Matsumoto N, 1999, GENOMICS, V56, P179, DOI 10.1006/geno.1998.5673
   May R, 2008, STEM CELLS, V26, P630, DOI 10.1634/stemcells.2007-0621
   Mosieniak G, 2012, MECH AGEING DEV, V133, P444, DOI 10.1016/j.mad.2012.05.004
   Mujoo K, 2012, PROTEIN CELL, V3, P535, DOI 10.1007/s13238-012-2053-2
   Nakanishi Y, 2013, NAT GENET, V45, P98, DOI 10.1038/ng.2481
   Ning XY, 2013, CANCER BIOL THER, V14, P295, DOI 10.4161/cbt.23622
   O'Sullivan-Coyne G, 2009, BRIT J CANCER, V101, P1585, DOI 10.1038/sj.bjc.6605308
   Paglin S, 2001, CANCER RES, V61, P439
   Park YS, 2012, ONCOL REP, V27, P339, DOI 10.3892/or.2011.1532
   Patschan S, 2008, AM J PHYSIOL-HEART C, V294, pH1119, DOI 10.1152/ajpheart.00713.2007
   Ponnurangam S, 2012, MOL CANCER THER, V11, P963, DOI 10.1158/1535-7163.MCT-11-0999
   Saha S, 2012, ANTICANCER RES, V32, P2567
   Sarkar S, 2012, INT J CANCER, V131, pE1088, DOI 10.1002/ijc.27615
   Sarkar S, 2011, GASTROENTEROLOGY, V140, P583, DOI 10.1053/j.gastro.2010.08.054
   Schepers AG, 2012, SCIENCE, V337, P730, DOI 10.1126/science.1224676
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Singh P, 1996, CANCER RES, V56, P4111
   Singh P, 2012, CURR COLORECT CANC R, V8, P277, DOI 10.1007/s11888-012-0144-3
   Singh P, 2010, AM J PHYSIOL-GASTR L, V298, pG551, DOI 10.1152/ajpgi.00497.2009
   Sureban SM, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-40
   Umar S, 2008, ONCOGENE, V27, P5599, DOI 10.1038/onc.2008.169
   Umar S, 2009, J BIOL CHEM, V284, P22274, DOI 10.1074/jbc.M109.020941
   Verissimo CS, 2010, ENDOCR-RELAT CANCER, V17, P399, DOI 10.1677/ERC-09-0301
   Wang SY, 2011, INT J BIOCHEM CELL B, V43, P1263, DOI 10.1016/j.biocel.2011.05.010
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Yu YJ, 2009, TRANSL ONCOL, V2, P321, DOI 10.1593/tlo.09193
   Zhuang WZ, 2012, CANCER SCI, V103, P684, DOI 10.1111/j.1349-7006.2011.02198.x
NR 42
TC 81
Z9 91
U1 1
U2 35
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD MAY 1
PY 2014
VL 74
IS 9
BP 2487
EP 2498
DI 10.1158/0008-5472.CAN-13-3536
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AH1ZH
UT WOS:000335920000012
PM 24626093
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Lee, KTW
   Islam, F
   Vider, J
   Martin, J
   Chruscik, A
   Lu, CT
   Gopalan, V
   Lam, AKY
AF Lee, Katherine Ting-Wei
   Islam, Farhadul
   Vider, Jelena
   Martin, Jeremy
   Chruscik, Anna
   Lu, Cu-Tai
   Gopalan, Vinod
   King-Yin Lam, Alfred
TI Overexpression of family with sequence similarity 134, member B
   (FAM134B) in colon cancers and its tumor suppressive properties in vitro
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE FAM134B; MIF; p53; mitochondrial function; colorectal; colon; cancer
ID MIGRATION-INHIBITORY-FACTOR; EXPRESSION; MUTATIONS; STRESS; JK1;
   MITOCHONDRIA; CROSSTALK; AUTOPHAGY; PROTEIN; UPR
AB This study aims to investigate the overexpression-induced properties of tumor suppressorFAM134B(family with sequence similarity 134, member B) in colon cancer, examine the potential gene regulators ofFAM134Bexpression and its impact on mitochondrial function.FAM134Bwas overexpressed in colon cancer and non-neoplastic colonic epithelial cells. Various cell-based assays including apoptosis, cell cycle, cell proliferation, clonogenic, extracellular flux and wound healing assays were performed. Western blot analysis was used to confirm and identify potential interacting partners ofFAM134B in vitro. Immunohistochemistry and qPCR were employed to determine the expressions of MIF andFAM134B, respectively, on 63 patients with colorectal carcinoma. Results showed thatFAM134Bis involved in the cell cycle and mitochondrial function of colon cancer. Overexpression ofFAM134Bwas coupled with increased expression levels of APC, p53, and MIF. Increased expression of both APC and p53 further validates the potential role of tumor suppressorFAM134Bin regulating cancer progression through the WNT/ss-catenin signaling pathway. In approximately 70% of the patients with colorectal cancer,FAM134Bdownregulation was correlated with MIF protein overexpression while the remaining 30% showed concurrent expression ofFAM134Band MIF (P= .045). High expression of MIF coupled with low expression ofFAM134Bis associated with microsatellite instability status in colorectal carcinomas (P= .049).FAM134Bmay exert its tumor suppressive function through affecting cell cycle, mitochondrial function via potentially interacting with MIF and p53.
C1 [Lee, Katherine Ting-Wei; Islam, Farhadul; Martin, Jeremy; Chruscik, Anna; Gopalan, Vinod; King-Yin Lam, Alfred] Griffith Univ, Sch Med, Canc Mol Pathol, Gold Coast, Qld, Australia.
   [Islam, Farhadul] Univ Rajshahi, Dept Biochem & Mol Biol, Rajshahi, Bangladesh.
   [Vider, Jelena] Griffith Univ, Sch Med Sci, Gold Coast, Qld, Australia.
   [Lu, Cu-Tai] Gold Coast Univ Hosp, Dept Surg, Gold Coast, Qld, Australia.
RP Lam, AKY (corresponding author), Griffith Univ, Sch Med, Pathol, Gold Coast, Qld 4222, Australia.
EM a.lam@griffith.edu.au
RI Vider, Jelena/B-9663-2011; Lam, Alfred/C-1652-2008; Chruścik,
   Anna/ABB-1328-2021
OI Vider, Jelena/0000-0003-1696-9812; Lam, Alfred/0000-0003-2771-564X;
   Chruścik, Anna/0000-0003-4147-9022; Lee, Katherine
   Ting-Wei/0000-0003-2068-7762; Lu, Cu Tai/0000-0001-9565-3749
FU HDR scholarship from Griffith University; Menzies Health Institute
   Queensland; Asian Foundation for Tropical Medicine; Griffith
   UniversityGriffith University; School of Medicine, Griffith University
FX The project was supported by the HDR scholarship from Griffith
   University and funding from Menzies Health Institute Queensland and
   Asian Foundation for Tropical Medicine. In addition, we would like to
   acknowledge the paper completion assistance from the School of Medical
   Science, Griffith University, HDR scholarship from Griffith University,
   research funding to support early career researcher from School of
   Medicine, Griffith University in 2019.
CR AHMED D, 2013, ONCOGENESIS, V0002, DOI DOI 10.1038/ONCSIS.2013.35
   BERNICK EP, 2010, BMC CELL BIOL, V0011, DOI DOI 10.1186/1471-2121-11-70
   CHAN B, 2007, J HOSP TOUR EDUC, V0019, P00006, DOI DOI 10.1080/10963758.2007.10696885
   COOPER DJ, 2017, MOL CELL NEUROSCI, V0080, P00161, DOI DOI 10.1016/J.MCN.2016.07.001
   DAI X, 2017, SCI REP UK, V0007, DOI DOI 10.1038/S41598-017-07189-6
   DAVE M, 2017, GENOM PROTEOM BIOINF, V0015, P00339, DOI DOI 10.1016/J.GPB.2017.03.005
   DE R, 2018, J BIOL CHEM, V0293, P01974, DOI DOI 10.1074/JBC.RA118.003935
   DOW LE, 2015, CELL, V0161, P01539, DOI DOI 10.1016/J.CELL.2015.05.033
   DROST J, 2015, NATURE, V0521, P00043, DOI DOI 10.1038/NATURE14415
   FAN ZL, 2012, BIOINTERPHASES, V0007, DOI DOI 10.1007/S13758-011-0010-X
   FEARON ER, 2011, ANNU REV PATHOL-MECH, V0006, P00479, DOI DOI 10.1146/ANNUREV-PATHOL-011110-130235
   FRANKEN NAP, 2006, NAT PROTOC, V0001, P02315, DOI DOI 10.1038/NPROT.2006.339
   Fregno I, 2018, F1000RES, V7, P454
   Hamilton SR, 2010, WHO CLASSIFICATION T, V4
   HAQUE MH, 2016, SCI REP UK, V0006, DOI DOI 10.1038/SREP29173
   HE XX, 2009, MOL MED, V0015, P00001, DOI DOI 10.2119/MOLMED.2008.00107
   IORIO A, 2015, CLIN RESPIR J, V0009, P00481, DOI DOI 10.1111/CRJ.12170
   ISLAM F, 2017, MOL CARCINOGEN, V0056, P00238, DOI DOI 10.1002/MC.22488
   ISLAM F, 2018, GENE CHROMOSOME CANC, V0057, P00240, DOI DOI 10.1002/GCC.22525
   ISLAM F, 2017, EXP CELL RES, V0357, P00260, DOI DOI 10.1016/J.YEXCR.2017.05.021
   ISLAM F, 2018, MOL CARCINOGEN, V0057, P01480, DOI DOI 10.1002/MC.22871
   ISLAM F, 2018, J CELL PHYSIOL, V0233, P04479, DOI DOI 10.1002/JCP.26384
   ISLAM F, 2017, HUM GENET, V0136, P00321, DOI DOI 10.1007/S00439-017-1760-4
   KASEM K, 2014, EXP MOL PATHOL, V0097, P00099, DOI DOI 10.1016/J.YEXMP.2014.06.002
   KASEM K, 2014, EXP CELL RES, V0326, P00166, DOI DOI 10.1016/J.YEXCR.2014.06.013
   KASEM K, 2014, EXP MOL PATHOL, V0097, P00031, DOI DOI 10.1016/J.YEXMP.2014.05.001
   KATT ME, 2016, FRONT BIOENG BIOTECH, V0004, DOI DOI 10.3389/FBIOE.2016.00012
   KHAMINETS A, 2015, NATURE, V0522, P00354, DOI DOI 10.1038/NATURE14498
   KOK T, 2018, DRUG DISCOV TODAY, V0023, P01910, DOI DOI 10.1016/J.DRUDIS.2018.06.017
   KONG FY, 2018, ONCOGENE, V0037, P05982, DOI DOI 10.1038/S41388-018-0387-9
   KURTH I, 2009, NAT GENET, V0041, P01179, DOI DOI 10.1038/NG.464
   LEE KTW, 2018, EUR J CELL BIOL, V0097, P00230, DOI DOI 10.1016/J.EJCB.2018.03.002
   LI ZJ, 2015, BLOOD, V0126, P02005, DOI DOI 10.1182/BLOOD-2015-04-639062
   MAMOORI A, 2017, J CLIN PATHOL, V0070, P00308, DOI DOI 10.1136/JCLINPATH-2016-203972
   MELCHIOTTI R, 2014, BMC MED GENET, V0015, DOI DOI 10.1186/1471-2350-15-73
   Milburn JJ, 2017, AJCC CANC STAGING MA, VEight
   MITTELBRONN M, 2011, ACTA NEUROPATHOL, V0122, P00353, DOI DOI 10.1007/S00401-011-0858-3
   PENG Y, 2018, AGING CELL, V0017
   RAO RV, 2006, CELL DEATH DIFFER, V0013, P00415, DOI DOI 10.1038/SJ.CDD.4401761
   RUBINSZTEIN DC, 2015, NATURE, V0522, P00291
   SENFT D, 2015, TRENDS BIOCH SCI, V0040, P00141, DOI DOI 10.1016/j.tibs.2015.01.002
   SONG IS, 2015, BMB REP, V0048, P00539, DOI DOI 10.5483/BMBREP.2015.48.10.179
   SONG SL, 2018, J CELL PHYSIOL, V0233, P03867, DOI DOI 10.1002/JCP.26137
   VANDERHEIDEN MG, 2017, CELL, V0168, DOI DOI 10.1016/J.CELL.2016.12.039
   VERJANS E, 2009, BMC CANCER, V0009, DOI DOI 10.1186/1471-2407-9-230
   Yadav R.K., 2014, J CANC PREV, V19, P75
   ZHU XD, 2019, INT J MOL MED, V0044, P00643, DOI DOI 10.3892/IJMM.2019.4213
   ZONG WX, 2016, MOL CELL, V0061, P00667, DOI DOI 10.1016/J.MOLCEL.2016.02.011
NR 48
TC 0
Z9 0
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD OCT 2
PY 2020
VL 21
IS 10
BP 954
EP 962
DI 10.1080/15384047.2020.1810535
EA AUG 2020
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA OD5HV
UT WOS:000564161300001
PM 32857678
OA Green Accepted, Bronze, Green Published
DA 2022-04-25
ER

PT J
AU Li, YC
   Li, CF
   Li, DD
   Yang, L
   Jin, JP
   Zhang, B
AF Li, Yongchao
   Li, Changfeng
   Li, Dandan
   Yang, Lei
   Jin, Jingpeng
   Zhang, Bin
TI lncRNA KCNQ1OT1 enhances the chemoresistance of oxaliplatin in colon
   cancer by targeting the miR-34a/ATG4B pathway
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE KCNQ1OT1; colorectal cancer; protective autophagy; miR-34a; Atg4B;
   chemoresistance
ID COLORECTAL-CANCER; MOLECULAR-MECHANISMS; AUTOPHAGY; STATISTICS;
   RESISTANCE
AB Purpose: The chemoresistance of colon cancer to oxaliplatin (L-OHP) indicates poor prognosis. Long non-coding RNA (lncRNA) KCNQ1OT1 (KCNQ1 opposite strand/antisense transcript 1) has been shown to participate in the tumorigenesis of several types of cancers. However, little is known about the role of KCNQ1OT1 in the chemoresistance and prognosis of colon cancer.
   Materials and methods: Quantitative-PCR and Western blot were used to measure the expression profiles of KCNQ1OT1, miR-34a, and Atg4B in colon cancer tissues and cells. Cell viability assay and flow cytometry were used to examine their effects on cell proliferation and death. Cleavage of LC3 and GFP-LC3 plasmid transfection were used to detect autophagic activity. Double luciferase reporter assay was used to verify the interactions between miRNA and lncRNA or mRNA. Xenograft tumor model was used to verify the effects of KCNQ1OT1 in vivo.
   Results: In this study, it is shown that the expression level of KCNQ1OT1 was increased in tumor, which indicated poor prognosis in colon cancer patients. Using colon cancer cell lines HCT116 and SW480, it was demonstrated that knockdown of KCNQ1OT1 decreased the cell viability and increased the apoptosis rates upon L-OHP treatment. Further studies indicated that Atg4B upregulation was partially responsible for KCNQ1OT1-induced protective autophagy and chemoresistance. Moreover, miR-34a functioned as a bridge between KCNQ1OT1 and Atg4B, which could be sponged by KCNQ1OT1, while it could also bind to the 3'-UTR of Atg4B and downregulate its expressions. Finally, we show that the KCNQ1OT1/miR-34a/Atg4B axis regulated the chemoresistance of colon cancer cells in vitro and in vivo.
   Conclusion: lncRNA KCNQ1OT1 promoted the chemoresistance of colon cancer by sponging miR-34a, thus upregulating the expressions of Atg4B and enhancing protective autophagy. KCNQ1OT1 might become a promising target for colon cancer therapeutics.
C1 [Li, Yongchao] Jilin Univ, China Japan Union Hosp, Dept Gastrointestinal Surg, Changchun 130033, Jilin, Peoples R China.
   [Li, Changfeng; Li, Dandan; Yang, Lei; Jin, Jingpeng; Zhang, Bin] Jilin Univ, China Japan Union Hosp, Dept Endoscopy Ctr, 126 Xiantai St, Changchun 130033, Jilin, Peoples R China.
RP Li, CF (corresponding author), Jilin Univ, China Japan Union Hosp, Dept Endoscopy Ctr, 126 Xiantai St, Changchun 130033, Jilin, Peoples R China.
EM changfengli1975@163.com
CR Agostini M, 2014, ONCOTARGET, V5, P872, DOI 10.18632/oncotarget.1825
   Akao Y, 2011, CANCER LETT, V300, P197, DOI 10.1016/j.canlet.2010.10.006
   Beg MS, 2017, INVEST NEW DRUG, V35, P180, DOI 10.1007/s10637-016-0407-y
   Bortnik S, 2016, ONCOTARGET, V7, P66970, DOI 10.18632/oncotarget.11408
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Farooqi AA, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102089
   Gao J, 2015, ONCOGENE, V34, P4142, DOI 10.1038/onc.2014.348
   Ghandadi M, 2016, CURR PHARM DESIGN, V22, P933, DOI 10.2174/1381612822666151209153729
   Hemelaar J, 2003, J BIOL CHEM, V278, P51841, DOI 10.1074/jbc.M308762200
   Higashimoto K, 2006, CYTOGENET GENOME RES, V113, P306, DOI 10.1159/000090846
   Hiyoshi Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124899
   Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027
   Kastl L, 2012, BREAST CANCER RES TR, V131, P445, DOI 10.1007/s10549-011-1424-3
   Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167
   Korostowski L, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002956
   Kumar A, 2015, FUTURE MED CHEM, V7, P1535, DOI 10.4155/fmc.15.88
   Lai MG, 2015, MOL MED REP, V11, P3301, DOI 10.3892/mmr.2015.3182
   Li CF, 2018, DEV CELL, V46, P441, DOI 10.1016/j.devcel.2018.07.012
   Li CF, 2017, BIOCHEM BIOPH RES CO, V491, P552, DOI 10.1016/j.bbrc.2017.03.042
   Li CY, 2018, WISEC'18: PROCEEDINGS OF THE 11TH ACM CONFERENCE ON SECURITY & PRIVACY IN WIRELESS AND MOBILE NETWORKS, P1, DOI 10.1145/3212480.3212496
   Li XJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.270
   Li Y, 2018, J IMMUNOL RES, V2018, DOI [10.1155/2018/7198514, 10.1155/2018/7498514]
   Liao HQ, 2016, ONCOL REP, V35, P64, DOI 10.3892/or.2015.4331
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Martinez-Balibrea E, 2015, MOL CANCER THER, V14, P1767, DOI 10.1158/1535-7163.MCT-14-0636
   Misso G, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2014.47
   Nagano T, 2011, CELL, V145, P178, DOI 10.1016/j.cell.2011.03.014
   Ni ZH, 2018, AUTOPHAGY, V14, P685, DOI 10.1080/15548627.2017.1407887
   Ogawa T, 2012, CANCER SCI, V103, P1737, DOI 10.1111/j.1349-7006.2012.02338.x
   Pandey RR, 2008, MOL CELL, V32, P232, DOI 10.1016/j.molcel.2008.08.022
   Paraskevopoulou MD, 2016, NUCLEIC ACIDS RES, V44, pD231, DOI 10.1093/nar/gkv1270
   Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10
   Rafiee A, 2018, BIOTECHNOL GENET ENG, V34, P153, DOI 10.1080/02648725.2018.1471566
   Rapti SM, 2017, CLIN BIOCHEM, V50, P918, DOI 10.1016/j.clinbiochem.2017.06.004
   Ren FH, 2015, INT J CLIN EXP MED, V8, P17377
   Ren KM, 2017, CANCER CHEMOTH PHARM, V80, P243, DOI 10.1007/s00280-017-3356-z
   Satoo K, 2009, EMBO J, V28, P1341, DOI 10.1038/emboj.2009.80
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Sugawara K, 2005, J BIOL CHEM, V280, P40058, DOI 10.1074/jbc.M509158200
   Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20
   Wang J, 2015, ONCOTARGETS THER, V8, P2709, DOI 10.2147/OTT.S84043
   Workman P, 2010, BRIT J CANCER, V102, P1555, DOI 10.1038/sj.bjc.6605642
   Wu QB, 2018, MOL CLIN ONCOL, V8, P523, DOI 10.3892/mco.2018.1578
   Wu SF, 2016, TUMOR BIOL, V37, P6943, DOI 10.1007/s13277-015-4587-4
   Wu YR, 2016, AUTOPHAGY, V12, P1105, DOI 10.1080/15548627.2016.1173798
   Yang ZF, 2015, J BIOL CHEM, V290, P26549, DOI 10.1074/jbc.M115.658088
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Zhang SY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0793-5
   Zhang Y, 2017, ONCOTARGET, V8, DOI 10.18632/oncotarget.20883
NR 49
TC 69
Z9 71
U1 4
U2 11
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2019
VL 12
BP 2649
EP 2660
DI 10.2147/OTT.S188054
PG 12
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA HS4VH
UT WOS:000463866800001
PM 31040703
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Mao, LP
   Yang, JX
   Yue, JX
   Chen, Y
   Zhou, HR
   Fan, DD
   Zhang, QH
   Buraschi, S
   Iozzo, RV
   Bi, XL
AF Mao, Liping
   Yang, Jinxue
   Yue, Jiaxin
   Chen, Yang
   Zhou, Hongrui
   Fan, Dongdong
   Zhang, Qiuhua
   Buraschi, Simone
   Iozzo, Renato V.
   Bi, Xiuli
TI Decorin deficiency promotes epithelial-mesenchymal transition and colon
   cancer metastasis
SO MATRIX BIOLOGY
LA English
DT Article
DE Decorin; Tumor microenvironment; EMT; AOM/DS; Colorectal cancer;
   Celecoxib
ID LEUCINE-RICH PROTEOGLYCANS; GROWTH-FACTOR RECEPTOR; COLORECTAL-CANCER;
   GENE-EXPRESSION; IN-VIVO; TUMOR MICROENVIRONMENT; EXTRACELLULAR-MATRIX;
   DOWN-REGULATION; VII COLLAGEN; AUTOPHAGY
AB The tumor microenvironment encompasses a complex cellular network that includes cancer-associated fibroblasts, inflammatory cells, neo-vessels, and an extracellular matrix enriched in angiogenic growth factors. Decorin is one of the main components of the tumor stroma, but it is not expressed by cancer cells. Lack of this proteoglycan correlates with down-regulation of E-cadherin and induction of beta-catenin signaling. In this study, we investigated the role of a decorin-deficient tumor microenvironment in colon carcinoma progression and metastasis. We utilized an established model of colitis-associated cancer by administering Azoxymethane/Dextran sodium sulfate to adult wild-type and Dcn(-/-) mice. We discovered that after 12 weeks, all the animals developed intestinal tumors independently of their genotype. However, the number of intestinal neoplasms was significantly higher in the Dcn(-/-) microenvironment vis-a-vis wild-type mice. Mechanistically, we found that under unchallenged basal conditions, the intestinal epithelium of the Dcn(-/-) mice showed a significant increase in the protein levels of epithelial-mesenchymal transition associated factors including Snail, Slug, Twist, and MMP2. In comparison, in the colitis-associated cancer evoked in the Dcn(-/-) mice, we found that intercellular adhesion molecule 1 (ICAM-1) was also significantly increased, in parallel with epithelial-mesenchymal transition signaling pathway-related factors. Furthermore, a combined Celecoxib/decorin treatment revealed a promising therapeutic efficacy in treating human colorectal cancer cells, in decorin-deficient animals. Collectively, our results shed light on colorectal cancer progression and provide a protein-based therapy, i.e., treatment using recombinant decorin, to target the tumor microenvironment. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Mao, Liping; Yang, Jinxue; Yue, Jiaxin; Chen, Yang; Zhou, Hongrui; Fan, Dongdong; Bi, Xiuli] Liaoning Univ, Coll Life Sci, Shenyang 110036, Peoples R China.
   [Zhang, Qiuhua] Liaoning Univ Tradit Chinese Med, Dept Pharmacol, Shenyang 110036, Peoples R China.
   [Buraschi, Simone; Iozzo, Renato V.] Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA.
   [Buraschi, Simone; Iozzo, Renato V.] Thomas Jefferson Univ, Canc Cell Biol & Signaling Program, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA.
RP Bi, XL (corresponding author), Liaoning Univ, Coll Life Sci, Shenyang 110036, Peoples R China.; Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA.; Iozzo, RV (corresponding author), Thomas Jefferson Univ, Canc Cell Biol & Signaling Program, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA.
EM renato.iozzo@jefferson.edu; xiulibi@lnu.edu.cn
OI Buraschi, Simone/0000-0002-4233-7627
FU National Nature Science foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81472821]; LiaoNing Revitalization Talents
   Program [XLYC 1807058]; National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [CA39481]; Key Grant of Education department of Liaoning Province
   [LZD201904]
FX We thank Thomas Neill for critically reading of the manuscript. This
   study was funded by National Nature Science foundation of China
   (Grants#: 81472821) LiaoNing Revitalization Talents Program (#XLYC
   1807058), in part by National Institutes of Health grant CA39481 (to
   RVI), and partially supported by Key Grant of Education department of
   Liaoning Province (LZD201904).
CR ALVAREZ RJ, 1992, KIDNEY INT, V41, P14, DOI 10.1038/ki.1992.3
   Baghy K, 2013, FEBS J, V280, P2150, DOI 10.1111/febs.12215
   Baghy K, 2012, J HISTOCHEM CYTOCHEM, V60, P262, DOI 10.1369/0022155412438104
   Baghy K, 2011, LAB INVEST, V91, P439, DOI 10.1038/labinvest.2010.172
   Bi XL, 2008, CARCINOGENESIS, V29, P1435, DOI 10.1093/carcin/bgn141
   Bi XL, 2016, MOL CARCINOGEN, V55, P1786, DOI 10.1002/mc.22427
   Bi XL, 2012, CARCINOGENESIS, V33, P326, DOI 10.1093/carcin/bgr293
   Bix G, 2006, J NATL CANCER I, V98, P1634, DOI 10.1093/jnci/djj441
   BJERKNES M, 1981, ANAT REC, V199, P565, DOI 10.1002/ar.1091990412
   Buraschi S, 2019, MATRIX BIOL, V75-76, P260, DOI 10.1016/j.matbio.2017.10.005
   Buraschi S, 2013, P NATL ACAD SCI USA, V110, pE2582, DOI 10.1073/pnas.1305732110
   Buraschi Simone, 2010, J Biol Chem, V285, P42075, DOI 10.1074/jbc.M110.172841
   Cecchin E, 2018, DRUG RESIST UPDATE, V39, P18, DOI 10.1016/j.drup.2018.07.001
   Cianfarani F, 2019, MATRIX BIOL, V81, P3, DOI 10.1016/j.matbio.2018.12.001
   Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200
   Cummings M, 2019, J PATHOL, V247, P21, DOI 10.1002/path.5160
   DANIELSON KG, 1993, GENOMICS, V15, P146, DOI 10.1006/geno.1993.1022
   Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729
   De Robertis Mariangela, 2011, J Carcinog, V10, P9, DOI 10.4103/1477-3163.78279
   Dinicola S, 2018, J CELL PHYSIOL, V233, P4935, DOI 10.1002/jcp.26323
   Dunkman AA, 2013, MATRIX BIOL, V32, P3, DOI 10.1016/j.matbio.2012.11.005
   Fakih MG, 2015, J CLIN ONCOL, V33, P1809, DOI 10.1200/JCO.2014.59.7633
   Ferdous Z, 2007, J BIOL CHEM, V282, P35887, DOI 10.1074/jbc.M705180200
   Fetting JL, 2014, DEVELOPMENT, V141, P17, DOI 10.1242/dev.089078
   Godwin ARF, 2019, MATRIX BIOL, V84, P17, DOI 10.1016/j.matbio.2019.06.006
   Goldoni S, 2004, J BIOL CHEM, V279, P6606, DOI 10.1074/jbc.M310342200
   Goldoni S, 2008, INT J CANCER, V123, P2473, DOI 10.1002/ijc.23930
   Goldoni S, 2008, AM J PATHOL, V173, P844, DOI 10.2353/ajpath.2008.080275
   Goldoni S, 2009, J CELL BIOL, V185, P743, DOI 10.1083/jcb.200901129
   Goyal A, 2014, MATRIX BIOL, V34, P46, DOI 10.1016/j.matbio.2013.12.011
   Gubbiotti MA, 2016, MATRIX BIOL, V55, P7, DOI 10.1016/j.matbio.2016.09.009
   Horvath Z, 2014, MATRIX BIOL, V35, P194, DOI 10.1016/j.matbio.2013.11.004
   Iozzo RV, 2018, MATRIX BIOL, V71-72, P1, DOI 10.1016/j.matbio.2018.03.023
   Iozzo RV, 2015, MATRIX BIOL, V42, P11, DOI 10.1016/j.matbio.2015.02.003
   Iozzo RV, 2011, J BIOL CHEM, V286, P34712, DOI 10.1074/jbc.M111.262766
   Iozzo RV, 2011, J CELL MOL MED, V15, P1013, DOI 10.1111/j.1582-4934.2010.01236.x
   Iozzo RV, 2010, FEBS J, V277, P3863, DOI 10.1111/j.1742-4658.2010.07796.x
   IOZZO RV, 1993, EXPERIENTIA, V49, P447, DOI 10.1007/BF01923588
   Iozzo RV, 1999, PROG NUCLEIC ACID RE, V62, P19
   Iozzo RV, 1999, P NATL ACAD SCI USA, V96, P3092, DOI 10.1073/pnas.96.6.3092
   IOZZO RV, 1988, CANCER METAST REV, V7, P39, DOI 10.1007/BF00048277
   Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609
   Izzi Valerio, 2019, Matrix Biol Plus, V1, P100004, DOI 10.1016/j.mbplus.2019.04.001
   Jarvinen TAH, 2020, NANOMATERIALS-BASEL, V10, DOI 10.3390/nano10020226
   Karamanos Nikos K, 2019, Matrix Biol, V75-76, P1, DOI 10.1016/j.matbio.2018.08.007
   Karamanos NK, 2018, CHEM REV, V118, P9152, DOI 10.1021/acs.chemrev.8b00354
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Koistinen V, 2017, MATRIX BIOL, V63, P38, DOI 10.1016/j.matbio.2016.12.007
   Liu B, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-016-0378-2
   Liu Z, 2017, HUM GENE THER, V28, P667, DOI 10.1089/hum.2017.033
   Marquardt S, 2018, SEMIN CANCER BIOL, V53, P90, DOI 10.1016/j.semcancer.2018.06.006
   MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692
   Merline R, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001868
   Mohammed A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082332
   Moreth K, 2012, CELL CYCLE, V11, P2084, DOI 10.4161/cc.20316
   Naba A, 2017, SCI REP-UK, V7, DOI 10.1038/srep40495
   Naba A, 2016, MATRIX BIOL, V49, P10, DOI 10.1016/j.matbio.2015.06.003
   Neil JR, 2008, CARCINOGENESIS, V29, P2227, DOI 10.1093/carcin/bgn202
   Neill T, 2017, J BIOL CHEM, V292, P16211, DOI 10.1074/jbc.M116.769950
   Neill T, 2016, ADV DRUG DELIVER REV, V97, P174, DOI 10.1016/j.addr.2015.10.016
   Neill T, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.975645
   Neill T, 2015, BIOCHEMISTRY-US, V54, P4583, DOI 10.1021/acs.biochem.5b00653
   Neill T, 2013, AUTOPHAGY, V9, P1626, DOI 10.4161/auto.25881
   Neill T, 2012, J BIOL CHEM, V287, P5492, DOI 10.1074/jbc.M111.283499
   Nyman MC, 2015, J HISTOCHEM CYTOCHEM, V63, P710, DOI 10.1369/0022155415590830
   Parang B, 2016, METHODS MOL BIOL, V1422, P297, DOI 10.1007/978-1-4939-3603-8_26
   Plaks V, 2015, CELL STEM CELL, V16, P225, DOI 10.1016/j.stem.2015.02.015
   Preca BT, 2017, ONCOTARGET, V8, P11530, DOI 10.18632/oncotarget.14563
   Robinson KA, 2017, MATRIX BIOL, V64, P81, DOI 10.1016/j.matbio.2017.08.004
   Rosette C, 2005, CARCINOGENESIS, V26, P943, DOI 10.1093/carcin/bgi070
   Rousselle P, 2019, MATRIX BIOL, V75-76, P12, DOI 10.1016/j.matbio.2018.01.002
   RUDNICKA L, 1994, J CLIN INVEST, V93, P1709, DOI 10.1172/JCI117154
   RYYNANEN M, 1992, J CLIN INVEST, V89, P974, DOI 10.1172/JCI115680
   Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507
   Santra M, 2002, J BIOL CHEM, V277, P35671, DOI 10.1074/jbc.M205317200
   SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016
   Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200
   Schaefer L, 2002, AM J PATHOL, V160, P1181, DOI 10.1016/S0002-9440(10)64937-1
   Schaefer L, 2008, J BIOL CHEM, V283, P21305, DOI 10.1074/jbc.R800020200
   Schaefer L, 2017, FEBS J, V284, P10, DOI 10.1111/febs.13963
   Schaefer L, 2012, CURR OPIN GENET DEV, V22, P56, DOI 10.1016/j.gde.2011.12.002
   Seidler DG, 2006, J BIOL CHEM, V281, P26408, DOI 10.1074/jbc.M602853200
   Socovich AM, 2019, SEMIN CELL DEV BIOL, V89, P157, DOI 10.1016/j.semcdb.2018.06.005
   Strasser-Weippl K, 2018, JNCI-J NATL CANCER I, V110, P1003, DOI 10.1093/jnci/djy017
   Suhovskih AV, 2015, CELL TISSUE RES, V361, P833, DOI 10.1007/s00441-015-2141-8
   Theocharis AD, 2019, FEBS J, V286, P2830, DOI 10.1111/febs.14818
   Theocharis AD, 2019, MATRIX BIOL, V75-76, P220, DOI 10.1016/j.matbio.2017.10.008
   Theocharis AD, 2016, ADV DRUG DELIVER REV, V97, P4, DOI 10.1016/j.addr.2015.11.001
   Theocharis AD, 2015, BBA-REV CANCER, V1855, P276, DOI 10.1016/j.bbcan.2015.03.006
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Torres A, 2017, J BIOL CHEM, V292, P5055, DOI 10.1074/jbc.M116.753632
   Wang K, 2020, BRIT J CANCER, V123, P410, DOI 10.1038/s41416-020-0902-y
   Weis SM, 2005, MATRIX BIOL, V24, P313, DOI 10.1016/j.matbio.2005.05.003
   Xaus J, 2001, BLOOD, V98, P2124, DOI 10.1182/blood.V98.7.2124
   Xu W, 2015, GENE THER, V22, P247, DOI 10.1038/gt.2014.110
   Yang YF, 2015, HUM GENE THER, V26, P813, DOI 10.1089/hum.2015.098
   Zhang W, 2020, HUM GENE THER, V31, P651, DOI 10.1089/hum.2019.352
   Zhang W, 2018, ONCOTARGET, V9, P5480, DOI 10.18632/oncotarget.23869
   Zoeller JJ, 2008, J CELL BIOL, V181, P381, DOI 10.1083/jcb.200708022
   Zoeller JJ, 2009, J BIOL CHEM, V284, P11728, DOI 10.1074/jbc.M808991200
NR 100
TC 12
Z9 12
U1 5
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0945-053X
EI 1569-1802
J9 MATRIX BIOL
JI Matrix Biol.
PD JAN
PY 2021
VL 95
BP 1
EP 14
DI 10.1016/j.matbio.2020.10.001
EA FEB 2021
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA QG7WR
UT WOS:000617794300001
PM 33065248
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Horng, CT
   Wu, YJ
   Chen, PN
   Chu, SC
   Tsai, CM
   Hsieh, YS
AF Horng, Chi-Ting
   Wu, Yueh-Jung
   Chen, Pei-Ni
   Chu, Shu-Chen
   Tsai, Chun-Miao
   Hsieh, Yih-Shou
TI Koelreuteria Formosana Extract Induces Growth Inhibition and Cell Death
   in Human Colon Carcinoma Cells via G2/M Arrest and LC3-II
   Activation-Dependent Autophagy
SO NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
LA English
DT Article
ID CANCER CELLS; IN-VITRO; KINASE INHIBITORS; CYCLE ARREST; APOPTOSIS;
   BERBERINE; INDUCTION; PROTEIN; VIVO
AB Autophagy is a self-destructive process that degrades cytoplasmic constituents. In our previous study, Koelreuteria formosana ethanolic extract (KFEE), which is obtained from natural plants endemic to Taiwan, has inhibited cell metastasis in renal carcinoma cells. However, the anticancer effects of KFEE on colon cancer remain unclear. In this study, KFEE exerted a strong cytotoxic effect on DLD-1 and COLO 205 human colorectal cancer cell lines. KFEE effectively inhibited cancer cell proliferation, induced G2/M-phase arrest associated with downregulaton of cyclin E, cyclin B and cdc25C and upregulation of p21, and induced cell death by activating autophagy but did not cause apoptotic cell death. Exposed KFEE cells showed increased levels of acridine orange, autophagic vacuoles, and LC3-II proteins, which are specific autophagic markers. Bcl-2, p-Akt, and p-mTOR levels, which have been implicated in autophagic downregulation, were decreased after KFEE treatment. Autophagy inhibitor 3-methyladenosine and bafilomycin-A1 and genetic silencing of LC3 attenuated KFEE-induced growth inhibition. These findings suggested that KFEE causes cytostatic effect through autophagy. In xenograft studies, oral administration of KFEE had significantly inhibited the tumor growth in nude mice that had received subcutaneous injection of DLD-1 cells. KFEE is a promising candidate in phytochemical-based, mechanistic, and pathway-targeted cancer prevention strategies.
C1 [Horng, Chi-Ting] Kaohsiung Armed Forces Gen Hosp, Med Educ Ctr, Kaohsiung, Taiwan.
   [Horng, Chi-Ting; Chen, Pei-Ni; Tsai, Chun-Miao; Hsieh, Yih-Shou] Chung Shang Med Univ, Inst Biochem Microbiol & Immunol, 110,Sect 1,Jianguo N Rd, Taichung 402, Taiwan.
   [Wu, Yueh-Jung] Kaohsiung Armed Forces Gen Hosp, Dept Colorectal Surg, Kaohsiung, Taiwan.
   [Chu, Shu-Chen] Cent Taiwan Univ Sci & Technol, Inst & Dept Food Sci, Taichung, Taiwan.
   [Hsieh, Yih-Shou] Chung Shan Med Univ Hosp, Clin Lab, Taichung, Taiwan.
EM csmcysh@csmu.edu.tw
FU Kaohsiung Armed Forces General Hospital [104-15]
FX This study was supported by grants of Kaohsiung Armed Forces General
   Hospital [104-15].
CR Abal M, 2004, ONCOGENE, V23, P1737, DOI 10.1038/sj.onc.1207299
   ABOUSHOER M, 1993, J NAT PROD, V56, P967, DOI 10.1021/np50096a027
   Chang CJ, 1996, IN VIVO, V10, P185
   Chen CH, 2009, MOLECULES, V14, P2947, DOI 10.3390/molecules14082947
   Chen PN, 2005, NUTR CANCER, V53, P232, DOI 10.1207/s15327914nc5302_12
   Chen PN, 2011, J AGR FOOD CHEM, V59, P3836, DOI 10.1021/jf1049408
   Chu SC, 2014, MOL PHARMACOL, V86, P609, DOI 10.1124/mol.114.094037
   Chu SC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101579
   Chu SC, 2014, INTEGR CANCER THER, V13, P259, DOI 10.1177/1534735413510559
   ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8
   Gao P, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-123
   Gewirtz DA, 2013, AUTOPHAGY, V9, P1263, DOI 10.4161/auto.25233
   GRANA X, 1995, ONCOGENE, V11, P211
   Ho YS, 2001, INT J CANCER, V91, P393, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1070&gt;3.0.CO;2-#
   Hsin IL, 2011, AUTOPHAGY, V7, P873, DOI 10.4161/auto.7.8.15698
   Hu FW, 2012, MOL NUTR FOOD RES, V56, P1247, DOI 10.1002/mnfr.201200150
   Huang AC, 2013, INT J ONCOL, V43, P485, DOI 10.3892/ijo.2013.1952
   Lin CY, 2014, MOL MED REP, V10, P3334, DOI 10.3892/mmr.2014.2587
   Lin CY, 2014, FOOD CHEM, V146, P299, DOI 10.1016/j.foodchem.2013.09.018
   Liu N, 2013, ONCOL REP, V30, P2677, DOI 10.3892/or.2013.2771
   Mantena SK, 2006, MOL CANCER THER, V5, P296, DOI 10.1158/1535-7163.MCT-05-0448
   Mohammadzadeh M, 2013, INTEGR CANCER THER, V12, P496, DOI 10.1177/1534735413485417
   Park SH, 2012, TOXICOL LETT, V212, P252, DOI 10.1016/j.toxlet.2012.06.007
   Raghavan D, 1997, EUR J CANCER, V33, P566, DOI 10.1016/S0959-8049(96)00510-2
   Speirs CK, 2011, AM J CANCER RES, V1, P43
   Swanton C, 2004, LANCET ONCOL, V5, P27, DOI 10.1016/S1470-2045(03)01321-4
   Tacar O, 2013, J PHARM PHARMACOL, V65, P1577, DOI 10.1111/jphp.12144
NR 27
TC 4
Z9 5
U1 0
U2 9
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0163-5581
EI 1532-7914
J9 NUTR CANCER
JI Nutr. Cancer
PY 2017
VL 69
IS 1
BP 44
EP 55
DI 10.1080/01635581.2017.1247889
PG 12
WC Oncology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Nutrition & Dietetics
GA EI6QD
UT WOS:000392619700005
PM 27880045
DA 2022-04-25
ER

PT J
AU Chen, MC
   Lee, NH
   Hsu, HH
   Ho, TJ
   Tu, CC
   Hsieh, DJY
   Lin, YM
   Chen, LM
   Kuo, WW
   Huang, CY
AF Chen, Ming-Cheng
   Lee, Nien-Hung
   Hsu, Hsi-Hsien
   Ho, Tsung-Jung
   Tu, Chuan-Chou
   Hsieh, Dennis Jine-Yuan
   Lin, Yueh-Min
   Chen, Li-Mien
   Kuo, Wei-Wen
   Huang, Chih-Yang
TI Thymoquinone Induces Caspase-Independent, Autophagic Cell Death in
   CPT-11-Resistant LoVo Colon Cancer via Mitochondrial Dysfunction and
   Activation of JNK and p38
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE apoptosis; autophagy; caspase-independent; CPT-11-R LoVo colon cancer
   cells; thymoquinone
ID NF-KAPPA-B; CHEMORESISTANCE; MECHANISMS; DRUG; CHEMOTHERAPY; METASTASIS;
   INHIBITION; PREVENTION; RESISTANCE; THERAPIES
AB Chemotherapy causes unwanted side effects and chemoresistance, limiting its effectiveness. Therefore, phytochemicals are now used as alternative treatments. Thymoquinone (TQ) is used to treat different cancers, including colon cancer. The irinotecan-resistant (CPT-11-R) LoVo colon cancer cell line was previously constructed by stepwise CPT-11 challenges to untreated parental LoVo cells. TQ dose-dependently increased the total cell death index and activated apoptosis at 2 mu M, which then diminished at increasing doses. The possibility of autophagic cell death was then investigated. TQ caused mitochondrial outer membrane permeability (MOMP) and activated autophagic cell death. JNK and p38 inhibitors (SP600125 and SB203580, respectively) reversed TQ autophagic cell death. TQ was also found to activate apoptosis before autophagy, and the direction of cell death was switched toward autophagic cell death at initiation of autophagosome formation. Therefore, TQ resulted in caspase-independent, autophagic cell death via MOMP and activation of JNK and p38 in CPT-11-R LoVo colon cancer cells.
C1 [Chen, Ming-Cheng; Lee, Nien-Hung; Huang, Chih-Yang] China Med Univ, Grad Inst Basic Med Sci, Taichung 404, Taiwan.
   [Chen, Ming-Cheng] Taichung Vet Gen Hosp, Puli Branch, Nantou 545, Taiwan.
   [Hsu, Hsi-Hsien] Mackay Mem Hosp, Div Colorectal Surg, Taipei 104, Taiwan.
   [Hsu, Hsi-Hsien] Nursing & Management Coll, Mackay Med, Taipei 112, Taiwan.
   [Ho, Tsung-Jung] China Med Univ, Beigang Hosp, Chinese Med Dept, Yunlin 651, Taiwan.
   [Tu, Chuan-Chou; Chen, Li-Mien] Armed Force Taichung Gen Hosp, Div Chest Med, Dept Internal Med, Taichung 411, Taiwan.
   [Hsieh, Dennis Jine-Yuan] Chung Shan Med Univ, Sch Med Lab & Biotechnol, Taichung 402, Taiwan.
   [Hsieh, Dennis Jine-Yuan] Chung Shan Med Univ Hosp, Dept Clin Lab, Taichung 402, Taiwan.
   [Lin, Yueh-Min] Changhua Christian Hosp, Dept Pathol, Changhua 505, Taiwan.
   [Kuo, Wei-Wen] China Med Univ, Dept Biol Sci & Technol, Taichung 404, Taiwan.
   [Huang, Chih-Yang] China Med Univ, Grad Inst Chinese Med Sci, Taichung 404, Taiwan.
   [Huang, Chih-Yang] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung 413, Taiwan.
RP Huang, CY (corresponding author), China Med Univ, Grad Inst Basic Med Sci, Taichung 404, Taiwan.
EM cyhuang@mail.cmu.edu.tw
RI Yuang, Chih-Yang/O-5111-2015
OI Lee, Nien-Hung/0000-0001-5423-8880
FU Taiwan Ministry of Health and Welfare Clinical Trial and Research Center
   of Excellence [MOHW104-TDU-B-212-113002]
FX This study is supported in part by Taiwan Ministry of Health and Welfare
   Clinical Trial and Research Center of Excellence
   (MOHW104-TDU-B-212-113002).
CR Abdel-Fattah AFM, 2000, EUR J PHARMACOL, V400, P89, DOI 10.1016/S0014-2999(00)00340-X
   Aggarwal BB, 2006, CURR SIGNAL TRANSD T, V1, P25, DOI 10.2174/157436206775269235
   Al-Shabanah OA, 1998, J EXP CLIN CANC RES, V17, P193
   Altekruse SF, 1975, SEER CANC STAT REV
   Amin ARMR, 2009, J CLIN ONCOL, V27, P2712, DOI 10.1200/JCO.2008.20.6235
   Attoub S, 2013, FUND CLIN PHARMACOL, V27, P557, DOI 10.1111/j.1472-8206.2012.01056.x
   Baldwin AS, 2012, IMMUNOL REV, V246, P327, DOI 10.1111/j.1600-065X.2012.01095.x
   Chen HW, 2008, CANCER RES, V68, P7428, DOI 10.1158/0008-5472.CAN-07-6734
   Chen MC, 2014, CANCER LETT, V349, P51, DOI 10.1016/j.canlet.2014.03.023
   Cusack JC, 1999, DRUG RESIST UPDATE, V2, P271, DOI 10.1054/drup.1999.0094
   DREWINKO B, 1976, CANCER RES, V36, P467
   El-Najjar N, 2010, APOPTOSIS, V15, P183, DOI 10.1007/s10495-009-0421-z
   Gali-Muhtasib H, 2006, INT J BIOCHEM CELL B, V38, P1249, DOI 10.1016/j.biocel.2005.10.009
   Gonzalez-Polo RA, 2005, J CELL SCI, V118, P3091, DOI 10.1242/jcs.02447
   Gurung RL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012124
   Herman-Antosiewicz A, 2006, CANCER RES, V66, P5828, DOI 10.1158/0008-5472.CAN-06-0139
   Hsu SC, 2012, BIOMEDICINE-TAIWAN, V2, P108, DOI 10.1016/j.biomed.2012.03.003
   Hu HB, 2009, MOL CANCER THER, V8, P2833, DOI 10.1158/1535-7163.MCT-09-0288
   Ishihara N, 2009, DEV CELL, V17, P1, DOI 10.1016/j.devcel.2009.07.003
   Jafri SH, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-87
   Kueck A, 2007, GYNECOL ONCOL, V107, P450, DOI 10.1016/j.ygyno.2007.07.065
   Luqmani YA, 2005, MED PRIN PRACT, V14, P35, DOI 10.1159/000086183
   Marin JJG, 2012, CURR CANCER DRUG TAR, V12, P402
   Muniz Viviane P, 2013, Genes Cancer, V4, P273, DOI 10.1177/1947601913501074
   Oh SH, 2008, AUTOPHAGY, V4, P1009, DOI 10.4161/auto.6886
   Pan MH, 2011, MOL NUTR FOOD RES, V55, P32, DOI 10.1002/mnfr.201000412
   Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977
   Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102
   Singletary K, 2008, CANCER EPIDEM BIOMAR, V17, P1596, DOI 10.1158/1055-9965.EPI-07-2917
   Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952
   Torres MP, 2010, MOL CANCER THER, V9, P1419, DOI 10.1158/1535-7163.MCT-10-0075
   Uetsuka H, 2003, EXP CELL RES, V289, P27, DOI 10.1016/S0014-4827(03)00223-4
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Yi TF, 2008, MOL CANCER THER, V7, P1789, DOI 10.1158/1535-7163.MCT-08-0124
   Yim KL, 2011, RECENT RESULTS CANC, V185, P159, DOI 10.1007/978-3-642-03503-6_10
NR 35
TC 51
Z9 52
U1 2
U2 23
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
EI 1520-5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD FEB 11
PY 2015
VL 63
IS 5
BP 1540
EP 1546
DI 10.1021/jf5054063
PG 7
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Agriculture; Chemistry; Food Science & Technology
GA CB4CW
UT WOS:000349576800025
PM 25611974
DA 2022-04-25
ER

PT J
AU Wu, TY
   Cho, TY
   Lu, CK
   Liou, JP
   Chen, MC
AF Wu, Tung-Yun
   Cho, Ting-Yu
   Lu, Chung-Kuang
   Liou, Jing-Ping
   Chen, Mei-Chuan
TI Identification of 7-(4 '-Cyanophenyl)indoline-1-benzenesulfonamide as a
   mitotic inhibitor to induce apoptotic cell death and inhibit autophagy
   in human colorectal cancer cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MICROTUBULE-STABILIZING AGENT; 3-KINASE/MAMMALIAN TARGET; ANTICANCER
   ACTIVITY; PHOSPHORYLATION; CYCLE; NVP-BEZ235; RESISTANCE; MECHANISM;
   RADIATION; SURVIVAL
AB Targeting cellular mitosis in tumor cells is an attractive cancer treatment strategy. Here, we report that B220, a synthetic benzenesulfonamide compound, could represent a new mitotic inhibitor for the treatment of colorectal cancer. We examined the action mechanism of B220 in the colorectal carcinoma HCT116 cell line, and found that treatment of cells with B220 caused cells to accumulate in G2/M phase, with a concomitant induction of the mitotic phase markers, MPM2 and cyclin B1. After 48 h of B220 treatment, cells underwent apoptotic cell death via caspase-3 activation and poly(ADP ribose) polymerase (PARP) cleavage. In addition, B220 inhibits autophagy by blocking conversion of microtubule-associated protein 1 light chain 3 (LC3-I) to LC3-II and inhibiting autophagic flux. Notably, blockade of autophagy by pharmacological inhibition or using an Atg5-targeting shRNA reduced B220-induced cytotoxicity. Conversely, the autophagy inducer NVP-BEZ235 shows a synergistic interaction with B220 in HCT116 cells, indicating autophagy was required for the observed cell death. In summary, these results indicate B220 combined with the induction of autophagy using the dual PI3K/mTOR inhibitor, NVP-BEZ235, might be an attractive strategy for cancer therapy, and provides a framework for further development of B220 as a new therapeutic agent for colon cancer treatment.
C1 [Wu, Tung-Yun; Chen, Mei-Chuan] Taipei Med Univ, Coll Pharm, PhD Program Clin Drug Discovery Bot Herbs, Taipei, Taiwan.
   [Cho, Ting-Yu; Chen, Mei-Chuan] Taipei Med Univ, Coll Pharm, Grad Inst Pharmacognosy, Taipei, Taiwan.
   [Lu, Chung-Kuang] Minist Hlth & Welf, Natl Res Inst Chinese Med, Taipei, Taiwan.
   [Liou, Jing-Ping] Taipei Med Univ, Coll Pharm, Sch Pharm, Taipei, Taiwan.
RP Chen, MC (corresponding author), Taipei Med Univ, Coll Pharm, PhD Program Clin Drug Discovery Bot Herbs, Taipei, Taiwan.; Chen, MC (corresponding author), Taipei Med Univ, Coll Pharm, Grad Inst Pharmacognosy, Taipei, Taiwan.
EM mcchen1250@tmu.edu.tw
FU Ministry of Science and Technology of the Republic of ChinaMinistry of
   Science and Technology, China [MOST-103-2320-B-038-030-MY3]; Taipei
   Medical University [TMU102-AE1-B43]
FX We thank Core Facility Center of Taipei Medical University for the
   supports of deconvolution microscope. This research was supported by the
   Ministry of Science and Technology of the Republic of China (grant no.
   MOST-103-2320-B-038-030-MY3), and TMU102-AE1-B43 by Taipei Medical
   University.
CR Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039
   Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562
   Arthur CR, 2007, BIOCHEM PHARMACOL, V74, P981, DOI 10.1016/j.bcp.2007.07.003
   Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4
   Bursch W, 2000, ANN NY ACAD SCI, V926, P1, DOI 10.1111/j.1749-6632.2000.tb05594.x
   Castedo M, 2002, CELL DEATH DIFFER, V9, P1287, DOI 10.1038/sj.cdd.4401130
   Cerniglia GJ, 2012, MOL PHARMACOL, V82, P1230, DOI 10.1124/mol.112.080408
   Chang JY, 2010, MEDCHEMCOMM, V1, P152, DOI 10.1039/c0md00052c
   Chang ZX, 2013, INT J MOL MED, V31, P1449, DOI 10.3892/ijmm.2013.1351
   Changou CA, 2014, P NATL ACAD SCI USA, V111, P14147, DOI 10.1073/pnas.1404171111
   Chen CH, 2012, CANCER LETT, V315, P1, DOI 10.1016/j.canlet.2011.09.042
   Chen SH, 2016, SCIENCE, V351, P1204, DOI 10.1126/science.aac5610
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883
   Dasmahapatra G, 2006, MOL PHARMACOL, V69, P288, DOI 10.1124/mol.105.016154
   Deng X, 2001, J Natl Cancer Inst Monogr, P30
   Domenech E, 2015, NAT CELL BIOL, V17, P1304, DOI 10.1038/ncb3231
   Dybdal-Hargreaves NF, 2015, CLIN CANCER RES, V21, P2445, DOI 10.1158/1078-0432.CCR-14-3252
   Ferrandina G, 2012, CURR PHARM DESIGN, V18, P2793, DOI 10.2174/138161212800626238
   Fourest-Lieuvin A, 2006, MOL BIOL CELL, V17, P1041, DOI 10.1091/mbc.E05-07-0621
   Goldenson B, 2015, ONCOGENE, V34, P537, DOI 10.1038/onc.2014.14
   GOLSTEYN RM, 1994, J CELL SCI, V107, P1509
   Hadfield John A, 2003, Prog Cell Cycle Res, V5, P309
   Haldar S, 1998, CANCER RES, V58, P1609
   Jackson JR, 2007, NAT REV CANCER, V7, P107, DOI 10.1038/nrc2049
   Jahreiss L, 2008, TRAFFIC, V9, P574, DOI 10.1111/j.1600-0854.2008.00701.x
   Jiang K, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-551
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kanakkanthara A, 2016, NAT PROD REP, V33, P549, DOI 10.1039/c5np00146c
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Kavallaris M, 2010, NAT REV CANCER, V10, P194, DOI 10.1038/nrc2803
   Kimura S, 2008, CELL STRUCT FUNCT, V33, P109, DOI 10.1247/csf.08005
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kovalevich J, 2016, J PHARMACOL EXP THER, V357, P432, DOI 10.1124/jpet.115.231175
   Li JR, 2013, TOXICOL LETT, V220, P267, DOI 10.1016/j.toxlet.2013.04.021
   Li TH, 2007, CLIN CANCER RES, V13, P3413, DOI 10.1158/1078-0432.CCR-06-2923
   Lin J, 2014, AUTOPHAGY, V10, P2006, DOI 10.4161/auto.36293
   Linares JF, 2011, MOL CELL BIOL, V31, P105, DOI 10.1128/MCB.00620-10
   Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Matsushita M, 2007, J BIOL CHEM, V282, P6763, DOI 10.1074/jbc.M609876200
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Morton CL, 2007, INVEST NEW DRUG, V25, P285, DOI 10.1007/s10637-007-9042-y
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232
   Paglin S, 2001, CANCER RES, V61, P439
   Pattingre S, 2008, BIOCHIMIE, V90, P313, DOI 10.1016/j.biochi.2007.08.014
   Rodriguez A, 2006, CELL METAB, V3, P211, DOI 10.1016/j.cmet.2006.01.011
   Seitz C, 2013, INT J CANCER, V132, P2682, DOI 10.1002/ijc.27935
   Shamas-Din A, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008714
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Swami U, 2015, MAR DRUGS, V13, P5016, DOI 10.3390/md13085016
   Tan Q, 2016, NEOPLASIA, V18, P347, DOI 10.1016/j.neo.2016.04.003
   Thorburn A, 2014, MOL PHARMACOL, V85, P830, DOI 10.1124/mol.114.091850
   Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P1153, DOI 10.1038/cdd.2008.47
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Wood Kenneth W., 2001, Current Opinion in Pharmacology, V1, P370, DOI 10.1016/S1471-4892(01)00064-9
   Xi GM, 2011, CANCER LETT, V307, P141, DOI 10.1016/j.canlet.2011.03.026
   Yang CPH, 2016, P NATL ACAD SCI USA, V113, P11294, DOI 10.1073/pnas.1613286113
   Yang YP, 2013, ACTA PHARMACOL SIN, V34, P625, DOI 10.1038/aps.2013.5
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Zhou LL, 2014, CELL BIOL INT, V38, P737, DOI 10.1002/cbin.10259
   Zhu S, 2013, AUTOPHAGY, V9, P317, DOI 10.4161/auto.22923
NR 64
TC 8
Z9 8
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 29
PY 2017
VL 7
AR 12406
DI 10.1038/s41598-017-12795-5
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FI5NV
UT WOS:000412032000015
PM 28963527
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Linares, JF
   Zhang, X
   Martinez-Ordonez, A
   Duran, A
   Kinoshita, H
   Kasashima, H
   Nakanishi, N
   Nakanishi, Y
   Carelli, R
   Cappelli, L
   Arias, E
   Yashiro, M
   Ohira, M
   Patel, S
   Inghirami, G
   Loda, M
   Cuervo, AM
   Diaz-Meco, MT
   Moscat, J
AF Linares, Juan F.
   Zhang, Xiao
   Martinez-Ordonez, Anxo
   Duran, Angeles
   Kinoshita, Hiroto
   Kasashima, Hiroaki
   Nakanishi, Naoko
   Nakanishi, Yuki
   Carelli, Ryan
   Cappelli, Luca
   Arias, Esperanza
   Yashiro, Masakazu
   Ohira, Masaichi
   Patel, Sanjay
   Inghirami, Giorgio
   Loda, Massimo
   Cuervo, Ana Maria
   Diaz-Meco, Maria T.
   Moscat, Jorge
TI PKC lambda/iota inhibition activates an ULK2-mediated interferon
   response to repress tumorigenesis
SO MOLECULAR CELL
LA English
DT Article
ID GMP-AMP SYNTHASE; DNA SENSOR; IMMUNE CELLS; COLON-CANCER; AUTOPHAGY;
   INFLAMMATION; EXPRESSION; TUMORS; RESISTANCE; ADAPTER
AB The interferon (IFN) pathway is critical for cytotoxic T cell activation, which is central to tumor immunosurveillance and successful immunotherapy. We demonstrate here that PKC lambda/iota inactivation results in the hyper stimulation of the IFN cascade and the enhanced recruitment of CD8(+) T cells that impaired the growth of intestinal tumors. PKC lambda/iota directly phosphorylates and represses the activity of ULK2, promoting its degradation through an endosomal microautophagy-driven ubiquitin-dependent mechanism. Loss of PKC lambda/iota results in increased levels of enzymatically active ULK2, which, by direct phosphorylation, activates TBK1 to foster the activation of the STING-mediated IFN response. PKC lambda/iota inactivation also triggers autophagy, which prevents STING degradation by chaperone-mediated autophagy. Thus, PKC lambda/iota is a hub regulating the IFN pathway and three autophagic mechanisms that serve to maintain its homeostatic control. Importantly, single-cell multiplex imaging and bioinformatics analysis demonstrated that low PKC lambda/iota levels correlate with enhanced IFN signaling and good prognosis in colorectal cancer patients.
C1 [Linares, Juan F.; Zhang, Xiao; Martinez-Ordonez, Anxo; Duran, Angeles; Kinoshita, Hiroto; Carelli, Ryan; Cappelli, Luca; Patel, Sanjay; Inghirami, Giorgio; Loda, Massimo; Diaz-Meco, Maria T.; Moscat, Jorge] Weill Cornell Med, Dept Pathol & Lab Med, New York, NY 10065 USA.
   [Linares, Juan F.; Zhang, Xiao; Martinez-Ordonez, Anxo; Duran, Angeles; Kinoshita, Hiroto; Carelli, Ryan; Cappelli, Luca; Patel, Sanjay; Inghirami, Giorgio; Loda, Massimo; Diaz-Meco, Maria T.; Moscat, Jorge] Weill Cornell Med, Sandra & Edward Meyer Canc Ctr, New York, NY 10065 USA.
   [Kasashima, Hiroaki; Yashiro, Masakazu; Ohira, Masaichi] Osaka City Univ, Dept Gastroenterol Surg, Grad Sch Med, Abeno Ku, 1-4-3 Asahimachi, Osaka 5458585, Japan.
   [Nakanishi, Naoko] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Endocrinol & Metab, Kyoto, Japan.
   [Nakanishi, Yuki] Kyoto Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, Kyoto, Japan.
   [Arias, Esperanza; Cuervo, Ana Maria] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA.
   [Arias, Esperanza; Cuervo, Ana Maria] Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA.
   [Arias, Esperanza; Cuervo, Ana Maria] Albert Einstein Coll Med, Inst Aging Studies, Bronx, NY 10461 USA.
RP Diaz-Meco, MT; Moscat, J (corresponding author), Weill Cornell Med, Dept Pathol & Lab Med, New York, NY 10065 USA.; Diaz-Meco, MT; Moscat, J (corresponding author), Weill Cornell Med, Sandra & Edward Meyer Canc Ctr, New York, NY 10065 USA.
EM mtd4001@med.cornell.edu; jom4010@med.cornell.edu
RI ; Zhang, Xiao/L-6674-2013
OI KASASHIMA, HIROAKI/0000-0001-5234-4030; Zhang, Xiao/0000-0002-8213-6686;
   Nakanishi, Yuki/0000-0001-5493-6312; Arias,
   Esperanza/0000-0002-7836-5072; Cappelli, Luca
   Vincenzo/0000-0001-8090-3880
FU NCI of the National Institutes of HealthUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [R01CA207177, R01CA250025, R01CA218254,
   P50CA211024]; Center for Translational Pathology and the Multiparametric
   In Situ Imaging Laboratory in the Department of Pathology and Laboratory
   Medicine, Weill Cornell Medicine
FX Research was supported by grants by NCI of the National Institutes of
   Health under awards R01CA207177 and R01CA250025 to J.M.; R01CA218254 to
   M.T.D.-M.; and P50CA211024 to M.L. Project support for this research was
   provided in part by the Center for Translational Pathology and the
   Multipara-metric In Situ Imaging Laboratory in the Department of
   Pathology and Labora-tory Medicine, Weill Cornell Medicine. We thank Dr.
   Eduard Batlle (IRB Barce-lona, Spain) for generously providing MTO
   organoids. We thank Tavonna Bryant and Tararin Nikomborirak for
   technical assistance. J.M. and M.T.D.-M. are Homer T. Hirst III
   Professors of Oncology in Pathology.
CR Allen JJ, 2007, NAT METHODS, V4, P511, DOI 10.1038/nmeth1048
   Arijs I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007984
   Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444
   Benci JL, 2016, CELL, V167, P1540, DOI 10.1016/j.cell.2016.11.022
   Bezu L, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00187
   Bruni D, 2020, NAT REV CANCER, V20, P662, DOI 10.1038/s41568-020-0285-7
   Burdette DL, 2013, NAT IMMUNOL, V14, P19, DOI 10.1038/ni.2491
   Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225
   Ciechanover A, 2015, NAT REV MOL CELL BIO, V16, P322, DOI 10.1038/nrm3982
   De Sousa E Melo F, 2013, NAT MED, V19, P614, DOI 10.1038/nm.3174
   Dersh D, 2021, NAT REV IMMUNOL, V21, P116, DOI 10.1038/s41577-020-0390-6
   Duran A, 2011, MOL CELL, V44, P134, DOI 10.1016/j.molcel.2011.06.038
   Egan DF, 2015, MOL CELL, V59, P285, DOI 10.1016/j.molcel.2015.05.031
   El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042
   Galluzzi L, 2017, NAT REV CLIN ONCOL, V14, P247, DOI 10.1038/nrclinonc.2016.183
   Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139
   Gao JJ, 2016, CELL, V167, P397, DOI 10.1016/j.cell.2016.08.069
   Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909
   Germano G, 2017, NATURE, V552, P116, DOI 10.1038/nature24673
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7
   Hopfner KP, 2020, NAT REV MOL CELL BIO, V21, P501, DOI 10.1038/s41580-020-0244-x
   Hu MM, 2016, IMMUNITY, V45, P555, DOI 10.1016/j.immuni.2016.08.014
   Huang X, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2142-8
   Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105
   Kasashima H, 2021, DEV CELL, V56, P95, DOI 10.1016/j.devcel.2020.10.014
   Kimura S, 2008, CELL STRUCT FUNCT, V33, P109, DOI 10.1247/csf.08005
   Kudo Y, 2020, CANCER CELL, V38, P247, DOI 10.1016/j.ccell.2020.05.018
   Kugathasan S, 2008, NAT GENET, V40, P1211, DOI 10.1038/ng.203
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733
   Lee EJ, 2011, AUTOPHAGY, V7, P689, DOI 10.4161/auto.7.7.15450
   Lee HO, 2020, NAT GENET, V52, P594, DOI 10.1038/s41588-020-0636-z
   Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6
   Liao WT, 2019, CANCER CELL, V35, P559, DOI 10.1016/j.ccell.2019.02.008
   Linares JF, 2015, CELL REP, V12, P1339, DOI 10.1016/j.celrep.2015.07.045
   Linares JF, 2013, MOL CELL, V51, P283, DOI 10.1016/j.molcel.2013.06.020
   Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200
   Mandal R, 2019, SCIENCE, V364, P485, DOI 10.1126/science.aau0447
   Martini G, 2020, THER ADV MED ONCOL, V12, DOI 10.1177/1758835920936089
   Massey AC, 2006, P NATL ACAD SCI USA, V103, P5805, DOI 10.1073/pnas.0507436103
   Mlecnik B, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad6352
   Montero-Melendez T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076235
   Moscat J, 2020, AUTOPHAGY, V16, P1915, DOI 10.1080/15548627.2020.1797290
   Moscat J, 2016, CELL, V167, P606, DOI 10.1016/j.cell.2016.09.030
   Nakanishi Y, 2018, IMMUNITY, V49, P1132, DOI 10.1016/j.immuni.2018.09.013
   Nakanishi Y, 2016, CELL REP, V16, P3297, DOI 10.1016/j.celrep.2016.08.054
   Olsen J, 2009, INFLAMM BOWEL DIS, V15, P1032, DOI 10.1002/ibd.20879
   Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9
   Parra ER, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13942-8
   Patel SS, 2019, BLOOD, V134, P2059, DOI 10.1182/blood.2019002206
   Patel SS, 2020, METHODS MOL BIOL, V2055, P455, DOI 10.1007/978-1-4939-9773-2_21
   Pejaver V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19669-x
   Perera R, 2015, NATURE, V524, P361, DOI 10.1038/nature14587
   Poillet-Perez L, 2020, NAT CANCER, V1, P923, DOI 10.1038/s43018-020-00110-7
   Putz U, 2008, J BIOL CHEM, V283, P32621, DOI 10.1074/jbc.M804120200
   Qiu WR, 2015, J BIOMOL STRUCT DYN, V33, P1731, DOI 10.1080/07391102.2014.968875
   Reina-Campos M, 2019, CANCER CELL, V36, P218, DOI 10.1016/j.ccell.2019.07.010
   Reina-Campos M, 2019, CANCER CELL, V35, P385, DOI 10.1016/j.ccell.2019.01.018
   Saleiro D, 2015, CELL REP, V11, P605, DOI 10.1016/j.celrep.2015.03.056
   Samie M, 2018, NAT IMMUNOL, V19, P246, DOI 10.1038/s41590-017-0042-6
   Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/nmeth.2019, 10.1038/NMETH.2019]
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Singh R, 2009, NATURE, V458, P1131, DOI 10.1038/nature07976
   Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031
   Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458
   Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492
   Toedter G, 2011, AM J GASTROENTEROL, V106, P1272, DOI 10.1038/ajg.2011.83
   Tosolini M, 2011, CANCER RES, V71, P1263, DOI 10.1158/0008-5472.CAN-10-2907
   Traag VA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41695-z
   Van der Goten J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116117
   van der Walt S, 2014, PEERJ, V2, DOI 10.7717/peerj.453
   Vanhove W, 2015, INFLAMM BOWEL DIS, V21, P2673, DOI 10.1097/MIB.0000000000000535
   Vitale I, 2021, NAT MED, V27, P212, DOI 10.1038/s41591-021-01233-9
   Wolf FA, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-017-1382-0
   Yamamoto K, 2020, NATURE, V581, P100, DOI 10.1038/s41586-020-2229-5
   Yamazaki T, 2020, NAT IMMUNOL, V21, P1160, DOI 10.1038/s41590-020-0751-0
   Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958
   Zhang K, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav3262
   Zhang YG, 2014, J IMMUNOL, V193, P2394, DOI 10.4049/jimmunol.1302718
   Zhao P, 2018, CELL, V172, P731, DOI 10.1016/j.cell.2018.01.007
   Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051
NR 83
TC 2
Z9 2
U1 8
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1097-2765
EI 1097-4164
J9 MOL CELL
JI Mol. Cell
PD NOV 4
PY 2021
VL 81
IS 21
BP 4509
EP +
DI 10.1016/j.molcel.2021.08.039
EA NOV 2021
PG 29
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA WV7NW
UT WOS:000717420100001
PM 34560002
DA 2022-04-25
ER

PT J
AU Wiersma, VR
   de Bruyn, M
   Wei, YW
   van Ginkel, RJ
   Hirashima, M
   Niki, T
   Nishi, N
   Zhou, J
   Pouwels, SD
   Samplonius, DF
   Nijman, HW
   Eggleton, P
   Helfrich, W
   Bremer, E
AF Wiersma, Valerie R.
   de Bruyn, Marco
   Wei, Yunwei
   van Ginkel, Robert J.
   Hirashima, Mitsuomi
   Niki, Toshiro
   Nishi, Nozomu
   Zhou, Jin
   Pouwels, Simon D.
   Samplonius, Douwe F.
   Nijman, Hans W.
   Eggleton, Paul
   Helfrich, Wijnand
   Bremer, Edwin
TI The epithelial polarity regulator LGALS9/galectin-9 induces fatal
   frustrated autophagy in KRAS mutant colon carcinoma that depends on
   elevated basal autophagic flux
SO AUTOPHAGY
LA English
DT Article
DE autophagy; colon cancer; galectin-9; KRAS mutation; lysosomes
ID COLORECTAL-CANCER; CELL-DEATH; K-RAS; B-RAF; PROGNOSTIC-FACTOR;
   BREAST-CANCER; IN-VITRO; C-RAF; GALECTIN-9; RESISTANCE
AB Oncogenic mutation of KRAS (Kirsten rat sarcoma viral oncogene homolog) in colorectal cancer (CRC) confers resistance to both chemotherapy and EGFR (epidermal growth factor receptor)-targeted therapy. We uncovered that KRAS mutant (KRAS(mut)) CRC is uniquely sensitive to treatment with recombinant LGALS9/Galectin-9 (rLGALS9), a recently established regulator of epithelial polarity. Upon treatment of CRC cells, rLGALS9 rapidly internalizes via early- and late-endosomes and accumulates in the lysosomal compartment. Treatment with rLGALS9 is accompanied by induction of frustrated autophagy in KRAS(mut) CRC, but not in CRC with BRAF (B-Raf proto-oncogene, serine/threonine kinase) mutations (BRAF(mut)). In KRAS(mut) CRC, rLGALS9 acts as a lysosomal inhibitor that inhibits autophagosome-lysosome fusion, leading to autophagosome accumulation, excessive lysosomal swelling and cell death. This antitumor activity of rLGALS9 directly correlates with elevated basal autophagic flux in KRAS(mut) cancer cells. Thus, rLGALS9 has potent antitumor activity toward refractory KRAS(mut) CRC cells that may be exploitable for therapeutic use.
C1 [Wiersma, Valerie R.; Wei, Yunwei; van Ginkel, Robert J.; Samplonius, Douwe F.; Helfrich, Wijnand; Bremer, Edwin] Univ Groningen, Univ Med Ctr Groningen, Dept Surg, Translat Surg Oncol, Groningen, Netherlands.
   [de Bruyn, Marco; Nijman, Hans W.] Univ Groningen, Univ Med Ctr Groningen, Dept Obstet & Gynecol, Groningen, Netherlands.
   [Wei, Yunwei] Harbin Med Univ, Affiliated Hosp 1, Oncol & Endoscop Surg Dept, Harbin, Peoples R China.
   [Hirashima, Mitsuomi; Niki, Toshiro] Kagawa Univ, Fac Med, Dept Immunol & Immunopathol, Takamatsu, Kagawa 760, Japan.
   [Hirashima, Mitsuomi; Niki, Toshiro] GalPharma Co Ltd, Takamatsu, Kagawa, Japan.
   [Nishi, Nozomu] Kagawa Univ, Life Sci Res Ctr, Div Res Instrument & Equipment, Takamatsu, Kagawa 760, Japan.
   [Zhou, Jin; Helfrich, Wijnand] Harbin Med Univ, Affiliated Hosp 1, Dept Hematol,Key Lab Cell Transplantat, Heilongjiang Inst Hematol & Oncol,Minist Hlth, Harbin, Peoples R China.
   [Pouwels, Simon D.] Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, Dept Pathol & Med Biol,Expt Pulmonol & Inflammat, Groningen, Netherlands.
   [Eggleton, Paul; Bremer, Edwin] Univ Exeter, Sch Med, Exeter EX4 4QJ, Devon, England.
RP Bremer, E (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Surg, Translat Surg Oncol, Groningen, Netherlands.
EM e.bremer@umcg.nl
RI Bremer, Edwin S/B-7508-2016
OI Bremer, Edwin S/0000-0002-0325-7376; Helfrich,
   Wijnand/0000-0001-7004-3995; Eggleton, Paul/0000-0001-8244-2125; de
   Bruyn, Marco/0000-0001-9819-9131; Wiersma, Valerie/0000-0001-8012-0376;
   Nishi, Nozomu/0000-0001-7050-3226; Pouwels, Simon/0000-0001-7345-8061
FU Dutch Cancer Society grantKWF Kankerbestrijding [RUG2009-4355,
   RUG2009-4542, RUG2011-5206, RUG2012-5541, RUG2013-6209]; Netherlands
   Organization for Scientific ResearchNetherlands Organization for
   Scientific Research (NWO); Melanoma Research Alliance; Alexander von
   Humboldt FoundationAlexander von Humboldt Foundation
FX This work was supported by Dutch Cancer Society grants RUG2009-4355
   (E.B.), RUG2009-4542, RUG2011-5206, RUG2012-5541, RUG2013-6209 (to
   E.B./W.H.), the Netherlands Organization for Scientific Research (E.B.),
   the Melanoma Research Alliance (E.B.), and the Alexander von Humboldt
   Foundation (E.B/M.B.).
CR Barault L, 2008, INT J CANCER, V122, P2255, DOI 10.1002/ijc.23388
   Blasco RB, 2011, CANCER CELL, V19, P652, DOI 10.1016/j.ccr.2011.04.002
   Charette N, 2014, CURR OPIN ONCOL, V26, P454, DOI 10.1097/CCO.0000000000000088
   Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003
   Fehrenbacher N, 2008, CANCER RES, V68, P6623, DOI 10.1158/0008-5472.CAN-08-0463
   Freeman Alyson K, 2013, Small GTPases, V4, P180, DOI 10.4161/sgtp.26117
   Freeman AK, 2013, MOL CELL, V49, P751, DOI 10.1016/j.molcel.2012.12.018
   Fuster MM, 2005, NAT REV CANCER, V5, P526, DOI 10.1038/nrc1649
   Gooden MJM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065616
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535
   Irie A, 2005, CLIN CANCER RES, V11, P2962, DOI 10.1158/1078-0432.CCR-04-0861
   Kageshita T, 2002, INT J CANCER, V99, P809, DOI 10.1002/ijc.10436
   Karreth FA, 2011, CANCER DISCOV, V1, P128, DOI 10.1158/2159-8290.CD-10-0044
   Kim JS, 2004, CANCER RES, V64, P1932, DOI 10.1158/0008-5472.CAN-03-3862
   Kim MJ, 2011, J BIOL CHEM, V286, P12924, DOI 10.1074/jbc.M110.138958
   Klibi J, 2009, BLOOD, V113, P1957, DOI 10.1182/blood-2008-02-142596
   Lai K, 2014, J CLIN PATHOL, V67, P854, DOI 10.1136/jclinpath-2014-202529
   Lakshminarayan R, 2014, NAT CELL BIOL, V16, P592, DOI 10.1038/ncb2970
   Lavoie H, 2013, NAT CHEM BIOL, V9, P428, DOI [10.1038/NCHEMBIO.1257, 10.1038/nchembio.1257]
   Leisching G, 2015, INT J GYNECOL CANCER, V25, P380, DOI 10.1097/IGC.0000000000000365
   Liang M, 2008, J CANCER RES CLIN, V134, P899, DOI 10.1007/s00432-008-0352-z
   Liao XY, 2012, CLIN CANCER RES, V18, P2257, DOI 10.1158/1078-0432.CCR-11-2410
   Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500
   Maddodi N, 2010, J INVEST DERMATOL, V130, P1657, DOI 10.1038/jid.2010.26
   Magudia K, 2012, J CELL BIOL, V198, P185, DOI 10.1083/jcb.201202108
   Mancias JD, 2011, ONCOTARGET, V2, P1302
   Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Mishra R, 2010, P NATL ACAD SCI USA, V107, P17633, DOI 10.1073/pnas.1012424107
   Mo D, 2012, MOL BIOL CELL, V23, P3636, DOI 10.1091/mbc.E12-04-0329
   Morgan MJ, 2014, AUTOPHAGY, V10, P1814, DOI 10.4161/auto.32135
   Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521
   Nagae M, 2008, J MOL BIOL, V375, P119, DOI 10.1016/j.jmb.2007.09.060
   Nagahara K, 2008, J IMMUNOL, V181, P7660, DOI 10.4049/jimmunol.181.11.7660
   Nishi N, 2005, FEBS LETT, V579, P2058, DOI 10.1016/j.febslet.2005.02.054
   Nobumoto A, 2008, GLYCOBIOLOGY, V18, P735, DOI 10.1093/glycob/cwn062
   Nobumoto A, 2009, CLIN IMMUNOL, V130, P322, DOI 10.1016/j.clim.2008.09.014
   ONO K, 1994, J HISTOCHEM CYTOCHEM, V42, P659, DOI 10.1177/42.5.7512587
   Phipps AI, 2013, BRIT J CANCER, V108, P1757, DOI 10.1038/bjc.2013.118
   Preto A, 2008, J PATHOL, V214, P320, DOI 10.1002/path.2295
   Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a
   Schneider D, 2010, EUR J CELL BIOL, V89, P788, DOI 10.1016/j.ejcb.2010.07.001
   Straube T, 2013, TRAFFIC, V14, P1014, DOI 10.1111/tra.12086
   Strohecker AM, 2014, AUTOPHAGY, V10, P384, DOI 10.4161/auto.27320
   Strohecker AM, 2013, CANCER DISCOV, V3, P1272, DOI 10.1158/2159-8290.CD-13-0397
   Thurston TLM, 2012, NATURE, V482, P414, DOI 10.1038/nature10744
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   Wiersma VR, 2012, J INVEST DERMATOL, V132, P2302, DOI 10.1038/jid.2012.133
   Wiersma VR, 2013, MED RES REV, V33, pE102, DOI 10.1002/med.20249
   Yamauchi A, 2006, BREAST J, V12, pS196, DOI 10.1111/j.1075-122X.2006.00334.x
   Yoon YH, 2010, INVEST OPHTH VIS SCI, V51, P6030, DOI 10.1167/iovs.10-5278
NR 53
TC 27
Z9 28
U1 0
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD AUG
PY 2015
VL 11
IS 8
BP 1373
EP 1388
DI 10.1080/15548627.2015.1063767
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA CP6DZ
UT WOS:000359975900014
PM 26086204
OA Green Accepted, Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Saffari-Chaleshtori, J
   Asadi-Samani, M
   Rasouli, M
   Shafiee, SM
AF Saffari-Chaleshtori, Javad
   Asadi-Samani, Majid
   Rasouli, Maryam
   Shafiee, Sayed Mohammad
TI Autophagy and Ubiquitination as Two Major Players in Colorectal Cancer:
   A Review on Recent Patents
SO RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY
LA English
DT Review
DE Apoptosis; autophagy; cell proliferation; colon cancer; cell survival;
   ubiquitin-proteasome system
ID PROTEASOME INHIBITOR; ENDOPLASMIC-RETICULUM; TUMOR SUPPRESSION;
   PROGRESSION; INDUCTION; APOPTOSIS; EXPRESSION; CROSSTALK; MEMBRANES;
   CACHEXIA
AB Background: As one of the most commonly diagnosed cancers among men and women, Colorectal Cancer (CRC) leads to high rates of morbidity and mortality across the globe. Recent anti-CRC therapies are now targeting specific signaling pathways involved in colorectal carcinogenesis. Ubiquitin Proteasome System (UPS) and autophagy are two main protein quality control systems, which play major roles in the carcinogenesis of colorectal cancer. A balanced function of these two pathways is necessary for the regulation of cell proliferation and cell death.
   Objective: In this systematic review, we discuss the available evidence regarding the roles of autophagy and ubiquitination in progression and inhibition of CRC.
   Methods: The search terms "colorectal cancer" or "colon cancer" or "colorectal carcinoma" or "colon carcinoma" in combination with "ubiquitin proteasome" and "autophagy" were searched in PubMed, Web of Science, and Scopus databases, and also Google Patents (https://patents.google.com ) from January 2000 to Feb 2020.
   Results: The most important factors involved in UPS and autophagy have been investigated. There are many important factors involved in UPS and autophagy but this systematic review shows the studies that have mostly focused on the role of ATG, 20s proteasome and mTOR in CRC, and the more important factors such as ATG8, FIP200, and TIGAR factors that are effective in the regulation of autophagy in CRC cells have not been yet investigated.
   Conclusion: The most important factors involved in UPS and autophagy such as ATG, 20s proteasome and mTOR, ATG8, FIP200, and TIGAR can be considered in drug therapy for controlling or activating autophagy.
C1 [Saffari-Chaleshtori, Javad] Shahrekord Univ Med Sci, Clin Biochem Res Ctr, Basic Hlth Sci Inst, Shahrekord, Iran.
   [Asadi-Samani, Majid] Shahrekord Univ Med Sci, Cellular & Mol Res Ctr, Basic Hlth Sci Inst, Shahrekord, Iran.
   [Rasouli, Maryam; Shafiee, Sayed Mohammad] Shiraz Univ Med Sci, Sch Med, Dept Biochem, Shiraz, Iran.
RP Shafiee, SM (corresponding author), Shiraz Univ Med Sci, Sch Med, Dept Biochem, Shiraz, Iran.
EM shafieem@sums.ac.ir
RI Asadi-Samani, Majid/B-5732-2014; Saffari-Chaleshtori,
   Javad/AAD-4627-2022; Shafiee, Sayed Mohammad/W-5036-2017
OI Asadi-Samani, Majid/0000-0001-5623-8729; Shafiee, Sayed
   Mohammad/0000-0002-9221-2267
CR Akpinar HA, 2019, TOXINS, V11, DOI 10.3390/toxins11110615
   Alwers E, 2019, CLIN GASTROENTEROL H, V17, P402, DOI 10.1016/j.cgh.2017.12.038
   Bao WH, 2016, MOL MED REP, V13, P796, DOI 10.3892/mmr.2015.4599
   Bonacci T, 2018, EMBO J, V37, DOI 10.15252/embj.201798701
   Bonfili L, 2013, APOPTOSIS, V18, P1188, DOI 10.1007/s10495-013-0856-0
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Brnjic S, 2018, Protease deubiquitinating inhibitor screening, Patent No. [EP2756310, 2756310]
   Carew JS, 2010, J CELL MOL MED, V14, P2448, DOI 10.1111/j.1582-4934.2009.00832.x
   Carlsson SR, 2015, J CELL SCI, V128, P193, DOI 10.1242/jcs.141036
   Chou TF, 2013, CHEMMEDCHEM, V8, P297, DOI 10.1002/cmdc.201200520
   Cohen M, 2017, Compounds and methods used in assessing mono-parp activity, Patent No. [US20170146517, 20170146517]
   Cosper PF, 2011, CANCER RES, V71, P1710, DOI 10.1158/0008-5472.CAN-10-3145
   Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101
   Dong Z, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8010004
   Doxsey SJ, 2016, Modulation of midbody derivatives, Patent No. [WO2013036850, 2013036850]
   Dutta D, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2055-1
   Erdos A, 2016, Compound with anti-cancer properties, Patent No. [US20160339036, 20160339036]
   Fanelli GN, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1117-2
   Fang YY, 2015, CELL BIOL INT, V39, P891, DOI 10.1002/cbin.10463
   Farooqi AA, 2017, MECHANISTIC INSIGHTS, DOI [10.1016/j.cgh.2017.12.038, DOI 10.1016/J.CGH.2017.12.038]
   Fodde R, 2002, EUR J CANCER, V38, P867, DOI 10.1016/S0959-8049(02)00040-0
   Gori JL, 2018, Optimized crispr/cas9 systems and methods for gene editing in stem cells, Patent No. [CA2986310A1, 2986310]
   Gorski SM, 2011, Inhibition of autophagy genes in cancer chemotherapy, Patent No. [8076308, US8076308]
   Gupta I, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00011
   Harrison RG, 2018, Enzyme conjugate and prodrug cancer therapy, Patent No. [US9987241, 9987241]
   Hernandez-Borrero LJ, 2018, CELL CYCLE, V17, P557, DOI 10.1080/15384101.2017.1346762
   Hsu DZ, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-659
   Huang DD, 2018, CANCER METAST REV, V37, P173, DOI 10.1007/s10555-017-9726-5
   Huang X, 2019, ONCOGENE, V38, P1448, DOI 10.1038/s41388-018-0513-8
   Huyghe N, 2020, GASTROENTEROL REP, V8, P11, DOI 10.1093/gastro/goz061
   Ikeuchi K, 2009, INT J CANCER, V125, P2029, DOI 10.1002/ijc.24565
   Isozaki T, 2016, INT J ONCOL, V49, P144, DOI 10.3892/ijo.2016.3504
   Jeong WJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08230-6
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kevei E, 2017, FEBS LETT, V591, P2616, DOI 10.1002/1873-3468.12750
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim YJ, 2019, CANCER LETT, V440, P168, DOI 10.1016/j.canlet.2018.10.029
   Koncina E, 2020, CANCERS, V12, DOI 10.3390/cancers12020319
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029
   Kung CP, 2011, CRIT REV EUKAR GENE, V21, P71, DOI 10.1615/CritRevEukarGeneExpr.v21.i1.50
   Kwon HJ, 2019, Pharmaceutical compositions for inhibiting angiogenesis comprising plant-derived natural compound, Patent No. [US20170239266, 20170239266]
   Kwon YT, 2017, TRENDS BIOCHEM SCI, V42, P873, DOI 10.1016/j.tibs.2017.09.002
   Levine BC, 2017, Beclin 1 phosphorylation, Patent No. [US9671412, 9671412]
   Levy N, 2017, Proteasome inhibitors for treating a disorder related to an accumulation of non-degraded abnormal protein or a cancer, Patent No. [US20170368134, 20170368134]
   Li B, 2019, ACTA PHARMACOL SIN, V40, P111, DOI 10.1038/s41401-018-0001-2
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lin K, 2014, Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms, Patent No. [EP265561, 265561]
   Liu HW, 2018, BIOL REPROD, V99, P968, DOI 10.1093/biolre/ioy128
   Liu MJ, 2018, CANCER SCI, V109, P3055, DOI 10.1111/cas.13746
   Liu SP, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.405
   Liu Y, 2019, J BIOL CHEM, V294, P4572, DOI 10.1074/jbc.RA118.006057
   Lokireddy S, 2012, BIOCHEM J, V446, P23, DOI 10.1042/BJ20112024
   Lowe K, 2019, AM J CLIN ONCOL-CANC, V37, P523
   Luo T, 2016, AUTOPHAGY, V12, P1355, DOI 10.1080/15548627.2015.1034405
   Lyapina SA, 2005, Regulation of target protein activity through modifier proteins, Patent No. [US7291494, 7291494]
   Ma YM, 2015, ACTA PHARMACOL SIN, V36, P517, DOI 10.1038/aps.2014.157
   Maiuri MC, 2009, CELL DEATH DIFFER, V16, P87, DOI 10.1038/cdd.2008.131
   Maiuri MC, 2010, EMBO J, V29, P515, DOI 10.1038/emboj.2009.377
   Majeed M, 2016, 3-hydroxypterostilbene and therapeutic applications thereof, Patent No. [US20160058712, 20160058712]
   Mazure NM, 2010, CURR OPIN CELL BIOL, V22, P177, DOI 10.1016/j.ceb.2009.11.015
   McCord DE, 2015, Hydroxytyrosol and oleuropein com- positions for induction of DNA damage, cell death and LSD1 inhibition, Patent No. [US9144555, 9144555]
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Mochida K, 2015, NATURE, V522, P359, DOI 10.1038/nature14506
   Mooneyham A, 2017, METHODS MOL BIOL, V1513, P49, DOI 10.1007/978-1-4939-6539-7_5
   Morin PJ, 2019, J CLIN INVEST, V129, P503, DOI 10.1172/JCI125985
   Nanjundan M, 2012, Methods of treating ovarian cancer by modulating SnoN, Patent No. [US8211646, 8211646]
   Napoletano F, 2019, TRENDS CELL BIOL, V29, P323, DOI 10.1016/j.tcb.2018.12.007
   Necchi V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021317
   Nencioni A, 2019, Use of a fasting mimicking diet to enhance the efficacy of antiestrogens in cancer, Patent No. [US20190038591, 20190038591]
   Ochiya T, 2017, Agent for treating cancer, Patent No. [US9790492, 9790492]
   Pin F, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00213
   Pinner E, 2015, CD44 splice variants in neurodegenerative diseases, Patent No. [US9018180, 9018180]
   Pourgholami MH, 2018, Compounds for the treatment of mTOR pathway related diseases, Patent No. [US9790176, 9790176]
   Saffari-Chaleshtori J, 2017, GENETIKA-BELGRADE, V49, P235, DOI 10.2298/GENSR1701235S
   Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383
   SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0
   Seiwert N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.418
   Shafiee SM, 2014, IRAN J MED SCI, V39, P196
   Shafiee Sayed Mohammad, 2015, Asian Pac J Cancer Prev, V16, P3723
   Shafiee SM, 2013, MOL BIOL REP, V40, P7045, DOI 10.1007/s11033-013-2824-8
   Shaw RJGJ, 2015, Detecting DIXDC (dix domain-containing protein 1) expression to determine if a tumor will respond to fak and src kinase inhibitors, Patent No. [WO2016011065, 2016011065]
   Shen T, 2018, ENERGIES, V11, DOI 10.3390/en11030511
   Shi WN, 2017, ONCOTARGET, V8, P39605, DOI 10.18632/oncotarget.17174
   Simon K, 2016, CLIN INTERV AGING, V11, DOI 10.2147/CIA.S109285
   Song Shuling, 2018, Cell Physiol Biochem, V51, P2955, DOI 10.1159/000496047
   Sou Y, 2008, MOL BIOL CELL, V19, P4762, DOI 10.1091/mbc.E08-03-0309
   Statsyuk AV, 2019, Analogs of adenosine monophosphate (AMP) as inhibitors of ubiquitin-like modifier-activating enzyme ATG7, Patent No. [US10376515, 10376515]
   Stolz A, 2014, NAT CELL BIOL, V16, P495, DOI 10.1038/ncb2979
   Talbert E, 2014, J CACHEXIA SARCOPENI, V5, P321, DOI 10.1007/s13539-014-0141-2
   Thompson CB, 2018, Regulation of autophagy and cell survival, Patent No. [US20180030502, 20180030502]
   Uddin S, 2016, SEMIN CANCER BIOL, V36, P18, DOI 10.1016/j.semcancer.2015.09.008
   Varkaris A, 2019, BRIT J CANCER, V120, P340, DOI 10.1038/s41416-018-0360-y
   Wang CY, 2016, ONCOL REP, V36, P3014, DOI 10.3892/or.2016.5118
   Wang XJ, 2013, AUTOPHAGY, V9, P1500, DOI 10.4161/auto.25573
   White E, 2013, P NATL ACAD SCI USA, V100, P15077
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wild P, 2014, J CELL SCI, V127, P3, DOI 10.1242/jcs.140426
   Wong KW, 2017, Group of alkaloids, the novel autophagic enhancers for treatment of cancers and neurodegenerative conditions thereof, Patent No. [US9561222, 9561222]
   Wu C, 2012, Regulation of autophagy pathway phosphorylation and uses thereof, Patent No. [US8148088, 8148088]
   Wu WM, 2021, AUTOPHAGY, V17, P512, DOI [10.1080/15548627.2020.1725376, 10.1007/978-981-15-0470-9_1]
   Wu WKK, 2008, BIOCHEM BIOPH RES CO, V374, P258, DOI 10.1016/j.bbrc.2008.07.031
   Wu WKK, 2009, BIOCHEM BIOPH RES CO, V386, P598, DOI 10.1016/j.bbrc.2009.06.080
   Wu YH, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0031-8
   Xie JM, 2014, CANCER RES, V74, P5127, DOI 10.1158/0008-5472.CAN-13-3517
   Ye L, 2013, BIOCHEM BIOPH RES CO, V437, P300, DOI 10.1016/j.bbrc.2013.06.072
   Yu L, 2018, AUTOPHAGY, V14, P207, DOI 10.1080/15548627.2017.1378838
   Yuan J, 2012, Potent small molecule inhibitors of autophagy, and methods of use there of, Patent No. [US20120258975, 20120258975]
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
   Zientara-Rytter K, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8010040
NR 110
TC 1
Z9 1
U1 5
U2 7
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1574-8928
EI 2212-3970
J9 RECENT PAT ANTI-CANC
JI Recent Patents Anti-Canc. Drug Discov.
PY 2020
VL 15
IS 2
BP 143
EP 153
DI 10.2174/1574892815666200630103626
PG 11
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA OD6HK
UT WOS:000579952400004
PM 32603286
DA 2022-04-25
ER

PT J
AU Al-Emam, A
   Al-Shraim, M
   Eid, R
   Alfaifi, M
   Al-Shehri, M
   Moustafa, MF
   Radad, K
AF Al-Emam, Ahmed
   Al-Shraim, Mubarak
   Eid, Refaat
   Alfaifi, Mohamed
   Al-Shehri, Mohamed
   Moustafa, Mahmoud Fawzy
   Radad, Khaled
TI Ultrastructural changes induced by Solanum incanum aqueous extract on
   HCT 116 colon cancer cells
SO ULTRASTRUCTURAL PATHOLOGY
LA English
DT Article
DE Colon cancer; HCT 116 cells; herbs; Solanum incanum; ultrastructure
ID COLORECTAL-CANCER; METAANALYSIS; AUTOPHAGY; CYTOTOXICITY; AUTOSCHIZIS;
   APOPTOSIS; GROWTH; DEATH; RISK
AB Medicinal plants have recently gained increasing scientific interest as an important source of molecules with different therapeutic potentials. Accordingly, the present study was carried out to investigate ultrastructural changes induced by the aqueous extract of Solanum incanum (SI) fruit on human colorectal carcinoma cell line (HCT 116 cells). Examination of SI-treated HCT 116 cells with transmission electron microscopy (TEM) demonstrated numerous ultrastructural changes in the form of loss of the surface microvilli, mitochondrial damage and dilatation of cristae, and formation of autophagic vacuoles and increasing numbers of lipid droplets. Also, majority of the treated cells showed nuclear shrinkage with chromatin condensation and nucleolar changes. Moreover, some cells showed focal areas of cytoplasmic degeneration associating with formation of myelin figures and fatty globules. In conclusion, TEM was able to verify cytotoxicity of SI aqueous extract against HCT 116 colon cancer cells.
C1 [Al-Emam, Ahmed; Al-Shraim, Mubarak; Eid, Refaat; Radad, Khaled] King Khalid Univ, Coll Med, Dept Pathol, Abha, Saudi Arabia.
   [Al-Emam, Ahmed] Mansoura Univ, Dept Forens Med & Clin Toxicol, Fac Med, Mansoura, Egypt.
   [Alfaifi, Mohamed; Al-Shehri, Mohamed; Moustafa, Mahmoud Fawzy] King Khalid Univ, Coll Sci, Dept Biol, Abha, Saudi Arabia.
   [Moustafa, Mahmoud Fawzy] South Vally Univ, Fac Sci, Dept Bot, Qena, Egypt.
RP Radad, K (corresponding author), King Khalid Univ, Coll Med, Dept Pathol, Abha, Saudi Arabia.
EM khaledradad@hotmail.com
OI Alemam, Ahmed/0000-0002-5415-8992; Radad, Khaled/0000-0002-7620-8591
CR Almansour M, 2016, ULTRASTRUCT PATHOL, V40, P92, DOI 10.3109/01913123.2016.1150377
   Batista APC, 2014, MICRON, V59, P17, DOI 10.1016/j.micron.2013.12.003
   Bussmann RW, 2006, J ETHNOBIOL ETHNOMED, V2, DOI 10.1186/1746-4269-2-22
   Chan DSM, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0020456, 10.1371/journal.pone.0027218]
   Chauhan AK, 2017, ANTI-CANCER AGENT ME, V17, P1942, DOI 10.2174/1871520617666170327121228
   Cheng DL, 2015, WSPOLCZESNA ONKOL, V19, P36, DOI 10.5114/wo.2015.50011
   Dold AP, 2000, S AFR J SCI, V96, P467
   Fedirko V, 2011, ANN ONCOL, V22, P1958, DOI 10.1093/annonc/mdq653
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Gbelcova H, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-126
   Gilloteaux J, 2001, ULTRASTRUCT PATHOL, V25, P183, DOI 10.1080/019131201300343810
   Gilloteaux J, 1998, SCANNING, V20, P564
   Gomes LC, 2011, AUTOPHAGY, V7, P1251, DOI 10.4161/auto.7.10.16771
   Jess T, 2012, CLIN GASTROENTEROL H, V10, P639, DOI 10.1016/j.cgh.2012.01.010
   Jin XB, 2013, BIOL PHARM BULL, V36, P938, DOI 10.1248/bpb.b12-00935
   Liang PS, 2009, INT J CANCER, V124, P2406, DOI 10.1002/ijc.24191
   Ma YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053916
   Mosieniak G, 2012, MECH AGEING DEV, V133, P444, DOI 10.1016/j.mad.2012.05.004
   Mwonjoria J. K., 2014, INT J PHARM TOXICOLO, V2, P17, DOI DOI 10.14419/ijpt.v2i2.1454
   REN J, 1990, JPN J CANCER RES, V81, P920, DOI 10.1111/j.1349-7006.1990.tb02668.x
   Ricciardiello L, 2011, NAT REV GASTRO HEPAT, V8, P592, DOI 10.1038/nrgastro.2011.149
   Santos CR, 2012, FEBS J, V279, P2610, DOI 10.1111/j.1742-4658.2012.08644.x
   Shakibaei M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057218
   Shin DY, 2009, INT J ONCOL, V35, P1499, DOI 10.3892/ijo_00000469
   Tirinato L, 2015, STEM CELLS, V33, P35, DOI 10.1002/stem.1837
   Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179
   Wang GH, 2012, BIOCHEM J, V446, P415, DOI 10.1042/BJ20112050
   Wen SJ, 2013, FUTURE MED CHEM, V5, P53, DOI 10.4155/fmc.12.190
   Wong RSY, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-87
   Xie XD, 2015, ONCOL LETT, V10, P168, DOI 10.3892/ol.2015.3194
   Yamamuro S, 2015, INT J ONCOL, V47, P91, DOI 10.3892/ijo.2015.2992
   Ye LH, 2012, ANAT REC, V295, P417, DOI 10.1002/ar.21528
NR 32
TC 3
Z9 3
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0191-3123
EI 1521-0758
J9 ULTRASTRUCT PATHOL
JI Ultrastruct. Pathol.
PY 2018
VL 42
IS 3
BP 255
EP 261
DI 10.1080/01913123.2018.1447623
PG 7
WC Microscopy; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Microscopy; Pathology
GA GH9SE
UT WOS:000434008700006
PM 29565703
DA 2022-04-25
ER

PT J
AU Alves, S
   Castro, L
   Fernandes, MS
   Francisco, R
   Castro, P
   Priault, M
   Chaves, SR
   Moyer, MP
   Oliveira, C
   Seruca, R
   Corte-Real, M
   Sousa, MJ
   Preto, A
AF Alves, Sara
   Castro, Lisandra
   Fernandes, Maria Sofia
   Francisco, Rita
   Castro, Paula
   Priault, Muriel
   Chaves, Susana Rodrigues
   Moyer, Mary Pat
   Oliveira, Carla
   Seruca, Raquel
   Corte-Real, Manuela
   Sousa, Maria Joao
   Preto, Ana
TI Colorectal cancer-related mutant KRAS alleles function as positive
   regulators of autophagy
SO ONCOTARGET
LA English
DT Article
DE autophagy; KRAS mutations; colorectal cancer; humanized yeast;
   non-cancer colon cells
ID ADVANCED SOLID TUMORS; PHASE-I TRIAL; TARGETED THERAPIES; RAS ONCOGENES;
   MUTATIONS; HYDROXYCHLOROQUINE; INHIBITION; SURVIVAL; YEAST;
   MACROAUTOPHAGY
AB The recent interest to modulate autophagy in cancer therapy has been hampered by the dual roles of this conserved catabolic process in cancer, highlighting the need for tailored approaches. Since RAS isoforms have been implicated in autophagy regulation and mutation of the KRAS oncogene is highly frequent in colorectal cancer (CRC), we questioned whether/how mutant KRAS alleles regulate autophagy in CRC and its implications. We established two original models, KRAS-humanized yeast and KRAS-non-cancer colon cells and showed that expression of mutated KRAS up-regulates starvation-induced autophagy in both. Accordingly, KRAS down-regulation inhibited autophagy in CRC-derived cells harboring KRAS mutations. We further show that KRAS-induced autophagy proceeds via up-regulation of the MEK/ERK pathway in both colon models and that KRAS and autophagy contribute to CRC cell survival during starvation. Since KRAS inhibitors have proven difficult to develop, our results suggest using autophagy inhibitors as a combined/alternative therapeutic approach in CRCs with mutant KRAS.
C1 [Alves, Sara; Castro, Lisandra; Francisco, Rita; Castro, Paula; Chaves, Susana Rodrigues; Corte-Real, Manuela; Sousa, Maria Joao; Preto, Ana] Univ Minho, Dept Biol, CBMA Ctr Mol & Environm Biol, P-4710057 Braga, Portugal.
   [Priault, Muriel] Univ Bordeaux 2, CNRS, UMR5095, F-33076 Bordeaux, France.
   [Fernandes, Maria Sofia; Oliveira, Carla; Seruca, Raquel] Univ Porto, Inst Invest & Inovacao Saude, IPATIMUP Inst Mol Pathol & Immunol, P-4100 Oporto, Portugal.
   [Moyer, Mary Pat] INCELL Corp, San Antonio, TX USA.
RP Preto, A (corresponding author), Univ Minho, Dept Biol, CBMA Ctr Mol & Environm Biol, Campus Gualtar, P-4710057 Braga, Portugal.
EM apreto@bio.uminho.pt
RI Fernandes, Sofia/J-5712-2013; Alves, Sara/U-5006-2019; Corte-Real,
   Manuela/B-6328-2013; Oliveira, Carla/F-8188-2011; Chaves, Susana
   R/H-8786-2013; Sousa, Maria João/H-8775-2013; Preto, Ana/H-8112-2012
OI Fernandes, Sofia/0000-0002-5021-3253; Corte-Real,
   Manuela/0000-0002-1423-1331; Oliveira, Carla/0000-0001-8340-2264;
   Chaves, Susana R/0000-0002-6004-9872; Sousa, Maria
   João/0000-0001-9424-4150; Preto, Ana/0000-0002-7302-0630; Castro,
   Lisandra/0000-0003-3048-933X; Francisco, Rita/0000-0002-4398-3401;
   Seruca, Raquel/0000-0002-8851-4166; Alves, Sara/0000-0003-0404-5954;
   Priault, Muriel/0000-0001-8193-0389
FU FCT/MEC through Portuguese funds (PIDDAC) [PEst-OE/BIA/UI4050/2014]; FCT
   I.P. through the strategic funding [UID/BIA/04050/2013]; FCTPortuguese
   Foundation for Science and TechnologyEuropean Commission
   [PTDC/BIA-BCM/69448/2006, FCT-ANR/BEX-BCM/0175/2012, SFRH/BD/64695/2009,
   SFRH/BPD/89980/2012]
FX This work was supported by FCT/MEC through Portuguese funds (PIDDAC) -
   PEst-OE/BIA/UI4050/2014 and FCT I.P. through the strategic funding
   UID/BIA/04050/2013 as well as by FCT through projects
   PTDC/BIA-BCM/69448/2006 and FCT-ANR/BEX-BCM/0175/2012, as well as
   fellowships to S.A. (SFRH/BD/64695/2009) and S.R.C.
   (SFRH/BPD/89980/2012).
CR Ahearn IM, 2012, NAT REV MOL CELL BIO, V13, P39, DOI 10.1038/nrm3255
   Barault L, 2008, INT J CANCER, V122, P2255, DOI 10.1002/ijc.23388
   Benvenuti S, 2007, CANCER RES, V67, P2643, DOI 10.1158/0008-5472.CAN-06-4158
   Bora RS, 2012, MOL MED REP, V6, P9, DOI 10.3892/mmr.2012.871
   Camougrand N, 2003, MOL MICROBIOL, V47, P495, DOI 10.1046/j.1365-2958.2003.03311.x
   Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622
   Carpeno JD, 2013, TRANSL LUNG CANCER R, V2, P142, DOI 10.3978/j.issn.2218-6751.2013.02.07
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Di Fiore F, 2007, BRIT J CANCER, V96, P1166, DOI 10.1038/sj.bjc.6603685
   Elgendy M, 2011, MOL CELL, V42, P23, DOI 10.1016/j.molcel.2011.02.009
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Freeman DJ, 2008, CLIN COLORECTAL CANC, V7, P184, DOI 10.3816/CCC.2008.n.024
   Fuertes G, 2003, BIOCHEM J, V375, P75, DOI 10.1042/BJ20030282
   Furuta S, 2004, ONCOGENE, V23, P3898, DOI 10.1038/sj.onc.1207539
   Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438
   Kim JH, 2011, AUTOPHAGY, V7, P1187, DOI 10.4161/auto.7.10.16643
   Kim MJ, 2011, J BIOL CHEM, V286, P12924, DOI 10.1074/jbc.M110.138958
   Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435
   Kissova I, 2004, J BIOL CHEM, V279, P39068, DOI 10.1074/jbc.M406960200
   KOEFFLER HP, 1991, WESTERN J MED, V155, P505
   Leto SM, 2014, J MOL MED, V92, P709, DOI 10.1007/s00109-014-1161-2
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Lievre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906
   Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500
   Mahalingam D, 2014, AUTOPHAGY, V10, P1403, DOI 10.4161/auto.29231
   Mehrpour M, 2010, CELL RES, V20, P748, DOI 10.1038/cr.2010.82
   Merla Amartej, 2012, Chemother Res Pract, V2012, P387172, DOI 10.1155/2012/387172
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Moyer MP, 1996, IN VITRO CELL DEV-AN, V32, P315
   Oliveira C, 2007, ONCOGENE, V26, P158, DOI 10.1038/sj.onc.1209758
   Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200
   Pereira C, 2012, FEBS J, V279, P697, DOI 10.1111/j.1742-4658.2012.08477.x
   Preto A, 2008, J PATHOL, V214, P320, DOI 10.1002/path.2295
   Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612
   Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106
   Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199
   Rangwala R, 2014, AUTOPHAGY, V10, P1391, DOI 10.4161/auto.29119
   Rangwala R, 2014, AUTOPHAGY, V10, P1369, DOI 10.4161/auto.29118
   Raponi M, 2008, CURR OPIN PHARMACOL, V8, P413, DOI 10.1016/j.coph.2008.06.006
   Rosenfeld MR, 2014, AUTOPHAGY, V10, P1359, DOI 10.4161/auto.28984
   Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109
   Shintani T, 2004, J BIOL CHEM, V279, P29889, DOI 10.1074/jbc.M404399200
   Silva RD, 2012, CURR PHARM DESIGN, V18, P2492
   Vasan N, 2014, CLIN CANCER RES, V20, P3921, DOI 10.1158/1078-0432.CCR-13-1762
   Velho S, 2005, EUR J CANCER, V41, P1649, DOI 10.1016/j.ejca.2005.04.022
   Vogl DT, 2014, AUTOPHAGY, V10, P1380, DOI 10.4161/auto.29264
   Wan C, 2014, DRUG DELIV TRANSL RE, V4, P74, DOI 10.1007/s13346-013-0161-z
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
NR 55
TC 24
Z9 28
U1 0
U2 7
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 13
PY 2015
VL 6
IS 31
BP 30787
EP 30802
DI 10.18632/oncotarget.5021
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CU0DD
UT WOS:000363185200041
PM 26418750
OA gold, Green Submitted, Green Published
DA 2022-04-25
ER

PT J
AU Xie, QQ
   Liu, Y
   Li, XF
AF Xie, Qingqiang
   Liu, Yuan
   Li, Xuefeng
TI The interaction mechanism between autophagy and apoptosis in colon
   cancer
SO TRANSLATIONAL ONCOLOGY
LA English
DT Review
DE Colorectal carcinoma (CRC); Autophagy; Apoptosis; Interaction; Balance
ID LONG NONCODING RNA; CELECOXIB-INDUCED APOPTOSIS; SELECTIVE AUTOPHAGY;
   CARCINOMA CELLS; PATHWAY; PROLIFERATION; MITOCHONDRIA; ACTIVATION;
   INHIBITION; DEATH
AB Autophagy and apoptosis play crucial roles in tumorigenesis. Recent studies have shown that autophagy and apoptosis have a cross-talk relationship in anti-tumor therapy. It is well established that apoptosis is one of the main pathways of tumor cell death. While autophagy can occurs in tumors with opposite function: protective autophagy and lethal autophagy. Protective autophagy can inhibit tumor apoptosis induced by anticancer drugs, while lethal autophagy can induce tumor cell apoptosis in cooperation with anticancer drugs. Hence, autophagy and apoptosis have synergistic and antagonistic effects in tumor. Colorectal cancer is a common malignant tumor with high morbidity and mortality. In recent years, colorectal carcinoma has achieved improved clinical efficacy with drug treatment. Nonetheless, increasing drug-resistance limit the treatment efficacy, highlighting the urgency of exploring the molecular events that drive drug resistance. Researchers have found that autophagy is one of the major factors leading to drug resistance in colon cancer. Therefore, elucidating the interaction between autophagy and apoptosis is helpful to improve the efficacy of anticancer drugs in clinical treatment of colorectal cancer. This review attaches great importance to the relationship between autophagy and apoptosis and related factors in colorectal cancer.
C1 [Xie, Qingqiang; Liu, Yuan; Li, Xuefeng] Guangzhou Med Univ, Affiliated Hosp 6, Qingyuan Peoples Hosp, Guangzhou 511436, Peoples R China.
   [Xie, Qingqiang; Liu, Yuan; Li, Xuefeng] Guangzhou Med Univ, State Key Lab Resp Dis, Sino French Hoffmann Inst, Sch Basic Med Sci, Guangzhou 511436, Peoples R China.
   [Li, Xuefeng] Shenzhen Univ, Affiliated Hosp 3, Shenzhen Luohu Peoples Hosp, Shenzhen 518001, Peoples R China.
   [Li, Xuefeng] Chinese Acad Sci, South China Inst Stem Cell Biol & Regenerat Med, Guangzhou Inst Biomed & Hlth,Key Lab Regenerat Bi, Guangdong Prov Key Lab Stem Cell & Regenerat Med, Guangzhou 510530, Peoples R China.
RP Li, XF (corresponding author), Guangzhou Med Univ, Affiliated Hosp 6, Qingyuan Peoples Hosp, Guangzhou 511436, Peoples R China.; Li, XF (corresponding author), Guangzhou Med Univ, State Key Lab Resp Dis, Sino French Hoffmann Inst, Sch Basic Med Sci, Guangzhou 511436, Peoples R China.
EM xuefengli@gzhmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81972204, 81702327]; Natural Science
   Foundation of Guangdong ProvinceNational Natural Science Foundation of
   Guangdong Province [2019A1515011097]; Innovation Program of Shenzhen
   [JCYJ20180508165208399]; Science and Technology Planning Project of
   Guangzhou [201904010089]; China Postdoctoral Science FoundationChina
   Postdoctoral Science Foundation [2018M640834, 2019T120756]; State Key
   Lab of Respiratory Disease, Guangzhou Medical University
   [SKLRD-Z202002]; 111 Project from the Ministry of Education of
   ChinaMinistry of Education, China - 111 Project [D18010]
FX This work was supported by National Natural Science Foundation of China
   (81972204 and 81702327), Natural Science Foundation of Guangdong
   Province (2019A1515011097), Innovation Program of Shenzhen (Grant No.
   JCYJ20180508165208399), Science and Technology Planning Project of
   Guangzhou (201904010089), China Postdoctoral Science Foundation
   (2018M640834 and 2019T120756), the grant from the State Key Lab of
   Respiratory Disease, Guangzhou Medical University (SKLRD-Z202002), and
   the 111 Project (D18010) from the Ministry of Education of China.
CR Altman BJ, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008763
   An YJ, 2018, FOOD CHEM TOXICOL, V118, P514, DOI 10.1016/j.fct.2018.05.054
   Athamneh K, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030412
   Athamneh K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11202-3
   Bravo-San Pedro JM, 2015, AUTOPHAGY, V11, P452, DOI 10.1080/15548627.2015.1017191
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Brech A, 2009, MOL ONCOL, V3, P366, DOI 10.1016/j.molonc.2009.05.007
   Chaitanya GV, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-31
   Chappell WH, 2011, ONCOTARGET, V2, P135, DOI 10.18632/oncotarget.240
   Chen WQ, 2018, CHINESE J CANCER RES, V30, P1, DOI 10.21147/j.issn.1000-9604.2018.01.01
   Codogno P, 2006, NAT CELL BIOL, V8, P1045, DOI 10.1038/ncb1006-1045
   Coker-Gurkan A, 2015, ONCOL REP, V33, P2761, DOI 10.3892/or.2015.3918
   Colussi D, 2013, INT J MOL SCI, V14, P16365, DOI 10.3390/ijms140816365
   D'Amelio M, 2010, CELL DEATH DIFFER, V17, P1104, DOI 10.1038/cdd.2009.180
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Devenport SN, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111349
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014
   Fan Y, 2014, FEBS J, V281, P1750, DOI 10.1111/febs.12737
   Fandy TE, 2014, CLIN CANCER RES, V20, P1249, DOI 10.1158/1078-0432.CCR-13-1453
   Fesler Andrew, 2017, Cancer Transl Med, V3, P96, DOI 10.4103/ctm.ctm_64_16
   Fimia GM, 2010, CELL MOL LIFE SCI, V67, P1581, DOI 10.1007/s00018-010-0284-z
   Fu LL, 2013, INT J BIOCHEM CELL B, V45, P921, DOI 10.1016/j.biocel.2013.02.007
   Fu Q, 2016, ONCOL REP, V36, P3682, DOI 10.3892/or.2016.5195
   Fulda S, 2009, INT J CANCER, V124, P511, DOI 10.1002/ijc.24064
   Garufi A, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0596-z
   Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966
   Grasso S, 2016, EUR J MED CHEM, V122, P611, DOI 10.1016/j.ejmech.2016.06.043
   Green DR, 2014, CELL, V157, P65, DOI 10.1016/j.cell.2014.02.049
   Gross A, 2016, BBA-BIOENERGETICS, V1857, P1243, DOI 10.1016/j.bbabio.2016.01.017
   Gump JM, 2011, TRENDS CELL BIOL, V21, P387, DOI 10.1016/j.tcb.2011.03.007
   Haggar Fatima A, 2009, Clin Colon Rectal Surg, V22, P191, DOI 10.1055/s-0029-1242458
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hardie DG, 2015, CURR OPIN CELL BIOL, V33, P1, DOI 10.1016/j.ceb.2014.09.004
   Henshall DC, 2002, J NEUROSCI, V22, P8458
   Hoeppner DJ, 2001, NATURE, V412, P202, DOI 10.1038/35084103
   Hsuan SW, 2016, EUR J NUTR, V55, P491, DOI 10.1007/s00394-015-0866-5
   Huang SB, 2010, AUTOPHAGY, V6, P256, DOI 10.4161/auto.6.2.11124
   Ishikawa T, 2018, J CELL PHYSIOL, V233, P4825, DOI 10.1002/jcp.26285
   Ito H, 2005, INT J ONCOL, V26, P1401
   Jiang K, 2016, ONCOTARGET, V7, P25652, DOI 10.18632/oncotarget.8357
   Jiang T, 2015, FREE RADICAL BIO MED, V88, P199, DOI 10.1016/j.freeradbiomed.2015.06.014
   Jiao CJ, 2016, ONCOL REP, V36, P2960, DOI 10.3892/or.2016.5121
   Kaluzki I, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111329
   Kang JH, 2019, BIOMOL THER, V27, P34, DOI 10.4062/biomolther.2018.140
   Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kekelidze M, 2013, WORLD J GASTROENTERO, V19, P8502, DOI 10.3748/wjg.v19.i46.8502
   Kim KY, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2688-0
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327
   Lee HY, 2015, MAR DRUGS, V13, P543, DOI 10.3390/md13010543
   Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451
   Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li SY, 2017, ONCOL REP, V38, P1637, DOI 10.3892/or.2017.5849
   Li X, 2019, J ORG CHEM, V84, P9138, DOI 10.1021/acs.joc.9b01098
   Li YJ, 2017, CHIN J CANCER, V52, DOI 10.1186/s40880-017-0219-2
   Lin CH, 2017, TOXICOL SCI, V157, P196, DOI 10.1093/toxsci/kfx030
   Lin PY, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0417-6
   Liu SM, 2020, NAT RESOUR RES, V29, P1755, DOI 10.1007/s11053-019-09562-w
   Lu YH, 2017, GENE, V607, P41, DOI 10.1016/j.gene.2017.01.004
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001
   Maranhao SS, 2020, BIOORG MED CHEM LETT, V30, DOI 10.1016/j.bmcl.2019.126851
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069
   Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521
   Mundade Rasika, 2014, Oncoscience, V1, P400
   Nagappan A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174591
   Navarro-Yepes J, 2014, ANTIOXID REDOX SIGN, V21, P66, DOI 10.1089/ars.2014.5837
   Noguchi M, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2724-5
   Peng Y, 2017, LIFE SCI, V185, P63, DOI 10.1016/j.lfs.2017.07.024
   Petroni G, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2349-8
   Pistritto G, 2016, AGING-US, V8, P603, DOI 10.18632/aging.100934
   Plati J, 2008, J CELL BIOCHEM, V104, P1124, DOI 10.1002/jcb.21707
   Romanov J, 2012, EMBO J, V31, P4304, DOI 10.1038/emboj.2012.278
   Ruhle F, 2016, GENOM PROTEOM BIOINF, V14, P191, DOI 10.1016/j.gpb.2016.03.001
   Ryter Stefan W, 2014, Int J Cell Biol, V2014, P502676, DOI 10.1155/2014/502676
   Scherz-Shouval R, 2007, TRENDS CELL BIOL, V17, P422, DOI 10.1016/j.tcb.2007.07.009
   Sharma N, 2018, J ETHNOPHARMACOL, V211, P295, DOI 10.1016/j.jep.2017.09.034
   Shi XF, 2019, J PHOTOCH PHOTOBIO B, V198, DOI 10.1016/j.jphotobiol.2019.111586
   Si YR, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658-019-0175-8
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P145, DOI 10.3322/caac.21601
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Son Y, 2019, PHYTOTHER RES, V33, P1689, DOI 10.1002/ptr.6357
   Song FL, 2019, J CELL PHYSIOL, V234, P7420, DOI 10.1002/jcp.27500
   Su MF, 2013, J ONCOL, V2013, DOI 10.1155/2013/102735
   Tan H, 2019, J BUON, V24, P1143
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Tao R, 2017, ONCOL REP, V38, P1233, DOI 10.3892/or.2017.5779
   Kuwabara WMT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116410
   Tsutsumi S, 2006, ONCOGENE, V25, P1018, DOI 10.1038/sj.onc.1209139
   Wang YY, 2018, ONCOL RES, V26, P889, DOI 10.3727/096504017X15009419625178
   Wang Z, 2018, ACTA PHARMACOL SIN, V39, P1645, DOI 10.1038/aps.2017.192
   Won SJ, 2015, J CELL PHYSIOL, V230, P930, DOI 10.1002/jcp.24825
   Xin MG, 2005, J BIOL CHEM, V280, P10781, DOI 10.1074/jbc.M500084200
   Yang Y, 2016, ONCOL REP, V35, P1255, DOI 10.3892/or.2015.4484
   Zhang N, 2020, INT J BIOL SCI, V16, P147, DOI 10.7150/ijbs.36955
   Zhang XF, 2018, ONCOTARGET, V9, P3519, DOI 10.18632/oncotarget.23336
   Zhao Z, 2018, J CANCER, V9, P3407, DOI 10.7150/jca.24201
   Zheng YS, 2019, J CELL BIOCHEM, V120, P3922, DOI 10.1002/jcb.27676
   Zhou CX, 2017, ONCOTARGET, V8, P14736, DOI 10.18632/oncotarget.14718
   Zhou CX, 2016, TUMOR BIOL, V37, P3135, DOI 10.1007/s13277-015-4134-3
   Zhu BS, 2011, WORLD J GASTROENTERO, V17, P478, DOI 10.3748/wjg.v17.i4.478
NR 105
TC 26
Z9 28
U1 8
U2 22
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1936-5233
J9 TRANSL ONCOL
JI Transl. Oncol.
PD DEC
PY 2020
VL 13
IS 12
AR 100871
DI 10.1016/j.tranon.2020.100871
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA OA0VT
UT WOS:000577515200020
PM 32950931
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Wang, CX
   Shi, ZS
   Hong, ZS
   Pan, JP
   Chen, ZC
   Qiu, CZ
   Zhuang, HB
   Zheng, XC
AF Wang, Chunxiao
   Shi, Zesheng
   Hong, Zhongshi
   Pan, Jianpeng
   Chen, Zhichuan
   Qiu, Chengzhi
   Zhuang, Haibin
   Zheng, Xuecong
TI MicroRNA-1276 Promotes Colon Cancer Cell Proliferation by Negatively
   Regulating LACTB
SO CANCER MANAGEMENT AND RESEARCH
LA English
DT Article
DE microRNA; colonic neoplasms; cell proliferation; LACTB; miR-1276
ID METABOLISM; EXPRESSION; PROGNOSIS; PROTEIN
AB Purpose: LACTB, regulated by a variety of microRNAs (miRNAs), is proven to be a tumor suppressor. However, there are few reports that LACTB in colon cancer cells is regulated by miRNA. Therefore, the aim of this study was to explore the miRNAs that regulate LACTB in colon cancer.
   Patients and Methods: Data from TCGA were analyzed in starBase and GEPIA2, and Western blot and quantitative PCR (qPCR) were used to detect the expression of LACTB in colon cancer cell lines. MiRNAs targeting LACTB were predicted by MicroT-CDS, starBase, miRDB, mirDIP, and DIANA. The relationship between LACTB and miRNA was explored by dual-luciferase assay. MTT, propidium iodide (PI), Western blot, Annexin V-FITC/PI Kit, qPCR and transwell assay were used to detect the changes in cell proliferation, cell cycle, autophagy, apoptosis, epithelial-to-mesenchymal transition (EMT), cell migration, and invasiveness in colon cancer cells that overexpressed miR-1276 and/or LACTB.
   Results: The results showed that the LACTB mRNA level was lower and the miR-1276 level was higher in colon cancer than in normal tissue. MiR-1276 inhibited the expression of LACTB. Furthermore, overexpression of miR-1276 in colon cancer cells increased proliferation, migration, invasiveness and EMT, and decreased autophagy and apoptosis. Supplementing LACTB suppressed these effects of miR-1276.
   Conclusion: In conclusion, miR-1276, which may be a potential therapy for colon cancer, inhibits cell growth and promotes apoptosis by targeting LACTB in colon cancer cells.
C1 [Wang, Chunxiao; Shi, Zesheng; Hong, Zhongshi; Pan, Jianpeng; Chen, Zhichuan; Qiu, Chengzhi; Zhuang, Haibin; Zheng, Xuecong] Fujian Med Univ, Affiliated Hosp 2, Dept Gen Surg, 34 Zhongshan North Rd, Quanzhou 362000, Fujian, Peoples R China.
RP Hong, ZS (corresponding author), Fujian Med Univ, Affiliated Hosp 2, Dept Gen Surg, 34 Zhongshan North Rd, Quanzhou 362000, Fujian, Peoples R China.
EM hongzhongshi@163.com
OI Hong, Zhong-shi/0000-0003-1190-6839
FU Science and Technology Project of Quanzhou [2018Z127]; Educational
   Research Project for Young and Middle-aged Teachers of Fujian
   Educational Committee [JAT190216]; Startup Fund for scientific research
   of Fujian Medical University [2019QH1119]
FX Thank you for the financial support from the Science and Technology
   Project of Quanzhou (grant number 2018Z127), the Educational Research
   Project for Young and Middle-aged Teachers of Fujian Educational
   Committee (grant number JAT190216) and Startup Fund for scientific
   research of Fujian Medical University (grant number 2019QH1119).
CR Bertoli G, 2015, THERANOSTICS, V5, P1122, DOI 10.7150/thno.11543
   Brody H, 2015, NATURE, V521, pS1, DOI 10.1038/521S1a
   Cucchi D, 2017, CELL DEATH DIFFER, V24, P1137, DOI 10.1038/cdd.2017.60
   Du JJ, 2019, FASEB J, V33, P1911, DOI 10.1096/fj.201701394RRR
   Farazi TA, 2013, ADV EXP MED BIOL, V774, P1, DOI 10.1007/978-94-007-5590-1_1
   He JH, 2018, CELL PHYSIOL BIOCHEM, V49, P1539, DOI 10.1159/000493457
   Kahi CJ, 2016, GASTROENTEROLOGY, V150, P758, DOI 10.1053/j.gastro.2016.01.001
   Keckesova Z, 2017, NATURE, V543, P681, DOI 10.1038/nature21408
   Kumar Pradeep, 2018, Journal of Entomology and Zoology Studies, V6, P181
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li TH, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012131
   Li YZ, 2018, BIOCHEM BIOPH RES CO, V504, P277, DOI 10.1016/j.bbrc.2018.08.172
   Lu EY, 2017, BIOMED PHARMACOTHER, V85, P486, DOI 10.1016/j.biopha.2016.11.055
   Lu JB, 2016, ARCH BIOCHEM BIOPHYS, V590, P64, DOI 10.1016/j.abb.2015.11.007
   Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Smith TS, 2001, GENOMICS, V78, P12, DOI 10.1006/geno.2001.6643
   Torrano V, 2017, CELL METAB, V25, P997, DOI 10.1016/j.cmet.2017.04.027
   Wingo PA, 2003, CANCER-AM CANCER SOC, V97, P3133, DOI 10.1002/cncr.11380
   Wu YS, 2017, BIOL PHARM BULL, V40, P1747, DOI 10.1248/bpb.b17-00360
   Xiong DD, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1593-5
   Xu W, 2020, CANCER MANAG RES, V12, P5181, DOI 10.2147/CMAR.S250661
   Xue C, 2018, AM J TRANSL RES, V10, P4152
   Zeng KX, 2018, ONCOGENE, V37, P5534, DOI 10.1038/s41388-018-0352-7
   Zhan JW, 2017, THORAC CANCER, V8, P461, DOI 10.1111/1759-7714.12467
   Zhang H., 2019, WATER, V11, P1, DOI DOI 10.1186/S12935-019-1046-015
   Zhang J, 2018, CANCER MED-US, V7, P3351, DOI 10.1002/cam4.1576
   Zhou F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072290
NR 28
TC 4
Z9 4
U1 0
U2 2
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1179-1322
J9 CANCER MANAG RES
JI Cancer Manag. Res.
PY 2020
VL 12
BP 12185
EP 12195
DI 10.2147/CMAR.S278566
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA PA2RQ
UT WOS:000595481400007
PM 33273855
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Shen, PW
   Chou, YM
   Li, CL
   Liao, EC
   Huang, HS
   Yin, CH
   Chen, CL
   Yu, SJ
AF Shen, Pei-Wen
   Chou, Yu-Mei
   Li, Chia-Ling
   Liao, En-Chih
   Huang, Hung-Sen
   Yin, Chun-Hao
   Chen, Chien-Liang
   Yu, Sheng-Jie
TI Itraconazole improves survival outcomes in patients with colon cancer by
   inducing autophagic cell death and inhibiting transketolase expression
SO ONCOLOGY LETTERS
LA English
DT Article
DE colon cancer; autophagy; apoptosis; itraconazole; transketolase
ID TUMORIGENESIS; THERAPY; HEALTH
AB The incidence of colon cancer continues to increase annually, and it is the leading cause of cancer-associated mortality worldwide. Altering cell metabolism and inducing autophagic cell death have recently emerged as novel strategies in preventing tumor growth. Autophagy plays an essential role in energy production by degrading damaged cellular components and is also associated with tumor proliferation suppression. Itraconazole is an FDA-approved drug used as an antifungal medication and has been reported to induce autophagic cell death in breast cancer. However, the effects of itraconazole on cell metabolism and induction of apoptosis in colon cancer remain unclear. The present study analyzed extensive data from patients diagnosed with colon cancer using itraconazole between January 2011 and December 2015, from the Taiwanese National Health Insurance Research Database. The underlying molecular mechanisms of itraconazole in autophagy-induced cell death were also investigated. The results demonstrated that the 5-year survival rate was significantly higher in patients with colon cancer who received itraconazole treatment. In addition, itraconazole decreased the viability and cell colony formation, and induced cleaved caspase-3 expression and G(1) cell cycle arrest of COLO 205 and HCT 116 cells. Notably, itraconazole induced autophagy by enhancing LC3B and p62 expression. Following LC3 knockdown, the viability of itraconazole-treated COLO 205 and HCT 116 cells notably improved. Taken together, the results of the present study suggest that itraconazole may have a beneficial effect on patients with colon cancer, and its underlying molecular mechanisms may be associated with the induction of autophagic cell death.
C1 [Shen, Pei-Wen; Chou, Yu-Mei] Kaohsiung Vet Gen Hosp, Dept Anesthesiol, Kaohsiung 813, Taiwan.
   [Li, Chia-Ling] Taichung Vet Gen Hosp, Childrens Med Ctr, Taichung 407, Taiwan.
   [Liao, En-Chih] MacKay Med Coll, Dept Med, New Taipei 252, Taiwan.
   [Liao, En-Chih] MacKay Med Coll, Inst Biomed Sci, New Taipei 252, Taiwan.
   [Huang, Hung-Sen; Yin, Chun-Hao; Chen, Chien-Liang; Yu, Sheng-Jie] Kaohsiung Vet Gen Hosp, Dept Med Educ & Res, 386 Dazhong 1st Rd, Kaohsiung 813, Taiwan.
   [Chen, Chien-Liang] Kaohsiung Vet Gen Hosp, Div Nephrol, Kaohsiung 813, Taiwan.
RP Yu, SJ (corresponding author), Kaohsiung Vet Gen Hosp, Dept Med Educ & Res, 386 Dazhong 1st Rd, Kaohsiung 813, Taiwan.
EM sjyu@vghks.gov.tw
FU Kaohsiung Veterans General Hospital [VGHKS109-D04-1, VGHKS109-180]
FX The present study was partly supported by the Kaohsiung Veterans General
   Hospital (grant nos. VGHKS109-D04-1 and VGHKS109-180).
CR Aiello P, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/2075614
   Alhakamy NA, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11120685
   Antonarakis ES, 2013, ONCOLOGIST, V18, P163, DOI 10.1634/theoncologist.2012-314
   Bellmann R, 2017, INFECTION, V45, P737, DOI 10.1007/s15010-017-1042-z
   Bhatia A, 2019, INDIAN J PHARMACOL, V51, P116, DOI 10.4103/ijp.IJP_578_17
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Cao L, 2021, EUR J PHARMACOL, V890, DOI 10.1016/j.ejphar.2020.173647
   Chao YK, 2016, J CANCER, V7, P1804, DOI 10.7150/jca.15467
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Choi CH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06510-7
   Chu CW, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030473
   Deng HM, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02742-0
   Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4
   Farkkila N, 2015, ACTA ONCOL, V54, P454, DOI 10.3109/0284186X.2014.985797
   Gill KS, 2016, BBA-REV CANCER, V1866, P87, DOI 10.1016/j.bbcan.2016.06.005
   Hsieh CY, 2019, CLIN EPIDEMIOL, V11, P349, DOI 10.2147/CLEP.S196293
   Hu LH, 2007, ANTI-CANCER DRUG, V18, P427, DOI 10.1097/CAD.0b013e328013d99e
   Hu Q, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0526-0
   Huang F, 2018, WORLD J GASTROENTERO, V24, P4643, DOI 10.3748/wjg.v24.i41.4643
   Islam MA, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051405
   Jin SH, 2018, ONCOL REP, V39, P2473, DOI 10.3892/or.2018.6370
   Lan K, 2018, ONCOL LETT, V16, P3651, DOI 10.3892/ol.2018.9072
   LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31
   Lin CC, 2005, J FORMOS MED ASSOC, V104, P157
   Liu R, 2014, AUTOPHAGY, V10, P1241, DOI 10.4161/auto.28912
   Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   Onorati AV, 2018, CANCER-AM CANCER SOC, V124, P3307, DOI 10.1002/cncr.31335
   Pantziarka P, 2015, ECANCERMEDICALSCIENC, V9, DOI 10.3332/ecancer.2015.521
   Qin ZY, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1131-1
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Ricciardelli C, 2015, CLIN EXP METASTAS, V32, P441, DOI 10.1007/s10585-015-9718-1
   Rudin CM, 2013, J THORAC ONCOL, V8, P619, DOI 10.1097/JTO.0b013e31828c3950
   Runwal G, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46657-z
   STEPANOVA N G, 1987, Biokhimiya, V52, P1907
   Wang WP, 2020, BIOMED PHARMACOTHER, V131, DOI 10.1016/j.biopha.2020.110661
   Wang XY, 2017, CANCER LETT, V385, P128, DOI 10.1016/j.canlet.2016.10.034
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Watanabe T, 2018, INT J CLIN ONCOL, V23, P1, DOI 10.1007/s10147-017-1101-6
   Whitburn J, 2017, CURR UROL REP, V18, DOI 10.1007/s11934-017-0693-8
   Xiang YF, 2018, EXP THER MED, V15, P3537, DOI 10.3892/etm.2018.5828
   Yang YP, 2013, ACTA PHARMACOL SIN, V34, P625, DOI 10.1038/aps.2013.5
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
   Zheng J, 2012, ONCOL LETT, V4, P1151, DOI 10.3892/ol.2012.928
   Zonoobi Elham, 2018, Tanaffos, V17, P146
NR 45
TC 2
Z9 2
U1 0
U2 0
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD NOV
PY 2021
VL 22
IS 5
AR 768
DI 10.3892/ol.2021.13029
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA UT5TY
UT WOS:000698180500001
PM 34589147
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Xu, ZY
   Jiang, H
   Zhu, YH
   Wang, HF
   Jiang, J
   Chen, L
   Xu, WK
   Hu, T
   Cho, CH
AF Xu, Zhenyu
   Jiang, Hui
   Zhu, Yanhong
   Wang, Huifang
   Jiang, Jia
   Chen, Lu
   Xu, Wenke
   Hu, Tao
   Cho, Chi Hin
TI Cryptotanshinone induces ROS-dependent autophagy in multidrug-resistant
   colon cancer cells
SO CHEMICO-BIOLOGICAL INTERACTIONS
LA English
DT Article
DE Cryptotanshinone; Autophagy; Reactive oxygen species; Multidrug
   resistance; Colon cancer
ID SALVIA-MILTIORRHIZA; MOLECULAR DOCKING; INDUCED APOPTOSIS; P-GP;
   PATHWAY; DEATH; DIHYDROTANSHINONE; TANSHINONES; MECHANISMS; INDUCTION
AB The development of novel chemotherapeutic agents is highly desired for colon cancer treatment, in particular for the multidrug-resistant cancer types. Cryptotanshinone (CTS), an active quinoid diterpene isolated from Salvia miltiorrhiza Bunge, was previously reported to induce autophagy in various colon cancer cell lines. However, its mechanisms of action have not been fully understood. The current study aims to explore the mechanisms by which CTS induces autophagy in a multidrug-resistant human colon cancer cell line SW620 Ad300. Using MTT assay, CTS at 10 mu M exhibited no significant cytotoxicity on human normal colon fibroblasts CCD-18Co, but induced 45.67% and 48.35% cell death in SW620 and SW620 Ad300 cells, respectively. Further studies revealed that CTS induced weak apoptosis ( 9.37%) and significant caspase-independent cell death in SW620 Ad300 cells. In the same cell line, CTS also induced significant autophagy, which was found to promote cell death and to mediate the cytotoxicity of CTS in these multidrug-resistant cells. Moreover, activation of ROS-p38 MAPK-NF-kappa B signaling pathway was involved in autophagic cell death induced by CTS in SW620 Ad300 cells. Interestingly, our results also demonstrated a complementary relationship between CTS-induced apoptosis and autophagic cell death in SW620 Ad300 cells. Taken together, CTS induces autophagic cell death in SW620 Ad300 cells via the ROS-p38 MAPK-NF-kB signaling pathway, and it might be a potential candidate as a chemotherapeutic agent for the treatment of multidrug-resistant colon cancer. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Xu, Zhenyu; Jiang, Hui; Zhu, Yanhong; Wang, Huifang; Jiang, Jia; Chen, Lu; Xu, Wenke] Wannan Med Coll, Yijishan Affiliated Hosp, Dept Pharm, Wuhu, Anhui, Peoples R China.
   [Hu, Tao; Cho, Chi Hin] Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China.
   [Cho, Chi Hin] Southwest Med Univ, Sch Pharm, Dept Pharmacol, Lab Mol Pharmacol, Luzhou, Sichuan, Peoples R China.
RP Xu, WK (corresponding author), Wannan Med Coll, Yijishan Affiliated Hosp, Dept Pharm, Wuhu, Anhui, Peoples R China.; Hu, T (corresponding author), Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China.
EM 1447486817@qq.com; taohu1985@hotmail.com
RI Hu, Tao/O-2570-2014
OI Hu, Tao/0000-0002-0601-3078
CR Biomed, 2016, PHARMACOTHERAPY, V82, P319
   Chen WX, 2012, CANCER PREV RES, V5, P778, DOI 10.1158/1940-6207.CAPR-11-0551
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Fulda S, 2010, PLANTA MED, V76, P1075, DOI 10.1055/s-0030-1249961
   Hao WH, 2016, ANTI-CANCER AGENT ME, V16, P593, DOI 10.2174/1871520615666150907093036
   Hu T, 2013, J BIOMOL RES THER, V2, P110, DOI [10.4172/21677956.1000110, DOI 10.4172/21677956.1000110]
   Hu T, 2016, WORLD J GASTROENTERO, V22, P6876, DOI 10.3748/wjg.v22.i30.6876
   Hu T, 2015, CURR PHARM DESIGN, V21, P2960, DOI 10.2174/1381612821666150514104244
   Hu T, 2015, PHYTOMEDICINE, V22, P536, DOI 10.1016/j.phymed.2015.03.010
   Hu T, 2015, CHEM-BIOL INTERACT, V230, P1, DOI 10.1016/j.cbi.2015.02.006
   Hu T, 2014, PHYTOMEDICINE, V21, P1264, DOI 10.1016/j.phymed.2014.06.013
   Huang M, 2013, MOL CANCER THER, V12, P184, DOI 10.1158/1535-7163.MCT-12-0425
   Hui KF, 2016, ONCOTARGET, V7, P4454, DOI 10.18632/oncotarget.6601
   Lefranc F, 2007, ONCOLOGIST, V12, P1395, DOI 10.1634/theoncologist.12-12-1395
   Li LF, 2014, INT J MOL MED, V34, P372, DOI 10.3892/ijmm.2014.1786
   Li XQ, 2015, EUR J MED CHEM, V101, P560, DOI 10.1016/j.ejmech.2015.06.049
   Liang YJ, 2013, CELL BIOSCI, V3, DOI 10.1186/2045-3701-3-9
   Liu B, 2008, FREE RADICAL BIO MED, V44, P1529, DOI 10.1016/j.freeradbiomed.2008.01.011
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Mukhtar E, 2012, CURR DRUG TARGETS, V13, P1831, DOI 10.2174/138945012804545489
   Nahata A, 2013, INTEGR CANCER THER, V12, P236, DOI 10.1177/1534735412451997
   Park EJ, 2007, FOOD CHEM TOXICOL, V45, P1891, DOI 10.1016/j.fct.2007.04.005
   Park IJ, 2014, APOPTOSIS, V19, P615, DOI 10.1007/s10495-013-0929-0
   Tang S, 2011, INFLAMMATION, V34, P111, DOI 10.1007/s10753-010-9214-3
   THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464
   Wang L, 2013, LIFE SCI, V93, P344, DOI 10.1016/j.lfs.2013.07.007
   Wang L, 2016, LIFE SCI, V151, P224, DOI 10.1016/j.lfs.2016.02.083
   Wang L, 2015, PHYTOMEDICINE, V22, P1079, DOI 10.1016/j.phymed.2015.08.009
   Ye TH, 2016, BIOMED PHARMACOTHER, V82, P319, DOI 10.1016/j.biopha.2016.05.015
   Zhang X, 2012, CELL PROLIFERAT, V45, P466, DOI 10.1111/j.1365-2184.2012.00833.x
   Zhao WW, 2016, CELL ADHES MIGR, V10, P248, DOI 10.1080/19336918.2015.1119361
   Zhou XL, 2013, PHYTOMEDICINE, V20, P367, DOI 10.1016/j.phymed.2012.09.021
   Zhu ZJ, 2016, MOL CARCINOGEN, V55, P1399, DOI 10.1002/mc.22383
NR 33
TC 32
Z9 34
U1 1
U2 14
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009-2797
EI 1872-7786
J9 CHEM-BIOL INTERACT
JI Chem.-Biol. Interact.
PD AUG 1
PY 2017
VL 273
BP 48
EP 55
DI 10.1016/j.cbi.2017.06.003
PG 8
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA FB9OB
UT WOS:000406467500006
PM 28600121
DA 2022-04-25
ER

PT J
AU Basile, V
   Belluti, S
   Ferrari, E
   Gozzoli, C
   Ganassi, S
   Quaglino, D
   Saladini, M
   Imbriano, C
AF Basile, Valentina
   Belluti, Silvia
   Ferrari, Erika
   Gozzoli, Chiara
   Ganassi, Sonia
   Quaglino, Daniela
   Saladini, Monica
   Imbriano, Carol
TI bis-Dehydroxy-Curcumin Triggers Mitochondrial-Associated Cell Death in
   Human Colon Cancer Cells through ER-Stress Induced Autophagy
SO PLOS ONE
LA English
DT Article
ID ENDOPLASMIC-RETICULUM STRESS; BCL-2 FAMILY-MEMBERS; INDUCED APOPTOSIS;
   SIGNALING PATHWAYS; COLORECTAL-CANCER; GENE-EXPRESSION; UP-REGULATION;
   IN-VITRO; NF-Y; ACTIVATION
AB Background: The activation of autophagy has been extensively described as a pro-survival strategy, which helps to keep cells alive following deprivation of nutrients/growth factors and other stressful cellular conditions. In addition to cytoprotective effects, autophagy can accompany cell death. Autophagic vacuoles can be observed before or during cell death, but the role of autophagy in the death process is still controversial. A complex interplay between autophagy and apoptosis has come to light, taking into account that numerous genes, such as p53 and Bcl-2 family members, are shared between these two pathways.
   Methodology/Principal Findings: In this study we showed a potent and irreversible cytotoxic activity of the stable Curcumin derivative bis-DeHydroxyCurcumin (bDHC) on human colon cancer cells, but not on human normal cells. Autophagy is elicited by bDHC before cell death as demonstrated by increased autophagosome formation -measured by electron microscopy, fluorescent LC3 puncta and LC3 lipidation- and autophagic flux -measured by interfering LC3-II turnover. The accumulation of poly-ubiquitinated proteins and ER-stress occurred upstream of autophagy induction and resulted in cell death. Cell cycle and Western blot analyses highlighted the activation of a mitochondrial-dependent apoptosis, which involves caspase 7, 8, 9 and Cytochrome C release. Using pharmacological inhibitions and RNAi experiments, we showed that ER-stress induced autophagy has a major role in triggering bDHC-cell death.
   Conclusion/Significance: Our findings describe the mechanism through which bDHC promotes tumor selective inhibition of proliferation, providing unequivocal evidence of the role of autophagy in contrasting the proliferation of colon cancer cells.
C1 [Basile, Valentina; Belluti, Silvia; Gozzoli, Chiara; Ganassi, Sonia; Quaglino, Daniela; Imbriano, Carol] Univ Modena & Reggio Emilia, Dipartimento Sci Vita, Modena, Italy.
   [Ferrari, Erika; Saladini, Monica] Univ Modena & Reggio Emilia, Dipartimento Sci Chim & Geol, Modena, Italy.
RP Imbriano, C (corresponding author), Univ Modena & Reggio Emilia, Dipartimento Sci Vita, Via Campi 213-D, Modena, Italy.
EM cimbriano@unimo.it
RI Saladini, Monica/N-8596-2015; Imbriano, Carol/ABD-8204-2021; Quaglino,
   Daniela/A-9381-2010; BELLUTI, SILVIA/AAU-2625-2020; Ferrari,
   Erika/F-7742-2012; Basile, Valentina/S-3828-2016; Imbriano,
   Carol/C-9376-2015
OI Saladini, Monica/0000-0003-2515-8317; Imbriano,
   Carol/0000-0003-2864-4820; Quaglino, Daniela/0000-0002-4302-5078;
   BELLUTI, SILVIA/0000-0003-0846-9359; Ferrari, Erika/0000-0001-7627-2502;
   Basile, Valentina/0000-0003-3151-1228; Imbriano,
   Carol/0000-0003-2864-4820
FU Associazione Italiana per la Ricerca sul Cancro-MFAGFondazione AIRC per
   la ricerca sul cancro [6192]; Fondazione Cassa di Risparmio di Vignola
FX This work was supported by Associazione Italiana per la Ricerca sul
   Cancro-MFAG (grant number 6192 to CI) and Fondazione Cassa di Risparmio
   di Vignola to CI and EF. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Anand P, 2008, BIOCHEM PHARMACOL, V76, P1590, DOI 10.1016/j.bcp.2008.08.008
   Anand P, 2008, CANCER LETT, V267, P133, DOI 10.1016/j.canlet.2008.03.025
   Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r
   Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167
   Baliga B, 2003, CELL DEATH DIFFER, V10, P16, DOI 10.1038/sj.cdd.4401166
   Baritaud M, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.120
   Basile V, 2006, J BIOL CHEM, V281, P2347, DOI 10.1074/jbc.M507712200
   Basile V, 2009, BIOCHEM PHARMACOL, V78, P1305, DOI 10.1016/j.bcp.2009.06.105
   Benatti P, 2008, NUCLEIC ACIDS RES, V36, P1415, DOI 10.1093/nar/gkm1046
   Benatti P, 2011, NUCLEIC ACIDS RES, V39, P5356, DOI 10.1093/nar/gkr128
   Bernales S, 2006, PLOS BIOL, V4, P2311, DOI 10.1371/journal.pbio.0040423
   Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x
   Bielak-Zmijewska A, 2004, CANCER CHEMOTH PHARM, V53, P179, DOI 10.1007/s00280-003-0705-x
   Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523
   Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902
   Bush JA, 2001, EXP CELL RES, V271, P305, DOI 10.1006/excr.2001.5381
   Chen A, 2006, ONCOGENE, V25, P278, DOI [10.1038/sj.onc.1209019, 10.1038/sj.onc.1209573]
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Cuervo AM, 2004, MOL CELL BIOCHEM, V263, P55, DOI 10.1023/B:MCBI.0000041848.57020.57
   Cuervo AM, 2012, MOL ASPECTS MED, V33, P2, DOI 10.1016/j.mam.2011.09.001
   Ding WX, 2007, J BIOL CHEM, V282, P4702, DOI 10.1074/jbc.M609267200
   Donati G, 2006, NUCLEIC ACIDS RES, V34, P3116, DOI 10.1093/nar/gkl304
   Donovan M, 2004, BBA-MOL CELL RES, V1644, P133, DOI 10.1016/j.bbamcr.2003.08.011
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Eskelinen EL, 2005, CELL DEATH DIFFER, V12, P1468, DOI 10.1038/sj.cdd.4401721
   Faitova J, 2006, CELL MOL BIOL LETT, V11, P488, DOI 10.2478/s11658-006-0040-4
   Fass E, 2006, J BIOL CHEM, V281, P36303, DOI 10.1074/jbc.M607031200
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Ferrari E, 2011, J MED CHEM, V54, P8066, DOI 10.1021/jm200872q
   Fuchs JR, 2009, BIOORG MED CHEM LETT, V19, P2065, DOI 10.1016/j.bmcl.2009.01.104
   Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986
   Hatcher H, 2008, CELL MOL LIFE SCI, V65, P1631, DOI 10.1007/s00018-008-7452-4
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   He ZY, 2011, CANCER INVEST, V29, P208, DOI 10.3109/07357907.2010.550592
   Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200
   Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015
   Hoyer-Hansen M, 2007, MOL CELL, V25, P193, DOI 10.1016/j.molcel.2006.12.009
   Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776
   Ireson CR, 2002, CANCER EPIDEM BIOMAR, V11, P105
   Jiang ZH, 2010, MOL CANCER THER, V9, P558, DOI 10.1158/1535-7163.MCT-09-0627
   Jullig M, 2006, APOPTOSIS, V11, P627, DOI 10.1007/s10495-006-4990-9
   Kim H, 2009, MOL CELL, V36, P487, DOI 10.1016/j.molcel.2009.09.030
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260
   Lu CR, 2006, MOL CELL, V23, P121, DOI 10.1016/j.molcel.2006.05.023
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Martens JHA, 2005, EMBO J, V24, P800, DOI 10.1038/sj.emboj.7600545
   Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200
   Milacic V, 2008, CANCER RES, V68, P7283, DOI 10.1158/0008-5472.CAN-07-6246
   Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007
   Moragoda L, 2001, ANTICANCER RES, V21, P873
   Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513
   Nardo L, 2012, J PHYS CHEM A, V116, P9321, DOI 10.1021/jp307928a
   Ng APP, 2011, MOL CANCER RES, V9, P878, DOI 10.1158/1541-7786.MCR-10-0545
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Paglin S, 2001, CANCER RES, V61, P439
   Pallauf K, 2012, AGEING RES REV
   Priault M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008755
   Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676
   Ramachandran C, 2005, ANTICANCER RES, V25, P3293
   Ravindran J, 2009, AAPS J, V11, P495, DOI 10.1208/s12248-009-9128-x
   Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149
   Reuter S, 2008, BIOCHEM PHARMACOL, V76, P1340, DOI 10.1016/j.bcp.2008.07.031
   Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390
   Rosati E, 2010, BLOOD, V116, P2713, DOI 10.1182/blood-2010-03-275628
   Singletary K, 2008, CANCER EPIDEM BIOMAR, V17, P1596, DOI 10.1158/1055-9965.EPI-07-2917
   Speidel D, 2010, TRENDS CELL BIOL, V20, P14, DOI 10.1016/j.tcb.2009.10.002
   Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312
   Verfaillie T., 2010, INT J CELL BIOL, V2010, DOI [10.1155/2010/93050920145727, DOI 10.1155/2010/930509]
   Wang L, 2011, MOL CANCER THER, V10, P461, DOI 10.1158/1535-7163.MCT-10-0812
   Wu JC, 2011, MOL NUTR FOOD RES, V55, P1646, DOI 10.1002/mnfr.201100454
   Wu SH, 2010, ANTICANCER RES, V30, P2125
   Yamaguchi H, 2004, J BIOL CHEM, V279, P45495, DOI 10.1074/jbc.M406933200
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yoon MJ, 2010, FREE RADICAL BIO MED, V48, P713, DOI 10.1016/j.freeradbiomed.2009.12.016
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
   Yorimitsu T, 2006, J BIOL CHEM, V281, P30299, DOI 10.1074/jbc.M607007200
   You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353
   ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661
   Zhang X, 2012, CELL PROLIFERAT, V45, P466, DOI 10.1111/j.1365-2184.2012.00833.x
   Zhuang W, 2011, CANCER SCI, V103, P684
NR 87
TC 47
Z9 50
U1 0
U2 28
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 11
PY 2013
VL 8
IS 1
AR e53664
DI 10.1371/journal.pone.0053664
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 086RY
UT WOS:000314705800067
PM 23326480
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Yao, CW
   Kang, KA
   Piao, MJ
   Ryu, YS
   Fernando, PMDJ
   Oh, MC
   Park, JE
   Shilnikova, K
   Na, SY
   Jeong, SU
   Boo, SJ
   Hyun, JW
AF Yao, Cheng Wen
   Kang, Kyoung Ah
   Piao, Mei Jing
   Ryu, Yea Seong
   Fernando, Pattage Madushan Dilhara Jayatissa
   Oh, Min Chang
   Park, Jeong Eon
   Shilnikova, Kristina
   Na, Soo-Young
   Jeong, Seung Uk
   Boo, Sun-Jin
   Hyun, Jin Won
TI Reduced Autophagy in 5-Fluorouracil Resistant Colon Cancer Cells
SO BIOMOLECULES & THERAPEUTICS
LA English
DT Article
DE Autophagy; 5-Fluorouracil; SNUC5/5-FUR; Reactive oxygen species; Colon
   cancer
ID DEATH; CHLOROQUINE; ACTIVATION; MECHANISMS; STRESS; ASSAY
AB We investigated the role of autophagy in SNUC5/5-FUR, 5-fluorouracil (5 -FU) resistant SNUC5 colon cancer cells. SNUC5/5-FUR cells exhibited low level of autophagy, as determined by light microscopy, confocal microscopy, and flow cytometry following acridine orange staining, and the decreased level of GFP-LC3 puncta. In addition, expression of critical autophagic proteins such as Atg5, Beclin-1 and LC3-II and autophagic flux was diminished in SNUC5/5-FUR cells. Whereas production of reactive oxygen species (ROS) was significantly elevated in SNUC5/5-FUR cells, treatment with the ROS inhibitor N-acetyl cysteine further reduced the level of autophagy. Taken together, these results indicate that decreased autophagy is linked to 5 -FU resistance in SNUC5 colon cancer cells.
C1 [Yao, Cheng Wen; Kang, Kyoung Ah; Piao, Mei Jing; Ryu, Yea Seong; Fernando, Pattage Madushan Dilhara Jayatissa; Oh, Min Chang; Park, Jeong Eon; Shilnikova, Kristina; Hyun, Jin Won] Jeju Natl Univ, Sch Med 1, Jeju 63243, South Korea.
   [Yao, Cheng Wen; Kang, Kyoung Ah; Piao, Mei Jing; Ryu, Yea Seong; Fernando, Pattage Madushan Dilhara Jayatissa; Oh, Min Chang; Park, Jeong Eon; Shilnikova, Kristina; Hyun, Jin Won] Jeju Natl Univ, Inst Nucl Sci & Technol, Jeju 63243, South Korea.
   [Na, Soo-Young; Jeong, Seung Uk; Boo, Sun-Jin] Jeju Natl Univ, Sch Med 2, Jeju 63241, South Korea.
RP Hyun, JW (corresponding author), Jeju Natl Univ, Sch Med 1, Jeju 63243, South Korea.; Hyun, JW (corresponding author), Jeju Natl Univ, Inst Nucl Sci & Technol, Jeju 63243, South Korea.; Boo, SJ (corresponding author), Jeju Natl Univ, Sch Med 2, Jeju 63241, South Korea.
EM sunjinboo@jejunu.ac.kr; jinwonh@jejunu.ac.kr
FU Jeju National University Hospital Research Fund of Jeju National
   University
FX This work was supported by a research grant from the Jeju National
   University Hospital Research Fund of Jeju National University in 2015.
CR Bijnsdorp IV, 2010, INT J CANCER, V126, P2457, DOI 10.1002/ijc.24943
   CARMICHAEL J, 1987, CANCER RES, V47, P936
   Choi CH, 2011, J KOREAN SURG SOC, V81, P115, DOI 10.4174/jkss.2011.81.2.115
   Codogno P, 2012, NAT REV MOL CELL BIO, V13, P7, DOI 10.1038/nrm3249
   Dewaele M, 2010, AUTOPHAGY, V6, P838, DOI 10.4161/auto.6.7.12113
   Djavaheri-Mergny M, 2006, J BIOL CHEM, V281, P30373, DOI 10.1074/jbc.M602097200
   Fan CD, 2006, BIOORGAN MED CHEM, V14, P3218, DOI 10.1016/j.bmc.2005.12.035
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Grem JL, 2000, INVEST NEW DRUG, V18, P299, DOI 10.1023/A:1006416410198
   Jung GR, 2007, BASIC CLIN PHARMACOL, V101, P277, DOI 10.1111/j.1742-7843.2007.00115.x
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kang KA, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.149
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kim AD, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.273
   Kim AY, 2015, TOX RESEARCH, V31, P151, DOI 10.5487/TR.2015.31.2.151
   Kim BW, 2016, BMB REP, V49, P73, DOI 10.5483/BMBRep.2016.49.2.265
   Ku Ja-Lok, 2005, Cancer Res Treat, V37, P1, DOI 10.4143/crt.2005.37.1.1
   Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451
   Lee TB, 2009, BIOTECHNOL LETT, V31, P1485, DOI 10.1007/s10529-009-0039-9
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Liu EY, 2012, J CELL SCI, V125, P2349, DOI 10.1242/jcs.093708
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Morselli E, 2011, ANTIOXID REDOX SIGN, V14, P2251, DOI 10.1089/ars.2010.3478
   Nordman IC, 2006, ANZ J SURG, V76, P373, DOI 10.1111/j.1445-2197.2006.03726.x
   Sasaki K, 2012, ANTI-CANCER DRUG, V23, P675, DOI 10.1097/CAD.0b013e328353f8c7
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Wu M, 2015, PHYTOMEDICINE, V22, P902, DOI 10.1016/j.phymed.2015.06.008
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
NR 31
TC 22
Z9 24
U1 0
U2 8
PU KOREAN SOC APPLIED PHARMACOLOGY
PI SEOUL
PA RM 805, KOREAN FEDERATION SCIENCE & TECHNOLOGY B/D, 635-4 YEOKSAM-DONG,
   KANGNAM-GU, SEOUL, 135-703, SOUTH KOREA
SN 1976-9148
EI 2005-4483
J9 BIOMOL THER
JI Biomol. Ther.
PD MAY 1
PY 2017
VL 25
IS 3
BP 315
EP 320
DI 10.4062/biomolther.2016.069
PG 6
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA EU7LF
UT WOS:000401215600012
PM 27737524
OA Green Submitted, Green Published
DA 2022-04-25
ER

PT J
AU Hu, T
   Wang, L
   Zhang, L
   Lu, L
   Shen, J
   Chan, RLY
   Li, MX
   Wu, WKK
   To, KKW
   Cho, CH
AF Hu, Tao
   Wang, Lin
   Zhang, Lin
   Lu, Lan
   Shen, Jing
   Chan, Ruby L. Y.
   Li, Mingxing
   Wu, William K. K.
   To, Kenneth K. W.
   Cho, Chi Hin
TI Sensitivity of apoptosis-resistant colon cancer cells to tanshinones is
   mediated by autophagic cell death and p53-independent cytotoxicity
SO PHYTOMEDICINE
LA English
DT Article
DE Ciyptotanshinone; Dihydrotanshinone; Apoptosis resistance; Autophagic
   cell death; p53-independent cytotoxicity; Colon cancer
ID MULTIDRUG-RESISTANCE; TUMOR RESISTANCE; SURVIVAL; CRYPTOTANSHINONE;
   MUTATIONS; PATHWAY; ARREST
AB Background: Multidrug resistance (MDR) develops in nearly all patients with colon cancer. The reversal of MDR plays an important role in the success of colon cancer chemotherapy. One of the commonest mechanisms conferring MDR is the suppression of apoptosis in cancer cells.
   Purpose: This study investigated the sensitivity of cryptotanshinone (CTS) and dihydrotanshinone (DTS), two lipophilic tanshinones from a traditional Chinese medicine Salvia miltiorrhiza, in apoptosis-resistant colon cancer cells.
   Methods: Cell viability was measured by MTT assay. Cell cycle distribution and apoptosis were determined by flow cytometry. Protein levels were analyzed by western blot analysis. The formation of acidic vesicular organelles was visualized by acridine orange staining.
   Results: Experimental results showed that multidrug-resistant colon cancer cells SW620 Ad300 were sensitive to both CTS and DTS in terms of cell death, but with less induction of apoptosis when compared with the parental cells SW620, suggesting that other types of cell death such as autophagy could occur. Indeed, the two tanshinones induced more LC3B-II accumulation in SW620 Ad300 cells with increased autophagic flux. More importantly, cell viability was increased after autophagy inhibition, indicating that autophagy induced by the two tanshinones was pro-cell death. Besides, the cytotoxic actions of the two tanshinones were p53-independent, which could be useful in inhibiting the growth of apoptosis-resistant cancer cells with p53 defects.
   Conclusion: The current findings strongly Indicate that both CTS and DTS could inhibit the growth of apoptosis-resistant colon cancer cells through induction of autophagic cell death and p53-independent cytotoxicity. They are promising candidates to be further developed as therapeutic agents in the adjuvant therapy for colon cancer, especially for the apoptosis-resistant cancer types. (C) 2015 Elsevier GmbH. All rights reserved.
C1 [Hu, Tao; Wang, Lin; Zhang, Lin; Lu, Lan; Shen, Jing; Chan, Ruby L. Y.; Li, Mingxing; Cho, Chi Hin] Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China.
   [Wu, William K. K.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anesthesia & Intens Care, Hong Kong, Hong Kong, Peoples R China.
   [To, Kenneth K. W.] Chinese Univ Hong Kong, Fac Med, Sch Pharm, Hong Kong, Hong Kong, Peoples R China.
RP Hu, T (corresponding author), Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China.
EM taohu1985@hotmail.com
RI Wu, William K.K./A-3277-2009; Hu, Tao/O-2570-2014; Cho, Chi
   Hin/C-6543-2014; To, Kenneth K W/M-4500-2013
OI Wu, William K.K./0000-0002-5662-5240; Cho, Chi Hin/0000-0002-7658-3260;
   To, Kenneth K W/0000-0003-2755-0283; LI, Mingxing/0000-0001-5729-3850;
   Hu, Tao/0000-0002-0601-3078; WANG, LIN/0000-0001-7883-4900
FU Innovation and Technology Support Programme, Tier 3/Seed Projects,
   Innovation and Technology Commission, Hong Kong [ITS/212/12]; General
   Research Fund, Hong Kong Research Grant Council, Hong Kong [CUHK463613]
FX This work was supported by Innovation and Technology Support Programme,
   Tier 3/Seed Projects, Innovation and Technology Commission, Hong Kong
   (ITS/212/12) and General Research Fund, Hong Kong Research Grant
   Council, Hong Kong (CUHK463613). We thank Dr. Susan Bates (National
   Cancer Institute, Bethesda, MD, USA) for providing SW620 parental and
   resistant cells. We also thank Prof. Bert Vogelstein (Ludwig Center at
   Johns Hopkins University, Baltimore, MD, USA) for p53<SUP>-/-</SUP>
   HCT116 cells.
CR Billard C, 2013, MOL CANCER THER, V12, P1691, DOI 10.1158/1535-7163.MCT-13-0058
   Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4
   Dallas NA, 2009, CANCER RES, V69, P1951, DOI 10.1158/0008-5472.CAN-08-2023
   Fernald K, 2013, TRENDS CELL BIOL, V23, P620, DOI 10.1016/j.tcb.2013.07.006
   Fulda S, 2009, INT J CANCER, V124, P511, DOI 10.1002/ijc.24064
   Gill S, 2003, ALIMENT PHARM THER, V18, P683, DOI 10.1046/j.1365-2036.2003.01735.x
   Gordy C, 2012, PROTEIN CELL, V3, P17, DOI 10.1007/s13238-011-1127-x
   Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706
   GREENBLATT MS, 1994, CANCER RES, V54, P4855
   Hersey P, 2003, J CELL PHYSIOL, V196, P9, DOI 10.1002/jcp.10256
   Hu T, 2014, PHYTOMEDICINE, V21, P1264, DOI 10.1016/j.phymed.2014.06.013
   Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   LAI GM, 1991, INT J CANCER, V49, P696, DOI 10.1002/ijc.2910490512
   LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7
   Martinet W, 2009, CIRC RES, V104, P304, DOI 10.1161/CIRCRESAHA.108.188318
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   OConnor PM, 1997, CANCER RES, V57, P4285
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Park IJ, 2014, APOPTOSIS, V19, P615, DOI 10.1007/s10495-013-0929-0
   Reles A, 2001, CLIN CANCER RES, V7, P2984
   Tsai SL, 2007, BIOCHEM PHARMACOL, V74, P1575, DOI 10.1016/j.bcp.2007.08.009
   Yokoyama T, 2008, AUTOPHAGY, V4, P629, DOI 10.4161/auto.5941
   Yun SM, 2014, PHYTOTHER RES, V28, P458, DOI 10.1002/ptr.5015
NR 24
TC 58
Z9 62
U1 2
U2 31
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944-7113
J9 PHYTOMEDICINE
JI Phytomedicine
PD MAY 15
PY 2015
VL 22
IS 5
BP 536
EP 544
DI 10.1016/j.phymed.2015.03.010
PG 9
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA CI2VH
UT WOS:000354605000003
PM 25981919
DA 2022-04-25
ER

PT J
AU He, G
   Wang, Y
   Pang, XL
   Zhang, B
AF He, Gang
   Wang, Yan
   Pang, Xueli
   Zhang, Bo
TI Inhibition of autophagy induced by TSA sensitizes colon cancer cell to
   radiation
SO TUMOR BIOLOGY
LA English
DT Article
DE TSA; Colon cancer; Radiosensitivity; Autophagy; Apoptosis
ID HISTONE DEACETYLASE INHIBITOR; EXPRESSION; THERAPY; DEATH;
   RADIOSENSITIZATION; TRICHOSTATIN; ACETYLATION; PROGNOSIS; APOPTOSIS;
   PROTEIN
AB Radiotherapy is one of the main treatments for clinical cancer therapy. However, its application was limited due to lack of radiosensitivity in some cancers. Trichostatin A (TSA) is a classic histone deacetylases inhibitor (HDACi) that specifically inhibits the biochemical functions of HDAC and is demonstrated to be an active anticancer drug. However, whether it could sensitize colon cancer to radiation is not clear. Our results showed that TSA enhanced the radiosensitivity of colon cancer cells as determined by CCK-8 and clonogenic survival assay. Moreover, apoptotic cell death induced by radiation was enhanced by TSA treatment. Additionally, TSA also induced autophagic response in colon cancer cells, while autophagy inhibition led to cell apoptosis and enhanced the radiosensitivity of colon cancer cells. Our data suggested that inhibition of cytoprotective autophagy sensitizes cancer cell to radiation, which might be further investigated for clinical cancer radiotherapy.
C1 [He, Gang; Wang, Yan; Zhang, Bo] Third Mil Med Univ, Dept Med Genet, Chongqing 400038, Peoples R China.
   [Pang, Xueli] Third Mil Med Univ, Southwest Hosp, Dept Oncol, Chongqing, Peoples R China.
RP Zhang, B (corresponding author), Third Mil Med Univ, Dept Med Genet, Chongqing 400038, Peoples R China.
EM pangxueli79@gmail.com; bo_zhang@yahoo.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81272497]
FX This work was supported by grants from the National Natural Science
   Foundation of China (no. 81272497).
CR Akar U, 2008, AUTOPHAGY, V4, P669, DOI 10.4161/auto.6083
   [Anonymous], 2013, CANC GENE THER, V20, P375
   Benzina S, 2008, CANCER LETT, V264, P63, DOI 10.1016/j.canlet.2008.01.023
   Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Bots M, 2009, CLIN CANCER RES, V15, P3970, DOI 10.1158/1078-0432.CCR-08-2786
   Camphausen K, 2007, J CLIN ONCOL, V25, P4051, DOI 10.1200/JCO.2007.11.6202
   Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78
   Carafa V, 2011, RECENT PAT ANTI-CANC, V6, P131, DOI 10.2174/157489211793980088
   Caron C, 2005, BIOESSAYS, V27, P408, DOI 10.1002/bies.20210
   Chowdhury S, 2011, J BIOL CHEM, V286, P30937, DOI 10.1074/jbc.M110.212035
   Dai ZJ, 2013, INT J MOL SCI, V14, P273, DOI 10.3390/ijms14010273
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fantin VR, 2008, CANCER RES, V68, P3785, DOI 10.1158/0008-5472.CAN-07-6091
   Folkvord S, 2009, INT J RADIAT ONCOL, V74, P546, DOI 10.1016/j.ijrobp.2009.01.068
   Frew AJ, 2008, P NATL ACAD SCI USA, V105, P11317, DOI 10.1073/pnas.0801868105
   Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002
   Gammoh N, 2012, P NATL ACAD SCI USA, V109, P6561, DOI 10.1073/pnas.1204429109
   Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080
   Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Liu YB, 2013, TOXICOL LETT, V221, P23, DOI 10.1016/j.toxlet.2013.05.643
   Livesey KM, 2009, CURR OPIN INVEST DR, V10, P1269
   Lovey J, 2013, CANCER LETT, V335, P495, DOI 10.1016/j.canlet.2013.03.012
   Mottet D, 2010, CURR CANCER DRUG TAR, V10, P898, DOI 10.2174/156800910793358014
   Oh M, 2008, BIOCHEM BIOPH RES CO, V369, P1179, DOI 10.1016/j.bbrc.2008.03.019
   Ree AH, 2010, LANCET ONCOL, V11, P459, DOI 10.1016/S1470-2045(10)70058-9
   Rhodes LV, 2012, ONCOL REP, V27, P10, DOI 10.3892/or.2011.1488
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Sy LK, 2008, CANCER RES, V68, P10229, DOI 10.1158/0008-5472.CAN-08-1983
   Weichert W, 2008, LANCET ONCOL, V9, P139, DOI 10.1016/S1470-2045(08)70004-4
   Weichert W, 2009, CANCER LETT, V280, P168, DOI 10.1016/j.canlet.2008.10.047
NR 32
TC 22
Z9 23
U1 1
U2 10
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD FEB
PY 2014
VL 35
IS 2
BP 1003
EP 1011
DI 10.1007/s13277-013-1134-z
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AB8FT
UT WOS:000332026300019
PM 24122231
DA 2022-04-25
ER

PT J
AU Patel, S
   Waghela, B
   Shah, K
   Vaidya, F
   Mirza, S
   Patel, S
   Pathak, C
   Rawal, R
AF Patel, Shanaya
   Waghela, Bhargav
   Shah, Kanisha
   Vaidya, Foram
   Mirza, Sheefa
   Patel, Saumya
   Pathak, Chandramani
   Rawal, Rakesh
TI Silibinin, A Natural Blend In Polytherapy Formulation For Targeting
   Cd44v6 Expressing Colon Cancer Stem Cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID INDUCED AUTOPHAGIC DEATH; COLORECTAL-CANCER; TUMOR PROGRESSION;
   SUPPRESSES GROWTH; POOR-PROGNOSIS; FORCE-FIELD; SIMULATIONS; INHIBITORS;
   APOPTOSIS; CFLIP(L)
AB Colon cancer stem cells have been attributed to poor prognosis, therapeutic resistance and aggressive nature of the malignancy. Recent reports associated CD44v6 expression with relapse, metastasis and reduced 5-year survival of colon cancer patients, thereby making it a potential therapeutic target. Thus, in this study, comprehensive prediction and screening of CD44v6 against 1674 lead compounds was conducted. Silibinin was identified as a potential compound targeting CD44v6. Inorder to substantiate these findings, the cytotoxic effect of 5FU, Silibinin and 5FU+ Silibinin was assessed on human colon carcinoma cell line HCT116 derived CD44+ subpopulation. 5FU+ Silibinin inhibited cell proliferation of CD44+ subpopulation at lower concentration than Silibinin standalone. Further, corresponding to CD44v6 knockdown cells, 5FU+ Silibinin treatment significantly decreased CD44v6, Nanog, CTNNB1 and CDKN2A expression whereas increased E-cadherin expression in HCT116 derived CD44+ cells. Moreover, synergistic effect of these drugs suppressed sphere formation, inhibited cell migration, triggered PARP cleavage and perturbation in mitochondrial membrane potential, thereby activating intrinsic apoptotic pathways and induced autophagic cell death. Importantly, 5FU+ Silibinin could inhibit PI3K/MAPK dual activation and arrest the cell cycle at GO/G1 phase. Thus, our study suggests that inhibition of CD44v6 attenuates stemness of colon cancer stem cells and holds a prospect of potent therapeutic target.
C1 [Patel, Shanaya] Ahmedabad Univ, Div Biol & Life Sci, Sch Arts & Sci, Ahmadabad, Gujarat, India.
   [Patel, Shanaya; Waghela, Bhargav; Shah, Kanisha; Vaidya, Foram; Mirza, Sheefa; Patel, Saumya; Pathak, Chandramani; Rawal, Rakesh] Gujarat Univ, Dept Life Sci, Sch Sci, Ahmadabad, Gujarat, India.
   [Waghela, Bhargav; Shah, Kanisha; Vaidya, Foram; Mirza, Sheefa; Patel, Saumya; Pathak, Chandramani; Rawal, Rakesh] Indian Inst Adv Res, Dept Cell Biol, Gandhinagar, Gujarat, India.
RP Rawal, R (corresponding author), Gujarat Univ, Dept Life Sci, Sch Sci, Ahmadabad, Gujarat, India.; Rawal, R (corresponding author), Indian Inst Adv Res, Dept Cell Biol, Gandhinagar, Gujarat, India.
EM rakeshrawal@gujaratuniversity.ac.in
RI Pathak, Chandramani/E-4662-2016; Mirza, Sheefa/AAQ-8232-2021; Vaidya,
   Foram/AAI-2713-2021
OI Pathak, Chandramani/0000-0002-9389-8096; patel, Dr.
   Saumya/0000-0003-4919-1322
FU Gujarat Cancer & Research Institute, NCH Campus, Asarwa, Ahmedabad,
   Gujarat, India; Department of Biotechnology, Ministry of Science &
   Technology, Govt. of India [6242/P60/RGCB/PMD/DBT/CMPK/2015]
FX We sincerely appreciate the support by The Gujarat Cancer & Research
   Institute, NCH Campus, Asarwa, Ahmedabad, Gujarat, India. We also
   acknowledge Department of Biotechnology, Ministry of Science &
   Technology, Govt. of India for providing research grant under pilot
   project for young investigators in Cancer Biology
   (6242/P60/RGCB/PMD/DBT/CMPK/2015).
CR Agarwal C, 2003, ONCOGENE, V22, P8271, DOI 10.1038/sj.onc.1207158
   An H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141919
   Banky B, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-83
   Boman BM, 2008, J CLIN ONCOL, V26, P2828, DOI 10.1200/JCO.2008.17.6941
   Carethers John M, 2008, Therap Adv Gastroenterol, V1, P33, DOI 10.1177/1756283X08093607
   Duan WJ, 2011, J ASIAN NAT PROD RES, V13, P27, DOI 10.1080/10286020.2010.540757
   Duan WJ, 2011, BIOL PHARM BULL, V34, P47, DOI 10.1248/bpb.34.47
   Duan Y, 2003, J COMPUT CHEM, V24, P1999, DOI 10.1002/jcc.10349
   Edwards BK, 2010, CANCER-AM CANCER SOC, V116, P544, DOI 10.1002/cncr.24760
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8
   Fan CW, 2012, HEPATO-GASTROENTEROL, V59, P1421, DOI 10.5754/hge10727
   Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8
   Ghiso E, 2013, CURR OPIN PHARMACOL, V13, P511, DOI 10.1016/j.coph.2013.05.018
   Hospital Adam, 2015, Adv Appl Bioinform Chem, V8, P37, DOI 10.2147/AABC.S70333
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Ibrahim EE, 2012, STEM CELLS, V30, P2076, DOI 10.1002/stem.1182
   Jiang K, 2015, ONCOL REP, V33, P2711, DOI 10.3892/or.2015.3915
   Jijiwa M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024217
   Judd NP, 2012, CANCER RES, V72, P365, DOI 10.1158/0008-5472.CAN-11-1831
   Kauntz H, 2011, APOPTOSIS, V16, P1042, DOI 10.1007/s10495-011-0631-z
   Kaur M, 2010, NEOPLASIA, V12, P415, DOI 10.1593/neo.10188
   Kaur M, 2009, MOL CANCER THER, V8, P2366, DOI 10.1158/1535-7163.MCT-09-0304
   Kim SH, 2015, BIOCHEM BIOPH RES CO, V468, P151, DOI 10.1016/j.bbrc.2015.10.143
   Kim S, 2011, ANTICANCER RES, V31, P3767
   Krieger E, 2004, PROTEINS, V57, P678, DOI 10.1002/prot.20251
   Kumar S, 2014, ONCOTARGET, V5, P4972, DOI 10.18632/oncotarget.2068
   Louderbough JMV, 2011, MOL CANCER RES, V9, P1573, DOI 10.1158/1541-7786.MCR-11-0156
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Margelevicius M, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-185
   Meng HM, 2010, CANCER BIOL THER, V9, P295, DOI 10.4161/cbt.9.4.10666
   Mikhail Sameh, 2014, World J Stem Cells, V6, P606, DOI 10.4252/wjsc.v6.i5.606
   Orian-Rousseau V, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00154
   Peng J, 2008, CANCER J, V14, P54, DOI 10.1097/PPO.0b013e3181629a67
   Pikkemaat MG, 2002, PROTEIN ENG, V15, P185, DOI 10.1093/protein/15.3.185
   RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6
   Ranjan K, 2016, MOL CELL BIOCHEM, V422, P135, DOI 10.1007/s11010-016-2813-z
   Ranjan K, 2016, SCI REP-UK, V6, DOI 10.1038/srep22787
   Ricci-Vitiani L, 2009, J MOL MED, V87, P1097, DOI 10.1007/s00109-009-0518-4
   Rodon J, 2013, NAT REV CLIN ONCOL, V10, P143, DOI 10.1038/nrclinonc.2013.10
   Sahlberg SH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094621
   Saito S, 2013, ONCOL REP, V29, P1570, DOI 10.3892/or.2013.2273
   Sanchez-Garcia I, 2007, BIOESSAYS, V29, P1269, DOI 10.1002/bies.20679
   Shan JJ, 2012, HEPATOLOGY, V56, P1004, DOI 10.1002/hep.25745
   Stewart BWKP, 2015, WORLD CANC REPORT 20
   Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009
   TOLG C, 1993, NUCLEIC ACIDS RES, V21, P1225, DOI 10.1093/nar/21.5.1225
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   Ward RJ, 2007, ANNU REV PATHOL-MECH, V2, P175, DOI 10.1146/annurev.pathol.2.010506.091847
   Webb B, 2014, METHODS MOL BIOL, V1137, P1, DOI 10.1007/978-1-4939-0366-5_1
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Xiong BH, 2014, INT J ONCOL, V45, P1175, DOI 10.3892/ijo.2014.2498
   Zhou JY, 2016, ONCOTARGET, V7, P7657, DOI 10.18632/oncotarget.7084
NR 55
TC 17
Z9 17
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 16
PY 2018
VL 8
AR 16985
DI 10.1038/s41598-018-35069-0
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HA6TB
UT WOS:000450411700016
PM 30451890
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Islam, F
   Chaousis, S
   Wahab, R
   Gopalan, V
   Lam, AKY
AF Islam, Farhadul
   Chaousis, Stephanie
   Wahab, Riajul
   Gopalan, Vinod
   Lam, Alfred K. -Y.
TI Protein interactions of FAM134B with EB1 and APC/beta-catenin in vitro
   in colon carcinoma
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE APC; colorectal cancer; EB1; FAM134B; signaling pathways
ID CELL LUNG-CANCER; ENDOPLASMIC-RETICULUM TURNOVER; HEREDITARY SENSORY
   NEUROPATHY; COLORECTAL-CANCER; CLINICOPATHOLOGICAL SIGNIFICANCE;
   AUTONOMIC NEUROPATHY; ONCOGENIC PROPERTIES; SELECTIVE AUTOPHAGY;
   PROTEOMIC ANALYSIS; SIGNALING PATHWAY
AB FAM134B is an autophagy regulator of endoplasmic reticulum and acts as a cancer suppressor in colon cancer. However, the molecular signaling pathways by which FAM134B interacts within colon carcinogenesis is still unknown. Herein, this study aims to determine the interacting partners of FAM134B for the first time in colon cancer and to explore the precise location of FAM134B in cancer signalling pathways. Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) followed by anti-FAM134B co-immune precipitation of FAM134B interacting complex was used to identify the potential interactors of FAM134B in colon cancer cells. Western blot and confocal microscopic analysis were used to validate the physical interactions of FAM134B with the interactors. Lentiviral shRNA mediated silencing of FAM134B was used to examine the modulation of FAM134B interactors in cells. We have identified 29 novel binding partners, including CAP1, RPS28, FTH1, KDELR2, MAP4, EB1, PSMD6, PPIB/CYPB etc. Subsequent immunoassays confirmed the direct physical interactions of FAM134B with CAP1, EB1, CYPB, and KDELR2 in colon cancer cells. Exogenous suppression of FAM134B has led to significant upregulation of EB1 as well as reduction of KDELR2 expression. It was noted that overexpression of EB1 promotes WNT/-catenin signaling pathways via inactivating tumor suppressor APC followed by activating -catenin in colorectal carcinogenesis. This study has first time reported the gene signaling networks with which FAM134B interacts and noted that FAM134B is involved in the regulation of WNT/-catenin pathway by EB1-mediated modulating of APC in colon cancer cells.
C1 [Islam, Farhadul; Wahab, Riajul; Gopalan, Vinod; Lam, Alfred K. -Y.] Griffith Univ, Menzies Hlth Inst Queensland, Sch Med, Canc Mol Pathol, Gold Coast, Qld, Australia.
   [Islam, Farhadul] Univ Rajshahi, Dept Biochem & Mol Biol, Rajshahi, Bangladesh.
   [Chaousis, Stephanie] Griffith Univ, Australian Rivers Inst, Gold Coast, Qld, Australia.
   [Chaousis, Stephanie] Griffith Univ, Sch Environm, Gold Coast, Qld, Australia.
   [Gopalan, Vinod] Griffith Univ, Sch Med Sci, Menzies Hlth Inst Queensland, Gold Coast, Qld, Australia.
RP Gopalan, V (corresponding author), Griffith Univ, Sch Med & Med Sci, Gold Coast Campus, Gold Coast, Qld 4222, Australia.; Lam, AKY (corresponding author), Griffith Med Sch, Pathol, Gold Coast Campus, Gold Coast, Qld 4222, Australia.
EM v.gopalan@griffith.edu.au; a.lam@griffith.edu.au
RI Wahab, Riajul/AEC-9343-2022; Lam, Alfred/C-1652-2008; Gopalan,
   Vinod/C-4269-2016; Islam, Farhadul/R-5643-2017
OI Lam, Alfred/0000-0003-2771-564X; Gopalan, Vinod/0000-0003-0366-9482;
   Islam, Farhadul/0000-0001-5262-4702
FU Menzies Health Institute Queensland, Griffith University
FX Menzies Health Institute Queensland, Griffith University
CR Askham JM, 2000, ONCOGENE, V19, P1950, DOI 10.1038/sj.onc.1203498
   Baliban RC, 2012, J CLIN PERIODONTOL, V39, P203, DOI 10.1111/j.1600-051X.2011.01805.x
   Banerjee B, 2014, J CELL BIOL, V204, P947, DOI 10.1083/jcb.201307119
   Bu W, 2003, J BIOL CHEM, V278, P49721, DOI 10.1074/jbc.M306194200
   Chiramel AI, 2016, J INFECT DIS, V214, pS319, DOI 10.1093/infdis/jiw270
   Dai XF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07189-6
   Davidson GL, 2012, J NEUROL, V259, P1673, DOI 10.1007/s00415-011-6397-y
   Duret C, 2014, MUSCLE NERVE, V49, P774, DOI 10.1002/mus.24145
   Fan YC, 2016, ONCOL REP, V36, P1619, DOI 10.3892/or.2016.4936
   Fang F, 2009, AM J PATHOL, V174, P297, DOI 10.2353/ajpath.2009.080753
   Gainor JF, 2013, ONCOLOGIST, V18, P865, DOI 10.1634/theoncologist.2013-0095
   Gemoll T, 2017, ONCOTARGET, V8, P54939, DOI 10.18632/oncotarget.18978
   Green RA, 2005, MOL BIOL CELL, V16, P4609, DOI 10.1091/mbc.E05-03-0259
   Guo F, 2015, ASIAN PAC J TROP MED, V8, P319, DOI 10.1016/S1995-7645(14)60338-2
   Haque MH, 2016, SCI REP-UK, V6, DOI 10.1038/srep29173
   Honnappa S, 2005, EMBO J, V24, P261, DOI 10.1038/sj.emboj.7600529
   Islam F, 2018, J CELL PHYSIOL, V233, P4479, DOI 10.1002/jcp.26384
   Islam F, 2017, EXP CELL RES, V357, P260, DOI 10.1016/j.yexcr.2017.05.021
   Islam F, 2017, HUM GENET, V136, P321, DOI 10.1007/s00439-017-1760-4
   Islam F, 2017, MOL CARCINOGEN, V56, P238, DOI 10.1002/mc.22488
   Kasem K, 2014, EXP MOL PATHOL, V97, P99, DOI 10.1016/j.yexmp.2014.06.002
   Kasem K, 2014, EXP MOL PATHOL, V97, P31, DOI 10.1016/j.yexmp.2014.05.001
   Kasem K, 2014, EXP CELL RES, V326, P166, DOI 10.1016/j.yexcr.2014.06.013
   Khaminets A, 2015, NATURE, V522, P354, DOI 10.1038/nature14498
   Kikuchi T, 2012, MOL CELL PROTEOMICS, V11, P916, DOI 10.1074/mcp.M111.015370
   Kim MJ, 2013, CANCER LETT, V339, P15, DOI 10.1016/j.canlet.2013.07.027
   Kim Y, 2011, HEPATOLOGY, V54, P1661, DOI 10.1002/hep.24539
   Kong M, 2011, PSYCHIAT GENET, V21, P37, DOI 10.1097/YPG.0b013e3283413496
   Kumar V, 2013, ROBBINS PATHOLOGIC B
   Kurth I, 2009, NAT GENET, V41, P1179, DOI 10.1038/ng.464
   Lam AKY, 2008, HUM PATHOL, V39, P599, DOI 10.1016/j.humpath.2007.09.001
   Lam AKY, 2017, ENDOCR-RELAT CANCER, V24, pR109, DOI 10.1530/ERC-17-0014
   Lam AKY, 2011, AM J SURG, V202, P39, DOI 10.1016/j.amjsurg.2010.05.012
   Lennemann NJ, 2017, AUTOPHAGY, V13, P322, DOI 10.1080/15548627.2016.1265192
   LEWIS MJ, 1992, J MOL BIOL, V226, P913, DOI 10.1016/0022-2836(92)91039-R
   Murphy SM, 2012, J NEUROL NEUROSUR PS, V83, P119, DOI 10.1136/jnnp.2010.228965
   Rezaul Karim, 2010, Genes Cancer, V1, P251, DOI 10.1177/1947601910365896
   Ruggiero C, 2015, ONCOTARGET, V6, P3375, DOI 10.18632/oncotarget.3270
   Scheubert L, 2011, DNA RES, V18, P233, DOI 10.1093/dnares/dsr016
   SU LK, 1995, CANCER RES, V55, P2972
   Subramaniyan B, 2016, BIOMED PHARMACOTHER, V82, P413, DOI 10.1016/j.biopha.2016.05.027
   Tang JCO, 2001, CLIN CANCER RES, V7, P1539
   Tang WK, 2007, INT J MOL MED, V19, P915
   Wahab R, 2017, EUR J CELL BIOL, V96, P487, DOI 10.1016/j.ejcb.2017.07.003
   Xie SS, 2015, ONCOL REP, V33, P363, DOI 10.3892/or.2014.3577
   Zhang B, 2006, J PROTEOME RES, V5, P2909, DOI 10.1021/pr0600273
   Zhang TT, 2017, SCI REP-UK, V7, DOI 10.1038/srep45626
NR 47
TC 13
Z9 13
U1 1
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
EI 1098-2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD NOV
PY 2018
VL 57
IS 11
BP 1480
EP 1491
DI 10.1002/mc.22871
PG 12
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA GV7ML
UT WOS:000446311200005
PM 29964340
DA 2022-04-25
ER

PT J
AU Wang, HP
   Ye, T
   Cai, YK
   Chen, WJ
   Xie, HW
   Ke, CW
AF Wang, Huipeng
   Ye, Tao
   Cai, Yuankun
   Chen, Wenjie
   Xie, Hongwei
   Ke, Chongwei
TI Downregulation of Ascl2 promotes cell apoptosis by enhancing autophagy
   in colorectal cancer cells
SO JOURNAL OF GASTROINTESTINAL ONCOLOGY
LA English
DT Article
DE Autophagy; Ascl2; apoptosis; colorectal cancer (CRC)
ID BECLIN-1; LC3
AB Background: Colorectal cancer (CRC) is the third most common cancer, according to recently published literature. While the incidence and the mortality of CRC has decreased due to effective cancer screening measures, there has been an increase in the number of young patients diagnosed with colon cancer due to unclear reasons. As a target molecule of the Wnt signaling pathway, Ascl2 is an important marker of CRC stem cells and plays an important role in maintaining the nature of colon cancer stem/precursor cells. However, the role of Ascl2 in autophagy in CRC cells is rarely elucidated.
   Methods: In this study, we found that Ascl2 was increased in CRC compared with adjacent tissue. Downregulation of Ascl2 in CRC cells could suppress proliferation and invasion, and induce apoptosis, of CRC cells. Moreover, we found that autophagy-relative protein LC3 increased after Ascl2 knockdown. Furthermore, we treated CRC cells with autophagy inhibitors 3- MA (3-Methyladenine) and CQ (Chloroquine).
   Results: The results showed that autophagy inhibitors could prevent apoptosis, which was induced by Ascl2 knockdown. Finally, we confirmed that the downregulation of Ascl2 in CRC cells could alleviate the pathological process in vivo by xenograft experiment.
   Conclusions: Our findings indicated that si-Ascl2 (small/short interfering) exerted a tumor suppression function in CRC by inducing autophagic cell death, and suggest that Ascl2 targeted therapy represents a novel strategy for CRC treatment.
C1 [Wang, Huipeng; Ye, Tao; Cai, Yuankun; Chen, Wenjie; Xie, Hongwei; Ke, Chongwei] Fudan Univ, Peoples Hosp Shanghai 5, Dept Gen Surg, 801 Heqing Rd, Shanghai 200240, Peoples R China.
RP Xie, HW; Ke, CW (corresponding author), Fudan Univ, Peoples Hosp Shanghai 5, Dept Gen Surg, 801 Heqing Rd, Shanghai 200240, Peoples R China.
EM 13816819761@163.com; dr_kecw@163.com
FU Natural Science Foundation of Minhang, Shanghai [2018MHZ025,
   2018MHZ037]; Great Discipline Construction Project from The Fifth
   People's Hospital of Shanghai [2020WYZDZK02]; Leading Talent Foundation
   of Minhang, Shanghai [10-1]
FX This study was supported by the Natural Science Foundation of Minhang,
   Shanghai (No. 2018MHZ025), Natural Science Foundation of Minhang,
   Shanghai (No. 2018MHZ037) and the Great Discipline Construction Project
   from The Fifth People's Hospital of Shanghai (No. 2020WYZDZK02). Leading
   Talent Foundation of Minhang, Shanghai (No. 10-1).
CR Francois S, 2019, STEM CELL TRANSL MED, V8, P285, DOI 10.1002/sctm.18-0117
   Giatromanolaki A, 2010, J CLIN PATHOL, V63, P867, DOI 10.1136/jcp.2010.079525
   Guo GF, 2019, WORLD J GASTROENTERO, V25, P1840, DOI 10.3748/wjg.v25.i15.1840
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   Hale AN, 2013, AUTOPHAGY, V9, P951, DOI 10.4161/auto.24273
   Jubb AM, 2006, ONCOGENE, V25, P3445, DOI 10.1038/sj.onc.1209382
   Levy J, 2015, NAT CELL BIOL, V17, P1062, DOI 10.1038/ncb3206
   Lucas C, 2020, GASTROENTEROLOGY, V158, P1373, DOI 10.1053/j.gastro.2019.12.026
   Nozawa H, 2020, INT J COLORECTAL DIS, V35, P177, DOI 10.1007/s00384-019-03461-5
   Nozawa H, 2019, THER ADV MED ONCOL, V11, DOI 10.1177/1758835919838960
   Ou JJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08902-x
   Rosenbluh J, 2012, CELL, V151, P1457, DOI 10.1016/j.cell.2012.11.026
   Ryter SW, 2013, MOL CELLS, V36, P7, DOI 10.1007/s10059-013-0140-8
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Schmitz KJ, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0946-x
   Shang YY, 2017, EXP CELL RES, V360, P243, DOI 10.1016/j.yexcr.2017.09.014
   Shen T, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0638-9
   Singh SS, 2018, ONCOGENE, V37, P1142, DOI 10.1038/s41388-017-0046-6
   Sun K, 2013, CELL BIOSCI, V3, DOI 10.1186/2045-3701-3-35
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tanaka T, 2019, ANN SURG ONCOL, V26, P1401, DOI 10.1245/s10434-019-07172-7
   Thanikachalam K, 2019, NUTRIENTS, V11, DOI 10.3390/nu11010164
   Thorburn A, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001967
   van der Flier LG, 2009, CELL, V136, P903, DOI 10.1016/j.cell.2009.01.031
   Wang C, 2017, DEVELOPMENT, V144, P235, DOI 10.1242/dev.138099
   Wang QS, 2018, BIOCHEM BIOPH RES CO, V498, P1058, DOI 10.1016/j.bbrc.2018.03.118
   Zhang C, 2019, INT J COLORECTAL DIS, V34, P1661, DOI 10.1007/s00384-019-03362-7
   Zhou HY, 2016, CANCER BIOMARK, V17, P1, DOI 10.3233/CBM-160613
NR 28
TC 0
Z9 0
U1 2
U2 2
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2078-6891
EI 2219-679X
J9 J GASTROINTEST ONCOL
JI J. Gastrointest. Oncol.
PD APR
PY 2021
VL 12
IS 2
BP 630
EP 638
DI 10.21037/jgo-21-183
PG 9
WC Oncology; Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Gastroenterology & Hepatology
GA RV8MM
UT WOS:000646081100036
PM 34012655
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Shim, BY
   Sun, DS
   Won, HS
   Lee, MA
   Hong, SU
   Jung, JH
   Cho, HM
   Ko, YH
AF Shim, Byoung Yong
   Sun, Der Sheng
   Won, Hye Sung
   Lee, Myung Ah
   Hong, Soon Uk
   Jung, Ji-Han
   Cho, Hyeon-Min
   Ko, Yoon Ho
TI Role of autophagy-related protein expression in patients with rectal
   cancer treated with neoadjuvant chemoradiotherapy
SO BMC CANCER
LA English
DT Article
DE Rectal cancer; Neoadjuvant chemoradiotherapy; Autophagy; LC3 beta;
   Beclin-1; Prognosis
ID COLORECTAL-CANCER; TUMOR-SUPPRESSOR; COLON-CANCER; PREOPERATIVE
   RADIOTHERAPY; PROGNOSTIC-SIGNIFICANCE; BECLIN-1; CELLS; GENE; PATTERNS;
   THERAPY
AB Background: Autophagy, a cellular degradation process, has complex roles in tumourigenesis and resistance to cancer treatment in humans. The aim of this study was to explore the expression levels of autophagy-related proteins in patients with rectal cancer and evaluate their clinical role in the neoadjuvant chemoradiotherapy setting.
   Methods: All specimens evaluated were obtained from 101 patients with colorectal cancer who had undergone neoadjuvant chemoradiotherapy and curative surgery. The primary outcomes measured were the expression levels of two autophagy-related proteins (microtubule-associated protein 1 light chain 3 beta (LC3 beta) and beclin-1) by immunohistochemistry and their association with clinicopathological parameters and patient survival.
   Results: Among the 101 patients, the frequency of high expression of beclin-1 was 31.7 % (32/101) and that of LC3 beta was 46.5 % (47/101). A pathologic complete response was inversely associated with LC3 beta expression (P = 0.003) and alterations in the expression of autophagy-related proteins (P = 0.046). In the multivariate analysis, however, autophagy-related protein expression did not show prognostic significance for relapse-free survival or overall survival.
   Conclusions: High expression of autophagy-related proteins shows a strong negative association with the efficacy of neoadjuvant chemoradiotherapy in patients with rectal cancer. Autophagy has clear implications as a therapeutic target with which to improve the efficacy of neoadjuvant chemoradiotherapy.
C1 [Shim, Byoung Yong; Sun, Der Sheng; Won, Hye Sung; Lee, Myung Ah; Ko, Yoon Ho] Catholic Univ Korea, Coll Med, Dept Internal Med, Div Oncol, Seoul, South Korea.
   [Lee, Myung Ah; Ko, Yoon Ho] Catholic Univ Korea, Coll Med, Canc Res Inst, Seoul, South Korea.
   [Hong, Soon Uk] Chung Ang Univ, Coll Med, Dept Pathol, Seoul 156756, South Korea.
   [Jung, Ji-Han] Catholic Univ Korea, Coll Med, Dept Hosp Pathol, Seoul, South Korea.
   [Cho, Hyeon-Min] Catholic Univ Korea, Coll Med, Dept Gen Surg, Seoul, South Korea.
RP Ko, YH (corresponding author), Catholic Univ Korea, Coll Med, Dept Internal Med, Div Oncol, Seoul, South Korea.; Ko, YH (corresponding author), Catholic Univ Korea, Coll Med, Canc Res Inst, Seoul, South Korea.
EM koyoonho@catholic.ac.kr
FU Uijeongbu St Mary's Hospital
FX This study was supported by in part by Uijeongbu St Mary's Hospital
   research fund (Ko YH and Sun DS).
CR Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562
   Bosset JF, 2006, NEW ENGL J MED, V355, P1114, DOI 10.1056/NEJMoa060829
   Bristol ML, 2013, J PHARMACOL EXP THER, V344, P544, DOI 10.1124/jpet.112.199802
   Budinska E, 2013, J PATHOL, V231, P63, DOI 10.1002/path.4212
   Bujko K, 2004, RADIOTHER ONCOL, V72, P15, DOI 10.1016/j.radonc.2003.12.006
   Chen YS, 2009, PATHOL ONCOL RES, V15, P487, DOI 10.1007/s12253-008-9143-8
   Choi JH, 2014, GASTROENT RES PRACT, V2014, DOI 10.1155/2014/179586
   ClinicalTrials.gov, HYDR CAP OX BEV TREA
   Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966
   Giatromanolaki A, 2010, J CLIN PATHOL, V63, P867, DOI 10.1136/jcp.2010.079525
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Han Y, 2014, ASIAN PAC J CANCER P, V15, P4583, DOI 10.7314/APJCP.2014.15.11.4583
   Hu YL, 2012, CANCER RES, V72, P4294, DOI 10.1158/0008-5472.CAN-12-1076
   Hur H, 2014, DIS COLON RECTUM, V57, P592, DOI 10.1097/DCR.0000000000000109
   Kim MJ, 2011, J BIOL CHEM, V286, P12924, DOI 10.1074/jbc.M110.138958
   Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811
   Ko YH, 2013, PANCREAS, V42, P829, DOI 10.1097/MPA.0b013e318279d0dc
   Koneri K, 2007, ANTICANCER RES, V27, P1453
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Li DD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045058
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   Morselli E, 2011, CELL CYCLE, V10, P2763, DOI 10.4161/cc.10.16.16868
   Morselli E, 2009, BBA-MOL CELL RES, V1793, P1524, DOI 10.1016/j.bbamcr.2009.01.006
   Paillas S, 2012, AUTOPHAGY, V8, P1098, DOI 10.4161/auto.20268
   Sasaki K, 2012, ANTI-CANCER DRUG, V23, P675, DOI 10.1097/CAD.0b013e328353f8c7
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Sauer R, 2004, NEW ENGL J MED, V351, P1731, DOI 10.1056/NEJMoa040694
   Schonewolf CA, 2014, WORLD J GASTRO ONCOL, V6, P74, DOI 10.4251/wjgo.v6.i3.74
   Shen Y, 2008, AUTOPHAGY, V4, P1067, DOI 10.4161/auto.6827
   Spolverato Gaya, 2011, Cancers (Basel), V3, P2176, DOI 10.3390/cancers3022176
   Sui XB, 2011, AUTOPHAGY, V7, P565, DOI 10.4161/auto.7.6.14073
   Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634
   Tougeron D, 2014, J CLIN ONCOL S3, V32, P2318
   Winardi D, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/723176
   Won KY, 2010, HUM PATHOL, V41, P107, DOI 10.1016/j.humpath.2009.07.006
   Wu DH, 2014, TUMOR BIOL, V35, P12225, DOI 10.1007/s13277-014-2531-7
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yang ZL, 2015, CLIN RES HEPATOL GAS, V39, P98, DOI 10.1016/j.clinre.2014.06.014
   Yoshioka A, 2008, INT J ONCOL, V33, P461, DOI 10.3892/ijo_00000028
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zheng Hai-yang, 2012, Cancer Biology Medicine, V9, P105, DOI 10.3969/j.issn.2095-3941.2012.02.004
NR 48
TC 7
Z9 9
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD MAR 10
PY 2016
VL 16
AR 207
DI 10.1186/s12885-016-2250-0
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DF9HT
UT WOS:000371672400005
PM 26965179
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Huo, HZ
   Zhou, ZY
   Wang, B
   Qin, J
   Liu, WY
   Gu, Y
AF Huo, Hai-zhong
   Zhou, Zhi-yuan
   Wang, Bing
   Qin, Jian
   Liu, Wen-yong
   Gu, Yan
TI Dramatic suppression of colorectal cancer cell growth by the dual mTORC1
   and mTORC2 inhibitor AZD-2014
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Colorectal cancer; AZD-2014; mTOR complexes; Autophagy; Signaling
ID ACTIVATED PROTEIN-KINASE; DRUG-RESISTANCE; FACTOR RECEPTOR;
   COLON-CANCER; AUTOPHAGY; PATHWAY; DEATH; HEAD
AB Colorectal cancer is a major contributor of cancer-related mortality. The mammalian target or rapamycin (mTOR) signaling is frequently hyper-activated in colorectal cancers, promoting cancer progression and chemo-resistance. In the current study, we investigated the anti-colorectal cancer effect of a novel mTOR complex 1 (mTORC1) and mTORC2 dual inhibitor: AZD-2014. In cultured colorectal cancer cell lines, AZD-2014 significantly inhibited cancer cell growth without inducing significant cell apoptosis. AZD-2014 blocked activation of both mTORC1 (S6K and S6 phosphorylation) and mTORC2 (Akt Ser 473 phosphorylation), and activated autophagy in colorectal cancer cells. Meanwhile, autophagy inhibition by 3-methyaldenine (3-MA) and hydroxychloroquine, as well as by siRNA knocking down of Beclin-1 or ATG-7, inhibited AZD-2014-induced cytotoxicity, while the apoptosis inhibitor had no rescue effect. In vivo, AZD-2014 oral administration significantly inhibited the growth of HT-29 cell xenograft in SCID mice, and the mice survival was dramatically improved. At the same time, in xenografted tumors administrated with AZD-2014, the activation of mTORC1 and mTORC2 were largely inhibited, and autophagic markers were significantly increased. Thus, AZD-2014 inhibits colorectal cancer cell growth both in vivo and in vitro. Our results suggest that AZD-2014 may be further investigated for colorectal cancer therapy in clinical trials. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Huo, Hai-zhong; Zhou, Zhi-yuan; Wang, Bing; Qin, Jian; Liu, Wen-yong; Gu, Yan] Shanghai Jiao Tong Univ, Dept Gen Surg, Sch Med, Peoples Hosp 9, Shanghai 200011, Peoples R China.
RP Gu, Y (corresponding author), Shanghai Jiao Tong Univ, Dept Gen Surg, Sch Med, Peoples Hosp 9, 639 Zhizhaoju Rd, Shanghai 200011, Peoples R China.
EM drguyan@hotmail.com
RI Gu, Yan/AFQ-1163-2022
CR Amaravadi RK, 2007, CLIN CANCER RES, V13, P7271, DOI 10.1158/1078-0432.CCR-07-1595
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Bruzzese F, 2006, CLIN CANCER RES, V12, P617, DOI 10.1158/1078-0432.CCR-05-1671
   Chen A, 2006, ONCOGENE, V25, P278, DOI [10.1038/sj.onc.1209019, 10.1038/sj.onc.1209573]
   Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105
   Craighead MW, 1999, J NEUROSCI RES, V57, P236, DOI 10.1002/(SICI)1097-4547(19990715)57:2<236::AID-JNR9>3.0.CO;2-D
   Din FVN, 2012, GASTROENTEROLOGY, V142, P1504, DOI 10.1053/j.gastro.2012.02.050
   Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007
   Ekstrand AI, 2010, FAM CANCER, V9, P125, DOI 10.1007/s10689-009-9293-1
   Fang DD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067258
   Gomez-Pinillos A, 2012, HEMATOL ONCOL CLIN N, V26, P483, DOI 10.1016/j.hoc.2012.02.014
   Gorlick R, 1999, SEMIN ONCOL, V26, P606
   Gustin DM, 2002, CANCER METAST REV, V21, P323, DOI 10.1023/A:1021271229476
   Hardie DG, 2012, CHEM BIOL, V19, P1222, DOI 10.1016/j.chembiol.2012.08.019
   Huo HZ, 2013, MOL CELL BIOCHEM, V378, P171, DOI 10.1007/s11010-013-1608-8
   Juhasz G, 2007, GENE DEV, V21, P3061, DOI 10.1101/gad.1600707
   Kim EH, 2007, CANCER RES, V67, P6314, DOI 10.1158/0008-5472.CAN-06-4217
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Longley DB, 2006, BBA-REV CANCER, V1766, P184, DOI 10.1016/j.bbcan.2006.08.001
   Mohandas K M, 1999, Indian J Gastroenterol, V18, P118
   Pike KG, 2013, BIOORG MED CHEM LETT, V23, P1212, DOI 10.1016/j.bmcl.2013.01.019
   Plowey ED, 2008, J NEUROCHEM, V105, P1048, DOI 10.1111/j.1471-4159.2008.05217.x
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Scarlatti F, 2008, CELL DEATH DIFFER, V15, P1318, DOI 10.1038/cdd.2008.51
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Sommer K, 2001, INT J ONCOL, V18, P1145
   Sugiyama M, 2009, INT J ONCOL, V34, P339, DOI 10.3892/ijo_00000156
   Sun SY, 2013, CANCER LETT, V340, P1, DOI 10.1016/j.canlet.2013.06.017
   Zaytseva YY, 2012, CANCER LETT, V319, P1, DOI 10.1016/j.canlet.2012.01.005
NR 31
TC 39
Z9 40
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 10
PY 2014
VL 443
IS 2
BP 406
EP 412
DI 10.1016/j.bbrc.2013.11.099
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA AA5TQ
UT WOS:000331162900011
PM 24309100
DA 2022-04-25
ER

PT J
AU Xu, JY
   Zheng, FC
   Yu, WS
AF Xu, Jiayou
   Zheng, Fuchang
   Yu, Wensheng
TI MicroRNA-129-5p-mediated inhibition of autophagy enhanced the
   radiosensitivity of human colon cancer cells
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Review
DE microRNA-129-5P; autophagy; beclin-1; radiosensitivity; colon cancer
ID GLIOMA STEM-CELLS; GASTRIC-CANCER; MAMMALIAN AUTOPHAGY;
   COLORECTAL-CANCER; MALIGNANT GLIOMA; CARCINOMA-CELLS; POOR-PROGNOSIS;
   EXPRESSION; RADIORESISTANCE; RADIATION
AB The efficacy and outcome of radiotherapy in the treatment of colon cancer are much limited by radioresistance. Studies show microRNAs are involved in radioresistance in many cancers. In the present study, we aimed to explore the role of microRNA-129-5p in regulating radioresistance of colon cancer cells and its underlying mechanism. In the present study, we established a radioresistant colon cancer cell line. Compared with control group, miRNA-129-5p was significantly reduced whereas the autophagy was enhanced in radioresistant colon cancer cell line. Exotic expression of miRNA-129-5p was capable to inhibit beclin-1, a critical autophagy gene, and suppressed autophagy activity. Furthermore, we found beclin-1 was the direct target of miR-129-5p as evidenced by in silico analysis and luciferase reporter assay. In addition, overexpression of miRNA-129-5p inhibited cell growth and colony formation ability and promoted irradiation-induced apoptosis of radioresistant colon cancer cells. By contrast, overexpression of beclin-1 abolished the effects of miRNA-129-5p. In vivo, miRNA-129-5p sensitized xenograft tumor to irradiation. Taken together, the present study suggested that miRNA-129-5p significantly augmented the radiosensitivity of colon cancer cells through inhibiting beclin-1-mediated autophagy, hinting a promising new molecular target for the treatment of colon cancer.
C1 [Xu, Jiayou; Zheng, Fuchang; Yu, Wensheng] Weifang Peoples Hosp, Dept Gen Surg, 151 Guangwen St, Weifang 261041, Shandong, Peoples R China.
RP Xu, JY (corresponding author), Weifang Peoples Hosp, Dept Gen Surg, 151 Guangwen St, Weifang 261041, Shandong, Peoples R China.
EM xujiayou121@163.com
FU Shandong province natural science foundation of China [ZR2009CM116]
FX Research supported by the Shandong province natural science foundation
   of China (NO. ZR2009CM116).
CR Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562
   Bao LJ, 2014, INT J CLIN EXP PATHO, V7, P1502
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Brest P, 2011, ENDOCR-RELAT CANCER, V18, P711, DOI 10.1530/ERC-10-0257
   Chaachouay H, 2011, RADIOTHER ONCOL, V99, P287, DOI 10.1016/j.radonc.2011.06.002
   Cheng H, 2013, CURR MOL MED, V13, P1368, DOI 10.2174/15665240113139990060
   Crane CH, 2003, CANCER-AM CANCER SOC, V97, P517, DOI 10.1002/cncr.11075
   Daido S, 2005, CANCER RES, V65, P4368, DOI 10.1158/0008-5472.CAN-04-4202
   Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074
   Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179
   Han Melinda Y, 2014, Nano Converg, V1, P1, DOI 10.1186/s40580-014-0001-y
   Hatley ME, 2010, CANCER CELL, V18, P282, DOI 10.1016/j.ccr.2010.08.013
   Hedstrom G, 2013, INT J HEMATOL, V97, P465, DOI 10.1007/s12185-013-1303-2
   Hou ZB, 2012, MOL MED REP, V6, P501, DOI 10.3892/mmr.2012.946
   Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818
   Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868
   Ito H, 2005, INT J ONCOL, V26, P1401
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Liu CL, 2010, J NEUROCHEM, V115, P68, DOI 10.1111/j.1471-4159.2010.06905.x
   Liu Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035800
   Mannino M, 2011, MOL ONCOL, V5, P374, DOI 10.1016/j.molonc.2011.05.001
   Mazure NM, 2010, CURR OPIN CELL BIOL, V22, P177, DOI 10.1016/j.ceb.2009.11.015
   Miao LJ, 2014, TUMOR BIOL, V35, P7097, DOI 10.1007/s13277-014-1961-6
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Mlcochova J, 2013, J CANCER RES CLIN, V139, P1615, DOI 10.1007/s00432-013-1470-9
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   Ricard D, 2012, LANCET, V379, P1984, DOI 10.1016/S0140-6736(11)61346-9
   Rodel C, 2005, J CLIN ONCOL, V23, P8688, DOI 10.1200/JCO.2005.02.1329
   Roth P, 2011, J NEUROCHEM, V118, P449, DOI 10.1111/j.1471-4159.2011.07307.x
   Shang LB, 2011, P NATL ACAD SCI USA, V108, P4788, DOI 10.1073/pnas.1100844108
   Skvortsov S, 2011, RADIOTHER ONCOL, V101, P177, DOI 10.1016/j.radonc.2011.05.067
   Wang B, 2014, J NEUROCHEM, V130, P720, DOI 10.1111/jnc.12765
   Wang JL, 2010, STEM CELLS, V28, P17, DOI 10.1002/stem.261
   Wang M, 2012, MOL MED REP, V5, P1514, DOI 10.3892/mmr.2012.828
   Wang P, 2013, GASTROENTEROLOGY, V145, P1133, DOI 10.1053/j.gastro.2013.07.048
   Xu CJ, 2014, TUMOR BIOL, V35, P9701, DOI 10.1007/s13277-014-2274-5
   Yao Q, 2011, TUMOR BIOL, V32, P1163, DOI 10.1007/s13277-011-0219-9
   Yu H, 2013, INT J CLIN EXP PATHO, V6, P2904
   Zhang JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081366
NR 39
TC 0
Z9 0
U1 0
U2 3
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2016
VL 9
IS 12
BP 12179
EP 12187
PG 9
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA EF5YP
UT WOS:000390406200001
DA 2022-04-25
ER

PT J
AU Kauntz, H
   Bousserouel, S
   Gosse, F
   Raul, F
AF Kauntz, Henriette
   Bousserouel, Souad
   Gosse, Francine
   Raul, Francis
TI Silibinin triggers apoptotic signaling pathways and autophagic survival
   response in human colon adenocarcinoma cells and their derived
   metastatic cells
SO APOPTOSIS
LA English
DT Article
DE Colon cancer; Flavonoids; Apoptosis; Autophagy; TRAIL; Mitochondria
ID SILYBIN-PHYTOSOME; SUPPRESSES GROWTH; CANCER-CELLS; CYCLE ARREST; DEATH;
   RESVERATROL; ACTIVATION; TRAIL; CHEMOPREVENTION; PROLIFERATION
AB Silibinin, a flavonolignan isolated from the milk thistle plant (Silybum marianum), possesses antineoplastic properties. In vitro and in vivo studies have recently shown that silibinin inhibits the growth of colorectal cancer (CRC). The present study investigates the mechanisms of silibinin-induced cell death using an in vitro model of human colon cancer progression, consisting of primary tumor cells (SW480) and their derived metastatic cells (SW620) isolated from a metastasis of the same patient. Silibinin induced apoptotic cell death evidenced by DNA fragmentation and activation of caspase-3 in both cell lines. Silibinin enhanced the expression (protein and mRNA) of TNF-related apoptosis-inducing ligand (TRAIL) death receptors (DR4/DR5) at the cell surface in SW480 cells, and induced their expression in TRAIL-resistant SW620 cells normally not expressing DR4/DR5. Caspase-8 and -10 were activated demonstrating the involvement of the extrinsic apoptotic pathway in silibinin-treated SW480 and SW620 cells. The protein Bid was cleaved in SW480 cells indicating a cross-talk between extrinsic and intrinsic apoptotic pathway. We demonstrated that silibinin activated also the intrinsic apoptotic pathway in both cell lines, including the perturbation of the mitochondrial membrane potential, the release of cytochrome c into the cytosol and the activation of caspase-9. Simultaneously to apoptosis, silibinin triggered an autophagic response. The inhibition of autophagy with a specific inhibitor enhanced cell death, suggesting a cytoprotective function for autophagy in silibinin-treated cells. Taken together, our data show that silibinin initiated in SW480 and SW620 cells an autophagic-mediated survival response overwhelmed by the activation of both the extrinsic and intrinsic apoptotic pathways.
C1 [Kauntz, Henriette; Bousserouel, Souad; Gosse, Francine; Raul, Francis] Univ Strasbourg, IRCAD, Lab Nutr Canc Prevent, EA 4438, F-67091 Strasbourg, France.
RP Raul, F (corresponding author), Univ Strasbourg, IRCAD, Lab Nutr Canc Prevent, EA 4438, 1 Pl Hop, F-67091 Strasbourg, France.
EM francis.raul@ircad.u-strasbg.fr
FU Conseil Regional d'Alsace, FranceRegion Grand-Est
FX Henriette Kauntz is supported by a fellowship provided by the Conseil
   Regional d'Alsace, France.
CR Agarwal C, 2003, ONCOGENE, V22, P8271, DOI 10.1038/sj.onc.1207158
   de la Lastral CA, 2007, BIOCHEM SOC T, V35, P1156, DOI 10.1042/BST0351156
   Bijnsdorp IV, 2010, INT J CANCER, V126, P2457, DOI 10.1002/ijc.24943
   Chen Q, 2003, CELL DEATH DIFFER, V10, P323, DOI 10.1038/sj.cdd.4401148
   Cheung CWY, 2010, ANTI-CANCER AGENT ME, V10, P186
   Choi CH, 2010, MOL PHARMACOL, V78, P114, DOI 10.1124/mol.110.063495
   Cooper K, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI [10.3310/hta.14320, 10.3310/hta14320]
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   Duan WJ, 2010, J PHARMACOL SCI, V113, P48, DOI 10.1254/jphs.09315FP
   Ferlay J, 2010, EUR J CANCER, V46, P765, DOI 10.1016/j.ejca.2009.12.014
   Fischer B, 2005, BIOCHEM BIOPH RES CO, V334, P533, DOI 10.1016/j.bbrc.2005.06.125
   Flaig TW, 2007, INVEST NEW DRUG, V25, P139, DOI 10.1007/s10637-006-9019-2
   Flaig TW, 2010, PROSTATE, V70, P848, DOI 10.1002/pros.21118
   Gazak R, 2007, CURR MED CHEM, V14, P315, DOI 10.2174/092986707779941159
   Ghobrial IM, 2005, CA-CANCER J CLIN, V55, P178, DOI 10.3322/canjclin.55.3.178
   Gosse F, 2006, INT J ONCOL, V29, P423
   Gupta SC, 2010, CANCER METAST REV, V29, P405, DOI 10.1007/s10555-010-9235-2
   Gura T, 1997, SCIENCE, V277, P768, DOI 10.1126/science.277.5327.768
   Hewitt RE, 2000, J PATHOL, V192, P446
   Hogan FS, 2007, J SURG RES, V143, P58, DOI 10.1016/j.jss.2007.03.080
   Hoh C, 2006, CLIN CANCER RES, V12, P2944, DOI 10.1158/1078-0432.CCR-05-2724
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Kaur M, 2010, NEOPLASIA, V12, P415, DOI 10.1593/neo.10188
   Kaur M, 2009, MOL CANCER THER, V8, P2366, DOI 10.1158/1535-7163.MCT-09-0304
   Kim KH, 2000, CLIN CANCER RES, V6, P335
   Kong CKL, 2009, BIOCHEM PHARMACOL, V77, P1487, DOI 10.1016/j.bcp.2009.02.008
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Low ICC, 2010, ANTIOXID REDOX SIGN, V13, P807, DOI 10.1089/ars.2009.3050
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Maldonado ME, 2009, J CANC MOL, V5, P21
   Milhas D, 2005, J BIOL CHEM, V280, P19836, DOI 10.1074/jbc.M414358200
   Naithani R, 2008, CURR MED CHEM, V15, P1044, DOI 10.2174/092986708784221403
   Novo D, 1999, CYTOMETRY, V35, P55, DOI 10.1002/(SICI)1097-0320(19990101)35:1<55::AID-CYTO8>3.0.CO;2-2
   Opipari AW, 2004, CANCER RES, V64, P696, DOI 10.1158/0008-5472.CAN-03-2404
   Paglin S, 2001, CANCER RES, V61, P439
   Pan MH, 2011, MOL NUTR FOOD RES, V55, P32, DOI 10.1002/mnfr.201000412
   Riccardi C, 2006, NAT PROTOC, V1, P1458, DOI 10.1038/nprot.2006.238
   Russo M, 2010, BIOCHEM PHARMACOL, V80, P674, DOI 10.1016/j.bcp.2010.03.011
   Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304
   Singh RP, 2006, MOL CARCINOGEN, V45, P436, DOI 10.1002/mc.20223
   Singh RP, 2005, EUR J CANCER, V41, P1969, DOI 10.1016/j.ejca.2005.03.033
   Tyagi A, 2009, CANCER PREV RES, V2, P74, DOI 10.1158/1940-6207.CAPR-08-0095
   West NJ, 2009, CANCER EPIDEM BIOMAR, V18, P1680, DOI 10.1158/1055-9965.EPI-09-0006
   Yang SY, 2009, TRENDS MOL MED, V15, P225, DOI 10.1016/j.molmed.2009.03.003
NR 44
TC 58
Z9 62
U1 0
U2 13
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1360-8185
EI 1573-675X
J9 APOPTOSIS
JI Apoptosis
PD OCT
PY 2011
VL 16
IS 10
BP 1042
EP 1053
DI 10.1007/s10495-011-0631-z
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 889SK
UT WOS:000300093300007
PM 21779837
DA 2022-04-25
ER

PT J
AU Li, CH
   Zhang, K
   Pan, GZ
   Ji, HY
   Li, CY
   Wang, XW
   Hu, X
   Liu, RC
   Deng, LF
   Wang, Y
   Yang, LQ
   Cui, HJ
AF Li, Changhong
   Zhang, Kui
   Pan, Guangzhao
   Ji, Haoyan
   Li, Chongyang
   Wang, Xiaowen
   Hu, Xin
   Liu, Ruochen
   Deng, Longfei
   Wang, Yi
   Yang, Liqun
   Cui, Hongjuan
TI Dehydrodiisoeugenol inhibits colorectal cancer growth by endoplasmic
   reticulum stress-induced autophagic pathways
SO JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
LA English
DT Article
DE Colorectal cancer; Dehydrodiisoeugenol (DEH); Autophagy inhibition;
   Endoplasmic reticulum (ER) stress; Anticancer agent
ID COLON-CANCER; CELL-DEATH; ACTIVATION; METABOLITES; MODULATION;
   EXPRESSION; GUIDELINES; RECEPTORS; APOPTOSIS; DISEASE
AB Background Dehydrodiisoeugenol (DEH), a novel lignan component extracted from nutmeg, which is the seed of Myristica fragrans Houtt, displays noticeable anti-inflammatory and anti-allergic effects in digestive system diseases. However, the mechanism of its anticancer activity in gastrointestinal cancer remains to be investigated. Methods In this study, the anticancer effect of DEH on human colorectal cancer and its underlying mechanism were evaluated. Assays including MTT, EdU, Plate clone formation, Soft agar, Flow cytometry, Electron microscopy, Immunofluorescence and Western blotting were used in vitro. The CDX and PDX tumor xenograft models were used in vivo. Results Our findings indicated that treatment with DEH arrested the cell cycle of colorectal cancer cells at the G1/S phase, leading to significant inhibition in cell growth. Moreover, DEH induced strong cellular autophagy, which could be inhibited through autophagic inhibitors, with a rction in the DEH-induced inhibition of cell growth in colorectal cancer cells. Further analysis indicated that DEH also induced endoplasmic reticulum (ER) stress and subsequently stimulated autophagy through the activation of PERK/eIF2 alpha and IRE1 alpha/XBP-1 s/CHOP pathways. Knockdown of PERK or IRE1 alpha significantly decreased DEH-induced autophagy and retrieved cell viability in cells treated with DEH. Furthermore, DEH also exhibited significant anticancer activities in the CDX- and PDX-models. Conclusions Collectively, our studies strongly suggest that DEH might be a potential anticancer agent against colorectal cancer by activating ER stress-induced inhibition of autophagy.
C1 [Li, Changhong; Zhang, Kui; Pan, Guangzhao; Ji, Haoyan; Li, Chongyang; Wang, Xiaowen; Hu, Xin; Liu, Ruochen; Deng, Longfei; Yang, Liqun; Cui, Hongjuan] Southwest Univ, Coll Sericulture Text & Biomass Sci, State Key Lab Silkworm Genome Biol, 2 Tiansheng Rd, Chongqing 400716, Peoples R China.
   [Li, Changhong; Zhang, Kui; Pan, Guangzhao; Ji, Haoyan; Li, Chongyang; Wang, Xiaowen; Hu, Xin; Liu, Ruochen; Deng, Longfei; Yang, Liqun; Cui, Hongjuan] Southwest Univ, Med Res Inst, Canc Ctr, Chongqing 400716, Peoples R China.
   [Li, Changhong; Wang, Yi; Yang, Liqun; Cui, Hongjuan] Southwest Univ, Peoples Hosp Chongqing 9, Affiliated Hosp, Chongqing 400716, Peoples R China.
RP Yang, LQ (corresponding author), Southwest Univ, Coll Sericulture Text & Biomass Sci, State Key Lab Silkworm Genome Biol, 2 Tiansheng Rd, Chongqing 400716, Peoples R China.; Yang, LQ (corresponding author), Southwest Univ, Med Res Inst, Canc Ctr, Chongqing 400716, Peoples R China.; Yang, LQ (corresponding author), Southwest Univ, Peoples Hosp Chongqing 9, Affiliated Hosp, Chongqing 400716, Peoples R China.
EM cysylq@swu.edu.cn
RI Zhang, Kui/AAE-9324-2022
OI Zhang, Kui/0000-0001-9618-610X
FU National Key Research and Development Program of China [2016YFC1302204,
   2017YFC1308601]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China (NSFC) [31672496, 31802142,
   81872071]; Fundamental Research Funds for the Central
   UniversitiesFundamental Research Funds for the Central Universities
   [XDJK2020B006, XDJK2019C089]; China Postdoctoral Science FoundationChina
   Postdoctoral Science Foundation [2019 T120801, 2017 M620408]; Chongqing
   Natural Science foundation of Chongqing [cstc2019jcyj-zdxmX0033];
   Chongqing University Innovation Team Building Program [CXTDX201601010];
   Eyas Program of the Youth Innovative Talents Cultivation in Chongqing
   [CY200237]
FX This work was supported by the National Key Research and Development
   Program of China (2016YFC1302204, 2017YFC1308601), the National Natural
   Science Foundation of China (31672496, 31802142 and 81872071), project
   funded by the Fundamental Research Funds for the Central Universities
   (XDJK2020B006, XDJK2019C089), the China Postdoctoral Science Foundation
   (2019 T120801 and 2017 M620408), Chongqing Natural Science foundation of
   Chongqing (cstc2019jcyj-zdxmX0033), Chongqing University Innovation Team
   Building Program funded projects (CXTDX201601010) and the Eyas Program
   of the Youth Innovative Talents Cultivation in Chongqing (CY200237).
CR Al-Rawi SS, 2011, PROC FOOD SCI, V1, P1946, DOI 10.1016/j.profoo.2011.09.286
   Chen XZ, 2014, CHIN J INTEGR MED, V20, P450, DOI 10.1007/s11655-013-1544-1
   Choi JH, 2016, ONCOL LETT, V11, P2861, DOI 10.3892/ol.2016.4286
   Codogno P, 2010, CELL METAB, V11, P449, DOI 10.1016/j.cmet.2010.05.006
   Daniels MS, 2017, J CLIN ONCOL, V35, P2588, DOI 10.1200/JCO.2017.72.7222
   Deng GX, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-019-1487-2
   El-Alfy AT, 2009, J ETHNOPHARMACOL, V126, P280, DOI 10.1016/j.jep.2009.08.026
   Fang ZJ, 2018, CANCER LETT, V415, P58, DOI 10.1016/j.canlet.2017.11.040
   Gao C, 2010, NAT CELL BIOL, V12, P781, DOI 10.1038/ncb2082
   Hoyer-Hansen M, 2007, CELL DEATH DIFFER, V14, P1576, DOI 10.1038/sj.cdd.4402200
   Huang C, 2020, MOL BIOMED, V1, P1, DOI [10.1186/s43556-020-00003-2, DOI 10.1186/S43556-020-00003-2]
   Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755
   Krishnamachary B, 2003, CANCER RES, V63, P1138
   Lach-Trifilieff E, 2014, MOL CELL BIOL, V34, P606, DOI 10.1128/MCB.01307-13
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li C., 2020, DEV COMP IMMUNOL, V114, DOI DOI 10.1016/J.DCI.2020.103869
   Li F, 2015, J PROTEOME RES, V14, P1937, DOI 10.1021/pr5013152
   Li F, 2012, BIOMED CHROMATOGR, V26, P703, DOI 10.1002/bmc.1717
   Li TL, 2013, AUTOPHAGY, V9, P1057, DOI 10.4161/auto.24632
   Liu TY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10780-2
   Lv QQ, 2017, J PHARMACEUT BIOMED, V145, P725, DOI 10.1016/j.jpba.2017.07.045
   Maheswari U, 2018, APOPTOSIS, V23, P210, DOI 10.1007/s10495-018-1449-8
   Mikhaylova O, 2012, CANCER CELL, V21, P532, DOI 10.1016/j.ccr.2012.02.019
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Murakami Y, 2005, ARCH BIOCHEM BIOPHYS, V434, P326, DOI 10.1016/j.abb.2004.11.013
   New M, 2020, BIOLOGY-BASEL, V9, DOI 10.3390/biology9010007
   Pal M, 2014, IMMUNOL CELL BIOL, V92, P331, DOI 10.1038/icb.2014.16
   Pettersen K, 2020, J CACHEXIA SARCOPENI, V11, P195, DOI 10.1002/jcsm.12489
   Prakash E, 2013, UJFNS, V1, P1, DOI DOI 10.13189/UJFNS.2013.010101
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Rogov V, 2014, MOL CELL, V53, P167, DOI 10.1016/j.molcel.2013.12.014
   Schepetkin IA, 2016, J AGR FOOD CHEM, V64, P7156, DOI 10.1021/acs.jafc.6b03205
   Sepulveda AR, 2017, AM J CLIN PATHOL, V147, P221, DOI 10.1093/ajcp/aqw209
   Shimodaira Y, 2014, BIOCHEM BIOPH RES CO, V445, P524, DOI 10.1016/j.bbrc.2014.02.054
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Simmonds P, 2000, LANCET, V356, P968, DOI 10.1016/S0140-6736(00)02713-6
   Smeby J, 2018, ANN ONCOL, V29, P1227, DOI 10.1093/annonc/mdy085
   Towers CG, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201909033
   von Haehling S, 2017, J CACHEXIA SARCOPENI, V8, P1081, DOI 10.1002/jcsm.12261
   Wang FQ, 2017, FITOTERAPIA, V121, P86, DOI 10.1016/j.fitote.2017.06.021
   Wang SW, 2000, J FOOD DRUG ANAL, V8, P248
   Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594
   Xu DQ, 2016, EMBO J, V35, P496, DOI 10.15252/embj.201592864
   Xu DQ, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4570
   Xu DQ, 2016, AUTOPHAGY, V12, P1047, DOI 10.1080/15548627.2016.1163459
   Yang AH, 2015, CHEM-BIOL INTERACT, V237, P133, DOI 10.1016/j.cbi.2015.06.018
   Yang J, 2020, J CELL MOL MED, V24, P4245, DOI 10.1111/jcmm.15086
   Yin C, 2019, FASEB J, V33, P14036, DOI 10.1096/fj.201900233RR
   Zhang K., 2018, CELL DEATH DIS, V9, P1
   Zhang Z, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00213-8
NR 51
TC 1
Z9 1
U1 5
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1756-9966
J9 J EXP CLIN CANC RES
JI J. Exp. Clin. Cancer Res.
PD APR 10
PY 2021
VL 40
IS 1
AR 125
DI 10.1186/s13046-021-01915-9
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA RL6WB
UT WOS:000639109700002
PM 33838688
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Pal, I
   Parida, S
   Kumar, BNP
   Banik, P
   Dey, KK
   Chakraborty, S
   Bhutia, SK
   Mandal, M
AF Pal, Ipsita
   Parida, Sheetal
   Kumar, B. N. Prashanth
   Banik, Payel
   Dey, Kaushik Kumar
   Chakraborty, Sandipan
   Bhutia, Sujit K.
   Mandal, Mahitosh
TI Blockade of autophagy enhances proapoptotic potential of BI-69A11, a
   novel Akt inhibitor, in colon carcinoma
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Autophagy; Colon cancer; Apoptosis; Beclin-1; BI-69A11; HSP90
ID ACTIVATED PROTEIN-KINASE; BECLIN 1; COLORECTAL-CANCER; TARGETING
   AUTOPHAGY; APOPTOSIS; TUMORIGENESIS; CHLOROQUINE; GROWTH;
   PHOSPHORYLATION; MUTATIONS
AB BI-69A11, novel Akt inhibitor, is currently drawing much attention due to its intriguing effect in inducing apoptosis in melanoma, breast, prostate and colon cancer. However, earlier reports reveal that PI3K/Akt/mTOR inhibitors promote autophagy at the early stage as a survival mechanism that might affect its apoptotic potential. It is necessary to investigate whether BI-69A11 mediated apoptosis is associated with autophagy for enhancing its therapeutic efficacy. Here, we found that BI-69A11 induced autophagy at earlier time point through the inhibition of Akt/mTOR/p70S6kinase pathway. Dose-dependent and time-dependent conversion of LC3-I to LC3-II, increased accumulation of LC3-GFP dots in cytoplasm and increase in other autophagic markers such as Beclin-1, firmly supported the fact that BI-69A11 induces autophagy. Atg5, Atg7 and Beclin-1 siRNA mediated genetic attenuation and pre-treatment with pharmacological inhibitor 3-MA and CQ diminished the autophagy and increased the propensity of cell death towards apoptosis. It was also suggested that BI-69A11 mediated interaction between Akt, HSP-90 and Beclin-1 maintained the fine balance between autophagy and apoptosis. Interaction between Beclin-1 and HSP90 is one of the prime causes of induction of autophagy. Here, we also generated a novel combination therapy by pretreatment with CQ that inhibited the autophagy and accelerated the apoptotic potential of BI-69A11. In summary; our findings suggest that induction of autophagy lead to the resistance of colon cancer towards BI-69A11 mediated apoptosis. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Pal, Ipsita; Parida, Sheetal; Kumar, B. N. Prashanth; Banik, Payel; Dey, Kaushik Kumar; Mandal, Mahitosh] Indian Inst Technol, Sch Med Sci & Technol, Kharagpur 721302, W Bengal, India.
   [Chakraborty, Sandipan] Apollo Gleneagles Hosp, Kolkata, W Bengal, India.
   [Bhutia, Sujit K.] Natl Inst Technol Rourkela, Dept Life Sci, Rourkela, Odisha, India.
RP Mandal, M (corresponding author), Indian Inst Technol, Sch Med Sci & Technol, Kharagpur 721302, W Bengal, India.
EM mahitosh@smst.iikgp.ernet.in
RI Bhusetty Nagesh, Prashanth Kumar/ABH-4999-2020; Dey, Kaushik
   Kumar/H-5997-2018; Mandal, Mahitosh/Q-7421-2016; Pal,
   Ipsita/AAX-4410-2020
OI Bhusetty Nagesh, Prashanth Kumar/0000-0003-3518-405X; Dey, Kaushik
   Kumar/0000-0002-9594-6362; Mandal, Mahitosh/0000-0003-3861-3323; 
FU University Grant CommissionUniversity Grants Commission, India
   [20-12/2009(ii)EU-IV]
FX We thank University Grant Commission for providing of fellowship
   (20-12/2009(ii)EU-IV). We thank Dr. Rupesh dash and Priyanka Halder for
   helpful discussions and proofing of this manuscript. We also thank Dr. P
   B Fisher and Dr. Maurizio Pellecchia for providing us the key compound
   BI-69A11 for research purpose and for their kind help.
CR Abrahamsen H, 2012, FEBS LETT, V586, P1584, DOI 10.1016/j.febslet.2012.04.046
   Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Andreyev HJN, 1998, J NATL CANCER I, V90, P675, DOI 10.1093/jnci/90.9.675
   Bagatell R, 2004, MOL CANCER THER, V3, P1021
   Bhutia SK, 2013, ADV CANCER RES, V118, P61, DOI 10.1016/B978-0-12-407173-5.00003-0
   Decuypere Jean-Paul, 2012, Cells, V1, P284, DOI 10.3390/cells1030284
   Din FVN, 2012, GASTROENTEROLOGY, V142, P1504, DOI 10.1053/j.gastro.2012.02.050
   Drullion C, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.111
   Dunlop EA, 2011, AUTOPHAGY, V7, P737, DOI 10.4161/auto.7.7.15491
   Easton JB, 2006, ONCOGENE, V25, P6436, DOI 10.1038/sj.onc.1209886
   Feng YM, 2011, PIGM CELL MELANOMA R, V24, P703, DOI 10.1111/j.1755-148X.2011.00867.x
   Forino M, 2005, J MED CHEM, V48, P2278, DOI 10.1021/jm048962u
   Gaitonde S, 2009, PIGM CELL MELANOMA R, V22, P187, DOI 10.1111/j.1755-148X.2009.00544.x
   Han WD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018691
   He CC, 2010, CURR OPIN CELL BIOL, V22, P140, DOI 10.1016/j.ceb.2010.01.001
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367
   Hostein I, 2001, CANCER RES, V61, P4003
   Jiang QA, 2011, MOL BIOL CELL, V22, P1167, DOI 10.1091/mbc.E10-10-0860
   Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Li XQ, 2010, CANCER RES, V70, P5942, DOI 10.1158/0008-5472.CAN-10-0157
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Miyaki M, 2007, INT J CANCER, V121, P1627, DOI 10.1002/ijc.22829
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Mizushima N, 2009, METHOD ENZYMOL, V452, P13, DOI 10.1016/S0076-6879(08)03602-1
   Moser C., 2009, ANTICANCER RES, V29
   Nosho K, 2008, NEOPLASIA, V10, P534, DOI 10.1593/neo.08336
   Pal I, 2014, BRIT J CANCER, V111, P101, DOI 10.1038/bjc.2014.227
   Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491
   Puissant A, 2012, AM J CANCER RES, V2, P397
   Puissant A, 2010, CELL CYCLE, V9, P3470, DOI 10.4161/cc.9.17.13048
   Rajput S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061342
   Rosenfeldt MT, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001306
   Sarkar S, 2010, CANCER BIOL THER, V9, P592, DOI 10.4161/cbt.9.8.11103
   Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533
   Seitz C, 2013, INT J CANCER, V132, P2682, DOI 10.1002/ijc.27935
   Shimizu S, 2012, INT J CANCER, V131, P548, DOI 10.1002/ijc.26374
   Solomon VR, 2009, EUR J PHARMACOL, V625, P220, DOI 10.1016/j.ejphar.2009.06.063
   Sotelo J, 2006, ANN INTERN MED, V144, P337, DOI 10.7326/0003-4819-144-5-200603070-00008
   Tschan MP, 2010, J INTERN MED, V268, P410, DOI 10.1111/j.1365-2796.2010.02266.x
   Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777
   Wang RC, 2012, SCIENCE, V338, P956, DOI 10.1126/science.1225967
   Xu CF, 2011, FASEB J, V25, P2700, DOI 10.1096/fj.10-167676
NR 49
TC 9
Z9 9
U1 1
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD OCT 15
PY 2015
VL 765
BP 217
EP 227
DI 10.1016/j.ejphar.2015.08.039
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CV4PN
UT WOS:000364249100027
PM 26306675
DA 2022-04-25
ER

PT J
AU Devenport, SN
   Shah, YM
AF Devenport, Samantha N.
   Shah, Yatrik M.
TI Functions and Implications of Autophagy in Colon Cancer
SO CELLS
LA English
DT Review
DE autophagy; nutrient; cancer; colon
ID HYPOXIA-INDUCED AUTOPHAGY; TUMOR-CELL SURVIVAL; COLORECTAL-CANCER;
   EPITHELIAL-CELLS; MITOPHAGY; PROTEIN; DEGRADATION; INHIBITION;
   EXPRESSION; STARVATION
AB Autophagy is an essential function to breakdown cellular proteins and organelles to recycle for new nutrient building blocks. In colorectal cancer, the importance of autophagy is becoming widely recognized as it demonstrates both pro- and anti-tumorigenic functions. In colon cancer, cell autonomous and non-autonomous roles for autophagy are essential in growth and progression. However, the mechanisms downstream of autophagy (to reduce or enhance tumor growth) are not well known. Additionally, the signals that activate and coordinate autophagy for tumor cell growth and survival are not clear. Here, we highlight the context- and cargo-dependent role of autophagy in proliferation, cell death, and cargo breakdown.
C1 [Devenport, Samantha N.; Shah, Yatrik M.] Univ Michigan, Cellular & Mol Biol, Ann Arbor, MI 48109 USA.
   [Devenport, Samantha N.; Shah, Yatrik M.] Univ Michigan, Internal Med, Div Gastroenterol, Mol & Integrat Physiol, Ann Arbor, MI 48109 USA.
   [Devenport, Samantha N.; Shah, Yatrik M.] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA.
RP Shah, YM (corresponding author), Univ Michigan, Cellular & Mol Biol, Ann Arbor, MI 48109 USA.; Shah, YM (corresponding author), Univ Michigan, Internal Med, Div Gastroenterol, Mol & Integrat Physiol, Ann Arbor, MI 48109 USA.; Shah, YM (corresponding author), Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA.
EM sdevenpo@umich.edu; shahy@umich.edu
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01CA148828, R01DK095201, T32GM007315,
   T32CA140044]; NATIONAL CANCER INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [T32CA140044, R01CA148828] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND
   KIDNEY DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK095201] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [T32GM007315] Funding Source: NIH RePORTER
FX This work was supported by the NIH, R01CA148828 and R01DK095201 to
   Y.M.S, and T32GM007315 and T32CA140044 to S.N.D.
CR Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Al Azzaz J, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03149
   Alves S, 2015, ONCOTARGET, V6, P30787, DOI 10.18632/oncotarget.5021
   An H, 2018, NAT CELL BIOL, V20, P135, DOI 10.1038/s41556-017-0007-x
   Anding AL, 2017, DEV CELL, V41, P10, DOI 10.1016/j.devcel.2017.02.016
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Bhujabal Z, 2017, EMBO REP, V18, P947, DOI 10.15252/embr.201643147
   Boyle KA, 2018, J BIOL CHEM, V293, P14891, DOI 10.1074/jbc.RA117.001469
   Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Burger E, 2018, CELL HOST MICROBE, V23, P177, DOI 10.1016/j.chom.2018.01.001
   Canavan C, 2006, ALIMENT PHARM THER, V23, P1097, DOI 10.1111/j.1365-2036.2006.02854.x
   Carew JS, 2010, J CELL MOL MED, V14, P2448, DOI 10.1111/j.1582-4934.2009.00832.x
   Che J, 2019, MOL CARCINOGEN, V58, P1234, DOI 10.1002/mc.23006
   Cho DH, 2012, ANTICANCER RES, V32, P4091
   Chourasia AH, 2015, EMBO REP, V16, P1145, DOI 10.15252/embr.201540759
   Cianci R, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/2912539
   Conway KL, 2013, GASTROENTEROLOGY, V145, P1347, DOI 10.1053/j.gastro.2013.08.035
   Costa JR, 2016, ONCOTARGET, V7, P41203, DOI 10.18632/oncotarget.9754
   CUERVO AM, 1995, EUR J BIOCHEM, V227, P792, DOI 10.1111/j.1432-1033.1995.tb20203.x
   Dany M, 2016, BLOOD, V128, P1944, DOI 10.1182/blood-2016-04-708750
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Dengjel J, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.014035
   DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8
   Dong Y, 2019, EUR REV MED PHARMACO, V23, P1047, DOI 10.26355/eurrev_201902_16992
   Eaden JA, 2001, GUT, V48, P526, DOI 10.1136/gut.48.4.526
   Eiyama A, 2013, FEBS LETT, V587, P1787, DOI 10.1016/j.febslet.2013.04.030
   Eling Nils, 2015, Oncoscience, V2, P517
   Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235
   Fitzwalter BE, 2018, DEV CELL, V44, P555, DOI 10.1016/j.devcel.2018.02.014
   Gao C, 2010, NAT CELL BIOL, V12, P781, DOI 10.1038/ncb2082
   Garbar C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07489-x
   Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012
   Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Guo WJ, 2014, AUTOPHAGY, V10, P972, DOI 10.4161/auto.28374
   Hollville E, 2014, MOL CELL, V55, P451, DOI 10.1016/j.molcel.2014.06.001
   Hooper LV, 2012, SCIENCE, V336, P1268, DOI 10.1126/science.1223490
   Howlader N, 2016, SEER CANC STAT REV 1
   Hu B, 2013, P NATL ACAD SCI USA, V110, P9862, DOI 10.1073/pnas.1307575110
   Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831
   Iwata J, 2006, J BIOL CHEM, V281, P4035, DOI 10.1074/jbc.M512283200
   Jiang GM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0944-z
   Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249
   Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131
   Kameyama H, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957-018-1428-0
   Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509
   Katarzyna ZR, 2016, BIOCHEM SOC T, V44, P431, DOI 10.1042/BST20150268
   Kim J, 2018, BIOCHEM BIOPH RES CO, V496, P159, DOI 10.1016/j.bbrc.2018.01.017
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kohli L, 2013, CANCER RES, V73, P4395, DOI 10.1158/0008-5472.CAN-12-3765
   Kon M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003182
   Kostic AD, 2013, CELL HOST MICROBE, V14, P207, DOI 10.1016/j.chom.2013.07.007
   Kosumi K, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1284720
   Koustas E, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207227
   Kuballa P, 2012, ANNU REV IMMUNOL, V30, P611, DOI 10.1146/annurev-immunol-020711-074948
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levy J, 2015, NAT CELL BIOL, V17, P1062, DOI 10.1038/ncb3206
   Liu C, 2018, BIOCHEM PHARMACOL, V155, P366, DOI 10.1016/j.bcp.2018.07.010
   Liu L, 2011, LEUKEMIA, V25, P23, DOI 10.1038/leu.2010.225
   Liu L, 2014, CELL RES, V24, P787, DOI 10.1038/cr.2014.75
   Liu L, 2012, NAT CELL BIOL, V14, P177, DOI 10.1038/ncb2422
   Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500
   Louandre C, 2013, INT J CANCER, V133, P1732, DOI 10.1002/ijc.28159
   Lu CM, 2014, GASTROENTEROLOGY, V146, P188, DOI 10.1053/j.gastro.2013.09.006
   Mai CT, 2019, MOL IMMUNOL, V105, P76, DOI 10.1016/j.molimm.2018.10.015
   Mancias JD, 2014, NATURE, V509, P105, DOI 10.1038/nature13148
   Manz DH, 2016, ANN NY ACAD SCI, V1368, P149, DOI 10.1111/nyas.13008
   Martins WK, 2016, AUTOPHAGY IN CURRENT TRENDS IN CELLULAR PHYSIOLOGY AND PATHOLOGY, P349, DOI 10.5772/63976
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mathew R, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.975638
   Mathew R, 2014, MOL CELL, V55, P916, DOI 10.1016/j.molcel.2014.07.019
   Meijer AJ, 2015, AMINO ACIDS, V47, P2037, DOI 10.1007/s00726-014-1765-4
   Mejlvang J, 2018, J CELL BIOL, V217, P3640, DOI 10.1083/jcb.201711002
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Mo SB, 2019, CARCINOGENESIS, V40, P861, DOI 10.1093/carcin/bgz031
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   National Cancer Institute, 2017, SURV EP END RES SEER
   NELSON RL, 1994, JNCI-J NATL CANCER I, V86, P455, DOI 10.1093/jnci/86.6.455
   Nighot PK, 2015, J BIOL CHEM, V290, P7234, DOI 10.1074/jbc.M114.597492
   Niklaus M, 2017, ONCOTARGET, V8, P54604, DOI 10.18632/oncotarget.17554
   Onodera J, 2005, J BIOL CHEM, V280, P31582, DOI 10.1074/jbc.M506736200
   Pott J, 2018, AUTOPHAGY, V14, P1460, DOI 10.1080/15548627.2018.1450021
   Poulogiannis G, 2010, P NATL ACAD SCI USA, V107, P15145, DOI 10.1073/pnas.1009941107
   Pyo JO, 2012, EXP MOL MED, V44, P73, DOI 10.3858/emm.2012.44.2.029
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Roczniak-Ferguson A, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002790
   Sakitani K, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1789-5
   Sanchez-Garrido J, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aat6903
   Sargent G, 2016, J CELL BIOL, V214, P677, DOI 10.1083/jcb.201511034
   Scherz-Shouval R, 2010, P NATL ACAD SCI USA, V107, P18511, DOI 10.1073/pnas.1006124107
   Schroll MM, 2017, J PROTEOME RES, V16, P3009, DOI 10.1021/acs.jproteome.7b00293
   Schroll MM, 2016, NUTR RES, V36, P1068, DOI 10.1016/j.nutres.2016.08.002
   Shao LN, 2016, MOL MED REP, V13, P2661, DOI 10.3892/mmr.2016.4820
   Shi J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.278
   Shirane M, 2003, NAT CELL BIOL, V5, P28, DOI 10.1038/ncb894
   Shuvayeva G, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/505041
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Sui SY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1564-7
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Tampakis A, 2014, ANTI-CANCER AGENT ME, V14, P1220, DOI 10.2174/1871520614666140919095828
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Thomas M, 2018, CELL BIOCHEM FUNCT, V36, P65, DOI 10.1002/cbf.3318
   Travassos LH, 2010, NAT IMMUNOL, V11, P55, DOI 10.1038/ni.1823
   Triner D, 2019, GASTROENTEROLOGY, V156, P1467, DOI 10.1053/j.gastro.2018.12.003
   Vakifahmetoglu-Norberg H, 2016, GENE DEV, V30, P870, DOI 10.1101/gad.280453.116
   da Silva-Camargo CCV, 2018, CANCER BIOL MED, V15, P61, DOI 10.20892/j.issn.2095-3941.2017.0136
   Vives-Bauza C, 2010, P NATL ACAD SCI USA, V107, P378, DOI 10.1073/pnas.0911187107
   von Stockum Sophia, 2018, Oncotarget, V9, P12550, DOI 10.18632/oncotarget.23799
   Waite KA, 2016, J BIOL CHEM, V291, P3239, DOI 10.1074/jbc.M115.699124
   Walter KM, 2014, CELL METAB, V20, P882, DOI 10.1016/j.cmet.2014.09.017
   Wang HW, 2014, J CANCER RES CLIN, V140, P561, DOI 10.1007/s00432-014-1596-4
   Wang SL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00693
   Wang XF, 2016, CLIN CANCER RES, V22, P1445, DOI 10.1158/1078-0432.CCR-15-0732
   Wei Y, 2019, INT J BIOL SCI, V15, P942, DOI 10.7150/ijbs.30930
   Weil J, 2016, NAT IMMUNOL, V17, P277, DOI 10.1038/ni.3365
   Wiegering A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075292
   Wu YH, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0031-8
   Wyant GA, 2018, SCIENCE, V360, P751, DOI 10.1126/science.aar2663
   Xiao T, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1113-9
   Xie Y, 2016, CELL DEATH DIFFER, V23, P369, DOI 10.1038/cdd.2015.158
   Xu Y, 2019, CELL, V178, P552, DOI 10.1016/j.cell.2019.06.007
   Xue X, 2014, AM J PHYSIOL-GASTR L, V307, pG187, DOI 10.1152/ajpgi.00112.2014
   Yachida S, 2019, NAT MED, V25, P968, DOI 10.1038/s41591-019-0458-7
   Yan C, 2018, ANTICANCER RES, V38, P617, DOI 10.21873/anticanres.12266
   Yang LY, 2018, APPL ENVIRON MICROB, V84, DOI 10.1128/AEM.00880-18
   Yao CW, 2017, BIOMOL THER, V25, P315, DOI 10.4062/biomolther.2016.069
   Yao Y, 2017, BIOMOLECULES, V7, DOI 10.3390/biom7030051
   Yoo SM, 2018, MOL CELLS, V41, P18, DOI 10.14348/molcells.2018.2277
   You PT, 2018, BIOMED PHARMACOTHER, V98, P619, DOI 10.1016/j.biopha.2017.12.057
   Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028
   Zhang TM, 2016, J BIOL CHEM, V291, P21616, DOI 10.1074/jbc.M116.733410
   Zheng YT, 2009, J IMMUNOL, V183, P5909, DOI 10.4049/jimmunol.0900441
   Zhou J, 2015, AUTOPHAGY, V11, P1259, DOI 10.1080/15548627.2015.1056970
   Zhu YY, 2013, J BIOL CHEM, V288, P1099, DOI 10.1074/jbc.M112.399345
   Ziegler PK, 2018, CELL, V174, P88, DOI 10.1016/j.cell.2018.05.028
NR 137
TC 28
Z9 28
U1 3
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD NOV
PY 2019
VL 8
IS 11
AR 1349
DI 10.3390/cells8111349
PG 18
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA JV3LB
UT WOS:000502266700047
PM 31671556
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Inoue, T
   Hayashi, Y
   Tsujii, Y
   Yoshii, S
   Sakatani, A
   Kimura, K
   Uema, R
   Kato, M
   Saiki, H
   Shinzaki, S
   Iijima, H
   Takehara, T
AF Inoue, Takanori
   Hayashi, Yoshito
   Tsujii, Yoshiki
   Yoshii, Shunsuke
   Sakatani, Akihiko
   Kimura, Keiichi
   Uema, Ryotaro
   Kato, Minoru
   Saiki, Hirotsugu
   Shinzaki, Shinichiro
   Iijima, Hideki
   Takehara, Tetsuo
TI Suppression of autophagy promotes fibroblast activation in p53-deficient
   colorectal cancer cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MICRORNA TARGET PREDICTION; TUMOR; GROWTH; PROGRESSION; METASTASIS;
   METABOLISM
AB Deficiency of p53 in cancer cells activates the transformation of normal tissue fibroblasts into carcinoma-associated fibroblasts; this promotes tumor progression through a variety of mechanisms in the tumor microenvironment. The role of autophagy in carcinoma-associated fibroblasts in tumor progression has not been elucidated. We aimed to clarify the significance of autophagy in fibroblasts, focusing on the TP53 status in co-cultured human colorectal cancer cell lines (TP53-wild-type colon cancer, HCT116; TP53-mutant colon cancer, HT29; fibroblast, CCD-18Co) in vitro. Autophagy in fibroblasts was significantly suppressed in association with ACTA2, CXCL12, TGF beta 1, VEGFA, FGF2, and PDGFRA mRNA levels, when co-cultured with p53-deficient HCT116(sh p53) cells. Exosomes isolated from the culture media of HCT116(sh p53) cells significantly suppressed autophagy in fibroblasts via inhibition of ATG2B. Exosomes derived from TP53-mutant HT29 cells also suppressed autophagy in fibroblasts. miR-4534, extracted from the exosomes of HCT116(sh p53) cells, suppressed ATG2B in fibroblasts. In conclusion, a loss of p53 function in colon cancer cells promotes the activation of surrounding fibroblasts through the suppression of autophagy. Exosomal miRNAs derived from cancer cells may play a pivotal role in the suppression of autophagy.
C1 [Inoue, Takanori; Hayashi, Yoshito; Tsujii, Yoshiki; Yoshii, Shunsuke; Sakatani, Akihiko; Kimura, Keiichi; Uema, Ryotaro; Kato, Minoru; Saiki, Hirotsugu; Shinzaki, Shinichiro; Iijima, Hideki; Takehara, Tetsuo] Osaka Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, Suita, Osaka, Japan.
RP Takehara, T (corresponding author), Osaka Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, Suita, Osaka, Japan.
EM takehara@gh.med.osaka-u.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology, Japan
   (JSPS KAKENHI) [JP17K15944, JP15K19326, JP19K08420]
FX This study was supported by grants from the Ministry of Education,
   Culture, Sports, Science and Technology, Japan (JSPS KAKENHI JP17K15944
   to S.Y., JP15K19326 and JP19K08420 to Y.H.).
CR Baroni S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.224
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   CARSON DA, 1995, LANCET, V346, P1009, DOI 10.1016/S0140-6736(95)91693-8
   Chaudhri VK, 2013, MOL CANCER RES, V11, P579, DOI 10.1158/1541-7786.MCR-12-0437-T
   Del Principe D, 2013, J PATHOL, V229, P208, DOI 10.1002/path.4115
   Elkhattouti A, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00158
   Fujita Y, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.28388
   Gascard P, 2016, GENE DEV, V30, P1002, DOI 10.1101/gad.279737.116
   Gu JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052465
   Hayashi Y, 2016, CARCINOGENESIS, V37, P972, DOI 10.1093/carcin/bgw085
   Herrera M, 2013, CLIN CANCER RES, V19, P5914, DOI 10.1158/1078-0432.CCR-13-0694
   Koliaraki V, 2017, GASTROENTEROLOGY, V152, P964, DOI 10.1053/j.gastro.2016.11.049
   Li DD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045058
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Mah LY, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008821
   Melling GE, 2018, CARCINOGENESIS, V39, P798, DOI 10.1093/carcin/bgy032
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Nip H, 2016, ONCOTARGET, V7, P68371, DOI 10.18632/oncotarget.12031
   Novo D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07339-y
   Pang WJ, 2015, CANCER SCI, V106, P1362, DOI 10.1111/cas.12747
   Pavlides S, 2012, ANTIOXID REDOX SIGN, V16, P1264, DOI 10.1089/ars.2011.4243
   Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865
   Santana-Codina N, 2017, ANNU REV CANC BIOL, V1, P19, DOI 10.1146/annurev-cancerbio-041816-122338
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Shinagawa K, 2010, INT J CANCER, V127, P2323, DOI 10.1002/ijc.25440
   Strohecker AM, 2013, CANCER DISCOV, V3, P1272, DOI 10.1158/2159-8290.CD-13-0397
   Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Tanaka K, 2015, CARCINOGENESIS, V36, P894, DOI 10.1093/carcin/bgv067
   Tang ZY, 2019, AUTOPHAGY, V15, P2165, DOI 10.1080/15548627.2019.1666594
   Valverde DP, 2019, J CELL BIOL, V218, P1787, DOI 10.1083/jcb.201811139
   Wang Q, 2016, CELL CYCLE, V15, P1376, DOI 10.1080/15384101.2016.1170269
   Wang XW, 2016, BIOINFORMATICS, V32, P1316, DOI 10.1093/bioinformatics/btw002
   Wong N, 2015, NUCLEIC ACIDS RES, V43, pD146, DOI 10.1093/nar/gku1104
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yoshii S, 2019, CANCER SCI, V110, P2396, DOI 10.1111/cas.14084
   Yu L, 2018, AUTOPHAGY, V14, P207, DOI 10.1080/15548627.2017.1378838
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zhang YY, 2019, J CELL BIOCHEM, V120, P13187, DOI 10.1002/jcb.28593
NR 39
TC 1
Z9 1
U1 5
U2 5
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 30
PY 2021
VL 11
IS 1
AR 19524
DI 10.1038/s41598-021-98865-1
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA WA2RB
UT WOS:000702737500056
PM 34593902
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Xiao, T
   Zhu, W
   Huang, W
   Lu, SS
   Li, XH
   Xiao, ZQ
   Yi, H
AF Xiao, Ta
   Zhu, Wei
   Huang, Wei
   Lu, Shan-Shan
   Li, Xin-Hui
   Xiao, Zhi-Qiang
   Yi, Hong
TI RACK1 promotes tumorigenicity of colon cancer by inducing cell autophagy
SO CELL DEATH & DISEASE
LA English
DT Article
ID PROTEIN; SENESCENCE; RECEPTOR; ACTIVATION; CARCINOMA; GROWTH; JNK;
   PHOSPHORYLATION; EXPRESSION; PREDICTOR
AB RACK1 is upregulated in the various types of human cancers, and considered to play a role in the development and progression of human cancer. However, the role and mechanism of RACK in the colon cancer are poorly understood. In this study, we detected RACK1 expression in 63 normal colonic mucosa, 60 colonic inflammatory polyps, 60 colonic adenomas, 180 colon adenocarcinomas, and 40 lymph node metastases by immunohistochemistry, and observed that RACK1 expression was progressively elevated in the carcinogenic process of human colonic epithelium, and RACK1 expressional levels were positively correlated with the malignant degree and lymph node metastasis of colon cancers, and negatively correlated with the patient survival. With a combination of loss-of-function and gain-of-function approaches, we observed that RACK1 promoted colon cancer cell proliferation, inhibited colon cancer cell apoptosis, and enhanced the anchorage-independent and xenograft growth of colon cancer cells. Moreover, we found that RACK1-induced autophagy of colon cancer cells; RACK1-induced autophagy promoted colon cancer cell proliferation and inhibited colon cancer cell apoptosis. Our data suggest that RACK1 acts as an oncogene in colon cancer, and RACK1-induced autophagy promotes proliferation and survival of colon cancer, highlighting the therapeutic potential of autophagy inhibitor in the colon cancer with high RACK1 expression.
C1 [Xiao, Ta; Zhu, Wei; Huang, Wei; Lu, Shan-Shan; Li, Xin-Hui; Xiao, Zhi-Qiang; Yi, Hong] Cent South Univ, Xiangya Hosp, Res Ctr Carcinogenesis & Targeted Therapy, Changsha 410008, Hunan, Peoples R China.
   [Xiao, Ta] Chinese Acad Med Sci, Inst Dermatol, Nanjing 210042, Jiangsu, Peoples R China.
   [Xiao, Ta] Peking Union Med Coll, Nanjing 210042, Jiangsu, Peoples R China.
   [Zhu, Wei] Cent South Univ, Xiangya Hosp, Dept Pathol, Changsha 410008, Hunan, Peoples R China.
RP Xiao, ZQ; Yi, H (corresponding author), Cent South Univ, Xiangya Hosp, Res Ctr Carcinogenesis & Targeted Therapy, Changsha 410008, Hunan, Peoples R China.
EM zqxiao2001@hotmail.com; yi_hong@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81172302, 81472801, 81672687]
FX This work was supported by the National Natural Science Foundation of
   China (81172302, 81472801, and 81672687).
CR Almasi S, 2018, J BIOL CHEM, V293, P3637, DOI 10.1074/jbc.M117.817635
   Anding AL, 2015, CURR TOP DEV BIOL, V114, P67, DOI 10.1016/bs.ctdb.2015.07.012
   Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204
   Berns H, 2000, FASEB J, V14, P2549, DOI 10.1096/fj.99-1038com
   Caino MC, 2009, APOPTOSIS, V14, P392, DOI 10.1007/s10495-009-0316-z
   Cao XX, 2010, INT J CANCER, V127, P1172, DOI 10.1002/ijc.25120
   Carey JP, 2013, ANTICANCER RES, V33, P4271
   Dimri GP, 2005, CANCER CELL, V7, P505, DOI 10.1016/j.ccr.2005.05.025
   Egidy G, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-34
   Erbil S, 2016, J BIOL CHEM, V291, P16753, DOI 10.1074/jbc.M115.708081
   Erdi B, 2012, AUTOPHAGY, V8, P1124, DOI 10.4161/auto.20069
   Fimia GM, 2010, CELL MOL LIFE SCI, V67, P1581, DOI 10.1007/s00018-010-0284-z
   Gandin Valentina, 2013, Genes Cancer, V4, P369, DOI 10.1177/1947601913486348
   Guo YY, 2013, HEPATOLOGY, V57, P140, DOI 10.1002/hep.25978
   He QY, 2015, ONCOTARGET, V6, P16422, DOI 10.18632/oncotarget.3847
   Huang XL, 2017, ANTI-CANCER DRUG, V28, P596, DOI 10.1097/CAD.0000000000000499
   Jin SJ, 2014, MOL BIOL REP, V41, P3393, DOI 10.1007/s11033-014-3201-y
   Jin SK, 2008, AUTOPHAGY, V4, P563, DOI 10.4161/auto.5830
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kelekar A, 2005, ANN NY ACAD SCI, V1066, P259, DOI 10.1196/annals.1363.015
   Kraus S, 2006, CANCER RES, V66, P11047, DOI 10.1158/0008-5472.CAN-06-0596
   Laberge RM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.199
   Levine B, 2006, AUTOPHAGY, V2, P65, DOI 10.4161/auto.2.2.2457
   Li JJ, 2015, ONCOGENE, V34, P1890, DOI 10.1038/onc.2014.127
   Lin P, 2014, BIOCHEM BIOPH RES CO, V446, P1268, DOI 10.1016/j.bbrc.2014.03.114
   Lopez-Bergami P, 2005, MOL CELL, V19, P309, DOI 10.1016/j.molcel.2005.06.025
   Lopez-Bergami P, 2008, INT J BIOCHEM CELL B, V40, P1055, DOI 10.1016/j.biocel.2007.11.011
   Maclean KH, 2008, J CLIN INVEST, V118, P79, DOI 10.1172/JCI33700
   Mamidipudi V, 2007, ONCOGENE, V26, P2914, DOI 10.1038/sj.onc.1210091
   McCahill A, 2002, MOL PHARMACOL, V62, P1261, DOI 10.1124/mol.62.6.1261
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mukhopadhyay S, 2014, APOPTOSIS, V19, P555, DOI 10.1007/s10495-014-0967-2
   Myklebust LM, 2011, THYROID, V21, P1217, DOI 10.1089/thy.2010.0186
   Nagashio R, 2010, LUNG CANCER, V69, P54, DOI 10.1016/j.lungcan.2009.09.015
   RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839
   Ron D, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-53
   Ruan YY, 2012, J CLIN INVEST, V122, P2554, DOI 10.1172/JCI58488
   Saretzki G, 2010, CURR PHARM DESIGN, V16, P79, DOI 10.2174/138161210789941874
   Shi S, 2012, J BIOL CHEM, V287, P7845, DOI 10.1074/jbc.M111.315416
   Su MF, 2013, J ONCOL, V2013, DOI 10.1155/2013/102735
   Subauste MC, 2009, CANCER BIOL THER, V8, P2297
   Vasilevskaya IA, 2016, MOL CANCER RES, V14, P753, DOI 10.1158/1541-7786.MCR-16-0035
   Wang Z, 2009, EUR J CANCER, V45, P490, DOI 10.1016/j.ejca.2008.11.012
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yi H, 2010, J PROTEOME RES, V9, P1416, DOI 10.1021/pr9009386
   Zeng GQ, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.013946
   Zhao YW, 2015, CELL REP, V13, P1407, DOI 10.1016/j.celrep.2015.10.011
   Zheng Z, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.211
NR 49
TC 26
Z9 27
U1 6
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD NOV 19
PY 2018
VL 9
AR 1148
DI 10.1038/s41419-018-1113-9
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA HA8TC
UT WOS:000450565200005
PM 30451832
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Kaluzki, I
   Hailemariam-Jahn, T
   Doll, M
   Kaufmann, R
   Balermpas, P
   Zoller, N
   Kippenberger, S
   Meissner, M
AF Kaluzki, Irina
   Hailemariam-Jahn, Tsige
   Doll, Monika
   Kaufmann, Roland
   Balermpas, Panagiotis
   Zoeller, Nadja
   Kippenberger, Stefan
   Meissner, Markus
TI Dimethylfumarate Inhibits Colorectal Carcinoma Cell Proliferation:
   Evidence for Cell Cycle Arrest, Apoptosis and Autophagy
SO CELLS
LA English
DT Article
DE dimethylfumarate; colorectal carcinoma; p21; cell cycle arrest; cyclin
   D1; p62; LC3 I/II; caspase-8; autophagy
ID COLON-CANCER CELLS; TUMOR-CELLS; P21; INDUCTION; EXPRESSION; GROWTH
AB Recent studies have proven that Dimethylfumarate (DMF) has a marked anti-proliferative impact on diverse cancer entities e.g., on malignant melanoma. To explore its anti-tumorigenic potential, we examined the effects of DMF on human colon carcinoma cell lines and the underlying mechanisms of action. Human colon cancer cell line HT-29 and human colorectal carcinoma cell line T84 were treated with or without DMF. Effects of DMF on proliferation, cell cycle progression, and apoptosis were analyzed mainly by Bromodeoxyuridine (BrdU)- and Lactatdehydrogenase (LDH)-assays, caspase activation, flowcytometry, immunofluorescence, and immunoblotting. In addition, combinational treatments with radiation and chemotherapy were performed. DMF inhibits cell proliferation in both cell lines. It was shown that DMF induces a cell cycle arrest in G0/G1 phase, which is accompanied by upregulation of p21 and downregulation of cyclin D1 and Cyclin dependent kinase (CDK)4. Furthermore, upregulation of autophagy associated proteins suggests that autophagy is involved. In addition, the activation of apoptotic markers provides evidence that apoptosis is involved. Our results show that DMF supports the action of oxaliplatin in a synergetic manner and failed synergy with radiation. We demonstrated that DMF has distinct anti-tumorigenic, cell dependent effects on colon cancer cells by arresting cell cycle in G0/G1 phase as well as activating both the autophagic and apoptotic pathways and synergizes with chemotherapy.
C1 [Kaluzki, Irina; Hailemariam-Jahn, Tsige; Doll, Monika; Kaufmann, Roland; Zoeller, Nadja; Kippenberger, Stefan; Meissner, Markus] Goethe Univ, Dept Dermatol Venereol & Allergol, D-60323 Frankfurt, Germany.
   [Balermpas, Panagiotis] Univ Spital Zurich, Dept Radiat Oncol, CH-8091 Zurich, Switzerland.
RP Meissner, M (corresponding author), Goethe Univ, Dept Dermatol Venereol & Allergol, D-60323 Frankfurt, Germany.
EM irina.kaluzki@kgu.de; rita_th@web.de; monika.doll@kgu.de;
   roland.kaufmann@kgu.de; panagiotis.balermpas@usz.ch;
   nadja.zoeller@kgu.de; kippenberger@em.uni-frankfurt.de;
   markus.meissner@kgu.de
RI Meissner, Markus/AAP-8179-2020
OI Balermpas, Panagiotis/0000-0001-5261-6446
FU Kurt and Eva Herrmann scholarship, 2013; Brigitte and Konstanze
   Wegener-Stiftung [6b]
FX This research was funded by the Kurt and Eva Herrmann scholarship, 2013
   (I.K.) and the Brigitte and Konstanze Wegener-Stiftung grant number 6b
   (M.M.).
CR Afrin S, 2018, FOOD FUNCT, V9, P2145, DOI [10.1039/C8FO00164B, 10.1039/c8fo00164b]
   Begleiter A, 2003, CANCER EPIDEM BIOMAR, V12, P566
   Boivin A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014558
   Booth L, 2014, CANCER BIOL THER, V15, P1646, DOI 10.4161/15384047.2014.967992
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chen XP, 2019, J BUON, V24, P488
   Di Giacomo V, 2015, CELL MOL BIOL, V61, P17
   Fan JD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116782
   Gao GY, 2018, BIOMED PHARMACOTHER, V108, P1208, DOI 10.1016/j.biopha.2018.06.172
   Gerhardt S, 2015, J INFLAMM-LOND, V12, DOI 10.1186/s12950-015-0094-z
   Hanot M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044367
   Kaluzki I, 2016, TUMOR BIOL, V37, P13627, DOI 10.1007/s13277-016-5285-6
   Kang HJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061411
   Kirlin WG, 1999, J NUTR, V129, P1827, DOI 10.1093/jn/129.10.1827
   Li X, 2012, INT J BIOL SCI, V8, P901, DOI 10.7150/ijbs.4554
   Loewe R, 2002, J IMMUNOL, V168, P4781, DOI 10.4049/jimmunol.168.9.4781
   Loewe R, 2006, CANCER RES, V66, P11888, DOI 10.1158/0008-5472.CAN-06-2397
   Ma K, 2016, ONCOL REP, V36, P1807, DOI 10.3892/or.2016.5003
   Ma ZG, 2016, ACTA BIOMATER, V44, P323, DOI 10.1016/j.actbio.2016.08.021
   Meissner M, 2011, J INVEST DERMATOL, V131, P1356, DOI 10.1038/jid.2011.46
   Mizushima N, 2018, NAT CELL BIOL, V20, P521, DOI 10.1038/s41556-018-0092-5
   Odom RY, 2009, NUTR CANCER, V61, P332, DOI 10.1080/01635580802549982
   Oh CJ, 2014, REDOX BIOL, V2, P855, DOI 10.1016/j.redox.2014.06.003
   Rezaei PF, 2012, DARU, V20, DOI 10.1186/2008-2231-20-101
   Singh P, 2017, NEOPLASIA, V19, P175, DOI 10.1016/j.neo.2016.12.001
   Singh SK, 2017, ONCOTARGET, V8, P17216, DOI 10.18632/oncotarget.15303
   Son Y, 2019, PHYTOTHER RES, V33, P1689, DOI 10.1002/ptr.6357
   Tsubaki M, 2014, BIOMED PHARMACOTHER, V68, P999, DOI 10.1016/j.biopha.2014.09.009
   Valesky EM, 2016, EXP DERMATOL, V25, P200, DOI 10.1111/exd.12907
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Vego H, 2016, CELL MOL IMMUNOL, V13, P57, DOI 10.1038/cmi.2014.114
   Wang YF, 2015, ONCOTARGET, V6, P39692, DOI 10.18632/oncotarget.5625
   Werdenberg D, 2003, BIOPHARM DRUG DISPOS, V24, P259, DOI 10.1002/bdd.364
   Xie X, 2015, BRIT J PHARMACOL, V172, P3929, DOI 10.1111/bph.13184
   Yamazoe Y, 2009, CELL BIOL INT, V33, P1087, DOI 10.1016/j.cellbi.2009.06.027
NR 35
TC 15
Z9 15
U1 1
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD NOV
PY 2019
VL 8
IS 11
AR 1329
DI 10.3390/cells8111329
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA JV3LB
UT WOS:000502266700027
PM 31661890
OA Green Published, Green Accepted, gold
DA 2022-04-25
ER

PT J
AU Fan, XJ
   Wang, Y
   Wang, L
   Zhu, MY
AF Fan, Xiang-Jun
   Wang, Yao
   Wang, Lei
   Zhu, Mingyan
TI Salidroside induces apoptosis and autophagy in human colorectal cancer
   cells through inhibition of PI3K/Akt/mTOR pathway
SO ONCOLOGY REPORTS
LA English
DT Article
DE autophagy; apoptosis; human colon cancer HT-29 cells; salidroside;
   PI3K/Akt/mTOR pathways
ID SIGNALING PATHWAYS; COLON-CANCER; G(2)/M ARREST; CYCLE ARREST; P38 MAPK;
   DEATH; INDUCTION; PLUMBAGIN; GROWTH; MTOR
AB The role of salidroside in colon cancer remains unknown. Here we show that salidroside, a phenylpropanoid glycoside extracted from Rhodiola rosea, exhibited potent anti-proliferative properties in human colorectal cancer cells via inducing apoptosis and autophagy. We ascertained that salidroside exerts an inhibitory effect on the proliferation of human colorectal cancer cells in a dose-dependent manner. In addition, salidroside induced cell apoptosis, accompanied by an increase of chromatin condensation and nuclear fragmentation, and a decrease of Bcl-2/Bax protein expression ratio. We also found that salidroside induced autophagy, evidenced by increased LC3(+) autophagic vacuoles, positive acridine orange-stained cells, enhanced conversion of LC3-I to LC3-II, and elevation of Beclin-1. Treatment with autophagy-specific inhibitors [3-methyladenine (3-MA) and bafilomycin A1 (BA)] enhanced salidroside-induced apoptosis, indicating that salidroside-mediated autophagy may protect HT29 cells from undergoing apoptotic cell death. Additionally, salidroside decreased the phosphorylation of PI3K, Akt and mTOR. Treatment with PI3K inhibitor LY294002 augmented the effects of salidroside on the expression of Akt and mTOR. These findings indicate that salidroside could suppress the PI3K/Akt/mTOR signaling pathways. This study may provide a rationale for future clinical application using salidroside as a chemotherapeutic agent for human colorectal cancer.
C1 [Fan, Xiang-Jun; Wang, Yao; Wang, Lei; Zhu, Mingyan] Nantong Univ, Affiliated Hosp, Dept Gen Surg, 20 Xisi Rd, Nantong 226001, Jiangsu, Peoples R China.
RP Zhu, MY (corresponding author), Nantong Univ, Affiliated Hosp, Dept Gen Surg, 20 Xisi Rd, Nantong 226001, Jiangsu, Peoples R China.
EM zmyntfy@163.com
FU Technological Innovation and Demonstration of Social Undertakings
   Projects of Nantong, Jiangsu, China [HS2014049]
FX This study was supported by the Technological Innovation and
   Demonstration of Social Undertakings Projects (HS2014049) of Nantong,
   Jiangsu, China.
CR Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322
   Bar-Am O, 2005, FASEB J, V19, P1899, DOI 10.1096/fj.05-3794fje
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78
   Chaabane W, 2013, ARCH IMMUNOL THER EX, V61, P43, DOI 10.1007/s00005-012-0205-y
   CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615
   Ellington AA, 2006, CARCINOGENESIS, V27, P298, DOI 10.1093/carcin/bgi214
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Hsuan SW, 2016, EUR J NUTR, V55, P491, DOI 10.1007/s00394-015-0866-5
   Hu XL, 2010, CELL BIOL TOXICOL, V26, P499, DOI 10.1007/s10565-010-9159-1
   Hu XL, 2010, BIOCHEM BIOPH RES CO, V398, P62, DOI 10.1016/j.bbrc.2010.06.033
   Hung SK, 2011, PHYTOMEDICINE, V18, P235, DOI 10.1016/j.phymed.2010.08.014
   Jiang Q, 2012, BMB REP, V45, P194, DOI 10.5483/BMBRep.2012.45.3.194
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kaser A, 2011, GASTROENTEROLOGY, V140, P1738, DOI 10.1053/j.gastro.2011.02.048
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1
   Li JP, 2015, DRUG DES DEV THER, V9, P1627, DOI 10.2147/DDDT.S75378
   Liu XH, 2012, J HUAZHONG U SCI-MED, V32, P669, DOI 10.1007/s11596-012-1015-5
   Liu YL, 2010, AUTOPHAGY, V6, P1057, DOI 10.4161/auto.6.8.13365
   Liu ZB, 2012, MOL CARCINOGEN, V51, P257, DOI 10.1002/mc.20780
   Maira SM, 2009, FUTURE MED CHEM, V1, P137, DOI 10.4155/FMC.09.5
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Morgensztern D, 2005, ANTI-CANCER DRUG, V16, P797, DOI 10.1097/01.cad.0000173476.67239.3b
   Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0
   Paglin S, 2001, CANCER RES, V61, P439
   Pan ST, 2015, DRUG DES DEV THER, V9, P1601, DOI 10.2147/DDDT.S76057
   Panossian A, 2010, PHYTOMEDICINE, V17, P481, DOI 10.1016/j.phymed.2010.02.002
   Periyasamy-Thandavan S, 2009, AM J PHYSIOL-RENAL, V297, pF244, DOI 10.1152/ajprenal.00033.2009
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Rodon J, 2013, NAT REV CLIN ONCOL, V10, P143, DOI 10.1038/nrclinonc.2013.10
   Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272
   Shrivastava A, 2011, MOL CANCER THER, V10, P1161, DOI 10.1158/1535-7163.MCT-10-1100
   Skopinska-Rozewska E, 2008, POL J VET SCI, V11, P97
   Su MF, 2013, J ONCOL, V2013, DOI 10.1155/2013/102735
   Sun C, 2012, PHYTOMEDICINE, V19, P355, DOI 10.1016/j.phymed.2011.09.070
   Sun KX, 2015, INT J CLIN EXP PATHO, V8, P615
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Tsai JP, 2015, ONCOTARGET, V6, P28851, DOI 10.18632/oncotarget.4767
   Tu YF, 2008, J MED FOOD, V11, P413, DOI 10.1089/jmf.2007.0736
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   Wang F, 2015, DRUG DES DEV THER, V9, P537, DOI 10.2147/DDDT.S73689
   Wang J, 2014, ONCOL LETT, V7, P1159, DOI 10.3892/ol.2014.1863
   Wang K, 2011, AUTOPHAGY, V7, P966, DOI 10.4161/auto.7.9.15863
   Wang XW, 2014, WORLD J GASTROENTERO, V20, P4178, DOI 10.3748/wjg.v20.i15.4178
   Woodle ES, 1998, TRANSPLANTATION, V66, P681, DOI 10.1097/00007890-199809270-00001
   Wu P, 2010, CURR MED CHEM, V17, P4326, DOI 10.2174/092986710793361234
   Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yim NH, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/231874
   Zhang DM, 2013, CARCINOGENESIS, V34, P1331, DOI 10.1093/carcin/bgt060
   Zhang X, 2012, CELL PROLIFERAT, V45, P466, DOI 10.1111/j.1365-2184.2012.00833.x
   Zhang YS, 2013, CHINESE J CANCER RES, V25, P520, DOI 10.3978/j.issn.1000-9604.2013.10.01
   Zhou ZW, 2015, DRUG DES DEV THER, V9, P1511, DOI 10.2147/DDDT.S75976
NR 59
TC 69
Z9 77
U1 2
U2 33
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD DEC
PY 2016
VL 36
IS 6
BP 3559
EP 3567
DI 10.3892/or.2016.5138
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ED2DG
UT WOS:000388653200057
PM 27748934
OA Bronze
DA 2022-04-25
ER

PT J
AU Zhao, YL
   Li, ETS
   Wang, MF
AF Zhao, Yueliang
   Li, Edmund T. S.
   Wang, Mingfu
TI Alisol B 23-acetate induces autophagic-dependent apoptosis in human
   colon cancer cells via ROS generation and JNK activation
SO ONCOTARGET
LA English
DT Article
DE alisol B 23-acetate; autophagy; apoptosis; ROS; JNK
ID REACTIVE OXYGEN; PROTEIN-KINASES; DEATH; INHIBITION; TRITERPENE;
   OSTEOSARCOMA; LYMPHOCYTES; MECHANISMS; ALISMATIS; RHIZOMA
AB Alisol B 23-acetate (AB23A), a natural triterpenoid from the rhizome of Alisma orientale, a Chinese medicinal herb, has multiple physiological activities including anticancer. However, its effect on human colon cancer and the underlying mechanism are not clear. Here, we reported for the first time that AB23A induced cell cycle G(1) phase arrest and apoptotic cell death in colon cancer cells. Autophagy also occurred in AB23A-treated HCT116 cells as evidenced by the accumulation of microtubule-associated protein 1 light chain 3 form II (LC3-II) and degradation of SQSTM1/p62. An autophagy inhibitor, 3-methyladenine (3-MA) was found to attenuate AB23A-mediated autophagy, apoptosis, and cell death, indicating that AB23A-induced apoptotic response was dependent on the induction of autophagy. In addition, the treatment of HCT116 cells with AB23A resulted in the generation of reactive oxygen species (ROS) and phosphorylation of c-Jun N-terminal kinase (JNK). A ROS scavenger, N-acetylcysteine (NAC) and a JNK-specific inhibitor, SP600125 attenuated AB23A-induced autophagy and apoptotic cell death. Moreover, NAC was able to eliminate AB23A-induced JNK phosphorylation. This finding provides a novel mechanism of action of AB23A in colon cancer HCT116 cells that AB23A induces autophagic-dependent apoptotic cell death in colon cancer cells, at least in part, though the accumulation of intracellular ROS and subsequent activation of JNK.
C1 [Zhao, Yueliang; Li, Edmund T. S.; Wang, Mingfu] Univ Hong Kong, Sch Biol Sci, Hong Kong, Hong Kong, Peoples R China.
RP Wang, MF (corresponding author), Univ Hong Kong, Sch Biol Sci, Hong Kong, Hong Kong, Peoples R China.
EM mfwang@hku.hk
RI Wang, Mingfu/AAT-3292-2021; Wang, Mingfu/D-3136-2009
OI Wang, Mingfu/0000-0003-1469-3963
FU Hong Kong Research Grants Council (GRF)Hong Kong Research Grants Council
   [17154816]
FX The research was supported by the Hong Kong Research Grants Council (GRF
   Project No.: 17154816).
CR Avisetti DR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087050
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Bodas M, 2016, FREE RADICAL BIO MED, V97, P441, DOI 10.1016/j.freeradbiomed.2016.06.017
   BRUNETTI M, 1995, BLOOD, V86, P4199, DOI 10.1182/blood.V86.11.4199.bloodjournal86114199
   Chang ZQ, 2014, TUMOR BIOL, V35, P753, DOI 10.1007/s13277-013-1102-7
   Chen HW, 2001, EUR J PHARMACOL, V419, P127, DOI 10.1016/S0014-2999(01)00983-9
   Chen YQ, 2007, J CELL SCI, V120, P4155, DOI 10.1242/jcs.011163
   Chou CC, 2003, EUR J PHARM SCI, V19, P403, DOI 10.1016/S0928-0987(03)00144-1
   Fruehauf JP, 2007, CLIN CANCER RES, V13, P789, DOI 10.1158/1078-0432.CCR-06-2082
   Han XZ, 2012, CARCINOGENESIS, V33, P868, DOI 10.1093/carcin/bgs029
   Huang YT, 2006, CANCER LETT, V231, P270, DOI 10.1016/j.canlet.2005.02.011
   Ikeda T, 2003, CANCER RES, V63, P5551
   Jiang ZY, 2006, PLANTA MED, V72, P951, DOI 10.1055/s-2006-947178
   Jin HG, 2012, ARCH PHARM RES, V35, P1919, DOI 10.1007/s12272-012-1108-5
   Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131
   Kyriakis JM, 2011, PHYSIOL REV, V81, P807
   Li HY, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.543
   Liao YJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.66
   Mann J, 2002, NAT REV CANCER, V2, P143, DOI 10.1038/nrc723
   Martinez-Revelles S, 2013, ANTIOXID REDOX SIGN, V18, P51, DOI 10.1089/ars.2011.4335
   Meng Q, 2015, PHARM RES-DORDR, V32, P3688, DOI 10.1007/s11095-015-1727-x
   Meng Q, 2015, FOOD FUNCT, V6, P1241, DOI [10.1039/c5fo00082c, 10.1039/C5FO00082C]
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004
   Shen HM, 2006, FREE RADICAL BIO MED, V40, P928, DOI 10.1016/j.freeradbiomed.2005.10.056
   Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304
   Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556
   Wondrak GT, 2009, ANTIOXID REDOX SIGN, V11, P3013, DOI 10.1089/ARS.2009.2541
   Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016
   Yang WH, 2011, J CELL BIOCHEM, V112, P1601, DOI 10.1002/jcb.23072
   Yen CC, 2014, ONCOTARGET, V5, P716, DOI 10.18632/oncotarget.1704
   Zhang LL, 2016, PHYTOMEDICINE, V23, P800, DOI 10.1016/j.phymed.2016.04.003
   Zhao YL, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201600437
   Zhao YL, 2016, EUR J CANCER, V68, P38, DOI 10.1016/j.ejca.2016.09.001
   Zou P, 2015, ONCOTARGET, V6, P5860, DOI 10.18632/oncotarget.3333
NR 37
TC 14
Z9 17
U1 0
U2 14
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 19
PY 2017
VL 8
IS 41
BP 70239
EP 70249
DI 10.18632/oncotarget.19605
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FH4TA
UT WOS:000411153300081
PM 29050275
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Liang, C
   Feng, P
   Ku, B
   Dotan, I
   Canaani, D
   Oh, BH
   Jung, JU
AF Liang, Chengyu
   Feng, Pinghui
   Ku, Bonsu
   Dotan, Iris
   Canaani, Dan
   Oh, Byung-Ha
   Jung, Jae U.
TI Autophagic and tumour suppressor activity of a novel Beclin1-binding
   protein UVRAG
SO NATURE CELL BIOLOGY
LA English
DT Article
ID CELL-DEATH; IN-VIVO; INDUCED APOPTOSIS; COLON-CANCER; VIRAL BCL-2; GENE;
   BECLIN-1; INHIBITION; IDENTIFICATION; MACROAUTOPHAGY
AB Autophagy, the degradation of cytoplasmic components, is an evolutionarily conserved homeostatic process involved in environmental adaptation, lifespan determination and tumour development. The tumor suppressor Beclin1 is part of the PI( 3) kinase class III ( PI( 3) KC3) lipid-kinase complex that induces autophagy. The autophagic activity of the Beclin1-PI( 3) KC3 complex, however, is suppressed by Bcl-2. Here, we report the identification of a novel coiled-coil UV irradiation resistance-associated gene ( UVRAG) as a positive regulator of the Beclin1-PI( 3) KC3 complex. UVRAG, a tumour suppressor candidate that is monoallelically mutated at high frequency in human colon cancers, associates with the Beclin1-Bcl-2-PI( 3) KC3 multiprotein complex, where UVRAG and Beclin1 interdependently induce autophagy. UVRAG-mediated activation of the Beclin1-PI( 3) KC3 complex promotes autophagy and also suppresses the proliferation and tumorigenicity of human colon cancer cells. These results identify UVRAG as an essential component of the Beclin1-PI( 3) KC3 lipid kinase complex that is an important signalling checkpoint for autophagy and tumour-cell growth.
C1 Harvard Univ, New England Reg Primate Res Ctr, Sch Med, Dept Microbiol & Mol Genet, Southborough, MA 01772 USA.
   Harvard Univ, New England Reg Primate Res Ctr, Sch Med, Div Tumor Virol, Southborough, MA 01772 USA.
   Pohang Univ Sci & Technol, Ctr Biomol Recognit, Dept Life Sci, Pohang 790784, South Korea.
   Tel Aviv Univ, Dept Biochem, IL-69978 Tel Aviv, Israel.
RP Jung, JU (corresponding author), Harvard Univ, New England Reg Primate Res Ctr, Sch Med, Dept Microbiol & Mol Genet, 1 Pine Hill Dr, Southborough, MA 01772 USA.
EM jae_jung@hms.harvard.edu
RI Oh, Byung-Ha/C-2061-2011
OI Ku, Bonsu/0000-0003-1784-8975; LIANG, CHENGYU/0000-0001-6082-2143
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [CA31363, CA91819, CA82057, CA106156] Funding Source: Medline; NCRR NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [RR00168] Funding Source: Medline; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R01CA082057, R01CA106156, R01CA091819, R01CA031363] Funding Source: NIH
   RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Research Resources (NCRR) [P51RR000168] Funding
   Source: NIH RePORTER
CR Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200
   Bekri S, 1997, CYTOGENET CELL GENET, V79, P125, DOI 10.1159/000134699
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   de Lima BD, 2005, J GEN VIROL, V86, P31, DOI 10.1099/vir.0.80480-0
   Furuya N, 2005, AUTOPHAGY, V1, P46, DOI 10.4161/auto.1.1.1542
   Gangappa S, 2002, J EXP MED, V195, P931, DOI 10.1084/jem.20011825
   Goi T, 2003, SURG TODAY, V33, P702, DOI 10.1007/s00595-002-2567-y
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Iida A, 2000, HUM GENET, V106, P277, DOI 10.1007/s004390051038
   Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178
   Jia L, 1997, BRIT J HAEMATOL, V98, P673, DOI 10.1046/j.1365-2141.1997.2623081.x
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519
   Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620
   Levine B, 2005, CELL, V120, P159, DOI 10.1016/j.cell.2005.01.005
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Loh J, 2005, PLOS PATHOG, V1, P80, DOI 10.1371/journal.ppat.0010010
   Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   Mills KR, 2004, P NATL ACAD SCI USA, V101, P3438, DOI 10.1073/pnas.0400443101
   Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704
   Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Perelman B, 1997, GENOMICS, V41, P397, DOI 10.1006/geno.1997.4623
   Polster BM, 2004, BBA-MOL CELL RES, V1644, P211, DOI 10.1016/j.bbamcr.2003.11.001
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Roy DJ, 2000, ARCH VIROL, V145, P2411, DOI 10.1007/s007050070030
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   Thorburn J, 2005, MOL BIOL CELL, V16, P1189, DOI 10.1091/mbc.E04-10-0906
   Vieira OV, 2001, J CELL BIOL, V155, P19, DOI 10.1083/jcb.200107069
   Virgin HW, 1997, J VIROL, V71, P5894, DOI 10.1128/JVI.71.8.5894-5904.1997
   Wang GH, 1999, J GEN VIROL, V80, P2737, DOI 10.1099/0022-1317-80-10-2737
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
NR 39
TC 766
Z9 811
U1 1
U2 62
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-7392
EI 1476-4679
J9 NAT CELL BIOL
JI Nat. Cell Biol.
PD JUL
PY 2006
VL 8
IS 7
BP 688
EP U94
DI 10.1038/ncb1426
PG 25
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 060YJ
UT WOS:000238837800011
PM 16799551
DA 2022-04-25
ER

PT J
AU Pellerito, C
   Emanuele, S
   Ferrante, F
   Celesia, A
   Giuliano, M
   Fiore, T
AF Pellerito, Claudia
   Emanuele, Sonia
   Ferrante, Francesco
   Celesia, Adriana
   Giuliano, Michela
   Fiore, Tiziana
TI Tributyltin(IV) ferulate, a novel synthetic ferulic acid derivative,
   induces autophagic cell death in colon cancer cells: From chemical
   synthesis to biochemical effects
SO JOURNAL OF INORGANIC BIOCHEMISTRY
LA English
DT Article
DE Organotin(IV); Ferulic acid; Colon cancer cytotoxicity; Autophagic cell
   death; p62; LC3
ID CORRELATED MOLECULAR CALCULATIONS; SPECTROSCOPIC FT-IR; GAUSSIAN-BASIS
   SETS; OXIDATIVE STRESS; BIOLOGICAL-ACTIVITY; POTENTIAL APPROACH; C-13
   NMR; COMPLEXES; APOPTOSIS; SHIFTS
AB Ferulic acid (FA) is a natural phenolic phytochemical that has low toxicity and exhibits therapeutic effects against various diseases, behaving as an antioxidant. FA also displays modest antitumor properties that have been reported at relatively high concentrations. With the aim of improving the anti-tumor efficacy of FA, we synthesized the novel compound tributyltin(IV) ferulate (TBT-F). The coordination environment at the tin center was investigated spectroscopically. Following synthesis, chemical characterization and computational analysis, we evaluated TBT-F effects in colon cancer cells. The results showed that TBT-F, at nanomolar range concentrations, was capable of reducing the viability of HCT116, HT-29 and Caco-2 colon cancer cells. On the other hand, FA was completely inefficacious at the same treatment conditions. Cell viability reduction induced by TBT-F was associated with G2/M cell cycle arrest, increase in membrane permeabilization and appearance of typical morphological signs. TBT-F-induced cell death seemed not to involve apoptotic or necroptotic markers whereas autophagic vacuoles appearance and increase in LC3-II and p62 autophagic proteins were observed after treatment with the compound. The autophagy inhibitor bafylomicin A1 markedly prevented the effect of TBT-F on colon cancer cells, thus indicating that autophagy is triggered as a cell death process.
   Taken together, our results strongly suggest that the novel ferulic derivative TBT-F is a promising therapeutic agent for colon cancer since it is capable of triggering autophagic (type-II) cell death that may be important in case of resistance to classic apoptosis.
C1 [Pellerito, Claudia; Ferrante, Francesco; Fiore, Tiziana] Univ Palermo, Dipartimento Fis & Chim Emilio Segre DiFC, Viale Sci,Ed 17, I-90128 Palermo, Italy.
   [Pellerito, Claudia; Fiore, Tiziana] CIRCMSB, Via Celso Ulpiani 27, I-70125 Bari, Italy.
   [Emanuele, Sonia; Celesia, Adriana] Univ Palermo, Dipartimento Biomed Neurosci & Diagnost Avanzata, Via Vespro 129, I-90127 Palermo, Italy.
   [Giuliano, Michela] Univ Palermo, Dipartimento Sci & Tecnol Biol Chim & Farmaceut S, Via Vespro 129, I-90127 Palermo, Italy.
RP Fiore, T (corresponding author), Dipartimento Fis & Chim, Viale Sci,Ed 17, I-90128 Palermo, Italy.
EM tiziana.fiore@unipa.it
FU Universita degli Studi di Palermo, Italy [FFR_D08_FIORE]; PON R&C,
   Infrastrutture e del PO FESR, Regione Sicilia-Misura 4.1.2.A
   [PONa3_00273]
FX The AA gratefully acknowledges the financial support of the Universita
   degli Studi di Palermo, Italy (FFR_D08_FIORE). NMR and ESI-MS
   experimental data were provided by ATeN Center -Advanced Technologies
   Network Center -(Universita degli Studi di Palermo, Italy) funded by PON
   R&C, Infrastrutture (Progetto PONa3_00273) e del PO FESR, Regione
   Sicilia-Misura 4.1.2.A.
CR Avalle P, 2002, PHYS CHEM CHEM PHYS, V4, P5925, DOI 10.1039/b208435j
   Azam S, 2004, TOXICOL IN VITRO, V18, P555, DOI 10.1016/j.tiv.2003.12.012
   Baul TSB, 2006, J ORGANOMET CHEM, V691, P952, DOI 10.1016/j.jorganchem.2005.10.057
   BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913
   Bertazzi N, 2007, DALTON T, P1440, DOI 10.1039/b616330k
   Birt DF, 2014, TOXICOL PATHOL, V42, P182, DOI 10.1177/0192623313506791
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Breininger SP, 2019, P NUTR SOC, V78, P426, DOI 10.1017/S0029665119000533
   Brumatti G, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad3099
   Carraher CE, 2016, J INORG ORGANOMET P, V26, P1351, DOI 10.1007/s10904-016-0363-1
   Casella G, 2008, INORG CHEM, V47, P4796, DOI 10.1021/ic8000976
   Casella G, 2009, EUR J ORG CHEM, V2009, P3526, DOI 10.1002/ejoc.200900197
   Chan AT, 2010, GASTROENTEROLOGY, V138, P2029, DOI 10.1053/j.gastro.2010.01.057
   Cheng YH, 2016, BIOMATERIALS, V103, P207, DOI 10.1016/j.biomaterials.2016.06.060
   Costantini F, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121547
   D'Arcy MS, 2019, CELL BIOL INT, V43, P582, DOI 10.1002/cbin.11137
   Damasceno SS, 2017, CURR PHARM DESIGN, V23, P3015, DOI 10.2174/1381612822666161208145508
   DANISH M, 1995, POLYHEDRON, V14, P3115, DOI 10.1016/0277-5387(95)00080-C
   DEACON GB, 1985, INORG CHIM A-ART LET, V104, P41, DOI 10.1016/S0020-1693(00)83783-4
   DUNNING TH, 1989, J CHEM PHYS, V90, P1007, DOI 10.1063/1.456153
   Emanuele S, 2018, NUTRIENTS, V10, DOI 10.3390/nu10101490
   Emanuele S, 2018, REND LINCEI-SCI FIS, V29, P397, DOI 10.1007/s12210-018-0704-9
   Frisch M. J., 2009, GAUSSIAN 09 REVISION
   Gao JH, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0595-y
   Ghosh S, 2018, FOOD CHEM TOXICOL, V118, P272, DOI 10.1016/j.fct.2018.05.029
   Gottlieb HE, 1997, J ORG CHEM, V62, P7512, DOI 10.1021/jo971176v
   HOLECEK J, 1986, INORG CHIM ACTA, V118, pL15, DOI 10.1016/S0020-1693(00)86395-1
   Kalinowska M, 2014, SPECTROCHIM ACTA A, V122, P631, DOI 10.1016/j.saa.2013.11.089
   Katsuragi Y, 2015, FEBS J, V282, P4672, DOI 10.1111/febs.13540
   Kikuzaki H, 2002, J AGR FOOD CHEM, V50, P2161, DOI 10.1021/jf011348w
   Kriel J, 2019, CELL DEATH DIFFER, V26, P640, DOI 10.1038/s41418-018-0267-4
   Kulbay M, 2019, TOXICOLOGY, V426, DOI 10.1016/j.tox.2019.152255
   Kumar Naresh, 2014, Biotechnol Rep (Amst), V4, P86, DOI 10.1016/j.btre.2014.09.002
   Kutzelnigg W., 1990, NMR BASIC PRINCIPLES, P165, DOI DOI 10.1007/978-3-642-75932-1_3
   Lamark T, 2017, ESSAYS BIOCHEM, V61, P609, DOI 10.1042/EBC20170035
   LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785
   Lee YK, 2016, BMB REP, V49, P424, DOI 10.5483/BMBRep.2016.49.8.081
   Levine B, 2019, CELL, V176, P11, DOI 10.1016/j.cell.2018.09.048
   Lewandowski W, 2005, J INORG BIOCHEM, V99, P1407, DOI 10.1016/j.jinorgbio.2005.04.010
   Li YJ, 2017, CHIN J CANCER, V36, DOI 10.1186/s40880-017-0229-0
   Matczak P, 2010, J MOL STRUC-THEOCHEM, V950, P83, DOI 10.1016/j.theochem.2010.03.030
   Maurya DK, 2010, FOOD CHEM TOXICOL, V48, P3369, DOI 10.1016/j.fct.2010.09.006
   Mori T, 2017, J BIOL CHEM, V292, P11310, DOI 10.1074/jbc.M116.762658
   NADVORNIK M, 1984, J ORGANOMET CHEM, V275, P43, DOI 10.1016/0022-328X(84)80576-8
   Nath M., 2012, CHEM SUSTAINABLE DEV, P301
   Nath M, 2014, INORG CHIM ACTA, V423, P70, DOI 10.1016/j.ica.2014.02.034
   Neumann W. P., 1970, ORGANIC CHEM TIN
   Notaro A, 2014, INT J BIOL SCI, V10, P466, DOI 10.7150/ijbs.8337
   Pan GX, 2002, J WOOD CHEM TECHNOL, V22, P137, DOI 10.1081/WCT-120013358
   Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371
   Pellerito C, 2015, J INORG BIOCHEM, V150, P18, DOI 10.1016/j.jinorgbio.2015.06.001
   Pellerito O, 2013, J INORG BIOCHEM, V125, P16, DOI 10.1016/j.jinorgbio.2013.04.008
   Peterson KA, 2003, J CHEM PHYS, V119, P11099, DOI 10.1063/1.1622923
   Portanova P, 2008, INT J ONCOL, V33, P325, DOI 10.3892/ijo_00000012
   Rosa LD, 2018, MOLECULES, V23, DOI 10.3390/molecules23102569
   Sadiq-ur-Rehman, 2015, HETEROATOM CHEM, V26, P417, DOI 10.1002/hc.21276
   Song Y. F., 2016, EVID-BASED COMPL ALT, V2016, P1, DOI DOI 10.1089/AID.2015.0351
   STEPHENS PJ, 1994, J PHYS CHEM-US, V98, P11623, DOI 10.1021/j100096a001
   Sudhagar S, 2018, BIOTECHNOL LETT, V40, P257, DOI 10.1007/s10529-017-2475-2
   Swislocka R, 2013, SPECTROCHIM ACTA A, V100, P21, DOI 10.1016/j.saa.2012.01.048
   Tabassum S, 2006, J ORGANOMET CHEM, V691, P1761, DOI 10.1016/j.jorganchem.2005.12.033
   Thanikachalam K, 2019, NUTRIENTS, V11, DOI 10.3390/nu11010164
   Turner ND, 2017, EXP BIOL MED, V242, P813, DOI 10.1177/1535370217693117
   Vivas-Reyes R, 2002, J PHYS CHEM A, V106, P2753, DOI 10.1021/jp0145917
   Wang T, 2016, AM J TRANSL RES, V8, P968
   Willem R, 1997, J ORGANOMET CHEM, V531, P151, DOI 10.1016/S0022-328X(96)06686-7
   WOLINSKI K, 1990, J AM CHEM SOC, V112, P8251, DOI 10.1021/ja00179a005
   WOON DE, 1993, J CHEM PHYS, V98, P1358, DOI 10.1063/1.464303
   Wrackmeyer B, 1999, ANN R NMR S, V38, P203, DOI 10.1016/S0066-4103(08)60038-1
   Zdunska K, 2018, SKIN PHARMACOL PHYS, V31, P332, DOI 10.1159/000491755
NR 70
TC 14
Z9 14
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0162-0134
EI 1873-3344
J9 J INORG BIOCHEM
JI J. Inorg. Biochem.
PD APR
PY 2020
VL 205
AR 110999
DI 10.1016/j.jinorgbio.2020.110999
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Inorganic & Nuclear
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA KX8IT
UT WOS:000522119300017
PM 31986423
DA 2022-04-25
ER

PT J
AU Yu, NH
   Zhu, H
   Yang, Y
   Tao, YM
   Tan, FB
   Pei, Q
   Zhou, Y
   Song, XP
   Tan, QR
   Pei, HP
AF Yu, Nanhui
   Zhu, Hong
   Yang, Yuan
   Tao, Yiming
   Tan, Fengbo
   Pei, Qian
   Zhou, Yuan
   Song, Xiangping
   Tan, Qiurong
   Pei, Haiping
TI Combination of Fe/Cu -chelators and docosahexaenoic acid: an exploration
   for the treatment of colorectal cancer
SO ONCOTARGET
LA English
DT Article
DE combination of Fe/Cu -chelators and docosahexaenoic acid; myeloid cell
   leukemia-1 (Mcl-1); apoptosis; ubiquitination; colorectal cancer
ID IRON CHELATORS; ANTITUMOR-ACTIVITY; SURVIVORSHIP STATISTICS; OXIDATIVE
   STRESS; COPPER COMPLEX; CELLS; AUTOPHAGY; TARGET; COLON; 5-FLUOROURACIL
AB Colorectal cancer (CRC) is one of the major causes of cancer deaths in the world. 5-fluorouracil (5-FU) -based chemotherapy is a common choice for patients with CRC; unfortunately, the benefit is rather limited due to the acquisition of drug resistance. Therefore, the alternative therapeutic strategies are required. The activation of autophagic mechanism was considered as the main cause of the acquisition of drug resistance in 5-FU treatment. Docosahexaenoic acid (DHA), a fatty acid, has been regarded as an efficient anticancer agent and can improve the drug resistance in conventional cancer therapy by a low basal level of autophagy in colon cancer cells. Moreover, removal of iron or copper by metal chelators could cause ROS levels increase and mediate cancer cell cytotoxicity led by autophagy. In the present study, we constructed a combination of 5-FU, 1:1 mixture of metal chelators di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone hydrochloride (DpC) and N, N, N', N'-tetrakis-[2-pyridylmethyl]-ethylenediamine (TPEN) named DTN, and DHA to evaluate the anticancer effect of this combination, compared to the traditional 5-FU-based chemotherapy; further we investigated the underlying mechanism. Through inducing ROS-mediated degradation of Mcl-1 ubiquitination, the triple combination of 5-FU, DTN and DHA resulted in the elevated apoptosis in CRC cells, thus to reduce the tumor size and weight. Taken together, this study suggests the triple combination of 5-FU+DTN+DHA exhibits an effective anticancer activity of overcoming drug resistance in colorectal cancer, mechanism as the elevated apoptosis mediated by an increase of ROS and Mcl-1 ubiquitination, may be a novel strategy for clinical colon cancer treatment.
C1 [Yu, Nanhui; Zhu, Hong; Tao, Yiming; Tan, Fengbo; Pei, Qian; Zhou, Yuan; Song, Xiangping; Pei, Haiping] Cent S Univ, Xiangya Hosp, Dept Gastrointestinal Surg, Changsha 410008, Hunan, Peoples R China.
   [Yu, Nanhui; Tan, Qiurong] Changsha Hosp Maternal & Child Hlth Care, Dept Pharm, Changsha 410007, Hunan, Peoples R China.
   [Yang, Yuan] Hunan Univ Med, Dept Lab Med, Dong Med Key Lab Hunan Prov, Changsha 418000, Hunan, Peoples R China.
RP Pei, HP (corresponding author), Cent S Univ, Xiangya Hosp, Dept Gastrointestinal Surg, Changsha 410008, Hunan, Peoples R China.
EM haiping1977pei@163.com
RI SONG, XIANGPING/AAH-7273-2019
OI Yu, Nanhui/0000-0001-5474-2198
FU Key research and development plan and technical innovation guidance
   project of Hunan Province [2016WK2034]; Natural Science Foundation of
   Hunan ProvinceNatural Science Foundation of Hunan Province [2016JJ6106];
   Scientific Research Project of Hunan province education department
   [14C0911]; Youth science and Technology Talents of Hunan University of
   Medicine (China) [[2013] 49-1]; Science and Technology Plan Fund in
   Hunan Province, People's Republic of China [2015SK2020, 2015WK3011];
   CSCO Clinic Tumor Research Foundation [Y-MX2014-002]
FX This study was sponsored by the Key research and development plan and
   technical innovation guidance project of Hunan Province (2016WK2034),
   Natural Science Foundation of Hunan Province (2016JJ6106), Scientific
   Research Project of Hunan province education department (14C0911), Youth
   science and Technology Talents of Hunan University of Medicine
   (No.[2013] 49-1) China), the Science and Technology Plan Fund in Hunan
   Province, People's Republic of China (2015SK2020 and 2015WK3011) and
   CSCO Clinic Tumor Research Foundation (Y-MX2014-002).
CR ARSLAN P, 1985, J BIOL CHEM, V260, P2719
   Chakraborty A, 2010, EUR J PHARMACOL, V647, P1, DOI 10.1016/j.ejphar.2010.08.003
   Choi WY, 2005, J BIOL CHEM, V280, P3295, DOI 10.1074/jbc.M409930200
   Denoyer D, 2015, METALLOMICS, V7, P1459, DOI 10.1039/c5mt00149h
   DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235
   Finney L, 2007, P NATL ACAD SCI USA, V104, P2247, DOI 10.1073/pnas.0607238104
   Fong MY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042265
   Gupte A, 2009, CANCER TREAT REV, V35, P32, DOI 10.1016/j.ctrv.2008.07.004
   Gutierrez E, 2014, J BIOL CHEM, V289, P33568, DOI 10.1074/jbc.M114.599480
   Han Ying, 2005, Chin J Dig Dis, V6, P82, DOI 10.1111/j.1443-9573.2005.00197.x
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hector S, 2008, CANCER CHEMOTH PHARM, V62, P517, DOI 10.1007/s00280-007-0633-2
   Holch J, 2016, VISC MED, V32, P178, DOI 10.1159/000446052
   Hu B, 2010, P NATL ACAD SCI USA, V107, P21635, DOI 10.1073/pnas.1016814108
   Hwang JJ, 2010, BIOMETALS, V23, P997, DOI 10.1007/s10534-010-9346-9
   Janakiram NB, 2009, CANCER PREV RES, V2, P52, DOI 10.1158/1940-6207.CAPR-08-0140
   Jansson PJ, 2010, J MED CHEM, V53, P5759, DOI 10.1021/jm100561b
   Jing K, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.477
   Kalinowski DS, 2007, J MED CHEM, V50, P6212, DOI 10.1021/jm070839q
   Kalinowski DS, 2005, PHARMACOL REV, V57, P547, DOI 10.1124/pr.57.4.2
   Kanno S, 2013, INT J ONCOL, V43, P1413, DOI 10.3892/ijo.2013.2093
   Kazi A, 2011, J BIOL CHEM, V286, P9382, DOI 10.1074/jbc.M110.203638
   Lim K, 2008, CANCER RES, V68, P553, DOI 10.1158/0008-5472.CAN-07-2295
   Lovejoy DB, 2011, CANCER RES, V71, P5871, DOI 10.1158/0008-5472.CAN-11-1218
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   Mojsa B, 2014, CELLS-BASEL, V3, P418, DOI 10.3390/cells3020418
   Notte A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.167
   Park GT, 2017, CANCER RES TREAT, V49, P79, DOI 10.4143/crt.2015.503
   Pettersen K, 2016, FREE RADICAL BIO MED, V90, P158, DOI 10.1016/j.freeradbiomed.2015.11.018
   Siddiqui RA, 2008, CHEM PHYS LIPIDS, V153, P47, DOI 10.1016/j.chemphyslip.2008.02.009
   Siddiqui RA, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-418
   Singh NP, 2004, ANTICANCER RES, V24, P2277
   Su YC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148408
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Tapiero H, 2003, BIOMED PHARMACOTHER, V57, P399, DOI 10.1016/S0753-3322(03)00081-7
   Tong JS, 2017, CANCER RES, V77, P2512, DOI 10.1158/0008-5472.CAN-16-3242
   Trinder D, 1996, HEPATOLOGY, V23, P1512, DOI 10.1002/hep.510230631
   Vavrova J, 2014, FOLIA BIOL-PRAGUE, V60, P53
   Whitnall M, 2006, P NATL ACAD SCI USA, V103, P14901, DOI 10.1073/pnas.0604979103
   Yuan J, 2004, BLOOD, V104, P1450, DOI 10.1182/blood-2004-03-0868
   Zajakina A, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-460
   Zhou J, 2015, AUTOPHAGY, V11, P1259, DOI 10.1080/15548627.2015.1056970
NR 42
TC 5
Z9 5
U1 0
U2 9
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 1
PY 2017
VL 8
IS 31
BP 51478
EP 51491
DI 10.18632/oncotarget.17807
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FC3CZ
UT WOS:000406717200102
PM 28881661
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Osorio-Vega, H
   Finol, HJ
   Roschman-Gonzalez, A
   Sardina, C
AF Osorio-Vega, H.
   Finol, H. J.
   Roschman-Gonzalez, A.
   Sardina, C.
TI COLON ADENOCARCINOMA AND CELL DEATH TYPES: AN ULTRASTRUCTURAL STUDY
SO ACTA MICROSCOPICA
LA English
DT Article
DE Human colon adenocarcinoma; ultrastructure; apoptosis; autophagy;
   necrosis
ID APOPTOSIS; AUTOPHAGY; CANCER; NECROSIS
AB Three forms of cell death were found in human colon adenocarcinoma (HCAC), apoptosis, autophagy, and necrosis, by transmission electron microscopy. Apoptosis was characterized by chromatin hypercondensation and formation of apoptotic bodies, which were covered by plasma membrane. In autophagic cell death, autophagosomes of different complexities were observed along the process of cell degeneration which preceded nuclear collapse. In necrosis, cytoplasmic organelles, most notably mitochondria, were swollen, and plasma membrane was broken down causing the release of the cellular content into the extracellular space.
C1 [Osorio-Vega, H.; Finol, H. J.; Roschman-Gonzalez, A.] Cent Univ Venezuela, Fac Sci, Ctr Electron Microscopy, Caracas, Venezuela.
   [Sardina, C.] Caracas Univ Hosp, Coloproctol Unit, Caracas, Venezuela.
RP Finol, HJ (corresponding author), Cent Univ Venezuela, Fac Sci, Ctr Electron Microscopy, Caracas, Venezuela.
EM hector.finol@gmail.com
CR ANILKUMAR TV, 1992, BRIT J CANCER, V65, P552, DOI 10.1038/bjc.1992.113
   Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852
   de Bruin EC, 2008, CANCER TREAT REV, V34, P737, DOI 10.1016/j.ctrv.2008.07.001
   Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Fulda S, 2013, CANCER BIOL THER, V14, P999, DOI 10.4161/cbt.26428
   GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3
   GUNDERSON LL, 1974, CANCER-AM CANCER SOC, V34, P1278, DOI 10.1002/1097-0142(197410)34:4<1278::AID-CNCR2820340440>3.0.CO;2-F
   Koehler BC, 2014, WORLD J GASTROENTERO, V20, P1923, DOI 10.3748/wjg.v20.i8.1923
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   Kubisch J, 2013, SEMIN CANCER BIOL, V23, P252, DOI 10.1016/j.semcancer.2013.06.009
   Nunes T, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/218493
   Partik G, 1998, VIRCHOWS ARCH, V432, P415, DOI 10.1007/s004280050185
   Schaper J, 1999, CIRC RES, V85, P867, DOI 10.1161/01.RES.85.9.867
   Tatebe S, 1996, INT J CANCER, V65, P173, DOI 10.1002/(SICI)1097-0215(19960117)65:2<173::AID-IJC8>3.0.CO;2-W
   Todde V, 2009, BBA-MOL BASIS DIS, V1792, P3, DOI 10.1016/j.bbadis.2008.10.016
   Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970
   Watanabe M, 2002, MICROSC MICROANAL, V8, P375, DOI 10.1017/S1431927602010346
   ZAKERI Z, 1995, CELL DEATH DIFFER, V2, P87
NR 19
TC 2
Z9 3
U1 0
U2 0
PU COMITE INTERAMERICANO SOC MICROSCOPIA ELECTRONICA-CIASEM
PI CARACAS
PA CARRETERA PANAMERICANA KM 11, APARTADO POSTAL 20632, CARACAS, 1020-A,
   VENEZUELA
SN 0798-4545
EI 2224-8927
J9 ACTA MICROSC
JI Acta Microsc.
PY 2016
VL 25
IS 2
BP 65
EP 70
PG 6
WC Microscopy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Microscopy
GA DQ0RV
UT WOS:000378908500003
DA 2022-04-25
ER

PT J
AU Athamneh, K
   El Hasasna, H
   Al Samri, H
   Attoub, S
   Arafat, K
   Benhalilou, N
   Al Rashedi, A
   Al Dhaheri, Y
   AbuQamar, S
   Eid, A
   Iratni, R
AF Athamneh, Khawlah
   El Hasasna, Hussain
   Al Samri, Halima
   Attoub, Samir
   Arafat, Kholoud
   Benhalilou, Nehla
   Al Rashedi, Asma
   Al Dhaheri, Yusra
   AbuQamar, Synan
   Eid, Ali
   Iratni, Rabah
TI Rhus coriaria increases protein ubiquitination, proteasomal degradation
   and triggers non-canonical Beclin-1-independent autophagy and apoptotic
   cell death in colon cancer cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MUTANT P53; BREAST-CANCER; MAMMALIAN TARGET; GROWTH; INHIBITION; SYSTEM;
   L.; MITOCHONDRIA; RESVERATROL; ANTIOXIDANT
AB Colorectal cancer is the fourth leading cause of cancer-related deaths worldwide. Here, we investigated the anticancer effect of Rhus coriaria extract (RCE) on HT-29 and Caco-2 human colorectal cancer cells. We found that RCE significantly inhibited the viability and colony growth of colon cancer cells. Moreover, RCE induced Beclin-1-independent autophagy and subsequent caspase-7-dependent apoptosis. Blocking of autophagy by chloroquine significantly reduced RCE-induced cell death, while blocking of apoptosis had no effect on RCE-induced cell death. Mechanistically, RCE inactivated the AKT/mTOR pathway by promoting the proteasome-dependent degradation of both proteins. Strikingly, we also found that RCE targeted Beclin-1, p53 and procaspase-3 to degradation. Proteasome inhibition by MG-132 not only restored these proteins to level comparable to control cells, but also reduced RCE-induced cell death and blocked the activation of autophagy and apoptosis. The proteasomal degradation of mTOR, which occurred only 3 hours post-RCE treatment was concomitant with an overall increase in the level of ubiquitinated proteins and translated stimulation of proteolysis by the proteasome. Our findings demonstrate that Rhus coriaria possesses strong anti-colon cancer activity through stimulation of proteolysis as well as induction of autophagic and apoptotic cell death, making it a potential and valuable source of novel therapeutic cancer drug.
C1 [Athamneh, Khawlah; El Hasasna, Hussain; Al Samri, Halima; Benhalilou, Nehla; Al Rashedi, Asma; Al Dhaheri, Yusra; AbuQamar, Synan; Iratni, Rabah] United Arab Emirates Univ, Coll Sci, Dept Biol, POB 15551, Al Ain, U Arab Emirates.
   [Attoub, Samir; Arafat, Kholoud] United Arab Emirates Univ, Coll Med & Hlth Sci, Dept Pharmacol & Therapeut, POB 17666, Al Ain, U Arab Emirates.
   [Eid, Ali] Amer Univ Beirut, Fac Med, Dept Pharmacol & Toxicol, POB 11-0236, Beirut, Lebanon.
RP Iratni, R (corresponding author), United Arab Emirates Univ, Coll Sci, Dept Biol, POB 15551, Al Ain, U Arab Emirates.
EM R_iratni@uaeu.ac.ae
RI AbuQamar, Synan/AAV-1229-2021; Attoub, Samir/N-6852-2018; Eid, Ali
   Hussein/ABD-6291-2021
OI AbuQamar, Synan/0000-0002-2129-7689; Eid, Ali
   Hussein/0000-0003-3004-5675
FU UAEU Program for Advanced Research [31S111-UPAR]; Zayed Center for
   Health Sciences (ZCHS) research grant [31R086]
FX This work was supported by UAEU Program for Advanced Research (Grant
   31S111-UPAR) and by the Zayed Center for Health Sciences (ZCHS) research
   grant (grant 31R086) to Rabah Iratni.
CR Abu-Reidah IM, 2015, FOOD CHEM, V166, P179, DOI 10.1016/j.foodchem.2014.06.011
   Al Dhaheri Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109630
   AlQurashi N, 2013, HUM PATHOL, V44, P2089, DOI 10.1016/j.humpath.2013.03.014
   Benbrook D. M., 2012, Experimental Oncology, V34, P286
   Bhattacharyya S, 2014, NAT REV MOL CELL BIO, V15, P122, DOI 10.1038/nrm3741
   Bossi G, 2006, ONCOGENE, V25, P304, DOI 10.1038/sj.onc.1209026
   CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615
   Codogno P, 2012, NAT REV MOL CELL BIO, V13, P7, DOI 10.1038/nrm3249
   Cragg GM, 2005, J ETHNOPHARMACOL, V100, P72, DOI 10.1016/j.jep.2005.05.011
   Cragg GM, 2000, EXPERT OPIN INV DRUG, V9, P2783, DOI 10.1517/13543784.9.12.2783
   Dikic I, 2017, ANNU REV BIOCHEM, V86, P193, DOI 10.1146/annurev-biochem-061516-044908
   Din FVN, 2012, GASTROENTEROLOGY, V142, P1504, DOI 10.1053/j.gastro.2012.02.050
   Dogan A, 2016, PHARM BIOL, V54, P2092, DOI 10.3109/13880209.2016.1145702
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   El Hasasna H, 2016, SCI REP-UK, V6, DOI 10.1038/srep21144
   El Hasasna H, 2015, SCI REP-UK, V5, DOI 10.1038/srep13013
   Fojo T, 2002, DRUG RESIST UPDATE, V5, P209, DOI 10.1016/S1368-7646(02)00119-X
   Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112
   Gulhati P, 2009, CLIN CANCER RES, V15, P7207, DOI 10.1158/1078-0432.CCR-09-1249
   Ibrahim M. A. - R., JORDAN J BIOL SCI, V7, P233
   Ji CH, 2017, MOL CELLS, V40, P441, DOI 10.14348/molcells.2017.0115
   Kaczirek K, 2004, J CLIN ENDOCR METAB, V89, P2397, DOI 10.1210/jc.2003-031314
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Kondo Y, 2006, AUTOPHAGY, V2, P85, DOI 10.4161/auto.2.2.2463
   Kosar M, 2007, FOOD CHEM, V103, P952, DOI 10.1016/j.foodchem.2006.09.049
   Lee ATC, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-16
   Lee JY, 2010, EMBO J, V29, P969, DOI 10.1038/emboj.2009.405
   Lilienbaum Alain, 2013, Int J Biochem Mol Biol, V4, P1
   Liu WJ, 2016, CELL MOL BIOL LETT, V21, DOI 10.1186/s11658-016-0031-z
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672
   Memmott RM, 2009, CELL SIGNAL, V21, P656, DOI 10.1016/j.cellsig.2009.01.004
   Mohammadi S, 2010, DARU, V18, P270
   Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021
   Nalepa G, 2006, NAT REV DRUG DISCOV, V5, P596, DOI 10.1038/nrd2056
   Nasar-Abbas SM, 2004, INT J FOOD MICROBIOL, V97, P63, DOI 10.1016/j.ijfoodmicro.2004.04.009
   Nedelsky NB, 2008, BBA-MOL BASIS DIS, V1782, P691, DOI 10.1016/j.bbadis.2008.10.002
   Onkar S., 2011, INT RES J PHARM, V2, P188
   Pandey UB, 2007, NATURE, V447, P859, DOI 10.1038/nature05853
   Panico A, 2009, J MED PLANTS RES, V3, P855
   Rayne S, 2007, PLANT FOOD HUM NUTR, V62, P165, DOI 10.1007/s11130-007-0058-4
   ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6
   Scarlatti F, 2008, CELL DEATH DIFFER, V15, P1318, DOI 10.1038/cdd.2008.51
   Selivanova G, 2001, Curr Opin Investig Drugs, V2, P1136
   Shabbir A, 2012, J ANIM PLANT SCI, V22, P505
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Shrivastava A, 2011, MOL CANCER THER, V10, P1161, DOI 10.1158/1535-7163.MCT-10-1100
   Suh SS, 2012, P NATL ACAD SCI USA, V109, P5316, DOI 10.1073/pnas.1202465109
   Sun L, 2015, AM J CANCER RES, V5, P2626
   Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908
   Trincheri NF, 2008, CARCINOGENESIS, V29, P381, DOI 10.1093/carcin/bgm271
   Vijayakumaran R, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00284
   Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675
   Wang CH, 2015, BBA-MOL BASIS DIS, V1852, P188, DOI 10.1016/j.bbadis.2014.07.028
   World Health Organization, CANCER
   Xue L, 2001, CURR BIOL, V11, P361, DOI 10.1016/S0960-9822(01)00100-2
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
   Yuan HX, 2013, MOL CELL, V49, P379, DOI 10.1016/j.molcel.2013.01.019
   Zhang YN, 2014, NATURE, V513, P440, DOI 10.1038/nature13492
   Zhao J, 2007, CELL METAB, V6, P472, DOI 10.1016/j.cmet.2007.11.004
   Zhao JH, 2015, P NATL ACAD SCI USA, V112, P15790, DOI 10.1073/pnas.1521919112
NR 61
TC 25
Z9 26
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 14
PY 2017
VL 7
AR 11633
DI 10.1038/s41598-017-11202-3
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FG9DM
UT WOS:000410739000131
PM 28912474
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Pan, Z
   Xie, YP
   Bai, J
   Lin, QY
   Cui, XN
   Zhang, NN
AF Pan, Zhe
   Xie, Yunpeng
   Bai, Jie
   Lin, Qiuyue
   Cui, Xiaonan
   Zhang, Ningning
TI Bufalin suppresses colorectal cancer cell growth through promoting
   autophagy in vivo and in vitro
SO RSC ADVANCES
LA English
DT Article
ID HUMAN HEPATOCELLULAR-CARCINOMA; INDUCED APOPTOSIS; ARSENIC TRIOXIDE;
   COLON-CANCER; DEATH; MECHANISMS; PI3K/AKT; ARREST
AB Specific groups in Asia, including the Chinese, are more susceptible to colorectal cancer (CRC). The best strategy for anticancer drug action is to induce cancer cell apoptosis and autophagy. Bufalin is a potent inducer of apoptosis in some human cancer cell lines, but bufalin has barely been evaluated in colorectal cancer cells as a potent autophagy inducing agent. The aim of this study was to investigate the roles and interactions of bufalin in autophagy and the effects of the drug on human colorectal cancer. We applied bufalin and autophagy inhibitors (CQ and 3-MA) in LoVo cells to investigate their potential anticancer bioactivity under certain concentrations of bufalin to monitor autophagy and cell proliferation in vivo and in vitro. Bufalin induced autophagy of LoVo and inhibited proliferation of LoVo cells. Bufalin inhibited the expression of autophagy-related (ATG) proteins and tumor growth in vivo. Our studies identified that bufalin could potentially be a small molecule inhibitor for cancer therapy.
C1 [Pan, Zhe; Xie, Yunpeng; Lin, Qiuyue; Cui, Xiaonan; Zhang, Ningning] Dalian Med Univ, Affiliated Hosp 1, Dalian 116021, Liaoning, Peoples R China.
   [Bai, Jie] Dalian Med Univ, Sch Publ Hlth, Dalian 116044, Liaoning, Peoples R China.
RP Cui, XN; Zhang, NN (corresponding author), Dalian Med Univ, Affiliated Hosp 1, Dalian 116021, Liaoning, Peoples R China.
EM Xiaonan_cui@163.com; zhangningning@dmu.edu.cn
RI Xie, Yunpeng/AAD-5158-2019
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81800142, 81600197]; Basic Scientific
   Research Projects of Colleges and Universities in Liaoning Province
   [LQ2017021]
FX This study was supported by the National Natural Science Foundation of
   China (81800142, 81600197); the funds from Basic Scientific Research
   Projects of Colleges and Universities in Liaoning Province (LQ2017021).
CR Andre T, 2009, J CLIN ONCOL, V27, P3109, DOI 10.1200/JCO.2008.20.6771
   Bellodi C, 2009, J CLIN INVEST, V119, P1109, DOI 10.1172/JCI35660
   Cao BY, 2014, SCI REP-UK, V4, DOI 10.1038/srep05749
   Chiu HW, 2009, AUTOPHAGY, V5, P472, DOI 10.4161/auto.5.4.7759
   Han KQ, 2007, WORLD J GASTROENTERO, V13, P3374, DOI 10.3748/wjg.v13.i24.3374
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Hu FL, 2014, APOPTOSIS, V19, P210, DOI 10.1007/s10495-013-0914-7
   Huang Q, 2016, APOPTOSIS, V21, P749, DOI 10.1007/s10495-016-1243-4
   Kang XH, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/243859
   Kim DK, 2009, CANCER RES, V69, P923, DOI 10.1158/0008-5472.CAN-08-2115
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Li D, 2009, ANTI-CANCER DRUG, V20, P59, DOI 10.1097/CAD.0b013e3283160fd6
   Liu DL, 2011, MED ONCOL, V28, P105, DOI 10.1007/s12032-009-9397-3
   Liu YL, 2010, AUTOPHAGY, V6, P1057, DOI 10.4161/auto.6.8.13365
   Marchetti S, 2007, BRIT J CANCER, V97, P577, DOI 10.1038/sj.bjc.6603925
   Marin JJG, 2012, DRUG METAB REV, V44, P148, DOI 10.3109/03602532.2011.638303
   Meng ZQ, 2009, CANCER-AM CANCER SOC, V115, P5309, DOI 10.1002/cncr.24602
   Ng SC, 2013, BRIT MED BULL, V105, P29, DOI 10.1093/bmb/lds040
   Pattingre S, 2009, J BIOL CHEM, V284, P2719, DOI 10.1074/jbc.M805920200
   Qian WB, 2007, LEUKEMIA RES, V31, P329, DOI 10.1016/j.leukres.2006.06.021
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Sun L., 2011, J EVIDENCE BASED COM, V2011
   Takai N, 2008, INT J MOL MED, V21, P637
   Takai N, 2012, ASIAN PAC J CANCER P, V13, P399, DOI 10.7314/APJCP.2012.13.1.399
   Watabe M, 1998, ONCOGENE, V16, P779, DOI 10.1038/sj.onc.1201592
   Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016
   Yeh JY, 2003, PROSTATE, V54, P112, DOI 10.1002/pros.10172
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
   Zhang NN, 2016, CELL PHYSIOL BIOCHEM, V40, P1559, DOI 10.1159/000453206
NR 31
TC 4
Z9 5
U1 5
U2 13
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2018
VL 8
IS 68
BP 38910
EP 38918
DI 10.1039/c8ra06566g
PG 9
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA HB5HQ
UT WOS:000451090800025
OA gold
DA 2022-04-25
ER

PT J
AU Kim, SW
   Lee, JH
   Moon, JH
   Nazim, UMD
   Lee, YJ
   Seol, JW
   Hur, J
   Eo, SK
   Lee, JH
   Park, SY
AF Kim, Sung-Wook
   Lee, Ju-Hee
   Moon, Ji-Hong
   Nazim, Uddin M. D.
   Lee, You-Jin
   Seol, Jae-Won
   Hur, Jin
   Eo, Seong-Kug
   Lee, John-Hwa
   Park, Sang-Youel
TI Niacin alleviates TRAIL-mediated colon cancer cell death via autophagy
   flux activation
SO ONCOTARGET
LA English
DT Article
DE niacin; autophagy; TRAIL; death receptor; mitochondrial membrane
   potential
ID APOPTOSIS-INDUCING LIGAND; DEFECTIVE APOPTOSIS; PROSTATE-CANCER;
   NEURONAL CELLS; SURVIVAL; RECEPTORS; PROTEIN; NECROSIS; MITOCHONDRIA;
   APO2L/TRAIL
AB Niacin, also known as vitamin B3 or nicotinamide is a water-soluble vitamin that is present in black beans and rice among other foods. Niacin is well known as an inhibitor of metastasis in human breast carcinoma cells but the effect of niacin treatment on TRAIL-mediated apoptosis is unknown. Here, we show that niacin plays an important role in the regulation of autophagic flux and protects tumor cells against TRAIL-mediated apoptosis. Our results indicated that niacin activated autophagic flux in human colon cancer cells and the autophagic flux activation protected tumor cells from TRAIL-induced dysfunction of mitochondrial membrane potential and tumor cell death. We also demonstrated that ATG5 siRNA and autophagy inhibitor blocked the niacin-mediated inhibition of TRAIL-induced apoptosis. Taken together, our study is the first report demonstrating that niacin inhibits TRAIL-induced apoptosis through activation of autophagic flux in human colon cancer cells. And our results also suggest that autophagy inhibitors including genetic and pharmacological tools may be a successful therapeutics during anticancer therapy using TRAIL.
C1 [Kim, Sung-Wook; Lee, Ju-Hee; Moon, Ji-Hong; Nazim, Uddin M. D.; Lee, You-Jin; Seol, Jae-Won; Hur, Jin; Eo, Seong-Kug; Lee, John-Hwa; Park, Sang-Youel] Chonbuk Natl Univ, Biosafety Res Inst, Dept Biochem, Coll Vet Med, Jeonju 561756, Jeonbuk, South Korea.
RP Park, SY (corresponding author), Chonbuk Natl Univ, Biosafety Res Inst, Dept Biochem, Coll Vet Med, Jeonju 561756, Jeonbuk, South Korea.
EM sypark@chonbuk.ac.kr
RI Park, Sang-Youel/D-5966-2012
OI Park, Sang-Youel/0000-0003-0575-6045
FU National Research Foundation of Korea (NRF) - Korean government (MISP)
   [2013R1A4A1069486]
FX This study was supported by a grant from the National Research
   Foundation of Korea (NRF), funded by the Korean government (MISP)
   (2013R1A4A1069486).
CR Abdulghani J, 2010, EXPERT OPIN THER TAR, V14, P1091, DOI 10.1517/14728222.2010.519701
   Aubert S, 1996, J CELL BIOL, V133, P1251, DOI 10.1083/jcb.133.6.1251
   Bhansali SG, 2006, TOXICOL MECH METHOD, V16, P173, DOI 10.1080/15376520500194726
   Cantarella L, 2011, ENZYME MICROB TECH, V48, P345, DOI 10.1016/j.enzmictec.2010.12.010
   Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736
   Chhipa RR, 2011, CELL SIGNAL, V23, P1466, DOI 10.1016/j.cellsig.2011.04.008
   Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722
   Galligan L, 2005, MOL CANCER THER, V4, P2026, DOI 10.1158/1535-7163.MCT-05-0262
   Hayashi T, 2003, RECENT PROG HORM RES, V58, P131, DOI 10.1210/rp.58.1.131
   Hellwig CT, 2012, MOL CANCER THER, V11, P3, DOI 10.1158/1535-7163.MCT-11-0434
   Herrero-Martin G, 2009, EMBO J, V28, P677, DOI 10.1038/emboj.2009.8
   Hughes MA, 2009, MOL CELL, V35, P265, DOI 10.1016/j.molcel.2009.06.012
   Itakura E, 2011, J CELL BIOL, V192, P17, DOI 10.1083/jcb.201009067
   Jeong JK, 2011, INT J MOL MED, V27, P689, DOI 10.3892/ijmm.2011.626
   Jin ZY, 2009, CELL, V137, P721, DOI 10.1016/j.cell.2009.03.015
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kirkland JB, 2003, NUTR CANCER, V46, P110, DOI 10.1207/S15327914NC4602_02
   Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Kourtis N, 2009, CELL DEATH DIFFER, V16, P21, DOI 10.1038/cdd.2008.120
   Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738
   Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Leong S, 2009, J CLIN ONCOL, V27, P4413, DOI 10.1200/JCO.2008.21.7422
   Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998
   LUTSKII K M, 1951, Dokl Akad Nauk SSSR, V80, P919
   MAJNO G, 1995, AM J PATHOL, V146, P3
   Mora R, 2009, GLIA, V57, P561, DOI 10.1002/glia.20785
   MOUNTZ JD, 1994, ARTHRITIS RHEUM, V37, P1415, DOI 10.1002/art.1780371002
   Nakatogawa H, 2007, CELL, V130, P165, DOI 10.1016/j.cell.2007.05.021
   NODA T, 1995, BIOCHEM BIOPH RES CO, V210, P126, DOI 10.1006/bbrc.1995.1636
   Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815
   Petersen A, 2001, HUM MOL GENET, V10, P1243, DOI 10.1093/hmg/10.12.1243
   Prakash R, 2008, GEN HOSP PSYCHIAT, V30, P581, DOI 10.1016/j.genhosppsych.2008.04.011
   REUNANEN H, 1985, HISTOCHEMISTRY, V83, P513, DOI 10.1007/BF00492453
   Salim T, 2013, INT J CANCER, V133, P807, DOI 10.1002/ijc.28074
   Santidrian AF, 2013, J CLIN INVEST, V123, P1068, DOI 10.1172/JCI64264
   Saraste A, 2000, CARDIOVASC RES, V45, P528, DOI 10.1016/S0008-6363(99)00384-3
   Selimi F, 2003, NEURON, V37, P813, DOI 10.1016/S0896-6273(03)00093-X
   Seo JS, 2010, J NEUROCHEM, V112, P715, DOI 10.1111/j.1471-4159.2009.06496.x
   Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818
   Singh K, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-70
   Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x
   Stegehuis JH, 2010, DRUG RESIST UPDATE, V13, P2, DOI 10.1016/j.drup.2009.11.001
   Sun HW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112310
   Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x
   van Geelen CM, 2006, J CLIN ONCOL, V24, P4998, DOI 10.1200/JCO.2006.06.8809
   Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627
   Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517
   Wu Zhaoju, 2010, Genes Cancer, V1, P40, DOI 10.1177/1947601909358324
   Xie ZP, 2008, MOL BIOL CELL, V19, P3290, DOI 10.1091/mbc.E07-12-1292
NR 51
TC 22
Z9 23
U1 1
U2 12
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 26
PY 2016
VL 7
IS 4
BP 4356
EP 4368
DI 10.18632/oncotarget.5374
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DD5HA
UT WOS:000369952400052
PM 26517672
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Greene, LM
   Nolan, DP
   Regan-Komito, D
   Campiani, G
   Williams, DC
   Zisterer, DM
AF Greene, Lisa M.
   Nolan, Derek P.
   Regan-Komito, Daniel
   Campiani, Giuseppe
   Williams, D. Clive
   Zisterer, Daniela M.
TI Inhibition of late-stage autophagy synergistically enhances
   pyrrolo-1,5-benzoxazepine-6-induced apoptotic cell death in human colon
   cancer cells
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE pyrrolo-1,5-benzoxazepines autophagy apoptosis
ID MYELOID-LEUKEMIA CELLS; IN-VITRO; BREAST-CANCER; IMATINIB MESYLATE;
   TARGETING AGENT; BAFILOMYCIN; LYSOSOMES; FUSION; VIVO; MACROAUTOPHAGY
AB The pyrrolo-1,5-benzoxazepines (PBOXs) are a novel group of selective apoptotic agents displaying promising therapeutic potential in both ex vivo chemotherapy-refractory patient samples and in vivo murine carcinoma models. In this report, we present novel data concerning the induction of autophagy by the PBOXs in adenocarcinoma-derived colon cancer cells. Autophagy is a lysosome-dependent degradative pathway recently associated with chemotherapy. However, whether autophagy facilitates cell survival in response to chemotherapy or contributes to chemotherapy-induced cell death is highly controversial. Autophagy was identified by enhanced expression of LC3B-II, an autophagosome marker, an increase in the formation of acridine orange-stained cells, indicative of increased vesicle formation and electron microscopic confirmation of autophagic structures. The vacuolar H+ ATPase inhibitor bafilomycin-A1 (BAF-A1) inhibited vesicle formation and enhanced the apoptotic potential of PBOX-6. These findings suggest a cytoprotective role of autophagy in these cells following prolonged exposure to PBOX-6. Furthermore, BAF-A1 and PBOX-6 interactions were determined to be synergistic and caspase-dependent. Potentiation of PBOX-6-induced apoptosis by BAF-A1 was associated with a decrease in the levels of the anti-apoptotic protein, Mcl-1. The data provide evidence that autophagy functions as a survival mechanism in colon cancer cells to PBOX-6-induced apoptosis and a rationale for the use of autophagy inhibitors to further enhance PBOX-6-induced apoptosis in colon cancer.
C1 [Greene, Lisa M.; Nolan, Derek P.; Regan-Komito, Daniel; Williams, D. Clive; Zisterer, Daniela M.] Univ Dublin Trinity Coll, Sch Biochem & Immunol, Trinity Biomed Sci Inst, Dublin 2, Ireland.
   [Campiani, Giuseppe] European Res Ctr Drug Discovery & Dev, I-53100 Siena, Italy.
RP Zisterer, DM (corresponding author), Univ Dublin Trinity Coll, Sch Biochem & Immunol, 152-160 Pearse St, Dublin 2, Ireland.
EM dzistrer@tcd.ie
OI Zisterer, Daniela/0000-0001-5005-1023; Nolan, Derek/0000-0002-3742-4304
FU Health Research Board Ireland
FX We would like to thank the Health Research Board Ireland for funding the
   project.
CR Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Bright SA, 2010, BRIT J CANCER, V102, P1474, DOI 10.1038/sj.bjc.6605670
   Bright SA, 2010, BIOCHEM PHARMACOL, V80, P31, DOI 10.1016/j.bcp.2010.02.019
   Bright SA, 2009, BIOCHEM PHARMACOL, V77, P310, DOI 10.1016/j.bcp.2008.10.008
   Campiani G, 1996, J MED CHEM, V39, P3435, DOI 10.1021/jm960251b
   Cerniglia GJ, 2012, MOL PHARMACOL, V82, P1230, DOI 10.1124/mol.112.080408
   Clarke PGH, 2012, AUTOPHAGY, V8, P867, DOI 10.4161/auto.20380
   Cook KL, 2011, EXPERT REV ANTICANC, V11, P1283, DOI [10.1586/era.11.111, 10.1586/ERA.11.111]
   Forde JC, 2011, CANCER BIOL THER, V11, P421, DOI 10.4161/cbt.11.4.14183
   Garcia-Echeverria C, 2008, ONCOGENE, V27, P5511, DOI 10.1038/onc.2008.246
   Greene LM, 2008, MOL PHARMACOL, V73, P419, DOI 10.1124/mol.107.039024
   Greene LM, 2007, J PHARMACOL EXP THER, V321, P288, DOI 10.1124/jpet.106.116640
   Greene LM, 2012, BIOCHEM PHARMACOL, V84, P612, DOI 10.1016/j.bcp.2012.06.005
   Greene LM, 2005, ONCOL REP, V14, P1357
   Han WD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028491
   Hettiarachchi KD, 2006, CELL BIOL TOXICOL, V22, P169, DOI 10.1007/s10565-006-0054-8
   Huynh KK, 2007, EMBO J, V26, P313, DOI 10.1038/sj.emboj.7601511
   Jahreiss L, 2008, TRAFFIC, V9, P574, DOI 10.1111/j.1600-0854.2008.00701.x
   Kanematsu S, 2010, ANTICANCER RES, V30, P3381
   Kimura T, 2013, CANCER RES, V73, P3, DOI 10.1158/0008-5472.CAN-12-2464
   Klionsky DJ, 2008, AUTOPHAGY, V4, P849, DOI 10.4161/auto.6845
   Kundra R, 1999, J BIOL CHEM, V274, P31039, DOI 10.1074/jbc.274.43.31039
   Li DD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045058
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Liang B, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-213
   Luo SQ, 2013, AUTOPHAGY, V9, P104, DOI 10.4161/auto.22399
   Maginn EN, 2011, BRIT J CANCER, V104, P281, DOI 10.1038/sj.bjc.6606035
   Maycotte P, 2011, CANCER BIOL THER, V11, P127, DOI 10.4161/cbt.11.2.14627
   Mc Gee MM, 2004, J PHARMACOL EXP THER, V310, P1084, DOI 10.1124/jpet.104.067561
   McElligott AM, 2009, CANCER RES, V69, P8366, DOI 10.1158/0008-5472.CAN-09-0131
   Mulligan JM, 2006, MOL PHARMACOL, V70, P60, DOI 10.1124/mol.105.021204
   Nakatogawa H, 2009, NAT REV MOL CELL BIO, V10, P458, DOI 10.1038/nrm2708
   Nathwani SM, 2010, ONCOL REP, V24, P1499, DOI 10.3892/or_00001011
   Nathwani SM, 2010, CANCER CHEMOTH PHARM, V66, P585, DOI 10.1007/s00280-009-1200-9
   Nathwani SM, 2010, CANCER CHEMOTH PHARM, V65, P289, DOI 10.1007/s00280-009-1033-6
   Paillas S, 2012, AUTOPHAGY, V8, P1098, DOI 10.4161/auto.20268
   Pliyev BK, 2012, APOPTOSIS, V17, P1050, DOI 10.1007/s10495-012-0738-x
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   Rubinstein AD, 2011, MOL CELL, V44, P698, DOI 10.1016/j.molcel.2011.10.014
   Sasazawa Y, 2009, CANCER SCI, V100, P1460, DOI 10.1111/j.1349-7006.2009.01194.x
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Shen SS, 2012, AUTOPHAGY, V8, P1, DOI 10.4161/auto.8.1.16618
   Swampillai AL, 2012, CLIN ONCOL-UK, V24, P387, DOI 10.1016/j.clon.2011.09.010
   Trmcic MV, 2012, ORG BIOMOL CHEM, V10, P4933, DOI 10.1039/c2ob25514f
   Wu YC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037572
   Wu YC, 2009, BIOCHEM BIOPH RES CO, V382, P451, DOI 10.1016/j.bbrc.2009.03.051
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yogalingam G, 2008, J BIOL CHEM, V283, P35941, DOI 10.1074/jbc.M804543200
   Zhu S, 2013, AUTOPHAGY, V9, P317, DOI 10.4161/auto.22923
   Zisterer DM, 2001, BIOCHEM SOC T, V29, P704, DOI 10.1042/BST0290704
   Zois CE, 2009, AUTOPHAGY, V5, P442, DOI 10.4161/auto.5.4.7667
NR 52
TC 16
Z9 17
U1 0
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD SEP
PY 2013
VL 43
IS 3
BP 927
EP 935
DI 10.3892/ijo.2013.1989
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 190XD
UT WOS:000322375900028
PM 23799546
OA Bronze
DA 2022-04-25
ER

PT J
AU Therachiyil, L
   Haroon, J
   Sahir, F
   Siveen, KS
   Uddin, S
   Kulinski, M
   Buddenkotte, J
   Steinhoff, M
   Krishnankutty, R
AF Therachiyil, Lubna
   Haroon, Javeria
   Sahir, Fairooz
   Siveen, Kodappully S.
   Uddin, Shahab
   Kulinski, Michal
   Buddenkotte, Joerg
   Steinhoff, Martin
   Krishnankutty, Roopesh
TI Dysregulated Phosphorylation of p53, Autophagy and Stemness Attributes
   the Mutant p53 Harboring Colon Cancer Cells Impaired Sensitivity to
   Oxaliplatin
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE colon cancer; HCT 116; HT 29; p53; oxaliplatin; autophagy; therapy; drug
   resistance
ID TUMOR-SUPPRESSOR; SER46 PHOSPHORYLATION; COLORECTAL-CANCER;
   DRUG-RESISTANCE; BAX/BCL-2 RATIO; APOPTOSIS; PROTEIN; ACTIVATION;
   CHEMOSENSITIVITY; CHEMORESISTANCE
AB Colorectal cancer (CRC) forms one of the highest ranked cancer types in the world with its increasing incidence and mortality rates despite the advancement in cancer therapeutics. About 50% of human CRCs are reported to have defective p53 expression resultant ofTP53gene mutation often contributing to drug resistance. The current study was aimed to investigate the response of wild-typeTP53harboring HCT 116 and mutantTP53harboring HT 29 colon cancer cells to chemotherapeutic drug oxaliplatin (OX) and to elucidate the underlying molecular mechanisms of sensitivity/resistance in correlation to their p53 status. OX inhibited growth of wild-type p53-harboring colon cancer cells via p53/p21-Bax mediated apoptosis. Our study revealed that dysregulated phosphorylation of p53, autophagy as well as cancer stemness attributes the mutant p53-harboring colon cancer cells impaired sensitivity to OX.
C1 [Therachiyil, Lubna; Haroon, Javeria; Sahir, Fairooz; Siveen, Kodappully S.; Uddin, Shahab; Kulinski, Michal; Buddenkotte, Joerg; Steinhoff, Martin; Krishnankutty, Roopesh] Hamad Med Corp, Acad Hlth Syst, Translat Res Inst, Doha, Qatar.
   [Therachiyil, Lubna] Qatar Univ, Coll Pharm, Dept Pharmaceut Sci, Doha, Qatar.
   [Uddin, Shahab; Buddenkotte, Joerg; Steinhoff, Martin] Hamad Med Corp, Dept Dermatol & Venereol, Doha, Qatar.
   [Steinhoff, Martin] Qatar Fdn Educ, Weill Cornell Med Qatar, Dept Med, Doha, Qatar.
   [Steinhoff, Martin] Weill Cornell Med, Dept Med, New York, NY USA.
   [Steinhoff, Martin] Qatar Univ, Coll Med, Doha, Qatar.
RP Krishnankutty, R (corresponding author), Hamad Med Corp, Acad Hlth Syst, Translat Res Inst, Doha, Qatar.
EM rkrishnankutty@hamad.qa
RI Krishnankutty, Roopesh/M-5836-2015
OI Krishnankutty, Roopesh/0000-0002-1496-6135; Uddin,
   Shahab/0000-0003-1886-6710
FU Medical Research Center at Hamad Medical Corporation [15264/15]
FX The study was supported by the Medical Research Center at Hamad Medical
   Corporation (grant: MRC#15264/15).
CR Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576
   Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709
   Arandkar S, 2018, P NATL ACAD SCI USA, V115, P6410, DOI 10.1073/pnas.1719076115
   Bar JK, 2009, INT J GYNECOL CANCER, V19, P1322, DOI 10.1111/IGC.0b013e3181b70465
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863
   CHEN HY, 2019, SCI REP UK, V0009
   Chen N, 2009, BBA-MOL CELL RES, V1793, P1516, DOI 10.1016/j.bbamcr.2008.12.013
   Cojoc M, 2015, SEMIN CANCER BIOL, V31, P16, DOI 10.1016/j.semcancer.2014.06.004
   Cox ML, 2010, CELL SIGNAL, V22, P564, DOI 10.1016/j.cellsig.2009.11.014
   CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X
   Dai C, 2010, TRENDS MOL MED, V16, P528, DOI 10.1016/j.molmed.2010.09.002
   Le DDT, 2019, INT J ONCOL, V54, P702, DOI 10.3892/ijo.2018.4634
   Desantis V, 2018, TRANSL ONCOL, V11, P1350, DOI 10.1016/j.tranon.2018.08.014
   Di Francesco AM, 2002, CELL MOL LIFE SCI, V59, P1914, DOI 10.1007/PL00012514
   Dong ZW, 2016, BLOOD REV, V30, P369, DOI 10.1016/j.blre.2016.04.005
   Donnenberg VS, 2005, J CLIN PHARMACOL, V45, P872, DOI 10.1177/0091270005276905
   Du C, 2016, ONCOTARGET, V7, P2823, DOI 10.18632/oncotarget.6555
   Faivre S, 2003, BIOCHEM PHARMACOL, V66, P225, DOI 10.1016/S0006-2952(03)00260-0
   Farnebo M, 2010, BIOCHEM BIOPH RES CO, V396, P85, DOI 10.1016/j.bbrc.2010.02.152
   Favoriti P, 2016, UPDATES SURG, V68, P7, DOI 10.1007/s13304-016-0359-y
   Feng LJ, 2006, CELL CYCLE, V5, P2812, DOI 10.4161/cc.5.23.3526
   Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007
   Gao Y, 2015, INT SYM COMPUT INTEL, P21, DOI 10.1109/ISCID.2015.27
   Hasan S, 2018, BIOINFORMATION, V14, P80, DOI 10.6026/97320630014080
   He C, 2017, CHEMOTHERAPY, V62, P43, DOI 10.1159/000446361
   Hoogervorst EM, 2005, CANCER RES, V65, P3610, DOI 10.1158/0008-5472.CAN-04-4328
   Hsu HH, 2018, J CELL PHYSIOL, V233, P5458, DOI 10.1002/jcp.26406
   Hu YL, 2012, CANCER RES, V72, P4294, DOI 10.1158/0008-5472.CAN-12-1076
   Huang Z, 2016, INT J CANCER, V139, P23, DOI 10.1002/ijc.29990
   HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5
   James A, 2014, NUCLEUS-PHILA, V5, P402, DOI 10.4161/nucl.32235
   Ji MM, 2015, AUTOPHAGY, V11, P2160, DOI 10.1080/15548627.2015.1082024
   Jiang CL, 2017, ONCOL REP, V38, P2351, DOI 10.3892/or.2017.5924
   Jin SK, 2005, AUTOPHAGY, V1, P171, DOI 10.4161/auto.1.3.2051
   Kandioler D, 2014, J THORAC CARDIOV SUR, V148, P2280, DOI 10.1016/j.jtcvs.2014.06.079
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634
   Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167
   Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9
   Khodapasand Ehsan, 2015, Iranian Biomedical Journal, V19, P69, DOI 10.6091/ibj.1366.2015
   Kim EM, 2017, CANCER RES, V77, P3092, DOI 10.1158/0008-5472.CAN-16-2098
   Kim J, 2014, EMBO REP, V15, P1062, DOI 10.15252/embr.201438587
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Lai HH, 2018, BIOCHEM BIOPH RES CO, V506, P87, DOI 10.1016/j.bbrc.2018.10.071
   Leo R, 2019, CANCERS, V11, DOI 10.3390/cancers11101478
   Levine AJ, 2019, J MOL CELL BIOL, V11, P524, DOI 10.1093/jmcb/mjz026
   Li H., 2019, INT J MOL SCI, V20
   LI Y, 2017, CHIN J CANCER, V0036
   Lin CI, 2010, MOL CANCER RES, V8, P1217, DOI 10.1158/1541-7786.MCR-10-0162
   Lintoiu-Ursut B, 2015, J Med Life, V8 Spec Issue, P12
   Liu DP, 2010, ONCOGENE, V29, P949, DOI 10.1038/onc.2009.376
   Matsumoto M, 2004, ONCOLOGY-BASEL, V67, P143, DOI 10.1159/000081001
   Matsuoka M, 2001, BIOCHEM BIOPH RES CO, V282, P1120, DOI 10.1006/bbrc.2001.4700
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565
   MIYASHITA T, 1995, CELL, V80, P293
   Mohammed MK, 2016, GENES DIS, V3, P11, DOI 10.1016/j.gendis.2015.12.004
   Molchadsky A, 2017, CARCINOGENESIS, V38, P347, DOI 10.1093/carcin/bgw092
   Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021
   Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008
   Olivos DJ, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17121982
   Park EK, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.313
   Perri F, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.12.40
   Qian HR, 2016, ONCOTARGET, V7, P17641, DOI 10.18632/oncotarget.7508
   Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x
   Raymond E, 1998, ANN ONCOL, V9, P1053, DOI 10.1023/A:1008213732429
   REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1
   Rivlin N, 2015, SEMIN CANCER BIOL, V32, P10, DOI 10.1016/j.semcancer.2013.12.006
   Shetzer Y, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026203
   Shetzer Y, 2014, CARCINOGENESIS, V35, P1196, DOI 10.1093/carcin/bgu073
   Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X
   Soni M, 2018, MOL CANCER RES, V16, P1348, DOI 10.1158/1541-7786.MCR-17-0634
   Taira N, 2007, MOL CELL, V25, P725, DOI 10.1016/j.molcel.2007.02.007
   Takebe N, 2015, NAT REV CLIN ONCOL, V12, P445, DOI 10.1038/nrclinonc.2015.61
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Tasdemir E, 2008, AUTOPHAGY, V4, P810, DOI 10.4161/auto.6486
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012
   Urushibara S, 2017, ANTICANCER RES, V37, P4085, DOI 10.21873/anticanres.11795
   Velculescu VE, 1996, CLIN CHEM, V42, P858
   Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048
   VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8
   Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675
   Wawryk-Gawda E, 2014, PROTOPLASMA, V251, P525, DOI 10.1007/s00709-013-0548-1
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Xie XL, 2017, MOL CANCER RES, V15, P328, DOI 10.1158/1541-7786.MCR-16-0257-T
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yang T, 2019, CAN J GASTROENTEROL, V2019, DOI 10.1155/2019/9015453
   Yap DBS, 2004, CANCER RES, V64, P4749, DOI 10.1158/0008-5472.CAN-1305-2
   Young KH, 2008, BLOOD, V112, P3088, DOI 10.1182/blood-2008-01-129783
   YU G, 2019, INT J MOL SCI, V0020
   Yuan SL, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/9390878
   Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637
   Zheng H-C., 2017, MOLECULAR MECHANISMS
NR 96
TC 5
Z9 5
U1 2
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD AUG 28
PY 2020
VL 10
AR 1744
DI 10.3389/fonc.2020.01744
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA NP9VA
UT WOS:000570517000001
PM 32984059
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Sun, GC
   Zheng, ZP
   Lee, MH
   Xu, YJ
   Kang, S
   Dong, ZG
   Wang, MF
   Gu, ZN
   Li, HT
   Chen, W
AF Sun, Guochuan
   Zheng, Zongping
   Lee, Mee-Hyun
   Xu, Yijuan
   Kang, Soouk
   Dong, Zigang
   Wang, Mingfu
   Gu, Zhennan
   Li, Haitao
   Chen, Wei
TI Chemoprevention of Colorectal Cancer by Artocarpin, a Dietary
   Phytochemical from Artocarpus heterophyllus
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE Artocarpus heterophyllus; artocarpin; colorectal cancer; Akt
ID MOLECULAR TARGETS; CELLS; MUTATIONS
AB Artocarpus heterophyllus is an evergreen tree distributed in tropical regions, and its fruit (jackfruit) is well-known as the world's largest tree-borne fruit. Although A. heterophyllus has been widely used in folk medicines against inflammation, its potential in cancer chemoprevention remains unclear. Herein we identified artocarpin from A. heterophyllus as a promising colorectal cancer chemopreventive agent by targeting Akt kinase. Phenotypically, artocarpin exhibited selective cytotoxicity against human colon cancer cells. Artocarpin impaired the anchorage-independent growth capability, suppressed colon cancer cell growth, and induced a G1 phase cell cycle arrest which was followed by apoptotic as well as autophagic cell death. Mechanistic studies revealed that artocarpin directly targeted Akt 1 and 2 kinase activity evidenced by in vitro kinase assay, ex vivo binding assay as well as Akt downstream cellular signal transduction. Importantly, oral administration of artocarpin attenuated colitis-associated colorectal tumorigenesis in mice. Taken together, artocarpin, a bioactive component of A. heterophyllus, might merit investigation as a potential colorectal cancer chemopreventive agent.
C1 [Sun, Guochuan; Zheng, Zongping; Xu, Yijuan; Gu, Zhennan; Li, Haitao; Chen, Wei] Jiangnan Univ, Sch Food Sci & Technol, Wuxi 214122, Peoples R China.
   [Lee, Mee-Hyun; Kang, Soouk; Dong, Zigang] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA.
   [Wang, Mingfu] Univ Hong Kong, Sch Biol Sci, Hong Kong, Hong Kong, Peoples R China.
   [Chen, Wei] Beijing Technol & Business Univ, Beijing Innovat Ctr Food Nutr & Human Hlth, Beijing 100048, Peoples R China.
RP Li, HT; Chen, W (corresponding author), Jiangnan Univ, Sch Food Sci & Technol, Wuxi 214122, Peoples R China.; Chen, W (corresponding author), Beijing Technol & Business Univ, Beijing Innovat Ctr Food Nutr & Human Hlth, Beijing 100048, Peoples R China.
EM liht@jiangnan.edu.cn; weichen@jiangnan.edu.cn
RI Zheng, Zong-Ping/A-7400-2011; Wang, Mingfu/AAT-3292-2021; Wang,
   Mingfu/D-3136-2009
OI Zheng, Zong-Ping/0000-0002-0261-3711; Wang, Mingfu/0000-0003-1469-3963
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81402366, 31530056]; Jiangsu Specially
   Appointed Professor; Fundamental Research Funds for the Central
   UniversitiesFundamental Research Funds for the Central Universities
   [JUSRP11549, JUSRP51501]
FX This work was supported by the National Natural Science Foundation of
   China (81402366, 31530056, National Youth 1000 Talents Plan), Jiangsu
   Specially Appointed Professor, and the Fundamental Research Funds for
   the Central Universities (JUSRP11549 and JUSRP51501).
CR Arber N, 2006, NEW ENGL J MED, V355, P885, DOI 10.1056/NEJMoa061652
   Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753
   Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493
   Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5
   Fang SC, 2008, J AGR FOOD CHEM, V56, P4463, DOI 10.1021/jf800444g
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Isakoff SJ, 2005, CANCER RES, V65, P10992, DOI 10.1158/0008-5472.CAN-05-2612
   Janne PA, 2000, NEW ENGL J MED, V342, P1960, DOI 10.1056/NEJM200006293422606
   Khan MW, 2013, CLIN CANCER RES, V19, P2342, DOI 10.1158/1078-0432.CCR-12-2623
   Lee G, 2010, GASTROENTEROLOGY, V139, P869, DOI 10.1053/j.gastro.2010.05.037
   Lee KW, 2011, NAT REV CANCER, V11, P211, DOI 10.1038/nrc3017
   Li HT, 2014, CANCER RES, V74, P243, DOI 10.1158/0008-5472.CAN-13-2245
   Li HT, 2010, BRIT J PHARMACOL, V160, P1352, DOI 10.1111/j.1476-5381.2010.00785.x
   Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094
   Park H, 2007, CANCER RES, V67, P5717, DOI 10.1158/0008-5472.CAN-07-0056
   Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   William WN, 2009, NAT REV DRUG DISCOV, V8, P213, DOI 10.1038/nrd2663
   Zheng ZP, 2014, J AGR FOOD CHEM, V62, P5519, DOI 10.1021/jf500159z
   Zheng ZP, 2009, J AGR FOOD CHEM, V57, P6649, DOI 10.1021/jf9014685
NR 20
TC 22
Z9 22
U1 2
U2 26
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
EI 1520-5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD MAY 3
PY 2017
VL 65
IS 17
BP 3474
EP 3480
DI 10.1021/acs.jafc.7b00278
PG 7
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Agriculture; Chemistry; Food Science & Technology
GA EU1SX
UT WOS:000400802600007
PM 28391699
DA 2022-04-25
ER

PT J
AU Haruki, K
   Kosumi, K
   Hamada, T
   Twombly, TS
   Vayrynen, JP
   Kim, SA
   Masugi, Y
   Qian, ZR
   Mima, K
   Baba, Y
   da Silva, A
   Borowsky, J
   Arima, K
   Fujiyoshi, K
   Lau, MC
   Li, PL
   Guo, CG
   Chen, Y
   Song, MY
   Nowak, JA
   Nishihara, R
   Yanaga, K
   Zhang, XH
   Wu, KN
   Bullman, S
   Garrett, WS
   Huttenhower, C
   Meyerhardt, JA
   Giannakis, M
   Chan, AT
   Fuchs, CS
   Ogino, S
AF Haruki, Koichiro
   Kosumi, Keisuke
   Hamada, Tsuyoshi
   Twombly, Tyler S.
   Vayrynen, Juha P.
   Kim, Sun A.
   Masugi, Yohei
   Qian, Zhi Rong
   Mima, Kosuke
   Baba, Yoshifumi
   da Silva, Annacarolina
   Borowsky, Jennifer
   Arima, Kota
   Fujiyoshi, Kenji
   Lau, Mai Chan
   Li, Peilong
   Guo, Chunguang
   Chen, Yang
   Song, Mingyang
   Nowak, Jonathan A.
   Nishihara, Reiko
   Yanaga, Katsuhiko
   Zhang, Xuehong
   Wu, Kana
   Bullman, Susan
   Garrett, Wendy S.
   Huttenhower, Curtis
   Meyerhardt, Jeffrey A.
   Giannakis, Marios
   Chan, Andrew T.
   Fuchs, Charles S.
   Ogino, Shuji
TI Association of autophagy status with amount of Fusobacterium nucleatum
   in colorectal cancer
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE Colorectal neoplasms; Immunology; Microbiology; Microbiome; Molecular
   pathological epidemiology; Tumour microenvironment
ID GUT MICROBIOTA; BECLIN 1; EXPRESSION; PROGNOSIS; SURVIVAL; INFECTION;
   PROTEINS; PATTERNS; ASPIRIN; BINDING
AB Fusobacterium nucleatum (F. nucleatum), which has been associated with colorectal carcinogenesis, can impair anti-tumour immunity, and actively invade colon epithelial cells. Considering the critical role of autophagy in host defence against microorganisms, we hypothesised that autophagic activity of tumour cells might influence the amount of F. nucleatum in colorectal cancer tissue. Using 724 rectal and colon cancer cases within the Nurses' Health Study and the Health Professionals Follow-up Study, we evaluated autophagic activity of tumour cells by immunohistochemical analyses of BECN1 (beclin 1), MAP1LC3 (LC3), and SQSTM1 (p62) expression. We measured the amount of F. nucleatum DNA in tumour tissue by quantitative polymerase chain reaction (PCR). We conducted multivariable ordinal logistic regression analyses to examine the association of tumour BECN1, MAP1LC3, and SQSTM1 expression with the amount of F. nucleatum, adjusting for potential confounders, including microsatellite instability status; CpG island methylator phenotype; long-interspersed nucleotide element-1 methylation; and KRAS, BRAF, and PIK3CA mutations. Compared with BECN1-low cases, BECN1-intermediate and BECN1-high cases were associated with lower amounts of F. nucleatum with odds ratios (for a unit increase in three ordinal categories of the amount of F. nucleatum) of 0.54 (95% confidence interval, 0.29-0.99) and 0.31 (95% confidence interval, 0.16-0.60), respectively (P-trend < 0.001 across ordinal BECN1 categories). Tumour MAP1LC3 and SQSTM1 levels were not significantly associated with the amount of F. nucleatum (P-trend > 0.06). Tumour BECN1, MAP1LC3, and SQSTM1 levels were not significantly associated with patient survival (P-trend > 0.10). In conclusion, tumour BECN1 expression is inversely associated with the amount of F. nucleatum in colorectal cancer tissue, suggesting a possible role of autophagy in the elimination of invasive microorganisms. (c) 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
C1 [Haruki, Koichiro; Kosumi, Keisuke; Hamada, Tsuyoshi; Twombly, Tyler S.; Vayrynen, Juha P.; Kim, Sun A.; Masugi, Yohei; Qian, Zhi Rong; Mima, Kosuke; Baba, Yoshifumi; da Silva, Annacarolina; Borowsky, Jennifer; Arima, Kota; Fujiyoshi, Kenji; Lau, Mai Chan; Li, Peilong; Guo, Chunguang; Chen, Yang; Nowak, Jonathan A.; Nishihara, Reiko; Ogino, Shuji] Brigham & Womens Hosp, Dept Pathol, Program MPE Mol Pathol Epidemiol, 221 Longwood Ave,EBRC Room 404A, Boston, MA 02115 USA.
   [Haruki, Koichiro; Kosumi, Keisuke; Hamada, Tsuyoshi; Twombly, Tyler S.; Vayrynen, Juha P.; Kim, Sun A.; Masugi, Yohei; Qian, Zhi Rong; Mima, Kosuke; Baba, Yoshifumi; da Silva, Annacarolina; Borowsky, Jennifer; Arima, Kota; Fujiyoshi, Kenji; Lau, Mai Chan; Li, Peilong; Guo, Chunguang; Chen, Yang; Song, Mingyang; Nowak, Jonathan A.; Nishihara, Reiko; Zhang, Xuehong; Wu, Kana; Bullman, Susan; Garrett, Wendy S.; Meyerhardt, Jeffrey A.; Giannakis, Marios; Chan, Andrew T.; Ogino, Shuji] Harvard Med Sch, Boston, MA 02115 USA.
   [Haruki, Koichiro; Yanaga, Katsuhiko] Jikei Univ, Sch Med, Dept Surg, Tokyo, Japan.
   [Vayrynen, Juha P.; Bullman, Susan; Garrett, Wendy S.; Meyerhardt, Jeffrey A.; Giannakis, Marios] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Vayrynen, Juha P.] Univ Oulu, Oulu Univ Hosp, Med Res Ctr Oulu, Canc & Translat Med Res Unit, Oulu, Finland.
   [Qian, Zhi Rong] Sun Yat Sen Univ, Affiliated Hosp 7, Sci Res Ctr, Shenzhen, Peoples R China.
   [Qian, Zhi Rong] Sun Yat Sen Univ, Affiliated Hosp 7, Digest Dis Ctr, Shenzhen, Peoples R China.
   [Borowsky, Jennifer] Massachusetts Gen Hosp, Dept Pathol, Ctr Integrated Diagnost, Boston, MA 02114 USA.
   [Song, Mingyang; Nishihara, Reiko; Wu, Kana] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA.
   [Song, Mingyang; Chan, Andrew T.] Massachusetts Gen Hosp, Clin & Translat Epidemiol Unit, Boston, MA 02114 USA.
   [Song, Mingyang; Chan, Andrew T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
   [Nishihara, Reiko; Wu, Kana; Ogino, Shuji] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
   [Nishihara, Reiko; Huttenhower, Curtis] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA.
   [Zhang, Xuehong; Wu, Kana; Chan, Andrew T.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.
   [Bullman, Susan; Garrett, Wendy S.; Huttenhower, Curtis; Giannakis, Marios; Ogino, Shuji] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
   [Garrett, Wendy S.; Chan, Andrew T.] Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA USA.
   [Giannakis, Marios] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
   [Fuchs, Charles S.] Yale Canc Ctr, New Haven, CT USA.
   [Fuchs, Charles S.] Yale Sch Med, Dept Med, New Haven, CT USA.
   [Fuchs, Charles S.] Smilow Canc Hosp, New Haven, CT USA.
   [Ogino, Shuji] Dana Farber Harvard Canc Ctr, Canc Immunol Program, Boston, MA USA.
   [Ogino, Shuji] Dana Farber Harvard Canc Ctr, Canc Epidemiol Program, Boston, MA USA.
RP Ogino, S (corresponding author), Brigham & Womens Hosp, Dept Pathol, Program MPE Mol Pathol Epidemiol, 221 Longwood Ave,EBRC Room 404A, Boston, MA 02115 USA.
EM sogino@bwh.harvard.edu
RI Masugi, Yohei/E-6980-2014; Väyrynen, Juha P/B-5023-2018; Lau, Mai
   Chan/L-5186-2019
OI Masugi, Yohei/0000-0002-6952-4043; Väyrynen, Juha P/0000-0002-8683-2996;
   Lau, Mai Chan/0000-0002-7698-4697; Borowsky,
   Jennifer/0000-0003-3957-1364; Haruki, Koichiro/0000-0002-1686-3228; Li,
   Peilong/0000-0002-7441-6514; Garrett, Wendy/0000-0002-5092-0150
FU US National Institutes of Health (NIH)United States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USA [P01 CA87969,
   UM1 CA186107, P01 CA55075, UM1 CA167552, U01 CA167552, P50 CA127003, R01
   CA118553, R01 CA169141, R01 CA137178, K24 DK098311, R35 CA197735, R01
   CA151993, K07 CA190673, K07 CA188126]; Cancer Research UK's Grand
   Challenge Initiative [C10674/A27140]; Dana-Farber Harvard Cancer Center
   [2016-02]; Stand Up to Cancer Colorectal Cancer Dream Team Translational
   Research Grant [SU2C-AACR-DT22-17]; Project P Fund; Friends of the
   Dana-Farber Cancer Institute; Bennett Family Fund; Entertainment
   Industry Foundation through National Colorectal Cancer Research
   Alliance; SU2C; Uehara Memorial FoundationUehara Memorial Foundation;
   Mitsukoshi Health and Welfare Foundation; Japan Society for the
   Promotion of ScienceMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT)Japan Society for the Promotion of Science
   [JP2017-0775, JP2018-60083]; JSPS Fujita Memorial Fund for Medical
   Research; Australia Awards-Endeavour Scholarships and Fellowships
   ProgramAustralian GovernmentDepartment of Industry, Innovation and
   Science; ASCO Conquer Cancer Foundation Career Development Award
FX This work was supported by US National Institutes of Health (NIH) grants
   (P01 CA87969 to MJ Stampfer; UM1 CA186107 to MJ Stampfer; P01 CA55075 to
   WC Willett; UM1 CA167552 to WC Willett; U01 CA167552 to WC Willett and
   LA Mucci; P50 CA127003 to CSF; R01 CA118553 to CSF; R01 CA169141 to CSF;
   R01 CA137178 to ATC; K24 DK098311 to ATC; R35 CA197735 to SO; R01
   CA151993 to SO; K07 CA190673 to RN; and K07 CA188126 to XZ); by Cancer
   Research UK's Grand Challenge Initiative (C10674/A27140 to WSG, MG, CH,
   and SO); by Nodal Award (2016-02) from the Dana-Farber Harvard Cancer
   Center (to SO); by the Stand Up to Cancer Colorectal Cancer Dream Team
   Translational Research Grant (SU2C-AACR-DT22-17 to CSF. and MG),
   administered by the American Association for Cancer Research, a
   scientific partner of SU2C; and by grants from the Project P Fund, The
   Friends of the Dana-Farber Cancer Institute, Bennett Family Fund, and
   the Entertainment Industry Foundation through National Colorectal Cancer
   Research Alliance and SU2C. KH was supported by fellowship grants from
   the Uehara Memorial Foundation and the Mitsukoshi Health and Welfare
   Foundation. KK was supported by grants from Overseas Research Fellowship
   (JP2017-0775) from Japan Society for the Promotion of Science and JSPS
   Fujita Memorial Fund for Medical Research. KA was supported by a grant
   from Overseas Research Fellowship (JP2018-60083) from Japan Society for
   the Promotion of Science. JB was supported by a grant from the Australia
   Awards-Endeavour Scholarships and Fellowships Program. KF was supported
   by a fellowship grant from the Uehara Memorial Foundation. MG is
   supported by an ASCO Conquer Cancer Foundation Career Development Award.
   ATC is a Stuart and Suzanne Steele MGH Research Scholar. The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of NIH. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abed J, 2016, CELL HOST MICROBE, V20, P215, DOI 10.1016/j.chom.2016.07.006
   Amaravadi RK, 2019, CANCER DISCOV, V9, P1167, DOI 10.1158/2159-8290.CD-19-0292
   Benjamin DJ, 2018, NAT HUM BEHAV, V2, P6, DOI 10.1038/s41562-017-0189-z
   Bullman S, 2017, SCIENCE, V358, P1443, DOI 10.1126/science.aal5240
   Castellarin M, 2012, GENOME RES, V22, P299, DOI 10.1101/gr.126516.111
   Chan AT, 2007, NEW ENGL J MED, V356, P2131, DOI 10.1056/NEJMoa067208
   Chan AT, 2010, CANCER EPIDEM BIOMAR, V19, P2777, DOI 10.1158/1055-9965.EPI-10-0529
   Deretic V, 2013, NAT REV IMMUNOL, V13, P722, DOI 10.1038/nri3532
   Fukuda S, 2011, NATURE, V469, P543, DOI 10.1038/nature09646
   Garrett WS, 2019, SCIENCE, V364, P1133, DOI 10.1126/science.aaw2367
   Giatromanolaki A, 2010, J CLIN PATHOL, V63, P867, DOI 10.1136/jcp.2010.079525
   Gomes LC, 2014, MOL CELL, V54, P224, DOI 10.1016/j.molcel.2014.03.009
   Goodman B, 2018, J PATHOL, V244, P667, DOI 10.1002/path.5047
   Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   Gur C, 2015, IMMUNITY, V42, P344, DOI 10.1016/j.immuni.2015.01.010
   Hale VL, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0586-6
   Hamada T, 2019, J PATHOL, V247, P615, DOI 10.1002/path.5236
   Hamada T, 2018, CANCER IMMUNOL RES, V6, P1327, DOI 10.1158/2326-6066.CIR-18-0174
   Hamada T, 2017, J CLIN ONCOL, V35, P1836, DOI 10.1200/JCO.2016.70.7547
   Han Y, 2014, ASIAN PAC J CANCER P, V15, P4583, DOI 10.7314/APJCP.2014.15.11.4583
   Heath RJ, 2016, CELL REP, V17, P2183, DOI 10.1016/j.celrep.2016.11.005
   Hu W, 2019, SEMIN CELL DEV BIOL
   Huang J, 2009, P NATL ACAD SCI USA, V106, P6226, DOI 10.1073/pnas.0811045106
   Hubber A, 2017, SCI REP-UK, V7, DOI 10.1038/srep44795
   Jiang XJ, 2015, J CLIN INVEST, V125, P47, DOI 10.1172/JCI73942
   Kostic AD, 2013, CELL HOST MICROBE, V14, P207, DOI 10.1016/j.chom.2013.07.007
   Kostic AD, 2012, GENOME RES, V22, P292, DOI 10.1101/gr.126573.111
   Kosumi K, 2018, AM J PATHOL, V188, P2839, DOI 10.1016/j.ajpath.2018.08.015
   Kosumi K, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1284720
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Laforest-Lapointe I, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00788
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Levy J, 2015, NAT CELL BIOL, V17, P1062, DOI 10.1038/ncb3206
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Liu B, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.422
   Liu L, 2018, EUR J EPIDEMIOL, V33, P381, DOI 10.1007/s10654-017-0346-8
   Mima K, 2016, CLIN TRANSL GASTROEN, V7, DOI 10.1038/ctg.2016.53
   Mima K, 2016, GUT, V65, P1973, DOI 10.1136/gutjnl-2015-310101
   Mima K, 2015, JAMA ONCOL, V1, P653, DOI 10.1001/jamaoncol.2015.1377
   Mimouna S, 2014, AUTOPHAGY, V10, P2333, DOI 10.4161/15548627.2014.984275
   Nishihara R, 2013, NEW ENGL J MED, V369, P1095, DOI 10.1056/NEJMoa1301969
   Noman MZ, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1452583
   Nosho K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003698
   Ogino S, 2019, ANNU REV PATHOL-MECH, V14, P83, DOI 10.1146/annurev-pathmechdis-012418-012818
   Ogino S, 2018, GUT, V67, P1168, DOI 10.1136/gutjnl-2017-315537
   Ogino S, 2011, GUT, V60, P397, DOI 10.1136/gut.2010.217182
   Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954
   Punt CJA, 2017, NAT REV CLIN ONCOL, V14, P235, DOI 10.1038/nrclinonc.2016.171
   Rajpoot M, 2018, SEMIN CANCER BIOL, V52, P1, DOI 10.1016/j.semcancer.2018.02.003
   Rooks MG, 2016, NAT REV IMMUNOL, V16, P341, DOI 10.1038/nri.2016.42
   Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706
   Rubinstein MR, 2013, CELL HOST MICROBE, V14, P195, DOI 10.1016/j.chom.2013.07.012
   Schmitz KJ, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0946-x
   Seaman SR, 2013, STAT METHODS MED RES, V22, P278, DOI 10.1177/0962280210395740
   Smith AG, 2019, J PATHOL, V247, P708, DOI 10.1002/path.5222
   Tattoli I, 2012, CELL HOST MICROBE, V11, P563, DOI 10.1016/j.chom.2012.04.012
   Tilg H, 2018, CANCER CELL, V33, P954, DOI 10.1016/j.ccell.2018.03.004
   Ubeda C, 2017, CLIN TRANSL IMMUNOL, V6, DOI 10.1038/cti.2017.2
   Yachida S, 2019, NAT MED, V25, P968, DOI 10.1038/s41591-019-0458-7
   Yamauchi M, 2012, GUT, V61, P847, DOI 10.1136/gutjnl-2011-300865
   Yang MP, 2015, ONCOTARGET, V6, P7084, DOI 10.18632/oncotarget.3054
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Zhang L, 2018, J PATHOL, V244, P432, DOI 10.1002/path.5033
NR 64
TC 14
Z9 14
U1 2
U2 30
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
EI 1096-9896
J9 J PATHOL
JI J. Pathol.
PD APR
PY 2020
VL 250
IS 4
BP 397
EP 408
DI 10.1002/path.5381
EA FEB 2020
PG 12
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA KU6AT
UT WOS:000510540000001
PM 31880318
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Hernandez-Balmaseda, I
   Guerra, IR
   Declerck, K
   Isidron, JAH
   Perez-Novo, C
   Van Camp, G
   De Wever, O
   Gonzalez, K
   Labrada, M
   Carr, A
   Dantas-Cassali, G
   dos Reis, DC
   Delgado-Roche, L
   Nunez, RR
   Delgado-Hernandez, R
   Fernandez, MD
   Paz-Lopes, MT
   Vanden Berghe, W
AF Hernandez-Balmaseda, Ivones
   Guerra, Idania Rodeiro
   Declerck, Ken
   Herrera Isidron, Jose Alfredo
   Perez-Novo, Claudina
   Van Camp, Guy
   De Wever, Olivier
   Gonzalez, Kethia
   Labrada, Mayrel
   Carr, Adriana
   Dantas-Cassali, Geovanni
   dos Reis, Diego Carlos
   Delgado-Roche, Livan
   Nunez, Roberto Rafael
   Delgado-Hernandez, Rene
   Fernandez, Miguel David
   Paz-Lopes, Miriam T.
   Vanden Berghe, Wim
TI Marine Seagrass Extract of Thalassia testudinum Suppresses Colorectal
   Tumor Growth, Motility and Angiogenesis by Autophagic Stress and
   Immunogenic Cell Death Pathways
SO MARINE DRUGS
LA English
DT Article
DE Thalassia testudinum; cytotoxicity; antitumor; anti-angiogenic; gene
   expression
AB Marine plants have become an inexhaustible reservoir of new phytopharmaceuticals for cancer treatment. We demonstrate in vitro/in vivo antitumor efficacy of a standardized polyphenol extract from the marine angiosperm Thalassia testudinum (TTE) in colon tumor cell lines (RKO, SW480, and CT26) and a syngeneic allograft murine colorectal cancer model. MTT assays revealed a dose-dependent decrease of cell viability of RKO, CT26, and SW480 cells upon TTE treatment with IC50 values of, respectively, 175, 115, and 60 mu g/mL. Furthermore, TTE significantly prevented basal and bFGF-induced angiogenesis in the chicken chorioallantoic membrane angiogenesis assay. In addition, TTE suppressed bFGF-induced migration of endothelial cells in a wound closure assay. Finally, TTE treatment abrogated CT26 colorectal cancer growth and increased overall organism survival in a syngeneic murine allograft model. Corresponding transcriptome profiling and pathway analysis allowed for the identification of the mechanism of action for the antitumor effects of TTE. In line with our in vitro/in vivo results, TTE treatment triggers ATF4-P53-NF kappa B specific gene expression and autophagy stress pathways. This results in suppression of colon cancer cell growth, cell motility, and angiogenesis pathways in vitro and in addition promotes antitumor immunogenic cell death in vivo.
C1 [Hernandez-Balmaseda, Ivones; Guerra, Idania Rodeiro; Gonzalez, Kethia; Delgado-Roche, Livan; Nunez, Roberto Rafael; Fernandez, Miguel David] Inst Ciencias Mar ICIMAR, Calle Loma 14 E-35 & 37,Plaza Revoluc, Havana 10400, Cuba.
   [Declerck, Ken; Perez-Novo, Claudina; Vanden Berghe, Wim] Univ Antwerp, Dept Biomed Sci, Lab Prot Sci Prote & Epigenet Signaling PPES, Campus Drie Eiken,Bldg S,4th Floor,Univ Pl 1, B-2610 Antwerp, Belgium.
   [Declerck, Ken; Perez-Novo, Claudina; Vanden Berghe, Wim] Univ Antwerp, Dept Biomed Sci, Integrated Personalized & Precis Oncol Network IP, Campus Drie Eiken,Bldg S,4th Floor,Univ Pl 1, B-2610 Antwerp, Belgium.
   [Herrera Isidron, Jose Alfredo] Univ Habana, Inst Ciencia & Tecnol Mat IMRE, Plaza Revoluc, Havana 10400, Cuba.
   [Van Camp, Guy] Univ Antwerp, Ctr Med Genet, Prins Boudewijnlaan 43, B-2650 Edegem, Belgium.
   [Van Camp, Guy] Antwerp Univ Hosp, Prins Boudewijnlaan 43, B-2650 Edegem, Belgium.
   [De Wever, Olivier] UZ Gent, Canc Res Inst Ghent CRIG, Dept Radiat Oncol & Expt Canc Res, Lab Expt Canc Res, B-9000 Ghent, Belgium.
   [Labrada, Mayrel; Carr, Adriana] Ctr Mol Immunol, Calle 17, Havana 11300, Cuba.
   [Dantas-Cassali, Geovanni; dos Reis, Diego Carlos; Paz-Lopes, Miriam T.] Fed Univ Minas Gerais UFMG, Inst Biol Sci ICB, BR-31207901 Belo Horizonte, MG, Brazil.
   [Delgado-Hernandez, Rene] Univ La Habana, Inst Farm & Alimentos IFAL, UH, Ave 23 21425 Entre 214 & 222, Havana 13600, Cuba.
   [Delgado-Hernandez, Rene] Univ Santader UDES, Fac Ciencias Nat & Agr, Bucaramanga 680002, Colombia.
RP Guerra, IR (corresponding author), Inst Ciencias Mar ICIMAR, Calle Loma 14 E-35 & 37,Plaza Revoluc, Havana 10400, Cuba.; Vanden Berghe, W (corresponding author), Univ Antwerp, Dept Biomed Sci, Lab Prot Sci Prote & Epigenet Signaling PPES, Campus Drie Eiken,Bldg S,4th Floor,Univ Pl 1, B-2610 Antwerp, Belgium.; Vanden Berghe, W (corresponding author), Univ Antwerp, Dept Biomed Sci, Integrated Personalized & Precis Oncol Network IP, Campus Drie Eiken,Bldg S,4th Floor,Univ Pl 1, B-2610 Antwerp, Belgium.
EM ivones@icimar.cu; idania.rodeiro@infomed.sld.cu;
   ken.declerck90@hotmail.com; jose@imre.uh.cu;
   Claudina.PerezNovo@uantwerpen.be; guy.vancamp@uantwerpen.be;
   olivier.dewever@ugent.be; kethia@icimar.cu; mayrel@cim.sld.cu;
   adriana@cim.sld.cu; cassalig@icb.ufmg.br; dcarlosreis@yahoo.com.br;
   ldelgado@liomont.com.mx; robertico@icimar.cu; rdelgado@ifal.uh.cu;
   migueldavid@icimar.cu; mtpl@icb.ufmg.br; wim.vandenberghe@uantwerpen.be
RI Lopes, Miriam T P/A-7732-2015; Van Camp, Guy/F-3386-2013; Hernandez,
   Rene Delgado/AAS-5111-2021; Berghe, Wim Vanden/S-6425-2018; Novo,
   Claudina A Perez/E-6098-2011; de wever, olivier/J-3094-2013; Rodeiro
   Guerra, Idania/H-7713-2014
OI Lopes, Miriam T P/0000-0001-9980-3169; Van Camp,
   Guy/0000-0001-5105-9000; Hernandez, Rene Delgado/0000-0001-7051-7871;
   Berghe, Wim Vanden/0000-0003-0161-7355; Novo, Claudina A
   Perez/0000-0003-4562-4346; de wever, olivier/0000-0002-5453-760X;
   Hernandez Balmaseda, Ivones/0000-0001-5276-0851; Herrera Isidron, Jose
   Alfredo/0000-0003-2244-7180; Rodeiro Guerra, Idania/0000-0002-2692-6050;
   Labrada Mon, Mayrel/0000-0003-4603-0988
FU (CITMA), Cuba [P211LH005-019]; (CNPq), BrazilConselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPQ) [PVE400768/2014-3];
   (Flemish VLIR collaboration program), Belgium [ZEIN2011PR383,
   ZEIN2016PR418]
FX This work was supported by P211LH005-019 project (CITMA), Cuba; Visiting
   Research Program, PVE400768/2014-3 project (CNPq), Brazil, and the
   projects ZEIN2011PR383 and ZEIN2016PR418 (Flemish VLIR collaboration
   program), Belgium.
CR Alves C, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00777
   Ambasta RK, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0665-z
   Ansoar Y, 2014, J PHARM PHARMACOGN R, V2, P183
   ATCC American Type Culture Collection https://www.atcc.org/en/Landing_Pages/Cancer_and_Normal_Cell_Lines_by_Tissue_Type.aspx, COL CANC NORM CELL L
   Attoub S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053087
   Awad RM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01977
   Benvenuto M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186635
   Boopathy NS, 2010, J ONCOL, V2010, DOI 10.1155/2010/214186
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Cao ZJ, 2017, CELL PHYSIOL BIOCHEM, V43, P1803, DOI 10.1159/000484066
   Minh CV, 2015, ARCH PHARM RES, V38, P1443, DOI 10.1007/s12272-014-0490-6
   Crawford S, 2014, THER ADV MED ONCOL, V6, P52, DOI 10.1177/1758834014521111
   Dai J, 2016, TOXICOL APPL PHARM, V311, P106, DOI 10.1016/j.taap.2016.09.016
   De Salud A.E., 2019, DIRECCION REGISTROS, V2020, P70
   Delgado-Hernandez R, 2020, MELANOMA RES, V30, P39, DOI 10.1097/CMR.0000000000000647
   Delgado-Roche L, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.592985
   Denton D, 2019, CELL DEATH DIFFER, V26, P605, DOI 10.1038/s41418-018-0252-y
   Dias PF, 2005, CANCER CHEMOTH PHARM, V56, P436, DOI 10.1007/s00280-004-0995-7
   Ding M, 2006, J BIOL CHEM, V281, P17359, DOI 10.1074/jbc.M600861200
   Evans JP, 2016, CRIT REV ONCOL HEMAT, V98, P94, DOI 10.1016/j.critrevonc.2015.10.009
   Fernandez MD, 2003, AVICENNIA, V16, P31
   Ganesan K, 2017, NUTRIENTS, V9, DOI 10.3390/nu9050455
   Garateix A, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-10
   Garris CS, 2018, IMMUNITY, V49, P1148, DOI 10.1016/j.immuni.2018.09.024
   Hanze J, 2020, TARGET ONCOL, V15, P377, DOI 10.1007/s11523-020-00728-8
   Halvey PJ, 2014, CANCER RES, V74, P387, DOI 10.1158/0008-5472.CAN-13-2488
   Han H, 2018, NUCLEIC ACIDS RES, V46, pD380, DOI 10.1093/nar/gkx1013
   Hou W, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.493
   Illam SP, 2017, RECENT PAT ANTI-CANC, V12, P234, DOI 10.2174/1574892812666170424150407
   Jorgovanovic D, 2020, BIOMARK RES, V8, DOI 10.1186/s40364-020-00228-x
   Khalifa SAM, 2019, MAR DRUGS, V17, DOI 10.3390/md17090491
   Li CH, 2013, J NUTR BIOCHEM, V24, P1766, DOI 10.1016/j.jnutbio.2013.03.006
   Lin RJ, 2018, CANCER MANAG RES, V10, P4237, DOI 10.2147/CMAR.S162383
   LLANIO M, 2006, PHARMACOLOGYONLINE, V3, P594
   Mandai M, 2016, CLIN CANCER RES, V22, P2329, DOI 10.1158/1078-0432.CCR-16-0224
   Martinez-Daranas B, 2018, B MAR SCI, V94, P269, DOI 10.5343/bms.2017.1014
   Mayer R.J., 2018, HARRISONS PRINCIPLES, V20th ed., P575
   Menendez R, 2014, J PHARM PHARMACOGN R, V2, P53
   Newman DJ, 2020, J NAT PROD, V83, P770, DOI 10.1021/acs.jnatprod.9b01285
   Ngaffo CMN, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e05412
   Nguyen A, 2018, CELL REP, V24, P642, DOI 10.1016/j.celrep.2018.06.040
   Ohnishi K, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9121193
   Palmieri D, 2015, ADV MED SCI-POLAND, V60, P287, DOI 10.1016/j.advms.2015.05.003
   Pereira RB, 2019, MAR DRUGS, V17, DOI 10.3390/md17060329
   Regalado EL, 2012, NAT PROD COMMUN, V7, P47
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Rodeiro I, 2008, TOXICOL IN VITRO, V22, P1242, DOI 10.1016/j.tiv.2008.04.006
   Rodeiro I, 2018, J PHARM PHARMACOL, V70, P1553, DOI 10.1111/jphp.13001
   Rudd CE, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aaz8128
   Shao YF, 2015, FOOD CHEM, V180, P86, DOI 10.1016/j.foodchem.2015.02.027
   Singh D, 2019, RECENT PAT ANTI-CANC, V14, P298, DOI 10.2174/1574892814666191026095728
   Strauss L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aay1863
   Su J, 2017, ONCOL REP, V37, P1565, DOI 10.3892/or.2017.5428
   Sung Bokyung, 2016, J Cancer Prev, V21, P216, DOI 10.15430/JCP.2016.21.4.216
   Suttana W, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-99
   Tuorkey MJ, 2016, EUR J CANCER PREV, V25, P65, DOI 10.1097/CEJ.0000000000000128
   Villalobos-Ayala K, 2020, CANCERS, V12, DOI 10.3390/cancers12123631
   Wei W, 2019, J BUON, V24, P936
   WHO, 2019, WHO GLOB REP TRAD CO
   Wu JY, 2020, PHYTOMEDICINE, V68, DOI 10.1016/j.phymed.2020.153173
   Yao YY, 2019, ONCOL REP, V42, P131, DOI 10.3892/or.2019.7136
   Yin SY, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00386
   Yuan L, 2017, J PROTEOMICS, V161, P1, DOI 10.1016/j.jprot.2017.04.005
   Zhang YQ, 2017, GUT, V66, P124, DOI 10.1136/gutjnl-2016-312078
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6
   Zidorn C, 2016, PHYTOCHEMISTRY, V124, P5, DOI 10.1016/j.phytochem.2016.02.004
   Zohreh B, 2019, ANTI-CANCER AGENT ME, V19, P1535, DOI 10.2174/1871520619666190704102708
NR 67
TC 2
Z9 2
U1 1
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-3397
J9 MAR DRUGS
JI Mar. Drugs
PD FEB
PY 2021
VL 19
IS 2
AR 52
DI 10.3390/md19020052
PG 17
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA QN8RV
UT WOS:000622720200001
PM 33499163
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Lai, HW
   Wei, JCC
   Hung, HC
   Lin, CC
AF Lai, Hsin-Wu
   Wei, James Cheng-Chung
   Hung, Hung-Chang
   Lin, Chun-Che
TI Adenine Inhibits the Growth of Colon Cancer Cells via AMP-Activated
   Protein Kinase Mediated Autophagy
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID COLORECTAL-CANCER; PATHOGENESIS
AB Background. Adenine is involved in a variety of cell biological processes and has been explored for pharmacological uses. Its therapeutic use for managing cancer is of great interest. In the present study, we investigated the anticancer effects of adenine and the underlying mechanism in colon cancer cells. Methods. Cell viability was measured using the MTT assay. Levels of phosphorylation and protein expression were determined using western blotting. qPCR was carried out to determine the changes in mRNA expression of genes of interest. Results. Adenine significantly inhibited the viability of colon cancer cells, HT29 and Caco-2 cells, in a dose-dependent manner. Adenine induced significant apoptosis in HT29 cells, whereas Caco-2 cells exhibited less apoptotic responses. The data showed that adenine activated AMP-activated protein kinase (AMPK) signaling contributing to autophagic cell death through mTOR in both colon cancer cell lines. Conclusions. Our findings suggest that adenine inhibits the growth of colon cancer cells. Anticancer activity of adenine in colon cancer cells is attributable to the activation of apoptotic signaling and in turn the AMPK/mTOR pathway. Adenine represents a natural compound with anticancer potency.
C1 [Lai, Hsin-Wu; Wei, James Cheng-Chung; Hung, Hung-Chang; Lin, Chun-Che] Chung Shan Med Univ, Inst Med, Taichung, Taiwan.
   [Lai, Hsin-Wu; Hung, Hung-Chang] Nantou Hosp, Div Gastroenterol, Dept Internal Med, Minist Hlth & Welf, Taipei, Taiwan.
   [Wei, James Cheng-Chung] Chung Shan Med Univ Hosp, Div Allergy Immunol & Rheumatol, Dept Med, Taichung, Taiwan.
   [Wei, James Cheng-Chung] China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan.
   [Hung, Hung-Chang] Cent Taiwan Univ Sci & Technol, Dept Healthcare Adm, Taichung, Taiwan.
   [Lin, Chun-Che] Chung Shan Med Univ Hosp, Div Gastroenterol, Dept Internal Med, Taichung, Taiwan.
RP Wei, JCC (corresponding author), Chung Shan Med Univ, Inst Med, Taichung, Taiwan.; Wei, JCC (corresponding author), Chung Shan Med Univ Hosp, Div Allergy Immunol & Rheumatol, Dept Med, Taichung, Taiwan.; Wei, JCC (corresponding author), China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan.
EM wei3228@gmail.com
RI Wei, James Cheng-Chung/AAL-8947-2020
OI Wei, James Cheng-Chung/0000-0002-1235-0679
CR Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Carling D, 2017, CURR OPIN CELL BIOL, V45, P31, DOI 10.1016/j.ceb.2017.01.005
   Chen CC, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/692061
   Chen SY, 2017, ONCOL LETT, V14, P5575, DOI 10.3892/ol.2017.6890
   Cheng YF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142283
   Han M, 2017, ONCOTARGET, V8, P94286, DOI 10.18632/oncotarget.21690
   Hosoi T, 2018, IMMUN INFLAMM DIS, V6, P97, DOI 10.1002/iid3.200
   Huang BP, 2015, DNA CELL BIOL, V34, P133, DOI 10.1089/dna.2014.2630
   Kim DE, 2015, MOL CELLS, V38, P138, DOI 10.14348/molcells.2015.2193
   Kou B, 2017, ONCOL REP, V38, P3137, DOI 10.3892/or.2017.5988
   Lai K, 2014, J CLIN PATHOL, V67, P854, DOI 10.1136/jclinpath-2014-202529
   Leu JG, 2018, EUR J PHARMACOL, V818, P569, DOI 10.1016/j.ejphar.2017.11.027
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   LUTHJE J, 1989, BLUT, V59, P367, DOI 10.1007/BF00321207
   Mogavero A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16149-z
   Rehman G, 2014, ARCH PHARM, V347, P457, DOI 10.1002/ardp.201300402
   Ristica B, 2014, EXP CELL RES, V326, P90, DOI 10.1016/j.yexcr.2014.05.021
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Scioli MG, 2014, J VASC RES, V51, P327, DOI 10.1159/000365926
   Sesen J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123721
   Silwal P, 2018, KOREAN J PHYSIOL PHA, V22, P379, DOI 10.4196/kjpp.2018.22.4.379
   Silwal P, 2015, MOL IMMUNOL, V65, P242, DOI 10.1016/j.molimm.2015.01.021
   Watanabe S, 2003, J NEUROSCI RES, V74, P754, DOI 10.1002/jnr.10790
   Yoshimi Y, 2003, BRAIN RES, V991, P113, DOI 10.1016/j.brainres.2003.08.017
   Young GH, 2015, J PROTEOMICS, V120, P204, DOI 10.1016/j.jprot.2015.03.012
NR 26
TC 6
Z9 6
U1 2
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD SEP 12
PY 2019
VL 2019
AR 9151070
DI 10.1155/2019/9151070
PG 7
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA JA2GV
UT WOS:000487636100003
PM 31611925
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhang, Y
   Zhang, Z
   Wang, D
   Xu, JZ
   Li, YH
   Wang, H
   Li, J
   Mo, SW
   Zhang, YC
   Lin, YQ
   Fan, XZ
   Li, EM
   Huang, J
   Fan, HH
   Yi, Y
AF Zhang, Yang
   Zhang, Zheng
   Wang, Dong
   Xu, Jianzhen
   Li, Yanhui
   Wang, Hong
   Li, Jin
   Mo, Shaowen
   Zhang, Yuncong
   Lin, Yunqing
   Fan, Xiuzhao
   Li, Enmin
   Huang, Jian
   Fan, Huihui
   Yi, Ying
TI Multidimensional Integration Analysis of Autophagy-related Modules in
   Colorectal Cancer
SO LETTERS IN ORGANIC CHEMISTRY
LA English
DT Article
DE Colorectal cancer; autophagy; co-expression modules; multidimensional
   analysis; COAD; WGCNA
ID CELL-DEATH; COLON-CANCER; DIFFERENTIAL EXPRESSION; BIOINFORMATICS
   RESOURCE; PROTEIN-SYNTHESIS; TUMOR-SUPPRESSOR; UPDATED RESOURCE;
   GENE-EXPRESSION; APOPTOSIS; DATABASE
AB Colorectal cancer (CRC) is a common malignant tumor of the digestive tract occurring in the colon, which mainly divided into adenocarcinoma, mucinous adenocarcinoma, and undifferentiated carcinoma. However, autophagy is related to the occurrence and development of various kinds of human diseases such as cancer. There is little research on the relationship between CRC and autophagy. Hence, we performed multidimensional integration analysis to systematically explore potential relationship between autophagy and CRC. Based on gene expression datasets of colon adenocarcinoma (COAD) and protein-protein interactions (PPIs), we first identified 12 autophagy-related modules in COAD using WGCNA. Then, 9 module pairs which with significantly crosstalk were deciphered, a total of 6 functional modules. Autophagy-related genes in these modules were closely related with CRC, emphasizing that the important role of autophagy-related genes in CRC, including PPP2CA and EIF4E, etc. In addition to, by integrating transcription factor (TF)-target and RNA-associated interactions, a regulation network was constructed, in which 42 TFs (including SMAD3 and TPS3, etc.) and 20 miRNAs (including miR-20 and miR-30a, etc.) were identified as pivot regulators. Pivot TFs were mainly involved in cell cycle, cell proliferation and pathways in cancer. And pivot miRNAs were demonstrated associated with CRC. It suggests that these pivot regulators might be have an effect on the development of CRC by regulating autophagy. In a word, our results suggested that multidimensional integration strategy provides a novel approach to discover potential relationships between autophagy and CRC, and further improves our understanding of autophagy and tumor in human.
C1 [Zhang, Yang; Wang, Dong; Huang, Jian] Univ Elect Sci & Technol China, Ctr Informat Biol, Chengdu 610054, Sichuan, Peoples R China.
   [Zhang, Zheng] Nanjing Audit Univ, Dept Phys Educ, Nanjing, Jiangsu, Peoples R China.
   [Wang, Dong; Wang, Hong; Li, Jin; Mo, Shaowen; Zhang, Yuncong; Lin, Yunqing; Fan, Xiuzhao; Fan, Huihui; Yi, Ying] Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin, Heilongjiang, Peoples R China.
   [Xu, Jianzhen; Li, Enmin] Shantou Univ, Med Coll, Key Lab Mol Biol High Canc Incidence Coastal Chao, Shantou 515041, Peoples R China.
   [Xu, Jianzhen; Li, Enmin] Shantou Univ, Med Coll, Dept Biochem & Mol Biol, Shantou 515041, Peoples R China.
   [Li, Yanhui] Peking Univ, Hlth Sci Ctr, Inst Cardiovasc Sci, Beijing, Peoples R China.
   [Li, Yanhui] Peking Univ, Hlth Sci Ctr, Key Lab Mol Cardiovasc Sci, Beijing, Peoples R China.
RP Huang, J (corresponding author), Univ Elect Sci & Technol China, Ctr Informat Biol, Chengdu 610054, Sichuan, Peoples R China.; Fan, HH; Yi, Y (corresponding author), Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin, Heilongjiang, Peoples R China.
EM hj@uestc.edu.cn; fanhuihui@hrbmu.edu.cn; yiying@hrbmu.edu.cn
RI Huang, Jian/G-8437-2011; Wang, Dong/ABC-2499-2021; Fan,
   Huihui/AGB-0221-2022
OI Huang, Jian/0000-0003-3282-8892; Fan, Huihui/0000-0003-4233-5389
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31501075]; Scientific Research Fund of
   Heilongjiang Provincial Education Department [12541426]
FX This work was supported by the National Natural Science Foundation of
   China (31501075); Scientific Research Fund of Heilongjiang Provincial
   Education Department (12541426).
CR Bakirtzi K, 2011, GASTROENTEROLOGY, V141, P1749, DOI 10.1053/j.gastro.2011.07.038
   Balakumaran BS, 2009, CANCER RES, V69, P7803, DOI 10.1158/0008-5472.CAN-09-0910
   Baraniskin A, 2012, CARCINOGENESIS, V33, P732, DOI 10.1093/carcin/bgs020
   Chai HJ, 2011, ACTA BIOCH BIOPH SIN, V43, P217, DOI 10.1093/abbs/gmq125
   Chevrier S, 2014, INT J ONCOL, V45, P1167, DOI 10.3892/ijo.2014.2528
   Choi MS, 2013, EXP DERMATOL, V22, P491, DOI 10.1111/exd.12175
   Cui TY, 2018, NUCLEIC ACIDS RES, V46, pD371, DOI 10.1093/nar/gkx1025
   Donohoe DR, 2011, CELL METAB, V13, P517, DOI 10.1016/j.cmet.2011.02.018
   Golob-Schwarzl N, 2017, ONCOTARGET, V8, P101224, DOI 10.18632/oncotarget.20642
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Groulx JF, 2012, AUTOPHAGY, V8, P893, DOI 10.4161/auto.19738
   Guan X, 2015, ONCOTARGET, V6, P37609, DOI 10.18632/oncotarget.6067
   Han H, 2018, NUCLEIC ACIDS RES, V46, pD380, DOI 10.1093/nar/gkx1013
   Heras-Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019
   Homma K, 2011, NUCLEIC ACIDS RES, V39, pD986, DOI 10.1093/nar/gkq995
   Hong SW, 2017, BIOCHEM BIOPH RES CO, V491, P303, DOI 10.1016/j.bbrc.2017.07.105
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Irahara N, 2010, DIAGN MOL PATHOL, V19, P157, DOI 10.1097/PDM.0b013e3181c93fd1
   Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971
   Jiang QH, 2009, NUCLEIC ACIDS RES, V37, pD98, DOI 10.1093/nar/gkn714
   Karban AS, 2004, HUM MOL GENET, V13, P35, DOI 10.1093/hmg/ddh008
   Lee HW, 2014, BMB REP, V47, P697, DOI 10.5483/BMBRep.2014.47.12.069
   Lee S, 2006, ONCOL REP, V16, P747
   Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260
   Li YH, 2015, NUCLEIC ACIDS RES, V43, pD578, DOI 10.1093/nar/gku903
   Liu FL, 2016, ONCOTARGET, V7, P4122, DOI 10.18632/oncotarget.6702
   Loo LWM, 2013, GENE CHROMOSOME CANC, V52, P450, DOI 10.1002/gcc.22043
   Lu BJ, 2007, CLIN CHIM ACTA, V378, P42, DOI 10.1016/j.cca.2006.10.024
   Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200
   Mattar Mark C, 2011, Gastrointest Cancer Res, V4, P53
   Milo R, 2002, SCIENCE, V298, P824, DOI 10.1126/science.298.5594.824
   Motoyama K, 2009, INT J ONCOL, V34, P1069, DOI 10.3892/ijo_00000233
   NOMOTO K, 1995, MOL CARCINOGEN, V12, P146, DOI 10.1002/mc.2940120306
   Pinero J, 2017, NUCLEIC ACIDS RES, V45, pD833, DOI 10.1093/nar/gkw943
   Qi J, 2014, ONCOGENE, V33, P4156, DOI 10.1038/onc.2013.397
   Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056
   Rho JH, 2008, J PROTEOME RES, V7, P2959, DOI 10.1021/pr8000892
   Rhoads RE, 1991, CURR OPIN CELL BIOL, V3, P1019, DOI 10.1016/0955-0674(91)90123-G
   Saiki S, 2011, AUTOPHAGY, V7, P176, DOI 10.4161/auto.7.2.14074
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Slattery ML, 2011, CANCER-AM CANCER SOC, V117, P4175, DOI 10.1002/cncr.26018
   Slattery ML, 2011, CANCER EPIDEM BIOMAR, V20, P57, DOI 10.1158/1055-9965.EPI-10-0843
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Takagi Y, 2000, GUT, V47, P268, DOI 10.1136/gut.47.2.268
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Thangaraju M, 2009, BIOCHEM J, V417, P379, DOI 10.1042/BJ20081132
   Tomczak Katarzyna, 2015, Contemp Oncol (Pozn), V19, pA68, DOI 10.5114/wo.2014.47136
   Tsoi H, 2017, ONCOGENE, V36, P6109, DOI 10.1038/onc.2017.86
   Turei D, 2015, AUTOPHAGY, V11, P155, DOI 10.4161/15548627.2014.994346
   Ueno T, 2008, AUTOPHAGY, V4, P692, DOI 10.4161/auto.6085
   Ulitsky I, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100144
   Wang HC, 2014, BIOCHEM BIOPH RES CO, V446, P1204, DOI 10.1016/j.bbrc.2014.03.086
   Wei W, 2016, CELL PHYSIOL BIOCHEM, V39, P1165, DOI 10.1159/000447823
   Winawer S, 2003, GASTROENTEROLOGY, V124, P544, DOI 10.1053/gast.2003.50044
   Wu D, 2015, AUTOPHAGY, V11, P1917, DOI 10.1080/15548627.2015.1089375
   Xie XL, 2012, AUTOPHAGY, V8, P1071, DOI 10.4161/auto.20250
   Yi Y, 2017, NUCLEIC ACIDS RES, V45, pD115, DOI 10.1093/nar/gkw1052
   Yu YX, 2012, ANN HUM GENET, V76, P269, DOI 10.1111/j.1469-1809.2012.00709.x
   Yuan Q, 2009, J CANCER RES CLIN, V135, P131, DOI 10.1007/s00432-008-0429-8
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zeestraten ECM, 2012, BRIT J CANCER, V106, P133, DOI 10.1038/bjc.2011.504
   Zhang HM, 2015, NUCLEIC ACIDS RES, V43, pD76, DOI 10.1093/nar/gku887
   Zhang T, 2017, NUCLEIC ACIDS RES, V45, pD135, DOI 10.1093/nar/gkw728
   Zhong M, 2013, CELL PHYSIOL BIOCHEM, V31, P209, DOI 10.1159/000343362
NR 64
TC 1
Z9 1
U1 1
U2 5
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570-1786
EI 1875-6255
J9 LETT ORG CHEM
JI Lett. Org. Chem.
PY 2019
VL 16
IS 4
BP 340
EP 346
DI 10.2174/1570178615666180914113224
PG 7
WC Chemistry, Organic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA HP5YQ
UT WOS:000461759900013
DA 2022-04-25
ER

PT J
AU Islam, F
   Gopalan, V
   Pillai, S
   Lu, CT
   Kasem, K
   Lam, AKY
AF Islam, Farhadul
   Gopalan, Vinod
   Pillai, Suja
   Lu, Cu-tai
   Kasem, Kais
   Lam, Alfred King-yin
TI Promoter hypermethylation inactivate tumor suppressor FAM134B and is
   associated with poor prognosis in colorectal cancer
SO GENES CHROMOSOMES & CANCER
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; ENDOPLASMIC-RETICULUM TURNOVER; HEREDITARY
   SENSORY NEUROPATHY; DNA METHYLATION; COLON-CANCER; CLINICOPATHOLOGICAL
   SIGNIFICANCE; AUTONOMIC NEUROPATHY; SELECTIVE AUTOPHAGY; GENE; MUTATIONS
AB The present study aims to examine promoter methylation status of FAM134B in a large cohort of patients with colorectal adenocarcinomas. The clinical significances and correlations of FAM134B promoter methylation with its expression are also analysed. Methylation-specific high-resolution melt-curve analysis followed by sequencing was used to identify FAM134B promoter methylation in colorectal adenomas (N = 32), colorectal adenocarcinomas (N = 164), matched adjacent non-neoplastic colorectal mucosae (N = 83) and colon cancer cell lines (N = 4). FAM134B expression was studied by real-time quantitative polymerase chain reaction, immunohistochemistry, and Western blots. FAM134B promoter methylation was more frequent in adenocarcinomas (52%; 85/164) when compared to that of adenomas (28%; 9/32) and non-neoplastic mucosae (35%; 29/83). Cancer cells exhibited higher methylation when compared to non-neoplastic cells. FAM134B promoter methylation was inversely correlated with low FAM134B copy number and mRNA/protein expressions, whereas in-vitro demethylation has restored FAM134B expression in colon cancer cells. FAM134B promoter methylation was associated with high histological grade (P = .025), presence of peri-neural infiltration (P = .012), lymphovascular invasion (P = .021), lymph node metastasis (P = .0001), distant metastasis (P = .0001) and advanced pathological stages (P = .0001). In addition, FAM134B promoter methylation correlated with cancer recurrence and poor survival rates of patients with colorectal adenocarcinomas. To conclude, FAM134B promoter methylation plays a key role in regulating FAM134B expression in vitro and in vivo, which in turn contributes to the prediction of the biological aggressiveness of colorectal adenocarcinomas. Furthermore, FAM134B methylation might act as a marker in predicting clinical prognosis in patients with colorectal adenocarcinomas.
C1 [Islam, Farhadul; Gopalan, Vinod; Pillai, Suja; Kasem, Kais; Lam, Alfred King-yin] Griffith Univ, Sch Med, Canc Mol Pathol, Nathan, Qld, Australia.
   [Islam, Farhadul; Gopalan, Vinod; Pillai, Suja; Kasem, Kais; Lam, Alfred King-yin] Griffith Univ, Menzies Hlth Inst Queensland, Nathan, Qld, Australia.
   [Islam, Farhadul] Univ Rajshahi, Dept Biochem & Mol Biol, Rajshahi 6205, Bangladesh.
   [Pillai, Suja] Univ Queensland, Sch Biomed Sci, Brisbane, Qld, Australia.
   [Lu, Cu-tai] Gold Coast Hosp, Dept Surg, Gold Coast, Qld, Australia.
RP Lam, AKY (corresponding author), Griffith Med Sch, Pathol, Gold Coast Campus, Gold Coast, Qld 4222, Australia.
EM a.lam@griffith.edu.au
RI Pillai, Suja/AAG-4056-2019; Lam, Alfred/C-1652-2008; Islam,
   Farhadul/R-5643-2017
OI Pillai, Suja/0000-0002-6572-1840; Lam, Alfred/0000-0003-2771-564X; Lu,
   Cu Tai/0000-0001-9565-3749; Islam, Farhadul/0000-0001-5262-4702
FU Menzies Health Institute Queensland; Griffith UniversityGriffith
   University
FX Griffith University; Menzies Health Institute Queensland
CR BATSAKIS JG, 1985, ANN OTO RHINOL LARYN, V94, P426
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Chiramel AI, 2016, J INFECT DIS, V214, pS319, DOI 10.1093/infdis/jiw270
   Dai XF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07189-6
   Davidson GL, 2012, J NEUROL, V259, P1673, DOI 10.1007/s00415-011-6397-y
   Duret C, 2014, MUSCLE NERVE, V49, P774, DOI 10.1002/mus.24145
   Fleming M, 2012, J GASTROINTEST ONCOL, V3, P153, DOI 10.3978/j.issn.2078-6891.2012.030
   Gallois C, 2016, CRIT REV ONCOL HEMAT, V99, P74, DOI 10.1016/j.critrevonc.2015.11.001
   Giovannucci E, 2005, JNCI-J NATL CANCER I, V97, P1317, DOI 10.1093/jnci/dji305
   GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531
   Gopalan V, 2016, EXP CELL RES, V348, P146, DOI 10.1016/j.yexcr.2016.09.010
   Hamilton S. R., 2010, WHO CLASSIFICATION T, V134
   Haque MH, 2017, ANAL CHIM ACTA, V976, P84, DOI 10.1016/j.aca.2017.04.034
   Haque MH, 2016, SCI REP-UK, V6, DOI 10.1038/srep29173
   HARDCASTLE JD, 1984, J ROY SOC MED, V77, P673, DOI 10.1177/014107688407700812
   Harris EI, 2008, AM J SURG PATHOL, V32, P1816, DOI 10.1097/PAS.0b013e3181816083
   Hinoue T, 2012, GENOME RES, V22, P271, DOI 10.1101/gr.117523.110
   Islam F, 2017, EXP CELL RES, V357, P260, DOI 10.1016/j.yexcr.2017.05.021
   Islam F, 2017, HUM PATHOL, V62, P141, DOI 10.1016/j.humpath.2017.01.014
   Islam F, 2017, HUM GENET, V136, P321, DOI 10.1007/s00439-017-1760-4
   Islam F, 2017, MOL CARCINOGEN, V56, P238, DOI 10.1002/mc.22488
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   Jessup JM, 2017, AJCC CANC STAGING MA, P251, DOI DOI 10.1007/978-3-319-40618-3_20
   Kasem K, 2014, EXP MOL PATHOL, V97, P99, DOI 10.1016/j.yexmp.2014.06.002
   Kasem K, 2014, EXP MOL PATHOL, V97, P31, DOI 10.1016/j.yexmp.2014.05.001
   Kasem K, 2014, EXP CELL RES, V326, P166, DOI 10.1016/j.yexcr.2014.06.013
   Khaminets A, 2015, NATURE, V522, P354, DOI 10.1038/nature14498
   Kong M, 2011, PSYCHIAT GENET, V21, P37, DOI 10.1097/YPG.0b013e3283413496
   KRASNA MJ, 1988, CANCER-AM CANCER SOC, V61, P1018, DOI 10.1002/1097-0142(19880301)61:5<1018::AID-CNCR2820610527>3.0.CO;2-H
   Kurth I, 2009, NAT GENET, V41, P1179, DOI 10.1038/ng.464
   Lam AKY, 2012, INT J COLORECTAL DIS, V27, P1303, DOI 10.1007/s00384-012-1474-y
   Liebig C, 2009, CANCER-AM CANCER SOC, V115, P3379, DOI 10.1002/cncr.24396
   Melchiotti R, 2014, BMC MED GENET, V15, DOI 10.1186/1471-2350-15-73
   Murphy SM, 2012, J NEUROL NEUROSUR PS, V83, P119, DOI 10.1136/jnnp.2010.228965
   Okugawa Y, 2015, GASTROENTEROLOGY, V149, P1204, DOI 10.1053/j.gastro.2015.07.011
   Rao RV, 2006, CELL DEATH DIFFER, V13, P415, DOI 10.1038/sj.cdd.4401761
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Tang WK, 2007, INT J MOL MED, V19, P915
   van Rijnsoever M, 2002, GUT, V51, P797, DOI 10.1136/gut.51.6.797
   Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698
   Wojdacz TK, 2008, NAT PROTOC, V3, P1903, DOI 10.1038/nprot.2008.191
   Xing X, 2013, BRIT J CANCER, V108, P2542, DOI 10.1038/bjc.2013.251
   Yadav Raj Kumar, 2014, J Cancer Prev, V19, P75, DOI 10.15430/JCP.2014.19.2.75
   Zhou D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03133-w
NR 44
TC 11
Z9 11
U1 1
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1045-2257
EI 1098-2264
J9 GENE CHROMOSOME CANC
JI Gene Chromosomes Cancer
PD MAY
PY 2018
VL 57
IS 5
BP 240
EP 251
DI 10.1002/gcc.22525
PG 12
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA FY8LP
UT WOS:000427116500003
PM 29318692
OA Green Submitted, Green Published
DA 2022-04-25
ER

PT J
AU Kim, H
   Yin, KL
   Falcon, DM
   Xue, X
AF Kim, Hyeoncheol
   Yin, Kunlun
   Falcon, Daniel M.
   Xue, Xiang
TI The interaction of Hemin and Sestrin2 modulates oxidative stress and
   colon tumor growth
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE Sestrin2; Hemin; Oxidative stress; Colorectal cancer; Nuclear factor
   (erythroid-derived 2)-like 2
ID COLORECTAL-CANCER; AUTOPHAGIC DEGRADATION; MEAT CONSUMPTION;
   UP-REGULATION; NITRIC-OXIDE; DNA-DAMAGE; RED MEAT; NRF2; IRON;
   ACTIVATION
AB Several large epidemiological and animal studies demonstrate a direct correlation between dietary heme iron intake and/or systemic iron levels and cancer risk in several cancers including colorectal cancer (CRC). However, the precise mechanisms for how heme iron contributes to CRC and how cancer cells respond to heme iron-induced stress are still unclear. Previously we have shown that one of the stress-inducible proteins, Sestrin2 (SESN2), is a novel tumor suppressor in colon by limiting endoplasmic reticulum stress and mammalian target of rapamycin complex 1 (mTORC1) signaling and tumor growth. But the relationship between heme iron and SESN2, especially in the context of colon carcinogenesis, was not investigated previously. Here, we found that hemin dose-dependently increased SESN2 expression in an oxidative stress and nuclear factor (erythroid-derived 2)-like 2 (NFE2L2, NRF2)-dependent manner. Since SESN2 overexpression reduced hemin-induced oxidative stress, SESN2 could be an important target of NRF2 exerting antioxidant function. Indeed, expression of several oxidative stress responsive proteins such as NRF2 and its target genes was reduced by SESN2. Although we formerly reported that SESN2 expression was reduced after p53 mutation in colon tumors, mouse colon tumors, which have intact p53 and NRF2, induced SESN2 expression in response to iron stimulus. Although SESN2 overexpression decreased murine colon tumor cell growth both in vitro and in vivo, it rendered colon cancer cells more resistant to hemin-induced apoptosis and therefore promoted tumor growth during hemin treatment. Taken together, although SESN2 generally suppresses tumorigenesis, it can produce tumor-promoting role in iron-rich environment by suppressing oxidative stress-associated cancer cell death.
C1 [Kim, Hyeoncheol; Yin, Kunlun; Falcon, Daniel M.; Xue, Xiang] Univ New Mexico, Dept Biochem & Mol Biol, Albuquerque, NM 87131 USA.
RP Xue, X (corresponding author), Fitz Hall 259,915 Camino de Salud NE, Albuquerque, NM 87131 USA.
EM xxue@salud.unm.edu
RI Xue, Xiang/P-9071-2014
OI Xue, Xiang/0000-0003-4704-1814
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [K01DK114390];
   American Cancer SocietyAmerican Cancer Society [RSG-18-050-01-NEC];
   University of New Mexico Environmental Health Signature Program and
   Superfund [P42 ES025589]; Dedicated Health Research Funds from the
   University of New Mexico School of Medicine; NCIUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [2P30 CA118100]; Academic Science
   Education and Research Training program at the University of New Mexico
   Health Sciences Center(NIGMS Institutional Research and Academic Career
   Development Award) [K12-GM088021]; NATIONAL CANCER INSTITUTEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA118100]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND
   DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK) [K01DK114390] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Environmental
   Health Sciences (NIEHS) [P42ES025589] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [K12GM088021]
   Funding Source: NIH RePORTER
FX We thank Dr. Weiping Zou at University of Michigan for generously
   providing MC38 cells, Dr. Jun Hee Lee at University of Michigan for
   generously providing pLU-CMV-Flag-hSESN2 WT plasmid and editing the
   manuscript. This work was supported in part by the National Institutes
   of Health (K01DK114390), a Research Scholar Grant from the American
   Cancer Society (RSG-18-050-01-NEC), a Research Pilot Project Grant from
   University of New Mexico Environmental Health Signature Program and
   Superfund (P42 ES025589), and the Dedicated Health Research Funds from
   the University of New Mexico School of Medicine. Support for in vivo
   experiments in this paper was provided by the University of New Mexico
   Cancer Center Animal Models Shared Resource and a Shared Resources Pilot
   Project Award, funded by NCI 2P30 CA118100 (PI Willman, C.) "UNM Cancer
   Center Support Grant". D.M.F was supported by the Academic Science
   Education and Research Training program at the University of New Mexico
   Health Sciences Center(NIGMS Institutional Research and Academic Career
   Development Award; K12-GM088021). The authors have no financial
   conflicts of interest.
CR Abraham NG, 2008, PHARMACOL REV, V60, P79, DOI 10.1124/pr.107.07104
   Aldini G, 2018, FREE RADICAL RES, V52, P751, DOI 10.1080/10715762.2018.1468564
   Bae SH, 2013, CELL METAB, V17, P73, DOI 10.1016/j.cmet.2012.12.002
   Barcellos-de-Souza P, 2013, AM J PHYSIOL-CELL PH, V304, pC170, DOI 10.1152/ajpcell.00078.2012
   Bastide NM, 2015, CANCER RES, V75, P870, DOI 10.1158/0008-5472.CAN-14-2554
   Ben-Sahra I, 2013, CELL DEATH DIFFER, V20, P611, DOI 10.1038/cdd.2012.157
   Bonovolias ID, 2009, ONCOL RES, V17, P535, DOI 10.3727/096504009789745557
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Bryan HK, 2013, BIOCHEM PHARMACOL, V85, P705, DOI 10.1016/j.bcp.2012.11.016
   Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028
   Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569
   Budanov AV, 2002, ONCOGENE, V21, P6017, DOI 10.1038/sj.onc.1205877
   Byun JK, 2017, CELL REP, V20, P586, DOI 10.1016/j.celrep.2017.06.066
   Cannon J B, 1995, PDA J Pharm Sci Technol, V49, P77
   Cheung KL, 2014, MOL CARCINOGEN, V53, P77, DOI 10.1002/mc.21950
   Constante M, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01809
   Dutra FF, 2014, P NATL ACAD SCI USA, V111, pE4110, DOI 10.1073/pnas.1405023111
   Gabriel C, 1997, J PHARMACOL TOXICOL, V38, P93, DOI 10.1016/S1056-8719(97)00066-X
   Gemelli C, 2014, LIFE SCI, V107, P14, DOI 10.1016/j.lfs.2014.04.026
   GIOVANNUCCI E, 1994, CANCER RES, V54, P2390
   Glei M, 2006, MUTAT RES-FUND MOL M, V594, P162, DOI 10.1016/j.mrfmmm.2005.08.006
   Goldstein L, 2003, J NEUROSCI RES, V73, P113, DOI 10.1002/jnr.10633
   Gonzalez-Donquiles C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177549
   Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600
   Gulec S, 2014, AM J PHYSIOL-GASTR L, V307, pG397, DOI 10.1152/ajpgi.00348.2013
   Hasan RN, 2008, CIRC RES, V102, P42, DOI 10.1161/CIRCRESAHA.107.155143
   Ho A, 2016, TRENDS BIOCHEM SCI, V41, P621, DOI 10.1016/j.tibs.2016.04.005
   Hu HJ, 2015, DNA CELL BIOL, V34, P296, DOI 10.1089/dna.2014.2627
   Hwang HJ, 2018, MEDIAT INFLAMM, V2018, DOI [10.1155/2018/6209110, 10.1155/2018/6209140]
   Ishihara M, 2013, AM J PHYSIOL-RENAL, V305, pF495, DOI 10.1152/ajprenal.00642.2012
   Itoh T, 2001, BIOCONJUGATE CHEM, V12, P3, DOI 10.1021/bc000055q
   Kagan VE, 2001, ANTIOXID REDOX SIGN, V3, P189, DOI 10.1089/152308601300185160
   Khor TO, 2008, CANCER PREV RES, V1, P187, DOI 10.1158/1940-6207.CAPR-08-0028
   Kim H, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10025
   Kim TH, 2011, CANCER RES, V71, P2260, DOI 10.1158/0008-5472.CAN-10-3007
   Kopnin PB, 2007, CANCER RES, V67, P4671, DOI 10.1158/0008-5472.CAN-06-2466
   Kultz D, 2005, ANNU REV PHYSIOL, V67, P225, DOI 10.1146/annurev.physiol.67.040403.103635
   Larsson SC, 2006, INT J CANCER, V119, P2657, DOI 10.1002/ijc.22170
   Lee JH, 2010, SCIENCE, V327, P1223, DOI 10.1126/science.1182228
   Liu AQ, 2017, NEUROSCI LETT, V646, P1, DOI 10.1016/j.neulet.2016.10.043
   Loboda A, 2016, CELL MOL LIFE SCI, V73, P3221, DOI 10.1007/s00018-016-2223-0
   Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320
   Mullebner A, 2018, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00252
   Nagababu E, 2004, ANTIOXID REDOX SIGN, V6, P967, DOI 10.1089/ars.2004.6.967
   Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200
   Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003
   Oates PS, 2006, WORLD J GASTROENTERO, V12, P4281, DOI 10.3748/wjg.v12.i27.4281
   Owusu-Ansah E, 2008, PROTOCOL IN VIVO DET
   Pall Martin L., 2015, Shengli Xuebao, V67, P1
   Pasha M, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3296294
   Peng M, 2014, CELL, V159, P122, DOI 10.1016/j.cell.2014.08.038
   Rajagopal A, 2008, NATURE, V453, P1127, DOI 10.1038/nature06934
   Rhee SG, 2015, FREE RADICAL BIO MED, V88, P205, DOI 10.1016/j.freeradbiomed.2015.06.007
   Ro SH, 2016, ELIFE, V5, DOI 10.7554/eLife.12204
   Ro SH, 2014, FEBS J, V281, P3816, DOI 10.1111/febs.12905
   Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3
   Sandhu MS, 2001, CANCER EPIDEM BIOMAR, V10, P439
   Sebens S, 2011, J BIOL CHEM, V286, P40911, DOI 10.1074/jbc.M111.274902
   Seo K, 2015, CELL SIGNAL, V27, P1533, DOI 10.1016/j.cellsig.2015.03.003
   Sesink ALA, 1999, CANCER RES, V59, P5704
   Shayeghi M, 2005, CELL, V122, P789, DOI 10.1016/j.cell.2005.06.025
   Shen J, 2014, CELL REP, V7, P180, DOI 10.1016/j.celrep.2014.02.042
   Shimizu T, 2012, J INORG BIOCHEM, V108, P171, DOI 10.1016/j.jinorgbio.2011.08.018
   Shin BY, 2012, FREE RADICAL BIO MED, V53, P834, DOI 10.1016/j.freeradbiomed.2012.06.026
   Singh A, 2016, ACS CHEM BIOL, V11, P3214, DOI 10.1021/acschembio.6b00651
   Tong Ying-Hui, 2015, Chronic Dis Transl Med, V1, P175, DOI 10.1016/j.cdtm.2015.09.002
   Vasconcellos LRC, 2016, P NATL ACAD SCI USA, V113, pE7474, DOI 10.1073/pnas.1608928113
   Velasco-Miguel S, 1999, ONCOGENE, V18, P127, DOI 10.1038/sj.onc.1202274
   West AR, 2008, WORLD J GASTROENTERO, V14, P4101, DOI 10.3748/wjg.14.4101
   White C, 2013, CELL METAB, V17, P261, DOI 10.1016/j.cmet.2013.01.005
   WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404
   Xue X, 2017, P NATL ACAD SCI USA, V114, pE9608, DOI 10.1073/pnas.1712946114
   Xue X, 2016, CELL METAB, V24, P447, DOI 10.1016/j.cmet.2016.07.015
   Xue X, 2012, CANCER RES, V72, P2285, DOI 10.1158/0008-5472.CAN-11-3836
   Yang JH, 2015, FREE RADICAL BIO MED, V78, P156, DOI 10.1016/j.freeradbiomed.2014.11.002
NR 75
TC 18
Z9 18
U1 0
U2 23
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0041-008X
EI 1096-0333
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD JUL 1
PY 2019
VL 374
BP 77
EP 85
DI 10.1016/j.taap.2019.04.025
PG 9
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA IA9RD
UT WOS:000469893600008
PM 31054940
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Wu, S
   Qiu, YL
   Shao, YY
   Yin, SS
   Wang, R
   Pang, X
   Ma, JH
   Zhang, CZ
   Wu, B
   Koo, S
   Han, LF
   Zhang, Y
   Gao, XM
   Wang, T
   Yu, HY
AF Wu, Song
   Qiu, Yuling
   Shao, Yingying
   Yin, Shuangshuang
   Wang, Rui
   Pang, Xu
   Ma, Junhong
   Zhang, Chunze
   Wu, Bo
   Koo, Sangho
   Han, Lifeng
   Zhang, Yi
   Gao, Xiumei
   Wang, Tao
   Yu, Haiyang
TI Lycorine Displays Potent Antitumor Efficacy in Colon Carcinoma by
   Targeting STAT3
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE lycorine; STAT3; target; apoptosis; colorectal cancers
ID PROGRAMMED CELL-DEATH; DNA-BINDING DOMAIN; SIGNALING PATHWAY;
   CANCER-TREATMENT; AUTOPHAGY; APOPTOSIS; GROWTH; TRANSCRIPTION;
   METASTASIS; STATISTICS
AB Signal transducer and activator of transcription 3 (STAT3) is an attractive therapeutic target for cancer treatment. In this study, we identify lycorine is an effective inhibitor of STAT3, leading to repression of multiple oncogenic processes in colon carcinoma. Lycorine selectively inactivates phospho-STAT3 (Tyr-705), and subsequent molecular docking uncovers that lycorine directly binds to the SH2 domain of STAT3. Consequently, we find that lycorine exhibits anti-proliferative activity and induces cell apoptosis on human colorectal cancer (CRC) in vitro. Lycorine induces the activation of the caspase-dependent mitochondrial apoptotic pathway, as indicated by activation of caspase and increase of the ratio of Bax/Bcl-2 and mitochondria! depolarization. Overexpressing STAT3 greatly blocks these effects by lycorine in CRC cells. Finally, lycorine exhibits a potential therapeutic effect in xenograft colorectal tumors by targeting STAT3 without observed toxicity. Taken together, the present study indicates that lycorine acts as a promising inhibitor of STAT3, which blocks tumorigenesis in colon carcinoma.
C1 [Wu, Song; Shao, Yingying; Yin, Shuangshuang; Wang, Rui; Pang, Xu; Han, Lifeng; Zhang, Yi; Gao, Xiumei; Wang, Tao; Yu, Haiyang] Tianjin Univ Tradit Chinese Med, Tianjin State Key Lab Modern Chinese Med, Tianjin, Peoples R China.
   [Qiu, Yuling] Tianjin Med Univ, Sch Pharm, Tianjin, Peoples R China.
   [Ma, Junhong] Nankai Hosp, Dept Gastrointestinal Surg, Tianjin, Peoples R China.
   [Zhang, Chunze] Tianjin Union Med Ctr, Dept Colorectal Surg, Tianjin, Peoples R China.
   [Wu, Bo] China Med Univ, Sch Fundamental Sci, Shenyang, Liaoning, Peoples R China.
   [Koo, Sangho] Myongji Univ, Dept Chem, Seoul, South Korea.
RP Wang, T; Yu, HY (corresponding author), Tianjin Univ Tradit Chinese Med, Tianjin State Key Lab Modern Chinese Med, Tianjin, Peoples R China.
EM wangt@263.net; yuhaiyang19830116@hotmail.com
RI Koo, Sangho/AAR-4354-2020
OI Koo, Sangho/0000-0003-4725-1117
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81603253, 21711540293, 81673703, 81602614,
   81501578]; Natural Science Foundation of Tianjin CityNatural Science
   Foundation of Tianjin [15JCYBJC54900, 15PTCYSY00030]; Tianjin Health and
   Family Planning Commission [2017057]
FX This work was supported by from National Natural Science Foundation of
   China (Grant Nos. 81603253 and 21711540293 to HY, Grant No. 81673703 to
   TW, Grant No. 81602614 to YQ, Grant No. 81501578 to BD), Natural Science
   Foundation of Tianjin City (Grant No. 15JCYBJC54900 to HY, Grant No.
   15PTCYSY00030 to ZL), and Tianjin Health and Family Planning Commission
   (Grant No. 2017057 to CZ).
CR Berchtold MW, 2014, BBA-MOL CELL RES, V1843, P398, DOI 10.1016/j.bbamcr.2013.10.021
   Buenz E., 2018, TOXICOLOGY, V6, P509, DOI [10.1146/annurev-pharmtox-010617-052703, DOI 10.1146/ANNUREV-PHARMTOX-010617-052703]
   Chai EZP, 2016, PHARMACOL THERAPEUT, V162, P86, DOI 10.1016/j.pharmthera.2015.10.004
   Chelsky ZL, 2015, MOL PHARMACOL, V88, P524, DOI 10.1124/mol.115.099093
   David B, 2015, PHYTOCHEM REV, V14, P299, DOI 10.1007/s11101-014-9367-z
   Flusberg DA, 2015, TRENDS CELL BIOL, V25, P446, DOI 10.1016/j.tcb.2015.03.003
   Fuchs Y, 2015, NAT REV MOL CELL BIO, V16, P329, DOI 10.1038/nrm3999
   Fulda S, 2015, SEMIN CANCER BIOL, V31, P84, DOI 10.1016/j.semcancer.2014.05.002
   Furtek SL, 2016, ACS CHEM BIOL, V11, P308, DOI 10.1021/acschembio.5b00945
   Genini D, 2017, P NATL ACAD SCI USA, V114, pE4924, DOI 10.1073/pnas.1615730114
   Hata AN, 2015, CANCER DISCOV, V5, P475, DOI 10.1158/2159-8290.CD-15-0011
   Hu MC, 2015, ONCOTARGET, V6, P15348, DOI 10.18632/oncotarget.3610
   Huang C, 2018, CANCER RES, V78, P2825, DOI 10.1158/0008-5472.CAN-17-2314
   Huang HS, 2016, AUTOPHAGY, V12, P1687, DOI 10.1080/15548627.2016.1196313
   Huang W, 2016, ONCOGENE, V35, P783, DOI 10.1038/onc.2015.215
   Jin ZX, 2016, BIOMED PHARMACOTHER, V84, P1645, DOI 10.1016/j.biopha.2016.10.069
   Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8
   Lis C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17600-x
   Liu LJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.250
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   Namanja AT, 2016, J MOL BIOL, V428, P579, DOI 10.1016/j.jmb.2016.01.003
   Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055
   Roy MJ, 2014, BRIT J PHARMACOL, V171, P1973, DOI 10.1111/bph.12431
   Roy M, 2016, THERANOSTICS, V6, P2209, DOI 10.7150/thno.15584
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Siveen KS, 2014, BBA-REV CANCER, V1845, P136, DOI 10.1016/j.bbcan.2013.12.005
   Son DJ, 2017, THERANOSTICS, V7, P4632, DOI 10.7150/thno.18630
   Spitzner M, 2014, INT J CANCER, V134, P997, DOI 10.1002/ijc.28429
   Wake MS, 2015, FEBS J, V282, P2600, DOI 10.1111/febs.13285
   Wang J, 2017, ACTA BIOCH BIOPH SIN, V49, P771, DOI 10.1093/abbs/gmx076
   Wang Y, 2018, CANCER LETT, V415, P117, DOI 10.1016/j.canlet.2017.12.003
   Yeh JE, 2016, CHEMMEDCHEM, V11, P795, DOI 10.1002/cmdc.201500482
   Yu HY, 2017, MOL CANCER THER, V16, P2711, DOI 10.1158/1535-7163.MCT-17-0498
   Yu HY, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6218
   Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818
   Zhang T, 2017, ONCOGENE, V36, P6627, DOI 10.1038/onc.2017.270
   Zhang XL, 2010, BIOCHEM PHARMACOL, V79, P1398, DOI 10.1016/j.bcp.2010.01.001
   Zhao CG, 2016, TRENDS PHARMACOL SCI, V37, P47, DOI 10.1016/j.tips.2015.10.001
NR 39
TC 13
Z9 16
U1 3
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD AUG 8
PY 2018
VL 9
AR 881
DI 10.3389/fphar.2018.00881
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA GP7DB
UT WOS:000441051500001
PM 30135654
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Devenport, SN
   Singhal, R
   Radyk, MD
   Taranto, JG
   Kerk, SA
   Chen, B
   Goyert, JW
   Jain, C
   Das, NK
   Oravecz-Wilson, K
   Li, Z
   Greenson, JK
   Chen, YE
   Soleimanpour, SA
   Reddy, P
   Lyssiotis, CA
   Shah, YM
AF Devenport, Samantha N.
   Singhal, Rashi
   Radyk, Megan D.
   Taranto, Joseph G.
   Kerk, Samuel A.
   Chen, Brandon
   Goyert, Joshua W.
   Jain, Chesta
   Das, Nupur K.
   Oravecz-Wilson, Katherine
   Li Zhang
   Greenson, Joel K.
   Chen, Y. Eugene
   Soleimanpour, Scott A.
   Reddy, Pavan
   Lyssiotis, Costas A.
   Shah, Yatrik M.
TI Colorectal cancer cells utilize autophagy to maintain mitochondrial
   metabolism for cell proliferation under nutrient stress
SO JCI INSIGHT
LA English
DT Article
ID INDUCED APOPTOSIS; IRON HOMEOSTASIS; PANETH CELLS; KEY ROLE; MITOPHAGY;
   INHIBITION; SURVIVAL; MOUSE; MAINTENANCE; EXPRESSION
AB Cancer cells reprogram cellular metabolism to maintain adequate nutrient pools to sustain proliferation. Moreover, autophagy is a regulated mechanism to break down dysfunctional cellular components and recycle cellular nutrients. However, the requirement for autophagy and the integration in cancer cell metabolism is not clear in colon cancer. Here, we show a cell-autonomous dependency of autophagy for cell growth in colorectal cancer. Loss of epithelial autophagy inhibits tumor growth in both sporadic and colitis-associated cancer models. Genetic and pharmacological inhibition of autophagy inhibits cell growth in colon cancer-derived cell lines and patient-derived enteroid models. Importantly, normal colon epithelium and patient-derived normal enteroid growth were not decreased following autophagy inhibition. To couple the role of autophagy to cellular metabolism, a cell culture screen in conjunction with metabolomic analysis was performed. We identified a critical role of autophagy to maintain mitochondria' metabolites for growth. Loss of mitochondria! recycling through inhibition of mitophagy hinders colon cancer cell growth. These findings have revealed a cell-autonomous role of autophagy that plays a critical role in regulating nutrient pools in vivo and in cell models, and it provides therapeutic targets for colon cancer.
C1 [Devenport, Samantha N.; Chen, Brandon; Shah, Yatrik M.] Univ Michigan, Med Sch, Cellular & Mol Biol, Ann Arbor, MI 48109 USA.
   [Devenport, Samantha N.; Singhal, Rashi; Radyk, Megan D.; Taranto, Joseph G.; Kerk, Samuel A.; Chen, Brandon; Goyert, Joshua W.; Jain, Chesta; Das, Nupur K.; Li Zhang; Lyssiotis, Costas A.; Shah, Yatrik M.] Univ Michigan, Med Sch, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA.
   [Oravecz-Wilson, Katherine; Reddy, Pavan] Univ Michigan, Med Sch, Dept Hematol & Oncol, Ann Arbor, MI 48109 USA.
   [Greenson, Joel K.] Univ Michigan, Med Sch, Dept Pathol, Ann Arbor, MI 48109 USA.
   [Chen, Y. Eugene] Univ Michigan, Med Sch, Cardiovasc Ctr, Ann Arbor, MI 48109 USA.
   [Soleimanpour, Scott A.] Univ Michigan, Med Sch, Metab Endocrinol & Diabet, Ann Arbor, MI 48109 USA.
   [Reddy, Pavan; Lyssiotis, Costas A.; Shah, Yatrik M.] Univ Michigan, Med Sch, Rogel Canc Ctr, Ann Arbor, MI 48109 USA.
   [Lyssiotis, Costas A.; Shah, Yatrik M.] Univ Michigan, Med Sch, Internal Med, Div Gastroenterol, Ann Arbor, MI 48109 USA.
RP Shah, YM (corresponding author), Univ Michigan, Div Gastroenterol, Dept Mol & Integrat Physiol, Dept Internal Med,Med Sch, Ann Arbor, MI 48109 USA.
EM shahy@umich.edu
RI Das, Nupur/AAK-7877-2020
OI Das, Nupur/0000-0002-5652-1134; Chen, Brandon/0000-0002-6319-2228;
   Radyk, Megan/0000-0002-3660-2906; Goyert, Joshua/0000-0003-3820-970X;
   Soleimanpour, Scott/0000-0001-6777-4498; Kerk,
   Samuel/0000-0001-9786-2245
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01CA148828, R01DK095201,
   R01CA245546]; NCIUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R37CA237421, R01CA248160, R01CA244931, R01CA215607];
   University of Michigan GI SPORE Molecular Pathology and Biosample Core
   [P50CA130810]; Rogel Cancer Center [P30CA046592]; Center for
   Gastrointestinal Research [DK034933]; Department of DefenseUnited States
   Department of Defense [CA171086]; US Department of Veterans AffairsUS
   Department of Veterans Affairs [I01 BX004444]; JDRFJuvenile Diabetes
   Research Foundation [COE-2019-861, CDA-2016-189, SRA-2018-539];  [R01
   DK108921];  [T32 GM007315];  [5 T32 CA140044-9]
FX This work was supported by NIH grants R01CA148828, R01DK095201, and
   R01CA245546 to YMS. CAL was supported by the NCI (R37CA237421,
   R01CA248160, R01CA244931, and R01CA215607). SAS was supported by R01
   DK108921. SND was supported by T32 GM007315 and 5 T32 CA140044-9. CAL
   and YMS are supported by University of Michigan GI SPORE Molecular
   Pathology and Biosample Core (P50CA130810), Rogel Cancer Center
   (P30CA046592), and Center for Gastrointestinal Research (DK034933). This
   work was also supported by the Department of Defense (CA171086, YMS),
   the US Department of Veterans Affairs (I01 BX004444, SAS), and the JDRF
   (COE-2019-861, CDA-2016-189, and SRA-2018-539, SAS).
CR Abu-Remaileh M, 2017, SCIENCE, V358, P807, DOI 10.1126/science.aan6298
   Alves S, 2015, ONCOTARGET, V6, P30787, DOI 10.18632/oncotarget.5021
   Benjamin JL, 2013, CELL HOST MICROBE, V13, P723, DOI 10.1016/j.chom.2013.05.004
   Bhatt V, 2019, GENE DEV, V33, P150, DOI 10.1101/gad.320481.118
   Boyle KA, 2018, J BIOL CHEM, V293, P14891, DOI 10.1074/jbc.RA117.001469
   Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416
   Cadwell K, 2009, AUTOPHAGY, V5, P250, DOI 10.4161/auto.5.2.7560
   Chassaing Benoit, 2014, Curr Protoc Immunol, V104, DOI 10.1002/0471142735.im1525s104
   Cho DH, 2012, ANTICANCER RES, V32, P4091
   Chong J, 2018, NUCLEIC ACIDS RES, V46, pW486, DOI 10.1093/nar/gky310
   Dame MK, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.153049
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Dehghanizadeh S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192499
   Dong Y, 2019, EUR REV MED PHARMACO, V23, P1047, DOI 10.26355/eurrev_201902_16992
   Feng Y, 2013, AM J PATHOL, V183, P493, DOI 10.1016/j.ajpath.2013.04.013
   Fitzwalter BE, 2018, DEV CELL, V44, P555, DOI 10.1016/j.devcel.2018.02.014
   Franklin CL, 2017, LAB ANIMAL, V46, P114, DOI 10.1038/laban.1222
   Fujita N, 2008, MOL BIOL CELL, V19, P4651, DOI 10.1091/mbc.E08-03-0312
   Glas J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054338
   Guo JY, 2016, GENE DEV, V30, P1704, DOI 10.1101/gad.283416.116
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Halbrook CJ, 2019, CELL METAB, V29, P1390, DOI 10.1016/j.cmet.2019.02.001
   Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954
   Hinoi T, 2007, CANCER RES, V67, P9721, DOI 10.1158/0008-5472.CAN-07-2735
   Kabat AM, 2016, FRONT IMMUNOL, V7, P1, DOI 10.3389/fimmu.2016.00240
   Kambara T, 2004, GUT, V53, P1137, DOI 10.1136/gut.2003.037671
   Kamphorst JJ, 2015, CANCER RES, V75, P544, DOI 10.1158/0008-5472.CAN-14-2211
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kohli L, 2013, CANCER RES, V73, P4395, DOI 10.1158/0008-5472.CAN-12-3765
   Lazarou M, 2015, NATURE, V524, P309, DOI 10.1038/nature14893
   Lee HJ, 2019, METABOLOMICS, V15, DOI 10.1007/s11306-019-1564-8
   Levy J, 2015, NAT CELL BIOL, V17, P1062, DOI 10.1038/ncb3206
   Liu L, 2012, NAT CELL BIOL, V14, P177, DOI 10.1038/ncb2422
   Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500
   Mamantopoulos M, 2018, GUT MICROBES, V9, P374, DOI 10.1080/19490976.2017.1421888
   Martins WK, 2016, AUTOPHAGY IN CURRENT TRENDS IN CELLULAR PHYSIOLOGY AND PATHOLOGY, P349, DOI 10.5772/63976
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Niklaus M, 2017, ONCOTARGET, V8, P54604, DOI 10.18632/oncotarget.17554
   Pan HM, 2016, ONCOTARGET, V7, P21235, DOI 10.18632/oncotarget.6908
   Pan QF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00076-0
   Pickles S, 2018, CURR BIOL, V28, pR170, DOI 10.1016/j.cub.2018.01.004
   Pott J, 2018, AUTOPHAGY, V14, P1460, DOI 10.1080/15548627.2018.1450021
   Pott J, 2018, CELL HOST MICROBE, V23, P191, DOI 10.1016/j.chom.2017.12.017
   Poulogiannis G, 2010, P NATL ACAD SCI USA, V107, P15145, DOI 10.1073/pnas.1009941107
   Rojansky R, 2016, ELIFE, V5, DOI 10.7554/eLife.17896
   Russell RC, 2013, NAT CELL BIOL, V15, P741, DOI 10.1038/ncb2757
   Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047
   Shah YM, 2014, GASTROENTEROLOGY, V146, P630, DOI 10.1053/j.gastro.2013.12.031
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Thomas M, 2018, CELL BIOCHEM FUNCT, V36, P65, DOI 10.1002/cbf.3318
   Triner D, 2019, GASTROENTEROLOGY, V156, P1467, DOI 10.1053/j.gastro.2018.12.003
   Tsuboi K, 2015, J BIOL CHEM, V290, P20511, DOI 10.1074/jbc.M114.632257
   da Silva-Camargo CCV, 2018, CANCER BIOL MED, V15, P61, DOI 10.20892/j.issn.2095-3941.2017.0136
   Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611
   Villa E, 2017, CELL REP, V20, P2846, DOI 10.1016/j.celrep.2017.08.087
   Weber RA, 2020, MOL CELL, V77, P645, DOI 10.1016/j.molcel.2020.01.003
   Yang LY, 2018, APPL ENVIRON MICROB, V84, DOI 10.1128/AEM.00880-18
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yang ZF, 2015, J BIOL CHEM, V290, P26549, DOI 10.1074/jbc.M115.658088
   Yao CW, 2017, BIOMOL THER, V25, P315, DOI 10.4062/biomolther.2016.069
   Yin KL, 2021, CELL DEATH DIFFER, V28, P2421, DOI 10.1038/s41418-021-00760-9
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Zhu YY, 2013, J BIOL CHEM, V288, P1099, DOI 10.1074/jbc.M112.399345
   Ziegler PK, 2018, CELL, V174, P88, DOI 10.1016/j.cell.2018.05.028
NR 65
TC 4
Z9 4
U1 1
U2 3
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
EI 2379-3708
J9 JCI INSIGHT
JI JCI Insight
PD JUL 22
PY 2021
VL 6
IS 14
AR e138835
DI 10.1172/jci.insight.138835
PG 16
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA TP4JD
UT WOS:000677560000002
PM 34138755
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Chen, F
   Wang, CC
   Kim, E
   Harrison, LE
AF Chen, Fei
   Wang, Chia-Chi
   Kim, Eugene
   Harrison, Lawrence E.
TI Hyperthermia in combination with oxidative stress induces autophagic
   cell death in HT-29 colon cancer cells
SO CELL BIOLOGY INTERNATIONAL
LA English
DT Article
DE Autophagy; Oxidative stress; Colon cancer
ID MALIGNANT GLIOMA-CELLS; INTRAPERITONEAL CHEMOTHERAPY; APOPTOSIS;
   SURVIVAL; INDUCTION; CARCINOMA; EFFICACY; SURGERY; ARREST; ROS
AB The purpose of this study was to evaluate the mechanism of ROS-induced hyperthermic cell death in a colon cancer cell line. HT-29 colon cancer cells were exposed to heat (43 degrees C) in the presence of tert-butyl hydroperoxide (t-BOOH). t-BOOH combined with hyperthermia significantly decreased cell viability as compared with t-BOOH or hyperthermia alone. This decrease in cell numbers was associated with retardation in the S phase transit and not through apoptosis. Cell death was noted to be accompanied by specific features characteristic of autophagy: the presence of cytoplasmic autophagic vacuoles; autophagosome membrane association of microtubule-associated protein light chain 3; accumulation of acidic vesicular organelles; and increased incorporation of MDC in the autophagosome. Thermal sensitization through modulation of cellular ROS may represent a novel approach to increase the efficacy of hyperthermia as an anticancer modality. (C) 2008 International Federation for Cell Biology. Published by Elsevier Ltd. All rights reserved.
C1 [Chen, Fei; Wang, Chia-Chi; Kim, Eugene; Harrison, Lawrence E.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, Div Surg Oncol, Newark, NJ 07103 USA.
RP Harrison, LE (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, Div Surg Oncol, 185 S Orange Ave,MSB G524, Newark, NJ 07103 USA.
EM L.Harrison@UMDNJ.edu
CR Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094
   Butler R, 2000, CELL GROWTH DIFFER, V11, P49
   Chen Y, 2005, BIOCHEM BIOPH RES CO, V337, P52, DOI 10.1016/j.bbrc.2005.09.018
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0
   Ellington AA, 2005, CARCINOGENESIS, V26, P159, DOI 10.1093/carcin/bgh297
   Furuya N, 2005, AUTOPHAGY, V1, P46, DOI 10.4161/auto.1.1.1542
   Hempel SL, 1999, FREE RADICAL BIO MED, V27, P146, DOI 10.1016/S0891-5849(99)00061-1
   Hildebrandt B, 2002, CRIT REV ONCOL HEMAT, V43, P33, DOI 10.1016/S1040-8428(01)00179-2
   Jin ZY, 2005, CANCER BIOL THER, V4, P139, DOI 10.4161/cbt.4.2.1508
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Komata T, 2004, J NEURO-ONCOL, V68, P101, DOI 10.1023/B:NEON.0000027739.33842.6c
   Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738
   Lebedeva IV, 2005, ONCOGENE, V24, P585, DOI 10.1038/sj.onc.1208183
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Miller RA, 2001, CLIN CANCER RES, V7, P3215
   Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704
   Ng G, 2005, MOL CARCINOGEN, V43, P183, DOI 10.1002/mc.20097
   O'Reilly MA, 2005, ANTIOXID REDOX SIGN, V7, P108, DOI 10.1089/ars.2005.7.108
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Ohshiro K, 2008, AUTOPHAGY, V4, P104, DOI 10.4161/auto.5223
   Opipari AW, 2004, CANCER RES, V64, P696, DOI 10.1158/0008-5472.CAN-03-2404
   Reichman TW, 2005, J SURG ONCOL, V90, P51, DOI 10.1002/jso.20243
   Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213
   Rudin CM, 2003, CANCER RES, V63, P312
   Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777
   Vernon CC, 1996, INT J RADIAT ONCOL, V35, P731
   Verwaal VJ, 2003, J CLIN ONCOL, V21, P3737, DOI 10.1200/JCO.2003.04.187
   Wang CC, 2007, SURGERY, V142, P384, DOI 10.1016/j.surg.2007.03.013
   Yuki H, 2003, FREE RADICAL RES, V37, P631, DOI 10.1080/1071576031000088292
NR 30
TC 37
Z9 37
U1 0
U2 20
PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1065-6995
J9 CELL BIOL INT
JI Cell Biol. Int.
PD JUL
PY 2008
VL 32
IS 7
BP 715
EP 723
DI 10.1016/j.cellbi.2008.02.010
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 369CP
UT WOS:000260671400001
PM 18396422
DA 2022-04-25
ER

PT J
AU Fesler, A
   Guo, SX
   Liu, H
   Wu, N
   Ju, JF
AF Fesler, Andrew
   Guo, Shixiang
   Liu, Hua
   Wu, Ning
   Ju, Jingfang
TI Overcoming chemoresistance in cancer stem cells with the help of
   microRNAs in colorectal cancer
SO EPIGENOMICS
LA English
DT Article
DE apoptosis; autophagy; cancer stem cell; chemoresistance; chemotherapy;
   colorectal cancer; epigenetic; microenvironment; microRNA; stemness
ID COLON-CANCER; DIVISION; INHIBITION; EXPRESSION; AUTOPHAGY; DEATH
AB It has been recognized that acute resistance to chemotherapy mediated by post-transcriptional and translational control is crucial to influence response and survival in cancer treatment. Tumor cells are highly heterogeneous and have the ability to adapt a resistance phenotype through epigenetic regulations such as microRNAs. This poses a major challenge to the treatment of advanced stage colon cancer patients. Colon cancer stem cells have been identified as one of the major contributors to resistance of colon cancer to chemotherapy. Through various mechanisms, these cells are able to resist the effects of traditional chemotherapeutics. The challenge posed by these cells is further enhanced by their plastic nature, where cells can transition between non-stem cancer cells and cancer stem cells creating a moving target. In this editorial, we discuss some of the recent advancements in overcoming chemoresistance associated with colon cancer stem cells with the help of microRNAs.
C1 [Fesler, Andrew; Guo, Shixiang; Liu, Hua; Wu, Ning; Ju, Jingfang] SUNY Stony Brook, Sch Med, Dept Pathol, Stony Brook, NY 11794 USA.
RP Ju, JF (corresponding author), SUNY Stony Brook, Sch Med, Dept Pathol, Stony Brook, NY 11794 USA.
EM jingfang.ju@stonybrookmedicine.edu
FU National Institute of Health/National Cancer InstituteUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [R01CA15501904, R01CA19709801];
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R01CA155019, R01CA197098] Funding Source: NIH RePORTER
FX This study was supported by National Institute of Health/National Cancer
   Institute R01CA15501904 (J Ju), R01CA19709801 (J Ju). The authors have
   no other relevant affiliations or financial involvement with any
   organization or entity with a financial interest in or financial
   conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR American Cancer Society, 2013, CANC FACTS FIG 2015
   Bu PC, 2016, CELL STEM CELL, V18, P189, DOI 10.1016/j.stem.2016.01.006
   Bu PC, 2013, CELL STEM CELL, V12, P602, DOI 10.1016/j.stem.2013.03.002
   Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036
   Fang YT, 2012, ONCOL REP, V28, P2115, DOI 10.3892/or.2012.2054
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235
   Fesler Andrew, 2016, F1000Res, V5, P756, DOI 10.12688/f1000research.8363.1
   Fesler A, 2014, ONCOTARGETS THER, V7, P7, DOI 10.2147/OTT.S65548
   Hongo K, 2012, J SURG RES, V175, P278, DOI 10.1016/j.jss.2011.03.076
   Hwang WL, 2014, NAT CELL BIOL, V16, P268, DOI 10.1038/ncb2910
   Iliou MS, 2014, ONCOGENE, V33, P4003, DOI 10.1038/onc.2013.398
   Jin YH, 2016, DNA CELL BIOL, V35, P249, DOI 10.1089/dna.2015.3120
   Jones MF, P NATL ACAD SCI US, V112
   Karaayvaz M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.193
   Kobayashi S, 2012, STEM CELLS, V30, P2631, DOI 10.1002/stem.1257
   Le Rolle AF, 2016, ONCOTARGET, V7, P2159, DOI 10.18632/oncotarget.6818
   Lee MR, 2015, BIOCHEM BIOPH RES CO, V463, P229, DOI 10.1016/j.bbrc.2015.05.031
   Lotti F, 2013, J EXP MED, V210, P2851, DOI 10.1084/jem.20131195
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Sakaguchi M, 2016, MOL CANCER RES, V14, P354, DOI 10.1158/1541-7786.MCR-15-0380
   Song B, 2008, CLIN CANCER RES, V14, P8080, DOI 10.1158/1078-0432.CCR-08-1422
   Taniguchi H, 2016, CANCER SCI, V107, P1556, DOI 10.1111/cas.13069
   Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001
   Touil Y, 2014, CLIN CANCER RES, V20, P837, DOI 10.1158/1078-0432.CCR-13-1854
   Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048
   Wang L, 2016, ELIFE
   Wu SB, 2013, BIOCHEM BIOPH RES CO, V434, P898, DOI 10.1016/j.bbrc.2013.04.053
   Xi YG, 2006, CLIN CANCER RES, V12, P2014, DOI 10.1158/1078-0432.CCR-05-1853
   Yu YJ, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0372-7
   Zhai H, 2013, ONCOGENE, V32, P1570, DOI 10.1038/onc.2012.167
   Zhai HY, 2015, ONCOTARGET, V6, P19735, DOI 10.18632/oncotarget.3771
NR 33
TC 17
Z9 20
U1 2
U2 4
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1750-1911
EI 1750-192X
J9 EPIGENOMICS-UK
JI Epigenomics
PD JUN
PY 2017
VL 9
IS 6
BP 793
EP 796
DI 10.2217/epi-2017-0041
PG 4
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA EX4WZ
UT WOS:000403237600002
PM 28517961
DA 2022-04-25
ER

PT J
AU Dai, XL
   Liu, J
   Nian, Y
   Qiu, MH
   Luo, Y
   Zhang, JH
AF Dai, Xiaoli
   Liu, Jing
   Nian, Yin
   Qiu, Ming-Hua
   Luo, Ying
   Zhang, Jihong
TI A novel cycloartane triterpenoid from Cimicifuga induces apoptotic and
   autophagic cell death in human colon cancer HT-29 cells
SO ONCOLOGY REPORTS
LA English
DT Article
DE Cimicifuga; apoptosis; autophagy; colon cancer cells
ID COLORECTAL-CANCER; RECEPTOR; PATHWAY
AB The extract from Cimicifuga, a genus of flowering plants, has been demonstrated to have mainly therapeutic effects on menstrual and menopausal symptoms and also exhibits immunomodulatory, anti-inflammatory and antimicrobial activity. Moreover, the anticancer effects of Cimicifuga have been reported, but the underlying mechanism causing cancer cell death has been poorly described. The present study was designed to investigate the antitumor effects and underlying molecular mechanisms of cimigenol (KY17), a novel cycloartane triterpenoid from Cimicifuga. KY17-induced autophagy and apoptotic cell death in human colon cancer cells (HT-29) was investigated. KY17 treatment induced growth inhibition and apoptotic cell death in a concentration-dependent manner. The induction of apoptosis was confirmed by a change in cell morphology, and an increase in the G2/M phase, as well as increased protein levels of cleaved-caspase-8 and -3; cleavage of poly(ADP-ribose) polymerase (PARP) in the HT-29 cells following KY17 treatment. In addition, autophagy was evaluated by the accumulation of acridine orange, the appearance of green fluorescent protein-light-chain 3 (LC3) punctate structures and increased levels of LC3-II protein expression. Furthermore, combination treatment with the autophagy inhibitor bafilomycin A1 enhanced the induction of apoptosis by KY17. Taken together, the present study provides new insight into the role of KY17 as a potential antitumor compound. Combination of KY17 with an autophagy inhibitor may be a valuable strategy for the chemoprevention or treatment of colon cancer.
C1 [Dai, Xiaoli; Liu, Jing; Luo, Ying; Zhang, Jihong] Kunming Univ Sci & Technol, Fac Med, Lab Mol Genet Aging & Tumor, 727 Jing Ming Nan Rd, Kunming 650500, Yunnan, Peoples R China.
   [Nian, Yin; Qiu, Ming-Hua] Chinese Acad Sci, Kunming Inst Bot, State Key Lab Phytochem & Plant Resources West Ch, Kunming 650201, Yunnan, Peoples R China.
RP Zhang, JH (corresponding author), Kunming Univ Sci & Technol, Fac Med, Lab Mol Genet Aging & Tumor, 727 Jing Ming Nan Rd, Kunming 650500, Yunnan, Peoples R China.
EM zhjihong2000@126.com
RI Luo, Ying/AAQ-7666-2020
FU Natural Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [81260501, 81560601, 81302670, U1202221]; Nature Science
   Foundation of Yunnan ProvinceNatural Science Foundation of Yunnan
   Province [KKSY201460043]
FX The present study was financially supported by the Natural Science
   Foundation of China (nos. 81260501, 81560601, 81302670 and U1202221) and
   the Nature Science Foundation of Yunnan Province (no. KKSY201460043).
CR Center MM, 2009, CANCER EPIDEM BIOMAR, V18, P1688, DOI 10.1158/1055-9965.EPI-09-0090
   Degterev A, 2008, NAT REV MOL CELL BIO, V9, P378, DOI 10.1038/nrm2393
   El-Khoury V, 2014, LEUKEMIA, V28, P1636, DOI 10.1038/leu.2014.19
   Fang ZZ, 2011, PHYTOTHER RES, V25, P17, DOI 10.1002/ptr.3222
   Gupta S, 2003, INT J ONCOL, V22, P15
   Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710
   Hetz CA, 2005, BIOCHEM CELL BIOL, V83, P579, DOI 10.1139/o05-065
   Hyodo I, 2010, JPN J CLIN ONCOL, V40, pi38, DOI 10.1093/jjco/hyq125
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Konopleva M, 1999, ADV EXP MED BIOL, V457, P217
   Kumar S, 2007, CELL DEATH DIFFER, V14, P32, DOI 10.1038/sj.cdd.4402060
   Laubert T, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-24
   Levin B, 2008, CA-CANCER J CLIN, V58, P130, DOI 10.3322/CA.2007.0018
   Li Guo-Hui, 2013, Zhong Yao Cai, V36, P1640
   Li XQ, 2010, CANCER RES, V70, P5942, DOI 10.1158/0008-5472.CAN-10-0157
   Lu L, 2012, CHEM PHARM BULL, V60, P571, DOI 10.1248/cpb.60.571
   Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009
   Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X
   Radogna F, 2015, BIOCHEM PHARMACOL, V94, P1, DOI 10.1016/j.bcp.2014.12.018
   Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x
   Sun Li-Rong, 2005, Acta Botanica Yunnanica, V27, P331
   Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312
   Tian Z, 2007, CHEMOTHERAPY, V53, P257, DOI 10.1159/000102582
   Wan XM, 2011, INT J CANCER, V129, P1087, DOI 10.1002/ijc.25771
   Wang XD, 2001, GENE DEV, V15, P2922
   Waring P, 1999, IMMUNOL CELL BIOL, V77, P312, DOI 10.1046/j.1440-1711.1999.00837.x
   White E, 2010, CURR OPIN CELL BIOL, V22, P212, DOI 10.1016/j.ceb.2009.12.008
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Xiong F, 2010, CANCER EPIDEM BIOMAR, V19, P1855, DOI 10.1158/1055-9965.EPI-10-0210
NR 29
TC 8
Z9 11
U1 0
U2 10
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD APR
PY 2017
VL 37
IS 4
BP 2079
EP 2086
DI 10.3892/or.2017.5444
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EQ5QY
UT WOS:000398138900019
PM 28260002
OA Bronze
DA 2022-04-25
ER

PT J
AU Algehani, RA
   Abou Khouzam, R
   Hegazy, GA
   Alamoudi, AA
   El-Halawany, AM
   El Dine, RS
   Ajabnoor, GA
   Al-Abbasi, FA
   Baghdadi, MA
   Elsayed, I
   Hattori, M
   Al-Abd, AM
AF Algehani, Rinad A.
   Abou Khouzam, Raefa
   Hegazy, Gehan A.
   Alamoudi, Aliaa A.
   El-Halawany, Ali M.
   El Dine, Riham S.
   Ajabnoor, Ghada A.
   Al-Abbasi, Fahad A.
   Baghdadi, Mohammed A.
   Elsayed, Ibrahim
   Hattori, Masao
   Al-Abd, Ahmed M.
TI Colossolactone-G synergizes the anticancer properties of 5-fluorouracil
   and gemcitabine against colorectal cancer cells
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Colossolactone-G; Gemcitabine; 5-fluorouracil; Colorectal cancer;
   Apoptosis; Autophagy
ID COLON-CANCER; IN-VITRO; APOPTOSIS; AUTOPHAGY; RESISTANCE; CYTOTOXICITY;
   LEUCOVORIN; IRINOTECAN; BAX; DETERMINANTS
AB Several terpenoids were isolated from Ganoderma colossum with potential chemotherapeutic properties against different solid tumor cells. Herein, we further assessed the potential chemomodulatory effects of colossolactoneG to gemcitabine (GCB) and 5-fluorouracil (5-FU) against colorectal cancer cells. Colossolactone-G induced moderate cell killing effects against both HT-29 and HCT-116 cells, with IC50's of 90.5 +/- 1.7 mu M and 22.3 +/- 3.9 mu M, respectively. Equitoxic combination demonstrated a synergistic effect between colossolactone-G and GCB, or 5-FU with combination indices ranging from 0.22 to 0.67. Both GCB and 5-FU induced moderate cell cycle arrest at G0/G1-phase and S-phase. Despite colossolactone-G's lack of influence on cell cycle distribution, it significantly potentiated GCB- and 5-FU-induced cell cycle arrest. Similarly, colossolactone-G treatment alone did not induce pronounced apoptosis in both cell lines. However, 5-FU and GCB induced significant apoptosis which was further potentiated via combination with colossolactone-G. Furthermore, colossolactone-G significantly increased autophagic cell death response in both HCT-116 and HT-29 cells and potentiated 5-FU- and GCBinduced autophagic cell death. The influence of colossolactone-G alone or in combination with GCB or 5-FU on the apoptosis and autophagy were confirmed by qPCR analysis for the expression of several key apoptosis and autophagy genes such as, TRAIL, TP53INP1, BNIP3, hp62, ATG5, ATG7, Lamp2A and the golden standard for autophagy (LC3-II). In conclusion, a synergistic effect in terms of anticancer properties was observed when colossolactone-G was combined with 5-FU and GCB, where it influenced both apoptosis and autophagic cell death mechanisms.
C1 [Algehani, Rinad A.] King Abdulaziz Univ, King Fahd Med Res Ctr, Jeddah, Saudi Arabia.
   [Algehani, Rinad A.; Hegazy, Gehan A.; Alamoudi, Aliaa A.; Ajabnoor, Ghada A.] King Abdulaziz Univ, Fac Med, Clin Biochem Dept, Jeddah, Saudi Arabia.
   [Abou Khouzam, Raefa; Al-Abd, Ahmed M.] Gulf Med Univ, Thumbay Res Inst Precis Med, Ajman, U Arab Emirates.
   [Hegazy, Gehan A.; Al-Abd, Ahmed M.] Natl Res Ctr, Med Div, Giza, Egypt.
   [Hegazy, Gehan A.; Alamoudi, Aliaa A.] King Abdulaziz Univ, King Fahad Med Res Ctr, Regenerat Med Unit, Jeddah, Saudi Arabia.
   [El-Halawany, Ali M.; El Dine, Riham S.] Cairo Univ, Fac Pharm, Dept Pharmacognosy, Cairo, Egypt.
   [El-Halawany, Ali M.] Nawah Sci, Cairo, Egypt.
   [Al-Abbasi, Fahad A.] King Abdulaziz Univ, Fac Sci, Dept Biochem, Jeddah, Saudi Arabia.
   [Baghdadi, Mohammed A.] King Faisal Specialist Hosp & Res Ctr, Res Ctr, Jeddah, Saudi Arabia.
   [Elsayed, Ibrahim] Cairo Univ, Fac Pharm, Dept Pharmaceut & Ind Pharm, Cairo, Egypt.
   [Elsayed, Ibrahim; Al-Abd, Ahmed M.] Gulf Med Univ, Coll Pharm, Dept Pharmaceut Sci, PO 4184, Al Jurf, Ajman, U Arab Emirates.
   [Hattori, Masao] Univ Toyama, Inst Nat Med, Toyama, Japan.
RP Al-Abd, AM (corresponding author), Gulf Med Univ, Coll Pharm, Dept Pharmaceut Sci, PO 4184, Al Jurf, Ajman, U Arab Emirates.
EM ahmedmalabd@pharma.asu.edu.eg
RI El-Halawany, Ali M./ABE-2550-2021
OI Al-Abbasi, Fahad/0000-0001-5609-4913; alamoudi,
   aliaa/0000-0001-5428-8853; Baghdadi, Mohammed A./0000-0003-1469-3074
FU King Abdulaziz City for Science and Technology (KACST), Saudi Arabia
   [1-17-03009-0004]
FX This research was financially supported by King Abdulaziz City for
   Science and Technology (KACST), Saudi Arabia, grant number
   (1-17-03009-0004).
CR Abdel-Lateff A, 2016, Z NATURFORSCH C, V71, P29, DOI 10.1515/znc-2015-0160
   Agrawal D, 2012, J DRUG DELIV THER, V2
   Ahmad Aftab, 2013, Asian Pacific Journal of Tropical Biomedicine, V3, P337, DOI 10.1016/S2221-1691(13)60075-1
   Al-Abbasi FA, 2016, MOLECULES, V21, DOI 10.3390/molecules21070886
   Almutairi MS, 2012, ACTA CRYSTALLOGR E, V68, pO656, DOI 10.1107/S1600536812005065
   Anitha A, 2014, BBA-GEN SUBJECTS, V1840, P2730, DOI 10.1016/j.bbagen.2014.06.004
   Arnold CN, 2003, INT J CANCER, V106, P66, DOI 10.1002/ijc.11176
   Bashmail HA, 2020, MOLECULES, V25, DOI 10.3390/molecules25020426
   Bashmail HA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30046-z
   Bergman AM, 2002, DRUG RESIST UPDATE, V5, P19, DOI 10.1016/S1368-7646(02)00002-X
   Bold RJ, 1999, ANN SURG ONCOL, V6, P279, DOI 10.1007/s10434-999-0279-x
   Bravo-San Pedro JM, 2015, AUTOPHAGY, V11, P452, DOI 10.1080/15548627.2015.1017191
   Candioti LV, 2014, TALANTA, V124, P123, DOI 10.1016/j.talanta.2014.01.034
   Chen L, 2013, WORLD J GASTROENTERO, V19, P6814, DOI 10.3748/wjg.v19.i40.6814
   Chen SY, 2016, FITOTERAPIA, V114, P81, DOI 10.1016/j.fitote.2016.08.015
   CHOU TC, 1981, EUR J BIOCHEM, V115, P207, DOI 10.1111/j.1432-1033.1981.tb06218.x
   Chung Seyung S, 2018, Oncotarget, V9, P32943, DOI 10.18632/oncotarget.25993
   Coker-Gurkan A, 2014, EXP CELL RES, V328, P87, DOI 10.1016/j.yexcr.2014.07.022
   DIASIO RB, 1989, CLIN PHARMACOKINET, V16, P215, DOI 10.2165/00003088-198916040-00002
   Dmoszynska A, 2006, EUR J CLIN PHARMACOL, V62, P325, DOI 10.1007/s00228-006-0106-2
   Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1
   Druzhkova I, 2019, CLIN COLORECTAL CANC, V18, pE74, DOI 10.1016/j.clcc.2018.10.003
   Ehrhardt H, 2013, BRIT J PHARMACOL, V168, P1558, DOI 10.1111/bph.12068
   El Dine RS, 2008, CHEM PHARM BULL, V56, P642, DOI 10.1248/cpb.56.642
   Focaccetti C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115686
   Giacchetti S, 1999, ANN ONCOL, V10, P663, DOI 10.1023/A:1008347829017
   Gill BS, 2016, TUMOR BIOL, V37, P2789, DOI 10.1007/s13277-015-4709-z
   Gustavsson B, 2015, CLIN COLORECTAL CANC, V14, P1, DOI 10.1016/j.clcc.2014.11.002
   Hippert MM, 2006, CANCER RES, V66, P9349, DOI 10.1158/0008-5472.CAN-06-1597
   Huang Z, 2016, INT J CANCER, V139, P23, DOI 10.1002/ijc.29990
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P384, DOI 10.1038/nrclinonc.2011.82
   Khaleel SA, 2016, SCI REP-UK, V6, DOI 10.1038/srep36855
   Kleinwachter P, 2001, J NAT PROD, V64, P236, DOI 10.1021/np000437k
   Lei XF, 2012, BIOCHEM BIOPH RES CO, V417, P864, DOI 10.1016/j.bbrc.2011.12.063
   Li SY, 2017, ONCOL REP, V38, P1637, DOI 10.3892/or.2017.5849
   Limpert AS, 2018, TRENDS PHARMACOL SCI, V39, P1021, DOI 10.1016/j.tips.2018.10.004
   Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Miao X, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00421
   MIYASHITA T, 1994, ONCOGENE, V9, P1799
   Mohamed GA, 2017, J ETHNOPHARMACOL, V198, P302, DOI 10.1016/j.jep.2017.01.030
   Mokhtari RB, 2017, ONCOTARGET, V8, P38022, DOI 10.18632/oncotarget.16723
   Ofodile LN, 2005, PHYTOTHER RES, V19, P310, DOI 10.1002/ptr.1641
   Oguri T, 2006, MOL CANCER THER, V5, P1800, DOI 10.1158/1535-7163.MCT-06-0025
   Pandita A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107154
   Petak I, 2000, CLIN CANCER RES, V6, P4432
   Qian HR, 2017, ONCOTARGET, V8, P62759, DOI 10.18632/oncotarget.18663
   Sasaki K, 2012, ANTI-CANCER DRUG, V23, P675, DOI 10.1097/CAD.0b013e328353f8c7
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   Smith AG, 2019, J PATHOL, V247, P708, DOI 10.1002/path.5222
   Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984
   Tang JC, 2016, CHINESE MED J-PEKING, V129, P456, DOI 10.4103/0366-6999.176069
   Turner JL, 2017, CLIN COLORECTAL CANC, V16, pE119, DOI 10.1016/j.clcc.2016.09.004
   van Triest B, 1999, CLIN CANCER RES, V5, P643
   Wang E, 2014, BIOL BLOOD MARROW TR, V20, P1382, DOI 10.1016/j.bbmt.2014.04.025
   Wang S, 2016, J BREAST CANCER, V19, P231, DOI 10.4048/jbc.2016.19.3.231
   Won SJ, 2015, J CELL PHYSIOL, V230, P930, DOI 10.1002/jcp.24825
   Wu WKK, 2012, ONCOGENE, V31, P939, DOI 10.1038/onc.2011.295
   Yoshino T, 2007, JPN J CLIN ONCOL, V37, P686, DOI 10.1093/jjco/hym091
   Yousefi S, 2009, RESULTS PROBL CELL D, V49, P183, DOI 10.1007/400_2008_25
NR 62
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD AUG
PY 2021
VL 140
AR 111730
DI 10.1016/j.biopha.2021.111730
EA MAY 2021
PG 16
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA TE5YU
UT WOS:000670089200004
PM 34062410
OA gold
DA 2022-04-25
ER

PT J
AU Tan, SF
   Shi, HJ
   Ba, MC
   Lin, SQ
   Tang, HS
   Zeng, XQ
   Zhang, XL
AF Tan, Shifan
   Shi, Huijuan
   Ba, Mingchen
   Lin, Shengqv
   Tang, Hongsheng
   Zeng, Xiaoqi
   Zhang, Xiangliang
TI miR-409-3p sensitizes colon cancer cells to oxaliplatin by inhibiting
   Beclin-1-mediated autophagy
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE autophagy; chemoresistance; colon cancer; microRNA
ID HEPATOCELLULAR-CARCINOMA CELLS; MALIGNANT GLIOMA-CELLS;
   COLORECTAL-CANCER; INDUCED APOPTOSIS; METASTASIS; CHEMOTHERAPY;
   RADIATION; CHEMORESISTANCE; CONTRIBUTES; BIOGENESIS
AB The chemoresistance of colon cancer cells limits the efficacy of chemotherapy. miR-409-3p has been shown to be downregulated in various types of cancer. In the present study, we examined the role of miR-409-3p in colon cancer as well as the effects of miR-409-3p on the sensitivity of colon cancer cells to oxaliplatin. The expression of miR-409 was significantly downregulated in the human colon cancer cell lines compared with the normal colon epithelial cells. Importantly, the miR-409-3p expression levels were lower in human colon cancer patient samples than in normal colon tissues. Moreover, we observed a negative correlation between the miR-409-3p levels and resistance to oxaliplatin: the oxaliplatin-resistant colon cancer cells exhibited significantly downregulated miR-409-3p levels, but higher autophagic activity than the oxaliplatin- sensitive cells. Using bioinformatics analysis, we predicted that miR-409-3p miRNA binds to the key autophagy gene encoding Beclin-1. Our findings indicated that the overexpression of miR-409-3p inhibited Beclin-1 expression and autophagic activity by binding to the 3'-untranslated region of Beclin-1 mRNA. In addition, the overexpression of miR-409-3p enhanced the chemosensitivity of the oxaliplatin-sensitive and oxaliplatin-resistant colon cancer cells. The restoration of Beclin-1 abrogated these effects of miR-409-3p. In a xenograft model using nude mice, we examined the effects of miR-409-3p on tumor growth during chemotherapy. miR-409-3p overexpression sensitized the tumor to chemotherapy, while inhibiting chemotherapy-induced autophagy in a manner dependent on Beclin-1. The findings of our study suggest that miR-409-3p is capable of enhancing the chemosensitivity of colon cancer cells by inhibiting Beclin-1-mediated autophagy.
C1 [Tan, Shifan; Ba, Mingchen; Lin, Shengqv; Tang, Hongsheng; Zeng, Xiaoqi; Zhang, Xiangliang] Guangzhou Med Univ, Affiliated Canc Hosp, Sect 2, Dept Abdominal Surg, 78 Hengzhigang Rd, Guangzhou 510095, Guangdong, Peoples R China.
   [Shi, Huijuan] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou 510080, Guangdong, Peoples R China.
RP Zhang, XL (corresponding author), Guangzhou Med Univ, Affiliated Canc Hosp, Sect 2, Dept Abdominal Surg, 78 Hengzhigang Rd, Guangzhou 510095, Guangdong, Peoples R China.
EM zhxl7229@163.com
FU Guangdong Province Natural Science FundNational Natural Science
   Foundation of Guangdong Province [S2013010016662]; Health Bureau of
   Guangdong Province [A2014224, B2014196]; Science and Technology Planning
   Project of Guangdong Province [2013B021800284]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [81201932, 81372493]
FX The present study was supported by funding from the Guangdong Province
   Natural Science Fund (no. S2013010016662), the Health Bureau of
   Guangdong Province (nos. A2014224 and B2014196), the Science and
   Technology Planning Project of Guangdong Province (no. 2013B021800284)
   and the National Natural Science Foundation of China (nos. 81201932 and
   81372493).
CR Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bonetti A, 2014, ANTICANCER RES, V34, P423
   Chatterjee A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095716
   Chen JM, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0799-x
   Chen MC, 2014, CANCER LETT, V349, P51, DOI 10.1016/j.canlet.2014.03.023
   Chen YS, 2013, PATHOL RES PRACT, V209, P562, DOI 10.1016/j.prp.2013.06.006
   Coker-Gurkan A, 2014, EXP CELL RES, V328, P87, DOI 10.1016/j.yexcr.2014.07.022
   Fujiwara K, 2007, INT J ONCOL, V31, P753
   Gordeev S. S., 2014, Voprosy Onkologii (St. Petersburg), V60, P18
   He WS, 2012, ONCOL RES, V20, P251, DOI 10.3727/096504013X13589503483012
   Helgason GV, 2013, ESSAYS BIOCHEM, V55, P133, DOI [10.1042/bse0550133, 10.1042/BSE0550133]
   Herraez E, 2012, MOL PHARMACEUT, V9, P2565, DOI 10.1021/mp300178a
   Josson S, 2015, ONCOGENE, V34, P2690, DOI 10.1038/onc.2014.212
   Kang R, 2012, AM J OTOLARYNG, V33, P678, DOI 10.1016/j.amjoto.2012.05.005
   Kim EJ, 2013, J CELL BIOCHEM, V114, P1248, DOI 10.1002/jcb.24465
   Liu ML, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0533-x
   Lomonaco SL, 2009, INT J CANCER, V125, P717, DOI 10.1002/ijc.24402
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mendell JT, 2012, CELL, V148, P1172, DOI 10.1016/j.cell.2012.02.005
   Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421
   Oh JS, 2010, INT J RADIAT ONCOL, V76, P5, DOI 10.1016/j.ijrobp.2009.08.028
   Peng X, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.297
   Song JR, 2011, J CELL BIOCHEM, V112, P3406, DOI 10.1002/jcb.23274
   Song JR, 2009, AUTOPHAGY, V5, P1131, DOI 10.4161/auto.5.8.9996
   Tai Jun, 2013, Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V48, P499
   Lopez PJT, 2014, CLIN MED INSIGHTS-GA, V7, P33, DOI 10.4137/CGast.S14039
   Touil Y, 2014, CLIN CANCER RES, V20, P837, DOI 10.1158/1078-0432.CCR-13-1854
   Walker AS, 2014, J CANCER, V5, P44, DOI 10.7150/jca.7809
   Wang P, 2014, ONCOGENE, V33, P514, DOI 10.1038/onc.2012.598
   Wang P, 2013, MOL ONCOL, V7, P334, DOI 10.1016/j.molonc.2012.10.011
   Weng CH, 2012, CANCER LETT, V323, P171, DOI 10.1016/j.canlet.2012.04.010
   Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228
   Xu X, 2013, MOL CELLS, V36, P62, DOI 10.1007/s10059-013-0044-7
   Zhai H, 2013, ONCOGENE, V32, P1570, DOI 10.1038/onc.2012.167
   Zhang XL, 2012, WORLD J GASTROENTERO, V18, P646, DOI 10.3748/wjg.v18.i7.646
   Zheng B, 2012, ONCOGENE, V31, P4509, DOI 10.1038/onc.2011.581
   Zhou Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep05382
   Zhuang WZ, 2009, ACTA BIOCH BIOPH SIN, V41, P341, DOI 10.1093/abbs/gmp028
   Zou ZY, 2012, J BIOL CHEM, V287, P4148, DOI 10.1074/jbc.M111.307405
NR 39
TC 67
Z9 70
U1 0
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD APR
PY 2016
VL 37
IS 4
BP 1030
EP 1038
DI 10.3892/ijmm.2016.2492
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA DI4TS
UT WOS:000373492900018
PM 26935807
OA Bronze
DA 2022-04-25
ER

PT J
AU Xiong, L
   Liu, ZP
   Ouyang, GQ
   Lin, LW
   Huang, H
   Kang, HX
   Chen, W
   Miao, XY
   Wen, Y
AF Xiong, Li
   Liu, Zhipeng
   Ouyang, Guoqing
   Lin, Liangwu
   Huang, He
   Kang, Hongxiang
   Chen, Wei
   Miao, Xiongying
   Wen, Yu
TI Autophagy inhibition enhances photocytotoxicity of Photosan-II in human
   colorectal cancer cells
SO ONCOTARGET
LA English
DT Article
DE apoptosis; autophagy; photodynamic therapy; colorectal cancer;
   Photosan-II
ID THERAPY-INDUCED APOPTOSIS; DOUBLE-EDGED-SWORD; PHOTODYNAMIC THERAPY;
   IN-VIVO; RESISTANCE; RADIOTHERAPY; MODULATION; INITIATION; SURVIVAL;
   DEATH
AB Photodynamic therapy (PDT) has emerged as an attractive therapeutic treatment for colorectal cancer because of its accessibility through endoscopy and its ability to selectively target tumors without destroying the anatomical integrity of the colon. We therefore investigated the therapeutic relevance of the interplay between autophagy and apoptosis in Photosan-II (PS-II)-mediated photodynamic therapy (PS-PDT) in in vitro and in vivo models for human colorectal cancer. We observed that PS-PDT-induced dose-dependently triggered apoptosis and autophagy in both SW620 and HCT116 cells. PS-PDT-treated SW620 cells exhibited nuclear condensation and increased levels of cleaved caspase-3, PARP and Bax, which is reminiscent of apoptosis. PS-PDT also induced autophagic vacuoles, double membrane autophagosome structures and the autophagy-related proteins P62, Bcl-2, ATG7 and LC3-II. In addition, the AKT-mTOR pathway was downregulated, while AMPK was upregulated in PS-PDT-treated cells. Inhibiting autophagy using chloroquine or by downregulating ATG7 using shRNA further upregulated apoptosis, suggesting autophagy was probably was protective to PS-PDT-treated tumor cells. In vivo relevance was demonstrated when a combination of chloroquine and PS-PDT significantly reduced the tumor size in a xenograft mice model. Our findings demonstrate that combination therapy using PS-PDT and autophagy inhibitors may be an effective approach to treating colorectal cancer patients.
C1 [Xiong, Li; Liu, Zhipeng; Ouyang, Guoqing; Miao, Xiongying; Wen, Yu] Cent South Univ, Xiangya Hosp 2, Dept Gen Surg, Changsha, Hunan, Peoples R China.
   [Lin, Liangwu] Cent South Univ, China State Key Lab Powder Met, Changsha, Hunan, Peoples R China.
   [Huang, He] Cent South Univ, Xiangya Sch Med, Dept Histol & Embryol, Changsha, Hunan, Peoples R China.
   [Kang, Hongxiang] Acad Mil Med Sci, Inst Radiat Med, Beijing, Peoples R China.
   [Chen, Wei] Univ Texas Arlington, Dept Phys, POB 19059, Arlington, TX 76019 USA.
RP Wen, Y (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Gen Surg, Changsha, Hunan, Peoples R China.
EM 1850129046@qq.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81472738, 81372628, 81402536, 31571241,
   31660266]; Planned Science and Technology Project of Hunan province
   [2015GK3117, 2014WK2016]; Changsha Science and Technology Plan
   [K1205018-31]; Innovation Project of Ministry of Science and Technology
   [X8C1Y0K9]
FX This work was supported by the National Natural Science Foundation of
   China (Grant Nos. 81472738, 81372628, 81402536, 31571241, 31660266), the
   Planned Science and Technology Project of Hunan province (Grant No.
   2015GK3117, 2014WK2016), the Changsha Science and Technology Plan
   (K1205018-31), and the Innovation Project of Ministry of Science and
   Technology (Grant No. X8C1Y0K9).
CR Agostinis P, 2011, CA-CANCER J CLIN, V61, P250, DOI 10.3322/caac.20114
   Ahn MY, 2013, J ORAL PATHOL MED, V42, P17, DOI 10.1111/j.1600-0714.2012.01187.x
   Andrzejak M, 2011, AUTOPHAGY, V7, P979, DOI 10.4161/auto.7.9.15865
   Bonora M, 2015, ONCOGENE, V34, P1475, DOI 10.1038/onc.2014.96
   Castano AP, 2004, PHOTODIAGN PHOTODYN, V1, P279, DOI 10.1016/S1572-1000(05)00007-4
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Dewaele M, 2011, J CELL MOL MED, V15, P1402, DOI 10.1111/j.1582-4934.2010.01118.x
   Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071
   Du LH, 2014, J PHOTOCH PHOTOBIO B, V133, P1, DOI 10.1016/j.jphotobiol.2014.02.010
   Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kessel D, 2007, PHOTOCH PHOTOBIO SCI, V6, P1290, DOI 10.1039/b707953b
   Kessel D, 2006, LASER SURG MED, V38, P482, DOI 10.1002/lsm.20334
   Kessel D, 2009, METHOD ENZYMOL, V453, P1, DOI 10.1016/S0076-6879(08)04001-9
   Kimura T, 2013, CANCER RES, V73, P3, DOI 10.1158/0008-5472.CAN-12-2464
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Krishnan S, 2006, AM J CLIN ONCOL-CANC, V29, P562, DOI 10.1097/01.coc.0000236210.41199.91
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Lam M, 2001, J BIOL CHEM, V276, P47379, DOI 10.1074/jbc.M107678200
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Liu ZT, 2014, NANOSCALE RES LETT, V9, DOI 10.1186/1556-276X-9-319
   LOH CS, 1994, ENDOSCOPY, V26, P243, DOI 10.1055/s-2007-1008952
   Lu Y, 2008, J CELL BIOCHEM, V105, P1451, DOI 10.1002/jcb.21965
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Meijer AJ, 2007, AUTOPHAGY, V3, P238, DOI 10.4161/auto.3710
   Mornex F, 2006, INT J RADIAT ONCOL, V66, P1152, DOI 10.1016/j.ijrobp.2006.06.015
   Mroz Pawel, 2011, Cancers (Basel), V3, P2516, DOI 10.3390/cancers3022516
   Mulsow J, 2011, BRIT J SURG, V98, P1785, DOI 10.1002/bjs.7653
   Nakamura T, 2003, GASTROINTEST ENDOSC, V57, P266, DOI 10.1067/mge.2003.57
   Oleinick NL, 2002, PHOTOCH PHOTOBIO SCI, V1, P1, DOI 10.1039/b108586g
   Reiners JJ, 2010, AUTOPHAGY, V6, P7, DOI 10.4161/auto.6.1.10220
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Rusten TE, 2010, NAT CELL BIOL, V12, P207, DOI 10.1038/ncb0310-207
   Sadzuka Y, 2006, CANCER LETT, V241, P42, DOI 10.1016/j.canlet.2005.10.024
   Timmerman RD, 2009, CA-CANCER J CLIN, V59, P145, DOI 10.3322/caac.20013
   Vessoni AT, 2013, CELL DEATH DIFFER, V20, P1444, DOI 10.1038/cdd.2013.103
   Wang M, 2008, J BIOL CHEM, V283, P18678, DOI 10.1074/jbc.M801855200
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   WHITEHURST C, 1994, J UROLOGY, V151, P1411, DOI 10.1016/S0022-5347(17)35270-9
   Xue LY, 2010, AUTOPHAGY, V6, P248, DOI 10.4161/auto.6.2.11077
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yin L, 2009, INT J ONCOL, V34, P1691, DOI 10.3892/ijo_00000300
   Yoon HE, 2014, ONCOL REP, V31, P137, DOI 10.3892/or.2013.2856
NR 47
TC 21
Z9 23
U1 4
U2 19
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 24
PY 2017
VL 8
IS 4
BP 6419
EP 6432
DI 10.18632/oncotarget.14117
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EJ5WG
UT WOS:000393289000085
PM 28031534
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Estrada-Martinez, LE
   Moreno-Celis, U
   Cervantes-Jimenez, R
   Ferriz-Martinez, RA
   Blanco-Labra, A
   Garcia-Gasca, T
AF Elena Estrada-Martinez, Laura
   Moreno-Celis, Ulisses
   Cervantes-Jimenez, Ricardo
   Augusto Ferriz-Martinez, Roberto
   Blanco-Labra, Alejandro
   Garcia-Gasca, Teresa
TI Plant Lectins as Medical Tools against Digestive System Cancers
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE cancer; diagnosis tools; digestive system; plant lectins; therapeutic
   tools
ID KOREAN MISTLETOE LECTIN; ELECTROCHEMICAL IMPEDANCE SPECTROSCOPY;
   MEDIATED DRUG-DELIVERY; MANNOSE-BINDING LECTIN; A-INDUCED AUTOPHAGY;
   GASTRIC-CANCER; CONCANAVALIN-A; PANCREATIC-CANCER; ESOPHAGEAL
   ADENOCARCINOMA; IN-VITRO
AB Digestive system cancers-those of the esophagus, stomach, small intestine, colon-rectum, liver, and pancreas-are highly related to genetics and lifestyle. Most are considered highly mortal due to the frequency of late diagnosis, usually in advanced stages, caused by the absence of symptoms or masked by other pathologies. Different tools are being investigated in the search of a more precise diagnosis and treatment. Plant lectins have been studied because of their ability to recognize and bind to carbohydrates, exerting a variety of biological activities on animal cells, including anticancer activities. The present report integrates existing information on the activity of plant lectins on various types of digestive system cancers, and surveys the current state of research into their properties for diagnosis and selective treatment.
C1 [Elena Estrada-Martinez, Laura; Moreno-Celis, Ulisses; Cervantes-Jimenez, Ricardo; Augusto Ferriz-Martinez, Roberto; Garcia-Gasca, Teresa] Univ Autonoma Queretaro, Fac Ciencias Nat, Santiago De Queretaro 76230, Queretaro, Mexico.
   [Blanco-Labra, Alejandro] CINVESTAV Unidad Irapuato, Unidad Bioquim & Biotecnol Plantas, Guanajuato 36821, Mexico.
RP Garcia-Gasca, T (corresponding author), Univ Autonoma Queretaro, Fac Ciencias Nat, Santiago De Queretaro 76230, Queretaro, Mexico.
EM laurel_1610@hotmail.com; ulisses.morenoc@gmail.com;
   ricardocervantesjimenez@gmail.com; raffer712701@gmail.com;
   alejandroblancolabra@gmail.com; tggasca@uaq.edu.mx
RI Ferriz-Martínez, Roberto/Y-8923-2019; Blanco-Labra,
   Alejandro/K-9071-2019
OI Ferriz-Martínez, Roberto/0000-0002-2495-6985; GARCIA-GASCA,
   TERESA/0000-0002-8793-9963; Cervantes Jimenez,
   Ricardo/0000-0002-8951-4280; Moreno Celis, Ulisses/0000-0003-3751-6601
FU CONACYTConsejo Nacional de Ciencia y Tecnologia (CONACyT); CONACYT
   Ciencia Basica [CB-2014-01-241181]; PFCE; FOFI-UAQ
FX We thank CONACYT for the fellowship for Laura Elena Estrada-Martinez and
   the financial support of CONACYT Ciencia Basica (CB-2014-01-241181),
   PFCE-2016 and FOFI-UAQ 2015.
CR Abdullaev Fikrat I., 1997, Natural Toxins, V5, P157, DOI 10.1002/19970504NT6
   Aguiar J. P. N., 2015, INT MANUAL ONCOLOGY, P317
   [Anonymous], 1994, IARC Monogr Eval Carcinog Risks Hum, V61, P1
   Aparicio T, 2014, DIGEST LIVER DIS, V46, P97, DOI 10.1016/j.dld.2013.04.013
   Arab M. R., 2006, YAKTEH MED J, V7, P216
   Axon A, 2006, BEST PRACT RES CL GA, V20, P697, DOI 10.1016/j.bpg.2006.03.015
   Babal P, 2006, ACTA HISTOCHEM, V108, P133, DOI 10.1016/j.acthis.2006.03.003
   Bagaria A, 2006, J BIOL CHEM, V281, P34465, DOI 10.1074/jbc.M601777200
   Basu PS, 2003, CLIN BIOCHEM, V36, P373, DOI 10.1016/S0009-9120(03)00050-X
   Bhutia SK, 2016, INT J CANCER, V139, P457, DOI 10.1002/ijc.30055
   Bialecki Eldad S, 2005, HPB (Oxford), V7, P26, DOI 10.1080/13651820410024049
   Bies C, 2004, ADV DRUG DELIVER REV, V56, P425, DOI 10.1016/j.addr.2003.10.030
   Bird-Lieberman EL, 2012, NAT MED, V18, P315, DOI 10.1038/nm.2616
   Bosetti C, 2014, BEST PRACT RES CL GA, V28, P753, DOI 10.1016/j.bpg.2014.08.007
   Cagil F. Z., 2015, MED CHEM, V5, P124
   Calvo N, 2017, J MOL ENDOCRINOL, V59, P13, DOI 10.1530/JME-16-0216
   Cao JT, 2012, ANAL CHEM, V84, P6775, DOI 10.1021/ac3013048
   Chang CP, 2007, HEPATOLOGY, V45, P286, DOI 10.1002/hep.21509
   Chiba T, 2012, GASTROENTEROLOGY, V143, P550, DOI 10.1053/j.gastro.2012.07.009
   Cho KJ, 2008, CLIN CANCER RES, V14, P1310, DOI 10.1158/1078-0432.CCR-07-1441
   Christiansen MN, 2014, PROTEOMICS, V14, P525, DOI 10.1002/pmic.201300387
   Coleman HG, 2013, NUTR REV, V71, P474, DOI 10.1111/nure.12032
   Araujo LCC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081973
   CORREA P, 1992, CANCER RES, V52, P6735
   Coulibaly FS, 2017, AIMS MOL SCI, V4, P1, DOI 10.3934/molsci.2017.1.1
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Dan XL, 2016, MED RES REV, V36, P221, DOI 10.1002/med.21363
   Davies PCW, 2011, THEOR BIOL MED MODEL, V8, DOI 10.1186/1742-4682-8-30
   de Martel C, 2013, GASTROENTEROL CLIN N, V42, P219, DOI 10.1016/j.gtc.2013.01.003
   de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7
   De Mejia EG, 2005, CRIT REV FOOD SCI, V45, P425, DOI 10.1080/10408390591034445
   Deepa M, 2012, CHEM-BIOL INTERACT, V200, P38, DOI 10.1016/j.cbi.2012.08.025
   Dias RD, 2015, MOLECULES, V20, P519, DOI 10.3390/molecules20010519
   Ensign LM, 2012, ADV DRUG DELIVER REV, V64, P557, DOI 10.1016/j.addr.2011.12.009
   Etzler M. E., 1989, ANNU REV PLANT PHYS, V36, P209
   Fang EF, 2012, CANCER PREV RES, V5, P109, DOI 10.1158/1940-6207.CAPR-11-0203
   Fang EF, 2011, ARCH TOXICOL, V85, P1551, DOI 10.1007/s00204-011-0698-x
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Ferriz Martinez R.A., 2010, NEW APPROACHES TREAT, V1, P71
   Ferriz-Martinez R, 2015, TOXICOL REP, V2, P63, DOI 10.1016/j.toxrep.2014.10.015
   Fu LL, 2011, INT J BIOCHEM CELL B, V43, P1442, DOI 10.1016/j.biocel.2011.07.004
   Fuster MM, 2005, NAT REV CANCER, V5, P526, DOI 10.1038/nrc1649
   Futsukaichi T, 2015, SURG TODAY, V45, P1299, DOI 10.1007/s00595-015-1127-1
   Gabor F, 2002, INT J PHARM, V237, P227, DOI 10.1016/S0378-5173(02)00049-2
   Garcia-Gasca T, 2012, NUTR CANCER, V64, P1269, DOI 10.1080/01635581.2012.722246
   Gemeiner P, 2009, BIOTECHNOL ADV, V27, P1, DOI 10.1016/j.biotechadv.2008.07.003
   Ghazarian H, 2011, ACTA HISTOCHEM, V113, P236, DOI 10.1016/j.acthis.2010.02.004
   Giannakis M, 2008, P NATL ACAD SCI USA, V105, P4358, DOI 10.1073/pnas.0800668105
   Goggins M, 2005, J CLIN ONCOL, V23, P4524, DOI 10.1200/JCO.2005.19.711
   Gorelik E, 2001, CANCER METAST REV, V20, P245, DOI 10.1023/A:1015535427597
   Gupta G, 2010, OMICS, V14, P419, DOI 10.1089/omi.2009.0150
   Haab BB, 2011, METHODS MOL BIOL, V785, P223, DOI 10.1007/978-1-61779-286-1_15
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Herszenyi L, 2010, EUR REV MED PHARMACO, V14, P249
   Hirabayashi J, 2003, TRENDS BIOTECHNOL, V21, P141, DOI 10.1016/S0167-7799(03)00002-7
   Holmes RS, 2007, SEMIN RADIAT ONCOL, V17, P2, DOI 10.1016/j.semradonc.2006.09.003
   Howe J. R., 1999, CANCER, V86, P653
   Hu YF, 2013, BIOSENS BIOELECTRON, V43, P79, DOI 10.1016/j.bios.2012.11.028
   Huang LH, 2012, CELL PROLIFERAT, V45, P15, DOI 10.1111/j.1365-2184.2011.00800.x
   Huang WL, 2014, WORLD J GASTROENTERO, V20, P5474, DOI 10.3748/wjg.v20.i18.5474
   Hussain SP, 2007, INT J CANCER, V121, P2373, DOI 10.1002/ijc.23173
   Ikeda A, 2012, BIOMED CHROMATOGR, V26, P548, DOI 10.1002/bmc.1671
   Ina K, 2013, ANTI-CANCER AGENT ME, V13, P681, DOI 10.2174/1871520611313050002
   Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087
   Jakszyn P, 2013, INT J CANCER, V133, P2744, DOI 10.1002/ijc.28291
   Jelinek R, 2004, CHEM REV, V104, P5987, DOI 10.1021/cr0300284
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Jenner J, 2006, EXP HEMATOL, V34, P1212, DOI 10.1016/j.exphem.2006.04.016
   Jiang QL, 2015, CELL PROLIFERAT, V48, P17, DOI 10.1111/cpr.12155
   Jordinson M, 1999, GUT, V44, P709, DOI 10.1136/gut.44.5.709
   Julien S, 2012, BIOMOLECULES, V2, P435, DOI 10.3390/biom2040435
   Kabir SR, 2015, APPL BIOCHEM BIOTECH, V175, P2616, DOI 10.1007/s12010-014-1449-2
   Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308
   KASBAOUI L, 1989, CANCER RES, V49, P5317
   Kellokumpu S, 2002, FEBS LETT, V516, P217, DOI 10.1016/S0014-5793(02)02535-8
   Kenmochi E, 2015, MOLECULES, V20, P987, DOI 10.3390/molecules20010987
   Khil LY, 2007, WORLD J GASTROENTERO, V13, P2811, DOI 10.3748/wjg.v13.i20.2811
   Kim WH, 2004, MOL PHARMACOL, V66, P1383, DOI 10.1124/mol.104.001347
   Kong CY, 2014, CANCER EPIDEM BIOMAR, V23, P997, DOI 10.1158/1055-9965.EPI-13-1233
   Kratz E, 2003, CLIN CHIM ACTA, V331, P87, DOI 10.1016/S0009-8981(03)00084-6
   Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541
   Labenz J, 2015, DTSCH ARZTEBL INT, V112, P224, DOI 10.3238/arztebl.2015.0224
   Lafaro KJ, 2015, SURG ONCOL CLIN N AM, V24, P1, DOI 10.1016/j.soc.2014.09.001
   Lagergren J, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c6280
   Lam SK, 2011, FOOD CHEM, V126, P595, DOI 10.1016/j.foodchem.2010.11.049
   Layke JC, 2004, AM FAM PHYSICIAN, V69, P1133
   LEHR CM, 1992, PHARMACEUT RES, V9, P547, DOI 10.1023/A:1015804816582
   Lehrach H., 2017, MECH MOLECULAR CARCI, V2, P359
   Lei HY, 2007, AUTOPHAGY, V3, P402, DOI 10.4161/auto.4280
   Li C, 2009, J PROTEOME RES, V8, P483, DOI 10.1021/pr8007013
   Li CY, 2011, PROCESS BIOCHEM, V46, P533, DOI 10.1016/j.procbio.2010.10.005
   Li CY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101526
   Li YG, 2013, MOL BIOSYST, V9, P1877, DOI 10.1039/c3mb00013c
   Liljeblad M, 2000, GLYCOCONJUGATE J, V17, P323, DOI 10.1023/A:1007169621518
   Liu B, 2010, CANCER LETT, V287, P1, DOI 10.1016/j.canlet.2009.05.013
   Liu B, 2009, BBA-GEN SUBJECTS, V1790, P840, DOI 10.1016/j.bbagen.2009.04.020
   Liu B, 2009, AUTOPHAGY, V5, P432, DOI 10.4161/auto.5.3.7924
   Liu Z, 2013, CELL PROLIFERAT, V46, P509, DOI 10.1111/cpr.12054
   Liu Z, 2008, PHYTOMEDICINE, V15, P867, DOI 10.1016/j.phymed.2008.02.025
   Lyu SY, 2002, ARCH PHARM RES, V25, P93, DOI 10.1007/BF02975269
   Ma YH, 2008, WORLD J GASTROENTERO, V14, P5274, DOI 10.3748/wjg.14.5274
   Mac Dowall JE, 2000, J CLIN PATHOL, V53, P784, DOI 10.1136/jcp.53.10.784
   Macedo MLR, 2015, MOLECULES, V20, P2014, DOI 10.3390/molecules20022014
   MAKELA O, 1957, ANN MED EXP BIOL FEN, V35, P7
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Mao WM, 2011, ASIAN PAC J CANCER P, V12, P2461
   Mechref Y, 2009, J PROTEOME RES, V8, P2656, DOI 10.1021/pr8008385
   Mislovicova D, 2009, BIOLOGIA, V64, P1, DOI 10.2478/s11756-009-0029-3
   MODY R, 1995, J PHARMACOL TOX MET, V33, P1, DOI 10.1016/1056-8719(94)00052-6
   Mukhopadhyay S, 2014, ACTA PHARMACOL SIN, V35, P814, DOI 10.1038/aps.2014.15
   Mukhopadhyay S, 2014, FOOD CHEM TOXICOL, V64, P369, DOI 10.1016/j.fct.2013.11.046
   Munkley J, 2016, ONCOTARGET, V7, P35478, DOI 10.18632/oncotarget.8155
   Nciri N, 2015, J MED FOOD, V18, P1387, DOI 10.1089/jmf.2014.0193
   Neugut AI, 1998, CANCER EPIDEM BIOMAR, V7, P243
   Numico G, 2015, CURR OPIN ONCOL, V27, P351, DOI 10.1097/CCO.0000000000000203
   Otte JM, 2001, DIGESTION, V64, P169, DOI 10.1159/000048858
   Ouyang L, 2014, PHYTOMEDICINE, V21, P1658, DOI 10.1016/j.phymed.2014.08.002
   Pan WL, 2015, INT J BIOL MACROMOL, V81, P960, DOI 10.1016/j.ijbiomac.2015.09.034
   Panda PK, 2014, LIFE SCI, V111, P27, DOI 10.1016/j.lfs.2014.07.004
   Park WB, 2001, CANCER BIOTHER RADIO, V16, P439, DOI 10.1089/108497801753354348
   Pihikova D, 2015, OPEN CHEM, V13, P636, DOI 10.1515/chem-2015-0082
   Pinho SS, 2015, NAT REV CANCER, V15, P540, DOI 10.1038/nrc3982
   Pinho SS, 2013, TRENDS MOL MED, V19, P664, DOI [10.1016/j.molmed.2013.07.003, 10.1016/j.molmed.2013]
   Pizzo P.A., 2002, PRINCIPLES PRACTICE
   Podlech O, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/501796
   Pohl H, 2013, AM J GASTROENTEROL, V108, P200, DOI 10.1038/ajg.2012.387
   Prabhu RH, 2015, INT J NANOMED, V10, P1001, DOI 10.2147/IJN.S56932
   Pratt J, 2012, GLYCOBIOLOGY, V22, P1245, DOI 10.1093/glycob/cws093
   Pridgen EM, 2015, EXPERT OPIN DRUG DEL, V12, P1459, DOI 10.1517/17425247.2015.1018175
   Pryme IF, 2006, HISTOL HISTOPATHOL, V21, P285, DOI 10.14670/HH-21.285
   Przybylo M, 2005, BIOCHIMIE, V87, P133, DOI 10.1016/j.biochi.2004.12.003
   PUSZTAI A, 1990, DIGESTION, V46, P308, DOI 10.1159/000200402
   Pusztai A, 1996, TRENDS GLYCOSCI GLYC, V8, P149, DOI 10.4052/tigg.8.149
   PUSZTAI A, 1989, BIOCHEM SOC T, V17, P481, DOI 10.1042/bst0170481
   Qiu YH, 2008, J PROTEOME RES, V7, P1693, DOI 10.1021/pr700706s
   Rafiq S, 2013, PHYTOMEDICINE, V21, P30, DOI 10.1016/j.phymed.2013.08.005
   Raghav K, 2013, NAT REV CLIN ONCOL, V10, P534, DOI 10.1038/nrclinonc.2013.132
   Reddi AL, 2000, CANCER LETT, V149, P207, DOI 10.1016/S0304-3835(99)00363-8
   REDDY VVS, 1969, CANCER RES, V29, P1447
   Reynoso-Camacho R, 2003, FOOD CHEM TOXICOL, V41, P21, DOI 10.1016/S0278-6915(02)00215-6
   Rhodes JM, 2008, BIOCHEM SOC T, V36, P1482, DOI 10.1042/BST0361482
   Rostock M, 2005, ANTICANCER RES, V25, P1969
   Roy B, 2014, BIOMICROFLUIDICS, V8, DOI 10.1063/1.4882778
   Roy B, 2014, CHEM-BIOL INTERACT, V210, P96, DOI 10.1016/j.cbi.2014.01.003
   Ryan AM, 2011, CANCER EPIDEMIOL, V35, P309, DOI 10.1016/j.canep.2011.03.001
   Sasaki M, 2002, ALIMENT PHARM THER, V16, P633, DOI 10.1046/j.1365-2036.2002.01160.x
   Schumacher K, 2003, ANTICANCER RES, V23, P5081
   Schwarz RE, 1999, BRIT J CANCER, V80, P1754, DOI 10.1038/sj.bjc.6690593
   Seifert G, 2008, CANCER LETT, V264, P218, DOI 10.1016/j.canlet.2008.01.036
   Shah AK, 2015, MOL CELL PROTEOMICS, V14, P3023, DOI 10.1074/mcp.M115.050922
   SHARON N, 1993, TRENDS BIOCHEM SCI, V18, P221, DOI 10.1016/0968-0004(93)90193-Q
   SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581
   Sharon N, 2007, J BIOL CHEM, V282, P2753, DOI 10.1074/JBC.X600004200
   Shi Z, 2014, ACTA PHARMACOL SIN, V35, P248, DOI 10.1038/aps.2013.151
   Shiotani A, 2013, SEMIN CANCER BIOL, V23, P492, DOI 10.1016/j.semcancer.2013.07.004
   Silva FD, 2014, RES VET SCI, V96, P276, DOI 10.1016/j.rvsc.2014.01.005
   Singh R, 2006, GLYCOBIOLOGY, V16, P594, DOI 10.1093/glycob/cwj108
   Singh R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146110
   Sinha R, 2006, MOL CANCER THER, V5, P1909, DOI 10.1158/1535-7163.MCT-06-0141
   Sipponen P, 2000, GASTROENTEROL CLIN N, V29, P579, DOI 10.1016/S0889-8553(05)70131-X
   Smart JD, 2004, ADV DRUG DELIVER REV, V56, P481, DOI 10.1016/j.addr.2003.10.016
   Soreide K, 2015, CANCER LETT, V356, P281, DOI 10.1016/j.canlet.2014.03.028
   Sturm MB, 2015, GUT, V64, P1816, DOI 10.1136/gutjnl-2013-306706
   Tan P, 2015, GASTROENTEROLOGY, V149, P1153, DOI 10.1053/j.gastro.2015.05.059
   Thelin C., 2015, LUNG, V1, P13
   Troger W, 2013, EUR J CANCER, V49, P3788, DOI 10.1016/j.ejca.2013.06.043
   Tsai TL, 2014, CANCER RES, V74, DOI 10.1158/1538-7445.AM2014-1338
   Valadez-Vega C, 2014, MOLECULES, V19, P9610, DOI 10.3390/molecules19079610
   Vankemmelbeke M, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1061177
   VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97
   Varki A, 2009, ESSENTIALS GLYCOBIOL
   Walczak H, 2011, IMMUNOL REV, V244, P9, DOI 10.1111/j.1600-065X.2011.01066.x
   Wang CX, 2010, INT J PHARMACEUT, V400, P201, DOI 10.1016/j.ijpharm.2010.08.023
   Wang FS, 2014, HEPATOLOGY, V60, P2099, DOI 10.1002/hep.27406
   Wang HX, 2000, INT J BIOCHEM CELL B, V32, P365, DOI 10.1016/S1357-2725(99)00130-2
   Wang SY, 2011, BIOCHEM BIOPH RES CO, V406, P497, DOI 10.1016/j.bbrc.2011.02.049
   Wolfgang CL, 2013, CA-CANCER J CLIN, V63, P318, DOI 10.3322/caac.21190
   Wong MCS, 2017, SCI REP-UK, V7, DOI 10.1038/srep45846
   Wu A, 2008, GLYCOCONJ J, V26, P899
   Xiao XQ, 2015, PHYTOMEDICINE, V22, P238, DOI 10.1016/j.phymed.2014.12.004
   Xu PP, 2015, BIOTECHNOL PROGR, V31, P736, DOI 10.1002/btpr.2070
   Yamamoto K, 2005, ANAL BIOCHEM, V336, P28, DOI 10.1016/j.ab.2004.09.030
   Yamashita K, 2016, GASTRIC CANCER, V19, P531, DOI 10.1007/s10120-015-0491-2
   Yan QJ, 2010, FOOD CHEM, V122, P589, DOI 10.1016/j.foodchem.2010.03.015
   Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366
   Yoon TK, 1998, INT J IMMUNOPHARMACO, V20, P163, DOI 10.1016/S0192-0561(98)00024-1
   Zhang CZ, 2015, INVEST NEW DRUG, V33, P1, DOI 10.1007/s10637-014-0156-8
   Zhang M. W., 2012, MOL CARCINOG, V51, P1
   Zhang ZY, 2013, CANCER LETT, V336, P34, DOI 10.1016/j.canlet.2013.04.021
   Zhang ZT, 2010, PHYTOMEDICINE, V18, P25, DOI 10.1016/j.phymed.2010.05.013
   Zhao J, 2007, J PROTEOME RES, V6, P1864, DOI 10.1021/pr070062p
   Zhao J, 2006, J PROTEOME RES, V5, P1792, DOI 10.1021/pr060034r
   Zhou W, 2014, PROTEIN EXPRES PURIF, V93, P11, DOI 10.1016/j.pep.2013.09.018
   Zuo ZY, 2012, SPRINGERPLUS, V1, DOI 10.1186/2193-1801-1-13
   Zykova TA, 2017, EBIOMEDICINE, V18, P73, DOI 10.1016/j.ebiom.2017.04.003
NR 195
TC 12
Z9 14
U1 2
U2 17
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUL
PY 2017
VL 18
IS 7
AR 1403
DI 10.3390/ijms18071403
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA FF2SJ
UT WOS:000408746800075
PM 28671623
OA Green Submitted, gold, Green Published
DA 2022-04-25
ER

PT J
AU Simone, C
AF Simone, Cristiano
TI Signal-dependent control of autophagy and cell death in colorectal
   cancer cell - The role of the p38 pathway
SO AUTOPHAGY
LA English
DT Article
DE autophagy; apoptosis; colorectal cancer cells; p38 alpha; programmed
   cell death type II
ID HUMAN COLON-CANCER; HT-29 CELLS; MACROAUTOPHAGY; PROTEIN; CHROMATIN;
   INHIBITION; ACTIVATION; APOPTOSIS; P38-ALPHA; KINASES
AB Autophogy is a vacuolar process leading to the degradation of long-lived proteins and cytoplasmic organelles in eukaryotes. This process has an important role in normal and cancer cells during adaptation to changing environmental conditions, cellular and tissue remodeling, and cell death. 1,2 To date, several signaling cascades have been described to regulate autophagy in a cell type-specific and signal-dependent manner.(3) We found that pharmacological blockade of the p38 pathway in colorectal cancer cells, either by the inhibitor SB202190 or by genetic ablation of p38 alpha kinase, causes cell cycle arrest and autophagic cell death.(4) In these cells, a complex network of intracellular kinase cascades controls autophagy and survival since the effect of p38 alpha blockade is differentially affected by the pharmacological inhibition of MEK1, Pl(3)K class I and III, and mTOR or by the differentiation status. Collectively, our results suggest an opportunity for exploiting the pharmacological manipulation of the p38 alpha pathway in the treatment of colorectal cancer. Given the number of drugs, currently available or under development, that target the p38 pathway, it stands to reason that elucidating the molecular mechanisms that link p38 and autophagy might have an impact on the clinical translation of these drugs.
C1 Univ Bari, Div Med Genet, Dept Biomed Childhood, I-70124 Bari, Italy.
   Temple Univ, Coll Sci & Technol, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA.
RP Simone, C (corresponding author), Univ Bari, Div Med Genet, Dept Biomed Childhood, Piazza G Cesare 11, I-70124 Bari, Italy.
EM csimone@temple.edu
RI Simone, Cristiano/K-3452-2018
OI Simone, Cristiano/0000-0002-2628-7658
CR Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200
   Botti J, 2006, AUTOPHAGY, V2, P67, DOI 10.4161/auto.2.2.2458
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Chow CW, 2006, CELL, V127, P887, DOI 10.1016/j.cell.2006.11.015
   Comes F, 2007, CELL DEATH DIFFER, V14, P693, DOI 10.1038/sj.cdd.4402076
   Corcelle E, 2007, AUTOPHAGY, V3, P57, DOI 10.4161/auto.3424
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Edmunds JW, 2006, SCIENCE, V313, P449, DOI 10.1126/science.1131158
   Hiramoto T, 1999, ONCOGENE, V18, P3422, DOI 10.1038/sj.onc.1202691
   HOURI JJ, 1993, BIOCHEM BIOPH RES CO, V197, P805, DOI 10.1006/bbrc.1993.2550
   Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494
   Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269
   Klionsky DJ, 2007, AUTOPHAGY, V3, P181, DOI 10.4161/auto.3678
   Kuwamura H, 2007, ONCOL REP, V17, P781
   Lee MR, 2005, CURR MED CHEM, V12, P2979, DOI 10.2174/092986705774462914
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Lin ZS, 2004, MOL CELL PROTEOMICS, V3, P820, DOI 10.1074/mcp.M400008-MCP200
   Marx J, 2006, SCIENCE, V312, P1160, DOI 10.1126/science.312.5777.1160
   Moinova HR, 2002, P NATL ACAD SCI USA, V99, P4562, DOI 10.1073/pnas.062459899
   Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Simone C, 2006, J CELL PHYSIOL, V207, P309, DOI 10.1002/jcp.20514
   Simone C, 2004, NAT GENET, V36, P738, DOI 10.1038/ng1378
   Tassa A, 2003, BIOCHEM J, V376, P577, DOI 10.1042/BJ20030826
   Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777
   vom Dahl S, 2001, BIOCHEM J, V354, P31, DOI 10.1042/0264-6021:3540031
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
NR 28
TC 39
Z9 39
U1 1
U2 4
PU LANDES BIOSCIENCE
PI GEORGETOWN
PA 810 SOUTH CHURCH STREET, GEORGETOWN, TX 78626 USA
SN 1554-8627
J9 AUTOPHAGY
JI Autophagy
PD SEP-OCT
PY 2007
VL 3
IS 5
BP 468
EP 471
DI 10.4161/auto.4319
PG 4
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 201DR
UT WOS:000248812200009
PM 17495519
OA Bronze
DA 2022-04-25
ER

PT J
AU Adiseshaiah, PP
   Clogston, JD
   McLeland, CB
   Rodriguez, J
   Potter, TM
   Neun, BW
   Skoczen, SL
   Shanmugavelandy, SS
   Kester, M
   Stern, ST
   McNeil, SE
AF Adiseshaiah, Pavan P.
   Clogston, Jeffrey D.
   McLeland, Christopher B.
   Rodriguez, Jamie
   Potter, Timothy M.
   Neun, Barry W.
   Skoczen, Sarah L.
   Shanmugavelandy, Sriram S.
   Kester, Mark
   Stern, Stephan T.
   McNeil, Scott E.
TI Synergistic combination therapy with nanoliposomal C6-ceramide and
   vinblastine is associated with autophagy dysfunction in hepatocarcinoma
   and colorectal cancer models
SO CANCER LETTERS
LA English
DT Article
DE Combination therapy; Autophagy; Ceramide
ID PORCINE KIDNEY-CELLS; INDUCED APOPTOSIS; TARGETING AUTOPHAGY;
   TUMOR-GROWTH; CERAMIDE; TUMORIGENESIS; CYTOTOXICITY; INDUCTION;
   DELIVERY; BCL-2
AB Autophagy, a catabolic survival pathway, is gaining attention as a potential target in cancer. In human liver and colon cancer cells, treatment with an autophagy inducer, nanoliposomal C6-ceramide, in combination with the autophagy maturation inhibitor, vinblastine, synergistically enhanced apoptotic cell death. Combination treatment resulted in a marked increase in autophagic vacuole accumulation and decreased autophagy maturation, without diminution of the autophagy flux protein P62. In a colon cancer xenograft model, a single intravenous injection of the drug combination significantly decreased tumor growth in comparison to the individual treatments. Most importantly, the combination treatment did not result in increased toxicity as assessed by body weight loss. The mechanism of combination treatment-induced cell death both in vitro and in vivo appeared to be apoptosis. Supportive of autophagy flux blockade as the underlying synergy mechanism, treatment with other autophagy maturation inhibitors, but not autophagy initiation inhibitors, were similarly synergistic with C6-ceramide. Additionally, knockout of the autophagy protein Beclin-1 suppressed combination treatment-induced apoptosis in vitro. In conclusion, in vitro and in vivo data support a synergistic antitumor activity of the nanoliposomal C6-ceramide and vinblastine combination, potentially mediated by an autophagy mechanism. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Adiseshaiah, Pavan P.; Clogston, Jeffrey D.; McLeland, Christopher B.; Rodriguez, Jamie; Potter, Timothy M.; Neun, Barry W.; Skoczen, Sarah L.; Stern, Stephan T.; McNeil, Scott E.] SAIC Frederick Inc, Frederick Natl Lab Canc Res, Nanotechnol Characterizat Lab, Adv Technol Program, Frederick, MD 21702 USA.
   [Shanmugavelandy, Sriram S.; Kester, Mark] Penn State Univ, Dept Pharmacol, Coll Med, Hershey, PA 17033 USA.
RP Stern, ST (corresponding author), SAIC Frederick Inc, Frederick Natl Lab Canc Res, Nanotechnol Characterizat Lab, Adv Technol Program, Frederick, MD 21702 USA.
EM sternstephan@mail.nih.gov
RI Clogston, Jeffrey Dean/AAE-8982-2022; Adiseshaiah, Pavan/R-3917-2018;
   Kester, Mark/ABG-4615-2020; Nanotechnology Characterization Lab,
   (NCL)/K-8454-2012
OI Clogston, Jeffrey Dean/0000-0003-1860-9271; McNeil,
   Scott/0000-0002-7575-5198
FU National Cancer Institute, National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [HHSN261200800001E]; Ebberly
   Fund of Penn State College of Medicine
FX This project has been funded in whole or in part with federal funds from
   the National Cancer Institute, National Institutes of Health, under
   contract HHSN261200800001E. The content of this publication does not
   necessarily reflect the views or policies of the Department of Health
   and Human Services, nor does mention of trade names, commercial
   products, or organizations imply endorsement by the U.S. Government. The
   project was also funded, in part (MK), through support from the Ebberly
   Fund of Penn State College of Medicine.
CR Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   BERKENSTAM A, 1983, VIRCHOWS ARCH B, V44, P275, DOI 10.1007/BF02890177
   Boland B, 2008, J NEUROSCI, V28, P6926, DOI 10.1523/JNEUROSCI.0800-08.2008
   Bourbon NA, 2000, J BIOL CHEM, V275, P35617, DOI 10.1074/jbc.M007346200
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Coppola D, 2008, CANCER-AM CANCER SOC, V113, P2665, DOI 10.1002/cncr.23892
   Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Degtyarev M, 2008, J CELL BIOL, V183, P101, DOI 10.1083/jcb.200801099
   Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200
   Garcia-Ma S., 2012, CURR PHARM DES
   Guenther GG, 2008, P NATL ACAD SCI USA, V105, P17402, DOI 10.1073/pnas.0802781105
   Iqbal J, 2009, LEUKEMIA, V23, P1139, DOI 10.1038/leu.2009.3
   Ji C, 2010, ONCOGENE, V29, P6557, DOI 10.1038/onc.2010.379
   Johnson-Lyles DN, 2010, TOXICOL APPL PHARM, V248, P249, DOI 10.1016/j.taap.2010.08.008
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Karmakar Surajit, 2011, J Cancer Ther, V2, P77
   Kim HP, 2008, AUTOPHAGY, V4, P887, DOI 10.4161/auto.6767
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Kochl R, 2006, TRAFFIC, V7, P129, DOI 10.1111/j.1600-0854.2005.00368.x
   Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lieberman AP, 2012, AUTOPHAGY, V8, P719, DOI 10.4161/auto.19469
   Liu X, 2010, BLOOD, V116, P4192, DOI 10.1182/blood-2010-02-271080
   Marimpietri D, 2007, CLIN CANCER RES, V13, P3977, DOI 10.1158/1078-0432.CCR-06-2757
   Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200
   Marino G, 2010, ADV EXP MED BIOL, V694, P61
   Pattingre S, 2009, J BIOL CHEM, V284, P2719, DOI 10.1074/jbc.M805920200
   Ponnusamy S, 2010, FUTURE ONCOL, V6, P1603, DOI 10.2217/FON.10.116
   Potter TM, 2011, METHODS MOL BIOL, V697, P157, DOI 10.1007/978-1-60327-198-1_16
   Potter TM, 2011, METHODS MOL BIOL, V697, P167, DOI 10.1007/978-1-60327-198-1_17
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Seglen PO, 2010, AUTOPHAGY, V6, P542, DOI 10.4161/auto.6.4.11272
   Shi YH, 2011, AUTOPHAGY, V7, P1159, DOI 10.4161/auto.7.10.16818
   Solomon VR, 2009, EUR J PHARMACOL, V625, P220, DOI 10.1016/j.ejphar.2009.06.063
   Stern ST, 2008, TOXICOL SCI, V106, P140, DOI 10.1093/toxsci/kfn137
   Stover T, 2003, J PHARMACOL EXP THER, V307, P468, DOI 10.1124/jpet.103.054056
   Stover TC, 2005, CLIN CANCER RES, V11, P3465, DOI 10.1158/1078-0432.CCR-04-1770
   Tagaram HRS, 2011, GUT, V60, P695, DOI 10.1136/gut.2010.216671
   van Vlerken LE, 2010, AAPS J, V12, P171, DOI 10.1208/s12248-010-9174-4
   Wei YJ, 2008, AUTOPHAGY, V4, P949, DOI 10.4161/auto.6788
   White EJ, 2011, AM J CANCER RES, V1, P362
   Xie R, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-89
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zhou FF, 2011, FEBS J, V278, P403, DOI 10.1111/j.1742-4658.2010.07965.x
   Zhou Q, 2012, BIOCHEM PHARMACOL, V83, P1146, DOI 10.1016/j.bcp.2012.01.013
   Zolnik BS, 2008, DRUG METAB DISPOS, V36, P1709, DOI 10.1124/dmd.107.019679
NR 50
TC 51
Z9 52
U1 0
U2 45
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD SEP 1
PY 2013
VL 337
IS 2
BP 254
EP 265
DI 10.1016/j.canlet.2013.04.034
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 201JP
UT WOS:000323138200013
PM 23664889
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Klose, J
   Trefz, S
   Wagner, T
   Steffen, L
   Charrier, AP
   Radhakrishnan, P
   Volz, C
   Schmidt, T
   Ulrich, A
   Dieter, SM
   Ball, C
   Glimm, H
   Schneider, M
AF Klose, Johannes
   Trefz, Stefan
   Wagner, Tobias
   Steffen, Luca
   Charrier, Arsalie Preissendorfer
   Radhakrishnan, Praveen
   Volz, Claudia
   Schmidt, Thomas
   Ulrich, Alexis
   Dieter, Sebastian M.
   Ball, Claudia
   Glimm, Hanno
   Schneider, Martin
TI Salinomycin: Anti-tumor activity in a pre-clinical colorectal cancer
   model
SO PLOS ONE
LA English
DT Article
ID STEM-CELLS; INITIATING CELLS; GROWTH; APOPTOSIS; ANTICANCER; AUTOPHAGY;
   PEROXISOMES; METABOLISM
AB Objectives
   Salinomycin is a polyether antibiotic with selective activity against human cancer stem cells. The impact of salinomycin on patient-derived primary human colorectal cancer cells has not been investigated so far. Thus, here we aimed to investigate the activity of salinomycin against tumor initiating cells isolated from patients with colorectal cancer.
   Methods
   Primary tumor-initiating cells (TIC) isolated from human patients with colorectal liver metastases or from human primary colon carcinoma were exposed to salinomycin and compared to treatment with 5-FU and oxaliplatin. TICs were injected subcutaneously into NOD/SCID mice to induce a patient-derived mouse xenograft model of colorectal cancer. Animals were treated either with salinomycin, FOLFOX regimen, or salinomycin and FOLFOX. Human colorectal cancer cells were used to delineate an underlying molecular mechanism of salinomycin in this tumor entity.
   Results
   Applying TICs isolated from human patients with colorectal liver metastases or from human primary colon carcinoma, we demonstrated that salinomycin exerts increased antiproliferative activity compared to 5-fluorouracil and oxaliplatin treatment. Consistently, salinomycin alone or in combination with FOLFOX exerts superior antitumor activity compared to FOLFOX therapy in a patient-derived mouse xenograft model of colorectal cancer. Salinomycin induces apoptosis of human colorectal cancer cells, accompanied by accumulation of dysfunctional mitochondria and reactive oxygen species. These effects are associated with expressional down-regulation of superoxide dismutase-1 (SOD1) in response to salinomycin treatment.
   Conclusion
   Collectively, the results of this pre-clinical study indicate that salinomycin alone or in combination with 5-fluorouracil and oxaliplatin exerts increased antitumoral activity compared to common chemotherapy.
C1 [Klose, Johannes; Trefz, Stefan; Wagner, Tobias; Steffen, Luca; Charrier, Arsalie Preissendorfer; Radhakrishnan, Praveen; Volz, Claudia; Schmidt, Thomas; Ulrich, Alexis; Schneider, Martin] Heidelberg Univ, Dept Gen Visceral & Transplantat Surg, Heidelberg, Germany.
   [Dieter, Sebastian M.; Glimm, Hanno] Natl Ctr Tumor Dis NCT Heidelberg, Translat Funct Canc Genom, Heidelberg, Germany.
   [Dieter, Sebastian M.; Glimm, Hanno] German Canc Res Ctr, Heidelberg, Germany.
   [Ball, Claudia; Glimm, Hanno] Natl Ctr Tumor Dis NCT Dresden, Dept Translat Med Oncol, Dresden, Germany.
   [Ball, Claudia; Glimm, Hanno] German Canc Res Ctr, Dresden, Germany.
   [Glimm, Hanno] Tech Univ Dresden, Univ Hosp Carl Gustav Carus Dresden, Ctr Personalized Oncol, Dresden, Germany.
   [Glimm, Hanno] German Consortium Translat Canc Res DKTK Dresden, Dresden, Germany.
RP Klose, J (corresponding author), Heidelberg Univ, Dept Gen Visceral & Transplantat Surg, Heidelberg, Germany.
EM Johannes.Klose@med.uni-heidelberg.de
RI Schmidt, Thomas/Y-8431-2019
OI Schmidt, Thomas/0000-0002-7166-3675; Ball, Claudia/0000-0002-1749-3791;
   Dieter, Sebastian/0000-0003-1324-7638
FU DFGGerman Research Foundation (DFG)European Commission [KL-2843/2-1];
   Deutsche Krebshilfe (German Cancer Aid)Deutsche Krebshilfe;
   Colon-Resist-Net
FX This work was supported by DFG grant KL-2843/2-1 to Johannes Klose and
   by Deutsche Krebshilfe (German Cancer Aid) and Colon-Resist-Net to
   Claudia Ball and Hanno Glimm. The funder had no role in study design,
   data collection and analysis, decision to publish, or presentation of
   the manuscript.
CR Antonenkov VD, 2010, ANTIOXID REDOX SIGN, V13, P525, DOI 10.1089/ars.2009.2996
   Antoszczak M, 2015, ANTI-CANCER AGENT ME, V15, P575, DOI 10.2174/1871520615666150101130209
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Bonuccelli G, 2010, CELL CYCLE, V9, P3506, DOI 10.4161/cc.9.17.12731
   Borgstrom B, 2016, CHEMISTRY
   Borgstrom B, 2013, CHEM COMMUN, V49, P9944, DOI 10.1039/c3cc45983g
   Brown KM, 2018, J SURG RES, V227, P158, DOI 10.1016/j.jss.2018.02.018
   Brown KM, 2016, ONCOTARGET, V7, P66212, DOI 10.18632/oncotarget.11184
   Chen X, 2014, INT J MOL MED, V34, P35, DOI 10.3892/ijmm.2014.1752
   Chung SS, 2017, ANTICANCER RES, V37, P445, DOI 10.21873/anticanres.11336
   DANFORTH HD, 1977, POULTRY SCI, V56, P926, DOI 10.3382/ps.0560926
   de Aberasturi AL, 2016, CANCER LETT, V370, P165, DOI 10.1016/j.canlet.2015.10.012
   Melo FDE, 2017, NATURE, V543, P676, DOI 10.1038/nature21713
   Dewangan J, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317695035
   Dieter SM, 2011, CELL STEM CELL, V9, P357, DOI 10.1016/j.stem.2011.08.010
   Dong TT, 2011, ANN SURG ONCOL, V18, P1797, DOI 10.1245/s10434-011-1561-2
   Dubash TD, 2016, CANCER LETT, V371, P326, DOI 10.1016/j.canlet.2015.11.037
   Fan CW, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.337
   Fanali C, 2014, WORLD J GASTROENTERO, V20, P923, DOI 10.3748/wjg.v20.i4.923
   Fransen M, 2012, BBA-MOL BASIS DIS, V1822, P1363, DOI 10.1016/j.bbadis.2011.12.001
   Giessler KM, 2017, J EXP MED, V214, P2073, DOI 10.1084/jem.20162017
   Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
   Huang EH, 2009, CANCER RES, V69, P3382, DOI 10.1158/0008-5472.CAN-08-4418
   Huang XL, 2018, ACS CENTRAL SCI, V4, P760, DOI 10.1021/acscentsci.8b00257
   Huang XL, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2142-3
   Huczynski A, 2015, EUR J MED CHEM, V93, P33, DOI 10.1016/j.ejmech.2015.01.045
   Jiang J, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0680-z
   Juarez JC, 2008, P NATL ACAD SCI USA, V105, P7147, DOI 10.1073/pnas.0709451105
   Klonisch T, 2008, TRENDS MOL MED, V14, P450, DOI 10.1016/j.molmed.2008.08.003
   Klose J, 2017, BIOCHEM BIOPH RES CO, V1151, DOI [10.1016/j.biopha.2017.02.110, DOI 10.1016/J.BIOPHA.2017.02.110]
   Klose J, 2018, ONCOTARGET, V9, P3619, DOI 10.18632/oncotarget.23339
   Klose J, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2879-8
   Klose J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095970
   Li T, 2016, ONCOTARGET, V7, P26580, DOI 10.18632/oncotarget.8555
   Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154
   Lu DS, 2011, P NATL ACAD SCI USA, V108, P13253, DOI 10.1073/pnas.1110431108
   Markowska A, 2018, ADV CLIN EXP MED, V27, P1017, DOI 10.17219/acem/73999
   MIYAZAKI Y, 1974, J ANTIBIOT, V27, P814, DOI 10.7164/antibiotics.27.814
   Naujokat C, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/950658
   PLUMLEE KH, 1995, J VET DIAGN INVEST, V7, P419, DOI 10.1177/104063879500700327
   Radhakrishnan P, 2016, CANCER RES, V76, P2219, DOI 10.1158/0008-5472.CAN-15-1474
   Rai G, 2017, BIOMED PHARMACOTHER, V89, P1142, DOI 10.1016/j.biopha.2017.02.110
   Riccardi C, 2006, NAT PROTOC, V1, P1458, DOI 10.1038/nprot.2006.238
   Schenk M, 2015, CANCER LETT, V358, P161, DOI 10.1016/j.canlet.2014.12.037
   Schulze A, 2012, NATURE, V491, P364, DOI 10.1038/nature11706
   Seol HS, 2014, CANCER LETT, V345, P56, DOI 10.1016/j.canlet.2013.11.010
   Shimokawa M, 2017, NATURE, V545, P187, DOI 10.1038/nature22081
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Story Phillipa, 2004, N Z Med J, V117, pU799
   Tang QL, 2011, CANCER LETT, V311, P113, DOI 10.1016/j.canlet.2011.07.016
   Mai TT, 2017, NAT CHEM, V9, P1025, DOI [10.1038/NCHEM.2778, 10.1038/nchem.2778]
   Verdoodt B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044132
   Vlachogiannis G, 2018, SCIENCE, V359, P920, DOI 10.1126/science.aao2774
   Wang F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097414
   Weitz J, 2005, LANCET, V365, P153, DOI 10.1016/S0140-6736(05)17706-X
   Yu SN, 2017, ONCOL REP, V37, P3321, DOI 10.3892/or.2017.5615
   Zhang C, 2015, ONCOL REP, V34, P2469, DOI 10.3892/or.2015.4253
   Zhang XF, 2016, INT J NANOMED, V11, P3655, DOI 10.2147/IJN.S111279
   Zhou J, 2013, TOXICOL LETT, V222, P139, DOI 10.1016/j.toxlet.2013.07.022
   Zou ZZ, 2017, ONCOTARGET, V8, P22414, DOI 10.18632/oncotarget.5628
NR 60
TC 17
Z9 17
U1 2
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 14
PY 2019
VL 14
IS 2
AR e0211916
DI 10.1371/journal.pone.0211916
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HL5JX
UT WOS:000458763900030
PM 30763370
OA gold, Green Submitted, Green Published
DA 2022-04-25
ER

PT J
AU Celesia, A
   Morana, O
   Fiore, T
   Pellerito, C
   D'Anneo, A
   Lauricella, M
   Carlisi, D
   De Blasio, A
   Calvaruso, G
   Giuliano, M
   Emanuele, S
AF Celesia, Adriana
   Morana, Ornella
   Fiore, Tiziana
   Pellerito, Claudia
   D'Anneo, Antonella
   Lauricella, Marianna
   Carlisi, Daniela
   De Blasio, Anna
   Calvaruso, Giuseppe
   Giuliano, Michela
   Emanuele, Sonia
TI ROS-Dependent ER Stress and Autophagy Mediate the Anti-Tumor Effects of
   Tributyltin (IV) Ferulate in Colon Cancer Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE tributyltin (IV) derivative; ROS; oxidative stress; endoplasmic
   reticulum stress; autophagic cell death
ID OXIDATIVE STRESS; TRANSCRIPTION FACTOR; KEAP1-NRF2 PATHWAY; DUAL ROLE;
   APOPTOSIS; P62/SQSTM1; ACTIVATION; CROSSTALK; GENE; NRF2
AB Organotin compounds represent potential cancer therapeutics due to their pro-apoptotic action. We recently synthesized the novel organotin ferulic acid derivative tributyltin (IV) ferulate (TBT-F) and demonstrated that it displays anti-tumor properties in colon cancer cells related with autophagic cell death. The purpose of the present study was to elucidate the mechanism of TBT-F action in colon cancer cells. We specifically show that TBT-F-dependent autophagy is determined by a rapid generation of reactive oxygen species (ROS) and correlated with endoplasmic reticulum (ER) stress. TBT-F evoked nuclear factor erythroid-2 related factor 2 (Nrf2)-mediated antioxidant response and Nrf2 silencing by RNA interference markedly increased the anti-tumor efficacy of the compound. Moreover, as a consequence of ROS production, TBT-F increased the levels of glucose regulated protein 78 (Grp78) and C/EBP homologous protein (CHOP), two ER stress markers. Interestingly, Grp78 silencing produced significant decreasing effects on the levels of the autophagic proteins p62 and LC3-II, while only p62 decreased in CHOP-silenced cells. Taken together, these results indicate that ROS-dependent ER stress and autophagy play a major role in the TBT-F action mechanism in colon cancer cells and open a new perspective to consider the compound as a potential candidate for colon cancer treatment.
C1 [Celesia, Adriana; Lauricella, Marianna; Carlisi, Daniela; Emanuele, Sonia] Univ Palermo, Dept Biomed Neurosci & Adv Diagnost Bind, Biochem Bldg,Via Vespro 129, I-90127 Palermo, Italy.
   [Morana, Ornella; D'Anneo, Antonella; De Blasio, Anna; Calvaruso, Giuseppe; Giuliano, Michela] Univ Palermo, Dept Biol Chem & Pharmaceut Sci & Technol STEBICE, Lab Biochem, Via Vespro 129, I-90127 Palermo, Italy.
   [Fiore, Tiziana; Pellerito, Claudia] Univ Palermo, Dept Phys & Chem Emilio Segre DiFC, Viale Sci,Bldg 17, I-90128 Palermo, Italy.
   [Fiore, Tiziana; Pellerito, Claudia] Interuniv Consortium Res Chem Met Ions Biol Syst, Piazza Umberto 1, I-170121 Bari, Italy.
RP Emanuele, S (corresponding author), Univ Palermo, Dept Biomed Neurosci & Adv Diagnost Bind, Biochem Bldg,Via Vespro 129, I-90127 Palermo, Italy.; Giuliano, M (corresponding author), Univ Palermo, Dept Biol Chem & Pharmaceut Sci & Technol STEBICE, Lab Biochem, Via Vespro 129, I-90127 Palermo, Italy.
EM adriana.celesia@unipa.it; ornella.morana@gmail.com;
   tiziana.fiore@unipa.it; claudia.pellerito@unipa.it;
   antonella.danneo@unipa.it; marianna.lauricella@unipa.it;
   daniela.carlisi@unipa.it; anna.deblasio@unipa.it;
   giuseppe.calvaruso@unipa.it; michela.giuliano@unipa.it;
   sonia.emanuele@unipa.it
OI FIORE, Tiziana/0000-0002-0604-2696; LAURICELLA,
   Marianna/0000-0002-0157-3834; GIULIANO, Michela/0000-0002-5114-6267; DE
   BLASIO, Anna/0000-0003-2208-0366; D'ANNEO,
   Antonella/0000-0002-1785-8236; CARLISI, Daniela/0000-0002-5833-7904
FU Funding for Basic Activities Related to Research (Ministero
   dell'Istruzione, dell'Universita e della Ricerca), Italy
   [FFR-D15_006475]; Agenzia di Sviluppo della Sicilia Occidentale (ASSO
   s.r.l) [PJ_FUNZ_ATT_COMM_FLAG_D15-FLAG 2018]
FX This research was funded in part by the Funding for Basic Activities
   Related to Research (Ministero dell'Istruzione, dell'Universita e della
   Ricerca (FFR-D15_006475, 2018/2021), Italy, and by Agenzia di Sviluppo
   della Sicilia Occidentale (ASSO s.r.l, PJ_FUNZ_ATT_COMM_FLAG_D15-FLAG
   2018).
CR B'chir W, 2014, CELL SIGNAL, V26, P1385, DOI 10.1016/j.cellsig.2014.03.009
   B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563
   Carlisi D, 2014, ONCOL REP, V32, P167, DOI 10.3892/or.2014.3212
   Cernigliaro C, 2019, CANCERS, V11, DOI 10.3390/cancers11040505
   Collin F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102407
   Corazzari M, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00078
   Coutinho JVS, 2016, TOXICOL LETT, V260, P52, DOI 10.1016/j.toxlet.2016.08.007
   Emanuele S, 2018, NUTRIENTS, V10, DOI 10.3390/nu10101490
   Emanuele S, 2018, CHEM RES TOXICOL, V31, P201, DOI 10.1021/acs.chemrestox.7b00311
   Frias DP, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59930-3
   Galadari S, 2017, FREE RADICAL BIO MED, V104, P144, DOI 10.1016/j.freeradbiomed.2017.01.004
   Gao JH, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0595-y
   Gennari A, 2000, TOXICOL APPL PHARM, V169, P185, DOI 10.1006/taap.2000.9076
   Grun F, 2012, BIOCHEMICAL AND BIOLOGICAL EFFECTS OF ORGANOTINS, P53
   Higa A, 2012, CELL SIGNAL, V24, P1548, DOI 10.1016/j.cellsig.2012.03.011
   Hou LY, 2019, REDOX BIOL, V22, DOI 10.1016/j.redox.2019.101134
   Hu H, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03083
   Ishihara Y, 2012, NEUROCHEM INT, V60, P782, DOI 10.1016/j.neuint.2012.03.004
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Kanimozhi V, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-3186-1
   Kansanen E, 2013, REDOX BIOL, V1, P45, DOI 10.1016/j.redox.2012.10.001
   Katsuragi Yoshinori, 2016, Current Opinion in Toxicology, V1, P54, DOI 10.1016/j.cotox.2016.09.005
   Lamark T, 2017, ESSAYS BIOCHEM, V61, P609, DOI 10.1042/EBC20170035
   Lauricella M, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8100422
   Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010
   Li T, 2020, CANCER SCI, V111, P1156, DOI 10.1111/cas.14321
   Lin YN, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109249
   Liu ZW, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/2525967
   Lu HY, 2017, MOL MED REP, V16, P1493, DOI 10.3892/mmr.2017.6681
   Moloney JN, 2018, SEMIN CELL DEV BIOL, V80, P50, DOI 10.1016/j.semcdb.2017.05.023
   Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386
   Nakanishi Tsuyoshi, 2006, Environmental Sciences, V13, P89
   Nishitoh H, 2012, J BIOCHEM, V151, P217, DOI 10.1093/jb/mvr143
   Notaro A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205235
   Oh HJ, 2020, CYTOKINE, V127, DOI 10.1016/j.cyto.2019.154959
   Panieri E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.105
   Pellerito C, 2020, J INORG BIOCHEM, V205, DOI 10.1016/j.jinorgbio.2020.110999
   Pellerito L, 2002, COORDIN CHEM REV, V224, P111, DOI 10.1016/S0010-8545(01)00399-X
   Perillo B, 2020, EXP MOL MED, V52, P192, DOI 10.1038/s12276-020-0384-2
   Rashid HO, 2015, AUTOPHAGY, V11, P1956, DOI 10.1080/15548627.2015.1091141
   Revtech Europe, 1998, ETHIOP J HEALTH SCI
   Sies H, 2020, NAT REV MOL CELL BIO, V21, P363, DOI 10.1038/s41580-020-0230-3
   Song SL, 2017, J CELL PHYSIOL, V232, P2977, DOI 10.1002/jcp.25785
   Tang B, 2015, AUTOPHAGY, V11, P344, DOI 10.1080/15548627.2015.1023682
   Tonelli C, 2018, ANTIOXID REDOX SIGN, V29, P1727, DOI 10.1089/ars.2017.7342
   Yamamoto M, 2018, PHYSIOL REV, V98, P1169, DOI 10.1152/physrev.00023.2017
   Yang ZK, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-017-0664-4
   Yasuda D, 2020, FREE RADICAL RES, V54, P859, DOI 10.1080/10715762.2020.1732955
   Yun S, 2017, ANTICANCER RES, V37, P2975, DOI 10.21873/anticanres.11651
   Yuzefovych LV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054059
   Zdunska K, 2018, SKIN PHARMACOL PHYS, V31, P332, DOI 10.1159/000491755
   Zeeshan HMA, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030327
   Zhang XY, 2015, MOL BRAIN, V8, DOI 10.1186/s13041-015-0112-3
   Zhang Z, 2019, REDOX BIOL, V25, DOI 10.1016/j.redox.2018.11.005
   Zhou Z, 2019, J CANCER, V10, P3427, DOI 10.7150/jca.30318
NR 55
TC 8
Z9 8
U1 4
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2020
VL 21
IS 21
AR 8135
DI 10.3390/ijms21218135
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA OQ9WV
UT WOS:000589128000001
PM 33143349
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Chiou, SK
   Hoa, N
   Ge, LS
   Jadus, MR
AF Chiou, Shiun-Kwei
   Hoa, Neil
   Ge, Lisheng
   Jadus, Martin R.
TI Nutrient Availability Alters the Effect of Autophagy on Sulindac
   Sulfide-Induced Colon Cancer Cell Apoptosis
SO GASTROENTEROLOGY RESEARCH AND PRACTICE
LA English
DT Article
ID BECLIN 1; SURVIVIN; NSAIDS; DEATH; INHIBITION; MECHANISM; MODEL
AB Autophagy is a catabolic process by which a cell degrades its intracellular materials to replenish itself. Induction of autophagy under various cellular stress stimuli can lead to either cell survival or cell death via apoptotic and/or autophagic (nonapoptotic) pathways. The NSAID sulindac sulfide induces apoptosis in colon cancer cells. Here, we show that inhibition of autophagy under serum-deprived conditions resulted in significant reductions of sulindac sulfide-induced apoptosis in HT-29 colon cancer cells. In contrast, inhibition of autophagy under conditions where serum is available significantly increased sulindac sulfide-induced apoptosis in HT-29 cells. We previously showed that the apoptosis inhibitor, survivin, plays a role in regulating NSAID-induced apoptosis and autophagic cell death. Here, we show that survivin protein half-life is increased in the presence of autophagy inhibitors under serum-deprived conditions, but not under conditions when serum is available. Thus, the increased levels of survivin may be a factor contributing to inhibition of sulindac sulfide-induced apoptosis under serum-deprived conditions. These results suggest that whether a cell lives or dies due to autophagy induction depends on the balance of factors that regulate both autophagic and apoptotic processes.
C1 [Chiou, Shiun-Kwei; Hoa, Neil; Ge, Lisheng; Jadus, Martin R.] Vet Affairs Med Ctr, Div Res, Long Beach, CA 90822 USA.
   [Chiou, Shiun-Kwei] Univ Calif Irvine, Dept Med, Orange, CA 92868 USA.
   [Jadus, Martin R.] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, UCI Pathol Dept, Irvine, CA 92697 USA.
   [Jadus, Martin R.] Univ Calif Irvine, UC Irvine Sch Med, Chao Comprehens Canc Ctr, Neurooncol Program, Orange, CA 92868 USA.
RP Chiou, SK (corresponding author), Vet Affairs Med Ctr, Div Res, 5901 E 7th St, Long Beach, CA 90822 USA.
EM shiun-kwei.chiou@va.gov
FU VA Merit Review awardUS Department of Veterans Affairs; SCIRE small
   grant
FX This work was funded by the VA Merit Review award, and the SCIRE small
   grant to S.-K. Chiou.
CR Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Bauvy C, 2001, EXP CELL RES, V268, P139, DOI 10.1006/excr.2001.5285
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Chiou SK, 2007, BIOCHEM PHARMACOL, V74, P1485, DOI 10.1016/j.bcp.2007.07.024
   Chiou SK, 2011, BIOCHEM PHARMACOL, V81, P1317, DOI 10.1016/j.bcp.2011.03.019
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   Debnath J, 2005, AUTOPHAGY, V1, P66, DOI 10.4161/auto.1.2.1738
   Gump JM, 2011, TRENDS CELL BIOL, V21, P387, DOI 10.1016/j.tcb.2011.03.007
   Gupta A, 2010, P NATL ACAD SCI USA, V107, P14333, DOI 10.1073/pnas.1000248107
   Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Kuma A, 2002, J BIOL CHEM, V277, P18619, DOI 10.1074/jbc.M111889200
   Lepine S, 2011, J BIOL CHEM, V286, P44380, DOI 10.1074/jbc.M111.257519
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Mandayam S, 2007, APOPTOSIS, V12, P1109, DOI 10.1007/s10495-006-0011-2
   Mirzoeva OK, 2011, J MOL MED, V89, P877, DOI 10.1007/s00109-011-0774-y
   MORTIMORE GE, 1987, ANNU REV NUTR, V7, P539, DOI 10.1146/annurev.nu.07.070187.002543
   Niu TK, 2010, FEBS LETT, V584, P3519, DOI 10.1016/j.febslet.2010.07.018
   Pattingre S, 2008, BIOCHIMIE, V90, P313, DOI 10.1016/j.biochi.2007.08.014
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Saiki S, 2011, AUTOPHAGY, V7, P176, DOI 10.4161/auto.7.2.14074
   Tanida I, 2004, J BIOL CHEM, V279, P47704, DOI 10.1074/jbc.M407016200
   Thorburn A, 2008, APOPTOSIS, V13, P1, DOI 10.1007/s10495-007-0154-9
   Zhang T, 2004, J PHARMACOL EXP THER, V308, P434, DOI 10.1124/jpet.103.059378
NR 27
TC 2
Z9 2
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687-6121
EI 1687-630X
J9 GASTROENT RES PRACT
JI Gastroenterol. Res. Pract.
PY 2012
VL 2012
AR 897678
DI 10.1155/2012/897678
PG 9
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 054AS
UT WOS:000312317000001
PM 23431290
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Thyagarajan, A
   Jedinak, A
   Nguyen, H
   Terry, C
   Baldridge, LA
   Jiang, JH
   Sliva, D
AF Thyagarajan, Anita
   Jedinak, Andrej
   Nguyen, Hai
   Terry, Colin
   Baldridge, Lee Ann
   Jiang, Jiahua
   Sliva, Daniel
TI Triterpenes From Ganoderma Lucidum Induce Autophagy in Colon Cancer
   Through the Inhibition of p38 Mitogen-Activated Kinase (p38 MAPK)
SO NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
LA English
DT Article
ID WATER-SOLUBLE EXTRACT; CELL-CYCLE ARREST; REI-SHI MYCELIA; HUMAN BREAST;
   POLYSACCHARIDES ENHANCE; CULTURED MEDIUM; LUNG-CANCER; TUMOR-CELLS;
   APOPTOSIS; MUSHROOM
AB Medicinal mushroom Ganoderma lucidum is one of the most esteemed natural products that have been used in the traditional Chinese medicine. In this article, we demonstrate that G. lucidum triterpene extract (GLT) suppresses proliferation of human colon cancer cells HT-29 and inhibits tumor growth in a xenograft model of colon cancer. These effects of GLT are associated with the cell cycle arrest at G0/G1 and the induction of the programmed cell death Type II-autophagy in colon cancer cells. Here, we show that GLT induces formation of autophagic vacuoles and upregulates expression of Beclin-1 (1.3-fold increase) and LC-3 (7.3-fold increase) proteins in colon cancer cells and in tumors in a xenograft model (Beclin-1, 3.9-fold increase; LC-3, 1.9-fold increase). Autophagy is mediated through the inhibition of p38 mitogen-activated protein kinase (p38 MAPK) because p38 MAPK inhibitor, SB202190, induces autophagy and expression of Beclin-1 (1.2-fold increase) and LC-3 (7.4-fold increase), and GLT suppresses phosphorylation of p38 MAPK (approximate to 60% inhibition) in colon cancer cells. Taken together, our data demonstrate a novel mechanism responsible for the inhibition of colon cancer cells by G. lucidum and suggest GLT as natural product for the treatment of colon cancer.
C1 [Sliva, Daniel] Methodist Res Inst, Canc Res Lab, Indianapolis, IN 46202 USA.
   [Baldridge, Lee Ann; Sliva, Daniel] Indiana Univ, Sch Med, Indianapolis, IN USA.
RP Sliva, D (corresponding author), Methodist Res Inst, Canc Res Lab, 1800 N Capitol Ave,E504, Indianapolis, IN 46202 USA.
EM dsliva@clarian.org
RI Jedinak, Andrej/AAB-7354-2020
FU Methodist Research Institute, Clarian Health, Inc.
FX This work was supported by the Methodist Research Institute, Clarian
   Health, Inc. We thank Shailesh Dudhgaonkar for his help with animal
   experiments.
CR CHANG AW, 1999, INT J MED MUSHROOMS, V1, P139
   Cheung KL, 2008, AAPS J, V10, P277, DOI 10.1208/s12248-008-9032-9
   Comes F, 2007, CELL DEATH DIFFER, V14, P693, DOI 10.1038/sj.cdd.4402076
   Ellington AA, 2006, CARCINOGENESIS, V27, P298, DOI 10.1093/carcin/bgi214
   Ellington AA, 2005, CARCINOGENESIS, V26, P159, DOI 10.1093/carcin/bgh297
   Gao JJ, 2002, CHEM PHARM BULL, V50, P837, DOI 10.1248/cpb.50.837
   Gao YH, 2005, J MED FOOD, V8, P159, DOI 10.1089/jmf.2005.8.159
   Gao YH, 2003, FOOD REV INT, V19, P275, DOI 10.1081/FRI-120023480
   Hong KJ, 2004, PHYTOTHER RES, V18, P768, DOI 10.1002/ptr.1495
   Hsu CL, 2008, J AGR FOOD CHEM, V56, P3973, DOI 10.1021/jf800006u
   Hu HB, 2002, INT J CANCER, V102, P250, DOI 10.1002/ijc.10707
   Hua KF, 2007, J CELL PHYSIOL, V212, P537, DOI 10.1002/jcp.21050
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Jiang JH, 2004, NUTR CANCER, V49, P209, DOI 10.1207/s15327914nc4902_13
   Jiang JH, 2004, INT J ONCOL, V24, P1093
   Jiang JH, 2006, INT J ONCOL, V29, P695
   Kim HJ, 2002, INT J CANCER, V97, P531, DOI 10.1002/ijc.10111
   Kirkegaard K, 2004, NAT REV MICROBIOL, V2, P301, DOI 10.1038/nrmicro865
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Lee S, 1998, PLANTA MED, V64, P303, DOI 10.1055/s-2006-957439
   Li CJ, 2006, NAT PROD RES, V20, P985, DOI 10.1080/14786410600921466
   Li CH, 2005, LIFE SCI, V77, P252, DOI 10.1016/j.lfs.2004.09.045
   Li CJ, 2005, NAT PROD RES, V19, P461, DOI 10.1080/14786410412331272077
   Li EK, 2007, ARTHRIT RHEUM-ARTHR, V57, P1143, DOI 10.1002/art.22994
   LIEU CW, 1992, ANTICANCER RES, V12, P1211
   LIN CN, 1991, J NAT PROD, V54, P998, DOI 10.1021/np50076a012
   Lin KI, 2006, J BIOL CHEM, V281, P24111, DOI 10.1074/jbc.M601106200
   Lin ZB, 2005, J PHARMACOL SCI, V99, P144, DOI 10.1254/jphs.CRJ05008X
   Liu J, 2006, BIOL PHARM BULL, V29, P392, DOI 10.1248/bpb.29.392
   Lu HM, 2003, ONCOL REP, V10, P375
   Lu HM, 2002, INT J MOL MED, V9, P113
   LUI B, 2008, CANC LETT
   Ma JY, 2002, J NAT PROD, V65, P72, DOI 10.1021/np010385e
   Min BS, 2000, CHEM PHARM BULL, V48, P1026
   Muller CI, 2006, LEUKEMIA RES, V30, P841, DOI 10.1016/j.leukres.2005.12.004
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Singletary K, 2008, CANCER EPIDEM BIOMAR, V17, P1596, DOI 10.1158/1055-9965.EPI-07-2917
   Sliva D, 2003, J ALTERN COMPLEM MED, V9, P491, DOI 10.1089/107555303322284776
   Sliva D, 2001, CANCER INVEST, V19, P783, DOI 10.1081/CNV-100107739
   Stanley G, 2005, BIOCHEM BIOPH RES CO, V330, P46, DOI 10.1016/j.bbrc.2005.02.116
   Tang GM, 2008, HUM MOL GENET, V17, P1540, DOI 10.1093/hmg/ddn042
   Tang W, 2006, LIFE SCI, V80, P205, DOI 10.1016/j.lfs.2006.09.001
   Thyagarajan A, 2006, INT J MOL MED, V18, P657
   TOTH JO, 1983, TETRAHEDRON LETT, V24, P1081
   Wachtel-Galor S, 2004, BRIT J NUTR, V91, P263, DOI 10.1079/BJN20041039
   Wang SY, 1997, INT J CANCER, V70, P699, DOI 10.1002/(SICI)1097-0215(19970317)70:6&lt;699::AID-IJC12&gt;3.0.CO;2-5
   Wasser SP, 2005, ENCY DIETARY SUPPLEM, P603
   World Cancer Research Fund and American Institute for Cancer Rsearch, 2007, FOOD NUTR PHYS ACT P
   Wu TS, 2001, J NAT PROD, V64, P1121, DOI 10.1021/np010115w
   Xu ZX, 2007, CELL DEATH DIFFER, V14, P1948, DOI 10.1038/sj.cdd.4402207
   Yuen JWM, 2008, NUTR CANCER, V60, P109, DOI 10.1080/01635580701525869
   Zhu M, 1999, PHYTOTHER RES, V13, P529, DOI 10.1002/(SICI)1099-1573(199909)13:6&lt;529::AID-PTR481&gt;3.0.CO;2-X
   Zhu XL, 2007, J ETHNOPHARMACOL, V111, P219, DOI 10.1016/j.jep.2006.11.013
NR 54
TC 87
Z9 101
U1 5
U2 37
PU LAWRENCE ERLBAUM ASSOC INC-TAYLOR & FRANCIS
PI PHILADELPHIA
PA 325 CHESTNUT STREET, STE 800, PHILADELPHIA, PA 19106 USA
SN 0163-5581
J9 NUTR CANCER
JI Nutr. Cancer
PY 2010
VL 62
IS 5
BP 630
EP 640
AR PII 923265873
DI 10.1080/01635580903532390
PG 11
WC Oncology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Nutrition & Dietetics
GA 615FS
UT WOS:000279120100009
PM 20574924
DA 2022-04-25
ER

PT J
AU Liu, J
   Long, SY
   Wang, HN
   Liu, NN
   Zhang, CC
   Zhang, LL
   Zhang, YJ
AF Liu, Jing
   Long, Shuaiyu
   Wang, Huanan
   Liu, Nannan
   Zhang, Chuchu
   Zhang, Lingling
   Zhang, Yingjie
TI Blocking AMPK/ULK1-dependent autophagy promoted apoptosis and suppressed
   colon cancer growth
SO CANCER CELL INTERNATIONAL
LA English
DT Article
DE Colon cancer; Autophagy; Apoptosis; NVP-BEZ235; CQ
ID ADVANCED SOLID TUMORS; PHASE-I TRIAL; COLORECTAL-CANCER; MTOR; AMPK;
   NVP-BEZ235; INHIBITOR; PATHWAY; CELLS; HYDROXYCHLOROQUINE
AB Background Autophagy is an evolutionarily conserved process through which cells degrade and recycle cytoplasm. The relation among autophagy, apoptosis and tumor is highly controversial until now and the molecular mechanism is poorly understood. Methods Cell viability and apoptosis were detected by CCK8, crystal violet staining, Hoechst333342 staining and flow cytometry. The expression of AMPK and ULK1 was analyzed by western blotting. Colon cancer growth suppression by NVP-BEZ235 or CQ in vivo was studied in a tumor xenograft mouse model. Results Our previous study revealed that NVP-BEZ235 suppressed colorectal cancer growth via inducing apoptosis, however later, we found it also initiated autophagy simultaneously. In this present study, our results show that NVP-BEZ235 induced autophagy through AMPK/ULK1 pathway in colon cancer cells. Blocking autophagy by knocking down AMPK or ULK1 inhibited cell proliferation and further promoted NVP-BEZ235 induced apoptosis. Meantime, the autophagy inhibitor chloroquine (CQ) shows obvious effect on inhibiting cell proliferation but not on inducing apoptosis, while it significantly increased NVP-BEZ235 induced apoptosis. Furthermore, the combinational therapy of NVP-BEZ235 and CQ shows synergistic antitumor effects in colon cancer in vivo. Conclusion NVP-BEZ235 induced AMPK/ULK1-dependent autophagy. Targeting this autophagy suppressed colon cancer growth through further promoting apoptosis, which is a potential therapeutic option for clinical patients.
C1 [Liu, Jing; Long, Shuaiyu; Liu, Nannan; Zhang, Chuchu; Zhang, Yingjie] Hunan Univ, Coll Biol, Changsha 410082, Hunan, Peoples R China.
   [Wang, Huanan; Zhang, Lingling] Cent S Univ, Xiangya Hosp 3, Dept Lab Med, Changsha 410013, Peoples R China.
   [Wang, Huanan] Zhejiang Univ, Coll Anim Sci, Dept Vet Med, Hangzhou, Peoples R China.
   [Zhang, Yingjie] Hunan Univ, Shenzhen Inst, Shenzhen, Peoples R China.
RP Zhang, YJ (corresponding author), Hunan Univ, Coll Biol, Changsha 410082, Hunan, Peoples R China.; Zhang, YJ (corresponding author), Hunan Univ, Shenzhen Inst, Shenzhen, Peoples R China.
EM yingjiezhang@hnu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31801140, 31701132, 31602118]; Basic
   Research Program of Shenzhen Municipal Science and Technology Innovation
   Committee [JCYJ20160530192802733]; Fundamental Research Funds for the
   Central South Universities [531118040098, 14700-502044001]; College of
   Biology, Hunan University
FX We would like to thank the support of the National Natural Science
   Foundation of China (31801140, 31701132 and 31602118), the Basic
   Research Program of Shenzhen Municipal Science and Technology Innovation
   Committee (JCYJ20160530192802733), the Fundamental Research Funds for
   the Central South Universities (Nos. 531118040098 and 14700-502044001),
   and the start funds from College of Biology, Hunan University.
CR Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Chen PJ, 2017, FREE RADICAL BIO MED, V104, P280, DOI 10.1016/j.freeradbiomed.2017.01.033
   Dienstmann R, 2014, MOL CANCER THER, V13, P1021, DOI 10.1158/1535-7163.MCT-13-0639
   Gordy C, 2012, PROTEIN CELL, V3, P17, DOI 10.1007/s13238-011-1127-x
   Hardie DG, 2015, CURR OPIN CELL BIOL, V33, P1, DOI 10.1016/j.ceb.2014.09.004
   Hardie DG, 2014, CELL METAB, V20, P939, DOI 10.1016/j.cmet.2014.09.013
   Herzig S, 2018, NAT REV MOL CELL BIO, V19, P121, DOI 10.1038/nrm.2017.95
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mei ZB, 2016, ANN ONCOL, V27, P1836, DOI 10.1093/annonc/mdw264
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Morgan MJ, 2018, P NATL ACAD SCI USA, V115, pE8479, DOI 10.1073/pnas.1706526115
   Ou BC, 2016, CANCER LETT, V380, P457, DOI 10.1016/j.canlet.2016.07.004
   Pan HT, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1653-7
   Rangwala R, 2014, AUTOPHAGY, V10, P1391, DOI 10.4161/auto.29119
   Rangwala R, 2014, AUTOPHAGY, V10, P1369, DOI 10.4161/auto.29118
   Salony, 2016, MOL CANCER THER, V15, P142, DOI 10.1158/1535-7163.MCT-15-0414
   Seitz C, 2013, INT J CANCER, V132, P2682, DOI 10.1002/ijc.27935
   Shang LB, 2011, AUTOPHAGY, V7, P924, DOI 10.4161/auto.7.8.15860
   Slattery ML, 2010, CARCINOGENESIS, V31, P1604, DOI 10.1093/carcin/bgq142
   Sun L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0943-9
   Thomas HE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003923
   Wang H, 2019, CANCER GENE THER, DOI [10.1038/s41417-019-0117, DOI 10.1038/S41417-019-0117]
   Wang HN, 2015, ONCOTARGET, V6, P14385, DOI 10.18632/oncotarget.3775
   Yang SY, 2009, TRENDS MOL MED, V15, P225, DOI 10.1016/j.molmed.2009.03.003
   Yu JSL, 2016, DEVELOPMENT, V143, P3050, DOI 10.1242/dev.137075
   Zheng XN, 2013, MOL CANCER THER, V12, P777, DOI 10.1158/1535-7163.MCT-12-1146
NR 31
TC 20
Z9 20
U1 6
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475-2867
J9 CANCER CELL INT
JI Cancer Cell Int.
PD DEC 13
PY 2019
VL 19
IS 1
AR 336
DI 10.1186/s12935-019-1054-0
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA KK3LN
UT WOS:000512647900001
PM 31871431
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Pajak, B
   Kania, E
   Gajkowska, B
   Orzechowski, A
AF Pajak, Beata
   Kania, Elzbieta
   Gajkowska, Barbara
   Orzechowski, Arkadiusz
TI Verapamil-induced autophagy-like process in colon adenocarcinoma COLO
   205 cells; the ultrastructural studies
SO PHARMACOLOGICAL REPORTS
LA English
DT Article
DE verapamil; autophagy; transmission electron microscopy; colon cancer;
   cell death
ID ENDOPLASMIC-RETICULUM STRESS; CANCER; PROTEIN; DEATH; PROTEASOME
AB Background: Verapamil (Ver) is a well known, worldwide used drug to correct cardiac arrhythmias. The main Ver target is the L-type calcium channel. Modulation of calcium homeostasis vaulted Ver into use in medical applications.
   Methods: To examine COLO 205 cells morphology after Ver treatment, an electron microscopy technique was used.
   Results: This study shows ultrastructural evidence that Ver initiates autophagy-like process in human colon adenocarcinoma COLO 205 cells. TEM photographs revealed the presence of differently developed autophagic vacuoles in response to Ver administration. Furthermore, extensive ultrastructural cell alterations confirmed that cancer cells died via necrosis or apoptosis, as demonstrated by ruptured plasma membrane or condensed chromatin, respectively.
   Conclusions: It is the evidence that apoptosis resistant COLO 205 cells are overruled by autophagy-like process. Autophagy-like cell death could be a promising venue to delete cancer cells. Ver appears to be a new potentially effective anticancer compound.
C1 [Pajak, Beata; Kania, Elzbieta; Gajkowska, Barbara; Orzechowski, Arkadiusz] Polish Acad Sci, Mossakowski Med Res Ctr, PL-02105 Warsaw, Poland.
   [Orzechowski, Arkadiusz] Warsaw Univ Life Sci SGGW, Fac Vet Med, Dept Physiol Sci, PL-02776 Warsaw, Poland.
RP Pajak, B (corresponding author), Polish Acad Sci, Mossakowski Med Res Ctr, Pawinskiego 5, PL-02105 Warsaw, Poland.
EM bepaj@wp.pl
OI Pajak, Beata/0000-0002-3565-8860
FU Ministry of Science and Higher Education in PolandMinistry of Science
   and Higher Education, Poland [NN 401 031 538]; Ministry of Science and
   Higher Education For Young Outstanding Scientists in PolandMinistry of
   Science and Higher Education, Poland
FX Support for this work was provided by grant No. NN 401 031 538 from the
   Ministry of Science and Higher Education in Poland. Beata Pajak is
   granted by fellowship from the Ministry of Science and Higher Education
   For Young Outstanding Scientists in Poland.
CR Borges NCD, 2005, J CHROMATOGR B, V827, P165, DOI 10.1016/j.jchromb.2005.07.012
   Capiod T., 2007, V45, P405
   Chen X, 2002, J BIOL CHEM, V277, P13045, DOI 10.1074/jbc.M110636200
   Ding WX, 2008, AUTOPHAGY, V4, P141, DOI 10.4161/auto.5190
   Kuo TC, 2011, BIOCHEM PHARMACOL, V81, P1136, DOI 10.1016/j.bcp.2011.02.013
   Loza J, 1995, BONE S4, V16, p314S
   Malhotra JD, 2007, ANTIOXID REDOX SIGN, V9, P2277, DOI 10.1089/ars.2007.1782
   Meister S, 2010, NEOPLASIA, V12, P550, DOI 10.1593/neo.10228
   Notte A, 2011, BIOCHEM PHARMACOL, V82, P427, DOI 10.1016/j.bcp.2011.06.015
   Pajak B, 2007, ANTI-CANCER DRUG, V18, P55, DOI 10.1097/CAD.0b013e32800fee9e
   Pajak Beata, 2004, Postepy Hig Med Dosw (Online), V58, P428
   Sun Y, 2009, POSTGRAD MED J, V85, P134, DOI 10.1136/pgmj.2008.072629
   Suwalsky M, 2010, J CHIL CHEM SOC, V55, P1, DOI 10.4067/S0717-97072010000100002
   Ugocsai K, 2005, IN VIVO, V19, P433
   Wagner-Souza K, 2008, INT J MOL MED, V22, P237, DOI 10.3892/ijmm_00000014
   Wang XT, 2000, AM J PATHOL, V157, P1549, DOI 10.1016/S0002-9440(10)64792-X
   Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203
NR 17
TC 14
Z9 14
U1 0
U2 4
PU POLISH ACAD SCIENCES INST PHARMACOLOGY
PI KRAKOW
PA SMETNA 12, 31-343 KRAKOW, POLAND
SN 1734-1140
J9 PHARMACOL REP
JI Pharmacol. Rep.
PD JUL-AUG
PY 2012
VL 64
IS 4
BP 991
EP 996
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 028KF
UT WOS:000310420500024
PM 23087153
DA 2022-04-25
ER

PT J
AU An, CH
   Kim, MS
   Yoo, NJ
   Park, SW
   Lee, SH
AF An, Chang Hyeok
   Kim, Min Sung
   Yoo, Nam Jin
   Park, Sang Wook
   Lee, Sug Hyung
TI Mutational and expressional analyses of ATG5, an autophagy-related gene,
   in gastrointestinal cancers
SO PATHOLOGY RESEARCH AND PRACTICE
LA English
DT Article
DE ATG5; Autophagy; Mutation; Expression; Cancer
ID INACTIVATING MUTATIONS; MICROSATELLITE INSTABILITY; APOPTOSIS; DEATH;
   CARCINOMAS; NECROSIS; ROLES
AB There is mounting evidence that alterations of cell death processes are involved in cancer pathogenesis. ATG5 is a key regulator of autophagic and apoptotic cell death. The aim of this study was to see whether alterations of ATG5 protein expression and somatic mutation of ATG5 gene are features of human gastrointestinal cancers. In this study, we analyzed ATG5 somatic mutation in 45 gastric, 45 colorectal, and 45 hepatocellular carcinomas by single-strand conformation polymorphism (SSCP). Also, we analyzed ATG5 protein expression in 100 gastric, as well as in 95 colorectal and hepatocellular carcinomas using immunohistochemistry. Overall, we detected two somatic missense mutations of ATG5 gene in the coding sequences p.Leu112Phe and p.His41Tyr. The mutations were observed in one gastric and one hepatocellular carcinoma. Immunohistochemically, ATG5 protein was well expressed in normal stomach, colon, and liver epithelial cells, while it was lost in 21 (21%) of the gastric carcinomas, in 22 (23%) of the colorectal carcinomas, and in 5 (10%) of the hepatocellular carcinomas. Our data suggest that ATG5 gene could be altered in gastrointestinal cancers at the mutational or expressional level. Despite the low incidences of the alterations, our data led us to conclude that somatic mutation and loss of expression of ATG5 gene might play a role in gastrointestinal cancer pathogenesis by altering autophagic and apoptotic cell death. (C) 2011 Elsevier GmbH. All rights reserved.
C1 [Kim, Min Sung; Yoo, Nam Jin; Park, Sang Wook; Lee, Sug Hyung] Catholic Univ Korea, Coll Med, Dept Pathol, Seoul, South Korea.
   [An, Chang Hyeok] Catholic Univ Korea, Coll Med, Dept Gen Surg, Seoul, South Korea.
RP Lee, SH (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, Seoul, South Korea.
EM suhulee@catholic.ac.kr
FU National Research Foundation of KoreaNational Research Foundation of
   Korea [2009-007-1498]
FX This study was supported by a grant from National Research Foundation of
   Korea (2009-007-1498).
CR Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011
   Hammond EM, 1998, FEBS LETT, V425, P391, DOI 10.1016/S0014-5793(98)00266-X
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509
   Kim HS, 2003, GASTROENTEROLOGY, V125, P708, DOI 10.1016/S0016-5085(03)01059-X
   Kim MS, 2008, HUM PATHOL, V39, P1059, DOI 10.1016/j.humpath.2007.11.013
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Lee JW, 2007, APMIS, V115, P750, DOI 10.1111/j.1600-0463.2007.apm_640.x
   Lee JW, 2004, CARCINOGENESIS, V25, P1371, DOI 10.1093/carcin/bgh145
   Lee SH, 1999, ONCOGENE, V18, P3754, DOI 10.1038/sj.onc.1202769
   LEITHAUSER F, 1993, LAB INVEST, V69, P415
   MARX J, 2001, HUM PATHOL, V32, P461
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Pyo JO, 2005, J BIOL CHEM, V280, P20722, DOI 10.1074/jbc.M413934200
   Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7
   Shin MS, 2002, BLOOD, V99, P4094, DOI 10.1182/blood.V99.11.4094
   Tanida I, 2002, J BIOL CHEM, V277, P13739, DOI 10.1074/jbc.M200385200
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
NR 21
TC 54
Z9 59
U1 0
U2 11
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0344-0338
J9 PATHOL RES PRACT
JI Pathol. Res. Pract.
PY 2011
VL 207
IS 7
BP 433
EP 437
DI 10.1016/j.prp.2011.05.002
PG 5
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 802GJ
UT WOS:000293497000006
PM 21664058
DA 2022-04-25
ER

PT J
AU Salesse, L
   Lucas, C
   Hoang, MHT
   Sauvanet, P
   Rezard, A
   Rosenstiel, P
   Damon-Soubeyrand, C
   Barnich, N
   Godfraind, C
   Dalmasso, G
   Nguyen, HTT
AF Salesse, Laurene
   Lucas, Cecily
   Hoang, My Hanh Thi
   Sauvanet, Pierre
   Rezard, Alexandra
   Rosenstiel, Philip
   Damon-Soubeyrand, Christelle
   Barnich, Nicolas
   Godfraind, Catherine
   Dalmasso, Guillaume
   Nguyen, Hang Thi Thu
TI Colibactin-Producing Escherichia coli Induce the Formation of Invasive
   Carcinomas in a Chronic Inflammation-Associated Mouse Model
SO CANCERS
LA English
DT Article
DE colorectal cancer; microbiota; colibactin-producing E; coli; autophagy;
   toxin
ID AUTOPHAGY-RELATED SIGNATURE; COLORECTAL-CANCER; TUMOR-GROWTH;
   MICROBIOTA; CARCINOGENESIS; IDENTIFICATION; GENES; GUT
AB Simple Summary
   Changes in the composition of the intestinal flora have been reported in patients with colorectal cancer, the second leading cause of cancer death in the world, with an increase in so-called "harmful" bacteria. Among these, Escherichia coli producing colibactin, a toxin that causes DNA damage, has attracted the interest of many research groups. Here, we showed that infection of wild-type mice with a colibactin-producing E. coli (CoPEC) strain, isolated from a patient with colorectal cancer, combined with chronic inflammation induced the formation of invasive colonic tumors, i.e., tumors that spread beyond epithelial layer and grow into surrounding tissues. We also showed that autophagy, a cell defense process, is necessary to inhibit the tumorigenesis induced by CoPEC. Thus, this work highlights the role of CoPEC as a driver of colorectal cancer development, and suggests that targeting autophagy could be a promising strategy to inhibit the protumoral effects of these bacteria.
   Background: Escherichia coli producing the genotoxin colibactin (CoPEC or colibactin-producing E. coli) abnormally colonize the colonic mucosa of colorectal cancer (CRC) patients. We previously showed that deficiency of autophagy in intestinal epithelial cells (IECs) enhances CoPEC-induced colorectal carcinogenesis in Apc(Min/+) mice. Here, we tested if CoPEC trigger tumorigenesis in a mouse model lacking genetic susceptibility or the use of carcinogen. Methods: Mice with autophagy deficiency in IECs (Atg16l1( increment IEC)) or wild-type mice (Atg16l1(flox/flox)) were infected with the CoPEC 11G5 strain or the mutant 11G5 increment clbQ incapable of producing colibactin and subjected to 12 cycles of DSS treatment to induce chronic colitis. Mouse colons were used for histological assessment, immunohistochemical and immunoblot analyses for DNA damage marker. Results: 11G5 or 11G5 increment clbQ infection increased clinical and histological inflammation scores, and these were further enhanced by IEC-specific autophagy deficiency. 11G5 infection, but not 11G5 increment clbQ infection, triggered the formation of invasive carcinomas, and this was further increased by autophagy deficiency. The increase in invasive carcinomas was correlated with enhanced DNA damage and independent of inflammation. Conclusions: CoPEC induce colorectal carcinogenesis in a CRC mouse model lacking genetic susceptibility and carcinogen. This work highlights the role of (i) CoPEC as a driver of CRC development, and (ii) autophagy in inhibiting the carcinogenic properties of CoPEC.
C1 [Salesse, Laurene; Lucas, Cecily; Hoang, My Hanh Thi; Sauvanet, Pierre; Rezard, Alexandra; Barnich, Nicolas; Godfraind, Catherine; Dalmasso, Guillaume; Nguyen, Hang Thi Thu] Univ Clermont Auvergne, M2iSH, UMR 1071 Inserm, INRAE USC 2018,CRNH, F-63001 Clermont Ferrand, France.
   [Hoang, My Hanh Thi] Vietnam Natl Univ VNU, Univ Sci, Dept Cell Biol, Fac Biol, Hanoi 100000, Vietnam.
   [Sauvanet, Pierre] CHU Estaing, Dept Digest & Hepatobiliary Surg, F-63001 Clermont Ferrand, France.
   [Rosenstiel, Philip] Univ Kiel, Inst Clin Mol Biol, D-24148 Kiel, Germany.
   [Rosenstiel, Philip] Univ Hosp Schleswig Holstein, D-24148 Kiel, Germany.
   [Damon-Soubeyrand, Christelle] Univ Clermont Auvergne, CNRS UMR 6293 INSERM U110, GReD, F-63001 Clermont Ferrand, France.
   [Godfraind, Catherine] CHU Gabriel Montpied, Dept Pathol, F-63001 Clermont Ferrand, France.
RP Nguyen, HTT (corresponding author), Univ Clermont Auvergne, M2iSH, UMR 1071 Inserm, INRAE USC 2018,CRNH, F-63001 Clermont Ferrand, France.
EM laurene.salesse@uca.fr; cecily.lucas@uca.fr; thi_my_hanh.hoang@uca.fr;
   pierre.sauvanet@uca.fr; alexandra.rezard@uca.fr; p.rosenstiel@mucosa.de;
   christelle.soubeyrand-damon@uca.fr; nicolas.barnich@uca.fr;
   cgodfraind@chu-clermontferrand.fr; guillaume.dalmasso@uca.fr;
   hang.nguyen@uca.fr
RI Nguyen, Hang/N-2441-2018
OI Nguyen, Hang/0000-0001-7431-5126; Lucas, Cecily/0000-0002-4276-723X
FU Ministere de la Recherche et de la Technologie, Inserm (Institut
   national de la sante et de la recherche medicale) [UMR1071]; Agence
   Nationale de la Recherche of the French government through the program
   "Investissements d'Avenir"French National Research Agency (ANR)
   [16-IDEX-0001 I-SITE CAP 20-25]; European Union FP7 People Marie Curie
   International Incoming Fellowship; DFG (Deutsche Forschungsgemeinschaft)
   ExC Precision Medicine in Chronic InflammationGerman Research Foundation
   (DFG); INRAE (Institut national de recherche en agriculture,
   alimentation et environnement; USC 2018)
FX This research was funded by the Ministere de la Recherche et de la
   Technologie, Inserm (Institut national de la sante et de la recherche
   medicale; UMR1071), INRAE (Institut national de recherche en
   agriculture, alimentation et environnement; USC 2018), the Agence
   Nationale de la Recherche of the French government through the program
   "Investissements d'Avenir" (16-IDEX-0001 I-SITE CAP 20-25) (to Hang
   Nguyen), the European Union FP7 People Marie Curie International
   Incoming Fellowship (to Hang Nguyen) and the DFG (Deutsche
   Forschungsgemeinschaft) ExC Precision Medicine in Chronic Inflammation
   and the CRC1182 project C2 (to Philip Rosenstiel).
CR Arthur JC, 2012, SCIENCE, V338, P120, DOI 10.1126/science.1224820
   Bonnet M, 2014, CLIN CANCER RES, V20, P859, DOI 10.1158/1078-0432.CCR-13-1343
   Bossuet-Greif N, 2018, MBIO, V9, DOI 10.1128/mBio.02393-17
   Bretin A, 2016, AUTOPHAGY, V12, P770, DOI 10.1080/15548627.2016.1156823
   Buc E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056964
   Cao YJ, 2019, CLIN CHIM ACTA, V489, P10, DOI 10.1016/j.cca.2018.11.028
   Cougnoux A, 2014, GUT, V63, P1932, DOI 10.1136/gutjnl-2013-305257
   Cuevas-Ramos G, 2010, P NATL ACAD SCI USA, V107, P11537, DOI 10.1073/pnas.1001261107
   Dejea CM, 2018, SCIENCE, V359, P592, DOI 10.1126/science.aah3648
   Grivennikov SI, 2013, SEMIN IMMUNOPATHOL, V35, P229, DOI 10.1007/s00281-012-0352-6
   Nguyen HTT, 2014, GASTROENTEROLOGY, V146, P508, DOI 10.1053/j.gastro.2013.10.021
   Haruki K, 2020, J PATHOL, V250, P397, DOI 10.1002/path.5381
   Hu DX, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02323-x
   Huang Z, 2019, DOSE-RESPONSE, V17, DOI 10.1177/1559325819894179
   Iyadorai T, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228217
   Kliosnky D, 2016, AUTOPHAGY, V12, P443, DOI 10.1080/15548627.2016.1147886
   Larabi A, 2020, AUTOPHAGY, V16, P38, DOI 10.1080/15548627.2019.1635384
   Lee JG, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226907
   Levine B, 2019, CELL, V176, P11, DOI 10.1016/j.cell.2018.09.048
   Li L, 2019, EBIOMEDICINE, V48, P301, DOI 10.1016/j.ebiom.2019.09.021
   Li YH, 2012, CARCINOGENESIS, V33, P1231, DOI 10.1093/carcin/bgs137
   Liu Y, 2019, AGING-US, V11, P11440, DOI 10.18632/aging.102544
   Lucas C, 2020, GASTROENTEROLOGY, V158, P1373, DOI 10.1053/j.gastro.2019.12.026
   Lucas C, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061310
   Matsuzawa-Ishimoto Y, 2017, J EXP MED, V214, P3687, DOI 10.1084/jem.20170558
   Mattiuzzi C, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.07.91
   MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722
   Nougayrede JP, 2006, SCIENCE, V313, P848, DOI 10.1126/science.1127059
   Pleguezuelos-Manzano C, 2020, NATURE, V580, P269, DOI 10.1038/s41586-020-2080-8
   Quach C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13475-w
   Rothkamm K, 2015, ENVIRON MOL MUTAGEN, V56, P491, DOI 10.1002/em.21944
   Tanaka T, 2003, CANCER SCI, V94, P965, DOI 10.1111/j.1349-7006.2003.tb01386.x
   Thomas AM, 2019, NAT MED, V25, P667, DOI 10.1038/s41591-019-0405-7
   Tomkovich S, 2017, CANCER RES, V77, P2620, DOI 10.1158/0008-5472.CAN-16-3472
   Wang SS, 2019, ONCOTARGETS THER, V12, P3695, DOI 10.2147/OTT.S197676
   Wilson MR, 2019, SCIENCE, V363, P709, DOI 10.1126/science.aar7785
   Wirbel J, 2019, NAT MED, V25, P679, DOI 10.1038/s41591-019-0406-6
   Wong SH, 2017, GASTROENTEROLOGY, V153, P1621, DOI 10.1053/j.gastro.2017.08.022
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Yue PP, 2020, BIOMED PHARMACOTHER, V126, DOI 10.1016/j.biopha.2020.110080
   Zhao YG, 2019, CURR OPIN CELL BIOL, V61, P117, DOI 10.1016/j.ceb.2019.08.003
NR 41
TC 5
Z9 5
U1 1
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD MAY
PY 2021
VL 13
IS 9
AR 2060
DI 10.3390/cancers13092060
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA SB3UB
UT WOS:000649922600001
PM 33923277
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Che, J
   Wang, WS
   Huang, Y
   Zhang, L
   Zhao, J
   Zhang, P
   Yuan, XL
AF Che, Jing
   Wang, Wenshan
   Huang, Yu
   Zhang, Lu
   Zhao, Jing
   Zhang, Peng
   Yuan, Xianglin
TI miR-20a inhibits hypoxia-induced autophagy by targeting ATG5/FIP200 in
   colorectal cancer
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE ATG5; autophagy; colorectal cancer; FIP200; hypoxia; miR-20a
ID COLON-CANCER; REGULATES AUTOPHAGY; BREAST-CANCER; MICROENVIRONMENT;
   CONTRIBUTES; METASTASIS; MACHINERY; FIP200; PROGRESSION; STARVATION
AB Autophagy is a highly conserved lysosome-mediated protective cellular process in which cytosolic components, including damaged organelles and long-lived proteins, are cleared. Many studies have shown that autophagy was upregulated in hypoxic regions. However, the precise molecular mechanism of hypoxia-induced autophagy in colorectal cancer (CRC) is still elusive. In this study, we found that miR-20a was significantly downregulated under hypoxia in colon cancer cells, and overexpression of miR-20a alleviated hypoxia-induced autophagy. Moreover, miR-20a inhibits the hypoxia-induced autophagic flux by targeting multiple key regulators of autophagy, including ATG5 and FIP200. Furthermore, by dual-luciferase assay we demonstrated that miR-20a directly targeted the 3 '-untranslated region of ATG5 and FIP200, regulating their messenger RNA and protein levels. In addition, reintroduction of exogenous ATG5 or FIP200 partially reversed miR-20a-mediated autophagy inhibition under hypoxia. A negative correlation between miR-20a and its target genes is observed in the hypoxic region of colon cancer tissues. Taken together, our findings suggest that hypoxia-mediated autophagy was regulated by miR-20a/ATG5/FI200 signaling pathway in CRC. miR-20a-mediated autophagy defect that might play an important role in hypoxia-induced autophagy during colorectal tumorigenesis.
C1 [Che, Jing; Huang, Yu; Zhang, Lu; Zhao, Jing; Zhang, Peng; Yuan, Xianglin] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China.
   [Che, Jing] Wuhan Univ, Coll Life Sci, Natl Demonstrat Ctr Expt Biol, Wuhan, Hubei, Peoples R China.
   [Wang, Wenshan] Univ Penn, Dept Cell & Dev Biol, Inst Diabet Obes & Metab, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Zhang, P (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China.
EM pengzhang@tjh.tjmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81202095, 81441087]
FX National Natural Science Foundation of China, Grant/Award Numbers:
   81202095, 81441087
CR Azab AK, 2012, BLOOD, V119, P5782, DOI 10.1182/blood-2011-09-380410
   Bracken CP, 2016, NAT REV GENET, V17, P719, DOI 10.1038/nrg.2016.134
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Caporarello N, 2017, MOL MED REP, V16, P4393, DOI 10.3892/mmr.2017.7179
   Chen DP, 2018, AUTOPHAGY, V14, P1335, DOI 10.1080/15548627.2018.1474994
   Chen HY, 2012, CANCER RES, V72, P3631, DOI 10.1158/0008-5472.CAN-12-0667
   Chen JQ, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0085161, 10.1371/journal.pone.0101277]
   Chen R, 2018, APOPTOSIS, V23, P459, DOI 10.1007/s10495-018-1477-4
   Conkrite K, 2011, GENE DEV, V25, P1734, DOI 10.1101/gad.17027411
   Fakih MG, 2015, J CLIN ONCOL, V33, P1809, DOI 10.1200/JCO.2014.59.7633
   Feng YC, 2014, CELL RES, V24, P24, DOI 10.1038/cr.2013.168
   Frankel LB, 2011, EMBO J, V30, P4628, DOI 10.1038/emboj.2011.331
   Fukumura D, 2007, J CELL BIOCHEM, V101, P937, DOI 10.1002/jcb.21187
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Gebert LFR, 2019, NAT REV MOL CELL BIO, V20, P21, DOI 10.1038/s41580-018-0045-7
   Gibson SB, 2012, J PATHOL, V228, P434, DOI 10.1002/path.4100
   Gu MJ, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/s12876-014-0193-y
   Guo JY, 2016, GENE DEV, V30, P1704, DOI 10.1101/gad.283416.116
   Guo WN, 2017, THERANOSTICS, V7, P2231, DOI 10.7150/thno.18835
   Gupta A, 2018, J BIOSCIENCES, V43, P739, DOI 10.1007/s12038-018-9789-7
   Hall DP, 2014, CANCER CELL, V26, P738, DOI 10.1016/j.ccell.2014.09.015
   Hanada T, 2007, J BIOL CHEM, V282, P37298, DOI 10.1074/jbc.C700195200
   Hara T, 2008, J CELL BIOL, V181, P497, DOI 10.1083/jcb.200712064
   Hase K, 2015, NUCLEIC ACIDS RES, V43, P6439, DOI 10.1093/nar/gkv579
   He M, 2013, CELL DEATH DIFFER, V20, P408, DOI 10.1038/cdd.2012.130
   Hoare M, 2011, SEMIN CANCER BIOL, V21, P397, DOI 10.1016/j.semcancer.2011.09.004
   Hongo K, 2013, J SURG RES, V182, P75, DOI 10.1016/j.jss.2012.08.034
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kim CW, 2018, CANCER LETT, V416, P31, DOI 10.1016/j.canlet.2017.12.018
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Kohlhapp FJ, 2015, ONCOGENE, V34, P5857, DOI 10.1038/onc.2015.89
   Korkmaz G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082556
   Korkmaz G, 2012, AUTOPHAGY, V8, P165, DOI 10.4161/auto.8.2.18351
   Koustas E, 2017, CANCER LETT, V396, P94, DOI 10.1016/j.canlet.2017.03.023
   Li SF, 2016, LIFE SCI, V147, P143, DOI 10.1016/j.lfs.2016.01.044
   Liu L, 2017, ONCOGENE, V36, P5874, DOI 10.1038/onc.2017.193
   Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863
   Ma XY, 2017, J BIOL CHEM, V292, P17046, DOI 10.1074/jbc.M117.805655
   Madanecki P, 2013, CELL MOL BIOL LETT, V18, P47, DOI 10.2478/s11658-012-0037-0
   Merlano M, 2016, ESMO OPEN, V1, DOI 10.1136/esmoopen-2016-000082
   Mogilyansky E, 2013, CELL DEATH DIFFER, V20, P1603, DOI 10.1038/cdd.2013.125
   Navratilova J, 2013, CHEMOTHERAPY, V59, P112, DOI 10.1159/000353915
   Nelson C, 2014, MOL CELL, V56, P376, DOI 10.1016/j.molcel.2014.09.011
   Park JK, 2016, J CELL BIOL, V215, P667, DOI 10.1083/jcb.201604032
   Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394
   Reggiori F, 2013, GENETICS, V194, P341, DOI 10.1534/genetics.112.149013
   Rouschop KMA, 2009, RADIOTHER ONCOL, V92, P411, DOI 10.1016/j.radonc.2009.06.029
   Rupaimoole R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6202
   Spowart JE, 2012, J PATHOL, V228, P437, DOI 10.1002/path.4090
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Sun KT, 2015, BONE, V73, P145, DOI 10.1016/j.bone.2014.11.026
   Taguchi A, 2008, CANCER RES, V68, P5540, DOI 10.1158/0008-5472.CAN-07-6460
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Tan Q, 2016, NEOPLASIA, V18, P347, DOI 10.1016/j.neo.2016.04.003
   Tekirdag KA, 2013, AUTOPHAGY, V9, P374, DOI 10.4161/auto.23117
   Wang F, 2016, SCI REP-UK, V6, DOI 10.1038/srep33229
   Wang IK, 2015, LIFE SCI, V136, P133, DOI 10.1016/j.lfs.2015.07.002
   Wang L, 2015, BIOCHEM BIOPH RES CO, V458, P816, DOI 10.1016/j.bbrc.2015.02.037
   Wang P, 2013, GASTROENTEROLOGY, V145, P1133, DOI 10.1053/j.gastro.2013.07.048
   Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011
   Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
   Yu Y, 2012, AUTOPHAGY, V8, P853, DOI 10.4161/auto.20053
   Yu ZR, 2010, P NATL ACAD SCI USA, V107, P8231, DOI 10.1073/pnas.1002080107
   Zhang Y, 2014, CARDIOVASC RES, V102, P68, DOI 10.1093/cvr/cvu011
NR 65
TC 20
Z9 21
U1 8
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
EI 1098-2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD JUL
PY 2019
VL 58
IS 7
BP 1234
EP 1247
DI 10.1002/mc.23006
PG 14
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA IC2KR
UT WOS:000470789200013
PM 30883936
DA 2022-04-25
ER

PT J
AU Lee, JH
   Yun, CW
   Han, YS
   Kim, S
   Jeong, D
   Kwon, HY
   Kim, H
   Baek, MJ
   Lee, SH
AF Lee, Jun Hee
   Yun, Chul Won
   Han, Yong-Seok
   Kim, SangMin
   Jeong, Dongjun
   Kwon, Hyog Young
   Kim, Hyeongjoo
   Baek, Moo-Jun
   Lee, Sang Hun
TI Melatonin and 5-fluorouracil co-suppress colon cancer stem cells by
   regulating cellular prion protein-Oct4 axis
SO JOURNAL OF PINEAL RESEARCH
LA English
DT Article
DE cancer stem cell; cellular prion protein; melatonin; Oct4
ID EPITHELIAL-MESENCHYMAL TRANSITION; HEAT-SHOCK PROTEINS; TUMOR
   PROGRESSION; OCT4; AUTOPHAGY; APOPTOSIS; EXPRESSION; CARCINOMA;
   PROMOTES; INHIBITION
AB Melatonin suppresses tumor development. However, the exact relationship between melatonin and cancer stem cells (CSCs) is poorly understood. This study found that melatonin inhibits colon CSCs by regulating the PrPC-Oct4 axis. In specimens from patients with colorectal cancer, the expressions of cellular prion protein (PrPC) and Oct4 were significantly correlated with metastasis and tumor stages. Co-treatment with 5-fluorouracil (5-FU) and melatonin inhibited the stem cell markers Oct4, Nanog, Sox2, and ALDH1A1 by downregulating PrPC. In this way, tumor growth, proliferation, and tumor-mediated angiogenesis were suppressed. In colorectal CSCs, PRNP overexpression protects Oct4 against inhibition by 5-FU and melatonin. In contrast, Nanog, Sox2, and ALDH1A1 have no such protection. These results indicate that PrPC directly regulates Oct4, whereas it indirectly regulates Nanog, Sox2, and ALDH1A1. Taken together, our findings suggest that co-treatment with anticancer drug and melatonin is a potential therapy for colorectal cancer. Furthermore, PrPC maintains cancer stemness during tumor progression. Therefore, targeting the PrPC-Oct4 axis may prove instrumental in colorectal cancer therapy.
C1 [Lee, Jun Hee] Univ Alabama Birmingham, Sch Med, Dept Pharmacol & Toxicol, Birmingham, AL USA.
   [Yun, Chul Won; Han, Yong-Seok; Kim, SangMin; Lee, Sang Hun] Soonchunhyang Univ, Seoul Hosp, Med Sci Res Inst, Seoul, South Korea.
   [Jeong, Dongjun] Soonchunhyang Univ, Coll Med, Dept Pathol, Cheonan, South Korea.
   [Kwon, Hyog Young] Soonchunhyang Univ, Soonchunhyang Inst Medi Bio Sci SIMS, Cheonan, South Korea.
   [Kim, Hyeongjoo] Soonchunhyang Univ, Coll Med, Soonchunhyang Med Sci Res Inst, Cheonan, South Korea.
   [Baek, Moo-Jun] Soonchunhyang Univ, Coll Med, Dept Surg, Cheonan, South Korea.
   [Lee, Sang Hun] Soonchunhyang Univ, Coll Med, Dept Biochem, Cheonan, South Korea.
RP Lee, SH (corresponding author), Soonchunhyang Univ, Seoul Hosp, Med Sci Res Inst, Seoul, South Korea.
EM jhlee0407@sch.ac.kr; ykckss1114@nate.com
RI Baek, Moo-Jun/W-1736-2019; lee, sang hun/Q-4650-2019
OI Baek, Moo-Jun/0000-0003-3567-6687; lee, sang hun/0000-0002-9005-5966
FU National Research Foundation of KoreaNational Research Foundation of
   Korea [NRF2016R1D-1A3B01007727, NRF2017M3A9B4032528]
FX National Research Foundation of Korea, Grant/Award Number:
   NRF2016R1D-1A3B01007727 and NRF2017M3A9B4032528
CR BOUSQUET PF, 1995, CANCER RES, V55, P1176
   Bu PC, 2013, CELL STEM CELL, V12, P602, DOI 10.1016/j.stem.2013.03.002
   Buldak RJ, 2015, MOL MED REP, V12, P2275, DOI 10.3892/mmr.2015.3599
   Casado-Zapico S, 2010, J PINEAL RES, V48, P72, DOI 10.1111/j.1600-079X.2009.00727.x
   Cheng YY, 2014, MOL CARCINOGEN, V53, P686, DOI 10.1002/mc.22021
   Dai XZ, 2013, ONCOL REP, V29, P155, DOI 10.3892/or.2012.2086
   de Wit M, 2012, GUT, V61, P855, DOI 10.1136/gutjnl-2011-300511
   Du L, 2013, CANCER RES, V73, P2682, DOI 10.1158/0008-5472.CAN-12-3759
   Esch D, 2013, NAT CELL BIOL, V15, P295, DOI 10.1038/ncb2680
   Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027
   Garcia JJ, 2014, J PINEAL RES, V56, P225, DOI 10.1111/jpi.12128
   Hong Y, 2014, J PINEAL RES, V56, P264, DOI 10.1111/jpi.12119
   Hu TS, 2008, CANCER RES, V68, P6533, DOI 10.1158/0008-5472.CAN-07-6642
   Iglesia RP, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0518-1
   Izumiya M, 2012, ANTICANCER RES, V32, P3847
   Jan JE, 2009, J PINEAL RES, V46, P1, DOI 10.1111/j.1600-079X.2008.00628.x
   Kim KJ, 2013, J PINEAL RES, V54, P264, DOI 10.1111/j.1600-079X.2012.01030.x
   Kim Ran-Ju, 2011, Lab Anim Res, V27, P147, DOI 10.5625/lar.2011.27.2.147
   Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006
   Lee JH, 2017, ONCOGENE, V36, P6555, DOI 10.1038/onc.2017.263
   Lee JH, 2018, BIOMOL THER, V26, P313, DOI 10.4062/biomolther.2017.033
   Lee JH, 2018, ANTICANCER RES, V38, P1993, DOI 10.21873/anticanres.12437
   Leon J, 2014, J PINEAL RES, V56, P415, DOI 10.1111/jpi.12131
   Li QQ, 2009, CELL MOL LIFE SCI, V66, P504, DOI 10.1007/s00018-008-8548-6
   Li QQ, 2011, CANCER SCI, V102, P400, DOI 10.1111/j.1349-7006.2010.01811.x
   Lianos GD, 2015, CANCER LETT, V360, P114, DOI 10.1016/j.canlet.2015.02.026
   Lin YJ, 2012, MOL CELL, V48, P627, DOI 10.1016/j.molcel.2012.08.030
   Linden R, 2012, CELL MOL LIFE SCI, V69, P1105, DOI 10.1007/s00018-011-0847-7
   Lopes MH, 2015, ONCOGENE, V34, P3305, DOI 10.1038/onc.2014.261
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Martin-Lanneree S, 2014, FRONT CELL DEV BIOL, V2, DOI 10.3389/fcell.2014.00055
   Mirzaei MR, 2016, CELL J, V17, P608
   Peralta OA, 2011, DIFFERENTIATION, V81, P68, DOI 10.1016/j.diff.2010.09.181
   Plaimee P, 2015, CELL PROLIFERAT, V48, P67, DOI 10.1111/cpr.12158
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Santos TG, 2015, PRION, V9, P165, DOI 10.1080/19336896.2015.1027855
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Singh BN, 2012, BIOCHEM PHARMACOL, V84, P1154, DOI 10.1016/j.bcp.2012.08.007
   Su SC, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12370
   Su ZY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0321-5
   Wang QW, 2012, ONCOL REP, V28, P2029, DOI 10.3892/or.2012.2025
   Wang XQ, 2010, HEPATOLOGY, V52, P528, DOI 10.1002/hep.23692
   Wang YJ, 2015, AM J PHYSIOL-CELL PH, V309, pC709, DOI 10.1152/ajpcell.00212.2015
   Weissmann C, 2004, NAT REV MICROBIOL, V2, P861, DOI 10.1038/nrmicro1025
   Wen KM, 2013, CANCER LETT, V333, P56, DOI 10.1016/j.canlet.2013.01.009
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Yin X, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0119-3
   Young MM, 2012, J BIOL CHEM, V287, P12455, DOI 10.1074/jbc.M111.309104
   Zomosa-Signoret V, 2008, VET RES, V39, DOI 10.1051/vetres:2007048
NR 49
TC 57
Z9 58
U1 1
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-3098
EI 1600-079X
J9 J PINEAL RES
JI J. Pineal Res.
PD NOV
PY 2018
VL 65
IS 4
AR e12519
DI 10.1111/jpi.12519
PG 16
WC Endocrinology & Metabolism; Neurosciences; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Neurosciences & Neurology; Physiology
GA GX8YF
UT WOS:000448081600004
PM 30091203
DA 2022-04-25
ER

PT J
AU Phan, T
   Nguyen, VH
   Salazar, MA
   Wong, P
   Diamond, DJ
   Yim, JH
   Melstrom, LG
AF Phan, Thuy
   Nguyen, Vu H.
   Salazar, Marcela A'lincourt
   Wong, Paul
   Diamond, Don J.
   Yim, John H.
   Melstrom, Laleh G.
TI Inhibition of Autophagy Amplifies Baicalein-Induced Apoptosis in Human
   Colorectal Cancer
SO MOLECULAR THERAPY-ONCOLYTICS
LA English
DT Article
ID PROTEIN-KINASE; COLON-CANCER; CELL-DEATH; PATHWAY; TNFRSF10C; VIRUS
AB Baicalein is a Chinese herbal compound extracted from Scutel-laria baicalensis that has anti-tumor properties. The aim of this study was to elucidate the mechanisms of action of baicalein against human colorectal cancer cell lines and to assess whether the anti-proliferative effects of baicalein may be amplified with autophagy inhibition. Human colon cancer cell lines (HT-29, HCT-116, SW480, and SW620) were treated with baicalein alone and in combination with the autophagy inhibitor chloroquine (CQ). Baicalein reduced cell viability in all four colon cancer lines in a dose-dependent fashion. Combination treatment of baicalein and the autophagy inhibitor CQ significantly decreased cell viability compared with baicalein alone in HT-29 and HCT-116 cell lines. Western blot analysis of the HCT-116 cell line treated with both baicalein and CQ demonstrated increased expression of LC3-II, a component of autophagy. The combination of baicalein with CQ culminated in activation of caspase-3-mediated apoptosis. These findings demonstrate that inhibition of autophagy enhanced apoptotic cell death induced by baicalein treatment in colon cancer cell lines. Future work will assess other targetable apoptotic pathways activated by baicalein and autophagy inhibition.
C1 [Phan, Thuy; Wong, Paul; Yim, John H.; Melstrom, Laleh G.] City Hope Med Ctr, Dept Surg, 1500 E Duarte Rd, Duarte, CA 91010 USA.
   [Melstrom, Laleh G.] City Hope Med Ctr, Dept Immunooncol, Duarte, CA 91010 USA.
   [Nguyen, Vu H.; Salazar, Marcela A'lincourt; Diamond, Don J.] City Hope Med Ctr, Dept Hematol, Duarte, CA 91010 USA.
RP Melstrom, LG (corresponding author), City Hope Med Ctr, Dept Surg, 1500 E Duarte Rd, Duarte, CA 91010 USA.
EM lmelstrom@coh.org
OI Wong, Paul/0000-0002-5833-0331
CR Advani S, 2019, J SURG ONCOL, V119, P642, DOI 10.1002/jso.25441
   Bie B., BIOMED PHARMACOTHER, V93, P1285
   Chao JI, 2007, MOL CANCER THER, V6, P3039, DOI 10.1158/1535-7163.MCT-07-0281
   Chen KJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057704
   Cheng YH, 2012, TOXICOL APPL PHARM, V263, P360, DOI 10.1016/j.taap.2012.07.010
   Cheng Y, 2009, PROSTATE, V69, P327, DOI 10.1002/pros.20882
   Chughtai SA, 1999, ONCOGENE, V18, P657, DOI 10.1038/sj.onc.1202340
   D'Arcy MS, 2019, CELL BIOL INT, V43, P582, DOI 10.1002/cbin.11137
   de Oliveira MR, 2015, PHARMACOL RES, V100, P296, DOI 10.1016/j.phrs.2015.08.021
   Ding Y, 2014, ARCH VIROL, V159, P3269, DOI 10.1007/s00705-014-2192-2
   Dou Jie, 2018, Oncotarget, V9, P20089, DOI 10.18632/oncotarget.24015
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Fakih MG, 2015, J CLIN ONCOL, V33, P1809, DOI 10.1200/JCO.2014.59.7633
   Gao JB, 2011, MOL CANCER THER, V10, P1774, DOI 10.1158/1535-7163.MCT-11-0304
   Gao Y, 2016, MED CHEM RES, V25, P1515, DOI 10.1007/s00044-016-1607-x
   Gilmore TD, 1996, ONCOGENE, V13, P1367
   Huang Y, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-48
   Ji S, 2015, J ETHNOPHARMACOL, V176, P475, DOI 10.1016/j.jep.2015.11.018
   Jing K, 2012, EXP MOL MED, V44, P69, DOI 10.3858/emm.2012.44.2.028
   Kim Dong Hwan, 2014, J Cancer Prev, V19, P153, DOI 10.15430/JCP.2014.19.3.153
   Kim DH, 2013, INT J ONCOL, V43, P1652, DOI 10.3892/ijo.2013.2086
   Kim SJ, 2012, MOL MED REP, V6, P1443, DOI 10.3892/mmr.2012.1085
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li HL, 2013, MOL MED REP, V7, P266, DOI 10.3892/mmr.2012.1123
   Liu Y, 2019, ONCOL LETT, V18, P3188, DOI 10.3892/ol.2019.10617
   Macartney-Coxson DP, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-187
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Moghaddam E, 2014, SCI REP-UK, V4, DOI 10.1038/srep05452
   Murphy TM, 2008, ENDOCR-RELAT CANCER, V15, P11, DOI 10.1677/ERC-07-0208
   Pang HX, 2016, CLIN DRUG INVEST, V36, P713, DOI 10.1007/s40261-016-0418-7
   Sandhu J, 2019, J SURG ONCOL, V119, P564, DOI 10.1002/jso.25421
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Su MQ, 2018, INT J ONCOL, V53, P750, DOI 10.3892/ijo.2018.4402
   Tanenbaum DG, 2016, J GASTROINTEST ONCOL, V7, P306, DOI 10.21037/jgo.2015.11.04
   Taniguchi H, 2008, CANCER RES, V68, P8918, DOI 10.1158/0008-5472.CAN-08-1120
   Wang CZ, 2020, CLIN TRANSL ONCOL, V22, P1013, DOI 10.1007/s12094-019-02225-5
   Wang M, 2019, AM J TRANSL RES, V11, P3341
   Wang QD, 2003, J BIOL CHEM, V278, P51091, DOI 10.1074/jbc.M306541200
   Wang YF, 2015, PHYTOTHER RES, V29, P674, DOI 10.1002/ptr.5298
   Wang YJ, 2015, CANCER LETT, V358, P170, DOI 10.1016/j.canlet.2014.12.033
   Wen X, 2013, FREE RADICAL BIO MED, V65, P402, DOI 10.1016/j.freeradbiomed.2013.07.013
   White E, 2015, CLIN CANCER RES, V21, P5037, DOI 10.1158/1078-0432.CCR-15-0490
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Yan WJ, 2018, DRUG DES DEV THER, V12, P3961, DOI 10.2147/DDDT.S181939
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Zhang S, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-018-0985-y
   Zhong XC, 2019, J CANCER PREV, V24, P129, DOI 10.15430/JCP.2019.24.2.129
NR 50
TC 6
Z9 7
U1 4
U2 23
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2372-7705
J9 MOL THER-ONCOLYTICS
JI Mol. Ther.-Oncolytics
PD DEC 16
PY 2020
VL 19
BP 1
EP 7
DI 10.1016/j.omto.2020.08.016
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA PG9LE
UT WOS:000600047100001
PM 33024814
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Wen, YA
   Xing, XP
   Harris, JW
   Zaytseva, YY
   Mitov, MI
   Napier, DL
   Weiss, HL
   Evers, BM
   Gao, TY
AF Wen, Yang-An
   Xing, Xiaopeng
   Harris, Jennifer W.
   Zaytseva, Yekaterina Y.
   Mitov, Mihail I.
   Napier, Dana L.
   Weiss, Heidi L.
   Evers, B. Mark
   Gao, Tianyan
TI Adipocytes activate mitochondrial fatty acid oxidation and autophagy to
   promote tumor growth in colon cancer
SO CELL DEATH & DISEASE
LA English
DT Article
ID BODY-MASS INDEX; COLORECTAL-CANCER; PROTEIN-KINASE; CA2+ INFLUX;
   OBESITY; CELLS; METABOLISM; PHLPP; CHEMOTHERAPY; PROGRESSION
AB Obesity has been associated with increased incidence and mortality of a wide variety of human cancers including colorectal cancer. However, the molecular mechanism by which adipocytes regulate the metabolism of colon cancer cells remains elusive. In this study, we showed that adipocytes isolated from adipose tissues of colon cancer patients have an important role in modulating cellular metabolism to support tumor growth and survival. Abundant adipocytes were found in close association with invasive tumor cells in colon cancer patients. Co-culture of adipocytes with colon cancer cells led to a transfer of free fatty acids that released from the adipocytes to the cancer cells. Uptake of fatty acids allowed the cancer cells to survive nutrient deprivation conditions by upregulating mitochondrial fatty acid beta-oxidation. Mechanistically, co-culture of adipocytes or treating cells with fatty acids induced autophagy in colon cancer cells as a result of AMPK activation. Inhibition of autophagy attenuated the ability of cancer cells to utilize fatty acids and blocked the growth-promoting effect of adipocytes. In addition, we found that adipocytes stimulated the expression of genes associated with cancer stem cells and downregulated genes associated with intestinal epithelial cell differentiation in primary colon cancer cells and mouse tumor organoids. Importantly, the presence of adipocytes promoted the growth of xenograft tumors in vivo. Taken together, our results show that adipocytes in the tumor microenvironment serve as an energy provider and a metabolic regulator to promote the growth and survival of colon cancer cells.
C1 [Wen, Yang-An; Xing, Xiaopeng; Harris, Jennifer W.; Zaytseva, Yekaterina Y.; Mitov, Mihail I.; Napier, Dana L.; Weiss, Heidi L.; Evers, B. Mark; Gao, Tianyan] Univ Kentucky, Markey Canc Ctr, Lexington, KY USA.
   [Harris, Jennifer W.; Evers, B. Mark] Univ Kentucky, Dept Surg, Lexington, KY USA.
   [Zaytseva, Yekaterina Y.] Univ Kentucky, Dept Toxicol & Canc Biol, Lexington, KY USA.
   [Gao, Tianyan] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.
RP Gao, TY (corresponding author), Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.
EM tianyan.gao@uky.edu
FU National Center for Advancing Translational Sciences (NIH)
   [UL1TR000117]; Redox Metabolism, Biospecimen and Tissue Procurement;
   Biostatistics and Bioinformatics Shared Resource Facility of the
   University of Kentucky Markey Cancer Center [P30CA177558]; 
   [R01CA133429]; NATIONAL CANCER INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [R01CA133429, P30CA177558, R01CA208343]
   Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR000117] Funding Source:
   NIH RePORTER
FX This work was supported by R01CA133429 (TG) and the National Center for
   Advancing Translational Sciences (NIH) through grant UL1TR000117. The
   studies were conducted with support provided by the Redox Metabolism,
   Biospecimen and Tissue Procurement, and Biostatistics and Bioinformatics
   Shared Resource Facility of the University of Kentucky Markey Cancer
   Center (P30CA177558).
CR Basu S., 2016, F1000RES, V5
   Beyaz S, 2016, NATURE, V531, P53, DOI 10.1038/nature17173
   Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423
   Carracedo A, 2013, NAT REV CANCER, V13, P227, DOI 10.1038/nrc3483
   Cheung AF, 2010, ONCOGENE, V29, P1857, DOI 10.1038/onc.2009.457
   Fang KM, 2008, CARDIOVASC RES, V78, P533, DOI 10.1093/cvr/cvn030
   Fujiwara K, 2007, ENDOCRINOLOGY, V148, P2496, DOI 10.1210/en.2006-1156
   Galluzzi L, 2014, CELL, V159, P1263, DOI 10.1016/j.cell.2014.11.006
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
   Iyengar NM, 2015, ANNU REV MED, V66, P297, DOI 10.1146/annurev-med-050913-022228
   Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001
   Khaldoun SA, 2014, MOL BIOL CELL, V25, P118, DOI 10.1091/mbc.E13-06-0324
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kondo J, 2011, P NATL ACAD SCI USA, V108, P6235, DOI 10.1073/pnas.1015938108
   Lazar I, 2016, CANCER RES, V76, P4051, DOI 10.1158/0008-5472.CAN-16-0651
   Li X, 2014, GASTROENTEROLOGY, V146, P1301, DOI 10.1053/j.gastro.2014.02.003
   Liu J, 2009, ONCOGENE, V28, P994, DOI 10.1038/onc.2008.450
   Liu K, 2013, CELL DEATH DIFFER, V20, P3, DOI 10.1038/cdd.2012.63
   Mathew R, 2011, COLD SH Q B, V76, P389, DOI 10.1101/sqb.2012.76.011015
   Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a
   Nieman KM, 2013, BBA-MOL CELL BIOL L, V1831, P1533, DOI 10.1016/j.bbalip.2013.02.010
   Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492
   Pais R, 2009, WORLD J GASTROENTERO, V15, P5141, DOI 10.3748/wjg.15.5141
   Park SY, 2011, INT J OBES LOND, V36, P273
   Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X
   Renehan AG, 2015, NAT REV CANCER, V15, P484, DOI 10.1038/nrc3967
   Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050
   Sheen JH, 2011, CANCER CELL, V19, P613, DOI 10.1016/j.ccr.2011.03.012
   Singh R, 2009, NATURE, V458, P1131, DOI 10.1038/nature07976
   Sinicrope FA, 2013, CANCER-AM CANCER SOC, V119, P1528, DOI 10.1002/cncr.27938
   Sinicrope FA, 2010, CLIN CANCER RES, V16, P1884, DOI 10.1158/1078-0432.CCR-09-2636
   Uchida H, 2010, CANCER SCI, V101, P1731, DOI 10.1111/j.1349-7006.2010.01571.x
   Wasan HS, 1997, P NATL ACAD SCI USA, V94, P3308, DOI 10.1073/pnas.94.7.3308
   Wen YA, 2015, BBA-MOL BASIS DIS, V1852, P2013, DOI 10.1016/j.bbadis.2015.07.012
   Wen YA, 2013, MOL CELL BIOL, V33, P4594, DOI 10.1128/MCB.00695-13
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788
   Yang K, 1998, CANCER RES, V58, P5713
NR 38
TC 111
Z9 115
U1 1
U2 18
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD FEB
PY 2017
VL 8
AR e2593
DI 10.1038/cddis.2017.21
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EK1JD
UT WOS:000393680700013
PM 28151470
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Peng, Y
   Miao, HM
   Wu, S
   Yang, WW
   Zhang, Y
   Xie, GF
   Xie, X
   Li, JJ
   Shi, CM
   Ye, LL
   Sun, W
   Wang, LT
   Liang, HJ
   Ou, JJ
AF Peng, Yuan
   Miao, Hongming
   Wu, Shuang
   Yang, Weiwen
   Zhang, Yue
   Xie, Ganfeng
   Xie, Xiong
   Li, Jianjun
   Shi, Chunmeng
   Ye, Lilin
   Sun, Wei
   Wang, Liting
   Liang, Houjie
   Ou, Juanjuan
TI ABHD5 interacts with BECN1 to regulate autophagy and tumorigenesis of
   colon cancer independent of PNPLA2
SO AUTOPHAGY
LA English
DT Article
DE ABHD5; autophagy; colorectal cancer; genome instability; tumorigenesis
ID ADIPOSE TRIGLYCERIDE LIPASE; TUMOR-SUPPRESSOR; BECLIN 1;
   MOLECULAR-MECHANISMS; GENE-TRANSCRIPTION; HEPATIC STEATOSIS; CELL-DEATH;
   CLEAVAGE; LIVER; METABOLISM
AB Autophagy critically contributes to metabolic reprogramming and chromosomal stability. It has been reported that monoallelic loss of the essential autophagy gene BECN1 (encoding BECN1/Beclin 1) promotes cancer development and progression. However, the mechanism by which BECN1 is inactivated in malignancy remains largely elusive. We have previously reported a tumor suppressor role of ABHD5 (abhydrolase domain containing 5), a co-activator of PNPLA2 (patatin like phospholipase domain containing 2) in colorectal carcinoma (CRC). Here we report a noncanonical role of ABHD5 in regulating autophagy and CRC tumorigenesis. ABHD5 directly competes with CASP3 for binding to the cleavage sites of BECN1, and consequently prevents BECN1 from being cleaved by CASP3. ABHD5 deficiency provides CASP3 an advantage to cleave and inactivate BECN1, thus impairing BECN1-induced autophagic flux and augmenting genomic instability, which subsequently promotes tumorigenesis. Notably, clinical data also confirm that ABHD5 proficiency is significantly correlated with the expression levels of BECN1, LC3-II and CASP3 in human CRC tissues. Our findings suggest that ABHD5 possesses a PNPLA2-independent function in regulating autophagy and tumorigenesis, further establishing the tumor suppressor role of ABHD5, and offering an opportunity to develop new approaches aimed at preventing CRC carcinogenesis.
C1 [Peng, Yuan; Miao, Hongming; Wu, Shuang; Yang, Weiwen; Zhang, Yue; Xie, Ganfeng; Xie, Xiong; Li, Jianjun; Liang, Houjie; Ou, Juanjuan] Third Mil Med Univ, Southwest Hosp, Dept Oncol, Chongqing 400038, Peoples R China.
   [Peng, Yuan; Miao, Hongming; Wu, Shuang; Yang, Weiwen; Zhang, Yue; Xie, Ganfeng; Xie, Xiong; Li, Jianjun; Liang, Houjie; Ou, Juanjuan] Third Mil Med Univ, Southwest Hosp, Southwest Canc Ctr, Chongqing 400038, Peoples R China.
   [Shi, Chunmeng] Third Mil Med Univ, Chongqing Engn Res Ctr Nanomed, State Key Labortory Trauma Burns & Combined Injur, Inst Combined Injury,Coll Prevent Med, Chongqing, Peoples R China.
   [Ye, Lilin] Third Mil Med Univ, Inst Immunol, Chongqing, Peoples R China.
   [Sun, Wei; Wang, Liting] Third Mil Med Univ, Biomed Anal Ctr, Chongqing, Peoples R China.
RP Liang, HJ; Ou, JJ (corresponding author), Third Mil Med Univ, Southwest Hosp, Dept Oncol, Chongqing 400038, Peoples R China.; Liang, HJ; Ou, JJ (corresponding author), Third Mil Med Univ, Southwest Hosp, Southwest Canc Ctr, Chongqing 400038, Peoples R China.
EM lianghoujie@sina.com; ojj521000@sina.com
RI miao, hongming/AAV-8561-2020
OI Ye, Lilin/0000-0003-0778-3311; Shi, Chunmeng/0000-0002-8264-738X
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81370063, 81172114, 81302136, 81272364];
   National Basic Research Program of China (973 Program)National Basic
   Research Program of China [2014CB560703]
FX This work was supported in part by grant numbers 81370063 (J.O.),
   81172114 (J.L.), grant numbers 81302136 (H.M.) and 81272364 (H.L.) from
   the National Natural Science Foundation of China, and 2014CB560703
   (H.L.) from the National Basic Research Program of China (973 Program).
CR Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Das SK, 2011, SCIENCE, V333, P233, DOI 10.1126/science.1198973
   de Reynies A, 2009, J CLIN ONCOL, V27, P1108, DOI 10.1200/JCO.2008.18.5678
   DeBerardinis RJ, 2012, CELL, V148, P1132, DOI 10.1016/j.cell.2012.02.032
   DETER RL, 1967, J CELL BIOL, V35, pC11, DOI 10.1083/jcb.35.2.C11
   Diao JJ, 2015, NATURE, V520, P563, DOI 10.1038/nature14147
   Djavaheri-Mergny M, 2010, ONCOGENE, V29, P1717, DOI 10.1038/onc.2009.519
   Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925
   Fischer J, 2007, NAT GENET, V39, P28, DOI 10.1038/ng1951
   Frezza C, 2011, J MOL MED, V89, P213, DOI 10.1007/s00109-011-0728-4
   Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Guo F, 2013, J LIPID RES, V54, P2109, DOI 10.1194/jlr.M035519
   Haemmerle G, 2011, NAT MED, V17, P1076, DOI 10.1038/nm.2439
   Heng K, 2013, EPILEPSIA, V54, P1535, DOI 10.1111/epi.12246
   Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784
   Lass A, 2006, CELL METAB, V3, P309, DOI 10.1016/j.cmet.2006.03.005
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Li H, 2011, CANCER RES, V71, P3625, DOI 10.1158/0008-5472.CAN-10-4475
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037
   Lyssiotis CA, 2012, CELL, V151, P1155, DOI 10.1016/j.cell.2012.11.020
   Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642
   Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924
   Nomura DK, 2010, CELL, V140, P49, DOI 10.1016/j.cell.2009.11.027
   Norman JM, 2010, AUTOPHAGY, V6, P1042, DOI 10.4161/auto.6.8.13337
   Ou JJ, 2014, CELL REP, V9, P1798, DOI 10.1016/j.celrep.2014.11.016
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Radner FPW, 2010, J BIOL CHEM, V285, P7300, DOI 10.1074/jbc.M109.081877
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Rohn TT, 2011, NEUROBIOL DIS, V43, P68, DOI 10.1016/j.nbd.2010.11.003
   Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404
   Schneider JL, 2014, CELL METAB, V20, P417, DOI 10.1016/j.cmet.2014.06.009
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Shpilka T, 2015, EMBO J, V34, P2117, DOI 10.15252/embj.201490315
   Shpilka T, 2015, P NATL ACAD SCI USA, V112, P1434, DOI 10.1073/pnas.1409476112
   Takahashi Y, 2009, CELL DEATH DIFFER, V16, P947, DOI 10.1038/cdd.2009.19
   Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wirawan E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.16
   Wu JW, 2011, HEPATOLOGY, V54, P122, DOI 10.1002/hep.24338
   Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018
   Yoshimori T, 2004, BIOCHEM BIOPH RES CO, V313, P453, DOI 10.1016/j.bbrc.2003.07.023
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zeineldin M, 2013, CANCER RES, V73, P2389, DOI 10.1158/0008-5472.CAN-12-4607
   Zhu YS, 2010, PROTEIN CELL, V1, P468, DOI 10.1007/s13238-010-0048-4
NR 54
TC 39
Z9 40
U1 4
U2 14
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PY 2016
VL 12
IS 11
BP 2167
EP 2182
DI 10.1080/15548627.2016.1217380
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EB8TW
UT WOS:000387665000015
PM 27559856
OA Green Published
DA 2022-04-25
ER

PT J
AU Tang, Y
   Chen, Y
   Jiang, H
   Nie, D
AF Tang, Y.
   Chen, Y.
   Jiang, H.
   Nie, D.
TI Short-chain fatty acids induced autophagy serves as an adaptive strategy
   for retarding mitochondria-mediated apoptotic cell death
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Article
DE short-chain fatty acids; autophagy; apoptosis; mitochondrial; colon
   cancer
ID ACTIVATED PROTEIN-KINASE; PERMEABILITY TRANSITION; OXIDATIVE STRESS;
   PROSTATE-CANCER; CYTOCHROME-C; PHOSPHORYLATION; INDUCTION; CASPASE-3;
   BUTYRATE; SURVIVAL
AB Short-chain fatty acids (SCFAs) are the major by-products of bacterial fermentation of undigested dietary fibers in the large intestine. SCFAs, mostly propionate and butyrate, inhibit proliferation and induce apoptosis in colon cancer cells, but clinical trials had mixed results regarding the anti-tumor activities of SCFAs. Herein we demonstrate that propionate and butyrate induced autophagy in human colon cancer cells to dampen apoptosis whereas inhibition of autophagy potentiated SCFA induced apoptosis. Colon cancer cells, after propionate treatment, exhibited extensive characteristics of autophagic proteolysis: increased LC3-I to LC3-II conversion, acidic vesicular organelle development, and reduced p62/SQSTM1 expression. Propionate-induced autophagy was associated with decreased mTOR activity and enhanced AMP kinase activity. The elevated AMPK alpha phosphorylation was associated with cellular ATP depletion and overproduction of reactive oxygen species due to mitochondrial dysfunction involving the induction of MPT and loss of Lambda psi. In this context, mitochondria biogenesis was initiated to recover cellular energy homeostasis. Importantly, when autophagy was prevented either pharmacologically (3-MA or chloroquine) or genetically (knockdown of ATG5 or ATG7), the colon cancer cells became sensitized toward propionate-induced apoptosis through activation of caspase-7 and caspase-3. The observations indicate that propionate-triggered autophagy serves as an adaptive strategy for retarding mitochondria-mediated apoptotic cell death, whereas application of an autophagy inhibitor (Chloroquine) is expected to enhance the therapeutic efficacy of SCFAs in inducing colon tumor cell apoptosis. Cell Death and Differentiation (2011) 18, 602-618; doi:10.1038/cdd.2010.117; published online 8 October 2010
C1 [Tang, Y.; Chen, Y.; Jiang, H.; Nie, D.] So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, Springfield, IL 62794 USA.
   [Tang, Y.; Chen, Y.; Jiang, H.; Nie, D.] Simmons Canc Inst, Springfield, IL USA.
   [Tang, Y.; Jiang, H.] So Illinois Univ, Mol Biol Microbiol & Biochem Grad Program, Grad Sch, Carbondale, IL 62901 USA.
RP Nie, D (corresponding author), So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, POB 19626, Springfield, IL 62794 USA.
EM dnie@siumed.edu
CR Amaravadi RK, 2007, CLIN CANCER RES, V13, P7271, DOI 10.1158/1078-0432.CCR-07-1595
   Aoyama M, 2010, NUTRITION, V26, P653, DOI 10.1016/j.nut.2009.07.006
   Chen Y, 2007, CANCER RES, V67, P10361, DOI 10.1158/0008-5472.CAN-06-4758
   Chiang GG, 2005, J BIOL CHEM, V280, P25485, DOI 10.1074/jbc.M501707200
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Cook SI, 1998, ALIMENT PHARM THER, V12, P499, DOI 10.1046/j.1365-2036.1998.00337.x
   CUMMINGS JH, 1984, SCAND J GASTROENTERO, V19, P89
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518
   Emerling BM, 2009, FREE RADICAL BIO MED, V46, P1386, DOI 10.1016/j.freeradbiomed.2009.02.019
   Eskelinen EL, 2002, MOL BIOL CELL, V13, P3355, DOI 10.1091/mbc.E02-02-0114
   HAGUE A, 1995, INT J CANCER, V60, P400, DOI 10.1002/ijc.2910600322
   HEERDT BG, 1994, CANCER RES, V54, P3288
   Herman-Antosiewicz A, 2006, CANCER RES, V66, P5828, DOI 10.1158/0008-5472.CAN-06-0139
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Jan G, 2002, CELL DEATH DIFFER, V9, P179, DOI 10.1038/sj.cdd.4400935
   Kanno T, 2004, FREE RADICAL RES, V38, P27, DOI 10.1080/10715760310001626266
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035
   Lemasters JJ, 2005, REJUV RES, V8, P3, DOI 10.1089/rej.2005.8.3
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7
   Medina V, 1997, CANCER RES, V57, P3697
   Meley D, 2006, J BIOL CHEM, V281, P34870, DOI 10.1074/jbc.M605488200
   Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2
   Rodenburg W, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-144
   Rodriguez-Enriquez S, 2004, INT J BIOCHEM CELL B, V36, P2463, DOI 10.1016/j.biocel.2004.04.009
   Ruemmele FM, 1999, CELL DEATH DIFFER, V6, P729, DOI 10.1038/sj.cdd.4400545
   Rutter GA, 2003, BIOCHEM J, V375, P1, DOI 10.1042/BJ20030048
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509
   Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437
   TROCK B, 1990, JNCI-J NATL CANCER I, V82, P650, DOI 10.1093/jnci/82.8.650
   Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200
   Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599
NR 40
TC 101
Z9 105
U1 1
U2 28
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1350-9047
EI 1476-5403
J9 CELL DEATH DIFFER
JI Cell Death Differ.
PD APR
PY 2011
VL 18
IS 4
BP 602
EP 618
DI 10.1038/cdd.2010.117
PG 17
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 734DY
UT WOS:000288314800004
PM 20930850
OA Green Accepted, hybrid, Green Published
DA 2022-04-25
ER

PT J
AU Hu, T
   Li, Z
   Gao, CY
   Cho, CH
AF Hu, Tao
   Li, Zhen
   Gao, Chun-Ying
   Cho, Chi Hin
TI Mechanisms of drug resistance in colon cancer and its therapeutic
   strategies
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Review
DE Colon cancer; Drug resistance; ATP-binding cassette transporters;
   Evasion of apoptosis; Autophagy
ID GROWTH-FACTOR-RECEPTOR; OVERCOMING MULTIDRUG-RESISTANCE; SYNTHETASE
   GENE-EXPRESSION; CETUXIMAB PLUS IRINOTECAN; TYROSINE-KINASE INHIBITOR;
   AUTOPHAGIC CELL-DEATH; COLORECTAL-CANCER; BREAST-CANCER; P-GP; PHASE-I
AB Drug resistance develops in nearly all patients with colon cancer, leading to a decrease in the therapeutic efficacies of anticancer agents. This review provides an up-to-date summary on over-expression of ATP-binding cassette (ABC) transporters and evasion of apoptosis, two representatives of transport-based and non-transport-based mechanisms of drug resistance, as well as their therapeutic strategies. Different ABC transporters were found to be up-regulated in colon cancer, which can facilitate the efflux of anticancer drugs out of cancer cells and decrease their therapeutic effects. Inhibition of ABC transporters by suppressing their protein expressions or co-administration of modulators has been proven as an effective approach to sensitize drug-resistant cancer cells to anticancer drugs in vitro. On the other hand, evasion of apoptosis observed in drug-resistant cancers also results in drug resistance to anticancer agents, especially to apoptosis inducers. Restoration of apoptotic signals by BH3 mimetics or epidermal growth factor receptor inhibitors and inhibition of cancer cell growth by alternative cell death pathways, such as autophagy, are effective means to treat such resistant cancer types. Given that the drug resistance mechanisms are different among colon cancer patients and may change even in a single patient at different stages, personalized and specific combination therapy is proposed to be more effective and safer for the reversal of drug resistance in clinics.
C1 [Hu, Tao; Cho, Chi Hin] Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China.
   [Li, Zhen] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
   [Gao, Chun-Ying] Univ Washington, Sch Pharm, Dept Pharmaceut, Seattle, WA 98195 USA.
RP Hu, T (corresponding author), Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China.
EM taohu1985@hotmail.com
RI Cho, Chi Hin/C-6543-2014; Hu, Tao/O-2570-2014
OI Cho, Chi Hin/0000-0002-7658-3260; Hu, Tao/0000-0002-0601-3078
CR Ahmed-Belkacem A, 2005, CANCER RES, V65, P4852, DOI 10.1158/0008-5472.CAN-04-1817
   Ahmed-Belkacem A, 2007, J MED CHEM, V50, P1933, DOI 10.1021/jm061450q
   Attardi LD, 2004, NAT GENET, V36, P7, DOI 10.1038/ng0104-7
   Benhattar J, 1996, INT J CANCER, V69, P190, DOI 10.1002/(SICI)1097-0215(19960621)69:3<190::AID-IJC7>3.0.CO;2-V
   BENSON AB, 1985, CANCER TREAT REP, V69, P795
   Bentires-Alj M, 2003, ONCOGENE, V22, P90, DOI 10.1038/sj.onc.1206056
   Besbes S, 2016, CRIT REV ONCOL HEMAT, V100, P32, DOI 10.1016/j.critrevonc.2016.02.003
   Billard C, 2013, MOL CANCER THER, V12, P1691, DOI 10.1158/1535-7163.MCT-13-0058
   Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225
   Bogdanowicz BS, 2017, J ONCOL PHARM PRACT, V23, P203, DOI 10.1177/1078155216634179
   Boyer J, 2004, CLIN CANCER RES, V10, P2158, DOI 10.1158/1078-0432.CCR-03-0362
   Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863
   Burger H, 2005, CANCER BIOL THER, V4, P747, DOI 10.4161/cbt.4.7.1826
   Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5
   Carew JS, 2007, BLOOD, V110, P313, DOI 10.1182/blood-2006-10-050260
   CHAPMAN RS, 1994, CANCER RES, V54, P5131
   CHAPMAN RS, 1995, MOL PHARMACOL, V48, P334
   Chearwae W, 2006, CANCER CHEMOTH PHARM, V57, P376, DOI 10.1007/s00280-005-0052-1
   Chen JQ, 2014, NANOSCALE RES LETT, V9, DOI 10.1186/1556-276X-9-86
   Cheng Y, 2013, PHARMACOL REV, V65, P1162, DOI 10.1124/pr.112.007120
   Chikazawa N, 2010, ANTICANCER RES, V30, P2041
   Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734
   Choudhuri S, 2006, INT J TOXICOL, V25, P231, DOI 10.1080/10915810600746023
   Cihalova D, 2015, BIOCHEM PHARMACOL, V98, P465, DOI 10.1016/j.bcp.2015.08.099
   Crowley E, 2010, METHODS MOL BIOL, V596, P405, DOI 10.1007/978-1-60761-416-6_18
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4
   Dallas NA, 2009, CANCER RES, V69, P1951, DOI 10.1158/0008-5472.CAN-08-2023
   Deeley RG, 2006, FEBS LETT, V580, P1103, DOI 10.1016/j.febslet.2005.12.036
   Dharmapuri G, 2015, LEUKEMIA RES, V39, P696, DOI 10.1016/j.leukres.2015.02.013
   Ding ZY, 2010, J CANCER RES CLIN, V136, P1697, DOI 10.1007/s00432-010-0828-5
   DRAKE FH, 1987, J BIOL CHEM, V262, P16739
   Duan HC, 2015, DRUG METAB DISPOS, V43, P1773, DOI 10.1124/dmd.115.064824
   Ekblad L, 2010, ANTI-CANCER DRUG, V21, P523, DOI 10.1097/CAD.0b013e328337b867
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Erlichman C, 2001, CANCER RES, V61, P739
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Fernald K, 2013, TRENDS CELL BIOL, V23, P620, DOI 10.1016/j.tcb.2013.07.006
   Fichtner I, 2004, EUR J CANCER, V40, P298, DOI 10.1016/j.ejca.2003.10.011
   FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265
   Fu D, 2012, INT J BIOCHEM CELL B, V44, P461, DOI 10.1016/j.biocel.2011.12.009
   Fulda S, 2009, INT J CANCER, V124, P511, DOI 10.1002/ijc.24064
   Gariboldi MB, 2015, CANCER LETT, V364, P156, DOI 10.1016/j.canlet.2015.05.008
   Giacomini KM, 2010, NAT REV DRUG DISCOV, V9, P215, DOI 10.1038/nrd3028
   Gill S, 2003, ALIMENT PHARM THER, V18, P683, DOI 10.1046/j.1365-2036.2003.01735.x
   Gillet JP, 2010, METHODS MOL BIOL, V596, P47, DOI 10.1007/978-1-60761-416-6_4
   Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706
   Gradilone A, 2008, CURR CANCER DRUG TAR, V8, P414, DOI 10.2174/156800908785133178
   GREENBLATT MS, 1994, CANCER RES, V54, P4855
   HAO XY, 1994, BIOCHEM J, V297, P59, DOI 10.1042/bj2970059
   Haupt S, 2003, J CELL SCI, V116, P4077, DOI 10.1242/jcs.00739
   Hemann MT, 2006, CELL DEATH DIFFER, V13, P1256, DOI 10.1038/sj.cdd.4401962
   Herbst RS, 2004, INT J RADIAT ONCOL, V59, P21, DOI 10.1016/j.ijrobp.2003.11.041
   Herraez E, 2012, MOL PHARMACEUT, V9, P2565, DOI 10.1021/mp300178a
   Hinoshita E, 2000, CLIN CANCER RES, V6, P2401
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Hu T, 2013, J BIOMOL RES THER, V2, P110, DOI [10.4172/21677956.1000110, DOI 10.4172/21677956.1000110]
   Hu T, 2015, CURR PHARM DESIGN, V21, P2960, DOI 10.2174/1381612821666150514104244
   Hu T, 2015, PHYTOMEDICINE, V22, P536, DOI 10.1016/j.phymed.2015.03.010
   Hu T, 2014, PHYTOMEDICINE, V21, P1264, DOI 10.1016/j.phymed.2014.06.013
   Ikegami Y, 2000, J CELL PHYSIOL, V185, P293, DOI 10.1002/1097-4652(200011)185:2<293::AID-JCP14>3.0.CO;2-C
   Jendzelovsky R, 2009, PHOTOCH PHOTOBIO SCI, V8, P1716, DOI 10.1039/b9pp00086k
   Jiang PD, 2014, CELL RES, V24, P69, DOI 10.1038/cr.2013.161
   Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8
   JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7
   Jung KA, 2015, MOL PHARMACOL, V87, P465, DOI 10.1124/mol.114.096065
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Kaseb AO, 2016, ONCOTARGETS THER, V9, P773, DOI 10.2147/OTT.S91977
   Ke EE, 2016, THER ADV RESPIR DIS, V10, P256, DOI 10.1177/1753465816634545
   Klappe K, 2004, INT J CANCER, V110, P511, DOI 10.1002/ijc.20140
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kowalski P, 2005, MOL THER, V11, P508, DOI 10.1016/j.ymthe.2004.11.016
   Krishna R, 2000, EUR J PHARM SCI, V11, P265, DOI 10.1016/S0928-0987(00)00114-7
   Lefranc F, 2007, ONCOLOGIST, V12, P1395, DOI 10.1634/theoncologist.12-12-1395
   Levine B, 2015, J CLIN INVEST, V125, P14, DOI 10.1172/JCI73938
   LEWIS AD, 1989, BRIT J CANCER, V60, P327, DOI 10.1038/bjc.1989.280
   Li CY, 2012, ASIAN PAC J CANCER P, V13, P3757, DOI 10.7314/APJCP.2012.13.8.3757
   Li LF, 2014, INT J MOL MED, V34, P372, DOI 10.3892/ijmm.2014.1786
   Li XQ, 2015, EUR J MED CHEM, V101, P560, DOI 10.1016/j.ejmech.2015.06.049
   Li Y, 2010, DRUG METAB REV, V42, P590, DOI 10.3109/03602531003758690
   Lian FR, 1999, NUTR CANCER, V33, P125, DOI 10.1207/S15327914NC330202
   Liu Y, 2006, P NATL ACAD SCI USA, V103, P976, DOI 10.1073/pnas.0510146103
   Liu Zhen, 2010, Chin J Cancer, V29, P661
   Lo Nigro C, 2016, WORLD J GASTRO ONCOL, V8, P222, DOI 10.4251/wjgo.v8.i2.222
   Lo YL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090180
   Lo YL, 2013, BIOMED PHARMACOTHER, V67, P261, DOI 10.1016/j.biopha.2012.12.002
   LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0
   LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7
   LV Y, 2015, ONCOTARGETS THERAPY, V8, P1941, DOI DOI 10.2147/0TT.S82835
   Maamer-Azzabi A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.328
   Mahyar-Roemer M, 2001, INT J CANCER, V94, P615, DOI 10.1002/ijc.1516
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Martinet W, 2009, CIRC RES, V104, P304, DOI 10.1161/CIRCRESAHA.108.188318
   McDevitt CA, 2006, STRUCTURE, V14, P1623, DOI 10.1016/j.str.2006.08.014
   Meijer GA, 1999, J CLIN PATHOL, V52, P450, DOI 10.1136/jcp.52.6.450
   Meschini S, 2000, INT J CANCER, V87, P615, DOI 10.1002/1097-0215(20000901)87:5<615::AID-IJC1>3.0.CO;2-4
   Miyake K, 1999, CANCER RES, V59, P8
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Morita H, 2005, BIOORG MED CHEM LETT, V15, P1051, DOI 10.1016/j.bmcl.2004.12.026
   Mukhtar E, 2012, CURR DRUG TARGETS, V13, P1831, DOI 10.2174/138945012804545489
   Nabekura T, 2010, TOXINS, V2, P1207, DOI 10.3390/toxins2061207
   Neerati Prasad, 2013, J Cancer Sci Ther, V5, P313
   O'Connor R, 2007, CANCER CHEMOTH PHARM, V59, P79, DOI 10.1007/s00280-006-0240-7
   OConnor PM, 1997, CANCER RES, V57, P4285
   Okamoto K, 2015, MOL CANCER RES, V13, P659, DOI 10.1158/1541-7786.MCR-14-0476
   Ou SHI, 2015, DRUG DES DEV THER, V9, P5641, DOI 10.2147/DDDT.S52787
   Palmeira A, 2012, CURR MED CHEM, V19, P1946, DOI 10.2174/092986712800167392
   Pusztai L, 2005, CANCER-AM CANCER SOC, V104, P682, DOI 10.1002/cncr.21227
   Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941
   Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012
   Reles A, 2001, CLIN CANCER RES, V7, P2984
   Robey RW, 2007, CANCER METAST REV, V26, P39, DOI 10.1007/s10555-007-9042-6
   Ross DD, 1999, J NATL CANCER I, V91, P429, DOI 10.1093/jnci/91.5.429
   Rowinsky EK, 1998, J CLIN ONCOL, V16, P2964, DOI 10.1200/JCO.1998.16.9.2964
   Saloura V, 2014, CANCER CHEMOTH PHARM, V73, P1227, DOI 10.1007/s00280-014-2459-z
   Samuel T, 2002, CELL CYCLE, V1, P162, DOI 10.4161/cc.1.3.118
   Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102
   Sharom FJ, 2006, BIOCHEM CELL BIOL, V84, P979, DOI 10.1139/O06-199
   Shukla S, 2009, PHARM RES-DORDR, V26, P480, DOI 10.1007/s11095-008-9735-8
   Slot AJ, 2011, ESSAYS BIOCHEM, V50, P179, DOI [10.1042/BSE0500179, 10.1042/bse0500179]
   Sobrero AF, 2008, J CLIN ONCOL, V26, P2311, DOI 10.1200/JCO.2007.13.1193
   Solary E, 1996, EUR RESPIR J, V9, P1293, DOI 10.1183/09031936.96.09061293
   SPOELSTRA EC, 1991, BIOCHEM PHARMACOL, V41, P349, DOI 10.1016/0006-2952(91)90531-9
   Stein A, 2011, EUR J CANCER, V47, pS312, DOI 10.1016/S0959-8049(11)70183-6
   Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984
   Takara K, 2006, CURR PHARM DESIGN, V12, P273, DOI 10.2174/138161206775201965
   Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640
   Tatebe S, 2002, BIOCHEM BIOPH RES CO, V290, P1427, DOI 10.1006/bbrc.2002.6367
   Thomas Hilary, 2003, Cancer Control, V10, P159
   Tothova E, 2002, NEOPLASMA, V49, P141
   Traini R, 2010, MOL CANCER THER, V9, P2007, DOI 10.1158/1535-7163.MCT-10-0257
   Vacchelli E, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23510
   van der Holt B, 2005, BLOOD, V106, P2646, DOI 10.1182/blood-2005-04-1395
   van Zanden JJ, 2005, BIOCHEM PHARMACOL, V69, P1657, DOI 10.1016/j.bcp.2005.03.001
   Wang L, 2013, LIFE SCI, V93, P344, DOI 10.1016/j.lfs.2013.07.007
   Wang L, 2015, PHYTOMEDICINE, V22, P1079, DOI 10.1016/j.phymed.2015.08.009
   Wang T, 2015, J BIOL CHEM, V290, P448, DOI 10.1074/jbc.M114.590364
   Ward AB, 2013, P NATL ACAD SCI USA, V110, P13386, DOI 10.1073/pnas.1309275110
   Warner E, 1998, CLIN CANCER RES, V4, P1451
   Whibley C, 2009, NAT REV CANCER, V9, P95, DOI 10.1038/nrc2584
   White NJ, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P301
   Wilson BJ, 2011, CANCER RES, V71, P5307, DOI 10.1158/0008-5472.CAN-11-0221
   Wu CP, 2011, CURR PHARM BIOTECHNO, V12, P609, DOI 10.2174/138920111795163887
   Wu Chung-Pu, 2008, Curr Mol Pharmacol, V1, P93
   Wu CP, 2005, FEBS J, V272, P4725, DOI 10.1111/j.1742-4658.2005.04888.x
   Wu Y, 2016, COLLOID SURFACE B, V138, P60, DOI 10.1016/j.colsurfb.2015.11.041
   Xie N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103463
   YAHANDA AM, 1992, J CLIN ONCOL, V10, P1624, DOI 10.1200/JCO.1992.10.10.1624
   Yuan JH, 2009, CANCER CHEMOTH PHARM, V63, P1103, DOI 10.1007/s00280-008-0838-z
   Zhang H, 2014, BRIT J PHARMACOL, V171, P5845, DOI 10.1111/bph.12889
   Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989
   Zhang WX, 2009, EXPERT OPIN DRUG MET, V5, P789, DOI 10.1517/17425250902997967
   Zhang X, 2012, CELL PROLIFERAT, V45, P466, DOI 10.1111/j.1365-2184.2012.00833.x
   Zhang YC, 2015, MAR DRUGS, V13, P2267, DOI 10.3390/md13042267
   Zhu MM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041763
   Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0
NR 156
TC 175
Z9 180
U1 9
U2 58
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD AUG 14
PY 2016
VL 22
IS 30
BP 6876
EP 6889
DI 10.3748/wjg.v22.i30.6876
PG 14
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA DS4SC
UT WOS:000380770400010
PM 27570424
OA Green Published, hybrid
HC Y
HP N
DA 2022-04-25
ER

PT J
AU Lee, M
   Yang, CW
   Song, G
   Lim, W
AF Lee, Minkyeong
   Yang, Changwon
   Song, Gwonhwa
   Lim, Whasun
TI Eupatilin Impacts on the Progression of Colon Cancer by Mitochondria
   Dysfunction and Oxidative Stress
SO ANTIOXIDANTS
LA English
DT Article
DE eupatilin; colon cancer; apoptosis; oxidative stress; drug resistance
ID WILD-TYPE; ARTEMISIA PLANTS; CELL-DEATH; APOPTOSIS; AUTOPHAGY;
   PROLIFERATION; MIGRATION; SURVIVAL; INVASION; CYCLE
AB Colon cancer is one of the most frequently diagnosed cancer types. Some colon cancer cases resist standard anticancer drugs. Therefore, many studies have focused on developing therapeutic supplements using natural products with low side effects and broad physiological activity. Eupatilin is a flavonoid that is mainly extracted from artemisia and promotes apoptosis in numerous cancer types. However, since the current understanding of its physiological mechanisms on colon cancer cells is insufficient, we investigated how eupatilin affects the growth of two colon cancer cell lines, namely HCT116 and HT29. Our results showed that eupatilin inhibits cell viability and induces apoptosis accompanied by mitochondrial depolarization. It also induces oxidative stress in colon cancer cells and regulates the expression of proteins involved in the endoplasmic reticulum stress and autophagic process. Moreover, eupatilin may target the PI3K/AKT and mitogen-activated protein kinase (MAPK) signaling pathways in colon cancer cells. It also prevents colon cancer cell invasion. Furthermore, eupatilin has a synergistic effect with 5-fluorouracil (5-FU; a standard anticancer drug) on 5-FU-resistant HCT116 cells. These results suggest that eupatilin can be developed as an adjuvant to enhance traditional anticancer drugs in colon cancer.
C1 [Lee, Minkyeong; Lim, Whasun] Kookmin Univ, Coll Sci & Technol, Dept Food & Nutr, Seoul 02707, South Korea.
   [Yang, Changwon; Song, Gwonhwa] Korea Univ, Coll Life Sci & Biotechnol, Inst Anim Mol Biotechnol, Seoul 02841, South Korea.
   [Yang, Changwon; Song, Gwonhwa] Korea Univ, Coll Life Sci & Biotechnol, Dept Biotechnol, Seoul 02841, South Korea.
RP Lim, W (corresponding author), Kookmin Univ, Coll Sci & Technol, Dept Food & Nutr, Seoul 02707, South Korea.; Song, G (corresponding author), Korea Univ, Coll Life Sci & Biotechnol, Inst Anim Mol Biotechnol, Seoul 02841, South Korea.; Song, G (corresponding author), Korea Univ, Coll Life Sci & Biotechnol, Dept Biotechnol, Seoul 02841, South Korea.
EM m2019546@kookmin.ac.kr; ycw117@korea.ac.kr; ghsong@korea.ac.kr;
   wlim@kookmin.ac.kr
RI Yang, Changwon/AAV-7336-2021; Lim, Whasun/AAP-3156-2020
OI Yang, Changwon/0000-0001-5326-9124; Lim, Whasun/0000-0002-1328-0465
FU National Research Foundation of Korea (NRF) - Korea government (MSIT)
   [2021R1A2C2005841, 2021R1C1C1009807]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (MSIT) (No. 2021R1A2C2005841
   & 2021R1C1C1009807).
CR Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Bursch W, 2000, ANN NY ACAD SCI, V926, P1, DOI 10.1111/j.1749-6632.2000.tb05594.x
   Chambers JW, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M111.223602
   Cho JH, 2011, FOOD CHEM TOXICOL, V49, P1737, DOI 10.1016/j.fct.2011.04.019
   Choi EJ, 2011, LIFE SCI, V88, P1121, DOI 10.1016/j.lfs.2011.04.011
   Chun SY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-293
   Cristofaro M, 2015, BBA-MOL BASIS DIS, V1852, P1719, DOI 10.1016/j.bbadis.2015.05.009
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Fei XW, 2019, CANCER MANAG RES, V11, P4781, DOI 10.2147/CMAR.S207257
   Foty R, 2011, JOVE-J VIS EXP, DOI 10.3791/2720
   Gheytanchi E, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-021-01898-9
   Jegal KH, 2016, APOPTOSIS, V21, P642, DOI 10.1007/s10495-016-1233-6
   Jeong WJ, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0049-y
   Kim MJ, 2005, J ENVIRON PATHOL TOX, V24, P261, DOI 10.1615/JEnvironPatholToxicolOncol.v24.i4.30
   Landre T, 2015, INT J COLORECTAL DIS, V30, P1305, DOI 10.1007/s00384-015-2296-5
   Lee JY, 2020, CANCERS, V12, DOI 10.3390/cancers12061459
   Lim W, 2017, J CELL PHYSIOL, V232, P331, DOI 10.1002/jcp.25423
   Lin PL, 2014, CARCINOGENESIS, V35, P2175, DOI 10.1093/carcin/bgu110
   Martucciello S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21061905
   Nam SY, 2008, EXP BIOL MED, V233, P180, DOI 10.3181/0707-RM-186
   Park BB, 2013, TUMOR BIOL, V34, P875, DOI 10.1007/s13277-012-0621-y
   Park JY, 2018, BIOORG MED CHEM LETT, V28, P3150, DOI 10.1016/j.bmcl.2018.08.034
   Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004
   Pinton P, 2008, ONCOGENE, V27, P6407, DOI 10.1038/onc.2008.308
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Rosa A, 2020, FOOD FUNCT, V11, P5179, DOI [10.1039/d0fo00777c, 10.1039/D0FO00777C]
   Sauer H, 2001, CELL PHYSIOL BIOCHEM, V11, P173, DOI 10.1159/000047804
   Schonthal AH, 2012, SCIENTIFICA, V2012, DOI 10.6064/2012/857516
   Seo HJ, 2001, MUTAT RES-GEN TOX EN, V496, P191, DOI 10.1016/S1383-5718(01)00234-0
   Serttas R, 2021, ANTI-CANCER AGENT ME, V21, P372, DOI 10.2174/1871520620666200811113549
   Seto S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0086017
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Siraj AK, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109572
   Storey S, 2008, NAT REV DRUG DISCOV, V7, P971, DOI 10.1038/nrd2662
   Swart C, 2016, EUR J CELL BIOL, V95, P598, DOI 10.1016/j.ejcb.2016.10.005
   Tay KH, 2014, CELL SIGNAL, V26, P287, DOI 10.1016/j.cellsig.2013.11.008
   Teimoori-Toolabi L, 2015, ANTI-CANCER DRUG, V26, P187, DOI 10.1097/CAD.0000000000000175
   Touil Y, 2014, CLIN CANCER RES, V20, P837, DOI 10.1158/1078-0432.CCR-13-1854
   Wang XN, 2018, ONCOL REP, V39, P2942, DOI 10.3892/or.2018.6390
   Wang YW, 2016, MOL MED REP, V13, P1141, DOI 10.3892/mmr.2015.4671
   Webber EM, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1093-4
   Xie Q, 2016, WORLD J GASTROENTERO, V22, P7342, DOI 10.3748/wjg.v22.i32.7342
   Zhong WF, 2016, ONCOL LETT, V12, P2894, DOI 10.3892/ol.2016.4989
NR 45
TC 1
Z9 1
U1 5
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD JUN
PY 2021
VL 10
IS 6
AR 957
DI 10.3390/antiox10060957
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA TB3SJ
UT WOS:000667866800001
PM 34203665
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Wang, S
   Li, LM
   Zhou, YG
   He, Y
   Wei, YS
   Tao, AL
AF Wang, Shan
   Li, Linmei
   Zhou, Yaguang
   He, Ying
   Wei, Yisheng
   Tao, Ailin
TI Heterotypic cell-in-cell structures in colon cancer can be regulated by
   IL-6 and lead to tumor immune escape
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Cell-in-cell; Colorectal cancer; Lymphocyte; IL-6; Autophagy; Immune
   escape
ID CANNIBALISM; AUTOPHAGY; ENTOSIS; RESISTANCE; DEATH
AB Heterotypic CICs (cell-in-cell structures) have been found between tumor cells and various immune cells in a variety of cancer tissues. The frequency of CICs has been found to correlate with tumor malignancy in some studies but not in others. Herein, we examined in depth the CICs observed in colon cancer to determine their potential significance in disease progression. Heterotypic CICs were observed by histochemistry between epithelial cells and lymphocytes in an expanded spectrum of colon tissue from colitis to cancer and in vitro studies were performed using the colonic tumor cell line HCT8 and human peripheral blood lymphocytes. Our data revealed that the CICs formed by colonic epithelial cells and infiltrated lymphocytes not only positively correlated with tumor malignancy but also were upregulated by the inflammatory cytokine IL-6. In addition, we observed that colon cancer cells could initiate autophagy for survival after cytotoxic lymphocyte internalization and that IL-6 could also be involved in this process to promote the death of lymphocytes in CIC structures. Furthermore, certain changes were observed in tumor cells after experiencing CICs. Our findings suggest that CICs formed by colon cancer cells and lymphocytes contribute to tumor escape from immune surveillance, which could be facilitated by IL-6, and might represent a previously undescribed pathway for tumor cells to adapt and evade host immune defense.
C1 [Wang, Shan; Li, Linmei; He, Ying; Tao, Ailin] Guangzhou Med Univ, Guangdong Prov Key Lab Allergy & Clin Immunol, Ctr Inflammat Immunol & Immune Mediated Dis, State Key Lab Resp Dis,Affiliated Hosp 2, Guangzhou 510260, Guangdong, Peoples R China.
   [Zhou, Yaguang; Wei, Yisheng] Guangzhou Med Univ, Affiliated Hosp 2, Dept Gastrointestinal Surg, Guangzhou 510260, Guangdong, Peoples R China.
RP Tao, AL (corresponding author), Guangzhou Med Univ, Guangdong Prov Key Lab Allergy & Clin Immunol, Ctr Inflammat Immunol & Immune Mediated Dis, State Key Lab Resp Dis,Affiliated Hosp 2, Guangzhou 510260, Guangdong, Peoples R China.; Wei, YS (corresponding author), Guangzhou Med Univ, Affiliated Hosp 2, Dept Gastrointestinal Surg, Guangzhou 510260, Guangdong, Peoples R China.
EM taoailin@gzhmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81871266]; Guangzhou Science and Technology
   Plan Foundation [201604020008]
FX This work was supported by the National Natural Science Foundation of
   China (81402025, Shan Wang), the National Natural Science Foundation of
   China (81871266, Ailin Tao), Guangzhou Science and Technology Plan
   Foundation (201604020008).
CR Caruso R. A., 2012, Experimental Oncology, V34, P306
   Durgan J, 2017, ELIFE, V6, DOI 10.7554/eLife.27134
   Fais S, 2018, NAT REV CANCER, V18, P758, DOI 10.1038/s41568-018-0073-9
   Fais S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0111-7
   Fais S, 2012, TRENDS MOL MED, V18, P4, DOI 10.1016/j.molmed.2011.09.001
   Florey O, 2011, NAT CELL BIOL, V13, P1335, DOI 10.1038/ncb2363
   Fofaria NM, 2015, CARCINOGENESIS, V36, P142, DOI 10.1093/carcin/bgu233
   Hamann JC, 2017, CELL REP, V20, P201, DOI 10.1016/j.celrep.2017.06.037
   Hayakawa K, 2016, NATURE, V535, P551, DOI 10.1038/nature18928
   He MF, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.147
   Huang HY, 2015, ONCOTARGET, V6, P20278, DOI 10.18632/oncotarget.4275
   Kaczmarek E, 2014, PATHOL RES PRACT, V210, P147, DOI 10.1016/j.prp.2013.11.007
   Kumari N, 2016, TUMOR BIOL, V37, P11553, DOI 10.1007/s13277-016-5098-7
   Lin HY, 2012, J AGR FOOD CHEM, V60, P2480, DOI 10.1021/jf204362n
   Lozupone F, 2015, CURR MOL MED, V15, P836, DOI 10.2174/1566524015666151026100916
   Lozupone F, 2015, ONCOGENE, V34, P5163, DOI 10.1038/onc.2014.437
   Lozupone F, 2009, EMBO REP, V10, P1348, DOI 10.1038/embor.2009.236
   Lugini L, 2006, CANCER RES, V66, P3629, DOI 10.1158/0008-5472.CAN-05-3204
   Mailleux AA, 2011, M S-MED SCI, V27, P689, DOI 10.1051/medsci/2011278003
   Marino ML, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.67
   Marino ML, 2012, J BIOL CHEM, V287, P30664, DOI 10.1074/jbc.M112.339127
   Matassa DS, 2016, CELL DEATH DIFFER, V23, P1542, DOI 10.1038/cdd.2016.39
   Ni C, 2015, CELL RES, V25, P785, DOI 10.1038/cr.2015.50
   Overholtzer M, 2008, NAT REV MOL CELL BIO, V9, P796, DOI 10.1038/nrm2504
   Overholtzer M, 2007, CELL, V131, P966, DOI 10.1016/j.cell.2007.10.040
   Perez E, 2017, CELL DEATH DIFFER, V24, P759, DOI 10.1038/cdd.2017.39
   Pietrocola F, 2016, AUTOPHAGY, V12, P1962, DOI 10.1080/15548627.2016.1214778
   Poillet-Perez L, 2018, NATURE, V563, P569, DOI 10.1038/s41586-018-0697-7
   Sierro F, 2015, CURR MOL MED, V15, P819, DOI 10.2174/1566524015666151026102143
   Sun Q, 2014, CELL RES, V24, P1299, DOI 10.1038/cr.2014.138
   Takeuchi M, 2010, J MOL CELL BIOL, V2, P139, DOI 10.1093/jmcb/mjq002
   Wang S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.352
   Wang Y, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.25988
NR 33
TC 9
Z9 9
U1 1
U2 12
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD SEP 1
PY 2019
VL 382
IS 1
AR 111447
DI 10.1016/j.yexcr.2019.05.028
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA IO4CS
UT WOS:000479327700007
PM 31150612
DA 2022-04-25
ER

PT J
AU Rodriguez, ME
   Catrinacio, C
   Ropolo, A
   Rivarola, VA
   Vaccaro, MI
AF Rodriguez, M. E.
   Catrinacio, C.
   Ropolo, A.
   Rivarola, V. A.
   Vaccaro, M. I.
TI A novel HIF-1 alpha/VMP1-autophagic pathway induces resistance to
   photodynamic therapy in colon cancer cells
SO PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES
LA English
DT Article
ID INDUCED AUTOPHAGY; HIF-1-ALPHA STABILIZATION; TRANSCRIPTIONAL ACTIVITY;
   TUMOR HYPOXIA; APOPTOSIS; PROMOTES; CHEMOTHERAPY; MECHANISMS; INDUCTION;
   PROTEIN
AB Colon cancer is the third most frequent cancer and the fourth most common cause of cancer-related mortality worldwide and the standard therapy is surgical resection plus adjuvant chemotherapy. Photodynamic therapy (PDT) has been proposed as an adjuvant therapy because it can prevent the tumor recurrence after surgical excision in colon cancer patients. Hypoxia is a common feature in solid tumors and leads to chemo/radioresistance. Recently, it has been shown that in response to hypoxia, cells can induce HIF-1 alpha-mediated autophagy to survive in this hostile microenvironment. Moreover, hypoxia and autophagy have been implicated in the resistance to antitumor PDT. However, the molecular signals by which HIF-1 alpha induces autophagy in the PDT context have not been studied yet. Here we evaluate the interplay between HIF-1 alpha and autophagy as well as the underlying mechanism in the PDT resistance of colon cancer cells. Our study demonstrates that HIF-1 alpha stabilization significantly increases VMP1-related autophagy through binding to hypoxia responsive elements in the VMP1 promoter. We show that HIF-1 alpha-induced autophagy increases colon cancer cell survival as well as decreases cell death after PDT. Moreover, here we demonstrate that HIF-1 alpha-induced autophagy is mediated by VMP1 expression, since the downregulation of VMP1 by the RNA interference strategy reduces HIF-1 alpha-induced autophagy and cell survival after PDT. In conclusion, PDT induces autophagy as a survival mechanism and the induction of the novel HIF-1 alpha/VMP1-autophagic pathway may explain, at least in part, the resistance of colon cancer cells to PDT. The knowledge of the molecular mechanisms involved in PDT resistance may lead to more accurate therapeutic strategies.
C1 [Rodriguez, M. E.; Rivarola, V. A.] Univ Nacl Rio Cuarto, Dept Biol Mol, RA-5800 Cordoba, Argentina.
   [Rodriguez, M. E.; Catrinacio, C.; Ropolo, A.; Vaccaro, M. I.] Univ Buenos Aires, CONICET, Fac Farm & Bioquim, Inst Bioquim & Med Mol IBIMOL, Buenos Aires, DF, Argentina.
RP Vaccaro, MI (corresponding author), Univ Buenos Aires, CONICET, Fac Farm & Bioquim, Inst Bioquim & Med Mol IBIMOL, Buenos Aires, DF, Argentina.
EM mvaccaro@ffyb.uba.ar
RI Vaccaro, Maria I./L-8348-2017; Rodriguez, Matias/Q-4760-2017
OI Ropolo, Alejandro/0000-0003-4321-196X; Rivarola, v/0000-0001-7924-1445;
   Vaccaro, Maria/0000-0002-2456-747X; Rodriguez,
   Matias/0000-0002-5819-670X
CR Amelio I, 2015, TRENDS BIOCHEM SCI, V40, P425, DOI 10.1016/j.tibs.2015.04.007
   Balamurugan K, 2016, INT J CANCER, V138, P1058, DOI 10.1002/ijc.29519
   BARR H, 1990, BRIT J CANCER, V62, P730, DOI 10.1038/bjc.1990.368
   Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367
   Brown SB, 2004, LANCET ONCOL, V5, P497, DOI 10.1016/S1470-2045(04)01529-3
   Casas A, 2011, CURR MED CHEM, V18, P2486, DOI 10.2174/092986711795843272
   Castano AP, 2005, PHOTODIAGN PHOTODYN, V2, P1, DOI 10.1016/S1572-1000(05)00030-X
   Choi H, 2016, AUTOPHAGY, V12, P1631, DOI 10.1080/15548627.2016.1192753
   Cosse JP, 2008, ANTI-CANCER AGENT ME, V8, P790, DOI 10.2174/187152008785914798
   Curtis MJ, 2015, BRIT J PHARMACOL, V172, P3461, DOI 10.1111/bph.12856
   De Greef K, 2016, WORLD J GASTROENTERO, V22, P7215, DOI 10.3748/wjg.v22.i32.7215
   Del Bello B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057236
   Dewaele M, 2011, J CELL MOL MED, V15, P1402, DOI 10.1111/j.1582-4934.2010.01118.x
   Fan CD, 2006, BIOORGAN MED CHEM, V14, P3218, DOI 10.1016/j.bmc.2005.12.035
   FOSTER TH, 1991, RADIAT RES, V126, P296, DOI 10.2307/3577919
   Francois A, 2011, INT J ONCOL, V39, P1537, DOI 10.3892/ijo.2011.1174
   Gariboldi MB, 2015, CANCER LETT, V364, P156, DOI 10.1016/j.canlet.2015.05.008
   Grasso D, 2011, J BIOL CHEM, V286, P8308, DOI 10.1074/jbc.M110.197301
   Harhaji-Trajkovic L, 2009, J CELL MOL MED, V13, P3644, DOI 10.1111/j.1582-4934.2009.00663.x
   Heaney RM, 2015, WORLD J GASTRO ONCOL, V7, P445, DOI 10.4251/wjgo.v7.i12.445
   Ji ZY, 2006, CANCER LETT, V244, P182, DOI 10.1016/j.canlet.2005.12.010
   Jung SN, 2008, CARCINOGENESIS, V29, P713, DOI 10.1093/carcin/bgn032
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620
   LaGory EL, 2016, NAT CELL BIOL, V18, P356, DOI 10.1038/ncb3330
   Lee JY, 2013, CELL PHYSIOL BIOCHEM, V32, P417, DOI 10.1159/000354448
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Li YN, 2014, TOXICOL LETT, V224, P165, DOI 10.1016/j.toxlet.2013.10.029
   Lin L, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.985913
   Liu DL, 2011, MED ONCOL, V28, P105, DOI 10.1007/s12032-009-9397-3
   Liu T, 2014, INT J MOL MED, V33, P1236, DOI 10.3892/ijmm.2014.1661
   Lo Re AE, 2012, J BIOL CHEM, V287, P25325, DOI 10.1074/jbc.M112.370809
   Lopez-Sanchez LM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099143
   Ma XH, 2011, CLIN CANCER RES, V17, P3478, DOI 10.1158/1078-0432.CCR-10-2372
   Maycotte P, 2012, AUTOPHAGY, V8, P200, DOI 10.4161/auto.8.2.18554
   Michiels C, 2016, BBA-REV CANCER, V1866, P76, DOI 10.1016/j.bbcan.2016.06.004
   Sanabria LM, 2013, BBA-REV CANCER, V1835, P36, DOI 10.1016/j.bbcan.2012.10.001
   Mitra S, 2006, MOL CANCER THER, V5, P3268, DOI 10.1158/1535-7163.MCT-06-0421
   Molejon MI, 2013, AUTOPHAGY, V9, P933, DOI 10.4161/auto.24390
   Molejon MI, 2013, SCI REP-UK, V3, DOI 10.1038/srep01055
   O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066
   Oniszczuk A, 2016, BIOMED PHARMACOTHER, V83, P912, DOI 10.1016/j.biopha.2016.07.058
   Pardo R, 2010, PANCREATOLOGY, V10, P19, DOI 10.1159/000264680
   Pericas JM, 2016, NEW ENGL J MED, V375, P387, DOI [10.1056/NEJMra1513581, 10.1056/NEJMc1604867]
   Ropolo A, 2007, J BIOL CHEM, V282, P37124, DOI 10.1074/jbc.M706956200
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Shibata T, 2000, GENE THER, V7, P493, DOI 10.1038/sj.gt.3301124
   Shishkova N, 2013, J Gastrointest Cancer, V44, P251, DOI 10.1007/s12029-013-9496-4
   Sitnik TM, 1998, BRIT J CANCER, V77, P1386, DOI 10.1038/bjc.1998.231
   Sun Y, 2015, INT J ONCOL, V46, P750, DOI 10.3892/ijo.2014.2745
   Terman A, 2005, CARDIOVASC RES, V68, P355, DOI 10.1016/j.cardiores.2005.08.014
   Tittarelli A, 2015, J BIOL CHEM, V290, P23670, DOI 10.1074/jbc.M115.651547
   Tu PH, 2016, ONCOL REP, V35, P3209, DOI 10.3892/or.2016.4703
   Vaccaro MI, 2008, AUTOPHAGY, V4, P388, DOI 10.4161/auto.5656
   Vordermark D, 2005, CANCER LETT, V230, P122, DOI 10.1016/j.canlet.2004.12.040
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   Wilkinson S, 2009, GENE DEV, V23, P1283, DOI 10.1101/gad.521709
   Yang X, 2015, CELL BIOSCI, V5, DOI 10.1186/s13578-015-0005-2
   Yoo JO, 2012, INT REV CEL MOL BIO, V295, P139, DOI 10.1016/B978-0-12-394306-4.00010-1
NR 60
TC 32
Z9 33
U1 4
U2 28
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1474-905X
EI 1474-9092
J9 PHOTOCH PHOTOBIO SCI
JI Photochem. Photobiol. Sci.
PD NOV 1
PY 2017
VL 16
IS 11
BP 1631
EP 1642
DI 10.1039/c7pp00161d
PG 12
WC Biochemistry & Molecular Biology; Biophysics; Chemistry, Physical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Chemistry
GA FM2HV
UT WOS:000414806700006
PM 28936522
DA 2022-04-25
ER

PT J
AU Zhao, YL
   Fan, DM
   Zheng, ZP
   Li, ETS
   Chen, F
   Cheng, KW
   Wang, MF
AF Zhao, Yueliang
   Fan, Daming
   Zheng, Zong-Ping
   Li, Edmund T. S.
   Chen, Feng
   Cheng, Ka-Wing
   Wang, Mingfu
TI 8-C-(E-phenylethenyl)quercetin from onion/beef soup induces autophagic
   cell death in colon cancer cells through ERK activation
SO MOLECULAR NUTRITION & FOOD RESEARCH
LA English
DT Article
DE Autophagy; Colon cancer; ERK activation; 8-C-(E-phenylethenyl)quercetin;
   Onion; beef soup
ID HETEROCYCLIC AMINE FORMATION; MAILLARD REACTION; BEEF PATTIES; SIGNALING
   PATHWAY; PHENYLACETALDEHYDE; INHIBITION; PREVENTION; THERAPY; DISEASE;
   GROWTH
AB ScopeQuercetin, a flavonoid, widely distributed in edible fruits and vegetables, was reported to effectively inhibit 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine (PhIP) formation in a food model (roast beef patties) with itself being converted into a novel compound 8-C-(E-phenylethenyl)quercetin (8-CEPQ). Here we investigated whether 8-CEPQ could be formed in a real food system, and tested its anticancer activity in human colon cancer cell lines.
   Methods and resultsLC-MS was applied for the determination of 8-CEPQ formation in onion/beef soup. Anticancer activity of 8-CEPQ was evaluated by using cell viability assay and flow cytometry. Results showed that 8-CEPQ suppressed proliferationand caused G(2) phase arrest in colon cancer cells. Based on immunofluorescent staining assay, western blot assay, and RNA knockdown data, we found that 8-CEPQ did not cause apoptotic cell death. Instead, it induced autophagic cell death. Moreover, treatment with 8-CEPQ induced phosphorylation of extracellular signal-regulated kinase (ERK). Inhibition of ERK phosphorylation by the mitogen-activated protein kinasekinase (MEK)/ERK inhibitor U0126 attenuated 8-CEPQ-induced autophagy and reversed 8-CEPQ-mediated cell growth inhibition.
   ConclusionOur results demonstrate that 8-CEPQ, a novel quercetin derivative, could be formed in onion/beef soup. 8-CEPQ inhibited colon cancer cell growth by inducing autophagic cell death through ERK activation.
C1 [Zhao, Yueliang; Fan, Daming; Zheng, Zong-Ping; Li, Edmund T. S.; Wang, Mingfu] Univ Hong Kong, Sch Biol Sci, Hong Kong, Hong Kong, Peoples R China.
   [Chen, Feng; Cheng, Ka-Wing] Peking Univ, Inst Food & Bioresource Engn, Coll Engn, Beijing, Peoples R China.
RP Cheng, KW (corresponding author), Peking Univ, Inst Food & Bioresource Engn, Coll Engn, Beijing, Peoples R China.
EM kwcheng@pku.edu.cn; mfwang@hku.hk
RI Cheng, Ka Wing/V-9433-2019; Wang, Mingfu/AAT-3292-2021; Zheng,
   Zong-Ping/A-7400-2011; Wang, Mingfu/D-3136-2009
OI Zheng, Zong-Ping/0000-0002-0261-3711; Wang, Mingfu/0000-0003-1469-3963;
   Cheng, Ka Wing/0000-0002-1201-312X; Fan, Daming/0000-0002-4907-9034
FU Hong Kong Research Grants Council (GRF Project) [17154816]
FX The research was supported by the Hong Kong Research Grants Council (GRF
   Project No.: 17154816). The authors would like to thank Ms. Dorothy M.C.
   Chan and Ms. Iris M.Y. Tse for their technical support and kind advice
   on this research.
CR Blade C, 2013, MOL NUTR FOOD RES, V57, P58, DOI 10.1002/mnfr.201200454
   Carew JS, 2007, AUTOPHAGY, V3, P464, DOI 10.4161/auto.4311
   Chen SY, 2011, AUTOPHAGY, V7, P217, DOI 10.4161/auto.7.2.14212
   Cheng K.Y., 2009, THESIS
   Cheng KW, 2008, CHEM RES TOXICOL, V21, P2026, DOI 10.1021/tx800220h
   Cheng KW, 2007, J AGR FOOD CHEM, V55, P10359, DOI 10.1021/jf071820z
   Cheng KW, 2007, MOL NUTR FOOD RES, V51, P969, DOI 10.1002/mnfr.200700032
   Cheng KW, 2009, MOL NUTR FOOD RES, V53, P716, DOI 10.1002/mnfr.200800206
   Del Rio D, 2013, ANTIOXID REDOX SIGN, V18, P1818, DOI 10.1089/ars.2012.4581
   Gibis M, 2007, J AGR FOOD CHEM, V55, P10240, DOI 10.1021/jf071720t
   Grkovic S, 2013, ONCOGENE, V32, P2412, DOI 10.1038/onc.2012.264
   Hashimoto D, 2014, EUR J CANCER, V50, P1382, DOI 10.1016/j.ejca.2014.01.011
   Hoyer-Hansen M, 2008, AUTOPHAGY, V4, P574, DOI 10.4161/auto.5921
   Huang J, 2007, CELL CYCLE, V6, P1837, DOI 10.4161/cc.6.15.4511
   Jaeger H, 2010, PATHOL BIOL, V58, P207, DOI 10.1016/j.patbio.2009.09.016
   Janoszka B, 2010, FOOD CHEM, V120, P463, DOI 10.1016/j.foodchem.2009.10.039
   Kondo Y, 2006, AUTOPHAGY, V2, P85, DOI 10.4161/auto.2.2.2463
   Lachman J., 2003, Zahradnictvi (Horticultural Science), V30, P142
   Li DD, 2009, ONCOGENE, V28, P886, DOI 10.1038/onc.2008.441
   Li HT, 2014, CANCER RES, V74, P243, DOI 10.1158/0008-5472.CAN-13-2245
   Liu WT, 2011, AUTOPHAGY, V7, P166, DOI 10.4161/auto.7.2.14043
   Martins SIFS, 2000, TRENDS FOOD SCI TECH, V11, P364, DOI 10.1016/S0924-2244(01)00022-X
   Murakami A, 2008, CANCER LETT, V269, P315, DOI 10.1016/j.canlet.2008.03.046
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200
   Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x
   Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200
   Rothwell JA, 2015, MOL NUTR FOOD RES, V59, P160, DOI 10.1002/mnfr.201400494
   Russo M, 2012, BIOCHEM PHARMACOL, V83, P6, DOI 10.1016/j.bcp.2011.08.010
   Scalbert A, 2005, CRIT REV FOOD SCI, V45, P287, DOI 10.1080/1040869059096
   Sivaprasad U, 2008, J CELL MOL MED, V12, P1265, DOI 10.1111/j.1582-4934.2008.00282.x
   Somoza V, 2005, MOL NUTR FOOD RES, V49, P663, DOI 10.1002/mnfr.200500034
   Wong D, 2012, FOOD CHEM, V133, P760, DOI 10.1016/j.foodchem.2012.01.089
   Wu JC, 2015, MOL NUTR FOOD RES, V59, P2511, DOI 10.1002/mnfr.201500373
   Wu WKK, 2010, AUTOPHAGY, V6, P228, DOI 10.4161/auto.6.2.11042
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
   Zhang Y, 2015, MOL NUTR FOOD RES, V59, P1443, DOI 10.1002/mnfr.201500016
   Zhao Y., 2017, MOL NUTR FOOD RES
   Zheng ZP, 2016, FOOD CHEM, V197, P1085, DOI 10.1016/j.foodchem.2015.11.104
   Zhu Q, 2016, FOOD FUNCT, V7, P1057, DOI 10.1039/c5fo01055a
NR 40
TC 38
Z9 40
U1 2
U2 50
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1613-4125
EI 1613-4133
J9 MOL NUTR FOOD RES
JI Mol. Nutr. Food Res.
PD FEB
PY 2017
VL 61
IS 2
AR 1600437
DI 10.1002/mnfr.201600437
PG 10
WC Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology
GA EL7ZV
UT WOS:000394840800017
PM 27670274
DA 2022-04-25
ER

PT J
AU Xu, ZH
   Yang, KL
   Li, XH
AF Xu, Zhiheng
   Yang, Kailun
   Li, Xiaohua
TI Inhibitory effect of glucocorticoid receptor on colorectal cancer growth
   by inhibiting glycolysis through autophagy
SO MATERIALS EXPRESS
LA English
DT Article
DE Colon Cancer; LoVo Cells; Glucocorticoid Receptor; Glycolysis
ID NUMBER VARIATION ANALYSIS; MAGNETIC NANOPARTICLES; EXPRESSION;
   METABOLISM; GLUCOSE; TARGET; CELLS; LIVER; GLUCONEOGENESIS; CORTISOL
AB Glucocorticoid receptor (GR) affects the development and progression of most malignant tumors by regulating autophagy. The GR gene is not expressed in colon cancer. To explore the role and mechanism of GR in colon cancer, dexamethasone (DXM) was used to stimulate the expression of GR. The expression of the autophagy markers Beclin 1 (BECN1) and light chain 3 (LC3B) was then detected by qRT-PCR and western blotting. The effects of the differential expression of GR on autophagy, ATP, lactic acid accumulation, and glucose utilization in colon cancer cells were studied. Differential expression of GR affected glycolysis, apoptosis, and migration of colon cancer cells, as determined by flow cytometry and cell viability and migration assays, respectively. The DXM-induced elevation of GR expression significantly promoted the expression of the autophagy-related genes BECN1 and LC3B, and decreased the ATP production, lactic acid accumulation, and glucose uptake in colon cancer cells. These events resulted in the inhibition of colon cancer cell growth, which also involved decreased cell viability and mobility and increased rate of apoptosis. These findings indicate that the GR can promote autophagy and inhibit glycolysis in colon cancer cells, reduce their proliferation and migration, and promote their apoptosis in vitro.
C1 [Xu, Zhiheng] Guangzhou Univ Tradit Chinese Med, Gastrointestinal Thyroid Surg, Affiliated Hosp 1, Guangzhou 510405, Guangdong, Peoples R China.
   [Yang, Kailun; Li, Xiaohua] Guangzhou Univ Chinese Med, Clin Med Inst 1, Guangzhou 510405, Guangdong, Peoples R China.
RP Xu, ZH (corresponding author), Guangzhou Univ Tradit Chinese Med, Gastrointestinal Thyroid Surg, Affiliated Hosp 1, Guangzhou 510405, Guangdong, Peoples R China.
EM 994830503@qq.com
CR Canalis E, 2002, J PEDIATR ENDOCR MET, V15, P1341
   Chen SY, 2017, ONCOL LETT, V14, P5575, DOI 10.3892/ol.2017.6890
   Chen Z, 2018, NANOSCI NANOTECH LET, V10, P60, DOI 10.1166/nnl.2018.2595
   De P, 2014, ONCOTARGET, V5, P4581, DOI 10.18632/oncotarget.2127
   Deng J., 2019, AUTOPHAGY, P1
   Ding LJ, 2017, PHARMACOLOGY, V99, P188, DOI 10.1159/000452340
   Grempler R, 2007, DIABETES, V56, P2235, DOI 10.2337/db06-1660
   Guan J, 2017, ARCH PATHOL LAB MED, V141, P851, DOI 10.5858/arpa.2016-0361-RA
   Guo CM, 2014, ENDOCRINOLOGY, V155, P3017, DOI 10.1210/en.2013-1848
   Hong H., 2010, CANCER, V101, P83
   Hong M, 2013, CLIN EXP VACCINE RES, V2, P66, DOI 10.7774/cevr.2013.2.1.66
   Huang R., 2019, SMALL, V15, P1
   Johnson J A, 1972, Adv Metab Disord, V60, P1
   Kalaitzis J, 2010, WORLD J SURG ONCOL, V8, DOI 10.1186/1477-7819-8-17
   Kawaguchi T, 2001, P NATL ACAD SCI USA, V98, P13710, DOI 10.1073/pnas.231370798
   Kawamura A, 1998, NEUROL MED-CHIR, V38, P633, DOI 10.2176/nmc.38.633
   Kim ST, 2012, REPROD SCI, V19, P92, DOI 10.1177/1933719111414209
   Ladoire S, 2015, AUTOPHAGY, V11, P1878, DOI 10.1080/15548627.2015.1082022
   Liu HN, 2017, J BIOMED NANOTECHNOL, V13, P1333, DOI 10.1166/jbn.2017.2418
   Liu JT, 2016, MED ONCOL, V33, DOI 10.1007/s12032-015-0721-9
   Liu M, 2015, THERANOSTICS, V5, P71, DOI 10.7150/thno.10117
   Marek CB, 2011, CHEM-BIOL INTERACT, V193, P22, DOI 10.1016/j.cbi.2011.04.010
   Marin-Hernandez A, 2006, FEBS J, V273, P1975, DOI 10.1111/j.1742-4658.2006.05214.x
   MelendezHevia E, 1997, EUR J BIOCHEM, V244, P527, DOI 10.1111/j.1432-1033.1997.t01-1-00527.x
   Mou XB, 2016, CHINESE CHEM LETT, V27, P1661, DOI 10.1016/j.cclet.2016.04.005
   Nakahira K, 2013, AM J PHYSIOL-LUNG C, V305, pL93, DOI 10.1152/ajplung.00072.2013
   Rui LY, 2014, COMPR PHYSIOL, V4, P177, DOI 10.1002/cphy.c130024
   Salska A, 2016, ACTA CARDIOL, V71, P505, DOI [10.1080/AC.71.5.3167493, 10.2143/AC.71.5.3167493]
   Schembri J, 2017, ANN GASTROENTEROL, V30, P257, DOI 10.20524/aog.2017.0126
   Sun Ye, 2018, Acta Veterinaria et Zootechnica Sinica, V49, P2340
   Sundahl N, 2015, PHARMACOL THERAPEUT, V152, P28, DOI 10.1016/j.pharmthera.2015.05.001
   Teles M, 2013, MAR BIOTECHNOL, V15, P104, DOI 10.1007/s10126-012-9467-y
   Teng JA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149822
   Xiao XY, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-151
   Yang HW, 2017, J BIOMED NANOTECHNOL, V13, P655, DOI 10.1166/jbn.2017.2386
   Zhang E., 2011, PLOS ONE, V6, P1
NR 36
TC 3
Z9 3
U1 0
U2 7
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 2158-5849
EI 2158-5857
J9 MATER EXPRESS
JI Mater. Express
PD MAR
PY 2020
VL 10
IS 3
BP 363
EP 373
DI 10.1166/mex.2020.1648
PG 11
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Materials Science
GA KR7ET
UT WOS:000517779400006
DA 2022-04-25
ER

PT J
AU Sheng, QS
   Li, F
   Chen, GP
   Li, JC
   Li, J
   Wang, YF
   Lu, YY
   Li, Q
   Li, MQ
   Chai, KQ
AF Sheng, Qinsong
   Li, Fei
   Chen, Guanping
   Li, Jiacheng
   Li, Jing
   Wang, YiFan
   Lu, Yingyan
   Li, Qun
   Li, Mingqian
   Chai, Kequn
TI Ursolic Acid Regulates Intestinal Microbiota and Inflammatory Cell
   Infiltration to Prevent Ulcerative Colitis
SO JOURNAL OF IMMUNOLOGY RESEARCH
LA English
DT Article
ID SIGNALING PATHWAYS; COLORECTAL-CANCER; GROWTH; MODEL; ANTIBACTERIAL;
   MECHANISMS; APOPTOSIS; AUTOPHAGY; SEQUENCES
AB Ulcerative colitis (UC) is a chronic and relapsing inflammatory bowel disorder in the colon and rectum leading to low life-quality and high societal costs. Ursolic acid (UA) is a natural product with pharmacological and biological activities. The studies are aimed at investigating the protective and treatment effects of UA against the dextran sulfate sodium- (DSS-) induced UC mouse model and its underlying mechanism. UA was orally administered at different time points before and after the DSS-induced model. Mice body weight, colon length, and histological analysis were used to evaluate colon tissue damage and therapeutic evaluation. Intestinal transcriptome and microbe 16 s sequencing was used to analyze the mechanisms of UA in the prevention and treatment of UC. The early prevention effect of UA could effectively delay mouse weight loss and colon length shorten. UA alleviated UC inflammation and lowered serum and colon IL-6 levels. Three classical inflammatory pathways: MAPKs, IL-6/STAT3, and PI3K were downregulated by UA treatment. The proportion of macrophages and neutrophils in inflammatory cell infiltration was reduced in UA treatment groups. UA could significantly reduce the richness of intestinal flora to avoid the inflammatory response due to the destruction of the intestinal epithelial barrier. The function of UA against UC was through reducing intestinal flora abundance and regulating inflammatory and fatty acid metabolism signaling pathways to affect immune cell infiltration and cytokine expression.
C1 [Sheng, Qinsong] Zhejiang Univ, Affiliated Hosp 1, Dept Colorectal & Anal Surg, Coll Med, Hangzhou, Peoples R China.
   [Li, Fei; Li, Jiacheng; Li, Qun] Sichuan Normal Univ, Coll Life Sci, Chengdu 610101, Sichuan, Peoples R China.
   [Li, Fei; Chen, Guanping; Li, Jiacheng; Li, Jing; Wang, YiFan; Lu, Yingyan; Li, Mingqian; Chai, Kequn] Zhejiang Acad Tradit Chinese Med, Tongde Hosp Zhejiang Prov, Canc Inst Integrated Tradit Chinese & Western Med, Hangzhou 310012, Zhejiang, Peoples R China.
RP Li, MQ; Chai, KQ (corresponding author), Zhejiang Acad Tradit Chinese Med, Tongde Hosp Zhejiang Prov, Canc Inst Integrated Tradit Chinese & Western Med, Hangzhou 310012, Zhejiang, Peoples R China.
EM shengqinsong@zju.edu.cn; 1689458645@qq.com; beyond_cgp@163.com;
   1767371131@qq.com; lijing87.2.8@163.com; yifan.wang11@foxmail.com;
   1416941280@qq.com; liqun01234@163.com; limingqian613@163.com;
   ckq_official@163.com
OI Li, Mingqian/0000-0002-3296-6868
FU Natural Science Foundation of Zhejiang provinceNatural Science
   Foundation of Zhejiang Province [LY19H280005, LY18H160018, LQ19H030004];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81673809, 82074093]; Scientific and
   Technological Program of Zhejiang province [2017F10024]; Traditional
   Chinese Medicine Scientific Program of Zhejiang province [2016ZQ002]
FX The work was supported by grants from the Natural Science Foundation of
   Zhejiang province (Grant Nos. LY19H280005, LY18H160018, and
   LQ19H030004), National Natural Science Foundation of China (Grant Nos.
   81673809 and 82074093), Scientific and Technological Program of Zhejiang
   province (Grant No. 2017F10024), and Traditional Chinese Medicine
   Scientific Program of Zhejiang province (Grant No. 2016ZQ002).
CR Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303
   Chen ZY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01286
   Chun J, 2014, LIFE SCI, V110, P23, DOI 10.1016/j.lfs.2014.06.018
   DIELEMAN LA, 1994, GASTROENTEROLOGY, V107, P1643, DOI 10.1016/0016-5085(94)90803-6
   Edgar RC, 2013, NAT METHODS, V10, P996, DOI [10.1038/NMETH.2604, 10.1038/nmeth.2604]
   Farrell RJ, 2002, LANCET, V359, P331, DOI 10.1016/S0140-6736(02)07499-8
   Fujio-Vejar S, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01221
   Furrie E, 2004, GUT, V53, P91, DOI 10.1136/gut.53.1.91
   Hawkins PT, 2015, BBA-MOL CELL BIOL L, V1851, P882, DOI 10.1016/j.bbalip.2014.12.006
   HUANG MT, 1994, CANCER RES, V54, P701
   Imam T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01212
   Jager S, 2009, MOLECULES, V14, P2016, DOI 10.3390/molecules14062016
   Jang SE, 2014, J AGR FOOD CHEM, V62, P9711, DOI 10.1021/jf501487v
   Kaminska B, 2005, BBA-PROTEINS PROTEOM, V1754, P253, DOI 10.1016/j.bbapap.2005.08.017
   Khan I, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8030126
   Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]
   Kunkel SD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039332
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559
   Le Berre C, 2020, CLIN GASTROENTEROL H, V18, P14, DOI 10.1016/j.cgh.2019.07.005
   Lewinska A, 2017, APOPTOSIS, V22, P800, DOI 10.1007/s10495-017-1353-7
   Li J, 2015, INFLAMM BOWEL DIS, V21, P139, DOI 10.1097/MIB.0000000000000215
   Li XN, 2009, DIABETES, V58, P2246, DOI 10.2337/db08-1512
   Liu BH, 2016, MOL MED REP, V13, P4779, DOI 10.3892/mmr.2016.5094
   Luo J, 2017, EXP THER MED, V14, P3623, DOI 10.3892/etm.2017.4965
   Ma JQ, 2015, CLIN RES HEPATOL GAS, V39, P188, DOI 10.1016/j.clinre.2014.09.007
   MACDERMOTT RP, 1988, ADV IMMUNOL, V42, P285, DOI 10.1016/S0065-2776(08)60848-2
   Magoc T, 2011, BIOINFORMATICS, V27, P2957, DOI 10.1093/bioinformatics/btr507
   Marchal-Bressenot A, 2016, GUT, V65, P1919, DOI 10.1136/gutjnl-2016-312722
   Nishida A, 2018, CLIN J GASTROENTEROL, V11, P1, DOI 10.1007/s12328-017-0813-5
   O'Neill HM, 2013, MOL CELL ENDOCRINOL, V366, P135, DOI 10.1016/j.mce.2012.06.019
   Ooi CJ, 1999, CURR OPIN GASTROEN, V15, P298, DOI 10.1097/00001574-199907000-00004
   Prasad S, 2012, CLIN CANCER RES, V18, P4942, DOI 10.1158/1078-0432.CCR-11-2805
   Scoville EA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39232-z
   Seo DY, 2018, KOREAN J PHYSIOL PHA, V22, P235, DOI 10.4196/kjpp.2018.22.3.235
   Shores DR, 2011, INFLAMM BOWEL DIS, V17, P2192, DOI 10.1002/ibd.21560
   Volarevic V, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8070709
   Wan SZ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01321
   Wan SZ, 2020, PEERJ, V8, DOI 10.7717/peerj.9050
   Wang CM, 2016, MOLECULES, V21, DOI 10.3390/molecules21070884
   Wang CM, 2016, MOLECULES, V21, DOI 10.3390/molecules21020139
   Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07
   Wang SW, 2014, INT J ONCOL, V44, P1032, DOI 10.3892/ijo.2014.2259
   Wera O, 2016, J CLIN MED, V5, DOI 10.3390/jcm5120118
   Wiese DM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156387
   Wu W, 2016, INFLAMM BOWEL DIS, V22, P1473, DOI 10.1097/MIB.0000000000000775
   Yang LJ, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0330-2
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhang SL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01674
   Zhang W, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00956
   Zhou L, 2013, ORAL DIS, V19, P494, DOI 10.1111/odi.12031
   Zuo T, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02247
NR 51
TC 3
Z9 3
U1 4
U2 10
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-8861
EI 2314-7156
J9 J IMMUNOL RES
JI J Immunol. Res.
PD MAY 3
PY 2021
VL 2021
AR 6679316
DI 10.1155/2021/6679316
PG 16
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA SX1CY
UT WOS:000664950500001
PM 34007853
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Ahn, CH
   Jeong, EG
   Lee, JW
   Kim, MS
   Kim, SH
   Kim, SS
   Yoo, NJ
   Lee, SH
AF Ahn, Chang Hyeok
   Jeong, Eun Goo
   Lee, Jong Woo
   Kim, Min Sung
   Kim, Sung Hee
   Kim, Sung Soo
   Yoo, Nam Jin
   Lee, Sug Hyung
TI Expression of beclin-1, an autophagy-related protein, in gastric and
   colorectal cancers
SO APMIS
LA English
DT Article
DE Beclin-1; autophagy; expression; gastric cancer; colorectal cancer
ID TUMOR-SUPPRESSOR; INACTIVATING MUTATIONS; INDUCED APOPTOSIS; GENE;
   TUMORIGENESIS; CARCINOMAS; CASPASE-9; DEATH
AB Autophagy plays important roles in both cell death and cell survival. Beclin-1, a key regulator of autophagy formation, has been considered as a haploinsufficient tumor suppressor. Loss of expression or point mutation could serve as a mechanism of loss of beclin-1 tumor suppressor function in cancers. However, our recent study revealed that point mutation of the beclin-1 gene is a rare event in common human cancers. In this study we investigated beclin-1 protein expression in 103 colorectal and 60 gastric carcinoma tissues by immunohistochemistry using a tissue microarray approach. In the cancers, expression of beclin-1 was detected in 95% of the colorectal carcinomas and 83% of the gastric carcinomas. In contrast, normal mucosal cells of both stomach and colon showed no or very weak expression of beclin-1. There was no significant association of beclin-1 expression with clinocopathologic characteristics, including invasion, metastasis and stage. The beclin-1 expression of colorectal and gastric cancers in the present study is quite in contrast to that of the breast cancers in the previous study, which showed a decreased beclin-1 expression in breast cancer cells compared to normal breast cells. Our data indicate that beclin-1 inactivation by loss of expression may not occur in colorectal and gastric cancers. Rather, increased expression of beclin-1 in the malignant colorectal and gastric epithelial cells compared to their normal mucosal epithelial cells suggests that neo-expression of beclin-1 may play a role in both colorectal and gastric tumorigenesis.
C1 [Jeong, Eun Goo; Lee, Jong Woo; Kim, Min Sung; Kim, Sung Hee; Yoo, Nam Jin; Lee, Sug Hyung] Catholic Univ, Coll Med, Dept Pathol, Seoul 137701, South Korea.
   [Ahn, Chang Hyeok] Catholic Univ, Coll Med, Dept Surg, Seoul 137701, South Korea.
   [Kim, Sung Hee] Catholic Univ, Coll Med, Dept Internal Med, Seoul 137701, South Korea.
RP Lee, SH (corresponding author), Catholic Univ, Coll Med, Dept Pathol, 505 Banpo Dong, Seoul 137701, South Korea.
EM suhulee@catholic.ac.kr
CR Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Daniel F, 2006, WORLD J GASTROENTERO, V12, P2895, DOI 10.3748/wjg.v12.i18.2895
   Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011
   Furuya D, 2005, EXP CELL RES, V307, P26, DOI 10.1016/j.yexcr.2005.02.023
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Kim HS, 2003, GASTROENTEROLOGY, V125, P708, DOI 10.1016/S0016-5085(03)01059-X
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Lee JW, 2007, APMIS, V115, P750, DOI 10.1111/j.1600-0463.2007.apm_640.x
   Lee SH, 1999, ONCOGENE, V18, P3754, DOI 10.1038/sj.onc.1202769
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liang XH, 2001, CANCER RES, V61, P3443
   Marx J, 2006, SCIENCE, V312, P1160, DOI 10.1126/science.312.5777.1160
   Miracco C, 2007, INT J ONCOL, V30, P429
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7
   Shin MS, 2002, BLOOD, V99, P4094, DOI 10.1182/blood.V99.11.4094
   Yoo NJ, 2007, APMIS, V115, P354, DOI 10.1111/j.1600-0463.2007.apm_632.x
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
NR 22
TC 168
Z9 187
U1 1
U2 21
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0903-4641
J9 APMIS
JI APMIS
PD DEC
PY 2007
VL 115
IS 12
BP 1344
EP 1349
DI 10.1111/j.1600-0463.2007.00858.x
PG 6
WC Immunology; Microbiology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Microbiology; Pathology
GA 244IM
UT WOS:000251859600003
PM 18184403
DA 2022-04-25
ER

PT J
AU Cho, YY
   Kim, DJ
   Lee, HS
   Jeong, CH
   Cho, EJ
   Kim, MO
   Byun, S
   Lee, KY
   Yao, K
   Carper, A
   Langfald, A
   Bode, AM
   Dong, ZG
AF Cho, Yong-Yeon
   Kim, Dong Joon
   Lee, Hye Suk
   Jeong, Chul-Ho
   Cho, Eun-Jin
   Kim, Myong-Ok
   Byun, Sanguine
   Lee, Kun-Yeong
   Yao, Ke
   Carper, Andria
   Langfald, Alyssa
   Bode, Ann M.
   Dong, Zigang
TI Autophagy and Cellular Senescence Mediated by Sox2 Suppress Malignancy
   of Cancer Cells
SO PLOS ONE
LA English
DT Article
ID INHIBITION; INDUCTION; GROWTH; DEATH; PTEN; PLURIPOTENCY; MECHANISMS;
   PHENOTYPE; APOPTOSIS; PATHWAY
AB Autophagy is a critical cellular process required for maintaining cellular homeostasis in health and disease states, but the molecular mechanisms and impact of autophagy on cancer is not fully understood. Here, we found that Sox2, a key transcription factor in the regulation of the "stemness'' of embryonic stem cells and induced-pluripotent stem cells, strongly induced autophagic phenomena, including intracellular vacuole formation and lysosomal activation in colon cancer cells. The activation occurred through Sox2-mediated ATG10 gene expression and resulted in the inhibition of cell proliferation and anchorage-independent colony growth ex vivo and tumor growth in vivo. Further, we found that Sox2-induced-autophagy enhanced cellular senescence by up-regulating tumor suppressors or senescence factors, including p16(INK4a), p21 and phosphorylated p53 (Ser15). Notably, knockdown of ATG10 in Sox2-expressing colon cancer cells restored cancer cell properties. Taken together, our results demonstrated that regulation of autophagy mediated by Sox2 is a mechanism-driven novel strategy to treat human colon cancers.
C1 [Kim, Dong Joon; Jeong, Chul-Ho; Cho, Eun-Jin; Kim, Myong-Ok; Byun, Sanguine; Lee, Kun-Yeong; Yao, Ke; Carper, Andria; Langfald, Alyssa; Bode, Ann M.; Dong, Zigang] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA.
   [Cho, Yong-Yeon; Lee, Hye Suk] Catholic Univ Korea, Coll Pharm, Gyeonggi Do, South Korea.
RP Cho, YY (corresponding author), Catholic Univ Korea, Coll Pharm, Gyeonggi Do, South Korea.
EM yongyeon@catholic.ac.kr; zgdong@hi.umn.edu
RI Byun, Sanguine/AAR-5451-2021; Cho, Yong-Yeon/AAD-4263-2020
OI Byun, Sanguine/0000-0003-3903-5887
FU Hormel Foundation; National Institutes of HealthUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USA
   [CA111536, CA120388, CA077646, R37CA081064, ES016548]; Catholic
   University of Korea [M-2011-B0002-00025]; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R01CA120388, R01CA111536, R37CA081064, R01CA077646] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Environmental Health
   Sciences (NIEHS) [R01ES016548] Funding Source: NIH RePORTER
FX This work was supported in part by The Hormel Foundation and National
   Institutes of Health grants CA111536, CA120388, CA077646, R37CA081064
   and ES016548, and by the Research Fund, M-2011-B0002-00025 of The
   Catholic University of Korea. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Altman BJ, 2009, MOL BIOL CELL, V20, P1180, DOI 10.1091/mbc.E08-08-0829
   Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)82148-6
   Chen YP, 2008, J BIOL CHEM, V283, P17969, DOI 10.1074/jbc.M802917200
   Choi HJ, 2006, GLYCOBIOLOGY, V16, P573, DOI 10.1093/glycob/cwj105
   Colakoglu T, 2008, AM J SURG, V195, P719, DOI 10.1016/j.amjsurg.2007.05.061
   COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935
   Ertmer A, 2007, LEUKEMIA, V21, P936, DOI 10.1038/sj.leu.2404606
   Ferbeyre G, 2000, GENE DEV, V14, P2015
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Gu PL, 2005, MOL CELL BIOL, V25, P8507, DOI 10.1128/MCB.25.19.8507-8519.2005
   Huang SB, 2010, AUTOPHAGY, V6, P256, DOI 10.4161/auto.6.2.11124
   Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Kim S, 2002, GASTROENTEROLOGY, V123, P1163, DOI 10.1053/gast.2002.36043
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kourtis N, 2009, CELL DEATH DIFFER, V16, P21, DOI 10.1038/cdd.2008.120
   Kuo TC, 2011, NAT CELL BIOL, V13, P1214, DOI 10.1038/ncb2332
   Lee SB, 2007, EMBO REP, V8, P360, DOI 10.1038/sj.embor.7400917
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Menendez JA, 2011, CELL CYCLE, V10, P3658, DOI 10.4161/cc.10.21.18128
   Narita M, 2006, CELL, V126, P503, DOI 10.1016/j.cell.2006.05.052
   Oh S, 2011, CELL DEATH DIFFER, V18, P452, DOI 10.1038/cdd.2010.116
   Otsubo T, 2008, BRIT J CANCER, V98, P824, DOI 10.1038/sj.bjc.6604193
   Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127
   RHEINWALD JG, 1981, CANCER RES, V41, P1657
   Rodriguez-Pinilla SM, 2007, MODERN PATHOL, V20, P474, DOI 10.1038/modpathol.3800760
   Sauer H, 2004, EXP CELL RES, V294, P313, DOI 10.1016/j.yexcr.2003.10.032
   Scarlatti F, 2004, J BIOL CHEM, V279, P18384, DOI 10.1074/jbc.M313561200
   Schmelter M, 2006, FASEB J, V20, P1182, DOI 10.1096/fj.05-4723fje
   SCHWEICHEL JU, 1973, TERATOLOGY, V7, P253, DOI 10.1002/tera.1420070306
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Singletary K, 2008, CANCER EPIDEM BIOMAR, V17, P1596, DOI 10.1158/1055-9965.EPI-07-2917
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tay Y, 2008, NATURE, V455, P1124, DOI 10.1038/nature07299
   Tsang CK, 2007, DRUG DISCOV TODAY, V12, P112, DOI 10.1016/j.drudis.2006.12.008
   Turcotte S, 2010, CURR OPIN CELL BIOL, V22, P246, DOI 10.1016/j.ceb.2009.12.007
   Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000
   Wacnik PW, 2005, PAIN, V115, P95, DOI 10.1016/j.pain.2005.02.024
   Wang RC, 2010, FEBS LETT, V584, P1417, DOI 10.1016/j.febslet.2010.01.009
   Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zhang XL, 2005, J BIOL CHEM, V280, P19635, DOI 10.1074/jbc.M502262200
   Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4
NR 49
TC 25
Z9 34
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 25
PY 2013
VL 8
IS 2
AR e57172
DI 10.1371/journal.pone.0057172
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 115ZB
UT WOS:000316849500075
PM 23451179
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhang, R
   Xu, J
   Zhao, J
   Bai, JH
AF Zhang, Rui
   Xu, Jian
   Zhao, Jian
   Bai, Jinghui
TI Mir-30d suppresses cell proliferation of colon cancer cells by
   inhibiting cell autophagy and promoting cell apoptosis
SO TUMOR BIOLOGY
LA English
DT Article
DE MiR-30d; colon cancer; apoptosis; autophagy
ID LUNG-CANCER; COLORECTAL-CANCER; UBIQUITIN LIGASES; MIRNA EXPRESSION;
   PROSTATE-CANCER; BREAST-CANCER; REGULATOR; PATHWAY
AB MiR-30 family plays an important role in the tumorigenesis of human cancers. The aim of the study is to investigate the role of miR-30d in human colon cancer cell lines and explore the molecular mechanism in the proliferation of colon cancer cells. The expression of miR-30d was determined by real-time polymerase chain reaction assay in colon cancer cell lines (HCT15, HCT116, HT-29, DLD-1, and SW480) and the results demonstrated that miR-30d level was significantly decreased in human colon cancer cell lines, compared with normal colon epithelial cell line. Transfection with miR-30d mimics inhibited cell proliferation, and transfection with miR-30d inhibitors significantly promoted cell viability of colon cancer cells. Furthermore, TargetScan analysis predicted that miR-30d interacted with messenger RNA on its 3 boxed times untranslated region of ATG5, phosphoinositide 3-kinase, and Beclin1 to negatively regulate cell autophagy in colon cancer cells. Moreover, transfection with miR-30d induced cell arrest at G2/M phase of HT-29 cells. Overexpression of miR-30d mimics inhibited cell viability probably due to the inhibition of cell autophagy and promotion of cell apoptosis. Thus, MiR-30d inhibited cell autophagy by directly targeting messenger RNA of ATG5, phosphoinositide 3-kinase, and Beclin1 and promoted cell apoptosis of human colon cancer cells. It is helpful to clarify the function of miR-30d in tumorigenesis of human cancers.
C1 [Zhang, Rui; Xu, Jian; Zhao, Jian] China Med Univ, Canc Hosp, Liaoning Canc Hosp & Inst, Dept Colorectal Surg, Shenyang, Peoples R China.
   [Bai, Jinghui] China Med Univ, Canc Hosp, Liaoning Canc Hosp & Inst, Dept Internal Med, 44 Xiaoheyan Rd, Shenyang 110042, Liaoning, Peoples R China.
RP Bai, JH (corresponding author), China Med Univ, Canc Hosp, Liaoning Canc Hosp & Inst, Dept Internal Med, 44 Xiaoheyan Rd, Shenyang 110042, Liaoning, Peoples R China.
EM baijinghuibio@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81672427]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This work
   was supported by the National Natural Science Fund from the National
   Natural Science Foundation of China (Grant No. 81672427).
CR Ganju A, 2017, DRUG DISCOV TODAY, V22, P424, DOI 10.1016/j.drudis.2016.10.014
   Gaziel-Sovran A, 2011, CANCER CELL, V20, P104, DOI 10.1016/j.ccr.2011.05.027
   Gray RT, 2016, CANCER EPIDEMIOL, V45, P71, DOI 10.1016/j.canep.2016.10.004
   Hulf T, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-54
   Jia KG, 2016, MOL MED REP, V14, P184, DOI 10.3892/mmr.2016.5246
   Kara M, 2016, GENE, V587, P173, DOI 10.1016/j.gene.2016.05.006
   Kobayashi N, 2012, ONCOTARGET, V3, P1455
   Lin J, 2016, TUMOR BIOL, V37, P15835, DOI 10.1007/s13277-016-5410-6
   Liu YQ, 2014, ASIAN PAC J CANCER P, V15, P2169, DOI 10.7314/APJCP.2014.15.5.2169
   McGuire S, 2014, ADV NUTR, V5, P456, DOI 10.3945/an.114.006171
   Mei Q, 2014, EXPERT REV ANTICANC, V14, P1515, DOI 10.1586/14737140.2014.953935
   Moriarity A, 2016, THER ADV MED ONCOL, V8, P276, DOI 10.1177/1758834016646734
   Nishitani H, 2006, EMBO J, V25, P1126, DOI 10.1038/sj.emboj.7601002
   Peng Li, 2010, Zhonghua Gan Zang Bing Za Zhi, V18, P148, DOI 10.3760/cma.j.issn.1007-3418.2010.02.017
   Ramalingam Satish, 2015, Curr Pharmacol Rep, V1, P141
   Salim H, 2012, BRIT J CANCER, V107, P1361, DOI 10.1038/bjc.2012.382
   Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620
   Sharif S, 2012, CURR COLORECT CANC R, V8, P225, DOI 10.1007/s11888-012-0132-7
   Su SF, 2013, ONCOGENE, V32, P4694, DOI 10.1038/onc.2012.483
   Vorvis C, 2016, FUTURE ONCOL, V12, P1135, DOI 10.2217/fon-2015-0050
   Wu CL, 2013, CELL SIGNAL, V25, P1212, DOI 10.1016/j.cellsig.2013.01.028
   Xu TS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152792
   Xuan HQ, 2015, BIOCHEMISTRY-MOSCOW+, V80, P276, DOI 10.1134/S0006297915030037
   Yang XJ, 2013, BIOCHEM BIOPH RES CO, V431, P617, DOI 10.1016/j.bbrc.2012.12.083
   Zhang WC, 2014, TUMOR BIOL, V35, P6235, DOI 10.1007/s13277-014-2202-8
   Zhang Y, 2014, BIOCHEM PHARMACOL, V87, P562, DOI 10.1016/j.bcp.2013.12.004
NR 26
TC 29
Z9 32
U1 4
U2 12
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JUN 27
PY 2017
VL 39
IS 6
BP 1
EP 9
AR 703984
DI 10.1177/1010428317703984
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EZ2OX
UT WOS:000404549700001
PM 28651493
OA gold
DA 2022-04-25
ER

PT J
AU Zhang, HH
   Cao, RH
   Zeng, F
   Fan, WX
   Guo, L
   Ma, Q
   Ke, SB
AF Zhang, Huihui
   Cao, Rihui
   Zeng, Feng
   Fan, Wenxi
   Guo, Liang
   Ma, Qin
   Ke, Shaobo
TI Bivalent beta-Carbolines Inhibit Colorectal Cancer Growth through
   Inducing Autophagy
SO CHEMICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE bivalent beta-carboline; antiproliferative; colorectal cancer; autophagy
ID DERIVATIVES; DESIGN; ALKALOIDS; MECHANISM
AB In this study, a series of alkyl diamine linked bivalent beta-carbolines was synthesized and evaluated as antitumor agent. The results demonstrated that most compounds displayed good antiproliferative activities with IC50 value lower than 10 mu M against a panel of human tumor cell lines, and compound 8 was found to be the most potent antiproliferative agent with IC50 value of 1.39, 1.96, 1.42, 1.49, 1.32, 1.96 and 1.63 mu M against human breast cancer cell line (MCF-7), human adenocarcinoma cell line (769-P), human malighant melanoma cell line (A375), human ovarian cancer cell line (SK-OV-3), human colon carcinoma cell line (HCT-116), human gastric cancer cell line (BGC-823) and human esophageal squamous carcinoma cell line (Eca-109), respectively. Further investigations on mechanism of action of this class of compound demonstrated that the representative compound 8 inhibited colorectal cancer growth through inducing autophagy.
C1 [Zhang, Huihui] Hunan Normal Univ, Sch Med, Dept Lab Med, Coll Key Lab Study & Discovery Small Targeted Mol, Changsha 410013, Hunan, Peoples R China.
   [Cao, Rihui] Sun Yat Sen Univ, Sch Chem, 135 Xin Gang West Rd, Guangzhou 510275, Peoples R China.
   [Zeng, Feng; Ke, Shaobo] Wuhan Univ, Renmin Hosp, Ctr Canc, Wuhan 430060, Peoples R China.
   [Fan, Wenxi; Guo, Liang; Ma, Qin] Xinjiang Huashidan Pharmaceut Co Ltd, 45 He Nan East Rd, Urumqi 830011, Peoples R China.
RP Ke, SB (corresponding author), Wuhan Univ, Renmin Hosp, Ctr Canc, Wuhan 430060, Peoples R China.
EM kkkwhu@sina.com
FU General Project of Hunan Health Commission [C2016045]; National Natural
   Science Foundation of China (NSFC)National Natural Science Foundation of
   China (NSFC) [81602450]; Chen Xiaoping Hepatobiliary and Panpancreatic
   Malignant Tumors Research Fund of Hubei Province
   [CXPJJH11900001-2019348]; Huxiang High-Level Talent Innovation Team
   [2018RS3072]
FX This work was supported by grants from General Project of Hunan Health
   Commission (C2016045) and National Natural Science Foundation of China
   (NSFC) [81602450] and Chen Xiaoping Hepatobiliary and Panpancreatic
   Malignant Tumors Research Fund of Hubei Province, CXPJJH11900001-2019348
   and Huxiang High-Level Talent Innovation Team (2018RS3072).
CR Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Barbosa VA, 2011, BIOORGAN MED CHEM, V19, P6400, DOI 10.1016/j.bmc.2011.08.059
   Cao RH, 2007, CURR MED CHEM, V14, P479, DOI 10.2174/092986707779940998
   Cao RH, 2013, EUR J MED CHEM, V60, P135, DOI 10.1016/j.ejmech.2012.11.045
   Chaires JB, 1997, J MED CHEM, V40, P261, DOI 10.1021/jm9607414
   Chen Q, 2016, BIOORG MED CHEM LETT, V26, P5065, DOI 10.1016/j.bmcl.2016.08.084
   Chen YF, 2015, BIOORG MED CHEM LETT, V25, P3873, DOI 10.1016/j.bmcl.2015.07.058
   Galluzzi L, 2017, NAT REV DRUG DISCOV, V16, P487, DOI 10.1038/nrd.2017.22
   Ge D, 2020, CHEM PHARM BULL, V68, P244, DOI 10.1248/cpb.c19-00851
   Gu HL, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103179
   Guo L, 2018, EUR J MED CHEM, V147, P253, DOI 10.1016/j.ejmech.2018.02.003
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Li SZ, 2013, BIOCHEM BIOPH RES CO, V437, P325, DOI 10.1016/j.bbrc.2013.06.088
   Li SZ, 2019, EUR J MED CHEM, V162, P666, DOI 10.1016/j.ejmech.2018.11.048
   Li Y, 2018, EUR J MED CHEM, V152, P516, DOI 10.1016/j.ejmech.2018.05.003
   Liang X, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-10
   Lin YC, 2017, KAOHSIUNG J MED SCI, V33, P215, DOI 10.1016/j.kjms.2017.01.004
   Nawrocki ST, 2020, CANCERS, V12, DOI 10.3390/cancers12103005
   PHILLIPS DR, 1992, INVEST NEW DRUG, V10, P79, DOI 10.1007/BF00873121
   Shi BX, 2013, EUR J MED CHEM, V60, P10, DOI 10.1016/j.ejmech.2012.11.033
   Sun BL, 2021, CHEM PHARM BULL, V69, P472, DOI 10.1248/cpb.c21-00021
   Tsuchiya H, 1999, CHEM PHARM BULL, V47, P440, DOI 10.1248/cpb.47.440
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
   Zhang GX, 2013, EUR J MED CHEM, V65, P21, DOI 10.1016/j.ejmech.2013.04.031
   Zhang XF, 2016, SCI REP-UK, V6, DOI 10.1038/srep33204
   Zhang ZY, 2017, EUR J MED CHEM, V140, P239, DOI 10.1016/j.ejmech.2017.09.017
NR 26
TC 0
Z9 0
U1 7
U2 7
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN
SN 0009-2363
J9 CHEM PHARM BULL
JI Chem. Pharm. Bull.
PD NOV
PY 2021
VL 69
IS 11
BP 1104
EP 1109
PG 6
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Chemistry
GA XG8AG
UT WOS:000724969900010
PM 34719593
OA gold
DA 2022-04-25
ER

PT J
AU Yoo, BH
   Khan, IA
   Koomson, A
   Gowda, P
   Sasazuki, T
   Shirasawa, S
   Gujar, S
   Rosen, KV
AF Yoo, Byong Hoon
   Khan, Iman Aftab
   Koomson, Ananda
   Gowda, Pramod
   Sasazuki, Takehiko
   Shirasawa, Senji
   Gujar, Shashi
   Rosen, Kirill V.
TI Oncogenic RAS-induced downregulation of ATG12 is required for survival
   of malignant intestinal epithelial cells
SO AUTOPHAGY
LA English
DT Article
DE apoptosis; ATG12; autophagy; colorectal cancer; RAS
ID K-RAS; PROTEIN-KINASE; UP-REGULATION; INDUCED TRANSFORMATION;
   EXTRACELLULAR-MATRIX; PROMOTES APOPTOSIS; COLORECTAL TUMORS; MEK
   INHIBITION; COLON-CANCER; AUTOPHAGY
AB Activating mutations of RAS GTPase contribute to the progression of many cancers, including colorectal carcinoma. So far, attempts to develop treatments of mutant RAS-carrying cancers have been unsuccessful due to insufficient understanding of the salient mechanisms of RAS signaling. We found that RAS downregulates the protein ATG12 in colon cancer cells. ATG12 is a mediator of autophagy, a process of degradation and reutilization of cellular components. In addition, ATG12 can kill cells via autophagy-independent mechanisms. We established that RAS reduces ATG12 levels in cancer cells by accelerating its proteasomal degradation. We further observed that RAS-dependent ATG12 loss in these cells is mediated by protein kinases MAP2K/MEK and MAPK1/ERK2-MAPK3/ERK1, known effectors of RAS. We also demonstrated that the reversal of the effect of RAS on ATG12 achieved by the expression of exogenous ATG12 in cancer cells triggers both apoptotic and nonapoptotic signals and efficiently kills the cells. ATG12 is known to promote autophagy by forming covalent complexes with other autophagy mediators, such as ATG5. We found that the ability of ATG12 to kill oncogenic RAS-carrying malignant cells does not require covalent binding of ATG12 to other proteins. In summary, we have identified a novel mechanism by which oncogenic RAS promotes survival of malignant intestinal epithelial cells. This mechanism is driven by RAS-dependent loss of ATG12 in these cells.
C1 [Yoo, Byong Hoon; Khan, Iman Aftab; Koomson, Ananda; Gowda, Pramod; Rosen, Kirill V.] Dalhousie Univ, Dept Pediat, Atlantic Res Ctr, Halifax, NS, Canada.
   [Yoo, Byong Hoon; Khan, Iman Aftab; Koomson, Ananda; Gowda, Pramod; Rosen, Kirill V.] Dalhousie Univ, Dept Biochem & Mol Biol, Atlantic Res Ctr, Halifax, NS, Canada.
   [Sasazuki, Takehiko] Kyushu Univ, Inst Adv Study, Fukuoka, Japan.
   [Shirasawa, Senji] Fukuoka Univ, Dept Cell Biol, Fac Med, Fukuoka, Japan.
   [Shirasawa, Senji] Fukuoka Univ, Ctr Adv Mol Med, Fukuoka, Japan.
   [Gujar, Shashi] Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS, Canada.
RP Rosen, KV (corresponding author), Atlantic Res Ctr, CRC, Rm C-304,5849 Univ Ave,POB 15000, Halifax, NS B3H 4R2, Canada.
EM kirill.rosen@dal.ca
OI Gujar, Shashi/0000-0002-5427-0829; Rosen, Kirill/0000-0002-4317-9907
FU IWK Health Center; Canadian Institutes of Health Research/ Nova Scotia
   Regional Partnership Program (CIHR/NS RPP) [125109]; IWK Health Center
   Research Associateship
FX This study was supported by the Canadian Institutes of Health
   Research/Nova Scotia Regional Partnership Program (CIHR/NS RPP)
   operating grant 125109 and a grant from the IWK Health Center.; Byong
   Yoo was a recipient of the IWK Health Center Research Associateship.
CR Akinleye A, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-27
   ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489
   ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5
   Berezovskaya O, 2005, CANCER RES, V65, P2378, DOI 10.1158/0008-5472.CAN-04-2649
   Blasco RB, 2011, CANCER CELL, V19, P652, DOI 10.1016/j.ccr.2011.04.002
   Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788
   Corcoran RB, 2013, CANCER CELL, V23, P121, DOI 10.1016/j.ccr.2012.11.007
   Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111
   Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765
   Du GJ, 2006, CANCER LETT, V232, P179, DOI 10.1016/j.canlet.2005.02.012
   Dunn EF, 2011, ONCOGENE, V30, P561, DOI 10.1038/onc.2010.430
   Fang S, 2004, CELL MOL LIFE SCI, V61, P1546, DOI 10.1007/s00018-004-4129-5
   Feng YC, 2014, CELL RES, V24, P24, DOI 10.1038/cr.2013.168
   Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701
   Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9
   Fujita N, 2008, MOL BIOL CELL, V19, P2092, DOI 10.1091/mbc.E07-12-1257
   Glockzin S, 2003, MOL CELL BIOL, V23, P8960, DOI 10.1128/MCB.23.24.8960-8969.2003
   Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113
   Haigis KM, 2011, NAT GENET, V43, P177, DOI 10.1038/ng0311-177
   Haller M, 2014, AUTOPHAGY, V10, P2269, DOI 10.4161/15548627.2014.981914
   Hammond EM, 2005, BIOCHEM BIOPH RES CO, V331, P718, DOI 10.1016/j.bbrc.2005.03.154
   Hay-Koren A, 2011, MOL BIOL CELL, V22, P399, DOI 10.1091/mbc.E10-05-0440
   Hayes TK, 2016, CANCER CELL, V29, P75, DOI 10.1016/j.ccell.2015.11.011
   Heredia JE, 2013, CELL, V153, P376, DOI 10.1016/j.cell.2013.02.053
   Holt KH, 1996, MOL CELL BIOL, V16, P577
   Isasa M, 2010, MOL CELL, V38, P733, DOI 10.1016/j.molcel.2010.05.001
   Janssen KP, 2002, GASTROENTEROLOGY, V123, P492, DOI 10.1053/gast.2002.34786
   Jin JP, 2007, NATURE, V447, P1135, DOI 10.1038/nature05902
   Joneson T, 1999, MOL CELL BIOL, V19, P5892
   Kaiser WJ, 2011, NATURE, V471, P368, DOI 10.1038/nature09857
   Khan IA, 2016, ONCOGENE, V35, P5759, DOI 10.1038/onc.2016.109
   KhosraviFar R, 1998, ADV CANCER RES, V72, P57
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Lee YS, 2013, CELL, V153, P413, DOI 10.1016/j.cell.2013.03.001
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1
   Liu Z, 2006, ONCOGENE, V25, P7680, DOI 10.1038/sj.onc.1209753
   Liu ZP, 2005, J BIOL CHEM, V280, P37383, DOI 10.1074/jbc.M503724200
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   Malhotra R, 2015, AUTOPHAGY, V11, P145, DOI 10.1080/15548627.2014.998917
   Meier P, 2007, MOL CELL, V28, P746, DOI 10.1016/j.molcel.2007.11.016
   Meilhac O, 1999, FASEB J, V13, P485, DOI 10.1096/fasebj.13.3.485
   MITSUDOMI T, 1991, CANCER RES, V51, P4999
   Morris EJ, 2013, CANCER DISCOV, V3, P742, DOI 10.1158/2159-8290.CD-13-0070
   Murrow L, 2015, NAT CELL BIOL, V17, P300, DOI 10.1038/ncb3112
   Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003
   O'Donnell MA, 2011, NAT CELL BIOL, V13, P1437, DOI 10.1038/ncb2362
   PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0
   QUARONI A, 1981, J NATL CANCER I, V67, P1353
   Radoshevich L, 2010, CELL, V142, P590, DOI 10.1016/j.cell.2010.07.018
   RAK J, 1995, CANCER RES, V55, P4575
   RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587
   Rak Janusz, 1999, Neoplasia (New York), V1, P23, DOI 10.1038/sj.neo.7900001
   Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026
   Rogers C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14128
   Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7
   Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447
   Rosen K, 2002, J BIOL CHEM, V277, P46123, DOI 10.1074/jbc.M207883200
   Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200
   Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865
   Rubinstein AD, 2011, MOL CELL, V44, P698, DOI 10.1016/j.molcel.2011.10.014
   Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4
   Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088
   Shaul YD, 2007, BBA-MOL CELL RES, V1773, P1213, DOI 10.1016/j.bbamcr.2006.10.005
   SHAW P, 1991, ONCOGENE, V6, P2121
   Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2
   SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203
   Singh A, 2012, CELL, V148, P639, DOI 10.1016/j.cell.2011.12.033
   Smakman N, 2006, CANCER RES, V66, P5403, DOI 10.1158/0008-5472.CAN-05-4108
   Stephen AG, 2014, CANCER CELL, V25, P272, DOI 10.1016/j.ccr.2014.02.017
   Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045
   Tang ZJ, 2015, CELL, V160, P729, DOI 10.1016/j.cell.2015.01.028
   Uhlen M, 2005, MOL CELL PROTEOMICS, V4, P1920, DOI 10.1074/mcp.M500279-MCP200
   Vachon PH, 2002, GASTROENTEROLOGY, V123, P1980, DOI 10.1053/gast.2002.37072
   van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R
   Vanden Berghe T, 2010, CELL DEATH DIFFER, V17, P922, DOI 10.1038/cdd.2009.184
   VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241
   Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058
   Yoo BH, 2015, ONCOGENE, V34, P4939, DOI 10.1038/onc.2014.415
   Yoo BH, 2015, AUTOPHAGY, V11, P1230, DOI 10.1080/15548627.2015.1056968
   Yoo BH, 2012, INT J CANCER, V131, P357, DOI 10.1002/ijc.26368
   Yoo BH, 2011, J BIOL CHEM, V286, P38894, DOI 10.1074/jbc.M111.290692
   Yoo BH, 2009, AUTOPHAGY, V5, P1166, DOI 10.4161/auto.5.8.10167
   Yoo BH, 2010, J BIOL CHEM, V285, P5438, DOI 10.1074/jbc.M109.046789
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
   Yuan JY, 2016, CELL, V167, P1693, DOI 10.1016/j.cell.2016.11.047
NR 86
TC 4
Z9 4
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PY 2018
VL 14
IS 1
BP 134
EP 151
DI 10.1080/15548627.2017.1370171
PG 18
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FY7NS
UT WOS:000427049900010
PM 28933585
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Yang, CG
   Zhang, YB
   Du, WF
   Cheng, HG
   Li, CB
AF Yang, Chenggang
   Zhang, Yanbo
   Du, Wenfeng
   Cheng, Honggang
   Li, Chaobin
TI Eukaryotic translation initiation factor 3 subunit G promotes human
   colorectal cancer
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE EIF3G; colorectal cancer; proliferation; apoptosis; autophagy
ID AUTOPHAGY; EIF3; OVEREXPRESSION; CHEMOTHERAPY; PROGRESSION; RESECTION
AB In this study, we investigated the role of eukaryotic translation initiation factor 3 subunit G (EIF3G) in colorectal cancer. Immunohistochemical analysis showed higher EIF3G expression in stage IV human colorectal cancer tissues than in adjacent normal tissues (P<0.01). EIF3G short hairpin RNA (shRNA) knockdown in HCT116 colon cancer cells reduced proliferation and increased apoptosis as compared to control. EIF3G knockdown also increased autophagy and reduced mTOR signaling, as evidenced by low phospho-AKT, phospho-S6K and phospho-4EBP1 levels. Functional experiments indicated that overexpression of EIF3G promoted HCT-116 cells proliferation, migration and xenograft tumor growth. Finally, we observed lower xenograft tumor weights and volumes with EIF3G-silenced HCT116 cells than with control cells. These findings demonstrate that EIF3G promotes colon cancer growth and is a potential therapeutic target.
C1 [Yang, Chenggang; Zhang, Yanbo; Du, Wenfeng; Cheng, Honggang; Li, Chaobin] Liaocheng Peoples Hosp, Dept Gastrointestinal Surg, 67 Dongchang West Rd, Liaocheng 252000, Shandong, Peoples R China.
RP Yang, CG (corresponding author), Liaocheng Peoples Hosp, Dept Gastrointestinal Surg, 67 Dongchang West Rd, Liaocheng 252000, Shandong, Peoples R China.
EM baker-ham123@163.com
FU Shandong Provincial Natural Science Foundation, ChinaNatural Science
   Foundation of Shandong Province [ZR2015HL082]
FX This study was supported by ZR2015HL082 Shandong Provincial Natural
   Science Foundation, China ZR2015HL082.
CR Baba Y, 2011, CANCER-AM CANCER SOC, V117, P1399, DOI 10.1002/cncr.25630
   Dang SP, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0245-4
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Dienstmann R, 2011, CANCER J, V17, P114, DOI 10.1097/PPO.0b013e318212f844
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fernandez-Peralta AM, 2005, CANCER GENET CYTOGEN, V157, P18, DOI 10.1016/j.cancergencyto.2004.05.008
   Gao Y, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0518-x
   Haigis KM, 2008, NAT GENET, V40, P600, DOI 10.1038/ng.115
   Hershey JWB, 2015, BBA-GENE REGUL MECH, V1849, P792, DOI 10.1016/j.bbagrm.2014.10.005
   House MG, 2011, ANN SURG, V254, P851, DOI 10.1097/SLA.0b013e31822f4f88
   Jager S, 2012, NATURE, V481, P365, DOI 10.1038/nature10719
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Lin YY, 2016, FEBS OPEN BIO, V6, P1201, DOI 10.1002/2211-5463.12137
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Modelska A, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.542
   Negri FV, 2010, BRIT J CANCER, V102, P162, DOI 10.1038/sj.bjc.6605471
   Nesbit AD, 2015, PHOTOSYNTH RES, V126, P147, DOI 10.1007/s11120-015-0074-4
   Sartore-Bianchi A, 2009, CANCER RES, V69, P1851, DOI 10.1158/0008-5472.CAN-08-2466
   Sha Z, 2009, MOL CELL, V36, P141, DOI 10.1016/j.molcel.2009.09.026
   Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442
   Smith MD, 2016, STRUCTURE, V24, P886, DOI 10.1016/j.str.2016.02.024
   Society. AC, 2014, COL CANC FACTS FIG 2
   Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042
   Spilka R, 2013, CANCER LETT, V340, P9, DOI 10.1016/j.canlet.2013.06.019
   Tomlinson JS, 2007, J CLIN ONCOL, V25, P4575, DOI 10.1200/JCO.2007.11.0833
   Unbehaun A, 2004, GENE DEV, V18, P3078, DOI 10.1101/gad.1255704
   Zhang LL, 2007, J BIOL CHEM, V282, P5790, DOI 10.1074/jbc.M606284200
   Zheng QL, 2016, MOL MED REP, V13, P2973, DOI 10.3892/mmr.2016.4935
   Zhou CS, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-14
NR 29
TC 8
Z9 8
U1 0
U2 1
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2019
VL 11
IS 2
BP 612
EP +
PG 13
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA HN2FN
UT WOS:000460001200008
PM 30899366
DA 2022-04-25
ER

PT J
AU Zhang, Y
   Liu, Y
   Zhou, YX
   Zheng, ZM
   Tang, WQ
   Song, MZ
   Wang, JL
   Wang, KP
AF Zhang, Yu
   Liu, Yan
   Zhou, Yinxing
   Zheng, Ziming
   Tang, Wenqi
   Song, Mengzi
   Wang, Jinglin
   Wang, Kaiping
TI Lentinan inhibited colon cancer growth by inducing endoplasmic reticulum
   stress-mediated autophagic cell death and apoptosis
SO CARBOHYDRATE POLYMERS
LA English
DT Article
DE Lentinan; Direct antitumour; NOD; SCID mice; Endoplasmic reticulum
   stress; Autophagy; Apoptosis
ID ER STRESS; POLYSACCHARIDE LENTINAN; HUMANIZED MICE; CYCLE ARREST;
   IN-VITRO; EDODES; CROSSTALK; KINASES; MODEL; VIVO
AB Lentinan (SLNT) has been shown to be directly cytotoxic to cancer cells. However, this direct antitumour effect has not been thoroughly investigated in vivo, and the mechanism remains unclear. We aimed to examine the direct antitumour effect of SLNT on human colon cancer and the mechanism in vivo and in vitro. SLNT significantly inhibited tumour growth and induced autophagy and endoplasmic reticulum stress (ERS) in HT-29 cells and tumour-bearing nonobese diabetic (NOD)/severe combined immunodeficiency (SCID) mice. Experiments with the autophagy inhibitors chloroquine (CQ) and 3-methyladenine (3-MA) showed that autophagy facilitated the antitumour effect of SLNT. Moreover, ERS was identified as the common upstream regulator of SLNT-induced increases in Ca2+concentrations, autophagy and apoptosis by using ERS inhibitors. In summary, our study demonstrated that SLNT exerted direct antitumour effects on human colon cancer via ERS-mediated autophagy and apoptosis, providing a novel understanding of SLNT as an anti-colon cancer therapy.
C1 [Zhang, Yu; Liu, Yan; Zheng, Ziming; Wang, Jinglin] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pharm, Wuhan 430030, Peoples R China.
   [Zhang, Yu; Liu, Yan; Zheng, Ziming; Wang, Jinglin] Hubei Prov Clin Res Ctr Precis Med Crit Illness, Wuhan 430030, Peoples R China.
   [Zhou, Yinxing; Tang, Wenqi; Song, Mengzi; Wang, Kaiping] Huazhong Univ Sci & Technol, Tongji Med Coll Pharm, Hubei Key Lab Nat Med Chem & Resource Evaluat, Wuhan 430030, Peoples R China.
RP Wang, JL (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pharm, Wuhan 430030, Peoples R China.; Wang, JL (corresponding author), Hubei Prov Clin Res Ctr Precis Med Crit Illness, Wuhan 430030, Peoples R China.; Wang, KP (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll Pharm, Hubei Key Lab Nat Med Chem & Resource Evaluat, Wuhan 430030, Peoples R China.
EM linlinvc202@163.com; wkpzcq@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81974509]
FX This work is supported by the National Natural Science Foundation of
   China (Grant No. 81974509). The authors thank the Analysis and Testing
   Center of Huazhong University of Science and Technology for their
   technical assistance.
CR Amaravadi RK, 2019, CANCER DISCOV, V9, P1167, DOI 10.1158/2159-8290.CD-19-0292
   Bakchoul T, 2015, J THROMB HAEMOST, V13, P872, DOI 10.1111/jth.12879
   Bian YC, 2020, INT J BIOL MACROMOL, V162, P107, DOI 10.1016/j.ijbiomac.2020.06.054
   Bisen PS, 2010, CURR MED CHEM, V17, P2419, DOI 10.2174/092986710791698495
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chen YJ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2004-4
   Cheng X, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.384
   Ciechomska IA, 2013, ONCOGENE, V32, P1518, DOI 10.1038/onc.2012.174
   Deniaud A, 2008, ONCOGENE, V27, P285, DOI 10.1038/sj.onc.1210638
   Driscoll J. J., 2015, MOL CROSS TALK AUTOP
   Fernandez A, 2015, J PINEAL RES, V59, P292, DOI 10.1111/jpi.12264
   He K, 2016, ONCOGENE, V35, P148, DOI 10.1038/onc.2015.79
   Kupfahl C, 2006, INT IMMUNOPHARMACOL, V6, P686, DOI 10.1016/j.intimp.2005.10.008
   Li WY, 2018, J FUNCT FOODS, V45, P75, DOI 10.1016/j.jff.2018.03.024
   Liu C, 2020, SCI TOTAL ENVIRON, V712, DOI 10.1016/j.scitotenv.2019.136480
   Luciani DS, 2009, DIABETES, V58, P422, DOI 10.2337/db07-1762
   MAEDA YY, 1971, NATURE, V229, P634, DOI 10.1038/229634a0
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   McLean K, 2009, GYNECOL ONCOL, V112, P623, DOI 10.1016/j.ygyno.2008.11.028
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   Moradali MF, 2007, INT IMMUNOPHARMACOL, V7, P701, DOI 10.1016/j.intimp.2007.01.008
   Murata Y, 2002, INT IMMUNOPHARMACOL, V2, P673, DOI 10.1016/S1567-5769(01)00212-0
   Oakes SA, 2015, ANNU REV PATHOL-MECH, V10, P173, DOI 10.1146/annurev-pathol-012513-104649
   Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596
   Onorati AV, 2018, CANCER-AM CANCER SOC, V124, P3307, DOI 10.1002/cncr.31335
   Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x
   Pan Z, 2021, CARBOHYD POLYM, V258, DOI 10.1016/j.carbpol.2020.117596
   Pauly M, 2017, BBA-MOL BASIS DIS, V1863, P2229, DOI 10.1016/j.bbadis.2017.06.009
   Qi WC, 2020, CARBOHYD POLYM, V237, DOI 10.1016/j.carbpol.2020.116113
   Quan JH, 2020, TOXICOLOGY, V442, DOI 10.1016/j.tox.2020.152540
   Shi SM, 2016, ONCOL REP, V35, P2606, DOI 10.3892/or.2016.4680
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Sun SQ, 2019, J ETHNOPHARMACOL, V238, DOI 10.1016/j.jep.2019.111857
   Sun XL, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109144
   Taguchi T, 1983, Gan To Kagaku Ryoho, V10, P387
   Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046
   Tyagi RK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02550
   Wang JL, 2017, ONCOTARGET, V8, P610, DOI 10.18632/oncotarget.13481
   Wang KP, 2013, J AGR FOOD CHEM, V61, P9849, DOI 10.1021/jf403291w
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Xu XJ, 2011, J BIOL CHEM, V286, P31194, DOI 10.1074/jbc.M111.246470
   Xu YZ, 2016, ONCOL REP, V35, P2081, DOI 10.3892/or.2016.4603
   Yang B, 2017, BIOMED PHARMACOTHER, V89, P1027, DOI 10.1016/j.biopha.2017.02.065
   Yang X, 2018, MAR DRUGS, V16, DOI 10.3390/md16110454
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yong KSM, 2018, ARCH IMMUNOL THER EX, V66, P245, DOI 10.1007/s00005-018-0506-x
   Yoshino S., 2000, ANTICANCER RES, V20
   You RX, 2014, PHYTOTHER RES, V28, P1837, DOI 10.1002/ptr.5209
   Yu KN, 2015, FOOD CHEM TOXICOL, V85, P106, DOI 10.1016/j.fct.2015.08.001
   Zhang M, 2019, PROG MOL BIOL TRANSL, V163, P297, DOI 10.1016/bs.pmbts.2019.02.013
   Zhang Y., 2019, ANTIMICROB AGENTS CH, V63
   Zhang Y, 2019, INT J BIOL MACROMOL, V139, P233, DOI 10.1016/j.ijbiomac.2019.07.209
   Zhao MY, 2019, CARBOHYD POLYM, V224, DOI 10.1016/j.carbpol.2019.115171
NR 54
TC 4
Z9 4
U1 23
U2 46
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0144-8617
EI 1879-1344
J9 CARBOHYD POLYM
JI Carbohydr. Polym.
PD SEP 1
PY 2021
VL 267
AR 118154
DI 10.1016/j.carbpol.2021.118154
EA MAY 2021
PG 13
WC Chemistry, Applied; Chemistry, Organic; Polymer Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Polymer Science
GA SU4DA
UT WOS:000663089200009
PM 34119128
DA 2022-04-25
ER

PT J
AU Xiong, HY
   Guo, XL
   Bu, XX
   Zhang, SS
   Ma, NN
   Song, JR
   Hu, F
   Tao, SF
   Sun, K
   Li, R
   Wu, MC
   Wei, LX
AF Xiong, Hai-yan
   Guo, Xian-ling
   Bu, Xin-xin
   Zhang, Shan-shan
   Ma, Nan-nan
   Song, Jian-rui
   Hu, Fei
   Tao, Shuang-fen
   Sun, Kai
   Li, Rong
   Wu, Meng-chao
   Wei, Li-xin
TI Autophagic cell death induced by 5-FU in Bax or PUMA deficient human
   colon cancer cell
SO CANCER LETTERS
LA English
DT Article
DE Autophagic cell death; Apoptosis; Bax; PUMA; mTOR
ID MALIGNANT GLIOMA-CELLS; MAMMALIAN TARGET; TUMOR-SUPPRESSOR; KINASE-B;
   APOPTOSIS; INHIBITION; PROTEIN; DISEASE; MACROAUTOPHAGY; CHEMOTHERAPY
AB Autophagy is a membrane process that results in the transporting of cellular contents to lysosomes for degradation. Autophagic cell death is another way of programed cell death called type If PCD, which has complicated connection with apoptosis, both of these two types of cell death play an important role in tumor development. In this study, we investigated chemotherapeutic agent induced cell death pathway in wild type (WT), Bax(-/-) and PUMA(-/-) HCT116 cells. Bax or PUMA deficient cells had similar chemosensitivity to VV7 cells but were defective in undergoing apoptosis. The results of electron microscopy and GFP-LC3 localization assay showed that autophagy was induced in Bax or PUMA deficient cells but not in WT cells. mTOR activity was decreased in Bax or PUMA deficient cells which further indicated the up-regulation of autophagy. Inhibition of autophagy by 3-Methyladenine (3-MA) decreased the cell death in Bax or PUMA deficient cells. Taken together, these results suggest that autophagic cell death can be used as an alternative cell death pathway in apoptosis defective cells and may bring a new target for cancer therapy. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
C1 [Xiong, Hai-yan; Guo, Xian-ling; Bu, Xin-xin; Zhang, Shan-shan; Ma, Nan-nan; Song, Jian-rui; Hu, Fei; Tao, Shuang-fen; Sun, Kai; Li, Rong; Wu, Meng-chao; Wei, Li-xin] Second Mil Med Univ, Tumor Immunol & Gene Therapy Ctr, Eastern Hepatobiliary Surg Hosp, Shanghai 200438, Peoples R China.
RP Wei, LX (corresponding author), Second Mil Med Univ, Tumor Immunol & Gene Therapy Ctr, Eastern Hepatobiliary Surg Hosp, 225 Changhai Rd, Shanghai 200438, Peoples R China.
EM lixinwei@smmu.edu.cn
RI ma, nan/AAF-6968-2020
OI ma, nan/0000-0003-4006-1003
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [30700981, 30801347, 0870974]; Commission of
   Science and Technology of Shanghai MunicipalityScience & Technology
   Commission of Shanghai Municipality (STCSM) [045407047, 08XD14003];
   National Key Sci-Tech Special Project of China [2008ZX10002-019,
   2008ZX10002-025]
FX We thank Dr. Chuanshu Huang for providing us with cell line and Dr.
   Shengkan Jin for providing us with the GFP-LC3 plasmid. This project was
   supported by the Special Funds for National Natural Science Foundation
   of China (Grant Nos.: 30700981, 30801347 and 0870974), the Commission of
   Science and Technology of Shanghai Municipality (Grant Nos.: 045407047
   and 08XD14003), National Key Sci-Tech Special Project of China (Grant
   Nos.: 2008ZX10002-019 and 2008ZX10002-025).
CR Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200
   Bauvy C, 2001, EXP CELL RES, V268, P139, DOI 10.1006/excr.2001.5285
   Cao C, 2006, CANCER RES, V66, P10040, DOI 10.1158/0008-5472.CAN-06-0802
   Cui Q, 2007, BIOL PHARM BULL, V30, P859, DOI 10.1248/bpb.30.859
   Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7
   Degenhardt K, 2002, J BIOL CHEM, V277, P14127, DOI 10.1074/jbc.M109939200
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1
   GUNN JM, 1977, NATURE, V266, P58, DOI 10.1038/266058a0
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Huang J, 2007, CELL CYCLE, V6, P1837, DOI 10.4161/cc.6.15.4511
   Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Kim KW, 2006, J BIOL CHEM, V281, P36883, DOI 10.1074/jbc.M607094200
   Kirkegaard K, 2004, NAT REV MICROBIOL, V2, P301, DOI 10.1038/nrmicro865
   KISEN GO, 1993, CARCINOGENESIS, V14, P2501, DOI 10.1093/carcin/14.12.2501
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998
   Meijer Alfred J., 2006, Molecular Aspects of Medicine, V27, P411, DOI 10.1016/j.mam.2006.08.002
   Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657
   Mochizuki T, 2002, J BIOL CHEM, V277, P2790, DOI 10.1074/jbc.M106361200
   Paglin S, 2001, CANCER RES, V61, P439
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Scarlatti F, 2004, J BIOL CHEM, V279, P18384, DOI 10.1074/jbc.M313561200
   Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Takeuchi H, 2004, BRIT J CANCER, V90, P1069, DOI 10.1038/sj.bjc.6601605
   Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008
   von Bultzingslowen I, 2001, ORAL ONCOL, V37, P537, DOI 10.1016/S1368-8375(01)00009-4
   Wang L, 2007, APOPTOSIS, V12, P1489, DOI 10.1007/s10495-007-0073-9
   Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
NR 35
TC 63
Z9 68
U1 1
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD FEB 1
PY 2010
VL 288
IS 1
BP 68
EP 74
DI 10.1016/j.canlet.2009.06.039
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 561PY
UT WOS:000274991700009
PM 19660860
DA 2022-04-25
ER

PT J
AU Sha, MQ
   Mao, GX
   Wang, GF
   Chen, YF
   Wu, XJ
   Wang, Z
AF Sha, Mingquan
   Mao, Genxiang
   Wang, Guofu
   Chen, Yufeng
   Wu, Xiaojian
   Wang, Zhen
TI DZNep inhibits the proliferation of colon cancer HCT116 cells by
   inducing senescence and apoptosis
SO ACTA PHARMACEUTICA SINICA B
LA English
DT Article
DE EZH2; Human colon cancer HCT116 cells; DZNep; Anti-cancer mechanisms
ID ZESTE HOMOLOG 2; HISTONE METHYLTRANSFERASE EZH2; COLORECTAL-CANCER;
   POLYCOMB PROTEIN; ENHANCER; GROWTH; AUTOPHAGY; THERAPY; GENE
AB EZH2 is over-expressed in human colon cancer and is closely associated with tumor proliferation, metastasis and poor prognosis. Targeting and inhibiting EZH2 may he an effective therapeutic strategy for colon cancer. 31Deazaneplanocin A (DZNeN, as an EZH2 inhibitor, can suppress cancer cell growth. However, the anti-cancer role of DZNep in colon cancer cells has been rarely studied. In this study, we demonstrate that DZNep can inhibit the growth and survival of colon cancer HCT116 cells by inducing cellular senescence and apoptosis. The study provides a novel view of anti-cancer mechanisms of DZNep in human colon cancer cells. (C) 2015 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
C1 [Sha, Mingquan; Wang, Zhen] Chinese Acad Med Sci, Inst Med Biotechnol, Beijing 100050, Peoples R China.
   [Sha, Mingquan; Wang, Zhen] Peking Union Med Coll, Beijing 100050, Peoples R China.
   [Mao, Genxiang; Wang, Guofu] Zhejiang Hosp, Zhejiang Prov Key Lab Geriatr, Hangzhou 310013, Zhejiang, Peoples R China.
   [Mao, Genxiang; Wang, Guofu] Zhejiang Hosp, Geriatr Inst Zhejiang Prov, Hangzhou 310013, Zhejiang, Peoples R China.
   [Chen, Yufeng; Wu, Xiaojian] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, Guangzhou 510635, Guangdong, Peoples R China.
RP Wu, XJ (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, Guangzhou 510635, Guangdong, Peoples R China.
EM wxjmqy2003@yahoo.com; wangzhen@imb.pumc.edu.cn
OI Wang, Zhen/0000-0002-6377-3890
FU Sino-Singapore Collaboration Project from the Ministry of Science and
   Technology (MOST) of China [2013DFG32990]; National Natural Science
   Foundation of China (NSFC)National Natural Science Foundation of China
   (NSFC) [81373438, 31201040]; National Mega-Project for Innovative Drugs
   by MOST [2012ZX09301002-001-015]
FX This project is co-sponsored by Sino-Singapore Collaboration Project
   from the Ministry of Science and Technology (MOST) of China (No.
   2013DFG32990), National Natural Science Foundation of China (NSFC Nos.
   81373438 and 31201040), and National Mega-Project for Innovative Drugs
   by MOST (No. 2012ZX09301002-001-015).
CR Bai J, 2014, CELL PROLIFERAT, V47, P211, DOI 10.1111/cpr.12103
   Bai J, 2014, DNA CELL BIOL, V33, P337, DOI 10.1089/dna.2014.2340
   Bardhan Kankana, 2013, Cancers (Basel), V5, P676, DOI 10.3390/cancers5020676
   Benoit YD, 2013, EXP CELL RES, V319, P1463, DOI 10.1016/j.yexcr.2013.04.006
   Benoit YD, 2013, J CELL PHYSIOL, V228, P764, DOI 10.1002/jcp.24224
   Choi HJ, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-39
   Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347
   Crea F, 2012, CANCER METAST REV, V31, P753, DOI 10.1007/s10555-012-9387-3
   Ferraro A, 2013, INT J BIOCHEM CELL B, V45, P243, DOI 10.1016/j.biocel.2012.10.009
   Fussbroich B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021651
   Ishikawa S, 2014, INT J CANCER, V135, P2528, DOI 10.1002/ijc.28672
   Jung HY, 2013, MOL CELL, V52, P193, DOI 10.1016/j.molcel.2013.08.028
   Kikuchi J, 2012, LUNG CANCER, V78, P138, DOI 10.1016/j.lungcan.2012.08.003
   Kumari A, 2015, CELL DEATH DIFFER, V22, P311, DOI 10.1038/cdd.2014.146
   Li L, 2014, ONCOTARGETS THER, V7, P1817, DOI 10.2147/OTT.S48409
   Luo ZG, 2012, CANCER RES, V72, P3360, DOI 10.1158/0008-5472.CAN-12-0388
   Mosieniak G, 2012, MECH AGEING DEV, V133, P444, DOI 10.1016/j.mad.2012.05.004
   Ougolkov AV, 2008, CLIN CANCER RES, V14, P6790, DOI 10.1158/1078-0432.CCR-08-1013
   Shen L, 2013, ONCOTARGETS THER, V6, P321, DOI 10.2147/OTT.S42453
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Tonini T, 2008, J CELL PHYSIOL, V214, P295, DOI 10.1002/jcp.21241
   Tsang DPF, 2011, J GASTROEN HEPATOL, V26, P19, DOI 10.1111/j.1440-1746.2010.06447.x
   Wang Y, 2014, MOL CARCINOG
   Wu Z, 2011, CELL DEATH DIFFER, V18, P1771, DOI 10.1038/cdd.2011.48
NR 25
TC 21
Z9 24
U1 2
U2 12
PU INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
PI BEIJING
PA C/O EDITORIAL BOARD OF ACTA PHARMACEUTICA SINICA, 1 XIANNONGTAN ST,
   BEIJING, 100050, PEOPLES R CHINA
SN 2211-3835
EI 2211-3843
J9 ACTA PHARM SIN B
JI Acta Pharm. Sin. B
PD MAY
PY 2015
VL 5
IS 3
BP 188
EP 193
DI 10.1016/j.apsb.2015.01.011
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CP6PE
UT WOS:000360008900003
PM 26579445
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Qu, JY
   Zeng, C
   Zou, TT
   Chen, X
   Yang, XL
   Lin, ZH
AF Qu, Junyan
   Zeng, Cheng
   Zou, Tingting
   Chen, Xu
   Yang, Xiaolong
   Lin, Zhenghong
TI Autophagy Induction by Trichodermic Acid Attenuates Endoplasmic
   Reticulum Stress-Mediated Apoptosis in Colon Cancer Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE TDA; ER stress; apoptosis; autophagy; colorectal cancer
ID UNFOLDED PROTEIN RESPONSE; COLORECTAL-CANCER; ER-STRESS; M-COPA; GOLGI
   SYSTEM; DEATH; TUMOR; ACTIVATION; PATHWAY; THAPSIGARGIN
AB Colorectal cancer (CRC) is the third leading malignant tumor in the world, which has high morbidity and mortality. In this study we found that trichodermic acid (TDA), a secondary metabolite isolated from the plant endophytic fungus Penicillium ochrochloronthe with a variety of biological and pharmacological activities, exhibited the antitumor effects on colorectal cancer cells in vitro and in vivo. Our results showed that TDA inhibited the proliferation of colon cancer cells in a dose-dependent manner. TDA induces sustained endoplasmic reticulum stress, which triggers apoptosis through IRE1 alpha/XBP1 and PERK/ATF4/CHOP pathways. In addition, we found that TDA mediated endoplasmic reticulum stress also induces autophagy as a protective mechanism. Moreover, combined treatment of TDA with autophagy inhibitors significantly enhanced its anticancer effect. In conclusion, our results indicated that TDA can induce ER stress and autophagy mediated apoptosis, suggesting that targeting ER stress and autophagy may be an effective strategy for the treatment of CRC.
C1 [Qu, Junyan; Zeng, Cheng; Zou, Tingting; Chen, Xu; Lin, Zhenghong] Chongqing Univ, Sch Life Sci, Chongqing 401331, Peoples R China.
   [Yang, Xiaolong] South Cent Univ Nationalities, Sch Pharmaceut Sci, Modernizat Engn Technol Res Ctr Ethn Minor Med Hu, Wuhan 430074, Peoples R China.
RP Lin, ZH (corresponding author), Chongqing Univ, Sch Life Sci, Chongqing 401331, Peoples R China.; Yang, XL (corresponding author), South Cent Univ Nationalities, Sch Pharmaceut Sci, Modernizat Engn Technol Res Ctr Ethn Minor Med Hu, Wuhan 430074, Peoples R China.
EM qujunyan1229@yeah.net; cqzengcheng@163.com; tingtzou1997@163.com;
   chenxu_2021@163.com; yxl19830915@mail.scuec.edu.cn;
   zhenghonglin@cqu.edu.cn
OI Lin, Zhenghong/0000-0002-6354-0042
FU Natural Science FoundationNational Natural Science Foundation of China
   (NSFC) [cstc2020jcyj-msxmX0154]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [31571454,
   81872755, 82073714]; Talented Youth Cultivation Program from "the
   Fundamental Research Funds for the Central Universities", South-Central
   University for Nationalities [CZP20008]
FX This work was supported by Natural Science Foundation Project of CQ
   CSTC' (Grant cstc2020jcyj-msxmX0154 to Zhenghong Lin), supported by the
   National Natural Science Foundation of China (Grant No. 31571454 to
   Zhenghong Lin, and 81872755 and 82073714 to Xiao-long Yang), and
   supported by the Talented Youth Cultivation Program from "the
   Fundamental Research Funds for the Central Universities", South-Central
   University for Nationalities (No. CZP20008 to Xiao-long Yang).
CR Albayrak D, 2021, BIOCHEM GENET, V59, P159, DOI 10.1007/s10528-020-09996-5
   Almanza A, 2019, FEBS J, V286, P241, DOI 10.1111/febs.14608
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Banerjee A, 2011, J BIOL CHEM, V286, P29127, DOI 10.1074/jbc.M110.169771
   Banerjee A, 2017, DRUG DISCOV TODAY, V22, P1224, DOI 10.1016/j.drudis.2017.05.006
   Bejcek J, 2021, MOLECULES, V26, DOI 10.3390/molecules26071905
   Bhat TA, 2017, BBA-REV CANCER, V1867, P58, DOI 10.1016/j.bbcan.2016.12.002
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a
   Carew JS, 2006, BLOOD, V107, P222, DOI 10.1182/blood-2005-05-1923
   Casanova JE, 2007, TRAFFIC, V8, P1476, DOI 10.1111/j.1600-0854.2007.00634.x
   Center MM, 2009, CANCER EPIDEM BIOMAR, V18, P1688, DOI 10.1158/1055-9965.EPI-09-0090
   Chen YN, 2013, TRENDS CELL BIOL, V23, P547, DOI 10.1016/j.tcb.2013.06.005
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Denmeade SR, 2003, J NATL CANCER I, V95, P990, DOI 10.1093/jnci/95.13.990
   Devenport SN, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111349
   Dong L, 2018, ONCOGENE, V37, P2702, DOI 10.1038/s41388-018-0137-z
   Franzese C, 2019, RADIOTHER ONCOL, V133, P220, DOI 10.1016/j.radonc.2018.10.024
   Garrido W, 2014, CURR DRUG TARGETS, V15, P931, DOI 10.2174/1389450115666140826122315
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Gordaliza M, 2007, CLIN TRANSL ONCOL, V9, P767, DOI 10.1007/s12094-007-0138-9
   Gorska M, 2012, FRONT BIOSCI-LANDMRK, V17, P2269, DOI 10.2741/4050
   Guo ML, 2015, AUTOPHAGY, V11, P995, DOI 10.1080/15548627.2015.1052205
   Hadjipetrou A, 2017, WORLD J GASTROENTERO, V23, P6049, DOI 10.3748/wjg.v23.i33.6049
   Han J, 2013, NAT CELL BIOL, V15, P481, DOI 10.1038/ncb2738
   Hattori T, 2016, GENES CELLS, V21, P901, DOI 10.1111/gtc.12386
   Hensley K, 2015, NEUROBIOL DIS, V84, P50, DOI 10.1016/j.nbd.2015.03.002
   Hetz C, 2015, NAT CELL BIOL, V17, P829, DOI 10.1038/ncb3184
   Hiramatsu N, 2015, AM J PATHOL, V185, P1800, DOI 10.1016/j.ajpath.2015.03.009
   Ignashkova TI, 2017, TRAFFIC, V18, P530, DOI 10.1111/tra.12493
   Jager R, 2012, BIOL CELL, V104, P259, DOI 10.1111/boc.201100055
   Jardim DL, 2012, ANN ONCOL, V23, P1937, DOI 10.1093/annonc/mds074
   Jiang F, 2018, INT J MOL MED, V42, P1295, DOI 10.3892/ijmm.2018.3712
   Jiang XJ, 2015, J CLIN INVEST, V125, P47, DOI 10.1172/JCI73942
   Kaneko M, 2003, LIFE SCI, V74, P199, DOI 10.1016/j.lfs.2003.09.007
   Kim B, 2017, ANAT CELL BIOL, V50, P293, DOI 10.5115/acb.2017.50.4.293
   Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755
   Kim TW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0930-1
   Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325
   Lee CS, 2014, WORLD J GASTROENTERO, V20, P3751, DOI 10.3748/wjg.v20.i14.3751
   Lee JS, 2012, TOXICOL LETT, V211, P29, DOI 10.1016/j.toxlet.2012.02.017
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li DL, 2012, HELV CHIM ACTA, V95, P805, DOI 10.1002/hlca.201100417
   Li H, 2019, J CELL BIOCHEM, V120, P2391, DOI 10.1002/jcb.27570
   Lim EJ, 2015, APOPTOSIS, V20, P1087, DOI 10.1007/s10495-015-1135-z
   Lin ZH, 2013, CELL REP, V5, P1639, DOI 10.1016/j.celrep.2013.11.029
   Livesey KM, 2009, CURR OPIN INVEST DR, V10, P1269
   Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Nawrocki ST, 2005, CANCER RES, V65, P11510, DOI 10.1158/0008-5472.CAN-05-2394
   Nawrocki ST, 2005, CANCER RES, V65, P11658, DOI 10.1158/0008-5472.CAN-05-2370
   Newman DJ, 2000, NAT PROD REP, V17, P215, DOI 10.1039/a902202c
   Nishitoh H, 2012, J BIOCHEM, V151, P217, DOI 10.1093/jb/mvr143
   Obata Y, 2018, CANCER LETT, V415, P1, DOI 10.1016/j.canlet.2017.11.032
   Ohashi Y, 2016, CANCER RES, V76, P3895, DOI 10.1158/0008-5472.CAN-15-2220
   Ohashi Y, 2012, J BIOL CHEM, V287, P3885, DOI 10.1074/jbc.M111.316125
   OHUCHI K, 1989, BIOCHIM BIOPHYS ACTA, V1003, P9, DOI 10.1016/0005-2760(89)90091-X
   Onorati AV, 2018, CANCER-AM CANCER SOC, V124, P3307, DOI 10.1002/cncr.31335
   Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373
   Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683
   Qu JY, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041526
   Reid DW, 2014, CELL, V158, P1362, DOI 10.1016/j.cell.2014.08.012
   Rimpelova S, 2021, FOODS, V10, DOI 10.3390/foods10010136
   Rozpedek W, 2016, CURR MOL MED, V16, P533, DOI 10.2174/1566524016666160523143937
   Schonthal AH, 2013, BIOCHEM PHARMACOL, V85, P653, DOI 10.1016/j.bcp.2012.09.012
   Schwarz DS, 2016, CELL MOL LIFE SCI, V73, P79, DOI 10.1007/s00018-015-2052-6
   Serrano-Negron JE, 2018, GLYCOBIOLOGY, V28, P61, DOI 10.1093/glycob/cwx098
   Shi TT, 2017, CANCER CHEMOTH PHARM, V79, P287, DOI 10.1007/s00280-016-3197-1
   Shiina I, 2013, J MED CHEM, V56, P150, DOI 10.1021/jm301695c
   Skubnik J, 2021, PLANTS-BASEL, V10, DOI 10.3390/plants10030569
   Smith MH, 2011, SCIENCE, V334, P1086, DOI 10.1126/science.1209235
   Stevenson J, 2016, ANNU REV NUTR, V36, P511, DOI 10.1146/annurev-nutr-071715-051030
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184
   Teske BF, 2011, MOL BIOL CELL, V22, P4390, DOI 10.1091/mbc.E11-06-0510
   Thomas S, 2012, CANCER LETT, V325, P63, DOI 10.1016/j.canlet.2012.05.030
   Tsai DH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35780-y
   Valentini V, 2006, INT J RADIAT ONCOL, V64, P1129, DOI 10.1016/j.ijrobp.2005.09.017
   Verfaillie T., 2010, INT J CELL BIOL, V2010, P930509, DOI [DOI 10.1155/2010/930509, 10.1155/2010/930509]
   Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038
   Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800
   Wang P, 2013, GASTROENTEROLOGY, V145, P1133, DOI 10.1053/j.gastro.2013.07.048
   Watari K, 2012, INT J CANCER, V131, P310, DOI 10.1002/ijc.26356
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Wu YH, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0031-8
   You SP, 2018, MOL MED REP, V17, P4203, DOI 10.3892/mmr.2018.8444
   Yu L, 2020, ONCOGENE, V39, P4450, DOI 10.1038/s41388-020-1298-0
   Zhao LH, 2006, CURR OPIN CELL BIOL, V18, P444, DOI 10.1016/j.ceb.2006.06.005
   Zhao T, 2019, J ASIAN NAT PROD RES, V21, P851, DOI 10.1080/10286020.2018.1495197
   Zhu JZ, 2017, DIGEST DIS SCI, V62, P235, DOI 10.1007/s10620-016-4362-4
NR 94
TC 3
Z9 3
U1 5
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUN
PY 2021
VL 22
IS 11
AR 5566
DI 10.3390/ijms22115566
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA SQ1WC
UT WOS:000660149000001
PM 34070303
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Lin, LT
   Uen, WC
   Choong, CY
   Shi, YC
   Lee, BH
   Tai, CJ
   Tai, CJ
AF Lin, Liang-Tzung
   Uen, Wu-Ching
   Choong, Chen-Yen
   Shi, Yeu-Ching
   Lee, Bao-Hong
   Tai, Cheng-Jeng
   Tai, Chen-Jei
TI Paris Polyphylla Inhibits Colorectal Cancer Cells via Inducing Autophagy
   and Enhancing the Efficacy of Chemotherapeutic Drug Doxorubicin
SO MOLECULES
LA English
DT Article
DE folk medicine; DLD-1 cells; doxorubicin; chemotherapy; drug resistance
ID COMPLEMENTARY/ALTERNATIVE MEDICINE; APOPTOSIS; SURVIVAL; THERAPY; COLON
AB Colorectal cancer is one of the most common cancers worldwide and chemotherapy is the main approach for the treatment of advanced and recurrent cases. Developing an effective complementary therapy could help to improve tumor suppression efficiency and control adverse effects from chemotherapy. Paris polyphylla is a folk medicine for treating various forms of cancer, but its effect on colorectal cancer is largely unexplored. The aim of the present study is to investigate the tumor suppression efficacy and the mechanism of action of the ethanolic extract from P. polyphylla (EEPP) in DLD-1 human colorectal carcinoma cells and to evaluate its combined effect with chemotherapeutic drug doxorubicin. The data indicated that EEPP induced DLD-1 cell death via the upregulation of the autophagy markers, without triggering p53- and caspase-3-dependent apoptosis. Moreover, EEPP treatment in combination with doxorubicin enhanced cytotoxicity in these tumor cells. Pennogenin 3-O-beta-chacotrioside and polyphyllin VI were isolated from EEPP and identified as the main candidate active components. Our results suggest that EEPP deserves further evaluation for development as complementary chemotherapy for colorectal cancer.
C1 [Lin, Liang-Tzung] Taipei Med Univ, Coll Med, Sch Med, Dept Microbiol & Immunol, Taipei 11042, Taiwan.
   [Lin, Liang-Tzung] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei 11042, Taiwan.
   [Uen, Wu-Ching] Fujen Catholic Univ, Sch Med, New Taipei 24205, Taiwan.
   [Uen, Wu-Ching] Shin Kong Wu Ho Su Mem Hosp, Dept Hematol & Oncol, Taipei 11042, Taiwan.
   [Choong, Chen-Yen; Shi, Yeu-Ching; Lee, Bao-Hong; Tai, Cheng-Jeng] Taipei Med Univ Hosp, Div Hematol & Oncol, Dept Internal Med, Taipei 11042, Taiwan.
   [Tai, Cheng-Jeng] Taipei Med Univ, Coll Med, Sch Med, Div Hematol & Oncol,Dept Internal Med, Taipei 11042, Taiwan.
   [Tai, Chen-Jei] Taipei Univ Hosp, Dept Chinese Med, Taipei 11042, Taiwan.
   [Tai, Chen-Jei] Taipei Med Univ Hosp, Tradit Herbal Med Res Ctr, Taipei 11042, Taiwan.
   [Tai, Chen-Jei] Taipei Med Univ, Coll Med, Sch Med, Dept Obstet & Gynecol, Taipei 11042, Taiwan.
RP Tai, CJ (corresponding author), Taipei Univ Hosp, Dept Chinese Med, Taipei 11042, Taiwan.; Tai, CJ (corresponding author), Taipei Med Univ Hosp, Tradit Herbal Med Res Ctr, Taipei 11042, Taiwan.; Tai, CJ (corresponding author), Taipei Med Univ, Coll Med, Sch Med, Dept Obstet & Gynecol, Taipei 11042, Taiwan.
EM ltlin@tmu.edu.tw; m002047@ms.skh.org.tw; chenyen@tmu.edu.tw;
   jasmineycs@yahoo.com.tw; f96b47117@ntu.edu.tw; cjtai@tmu.edu.tw;
   chenjtai@tmu.edu.tw
OI Lin, Liang-Tzung/0000-0001-7374-7234
FU Taipei Medical University [108-TMU-TMUH-05]; Taipei Medical University
   Hospital [108-TMU-TMUH-05]; Ministry of Science and Technology (Taiwan,
   R.O.C.)Ministry of Science and Technology, Taiwan
   [MOST-106-2320-B-038-017]
FX This research work and subsidiary spending were supported by the Taipei
   Medical University and Taipei Medical University Hospital
   (108-TMU-TMUH-05), and the Ministry of Science and Technology
   (MOST-106-2320-B-038-017) (Taiwan, R.O.C.).
CR [Anonymous], 2009, CANC REGISTRY ANN RE
   Bushell M, 2000, CELL DEATH DIFFER, V7, P628, DOI 10.1038/sj.cdd.4400699
   Coleman MP, 2008, LANCET ONCOL, V9, P730, DOI 10.1016/S1470-2045(08)70179-7
   CUMMINGS J, 1993, ANN ONCOL, V4, P533, DOI 10.1093/oxfordjournals.annonc.a058584
   De Dosso S, 2009, CANCER TREAT REV, V35, P160, DOI 10.1016/j.ctrv.2008.10.001
   Ernst E, 1998, CANCER-AM CANCER SOC, V83, P777, DOI 10.1002/(SICI)1097-0142(19980815)83:4<777::AID-CNCR22>3.0.CO;2-O
   He H, 2014, ASIAN PAC J CANCER P, V15, P10911, DOI 10.7314/APJCP.2014.15.24.10911
   Hsu WH, 2012, FREE RADICAL BIO MED, V53, P1643, DOI 10.1016/j.freeradbiomed.2012.08.587
   Hsu WH, 2010, J SCI FOOD AGR, V90, P2709, DOI 10.1002/jsfa.4144
   Kim JY, 2012, ARCH ORAL BIOL, V57, P1018, DOI 10.1016/j.archoralbio.2012.04.005
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Kopetz S, 2008, ONCOLOGY-NY, V22, P260
   Li FR, 2012, ASIAN PAC J CANCER P, V13, P205, DOI 10.7314/APJCP.2012.13.1.205
   Li Y, 2013, MOLECULES, V18, P12916, DOI 10.3390/molecules181012916
   Li YH, 2014, BIOCHEM PHARMACOL, V88, P150, DOI 10.1016/j.bcp.2014.01.018
   Liu YL, 2010, AUTOPHAGY, V6, P1057, DOI 10.4161/auto.6.8.13365
   Man SL, 2012, PHYTOTHER RES, V26, P1449, DOI 10.1002/ptr.4609
   Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421
   Nahimana A, 2009, BLOOD, V113, P3276, DOI 10.1182/blood-2008-08-173369
   Patterson RE, 2002, J ALTERN COMPLEM MED, V8, P477, DOI 10.1089/107555302760253676
   Qi FH, 2010, BIOSCI TRENDS, V4, P297
   Richardson MA, 2000, J CLIN ONCOL, V18, P2505, DOI 10.1200/JCO.2000.18.13.2505
   Tai CJ, 2013, EVID-BASED COMPL ALT, V2013, DOI [10.1155/2013/514719, 10.1155/2013/121725]
   Wang CW, 2016, MOLECULES, V21, DOI 10.3390/molecules21060727
   Xu W, 2006, EUR J CANCER CARE, V15, P397, DOI 10.1111/j.1365-2354.2006.00685.x
   Ye MX, 2012, PHYTOMEDICINE, V19, P779, DOI 10.1016/j.phymed.2012.03.005
   Youns Mahmoud, 2010, Curr Drug Discov Technol, V7, P37
   Zhang C, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1036-x
NR 28
TC 14
Z9 14
U1 2
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD JUN 1
PY 2019
VL 24
IS 11
AR 2102
DI 10.3390/molecules24112102
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA IE8NT
UT WOS:000472631000075
PM 31163662
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Li, TY
   Chiang, BH
AF Li, Ting-Yi
   Chiang, Been-Huang
TI 6-shogaol induces autophagic cell death then triggered apoptosis in
   colorectal adenocarcinoma HT-29 cells
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Colorectal cancer; HT 29; 6-shogaol; Autophagy; Apoptosis
ID REGULATES AUTOPHAGY; ACTIVATION; ARREST
AB 6-shogaol is a phytochemical of dietary ginger, we found that 6-shogaol could induced both autophagic and apoptotic death in human colon adenocarcinoma (HT-29) cells. Results of this study showed that 6-shogal induced cell cycle arrest, autophagy, and apoptosis in HT-29 cells in a time sequence. After 6 h, 6-shogal induced apparent G2/M arrest, then the HT-29 cells formed numerous autophagosomes in each phase of the cell cycle. After 18 h, increases in acidic vesicles and LAMP-1 (Lysosome-associated membrane proteins 1) showed that 6-shogaol had caused autophagic cell death. After 24 h, cell shrinkage and Caspase-3/7 activities rising, suggesting that apoptotic cell death had increased. And after 48 h, the result of TUNEL assay indicated the highest occurrence of apoptosis upon 6-shogaol treatment. It appeared that apoptosis is triggered by autophagy in 6-shogaol treated HT-29 cells, the damage of autophagic cell death initiated apoptosis program. (C) 2017 Elsevier Masson SAS. All rights reserved.
C1 [Li, Ting-Yi; Chiang, Been-Huang] Natl Taiwan Univ, Inst Food Sci & Technol, Taipei 10617, Taiwan.
RP Chiang, BH (corresponding author), Natl Taiwan Univ, Inst Food Sci & Technol, 1,Sect 4,Roosevelt Rd, Taipei 106, Taiwan.
EM bhchiang@ntu.edu.tw
CR Akimoto M., 2015, PLOS ONE, V10
   Annamalai G, 2016, BIOMED PHARMACOTHER, V82, P226, DOI 10.1016/j.biopha.2016.04.044
   Chen CY, 2007, J AGR FOOD CHEM, V55, P948, DOI 10.1021/jf0624594
   Dancey J, 2010, NAT REV CLIN ONCOL, V7, P209, DOI 10.1038/nrclinonc.2010.21
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Dugasani S, 2010, J ETHNOPHARMACOL, V127, P515, DOI 10.1016/j.jep.2009.10.004
   Ellington AA, 2005, CARCINOGENESIS, V26, P159, DOI 10.1093/carcin/bgh297
   Esposti DD, 2010, AUTOPHAGY, V6, P172, DOI 10.4161/auto.6.1.10699
   Franke J, 2014, BMC VET RES, V10, DOI 10.1186/1746-6148-10-119
   Gan FF, 2011, APOPTOSIS, V16, P856, DOI 10.1007/s10495-011-0611-3
   Gao C, 2010, NAT CELL BIOL, V12, P781, DOI 10.1038/ncb2082
   Geng JF, 2008, EMBO REP, V9, P859, DOI 10.1038/embor.2008.163
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Hu R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039664
   Hung JY, 2009, J AGR FOOD CHEM, V57, P9809, DOI 10.1021/jf902315e
   Ishiguro K, 2008, FEBS LETT, V582, P3531, DOI 10.1016/j.febslet.2008.09.027
   Kaminskyy V, 2011, AUTOPHAGY, V7, P83, DOI 10.4161/auto.7.1.13893
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kim KW, 2006, J BIOL CHEM, V281, P36883, DOI 10.1074/jbc.M607094200
   Knecht E, 2009, CELL MOL LIFE SCI, V66, P2427, DOI 10.1007/s00018-009-0030-6
   Kourtis N, 2009, CELL DEATH DIFFER, V16, P21, DOI 10.1038/cdd.2008.120
   Kumar D, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-171
   Lebovitz CB, 2012, CLIN CANCER RES, V18, P1214, DOI 10.1158/1078-0432.CCR-11-2465
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522
   Pan MH, 2008, CHEM SOC REV, V37, P2558, DOI 10.1039/b801558a
   Pan MH, 2008, MOL NUTR FOOD RES, V52, P527, DOI 10.1002/mnfr.200700157
   Ramakrishnan S, 2007, AUTOPHAGY, V3, P512
   Ray A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137614
   Saiki S, 2011, AUTOPHAGY, V7, P176, DOI 10.4161/auto.7.2.14074
   Scarlatti F, 2008, CELL DEATH DIFFER, V15, P1318, DOI 10.1038/cdd.2008.51
   Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952
   Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634
   Wei QY, 2005, J ETHNOPHARMACOL, V102, P177, DOI 10.1016/j.jep.2005.05.043
   Weng CJ, 2012, MOL NUTR FOOD RES, V56, P1304, DOI 10.1002/mnfr.201200173
   Wu JJ, 2015, EUR J PHARMACOL, V762, P449, DOI 10.1016/j.ejphar.2015.06.032
   Yang Chao, 2001, Electric Power Automation Equipment, V21, P1
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
NR 39
TC 14
Z9 17
U1 0
U2 10
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD SEP
PY 2017
VL 93
BP 208
EP 217
DI 10.1016/j.biopha.2017.06.038
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA FE0PU
UT WOS:000407923000023
PM 28641163
DA 2022-04-25
ER

PT J
AU Karakas, HE
   Gozuacik, D
AF Karakas, Hacer Ezgi
   Gozuacik, Devrim
TI Autophagy and cancer
SO TURKISH JOURNAL OF BIOLOGY
LA English
DT Review
DE Autophagy; stress; cancer; tumor; oncogenes; tumor suppressors;
   metastasis; cell death; chemotherapy
ID INTERACTING FACTOR-I; CHAPERONE-MEDIATED AUTOPHAGY; TUMOR-SUPPRESSOR
   GENE; UNC-51-LIKE KINASE 1; INDUCED CELL-DEATH; DECREASED EXPRESSION;
   REGULATES AUTOPHAGY; POOR-PROGNOSIS; BREAST-CANCER; COLON-CANCER
AB Autophagy is an evolutionary conserved intracellular degradation and stress response mechanism that is mainly responsible for the breakdown and recycling of cytoplasmic materials, including long-lived proteins, protein aggregates, and damaged organelles. In this way, autophagy provides the cell with building blocks and allows the maintenance of homeostasis under stress conditions such as growth factor deficiency, nutrient deprivation, hypoxia, and toxins. Consequently, abnormalities of autophagy contribute to a number of pathologies ranging from neurodegenerative diseases to cancer. Autophagy was reported to have a dual role in cancer. Depending on cancer stage, autophagy seems to act as tumor suppressor or as a mechanism supporting tumor growth and spread. In this review, we provide a summary of the relevant literature and discuss the role of autophagy in cancer formation and chemotherapy responses.
C1 [Karakas, Hacer Ezgi; Gozuacik, Devrim] Sabanci Univ, Fac Engn & Nat Sci, Mol Biol Genet & Bioengn Program, Istanbul, Turkey.
RP Gozuacik, D (corresponding author), Sabanci Univ, Fac Engn & Nat Sci, Mol Biol Genet & Bioengn Program, Istanbul, Turkey.
EM dgozuacik@sabanciuniv.edu
RI Devrim, Gozuacik/C-3330-2008; Karakas, Hacer Ezgi/B-6566-2016
OI Devrim, Gozuacik/0000-0001-7739-2346; Karakas, Hacer
   Ezgi/0000-0001-5368-5064
FU Scientific and Technological Research Council of Turkey (TUBITAK)Turkiye
   Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [112T685]; Sabanci
   UniversitySabanci University; EMBO Strategic Development Installation
   Grant (EMBO-SDIG); Turkish Academy of Sciences (TUBA) GEBIP awardTurkish
   Academy of Sciences; TUBITAK-BIDEB scholarship for PhD studiesTurkiye
   Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)
FX We are grateful to Amal Araciche, Peter Schuller, Cenk Kig Kumsal Ayse
   Tekirdag, and Yunus Akkoc for critical reading of the manuscript. This
   work was supported by the Scientific and Technological Research Council
   of Turkey (TUBITAK), grant number 112T685, and Sabanci University. DG is
   the recipient of an EMBO Strategic Development Installation Grant
   (EMBO-SDIG) and Turkish Academy of Sciences (TUBA) GEBIP award. HEK was
   supported by a TUBITAK-BIDEB scholarship for PhD studies.
CR Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   An CH, 2011, PATHOL RES PRACT, V207, P433, DOI 10.1016/j.prp.2011.05.002
   Bareford MD, 2011, CANCER RES, V71, P4955, DOI 10.1158/0008-5472.CAN-11-0898
   Beau I, 2008, TRENDS CELL BIOL, V18, P311, DOI 10.1016/j.tcb.2008.05.001
   Bellodi C, 2009, J CLIN INVEST, V119, P1109, DOI 10.1172/JCI35660
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Bensaad K, 2009, EMBO J, V28, P3015, DOI 10.1038/emboj.2009.242
   Berthier A, 2010, BRIT J CANCER, V102, P1024, DOI 10.1038/sj.bjc.6605568
   Betin VMS, 2009, J CELL SCI, V122, P2554, DOI 10.1242/jcs.046250
   Brigger D, 2013, BIOCHEM BIOPH RES CO, V438, P283, DOI 10.1016/j.bbrc.2013.07.056
   Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467
   Carew JS, 2007, BLOOD, V110, P313, DOI 10.1182/blood-2006-10-050260
   Carew JS, 2010, J CELL MOL MED, V14, P2448, DOI 10.1111/j.1582-4934.2009.00832.x
   Carneiro LAM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00361
   Chano T, 2002, NAT GENET, V31, P285, DOI 10.1038/ng911
   Chittaranjan S, 2014, CLIN CANCER RES, V20, P3159, DOI 10.1158/1078-0432.CCR-13-2060
   Cho DH, 2012, ANTICANCER RES, V32, P4091
   Choi J, 2013, HISTOPATHOLOGY, V62, P275, DOI 10.1111/his.12002
   Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751
   CLIBY W, 1993, CANCER RES, V53, P2393
   Copetti T, 2009, MOL CELL BIOL, V29, P2594, DOI 10.1128/MCB.01396-08
   Coppola D, 2008, CANCER-AM CANCER SOC, V113, P2665, DOI 10.1002/cncr.23892
   Coppola D, 2008, CLIN GENITOURIN CANC, V6, P117, DOI 10.3816/CGC.2008.n.018
   Coppola D, 2011, PANCREAS, V40, P433, DOI 10.1097/MPA.0b013e318205eb03
   Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Degtyarev M, 2008, J CELL BIOL, V183, P101, DOI 10.1083/jcb.200801099
   Deng Q, 2013, JPN J CLIN ONCOL, V43, P1261, DOI 10.1093/jjco/hyt160
   Ding ZB, 2008, CANCER RES, V68, P9167, DOI 10.1158/0008-5472.CAN-08-1573
   Dong LW, 2011, AUTOPHAGY, V7, P1222, DOI 10.4161/auto.7.10.16610
   Dong M, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0355-0
   Eberhart K, 2014, AUTOPHAGY: CANCER, OTHER PATHOLOGIES, INFLAMMATION, IMMUNITY, INFECTION, AND AGING, VOL 1: MOLECULAR MECHANISMS, P179, DOI 10.1016/B978-0-12-405530-8.00013-3
   Egan DF, 2011, AUTOPHAGY, V7, P645, DOI 10.4161/auto.7.6.15123
   Elgendy M, 2011, MOL CELL, V42, P23, DOI 10.1016/j.molcel.2011.02.009
   Eskelinen EL, 2003, TRENDS CELL BIOL, V13, P137, DOI 10.1016/S0962-8924(03)00005-9
   Fabre C, 2007, ONCOGENE, V26, P4071, DOI 10.1038/sj.onc.1210187
   Fujii S, 2008, CANCER SCI, V99, P1813, DOI 10.1111/j.1349-7006.2008.00893.x
   Fujita N, 2008, MOL BIOL CELL, V19, P2092, DOI 10.1091/mbc.E07-12-1257
   Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002
   Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092
   FUTREAL PA, 1992, CANCER RES, V52, P2624
   Gandemer V, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-385
   Geoerger B, 2001, CANCER RES, V61, P1527
   Gewirtz DA, 2009, AUTOPHAGY, V5, P1232, DOI 10.4161/auto.5.8.9896
   Gozuacik D, 2008, CELL DEATH DIFFER, V15, P1875, DOI 10.1038/cdd.2008.121
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1
   Grunwald V, 2002, CANCER RES, V62, P6141
   Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008
   Guo JY, 2013, CELL, V155, P1216, DOI 10.1016/j.cell.2013.11.019
   Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425
   Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248
   Hu N, 2005, CANCER RES, V65, P2542, DOI 10.1158/0008-5472.CAN-04-3247
   Huang JJ, 2010, AUTOPHAGY, V6, P777, DOI 10.4161/auto.6.6.12784
   Huang X, 2010, J CLIN NEUROSCI, V17, P1515, DOI 10.1016/j.jocn.2010.03.051
   Huijbers A, 2012, ENDOCR-RELAT CANCER, V19, pL15, DOI 10.1530/ERC-11-0302
   Huo YY, 2013, CANCER DISCOV, V3, P894, DOI 10.1158/2159-8290.CD-13-0011
   Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094
   Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003
   Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178
   Iqbal J, 2009, LEUKEMIA, V23, P1139, DOI 10.1038/leu.2009.3
   Itakura E, 2012, CELL, V151, P1256, DOI 10.1016/j.cell.2012.11.001
   Itakura E, 2010, AUTOPHAGY, V6, P764, DOI 10.4161/auto.6.6.12709
   Itakura E, 2008, MOL BIOL CELL, V19, P5360, DOI 10.1091/mbc.E08-01-0080
   Jahreiss L, 2008, TRAFFIC, V9, P574, DOI 10.1111/j.1600-0854.2008.00701.x
   Jiang L, 2014, INT J CLIN EXP MED, V7, P1349
   Jiang S, 2011, CANCER SCI, V102, P1568, DOI 10.1111/j.1349-7006.2011.01964.x
   Jiang ZF, 2012, MOL BIOL REP, V39, P259, DOI 10.1007/s11033-011-0734-1
   Jo YK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052705
   Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249
   Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870
   Kauppi M, 2002, J CELL SCI, V115, P899
   Kaushik S, 2012, TRENDS CELL BIOL, V22, P407, DOI 10.1016/j.tcb.2012.05.006
   Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim KW, 2008, AUTOPHAGY, V4, P659, DOI 10.4161/auto.6058
   Kim MS, 2008, HUM PATHOL, V39, P1059, DOI 10.1016/j.humpath.2007.11.013
   Kim SY, 2008, PATHOLOGY, V40, P553, DOI 10.1080/00313020802320440
   Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263
   Klebig C, 2005, CANCER RES, V65, P394
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Klionsky DJ, 2005, AUTOPHAGY, V1, P59, DOI 10.4161/auto.1.1.1536
   Klionsky DJ, 2014, NAT STRUCT MOL BIOL, V21, P336, DOI 10.1038/nsmb.2787
   Knaevelsrud H, 2010, AUTOPHAGY, V6, P863, DOI 10.4161/auto.6.7.13033
   Ko YH, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/329839
   Korkmaz G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082556
   Korkmaz G, 2012, AUTOPHAGY, V8, P165, DOI 10.4161/auto.8.2.18351
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984
   Kraft C, 2009, BBA-MOL CELL RES, V1793, P1404, DOI 10.1016/j.bbamcr.2009.02.006
   Kuma A, 2010, SEMIN CELL DEV BIOL, V21, P683, DOI 10.1016/j.semcdb.2010.03.002
   Laddha SV, 2014, MOL CANCER RES, V12, P485, DOI 10.1158/1541-7786.MCR-13-0614
   Lazova R, 2010, J CUTAN PATHOL, V37, P256, DOI 10.1111/j.1600-0560.2009.01359.x
   Lee IH, 2009, J BIOL CHEM, V284, P6322, DOI 10.1074/jbc.M807135200
   Lee JW, 2007, APMIS, V115, P750, DOI 10.1111/j.1600-0463.2007.apm_640.x
   Lee JW, 2006, PATHOLOGY, V38, P312, DOI 10.1080/00313020600820880
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li XQ, 2010, AUTOPHAGY, V6, P1066, DOI 10.4161/auto.6.8.13366
   Li ZD, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-98
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lin CI, 2010, MOL CANCER RES, V8, P1217, DOI 10.1158/1541-7786.MCR-10-0162
   Liu C, 2014, ONCOL REP, V31, P2043, DOI 10.3892/or.2014.3096
   Liu J, 2011, TUMOR BIOL, V32, P1113, DOI 10.1007/s13277-011-0211-4
   Liu Quan, 2008, Ai Zheng, V27, P25
   Livesey KM, 2009, CURR OPIN INVEST DR, V10, P1269
   Lock R, 2014, CANCER DISCOV, V4, P466, DOI 10.1158/2159-8290.CD-13-0841
   Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512
   Luo S, 2010, CELL DEATH DIFFER, V17, P268, DOI 10.1038/cdd.2009.121
   Luo SM, 2010, J CELL PHYSIOL, V224, P414, DOI 10.1002/jcp.22137
   Ma Y, 2013, MOL BIOL REP, V40, P469, DOI 10.1007/s11033-012-2082-1
   Ma YT, 2013, IMMUNITY, V39, P211, DOI 10.1016/j.immuni.2013.07.017
   Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689
   Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001
   Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958
   Fader CM, 2009, BBA-MOL CELL RES, V1793, P1901, DOI 10.1016/j.bbamcr.2009.09.011
   Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200
   Martin AP, 2009, CANCER BIOL THER, V8, P2084
   Massey AC, 2006, CURR TOP DEV BIOL, V73, P205, DOI 10.1016/S0070-2153(05)73007-6
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Mathew R, 2009, METHOD ENZYMOL, V453, P53, DOI 10.1016/S0076-6879(08)04004-4
   Matsunaga K, 2010, J CELL BIOL, V190, P511, DOI 10.1083/jcb.200911141
   Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002
   Meley D, 2006, J BIOL CHEM, V281, P34870, DOI 10.1074/jbc.M605488200
   Miao YF, 2010, HEPATO-GASTROENTEROL, V57, P257
   Mijaljica D, 2011, AUTOPHAGY, V7, P252, DOI 10.4161/auto.7.2.14225
   Miracco C, 2007, INT J ONCOL, V30, P429
   Miracco C, 2010, HUM PATHOL, V41, P503, DOI 10.1016/j.humpath.2009.09.004
   Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Mizushima N, 2010, NAT CELL BIOL, V12, P823, DOI 10.1038/ncb0910-823
   Mondesire WH, 2004, CLIN CANCER RES, V10, P7031, DOI 10.1158/1078-0432.CCR-04-0361
   Morselli E, 2009, BBA-MOL CELL RES, V1793, P1524, DOI 10.1016/j.bbamcr.2009.01.006
   Muenz C, 2009, ANNU REV IMMUNOL, V27, P423, DOI 10.1146/annurev.immunol.021908.132537
   Munafo DB, 2002, TRAFFIC, V3, P472, DOI 10.1034/j.1600-0854.2002.30704.x
   Murrow L, 2013, ANNU REV PATHOL-MECH, V8, P105, DOI 10.1146/annurev-pathol-020712-163918
   Nakatogawa H, 2009, NAT REV MOL CELL BIO, V10, P458, DOI 10.1038/nrm2708
   Nicoli ER, 2014, ROM J MORPHOL EMBRYO, V55, P57
   Nicotra G, 2010, MODERN PATHOL, V23, P937, DOI 10.1038/modpathol.2010.80
   Nomura H, 2009, HUM PATHOL, V40, P83, DOI 10.1016/j.humpath.2008.06.018
   Oral O, 2012, APOPTOSIS, V17, P810, DOI 10.1007/s10495-012-0735-0
   Othman EQG, 2009, J CLIN LAB ANAL, V23, P249, DOI 10.1002/jcla.20309
   Otomo C, 2013, NAT STRUCT MOL BIOL, V20, P59, DOI 10.1038/nsmb.2431
   Paglin S, 2001, CANCER RES, V61, P439
   Pandya KJ, 2007, J THORAC ONCOL, V2, P1036, DOI 10.1097/JTO.0b013e318155a439
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Plantinga TS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094086
   Qin ZZ, 2013, GENE, V527, P491, DOI 10.1016/j.gene.2013.06.067
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Rao S, 2014, AUTOPHAGY, V10, P529, DOI 10.4161/auto.27643
   Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362
   Reef S, 2006, MOL CELL, V22, P463, DOI 10.1016/j.molcel.2006.04.014
   Roberts SS, 2004, J CLIN ONCOL, V22, P4127, DOI 10.1200/JCO.2004.02.032
   Roberts SS, 2009, PATHOL ONCOL RES, V15, P645, DOI 10.1007/s12253-009-9165-x
   Rothe K, 2014, BLOOD, V123, P3622, DOI 10.1182/blood-2013-07-516807
   Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027
   Rubinstein AD, 2012, J CELL SCI, V125, P5259, DOI 10.1242/jcs.115865
   RUSSELL SEH, 1990, ONCOGENE, V5, P1581
   SAITO H, 1993, CANCER RES, V53, P3382
   Salih DAM, 2008, CURR OPIN CELL BIOL, V20, P126, DOI 10.1016/j.ceb.2008.02.005
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Satoo K, 2009, EMBO J, V28, P1341, DOI 10.1038/emboj.2009.80
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Schlottmann S, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/725854
   Schneider JL, 2014, CURR OPIN GENET DEV, V26, P16, DOI 10.1016/j.gde.2014.04.003
   Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676
   Shaid S, 2013, CELL DEATH DIFFER, V20, P21, DOI 10.1038/cdd.2012.72
   Shani G, 2004, MOL CELL BIOL, V24, P8611, DOI 10.1128/MCB.24.19.8611-8626.2004
   Shen Y, 2008, AUTOPHAGY, V4, P1067, DOI 10.4161/auto.6827
   Shi YJ, 2002, CANCER RES, V62, P5027
   Shingu T, 2009, INT J CANCER, V124, P1060, DOI 10.1002/ijc.24030
   Sivridis E, 2011, MELANOMA RES, V21, P188, DOI 10.1097/CMR.0b013e328346612c
   Steelman LS, 2008, ONCOGENE, V27, P4086, DOI 10.1038/onc.2008.49
   Strohecker AM, 2013, CANCER DISCOV, V3, P1272, DOI 10.1158/2159-8290.CD-13-0397
   Su MF, 2013, J ONCOL, V2013, DOI 10.1155/2013/102735
   Sun QM, 2008, P NATL ACAD SCI USA, V105, P19211, DOI 10.1073/pnas.0810452105
   Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634
   Takahashi Y, 2013, BLOOD, V121, P1622, DOI 10.1182/blood-2012-10-459826
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Tang J, 2012, BREAST CANCER RES TR, V134, P549, DOI 10.1007/s10549-012-2080-y
   Tangir J, 1996, ONCOGENE, V12, P735
   Tasdemir E, 2008, AUTOPHAGY, V4, P810, DOI 10.4161/auto.6486
   Tekirdag KA, 2014, AUTOPHAGY CANC OTHER, P1
   Tekirdag KA, 2013, AUTOPHAGY, V9, P374, DOI 10.4161/auto.23117
   Uttenweiler A, 2005, J BIOL CHEM, V280, P33289, DOI 10.1074/jbc.M506086200
   van der Vaart A, 2008, TRAFFIC, V9, P281, DOI 10.1111/j.1600-0854.2007.00674.x
   Viry E, 2014, BIOCH PHARM IN PRESS
   Vousden KH, 2009, BIOCHEM SOC T, V37, P511, DOI 10.1042/BST0370511
   Wang RC, 2012, SCIENCE, V338, P956, DOI 10.1126/science.1225967
   Wang Zan-Hong, 2006, Sichuan Da Xue Xue Bao Yi Xue Ban, V37, P860
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   White E, 2013, GENE DEV, V27, P2065, DOI 10.1101/gad.228122.113
   White E, 2010, CURR OPIN CELL BIOL, V22, P212, DOI 10.1016/j.ceb.2009.12.008
   Wong E, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a006734
   Wu H, 2006, CANCER RES, V66, P3015, DOI 10.1158/0008-5472.CAN-05-1554
   Wu Zhaoju, 2010, Genes Cancer, V1, P40, DOI 10.1177/1947601909358324
   Xia HG, 2010, AUTOPHAGY, V6, P61, DOI 10.4161/auto.6.1.10326
   Xu HT, 2013, INT J CLIN EXP PATHO, V6, P711
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yoshioka A, 2008, INT J ONCOL, V33, P461, DOI 10.3892/ijo_00000028
   Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Yu K, 2010, CANCER RES, V70, P621, DOI 10.1158/0008-5472.CAN-09-2340
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zalckvar E, 2009, AUTOPHAGY, V5, P720, DOI 10.4161/auto.5.5.8625
   Zhang ZC, 2009, J HUAZHONG U SCI-MED, V29, P737, DOI 10.1007/s11596-009-0613-3
   Zhao X, 2014, CURR MOL MED, V14, P555, DOI 10.2174/1566524014666140414211223
   Zhong Y, 2009, AUTOPHAGY, V5, P890, DOI 10.4161/auto.9162
   Zhu H, 2009, AUTOPHAGY, V5, P816, DOI 10.4161/auto.9064
NR 221
TC 9
Z9 9
U1 2
U2 16
PU TUBITAK SCIENTIFIC & TECHNICAL RESEARCH COUNCIL TURKEY
PI ANKARA
PA ATATURK BULVARI NO 221, KAVAKLIDERE, ANKARA, 00000, TURKEY
SN 1300-0152
EI 1303-6092
J9 TURK J BIOL
JI Turk. J. Biol.
PY 2014
VL 38
IS 6
BP 720
EP 739
DI 10.3906/biy-1408-16
PG 20
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA AU2FF
UT WOS:000345431100004
OA Bronze, Green Submitted
DA 2022-04-25
ER

PT J
AU Wu, L
   He, K
   Ding, QS
   Wang, Z
   Xiang, GA
   Yu, HG
AF Wu Lu
   He Ke
   Ding Qianshan
   Wang Zhen
   Xiang Guoan
   Yu Honggang
TI Apatinib has anti-tumor effects and induces autophagy in colon cancer
   cells
SO IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES
LA English
DT Article
DE Apatinib; Apoptosis; Autophagy; Colon cancer; Migration; mTOR
ID GASTRIC-CANCER; COLORECTAL-CANCER; TYROSINE KINASE; INHIBITOR; GROWTH;
   DISEASE; PHARMACOKINETICS; METABOLISM; PROTEINS; YN968D1
AB Objective(s): Apatinib recently has been used to treat patients with gastric cancer, but the function of apatinib in colon cancer remains unclear. This study was conducted to investigate the impacts of apatinib on the biological function and its potential mechanism of colon cancer cells in vitro.
   Materials and Methods: The effect of apatinib in colon cancer cells were detected by assessing cell viability, migration and invasion capabilities. Apoptosis cells and the cell cycle distribution of colon cancer cells were analyzed by flow cytometry. The potential mechanism was investigated via autophagy related proteins and pathways in vitro.
   Results: The proliferation, migration and invasion of colon cancer cells were inhibited when they were treated with different concentration of apatinib (20, 40 mu M). When HCT116 and SW480 cells were treated with apatinib at the concentration of 20 mu M, the apoptosis percentage were 3.7% and 5.8% respectively. As the drug concentration increased to 40 mu M., the the apoptosis percentage increased to 11.9% and 13.5%. Meanwhile, cell cycle was also altered. Furthermore, apatinib inhibited the expression of AKT-mTOR signaling pathway and increased the expression of LC3-II.
   Conclusion: Apatinib can significantly inhibit the malignant phenotype of colon cancer cells, and it was involved in regulation of autophagy.
C1 [Wu Lu; Ding Qianshan; Yu Honggang] Wuhan Univ, Dept Gastroenterol, Renmin Hosp, Wuhan 430060, Hubei, Peoples R China.
   [Wu Lu] Wuhan Univ, Hubei Key Lab Digest Syst, Renmin Hosp, Wuhan, Hubei, Peoples R China.
   [He Ke; Xiang Guoan] Guangdong Second Prov Gen Hosp, Dept Gen Surg, Guangzhou, Guangdong, Peoples R China.
   [Wang Zhen] Jiangsu Hengrui Med Co Ltd, Lian Yungang 222047, Peoples R China.
RP Yu, HG (corresponding author), Wuhan Univ, Renmin Hosp, Dept Gastroenterol, Hubei Key Lab Digest Syst, Zhangzhidong Rd 99, Wuhan 430061, Hubei, Peoples R China.
EM yhg_rmhwh@163.com
CR AHLBERG J, 1985, EXP MOL PATHOL, V42, P78, DOI 10.1016/0014-4800(85)90020-6
   Aoyama T, 2016, NAT REV CLIN ONCOL, V13, P268, DOI 10.1038/nrclinonc.2016.53
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Chan MMK, 2015, BIOL-TARGETS THER, V9, P93, DOI 10.2147/BTT.S62777
   Chatterjee S, 2013, J CLIN INVEST, V123, P1732, DOI 10.1172/JCI65385
   Ding JF, 2013, DRUG METAB DISPOS, V41, P1195, DOI 10.1124/dmd.112.050310
   Ding JF, 2012, J CHROMATOGR B, V895, P108, DOI 10.1016/j.jchromb.2012.03.027
   Fontanella C, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2014.08.14
   Fornaro L, 2016, J CLIN ONCOL
   Gill S, 2003, ALIMENT PHARM THER, V18, P683, DOI 10.1046/j.1365-2036.2003.01735.x
   Hu T, 2016, WORLD J GASTROENTERO, V22, P6876, DOI 10.3748/wjg.v22.i30.6876
   Ivy SP, 2009, NAT REV CLIN ONCOL, V6, P569, DOI 10.1038/nrclinonc.2009.130
   Jayson GC, 2016, LANCET, V388, P518, DOI 10.1016/S0140-6736(15)01088-0
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Lee JJ, 2014, CLIN COLORECTAL CANC, V13, P135, DOI 10.1016/j.clcc.2014.02.001
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-529
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7
   Roviello G, 2016, EXPERT REV GASTROENT, V10, P887, DOI 10.1080/17474124.2016.1209407
   Roviello G, 2016, CANCER LETT, V372, P187, DOI 10.1016/j.canlet.2016.01.014
   Schaaf MBE, 2016, FASEB J, V30, P3961, DOI 10.1096/fj.201600698R
   Scott AJ, 2015, DRUG TODAY, V51, P223, DOI 10.1358/dot.2015.51.4.2320599
   Thomas Hilary, 2003, Cancer Control, V10, P159
   Tian S, 2011, CANCER SCI, V102, P1374, DOI 10.1111/j.1349-7006.2011.01939.x
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
   Yang J, 2013, INT J BIOL SCI, V9, P1121, DOI 10.7150/ijbs.6666
NR 27
TC 37
Z9 41
U1 1
U2 11
PU MASHHAD UNIV MED SCIENCES
PI MASHHAD
PA VICE-CHANCELLOR FOR RES CTR OFF IJBMS, DANESHGAH ST, PO BOX 9138813944 -
   445, MASHHAD, 00000, IRAN
SN 2008-3866
EI 2008-3874
J9 IRAN J BASIC MED SCI
JI Iran. J. Basic Med. Sci.
PD SEP
PY 2017
VL 20
IS 9
BP 990
EP 995
PG 6
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA FF7RC
UT WOS:000409212700004
PM 29085592
DA 2022-04-25
ER

PT J
AU Li, J
   Hou, N
   Faried, A
   Tsutsumi, S
   Takeuchi, T
   Kuwano, H
AF Li, Jie
   Hou, Ni
   Faried, Ahmad
   Tsutsumi, Soichi
   Takeuchi, Toshiyuki
   Kuwano, Hiroyuki
TI Inhibition of Autophagy by 3-MA Enhances the Effect of 5-FU-Induced
   Apoptosis in Colon Cancer Cells
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Article
ID 1ST-LINE TREATMENT; ADJUVANT TREATMENT; COLORECTAL-CANCER; MAMMALIAN
   TARGET; DEATH; PROTEINS; 5-FLUOROURACIL; TUMORIGENESIS; FLUOROURACIL;
   MECHANISMS
AB 5-fluorouracil-(5-FU)-based adjuvant chemotherapy is widely used for the treatment of colorectal cancer. However, 5-FU resistance in the course of treatment has become more common. Therefore, new therapeutic strategies and/or new adjuvant drugs still need to be explored.
   Two colon-cancer-derived cell lines, colon26 and HT29, were used to investigate the effect of 5-FU, 3-methyladenine (3-MA, an autophagy inhibitor), or their combination on apoptotic cell death and autophagy. MTT assay, Hochest plus propidium iodide (PI) staining, and DNA fragmentation assay were used to observe apoptosis. Meanwhile, monodansylcadaverine (MDC) was used to detect autophagy. Finally, immunoblotting assay was used to explore the molecular change that occurred.
   We observed the apoptosis induced by 5-FU in colon cancer cells. Meanwhile, autophagy was also stimulated. The combination treatment of 3-MA and 5-FU significantly increased the apoptotic cell death. By isolating the subcellular fractions of mitochondria and cytosol, we observed that the release of cytochrome c was increased in combination-treated cells. Cytochrome c resulted in the activation of caspase-3, thus activating PARP. Moreover, the anti-apoptotic protein, Bcl-xL, was significantly downregulated by 3-MA.
   Our results suggest that 5-FU-induced apoptosis in colon cancer cells can be enhanced by the inhibitor of autophagy, 3-MA. Autophagy might play a role as a self-defense mechanism in 5-FU-treated colon cancer cells, and its inhibition could be a promising strategy for the adjuvant chemotherapy of colon cancer.
C1 [Li, Jie; Faried, Ahmad; Tsutsumi, Soichi; Kuwano, Hiroyuki] Gunma Univ, Grad Sch Med, Dept Gen Surg Sci Surg 1, Gunma 3718511, Japan.
   [Hou, Ni; Takeuchi, Toshiyuki] Gunma Univ, Inst Mol & Cellular Regulat, Dept Mol Med, Maebashi, Gunma 371, Japan.
RP Li, J (corresponding author), Gunma Univ, Grad Sch Med, Dept Gen Surg Sci Surg 1, Gunma 3718511, Japan.
EM lijie@med.gunma-u.ac.jp
FU 21st Century COE Program, JapanMinistry of Education, Culture, Sports,
   Science and Technology, Japan (MEXT); Japan Society for the Promotion of
   Science (JSPS)Ministry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT)Japan Society for the Promotion of Science
FX This work was supported by the 21st Century COE Program, Japan and the
   Japan Society for the Promotion of Science (JSPS) for A. Faried.
CR ABEDIN MJ, 2006, CELL DEATH DIFFER, V22, P1
   Bauvy C, 2001, EXP CELL RES, V268, P139, DOI 10.1006/excr.2001.5285
   BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3
   Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595
   Cao C, 2006, CANCER RES, V66, P10040, DOI 10.1158/0008-5472.CAN-06-0802
   Chau I, 2006, ANN ONCOL, V17, P1347, DOI 10.1093/annonc/mdl029
   Chau I, 2002, CANCER TREAT REV, V28, P223, DOI 10.1016/S0305-7372(02)00047-6
   Cui Q, 2006, J PHARMACOL SCI, V101, P230, DOI 10.1254/jphs.FPJ06003X
   Ding WX, 2007, J BIOL CHEM, V282, P4702, DOI 10.1074/jbc.M609267200
   Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1
   Giacchetti S, 2000, J CLIN ONCOL, V18, P136, DOI 10.1200/JCO.2000.18.1.136
   Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1
   Grem JL, 2000, INVEST NEW DRUG, V18, P299, DOI 10.1023/A:1006416410198
   Herman-Antosiewicz A, 2006, CANCER RES, V66, P5828, DOI 10.1158/0008-5472.CAN-06-0139
   Hoorens A, 1996, J CLIN INVEST, V98, P1568, DOI 10.1172/JCI118950
   Huerta S, 2006, AM J SURG, V191, P517, DOI 10.1016/j.amjsurg.2005.11.009
   Iwamaru A, 2007, ONCOGENE, V26, P1840, DOI 10.1038/sj.onc.1209992
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485
   Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002
   Munafo DB, 2001, J CELL SCI, V114, P3619
   Ng G, 2005, MOL CARCINOGEN, V43, P183, DOI 10.1002/mc.20097
   Nordman IC, 2006, ANZ J SURG, V76, P373, DOI 10.1111/j.1445-2197.2006.03726.x
   Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0
   Paglin S, 2001, CANCER RES, V61, P439
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254
   Wils J, 2001, ANN ONCOL, V12, P13, DOI 10.1023/A:1008357725209
   Xu R, 2006, HISTOL HISTOPATHOL, V21, P867, DOI 10.14670/HH-21.867
   Yan CH, 2006, TOXICON, V47, P521, DOI 10.1016/j.toxicon.2006.01.010
   Zhu HB, 2005, MOL CANCER THER, V4, P451
NR 40
TC 215
Z9 244
U1 0
U2 36
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD MAR
PY 2009
VL 16
IS 3
BP 761
EP 771
DI 10.1245/s10434-008-0260-0
PG 11
WC Oncology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Surgery
GA 407GN
UT WOS:000263351700029
PM 19116755
DA 2022-04-25
ER

PT J
AU Tanabe, H
   Kuribayashi, K
   Tsuji, N
   Tanaka, M
   Kobayashi, D
   Watanabe, N
AF Tanabe, Hiromi
   Kuribayashi, Kageaki
   Tsuji, Naoki
   Tanaka, Maki
   Kobayashi, Daisuke
   Watanabe, Naoki
TI Sesamin induces autophagy in colon cancer cells by reducing tyrosine
   phosphorylation of EphA1 and EphB2
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE sesamin; autophagy; EphA1; EphB2; colorectal cancer; receptor tyrosine
   kinase
ID COLORECTAL-CANCER; PROTEIN-DEGRADATION; TUMOR-SUPPRESSOR; INHIBITION;
   RECEPTOR; PROLIFERATION; MECHANISMS; GENE; RATS; HYPERTENSION
AB Receptor tyrosine kinase EphB2 and autophagic machinery are known as tumor suppressors; however, the connection remains to be elucidated. Here, we show the link between EphB2 and autophagy. Sesamin, a major lignan in sesame oil, induced autophagy in the human colon cancer cell lines HT29 and LS180, as shown by electron microscopy, as well as Western blotting and immunofluorescence imaging using an anti-LC3 antibody. Receptor tyrosine kinase array analysis revealed that sesamin treatment increased the levels of unphosphorylated -EphA1 and EphB2 in HT29 cells. Silencing of EphA1 and EphB2 blocked sesamin-induced autophagy as well as sesamin-induced loss of cell viability. These results show that EphA1 and EphB2 play a critical role in this process. The present study reveals a novel function for EphA1 and EphB2 in the induction of autophagy, suggesting a tumor suppressor role for these proteins in colorectal cancer.
C1 [Tanabe, Hiromi; Kuribayashi, Kageaki; Tsuji, Naoki; Tanaka, Maki; Kobayashi, Daisuke; Watanabe, Naoki] Sapporo Med Univ, Sch Med, Dept Clin Lab Med, Chuo Ku, Sapporo, Hokkaido 0608543, Japan.
RP Watanabe, N (corresponding author), Sapporo Med Univ, Sch Med, Dept Clin Lab Med, Chuo Ku, South 1,West 16, Sapporo, Hokkaido 0608543, Japan.
EM watanabn@sapmed.ac.jp
OI Kuribayashi, Kageaki/0000-0002-4618-1543
CR Alazzouzi H, 2005, CANCER RES, V65, P10170, DOI 10.1158/0008-5472.CAN-05-2580
   Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626
   CANUTO RA, 1993, CARCINOGENESIS, V14, P2581, DOI 10.1093/carcin/14.12.2581
   COCKLE SM, 1984, BIOCHEM J, V221, P53, DOI 10.1042/bj2210053
   Cortina C, 2007, NAT GENET, V39, P1376, DOI 10.1038/ng.2007.11
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   GRONOSTAJSKI RM, 1984, J CELL PHYSIOL, V119, P127, DOI 10.1002/jcp.1041190120
   GUNN JM, 1977, NATURE, V266, P58, DOI 10.1038/266058a0
   Guo DL, 2006, CARCINOGENESIS, V27, P454, DOI 10.1093/carcin/bgi259
   Harikumar KB, 2010, MOL CANCER RES, V8, P751, DOI 10.1158/1541-7786.MCR-09-0565
   Hippert MM, 2006, CANCER RES, V66, P9349, DOI 10.1158/0008-5472.CAN-06-1597
   HIROSE N, 1991, J LIPID RES, V32, P629
   Holmberg J, 2006, CELL, V125, P1151, DOI 10.1016/j.cell.2006.04.030
   Jubb AM, 2005, CLIN CANCER RES, V11, P5181, DOI 10.1158/1078-0432.CCR-05-0143
   KISEN GO, 1993, CARCINOGENESIS, V14, P2501, DOI 10.1093/carcin/14.12.2501
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   KNECHT E, 1984, EXP CELL RES, V154, P224, DOI 10.1016/0014-4827(84)90682-7
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Levine B, 2008, NAT CELL BIOL, V10, P637, DOI 10.1038/ncb0608-637
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   LOCKWOOD TD, 1982, BIOCHEM J, V206, P251, DOI 10.1042/bj2060251
   MATSUMURA Y, 1995, BIOL PHARM BULL, V18, P1016, DOI 10.1248/bpb.18.1016
   Miyahara Y, 2000, INT J MOL MED, V6, P43
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Munafo DB, 2001, J CELL SCI, V114, P3619
   Nabekura T, 2008, CANCER CHEMOTH PHARM, V62, P867, DOI 10.1007/s00280-007-0676-4
   Noguchi T, 2001, HYPERTENS RES, V24, P735, DOI 10.1291/hypres.24.735
   Ogawa Hiroshi, 1995, Clinical and Experimental Pharmacology and Physiology, V22, pS310, DOI 10.1111/j.1440-1681.1995.tb02932.x
   Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011
   Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806
   PRAML C, 1995, ONCOGENE, V11, P1357
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   SCHWARZE PE, 1985, EXP CELL RES, V157, P15, DOI 10.1016/0014-4827(85)90148-X
   Vasilcanu D, 2004, ONCOGENE, V23, P7854, DOI 10.1038/sj.onc.1208065
   Yokota T, 2007, CANCER SCI, V98, P1447, DOI 10.1111/j.1349-7006.2007.00560.x
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zogopoulos G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002885
NR 39
TC 18
Z9 20
U1 0
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
J9 INT J ONCOL
JI Int. J. Oncol.
PD JUL
PY 2011
VL 39
IS 1
BP 33
EP 40
DI 10.3892/ijo.2011.1011
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 775ZS
UT WOS:000291504900005
PM 21503576
OA Bronze
DA 2022-04-25
ER

PT J
AU Feng, Q
   Wang, HJ
   Pang, JY
   Ji, LY
   Han, JD
   Wang, Y
   Qi, XX
   Liu, ZQ
   Lu, LL
AF Feng, Qian
   Wang, Haojia
   Pang, Jiaying
   Ji, Liyan
   Han, Jiada
   Wang, Ying
   Qi, Xiaoxiao
   Liu, Zhongqiu
   Lu, Linlin
TI Prevention of Wogonin on Colorectal Cancer Tumorigenesis by Regulating
   p53 Nuclear Translocation
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE wogonin; colorectal cancer; p53 nuclear translocation; endoplasmic
   reticulum stress; apoptosis; autophagy
ID ENDOPLASMIC-RETICULUM STRESS; APOPTOSIS; AUTOPHAGY; PATHWAYS; DEATH;
   CELLS; GRP78
AB The tumor suppressor protein p53 plays an important role in the development and progression of colon cancer, and the subcellular organelle localization directly affects its function. Wogonin (5,7-dihydroxy-8-methoxyflavone), a mono-flavonoid extracted from root of Scutellaria baicalensis Georgi, possesses acceptable toxicity and has been used in colorectal cancer (CRC) chemoprevention in pre-clinical trials by oncologist. However, the underlying anti-colon cancer mechanisms of wogonin are not yet fully understood. In the present study, the effect of wogonin on the initiation and development of colitis-associated cancer through p53 nuclear translocation was explored. AOM-DSS CRC animal model and human CRC HCT-116 cell model were used to evaluate the in vivo and in vitro anti-colon cancer action of wogonin. We observed that wogonin showed a dramaticlly preventive effect on colon cancer. Our results showed that wogonin caused apoptotic cell death in human CRC HCT-116 cell through increased endoplasmic reticulum (ER) stress. Meanwhile, excessive ER stress facilitated the cytoplasmic localization of p53 through increasing phosphor-p53 at S315 and S376 sites, induced caspase-dependent apoptosis and inhibited autophagy. Furthermore, we verified the chemoprevention effect and toxicity of wogonin in vivo by utilizing an AOM-DSS colon cancer animal model. We found that wogonin not only reduced tumor multiplicity, preserved colon length to normal (6.79 +/- 0.34 to 7.41 +/- 0.56, P < 0.05) but also didn't induce side effects on various organs. In conclusion, these results explain the anti-tumor effect of wogonin in CRC and suggest wogonin as a potential therapeutic candidate for the therapeutic strategy in CRC treatment.
C1 [Feng, Qian; Wang, Haojia; Pang, Jiaying; Ji, Liyan; Han, Jiada; Wang, Ying; Qi, Xiaoxiao; Liu, Zhongqiu; Lu, Linlin] Guangzhou Univ Chinese Med, Int Inst Translat Chinese Med, Guangzhou, Guangdong, Peoples R China.
   [Feng, Qian] Guangzhou Univ Chinese Med, Postdoctoral Res Stn, Guangzhou, Guangdong, Peoples R China.
RP Liu, ZQ; Lu, LL (corresponding author), Guangzhou Univ Chinese Med, Int Inst Translat Chinese Med, Guangzhou, Guangdong, Peoples R China.
EM liuzq@gzucm.edu.cn; lllu@gzucm.edu.cn
RI Liu, Zhongqiu/ABB-8204-2021; lu, Linlin/K-6600-2016
OI lu, Linlin/0000-0002-9943-2422
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81473410, 81503466]; Science and Technology
   Project of Guangzhou City [151800014]; Guangdong Natural Science
   Foundation Province [2015AD030312012]; Traditional Chinese Medicine
   Bureau of Guangdong Province [20174004]
FX This project was supported by the grants of the National Natural Science
   Foundation of China (Grant Nos. 81473410 and 81503466), the Science and
   Technology Project of Guangzhou City (Grant No. 151800014), the
   Guangdong Natural Science Foundation Province (Grant No.
   2015AD030312012), and the Traditional Chinese Medicine Bureau of
   Guangdong Province (Grant No. 20174004).
CR Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Carrasco DR, 2007, CANCER CELL, V11, P349, DOI 10.1016/j.ccr.2007.02.015
   Cheong H, 2012, NAT BIOTECHNOL, V30, P671, DOI 10.1038/nbt.2285
   Das V, 2017, BIOMED PHARMACOTHER, V87, P8, DOI 10.1016/j.biopha.2016.12.064
   Fan YF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09917-4
   Fernandez-Bautista N, 2017, PLANT CELL ENVIRON, V40, P1341, DOI 10.1111/pce.12927
   Gao JY, 2011, TOXICOL APPL PHARM, V254, P221, DOI 10.1016/j.taap.2011.03.016
   Ge WL, 2015, J MOL NEUROSCI, V56, P652, DOI 10.1007/s12031-015-0530-9
   Hu CJ, 2015, ONCOL REP, V33, P3146, DOI 10.3892/or.2015.3896
   Iwao C, 2014, SCI REP-UK, V4, DOI 10.1038/srep04419
   Kim SJ, 2012, MOL MED REP, V6, P1443, DOI 10.3892/mmr.2012.1085
   Lee DH, 2012, CELL SIGNAL, V24, P2216, DOI 10.1016/j.cellsig.2012.07.019
   Lee E, 2006, CANCER RES, V66, P7849, DOI 10.1158/0008-5472.CAN-06-1660
   Levy J, 2016, M S-MED SCI, V32, P339, DOI 10.1051/medsci/20163204009
   Martinez-Revelles S, 2017, ANTIOXID REDOX SIGN, V27, P379, DOI 10.1089/ars.2016.6642
   Neska J, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060903
   Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x
   Pyrko P, 2007, CANCER RES, V67, P9809, DOI 10.1158/0008-5472.CAN-07-0625
   Qian C, 2014, FREE RADICAL RES, V48, P607, DOI 10.3109/10715762.2014.897342
   Qu LK, 2004, GENE DEV, V18, P261, DOI 10.1101/gad.1165804
   Sakitani K, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1789-5
   Shi Dingding, 2012, Genes Cancer, V3, P240, DOI 10.1177/1947601912455199
   Shuda M, 2003, J HEPATOL, V38, P605, DOI 10.1016/S0168-8278(03)00029-1
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184
   Tang JJ, 2015, CANCER LETT, V363, P101, DOI 10.1016/j.canlet.2015.04.014
   Tsai CF, 2012, INT J MOL SCI, V13, P9877, DOI 10.3390/ijms13089877
   Xu SJ, 2015, CELL MOL NEUROBIOL, V35, P389, DOI 10.1007/s10571-014-0134-x
   Yin JJ, 2012, AUTOPHAGY, V8, P158, DOI 10.4161/auto.8.2.18807
   Yu L, 2018, AUTOPHAGY, V14, P207, DOI 10.1080/15548627.2017.1378838
   Zhang X, 2016, MOL CELL, V64, P803, DOI 10.1016/j.molcel.2016.10.002
NR 31
TC 18
Z9 20
U1 9
U2 15
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 23
PY 2018
VL 9
AR 1356
DI 10.3389/fphar.2018.01356
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA HB5IS
UT WOS:000451094200001
PM 30532707
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Ragusa, S
   Cheng, J
   Ivanov, KI
   Zangger, N
   Ceteci, F
   Bernier-Latmani, J
   Milatos, S
   Joseph, JM
   Tercier, S
   Bouzourene, H
   Bosman, FT
   Letovanec, I
   Marra, G
   Gonzalez, M
   Cammareri, P
   Sansom, OJ
   Delorenzi, M
   Petrova, TV
AF Ragusa, Simone
   Cheng, Jianpin
   Ivanov, Konstantin I.
   Zangger, Nadine
   Ceteci, Fatih
   Bernier-Latmani, Jeremiah
   Milatos, Stavros
   Joseph, Jean-Marc
   Tercier, Stephane
   Bouzourene, Hanifa
   Bosman, Fredrik T.
   Letovanec, Igor
   Marra, Giancarlo
   Gonzalez, Michel
   Cammareri, Patrizia
   Sansom, Owen J.
   Delorenzi, Mauro
   Petrova, Tatiana V.
TI PROX1 Promotes Metabolic Adaptation and Fuels Outgrowth of Wnt(high)
   Metastatic Colon Cancer Cells
SO CELL REPORTS
LA English
DT Article
ID STEM-CELLS; BRAF; CHLOROQUINE; PROGRESSION; TRANSITION; EXPRESSION;
   EXPANSION; AUTOPHAGY; KRAS
AB The Wnt pathway is abnormally activated in the majority of colorectal cancers, and significant knowledge has been gained in understanding its role in tumor initiation. However, the mechanisms of metastatic outgrowth in colorectal cancer remain a major challenge. We report that autophagy-dependent metabolic adaptation and survival of metastatic colorectal cancer cells is regulated by the target of oncogenic Wnt signaling, homeobox transcription factor PROX1, expressed by a subpopulation of colon cancer progenitor/stem cells. We identify direct PROX1 target genes and show that repression of a proapoptotic member of the BCL2 family, BCL2L15, is important for survival of PROX1(+) cells under metabolic stress. PROX1 inactivation after the establishment of metastases prevented further growth of lesions. Furthermore, autophagy inhibition efficiently targeted metastatic PROX1(+) cells, suggesting a potential therapeutic approach. These data identify PROX1 as a key regulator of the transcriptional network contributing to metastases outgrowth in colorectal cancer.
C1 [Ragusa, Simone; Cheng, Jianpin; Ivanov, Konstantin I.; Bernier-Latmani, Jeremiah; Milatos, Stavros; Delorenzi, Mauro; Petrova, Tatiana V.] CHU Vaudois, Dept Oncol, CH-1066 Lausanne, Switzerland.
   [Ragusa, Simone; Cheng, Jianpin; Ivanov, Konstantin I.; Bernier-Latmani, Jeremiah; Milatos, Stavros; Delorenzi, Mauro; Petrova, Tatiana V.] Univ Lausanne, CH-1066 Lausanne, Switzerland.
   [Petrova, Tatiana V.] Univ Lausanne, Dept Biochem, CH-1066 Lausanne, Switzerland.
   [Petrova, Tatiana V.] Ecole Polytech Fed Lausanne, Swiss Inst Canc Res, CH-1015 Lausanne, Switzerland.
   [Zangger, Nadine; Delorenzi, Mauro] Swiss Inst Bioinformat, SIB Bioinformat Core Facil, CH-1015 Lausanne, Switzerland.
   [Ceteci, Fatih; Cammareri, Patrizia; Sansom, Owen J.] Cancer Res UK Beatson Inst, Glasgow G61 1BD, Lanark, Scotland.
   [Joseph, Jean-Marc; Tercier, Stephane] CHU Vaudois, Serv Chirurg Pediat, CH-1011 Lausanne, Switzerland.
   [Bouzourene, Hanifa] Univ Lausanne, UNISciences, UniLabs, CH-1066 Lausanne, Switzerland.
   [Bosman, Fredrik T.; Letovanec, Igor] CHU Vaudois, Inst Univ Pathol, CH-1011 Lausanne, Switzerland.
   [Marra, Giancarlo] Univ Zurich, Instit Mol Canc Res, CH-8057 Zurich, Switzerland.
   [Gonzalez, Michel] CHU Vaudois, Div Thorac Surg, CH-1011 Lausanne, Switzerland.
   [Delorenzi, Mauro] Univ Lausanne, Ludwig Ctr Canc Res, CH-1066 Lausanne, Switzerland.
RP Petrova, TV (corresponding author), CHU Vaudois, Dept Oncol, CH-1066 Lausanne, Switzerland.
EM tatiana.petrova@unil.ch
RI Ivanov, Konstantin/C-4644-2015
OI Ivanov, Konstantin/0000-0001-9198-5674; Cammareri,
   Patrizia/0000-0002-5888-6903; Bernier-Latmani,
   Jeremiah/0000-0002-6407-1049; Sansom, Owen J./0000-0001-9540-3010;
   gonzalez, michel/0000-0001-8705-4279
FU Swiss National Science FoundationSwiss National Science Foundation
   (SNSF)European Commission [PPP0033-114898, 31003A-141225]; Swiss Bridge
   Foundation; NCCR Molecular OncologySwiss National Science Foundation
   (SNSF); Association for the International Cancer Research UK; Oncosuisse
   [KLS-02570-02-2010]; CRUKCancer Research UK; ERCEuropean Research
   Council (ERC)European Commission; EUEuropean Commission [278568]; Medic
   Foundation; Cancer Research UKCancer Research UK [12481] Funding Source:
   researchfish
FX We thank P. Andreux and K. Schoonjans for help with metabolic
   experiments; I. Stamenkovic for critical comments; M. De Palma for help
   with lentivirus preparation; J. Huelsken for intestinal organoid
   protocols; S. Robin for villin-CreERT2 mice; M. Jaquet, C. Beauverd, and
   R. Haider for technical assistance; F. Derouet for tail vein injections;
   and A. Sabine for help with graphism. We thank Lausanne Genomics
   Technologies Facility, the Cellular Imaging Facility, Mouse Pathology
   Facility, and Mouse Animal Facility of the University of Lausanne. The
   work was supported by Swiss National Science Foundation (PPP0033-114898
   to T.V.P. and 31003A-141225 to G.M.), Swiss Bridge Foundation, NCCR
   Molecular Oncology, Association for the International Cancer Research
   UK, Oncosuisse (KLS-02570-02-2010), CRUK, ERC investigator award
   ''COLONCAN'' (to O.J.S.), EU FP7 grant no. 278568 ''PRIMES,'' and Medic
   Foundation.
CR Baluk P, 2005, J CLIN INVEST, V115, P247, DOI 10.1172/JCI200522037
   Bhowmick NA, 2012, CANCER CELL, V22, P563, DOI 10.1016/j.ccr.2012.10.011
   Budinska E, 2013, J PATHOL, V231, P63, DOI 10.1002/path.4212
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Clevers H, 2013, CELL, V154, P274, DOI 10.1016/j.cell.2013.07.004
   Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4
   De Roock W, 2011, LANCET ONCOL, V12, P594, DOI 10.1016/S1470-2045(10)70209-6
   de Sousa e Melo F, 2011, CELL STEM CELL, V9, P476, DOI 10.1016/j.stem.2011.10.008
   Dempsey CE, 2005, FEBS LETT, V579, P3646, DOI 10.1016/j.febslet.2005.05.050
   Dolznig H, 2011, AM J PATHOL, V179, P487, DOI 10.1016/j.ajpath.2011.03.015
   Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235
   Friedrich T, 2013, CARCINOGENESIS, V34, P2109, DOI 10.1093/carcin/bgt142
   Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003
   Hirschhaeuser F, 2010, J BIOTECHNOL, V148, P3, DOI 10.1016/j.jbiotec.2010.01.012
   Janiszewska M, 2012, GENE DEV, V26, P1926, DOI 10.1101/gad.188292.112
   Jung P, 2011, NAT MED, V17, P1225, DOI 10.1038/nm.2470
   Kimura T, 2013, CANCER RES, V73, P3, DOI 10.1158/0008-5472.CAN-12-2464
   Koehler AN, 2010, CURR OPIN CHEM BIOL, V14, P331, DOI 10.1016/j.cbpa.2010.03.022
   Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418
   Lu MH, 2012, CLIN CANCER RES, V18, P6416, DOI 10.1158/1078-0432.CCR-12-0832
   Martorell O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088413
   Mathias RT, 1997, PHYSIOL REV, V77, P21, DOI 10.1152/physrev.1997.77.1.21
   Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   OLIVER G, 1993, MECH DEVELOP, V44, P3, DOI 10.1016/0925-4773(93)90012-M
   Petrova TV, 2008, CANCER CELL, V13, P407, DOI 10.1016/j.ccr.2008.02.020
   Roth AD, 2010, J CLIN ONCOL, V28, P466, DOI 10.1200/JCO.2009.23.3452
   Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175
   Sasaki K, 2012, ANTI-CANCER DRUG, V23, P675, DOI 10.1097/CAD.0b013e328353f8c7
   Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050
   Schepers AG, 2012, SCIENCE, V337, P730, DOI 10.1126/science.1224676
   Sheffer M, 2009, P NATL ACAD SCI USA, V106, P7131, DOI 10.1073/pnas.0902232106
   Sonoshita M, 2011, CANCER CELL, V19, P125, DOI 10.1016/j.ccr.2010.11.008
   Spaderna S, 2008, CANCER RES, V68, P537, DOI 10.1158/0008-5472.CAN-07-5682
   Steffensen KR, 2004, EMBO REP, V5, P613, DOI 10.1038/sj.embor.7400147
   Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009
   TRAYHURN P, 1972, BIOCHEM J, V129, P507, DOI 10.1042/bj1290507
   Truninger K, 2005, GASTROENTEROLOGY, V128, P1160, DOI 10.1053/j.gastro.2005.01.056
   Van Emburgh B.O., 2014, MOL ONCOL
   Cespedes MV, 2007, AM J PATHOL, V170, P1077, DOI 10.2353/ajpath.2007.060773
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wiener Z., 2014, CELL REP
   Wolf MJ, 2012, CANCER CELL, V22, P91, DOI 10.1016/j.ccr.2012.05.023
   Zeelenberg IS, 2003, CANCER RES, V63, P3833
NR 44
TC 45
Z9 46
U1 0
U2 14
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD SEP 25
PY 2014
VL 8
IS 6
BP 1957
EP 1973
DI 10.1016/j.celrep.2014.08.041
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AR9BZ
UT WOS:000343867400033
PM 25242332
OA Green Published, Green Accepted, gold
DA 2022-04-25
ER

PT J
AU Coker-Gurkan, A
   Arisan, ED
   Obakan, P
   Akalln, K
   Ozbey, U
   Palavan-Unsal, N
AF Coker-Gurkan, Ajda
   Arisan, Elif Damla
   Obakan, Pinar
   Akalln, Kubra
   Ozbey, Utku
   Palavan-Unsal, Narcin
TI Purvalanol induces endoplasmic reticulum stress-mediated apoptosis and
   autophagy in a time-dependent manner in HCT116 colon cancer cells
SO ONCOLOGY REPORTS
LA English
DT Article
DE purvalanol; endoplasmic reticulum stress; autophagy; apoptosis; colon
   cancer
ID UNFOLDED PROTEIN RESPONSE; POLYAMINE CATABOLIC PATHWAY; TRANSCRIPTION
   FACTORS; CARCINOMA CELLS; ER STRESS; INHIBITORS; INDUCTION; KINASES;
   CHOP; CALRETICULIN
AB Purvalanol, a novel cyclin-dependent kinase inhibitor, is referred to as a strong apoptotic inducer which causes cell cycle arrest in various cancer cells such as prostate, breast and colon cancer cell lines. Various physiological and pathological conditions such as glucose starvation, inhibition of protein glycosylation and oxidative stress may cause an accumulation of unfolded proteins in the endoplasmic reticulum (ER), leading to the unfolded protein response (UPR) and autophagy. Lacking proteosomal function on aggregates of unfolded proteins, ER stress may induce autophagic machinery. Autophagy, an evolutionarily conserved process, is characterized by massive degradation of cytosolic contents. In the present study, our aim was to determine the time-dependent, ER-mediated apoptotic and autophagy induction of purvalanol in HCT 116 colon cancer cells. Fifteen micromoles of purvalanol induced a reduction in cell viability by 20 and 35% within 24 and 48 h, respectively. HCT 116 colon cancer cells were exposed to purvalanol, which activated ER stress via upregulation of PERK, IREl alpha gene expression, eIF-2 alpha phosphorylation and ATF-6 cleavage at early time-points in the HCT 116 colon cancer cells. Moreover, we determined that during purvalanol-mediated ER stress, autophagic machinery was also activated prior to apoptotic cell death finalization. Beclin-1 and Atg-5 expression levels were upregulated and LC3 was cleaved after a 6 h purvalanol treatment. Purvalanol induced mitochondrial membrane potential loss, caspase-7 and caspase-3 activation and PARP cleavage following a 48 h treatment. Thus, we conclude that the anticancer effect of purvalanol in HCT 116 cells was due to ER stress-mediated apoptosis; however, purvalanol triggered autophagy, which functions as a cell survival mechanism at early time-points.
C1 [Coker-Gurkan, Ajda; Arisan, Elif Damla; Obakan, Pinar; Akalln, Kubra; Ozbey, Utku; Palavan-Unsal, Narcin] Istanbul Kultur Univ, Dept Mol Biol & Genet, Sci & Letters Fac, TR-34156 Bakirkoy Istanbul, Turkey.
RP Coker-Gurkan, A (corresponding author), Istanbul Kultur Univ, Dept Mol Biol & Genet, Sci & Letters Fac, Atakoy Campus, TR-34156 Bakirkoy Istanbul, Turkey.
EM a.coker@iku.edu.tr
RI Arisan, Elif Damla/W-8682-2019; Arisan, ElifDamla/AAB-1173-2021; OBAKAN,
   PINAR/D-2836-2015
OI Arisan, Elif Damla/0000-0002-4844-6381; Unsal Palavan,
   Narcin/0000-0002-2945-540X; Gurkan, Ajda/0000-0003-1475-2417
FU Istanbul Kultur University Scientific Projects Support CenterIstanbul
   Kultur University; TUBITAK Scientific Projects Support CenterTurkiye
   Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [2209]
FX The present study was supported by the Istanbul Kultur University
   Scientific Projects Support Center and the TUBITAK Scientific Projects
   Support Center (2209 program).
CR Arisan ED, 2014, CURR PHARM DESIGN, V20, P180, DOI 10.2174/13816128113199990029
   BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453
   Carra S, 2009, J BIOL CHEM, V284, P5523, DOI 10.1074/jbc.M807440200
   Chiu SC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033742
   Cui Q, 2007, BIOL PHARM BULL, V30, P859, DOI 10.1248/bpb.30.859
   Gray N, 1999, CURR MED CHEM, V6, P859
   Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533
   Gurkan AC, 2013, APOPTOSIS, V18, P1536, DOI 10.1007/s10495-013-0885-8
   Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5
   Harper JW, 2001, CHEM REV, V101, P2511, DOI 10.1021/cr0001030
   Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787
   Hu R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039664
   Iizuka D, 2007, RADIAT RES, V167, P563, DOI 10.1667/RR0622.1
   Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211
   Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165-6147(02)02071-0
   Ku B, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040025
   Kumar D, 2014, CANCER LETT, V343, P179, DOI 10.1016/j.canlet.2013.10.003
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Lu YC, 2011, AM J PATHOL, V179, P1425, DOI 10.1016/j.ajpath.2011.05.015
   Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6
   Martinet W, 2009, CLIN SCI, V116, P697, DOI 10.1042/CS20080508
   McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001
   Molinari M, 2004, MOL CELL, V13, P125, DOI 10.1016/S1097-2765(03)00494-5
   Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200
   Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731
   Obakan P, 2014, MOL BIOL REP, V41, P145, DOI 10.1007/s11033-013-2847-1
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Park SH, 2013, FOOD CHEM TOXICOL, V56, P100, DOI 10.1016/j.fct.2013.02.022
   Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690
   Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027
   Schonthal AH, 2009, CANCER LETT, V275, P163, DOI 10.1016/j.canlet.2008.07.005
   Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056
   Urano F, 2000, J CELL SCI, V113, P3697
   Vidal RL, 2012, AUTOPHAGY, V8, P970, DOI 10.4161/auto.20139
   Villerbu N, 2002, INT J CANCER, V97, P761, DOI 10.1002/ijc.10125
   Yoshida H, 2001, MOL CELL BIOL, V21, P1239, DOI 10.1128/MCB.21.4.1239-1248.2001
   Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741
   Yoshida H, 2004, SEIKAGAKU, V76, P617
   Zhang R, 2013, ONCOL REP, V29, P1365, DOI 10.3892/or.2013.2270
   Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982
   Zuppini A, 2002, BIOCHEMISTRY-US, V41, P2850, DOI 10.1021/bi015967+
NR 42
TC 10
Z9 12
U1 0
U2 17
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD JUN
PY 2015
VL 33
IS 6
BP 2761
EP 2770
DI 10.3892/or.2015.3918
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CI8YX
UT WOS:000355058700014
PM 25901510
OA Bronze
DA 2022-04-25
ER

PT J
AU Zhu, JH
   Liu, MH
   Liu, YF
   Zhang, YT
   Yang, B
   Zhang, W
AF Zhu, Jinhua
   Liu, Meihui
   Liu, Yuanfen
   Zhang, Yiting
   Yang, Bing
   Zhang, Wei
TI Zoledronic Acid Regulates Autophagy and Induces Apoptosis in Colon
   Cancer Cell Line CT26
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID COLORECTAL-CANCER; POPULATION; INHIBITION; DISEASE; GROWTH
AB Zoledronic acid (ZOL) is the third generation of bisphosphonates, which can inhibit many tumors growth, especially to inhibit the growth of colon cancer. However, the molecular mechanism is still very mysterious. In this study, we observed that ZOL could regulate CT26 colon cancer cells autophagy, promote CT26 cells apoptosis, and inhibit CT26 cells proliferation. Western blotting analysis showed that proapoptosis protein caspase-3 was basically unchanged, whereas the expression of the activated caspase-3 was significantly increased, after CT26 cells were treated with different doses of zoledronic acid. Western blot also showed that ZOL could significantly affect the expression of p-p53 and autophagy-related proteins beclin-1 and p62. In conclusion, the antitumor effect of ZOL on CT26 colon cancer cells in vitro is achieved by apoptosis induction and autophagy regulation, resulting in inhibition of cell proliferation.
C1 [Zhu, Jinhua; Liu, Meihui; Liu, Yuanfen; Zhang, Wei] Jiangsu Hlth Vocat Coll, Nanjing, Jiangsu, Peoples R China.
   [Zhang, Yiting] Nanjing Univ, Coll Med, Nanjing, Jiangsu, Peoples R China.
   [Yang, Bing] Nanjing Univ Chinese Med, Sch Pharm, Nanjing, Jiangsu, Peoples R China.
RP Zhang, W (corresponding author), Jiangsu Hlth Vocat Coll, Nanjing, Jiangsu, Peoples R China.
EM zydzw0810@163.com
FU Health Department of Jiangsu Province [H201430]
FX This study was supported by the Medical Research Projects of the Health
   Department of Jiangsu Province (H201430).
CR Al-Agha AE, 2015, SAUDI MED J, V36, P1312, DOI 10.15537/smj.2015.11.12590
   Baykan EK, 2014, OSTEOPOROSIS INT, V25, P2221, DOI 10.1007/s00198-014-2752-z
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Evdokiou A., BONE, V33
   Grizzo FMF, 2015, CALCIFIED TISSUE INT, V97, P421, DOI 10.1007/s00223-015-0028-z
   Han FS, 2016, ASIAN PAC J TROP MED, V9, P164, DOI 10.1016/j.apjtm.2016.01.005
   Heravi RE, 2012, GENES GENOM, V34, P199, DOI 10.1007/s13258-011-0168-0
   Kato J., INT J CANC, V138, P1516
   Lin JF, 2011, J UROLOGY, V185, P1490, DOI 10.1016/j.juro.2010.11.045
   Morad SAF, 2013, BIOCHEM PHARMACOL, V85, P1057, DOI 10.1016/j.bcp.2013.01.015
   Neville-Webbe HL, 2003, PALLIATIVE MED, V17, P539, DOI 10.1191/0269216303pm800ra
   Ochiai H, 2012, SURG TODAY, V42, P164, DOI 10.1007/s00595-011-0044-1
   Pedersen JW, 2013, BRIT J CANCER, V108, P107, DOI 10.1038/bjc.2012.517
   Sakitani K., 2015, BMC CANCER, V15, P1
   Singh T, 2015, J DRUG TARGET, V23, P1, DOI 10.3109/1061186X.2014.950668
   Tamura T, 2011, ONCOL REP, V25, P1139, DOI 10.3892/or.2011.1152
   Wan Y, 2014, ONCOL LETT, V7, P1738, DOI 10.3892/ol.2014.1959
   Wang IT, 2014, TUMOR BIOL, V35, P11913, DOI 10.1007/s13277-014-2460-5
   Yang SY, 2009, TRENDS MOL MED, V15, P225, DOI 10.1016/j.molmed.2009.03.003
   Zhao YL, 2016, EUR J CANCER, V68, P38, DOI 10.1016/j.ejca.2016.09.001
NR 20
TC 6
Z9 6
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2017
VL 2017
AR 7203584
DI 10.1155/2017/7203584
PG 6
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA FR2NI
UT WOS:000418903500001
PM 29457036
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Scarlatti, F
   Bauvy, C
   Ventruti, A
   Sala, G
   Cluzeaud, F
   Vandewalle, A
   Ghidoni, R
   Codogno, P
AF Scarlatti, F
   Bauvy, C
   Ventruti, A
   Sala, G
   Cluzeaud, F
   Vandewalle, A
   Ghidoni, R
   Codogno, P
TI Ceramide-mediated macroautophagy involves inhibition of protein kinase B
   and up-regulation of beclin 1
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID ISOLATED RAT HEPATOCYTES; PROGRAMMED CELL-DEATH; HUMAN COLON-CANCER;
   INDUCED APOPTOSIS; SIGNAL-TRANSDUCTION; AUTOPHAGIC VACUOLES;
   TUMOR-SUPPRESSOR; HT-29 CELLS; GROWTH ARREST; AKT KINASE
AB The sphingolipid ceramide is involved in the cellular stress response. Here we demonstrate that ceramide controls macroautophagy, a major lysosomal catabolic pathway. Exogenous C-2-ceramide stimulates macroautophagy (proteolysis and accumulation of autophagic vacuoles) in the human colon cancer HT-29 cells by increasing the endogenous pool of long chain ceramides as demonstrated by the use of the ceramide synthase inhibitor fumonisin B-1. Ceramide reverted the interleukin 13-dependent inhibition of macroautophagy by interfering with the activation of protein kinase B. In addition, C-2-ceramide stimulated the expression of the autophagy gene product beclin 1. Ceramide is also the mediator of the tamoxifen-dependent accumulation of autophagic vacuoles in the human breast cancer MCF-7 cells. Monodansylcadaverine staining and electron microscopy showed that this accumulation was abrogated by myriocin, an inhibitor of de novo synthesis ceramide. The tamoxifen-dependent accumulation of vacuoles was mimicked by 1-phenyl-2-decanoylamino-3-morpholino-1-propanol, an inhibitor of glucosylceramide synthase. 1-Phenyl-2-decanoylamino-3-morpholino-1-propanol, tamoxifen, and C-2-ceramide stimulated the expression of beclin 1, whereas myriocin antagonized the tamoxifen-dependent up-regulation. Tamoxifen and C-2-ceramide interfere with the activation of protein kinase B, whereas myriocin relieved the inhibitory effect of tamoxifen. In conclusion, the control of macroautophagy by ceramide provides a novel function for this lipid mediator in a cell process with major biological outcomes.
C1 INSERM, U504, F-94807 Villejuif, France.
   San Paolo Med Sch, Biochem & Mol Biol Lab, I-20142 Milan, Italy.
   INSERM, U478, F-75870 Paris 18, France.
RP Codogno, P (corresponding author), INSERM, U504, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.
EM codogno@vjf.inserm.fr
RI Codogno, Patrice/G-1384-2013
OI Codogno, Patrice/0000-0002-5492-3180; GHIDONI,
   RICCARDO/0000-0002-6300-5867
CR Abeliovich H, 2003, MOL BIOL CELL, V14, P477, DOI 10.1091/mbc.E02-07-0413
   Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025
   Alesse E, 1998, CELL DEATH DIFFER, V5, P381, DOI 10.1038/sj.cdd.4400358
   AMES BN, 1960, J BIOL CHEM, V235, P769
   Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200
   Arico S, 2002, J BIOL CHEM, V277, P27613, DOI 10.1074/jbc.M201119200
   BABA M, 1994, J CELL BIOL, V124, P903, DOI 10.1083/jcb.124.6.903
   Baehrecke EH, 2003, CELL DEATH DIFFER, V10, P940, DOI 10.1038/sj.cdd.4401280
   Bergamini E, 2003, BIOMED PHARMACOTHER, V57, P203, DOI 10.1016/S0753-3322(03)00048-9
   BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3
   Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com
   Bleicher RJ, 2002, BBA-MOL CELL BIOL L, V1585, P172, DOI 10.1016/S1388-1981(02)00338-4
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x
   BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320
   Bourbon NA, 2002, J BIOL CHEM, V277, P3286, DOI 10.1074/jbc.M110541200
   Bursch W, 2000, J CELL SCI, V113, P1189
   Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852
   CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615
   Deigner HP, 2001, FASEB J, V15, P807, DOI 10.1096/fj.15.3.807
   Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1
   Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8
   FENGSRUD M, 1995, EXP CELL RES, V221, P504, DOI 10.1006/excr.1995.1402
   Furuya N., 2004, AUTOPHAGY, P244
   Ghidoni R, 1996, EUR J BIOCHEM, V237, P454, DOI 10.1111/j.1432-1033.1996.0454k.x
   Ghidoni R, 1999, BBA-MOL CELL BIOL L, V1439, P17, DOI 10.1016/S1388-1981(99)00074-8
   Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k
   Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094
   Kanazawa T, 2004, J BIOL CHEM, V279, P8452, DOI 10.1074/jbc.M306337200
   Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061
   Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X
   Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1
   Kolesnick R, 2003, ONCOGENE, V22, P5897, DOI 10.1038/sj.onc.1206702
   Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127
   Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897
   Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4
   Levade T, 2002, NEUROCHEM RES, V27, P601, DOI 10.1023/A:1020215815013
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liou W, 1997, J CELL BIOL, V136, P61, DOI 10.1083/jcb.136.1.61
   Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4
   Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375
   Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465
   Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782
   Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200
   Mortimore G. E., 1994, CELLULAR PROTEOLYTIC, P65
   MORTIMORE GE, 1977, NATURE, V270, P174, DOI 10.1038/270174a0
   Nishino Ichizo, 2003, Curr Neurol Neurosci Rep, V3, P64, DOI 10.1007/s11910-003-0040-y
   Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963
   Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0
   Ogretmen B, 2002, J BIOL CHEM, V277, P12960, DOI 10.1074/jbc.M110699200
   Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522
   Otto GP, 2003, J BIOL CHEM, V278, P17636, DOI 10.1074/jbc.M212467200
   Paglin S, 2001, CANCER RES, V61, P439
   Pelled D, 2002, J BIOL CHEM, V277, P1957, DOI 10.1074/jbc.M104677200
   Perry DK, 1999, TRENDS BIOCHEM SCI, V24, P226, DOI 10.1016/S0968-0004(99)01407-3
   Petiot A, 1999, BIOCHEM J, V337, P289, DOI 10.1042/0264-6021:3370289
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Powell DJ, 2003, MOL CELL BIOL, V23, P7794, DOI 10.1128/MCB.23.21.7794-7808.2003
   PREISS J, 1986, J BIOL CHEM, V261, P8597
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Riboni L, 1997, PROG LIPID RES, V36, P153, DOI 10.1016/S0163-7827(97)00008-8
   Saftig P, 2001, TRENDS MOL MED, V7, P37, DOI 10.1016/S1471-4914(00)01868-2
   Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330
   SCHWEICHEL JU, 1973, TERATOLOGY, V7, P253, DOI 10.1002/tera.1420070306
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509
   Selzner M, 2001, CANCER RES, V61, P1233
   Stefanis DD, 2002, BIOL CHEM, V383, P989, DOI 10.1515/BC.2002.106
   STROMHAUG PE, 1993, BIOCHEM J, V291, P115, DOI 10.1042/bj2910115
   Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457
   van Sluijters DA, 2000, BIOCHEM J, V351, P545, DOI 10.1042/0264-6021:3510545
   Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001
   Yuan J, 2003, NEURON, V40, P401, DOI 10.1016/S0896-6273(03)00601-9
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568
NR 77
TC 347
Z9 372
U1 0
U2 18
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 30
PY 2004
VL 279
IS 18
BP 18384
EP 18391
DI 10.1074/jbc.M313561200
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 815KP
UT WOS:000221041500036
PM 14970205
OA hybrid
DA 2022-04-25
ER

PT J
AU Athamneh, K
   Alneyadi, A
   Alsamri, H
   Alrashedi, A
   Palakott, A
   El-Tarabily, KA
   Eid, AH
   Al Dhaheri, Y
   Iratni, R
AF Athamneh, Khawlah
   Alneyadi, Aysha
   Alsamri, Halima
   Alrashedi, Asma
   Palakott, Abdulrasheed
   El-Tarabily, Khaled A.
   Eid, Ali H.
   Al Dhaheri, Yusra
   Iratni, Rabah
TI Origanum majorana Essential Oil Triggers p38 MAPK-Mediated Protective
   Autophagy, Apoptosis, and Caspase-Dependent Cleavage of P70S6K in
   Colorectal Cancer Cells
SO BIOMOLECULES
LA English
DT Article
DE Origanum majorana; colon cancer; autophagy; apoptosis; p38MAPK; p70S6K
ID ANTIMICROBIAL ACTIVITY; MAMMALIAN TARGET; L.; KINASE; TUMORIGENESIS;
   SUPPRESSION; INHIBITION; RESISTANCE; LIFE
AB Colorectal cancer (CRC) is the third most common type of cancer in terms of incidence and mortality worldwide. Here we have investigated the anti-colon cancer potential of Origanum majorana essential oil (OMEO) and its underlying mechanisms of action. We showed that OMEO significantly inhibited the cellular viability and colony growth of human HT-29 colorectal cancer cells. OMEO induced protective autophagy, associated with downregulation of the mTOR/p70S6K pathway, and activated caspase-8 and caspase-9-dependent apoptosis. Blockade of autophagy with 3-methyladenine (3-MA) and chloroquine (CQ), two autophagy inhibitors, potentiated the OMEO-induced apoptotic cell death. Inversely, inhibition of apoptosis with the pan-caspase inhibitor, Z-VAD-FMK, significantly reduced cell death, suggesting that apoptosis represents the main mechanism of OMEO-induced cell death. Mechanistically, we found that OMEO induces protective autophagy and apoptotic cells death via the activation of the p38 MAPK signaling pathway. Pharmacological inhibition of p38 MAPK by the p38 inhibitors SB 202190 and SB 203580 not only significantly decreased apoptotic cell death, but also reduced the autophagy level in OMEO treated HT-29 cells. Strikingly, we found that OMEO also induces p38 MAPK-mediated caspase-dependent cleavage of p70S6K, a protein reported to be overexpressed in colon cancer and associated with drug resistance. Our findings suggest that OMEO inhibits colon cancer through p38 MAPK-mediated protective autophagy and apoptosis associated with caspase-dependent cleavage of p70S6K. To the best of our knowledge, this study is the first to report on the implications of the p38 MAPK signaling pathway in targeting p70S6K to caspase cleavage.
C1 [Athamneh, Khawlah; Alneyadi, Aysha; Alsamri, Halima; Alrashedi, Asma; Palakott, Abdulrasheed; El-Tarabily, Khaled A.; Al Dhaheri, Yusra; Iratni, Rabah] United Arab Emirates Univ, Coll Sci, Dept Biol, POB 15551, Al Ain, U Arab Emirates.
   [El-Tarabily, Khaled A.] United Arab Emirates Univ, Khalifa Ctr Genet Engn & Biotechnol, POB 15551, Al Ain, U Arab Emirates.
   [Eid, Ali H.] Amer Univ Beirut, Fac Med, Dept Pharmacol & Toxicol, Beirut 11072020, Lebanon.
RP Iratni, R (corresponding author), United Arab Emirates Univ, Coll Sci, Dept Biol, POB 15551, Al Ain, U Arab Emirates.
EM 200834888@uaeu.ac.ae; 200907889@uaeu.ac.ae; 200813902@uaeu.ac.ae;
   201003061@uaeu.ac.ae; abdulrasheed1984@uaeu.ac.ae; ktarabily@uaeu.ac.ae;
   ae81@aub.edu.lb; yusra.aldhaheri@uaeu.ac.ae; R_iratni@uaeu.ac.ae
RI El-Tarabily, Khaled/AAD-9835-2019; Eid, Ali Hussein/ABD-6291-2021
OI El-Tarabily, Khaled/0000-0002-8189-7088; Eid, Ali
   Hussein/0000-0003-3004-5675; Alneyadi, Aysha/0000-0002-6450-4713
FU Al Jalila FoundationAl Jalila Foundation (AJF) [21S102-AJF2018007]; UAEU
   Start-Up grant [31S260]
FX This work was supported by the Al Jalila Foundation (Grant
   #21S102-AJF2018007) and by the UAEU Start-Up grant (Grant #31S260).
CR Adorjan B, 2010, FLAVOUR FRAG J, V25, P407, DOI 10.1002/ffj.2024
   Al Dhaheri Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068808
   Al Dhaheri Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056649
   Al-Howiriny T, 2009, AM J CHINESE MED, V37, P531, DOI 10.1142/S0192415X0900703X
   Amor G, 2019, MOLECULES, V24, DOI 10.3390/molecules24224021
   Balunas MJ, 2005, LIFE SCI, V78, P431, DOI 10.1016/j.lfs.2005.09.012
   Benbrook D. M., 2012, Experimental Oncology, V34, P286
   Benhalilou N, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00795
   Dantas A.D., 2016, SCI WORLD J, V2016
   Della Pepa T, 2019, MOLECULES, V24, DOI 10.3390/molecules24142576
   Dhar R, 2009, BIOCHEMISTRY-US, V48, P1474, DOI 10.1021/bi801840s
   Dolado Ignacio, 2008, V20, P99, DOI 10.1007/4735_2007_0245
   Duletic S., 2018, J APPL BOT FOOD QUAL, V91
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Fathy SA, 2016, CELL MOL BIOL, V62, P80, DOI 10.14715/cmb/2016.62.10.13
   Fenton TR, 2011, INT J BIOCHEM CELL B, V43, P47, DOI 10.1016/j.biocel.2010.09.018
   Ge J, 2013, BIOMED ENVIRON SCI, V26, P902, DOI 10.3967/bes2013.019
   Goel P, 2015, PHYTO PHARM REV, V6, P261
   Grasso S, 2014, NEOPLASIA, V16, P845, DOI 10.1016/j.neo.2014.08.011
   Gulhati P, 2009, CLIN CANCER RES, V15, P7207, DOI 10.1158/1078-0432.CCR-09-1249
   Han JH, 2007, TRENDS BIOCHEM SCI, V32, P364, DOI 10.1016/j.tibs.2007.06.007
   Jiang Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.200
   Kawase K. Y. F., 2013, International Journal of Research and Reviews in Applied Sciences, V14, P238
   Kim KY, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051088
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   Leeja L, 2007, J ENVIRON BIOL, V28, P145
   Li PD, 2012, MED ONCOL, V29, P3070, DOI 10.1007/s12032-012-0268-y
   Liu MH, 2018, INT J ONCOL, V53, P1363, DOI 10.3892/ijo.2018.4465
   Lu QJ, 2015, ONCOL LETT, V10, P277, DOI 10.3892/ol.2015.3228
   Makrane H, 2019, J ETHNOPHARMACOL, V228, P40, DOI 10.1016/j.jep.2018.08.036
   Mossa ATH, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/859085
   Nakamura JL, 2008, CANCER RES, V68, P6516, DOI 10.1158/0008-5472.CAN-07-6188
   Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055
   Nobili S, 2009, PHARMACOL RES, V59, P365, DOI 10.1016/j.phrs.2009.01.017
   Nurzynska-Wierdak R, 2015, J ESSENT OIL BEAR PL, V18, P1482, DOI 10.1080/0972060X.2013.831569
   Peluso G, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/2605628
   Petrovska Biljana Bauer, 2012, Pharmacogn Rev, V6, P1, DOI 10.4103/0973-7847.95849
   Piedfer M, 2013, BBA-MOL CELL RES, V1833, P1316, DOI 10.1016/j.bbamcr.2013.02.016
   Rajkumar S, 2007, TROP BIOMED, V24, P71
   Ramos S, 2011, J ESSENT OIL RES, V23, P45, DOI 10.1080/10412905.2011.9700481
   Raut JS, 2014, IND CROP PROD, V62, P250, DOI 10.1016/j.indcrop.2014.05.055
   Rezzoug M, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2556-y
   Rubinstein AD, 2012, J CELL SCI, V125, P5259, DOI 10.1242/jcs.115865
   Soliman AM, 2016, NUTRIENTS, V8, DOI 10.3390/nu8050264
   Sonika Jain, 2016, Pharmacognosy Journal, V8, P87, DOI 10.5530/pj.2016.2.1
   Tabanca N, 2004, J ESSENT OIL RES, V16, P248, DOI 10.1080/10412905.2004.9698713
   Tasdemir D, 2019, MOLECULES, V24, DOI 10.3390/molecules24234421
   Vagi E, 2005, FOOD RES INT, V38, P51, DOI 10.1016/j.foodres.2004.07.006
   Xiao X, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0880-6
   Yamnik RL, 2009, J BIOL CHEM, V284, P6361, DOI 10.1074/jbc.M807532200
   Yazdanparast R, 2008, VASC PHARMACOL, V48, P32, DOI 10.1016/j.vph.2007.11.003
NR 51
TC 15
Z9 15
U1 1
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2218-273X
J9 BIOMOLECULES
JI Biomolecules
PD MAR
PY 2020
VL 10
IS 3
AR 412
DI 10.3390/biom10030412
PG 18
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA LJ0PZ
UT WOS:000529877600063
PM 32155920
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Huangfu, LT
   Liang, HH
   Wang, GJ
   Su, XM
   Li, LQ
   Du, ZM
   Hu, MY
   Dong, YC
   Bai, X
   Liu, TY
   Yang, BF
   Shan, HL
AF Huangfu, Longtao
   Liang, Haihai
   Wang, Guojie
   Su, Xiaomin
   Li, Linqiang
   Du, Zhimin
   Hu, Meiyu
   Dong, Yuechao
   Bai, Xue
   Liu, Tianyi
   Yang, Baofeng
   Shan, Hongli
TI miR-183 regulates autophagy and apoptosis in colorectal cancer through
   targeting of UVRAG
SO ONCOTARGET
LA English
DT Article
DE autophagy; UVRAG; miR-183; apoptosis; colorectal cancer
ID CELL-DEATH; SIGNALING NETWORKS; INHIBIT AUTOPHAGY; COLON-CANCER; BECLIN
   1; MICRORNA; STARVATION; COMPLEX; METASTASIS; EXPRESSION
AB Ultraviolet radiation resistance-associated gene (UVRAG) is a well-known regulator of autophagy by promoting autophagosome formation and maturation. Multiple studies have implicated UVRAG in the pathogenesis of colorectal cancer. However, the mechanisms underlying the regulation of UVRAG are unclear. Here, we describe miR-183 as a new autophagy-inhibiting miRNA. Our results showed that induction of autophagy lead to down-regulation of miR-183 in colorectal cancer cells. And, over-expression of miR-183 resulted in the attenuation of rapamycinor starvation-induced autophagy in cancer cells, whereas inhibition of endogenous miR-183 stimulated autophagy and apoptosis. Additionally, either autophagy inhibitor 3-MA or pan-caspase inhibitor Z-VAD-FMK respectively or both treatments reversed AMO-183-induced cell death. Further studies showed that UVRAG is a target of miR183 and as a key regulator promotes autophagy and apoptosis. More importantly, overexpression of UVRAG rescued autophagic activity and induced apoptosis in presence of miR-183. Therefore, the present study investigated the promoting effect of miR-183 on colorectal cancer progression, which was considered to be mediated by autophagy and apoptosis through targeting of UVRAG.
C1 [Huangfu, Longtao; Liang, Haihai; Wang, Guojie; Su, Xiaomin; Hu, Meiyu; Dong, Yuechao; Bai, Xue; Liu, Tianyi; Yang, Baofeng; Shan, Hongli] Harbin Med Univ, Key Lab Cardiovasc Res, State Prov Key Labs Biomed Pharmaceut China, Dept Pharmacol,Minist Educ, Harbin 150081, Heilongjiang, Peoples R China.
   [Li, Linqiang] Harbin Med Univ, Affiliated Hosp 1, Dept Gen Surg, Harbin 150081, Heilongjiang, Peoples R China.
   [Du, Zhimin] Harbin Med Univ, Affiliated Hosp 2, Inst Clin Pharm, Harbin 150081, Heilongjiang, Peoples R China.
RP Shan, HL (corresponding author), Harbin Med Univ, Key Lab Cardiovasc Res, State Prov Key Labs Biomed Pharmaceut China, Dept Pharmacol,Minist Educ, Harbin 150081, Heilongjiang, Peoples R China.
EM shanhongli@ems.hrbmu.edu.cn
OI Su, Xiaomin/0000-0002-1621-4009
FU National Basic Research Program of China (973 program)National Basic
   Research Program of China [2013CB531104]; Funds for Creative Research
   Groups of the National Natural Science Foundation of China [81421063];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81230081, 31450009]; Postgraduate Research
   Innovation Fund of Harbin Medical University [YJSCX2014-13HYD]
FX This study was supported by National Basic Research Program of China
   (973 program, 2013CB531104); the Funds for Creative Research Groups of
   the National Natural Science Foundation of China (81421063); the Major
   Program of National Natural Science Foundation of China (81230081); and
   the National Natural Science Foundation of China (31450009); and the
   Postgraduate Research Innovation Fund of Harbin Medical University
   (YJSCX2014-13HYD).
CR Abraham D, 2011, CLIN CANCER RES, V17, P4772, DOI 10.1158/1078-0432.CCR-11-0242
   Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x
   Chai CY, 2007, TOXICOL LETT, V173, P48, DOI 10.1016/j.toxlet.2007.06.006
   Chen Y, 2014, APOPTOSIS, V19, P1177, DOI 10.1007/s10495-014-0999-7
   Chiu HW, 2015, CANCER LETT, V356, P762, DOI 10.1016/j.canlet.2014.10.025
   Faller WJ, 2015, NATURE, V517, P497, DOI 10.1038/nature13896
   Frankel LB, 2012, CARCINOGENESIS, V33, P2018, DOI 10.1093/carcin/bgs266
   Fu LL, 2012, INT J BIOCHEM CELL B, V44, P733, DOI 10.1016/j.biocel.2012.02.004
   Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608
   Goi T, 2003, SURG TODAY, V33, P702, DOI 10.1007/s00595-002-2567-y
   Gustavsson B, 2015, CLIN COLORECTAL CANC, V14, P1, DOI 10.1016/j.clcc.2014.11.002
   Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178
   Isakson P, 2010, BLOOD, V116, P2324, DOI 10.1182/blood-2010-01-261040
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Korkmaz G, 2012, AUTOPHAGY, V8, P165, DOI 10.4161/auto.8.2.18351
   Kovaleva V, 2012, CANCER RES, V72, P1763, DOI 10.1158/0008-5472.CAN-11-3671
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Liang CY, 2008, NAT CELL BIOL, V10, P776, DOI 10.1038/ncb1740
   Liang CY, 2007, AUTOPHAGY, V3, P69, DOI 10.4161/auto.3437
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Maiuri MC, 2009, CELL DEATH DIFFER, V16, P87, DOI 10.1038/cdd.2008.131
   McKnight NC, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004626
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Mukhopadhyay S, 2014, APOPTOSIS, V19, P555, DOI 10.1007/s10495-014-0967-2
   Nugent M, 2011, EJSO-EUR J SURG ONC, V37, P649, DOI 10.1016/j.ejso.2011.05.005
   Pan BZ, 2013, CANCER BIOTHER RADIO, V28, P573, DOI 10.1089/cbr.2012.1460
   Park JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100819
   Qiao SX, 2013, AUTOPHAGY, V9, P2087, DOI 10.4161/auto.26506
   Radogna F, 2015, BIOCHEM PHARMACOL, V94, P1, DOI 10.1016/j.bcp.2014.12.018
   Raskov H, 2014, WORLD J GASTROENTERO, V20, P18151, DOI 10.3748/wjg.v20.i48.18151
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Russell RC, 2013, NAT CELL BIOL, V15, P741, DOI 10.1038/ncb2757
   Sarver AL, 2010, CANCER RES, V70, P9570, DOI 10.1158/0008-5472.CAN-10-2074
   Sinha S, 2008, ONCOGENE, V27, pS137, DOI 10.1038/onc.2009.51
   Stiegelbauer V, 2014, WORLD J GASTROENTERO, V20, P11727, DOI 10.3748/wjg.v20.i33.11727
   Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634
   Tekirdag KA, 2013, AUTOPHAGY, V9, P374, DOI 10.4161/auto.23117
   Thoresen SB, 2010, EXP CELL RES, V316, P3368, DOI 10.1016/j.yexcr.2010.07.008
   Titone R, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/343542
   Ueno K, 2013, BRIT J CANCER, V108, P1659, DOI 10.1038/bjc.2013.125
   Valente G, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/462658
   Wong PM, 2013, AUTOPHAGY, V9, P124, DOI 10.4161/auto.23323
   Wu WKK, 2011, CARCINOGENESIS, V32, P247, DOI 10.1093/carcin/bgq243
   Xu L, 2014, ONCOL LETT, V8, P2345, DOI 10.3892/ol.2014.2504
   Yin XC, 2011, AUTOPHAGY, V7, P1242, DOI 10.4161/auto.7.10.16507
   Yin XC, 2011, EMBO REP, V12, P727, DOI 10.1038/embor.2011.79
   Zhang QH, 2013, GENE, V527, P26, DOI 10.1016/j.gene.2013.06.006
   Zhao Z, 2012, AUTOPHAGY, V8, P1392, DOI 10.4161/auto.21035
NR 50
TC 54
Z9 55
U1 1
U2 11
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 26
PY 2016
VL 7
IS 4
BP 4735
EP 4745
DI 10.18632/oncotarget.6732
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DD5HA
UT WOS:000369952400081
PM 26717041
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Paul, S
   Roy, D
   Pati, S
   Sa, G
AF Paul, Silpita
   Roy, Dia
   Pati, Subhadip
   Sa, Gaurisankar
TI The Adroitness of Andrographolide as a Natural Weapon Against Colorectal
   Cancer
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Review
DE Colorectal cancer; Andrographolide; Phytochemical; immunomodulator;
   Antitumor
ID ISLAND METHYLATOR PHENOTYPE; SOLID LIPID NANOPARTICLES; TRAIL-INDUCED
   APOPTOSIS; AUTOPHAGIC CELL-DEATH; IN-VITRO; TUMOR-GROWTH; COLON-CANCER;
   IMMUNOMODULATORY ACTIVITY; TISSUE DISTRIBUTION; LIVER-CANCER
AB The conventional carcinoma treatment generally encompasses the employment of radiotherapy, chemotherapy, surgery or use of cytotoxic drugs. However, recent advances in pharmacological research have divulged the importance of traditional treatments in cancer. The aim of the present review is to provide an overview of the importance of one such medicinal herb of Chinese and Indian origin: Andrographis paniculate on colorectal cancer with special emphasis on its principal bioactive component andrographolide (AGP) and its underlying mechanisms of action. AGP has long been known to possess medicinal properties. Studies led by numerous groups of researchers shed light on its molecular mechanism of action. AGP has been shown to act in a multi-faceted manner in context of colorectal cancer by targeting matrix metalloproteinase-9, Toll-like receptor or NF kappa B signaling pathways. In this review, we highlighted the recent studies that show that AGP can act as an effective immunomodulator by harnessing effective anti-tumor immune response. Recent studies strongly recommend further research on this compound and its analogues, especially under in-vivo condition to assess its actual potential as a prospective and efficient candidate against colorectal cancer. The current review deals with the roles of this phytomedicine in context of colorectal cancer and briefly describes its perspectives to emerge as an essential anti-cancer drug candidate. Finally, we also point out the drawbacks and difficulties in administration of AGP and indicate the use of nano-formulations of this phytomedicine for better therapeutic efficacy.
C1 [Paul, Silpita; Roy, Dia; Pati, Subhadip; Sa, Gaurisankar] Bose Inst, Div Mol Med, Kolkata, India.
RP Sa, G (corresponding author), Bose Inst, Div Mol Med, Kolkata, India.
EM gauri@jcbose.ac.in
FU Department of Biotechnology, Department of Science and Technology,
   Government of IndiaDepartment of Science & Technology (India)Department
   of Biotechnology (DBT) India
FX This work was supported by research grants Department of Biotechnology,
   Department of Science and Technology, Government of India. GS is
   National Academy of Science (India) Platinum Jubilee Senior Scientist.
CR Abu-Ghefreh AA, 2009, INT IMMUNOPHARMACOL, V9, P313, DOI 10.1016/j.intimp.2008.12.002
   Akbar S, 2011, ALTERN MED REV, V16, P66
   Al-Henhena N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111118
   Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828
   Arber N, 2006, NEW ENGL J MED, V355, P885, DOI 10.1056/NEJMoa061652
   Banerjee A, 2016, ONCOTARGET, V7, P41432, DOI 10.18632/oncotarget.9180
   Barault L, 2008, CANCER RES, V68, P8541, DOI 10.1158/0008-5472.CAN-08-1171
   Barber TD, 2008, P NATL ACAD SCI USA, V105, P3443, DOI 10.1073/pnas.0712384105
   Bera R, 2014, PHARM BIOL, V52, P321, DOI 10.3109/13880209.2013.836544
   Bilia AR, 2017, PLANTA MED, V83, P366, DOI 10.1055/s-0043-102949
   Bilia AR, 2016, J DRUG DELIV SCI TEC, V32, P241, DOI 10.1016/j.jddst.2015.09.007
   BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0
   BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0
   Butnariu M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60657-4
   Casamonti M, 2019, ENGINEERING-PRC, V5, P69, DOI 10.1016/j.eng.2018.12.004
   Cha YI, 2007, ANNU REV MED, V58, P239, DOI 10.1146/annurev.med.57.121304.131253
   CHAKRAVARTI R. N., 1951, INDIAN MED GAZ, V86, P96
   Chao HP, 2010, PLANTA MED, V76, P1827, DOI 10.1055/s-0030-1250039
   Chen DS, 2013, BIOORG MED CHEM LETT, V23, P3166, DOI 10.1016/j.bmcl.2013.04.010
   Chen W, 2012, CARCINOGENESIS, V33, P2190, DOI 10.1093/carcin/bgs264
   Chun Jae Yeon, 2010, Genes Cancer, V1, P868, DOI 10.1177/1947601910383416
   Churiyah, 2015, Hayati Journal of Biosciences, V22, P67
   Das S, 2018, ARTIF CELL NANOMED B, V46, pS751, DOI 10.1080/21691401.2018.1435549
   Davoodvandi A, 2019, CURR PHARM DESIGN, V25, P3225, DOI 10.2174/1381612825666190829154934
   Deng YY, 2019, INT J BIOL SCI, V15, P688, DOI 10.7150/ijbs.30847
   Dua VK, 2004, J ETHNOPHARMACOL, V95, P247, DOI 10.1016/j.jep.2004.07.008
   Farooqi AA, 2020, CANCERS, V12, DOI 10.3390/cancers12082159
   FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3
   Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967
   Grady WM, 1998, CANCER RES, V58, P3101
   Guo WJ, 2014, AUTOPHAGY, V10, P972, DOI 10.4161/auto.28374
   Nguyen HT, 2018, ONCOL LETT, V16, P9, DOI 10.3892/ol.2018.8679
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Haura EB, 2005, NAT CLIN PRACT ONCOL, V2, P315, DOI 10.1038/ncponc0195
   Hocker HJ, 2013, P NATL ACAD SCI USA, V110, P10201, DOI 10.1073/pnas.1300016110
   Hossain Md Sanower, 2014, ScientificWorldJournal, V2014, P274905, DOI 10.1155/2014/274905
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Iruretagoyena MI, 2005, J PHARMACOL EXP THER, V312, P366, DOI 10.1124/jpet.104.072512
   Iruretagoyena MI, 2006, J PHARMACOL EXP THER, V318, P59, DOI 10.1124/jpet.106.103259
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   Jaruchotikamol A, 2007, TOXICOL APPL PHARM, V224, P156, DOI 10.1016/j.taap.2007.07.008
   Jarvinen HJ, 2000, GASTROENTEROLOGY, V118, P829, DOI 10.1016/S0016-5085(00)70168-5
   Kasemsuk S, 2013, ARCH PHARM RES, V36, P1454, DOI 10.1007/s12272-013-0152-0
   Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838
   Kondo Y, 2004, CANCER METAST REV, V23, P29, DOI 10.1023/A:1025806911782
   Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784
   Koveitypour Z, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-019-0361-4
   Kumar D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139657
   Kumar RA, 2004, J ETHNOPHARMACOL, V92, P291, DOI 10.1016/j.jep.2004.03.004
   Kumar S, 2012, CURR MOL MED, V12, P952, DOI 10.2174/156652412802480826
   Lai YH, 2013, CARCINOGENESIS, V34, P1069, DOI 10.1093/carcin/bgt005
   Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0
   Li JL, 2007, EUR J PHARMACOL, V568, P31, DOI 10.1016/j.ejphar.2007.04.027
   Li XF, 2020, J INT MED RES, V48, DOI 10.1177/0300060520946169
   Li YC, 2012, LIFE SCI, V90, P962, DOI 10.1016/j.lfs.2012.04.044
   Lin HH, 2014, TOXICOL SCI, V139, P108, DOI 10.1093/toxsci/kfu032
   Lin HH, 2011, TOXICOL APPL PHARM, V250, P336, DOI 10.1016/j.taap.2010.11.014
   Liu SH, 2014, BIOCHEM PHARMACOL, V87, P229, DOI 10.1016/j.bcp.2013.10.014
   Liu Y, 2017, CELL PHYSIOL BIOCHEM, V44, P1396, DOI 10.1159/000485536
   Ma YQ, 2018, INT J NANOMED, V13, P3763, DOI 10.2147/IJN.S164228
   Madav S., 1995, Indian Journal of Pharmaceutical Sciences, V57, P121
   Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588
   MATSUDA T, 1994, CHEM PHARM BULL, V42, P1216, DOI 10.1248/cpb.42.1216
   McClements DJ, 2012, SOFT MATTER, V8, P1719, DOI 10.1039/c2sm06903b
   Mishra S. K., 2007, Pharmacognosy Reviews, V1, P283
   Mishra Siddhartha Kumar, 2015, Front Biosci (Elite Ed), V7, P255
   Naik SR, 2009, PLANTA MED, V75, P785, DOI 10.1055/s-0029-1185398
   Nateewattana J, 2014, EUR J PHARMACOL, V723, P148, DOI 10.1016/j.ejphar.2013.12.002
   Nateewattana J, 2013, INVEST NEW DRUG, V31, P320, DOI 10.1007/s10637-012-9868-9
   Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s
   Pan CW, 2017, ONCOTARGET, V8, P41202, DOI 10.18632/oncotarget.17149
   Parveen R, 2014, DRUG DEV IND PHARM, V40, P1206, DOI 10.3109/03639045.2013.810636
   Pratheeshkumar P, 2011, J ENVIRON PATHOL TOX, V30, P33, DOI 10.1615/JEnvironPatholToxicolOncol.v30.i1.40
   Qin LH, 2006, BIOL PHARM BULL, V29, P220, DOI 10.1248/bpb.29.220
   Rajagopal Sriram, 2003, J Exp Ther Oncol, V3, P147, DOI 10.1046/j.1359-4117.2003.01090.x
   Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a
   Ranjan A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20204981
   Reabroi S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26278-8
   Reabroi S, 2018, BIOMED PHARMACOTHER, V101, P414, DOI 10.1016/j.biopha.2018.02.119
   Roy P, 2012, CURR PHARM BIOTECHNO, V13, P2669, DOI 10.2174/138920112804724855
   Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182
   Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502
   Sareer O, 2014, NAT PROD RES, V28, P2081, DOI 10.1080/14786419.2014.924004
   Seoane J, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022277
   Shapouri-Moghaddam A, 2018, J CELL PHYSIOL, V233, P6425, DOI 10.1002/jcp.26429
   Sharda N, 2021, CLIN MED INSIGHTS-ON, V15, DOI 10.1177/11795549211012672
   Sheeja K, 2007, IMMUNOPHARM IMMUNOT, V29, P81, DOI 10.1080/08923970701282726
   Sheeja K, 2007, INTEGR CANCER THER, V6, P66, DOI 10.1177/1534735406298975
   Sheeja K, 2006, INTEGR CANCER THER, V5, P244, DOI 10.1177/1534735406291984
   Shi MD, 2008, CHEM-BIOL INTERACT, V174, P201, DOI 10.1016/j.cbi.2008.06.006
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P145, DOI 10.3322/caac.21601
   Sirion U, 2012, BIOORG MED CHEM LETT, V22, P49, DOI 10.1016/j.bmcl.2011.11.085
   Su M, 2017, DRUG DES DEV THER, V11, P3333, DOI 10.2147/DDDT.S140354
   Sukumari-Ramesh S, 2011, INT J DEV NEUROSCI, V29, P701, DOI 10.1016/j.ijdevneu.2011.06.002
   Tan ML, 2012, FOOD CHEM TOXICOL, V50, P431, DOI 10.1016/j.fct.2011.11.001
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Varma A, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep135
   von Karstedt S, 2017, NAT REV CANCER, V17, P352, DOI 10.1038/nrc.2017.28
   Wang W, 2010, ACTA PHARMACOL SIN, V31, P191, DOI 10.1038/aps.2009.205
   Wang WC, 2016, BIOCHEM PHARMACOL, V121, P8, DOI 10.1016/j.bcp.2016.09.024
   Wiart C, 2005, PHYTOTHER RES, V19, P1069, DOI 10.1002/ptr.1765
   Wolpin BM, 2008, GASTROENTEROLOGY, V134, P1296, DOI 10.1053/j.gastro.2008.02.098
   Wu Y, 2009, CELL CYCLE, V8, P3267, DOI 10.4161/cc.8.20.9699
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
   Xu L, 2009, J CHROMATOGR B, V877, P502, DOI 10.1016/j.jchromb.2008.12.065
   Xu YZ, 2019, NEUROCHEM RES, V44, P2619, DOI 10.1007/s11064-019-02883-5
   Yang L, 2009, CANCER LETT, V276, P180, DOI 10.1016/j.canlet.2008.11.015
   Yang T, 2013, J PHARM SCI-US, V102, P4414, DOI 10.1002/jps.23758
   Yang W, 2017, TOXICOL APPL PHARM, V327, P1, DOI 10.1016/j.taap.2017.04.022
   Zhang JM, 2014, EXPERT OPIN DRUG DEL, V11, P1367, DOI 10.1517/17425247.2014.924503
   Zhang R, 2017, ONCOL LETT, V14, P4305, DOI 10.3892/ol.2017.6669
   Zhou J, 2008, MOL CANCER THER, V7, P2170, DOI 10.1158/1535-7163.MCT-08-0071
   Zhou J, 2012, AUTOPHAGY, V8, P338, DOI 10.4161/auto.18721
   Zhou J, 2010, BIOCHEM PHARMACOL, V79, P1242, DOI 10.1016/j.bcp.2009.12.014
   Zhu YY, 2013, PROTEOMICS, V13, P169, DOI 10.1002/pmic.201200273
NR 115
TC 0
Z9 0
U1 7
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 2
PY 2021
VL 12
AR 731492
DI 10.3389/fphar.2021.731492
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA WY9JV
UT WOS:000719594100001
PM 34795581
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Sena, P
   Mariani, F
   Mancini, S
   Benincasa, M
   Magnani, G
   Pedroni, M
   Palumbo, C
   Roncucci, L
AF Sena, Paola
   Mariani, Francesco
   Mancini, Stefano
   Benincasa, Marta
   Magnani, Giulia
   Pedroni, Monica
   Palumbo, Carla
   Roncucci, Luca
TI Autophagy is upregulated during colorectal carcinogenesis, and in DNA
   microsatellite stable carcinomas
SO ONCOLOGY REPORTS
LA English
DT Article
DE autophagy; colorectal carcinogenesis; microadenoma; aberrant crypt foci;
   DNA microsatellite instability
ID CANCER-ASSOCIATED FIBROBLASTS; MISMATCH REPAIR; COLON-CANCER; GENOMIC
   INSTABILITY; THERAPEUTIC TARGET; BECLIN 1; EXPRESSION; LC3;
   5-FLUOROURACIL; CHEMOTHERAPY
AB Cancer cells are exposed to a wide range of stress sources, such as nutrient deprivation and hypoxia, as well as cytotoxic chemotherapy and radiotherapy. Certain forms of stress can also promote survival activating the metabolic autophagy pathway in cancer cells. Autophagy is dramatically increased in cancer cells. In these conditions, it is becoming evident that autophagy protects cells, by providing an alternative energy source and by eliminating dysfunctional organelles or proteins. Its role in tumorigenesis is more controversial and both the presence and the absence of autophagy have been implicated. Autophagy is known to be associated with the poor outcome of patients with various types of cancers, and its effectiveness as a prognostic marker in colorectal cancer was demonstrated by several studies. The inhibition of autophagy may be a potential therapeutic target in colorectal cancer. In vitro experiments have shown that the inhibition of autophagy increases 5-FU-induced apoptosis. There are two trials currently investigating the addition of chloroquine to 5-FU-based chemotherapy and bevacizumab. In the present study, we evaluated the expression of LC3B-II in samples of human colorectal microadenomas (i.e., dysplastic aberrant crypt foci) and carcinomas compared to normal mucosa. Furthermore, the expression pattern of LC3B-II was assessed in carcinomas classified as DNA microsatellite stable (MSS) and unstable (MSI). Thus, immunofluorescence techniques coupled with confocal microscopy and immunoblot experiments were performed. The results clearly showed a significant increase in expression of the autophagic key factor in microadenomas and carcinomas with respect to normal mucosa. In MSS carcinomas, the level of LC3B-II expression was higher than that in the MSI carcinomas.
C1 [Sena, Paola; Benincasa, Marta; Palumbo, Carla] Univ Modena & Reggio Emilia, Dept Biomed Metab & Neurosci, Sect Human Morphol, I-41125 Modena, Italy.
   [Mariani, Francesco; Mancini, Stefano; Magnani, Giulia; Pedroni, Monica; Roncucci, Luca] Univ Modena & Reggio Emilia, Dept Diagnost & Clin Med & Publ Hlth, I-41125 Modena, Italy.
RP Roncucci, L (corresponding author), Univ Modena & Reggio Emilia, Dept Diagnost & Clin Med & Publ Hlth, Via Pozzo 71, I-41125 Modena, Italy.
EM luca.roncucci@unimore.it
RI Mancini, Stefano/B-1190-2016; Sena, Paola/G-9394-2016; Magnani,
   Giulia/AGM-1833-2022; Roncucci, Luca/L-1392-2016; Palumbo,
   Carla/V-5905-2019
OI Mancini, Stefano/0000-0002-7350-5603; Sena, Paola/0000-0003-4724-8786;
   Roncucci, Luca/0000-0002-0410-1760; Palumbo, Carla/0000-0003-0587-0112
FU Associazione per la Ricerca sui Tumori Intestinali (ARTI)
FX The present study was supported by funds of the Associazione per la
   Ricerca sui Tumori Intestinali (ARTI), which also provided support to
   G.M. The authors wish to thank the Centro Interdipartimentale Grandi
   Strumenti (CIGS) of the University of Modena and Reggio Emilia, for
   software, instrument availability and assistance.
CR Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Beasley NJP, 2001, CANCER RES, V61, P5262
   Bonuccelli G, 2010, CELL CYCLE, V9, P3506, DOI 10.4161/cc.9.17.12731
   Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533
   Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622
   Choi SW, 2002, CLIN CANCER RES, V8, P2311
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Deschoolmeester V, 2008, J MOL DIAGN, V10, P154, DOI 10.2353/jmoldx.2008.070087
   Deschoolmeester V, 2011, CANCER MICROENVIRON, V4, P377, DOI 10.1007/s12307-011-0068-5
   Eveno C, 2010, ARCH SURG-CHICAGO, V145, P12, DOI 10.1001/archsurg.2009.224
   Fink D, 1998, CLIN CANCER RES, V4, P1
   Giatromanolaki A, 2013, COLORECTAL DIS, V15, pE223, DOI 10.1111/codi.12147
   Giatromanolaki A, 2010, J CLIN PATHOL, V63, P867, DOI 10.1136/jcp.2010.079525
   Gray RG, 2011, J CLIN ONCOL, V29, P4611, DOI 10.1200/JCO.2010.32.8732
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   Halling KC, 1999, JNCI-J NATL CANCER I, V91, P1295, DOI 10.1093/jnci/91.15.1295
   Hemminki A, 2000, GASTROENTEROLOGY, V119, P921, DOI 10.1053/gast.2000.18161
   Honscheid P, 2014, INT J RADIAT BIOL, V90, P628, DOI 10.3109/09553002.2014.907932
   Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094
   Jacob S, 2002, BIOCHIMIE, V84, P27, DOI 10.1016/S0300-9084(01)01362-1
   Jass JR, 1998, GUT, V42, P673, DOI 10.1136/gut.42.5.673
   Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   LOTHE RA, 1993, CANCER RES, V53, P5849
   Mariani F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054488
   Mariani F, 2009, CANCER LETT, V279, P221, DOI 10.1016/j.canlet.2009.02.001
   Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P3256, DOI 10.4161/cc.9.16.12553
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Miao YF, 2010, HEPATO-GASTROENTEROL, V57, P257
   Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005
   Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533
   O'Connell MJ, 2010, J CLIN ONCOL, V28, P3937, DOI 10.1200/JCO.2010.28.9538
   Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954
   Pavlides S, 2009, CELL CYCLE, V8, P3984, DOI 10.4161/cc.8.23.10238
   Pedroni M, 2007, DIS MARKERS, V23, P179, DOI 10.1155/2007/703129
   Salazar R, 2011, J CLIN ONCOL, V29, P17, DOI 10.1200/JCO.2010.30.1077
   Samowitz WS, 2001, CANCER EPIDEM BIOMAR, V10, P917
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Sena P, 2010, CANCER EPIDEM BIOMAR, V19, P351, DOI 10.1158/1055-9965.EPI-09-0438
   Stojic L, 2004, DNA REPAIR, V3, P1091, DOI 10.1016/j.dnarep.2004.06.006
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Suraweera N, 2002, GASTROENTEROLOGY, V123, P1804, DOI 10.1053/gast.2002.37070
   THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122
   van Lier MGF, 2012, J PATHOL, V226, P764, DOI 10.1002/path.3963
   Wang JR, 2008, AUTOPHAGY, V4, P947, DOI 10.4161/auto.6787
   Watanabe T, 2001, NEW ENGL J MED, V344, P1196, DOI 10.1056/NEJM200104193441603
   White E, 2010, CURR OPIN CELL BIOL, V22, P212, DOI 10.1016/j.ceb.2009.12.008
   Worthley DL, 2010, CANCER MICROENVIRON, V3, P117, DOI 10.1007/s12307-009-0033-8
   Xicola RM, 2007, JNCI-J NATL CANCER I, V99, P244, DOI 10.1093/jnci/djk033
   Yoshioka A, 2008, INT J ONCOL, V33, P461, DOI 10.3892/ijo_00000028
NR 60
TC 6
Z9 6
U1 1
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD DEC
PY 2015
VL 34
IS 6
BP 3222
EP 3230
DI 10.3892/or.2015.4326
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CV9OR
UT WOS:000364617000047
PM 26502823
OA Bronze, Green Submitted
DA 2022-04-25
ER

PT J
AU Ji, ML
   Feng, QY
   He, GD
   Yang, LL
   Tang, WT
   Lao, XY
   Zhu, DX
   Lin, Q
   Xu, PP
   Wei, Y
   Xu, JM
AF Ji, Meiling
   Feng, Qingyang
   He, Guodong
   Yang, Liangliang
   Tang, Wentao
   Lao, Xinyuan
   Zhu, Dexiang
   Lin, Qi
   Xu, Pingping
   Wei, Ye
   Xu, Jianmin
TI Silencing homeobox C6 inhibits colorectal cancer cell proliferation
SO ONCOTARGET
LA English
DT Article
DE colorectal cancer; proliferation; HOXC6; autophagy; mTOR
ID GENE-PRODUCT EXPRESSION; IMMUNOCYTOCHEMICAL DETECTION; PROSTATE-CANCER;
   HOXC6 EXPRESSION; AUTOPHAGY; B4; B3; CARCINOMAS; RECEPTOR; DISEASE
AB Homeobox C6 (HOXC6), a member of the homeobox family that encodes highly conserved transcription factors, plays a vital role in various carcinomas. In this study, we used a tissue microarray (TMA) consisting of 462 CRC samples to demonstrate that HOXC6 is more abundantly expressed in colorectal cancer (CRC) tissues than adjacent normal mucosa. Clinicopathological data indicated that higher HOXC6 expression correlated with poor overall survival and was associated with primary tumor location in the right colon, primary tumor (pT) stage 3/4 and primary node (pN) stage 1/2. Multivariate analysis showed that high HOXC6 expression was an independent risk factor for poor CRC patient prognosis. HOXC6 downregulation via lentivirus-mediated expression of HOXC6-targeting shRNA reduced HCT116 cell viability and colony formation in vitro, and reduced growth of subcutaneous xenografts in nude mouse. HOXC6 thus appears to promote CRC cell proliferation and tumorigenesis through autophagy inhibition and mTOR pathway activation.
C1 [Ji, Meiling; Feng, Qingyang; He, Guodong; Yang, Liangliang; Tang, Wentao; Lao, Xinyuan; Zhu, Dexiang; Lin, Qi; Xu, Pingping; Wei, Ye; Xu, Jianmin] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai 200433, Peoples R China.
RP Wei, Y; Xu, JM (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai 200433, Peoples R China.
EM wei.ye@zs-hospital.sh.cn; xujmin@aliyun.com
OI Yang, Liangliang/0000-0002-6909-8363
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81272390, 81372315]; National High
   Technology Research and Development ProgramNational High Technology
   Research and Development Program of China [2012AA02A506]
FX This work was supported by grants from the National Natural Science
   Foundation of China (81272390, 81372315) and the National High
   Technology Research and Development Program (2012AA02A506).
CR Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907
   Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11
   Ansari KI, 2011, J MOL BIOL, V411, P334, DOI 10.1016/j.jmb.2011.05.050
   Banreti A, 2014, DEV CELL, V28, P56, DOI 10.1016/j.devcel.2013.11.024
   Bijl J, 1996, BLOOD, V87, P1737, DOI 10.1182/blood.V87.5.1737.bloodjournal8751737
   Bodey B, 2000, ANTICANCER RES, V20, P3281
   Bodey B, 2000, ANTICANCER RES, V20, P1769
   Bodey B, 2000, ANTICANCER RES, V20, P2711
   Bodey B, 2000, ANTICANCER RES, V20, P2717
   CASTRONOVO V, 1994, BIOCHEM PHARMACOL, V47, P137, DOI 10.1016/0006-2952(94)90447-2
   FRIEDMANN Y, 1994, CANCER RES, V54, P5981
   Fujiki K, 2008, GASTROENTEROLOGY, V135, P907, DOI 10.1053/j.gastro.2008.06.034
   Grishina IB, 2005, DEV BIOL, V288, P334, DOI 10.1016/j.ydbio.2005.08.018
   Kim KJ, 2013, ONCOGENE, V32, P3339, DOI 10.1038/onc.2012.354
   Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Knaevelsrud H, 2010, FEBS LETT, V584, P2635, DOI 10.1016/j.febslet.2010.04.041
   Komatsu M, 2010, FEBS LETT, V584, P1374, DOI 10.1016/j.febslet.2010.02.017
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Leyten GHJM, 2015, CLIN CANCER RES, V21, P3061, DOI 10.1158/1078-0432.CCR-14-3334
   McCabe CD, 2008, CANCER RES, V68, P1988, DOI 10.1158/0008-5472.CAN-07-5843
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2007, ANNU REV NUTR, V27, P19, DOI 10.1146/annurev.nutr.27.061406.093749
   Moon SM, 2012, J BIOL CHEM, V287, P35678, DOI 10.1074/jbc.M112.361675
   Ramachandran S, 2005, ONCOGENE, V24, P188, DOI 10.1038/sj.onc.1207906
   Ricort JM, 2002, J BIOL CHEM, V277, P19448, DOI 10.1074/jbc.M200439200
   Rogov V, 2014, MOL CELL, V53, P167, DOI 10.1016/j.molcel.2013.12.014
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251
   Wang DD, 2014, HEPATO-GASTROENTEROL, V61, P2215, DOI 10.5754/hge14293
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Zhang Q, 2013, NEOPLASMA, V60, P439, DOI 10.4149/neo_2013_057
NR 32
TC 18
Z9 19
U1 0
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAY 17
PY 2016
VL 7
IS 20
BP 29216
EP 29227
DI 10.18632/oncotarget.8703
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DO4HO
UT WOS:000377742600038
PM 27081081
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Paillas, S
   Causse, A
   Marzi, L
   De Medina, P
   Poirot, M
   Denis, V
   Vezzio-Vie, N
   Espert, L
   Arzouk, H
   Coquelle, A
   Martineau, P
   Del Rio, M
   Pattingre, S
   Gongora, C
AF Paillas, Salome
   Causse, Annick
   Marzi, Laetitia
   De Medina, Philippe
   Poirot, Marc
   Denis, Vincent
   Vezzio-Vie, Nadia
   Espert, Lucile
   Arzouk, Hayat
   Coquelle, Arnaud
   Martineau, Pierre
   Del Rio, Maguy
   Pattingre, Sophie
   Gongora, Celine
TI MAPK14/p38 alpha confers irinotecan resistance to TP53-defective cells
   by inducing survival autophagy
SO AUTOPHAGY
LA English
DT Article
DE MAPK14/p38; survival autophagy; irinotecan resistance; colon cancer;
   chemotherapy
ID ACTIVATED PROTEIN-KINASE; CANCER CELLS; COLON-CANCER; COLORECTAL-CANCER;
   CYCLE ARREST; IN-VIVO; P38; P38-ALPHA; EXPRESSION; PHOSPHORYLATION
AB Recently we have shown that the mitogen-activated protein kinase (MAPK) MAPK14/p38 alpha is involved in resistance of colon cancer cells to camptothecin-related drugs. Here we further investigated the cellular mechanisms involved in such drug resistance and showed that, in HCT116 human colorectal adenocarcinoma cells in which TP53 was genetically ablated (HCT116-TP53KO), overexpression of constitutively active MAPK14/p38a decreases cell sensitivity to SN-38 (the active metabolite of irinotecan), inhibits cell proliferation and induces survival-autophagy. Since autophagy is known to facilitate cancer cell resistance to chemotherapy and radiation treatment, we then investigated the relationship between MAPK14/p38 alpha, autophagy and resistance to irinotecan. We demonstrated that induction of autophagy by SN38 is dependent on MAPK14/p38 alpha activation. Finally, we showed that inhibition of MAPK14/p38 alpha or autophagy both sensitizes HCT116-TP53KO cells to drug therapy. Our data proved that the two effects are interrelated, since the role of autophagy in drug resistance required the MAPK14/p38 alpha. Our results highlight the existence of a new mechanism of resistance to camptothecin-related drugs: upon SN38 induction, MAPK14/p38 alpha is activated and triggers survival-promoting autophagy to protect tumor cells against the cytotoxic effects of the drug. Colon cancer cells could thus be sensitized to drug therapy by inhibiting either MAPK14/p38 or autophagy.
C1 [Paillas, Salome; Causse, Annick; Marzi, Laetitia; Denis, Vincent; Vezzio-Vie, Nadia; Arzouk, Hayat; Coquelle, Arnaud; Martineau, Pierre; Del Rio, Maguy; Pattingre, Sophie; Gongora, Celine] IRCM, Montpellier, France.
   [Paillas, Salome; Causse, Annick; Marzi, Laetitia; Denis, Vincent; Vezzio-Vie, Nadia; Arzouk, Hayat; Coquelle, Arnaud; Martineau, Pierre; Del Rio, Maguy; Pattingre, Sophie; Gongora, Celine] Univ Montpellier I, Montpellier, France.
   [Paillas, Salome; Causse, Annick; Marzi, Laetitia; Denis, Vincent; Vezzio-Vie, Nadia; Arzouk, Hayat; Coquelle, Arnaud; Martineau, Pierre; Del Rio, Maguy; Pattingre, Sophie; Gongora, Celine] INSERM, U896, Montpellier, France.
   [Paillas, Salome; Causse, Annick; Marzi, Laetitia; Denis, Vincent; Vezzio-Vie, Nadia; Arzouk, Hayat; Coquelle, Arnaud; Martineau, Pierre; Del Rio, Maguy; Pattingre, Sophie; Gongora, Celine] CRLC Val dAurelle Paul Lamarque, Montpellier, France.
   [Espert, Lucile] CNRS UMI UMII, UMR5236, CPBS, Montpellier, France.
   [De Medina, Philippe; Poirot, Marc] Fac Med Toulouse, INSERM, U563, F-31073 Toulouse, Haute Garonne, France.
RP Gongora, C (corresponding author), IRCM, Montpellier, France.
EM celine.gongora@inserm.fr
RI Espert, Lucile/ABF-5614-2021; de Medina, Philippe/X-1358-2019; Poirot,
   Marc/C-7613-2009; Coquelle, Arnaud/AAE-5425-2020; Martineau,
   Pierre/N-4386-2017
OI Poirot, Marc/0000-0002-5711-6624; Martineau, Pierre/0000-0002-7993-7183;
   Pattingre, Sophie/0000-0001-6284-6050; GONGORA,
   Celine/0000-0001-9034-4031; de Medina, Philippe/0000-0002-9618-3133
FU INSERMInstitut National de la Sante et de la Recherche Medicale
   (Inserm)European Commission
FX Funds for this research were provided by INSERM.
CR Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039
   Avitzour M, 2007, FEBS J, V274, P963, DOI 10.1111/j.1742-4658.2007.05644.x
   Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845
   Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2
   Chiacchiera F, 2008, CANCER LETT, V265, P16, DOI 10.1016/j.canlet.2008.02.061
   Comes F, 2007, CELL DEATH DIFFER, V14, P693, DOI 10.1038/sj.cdd.4402076
   Cui Q, 2007, J PHARMACOL SCI, V105, P317, DOI 10.1254/jphs.FP0070336
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Gongora C, 2008, CANCER BIOL THER, V7, P822, DOI 10.4161/cbt.7.6.5838
   Haq R, 2002, CANCER RES, V62, P5076
   Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191
   Paillas S, 2011, CANCER RES, V71, P1041, DOI 10.1158/0008-5472.CAN-10-2726
   Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977
   Segal NH, 2009, ANNU REV MED, V60, P207, DOI 10.1146/annurev.med.60.041807.132435
   Tang GM, 2008, HUM MOL GENET, V17, P1540, DOI 10.1093/hmg/ddn042
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002
   Webber JL, 2010, EMBO J, V29, P27, DOI 10.1038/emboj.2009.321
   Weng MS, 2005, BIOCHEM PHARMACOL, V69, P1815, DOI 10.1016/j.bcp.2005.03.011
   Xu Y, 2002, ANN ONCOL, V13, P1841, DOI 10.1093/annonc/mdf337
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
NR 26
TC 61
Z9 64
U1 2
U2 17
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1554-8627
J9 AUTOPHAGY
JI Autophagy
PD JUL
PY 2012
VL 8
IS 7
BP 1098
EP 1112
DI 10.4161/auto.20268
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 993BX
UT WOS:000307830600008
PM 22647487
OA Green Submitted, Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Moon, JH
   Jeong, JK
   Park, SY
AF Moon, Ji-Hong
   Jeong, Jae-Kyo
   Park, Sang-Youel
TI Deferoxamine inhibits TRAIL-mediated apoptosis via regulation of
   autophagy in human colon cancer cells
SO ONCOLOGY REPORTS
LA English
DT Article
DE deferoxamine; TRAIL; autophagy; colon cancer
ID IRON CHELATION; COLORECTAL-CANCER; ANTICANCER DRUGS; HYPOXIA; SURVIVAL;
   MECHANISMS; DEATH; TUMORIGENESIS; EXPRESSION; LYSOSOMES
AB Deferoxamine (DFO), an iron chelator, has numerous clinical applications for patients presenting with iron overload in regards to the improvement in the quality of life and overall survival. In addition, experimental iron chelators have demonstrated potent anticancer properties. The present study investigated the effects of DFO on TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in colon cancer cells and and the mechanism involved. The experimental results showed that DFO treatment inhibited TRAIL-mediated cancer cell apoptosis by increasing Akt activation and decreasing caspase activation in human colon cancer cells. Furthermore, DFO treatment induced autophagy flux, and chloroquine, an autophagy inhibitor, blocked DFO-mediated inhibition of TRAIL-induced apoptosis. The present study demonstrated that DFO inhibited TRAIL-mediated tumor cell death via the autophagy pathway, and the results suggest that potent anticancer agent, DFO, can be an inhibitor against antitumor therapy including TRAIL protein.
C1 [Moon, Ji-Hong; Jeong, Jae-Kyo; Park, Sang-Youel] Chonbuk Natl Univ, Biosafety Res Inst, Coll Vet Med, Jeonju 561756, Jeonbuk, South Korea.
RP Park, SY (corresponding author), Chonbuk Natl Univ, Biosafety Res Inst, Coll Vet Med, Jeonju 561756, Jeonbuk, South Korea.
EM sypark@chonbuk.ac.kr
RI jeong, jae-kyo/ABC-5156-2020; Park, Sang-Youel/D-5966-2012
OI Park, Sang-Youel/0000-0003-0575-6045
FU National Research Foundation of Korea (NRF) - Korean Government
   [2013R1A1A2063931]
FX This study was supported by a grant from the National Research
   Foundation of Korea (NRF), funded by the Korean Government
   (2013R1A1A2063931).
CR Agarwal E, 2013, CELL SIGNAL, V25, P1711, DOI 10.1016/j.cellsig.2013.03.025
   Bedford MR, 2013, J CLIN PHARMACOL, V53, P885, DOI 10.1002/jcph.113
   Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Chaudhari AA, 2009, BIOCHEM BIOPH RES CO, V381, P513, DOI 10.1016/j.bbrc.2009.02.073
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107
   DETER RL, 1967, J CELL BIOL, V33, P437, DOI 10.1083/jcb.33.2.437
   Fu D, 2007, BLOOD, V110, P752, DOI 10.1182/blood-2007-03-076737
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Gustafsson AB, 2009, CIRC RES, V104, P150, DOI 10.1161/CIRCRESAHA.108.187427
   HERSHKO C, 1994, BAILLIERE CLIN HAEM, V7, P965, DOI 10.1016/S0950-3536(05)80133-7
   HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059
   Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831
   Ikeda Y, 2011, ATHEROSCLEROSIS, V215, P339, DOI 10.1016/j.atherosclerosis.2011.01.009
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Lieu Pauline T., 2001, Molecular Aspects of Medicine, V22, P1, DOI 10.1016/S0098-2997(00)00006-6
   Liu YP, 2014, CELL PHYSIOL BIOCHEM, V33, P1036, DOI 10.1159/000358674
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   MacFarlane M, 2003, TOXICOL LETT, V139, P89, DOI 10.1016/S0378-4274(02)00422-8
   Matsumoto G, 2011, MOL CELL, V44, P279, DOI 10.1016/j.molcel.2011.07.039
   Mazure NM, 2009, AUTOPHAGY, V5, P868, DOI 10.4161/auto.9042
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Nakayama K, 2009, J BIOCHEM, V146, P757, DOI 10.1093/jb/mvp167
   NELSON RL, 1992, FREE RADICAL BIO MED, V12, P161, DOI 10.1016/0891-5849(92)90010-E
   Nurtjahja-Tjendraputra E, 2007, BLOOD, V109, P4045, DOI 10.1182/blood-2006-10-047753
   Olivieri NF, 1997, BLOOD, V89, P739, DOI 10.1182/blood.V89.3.739
   Park KJ, 2007, CANCER RES, V67, P7327, DOI 10.1158/0008-5472.CAN-06-4766
   Rubinsztein DC, 2009, AUTOPHAGY, V5, P585, DOI 10.4161/auto.5.5.8823
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Singh K, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-70
   STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463
   Toyokuni S, 1996, FREE RADICAL BIO MED, V20, P553, DOI 10.1016/0891-5849(95)02111-6
   Wang K, 2011, AUTOPHAGY, V7, P966, DOI 10.4161/auto.7.9.15863
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Yun Z, 2002, DEV CELL, V2, P331, DOI 10.1016/S1534-5807(02)00131-4
   Zhang JY, 2002, NAT REV DRUG DISCOV, V1, P101, DOI 10.1038/nrd742
NR 40
TC 16
Z9 17
U1 0
U2 21
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD MAR
PY 2015
VL 33
IS 3
BP 1171
EP 1176
DI 10.3892/or.2014.3676
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CB6KL
UT WOS:000349735800019
PM 25524470
OA Bronze
DA 2022-04-25
ER

PT J
AU Aydinlik, S
   Erkisa, M
   Ari, F
   Celikler, S
   Ulukaya, E
AF Aydinlik, Seyma
   Erkisa, Merve
   Ari, Ferda
   Celikler, Serap
   Ulukaya, Engin
TI Palladium (II) Complex Enhances ROS-Dependent Apoptotic Effects via
   Autophagy Inhibition and Disruption of Multiple Signaling Pathways in
   Colorectal Cancer Cells
SO ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
LA English
DT Article
DE Apoptosis; autophagy; metal-based compounds; ROS; colorectal cancer;
   chloroquine
ID PLATINUM(II) SACCHARINATE COMPLEXES; COLON-CANCER; CYTOTOXIC ACTIVITY;
   IN-VITRO; 5-FLUOROURACIL; CHLOROQUINE; CHEMOTHERAPY; BEVACIZUMAB;
   COMBINATION; ACTIVATION
AB Background: Inhibition of autophagy is reported to be a therapeutically effective strategy in overcoming resistance that is a deadly outcome in cancer. One of the most common reasons for chemo-resistance to treatment is the patients with tumors exhibiting a KRAS mutation, which occurs in approximately 40% of colorectal cancer patients.
   Objective: Hence, we assessed whether a Palladium (Pd)(II) complex is a promising anticancer complex, compared to 5-fluorouracil in KRAS wt HT-29 and KRAS mutant HCT-15 cells.
   Methods: HCT-15 and HT-29 cells were used for colorectal cancer and Chloroquine (CQ) was used as an inhibitor of autophagy. In this context, cells were treated with Pd(II) complex and 5-FU in combination with CQ for 48h and cell viability was measured by SRB assay. Cell death mode was examined with M30 and M65 ELISA assays, using annexin V/propidium iodide. Autophagy was determined by Acridine Orange (AO) staining. Furthermore, the expressions of various autophagy and apoptosis-related proteins were evaluated with Western blotting. Luminex assay and the level of Reactive Oxygen Species (ROS) were examined.
   Results: Cell viability was found to decrease in a dose-dependent manner and CQ enhanced cytotoxic effect in Pd(II) and 5-FU treated cells in colorectal cancer cells. Our data showed that inhibition of autophagic flux significantly increased intrinsic apoptosis through the activation of ROS. We showed that combinatorial treatment with CQ induced apoptosis via the caspase-dependent mitochondrial pathway. Luminex analysis revealed that the combination resulted in a down-regulation of NF-?B/AKT/CREB signaling pathways in both cell lines, however, decreased Erk1/2 protein expression was only observed after treatment with CQ combination in HCT-15 cells.
   Conclusion: We suggest that the inhibition of autophagy along with Pd(II) and 5-FU treatment has a synergistic effect on KRAS-mutant colorectal cancer cells. Autophagy inhibition by CQ promotes apoptosis via blockade of the NF-?B/AKT/CREB and activation of ROS.
C1 [Aydinlik, Seyma; Ari, Ferda; Celikler, Serap] Uludag Univ, Fac Arts & Sci, Dept Biol, Bursa, Turkey.
   [Erkisa, Merve] Istinye Univ, Mol Canc Res Ctr, Istanbul, Turkey.
   [Ulukaya, Engin] Istinye Univ, Dept Clin Biochem, Fac Med, Istanbul, Turkey.
RP Ulukaya, E (corresponding author), Istinye Univ, Dept Clin Biochem, Fac Med, Istanbul, Turkey.
EM eulukaya@istinye.edu.tr
RI Aydinlik, Seyma/ABI-2909-2020; Arı, Ferda/AAG-7012-2021
OI Aydinlik, Seyma/0000-0001-5238-2432; Arı, Ferda/0000-0002-6729-7908;
   Ulukaya, Engin/0000-0003-4875-5472; Erkisa Genel,
   Merve/0000-0002-3127-742X
FU Scientific Research Projects Foundation (BAP) of the Uludag University
   of TurkeyUludag University; OUAP(T) [-2015/19]
FX This work was supported by funds from the Scientific Research Projects
   Foundation (BAP) of the Uludag University of Turkey [Project No.
   OUAP(T)-2015/19].
CR Abu-Surrah AS, 2010, EUR J MED CHEM, V45, P471, DOI 10.1016/j.ejmech.2009.10.029
   Ari F, 2013, BIOORGAN MED CHEM, V21, P6427, DOI 10.1016/j.bmc.2013.08.050
   Aydinlik S, 2019, BBA-GEN SUBJECTS, V1863, P903, DOI 10.1016/j.bbagen.2019.02.014
   Aydinlik S, 2017, BBA-GEN SUBJECTS, V1861, P49, DOI 10.1016/j.bbagen.2016.11.013
   Bijnsdorp IV, 2010, INT J CANCER, V126, P2457, DOI 10.1002/ijc.24943
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Cai Y, 2018, ONCOL LETT, V15, P1143, DOI 10.3892/ol.2017.7415
   Cevatemre B, 2015, TUMOR BIOL, V36, P6857, DOI 10.1007/s13277-015-3367-5
   Chang CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031808
   de la Cruz-Morcillo MA, 2012, ONCOGENE, V31, P1073, DOI 10.1038/onc.2011.321
   Devenport SN, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111349
   Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305
   Gimenez-Xavier P, 2008, INT J MOL MED, V22, P781, DOI 10.3892/ijmm_00000085
   Huang RH, 2017, CELL PHYSIOL BIOCHEM, V41, P1851, DOI 10.1159/000471933
   Huang YJ, 2019, J CANCER, V10, P4814, DOI 10.7150/jca.31408
   Icsel C, 2015, J INORG BIOCHEM, V152, P38, DOI 10.1016/j.jinorgbio.2015.08.026
   Karami K, 2018, NEW J CHEM, V42, P574, DOI 10.1039/c7nj03138f
   Lang WH, 2014, J BIOMOL SCREEN, V19, P1235, DOI 10.1177/1087057114545650
   Lee Y, 2018, MOL MED REP, V18, P4281, DOI 10.3892/mmr.2018.9488
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Li Q, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-1029-4
   Li XS, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-26
   Lin G, 2012, DIGEST DIS SCI, V57, P2325, DOI 10.1007/s10620-012-2172-x
   Liu L, 2017, ONCOL LETT, V14, P4319, DOI 10.3892/ol.2017.6687
   Liu SS, 2014, ARCH PHARM RES, V37, P1039, DOI 10.1007/s12272-013-0270-8
   Myeku N, 2011, J BIOL CHEM, V286, P22426, DOI 10.1074/jbc.M110.149252
   Recktenwald CV, 2007, PROTEOMICS, V7, P385, DOI 10.1002/pmic.200600506
   Sasaki K, 2012, ANTI-CANCER DRUG, V23, P675, DOI 10.1097/CAD.0b013e328353f8c7
   Schonewolf CA, 2014, WORLD J GASTRO ONCOL, V6, P74, DOI 10.4251/wjgo.v6.i3.74
   Son Yong, 2011, J Signal Transduct, V2011, P792639, DOI 10.1155/2011/792639
   Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113
   Ulukaya E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064278
   Voboril R, 2004, J SURG RES, V120, P178, DOI 10.1016/j.jss.2003.11.023
   Volarevic V, 2013, J BUON, V18, P131
   Wang JR, 2009, J BIOL CHEM, V284, P21412, DOI 10.1074/jbc.M109.026013
   Wang WG, 2003, INT J CANCER, V104, P504, DOI 10.1002/ijc.10972
   Weiss JT, 2014, FRONT CHEM, V2, DOI 10.3389/fchem.2014.00056
   Welch S, 2010, ANN ONCOL, V21, P1152, DOI 10.1093/annonc/mdp533
   Wu YY, 2020, INT J OPHTHALMOL-CHI, V13, P21, DOI 10.18240/ijo.2020.01.04
   Yan JH, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1355-0
   Yang PM, 2010, CANCER RES, V70, P7699, DOI 10.1158/0008-5472.CAN-10-1626
   Yilmaz VT, 2018, EUR J MED CHEM, V155, P609, DOI 10.1016/j.ejmech.2018.06.035
   Zhang JX, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4350965
   Zhou HY, 2016, CANCER BIOMARK, V17, P1, DOI 10.3233/CBM-160613
NR 45
TC 1
Z9 1
U1 4
U2 16
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1871-5206
EI 1875-5992
J9 ANTI-CANCER AGENT ME
JI Anti-Cancer Agents Med. Chem.
PY 2021
VL 21
IS 6
BP 1284
EP 1291
DI 10.2174/1871520620666200929153804
PG 8
WC Oncology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA QT0QB
UT WOS:000626296300001
PM 32990544
DA 2022-04-25
ER

PT J
AU Pourhanifeh, MH
   Vosough, M
   Mahjoubin-Tehran, M
   Hashemipour, M
   Nejati, M
   Abbasi-Kolli, M
   Sahebkar, A
   Mirzaei, H
AF Pourhanifeh, Mohammad Hossein
   Vosough, Massoud
   Mahjoubin-Tehran, Maryam
   Hashemipour, Maryam
   Nejati, Majid
   Abbasi-Kolli, Mohammad
   Sahebkar, Amirhossein
   Mirzaei, Hamed
TI Autophagy-related microRNAs: Possible regulatory roles and therapeutic
   potential in and gastrointestinal cancers
SO PHARMACOLOGICAL RESEARCH
LA English
DT Review
DE MicroRNA; Autophagy; Gastrointestinal cancer; Gastric cancer; Liver
   cancer; Pancreatic cancer; Esophageal cancer; Colorectal cancer;
   Biomarker; Epigenetic
ID HEPATOCELLULAR-CARCINOMA CELLS; PHASE-III TRIAL; CONFERS 5-FLUOROURACIL
   RESISTANCE; ADVANCED PANCREATIC-CANCER; COLORECTAL-CANCER;
   GASTRIC-CANCER; INHIBITS AUTOPHAGY; COLON-CANCER; DOWN-REGULATION;
   ENHANCES CHEMOSENSITIVITY
AB Gastrointestinal (GI) cancers with a high incidence rate and adverse complications are associated with severe morbidity and mortality around the world. It is well recognized that early detection of the disease results in longer survival rate and better quality of life. Autophagy, an intracellular regulatory process, has been shown to play an essential role in the pathogenesis of various malignancies including GI cancers. MicroRNAs (miRNAs) are small non-coding RNAs that have regulatory functions in tumor cells and possess potential diagnostic values in early detection of cancers. It has been recently demonstrated that these molecules have modulatory effects on multiple steps of autophagy process occurring in GI malignancies. In this review, we aimed to highlight the role of autophagy-related microRNAs on GI cancer as potential targets for cancer therapy.
C1 [Pourhanifeh, Mohammad Hossein] FDA, Halal Res Ctr IRI, Tehran, Iran.
   [Vosough, Massoud] ACECR, Royan Inst Stem Cell Biol & Technol, Dept Regenerat Med, Cell Sci Res Ctr, Tehran, Iran.
   [Mahjoubin-Tehran, Maryam] Mashhad Univ Med Sci, Student Res Comm, Mashhad, Razavi Khorasan, Iran.
   [Mahjoubin-Tehran, Maryam] Mashhad Univ Med Sci, Fac Med, Dept Med Biotechnol, Mashhad, Razavi Khorasan, Iran.
   [Hashemipour, Maryam] Kashan Univ Med Sci, Sch Med, Kashan, Iran.
   [Nejati, Majid] Kashan Univ Med Sci, Anat Sci Res Ctr, Inst Basic Sci, Kashan, Iran.
   [Abbasi-Kolli, Mohammad] Tarbiat Modares Univ, Fac Med Sci, Dept Med Genet, Tehran, Iran.
   [Sahebkar, Amirhossein] Mashhad Univ Med Sci, Neurogen Inflammat Res Ctr, Mashhad, Razavi Khorasan, Iran.
   [Sahebkar, Amirhossein] Mashhad Univ Med Sci, Sch Pharm, Mashhad, Razavi Khorasan, Iran.
   [Mirzaei, Hamed] Kashan Univ Med Sci, Res Ctr Biochem & Nutr Metab Dis, Inst Basic Sci, Kashan, Iran.
   [Sahebkar, Amirhossein] Mashhad Univ Med Sci, Biotechnol Res Ctr, Pharmaceut Technol Inst, Mashhad, Razavi Khorasan, Iran.
RP Mirzaei, H (corresponding author), Kashan Univ Med Sci, Res Ctr Biochem & Nutr Metab Dis, Inst Basic Sci, Kashan, Iran.; Sahebkar, A (corresponding author), Mashhad Univ Med Sci, Biotechnol Res Ctr, Pharmaceut Technol Inst, Mashhad, Razavi Khorasan, Iran.
EM Sahebkara@mums.ac.ir; mirzaei-h@kaums.ac.ir
RI Mirzaei, Hamed/X-2374-2018; Vosough, Massoud/AAR-8970-2021
OI Mirzaei, Hamed/0000-0002-9399-8281; Vosough,
   Massoud/0000-0001-5924-4366; Pourhanifeh, Mohammad
   Hossein/0000-0002-6752-2765; Mahjoubin-Tehran,
   Maryam/0000-0001-5719-5345
CR Abbas M, 2017, BIOMED PHARMACOTHER, V95, P1082, DOI 10.1016/j.biopha.2017.09.032
   Akkoc Y, 2020, BBA-MOL CELL RES, V1867, DOI 10.1016/j.bbamcr.2020.118662
   An Y, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.123
   Baradaran B, 2019, BIOMED PHARMACOTHER, V109, P1008, DOI 10.1016/j.biopha.2018.10.177
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Belalcazar A, 2017, CANCER-AM CANCER SOC, V123, P4924, DOI 10.1002/cncr.30944
   Berlin JD, 2002, J CLIN ONCOL, V20, P3270, DOI 10.1200/JCO.2002.11.149
   Bhutia SK, 2013, ADV CANCER RES, V118, P61, DOI 10.1016/B978-0-12-407173-5.00003-0
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Calabrese G, 2019, ONCOTARGETS THER, V12, P9571, DOI 10.2147/OTT.S221733
   Cao MJ, 2013, NANOSCALE, V5, P12120, DOI 10.1039/c3nr04056a
   Carlson EE, 2010, ACS CHEM BIOL, V5, P639, DOI 10.1021/cb100105c
   Chandra V, 2016, WORLD J GASTROENTERO, V22, P1787, DOI 10.3748/wjg.v22.i5.1787
   Chang Y, 2012, GASTROENTEROLOGY, V143, P177, DOI 10.1053/j.gastro.2012.04.009
   Che J, 2019, MOL CARCINOGEN, V58, P1234, DOI 10.1002/mc.23006
   Chen Gang, 2019, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V44, P87, DOI 10.11817/j.issn.1672-7347.2019.01.014
   Chen HX, 2017, CANCER SCI, V108, P1811, DOI 10.1111/cas.13315
   Chen H, 2020, CANCER LETT, V483, P114, DOI 10.1016/j.canlet.2020.01.037
   Chen JY, 2020, EUR REV MED PHARMACO, V24, P639, DOI 10.26355/eurrev_202001_20040
   Chen WQ, 2014, CHINESE J CANCER RES, V26, P48, DOI 10.3978/j.issn.1000-9604.2014.01.08
   Chen W, 2019, BIOMATERIALS, V192, P590, DOI 10.1016/j.biomaterials.2018.11.035
   Chen Y, 2020, ACTA MECH, V231, P1485, DOI 10.1007/s00707-019-02586-6
   Chen ZH, 2017, CELL DEATH DIFFER, V24, P212, DOI 10.1038/cdd.2016.111
   Chen Z, 2016, AM J TRANSL RES, V8, P1190
   CHOW WH, 1993, CANCER CAUSE CONTROL, V4, P163, DOI 10.1007/BF00053158
   Chu CA, 2019, EBIOMEDICINE, V43, P270, DOI 10.1016/j.ebiom.2019.04.010
   Colangelo T, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.29
   Cui L, 2019, INT J CLIN EXP PATHO, V12, P2989
   Davidson LA, 2009, CARCINOGENESIS, V30, P2077, DOI 10.1093/carcin/bgp245
   De Meyer GRY, 2015, CIRC RES, V116, P468, DOI 10.1161/CIRCRESAHA.116.303804
   Dite TA, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00628-y
   Du FJ, 2015, BIOMED PHARMACOTHER, V74, P169, DOI 10.1016/j.biopha.2015.08.005
   Du XM, 2018, EXP THER MED, V15, P599, DOI 10.3892/etm.2017.5354
   Dziki Lukasz, 2015, Pol Przegl Chir, V87, P459, DOI 10.1515/pjs-2015-0088
   Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074
   Fan H, 2018, ONCOL REP, V39, P1207, DOI 10.3892/or.2018.6194
   Favoriti P, 2016, UPDATES SURG, V68, P7, DOI 10.1007/s13304-016-0359-y
   Fawzy MS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187310
   Feber A, 2008, J THORAC CARDIOV SUR, V135, P255, DOI 10.1016/j.jtcvs.2007.08.055
   Feng J, 2017, WORLD J GASTROENTERO, V23, P4243, DOI 10.3748/wjg.v23.i23.4243
   Ferrari P, 2007, INT J CANCER, V121, P2065, DOI 10.1002/ijc.22966
   Frankel LB, 2012, CARCINOGENESIS, V33, P2018, DOI 10.1093/carcin/bgs266
   Fu Q, 2016, ONCOL REP, V36, P3682, DOI 10.3892/or.2016.5195
   Fu XT, 2018, CANCER LETT, V412, P108, DOI 10.1016/j.canlet.2017.10.012
   Gao AM, 2018, CHEM-BIOL INTERACT, V280, P45, DOI 10.1016/j.cbi.2017.11.020
   Ge YY, 2014, ONCOTARGET, V5, P6218, DOI 10.18632/oncotarget.2189
   Gu DN, 2017, CANCER LETT, V400, P69, DOI 10.1016/j.canlet.2017.04.020
   Gu YF, 2020, ANTI-CANCER DRUG, V31, P385, DOI 10.1097/CAD.0000000000000886
   Guo WH, 2018, J CANCER, V9, P4363, DOI 10.7150/jca.27533
   Han J, 2017, EXP CELL RES, V360, P328, DOI 10.1016/j.yexcr.2017.09.023
   Hao HB, 2017, MED MOL MORPHOL, V50, P76, DOI 10.1007/s00795-016-0150-7
   Hayes J, 2014, TRENDS MOL MED, V20, P460, DOI 10.1016/j.molmed.2014.06.005
   He CJ, 2015, ONCOTARGET, V6, P28867, DOI 10.18632/oncotarget.4814
   He W, 2016, LAB INVEST, V96, P317, DOI 10.1038/labinvest.2015.134
   Heinemann V, 2006, J CLIN ONCOL, V24, P3946, DOI 10.1200/JCO.2005.05.1490
   Herrmann R, 2007, J CLIN ONCOL, V25, P2212, DOI 10.1200/JCO.2006.09.0886
   Hesari A, 2019, INT J CANCER, V144, P1215, DOI 10.1002/ijc.31947
   Hu F, 2018, CANCER LETT, V416, P24, DOI 10.1016/j.canlet.2017.12.013
   Hu JL, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0028-8
   Hu JG, 2017, AUTOPHAGY, V13, P333, DOI 10.1080/15548627.2016.1256520
   Hu YR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0743-3
   Huang HJ, 2018, INT J ONCOL, V53, P2769, DOI 10.3892/ijo.2018.4593
   Huang KT, 2017, MOL THER-NUCL ACIDS, V9, P274, DOI 10.1016/j.omtn.2017.10.002
   Huang LM, 2018, CELL PHYSIOL BIOCHEM, V47, P747, DOI 10.1159/000490027
   Huangfu LT, 2016, ONCOTARGET, V7, P4735, DOI 10.18632/oncotarget.6732
   Hussain SP, 2016, INT J BIOL SCI, V12, P270, DOI 10.7150/ijbs.14950
   Hwang DW, 2017, PANCREAS, V46, P575, DOI 10.1097/MPA.0000000000000780
   Ikeda M, 2018, JPN J CLIN ONCOL, V48, P103, DOI 10.1093/jjco/hyx180
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Ji CX, 2018, DISCOV MED, V25, P265
   Jia H, 2019, PATHOL RES PRACT, V215, P697, DOI 10.1016/j.prp.2018.12.039
   Jiang XJ, 2015, J CLIN INVEST, V125, P47, DOI 10.1172/JCI73942
   Jin FF, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.461
   Jing Z, 2015, CANCER LETT, V356, P332, DOI 10.1016/j.canlet.2014.09.039
   Ju JA, 2013, BIOMARK GENOM MED, V5, P74, DOI 10.1016/j.bgm.2013.07.006
   Khani P, 2019, J NEUROCHEM, V148, P188, DOI 10.1111/jnc.14616
   Khemlina G, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0712-x
   Kim M, 2017, BIOMOL THER, V25, P609, DOI 10.4062/biomolther.2017.074
   Kong PF, 2017, MOL THER, V25, P1027, DOI 10.1016/j.ymthe.2017.01.013
   Kwon JJ, 2016, ONCOTARGET, V7, P71635, DOI 10.18632/oncotarget.11928
   Lan SH, 2014, AUTOPHAGY, V10, P1687, DOI 10.4161/auto.29959
   Lan SH, 2014, HEPATOLOGY, V59, P505, DOI 10.1002/hep.26659
   Lazcano-Ponce EC, 2001, CA-CANCER J CLIN, V51, P349, DOI 10.3322/canjclin.51.6.349
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Lee YC, 2016, GASTROENTEROLOGY, V150, P1113, DOI 10.1053/j.gastro.2016.01.028
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li BW, 2017, CANCER LETT, V410, P212, DOI 10.1016/j.canlet.2017.09.035
   Li CG, 2016, CANCER CHEMOTH PHARM, V78, P1199, DOI 10.1007/s00280-016-3178-4
   Li L, 2020, CURR MOL PHARMACOL, V13, P31, DOI 10.2174/1874467212666190809154518
   Li WJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1309-6
   Li XY, 2020, J CELL PHYSIOL, V235, P3402, DOI 10.1002/jcp.29230
   Liang GF, 2011, NANOSCALE RES LETT, V6, DOI 10.1186/1556-276X-6-447
   Liao D, 2018, EXP THER MED, V15, P1712, DOI 10.3892/etm.2017.5522
   Lin Y, 2017, MOL MED REP, V15, P2451, DOI 10.3892/mmr.2017.6289
   Lin Y, 2012, CARCINOGENESIS, V33, P2377, DOI 10.1093/carcin/bgs292
   Liu C, 2019, MOL CELL ENDOCRINOL, V493, DOI 10.1016/j.mce.2019.04.004
   Liu CX, 2019, CELL, V177, P865, DOI 10.1016/j.cell.2019.03.046
   Liu LD, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15016050
   Liu L, 2019, MOL THER-NUCL ACIDS, V17, P644, DOI 10.1016/j.omtn.2019.06.009
   Liu TY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114851
   Liu ZQ, 2016, BIOCHEM BIOPH RES CO, V473, P1268, DOI 10.1016/j.bbrc.2016.04.054
   Lu CH, 2018, ONCOTARGETS THER, V11, P4723, DOI 10.2147/OTT.S166264
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Luo YX, 2012, HEPATO-GASTROENTEROL, V59, P1398, DOI 10.5754/hge11676
   Menzies FM, 2015, NAT REV NEUROSCI, V16, P345, DOI 10.1038/nrn3961
   Mizushima N, 2010, CURR OPIN CELL BIOL, V22, P132, DOI 10.1016/j.ceb.2009.12.004
   Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525
   Mudduluru G, 2011, BIOSCIENCE REP, V31, P185, DOI 10.1042/BSR20100065
   Nahand JS, 2020, INT J CANCER, V146, P305, DOI 10.1002/ijc.32688
   Nahand JS, 2019, J CELL PHYSIOL, V234, P17064, DOI 10.1002/jcp.28457
   Netea-Maier RT, 2016, AUTOPHAGY, V12, P245, DOI 10.1080/15548627.2015.1071759
   Nyhan MJ, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2123-6
   O'Sullivan GC, 1999, GASTROENTEROLOGY, V116, P543, DOI 10.1016/S0016-5085(99)70175-7
   Ouyang B, 2018, ISCIENCE, V1, P16, DOI 10.1016/j.isci.2018.01.002
   Pardo R, 2010, PANCREATOLOGY, V10, P19, DOI 10.1159/000264680
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Peng H, 2020, AUTOPHAGY, V16, P698, DOI 10.1080/15548627.2019.1635381
   Peng Y, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2015.4
   Pottgen C, 2012, CANCER TREAT REV, V38, P599, DOI 10.1016/j.ctrv.2011.10.005
   Pourhanifeh MH, 2020, IUBMB LIFE, V72, P314, DOI 10.1002/iub.2211
   Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076
   Raju GSR, 2018, CANCER LETT, V419, P222, DOI 10.1016/j.canlet.2018.01.044
   Ren WW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0592-z
   Ren YL, 2017, CANCER LETT, V390, P126, DOI 10.1016/j.canlet.2017.01.009
   Rustgi AK, 2014, NEW ENGL J MED, V371, P2499, DOI 10.1056/NEJMra1314530
   Saxena R, 2019, CANCERS, V11, DOI 10.3390/cancers11111697
   Schwarzenbach H, 2014, NAT REV CLIN ONCOL, V11, P145, DOI 10.1038/nrclinonc.2014.5
   Shafabakhsh R, 2019, PHARMACOL RES, V147, DOI 10.1016/j.phrs.2019.104353
   Shi DL, 2019, ONCOTARGETS THER, V12, P9611, DOI 10.2147/OTT.S223598
   Shi KQ, 2015, ONCOTARGET, V6, P25093, DOI 10.18632/oncotarget.4437
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Stiuso P, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.8
   Storniolo AM, 1999, CANCER, V85, P1261, DOI 10.1002/(SICI)1097-0142(19990315)85:6<1261::AID-CNCR7>3.0.CO;2-T
   Su HF, 2019, ONCOL REP, V41, P599, DOI 10.3892/or.2018.6799
   Sugiyama T, 2016, CANCER SCI, V107, P1767, DOI 10.1111/cas.13091
   Sumbul AT, 2014, TUMOR BIOL, V35, P12713, DOI 10.1007/s13277-014-2596-3
   Sun C, 2017, WORLD J GASTROENTERO, V23, P1816, DOI 10.3748/wjg.v23.i10.1816
   Sun J, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0411-9
   Sun LH, 2017, AUTOPHAGY, V13, P703, DOI 10.1080/15548627.2017.1280217
   Sun WJ, 2019, MOL THER, V27, P1039, DOI 10.1016/j.ymthe.2019.02.010
   Sun WP, 2019, INT J CLIN EXP PATHO, V12, P2056
   Sun Y, 2015, INT J ONCOL, V46, P750, DOI 10.3892/ijo.2014.2745
   Tan SF, 2016, INT J MOL MED, V37, P1030, DOI 10.3892/ijmm.2016.2492
   Tang B, 2012, AUTOPHAGY, V8, P1045, DOI 10.4161/auto.20159
   Taniguchi K, 2015, CANCER LETT, V363, P17, DOI 10.1016/j.canlet.2015.03.026
   Thomas J, 2015, INT J MOL SCI, V16, P28063, DOI 10.3390/ijms161226080
   Tian S, 2017, ONCOTARGET, V8, P11071, DOI 10.18632/oncotarget.14360
   Tili E, 2010, BIOCHEM PHARMACOL, V80, P2057, DOI 10.1016/j.bcp.2010.07.003
   Vazquez-Aguirre A, 2019, ANTICANCER RES, V39, P3687, DOI 10.21873/anticanres.13517
   Wang F, 2016, SCI REP-UK, V6, DOI 10.1038/srep33229
   Wang J, 2018, AUTOPHAGY, V14, P1185, DOI 10.1080/15548627.2018.1458174
   Wang Jiping, 2020, Eur J Obstet Gynecol Reprod Biol X, V5, P100103, DOI 10.1016/j.eurox.2019.100103
   Wang P, 2013, GASTROENTEROLOGY, V145, P1133, DOI 10.1053/j.gastro.2013.07.048
   Wang SH, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01460
   Wang S, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-017-0003-0
   Wang YN, 2017, ONCOL LETT, V14, P3566, DOI 10.3892/ol.2017.6573
   Wang YF, 2019, ONCOTARGETS THER, V12, P4621, DOI 10.2147/OTT.S196992
   Wang Z, 2019, BIOMED PHARMACOTHER, V119, DOI 10.1016/j.biopha.2019.109428
   Wang ZC, 2019, INT J BIOCHEM CELL B, V111, P63, DOI 10.1016/j.biocel.2019.01.020
   Wang ZY, 2014, ONCOTARGET, V5, P7013, DOI 10.18632/oncotarget.2192
   Wei HM, 2019, INT IMMUNOPHARMACOL, V73, P72, DOI 10.1016/j.intimp.2019.04.049
   Weng JY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0189-y
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wu K, 2016, SAUDI J GASTROENTERO, V22, P30, DOI 10.4103/1319-3767.173756
   Xi ZW, 2019, INT J ONCOL, V54, P239, DOI 10.3892/ijo.2018.4609
   Xiao RL, 2015, BIOMED PHARMACOTHER, V74, P138, DOI 10.1016/j.biopha.2015.08.006
   Xin L, 2019, INT J BIOL MACROMOL, V122, P1046, DOI 10.1016/j.ijbiomac.2018.09.051
   Xiong J, 2017, ONCOTARGET, V8, P6555, DOI 10.18632/oncotarget.14149
   Xu LB, 2014, J HEPATOL, V60, P590, DOI 10.1016/j.jhep.2013.10.028
   Xu N, 2012, BIOCHEM BIOPH RES CO, V423, P826, DOI 10.1016/j.bbrc.2012.06.048
   Xu W.P., 2019, GUT
   Xu YH, 2013, ONCOL REP, V29, P2019, DOI 10.3892/or.2013.2338
   Xu ZP, 2019, CANCER LETT, V449, P226, DOI 10.1016/j.canlet.2019.02.026
   Yan LK, 2017, BIOMED PHARMACOTHER, V96, P974, DOI 10.1016/j.biopha.2017.11.138
   Yang A, 2014, CANCER DISCOV, V4, P905, DOI 10.1158/2159-8290.CD-14-0362
   Yang C, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-019-1064-y
   Yang CW, 2020, J BIOMAT SCI-POLYM E, V31, P622, DOI 10.1080/09205063.2019.1706149
   Yang C, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1308-3
   Yang Chun, 2015, Tumour Biol
   Yang J, 2018, FRONT BIOSCI-LANDMRK, V23, P388, DOI 10.2741/4596
   Yang L, 2010, ANN ONCOL, V21, P389, DOI 10.1093/annonc/mdp303
   Yang L, 2019, GENE, V697, P94, DOI 10.1016/j.gene.2019.02.036
   Yang L, 2018, ONCOL LETT, V16, P5355, DOI 10.3892/ol.2018.9269
   Yang SH, 2011, AUTOPHAGY, V7, P912, DOI 10.4161/auto.7.8.15762
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yang XJ, 2016, WORLD J GASTROENTERO, V22, P3978, DOI 10.3748/wjg.v22.i15.3978
   Yang XD, 2016, ONCOTARGET, V7, P79603, DOI 10.18632/oncotarget.12873
   Yang X, 2015, CELL BIOSCI, V5, DOI 10.1186/s13578-015-0005-2
   Yang YF, 2018, ONCOL LETT, V16, P7295, DOI 10.3892/ol.2018.9513
   Yu GQ, 2017, ONCOL REP, V37, P1123, DOI 10.3892/or.2016.5326
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Yu XF, 2017, SCI REP-UK, V7, DOI 10.1038/srep42226
   Yu ZR, 2010, AM J PATHOL, V176, P1058, DOI 10.2353/ajpath.2010.090664
   Yuan KT, 2018, TECHNOL CANCER RES T, V17, DOI 10.1177/1533033818806499
   Yuan LW, 2016, WORLD J GASTROENTERO, V22, P2046, DOI 10.3748/wjg.v22.i6.2046
   Yuan P, 2016, BIOCHEM BIOPH RES CO, V478, P1067, DOI 10.1016/j.bbrc.2016.08.065
   Yuan Y, 2018, INT J MOL MED, V42, P3562, DOI 10.3892/ijmm.2018.3871
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
   Zhai H, 2013, ONCOGENE, V32, P1570, DOI 10.1038/onc.2012.167
   Zhai HY, 2015, ONCOTARGET, V6, P19735, DOI 10.18632/oncotarget.3771
   Zhai HY, 2013, CELL CYCLE, V12, P246, DOI 10.4161/cc.23273
   Zhang DJ, 2017, INT J CANCER, V140, P2298, DOI 10.1002/ijc.30656
   Zhang F, 2019, BRAZ J MED BIOL RES, V52, DOI [10.1590/1414-431X20187843, 10.1590/1414-431x20187843]
   Zhang H, 2019, DNA CELL BIOL, V38, P857, DOI 10.1089/dna.2019.4770
   Zhang HS, 2016, ARCH BIOCHEM BIOPHYS, V598, P50, DOI 10.1016/j.abb.2016.03.031
   Zhang HH, 2015, CANCER LETT, V356, P781, DOI 10.1016/j.canlet.2014.10.029
   Zhang K, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0344-0
   Zhang P, 2019, AUTOPHAGY, V15, P1668, DOI 10.1080/15548627.2019.1633863
   Zhang R, 2017, TUMOR BIOL, V39, P1, DOI 10.1177/1010428317703984
   Zhang W, 2014, EUR PHYS J B, V87, P1, DOI 10.1140/epjb/e2013-40506-4
   Zhang XL, 2015, ONCOL REP, V34, P1557, DOI 10.3892/or.2015.4078
   Zhang X, 2019, MOL CANCER, V18, DOI 10.1186/s12943-018-0935-5
   Zhang X, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0993-y
   Zhang XF, 2019, BIOCHEM BIOPH RES CO, V510, P508, DOI 10.1016/j.bbrc.2019.01.109
   Zhao J, 2016, GENE, V576, P828, DOI 10.1016/j.gene.2015.11.013
   Zhao PX, 2017, NANOMED-NANOTECHNOL, V13, P2507, DOI 10.1016/j.nano.2017.05.010
   Zheng B, 2018, NANOMEDICINE-UK, V13, P769, DOI 10.2217/nnm-2017-0345
   Zheng S, 2019, J BIOSCIENCES, V44, DOI 10.1007/s12038-019-9918-y
   Zheng YS, 2019, J CELL BIOCHEM, V120, P3922, DOI 10.1002/jcb.27676
   Zhou HY, 2016, CANCER BIOMARK, V17, P1, DOI 10.3233/CBM-160613
   Zhou L, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317694313
   Zhou P, 2020, EXP THER MED, V19, P1112, DOI 10.3892/etm.2019.8293
   Zou XW, 2020, ONCOTARGETS THER, V13, P225, DOI 10.2147/OTT.S227015
NR 227
TC 28
Z9 28
U1 6
U2 10
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-6618
EI 1096-1186
J9 PHARMACOL RES
JI Pharmacol. Res.
PD NOV
PY 2020
VL 161
AR 105133
DI 10.1016/j.phrs.2020.105133
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA PI3JG
UT WOS:000600990100034
PM 32822869
DA 2022-04-25
ER

PT J
AU Chen, WTL
   Yang, HB
   Ke, TW
   Liao, WL
   Hung, SY
AF Chen, William Tzu-Liang
   Yang, Han-Bin
   Ke, Tao-Wei
   Liao, Wen-Ling
   Hung, Shih-Ya
TI Serum DJ-1 Is a Biomarker of Colorectal Cancer and DJ-1 Activates
   Mitophagy to Promote Colorectal Cancer Progression
SO CANCERS
LA English
DT Article
DE autophagy; biomarker; colorectal cancer; DJ-1; mitophagy
ID COLON-CANCER; EXPRESSION; AUTOPHAGY; INVASION; PATHWAY; PROTEIN; PARKIN;
   CELLS; MITOCHONDRIA; MECHANISMS
AB Simple Summary Colorectal cancer is common cancer, and currently used serum markers for detecting colorectal cancer lack excellent diagnostic accuracy. In the present study, we collected matched tumor and adjacent normal tissues and serum from patients and cancer cells to demonstrate the clinical value of DJ-1 in colorectal cancer and the role of DJ-1-induced mitophagy in colorectal cancer progression. Our data indicate that DJ-1 might be clinically valuable as serum and tissue biomarkers for predicting the TNM (tumor-node-metastasis) stage in colorectal cancer patients. Besides, DJ-1 knockdown enhanced intracellular reactive oxygen species generation and damaged mitochondrial accumulation and mitophagy inhibition in metastatic colorectal adenocarcinoma cells. Since DJ-1-induced mitophagy promotes tumor progression, DJ-1 inhibition is a potential therapeutic strategy for colorectal cancer treatment. Colorectal cancer is the second most common cancer and the third cancer-associated death in Taiwan. Currently used serum markers for detecting colorectal cancer lack excellent diagnostic accuracy, which results in colorectal cancer being often recognized too late for successful therapy. Mitophagy is the selective autophagic degradation of damaged or excessive mitochondria. DJ-1 is an antioxidant protein that attenuates oxidative stress and maintains mitochondrial quality through activating mitophagy. Mitophagy activation contributes to anti-cancer drug resistance. However, the role of DJ-1-induced mitophagy in colorectal cancer progression remains unclear. In the present study, we collected matched tumor and adjacent normal tissues and serum from patients and cancer cells to demonstrate the clinical value and physiological function of DJ-1 in colorectal cancer. We found that DJ-1 increased in tumor tissues and serum; it was positively correlated with TNM (tumor-node-metastasis) stages of colorectal cancer patients. Through stable knockdown DJ-1 expression in metastatic colorectal adenocarcinoma cells SW620, DJ-1 knockdown inhibited cancer cell survival, migration, and colony formation. In SW620 cells, DJ-1 knockdown induced an incomplete autophagic response that did not affect ATP production; DJ-1 knockdown enhanced intracellular reactive oxygen species generation and damaged mitochondrial accumulation and mitophagy inhibition. It suggests that DJ-1 knockdown inhibits mitophagy that causes metastatic colorectal adenocarcinoma cells to be unable to remove damaged mitochondria and further enhance cancer cell apoptosis. Our data indicate that DJ-1 might be clinically valuable as serum and tissue biomarkers for predicting the TNM stage in colorectal cancer patients. Since DJ-1-induced mitophagy promotes tumor progression, DJ-1 inhibition is a potential therapeutic strategy for colorectal cancer treatment.
C1 [Chen, William Tzu-Liang] China Med Univ, Sch Med, Taichung 40402, Taiwan.
   [Chen, William Tzu-Liang] China Med Univ, Dept Colorectal Surg, Hsinchu Hosp, Zhubei City 30272, Taiwan.
   [Yang, Han-Bin] China Med Univ, PhD Program Aging, Taichung 40402, Taiwan.
   [Ke, Tao-Wei] China Med Univ Hosp, Div Colorectal Surg, Taichung 40447, Taiwan.
   [Liao, Wen-Ling] China Med Univ, Grad Inst Integrated Med, Taichung 40202, Taiwan.
   [Liao, Wen-Ling] China Med Univ Hosp, Ctr Personalized Med, Dept Med Res, Taichung 40447, Taiwan.
   [Hung, Shih-Ya] China Med Univ Hosp, Dept Med Res, Div Surg, Taichung 40447, Taiwan.
   [Hung, Shih-Ya] China Med Univ, Grad Inst Acupuncture Sci, Taichung 40402, Taiwan.
RP Hung, SY (corresponding author), China Med Univ Hosp, Dept Med Res, Div Surg, Taichung 40447, Taiwan.; Hung, SY (corresponding author), China Med Univ, Grad Inst Acupuncture Sci, Taichung 40402, Taiwan.
EM wtchen@mail.cmuh.org.tw; alex23206567@yahoo.com.tw;
   D18047@mail.cmuh.org.tw; wl0129@mail.cmu.edu.tw;
   shihyahung@mail.cmu.edu.tw
RI Chen, William Tzu-Liang/ABA-5673-2021
FU Ministry of Science and Technology of TaiwanMinistry of Science and
   Technology, Taiwan [MOST 108-2320-B-039-029-MY3]; China Medical
   UniversityChina Medical University [CMU109-MF-49]
FX This work was supported by grants from the Ministry of Science and
   Technology of Taiwan (MOST 108-2320-B-039-029-MY3) and China Medical
   University (CMU109-MF-49).
CR An CN, 2018, NEUROSCI LETT, V665, P236, DOI 10.1016/j.neulet.2017.12.023
   Ashrafi G, 2013, CELL DEATH DIFFER, V20, P31, DOI 10.1038/cdd.2012.81
   Baptista-Hon DT, 2014, BRIT J ANAESTH, V113, P39, DOI 10.1093/bja/aeu104
   Bernardini JP, 2017, ONCOGENE, V36, P1315, DOI 10.1038/onc.2016.302
   Chen JH, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0513-z
   Choi KS, 2012, EXP MOL MED, V44, P109, DOI 10.3858/emm.2012.44.2.033
   Davidson B, 2008, HUM PATHOL, V39, P87, DOI 10.1016/j.humpath.2007.05.014
   Ding WX, 2012, BIOL CHEM, V393, P547, DOI 10.1515/hsz-2012-0119
   Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4
   Fan J, 2008, J BIOL CHEM, V283, P4022, DOI 10.1074/jbc.M707176200
   Fan XJ, 2016, ONCOL REP, V36, P3559, DOI 10.3892/or.2016.5138
   Gao H, 2012, J MOL BIOL, V423, P232, DOI 10.1016/j.jmb.2012.06.034
   Ghosh S, 2016, SCI REP-UK, V6, DOI 10.1038/srep32593
   He XY, 2011, J DIGEST DIS, V12, P131, DOI 10.1111/j.1751-2980.2011.00488.x
   Health Promotion Administration Ministry of Health and Welfare Taiwan, 2018, CANC REGISTRY ANN RE
   Heras-Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019
   Hewitt RE, 2000, J PATHOL, V192, P446
   Hung SY, 2009, AUTOPHAGY, V5, P502, DOI 10.4161/auto.5.4.8096
   Jelski W, 2020, CANCER MANAG RES, V12, P4789, DOI 10.2147/CMAR.S253369
   Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487
   Joselin AP, 2012, HUM MOL GENET, V21, P4888, DOI 10.1093/hmg/dds325
   Lin MW, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9010037
   Lin Y, 2018, CANCER MED-US, V7, P809, DOI 10.1002/cam4.1325
   Liu H, 2008, BIOCHEM BIOPH RES CO, V375, P477, DOI 10.1016/j.bbrc.2008.08.046
   Maita C, 2008, NEUROSCI LETT, V431, P86, DOI 10.1016/j.neulet.2007.11.027
   Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386
   Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232
   Osellame LD, 2012, BEST PRACT RES CL EN, V26, P711, DOI 10.1016/j.beem.2012.05.003
   Pardo M, 2006, INT J CANCER, V119, P1014, DOI 10.1002/ijc.21942
   Raefsky SM, 2017, FREE RADICAL BIO MED, V102, P203, DOI 10.1016/j.freeradbiomed.2016.11.045
   Raninga PV, 2017, ADV EXP MED BIOL, V1037, P67, DOI 10.1007/978-981-10-6583-5_6
   Sabates-Beliver J, 2007, MOL CANCER RES, V5, P1263, DOI 10.1158/1541-7786.MCR-07-0267
   Sahni S, 2014, J CLIN PATHOL, V67, P656, DOI 10.1136/jclinpath-2014-202356
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Scarffe LA, 2014, TRENDS NEUROSCI, V37, P315, DOI 10.1016/j.tins.2014.03.004
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Stolz A, 2014, NAT CELL BIOL, V16, P495, DOI 10.1038/ncb2979
   Thomas KJ, 2011, HUM MOL GENET, V20, P40, DOI 10.1093/hmg/ddq430
   Tsikitis VL, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-336
   Tsuchiya B, 2012, HISTOPATHOLOGY, V61, P69, DOI 10.1111/j.1365-2559.2012.04202.x
   Vilchez D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6659
   Vogel A, 2017, CANCER TREAT REV, V59, P54, DOI 10.1016/j.ctrv.2017.04.007
   Wang JW, 2020, CANCER MED-US, V9, P361, DOI 10.1002/cam4.2673
   Wang WM, 2020, ONCOL REP, V44, P77, DOI 10.3892/or.2020.7593
   Zheng H, 2018, CANCER MANAG RES, V10, P4615, DOI 10.2147/CMAR.S172008
   Zhou J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0883-4
NR 46
TC 0
Z9 0
U1 2
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD AUG
PY 2021
VL 13
IS 16
AR 4151
DI 10.3390/cancers13164151
PG 18
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA UF8CP
UT WOS:000688796900001
PM 34439303
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Liu, S
   Li, X
   Li, Q
   Liu, HJ
   Shi, YL
   Zhuo, HQ
   Li, CS
   Zhu, HJ
AF Liu, Shuai
   Li, Xin
   Li, Qing
   Liu, Hongjun
   Shi, Yulong
   Zhuo, Hongqing
   Li, Chensheng
   Zhu, Huijuan
TI Silencing Livin improved the sensitivity of colon cancer cells to
   5-fluorouracil by regulating crosstalk between apoptosis and autophagy
SO ONCOLOGY LETTERS
LA English
DT Article
DE apoptosis; autophagy; chemotherapeutic sensitivity; colon cancer; Livin
ID COLORECTAL-CANCER; PROTEIN FAMILY; GENE-EXPRESSION; CHEMOSENSITIVITY;
   PROLIFERATION; RESISTANCE; INHIBITOR; SURVIVAL; IAP; CISPLATIN
AB Colorectal cancer (CRC) is the third most common cause of cancer-associated mortality worldwide. Currently, 5-fluorouracil (5-FU) remains a widely used chemotherapeutic drug in the treatment of CRC; however, 5-FU resistance during treatment has become a common problem. Livin, a member of the inhibitor of apoptosis protein family, is considered to be associated with tumor resistance to chemotherapy. In the present study, Livin-silenced cells were generated by introducing a lentivirus into HCT116 and SW620 colon cancer cell lines. Acridine orange/ethidium bromide staining was used as an indicator of cell death. Western blot analysis was performed to detect protein expression levels, and transmission electron microscopy was used to assess autophagy. The half-maximal inhibitory concentration of 5-FU in colon cancer cells was evaluated using a Cell Counting Kit-8 assay. The results of the present study confirmed that silencing Livin significantly enhanced colon cancer cell death in the presence of 5-FU, increased expression levels of various apoptosis-and autophagyassoci-ated proteins and augmented chemotherapeutic sensitivity to 5-FU. Furthermore, the present study demonstrated that this effect may be reversed when autophagy or apoptosis was inhibited, indicating that apoptosis and autophagy were involved in this process. The protein kinase B signaling pathway and B-cell lymphoma-2 expression levels significantly decreased following Livin knockdown, suggesting they may contribute to the regulation of apoptosis and autophagy crosstalk, which caused the Livin knockdown-induced cell death observed.
C1 [Liu, Shuai; Li, Xin; Li, Qing] Shandong Univ, Shandong Prov Hosp, Dept Urol, Jinan 250012, Shandong, Peoples R China.
   [Li, Qing] Yucheng Peoples Hosp, Dept Urol, Yucheng 251200, Shandong, Peoples R China.
   [Liu, Hongjun; Shi, Yulong; Zhuo, Hongqing; Li, Chensheng] Shandong Univ, Shandong Prov Hosp, Dept Gastrointestinal Surg, 324 Jinan Rd, Jinan 250012, Shandong, Peoples R China.
   [Zhu, Huijuan] Kaifeng Childrens Hosp Henan Prov, Dept Pharm, Intravenous Admixture Serv, Kaifeng 475000, Henan, Peoples R China.
RP Li, CS (corresponding author), Shandong Univ, Shandong Prov Hosp, Dept Gastrointestinal Surg, 324 Jinan Rd, Jinan 250012, Shandong, Peoples R China.
EM chensheng76@163.com
FU Shandong Key Research and Development Project [2014GSF118134,
   2015GSF118055]; Medicine and Healthcare Technology Development Project
   of Shandong Province [2014WS0341]; Natural Science Foundation of
   Shandong ProvinceNatural Science Foundation of Shandong Province
   [BS2010YY060, ZR2014HM111, ZR2014HP105]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [81602227]
FX The present study was supported by the Shandong Key Research and
   Development Project (grant nos. 2014GSF118134 and 2015GSF118055), the
   Medicine and Healthcare Technology Development Project of Shandong
   Province (grant no. 2014WS0341), the Natural Science Foundation of
   Shandong Province (grant nos. BS2010YY060, ZR2014HM111 and ZR2014HP105)
   and the National Natural Science Foundation of China (grant no.
   81602227).
CR An W, 2004, J KOREAN MED SCI, V19, P560, DOI 10.3346/jkms.2004.19.4.560
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Bialik S, 2010, CURR OPIN CELL BIOL, V22, P199, DOI 10.1016/j.ceb.2009.11.004
   Cheng Y, 2011, CANCER RES, V71, P2654, DOI 10.1158/0008-5472.CAN-10-2889
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Ding ZY, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-281
   Ding ZY, 2013, TUMOR BIOL, V34, P683, DOI 10.1007/s13277-012-0596-8
   Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3
   Endo T, 2004, CANCER IMMUNOL IMMUN, V53, P770, DOI 10.1007/s00262-004-0534-8
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019
   Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15
   Grem JL, 2000, INVEST NEW DRUG, V18, P299, DOI 10.1023/A:1006416410198
   Hannun YA, 1997, BLOOD, V89, P1845, DOI 10.1182/blood.V89.6.1845
   He SS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8839
   Hirano Seishiro, 2012, Methods Mol Biol, V926, P87, DOI 10.1007/978-1-62703-002-1_6
   Janes KA, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005966
   Kasibhatla S., 2006, COLD SPRING HARB PRO, V2006, P4493, DOI [10.1101/pdb.prot4493, DOI 10.1101/PDB.PR0T4493]
   Li S, 2017, AM J TRANSL RES, V9, P2065
   Liang SR, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-106
   Liu B, 2007, CANCER LETT, V250, P168, DOI 10.1016/j.canlet.2006.09.024
   Liu M. N., 2016, SCI REP, V5, P6
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Lopes RB, 2007, INT J CANCER, V120, P2344, DOI 10.1002/ijc.22554
   Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908
   Miura K, 2011, SURG TODAY, V41, P175, DOI 10.1007/s00595-010-4390-1
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Myung DS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073262
   Nachmias B, 2004, SEMIN CANCER BIOL, V14, P231, DOI 10.1016/j.semcancer.2004.04.002
   Nakamura Y, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-100
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Overbergh L, 2005, CYTOKINE, V31, P454, DOI 10.1016/j.cyto.2005.07.002
   Pietrocola F, 2016, AUTOPHAGY, V12, P1962, DOI 10.1080/15548627.2016.1214778
   Saunders M, 2006, BRIT J CANCER, V95, P131, DOI 10.1038/sj.bjc.6603233
   Sui XB, 2014, SCI REP-UK, V4, DOI 10.1038/srep04694
   Sui XB, 2011, AUTOPHAGY, V7, P565, DOI 10.4161/auto.7.6.14073
   Wang R, 2008, CANCER GENE THER, V15, P402, DOI 10.1038/cgt.2008.16
   Wang XD, 2010, CLIN BIOCHEM, V43, P655, DOI 10.1016/j.clinbiochem.2010.02.004
   Xi RC, 2011, ONKOLOGIE, V34, P428, DOI 10.1159/000331132
   Yang J, 2015, INT J MOL SCI, V16, P25744, DOI 10.3390/ijms161025744
   Yu JH, 2008, J PHARMACOL SCI, V107, P295, DOI 10.1254/jphs.08091FP
   Zhang HH, 2015, CANCER LETT, V356, P781, DOI 10.1016/j.canlet.2014.10.029
   Zhang JJ, 2011, CANCER-AM CANCER SOC, V117, P86, DOI 10.1002/cncr.25522
   Zhou FF, 2011, FEBS J, V278, P403, DOI 10.1111/j.1742-4658.2010.07965.x
   Zhuang L, 2015, MOL MED REP, V12, P547, DOI 10.3892/mmr.2015.3372
NR 48
TC 7
Z9 10
U1 0
U2 0
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD MAY
PY 2018
VL 15
IS 5
BP 7707
EP 7715
DI 10.3892/ol.2018.8282
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GF3DN
UT WOS:000431825900214
PM 29740490
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Wang, YF
   Lin, KL
   Xu, TC
   Wang, LL
   Fu, LY
   Zhang, GM
   Ai, J
   Jiao, YJ
   Zhu, RR
   Han, XY
   Cai, H
AF Wang, Yongfeng
   Lin, Kaili
   Xu, Tianchun
   Wang, Liuli
   Fu, Liangyin
   Zhang, Guangming
   Ai, Jing
   Jiao, Yajun
   Zhu, Rongrong
   Han, Xiaoyong
   Cai, Hui
TI Development and validation of prognostic model based on the analysis of
   autophagy-related genes in colon cancer
SO AGING-US
LA English
DT Article
DE colon cancer; autophagy; gene signature; prognosis model; immune
   microenvironment
ID COLORECTAL-CANCER; TUMOR PROGRESSION; PROTEIN; PREDICT; ATG101; LNCRNA
AB Background: Autophagy, a process of self-digestion, is closely related to multiple biological processes of colon cancer. This study aimed to construct and evaluate prognostic signature of autophagy-related genes (ARGs) to predict overall survival (OS) in colon cancer patients.
   Materials and Methods: First, a total of 234 ARGs were downloaded via The Cancer Genome Atlas (TCGA) database. Based on the TCGA dataset, differentially expressed ARGs were identified in colon cancer. The univariate and multivariate Cox regression analysis was performed to screen prognostic ARGs to construct the prognostic model. The feasibility of the prognostic model was evaluated using receiver operating characteristic curves and Kaplan-Meier curves. A prognostic model integrating the gene signature with clinical parameters was established with a nomogram.
   Results: We developed an autophagy risk signature based on the 6 ARGs (ULK3, ATG101, MAP1LC3C, TSC1, DAPK1, and SERPINA1). The risk score was positively correlated with poor outcome and could independently predict prognosis. Furthermore, the autophagy-related signature could effectively reflect the levels of immune cell type fractions and indicate an immunosuppressive microenvironment.
   Conclusion: We innovatively identified and validated 6 autophagy-related gene signature that can independently predict prognosis and reflect overall immune response intensity in the colon cancer microenvironment.
C1 [Wang, Yongfeng; Fu, Liangyin; Zhang, Guangming; Ai, Jing; Zhu, Rongrong; Cai, Hui] Univ Chinese Med, Clin Med Coll Gansu 1, Lanzhou 730000, Gansu, Peoples R China.
   [Wang, Yongfeng; Wang, Liuli; Cai, Hui] Gansu Prov Hosp, Gen Surg Clin Med Ctr, Lanzhou 730000, Gansu, Peoples R China.
   [Wang, Liuli] Lanzhou Univ, Clin Med Coll 1, Lanzhou 730000, Gansu, Peoples R China.
   [Lin, Kaili; Jiao, Yajun; Han, Xiaoyong] Ning Xia Med Univ, Grad Sch, Yinchuan 750004, Ning Xia, Peoples R China.
   [Wang, Yongfeng; Cai, Hui] Gansu Prov Hosp, Key Lab Mol Diagnost & Precis Med Surg Oncol Gans, Lanzhou 730000, Gansu, Peoples R China.
   [Xu, Tianchun] Gansu Prov Hosp, Intelligent Med Lab, Lanzhou 730000, Gansu, Peoples R China.
RP Cai, H (corresponding author), Univ Chinese Med, Clin Med Coll Gansu 1, Lanzhou 730000, Gansu, Peoples R China.; Cai, H (corresponding author), Gansu Prov Hosp, Gen Surg Clin Med Ctr, Lanzhou 730000, Gansu, Peoples R China.; Cai, H (corresponding author), Gansu Prov Hosp, Key Lab Mol Diagnost & Precis Med Surg Oncol Gans, Lanzhou 730000, Gansu, Peoples R China.
EM caialonteam@163.com
FU Natural Science Foundation of Gansu Province, China [18JR3RA052];
   Lanzhou Talent Innovation and Entrepreneurship Project Task Contract
   [2016-RC-56]; Gansu Da Vinci robot highend diagnosis and treatment team
   construction project; National Key Research and Development Program
   [2018YFC1311500]; 2021 Graduate Innovation Fund Project of Gansu
   University of Chinese Medicine [2021CX54]
FX This study was supported by Natural Science Foundation of Gansu
   Province, China (No.18JR3RA052), Lanzhou Talent Innovation and
   Entrepreneurship Project Task Contract (No. 2016-RC-56), Gansu Da Vinci
   robot highend diagnosis and treatment team construction project,
   National Key Research and Development Program (No. 2018YFC1311500), and
   2021 Graduate Innovation Fund Project of Gansu University of Chinese
   Medicine, No. 2021CX54.
CR Ashrafizadeh M, 2021, ANTI-CANCER AGENT ME, V21, P679, DOI 10.2174/1871520620666200619180716
   Bian QL, 2019, ONCOL LETT, V18, P5043, DOI 10.3892/ol.2019.10866
   Bonam SR, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051321
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012
   Dong Y, 2020, FRONT GENET, V10, DOI 10.3389/fgene.2019.01284
   Du J, 2017, ACS APPL MATER INTER, V9, P42544, DOI 10.1021/acsami.7b13504
   Du JX, 2020, GENE, V762, DOI 10.1016/j.gene.2020.144974
   Ghareeb Ahmed E, 2018, Asian Pac J Cancer Prev, V19, P1685, DOI 10.22034/APJCP.2018.19.6.1685
   Gozuacik D, 2006, AUTOPHAGY, V2, P74, DOI 10.4161/auto.2.2.2459
   Guo XY, 2021, GASTROENTEROLOGY, V160, P1164, DOI 10.1053/j.gastro.2020.08.062
   Hong WF, 2020, MOL THER-NUCL ACIDS, V22, P937, DOI 10.1016/j.omtn.2020.10.002
   Jiang LC, 2020, ONCOL LETT, V20, DOI 10.3892/ol.2020.12141
   Kwon CH, 2015, ONCOTARGET, V6, P20312, DOI 10.18632/oncotarget.3964
   Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733
   Lee SJ, 2014, ANN SURG ONCOL, V21, pS634, DOI 10.1245/s10434-014-3729-z
   Liang C, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03233-y
   Lin QG, 2020, AGING-US, V12, P1366, DOI 10.18632/aging.102687
   Ljujic M, 2016, Mol Biol (Mosk), V50, P174, DOI 10.7868/S0026898416010122
   Maruyama T, 2018, J ANTIBIOT, V71, P72, DOI 10.1038/ja.2017.104
   Mercer CA, 2009, AUTOPHAGY, V5, P649, DOI 10.4161/auto.5.5.8249
   Nawrocki ST, 2020, CANCERS, V12, DOI 10.3390/cancers12103005
   Nutma E, 2021, J PATHOL, V253, P133, DOI 10.1002/path.5576
   Pasquier B, 2016, CELL MOL LIFE SCI, V73, P985, DOI 10.1007/s00018-015-2104-y
   Sanoff HK, 2008, J CLIN ONCOL, V26, P5721, DOI 10.1200/JCO.2008.17.7147
   Shapira MG, 2014, MOL MED, V20, P417, DOI 10.2119/molmed.2014.00054
   Shawky SA, 2019, MOL BIOL REP, V46, P4063, DOI 10.1007/s11033-019-04856-x
   Shen SP, 2020, CANCER BIOL MED, V17, P555, DOI 10.20892/j.issn.2095-3941.2020.0027
   Shi HJ, 2021, CANCER MED-US, V10, P3794, DOI 10.1002/cam4.3902
   Silva VR, 2020, CANCERS, V12, DOI 10.3390/cancers12113461
   Snyder RA, 2021, JNCI-J NATL CANCER I, V113, P770, DOI 10.1093/jnci/djaa182
   Tariq K, 2016, CANCER BIOL MED, V13, P120, DOI 10.28092/j.issn.2095-3941.2015.0103
   Thongchot S, 2018, MOL CARCINOGEN, V57, P1735, DOI 10.1002/mc.22893
   Wu LP, 2019, CANCER RES, V79, P1413, DOI 10.1158/0008-5472.CAN-18-2049
   Xiao YP, 2015, CANCER DISCOV, V5, P16, DOI 10.1158/2159-8290.CD-14-1397
   Xie YD, 2020, J CLIN INVEST, V130, P2111, DOI 10.1172/JCI133264
   Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111
   Zalckvar E, 2009, AUTOPHAGY, V5, P720, DOI 10.4161/auto.5.5.8625
   Zhang Z, 2021, CELL COMMUN SIGNAL, V19, DOI 10.1186/s12964-021-00721-2
   Zhou M, 2016, ONCOTARGET, V7, P12598, DOI 10.18632/oncotarget.7181
NR 40
TC 1
Z9 1
U1 6
U2 7
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD JUL 31
PY 2021
VL 13
IS 14
BP 19028
EP 19047
PG 20
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA TT4KO
UT WOS:000680319300005
PM 34315829
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Luo, Y
   Yoneda, J
   Ohmori, H
   Sasaki, T
   Shimbo, K
   Eto, S
   Kato, Y
   Miyano, H
   Kobayashi, T
   Sasahira, T
   Chihara, Y
   Kuniyasu, H
AF Luo, Yi
   Yoneda, Junya
   Ohmori, Hitoshi
   Sasaki, Takamitsu
   Shimbo, Kazutaka
   Eto, Sachise
   Kato, Yumiko
   Miyano, Hiroshi
   Kobayashi, Tsuyoshi
   Sasahira, Tomonori
   Chihara, Yoshitomo
   Kuniyasu, Hiroki
TI Cancer Usurps Skeletal Muscle as an Energy Repository
SO CANCER RESEARCH
LA English
DT Article
ID GLYCATION END-PRODUCTS; PYRUVATE-KINASE; AMINO-ACIDS; PROTEIN HMGB1;
   COLON-CANCER; METABOLISM; METASTASIS; AMPHOTERIN; GLUTAMINE; SYSTEM
AB Cancer cells produce energy through aerobic glycolysis, but contributions of host tissues to cancer energy metabolism are unclear. In this study, we aimed to elucidate the cancer-host energy production relationship, in particular, between cancer energy production and host muscle. During the development and progression of colorectal cancer, expression of the secreted autophagy-inducing stress protein HMGB1 increased in the muscle of tumor-bearing animals. This effect was associated with decreased expression of pyruvate kinase PKM1 and pyruvate kinase activity in muscle via the HMGB1 receptor for advanced glycation endproducts (RAGE). However, muscle mitochondrial energy production was maintained. In contrast, HMGB1 addition to colorectal cancer cells increased lactate fermentation. In the muscle, HMGB1 addition induced autophagy by decreasing levels of active mTOR and increasing autophagy-associated proteins, plasma glutamate, and C-13-glutamine incorporation into acetyl-Co Lambda. In a mouse model of colon carcinogenesis, a temporal increase in HMGB1 occurred in serum and colonic mucosa with an increase in autophagy associated with altered plasma free amino acid levels, increased glutamine, and decreased PKM1 levels. These differences were abolished by administration of an HMGB1 neutralizing antibody. Similar results were obtained in a mouse xenograft model of human colorectal cancer. Taken together, our findings suggest that HMGB1 released during tumorigenesis recruits muscle to supply glutamine to cancer cells as an energy source. (C)2013 AACR.
C1 [Luo, Yi; Ohmori, Hitoshi; Sasahira, Tomonori; Chihara, Yoshitomo; Kuniyasu, Hiroki] Nara Med Univ, Dept Mol Pathol, Kashihara, Nara 6348521, Japan.
   [Yoneda, Junya; Shimbo, Kazutaka; Eto, Sachise; Kato, Yumiko; Miyano, Hiroshi; Kobayashi, Tsuyoshi] Ajinomoto Co Inc, Inst Innovat, Kawasaki, Kanagawa, Japan.
   [Sasaki, Takamitsu] Fukuoka Univ, Sch Med, Dept Gastrointestinal Surg, Minami Ku, Fukuoka 81401, Japan.
RP Kuniyasu, H (corresponding author), Nara Med Univ, Dept Mol Pathol, 840 Shijo Cho, Kashihara, Nara 6348521, Japan.
EM cooninh@zb4.so-net.ne.jp
FU Japan Society for the Promotion of ScienceMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science [23659188, 23590430, 24590450]
FX This work was supported in part by Grant-in-Aid for Scientific Research
   from Japan Society for the Promotion of Science (23659188, 23590430, and
   24590450).
CR Bluemlein K, 2012, ONCOTARGET, V3, P1356
   Chihara Y, 2007, PATHOBIOLOGY, V74, P353, DOI 10.1159/000110029
   Choudry HA, 2006, J NUTR, V136, p314S, DOI 10.1093/jn/136.1.314S
   Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667
   Dang CV, 2012, GENE DEV, V26, P877, DOI 10.1101/gad.189365.112
   Dang CV, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.297pe75
   David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697
   DeBerardinis RJ, 2010, ONCOGENE, V29, P313, DOI 10.1038/onc.2009.358
   Delgado MA, 2009, CELL DEATH DIFFER, V16, P976, DOI 10.1038/cdd.2009.40
   Gardella S, 2002, EMBO REP, V3, P995, DOI 10.1093/embo-reports/kvf198
   HAMMER JA, 1981, BIOCHEM J, V198, P53, DOI 10.1042/bj1980053
   Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431
   Ioannou S, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/581837
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kadowaki M, 2003, J NUTR, V133, p2052S, DOI 10.1093/jn/133.6.2052S
   Kamaura M, 2010, CIRC J, V74, P2434, DOI 10.1253/circj.CJ-10-0150
   Kang R, 2010, CELL DEATH DIFFER, V17, P666, DOI 10.1038/cdd.2009.149
   Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038
   Kuniyasu H, 2003, INT J CANCER, V104, P722, DOI 10.1002/ijc.11016
   Kuniyasu H, 2003, ONCOL REP, V10, P445
   Kuniyasu H, 2002, J PATHOL, V196, P163, DOI 10.1002/path.1031
   Kuniyasu H, 2009, CELL PROLIFERAT, V42, P110, DOI 10.1111/j.1365-2184.2008.00577.x
   Lee H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034318
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Luo Y, 2013, EUR J CANCER, V49, P741, DOI 10.1016/j.ejca.2012.09.016
   Mazurek S, 2011, INT J BIOCHEM CELL B, V43, P969, DOI 10.1016/j.biocel.2010.02.005
   Miyagi Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024143
   Morifuji M, 2010, J AGR FOOD CHEM, V58, P8788, DOI 10.1021/jf101912n
   Ohmori H, 2011, EXPERT OPIN THER TAR, V15, P183, DOI 10.1517/14728222.2011.546785
   Ohmori H, 2010, PATHOBIOLOGY, V77, P210, DOI 10.1159/000296305
   Okamoto N, 2009, INT J MED MED SCI, V1, P1
   Okamoto T, 2002, FASEB J, V16, P1928, DOI 10.1096/fj.02-0030fje
   Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858
   Shelton LM, 2010, INT J CANCER, V127, P2478, DOI 10.1002/ijc.25431
   Shimbo K, 2009, RAPID COMMUN MASS SP, V23, P1483, DOI 10.1002/rcm.4026
   Sobin L.H., 2003, UICC TNM CLASSIFICAT, V6th
   Su HB, 2011, TRENDS CARDIOVAS MED, V21, P224, DOI 10.1016/j.tcm.2012.05.015
   Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626
   Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078
   Tisdale MJ, 2005, PHYSIOLOGY, V20, P340, DOI 10.1152/physiol.00019.2005
   Tomitsuka E, 2012, J BIOCHEM, V152, P171, DOI 10.1093/jb/mvs041
   Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504
   Wagenmakers AJM, 1998, EXERCISE SPORT SCI R, V26, P287
   WARBURG O, 1956, SCIENCE, V124, P269
   Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105
   Yang CD, 2009, CANCER RES, V69, P7986, DOI 10.1158/0008-5472.CAN-09-2266
NR 46
TC 73
Z9 77
U1 0
U2 12
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JAN 1
PY 2014
VL 74
IS 1
BP 330
EP 340
DI 10.1158/0008-5472.CAN-13-1052
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 284DZ
UT WOS:000329297600032
PM 24197136
OA Bronze
DA 2022-04-25
ER

PT J
AU Huo, HZ
   Wang, B
   Qin, J
   Guo, SY
   Liu, WY
   Gu, Y
AF Huo, Hai-zhong
   Wang, Bing
   Qin, Jian
   Guo, Shan-yu
   Liu, Wen-yong
   Gu, Yan
TI AMP-activated protein kinase (AMPK)/Ulk1-dependent autophagic pathway
   contributes to C6 ceramide-induced cytotoxic effects in cultured
   colorectal cancer HT-29 cells
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE C6 ceramide; AMPK/Ulk1 pathway; Autophagy; Colorectal cancer
ID COLON-CANCER; INDUCED APOPTOSIS; DRUG-RESISTANCE; UPSTREAM KINASE;
   MELANOMA-CELLS; GROWTH; DEATH; PHOSPHORYLATION; CHEMOTHERAPY; INHIBITION
AB Colorectal cancer is the second leading cause of cancer-related deaths. Drug resistance and/or off-target toxicity against normal cells limit the effectiveness of current chemotherapies for the treatment of colorectal cancer. In the current study, we studied the potential cytotoxic effects of short-chain and cell-permeable C6 ceramide in cultured colorectal cancer HT-29 cells and focused on the underlying mechanisms. We observed that C6 ceramide-induced HT-29 cell death and growth inhibition in a dose-and time-dependent manner. However, no significant apoptosis was observed in C6 ceramide-treated HT-29 cells. Our data support that autophagy contributed to C6 ceramide-induced cytotoxic effects, as autophagy inhibitors, 3-methyladenine (3-MA) and hydroxychloroquine, inhibited C6 ceramide's effect; however, autophagy activators, everolimus (RAD001) and temsirolimus, mimicked C6 ceramide effects and induced HT-29 cell death. Further, we indentified that AMP-activated protein kinase (AMPK)/Ulk1 signaling was required for autophagy induction by C6 ceramide, and AMPK silencing by a specific short hairpin RNA suppressed C6 ceramide-induced autophagy and cytotoxic effects. Reversely, forced activation of AMPK by its activator AICAR or by genetic manipulation caused autophagic death in HT-29 cells, which was inhibited by 3-MA. Our results suggest that autophagy, but not apoptosis, is a major contributor for C6 ceramide-induced cytotoxic effects in HT-29 cells, and activation of AMPK/Ulk1 is required for the process.
C1 [Huo, Hai-zhong; Wang, Bing; Qin, Jian; Guo, Shan-yu; Liu, Wen-yong; Gu, Yan] Shanghai Jiao Tong Univ, Sch Med, Dept Gen Surg, Peoples Hosp 9, Shanghai 200011, Peoples R China.
RP Gu, Y (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Dept Gen Surg, Peoples Hosp 9, 639 Zhizhaoju Rd, Shanghai 200011, Peoples R China.
EM drguyan@hotmail.com
RI Gu, Yan/AFQ-1163-2022
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC)
FX Funding/Support: This study was supported in part by the National
   Natural Science Foundation of China.
CR ABREUMARTIN MT, 1995, J IMMUNOL, V155, P4147
   Alexander A, 2010, P NATL ACAD SCI USA, V107, P4153, DOI 10.1073/pnas.0913860107
   Amaravadi RK, 2007, CLIN CANCER RES, V13, P7271, DOI 10.1158/1078-0432.CCR-07-1595
   Barak A, 2001, INVEST OPHTH VIS SCI, V42, P247
   Bektas M, 2005, ONCOGENE, V24, P178, DOI 10.1038/sj.onc.1208019
   Carling D, 2008, INT J OBESITY, V32, pS55, DOI 10.1038/ijo.2008.124
   Chen A, 2006, ONCOGENE, V25, P278, DOI [10.1038/sj.onc.1209019, 10.1038/sj.onc.1209573]
   Chen CL, 2008, BLOOD, V111, P4365, DOI 10.1182/blood-2007-08-106336
   Chen MB, 2011, J CELL PHYSIOL, V226, P1915, DOI 10.1002/jcp.22522
   Chen MB, 2011, CELL BIOCHEM BIOPHYS, V60, P311, DOI 10.1007/s12013-011-9153-0
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Craighead MW, 1999, J NEUROSCI RES, V57, P236, DOI 10.1002/(SICI)1097-4547(19990715)57:2<236::AID-JNR9>3.0.CO;2-D
   Dimanche-Boitrel MT, 2011, RECENT PAT ANTI-CANC, V6, P284, DOI 10.2174/157489211796957838
   Din FVN, 2012, GASTROENTEROLOGY, V142, P1504, DOI 10.1053/j.gastro.2012.02.050
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   Fillet M, 2003, BIOCHEM PHARMACOL, V65, P1633, DOI 10.1016/S0006-2952(03)00125-4
   Flowers M, 2012, BREAST CANCER RES TR, V133, P447, DOI 10.1007/s10549-011-1768-8
   Gorlick R, 1999, SEMIN ONCOL, V26, P606
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Gustin DM, 2002, CANCER METAST REV, V21, P323, DOI 10.1023/A:1021271229476
   Hardie DG, 2008, MOL CELL, V30, P263, DOI 10.1016/j.molcel.2008.04.012
   Hardie DG, 2012, CHEM BIOL, V19, P1222, DOI 10.1016/j.chembiol.2012.08.019
   Hartfield PJ, 1997, FEBS LETT, V401, P148, DOI 10.1016/S0014-5793(96)01460-3
   Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009
   Hwang JT, 2007, CANCER LETT, V247, P115, DOI 10.1016/j.canlet.2006.03.030
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055
   Jang KY, 2012, CANCER LETT, V319, P197, DOI 10.1016/j.canlet.2012.01.008
   Ji C, 2010, ONCOGENE, V29, P6557, DOI 10.1038/onc.2010.379
   Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027
   Kang MR, 2012, ONCOL REP, V27, P1407, DOI 10.3892/or.2012.1644
   Kefas BA, 2003, J MOL ENDOCRINOL, V30, P151, DOI 10.1677/jme.0.0300151
   Kim HS, 2012, BIOCHEM PHARMACOL, V83, P385, DOI 10.1016/j.bcp.2011.11.008
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Kurinna SM, 2004, CANCER RES, V64, P7852, DOI 10.1158/0008-5472.CAN-04-1552
   Lee JHW, 2009, J HYDRO-ENVIRON RES, V3, P1, DOI 10.1016/j.jher.2009.05.002
   Lee YK, 2010, CANCER LETT, V292, P228, DOI 10.1016/j.canlet.2009.12.005
   Lemos C, 2013, CURR PHARM DESIGN, V19, P841, DOI 10.2174/138161213804547277
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Lin CF, 2006, CURR MED CHEM, V13, P1609, DOI 10.2174/092986706777441986
   Longley DB, 2006, BBA-REV CANCER, V1766, P184, DOI 10.1016/j.bbcan.2006.08.001
   Mao CG, 2008, BBA-MOL CELL BIOL L, V1781, P424, DOI 10.1016/j.bbalip.2008.06.002
   Martin D, 2002, J BIOL CHEM, V277, P42943, DOI 10.1074/jbc.M201070200
   Meisse D, 2002, FEBS LETT, V526, P38, DOI 10.1016/S0014-5793(02)03110-1
   Mohandas K M, 1999, Indian J Gastroenterol, V18, P118
   Nagalingam A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3128
   Ponnusamy S, 2010, FUTURE ONCOL, V6, P1603, DOI 10.2217/FON.10.116
   Rocha GZ, 2011, CLIN CANCER RES, V17, P3993, DOI 10.1158/1078-0432.CCR-10-2243
   Rosenfeldt MT, 2011, CARCINOGENESIS, V32, P955, DOI 10.1093/carcin/bgr031
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Shang LB, 2011, P NATL ACAD SCI USA, V108, P4788, DOI 10.1073/pnas.1100844108
   Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100
   Sun H, 2011, CANCER LETT, V310, P118, DOI 10.1016/j.canlet.2011.06.010
   Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499
   Vaculova A, 2002, ANTICANCER RES, V22, P1635
   Weeks JC, 2012, NEW ENGL J MED, V367, P1616, DOI 10.1056/NEJMoa1204410
   Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031
   Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005
   Zhang WB, 2010, J BIOL CHEM, V285, P40461, DOI 10.1074/jbc.M110.164046
   Zheng QY, 2012, BIOCHEM BIOPH RES CO, V419, P741, DOI 10.1016/j.bbrc.2012.02.093
NR 61
TC 24
Z9 25
U1 0
U2 13
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300-8177
EI 1573-4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD JUN
PY 2013
VL 378
IS 1-2
BP 171
EP 181
DI 10.1007/s11010-013-1608-8
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 134BG
UT WOS:000318184100019
PM 23508272
DA 2022-04-25
ER

PT J
AU Ren, SX
   Shen, J
   Cheng, ASL
   Lu, L
   Chan, RLY
   Li, ZJ
   Wang, XJ
   Wong, CCM
   Zhang, L
   Ng, SSM
   Chan, FL
   Chan, FKL
   Yu, J
   Sung, JJY
   Wu, WKK
   Cho, CH
AF Ren, Shun X.
   Shen, Jin
   Cheng, Alfred S. L.
   Lu, Lan
   Chan, Ruby L. Y.
   Li, Zhi J.
   Wang, Xiao J.
   Wong, Clover C. M.
   Zhang, Lin
   Ng, Simon S. M.
   Chan, Franky L.
   Chan, Francis K. L.
   Yu, Jun
   Sung, Joseph J. Y.
   Wu, William K. K.
   Cho, Chi H.
TI FK-16 Derived from the Anticancer Peptide LL-37 Induces
   Caspase-Independent Apoptosis and Autophagic Cell Death in Colon Cancer
   Cells
SO PLOS ONE
LA English
DT Article
ID HUMAN ANTIMICROBIAL PEPTIDE; TUMOR-SUPPRESSOR; GLIOMA-CELLS; P53;
   CARCINOMA; BAX; INHIBITION; EXPRESSION; BILAYERS; MICELLES
AB Host immune peptides, including cathelicidins, have been reported to possess anticancer properties. We previously reported that LL-37, the only cathelicidin in humans, suppresses the development of colon cancer. In this study, the potential anticancer effect of FK-16, a fragment of LL-37 corresponding to residues 17 to 32, on cultured colon cancer cells was evaluated. FK-16 induced a unique pattern of cell death, marked by concurrent activation of caspase-independent apoptosis and autophagy. The former was mediated by the nuclear translocation of AIF and EndoG whereas the latter was characterized by enhanced expression of LC3-I/II, Atg5 and Atg7 and increased formation of LC3-positive autophagosomes. Knockdown of Atg5 or Atg7 attenuated the cytotoxicity of FK-16, indicating FK-16-induced autophagy was pro-death in nature. Mechanistically, FK-16 activated nuclear p53 to upregulate Bax and downregulate Bcl-2. Knockdown of p53, genetic ablation of Bax, or overexpression of Bcl-2 reversed FK-16-induced apoptosis and autophagy. Importantly, abolition of AIF/EndoG-dependent apoptosis enhanced FK-16-induced autophagy while abolition of autophagy augmented FK-16-induced AIF2/EndoG-dependent apoptosis. Collectively, FK-16 induces caspase-independent apoptosis and autophagy through the common p53-Bcl-2/Bax cascade in colon cancer cells. Our study also uncovered previously unknown reciprocal regulation between these two cell death pathways.
C1 [Ren, Shun X.; Shen, Jin; Lu, Lan; Chan, Ruby L. Y.; Li, Zhi J.; Wong, Clover C. M.; Zhang, Lin; Chan, Franky L.; Cho, Chi H.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China.
   [Cheng, Alfred S. L.; Wang, Xiao J.; Chan, Francis K. L.; Yu, Jun; Sung, Joseph J. Y.; Wu, William K. K.] Chinese Univ Hong Kong, Inst Digest Dis, Li Ka Shing Inst Hlth, Hong Kong, Hong Kong, Peoples R China.
   [Cheng, Alfred S. L.; Wang, Xiao J.; Chan, Francis K. L.; Yu, Jun; Sung, Joseph J. Y.; Wu, William K. K.] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China.
   [Ng, Simon S. M.] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China.
RP Wu, WKK (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Li Ka Shing Inst Hlth, Hong Kong, Hong Kong, Peoples R China.
EM wukakei@cuhk.edu.hk
RI Sung, Joseph J. Y./R-3203-2018; Chan, Franky L./M-1043-2018; Ng, Simon
   S. M./M-1219-2018; Cho, Chi Hin/C-6543-2014; ZHANG, Lin/O-9109-2015; Wu,
   William K.K./A-3277-2009; Yu, Jun/D-8569-2015; Chan, Francis K.
   L./F-4851-2010; Cheng, Alfred SL/C-3327-2014
OI Sung, Joseph J. Y./0000-0003-3125-5199; Chan, Franky
   L./0000-0003-0567-2052; Ng, Simon S. M./0000-0002-5389-9297; Cho, Chi
   Hin/0000-0002-7658-3260; ZHANG, Lin/0000-0003-1634-3780; Wu, William
   K.K./0000-0002-5662-5240; Yu, Jun/0000-0001-5008-2153; Chan, Francis K.
   L./0000-0001-7388-2436; Cheng, Alfred SL/0000-0003-2345-6951
CR Braff MH, 2006, CURR TOP MICROBIOL, V306, P91
   Durr UHN, 2006, BBA-BIOMEMBRANES, V1758, P1408, DOI 10.1016/j.bbamem.2006.03.030
   Eimer S, 2011, CANCER BIOL THER, V11, P1017, DOI 10.4161/cbt.11.12.15693
   Galluzzi L, 2008, CELL DEATH DIFFER, V15, P1113, DOI 10.1038/cdd.2008.28
   Henzler-Wildman KA, 2004, BIOCHEMISTRY-US, V43, P8459, DOI 10.1021/bi036284s
   Hoskin DW, 2008, BBA-BIOMEMBRANES, V1778, P357, DOI 10.1016/j.bbamem.2007.11.008
   Johansson J, 1998, J BIOL CHEM, V273, P3718, DOI 10.1074/jbc.273.6.3718
   Kaminskyy VO, 2012, AUTOPHAGY, V8, P1032, DOI 10.4161/auto.20123
   Kim EH, 2007, CANCER RES, V67, P6314, DOI 10.1158/0008-5472.CAN-06-4217
   Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545
   Lee JH, 2010, CANCER LETT, V290, P68, DOI 10.1016/j.canlet.2009.08.027
   Lehmann J, 2006, EUR UROL, V50, P141, DOI 10.1016/j.eururo.2005.12.043
   Levine B, 2008, NAT CELL BIOL, V10, P637, DOI 10.1038/ncb0608-637
   Li X, 2006, J AM CHEM SOC, V128, P5776, DOI 10.1021/ja0584875
   Lorin S, 2010, AUTOPHAGY, V6, P153, DOI 10.4161/auto.6.1.10537
   Mader JS, 2009, MOL CANCER RES, V7, P689, DOI 10.1158/1541-7786.MCR-08-0274
   Mader JS, 2005, MOL CANCER THER, V4, P612, DOI 10.1158/1535-7163.MCT-04-0077
   Melo MN, 2009, NAT REV MICROBIOL, V7, P245, DOI 10.1038/nrmicro2095
   Menendez D, 2009, NAT REV CANCER, V9, P724, DOI 10.1038/nrc2730
   MIYASHITA T, 1994, ONCOGENE, V9, P1799
   Mookherjee N, 2006, J IMMUNOL, V176, P2455, DOI 10.4049/jimmunol.176.4.2455
   Moon JY, 2006, BBA-BIOMEMBRANES, V1758, P1351, DOI 10.1016/j.bbamem.2006.02.003
   Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3
   Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587
   Porcelli F, 2008, BIOCHEMISTRY-US, V47, P5565, DOI 10.1021/bi702036s
   Qiao L, 2009, DRUG RESIST UPDATE, V12, P55, DOI 10.1016/j.drup.2009.02.002
   Ramamoorthy A, 2008, J AM CHEM SOC, V130, P11023, DOI 10.1021/ja802210u
   Rashmi R, 2008, ONCOGENE, V27, P1366, DOI 10.1038/sj.onc.1210783
   Ren SX, 2012, CANCER RES, V72, P6512, DOI 10.1158/0008-5472.CAN-12-2359
   Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948
   Salzman NH, 2003, NATURE, V422, P522, DOI 10.1038/nature01520
   Schroder-Borm H, 2005, FEBS LETT, V579, P6128, DOI 10.1016/j.febslet.2005.09.084
   Shen SS, 2012, AUTOPHAGY, V8, P1, DOI 10.4161/auto.8.1.16618
   Song KS, 2008, AUTOPHAGY, V4, P650, DOI 10.4161/auto.6057
   Steiger-Barraissoul S, 2009, APOPTOSIS, V14, P1274, DOI 10.1007/s10495-009-0396-9
   Strauss G, 2008, CELL DEATH DIFFER, V15, P332, DOI 10.1038/sj.cdd.4402272
   Sun CQ, 2006, CANCER RES, V66, P8542, DOI 10.1158/0008-5472.CAN-06-0294
   Thennarasu S, 2010, BIOPHYS J, V98, P248, DOI 10.1016/j.bpj.2009.09.060
   Turcotte S, 2008, CANCER CELL, V14, P90, DOI 10.1016/j.ccr.2008.06.004
   Wang GS, 2008, J BIOL CHEM, V283, P32637, DOI 10.1074/jbc.M805533200
   Wang GS, 2009, NUCLEIC ACIDS RES, V37, pD933, DOI 10.1093/nar/gkn823
   Wang W, 2008, CURR OPIN ONCOL, V20, P90, DOI 10.1097/CCO.0b013e3282f31d6f
   Wildman KAH, 2003, BIOCHEMISTRY-US, V42, P6545, DOI 10.1021/bi0273563
   Wu WKK, 2012, ONCOGENE, V31, P939, DOI 10.1038/onc.2011.295
   Wu WKK, 2010, INT J CANCER, V127, P1741, DOI 10.1002/ijc.25489
   Wu WKK, 2010, J CELL PHYSIOL, V223, P178, DOI 10.1002/jcp.22026
   Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989
   Zheng F, 2012, FREE RADICAL RES, V46, P740, DOI 10.3109/10715762.2012.670701
NR 48
TC 59
Z9 64
U1 2
U2 42
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 20
PY 2013
VL 8
IS 6
AR e63641
DI 10.1371/journal.pone.0063641
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 158JQ
UT WOS:000319966400025
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Koustas, E
   Papavassiliou, AG
   Karamouzis, MV
AF Koustas, Evangelos
   Papavassiliou, Athanasios G.
   Karamouzis, Michalis V.
TI The role of autophagy in the treatment of BRAF mutant colorectal
   carcinomas differs based on microsatellite instability status
SO PLOS ONE
LA English
DT Article
ID GROWTH-FACTOR RECEPTOR; COLON-CANCER; INHIBITORS; EGFR; PD-L1;
   TUMORIGENESIS; LYMPHOCYTES; COMBINATION; ACTIVATION; EXPRESSION
AB Autophagy has been identified as a catabolic mechanism in cells but its' role in cancer remains controversial. Autophagy has been characterized either as tumor suppressor or inducer mechanism in many tumor types. Monoclonal antibodies against EGFR (cetuximab and panitumumab) represent a major step in the treatment of mCRC. Several studies propose that cetuximab and panitumumab trigger autophagy which reveals a potential resistance mechanism to these agents. The last years immunotherapy appears to be a novel promising strategy for the treatment of patients with solid tumors, including colorectal cancer. Checkpoint inhibitors, such as anti-PD1 (nivolumab and pembrolizumab) and antiCTLA-4 (ipilimumab) antibodies have already been developed and applied in mCRC patients with MSI-H phenotype. The association between mtBRAF and autophagy or MSI status has already been characterized. In our study, we identify the autophagy initiation through anti-EGFR monoclonal antibodies and checkpoint inhibitors in colorectal carcinoma cell lines according to microsatellite status. The combination of autophagy inhibition, anti-EGFR antibodies and checkpoint inhibitors as well as autophagy targeting, MEK inhibition and anti-EGFR antibodies or checkpoint inhibitors appears to be the best treatment approach for microsatellite instability high and stable colorectal cancer cell lines, respectively. Both combinatorial approaches reduce cell viability through the induction of apoptotic cell death. The findings of this study point out the importance of different approach for the treatment of BRAF mutant metastatic colorectal cancers based on their microsatelite instability phenotype.
C1 [Koustas, Evangelos; Papavassiliou, Athanasios G.; Karamouzis, Michalis V.] Univ Athens, Sch Med, Dept Biol Chem, Mol Oncol Unit, Athens, Greece.
   [Karamouzis, Michalis V.] Univ Athens, Sch Med, Laiko Gen Hosp, Dept Internal Med 1, Athens, Greece.
RP Karamouzis, MV (corresponding author), Univ Athens, Sch Med, Dept Biol Chem, Mol Oncol Unit, Athens, Greece.; Karamouzis, MV (corresponding author), Univ Athens, Sch Med, Laiko Gen Hosp, Dept Internal Med 1, Athens, Greece.
EM mkaramouz@med.uoa.gr
RI Koustas, Evangelos/ABE-9336-2020; Karamouzis, Michalis/AAD-2860-2020
OI Karamouzis, Michalis/0000-0003-1369-8201
FU Hellenic Foundation for Research and Innovation (HFRI); General
   Secretariat for Research and Technology (GSRT), under the HFRI PhD
   Fellowship [GA. 665 (14482)]; Institute of Molecular Medicine and
   Biomedical Research
FX The research work was supported by the Hellenic Foundation for Research
   and Innovation (HFRI) and the General Secretariat for Research and
   Technology (GSRT), under the HFRI PhD Fellowship grant [GA. 665 (14482)]
   (to EK) and Institute of Molecular Medicine and Biomedical Research (to
   MVK). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Bendell JC, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3502
   Boland PM, 2017, CANCERS, V9, DOI 10.3390/cancers9050050
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Coker-Gurkan A, 2014, EXP CELL RES, V328, P87, DOI 10.1016/j.yexcr.2014.07.022
   Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139
   Gatalica Z, 2014, CANCER EPIDEM BIOMAR, V23, P2965, DOI 10.1158/1055-9965.EPI-14-0654
   Goulielmaki M, 2016, ONCOTARGET, V7, P9188, DOI 10.18632/oncotarget.6942
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Hinoue T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008357
   Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269
   Jutten B, 2014, CELL CYCLE, V13, P42, DOI 10.4161/cc.27518
   Karamouzis MV, 2007, JAMA-J AM MED ASSOC, V298, P70, DOI 10.1001/jama.298.1.70
   Koustas E, 2017, CANCER LETT, V396, P94, DOI 10.1016/j.canlet.2017.03.023
   Levy JMM, 2014, CANCER DISCOV, V4, P773, DOI 10.1158/2159-8290.CD-14-0049
   Li WQ, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-2
   Liu L, 2015, CLIN CANCER RES, V21, P1639, DOI 10.1158/1078-0432.CCR-14-2339
   Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863
   Loi S, 2016, CLIN CANCER RES, V22, P1499, DOI 10.1158/1078-0432.CCR-15-1125
   Manic G, 2014, MOL CELL ONCOL, V1, DOI 10.4161/mco.29911
   Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Moreau K, 2010, CURR OPIN CELL BIOL, V22, P206, DOI 10.1016/j.ceb.2009.12.002
   Oikonomou E, 2014, ONCOTARGET, V5, P11752, DOI 10.18632/oncotarget.2555
   Pasquier B, 2016, CELL MOL LIFE SCI, V73, P985, DOI 10.1007/s00018-015-2104-y
   Passardi A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061324
   Pauken KE, 2015, TRENDS IMMUNOL, V36, P265, DOI 10.1016/j.it.2015.02.008
   Pietrantonio F, 2015, EUR J CANCER, V51, P587, DOI 10.1016/j.ejca.2015.01.054
   Poklepovic A, 2014, AUTOPHAGY, V10, P1478, DOI 10.4161/auto.29428
   Punt CJA, 2017, NAT REV CLIN ONCOL, V14, P235, DOI 10.1038/nrclinonc.2016.171
   Qiu M, 2015, ONCOTARGET, V6, P1, DOI [10.18632/oncotarget.3147, DOI 10.18632/ONCOTARGET.3147]
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Quinn E, 2003, EUR J CANCER, V39, P469, DOI 10.1016/S0959-8049(02)00633-0
   Rampazzo E, 2010, BRIT J CANCER, V102, P1300, DOI 10.1038/sj.bjc.6605644
   Rangwala R, 2014, AUTOPHAGY, V10, P1369, DOI 10.4161/auto.29118
   Riihimaki M, 2016, SCI REP-UK, V6, DOI 10.1038/srep29765
   Robainas M, 2017, ONCOTARGETS THER, V10, P1803, DOI 10.2147/OTT.S132508
   Rowland A, 2015, BRIT J CANCER, V112, P1888, DOI 10.1038/bjc.2015.173
   Said EA, 2010, NAT MED, V16, P452, DOI 10.1038/nm.2106
   Saridaki Z, 2010, BRIT J CANCER, V102, P1762, DOI 10.1038/sj.bjc.6605694
   Sena P, 2015, ONCOL REP, V34, P3222, DOI 10.3892/or.2015.4326
   Sforza V, 2016, WORLD J GASTROENTERO, V22, P6345, DOI 10.3748/wjg.v22.i28.6345
   Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498
   Strohecker AM, 2014, AUTOPHAGY, V10, P384, DOI 10.4161/auto.27320
   Thiel A, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00281
   Vedeld HM, 2017, INT J CANCER, V141, P967, DOI 10.1002/ijc.30796
   Wang X, 2016, ONCOTARGETS THER, V9, P5023, DOI 10.2147/OTT.S105862
   Yang X, 2015, CELL BIOSCI, V5, DOI 10.1186/s13578-015-0005-2
   Yazdi Mohammad Hossein, 2015, Avicenna Journal of Medical Biotechnology, V7, P134
NR 49
TC 13
Z9 13
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 14
PY 2018
VL 13
IS 11
AR e0207227
DI 10.1371/journal.pone.0207227
PG 23
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HA3GQ
UT WOS:000450138500079
PM 30427914
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Selvakumaran, M
   Amaravadi, RK
   Vasilevskaya, IA
   O'Dwyer, PJ
AF Selvakumaran, Muthu
   Amaravadi, Ravi K.
   Vasilevskaya, Irina A.
   O'Dwyer, Peter J.
TI Autophagy Inhibition Sensitizes Colon Cancer Cells to Antiangiogenic and
   Cytotoxic Therapy
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID HYPOXIA-INDUCED AUTOPHAGY; HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER;
   FLUOROURACIL; BEVACIZUMAB; LEUCOVORIN; BNIP3; ANGIOGENESIS; OXALIPLATIN;
   IRINOTECAN
AB Purpose: Autophagy is a critical survival pathway for cancer cells under conditions of nutrient or oxygen limitation, or cell stress. As a consequence of antiangiogenic therapy, solid tumors encounter hypoxia induction and imbalances in nutrient supply. We wished to determine the role of autophagy in protection of tumor cells from the effects of antiangiogenic therapy and chemotherapy. We examined the effect of inhibiting autophagy on hypoxic colon cancer cells in vitro and on bevacizumab- and oxaliplatin-treated mouse xenografts in vivo.
   Experimental Design: The autophagic response to hypoxia and DNA-damaging agents was assessed by fluorescent microscopic imaging, autophagy-related gene expression, and by electron microscopic ultrastructural analysis. Pharmacologic and molecular approaches to autophagy inhibition were taken in a panel of colon cancer cell lines. Mouse xenograft models were treated with combinations of oxaliplatin, bevacizumab, and chloroquine to assess effects on tumor growth reduction and on pharmacodynamic markers of autophagy inhibition.
   Results: Autophagy was induced in colon cancer models by exposure to both hypoxia and oxaliplatin. Inhibition of autophagy, either with chloroquine or by downregulation of beclin1 or of ATG5, enhanced sensitivity to oxaliplatin under normal and hypoxic conditions in a synergistic manner. Both bevacizumab and oxaliplatin treatments activate autophagy in HT29 murine xenografts. The addition of chloroquine to bevacizumab- based treatment provided greater tumor control in concert with evidence of autophagy inhibition.
   Conclusions: These findings implicate autophagy as a mechanism of resistance to antiangiogenic therapies and support investigation of inhibitory approaches in the management of this disease. (C) 2013 AACR.
C1 [Selvakumaran, Muthu; Amaravadi, Ravi K.; Vasilevskaya, Irina A.; O'Dwyer, Peter J.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19014 USA.
RP O'Dwyer, PJ (corresponding author), Univ Penn, 16 Penn Tower,3400 Spruce St, Philadelphia, PA 19014 USA.
EM peter.odwyer@uphs.upenn.edu
FU National Cancer Institute (NCI)/NIH/Department of Health and Human
   Services (DHHS) [CA49820, CA158377]; NATIONAL CANCER INSTITUTEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA049820,
   R01CA158377] Funding Source: NIH RePORTER
FX This work is supported in part by CA49820 and CA158377 from National
   Cancer Institute (NCI)/NIH/Department of Health and Human Services
   (DHHS).
CR Amaravadi RK, 2007, CLIN CANCER RES, V13, P7271, DOI 10.1158/1078-0432.CCR-07-1595
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Azad MB, 2008, AUTOPHAGY, V4, P195, DOI 10.4161/auto.5278
   Bacon AL, 2007, ONCOGENE, V26, P132, DOI 10.1038/sj.onc.1209761
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Cao D, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-432
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Dikov DI, 2007, AM J CLIN PATHOL, V127, P792, DOI 10.1309/URPQC0KYE97WG111
   Du JH, 2012, AM J PHYSIOL-CELL PH, V302, pC383, DOI 10.1152/ajpcell.00164.2011
   Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021
   Esumi H, 2002, J BIOL CHEM, V277, P32791, DOI 10.1074/jbc.M112270200
   Frezza C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024411
   Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305
   Goel S, 2011, PHYSIOL REV, V91, P1071, DOI 10.1152/physrev.00038.2010
   Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046
   Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0
   Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Lee SJ, 2011, AUTOPHAGY, V7, P829, DOI 10.4161/auto.7.8.15598
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Martin N, 2007, COMPUSYN SOFTWARE DR
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Matsumoto S, 2011, CANCER RES, V71, P6350, DOI 10.1158/0008-5472.CAN-11-2025
   Mazure NM, 2009, AUTOPHAGY, V5, P868, DOI 10.4161/auto.9042
   Murai M, 2005, CLIN CANCER RES, V11, P1021
   Nakatogawa H, 2007, CELL, V130, P165, DOI 10.1016/j.cell.2007.05.021
   Nakatogawa H, 2009, NAT REV MOL CELL BIO, V10, P458, DOI 10.1038/nrm2708
   Rakitina TV, 2007, BIOCHEM PHARMACOL, V73, P1715, DOI 10.1016/j.bcp.2007.01.037
   Ramakrishnan S, 2007, AUTOPHAGY, V3, P512
   Reynolds TY, 1996, CANCER RES, V56, P5754
   Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027
   Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302
   Selvakumaran M, 2008, BIOCHEM PHARMACOL, V75, P627, DOI 10.1016/j.bcp.2007.09.029
   Shi YH, 2011, AUTOPHAGY, V7, P1159, DOI 10.4161/auto.7.10.16818
   Song JR, 2009, AUTOPHAGY, V5, P1131, DOI 10.4161/auto.5.8.9996
   Sorensen AG, 2012, CANCER RES, V72, P402, DOI 10.1158/0008-5472.CAN-11-2464
   Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817
   Vasilevskaya IA, 2008, MOL PHARMACOL, V74, P246, DOI 10.1124/mol.107.044644
   VAUPEL P, 1989, CANCER RES, V49, P6449
   Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yao K, 2005, BRIT J CANCER, V93, P1356, DOI 10.1038/sj.bjc.6602864
   Yoo YG, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002072
   Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200
NR 50
TC 135
Z9 144
U1 4
U2 31
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUN 1
PY 2013
VL 19
IS 11
BP 2995
EP 3007
DI 10.1158/1078-0432.CCR-12-1542
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 155FF
UT WOS:000319732000024
PM 23461901
DA 2022-04-25
ER

PT J
AU Raina, K
   Agarwal, C
   Wadhwa, R
   Serkova, NJ
   Agarwal, R
AF Raina, Komal
   Agarwal, Chapla
   Wadhwa, Ritambhara
   Serkova, Natalie J.
   Agarwal, Rajesh
TI Energy deprivation by silibinin in colorectal cancer cells A
   double-edged sword targeting both apoptotic and autophagic machineries
SO AUTOPHAGY
LA English
DT Article
DE colorectal cancer; silibinin; autophagy; oxidative stress; energy
   restrictions
ID ACTIVATED PROTEIN-KINASE; MONITORING AUTOPHAGY; CHEMOPREVENTIVE AGENT;
   ELECTRON-MICROSCOPY; SUPPRESSES GROWTH; MAMMALIAN-CELLS; CULTURED-CELLS;
   COLON-CANCER; HT-29 CELLS; DEATH
AB Small molecules with the potential to initiate different types of programmed cell death could be useful adjunct therapy' where current anticancer modalities fail to generate significant activity due to a defective apoptotic machinery or resistance of cancer cells to the specific death mechanism induced by that treatment. The current study identified silibinin, for the first time, as one such natural agent, having dual efficacy against colorectal cancer (CRC) cells. First, silibinin rapidly induced oxidative stress in CRC SW480 cells due to reactive oxygen species (ROS) generation with a concomitant dissipation of mitchondrial potential ((m)) and cytochrome c release leading to mild apoptosis as a biological effect. However, with increased exposure to silibinin, cytoplasmic vacuolization intensified within the cells followed by sequestration of the organelles, which inhibits the further release of cytochrome c. Interestingly, this decrease in apoptotic response correlated with increased autophagic events as evidenced by tracking the dynamics of LC3-II within the cells. Mechanistic studies revealed that silibinin strongly inhibited PIK3CA-AKT-MTOR but activated MAP2K1/2-MAPK1/3 pathways for its biological effects. Corroborating these effects, endoplasmic reticulum stress was generated and glucose uptake inhibition as well as energy restriction were induced by silibinin, thus, mimicking starvation-like conditions. Further, the cellular damage to tumor cells by silibinin was severe and irreparable due to sustained interference in essential cellular processes such as mitochondrial metabolism, phospholipid and protein synthesis, suggesting that silibinin harbors a deadly double-edged sword' against CRC cells thereby further advocating its clinical effectiveness against this malignancy.
C1 [Raina, Komal; Agarwal, Chapla; Wadhwa, Ritambhara; Agarwal, Rajesh] Univ Colorado, Dept Pharmacal Sci, Skaggs Sch Pharm, Aurora, CO 80045 USA.
   [Serkova, Natalie J.] Univ Colorado, Dept Anesthesiol & Radiol, Aurora, CO USA.
   [Agarwal, Chapla; Serkova, Natalie J.; Agarwal, Rajesh] Univ Colorado, Ctr Canc, Aurora, CO USA.
RP Agarwal, R (corresponding author), Univ Colorado, Dept Pharmacal Sci, Skaggs Sch Pharm, Anschutz Med Campus, Aurora, CO 80045 USA.
EM rajesh.agarwal@ucdenver.edu
FU University of Colorado Cancer Center [CA046934]; Colorado Clinical and
   Translational Sciences Institute [RR025780]; RO1 grant [CA112304];
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R01CA112304, P30CA046934] Funding Source: NIH RePORTER;
   NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Research Resources (NCRR) [UL1RR025780] Funding Source: NIH
   RePORTER
FX Supported by RO1 grant CA112304, University of Colorado Cancer Center
   P30 grant CA046934, and Colorado Clinical and Translational Sciences
   Institute UL1 award RR025780.
CR Agarwal C, 2003, ONCOGENE, V22, P8271, DOI 10.1038/sj.onc.1207158
   American Cancer Society, CANC FACTS FIG 2012
   Asghar U, 2010, CLIN COLORECTAL CANC, V9, P274, DOI 10.3816/CCC.2010.n.040
   Bampton ETW, 2005, AUTOPHAGY, V1, P23, DOI 10.4161/auto.1.1.1495
   Chau I, 2006, ANN ONCOL, V17, P1347, DOI 10.1093/annonc/mdl029
   Day BJ, 1999, FREE RADICAL BIO MED, V26, P730, DOI 10.1016/S0891-5849(98)00261-5
   Denkert C, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-72
   Desai BN, 2002, P NATL ACAD SCI USA, V99, P4319, DOI 10.1073/pnas.261702698
   Eskelinen EL, 2008, AUTOPHAGY, V4, P257, DOI 10.4161/auto.5179
   Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222
   Griffin JL, 2004, NAT REV CANCER, V4, P551, DOI 10.1038/nrc1390
   Griffin JL, 2007, J PROTEOME RES, V6, P498, DOI 10.1021/pr060464h
   Gu M, 2010, MOL CARCINOGEN, V49, P1, DOI 10.1002/mc.20560
   Hail N, 2008, FREE RADICAL BIO MED, V44, P1382, DOI 10.1016/j.freeradbiomed.2007.12.034
   Haller AA, 1997, P NATL ACAD SCI USA, V94, P8521, DOI 10.1073/pnas.94.16.8521
   Hoh C, 2006, CLIN CANCER RES, V12, P2944, DOI 10.1158/1078-0432.CCR-05-2724
   Hoyer-Hansen M, 2005, CELL DEATH DIFFER, V12, P1297, DOI 10.1038/sj.cdd.4401651
   Javvadi P, 2008, MOL PHARMACOL, V73, P1491, DOI 10.1124/mol.107.043554
   Jiang WQ, 2008, CANCER RES, V68, P5492, DOI 10.1158/0008-5472.CAN-07-6721
   Kaur M, 2010, NEOPLASIA, V12, P415, DOI 10.1593/neo.10188
   Kaur M, 2009, MOL CANCER THER, V8, P2366, DOI 10.1158/1535-7163.MCT-09-0304
   Kimura S, 2009, METHOD ENZYMOL, V452, P1, DOI 10.1016/S0076-6879(08)03601-X
   Klawitter J, 2009, BRIT J CANCER, V100, P923, DOI 10.1038/sj.bjc.6604946
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Kondo Y, 2006, AUTOPHAGY, V2, P85, DOI 10.4161/auto.2.2.2463
   Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Lin X, 2007, BIOCHEM J, V406, P215, DOI 10.1042/BJ20070186
   McCubrey JA, 2006, ANTIOXID REDOX SIGN, V8, P1775, DOI 10.1089/ars.2006.8.1775
   Meley D, 2006, J BIOL CHEM, V281, P34870, DOI 10.1074/jbc.M605488200
   Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Munafo DB, 2001, J CELL SCI, V114, P3619
   Negre-Salvayre A, 2002, METHOD ENZYMOL, V352, P62
   Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200
   Pyronnet S, 2001, GENE DEV, V15, P2083, DOI 10.1101/gad.889201
   Raina K, 2009, CANCER RES, V69, P3731, DOI 10.1158/0008-5472.CAN-09-0096
   Rajamanickam S, 2010, CANCER RES, V70, P2368, DOI 10.1158/0008-5472.CAN-09-3249
   Rajamanickam S, 2009, PHARM RES-DORDR, V26, P2558, DOI 10.1007/s11095-009-9968-1
   Ravichandran K, 2010, CLIN CANCER RES, V16, P4595, DOI 10.1158/1078-0432.CCR-10-1213
   Reggiori F, 2005, CURR OPIN CELL BIOL, V17, P415, DOI 10.1016/j.ceb.2005.06.007
   Serkova NJ, 2007, CURR OPIN MOL THER, V9, P572
   Serkova NJ, 2006, EXPERT REV MOL DIAGN, V6, P717, DOI 10.1586/14737159.6.5.717
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Singh RP, 2008, CANCER RES, V68, P2043, DOI 10.1158/0008-5472.CAN-07-6247
   Thorburn A, 2008, APOPTOSIS, V13, P1, DOI 10.1007/s10495-007-0154-9
   Tyagi A, 2003, ONCOGENE, V22, P1302, DOI 10.1038/sj.onc.1206265
   Velmurugan B, 2010, PHARM RES-DORDR, V27, P2085, DOI 10.1007/s11095-010-0207-6
   Verfaillie T., 2010, INT J CELL BIOL, V2010, P930509, DOI [DOI 10.1155/2010/930509, 10.1155/2010/930509]
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   Wang HL, 2010, FUTURE ONCOL, V6, P1395, DOI 10.2217/FON.10.107
   Wils J, 2001, ANN ONCOL, V12, P13, DOI 10.1023/A:1008357725209
   Yla-Anttila P, 2009, METHOD ENZYMOL, V452, P143, DOI 10.1016/S0076-6879(08)03610-0
   Zhang Z, 2003, FREE RADICAL BIO MED, V34, P1333, DOI 10.1016/S0891-5849(03)00145-X
NR 56
TC 54
Z9 57
U1 0
U2 13
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD MAY 1
PY 2013
VL 9
IS 5
BP 697
EP 713
DI 10.4161/auto.23960
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 201WQ
UT WOS:000323174100007
PM 23445752
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Sharma, T
   Radosevich, JA
   Mandal, CC
AF Sharma, Tanu
   Radosevich, James A.
   Mandal, Chandi C.
TI Dual Role of microRNAs in Autophagy of Colorectal Cancer
SO ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS
LA English
DT Review
DE Colorectal cancer; microRNA; autophagy; non-coding RNA; tumor
   suppressor; tumor promoter
ID CONFERS 5-FLUOROURACIL RESISTANCE; COLON-CANCER; INHIBITS AUTOPHAGY;
   CELLS PROLIFERATION; THERAPEUTIC TARGET; TUMOR-CELLS; GROWTH;
   MECHANISMS; EXPRESSION; APOPTOSIS
AB Autophagy is an evolutionarily conserved pathway that eliminates unwanted proteins out of the cell and increases cell survival. However, dysfunctional autophagy is associated with cancer progression, cellular adaptation, cancer metastasis and makes it an attractive therapeutic target. MicroRNAs (miRNAs) are small single-stranded non-coding RNA molecules that usually bind to 3'UTR of mRNAs. This interaction eventually inhibits protein synthesis by repressing translation and/or by degrading mRNAs. miRNAs play a crucial role in the regulation of autophagy and also behave as both tumor suppressors and promoters in colorectal cancer. This paper defines an overall molecular view of how miRNAs regulate the dual role of autophagy in colorectal cancer. It also highlights how long noncoding RNAs modulate miRNAs expression to regulate autophagy in colorectal cancer. Thus, targeting autophagy by miRNAs seems to be a potential therapeutic strategy for colorectal cancer.
C1 [Sharma, Tanu; Mandal, Chandi C.] Cent Univ Rajasthan, Dept Biochem, NH-8 Bandarsindri, Ajmer 305817, Rajasthan, India.
   [Radosevich, James A.] Univ Illinois, Coll Dent, Dept Oral Med & Diagnost Sci, Chicago, IL 60612 USA.
RP Mandal, CC (corresponding author), Cent Univ Rajasthan, Dept Biochem, NH-8 Bandarsindri, Ajmer 305817, Rajasthan, India.
EM chandicmandal@gmail.com
OI Mandal, Chandi/0000-0002-2292-6635; Radosevich, James
   A/0000-0003-4633-480X
FU Department of Biotechnology [6242-P9/RGCB/PMD/DBT/CCML/2015]; University
   Grant CommissionUniversity Grants Commission, India [3049/2014 (BSR)];
   Department of Science and Technology (India)-Russian Foundation for
   Basic Research [INT/RUS/RFBR/P-256]
FX The study was funded by the Department of Biotechnology (Grant Number:
   6242-P9/RGCB/PMD/DBT/CCML/2015], University Grant Commission [Grant
   Number: 3049/2014 (BSR)] and Department of Science and Technology
   (India)-Russian Foundation for Basic Research (Grant Number:
   INT/RUS/RFBR/P-256).
CR Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   ASHFORD TP, 1962, J CELL BIOL, V12, P198, DOI 10.1083/jcb.12.1.198
   Avalos Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/603980
   Binefa G, 2014, WORLD J GASTROENTERO, V20, P6786, DOI 10.3748/wjg.v20.i22.6786
   Booton R, 2014, CHEST, V146, P193, DOI 10.1378/chest.13-2736
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chaachouay H, 2011, RADIOTHER ONCOL, V99, P287, DOI 10.1016/j.radonc.2011.06.002
   Chen JC, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9090467
   Chen QY, 2016, BIOCHEM BIOPH RES CO, V474, P168, DOI 10.1016/j.bbrc.2016.04.090
   Chen Z, 2016, AM J TRANSL RES, V8, P1190
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Christensen LL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096767
   Da Silva FC, 2016, ANTICANCER RES, V36, P4399, DOI 10.21873/anticanres.10983
   Dikaiakos P, 2015, CANCER BIOMARK, V15, P157, DOI 10.3233/CBM-140449
   Ding L, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092791
   Frankel LB, 2011, EMBO J, V30, P4628, DOI 10.1038/emboj.2011.331
   Fu Q, 2016, ONCOL REP, V36, P3682, DOI 10.3892/or.2016.5195
   Fujiya M, 2014, ONCOGENE, V33, P4847, DOI 10.1038/onc.2013.429
   Hahn MM, 2016, CELL ONCOL, V39, P491, DOI 10.1007/s13402-016-0284-6
   Han J, 2017, EXP CELL RES, V360, P328, DOI 10.1016/j.yexcr.2017.09.023
   Hao HB, 2017, MED MOL MORPHOL, V50, P76, DOI 10.1007/s00795-016-0150-7
   Hong L, 2013, EXPERT OPIN THER TAR, V17, P1073, DOI 10.1517/14728222.2013.819853
   Hu JL, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0028-8
   Huangfu LT, 2016, ONCOTARGET, V7, P4735, DOI 10.18632/oncotarget.6732
   Humbert M, 2013, BIOCHEM BIOPH RES CO, V431, P264, DOI 10.1016/j.bbrc.2012.12.120
   Jardon M.A., 2013, AUTOPHAGY STRUCTURE
   Javanmardi S, 2016, CURR GENE THER, V16, P375, DOI 10.2174/1566523217666170102105119
   Ji CX, 2018, DISCOV MED, V25, P265
   Jin GY, 2019, CANCER CHEMOTH PHARM, V84, P315, DOI 10.1007/s00280-019-03867-6
   Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105
   Li BL, 2016, BIOMED PHARMACOTHER, V79, P93, DOI 10.1016/j.biopha.2016.01.045
   Li JG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141168
   Li LC, 2016, BIOCHEM BIOPH RES CO, V479, P343, DOI 10.1016/j.bbrc.2016.09.078
   Li WJ, 2016, AGING CELL, V15, P370, DOI 10.1111/acel.12441
   Liao D, 2018, EXP THER MED, V15, P1712, DOI 10.3892/etm.2017.5522
   Liu LD, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15016050
   Liu L, 2019, MOL THER-NUCL ACIDS, V17, P644, DOI 10.1016/j.omtn.2019.06.009
   Liu ML, 2018, WORLD J GASTROENTERO, V24, P1004, DOI 10.3748/wjg.v24.i9.1004
   Nugent M, 2011, EJSO-EUR J SURG ONC, V37, P649, DOI 10.1016/j.ejso.2011.05.005
   Pan XA, 2010, CANCER BIOL THER, V10, P1224, DOI 10.4161/cbt.10.12.14252
   Sarver AL, 2010, CANCER RES, V70, P9570, DOI 10.1158/0008-5472.CAN-10-2074
   Sha QK, 2019, ARTIF CELL NANOMED B, V47, P1057, DOI 10.1080/21691401.2018.1544143
   Slattery ML, 2017, MODERN PATHOL, V30, P1152, DOI 10.1038/modpathol.2017.38
   Sridharan M, 2014, ONCOLOGY-NY, V28, P110
   Stiegelbauer V, 2014, WORLD J GASTROENTERO, V20, P11727, DOI 10.3748/wjg.v20.i33.11727
   Su M, 2015, CELL DEATH DIFFER, V22, P986, DOI 10.1038/cdd.2014.187
   Sumbul AT, 2014, TUMOR BIOL, V35, P12713, DOI 10.1007/s13277-014-2596-3
   Sun C, 2017, WORLD J GASTROENTERO, V23, P1816, DOI 10.3748/wjg.v23.i10.1816
   Tan SF, 2016, INT J MOL MED, V37, P1030, DOI 10.3892/ijmm.2016.2492
   Taniguchi K, 2015, CANCER LETT, V363, P17, DOI 10.1016/j.canlet.2015.03.026
   Taylor CM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003505
   Ueno K, 2013, BRIT J CANCER, V108, P1659, DOI 10.1038/bjc.2013.125
   Wang YF, 2019, ONCOTARGETS THER, V12, P4621, DOI 10.2147/OTT.S196992
   Wei R, 2017, ONCOTARGET, V8, P16633, DOI 10.18632/oncotarget.15114
   Wu WKK, 2011, CARCINOGENESIS, V32, P247, DOI 10.1093/carcin/bgq243
   Xie Y, 2019, ARTIF CELL NANOMED B, V47, P1722, DOI 10.1080/21691401.2019.1606006
   Yang WZ, 2016, CELL PHYSIOL BIOCHEM, V38, P2366, DOI 10.1159/000445589
   Yang XD, 2016, ONCOTARGET, V7, P79603, DOI 10.18632/oncotarget.12873
   Yu XF, 2017, SCI REP-UK, V7, DOI 10.1038/srep42226
   Zhai H, 2013, ONCOGENE, V32, P1570, DOI 10.1038/onc.2012.167
   Zhai HY, 2015, ONCOTARGET, V6, P19735, DOI 10.18632/oncotarget.3771
   Zhang QH, 2013, GENE, V527, P26, DOI 10.1016/j.gene.2013.06.006
   Zhang R, 2017, TUMOR BIOL, V39, P1, DOI 10.1177/1010428317703984
   Zheng YS, 2019, J CELL BIOCHEM, V120, P3922, DOI 10.1002/jcb.27676
   Zhou HY, 2016, CANCER BIOMARK, V17, P1, DOI 10.3233/CBM-160613
NR 65
TC 2
Z9 2
U1 1
U2 1
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1871-5303
EI 2212-3873
J9 ENDOCR METAB IMMUNE
JI Endocr. Metab. Immune Disord.-Drug Targets
PY 2021
VL 21
IS 1
BP 56
EP 66
DI 10.2174/1871530320666200519075908
PG 11
WC Endocrinology & Metabolism; Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Immunology; Pharmacology & Pharmacy
GA QA4UO
UT WOS:000613440100008
PM 32427088
DA 2022-04-25
ER

PT J
AU Reszegi, A
   Horvath, Z
   Karaszi, K
   Regos, E
   Postnikova, V
   Tatrai, P
   Kiss, A
   Schaff, Z
   Kovalszky, I
   Baghy, K
AF Reszegi, Andrea
   Horvath, Zsolt
   Karaszi, Katalin
   Regos, Eszter
   Postnikova, Victoria
   Tatrai, Peter
   Kiss, Andras
   Schaff, Zsuzsa
   Kovalszky, Ilona
   Baghy, Kornelia
TI The Protective Role of Decorin in Hepatic Metastasis of Colorectal
   Carcinoma
SO BIOMOLECULES
LA English
DT Article
DE decorin; ECM; colorectal carcinoma; RTK; signaling; liver metastasis
ID GROWTH-FACTOR RECEPTOR; EXTRACELLULAR-MATRIX; EXPRESSING DECORIN;
   SIGNALING PATHWAY; TUMOR-GROWTH; IN-VIVO; AUTOPHAGY; LIVER; AMPK;
   PROTEOGLYCANS
AB Decorin, the prototype member of the small leucine-rich proteoglycan gene family of extracellular matrix (ECM) proteins, acts as a powerful tumor suppressor by inducing the p21(Waf1/Cip1)cyclin-dependent kinase inhibitor, as well as through its ability to directly bind and block the action of several tyrosine kinase receptors. Our previous studies suggested that the lack of decorin promotes hepatic carcinogenesis in mice. Based on this, we set out to investigate whether excess decorin may protect against the liver metastases of colon carcinoma. We also analyzed the effect of decorin in tissue microarrays of human colon carcinoma liver metastasis and examined whether the tumor cells can directly influence the decorin production of myofibroblasts. In humans, low levels of decorin in the liver facilitated the development of colon carcinoma metastases in proportion with more aggressive phenotypes, indicating a possible antitumor action of the proteoglycan. In vitro, colon carcinoma cells inhibited decorin expression in LX2 hepatic stellate cells. Moreover, liver-targeted decorin delivery in mice effectively attenuated metastasis formation of colon cancer. Overexpressed decorin reduced the activity of multiple receptor tyrosine kinases (RTKs) including the epidermal growth factor receptor (EGFR), an important player in colorectal cancer (CRC) pathogenesis. Downstream of that, we observed weakened signaling of ERK1/2, PLC gamma, Akt/mTOR, STAT and c-Jun pathways, while p38 MAPK/MSK/CREB and AMPK were upregulated culminating in enhanced p53 function. In conclusion, decorin may effectively inhibit metastatic tumor formation in the liver.
C1 [Reszegi, Andrea; Horvath, Zsolt; Karaszi, Katalin; Regos, Eszter; Postnikova, Victoria; Kovalszky, Ilona; Baghy, Kornelia] Semmelweis Univ, Dept Pathol & Expt Canc Res 1, Ulloi St 26, H-1085 Budapest, Hungary.
   [Tatrai, Peter] Solvo Biotechnol, H-1117 Budapest, Hungary.
   [Kiss, Andras; Schaff, Zsuzsa] Semmelweis Univ, Dept Pathol 2, H-1091 Budapest, Hungary.
RP Baghy, K (corresponding author), Semmelweis Univ, Dept Pathol & Expt Canc Res 1, Ulloi St 26, H-1085 Budapest, Hungary.
EM areszegi2@gmail.com; opponent01@gmail.com; tika0604@gmail.com;
   eszter.regos.88@gmail.com; postnikova.victoria@gmail.com;
   tatrai@solvo.com; kiss.andras@med.semmelweis-univ.hu;
   schaff.zsuzsa@med.semmelweis-univ.hu;
   kovalszky.ilona@med.semmelweis-univ.hu;
   baghy.kornelia@med.semmelweis-univ.hu
RI Tatrai, Peter/AAR-6014-2020; Kovalszky, Ilona/ABH-2832-2020; Baghy,
   Kornélia/ABH-2549-2020
OI Tatrai, Peter/0000-0001-9726-1992; Kovalszky, Ilona/0000-0002-0179-3378;
   Baghy, Kornélia/0000-0002-5323-2775; Regos, Eszter/0000-0002-1707-1943;
   Karaszi, Katalin/0000-0002-9188-1987; Reszegi,
   Andrea/0000-0001-6902-7883
FU HUNGARIAN SCIENTIFIC RESEARCH FUNDOrszagos Tudomanyos Kutatasi
   Alapprogramok (OTKA) [105763, 100904, 119283, 128881]; Scholarship For
   The Young Talents Of The Nation (NFTO) [NTP-NFTO-19-B-0037,
   NTP-NFTO-18-B-0165]; EUH2020 MSCA-RISE project [645756]; Hungarian
   National Research, Development and Innovation Office (NKFIH)
   [NVKP_16-1-2016-0004]
FX This research was funded by the HUNGARIAN SCIENTIFIC RESEARCH FUND grant
   number 105763 (to KB), 100904, 119283 (to IK), 128881 (to AK), by
   Scholarship For The Young Talents Of The Nation (NFTO NTP-NFTO-19-B-0037
   and NTP-NFTO-18-B-0165 to AR) and by EUH2020 MSCA-RISE project #645756
   "GLYCANC" (to IK). The study and publishing of the article was also
   supported by NVKP_16-1-2016-0004 grant of the Hungarian National
   Research, Development and Innovation Office (NKFIH).
CR Adiseshaiah P, 2008, BIOCHEM BIOPH RES CO, V371, P304, DOI 10.1016/j.bbrc.2008.04.063
   Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11
   Araki K, 2009, ONCOLOGY-BASEL, V77, P92, DOI 10.1159/000228253
   Arriazu E, 2014, ANTIOXID REDOX SIGN, V21, P1078, DOI 10.1089/ars.2013.5697
   Baghy K, 2016, WORLD J GASTROENTERO, V22, P379, DOI 10.3748/wjg.v22.i1.379
   Baghy K, 2013, FEBS J, V280, P2150, DOI 10.1111/febs.12215
   Baghy K, 2011, LAB INVEST, V91, P439, DOI 10.1038/labinvest.2010.172
   Baiocchini A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151736
   Bi XL, 2008, CARCINOGENESIS, V29, P1435, DOI 10.1093/carcin/bgn141
   Bi XL, 2012, CARCINOGENESIS, V33, P326, DOI 10.1093/carcin/bgr293
   Bostrom P, 2017, CANCER MICROENVIRON, V10, P39, DOI 10.1007/s12307-017-0195-8
   Bostrom P, 2013, HISTOCHEM CELL BIOL, V139, P161, DOI 10.1007/s00418-012-1026-0
   Bousoik E, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00287
   Brandan E, 2008, MATRIX BIOL, V27, P700, DOI 10.1016/j.matbio.2008.07.004
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Breitkopf K, 2005, CYTOKINE, V31, P349, DOI 10.1016/j.cyto.2005.06.005
   Cawthorn TR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030992
   Chow FCL, 2019, WORLD J HEPATOL, V11, P150, DOI 10.4254/wjh.v11.i2.150
   Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200
   Farhood B, 2019, WSPOLCZESNA ONKOL, V23, P7, DOI 10.5114/wo.2019.84112
   Ferdous Z, 2008, BIOMATERIALS, V29, P2740, DOI 10.1016/j.biomaterials.2008.03.018
   Florescu-Tenea R M, 2019, Curr Health Sci J, V45, P134, DOI 10.12865/CHSJ.45.02.02
   Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541
   Garcia-Foncillas J, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00849
   Giebler HA, 2000, MOL CELL BIOL, V20, P4849, DOI 10.1128/MCB.20.13.4849-4858.2000
   Goldoni S, 2008, AM J PATHOL, V173, P844, DOI 10.2353/ajpath.2008.080275
   Goldoni S, 2009, J CELL BIOL, V185, P743, DOI 10.1083/jcb.200901129
   Golubnitschaja O, 2016, CLIN EXP METASTAS, V33, P743, DOI 10.1007/s10585-016-9816-8
   Gomes AS, 2018, PHARMACOL RES, V131, P75, DOI 10.1016/j.phrs.2018.03.015
   Goyal A, 2014, MATRIX BIOL, V34, P46, DOI 10.1016/j.matbio.2013.12.011
   Guo YJ, 2020, EXP THER MED, V19, P1997, DOI 10.3892/etm.2020.8454
   Hardie DG, 2016, TRENDS CELL BIOL, V26, P190, DOI 10.1016/j.tcb.2015.10.013
   Hoppener DJ, 2019, CLIN EXP METASTAS, V36, P311, DOI 10.1007/s10585-019-09975-0
   Horvath Z, 2014, MATRIX BIOL, V35, P194, DOI 10.1016/j.matbio.2013.11.004
   Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489
   Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551
   Jarvelainen H, 2006, WOUND REPAIR REGEN, V14, P443, DOI 10.1111/j.1743-6109.2006.00150.x
   Kankanamalage SG, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0287-1
   Kankanamalage SG, 2017, AUTOPHAGY, V13, P969, DOI 10.1080/15548627.2017.1286431
   Khan GA, 2011, MOL ENDOCRINOL, V25, P1431, DOI 10.1210/me.2010-0426
   Kleinert M, 2016, MOL METAB, V5, P646, DOI 10.1016/j.molmet.2016.06.007
   KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683
   Lala PK, 2016, CELL ADHES MIGR, V10, P111, DOI 10.1080/19336918.2015.1106669
   Liu Z, 2017, HUM GENE THER, V28, P667, DOI 10.1089/hum.2017.033
   Martinelli E, 2020, ANN ONCOL, V31, P30, DOI 10.1016/j.annonc.2019.10.007
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Na Y, 2015, J CONTROL RELEASE, V220, P766, DOI 10.1016/j.jconrel.2015.10.015
   Nayak S, 2013, INDIAN J PATHOL MICR, V56, P204, DOI 10.4103/0377-4929.120366
   Neill T, 2016, ADV DRUG DELIVER REV, V97, P174, DOI 10.1016/j.addr.2015.10.016
   Neill T, 2012, AM J PATHOL, V181, P380, DOI 10.1016/j.ajpath.2012.04.029
   Nyman MC, 2015, J HISTOCHEM CYTOCHEM, V63, P710, DOI 10.1369/0022155415590830
   Papa S, 2019, ONCOGENE, V38, P2223, DOI 10.1038/s41388-018-0582-8
   Reed CC, 2002, ONCOGENE, V21, P3688, DOI 10.1038/sj.onc.1205470
   Regos E, 2018, MATRIX BIOL, V68-69, P474, DOI 10.1016/j.matbio.2018.02.008
   Reszegi A, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00645
   Ruehland C, 2007, FEBS J, V274, P4246, DOI 10.1111/j.1742-4658.2007.05951.x
   Sainio A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076190
   Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507
   Schaefer L, 2002, AM J PATHOL, V160, P1181, DOI 10.1016/S0002-9440(10)64937-1
   Schaefer L, 2017, FEBS J, V284, P10, DOI 10.1111/febs.13963
   Schonherr E, 2005, J BIOL CHEM, V280, P15767, DOI 10.1074/jbc.M500451200
   Shintani K, 2008, ONCOL REP, V19, P1533
   Theocharis AD, 2016, ADV DRUG DELIVER REV, V97, P4, DOI 10.1016/j.addr.2015.11.001
   Thornton TM, 2009, INT J BIOL SCI, V5, P44, DOI 10.7150/ijbs.5.44
   Tralhao JG, 2003, FASEB J, V17, P464, DOI 10.1096/fj.02-0534fje
   Tsuchida T, 2017, NAT REV GASTRO HEPAT, V14, P397, DOI 10.1038/nrgastro.2017.38
   Ueno H, 2015, ANN SURG ONCOL, V22, P1504, DOI 10.1245/s10434-014-4149-9
   Wang ZY, 2016, EXPERIENTIA SUPPL, V107, P203, DOI 10.1007/978-3-319-43589-3_9
   Weis SM, 2005, MATRIX BIOL, V24, P313, DOI 10.1016/j.matbio.2005.05.003
   Wells RG, 2008, CLIN LIVER DIS, V12, P759, DOI 10.1016/j.cld.2008.07.008
   Wu GS, 2004, CANCER BIOL THER, V3, P156, DOI 10.4161/cbt.3.2.614
   Xu W, 2015, GENE THER, V22, P247, DOI 10.1038/gt.2014.110
   Yang YF, 2015, HUM GENE THER, V26, P813, DOI 10.1089/hum.2015.098
NR 73
TC 2
Z9 2
U1 3
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2218-273X
J9 BIOMOLECULES
JI Biomolecules
PD AUG
PY 2020
VL 10
IS 8
AR 1199
DI 10.3390/biom10081199
PG 17
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA OC0IB
UT WOS:000578845700001
PM 32824864
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Lyu, Q
   Tou, FF
   Su, H
   Wu, XY
   Chen, XY
   Zheng, Z
AF Lyu, Qing
   Tou, Fangfang
   Su, Hong
   Wu, Xiaoyong
   Chen, Xinyi
   Zheng, Zhi
TI The natural product peiminine represses colorectal carcinoma tumor
   growth by inducing autophagic cell death
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Peiminine; Autophagy; Natural product; Autophagic cell death
ID CANCER; DISEASE; ULK1; AMPK; ADIPOGENESIS; CONTRIBUTES; DYSFUNCTION;
   SUPPRESSES; ACTIVATION; STARVATION
AB Autophagy is evolutionarily conservative in eukaryotic cells that engulf cellular long-lived proteins and organelles, and it degrades the contents through fusion with lysosomes, via which the cell acquires recycled building blocks for the synthesis of new molecules. In this study, we revealed that peiminine induces cell death and enhances autophagic flux in colorectal carcinoma HCT-116 cells. We determined that peiminine enhances the autophagic flux by repressing the phosphorylation of mTOR through inhibiting upstream signals. Knocking down ATG5 greatly reduced the peiminine-induced cell death in wild-type HCT-116 cells, while treating Bax/Bak-deficient cells with peiminine resulted in significant cell death. In summary, our discoveries demonstrated that peiminine represses colorectal carcinoma cell proliferation and cell growth by inducing autophagic cell death. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Lyu, Qing] Tsinghua Univ, Sch Life Sci, Beijing 100084, Peoples R China.
   [Lyu, Qing] Tsinghua Univ, Grad Sch Shenzhen, Div Life Sci, Key Lab Hlth Sci & Technol, Shenzhen 518055, Peoples R China.
   [Tou, Fangfang; Zheng, Zhi] Jiangxi Canc Hosp, Jiangxi Prov Key Lab Oncol Translat Med, Nanchang 330029, Peoples R China.
   [Su, Hong; Wu, Xiaoyong] Guiyang Coll Tradit Chinese Med, Affiliated Hosp 1, Guiyang 550002, Peoples R China.
   [Chen, Xinyi] Beijing Univ Chinese Med, Dept Hematol & Oncol, Beijing 100029, Peoples R China.
RP Chen, XY (corresponding author), Beijing Univ Chinese Med, Dept Hematol & Oncol, Beijing 100029, Peoples R China.
EM zheng_sheva@hotmail.com
RI Lyu, Qing/AAF-5181-2021
OI Lyu, Qing/0000-0002-1325-6828
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81260592]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81260592). The funding institute had no role in study design,
   data collection and analysis, decision to publish or preparation of the
   manuscript.
CR Baerga R, 2009, AUTOPHAGY, V5, P1118, DOI 10.4161/auto.5.8.9991
   Esposti MD, 2003, BIOCHEM BIOPH RES CO, V304, P455, DOI 10.1016/S0006-291X(03)00617-X
   Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1
   Kang C, 2007, GENE DEV, V21, P2161, DOI 10.1101/gad.1573107
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620
   Ko H, 2011, J CELL BIOCHEM, V112, P2471, DOI 10.1002/jcb.23171
   Kristensen AR, 2008, MOL CELL PROTEOMICS, V7, P2419, DOI 10.1074/mcp.M800184-MCP200
   Lai K, 2014, J CLIN PATHOL, V67, P854, DOI 10.1136/jclinpath-2014-202529
   Lee S, 2005, GYNECOL ONCOL, V97, P26, DOI 10.1016/j.ygyno.2004.11.051
   Massey AC, 2006, CURR TOP DEV BIOL, V73, P205, DOI 10.1016/S0070-2153(05)73007-6
   Meijer A.J., 2014, AMINO ACIDS
   Meijer Alfred J., 2006, Molecular Aspects of Medicine, V27, P411, DOI 10.1016/j.mam.2006.08.002
   Meijer AJ, 2011, CURR BIOL, V21, pR227, DOI 10.1016/j.cub.2011.02.007
   Mizushima N, 2007, ANNU REV NUTR, V27, P19, DOI 10.1146/annurev.nutr.27.061406.093749
   Nazio F, 2013, NAT CELL BIOL, V15, P406, DOI 10.1038/ncb2708
   Pivtoraiko VN, 2010, J NEUROCHEM, V114, P1193, DOI 10.1111/j.1471-4159.2010.06838.x
   Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Shang LB, 2011, AUTOPHAGY, V7, P924, DOI 10.4161/auto.7.8.15860
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Shimizu S, 2014, INT J MOL SCI, V15, P3145, DOI 10.3390/ijms15023145
   Tachibana Ken, 2006, Tanpakushitsu Kakusan Koso, V51, P1519
   Takahashi Y, 2005, MOL CELL BIOL, V25, P9369, DOI 10.1128/MCB.25.21.9369-9382.2005
   Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254
   Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Xue Yan, 2005, Yaoxue Xuebao, V40, P550
   Zhao L, 2014, MOL NUTR FOOD RES, V58, P569, DOI 10.1002/mnfr.201300157
NR 29
TC 27
Z9 29
U1 4
U2 25
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUN 19
PY 2015
VL 462
IS 1
BP 38
EP 45
DI 10.1016/j.bbrc.2015.04.102
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA CJ6XL
UT WOS:000355638400007
PM 25935480
DA 2022-04-25
ER

PT J
AU Lv, YZ
   Li, B
   Han, KN
   Xiao, Y
   Yu, XJ
   Ma, Y
   Jiao, Z
   Gao, JJ
AF Lv, Yongzhu
   Li, Bing
   Han, Kunna
   Xiao, Yang
   Yu, Xianjun
   Ma, Yong
   Jiao, Zhan
   Gao, Jianjun
TI The Nedd8-activating enzyme inhibitor MLN4924 suppresses colon cancer
   cell growth via triggering autophagy
SO KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY
LA English
DT Article
DE Autophagy; Cell growth; Colon cancer; MLN4924; Neddylation
ID COLORECTAL-CANCER; E3 LIGASE; NEDDYLATION; APOPTOSIS; PATHWAYS; PROTEIN;
   DEATH; SENESCENCE; MATURATION; SURVIVAL
AB Neddylation is a post-translational protein modification process. MLN4924 is a newly discovered pharmaceutical neddylation inhibitor that suppresses cancer growth with several cancer types. in our study, we first investigated the effect of MLN4924 on colon cancer cells (HCT116 and HT29). MLN4924 significantly inhibited the neddylation of cullin-1 and colon cancer cell growth in a time and dose-dependent manner. MLN4924 induced 62/M cell cycle arrest and apoptosis in HCT116 and HT29 cells. Moreover, MLN4924 also triggered autophagy in HCT116 and HT29 cells via suppressing the PI3K/AKT/mTOR pathway. Inhibiting autophagy by autophagy inhibitor 3-MA or ATGS knockdown reversed the function of MLN4924 in suppressing colon cancer cell growth and cell death. Interestingly, MLN4924 suppresses colon cell growth in a xenograft model. Together, our finding revealed that blocking neddylation is an attractive colon cancer therapy strategy, and autophagy might act as a novel anti-cancer mechanism for the treatment of colon cancer by MLN4924.
C1 [Lv, Yongzhu; Li, Bing; Han, Kunna; Yu, Xianjun; Ma, Yong; Jiao, Zhan; Gao, Jianjun] 210 Hosp Chinese Peoples Liberat Army, Dept Gen Surg, Dalian 116021, Peoples R China.
   [Xiao, Yang] Dalian Univ, Affiliated Zhongshan Hosp, Dept Gynecol & Obstet, Dalian 116001, Peoples R China.
RP Gao, JJ (corresponding author), 210 Hosp Chinese Peoples Liberat Army, Dept Gen Surg, Dalian 116021, Peoples R China.
EM gaojianjun210@163.com
CR Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Deegan S, 2012, THESIS
   Deng SJ, 2015, FOOD CHEM TOXICOL, V75, P173, DOI 10.1016/j.fct.2014.11.019
   Gil J, 2016, BIOMARK MED, V10, P1081, DOI 10.2217/bmm-2016-0083
   Heerva E, 2018, J GASTROINTEST CANC, V49, P245, DOI 10.1007/s12029-017-9927-8
   Heras-Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019
   Jia LJ, 2011, NEOPLASIA, V13, P561, DOI 10.1593/neo.11420
   Jiang K, 2016, ONCOTARGET, V7, P25652, DOI 10.18632/oncotarget.8357
   Kelekar A, 2005, ANN NY ACAD SCI, V1066, P259, DOI 10.1196/annals.1363.015
   Kenific CM, 2015, TRENDS CELL BIOL, V25, P37, DOI 10.1016/j.tcb.2014.09.001
   Kim JH, 2015, BMB REP, V48, P129, DOI 10.5483/BMBRep.2015.48.3.048
   Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Koskela A, 2016, ACTA OPHTHALMOL, V94, pS256
   Lan HY, 2016, SCI REP-UK, V6, DOI 10.1038/srep24218
   Maxwell PJ, 2016, CURRENT CONTROVERSIE
   Merlet J, 2009, CELL MOL LIFE SCI, V66, P1924, DOI 10.1007/s00018-009-8712-7
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Nawrocki ST, 2012, EXPERT OPIN INV DRUG, V21, P1563, DOI 10.1517/13543784.2012.707192
   Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x
   Petrelli F, 2013, ANN ONCOL, V24, P186, DOI 10.1093/annonc/mds289
   Ryabaya OO, 2015, BIOL B REV, V5, P579
   Shen HM, 2011, AUTOPHAGY, V7, P457, DOI 10.4161/auto.7.5.14226
   Song Lele, 2016, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V41, P9, DOI 10.11817/j.issn.1672-7347.2016.01.002
   Sui YY, 2015, BIOCHEM BIOPH RES CO, V461, P653, DOI 10.1016/j.bbrc.2015.04.085
   Tanida I, 2011, ANTIOXID REDOX SIGN, V14, P2201, DOI 10.1089/ars.2010.3482
   Wan JF, 2016, TECHNOL CANCER RES T, V15, P527, DOI 10.1177/1533034615588197
   Wang YC, 2015, CANCER BIOL THER, V16, P420, DOI 10.1080/15384047.2014.1003003
   Watson IR, 2011, CANCER CELL, V19, P168, DOI 10.1016/j.ccr.2011.01.002
   Xu JF, 2015, MOL CELL PROTEOMICS, V14, P499, DOI 10.1074/mcp.M114.045211
   Zhang Y, 2016, ONCOTARGET, V7, P45263, DOI 10.18632/oncotarget.9481
   Zhao Y, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.125
   Zhao YC, 2014, ANTIOXID REDOX SIGN, V21, P2383, DOI 10.1089/ars.2013.5795
   Zheng WW, 2017, MOL MED REP, V15, P2795, DOI 10.3892/mmr.2017.6305
NR 34
TC 6
Z9 7
U1 1
U2 7
PU KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY
PI SEOUL
PA C/O EDITORIAL OFFICE, 448-13 SEOKYO-DONG, SEOUL, SOUTH KOREA
SN 1226-4512
EI 2093-3827
J9 KOREAN J PHYSIOL PHA
JI KOREAN J. PHYSIOL. PHARMACOL.
PD NOV
PY 2018
VL 22
IS 6
BP 617
EP 625
DI 10.4196/kjpp.2018.22.6.617
PG 9
WC Pharmacology & Pharmacy; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Physiology
GA GY0IP
UT WOS:000448200000002
PM 30402022
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Wei, MF
   Chen, MW
   Chen, KC
   Lou, PJ
   Lin, SYF
   Hung, SC
   Hsiao, M
   Yao, CJ
   Shieh, MJ
AF Wei, Ming-Feng
   Chen, Min-Wei
   Chen, Ke-Cheng
   Lou, Pei-Jen
   Lin, Susan Yun-Fan
   Hung, Shih-Chieh
   Hsiao, Michael
   Yao, Cheng-Jung
   Shieh, Ming-Jium
TI Autophagy promotes resistance to photodynamic therapy-induced apoptosis
   selectively in colorectal cancer stem-like cells
SO AUTOPHAGY
LA English
DT Article
DE apoptosis; autophagy; autophagy-related proteins; cancer stem-like
   cells; colonosphere; colorectal cancer; photodynamic therapy; prominin 1
   (PROM1)/CD133; tumorigenicity
ID IN-VITRO; INHIBITION; DEATH; GLIOBLASTOMA; PROTEIN; COLON;
   PHOTOSENSITIZERS; MACROAUTOPHAGY; OXYGENATION; MECHANISMS
AB Recent studies have indicated that cancer stem-like cells (CSCs) exhibit a high resistance to current therapeutic strategies, including photodynamic therapy (PDT), leading to the recurrence and progression of colorectal cancer (CRC). In cancer, autophagy acts as both a tumor suppressor and a tumor promoter. However, the role of autophagy in the resistance of CSCs to PDT has not been reported. In this study, CSCs were isolated from colorectal cancer cells using PROM1/CD133 (prominin 1) expression, which is a surface marker commonly found on stem cells of various tissues. We demonstrated that PpIX-mediated PDT induced the formation of autophagosomes in PROM1/CD133(+) cells, accompanied by the upregulation of autophagy-related proteins ATG3, ATG5, ATG7, and ATG12. The inhibition of PDT-induced autophagy by pharmacological inhibitors and silencing of the ATG5 gene substantially triggered apoptosis of PROM1/CD133(+) cells and decreased the ability of colonosphere formation in vitro and tumorigenicity in vivo. In conclusion, our results revealed a protective role played by autophagy against PDT in CSCs and indicated that targeting autophagy could be used to elevate the PDT sensitivity of CSCs. These findings would aid in the development of novel therapeutic approaches for CSC treatment.
C1 [Wei, Ming-Feng; Chen, Ke-Cheng; Lin, Susan Yun-Fan; Shieh, Ming-Jium] Natl Taiwan Univ, Inst Biomed Engn, Taipei 10764, Taiwan.
   [Chen, Min-Wei; Shieh, Ming-Jium] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan.
   [Chen, Ke-Cheng] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan.
   [Lou, Pei-Jen] Natl Taiwan Univ Hosp, Dept Otolaryngol, Taipei, Taiwan.
   [Hung, Shih-Chieh] Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan.
   [Hsiao, Michael] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan.
   [Yao, Cheng-Jung] Taipei Med Univ, Municipal Wan Fang Hosp, Taipei, Taiwan.
RP Shieh, MJ (corresponding author), Natl Taiwan Univ, Inst Biomed Engn, Taipei 10764, Taiwan.
EM soloman@ntu.edu.tw
RI Hsiao, Michael/U-6238-2019
OI Hsiao, Michael/0000-0001-8529-9213; LOU, PEI-JEN/0000-0002-3383-8593
FU National Science Council, ROCMinistry of Science and Technology, Taiwan
   [NSC 100-2218-E-002-002]; Ministry of Health and Welfare, ROC
   [MOHW103-TDU-N-211-133006]
FX This research was funded by the National Science Council, ROC (NSC
   100-2218-E-002-002) and the Ministry of Health and Welfare, ROC
   (MOHW103-TDU-N-211-133006).
CR Al-Hajj M, 2004, CURR OPIN GENET DEV, V14, P43, DOI 10.1016/j.gde.2003.11.007
   Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562
   Baumann M, 2008, NAT REV CANCER, V8, P545, DOI 10.1038/nrc2419
   Bauvy C, 2001, EXP CELL RES, V268, P139, DOI 10.1006/excr.2001.5285
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Brackett CM, 2011, LASER SURG MED, V43, P676, DOI 10.1002/lsm.21107
   Carew Jennifer S, 2012, Cancer Manag Res, V4, P357, DOI 10.2147/CMAR.S26133
   Chen HY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056878
   Chen Q, 2002, PHOTOCHEM PHOTOBIOL, V76, P197, DOI 10.1562/0031-8655(2002)076<0197:IOTRBM>2.0.CO;2
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Coupienne I, 2011, BIOCHEM PHARMACOL, V81, P606, DOI 10.1016/j.bcp.2010.12.015
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590
   Dewaele M, 2011, J CELL MOL MED, V15, P1402, DOI 10.1111/j.1582-4934.2010.01118.x
   Eimer S, 2011, CANCER BIOL THER, V11, P1017, DOI 10.4161/cbt.11.12.15693
   Eskelinen EL, 2008, INT REV CEL MOL BIO, V266, P207, DOI 10.1016/S1937-6448(07)66005-5
   Geltzer A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005022.pub3
   Gibson SB, 2010, AUTOPHAGY, V6, P835, DOI 10.4161/auto.6.7.13335
   Gomer CJ, 1996, CANCER RES, V56, P2355
   GOMER CJ, 1991, PHOTOCHEM PHOTOBIOL, V53, P275, DOI 10.1111/j.1751-1097.1991.tb03934.x
   Gong C, 2013, ONCOGENE, V32, P2261, DOI 10.1038/onc.2012.252
   Gong C, 2012, AUTOPHAGY, V8, P1853, DOI 10.4161/auto.21996
   Guo XL, 2013, J MOL MED, V91, P473, DOI 10.1007/s00109-012-0966-0
   Hanada T, 2007, J BIOL CHEM, V282, P37298, DOI 10.1074/jbc.C700195200
   He WY, 2012, AUTOPHAGY, V8, P1811, DOI 10.4161/auto.22145
   Henderson BW, 2000, CANCER RES, V60, P525
   Ito H, 2005, INT J ONCOL, V26, P1401
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Jendzelovsky R, 2009, PHOTOCH PHOTOBIO SCI, V8, P1716, DOI 10.1039/b9pp00086k
   Jin F, 2008, NEUROSCIENCE, V154, P541, DOI 10.1016/j.neuroscience.2008.03.054
   Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808
   Katayama M, 2007, CELL DEATH DIFFER, V14, P548, DOI 10.1038/sj.cdd.4402030
   Kim EH, 2007, CANCER RES, V67, P6314, DOI 10.1158/0008-5472.CAN-06-4217
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Levine B, 2005, CELL, V120, P159, DOI 10.1016/j.cell.2005.01.005
   Li YY, 2013, LUNG CANCER, V81, P354, DOI 10.1016/j.lungcan.2013.05.012
   Lomonaco SL, 2009, INT J CANCER, V125, P717, DOI 10.1002/ijc.24402
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   MOAN J, 1992, PHOTOCHEM PHOTOBIOL, V55, P931, DOI 10.1111/j.1751-1097.1992.tb08541.x
   Morgan J, 2010, MOL PHARMACEUT, V7, P1789, DOI 10.1021/mp100154j
   Mulsow J, 2011, BRIT J SURG, V98, P1785, DOI 10.1002/bjs.7653
   Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816
   Oral O, 2012, APOPTOSIS, V17, P810, DOI 10.1007/s10495-012-0735-0
   Pan XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056679
   Peng Q, 1996, ULTRASTRUCT PATHOL, V20, P109, DOI 10.3109/01913129609016306
   Piette J, 2003, BIOCHEM PHARMACOL, V66, P1651, DOI 10.1016/S0006-2952(03)00539-2
   Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626
   Pyo JO, 2005, J BIOL CHEM, V280, P20722, DOI 10.1074/jbc.M413934200
   Reiners JJ, 2010, AUTOPHAGY, V6, P7, DOI 10.4161/auto.6.1.10220
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Rich JN, 2007, CANCER RES, V67, P8980, DOI 10.1158/0008-5472.CAN-07-0895
   Robey RW, 2005, CANCER BIOL THER, V4, P187
   Sasnauskiene A, 2009, AUTOPHAGY, V5, P743, DOI 10.4161/auto.5.5.8701
   Shen SS, 2012, AUTOPHAGY, V8, P1, DOI 10.4161/auto.8.1.16618
   Shimizu S, 2012, INT J CANCER, V131, P548, DOI 10.1002/ijc.26374
   Shmelkov SV, 2005, INT J BIOCHEM CELL B, V37, P715, DOI 10.1016/j.biocel.2004.08.010
   Song JR, 2011, J CELL BIOCHEM, V112, P3406, DOI 10.1002/jcb.23274
   Song LL, 2007, EXPERT OPIN BIOL TH, V7, P431, DOI 10.1517/14712598.7.4.431
   Tanida I, 2002, J BIOL CHEM, V277, P13739, DOI 10.1074/jbc.M200385200
   TRAGANOS F, 1994, METHOD CELL BIOL, V41, P185
   Tseng HC, 2011, CHEM-BIOL INTERACT, V192, P201, DOI 10.1016/j.cbi.2011.03.011
   Wang JB, 2007, HEPATO-GASTROENTEROL, V54, P718
   WEISHAUPT KR, 1976, CANCER RES, V36, P2326
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Wu SB, 2013, BIOCHEM BIOPH RES CO, V434, P898, DOI 10.1016/j.bbrc.2013.04.053
   XUE LY, 1995, PHOTOCHEM PHOTOBIOL, V62, P135, DOI 10.1111/j.1751-1097.1995.tb05249.x
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Yue W, 2013, AUTOPHAGY, V9, P714, DOI 10.4161/auto.23997
NR 68
TC 122
Z9 130
U1 10
U2 57
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD JUL
PY 2014
VL 10
IS 7
BP 1179
EP 1192
DI 10.4161/auto.28679
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AL2HG
UT WOS:000338946000003
PM 24905352
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Goulielmaki, M
   Koustas, E
   Moysidou, E
   Vlassi, M
   Sasazuki, T
   Shirasawa, S
   Zografos, G
   Oikonomou, E
   Pintzas, A
AF Goulielmaki, Maria
   Koustas, Evangelos
   Moysidou, Eirini
   Vlassi, Margarita
   Sasazuki, Takehiko
   Shirasawa, Senji
   Zografos, George
   Oikonomou, Eftychia
   Pintzas, Alexander
TI BRAF associated autophagy exploitation: BRAF and autophagy inhibitors
   synergise to efficiently overcome resistance of BRAF mutant colorectal
   cancer cells
SO ONCOTARGET
LA English
DT Article
DE colorectal cancer; BRAF inhibitors; autophagy inhibitors; synergistic
   treatments
ID COLON-CANCER; RAS ONCOGENES; BRAF(V600E); MELANOMA; TUMORIGENESIS;
   INDUCTION; PATHWAY; TRANSFORMATION; VEMURAFENIB; SENSITIVITY
AB Autophagy is the basic catabolic mechanism that involves cell degradation of unnecessary or dysfunctional cellular components. Autophagy has a controversial role in cancer - both in protecting against tumor progression by isolation of damaged organelles, or by potentially contributing to cancer growth. The impact of autophagy in RAS induced transformation still remains to be further analyzed based on the differential effect of RAS isoforms and tumor cell context. In the present study, the effect of KRAS/BRAF/PIK3CA oncogenic pathways on the autophagic cell properties and on main components of the autophagic machinery like p62 (SQSTM1), Beclin-1 (BECN1) and MAP1LC3 (LC3) in colon cancer cells was investigated. This study provides evidence that BRAF oncogene induces the expression of key autophagic markers, like LC3 and BECN1 in colorectal tumor cells. Herein, PI3K/AKT/MTOR inhibitors induce autophagic tumor properties, whereas RAF/MEK/ERK signalling inhibitors reduce expression of autophagic markers. Based on the ineffectiveness of BRAFV600E inhibitors in BRAFV600E bearing colorectal tumors, the BRAF related autophagic properties in colorectal cancer cells are further exploited, by novel combinatorial anti-cancer protocols. Strong evidence is provided here that pre-treatment of autophagy inhibitor 3-MA followed by its combination with BRAFV600E targeting drug PLX4720 can synergistically sensitize resistant colorectal tumors. Notably, colorectal cancer cells are very sensitive to mono-treatments of another autophagy inhibitor, Bafilomycin A1. The findings of this study are expected to provide novel efficient protocols for treatment of otherwise resistant colorectal tumors bearing BRAFV600E, by exploiting the autophagic properties induced by BRAF oncogene.
C1 [Goulielmaki, Maria; Koustas, Evangelos; Moysidou, Eirini; Vlassi, Margarita; Oikonomou, Eftychia; Pintzas, Alexander] Natl Hellen Res Fdn, Inst Biol Med Chem & Biotechnol, Lab Signal Mediated Gene Express, Athens, Greece.
   [Sasazuki, Takehiko] Kyushu Univ, Inst Adv Study, Fukuoka 812, Japan.
   [Shirasawa, Senji] Kyushu Univ, Fac Med, Dept Cell Biol, Fukuoka 812, Japan.
   [Zografos, George] Gen Hosp Athens G Gennimatas, Dept Surg 3, Athens, Greece.
RP Pintzas, A (corresponding author), Natl Hellen Res Fdn, Inst Biol Med Chem & Biotechnol, Lab Signal Mediated Gene Express, Athens, Greece.
EM apint@eie.gr
RI Koustas, Evangelos/ABE-9336-2020
OI Moysidou, Eirini/0000-0002-3182-9159
FU European UnionEuropean Commission; General Secretariat of Research and
   Technology (GSRT) SINERGASIA "POM" [09SYN-11-675]; General Secretariat
   of Research and Technology (GSRT) KRIPIS "STHENOS" [MIS 447985]
FX This work was supported by FP6 and FP7 European Union grants, as well as
   by grants from the General Secretariat of Research and Technology (GSRT)
   SINERGASIA "POM" 09SYN-11-675 and KRIPIS "STHENOS" MIS 447985.
CR Akalay I, 2013, CANCER RES, V73, P2418, DOI 10.1158/0008-5472.CAN-12-2432
   Aredia Francesca, 2012, Cells, V1, P520, DOI 10.3390/cells1030520
   Basile KJ, 2012, AM J CANCER RES, V2, P726
   Bokobza SM, 2014, ONCOTARGET, V5, P4765, DOI 10.18632/oncotarget.2017
   Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454
   Carew Jennifer S, 2012, Cancer Manag Res, V4, P357, DOI 10.2147/CMAR.S26133
   Chou TC, 2008, LEUKEMIA LYMPHOMA, V49, P2059, DOI 10.1080/10428190802353591
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Coffee EM, 2013, CLIN CANCER RES, V19, P2688, DOI 10.1158/1078-0432.CCR-12-2556
   Coker-Gurkan A, 2014, EXP CELL RES, V328, P87, DOI 10.1016/j.yexcr.2014.07.022
   Condelli V, 2015, ONCOTARGET, V6, P22298, DOI 10.18632/oncotarget.4263
   Connolly K, 2014, CURR ONCOL, V21, pE151, DOI 10.3747/co.21.1661
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Elgendy M, 2011, MOL CELL, V42, P23, DOI 10.1016/j.molcel.2011.02.009
   Falchook GS, 2013, ONCOTARGET, V4, P310, DOI 10.18632/oncotarget.864
   Giatromanolaki A, 2010, J CLIN PATHOL, V63, P867, DOI 10.1136/jcp.2010.079525
   Goodall ML, 2014, AUTOPHAGY, V10, P1120, DOI 10.4161/auto.28594
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Hagenbuchner J, 2010, J BIOL CHEM, V285, P6904, DOI 10.1074/jbc.M109.038331
   Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833
   Hingorani SR, 2003, CANCER RES, V63, P5198
   Hucl T, 2007, CELL CYCLE, V6, P1336, DOI 10.4161/cc.6.11.4359
   Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Lee JW, 2007, APMIS, V115, P750, DOI 10.1111/j.1600-0463.2007.apm_640.x
   Lefort S, 2014, AUTOPHAGY, V10, P2122, DOI 10.4161/15548627.2014.981788
   Levy JMM, 2014, AUTOPHAGY, V10, P2077, DOI 10.4161/auto.36138
   Levy JMM, 2014, CANCER DISCOV, V4, P773, DOI 10.1158/2159-8290.CD-14-0049
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926
   Liu YL, 2010, AUTOPHAGY, V6, P1057, DOI 10.4161/auto.6.8.13365
   Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037
   Maes H, 2013, TRENDS MOL MED, V19, P428, DOI 10.1016/j.molmed.2013.04.005
   Makrodouli E, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-118
   Matsushita M, 2007, J BIOL CHEM, V282, P6763, DOI 10.1074/jbc.M609876200
   McArthur GA, 2012, J CLIN ONCOL, V30, P1628, DOI 10.1200/JCO.2011.39.1938
   McCubrey JA, 2012, ONCOTARGET, V3, P1505
   Meng J, 2010, PLOS ONE, V27
   Miracco C, 2007, INT J ONCOL, V30, P429
   Moreau K, 2010, CURR OPIN CELL BIOL, V22, P206, DOI 10.1016/j.ceb.2009.12.002
   Morgan MJ, 2014, AUTOPHAGY, V10, P1814, DOI 10.4161/auto.32135
   Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626
   Oikonomou E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021632
   Oikonomou E, 2009, NEOPLASIA, V11, P1116, DOI 10.1593/neo.09514
   Paglin S, 2001, CANCER RES, V61, P439
   Poklepovic A, 2014, AUTOPHAGY, V10, P1478, DOI 10.4161/auto.29428
   Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Prasetyanti PR, 2015, ONCOTARGET, V6, P16902, DOI 10.18632/oncotarget.4642
   Psahoulia FH, 2007, CARCINOGENESIS, V28, P1021, DOI 10.1093/carcin/bgl232
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Rangwala R, 2014, AUTOPHAGY, V10, P1369, DOI 10.4161/auto.29118
   Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690
   Roberts ML, 2006, INT J CANCER, V118, P616, DOI 10.1002/ijc.21386
   Saturno Grazia, 2013, Oncotarget, V4, P1185
   SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203
   Sridharan Savitha, 2011, Cancers (Basel), V3, P2630, DOI 10.3390/cancers3022630
   Strohecker AM, 2014, CANCER DISCOV, V4, P766, DOI 10.1158/2159-8290.CD-14-0196
   Strohecker AM, 2014, AUTOPHAGY, V10, P384, DOI 10.4161/auto.27320
   Takahashi S, 2003, INT J CANCER, V106, P310, DOI 10.1002/ijc.11205
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Todde V, 2009, BBA-MOL BASIS DIS, V1792, P3, DOI 10.1016/j.bbadis.2008.10.016
   Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105
   Vijapurkar U, 2012, CANCER LETT, V326, P168, DOI 10.1016/j.canlet.2012.08.011
   Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yoo BH, 2010, J BIOL CHEM, V285, P5438, DOI 10.1074/jbc.M109.046789
NR 68
TC 47
Z9 48
U1 0
U2 3
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD FEB 23
PY 2016
VL 7
IS 8
BP 9188
EP 9221
DI 10.18632/oncotarget.6942
PG 34
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DL4OW
UT WOS:000375618100058
PM 26802026
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Mishra, SK
   Kang, JH
   Song, KH
   Park, MS
   Kim, DK
   Park, YJ
   Choi, C
   Kim, HM
   Kim, MK
   Oh, SH
AF Mishra, S. K.
   Kang, J. -H.
   Song, K. -H.
   Park, M. S.
   Kim, D. -K.
   Park, Y. -J.
   Choi, C.
   Kim, H. M.
   Kim, M. K.
   Oh, S. H.
TI INONOTUS OBLIQUUS SUPPRESSES PROLIFERATION OF COLORECTAL CANCER CELLS
   AND TUMOR GROWTH IN MICE MODELS BY DOWNREGULATION OF
   beta-CATENIN/NF-kappa B-SIGNALING PATHWAYS
SO EUROPEAN JOURNAL OF INFLAMMATION
LA English
DT Article
DE anti-inflammation; colorectal carcinoma; Inonotus obliquus: natural
   product; Wnt/beta-catenin
ID INFLAMMATORY-BOWEL-DISEASE; COLON-CANCER; RECEPTOR ANTAGONIST;
   ULCERATIVE-COLITIS; WATER EXTRACT; APOPTOSIS; MUSHROOM; INDUCTION
AB Chaga mushroom (Inonotus obliquus) has been used as a folk remedy for several illnesses including gastrointestinal disorders. We recently reported the potent anti-inflammatory effect of chaga extract in experimental colitis. However, its effects on colorectal cancer (CRC) have not been clearly elucidated. We investigated the effects of an aqueous extract of Inonotus obliquus (IOAE) in vitro in HCT116 and DLD1 cell lines and in vivo for adenoma in APC(Min/+) mice and colitis-associated colon cancer in AOM/DSS-treated mice. Results show that IOAE suppressed the proliferation of both cell lines, and inhibited the growth of intestinal polyps in APC(Min/+) and colon tumors in AOM/DSS-treated mice. IOAE induced mitochondrial intrinsic pathway of apoptosis, autophagy, and S phase cell cycle arrest. IOAE suppressed the expression levels of iNOS and Cox-2 and mRNA levels of pro-inflammatory cytokines (IL-6, IL-1 beta, TNF-alpha and IFN-gamma) in the intestine of mice models. IOAE suppressed the nuclear levels of P-catenin and inhibited its downstream targets (cyclin D1 and c-Myc) along with CRC oncogene CDK8. IOAE inhibited the expression of NF-kappa B at cytoplasmic and nuclear levels. Our results demonstrate that IOAE possess potent anti-inflammatory and anti-proliferative properties through downregulation of Wnt/beta-catenin and NF-kappa B pathways. Considering recent anticancer approaches involving natural products with minimal side effects, we advocate that Inonotus obliquus could be a beneficial supplement in prevention of colorectal cancer.
C1 [Kang, J. -H.; Choi, C.] Chung Ang Univ, Dept Food & Nutr, Div Nat Sci, Ansung, South Korea.
   [Kang, J. -H.; Song, K. -H.] Natl Canc Ctr, Div Canc Biol, Goyang Si, South Korea.
   [Park, M. S.; Kim, D. -K.; Park, Y. -J.] Natl Canc Ctr, Anim Sci Branch, Goyang Si, South Korea.
   [Kim, M. K.] Natl Canc Ctr, Div Canc Epidemiol & Prevent, Carcinogenesis Branch, Goyang Si, South Korea.
RP Oh, SH (corresponding author), Gachon Univ, Gachon Inst Pharmaceut Sci, 7-45 Songdo Dong, Inchon 406840, South Korea.
EM alrud@ncc.re.kr; eyeball@gachon.ac.kr
RI Oh, Seung/AAN-6744-2021
FU Global Core Research Center (GCRC) from the National Research Foundation
   (NRF), Ministry of Education, Science and Technology (MEST), Republic of
   Korea [20110030678]; Korean Health Industry Development Industries
   (KHIDI); National Center for Efficacy Evaluation for the Development of
   Health Products Targeting Digestive Diseases
FX This work was financially supported by the Global Core Research Center
   (GCRC) Grant (No. 20110030678) from the National Research Foundation
   (NRF), Ministry of Education, Science and Technology (MEST), Republic of
   Korea and was also supported by the grant from Korean Health Industry
   Development Industries (KHIDI) and National Center for Efficacy
   Evaluation for the Development of Health Products Targeting Digestive
   Diseases.
CR Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7
   Chen CaiFa, 2007, American Journal of Pharmacology and Toxicology, V2, P10
   Cheong H, 2012, NAT BIOTECHNOL, V30, P671, DOI 10.1038/nbt.2285
   Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4
   Dionne S, 1998, CLIN EXP IMMUNOL, V112, P435
   Firestein R, 2008, NATURE, V455, P547, DOI 10.1038/nature07179
   Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710
   Hu HH, 2009, J BIOSCI BIOENG, V107, P42, DOI 10.1016/j.jbiosc.2008.09.004
   Kim HG, 2007, J MED FOOD, V10, P80, DOI 10.1089/jmf.2006.156
   Lazarova DL, 2004, INT J CANCER, V110, P523, DOI 10.1002/ijc.20152
   Lee SH, 2009, PHYTOTHER RES, V23, P1784, DOI 10.1002/ptr.2836
   Martinez ME, 2005, RECENT RESULTS CANC, V166, P177
   Mishra SK, 2013, MOL CELLS, V36, P219, DOI 10.1007/s10059-013-0050-9
   Mishra SK, 2012, J ETHNOPHARMACOL, V143, P524, DOI 10.1016/j.jep.2012.07.008
   MISHRA SK, 2012, FOOD NUTR COMPON FOC, P485, DOI DOI 10.1039/9781849735506-00485
   MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722
   Najafzadeh M, 2007, BIOFACTORS, V31, P191, DOI 10.1002/biof.5520310306
   OKAYASU I, 1990, GASTROENTEROLOGY, V98, P694, DOI 10.1016/0016-5085(90)90290-H
   Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5
   Shashkina MY, 2006, PHARM CHEM J+, V40, P560, DOI [10.1007/s11094-006-0194-4, DOI 10.1007/S11094-006-0194-4]
   Suh Y, 2009, CARCINOGENESIS, V30, P300, DOI 10.1093/carcin/bgn269
   Surh YJ, 2001, MUTAT RES-FUND MOL M, V480, P243, DOI 10.1016/S0027-5107(01)00183-X
   Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058
   Tountas NA, 1999, GASTROENTEROLOGY, V117, P806, DOI 10.1016/S0016-5085(99)70338-0
   Wang MT, 2007, CANCER METAST REV, V26, P525, DOI 10.1007/s10555-007-9096-5
   Wang SL, 2009, CELL MOL IMMUNOL, V6, P327, DOI 10.1038/cmi.2009.43
   Youn MA, 2008, WORLD J GASTROENTERO, V14, P511, DOI 10.3748/wjg.14.511
   Youn MJ, 2009, J ETHNOPHARMACOL, V121, P21, DOI 10.1016/j.jep.2008.10.016
   Ziegler DS, 2008, CURR OPIN ONCOL, V20, P97, DOI 10.1097/CCO.0b013e3282f310f6
NR 29
TC 12
Z9 12
U1 2
U2 25
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1721-727X
J9 EUR J INFLAMM
JI Eur. J. Inflamm.
PD SEP-DEC
PY 2013
VL 11
IS 3
BP 615
EP 629
DI 10.1177/1721727X1301100306
PG 15
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 287HS
UT WOS:000329533300006
OA Bronze
DA 2022-04-25
ER

PT J
AU Luan, YP
   Li, YM
   Zhu, LN
   Zheng, SQ
   Mao, DC
   Chen, ZX
   Cao, Y
AF Luan, Yunpeng
   Li, Yanmei
   Zhu, Lina
   Zheng, Shuangqing
   Mao, Dechang
   Chen, Zhuxue
   Cao, Yong
TI Codonopis bulleynana Forest ex Diels inhibits autophagy and induces
   apoptosis of colon cancer cells by activating the NF-kappa B signaling
   pathway
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE Codonopis bulleynana Forest ex Diels; oxaliplatin; autophagy; nuclear
   factor-kappa B pathway; pyrrolidine dithiocarbamate
ID COLORECTAL-CANCER; MECHANISMS; RADIATION; MEDICINE; DEATH
AB Despite its favorable clinical efficacy, oxaliplatin-based chemotherapy frequently results in treatment withdrawal and induces liver damage in colon cancer. Therefore, it is important to develop novel drugs, which can safely and effectively complement or replace the therapeutic effects of oxaliplatin. Codonopis bulleynana Forest ex Diels (cbFeD) has wide range of pharmacological effects, including anticancer effects. In the present study, the anticancer activity of cbFeD and its potential molecular mechanisms were investigated. In vitro, cell counting kit-8 assays and flow cytometry were used to assess the anti-proliferation and apoptosis-promoting activities of cbFeD. Transmission electron microscopy was used to monitor the autophagic vesicles. Immunofluorescence staining was performed to observe the nuclear translocation of p65 and the fluorescence of microtubule-associated protein 1 light chain 3 (LC3) B-II. The protein expression levels of p65, inhibitor of nuclear factor (NF)-kappa B (I kappa B) a, LC3B-I, LC3B-II and Beclin-1 were detected using western blot analysis. In vivo, the antitumor effect of cbFeD was assessed in colon cancer-bearing nude mice as a model. H&E staining and immunohistochemistry (IHC) were performed, with oxaliplatin set as a positive control. The results showed that cbFeD inhibited cell proliferation and promoted cell apoptosis in a dose-dependent manner. The effects of a high dose of cbFeD on colon cancer cells were similar to those of oxaliplatin. In HCT116 and SW480 cells, cbFeD inhibited the expression of I kappa B alpha, LC3B-I/II and Beclin-1, and the results of western blot analysis and immunofluorescence showed that, in the cells treated with cbFeD, p65 gradually entered nuclei in a dose-dependent manner, and the expression of LC3B-II was gradually reduced. The results of the acridine orangestaining and electron microscopy demonstrated fewer autophagic vesicles in the high-dose cbFeD group and the oxaliplatin group. The high dose of cbFeD reversed the effect of pyrrolidine dithiocarbamate, a p65-inhibitor, on the expression of p65, LC3B-I, LC3B-II and Beclin-1, and on the production of autophagic vacuoles. The high dose of cbFeD and oxaliplatin also suppressed tumorigenicity in vivo. The results of the H&E and IHC staining confirmed the inhibition of autophagy (LC3 and Beclin-1) and activation of p65 by treatment with the high dose of cbFeD and oxaliplatin. Taken together, cbFeD exhibited an antitumor effect in colon cancer cells by inhibiting autophagy through activation of the NF-kappa B pathway. Therefore, cbFeD may be a promising Chinese herbal compound for development for use in cancer therapy.
C1 [Luan, Yunpeng; Li, Yanmei; Zhu, Lina; Mao, Dechang; Chen, Zhuxue; Cao, Yong] Southwest Forestry Univ, Sch Life Sci, Dept Life Technol Teaching & Res, 300 Bailong Temple, Kunming 652400, Yunnan, Peoples R China.
   [Zheng, Shuangqing] Kunming Pharmaceut Corp, Kunming 652400, Yunnan, Peoples R China.
RP Cao, Y (corresponding author), Southwest Forestry Univ, Sch Life Sci, Dept Life Technol Teaching & Res, 300 Bailong Temple, Kunming 652400, Yunnan, Peoples R China.
EM 1820059756@qq.com
OI Luan, Yunpeng/0000-0002-6627-0906
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [61363061]
FX The study was supported by the National Natural Science Foundation of
   China (grant no. 61363061).
CR Alajez NM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167455
   Arber N, 2008, GASTROENTEROLOGY, V134, P1224, DOI 10.1053/j.gastro.2008.02.012
   Baldwin AS, 2012, IMMUNOL REV, V246, P327, DOI 10.1111/j.1600-065X.2012.01095.x
   Chen ST, 2016, MOLECULES, V21, DOI 10.3390/molecules21121677
   Chen SL, 2016, EXP THER MED, V12, P2003, DOI 10.3892/etm.2016.3588
   Chen Z, 2009, J CHIN MED MAT, V11, P1731
   CHEN Zi-jun1, 2009, SHANGHAI J TRADITION, V43, P68
   [陈子珺 Chen Zijun], 2012, [中成药, Chinese Traditional Patent Medicine], V34, P1848
   Dong LD, 2015, YUNNAN CHIN MED J, V36, P66
   Dutta D, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2055-1
   Jiang HP, 2017, J BIOCHEM MOL TOXIC, V31, DOI 10.1002/jbt.21888
   Katz ML, 2016, J CANC ED
   Liu D, 2017, CHIN J INTEGR MED, V23, P312, DOI 10.1007/s11655-016-2271-1
   Liu PinHua, 2014, Southwest China Journal of Agricultural Sciences, V27, P1894
   Lu YX, 2016, CANCER LETT, V380, P87, DOI 10.1016/j.canlet.2016.06.014
   O'Donovan TR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134676
   Paglin S, 2001, CANCER RES, V61, P439
   Panganiban RAM, 2013, INT J MOL SCI, V14, P15931, DOI 10.3390/ijms140815931
   Panteleimonitis S, 2016, WORLD J GASTRO SURG, V8, P744, DOI 10.4240/wjgs.v8.i11.744
   Rocha R, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-3650-y
   Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272
   Samuel T, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-599
   Shan JZ, 2016, PROTEIN CELL, V7, P571, DOI 10.1007/s13238-016-0295-0
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Sommerer C, 2016, KIDNEY DIS-BASEL, V2, P120, DOI 10.1159/000449394
   Tan SS, 2015, ONCOL LETT, V9, P2056, DOI 10.3892/ol.2015.2996
   Wang Bishi, 2015, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V31, P898
   Wang M, 2008, J BIOL CHEM, V283, P18678, DOI 10.1074/jbc.M801855200
   WHITEHURST C, 1994, J UROLOGY, V151, P1411, DOI 10.1016/S0022-5347(17)35270-9
   Xiong L, 2017, ONCOTARGET, V8, P6419, DOI 10.18632/oncotarget.14117
   Yang J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167540
   Zeng Y, 2015, EXP CELL RES, V339, P90, DOI 10.1016/j.yexcr.2015.08.013
NR 32
TC 8
Z9 10
U1 1
U2 15
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD MAR
PY 2018
VL 41
IS 3
BP 1305
EP 1314
DI 10.3892/ijmm.2017.3337
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FV9ON
UT WOS:000424918000013
PM 29286074
OA Green Published, hybrid, Green Submitted
DA 2022-04-25
ER

PT J
AU Saint-Martin, A
   Martinez-Rios, J
   Castaneda-Patlan, MC
   Sarabia-Sanchez, MA
   Tejeda-Munoz, N
   Chinney-Herrera, A
   Soldevila, G
   Benelli, R
   Santoyo-Ramos, P
   Poggi, A
   Robles-Flores, M
AF Saint-Martin, Abril
   Martinez-Rios, Jacobo
   Cristina Castaneda-Patlan, M.
   Angel Sarabia-Sanchez, Miguel
   Tejeda-Munoz, Nydia
   Chinney-Herrera, Alberto
   Soldevila, Gloria
   Benelli, Roberto
   Santoyo-Ramos, Paula
   Poggi, Alessandro
   Robles-Flores, Martha
TI Functional Interaction of Hypoxia-Inducible Factor 2-Alpha and Autophagy
   Mediates Drug Resistance in Colon Cancer Cells
SO CANCERS
LA English
DT Article
DE colon cancer; hypoxia-inducible factors; drug resistance; autophagy
ID HIF-2-ALPHA; HIF-1-ALPHA; INHIBITION; RADIORESISTANCE; 5-FLUOROURACIL;
   HIF2-ALPHA; ANTAGONIST; EXPRESSION; GENES; ROLES
AB Hypoxia and the accumulation of hypoxia-inducible factors (HIFs) in tumors have been associated with therapeutic resistance and with autophagy establishment. We examined the effects of stable knockdown of HIF-1 alpha or HIF-2 alpha expression on autophagy and drug resistance in colon cancer cells. We found that under normoxic conditions, malignant cells exhibit increased basal levels of autophagy, compared with non-malignant cells, in addition to the previously reported coexpression of HIF-1 alpha and HIF-2 alpha. Knockdown of HIF-1 alpha or HIF-2 alpha expression resulted in increased autophagic and apoptotic cell death, indicating that the survival of cells is HIF-dependent. Cytotoxic-induced cell death was significantly increased by knockdown of HIFs but not by autophagy inhibition. Strikingly, although malignancy-resistant cells were sensitized to death by nutrient stress, the combination with HIF-2 alpha, depletion, but not with HIF-1 alpha depletion, induced severe cell death. Oxidative stress levels were significantly increased as a result of HIF-2 alpha specific inhibition or silencing suggesting that this may contribute to sensitize cells to death. The in vitro results were confirmed in vivo using a xenograft mouse model. We found that coordinated autophagy and mTOR inhibition enhanced cell death and induced tumor remission only in HIF-2 alpha-silenced cells. Finally, using a specific HIF-2 alpha inhibitor alone or in combination with drugs in patient-derived primary colon cancer cells, overcame their resistance to 5-FU or CCI-779, thus emphasizing the crucial role played by HIF-2 alpha in promoting resistance and cell survival.
C1 [Saint-Martin, Abril; Cristina Castaneda-Patlan, M.; Angel Sarabia-Sanchez, Miguel; Tejeda-Munoz, Nydia; Santoyo-Ramos, Paula; Robles-Flores, Martha] Univ Nacl Autonoma Mexico, Fac Med, Dept Biochem, Mexico City 04510, DF, Mexico.
   [Martinez-Rios, Jacobo; Chinney-Herrera, Alberto; Soldevila, Gloria] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Immunol, Mexico City 04510, DF, Mexico.
   [Benelli, Roberto] IRCCS Osped Policlin San Martino, Immunol Unit, I-16132 Genoa, Italy.
   [Santoyo-Ramos, Paula; Poggi, Alessandro] IRCCS Osped Policlin San Martino, Mol Oncol & Angiogenesis Unit, I-16132 Genoa, Italy.
RP Robles-Flores, M (corresponding author), Univ Nacl Autonoma Mexico, Fac Med, Dept Biochem, Mexico City 04510, DF, Mexico.
EM abrilsaint@hotmail.com; jacobomartinezrios@yahoo.com.mx;
   cristi_ccp@yahoo.com; mike_sarabia@hotmail.com; nydia.tejeda@gmail.com;
   alder_30@hotmail.com; soldevi@unam.mx; roberto.benelli@hsanmartino.it;
   paula_ab@yahoo.com; alessandro.poggi@hsanmartino.it; rmartha@unam.mx
RI Munoz, Nydia Tejeda/ABF-3038-2020; Benelli, Roberto/AAF-3143-2019;
   Poggi, Alessandro/K-6664-2016
OI Munoz, Nydia Tejeda/0000-0001-8314-412X; Benelli,
   Roberto/0000-0002-9769-0954; Poggi, Alessandro/0000-0002-1860-430X;
   Castaneda-Patlan, Maria Cristina/0000-0002-2551-4847; Soldevila,
   Gloria/0000-0003-1539-2548; Saint Martin, Abril/0000-0003-3294-1879
FU Universidad Nacional Autonoma de Mexico (DGAPA-UNAM)Universidad Nacional
   Autonoma de Mexico [IN215514, IN225717]; CONACYTConsejo Nacional de
   Ciencia y Tecnologia (CONACyT) [FOSSIS 2017-289600]
FX This research was supported by grants from Universidad Nacional Autonoma
   de Mexico (DGAPA-UNAM IN215514 and IN225717) and from CONACYT (FOSSIS
   2017-289600).
CR Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35
   Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Bertout JA, 2009, P NATL ACAD SCI USA, V106, P14391, DOI 10.1073/pnas.0907357106
   Bohensky J, 2009, ARTHRITIS RHEUM-US, V60, P1406, DOI 10.1002/art.24444
   Bracht K, 2010, BRIT J CANCER, V103, P340, DOI 10.1038/sj.bjc.6605780
   Brown LM, 2006, MOL PHARMACOL, V69, P411, DOI 10.1124/mol.105.015743
   Carroll VA, 2006, CANCER RES, V66, P6264, DOI 10.1158/0008-5472.CAN-05-2519
   Chen WF, 2016, NATURE, V539, P112, DOI 10.1038/nature19796
   Cho H, 2016, NATURE, V539, P107, DOI 10.1038/nature19795
   Choi JH, 2012, APMIS, V120, P597, DOI 10.1111/j.1600-0463.2012.02876.x
   Doi N, 2015, EXP CELL RES, V333, P249, DOI 10.1016/j.yexcr.2015.03.009
   Franovic A, 2007, P NATL ACAD SCI USA, V104, P13092, DOI 10.1073/pnas.0702387104
   Franovic A, 2009, P NATL ACAD SCI USA, V106, P21306, DOI 10.1073/pnas.0906432106
   Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006
   Heberle AM, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723548.2014.970489
   Imamura T, 2009, INT J CANCER, V124, P763, DOI 10.1002/ijc.24032
   Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019
   Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183
   Koh MY, 2011, CANCER RES, V71, P4015, DOI 10.1158/0008-5472.CAN-10-4142
   Kubisch J, 2013, SEMIN CANCER BIOL, V23, P252, DOI 10.1016/j.semcancer.2013.06.009
   Lee CL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009155
   Liu XW, 2010, PHARMACOL RES, V62, P416, DOI 10.1016/j.phrs.2010.07.002
   Mazure NM, 2010, CURR OPIN CELL BIOL, V22, P177, DOI 10.1016/j.ceb.2009.11.015
   Menrad H, 2010, HEPATOLOGY, V51, P2183, DOI 10.1002/hep.23597
   Munster T, 2002, ARTHRITIS RHEUM-US, V46, P1460, DOI 10.1002/art.10307
   Nardinocchi L, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-1
   Pietrocola F, 2013, SEMIN CANCER BIOL, V23, P310, DOI 10.1016/j.semcancer.2013.05.008
   Robles-Flores M, 2017, J CELL SIGNAL, V2, P154, DOI 10.4172/2161-0495.1000154
   Rohwer N, 2011, DRUG RESIST UPDATE, V14, P191, DOI 10.1016/j.drup.2011.03.001
   Santoyo-Ramos P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112580
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Scheuermann TH, 2013, NAT CHEM BIOL, V9, P271, DOI [10.1038/NCHEMBIO.1185, 10.1038/nchembio.1185]
   Schonewolf CA, 2014, WORLD J GASTRO ONCOL, V6, P74, DOI 10.4251/wjgo.v6.i3.74
   Schulz K, 2012, FEBS LETT, V586, P1652, DOI 10.1016/j.febslet.2012.04.039
   Scortegagna M, 2003, NAT GENET, V35, P331, DOI 10.1038/ng1266
   Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005
   Taniguchi CM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008523
   Wallace EM, 2016, CANCER RES, V76, P5491, DOI 10.1158/0008-5472.CAN-16-0473
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Wigerup C, 2016, PHARMACOL THERAPEUT, V164, P152, DOI 10.1016/j.pharmthera.2016.04.009
   Xie XQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055096
   Yun Z, 2014, ADV EXP MED BIOL, V772, P41, DOI 10.1007/978-1-4614-5915-6_2
   Zheng Hai-yang, 2012, Cancer Biology Medicine, V9, P105, DOI 10.3969/j.issn.2095-3941.2012.02.004
   Zhou JC, 2014, INT J RADIAT ONCOL, V90, P942, DOI 10.1016/j.ijrobp.2014.06.065
NR 46
TC 10
Z9 10
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2072-6694
J9 CANCERS
JI Cancers
PD JUN
PY 2019
VL 11
IS 6
AR 755
DI 10.3390/cancers11060755
PG 19
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA II7CZ
UT WOS:000475351200019
PM 31151160
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Gao, GY
   Ma, J
   Lu, P
   Jiang, X
   Chang, C
AF Gao, Guang-Yi
   Ma, Jun
   Lu, Peng
   Jiang, Xuan
   Chang, Cheng
TI Ophiopogonin B induces the autophagy and apoptosis of colon cancer cells
   by activating JNK/c-Jun signaling pathway
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Colon cancer; Ophiopogonin B; JNK/c-Jun; Autophagy; Apoptosis
ID COLORECTAL-CANCER; GASTRIC-CANCER; BECLIN 1; EXPRESSION; CARCINOMA;
   DEATH; BCL-2; PROLIFERATION; DEGRADATION; P62/SQSTM1
AB Objective: To investigate the effect of Ophiopogonin B (OP-B) on the autophagy and apoptosis of colon cancer cells via the regulation of JNK/c-Jun signaling pathway.
   Methods: Colon cancer cell lines (HT-29 and HCT-116) were treated with various concentrations of OP-B (0, 5, 10and 20 mu mol/l) and JNK inhibitor SP600125. MTT assay, flow cytometry, immunofluorescence staining were used to detect the biological function ofHT-29 and HCT-116 cells, and expressions of autophagy-, apoptotic-and pathway-related proteins were measured by Western Blot. Moreover, a nude mice model with transplanted tumor was used to observe the effect of OP-B on the growth, autophagy and apoptosis of the transplanted tumor of colon cancer.
   Results: The results demonstrated that OP-B suppressed the proliferation of HT-29 and HCT-116 cell lines through the G0/G1 phase cell cycle arrest. Moreover, OP-B induced apoptosis by inhibiting the expression of Bax and cleaved caspase 3 and promoting the expression of Bcl-2. Treatment with OP-B also increased the expression of Beclin 1 and the conversion of LC3I to LC3II with the activation of JNK/c-Jun signaling pathway, but reduced the expression of P62, whereas SP600125 (an inhibitor of JNK) reversed these process. In addition, the xenograft model using HCT-116 cells provided further evidence of the inhibition of OP-B on tumor proliferation. Immunohistochemistry detection verified that OP-B enhance the positive expression rate of LC3, and increase the apoptosis index of tumor cells in vivo. Importantly, all these changes induced by OP-B were clearly in a dosedependent manner.
   Conclusion: OP-B may induce cell autophagy, apoptosis and cell cycle arrest by activating the JNK/c-Jun signaling pathway, thereby inhibiting the growth of colon cancer.
C1 [Gao, Guang-Yi] Xuzhou Med Univ, Affiliated Huaian Hosp, Huaian Peoples Hosp 2, Dept Tradit Chinese Med, 62 Huaihai South Rd, Huaian 223002, Jiangsu, Peoples R China.
   [Ma, Jun] Nanjing Univ Chinese Med, Affiliated Huaian Hosp, Huaian Hosp Chinese Med, Dept Oncol, Nanjing, Jiangsu, Peoples R China.
   [Lu, Peng] Yangzhou Univ, Med Acad, Huaian Matern & Child Healthcare Hosp, Dept Pharm, Huaian, Jiangsu, Peoples R China.
   [Jiang, Xuan] Xuzhou Med Univ, Affiliated Huaian Hosp, Huaian Peoples Hosp 2, Dept Oncol, Huaian, Jiangsu, Peoples R China.
   [Chang, Cheng] Nanjing Jianzhong Hosp Tradit Chinese Med, Internal Med Tradit Chinese Med, Nanjing, Jiangsu, Peoples R China.
RP Gao, GY (corresponding author), Xuzhou Med Univ, Affiliated Huaian Hosp, Huaian Peoples Hosp 2, Dept Tradit Chinese Med, 62 Huaihai South Rd, Huaian 223002, Jiangsu, Peoples R China.
EM guangyi_gg@sina.com
CR Ahmed FE, 2003, J ENVIRON SCI HEAL C, V21, P65, DOI 10.1081/GNC-120026233
   Alirezaei M, 2015, AUTOPHAGY, V11, P1389, DOI 10.1080/15548627.2015.1063769
   Bayne K, 1996, Physiologist, V39, P208
   Bayne K, 1996, PHYSIOLOGIST, V39, P208
   Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4
   Chen MJ, 2016, INT J ONCOL, V49, P316, DOI 10.3892/ijo.2016.3514
   Chen MJ, 2013, ONCOL REP, V29, P430, DOI 10.3892/or.2012.2131
   Chen MC, 2015, J AGR FOOD CHEM, V63, P1540, DOI 10.1021/jf5054063
   Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4
   Eimani BG, 2014, CELL J, V15, P356
   Guo JL, 2008, J HUAZHONG U SCI-MED, V28, P281, DOI 10.1007/s11596-008-0311-6
   Holt SV, 2011, TOXICOL PATHOL, V39, P516, DOI 10.1177/0192623310396903
   Jiang QG, 2014, MOL BIOL REP, V41, P3359, DOI 10.1007/s11033-014-3198-2
   Jing Z, 2016, ONCOTARGET, V7, P61509, DOI 10.18632/oncotarget.11385
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kantara C, 2014, CANCER RES, V74, P2487, DOI 10.1158/0008-5472.CAN-13-3536
   Kim YJ, 2015, BIOORG MED CHEM LETT, V25, P2559, DOI 10.1016/j.bmcl.2015.04.054
   Kitanaka Chifumi, 2013, Genes Cancer, V4, P388, DOI 10.1177/1947601912474892
   Li DD, 2009, ONCOGENE, V28, P886, DOI 10.1038/onc.2008.441
   Lorin S, 2010, AUTOPHAGY, V6, P153, DOI 10.4161/auto.6.1.10537
   Masuda G, 2016, ANTICANCER RES, V36, P129
   Mehan S, 2011, J MOL NEUROSCI, V43, P376, DOI 10.1007/s12031-010-9454-6
   Odonkor CA, 2009, CANCER INVEST, V27, P417, DOI 10.1080/07357900802438585
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Prizment AE, 2010, CANCER EPIDEM BIOMAR, V19, P2229, DOI 10.1158/1055-9965.EPI-10-0522
   Qi FH, 2015, BIOSCI TRENDS, V9, P16, DOI 10.5582/bst.2015.01019
   Raychaudhuri S, 2013, J HEALTHC ENG, V4, P47, DOI 10.1260/2040-2295.4.1.47
   Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6
   Su CC, 2012, EXP THER MED, V3, P555, DOI 10.3892/etm.2011.441
   Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019
   Tsukahara S, 2006, NEUROIMMUNOMODULAT, V13, P63, DOI 10.1159/000094829
   Uen YH, 2015, SCI REP-UK, V5, DOI 10.1038/srep09360
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   Wu CX, 2015, OPEN BIOL, V5, DOI 10.1098/rsob.140171
   Xavier CPR, 2013, J NUTR BIOCHEM, V24, P706, DOI 10.1016/j.jnutbio.2012.04.004
   Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016
   Zamora-Ros R, 2015, GENES NUTR, V10, DOI 10.1007/s12263-014-0447-x
   Zang QQ, 2016, J INTEGR MED-JIM, V14, P51, DOI 10.1016/S2095-4964(16)60238-8
   Zhang WY, 2016, MOL MED REP, V13, P4981, DOI 10.3892/mmr.2016.5198
NR 39
TC 21
Z9 24
U1 3
U2 15
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD DEC
PY 2018
VL 108
BP 1208
EP 1215
DI 10.1016/j.biopha.2018.06.172
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA HA2UZ
UT WOS:000450101800135
PM 30372822
OA hybrid
DA 2022-04-25
ER

PT J
AU Chen, ST
   Lee, TY
   Tsai, TH
   Lin, YC
   Lin, CP
   Shieh, HR
   Hsu, ML
   Chi, CW
   Lee, MC
   Chang, HH
   Chen, YJ
AF Chen, Shun-Ting
   Lee, Tzung-Yan
   Tsai, Tung-Hu
   Lin, Yin-Cheng
   Lin, Chin-Ping
   Shieh, Hui-Ru
   Hsu, Ming-Ling
   Chi, Chih-Wen
   Lee, Ming-Cheng
   Chang, Hen-Hong
   Chen, Yu-Jen
TI The Traditional Chinese Medicine DangguiBuxue Tang Sensitizes Colorectal
   Cancer Cells to Chemoradiotherapy
SO MOLECULES
LA English
DT Article
DE DangguiBuxue Tang; colorectal cancer; chemotherapy; radiotherapy
ID RADIX-ANGELICAE-SINENSIS; SIGNAL-REGULATED KINASE; HERBAL DECOCTION;
   BUXUE-TANG; AUTOPHAGY; ASTRAGALI; STATISTICS; TOXICITY; SURVIVAL
AB Chemotherapy is an important treatment modality for colon cancer, and concurrent chemoradiation therapy (CCRT) is the preferred treatment route for patients with stage II and III rectal cancer. We examined whether DangguiBuxue Tang (DBT), a traditional Chinese herbal extract, sensitizes colorectal cancer cells to anticancer treatments. The polysaccharide-depleted fraction of DBT (DBT-PD) contains greater amounts of astragaloside IV (312.626 mu g/g) and ferulic acid (1.404 mu g/g) than does the original formula. Treatment of the murine colon carcinoma cell line (CT26) with DBT-PD inhibits growth, whereas treatment with comparable amounts of purified astragaloside IV and ferulic acid showed no significant effect. Concurrent treatment with DBT-PD increases the growth inhibitory effect of 5-fluorouracil up to 4.39-fold. DBT-PD enhances the effect of radiation therapy (RT) with a sensitizer enhancement ratio (SER) of up to 1.3. It also increases the therapeutic effect of CCRT on CT26 cells. Cells treated with DBP-PD showed ultrastructural changes characteristic of autophagy, including multiple cytoplasmic vacuoles with double-layered membranes, vacuoles containing remnants of degraded organelles, marked swelling and vacuolization of mitochondria, and autolysosome-like vacuoles. We conclude that DBT-PD induces autophagy-associated cell death in CT26 cells, and may have potential as a chemotherapy or radiotherapy sensitizer in colorectal cancer treatment.
C1 [Chen, Shun-Ting] Buddhist Tzu Chi Gen Hosp, Taipei Branch, Dept Chinese Med, New Taipei 23142, Taiwan.
   [Chen, Shun-Ting; Lee, Tzung-Yan] Chang Gung Univ, Grad Inst Tradit Chinese Med, Sch Chinese Med, Coll Med, Taoyuan 33302, Taiwan.
   [Chen, Shun-Ting] Chang Gung Univ, Grad Inst Clin Med Sci, Coll Med, Taoyuan 33302, Taiwan.
   [Tsai, Tung-Hu] Natl Yang Ming Univ, Inst Tradit Med, Sch Med, Taipei 11221, Taiwan.
   [Lin, Yin-Cheng; Lin, Chin-Ping; Shieh, Hui-Ru; Hsu, Ming-Ling; Chi, Chih-Wen; Chen, Yu-Jen] Mackay Mem Hosp, Dept Med Res, Taipei 25160, Taiwan.
   [Lee, Ming-Cheng] Buddhist Tzu Chi Gen Hosp, Taipei Branch, Dept Res, New Taipei 23141, Taiwan.
   [Chang, Hen-Hong] China Med Univ, Sch Postbaccalaureate Chinese Med, Taichung 40402, Taiwan.
   [Chang, Hen-Hong] China Med Univ, Res Ctr Chinese Med & Acupuncture, Taichung 40402, Taiwan.
   [Chang, Hen-Hong; Chen, Yu-Jen] China Med Univ Hosp, Dept Chinese Med, Taichung 40402, Taiwan.
   [Chen, Yu-Jen] Mackay Mem Hosp, Dept Radiat Oncol, Taipei 25160, Taiwan.
RP Chen, YJ (corresponding author), Mackay Mem Hosp, Dept Med Res, Taipei 25160, Taiwan.; Chang, HH (corresponding author), China Med Univ, Sch Postbaccalaureate Chinese Med, Taichung 40402, Taiwan.; Chang, HH (corresponding author), China Med Univ, Res Ctr Chinese Med & Acupuncture, Taichung 40402, Taiwan.; Chang, HH; Chen, YJ (corresponding author), China Med Univ Hosp, Dept Chinese Med, Taichung 40402, Taiwan.; Chen, YJ (corresponding author), Mackay Mem Hosp, Dept Radiat Oncol, Taipei 25160, Taiwan.
EM cst.tp.tw@gmail.com; joejoylee@gmail.com; thtsai@ym.edu.tw;
   eric7772330@gmail.com; cplin66@gmail.com; ru123@ms1.mmh.org.tw;
   sabinehsu@gmail.com; cwchid48906003@gmail.com; sardorna@yahoo.com.tw;
   tcmchh55@mail.cmu.edu.tw; chenmdphd@gmail.com
RI Tsai, Tung-Hu/AAG-4558-2021
OI Tsai, Tung-Hu/0000-0002-9007-2547
FU Mackay Memorial Hospital [MMH-E-105-13, MMH-E-104-13]; China Medical
   University under the Aim of Top University Plan of Ministry of
   Education, Taiwan
FX This study was supported by Mackay Memorial Hospital (grant numbers
   MMH-E-105-13 and MMH-E-104-13) and China Medical University under the
   Aim of Top University Plan of Ministry of Education, Taiwan.
CR Chiu PY, 2007, PLANTA MED, V73, P134, DOI 10.1055/s-2006-957068
   Choi RCY, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nen085
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Dong TTX, 2006, J AGR FOOD CHEM, V54, P2767, DOI 10.1021/jf053163l
   Gao QT, 2008, PLANTA MED, V74, P392, DOI 10.1055/s-2008-1034322
   Gao QT, 2007, FEBS LETT, V581, P5087, DOI 10.1016/j.febslet.2007.09.053
   Gao QT, 2007, FEBS LETT, V581, P233, DOI 10.1016/j.febslet.2006.12.018
   Gao QT, 2006, PLANTA MED, V72, P1227, DOI 10.1055/s-2006-947186
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Lam W, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-490
   Li D.Y., 2011, DIFFERENTIATION ENDO, P24
   Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660
   O'Connell JB, 2004, JNCI-J NATL CANCER I, V96, P1420, DOI 10.1093/jnci/djh275
   Ondrej M, 2016, RADIOTHER ONCOL, V119, P265, DOI 10.1016/j.radonc.2016.02.028
   Panganiban RAM, 2013, INT J MOL SCI, V14, P15931, DOI 10.3390/ijms140815931
   Roh MS, 2009, J CLIN ONCOL, V27, P5124, DOI 10.1200/JCO.2009.22.0467
   Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272
   Saif MW, 2014, CANCER CHEMOTH PHARM, V73, P373, DOI 10.1007/s00280-013-2359-7
   Sauer R, 2004, NEW ENGL J MED, V351, P1731, DOI 10.1056/NEJMoa040694
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Wang CC, 2013, MENOPAUSE, V20, P223, DOI 10.1097/gme.0b013e318267f64e
   Wang W, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/518609
   Yang M, 2009, J ETHNOPHARMACOL, V124, P87, DOI 10.1016/j.jep.2009.04.007
   Zhang N, 2016, AM J CANCER RES, V6, P97
NR 26
TC 14
Z9 17
U1 1
U2 21
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1420-3049
J9 MOLECULES
JI Molecules
PD DEC
PY 2016
VL 21
IS 12
AR 1677
DI 10.3390/molecules21121677
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA EI0CQ
UT WOS:000392140100071
PM 27929437
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Kosumi, K
   Masugi, Y
   Yang, JH
   Qian, ZR
   Kim, SA
   Li, WW
   Shi, Y
   da Silva, A
   Hamada, T
   Liu, L
   Gu, M
   Twombly, TS
   Cao, Y
   Barbie, DA
   Nosho, K
   Baba, H
   Garrett, WS
   Meyerhardt, JA
   Giovannucci, EL
   Chan, AT
   Fuchs, CS
   Ogino, S
   Nishihara, R
AF Kosumi, Keisuke
   Masugi, Yohei
   Yang, Juhong
   Qian, Zhi Rong
   Kim, Sun A.
   Li, Wanwan
   Shi, Yan
   da Silva, Annacarolina
   Hamada, Tsuyoshi
   Liu, Li
   Gu, Mancang
   Twombly, Tyler S.
   Cao, Yin
   Barbie, David A.
   Nosho, Katsuhiko
   Baba, Hideo
   Garrett, Wendy S.
   Meyerhardt, Jeffery A.
   Giovannucci, Edward L.
   Chan, Andrew T.
   Fuchs, Charles S.
   Ogino, Shuji
   Nishihara, Reiko
TI Tumor SQSTM1 (p62) expression and T cells in colorectal cancer
SO ONCOIMMUNOLOGY
LA English
DT Article
DE Adenocarcinoma; colorectum; immunoprevention; immunotherapy; molecular
   pathology
ID ISLAND METHYLATOR PHENOTYPE; IMMUNE-RESPONSES; MICROSATELLITE
   INSTABILITY; MOLECULAR SUBTYPES; P62/SEQUESTOSOME 1; CROSS-PRESENTATION;
   PIK3CA MUTATION; BRAF MUTATION; ASPIRIN USE; AUTOPHAGY
AB Evidence suggests that activation of autophagy in neoplastic cells potentiates antitumor immunity through cross-presentation of tumor-associated antigens to T cells and release of immune mediators. The SQSTM1 (sequestosome 1, p62) protein is degraded by activated autophagy, and might enhance immune response to tumor cells. We hypothesized that tumor SQSTM1 expression level might be inversely associated with T-cell densities in colorectal carcinoma tissue. We evaluated tumor SQSTM1 expression by immunohistochemistry in 601 rectal and colon cancer cases within the Nurses' Health Study and Health Professionals Follow-up Study. Ordinal logistic regression analyses were conducted to assess the association of tumor SQSTM1 expression with CD3(+), CD8(+), CD45RO (PTPRC)(+), or FOXP3(+) cell density in tumor tissue, controlling for potential confounders, including tumor status of microsatellite instability, CpG island methylator phenotype, long interspersed nucleotide element-1 methylation level, and KRAS, BRAF, and PIK3CA mutations. Tumor SQSTM1 expression level was inversely associated with FOXP3(+) cell density (p(trend) = 0.006), but not with CD3(+), CD8(+), or CD45RO(+) cell density (with the adjusted a level of 0.01 for multiple hypothesis testing). For a unit increase in quartile categories of FOXP3(+) cell density, multivariable odds ratios were 0.66 [95% confidence interval (CI), 0.45-0.98] for intermediate-level SQSTM1 expression, and 0.55 (95% CI, 0.36- 0.83) for high-level SQSTM1 expression, compared with low-level SQSTM1 expression. Tumor SQSTM1 expression is inversely associated with FOXP3(+) cell density in colorectal cancer tissue, suggesting a possible role of SQSTM1-expressing carcinoma cells on regulatory T cells in the tumor microenvironment.
C1 [Kosumi, Keisuke; Masugi, Yohei; Qian, Zhi Rong; Li, Wanwan; Shi, Yan; da Silva, Annacarolina; Hamada, Tsuyoshi; Liu, Li; Gu, Mancang; Twombly, Tyler S.; Barbie, David A.; Garrett, Wendy S.; Meyerhardt, Jeffery A.; Fuchs, Charles S.; Ogino, Shuji; Nishihara, Reiko] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA.
   [Kosumi, Keisuke; Masugi, Yohei; Qian, Zhi Rong; Li, Wanwan; Shi, Yan; da Silva, Annacarolina; Hamada, Tsuyoshi; Liu, Li; Gu, Mancang; Twombly, Tyler S.; Cao, Yin; Barbie, David A.; Garrett, Wendy S.; Meyerhardt, Jeffery A.; Giovannucci, Edward L.; Fuchs, Charles S.; Ogino, Shuji; Nishihara, Reiko] Harvard Med Sch, Boston, MA USA.
   [Yang, Juhong] Tianjin Med Univ, Collaborat Innovat Ctr Tianjin Med Epigenet, Key Lab Hormone & Dev, Minist Hlth,Metab Dis Hosp, Tianjin, Peoples R China.
   [Yang, Juhong] Tianjin Med Univ, Tianjin Inst Endocrinol, Tianjin, Peoples R China.
   [Kim, Sun A.] NCI, Human Carcinogenesis Lab, NIH, Bldg 37, Bethesda, MD 20892 USA.
   [Liu, Li; Cao, Yin; Giovannucci, Edward L.; Nishihara, Reiko] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA.
   [Cao, Yin; Chan, Andrew T.] Massachusetts Gen Hosp, Clin & Translat Epidemiol Unit, Boston, MA 02114 USA.
   [Cao, Yin; Chan, Andrew T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
   [Nosho, Katsuhiko] Sapporo Med Univ, Sch Med, Dept Gastroenterol Rheumatol & Clin Immunol, Sapporo, Hokkaido, Japan.
   [Baba, Hideo] Kumamoto Univ, Grad Sch Med Sci, Dept Surg Gastroenterol, Kumamoto, Japan.
   [Garrett, Wendy S.] Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA USA.
   [Giovannucci, Edward L.; Chan, Andrew T.; Fuchs, Charles S.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA.
   [Giovannucci, Edward L.; Ogino, Shuji; Nishihara, Reiko] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
   [Chan, Andrew T.] Broad Inst MIT & Harvard, Cambridge, MA USA.
   [Ogino, Shuji; Nishihara, Reiko] Brigham & Womens Hosp, Dept Pathol, Div MPE Mol Pathol Epidemiol, 450 Brookline Ave,DFCI Room SM1036, Boston, MA 02215 USA.
   [Ogino, Shuji] Dana Farber Canc Inst, Dept Oncol Pathol, Boston, MA 02115 USA.
   [Nishihara, Reiko] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA.
RP Ogino, S; Nishihara, R (corresponding author), Brigham & Womens Hosp, Dept Pathol, Div MPE Mol Pathol Epidemiol, 450 Brookline Ave,DFCI Room SM1036, Boston, MA 02215 USA.
EM shuji_ogino@dfci.harvard.edu; rnishihara@hsph.harvard.edu
RI Masugi, Yohei/E-6980-2014; Masugi, Yohei/W-8215-2019; Cao,
   Yin/ABE-2332-2021
OI Masugi, Yohei/0000-0002-6952-4043; Masugi, Yohei/0000-0002-6952-4043;
   Cao, Yin/0000-0001-9835-7662; Garrett, Wendy/0000-0002-5092-0150; Ogino,
   Shuji/0000-0002-3909-2323; Shi, Yan/0000-0001-9777-8836
FU U.S. National Institutes of Health (NIH)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA [P01
   CA87969, UM1 CA186107, P01 CA55075, UM1 CA167552, P50 CA127003, R01
   CA137178, R01 CA151993, R35 CA197735, K07 CA190673]; Dana-Farber Harvard
   Cancer Center; Project P Fund; Friends of the Dana-Farber Cancer
   Institute; Bennett Family Fund; Entertainment Industry Foundation
   through National Colorectal Cancer Research Alliance; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [81200612]; Tianjin City High School Science & Technology Fund
   Planning Project [20102217]; Japanese Society for the Promotion of
   ScienceMinistry of Education, Culture, Sports, Science and Technology,
   Japan (MEXT)Japan Society for the Promotion of Science; Keio Gijuku
   Fukuzawa Memorial Fund; Uehara Memorial FoundationUehara Memorial
   Foundation; Mochida Memorial Foundation for Medical and Pharmaceutical
   Research; NATIONAL CANCER INSTITUTEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [R01CA169141, R35CA197735, R01CA118553,
   K07CA190673] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
   [P30DK043351] Funding Source: NIH RePORTER
FX This work was supported by U.S. National Institutes of Health (NIH)
   grants [P01 CA87969 to M.J. Stampfer; UM1 CA186107 to M.J. Stampfer; P01
   CA55075 to W.C. Willett; UM1 CA167552 to W.C. Willett; P50 CA127003 to
   C.S.F.; R01 CA137178 to A.T.C.; R01 CA151993 to S.O.; R35 CA197735 to
   S.O.; and K07 CA190673 to R.N.]; Nodal Award (to S.O.) from the
   Dana-Farber Harvard Cancer Center; and by grants from the Project P
   Fund, the Friends of the Dana-Farber Cancer Institute, Bennett Family
   Fund, and the Entertainment Industry Foundation through National
   Colorectal Cancer Research Alliance. J. Y is supported by National
   Natural Science Foundation of China (81200612); Tianjin City High School
   Science & Technology Fund Planning Project (20102217). K.K. is supported
   by a grant from Program for Advancing Strategic International Networks
   to Accelerate the Circulation of Talented Researchers from Japanese
   Society for the Promotion of Science. Y.M. is supported by a fellowship
   grant of the Keio Gijuku Fukuzawa Memorial Fund for the Advancement of
   Education and Research. T.H. was supported by a fellowship grant from
   the Uehara Memorial Foundation and by a grant from the Mochida Memorial
   Foundation for Medical and Pharmaceutical Research.
CR Andersen AN, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00167
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4
   Cao Y, 2016, GASTROENTEROLOGY, V151, P879, DOI 10.1053/j.gastro.2016.07.030
   Chan AT, 2007, NEW ENGL J MED, V356, P2131, DOI 10.1056/NEJMoa067208
   Colussi D, 2013, INT J MOL SCI, V14, P16365, DOI 10.3390/ijms140816365
   Cui J, 2016, AUTOPHAGY, V12, P1210, DOI 10.1080/15548627.2016.1173801
   Deretic V, 2013, NAT REV IMMUNOL, V13, P722, DOI 10.1038/nri3532
   Di Caro G, 2013, J CELL MOL MED, V17, P1088, DOI 10.1111/jcmm.12117
   Dienstmann R, 2017, NAT REV CANCER, V17, P79, DOI 10.1038/nrc.2016.126
   Elliott MR, 2009, NATURE, V461, P282, DOI 10.1038/nature08296
   English L, 2009, NAT IMMUNOL, V10, P480, DOI 10.1038/ni.1720
   Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139
   Galon J, 2014, J PATHOL, V232, P199, DOI 10.1002/path.4287
   Goulielmaki M, 2016, ONCOTARGET, V7, P9188, DOI 10.18632/oncotarget.6942
   Imamura Y, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-135
   Kanayama M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6779
   Katsuragi Y, 2015, FEBS J, V282, P4672, DOI 10.1111/febs.13540
   Kaur J, 2015, NAT REV MOL CELL BIO, V16, P461, DOI 10.1038/nrm4024
   Kocarnik JM, 2015, GASTROENTEROL REP, V3, P269, DOI 10.1093/gastro/gov046
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   Ladoire S, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1174801
   Ladoire S, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1160193
   Ladoire S, 2016, AUTOPHAGY, V12, P864, DOI 10.1080/15548627.2016.1154244
   Ladoire S, 2011, CANCER IMMUNOL IMMUN, V60, P909, DOI 10.1007/s00262-011-1046-y
   Lamb CA, 2013, NAT REV MOL CELL BIO, V14, P759, DOI 10.1038/nrm3696
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Lee Y, 2015, CELL REP, V13, P223, DOI 10.1016/j.celrep.2015.09.005
   Li YH, 2008, CANCER RES, V68, P6889, DOI 10.1158/0008-5472.CAN-08-0161
   Li YH, 2012, CANCER RES, V72, P3535, DOI 10.1158/0008-5472.CAN-11-3103
   Li YH, 2011, CLIN CANCER RES, V17, P7047, DOI 10.1158/1078-0432.CCR-11-0951
   Liao XY, 2012, NEW ENGL J MED, V367, P1596, DOI 10.1056/NEJMoa1207756
   Liao XY, 2012, CLIN CANCER RES, V18, P2257, DOI 10.1158/1078-0432.CCR-11-2410
   Liston A, 2014, NAT REV IMMUNOL, V14, P154, DOI 10.1038/nri3605
   Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863
   Ma YT, 2013, IMMUNITY, V39, P211, DOI 10.1016/j.immuni.2013.07.017
   Martinez-Useros J, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0772-5
   Martins I, 2012, AUTOPHAGY, V8, P413, DOI 10.4161/auto.19009
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Mei Z, 2014, BRIT J CANCER, V110, P1595, DOI 10.1038/bjc.2014.46
   Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347
   Mima K, 2016, GUT, V65, P1973, DOI 10.1136/gutjnl-2015-310101
   Mima K, 2015, JAMA ONCOL, V1, P653, DOI 10.1001/jamaoncol.2015.1377
   Mlecnik B, 2016, IMMUNITY, V44, P698, DOI 10.1016/j.immuni.2016.02.025
   Mlecnik B, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007240
   Nishihara R, 2013, NEW ENGL J MED, V369, P1095, DOI 10.1056/NEJMoa1301969
   Nishihara R, 2013, JAMA-J AM MED ASSOC, V309, P2563, DOI 10.1001/jama.2013.6599
   Nosho K, 2010, J PATHOL, V222, P350, DOI 10.1002/path.2774
   Nosho K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003698
   Ogino S, 2016, EPIDEMIOLOGY, V27, P602, DOI 10.1097/EDE.0000000000000471
   Ogino S, 2012, EXPERT REV MOL DIAGN, V12, P621, DOI [10.1586/ERM.12.46, 10.1586/erm.12.46]
   Ogino S, 2011, NAT REV CLIN ONCOL, V8, P711, DOI 10.1038/nrclinonc.2011.122
   Ogino S, 2009, CLIN CANCER RES, V15, P6412, DOI 10.1158/1078-0432.CCR-09-1438
   Ogino S, 2009, GUT, V58, P90, DOI 10.1136/gut.2008.155473
   Okugawa Y, 2015, GASTROENTEROLOGY, V149, P1204, DOI 10.1053/j.gastro.2015.07.011
   Palmqvist R, 2013, CURR COLORECT CANC R, V9, P372, DOI 10.1007/s11888-013-0192-3
   Pan HM, 2016, ONCOTARGET, V7, P21235, DOI 10.18632/oncotarget.6908
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954
   Pietrocola F, 2016, AUTOPHAGY, V12, P1962, DOI 10.1080/15548627.2016.1214778
   Postow MA, 2015, J CLIN ONCOL, V33, P1974, DOI 10.1200/JCO.2014.59.4358
   Ren F, 2014, MOL CELL BIOCHEM, V385, P95, DOI 10.1007/s11010-013-1818-0
   Rescigno T, 2017, MOLECULES, V22, DOI 10.3390/molecules22010105
   Rogov V, 2014, MOL CELL, V53, P167, DOI 10.1016/j.molcel.2013.12.014
   Roy HK, 2017, GUT, V66, P285, DOI 10.1136/gutjnl-2015-309996
   Saito T, 2016, NAT MED, V22, P679, DOI 10.1038/nm.4086
   Shang B, 2015, SCI REP-UK, V5, DOI 10.1038/srep15179
   Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172
   Tang B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165701
   Taniguchi K, 2016, FEBS LETT, V590, P2375, DOI 10.1002/1873-3468.12301
   Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271
   Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001
   Tsai WT, 2016, J BIOL CHEM, V291, P19299, DOI 10.1074/jbc.M115.686683
   Umemura A, 2016, CANCER CELL, V29, P935, DOI 10.1016/j.ccell.2016.04.006
   Yamauchi M, 2012, GUT, V61, P794, DOI 10.1136/gutjnl-2012-302014
   Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051
NR 76
TC 8
Z9 8
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2162-402X
J9 ONCOIMMUNOLOGY
JI OncoImmunology
PY 2017
VL 6
IS 3
AR e1284720
DI 10.1080/2162402X.2017.1284720
PG 9
WC Oncology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Immunology
GA EQ3QV
UT WOS:000397988500022
PM 28405513
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Du, CZ
   Huang, DD
   Peng, YF
   Yao, YF
   Zhao, Y
   Yang, Y
   Wang, HY
   Cao, LL
   Zhu, WG
   Gu, J
AF Du, Changzheng
   Huang, Dandan
   Peng, Yifan
   Yao, Yunfeng
   Zhao, Ying
   Yang, Yang
   Wang, Haiying
   Cao, Linlin
   Zhu, Wei-Guo
   Gu, Jin
TI 5-Fluorouracil targets histone acetyltransferases p300/CBP in the
   treatment of colorectal cancer
SO CANCER LETTERS
LA English
DT Article
DE Colorectal cancer; 5-Fluorouracil; Histone acetyltransferases;
   Chemotherapy; Prognosis
ID CHAPERONE-MEDIATED AUTOPHAGY; TUMOR-SUPPRESSOR GENE; SURVIVAL FACTOR
   MEF2D; THYMIDYLATE SYNTHASE; COLON-CANCER; ACETYLATION; INHIBITOR;
   EXPRESSION; CELLS; PROGNOSIS
AB Although 5-fluorouracil (5-FU) is known to interfere with the synthesis of ribonucleic acid and deoxyribonucleic acid, the mechanism underlying its therapeutic efficacy in colorectal cancer (CRC) has not been fully elucidated. We aimed to investigate the influence of 5-FU on histone acetylation, a well-established anti-cancer target, to reveal novel pharmacological effects of 5-FU and their significance for CRC therapy. Results demonstrated that 5-FU induces global histone de-acetylation in multiple CRC cell lines. We identified that 5-FU reduces the binding ability of histone acetyltransferases p300 and CBP to chromatin, and induces their degradation through lysosome. Further work revealed that the degradation of p300/CBP induced by 5-FU was dependent on chaperone-mediated autophagy, mediated by heat-shock cognate protein 70 kDa (hsc70) and lysosomal-associated membrane protein 2A (LAMP2A). Moreover, the degradation of p300/CBP is relevant to cellular resistance to 5-FU, since blocking the degradation enhances 5-FU's cytotoxicity in CRC cells. From clinical data, we demonstrated that low expression of p300/CBP in CRC tissue was closely associated with poor clinical response to 5-FU based-chemotherapy, based on the analysis of 262 colorectal samples from the patients receiving 5-FU treatment: compared to cases with high expression of p300/CBP, those with low expression had lower long-term disease-free survival rate and increased early-progression. These results elucidate a novel pharmacological effect of 5-FU involving global histone de-acetylation by promoting the degradation of p300/CBP, and highlights p300 and CBP as promising predictors of chemo-sensitivity to 5-FU treatment. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Du, Changzheng; Huang, Dandan; Peng, Yifan; Yao, Yunfeng; Gu, Jin] Peking Univ, Canc Hosp, Gastrointestinal Canc Ctr, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing, Peoples R China.
   [Zhao, Ying; Yang, Yang; Wang, Haiying; Cao, Linlin; Zhu, Wei-Guo] Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing, Peoples R China.
   [Zhu, Wei-Guo] Shenzhen Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 3688 Nanhai Rd, Shenzhen 518060, Guangdong, Peoples R China.
   [Gu, Jin] Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China.
   [Gu, Jin] Peking Univ, Shougang Hosp, Beijing, Peoples R China.
RP Zhu, WG (corresponding author), Shenzhen Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 3688 Nanhai Rd, Shenzhen 518060, Guangdong, Peoples R China.; Gu, J (corresponding author), Peking Univ, Canc Hosp, Gastrointestinal Canc Ctr, 52 Fu Cheng Rd, Beijing 100142, Peoples R China.
EM zhuweiguo@szu.edu.cn; zIgujin@126.com
RI Du, Chang-Zheng/I-9784-2019
OI Du, Chang-Zheng/0000-0001-9016-4401; Zhu, Wei-Guo/0000-0001-8385-6581;
   Wang, Haiying/0000-0001-7729-0649; Yang, Yang/0000-0002-8737-590X
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [NSFC91319302]; Beijing Municipal
   Administration of Hospitals' Youth Program [QML20161105]; Discipline
   Construction Funding of Shenzhen; Shenzhen Municipal Commission of
   Science and Technology Innovation [JCYJ20160427104855100]
FX This work was supported by National Natural Science Foundation of China
   grants NSFC91319302; Beijing Municipal Administration of Hospitals'
   Youth Program QML20161105; Discipline Construction Funding of Shenzhen
   (2016) and Shenzhen Municipal Commission of Science and Technology
   Innovation grants JCYJ20160427104855100.
CR Agrawal-Singh S, 2012, BLOOD, V119, P2346, DOI 10.1182/blood-2011-06-358705
   Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709
   Cao LL, 2016, ONCOGENE, V35, P301, DOI 10.1038/onc.2015.81
   Chen Y, 2012, INT J BIOL MARKER, V27, P203, DOI 10.5301/JBM.2012.9584
   Chung H, 2010, CANCER BIOL THER, V10, P1148, DOI 10.4161/cbt.10.11.13447
   de la Cruz-Morcillo MA, 2012, ONCOGENE, V31, P1073, DOI 10.1038/onc.2011.321
   Dice JF, 2007, AUTOPHAGY, V3, P295, DOI 10.4161/auto.4144
   Du TF, 2013, EXP MOL PATHOL, V95, P38, DOI 10.1016/j.yexmp.2013.04.003
   Esin E, 2016, CANCER TREAT REV, V42, P82, DOI 10.1016/j.ctrv.2015.10.012
   Gao L, 2014, ANTIOXID REDOX SIGN, V20, P2936, DOI 10.1089/ars.2013.5399
   Giacchetti S, 2000, J CLIN ONCOL, V18, P136, DOI 10.1200/JCO.2000.18.1.136
   Grogan BC, 2011, BIOCHEMISTRY-US, V50, P618, DOI 10.1021/bi102046h
   Gu XL, 2013, NEUROBIOL AGING, V34, P1069, DOI 10.1016/j.neurobiolaging.2012.10.013
   Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100
   Henry RA, 2013, BIOCHEMISTRY-US, V52, P5746, DOI 10.1021/bi400684q
   Huh JW, 2013, J SURG ONCOL, V108, P374, DOI 10.1002/jso.23405
   Ishihama K, 2007, J CLIN PATHOL, V60, P1205, DOI 10.1136/jcp.2005.029165
   Ji M, 2008, CELL SIGNAL, V20, P1452, DOI 10.1016/j.cellsig.2008.03.013
   Jin QH, 2011, EMBO J, V30, P249, DOI 10.1038/emboj.2010.318
   Kaushik S, 2012, TRENDS CELL BIOL, V22, P407, DOI 10.1016/j.tcb.2012.05.006
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Krubasik D, 2006, BRIT J CANCER, V94, P1326, DOI 10.1038/sj.bjc.6603101
   Kuczynski EA, 2013, NAT REV CLIN ONCOL, V10, P571, DOI 10.1038/nrclinonc.2013.158
   Lee JH, 2006, MOL CANCER THER, V5, P3085, DOI 10.1158/1535-7163.MCT-06-0419
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Lu Z, 2006, ONCOGENE, V25, P230, DOI 10.1038/sj.onc.1209025
   Marcu MG, 2006, MED CHEM, V2, P169, DOI 10.2174/157340606776056133
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Okada K, 2016, ONCOL REP, V36, P1875, DOI 10.3892/or.2016.5008
   Perez-Salvia M, 2015, EPIGENETICS-US, V10, P446, DOI 10.1080/15592294.2015.1039222
   Picaud S, 2015, CANCER RES, V75, P5106, DOI 10.1158/0008-5472.CAN-15-0236
   Price BD, 2013, CELL, V152, P1344, DOI 10.1016/j.cell.2013.02.011
   Rebecca VW, 2016, ONCOGENE, V35, P1, DOI 10.1038/onc.2015.99
   Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197
   Schmoll HJ, 2012, ANN ONCOL, V23, P2479, DOI 10.1093/annonc/mds236
   Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874
   Sun HY, 2016, HUM PATHOL, V50, P101, DOI 10.1016/j.humpath.2015.11.008
   Szerlong HJ, 2010, J BIOL CHEM, V285, P31954, DOI 10.1074/jbc.M110.148718
   Tamagawa H, 2013, EJSO-EUR J SURG ONC, V39, P655, DOI 10.1016/j.ejso.2013.02.023
   Tang M, 2017, THERANOSTICS, V7, P1346, DOI 10.7150/thno.18804
   Tejpar S, 2011, JNCI-J NATL CANCER I, V103, P841, DOI 10.1093/jnci/djr170
   Tessarz P, 2014, NAT REV MOL CELL BIO, V15, P703, DOI 10.1038/nrm3890
   Toiber D, 2013, MOL CELL, V51, P454, DOI 10.1016/j.molcel.2013.06.018
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Unnikrishnan A, 2010, NAT STRUCT MOL BIOL, V17, P430, DOI 10.1038/nsmb.1780
   Yang Q, 2009, SCIENCE, V323, P124, DOI 10.1126/science.1166088
NR 46
TC 34
Z9 35
U1 1
U2 35
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD AUG 1
PY 2017
VL 400
BP 183
EP 193
DI 10.1016/j.canlet.2017.04.033
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EY0NO
UT WOS:000403655200019
PM 28465257
DA 2022-04-25
ER

PT J
AU Nozaki, R
   Kono, T
   Bochimoto, H
   Watanabe, T
   Oketani, K
   Sakamaki, Y
   Okubo, N
   Nakagawa, K
   Takeda, H
AF Nozaki, Reo
   Kono, Toru
   Bochimoto, Hiroki
   Watanabe, Tsuyoshi
   Oketani, Kaori
   Sakamaki, Yuichi
   Okubo, Naoto
   Nakagawa, Koji
   Takeda, Hiroshi
TI Zanthoxylum fruit extract from Japanese pepper promotes autophagic cell
   death in cancer cells
SO ONCOTARGET
LA English
DT Article
DE autophagy; autophagic cell death; vacuolization; colon cancer;
   zanthoxylum fruit
ID JNK; PIPERITUM; INVOLVEMENT; SUPPRESSES; GROWTH; COLON
AB Zanthoxylum fruit, obtained from the Japanese pepper plant (Zanthoxylum piperitum De Candolle), and its extract (Zanthoxylum fruit extract, ZFE) have multiple physiological activities (e.g., antiviral activity). However, the potential anticancer activity of ZFE has not been fully examined. In this study, we investigated the ability of ZFE to induce autophagic cell death (ACD). ZFE caused remarkable autophagy-like cytoplasmic vacuolization, inhibited cell proliferation, and ultimately induced cell death in the human cancer cell lines DLD-1, HepG2, and Caco-2, but not in A549, MCF7, or WiDr cells. ZFE increased the level of LC3-II protein, a marker of autophagy. Knockdown of ATG5 using siRNA inhibited ZFE-induced cytoplasmic vacuolization and cell death. Moreover, in cancer cells that could be induced to undergo cell death by ZFE, the extract increased the phosphorylation of c-Jun N-terminal kinase (JNK), and the JNK inhibitor SP600125 attenuated both vacuolization and cell death. Based on morphology and expression of marker proteins, ZFE-induced cell death was neither apoptosis nor necrosis. Normal intestinal cells were not affected by ZFE. Taken together, our findings show that ZFE induces JNK-dependent ACD, which appears to be the main mechanism underlying its anticancer activity, suggesting a promising starting point for anticancer drug development.
C1 [Nozaki, Reo; Kono, Toru; Oketani, Kaori; Sakamaki, Yuichi; Okubo, Naoto; Nakagawa, Koji; Takeda, Hiroshi] Hokkaido Univ, Fac Pharmaceut Sci, Pathophysiol & Therapeut, Sapporo, Hokkaido, Japan.
   [Kono, Toru] Sapporo Higashi Tokushukai Hosp, Ctr Clin & Biomed Res, Sapporo, Hokkaido, Japan.
   [Bochimoto, Hiroki; Watanabe, Tsuyoshi] Asahikawa Med Univ, Dept Microscop Anat & Cell Biol, Asahikawa, Hokkaido, Japan.
RP Kono, T (corresponding author), Hokkaido Univ, Fac Pharmaceut Sci, Pathophysiol & Therapeut, Sapporo, Hokkaido, Japan.; Kono, T (corresponding author), Sapporo Higashi Tokushukai Hosp, Ctr Clin & Biomed Res, Sapporo, Hokkaido, Japan.
EM kono@toru-kono.com
OI Bochimoto, Hiroki/0000-0002-1708-0348
FU Grants-in-Aid for Scientific ResearchMinistry of Education, Culture,
   Sports, Science and Technology, Japan (MEXT)Japan Society for the
   Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)
   [15K18951] Funding Source: KAKEN
CR Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167
   Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301
   Fulda S, 2015, ONCOGENE, V34, P5105, DOI 10.1038/onc.2014.458
   Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Gwon SY, 2012, J NUTR SCI VITAMINOL, V58, P393, DOI 10.3177/jnsv.58.393
   Ha SY, 2014, J MICROBIOL, V52, P340, DOI 10.1007/s12275-014-4073-5
   Harvey AL, 2015, NAT REV DRUG DISCOV, V14, P111, DOI 10.1038/nrd4510
   Hirokawa Y, 2006, CANCER BIOL THER, V5, P305, DOI 10.4161/cbt.5.3.2404
   Jeong CH, 2004, BIOSCI BIOTECH BIOCH, V68, P1984, DOI 10.1271/bbb.68.1984
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kimura T, 2013, CANCER RES, V73, P3, DOI 10.1158/0008-5472.CAN-12-2464
   Kono T, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00159
   Kono T, 2011, J GASTROENTEROL, V46, P1187, DOI 10.1007/s00535-011-0438-2
   Kono T, 2009, SURGERY, V146, P837, DOI 10.1016/j.surg.2009.06.012
   Kubota K, 2015, AM J PHYSIOL-GASTR L, V308, pG579, DOI 10.1152/ajpgi.00114.2014
   Lee J, 2011, J PHARM PHARMACOL, V63, P840, DOI 10.1111/j.2042-7158.2011.01277.x
   Li X, 2010, J ETHNOPHARMACOL, V129, P197, DOI 10.1016/j.jep.2010.03.003
   Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005
   Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522
   Opipari AW, 2004, CANCER RES, V64, P696, DOI 10.1158/0008-5472.CAN-03-2404
   Pan HM, 2016, ONCOTARGET, V7, P21235, DOI 10.18632/oncotarget.6908
   Park YD, 2007, BIOL PHARM BULL, V30, P205, DOI 10.1248/bpb.30.205
   Puissant A, 2010, CANCER RES, V70, P1042, DOI 10.1158/0008-5472.CAN-09-3537
   Shen HM, 2011, AUTOPHAGY, V7, P457, DOI 10.4161/auto.7.5.14226
   Shimizu S, 2010, ONCOGENE, V29, P2070, DOI 10.1038/onc.2009.487
   Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189
   Vegliante R, 2016, CARCINOGENESIS, V37, P233, DOI 10.1093/carcin/bgw003
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Yang ZNJ, 2011, CANCER BIOL THER, V11, P169, DOI 10.4161/cbt.11.2.14663
   Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103
   Zhang C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147405
   Zhou Y.Y., 2015, BIOSCIENCE REP, P35
NR 38
TC 7
Z9 7
U1 2
U2 10
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 25
PY 2016
VL 7
IS 43
BP 70437
EP 70446
DI 10.18632/oncotarget.11926
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EB5VI
UT WOS:000387448300102
PM 27626481
OA gold, Green Submitted, Green Published
DA 2022-04-25
ER

PT J
AU Lee, YJ
   Cho, JM
   Sai, S
   Oh, JY
   Park, JA
   Oh, SJ
   Park, M
   Kwon, J
   Shin, US
   Baek, JH
   Lim, SH
   Song, JY
   Hwang, SG
   Kim, EH
AF Lee, Yeon-Joo
   Cho, Jae-Min
   Sai, Sei
   Oh, Ju Yeon
   Park, Ji-Ae
   Oh, Se Jong
   Park, Misun
   Kwon, Junhye
   Shin, Ui Sup
   Baek, Jeong-Hwa
   Lim, Sun Ha
   Song, Jie-Young
   Hwang, Sang-Gu
   Kim, Eun Ho
TI 5-Fluorouracil as a Tumor-Treating Field-Sensitizer in Colon Cancer
   Therapy
SO CANCERS
LA English
DT Article
DE tumor-treating fields; colon cancer; 5-fluorouracil
ID CELLS IN-VITRO; ADJUVANT THERAPY; CHEMOTHERAPY; GLIOBLASTOMA;
   COMBINATION; MECHANISMS; TTFIELDS; TRIAL; LINES
AB Colorectal cancer (CRC) is a major cause of mortality that can be treated effectively with chemotherapy and radiotherapy, although resistance to these therapeutic modalities often occurs. Tumor-treating fields (TTFields) can block tumor growth by selectively impairing tumor cell division. In this study, we investigated the mechanism by which 5-fluorouracil (5-FU) sensitizes tumor cells to TTFields. Human HCT116 and SW480 CRC cells were treated with 5-FU and/or TTFields, and characterized in vitro in terms of cell viability, apoptosis through reactive oxygen species production, autophagy, and metastatic potentials. The biological effects of 5-FU and/or TTFields were studied via positron emission tomography and computed tomography on xenograft tumor growth and were confirmed with organoid models of patients. Our results revealed that combination treatment with 5-FU and TTFields increased the efficiency of TTFields therapy in colon cancer cells by downregulating signaling pathways associated with cell proliferation, survival, cell invasion, and migration while upregulating pathways mediating apoptosis and autophagic cell death. The novel mechanistic insights gleaned in this study suggest that combination therapy with TTFields and 5-FU may be effective in treating CRC, although safety and efficacy testing in patients with CRC will need to be performed before this strategy can be implemented clinically for TTF-sensitization.
C1 [Lee, Yeon-Joo; Cho, Jae-Min; Song, Jie-Young; Hwang, Sang-Gu] Korea Inst Radiol & Med Sci, Div Radiat Biomed Res, Seoul 01812, South Korea.
   [Sai, Sei] Natl Inst Radiol Sci, Dept Basic Med Sci Radiat Damages, Chiba 2638555, Japan.
   [Oh, Ju Yeon] Korea Univ, Sch Life Sci & Biotechnol, Lab Biochem, Anam Ro 145, Seoul 136701, South Korea.
   [Park, Ji-Ae; Oh, Se Jong] Korea Inst Radiol & Med Sci, Div Appl RI, Seoul 01812, South Korea.
   [Park, Misun; Kwon, Junhye] Korea Inst Radiol & Med Sci, Korea Canc Ctr Hosp, Dept Radiol & Clin Res, Seoul 01812, South Korea.
   [Shin, Ui Sup] Korea Inst Radiol & Med Sci, Dept Surg, Seoul 01812, South Korea.
   [Baek, Jeong-Hwa] Dongnam Inst Radiol & Med Sci, Res Ctr, Radiat Biol Res Team, Busan 46033, South Korea.
   [Lim, Sun Ha; Kim, Eun Ho] Daegu Catholic Univ, Sch Med, Dept Biochem, 33,17 Gil, Daegu 42472, South Korea.
RP Hwang, SG (corresponding author), Korea Inst Radiol & Med Sci, Div Radiat Biomed Res, Seoul 01812, South Korea.; Kim, EH (corresponding author), Daegu Catholic Univ, Sch Med, Dept Biochem, 33,17 Gil, Daegu 42472, South Korea.
EM eyeonjoo@kirams.re.kr; chojaemin09@yuhs.ac; sai.sei@qst.go.jp;
   songoh10@korea.ac.kr; jpark@kirams.re.kr; osj5353@kirams.re.kr;
   usre@kirams.re.kr; jhkwon@kirams.re.kr; uisupshin@kirams.re.kr;
   jihan918@dirams.re.kr; sunhalimha@gmail.com; immu@kirams.re.kr;
   sgh63@kcch.re.kr; eh140149@cu.ac.kr
OI Lee, Yeon-Joo/0000-0002-6605-8761; Park, Ji Ae/0000-0001-6109-802X;
   baeg, jeonghwa/0000-0001-5364-0026; Song, Jie-Young/0000-0002-5769-3886;
   Oh, Se Jong/0000-0002-9688-1425
FU National Research Foundation of Korea (NRF)National Research Foundation
   of Korea [2017K2A9A2A08000212]; KIRAMS - Ministry of Science, ICT (MSIP)
   Republic of Korea [50531-2019, 50538-2019]; Creative Allied Project of
   the National Research Council of Science and Technology [CAP-15-06-ETRI]
FX This work was supported by a National Research Foundation of Korea (NRF)
   grant (2017K2A9A2A08000212) and a grant from the KIRAMS, which was
   funded by the Ministry of Science, ICT (MSIP) Republic of Korea
   (50531-2019, 50538-2019) and the Creative Allied Project
   (CAP-15-06-ETRI) of the National Research Council of Science and
   Technology.
CR Bracht K, 2010, BRIT J CANCER, V103, P340, DOI 10.1038/sj.bjc.6605780
   CARPENTIER Y, 1993, ANTICANCER RES, V13, P2177
   Ceresoli GL, 2019, LANCET ONCOL, V20, P1702, DOI 10.1016/S1470-2045(19)30532-7
   Davies AM, 2013, ANN NY ACAD SCI, V1291, P86, DOI 10.1111/nyas.12112
   De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Giladi M., 2016, J IMMUNOL, V196
   Giladi M, 2018, NEURO-ONCOLOGY, V20, P66
   Giladi M, 2017, RADIAT ONCOL, V12, DOI 10.1186/s13014-017-0941-6
   Giladi M, 2014, PANCREATOLOGY, V14, P54, DOI 10.1016/j.pan.2013.11.009
   Goodwin Rachel A, 2009, Clin Colon Rectal Surg, V22, P251, DOI 10.1055/s-0029-1242465
   Guo SJ, 2015, AUTOPHAGY, V11, P560, DOI 10.1080/15548627.2015.1017181
   Jeong H, 2014, APPL PHYS LETT, V105, DOI 10.1063/1.4902112
   Jo Y, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113684
   Kim EH, 2019, ONCOGENE, V38, P6630, DOI 10.1038/s41388-019-0882-7
   Kim EH, 2016, ONCOTARGET, V7, P65125, DOI 10.18632/oncotarget.11372
   Kirson ED, 2007, P NATL ACAD SCI USA, V104, P10152, DOI 10.1073/pnas.0702916104
   Kirson Eilon D, 2009, BMC Med Phys, V9, P1, DOI 10.1186/1756-6649-9-1
   KROOK JE, 1991, NEW ENGL J MED, V324, P709, DOI 10.1056/NEJM199103143241101
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Malet-Martino M, 2002, ONCOLOGIST, V7, P288, DOI 10.1634/theoncologist.7-4-288
   Mhaidat NM, 2014, ONCOL LETT, V8, P699, DOI 10.3892/ol.2014.2211
   Mun EJ, 2018, CLIN CANCER RES, V24, P266, DOI 10.1158/1078-0432.CCR-17-1117
   NCCN, 2016, CLIN PRACT GUID ONC
   Park JI, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819868225
   Pless M, 2013, LUNG CANCER, V81, P445, DOI 10.1016/j.lungcan.2013.06.025
   Saltz LB, 2002, SURG CLIN N AM, V82, P1035, DOI 10.1016/S0039-6109(02)00041-5
   Seiwert TY, 2007, NAT CLIN PRACT ONCOL, V4, P86, DOI 10.1038/ncponc0714
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Stupp R, 2015, JAMA-J AM MED ASSOC, V314, P2535, DOI 10.1001/jama.2015.16669
   Stupp R, 2012, EUR J CANCER, V48, P2192, DOI 10.1016/j.ejca.2012.04.011
   Uchiyama Kimio, 2007, Gan To Kagaku Ryoho, V34, P43
   VALERIOTE F, 1975, CANCER CHEMOTH REP 1, V59, P895
   Voloshin T, 2016, INT J CANCER, V139, P2850, DOI 10.1002/ijc.30406
   Yang SY, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-158
   Zhang N, 2008, MOLECULES, V13, P1551, DOI 10.3390/molecules13081551
NR 36
TC 9
Z9 10
U1 1
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD DEC
PY 2019
VL 11
IS 12
AR 1999
DI 10.3390/cancers11121999
PG 18
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA KC7VZ
UT WOS:000507382100176
PM 31842288
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Tsukahara, T
   Matsuda, Y
   Haniu, H
AF Tsukahara, Tamotsu
   Matsuda, Yoshikazu
   Haniu, Hisao
TI PSF Knockdown Enhances Apoptosis via Downregulation of LC3B in Human
   Colon Cancer Cells
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID AUTOPHAGY; PROTEIN; RNA; MUTATIONS; BINDING; GENES
AB Our previous study demonstrated that PTB-associated splicing factor (PSF) is an important regulator of cell death and plays critical roles in the survival and growth of colon cancer cells. However, the molecular mechanism that activates these downstream signaling events remains unknown. To address this issue, we investigated the effects of PSF knockdown in two different colon cancer cell lines, DLD-1 and HT-29. We found that knockdown of PSF markedly decreased the autophagic molecule LC3B in DLD-1 cells but not in HT-29 cells. Furthermore, DLD-1 cells were more susceptible to PSF knockdown-induced cell growth inhibition and apoptosis than HT-29 cells. This susceptibility is probably a result of LC3B inhibition, given the known relationship between autophagy and apoptosis. C3B is associated with a number of physiological processes, including cell growth and apoptotic cell death. Our results suggest that autophagy is inhibited by PSF knockdown and that apoptosis and cell growth inhibition may act together to mediate the PSF-LC3B signaling pathway. Furthermore, we found that the peroxisome proliferator-activated receptor gamma (PPAR gamma)-PSF complex induced LC3B downregulation in DLD-1 cells. The results of this study identify a new physiological role for the PSF-LC3B axis as a potential endogenous modulator of colon cancer treatment.
C1 [Tsukahara, Tamotsu] Kanazawa Med Univ, Dept Hematol & Immunol, Uchinada, Ishikawa 9200293, Japan.
   [Matsuda, Yoshikazu] Nihon Pharmaceut Univ, Clin Pharmacol Educ Ctr, Ina, Saitama 3620806, Japan.
   [Haniu, Hisao] Shinshu Univ, Dept Orthopaed Surg, Sch Med, Matsumoto, Nagano 3908621, Japan.
RP Haniu, H (corresponding author), Shinshu Univ, Dept Orthopaed Surg, Sch Med, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.
EM wadia781@yahoo.co.jp
RI Tsukahara, Tamotsu/ABB-3631-2021
OI Tsukahara, Tamotsu/0000-0001-6469-920X
FU Astellas Foundation for Research on Metabolic Disorders
FX This work was supported by research grants from the Astellas Foundation
   for Research on Metabolic Disorders (to Tamotsu Tsukahara) and a
   Grant-in-Aid for Takeda Science Foundation (to Tamotsu Tsukahara).
CR Altman BJ, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008763
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   DE DUVE CHRISTIAN, 1963, SCI AMER, V208, P64
   Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014
   Ghavami S, 2009, J MED GENET, V46, P497, DOI 10.1136/jmg.2009.066944
   Ghobrial IM, 2005, CA-CANCER J CLIN, V55, P178, DOI 10.3322/canjclin.55.3.178
   Gupta RA, 2001, J BIOL CHEM, V276, P29681, DOI 10.1074/jbc.M103779200
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811
   Kondo Y, 2006, AUTOPHAGY, V2, P85, DOI 10.4161/auto.2.2.2463
   Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100
   MANN SS, 1994, J BIOL CHEM, V269, P11492
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Munafo DB, 2001, J CELL SCI, V114, P3619
   O'Malley BW, 2009, CANCER RES, V69, P8217, DOI 10.1158/0008-5472.CAN-09-2223
   PATTON JG, 1993, GENE DEV, V7, P393, DOI 10.1101/gad.7.3.393
   Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002
   Song X, 2005, P NATL ACAD SCI USA, V102, P12189, DOI 10.1073/pnas.0505179102
   Song X, 2004, P NATL ACAD SCI USA, V101, P621, DOI 10.1073/pnas.0307794100
   Tanida I, 2004, J BIOL CHEM, V279, P47704, DOI 10.1074/jbc.M407016200
   Tsukahara T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058749
   Wang G, 2009, P NATL ACAD SCI USA, V106, P16794, DOI 10.1073/pnas.0909022106
   Wu JR, 2006, EMERGING THERAPEUTIC ULTRASOUND, P1, DOI 10.1142/9789812774125_0001
NR 27
TC 9
Z9 10
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2013
VL 2013
AR 204973
DI 10.1155/2013/204973
PG 8
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 249PB
UT WOS:000326788000001
PM 24288667
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Kim, Y
   Kim, YS
   Kim, DE
   Lee, JS
   Song, JH
   Kim, HG
   Cho, DH
   Jeong, SY
   Jin, DH
   Jang, SJ
   Seol, HS
   Suh, YA
   Lee, SJ
   Kim, CS
   Koh, JY
   Hwang, JJ
AF Kim, Yunha
   Kim, Yong-Sook
   Kim, Dong Eun
   Lee, Jee Suk
   Song, Ji Hoon
   Kim, Ha-Gyeong
   Cho, Dong-Hyung
   Jeong, Seong-Yun
   Jin, Dong-Hoon
   Jang, Se Jin
   Seol, Hyang-Sook
   Suh, Young-Ah
   Lee, Seung Jin
   Kim, Choung-Soo
   Koh, Jae-Young
   Hwang, Jung Jin
TI BIX-01294 induces autophagy-associated cell death via EHMT2/G9a
   dysfunction and intracellular reactive oxygen species production
SO AUTOPHAGY
LA English
DT Article
DE autophagy; BIX-01294; EHMT2; G9a; histone methyltransferase; ROS
ID HISTONE LYSINE METHYLATION; GLIOMA-CELLS; CANCER; METHYLTRANSFERASE;
   G9A; CHLOROQUINE; CHAETOCIN; TUMORIGENESIS; DISRUPTION; INHIBITION
AB We screened a chemical library in MCF-7 cells stably expressing green fluorescent protein (GFP)-conjugated microtubule-associated protein 1 light chain 3 (LC3) (GFP-LC3-MCF-7) using cell-based assay, and identified BIX-01294 (BIX), a selective inhibitor of euchromatic histone-lysine N-methyltransferase 2 (EHMT2), as a strong autophagy inducer. BIX enhanced formation of GFP-LC3 puncta, LC3-II, and free GFP, signifying autophagic activation. Inhibition of these phenomena with chloroquine and increasement in punctate dKeima ratio (550/438) signal indicated that BIX activated autophagic flux. BIX-induced cell death was suppressed by the autophagy inhibitor, 3-methyladenine, or siRNA against BECN1 (VPS30/ATG6), ATG5, and ATG7, but not by caspase inhibitors. Moreover, EHMT2 siRNA augmented GFP-LC3 puncta, LC3-II, free GFP, and cell death, implying that inhibition of EHMT2 caused autophagy-mediated cell death. Treatment with EHMT2 siRNA and BIX accumulated intracellular reactive oxygen species (ROS). BIX augmented mitochondrial superoxide via NADPH oxidase activation. In addition, BIX increased hydrogen peroxide and glutathione redox potential in both cytosol and mitochondria. Treatment with N-acetyl-L-cysteine (NAC) or diphenyleneiodonium chloride (DPI) decreased BIX-induced LC3-II, GFP-LC3 puncta, and cell death, indicating that ROS instigated autophagy-dependent cell death triggered by BIX. We observed that BIX potentiated autophagy-dependent and caspase-independent cell death in estrogen receptor (ESR)-negative SKBr3 and ESR-positive MCF-7 breast cancer cells, HCT116 colon cancer cells, and importantly, in primary human breast and colon cancer cells. Together, the results suggest that BIX induces autophagy-dependent cell death via EHMT2 dysfunction and intracellular ROS accumulation in breast and colon cancer cells, therefore EHMT2 inhibition can be an effective therapeutic strategy for cancer treatment.
C1 [Kim, Yunha; Kim, Yong-Sook; Kim, Dong Eun; Lee, Jee Suk; Song, Ji Hoon; Kim, Ha-Gyeong; Jeong, Seong-Yun; Jin, Dong-Hoon; Suh, Young-Ah; Lee, Seung Jin; Kim, Choung-Soo; Hwang, Jung Jin] Univ Ulsan, Coll Med, Asan Med Ctr, Inst Innovat Canc Res, Seoul, South Korea.
   [Cho, Dong-Hyung] Kyung Hee Univ, Grad Sch East West Med Sci, Gyeonggi Do, South Korea.
   [Jang, Se Jin; Seol, Hyang-Sook] Asan Med Ctr, Dept Pathol, Seoul, South Korea.
   [Kim, Choung-Soo] Asan Med Ctr, Dept Urol, Seoul, South Korea.
   [Koh, Jae-Young] Univ Ulsan, Coll Med, Asan Med Ctr, Neural Injury Res Lab,Dept Neurol, Seoul, South Korea.
   [Hwang, Jung Jin] Asan Med Ctr, Asan Inst Life Sci, Seoul, South Korea.
RP Hwang, JJ (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, Inst Innovat Canc Res, Seoul, South Korea.
EM jjhwang@amc.seoul.kr
RI KIM, Yunha/J-4698-2019; Hwang, Jung Jin/F-3424-2014; Koh,
   Jae-Young/C-9014-2011
OI Koh, Jae-Young/0000-0002-4318-495X; Lee, Seung Jin/0000-0003-0625-7774
FU Korea Health Technology R&D Project, Ministry of Health Welfare
   [A062254, A092042]; Basic Science Research Program through the National
   Research Foundation of Korea (NRF); Ministry of Education, Science and
   TechnologyMinistry of Education, Science and Technology, Republic of
   Korea [2012R1A1A2007337]; Asan Institute for Life Sciences, Republic of
   Korea [2011-450]
FX This study was supported by a grant from the Korea Health Technology R&D
   Project, Ministry of Health & Welfare (A062254 and A092042), Basic
   Science Research Program through the National Research Foundation of
   Korea (NRF) funded by the Ministry of Education, Science and Technology
   (2012R1A1A2007337), and the Asan Institute for Life Sciences (2011-450),
   Republic of Korea.
CR Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI 10.1089/ARS.2008.2270
   Chang YQ, 2009, NAT STRUCT MOL BIOL, V16, P312, DOI 10.1038/nsmb.1560
   Chen MW, 2010, CANCER RES, V70, P7830, DOI 10.1158/0008-5472.CAN-10-0833
   Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003
   Cheng WT, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-91
   Cho HS, 2011, NEOPLASIA, V13, P676, DOI 10.1593/neo.11512
   Clarke PGH, 2012, AUTOPHAGY, V8, P867, DOI 10.4161/auto.20380
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   Eskelinen EL, 2005, CELL DEATH DIFFER, V12, P1468, DOI 10.1038/sj.cdd.4401721
   Geng Y, 2010, NEURO-ONCOLOGY, V12, P473, DOI 10.1093/neuonc/nop048
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Huang J, 2010, J BIOL CHEM, V285, P9636, DOI 10.1074/jbc.M109.062588
   Huang J, 2007, CELL CYCLE, V6, P1837, DOI 10.4161/cc.6.15.4511
   Hwang JJ, 2010, BIOMETALS, V23, P997, DOI 10.1007/s10534-010-9346-9
   Illner D, 2010, EXP CELL RES, V316, P1662, DOI 10.1016/j.yexcr.2010.03.008
   Isham CR, 2007, BLOOD, V109, P2579, DOI 10.1182/blood-2006-07-027326
   Jaber N, 2012, P NATL ACAD SCI USA, V109, P2003, DOI 10.1073/pnas.1112848109
   Janicke RU, 2009, BREAST CANCER RES TR, V117, P219, DOI 10.1007/s10549-008-0217-9
   Jenuwein T, 2006, FEBS J, V273, P3121, DOI 10.1111/j.1742-4658.2006.05343.x
   Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095
   Katayama H, 2011, CHEM BIOL, V18, P1042, DOI 10.1016/j.chembiol.2011.05.013
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kondo Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002037
   Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017
   Lakshmikuttyamma A, 2010, ONCOGENE, V29, P576, DOI 10.1038/onc.2009.361
   Li WL, 2010, TRENDS PHARMACOL SCI, V31, P36, DOI 10.1016/j.tips.2009.10.002
   Lipinski MM, 2010, AUTOPHAGY, V6, P1218, DOI 10.4161/auto.6.8.13772
   Liu JJ, 2011, CANCER LETT, V300, P105, DOI 10.1016/j.canlet.2010.10.001
   Liu YL, 2010, AUTOPHAGY, V6, P1057, DOI 10.4161/auto.6.8.13365
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Morgan B, 2011, FREE RADICAL BIO MED, V51, P1943, DOI 10.1016/j.freeradbiomed.2011.08.035
   Mund C, 2010, BIOESSAYS, V32, P949, DOI 10.1002/bies.201000061
   Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2
   Portt L, 2011, BBA-MOL CELL RES, V1813, P238, DOI 10.1016/j.bbamcr.2010.10.010
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Robert T, 2011, NATURE, V471, P74, DOI 10.1038/nature09803
   Roy S, 2010, SEMIN IMMUNOPATHOL, V32, P383, DOI 10.1007/s00281-010-0213-0
   Shi Y, 2008, CELL STEM CELL, V3, P568, DOI 10.1016/j.stem.2008.10.004
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Tibodeau JD, 2009, ANTIOXID REDOX SIGN, V11, P1097, DOI [10.1089/ars.2008.2318, 10.1089/ARS.2008.2318]
   Varier RA, 2011, BBA-REV CANCER, V1815, P75, DOI 10.1016/j.bbcan.2010.10.002
   Vedadi M, 2011, NAT CHEM BIOL, V7, P566, DOI [10.1038/nchembio.599, 10.1038/NCHEMBIO.599]
   Wang RC, 2012, SCIENCE, V338, P956, DOI 10.1126/science.1225967
   Webb JL, 2004, INT J BIOCHEM CELL B, V36, P2541, DOI 10.1016/j.biocel.2004.02.003
   Wilson Eden N., 2011, Hormones & Cancer, V2, P272, DOI 10.1007/s12672-011-0081-7
   Yoon YH, 2010, INVEST OPHTH VIS SCI, V51, P6030, DOI 10.1167/iovs.10-5278
NR 51
TC 107
Z9 108
U1 1
U2 40
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD DEC 1
PY 2013
VL 9
IS 12
BP 2126
EP 2139
DI 10.4161/auto.26308
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 270DT
UT WOS:000328299800016
PM 24322755
OA Bronze
DA 2022-04-25
ER

PT J
AU Cao, HH
   Zhang, W
   Liang, JL
AF Cao, Honghua
   Zhang, Wei
   Liang, Junlin
TI Inhibition of IL17A promotes bufalin-induced apoptosis in colon cancer
   cells via miR-96/DDIT3
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Bufalin; IL17A; DDIT3; colon cancer; miR-96
ID INFLAMMATORY-BOWEL-DISEASE; COLORECTAL-CANCER; NUCLEAR-PROTEIN;
   PROLIFERATION; CHOP; RECK; CHOP/GADD153; EXPRESSION; AUTOPHAGY; ROLES
AB Bufalin is used clinically to treat patients with many solid malignant tumors. However, the mechanisms remain to be further elucidated. Our study focused on IL17A involved in bufacin inducing apoptosis of colon cancer cells. The data showed that bufalin could induce colon cancer cell apoptosis via inhibiting IL17A. Ectopic expression of IL17A promoted the proliferation and induced anti-apoptosis of colon cancer cells by MTT and flow cytometry analysis. Further study verified bufalin inhibiting IL17A induced apoptosis was through miR-96-DDIT3, our study demonstrated that bufalin may inhibit the proliferation and promote the apoptosis of colon cancer cells. Bufalin-associated IL-17A inhibition may indirectly be involved in cell proliferation and apoptosis by miR-96 targeting DDIT3, pointing to use as a potential molecular target of bufacin in colon cancer therapy.
C1 [Cao, Honghua; Zhang, Wei] Guigang City Peoples Hosp, Dept Gastrointestinal Surg, Guigang, Guangxi, Peoples R China.
   [Liang, Junlin] Guangxi Med Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, 6 Shuangyong Rd, Nanning 53000, Guangxi, Peoples R China.
RP Liang, JL (corresponding author), Guangxi Med Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, 6 Shuangyong Rd, Nanning 53000, Guangxi, Peoples R China.
EM ljunlin15@sina.com
CR Chiba T, 2012, GASTROENTEROLOGY, V143, P550, DOI 10.1053/j.gastro.2012.07.009
   Chin CC, 2015, J CELL PHYSIOL, V230, P1430, DOI 10.1002/jcp.24796
   Chung AS, 2013, NAT MED, V19, P1114, DOI 10.1038/nm.3291
   Fendler A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080807
   Feng J, 2014, ONCOTARGET, V5, P5832, DOI 10.18632/oncotarget.2200
   Gao F, 2015, MOL MED REP, V11, P1200, DOI 10.3892/mmr.2014.2854
   Giovannucci E, 2002, GASTROENTEROL CLIN N, V31, P925, DOI 10.1016/S0889-8553(02)00057-2
   Guo HZ, 2014, MOL CELL BIOCHEM, V390, P155, DOI 10.1007/s11010-014-1966-x
   Haflidadottir BS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072400
   Hu Q, 2014, INT J NANOMED, V9, P4035, DOI 10.2147/IJN.S64708
   Huang X, 2014, INT J MOL MED, V34, P1599, DOI 10.3892/ijmm.2014.1940
   Itzkowitz SH, 2004, AM J PHYSIOL-GASTR L, V287, pG7, DOI 10.1152/ajpgi.00079.2004
   Li LQ, 2013, CLIN IMMUNOL, V148, P246, DOI 10.1016/j.clim.2013.05.003
   Lin HX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015797
   Ma Y, 2014, ONCOTARGET, V5, P9169, DOI 10.18632/oncotarget.2396
   Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2
   Maytin EV, 2001, EXP CELL RES, V267, P193, DOI 10.1006/excr.2001.5248
   Omrane I, 2014, TUMOR BIOL, V35, P6627, DOI 10.1007/s13277-014-1890-4
   Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373
   RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Ubeda M, 1996, MOL CELL BIOL, V16, P1479
   Wang KP, 2014, IMMUNITY, V41, P1052, DOI 10.1016/j.immuni.2014.11.009
   Wang YM, 2012, CANCER RES, V72, P4037, DOI 10.1158/0008-5472.CAN-12-0103
   Xia HF, 2014, BIOMED PHARMACOTHER, V68, P951, DOI 10.1016/j.biopha.2014.10.023
   Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016
   Xu XM, 2012, ONCOL LETT, V4, P339, DOI 10.3892/ol.2012.714
   Yan ZY, 2014, FEBS LETT, V588, P3038, DOI 10.1016/j.febslet.2014.06.017
   Yu JJ, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0910-y
   Zhang JF, 2014, ONCOL REP, V31, P1357, DOI 10.3892/or.2013.2934
   Zhu ZT, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-228
NR 31
TC 2
Z9 2
U1 0
U2 3
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2016
VL 9
IS 4
BP 4360
EP 4367
PG 8
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA DO2HZ
UT WOS:000377601900007
DA 2022-04-25
ER

PT J
AU Fu, CH
   Tian, G
   Duan, JY
   Liu, K
   Zhang, C
   Yan, WQ
   Wang, Y
AF Fu, Changhao
   Tian, Geer
   Duan, Jinyue
   Liu, Kun
   Zhang, Chen
   Yan, Weiqun
   Wang, Yi
TI Therapeutic Antitumor Efficacy of Cancer Stem Cell-Derived DRibble
   Vaccine on Colorectal Carcinoma
SO INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE DRips-Containing Blebs (DRibbles); Dendritic Cells; Cancer Stem Cells;
   Autophagosome; Colorectal Cancer
ID DENDRITIC CELLS; CROSS-PRESENTATION; IMMUNE-RESPONSES; TUMOR LYSATE;
   IN-VITRO; AUTOPHAGOSOME VACCINE; ANTIGEN; MECHANISM; PEPTIDE; CD86
AB Dendritic cell (DC)-based immunotherapy has been a promising strategy for colon cancer therapy, but the efficacy of dendritic cell vaccines is in part limited by immunogenicity of loaded antigens. In this study, we aimed to identify a putative tumor antigen that can generate or enhance anti-tumor immune responses against colon cancer. CD44+ colon cancer stem cells (CCSCs) were isolated from mouse colorectal carcinoma CT-26 cell cultures and induced to form defective ribosomal products-containing autophagosome-rich blebs (DRibbles) by treatment with rapamycin, bortezomib, and ammonium chloride. DRibbles were characterized by western blot and transmission electron microscopy. DCs generated from the mice bone marrow monocytes were cocultured with DRibbles, then surface markers of DCs were analyzed by flow cytometry. Meanwhile, the efficacy of DRibble-DCs was examined in vivo. Our results showed that CCSC-derived DRibbles upregulated CD80, CD86, major histocompatibility complex (MHC)-I, and MHC-II on DCs and induced proliferation of mouse splenic lymphocytes and CD8+ T cells. In a model of colorectal carcinoma using BALB/c mice with robust tumor growth and mortality, DC vaccine pulsed with CCSC-derived DRibbles suppressed tumor growth and extended survival. A lactate dehydrogenase test indicated a strong cytolytic activity of cytotoxic T-cells derived from mice vaccinated with CCSC-derived DRibbles against CT-26 cells. Furthermore, flow cytometry analyses showed that the percentages of IFN-gamma-producing CD8+ T-cells were increased in SD-DC group compare with the other groups. These findings provide a rationale for novel immunotherapeutic anti-tumor approaches based on DRibbles derived from colon cancer stem cells.
C1 [Fu, Changhao; Tian, Geer; Duan, Jinyue; Liu, Kun; Wang, Yi] Jilin Univ, Sch Pharmaceut Sci, Dept Regenerat Med, Changchun 130021, Jilin, Peoples R China.
   [Fu, Changhao] Stanford Univ Med Sch, VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA.
   [Zhang, Chen] Minjiang Univ, Inst Oceanog, Fuzhou 350108, Fujian, Peoples R China.
   [Yan, Weiqun] Jilin Univ, Med Inst Regenerat Sci, Changchun 130021, Jilin, Peoples R China.
RP Wang, Y (corresponding author), Jilin Univ, Sch Pharmaceut Sci, Dept Regenerat Med, Changchun 130021, Jilin, Peoples R China.
EM wangyi@jlu.edu.cn
FU Jilin Province Science and Technology Support Program [20200404121YY];
   Education Department of Jilin Province [JJKH20201122KJ]; Jilin Province
   Health Technology Innovation Project [2017J062]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [81801849]
FX Funding source This work was supported by Jilin Province Science and
   Technology Support Program [Grant number 20200404121YY] ; Education
   Department of Jilin Province [Grant number JJKH20201122KJ] ; Jilin
   Province Health Technology Innovation Project [Grant number 2017J062] ;
   and National Natural Science Foundation of China [Grant number 81801849]
   .
CR Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025
   Beyersdorf N, 2015, IMMUNOTARGETS THER, V4, P111, DOI 10.2147/ITT.S61647
   Boczkowski D, 1996, J EXP MED, V184, P465, DOI 10.1084/jem.184.2.465
   Constantino J, 2016, TRANSL RES, V168, P74, DOI 10.1016/j.trsl.2015.07.008
   Dong H, 2018, CANCER MANAG RES, V10, P493, DOI 10.2147/CMAR.S155914
   Fabrizi E, 2010, WORLD J GASTROENTERO, V16, P3871, DOI 10.3748/wjg.v16.i31.3871
   Fields RC, 1998, P NATL ACAD SCI USA, V95, P9482, DOI 10.1073/pnas.95.16.9482
   Fu CH, 2019, ONCOL LETT, V18, P5897, DOI 10.3892/ol.2019.10952
   Gilboa E, 2007, J CLIN INVEST, V117, P1195, DOI 10.1172/JCI31205
   Gueguen M, 1996, P NATL ACAD SCI USA, V93, P14692, DOI 10.1073/pnas.93.25.14692
   HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904
   INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693
   International Agency for Research on Cancer,, CANC FACT SHEETS
   Jagannath C, 2009, NAT MED, V15, P267, DOI 10.1038/nm.1928
   Jeannin P, 2000, IMMUNITY, V13, P303, DOI 10.1016/S1074-7613(00)00030-3
   Joffre OP, 2012, NAT REV IMMUNOL, V12, P557, DOI 10.1038/nri3254
   Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808
   Phi LTH, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/5416923
   Lee WC, 2005, J IMMUNOTHER, V28, P496, DOI 10.1097/01.cji.0000171291.72039.e2
   Li YH, 2008, CANCER RES, V68, P6889, DOI 10.1158/0008-5472.CAN-08-0161
   Li YH, 2011, CLIN CANCER RES, V17, P7047, DOI 10.1158/1078-0432.CCR-11-0951
   Li YH, 2009, AUTOPHAGY, V5, P576, DOI 10.4161/auto.5.4.8366
   LINSLEY PS, 1995, J BIOL CHEM, V270, P15417, DOI 10.1074/jbc.270.25.15417
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328
   Rainone V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146622
   Rains N, 2001, HEPATO-GASTROENTEROL, V48, P347
   Salem ML, 2017, BIOMED PHARMACOTHER, V93, P286, DOI 10.1016/j.biopha.2017.06.046
   Schmid D, 2007, IMMUNITY, V26, P79, DOI 10.1016/j.immuni.2006.10.018
   Schnurr M, 2001, CANCER RES, V61, P6445
   Su H, 2015, INT J NANOMED, V10, P1921, DOI 10.2147/IJN.S74204
   Su S, 2013, ASIAN PAC J CANCER P, V14, P3109, DOI 10.7314/APJCP.2013.14.5.3109
   Ueda G, 2004, CANCER SCI, V95, P248, DOI 10.1111/j.1349-7006.2004.tb02211.x
   Yewdell JW, 1996, J IMMUNOL, V157, P1823
   Yi YX, 2015, CHINESE J CANCER RES, V27, P597, DOI 10.3978/j.issn.1000-9604.2015.12.07
   Yi YX, 2012, ONCOIMMUNOLOGY, V1, P976, DOI 10.4161/onci.20059
NR 36
TC 0
Z9 0
U1 3
U2 4
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449-1907
J9 INT J MED SCI
JI Int. J. Med. Sci.
PY 2021
VL 18
IS 14
BP 3249
EP 3260
DI 10.7150/ijms.61510
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA TX7YM
UT WOS:000683304200020
PM 34400894
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhao, YL
   Hu, XQ
   Zuo, XY
   Wang, MF
AF Zhao, Yueliang
   Hu, Xiaoqian
   Zuo, Xinyuan
   Wang, Mingfu
TI Chemopreventive effects of some popular phytochemicals on human colon
   cancer: a review
SO FOOD & FUNCTION
LA English
DT Review
ID CELL-CYCLE ARREST; NF-KAPPA-B; GRAPE SEED PROANTHOCYANIDINS;
   COLORECTAL-CARCINOMA CELLS; SWEET-POTATO PROTEIN; IN-VITRO;
   (-)-EPIGALLOCATECHIN GALLATE; INHIBITS PROLIFERATION; DIETARY
   POLYPHENOLS; MOLECULAR TARGETS
AB Colon cancer is one of the major causes of morbidity and mortality worldwide. Dietary phytochemicals have been drawing increasing attention for colon cancer prevention and treatment due to their chemical diversity, biological activity, easy availability, lack of toxic effects, and ability to modulate various signal transduction pathways and cell processes. The chemoprotective effects elicited by phytochemicals include antioxidative and anti-inflammatory activities, induction of phase II enzymes, cell cycle arrest, apoptosis, autophagy, and changes in gut microbiota. The present review summarizes the main chemopreventive properties of selected phytochemicals (carotenoids, flavonoids, flavonolignan, proanthocyanidin, isothiocyanates, terpenoids, peptides, and medicinal plant extracts) against colon cancer. It is found that these phytochemicals exhibit their anti-colon cancer activity through the modulation of various signaling pathways involved in the regulation of chronic inflammation, cell cycle, autophagy, apoptosis, metastasis, and angiogenesis. These phytochemicals could be helpful starting points in the design and development of novel colon cancer chemopreventive agents.
C1 [Zhao, Yueliang; Hu, Xiaoqian; Wang, Mingfu] Shanghai Ocean Univ, Coll Food Sci & Technol, Shanghai 201306, Peoples R China.
   [Zhao, Yueliang; Hu, Xiaoqian; Wang, Mingfu] Minist Agr, Lab Qual & Safety Risk Assessment Aquat Prod Stor, Shanghai 201306, Peoples R China.
   [Zuo, Xinyuan] Dalian Univ Technol, Sch Petr & Chem Engn, 2 Dagong Rd, Panjin City, Liaoning, Peoples R China.
   [Wang, Mingfu] Univ Hong Kong, Sch Biol Sci, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.
RP Wang, MF (corresponding author), Shanghai Ocean Univ, Coll Food Sci & Technol, Shanghai 201306, Peoples R China.; Wang, MF (corresponding author), Minist Agr, Lab Qual & Safety Risk Assessment Aquat Prod Stor, Shanghai 201306, Peoples R China.; Wang, MF (corresponding author), Univ Hong Kong, Sch Biol Sci, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.
EM mfwang@hku.hk
RI Wang, Mingfu/AAT-3292-2021; Wang, Mingfu/D-3136-2009
OI Wang, Mingfu/0000-0003-1469-3963
FU National Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [31671821]
FX This research work is partially supported by the general research
   project of the National Science Foundation of China (grant no.
   31671821).
CR Abe N, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.495
   Abu-Amero KK, 2016, NUTRIENTS, V8, DOI 10.3390/nu8040200
   Adachi S, 2009, CARCINOGENESIS, V30, P1544, DOI 10.1093/carcin/bgp166
   Adiwidjaja J, 2017, EXPERT OPIN DRUG MET, V13, P953, DOI 10.1080/17425255.2017.1360279
   Amado NG, 2014, INT J MOL SCI, V15, P12094, DOI 10.3390/ijms150712094
   Anwar S, 2016, MOL MED REP, V14, P1397, DOI 10.3892/mmr.2016.5397
   Araujo JR, 2011, NUTR RES, V31, P77, DOI 10.1016/j.nutres.2011.01.006
   Arigesavan K, 2015, BIOCHEM BIOPH RES CO, V461, P314, DOI 10.1016/j.bbrc.2015.04.030
   Ashkenazi A, 2017, NAT REV DRUG DISCOV, V16, P273, DOI 10.1038/nrd.2016.253
   Banerjee A, 2016, ONCOTARGET, V7, P41432, DOI 10.18632/oncotarget.9180
   Beaugerie L, 2015, NEW ENGL J MED, V372, P1441, DOI 10.1056/NEJMra1403718
   Belcheva A, 2015, BIOESSAYS, V37, P403, DOI 10.1002/bies.201400204
   Bock KW, 2006, BIOCHEM PHARMACOL, V72, P393, DOI 10.1016/j.bcp.2006.01.017
   Byun S, 2016, MOL NUTR FOOD RES, V60, P1068, DOI 10.1002/mnfr.201501011
   Cao HH, 2016, INT J CLIN EXP PATHO, V9, P4360
   Carini F, 2017, J BIOL REG HOMEOS AG, V31, P769
   Chang CY, 2018, J AGR FOOD CHEM, V66, P5549, DOI 10.1021/acs.jafc.8b01445
   Chang J, 2015, J ANIM PLANT SCI, V25, P1441
   Chao HP, 2010, PLANTA MED, V76, P1827, DOI 10.1055/s-0030-1250039
   Charepalli V, 2016, CANCERS, V8, DOI 10.3390/cancers8030029
   Charepalli V, 2015, J NUTR BIOCHEM, V26, P1641, DOI 10.1016/j.jnutbio.2015.08.005
   Chen H, 2014, PROTEOMICS, V14, P51, DOI 10.1002/pmic.201300101
   Chen HJ, 2012, BIOCHEM PHARMACOL, V84, P1143, DOI 10.1016/j.bcp.2012.08.011
   Chen LL, 2018, CARCINOGENESIS, V39, P471, DOI 10.1093/carcin/bgy009
   Chen ST, 2017, ONCOTARGET, V8, P88563, DOI 10.18632/oncotarget.19902
   Chen ST, 2016, MOLECULES, V21, DOI 10.3390/molecules21121677
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Chen XX, 2017, J AGR FOOD CHEM, V65, P1566, DOI 10.1021/acs.jafc.6b05376
   Chen ZR, 2017, EXP THER MED, V14, P3533, DOI 10.3892/etm.2017.4951
   Cheung KL, 2010, CARCINOGENESIS, V31, P880, DOI 10.1093/carcin/bgp285
   Cheung KL, 2010, AAPS J, V12, P87, DOI 10.1208/s12248-009-9162-8
   Chintharlapalli S, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-371
   Chio IIC, 2017, TRENDS MOL MED, V23, P411, DOI 10.1016/j.molmed.2017.03.004
   Chiste RC, 2014, J FOOD SCI, V79, pH1841, DOI 10.1111/1750-3841.12580
   Choi KS, 2012, EXP MOL MED, V44, P109, DOI 10.3858/emm.2012.44.2.033
   Choi SY, 2006, BIOFACTORS, V27, P137, DOI 10.1002/biof.5520270112
   Cvorovic J, 2010, ARCH BIOCHEM BIOPHYS, V501, P151, DOI 10.1016/j.abb.2010.05.019
   Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722
   Dattatreya Satya, 2013, South Asian J Cancer, V2, P179, DOI 10.4103/2278-330X.114152
   Dia VP, 2016, SCI REP-UK, V6, DOI 10.1038/srep33532
   Dia VP, 2011, MOL NUTR FOOD RES, V55, P623, DOI 10.1002/mnfr.201000419
   Dia VP, 2010, CANCER LETT, V295, P44, DOI 10.1016/j.canlet.2010.02.010
   Dickinson SE, 2015, MOL CARCINOGEN, V54, P1513, DOI 10.1002/mc.22224
   Pham DNT, 2013, AM J CLIN NUTR, V98, P413, DOI 10.3945/ajcn.113.060996
   Elfahri KR, 2016, J DAIRY SCI, V99, P31, DOI 10.3168/jds.2015-10160
   Juan ME, 2012, PHARMACOL RES, V65, P584, DOI 10.1016/j.phrs.2012.03.010
   Engelbrecht AM, 2007, CANCER LETT, V258, P144, DOI 10.1016/j.canlet.2007.08.020
   Fan K, 2015, ANTI-CANCER DRUG, V26, P813, DOI 10.1097/CAD.0000000000000263
   Fan X, 2018, CELL PHYSIOL BIOCHEM, V46, P1317, DOI 10.1159/000489147
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fimognari C, 2007, MUTAT RES-REV MUTAT, V635, P90, DOI 10.1016/j.mrrev.2006.10.004
   Forester SC, 2014, MOL CARCINOGEN, V53, P432, DOI 10.1002/mc.21974
   Fouad MA, 2013, HUM EXP TOXICOL, V32, P1067, DOI 10.1177/0960327113475679
   Fouad YA, 2017, AM J CANCER RES, V7, P1016
   Furtado RA, 2008, TOXICOL PATHOL, V36, P576, DOI 10.1177/0192623308317423
   Ganai AA, 2015, BIOMED PHARMACOTHER, V76, P30, DOI 10.1016/j.biopha.2015.10.026
   Goncalves P., 2010, FASEB J, V24, P965
   Goncalves P, 2011, NUTR CANCER, V63, P282, DOI 10.1080/01635581.2011.523166
   Gonzalez-Mauraza H, 2014, J PHYSIOL BIOCHEM, V70, P163, DOI 10.1007/s13105-013-0290-3
   Gonzalez-Montoya M, 2018, FOOD CHEM, V242, P75, DOI 10.1016/j.foodchem.2017.09.035
   Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019
   Grudzinski W, 2018, SPECTROCHIM ACTA A, V188, P57, DOI 10.1016/j.saa.2017.06.041
   Gupta P, 2014, MOL NUTR FOOD RES, V58, P1685, DOI 10.1002/mnfr.201300684
   Hernandez-Ledesma B, 2013, PROTEIN PEPTIDE LETT, V20, P424, DOI 10.2174/092986613805290327
   Hu MT, 2017, INT J CLIN EXP MED, V10, P10400
   Huang M, 2012, EXPERT OPIN INV DRUG, V21, P1801, DOI 10.1517/13543784.2012.727395
   Huang SS, 2012, INT J MOL MED, V30, P1410, DOI 10.3892/ijmm.2012.1147
   Huang XD, 2014, NAT PROD RES, V28, P914, DOI 10.1080/14786419.2014.889133
   Ji Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078700
   Jia SS, 2013, ONCOL REP, V29, P349, DOI 10.3892/or.2012.2093
   Jiang QQ, 2015, EXP THER MED, V10, P1602, DOI 10.3892/etm.2015.2692
   Jie Y, 2017, CANCER GENE THER, V24, P361, DOI 10.1038/cgt.2017.25
   Jin YY, 2017, EXP THER MED, V14, P5527, DOI 10.3892/etm.2017.5242
   Garcia-Nebot MJ, 2014, FOOD CHEM TOXICOL, V65, P155, DOI 10.1016/j.fct.2013.12.021
   Juge N, 2007, CELL MOL LIFE SCI, V64, P1105, DOI 10.1007/s00018-007-6484-5
   Kang NJ, 2011, PHARMACOL THERAPEUT, V130, P310, DOI 10.1016/j.pharmthera.2011.02.004
   Karimian A, 2016, DNA REPAIR, V42, P63, DOI 10.1016/j.dnarep.2016.04.008
   Kasdagly M, 2014, NUTRITION, V30, P1242, DOI 10.1016/j.nut.2014.02.016
   Kashyap D., 2016, AUSTIN ANDROLOGY, V1, P1010
   Khan I, 2018, NUTR CANCER, V70, P787, DOI 10.1080/01635581.2018.1470649
   Kim DH, 2015, INT J ONCOL, V47, P2226, DOI 10.3892/ijo.2015.3200
   Kim HJ, 2010, J AGR FOOD CHEM, V58, P8643, DOI 10.1021/jf101510z
   Kim J, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.119
   Kim JM, 2008, J AGR FOOD CHEM, V56, P8427, DOI 10.1021/jf801342p
   Kim M, 2009, INT J CANCER, V124, P264, DOI 10.1002/ijc.23923
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kotecha R, 2016, ONCOTARGET, V7, P52517, DOI 10.18632/oncotarget.9593
   Koyama M, 2013, ONCOL REP, V29, P779, DOI 10.3892/or.2012.2167
   Kresty LA, 2016, J BERRY RES, V6, P251, DOI 10.3233/JBR-160125
   Kumar VK, 2010, ENVIRON TOXICOL PHAR, V29, P50, DOI 10.1016/j.etap.2009.09.006
   Kuppusamy P, 2014, ACTA PHARM SIN B, V4, P173, DOI 10.1016/j.apsb.2014.04.002
   Lambert JD, 2003, J NUTR, V133, p3262S, DOI 10.1093/jn/133.10.3262S
   Larsen CA, 2010, ARCH BIOCHEM BIOPHYS, V501, P52, DOI 10.1016/j.abb.2010.03.017
   Lee YH, 2018, CANCER LETT, V431, P219, DOI 10.1016/j.canlet.2018.05.036
   Lee Y, 2014, INT J ONCOL, V44, P1599, DOI 10.3892/ijo.2014.2339
   Leonardi T, 2010, EXP BIOL MED, V235, P710, DOI 10.1258/ebm.2010.009359
   Lewandowska H, 2016, J NUTR BIOCHEM, V32, P1, DOI 10.1016/j.jnutbio.2015.11.006
   Li CH, 2013, J NUTR BIOCHEM, V24, P1766, DOI 10.1016/j.jnutbio.2013.03.006
   Li HT, 2014, CANCER RES, V74, P243, DOI 10.1158/0008-5472.CAN-13-2245
   Li HT, 2010, BRIT J PHARMACOL, V160, P1352, DOI 10.1111/j.1476-5381.2010.00785.x
   Li HT, 2010, EUR J PHARMACOL, V637, P55, DOI 10.1016/j.ejphar.2010.04.009
   Li HT, 2009, BIOCHEM PHARMACOL, V78, P1224, DOI 10.1016/j.bcp.2009.06.109
   Li H, 2016, INT J CLIN EXP MED, V9, P2423
   Li K, 2017, INT J CLIN EXP MED, V10, P10535
   Li MY, 2017, SCI REP-UK, V7, DOI 10.1038/srep42176
   Li PG, 2013, WORLD J GASTROENTERO, V19, P3300, DOI 10.3748/wjg.v19.i21.3300
   Li S, 2018, ANTI-CANCER DRUG, V29, P234, DOI [10.1097/CAD.0000000000000590, 10.1097/cad.0000000000000590]
   Liang YS, 2018, FOOD NUTR RES, V62, DOI 10.29219/fnr.v62.1384
   Lim S, 2013, MOL NUTR FOOD RES, V57, P1908, DOI 10.1002/mnfr.201300040
   Lin JM, 2015, ONCOL LETT, V9, P1962, DOI 10.3892/ol.2015.2956
   Lin JM, 2014, INTEGR CANCER THER, V13, P240, DOI 10.1177/1534735413508811
   Lin JM, 2013, INT J ONCOL, V42, P651, DOI 10.3892/ijo.2012.1753
   Lin JM, 2010, INT J ONCOL, V37, P1331, DOI 10.3892/ijo_00000785
   Lin MH, 2012, EXP THER MED, V4, P307, DOI 10.3892/etm.2012.599
   Lin W, 2015, ONCOL REP, V33, P1922, DOI 10.3892/or.2015.3784
   Lippert E, 2017, DIGESTION, V95, P275, DOI 10.1159/000475524
   Little CH, 2017, CRIT REV FOOD SCI, V57, P2310, DOI 10.1080/10408398.2014.997866
   Liu XY, 2017, BIOCHEM BIOPH RES CO, V491, P209, DOI 10.1016/j.bbrc.2017.07.078
   Liu Y, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091908
   de Las Hazas MCL, 2017, J AGR FOOD CHEM, V65, P6477, DOI 10.1021/acs.jafc.6b04096
   Lu MS, 2015, EUR J NUTR, V54, P619, DOI 10.1007/s00394-014-0743-7
   Vital DAL, 2014, FOOD CHEM, V157, P347, DOI 10.1016/j.foodchem.2014.02.050
   Luo Y, 2014, TUMOR BIOL, V35, P11483, DOI 10.1007/s13277-014-2487-7
   Madiwale GP, 2012, J AGR FOOD CHEM, V60, P11088, DOI 10.1021/jf303528p
   Martin SL, 2018, CURR CANCER DRUG TAR, V18, P97, DOI 10.2174/1568009617666170206104032
   Mileo AM, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/6475624
   Montales MTE, 2015, GENES NUTR, V10, DOI 10.1007/s12263-015-0499-6
   Mutoh H, 2000, JPN J CANCER RES, V91, P686
   Nandurkar NS, 2014, J MED CHEM, V57, P7478, DOI 10.1021/jm500870u
   Neighbors J. D., 2018, CURR PHARM REP, V4, DOI DOI 10.1007/S40495-018-0128-3
   Nguyen Anthony V, 2009, Cancer Manag Res, V1, P25
   Nishino H, 2002, CANCER METAST REV, V21, P257, DOI 10.1023/A:1021206826750
   Nishino H, 2000, BIOFACTORS, V13, P89, DOI 10.1002/biof.5520130115
   Palozza P, 2005, J NUTR, V135, P129, DOI 10.1093/jn/135.1.129
   Palozza P, 2003, J NUTR, V133, P381, DOI 10.1093/jn/133.2.381
   Palozza P, 2010, CARCINOGENESIS, V31, P1813, DOI 10.1093/carcin/bgq157
   Park CH, 2005, BIOCHEM BIOPH RES CO, V328, P227, DOI 10.1016/j.bbrc.2004.12.151
   Park KW, 2014, INT J ONCOL, V44, P1309, DOI 10.3892/ijo.2014.2281
   Park MH, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5020015
   Parrish Amanda B, 2013, Cold Spring Harb Perspect Biol, V5, DOI 10.1101/cshperspect.a008672
   Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371
   Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204
   Pierini R, 2008, BRIT J NUTR, V99, pES53, DOI 10.1017/S0007114508965764
   Pintova S, 2017, ANTICANCER RES, V37, P1647, DOI 10.21873/anticanres.11495
   Porta C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00064
   Priego S, 2008, MOL CANCER THER, V7, P3330, DOI 10.1158/1535-7163.MCT-08-0363
   Priyadarsini RV, 2012, CURR PHARM BIOTECHNO, V13, P125
   Qi F, 2016, ONCOL REP, V35, P511, DOI 10.3892/or.2015.4378
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Raina K, 2016, J BIOMED RES, V30, P452, DOI 10.7555/JBR.30.20150111
   Raina K, 2013, MOL CARCINOGEN, V52, P195, DOI 10.1002/mc.21843
   Rajendran P, 2013, EPIGENETICS-US, V8, P612, DOI 10.4161/epi.24710
   Rajendran P, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-68
   Ramirez de Molina Ana, 2015, J Pharmacol Exp Ther, V353, P433, DOI 10.1124/jpet.114.221796
   Ramos S, 2008, MOL NUTR FOOD RES, V52, P507, DOI 10.1002/mnfr.200700326
   Reddy L, 2003, PHARMACOL THERAPEUT, V99, P1, DOI 10.1016/S0163-7258(03)00042-1
   Ren Z, 2017, TOXICOLOGY, V392, P11, DOI 10.1016/j.tox.2017.10.002
   Rossi M, 2010, CANCER CAUSE CONTROL, V21, P243, DOI 10.1007/s10552-009-9455-3
   Rzeski W, 2006, N-S ARCH PHARMACOL, V374, P11, DOI 10.1007/s00210-006-0090-1
   Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803
   Sah BNP, 2016, INT DAIRY J, V63, P99, DOI 10.1016/j.idairyj.2016.08.003
   Sah BNP, 2015, COMPR REV FOOD SCI F, V14, P123, DOI 10.1111/1541-4337.12126
   Sakai R, 2012, J FOOD DRUG ANAL, V20, P389
   Sanchez-Fidalgo S, 2010, EUR J PHARMACOL, V633, P78, DOI 10.1016/j.ejphar.2010.01.025
   Satomi Y, 2013, ONCOL LETT, V6, P860, DOI 10.3892/ol.2013.1457
   Scolastici C, 2007, TOXICOL IN VITRO, V21, P840, DOI 10.1016/j.tiv.2007.01.020
   Seidel DV, 2017, SEMIN CANCER BIOL, V46, P191, DOI 10.1016/j.semcancer.2017.06.009
   Sengupta A, 2006, EUR J CANCER PREV, V15, P301, DOI 10.1097/00008469-200608000-00005
   Shalapour S, 2015, J CLIN INVEST, V125, P3347, DOI 10.1172/JCI80007
   Shan BE, 2009, CANCER INVEST, V27, P604, DOI 10.1080/07357900802337191
   Sharma M, 2010, J AGR FOOD CHEM, V58, P3965, DOI 10.1021/jf902857v
   Sharma SH, 2018, BIOMED PHARMACOTHER, V100, P367, DOI 10.1016/j.biopha.2018.02.035
   Sharma SH, 2017, EUR J PHARMACOL, V796, P20, DOI 10.1016/j.ejphar.2016.12.019
   Shen A, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/679436
   Shi MD, 2008, CHEM-BIOL INTERACT, V174, P201, DOI 10.1016/j.cbi.2008.06.006
   Shi MD, 2009, CHEM-BIOL INTERACT, V180, P344, DOI 10.1016/j.cbi.2009.04.011
   Shimizu M, 2005, CLIN CANCER RES, V11, P2735, DOI 10.1158/1078-0432.CCR-04-2014
   Shimizu M, 2008, CANCER PREV RES, V1, P298, DOI 10.1158/1940-6207.CAPR-08-0045
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Singh BN, 2011, BIOCHEM PHARMACOL, V82, P1807, DOI 10.1016/j.bcp.2011.07.093
   Singh RK, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1175-y
   Singletary K, 2008, CANCER EPIDEM BIOMAR, V17, P1596, DOI 10.1158/1055-9965.EPI-07-2917
   Singletary KW, 2001, NUTR CANCER, V39, P252, DOI 10.1207/S15327914nc392_15
   Song HM, 2016, BIOMOL THER, V24, P140, DOI 10.4062/biomolther.2015.109
   Sporn MB, 2000, CARCINOGENESIS, V21, P525, DOI 10.1093/carcin/21.3.525
   Su LY, 2015, ACTA PHARMACOL SIN, V36, P1514, DOI 10.1038/aps.2015.80
   Sun BC, 2014, TRENDS PHARMACOL SCI, V35, P349, DOI 10.1016/j.tips.2014.04.011
   Sun GC, 2017, J AGR FOOD CHEM, V65, P3474, DOI 10.1021/acs.jafc.7b00278
   Sun J, 2017, ONCOL REP, V38, P1420, DOI 10.3892/or.2017.5826
   Sung Bokyung, 2016, J Cancer Prev, V21, P216, DOI 10.15430/JCP.2016.21.4.216
   Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189
   Szakiel A, 2012, PHYTOCHEM REV, V11, P263, DOI 10.1007/s11101-012-9241-9
   Tanaka T, 2012, MOLECULES, V17, P3202, DOI 10.3390/molecules17033202
   Tang FY, 2008, MOL NUTR FOOD RES, V52, P646, DOI 10.1002/mnfr.200700272
   Tang FY, 2011, J AGR FOOD CHEM, V59, P9011, DOI 10.1021/jf2017644
   Taniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142
   Thakur R, 2013, J CELL MOL MED, V17, P449, DOI 10.1111/jcmm.12033
   Tin MMY, 2007, CARCINOGENESIS, V28, P1347, DOI 10.1093/carcin/bgl238
   Tong QY, 2014, TOXICOL APPL PHARM, V281, P166, DOI 10.1016/j.taap.2014.07.026
   Tseng A, 2016, ONCOL REP, V35, P659, DOI 10.3892/or.2015.4441
   Ullah F, 2017, ARCH TOXICOL, V91, P1623, DOI 10.1007/s00204-017-1939-4
   Umesalma S, 2014, MOL CELL BIOCHEM, V388, P157, DOI 10.1007/s11010-013-1907-0
   Vanamala J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-238
   Wan Y, 2017, EXP THER MED, V14, P3901, DOI 10.3892/etm.2017.4972
   Wang J, 2015, GASTROENT RES PRACT, V2015, DOI 10.1155/2015/457193
   Wang M, 2012, CHINESE J PHYSIOL, V55, P134, DOI 10.4077/CJP.2012.BAA085
   Wang Q, 2018, PHYTOMEDICINE, V39, P160, DOI 10.1016/j.phymed.2017.12.029
   Wang WQ, 2000, MOL CARCINOGEN, V28, P102
   Wei LH, 2017, CHIN J INTEGR MED, V23, P858, DOI 10.1007/s11655-017-2775-3
   Wei LH, 2014, MOL MED REP, V9, P261, DOI 10.3892/mmr.2013.1760
   William WN, 2009, NAT REV DRUG DISCOV, V8, P213, DOI 10.1038/nrd2663
   Wu HZ, 2008, BIOMED PHARMACOTHER, V62, P613, DOI 10.1016/j.biopha.2008.06.036
   Wu H, 2010, MOL NUTR FOOD RES, V54, P1296, DOI 10.1002/mnfr.200900409
   Xu M, 2016, ONCOL LETT, V11, P3075, DOI 10.3892/ol.2016.4331
   Yan ZK, 2017, ONCOL LETT, V14, P7923, DOI 10.3892/ol.2017.7245
   Yang CS, 2000, BIOFACTORS, V13, P73, DOI 10.1002/biof.5520130113
   Yang L, 2016, SEMIN ONCOL, V43, P146, DOI 10.1053/j.seminoncol.2015.09.013
   Yang X, 2015, CELL BIOSCI, V5, DOI 10.1186/s13578-015-0005-2
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yin TF, 2016, WORLD J GASTROENTERO, V22, P7058, DOI 10.3748/wjg.v22.i31.7058
   Yousr MN, 2017, NUTR CANCER, V69, P674, DOI 10.1080/01635581.2017.1295087
   Yuan ZT, 2017, ONCOTARGET, V8, P48012, DOI 10.18632/oncotarget.18225
   Yun JM, 2009, MOL CARCINOGEN, V48, P260, DOI 10.1002/mc.20477
   Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304
   Zhang J, 2017, ONCOTARGET, V8, P91223, DOI 10.18632/oncotarget.20077
   Zhang L, 2017, ONCOL REP, V37, P3695, DOI 10.3892/or.2017.5625
   Zhang L, 2014, MOL MED REP, V9, P701, DOI 10.3892/mmr.2013.1864
   Zhang M, 2018, INT J FOOD SCI TECH, V53, P525, DOI 10.1111/ijfs.13625
   Zhang NN, 2016, CELL PHYSIOL BIOCHEM, V40, P1559, DOI 10.1159/000453206
   Zhao Y., 2015, HDB FOOD CHEM, P967
   Zhao YL, 2017, ONCOTARGET, V8, P70239, DOI 10.18632/oncotarget.19605
   Zhao YL, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201600437
   Zhao YL, 2016, EUR J CANCER, V68, P38, DOI 10.1016/j.ejca.2016.09.001
   Zhou J, 2005, CURR DRUG METAB, V6, P289, DOI 10.2174/1389200054633853
   Ziegler DS, 2008, CURR OPIN ONCOL, V20, P97, DOI 10.1097/CCO.0b013e3282f310f6
NR 236
TC 47
Z9 48
U1 7
U2 80
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2042-6496
EI 2042-650X
J9 FOOD FUNCT
JI Food Funct.
PD SEP 1
PY 2018
VL 9
IS 9
BP 4548
EP 4568
DI 10.1039/c8fo00850g
PG 21
WC Biochemistry & Molecular Biology; Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Food Science & Technology
GA GU3YO
UT WOS:000445216900002
PM 30118121
DA 2022-04-25
ER

PT J
AU Koneri, K
   Goi, T
   Hirono, Y
   Katayama, K
   Yamaguchi, A
AF Koneri, Kenji
   Goi, Takanori
   Hirono, Yasuo
   Katayama, Kanji
   Yamaguchi, Akio
TI Beclin 1 gene inhibits tumor growth in colon cancer cell lines
SO ANTICANCER RESEARCH
LA English
DT Article
DE colon cancer; Beclin 1 gene; cell cycle
ID MAMMALIAN-CELLS; AUTOPHAGY GENE; PROTEIN; CYCLE; SUPPRESSOR; COMPLEX;
   KINASE; TUMORIGENESIS; TRANSITION; RECEPTOR
AB Background: The Beclin 1 gene binds to the apoptosis-inhibiting protein Bcl-2. The expression and function of the Beclin 1 gene in four colorectal cancer cell lines (HT29, DLD-1, SW480, SW620) was investigated. Materials and Methods: The expression of Beclin 1 mRNA was examined by reverse transcription-polymerase chain reaction (RT-PCR), the cell growth rate of a stable cell line established after transfection of the Beclin 1 gene into low Beclin 1-expressing HT29 colon cancer cells. In addition, changes in cell cycle were investigated by flow cytometry, and the expression levels of cell cycle related proteins in the Beclin 1 transfected colon cancer cell line were assessed. Results: The expression level of Beclin 1 mRNA in the colon cancer cell lines was variable. Transfection of the low Beclin 1 gene-expressing colon cancer cell line with the Beclin 1 gene resulted in cell growth inhibition. The cell cycle analysis showed that the percentage of G1-phase cells was significantly higher in Beclin 1 transfectants than in mock transfected cells. The expression levels of cyclin E and phosphorylated Rb were decreased. Conclusion: These results indicate that Beclin 1 can inhibit the growth of colorectal cancer cells.
C1 Univ Fukui, Fac Med, Dept Surg Gastroenterol, Matsuoka, Fukui 9101193, Japan.
RP Yamaguchi, A (corresponding author), Univ Fukui, Dept Surg 1, 23-3,Eiheiji Cho, Matsuoka, Fukui 9101193, Japan.
EM akio@fmsrsa.fukui-med.ac.jp
RI Hirono, Yasuo/E-9383-2011
CR Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812
   Goi T, 2004, CANCER RES, V64, P1906, DOI 10.1158/0008-5472.CAN-3696-2
   Goi T, 1998, BRIT J CANCER, V77, P466, DOI 10.1038/bjc.1998.74
   GRANA X, 1995, ONCOGENE, V11, P211
   HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775
   Kametaka S, 1998, J BIOL CHEM, V273, P22284, DOI 10.1074/jbc.273.35.22284
   KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288
   Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Masciullo V, 2000, INT J ONCOL, V17, P897
   Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782
   OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612
   PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Seaman MNJ, 1997, J CELL BIOL, V137, P79, DOI 10.1083/jcb.137.1.79
   TSAI LH, 1993, ONCOGENE, V8, P1593
   Yue ZY, 2002, NEURON, V35, P921, DOI 10.1016/S0896-6273(02)00861-9
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
NR 19
TC 68
Z9 77
U1 0
U2 3
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD MAY-JUN
PY 2007
VL 27
IS 3B
BP 1453
EP 1457
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 170GL
UT WOS:000246650700010
PM 17595761
DA 2022-04-25
ER

PT J
AU Zhang, YL
   Li, C
   Liu, XF
   Wang, YL
   Zhao, R
   Yang, YM
   Zheng, X
   Zhang, Y
   Zhang, X
AF Zhang, Yanli
   Li, Chen
   Liu, Xinfeng
   Wang, Yanlei
   Zhao, Rui
   Yang, Yongmei
   Zheng, Xin
   Zhang, Yi
   Zhang, Xin
TI circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through
   autophagy by sponging miR-637
SO EBIOMEDICINE
LA English
DT Article
DE Colorectal cancer; Chemoresistance; circHIPK3; Autophagy; miR-637; STAT3
ID COLON-CANCER; CIRCULAR RNAS; CELL-GROWTH; IN-VITRO; TUMORIGENESIS;
   CARCINOMA; SURVIVAL; MACROAUTOPHAGY; FLUOROURACIL; COMBINATION
AB Background: Resistance to oxaliplatin-based chemotherapy is a major cause of recurrence in colorectal cancer (CRC) patients. There is increasing evidence indicating that circHIPK3 is involved in the development and progression of tumours. However, little is known about the potential role of circHIPK3 in CRC chemotherapy and its molecular mechanisms in chemoresistance also remain unclear.
   Methods: Quantitative real-time PCR was performed to detect circHIPK3 expression in tissues of 2 cohorts of CRC patients who received oxaliplatin-based chemotherapy. The chemoresistant effects of circHIPK3 were assessed by cell viability, apoptosis, and autophagy assays. The relationship between circHIPK3, miR-637, and STAT3 mRNA was confirmed by biotinylated RNA pull-down, luciferase reporter, and western blot assays.
   Findings: In the pilot study, increased circHIPK3 expression was observed in chemoresistant CRC patients. Functional assays showed that circHIPK3 promoted oxaliplatin resistance, which was dependent on inhibition of autophagy. Mechanistically, circHIPK3 sponged miR-637 to promote STAT3 expression, thereby activating the downstream Bcl-2/beclinl signalling pathway. A clinical cohort study showed that circHIPK3 was upregulated in tissues from recurrent CRC patients and correlated with tumour size, regional lymph node metastasis, distant metastasis, and survival.
   Interpretation: circHIPK3 functions as a chemoresistant gene in CRC cells by targeting the miR-637/STAT3/Bcl-2/beclinl axis and might be a prognostic predictor for CRC patients who receive oxaliplatin-based chemotherapy. (C) 2019 The Author(s). Published by Elsevier B.V.
C1 [Li, Chen; Zhao, Rui; Yang, Yongmei; Zheng, Xin; Zhang, Yi; Zhang, Xin] Shandong Univ, Dept Clin Lab, Qilu Hosp, 107 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.
   [Zhang, Yanli; Liu, Xinfeng] Shandong Prov Third Hosp, Dept Clin Lab, Jinan 250031, Shandong, Peoples R China.
   [Wang, Yanlei] Shandong Univ, Dept Gen Surg, Qilu Hosp, Jinan 250012, Shandong, Peoples R China.
RP Zhang, X (corresponding author), Shandong Univ, Dept Clin Lab, Qilu Hosp, 107 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.
EM xinzhang@sdu.edu.cn
OI Zhang, Xin/0000-0003-2138-5600
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81301506]; Shandong Medical and Health
   Technology Development Project [2018WSB20002]; Shandong Key Research and
   Development Program [2016CSF201122]; Natural Science Foundation of
   Shandong ProvinceNatural Science Foundation of Shandong Province
   [ZR2017MH044]; Jinan Science and Technology Development Plan [201805084,
   201805003]
FX This study was supported by National Natural Science Foundation of China
   (81301506), Shandong Medical and Health Technology Development
   Project(2018WSB20002), Shandong Key Research and Development Program
   (2016CSF201122), Natural Science Foundation of Shandong Province
   (ZR2017MH044), Jinan Science and Technology Development Plan(201805084,
   201805003). The funders had no role in study design, data collection,
   data analysis, interpretation, and writing of the manuscript.
CR Alves S, 2015, ONCOTARGET, V6, P30787, DOI 10.18632/oncotarget.5021
   Andre T, 2009, J CLIN ONCOL, V27, P3109, DOI 10.1200/JCO.2008.20.6771
   Aoki M, 2017, CURR TOP MICROBIOL, V407, P153, DOI 10.1007/82_2017_6
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Bryant KL, 2019, NAT MED, V25, P628, DOI 10.1038/s41591-019-0368-8
   Chen GW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0204-3
   Chen YH, 2016, J MED GENET, V53, P359, DOI 10.1136/jmedgenet-2016-103758
   Cheng XW, 2019, AUTOPHAGY, V15, P1120, DOI [10.1080/15548627.2019.1596500, 10.1080/15548627.2019.1634945]
   DelBufalo D, 1996, BRIT J CANCER, V74, P387, DOI 10.1038/bjc.1996.370
   Fulda S, 2015, ONCOGENE, V34, P5105, DOI 10.1038/onc.2014.458
   Galluzzi L, 2017, NAT REV CLIN ONCOL, V14, P247, DOI 10.1038/nrclinonc.2016.183
   Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046
   Goulielmaki M, 2016, ONCOTARGET, V7, P9188, DOI 10.18632/oncotarget.6942
   GU MJ, 2014, GASTROENT RES PRACT, V14
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Hu HQ, 2018, BIOCHEM BIOPH RES CO, V503, P2400, DOI 10.1016/j.bbrc.2018.06.168
   Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112
   Jin PC, 2018, BIOCHEM BIOPH RES CO, V503, P1570, DOI 10.1016/j.bbrc.2018.07.081
   Ke ZY, 2019, J CELL PHYSIOL, V234, P1699, DOI 10.1002/jcp.27041
   Kim YS, 2014, YONSEI MED J, V55, P1484, DOI 10.3349/ymj.2014.55.6.1484
   Kinsey CG, 2019, NAT MED, V25, P620, DOI 10.1038/s41591-019-0367-9
   Li JX, 2018, EUR REV MED PHARMACO, V22, P1265, DOI 10.26355/eurrev_201803_14467
   Li PL, 2017, MOL THER-NUCL ACIDS, V8, P356, DOI 10.1016/j.omtn.2017.07.007
   Li SY, 2017, ONCOL REP, V38, P1637, DOI 10.3892/or.2017.5849
   Li YW, 2017, EMBO REP, V18, P1646, DOI 10.15252/embr.201643581
   Liu N, 2018, EUR REV MED PHARMACO, V22, P3713, DOI 10.26355/eurrev_201806_15250
   Liu T, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0981-7
   Liu XZ, 2017, J CELL BIOL, V216, P1301, DOI 10.1083/jcb.201608039
   Ma XH, 2014, J CLIN INVEST, V124, P1406, DOI 10.1172/JCI70454
   Ma XL, 2018, J CANCER, V9, P1856, DOI 10.7150/jca.24619
   Mehrpour M, 2010, CELL RES, V20, P748, DOI 10.1038/cr.2010.82
   O'Connell JB, 2004, JNCI-J NATL CANCER I, V96, P1420, DOI 10.1093/jnci/djh275
   O'Donovan TR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134676
   Pan XF, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1660-8
   Pattingre S, 2008, BIOCHIMIE, V90, P313, DOI 10.1016/j.biochi.2007.08.014
   Pekarcikova L, 2016, CELL SIGNAL, V28, P924, DOI [10.1016/j.cellsig2016.04.007, 10.1016/j.cellsig.2016.04.007]
   Que T, 2015, ONCOGENE, V34, P4952, DOI 10.1038/onc.2014.419
   Ren WW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0592-z
   Sahni S, 2014, J CLIN PATHOL, V67, P656, DOI 10.1136/jclinpath-2014-202356
   Schaaf MBE, 2016, FASEB J, V30, P3961, DOI 10.1096/fj.201600698R
   Schmitz KJ, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0946-x
   Shan K, 2017, CIRCULATION, V136, P1629, DOI 10.1161/CIRCULATIONAHA.117.029004
   Shibata M, 2009, BIOCHEM BIOPH RES CO, V382, P419, DOI 10.1016/j.bbrc.2009.03.039
   Shiovitz Stacey, 2015, Curr Gastroenterol Rep, V17, P431, DOI 10.1007/s11894-015-0431-7
   Sinha S, 2008, ONCOGENE, V27, pS137, DOI 10.1038/onc.2009.51
   Spitzner M, 2014, INT J CANCER, V134, P997, DOI 10.1002/ijc.28429
   Strohecker AM, 2014, AUTOPHAGY, V10, P384, DOI 10.4161/auto.27320
   Wang LQ, 2019, INT J BIOCHEM CELL B, V106, P46, DOI 10.1016/j.biocel.2018.09.015
   Wang S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.485
   Wu SH, 2015, INT J CLIN EXP PATHO, V8, P3882
   Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796
   Xu RL, 2018, EXP CELL RES, V363, P310, DOI 10.1016/j.yexcr.2018.01.026
   Yao H, 2019, BIOSCIENCE REP, P15
   You LK, 2015, AUTOPHAGY, V11, P729, DOI 10.1080/15548627.2015.1017192
   Yu HY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0660-4
   Zeng K, 2018, CELL DEATH DIS, V9, P152
   Zhang JF, 2011, HEPATOLOGY, V54, P2137, DOI 10.1002/hep.24595
   Zheng QP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11215
   Zhou ZB, 2019, MOL THER, V27, P531, DOI 10.1016/j.ymthe.2019.01.006
NR 59
TC 51
Z9 51
U1 5
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352-3964
J9 EBIOMEDICINE
JI EBioMedicine
PD OCT
PY 2019
VL 48
BP 277
EP 288
DI 10.1016/j.ebiom.2019.09.051
PG 12
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA JJ0CR
UT WOS:000493830800033
PM 31631038
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Koehler, BC
   Jager, D
   Schulze-Bergkamen, H
AF Koehler, Bruno Christian
   Jaeger, Dirk
   Schulze-Bergkamen, Henning
TI Targeting cell death signaling in colorectal cancer: Current strategies
   and future perspectives
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Colorectal cancer; Apoptosis; Necroptosis; Autophagy; Clinical trial;
   Bcl-2 proteins; BH-3 mimetics; Inflammatory bowel disease
ID APOPTOSIS-INDUCING LIGAND; TRAIL-INDUCED APOPTOSIS; X-LINKED INHIBITOR;
   PHASE-I TRIAL; FAS-MEDIATED APOPTOSIS; COLON-CARCINOMA CELLS;
   TUMOR-GROWTH; RECEPTOR 5; PHARMACODYNAMIC BIOMARKERS; OBLIMERSEN SODIUM
AB The evasion from controlled cell death induction has been considered as one of the hallmarks of cancer cells. Defects in cell death signaling are a fundamental phenomenon in colorectal cancer. Nearly any non-invasive cancer treatment finally aims to induce cell death. However, apoptosis resistance is the major cause for insufficient therapeutic success and disease relapse in gastrointestinal oncology. Various compounds have been developed and evaluated with the aim to meet with this obstacle by triggering cell death in cancer cells. The aim of this review is to illustrate current approaches and future directions in targeting cell death signaling in colorectal cancer. The complex signaling network of apoptosis will be demonstrated and the "druggability" of targets will be identified. In detail, proteins regulating mitochondrial cell death in colorectal cancer, such as Bcl-2 and survivin, will be discussed with respect to potential therapeutic exploitation. Death receptor signaling and targeting in colorectal cancer will be outlined. Encouraging clinical trials including cell death based targeted therapies for colorectal cancer are under way and will be demonstrated. Our conceptual understanding of cell death in cancer is rapidly emerging and new types of controlled cellular death have been identified. To meet this progress in cell death research, the implication of autophagy and necroptosis for colorectal carcinogenesis and therapeutic approaches will also be depicted. The main focus of this topic highlight will be on the revelation of the complex cell death concepts in colorectal cancer and the bridging from basic research to clinical use. (C) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.
C1 [Koehler, Bruno Christian; Jaeger, Dirk; Schulze-Bergkamen, Henning] Univ Heidelberg Hosp, Natl Ctr Tumor Dis, D-69120 Heidelberg, Germany.
RP Schulze-Bergkamen, H (corresponding author), Univ Heidelberg Hosp, Natl Ctr Tumor Dis, Neuenheimer Feld 460, D-69120 Heidelberg, Germany.
EM henning.schulze@med.uni-heidelberg.de
FU Medical Faculty of the University of Heidelberg, Germany; German
   Research FoundationGerman Research Foundation (DFG) [DFG SCHU 1443/4-1]
FX BCK holds a Postdoctoral-Fellowship from the Medical Faculty of the
   University of Heidelberg, Germany. HSB receives grants from the German
   Research Foundation (DFG SCHU 1443/4-1). All authors are members of the
   colorectal cancer clinical research unit at the University Hospital
   Heidelberg, Germany (KFO227).
CR Altomare I, 2013, EXPERT OPIN PHARMACO, V14, P505, DOI 10.1517/14656566.2013.770473
   Altomare I, 2011, ONCOLOGIST, V16, P1131, DOI 10.1634/theoncologist.2011-0078
   Anguiano-Hemandez YM, 2007, ANTI-CANCER AGENT ME, V7, P467
   Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305
   Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821
   Bank A, 2008, CANCER RES, V68, P276, DOI 10.1158/0008-5472.CAN-07-5242
   Baretton GB, 1996, CANCER, V77, P255, DOI 10.1002/(SICI)1097-0142(19960115)77:2<255::AID-CNCR6>3.0.CO;2-L
   Basile V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053664
   Becker C, 2013, GASTROENTEROLOGY, V144, P283, DOI 10.1053/j.gastro.2012.11.035
   Biggers JW, 2013, CANCER CHEMOTH PHARM, V71, P441, DOI 10.1007/s00280-012-2024-6
   Call JA, 2008, LANCET ONCOL, V9, P1002, DOI 10.1016/S1470-2045(08)70209-2
   Castellano D, 2013, ONCOLOGIST, V18, P46, DOI 10.1634/theoncologist.2012-0263
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Choi JH, 2012, APMIS, V120, P597, DOI 10.1111/j.1600-0463.2012.02876.x
   Chu C, 2013, FUND CLIN PHARMACOL, V27, P434, DOI 10.1111/j.1472-8206.2012.01035.x
   Citrin D, 2010, ONCOLOGY-BASEL, V79, P382, DOI 10.1159/000323488
   Cohn AL, 2013, ANN ONCOL, V24, P1777, DOI 10.1093/annonc/mdt057
   Cummings J, 2006, BRIT J CANCER, V95, P42, DOI 10.1038/sj.bjc.6603220
   Cummins Jordan M., 2004, Cancer Research, V64, P3006
   Dai Y, 2007, CANCER RES, V67, P2908, DOI 10.1158/0008-5472.CAN-07-0082
   de la Chapelle A, 2004, NAT REV CANCER, V4, P769, DOI 10.1038/nrc1453
   De Saint-Hubert M, 2012, CURR PHARM BIOTECHNO, V13, P571, DOI 10.2174/138920112799436320
   Dean E, 2009, J CLIN ONCOL, V27, P1660, DOI 10.1200/JCO.2008.19.5677
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602
   Ding WX, 2009, MOL CANCER THER, V8, P2036, DOI 10.1158/1535-7163.MCT-08-1169
   Fadeel B, 2008, CELL DEATH DIFFER, V15, P443, DOI 10.1038/sj.cdd.4402265
   Feagins LA, 2009, NAT REV GASTRO HEPAT, V6, P297, DOI 10.1038/nrgastro.2009.44
   Foersch S, 2012, DIGEST DIS, V30, P469, DOI 10.1159/000341692
   Forero-Torres A, 2010, CANCER BIOTHER RADIO, V25, P13, DOI 10.1089/cbr.2009.0673
   Fulda S, 2013, CANCER BIOL THER, V14, P999, DOI 10.4161/cbt.26428
   GONG J, 2013, MOL CARCINOG, DOI DOI 10.1002/MC.22027]
   Gong J, 2006, MOL CANCER THER, V5, P2991, DOI 10.1158/1535-7163.MCT-06-0188
   Grassilli E, 2013, CLIN CANCER RES, V19, P3820, DOI 10.1158/1078-0432.CCR-12-3289
   Greene LM, 2012, BIOCHEM PHARMACOL, V84, P612, DOI 10.1016/j.bcp.2012.06.005
   Gross A, 2006, CELL CYCLE, V5, P582, DOI 10.4161/cc.5.6.2575
   Groulx JF, 2012, AUTOPHAGY, V8, P893, DOI 10.4161/auto.19738
   Gunther C, 2011, NATURE, V477, P335, DOI 10.1038/nature10400
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hao XP, 1997, PATHOBIOLOGY, V65, P140, DOI 10.1159/000164115
   Harpaz N, 2013, BEST PRACT RES CL GA, V27, P257, DOI 10.1016/j.bpg.2013.03.014
   Harrison LRE, 2011, J CLIN INVEST, V121, P1075, DOI 10.1172/JCI43505
   Hector S, 2009, BBA-REV CANCER, V1795, P117, DOI 10.1016/j.bbcan.2008.12.002
   Hehlgans S, 2013, RADIOTHER ONCOL, V108, P32, DOI 10.1016/j.radonc.2013.06.006
   Hemmerle T, 2013, BRIT J CANCER, V109, P1206, DOI 10.1038/bjc.2013.421
   Herman JM, 2013, J CLIN ONCOL, V31, P886, DOI 10.1200/JCO.2012.44.7516
   Hernandez A, 2001, J GASTROINTEST SURG, V5, P56, DOI 10.1016/S1091-255X(01)80014-7
   Hernandez A, 2001, SURGERY, V130, P265, DOI 10.1067/msy.2001.115897
   Hernandez-Breijo B, 2011, WORLD J GASTROENTERO, V17, P3899, DOI 10.3748/wjg.v17.i34.3899
   Hoogwater FJH, 2012, BBA-REV CANCER, V1826, P189, DOI 10.1016/j.bbcan.2012.03.007
   Hotchkiss RS, 2009, NEW ENGL J MED, V361, P1570, DOI 10.1056/NEJMra0901217
   Houghton JA, 1997, CLIN CANCER RES, V3, P2205
   Huang CY, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.149
   Huang SB, 2010, AUTOPHAGY, V6, P256, DOI 10.4161/auto.6.2.11124
   Huerta S, 2010, SURGERY, V148, P346, DOI 10.1016/j.surg.2010.05.006
   Jain MV, 2013, J CELL MOL MED, V17, P12, DOI 10.1111/jcmm.12001
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Jendrossek V, 2013, CANCER LETT, V332, P313, DOI 10.1016/j.canlet.2011.01.012
   Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465
   Jouan-Lanhouet S, 2012, CELL DEATH DIFFER, V19, P2003, DOI 10.1038/cdd.2012.90
   Joudeh J, 2012, EXPERT OPIN INV DRUG, V21, P363, DOI 10.1517/13543784.2012.652302
   Kameshima H, 2011, CANCER SCI, V102, P1181, DOI 10.1111/j.1349-7006.2011.01918.x
   Kasper HU, 2010, IN VIVO, V24, P653
   Kaufmann T, 2012, CELL DEATH DIFFER, V19, P42, DOI 10.1038/cdd.2011.121
   Kelley SK, 2001, J PHARMACOL EXP THER, V299, P31
   Kim HS, 2003, GASTROENTEROLOGY, V125, P708, DOI 10.1016/S0016-5085(03)01059-X
   Kim HS, 2010, IMMUNOL LETT, V131, P73, DOI 10.1016/j.imlet.2010.03.001
   Kim SW, 2013, PROSTATE, V73, P296, DOI 10.1002/pros.22574
   Ko CH, 2007, INT J CANCER, V121, P1670, DOI 10.1002/ijc.22910
   Koehler BC, 2009, WORLD J GASTROENTERO, V15, P5924, DOI 10.3748/wjg.15.5924
   Krajewska M, 1996, CANCER RES, V56, P2422
   Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728
   Krause BJ, 2010, NUKLEARMED-NUCL MED, V49, pS41
   Kreuzaler P, 2012, NAT REV CANCER, V12, P411, DOI 10.1038/nrc3264
   Krieg A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065338
   Kumar GK, 2011, INT IMMUNOPHARMACOL, V11, P724, DOI 10.1016/j.intimp.2011.01.022
   LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569
   LaCasse EC, 2006, CLIN CANCER RES, V12, P5231, DOI 10.1158/1078-0432.CCR-06-0608
   Laurent-Puig P, 1999, EUR J CANCER PREV, V8, pS39
   LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274
   Lee EW, 2012, BMB REP, V45, P496, DOI 10.5483/BMBRep.2012.45.9.186
   Lejeune F J, 2006, Bull Cancer, V93, pE90
   Li M, 2012, MOL THER, V20, P46, DOI 10.1038/mt.2011.197
   Linder S, 2004, CANCER LETT, V214, P1, DOI 10.1016/j.canlet.2004.06.032
   Linder S, 2010, EXPERT REV MOL DIAGN, V10, P353, DOI [10.1586/erm.10.14, 10.1586/ERM.10.14]
   Lipson EJ, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23661
   Liu LU, 1999, GUT, V45, P45, DOI 10.1136/gut.45.1.45
   Manne U, 1997, INT J CANCER, V74, P346, DOI 10.1002/(SICI)1097-0215(19970620)74:3<346::AID-IJC19>3.0.CO;2-9
   Manne U, 2011, CANCER BIOMARK, V9, P235, DOI 10.3233/CBM-2011-0160
   Manzo F, 2009, INT J BIOCHEM CELL B, V41, P460, DOI 10.1016/j.biocel.2007.12.012
   Marini P, 2006, ONCOGENE, V25, P5145, DOI 10.1038/sj.onc.1209516
   Matkowskyj KA, 2013, ARCH PATHOL LAB MED, V137, P338, DOI 10.5858/arpa.2012-0086-RA
   Mazumder S, 2012, CANCER RES, V72, P3069, DOI 10.1158/0008-5472.CAN-11-4106
   Merchant MS, 2012, J CLIN ONCOL, V30, P4141, DOI 10.1200/JCO.2012.44.1055
   Mita MM, 2006, ANN ONCOL, V17, P313, DOI 10.1093/annonc/mdj067
   Miura K, 2011, SURG TODAY, V41, P175, DOI 10.1007/s00595-010-4390-1
   Mohr A, 2008, ONCOGENE, V27, P763, DOI 10.1038/sj.onc.1210673
   Moreira JN, 2006, REV RECENT CLIN TRIA, V1, P217, DOI 10.2174/157488706778250050
   Motoki K, 2005, CLIN CANCER RES, V11, P3126, DOI 10.1158/1078-0432.CCR-04-1867
   Neumann H, 2011, WORLD J GASTROENTERO, V17, P3184, DOI 10.3748/wjg.v17.i27.3184
   Ng K, 2013, CLIN CANCER RES, V19, P3987, DOI 10.1158/1078-0432.CCR-13-0027
   Nijkamp MW, 2010, J HEPATOL, V53, P1069, DOI 10.1016/j.jhep.2010.04.040
   Okumura K, 2008, CLIN CANCER RES, V14, P8132, DOI 10.1158/1078-0432.CCR-08-1665
   Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x
   Pan Y, 2011, BRIT J CANCER, V105, P1830, DOI 10.1038/bjc.2011.456
   Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239
   Pennarun B, 2013, J PATHOL, V229, P410, DOI 10.1002/path.4138
   Qiu YH, 2012, IUBMB LIFE, V64, P757, DOI 10.1002/iub.1064
   Raats DAE, 2011, CELL ONCOL, V34, P307, DOI 10.1007/s13402-011-0026-8
   Raina K, 2013, AUTOPHAGY, V9, P697, DOI 10.4161/auto.23960
   Rosevear HM, 2010, CURR OPIN INVEST DR, V11, P688
   Sale MJ, 2013, BIOCHEM J, V450, P285, DOI 10.1042/BJ20121212
   Sasaki K, 2012, ANTI-CANCER DRUG, V23, P675, DOI 10.1097/CAD.0b013e328353f8c7
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Sheard MA, 1997, INT J CANCER, V73, P757, DOI 10.1002/(SICI)1097-0215(19971127)73:5<757::AID-IJC24>3.0.CO;2-1
   Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170
   Siegemund M, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.29
   Sinicrope FA, 2004, CLIN CANCER RES, V10, P8284, DOI 10.1158/1078-0432.CCR-04-1289
   Soetikno R, 2013, GASTROENTEROLOGY, V144, P1349, DOI 10.1053/j.gastro.2013.04.008
   Sotelo J, 2006, ANN INTERN MED, V144, P337, DOI 10.7326/0003-4819-144-5-200603070-00008
   Spitaleri G, 2013, J CANCER RES CLIN, V139, P447, DOI 10.1007/s00432-012-1327-7
   Steller EJA, 2011, EMBO REP, V12, P931, DOI 10.1038/embor.2011.129
   Strater J, 2002, GASTROENTEROLOGY, V122, P659, DOI 10.1053/gast.2002.31889
   Sugita J, 2002, JPN J CANCER RES, V93, P320, DOI 10.1111/j.1349-7006.2002.tb02175.x
   Tai CJ, 2013, EVID-BASED COMPL ALT, V2013, DOI [10.1155/2013/514719, 10.1155/2013/121725]
   Tenesa A, 2009, NAT REV GENET, V10, P353, DOI 10.1038/nrg2574
   Thippeswamy BS, 2011, EUR J PHARMACOL, V654, P100, DOI 10.1016/j.ejphar.2010.12.012
   Tian ML, 2011, CANCER BIOL THER, V12, P896, DOI 10.4161/cbt.12.10.17679
   Tillman DM, 1998, CELL DEATH DIFFER, V5, P450, DOI 10.1038/sj.cdd.4400369
   Timme CR, 2013, APOPTOSIS, V18, P1163, DOI 10.1007/s10495-013-0883-x
   Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970
   Villa-Morales M, 2012, EXPERT OPIN THER TAR, V16, P85, DOI 10.1517/14728222.2011.628937
   Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124
   Wang WS, 2006, CARCINOGENESIS, V27, P1113, DOI 10.1093/carcin/bgi351
   Watson AJM, 2004, GUT, V53, P1701, DOI 10.1136/gut.2004.052704
   Welz PS, 2011, NATURE, V477, P330, DOI 10.1038/nature10273
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wiedenmann N, 2007, INVEST NEW DRUG, V25, P411, DOI 10.1007/s10637-007-9058-3
   Wolpin BM, 2013, ONCOLOGIST, V18, P377, DOI 10.1634/theoncologist.2012-0378
   Yada A, 2008, ANN ONCOL, V19, P1060, DOI 10.1093/annonc/mdn015
   Yang C, 2012, CELL BIOL INT, V36, P289, DOI 10.1042/CBI20100825
   Yang WL, 2012, J SURG ONCOL, V106, P680, DOI 10.1002/jso.23184
   Yao Hang, 2008, Zhonghua Wei Chang Wai Ke Za Zhi, V11, P61
   Yip KW, 2008, ONCOGENE, V27, P6398, DOI 10.1038/onc.2008.307
   YOUNG NL, 1982, J LIPID RES, V23, P831
   Yu XF, 2013, EXPERT REV ANTICANC, V13, P883, DOI 10.1586/14737140.2013.811180
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zheng HX, 2013, ONCOGENE, V32, P1183, DOI 10.1038/onc.2012.126
   Zhou ZR, 2012, PROTEIN CELL, V3, P811, DOI 10.1007/s13238-012-2083-9
   Zhu Q, 2005, WORLD J GASTROENTERO, V11, P6125, DOI 10.3748/wjg.v11.i39.6125
   2007, DRUGS R D, V8, P321
NR 151
TC 38
Z9 38
U1 2
U2 19
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD FEB 28
PY 2014
VL 20
IS 8
BP 1923
EP 1934
DI 10.3748/wjg.v20.i8.1923
PG 12
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA AB7GP
UT WOS:000331957900004
PM 24587670
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Grossi, V
   Liuzzi, M
   Murzilli, S
   Martelli, N
   Napoli, A
   Ingravallo, G
   Del Rio, A
   Simone, C
AF Grossi, Valentina
   Liuzzi, Micaela
   Murzilli, Stefania
   Martelli, Nicola
   Napoli, Anna
   Ingravallo, Giuseppe
   Del Rio, Alberto
   Simone, Cristiano
TI Sorafenib inhibits p38 alpha activity in colorectal cancer cells and
   synergizes with the DFG-in inhibitor SB202190 to increase apoptotic
   response
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE protein kinase; DFG-in and DFG-out; conformations; sorafenib; type-I and
   type-II inhibitors; colorectal cancer; p38 alpha; BRAF; MEK/ERK;
   apoptosis
ID MULTIKINASE INHIBITOR; AMPK-FOXO3A AXIS; PATHWAY; GROWTH; AUTOPHAGY;
   TARGETS; COLON; RAF; DISCOVERY; BLOCKADE
AB In the search for new strategies to efficiently fight colorectal cancer, efforts are being increasingly focused on targeting regulatory signaling pathways involved in cancer-specific features. As a result, several studies have recently addressed the therapeutic potential of molecularly-targeted drugs capable of inhibiting the activity of protein kinases involved in relevant signaling cascades. Here we show that simultaneous inhibition of the DFG-in and DFG-out conformations of p38 alpha by means of type-I and type-II inhibitors is beneficial to impair more efficiently its kinase activity. Moreover, we found that SB202190 (type-I) and sorafenib (type-II) synergize at the molecular and biological level, as co-treatment with these compounds enhances tumor growth inhibition and induction of apoptosis both in colorectal cancer cell lines and animal models. These results support the need to reconsider sorafenib as a therapeutic agent against colorectal cancer and provide new insights that underline the importance to elucidate the activity of protein kinase inhibitors for the treatment of colorectal carcinoma.
C1 [Del Rio, Alberto] Alma Mater Studiorum Univ Bologna, Dept Expt Pathol, Lab Biochemoinformat, Bologna, Italy.
   [Grossi, Valentina] IRCCS S Bellis, Canc Genet Lab, Castellana Grotte, Italy.
   [Liuzzi, Micaela; Napoli, Anna; Ingravallo, Giuseppe] Univ Bari, DIM, Div Anat Pathol, Bari, Italy.
   [Murzilli, Stefania; Martelli, Nicola] Consorzio Mario NegriSud, Dept Translat Pharmacol, Lab Lipid Metab & Canc, Santa Maria Imbaro, Italy.
   [Murzilli, Stefania] Consorzio Mario NegriSud, Dept Translat Pharmacol, Anim Care Facil, Santa Maria Imbaro, Italy.
   [Martelli, Nicola] Consorzio Mario NegriSud, Dept Translat Pharmacol, Flow Cytometry Facil, Santa Maria Imbaro, Italy.
   [Simone, Cristiano] Univ Bari, Div Med Genet, Bari, Italy.
   [Simone, Cristiano] Consorzio Mario NegriSud, Dept Translat Pharmacol, Lab Signal Dependent Transcript, Santa Maria Imbaro, Italy.
RP Del Rio, A (corresponding author), Alma Mater Studiorum Univ Bologna, Dept Expt Pathol, Lab Biochemoinformat, Bologna, Italy.
EM alberto.delrio@gmail.com; cristiano.simone@uniba.it
RI Ingravallo, Giuseppe/Q-1477-2016; INGRAVALLO, Giuseppe/N-2466-2019; Del
   Rio, Alberto/F-5230-2010; Simone, Cristiano/K-3452-2018; GROSSI,
   Valentina/O-6546-2019; Grossi, Valentina/K-9821-2016
OI Ingravallo, Giuseppe/0000-0002-4792-3545; INGRAVALLO,
   Giuseppe/0000-0002-4792-3545; Del Rio, Alberto/0000-0002-1890-6797;
   Simone, Cristiano/0000-0002-2628-7658; GROSSI,
   Valentina/0000-0003-3843-1618; Grossi, Valentina/0000-0003-3843-1618
FU Italian Association for Cancer Research (AIRC)Fondazione AIRC per la
   ricerca sul cancro [IG10177, 6266]
FX This article is dedicated to the memory of Margherita D'Aprile and
   Gianni Iannuzzi. We thank Dr Francesco Paolo Jori for his helpful
   discussion during the preparation of the manuscript and editorial
   assistance, and Dr Giovanna Forte for contribution in preparing the
   illustrations. This work was partially supported by an Investigator
   Grant 2010 (IG10177) (to C.S.) and by the Start-Up Grant (no. 6266 to
   A.D.R) from the Italian Association for Cancer Research (AIRC). Bayer
   Italia is gratefully acknowledged for providing Sorafenib.
CR Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225
   Carnero A, 2010, CURR PHARM DESIGN, V16, P34, DOI 10.2174/138161210789941865
   Chiacchiera F, 2009, CELL DEATH DIFFER, V16, P1203, DOI 10.1038/cdd.2009.36
   Chiacchiera F, 2008, CANCER LETT, V265, P16, DOI 10.1016/j.canlet.2008.02.061
   Chiacchiera F, 2012, CANCER LETT, V324, P98, DOI 10.1016/j.canlet.2012.05.006
   Chiacchiera F, 2010, CELL CYCLE, V9, P1091, DOI 10.4161/cc.9.6.11035
   Chiacchiera F, 2009, AUTOPHAGY, V5, P1030, DOI 10.4161/auto.5.7.9252
   Comes F, 2007, CELL DEATH DIFFER, V14, P693, DOI 10.1038/sj.cdd.4402076
   Dal Lago L, 2008, ONCOLOGIST, V13, P845, DOI 10.1634/theoncologist.2007-0233
   Dar AC, 2012, NATURE, V486, P80, DOI 10.1038/nature11127
   Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6
   Filomia F, 2010, BIOORGAN MED CHEM, V18, P6805, DOI 10.1016/j.bmc.2010.07.047
   Gillissen B, 2010, J CELL BIOL, V188, P851, DOI 10.1083/jcb.200912070
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Knight ZA, 2010, NAT REV CANCER, V10, P130, DOI 10.1038/nrc2787
   Kufareva I, 2008, J MED CHEM, V51, P7921, DOI 10.1021/jm8010299
   Liu Y, 2006, NAT CHEM BIOL, V2, P358, DOI 10.1038/nchembio799
   Matrone A, 2010, INT J GYNECOL CANCER, V20, P203, DOI 10.1111/IGC.0b013e3181c8ca12
   Montagut C, 2009, CANCER LETT, V283, P125, DOI 10.1016/j.canlet.2009.01.022
   Namboodiri HV, 2010, BIOCHEMISTRY-US, V49, P3611, DOI 10.1021/bi100070r
   Pierotti MA, 2011, NAT REV CLIN ONCOL, V8, P161, DOI 10.1038/nrclinonc.2011.3
   Rinehart J, 2004, J CLIN ONCOL, V22, P4456, DOI 10.1200/JCO.2004.01.185
   Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533
   Segal NH, 2009, ANNU REV MED, V60, P207, DOI 10.1146/annurev.med.60.041807.132435
   Wickenden JA, 2008, ONCOGENE, V27, P7150, DOI 10.1038/onc.2008.335
   Wilhelm S, 2006, NAT REV DRUG DISCOV, V5, P835, DOI 10.1038/nrd2130
   Wilhelm SM, 2008, MOL CANCER THER, V7, P3129, DOI 10.1158/1535-7163.MCT-08-0013
   Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443
NR 28
TC 17
Z9 21
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD DEC
PY 2012
VL 13
IS 14
BP 1471
EP 1481
DI 10.4161/cbt.22254
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 052QD
UT WOS:000312212200016
PM 22986232
OA Bronze, Green Published
DA 2022-04-25
ER

PT J
AU Tai, CJ
   Wang, CK
   Tai, CJ
   Lin, YF
   Lin, CS
   Jian, JY
   Chang, YJ
   Chang, CC
AF Tai, Chen-Jei
   Wang, Chien-Kai
   Tai, Cheng-Jeng
   Lin, Yi-Feng
   Lin, Chi-Shian
   Jian, Jiun-Yu
   Chang, Yu-Jia
   Chang, Chun-Chao
TI Aqueous Extract of Solanum nigrum Leaves Induces Autophagy and Enhances
   Cytotoxicity of Cisplatin, Doxorubicin, Docetaxel, and 5-Fluorouracil in
   Human Colorectal Carcinoma Cells
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID COLON-CANCER; COMPLEMENTARY/ALTERNATIVE MEDICINE; ADJUVANT THERAPY;
   APOPTOSIS; CHEMOTHERAPY; INDUCTION; HEPG2; ACTIVATION; CASPASE-3;
   PATHWAYS
AB Colorectal cancer is a common cancer worldwide, and chemotherapy is a mainstream approach for advanced and recurrent cases. Development of effective complementary drugs could help improve tumor suppression efficiency and control adverse effects from chemotherapy. The aqueous extract of Solanum nigrum leaves (AE-SN) is an essential component in many traditional Chinese medicine formulas for treating cancer, but there is a lack of evidence verifying its tumor suppression efficacy in colorectal cancer. The purpose of this study is to evaluate the tumor suppression efficacy of AE-SN using DLD-1 and HT-29 human colorectal carcinoma cells and examine the combined drug effect when combined with the chemotherapeutic drugs cisplatin, doxorubicin, docetaxel, and 5-fluorouracil. The results indicated that AE-SN induced autophagy via microtubule-associated protein 1 light chain 3 A/B II accumulation but not caspase-3-dependent apoptosis in both cell lines. The IC(50)s after 48 hours of treatment were 0.541 and 0.948 mg/ml AE-SN in DLD-1 and HT-29, respectively. AE-SN also demonstrated a combined drug effect with all tested drugs by enhancing cytotoxicity in tumor cells. Our results suggest that AE-SN has potential in the development of complementary chemotherapy for colorectal cancer.
C1 [Tai, Chen-Jei; Wang, Chien-Kai] Taipei Med Univ Hosp, Dept Chinese Med, Taipei 11031, Taiwan.
   [Tai, Chen-Jei; Wang, Chien-Kai; Jian, Jiun-Yu] Taipei Med Univ, Coll Med, Sch Med, Dept Obstet & Gynecol, Taipei 11031, Taiwan.
   [Wang, Chien-Kai; Tai, Cheng-Jeng] Taipei Med Univ Hosp, Dept Internal Med, Div Hematol & Oncol, Taipei 11031, Taiwan.
   [Wang, Chien-Kai; Tai, Cheng-Jeng; Chang, Chun-Chao] Taipei Med Univ, Coll Med, Sch Med, Dept Internal Med, Taipei 11031, Taiwan.
   [Lin, Yi-Feng] Chi Mei Hosp Chiali, Dept Surg, Div Gen Surg, Tainan 72263, Taiwan.
   [Lin, Chi-Shian] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei 11031, Taiwan.
   [Chang, Yu-Jia] Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei 11031, Taiwan.
   [Chang, Yu-Jia] Taipei Med Univ & Hosp, Dept Surg, Taipei 11031, Taiwan.
   [Chang, Yu-Jia] Taipei Med Univ, Taipei Med Univ Hosp, Dept Surg, Div Gen Surg, Taipei 11031, Taiwan.
   [Chang, Chun-Chao] Taipei Med Univ Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, Taipei 11031, Taiwan.
RP Chang, CC (corresponding author), Taipei Med Univ, Coll Med, Sch Med, Dept Internal Med, Taipei 11031, Taiwan.
EM chunchao@tmu.edu.tw
RI Jian, Jiun-Yu/E-8605-2014
OI Jian, Jiun-Yu/0000-0002-5767-8803; Wang, Chien-Kai/0000-0002-9162-6820;
   Chang, Yu-Jia/0000-0003-3978-3244
FU Chi Mei Medical Center [101CM-TMU-12-3]
FX This work was supported by Chi Mei Medical Center (101CM-TMU-12-3).
CR An Lei, 2006, Zhongguo Zhong Yao Za Zhi, V31, P1225
   [Anonymous], 2006, CANC REG ANN REP
   Chendil D, 2000, CANCER, V89, P1893, DOI 10.1002/1097-0142(20001101)89:9<1893::AID-CNCR4>3.3.CO;2-2
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Coleman MP, 2008, LANCET ONCOL, V9, P730, DOI 10.1016/S1470-2045(08)70179-7
   CUMMINGS J, 1993, ANN ONCOL, V4, P533, DOI 10.1093/oxfordjournals.annonc.a058584
   De Dosso S, 2009, CANCER TREAT REV, V35, P160, DOI 10.1016/j.ctrv.2008.10.001
   de Gramont A, 2011, CLIN COLORECTAL CANC, V10, P218, DOI 10.1016/j.clcc.2011.10.001
   Ernst E, 1998, CANCER-AM CANCER SOC, V83, P777, DOI 10.1002/(SICI)1097-0142(19980815)83:4<777::AID-CNCR22>3.0.CO;2-O
   Forrest RA, 2012, BIOCHEM PHARMACOL, V83, P1602, DOI 10.1016/j.bcp.2012.02.026
   Ganansia-Leymarie Valerie, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P291, DOI 10.2174/1568011033482422
   Hu K, 1999, PLANTA MED, V65, P35, DOI 10.1055/s-1999-13958
   Huang HC, 2010, J AGR FOOD CHEM, V58, P8699, DOI 10.1021/jf101003v
   Ji YB, 2008, J ETHNOPHARMACOL, V115, P194, DOI 10.1016/j.jep.2007.09.023
   Kopetz S, 2008, ONCOLOGY-NY, V22, P260
   Lee SJ, 2005, ONCOL REP, V14, P789
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Lin HM, 2007, J AGR FOOD CHEM, V55, P3620, DOI 10.1021/jf062406m
   Lombardi L, 2010, CANCER TREAT REV, V36, pS34, DOI 10.1016/S0305-7372(10)70018-9
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Mano MS, 2008, CLIN COLORECTAL CANC, V7, P178, DOI 10.3816/CCC.2008.n.023
   MCCARTHY SL, 1990, BIOPOLYMERS, V29, P823, DOI 10.1002/bip.360290416
   Oh PS, 2007, J BIOMED SCI, V14, P223, DOI 10.1007/s11373-006-9140-4
   Patterson RE, 2002, J ALTERN COMPLEM MED, V8, P477, DOI 10.1089/107555302760253676
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Qi FH, 2010, BIOSCI TRENDS, V4, P297
   Rajesh D, 1999, MOL PHARMACOL, V56, P515, DOI 10.1124/mol.56.3.515
   Richardson MA, 2000, J CLIN ONCOL, V18, P2505, DOI 10.1200/JCO.2000.18.13.2505
   Shokrzadeh M, 2010, PHARMACOGN MAG, V6, P176, DOI 10.4103/0973-1296.66931
   Son YO, 2003, FOOD CHEM TOXICOL, V41, P1421, DOI 10.1016/S0278-6915(03)00161-3
   Tai CJ, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/859185
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Xu W, 2006, EUR J CANCER CARE, V15, P397, DOI 10.1111/j.1365-2354.2006.00685.x
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Youns Mahmoud, 2010, Curr Drug Discov Technol, V7, P37
   Zhang F, 2010, ONCOL REP, V24, P1297, DOI 10.3892/or_00000986
NR 39
TC 33
Z9 35
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PY 2013
VL 2013
AR 514719
DI 10.1155/2013/514719
PG 12
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA 177SE
UT WOS:000321394900001
PM 23843876
OA Green Submitted, gold, Green Published
DA 2022-04-25
ER

PT J
AU Wu, WKK
   Wu, YC
   Yu, L
   Li, ZJ
   Sung, JJY
   Cho, CH
AF Wu, William Ka Kei
   Wu, Ya Chun
   Yu, Le
   Li, Zhi Jie
   Sung, Joseph Jao Yiu
   Cho, Chi Hin
TI Induction of autophagy by proteasome inhibitor is associated with
   proliferative arrest in colon cancer cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE proteasome inhibitor; colon cancer; proliferation; autophagy; LC3
ID PROTEIN-DEGRADATION; BORTEZOMIB; PATHWAYS; UBIQUITINATION;
   MACROAUTOPHAGY; MG-132; ROLES; LINK; LC3
AB The ubiquitin-proteasome system (UPS) and lysosome-dependent macroautophagy (autophagy) are two major intracellular pathways for protein degradation. Blockade of UPS by proteasome inhibitors has been shown to activate autophagy. Recent evidence also suggests that proteasome inhibitors may inhibit cancer growth. In this study, the effect of a proteasome inhibitor MG-132 on the proliferation and autophagy of cultured colon cancer cells (HT-29) was elucidated. Results showed that MG-132 inhibited HT-29 cell proliferation and induced G(2)/M cell cycle arrest which was associated with the formation of LC3(+) autophagic vacuoles and the accumulation of acidic vesicular organelles. MG-132 also increased the protein expression of LC3-I and -II in a time-dependent manner. In this connection, 3-methyladenine, a Class III phosphoinositide 3-kinase inhibitor, significantly abolished the formation of LC3(+) autophagic vacuoles and the expression of LC3-II but not LC3-I induced by MG-132. Taken together, this study demonstrates that inhibition of proteasome in colon cancer cells lowers cell proliferation and activates autophagy. This discovery may shed a new light on the novel function of proteasome in the regulation of autophagy and proliferation in colon cancer cells. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Wu, William Ka Kei; Wu, Ya Chun; Yu, Le; Li, Zhi Jie; Cho, Chi Hin] Chinese Univ Hong Kong, Dept Pharmacol, Shatin, Hong Kong, Peoples R China.
   [Wu, William Ka Kei; Sung, Joseph Jao Yiu] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China.
   [Wu, William Ka Kei; Sung, Joseph Jao Yiu; Cho, Chi Hin] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China.
   [Wu, Ya Chun] Zhejiang Univ, Dept Med, Affiliated Hosp 1, Coll Med, Hangzhou 310003, Zhejiang, Peoples R China.
RP Cho, CH (corresponding author), Chinese Univ Hong Kong, Dept Pharmacol, Basic Med Sci Bldg, Shatin, Hong Kong, Peoples R China.
EM wukakei@cuhk.edu.hk; chcho@cuhk.edu.hk
RI Cho, Chi Hin/C-6543-2014; Wu, William K.K./A-3277-2009; Sung, Joseph J.
   Y./R-3203-2018
OI Cho, Chi Hin/0000-0002-7658-3260; Wu, William K.K./0000-0002-5662-5240;
   Sung, Joseph J. Y./0000-0003-3125-5199
FU Hong Kong Research Grants CouncilHong Kong Research Grants Council [CUHK
   7499/05M]
FX This work is supported by the Hong Kong Research Grants Council (CUHK
   7499/05M).
CR Backer JM, 2008, BIOCHEM J, V410, P1, DOI 10.1042/BJ20071427
   Bialik S, 2008, ADV EXP MED BIOL, V615, P177, DOI 10.1007/978-1-4020-6554-5_9
   Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546
   Chang YC, 1998, CELL GROWTH DIFFER, V9, P79
   Davies AM, 2007, CLIN CANCER RES, V13, p4647S, DOI 10.1158/1078-0432.CCR-07-0334
   Ding WX, 2007, AM J PATHOL, V171, P513, DOI 10.2353/ajpath.2007.070188
   Ellington AA, 2005, CARCINOGENESIS, V26, P159, DOI 10.1093/carcin/bgh297
   Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263
   Hansen K, 2007, J NEUROCHEM, V103, P259, DOI 10.1111/j.1471-4159.2007.04753.x
   Ito S, 2007, INT J ONCOL, V31, P261
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Komata T, 2004, J NEURO-ONCOL, V68, P101, DOI 10.1023/B:NEON.0000027739.33842.6c
   Kumar A, 2007, CELL CYCLE, V6, P1696, DOI 10.4161/cc.6.14.4492
   Kuo PL, 2006, MOL CANCER THER, V5, P3209, DOI 10.1158/1535-7163.MCT-06-0478
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Maki CG, 1996, CANCER RES, V56, P2649
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798
   Paglin S, 2001, CANCER RES, V61, P439
   Pandey UB, 2007, NATURE, V447, P859, DOI 10.1038/nature05853
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Papandreou CN, 2004, J CLIN ONCOL, V22, P2108, DOI 10.1200/JCO.2004.02.106
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M
   Richardson PG, 2006, ANNU REV MED, V57, P33, DOI 10.1146/annurev.med.57.042905.122625
   Rodriguez MS, 1996, ONCOGENE, V12, P2425
   Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291
   Tobinai K, 2007, INT J CLIN ONCOL, V12, P318, DOI 10.1007/s10147-007-0695-5
   Wu WKK, 2008, BRIT J PHARMACOL, V154, P632, DOI 10.1038/bjp.2008.115
   Wu WKK, 2008, BIOCHEM BIOPH RES CO, V371, P209, DOI 10.1016/j.bbrc.2008.04.059
NR 32
TC 65
Z9 67
U1 0
U2 11
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 19
PY 2008
VL 374
IS 2
BP 258
EP 263
DI 10.1016/j.bbrc.2008.07.031
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 339TL
UT WOS:000258600100016
PM 18638451
DA 2022-04-25
ER

PT J
AU Xia, YH
   Cheng, CR
   Yao, SY
   Zhang, Q
   Wang, Y
   Ji, ZN
AF Xia, Yong-hui
   Cheng, Chuan-rong
   Yao, Shu-yan
   Zhang, Qing
   Wang, Ying
   Ji, Zhao-ning
TI L-Securinine induced the human colon cancer SW480 cell autophagy and its
   molecular mechanism
SO FITOTERAPIA
LA English
DT Article
DE L-Securinine; Autophagy; SW480 cell; Colon cancer
ID APOPTOSIS; INHIBITION; TUMORIGENESIS; RESISTANCE; INDUCTION; INCREASES;
   BECLIN-1; RECEPTOR; DEATH
AB Aims: To investigate the anti-tumor effects of L-securinine inducing colon cancer SW480 cell autophagy and explore its potential molecular mechanism.
   Main methods: MTT method was used to detect the antitumor effect of SW480 cells cultured with L-securinine in vitro. Light and electron microscopy were used to observe SW480 cells treated with L-securinine morphological changes. Flow cytometry was used to observe the apoptotic ratio and cell cycle inducing with the L-securinine in SW480 cells, and the autophagic apoptosis ratio was determined by FITC-conjugated annexin V by flow cytometry (FCM). FCM was applied to analysis cell cycle: the expression of autophagy gene Beclin-1 was examined by reverse transcriptase polymerase chain reaction (RT-PCR).
   Key findings: The generation depression effects of SW480 cells cultured in vitro were detected by MU method (P<0.05), and there were dosage-time dependent relationships. Numerous autophagic vacuoles and empty vacuoles were observed in SW480 cells treated with 2.5 mu ML-securinine for 48 h by electron microscopy, and the process of cell division that got less was observed. Through flow cytometry. a number of observed autophagic cells were obviously increased, and G1/S phase was retarded. L-Securinine tended to arrest cells at the G1 phase of the cell cycle. The percentage of the apoptotic cells increased as treatment duration and concentrations increased. Beclin-1 expression enhanced with L-securinine concentration increased.
   Significance: L-Securinine has an anti-tumor effect against colon cancer SW480 cell. The L-securinine can induce striking autophagy in SW480 cell in vitro. The autophagy induced by L-securinine is related with upregulating the expression of autophagy gene Beclin-1. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Ji, Zhao-ning] Yijishan Hosp, Ctr Canc, Wannan Med Coll, Wuhu 241001, Peoples R China.
   [Xia, Yong-hui; Cheng, Chuan-rong; Yao, Shu-yan; Zhang, Qing] Wannan Med Coll, Dept Oncol, Wuhu 241001, Peoples R China.
   [Wang, Ying] JiNan Univ, Inst Tradit Chinese Med & Nat Prod, Guangzhou 510632, Guangdong, Peoples R China.
RP Ji, ZN (corresponding author), Yijishan Hosp, Ctr Canc, Wannan Med Coll, Wuhu 241001, Peoples R China.
EM jzning@163.com
FU Natural Science Foundation of AnHui ProvinceNatural Science Foundation
   of Anhui Province [090413123]
FX This work was supported by the Fund of Natural Science Foundation of
   AnHui Province (Grant No. 090413123).We would particularly like to thank
   Institute of Traditional Chinese Medicine & Natural Products, JiNan
   University for providing pure sample of L-securinine.
CR Dong NZ, 1999, CHIN TRADIT PAT MED, V21, P193
   Jablonski EM, 2007, CANCER LETT, V250, P36, DOI 10.1016/j.canlet.2006.09.013
   JIANG X, 1982, Tianjin Medical Journal, V10, P99
   Kametaka S, 1998, J BIOL CHEM, V273, P22284, DOI 10.1074/jbc.273.35.22284
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Kondo Y, 1998, ONCOGENE, V16, P2243, DOI 10.1038/sj.onc.1201754
   Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lin H., 1998, CHIN J HOSP PHARM, V8, P226
   Liu WJ, 1999, CHINESE PHARMACOL B, V15, P135
   Mandal M, 1997, J BIOL CHEM, V272, P14183, DOI 10.1074/jbc.272.22.14183
   Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657
   Pelicano H, 2003, J BIOL CHEM, V278, P37832, DOI 10.1074/jbc.M301546200
   Peng J-Z, 1994, J NINGXIA MED COLL, V16
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   SAITO S, 1963, TETRAHEDRON, V19, P2085, DOI 10.1016/0040-4020(63)85024-3
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Seaman MNJ, 1997, J CELL BIOL, V137, P79, DOI 10.1083/jcb.137.1.79
   Walker T, 2009, MOL PHARMACOL, V76, P342, DOI 10.1124/mol.109.056523
   Wang JR, 2008, AUTOPHAGY, V4, P947, DOI 10.4161/auto.6787
   Wang WS, 2006, CARCINOGENESIS, V27, P1113, DOI 10.1093/carcin/bgi351
   Xing JD, 1996, CHIN PHARM J, V31, P684
   YANG C, 1981, Tianjin Medical Journal, V9, P662
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
   Yue ZY, 2002, NEURON, V35, P921, DOI 10.1016/S0896-6273(02)00861-9
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zheng X, 2003, BIOORG MED CHEM LETT, V13, P881, DOI 10.1016/S0960-894X(02)01081-8
NR 27
TC 19
Z9 21
U1 1
U2 18
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0367-326X
EI 1873-6971
J9 FITOTERAPIA
JI Fitoterapia
PD DEC
PY 2011
VL 82
IS 8
BP 1258
EP 1264
DI 10.1016/j.fitote.2011.08.015
PG 7
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 854LB
UT WOS:000297494900018
PM 21907765
DA 2022-04-25
ER

PT J
AU Gu, XY
   Jiang, Y
   Li, MQ
   Han, P
   Liu, YL
   Cui, BB
AF Gu, Xin-Yue
   Jiang, Yang
   Li, Ming-Qi
   Han, Peng
   Liu, Yan-Long
   Cui, Bin-Bin
TI Over-expression of EGFR regulated by RARA contributes to 5-FU resistance
   in colon cancer
SO AGING-US
LA English
DT Article
DE autophagy; drug sensitivity; EGFR; 5-fluorouracil
ID AUTOPHAGY INHIBITOR; THERAPEUTIC TARGET; GROWTH; OVEREXPRESSION;
   TUMORIGENESIS; INDUCTION; RECEPTOR; GENE
AB A promising new strategy for cancer therapy is to target the autophagic pathway. However, comprehensive characterization of autophagy genes and their clinical relevance in cancer is still lacking. Here, we systematically characterized alterations of autophagy genes in multiple cancer lines by analyzing data from The Cancer Genome Atlas and CellMiner database. Interactions between autophagy genes and clinically actionable genes (CAGs) were identified by analyzing co-expression, protein-protein interactions (PPIs) and transcription factor (TF) data. A key subnetwork was identified that included 18 autophagy genes and 22 CAGs linked by 28 PPI pairs and 1 TF-target pair, which was EGFR targeted by RARA. Alterations in the expression of autophagy genes were associated with patient survival in multiple cancer types. RARA and EGFR were associated with worse survival in colorectal cancer patients. The regulatory role of EGFR in 5-FU resistance was validated in colon cancer cells in vivo and in vitro. EGFR contributed to 5-FU resistance in colon cancer cells through autophagy induction, and EGFR overexpression in 5-FU resistant colon cancer was regulated by RARA. The present study provides a comprehensive analysis of autophagy in different cancer cell lines and highlights the potential clinical utility of targeting autophagy genes.
C1 [Gu, Xin-Yue; Li, Ming-Qi; Han, Peng; Liu, Yan-Long; Cui, Bin-Bin] Harbin Med Univ, Dept Colorectal Surg, Canc Hosp, Harbin 150040, Peoples R China.
   [Jiang, Yang] Harbin Med Univ, Dept Pathol, Canc Hosp, Harbin 150040, Peoples R China.
RP Cui, BB (corresponding author), Harbin Med Univ, Dept Colorectal Surg, Canc Hosp, Harbin 150040, Peoples R China.
EM cbb2888@163.com
RI Liu, Yanlong/AAL-3503-2021
FU Nn10 program of Harbin Medical University Cancer Hospital; Natural
   Science Foundation of Heilongjiang Province of ChinaNatural Science
   Foundation of Heilongjiang Province [ZD2017019]
FX This work was supported by grants from Nn10 program of Harbin Medical
   University Cancer Hospital and Natural Science Foundation of
   Heilongjiang Province of China (ZD2017019).
CR Abdel-Mohsen Mohamed Ahmed, 2016, Asian Pac J Cancer Prev, V17, P1285
   Akil H, 2016, WORLD J GASTROENTERO, V22, P490, DOI 10.3748/wjg.v22.i2.490
   Bao LJ, 2015, MOL MED REP, V11, P91, DOI 10.3892/mmr.2014.2671
   Bisaro B, 2016, ONCOTARGET, V7, P4442, DOI 10.18632/oncotarget.6710
   Feng Y, 2016, ONCOTARGET, V7, P81402, DOI 10.18632/oncotarget.13233
   Ge J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110293
   Gueguinou M, 2016, ONCOTARGET, V7, P36168, DOI 10.18632/oncotarget.8786
   Herreros-Villanueva M, 2012, MOL BIOL REP, V39, P5387, DOI 10.1007/s11033-011-1337-6
   Hu XJ, 2018, CANCER LETT, V425, P1, DOI 10.1016/j.canlet.2018.03.024
   Iorio F, 2016, CELL, V166, P740, DOI 10.1016/j.cell.2016.06.017
   Jutten B, 2014, CELL CYCLE, V13, P42, DOI 10.4161/cc.27518
   Katreddy RR, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-017-0021-7
   Kim MS, 2011, APMIS, V119, P802, DOI 10.1111/j.1600-0463.2011.02812.x
   Klionsky DJ, 2014, AUTOPHAGY, V10, P715, DOI 10.4161/auto.28813
   Koustas E, 2017, CANCER LETT, V396, P94, DOI 10.1016/j.canlet.2017.03.023
   Lafky JM, 2008, BBA-REV CANCER, V1785, P232, DOI 10.1016/j.bbcan.2008.01.001
   Law V, 2014, NUCLEIC ACIDS RES, V42, pD1091, DOI 10.1093/nar/gkt1068
   Li HS, 2017, CELL SIGNAL, V35, P223, DOI 10.1016/j.cellsig.2017.04.012
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Marinkovic M, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8023821
   McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109
   Mina M, 2015, SCI REP-UK, V5, DOI 10.1038/srep11999
   Molnar B, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4609-x
   Naumann P, 2011, INT J ONCOL, V39, P101, DOI 10.3892/ijo.2011.1025
   Pan YZ, 2011, CLIN CANCER RES, V17, P3248, DOI 10.1158/1078-0432.CCR-10-0890
   Park HS, 2014, MODERN PATHOL, V27, P1212, DOI 10.1038/modpathol.2013.251
   Perera R, 2015, NATURE, V524, P361, DOI 10.1038/nature14587
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Reinhold WC, 2012, CANCER RES, V72, P3499, DOI 10.1158/0008-5472.CAN-12-1370
   Rubinstein AD, 2012, J CELL SCI, V125, P5259, DOI 10.1242/jcs.115865
   Salvatori L, 2011, BIOMED PHARMACOTHER, V65, P307, DOI 10.1016/j.biopha.2011.03.007
   Sooro MA, 2018, INT J CANCER, V143, P2116, DOI 10.1002/ijc.31398
   Tong M, 2018, J HEPATOL, V69, P826, DOI 10.1016/j.jhep.2018.05.034
   Wingender E, 2008, BRIEF BIOINFORM, V9, P326, DOI 10.1093/bib/bbn016
   Wu ZM, 2018, MOL MED REP, V17, P7875, DOI 10.3892/mmr.2018.8818
   Xu NQ, 2016, ONCOTARGET, V7, P3884, DOI 10.18632/oncotarget.6461
   Yaeger R, 2017, CANCER RES, V77, P6513, DOI 10.1158/0008-5472.CAN-17-0768
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Ye F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080397
   Yun M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117375
   Zhang L, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.139
   Zhang P, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0661-7
   Zhang XD, 2014, THERANOSTICS, V4, P1085, DOI 10.7150/thno.9933
   Zhu JL, 2017, MOL THER-NUCL ACIDS, V7, P299, DOI 10.1016/j.omtn.2017.04.012
NR 45
TC 7
Z9 7
U1 2
U2 7
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD JAN 15
PY 2020
VL 12
IS 1
BP 156
EP 177
DI 10.18632/aging.102607
PG 22
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA KC5QX
UT WOS:000507233100011
PM 31896739
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Mori, S
   Sawada, T
   Okada, T
   Ohsawa, T
   Adachi, M
   Keiichi, K
AF Mori, Shozo
   Sawada, Tokihiko
   Okada, Toshie
   Ohsawa, Tatsushi
   Adachi, Masakazu
   Keiichi, Kubota
TI New anti-proliferative agent, MK615, from Japanese apricot "Prunus mume"
   induces striking autophagy in colon cancer cells in vitro
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE colon cancer; Japanese apricot; Prunus mume; autophagy; apoptosis; MK615
ID MOLECULAR MACHINERY; COLORECTAL-CANCER; THERAPY; DEATH; MECHANISM;
   APOPTOSIS; MACROAUTOPHAGY; DEGRADATION; INHIBITION; RADIATION
AB AIM: To investigate the anti-neoplastic effects of MK615, an extract from the Japanese apricot (Prunus mume), against colon cancer cells.
   METHODS: Three colon cancer cell lines, SW480, COLO, and WiDr, were cultured with MK615. Growth inhibition was evaluated by cell proliferation assay and killing activity was determined by lactate dehydrogenase assay. Induction of apoptosis was evaluated by annexin V flow cytometry. Morphological changes were studied by light and electron microscopy, and immunofluorescence staining with Atg8.
   RESULTS: MK615 inhibited growth and lysed SW480, COLO and WiDr cells in a dose-dependent manner. Annexin V flow cytometry showed that MK615 induced apoptosis after 6 h incubation, at which point the occurrence of apoptotic cells was 68.0%, 65.7% and 64.7% for SW480, COLO, and WiDr cells, respectively. Light and electron microscopy, and immunofluorescence staining with Atg8 revealed that MK615 induced massive cytoplasmic vacuoles (autophagosomes) in all three cell lines.
   CONCLUSION: MK615 has an anti-neoplastic effect against colon cancer cells. The effect may be exerted by induction of apoptosis and autophagy. (C) 2007 WJG. All rights reserved.
C1 [Mori, Shozo; Sawada, Tokihiko; Okada, Toshie; Keiichi, Kubota] Dokkyo Univ, Sch Med, Dept Surg 2, Shimotsuga, Tochigi 3210293, Japan.
   [Ohsawa, Tatsushi; Adachi, Masakazu] Japan Apricot Co Ltd, Gunma 3700073, Japan.
RP Sawada, T (corresponding author), Dokkyo Univ, Sch Med, Dept Surg 2, Kitakobayashi 880, Shimotsuga, Tochigi 3210293, Japan.
EM tsawada@dokkyomed.ac.jp
CR Adachi M, 2007, INT J FOOD PROP, V10, P375, DOI 10.1080/10942910600547624
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Bursch W, 2000, J CELL SCI, V113, P1189
   Bursch W, 2000, ANN NY ACAD SCI, V926, P1, DOI 10.1111/j.1749-6632.2000.tb05594.x
   Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595
   Corcelle E, 2006, CANCER RES, V66, P6861, DOI 10.1158/0008-5472.CAN-05-3557
   Ellington AA, 2005, CARCINOGENESIS, V26, P159, DOI 10.1093/carcin/bgh297
   Gewirtz DA, 2007, AUTOPHAGY, V3, P249, DOI 10.4161/auto.3723
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Huang WP, 2002, CELL STRUCT FUNCT, V27, P409, DOI 10.1247/csf.27.409
   Hunter AM, 2007, APOPTOSIS, V12, P1543, DOI 10.1007/s10495-007-0087-3
   Kabore AF, 2004, CURR CANCER DRUG TAR, V4, P147, DOI 10.2174/1568009043481551
   Kim KW, 2006, J BIOL CHEM, V281, P36883, DOI 10.1074/jbc.M607094200
   Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263
   Kirkegaard K, 2004, NAT REV MICROBIOL, V2, P301, DOI 10.1038/nrmicro865
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Meiler J, 2006, CURR DRUG TARGETS, V7, P1361, DOI 10.2174/138945006778559175
   Monga DK, 2006, ANN SURG ONCOL, V13, P1021, DOI 10.1245/ASO.2006.08.015
   Nakagawa A, 2007, BREAST J, V13, P44, DOI 10.1111/j.1524-4741.2006.00361.x
   Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0
   OTSUKA H, 1978, EXP CELL RES, V112, P127, DOI 10.1016/0014-4827(78)90533-5
   Penn L Z, 2001, Curr Opin Investig Drugs, V2, P684
   Ravikumar B, 2005, NAT GENET, V37, P771, DOI 10.1038/ng1591
   Takeuchi H, 2004, INT J ONCOL, V25, P57
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Terstriep S, 2006, EXPERT REV ANTICANC, V6, P921, DOI 10.1586/14737140.6.6.921
   Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040
   Yao KC, 2003, J NEUROSURG, V98, P378, DOI 10.3171/jns.2003.98.2.0378
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
   Yoshimori T, 2004, BIOCHEM BIOPH RES CO, V313, P453, DOI 10.1016/j.bbrc.2003.07.023
NR 30
TC 34
Z9 34
U1 0
U2 7
PU W J G PRESS
PI BEIJING
PA APT 1066, YISHOU GARDEN, NO 58, NORTH LANGXINZHUANG RD, PO BOX 2345,
   BEIJING 100023, PEOPLES R CHINA
SN 1007-9327
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD DEC 28
PY 2007
VL 13
IS 48
BP 6512
EP 6517
DI 10.3748/wjg.13.6512
PG 6
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 247AH
UT WOS:000252049000009
PM 18161921
OA Green Published
DA 2022-04-25
ER

PT J
AU Kim, Y
   Oh, S
   Yun, HS
   Oh, S
   Kim, SH
AF Kim, Y.
   Oh, S.
   Yun, H. S.
   Oh, S.
   Kim, S. H.
TI Cell-bound exopolysaccharide from probiotic bacteria induces autophagic
   cell death of tumour cells
SO LETTERS IN APPLIED MICROBIOLOGY
LA English
DT Article
DE antitumour activity; autophagy; cb-EPS; two-dimensional polyacrylamide
   gel electrophoresis (2D-PAGE)
ID ESCHERICHIA-COLI O157-H7; STRESS-INDUCED AUTOPHAGY; EXPRESSION;
   INHIBITION; TUMORIGENESIS; PROTEINS; STRAINS; ACID
AB Aim:
   Lactic acid bacteria (LAB) are beneficial micro-organisms that have been associated with several probiotic effects in both humans and animals. Here, using proteome analysis, we investigate the antitumour effects of cell-bound exopolysaccharides (cb-EPS) isolated from Lactobacillus acidophilus 606 on colon cancer cells and explore the proteins critical for their antitumour activity.
   Methods and Results:
   cb-EPS inhibited the proliferation of HT-29 colon cancer cells by directly affecting cell morphology and not the cell cycle. Using two-dimensional polyacrylamide gel electrophoresis coupled with matrix-assisted laser desorption-ionization time-of-flight mass spectrometry (MALDI-TOF/MS) and immunoblot analysis, we found that cb-EPS dramatically induced Beclin-1 and GRP78, and affected Bcl-2 and Bak regulation.
   Conclusions:
   The results of this study indicate that cb-EPS are antitumourigenic against HT-29 colon cancer cells and that this activity is because of the activation of autophagic cell death promoted directly by the induction of Beclin-1 and GRP78, as well as indirectly through the induction of Bcl-2 and Bak.
   Significance and Impact of the Study:
   These results may contribute to understanding the novel mechanisms by which probiotic bacteria induce tumour cell death via autophagy.
C1 [Yun, H. S.; Kim, S. H.] Korea Univ, Div Food Biosci & Technol, Seoul 136701, South Korea.
   [Kim, Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA USA.
   [Oh, S.] Korea Univ, Div Cellular & Dev Biol, Brain Korea Program Biomed Sci 21, Seoul 136701, South Korea.
   [Oh, S.] Chonnam Natl Univ, Dept Anim Sci, Kwangju, South Korea.
RP Kim, SH (corresponding author), Korea Univ, Div Food Biosci & Technol, 1,5 Ka Anam Dong, Seoul 136701, South Korea.
EM saehkim@korea.ac.kr
FU Korea government (MEST)Ministry of Education, Science and Technology,
   Republic of KoreaKorean Government [R01-2008-000-20593-0]; Korean
   Government (MOEHRD)Ministry of Education & Human Resources Development
   (MOEHRD), Republic of KoreaKorean Government [KRF-F00025]
FX This study was supported by a Korea Science and Engineering Foundation
   (KOSEF) grant funded by the Korea government (MEST)
   (R01-2008-000-20593-0). Y. Kim was supported by a Korea Research
   Foundation Grant funded by the Korean Government (MOEHRD) (KRF-F00025).
CR Arlorio M, 2009, J AGR FOOD CHEM, V57, P10612, DOI 10.1021/jf902419t
   Belury MA, 2002, J NUTR, V132, P2995, DOI 10.1093/jn/131.10.2995
   Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595
   Choi SS, 2006, LETT APPL MICROBIOL, V42, P452, DOI 10.1111/j.1472-765X.2006.01913.x
   Di Marzio L, 2001, NUTR CANCER, V40, P185, DOI 10.1207/S15327914NC402_16
   Ding WX, 2007, J BIOL CHEM, V282, P4702, DOI 10.1074/jbc.M609267200
   Ertmer A, 2007, LEUKEMIA, V21, P936, DOI 10.1038/sj.leu.2404606
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   KATO I, 1994, INT J IMMUNOPHARMACO, V16, P29, DOI 10.1016/0192-0561(94)90116-3
   Kim JU, 2006, J MICROBIOL BIOTECHN, V16, P939
   Kim YH, 2006, PROTEOMICS, V6, P6181, DOI 10.1002/pmic.200600320
   Kim Y, 2008, FOOD CONTROL, V19, P1042, DOI 10.1016/j.foodcont.2007.10.014
   Kim Y, 2009, BIOCHEM BIOPH RES CO, V379, P324, DOI 10.1016/j.bbrc.2008.12.053
   Kondo Y, 2006, AUTOPHAGY, V2, P85, DOI 10.4161/auto.2.2.2463
   Lee YH, 2008, TOXICOL APPL PHARM, V231, P43, DOI 10.1016/j.taap.2008.03.025
   Li DD, 2009, ONCOGENE, V28, P886, DOI 10.1038/onc.2008.441
   Li J, 2008, CELL DEATH DIFFER, V15, P1460, DOI 10.1038/cdd.2008.81
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Moretti L, 2007, AUTOPHAGY, V3, P142, DOI 10.4161/auto.3607
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Scarlatti F, 2004, J BIOL CHEM, V279, P18384, DOI 10.1074/jbc.M313561200
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Sun Y, 2010, CANCER LETT, V294, P204, DOI 10.1016/j.canlet.2010.02.001
   Szczesna-Skorupa E, 2004, J BIOL CHEM, V279, P13953, DOI 10.1074/jbc.M312170200
   YUE Z, 1999, P NATL ACAD SCI USA, V100, P15077
NR 26
TC 82
Z9 86
U1 3
U2 28
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0266-8254
EI 1472-765X
J9 LETT APPL MICROBIOL
JI Lett. Appl. Microbiol.
PD AUG
PY 2010
VL 51
IS 2
BP 123
EP 130
DI 10.1111/j.1472-765X.2010.02859.x
PG 8
WC Biotechnology & Applied Microbiology; Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Microbiology
GA 623OB
UT WOS:000279750600001
PM 20536712
OA Bronze
DA 2022-04-25
ER

PT J
AU Park, JM
   Huang, SB
   Wu, TT
   Foster, NR
   Sinicrope, FA
AF Park, Jae Myung
   Huang, Shengbing
   Wu, Tsung-Teh
   Foster, Nathan R.
   Sinicrope, Frank A.
TI Prognostic impact of Beclin 1, p62/sequestosome 1 and LC3 protein
   expression in colon carcinomas from patients receiving 5-fluorouracil as
   adjuvant chemotherapy
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE autophagy; Beclin 1; p62/sequestosome 1; LC3; colon cancer;
   5-fluorouracil
ID TUMOR-SUPPRESSOR GENE; INDUCED CELL-DEATH; COLORECTAL-CANCER; AUTOPHAGY
   GENE; REGULATES AUTOPHAGY; INDUCED APOPTOSIS; DRUG-RESISTANCE;
   POOR-PROGNOSIS; P62; INHIBITION
AB Autophagy is a cellular degradation process that can be activated in tumor cells to confer stress tolerance. During autophagy initiation and autophagosome formation, Beclin 1 binds microtubule-associated protein-1 light chain 3 (LC3I) that is converted to its membrane-bound form (LC3II) and interacts with the ubiquitin-binding protein p62/sequestosome 1 (SQSTM1). We determined the association of Beclin 1, LC3 and p62 protein expression with clinical outcome in resected stage II and III colon carcinomas (n = 178) from participants in 5-fluororuacil (5-FU)-based adjuvant therapy trials. The immunopercentage for each marker was determined and dichotomized for analysis with overall survival (OS) using Cox models. We found that autophagy markers localized to the tumor cell cytoplasm and showed increased expression relative to normal epithelial cells. Overexpression of Beclin 1, LC3 and p62 proteins were detected in 69, 79 and 85% of tumors, respectively. Expression levels were not significantly associated with clinicopathological variables. In a multivariable analysis adjusting for tumor grade, stage and patient age, Beclin 1 overexpression was independently associated with worse OS [hazard ratio (HR), 1.82; 95% confidence interval (CI), 1.0-3.3; p = 0.042] in patients who received 5-FU-based adjuvant therapy. Neither LC3 nor p62 overexpression was prognostic. In conclusion, Beclin 1 overexpression was associated with reduced survival in colon cancer patients treated with adjuvant 5-FU. These data are consistent with preclinical evidence indicating that autophagy can protect colon cancer cells from 5-FU and support the targeting of autophagy for therapeutic advantage in this malignancy.
C1 [Park, Jae Myung; Huang, Shengbing; Sinicrope, Frank A.] Mayo Clin, Dept Med, Rochester, MN 55905 USA.
   [Park, Jae Myung; Huang, Shengbing; Wu, Tsung-Teh; Foster, Nathan R.; Sinicrope, Frank A.] Mayo Canc Ctr, Rochester, MN USA.
   [Wu, Tsung-Teh] Mayo Clin, Dept Pathol & Lab Med, Rochester, MN USA.
   [Foster, Nathan R.] Mayo Clin, Dept Biomed Stat & Informat, Rochester, MN USA.
   [Sinicrope, Frank A.] Mayo Clin, Dept Oncol, Rochester, MN USA.
RP Sinicrope, FA (corresponding author), Mayo Clin, Dept Med, Rochester, MN 55905 USA.
EM sinicrope.frank@mayo.edu
FU National Cancer InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [5 K05 CA142885]; Mayo Clinic Center for Cell Signaling
   in Gastroenterology [NIDDK P30DK084567]; NATIONAL CANCER INSTITUTEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [K05CA142885]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND
   DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30DK084567] Funding
   Source: NIH RePORTER
FX This work was supported, in part, by a grant from the National Cancer
   Institute 5 K05 CA142885 (FAS) and from the Mayo Clinic Center for Cell
   Signaling in Gastroenterology (NIDDK P30DK084567).
CR Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Allegra CJ, 2002, J CLIN ONCOL, V20, P1735, DOI 10.1200/JCO.2002.07.080
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562
   Bellodi C, 2009, J CLIN INVEST, V119, P1109, DOI 10.1172/JCI35660
   Carew JS, 2007, BLOOD, V110, P313, DOI 10.1182/blood-2006-10-050260
   Chen YS, 2009, PATHOL ONCOL RES, V15, P487, DOI 10.1007/s12253-008-9143-8
   Compton C, 2000, CANCER-AM CANCER SOC, V88, P1739, DOI 10.1002/(SICI)1097-0142(20000401)88:7<1739::AID-CNCR30>3.0.CO;2-T
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Ding ZB, 2008, CANCER RES, V68, P9167, DOI 10.1158/0008-5472.CAN-08-1573
   Djavaheri-Mergny M, 2010, ONCOGENE, V29, P1717, DOI 10.1038/onc.2009.519
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   Guo XL, 2012, CANCER LETT, V320, P171, DOI 10.1016/j.canlet.2012.03.002
   Han J, 2008, J BIOL CHEM, V283, P19665, DOI 10.1074/jbc.M710169200
   Huang JJ, 2010, AUTOPHAGY, V6, P777, DOI 10.4161/auto.6.6.12784
   Huang SB, 2011, J BIOL CHEM, V286, P40002, DOI 10.1074/jbc.M111.297432
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI 10.3322/caac.20073
   Jin ZY, 2009, CELL, V137, P721, DOI 10.1016/j.cell.2009.03.015
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kang R, 2010, CELL DEATH DIFFER, V17, P666, DOI 10.1038/cdd.2009.149
   Kitamura H, 2006, HISTOPATHOLOGY, V48, P157, DOI 10.1111/j.1365-2559.2005.02313.x
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li ZD, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-98
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Longley DB, 2006, BBA-REV CANCER, V1766, P184, DOI 10.1016/j.bbcan.2006.08.001
   Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594
   Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512
   Luo S, 2010, CELL DEATH DIFFER, V17, P268, DOI 10.1038/cdd.2009.121
   Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Matsushita M, 2007, J BIOL CHEM, V282, P6763, DOI 10.1074/jbc.M609876200
   Miracco C, 2007, INT J ONCOL, V30, P429
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   O'Connell MJ, 2006, CLIN COLORECTAL CANC, V6, P133, DOI 10.3816/CCC.2006.n.030
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Pattingre S, 2008, BIOCHIMIE, V90, P313, DOI 10.1016/j.biochi.2007.08.014
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Rolland P, 2007, ENDOCR-RELAT CANCER, V14, P73, DOI 10.1677/erc.1.01312
   Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Sinha S, 2008, ONCOGENE, V27, pS137, DOI 10.1038/onc.2009.51
   Thompson HGR, 2003, ONCOGENE, V22, P2322, DOI 10.1038/sj.onc.1206325
   Wan XB, 2010, AUTOPHAGY, V6, P395, DOI 10.4161/auto.6.3.11303
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Young MM, 2012, J BIOL CHEM, V287, P12455, DOI 10.1074/jbc.M111.309104
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200
   Zhu H, 2009, AUTOPHAGY, V5, P816, DOI 10.4161/auto.9064
NR 58
TC 94
Z9 96
U1 0
U2 16
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1538-4047
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD FEB
PY 2013
VL 14
IS 2
BP 100
EP 107
DI 10.4161/cbt.22954
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 083MP
UT WOS:000314468700006
PM 23192274
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Hu, F
   Wei, F
   Wang, YL
   Wu, BB
   Fang, Y
   Xiong, B
AF Hu, Fen
   Wei, Fei
   Wang, Yulei
   Wu, Bibo
   Fang, Yuan
   Xiong, Bin
TI EGCG synergizes the therapeutic effect of cisplatin and oxaliplatin
   through autophagic pathway in human colorectal cancer cells
SO JOURNAL OF PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE EGCG; Cisplatin; Oxaliplatin; Autophagic death
ID GREEN TEA POLYPHENOL; EPIGALLOCATECHIN GALLATE; PROSTATE-CANCER;
   COLON-CANCER; APOPTOSIS; DEATH; CHEMOTHERAPY; SUPEROXIDE; INHIBITORS
AB Application of the platinum-based chemotherapy for colorectal cancer is restricted due to its severe cytotoxic effects. In this study we used synergistic strategies by combining (-)-Epigallocatechin gallate (EGCG) with cisplatin or oxaliplatin to minimize the ill effects of platinum-based therapy. MTS assay was used to examine the effect of EGCG, cisplatin and oxaliplatin on the proliferation of human colorectal cancer DLD-1 and HT-29 cells. Autophagic process was evaluated by detection of LC3-II protein, auto-phagosome formation, and quantification of Acidic Vesicular. Treatment of DLD-1 and HT-29 cells with EGCG plus cisplatin or oxaliplatin showed a synergistic effect on inhibition of cell proliferation and induction of cell death. EGCG enhanced the effect of cisplatin and oxaliplatin-induced autophagy in DLD-1 and HT-29 cells, as characterized by the accumulation of LC3-II protein, the increase of acidic vesicular organelles (AVOs), and the formation of autophagosome. In addition, transfection of DLD-1 and HT-29 cells with siRNA against ATG genes reduced EGCG synergistic effect. Our findings suggest that combining EGCG with cisplatin or oxaliplatin could potentiate the cytotoxicity of cisplatin and oxaliplatin in colorectal cancer cells through autophagy related pathway. (C) 2015 Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.
C1 [Hu, Fen; Wang, Yulei; Wu, Bibo; Fang, Yuan; Xiong, Bin] Wuhan Univ, Zhongnan Hosp, Hubei Canc Clin Study Ctr, Dept Oncol,Hubei Key Lab Tumor Biol Behav, Wuhan 430071, Peoples R China.
   [Wei, Fei] Wuhan Univ, Sch Med, Res Ctr Food & Drug Evaluat,State Key Lab Virol, Inst Med Virol,Natl Lab Antiviral & Tumor Traditi, Wuhan 430071, Peoples R China.
RP Xiong, B (corresponding author), Wuhan Univ, Zhongnan Hosp, Hubei Canc Clin Study Ctr, Dept Oncol,Hubei Key Lab Tumor Biol Behav, Wuhan 430071, Peoples R China.
EM hu.fen1989@163.com; fei.wei@qut.edu.au; whu_yuleiwang@qq.com;
   bibo2006@163.com; fy_whu@126.com; binxiong1961@whu.edu.cn
OI Wang, Yulei/0000-0002-6495-3391
FU National High Technology Research and Development Program of
   ChinaNational High Technology Research and Development Program of China
   [2012AA02A502, 2012AA02A506]
FX This work was supported by the grant from National High Technology
   Research and Development Program of China (Project No. 2012AA02A502,
   2012AA02A506).
CR Azam S, 2004, TOXICOL IN VITRO, V18, P555, DOI 10.1016/j.tiv.2003.12.012
   Chen Y, 2009, CELL DEATH DIFFER, V16, P1040, DOI 10.1038/cdd.2009.49
   Chen YQ, 2007, J CELL SCI, V120, P4155, DOI 10.1242/jcs.011163
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Collins QF, 2007, J BIOL CHEM, V282, P30143, DOI 10.1074/jbc.M702390200
   Ding ZB, 2011, CLIN CANCER RES, V17, P6229, DOI 10.1158/1078-0432.CCR-11-0816
   Duan WJ, 2010, J PHARMACOL SCI, V113, P48, DOI 10.1254/jphs.09315FP
   Fruehauf JP, 2007, CLIN CANCER RES, V13, P789, DOI 10.1158/1078-0432.CCR-06-2082
   Fujiki H, 2014, J CANC RES CLIN ONCO
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hwang JT, 2007, CANCER LETT, V247, P115, DOI 10.1016/j.canlet.2006.03.030
   Inguscio Valentina, 2012, Cells, V1, P464, DOI 10.3390/cells1030464
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Khan N, 2014, CARCINOGENESIS, V35, P415, DOI 10.1093/carcin/bgt321
   Kim EH, 2007, CANCER RES, V67, P6314, DOI 10.1158/0008-5472.CAN-06-4217
   Kim HS, 2013, J BIOL CHEM, V288, P22693, DOI 10.1074/jbc.M113.477505
   Kim SY, 2014, BIOCHEM PHARMACOL, V88, P178, DOI 10.1016/j.bcp.2014.01.027
   Kwatra D, 2013, J PHARM SCI-US, V102, P4444, DOI 10.1002/jps.23753
   Li W, 2011, BIOCHEM PHARMACOL, V81, P1152, DOI 10.1016/j.bcp.2011.02.015
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   O'Connor ES, 2011, J CLIN ONCOL, V29, P3381, DOI 10.1200/JCO.2010.34.3426
   Ondrouskova E, 2014, KLIN ONKOL S, V27, P7
   Pachman DR, 2011, CLIN PHARMACOL THER, V90, P377, DOI 10.1038/clpt.2011.115
   Proniuk S, 2002, J PHARM SCI, V91, P111, DOI 10.1002/jps.10009
   Qanungo S, 2005, CARCINOGENESIS, V26, P958, DOI 10.1093/carcin/bgi040
   Shafique K, 2012, NUTR CANCER, V64, P790, DOI 10.1080/01635581.2012.690063
   Shi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051076
   Suganuma M, 2011, CANCER SCI, V102, P317, DOI 10.1111/j.1349-7006.2010.01805.x
   Tanida I, 2011, ANTIOXID REDOX SIGN, V14, P2201, DOI 10.1089/ars.2010.3482
   Wang BL, 2014, J PHARM SCI-US, V103, P3994, DOI 10.1002/jps.24216
   Wong VKW, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.217
NR 31
TC 57
Z9 62
U1 1
U2 14
PU JAPANESE PHARMACOLOGICAL SOC
PI KYOTO
PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI-EBISUGAWA NAKAGYO-KU, KYOTO, 604,
   JAPAN
SN 1347-8613
EI 1347-8648
J9 J PHARMACOL SCI
JI J. Pharmacol. Sci.
PD MAY
PY 2015
VL 128
IS 1
BP 27
EP 34
DI 10.1016/j.jphs.2015.04.003
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CJ5VE
UT WOS:000355559300004
PM 26003085
OA gold
DA 2022-04-25
ER

PT J
AU Wu, SB
   Wang, XW
   Chen, JX
   Chen, YX
AF Wu, Shaobin
   Wang, Xianwei
   Chen, Jinxiang
   Chen, Yuxiang
TI Autophagy of cancer stem cells is involved with chemoresistance of colon
   cancer cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Colon cancer; Cancer stem cell; Chemoresistance; Cdx1; Paclitaxel
ID COLORECTAL-CANCER; TUMOR-CELLS; RESISTANCE; RADIATION; CDX2
AB Background: Chemoresistance is a major cause of treatment failure in colon cancer, and cancer stem cells have been found to be involved in the chemoresistance of colon cancer. However, the mechanisms driving the chemoresistance of colon cancer stem cells have not been addressed.
   Methods: In this study, we investigated the cytotoxicity of paclitaxel in CD44(+)CD24(+) SW1222 colon cancer cells expressing Cdx1 (CD44(+)CD24(+)Cdx1(+) stem cells) and CD44(+)CD24(+) HCf116 colon cancer cells expressing wild-type p53 (CD44(+)CD24(+)p53wt stem cells).
   Results: SW1222 cells were more resistant to paclitaxel-induced cytotoxicity than HCT116 cells. Conversely, HCT-116 cells had higher matrigel colony formation ability than SW1222 cells. The isolated CD44(+)CD24(+)Cdx1(+) cells showed higher resistance to paclitaxel-induced cytotoxicity than CD44(+)CD2ep53wt cells. The resistance of CD44(+)CD24(+)Cdx1(+) cells to paclitaxel is associated with upregulation of Cdx1 and Bcl-2 expression, caspase-3 activity, and the ratio of LC3-II/LC3-I. The sensitivity of CD44(+)CD24(+)p53wt cells to paclitaxel is associated with the downregulation of Bc1-2 expression, upregulation of Bax levels, and upregulation of caspase-3 activity. Silencing of Cdx1 expression and treatment with lysosomal inhibitor bafilomycin A increased paclitaxel-induced cytotoxicity in CD44(+)CD24(+)Cdx1(+) cells. Conversely, overexpression of Cdxl decreased cell death in CD44(+)CD24(+)p53wt cells. Intratumoral injection of Cdxl siRNA significantly inhibited tumor growth in a xenograft tumor model inoculated with CD44(+)CD24(+)Cdx1(+) cancer cells.
   Conclusion: Cdxl exerts a protective role in colon cancer stem cells, which play a crucial role in chemoresistance to paclitaxel through activation of autophagy. Autophagy is activated though the Cdx1-Bcl-2-LC3 pathway. In contrast, p53 exerts a major role in apoptosis and inhibits autophagy in colon cancer stem cells. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Wu, Shaobin; Wang, Xianwei; Chen, Jinxiang] Cent S Univ, Xiangya Hosp, Dept Gen Surg, Changsha 410008, Hunan, Peoples R China.
   [Chen, Yuxiang] Cent S Univ, Xiangya Hosp, Hepatobiliary & Enter Surg Res Ctr, Changsha 410008, Hunan, Peoples R China.
RP Chen, YX (corresponding author), Cent S Univ, Xiangya Hosp, Hepatobiliary & Enter Surg Res Ctr, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.
EM chenyx008@yahoo.cn
RI Chen, Yu/Y-3292-2019
CR Ades S, 2009, ONCOLOGY-NY, V23, P162
   Chaachouay H, 2011, RADIOTHER ONCOL, V99, P287, DOI 10.1016/j.radonc.2011.06.002
   Dave B, 2009, J MAMMARY GLAND BIOL, V14, P79, DOI 10.1007/s10911-009-9117-9
   Djeu JY, 2009, ADV CANCER RES, V105, P77, DOI 10.1016/S0065-230X(09)05005-2
   Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100
   Koslowski M, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-77
   Lara-Padilla E, 2012, CURR STEM CELL RES T, V7, P26, DOI 10.2174/157488812798483412
   Li J, 2011, MOL CELL BIOCHEM, V357, P31, DOI 10.1007/s11010-011-0872-8
   Lin HM, 2007, J AGR FOOD CHEM, V55, P3620, DOI 10.1021/jf062406m
   Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030
   Moucadel V, 2002, BIOCHEM BIOPH RES CO, V297, P607, DOI 10.1016/S0006-291X(02)02250-7
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Russo A, 2005, J CLIN ONCOL, V23, P7518, DOI 10.1200/JCO.2005.00.471
   Warr MR, 2013, NATURE, V494, P323, DOI 10.1038/nature11895
   Xu AG, 2010, WORLD J GASTROENTERO, V16, P960, DOI 10.3748/wjg.v16.i8.960
   Zhang XW, 2004, CANCER RES, V64, P8139, DOI 10.1158/0008-5472.CAN-03-2301
   Zhang XW, 2003, CLIN CANCER RES, V9, P1155
NR 17
TC 49
Z9 55
U1 0
U2 29
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAY 17
PY 2013
VL 434
IS 4
BP 898
EP 903
DI 10.1016/j.bbrc.2013.04.053
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 161SI
UT WOS:000320213200033
PM 23624503
DA 2022-04-25
ER

PT J
AU Zhu, ML
   Zhang, PM
   Jiang, M
   Yu, SW
   Wang, L
AF Zhu, Ming-liang
   Zhang, Pei-min
   Jiang, Min
   Yu, Shu-wen
   Wang, Lu
TI Myricetin induces apoptosis and autophagy by inhibiting PI3K/Akt/mTOR
   signalling in human colon cancer cells
SO BMC COMPLEMENTARY MEDICINE AND THERAPIES
LA English
DT Article
DE Myricetin; Autophagy; Apoptosis; Colon cancer; 3-MA
ID PROSTATE-CANCER; STEM-CELLS; DEATH; PROLIFERATION; STATISTICS;
   FLAVONOIDS; QUERCETIN; INDUCTION; PATHWAY
AB Background The compound 3,3 ',4 ',5,5 ',7-hexahydroxyflavone (myricetin) is a natural flavonoid with antitumour activity. Most of the studies on myricetin have focused on the induction of tumour cell apoptosis, and little is known about the regulatory effects of myricetin on autophagy in colorectal cancer. Methods Here, we studied the effects of myricetin on colon cancer cell proliferation, apoptosis and autophagy. We detected colon cancer cell apoptosis induced by myricetin via flow cytometry and Hoechst 33258 staining. Transmission electron microscopy was performed to observe the morphological changes associated with autophagy. The expression levels of apoptosis-, autophagy- and PI3K/Akt/mTOR signalling-related proteins were measured by Western blot analysis. Results This study confirmed that myricetin inhibits the proliferation of 4 kinds of colon cancer cell lines. Myricetin induced cell apoptosis and autophagy by inhibiting PI3K/Akt/mTOR signalling pathway. In addition, the inhibition of autophagy with 3-methyladenine (3-MA) promoted the apoptosis of myricetin-treated colon cancer cells. Conclusions Considering that myricetin induces apoptosis and autophagy in colon cancer cells, myricetin may become a viable candidate for chemotherapy; it could be used to exert tumour inhibitory effects alone or as adjuvant chemotherapy to inhibit autophagy. These studies may provide further evidence for the potential use of myricetin in the treatment of colon cancer.
C1 [Zhu, Ming-liang; Jiang, Min; Yu, Shu-wen; Wang, Lu] Shandong Univ, Sch Pharmaceut Sci, Cheeloo Coll Med, Jinan 250012, Peoples R China.
   [Zhang, Pei-min; Yu, Shu-wen; Wang, Lu] Shandong Univ, Jinan Cent Hosp, Dept Pharm, Cheeloo Coll Med, Jinan 250013, Peoples R China.
RP Yu, SW; Wang, L (corresponding author), Shandong Univ, Sch Pharmaceut Sci, Cheeloo Coll Med, Jinan 250012, Peoples R China.
EM yaoxuebu2012@163.com; lulucc@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81803570]; Postdoctoral Science Foundation
   of ChinaChina Postdoctoral Science Foundation [2019 M652411];
   Postdoctoral Innovation Project of Shandong Province [201902044]; Jinan
   Science and Technology Bureau [201907111]
FX This work was supported by the National Natural Science Foundation of
   China (81803570), the Postdoctoral Science Foundation of China (2019
   M652411), the Postdoctoral Innovation Project of Shandong Province
   (201902044) and the Jinan Science and Technology Bureau (201907111).
CR Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Bursch W, 2000, ANN NY ACAD SCI, V926, P1, DOI 10.1111/j.1749-6632.2000.tb05594.x
   CANADA AT, 1990, FREE RADICAL BIO MED, V9, P441, DOI 10.1016/0891-5849(90)90022-B
   Cao JP, 2018, ANAT REC, V301, P786, DOI 10.1002/ar.23754
   Chen LM, 2017, ONCOTARGET, V8, P63911, DOI 10.18632/oncotarget.19201
   Devi KP, 2015, LIFE SCI, V142, P19, DOI 10.1016/j.lfs.2015.10.004
   Feng JF, 2015, MOL CELL BIOCHEM, V408, P163, DOI 10.1007/s11010-015-2492-1
   Hung AC, 2016, CANCER LETT, V371, P251, DOI 10.1016/j.canlet.2015.11.035
   Jeganathan B, 2016, INT J FOOD SCI, V2016
   Jing K, 2011, AUTOPHAGY, V7, P1348, DOI 10.4161/auto.7.11.16658
   Johnson SM, 2010, J AM COLL SURGEONS, V210, P767, DOI 10.1016/j.jamcollsurg.2009.12.008
   Kandala PK, 2012, ONCOTARGET, V3, P435
   Kaur P, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2432-9
   Kim ME, 2014, ANTICANCER RES, V34, P701
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   Kumar D, 2014, CANCER LETT, V343, P179, DOI 10.1016/j.canlet.2013.10.003
   Kuntz S, 1999, EUR J NUTR, V38, P133, DOI 10.1007/s003940050054
   Lee EB, 2017, ONCOTARGET, V8, P99637, DOI 10.18632/oncotarget.21005
   Lee JH, 2018, FOOD CHEM TOXICOL, V116, P315, DOI 10.1016/j.fct.2018.04.053
   Li SG, 2013, PLOS ONE, V8
   Lin Hongsheng, 2011, Front Med, V5, P127, DOI 10.1007/s11684-011-0137-7
   Maes H, 2013, TRENDS MOL MED, V19, P428, DOI 10.1016/j.molmed.2013.04.005
   Manfredi GI, 2015, ENDOCRINE, V48, P363, DOI 10.1007/s12020-014-0380-1
   Miean KH, 2001, J AGR FOOD CHEM, V49, P3106, DOI 10.1021/jf000892m
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   Nirmala Parthasarathy, 2011, J Exp Ther Oncol, V9, P101
   Phillips PA, 2011, CANCER LETT, V308, P181, DOI 10.1016/j.canlet.2011.05.002
   Qi WC, 2020, ONCOL REP, V43, P839, DOI 10.3892/or.2020.7484
   Rodgers EH, 1998, CHEM-BIOL INTERACT, V116, P213, DOI 10.1016/S0009-2797(98)00092-1
   Shiomi K, 2013, FOOD CHEM, V139, P910, DOI 10.1016/j.foodchem.2013.01.009
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Sun W, 2017, ONCOL REP, V38, P3347, DOI 10.3892/or.2017.6056
   Swart C, 2016, EUR J CELL BIOL, V95, P598, DOI 10.1016/j.ejcb.2016.10.005
   Taguchi-Atarashi N, 2010, TRAFFIC, V11, P468, DOI 10.1111/j.1600-0854.2010.01034.x
   Wang B, 2018, BIOCHEM BIOPH RES CO, V499, P156, DOI 10.1016/j.bbrc.2018.03.091
   Wang LY, 2009, ARCH BIOCHEM BIOPHYS, V481, P116, DOI 10.1016/j.abb.2008.10.021
   Wang WH, 2018, PHARMAZIE, V73, P402, DOI 10.1691/ph.2018.8402
   Xia P, 2015, AM J CANCER RES, V5, P1602
   Yao XF, 2016, TOXICOL SCI, V153, P198, DOI 10.1093/toxsci/kfw118
   Ye C, 2018, CELL PHYSIOL BIOCHEM, V48, P1230, DOI 10.1159/000492009
   Yu FF, 2019, TOXINS, V11, DOI 10.3390/toxins11050260
   Zhang K, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0344-0
   Zhang SJ, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-68
   Zhao ZQ, 2016, ONCOL LETT, V12, P63, DOI 10.3892/ol.2016.4606
NR 44
TC 9
Z9 9
U1 4
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2662-7671
J9 BMC COMPLEMENT MED
JI BMC Complement. Med. Ther.
PD JUL 6
PY 2020
VL 20
IS 1
AR 209
DI 10.1186/s12906-020-02965-w
PG 9
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA MM3MI
UT WOS:000550063300001
PM 32631392
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Emanuele, S
   Notaro, A
   Piccionello, AP
   Maggio, A
   Lauricella, M
   D'Anneo, A
   Cernigliaro, C
   Calvaruso, G
   Giuliano, M
AF Emanuele, Sonia
   Notaro, Antonietta
   Piccionello, Antonio Palumbo
   Maggio, Antonella
   Lauricella, Marianna
   D'Anneo, Antonella
   Cernigliaro, Cesare
   Calvaruso, Giuseppe
   Giuliano, Michela
TI Sicilian Litchi Fruit Extracts Induce Autophagy versus Apoptosis Switch
   in Human Colon Cancer Cells
SO NUTRIENTS
LA English
DT Article
DE Litchi chinensis; anti-tumor activity; autophagy; colon cancer
ID IN-VITRO; ANTIOXIDANT; CHINENSIS; TUMORIGENESIS; PERICARP; STRESS; PULP
AB Litchi chinensis Sonnerat is a tropical tree whose fruits contain significant amounts of bioactive polyphenols. Litchi cultivation has recently spread in Sicily where the climate conditions are particularly favorable for this crop. Recent findings have shown that Litchi extracts display anti-tumor and pro-apoptotic effects in vitro, but the precise underlying mechanisms have not been fully elucidated. In this study, we report for the first time the effects of Sicilian litchi fruit extracts on colon cancer cells. The results indicated that litchi exocarp, mesocarp and endocarp fractions reduce the viability and clonogenic growth of HT29 cells. These effects were due to cell cycle arrest in the G2/M phase followed by caspase-dependent cell death. Interestingly, litchi exocarp and endocarp triggered a precocious autophagic response (16-24 h), which was accompanied by an increase in the level of autophagy related 1/autophagy activating kinase 1 (ATG1/ULK1), beclin-1, microtubule associated protein 1 light chain 3 (LC3)-II and p62 proteins. Autophagy inhibition by bafilomycin A1 or beclin-1 silencing increased cell death, thus suggesting that autophagy was initially triggered as a pro-survival response. Significant effects of Litchi extracts were also observed in other colon cancer cells, including HCT116 and Caco-2 cells. On the other hand, differentiated Caco-2 cells, a model of human enterocytes, appeared to be insensitive to the extracts at the same treatment conditions. High-Performance Liquid Chromatography-Electrospray Ionization-Quadrupole-Time-Of-Flight HPLC/ESI/Q-TOF evidenced the presence of some polyphenolic compounds, specifically in exocarp and endocarp extracts, that can account for the observed biological effects. The results obtained suggest a potential therapeutic efficacy of polyphenolic compounds purified from Sicilian Litchi fractions for the treatment of colon cancer. Moreover, our findings indicate that modulation of autophagy can represent a tool to improve the effectiveness of these agents and potentiate the anti-tumor response of colon cancer cells.
C1 [Emanuele, Sonia; Lauricella, Marianna; Cernigliaro, Cesare] Univ Palermo, Dept Expt Biomed & Clin Neurosci BIONEC, Lab Biochem, I-90127 Palermo, Italy.
   [Notaro, Antonietta; Piccionello, Antonio Palumbo; Maggio, Antonella; D'Anneo, Antonella; Calvaruso, Giuseppe; Giuliano, Michela] Univ Palermo, Dept Biol Chem & Pharmaceut Sci & Technol STEBICE, I-90133 Palermo, Italy.
RP Giuliano, M (corresponding author), Univ Palermo, Dept Biol Chem & Pharmaceut Sci & Technol STEBICE, I-90133 Palermo, Italy.
EM sonia.emanuele@unipa.it; antonietta.notaro@unipa.it;
   antonio.palumbopiccionello@unipa.it; antonella.maggio@unipa.it;
   marianna.lauricella@unipa.it; antonella.danneo@unipa.it;
   cesare.cernigliaro@unipa.it; giuseppe.calvaruso@unipa.it;
   michela.giuliano@unipa.it
RI Piccionello, Antonio Palumbo/V-6634-2017; D’Anneo,
   Antonella/P-1064-2019; Lauricella, Marianna/ABD-1263-2020; Maggio,
   Antonella Maria/AAW-2804-2021
OI Piccionello, Antonio Palumbo/0000-0003-4402-5798; D’Anneo,
   Antonella/0000-0002-1785-8236; Maggio, Antonella
   Maria/0000-0002-0861-626X; GIULIANO, Michela/0000-0002-5114-6267;
   LAURICELLA, Marianna/0000-0002-0157-3834; CERNIGLIARO,
   Cesare/0000-0002-0264-4921
FU Gruppo Azione Locale (GAL) of Golfo di Castellammare, Italy [17/2015,
   313B]
FX This research was funded by Gruppo Azione Locale (GAL) of Golfo di
   Castellammare, Italy (Progetto Operativo n. 17/2015, misura 313B).
CR Alegre F, 2018, BRIT J PHARMACOL, V175, P440, DOI 10.1111/bph.14093
   Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4
   Campanella C, 2016, ONCOTARGET, V7, P28849, DOI 10.18632/oncotarget.6680
   Cicco N, 2009, MICROCHEM J, V91, P107, DOI 10.1016/j.microc.2008.08.011
   Cohen-Kaplan V, 2016, ONCOTARGET, V7, P83833, DOI 10.18632/oncotarget.13805
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Emanuele S, 2017, NUTRIENTS, V9, DOI 10.3390/nu9090992
   Guo HW, 2017, SCI REP-UK, V7, DOI 10.1038/srep41656
   Hsu CP, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/341479
   Hu XQ, 2015, DRUG DISCOV THER, V9, P116, DOI 10.5582/ddt.2015.01022
   Huang F, 2016, INT J BIOL MACROMOL, V92, P1067, DOI 10.1016/j.ijbiomac.2016.08.021
   Huang F, 2015, FOOD FUNCT, V6, P2598, DOI [10.1039/c5fo00249d, 10.1039/C5FO00249D]
   Ibrahim SRM, 2015, J ETHNOPHARMACOL, V174, P492, DOI 10.1016/j.jep.2015.08.054
   Kilari Eswar Kumar, 2016, Pharmacogn Rev, V10, P60, DOI 10.4103/0973-7847.176548
   Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984
   Lauricella M, 2017, NUTRIENTS, V9, DOI 10.3390/nu9050525
   Lauricella M, 2016, INT J ONCOL, V49, P352, DOI 10.3892/ijo.2016.3495
   Li JR, 2007, MOLECULES, V12, P745, DOI 10.3390/12040745
   Li W, 2012, MOLECULES, V17, P14954, DOI 10.3390/molecules171214954
   Menzel CM, 2005, LITCHI AND LONGAN: BOTANY, PRODUCTION AND USES, P1, DOI 10.1079/9780851996967.0000
   Natoli M, 2012, TOXICOL IN VITRO, V26, P1243, DOI 10.1016/j.tiv.2012.03.009
   Niedzwiecki A, 2016, NUTRIENTS, V8, DOI 10.3390/nu8090552
   Nishimura T, 2017, AUTOPHAGY, V13, P1795, DOI 10.1080/15548627.2017.1358344
   Notaro A, 2014, INT J BIOL SCI, V10, P466, DOI 10.7150/ijbs.8337
   Pellerito O, 2014, APOPTOSIS, V19, P1029, DOI 10.1007/s10495-014-0985-0
   Pietrocola F, 2012, CELL CYCLE, V11, P3851, DOI 10.4161/cc.22027
   Portanova P, 2008, INT J ONCOL, V33, P325, DOI 10.3892/ijo_00000012
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Song LH, 2017, MOLECULES, V22, DOI 10.3390/molecules22111934
   Swart C, 2016, EUR J CELL BIOL, V95, P598, DOI 10.1016/j.ejcb.2016.10.005
   Testa R, 2018, SUSTAINABILITY-BASEL, V10, DOI 10.3390/su10051436
   Wang XJ, 2006, TOXICOL APPL PHARM, V215, P168, DOI 10.1016/j.taap.2006.02.004
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Yamanishi R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093818
NR 35
TC 24
Z9 24
U1 2
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2072-6643
J9 NUTRIENTS
JI Nutrients
PD OCT
PY 2018
VL 10
IS 10
AR 1490
DI 10.3390/nu10101490
PG 18
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA GY7UM
UT WOS:000448821300156
PM 30322062
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Shintani, M
   Sangawa, A
   Yamao, N
   Kamoshida, S
AF Shintani, Michiko
   Sangawa, Akiko
   Yamao, Naoki
   Kamoshida, Shingo
TI Smac/DIABLO expression in human gastrointestinal carcinoma: Association
   with clinicopathological parameters and survivin expression
SO ONCOLOGY LETTERS
LA English
DT Article
DE survivin; Smac/DIABLO; immunohistochemistry; apoptosis
ID APOPTOSIS PROTEIN FAMILY; COLORECTAL-CANCER; GASTRIC-CANCER;
   IMMUNOHISTOCHEMICAL ANALYSIS; CYTOPLASMIC SURVIVIN; CELL-DEATH;
   PROGNOSIS; ADENOCARCINOMA; INHIBITOR; THERAPY
AB Lack of apoptosis is a key factor in carcinogenesis and tumor progression. Survivin is a member of the inhibitor of apoptosis protein (IA P) family. Second mitochondria-derived activator of caspases/direct inhibitor of apoptosis-binding protein with low pI (Smac/DIABLO) is an antagonist of IAPs. Recently, Smac/DIABLO was identified as a potent therapeutic target. However, the clinical significance of Smac/DIABLO in gastrointestinal carcinomas remains unclear. In the present study, Smac/DIABLO expression was analyzed by immunohistochemistry in 72 gastric adenocarcinomas and 78 colorectal adenocarcinomas. The expression of Smac/DIABLO was significantly higher in colorectal carcinoma than in gastric carcinoma. Additionally, a correlation was found between the expression of Smac/DIABLO and nuclear survivin in well- to moderately-differentiated colorectal adenocarcinomas (r=0.245; P<0.01). Based on these results, it was hypothesized that gastric and colorectal carcinomas differ in the level of Smac/DIABLO expression. Our previous studies revealed that the expression of cleaved caspase-9 was significantly lower in colorectal carcinoma than in gastric carcinoma (P<0.0001). Conversely, the expression levels of microtubule-associated protein 1 light chain 3 (LC3), an autophagy marker, and survivin were significantly higher in colon cancer than in gastric cancer (P<0.0001 and P<0.01, respectively). Taken together, these results indicate that not only LC3 and survivin expression, but also Smac/DIABLO expression, are significantly higher in colorectal carcinoma than in gastric carcinoma. We hypothesize that the analysis of Smac/DIABLO, survivin and LC3 expression in colorectal carcinoma is likely to aid cancer therapy due to the involvement of these markers in apoptosis and/or autophagy.
C1 [Shintani, Michiko; Sangawa, Akiko; Kamoshida, Shingo] Kobe Univ, Grad Sch Hlth Sci, Div Med Biophys, Pathol Lab, Kobe, Hyogo 6540142, Japan.
   [Sangawa, Akiko] Osaka Red Cross Hosp, Dept Diagnost Pathol, Osaka 5438555, Japan.
   [Yamao, Naoki] Kuma Hosp, Dept Clin Lab, Kobe, Hyogo 6500011, Japan.
RP Shintani, M (corresponding author), Kobe Univ, Grad Sch Hlth Sci, Div Med Biophys, Pathol Lab, 7-10-2 Tomogaoka, Kobe, Hyogo 6540142, Japan.
EM mtshin@kobe-u.ac.jp
OI yamao, naoki/0000-0002-0999-7420
FU Japan Society for the Promotion of ScienceMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science [23590396]
FX The authors would like to thank Dr Masayuki Shintaku and Dr Toshihiko
   Miyake for their kind support. This study was supported by a
   Grant-in-Aid for Scientific Research (grant no. 23590396) from the Japan
   Society for the Promotion of Science.
CR Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917
   Andersen MH, 2007, CLIN CANCER RES, V13, P5991, DOI 10.1158/1078-0432.CCR-07-0686
   Cheung HH, 2006, CLIN CANCER RES, V12, P3238, DOI 10.1158/1078-0432.CCR-06-0817
   Choi J, 2012, ANTICANCER RES, V32, P559
   Da Silva LC, 2013, ANTICANCER RES, V33, P647
   Endo K, 2009, ONCOL REP, V21, P351, DOI 10.3892/or_00000229
   Fang YJ, 2009, INT J COLORECTAL DIS, V24, P875, DOI 10.1007/s00384-009-0725-z
   Grzybowska-Izydorczyk O, 2010, EUR J CANCER, V46, P800, DOI 10.1016/j.ejca.2009.11.023
   KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J
   Kim MA, 2011, VIRCHOWS ARCH, V459, P503, DOI 10.1007/s00428-011-1150-6
   Knauer SK, 2007, CELL CYCLE, V6, P518, DOI 10.4161/cc.6.5.3902
   Lavrik IN, 2005, J CLIN INVEST, V115, P2665, DOI 10.1172/JCI26252
   Lee YY, 2009, DIS MARKERS, V26, P9, DOI [10.1155/2009/821543, 10.3233/DMA-2009-0598]
   Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327
   Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242
   Lima FD, 2009, ONCOL REP, V22, P295, DOI 10.3892/or_00000437
   Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101
   Miura K, 2011, SURG TODAY, V41, P175, DOI 10.1007/s00595-010-4390-1
   Okada E, 2001, CANCER LETT, V163, P109, DOI 10.1016/S0304-3835(00)00677-7
   Ponnelle T, 2005, J CANCER RES CLIN, V131, P504, DOI 10.1007/s00432-005-0682-z
   Qi GY, 2009, ONCOL REP, V22, P557, DOI 10.3892/or_00000471
   Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7
   Sah NK, 2006, CANCER LETT, V244, P164, DOI 10.1016/j.canlet.2006.03.007
   Shibata T, 2008, ANN SURG ONCOL, V15, P3579, DOI 10.1245/s10434-008-0062-4
   Shintani M, 2013, INT J CLIN EXP PATHO, V6, P2919
   Shintani M, 2011, BIOMED RES-TOKYO, V32, P379, DOI 10.2220/biomedres.32.379
   Shiozaki EN, 2004, TRENDS BIOCHEM SCI, V29, P486, DOI 10.1016/j.tibs.2004.07.003
   Song ZY, 2003, J BIOL CHEM, V278, P23130, DOI 10.1074/jbc.M300957200
   Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125
   Stauber RH, 2007, CANCER RES, V67, P5999, DOI 10.1158/0008-5472.CAN-07-0494
   Vallbohmer D, 2009, J SURG ONCOL, V99, P409, DOI 10.1002/jso.21271
   Wang TT, 2007, WORLD J GASTROENTERO, V13, P2784, DOI 10.3748/wjg.v13.i20.2784
   Wittekind, 2009, TNM CLASSIFICATION M
   Wrzesien-Kus A, 2004, APOPTOSIS, V9, P705, DOI 10.1023/B:APPT.0000045788.61012.b2
   Yan HJ, 2012, MED ONCOL, V29, P168, DOI 10.1007/s12032-011-9819-x
   Yoo NJ, 2003, APMIS, V111, P382, DOI 10.1034/j.1600-0463.2003.t01-1-1110202.x
   Zheng LD, 2005, WORLD J GASTROENTERO, V11, P79, DOI 10.3748/wjg.v11.i1.79
NR 37
TC 10
Z9 13
U1 0
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD DEC
PY 2014
VL 8
IS 6
BP 2581
EP 2586
DI 10.3892/ol.2014.2598
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AU9YT
UT WOS:000345948600044
PM 25364431
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Groulx, JF
   Khalfaoui, T
   Benoit, YD
   Bernatchez, G
   Carrier, JC
   Basora, N
   Beaulieu, JF
AF Groulx, Jean-Francois
   Khalfaoui, Taoufik
   Benoit, Yannick D.
   Bernatchez, Gerald
   Carrier, Julie C.
   Basora, Nuria
   Beaulieu, Jean-Francois
TI Autophagy is active in normal colon mucosa
SO AUTOPHAGY
LA English
DT Article
DE BECN1; p62/SQSTM1; autophagy; colon; epithelium; cancer
ID STEM-CELLS; BECLIN 1; CANCER; DISEASE; TUMORIGENESIS; EXPRESSION;
   PROGNOSIS; PROTEIN; GENE; DEGRADATION
AB Recently, autophagy has been found to be strongly activated in colon cancer cells, but few studies have addressed the normal colon mucosa. The aim of this study was to characterize autophagy in normal human intestinal cells. We used the expression of LC3-II and BECN1 as well as SQSTM1 as markers of autophagy activity. Using the normal human intestinal epithelial crypt (HIEC) cell experimental model, we found that autophagy was much more active in undifferentiated cells than in differentiated cells. In the normal adult colonic mucosa, BECN1 was found in the proliferative epithelial cells of the lower part of the gland while SQSTM1 was predominantly found in the differentiated cells of the upper part of the gland and surface epithelium. Interestingly, the weak punctate pattern of SQSTM1 expression in the lower gland colocalized with BECN1-labeled autophagosomes. The usefulness of SQSTM1 as an active autophagy marker was confirmed in colon cancer specimens at the protein and transcript levels. In conclusion, our results show that autophagy is active in the colonic gland and is associated with the intestinal proliferative/undifferentiated and progenitor cell populations.
C1 [Groulx, Jean-Francois; Khalfaoui, Taoufik; Benoit, Yannick D.; Bernatchez, Gerald; Carrier, Julie C.; Basora, Nuria; Beaulieu, Jean-Francois] Univ Sherbrooke, CIHR Team Digest Epithelium, Dept Anat & Cell Biol, Fac Med & Hlth Sci, Sherbrooke, PQ J1K 2R1, Canada.
RP Beaulieu, JF (corresponding author), Univ Sherbrooke, CIHR Team Digest Epithelium, Dept Anat & Cell Biol, Fac Med & Hlth Sci, Sherbrooke, PQ J1K 2R1, Canada.
EM Jean-Francois.Beaulieu@USherbrooke.ca
OI Benoit, Yannick/0000-0002-6677-4020
FU Canadian Institutes of Health ResearchCanadian Institutes of Health
   Research (CIHR) [MOP-57727, MOP-97836]; Canadian Research Chair in
   Intestinal Physiopathology
FX The work was supported by the Canadian Institutes of Health Research
   Grants MOP-57727 and MOP-97836 (to J.F.B.). J.F.B. is the recipient of a
   Canadian Research Chair in Intestinal Physiopathology and is a member of
   the FRSQ-funded Centre de Recherche Clinique Etienne Lebel of the CHUS.
CR Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Benoit YD, 2010, AM J PHYSIOL-GASTR L, V298, pG504, DOI 10.1152/ajpgi.00265.2009
   Besson D, 2011, MOL CELL PROTEOMICS, V10, DOI [10.1074/mcp.M111.009712-1, 10.1074/mcp.M111.009712]
   Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416
   Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78
   Dydensborg AB, 2006, AM J PHYSIOL-GASTR L, V290, pG1067, DOI 10.1152/ajpgi.00234.2005
   Dydensborg AB, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-223
   Edelblum KL, 2006, INFLAMM BOWEL DIS, V12, P413, DOI 10.1097/01.MIB.0000217334.30689.3e
   Francoeur C, 2009, GASTROENTEROLOGY, V136, P268, DOI 10.1053/j.gastro.2008.10.014
   Gagne D, 2010, J CELL PHYSIOL, V222, P387, DOI 10.1002/jcp.21963
   Gao C, 2010, NAT CELL BIOL, V12, P781, DOI 10.1038/ncb2082
   GAO X, 1995, CANCER RES, V55, P1002
   HOURI JJ, 1993, BIOCHEM BIOPH RES CO, V197, P805, DOI 10.1006/bbrc.1993.2550
   Ichimura Y, 2008, AUTOPHAGY, V4, P1063, DOI 10.4161/auto.6826
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Klionsky DJ, 2009, NEW ENGL J MED, V360, P1785, DOI 10.1056/NEJMcibr0810347
   Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X
   Knaevelsrud H, 2010, AUTOPHAGY, V6, P863, DOI 10.4161/auto.6.7.13033
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Korolchuk VI, 2009, MOL CELL, V33, P517, DOI 10.1016/j.molcel.2009.01.021
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Liang CY, 2007, AUTOPHAGY, V3, P69, DOI 10.4161/auto.3437
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liu WL, 2008, CLIN CANCER RES, V14, P1041, DOI 10.1158/1078-0432.CCR-07-4125
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Mehrpour M, 2010, CELL RES, V20, P748, DOI 10.1038/cr.2010.82
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2010, NAT CELL BIOL, V12, P823, DOI 10.1038/ncb0910-823
   Pardo R, 2010, PANCREATOLOGY, V10, P19, DOI 10.1159/000264680
   Perreault N, 1996, EXP CELL RES, V224, P354, DOI 10.1006/excr.1996.0145
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Santos R. X., 2010, Central Nervous System Agents in Medicinal Chemistry, V10, P158
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Sivridis E, 2010, AM J PATHOL, V176, P2477, DOI 10.2353/ajpath.2010.090049
   Sun QM, 2009, AUTOPHAGY, V5, P713, DOI 10.4161/auto.5.5.8524
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Teller IC, 2007, DEV DYNAM, V236, P1980, DOI 10.1002/dvdy.21186
   Van der Flier LG, 2009, GASTROENTEROLOGY, V137, P15, DOI 10.1053/j.gastro.2009.05.035
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yoshioka A, 2008, INT J ONCOL, V33, P461, DOI 10.3892/ijo_00000028
   Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zatloukal K, 2002, AM J PATHOL, V160, P255, DOI 10.1016/S0002-9440(10)64369-6
   Zhao Y, 2010, NAT CELL BIOL, V12, P665, DOI 10.1038/ncb2069
NR 54
TC 27
Z9 27
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD JUN
PY 2012
VL 8
IS 6
BP 893
EP 902
DI 10.4161/auto.19738
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 984MI
UT WOS:000307193400004
PM 22652752
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Kim, AD
   Kang, KA
   Kim, HS
   Kim, DH
   Choi, YH
   Lee, SJ
   Kim, HS
   Hyun, JW
AF Kim, A. D.
   Kang, K. A.
   Kim, H. S.
   Kim, D. H.
   Choi, Y. H.
   Lee, S. J.
   Kim, H. S.
   Hyun, J. W.
TI A ginseng metabolite, compound K, induces autophagy and apoptosis via
   generation of reactive oxygen species and activation of JNK in human
   colon cancer cells
SO CELL DEATH & DISEASE
LA English
DT Article
DE apoptosis; autophagy; compound K; reactive oxygen species; colon cancer
ID DEATH; PATHWAY; SAPONIN; LC3; CROSSTALK; PROTEINS; ASSAY
AB Compound K (20-O-(beta-D-glucopyranosyl)-20(S)-protopanaxadiol) is an active metabolite of ginsenosides and induces apoptosis in various types of cancer cells. This study investigated the role of autophagy in compound K-induced cell death of human HCT-116 colon cancer cells. Compound K activated an autophagy pathway characterized by the accumulation of vesicles, the increased positive acridine orange-stained cells, the accumulation of LC3-II, and the elevation of autophagic flux. Whereas blockade of compound K-induced autophagy by 3-methyladenein and bafilomycin A1 significantly increased cell viability. In addition, compound K augmented the time-dependent expression of the autophagy-related proteins Atg5, Atg6, and Atg7. However, knockdown of Atg5, Atg6, and Atg7 markedly inhibited the detrimental impact of compound K on LC3-II accumulation and cell vitality. Compound K-provoked autophagy was also linked to the generation of intracellular reactive oxygen species (ROS); both of these processes were mitigated by the pre-treatment of cells with the antioxidant N-acetylcysteine. Moreover, compound K activated the c-Jun NH2-terminal kinase (JNK) signaling pathway, whereas downregulation of JNK by its specific inhibitor SP600125 or by small interfering RNA against JNK attenuated autophagy-mediated cell death in response to compound K. Compound K also provoked apoptosis, as evidenced by an increased number of apoptotic bodies and sub-G(1) hypodiploid cells, enhanced activation of caspase-3 and caspase-9, and modulation of Bcl-2 and Bcl-2-associated X protein expression. Notably, compound K-stimulated autophagy as well as apoptosis was induced by disrupting the interaction between Atg6 and Bcl-2. Taken together, these results indicate that the induction of autophagy and apoptosis by compound K is mediated through ROS generation and JNK activation in human colon cancer cells.
C1 [Kim, A. D.; Kang, K. A.; Hyun, J. W.] Jeju Natl Univ, Sch Med, Cheju 690756, South Korea.
   [Kim, A. D.; Kang, K. A.; Hyun, J. W.] Jeju Natl Univ, Inst Nucl Sci & Technol, Cheju 690756, South Korea.
   [Kim, H. S.] Ewha Womans Univ, Dept Neurosci, Coll Med, Seoul, South Korea.
   [Kim, D. H.] Kyung Hee Univ, Dept Microbial Chem, Coll Pharm, Seoul, South Korea.
   [Choi, Y. H.] Dong Eui Univ, Dept Biochem, Coll Oriental Med, Pusan, South Korea.
   [Choi, Y. H.] Dong Eui Univ, Res Inst Oriental Med, Pusan, South Korea.
   [Lee, S. J.] Hanyang Univ, Dept Chem, Res Inst Nat Sci, Seoul 133791, South Korea.
   [Kim, H. S.] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea.
RP Hyun, JW (corresponding author), Jeju Natl Univ, Sch Med, Cheju 690756, South Korea.
EM jinwonh@jejunu.ac.kr
FU National R&D Program for Cancer Control, Ministry for Health and
   Welfare, Republic of Korea [1120340]
FX This study was supported by a grant from the National R&D Program for
   Cancer Control, Ministry for Health and Welfare, Republic of Korea
   (1120340).
CR Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI 10.1089/ARS.2008.2270
   Byun JY, 2009, CARCINOGENESIS, V30, P1880, DOI 10.1093/carcin/bgp235
   Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78
   CARMICHAEL J, 1987, CANCER RES, V47, P936
   Chae S, 2009, J AGR FOOD CHEM, V57, P5777, DOI 10.1021/jf900331g
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   DOOLITTLE MH, 1991, ANAL BIOCHEM, V195, P364, DOI 10.1016/0003-2697(91)90342-Q
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96
   Gao M, 2008, CANCER RES, V68, P9348, DOI 10.1158/0008-5472.CAN-08-1642
   Hasegawa H, 1996, PLANTA MED, V62, P453, DOI 10.1055/s-2006-957938
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Jiang Q, 2012, BMB REP, V45, P194, DOI 10.5483/BMBRep.2012.45.3.194
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041
   Kang KA, 2005, ARCH PHARM RES, V28, P685, DOI 10.1007/BF02969359
   Kang KA, 2006, BIOTECHNOL BIOPROC E, V11, P7, DOI 10.1007/BF02931861
   KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J
   Kim AD, 2010, ENVIRON TOXICOL PHAR, V30, P134, DOI 10.1016/j.etap.2010.04.008
   Kim DY, 2009, J AGR FOOD CHEM, V57, P10573, DOI 10.1021/jf902700h
   Kim YK, 2012, BIOMOL THER, V20, P393, DOI 10.4062/biomolther.2012.20.4.393
   Laubenbacher R, 2009, BBA-REV CANCER, V1796, P129, DOI 10.1016/j.bbcan.2009.06.001
   Lee IK, 2010, INT J MOL SCI, V11, P4916, DOI 10.3390/ijms11124916
   Lee JY, 2005, CARCINOGENESIS, V26, P359, DOI 10.1093/carcin/bgh313
   Li DD, 2009, ONCOGENE, V28, P886, DOI 10.1038/onc.2008.441
   Ling LU, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.12
   Liu J, 2005, CELL RES, V15, P36, DOI 10.1038/sj.cr.7290262
   LoPiccolo J, 2008, DRUG RESIST UPDATE, V11, P32, DOI 10.1016/j.drup.2007.11.003
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Maiuri MC, 2010, EMBO J, V29, P515, DOI 10.1038/emboj.2009.377
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O
   Orrenius S, 2007, ANNU REV PHARMACOL, V47, P143, DOI 10.1146/annurev.pharmtox.47.120505.105122
   Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Pattingre S, 2006, CANCER RES, V66, P2885, DOI 10.1158/0008-5472.CAN-05-4412
   Periyasamy-Thandavan S, 2009, AM J PHYSIOL-RENAL, V297, pF244, DOI 10.1152/ajprenal.00033.2009
   ROSENKRANZ AR, 1992, J IMMUNOL METHODS, V156, P39, DOI 10.1016/0022-1759(92)90008-H
   Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272
   Scherz-Shouval R, 2019, EMBO J, V38, DOI 10.15252/embj.2019101812
   Shen S, 2011, ONCOGENE, V30, P4544, DOI 10.1038/onc.2011.168
   Shen T, 2011, J GINSENG RES, V35, P200, DOI 10.5142/jgr.2011.35.2.200
   Shin JY, 2012, J GINSENG RES, V36, P86, DOI 10.5142/jgr.2012.36.1.86
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Trejo-Solis C, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-156
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Yim HW, 2005, CANCER RES, V65, P1952, DOI 10.1158/0008-5472.CAN-04-1740
NR 49
TC 119
Z9 125
U1 6
U2 47
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD AUG
PY 2013
VL 4
AR e750
DI 10.1038/cddis.2013.273
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 214PK
UT WOS:000324146000007
PM 23907464
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Miki, H
   Uehara, N
   Kimura, A
   Sasaki, T
   Yuri, T
   Yoshizawa, K
   Tsubura, A
AF Miki, Hisanori
   Uehara, Norihisa
   Kimura, Ayako
   Sasaki, Tomo
   Yuri, Takashi
   Yoshizawa, Katsuhiko
   Tsubura, Airo
TI Resveratrol induces apoptosis via ROS-triggered autophagy in human colon
   cancer cells
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE resveratrol; reactive oxygen species; autophagy; apoptosis; caspase-8;
   colon cancer; HT-29; COLO 201
ID DEATH; MITOCHONDRIA; INHIBITION; MODULATION; EXPRESSION; PATHWAY;
   GROWTH; ACID
AB Resveratrol (Res; 3,41,5-trihydroxy-trans-stilbene), which is a polyphenol found in grapes, can block cell proliferation and induce growth arrest and/or cell death in several types of cancer cells. However, the precise mechanisms by which Res exerts anticancer effects remain poorly understood. Res blocked both anchorage-dependent and -independent growth of HT-29 and COLO 201 human colon cancer cells in a dose- and time-dependent manner. Annexin V staining and Western blot analysis revealed that Res induced apoptosis accompanied by an increase in Caspase-8 and Caspase-3 cleavage. In HT-29 cells, Res caused autophagy as characterized by the appearance of autophagic vacuoles by electron microscopy and elevation of microtubule-associated protein 1 light chain 3 (LC3)-II by immunoblotting, which was associated with the punctuate pattern of LC3 detected by fluorescein microscopy. Inhibition of Res-induced autophagy by the autophagy inhibitor 3-methyladenine caused a significant decrease in apoptosis accompanied by decreased cleavage of Casapse-8 and Caspase-3, indicating that Res-induced autophagy was cytotoxic. However, inhibition of Res-induced apoptosis by the pan-caspase inhibitor Z-VAD(OMe)-FMK did not decrease autophagy but elevated LC3-II levels. Interestingly, Res increased the intracellular reactive oxygen species (ROS) level, which correlated to the induction of Casapse-8 and Caspase-3 cleavage and the elevation of LC3-II; treatment with ROS scavenger N-acetyl cysteine diminished this effect. Therefore, the effect of Res on the induction of apoptosis via autophagy is mediated through ROS in human colon cancer cells.
C1 [Miki, Hisanori; Uehara, Norihisa; Kimura, Ayako; Sasaki, Tomo; Yuri, Takashi; Yoshizawa, Katsuhiko; Tsubura, Airo] Kansai Med Univ, Dept Pathol 2, Moriguchi, Osaka 5708506, Japan.
RP Tsubura, A (corresponding author), Kansai Med Univ, Dept Pathol 2, Moriguchi, Osaka 5708506, Japan.
EM tsubura@takii.kmu.ac.jp
RI Uehara, Norihisa/F-5933-2012; Uehara, Norihisa/ABB-8106-2020
CR Athar M, 2007, TOXICOL APPL PHARM, V224, P274, DOI 10.1016/j.taap.2006.12.025
   Chau I, 2006, ANN ONCOL, V17, P1347, DOI 10.1093/annonc/mdl029
   Chen Z, 2010, EUR J PHARMACOL, V643, P170, DOI 10.1016/j.ejphar.2010.06.025
   Chen ZH, 2010, P NATL ACAD SCI USA, V107, P18880, DOI 10.1073/pnas.1005574107
   Juan ME, 2008, J AGR FOOD CHEM, V56, P4813, DOI 10.1021/jf800175a
   Fawcett H, 2005, INT J ONCOL, V27, P1717
   Fulda S, 2006, CANCER DETECT PREV, V30, P217, DOI 10.1016/j.cdp.2006.03.007
   Ganapathy S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015627
   Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1
   Huang CS, 1999, CARCINOGENESIS, V20, P237, DOI 10.1093/carcin/20.2.237
   Huerta S, 2006, AM J SURG, V191, P517, DOI 10.1016/j.amjsurg.2005.11.009
   Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218
   Johnson WD, 2011, FOOD CHEM TOXIC 0910
   Kanematsu S, 2010, ANTICANCER RES, V30, P3381
   Kim MY, 2009, ANTICANCER RES, V29, P3733
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kondo Y, 2006, AUTOPHAGY, V2, P85, DOI 10.4161/auto.2.2.2463
   Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Liang YC, 2003, BIOCHEM PHARMACOL, V65, P1053, DOI 10.1016/S0006-2952(03)00011-X
   Liao PC, 2010, J MED FOOD, V13, P1415, DOI 10.1089/jmf.2010.1126
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Nakagawa H, 2001, J CANCER RES CLIN, V127, P258, DOI 10.1007/s004320000190
   Opipari AW, 2004, CANCER RES, V64, P696, DOI 10.1158/0008-5472.CAN-03-2404
   Puissant A, 2010, CANCER RES, V70, P1042, DOI 10.1158/0008-5472.CAN-09-3537
   Reis-Sobreiro M, 2009, ONCOGENE, V28, P3221, DOI 10.1038/onc.2009.183
   Roig P, 1999, LIFE SCI, V64, P1517, DOI 10.1016/S0024-3205(99)00088-0
   Scarlatti F, 2008, CELL DEATH DIFFER, V15, P1318, DOI 10.1038/cdd.2008.51
   SCHATZKIN A, 1995, EUR J CANCER, V31A, P1198, DOI 10.1016/0959-8049(95)00138-9
   Shankar S, 2007, MOL CELL BIOCHEM, V304, P273, DOI 10.1007/s11010-007-9510-x
   Shih A, 2002, J CLIN ENDOCR METAB, V87, P1223, DOI 10.1210/jc.87.3.1223
   Trincheri NF, 2008, CARCINOGENESIS, V29, P381, DOI 10.1093/carcin/bgm271
   Uehara N, 2008, MOL CANCER RES, V6, P186, DOI 10.1158/1541-7786.MCR-07-0254
   Wang QL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017234
   Wenzel U, 2005, APOPTOSIS, V10, P359, DOI 10.1007/s10495-005-0810-x
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Wong CH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009996
   Xu R, 2006, HISTOL HISTOPATHOL, V21, P867, DOI 10.14670/HH-21.867
NR 39
TC 147
Z9 159
U1 0
U2 16
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD APR
PY 2012
VL 40
IS 4
BP 1020
EP 1028
DI 10.3892/ijo.2012.1325
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 910LI
UT WOS:000301637800015
PM 22218562
OA Green Submitted, Bronze, Green Published
DA 2022-04-25
ER

PT J
AU Wu, HC
   Liu, JQ
   Yin, Y
   Zhang, D
   Xia, PP
   Zhu, GQ
AF Wu, Hucong
   Liu, Jiaqi
   Yin, Yi
   Zhang, Dong
   Xia, Pengpeng
   Zhu, Guoqiang
TI Therapeutic Opportunities in Colorectal Cancer: Focus on Melatonin
   Antioncogenic Action
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Review
ID COLON CARCINOGENESIS; PROLIFERATIVE ACTIVITY; AUTOPHAGY; CELLS;
   APOPTOSIS; EXPRESSION; ANGIOGENESIS; TUMORS; 1,2-DIMETHYLHYDRAZINE;
   SENESCENCE
AB Colorectal cancer (CRC) influences individual health worldwide with high morbidity and mortality. Melatonin, which shows multiple physiological functions (e.g., circadian rhythm, immune modulation, and antioncogenic action), can be present in almost all organisms and found in various tissues including gastrointestinal tract. Notably, melatonin disruption is closely associated with the elevation of CRC incidence, indicating that melatonin is effective in suppressing CRC development and progression. Mechanistically, melatonin favors in activating apoptosis and colon cancer immunity, while reducing proliferation, autophagy, metastasis, and angiogenesis, thereby exerting its anticarcinogenic effects.)is review highlights that melatonin can be an adjuvant therapy and be beneficial in treating patients suffering from CRC.
C1 [Wu, Hucong; Liu, Jiaqi; Yin, Yi; Zhang, Dong; Xia, Pengpeng; Zhu, Guoqiang] Yangzhou Univ, Coll Vet Med, Yangzhou 225009, Jiangsu, Peoples R China.
   [Wu, Hucong; Liu, Jiaqi; Yin, Yi; Xia, Pengpeng; Zhu, Guoqiang] Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou 225009, Jiangsu, Peoples R China.
RP Zhu, GQ (corresponding author), Yangzhou Univ, Coll Vet Med, Yangzhou 225009, Jiangsu, Peoples R China.; Zhu, GQ (corresponding author), Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou 225009, Jiangsu, Peoples R China.
EM yzgqzhu@yzu.edu.cn
RI Xia, pengpeng/AAR-1874-2020
OI Xia, pengpeng/0000-0002-3693-1312
FU National Key Research and Development Program of China [2017YFD0500203,
   2017YFD 0500105, 2016YDF0500905]; Chinese National Science
   FoundationNational Natural Science Foundation of China (NSFC) [31672579,
   30571374, 30771603, 31092136, 31270171]; Yangzhou Science and Technology
   Bureau International Cooperation Project [YZ2018154]; Priority Academic
   Program of Development Jiangsu High Education Institution
FX This work was partially supported by Grant nos. 2017YFD0500203, 2017YFD
   0500105, and 2016YDF0500905 from the National Key Research and
   Development Program of China, grants from the Chinese National Science
   Foundation Grant (Nos. 31672579, 30571374, 30771603, 31092136,
   31270171), and a project funded by the Priority Academic Program of
   Development Jiangsu High Education Institution and it grants from the
   Yangzhou Science and Technology Bureau International Cooperation Project
   (YZ2018154).
CR Abdel-Gawad Iman A, 2008, J Egypt Natl Canc Inst, V20, P216
   Abusnina A, 2015, THROMB HAEMOSTASIS, V113, P319, DOI 10.1160/TH14-05-0454
   Acuna-Castroviejo D, 2014, CELL MOL LIFE SCI, V71, P2997, DOI 10.1007/s00018-014-1579-2
   Anisimov V. N., 2011, NEUROENDOCRINOLOGY L, V27, P35
   Anisimov Vladimir N, 2012, Curr Aging Sci, V5, P170
   Anisimov VN, 1999, EXP TOXICOL PATHOL, V51, P47, DOI 10.1016/S0940-2993(99)80062-1
   Anisimov VN, 1997, CARCINOGENESIS, V18, P1549, DOI 10.1093/carcin/18.8.1549
   Anisimov VN, 2000, EXP TOXICOL PATHOL, V52, P71, DOI 10.1016/S0940-2993(00)80022-6
   Batista APC, 2014, MICRON, V59, P17, DOI 10.1016/j.micron.2013.12.003
   Bubenik GA, 2008, J PHYSIOL PHARMACOL, V59, P33
   Bubenik GA, 2002, DIGEST DIS SCI, V47, P2336, DOI 10.1023/A:1020107915919
   Conti A, 2000, J PINEAL RES, V28, P193, DOI 10.1034/j.1600-079X.2000.280401.x
   Coto-Montes A, 2006, AUTOPHAGY, V2, P126, DOI 10.4161/auto.2.2.2351
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Dong BJ, 2014, EXPERT REV CLIN IMMU, V10, P1547, DOI 10.1586/1744666X.2014.962515
   DUBBELS R, 1995, J PINEAL RES, V18, P28, DOI 10.1111/j.1600-079X.1995.tb00136.x
   Farriol M, 2000, J APPL TOXICOL, V20, P21, DOI 10.1002/(SICI)1099-1263(200001/02)20:1<21::AID-JAT623>3.0.CO;2-M
   Favero G, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01086
   Gacche RN, 2013, PROG BIOPHYS MOL BIO, V113, P333, DOI 10.1016/j.pbiomolbio.2013.10.001
   Gao J, 2019, CHEM-BIOL INTERACT, V297, P50, DOI 10.1016/j.cbi.2018.10.014
   Gao Y, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12380
   Gelfand MV, 2014, ELIFE, V3, DOI 10.7554/eLife.03720
   Guo YC, 2010, J HUAZHONG U SCI-MED, V30, P1, DOI 10.1007/s11596-010-0101-9
   Hardeland R, 2005, ENDOCRINE, V27, P119, DOI 10.1385/ENDO:27:2:119
   Hill SM, 2009, INTEGR CANCER THER, V8, P337, DOI 10.1177/1534735409353332
   Hong Y, 2014, J PINEAL RES, V56, P264, DOI 10.1111/jpi.12119
   Huang P, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/3405278
   Johnson CM, 2013, CANCER CAUSE CONTROL, V24, P1207, DOI 10.1007/s10552-013-0201-5
   Kannen V, 2011, BIOCHEM BIOPH RES CO, V405, P593, DOI 10.1016/j.bbrc.2011.01.074
   KHOORY R, 1988, J PINEAL RES, V5, P251, DOI 10.1111/j.1600-079X.1988.tb00651.x
   Kong FL, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/8721503
   Kongsuphol P, 2009, J PINEAL RES, V46, P199, DOI 10.1111/j.1600-079X.2008.00648.x
   Kos-Kudla B, 2002, NEUROENDOCRINOL LETT, V23, P239
   Kossoy G, 2000, ONCOL REP, V7, P1401
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   Kvetnaia T V, 2003, Adv Gerontol, V12, P132
   Leon J, 2014, J PINEAL RES, V56, P415, DOI 10.1111/jpi.12131
   Lin CL, 2019, IN VIVO, V33, P573, DOI 10.21873/invivo.11513
   Liu Z, 2017, MOL MED REP, V16, P9383, DOI 10.3892/mmr.2017.7836
   Mehta A, 2019, LIFE SCI, V230, P150, DOI 10.1016/j.lfs.2019.05.043
   Nopparat C, 2010, J PINEAL RES, V49, P382, DOI 10.1111/j.1600-079X.2010.00805.x
   Papantoniou K, 2018, INT J CANCER, V143, P2709, DOI 10.1002/ijc.31655
   Parent ME, 2012, AM J EPIDEMIOL, V176, P751, DOI 10.1093/aje/kws318
   Park JH, 2016, PHYTOMEDICINE, V23, P1716, DOI 10.1016/j.phymed.2016.10.010
   Park SY, 2010, J PINEAL RES, V48, P178, DOI 10.1111/j.1600-079X.2009.00742.x
   Pechanova O, 2014, INT J MOL SCI, V15, P17920, DOI 10.3390/ijms151017920
   POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x
   Polidarova L, 2017, CHRONOBIOL INT, V34, P1273, DOI 10.1080/07420528.2017.1361436
   Qiu Y, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.8378
   RAIKHLIN NT, 1975, NATURE, V255, P344, DOI 10.1038/255344a0
   REITER RJ, 1991, MOL CELL ENDOCRINOL, V79, pC153, DOI 10.1016/0303-7207(91)90087-9
   Ren WK, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12394
   Roncucci L, 2015, EUR J INTERN MED, V26, P752, DOI 10.1016/j.ejim.2015.08.019
   Ryabykh T. P., 2000, Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, P30
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Silveira AP, 2011, HEAD NECK ONCOL, V3, DOI 10.1186/1758-3284-3-3
   Srinivasan V, 2011, RECENT PATENTS ENDOC, V5, P109, DOI 10.2174/187221411799015408
   Stigliano V, 2014, WORLD J GASTROENTERO, V20, P12420, DOI 10.3748/wjg.v20.i35.12420
   Tan DX, 2016, J PINEAL RES, V61, P27, DOI 10.1111/jpi.12336
   Tan DX, 2014, INT J MOL SCI, V15, P15858, DOI 10.3390/ijms150915858
   Tanaka T, 2009, CHEM-BIOL INTERACT, V177, P128, DOI 10.1016/j.cbi.2008.10.047
   Thakur RK, 2014, NUCLEIC ACIDS RES, V42, P11589, DOI 10.1093/nar/gku860
   Tilg H, 2018, CANCER CELL, V33, P954, DOI 10.1016/j.ccell.2018.03.004
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Tosches MA, 2014, CELL, V159, P46, DOI 10.1016/j.cell.2014.07.042
   Toso A, 2014, CELL REP, V9, P75, DOI 10.1016/j.celrep.2014.08.044
   Trivedi PP, 2016, MOL CARCINOGEN, V55, P255, DOI 10.1002/mc.22274
   Ushio-Fukai M, 2004, MOL CELL BIOCHEM, V264, P85, DOI 10.1023/B:MCBI.0000044378.09409.b5
   Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620
   Wang JS, 2013, J PINEAL RES, V54, P406, DOI 10.1111/jpi.12035
   Winczyk K, 2002, TUMOR BIOL, V23, P298, DOI 10.1159/000068569
   Winczyk K, 2001, J PINEAL RES, V31, P179, DOI 10.1034/j.1600-079x.2001.310213.x
   Xia YY, 2019, J PINEAL RES, V66, DOI 10.1111/jpi.12547
   Yang Y, 2017, MOLECULES, V22, DOI 10.3390/molecules22030453
   YIN J, 2013, JOURNAL OF PINEAL RE, V62, DOI DOI 10.7498/APS.62.084205
   Yuan QH, 2019, J CELL BIOCHEM, V120, P552, DOI 10.1002/jcb.27411
   Yun CW, 2018, ANTICANCER RES, V38, P3951, DOI 10.21873/anticanres.12681
   Zhang S, 2013, BIOTECH HISTOCHEM, V88, P281, DOI 10.3109/10520295.2013.769633
   Zhang YM, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008242
   Zhu JZ, 2017, DIGEST DIS SCI, V62, P235, DOI 10.1007/s10620-016-4362-4
   Zou Duo-Bing, 2015, Asian Pac J Cancer Prev, V16, P5835
NR 81
TC 15
Z9 15
U1 5
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD SEP 17
PY 2019
VL 2019
AR 9740568
DI 10.1155/2019/9740568
PG 6
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA JH7HM
UT WOS:000492938700003
PM 31637261
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Huang, HL
   Chen, WC
   Hsu, HP
   Cho, CY
   Hung, YH
   Wang, CY
   Lai, MD
AF Huang, Hau-Lun
   Chen, Wei-Ching
   Hsu, Hui-Ping
   Cho, Chien-Yu
   Hung, Yu-Hsuan
   Wang, Chih-Yang
   Lai, Ming-Derg
TI Silencing of argininosuccinate lyase inhibits colorectal cancer
   formation
SO ONCOLOGY REPORTS
LA English
DT Article
DE argininosuccinate lyase; nitric oxide; autophagy; endoplasmic reticulum;
   cyclin A; colorectal cancer
ID NITRIC-OXIDE PRODUCTION; BODY-MASS INDEX; L-ARGININE;
   CELL-PROLIFERATION; SYNTHASE GENE; BREAST-CANCER; TUMOR-GROWTH;
   AUTOPHAGY; DEPRIVATION; EXPRESSION
AB Arginine and nitric oxide (NO) are important mediators of tumorigenesis in various types of cancer. Dysregulation of NO content by argininosuccinate lyase (ASL) has been previously demonstrated to inhibit the proliferation of liver and breast cancer cells. However, the function of ASL in colon cancer is not well defined. The present study aimed to determine the effect of ASL on colon cancer. Western blot analysis indicated that ASL expression was induced by endoplasmic reticulum stress in HCT116 and SW480 colon cancer cells. Additionally, the expression of ASL in colon cancer tissues was enhanced compared with that in the adjacent normal tissues, and the patients with colon cancer with higher ASL expression exhibited poorer survival rates. Transfection of ASL-targeting short hairpin RNA (shRNA) into HCT116 cells inhibited cell proliferation and decreased anchorage-independent growth in a soft agar assay. In addition, when injected subcutaneously into NOD/SCID mice, stable transfectant ASL-downregulated HCT116 cells exhibited decreased in vivo tumorigenic ability. Flow cytometric analysis of cell cycle progression indicated that ASL-targeting shRNA induced G2/M arrest, and western blot analysis showed that the inhibition of ASL was accompanied by cyclin A2 degradation. Furthermore, ASL-targeting shRNA resulted in increased autophagosomes and decreased NO levels. Inhibition of NO by the NO synthase inhibitor L-NMMA significantly reduced cell proliferation and colony formation. In summary, the results of the present study indicated that ASL-targeting shRNA-induced growth inhibition is associated with decreased cyclin A2 expression and NO content in colon cancer.
C1 [Huang, Hau-Lun; Chen, Wei-Ching; Cho, Chien-Yu; Hung, Yu-Hsuan; Wang, Chih-Yang; Lai, Ming-Derg] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan, Taiwan.
   [Huang, Hau-Lun; Chen, Wei-Ching; Cho, Chien-Yu; Hung, Yu-Hsuan; Wang, Chih-Yang; Lai, Ming-Derg] Natl Cheng Kung Univ, Coll Med, Dept Biochem & Mol Biol, 1 Univ Rd, Tainan 701, Taiwan.
   [Hsu, Hui-Ping] Natl Cheng Kung Univ, Coll Med, Dept Surg, Tainan, Taiwan.
   [Lai, Ming-Derg] Natl Cheng Kung Univ, Coll Med, Ctr Infect Dis & Signaling Res, Tainan, Taiwan.
RP Lai, MD (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Biochem & Mol Biol, 1 Univ Rd, Tainan 701, Taiwan.
EM a1211207@mail.ncku.edu.tw
RI Lai, Ming-Derg/M-8028-2014
OI Wang, Chih-Yang/0000-0002-4137-5074
FU National Science Council (Taiwan)Ministry of Science and Technology,
   Taiwan [NSC-100-2325-B-006-008]; National Health Research Institute,
   TaiwanNational Health Research Institutes - Taiwan [NHRI-EX100-9927B1];
   Department of Health, Executive Yuan (Taiwan) [DOH101-TD-C-111-003]
FX The present study was supported by a grant to M.-D. Lai,
   (NSC-100-2325-B-006-008) from the National Science Council (Taiwan) and
   (NHRI-EX100-9927B1) from the National Health Research Institute, Taiwan
   to establish Centers of Excellence for Cancer Research in Taiwan,
   (DOH101-TD-C-111-003) Department of Health, Executive Yuan (Taiwan).
CR ARNAL JF, 1995, J CLIN INVEST, V95, P2565, DOI 10.1172/JCI117957
   BACH SJ, 1965, BRIT J CANCER, V19, P379, DOI 10.1038/bjc.1965.45
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Delage B, 2010, INT J CANCER, V126, P2762, DOI 10.1002/ijc.25202
   Ensor CM, 2002, CANCER RES, V62, P5443
   Erez A, 2011, NAT MED, V17, P1619, DOI 10.1038/nm.2544
   Forbes TA, 2012, CANC RES S8, V11, P5456
   GALONS JP, 1989, BIOCHIMIE, V71, P949, DOI 10.1016/0300-9084(89)90077-1
   Gerber M, 1999, EUR J CANCER PREV, V8, P77, DOI 10.1097/00008469-199904000-00002
   Giskeodegard GF, 2015, BRIT J CANCER, V113, P1712, DOI 10.1038/bjc.2015.411
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665
   Huang HL, 2015, ONCOL REP, V34, P3131, DOI 10.3892/or.2015.4280
   Huang HL, 2013, MOL CANCER THER, V12, P2505, DOI 10.1158/1535-7163.MCT-12-0863
   Huerta S, 2008, INT J ONCOL, V33, P909, DOI 10.3892/ijo_00000079
   JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392
   Juang SH, 1998, HUM GENE THER, V9, P845, DOI 10.1089/hum.1998.9.6-845
   Kinross JM, 2013, SURGERY, V154, P1185, DOI 10.1016/j.surg.2013.06.018
   Lamb J, 2000, EXP CELL RES, V255, P238, DOI 10.1006/excr.1999.4779
   Liu JB, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-686
   Luo B, 2013, ONCOGENE, V32, P805, DOI 10.1038/onc.2012.130
   Ma QY, 2007, CLIN CANCER RES, V13, P7407, DOI 10.1158/1078-0432.CCR-07-0751
   Ma QY, 1999, J SURG RES, V81, P181, DOI 10.1006/jsre.1998.5512
   Motoo Y, 2000, PANCREAS, V20, P61, DOI 10.1097/00006676-200001000-00009
   Nagasaka H, 2009, METABOLISM, V58, P278, DOI 10.1016/j.metabol.2008.09.025
   Ning Y, 2010, OBES REV, V11, P19, DOI 10.1111/j.1467-789X.2009.00613.x
   Nugent JL, 2014, J PROTEOME RES, V13, P1921, DOI 10.1021/pr4009783
   Pieper GM, 1998, HYPERTENSION, V31, P1047, DOI 10.1161/01.HYP.31.5.1047
   Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X
   Sakitani K, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1789-5
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   SHIKE M, 1990, B WORLD HEALTH ORGAN, V68, P377
   Singh R, 2000, CANCER RES, V60, P3305
   Szende Bela, 2001, Cancer Cell Int, V1, P3, DOI 10.1186/1475-2867-1-3
   Tuominen I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060939
   Vissers YLJ, 2005, AM J CLIN NUTR, V81, P1142
   Wang YG, 2012, CANCER RES, V72, P5396, DOI 10.1158/0008-5472.CAN-12-0474
   Willett WC, 2005, JAMA-J AM MED ASSOC, V293, P233, DOI 10.1001/jama.293.2.233
   XIE KP, 1995, J EXP MED, V181, P1333, DOI 10.1084/jem.181.4.1333
   Xu XS, 2016, ONCOTARGET, V7, P5023, DOI 10.18632/oncotarget.6517
   YEATMAN TJ, 1991, ARCH SURG-CHICAGO, V126, P1376
   Yerushalmi HF, 2006, MOL CARCINOGEN, V45, P764, DOI 10.1002/mc.20246
NR 44
TC 13
Z9 13
U1 0
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD JAN
PY 2017
VL 37
IS 1
BP 163
EP 170
DI 10.3892/or.2016.5221
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EF9GX
UT WOS:000390639800020
PM 27840980
OA Bronze
DA 2022-04-25
ER

PT J
AU Yoo, HY
   Park, SY
   Chang, SY
   Kim, SH
AF Yoo, Hee Young
   Park, So Yeon
   Chang, Sun-Young
   Kim, So Hee
TI Regulation of Butyrate-Induced Resistance through AMPK Signaling Pathway
   in Human Colon Cancer Cells
SO BIOMEDICINES
LA English
DT Article
DE butyrate resistance; colon cancer; AMPK; autophagy; ACC; Akt; mTOR
ID COLORECTAL-CANCER; DRUG-RESISTANCE; AUTOPHAGY; METABOLISM; ACQUISITION;
   INHIBITION
AB Butyrates inhibit cell growth in colon cancer cells by inhibiting histone deacetylases. However, chronic exposure to butyrates induces butyrate resistance in colon cancer cells. The mechanism underlying the acquisition of resistance is not yet fully understood. Here, butyrate-resistant (BR) colon cancer cells were developed in HCT116, HT29, and SW480 human colon cancer cells and were confirmed by the increase in the inhibitory concentrations of cell growth by 50% (IC50) compared to their respective parental (PT) cells. Chronic exposure to butyrate induced autophagy via higher expression of Beclin-1 and LC3B-II. The AMP-activated protein kinase (AMPK) was downregulated along with the activation of Akt and mammalian target of rapamycin (mTOR) and decrease in acetyl-CoA carboxylase (ACC) in BR colon cancer cells compared to those in their respective PT cells. Activation of AMPK by AICAR treatment in BR colon cancer cells suppressed cell proliferation by inhibiting Akt and mTOR and activating ACC. Taken together, chronic exposure to butyrate increased butyrate resistance in human colon cancer by inducing protective autophagy through the downregulation of AMPK/ACC and activation of Akt/mTOR signaling. Activation of AMPK restored sensitivity to butyrate by the inhibition of Akt/mTOR, suggesting that AMPK could be a therapeutic target for BR colon cancers.
C1 [Kim, So Hee] Ajou Univ, Coll Pharm, Suwon 16499, South Korea.
   Ajou Univ, Res Inst Pharmaceut Sci & Technol, Suwon 16499, South Korea.
RP Kim, SH (corresponding author), Ajou Univ, Coll Pharm, Suwon 16499, South Korea.
EM yoo1454@ajou.ac.kr; qkrth0413@ajou.ac.kr; sychang@ajou.ac.kr;
   shkim67@ajou.ac.kr
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) [NRF-2018R1A2B6004895, NRF-2021R1A2C1011142]
FX Funding This research was funded by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF) through the
   Ministry of Science, ICT, and Future Planning, NRF-2018R1A2B6004895 and
   NRF-2021R1A2C1011142.
CR Bae SH, 2018, BIOMOL THER, V26, P494, DOI 10.4062/biomolther.2018.042
   Barrasa JI, 2012, BBA-MOL CELL RES, V1823, P2201, DOI 10.1016/j.bbamcr.2012.08.008
   Bertotti A, 2015, CLIN CANCER RES, V21, P3377, DOI 10.1158/1078-0432.CCR-14-0848
   Beyer-Sehlmeyer G, 2003, BRIT J NUTR, V90, P1057, DOI 10.1079/BJN20031003
   Bhutia SK, 2013, ADV CANCER RES, V118, P61, DOI 10.1016/B978-0-12-407173-5.00003-0
   Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4
   Blouin JM, 2011, INT J CANCER, V128, P2591, DOI 10.1002/ijc.25599
   Chen GA, 2011, CLIN CANCER RES, V17, P817, DOI 10.1158/1078-0432.CCR-10-1789
   de Silanes IL, 2004, CANCER RES, V64, P4593, DOI 10.1158/0008-5472.CAN-04-0711
   Derjuga A, 2001, J BIOL CHEM, V276, P37815
   Goncalves P, 2013, CURR DRUG METAB, V14, P994
   Han F, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07188-9
   Kang HR, 2016, ONCOL REP, V36, P1119, DOI 10.3892/or.2016.4838
   Kwon Y, 2019, CANCERS, V11, DOI 10.3390/cancers11091374
   Li XY, 2019, BIOMED PHARMACOTHER, V119, DOI 10.1016/j.biopha.2019.109415
   Liu HL, 2008, MOL CANCER THER, V7, P263, DOI 10.1158/1535-7163.MCT-07-0445
   Luo JT, 2017, CANCER LETT, V384, P39, DOI 10.1016/j.canlet.2016.09.020
   Luo XJ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0646-3
   Luo ZJ, 2005, TRENDS PHARMACOL SCI, V26, P69, DOI 10.1016/j.tips.2004.12.011
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Meyer G, 2013, CURR PHARM DESIGN, V19, P6912, DOI 10.2174/138161281939131127122510
   Nyfeler B, 2016, AUTOPHAGY, V12, P1206, DOI 10.1080/15548627.2016.1170265
   Panda PK, 2015, SEMIN CELL DEV BIOL, V39, P43, DOI 10.1016/j.semcdb.2015.02.013
   Perez-Hernandez M, 2019, CANCERS, V11, DOI 10.3390/cancers11101599
   Ramnath N, 2014, J THORAC ONCOL, V9, P473, DOI 10.1097/JTO.0000000000000114
   Rattan R, 2005, J BIOL CHEM, V280, P39582, DOI 10.1074/jbc.M507443200
   Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676
   Sobhakumari A, 2013, TOXICOL APPL PHARM, V272, P736, DOI 10.1016/j.taap.2013.07.013
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Talukdar S, 2018, AUTOPHAGY, V14, P1845, DOI 10.1080/15548627.2018.1502564
   Talukdar S, 2018, P NATL ACAD SCI USA, V115, P5768, DOI 10.1073/pnas.1721650115
   Wang ZY, 2016, EXPERIENTIA SUPPL, V107, P203, DOI 10.1007/978-3-319-43589-3_9
   Wang ZY, 2016, CURR DRUG TARGETS, V17, P853, DOI 10.2174/1389450116666150316223655
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Xiang HG, 2020, ACTA PHARMACOL SIN B, V10, P569, DOI 10.1016/j.apsb.2019.10.003
   Xie QS, 2021, ACTA PHARMACOL SIN, V42, P470, DOI 10.1038/s41401-020-0402-x
   Zhai B, 2014, MOL CANCER THER, V13, P1589, DOI 10.1158/1535-7163.MCT-13-1043
   Zhang JT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147218
   Zhao L, 2018, ANTI-CANCER DRUG, V29, P227, DOI 10.1097/CAD.0000000000000588
   Zhou YF, 2013, MOL CANCER THER, V12, P2782, DOI 10.1158/1535-7163.MCT-13-0098
NR 40
TC 1
Z9 1
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2227-9059
J9 BIOMEDICINES
JI Biomedicines
PD NOV
PY 2021
VL 9
IS 11
AR 1604
DI 10.3390/biomedicines9111604
PG 14
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA XG9UQ
UT WOS:000725091200001
PM 34829834
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhang, X
   Yang, H
   Yue, SQ
   He, GB
   Qu, SB
   Zhang, ZC
   Ma, B
   Ding, R
   Peng, W
   Zhang, HT
   Yang, ZX
   Dou, KF
   Tao, KS
   Li, X
AF Zhang, Xuan
   Yang, Hua
   Yue, Shuqiang
   He, Guangbin
   Qu, Shibin
   Zhang, Zhuochao
   Ma, Ben
   Ding, Rui
   Peng, Wei
   Zhang, Hongtao
   Yang, Zhaoxu
   Dou, Kefeng
   Tao, Kaishan
   Li, Xiao
TI The mTOR inhibition in concurrence with ERK1/2 activation is involved in
   excessive autophagy induced by glycyrrhizin in hepatocellular carcinoma
SO CANCER MEDICINE
LA English
DT Article
DE Autophagy; ERK1/2; glycyrrhizin; hepatocellular carcinoma; mTOR
ID ADENOCARCINOMA CELL-GROWTH; COLON-CANCER CELLS; PROMYELOTIC LEUKEMIA;
   PI3K/AKT PATHWAY; ACID; APOPTOSIS; DEATH; MACROAUTOPHAGY; INDUCTION;
   HEPATOMA
AB Autophagy is a life phenomenon in which autophagosomes remove damaged or aging organelles and long-lived circulating proteins to maintain the cell's stability. However, disorders of excessive autophagy are a response of cancer cells to a variety of anticancer treatments which lead to cancer cell death. The Akt/mammalian target of rapamycin (mTOR) and the extracellular signal-regulated kinase 1/2 (ERK1/2) pathways are both involved in nutrient-induced autophagic phenomenon and exhibit vital relevance to oncogenesis in various cancer cell types, including hepatocellular carcinoma (HCC). However, the influence of autophagy for cancer cell death remains controversial and few scientists have investigated the variation of these two signaling pathways in cancer cell autophagic phenomenon induced by anticancer treatment simultaneously. Here, we explored the anticancer efficacy and mechanisms of glycyrrhizin (GL), a bioactive compound of licorice with little toxicity in normal cells. It is interesting that inhibition of Akt/mTOR signaling in concurrence with enhanced ERK1/2 activity exists in GL-induced autophagy and cytotoxicity in HepG2 and MHCC97-H hepatocellular carcinoma cells. These results imply that the GL-related anticancer ability might correlate with the induction of autophagy. The influence of induced autophagic phenomenon on cell viability might depend on the severity of autophagy and be pathway specific. In the subsequent subcutaneous xenograft experiment in vivo with MHCC97-H cells, GL obviously exhibited its inhibitory efficacy in tumor growth via inducing excess autophagy in MHCC97-H cells (P<0.05). Our data prompt that GL possesses a property of excess autophagic phenomenon induction in HCC and exerts high anticancer efficacy in vitro and in vivo. This warrants further investigation toward possible clinical applications in patients with HCC.
C1 [Zhang, Xuan; Qu, Shibin; Zhang, Zhuochao; Ma, Ben; Ding, Rui; Peng, Wei; Zhang, Hongtao; Yang, Zhaoxu; Dou, Kefeng; Tao, Kaishan; Li, Xiao] Fourth Mil Med Univ, Xijing Hosp, Dept Hepatobiliary Surg, Xian, Shaanxi, Peoples R China.
   [Yang, Hua] Xian 1 Hosp, Dept Geriatr, Xian, Shaanxi, Peoples R China.
   [Yue, Shuqiang] Fourth Mil Med Univ, Xijing Hosp, Dept Surg Oncol, Xian, Shaanxi, Peoples R China.
   [He, Guangbin] Fourth Mil Med Univ, Xijing Hosp, Dept Ultrasound Diag, Xian, Shaanxi, Peoples R China.
RP Dou, KF; Tao, KS; Li, X (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Hepatobiliary Surg, Xian, Shaanxi, Peoples R China.
EM doukef@fmmu.edu.cn; taokaishan0686@163.com; lixiao0076@163.com
RI Zhang, Xuan/L-3020-2019
OI /0000-0002-6624-5532
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81272648, 81201926]; Shaanxi Resource-based
   Industry Key Technology [2015KTCL-03-011]
FX This study was supported by the National Natural Science Foundation of
   China (81272648 and 81201926) and Shaanxi Resource-based Industry Key
   Technology (2015KTCL-03-011).
CR Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200
   Ashfaq UA, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-112
   Bursch W, 2000, ANN NY ACAD SCI, V926, P1, DOI 10.1111/j.1749-6632.2000.tb05594.x
   Chen SN, 2011, MED HYPOTHESES, V77, P206, DOI 10.1016/j.mehy.2011.04.013
   Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233
   Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7
   Cherng JM, 2011, RADIAT RES, V176, P177, DOI 10.1667/RR2510.1
   Chueh FS, 2012, ONCOL REP, V28, P2069, DOI 10.3892/or.2012.2029
   Declercq W, 2009, CELL, V138, P229, DOI 10.1016/j.cell.2009.07.006
   Denton D, 2012, CELL DEATH DIFFER, V19, P87, DOI 10.1038/cdd.2011.146
   Ellington AA, 2006, CARCINOGENESIS, V27, P298, DOI 10.1093/carcin/bgi214
   Gurpinar E, 2013, MOL CANCER THER, V12, P663, DOI 10.1158/1535-7163.MCT-12-0785
   He SQ, 2015, INT J CLIN EXP PATHO, V8, P5175
   Hibasami H, 2006, INT J MOL MED, V17, P215
   Hibasami H, 2005, INT J MOL MED, V16, P233
   Huang RY, 2014, CELL PHYSIOL BIOCHEM, V33, P375, DOI 10.1159/000356677
   Huitzil-Melendez FD, 2010, J CLIN ONCOL, V28, P2889, DOI 10.1200/JCO.2009.25.9895
   Ishida T, 2012, EVID-BASED COMPL ALT, V2012, P1, DOI 10.1155/2012/650514
   Kim KJ, 2013, PHYTOTHER RES, V27, P841, DOI 10.1002/ptr.4800
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Kumar D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139657
   Laconi S, 2014, PHYTOTHER RES, V28, P1890, DOI 10.1002/ptr.5189
   Lamy L, 2013, CANCER CELL, V23, P435, DOI 10.1016/j.ccr.2013.02.017
   Li JY, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/872139
   Li S, 2014, NEUROL SCI, V35, P1115, DOI 10.1007/s10072-014-1661-4
   Liu YL, 2010, AUTOPHAGY, V6, P1057, DOI 10.4161/auto.6.8.13365
   Llovet JM, 2008, HEPATOLOGY, V48, P1312, DOI 10.1002/hep.22506
   Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200
   Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200
   Raha S, 2015, INT J ONCOL, V47, P1061, DOI 10.3892/ijo.2015.3095
   Raphael TJ, 2008, IMMUNOPHARM IMMUNOT, V30, P243, DOI [10.1080/08923970701675044, 10.1080/08923970701675044 ]
   Sandri GBL, 2016, HEPATOL SURG NUTR, V5, P478, DOI 10.21037/hbsn.2016.05.05
   Selvaraj S, 2016, MOL CARCINOGEN, V55, P818, DOI 10.1002/mc.22324
   Shigemitsu K, 1999, J BIOL CHEM, V274, P1058, DOI 10.1074/jbc.274.2.1058
   Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640
   Talarico C, 2016, ONCOTARGET, V7, DOI 10.18632/oncotarget.7520
   Tang ZH, 2015, PLANTA MED, V81, P1670, DOI 10.1055/s-0035-1558227
   Teng LS, 2014, INT J MOL MED, V34, P742, DOI 10.3892/ijmm.2014.1830
   Thirugnanam S, 2008, ONCOL REP, V20, P1387, DOI 10.3892/or_00000157
   Tu CT, 2012, INT IMMUNOPHARMACOL, V14, P410, DOI 10.1016/j.intimp.2012.08.013
   Youn CK, 2015, INT J PEDIATR OTORHI, V79, P1814, DOI 10.1016/j.ijporl.2015.08.012
   Zhang X, 2015, J HUAZHONG U SCI-MED, V35, P378, DOI 10.1007/s11596-015-1441-2
NR 43
TC 23
Z9 25
U1 4
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2045-7634
J9 CANCER MED-US
JI Cancer Med.
PD AUG
PY 2017
VL 6
IS 8
BP 1941
EP 1951
DI 10.1002/cam4.1127
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FD3JI
UT WOS:000407428900010
PM 28675698
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Kim, SY
   Song, XX
   Zhang, L
   Bartlett, DL
   Lee, YJ
AF Kim, Seog-Young
   Song, Xinxin
   Zhang, Lin
   Bartlett, David L.
   Lee, Yong J.
TI Role of Bcl-xL/Beclin-1 in interplay between apoptosis and autophagy in
   oxaliplatin and bortezomib-induced cell death
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Oxaliplatin; Bortezomib; Mitochondria-dependent pathway; Bcl-xL;
   Beclin-1
ID ENDOPLASMIC-RETICULUM STRESS; CASPASE-MEDIATED CLEAVAGE; HUMAN
   COLON-CANCER; BCL-X-L; BECLIN 1; PHOSPHATIDYLINOSITOL 3-KINASE;
   PROTEASOME INHIBITION; COLORECTAL-CANCER; JNK1-MEDIATED PHOSPHORYLATION;
   REGULATES AUTOPHAGY
AB Recent studies indicate that a complex relationship exists between autophagy and apoptosis. In this study we investigated a regulatory relationship between autophagy and apoptosis in colorectal cancer cells utilizing molecular and biochemical approaches. For this study, human colorectal carcinoma HCT116 and CX-1 cells were treated with two chemotherapeutic agents-oxaliplatin, which induces apoptosis, and bortezomib, which triggers both apoptosis and autophagy. A combinatorial treatment of oxaliplatin and bortezomib caused a synergistic induction of apoptosis which was mediated through an increase in caspase activation. The combinational treatment of oxaliplatin and bortezomib promoted the JNK-Bcl-xL-Bax pathway which modulated the synergistic effect through the mitochondria-dependent apoptotic pathway. JNK signaling led to Bcl-xL phosphorylation at serine 62, oligomerization of Bax, alteration of mitochondrial membrane potential, and subsequent cytochrome c release. Overexpression of dominant-negative mutant of Bcl-xL (S62A), but not dominant-positive mutant of Bcl-xL (S62D), suppressed cytochrome c release and synergistic death effect. Interestingly, Bcl-xL also affected autophagy through alteration of interaction with Beclin-1. Beclin-1 was dissociated from Bcl-xL and initiated autophagy during treatment with oxaliplatin and bortezomib. However, activated caspase 8 cleaved Beclin-1 and suppressed Beclin-1-associated autophagy and enhanced apoptosis. A combinatorial treatment of oxaliplatin and bortezomib-induced Beclin-1 cleavage was abolished in Beclin-1 double mutant (D133AA/D149A) knock-in HCT116 cells, restoring the autophagy-promoting function of Beclin-1 and suppressing the apoptosis induced by the combination therapy. In addition, the combinatorial treatment significantly inhibited colorectal cancer xenografts' tumor growth. An understanding of the molecular mechanisms of crosstalk between apoptosis and autophagy will support the application of combinatorial treatment to colorectal cancer. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Kim, Seog-Young; Song, Xinxin; Bartlett, David L.; Lee, Yong J.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA.
   [Zhang, Lin; Lee, Yong J.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA.
RP Lee, YJ (corresponding author), Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA.
EM leeyj@upmc.edu
RI Zhang, Lin/A-7389-2009
OI Zhang, Lin/0000-0003-0018-3903
FU NCIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R01CA140554, R01CA106348, R01CA121105];  [P30CA047904]; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R01CA121105, R01CA140554, P30CA047904, R01CA106348] Funding Source: NIH
   RePORTER
FX This work was supported by the following grant: NCI grant R01CA140554
   (Y.J.L.), R01CA106348 (L.Z.) and R01CA121105 (L.Z.) This project used
   the UPCI Core Facility and was supported in part by award P30CA047904.
CR Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   American Cancer Society, 2013, CANC FACTS FIG 2013
   Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709
   Arango D, 2004, BRIT J CANCER, V91, P1931, DOI 10.1038/sj.bjc.6602215
   Basu A, 2003, FEBS LETT, V538, P41, DOI 10.1016/S0014-5793(03)00131-5
   Campbell RA, 2010, EUR J HAEMATOL, V84, P201, DOI 10.1111/j.1600-0609.2009.01384.x
   Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622
   Djavaheri-Mergny M, 2010, ONCOGENE, V29, P1717, DOI 10.1038/onc.2009.519
   Esteve Juan M, 2011, World J Biol Chem, V2, P232, DOI 10.4331/wjbc.v2.i10.232
   Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925
   Furuya N, 2005, AUTOPHAGY, V1, P46, DOI 10.4161/auto.1.1.1542
   Gordy C, 2012, PROTEIN CELL, V3, P17, DOI 10.1007/s13238-011-1127-x
   Goyle S, 2005, DIGEST SURG, V22, P401, DOI 10.1159/000091441
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   He W, 2013, ONCOGENE, P1
   Hill DS, 2009, CLIN CANCER RES, V15, P1192, DOI 10.1158/1078-0432.CCR-08-2150
   Hou W, 2010, AUTOPHAGY, V6, P891, DOI 10.4161/auto.6.7.13038
   Itakura E, 2008, MOL BIOL CELL, V19, P5360, DOI 10.1091/mbc.E08-01-0080
   Jia L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032584
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322
   Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061
   Labussiere M, 2008, ONCOL REP, V20, P1283, DOI 10.3892/or_00000142
   Li H, 2011, CANCER RES, V71, P3625, DOI 10.1158/0008-5472.CAN-10-4475
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Macdonald JS, 2001, NEW ENGL J MED, V345, P725, DOI 10.1056/NEJMoa010187
   Nannizzi S, 2010, CANCER CHEMOTH PHARM, V66, P547, DOI 10.1007/s00280-009-1195-2
   Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200
   Rajkumar SV, 2005, J CLIN ONCOL, V23, P630, DOI 10.1200/JCO.2005.11.030
   Richardson PG, 2006, ANNU REV MED, V57, P33, DOI 10.1146/annurev.med.57.042905.122625
   Rothenberg ML, 2001, J CLIN ONCOL, V19, P3801, DOI 10.1200/JCO.2001.19.18.3801
   Selimovic D, 2013, CELL SIGNAL, V25, P308, DOI 10.1016/j.cellsig.2012.10.004
   Sinha S, 2008, ONCOGENE, V27, pS137, DOI 10.1038/onc.2009.51
   Song XX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073654
   Song XX, 2012, MOL CANCER RES, V10, P1567, DOI 10.1158/1541-7786.MCR-12-0209-T
   Stein A, 2012, EXPERT OPIN PHARMACO, V13, P125, DOI 10.1517/14656566.2012.643870
   Suh KS, 2008, FUTURE ONCOL, V2, P149
   Sun QM, 2008, P NATL ACAD SCI USA, V105, P19211, DOI 10.1073/pnas.0810452105
   Ubersax JA, 2007, NAT REV MOL CELL BIO, V8, P530, DOI 10.1038/nrm2203
   Upreti M, 2008, J BIOL CHEM, V283, P35517, DOI 10.1074/jbc.M805019200
   Van Cutsem E, 2010, ANN ONCOL, V21, pv93, DOI 10.1093/annonc/mdq222
   Waters JP, 2013, J PATHOL, V230, P241, DOI 10.1002/path.4188
   Wei YJ, 2008, AUTOPHAGY, V4, P949, DOI 10.4161/auto.6788
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   Wirawan E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.16
   Xu Y, 2012, CANCER LETT, V314, P232, DOI 10.1016/j.canlet.2011.09.034
   Yoo JS, 2008, J CELL BIOCHEM, V103, P98, DOI 10.1002/jcb.21389
   Zalckvar E, 2009, AUTOPHAGY, V5, P720, DOI 10.4161/auto.5.5.8625
   Zalckvar E, 2009, EMBO REP, V10, P285, DOI 10.1038/embor.2008.246
   Zhai D, 2006, CELL DEATH DIFFER, V13, P1419, DOI 10.1038/sj.cdd.4401937
   Zhou FF, 2011, FEBS J, V278, P403, DOI 10.1111/j.1742-4658.2010.07965.x
NR 51
TC 44
Z9 52
U1 0
U2 24
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
EI 1873-2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD MAR 15
PY 2014
VL 88
IS 2
BP 178
EP 188
DI 10.1016/j.bcp.2014.01.027
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AD0DC
UT WOS:000332903600006
PM 24486574
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Wang, LJ
   Zhu, YR
   Wang, SW
   Zhao, S
AF Wang, Lijun
   Zhu, Yun-Rong
   Wang, Shaowei
   Zhao, Song
TI Autophagy inhibition sensitizes WYE-354-induced anti-colon cancer
   activity in vitro and in vivo
SO TUMOR BIOLOGY
LA English
DT Article
DE Colon cancer; mTORC1/2; WYE-354; Autophagy; Chemo-sensitization
ID COLORECTAL-CANCER; PRECLINICAL EVALUATION; INDUCED APOPTOSIS; MTOR;
   PROTEIN; PHOSPHORYLATION; CHEMOTHERAPY; STRATEGIES; THERAPY; TARGET
AB Mammalian target of rapamycin (mTOR) complex 1 (mTORC1) and mTORC2 are frequently dysregulated in human colon cancers. In the present study, we evaluated the potential anti-colon cancer cell activity by a novel mTORC1/2 dual inhibitor WYE-354. We showed that WYE-354 was anti-survival and anti-proliferative when adding to primary (patient-derived) and established (HCT-116, HT-29, Caco-2, LoVo, and DLD-1 lines) colon cancer cells. In addition, WYE-354 treatment activated caspase-dependent apoptosis in the colon cancer cells. Mechanistically, WYE-354 blocked mTORC1 and mTORC2 activation. Meanwhile, it also induced autophagy activation in the colon cancer cells. Autophagy inhibitors (bafilomycin A1 and 3-methyladenine), or shRNA-mediated knockdown of autophagy elements (Beclin-1 and ATG-5), remarkably sensitized WYE-354-mediated anti-colon cancer cell activity in vitro. Further studies showed that WYE-354 administration inhibited HT-29 xenograft growth in severe combined immunodeficient (SCID) mice. Importantly, its activity in vivo was further potentiated with co-administration of the autophagy inhibitor 3-MA. Phosphorylations of Akt (Ser-473) and S6 were also decreased in WYE-354-treated HT-29 xenografts. Together, these pre-clinical results demonstrate the potent anti-colon cancer cell activity by WYE-354, and its activity may be further augmented with autophagy inhibition.
C1 [Wang, Lijun; Wang, Shaowei] Tianjin Hosp, Dept Gen Surg, 406 Jiefang South Rd, Tianjin 300211, Peoples R China.
   [Zhu, Yun-Rong] Southeast Univ, Affiliated Jiangyin Hosp, Dept Orthoped, Coll Med, Jiangyin City 214400, Peoples R China.
   [Zhao, Song] Hebei Med Univ, Dept Pathophysiol, Shijiazhuang, Peoples R China.
RP Wang, SW (corresponding author), Tianjin Hosp, Dept Gen Surg, 406 Jiefang South Rd, Tianjin 300211, Peoples R China.
EM wangshaoweidr@sohu.com
CR Alcarraz-Vizan G, 2014, BBA-GEN SUBJECTS, V1840, P1634, DOI 10.1016/j.bbagen.2013.12.024
   Chen B, 2015, DNA CELL BIOL
   Chen MB, 2015, CARCINOGENESIS, V36, P1061, DOI 10.1093/carcin/bgv094
   Chen MB, 2014, CELL SIGNAL, V26, P102, DOI 10.1016/j.cellsig.2013.07.017
   Chen MB, 2013, CELL SIGNAL, V25, P1993, DOI 10.1016/j.cellsig.2013.05.026
   Chen MB, 2011, J CELL PHYSIOL, V226, P1915, DOI 10.1002/jcp.22522
   Chen XG, 2010, MOL CARCINOGEN, V49, P603, DOI 10.1002/mc.20628
   Dancey J, 2010, NAT REV CLIN ONCOL, V7, P209, DOI 10.1038/nrclinonc.2010.21
   Ekstrand AI, 2010, FAM CANCER, V9, P125, DOI 10.1007/s10689-009-9293-1
   Francipane MG, 2014, ONCOTARGET, V5, P49, DOI 10.18632/oncotarget.1548
   Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204
   Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Hubbard JM, 2015, NAT REV CLIN ONCOL, V12, P73, DOI 10.1038/nrclinonc.2014.233
   Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249
   Kerr D, 2003, NAT REV CANCER, V3, P615, DOI 10.1038/nrc1147
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim KH, 2014, NAT REV ENDOCRINOL
   Kuipers EJ, 2013, NAT REV CLIN ONCOL, V10, P130, DOI 10.1038/nrclinonc.2013.12
   Leake Isobel, 2014, Nat Rev Gastroenterol Hepatol, V11, P270, DOI 10.1038/nrgastro.2014.60
   Li C, 2015, CANCER BIOL THER, V16, P34, DOI 10.4161/15384047.2014.972274
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li Q, 2013, BIOCHEM BIOPH RES CO, V440, P701, DOI 10.1016/j.bbrc.2013.09.130
   Ma J, 2012, J BIOL CHEM, V287, P34149, DOI 10.1074/jbc.M112.382812
   Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   McCarthy N, 2013, NAT REV CANCER, V13, P297, DOI [10.1038/nrc3509, 10.1038/nrc3909]
   Metzger-Filho O, 2010, CURR CLIN PHARMACOL, V5, P166, DOI 10.2174/157488410791498716
   Moyer MP, 1996, IN VITRO CELL DEV-AN, V32, P315
   Palta M, 2014, NAT REV CLIN ONCOL, V11, P182, DOI 10.1038/nrclinonc.2014.43
   Pandurangan AK, 2013, ASIAN PAC J CANCER P, V14, P2201, DOI 10.7314/APJCP.2013.14.4.2201
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974
   Schmoll HJ, 2014, NAT REV CLIN ONCOL, V11, P79, DOI 10.1038/nrclinonc.2013.254
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Shimobayashi M, 2014, NAT REV MOL CELL BIO, V15, P155, DOI 10.1038/nrm3757
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Vilar E, 2011, MOL CANCER THER, V10, P395, DOI 10.1158/1535-7163.MCT-10-0905
   Yu K, 2009, CANCER RES, V69, P6232, DOI 10.1158/0008-5472.CAN-09-0299
   Zhang YJ, 2009, ANN SURG ONCOL, V16, P2617, DOI 10.1245/s10434-009-0555-9
   Zheng B, 2015, CANCER LETT, V357, P468, DOI 10.1016/j.canlet.2014.11.012
   Zhou HY, 2012, CHIN J CANCER, V31, P8, DOI 10.5732/cjc.011.10281
   Zhu YR, 2014, BIOCHEM BIOPH RES CO, V451, P112, DOI 10.1016/j.bbrc.2014.07.077
NR 43
TC 10
Z9 11
U1 0
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD SEP
PY 2016
VL 37
IS 9
BP 11743
EP 11752
DI 10.1007/s13277-016-5018-x
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EB0ZJ
UT WOS:000387075400018
PM 27020593
DA 2022-04-25
ER

PT J
AU Bhardwaj, M
   Cho, HJ
   Paul, S
   Jakhar, R
   Khan, I
   Lee, SJ
   Kim, BY
   Krishnan, M
   Khaket, TP
   Lee, HG
   Kang, SC
AF Bhardwaj, Monika
   Cho, Hee Jun
   Paul, Souren
   Jakhar, Rekha
   Khan, Imran
   Lee, Seon-Jin
   Kim, Bo-Yeon
   Krishnan, Manigandan
   Khaket, Tejinder Pal
   Lee, Hee Gu
   Kang, Sun Chul
TI Vitexin induces apoptosis by suppressing autophagy in multi-drug
   resistant colorectal cancer cells
SO ONCOTARGET
LA English
DT Article
DE apoptosis; autophagy; colorectal cancer; multidrug resistance; vitexin
ID HEAT-SHOCK; CARCINOMA CELLS; MDR1 GENE; IN-VITRO; EXPRESSION;
   TRANSPORTERS; CHEMORESISTANCE; SURVIVAL; FACTOR-1; FAMILY
AB Cancer treatment is limited due to the diverse multidrug resistance acquired by cancer cells and the collateral damage caused to adjacent normal cells by chemotherapy. The flavonoid compound vitexin exhibits anti-oxidative, anti-inflammatory and anti-tumor activity. This study elucidated the antitumor effects of vitexin and its underlying mechanisms in a multi-drug resistant human colon cancer cell line (HCT-116DR), which exhibits higher levels of multidrug-resistant protein 1 (MDR1) expression as compared with its parental cell line (HCT-116). Here, we observed that vitexin suppressed MDR-1 expression and activity in HCT-116DR cells and showed cytotoxic effect in HCT-116DR cells by inhibiting autophagy and inducing apoptosis in a concentration-dependent manner. Additionally, vitexin treatment caused cleavage of caspase-9 and caspase-3, and upregulated the expression of the pro-apoptotic proteins, BID and Bax. Moreover, the expression of autophagy-related proteins, such as ATG5, Beclin-1 and LC3-II, was markedly reduced by vitexin treatment. Furthermore, in vivo experiments showed that vitexin induced apoptosis and suppressed tumor growth in HCT-116DR xenograft model. These results revealed that vitexin induced apoptosis through suppression of autophagy in vitro and in vivo and provide insight into the therapeutic potential of vitexin for the treatment of chemo-resistant colorectal cancer.
C1 [Bhardwaj, Monika; Paul, Souren; Jakhar, Rekha; Khan, Imran; Krishnan, Manigandan; Khaket, Tejinder Pal; Kang, Sun Chul] Daegu Univ, Dept Biotechnol, Kyongsan, Kyoungbook, South Korea.
   [Cho, Hee Jun; Lee, Seon-Jin; Lee, Hee Gu] Korea Res Inst Biosci & Biotechnol, Immunotherapy Convergence Res Ctr, Daejeon, South Korea.
   [Lee, Seon-Jin; Kim, Bo-Yeon; Lee, Hee Gu] Univ Sci & Technol, Dept Biomol Sci, Daejeon, South Korea.
   [Kim, Bo-Yeon] Korea Res Inst Biosci & Biotechnol, Anticanc Agents Res Ctr, World Class Inst, Ochang, Cheongwon, South Korea.
RP Kang, SC (corresponding author), Daegu Univ, Dept Biotechnol, Kyongsan, Kyoungbook, South Korea.; Lee, HG (corresponding author), Korea Res Inst Biosci & Biotechnol, Immunotherapy Convergence Res Ctr, Daejeon, South Korea.; Lee, HG (corresponding author), Univ Sci & Technol, Dept Biomol Sci, Daejeon, South Korea.
EM hglee@kribb.re.kr; sckang@daegu.ac.kr
RI Shubhakaran, Khichar/AAH-2454-2020; Lee, Seon-Jin/AAJ-8258-2020; Khaket,
   Tej/I-6260-2015
OI Shubhakaran, Khichar/0000-0001-5515-7572; Manigandan,
   Krishnan/0000-0002-4998-4405; Lee, Seon-Jin/0000-0001-7214-7536
FU National Research Foundation (NRF) of South Korea [2016R1A2B4009227,
   2017R1A2B2005629, 2016H1D3A1938249, 2017R1D1A1B03036569]
FX This research was funded by the National Research Foundation (NRF) of
   South Korea (2016R1A2B4009227, 2017R1A2B2005629, 2016H1D3A1938249 and
   2017R1D1A1B03036569).
CR Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322
   An F, 2012, NEURAL REGEN RES, V7, P2565, DOI 10.3969/j.issn.1673-5374.2012.33.001
   AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289
   Bhardwaj M, 2017, ONCOTARGET, V5
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   CHIN KV, 1990, J BIOL CHEM, V265, P221
   Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020
   de Grouw EPLM, 2006, LEUKEMIA, V20, P750, DOI 10.1038/sj.leu.2404131
   de Thonel A, 2012, INT J BIOCHEM CELL B, V44, P1593, DOI 10.1016/j.biocel.2012.06.012
   Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317
   FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265
   Fu T, 2016, ACTA PHARMACOL SIN, V37, P505, DOI 10.1038/aps.2015.148
   GAITAN E, 1995, J CLIN ENDOCR METAB, V80, P1144, DOI 10.1210/jc.80.4.1144
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Halliwell B, 2008, ARCH BIOCHEM BIOPHYS, V476, P107, DOI 10.1016/j.abb.2008.01.028
   Ismail Hassan Fahmi, 2017, J Tradit Complement Med, V7, P452, DOI 10.1016/j.jtcme.2016.12.006
   KIOKA N, 1992, FEBS LETT, V301, P37, DOI 10.1016/0014-5793(92)80205-U
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Krishnamurthy K, 2012, P NATL ACAD SCI USA, V109, P9023, DOI 10.1073/pnas.1200731109
   Kumar A, 2015, FUTURE MED CHEM, V7, P1535, DOI 10.4155/fmc.15.88
   Lage H, 2016, RECENT RESULTS CANC, V209, P87, DOI 10.1007/978-3-319-42934-2_6
   LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957
   Lorin S, 2013, SEMIN CANCER BIOL, V23, P361, DOI 10.1016/j.semcancer.2013.06.007
   Meschini S, 2007, TOXICOL IN VITRO, V21, P197, DOI 10.1016/j.tiv.2006.09.007
   Meschini S, 2000, INT J CANCER, V87, P615, DOI 10.1002/1097-0215(20000901)87:5<615::AID-IJC1>3.0.CO;2-4
   Modok S, 2006, CURR OPIN PHARMACOL, V6, P350, DOI 10.1016/j.coph.2006.01.009
   Roos WP, 2016, NAT REV CANCER, V16, P20, DOI 10.1038/nrc.2015.2
   Schinkel AH, 2012, ADV DRUG DELIVER REV, V64, P138, DOI 10.1016/j.addr.2012.09.027
   Song JR, 2009, AUTOPHAGY, V5, P1131, DOI 10.4161/auto.5.8.9996
   Stein A, 2011, EUR J CANCER, V47, pS312, DOI 10.1016/S0959-8049(11)70183-6
   Sun YL, 2012, CHIN J CANCER, V31, P51, DOI 10.5732/cjc.011.10466
   Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984
   Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312
   Vilaboa NE, 2000, J BIOL CHEM, V275, P24970, DOI 10.1074/jbc.M909136199
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
   Zhou YJ, 2009, CLIN CANCER RES, V15, P5161, DOI 10.1158/1078-0432.CCR-09-0661
   Zhu Q, 2016, SCI REP-UK, V6, DOI 10.1038/srep19266
   Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3
NR 38
TC 40
Z9 43
U1 1
U2 7
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 9
PY 2018
VL 9
IS 3
BP 3278
EP 3291
DI 10.18632/oncotarget.22890
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FS3GU
UT WOS:000419669600027
PM 29423046
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Chok, KC
   Koh, RY
   Ng, MG
   Ng, PY
   Chye, SM
AF Chok, Kian Chung
   Koh, Rhun Yian
   Ng, Ming Guan
   Ng, Pei Ying
   Chye, Soi Moi
TI Melatonin Induces Autophagy via Reactive Oxygen Species-Mediated
   Endoplasmic Reticulum Stress Pathway in Colorectal Cancer Cells
SO MOLECULES
LA English
DT Article
DE melatonin; autophagy; colorectal cancer cells; reactive oxygen species;
   endoplasmic reticulum stress
ID PROLIFERATION; APOPTOSIS; CHAPERONE; SYSTEM; AMPK; AKT
AB Even though an increasing number of anticancer treatments have been discovered, the mortality rates of colorectal cancer (CRC) have still been high in the past few years. It has been discovered that melatonin has pro-apoptotic properties and counteracts inflammation, proliferation, angiogenesis, cell invasion, and cell migration. In previous studies, melatonin has been shown to have an anticancer effect in multiple tumors, including CRC, but the underlying mechanisms of melatonin action on CRC have not been fully explored. Thus, in this study, we investigated the role of autophagy pathways in CRC cells treated with melatonin. In vitro CRC cell models, HT-29, SW48, and Caco-2, were treated with melatonin. CRC cell death, oxidative stress, and autophagic vacuoles formation were induced by melatonin in a dose-dependent manner. Several autophagy pathways were examined, including the endoplasmic reticulum (ER) stress, 5 '-adenosine monophosphate-activated protein kinase (AMPK), phosphoinositide 3-kinase (PI3K), serine/threonine-specific protein kinase (Akt), and mammalian target of rapamycin (mTOR) signaling pathways. Our results showed that melatonin significantly induced autophagy via the ER stress pathway in CRC cells. In conclusion, melatonin demonstrated a potential as an anticancer drug for CRC.
C1 [Chok, Kian Chung; Ng, Ming Guan] Int Med Univ, Sch Hlth Sci, Kuala Lumpur 57000, Malaysia.
   [Koh, Rhun Yian; Chye, Soi Moi] Int Med Univ, Sch Hlth Sci, Div Biomed Sci & Biotechnol, Kuala Lumpur 57000, Malaysia.
   [Ng, Pei Ying] Int Med Univ, Sch Postgrad, Kuala Lumpur 57000, Malaysia.
RP Chye, SM (corresponding author), Int Med Univ, Sch Hlth Sci, Div Biomed Sci & Biotechnol, Kuala Lumpur 57000, Malaysia.
EM chok.kianchung@student.imu.edu.my; rhunyian_koh@imu.edu.my;
   NG.MINGGUAN@student.imu.edu.my; NG.PEIYING@student.imu.edu.my;
   chye_soimoi@imu.edu.my
OI Chok, Kian Chung/0000-0002-1440-4861
FU International Medical University [BMSc I-2020 (08), BMSc I-2019 (02),
   BMSc I-2018 (09)]
FX This research was funded by International Medical University, grant
   numbers are BMSc I-2020 (08), BMSc I-2019 (02) and BMSc I-2018 (09).
CR Akbarzadeh M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16940-y
   Araghi M, 2019, INT J CANCER, V144, P2992, DOI 10.1002/ijc.32055
   Basile V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053664
   Bejarano I, 2011, BASIC CLIN PHARMACOL, V108, P14, DOI 10.1111/j.1742-7843.2010.00619.x
   BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Carbajo-Pescador S, 2013, BRIT J CANCER, V109, P83, DOI 10.1038/bjc.2013.285
   Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005
   Chen F, 2020, BONE RES, V8, DOI 10.1038/s41413-020-0087-2
   Codogno P, 2012, NAT REV MOL CELL BIO, V13, P7, DOI 10.1038/nrm3249
   Ding WX, 2007, J BIOL CHEM, V282, P4702, DOI 10.1074/jbc.M609267200
   Dutta D, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2055-1
   Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664
   Farriol M, 2000, J APPL TOXICOL, V20, P21, DOI 10.1002/(SICI)1099-1263(200001/02)20:1<21::AID-JAT623>3.0.CO;2-M
   Feng Q, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01356
   Fernandez A, 2015, J PINEAL RES, V59, P292, DOI 10.1111/jpi.12264
   Gao Y, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12380
   Garg MB, 2012, BRIT J CANCER, V107, P1525, DOI 10.1038/bjc.2012.421
   Ghorbani-Anarkooli M., 2019, TEHRAN U MED J, V77, P26
   Gonzalez-Polo RA, 2005, J CELL SCI, V118, P3091, DOI 10.1242/jcs.02447
   Hahn-Windgassen A, 2005, J BIOL CHEM, V280, P32081, DOI 10.1074/jbc.M502876200
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
   Hayashi-Nishino M, 2009, NAT CELL BIOL, V11, P1433, DOI 10.1038/ncb1991
   Huang YY, 2021, J CELL MOL MED, V25, P1480, DOI 10.1111/jcmm.16237
   Jang M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30977-7
   Ji GY, 2021, MOL MED REP, V23, DOI 10.3892/mmr.2021.11826
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kasi R., 2020, CLIN CANC DRUGS, V7, P44, DOI 10.2174/2212697X06666191116151114
   Kim HS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092627
   Kim JY, 2012, ARCH ORAL BIOL, V57, P1018, DOI 10.1016/j.archoralbio.2012.04.005
   Kim SW, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59314-7
   Kontek R, 2014, TOXICOL IN VITRO, V28, P282, DOI 10.1016/j.tiv.2013.11.007
   Kranz P, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.369
   Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451
   Lee JH, 2018, J PINEAL RES, V65, DOI 10.1111/jpi.12519
   Lee WJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep10420
   Lepine S, 2011, CELL DEATH DIFFER, V18, P350, DOI 10.1038/cdd.2010.104
   Liu JY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33229-w
   Liu R, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471-2121-14-1
   Liu Y, 2017, INT J CLIN EXP MED, V10, P14109
   Lu YX, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.330
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Nagelkerke A, 2015, SEMIN CANCER BIOL, V31, P89, DOI 10.1016/j.semcancer.2014.05.004
   Paglin S, 2001, CANCER RES, V61, P439
   Pearce A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184360
   Plaimee P, 2015, CELL PROLIFERAT, V48, P67, DOI 10.1111/cpr.12158
   Rodolfo C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167672
   Ruiz L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0603-0
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943
   Talib WH, 2018, MOLECULES, V23, DOI 10.3390/molecules23030518
   Thome MP, 2016, J CELL SCI, V129, P4622, DOI 10.1242/jcs.195057
   Tiong YL, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8070198
   Tripathi DN, 2013, P NATL ACAD SCI USA, V110, pE2950, DOI 10.1073/pnas.1307736110
   Van Cutsem E, 2014, ANN ONCOL, V25, P1, DOI 10.1093/annonc/mdu260
   Wang JS, 2012, J PINEAL RES, V53, P77, DOI 10.1111/j.1600-079X.2012.00973.x
   Wang SY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0171-5
   Williams DB, 2006, J CELL SCI, V119, P615, DOI 10.1242/jcs.02856
   Xie QQ, 2020, TRANSL ONCOL, V13, DOI 10.1016/j.tranon.2020.100871
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
   Yan GG, 2020, BIOMED PHARMACOTHER, V123, DOI 10.1016/j.biopha.2020.109811
   Yao WS, 2020, BIOCHEM PHARMACOL, V171, DOI 10.1016/j.bcp.2019.113680
   Yoon YM, 2016, SCI REP-UK, V6, DOI 10.1038/srep39838
   Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103
   Zhang HM, 2014, J PINEAL RES, V57, P131, DOI 10.1111/jpi.12162
NR 65
TC 2
Z9 2
U1 7
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD AUG
PY 2021
VL 26
IS 16
AR 5038
DI 10.3390/molecules26165038
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA UH7UD
UT WOS:000690129900001
PM 34443626
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Pandurangan, AK
   Ismail, S
   Esa, NM
   Munusamy, MA
AF Pandurangan, Ashok Kumar
   Ismail, Salmiah
   Esa, Norhaizan Mohd
   Munusamy, Murugan A.
TI Inositol-6 phosphate inhibits the mTOR pathway and induces
   autophagy-mediated death in HT-29 colon cancer cells
SO ARCHIVES OF MEDICAL SCIENCE
LA English
DT Article
DE inositol-6-phosphate; colorectal cancer; autophagy; mammalian target of
   rapamycin; apoptosis
ID COLORECTAL-CANCER; RICE-BRAN; PHYTIC ACID; SIGNALING PATHWAY; APOPTOSIS;
   PI3K/AKT/MTOR; INVOLVEMENT; ARREST; IP6
AB Introduction: Colorectal cancer (CRC) is common, with a worldwide incidence estimated at more than 1 million cases annually. Therefore, the search for agents for CRC treatment is highly warranted. Inosito1-6 phosphate (IP6) is enriched in rice bran and possesses many beneficial effects. In the present study the effect of IP6 on autophagy-mediated death by modulating the mTOR pathway in HT-29 colon cancer cells was studied.
   Material and methods: Autophagy was assessed by acridine orange (AO) staining, transmission electron microscopy, and western blotting to detect LC3-II and Beclin 1. Akt/mTOR signaling protein expression was also analyzed by western blotting. Apoptosis was analyzed by annexin V staining.
   Results: Incubation of cells with IP6 resulted in downregulation of the p-Akt at 3h. Along with that confocal microscopic analysis of p-AKT, IP6 administration resulted that a diminished expression of p-Akt. mTOR pathway regulates autophagy and incubation with IP6 to HT-29 cells showed decreased expression of p-70S6Kinase, 4-EBP-1 in a time-dependent manner. Inositol-6 phosphate (10 Ng/ml, 24 and 48 h) induced autophagic vesicles, as confirmed by AO staining and transmission electron microscopy. We also found increased expression of LC3-II and Beclin 1 in a time-dependent manner after incubation with IP6. Furthermore, IP6 induced apoptosis, as revealed by annexin V staining.
   Conclusions: Our results clearly indicate that IP6 induces autophagy by inhibiting the Akt/mTOR pathway.
C1 [Pandurangan, Ashok Kumar] Univ Malaya, Fac Med, Dept Pharmacol, Kuala Lumpur, Malaysia.
   [Pandurangan, Ashok Kumar; Ismail, Salmiah; Esa, Norhaizan Mohd] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Nutr & Dietet, Serdang 43400, Selangor, Malaysia.
   [Munusamy, Murugan A.] King Saud Univ, Coll Sci, Dept Bot & Microbiol, Riyadh, Saudi Arabia.
RP Esa, NM (corresponding author), Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Nutr & Dietet, Serdang 43400, Selangor, Malaysia.
EM nhaizan@upm.edu.my
RI Mohd.-Esa, Norhaizan/ABA-2783-2021; Pandurangan, Ashok Kumar/M-7335-2013
OI Pandurangan, Ashok Kumar/0000-0003-2824-1757
FU Fundamental Research Grant Scheme (FRGS), Malaysia [5524455]; Deanship
   of Scientific Research at King Saud UniversityKing Saud University
   [RG-1435-057]
FX Dr. Norhaizan greatly acknowledges the Fundamental Research Grant Scheme
   (FRGS), Malaysia (Grant Number: 5524455) for financial assistance. The
   authors would like to extend their sincere appreciation to the Deanship
   of Scientific Research at King Saud University for funding this work
   (Research Group No. RG-1435-057).
CR Chan WY, 2003, TOXICOLOGY, V186, P191, DOI 10.1016/S0300-483X(02)00746-1
   Din FVN, 2012, GASTROENTEROLOGY, V142, P1504, DOI 10.1053/j.gastro.2012.02.050
   Fujishita T, 2008, P NATL ACAD SCI USA, V105, P13544, DOI 10.1073/pnas.0800041105
   Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008
   Huerta S, 2006, AM J SURG, V191, P517, DOI 10.1016/j.amjsurg.2005.11.009
   Irani S, 2015, ARCH MED SCI, V11, P1286, DOI 10.5114/aoms.2015.48221
   Jariwalla RJ, 2001, DRUG EXP CLIN RES, V27, P17
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Lai MD, 2007, CURR GENOMICS, V8, P43
   Lai YJ, 2016, MOLECULES, V21, DOI 10.3390/molecules21050553
   Lee Y, 2014, INT J ONCOL, V44, P1599, DOI 10.3892/ijo.2014.2339
   Lin L, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.985913
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Norazalina S, 2010, EXP TOXICOL PATHOL, V62, P259, DOI 10.1016/j.etp.2009.04.002
   Norazalina S, 2011, AFR J BIOTECHNOL, V10, P16646, DOI 10.5897/AJB11.699
   Nurul-Husna S, 2010, J MED PLANTS RES, V4, P2283
   Pandurangan AK, 2014, HUM EXP TOXICOL, V33, P1176, DOI 10.1177/0960327114522502
   Pandurangan AK, 2013, ASIAN PAC J CANCER P, V14, P5543, DOI 10.7314/APJCP.2013.14.10.5543
   Pandurangan AK, 2013, J ENVIRON PATHOL TOX, V32, P131, DOI 10.1615/JEnvironPatholToxicolOncol.2013007522
   Pandurangan AK, 2013, ASIAN PAC J CANCER P, V14, P2201, DOI 10.7314/APJCP.2013.14.4.2201
   Parkhitko AA, 2013, BIOCHEMISTRY-MOSCOW+, V78, P355, DOI 10.1134/S0006297913040044
   Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2
   Saadatdoust Z, 2015, J NUTR BIOCHEM, V26, P1547, DOI 10.1016/j.jnutbio.2015.07.024
   Sadagopan SKA, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0266-y
   Shafie NH, 2013, INT J MOL SCI, V14, P23545, DOI 10.3390/ijms141223545
   Shafie NH, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/681027
   Shamsuddin AM, 2002, INT J FOOD SCI TECH, V37, P769, DOI 10.1046/j.1365-2621.2002.00620.x
   Sheng WY, 2015, ARCH MED SCI, V11, P699, DOI 10.5114/aoms.2015.53288
   Suh Y, 2010, CARCINOGENESIS, V31, P1424, DOI 10.1093/carcin/bgq115
   Towers CG, 2016, EBIOMEDICINE, V14, P15, DOI 10.1016/j.ebiom.2016.10.034
   Wani ZA, 2016, FOOD CHEM TOXICOL, V87, P1, DOI 10.1016/j.fct.2015.11.016
   Wee Lee Heng, 2015, Asian Pac J Cancer Prev, V16, P6549
   Wu DS, 2016, MOLECULES, V21, DOI 10.3390/molecules21081001
   Wu JQ, 2017, J CELL MOL MED, V21, P1171, DOI 10.1111/jcmm.13049
   Zhang CC, 2015, ARCH MED SCI, V11, P1081, DOI 10.5114/aoms.2015.54865
NR 35
TC 11
Z9 14
U1 2
U2 5
PU TERMEDIA PUBLISHING HOUSE LTD
PI POZNAN
PA KLEEBERGA ST 2, POZNAN, 61-615, POLAND
SN 1734-1922
EI 1896-9151
J9 ARCH MED SCI
JI Arch. Med. Sci.
PD OCT
PY 2018
VL 14
IS 6
BP 1281
EP 1288
DI 10.5114/aoms.2018.76935
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX8NY
UT WOS:000448045000009
PM 30393482
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Zhan, Y
   Gong, K
   Chen, C
   Wang, HQ
   Li, WH
AF Zhan, Yao
   Gong, Ke
   Chen, Chao
   Wang, Haiqing
   Li, Wenhua
TI P38 MAP kinase functions as a switch in MS-275-induced reactive oxygen
   species-dependent autophagy and apoptosis in Human colon Cancer cells
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE MS-275; Reactive oxygen species; Autophagy; Apoptosis; p38; Free
   radicals
ID HISTONE DEACETYLASE INHIBITOR; VIVO ANTITUMOR-ACTIVITY;
   HEPATOCELLULAR-CARCINOMA; LEUKEMIA-CELLS; PROTEIN; MS-275; DEATH;
   GROWTH; DEGRADATION; ACTIVATION
AB MS-275 is a synthetic benzamide derivative of the histone deacetylase inhibitor and is currently in phase I/II clinical trials. Many reports have shown that the anti-tumor activity of MS-275 in several types of cancer is mainly attributable to its capacity to induce the apoptotic death of tumor cells. It remains unclear if autophagy is involved in MS-275 treatment of cancer cells. Here, we first show that MS-275 induces human colon cancer cell HCT116 autophagy as well as apoptosis. Short-term treatment (24 h) induced HCT116 cells to undergo autophagy with dependence on intracellular reactive oxygen species production and ERK activation. The activated reactive oxygen species/ERK signal promoted Atg7 protein expression, which triggered MS-275-induced cancer cell autophagy. However, after prolonged treatment with MS-275 (over 48 h), autophagic cells turned apoptotic, which was also dependent on reactive oxygen species generation. Interestingly, we found that p38 MAP kinase played a vital role in the switch from autophagy to apoptosis in MS-275-induced human colon cancer cells. High expression of p38 induced cell autophagy, but low expression resulted in apoptosis. In addition, observations in vivo are strongly consistent with the in vitro results. Therefore, these findings extend our understanding of the action of MS-275 in inducing cancer cell death and suggest that it may be a promising clinical chemotherapeutic agent with multiple effects. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Zhan, Yao; Gong, Ke; Chen, Chao; Wang, Haiqing; Li, Wenhua] Wuhan Univ, Coll Life Sci, Wuhan 430072, Peoples R China.
RP Li, WH (corresponding author), Wuhan Univ, Coll Life Sci, Wuhan 430072, Peoples R China.
EM whli@whu.edu.cn
FU National Basic Research Program of ChinaNational Basic Research Program
   of China [2010CB529800]; National Nature Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81072151];
   Chinese 111 ProjectMinistry of Education, China - 111 Project [B06018];
   Major Scientific and Technological Special Project for the "Significant
   Creation of New Drugs" [2011ZX09102-001-32, 2010ZX09401]
FX This work was supported by the National Basic Research Program of China
   (2010CB529800), the National Nature Science Foundation of China
   (81072151), the Chinese 111 Project (B06018), and the Major Scientific
   and Technological Special Project for the "Significant Creation of New
   Drugs" (2011ZX09102-001-32, 2010ZX09401).
CR Acharya AB, 2004, ARCH DIS CHILD-FETAL, V89, pF17, DOI 10.1136/fn.89.1.F17
   Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705
   Bauvy C, 2001, EXP CELL RES, V268, P139, DOI 10.1006/excr.2001.5285
   Berger SL, 2001, ONCOGENE, V20, P3007, DOI 10.1038/sj.onc.1204324
   Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78
   Cecconi F, 2008, DEV CELL, V15, P344, DOI 10.1016/j.devcel.2008.08.012
   Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   Donadelli M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.36
   Dubey P, 2003, P NATL ACAD SCI USA, V100, P1232, DOI 10.1073/pnas.0337418100
   Edinger AL, 2003, CANCER CELL, V4, P422, DOI 10.1016/S1535-6108(03)00306-4
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Hanajiri K, 2005, J GASTROENTEROL, V40, P1005, DOI 10.1007/s00535-005-1667-z
   Haughian JM, 2009, INT J CANCER, V125, P2556, DOI 10.1002/ijc.24633
   Hess-Stumpp H, 2007, INT J BIOCHEM CELL B, V39, P1388, DOI 10.1016/j.biocel.2007.02.009
   Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283
   Jaboin J, 2002, CANCER RES, V62, P6108
   Jemal M, 2003, J CHROMATOGR B, V795, P273, DOI 10.1016/S1570-0232(03)00589-0
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kirkegaard K, 2004, NAT REV MICROBIOL, V2, P301, DOI 10.1038/nrmicro865
   KISEN GO, 1993, CARCINOGENESIS, V14, P2501, DOI 10.1093/carcin/14.12.2501
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Klionsky DJ, 2005, AUTOPHAGY, V1, P65, DOI 10.4161/auto.1.2.1899
   Kouraklis G., 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P477, DOI 10.2174/1568011023353921
   Lee BI, 2001, CANCER RES, V61, P931
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Liang C, 2010, CELL DEATH DIFFER, V17, P1807, DOI 10.1038/cdd.2010.115
   Liu CY, 2011, INT J CANCER, V129, P1519, DOI 10.1002/ijc.25817
   Liu J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-183
   Lucas DM, 2004, LEUKEMIA, V18, P1207, DOI 10.1038/sj.leu.2403388
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079
   McLean L, 2008, INT J CANCER, V122, P1665, DOI 10.1002/ijc.23244
   Merghoub T, 2001, BLOOD CELL MOL DIS, V27, P231, DOI 10.1006/bcmd.2001.0385
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966
   Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0
   Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200
   Park MA, 2008, CANCER BIOL THER, V7, P1648, DOI 10.4161/cbt.7.10.6623
   Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004
   Pisani P, 1999, INT J CANCER, V83, P870
   Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6
   Reiners JJ, 2010, AUTOPHAGY, V6, P7, DOI 10.4161/auto.6.1.10220
   Rosato RR, 2003, CANCER RES, V63, P3637
   Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592
   Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836
   Walkinshaw DR, 2008, CURR ONCOL, V15, P237
   Wallace MB, 2003, AM J RESP CRIT CARE, V167, P1670, DOI 10.1164/rccm.200211-1297OC
   Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232
NR 52
TC 52
Z9 52
U1 1
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD AUG 1
PY 2012
VL 53
IS 3
BP 532
EP 543
DI 10.1016/j.freeradbiomed.2012.05.018
PG 12
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 986DP
UT WOS:000307321500015
PM 22634147
DA 2022-04-25
ER

PT J
AU Gil, J
   Ramsey, D
   Pawlowski, P
   Szmida, E
   Leszczynski, P
   Bebenek, M
   Sasiadek, MM
AF Gil, Justyna
   Ramsey, David
   Pawlowski, Pawel
   Szmida, Elzbieta
   Leszczynski, Przemyslaw
   Bebenek, Marek
   Sasiadek, Maria M.
TI The Influence of Tumor Microenvironment on ATG4D Gene Expression in
   Colorectal Cancer Patients
SO MEDICAL ONCOLOGY
LA English
DT Article
DE Colorectal cancer; Autophagy; ATG; LC3; GABARAP; Relative expression
ID DOWN-REGULATION; AUTOPHAGY; LC3; APOPTOSIS; EFFICACY; ROLES
AB Despite great progress in research on the subject, the involvement of autophagy in colorectal cancer (CRC) pathogenesis (initiation, progression, metastasis) remains obscure and controversial. Autophagy is a catabolic process, fundamental to cell viability and connected with degradation/recycling of proteins and organelles. In this study, we aimed at investigating the relative expression level of mRNA via Real-Time PCR of 16 chosen genes belonging to Atg8 mammalian orthologs and their conjugation system, comprising GABARAP, GABARAPL1, GABARAPL2, MAP1LC3A, MAP1LC3B, MAP1LC3C, ATG3, ATG7, ATG10, ATG4A, ATG4B, ATG4C, ATG4D, and three genes encoding proteins building the multimeric ATG16L1 complex, namely ATG5, ATG12, and ATG16L1, in 73 colorectal tumors and paired adjacent normal colon mucosa. Our study demonstrated the relative downregulation of all examined genes in CRC tissues in comparison to adjacent noncancerous mucosa, with the highest rate of expression in both tumor and non-tumor tissues observed for GAPARBPL2 and the lowest for MAP1LC3C. Moreover, in patients with advanced-stage tumors and high values of regional lymph nodes, statistically significant downregulation of ATG4D expression in adjacent normal cells was observed. Our study confirms the role of autophagy genes as cancer suppressors in colorectal carcinogenesis. Furthermore, in regard to the ATG4D gene, we observed the influence of tumor microenvironments on gene expression in adjacent colon mucosa.
C1 [Gil, Justyna; Pawlowski, Pawel; Szmida, Elzbieta; Sasiadek, Maria M.] Wroclaw Med Univ, Dept Genet, PL-50368 Wroclaw, Poland.
   [Ramsey, David] Wroclaw Univ Technol, Dept Operat Res, PL-50372 Wroclaw, Poland.
   [Leszczynski, Przemyslaw] Wroclaw Med Univ, Dept Biol & Med Parasitol, PL-50345 Wroclaw, Poland.
   [Bebenek, Marek] Lower Silesian Oncol Ctr, Dept Surg Oncol 1, PL-53413 Wroclaw, Poland.
RP Gil, J (corresponding author), Wroclaw Med Univ, Dept Genet, PL-50368 Wroclaw, Poland.
EM justyna.gil@umed.wroc.pl; david.ramsey@pwr.edu.pl; paweltoxic@tlen.pl;
   elzbieta.szmida@umed.wroc.pl; przemyslaw.leszczynski@umed.wroc.pl;
   marek.bebenek@onkomed.pl; maria.sasiadek@umed.wroc.pl
RI /L-5618-2019
OI /0000-0003-0991-7686; Sasiadek, Maria/0000-0002-7599-7074; Bebenek,
   Marek/0000-0001-7716-5960; Szmida, Elzbieta/0000-0003-3108-0165;
   Leszczynski, Przemyslaw/0000-0002-4181-4997; Ramsey,
   David/0000-0002-7186-1436
FU Narodowe Centrum NaukiNational Science Centre, Poland
   [DEC-2012/07/D/NZ5/04305] Funding Source: Medline
CR Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204
   Betin VMS, 2009, J CELL SCI, V122, P2554, DOI 10.1242/jcs.046250
   Bortnik S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071496
   Chang YT, 2011, EUR J CLIN INVEST, V41, P84, DOI 10.1111/j.1365-2362.2010.02383.x
   Chen ZH, 2013, DIGEST DIS SCI, V58, P2887, DOI 10.1007/s10620-013-2732-8
   Cho DH, 2012, ANTICANCER RES, V32, P4091
   Choi JH, 2014, GASTROENT RES PRACT, V2014, DOI 10.1155/2014/179586
   Costa JR, 2016, ONCOTARGET, V7, P41203, DOI 10.18632/oncotarget.9754
   Dower CM, 2018, AUTOPHAGY, V14, P1110, DOI 10.1080/15548627.2018.1450020
   El Andaloussi A, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.41
   Galluzzi L, 2017, EMBO J, V36, P1811, DOI 10.15252/embj.201796697
   Gil J, 2017, MED ONCOL, V34, DOI 10.1007/s12032-016-0869-y
   Gil J, 2016, BIOMARK MED, V10, P1081, DOI 10.2217/bmm-2016-0083
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   Hervouet E, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1761-4
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Klionsky DJ, 2010, AUTOPHAGY, V6, P438, DOI 10.4161/auto.6.4.12244
   Le Grand JN, 2011, AUTOPHAGY, V7, P1098, DOI 10.4161/auto.7.10.15904
   MIAO Y, HEPATOGASTROENTEROLO, V57, P257
   Mizushima N, 2010, NAT CELL BIOL, V12, P823, DOI 10.1038/ncb0910-823
   Murai M, 2005, CLIN CANCER RES, V11, P1021
   Nguyen TG, 2014, ASSAY DRUG DEV TECHN, V12, P176, DOI 10.1089/adt.2013.561
   Saha S, 2018, BIOMED PHARMACOTHER, V104, P485, DOI 10.1016/j.biopha.2018.05.007
   Schaaf MBE, 2016, FASEB J, V30, P3961, DOI 10.1096/fj.201600698R
   Shpilka T, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-7-226
   Wang L, 2015, CANCER BIOL THER, V16, P383, DOI 10.1080/15384047.2014.1002331
   Wild P, 2014, J CELL SCI, V127, P3, DOI 10.1242/jcs.140426
   Yang MP, 2015, ONCOTARGET, V6, P7084, DOI 10.18632/oncotarget.3054
   Yoshioka A, 2008, INT J ONCOL, V33, P461, DOI 10.3892/ijo_00000028
   Yu ZQ, 2012, AUTOPHAGY, V8, P883, DOI 10.4161/auto.19652
   Zhang L, 2016, CANCER LETT, V373, P19, DOI 10.1016/j.canlet.2016.01.022
NR 33
TC 21
Z9 21
U1 1
U2 14
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1357-0560
EI 1559-131X
J9 MED ONCOL
JI Med. Oncol.
PD DEC
PY 2018
VL 35
IS 12
AR 159
DI 10.1007/s12032-018-1220-6
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GY7YP
UT WOS:000448834300002
PM 30374741
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Bednarczyk, M
   Muc-Wierzgon, M
   Waniczek, D
   Fatyga, E
   Klakla, K
   Mazurek, U
   Wierzgon, J
AF Bednarczyk, M.
   Muc-Wierzgon, M.
   Waniczek, D.
   Fatyga, E.
   Klakla, K.
   Mazurek, U.
   Wierzgon, J.
TI AUTOPHAGY-RELATED GENE EXPRESSION IN COLORECTAL CANCER PATIENTS
SO JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
LA English
DT Article
DE autophagy; autophagy-related genes; colorectal cancer; healthy tissues;
   clinical stages
ID MITOCHONDRIAL; ROLES; DEATH
AB There is evidence that autophagy can play a dual role in tumor cells - as a tumor suppressor, and a process involved in tumor cell survival. The aim of this work was to assess the expression of the genes engaged in the autophagy process in biopsies taken from the colon, confirmed as adenocarcinoma, and normal tissue and to relate them to the clinical stage of the tumor. A total of 20 pairs of surgically removed tumors and healthy (marginal) tissue samples from colorectal cancer patients at clinical stages (CS) I-IV were analyzed. Gene expression profile analysis was performed using HG-U133A microarrays. Differentially expressed genes were identified, using the PL-Grid Infrastructure. Only for CSI, there were two specific genes: FOXO1 and BNIP1; further in CSII - LAMP2, MET and BCL2L, in CSIII HIF1A and 2 ID mRNAs for HGF and 18 genes were specific for CSIV in comparison to controls. PINK1 is the only gene that differentiates all transcriptome groups from controls. Furthermore, examination of the expression of genes associated with the autophagy process may allow for better knowledge and understanding of the processes occurring during the development of colon cancer. The presented genes may be used as prognostic markers of clinical stages of colorectal cancer, contributing to the development of new lines of therapy focused on reducing metastasis of the primary tumor.
C1 [Bednarczyk, M.; Mazurek, U.] Med Univ Silesia, Sch Pharm, Dept Mol Biol, Div Lab Med Sosnowiec, Sosnowiec, Poland.
   [Bednarczyk, M.; Muc-Wierzgon, M.; Fatyga, E.; Klakla, K.] Med Univ Silesia, Sch Publ Hlth, Dept Internal Med, Zeromskiego 7 St, PL-41902 Bytom, Poland.
   [Waniczek, D.] Med Univ Silesia, Chair Gen Colorectal & Polytrauma Surg, Dept Propedeut Surg, SHS Katowice, Bytom, Poland.
   [Wierzgon, J.] Maria Sklodowska Curie Mem Canc Ctr, Dept Oncol & Reconstruct Surg, Gliwice, Poland.
   [Wierzgon, J.] Inst Oncol, Gliwice Branch, Gliwice, Poland.
RP Muc-Wierzgon, M (corresponding author), Med Univ Silesia, Sch Publ Hlth, Dept Internal Med, Zeromskiego 7 St, PL-41902 Bytom, Poland.
EM mwierzgon@sum.edu.plm
RI Waniczek, Dariusz/ABD-1692-2020
OI Waniczek, Dariusz/0000-0002-0410-8604; Muc-Wierzgon,
   Malgorzata/0000-0001-6562-7072; Wierzgon, Janusz/0000-0001-5746-5720;
   Fatyga, Edyta/0000-0003-0389-206X; Bednarczyk,
   Martyna/0000-0001-8360-9126
CR Arena G, 2013, CELL DEATH DIFFER, V20, P920, DOI 10.1038/cdd.2013.19
   Badadani M., 2012, ISRN CELL BIOL, V2012, P1, DOI DOI 10.5402/2012/927064
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Braczkowski R, 2001, J BIOL REG HOMEOS AG, V15, P366
   Chen ZH, 2013, DIGEST DIS SCI, V58, P2887, DOI 10.1007/s10620-013-2732-8
   Feng YC, 2014, CELL RES, V24, P24, DOI 10.1038/cr.2013.168
   Gil J, 2016, BIOMARK MED, V10, P1081, DOI 10.2217/bmm-2016-0083
   Groulx JF, 2012, AUTOPHAGY, V8, P893, DOI 10.4161/auto.19738
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   Ivankovic D, 2016, J NEUROCHEM, V136, P388, DOI 10.1111/jnc.13412
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Lockshin RA, 2004, INT J BIOCHEM CELL B, V36, P2405, DOI 10.1016/j.biocel.2004.04.011
   Nagelkerke A, 2015, SEMIN CANCER BIOL, V31, P89, DOI 10.1016/j.semcancer.2014.05.004
   Rosenfeldt MT, 2011, CARCINOGENESIS, V32, P955, DOI 10.1093/carcin/bgr031
   Ye LC, 2015, J BIOL REG HOMEOS AG, V29, P307
NR 15
TC 5
Z9 6
U1 0
U2 2
PU BIOLIFE SAS
PI SILVA MARINA (TE)
PA VIA S STEFANO 39 BIS, 64029 SILVA MARINA (TE), ITALY
SN 0393-974X
EI 1724-6083
J9 J BIOL REG HOMEOS AG
JI J. Biol. Regul. Homeost. Agents
PD OCT-DEC
PY 2017
VL 31
IS 4
BP 923
EP 927
PG 5
WC Endocrinology & Metabolism; Immunology; Medicine, Research &
   Experimental; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Immunology; Research & Experimental
   Medicine; Physiology
GA FX6HP
UT WOS:000426184600009
PM 29254294
DA 2022-04-25
ER

PT J
AU Li, WY
   Liu, C
   Huang, ZL
   Shi, L
   Zhong, CAQ
   Zhou, WW
   Meng, PP
   Li, ZY
   Wang, SY
   Luo, FH
   Yan, JH
   Wu, T
AF Li, Wanyun
   Liu, Cong
   Huang, Zilan
   Shi, Lei
   Zhong, Chuanqi
   Zhou, Wenwen
   Meng, Peipei
   Li, Zhenyu
   Wang, Shengyu
   Luo, Fanghong
   Yan, Jianghua
   Wu, Ting
TI AKR1B10 negatively regulates autophagy through reducing GAPDH upon
   glucose starvation in colon cancer
SO JOURNAL OF CELL SCIENCE
LA English
DT Article
DE Neuropilin1; NRP1; Aldo-keto reductase family 1 B10; AKR1B10; Glucose
   starvation; Glyceraldehyde-3-phosphate dehydrogenase; GAPDH; Nuclear
   translocation; Reductase activity
ID KETO REDUCTASE 1B10; COLORECTAL-CANCER; CORTICAL-NEURONS; NRF2
   ACTIVATION; RETENTION TIME; CELLS REVEALS; MEMBER B10; IDENTIFICATION;
   NEUROPILIN-1; TUMOR
AB Autophagy is considered to be an important switch for facilitating normal to malignant cell transformation during colorectal cancer development. Consistent with other reports, we found that the membrane receptor Neuropilin1 (NRP1) is greatly upregulated in colon cancer cells that underwent autophagy upon glucose deprivation. However, the mechanism underlying NRP1 regulation of autophagy is unknown. We found that knockdown of NRP1 inhibits autophagy and largely upregulates the expression of aldo-keto reductase family 1 B10 (AKR1B10). Moreover, we demonstrated that AKR1B10 interacts with and inhibits the nuclear importation of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and then subsequently represses autophagy. Interestingly, we also found that an NADPH-dependent reduction reaction could be induced when AKR1B10 interacts with GAPDH, and the reductase activity of AKR1B10 is important for its repression of autophagy. Together, our findings unravel a novel mechanism of NRP1 in regulating autophagy through AKR1B10.
C1 [Li, Wanyun; Liu, Cong; Huang, Zilan; Shi, Lei; Zhou, Wenwen; Meng, Peipei; Li, Zhenyu; Wang, Shengyu; Luo, Fanghong; Yan, Jianghua; Wu, Ting] Xiamen Univ, Sch Med, Canc Res Ctr, Xiamen 361000, Peoples R China.
   [Zhong, Chuanqi] Xiamen Univ, Sch Life Sci, Innovat Ctr Cellular Signaling Network, State Key Lab Cellular Stress Biol, Xiamen 361000, Peoples R China.
   [Wu, Ting] Xiamen Univ, Sch Med, Dept Basic Med, Xiamen 361000, Peoples R China.
   [Wu, Ting] Xiamen Univ, Xiangan Hosp, Sch Med, Res Ctr Retroperitoneal Tumor Comm Oncol Soc Chin, Xiamen 361000, Peoples R China.
   [Wu, Ting] Joint Lab Xiamen Univ Sch Med & Shanghai Jiangxia, Xiamen 361000, Peoples R China.
RP Luo, FH; Yan, JH; Wu, T (corresponding author), Xiamen Univ, Sch Med, Canc Res Ctr, Xiamen 361000, Peoples R China.; Wu, T (corresponding author), Xiamen Univ, Sch Med, Dept Basic Med, Xiamen 361000, Peoples R China.; Wu, T (corresponding author), Xiamen Univ, Xiangan Hosp, Sch Med, Res Ctr Retroperitoneal Tumor Comm Oncol Soc Chin, Xiamen 361000, Peoples R China.; Wu, T (corresponding author), Joint Lab Xiamen Univ Sch Med & Shanghai Jiangxia, Xiamen 361000, Peoples R China.
EM luofanghong@xmu.edu.cn; jhyan@xmu.edu.cn; wuting78@189.cn
OI Liu, Cong/0000-0003-1927-5912; Shi, Lei/0000-0002-3378-1590
FU National Basic Research Program of China (973 Program)National Basic
   Research Program of China [2015CB553800]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [31401180, 81773770]; Special Fund of Public Welfare Research Institutes
   in Fujian Province [2018parallel toR1036-1, 2018parallel toR1036-3,
   2019R1001-2]; Shanghai Jiangxia Blood Technology Co., Ltd
   [0070-K81B0019]
FX This work was supported by the National Basic Research Program of China
   (973 Program 2015CB553800), the National Natural Science Foundation of
   China (31401180 and 81773770); the Special Fund of Public Welfare
   Research Institutes in Fujian Province (2018 parallel to R1036-1, 2018
   parallel to R1036-3 and 2019R1001-2); and the research fund of Shanghai
   Jiangxia Blood Technology Co., Ltd (0070-K81B0019).
CR Agyeman AS, 2012, BREAST CANCER RES TR, V132, P175, DOI 10.1007/s10549-011-1536-9
   Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Arhzaouy K, 2019, AUTOPHAGY, V15, P1082, DOI 10.1080/15548627.2019.1569933
   Baba SP, 2018, J MOL CELL CARDIOL, V118, P183, DOI 10.1016/j.yjmcc.2018.04.002
   Bae D, 2008, J BIOL CHEM, V283, P28074, DOI 10.1074/jbc.M804203200
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Cackowski FC, 2004, GENOMICS, V84, P82, DOI 10.1016/j.ygeno.2004.02.001
   Cao DL, 1998, J BIOL CHEM, V273, P11429, DOI 10.1074/jbc.273.19.11429
   Chang CM, 2015, MOL CELL, V60, P930, DOI 10.1016/j.molcel.2015.10.037
   Chung YT, 2012, MODERN PATHOL, V25, P758, DOI 10.1038/modpathol.2011.191
   Ding J, 2018, BMB REP, V51, P630, DOI 10.5483/BMBRep.2018.51.12.140
   Endo S, 2009, ARCH BIOCHEM BIOPHYS, V487, P1, DOI 10.1016/j.abb.2009.05.009
   Escher C, 2012, PROTEOMICS, V12, P1111, DOI 10.1002/pmic.201100463
   Fang C, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005623
   Fukumoto S, 2005, CLIN CANCER RES, V11, P1776, DOI 10.1158/1078-0432.CCR-04-1238
   Gagnon ML, 2000, P NATL ACAD SCI USA, V97, P2573, DOI 10.1073/pnas.040337597
   Gallego O, 2007, P NATL ACAD SCI USA, V104, P20764, DOI 10.1073/pnas.0705659105
   Glinka Y, 2008, J LEUKOCYTE BIOL, V84, P302, DOI 10.1189/jlb.0208090
   Ha J, 2015, MOL ASPECTS MED, V46, P46, DOI 10.1016/j.mam.2015.08.002
   He Y, 2018, CELL MOL BIOL, V64, P64, DOI 10.14715/cmb/2018.64.9.10
   Hendricks C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165153
   Heo Hye Young, 2010, Exp Neurobiol, V19, P97, DOI 10.5607/en.2010.19.2.97
   Huang CF, 2016, ONCOTARGET, V7, P43779, DOI 10.18632/oncotarget.9672
   Huang CH, 2019, BIOTECHNOL PROGR, V35, DOI 10.1002/btpr.2787
   Huang R, 2015, MOL CELL, V57, P456, DOI 10.1016/j.molcel.2014.12.013
   Huang XP, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11580-4
   Hubbard JM, 2015, NAT REV CLIN ONCOL, V12, P73, DOI 10.1038/nrclinonc.2014.233
   Ju JS, 2010, AUTOPHAGY, V6, P929, DOI 10.4161/auto.6.7.12785
   Jung DW, 2014, CHEM BIOL, V21, P1533, DOI 10.1016/j.chembiol.2014.08.017
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004
   Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   Lamb CA, 2013, BIOESSAYS, V35, P34, DOI 10.1002/bies.201200130
   Lau A, 2010, MOL CELL BIOL, V30, P3275, DOI 10.1128/MCB.00248-10
   Li TT, 2014, J BIOL CHEM, V289, P3775, DOI 10.1074/jbc.M113.531640
   Liang XC, 2019, LIFE SCI, V221, P35, DOI 10.1016/j.lfs.2019.02.012
   Liang ZW, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0706-z
   Liao D, 2018, EXP THER MED, V15, P1712, DOI 10.3892/etm.2017.5522
   Liu TJJ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1363-1
   Luo DX, 2011, BIOCHEM J, V438, P71, DOI 10.1042/BJ20110111
   Luo DX, 2013, J BIOL CHEM, V288, P36733, DOI 10.1074/jbc.M113.514877
   Ma J, 2019, NUCLEIC ACIDS RES, V47, pD1211, DOI 10.1093/nar/gky869
   Ma J, 2012, INT J CANCER, V131, pE862, DOI 10.1002/ijc.27618
   Matsunaga T, 2012, DRUG METAB PHARMACOK, V27, P553, DOI 10.2133/dmpk.DMPK-12-NT-012
   Matsunaga T, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00005
   Mei B, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2428-x
   Morozova O, 2010, CLIN CANCER RES, V16, P4572, DOI 10.1158/1078-0432.CCR-10-0627
   Mowers EE, 2018, FEBS J, V285, P1751, DOI 10.1111/febs.14388
   Nishinaka T, 2015, CHEM-BIOL INTERACT, V234, P274, DOI 10.1016/j.cbi.2014.11.013
   Nishinaka T, 2011, CHEM-BIOL INTERACT, V191, P185, DOI 10.1016/j.cbi.2011.01.026
   Ogueta M, 2018, CURR BIOL, V28, P1725, DOI 10.1016/j.cub.2018.04.016
   Ohashi T, 2013, MOL CANCER RES, V11, P1554, DOI 10.1158/1541-7786.MCR-13-0330-T
   Palta M, 2014, NAT REV CLIN ONCOL, V11, P182, DOI 10.1038/nrclinonc.2014.43
   Pang HB, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5904
   Parker SJ, 2015, MOL CELL PROTEOMICS, V14, P2800, DOI 10.1074/mcp.O114.042267
   Poillet-Perez L, 2019, GENE DEV, V33, P610, DOI 10.1101/gad.325514.119
   Puccini A, 2018, NAT REV CLIN ONCOL, V15, P77, DOI 10.1038/nrclinonc.2017.185
   Reiter L, 2011, NAT METHODS, V8, P430, DOI [10.1038/NMETH.1584, 10.1038/nmeth.1584]
   Roach WG, 2007, BIOCHEM J, V403, P353, DOI 10.1042/BJ20061798
   Rost HL, 2016, NAT METHODS, V13, P741, DOI [10.1038/NMETH.3959, 10.1038/nmeth.3959]
   Rosenberger G, 2017, NAT METHODS, V14, P921, DOI [10.1038/NMETH.4398, 10.1038/nmeth.4398]
   Rost HL, 2016, NAT METHODS, V13, P777, DOI [10.1038/NMETH.3954, 10.1038/nmeth.3954]
   Schmoll HJ, 2014, NAT REV CLIN ONCOL, V11, P79, DOI 10.1038/nrclinonc.2013.254
   Seidler NW, 2013, ADV EXP MED BIOL, V985, P1, DOI 10.1007/978-94-007-4716-6_1
   Shen YM, 2007, CELL RES, V17, P650, DOI 10.1038/cr.2007.57
   Shi L, 2020, EUR J PHARMACOL, V883, DOI 10.1016/j.ejphar.2020.173167
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Sirover MA, 2012, J CELL BIOCHEM, V113, P2193, DOI 10.1002/jcb.24113
   Sirover MA, 2011, BBA-GEN SUBJECTS, V1810, P741, DOI 10.1016/j.bbagen.2011.05.010
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Takemura M, 2011, J NAT PROD, V74, P1201, DOI 10.1021/np200118q
   Tao Qi, 2003, Angiogenesis, V6, P39
   Tian CH, 2019, J PHARMACOL EXP THER, V371, P642, DOI 10.1124/jpet.119.261792
   Tooze SA, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018358
   Tsou CC, 2015, NAT METHODS, V12, P258, DOI [10.1038/NMETH.3255, 10.1038/nmeth.3255]
   van Weverwijk A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10592-4
   Wang YY, 2017, SCI REP-UK, V7, DOI 10.1038/srep42199
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wyler E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12894-z
   Yamada M, 2019, FASEB J, V33, P8022, DOI 10.1096/fj.201900133R
   Yang JS, 2018, NATURE, V561, P263, DOI 10.1038/s41586-018-0475-6
   Yang J, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1427-2
   Yang JL, 2020, AGING-US, V12, P10370, DOI 10.18632/aging.103263
   Yang Y, 2019, CELL MOL BIOL, V65, P63, DOI 10.14715/cmb/2019.65.4.10
   Yoshitake H, 2007, INT J GYNECOL CANCER, V17, P1300, DOI 10.1111/j.1525-1438.2007.00932.x
   Yu L, 2018, AUTOPHAGY, V14, P207, DOI 10.1080/15548627.2017.1378838
   Zhang DQ, 2019, CHEM-BIOL INTERACT, V306, P104, DOI 10.1016/j.cbi.2019.04.014
   Zhang QQ, 2019, J CANCER, V10, P1197, DOI 10.7150/jca.28908
   Zhang SN, 2019, J ASIAN NAT PROD RES, V21, P522, DOI 10.1080/10286020.2018.1461087
   Zhang YW, 2016, NUCLEIC ACIDS RES, V44, P761, DOI 10.1093/nar/gkv1465
   Zhong MY, 2020, INT J BIOL SCI, V16, P272, DOI 10.7150/ijbs.37906
   Zhong XY, 2018, CELL REP, V24, P3207, DOI 10.1016/j.celrep.2018.08.066
   Zhou B, 2019, BIOCHEM BIOPH RES CO, V510, P65, DOI 10.1016/j.bbrc.2019.01.032
NR 96
TC 3
Z9 3
U1 19
U2 31
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 0021-9533
EI 1477-9137
J9 J CELL SCI
JI J. Cell Sci.
PD APR
PY 2021
VL 134
IS 8
AR jcs255273
DI 10.1242/jcs.255273
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA SF9ZU
UT WOS:000653106900015
PM 33758077
OA Bronze
DA 2022-04-25
ER

PT J
AU Kumar, B
   Ahmad, R
   Sharma, S
   Gowrikumar, S
   Primeaux, M
   Rana, S
   Natarajan, A
   Oupicky, D
   Hopkins, CR
   Dhawan, P
   Singh, AB
AF Kumar, Balawant
   Ahmad, Rizwan
   Sharma, Swagat
   Gowrikumar, Saiprasad
   Primeaux, Mark
   Rana, Sandeep
   Natarajan, Amarnath
   Oupicky, David
   Hopkins, Corey R.
   Dhawan, Punita
   Singh, Amar B.
TI PIK3C3 Inhibition Promotes Sensitivity to Colon Cancer Therapy by
   Inhibiting Cancer Stem Cells
SO CANCERS
LA English
DT Article
DE autophagy; 5-FloroUracil; PI3KC3; chemoresistance; cancer stem cells
ID AUTOPHAGY INHIBITOR; TARGETING AUTOPHAGY; BETA-CATENIN; STRATEGIES;
   RESISTANCE; EXPANSION; POTENT; CSCS
AB Simple Summary
   Colorectal cancer (CRC) represents a heterogeneous population of tumor cells and cancer stem cells (CSCs) where CSCs are postulated to resist the chemotherapy, and support cancer malignancy. Eliminating CSC can therefore improve CRC therapy and patient survival; however, such strategies have not yielded the desired outcome. Inhibiting autophagy has shown promise in suppressing therapy resistance; however, current autophagy inhibitors have failed in the clinical trials. In the current study, we provided data supporting the efficacy of 36-077, a potent inhibitor of PIK3C3/VPS34, in inhibiting autophagy to kill the CSC to promote the efficacy of colon cancer therapy.
   Background: Despite recent advances in therapies, resistance to chemotherapy remains a critical problem in the clinical management of colorectal cancer (CRC). Cancer stem cells (CSCs) play a central role in therapy resistance. Thus, elimination of CSCs is crucial for effective CRC therapy; however, such strategies are limited. Autophagy promotes resistance to cancer therapy; however, whether autophagy protects CSCs to promote resistance to CRC-therapy is not well understood. Moreover, specific and potent autophagy inhibitors are warranted as clinical trials with hydroxychloroquine have not been successful. Methods: Colon cancer cells and tumoroids were used. Fluorescent reporter-based analysis of autophagy flux, spheroid and side population (SP) culture, and qPCR were done. We synthesized 36-077, a potent inhibitor of PIK3C3/VPS34 kinase, to inhibit autophagy. Combination treatments were done using 5-fluorouracil (5-FU) and 36-077. Results: The 5-FU treatment induced autophagy only in a subset of the treated colon cancer. These autophagy-enriched cells also showed increased expression of CSC markers. Co-treatment with 36-077 significantly improved efficacy of the 5-FU treatment. Mechanistic studies revealed that combination therapy inhibited GSK-3 beta/Wnt/beta-catenin signaling to inhibit CSC population. Conclusion: Autophagy promotes resistance to CRC-therapy by specifically promoting GSK-3 beta/Wnt/beta-catenin signaling to promote CSC survival, and 36-077, a PIK3C3/VPS34 inhibitor, helps promote efficacy of CRC therapy.
C1 [Kumar, Balawant; Ahmad, Rizwan; Gowrikumar, Saiprasad; Primeaux, Mark; Dhawan, Punita; Singh, Amar B.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, 985870 Nebraska Med Ctr, Omaha, NE 68198 USA.
   [Sharma, Swagat; Oupicky, David; Hopkins, Corey R.] Univ Nebraska Med Ctr, Coll Pharm, Dept Pharmaceut Sci, Omaha, NE 68198 USA.
   [Rana, Sandeep; Natarajan, Amarnath] Univ Nebraska Med Ctr, Eppley Inst, Canc Res Program, Omaha, NE 68198 USA.
   [Natarajan, Amarnath; Dhawan, Punita; Singh, Amar B.] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA.
   [Dhawan, Punita; Singh, Amar B.] VA Nebraska Western Iowa Hlth Care Syst, Omaha, NE 68105 USA.
RP Singh, AB (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, 985870 Nebraska Med Ctr, Omaha, NE 68198 USA.; Singh, AB (corresponding author), Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA.; Singh, AB (corresponding author), VA Nebraska Western Iowa Hlth Care Syst, Omaha, NE 68105 USA.
EM balawant.kumar@unmc.edu; rizwan.ahmad@unmc.edu; swagat.sharma@unmc.edu;
   sai.gowrikumar@unmc.edu; mark.primeaux@unmc.edu; sandeep.rana@nih.gov;
   anatarajan@unmc.edu; david.oupicky@unmc.edu; corey.hopkins@unmc.edu;
   punita.dhawan@unmc.edu; amar.singh@unmc.edu
RI kumar, Balawant/ABB-2847-2021; Kumar, Balawant/AAW-9616-2021; Oupicky,
   David/AAR-1655-2021
OI kumar, Balawant/0000-0002-8187-3078; rana, sandeep/0000-0001-5802-5970;
   Primeaux, Mark/0000-0001-7589-3745; Natarajan,
   Amarnath/0000-0001-5067-0203
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [DK124095, CA216746];
   Veterans Health Merit award [BX002761, BX002086]
FX This research was supported in part by the funds from the National
   Institutes of Health (DK124095 to A.B.S., and D.O.) and CA216746 (P.D.),
   Veterans Health Merit award BX002761 (A.B.S.) and BX002086 (P.D.).
CR Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797
   AGUIAR JUNIOR Samuel, 2020, Arq. Gastroenterol., V57, P172, DOI [10.1590/S0004-2803.202000000-32, 10.1590/s0004-2803.202000000-32]
   Ahmad R, 2014, MUCOSAL IMMUNOL, V7, P1340, DOI 10.1038/mi.2014.21
   Ahmad R, 2017, ONCOTARGET, V8, P87718, DOI 10.18632/oncotarget.21190
   Ali MY, 2015, JOVE-J VIS EXP, DOI 10.3791/52532
   Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Avalos Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/603980
   Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409
   Beck B, 2013, NAT REV CANCER, V13, P727, DOI 10.1038/nrc3597
   Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741
   Cho YH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19173-2
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Chude CI, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061279
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Das M, 2018, INT J BIOCHEM CELL B, V103, P115, DOI 10.1016/j.biocel.2018.08.011
   de Francesco EM, 2018, BIOCHEM J, V475, P1611, DOI 10.1042/BCJ20170164
   Dhawan P, 2011, CURR TOP MED CHEM, V11, P1592
   Drouillard A, 2019, CANCER EPIDEMIOL, V61, P124, DOI 10.1016/j.canep.2019.06.001
   Dyczynski M, 2018, CANCER LETT, V435, P32, DOI 10.1016/j.canlet.2018.07.028
   Fatehullah A, 2016, NAT CELL BIOL, V18, P246, DOI 10.1038/ncb3312
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X
   Honda A, 2016, ACS MED CHEM LETT, V7, P72, DOI 10.1021/acsmedchemlett.5b00335
   Jiffry J, 2021, CLIN CANCER RES, V27, P865, DOI 10.1158/1078-0432.CCR-20-2385
   Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269
   Kaizuka T, 2016, MOL CELL, V64, P835, DOI 10.1016/j.molcel.2016.09.037
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Lade AG, 2011, DEV DYNAM, V240, P486, DOI 10.1002/dvdy.22522
   Levy J, 2015, NAT CELL BIOL, V17, P1062, DOI 10.1038/ncb3206
   Li GD, 2019, ACTA PHARMACOL SIN B, V9, P537, DOI 10.1016/j.apsb.2019.01.016
   Liu FC, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2631-9
   Liu T, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00408
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Meunier G, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-00278-8
   Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Nager M, 2018, AUTOPHAGY, V14, P619, DOI 10.1080/15548627.2017.1423439
   Nguyen LV, 2012, NAT REV CANCER, V12, P133, DOI 10.1038/nrc3184
   Noman MZ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax7881
   O'Hara MH, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3545
   Pasquier B, 2015, AUTOPHAGY, V11, P725, DOI 10.1080/15548627.2015.1033601
   Pavlovic Z, 2018, MABS-AUSTIN, V10, P1157, DOI 10.1080/19420862.2018.1515565
   Perez-Hernandez M, 2019, CANCERS, V11, DOI 10.3390/cancers11101599
   Petherick KJ, 2013, EMBO J, V32, P1903, DOI 10.1038/emboj.2013.123
   Rennoll Sherri, 2015, World J Biol Chem, V6, P290, DOI 10.4331/wjbc.v6.i4.290
   Rich JN, 2007, CELL STEM CELL, V1, P353, DOI 10.1016/j.stem.2007.09.011
   Ronan B, 2014, NAT CHEM BIOL, V10, P1013, DOI 10.1038/nchembio.1681
   Rosenfeld MR, 2014, AUTOPHAGY, V10, P1359, DOI 10.4161/auto.28984
   Schatoff EM, 2017, CURR COLORECT CANC R, V13, P101, DOI 10.1007/s11888-017-0354-9
   Schepers A, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007989
   Shaheen S, 2016, STEM CELL REV REP, V12, P492, DOI 10.1007/s12015-016-9664-6
   Siegel RL, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw322
   Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215
   Smith AG, 2019, J PATHOL, V247, P708, DOI 10.1002/path.5222
   Takebe N, 2015, NAT REV CLIN ONCOL, V12, P445, DOI 10.1038/nrclinonc.2015.61
   Taniguchi K, 2017, P NATL ACAD SCI USA, V114, P1643, DOI 10.1073/pnas.1620290114
   Thorburn A, 2014, MOL PHARMACOL, V85, P830, DOI 10.1124/mol.114.091850
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818
   Yu Yang, 2012, Front Biosci (Elite Ed), V4, P1528
NR 61
TC 5
Z9 5
U1 8
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD MAY
PY 2021
VL 13
IS 9
AR 2168
DI 10.3390/cancers13092168
PG 19
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA SB3FU
UT WOS:000649885500001
PM 33946505
OA Green Published
DA 2022-04-25
ER

PT J
AU Boyle, KA
   Van Wickle, J
   Hill, RB
   Marchese, A
   Kalyanaraman, B
   Dwinell, MB
AF Boyle, Kathleen A.
   Van Wickle, Jonathan
   Hill, R. Blake
   Marchese, Adriano
   Kalyanaraman, Balaraman
   Dwinell, Michael B.
TI Mitochondria-targeted drugs stimulate mitophagy and abrogate colon
   cancer cell proliferation
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE AMP-activated kinase (AMPK); cancer biology; cell growth; mitophagy;
   mitochondrial metabolism; colon cancer; KRAS proto-oncogene; cell
   proliferation; metformin
ID ACTIVATED PROTEIN-KINASE; COLORECTAL-CANCER; CARCINOMA-CELLS; IN-VIVO;
   S6 KINASE; AUTOPHAGY; GROWTH; PHOSPHORYLATION; ANTIOXIDANT; THERAPY
AB Mutations in the KRAS proto-oncogene are present in 50% of all colorectal cancers and are increasingly associated with chemotherapeutic resistance to frontline biologic drugs. Accumulating evidence indicates key roles for overactive KRAS mutations in the metabolic reprogramming from oxidative phosphorylation to aerobic glycolysis in cancer cells. Here, we sought to exploit the more negative membrane potential of cancer cell mitochondria as an untapped avenue for interfering with energy metabolism in KRAS variant-containing and KRAS WT colorectal cancer cells. Mitochondrial function, intracellular ATP levels, cellular uptake, energy sensor signaling, and functional effects on cancer cell proliferation were assayed. 3-Carboxyl proxyl nitroxide (Mito-CP) and Mito-Metformin, two mitochondria-targeted compounds, depleted intracellular ATP levels and persistently inhibited ATP-linked oxygen consumption in both KRAS WT and KRAS variant-containing colon cancer cells and had only limited effects on nontransformed intestinal epithelial cells. These anti-proliferative effects reflected the activation of AMP-activated protein kinase (AMPK) and the phosphorylation-mediated suppression of the mTOR target ribosomal protein S6 kinase B1 (RPS6KB1 or p70S6K). Moreover, Mito-CP and Mito-Metformin released Unc-51-like autophagy-activating kinase 1 (ULK1) from mTOR-mediated inhibition, affected mitochondrial morphology, and decreased mitochondrial membrane potential, all indicators of mitophagy. Pharmacological inhibition of the AMPK signaling cascade mitigated the anti-proliferative effects of Mito-CP and Mito-Metformin. This is the first demonstration that drugs selectively targeting mitochondria induce mitophagy in cancer cells. Targeting bioenergetic metabolism with mitochondria-targeted drugs to stimulate mitophagy provides an attractive approach for therapeutic intervention in KRAS WT and overactive mutant-expressing colon cancer.
C1 [Boyle, Kathleen A.; Van Wickle, Jonathan; Dwinell, Michael B.] Med Coll Wisconsin, Dept Microbiol & Immunol, Milwaukee, WI 53226 USA.
   [Hill, R. Blake; Marchese, Adriano] Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.
   [Kalyanaraman, Balaraman] Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA.
   [Dwinell, Michael B.] Med Coll Wisconsin, Dept Surg, 8700 W Wisconsin Ave, Milwaukee, WI 53226 USA.
   [Boyle, Kathleen A.; Hill, R. Blake; Marchese, Adriano; Kalyanaraman, Balaraman; Dwinell, Michael B.] Med Coll Wisconsin, MCW Canc Ctr, Milwaukee, WI 53226 USA.
RP Dwinell, MB (corresponding author), 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.
EM mdwinell@mcw.edu
FU NCI, National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [U01 CA178960, R01 CA152810]; Medical College of
   Wisconsin Cancer Center; Advancing a Healthier Wisconsin Endowment;
   Bobbie Nick Voss Charitable Foundation; NATIONAL CANCER INSTITUTEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [U01CA178960,
   R01CA152810] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL
   MEDICAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [R01GM122889, R01GM067180] Funding
   Source: NIH RePORTER
FX This work was supported by grants from the NCI, National Institutes of
   Health Grants U01 CA178960 (to M. B. D. and B. K.) and R01 CA152810 (to
   B. K.), the Medical College of Wisconsin Cancer Center (to M. B. D. and
   B. K.), the Advancing a Healthier Wisconsin Endowment (to M. B. D.), and
   the Bobbie Nick Voss Charitable Foundation continuing philanthropic
   donations (to M. B. D.). M. B. D. has ownership interests in Protein
   Foundry, LLC. The content is solely the responsibility of the authors
   and does not necessarily represent the official views of the National
   Institutes of Health.
CR Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11
   American Cancer Society, CANC FACTS FIG 2017
   Beckham TH, 2013, J PHARMACOL EXP THER, V344, P167, DOI 10.1124/jpet.112.199216
   Bryant KL, 2014, TRENDS BIOCHEM SCI, V39, P91, DOI 10.1016/j.tibs.2013.12.004
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Callahan J, 2006, BIOMACROMOLECULES, V7, P2347, DOI 10.1021/bm060336m
   Chandran K, 2009, BIOPHYS J, V96, P1388, DOI 10.1016/j.bpj.2008.10.042
   Cheng G, 2014, BRIT J CANCER, V111, P85, DOI 10.1038/bjc.2014.272
   Cheng G, 2016, CANCER RES, V76, P3904, DOI 10.1158/0008-5472.CAN-15-2534
   Cheng G, 2015, CANCER LETT, V365, P96, DOI 10.1016/j.canlet.2015.05.016
   Cheng G, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-285
   Cheng G, 2012, CANCER RES, V72, P2634, DOI 10.1158/0008-5472.CAN-11-3928
   Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389
   Cunniff B, 2013, J CELL PHYSIOL, V228, P835, DOI 10.1002/jcp.24232
   Czarny P, 2015, INT J MOL SCI, V16, P2641, DOI 10.3390/ijms16022641
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Dhanasekaran A, 2005, FREE RADICAL BIO MED, V39, P567, DOI 10.1016/j.freeradbiomed.2005.04.016
   Dilip A, 2013, ANTI-CANCER DRUG, V24, P881, DOI 10.1097/CAD.0b013e32836442c6
   Divakaruni AS, 2013, P NATL ACAD SCI USA, V110, P5422, DOI 10.1073/pnas.1303360110
   Dong LF, 2011, FREE RADICAL BIO MED, V50, P1546, DOI 10.1016/j.freeradbiomed.2011.02.032
   Dranka BP, 2011, FREE RADICAL BIO MED, V51, P1621, DOI 10.1016/j.freeradbiomed.2011.08.005
   Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683
   Ellington AA, 2005, CARCINOGENESIS, V26, P159, DOI 10.1093/carcin/bgh297
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Hemmings BA, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011189
   Higurashi T, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-118
   Hosono K, 2010, MOL CARCINOGEN, V49, P662, DOI 10.1002/mc.20637
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003
   Kashatus JA, 2015, MOL CELL, V57, P537, DOI 10.1016/j.molcel.2015.01.002
   Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200
   Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Masui K, 2014, TRENDS ENDOCRIN MET, V25, P364, DOI 10.1016/j.tem.2014.04.002
   Millard M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013131
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Modica-Napolitano JS, 2001, ADV DRUG DELIVER REV, V49, P63, DOI 10.1016/S0169-409X(01)00125-9
   Mukhopadhyay P, 2012, FREE RADICAL BIO MED, V52, P497, DOI 10.1016/j.freeradbiomed.2011.11.001
   Murphy MP, 1997, TRENDS BIOTECHNOL, V15, P326, DOI 10.1016/S0167-7799(97)01068-8
   NADAKAVUKAREN KK, 1985, CANCER RES, V45, P6093
   Neufeld TP, 2010, CURR OPIN CELL BIOL, V22, P157, DOI 10.1016/j.ceb.2009.11.005
   Panda PK, 2015, SEMIN CELL DEV BIOL, V39, P43, DOI 10.1016/j.semcdb.2015.02.013
   Patel BB, 2008, INT J CANCER, V122, P267, DOI 10.1002/ijc.23097
   PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x
   Perry SW, 2011, BIOTECHNIQUES, V50, P98, DOI 10.2144/000113610
   Psahoulia FH, 2007, CARCINOGENESIS, V28, P1021, DOI 10.1093/carcin/bgl232
   Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2
   QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248
   Rao VA, 2010, J BIOL CHEM, V285, P34447, DOI 10.1074/jbc.M110.133579
   Rodriguez-Enriquez S, 2012, BBA-BIOENERGETICS, V1817, P1597, DOI 10.1016/j.bbabio.2012.05.005
   Salabei JK, 2014, NAT PROTOC, V9, P421, DOI 10.1038/nprot.2014.018
   Senft D, 2016, CURR OPIN CELL BIOL, V39, P43, DOI 10.1016/j.ceb.2016.02.001
   Serasinghe MN, 2015, MOL CELL, V57, P521, DOI 10.1016/j.molcel.2015.01.003
   Smith JM, 2005, AM J PHYSIOL-GASTR L, V288, pG316, DOI 10.1152/ajpgi.00208.2004
   Smith RAJ, 1999, EUR J BIOCHEM, V263, P709, DOI 10.1046/j.1432-1327.1999.00543.x
   Smith RAJ, 2003, P NATL ACAD SCI USA, V100, P5407, DOI 10.1073/pnas.0931245100
   Smith RAJ, 2008, ANN NY ACAD SCI, V1147, P105, DOI 10.1196/annals.1427.003
   Starenki D, 2013, J CLIN ENDOCR METAB, V98, P1529, DOI 10.1210/jc.2012-3671
   Stipanuk MH, 2009, NUTR REV, V67, P677, DOI 10.1111/j.1753-4887.2009.00252.x
   SUMMERHAYES IC, 1982, P NATL ACAD SCI-BIOL, V79, P5292, DOI 10.1073/pnas.79.17.5292
   Tchevkina E., 2012, PROTEIN PHOSPHORYLAT, P1, DOI [10.5772/2944, DOI 10.5772/2944]
   Tomimoto A, 2008, CANCER SCI, V99, P2136, DOI 10.1111/j.1349-7006.2008.00933.x
   Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107
   Wendt MK, 2006, ONCOGENE, V25, P4986, DOI 10.1038/sj.onc.1209505
   Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621
   Yeung TM, 2010, P NATL ACAD SCI USA, V107, P3722, DOI 10.1073/pnas.0915135107
   Yin N, 2017, J BIOL CHEM, V292, P15070, DOI 10.1074/jbc.M117.779488
   Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058
   Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028
   Zhang ZJ, 2011, DIABETES CARE, V34, P2323, DOI 10.2337/dc11-0512
   Zhao BZ, 2016, GENES DIS, V3, P82, DOI 10.1016/j.gendis.2015.12.002
   Zielonka J, 2017, CHEM REV, V117, P10043, DOI 10.1021/acs.chemrev.7b00042
NR 76
TC 56
Z9 56
U1 4
U2 28
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP 21
PY 2018
VL 293
IS 38
BP 14891
EP 14904
DI 10.1074/jbc.RA117.001469
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA GV5PS
UT WOS:000446155000024
PM 30087121
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Wubetu, GY
   Utsunomiya, T
   Ishikawa, D
   Ikemoto, T
   Yamada, S
   Morine, Y
   Iwahashi, S
   Saito, Y
   Arakawa, Y
   Imura, S
   Arimochi, H
   Shimada, M
AF Wubetu, Gizachew Yismaw
   Utsunomiya, Tohru
   Ishikawa, Daichi
   Ikemoto, Tetsuya
   Yamada, Shinichiro
   Morine, Yuji
   Iwahashi, Shuichi
   Saito, Yu
   Arakawa, Yusuke
   Imura, Satoru
   Arimochi, Hideki
   Shimada, Mitsuo
TI Branched Chain Amino Acid Suppressed Insulin-initiated Proliferation of
   Human Cancer Cells Through Induction of Autophagy
SO ANTICANCER RESEARCH
LA English
DT Article
DE Autophagy; BCAA; colorectal cancer; insulin; liver cancer
ID COLORECTAL-CANCER; SUPPLEMENTATION; GROWTH; COLON; APOPTOSIS;
   TUMORIGENESIS; INHIBITION; SURVIVAL; OBESITY; TUMORS
AB Background: Branched chain amino acid (BCAA) dietary supplementation inhibits activation of the insulin-like growth factor (IGF)/IGF-I receptor (IGF-IR) axis in diabetic animal models. However, the in vitro effect of BCAA on human cancer cell lines under hyper-insulinemic conditions remains unclear. Materials and Methods: Colon (HCT-116) and hepatic (HepG2) tumor cells were treated with varying concentrations of BCAA with or without fluorouracil (5-FU). The effect of BCAA on insulin-initiated proliferation was determined. Gene and protein expression was analyzed by quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting, respectively. Results: BCAA supplementation had no significant effect on cell proliferation and did not show significant synergistic or antagonistic effects with 5-FU. However, BCAA significantly decreased insulin-initiated proliferation of human colon and hepatic cancer cell lines in vitro. BCAA supplementation caused a marked decrease in activated IGF-IR expression and significantly enhanced both mRNA and protein expression of LC3-II and BECN1 (BECLIN-1). Conclusion: BCAA could be a useful chemopreventive modality for cancer in hyperinsulinemic conditions.
C1 [Wubetu, Gizachew Yismaw; Utsunomiya, Tohru; Ishikawa, Daichi; Ikemoto, Tetsuya; Yamada, Shinichiro; Morine, Yuji; Iwahashi, Shuichi; Saito, Yu; Arakawa, Yusuke; Imura, Satoru; Shimada, Mitsuo] Univ Tokushima, Dept Surg, Shinkuracho, Tokushima 7708503, Japan.
   [Arimochi, Hideki] Univ Tokushima, Dept Immunol & Parasitol, Shinkuracho, Tokushima 7708503, Japan.
RP Shimada, M (corresponding author), Univ Tokushima, Dept Surg, 3-18-15 Kuramoto Cho, Shinkuracho, Tokushima 7708503, Japan.
EM mitsuo.shimada@tokushima-u.ac.jp
OI Ikemoto, Tetsuya/0000-0001-9800-1359
FU Institute of Health Biosciences, The University of Tokushima Graduate
   School, Tokushima, Japan
FX This study was supported by the Institute of Health Biosciences, The
   University of Tokushima Graduate School, Tokushima, Japan.
CR Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200
   Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408
   Chang CK, 2003, DIABETOLOGIA, V46, P595, DOI 10.1007/s00125-003-1109-5
   Cho DH, 2012, ANTICANCER RES, V32, P4091
   Corpet DE, 1997, NUTR CANCER, V27, P316, DOI 10.1080/01635589709514543
   Degtyarev M, 2008, J CELL BIOL, V183, P101, DOI 10.1083/jcb.200801099
   Durai R, 2005, INT J COLORECTAL DIS, V20, P203, DOI 10.1007/s00384-004-0675-4
   Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje
   Frezza EE, 2006, GUT, V55, P285, DOI 10.1136/gut.2005.073163
   Govannucci E, 2007, GASTROENTEROLOGY, V132, P2208, DOI 10.1053/j.gastro.2007.03.050
   Gu YP, 2004, FEBS LETT, V577, P357, DOI 10.1016/j.febslet.2004.10.040
   Hagiwara A, 2012, J CELL PHYSIOL, V227, P2097, DOI 10.1002/jcp.22941
   Huang SB, 2010, AUTOPHAGY, V6, P256, DOI 10.4161/auto.6.2.11124
   Iwasa J, 2010, CANCER SCI, V101, P460, DOI 10.1111/j.1349-7006.2009.01402.x
   Kawaguchi T, 2008, INT J MOL MED, V22, P105
   Lin HM, 2007, J AGR FOOD CHEM, V55, P3620, DOI 10.1021/jf062406m
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   Marchesini G, 2005, J NUTR, V135, p1596S, DOI 10.1093/jn/135.6.1596S
   Marchesini G, 2003, GASTROENTEROLOGY, V124, P1792, DOI 10.1016/S0016-5085(03)00323-8
   Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200
   Miuma S, 2012, J CELL BIOCHEM, V113, P3113, DOI 10.1002/jcb.24188
   Moriwaki H, 2004, BIOCHEM BIOPH RES CO, V313, P405, DOI 10.1016/j.bbrc.2003.07.016
   Muto Y, 2005, CLIN GASTROENTEROL H, V3, P705, DOI 10.1016/S1542-3565(05)00017-0
   Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X
   Shimizu M, 2009, CLIN CANCER RES, V15, P3068, DOI 10.1158/1078-0432.CCR-08-2093
   SINGH P, 1993, GASTROENTEROLOGY, V105, P1218, DOI 10.1016/0016-5085(93)90971-E
   Tran TT, 1996, CANCER EPIDEM BIOMAR, V5, P1013
   Wiseman M, 2008, P NUTR SOC, V67, P2072
   Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016
   Yoshiji H, 2009, J GASTROENTEROL, V44, P483, DOI 10.1007/s00535-009-0031-0
NR 30
TC 13
Z9 14
U1 0
U2 7
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD SEP
PY 2014
VL 34
IS 9
BP 4789
EP 4796
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AP1VS
UT WOS:000341860700021
PM 25202059
DA 2022-04-25
ER

PT J
AU Sikder, MOF
   Sivaprakasam, S
   Brown, MP
   Thangaraju, M
   Bhutia, YD
   Ganapathy, V
AF Sikder, Mohd O. F.
   Sivaprakasam, Sathish
   Brown, Mothy P.
   Thangaraju, Muthusamy
   Bhutia, Yangzom D.
   Ganapathy, Vadivel
TI SLC6A14, a Na+/Cl--coupled amino acid transporter, functions as a tumor
   promoter in colon and is a target for Wnt signaling
SO BIOCHEMICAL JOURNAL
LA English
DT Article
ID COLORECTAL-CANCER; ATB(0,+) SLC6A14; UP-REGULATION; DRUG TARGET;
   EXPRESSION; CELLS; ANTIPORTER; SYSTEM; GROWTH; RELEVANCE
AB SLC6A14 is a Na+/Cl--coupled transporter for neutral and cationic amino acids. It is expressed at basal levels in the normal colon but is up-regulated in colon cancer. However, the relevance of this up-regulation to cancer progression and the mechanisms involved in the up-regulation remain unknown. Here, we show that SLC6A14 is essential for colon cancer and that its up-regulation involves, at least partly, Wnt signaling. The up-regulation of the transporter is evident in most human colon cancer cell lines and also in a majority of patient-derived xenografts. These findings are supported by publicly available TCGA (The Cancer Genome Atlas) database. Treatment of colon cancer cells with a-methyltryptophan (alpha-MT), a blocker of SLC6A14, induces amino acid deprivation, decreases mTOR activity, increases autophagy, promotes apoptosis, and suppresses cell proliferation and invasion. In xenograft and syngeneic mouse tumor models, silencing of SLC6A14 by shRNA or blocking its function by a-MT reduces tumor growth. Similarly, the deletion of Slc6a14 in mice protects against colon cancer in two different experimental models (inflammation-associated colon cancer and genetically driven colon cancer). In colon cancer cells, expression of the transporter is reduced by Wnt antagonist or by silencing of beta-catenin whereas Wnt agonist or overexpression of beta-catenin shows the opposite effect. Finally, SLC6A14 as a target for beta-catenin is confirmed by chromatin immunoprecipitation. These studies demonstrate that SLC6A14 plays a critical role in the promotion of colon cancer and that its up-regulation in cancer involves Wnt signaling. These findings identify SLC6A14 as a promising drug target for the treatment of colon cancer.
C1 [Sikder, Mohd O. F.; Sivaprakasam, Sathish; Brown, Mothy P.; Bhutia, Yangzom D.; Ganapathy, Vadivel] Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA.
   [Thangaraju, Muthusamy] Augusta Univ, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.
RP Ganapathy, V (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA.
EM vadivel.ganapathy@ttuhsc.edu
RI Sivaprakasam, Sathish/E-9367-2018
OI Sivaprakasam, Sathish/0000-0002-9230-0144
FU Welch Endowed Chair in Biochemistry at Texas Tech University Health
   Sciences Center [BI-0028]
FX This work was supported by the Welch Endowed Chair in Biochemistry,
   Grant no. BI-0028, at Texas Tech University Health Sciences Center.
CR Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   Arena Elizabeth A, 2013, Adv Surg, V47, P199
   Averous J, 2004, J BIOL CHEM, V279, P5288, DOI 10.1074/jbc.M311862200
   Babu E, 2015, BIOCHEM J, V469, P17, DOI 10.1042/BJ20150437
   Bai JW, 2016, EUR REV MED PHARMACO, V20, P4682
   Baltruskeviciene E, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3575-z
   Behrooz AB, 2019, J DRUG TARGET, V27, P257, DOI 10.1080/1061186X.2018.1479756
   Bhutia YD, 2016, BBA-MOL CELL RES, V1863, P2531, DOI 10.1016/j.bbamcr.2015.12.017
   Bhutia YD, 2014, ASIAN J PHARM SCI, V9, P293, DOI 10.1016/j.ajps.2014.04.004
   Bhutia YD, 2015, CANCER RES, V75, P1782, DOI 10.1158/0008-5472.CAN-14-3745
   Bridges CC, 2001, INVEST OPHTH VIS SCI, V42, P47
   Brown TP, 2020, PHARMACOL THERAPEUT, V206, DOI 10.1016/j.pharmthera.2019.107451
   Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002
   Chao CL, 2012, LAB INVEST, V92, P420, DOI 10.1038/labinvest.2011.185
   Chen H, 2004, J BIOL CHEM, V279, P50829, DOI 10.1074/jbc.M409173200
   Christie M, 2013, ONCOGENE, V32, P4675, DOI 10.1038/onc.2012.486
   Coothankandaswamy V, 2016, BRIT J PHARMACOL, V173, P3292, DOI 10.1111/bph.13616
   Coothankandaswamy V, 2013, BIOCHEM J, V450, P169, DOI 10.1042/BJ20121248
   Cormerais Y, 2018, J BIOL CHEM, V293, P2877, DOI 10.1074/jbc.RA117.001342
   de Sousa e Melo F, 2011, CELL STEM CELL, V9, P476, DOI 10.1016/j.stem.2011.10.008
   Dun Y, 2006, CELL TISSUE RES, V324, P189, DOI 10.1007/s00441-005-0116-x
   El Ansari R, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-0946-6
   Fuchs BC, 2005, SEMIN CANCER BIOL, V15, P254, DOI 10.1016/j.semcancer.2005.04.005
   Ganapathy V, 2009, PHARMACOL THERAPEUT, V121, P29, DOI 10.1016/j.pharmthera.2008.09.005
   Gupta N, 2006, GYNECOL ONCOL, V100, P8, DOI 10.1016/j.ygyno.2005.08.016
   Gupta N, 2005, BBA-MOL BASIS DIS, V1741, P215, DOI 10.1016/j.bbadis.2005.04.002
   Hong Y, 2010, CLIN EXP METASTAS, V27, P83, DOI 10.1007/s10585-010-9305-4
   Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038
   Jiang L, 2015, NATURE, V520, P57, DOI 10.1038/nature14344
   Karunakaran S, 2008, BIOCHEM J, V414, P343, DOI 10.1042/BJ20080622
   Karunakaran S, 2011, J BIOL CHEM, V286, P31830, DOI 10.1074/jbc.M111.229518
   Koppula P, 2017, J BIOL CHEM, V292, P14240, DOI 10.1074/jbc.M117.798405
   Lewerenz J, 2013, ANTIOXID REDOX SIGN, V18, P522, DOI 10.1089/ars.2011.4391
   Liu Q, 2018, CANCER MANAG RES, V10, P2303, DOI 10.2147/CMAR.S165188
   Mariotto AB, 2011, JNCI-J NATL CANCER I, V103, P117, DOI 10.1093/jnci/djq495
   Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588
   Markowitz SD, 2002, CANCER CELL, V1, P233, DOI 10.1016/S1535-6108(02)00053-3
   Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Scalise M, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00096
   Scalise M, 2018, FRONT CHEM, V6, DOI 10.3389/fchem.2018.00243
   Schneikert J, 2007, GUT, V56, P417, DOI 10.1136/gut.2006.093310
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Sikder MOF, 2018, AAPS J, V20, DOI 10.1208/s12248-017-0164-7
   Tariq K, 2016, CANCER BIOL MED, V13, P120, DOI 10.28092/j.issn.2095-3941.2015.0103
   Timmerman LA, 2013, CANCER CELL, V24, P450, DOI 10.1016/j.ccr.2013.08.020
   van Geldermalsen M, 2016, ONCOGENE, V35, P3201, DOI 10.1038/onc.2015.381
   Venkateswaran N, 2019, GENE DEV, V33, P1236, DOI 10.1101/gad.327056.119
   Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304
   Zhao XA, 2019, AGING CELL, V18, DOI 10.1111/acel.12947
NR 50
TC 10
Z9 10
U1 0
U2 1
PU PORTLAND PRESS LTD
PI LONDON
PA 5TH FLR, 90 HIGH HOLBORN, LONDON WC1V 6LJ, ENGLAND
SN 0264-6021
EI 1470-8728
J9 BIOCHEM J
JI Biochem. J.
PD APR
PY 2020
VL 477
IS 8
BP 1409
EP 1425
DI 10.1042/BCJ20200099
PG 17
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA LG7VG
UT WOS:000528303100005
PM 32219372
OA hybrid, Green Published
DA 2022-04-25
ER

PT J
AU Hwang, CH
   Lin, YL
   Liu, YK
   Chen, CH
   Wu, HY
   Chang, CC
   Chang, CY
   Chang, YK
   Chiu, YH
   Liao, KW
   Lai, YK
AF Hwang, Chia-Hsiang
   Lin, Yu-Ling
   Liu, Yen-Ku
   Chen, Chia-Hung
   Wu, Hsin-Yi
   Chang, Cheng-Chang
   Chang, Chao-Yuan
   Chang, Yu-Kuo
   Chiu, Yi-Han
   Liao, Kuang-Wen
   Lai, Yiu-Kay
TI 7,7 ''-Dimethoxyagastisflavone-induced Apoptotic or Autophagic Cell
   Death in Different Cancer Cells
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE 7; 7 ''-dimethoxyagastisflavone; biflavonoid; Taxus media cv; Hicksii;
   apoptosis; autophagy
ID BACCATIN III; PACLITAXEL; NECROSIS; AGATHIS
AB 7,7''-Dimethoxyagastisflavone (DMGF), a biflavonoid isolated from the needles of Taxus X media cv. Hicksii, was evaluated for its antiproliferative and antineoplastic effects in three human cancer cell lines. Interestingly, DMGF caused cell death via different pathways in different cancer cells. DMGF induced apoptosis, activated caspase-3 activity and changed the mitochondrial membrane potential in HT-29 human colon cancer cells. However, the apoptotic pathway is not the major pathway involved in DMGF-induced cell death in A549 human lung cancer cells and HepG2 human hepatoma cells. Treatment with 3-MA, an inhibitor of autophagy, significantly decreased DMGF-induced cell death in HepG2 and A549 cells, but did not affect DMGF-induced cell death in HT-29 cells. Following DMGF treatment, the HepG2 cells increased expression of LC3B-II, a marker used to monitor autophagy in cells. Thus, DMGF induced apoptotic cell death in HT-29 cells, triggered both apoptotic and autophagic death in A549 cells and induced autophagic cell death in HepG2 cells. Copyright (C) 2011 John Wiley & Sons, Ltd.
C1 [Wu, Hsin-Yi; Liao, Kuang-Wen] Natl Chiao Tung Univ, Dept Biol Sci & Technol, Hsinchu 30050, Taiwan.
   [Hwang, Chia-Hsiang; Lai, Yiu-Kay] Natl Tsing Hua Univ, Dept Life Sci, Inst Biotechnol, Hsinchu 30013, Taiwan.
   [Hwang, Chia-Hsiang; Chang, Cheng-Chang; Chang, Chao-Yuan; Chang, Yu-Kuo] Yung Shin Pharmaceut Ind Co Ltd, Taichung, Taiwan.
   [Lin, Yu-Ling; Liu, Yen-Ku; Chen, Chia-Hung; Liao, Kuang-Wen] Natl Chiao Tung Univ, Inst Mol Med & Bioengn, Hsinchu 30050, Taiwan.
   [Chiu, Yi-Han] Tzu Chi Univ, Dept Life Sci, Hualien, Taiwan.
RP Liao, KW (corresponding author), Natl Chiao Tung Univ, Dept Biol Sci & Technol, Hsinchu 30050, Taiwan.
EM liaonms@pchome.com.tw; yklai@life.nthu.edu.tw
RI Chiu, Yi-Han/AAL-8783-2021
OI Chiu, Yi-Han/0000-0001-6209-7897
FU Yung-Shin Pharmaceutical Industry Co., Ltd [98 C117]
FX The authors acknowledge the financial assistance provided by Yung-Shin
   Pharmaceutical Industry Co., Ltd under the cooperative grant scheme
   (Project No. 98 C117).
CR Amaravadi RK, 2007, CLIN CANCER RES, V13, P7271, DOI 10.1158/1078-0432.CCR-07-1595
   Baloglu E, 1999, J NAT PROD, V62, P1068, DOI 10.1021/np990040k
   Barth S, 2010, J PATHOL, V221, P117, DOI 10.1002/path.2694
   Chattopadhyay SK, 2006, BIOORG MED CHEM LETT, V16, P2446, DOI 10.1016/j.bmcl.2006.01.077
   Choi IK, 2010, BIOCHEM BIOPH RES CO, V393, P849, DOI 10.1016/j.bbrc.2010.02.097
   Cotter TG, 2009, NAT REV CANCER, V9, P501, DOI 10.1038/nrc2663
   Dai J, 2006, CHEM PHARM BULL, V54, P306, DOI 10.1248/cpb.54.306
   Georgopoulou K, 2007, PLANTA MED, V73, P1081, DOI 10.1055/s-2007-981579
   Goncalez E, 2001, BRAZ J MED BIOL RES, V34, P1453, DOI 10.1590/S0100-879X2001001100013
   Guruvayoorappan Chandrasekharan, 2008, J Exp Ther Oncol, V7, P207
   Hung JY, 2009, J AGR FOOD CHEM, V57, P9809, DOI 10.1021/jf902315e
   Jiang SG, 2008, INT J ONCOL, V33, P103
   KHAN NU, 1972, TETRAHEDRON, V28, P5689, DOI 10.1016/S0040-4020(01)88913-4
   Ko H, 2009, BIOSCI BIOTECH BIOCH, V73, P2183, DOI 10.1271/bbb.90250
   Krysko DV, 2008, METHODS, V44, P205, DOI 10.1016/j.ymeth.2007.12.001
   Miller MC, 1999, CANCER CHEMOTH PHARM, V44, P444, DOI 10.1007/s002800051117
   NICOLAOU KC, 1994, NATURE, V367, P630, DOI 10.1038/367630a0
   OFMAN DJ, 1995, PHYTOCHEMISTRY, V38, P1223, DOI 10.1016/0031-9422(94)00783-P
   Pang XF, 2009, CANCER RES, V69, P518, DOI 10.1158/0008-5472.CAN-08-2531
   Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6
   Rello S, 2005, APOPTOSIS, V10, P201, DOI 10.1007/s10495-005-6075-6
   Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J
   Yu J, 2003, CANCER BIOL THER, V2, P694
NR 23
TC 11
Z9 11
U1 1
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0951-418X
J9 PHYTOTHER RES
JI Phytother. Res.
PD APR
PY 2012
VL 26
IS 4
BP 528
EP 534
DI 10.1002/ptr.3583
PG 7
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 923LE
UT WOS:000302620000009
PM 21915931
DA 2022-04-25
ER

PT J
AU Koukourakis, MI
   Giatromanolaki, A
   Sivridis, E
   Pitiakoudis, M
   Gatter, KC
   Harris, AL
AF Koukourakis, M. I.
   Giatromanolaki, A.
   Sivridis, E.
   Pitiakoudis, M.
   Gatter, K. C.
   Harris, A. L.
TI Beclin 1 over- and underexpression in colorectal cancer: distinct
   patterns relate to prognosis and tumour hypoxia
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE Beclin 1; colon cancer; autophagy; HIF1 alpha; LDH
ID AUTOPHAGY-RELATED PROTEIN; HEPATOCELLULAR-CARCINOMA; EXPRESSION; CELLS;
   GENE; TUMORIGENESIS; ANGIOGENESIS; ASSOCIATION; INHIBITION; PATHWAY
AB INTRODUCTION: Autophagy enables cells to recycle long-lived proteins or damaged organelles. Beclin 1, the mammalian orthologue of the yeast Apg6/Vps30 gene, functions as a scaffold for the formation of autophagosomes.
   MATERIALS AND METHODS: The immunohistochemical patterns of Beclin 1 expression and their prognostic relevance were studied in formalin-fixed tissues from 155 patients with colorectal adenocarcinoma treated with surgery alone.
   RESULTS: Using the weak homogeneous expression of Beclin 1 in normal colonic tissues as a basis for assessing tumours, the following grouping/staining patterns were recognised in colorectal carcinomas: a normal-like pattern in 62 of 155 (40%) cases, an underexpression pattern in 24 of 155 (15.5%) cases, extensive overexpression of Beclin 1 in 33 of 155 (21.3%) tumours and limited overexpression of the protein in 36 of 155 (23.2%) tumours. Extensive overexpression of Beclin 1 was significantly linked with overexpression of HIF1 alpha and LDH5, as well as with high histological grade, vascular invasion and nodal involvement. Furthermore, patients with extensive over-or underexpression of Beclin 1 had a significantly poorer overall survival compared with the other two groups (P<0.0001). Beclin 1 had an independent prognostic relevance in multivariate analysis.
   CONCLUSIONS: Beclin 1 has an important role in growth and metastasis of colorectal cancer. Loss of Beclin 1 expression (allelic loss or microRNA regulatory activity, as suggested in the literature) defines poor prognosis presumably by promoting anti-apoptotic pathways, while overexpression of the protein, being linked with tumour hypoxia and acidity, also defines subgroups of tumours with aggressive clinical behaviour. British Journal of Cancer (2010) 103, 1209-1214. doi:10.1038/sj.bjc.6605904 www.bjcancer.com Published online 14 September 2010 (C) 2010 Cancer Research UK
C1 [Koukourakis, M. I.] Democritus Univ Thrace, Dept Radiotherapy Oncol, Alexandroupolis 68100, Greece.
   [Koukourakis, M. I.; Giatromanolaki, A.; Sivridis, E.; Pitiakoudis, M.] Univ Gen Hosp Alexandroupolis, Alexandroupolis 68100, Greece.
   [Giatromanolaki, A.; Sivridis, E.] Democritus Univ Thrace, Dept Pathol, Alexandroupolis 68100, Greece.
   [Pitiakoudis, M.] Democritus Univ Thrace, Dept Surg, Alexandroupolis 68100, Greece.
   [Gatter, K. C.; Harris, A. L.] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Canc Res UK,Mol Oncol Labs, Oxford OX3 7LJ, England.
   [Gatter, K. C.; Harris, A. L.] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Oxford OX3 7LJ, England.
RP Koukourakis, MI (corresponding author), Democritus Univ Thrace, Dept Radiotherapy Oncol, Alexandroupolis 68100, Greece.
EM targ@her.forthnet.gr
RI Harris, Adrian/ABA-3343-2020
OI Harris, Adrian/0000-0003-1376-8409
FU Cancer Research UKCancer Research UK Funding Source: Medline
CR Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Anai S, 2007, MOL CANCER THER, V6, P101, DOI 10.1158/1535-7163.MCT-06-0367
   Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562
   Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78
   Chen YS, 2009, PATHOL ONCOL RES, V15, P487, DOI 10.1007/s12253-008-9143-8
   Ding ZB, 2008, CANCER RES, V68, P9167, DOI 10.1158/0008-5472.CAN-08-1573
   Holbrook, 1975, ENZYMES, V11, P191
   Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061
   Kim KW, 2008, AUTOPHAGY, V4, P659, DOI 10.4161/auto.6058
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Koukourakis MI, 2006, J CLIN ONCOL, V24, P4301, DOI 10.1200/JCO.2006.05.9501
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liang XH, 2001, CANCER RES, V61, P3443
   Maiuri MC, 2009, CELL DEATH DIFFER, V16, P87, DOI 10.1038/cdd.2008.131
   Mari M, 2007, NAT CELL BIOL, V9, P1125, DOI 10.1038/ncb1007-1125
   Miracco C, 2007, INT J ONCOL, V30, P429
   Pirtoli L, 2009, AUTOPHAGY, V5, P930, DOI 10.4161/auto.5.7.9227
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642
   Samokhvalov V, 2008, AUTOPHAGY, V4, P1034, DOI 10.4161/auto.6994
   Song JR, 2009, AUTOPHAGY, V5, P1131, DOI 10.4161/auto.5.8.9996
   Zhu H, 2009, AUTOPHAGY, V5, P816, DOI 10.4161/auto.9064
   Zois CE, 2009, AUTOPHAGY, V5, P442, DOI 10.4161/auto.5.4.7667
NR 25
TC 126
Z9 137
U1 0
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD OCT 12
PY 2010
VL 103
IS 8
BP 1209
EP 1214
DI 10.1038/sj.bjc.6605904
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 671WL
UT WOS:000283542900010
PM 20842118
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Cottone, L
   Capobianco, A
   Gualteroni, C
   Perrotta, C
   Bianchi, ME
   Rovere-Querini, P
   Manfredi, AA
AF Cottone, Lucia
   Capobianco, Annalisa
   Gualteroni, Chiara
   Perrotta, Cristiana
   Bianchi, Marco E.
   Rovere-Querini, Patrizia
   Manfredi, Angelo A.
TI 5-Fluorouracil causes leukocytes attraction in the peritoneal cavity by
   activating autophagy and HMGB1 release in colon carcinoma cells
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE 5-fluorouracil; autophagy; HMGB1; chemoattraction; peritoneal
   carcinomatosis
ID TUMOR-INFILTRATING LYMPHOCYTES; REGULATES AUTOPHAGY; CANCER-CELLS;
   MACROPHAGES; INFLAMMATION; CHEMOTHERAPY; RECRUITMENT; MIGRATION;
   IMMUNOTHERAPY; CHEMOTAXIS
AB Signals released by leukocytes contribute to tumor growth and influence the efficacy of antineoplastic treatments. The outcome of peritoneal carcinomatosis treatments is unsatisfactory, possibly because chemotherapy activates events that have in the long-term deleterious effects. In this study we offer evidence that 5-fluorouracile (5-FU), besides provoking apoptosis of MC38 colon carcinoma cells, induces a striking attraction of leukocytes both in an orthotopic model of colon carcinomatosis in vivo and in monocyte-migration assays in vitro. Leukocyte attraction depends on the presence of High Mobility Group Box 1 (HMGB1), an endogenous immune adjuvant and chemoattractant released by dying cells. Leukocyte recruitment is prevented in vivo and in vitro using blocking antibodies against HMGB1 and its competitive antagonist BoxA or by interfering with HMGB1 expression. Autophagy is required for leukocyte chemoattraction, since the latter abates upon pharmacological blockade of the autophagic flux while activation of autophagy per se, in the absence of death of colon carcinoma cells, is not sufficient to attract leukocytes. Our results identify autophagy induction and HMGB1 release in colon carcinoma cells as key events responsible for 5-FU elicited leukocyte attraction and define a novel rate-limiting target for combinatorial therapies.
   What's New? Anti-cancer drugs can sometimes help the tumors they are meant to destroy. One reason is because stressed or dying cancer cells release molecular factors that can attract leukocytes, and some of those leukocytes can contribute to tumor survival. In this study, the authors found that this is precisely what happens during intraperitoneal treatment of colon-cancer carcinomatosis with 5-fluorouracil (5-FU). Their results suggest that blocking autophagy and the release of HMGB1 are potential therapeutic targets for enhancing standard chemotherapy.
C1 [Cottone, Lucia; Capobianco, Annalisa; Gualteroni, Chiara; Rovere-Querini, Patrizia; Manfredi, Angelo A.] Ist Sci San Raffaele, Div Regenerat Med, I-20132 Milan, Italy.
   [Cottone, Lucia; Bianchi, Marco E.; Rovere-Querini, Patrizia; Manfredi, Angelo A.] Univ Vita Salute San Raffaele, Sch Med, Milan, Italy.
   [Perrotta, Cristiana] Univ Milan, Dept Biomed & Clin Sci L Sacco, Milan, Italy.
   [Bianchi, Marco E.] Ist Sci San Raffaele, Div Genet & Cell Biol, I-20132 Milan, Italy.
RP Manfredi, AA (corresponding author), Ist Sci San Raffaele, DIBIT 3A1, Via Olgettina 58, I-20132 Milan, Italy.
EM manfredi.angelo@hsr.it
RI Perrotta, Cristiana/I-2835-2016; Manfredi, Angelo A./C-7018-2014;
   Annalisa, Capobianco/AAN-3844-2020; Cottone, Lucia/W-4847-2019;
   Rovere-Querini, Patrizia/J-2340-2012; Bianchi, Marco Emilio/K-3417-2018
OI Perrotta, Cristiana/0000-0001-6680-4536; Manfredi, Angelo
   A./0000-0001-8370-6970; Bianchi, Marco Emilio/0000-0002-5329-6445;
   Cottone, Lucia/0000-0002-9397-4925
FU AIRC (Associazione Italiana Ricerca Cancro), MIUR, by the Ministero
   della SanitaFondazione AIRC per la ricerca sul cancro [IG11761]
FX Grant sponsor: AIRC (Associazione Italiana Ricerca Cancro), MIUR, by the
   Ministero della Sanita; Grant number: IG11761.
CR Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565
   Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622
   Bacci M, 2009, AM J PATHOL, V175, P547, DOI 10.2353/ajpath.2009.081011
   Bianchi ME, 2014, P NATL ACAD SCI USA, V111, P2866, DOI 10.1073/pnas.1324285111
   Bianchi ME, 2009, SCIENCE, V323, P1683, DOI 10.1126/science.1172794
   Bijnsdorp IV, 2010, INT J CANCER, V126, P2457, DOI 10.1002/ijc.24943
   Campana L, 2009, J LEUKOCYTE BIOL, V86, P609, DOI 10.1189/jlb.0908576
   Ceelen WP, 2013, MINERVA CHIR, V68, P77
   Chavakis E, 2007, CIRC RES, V100, P204, DOI 10.1161/01.RES.0000257774.55970.f4
   Cottone L, 2011, J NUCL MED, V52, P1770, DOI 10.2967/jnumed.111.089177
   Degryse B, 2001, J CELL BIOL, V152, P1197, DOI 10.1083/jcb.152.6.1197
   DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028
   Erez N, 2011, INT J CANCER, V128, P2536, DOI 10.1002/ijc.26032
   Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139
   Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022
   Kang R, 2013, CLIN CANCER RES, V19, P4046, DOI 10.1158/1078-0432.CCR-13-0495
   Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380
   Li W, 2013, BIOCHEM BIOPH RES CO, V436, P156, DOI 10.1016/j.bbrc.2013.04.109
   Liu L, 2011, LEUKEMIA, V25, P23, DOI 10.1038/leu.2010.225
   Lolmede K, 2009, J LEUKOCYTE BIOL, V85, P779, DOI 10.1189/jlb.0908579
   Lu B, 2014, P NATL ACAD SCI USA, V111, P3068, DOI 10.1073/pnas.1316925111
   Lu B, 2012, NATURE, V488, P670, DOI 10.1038/nature11290
   Mantovani A, 2010, CURR OPIN IMMUNOL, V22, P231, DOI 10.1016/j.coi.2010.01.009
   Nars MS, 2013, INT J CANCER, V132, P2471, DOI 10.1002/ijc.27801
   Orlova VV, 2007, EMBO J, V26, P1129, DOI 10.1038/sj.emboj.7601552
   Penzo M, 2010, J IMMUNOL, V184, P4497, DOI 10.4049/jimmunol.0903131
   RAUVALA H, 1987, J BIOL CHEM, V262, P16625
   Rauvala H, 2010, BBA-GENE REGUL MECH, V1799, P164, DOI 10.1016/j.bbagrm.2009.11.012
   Riuzzi F, 2006, J BIOL CHEM, V281, P8242, DOI 10.1074/jbc.M509436200
   Robinson-Smith TM, 2007, CANCER RES, V67, P5708, DOI 10.1158/0008-5472.CAN-06-4375
   ROSENBERG SA, 1986, SCIENCE, V233, P1318, DOI 10.1126/science.3489291
   Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102
   Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858
   Schiraldi M, 2012, J EXP MED, V209, P551, DOI 10.1084/jem.20111739
   Sconocchia G, 2011, INT J CANCER, V128, P2663, DOI 10.1002/ijc.25609
   Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626
   Tang D, 2010, ONCOGENE, V29, P5299, DOI 10.1038/onc.2010.261
   Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078
   Venereau E, 2013, MOL IMMUNOL, V55, P76, DOI 10.1016/j.molimm.2012.10.037
   Venereau E, 2012, J EXP MED, V209, P1519, DOI 10.1084/jem.20120189
   Vezzoli M, 2011, ANTIOXID REDOX SIGN, V15, P2161, DOI 10.1089/ars.2010.3341
   Yang J, 2012, MOL BIOL REP, V39, P3361, DOI 10.1007/s11033-011-1106-6
NR 42
TC 34
Z9 35
U1 0
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD MAR 15
PY 2015
VL 136
IS 6
BP 1381
EP 1389
DI 10.1002/ijc.29125
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AY6XD
UT WOS:000347705200044
PM 25098891
OA Bronze
DA 2022-04-25
ER

PT J
AU Wozniak, M
   Makuch, S
   Winograd, K
   Wisniewski, J
   Ziolkowski, P
   Agrawal, S
AF Wozniak, Marta
   Makuch, Sebastian
   Winograd, Kinga
   Wisniewski, Jerzy
   Ziolkowski, Piotr
   Agrawal, Siddarth
TI 6-Shogaol enhances the anticancer effect of 5-fluorouracil, oxaliplatin,
   and irinotecan via increase of apoptosis and autophagy in colon cancer
   cells in hypoxic/aglycemic conditions
SO BMC COMPLEMENTARY MEDICINE AND THERAPIES
LA English
DT Article
DE 5-fluorouracil; 6-shogaol; Autophagy; Chemosensitivity; Colon cancer;
   Hypoxia
ID DRUG-RESISTANCE; ACTIVATION; DEATH; MECHANISMS; THERAPY; PATHWAY
AB Background: The development and growth of colorectal cancer based on constitutive activation of numerous signaling pathways that stimulate proliferation and metastasis. Plant-derived agents excel by targeting multiple aspects of tumor progression. Previous investigations have shown that ginger derivatives-shogaols possess anti-cancer and anti-inflammatory effects. In the present study, we have examined the anti-cancer effects of 6-shogaol alongside with the most widely used chemotherapeutic agents/regimens in the tumor-like microenvironment conditions.
   Methods: Cytotoxicity on two colon cancer cell lines (SW480 and SW620) was measured by MTT test. Apoptosisassay, immunocytochemical and Western blotting analysis for autophagy and apoptosis detection were performed.
   Results: Here, we report that 6-shogaol by itself or in combination with chemotherapeutic agents/regimens exerted a cytotoxic effect on CRC cells. Cell death might be linked with the activation of autophagy and apoptosis-related pathways. In the tumor-like microenvironment, which is characterized by hypoxia and glucose starvation, 6-shogaol with chemotherapeutics is significantly more potent than conventional chemotherapy alone.
   Conclusions: Collectively, our data suggest that the addition of 6-shogaol to established chemotherapeutic regimens could potentially be a remarkable therapeutic strategy for colorectal cancer.
C1 [Wozniak, Marta; Makuch, Sebastian; Ziolkowski, Piotr; Agrawal, Siddarth] Wroclaw Med Univ, Dept Pathol, Ul K Marcinkowskiego, PL-150368 Wroclaw, Poland.
   [Winograd, Kinga] Wroclaw Univ Sci & Technol, Dept Chem, Wroclaw, Poland.
   [Wisniewski, Jerzy] Wroclaw Med Univ, Dept Biochem, Wroclaw, Poland.
   [Agrawal, Siddarth] Wroclaw Med Univ, Dept & Clin Internal Med Occupat Dis Hypertens &, Wroclaw, Poland.
RP Wozniak, M (corresponding author), Wroclaw Med Univ, Dept Pathol, Ul K Marcinkowskiego, PL-150368 Wroclaw, Poland.
EM marta1wozniak@wp.pl
RI Wiśniewski, Jerzy/AAV-7279-2020; Makuch, Sebastian/ABD-4283-2021;
   Ziolkowski, Piotr/AAU-2452-2021; Wozniak, Marta/ABD-2161-2021; Makuch,
   Sebastian/ABH-4515-2020
OI Wozniak, Marta/0000-0001-7978-6330; Makuch,
   Sebastian/0000-0002-9904-1181; Agrawal, Siddarth/0000-0003-1118-5090;
   Ziolkowski, Piotr/0000-0003-3036-2611
FU National Science CenterNational Science Centre, Poland
   [DEC-2015/19/N/NZ5/0001]; Wroclaw Medical University [STM.A011.17.005]
FX Funding by the National Science Center grant no. DEC-2015/19/N/NZ5/0001
   and Wroclaw Medical University STM.A011.17.005. The funders had no role
   in study design, data collection, and analysis, decision to publish, or
   preparation of the manuscript.
CR Ali BH, 2008, FOOD CHEM TOXICOL, V46, P409, DOI 10.1016/j.fct.2007.09.085
   Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709
   Annamalai G, 2016, BIOMED PHARMACOTHER, V82, P226, DOI 10.1016/j.biopha.2016.04.044
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615
   Fojo T, 2010, CLIN CANCER RES, V16, P5972, DOI 10.1158/1078-0432.CCR-10-1277
   Garg H, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0326-1
   Gonzalez-Vallinas M, 2013, NUTR REV, V71, P585, DOI 10.1111/nure.12051
   Graham J, 2004, NAT REV DRUG DISCOV, V3, P11, DOI 10.1038/nrd1287
   Gustavsson B, 2015, CLIN COLORECTAL CANC, V14, P1, DOI 10.1016/j.clcc.2014.11.002
   Hammond WA, 2016, THER ADV MED ONCOL, V8, P57, DOI 10.1177/1758834015614530
   Horsman MR, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00066
   Hu T, 2016, WORLD J GASTROENTERO, V22, P6876, DOI 10.3748/wjg.v22.i30.6876
   Hu X, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2016.47
   Hung JY, 2009, J AGR FOOD CHEM, V57, P9809, DOI 10.1021/jf902315e
   Jing XM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1089-9
   JOHNSON RC, 1964, J BACTERIOL, V87, P422, DOI 10.1128/JB.87.2.422-426.1964
   Kim SM, 2015, MOL CARCINOGEN, V54, P1132, DOI 10.1002/mc.22184
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Li TY, 2017, BIOMED PHARMACOTHER, V93, P208, DOI 10.1016/j.biopha.2017.06.038
   McCarty Mark F, 2004, Integr Cancer Ther, V3, P349, DOI 10.1177/1534735404270757
   National Cancer Institute, 2018, FAST STATS INTERACTI
   O'dwyer ST, 2007, COLOR DIS, V9, P186
   Onozuka H, 2011, CANCER SCI, V102, P975, DOI 10.1111/j.1349-7006.2011.01880.x
   Pan MH, 2008, MOL NUTR FOOD RES, V52, P527, DOI 10.1002/mnfr.200700157
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Ray A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137614
   Rohwer N, 2011, DRUG RESIST UPDATE, V14, P191, DOI 10.1016/j.drup.2011.03.001
   Safe S, 2016, PHYTOTHER RES, V30, P1723, DOI 10.1002/ptr.5669
   Saint-Martin A, 2019, CANCERS, V11, DOI 10.3390/cancers11060755
   Schneider A, 2008, NEOPLASIA, V10, P1295, DOI 10.1593/neo.08586
   Tan BS, 2013, CANCER LETT, V336, P127, DOI 10.1016/j.canlet.2013.04.014
   Tuorkey MJ, 2015, BIOMED ENVIRON SCI, V28, P808, DOI [10.1016/S0895-3988(15)30111-2, 10.3967/bes2015.112]
   Warin RF, 2014, J AGR FOOD CHEM, V62, P1352, DOI 10.1021/jf405573e
   Xu Y, 2002, ANN ONCOL, V13, P1841, DOI 10.1093/annonc/mdf337
   Yang GL, 2016, MOL MED REP, V13, P2583, DOI 10.3892/mmr.2016.4836
   Zhu YD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054677
NR 37
TC 9
Z9 9
U1 2
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2662-7671
J9 BMC COMPLEMENT MED
JI BMC Complement. Med. Ther.
PD MAY 11
PY 2020
VL 20
IS 1
AR 141
DI 10.1186/s12906-020-02913-8
PG 10
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA MM7TI
UT WOS:000550355300001
PM 32393373
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Garcia-Barros, M
   Coant, N
   Kawamori, T
   Wada, M
   Snider, AJ
   Truman, JP
   Wu, BX
   Furuya, H
   Clarke, CJ
   Bialkowska, AB
   Ghaleb, A
   Yang, VW
   Obeid, LM
   Hannun, YA
AF Garcia-Barros, Monica
   Coant, Nicolas
   Kawamori, Toshihiko
   Wada, Masayuki
   Snider, Ashley J.
   Truman, Jean-Philip
   Wu, Bill X.
   Furuya, Hideki
   Clarke, Christopher J.
   Bialkowska, Agnieszka B.
   Ghaleb, Amr
   Yang, Vincent W.
   Obeid, Lina M.
   Hannun, Yusuf A.
TI Role of neutral ceramidase in colon cancer
SO FASEB JOURNAL
LA English
DT Article
DE sphingolipids ceramide; aberrant crypt foci; azoxymethane; apoptosis
ID RENAL MESANGIAL CELLS; NECROSIS-FACTOR-ALPHA; SPHINGOSINE KINASE 1;
   BETA-CATENIN; COLORECTAL-CANCER; IN-VIVO; INTESTINAL TUMORIGENESIS;
   TUMOR-GROWTH; CRYPT FOCI; CF1 MICE
AB Alterations in sphingolipid metabolism, especially ceramide and sphingosine 1-phosphate, have been linked to colon cancer, suggesting that enzymes of sphingolipid metabolism may emerge as novel regulators and targets in colon cancer. Neutral ceramidase (nCDase), a key enzyme in sphingolipid metabolism that hydrolyzes ceramide into sphingosine, is highly expressed in the intestine; however, its role in colon cancer has not been defined. Here we show that molecular and pharmacological inhibition of nCDase in colon cancer cells increases ceramide, and this is accompanied by decreased cell survival and increased apoptosis and autophagy, with minimal effects on noncancerous cells. Inhibition of nCDase resulted in loss of beta-catenin and inhibition of ERK, components of pathways relevant for colon cancer development. Furthermore, inhibition of nCDase in a xenograft model delayed tumor growth and increased ceramide while decreasing proliferation. It is noteworthy that mice lacking nCDase treated with azoxymethane were protected from tumor formation. Taken together, these studies show that nCDase is pivotal for regulating initiation and development of colon cancer, and these data suggest that this enzyme is a suitable and novel target for colon cancer therapy.
C1 [Garcia-Barros, Monica; Coant, Nicolas; Wada, Masayuki; Snider, Ashley J.; Truman, Jean-Philip; Clarke, Christopher J.; Bialkowska, Agnieszka B.; Ghaleb, Amr; Yang, Vincent W.; Obeid, Lina M.; Hannun, Yusuf A.] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA.
   [Hannun, Yusuf A.] SUNY Stony Brook, Dept Biochem, Stony Brook, NY 11794 USA.
   [Hannun, Yusuf A.] SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA.
   [Hannun, Yusuf A.] SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA.
   [Garcia-Barros, Monica; Coant, Nicolas; Wada, Masayuki; Snider, Ashley J.; Truman, Jean-Philip; Clarke, Christopher J.; Obeid, Lina M.; Hannun, Yusuf A.] SUNY Stony Brook, Stony Brook Canc Ctr, Stony Brook, NY 11794 USA.
   [Kawamori, Toshihiko; Furuya, Hideki] Univ Hawaii, Ctr Canc, Canc Biol Program, Honolulu, HI 96822 USA.
   [Kawamori, Toshihiko] Tokyo Leon Clin, Res Inst Canc Prevent & Pathol Diag, Nagoya, Aichi, Japan.
   [Snider, Ashley J.; Obeid, Lina M.] Northport Vet Affairs Med Ctr, Northport, NY USA.
   [Wu, Bill X.] Med Univ South Carolina, Dept Biochem & Mol Biol, Charleston, SC USA.
RP Hannun, YA (corresponding author), Dept Biochem, 101 Nicolls Rd,T15,023, Stony Brook, NY 11794 USA.; Hannun, YA (corresponding author), Dept Pharmacol, 101 Nicolls Rd,T15,023, Stony Brook, NY 11794 USA.; Hannun, YA (corresponding author), Dept Pathol, 101 Nicolls Rd,T15,023, Stony Brook, NY 11794 USA.; Hannun, YA (corresponding author), Dept Med, 101 Nicolls Rd,T15,023, Stony Brook, NY 11794 USA.
EM yusuf.hannun@stonybrookmedicine.edu
RI Furuya, Hideki/AAH-5719-2021
OI Furuya, Hideki/0000-0002-9536-8662; COANT, Nicolas/0000-0001-9237-2132
FU U.S. National Institutes of Health, National Cancer InstituteUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [R01-CA172517,
   P01-CA97132, R01-CA172113]; ONO Co.; NATIONAL CANCER INSTITUTEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [P01CA097132,
   R01CA172517, R01CA172113] Funding Source: NIH RePORTER
FX This work was supported by U.S. National Institutes of Health, National
   Cancer Institute Grants R01-CA172517 (to Y.A.H.), P01-CA97132 (to
   L.M.O.), and R01-CA172113 (to V.W.Y.). The authors thank the Lipidomics
   Core facility at the State University of New York at Stony Brook for
   lipid analysis, the Lipidomic Facility at the Medical University of
   South Carolina for providing the nCDase inhibitor, the Flow Cytometry
   Core facility for assistance with cell cycle analysis, the Research Core
   Histology Laboratory at Stony Brook University for technical assistance,
   and Dr. Takuji Tanaka (certified pathologist and toxicologist; Gifu
   Municipal Hospital, Gifu, Japan) for assistance with AOM-induced tumors
   diagnosis. The laboratory of Dr. Y.A.H. has research support from ONO
   Co., for a distinct project.
CR Arnold CN, 2005, CANCER-AM CANCER SOC, V104, P2035, DOI 10.1002/cncr.21462
   Begagne E, 2014, J CLIN INVEST, V124, P5368, DOI 10.1172/JCI74188
   Bielawski J, 2010, ADV EXP MED BIOL, V688, P46
   BIRD RP, 1987, CANCER LETT, V37, P147, DOI 10.1016/0304-3835(87)90157-1
   BLAY J, 1985, BIOCHEM J, V225, P85, DOI 10.1042/bj2250085
   Brabletz T, 2000, AM J PATHOL, V156, P865, DOI 10.1016/S0002-9440(10)64955-3
   Castro ME, 2008, CARCINOGENESIS, V29, P491, DOI 10.1093/carcin/bgm246
   Chen Y, 2015, MOL CANCER THER, V14, P259, DOI 10.1158/1535-7163.MCT-14-0468-T
   Dahm F, 2008, BRIT J CANCER, V98, P98, DOI 10.1038/sj.bjc.6604099
   DILLEHAY DL, 1994, J NUTR, V124, P615, DOI 10.1093/jn/124.5.615
   El Alwani M, 2006, PHARMACOL THERAPEUT, V112, P171, DOI 10.1016/j.pharmthera.2006.04.004
   El Bawab S, 1999, J BIOL CHEM, V274, P27948, DOI 10.1074/jbc.274.39.27948
   Franzen R, 2002, J BIOL CHEM, V277, P46184, DOI 10.1074/jbc.M204034200
   Franzen R, 2001, J BIOL CHEM, V276, P35382, DOI 10.1074/jbc.M102153200
   Gandy KAO, 2013, BIOCHEM J, V449, P661, DOI 10.1042/BJ20120213
   Garcia-Barros M, 2014, BBA-MOL CELL BIOL L, V1841, P773, DOI 10.1016/j.bbalip.2013.09.007
   Garzotto M, 1998, CANCER RES, V58, P2260
   Green DW, 2001, J SURG RES, V101, P16, DOI 10.1006/jsre.2001.6241
   Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855
   Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329
   Hannun YA, 2011, J BIOL CHEM, V286, P27855, DOI 10.1074/jbc.R111.254359
   Hernandez-Corbacho MJ, 2015, J BIOL CHEM, V290, P25356, DOI 10.1074/jbc.M115.658658
   Hertervig E, 1997, CANCER, V79, P448, DOI 10.1002/(SICI)1097-0142(19970201)79:3<448::AID-CNCR4>3.3.CO;2-Z
   Huwiler A, 1999, J BIOL CHEM, V274, P7190, DOI 10.1074/jbc.274.11.7190
   Ito M, 2014, BBA-MOL CELL BIOL L, V1841, P682, DOI 10.1016/j.bbalip.2013.09.008
   Johnson RL, 2013, CANCER METAST REV, V32, P39, DOI 10.1007/s10555-012-9404-6
   Kawamori T, 2006, FASEB J, V20, P386, DOI 10.1096/fj.05-4331fje
   Kawamori T, 2009, FASEB J, V23, P405, DOI 10.1096/fj.08-117572
   KIM JH, 1986, CANCER RES, V46, P1120
   Kohno M, 2006, MOL CELL BIOL, V26, P7211, DOI 10.1128/MCB.02341-05
   Kono M, 2006, J BIOL CHEM, V281, P7324, DOI 10.1074/jbc.M508382200
   Kraveka JM, 2003, ARCH BIOCHEM BIOPHYS, V419, P110, DOI 10.1016/j.abb.2003.08.034
   Krutovskikh V A, 1994, IARC Sci Publ, P195
   Kung CP, 2011, CRIT REV EUKAR GENE, V21, P71, DOI 10.1615/CritRevEukarGeneExpr.v21.i1.50
   Liang J, 2013, CANCER CELL, V23, P107, DOI 10.1016/j.ccr.2012.11.013
   Marchesini N, 2007, BBA-MOL CELL BIOL L, V1771, P1418, DOI 10.1016/j.bbalip.2007.10.003
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Morad SAF, 2013, NAT REV CANCER, V13, P51, DOI 10.1038/nrc3398
   Nikolova-Karakashian MN, 2010, ADV EXP MED BIOL, V688, P86
   Novgorodov SA, 2011, J BIOL CHEM, V286, P25352, DOI 10.1074/jbc.M110.214866
   Osawa Y, 2005, J BIOL CHEM, V280, P27879, DOI 10.1074/jbc.M503002200
   Oskouian B, 2007, CELL CYCLE, V6, P522, DOI 10.4161/cc.6.5.3903
   Pattingre S, 2009, AUTOPHAGY, V5, P558, DOI 10.4161/auto.5.4.8390
   Pretlow TP, 2005, BBA-REV CANCER, V1756, P83, DOI 10.1016/j.bbcan.2005.06.002
   Roh H, 2001, CANCER RES, V61, P6563
   Rosenberg DW, 2009, CARCINOGENESIS, V30, P183, DOI 10.1093/carcin/bgn267
   Schmelz EM, 1996, CANCER RES, V56, P4936
   Schmelz EM, 2001, CANCER RES, V61, P6723
   Selzner M, 2001, CANCER RES, V61, P1233
   Stancevic B, 2010, FEBS LETT, V584, P1728, DOI 10.1016/j.febslet.2010.02.026
   Symolon H, 2011, MOL CANCER THER, V10, P648, DOI 10.1158/1535-7163.MCT-10-0754
   Tai CJ, 2012, POL J PATHOL, V63, P93
   Tan SSL, 2014, CLIN TRANSL GASTROEN, V5, DOI 10.1038/ctg.2013.21
   Tanaka K, 2012, J BIOCHEM, V151, P611, DOI 10.1093/jb/mvs033
   Uchida Y, 2010, J INVEST DERMATOL, V130, P2472, DOI 10.1038/jid.2010.153
   Usta J, 2001, BIOCHEMISTRY-US, V40, P9657, DOI 10.1021/bi010535k
   Venable ME, 2009, CELL BIOCHEM FUNCT, V27, P547, DOI 10.1002/cbf.1605
   Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701
   Verma UN, 2003, CLIN CANCER RES, V9, P1291
   Voelkel-Johnson C, 2005, MOL CANCER THER, V4, P1320, DOI 10.1158/1535-7163.MCT-05-0086
   VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901
   Wargovich Michael J, 2010, Cancers (Basel), V2, P1705, DOI 10.3390/cancers2031705
   White-Gilbertson S, 2009, ONCOGENE, V28, P1132, DOI 10.1038/onc.2008.468
   Wu BX, 2009, BBA-MOL CELL BIOL L, V1791, P730, DOI 10.1016/j.bbalip.2009.03.012
NR 64
TC 32
Z9 34
U1 0
U2 8
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD DEC
PY 2016
VL 30
IS 12
BP 4159
EP 4171
DI 10.1096/fj.201600611R
PG 13
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA EC5UG
UT WOS:000388201500022
PM 27609772
OA Green Published
DA 2022-04-25
ER

PT J
AU Trnski, D
   Sabol, M
   Gojevic, A
   Martinic, M
   Ozretic, P
   Musani, V
   Ramic, S
   Levanat, S
AF Trnski, Diana
   Sabol, Maja
   Gojevic, Ante
   Martinic, Marina
   Ozretic, Petar
   Musani, Vesna
   Ramic, Snjezana
   Levanat, Sonja
TI GSK3 beta and Gli3 play a role in activation of Hedgehog-Gli pathway in
   human colon cancer - Targeting GSK3 beta downregulates the signaling
   pathway and reduces cell proliferation
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
LA English
DT Article
DE Hedgehog signaling; Gli3; GSK3 beta; Autophagy; Apoptosis; Colon cancer
ID COLORECTAL-CANCER; SONIC HEDGEHOG; EXPRESSION; SUPPRESSOR; AUTOPHAGY;
   LITHIUM; APOPTOSIS; SUFU; GLYCOGEN-SYNTHASE-KINASE-3-BETA; INVOLVEMENT
AB The role of Hedgehog-Gli (Hh-Gli) signaling in colon cancer tumorigenesis has not yet been completely elucidated. Here we provide strong evidence of Hh-Gli signaling involvement in survival of colon cancer cells, with the main trigger of activation being deregulated GSK3 beta.
   Our clinical data reveals high expression levels of GSK3 beta and Gli3 in human colon cancer tissue samples, with positive correlation between GSK3 beta expression and DUKES' stage. Further experiments on colon cancer cell lines have shown that a deregulated GSK3 beta upregulates Hh-Gli signaling and positively affects colon cancer cell survival. We show that inhibition of GSK3 beta with lithium chloride enhances Gli3 processing into its repressor form, consequently downregulating Hh-Gli signaling, reducing cell proliferation and inducing cell death. Analysis of the molecular mechanisms revealed that lithium chloride enhances Gli3-SuFu-GSK3 beta complex formation leading to more efficient Gli3 cleavage and Hh-Gli signaling downregulation. This work proposes that activation of the Hh-Gli signaling pathway in colon cancer cells occurs non-canonically via deregulated GSK3 beta. Gli3 seems to be the main pathway effector, highlighting the activator potential of this transcription factor, which is highly dependent on GSK3 beta function and fine tuning of the Gli3-SuFu-GSK3 beta platform. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Trnski, Diana; Sabol, Maja; Martinic, Marina; Ozretic, Petar; Musani, Vesna; Levanat, Sonja] Rudjer Boskovic Inst, Div Mol Med, Zagreb 10000, Croatia.
   [Gojevic, Ante] Univ Hosp Ctr Zagreb, Dept Surg, Zagreb, Croatia.
   [Ramic, Snjezana] Univ Hosp Tumors, Sestre Milosrdnice Univ Hosp Ctr, Dept Pathol, Zagreb, Croatia.
RP Levanat, S (corresponding author), Rudjer Boskovic Inst, Div Mol Med, Bijenicka 54, Zagreb 10000, Croatia.
EM diana.trnski@irb.hr; maja.sabol@irb.hr; ante.gojevic@xnet.hr;
   marina.martinic.87@gmail.com; pozretic@irb.hr; vmusani@irb.hr;
   snjezana.ramic@zg.t-com.hr; levanat@irb.hr
RI Ozretić, Petar/G-5189-2014; Musani, Vesna/K-7972-2019; Sabol,
   Maja/G-4177-2011; Ramic, Snjezana/K-8650-2019; Trnski, Diana/N-6816-2015
OI Ozretić, Petar/0000-0001-9757-6636; Sabol, Maja/0000-0001-6968-2327;
   Musani, Vesna/0000-0001-9927-3727; Ramic, Snjezana/0000-0002-5916-8815;
   Trnski, Diana/0000-0003-2441-8439
FU Croatian Ministry of Science, Education and SportsMinistry of Science,
   Education and Sports, Republic of Croatia [098-0982464-2461]
FX The authors wish to thank Dr. Sanja Kapitanovic and Dr. Marijeta Kralj
   for the colon cancer cell lines, Dr. Marijeta Kralj and Dr. Ana-Matea
   Mikecin for help with autophagy analysis, Dr. Andreja Ambriovic-Ristov
   for the alpha-PARP and alpha-caspase-3 antibodies, Lucija Horvat for
   help with confocal microscopy. We also wish to thank all the patients
   who participated in this study, Dr. Fabijan Knezevic from the Sestre
   Milosrdnice University Hospital Center for the use of the autostainer
   and professor Romana Halapir Frankovic from the 5th High School (for
   math and science) in Zagreb for use of the microscope and camera. This
   study was funded by the Croatian Ministry of Science, Education and
   Sports (grant. no. 098-0982464-2461). The funding source had no role in
   the study design; in the collection, analysis and interpretation of
   data; in the writing of the report; and in the decision to submit the
   article for publication.
CR Bai CB, 2002, DEVELOPMENT, V129, P4753
   Bailey CM, 2008, MOL CELL BIOL, V28, P2235, DOI 10.1128/MCB.01866-07
   Bailey CM, 2009, DEV GROWTH DIFFER, V51, P473, DOI 10.1111/j.1440-169X.2009.01110.x
   Cao Q, 2006, CELL RES, V16, P671, DOI 10.1038/sj.cr.7310078
   Chatel G, 2007, INT J CANCER, V121, P2622, DOI 10.1002/ijc.22998
   Cohen MM, 2003, AM J MED GENET A, V123A, P5, DOI 10.1002/ajmg.a.20495
   Cohen Y, 1998, MED ONCOL, V15, P32, DOI 10.1007/BF02787342
   Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Eisenberg-Lerner A, 2009, APOPTOSIS, V14, P376, DOI 10.1007/s10495-008-0307-5
   Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379
   Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Jimenez-Sanchez M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2212
   Jope RS, 2007, NEUROCHEM RES, V32, P577, DOI 10.1007/s11064-006-9128-5
   Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004
   Jope RS, 2003, TRENDS PHARMACOL SCI, V24, P441, DOI 10.1016/S0165-6147(03)00206-2
   Kang HN, 2012, EXP CELL RES, V318, P539, DOI 10.1016/j.yexcr.2011.12.010
   Kim HM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060383
   Kim L, 2006, CURR DRUG TARGETS, V7, P1411, DOI 10.2174/1389450110607011411
   Kise Y, 2009, BIOCHEM BIOPH RES CO, V387, P569, DOI 10.1016/j.bbrc.2009.07.087
   Koch A, 2004, NEUROPATH APPL NEURO, V30, P532, DOI 10.1111/j.1365-2990.2004.00560.x
   Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031
   Kunnimalaiyaan M, 2007, MOL CANCER THER, V6, P1151, DOI 10.1158/1535-7163.MCT-06-0665
   Leovic D, 2012, HEAD NECK-J SCI SPEC, V34, P104, DOI 10.1002/hed.21696
   Luo J, 2009, CANCER LETT, V273, P194, DOI 10.1016/j.canlet.2008.05.045
   Masdehors P, 2000, EXP CELL RES, V257, P48, DOI 10.1006/excr.2000.4870
   Mazumdar T, 2011, ONCOTARGET, V2, P638
   Mazumdar T, 2011, CANCER RES, V71, P1092, DOI 10.1158/0008-5472.CAN-10-2315
   Meijer L, 2004, TRENDS PHARMACOL SCI, V25, P471, DOI 10.1016/j.tips.2004.07.006
   Merchant M, 2004, MOL CELL BIOL, V24, P8627, DOI 10.1128/MCB.24.19.8627-8641.2004
   Nowicki MO, 2008, NEURO-ONCOLOGY, V10, P690, DOI 10.1215/15228517-2008-041
   Pan Y, 2006, MOL CELL BIOL, V26, P3365, DOI 10.1128/MCB.26.9.3365-3377.2006
   Pandey GN, 2009, NEUROCHEM RES, V34, P274, DOI 10.1007/s11064-008-9770-1
   Pham NA, 2007, DIAGN PATHOL, V2, DOI 10.1186/1746-1596-2-8
   Ramalho-Santos M, 2000, DEVELOPMENT, V127, P2763
   Reimers MS, 2013, GASTROENTEROL REP, V1, P166, DOI 10.1093/gastro/got022
   Sabol M, 2012, INT J ONCOL, V41, P1411, DOI 10.3892/ijo.2012.1554
   Sacedon R, 2003, J HISTOCHEM CYTOCHEM, V51, P1557, DOI 10.1177/002215540305101115
   Sarkar S, 2005, J CELL BIOL, V170, P1101, DOI 10.1083/jcb.200504035
   Sasaki H, 1999, DEVELOPMENT, V126, P3915
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Shakoori A, 2005, BIOCHEM BIOPH RES CO, V334, P1365, DOI 10.1016/j.bbrc.2005.07.041
   Shakoori A, 2007, CANCER SCI, V98, P1388, DOI 10.1111/j.1349-7006.2007.00545.x
   Stecca B, 2010, J MOL CELL BIOL, V2, P84, DOI 10.1093/jmcb/mjp052
   Takenaka K, 2007, BIOCHEM BIOPH RES CO, V353, P501, DOI 10.1016/j.bbrc.2006.12.058
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Tempe D, 2006, MOL CELL BIOL, V26, P4316, DOI 10.1128/MCB.02183-05
   Tojo M, 2003, BRIT J DERMATOL, V148, P892, DOI 10.1046/j.1365-2133.2003.05284.x
   Varnat F, 2009, EMBO MOL MED, V1, P338, DOI 10.1002/emmm.200900039
   Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9
   Wang Y, 2013, HEPATOLOGY, V58, P995, DOI 10.1002/hep.26394
   Xu MH, 2012, MED ONCOL, V29, P1010, DOI 10.1007/s12032-011-9899-7
NR 53
TC 32
Z9 35
U1 0
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0925-4439
EI 1879-260X
J9 BBA-MOL BASIS DIS
JI Biochim. Biophys. Acta-Mol. Basis Dis.
PD DEC
PY 2015
VL 1852
IS 12
BP 2574
EP 2584
DI 10.1016/j.bbadis.2015.09.005
PG 11
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA CU8XL
UT WOS:000363827300002
PM 26385428
OA Bronze
DA 2022-04-25
ER

PT J
AU Qian, HR
   Shi, ZQ
   Zhu, HP
   Gu, LH
   Wang, XF
   Yang, Y
AF Qian, Hao-Ran
   Shi, Zhao-Qi
   Zhu, He-Pan
   Gu, Li-Hu
   Wang, Xian-Fa
   Yang, Yi
TI Interplay between apoptosis and autophagy in colorectal cancer
SO ONCOTARGET
LA English
DT Review
DE colorectal cancer; autophagy; apoptosis; cross-talk
ID ADVANCED SOLID TUMORS; COLON-CANCER; CELL-DEATH; THERAPEUTIC TARGET;
   TRIGGERS APOPTOSIS; CROSS-TALK; BCL-X; INHIBITION; EXPRESSION; PATHWAY
AB Autophagy and apoptosis are two pivotal mechanisms in mediating cell survival and death. Cross-talk of autophagy and apoptosis has been documented in the tumorigenesis and progression of cancer, while the interplay between the two pathways in colorectal cancer (CRC) has not yet been comprehensively summarized. In this study, we outlined the basis of apoptosis and autophagy machinery firstly, and then reviewed the recent evidence in cellular settings or animal studies regarding the interplay between them in CRC. In addition, several key factors that modulate the cross-talk between autophagy and apoptosis as well as its significance in clinical practice were discussed. Understanding of the interplay between the cell death mechanisms may benefit the translation of CRC treatment from basic research to clinical use.
C1 [Qian, Hao-Ran; Shi, Zhao-Qi; Zhu, He-Pan; Gu, Li-Hu; Wang, Xian-Fa] Zhejiang Univ, Sir Run Run Shaw Hosp, Surg Zhejiang Univ, Dept Gen Surg,Inst Minimally Invas,Sch Med, Hangzhou 310016, Zhejiang, Peoples R China.
   [Yang, Yi] Hangzhou Normal Univ, Sch Med, Hangzhou Key Lab Med Neurobiol, Dept Pharmacol, Hangzhou 310036, Zhejiang, Peoples R China.
RP Qian, HR (corresponding author), Zhejiang Univ, Sir Run Run Shaw Hosp, Surg Zhejiang Univ, Dept Gen Surg,Inst Minimally Invas,Sch Med, Hangzhou 310016, Zhejiang, Peoples R China.; Yang, Y (corresponding author), Hangzhou Normal Univ, Sch Med, Hangzhou Key Lab Med Neurobiol, Dept Pharmacol, Hangzhou 310036, Zhejiang, Peoples R China.
EM websterqian@126.com; yyang@hznu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81401043]; Zhejiang Provincial Natural
   Science Foundation of ChinaNatural Science Foundation of Zhejiang
   Province [LY17H310005, LY17H160027]
FX This study is supported by National Natural Science Foundation of China
   (81401043) and Zhejiang Provincial Natural Science Foundation of China
   (LY17H310005, LY17H160027).
CR Abraha AM, 2016, WORLD J GASTRO ONCOL, V8, P583, DOI 10.4251/wjgo.v8.i8.583
   Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Alonso MM, 2008, MOL THER, V16, P487, DOI 10.1038/sj.mt.6300400
   Amin A, 2015, INT J MOL SCI, V16, P1544, DOI 10.3390/ijms16011544
   BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Cai ZR, 2014, ANN SURG ONCOL, V21, P179, DOI 10.1245/s10434-013-3146-8
   Carew Jennifer S, 2012, Cancer Manag Res, V4, P357, DOI 10.2147/CMAR.S26133
   Chen JJ, 2017, ONCOTARGETS THER, V10, P811, DOI 10.2147/OTT.S125039
   Chen PJ, 2017, FREE RADICAL BIO MED, V104, P280, DOI 10.1016/j.freeradbiomed.2017.01.033
   Cho DH, 2012, ANTICANCER RES, V32, P4091
   Choi JH, 2014, GASTROENT RES PRACT, V2014, DOI 10.1155/2014/179586
   Cobanoglu B, 2015, INT J CLIN EXP MED, V8, P16071
   Coker-Gurkan A, 2015, ONCOL REP, V33, P2761, DOI 10.3892/or.2015.3918
   Coker-Gurkan A, 2014, EXP CELL RES, V328, P87, DOI 10.1016/j.yexcr.2014.07.022
   Colangelo T, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.29
   Coly PM, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00078
   Cordani M, 2016, MOL ONCOL, V10, P1008, DOI 10.1016/j.molonc.2016.04.001
   Cottone L, 2015, INT J CANCER, V136, P1381, DOI 10.1002/ijc.29125
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Feng Y, 2016, ONCOTARGET, V7, P81402, DOI 10.18632/oncotarget.13233
   Fu LL, 2013, INT J BIOCHEM CELL B, V45, P921, DOI 10.1016/j.biocel.2013.02.007
   Gil J, 2017, MED ONCOL, V34, DOI 10.1007/s12032-016-0869-y
   Gil J, 2016, BIOMARK MED, V10, P1081, DOI 10.2217/bmm-2016-0083
   GLAUMANN H, 1987, EXP MOL PATHOL, V47, P346, DOI 10.1016/0014-4800(87)90018-9
   Hale AN, 2013, AUTOPHAGY, V9, P951, DOI 10.4161/auto.24273
   Han Y, 2014, ASIAN PAC J CANCER P, V15, P4583, DOI 10.7314/APJCP.2014.15.11.4583
   He K, 2016, ONCOGENE, V35, P148, DOI 10.1038/onc.2015.79
   Hu T, 2015, PHYTOMEDICINE, V22, P536, DOI 10.1016/j.phymed.2015.03.010
   Huang SB, 2010, AUTOPHAGY, V6, P256, DOI 10.4161/auto.6.2.11124
   Huangfu LT, 2016, ONCOTARGET, V7, P4735, DOI 10.18632/oncotarget.6732
   Jing Z, 2016, CANCER LETT, V372, P226, DOI 10.1016/j.canlet.2016.01.006
   Kelly PN, 2011, CELL DEATH DIFFER, V18, P1414, DOI 10.1038/cdd.2011.17
   Kim SY, 2014, BIOCHEM PHARMACOL, V88, P178, DOI 10.1016/j.bcp.2014.01.027
   Kim SW, 2016, ONCOTARGET, V7, P4356, DOI 10.18632/oncotarget.5374
   Kim WK, 2016, J NAT PROD, V79, P1097, DOI 10.1021/acs.jnatprod.6b00006
   Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620
   Koehler BC, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1929-y
   Koehler BC, 2014, WORLD J GASTROENTERO, V20, P1923, DOI 10.3748/wjg.v20.i8.1923
   Lee HY, 2015, MAR DRUGS, V13, P543, DOI 10.3390/md13010543
   Lee Y, 2014, INT J ONCOL, V44, P1599, DOI 10.3892/ijo.2014.2339
   Li XL, 2015, WORLD J GASTROENTERO, V21, P84, DOI 10.3748/wjg.v21.i1.84
   Lindqvist LM, 2014, P NATL ACAD SCI USA, V111, P8512, DOI 10.1073/pnas.1406425111
   Liu L, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15027704
   Liu WJ, 2015, CANCER BIOL THER, V16, P511, DOI 10.1080/15384047.2015.1017691
   Mahalingam D, 2014, AUTOPHAGY, V10, P1403, DOI 10.4161/auto.29231
   Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689
   Mei LF, 2015, BRIT J PHARMACOL, V172, P2232, DOI 10.1111/bph.13045
   Nonnenmacher Lisa, 2016, Critical Reviews in Oncogenesis, V21, P253, DOI 10.1615/CritRevOncog.2016016987
   Park JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100819
   Patel S, 2016, ONCOTARGET, V7, P59087, DOI 10.18632/oncotarget.10824
   Qian HR, 2016, ONCOTARGET, V7, P17641, DOI 10.18632/oncotarget.7508
   Sakitani K, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1789-5
   Sasaki K, 2012, ANTI-CANCER DRUG, V23, P675, DOI 10.1097/CAD.0b013e328353f8c7
   Scherr AL, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.233
   Scopa CD, 2003, DIGEST DIS SCI, V48, P1990, DOI 10.1023/A:1026178506348
   Shan TD, 2016, ONCOTARGET, V7, P961, DOI 10.18632/oncotarget.5830
   Shi Y, 2015, J CELL MOL MED, V19, P535, DOI 10.1111/jcmm.12435
   SONG X, 2014, CELL DEATH DIS, V5
   Sueda T, 2016, SCI REP-UK, V6, DOI 10.1038/srep18949
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Tabernero J, 2008, J CLIN ONCOL, V26, P1603, DOI 10.1200/JCO.2007.14.5482
   Takahashi Y, 2005, MOL CELL BIOL, V25, P9369, DOI 10.1128/MCB.25.21.9369-9382.2005
   Tang Y, 2011, CELL DEATH DIFFER, V18, P602, DOI 10.1038/cdd.2010.117
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Wang L, 2015, PHYTOMEDICINE, V22, P1079, DOI 10.1016/j.phymed.2015.08.009
   Wang L, 2015, CANCER BIOL THER, V16, P383, DOI 10.1080/15384047.2014.1002331
   Wang WC, 2016, BIOCHEM PHARMACOL, V121, P8, DOI 10.1016/j.bcp.2016.09.024
   Wang XY, 2015, CANCER RES, V75, P5001, DOI 10.1158/0008-5472.CAN-15-0563
   Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108
   Wiedenmann N, 2007, INVEST NEW DRUG, V25, P411, DOI 10.1007/s10637-007-9058-3
   Wiegering A, 2017, NEOPLASIA, V19, P301, DOI 10.1016/j.neo.2017.01.007
   Wirawan E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.16
   Wolpin BM, 2013, ONCOLOGIST, V18, P377, DOI 10.1634/theoncologist.2012-0378
   Won SJ, 2015, J CELL PHYSIOL, V230, P930, DOI 10.1002/jcp.24825
   Wu SH, 2015, INT J CLIN EXP PATHO, V8, P3882
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Xiong HY, 2010, CANCER LETT, V288, P68, DOI 10.1016/j.canlet.2009.06.039
   Xiong L, 2017, ONCOTARGET, V8, P6419, DOI 10.18632/oncotarget.14117
   Yang JS, 2011, ACTA HISTOCHEM, V113, P810, DOI 10.1016/j.acthis.2011.01.002
   Yang L, 2016, ONCOL LETT, V12, P3771, DOI 10.3892/ol.2016.5213
   Yang XY, 2016, ONCOL LETT, V12, P102, DOI 10.3892/ol.2016.4590
   Yang ZL, 2015, CLIN RES HEPATOL GAS, V39, P98, DOI 10.1016/j.clinre.2014.06.014
   Yazbeck VY, 2008, EXP HEMATOL, V36, P443, DOI 10.1016/j.exphem.2007.12.008
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Zhang JT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147218
   Zhang X, 2016, J CANCER RES CLIN, V142, P453, DOI 10.1007/s00432-015-1997-z
   Zhao S, 2017, ONCOTARGET, V8, P7502, DOI 10.18632/oncotarget.10649
   Zhou CX, 2017, ONCOTARGET, V8, P14736, DOI 10.18632/oncotarget.14718
NR 91
TC 29
Z9 30
U1 1
U2 14
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 5
PY 2017
VL 8
IS 37
BP 62759
EP 62768
DI 10.18632/oncotarget.18663
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FF8GI
UT WOS:000409254200166
PM 28977986
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Guo, XZ
   Ye, XL
   Xiao, WZ
   Wei, XN
   You, QH
   Che, XH
   Cai, YJ
   Chen, F
   Yuan, H
   Liu, XJ
   Yu, MH
AF Guo, Xian-Zhi
   Ye, Xiao-Lei
   Xiao, Wei-Zhong
   Wei, Xue-Ni
   You, Qing-Hua
   Che, Xiao-Hang
   Cai, Yan-Jun
   Chen, Fang
   Yuan, Hao
   Liu, Xiao-Jian
   Yu, Ming-Hua
TI Downregulation of VMP1 confers aggressive properties to colorectal
   cancer
SO ONCOLOGY REPORTS
LA English
DT Article
DE vacuole membrane protein 1 colorectal cancer; lentivirus; invasion;
   proliferation; chemotherapy
ID HEPATOCELLULAR-CARCINOMA; CELL POLARITY; COLON-CANCER; BECLIN 1;
   AUTOPHAGY; EXPRESSION; METASTASIS; APOPTOSIS; PATTERNS; SURVIVAL
AB Vacuole membrane protein 1 (VMP1) was recently found to be involved in the process of tumor metastasis and is also considered to play a vital role in balancing apoptosis and autophagy. In the present study, the expression of VMP1 in colorectal cancer and matched adjacent non-cancerous tissues was evaluated by immunohistochemistry (IHC) for studying the role of VMP1 in the process of colorectal cancer. Kaplan-Meier analysis and the log-rank test were used to calculate the correlation of classic clinicopathological characteristics related to survival and the expression of VMP1. In vitro, a VMP1 stable gene silencing cell model was constructed using a lentiviral vector. The invasive ability and proliferation of colorectal cancer cells were evaluated by Transwell and MTT assays, respectively, and the underlying signaling pathway was explored by western blotting. Additionally, drug susceptibility to cisplatin, oxaliplatin and 5-FU was tested before and after VMP1 knockout. Finally, an animal model was constructed to explore the role of VMP1 in the physiopathologic process of colorectal cancer. Our results indicated that VMP1 showed increased expression in the adjacent non-cancer tissues compared with that in the colorectal cancer tissues. For different stages of colorectal cancer, expression of VMP1 had a negative correlation with the malignancy of the cancer. In clinical research, we also found that the median survival of patients with low VMP1 expression was much shorter than the survival of patients with high expression. In vitro, after infection with the lentivirus,,cells with VMP1 knockout gained significant aggressive properties in regards to invasion and proliferation, and the mechanisms may be related to the activation of the PI3K/Akt/ZO-1/E-cadherin pathway. We also found that shVMP1 cells were more sensitive to 5-FU, but not cisplatin and oxaliplatin. Finally, we found a higher number of formed nodules in nude mice after intraperitoneal injection with shVMP1 cells in the in vivo study.
C1 [Guo, Xian-Zhi; Liu, Xiao-Jian; Yu, Ming-Hua] Fudan Univ, Pudong Med Ctr, Shanghai Pudong Hosp, Dept Med Oncol, Shanghai 201399, Peoples R China.
   [Ye, Xiao-Lei; Che, Xiao-Hang] Ningbo Inst Med Sci, Drugs & Pharmacol Lab, Ningbo 315020, Zhejiang, Peoples R China.
   [Xiao, Wei-Zhong; Cai, Yan-Jun] Fudan Univ, Pudong Med Ctr, Dept Internal Neurol, Shanghai Pudong Hosp, Shanghai 201399, Peoples R China.
   [You, Qing-Hua] Fudan Univ, Pudong Med Ctr, Dept Pathol, Shanghai Pudong Hosp, Shanghai 201399, Peoples R China.
   [Yuan, Hao] Fudan Univ, Pudong Med Ctr, Dept Gen Surg, Shanghai Pudong Hosp, Shanghai 201399, Peoples R China.
   [Wei, Xue-Ni] China Pharmaceut Univ, Dept Pharmacol, Nanjing 211198, Jiangsu, Peoples R China.
   [Chen, Fang] Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou 510515, Guangdong, Peoples R China.
RP Liu, XJ (corresponding author), Fudan Univ, Pudong Med Ctr, Shanghai Pudong Hosp, Dept Med Oncol, 2800 Gongwei Rd, Shanghai 201399, Peoples R China.
EM lxj068@hotmail.com; ymh3011@hotmail.com
RI Liu, Xiaojian/E-3263-2015
OI Liu, Xiaojian/0000-0003-0694-2181; Che, Xiaohang/0000-0002-8910-0205
FU Young Medical Talents Training Program of Pudong Health Bureau of
   Shanghai [PWRq2012-31]; Academic Leaders Training Program of Pudong
   Health Bureau of Shanghai [PWRd2012-15]; Natural Science Foundation of
   Ningbo [2011A610048]
FX The present study was supported by the Young Medical Talents Training
   Program of Pudong Health Bureau of Shanghai (no. PWRq2012-31), the
   Academic Leaders Training Program of Pudong Health Bureau of Shanghai
   (no. PWRd2012-15), and the Natural Science Foundation of Ningbo (no.
   2011A610048).
CR Acosta Karina B, 2011, Recent Pat DNA Gene Seq, V5, P175
   Ando-Akatsuka Y, 1999, J CELL PHYSIOL, V179, P115, DOI 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T
   [Anonymous], 2006, Am J Vet Res, V67, P204
   Debnath J, 2005, AUTOPHAGY, V1, P66, DOI 10.4161/auto.1.2.1738
   Dusetti NJ, 2002, BIOCHEM BIOPH RES CO, V290, P641, DOI 10.1006/bbrc.2001.6244
   Giatromanolaki A, 2010, J CLIN PATHOL, V63, P867, DOI 10.1136/jcp.2010.079525
   Gilabert M, 2013, J CELL PHYSIOL, V228, P1834, DOI 10.1002/jcp.24343
   Grasso D, 2011, J BIOL CHEM, V286, P8308, DOI 10.1074/jbc.M110.197301
   Guo L, 2012, CANCER SCI, V103, P2110, DOI 10.1111/cas.12025
   Hu HK, 2011, SEMIN ONCOL, V38, P500, DOI 10.1053/j.seminoncol.2011.05.004
   Huang XF, 2009, OBES REV, V10, P610, DOI 10.1111/j.1467-789X.2009.00607.x
   Kenific CM, 2010, CURR OPIN CELL BIOL, V22, P241, DOI 10.1016/j.ceb.2009.10.008
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Lattanzi A, 2014, HUM MOL GENET, V23, P3250, DOI 10.1093/hmg/ddu034
   Liu Fen, 2013, Zhonghua Bing Li Xue Za Zhi, V42, P86, DOI 10.3760/cma.j.issn.0529-5807.2013.02.004
   Miao YF, 2010, HEPATO-GASTROENTEROL, V57, P257
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Molejon MI, 2013, AUTOPHAGY, V9, P933, DOI 10.4161/auto.24390
   Molejon MI, 2013, SCI REP-UK, V3, DOI 10.1038/srep01055
   Okegawa T, 2002, J UROLOGY, V167, P1836, DOI 10.1016/S0022-5347(05)65245-7
   Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954
   Qian QY, 2014, BIOCHEM BIOPH RES CO, V443, P1041, DOI 10.1016/j.bbrc.2013.12.090
   Reed Jennifer, 2002, Clin Colorectal Cancer, V2, P119, DOI 10.3816/CCC.2002.n.018
   Root DE, 2006, NAT METHODS, V3, P715, DOI 10.1038/NMETH924
   Sauermann M, 2008, ONCOGENE, V27, P1320, DOI 10.1038/sj.onc.1210743
   Song JR, 2011, J CELL BIOCHEM, V112, P3406, DOI 10.1002/jcb.23274
   Subramanya S, 2010, EXPERT OPIN BIOL TH, V10, P201, DOI 10.1517/14712590903448158
   Wodarz A, 2007, NAT CELL BIOL, V9, P1016, DOI 10.1038/ncb433
   Yang SY, 2011, ANN SURG ONCOL, V18, pS239, DOI 10.1245/s10434-011-1789-x
   Zhou Shi-quan, 2011, Zhonghua Yi Xue Za Zhi, V91, P2828
NR 30
TC 11
Z9 12
U1 0
U2 14
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD NOV
PY 2015
VL 34
IS 5
BP 2557
EP 2566
DI 10.3892/or.2015.4240
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CT5NO
UT WOS:000362857300042
PM 26328607
OA Bronze
DA 2022-04-25
ER

PT J
AU Liu, ZY
   Yang, L
   Zhong, CB
   Zhou, L
AF Liu, Zhongyuan
   Yang, Le
   Zhong, Chongbai
   Zhou, Ling
TI EZH2 regulates H2B phosphorylation and elevates colon cancer cell
   autophagy
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE ATG genes; cell autophagy; colon cancer; EZH2; histone phosphorylation
ID HISTONE; PATHOGENESIS; EXPRESSION; INSIGHTS; GENES
AB Epigenetic alterations, especially histone modification, play vital roles in the pathogenesis of colon cancer. Upregulation of the enhancer of zeste homolog 2 (EZH2) has been reported to contribute to the initiation and progression of colon cancer. This study analyzed the association between EZH2 and phosphorylation of H2B at tyrosine 37 (H2B(Y37ph)) in colon cancer tissues and cells, along with the influences of the EZH2-H2B(Y37ph) axis on colon cancer cell autophagy. Immunohistochemistry was utilized to assess EZH2 and H2B(Y37ph) expressions in clinical samples of colon cancer. Cell transfection was carried out to alter EZH2 and H2B(Y37ph) expressions in colon cancer cells. Co-immunoprecipitation analysis and glutathione-S-transferase (GST) pull down assay were conducted to analyze the association between EZH2 and H2B(Y37ph). Western blotting was utilized to measure proteins expressions related to cell autophagy. We found that there was a positive association between EZH2 and H2B(Y37ph) in colon cancer tissues and cells. EZH2 directly interacted with H2B and promoted H2B(Y37ph) in colon cancer cells using ATP as a phosphate donor. Moreover, EZH2 levated colon cancer cell autophagy in starvation condition. H2B(Y37ph) was required for EZH2-elevated colon cancer cell autophagy under starvation condition. The EZH2-H2B(Y37ph) axis elevated colon cancer cell autophagy possibly via activating transcriptional regulation of ATG genes. In conclusion, EZH2-elevated colon cancer initiation and progression at least in part via inducing colon cancer cell autophagy. EZH2 could phosphorylate H2B(Y37) and then induce transcription activation of ATG genes in colon cancer cells under starvation condition.
C1 [Liu, Zhongyuan; Yang, Le; Zhou, Ling] Jining 1 Peoples Hosp, Dept Gastrointestinal Surg, 6 Jiankang Rd, Jining 272011, Shandong, Peoples R China.
   [Liu, Zhongyuan] Jining Med Univ, Affiliated Jining Peoples Hosp 1, Jining, Peoples R China.
   [Zhong, Chongbai] Zoucheng Hosp Tradit Chinese Med, Dept Gen Surg, Zoucheng, Peoples R China.
RP Zhou, L (corresponding author), Jining 1 Peoples Hosp, Dept Gastrointestinal Surg, 6 Jiankang Rd, Jining 272011, Shandong, Peoples R China.
EM zhouling0017@sina.com
CR Ajiro K, 2000, J BIOL CHEM, V275, P439, DOI 10.1074/jbc.275.1.439
   Bain AL, 2017, METHODS MOL BIOL, V1599, P163, DOI 10.1007/978-1-4939-6955-5_13
   Borbone E, 2011, J CLIN ENDOCR METAB, V96, P1029, DOI 10.1210/jc.2010-1784
   Brehar A C, 2013, J Med Life, V6, P403
   Cavalcanti MCO, 2009, ANIM REPROD SCI, V111, P220, DOI 10.1016/j.anireprosci.2008.03.018
   Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156
   Chrun ES, 2017, PATHOL RES PRACT, V213, P1329, DOI 10.1016/j.prp.2017.06.013
   DEBORD DG, 1988, CANCER LETT, V41, P69
   Ferraro A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115276
   Fussbroich B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021651
   Giannis A, 2000, ANGEW CHEM INT EDIT, V39, P2261, DOI 10.1002/1521-3773(20000703)39:13<2261::AID-ANIE2261>3.0.CO;2-6
   Goel A, 2010, CURR OPIN GASTROEN, V26, P47, DOI 10.1097/MOG.0b013e328332b850
   Huqun, 2012, CANCER-AM CANCER SOC, V118, P1599, DOI 10.1002/cncr.26441
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Lau ATY, 2011, J BIOL CHEM, V286, P26628, DOI 10.1074/jbc.M110.215590
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Lin L, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.985913
   Liu F, 2016, ONCOTARGETS THER, V9, P5999, DOI 10.2147/OTT.S109342
   Liu Y, 2019, ONCOGENE, V38, P980, DOI 10.1038/s41388-018-0466-y
   Madani GK, 2018, J GASTROINTEST CANC, V49, P437, DOI 10.1007/s12029-017-9985-y
   Mahajan K, 2012, NAT STRUCT MOL BIOL, V19, P930, DOI 10.1038/nsmb.2356
   Moradian A, 2014, PROTEOMICS, V14, P489, DOI 10.1002/pmic.201300256
   Okugawa Y, 2015, GASTROENTEROLOGY, V149, P1204, DOI 10.1053/j.gastro.2015.07.011
   Ren WG, 2016, CANCER LETT, V375, P209, DOI 10.1016/j.canlet.2016.02.055
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Szpon Lukasz, 2016, Pol Przegl Chir, V88, P15, DOI 10.1515/pjs-2016-0021
   Tao JX, 2017, J CANCER RES CLIN, V143, P2211, DOI 10.1007/s00432-017-2479-2
   Tian L, 2013, AUTOPHAGY, V9, P1172, DOI 10.4161/auto.24731
   Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395
   Wigle TJ, 2011, FEBS LETT, V585, P3011, DOI 10.1016/j.febslet.2011.08.018
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yao YZ, 2016, GENES-BASEL, V7, DOI 10.3390/genes7100083
   Yu M, 2014, ONCOGENE, V33, P1538, DOI 10.1038/onc.2013.102
NR 33
TC 13
Z9 14
U1 4
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD FEB
PY 2020
VL 235
IS 2
BP 1494
EP 1503
DI 10.1002/jcp.29069
EA JUL 2019
PG 10
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA JQ2GV
UT WOS:000477553700001
PM 31283006
DA 2022-04-25
ER

PT J
AU Fu, W
   Li, X
   Lu, XP
   Zhang, LY
   Li, R
   Zhang, N
   Liu, S
   Yang, X
   Wang, Y
   Zhao, Y
   Meng, XB
   Zhu, WG
AF Fu, Wan
   Li, Xue
   Lu, Xiaopeng
   Zhang, Luyao
   Li, Ran
   Zhang, Nan
   Liu, Shan
   Yang, Xin
   Wang, Yue
   Zhao, Ying
   Meng, Xiangbao
   Zhu, Wei-Guo
TI A novel acridine derivative, LS-1-10 inhibits autophagic degradation and
   triggers apoptosis in colon cancer cells
SO CELL DEATH & DISEASE
LA English
DT Article
ID PHASE-II TRIAL; LYSOSOMAL MEMBRANE PERMEABILIZATION; MALIGNANT
   GLIOMA-CELLS; DNA-DAMAGE RESPONSE; TUMOR MICROENVIRONMENT; SEQUESTOSOME
   1/P62; TOPOISOMERASE-II; AMSACRINE; DEATH; INDUCTION
AB Autophagy promotes cancer cell survival and drug resistance by degrading harmful cellular components and maintaining cellular energy levels. Disruption of autophagy may be a promising approach to sensitize cancer cells to anticancer drugs. The combination of autophagic inhibitors, such as chloroquine (CQ) and lucanthone with conventional cancer therapeutics has been investigated in clinical trials, but adverse drug-drug interactions are a high possibility. Here we designed and synthesized a novel, small-molecule library based on an acridine skeleton and the CQ structure with various modifications and substitutions and screened the compounds for effective autophagy inhibition. We found that 9-chloro-2-(3-(dimethylamino) propyl) pyrrolo[2,3,4-kl] acridin-1(2H)-one (LS-1-10) was the most effective from our library at inhibiting autophagic-mediated degradation and could decrease the viability of multiple colon cancer cells. In addition, LS-1-10 induced DNA damage and caspase 8-mediated apoptosis. Overall, this small molecule was more efficient at reducing the viability of cancer cells than other conventional chemotherapeutic agents, such as CQ and amsacrine. The anticancer and autophagy-inhibiting activities of LS-1-10 were confirmed in vivo in a xenograft mouse model. Collectively, this study has identified a new and efficient single compound with both autophagy-inhibiting and anticancer activity, which may provide a novel approach for cancer therapy.
C1 [Fu, Wan; Li, Xue; Lu, Xiaopeng; Zhang, Luyao; Li, Ran; Zhang, Nan; Liu, Shan; Yang, Xin; Wang, Yue; Zhao, Ying; Meng, Xiangbao; Zhu, Wei-Guo] Peking Univ, Key Lab Carcinogenesis & Translat Res,Sch Basic M, State Key Lab Nat & Biomimet Drugs,Minist Educ,De, Beijing Key Lab Prot Posttranslat Modificat & Cel, Beijing 100191, Peoples R China.
   [Lu, Xiaopeng; Zhu, Wei-Guo] Shenzhen Univ, Sch Med, Dept Biochem & Mol Biol, Shenzhen 518060, Peoples R China.
   [Zhu, Wei-Guo] Peking Univ, Peking Tsinghua Univ Ctr Life Sci, Beijing 100871, Peoples R China.
RP Zhao, Y; Meng, XB; Zhu, WG (corresponding author), Peking Univ, Dept Biochem & Mol Biol, Key Lab Carcinogenesis & Translat Res, State Key Lab Nat & Biomimet Drugs,Minist Educ, Xueyuan Rd 38, Beijing 100191, Peoples R China.
EM zhaoying0812@bjmu.edu.cn; xbmeng@bjmu.edu.cn; zhuweiguo@bjmu.edu.cn
OI Zhu, Wei-Guo/0000-0001-8385-6581
FU National Key Research and Development Program of China (Protein
   Machinery and Life Science Grant ) [2013CB911000]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [31570812, 81530074, 81222028, 81621063, 81573272, 81472581];
   Discipline Construction Funding of Shenzhen; Shenzhen Municipal
   Commission of Science and Technology Innovation [JCYJ20160427104855100];
   Beijing Natural Science FoundationBeijing Natural Science Foundation
   [7162109]
FX This study was supported by the National Key Research and Development
   Program of China (Protein Machinery and Life Science Grant 2013CB911000)
   and the National Natural Science Foundation of China (grant numbers
   31570812, 81530074, 81621063, 81222028, 81621063, 81573272 and
   81472581); Discipline Construction Funding of Shenzhen (2016); the
   Shenzhen Municipal Commission of Science and Technology Innovation
   (grant number JCYJ20160427104855100) and the Beijing Natural Science
   Foundation (7162109). We thank Dr. Jessica Tamanini of ETediting for
   language editing.. XM and SL are inventors on a patent
   (CN201410065618.6), and patent applications (WO 2015/127878 A1,
   US-2017-0015664-A1, EP3098222 (A1), 2016-554241 (JP), 2015222590 (Au))
   held by Peking University that covers the preparation and use of
   acridine derivatives.
CR Albini A, 2007, NAT REV CANCER, V7, P139, DOI 10.1038/nrc2067
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   AMREIN PC, 1984, CANCER TREAT REP, V68, P923
   [Anonymous], 2016, EU patent application, Patent No. [EP3098222(A1)[P], 3098222]
   [Anonymous], 2016, AU patent application, Patent No. [2015222590[P], 201410065618]
   [Anonymous], 2016, JP patent application, Patent No. [2016-554241[P], 2016554241]
   [Anonymous], 2016, AU patent application, Patent No. [2015222590[P], 2015222590]
   BERNSTEIN HN, 1991, ANN OPHTHALMOL, V23, P292
   Boya P, 2008, ONCOGENE, V27, P6434, DOI 10.1038/onc.2008.310
   BRAMWELL VHC, 1984, EUR J CANCER CLIN ON, V20, P753, DOI 10.1016/0277-5379(84)90212-8
   Carew JS, 2007, AUTOPHAGY, V3, P464, DOI 10.4161/auto.4311
   Carew Jennifer S, 2012, Cancer Manag Res, V4, P357, DOI 10.2147/CMAR.S26133
   Carew JS, 2011, J BIOL CHEM, V286, P6602, DOI 10.1074/jbc.M110.151324
   CASSILETH PA, 1986, LEUKEMIA RES, V10, P1257, DOI 10.1016/0145-2126(86)90331-0
   Conus S, 2012, J BIOL CHEM, V287, P21142, DOI 10.1074/jbc.M111.306399
   CREECH RH, 1984, CANCER TREAT REP, V68, P1183
   CRENSHAW JM, 1995, BIOCHEMISTRY-US, V34, P13682, DOI 10.1021/bi00041a050
   Dassonneville L, 1999, BIOCHEM PHARMACOL, V58, P1307, DOI 10.1016/S0006-2952(99)00221-X
   DEBERNARDI B, 1984, CANCER TREAT REP, V68, P1051
   Denny WA, 2002, CURR MED CHEM, V9, P1655
   Efeyan A, 2015, NATURE, V517, P302, DOI 10.1038/nature14190
   Erdal H, 2005, P NATL ACAD SCI USA, V102, P192, DOI 10.1073/pnas.0408592102
   GLAUMANN H, 1987, EXP MOL PATHOL, V47, P346, DOI 10.1016/0014-4800(87)90018-9
   Green DR, 2014, CELL, V157, P65, DOI 10.1016/j.cell.2014.02.049
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Hou W, 2010, AUTOPHAGY, V6, P891, DOI 10.4161/auto.6.7.13038
   INAMASU M, 1984, CANCER TREAT REP, V68, P1411
   Kaminskyy V, 2012, BBA-PROTEINS PROTEOM, V1824, P44, DOI 10.1016/j.bbapap.2011.05.013
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   KAOSHAN CS, 1984, CANCER TREAT REP, V68, P989
   Kaur J, 2015, NAT REV MOL CELL BIO, V16, P461, DOI 10.1038/nrm4024
   Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Knowles HJ, 2007, FRONT BIOSCI-LANDMRK, V12, P4298, DOI 10.2741/2389
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Liao WJ, 2009, METHODS, V48, P46, DOI 10.1016/j.ymeth.2009.02.016
   Livesey KM, 2009, CURR OPIN INVEST DR, V10, P1269
   LOUIE AC, 1985, J CLIN ONCOL, V3, P562, DOI 10.1200/JCO.1985.3.4.562
   Luo MH, 2004, ANTICANCER RES, V24, P2127
   Luzio JP, 2007, NAT REV MOL CELL BIO, V8, P622, DOI 10.1038/nrm2217
   Martinez R, 2005, CURR MED CHEM, V12, P127, DOI 10.2174/0929867053363414
   Mbeunkui F, 2009, CANCER CHEMOTH PHARM, V63, P571, DOI 10.1007/s00280-008-0881-9
   McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109
   Meng X, 2015, Fused acridine derivative and pharmaceutical composition, preparation method and use thereof, Patent No. [WO 2015/127878 A1[P], 2015127878]
   Meng X, 2016, US patent application, Patent No. [US-2017-0015664-A1[P], 20170015664]
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mizushima N, 2010, NAT CELL BIOL, V12, P823, DOI 10.1038/ncb0910-823
   Nitiss JL, 2009, NAT REV CANCER, V9, P338, DOI 10.1038/nrc2607
   Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532
   Paglin S, 2001, CANCER RES, V61, P439
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   Robert T, 2011, NATURE, V471, P74, DOI 10.1038/nature09803
   Saftig P, 2009, NAT REV MOL CELL BIO, V10, P623, DOI 10.1038/nrm2745
   Schmidt A, 2015, ADV HETEROCYCL CHEM, V115, P287, DOI 10.1016/bs.aihch.2015.04.004
   Sehgal AR, 2015, LEUKEMIA, V29, P517, DOI 10.1038/leu.2014.349
   Seibenhener ML, 2004, MOL CELL BIOL, V24, P8055, DOI 10.1128/MCB.24.18.8055-8068.2004
   Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102
   Shen S, 2011, ONCOGENE, V30, P4544, DOI 10.1038/onc.2011.168
   Solomon VR, 2009, EUR J PHARMACOL, V625, P220, DOI 10.1016/j.ejphar.2009.06.063
   Wang YN, 2016, MOL CELL, V63, P34, DOI 10.1016/j.molcel.2016.05.027
   Wooten MW, 2008, J BIOL CHEM, V283, P6783, DOI 10.1074/jbc.M709496200
   Zhao Y, 2010, NAT CELL BIOL, V12, P665, DOI 10.1038/ncb2069
   Zhu K, 2010, ONCOGENE, V29, P451, DOI 10.1038/onc.2009.343
NR 69
TC 12
Z9 13
U1 4
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD OCT
PY 2017
VL 8
AR e3086
DI 10.1038/cddis.2017.498
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FL2CV
UT WOS:000414022900073
PM 28981103
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Din, FVN
   Valanciute, A
   Houde, VP
   Zibrova, D
   Green, KA
   Sakamoto, K
   Alessi, DR
   Dunlop, MG
AF Din, Farhat V. N.
   Valanciute, Asta
   Houde, Vanessa P.
   Zibrova, Daria
   Green, Kevin A.
   Sakamoto, Kei
   Alessi, Dario R.
   Dunlop, Malcolm G.
TI Aspirin Inhibits mTOR Signaling, Activates AMP-Activated Protein Kinase,
   and Induces Autophagy in Colorectal Cancer Cells
SO GASTROENTEROLOGY
LA English
DT Article
DE Chemoprevention; Colon Cancer; Oncogene; Tumor Suppressor
ID GROWTH; PROLIFERATION; METFORMIN; PATHWAY; LKB1; PHOSPHORYLATION;
   EXPRESSION; MORTALITY; APOPTOSIS; TARGET
AB BACKGROUND & AIMS: Aspirin reduces the incidence of and mortality from colorectal cancer (CRC) by unknown mechanisms. Cancer cells have defects in signaling via the mechanistic target of rapamycin (mTOR), which regulates proliferation. We investigated whether aspirin affects adenosine monophosphate-activated protein kinase (AMPK) and mTOR signaling in CRC cells. METHODS: The effects of aspirin on mTOR signaling, the ribosomal protein S6, S6 kinase 1 (S6K1), and eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) were examined in CRC cells by immunoblotting. Phosphorylation of AMPK was measured; the effects of loss of AMPK alpha on the aspirin-induced effects of mTOR were determined using small interfering RNA (siRNA) in CRC cells and in AMPK(alpha 1/alpha 2-/-) mouse embryonic fibroblasts. LC3 and ULK1 were used as markers of autophagy. We analyzed rectal mucosa samples from patients given 600 mg aspirin, once daily for 1 week. RESULTS: Aspirin reduced mTOR signaling in CRC cells by inhibiting the mTOR effectors S6K1 and 4E-BP1. Aspirin changed nucleotide ratios and activated AMPK in CRC cells. mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPK alpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR. Aspirin induced autophagy, a feature of mTOR inhibition. Aspirin and metformin (an activator of AMPK) increased inhibition of mTOR and Akt, as well as autophagy in CRC cells. Rectal mucosal samples from patients given aspirin had reduced phosphorylation of S6K1 and S6. CONCLUSIONS: Aspirin is an inhibitor of mTOR and an activator of AMPK, targeting regulators of intracellular energy homeostasis and metabolism. These could contribute to its protective effects against development of CRC.
C1 [Din, Farhat V. N.] Univ Edinburgh, Western Gen Hosp, MRC Inst Genet & Mol Med, Colon Canc Genet Grp,MRC Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland.
   [Din, Farhat V. N.; Valanciute, Asta; Dunlop, Malcolm G.] Univ Edinburgh, Inst Genet & Mol Med, Edinburgh EH4 2XU, Midlothian, Scotland.
   [Din, Farhat V. N.; Valanciute, Asta; Dunlop, Malcolm G.] Western Gen Hosp Edinburgh, Med Res Council Human Genet Unit, Edinburgh, Midlothian, Scotland.
   [Houde, Vanessa P.; Zibrova, Daria; Sakamoto, Kei; Alessi, Dario R.] Univ Dundee, Med Res Council Prot Phosphorylat Unit, Dundee, Scotland.
   [Green, Kevin A.] Univ Dundee, Coll Life Sci, Dundee, Scotland.
RP Din, FVN (corresponding author), Univ Edinburgh, Western Gen Hosp, MRC Inst Genet & Mol Med, Colon Canc Genet Grp,MRC Human Genet Unit, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.
EM Farhat.Din@igmm.ed.ac.uk
RI Dunlop, Malcolm G/F-1973-2011; sakamoto, kei/C-8806-2019; Din,
   Farhat/A-1944-2015
OI Dunlop, Malcolm G/0000-0002-3033-5851; sakamoto,
   kei/0000-0001-8839-5980; 
FU Cancer Research UKCancer Research UK [C26031/A11378]; CORE Charity;
   Cancer Research UKCancer Research UK [11378, 12076] Funding Source:
   researchfish; Medical Research CouncilUK Research & Innovation
   (UKRI)Medical Research Council UK (MRC)European Commission
   [MC_U127015387, MC_U127088492, MC_U127527198, MC_PC_U127527198] Funding
   Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research
   Council UK (MRC) [MC_PC_U127527198, MC_U127527198, MC_U127015387,
   MC_U127088492] Funding Source: UKRI
FX This work was funded by a clinician scientist fellowship to FVND from
   Cancer Research UK (C26031/A11378) and additional funding from a Centre
   grant to MGD from CORE Charity.
CR Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702
   Baba Y, 2010, BRIT J CANCER, V103, P1025, DOI 10.1038/sj.bjc.6605846
   Ben Sahra I, 2010, CANCER RES, V70, P2465, DOI 10.1158/0008-5472.CAN-09-2782
   Dibble CC, 2009, MOL CELL BIOL, V29, P5657, DOI 10.1128/MCB.00735-09
   Din FVN, 2010, GUT, V59, P1670, DOI 10.1136/gut.2009.203000
   Din FVN, 2004, BRIT J CANCER, V91, P381, DOI 10.1038/sj.bjc.6601913
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   Ericson K, 2010, P NATL ACAD SCI USA, V107, P2598, DOI 10.1073/pnas.0914018107
   Fogarty S, 2010, BBA-PROTEINS PROTEOM, V1804, P581, DOI 10.1016/j.bbapap.2009.09.012
   Fujishita T, 2008, P NATL ACAD SCI USA, V105, P13544, DOI 10.1073/pnas.0800041105
   Guertin DA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe24
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009
   Hawley SA, 2010, CELL METAB, V11, P554, DOI 10.1016/j.cmet.2010.04.001
   Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008
   Hosono K, 2010, CANCER PREV RES, V3, P1077, DOI 10.1158/1940-6207.CAPR-10-0186
   Huang SB, 2010, AUTOPHAGY, V6, P256, DOI 10.4161/auto.6.2.11124
   Huang X, 2008, BIOCHEM J, V412, P211, DOI 10.1042/BJ20080557
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Johnson SM, 2010, J AM COLL SURGEONS, V210, P767, DOI 10.1016/j.jamcollsurg.2009.12.008
   Kalender A, 2010, CELL METAB, V11, P390, DOI 10.1016/j.cmet.2010.03.014
   Keith CT, 2005, NAT REV DRUG DISCOV, V4, P71, DOI 10.1038/nrd1609
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06
   Lai MD, 2007, CURR GENOMICS, V8, P43
   Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011
   Levine YC, 2007, J BIOL CHEM, V282, P20351, DOI 10.1074/jbc.M702182200
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Naguib A, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-123
   O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925
   Parsons DW, 2005, NATURE, V436, P792, DOI 10.1038/436792a
   Pelucchi C, 2010, EUR J CANCER, V46, P1866, DOI 10.1016/j.ejca.2010.03.010
   Rothwell PM, 2010, LANCET, V376, P1741, DOI 10.1016/S0140-6736(10)61543-7
   Sakamoto K, 2006, AM J PHYSIOL-ENDOC M, V290, pE780, DOI 10.1152/ajpendo.00443.2005
   Sankhala K, 2009, TARGET ONCOL, V4, P135, DOI 10.1007/s11523-009-0107-z
   Shaw RJ, 2009, ACTA PHYSIOL, V196, P65, DOI 10.1111/j.1748-1716.2009.01972.x
   Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007
   She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023
   Shen ZL, 2010, AM J SURG, V200, P59, DOI 10.1016/j.amjsurg.2009.05.005
   Shiff SJ, 1996, EXP CELL RES, V222, P179, DOI 10.1006/excr.1996.0023
   Sparks CA, 2010, ONCOGENE, V29, P3733, DOI 10.1038/onc.2010.139
   Treins C, 2010, ONCOGENE, V29, P1003, DOI 10.1038/onc.2009.401
   Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866
   Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045
   Wallace K, 2005, CANCER EPIDEM BIOMAR, V14, P2082, DOI 10.1158/1055-9965.EPI-04-0757
   Wang W, 2002, MOL CELL BIOL, V22, P3425, DOI 10.1128/MCB.22.10.3425-3436.2002
   Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340
   Workman P, 2010, BRIT J CANCER, V102, P1555, DOI 10.1038/sj.bjc.6605642
   Wu WKK, 2009, BIOCHEM BIOPH RES CO, V382, P79, DOI 10.1016/j.bbrc.2009.02.140
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yin HY, 2006, BIOTECHNOL LETT, V28, P1263, DOI 10.1007/s10529-006-9084-9
   Zakikhani M, 2010, BREAST CANCER RES TR, V123, P271, DOI 10.1007/s10549-010-0763-9
NR 53
TC 251
Z9 264
U1 4
U2 118
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
EI 1528-0012
J9 GASTROENTEROLOGY
JI Gastroenterology
PD JUN
PY 2012
VL 142
IS 7
BP 1504
EP +
DI 10.1053/j.gastro.2012.02.050
PG 15
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 952GF
UT WOS:000304778700029
OA Green Published, Green Accepted
HC Y
HP N
DA 2022-04-25
ER

PT J
AU Tian, ML
   Wan, YL
   Tang, JQ
   Li, H
   Yu, G
   Zhu, J
   Ji, SQ
   Guo, H
   Zhang, N
   Li, WR
   Gai, JW
   Wang, L
   Dai, LF
   Liu, D
   Lei, LD
   Zhu, SG
AF Tian, Maolin
   Wan, Yuanlian
   Tang, Jianqiang
   Li, Hui
   Yu, Ge
   Zhu, Jing
   Ji, Shiqi
   Guo, Hui
   Zhang, Nan
   Li, Weiren
   Gai, Junwei
   Wang, Lei
   Dai, Lifang
   Liu, Die
   Lei, Liandi
   Zhu, Shigong
TI Depletion of tissue factor suppresses hepatic metastasis and tumor
   growth in colorectal cancer via the downregulation of MMPs and the
   induction of autophagy and apoptosis
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE MMPs; colon cancer; tissue factor; hepatic metastasis; autophagy;
   unfolded protein response (UPR); PERK
ID PROTEIN-SYNTHESIS
AB Tissue factor (TF) is a significant risk factor for hepatic metastasis in patients with colorectal cancer (CRC). However, the mechanism by which TF promotes hepatic metastasis in CRC remains elusive. In this study, we first confirmed that TF expression was significantly correlated with lymph node metastasis, hepatic metastasis and TNM staging in clinical CRC samples, and found that TF expression in colon cancer cell lines was correlated with the invasion ability. Next, by employing TF-overexpressing LOVO cell line as a model we demonstrated that lentivirus mediated knockdown of TF suppressed the migration and invasion of LOVO cells in vitro, and hepatic metastasis of colorectal cancer in nude mice orthotopic model. Mechanistically, we found that TF knockdown decreases colony formation ability and induced autophagy and apoptosis of LOVO cells, and this was at least partly mediated by the activation of unfolded protein response/PERK signaling. In conclusion, our data provide new insight into hepatic metastasis of CRC. Agents targeting TF should be developed as adjuvant therapeutics for CRC metastasis.
C1 [Tian, Maolin; Wan, Yuanlian; Tang, Jianqiang; Li, Hui; Yu, Ge; Zhu, Jing] Peking Univ First Hosp, Dept Gen Surg, Beijing, Peoples R China.
   [Ji, Shiqi; Guo, Hui; Zhang, Nan; Li, Weiren; Gai, Junwei; Wang, Lei] Peking Univ First Hosp, Dept Urol, Beijing, Peoples R China.
   [Dai, Lifang; Liu, Die] Peking Univ First Hosp, Dept Pediat, Beijing, Peoples R China.
   [Lei, Liandi] Peking Univ, Hlth Sci Anal Ctr, Beijing 100871, Peoples R China.
   [Zhu, Shigong] Peking Univ Hlth Sci Ctr, Dept Physiol & Pathophysiol, Beijing, Peoples R China.
   [Tian, Maolin] Capital Med Univ, Beijing Chaoyang Hosp, Dept Hernia & Abdominal Wall Surg, Beijing, Peoples R China.
RP Wan, YL (corresponding author), Peking Univ First Hosp, Dept Gen Surg, Beijing, Peoples R China.
EM wan@bjmu.edu.cn; tjq@hotmail.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [30872469]; National Natural Science Youth
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [30801092]
FX This work was supported by the grants from the National Natural Science
   Foundation of China (No. 30872469) and National Natural Science Youth
   Foundation of China (No. 30801092).
CR Cheng K. C., 2008, Hong Kong Medical Journal, V14, P432
   Deng L, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.9
   Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509
   Kenific CM, 2010, CURR OPIN CELL BIOL, V22, P241, DOI 10.1016/j.ceb.2009.10.008
   Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X
   Lee CJ, 2010, THROMB RES, V125, pS7, DOI 10.1016/j.thromres.2010.01.022
   Lin WS, 2009, NAT NEUROSCI, V12, P379, DOI 10.1038/nn.2273
   Mukherjee S, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-91
   Noda NN, 2008, GENES CELLS, V13, P1211, DOI 10.1111/j.1365-2443.2008.01238.x
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Pavitt GD, 2009, BIOCHEM SOC T, V37, P1298, DOI 10.1042/BST0371298
   Rak J, 2006, SEMIN THROMB HEMOST, V32, P54, DOI 10.1055/s-2006-933341
   Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027
   Satoo K, 2009, EMBO J, V28, P1341, DOI 10.1038/emboj.2009.80
   Scheper GC, 2007, NAT REV GENET, V8, P711, DOI 10.1038/nrg2142
   So MK, 2006, NAT BIOTECHNOL, V24, P339, DOI 10.1038/nbt1188
   Sorbye Halfdan, 2008, Tidsskr Nor Laegeforen, V128, P194
   Wang L, 2007, APOPTOSIS, V12, P1489, DOI 10.1007/s10495-007-0073-9
   Zerbib P, 2009, J SURG RES, V153, P239, DOI 10.1016/j.jss.2008.05.014
   Zhang XX, 2011, J BIOL CHEM, V286, P1429, DOI 10.1074/jbc.M110.146530
   Zucker S, 2004, CANCER METAST REV, V23, P101, DOI 10.1023/A:1025867130437
NR 21
TC 20
Z9 21
U1 2
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD NOV 15
PY 2011
VL 12
IS 10
BP 896
EP 907
DI 10.4161/cbt.12.10.17679
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 849ZW
UT WOS:000297165200006
PM 22052255
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Qian, K
   Sun, LY
   Zhou, GQ
   Ge, HX
   Meng, Y
   Li, JF
   Li, X
   Fang, XQ
AF Qian, Kun
   Sun, Laiyu
   Zhou, Guoqing
   Ge, Haixia
   Meng, Yue
   Li, Jingfen
   Li, Xiao
   Fang, Xinqiang
TI Trifluoperazine as an alternative strategy for the inhibition of tumor
   growth of colorectal cancer
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE apoptosis; autophagy; colorectal cancer; epithelial-mesenchymal
   transition; trifluoperazine
ID COLON-CANCER; CALMODULIN; THERAPY; SCHIZOPHRENIA; EXPRESSION; AUTOPHAGY;
   CELLS
AB The development of cancer in patients with schizophrenia is affected by genetic and environmental factors and antipsychotic medication. Several studies found that schizophrenia was associated with decreased risk of some cancers, and the neuroleptic medication might help to reduce the risk of colorectal cancer (CRC). Phenothiazine drugs including trifluoperazine (TFP) are widely used antipsychotic drugs and showed some antitumor effects, we here investigated the potential application of TFP in the treatment of colon cancer. A series doses of TFP were treated to the colon cancer cell line HCT116 and the inhibitory concentration (IC50) of TFP for HCT116 was determined by cell counting kit-8. The results indicated that the treatment of TFP impaired the cell vitality of HCT116 in a dose- and time-dependent manner. Meanwhile, the Edu assay demonstrated that the proliferation was also inhibited by TFP, which was accompanied with the induction of apoptosis and autophagy. The expression of CCNE1, CDK4, and antiapoptosis factor BCL-2 was downregulated but the proapoptosis factor BAX was upregulated. The autophagy inhibitor chloroquine could significantly reverse the TFP-induced apoptosis. Moreover, the ability of migration and invasion of HCT116 was found to be suppressed by TFP, which was associated with the inhibition of epithelial-mesenchymal transition (EMT). The function of TFP in vivo was further confirmed. The results showed that the administration of TFP remarkably abrogated the tumor growth with decreased tumor volume and proliferation index Ki-67 level in tumor tissues. The EMT phenotype was also confirmed to be inhibited by TFP in vivo, suggesting the promising antitumor effects of TFP in CRC.
C1 [Qian, Kun; Sun, Laiyu; Zhou, Guoqing; Ge, Haixia; Meng, Yue; Li, Jingfen; Li, Xiao; Fang, Xinqiang] Huzhou Univ, Coll Life Sci, 759 E 2nd Rd, Huzhou 313000, Zhejiang, Peoples R China.
RP Qian, K (corresponding author), Huzhou Univ, Coll Life Sci, 759 E 2nd Rd, Huzhou 313000, Zhejiang, Peoples R China.
EM qiankun@zjhu.edu.cn
FU Public Projects of Zhejiang Province [LGC19B070002]; Huzhou science and
   technology planning project [2016GY04]
FX Public Projects of Zhejiang Province, Grant/Award Number: LGC19B070002;
   Huzhou science and technology planning project, Grant/Award Number:
   2016GY04
CR Berchtold MW, 2014, BBA-MOL CELL RES, V1843, P398, DOI 10.1016/j.bbamcr.2013.10.021
   Booth LA, 2014, CELL SIGNAL, V26, P549, DOI 10.1016/j.cellsig.2013.11.028
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Brosius SN, 2014, J NEUROPATH EXP NEUR, V73, P1078, DOI 10.1097/NEN.0000000000000126
   Chen MH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027186
   Dalton SO, 2006, BRIT J CANCER, V95, P934, DOI 10.1038/sj.bjc.6603259
   Dienstmann R, 2015, J CLIN ONCOL, V33, P1787, DOI 10.1200/JCO.2014.60.0213
   Ding L, 2015, BBA-MOL BASIS DIS, V1852, P2494, DOI 10.1016/j.bbadis.2015.08.011
   Freeman HJ, 2013, WORLD J GASTROENTERO, V19, P8468, DOI 10.3748/wjg.v19.i46.8468
   Gangopadhyay S, 2007, MUTAT RES-GEN TOX EN, V633, P117, DOI 10.1016/j.mrgentox.2007.05.011
   Huang KY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S16-S10
   Ji JG, 2013, SCHIZOPHRENIA BULL, V39, P527, DOI 10.1093/schbul/sbs065
   Kim JH, 2015, WORLD J GASTROENTERO, V21, P5158, DOI 10.3748/wjg.v21.i17.5158
   Kim SE, 2015, WORLD J GASTROENTERO, V21, P5167, DOI 10.3748/wjg.v21.i17.5167
   Kurniali PC, 2014, WORLD J GASTROENTERO, V20, P1910, DOI 10.3748/wjg.v20.i8.1910
   Lee MS, 2007, CANCER RES, V67, P11359, DOI 10.1158/0008-5472.CAN-07-2235
   Polischouk AG, 2007, MOL CANCER THER, V6, P2303, DOI 10.1158/1535-7163.MCT-06-0402
   Preti A, 2011, PSYCHIAT INVEST, V8, P77, DOI 10.4306/pi.2011.8.2.77
   Pulkoski-Gross A, 2015, MOL PHARMACOL, V87, P501, DOI 10.1124/mol.114.096941
   Qi L, 2013, SCI CHINA LIFE SCI, V56, P1020, DOI 10.1007/s11427-013-4561-6
   Shin SY, 2006, EUR J PHARM SCI, V28, P300, DOI 10.1016/j.ejps.2006.03.002
   Shin SY, 2001, J BIOL CHEM, V276, P7797, DOI 10.1074/jbc.M009465200
   Tamas K, 2015, CANCER TREAT REV, V41, P671, DOI 10.1016/j.ctrv.2015.06.007
   Wiklund ED, 2010, INT J CANCER, V126, P28, DOI 10.1002/ijc.24813
   Yeh CT, 2012, AM J RESP CRIT CARE, V186, P1180, DOI 10.1164/rccm.201207-1180OC
   Yuan KY, 2015, ONCOTARGET, V6, P25308, DOI 10.18632/oncotarget.4490
NR 26
TC 12
Z9 12
U1 2
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD SEP
PY 2019
VL 120
IS 9
BP 15756
EP 15765
DI 10.1002/jcb.28845
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA IK7WN
UT WOS:000476804200147
PM 31081173
DA 2022-04-25
ER

PT J
AU Leng, ZG
   Lin, SJ
   Wu, ZR
   Guo, YH
   Cai, L
   Shang, HB
   Tang, H
   Xue, YJ
   Lou, MQ
   Zhao, WX
   Le, WD
   Zhao, WG
   Zhang, X
   Wu, ZB
AF Leng, Zhi Gen
   Lin, Shao Jian
   Wu, Ze Rui
   Guo, Yu Hang
   Cai, Lin
   Shang, Han Bing
   Tang, Hao
   Xue, Ya Jun
   Lou, Mei Qing
   Zhao, Wenxiu
   Le, Wei-Dong
   Zhao, Wei Guo
   Zhang, Xun
   Wu, Zhe Bao
TI Activation of DRD5 (dopamine receptor D5) inhibits tumor growth by
   autophagic cell death
SO AUTOPHAGY
LA English
DT Article
DE autophagic cell death; cabergoline; dopamine agonist; dopamine receptor
   D5; MTOR; prolactinoma; reactive oxygen species
ID UP-REGULATION; NEUROBLASTOMA-CELLS; PITUITARY-ADENOMAS; CANCER-THERAPY;
   PROLACTINOMAS; BROMOCRIPTINE; DEGRADATION; ANTAGONIST; PATHWAY;
   STIMULATION
AB Dopamine agonists such as bromocriptine and cabergoline have been successfully used in the treatment of pituitary prolactinomas and other neuroendocrine tumors. However, their therapeutic mechanisms are not fully understood. In this study we demonstrated that DRD5 (dopamine receptor D5) agonists were potent inhibitors of pituitary tumor growth. We further found that DRD5 activation increased production of reactive oxygen species (ROS), inhibited the MTOR pathway, induced macroautophagy/autophagy, and led to autophagic cell death (ACD) in vitro and in vivo. In addition, DRD5 protein was highly expressed in the majority of human pituitary adenomas, and treatment of different human pituitary tumor cell cultures with the DRD5 agonist SKF83959 resulted in growth suppression, and the efficacy was correlated with the expression levels of DRD5 in the tumors. Furthermore, we found that DRD5 was expressed in other human cancer cells such as glioblastomas, colon cancer, and gastric cancer. DRD5 activation in these cell lines suppressed their growth, inhibited MTOR activity, and induced autophagy. Finally, in vivo SKF83959 also inhibited human gastric cancer cell growth in nude mice. Our studies revealed novel mechanisms for the tumor suppressive effects of DRD5 agonists, and suggested a potential use of DRD5 agonists as a novel therapeutic approach in the treatment of different human tumors and cancers.
C1 [Leng, Zhi Gen; Wu, Ze Rui; Guo, Yu Hang; Cai, Lin; Wu, Zhe Bao] Wenzhou Med Univ, Affiliated Hosp 1, Dept Neurosurg, Wenzhou, Peoples R China.
   [Lin, Shao Jian; Shang, Han Bing; Tang, Hao; Zhao, Wei Guo; Wu, Zhe Bao] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Neurosurg, Shanghai, Peoples R China.
   [Xue, Ya Jun; Lou, Mei Qing] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Neurosurg, Shanghai, Peoples R China.
   [Le, Wei-Dong] Dalian Med Univ, Affiliated Hosp 1, Ctr Clin Res Neurol Dis, Dalian, Peoples R China.
   [Zhao, Wenxiu; Zhang, Xun] Massachusetts Gen Hosp, Neuroendocrine Res Lab, Boston, MA 02114 USA.
   [Zhao, Wenxiu; Zhang, Xun] Harvard Med Sch, Boston, MA 02114 USA.
   [Leng, Zhi Gen] Peoples Hosp Yichun City, Dept Neurosurg, Yichun 336000, Jiangxi, Peoples R China.
RP Zhang, X (corresponding author), Massachusetts Gen Hosp, Neuroendocrine Res Lab, Boston, MA 02114 USA.; Zhang, X (corresponding author), Harvard Med Sch, Boston, MA 02114 USA.; Wu, ZB (corresponding author), Ruijin Hosp, Dept Neurosurg, 197 Ruijin Er Rd, Shanghai 200025, Peoples R China.
EM xzhang5@mgh.harvard.edu; zhebaowu@aliyun.com
RI Wu, Zhe Bao/AAH-8078-2020; Cai, Lin/AAD-3411-2022
OI Wu, Zhe Bao/0000-0002-1611-8228; Cai, Lin/0000-0002-7087-4948
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81471392, 81271523]; Zhejiang Open
   Foundation of the Top Key Discipline [LKYJ015]; Shanghai Municipal
   Education Commission Gaofeng Clinical Medicine Grant Support [20161407]
FX This work was supported by the National Natural Science Foundation of
   China under Grant number 81471392 and 81271523; the Zhejiang Open
   Foundation of the Top Key Discipline under Grant number LKYJ015; and
   Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant
   Support under Grant number 20161407.
CR Banday AA, 2008, CURR HYPERTENS REP, V10, P268, DOI 10.1007/s11906-008-0051-9
   Radl DB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018097
   BEVAN JS, 1992, ENDOCR REV, V13, P220, DOI 10.1210/er.13.2.220
   Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4
   Borcherding DC, 2016, ONCOGENE, V35, P3103, DOI 10.1038/onc.2015.369
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chen J, 2004, J BIOL CHEM, V279, P39317, DOI 10.1074/jbc.M403891200
   Chen J, 2003, J BIOL CHEM, V278, P28089, DOI 10.1074/jbc.M303094200
   Chen Y, 2009, CELL DEATH DIFFER, V16, P1040, DOI 10.1038/cdd.2009.49
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Colao A, 2011, NAT REV ENDOCRINOL, V7, P267, DOI 10.1038/nrendo.2011.37
   da Silva WCN, 2012, NEUROBIOL LEARN MEM, V97, P271, DOI 10.1016/j.nlm.2012.01.005
   Dewaele M, 2010, AUTOPHAGY, V6, P838, DOI 10.4161/auto.6.7.12113
   Eom JM, 2010, BIOCHEM BIOPH RES CO, V391, P903, DOI 10.1016/j.bbrc.2009.11.161
   Fulda S, 2015, ONCOGENE, V34, P5105, DOI 10.1038/onc.2014.458
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966
   Gillam MP, 2006, ENDOCR REV, V27, P485, DOI 10.1210/er.2005-9998
   Gomez-Santos C, 2003, J NEUROSCI RES, V73, P341, DOI 10.1002/jnr.10663
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Kou X, 2014, CLIN EXP HYPERTENS, V36, P140, DOI 10.3109/10641963.2013.789048
   Lebovitz CB, 2012, CLIN CANCER RES, V18, P1214, DOI 10.1158/1078-0432.CCR-11-2465
   Lee M, 2015, CLIN CANCER RES, V21, P3204, DOI 10.1158/1078-0432.CCR-15-0288
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Li HW, 2008, J CLIN INVEST, V118, P2180, DOI 10.1172/JCI33637
   Li Q, 2014, MOL CELL ENDOCRINOL, V382, P377, DOI 10.1016/j.mce.2013.10.021
   Lin SJ, 2015, ONCOTARGET, V6, P39329, DOI 10.18632/oncotarget.5744
   Liu LP, 2008, J BIOL CHEM, V283, P31153, DOI 10.1074/jbc.M805056200
   Mikulak J, 2014, J IMMUNOL, V193, P2792, DOI 10.4049/jimmunol.1401114
   Mill J, 2004, AM J MED GENET B, V125B, P38, DOI 10.1002/ajmg.b.20127
   Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Monsalves E, 2014, ENDOCR-RELAT CANCER, V21, pR331, DOI 10.1530/ERC-14-0188
   POOLE B, 1981, J CELL BIOL, V90, P665, DOI 10.1083/jcb.90.3.665
   Prado C, 2013, ENDOCR METAB IMMUNE, V13, P184, DOI 10.2174/1871530311313020007
   Prado C, 2012, J IMMUNOL, V188, P3062, DOI 10.4049/jimmunol.1103096
   Rowther FB, 2010, NEUROENDOCRINOLOGY, V91, P256, DOI 10.1159/000279753
   Sachlos E, 2012, CELL, V149, P1284, DOI 10.1016/j.cell.2012.03.049
   Scherz-Shouval R, 2011, TRENDS BIOCHEM SCI, V36, P30, DOI 10.1016/j.tibs.2010.07.007
   Sheikhpour M, 2013, INT J IMMUNOPATH PH, V26, P393, DOI 10.1177/039463201302600212
   Shin JH, 2012, BIOL PHARM BULL, V35, P1069, DOI 10.1248/bpb.b12-00009
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234
   Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009
   Undieh AS, 2010, PHARMACOL THERAPEUT, V128, P37, DOI 10.1016/j.pharmthera.2010.05.003
   Wang JD, 2015, AUTOPHAGY, V11, P2057, DOI 10.1080/15548627.2015.1100930
   Wang WY, 2015, P NATL ACAD SCI USA, V112, pE1373, DOI 10.1073/pnas.1419669112
   Wei C, 2016, INT J CARDIOL, V203, P837, DOI 10.1016/j.ijcard.2015.11.006
   Wu ZB, 2006, J NEUROSURG, V104, P54, DOI 10.3171/jns.2006.104.1.54
   Wu ZB, 2010, J NEURO-ONCOL, V99, P25, DOI 10.1007/s11060-009-0107-y
   Yan H, 2013, J CELL BIOCHEM, V114, P103, DOI 10.1002/jcb.24306
   Yin T, 2015, MOL MED REP, V12, P4103, DOI 10.3892/mmr.2015.3967
   Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103
   Zhao Y, 2014, GENET MOL RES, V13, P1609, DOI 10.4238/2014.March.12.13
NR 56
TC 51
Z9 55
U1 2
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PY 2017
VL 13
IS 8
BP 1404
EP 1419
DI 10.1080/15548627.2017.1328347
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FF8JI
UT WOS:000409263400010
PM 28613975
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Zhai, HY
   Fesler, A
   Ba, YF
   Wu, S
   Ju, JF
AF Zhai, Haiyan
   Fesler, Andrew
   Ba, Yufeng
   Wu, Song
   Ju, Jingfang
TI Inhibition of colorectal cancer stem cell survival and invasive
   potential by hsa-miR-140-5p mediated suppression of Smad2 and autophagy
SO ONCOTARGET
LA English
DT Article
DE hsa-miR-140-5p; smad2; autophagy; metastasis; colon cancer stem cell
ID TGF-BETA; TUMOR-GROWTH; COLON-CANCER; DOWN-REGULATION; MICRORNA;
   METASTASIS; PROLIFERATION; RECEPTOR; MIR-140; ACTIVATION
AB Colorectal cancer (CRC) is the third highest mortality cancer in the United States and frequently metastasizes to liver and lung. Smad2 is a key element downstream of the TGF-beta signaling pathway to regulate cancer metastasis by promoting epithelial to mesenchymal transition and maintaining the cancer stem cell (CSC) phenotype. In this study, we show that hsa-miR-140-5p directly targets Smad2 and overexpression of hsa-miR-140-5p in CRC cell lines decreases Smad2 expression levels, leading decreased cell invasion and proliferation, and increasing cell cycle arrest. Ectopic expression of hsa-miR-140-5p in colorectal CSCs inhibited CSC growth and sphere formation in vitro by disrupting autophagy. We have systematically identified targets of hsa-miR-140-5p involved in autophagy. Furthermore, overexpression of hsa-miR-140-5p in CSCs abolished tumor formation and metastasis in vivo. In addition, there is a progressive loss of hsa-miR-140-5p expression from normal colorectal mucosa to primary tumor tissues, with further reduction in liver metastatic tissues. Higher hsa-miR-140 expression is significantly correlated with better survival in stage III and IV colorectal cancer patients. The functional and clinical significance of hsa-miR-140-5p suggests that it is a key regulator in CRC progression and metastasis, and may have potential as a novel therapeutic molecule to treat CRC.
C1 [Zhai, Haiyan; Fesler, Andrew; Ju, Jingfang] SUNY Stony Brook, Dept Pathol, Translat Res Lab, Stony Brook, NY 11794 USA.
   [Ba, Yufeng] Canc Hosp Henan, Dept Thorac Surg, Zhengzhou 450008, Henan, Peoples R China.
   [Wu, Song] SUNY Stony Brook, Dept Appl Math & Stat, Stony Brook, NY 11794 USA.
RP Ju, JF (corresponding author), SUNY Stony Brook, Dept Pathol, Translat Res Lab, Stony Brook, NY 11794 USA.
EM jingfang.ju@stonybrookmedicine.edu
FU National Cancer InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R01CA155019, R33CA147966]; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R01CA155019, R33CA147966] Funding Source: NIH RePORTER
FX We thank Stony Brook Medicine Research Histology Core Lab, especially
   Stephanie Burke and Mallory Korman, for technical support in clinical
   CRC tissue processing. This study was supported by National Cancer
   Institute R01CA155019 (J. Ju) and R33CA147966 (J. Ju).
CR Akbari A, 2014, DARU, V22, DOI 10.1186/2008-2231-22-47
   Alwan A, 2007, DISASTER MED PUBLIC, V1, P7, DOI 10.1097/DMP.0b013e3180676d32
   Bao YH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105991
   Bierie B, 2006, CYTOKINE GROWTH F R, V17, P29, DOI 10.1016/j.cytogfr.2005.09.006
   Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9
   Brown KA, 2007, J CELL BIOCHEM, V101, P9, DOI 10.1002/jcb.21255
   Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013
   Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137
   Elgendy M, 2011, MOL CELL, V42, P23, DOI 10.1016/j.molcel.2011.02.009
   Fais S, 2007, CANCER LETT, V258, P155, DOI 10.1016/j.canlet.2007.09.014
   Fang SH, 2010, ANN SURG, V251, P107, DOI 10.1097/SLA.0b013e3181b5da28
   Ghodgaonkar MM, 2009, CELL DEATH DIFFER, V16, P858, DOI 10.1038/cdd.2009.15
   Goldman M, 2013, NUCLEIC ACIDS RES, V41, pD949, DOI 10.1093/nar/gks1008
   Gong Y, 2014, BIOMED RES INT, V2014
   Guan JL, 2013, AUTOPHAGY, V9, P830, DOI 10.4161/auto.24132
   He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552
   Hegde Sanjay R, 2008, Expert Rev Gastroenterol Hepatol, V2, P135, DOI 10.1586/17474124.2.1.135
   Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023
   Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083
   Karaayvaz M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.193
   Kiyono K, 2009, CANCER RES, V69, P8844, DOI 10.1158/0008-5472.CAN-08-4401
   Korchynskyi O, 1999, INT J CANCER, V82, P197, DOI 10.1002/(SICI)1097-0215(19990719)82:2<197::AID-IJC8>3.0.CO;2-V
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Levy L, 2006, CYTOKINE GROWTH F R, V17, P41, DOI 10.1016/j.cytogfr.2005.09.009
   Li J, 2013, CARCINOGENESIS, V34, P1343, DOI 10.1093/carcin/bgt063
   Li Q, 2014, ONCOGENE, V33, P2589, DOI 10.1038/onc.2013.226
   Li WL, 2014, CELL PHYSIOL BIOCHEM, V34, P1466, DOI 10.1159/000366351
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Mancias JD, 2011, ONCOTARGET, V2, P1302
   Navarro F, 2010, J IMMUNOL, V184, P5939, DOI 10.4049/jimmunol.0902567
   Nitta T, 2014, INT J CLIN EXP PATHO, V7, P4913
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Park CY, 2014, CANCER LETT, V351, P72, DOI 10.1016/j.canlet.2014.05.006
   Park EY, 2014, CANCER RES, V74, P7573, DOI 10.1158/0008-5472.CAN-14-1140
   Rathod SS, 2014, FEBS OPEN BIO, V4, P485, DOI 10.1016/j.fob.2014.05.002
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Somanna A, 2002, J BIOL CHEM, V277, P25305, DOI 10.1074/jbc.M203034200
   Song B, 2009, ONCOGENE, V28, P4065, DOI 10.1038/onc.2009.274
   Tang F, DIFFERENTIATION, V79, P141
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001
   Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009
   Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3
   Wei B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039069
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4
   Yang H, 2013, HEPATOLOGY, V58, P205, DOI 10.1002/hep.26315
   Yingling JM, 2004, NAT REV DRUG DISCOV, V3, P1011, DOI 10.1038/nrd1580
   Zhai H, 2013, ONCOGENE, V32, P1570, DOI 10.1038/onc.2012.167
   Zhai HY, 2013, CELL CYCLE, V12, P246, DOI 10.4161/cc.23273
   Zhang M, 2011, CANCER RES, V71, P7155, DOI 10.1158/0008-5472.CAN-11-1212
   Zhao JS, 2009, CLIN CANCER RES, V15, P208, DOI 10.1158/1078-0432.CCR-08-0407
   Zhao Wenyue, 2014, Zhonghua Zhong Liu Za Zhi, V36, P739
   Zhu H, 2009, AUTOPHAGY, V5, P816, DOI 10.4161/auto.9064
   Zubeldia IG, 2013, EXP CELL RES, V319, P12, DOI 10.1016/j.yexcr.2012.11.004
NR 56
TC 89
Z9 96
U1 1
U2 15
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 14
PY 2015
VL 6
IS 23
BP 19735
EP 19746
DI 10.18632/oncotarget.3771
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CP8HY
UT WOS:000360135300042
PM 25980495
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Wu, YC
   Wu, WKK
   Li, YM
   Yu, L
   Li, ZJ
   Wong, CCM
   Li, HT
   Sung, JJY
   Cho, CH
AF Wu, Ya Chun
   Wu, William Ka Kei
   Li, Youming
   Yu, Le
   Li, Zhi Jie
   Wong, Clover Ching Man
   Li, Hai Tao
   Sung, Joseph Jao Yiu
   Cho, Chi Hin
TI Inhibition of macroautophagy by bafilomycin A(1) lowers proliferation
   and induces apoptosis in colon cancer cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Bafilomycin A(1); Macroautophagy; Proliferation; Colon cancer
ID PROTEASOME INHIBITOR; PROTEIN-DEGRADATION; H+-ATPASE; AUTOPHAGY;
   DISEASE; DEATH; PATHWAYS; SURVIVAL; MG-132; ROLES
AB Macroautophagy is a process by which cytoplasmic content and organelles are sequestered by double-membrane bound vesicles and subsequently delivered to lysosomes for degradation. Macroautophagy serves as a major intracellular pathway for protein degradation and as a pro-survival mechanism in time of stress by generating nutrients. In the present study, bafilomycin A(1) a vacuolar type H+-ATPase inhibitor, Suppresses macroautophagy by preventing acidification of lysosomes in colon cancer cells. Diminished macroautophagy was evidenced by the accumulation of undegraded LC3 protein. Suppression of macroautophagy by bafilomycin A(1) induced G(0)/G(1) cell cycle arrest and apoptosis which were accompanied by the down-regulation of cyclin D, and cyclin E, the up-regulation of p21(Cip1) as well as cleavages of caspases-3, -7, -8, and -9 and PARP. Further investigation revealed that bafilomycin A(1) increased the phosphorylation of ERK, JNK, and p38. In this regard, p38 inhibitor partially reversed the anti-proliferative effect of bafilomycin A(1). To conclude, inhibition of macroautophagy by bafilornycin A(1) lowers G(1)-S transition and induces apoptosis in colon cancer cells. Our results not only indicate that inhibitors of macroautophagy may be used therapeutically to inhibit cancer growth, but also delineate the relationship between macroautophagy and apoptosis. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Wu, Ya Chun; Wu, William Ka Kei; Yu, Le; Li, Zhi Jie; Wong, Clover Ching Man; Li, Hai Tao; Cho, Chi Hin] Chinese Univ Hong Kong, Dept Pharmacol, Shatin, Hong Kong, Peoples R China.
   [Wu, Ya Chun; Li, Youming] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Gastroenterol, Hangzhou 310003, Zhejiang, Peoples R China.
   [Wu, William Ka Kei; Sung, Joseph Jao Yiu; Cho, Chi Hin] Chinese Univ Hong Kong, Inst Digest Dis, Shatin, Hong Kong, Peoples R China.
   [Wu, William Ka Kei; Sung, Joseph Jao Yiu] Chinese Univ Hong Kong, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China.
RP Cho, CH (corresponding author), Chinese Univ Hong Kong, Dept Pharmacol, Basic Med Sci Bldg, Shatin, Hong Kong, Peoples R China.
EM wukakei@cuhk.edu.hk; chcho@cuhk.edu.hk
RI Cho, Chi Hin/C-6543-2014; Wu, William K.K./A-3277-2009; Sung, Joseph J.
   Y./R-3203-2018
OI Cho, Chi Hin/0000-0002-7658-3260; Wu, William K.K./0000-0002-5662-5240;
   Sung, Joseph J. Y./0000-0003-3125-5199
CR Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039
   Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Amaravadi RK, 2008, J CLIN INVEST, V118, P3837, DOI 10.1172/JCI37667
   Backer JM, 2008, BIOCHEM J, V410, P1, DOI 10.1042/BJ20071427
   Bialik S, 2008, ADV EXP MED BIOL, V615, P177, DOI 10.1007/978-1-4020-6554-5_9
   Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092
   Gagliardi S, 1999, CURR MED CHEM, V6, P1197
   Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kim KW, 2008, AUTOPHAGY, V4, P659, DOI 10.4161/auto.6058
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660
   Maiuri MC, 2009, CELL DEATH DIFFER, V16, P87, DOI 10.1038/cdd.2008.131
   Marshansky V, 2008, CURR OPIN CELL BIOL, V20, P415, DOI 10.1016/j.ceb.2008.03.015
   Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   MORTIMORE GE, 1983, P NATL ACAD SCI-BIOL, V80, P2179, DOI 10.1073/pnas.80.8.2179
   Paglin S, 2001, CANCER RES, V61, P439
   Park KJ, 2007, CANCER RES, V67, P7327, DOI 10.1158/0008-5472.CAN-06-4766
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291
   Scarlatti F, 2009, CELL DEATH DIFFER, V16, P12, DOI 10.1038/cdd.2008.101
   Serova M, 2008, MOL CANCER THER, V7, P915, DOI 10.1158/1535-7163.MCT-07-2060
   Shacka JJ, 2006, AUTOPHAGY, V2, P228, DOI 10.4161/auto.2703
   Shacka JJ, 2008, FRONT BIOSCI-LANDMRK, V13, P718, DOI 10.2741/2714
   Thoms HC, 2007, CANCER RES, V67, P1660, DOI 10.1158/0008-5472.CAN-06-1038
   Thorburn A, 2008, APOPTOSIS, V13, P1, DOI 10.1007/s10495-007-0154-9
   Tobinai K, 2007, INT J CLIN ONCOL, V12, P318, DOI 10.1007/s10147-007-0695-5
   Wu WKK, 2008, BRIT J PHARMACOL, V154, P632, DOI 10.1038/bjp.2008.115
   Wu WKK, 2008, BIOCHEM BIOPH RES CO, V371, P209, DOI 10.1016/j.bbrc.2008.04.059
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Yang DS, 2008, AM J PATHOL, V173, P665, DOI 10.2353/ajpath.2008.071176
   Yoshioka A, 2008, INT J ONCOL, V33, P461, DOI 10.3892/ijo_00000028
NR 33
TC 87
Z9 93
U1 0
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAY 1
PY 2009
VL 382
IS 2
BP 451
EP 456
DI 10.1016/j.bbrc.2009.03.051
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 434MR
UT WOS:000265279300043
PM 19289106
DA 2022-04-25
ER

PT J
AU Qiu, F
   Wang, Y
   Chu, XQ
   Wang, J
AF Qiu, Fei
   Wang, Yun
   Chu, Xianqun
   Wang, Jing
TI ASF1A regulates H4(Y72) phosphorylation and promotes autophagy in colon
   cancer cells via a kinase activity (Publication with Expression of
   Concern. See vol. 48, pg. 707, 2020)
SO ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
LA English
DT Article; Publication with Expression of Concern
DE Colon cancer; histone modification; ASF1A; H4Y72ph; autophagy
ID HISTONE CHAPERONE ASF1A; COLORECTAL-CANCER; SURVIVAL
AB Colon cancer is one of the most malignant cancers. Histone modification is closely related to tumour development. Our study explored the functions of anti-silencing function 1A (ASF1A) on H4(Y72ph) in colon cancer cells. Colon cancer cell lines and clinical specimens were obtained and/or transfected with full length ASF1A or interference mRNA to mimic or silence of ASF1A expression. Immunoprecipitation and GST pull down was used to target targeting ASF1A or H4(Y72ph). Cells were transfected with H4(WT) or H4(Y72ph)-expressing. An in vitro kinase activity assay was set to determine whether ASH A could phosphorylate H4. The severity of autophagy was measured by detecting number of autophagosomes, number of EGFP-LC3, LC3-II/I, percentage of degradation and expression of autophagy associated gene (ATG). ASF1A positively regulated H4(Y72ph); Immunoprecipitation assay and GST pull down results showed that ASF1A interacted directly with H4. In addition, ASF1A silence inhibited autophagosomes number, EGFP-LC3 number, LC3-II/I, percentage of degradation and ATG expression. Moreover, H4 Y72F impaired the promoting autophagy effects of ASF1A. The ASF1A-H4(Y72ph) axis promoted colon cancer autophagy via transcriptional regulation of ATG genes. ASF1A regulated H4(Y72ph) and promotes autophagy in colon cancer cells via a kinase activity through regulation of ATG.
C1 [Qiu, Fei; Wang, Yun; Chu, Xianqun; Wang, Jing] Jining 1 Peoples Hosp, Dept Gastrointestinal Surg, 6 Jiankang Rd, Jining 272000, Peoples R China.
   [Qiu, Fei] Jining Med Univ, Affiliated Jining Peoples Hosp Jining Med Univ 1, Jining, Peoples R China.
RP Wang, J (corresponding author), Jining 1 Peoples Hosp, Dept Gastrointestinal Surg, 6 Jiankang Rd, Jining 272000, Peoples R China.
EM wangjing0016hbs@sina.com
CR Ahluwalia A, 2014, CURR PHARM DESIGN, V20, P1041, DOI 10.2174/1381612819999131218175905
   Asare EA, 2016, CANCER-AM CANCER SOC, V122, P213, DOI 10.1002/cncr.29744
   Audia JE, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a019521
   Balakrishnan L, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9110346
   Chou RH, 2014, DEV CELL, V30, P224, DOI 10.1016/j.devcel.2014.06.008
   Deb M, 2016, GENE, V581, P75, DOI 10.1016/j.gene.2016.01.029
   Dhar S, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0284
   Drake KR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009806
   Dryhurst D, 2014, CANCER METAST REV, V33, P429, DOI 10.1007/s10555-013-9486-9
   Fullgrabe J, 2014, AUTOPHAGY, V10, P556, DOI 10.4161/auto.27280
   Gao Y, 2018, P NATL ACAD SCI USA, V115, pE6162, DOI 10.1073/pnas.1801909115
   Gonzalez-Munoz E, 2014, SCIENCE, V345, P822, DOI 10.1126/science.1254745
   Hanada T, 2007, J BIOL CHEM, V282, P37298, DOI 10.1074/jbc.C700195200
   Hattori N, 2014, BIOCHEM BIOPH RES CO, V455, P3, DOI 10.1016/j.bbrc.2014.08.140
   Henrique R, 2017, EBIOMEDICINE, V21, P45, DOI 10.1016/j.ebiom.2017.06.009
   Jaskelioff M, 2000, MOL CELL BIOL, V20, P3058, DOI 10.1128/MCB.20.9.3058-3068.2000
   Landreau P, 2015, J GASTROEN HEPATOL, V30, P82, DOI 10.1111/jgh.12685
   Lennartsson A, 2009, BBA-GEN SUBJECTS, V1790, P863, DOI 10.1016/j.bbagen.2008.12.006
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Liang XM, 2017, EBIOMEDICINE, V21, P104, DOI 10.1016/j.ebiom.2017.06.007
   Lin WM, 2015, GENET MOL RES, V14, P16905, DOI 10.4238/2015.December.14.18
   Muilenburg D, 2014, ANTICANCER RES, V34, P631
   Okugawa Y, 2015, GASTROENTEROLOGY, V149, P1204, DOI 10.1053/j.gastro.2015.07.011
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Tamas K, 2015, CANCER TREAT REV, V41, P671, DOI 10.1016/j.ctrv.2015.06.007
   Tessarz P, 2014, NAT REV MOL CELL BIO, V15, P703, DOI 10.1038/nrm3890
   Varghese F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096801
   Wang C, 2015, ONCOTARGET, V6, P29599, DOI 10.18632/oncotarget.5011
   Wen J, 2016, INT J MOL MED, V37, P126, DOI 10.3892/ijmm.2015.2409
   Wu L, 2017, IRAN J BASIC MED SCI, V20, P990, DOI 10.22038/IJBMS.2017.9263
   Yang JH, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.68
   Yang SC, 2018, INT J ADV MANUF TECH, V96, P2431, DOI 10.1007/s00170-018-1807-2
   Yang WY, 2014, J CANCER RES THER, V10, pC240, DOI 10.4103/0973-1482.151450
   Yoon J, 2018, J MOL BIOL, V430, P822, DOI 10.1016/j.jmb.2018.01.015
   Yoshii SR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091865
   Zeng MX, 2017, CELL MOL BIOL LETT, V22, DOI 10.1186/s11658-017-0041-5
NR 36
TC 3
Z9 3
U1 1
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2169-1401
EI 2169-141X
J9 ARTIF CELL NANOMED B
JI Artif. Cell. Nanomed. Biotechnol.
PY 2019
VL 47
IS 1
BP 2754
EP 2763
DI 10.1080/21691401.2019.1617725
PG 10
WC Biotechnology & Applied Microbiology; Engineering, Biomedical; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering; Materials Science
GA IH5XV
UT WOS:000474567700001
PM 31286799
OA gold
DA 2022-04-25
ER

PT J
AU Khan, S
AF Khan, Shahanavaj
TI Potential role of Escherichia coli DNA mismatch repair proteins in colon
   cancer
SO CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
LA English
DT Review
DE E. coli; DNA repair genes; In-silico; Protein targeting; Aetiology; CRC
ID CYTOLETHAL DISTENDING TOXIN; NONPOLYPOSIS COLORECTAL-CANCER;
   CROHNS-DISEASE; CELL-CYCLE; E. COLI; SUBCELLULAR-LOCALIZATION;
   INTESTINAL MICROFLORA; GENE-EXPRESSION; HOST-CELLS; MUTL-ALPHA
AB The epithelium of gastrointestinal tract organizes many innate defense systems against microbial intruders such as integrity of epithelial, rapid eviction of infected cells, quick turnover of epithelial cell, intrinsic immune responses and autophagy. However, Enteropathogenic Escherichia coli (EPEC) are equipped with well developed infectious tricks that evade the host defense systems and utilize the gastrointestinal epithelium as a multiplicative foothold. During multiplication on and within the epithelium, EPEC secrete various toxins that can weaken, usurp, and use many host cellular systems. However, the possible mechanisms of pathogenesis are still poorly elusive. Recent study reveals the existence of EPEC in colorectal cancer patients and their potential role in depletion of DNA mismatch repair (MMR) proteins of host cell in colonic cell lines. The EPEC colonised intracellularly in colon mucosa of colorectal carcinoma whereas extracellular strain was detected in mucosa of normal colon cells. Interestingly, alteration in MutS, MutL complexes and MUTYH of mammalian cells may be involved in development of CRC. These data propose that MMR of E. coli may be potential therapeutic targets and early detection biomarkers for CRC. This article reviews the potential role of E. coli MutS, MutL and MutY protein in CRC aetiology. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Khan, Shahanavaj] King Saud Univ, Coll Pharm, Dept Pharmaceut, Nanomed & Biotechnol Res Unit, Riyadh 11451, Saudi Arabia.
RP Khan, S (corresponding author), King Saud Univ, Coll Pharm, Dept Pharmaceut, Nanomed & Biotechnol Res Unit, POB 2457, Riyadh 11451, Saudi Arabia.
EM khan.shahanavaj@gmail.com
RI Khan, Shahanavaj/F-1032-2019
CR Acharya S, 2003, MOL CELL, V12, P233, DOI 10.1016/S1097-2765(03)00219-3
   [Anonymous], 2009, NAT CELL BIOL, V11, P509, DOI 10.1038/ncb0509-509b
   Antonic V, 2013, J CANCER, V4, P227, DOI 10.7150/jca.5835
   Arthur JC, 2012, SCIENCE, V338, P120, DOI 10.1126/science.1224820
   Barnich N, 2007, J CLIN INVEST, V117, P1566, DOI 10.1172/JCI30504
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Bonnet M, 2014, CLIN CANCER RES, V20, P859, DOI 10.1158/1078-0432.CCR-13-1343
   BORRESEN AL, 1995, HUM MOL GENET, V4, P2065, DOI 10.1093/hmg/4.11.2065
   Buc E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056964
   Charpentier X, 2004, J BACTERIOL, V186, P5486, DOI 10.1128/JB.186.16.5486-5495.2004
   Chou KC, 2008, NAT PROTOC, V3, P153, DOI 10.1038/nprot.2007.494
   Collins D, 2011, LANCET ONCOL, V12, P504, DOI 10.1016/S1470-2045(10)70186-8
   Conterno L, 2011, GENES NUTR, V6, P241, DOI 10.1007/s12263-011-0230-1
   Cougnoux A, 2014, GUT, V63, P1932, DOI 10.1136/gutjnl-2013-305257
   de Martel C, 2009, CRIT REV ONCOL HEMAT, V70, P183, DOI 10.1016/j.critrevonc.2008.07.021
   Edgar BA, 2001, CELL, V105, P297, DOI 10.1016/S0092-8674(01)00334-8
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fanaro S, 2003, ACTA PAEDIATR, V92, P48
   Fiorentini C, 1998, EXP CELL RES, V242, P341, DOI 10.1006/excr.1998.4057
   FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3
   Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7
   Friswell M, 2010, GUT LIVER, V4, P295, DOI 10.5009/gnl.2010.4.3.295
   Fukui K, 2008, J BIOL CHEM, V283, P12136, DOI 10.1074/jbc.M800110200
   Fukui K, 2010, J NUCLEIC ACIDS, V2010, DOI 10.4061/2010/260512
   Ge ZM, 2008, CELL MICROBIOL, V10, P1599, DOI 10.1111/j.1462-5822.2008.01173.x
   Ge ZM, 2007, CELL MICROBIOL, V9, P2070, DOI 10.1111/j.1462-5822.2007.00939.x
   GILLEN CD, 1994, GUT, V35, P651, DOI 10.1136/gut.35.5.651
   Glasser AL, 2001, INFECT IMMUN, V69, P5529, DOI 10.1128/IAI.69.9.5529-5537.2001
   Gronbaek K, 2007, APMIS, V115, P1039, DOI 10.1111/j.1600-0463.2007.apm_636.xml.x
   Haghjoo E, 2004, P NATL ACAD SCI USA, V101, P4614, DOI 10.1073/pnas.0400932101
   Hotopp JCD, 2007, SCIENCE, V317, P1753, DOI 10.1126/science.1142490
   Jenkins MA, 2006, CANCER EPIDEM BIOMAR, V15, P312, DOI 10.1158/1055-9965.EPI-05-0793
   Kaczmarczyk SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008889
   Kadyrov FA, 2007, J BIOL CHEM, V282, P37181, DOI 10.1074/jbc.M707617200
   Kadyrov FA, 2006, CELL, V126, P297, DOI 10.1016/j.cell.2006.05.039
   Kosugi S, 2009, P NATL ACAD SCI USA, V106, P10171, DOI 10.1073/pnas.0900604106
   Lara-Tejero M, 2001, INFECT IMMUN, V69, P4358, DOI 10.1128/IAI.69.7.4358-4365.2001
   Lee JC, 2009, J MICROBIOL, V47, P641, DOI 10.1007/s12275-009-0217-4
   Lu HT, 2006, MOL CANCER RES, V4, P221, DOI 10.1158/1541-7786.MCR-05-0261
   LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M
   Maddocks ODK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005517
   Maddocks ODK, 2013, MBIO, V4, DOI 10.1128/mBio.00152-13
   Mager DL, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-14
   Marches O, 2003, MOL MICROBIOL, V50, P1553, DOI 10.1046/j.1365-2958.2003.03821.x
   Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588
   Martin HM, 2004, GASTROENTEROLOGY, V127, P80, DOI 10.1053/j.gastro.2004.03.054
   Martinez-Medina Margarita, 2014, World J Gastrointest Pathophysiol, V5, P213, DOI 10.4291/wjgp.v5.i3.213
   Masotti A, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00137
   Masseret E, 2001, GUT, V48, P320, DOI 10.1136/gut.48.3.320
   Mauris J, 2010, J BIOL CHEM, V285, P11087, DOI 10.1074/jbc.M109.050955
   Mauris J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007175
   Meijer K, 2010, CURR OPIN CLIN NUTR, V13, P715, DOI 10.1097/MCO.0b013e32833eebe5
   Minarovits J, 2009, ACTA MICROBIOL IMM H, V56, P1, DOI 10.1556/AMicr.56.2009.1.1
   Molloy S, 2006, NAT REV MICROBIOL, V4, P4, DOI 10.1038/nrmicro1338
   Muller A, 2002, CANCER INVEST, V20, P102, DOI 10.1081/CNV-120000371
   Neish AS, 2009, GASTROENTEROLOGY, V136, P65, DOI 10.1053/j.gastro.2008.10.080
   Nougayrede JP, 2005, TRENDS MICROBIOL, V13, P103, DOI 10.1016/j.tim.2005.01.002
   OSWALD E, 1994, P NATL ACAD SCI USA, V91, P3814, DOI 10.1073/pnas.91.9.3814
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Paschos K, 2010, TRENDS MICROBIOL, V18, P439, DOI 10.1016/j.tim.2010.07.003
   Peterlongo P, 2005, INT J CANCER, V114, P505, DOI 10.1002/ijc.20767
   Pierleoni A, 2006, BIOINFORMATICS, V22, pE408, DOI 10.1093/bioinformatics/btl222
   Prolla TA, 1996, SEMIN CANCER BIOL, V7, P241, DOI 10.1006/scbi.1996.0032
   Raisch J, 2014, WORLD J GASTROENTERO, V20, P6560, DOI 10.3748/wjg.v20.i21.6560
   Rolhion N, 2007, INFLAMM BOWEL DIS, V13, P1277, DOI 10.1002/ibd.20176
   Rolhion N, 2007, MOL MICROBIOL, V63, P1684, DOI 10.1111/j.1365-2958.2007.05638.x
   Sassen S, 2008, VIRCHOWS ARCH, V452, P1, DOI 10.1007/s00428-007-0532-2
   Schwabe RF, 2013, NAT REV CANCER, V13, P800, DOI 10.1038/nrc3610
   Shahanavaj K, 2015, EXPERT REV ANTICANC, V15, P317, DOI 10.1586/14737140.2015.992785
   Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996
   Swidsinski A, 1998, GASTROENTEROLOGY, V115, P281, DOI 10.1016/S0016-5085(98)70194-5
   Taieb F, 2006, CELL MICROBIOL, V8, P1910, DOI 10.1111/j.1462-5822.2006.00757.x
   Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082
   Tjalsma H, 2012, NAT REV MICROBIOL, V10, P575, DOI 10.1038/nrmicro2819
   Toth I, 2003, J CLIN MICROBIOL, V41, P4285, DOI 10.1128/JCM.41.9.4285-4291.2003
   Touchon M, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000344
   Vajro P, 2013, J PEDIATR GASTR NUTR, V56, P461, DOI 10.1097/MPG.0b013e318284abb5
   WHEELER LA, 1975, CANCER RES, V35, P2962
   Wogan GN, 2012, ONCOTARGET, V3, P737
   Zitt M, 2007, DIS MARKERS, V23, P51, DOI 10.1155/2007/891967
NR 80
TC 25
Z9 26
U1 1
U2 25
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1040-8428
EI 1879-0461
J9 CRIT REV ONCOL HEMAT
JI Crit. Rev. Oncol./Hematol.
PD DEC
PY 2015
VL 96
IS 3
BP 475
EP 482
DI 10.1016/j.critrevonc.2015.05.002
PG 8
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Hematology
GA CY6RP
UT WOS:000366536800008
PM 26014615
DA 2022-04-25
ER

PT J
AU Wang, S
   Wang, KX
   Zhang, CD
   Zhang, WF
   Xu, Q
   Wang, YT
   Zhang, YL
   Li, Y
   Zhang, Y
   Zhu, HF
   Song, FZ
   Lei, YL
   Bu, YQ
AF Wang, Sen
   Wang, Kexin
   Zhang, Chundong
   Zhang, Wanfeng
   Xu, Qian
   Wang, Yitao
   Zhang, Yulin
   Li, Yi
   Zhang, Ying
   Zhu, Huifang
   Song, Fangzhou
   Lei, Yunlong
   Bu, Youquan
TI Overaccumulation of p53-mediated autophagy protects against betulinic
   acid-induced apoptotic cell death in colorectal cancer cells
SO CELL DEATH & DISEASE
LA English
DT Article
ID TUMOR-SUPPRESSOR P53; MUTANT P53; COLON-CANCER; CYTOTOXIC AUTOPHAGY;
   STRESS-RESPONSE; GASTRIC-CANCER; IN-VITRO; AKT-MTOR; THERAPY; PATHWAY
AB Betulinic acid (BA) exhibits cytotoxic activity against some cancer cells. However, the molecular mechanism of BA against CRC cells was little reported. Here, we proved that BA elicited CRC cells' growth inhibition and apoptosis in a dose-dependent manner. In addition, BA treatment induced autophagy via inhibiting the AKT-MTOR signaling pathway. Inhibition of autophagy by either administration of autophagic inhibitor chloroquine or siRNA-mediated knockdown of ATG5 could augment BA-induced apoptotic cell death as well as inhibition of cell proliferation. Moreover, we found that p53 was firstly activated by short exposure to BA and then was rapidly degraded via the ubiquitin-mediated degradation pathway in both wtp53 and mutp53 CRC cells. Notably, more preferential cytotoxicity of BA was obtained in mutp53 cells (IC50 values: HT29, 125 mu M; SW480, 58 mu M) rather than wtp53 cells (IC50 values: HCT116, 178 mu M). Further experiments demonstrated that siRNA-mediated p53 knockdown attenuated BA-induced autophagy, and forced overexpression of p53 augmented BA-induced autophagy, indicating that p53-enhanced BA-induced autophagy. Moreover, BA enhanced the sensitivity of mutp53 cells to chemotherapy drugs such as 5-FU and ADR by degradation of mutp53. Overall, our study proved that BA could induce CRC cell death by inducing apoptosis and reduce the overaccumulation of BA-induced protective autophagy by degrading wtp53 and mutp53 dependent on the ubiquitin-mediated degradation pathway to achieve killer effect, suggesting that BA might serve as a novel desirable drug for mutp53 cancer therapy.
C1 [Wang, Sen; Zhang, Chundong; Wang, Yitao; Li, Yi; Zhang, Ying; Zhu, Huifang; Song, Fangzhou; Lei, Yunlong; Bu, Youquan] Chongqing Med Univ, Dept Biochem & Mol Biol, Chongqing 400016, Peoples R China.
   [Wang, Sen; Zhang, Chundong; Wang, Yitao; Li, Yi; Zhang, Ying; Zhu, Huifang; Song, Fangzhou; Lei, Yunlong; Bu, Youquan] Chongqing Med Univ, Mol Med & Canc Res Ctr, Chongqing 400016, Peoples R China.
   [Wang, Kexin] Southwest Med Univ, Affiliated Hosp, Dept Radiol, Luzhou 646000, Sichuan, Peoples R China.
   [Zhang, Wanfeng] Chongqing Med Univ, Dept Bioinformat, Chongqing 400016, Peoples R China.
   [Xu, Qian] North Sichuan Med Coll, Dept Anesthesiol, Nanchong 637000, Sichuan, Peoples R China.
   [Zhang, Yulin] Chongqing Med Univ, Dept Basic Med, Chongqing 400016, Peoples R China.
RP Lei, YL; Bu, YQ (corresponding author), Chongqing Med Univ, Dept Biochem & Mol Biol, Mol Med & Canc Res Ctr, Yixueyuan Rd, Chongqing 400016, Peoples R China.
EM leiyunlong@126.com; buyqcn@aliyun.com
OI Zhang, Wanfeng/0000-0002-8717-1552; Wang, Sen/0000-0001-6358-1672; Lei,
   Yunlong/0000-0002-7918-0221; Bu, Youquan/0000-0002-0833-0640
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81401951, 81401889, 81501979]; Chongqing
   Natural Science FoundationNatural Science Foundation of Chongqing
   [cstc2016jcyjA0227]; Chongqing Municipal Education Commission
   [KJ1400207]
FX This work was supported by the National Natural Science Foundation of
   China (81401951 to YL, 81401889 to HZ, and 81501979 to CZ), Chongqing
   Natural Science Foundation (cstc2016jcyjA0227 to YL), and Scientific and
   Technological Research Program of Chongqing Municipal Education
   Commission (KJ1400207 to YL).
CR Bossi G, 2006, ONCOGENE, V25, P304, DOI 10.1038/sj.onc.1209026
   Bristol ML, 2012, AUTOPHAGY, V8, P739, DOI 10.4161/auto.19313
   Bykov VJN, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00021
   Carvajal LA, 2013, EMBO REP, V14, P414, DOI 10.1038/embor.2013.25
   Chadalapaka G, 2010, MOL CANCER RES, V8, P739, DOI 10.1158/1541-7786.MCR-09-0493
   Chen HY, 2011, CANCER PREV RES, V4, P973, DOI 10.1158/1940-6207.CAPR-10-0387
   Cheng Y, 2013, PHARMACOL REV, V65, P1162, DOI 10.1124/pr.112.007120
   Chintharlapalli S, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-371
   Dutta D, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2055-1
   Ehrhardt H, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.53
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112
   Frolova T S, 2015, Bioorg Khim, V41, P462
   Fu Q, 2016, ONCOL REP, V36, P3682, DOI 10.3892/or.2016.5195
   Fulda S, 1997, CANCER RES, V57, P4956
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Garg AK, 2005, ANTIOXID REDOX SIGN, V7, P1630, DOI 10.1089/ars.2005.7.1630
   Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966
   Gheorgheosu D, 2014, ANTI-CANCER AGENT ME, V14, P936, DOI 10.2174/1871520614666140223192148
   Gonzalez P, 2012, CELL DEATH DIFFER, V19, P1337, DOI 10.1038/cdd.2012.10
   Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986
   Hamacher-Brady A, 2012, ANTIOXID REDOX SIGN, V17, P756, DOI 10.1089/ars.2011.4410
   Hanel W, 2013, CELL DEATH DIFFER, V20, P898, DOI 10.1038/cdd.2013.17
   Hanel W, 2012, J CELL BIOCHEM, V113, P433, DOI 10.1002/jcb.23400
   He XQ, 2012, MOL MED, V18, P1491, DOI 10.2119/molmed.2012.00304
   Helgason GV, 2013, ESSAYS BIOCHEM, V55, P133, DOI [10.1042/bse0550133, 10.1042/BSE0550133]
   Joerger AC, 2016, ANNU REV BIOCHEM, V85, P375, DOI 10.1146/annurev-biochem-060815-014710
   Jonnalagadda SC, 2013, ANTI-CANCER AGENT ME, V13, P1477, DOI 10.2174/18715230113129990094
   Jung GR, 2007, BASIC CLIN PHARMACOL, V101, P277, DOI 10.1111/j.1742-7843.2007.00115.x
   Kasperczyk H, 2005, ONCOGENE, V24, P6945, DOI 10.1038/sj.onc.1208842
   Katsuragi Y, 2015, FEBS J, V282, P4672, DOI 10.1111/febs.13540
   Kelekar A, 2005, ANN NY ACAD SCI, V1066, P259, DOI 10.1196/annals.1363.015
   Kessler JH, 2007, CANCER LETT, V251, P132, DOI 10.1016/j.canlet.2006.11.003
   Khan I, 2016, EUR J MED CHEM, V108, P104, DOI 10.1016/j.ejmech.2015.11.018
   Kim NH, 2013, CELL CYCLE, V12, P1578, DOI 10.4161/cc.24739
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Lee JG, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0285-4
   Li D, 2011, CELL DEATH DIFFER, V18, P1904, DOI 10.1038/cdd.2011.71
   Li HH, 2017, GASTROENTEROLOGY, V153, P505, DOI 10.1053/j.gastro.2017.04.017
   Lorin S, 2013, SEMIN CANCER BIOL, V23, P361, DOI 10.1016/j.semcancer.2013.06.007
   Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001
   Meng RD, 2001, EXP CELL RES, V262, P154, DOI 10.1006/excr.2000.5073
   Mullauer FB, 2011, ANTI-CANCER DRUG, V22, P223, DOI 10.1097/CAD.0b013e3283421035
   Mullauer FB, 2010, ANTI-CANCER DRUG, V21, P215, DOI 10.1097/CAD.0b013e3283357c62
   Murrow L, 2013, ANNU REV PATHOL-MECH, V8, P105, DOI 10.1146/annurev-pathol-020712-163918
   Nakahira K, 2013, AM J PHYSIOL-LUNG C, V305, pL93, DOI 10.1152/ajplung.00072.2013
   Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   PISHA E, 1995, NAT MED, V1, P1046, DOI 10.1038/nm1095-1046
   Potze L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.139
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Su D., 2017, EVID-BASED COMPL ALT, V2017
   Sui XB, 2011, AUTOPHAGY, V7, P565, DOI 10.4161/auto.7.6.14073
   Tang JJ, 2015, CANCER LETT, V363, P101, DOI 10.1016/j.canlet.2015.04.014
   Tasdemir E, 2008, AUTOPHAGY, V4, P810, DOI 10.4161/auto.6486
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Tiwari R, 2014, CANCER INVEST, V32, P402, DOI 10.3109/07357907.2014.933234
   Tolstikova T G, 2006, Bioorg Khim, V32, P42
   Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864
   Wang K, 2011, AUTOPHAGY, V7, P966, DOI 10.4161/auto.7.9.15863
   Wang SY, 2011, INT J BIOCHEM CELL B, V43, P1263, DOI 10.1016/j.biocel.2011.05.010
   White E, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026120
   Wilson Eden N., 2011, Hormones & Cancer, V2, P272, DOI 10.1007/s12672-011-0081-7
   Wiman KG, 2010, ONCOGENE, V29, P4245, DOI 10.1038/onc.2010.188
   Xi YG, 2006, CLIN CANCER RES, V12, P2014, DOI 10.1158/1078-0432.CCR-05-1853
   Xu T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105768
   Yang LJ, 2012, ACTA PHARMACOL SIN, V33, P1542, DOI 10.1038/aps.2012.102
   Yin HM, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.357
   Yue XT, 2015, ELIFE, V4, DOI 10.7554/eLife.08401
   Zhai H, 2013, ONCOGENE, V32, P1570, DOI 10.1038/onc.2012.167
   Zhang XL, 2015, INT J MOL MED, V35, P1301, DOI 10.3892/ijmm.2015.2126
   Zhou HY, 2016, CANCER BIOMARK, V17, P1, DOI 10.3233/CBM-160613
   Zhou ST, 2012, CANCER LETT, V323, P115, DOI 10.1016/j.canlet.2012.02.017
   Zhou Y, 2014, CANCER SCI, V105, P1279, DOI 10.1111/cas.12494
   Zuco V, 2002, CANCER LETT, V175, P17, DOI 10.1016/S0304-3835(01)00718-2
NR 76
TC 29
Z9 30
U1 5
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD OCT
PY 2017
VL 8
AR e3087
DI 10.1038/cddis.2017.485
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FL2CV
UT WOS:000414022900072
PM 28981110
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU De Albuquerque-Xavier, AC
   Bastos, LGR
   De Freitas, JCM
   Leve, F
   De Souza, WF
   De Araujo, WM
   Wanderley, JLM
   Tanaka, MN
   De Souza, W
   Morgado-Diaz, JA
AF De Albuquerque-Xavier, Ana Cristina
   Bastos, Lilian Goncalves R.
   Madureira De Freitas, Julio Cesar, Jr.
   Leve, Fernanda
   De Souza, Waldemir Fernandez
   De Araujo, Wallace Martins
   Mendes Wanderley, Joao Luiz
   Tanaka, Marcelo Neves
   De Souza, Wanderley
   Morgado-Diaz, Jose Andres
TI Blockade of irradiation-induced autophagosome formation impairs
   proliferation but does not enhance cell death in HCT-116 human
   colorectal carcinoma cells
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE autophagy; colorectal cancer; radiotherapy; cell signaling;
   proliferation
ID CANCER-CELLS; IN-VITRO; RADIATION; BECLIN-1; PATHWAY; INHIBITION;
   MATURATION; VACUOLES; PHOSPHORYLATION; CONTRIBUTES
AB This work was undertaken to gain further information on the molecular mechanisms underlying autophagosome formation and its relation with tumor cell survival in response to radiation in colon cancer. A human colon cancer cell line, HCT-116, was examined with respect to cell survival after blockade of irradiation-induced autophagosome formation by pharmacological interference. Autophagosome formation was confirmed using a kinetic study with incorporated bovine serum albumin gold-conjugate (BSA-Au) analyzed by electron microscopy and an autophagosome-associated LC3B antibody measured by immunofluorescence and Western blotting. Annexin V/PI double staining was used to monitor cell death by apoptosis, and cell cycle profiles by flow cytometry. Ionizing radiation (IR) promoted autophagosome formation in the HCT-116 IR-surviving cells. Pharmacological interference showed that PI3K/Akt and Src were involved in early stages of autophagosome formation. IR alone decreased cell proliferation by arresting cells in the G(2)/M phase, and pharmacological interference of autophagosome formation decreased proliferation, but did not affect cell survival. Also, our data suggest that decreased proliferation caused by PI3K and Src inhibitors could be through S phase cell cycle delay. Our results clearly indicate that blockade of IR-induced autophagosome formation impairs proliferation but does not enhance cell death in colon cancer cells.
C1 [De Albuquerque-Xavier, Ana Cristina; Bastos, Lilian Goncalves R.; Madureira De Freitas, Julio Cesar, Jr.; Leve, Fernanda; De Souza, Waldemir Fernandez; De Araujo, Wallace Martins; Tanaka, Marcelo Neves; Morgado-Diaz, Jose Andres] Jose Alencar Natl Canc Inst, Div Cellular Biol, BR-20231050 Rio De Janeiro, RJ, Brazil.
   [Mendes Wanderley, Joao Luiz] Jose Alencar Natl Canc Inst, Div Expt Med, BR-20231050 Rio De Janeiro, RJ, Brazil.
   [Mendes Wanderley, Joao Luiz] Univ Fed Rio de Janeiro, Polo Univ, Rio De Janeiro, RJ, Brazil.
   [De Souza, Wanderley] Univ Fed Rio de Janeiro, Dept Cellular Biol & Parasitol, Carlos Chagas Biophys Inst, Rio De Janeiro, RJ, Brazil.
RP Morgado-Diaz, JA (corresponding author), Jose Alencar Natl Canc Inst, Div Cellular Biol, Rua Andre Cavalcanti,37-5 Andar, BR-20231050 Rio De Janeiro, RJ, Brazil.
EM jmorgado@inca.gov.br
RI de Souza, Waldemir/B-3612-2015; Araujo, Wallace/O-7736-2015; Wanderley,
   Joao Luiz/J-6711-2014; Morgado-Diaz, Jose A./A-9649-2010; de Freitas,
   Julio Cesar/M-5754-2013
OI de Souza, Waldemir/0000-0003-3258-6758; de Freitas, Julio
   Cesar/0000-0002-2070-1432; DE ARAUJO, WALLACE/0000-0003-2979-4070; Leve,
   Fernanda/0000-0001-5466-0950
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPQ); Ministerio da Satide, Brasil; Fundacao Carlos Chagas Filho de
   Amparo a Pesquisa do Estado de Rio de Janeiro (FAPERJ)Fundacao Carlos
   Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)
FX This study was sponsored by Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Ministerio da Satide, Brasil, and
   Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado de Rio de
   Janeiro (FAPERJ). We are grateful to Barbara DuRocher for her valuable
   help in the interpretation of the cell cycle experiments, Livia
   Goto-Silva for suggestions made at the beginning of the present study,
   the Programa de Cooperacao INCA/FIOCRUZ for the use of their facility
   and the employers of Departamento de Hemoterapia-INCA for the use of
   gamma irradiator.
CR Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Aki T, 2003, ONCOGENE, V22, P8529, DOI 10.1038/sj.onc.1207197
   Al-Ejeh F, 2010, ONCOGENE, V29, P6085, DOI 10.1038/onc.2010.407
   Albert JM, 2006, MOL CANCER THER, V5, P1183, DOI 10.1158/1535-7163.MCT-05-0400
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562
   Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200
   Brown JM, 1999, CANCER RES, V59, P1391
   Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595
   Chaachouay H, 2011, RADIOTHER ONCOL, V99, P287, DOI 10.1016/j.radonc.2011.06.002
   Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003
   Corcelle E, 2006, CANCER RES, V66, P6861, DOI 10.1158/0008-5472.CAN-05-3557
   Corcelle EA, 2009, FEBS J, V276, P6084, DOI 10.1111/j.1742-4658.2009.07332.x
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Degtyarev M, 2008, J CELL BIOL, V183, P101, DOI 10.1083/jcb.200801099
   Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493
   Eskelinen EL, 2005, AUTOPHAGY, V1, P1, DOI 10.4161/auto.1.1.1270
   FENGSRUD M, 1995, EXP CELL RES, V221, P504, DOI 10.1006/excr.1995.1402
   Finkel E, 1999, SCIENCE, V286, P2256, DOI 10.1126/science.286.5448.2256
   Furuta S, 2004, ONCOGENE, V23, P3898, DOI 10.1038/sj.onc.1207539
   Goldkorn T, 1997, BBA-MOL CELL RES, V1358, P289, DOI 10.1016/S0167-4889(97)00063-3
   Hamasaki M, 2010, FEBS LETT, V584, P1296, DOI 10.1016/j.febslet.2010.02.061
   John S, 2008, CANCER RES, V68, P7855, DOI 10.1158/0008-5472.CAN-07-5875
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kondo Y, 2006, AUTOPHAGY, V2, P85, DOI 10.4161/auto.2.2.2463
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002
   Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0
   Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200
   Paglin S, 2005, CANCER RES, V65, P11061, DOI 10.1158/0008-5472.CAN-05-1083
   Paglin S, 2001, CANCER RES, V61, P439
   Puyal J, 2012, NEUROSCIENTIST, V18, P224, DOI 10.1177/1073858411404948
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Razi M, 2009, J CELL BIOL, V185, P305, DOI 10.1083/jcb.200810098
   Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272
   Speake WJ, 2005, EJSO-EUR J SURG ONC, V31, P869, DOI 10.1016/j.ejso.2005.05.016
   Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Yuk JM, 2010, AUTOPHAGY, V6, P46, DOI 10.4161/auto.6.1.10325
   Zois CE, 2009, AUTOPHAGY, V5, P442, DOI 10.4161/auto.5.4.7667
NR 46
TC 2
Z9 2
U1 0
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD APR
PY 2012
VL 40
IS 4
BP 1267
EP 1276
DI 10.3892/ijo.2012.1329
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 910LI
UT WOS:000301637800044
PM 22246348
OA Bronze, Green Published
DA 2022-04-25
ER

PT J
AU Zhou, XH
   Kang, J
   Zhong, ZD
   Cheng, Y
AF Zhou, Xing-Hua
   Kang, Jian
   Zhong, Zhen-Dong
   Cheng, Yue
TI Osthole induces apoptosis of the HT-29 cells via endoplasmic reticulum
   stress and autophagy
SO ONCOLOGY LETTERS
LA English
DT Article
DE osthole; apoptosis; endoplasmic reticulum stress; autophagy; colon
   cancer
ID COLON-CANCER; INFLAMMATION; DYSFUNCTION; CROSSTALK
AB Endoplasmic reticulum stress (ERS) and autophagy are important pathways, which induce apoptosis of tumor cells. Osthole has been demonstrated to exert anticancer effects via the induction of apoptosis in several human colon cancer lines, but the mechanism underlying its involvement in the induction of ERS and autophagy in the human HT-29 colorectal cancer cell line remains unknown. The present study aimed to identify the possible signaling pathways involved in osthole-induced apoptosis of HT29 cells. Methodologically, colony formation and Cell Counting Kit-8 assays were used to assess cell proliferation and viability, respectively, while flow cytometry was performed to investigate apoptosis. Signaling pathways, including apoptosis, autophagy and ERS, were also investigated in the HT-29 cell line using western blot analysis. The results demonstrated that osthole inhibited cellular proliferation and viability in a dose-dependent manner. In addition, osthole induced the expression level of proteins associated with mitochondria-mediated cell apoptosis, autophagy and ERS. The association between autophagy and ERS in osthole-induced apoptosis in the HT-29 cell line was further clarified. Inhibiting cell autophagy with the inhibitor, 3-methyladenine, suppressed osthole-induced cell apoptosis and enhanced osthole-induced ERS. By contrast, alleviating ERS with the inhibitor, 4-phenylbutyric acid attenuated osthole-induced cell apoptosis and autophagy. In conclusion, osthole could significantly suppress the proliferation and viability of the HT-29 colorectal cancer cell line and induce cell apoptosis via autophagy and ERS. Furthermore, ERS may play a more important role in osthole-induced cell apoptosis.
C1 [Zhou, Xing-Hua; Kang, Jian; Cheng, Yue] Chengdu Univ Tradit Chinese Med, Affiliated Hosp, Dept Anorectal Dis, 39 Shier Qiao Rd, Chengdu 610075, Sichuan, Peoples R China.
   [Zhong, Zhen-Dong] Sichuan Prov Peoples Hosp, Anim Expt Res Inst, Chengdu 610000, Sichuan, Peoples R China.
RP Cheng, Y (corresponding author), Chengdu Univ Tradit Chinese Med, Affiliated Hosp, Dept Anorectal Dis, 39 Shier Qiao Rd, Chengdu 610075, Sichuan, Peoples R China.
EM msmscycy@hotmail.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81873073]; Science and Technology
   Development Fund of Affiliated Hospital of Chengdu University of
   Traditional Chinese Medicine [18MZ27]
FX The present study was supported by the National Natural Science
   Foundation of China (grant no. 81873073) and Science and Technology
   Development Fund of Affiliated Hospital of Chengdu University of
   Traditional Chinese Medicine (grant no. 18MZ27).
CR Almanza A, 2019, FEBS J, V286, P241, DOI 10.1111/febs.14608
   Bao YX, 2018, MOL MED REP, V17, P4561, DOI 10.3892/mmr.2018.8447
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025
   D'Arcy MS, 2019, CELL BIOL INT, V43, P582, DOI 10.1002/cbin.11137
   Devenport SN, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111349
   Di SY, 2019, INT J BIOL SCI, V15, P1637, DOI 10.7150/ijbs.33790
   Gong J, 2017, J ZHEJIANG UNIV-SC B, V18, P1, DOI 10.1631/jzus.B1600043
   Guzel E, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040792
   Hu T, 2016, WORLD J GASTROENTERO, V22, P6876, DOI 10.3748/wjg.v22.i30.6876
   Huang SM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/175247
   Jarzab A, 2017, POSTEP HIG MED DOSW, V71, P411
   Karagoz GE, 2019, CSH PERSPECT BIOL, V11, DOI 10.1101/cshperspect.a033886
   Latorraca LB, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69939-3
   Lei C, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000018791
   Li YL, 2018, EUR J PHARMACOL, V818, P525, DOI 10.1016/j.ejphar.2017.11.006
   Liang J, 2020, EUR J PHARMACOL, V874, DOI 10.1016/j.ejphar.2020.172990
   Liu WB, 2010, NEUROCHEM INT, V57, P206, DOI 10.1016/j.neuint.2010.05.011
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Oakes SA, 2020, AM J PATHOL, V190, P934, DOI 10.1016/j.ajpath.2020.01.010
   Park W, 2019, NUTRIENTS, V11, DOI 10.3390/nu11112777
   Pistritto G, 2016, AGING-US, V8, P603, DOI 10.18632/aging.100934
   Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028
   Shen ZL, 2019, ENVIRON TOXICOL, V34, P768, DOI 10.1002/tox.22743
   Shokoohinia Y, 2018, NUTRIENTS, V10, DOI 10.3390/nu10010036
   Siddiqui WA, 2015, ARCH TOXICOL, V89, P289, DOI 10.1007/s00204-014-1448-7
   Sisinni L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040857
   Song SL, 2017, J CELL PHYSIOL, V232, P2977, DOI 10.1002/jcp.25785
   Tang DZ, 2010, J BONE MINER RES, V25, P1234, DOI 10.1002/jbmr.21
   Verfaillie T., 2010, INT J CELL BIOL, V2010, P930509, DOI [DOI 10.1155/2010/930509, 10.1155/2010/930509]
   Wang LT, 2015, J BIOMED RES, V29, P132, DOI 10.7555/JBR.27.20120115
   Woo KJ, 2007, BIOCHEM PHARMACOL, V73, P68, DOI 10.1016/j.bcp.2006.09.015
   Xu XM, 2016, ONCOL LETT, V12, P3779, DOI 10.3892/ol.2016.5170
   Zhang H, 2019, HEPATOLOGY, V69, P1046, DOI 10.1002/hep.30300
   Zhang YY, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102146
NR 38
TC 0
Z9 0
U1 4
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD OCT
PY 2021
VL 22
IS 4
AR 726
DI 10.3892/ol.2021.12987
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA UB8HI
UT WOS:000686080000001
PM 34429766
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Jeong, S
   Kim, DY
   Kang, SH
   Yun, HK
   Kim, JL
   Kim, BR
   Park, SH
   Na, YJ
   Jo, MJ
   Jeong, YA
   Kim, BG
   Lee, DH
   Oh, SC
AF Jeong, Soyeon
   Kim, Dae Yeong
   Kang, Sang Hee
   Yun, Hye Kyeong
   Kim, Jung Lim
   Kim, Bo Ram
   Park, Seong Hye
   Na, Yoo Jin
   Jo, Min Jee
   Jeong, Yoon A.
   Kim, Bu Gyeom
   Lee, Dae-Hee
   Oh, Sang Cheul
TI Docosahexaenoic Acid Enhances Oxaliplatin-Induced Autophagic Cell Death
   via the ER Stress/Sesn2 Pathway in Colorectal Cancer
SO CANCERS
LA English
DT Article
DE Oxaliplatin; docosahexaenoic acid; Sestrin 2; autophagic cell death;
   colon cancer
ID APOPTOSIS; BEVACIZUMAB; INDUCTION; SESTRIN-2; ARREST; MTOR
AB Oxaliplatin is an anticancer drug administered to colorectal cancer (CRC) patients in combination with 5-fluorouracil and antibodies (bevacizumab and cetuximab), thereby significantly improving the survival rate of CRC. However, due to various side effects associated with the above treatment strategy, the need for combinatorial therapeutic strategies has emerged. Based on the demand for new combinatorial therapies and the known antitumor effects of the omega-3 polyunsaturated fatty acid, docosahexaenoic acid (DHA), we investigated the Oxaliplatin and DHA combination for its effect. Our results indicated that DHA further enhanced Oxaliplatin-induced cell viability and autophagic cell death, in vitro and in vivo. Oxaliplatin and DHA also increased the expression of Sestrin 2 (SESN2) and endoplasmic reticulum (ER) stress related C/EBP homologous protein (CHOP). Additionally, treatment with Oxaliplatin and DHA enhanced the binding of CHOP to the promotor region of SESN2, increasing SESN2 expression. These results suggested that DHA enhanced Oxaliplatin-induced reduction in cell viability and increase in autophagy via activating SESN2 and increasing ER stress. Thus, SESN2 may be an effective preclinical target for CRC treatment.
C1 [Jeong, Soyeon; Kim, Jung Lim; Kim, Bo Ram; Lee, Dae-Hee; Oh, Sang Cheul] Korea Univ, Guro Hosp, Coll Med, Dept Oncol, Seoul 08308, South Korea.
   [Kim, Dae Yeong; Yun, Hye Kyeong; Park, Seong Hye; Na, Yoo Jin; Jo, Min Jee; Jeong, Yoon A.; Kim, Bu Gyeom; Lee, Dae-Hee; Oh, Sang Cheul] Korea Univ, Coll Med, Grad Sch Med, Seoul 08308, South Korea.
   [Kang, Sang Hee] Korea Univ, Guro Hosp, Coll Med, Dept Surg, Seoul 08308, South Korea.
RP Lee, DH; Oh, SC (corresponding author), Korea Univ, Guro Hosp, Coll Med, Dept Oncol, Seoul 08308, South Korea.; Lee, DH; Oh, SC (corresponding author), Korea Univ, Coll Med, Grad Sch Med, Seoul 08308, South Korea.
EM neogene@korea.ac.kr; sachoh@korea.ac.kr
RI Kang, Sanghee/W-1117-2019
OI Kang, Sanghee/0000-0002-6097-8831; Jeong, Soyeon/0000-0002-4568-4579
FU National Research Foundation (NRF) of Korea - Korean government (MSIP)
   [NRF-2017R1A2B2011684, NRF-2017R1D1A1B03030703]
FX This work was supported by a National Research Foundation (NRF) of Korea
   grant funded by the Korean government (MSIP) (NRF-2017R1A2B2011684) and
   (NRF-2017R1D1A1B03030703). Moreover, we thank professor Kyu Lim for
   providing the GFP-LC3 vector, AA, alpha-LA, EPA.
CR Ambrosio S, 2017, ONCOGENE, V36, P6701, DOI 10.1038/onc.2017.267
   Areti A, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12393
   Bendell JC, 2012, ONCOLOGIST, V17, P1486, DOI 10.1634/theoncologist.2012-0190
   Bodmer D, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.457
   Bruning A, 2013, MOL ONCOL, V7, P1012, DOI 10.1016/j.molonc.2013.07.010
   D'Eliseo D, 2016, J CLIN MED, V5, DOI 10.3390/jcm5020015
   Dai JF, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-71
   Di Bartolomeo M, 2015, EUR J CANCER, V51, P473, DOI 10.1016/j.ejca.2014.12.020
   Esfahani A, 2016, BIOMARK RES, V4, DOI 10.1186/s40364-016-0066-3
   Garaeva AA, 2016, CELL CYCLE, V15, P64, DOI 10.1080/15384101.2015.1120929
   Hu XB, 2019, AUTOPHAGY, V15, P453, DOI 10.1080/15548627.2018.1520548
   Jakobsen CH, 2008, J LIPID RES, V49, P2089, DOI 10.1194/jlr.M700389-JLR200
   Jeong S, 2019, CANCER LETT, V447, P12, DOI 10.1016/j.canlet.2019.01.011
   Jeong S, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-481
   Jing K, 2011, AUTOPHAGY, V7, P1348, DOI 10.4161/auto.7.11.16658
   Kim HJ, 2017, FREE RADICAL BIO MED, V110, P81, DOI 10.1016/j.freeradbiomed.2017.05.026
   Kim N, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/239764
   Kim SY, 2014, BIOCHEM PHARMACOL, V88, P178, DOI 10.1016/j.bcp.2014.01.027
   Kim S, 2018, ONCOL REP, V39, P239, DOI 10.3892/or.2017.6101
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Li DD, 2016, ONCOTARGET, V7, P80842, DOI 10.18632/oncotarget.13099
   Liang YG, 2016, AUTOPHAGY, V12, P1229, DOI 10.1080/15548627.2016.1179403
   Mehmood Rao Khalid, 2014, World J Oncol, V5, P97, DOI 10.14740/wjon830w
   Morin C, 2013, RECENT PAT ANTI-CANC, V8, P319, DOI 10.2174/1574891X113089990032
   Murad LB, 2019, BIOFACTORS, V45, P24, DOI 10.1002/biof.1455
   Park M, 2017, J CANCER PREV, V22, P1, DOI 10.15430/JCP.2017.22.1.1
   Pasha M, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3296294
   Pathak Surajit, 2018, Oncotarget, V9, P7739, DOI 10.18632/oncotarget.22471
   Rashid HO, 2015, AUTOPHAGY, V11, P1956, DOI 10.1080/15548627.2015.1091141
   Ro SH, 2016, ELIFE, V5, DOI 10.7554/eLife.12204
   Sanli T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032035
   Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028
   Schlafli AM, 2016, ONCOTARGET, V7, P39544, DOI 10.18632/oncotarget.9647
   Shin JI, 2019, MOL CELLS, V42, P252, DOI 10.14348/molcells.2019.2440
   Shin S, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/568671
   Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442
   Song EA, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081257
   Tian T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030755
   VanderSluis L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122607
   Zhang L, 2019, AUTOPHAGY, V15, P391, DOI 10.1080/15548627.2018.1511503
   Zhang Y, 2016, CANCER LETT, V377, P117, DOI 10.1016/j.canlet.2016.04.037
NR 41
TC 15
Z9 15
U1 0
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD JUN 26
PY 2019
VL 11
IS 7
AR 982
DI 10.3390/cancers11070982
PG 18
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA IO4AV
UT WOS:000479322800093
PM 31337142
OA Green Submitted, gold, Green Published
DA 2022-04-25
ER

PT J
AU Bermudez, M
   Aguilar-Medina, M
   Lizarraga-Verdugo, E
   Avendano-Felix, M
   Silva-Benitez, E
   Lopez-Camarillo, C
   Ramos-Payan, R
AF Bermudez, Mercedes
   Aguilar-Medina, Maribel
   Lizarraga-Verdugo, Erik
   Avendano-Felix, Mariana
   Silva-Benitez, Erika
   Lopez-Camarillo, Cesar
   Ramos-Payan, Rosalio
TI LncRNAs as Regulators of Autophagy and Drug Resistance in Colorectal
   Cancer
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE lncRNA; colorectal cancer; autophagy; chemoresistance; drug resistance;
   macroautophagy
ID LONG NONCODING RNA; EPITHELIAL-MESENCHYMAL TRANSITION; MEDIATES
   METHOTREXATE RESISTANCE; ADENOCARCINOMA TRANSCRIPT 1; PROMOTES
   TUMOR-GROWTH; H19 ONCOFETAL RNA; CELL LUNG-CANCER; POOR-PROGNOSIS;
   PROSTATE-CANCER; COLON-CANCER
AB Colorectal cancer (CRC) is a common malignancy with 1. 8 million cases in 2018. Autophagy helps to maintain an adequate cancer microenvironment in order to provide nutritional supplement under adverse conditions such as starvation and hypoxia. Additionally, most of the cases of CRC are unresponsive to chemotherapy, representing a significant challenge for cancer therapy. Recently, autophagy induced by therapy has been shown as a unique mechanism of resistance to anticancer drugs. In this regard, long non-coding RNAs (lncRNAs) analysis are important for cancer detection, progression, diagnosis, therapy response, and prognostic values. With increasing development of quantitative detection techniques, lncRNAs derived from patients' non-invasive samples (i.e., blood, stools, and urine) has become into a novel approach in precision oncology. Tumorspecific GAS5, HOTAIR, H19, and MALAT are novels CRC related lncRNAs detected in patients. Nonetheless, the effect and mechanism of lncRNAs in cancer autophagy and chemoresistance have not been extensively characterized. Chemoresistance and autophagy are relevant for cancer treatment and lncRNAs play a pivotal role in resistance acquisition for several drugs. LncRNAs such as HAGLROS, KCNQ1OT1, and H19 are examples of lncRNAs related to chemoresistance leaded by autophagy. Finally, clinical implications of lncRNAs in CRC are relevant, since they have been associated with tumor differentiation, tumor size, histological grade, histological types, Dukes staging, degree of differentiation, lymph node metastasis, distant metastasis, recurrent free survival, and overall survival (OS).
C1 [Bermudez, Mercedes; Aguilar-Medina, Maribel; Lizarraga-Verdugo, Erik; Avendano-Felix, Mariana; Ramos-Payan, Rosalio] Univ Autonoma Sinaloa, Fac Ciencias Quim Biol, Culiacan, Sinaloa, Mexico.
   [Silva-Benitez, Erika] Univ Autonoma Sinaloa, Fac Odontol, Culiacan, Sinaloa, Mexico.
   [Lopez-Camarillo, Cesar] Univ Autonoma Ciudad Mexico, Posgrad Ciencias Genom, Mexico City, DF, Mexico.
RP Ramos-Payan, R (corresponding author), Univ Autonoma Sinaloa, Fac Ciencias Quim Biol, Culiacan, Sinaloa, Mexico.
EM rosaliorp@uas.edu.mx
RI ; Lopez-Camarillo, Cesar/I-1946-2019
OI Ramos-Payan, Rosalio/0000-0001-7500-7571; Lopez-Camarillo,
   Cesar/0000-0002-9417-2609
FU Consejo Nacional de Ciencia y Tecnologia CONACyT, MexicoConsejo Nacional
   de Ciencia y Tecnologia (CONACyT) [290311]
FX Consejo Nacional de Ciencia y Tecnologia CONACyT, Mexico (Grant 290311).
CR Alfarouk KO, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0221-1
   Ariel I, 1998, J CLIN PATHOL-MOL PA, V51, P21, DOI 10.1136/mp.51.1.21
   Arita T, 2013, ANTICANCER RES, V33, P3185
   Aune TM, 2016, J LEUKOCYTE BIOL, V99, P31, DOI 10.1189/jlb.1RI0815-389R
   Avalos Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/603980
   Berteaux N, 2005, J BIOL CHEM, V280, P29625, DOI 10.1074/jbc.M504033200
   Bian ZH, 2017, ONCOGENESIS, V6, DOI 10.1038/s41389-017-0008-4
   Bian ZH, 2016, SCI REP-UK, V6, DOI 10.1038/srep23892
   Bolha L, 2017, DIS MARKERS, V2017, DOI 10.1155/2017/7243968
   Bonasio R, 2014, ANNU REV GENET, V48, P433, DOI 10.1146/annurev-genet-120213-092323
   BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Byun HM, 2007, CANCER RES, V67, P10753, DOI 10.1158/0008-5472.CAN-07-0329
   Cabili MN, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0586-4
   Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611
   Chen CL, 2015, BIOMATERIALS, V44, P71, DOI 10.1016/j.biomaterials.2014.12.023
   Chen LL, 2016, TRENDS BIOCHEM SCI, V41, P761, DOI 10.1016/j.tibs.2016.07.003
   Chen YN, 2016, ONCOTARGET, V7, P52673, DOI 10.18632/oncotarget.10170
   Chen ZH, 2017, CELL DEATH DIFFER, V24, P212, DOI 10.1038/cdd.2016.111
   Cheng KW, 2018, ONCOL REP, V40, P2371, DOI 10.3892/or.2018.6584
   Clark MB, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000625
   Clark MB, 2011, SEMIN CELL DEV BIOL, V22, P366, DOI 10.1016/j.semcdb.2011.01.001
   Corra F, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00327
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Deng QW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103022
   Devenish RJ, 2015, CURR BIOL, V25, pR238, DOI 10.1016/j.cub.2015.01.045
   Ding DY, 2018, MOL CELLS, V41, P423, DOI 10.14348/molcells.2018.2258
   Ding J, 2018, ONCOGENE, V37, P5037, DOI 10.1038/s41388-018-0175-6
   Ding J, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0217-7
   Du LT, 2018, J CELL MOL MED, V22, P2838, DOI 10.1111/jcmm.13578
   Fan H, 2018, MOL MED REP, V17, P8309, DOI 10.3892/mmr.2018.8907
   Fang J, 2016, BIOCHEM BIOPH RES CO, V478, P811, DOI 10.1016/j.bbrc.2016.08.030
   Ferre F, 2016, BRIEF BIOINFORM, V17, P106, DOI 10.1093/bib/bbv031
   Fu JN, 2017, INT J BIOL MARKER, V32, pE428, DOI 10.5301/ijbm.5000303
   Gabory A, 2006, CYTOGENET GENOME RES, V113, P188, DOI 10.1159/000090831
   Gabory A, 2010, BIOESSAYS, V32, P473, DOI 10.1002/bies.200900170
   Galluzzi L, 2017, NAT REV DRUG DISCOV, V16, P487, DOI 10.1038/nrd.2017.22
   Ge XS, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0588-6
   Gill S, 2004, J CLIN ONCOL, V22, P1797, DOI 10.1200/JCO.2004.09.059
   Gu LQ, 2018, GENE, V666, P18, DOI 10.1016/j.gene.2018.03.100
   Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914
   Guo FJ, 2010, ACTA BIOCH BIOPH SIN, V42, P224, DOI 10.1093/abbs/gmq008
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Gutschner T, 2013, CANCER RES, V73, P1180, DOI 10.1158/0008-5472.CAN-12-2850
   Guttman M, 2012, NATURE, V482, P339, DOI 10.1038/nature10887
   Han D, 2016, ONCOTARGET, V7, P22159, DOI 10.18632/oncotarget.8063
   Han QR, 2019, ONCOGENE, V38, P3019, DOI 10.1038/s41388-018-0614-4
   Hangauer MJ, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003569
   Hemelaar J, 2003, J BIOL CHEM, V278, P51841, DOI 10.1074/jbc.M308762200
   Hibi K, 1996, CANCER RES, V56, P480
   Holubec L, 2016, ANTICANCER RES, V36, P4421, DOI 10.21873/anticanres.10985
   Hombach S, 2016, ADV EXP MED BIOL, V937, P3, DOI 10.1007/978-3-319-42059-2_1
   Hu B, 2014, TUMOR BIOL, V35, P8573, DOI 10.1007/s13277-014-2109-4
   Hu Dongzhi, 2018, Cell Physiol Biochem, V51, P2704, DOI 10.1159/000495961
   Huarte M, 2010, HUM MOL GENET, V19, pR152, DOI 10.1093/hmg/ddq353
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Iempridee T, 2018, FEBS OPEN BIO, V8, P1844, DOI 10.1002/2211-5463.12523
   Jarroux J, 2017, ADV EXP MED BIOL, V1008, P1, DOI 10.1007/978-981-10-5203-3_1
   Ji H, 2019, CANCER SCI, V110, P72, DOI 10.1111/cas.13838
   Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928
   Ji Q, 2014, BRIT J CANCER, V111, P736, DOI 10.1038/bjc.2014.383
   Jia H, 2010, RNA, V16, P1478, DOI 10.1261/rna.1951310
   Jiang XH, 2019, ONCOTARGETS THER, V12, P1059, DOI 10.2147/OTT.S192290
   Jin Y, 2017, EUR REV MED PHARMACO, V21, P3176
   Kang H, 2013, INT J MOL SCI, V14, P17204, DOI 10.3390/ijms140817204
   Kashi K, 2016, BBA-GENE REGUL MECH, V1859, P3, DOI 10.1016/j.bbagrm.2015.10.010
   Khachane AN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010316
   Kim ED, 2012, TRENDS PLANT SCI, V17, P16, DOI 10.1016/j.tplants.2011.10.008
   Kino T, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000568
   Klinge CM, 2018, ENDOCR-RELAT CANCER, V25, pR259, DOI 10.1530/ERC-17-0548
   Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620
   Kung CP, 2011, CRIT REV EUKAR GENE, V21, P71, DOI 10.1615/CritRevEukarGeneExpr.v21.i1.50
   Kurkjian C, 2009, AM J THER, V16, P412, DOI 10.1097/MJT.0b013e3181907ed9
   Lam MTY, 2014, TRENDS BIOCHEM SCI, V39, P170, DOI 10.1016/j.tibs.2014.02.007
   Lanzafame M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030682
   Lee H, 2014, MOL CELLS, V37, P540, DOI 10.14348/molcells.2014.0151
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li CF, 2017, BIOCHEM BIOPH RES CO, V491, P552, DOI 10.1016/j.bbrc.2017.03.042
   Li J, 2018, ONCOL REP, V39, P217, DOI 10.3892/or.2017.6082
   Li J, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-017-0478-7
   Li LX, 2017, ONCOL REP, V38, P1383, DOI 10.3892/or.2017.5828
   Li PL, 2017, MOL CANCER THER, V16, P739, DOI 10.1158/1535-7163.MCT-16-0591
   Li W, 2016, EUR REV MED PHARMACO, V20, P4874
   Li YC, 2019, ONCOTARGETS THER, V12, P2649, DOI 10.2147/OTT.S188054
   Li Y, 2016, TUMOR BIOL, V37, P14205, DOI 10.1007/s13277-016-5254-0
   Li Y, 2018, ONCOL REP, V39, P1619, DOI 10.3892/or.2018.6260
   Lian YF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07954-7
   Liang WC, 2015, ONCOTARGET, V6, P22513, DOI 10.18632/oncotarget.4154
   Lin K, 2018, DIGEST DIS SCI, V63, P2320, DOI 10.1007/s10620-018-5127-z
   Lin LY, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0834-9
   Lin R, 2007, ONCOGENE, V26, P851, DOI 10.1038/sj.onc.1209846
   Lin YL, 2018, TRANSL ONCOL, V11, P1225, DOI 10.1016/j.tranon.2018.07.016
   Liu L, 2018, CANCER BIOMARK, V22, P283, DOI 10.3233/CBM-171011
   Liu T, 2016, ONCOTARGET, V7, P85551, DOI 10.18632/oncotarget.13465
   Liu XH, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-92
   Liu XH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-464
   Liu XW, 2016, NAT CELL BIOL, V18, P431, DOI 10.1038/ncb3328
   Lodish H., 2008, MOL CELL BIOL
   Lorenzen JM, 2015, CLIN CHEM, V61, P1505, DOI 10.1373/clinchem.2015.243600
   Lu YY, 2017, NAT MED, V23, P1331, DOI 10.1038/nm.4424
   LUSTIG O, 1994, MOL REPROD DEV, V38, P239, DOI 10.1002/mrd.1080380302
   Mah LY, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008821
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Marshall John L, 2007, Gastrointest Cancer Res, V1, P146
   Martens-Uzunova ES, 2014, EUR UROL, V65, P1140, DOI 10.1016/j.eururo.2013.12.003
   Martini G, 2017, WORLD J GASTROENTERO, V23, P4675, DOI 10.3748/wjg.v23.i26.4675
   Mattick JS, 2015, NAT STRUCT MOL BIOL, V22, P5, DOI 10.1038/nsmb.2942
   Mishra DK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161800
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   MOERTEL CG, 1995, J CLIN ONCOL, V13, P2936, DOI 10.1200/JCO.1995.13.12.2936
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Moran VA, 2012, NUCLEIC ACIDS RES, V40, P6391, DOI 10.1093/nar/gks296
   Mourtada-Maarabouni M, 2009, ONCOGENE, V28, P195, DOI 10.1038/onc.2008.373
   Naganuma T, 2013, RNA BIOL, V10, P456, DOI 10.4161/rna.23547
   Ohtsuka M, 2016, EBIOMEDICINE, V13, P113, DOI 10.1016/j.ebiom.2016.10.026
   Pan SM, 2019, BBA-MOL CELL RES, V1866, P750, DOI 10.1016/j.bbamcr.2019.02.004
   Pan YF, 2018, CLIN CHIM ACTA, V480, P199, DOI 10.1016/j.cca.2018.02.019
   Parasramka MA, 2016, PHARMACOL THERAPEUT, V161, P67, DOI 10.1016/j.pharmthera.2016.03.004
   Patrushev LI, 2014, BIOCHEMISTRY-MOSCOW+, V79, P1442, DOI 10.1134/S0006297914130021
   Pawar K, 2016, SCI REP-UK, V6, DOI 10.1038/srep19416
   Peeters M, 2010, J CLIN ONCOL, V28, P4706, DOI 10.1200/JCO.2009.27.6055
   Pickard MR, 2013, BBA-MOL BASIS DIS, V1832, P1613, DOI 10.1016/j.bbadis.2013.05.005
   Pickard MR, 2015, GENES-BASEL, V6, P484, DOI 10.3390/genes6030484
   Ping GF, 2018, AM J TRANSL RES, V10, P138
   Qi P, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.NONRNA15-B42
   Qi P, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0524-4
   Qiao HP, 2013, ASIAN PAC J CANCER P, V14, P1077, DOI 10.7314/APJCP.2013.14.2.1077
   Qiao L, 2018, MOL CELL BIOCHEM, V441, P99, DOI 10.1007/s11010-017-3177-8
   Quinodoz S, 2014, TRENDS CELL BIOL, V24, P651, DOI 10.1016/j.tcb.2014.08.009
   Raguz S, 2008, BRIT J CANCER, V99, P387, DOI 10.1038/sj.bjc.6604510
   Ren J, 2018, THERANOSTICS, V8, P3932, DOI 10.7150/thno.25541
   Ricciuti B, 2016, MED ONCOL, V33, DOI 10.1007/s12032-016-0731-2
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902
   Santana-Codina N, 2017, ANNU REV CANC BIOL, V1, P19, DOI 10.1146/annurev-cancerbio-041816-122338
   Sartori DA, 2014, CURR OPIN ONCOL, V26, P259, DOI 10.1097/CCO.0000000000000065
   Schmidt LH, 2011, J THORAC ONCOL, V6, P1984, DOI 10.1097/JTO.0b013e3182307eac
   Senthebane DA, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071586
   Shan TD, 2016, ONCOTARGET, V7, P961, DOI 10.18632/oncotarget.5830
   Shi LL, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1332-8
   Shi YG, 2016, METHODS MOL BIOL, V1402, P43, DOI 10.1007/978-1-4939-3378-5_6
   Shi Y, 2015, INT J INF TECH DECIS, V14, P1, DOI 10.1142/S0219622015020022
   Shi YG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122679
   Song JP, 2019, J CELL BIOCHEM, V120, P6937, DOI 10.1002/jcb.27743
   Spurlock CF, 2016, J IMMUNOL, V197, P4509, DOI 10.4049/jimmunol.1600970
   Su J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.83
   Sun JN, 2014, NUCLEIC ACIDS RES, V42, P9588, DOI 10.1093/nar/gku549
   Sun L, 2018, J CANCER, V9, P2631, DOI 10.7150/jca.24978
   Sun ZQ, 2019, ONCOGENE, V38, P2627, DOI 10.1038/s41388-018-0628-y
   Svoboda M, 2014, CARCINOGENESIS, V35, P1510, DOI 10.1093/carcin/bgu055
   Tabernero J, 2015, LANCET ONCOL, V16, P499, DOI 10.1016/S1470-2045(15)70127-0
   Taft RJ, 2010, J PATHOL, V220, P126, DOI 10.1002/path.2638
   Tan DSW, 2010, EUR J CANCER, V46, P2166, DOI 10.1016/j.ejca.2010.03.019
   Tang DX, 2019, J CELL PHYSIOL, V234, P20816, DOI 10.1002/jcp.28687
   Tang DX, 2019, CELL SIGNAL, V57, P21, DOI 10.1016/j.cellsig.2019.01.013
   Tang HK, 2013, MOL MED REP, V7, P761, DOI 10.3892/mmr.2012.1254
   Tang SY, 2016, ONCOTARGET, V7, P73257, DOI 10.18632/oncotarget.12304
   Tanos V, 1999, EUR J OBSTET GYN R B, V85, P7, DOI 10.1016/S0301-2115(98)00275-9
   Tatangelo F, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1725-y
   Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986
   Tsang WP, 2010, CARCINOGENESIS, V31, P350, DOI 10.1093/carcin/bgp181
   Tseng JJ, 2009, MOL HUM REPROD, V15, P725, DOI 10.1093/molehr/gap071
   Uchida Shizuka, 2017, High Throughput, V6, DOI 10.3390/ht6030012
   Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620
   Wang HJ, 2018, BIOMED PHARMACOTHER, V106, P1607, DOI 10.1016/j.biopha.2018.07.131
   Wang M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1187-4
   Wang Q, 2017, ONCOTARGET, V8, P3441, DOI 10.18632/oncotarget.13840
   Wang Y, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0082-5
   Wang YG, 2016, FASEB J, V30, P3133, DOI 10.1096/fj.201500058R
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   World Health Organization (WHO), 2018, WHO CANC FACT SHEET
   Wu KF, 2017, EXP CELL RES, V350, P312, DOI 10.1016/j.yexcr.2016.12.003
   Xiao ZG, 2018, CELL PHYSIOL BIOCHEM, V46, P1275, DOI 10.1159/000489110
   Xiu YL, 2017, ONCOTARGET, V8, P31727, DOI 10.18632/oncotarget.15955
   Xu YJ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8010062
   Xu YL, 2018, MOL MED, V24, DOI 10.1186/s10020-018-0050-5
   Xue WJ, 2014, J CANCER RES THER, V10, pC218, DOI 10.4103/0973-1482.145881
   Yamada K, 2006, CANCER SCI, V97, P106, DOI 10.1111/j.1349-7006.2006.00147.x
   Yang JP, 2016, EUR REV MED PHARMACO, V20, P3980
   Yang LX, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.464
   Yang MH, 2015, BBA-MOL BASIS DIS, V1852, P166, DOI 10.1016/j.bbadis.2014.11.013
   Yang WW, 2018, ONCOL LETT, V16, P3365, DOI 10.3892/ol.2018.9052
   Yang WW, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/2767484
   Yang XD, 2016, ONCOL REP, V35, P479, DOI 10.3892/or.2015.4397
   Yang Y, 2017, ONCOL LETT, V13, P3151, DOI 10.3892/ol.2017.5841
   Yang Y, 2018, GENE THER, V25, P321, DOI 10.1038/s41434-018-0026-7
   Yang YN, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0660-6
   Yin DD, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0253-8
   Ying L, 2012, MOL BIOSYST, V8, P2289, DOI 10.1039/c2mb25070e
   Yoon JH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3939
   Yu AD, 2015, IMMUNOL CELL BIOL, V93, P277, DOI 10.1038/icb.2015.2
   Yu XH, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0771-y
   Yu ZY, 2018, ONCOL LETT, V15, P3127, DOI 10.3892/ol.2017.7677
   Yue B, 2016, MOL THER, V24, P2064, DOI 10.1038/mt.2016.180
   Zeng S, 2015, ONCOLOGIST, V20, P898, DOI 10.1634/theoncologist.2014-0475
   Zeng XZ, 2011, CELL CYCLE, V10, P579, DOI 10.4161/cc.10.4.14722
   Zhang ZB, 2016, MOL MED REP, V14, P2465, DOI 10.3892/mmr.2016.5572
   Zheng HT, 2014, INT J CLIN EXP PATHO, V7, P3174
   Zheng YS, 2019, J CELL BIOCHEM, V120, P3922, DOI 10.1002/jcb.27676
   Zhong XL, 2018, BIOMED PHARMACOTHER, V107, P382, DOI 10.1016/j.biopha.2018.07.118
   Zhu J, 2018, CELL PHYSIOL BIOCHEM, V51, P113, DOI 10.1159/000495168
   Zhuo CJ, 2017, ONCOTARGET, V8, P1429, DOI 10.18632/oncotarget.13637
   Zinovieva OL, 2018, BIOCHIMIE, V151, P67, DOI 10.1016/j.biochi.2018.05.021
NR 204
TC 54
Z9 55
U1 4
U2 12
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD OCT 2
PY 2019
VL 9
AR 1008
DI 10.3389/fonc.2019.01008
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA JO4MO
UT WOS:000497553900001
PM 31632922
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Alnuqaydan, AM
   Rah, B
   Almutary, AG
   Chauhan, SS
AF Alnuqaydan, Abdullah M.
   Rah, Bilal
   Almutary, Abdulmajeed G.
   Chauhan, Shailender Singh
TI Synergistic antitumor effect of 5-fluorouracil and withaferin-A induces
   endoplasmic reticulum stress-mediated autophagy and apoptosis in
   colorectal cancer cells
SO AMERICAN JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE Synergistic effect; endoplasmic reticulum; autophagy; apoptosis;
   colorectal cancer
ID ER STRESS; COLON-CANCER; C-MYC; BETA-CATENIN; G2/M ARREST; MECHANISMS;
   INHIBITION; PATHWAY; TARGET; GROWTH
AB The development of chemo-resistance against 5-fluorouracil (5-FU) in tumor cells is one of the main debacles in colorectal cancer (CRC) patients. A recent combination of 5-FU with oxaliplatin or cetuximab drastically improves the survival rate in CRC patients; however, the toxicity issue cannot be evaded completely. Thus, searching for novel drug combinations with high specificity and low toxicity is seemingly important. Owing to the less undesirable effects of natural products on normal cells, here we investigated the synergistic antitumor effect of withaferin-A (WA) in combination with 5-FU. Our results demonstrate that the combination of WA and 5-FU induces a significant antiproliferative effect and modulates endoplasmic reticulum (ER) stress in favor of cell death in colorectal cancer (CRC) cells. Mechanistically, the combination upregulates the expression of ER stress sensors (BiP, PERK, CHOP, ATF-4, and eIF2 alpha) and executes PERK axis mediated apoptosis in CRC cells. Additionally, the combined treatment of WA and 5-FU mediated ER stress induces autophagy and apoptosis, which were confirmed by immunoblotting, acridine orange (AO) staining and annexin-V FITC by flow cytometry. In contrast, inhibition of ER stress with salubrinal significantly decreases both autophagic and apoptotic cell populations. Moreover, pharmacological inhibition of either autophagy or apoptosis by their respective inhibitors 3-methyladenine (3-MA) or carbobenzoxy-valyl-alanylaspartyl-[O-methyl]-fluoro-methyl ketone (Z-VAD-FMK) decreases their respective population of cells but could not affect either of the population significantly. Finally, the combination attenuates the expression of beta-catenin pathway associated proteins and arrests cell cycle at the G(2)M phase in CRC cells. In summary, the combination of WA and 5-FU decreases cell viability by inducing ER stress-mediated induction of autophagy and apoptosis, inhibiting the beta-catenin pathway and arresting the cell cycle at a G(2)M phase in CRC cells.
C1 [Alnuqaydan, Abdullah M.; Rah, Bilal; Almutary, Abdulmajeed G.] Qassim Univ, Coll Appl Med Sci, Dept Med Biotechnol, GPO POB 6666, Buraydah 51452, Saudi Arabia.
   [Chauhan, Shailender Singh] Univ Arizona, Dept Cellular & Mol Med, Tucson, AZ USA.
RP Alnuqaydan, AM; Rah, B (corresponding author), Qassim Univ, Coll Appl Med Sci, Dept Med Biotechnol, GPO POB 6666, Buraydah 51452, Saudi Arabia.
EM ami.alnuqaydan@qu.edu.sa; b.rah@qu.edu.sa
RI Chauhan, Shailender Singh/AAM-5269-2020
OI Chauhan, Shailender Singh/0000-0002-1975-2734
FU Deanship of Scientific Research, Qassim University; Deputyship for
   Research & Innovation, Ministry of Education in Saudi Arabia
FX Researchers would like to thank the Deanship of Scientific Research,
   Qassim University for funding the publication of this project. The
   authors extend their appreciation to the Deputyship for Research &
   Innovation, Ministry of Education in Saudi Arabia for partial funding
   this research work through the post-doc project.
CR Ambroz M, 2017, MOLECULES, V22, DOI 10.3390/molecules22061021
   Anitha A, 2016, WIRES NANOMED NANOBI, V8, P151, DOI 10.1002/wnan.1353
   Basile D, 2017, EXPERT OPIN BIOL TH, V17, P709, DOI 10.1080/14712598.2017.1315405
   Brabletz T, 2000, AM J PATHOL, V156, P865, DOI 10.1016/S0002-9440(10)64955-3
   Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003
   Chi NC, 2011, THESIS
   De Angelis PM, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-20
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Falsey RR, 2006, NAT CHEM BIOL, V2, P33, DOI 10.1038/nchembio755
   Franko J, 2010, CANCER-AM CANCER SOC, V116, P3756, DOI 10.1002/cncr.25116
   Hahm ER, 2013, CURR CANCER DRUG TAR, V13, P640, DOI 10.2174/15680096113139990039
   Hu T, 2016, WORLD J GASTROENTERO, V22, P6876, DOI 10.3748/wjg.v22.i30.6876
   Jayaprakasam B, 2003, LIFE SCI, V74, P125, DOI 10.1016/j.lfs.2003.07.007
   Kadowaki H, 2004, J CHEM NEUROANAT, V28, P93, DOI 10.1016/j.jchemneu.2004.05.004
   Kakar SS, 2017, ONCOTARGET, V8, P74494, DOI 10.18632/oncotarget.20170
   Kang XJ, 2009, CELL DEATH DIFFER, V16, P966
   Keum N, 2017, ACTA PHARM SIN, V38, P885
   Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303
   Kruse KB, 2006, AUTOPHAGY, V2, P135, DOI 10.4161/auto.2.2.2388
   Lin JH, 2007, SCIENCE, V318, P944, DOI 10.1126/science.1146361
   Lin JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004170
   Liu JJ, 2011, CANCER LETT, V300, P105, DOI 10.1016/j.canlet.2010.10.001
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Louis SF, 2005, P NATL ACAD SCI USA, V102, P9613, DOI 10.1073/pnas.0407512102
   Luo B, 2013, ONCOGENE, V32, P805, DOI 10.1038/onc.2012.130
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mohan Royce, 2004, Angiogenesis, V7, P115, DOI 10.1007/s10456-004-1026-3
   Mukhopadhyay S, 2016, CRIT REV CL LAB SCI, V53, P228, DOI 10.3109/10408363.2015.1135103
   Munagala R, 2011, CARCINOGENESIS, V32, P1697, DOI 10.1093/carcin/bgr192
   Oh J, 2008, APOPTOSIS, V13, P1494, DOI 10.1007/s10495-008-0273-y
   Olmeda D, 2003, MOL BIOL CELL, V14, P2844, DOI 10.1091/mbc.E03-01-0865
   Rah B, 2015, AUTOPHAGY, V11, P314, DOI 10.1080/15548627.2015.1017182
   Rah B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044039
   Rougier P, 2005, SEMIN ONCOL, V32, pS15, DOI 10.1053/j.seminoncol.2005.07.020
   Rutkowski DT, 2007, TRENDS BIOCHEM SCI, V32, P469, DOI 10.1016/j.tibs.2007.09.003
   Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001
   Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028
   Sarkar S, 2014, ENDOCR-RELAT CANCER, V21, P113, DOI 10.1530/ERC-13-0315
   Schwartz Rowena N, 2004, J Manag Care Pharm, V10, pS2
   Sen N, 2007, CELL DEATH DIFFER, V14, P358, DOI 10.1038/sj.cdd.4402002
   Sheen JH, 2003, BRIT J CANCER, V89, P1479, DOI 10.1038/sj.bjc.6601307
   Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4
   Thorburn A, 2008, APOPTOSIS, V13, P1, DOI 10.1007/s10495-007-0154-9
   Treglia AS, 2012, HISTOL HISTOPATHOL, V27, P1, DOI 10.14670/HH-27.1
   Verfaillie T., 2010, INT J CELL BIOL, V2010, DOI [10.1155/2010/93050920145727, DOI 10.1155/2010/930509]
   WEISSENBERG M, 1977, J CHEM SOC PERK T 1, P795, DOI 10.1039/p19770000795
   Wu D, 2019, NANOSCALE RES LETT, V14, DOI 10.1186/s11671-019-3146-0
   Wu HJ, 2014, INT J BIOL SCI, V10, P1072, DOI 10.7150/ijbs.9719
   Wu J, 2006, CELL DEATH DIFFER, V13, P374, DOI 10.1038/sj.cdd.4401840
   Yang HJ, 2007, MOL PHARMACOL, V71, P426, DOI 10.1124/mol.106.030015
   Zou H, 2016, INT J NANOMED, V11, P1947, DOI 10.2147/IJN.S100744
NR 52
TC 23
Z9 23
U1 0
U2 4
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2156-6976
J9 AM J CANCER RES
JI Am. J. Cancer Res.
PY 2020
VL 10
IS 3
BP 799
EP 815
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA KY7DY
UT WOS:000522735400007
PM 32266092
DA 2022-04-25
ER

PT J
AU Mohapatra, P
   Preet, R
   Das, D
   Satapathy, SR
   Choudhuri, T
   Wyatt, MD
   Kundu, CN
AF Mohapatra, Purusottam
   Preet, Ranjan
   Das, Dipon
   Satapathy, Shakti Ranjan
   Choudhuri, Tathagata
   Wyatt, Michael D.
   Kundu, Chanakya Nath
TI Quinacrine-Mediated Autophagy and Apoptosis in Colon Cancer Cells Is
   Through a p53- and p21-Dependent Mechanism
SO ONCOLOGY RESEARCH
LA English
DT Article
DE Quinacrine (QC); Colon cancer; p21; p53; Autophagy; Apoptosis
ID BREAST-TUMOR CELLS; NF-KAPPA-B; CHLOROQUINE; DEATH; INHIBITION;
   ACTIVATION; INDUCTION; ROLES; CARCINOMA; THERAPY
AB We previously showed that quinacrine (QC), a small molecule antimalarial agent, also presented anticancer activity in breast cancer cells through activation of p53, p21, and inhibition of topoisomerase activity. Here we have systematically studied the detailed cell death mechanism of this drug using three colon cancer cell lines (HCT-116 parental, isogenic HCT-116 p53(-/-), and HCT-116 p21(-/-) sublines). QC caused a dose-dependent reduction in cell viability in all three cell lines. However, the parental cells were more susceptible to QC-mediated cell death, suggesting that p53- and p21-dependent processes were involved. QC-mediated cell death was measured with the following endpoints: the Bax/BcI-xL ratio, cleaved PARP, apoptotic nuclei visualized by DAPI staining, and COMET formation. In addition, markers of autophagy were measured. Acridine orange staining revealed increased accumulation of autophagic vacuoles (AVs) after QC treatment in a dose-dependent manner in parental cells, and decreased staining in isogenic HCT-116 p53-/- and HCT-116 P21(-/-) cells. Immunofluorescence of LC3B was significantly lowered in QC-treated cells lacking p53 or p2I, compared to the parental cells. Interestingly, the expression of the autophagy marker LC3B-II after exposure to QC was decreased in either p53 or p21 null cells compared to parental cells. After deletion of p21 in HCT-116 p53(-/-) cells, no change in LC3B-II expression was noted following QC treatment. Collectively, the results suggest that QC-mediated autophagy and apoptosis dependent on p53 and p21.
C1 [Wyatt, Michael D.] Univ S Carolina, S Carolina Coll Pharm, Dept Pharmaceut & Biomed Sci, Columbia, SC 29208 USA.
RP Kundu, CN (corresponding author), KIIT Univ, KIIT Sch Biotechnol, Campus-11, Bhubaneswar 751024, Orissa, India.
EM cnkundu@gmail.com
RI Satapathy, Shakti Ranjan/AAB-5787-2021; Das, Dipon/J-6991-2019; Das,
   Dipon/K-4554-2019; Choudhuri, Tathagata/F-8139-2011; Satapathy, Shakti
   Ranjan/L-3124-2018
OI Satapathy, Shakti Ranjan/0000-0002-3212-8960; Satapathy, Shakti
   Ranjan/0000-0002-3212-8960; Preet, Ranjan/0000-0001-6117-2701; Kundu,
   Chanakya/0000-0003-0297-1030; Mohapatra, Purusottam/0000-0001-8059-4141;
   Wyatt, Michael/0000-0003-1815-9565
FU Indian Council of Medical ResearchIndian Council of Medical Research
   (ICMR); Department of Biotechnology, Govt. of IndiaDepartment of
   Biotechnology (DBT) India
FX We acknowledge Prof Bert Vogelstein of Johns Hopkins. Baltimore for
   providing HCT-116 p53<SUP>-/-</SUP> and HCT-116 p21<SUP>-/-</SUP> cell
   lines. We are grateful to Mr. Bhabani Sankar Sahoo of Institute of Life
   Sciences, Bhubaneswar for excellent technical assistance with confocal
   laser microscopy. This work was supported by grants from Indian Council
   of Medical Research and Department of Biotechnology, Govt. of India. The
   authors state no conflict of interest.
CR Amaravadi RK, 2007, CLIN CANCER RES, V13, P7271, DOI 10.1158/1078-0432.CCR-07-1595
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863
   Chaachouay H, 2011, RADIOTHER ONCOL, V99, P287, DOI 10.1016/j.radonc.2011.06.002
   Di X, 2009, BIOCHEM PHARMACOL, V77, P1139, DOI 10.1016/j.bcp.2008.12.016
   Ehsanian R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-13
   Fujiwara K, 2008, J BIOL CHEM, V283, P388, DOI 10.1074/jbc.M611043200
   Geng Y, 2010, NEURO-ONCOLOGY, V12, P473, DOI 10.1093/neuonc/nop048
   Guan YQ, 2011, BIOMATERIALS, V32, P3637, DOI 10.1016/j.biomaterials.2011.01.060
   Guo C, 2009, ONCOGENE, V28, P1151, DOI 10.1038/onc.2008.460
   Gurova KV, 2005, P NATL ACAD SCI USA, V102, P17448, DOI 10.1073/pnas.0508888102
   Han WD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018691
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Jani TS, 2010, J BIOL CHEM, V285, P19162, DOI 10.1074/jbc.M109.091645
   Jing K, 2011, AUTOPHAGY, V7, P1348, DOI 10.4161/auto.7.11.16658
   Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738
   Kuo PL, 2006, MOL CANCER THER, V5, P3209, DOI 10.1158/1535-7163.MCT-06-0478
   Laussmann MA, 2011, CELL DEATH DIFFER, V18, P1584, DOI 10.1038/cdd.2011.27
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Lorin S, 2009, CANCER RES, V69, P6924, DOI 10.1158/0008-5472.CAN-09-1270
   LWAIKANAI E, 2008, AUTOPHAGY, V4, P322
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P2423, DOI 10.4161/cc.9.12.12048
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Portt L, 2011, BBA-MOL CELL RES, V1813, P238, DOI 10.1016/j.bbamcr.2010.10.010
   Preet R, 2012, INT J CANCER, V130, P1660, DOI 10.1002/ijc.26158
   Pyo JO, 2005, J BIOL CHEM, V280, P20722, DOI 10.1074/jbc.M413934200
   Ribas J, 2006, ONCOGENE, V25, P6304, DOI 10.1038/sj.onc.1209648
   Roninson Igor B, 2003, Methods Mol Biol, V222, P413
   Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272
   Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948
   Sarkar S, 2007, J BIOL CHEM, V282, P5641, DOI 10.1074/jbc.M609532200
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Scott RC, 2007, CURR BIOL, V17, P1, DOI 10.1016/j.cub.2006.10.053
   Shacka JJ, 2006, MOL PHARMACOL, V69, P1125, DOI 10.1124/mol.105.018408
   Shimizu S, 2012, INT J CANCER, V131, P548, DOI 10.1002/ijc.26374
   Shin SY, 2011, TOXICOL APPL PHARM, V254, P288, DOI 10.1016/j.taap.2011.05.003
   Solomon VR, 2009, EUR J PHARMACOL, V625, P220, DOI 10.1016/j.ejphar.2009.06.063
   Tasdemir Ezgi, 2008, V445, P29, DOI 10.1007/978-1-59745-157-4_3
   Tormo D, 2009, CANCER CELL, V16, P103, DOI 10.1016/j.ccr.2009.07.004
   Turcotte S, 2008, CANCER CELL, V14, P90, DOI 10.1016/j.ccr.2008.06.004
   Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147
   Wang RC, 2010, FEBS LETT, V584, P1417, DOI 10.1016/j.febslet.2010.01.009
   Wang SY, 2011, BIOCHEM BIOPH RES CO, V406, P497, DOI 10.1016/j.bbrc.2011.02.049
   Williams A, 2008, NAT CHEM BIOL, V4, P295, DOI 10.1038/nchembio.79
   Wilson Eden N., 2011, Hormones & Cancer, V2, P272, DOI 10.1007/s12672-011-0081-7
   Zaidi AU, 2001, J NEUROPATH EXP NEUR, V60, P937, DOI 10.1093/jnen/60.10.937
NR 49
TC 71
Z9 73
U1 0
U2 14
PU COGNIZANT COMMUNICATION CORP
PI PUTNAM VALLEY
PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA
SN 0965-0407
EI 1555-3906
J9 ONCOL RES
JI Oncol. Res.
PY 2012
VL 20
IS 2-3
BP 81
EP 91
DI 10.3727/096504012X13473664562628
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 036UX
UT WOS:000311058800004
PM 23193914
DA 2022-04-25
ER

PT J
AU You, HX
   Zhou, YH
   Tan, SY
   She, TH
AF You, Hong-Xia
   Zhou, Yan-Hong
   Tan, Shi-Yun
   She, Tong-Hui
TI Effects of silencing RIP1 with siRNA on the biological behavior of the
   LoVo human colon cancer cell line
SO ONCOLOGY LETTERS
LA English
DT Article
DE RNA interference; RIP1 gene; colorectal carcinoma
ID NF-KAPPA-B; DEATH DOMAIN; KINASE; INTERACTS; NECROSIS; COMPLEX;
   IMMUNOTHERAPY; NECROPTOSIS; METASTASIS; AUTOPHAGY
AB The present study aimed to investigate the effects of silencing RIP1 by small interfering RNA (siRNA) on the biological behavior of the LoVo human colorectal carcinoma cell line and to provide evidence for the feasibility of colorectal cancer gene therapy. LoVo cells were divided into the RIP1 siRNA group, the blank control group and the negative control group. Chemically synthesized siRNA targeting RIP1 (RIP1 siRNA) was transfected into LoVo cells. Following transfection of the RIP1-targeted siRNA into the LoVo cells, the expression of the RIP1 gene was effectively inhibited. The results demonstrated that RIP1 effectively regulated the malignant biological behavior of the LoVo colon cancer cell line. Furthermore, the proliferation, motility and invasiveness of LoVo cells were inhibited by siRNA knockdown of RIP1. The results revealed that the RIP1 gene has an important role in the regulation of proliferation and apoptosis in colorectal carcinoma cells.
C1 [You, Hong-Xia; Zhou, Yan-Hong; She, Tong-Hui] Hubei Univ Sci & Technol, Dept Gastroenterol, Xianning 437100, Hubei, Peoples R China.
   [You, Hong-Xia; Tan, Shi-Yun] Wuhan Univ, Renmin Hosp, Dept Gastroenterol, Wuhan 430060, Hubei, Peoples R China.
RP Zhou, YH (corresponding author), Hubei Univ Sci & Technol, Dept Gastroenterol, 88 Xianning Ave, Xianning 437100, Hubei, Peoples R China.
EM yanhongzhou326@gmail.com; tanshiyun@medmail.com.cn
FU Natural Science Foundation of Hubei ProvinceNatural Science Foundation
   of Hubei Province [2009CDZ001, 2010CDB06908]; Research Project of Hubei
   Educational Department [Q20092801]; Foundation for Young Scientists of
   the Health Department of Hubei Province [QJX2010-30]; Science and
   Technology Commission of Wuhan Municipality [201060938363-05]
FX The present study was supported by grants from the Natural Science
   Foundation of Hubei Province (no. 2009CDZ001), the Research Project of
   Hubei Educational Department (no. Q20092801), the Foundation for Young
   Scientists of the Health Department of Hubei Province (no. QJX2010-30),
   the Science and Technology Commission of Wuhan Municipality (no.
   201060938363-05) and the Natural Science Foundation of Hubei Province
   (no. 2010CDB06908).
CR Antonic V, 2013, J CANCER, V4, P227, DOI 10.7150/jca.5835
   Bellail AC, 2012, CANCER DISCOV, V2, P140, DOI 10.1158/2159-8290.CD-11-0172
   Bist P, 2011, ONCOGENE, V30, P3174, DOI 10.1038/onc.2011.28
   Boncheva V, 2013, CANCER GENE THER, V20, P157, DOI 10.1038/cgt.2013.5
   Calonge N, 2008, ANN INTERN MED, V149, P627, DOI 10.7326/0003-4819-149-9-200811040-00243
   Dai SM, 2010, J CELL MOL MED, V14, P710, DOI 10.1111/j.1582-4934.2009.00716.x
   Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085
   Ghafouri-Fard S, 2012, IMMUNOTHERAPY-UK, V4, P907, DOI [10.2217/IMT.12.87, 10.2217/imt.12.87]
   Handke W, 2012, MED MICROBIOL IMMUN, V201, P475, DOI 10.1007/s00430-012-0264-z
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X
   Kim SS, 2010, PATHOLOGY, V42, P50, DOI 10.3109/00313020903434421
   Lu JV, 2012, IMMUNOL REV, V249, P205, DOI 10.1111/j.1600-065X.2012.01147.x
   Messick CA, 2009, DIS COLON RECTUM, V52, P1535, DOI 10.1007/DCR.0b013e3181afbe05
   Meylan E, 2005, TRENDS BIOCHEM SCI, V30, P151, DOI 10.1016/j.tibs.2005.01.003
   Meylan E, 2004, NAT IMMUNOL, V5, P503, DOI 10.1038/ni1061
   Motavaf M, 2012, J VIRAL HEPATITIS, V19, P757, DOI 10.1111/jvh.12006
   O'Donnell MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041238
   Osborn SL, 2010, P NATL ACAD SCI USA, V107, P13034, DOI 10.1073/pnas.1005997107
   Park YH, 2013, BBA-PROTEINS PROTEOM, V1834, P292, DOI 10.1016/j.bbapap.2012.08.013
   STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1
   Tan SY, 2013, CHIN J CLIN ELECT ED, V7, P3892
   Van den Eynden GG, 2013, CANCER RES, V73, P2031, DOI 10.1158/0008-5472.CAN-12-3931
   Verbrugge I, 2012, CANCER DISCOV, V2, P112, DOI 10.1158/2159-8290.CD-11-0350
   Xie T, 2013, STRUCTURE, V21, P493, DOI 10.1016/j.str.2013.01.016
   Yang YB, 2011, MOL CELL BIOL, V31, P2774, DOI 10.1128/MCB.01139-10
   Ye YC, 2012, INT IMMUNOPHARMACOL, V14, P674, DOI 10.1016/j.intimp.2012.08.003
   Zhang JK, 2011, IMMUNOL RES, V51, P227, DOI 10.1007/s12026-011-8249-3
   Zhao J, 2012, P NATL ACAD SCI USA, V109, P5322, DOI 10.1073/pnas.1200012109
NR 29
TC 2
Z9 2
U1 0
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD JUN
PY 2014
VL 7
IS 6
BP 2065
EP 2072
DI 10.3892/ol.2014.2040
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AI0QY
UT WOS:000336555200064
PM 24932290
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Yang, JH
   Nishihara, R
   Zhang, XH
   Ogino, SJ
   Qian, ZR
AF Yang, Juhong
   Nishihara, Reiko
   Zhang, Xuehong
   Ogino, Shuji
   Qian, Zhi Rong
TI Energy sensing pathways: Bridging type 2 diabetes and colorectal cancer?
SO JOURNAL OF DIABETES AND ITS COMPLICATIONS
LA English
DT Article
DE PRKA; Biomarker; Carcinoma; Colon; Energy balance; Molecular pathologic
   epidemiology
ID BODY-MASS INDEX; MOLECULAR PATHOLOGICAL EPIDEMIOLOGY; ACTIVATED
   PROTEIN-KINASE; DISEASE-FREE SURVIVAL; DNA-DAMAGE; CELL-SURVIVAL;
   COLON-CANCER; RESVERATROL SUPPLEMENTATION; PRECISION MEDICINE;
   TUMOR-SUPPRESSOR
AB The recently rapid increase of obesity and type 2 diabetes mellitus has caused great burden to our society. A positive association between type 2 diabetes and risk of colorectal cancer has been reported by increasing epidemiological studies. The molecular mechanism of this connection remains elusive. However, type 2 diabetes may result in abnormal carbohydrate and lipid metabolism, high levels of circulating insulin, insulin growth factor-1, and adipocytolcines, as well as chronic inflammation. All these factors could lead to the alteration of energy sensing pathways such as the AMP activated kinase (PRKA), mechanistic (mammalian) target of rapamycin (mTOR), SIRT1, and autophagy signaling pathways. The resulted impaired SIRT1 and autophagy signaling pathway could increase the risk of gene mutation and cancer genesis by decreasing genetic stability and DNA mismatch repair. The dysregulated mTOR and PRKA pathway could remodel cell metabolism during the growth and metastasis of cancer in order for the cancer cell to survive the unfavorable microenvironment such as hypoxia and low blood supply. Moreover, these pathways may be coupling metabolic and epigenetic alterations that are central to oncogenic transformation. Further researches including molecular pathologic epidemiologic studies are warranted to better address the precise links between these two important diseases. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Yang, Juhong; Nishihara, Reiko; Ogino, Shuji; Qian, Zhi Rong] Dana Farber Canc Inst, Dept Oncol Pathol, 450 Brookline Ave, Boston, MA 02215 USA.
   [Yang, Juhong; Nishihara, Reiko; Ogino, Shuji; Qian, Zhi Rong] Harvard Med Sch, 450 Brookline Ave, Boston, MA 02215 USA.
   [Nishihara, Reiko; Ogino, Shuji] Brigham & Womens Hosp, Dept Pathol, Div MPE Mol Pathol Epidemiol, 75 Francis St, Boston, MA 02115 USA.
   [Nishihara, Reiko; Zhang, Xuehong; Ogino, Shuji] Harvard Med Sch, 75 Francis St, Boston, MA 02115 USA.
   [Nishihara, Reiko; Ogino, Shuji] Harvard Sch Publ Hlth, Dept Epidemiol, 677 Huntington Ave, Boston, MA 02115 USA.
   [Zhang, Xuehong] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA.
   [Yang, Juhong] Tianjin Med Univ, Collaborat Innovat Ctr Tianjin Med Epigenet 211, Key Lab Hormone & Dev, Minist Hlth,Metab Dis Hosp, Tianjin 300070, Peoples R China.
   [Yang, Juhong] Tianjin Med Univ, Tianjin Inst Endocrinol, Tianjin 300070, Peoples R China.
RP Yang, JH (corresponding author), Tianjin Med Univ, Dept Diabet Nephropathy, Tianjin Metab Dis Hosp, 66 Tongan Rd, Tianjin 300070, Peoples R China.; Qian, ZR (corresponding author), Harvard Med Sch, Dana Farber Canc Inst, Dept Oncol Pathol, 450 Brookline Ave,Room M420, Boston, MA 02215 USA.
EM megii0315@126.com; Zhirong_Qian@dfci.harvard.edu
OI Ogino, Shuji/0000-0002-3909-2323
FU U.S.A. National Institutes of Health (NIH)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA [K07
   CA190673, R01 CA151993, R35CA197735]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [81473472, 81200612]; Tianjin Municipal Natural Science Foundation of
   China [13JCZDJC30500]; Tianjin City High School Science &Technology Fund
   Planning Project [20102217]; NATIONAL CANCER INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [R01CA151993, K07CA190673,
   R35CA197735] Funding Source: NIH RePORTER
FX This work was supported by grants from the U.S.A. National Institutes of
   Health (NIH) [K07 CA190673 (to RN.), R01 CA151993 and R35CA197735 (to
   S.O.)]; National Natural Science Foundation of China (81473472,
   81200612); Tianjin Municipal Natural Science Foundation of China
   (13JCZDJC30500); Tianjin City High School Science &Technology Fund
   Planning Project (20102217).
CR Alayev A, 2013, J CELL PHYSIOL, V228, P1658, DOI 10.1002/jcp.24351
   Alnabulsi A, 2016, EXPERT REV PROTEOMIC, P1
   American Diabetes A. 3, 2016, DIABETES CARE, V39, P523
   An CH, 2011, PATHOL RES PRACT, V207, P433, DOI 10.1016/j.prp.2011.05.002
   Back JH, 2011, J BIOL CHEM, V286, P19100, DOI 10.1074/jbc.M111.240598
   Bardhan Kankana, 2013, Cancers (Basel), V5, P676, DOI 10.3390/cancers5020676
   Barone BB, 2008, JAMA-J AM MED ASSOC, V300, P2754, DOI 10.1001/jama.2008.824
   Benard A, 2015, HISTOPATHOLOGY, V66, P270, DOI 10.1111/his.12534
   Bhatt JK, 2012, NUTR RES, V32, P537, DOI 10.1016/j.nutres.2012.06.003
   Bigagli E, 2016, CELL ONCOL, V39, P545, DOI 10.1007/s13402-016-0299-z
   Blomain ES, 2016, EXPERT REV ANTICANC, V16, P465, DOI 10.1586/14737140.2016.1162102
   Bodmer M, 2012, CANCER EPIDEM BIOMAR, V21, P280, DOI 10.1158/1055-9965.EPI-11-0992-T
   Bordone L, 2007, AGING CELL, V6, P759, DOI 10.1111/j.1474-9726.2007.00335.x
   Bosetti C, 2013, ONCOLOGIST, V18, P148, DOI 10.1634/theoncologist.2012-0302
   Brasnyo P, 2011, BRIT J NUTR, V106, P383, DOI 10.1017/S0007114511000316
   Buhrmann C, 2016, NUTRIENTS, V8, DOI 10.3390/nu8030145
   Campbell PT, 2015, CANCER EPIDEM BIOMAR, V24, P1229, DOI 10.1158/1055-9965.EPI-15-0094
   Campbell PT, 2017, CANC CAUSES CONTROL
   Cardel M, 2014, CANCER MED-US, V3, P1458, DOI 10.1002/cam4.306
   Chang CC, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-47
   Chen X, 2014, ONCOL LETT, V8, P387, DOI 10.3892/ol.2014.2057
   Cho YH, 2014, INTEST RES, V12, P139, DOI 10.5217/ir.2014.12.2.139
   Cifarelli V, 2015, DIABETES, V64, P1632, DOI 10.2337/db14-1132
   Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196
   Colussi D, 2013, INT J MOL SCI, V14, P16365, DOI 10.3390/ijms140816365
   Dienstmann R, 2017, NAT REV CANCER, V17, P79, DOI 10.1038/nrc.2016.126
   Dobbin MM, 2013, NAT NEUROSCI, V16, P1008, DOI 10.1038/nn.3460
   Donohoe DR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046589
   Duca FA, 2015, NAT MED, V21, P506, DOI 10.1038/nm.3787
   Epplein M, 2014, CANCER EPIDEM BIOMAR, V23, P2613, DOI 10.1158/1055-9965.EPI-14-0848
   Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020
   Fujisawa T, 2008, GUT, V57, P1531, DOI 10.1136/gut.2008.159293
   GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404
   Giatromanolaki A, 2010, J CLIN PATHOL, V63, P867, DOI 10.1136/jcp.2010.079525
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Gonfloni S, 2014, BIOCHEM PHARMACOL, V92, P149, DOI 10.1016/j.bcp.2014.08.034
   Guarente L, 2000, GENE DEV, V14, P1021
   Guarente L, 2014, CELL METAB, V20, P706, DOI 10.1016/j.cmet.2014.10.015
   Ha BG, 2015, INT J ONCOL, V46, P2621, DOI 10.3892/ijo.2015.2942
   Habib SL, 2016, CELL CYCLE, V15, P3048, DOI 10.1080/15384101.2016.1231259
   Han JJ, 2015, GYNECOL ONCOL, V138, P668, DOI 10.1016/j.ygyno.2015.06.036
   Harmel E, 2014, ENDOCRINOLOGY, V155, P873, DOI 10.1210/en.2013-1750
   Haussinger D, 2006, ACTA PHYSIOL, V187, P249, DOI 10.1111/j.1748-1716.2006.01542.x
   He SS, 2015, AUTOPHAGY, V11, P1939, DOI 10.1080/15548627.2015.1086523
   He SS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8839
   Hearle N, 2006, CLIN CANCER RES, V12, P3209, DOI 10.1158/1078-0432.CCR-06-0083
   Heras-Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019
   Higurashi T, 2016, LANCET ONCOL, V17, P475, DOI 10.1016/S1470-2045(15)00565-3
   Hosono K, 2010, MOL CARCINOGEN, V49, P662, DOI 10.1002/mc.20637
   Hou XY, 2008, J BIOL CHEM, V283, P20015, DOI 10.1074/jbc.M802187200
   Hu FB, 1999, JNCI-J NATL CANCER I, V91, P542, DOI 10.1093/jnci/91.6.542
   Hua F, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8951
   Jaacks LM, 2016, BEST PRACT RES CL EN, V30, P331, DOI 10.1016/j.beem.2016.05.003
   Jang SH, 2012, J CLIN PATHOL, V65, P735, DOI 10.1136/jclinpath-2012-200685
   Jiang KW, 2014, CHINESE MED J-PEKING, V127, P2021, DOI 10.3760/cma.j.issn.0366-6999.20140044
   Joly E, 2009, J DIABETES, V1, P263, DOI 10.1111/j.1753-0407.2009.00043.x
   Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509
   Joven J, 2014, ADV EXP MED BIOL, V824, P43, DOI 10.1007/978-3-319-07320-0_6
   Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249
   Jung EJ, 2011, J LIPID RES, V52, P1617, DOI 10.1194/jlr.M015263
   Kabra N, 2009, J BIOL CHEM, V284, P18210, DOI 10.1074/jbc.M109.000034
   Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509
   Kimura T, 2010, J BIOL CHEM, V285, P4387, DOI 10.1074/jbc.M109.043869
   Knop FK, 2013, DIABETIC MED, V30, P1214, DOI 10.1111/dme.12231
   Kocarnik JM, 2015, GASTROENTEROL REP, V3, P269, DOI 10.1093/gastro/gov046
   Kudryavtseva AV, 2016, ONCOTARGET, V7, P53959, DOI 10.18632/oncotarget.9796
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   Kuller LH, 2013, AM J EPIDEMIOL, V178, P1350, DOI 10.1093/aje/kwt239
   Kwon B, 2015, BIOCHIMIE, V118, P141, DOI 10.1016/j.biochi.2015.09.006
   Laplante M, 2009, CURR BIOL, V19, pR1046, DOI 10.1016/j.cub.2009.09.058
   LAVECCHIA C, 1991, EUR J CANCER, V27, P582, DOI 10.1016/0277-5379(91)90223-Z
   Lee DF, 2007, CELL, V130, P440, DOI 10.1016/j.cell.2007.05.058
   Leprivier G, 2013, CELL, V153, P1064, DOI 10.1016/j.cell.2013.04.055
   Lettieri Barbato D, 2012, INT J CELL BIOL, V2012, DOI DOI 10.1155/2012/759583
   Lewis C, 2016, EUR J CANCER, V67, P191, DOI 10.1016/j.ejca.2016.08.009
   Li X, 2007, MOL CELL, V28, P91, DOI 10.1016/j.molcel.2007.07.032
   Lim JH, 2010, MOL CELL, V38, P864, DOI 10.1016/j.molcel.2010.05.023
   Lin HC, 2014, J CLIN PHARM THER, V39, P354, DOI 10.1111/jcpt.12151
   de Figueroa PL, 2015, ARTHRITIS RHEUMATOL, V67, P966, DOI 10.1002/art.39025
   Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4
   Luo ZF, 2009, ENDOCRINE, V36, P60, DOI 10.1007/s12020-009-9198-7
   Luo ZJ, 2010, FUTURE ONCOL, V6, P457, DOI 10.2217/FON.09.174
   Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672
   Martin ME, 2000, INT J BIOCHEM CELL B, V32, P633, DOI 10.1016/S1357-2725(00)00007-8
   Martinez-Useros J, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0772-5
   Mei ZB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091818
   Mills KT, 2013, DIS COLON RECTUM, V56, P1304, DOI 10.1097/DCR.0b013e3182a479f9
   Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421
   Moon HS, 2011, MOL CANCER THER, V10, P2234, DOI 10.1158/1535-7163.MCT-11-0545
   Nath KA, 2010, J CLIN INVEST, V120, P1026, DOI 10.1172/JCI42184
   Nemoto S, 2005, J BIOL CHEM, V280, P16456, DOI 10.1074/jbc.M501485200
   Ogino S, 2016, EPIDEMIOLOGY, V27, P602, DOI 10.1097/EDE.0000000000000471
   Ogino S, 2015, CANCER CAUSE CONTROL, V26, P959, DOI 10.1007/s10552-015-0596-2
   Ogino S, 2011, GUT, V60, P397, DOI 10.1136/gut.2010.217182
   Ogino S, 2010, J NATL CANCER I, V102, P365, DOI 10.1093/jnci/djq031
   Ogino S, 2009, CANCER EPIDEM BIOMAR, V18, P2513, DOI 10.1158/1055-9965.EPI-09-0451
   Ogino S, 2009, AM J GASTROENTEROL, V104, P2047, DOI 10.1038/ajg.2009.281
   Ogino S, 2008, J CLIN ONCOL, V26, P5713, DOI 10.1200/JCO.2009.22.8858
   Ogino S, 2009, CANCER EPIDEM BIOMAR, V18, P1849, DOI 10.1158/1055-9965.EPI-09-0181
   Park JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100819
   Patil H, 2017, DRUG DISCOV TODAY, V22, P111, DOI 10.1016/j.drudis.2016.09.022
   Rao-Bindal K, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.101
   Ren NSX, 2017, CURR BIOL, V27, P483, DOI 10.1016/j.cub.2016.12.047
   Rescigno T, 2017, MOLECULES, V22, DOI 10.3390/molecules22010105
   Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354
   Ruderman N, 2004, NAT REV DRUG DISCOV, V3, P340, DOI 10.1038/nrd1344
   Sakoda LC, 2015, CANCER PREV RES, V8, P174, DOI 10.1158/1940-6207.CAPR-14-0291
   Sanchez AMJ, 2012, J CELL BIOCHEM, V113, P695, DOI 10.1002/jcb.23399
   Sanli T, 2010, INT J RADIAT ONCOL, V78, P221, DOI 10.1016/j.ijrobp.2010.03.005
   Sehdev A, 2014, CANCER
   Sharma A, 2014, CLIN COLORECTAL CANC, V13, P54, DOI 10.1016/j.clcc.2013.10.002
   Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869
   Shi YK, 2014, LANCET, V383, P1947, DOI 10.1016/S0140-6736(14)60886-2
   Shirwany NA, 2014, FRONT BIOSCI-LANDMRK, V19, P447, DOI 10.2741/4218
   Singh SK, 2013, J EXP MED, V210, P987, DOI 10.1084/jem.20121608
   Singh S, 2013, CANCER EPIDEM BIOMAR, V22, P2258, DOI 10.1158/1055-9965.EPI-13-0429
   Smith EM, 2005, J BIOL CHEM, V280, P18717, DOI 10.1074/jbc.M414499200
   Smolkova K, 2011, INT J BIOCHEM CELL B, V43, P950, DOI 10.1016/j.biocel.2010.05.003
   Stein KB, 2010, DIGEST DIS SCI, V55, P1839, DOI 10.1007/s10620-009-0944-8
   Sticz T, 2016, J CLIN PATHOL
   Storozhuk Y, 2013, BRIT J CANCER, V108, P2021, DOI 10.1038/bjc.2013.187
   Sun L, 2012, DIGEST DIS SCI, V57, P1586, DOI 10.1007/s10620-012-2059-x
   Sylvetsky AC, 2015, WORLD J DIABETES, V6, P1355, DOI 10.4239/wjd.v6.i18.1355
   Takei N, 2014, FRONT MOL NEUROSCI, V7, DOI 10.3389/fnmol.2014.00028
   Thomas GV, 2006, NAT MED, V12, P122, DOI 10.1038/nm1337
   Tsilidis KK, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.g7607
   van de Poll-Franse LV, 2012, DIABETOLOGIA, V55, P2163, DOI 10.1007/s00125-012-2555-8
   Vargas T, 2014, MOL ONCOL, V8, P1469, DOI 10.1016/j.molonc.2014.05.015
   Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X
   Vazquez-Martin A, 2009, CELL CYCLE, V8, P3679, DOI 10.4161/cc.8.22.9905
   Vazquez-Martin A, 2009, CELL CYCLE, V8, P2385, DOI 10.4161/cc.8.15.9082
   Vu HT, 2014, WORLD J GASTROENTERO, V20, P6946, DOI 10.3748/wjg.v20.i22.6946
   Wang B, 2014, J CELL MOL MED, V18, P1599, DOI 10.1111/jcmm.12312
   Wang CH, 2012, BIOCHEM BIOPH RES CO, V425, P33, DOI 10.1016/j.bbrc.2012.07.044
   Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001
   Wei SO, 2010, J BIOL CHEM, V285, P9780, DOI 10.1074/jbc.M109.065466
   Weng M, 2016, T RES
   Xu HR, 2015, BBA-MOL CELL RES, V1853, P65, DOI 10.1016/j.bbamcr.2014.10.002
   Xu YF, 2013, CELL SIGNAL, V25, P2239, DOI 10.1016/j.cellsig.2013.07.008
   Yang CS, 2014, AUTOPHAGY, V10, P785, DOI 10.4161/auto.28072
   Yang IP, 2016, ONCOTARGET, V7, P18837, DOI 10.18632/oncotarget.7719
   Yang Q, 2013, MOL CANCER RES, V11, P1497, DOI 10.1158/1541-7786.MCR-13-0214
   Yang XL, 2015, NAT REV ENDOCRINOL, V11, P372, DOI 10.1038/nrendo.2015.37
   Yar AS, 2011, GENET MOL RES, V10, P2962, DOI 10.4238/2011.November.29.7
   Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245
   Zechner R, 2009, J LIPID RES, V50, P3, DOI 10.1194/jlr.R800031-JLR200
   Zhang MY, 2014, INT J MOL SCI, V15, P14372, DOI 10.3390/ijms150814372
   Zhou L, 2016, EXPERT REV PROTEOMIC, V13, P367, DOI 10.1586/14789450.2016.1159959
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
   Zulato E, 2014, BRIT J CANCER, V111, P25, DOI 10.1038/bjc.2014.274
NR 150
TC 19
Z9 19
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1056-8727
EI 1873-460X
J9 J DIABETES COMPLICAT
JI J. Diabetes Complications
PD JUL
PY 2017
VL 31
IS 7
BP 1228
EP 1236
DI 10.1016/j.jdiacomp.2017.04.012
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA EY6JK
UT WOS:000404088700027
PM 28465145
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Sasaki, K
   Tsuno, NH
   Sunami, E
   Kawai, K
   Hongo, K
   Hiyoshi, M
   Kaneko, M
   Murono, K
   Tada, N
   Nirei, T
   Takahashi, K
   Kitayama, J
AF Sasaki, Kazuhito
   Tsuno, Nelson H.
   Sunami, Eiji
   Kawai, Kazushige
   Hongo, Kumiko
   Hiyoshi, Masaya
   Kaneko, Manabu
   Murono, Koji
   Tada, Noriko
   Nirei, Takako
   Takahashi, Koki
   Kitayama, Joji
TI Resistance of colon cancer to 5-fluorouracil may be overcome by
   combination with chloroquine, an in vivo study
SO ANTI-CANCER DRUGS
LA English
DT Article
DE autophagy; chloroquine; colorectal cancer; 5-fluorouracil
ID CELL-DEATH; AUTOPHAGY; APOPTOSIS; INHIBITION; GROWTH; VITRO; ACTIVATION;
   INDUCTION; NECROSIS; DISEASE
AB Autophagy is a complex of adaptive cellular response that enhances cancer cell survival in the face of cellular stresses such as chemotherapy. Recently, chloroquine diphosphate (CQ), a widely used antimalarial drug, has been studied as a potential inhibitor of autophagy. Here, we aimed to investigate the role of CQ in potentiating the effect of 5-fluorouracil (5-FU), the chemotherapeutic agent of first choice for the treatment of colorectal cancer, in an animal model of colon cancer. The mouse colon cancer cell line colon26 was used. For the in-vivo study, colon26 cells were injected subcutaneously into BALB/c mice, which were treated with saline as a control, CQ (50 mg/kg/day), 5-FU (30 mg/kg/day), or the combination therapy (CQ plus 5-FU). The tumor volume ratio and body weight were monitored. After the sacrifice, tumor tissue protein extracts and tumor sections were prepared and subjected to immunoblotting for the analysis of autophagy-related and apoptosis-related proteins, and the terminal transferase uridyl end labeling assay. The combination of CQ resulted in the inhibition of 5-FU-induced autophagy and a significant enhancement in the 5-FU-induced inhibition of tumor growth. Furthermore, the combination treatment of CQ and 5-FU resulted in a significant increase in the ratio of apoptotic cells compared with other treatments. The expression levels of the proapoptotic proteins, namely Bad and Bax, were increased by the CQ treatment in the protein extracts from tumors. Our findings suggest that the combination therapy of CQ and 5-FU should be considered as an effective strategy for the treatment of colorectal cancer. Anti-Cancer Drugs 23:675-682 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
C1 [Sasaki, Kazuhito; Tsuno, Nelson H.; Sunami, Eiji; Kawai, Kazushige; Hongo, Kumiko; Hiyoshi, Masaya; Kaneko, Manabu; Murono, Koji; Tada, Noriko; Nirei, Takako; Kitayama, Joji] Univ Tokyo, Fac Med Sci, Dept Surg Oncol, Tokyo, Japan.
   [Tsuno, Nelson H.; Takahashi, Koki] Univ Tokyo, Fac Med Sci, Dept Transfus Med, Tokyo, Japan.
RP Sasaki, K (corresponding author), 7-3-1 Hongo,Bunkyo ku, Tokyo 1138655, Japan.
EM sasakik-sur@h.u-tokyo.ac.jp
RI Murono, Koji/AAC-3958-2020; Kawai, Kazushige/AAF-4334-2020
OI Kawai, Kazushige/0000-0002-5881-0036
CR Amaravadi RK, 2007, CLIN CANCER RES, V13, P7271, DOI 10.1158/1078-0432.CCR-07-1595
   AUGUSTIJNS P, 1992, EUR J CLIN PHARMACOL, V42, P429
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Breckenridge AM, 1997, ANN TROP MED PARASIT, V91, P727, DOI 10.1080/00034989760464
   Cecconi F, 2008, DEV CELL, V15, P344, DOI 10.1016/j.devcel.2008.08.012
   Chen TH, 2005, PHARMACOL RES, V51, P329, DOI 10.1016/j.phrs.2004.10.004
   Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002
   DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1
   Ding ZB, 2011, CLIN CANCER RES, V17, P6229, DOI 10.1158/1078-0432.CCR-11-0816
   Fan CD, 2006, BIOORGAN MED CHEM, V14, P3218, DOI 10.1016/j.bmc.2005.12.035
   Harris SM, 2005, BRIT J CANCER, V92, P722, DOI 10.1038/sj.bjc.6602403
   Jiang PD, 2008, CELL PHYSIOL BIOCHEM, V22, P431, DOI 10.1159/000185488
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kiffin R, 2004, MOL BIOL CELL, V15, P4829, DOI 10.1091/mbc.E04-06-0477
   Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Lim YJ, 2007, WORLD J GASTROENTERO, V13, P1947, DOI 10.3748/wjg.v13.i13.1947
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Meinao IM, 1996, LUPUS, V5, P237, DOI 10.1177/096120339600500313
   Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Nishikawa T, 2010, ANN SURG ONCOL, V17, P592, DOI 10.1245/s10434-009-0696-x
   Pandey AV, 2001, BIOCHEM J, V355, P333, DOI 10.1042/0264-6021:3550333
   Rahim R, 2009, ANTI-CANCER DRUG, V20, P736, DOI 10.1097/CAD.0b013e32832f4e50
   Rao R, 2012, MOL CANC THER, P24
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Solomon VR, 2009, EUR J PHARMACOL, V625, P220, DOI 10.1016/j.ejphar.2009.06.063
   Tasdemir Ezgi, 2008, V445, P29, DOI 10.1007/978-1-59745-157-4_3
   Xu R, 2006, HISTOL HISTOPATHOL, V21, P867, DOI 10.14670/HH-21.867
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
   Zhao H, 2005, RADIAT RES, V164, P250, DOI 10.1667/RR3436.1
   Zheng YZ, 2009, CANCER INVEST, V27, P286, DOI 10.1080/07357900802427927
NR 34
TC 49
Z9 49
U1 0
U2 17
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0959-4973
J9 ANTI-CANCER DRUG
JI Anti-Cancer Drugs
PD AUG
PY 2012
VL 23
IS 7
BP 675
EP 682
DI 10.1097/CAD.0b013e328353f8c7
PG 8
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 967GM
UT WOS:000305894700001
PM 22561420
DA 2022-04-25
ER

PT J
AU Bu, HQ
   Liu, DL
   Zhang, GL
   Chen, L
   Song, ZF
AF Bu, Heqi
   Liu, Dianlei
   Zhang, Guolin
   Chen, Li
   Song, Zhangfa
TI AMPK/mTOR/ULK1 Axis-Mediated Pathway Participates in Apoptosis and
   Autophagy Induction by Oridonin in Colon Cancer DLD-1 Cells
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE oridonin; AMPK/mTOR/ULK1 pathway; autophagy; apoptosis; colon cancer
ID PROTECTIVE AUTOPHAGY; DEATH; INHIBITION; STRESS
AB Background: Oridonin has been demonstrated to exert strong antitumor activities in various types of human cancers. Our previous study established that oridonin induced the apoptosis of and exerted an inhibitory effect on colon cancer cells in vitro and in vivo. However, the mechanisms behind the antitumor effects of oridonin on colorectal cancer are not clearly known. This study explored whether autophagy was involved in antitumorigenesis effects caused by the usage of oridonin in colon cancer and examined whether the AMPK/mTOR/ULK1 signaling pathway was involved in this process.
   Methods: Cell viability was determined using CCK-8 assay. The distribution of cell apoptosis was evaluated using flow cytometry. RT-PCR and Western blotting analysis were conducted to identify the key target genes and proteins involved in the AMPK/mTOR cascade. AMPK siRNA was used to disturb AMPK expression. A DLD-1 cell orthotopic transplantation tumor model was established to explore the anti-cancer effects in vivo.
   Results: Oridonin exhibited a suppressive effect on DLD-1 cells in a concentration- and time-dependent manner. Additionally, in a dose-dependent manner, oridonin induced cell apoptosis via inducing the protein expression levels of cleaved caspase-3, cleaved PARP and stimulated autophagy by increasing protein expression levels of Becin1, LC3-II, decreasing protein expression levels of LC3-I, p62, which were respectively attenuated and elevated by autophagy inhibitor 3-MA. Furthermore, oridonin upregulated the expression level of p-AMPK and downregulated the expression levels of p-mTOR, p-ULK1 in the DLD-1 cells in a dose-dependent manner. Moreover, knockdown of AMPK by a specific siRNA reversed the expression levels of proteins involved in the AMPK/mTOR pathway, autophagy and apoptosis. In addition, outcomes from the in vivo experiments also showed that oridonin treatment significantly repressed tumorigenic growth of DLD-1 cells without any side effects, which was accompanied by the upregulation of p-AMPK, LC3-II, active caspase-3 protein expression levels and the downregulation of p-mTOR and p-ULK1 protein expression levels.
   Conclusion: This study demonstrated that oridonin induced apoptosis and autophagy of colon cancer DLD-1 cells via regulating the AMPK/mTOR/ULK1 pathway, which indicated that oridonin may be used as a novel therapeutic intervention for patients with colorectal cancer.
C1 [Bu, Heqi; Zhang, Guolin; Chen, Li; Song, Zhangfa] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Colorectal Surg, Sch Med, 3 East Qingchun Rd, Hangzhou 310016, Peoples R China.
   [Bu, Heqi] Tongde Hosp Zhejiang Prov, Dept Coloproctol Surg, Hangzhou 310012, Peoples R China.
   [Liu, Dianlei] Zhejiang Univ, Womens Hosp, Dept Surg, Sch Med, Hangzhou 310006, Peoples R China.
RP Song, ZF (corresponding author), Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Colorectal Surg, Sch Med, 3 East Qingchun Rd, Hangzhou 310016, Peoples R China.
EM songzhangfa@zju.edu.cn
OI Zhang, Guolin/0000-0002-5836-4478
FU Science and Technology Planning Project of Zhejiang Province, China
   [2018KY325]; basic public welfare research project of Zhejiang
   [LGD19H160006]
FX This study was supported by Science and Technology Planning Project of
   Zhejiang Province, China (Grant no. 2018KY325) and the basic public
   welfare research project of Zhejiang (grant no. LGD19H160006).
CR Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11
   Bach DH, 2018, MOL THER-NUCL ACIDS, V12, P817, DOI 10.1016/j.omtn.2018.07.016
   Booth LA, 2019, SEMIN CANC BIOL
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chang TC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210274
   Chen Y, 2019, NEUROTOX RES, V36, P108, DOI 10.1007/s12640-019-00027-9
   Cheng X, 2018, CANCER LETT, V431, P105, DOI 10.1016/j.canlet.2018.05.046
   Cheng Y, 2019, INT J MOL MED, V44, P652, DOI 10.3892/ijmm.2019.4216
   Choudhary GS, 2015, METHODS MOL BIOL, V1219, P1, DOI 10.1007/978-1-4939-1661-0_1
   Duarte A, 2019, MOL CARCINOGEN, V58, P161, DOI 10.1002/mc.22911
   Duffy A, 2015, CANCER CHEMOTH PHARM, V75, P439, DOI 10.1007/s00280-014-2637-z
   El-kott AF, 2019, CLIN EXP PHARMACOL P, V46, P944, DOI 10.1111/1440-1681.13133
   Fan XJ, 2016, ONCOL REP, V36, P3559, DOI 10.3892/or.2016.5138
   Fukuda T, 2016, ONCOL LETT, V12, P2560, DOI 10.3892/ol.2016.4978
   He-Qi B, 2019, ONCOTARGETS THER, V12, P7467, DOI [10.2147/OTT.S22040111, DOI 10.2147/OTT.S2204011]
   Heqi B, 2019, TRANSL CANC RES, V8, P1782
   Huang Q, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051063
   Huang YH, 2017, ONCOTARGET, V8, P52783, DOI 10.18632/oncotarget.17189
   Hwang KE, 2015, ONCOTARGET, V6, P29482, DOI 10.18632/oncotarget.5022
   Islam MA, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051405
   Kaluzki I, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111329
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Li D, 2016, INT J MOL SCI, V17, P17
   Li Y, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0365-1
   Lin LT, 2019, MOLECULES, V24, DOI 10.3390/molecules24112102
   Liu RX, 2018, INT J ONCOL, V53, P2091, DOI 10.3892/ijo.2018.4527
   Lu J, 2014, J PHARMACOL SCI, V126, P56, DOI 10.1254/jphs.14079FP
   Mao K, 2011, CIRC RES, V108, P787, DOI 10.1161/RES.0b013e3182194c29
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Ni YY, 2018, J CELL BIOCHEM, V119, P6104, DOI 10.1002/jcb.26808
   Ou LL, 2017, INT J NANOMED, V12, P6633, DOI 10.2147/IJN.S140526
   Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x
   Qian HR, 2017, ONCOTARGET, V8, P62759, DOI 10.18632/oncotarget.18663
   Shahabipour F, 2017, CANCER LETT, V400, P325, DOI 10.1016/j.canlet.2017.03.020
   Shu YJ, 2014, ANTI-CANCER AGENT ME, V14, P1136, DOI 10.2174/1871520614666140223191626
   Sun J, 2019, INT J ONCOL, V54, P1601, DOI 10.3892/ijo.2019.4757
   Teng JF, 2019, PHARMACOL RES, V147, DOI 10.1016/j.phrs.2019.104396
   Wali AF, 2019, SAUDI PHARM J, V27, P767, DOI 10.1016/j.jsps.2019.04.013
   Wang HB, 2019, BIOCHEM BIOPH RES CO, V517, P477, DOI 10.1016/j.bbrc.2019.07.100
   Wei GF, 2019, J MED CHEM, V62, P8760, DOI 10.1021/acs.jmedchem.9b00644
   Wu QX, 2016, ONCOL REP, V35, P3341, DOI 10.3892/or.2016.4735
   Xie K, 2016, AUTOPHAGY, V12, P381, DOI 10.1080/15548627.2015.1134079
   Xing JJ, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12627
   Xu JM, 2018, MOLECULES, V23, DOI 10.3390/molecules23020474
   Xu Z, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030524
   Yamate-Morgan H, 2019, NEUROSCIENCE, V406, P667, DOI 10.1016/j.neuroscience.2019.01.038
   Yang HH, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00769
   Yao Z, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.35
   Zha QB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124355
   Zhai B, 2014, MOL CANCER THER, V13, P1589, DOI 10.1158/1535-7163.MCT-13-1043
   Zhang D, 2019, BIOCHEM BIOPH RES CO, V513, P594, DOI 10.1016/j.bbrc.2019.04.011
   Zhang DS, 2017, J AM SOC NEPHROL, V28, P1131, DOI 10.1681/ASN.2016030337
   Zhang RJ, 2019, ONCOTARGETS THER, V12, P4109, DOI 10.2147/OTT.S195615
   Zhou JY, 2019, J CELL PHYSIOL, V234, P19028, DOI 10.1002/jcp.28542
   Zhou L, 2013, ACTA PHARMACOL SIN, V34, P651, DOI 10.1038/aps.2013.12
NR 55
TC 6
Z9 6
U1 7
U2 15
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2020
VL 13
BP 8533
EP 8545
DI 10.2147/OTT.S262022
PG 13
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA OH7CW
UT WOS:000582753000001
PM 32904616
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Iftikhar, R
   Penrose, HM
   King, AN
   Samudre, JS
   Collins, ME
   Hartono, AB
   Lee, SB
   Lau, F
   Baddoo, M
   Flemington, EF
   Crawford, SE
   Savkovic, SD
AF Iftikhar, Rida
   Penrose, Harrison M.
   King, Angelle N.
   Samudre, Joshua S.
   Collins, Morgan E.
   Hartono, Alifiani B.
   Lee, Sean B.
   Lau, Frank
   Baddoo, Melody
   Flemington, Erik F.
   Crawford, Susan E.
   Savkovic, Suzana D.
TI Elevated ATGL in colon cancer cells and cancer stem cells promotes
   metabolic and tumorigenic reprogramming reinforced by obesity
SO ONCOGENESIS
LA English
DT Article
ID TRIGLYCERIDE LIPASE ATGL; LIPID-METABOLISM; DENSITY-LIPOPROTEIN;
   EXPRESSION; INFLAMMATION; AUTOPHAGY; GROWTH; FOXO3; PROLIFERATION;
   DEFICIENCY
AB Obesity is a worldwide epidemic associated with increased risk and progression of colon cancer. Here, we aimed to determine the role of adipose triglyceride lipase (ATGL), responsible for intracellular lipid droplet (LD) utilization, in obesity-driven colonic tumorigenesis. In local colon cancer patients, significantly increased ATGL levels in tumor tissue, compared to controls, were augmented in obese individuals. Elevated ATGL levels in human colon cancer cells (CCC) relative to non-transformed were augmented by an obesity mediator, oleic acid (OA). In CCC and colonospheres, enriched in colon cancer stem cells (CCSC), inhibition of ATGL prevented LDs utilization and inhibited OA-stimulated growth through retinoblastoma-mediated cell cycle arrest. Further, transcriptomic analysis of CCC, with inhibited ATGL, revealed targeted pathways driving tumorigenesis, and high-fat-diet obesity facilitated tumorigenic pathways. Inhibition of ATGL in colonospheres revealed targeted pathways in human colonic tumor crypt base cells (enriched in CCSC) derived from colon cancer patients. In CCC and colonospheres, we validated selected transcripts targeted by ATGL inhibition, some with emerging roles in colonic tumorigeneses (ATG2B, PCK2, PGAM1, SPTLC2, IGFBP1, and ABCC3) and others with established roles (MYC and MUC2). These findings demonstrate obesity-promoted, ATGL-mediated colonic tumorigenesis and establish the therapeutic significance of ATGL in obesity-reinforced colon cancer progression.
C1 [Iftikhar, Rida; Penrose, Harrison M.; King, Angelle N.; Samudre, Joshua S.; Collins, Morgan E.; Hartono, Alifiani B.; Lee, Sean B.; Baddoo, Melody; Flemington, Erik F.; Savkovic, Suzana D.] Tulane Univ, Sch Med, Dept Pathol & Lab Med, 1430 Tulane Ave, New Orleans, LA 70112 USA.
   [Lau, Frank] Louisiana State Univ, Hlth Sci Ctr, Dept Surg, New Orleans, LA USA.
   [Crawford, Susan E.] Univ Chicago, Pritzker Sch Med, NorthShore Univ Res Inst, Evanston, IL USA.
RP Savkovic, SD (corresponding author), Tulane Univ, Sch Med, Dept Pathol & Lab Med, 1430 Tulane Ave, New Orleans, LA 70112 USA.
EM ssavkovi@tulane.edu
OI Lee, Sean/0000-0001-6211-3498
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01 CA252055]; Crohn's & Colitis
   Foundation [663445]
FX We thank Dr. Jenisha Ghimire for her valuable technical support in this
   project. This work is supported by NIH award R01 CA252055 and by Crohn's
   & Colitis Foundation award 663445.
CR Accioly MT, 2008, CANCER RES, V68, P1732, DOI 10.1158/0008-5472.CAN-07-1999
   Al-Zoughbi W, 2016, ONCOTARGET, V7, P33832, DOI 10.18632/oncotarget.9418
   Alvina FB, 2021, ADV EXP MED BIOL, V1311, P161, DOI 10.1007/978-3-030-65768-0_12
   Ayob AZ, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0426-4
   Bardou M, 2013, GUT, V62, P933, DOI 10.1136/gutjnl-2013-304701
   Beyaz S, 2016, NATURE, V531, P53, DOI 10.1038/nature17173
   Bousquenaud M, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-1029-4
   Bozza PT, 2010, PROSTAG LEUKOTR ESS, V82, P243, DOI 10.1016/j.plefa.2010.02.005
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Castro-Oropeza R, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69907-x
   Chen GH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13398-w
   Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127
   Cotte AK, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02732-5
   Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017
   DeClercq V, 2015, CANCER LETT, V369, P336, DOI 10.1016/j.canlet.2015.10.001
   Dejure FR, 2017, EMBO J, V36, P3409, DOI 10.15252/embj.201796438
   Demark-Wahnefried W, 2012, CANCER EPIDEM BIOMAR, V21, P1244, DOI 10.1158/1055-9965.EPI-12-0485
   Deng T, 2016, ANNU REV PATHOL-MECH, V11, P421, DOI 10.1146/annurev-pathol-012615-044359
   Ecker C, 2018, CELL REP, V23, P741, DOI 10.1016/j.celrep.2018.03.084
   Fellmann C, 2013, CELL REP, V5, P1704, DOI 10.1016/j.celrep.2013.11.020
   Grace SA, 2017, ANTICANCER RES, V37, P699, DOI 10.21873/anticanres.11366
   Grahn THM, 2013, BIOCHEM BIOPH RES CO, V432, P296, DOI 10.1016/j.bbrc.2013.01.113
   He WL, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01549
   Heid H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090386
   Heller S, 2016, AM J PHYSIOL-GASTR L, V310, pG844, DOI 10.1152/ajpgi.00407.2015
   Hitosugi T, 2012, CANCER CELL, V22, P585, DOI 10.1016/j.ccr.2012.09.020
   Hojjati MR, 2005, BBA-MOL CELL BIOL L, V1737, P44, DOI 10.1016/j.bbalip.2005.08.006
   Huang K, 2019, CELL METAB, V30, P1107, DOI 10.1016/j.cmet.2019.09.014
   Humphries A, 2008, NAT REV CANCER, V8, P415, DOI 10.1038/nrc2392
   Ishikawa M, 2014, CANCERS, V6, P1570, DOI 10.3390/cancers6031570
   Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Kusakabe M, 2009, BIOCHEM BIOPH RES CO, V390, P1283, DOI 10.1016/j.bbrc.2009.10.137
   Lake AC, 2005, J LIPID RES, V46, P2477, DOI 10.1194/jlr.M500290-JLR200
   Lammers B, 2011, ARTERIOSCL THROM VAS, V31, P67, DOI 10.1161/ATVBAHA.110.215814
   Leithner K, 2015, ONCOGENE, V34, P1044, DOI 10.1038/onc.2014.47
   Li TW, 2020, NUCLEIC ACIDS RES, V48, pW509, DOI 10.1093/nar/gkaa407
   Lu X, 2010, CELL CYCLE, V9, P2719, DOI 10.4161/cc.9.14.12181
   Matsushita Y, 2021, CANCERS, V13, DOI 10.3390/cancers13030474
   Mayer N, 2013, NAT CHEM BIOL, V9, P785, DOI [10.1038/NCHEMBIO.1359, 10.1038/nchembio.1359]
   Menard JA, 2016, CANCER RES, V76, P4828, DOI 10.1158/0008-5472.CAN-15-2831
   Montal ED, 2015, MOL CELL, V60, P571, DOI 10.1016/j.molcel.2015.09.025
   Olejniczak-Keder A, 2019, INT J ONCOL, V55, P223, DOI 10.3892/ijo.2019.4809
   Ou JJ, 2014, CELL REP, V9, P1798, DOI 10.1016/j.celrep.2014.11.016
   Peiris-Pages M, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0712-6
   Peng Y, 2016, AUTOPHAGY, V12, P2167, DOI 10.1080/15548627.2016.1217380
   Penrose H, 2016, BIOCHEM BIOPH RES CO, V469, P370, DOI 10.1016/j.bbrc.2015.11.119
   Penrose HM, 2019, CELL MOL GASTROENTER, V7, P391, DOI 10.1016/j.jcmgh.2018.10.003
   Penrose HM, 2017, CARCINOGENESIS, V38, P302, DOI 10.1093/carcin/bgx001
   Petan Toni, 2020, Rev Physiol Biochem Pharmacol, DOI 10.1007/112_2020_51
   Pietrzyk Lukasz, 2015, Asian Pac J Cancer Prev, V16, P4161
   Popkin BM, 2012, NUTR REV, V70, P3, DOI 10.1111/j.1753-4887.2011.00456.x
   Qi WT, 2013, J BIOL CHEM, V288, P16274, DOI 10.1074/jbc.M113.470617
   Rawla P, 2019, GASTROENTEROL REV, V14, P89, DOI 10.5114/pg.2018.81072
   Reinfeld BI, 2021, NATURE, V593, P282, DOI 10.1038/s41586-021-03442-1
   Rubin SM, 2013, TRENDS BIOCHEM SCI, V38, P12, DOI 10.1016/j.tibs.2012.10.007
   Sanchez-Martinez R, 2015, ONCOTARGET, V6, P38719, DOI 10.18632/oncotarget.5340
   Schlager S, 2015, J LEUKOCYTE BIOL, V98, P837, DOI 10.1189/jlb.3A0515-206R
   Shin HD, 2005, DIABETOLOGIA, V48, P2025, DOI 10.1007/s00125-005-1917-x
   Snoeks L, 2009, LAB INVEST, V89, P1053, DOI 10.1038/labinvest.2009.66
   Straub BK, 2010, MODERN PATHOL, V23, P480, DOI 10.1038/modpathol.2009.191
   Tirinato L, 2015, STEM CELLS, V33, P35, DOI 10.1002/stem.1837
   Tomin T, 2018, J PROTEOME RES, V17, P1415, DOI 10.1021/acs.jproteome.7b00782
   Vargas T, 2015, ONCOTARGET, V6, P7348, DOI 10.18632/oncotarget.3130
   Wang HJ, 2010, MOL BIOL CELL, V21, P1991, DOI 10.1091/mbc.E09-05-0364
   Wang YY, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.87489
   Welte MA, 2017, BBA-MOL CELL BIOL L, V1862, P1260, DOI 10.1016/j.bbalip.2017.07.006
   Wen YA, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.21
   Yang DJ, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0221-6
   Yim CY, 2016, CANCER RES, V76, P1204, DOI 10.1158/0008-5472.CAN-15-2265
   Yin HF, 2021, J CELL MOL MED, V25, P3963, DOI 10.1111/jcmm.16349
   Yu JH, 2017, SCI CHINA LIFE SCI, V60, P46, DOI 10.1007/s11427-016-0322-x
   Zagani R, 2015, ONCOTARGET, V6, P28282, DOI 10.18632/oncotarget.5061
   Zechner R, 2009, J LIPID RES, V50, P3, DOI 10.1194/jlr.R800031-JLR200
   Zhang Xue-mei, 2016, Sichuan Da Xue Xue Bao Yi Xue Ban, V47, P184
   Zhao JS, 2017, ONCOTARGET, V8, P83602, DOI 10.18632/oncotarget.18787
   Zhu WK, 2020, J CELL BIOCHEM, V121, P1552, DOI 10.1002/jcb.29390
   Zhu X, 2020, WORLD J STEM CELLS, V12, P448, DOI 10.4252/wjsc.v12.i6.448
   Zimmermann R, 2004, SCIENCE, V306, P1383, DOI 10.1126/science.1100747
NR 79
TC 1
Z9 1
U1 3
U2 3
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2157-9024
J9 ONCOGENESIS
JI Oncogenesis
PD NOV 29
PY 2021
VL 10
IS 11
AR 82
DI 10.1038/s41389-021-00373-4
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA XE8PQ
UT WOS:000723644500001
PM 34845203
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Li, HB
   Yi, X
   Gao, JM
   Ying, XX
   Guan, HQ
   Li, JC
AF Li, Hai-bo
   Yi, Xin
   Gao, Jian-mei
   Ying, Xi-xiang
   Guan, Hong-quan
   Li, Jian-chun
TI Magnolol-induced H460 cells death via autophagy but not apoptosis
SO ARCHIVES OF PHARMACAL RESEARCH
LA English
DT Article
DE magnolol; H460; autophagy; apoptosis
ID LIVER-CANCER CELLS; TUMOR-SUPPRESSOR; HT-29 CELLS; HUMAN COLON;
   KINASE-B; MACROAUTOPHAGY; INHIBITION; PROTEIN; 3-METHYLADENINE;
   MECHANISMS
AB We have reported that the protective effect of Magnolol on TBHP-induced injury in human non-small lung cancer H460 cells is partially via a p53 dependent mechanism. In this study, we found that Magnolol displayed a stimulatory effect at low concentrations (<= 20 mu M) whilst inhibitory effect at high concentrations (>= 40 mu M) in H460 cells. To investigate the mechanism of inducing the biphasic effect in H460 cells with Magnolol, we showed that Magnolol stimulated DNA synthesis at low concentrations and displayed an inhibition effect at high concentrations in H460 cells. More importantly, the inhibition of DNA synthesis was accompanied by the S phase cell cycle arrest and the appearance of intense intracytoplasmic vacuoles. These vacuoles can be labeled by autophagic marker monodansylcadaverin (MDC), 3-methyladenine (3MA), an inhibitor of autophagy, was able to inhibit the occurrence of autophagy. The results of the LDH activity assay and TUNEL assay also showed that Magnolol at high concentrations inhibiting H460 cell growth was not via apoptotic pathway. Furthermore, accompanied by the occurrence of autophagy, the expression of phospho-Akt was down-regulated but PTEN significantly was up-regulated. In conclusion, Magnolol induces H460 cells death by autophagy but not apoptotic pathway. Blockade of PI3K/PTEN/Akt pathway is maybe related to Magnolol-induced autophagy. Autophagic cells death induction by Magnolol underlines the potential utility of its induction as a new cancer treatment modality.
C1 [Gao, Jian-mei; Li, Jian-chun] Shenyang Pharmaceut Univ, Dept Pharm, Shenyang 110016, Peoples R China.
   [Li, Hai-bo; Guan, Hong-quan] Liaoning Univ TCM, Sch Basic Med Sci, Shenyang 110032, Peoples R China.
   [Yi, Xin] Inst Basic Med Sci, Dept Pathobiol, Beijing 100850, Peoples R China.
   [Ying, Xi-xiang] Liaoning Univ TCM, Sch Pharm, Shenyang 110032, Peoples R China.
RP Li, JC (corresponding author), Shenyang Pharmaceut Univ, Dept Pharm, Wenhua Rd 103, Shenyang 110016, Peoples R China.
EM longqiaoqian@gmail.com
CR Abraham MC, 2004, TRENDS CELL BIOL, V14, P184, DOI 10.1016/j.tcb.2004.03.002
   Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200
   BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3
   Bowen ID, 1996, MICROSC RES TECHNIQ, V34, P202, DOI 10.1002/(SICI)1097-0029(19960615)34:3<202::AID-JEMT3>3.0.CO;2-R
   Brognard J, 2001, CANCER RES, V61, P3986
   BURSCH W, 1994, BIOCHEM CELL BIOL, V72, P669, DOI 10.1139/o94-088
   Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595
   Chang BS, 1998, PLANTA MED, V64, P367, DOI 10.1055/s-2006-957453
   CLARK AM, 1981, J PHARM SCI, V70, P951, DOI 10.1002/jps.2600700833
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923
   Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Ikeda K, 2002, BIOL PHARM BULL, V25, P1546, DOI 10.1248/bpb.25.1546
   Iwamaru A, 2007, ONCOGENE, V26, P1840, DOI 10.1038/sj.onc.1209992
   Jia L, 1997, BRIT J HAEMATOL, V98, P673, DOI 10.1046/j.1365-2141.1997.2623081.x
   Kishimoto H, 2007, BLOOD, V109, P3316, DOI 10.1182/blood-2006-07-038059
   KONOSHIMA T, 1991, J NAT PROD, V54, P816, DOI 10.1021/np50075a010
   Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897
   Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3
   Lee YM, 2001, EUR J PHARMACOL, V422, P159, DOI 10.1016/S0014-2999(01)01069-X
   LI H, IN PRESS, P53
   Lin SY, 2002, J CELL BIOCHEM, V84, P532, DOI 10.1002/jcb.10059
   Lin SY, 2001, MOL CARCINOGEN, V32, P73, DOI 10.1002/mc.1066
   Mizushima N, 2005, CELL DEATH DIFFER, V12, P1535, DOI 10.1038/sj.cdd.4401728
   Pattingre S, 2004, METHOD ENZYMOL, V390, P17
   Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200
   Pedro M, 2006, TOXICOL LETT, V164, P24, DOI 10.1016/j.toxlet.2005.11.007
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Rani MRS, 2002, J BIOL CHEM, V277, P38456, DOI 10.1074/jbc.M203204200
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Shih HC, 2004, SHOCK, V22, P358, DOI 10.1097/01.shk.0000142251.92887.94
   Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9
   Stroikin Y, 2004, EUR J CELL BIOL, V83, P583, DOI 10.1078/0171-9335-00433
   ZAKERI ZF, 1994, BIOCHEM CELL BIOL, V72, P603, DOI 10.1139/o94-080
NR 35
TC 41
Z9 49
U1 0
U2 15
PU PHARMACEUTICAL SOC KOREA
PI SEOUL
PA 1489-3 SUHCHO-DONG, SUHCHO-KU, SEOUL 137-071, SOUTH KOREA
SN 0253-6269
EI 1976-3786
J9 ARCH PHARM RES
JI Arch. Pharm. Res.
PD DEC
PY 2007
VL 30
IS 12
BP 1566
EP 1574
DI 10.1007/BF02977326
PG 9
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 246QC
UT WOS:000252021000011
PM 18254244
DA 2022-04-25
ER

PT J
AU Chen, Q
   Zhong, L
   Zhou, C
   Feng, Y
   Liu, QX
   Zhou, D
   Lu, X
   Du, GS
   Jian, D
   Luo, H
   Wang, D
   Zheng, H
   Qiu, Y
AF Chen, Qian
   Zhong, Li
   Zhou, Chao
   Feng, Yan
   Liu, Quan-xing
   Zhou, Dong
   Lu, Xiao
   Du, Guang-Sheng
   Jian, Dan
   Luo, Hao
   Wang, Dong
   Zheng, Hong
   Qiu, Yuan
TI Knockdown of Parkinson's disease-related gene ATP13A2 reduces
   tumorigenesis via blocking autophagic flux in colon cancer
SO CELL AND BIOSCIENCE
LA English
DT Article
DE Colon cancer; Autophagy; Tumorigenesis
ID EXPRESSION; CELLS; RISK; MAINTENANCE; SURVIVAL; IMPACT
AB Background Accumulating evidence shows that Parkinson's disease is negatively associated with colon cancer risk, indicating that Parkinson's disease family proteins may be involved in the initiation of colon cancer. Here, we aimed to identify a Parkinson's disease-related gene involved in colon cancer, elucidate the underlying mechanisms, and test whether it can be used as a target for cancer therapy. Methods We first screened colon cancer and normal tissues for differential expression of Parkinson's disease-associated genes and identified ATP13A2, which encodes cation-transporting ATPase 13A2, as a putative marker for colon cancer. We next correlated ATP13A2 expression with colon cancer prognosis. We performed a series of ATP13A2 knockdown and overexpression studies in vitro to identify the contribution of ATP13A2 in the stemness and invasive capacity of colon cancer cells. Additionally, autophagy flux assay were determined to explore the mechanism of ATP13A2 induced stemness. Finally, we knocked down ATP13A2 in mice using siRNA to determine whether it can be used as target for colon cancer treatment. Results Colon cancer patients with high ATP13A2 expression exhibit shorter overall survival than those with low ATP13A2. Functionally, ATP13A2 acts as a novel stimulator of stem-like traits. Furthermore, knockdown of ATP13A2 in HCT116 resulted in decreased levels of cellular autophagy. Additionally, bafilomycin A1, an autophagy inhibitor, reversed the ATP13A2-induced stemness of colon cancer cells. Lastly treatment with ATP13A2 siRNA reduced the volume of colon cancer xenografts in mice. Conclusions The PD-associated gene ATP13A2 is involved in colon cancer stemness through regulation of autophagy. Furthermore, ATP13A2 is a novel prognostic biomarker for colon cancer and is a potential target for colon cancer therapy.
C1 [Chen, Qian; Zhong, Li; Feng, Yan; Jian, Dan; Luo, Hao; Wang, Dong] Army Med Univ, Mil Med Univ 3, Daping Hosp, Canc Ctr, Chongqing 400037, Peoples R China.
   [Zhou, Chao; Du, Guang-Sheng; Qiu, Yuan] Army Med Univ, Mil Med Univ 3, Dept Gen Surg, Xinqiao Hosp, Chongqing 400037, Peoples R China.
   [Liu, Quan-xing; Zhou, Dong; Lu, Xiao; Zheng, Hong] Army Med Univ, Mil Med Univ 3, Dept Thorac Surg, Xinqiao Hosp, Chongqing 400037, Peoples R China.
   [Chen, Qian; Qiu, Yuan] Army Med Univ, Mil Med Univ 3, State Key Lab Trauma Burn & Combined Injury, Chongqing 400037, Peoples R China.
RP Qiu, Y (corresponding author), Army Med Univ, Mil Med Univ 3, Dept Gen Surg, Xinqiao Hosp, Chongqing 400037, Peoples R China.; Zheng, H (corresponding author), Army Med Univ, Mil Med Univ 3, Dept Thorac Surg, Xinqiao Hosp, Chongqing 400037, Peoples R China.
EM ziecoe@tmmu.edu.cn; xiaoq2037@qq.com
RI Zheng, Hong/O-9604-2018
OI Zheng, Hong/0000-0003-3725-4541; Luo, Hao/0000-0002-2321-9924; Liu,
   Quan-Xing/0000-0002-6725-385X
FU Surface Project of Chongqing Natural Science Foundation
   [csts2020jcyj-msx'mX0230]; Miaopu Talent Grant from Army medical
   University [2019R045]; Open Project Program of the State Key Laboratory
   of Trauma, Burn and Combined Injury, Third Military Medical University
   [SKLKF201904]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China (NSFC) [82002656]
FX This study was supported by grants from the Surface Project of Chongqing
   Natural Science Foundation (csts2020jcyj-msx'mX0230) and Miaopu Talent
   Grant from Army medical University (to Yuan Qiu 2019R045), the Open
   Project Program of the State Key Laboratory of Trauma, Burn and Combined
   Injury, Third Military Medical University (to Yuan Qiu SKLKF201904), and
   National Natural Science Foundation of China (82002656).
CR Boursi B, 2016, CANCER EPIDEMIOL, V43, P9, DOI 10.1016/j.canep.2016.05.007
   Boursi B, 2015, PHARMACOEPIDEM DR S, V24, P534, DOI 10.1002/pds.3765
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005
   Cufi S, 2011, CELL CYCLE, V10, P3871, DOI 10.4161/cc.10.22.17976
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Djarmati A, 2009, MOVEMENT DISORD, V24, P2104, DOI 10.1002/mds.22728
   Ganguli M, 2015, ALZ DIS ASSOC DIS, V29, P177, DOI 10.1097/WAD.0000000000000086
   Gusdon AM, 2012, NEUROBIOL DIS, V45, P962, DOI 10.1016/j.nbd.2011.12.015
   Hardy J, 2010, NEURON, V68, P201, DOI 10.1016/j.neuron.2010.10.014
   HAUSCHKA PV, 1970, BIOCHEMISTRY-US, V9, P3745, DOI 10.1021/bi00821a013
   Huang YJ, 2016, BLOOD, V127, P1459, DOI [10.1182/blood-2015-05648550, 10.1182/blood-2015-05-648550]
   Ibanez K, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004173
   Ji ZS, 2006, J BIOL CHEM, V281, P2683, DOI 10.1074/jbc.M506646200
   Keshavarzian A, 2015, MOVEMENT DISORD, V30, P1351, DOI 10.1002/mds.26307
   Lin CH, 2008, NEUROLOGY, V71, P1727, DOI 10.1212/01.wnl.0000335167.72412.68
   Lin Y, 2018, CANCER MED-US, V7, P809, DOI 10.1002/cam4.1325
   Liu F, 2010, BLOOD, V116, P4806, DOI 10.1182/blood-2010-06-288589
   Liu QX, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0646-y
   Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003
   Maycotte P, 2015, MOL CANCER RES, V13, P651, DOI 10.1158/1541-7786.MCR-14-0487
   Rao J, 2015, CANCER LETT, V358, P76, DOI 10.1016/j.canlet.2014.12.040
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Sharma JC, 2014, NEURODEGENER DIS MAN, V4, P309, DOI [10.2217/nmt.14.25, 10.2217/NMT.14.25]
   Shitashige M, 2010, CANCER RES, V70, P5024, DOI 10.1158/0008-5472.CAN-10-0306
   Su CJ, 2017, CNS NEUROSCI THER, V23, P717, DOI 10.1111/cns.12721
   Vidyadhara DJ, 2019, J NEUROCHEM, V150, P487, DOI 10.1111/jnc.14820
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Xie X, 2017, PARKINSONISM RELAT D, V35, P42, DOI 10.1016/j.parkreldis.2016.11.011
   Zheng H, 2018, CANCER MANAG RES, V10, P4615, DOI 10.2147/CMAR.S172008
NR 30
TC 5
Z9 5
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2045-3701
J9 CELL BIOSCI
JI Cell Biosci.
PD DEC 11
PY 2020
VL 10
IS 1
AR 144
DI 10.1186/s13578-020-00506-z
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA PG5CW
UT WOS:000599753700002
PM 33308286
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU John, S
   Briatka, T
   Rudolf, E
AF John, Stanislav
   Briatka, Tomas
   Rudolf, Emil
TI Diverse sensitivity of cells representing various stages of colon
   carcinogenesis to increased extracellular zinc: Implications for zinc
   chemoprevention
SO ONCOLOGY REPORTS
LA English
DT Article
DE apoptosis; autophagy; zinc; colon cancer; in vitro
ID ERK-DEPENDENT ACTIVATION; COLORECTAL-CANCER CELLS; APOPTOSIS; PATHWAY;
   DEATH; PROLIFERATION; NECROSIS; RECEPTOR; GROWTH
AB The relationship between zinc intake and risk of colon cancer is widely recognized: Despite reported mechanisms of zinc-mediated effects in colonic cells no information is available on whether zinc is capable of inducing cell death of malignant colonocytes. The present study shows that increased external zinc concentrations inhibit cell growth of three different colon cancer cell lines representing different stages of colon cancer: HCT-116, HT-29 and SW620 cells and induce their death. Of the tested cell lines, SW620 cells proved to be the most sensitive to externally added zinc and this sensitivity was at least partly due to increased levels of intracellular free zinc and the inability to overexpress metallothionein. Further studies into the mechanisms of zinc-induced cell injury and cell death revealed oxidative stress as the most important underlying mechanism activating stress kinase-dependent signaling, perturbation of mitochondria and plasma membrane damage. In addition, observed cell death in individual cell populations was cell line-dependent and variable including cells displaying features of apoptosis, necrosis, autophagy and other mixed-types. In conclusion, presented results for the first time show variability of responses to zinc in colon cancer at different stages as modeled in vitro and suggest that zinc-induced cell death despite common underlying mechanism(s) might have a variable nature.
C1 [John, Stanislav; Briatka, Tomas; Rudolf, Emil] Charles Univ Prague, Fac Med Hradec Kralove, Dept Med Biol & Genet, Hradec Kralove 50038 1, Czech Republic.
RP Rudolf, E (corresponding author), Charles Univ Prague, Fac Med Hradec Kralove, Dept Med Biol & Genet, Simkova 870, Hradec Kralove 50038 1, Czech Republic.
EM rudolf@lfhk.cuni.cz
RI Rudolf, Emil/B-5956-2017
OI Rudolf, Emil/0000-0002-9526-3174
FU GAUK [132808]; Ministry of Education [MSM 0021620820]
FX This study was supported by GAUK No. 132808 and Ministry of Education
   Research Project No. MSM 0021620820.
CR Azriel-Tamir H, 2004, J BIOL CHEM, V279, P51804, DOI 10.1074/jbc.M406581200
   Carter JW, 1997, NUTR CANCER, V27, P217, DOI 10.1080/01635589709514529
   De Flora S, 2005, MUTAT RES-FUND MOL M, V591, P8, DOI 10.1016/j.mrfmmm.2005.02.029
   Eom SJ, 2001, MOL PHARMACOL, V59, P981, DOI 10.1124/mol.59.5.981
   Fraker PJ, 1997, P SOC EXP BIOL MED, V215, P229, DOI 10.3181/00379727-215-44132
   Franklin RB, 2007, ARCH BIOCHEM BIOPHYS, V463, P211, DOI 10.1016/j.abb.2007.02.033
   Hamatake M, 2000, J BIOCHEM-TOKYO, V128, P933, DOI 10.1093/oxfordjournals.jbchem.a022844
   Jaiswal AS, 2004, J CELL BIOCHEM, V93, P345, DOI 10.1002/jcb.20156
   Kim YH, 1999, NEUROSCIENCE, V89, P175, DOI 10.1016/S0306-4522(98)00313-3
   Kondoh M, 2002, EUR J BIOCHEM, V269, P6204, DOI 10.1046/j.1432-1033.2002.03339.x
   Lansdown ABG, 2007, WOUND REPAIR REGEN, V15, P2, DOI 10.1111/j.1524-475X.2006.00179.x
   LEE HH, 1989, AM J PHYSIOL, V256, pG87, DOI 10.1152/ajpgi.1989.256.1.G87
   Liuzzi JP, 2004, ANNU REV NUTR, V24, P151, DOI 10.1146/annurev.nutr.24.012003.132402
   MacDonald RS, 2000, J NUTR, V130, p1500S, DOI 10.1093/jn/130.5.1500S
   Malhotra A, 2009, J ENVIRON PATHOL TOX, V28, P351, DOI 10.1615/JEnvironPatholToxicolOncol.v28.i4.90
   MATEO MCM, 1988, CLIN PHYSIOL BIOCH, V6, P321
   NELSON RL, 1987, ANTICANCER RES, V7, P259
   Park KS, 2004, EXP MOL MED, V36, P557, DOI 10.1038/emm.2004.71
   Park KS, 2003, AM J PHYSIOL-GASTR L, V285, pG1181, DOI 10.1152/ajpgi.00047.2003
   Park KS, 2002, BRIT J PHARMACOL, V137, P597, DOI 10.1038/sj.bjp.0704909
   Prasad AS, 1998, MOL CELL BIOCHEM, V188, P63, DOI 10.1023/A:1006868305749
   Provinciali M, 2002, FREE RADICAL BIO MED, V32, P431, DOI 10.1016/S0891-5849(01)00830-9
   SONG MK, 1993, J NATL CANCER I, V85, P667, DOI 10.1093/jnci/85.8.667
   Wu WD, 2005, AM J PHYSIOL-LUNG C, V289, pL883, DOI 10.1152/ajplung.00197.2005
NR 24
TC 24
Z9 24
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD MAR
PY 2011
VL 25
IS 3
BP 769
EP 780
DI 10.3892/or.2010.1124
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 727JF
UT WOS:000287794000020
PM 21206977
OA Bronze
DA 2022-04-25
ER

PT J
AU Wang, YY
   Luo, Q
   He, XL
   Wei, H
   Wang, T
   Shao, JC
   Jiang, XN
AF Wang, Yuanyuan
   Luo, Qin
   He, Xianlu
   Wei, He
   Wang, Ting
   Shao, Jichun
   Jiang, Xinni
TI Emodin Induces Apoptosis of Colon Cancer Cells via Induction of
   Autophagy in a ROS-Dependent Manner
SO ONCOLOGY RESEARCH
LA English
DT Article
DE Emodin; Colon cancer; Apoptosis; Autophagy; Reactive oxygen species
   (ROS)
ID OXIDATIVE STRESS; MITOCHONDRIA
AB Recent studies revealed that emodin extracted from Chinese herbs exhibits an anticancer effect on different cancer types, including colon cancer. However, the mechanism is not well understood. In our study, we confirmed that emodin treatment inhibited cell viability and induced apoptosis in colon cancer cells. Further experiments found that emodin was also able to induce autophagy, which is indispensible for apoptosis induced by emodin. More interestingly. emodin treatment also results in mitochondrial dysfunction and ROS accumulation in colon cancer cells. Finally, we stressed that ROS accumulation is essential for autophagy and apoptosis induced by emodin. In conclusion, emodin induces apoptosis in colon cancer cells through induction of autophagy, during which ROS generation is of the essence. Our findings improve understanding of emodin's effect on colon cancer suppression and provide a new theoretical basis for colon cancer therapy.
C1 [Wang, Yuanyuan; Luo, Qin; Wei, He; Wang, Ting; Jiang, Xinni] Chengdu Med Coll, Dept Biomed Sci, Chengdu 610051, Sichuan, Peoples R China.
   [He, Xianlu] China Natl Nucl Corp, Hosp 416, Chengdu Med Coll, Dept Gen Surg,Affiliated Hosp 2, Chengdu, Sichuan, Peoples R China.
   [Shao, Jichun] China Natl Nucl Corp, Hosp 416, Chengdu Med Coll, Dept Urol,Affiliated Hosp 2, Chengdu, Sichuan, Peoples R China.
RP Jiang, XN (corresponding author), Chengdu Med Coll, Dept Biomed Sci, Chengdu 610051, Sichuan, Peoples R China.; Shao, JC (corresponding author), China Natl Nucl Corp, Hosp 416, Chengdu Med Coll, Dept Urol,Affiliated Hosp 2, Chengdu, Sichuan, Peoples R China.
EM shaoji93@163.com; 404810676@qq.com
FU Key Fund Project of Sichuan Provincial Department of Education
   [16ZA0291]; Discipline Building Project of Biology of Chengdu Medical
   College [CYXK2012011]; Project of Research and Innovation Teams of
   Chengdu Medical College [CYTD15-02]
FX This work was supported by the Key Fund Project of Sichuan Provincial
   Department of Education (No. 16ZA0291), the Discipline Building Project
   of Biology of Chengdu Medical College (CYXK2012011), and the Project of
   Research and Innovation Teams of Chengdu Medical College (CYTD15-02).
CR Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4
   Fandy TE, 2014, CLIN CANCER RES, V20, P1249, DOI 10.1158/1078-0432.CCR-13-1453
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Galloway CA, 2012, J GEN PHYSIOL, V139, P455, DOI 10.1085/jgp.201210771
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451
   Lee KH, 2017, MOL MED REP, V15, P2163, DOI 10.3892/mmr.2017.6254
   Monisha BA, 2016, ADV EXP MED BIOL, V928, P47, DOI 10.1007/978-3-319-41334-1_3
   Navarro-Yepes J, 2014, ANTIOXID REDOX SIGN, V21, P66, DOI 10.1089/ars.2014.5837
   Ohsumi Y, 2014, CELL RES, V24, P9, DOI 10.1038/cr.2013.169
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Qiu MN, 2017, ONCOL LETT, V13, P1137, DOI 10.3892/ol.2016.5535
   Rahal A, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/761264
   Scherz-Shouval R, 2007, TRENDS CELL BIOL, V17, P422, DOI 10.1016/j.tcb.2007.07.009
   Su J, 2017, ONCOL REP, V37, P1565, DOI 10.3892/or.2017.5428
   Su ZY, 2015, ONCOTARGET, V6, P8474, DOI 10.18632/oncotarget.3523
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   Zhang F, 2017, ONCOTARGET, V8, P35460, DOI 10.18632/oncotarget.16727
   Zhang L, 2017, BIOMED PHARMACOTHER, V90, P222, DOI 10.1016/j.biopha.2017.03.046
   Zhang P, 2017, AUTOPHAGY, V17, P1, DOI DOI 10.2174/1566524018666171219101142
   Zhang SX, 2015, SCI REP-UK, V5, DOI 10.1038/srep13626
NR 21
TC 32
Z9 33
U1 7
U2 26
PU COGNIZANT COMMUNICATION CORP
PI PUTNAM VALLEY
PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA
SN 0965-0407
EI 1555-3906
J9 ONCOL RES
JI Oncol. Res.
PY 2018
VL 26
IS 6
BP 889
EP 899
DI 10.3727/096504017X15009419625178
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GM2LO
UT WOS:000437917600007
PM 28762328
OA Green Published
DA 2022-04-25
ER

PT J
AU Sheng, YH
   Giri, R
   Davies, J
   Schreiber, V
   Alabbas, S
   Movva, R
   He, YW
   Wu, A
   Hooper, J
   McWhinney, B
   Oancea, I
   Kijanka, G
   Hasnain, S
   Lucke, AJ
   Fairlie, DP
   McGuckin, MA
   Florin, TH
   Begun, J
AF Sheng, Yong Hua
   Giri, Rabina
   Davies, Julie
   Schreiber, Veronika
   Alabbas, Saleh
   Movva, Ramya
   He, Yaowu
   Wu, Andy
   Hooper, John
   McWhinney, Brett
   Oancea, Iulia
   Kijanka, Gregor
   Hasnain, Sumaira
   Lucke, Andrew J.
   Fairlie, David P.
   McGuckin, Michael A.
   Florin, Timothy H.
   Begun, Jakob
TI A Nucleotide Analog Prevents Colitis-Associated Cancer via Beta-Catenin
   Independently of Inflammation and Autophagy
SO CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE Colon Cancer; beta-Catenin; Thioguanine; Autophagy
ID BOWEL-DISEASE; COLORECTAL NEOPLASIA; RAC1 ACTIVATION; EXPRESSION;
   PATHWAY; RISK; AZATHIOPRINE; THIOPURINES; MODEL; 5-AMINOSALICYLATE
AB Colitis increases the risk of bowel cancer. We show in mouse models that a thioguanine nucleotide can inhibit Wnl/bcalenin signaling via Rac1 in colonic epithelial cells to prevent carcinogenesis. The novel mechanism is independent of inflammation and autophagy.
   BACKGROUND & AIMS: Chronic bowel inflammation increases the risk of colon cancer; colitis-associated cancer (CAC). Thiopurine treatments are associated with a reduction in dysplasia and CAC in inflammatory bowel disease (IBD). Abnormal Wnt/beta-catenin signalling is characteristic of >90% of colorectal cancers. Immunosuppression by thiopurines is via Rac1 GTPase, which also affects Wnt/beta-catenin signalling. Autophagy is implicated in colonic tumors, and topical delivery of the thiopurine thioguanine (TG) is known to alleviate colitis and augment autophagy. This study investigated the effects of TG in a murine model of CAC and potential mechanisms.
   METHODS: Colonic dysplasia was induced by exposure to azoxymethane (AOM) and dextran sodium sulfate (DSS) in wild-type (WT) mice and mice harboring intestinal epithelial cell-specific deletion of autophagy related 7 gene (Atg7(Delta IEC)). TG or vehicle was administered intrarectally, and the effect on tumor burden and beta-catenin activity was assessed. The mechanisms of action of TG were investigated in vitro and in vivo.
   RESULTS: TG ameliorated DSS colitis in wild-type but not Atg7(Delta IEC) mice, demonstrating that anti-inflammatory effects of locally delivered TG are autophagy-dependent. However, TG inhibited CAC in both wild-type and Atg7(Delta IEC) mice. This was associated with decreased beta-catenin activation/nuclear translocation demonstrating that TG's inhibition of tumorigenesis occurred independently of anti-inflammatory and pro-autophagic actions. These results were confirmed in cell lines, and the dependency on Rac1 GTPase was demonstrated by siRNA knockdown and overexpression of constitutively active Rac1.
   CONCLUSIONS: Our findings provide evidence for a new mechanism that could be exploited to improve CAC chemo-prophylactic approaches.
C1 [Sheng, Yong Hua; Giri, Rabina; Davies, Julie; Schreiber, Veronika; Alabbas, Saleh; Movva, Ramya; Florin, Timothy H.; Begun, Jakob] Univ Queensland, Translat Res Inst, Mater Res Inst, Inflammatory Bowel Dis Grp, Woolloongabba, Qld, Australia.
   [Sheng, Yong Hua; Hasnain, Sumaira; Begun, Jakob] Univ Queensland, Translat Res Inst, Mater Res Inst, Inflammatory Dis Biol & Therapeut Grp, Woolloongabba, Qld, Australia.
   [He, Yaowu; Hooper, John] Univ Queensland, Mater Res Inst, Canc Biol Grp, Woolloongabba, Qld, Australia.
   [Wu, Andy] Univ Queensland, Translat Res Inst, Mater Res Inst, Bones & Immunol Grp, Woolloongabba, Qld, Australia.
   [McWhinney, Brett] Queensland Pathol Serv, Herston, Qld, Australia.
   [Oancea, Iulia; Begun, Jakob] Univ Queensland, Fac Med, Sch Clin Med, Brisbane, Qld, Australia.
   [Kijanka, Gregor] Univ Queensland, Translat Res Inst, Mater Res Inst, Immune Profiling & Canc Grp, Woolloongabba, Qld, Australia.
   [McGuckin, Michael A.] Univ Melbourne, Fac Med Dent & Hlth Sci, Parkville, Vic, Australia.
   [Lucke, Andrew J.; Fairlie, David P.] Univ Queensland, ARC Ctr Excellence Adv Mol Imaging, Inst Mol Biosci, Brisbane, Qld, Australia.
RP Florin, TH; Begun, J (corresponding author), Univ Queensland, Translat Res Inst, Mater Res Inst, 37 Kent St, Brisbane, Qld 4102, Australia.
EM t.florin@uq.edu.au; jakob.begun@mater.uq.edu.au
RI Davies, Julie/AAU-7129-2021; sheng, yong H/C-5052-2013; Begun,
   Jakob/J-6793-2014; Hooper, John/C-1481-2016; Kijanka,
   Gregor/O-4300-2014; Hasnain, Sumaira/N-3412-2014
OI sheng, yong H/0000-0002-4623-9098; Begun, Jakob/0000-0001-5256-7672; Wu,
   Andy C/0000-0002-0864-4447; Schreiber, Veronika/0000-0001-6088-7828;
   Giri, Rabina/0000-0002-6712-6076; Hooper, John/0000-0003-1054-8486;
   Florin, Tim/0000-0003-1866-9848; HE, Yaowu/0000-0002-7828-263X; Davies,
   Julie/0000-0003-4035-6047; Kijanka, Gregor/0000-0003-2557-234X; Hasnain,
   Sumaira/0000-0001-8577-8628
FU Australian GovernmentAustralian GovernmentCGIAR; Mater Foundation; UQ
   Reginald Ferguson Fellowship; ARC grantAustralian Research Council;
   NHMRCNational Health and Medical Research Council (NHMRC) of Australia
FX The Translational Research Institute (TRI) is supported by a grant from
   the Australian Government. Mater Research Institute is supported by
   Mater Foundation. JB has a UQ Reginald Ferguson Fellowship. AJL is
   supported by an ARC grant and DPF by the NHMRC.
CR Augustin I, 2016, STEM CELL RES, V17, P607, DOI 10.1016/j.scr.2016.10.010
   Aust DE, 2002, CANCER, V94, P1421, DOI 10.1002/cncr.10334
   Axelrad JE, 2016, WORLD J GASTROENTERO, V22, P10103, DOI 10.3748/wjg.v22.i46.10103
   Baars JE, 2011, AM J GASTROENTEROL, V106, P319, DOI 10.1038/ajg.2010.428
   Beaugerie L, 2013, GASTROENTEROLOGY, V145, P166, DOI 10.1053/j.gastro.2013.03.044
   Bernstein CN, 2011, AM J GASTROENTEROL, V106, P731, DOI 10.1038/ajg.2011.50
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Cherciu Irina, 2014, Curr Health Sci J, V40, P153, DOI 10.12865/CHSJ.40.03.01
   Chuang SJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21476-w
   Claessen MMH, 2010, CELL ONCOL, V32, P303, DOI 10.3233/CLO-2009-0503
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Cooper HS, 2000, CARCINOGENESIS, V21, P757, DOI 10.1093/carcin/21.4.757
   de Boer NKH, 2019, GASTROENTEROLOGY, V156, P11, DOI 10.1053/j.gastro.2018.11.039
   De Robertis Mariangela, 2011, J Carcinog, V10, P9, DOI 10.4103/1477-3163.78279
   Dervieux T, 1998, CLIN CHEM, V44, P551
   Dieter SM, 2011, CELL STEM CELL, V9, P357, DOI 10.1016/j.stem.2011.08.010
   Duley JA, 2005, THER DRUG MONIT, V27, P647, DOI 10.1097/01.ftd.0000169061.52715.3e
   Esufali S, 2004, ONCOGENE, V23, P8260, DOI 10.1038/sj.onc.1208007
   Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235
   Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937
   Florin THJ, 2019, DRUG DISCOV TODAY, V24, P37, DOI 10.1016/j.drudis.2018.09.001
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Gavert N, 2007, J CELL BIOCHEM, V102, P820, DOI 10.1002/jcb.21505
   Gordillo J, 2015, J CROHNS COLITIS, V9, P1063, DOI 10.1093/ecco-jcc/jjv145
   Graham TA, 2000, CELL, V103, P885, DOI 10.1016/S0092-8674(00)00192-6
   Hofmann U, 2012, ANAL CHEM, V84, P1294, DOI 10.1021/ac2031699
   Hong Y, 2015, CANCER RES, V75, P656, DOI 10.1158/0008-5472.CAN-14-2377
   Jess T, 2014, CLIN GASTROENTEROL H, V12, P1793, DOI 10.1016/j.cgh.2014.05.019
   Khor B, 2011, NATURE, V474, P307, DOI 10.1038/nature10209
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Levy J, 2015, NAT CELL BIOL, V17, P1062, DOI 10.1038/ncb3206
   Li JN, 2011, PROTEINS, V79, P2794, DOI 10.1002/prot.23106
   Massey DCO, 2007, AUTOPHAGY, V3, P649, DOI 10.4161/auto.5075
   Mizushima N, 2010, NAT CELL BIOL, V12, P823, DOI 10.1038/ncb0910-823
   Najdi Rani, 2011, J Carcinog, V10, P5, DOI 10.4103/1477-3163.78111
   Neurath MF, 2019, CYTOKINE GROWTH F R, V45, P1, DOI 10.1016/j.cytogfr.2018.12.002
   Ng SC, 2017, LANCET, V390, P2769, DOI 10.1016/S0140-6736(17)32448-0
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Oancea I, 2017, GUT, V66, P59, DOI 10.1136/gutjnl-2015-310874
   Oancea I, 2013, GUT, V62, P594, DOI 10.1136/gutjnl-2012-302274
   Petherick KJ, 2013, EMBO J, V32, P1903, DOI 10.1038/emboj.2013.123
   Poppe D, 2006, J IMMUNOL, V176, P640, DOI 10.4049/jimmunol.176.1.640
   Qu DD, 2017, CANCER BIOL THER, V18, P237, DOI 10.1080/15384047.2017.1294292
   Ring DB, 2003, DIABETES, V52, P588, DOI 10.2337/diabetes.52.3.588
   Sarela AI, 2000, GUT, V46, P645, DOI 10.1136/gut.46.5.645
   Seinen ML, 2016, MOL DIAGN THER, V20, P551, DOI 10.1007/s40291-016-0232-1
   Shen P, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18092003
   Sheng YH, 2011, GUT, V60, P1661, DOI 10.1136/gut.2011.239194
   Spranger S, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1086862
   Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772
   Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058
   Tiede I, 2003, J CLIN INVEST, V111, P1133, DOI 10.1172/JCI200316432
   Trieb K, 2003, EUR J SURG ONCOL, V29, P379, DOI 10.1053/ejso.2002.1415
   van Dekken H, 2007, ACTA HISTOCHEM, V109, P266, DOI 10.1016/j.acthis.2007.02.007
   van Schaik FDM, 2012, GUT, V61, P235, DOI 10.1136/gut.2011.237412
   van Staa TP, 2005, GUT, V54, P1573, DOI 10.1136/gut.2005.070896
   White BD, 2012, GASTROENTEROLOGY, V142, P219, DOI 10.1053/j.gastro.2011.12.001
   WITTY JP, 1994, CANCER RES, V54, P4805
   Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052
   Wu YH, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0031-8
   Yu BX, 2013, ACS CHEM BIOL, V8, P524, DOI 10.1021/cb300564v
NR 61
TC 4
Z9 4
U1 1
U2 2
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 2352-345X
J9 CELL MOL GASTROENTER
JI Cell. Mol. Gastroenterol. Hepatol.
PY 2021
VL 11
IS 1
BP 33
EP 53
DI 10.1016/j.jcmgh.2020.05.012
PG 21
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA PH8BZ
UT WOS:000600632200003
PM 32497793
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Cabang, AB
   De Mukhopadhyay, K
   Meyers, S
   Morris, J
   Zimba, PV
   Wargovich, MJ
AF Cabang, April B.
   De Mukhopadhyay, Keya
   Meyers, Sarah
   Morris, Jay
   Zimba, Paul V.
   Wargovich, Michael J.
TI Therapeutic effects of the euglenoid ichthyotoxin, euglenophycin, in
   colon cancer
SO ONCOTARGET
LA English
DT Article
DE euglenophycin; colon cancer; ichthyotoxin; autophagy; therapy
ID MULTITARGET THERAPEUTICS; NATURAL-PRODUCTS; AUTOPHAGY; APOPTOSIS; CELLS;
   TRICHORMAMIDES; IDENTIFICATION; CHEMOTHERAPY; INHIBITION; SOLENOPSIN
AB Colorectal cancer (CRC) remains one of the most commonly diagnosed cancers and the 3rd leading cause of cancer-related mortality. The emergence of drug resistance poses a major challenge in CRC care or treatment. This can be addressed by determining cancer mechanisms, discovery of druggable targets, and development of new drugs. In search for novel agents, aquatic microorganisms offer a vastly untapped pharmacological source that can be developed for cancer therapeutics. In this study, we characterized the anti-colorectal cancer potential of euglenophycin, a microalgal toxin from Euglena sanguinea. The toxin (49.1-114.6 mu M) demonstrated cytotoxic, anti-proliferative, anti-clonogenic, and anti-migration effects against HCT116, HT29, and SW620 CRC cells. We identified G1 cell cycle arrest and cell type - dependent modulation of autophagy as mechanisms of growth inhibition. We validated euglenophycin's anti-tumorigenic activity in vivo using CRL:Nu(NCr) Foxn1(nu) athymic nude mouse CRC xenograft models. Intraperitoneal toxin administration (100 mg/kg; 5 days) decreased HCT116 and HT29 xenograft tumor volumes (n=10 each). Tumor inhibition was associated with reduced expression of autophagy negative regulator mechanistic target of rapamycin (mTOR) and decreased trend of serum pro-inflammatory cytokines. Together, these results provide compelling evidence that euglenophycin can be a promising anti-colorectal cancer agent targeting multiple cancer-promoting processes. Furthermore, this study supports expanding natural products drug discovery to freshwater niches as prospective sources of anti-cancer compounds.
C1 [Cabang, April B.; De Mukhopadhyay, Keya; Morris, Jay; Wargovich, Michael J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA.
   [Meyers, Sarah] Coll Charleston, Charleston, SC 29424 USA.
   [Zimba, Paul V.] Texas A&M Corpus Christi, Ctr Coastal Studies, Corpus Christi, TX 78412 USA.
   [Zimba, Paul V.] Texas A&M Corpus Christi, Dept Life Sci, Corpus Christi, TX 78412 USA.
RP Wargovich, MJ (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA.
EM wargovich@uthscsa.edu
RI Zimba, Paul V/O-2778-2013
OI Zimba, Paul V/0000-0001-6541-2055
FU Morris L. Lichtenstein, Jr. Medical Research Foundation
FX This study is supported by the Morris L. Lichtenstein, Jr. Medical
   Research Foundation.
CR Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35
   American Cancer Society, 2014, COL CANC FACTS FIG 2
   Arbiser JL, 2007, BLOOD, V109, P560, DOI 10.1182/blood-2006-06-029934
   Cathcart J, 2015, GENES DIS, V2, P26, DOI 10.1016/j.gendis.2014.12.002
   Chang TY, 2012, ACS MED CHEM LETT, V3, P1075, DOI 10.1021/ml300283f
   Cragg GM, 2016, MED PRIN PRACT, V25, P41, DOI 10.1159/000443404
   Cragg GM, 2013, BBA-GEN SUBJECTS, V1830, P3670, DOI 10.1016/j.bbagen.2013.02.008
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   Demetri GD, 2016, J CLIN ONCOL, V34, P786, DOI 10.1200/JCO.2015.62.4734
   El-Missiry MA, 2012, CHEM-BIOL INTERACT, V200, P119, DOI 10.1016/j.cbi.2012.10.013
   Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002
   He ML, 2016, J NEURO-ONCOL, V127, P261, DOI 10.1007/s11060-015-2044-2
   Housman G, 2014, CANCERS, V6, P1769, DOI 10.3390/cancers6031769
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Karlsson I, 2015, VASC CELL, V7, DOI 10.1186/s13221-015-0030-2
   Klose J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095970
   Levine B, 2008, NAT CELL BIOL, V10, P637, DOI 10.1038/ncb0608-637
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Li DD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045058
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li ZG, 2008, J CLIN INVEST, V118, P2697, DOI 10.1172/JCI33093
   Luo SW, 2015, BIOORGAN MED CHEM, V23, P3153, DOI 10.1016/j.bmc.2015.04.073
   Luo SW, 2014, J NAT PROD, V77, P1871, DOI 10.1021/np5003548
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   MORIMOTO T, 1995, PHYTOCHEMISTRY, V40, P1433, DOI 10.1016/0031-9422(95)00458-J
   Nakamura K, 2017, IMMUNOL CELL BIOL
   National Center for Biotechnology Information. PubChem Compound Database, 45255907 CID
   National Center for Biotechnology Information. PubChem Compound Database, 16043475 CID
   Reese ND, 2013, CURR HEMATOL MALIG R, V8, P141, DOI 10.1007/s11899-013-0156-3
   Seow HF, 2016, ONCOTARGETS THER, V9, P1899, DOI 10.2147/OTT.S95101
   Thomas C, 2016, ONCOTARGETS THER, V9, P5619, DOI 10.2147/OTT.S93517
   Thorburn A, 2014, MOL PHARMACOL, V85, P830, DOI 10.1124/mol.114.091850
   Vermeulen K, 2003, CELL PROLIFERAT, V36, P165, DOI 10.1046/j.1365-2184.2003.00267.x
   Viry E, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00246
   Wahome PG, 2015, MAR DRUGS, V13, P65, DOI 10.3390/md13010065
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wu ST, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929-016-0275-y
   Xie L, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00209
   Zimba PV, 2017, HARMFUL ALGAE, V63, P79, DOI 10.1016/j.hal.2017.01.010
   Zimba PV, 2010, TOXICON, V55, P100, DOI 10.1016/j.toxicon.2009.07.004
   Zimba PV, 2004, J FISH DIS, V27, P115, DOI 10.1046/j.1365-2761.2003.00512.x
   Zimba PV, 2016, J CANC BIOL TREAT, V3
   Zimmermann GR, 2007, DRUG DISCOV TODAY, V12, P34, DOI 10.1016/j.drudis.2006.11.008
NR 43
TC 8
Z9 8
U1 0
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD NOV 28
PY 2017
VL 8
IS 61
BP 104347
EP 104358
DI 10.18632/oncotarget.22238
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FS1TY
UT WOS:000419562500128
PM 29262645
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Rubio, MF
   Lira, MC
   Rosa, FD
   Sambresqui, AD
   Gumes, MCS
   Costas, MA
AF Fernanda Rubio, Maria
   Cecilia Lira, Maria
   Damian Rosa, Francisco
   Dario Sambresqui, Adrian
   Salazar Gumes, Maria Cecilia
   Alejandra Costas, Monica
TI RAC3 influences the chemoresistance of colon cancer cells through
   autophagy and apoptosis inhibition
SO CANCER CELL INTERNATIONAL
LA English
DT Article
DE Colorectal cancer; RAC3; Chemoresistance; Apoptosis; Autophagy
ID COLORECTAL-CANCER; COACTIVATOR; PROLIFERATION; BREAST; AIB1;
   OVEREXPRESSION; CHEMOTHERAPY; GROWTH; INFLAMMATION; PROGRESSION
AB Background: RAC3 coactivator overexpression has been implicated in tumorigenesis, contributing to inhibition of apoptosis and autophagy. Both mechanisms are involved in resistance to treatment with chemotherapeutic agents. The aim of this study was to investigate its role in chemoresistance of colorectal cancer.
   Methods: The sensitivity to 5-fluorouracil and oxaliplatin in colon cancer cells HT-29, HCT 116 and Lovo cell lines, expressing high or low natural levels of RAC3, was investigated using viability assays.
   Results: In HCT 116 cells, we found that although 5-fluorouracil was a poor inducer of apoptosis, autophagy was strongly induced, while oxaliplatin has shown a similar ability to induce both of them. However, in HCT 116 cells expressing a short hairpin RNA for RAC3, we found an increased sensitivity to both drugs if it is compared with control cells. 5-Fluorouracil and oxaliplatin treatment lead to an enhanced caspase 3-dependent apoptosis and produce an increase of autophagy. In addition, both process have shown to be trigged faster than in control cells, starting earlier after stimulation.
   Conclusions: Our results suggest that RAC3 expression levels influence the sensitivity to chemotherapeutic drugs. Therefore, the knowledge of RAC3 expression levels in tumoral samples could be an important contribution to design new improved therapeutic strategies in the future.
C1 [Fernanda Rubio, Maria; Cecilia Lira, Maria; Damian Rosa, Francisco; Dario Sambresqui, Adrian; Salazar Gumes, Maria Cecilia; Alejandra Costas, Monica] Univ Buenos Aires, Fac Med, Inst Invest Med A Lanari, Buenos Aires, DF, Argentina.
   [Fernanda Rubio, Maria; Cecilia Lira, Maria; Damian Rosa, Francisco; Alejandra Costas, Monica] Univ Buenos Aires, Inst Invest Med IDIM, Lab Mol Biol & Apoptosis, CONICET, Buenos Aires, DF, Argentina.
   [Dario Sambresqui, Adrian] UBA, Inst Invest Med Dr A Lanari, Dept Gastroenterol, Buenos Aires, DF, Argentina.
   [Salazar Gumes, Maria Cecilia] UBA, Dept Oncol, Inst Invest Med Dr A Lanari, Buenos Aires, DF, Argentina.
RP Costas, MA (corresponding author), Univ Buenos Aires, Fac Med, Inst Invest Med A Lanari, Buenos Aires, DF, Argentina.; Costas, MA (corresponding author), Univ Buenos Aires, Inst Invest Med IDIM, Lab Mol Biol & Apoptosis, CONICET, Buenos Aires, DF, Argentina.
EM mcostasra@hotmail.com
OI Costas, Monica/0000-0002-4773-3389
FU National Research Council of Argentina (CONICET)Consejo Nacional de
   Investigaciones Cientificas y Tecnicas (CONICET); Agencia Nacional de
   Promocion Cientifica y Tecnologica, ArgentinaANPCyT [ANPCyT Prestamo BID
   2014-1424]
FX This work has been supported by grants from the National Research
   Council of Argentina (CONICET 2015-2017), and Agencia Nacional de
   Promocion Cientifica y Tecnologica, Argentina (ANPCyT Prestamo BID
   2014-1424, 2016-2019).
CR Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Burandt E, 2013, BREAST CANCER RES TR, V137, P745, DOI 10.1007/s10549-013-2406-4
   Chen JF, 2016, ONCOTARGET, V7, P41540, DOI 10.18632/oncotarget.9236
   Chen Q, 2012, HEPATOLOGY, V55, P1820, DOI 10.1002/hep.25549
   Colo GP, 2008, ONCOGENE, V27, P2430, DOI 10.1038/sj.onc.1210900
   Colo GP, 2007, FEBS LETT, V581, P5075, DOI 10.1016/j.febslet.2007.09.052
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Fereshteh MP, 2008, CANCER RES, V68, P3697, DOI 10.1158/0008-5472.CAN-07-6702
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Larrosa PNF, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.218
   Larrosa PNF, 2012, CANCER SCI, V103, P2064, DOI 10.1111/cas.12019
   Franco D, 2002, CELL DEATH DIFFER, V9, P1090, DOI 10.1038/sj.cdd.4401074
   Galluzzi L, 2015, CANCER CELL, V28, P690, DOI 10.1016/j.ccell.2015.10.012
   Guan XY, 2000, CANCER GENET CYTOGEN, V123, P27, DOI 10.1016/S0165-4608(00)00306-X
   Guo JY, 2013, CELL, V155, P1216, DOI 10.1016/j.cell.2013.11.019
   He LR, 2009, CANCER SCI, V100, P1591, DOI 10.1111/j.1349-7006.2009.01224.x
   Hegde Sanjay R, 2008, Expert Rev Gastroenterol Hepatol, V2, P135, DOI 10.1586/17474124.2.1.135
   Kashani-Sabet M, 2009, CLIN CANCER RES, V15, P6987, DOI 10.1158/1078-0432.CCR-09-1777
   Ko CW, 2005, GASTROENTEROLOGY, V129, P1163, DOI 10.1053/j.gastro.2005.07.027
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kuang SQ, 2004, CANCER RES, V64, P1875, DOI 10.1158/0008-5472.CAN-03-3745
   Lech G, 2016, WORLD J GASTROENTERO, V22, P1745, DOI 10.3748/wjg.v22.i5.1745
   Li Z, 2012, WORLD J GASTROENTERO, V18, P855, DOI 10.3748/wjg.v18.i8.855
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Loo JM, 2015, CELL, V160, P393, DOI 10.1016/j.cell.2014.12.018
   Louie MC, 2004, MOL CELL BIOL, V24, P5157, DOI 10.1128/MCB.24.12.5157-5171.2004
   Ma Y, 2013, IMMUNITY, V38, P729, DOI 10.1016/j.immuni.2013.03.003
   Man SM, 2015, CELL, V162, P45, DOI 10.1016/j.cell.2015.06.001
   Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588
   Martins I, 2014, CELL DEATH DIFFER, V21, P79, DOI 10.1038/cdd.2013.75
   Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347
   Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704
   MOERTEL CG, 1994, NEW ENGL J MED, V330, P1136
   Morselli E, 2009, BBA-MOL CELL RES, V1793, P1524, DOI 10.1016/j.bbamcr.2009.01.006
   Rao S, 2014, AUTOPHAGY, V10, P529, DOI 10.4161/auto.27643
   Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.3.CO;2-Y
   Rubio MF, 2012, BBA-MOL CELL RES, V1823, P1119, DOI 10.1016/j.bbamcr.2012.01.009
   Tanner MM, 2000, CLIN CANCER RES, V6, P1833
   Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058
   Tsuji S, 2012, BRIT J CANCER, V106, P126, DOI 10.1038/bjc.2011.505
   Walter LC, 2001, JAMA-J AM MED ASSOC, V285, P2750, DOI 10.1001/jama.285.21.2750
   Werbajh S, 2000, FEBS LETT, V485, P195, DOI 10.1016/S0014-5793(00)02223-7
   Wiener Z, 2014, CELL REP, V8, P1943, DOI 10.1016/j.celrep.2014.08.034
   Wilson Joanne A P, 2010, Trans Am Clin Climatol Assoc, V121, P94
   Xie D, 2005, HUM PATHOL, V36, P777, DOI 10.1016/j.humpath.2005.05.007
   Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695
   Xu Y, 2010, ONCOGENE, V29, P3386, DOI 10.1038/onc.2010.90
   Yan J, 2006, CANCER RES, V66, P11039, DOI 10.1158/0008-5472.CAN-06-2442
   Yang SH, 2011, AUTOPHAGY, V7, P912, DOI 10.4161/auto.7.8.15762
   Zhou HJ, 2005, CANCER RES, V65, P7976, DOI 10.1158/0008-5472.CAN-04-4076
   Zhu YS, 2010, PROTEIN CELL, V1, P468, DOI 10.1007/s13238-010-0048-4
NR 52
TC 9
Z9 9
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1475-2867
J9 CANCER CELL INT
JI Cancer Cell Int.
PD NOV 28
PY 2017
VL 17
AR 111
DI 10.1186/s12935-017-0483-x
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FO4FW
UT WOS:000416798100002
PM 29209153
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Kim, SW
   Moon, JH
   Park, SY
AF Kim, Sung-Wook
   Moon, Ji-Hong
   Park, Sang-Youel
TI Activation of autophagic flux by epigallocatechin gallate mitigates
   TRAIL-induced tumor cell apoptosis via down-regulation of death
   receptors
SO ONCOTARGET
LA English
DT Article
DE EGCG; autophagy; TRAIL; death receptor
ID MEDIATED AUTOPHAGY; EPITHELIAL-CELLS; PROSTATE-CANCER; COLON-CANCER;
   SURVIVAL; PROTEIN; LIGAND; APO2L/TRAIL; COMBINATION; DEPRIVATION
AB Epigallocatechin gallate (EGCG) is a major polyphenol in green tea. Recent studies have reported that EGCG can inhibit TRAIL-induced apoptosis and activate autophagic flux in cancer cells. However, the mechanism behind these processes is unclear. The present study found that EGCG prevents tumor cell death by antagonizing the TRAIL pathway and activating autophagy flux. Our results indicate that EGCG dose-dependently inhibits TRAIL-induced apoptosis and decreases the binding of death receptor 4 and 5 (DR4 and 5) to TRAIL. In addition, EGCG activates autophagy flux, which is involved in the inhibition of TRAIL cell death. We confirmed that the protective effect of EGCG can be reversed using genetic and pharmacological tools through re-sensitization to TRAIL. The inhibition of autophagy flux affects not only the re-sensitization of tumor cells to TRAIL, but also the restoration of death receptor proteins. This study demonstrates that EGCG inhibits TRAIL-induced apoptosis through the manipulation of autophagic flux and subsequent decrease in number of death receptors. On the basis of these results, we suggest further consideration of the use of autophagy activators such as EGCG in combination anti-tumor therapy with TRAIL.
C1 [Kim, Sung-Wook; Moon, Ji-Hong; Park, Sang-Youel] Chonbuk Natl Univ, Coll Vet Med, Dept Vet Med, Biosafety Res Inst, Iksan 54596, Jeonbuk, South Korea.
RP Park, SY (corresponding author), Chonbuk Natl Univ, Coll Vet Med, Dept Vet Med, Biosafety Res Inst, Iksan 54596, Jeonbuk, South Korea.
EM sypark@chonbuk.ac.kr
RI Park, Sang-Youel/D-5966-2012
OI Park, Sang-Youel/0000-0003-0575-6045
FU National Research Foundation of Korea (NRF) - Korean government (MISP)
   [2016R1A2B2009293]
FX This study was supported by a grant from the National Research
   Foundation of Korea (NRF) funded by the Korean government (MISP)
   (2016R1A2B2009293).
CR Abdulghani J, 2010, EXPERT OPIN THER TAR, V14, P1091, DOI 10.1517/14728222.2010.519701
   Aubert S, 1996, J CELL BIOL, V133, P1251, DOI 10.1083/jcb.133.6.1251
   Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736
   Chhipa RR, 2011, CELL SIGNAL, V23, P1466, DOI 10.1016/j.cellsig.2011.04.008
   Hellwig CT, 2012, MOL CANCER THER, V11, P3, DOI 10.1158/1535-7163.MCT-11-0434
   Herrero-Martin G, 2009, EMBO J, V28, P677, DOI 10.1038/emboj.2009.8
   Huang W.J., 2013, PHARM BIOL, V1, P1, DOI DOI 10.3390/BI0M3030408
   Hughes MA, 2009, MOL CELL, V35, P265, DOI 10.1016/j.molcel.2009.06.012
   Itakura E, 2011, J CELL BIOL, V192, P17, DOI 10.1083/jcb.201009067
   Jeong JK, 2011, INT J MOL MED, V27, P689, DOI 10.3892/ijmm.2011.626
   Jin ZY, 2009, CELL, V137, P721, DOI 10.1016/j.cell.2009.03.015
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Katiyar SK, 2001, CARCINOGENESIS, V22, P287, DOI 10.1093/carcin/22.2.287
   Katiyar SK, 2001, INT J ONCOL, V18, P1307
   Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Kourtis N, 2009, CELL DEATH DIFFER, V16, P21, DOI 10.1038/cdd.2008.120
   Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Lee JH, 2015, ONCOTARGET, V6, P9701, DOI 10.18632/oncotarget.3832
   Leong S, 2009, J CLIN ONCOL, V27, P4413, DOI 10.1200/JCO.2008.21.7422
   Li CP, 2013, BIOCHEM BIOPH RES CO, V438, P739, DOI 10.1016/j.bbrc.2013.07.097
   Li H, 2014, NEUROSCI BULL, V30, P67, DOI 10.1007/s12264-013-1394-z
   Manohar M, 2013, J NUTR BIOCHEM, V24, P940, DOI 10.1016/j.jnutbio.2012.06.013
   Mora R, 2009, GLIA, V57, P561, DOI 10.1002/glia.20785
   Nakatogawa H, 2007, CELL, V130, P165, DOI 10.1016/j.cell.2007.05.021
   NODA T, 1995, BIOCHEM BIOPH RES CO, V210, P126, DOI 10.1006/bbrc.1995.1636
   Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815
   Petersen A, 2001, HUM MOL GENET, V10, P1243, DOI 10.1093/hmg/10.12.1243
   REUNANEN H, 1985, HISTOCHEMISTRY, V83, P513, DOI 10.1007/BF00492453
   Salim T, 2013, INT J CANCER, V133, P807, DOI 10.1002/ijc.28074
   Selimi F, 2003, NEURON, V37, P813, DOI 10.1016/S0896-6273(03)00093-X
   Seo JS, 2010, J NEUROCHEM, V112, P715, DOI 10.1111/j.1471-4159.2009.06496.x
   Sharma C, 2012, ASIAN PAC J CANCER P, V13, P4815, DOI 10.7314/APJCP.2012.13.9.4815
   Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818
   Singh K, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-70
   Stegehuis JH, 2010, DRUG RESIST UPDATE, V13, P2, DOI 10.1016/j.drup.2009.11.001
   van Geelen CM, 2006, J CLIN ONCOL, V24, P4998, DOI 10.1200/JCO.2006.06.8809
   Voelkel-Johnson C, 2005, MOL CANCER THER, V4, P1320, DOI 10.1158/1535-7163.MCT-05-0086
   Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627
   Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517
   Wu Zhaoju, 2010, Genes Cancer, V1, P40, DOI 10.1177/1947601909358324
   Xie ZP, 2008, MOL BIOL CELL, V19, P3290, DOI 10.1091/mbc.E07-12-1292
   Yamagata K, 2015, PHYTOMEDICINE, V22, P431, DOI 10.1016/j.phymed.2015.01.011
NR 44
TC 14
Z9 15
U1 0
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 4
PY 2016
VL 7
IS 40
BP 65660
EP 65668
DI 10.18632/oncotarget.11597
PG 9
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EB3QQ
UT WOS:000387281000086
PM 27582540
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Pellerito, O
   Notaro, A
   Sabella, S
   De Blasio, A
   Vento, R
   Calvaruso, G
   Giuliano, M
AF Pellerito, Ornella
   Notaro, Antonietta
   Sabella, Selenia
   De Blasio, Anna
   Vento, Renza
   Calvaruso, Giuseppe
   Giuliano, Michela
TI WIN induces apoptotic cell death in human colon cancer cells through a
   block of autophagic flux dependent on PPAR gamma down-regulation
SO APOPTOSIS
LA English
DT Article
DE Cannabinoids; PPAR gamma; ER stress; Autophagy/apoptosis interplay;
   Colon carcinoma cells
ID ENDOPLASMIC-RETICULUM STRESS; ER STRESS; CANNABINOID RECEPTORS;
   STIMULATION; NUCLEAR; ADIPOGENESIS; ACTIVATION; INHIBITOR; PROSTATE;
   THERAPY
AB Cannabinoids have been reported to possess anti-tumorigenic activity in cancer models although their mechanism of action is not well understood. Here, we show that the synthetic cannabinoid WIN55,212-2 (WIN)-induced apoptosis in colon cancer cell lines is accompanied by endoplasmic reticulum stress induction. The formation of acidic vacuoles and the increase in LC3-II protein indicated the involvement of autophagic process which seemed to play a pro-survival role against the cytotoxic effects of the drug. However, the enhanced lysosomal membrane permeabilization (LMP) blocked the autophagic flux after the formation of autophagosomes as demonstrated by the accumulation of p62 and LC3, two markers of autophagic degradation. Data also provided evidence for a role for nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR gamma) in cannabinoid signalling. PPAR gamma expression, at both protein and mRNA levels, was significantly down-regulated after WIN treatment and its inhibition, either by specific antagonists or by down-regulation via gene silencing, induced effects on cell viability as well as on ER stress and autophagic markers similar to those obtained in the presence of WIN. Moreover, the observation that the increase in p62 level and the induction of LMP were also modified by PPAR gamma antagonists seemed to indicate that PPAR gamma down-regulation was crucial to determinate the block of autophagic flux, thus confirming the critical role of PPAR gamma in WIN action. In conclusion, at our knowledge, our results are the first to show that the reduction of PPAR gamma levels contributes to WIN-induced colon carcinoma cell death by blocking the pro-survival autophagic response of cells.
C1 [Pellerito, Ornella] Univ Laval, Fac Med, Lab Cellular & Dev Genet, Dept Mol Biol Med Biochem & Pathol,PROTEO, Quebec City, PQ G1K 7P4, Canada.
   [Pellerito, Ornella] Univ Laval, IBIS, Quebec City, PQ, Canada.
   [Notaro, Antonietta; Sabella, Selenia; De Blasio, Anna; Vento, Renza; Calvaruso, Giuseppe; Giuliano, Michela] Univ Palermo, Policlin Univ, Dipartimento STEBICEF Sci & Tecnol Biol Chim & Fa, Lab Biochim, I-90127 Palermo, Italy.
RP Giuliano, M (corresponding author), Univ Palermo, Policlin Univ, Dipartimento STEBICEF Sci & Tecnol Biol Chim & Fa, Lab Biochim, Via Vespro 129, I-90127 Palermo, Italy.
EM michela.giuliano@unipa.it
OI Notaro, Antonietta/0000-0002-9822-0823
FU University of Palermo [ORPA07EZ5Z, ORPA06F3TB]
FX This work was supported by University of Palermo [Grant ORPA07EZ5Z and
   ORPA06F3TB].
CR Adiseshaiah PP, 2013, CANCER LETT, V337, P254, DOI 10.1016/j.canlet.2013.04.034
   Antunes F, 2001, BIOCHEM J, V356, P549, DOI 10.1042/0264-6021:3560549
   BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3
   Calvaruso G, 2007, ONCOL REP, V18, P447
   Carnero A, 2010, CURR PHARM DESIGN, V16, P34, DOI 10.2174/138161210789941865
   Dainese E, 2007, CURR MED CHEM, V14, P2702, DOI 10.2174/092986707782023235
   Di Marzo V, 2006, ANNU REV MED, V57, P553, DOI 10.1146/annurev.med.57.011205.135648
   Drago-Ferrante R, 2008, INT J ONCOL, V33, P677, DOI 10.3892/ijo_00000053
   Fu MG, 2003, BIOCHEM J, V370, P1019, DOI 10.1042/BJ20021503
   Giuliano M, 2009, BIOCHIMIE, V91, P457, DOI 10.1016/j.biochi.2008.11.003
   Guzman M, 2002, PHARMACOL THERAPEUT, V95, P175, DOI 10.1016/S0163-7258(02)00256-5
   Guzman M, 2003, NAT REV CANCER, V3, P745, DOI 10.1038/nrc1188
   Han SW, 2008, PPAR RES, V2008, DOI 10.1155/2008/254108
   He CQ, 2008, MOL CELL BIOCHEM, V308, P247, DOI 10.1007/s11010-007-9632-1
   HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991
   Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161
   Huang Y, 2010, CELL PROLIFERAT, V43, P147, DOI 10.1111/j.1365-2184.2009.00661.x
   Kang JH, 2012, J BIOL CHEM, V287, P15661, DOI 10.1074/jbc.M112.358473
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Kota BP, 2005, PHARMACOL RES, V51, P85, DOI 10.1016/j.phrs.2004.07.012
   Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984
   Lee JJ, 2012, ONCOGENE, V31, P3818, DOI 10.1038/onc.2011.543
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   O'Sullivan SE, 2007, BRIT J PHARMACOL, V152, P576, DOI 10.1038/sj.bjp.0707423
   Oamri Z, 2009, MOL CANCER THER, V8, P117
   Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596
   Park SH, 2010, J BIOL CHEM, V285, P35330, DOI 10.1074/jbc.M110.136259
   Pellerito O, 2010, MOL PHARMACOL, V77, P854, DOI 10.1124/mol.109.062257
   Rubino S, 2009, EUR J MED CHEM, V44, P1041, DOI 10.1016/j.ejmech.2008.06.023
   Salazar M, 2013, BBA-MOL CELL BIOL L, V1831, P1573, DOI 10.1016/j.bbalip.2013.03.014
   Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948
   Sarfaraz S, 2005, CANCER RES, V65, P1635, DOI 10.1158/0008-5472.CAN-04-3410
   Sarker KP, 2003, J NEUROCHEM, V85, P50, DOI 10.1046/j.1471-4159.2003.01663.x
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507
   Sreevalsan S, 2011, ANTICANCER RES, V31, P3799
   TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X
   Tsukahara T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058749
   van der Stelt M, 2005, NEUROMOL MED, V7, P37, DOI 10.1385/NMM:7:1-2:037
   Vara D, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.141
   Vara D, 2011, CELL DEATH DIFFER, V18, P1099, DOI 10.1038/cdd.2011.32
   Velasco G, 2004, NEUROPHARMACOLOGY, V47, P315, DOI 10.1016/j.neuropharm.2004.04.016
   Yang FG, 2005, ACTA PHARMACOL SIN, V26, P753, DOI 10.1111/j.1745-7254.2005.00753.x
   Yorimitsu T, 2007, AUTOPHAGY, V3, P160, DOI 10.4161/auto.3653
   Yorimitsu T, 2006, J BIOL CHEM, V281, P30299, DOI 10.1074/jbc.M607007200
   ZDOLSEK JM, 1990, PHOTOCHEM PHOTOBIOL, V51, P67, DOI 10.1111/j.1751-1097.1990.tb01685.x
NR 46
TC 38
Z9 40
U1 0
U2 13
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1360-8185
EI 1573-675X
J9 APOPTOSIS
JI Apoptosis
PD JUN
PY 2014
VL 19
IS 6
BP 1029
EP 1042
DI 10.1007/s10495-014-0985-0
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA AF5GQ
UT WOS:000334742400011
PM 24696378
DA 2022-04-25
ER

PT J
AU Katona, BW
   Hojnacki, T
   Glynn, RA
   Paulosky, KE
   Szigety, KM
   Cao, Y
   Zhang, XY
   Feng, ZJ
   He, X
   Ma, J
   Hua, XX
AF Katona, Bryson W.
   Hojnacki, Taylor
   Glynn, Rebecca A.
   Paulosky, Kayla E.
   Szigety, Katherine M.
   Cao, Yan
   Zhang, Xuyao
   Feng, Zijie
   He, Xin
   Ma, Jian
   Hua, Xianxin
TI Menin-mediated Repression of Glycolysis in Combination with Autophagy
   Protects Colon Cancer Against Small-molecule EGFR Inhibitors
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID TYROSINE KINASE INHIBITOR; MLL INTERACTION; RAS MUTATIONS; PHASE-II;
   GEFITINIB; RECEPTOR; GROWTH; TARGETS; TRIAL; CHEMOTHERAPY
AB Menin serves both tumor suppressor and promoter roles in a highly tumor-specific manner. In colorectal cancer, menin is over-expressed and plays a critical role in regulating transcription of SKP2, and combined treatment with a menin inhibitor and smallmolecule EGFR inhibitor (EGFRi) leads to synergistic killing of colorectal cancer cells. However, the full spectrum of menin function in colorectal cancer remains uncertain. Herein, we demonstrate that menin inhibition increases glycolysis in colorectal cancer cells. This menin inhibitor-induced increase in glycolysis occurs in an mTOR-independent manner and enhances the sensitivity of colorectal cancer cells to EGFRis. In addition, we show that EGFRis induce autophagy in colorectal cancer cells, which is important for cell survival in the setting of combined treatment with an EGFRi and menin inhibitor. Inhibition of autophagy with chloroquine further sensitizes colorectal cancers to treatment with the combination of an EGFRi and menin inhibitor. Together, these findings uncover a novel role for menin in colorectal cancer as a repressor of glycolysis and demonstrate that menin inhibitor-induced increases in glycolysis sensitize colorectal cancer cells to EGFRis. In addition, these findings illustrate the importance of autophagy as a protective mechanism against EGFRis, especially in the presence of menin inhibition. Ultimately, these data open the possibility of using menin-mediated regulation of glycolysis to potentially improve treatment modalities for colorectal cancer.
C1 [Katona, Bryson W.] Univ Penn, Perelman Sch Med, Div Gastroenterol, Philadelphia, PA 19104 USA.
   [Katona, Bryson W.; Hojnacki, Taylor; Glynn, Rebecca A.; Paulosky, Kayla E.; Szigety, Katherine M.; Cao, Yan; Zhang, Xuyao; Feng, Zijie; He, Xin; Ma, Jian; Hua, Xianxin] Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, Perelman Sch Med, 421 Curie Blvd,412 BRB 2-3, Philadelphia, PA 19104 USA.
RP Katona, BW; Hua, XX (corresponding author), Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, Perelman Sch Med, 421 Curie Blvd,412 BRB 2-3, Philadelphia, PA 19104 USA.; Katona, BW (corresponding author), Univ Penn, Perelman Sch Med, 3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA.; Katona, BW; Hua, XX (corresponding author), Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.
EM Bryson.Katona@pennmedicine.upenn.edu; huax@pennmedicine.upenn.edu
OI Paulosky, Kayla/0000-0001-9741-2228; Katona, Bryson/0000-0001-8186-9119;
   Feng, Zijie/0000-0002-5633-3686; He, Xin/0000-0002-2131-2092; Zhang,
   Xuyao/0000-0003-1654-5550
FU NIH/NIDDKUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [K08DK106489, R03DK120946];
   NIH/NCIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R01NCI563378]; Institute for Translational Medicine and Therapeutics
   [ITMAT014001]; NIH/NIDDKCenter for Molecular Studies in Digestive and
   Liver Diseases at the University of Pennsylvania [P30DK050306]
FX We would like to thank Dr. Anthony Mancuso at the University of
   Pennsylvania Laboratory for Quantitative Metabolomics for his assistance
   with the metabolism experiments. We would like to acknowledge the
   following support: NIH/NIDDK K08DK106489 (to B.W. Katona) and
   R03DK120946 (to B.W. Katona), NIH/NCI R01NCI563378 (to X. Hua), the
   Institute for Translational Medicine and Therapeutics (ITMAT014001, to
   X. Hua), and the NIH/NIDDKCenter for Molecular Studies in Digestive and
   Liver Diseases at the University of Pennsylvania (P30DK050306) including
   its pilot grant funding (to B.W. Katona) and its core facilities
   (molecular pathology and imaging, and cell culture).
CR American Cancer Society, 2019, CANC FACTS FIG 2015
   Baselga J, 2002, J CLIN ONCOL, V20, P4292, DOI 10.1200/JCO.2002.03.100
   Borkin D, 2015, CANCER CELL, V27, P589, DOI 10.1016/j.ccell.2015.02.016
   Brehmer D, 2005, CANCER RES, V65, P379
   Burrows F, 2018, P AACR NCI EORTC INT
   Cheng SC, 2014, SCIENCE, V345, P1579, DOI 10.1126/science.1250684
   Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Feng ZJ, 2017, ENDOCR-RELAT CANCER, V24, pT147, DOI 10.1530/ERC-17-0298
   Henson E, 2017, CANCERS, V9, DOI 10.3390/cancers9040027
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Katona Bryson W, 2019, Oncoscience, V6, P368, DOI 10.18632/oncoscience.485
   Katona BW, 2019, CANCER RES, V79, P2195, DOI 10.1158/0008-5472.CAN-18-2133
   Katona BW, 2014, CANCER BIOL THER, V15, P1677, DOI 10.4161/15384047.2014.972776
   Kindler HL, 2005, AM J CLIN ONCOL-CANC, V28, P340, DOI 10.1097/01.coc.0000159558.19631.d5
   Li JWY, 2018, MOL CELL ENDOCRINOL, V469, P98, DOI 10.1016/j.mce.2017.09.032
   Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037
   Luengo A, 2017, CELL CHEM BIOL, V24, P1161, DOI 10.1016/j.chembiol.2017.08.028
   MacKenzie MJ, 2005, INVEST NEW DRUG, V23, P165, DOI 10.1007/s10637-005-5862-9
   Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530
   Malik R, 2015, NAT MED, V21, P344, DOI 10.1038/nm.3830
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   McKillop D, 2005, MOL CANCER THER, V4, P641, DOI 10.1158/1535-7163.MCT-04-0329
   Onorati AV, 2018, CANCER-AM CANCER SOC, V124, P3307, DOI 10.1002/cncr.31335
   Patel S, 2016, ONCOTARGET, V7, P59087, DOI 10.18632/oncotarget.10824
   Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005
   Shi AB, 2012, BLOOD, V120, P4461, DOI 10.1182/blood-2012-05-429274
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Suzuki J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05854-6
   Tan XJ, 2015, CELL, V160, P145, DOI 10.1016/j.cell.2014.12.006
   Teng QX, 2019, DRUG DISCOV TODAY, V24, P2086, DOI 10.1016/j.drudis.2019.05.030
   Townsley CA, 2006, BRIT J CANCER, V94, P1136, DOI 10.1038/sj.bjc.6603055
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   Verma N, 2016, SCI REP-UK, V6, DOI 10.1038/srep33949
   Wei YJ, 2013, CELL, V154, P1269, DOI 10.1016/j.cell.2013.08.015
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Yamamoto N, 2011, MOL PHARMACOL, V80, P466, DOI 10.1124/mol.110.070862
   Yang YP, 2013, ACTA PHARMACOL SIN, V34, P625, DOI 10.1038/aps.2013.5
   Yu L, 2016, ONCOTARGET, V7, P38908, DOI 10.18632/oncotarget.7676
NR 41
TC 0
Z9 0
U1 4
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD NOV 1
PY 2020
VL 19
IS 11
BP 2319
EP 2329
DI 10.1158/1535-7163.MCT-20-0101
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA OP2KR
UT WOS:000587913900009
PM 32879052
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Zheng, C
   Zhang, Y
   Mao, W
   Li, Q
AF Zheng, Chao
   Zhang, Yu
   Mao, Wei
   Li, Qing
TI Increasing colorectal cancer cell sensitivity to oxaliplatin through
   hyperthermia and chloroquine treatment
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Colorectal cancer; hyperthermia; oxaliplatin; chloroquine; apoptosis;
   autophagy
ID COLON-CANCER; IN-VIVO; APOPTOSIS; DEATH; INHIBITOR; GLIOBLASTOMA;
   COMBINATION; AUTOPHAGY; REVEALS; MODEL
AB Colorectal cancer is the third most lethal form of cancer worldwide, with most patients dying of liver metastases. Patients with metastatic livers can be treated with hyperthermia therapy, which often uses IHP (Isolated Hepatic Perfusion). Hyperthermia has become as a highly anticipated method. Using traditional hyperthermia alone is unable to inhibit tumor cell proliferation. Tumor can be inhibited effectively by combining oxaliplatin with a 42 degrees C hot water bath. However, this combination has been shown to induce autophagy in colorectal cancer cell lines, which inhibits tumor cell death to some extent. In order to combat this problem, we used oxaliplatin in combination with autophagy inhibitor chloroquine (CQ) at 42 degrees C. We found that oxaliplatin combined with CQ at 42 degrees C induces caspase-dependent apoptosis in colorectal cancer cells. This treatment not only impacts BCL-2 family proteins, but also downregulates the HSP and IAP family proteins. Activated caspase and PRAP (poly ADP-ribose polymerase) proteins are all upregulated. The results are suggesting that oxaliplatin combined with CQ at 42 degrees C is a novel anti-tumor approach against colorectal cancer.
C1 [Zheng, Chao; Zhang, Yu; Mao, Wei; Li, Qing] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, 54 Youdian Rd, Hangzhou 310006, Zhejiang, Peoples R China.
RP Li, Q (corresponding author), Zhejiang Chinese Med Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, 54 Youdian Rd, Hangzhou 310006, Zhejiang, Peoples R China.
EM zyn515@126.com
CR Chen F, 2008, CELL BIOL INT, V32, P715, DOI 10.1016/j.cellbi.2008.02.010
   Chen HC, 2015, NAT CELL BIOL, V17, P1270, DOI 10.1038/ncb3236
   Fulda S, 2012, NAT REV DRUG DISCOV, V11, P109, DOI 10.1038/nrd3627
   Garcia S, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/837250
   Gorman AM, 2005, BIOCHEM BIOPH RES CO, V327, P801, DOI 10.1016/j.bbrc.2004.12.066
   Hui KKW, 2011, CELL DEATH DIFFER, V18, P1780, DOI 10.1038/cdd.2011.50
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131
   Karpel-Massler G, 2015, ONCOTARGET, V6, P36456, DOI 10.18632/oncotarget.5505
   Liang XL, 2014, MOL MED REP, V10, P719, DOI 10.3892/mmr.2014.2234
   Liu MY, 2015, INT J MOL MED, V36, P975, DOI 10.3892/ijmm.2015.2328
   Milan E, 2015, AUTOPHAGY, V11, P1161, DOI 10.1080/15548627.2015.1052928
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Pham PA, 2015, PLANT MOL BIOL, V89, P319, DOI 10.1007/s11103-015-0363-5
   Raemy E, 2014, CHEM PHYS LIPIDS, V179, P70, DOI 10.1016/j.chemphyslip.2013.12.002
   Rahmani M, 2015, HAEMATOLOGICA, V100, P1553, DOI 10.3324/haematol.2015.130351
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Song XX, 2012, MOL CANCER RES, V10, P1567, DOI 10.1158/1541-7786.MCR-12-0209-T
   Stankiewicz AR, 2005, J BIOL CHEM, V280, P38729, DOI 10.1074/jbc.M509497200
   Yang DH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097352
   Yang WS, 2014, CELL CYCLE, V13, P992, DOI 10.4161/cc.27880
   Zhang Shou-De, 2015, Chin J Nat Med, V13, P660, DOI 10.1016/S1875-5364(15)30063-7
   Zmuda F, 2015, J MED CHEM, V58, P8683, DOI 10.1021/acs.jmedchem.5b01324
NR 23
TC 0
Z9 0
U1 1
U2 6
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2016
VL 9
IS 2
BP 496
EP 508
PG 13
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA DG1EU
UT WOS:000371809200007
DA 2022-04-25
ER

PT J
AU Hou, N
   Han, J
   Li, J
   Liu, YX
   Qin, YN
   Ni, L
   Song, TS
   Huang, C
AF Hou, Ni
   Han, Jia
   Li, Jie
   Liu, Yingxun
   Qin, Yannan
   Ni, Lei
   Song, Tusheng
   Huang, Chen
TI MicroRNA Profiling in Human Colon Cancer Cells during
   5-Fluorouracil-Induced Autophagy
SO PLOS ONE
LA English
DT Article
ID PREDICTION; MECHANISMS; PROTEINS; TARGET
AB Autophagy modulation is now recognized as a potential therapeutic approach for cancer (including colorectal cancer), yet the molecular mechanisms regulating autophagy in response to cellular stress are still not well understood. MicroRNAs (miRNAs) have been found to play important roles in controlling many cellular functions, including growth, metabolism and stress response. The physiological importance of the miRNA-autophagy interconnection is only beginning to be elucidated. MiRNA microarray technology facilitates analysis of global miRNA expression in certain situations. In this study, we explored the expression profile of miRNAs during the response of human colon cancer cells (HT29s) to 5-FU treatment and nutrient starvation using miRNA microarray analysis. The alteration of miRNA expression showed the same pattern under both conditions was further testified by qRT-PCR in three human colon cancer cell lines. In addition, bioinformatic prediction of target genes, pathway analysis and gene network analysis were performed to better understand the roles of these miRNAs in the regulation of autophagy. We identified and selected four downregulated miRNAs including hsa-miR-302a-3p and 27 upregulated miRNAs under these two conditions as having the potential to target genes involved in the regulation of autophagy in human colon cancer cells. They have the potential to modulate autophagy in 5-FU-based chemotherapy in colorectal cancer.
C1 [Hou, Ni; Han, Jia; Liu, Yingxun; Qin, Yannan; Ni, Lei; Song, Tusheng; Huang, Chen] Xi An Jiao Tong Univ, Dept Genet & Mol Biol, Sch Med, Xian 710049, Peoples R China.
   [Li, Jie] Xi An Jiao Tong Univ, Affiliated Hosp 2, Sch Med, Dept Gen Surg, Xian 710049, Peoples R China.
   [Huang, Chen] Xi An Jiao Tong Univ, Key Lab Environm & Genes Related Dis, Sch Med, Xian 710049, Peoples R China.
   [Huang, Chen] Xi An Jiao Tong Univ, Cardiovasc Res Ctr, Sch Med, Xian 710049, Peoples R China.
RP Huang, C (corresponding author), Xi An Jiao Tong Univ, Dept Genet & Mol Biol, Sch Med, Xian 710049, Peoples R China.
EM hchen@mail.xjtu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31100969, 81172358]; Scientific Research
   Foundation for the Returned Overseas Chinese Scholars, State Education
   MinistryScientific Research Foundation for the Returned Overseas Chinese
   Scholars [2013-09]
FX This work was supported by grants from the National Natural Science
   Foundation of China (grant No. 31100969) and the Scientific Research
   Foundation for the Returned Overseas Chinese Scholars, State Education
   Ministry (2013-09) to Dr. Hou. It was also supported by a grant from the
   National Natural Science Foundation of China (grant No. 81172358) to Dr.
   Li. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Babar IA, 2008, FUTURE ONCOL, V4, P289, DOI 10.2217/14796694.4.2.289
   Chen KL, 2012, CANCER LETT, V317, P89, DOI 10.1016/j.canlet.2011.11.015
   Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003
   Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014
   Frankel LB, 2011, EMBO J, V30, P4628, DOI 10.1038/emboj.2011.331
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   HE L, 2004, NAT REV GENET, V5, P522
   Jegga AG, 2011, AUTOPHAGY, V7, P477, DOI 10.4161/auto.7.5.14811
   Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536
   Kubota C, 2010, J BIOL CHEM, V285, P667, DOI 10.1074/jbc.M109.053058
   Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06
   Kutmon M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082160
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Lorin S, 2013, SEMIN CANCER BIOL, V23, P361, DOI 10.1016/j.semcancer.2013.06.007
   Marsit CJ, 2006, CANCER RES, V66, P10843, DOI 10.1158/0008-5472.CAN-06-1894
   Meschini S, 2011, CURR CANCER DRUG TAR, V11, P357, DOI 10.2174/156800911794519707
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   O'Connell MJ, 2009, J CLIN ONCOL, V27, P3082, DOI 10.1200/JCO.2009.22.2919
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Perez-Rivas LG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091884
   Sethupathy P, 2006, NAT METHODS, V3, P881, DOI 10.1038/NMETH954
   Vlachos IS, 2012, NUCLEIC ACIDS RES, V40, pW498, DOI 10.1093/nar/gks494
   Wang XW, 2008, BIOINFORMATICS, V24, P325, DOI 10.1093/bioinformatics/btm595
   Yin JQ, 2008, TRENDS BIOTECHNOL, V26, P70, DOI 10.1016/j.tibtech.2007.11.007
   Yu Y, 2012, LEUKEMIA, V26, P1752, DOI 10.1038/leu.2012.65
   Zhai HY, 2013, CELL CYCLE, V12, P246, DOI 10.4161/cc.23273
   Zou ZY, 2012, J BIOL CHEM, V287, P4148, DOI 10.1074/jbc.M111.307405
NR 30
TC 18
Z9 18
U1 1
U2 40
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 19
PY 2014
VL 9
IS 12
AR e114779
DI 10.1371/journal.pone.0114779
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AX8WK
UT WOS:000347186200007
PM 25526515
OA gold, Green Submitted, Green Published
DA 2022-04-25
ER

PT J
AU Saleem, S
   Tariq, S
   Aleem, I
   Shaheed, SU
   Tahseen, M
   Atiq, A
   Hassan, S
   Abu Bakar, M
   Khattak, S
   Syed, AA
   Ahmad, AH
   Hussain, M
   Yusuf, MA
   Sutton, C
AF Saleem, Saira
   Tariq, Sahrish
   Aleem, Iffat
   Shaheed, Sadr-ul
   Tahseen, Muhammad
   Atiq, Aribah
   Hassan, Sadia
   Abu Bakar, Muhammad
   Khattak, Shahid
   Syed, Aamir Ali
   Ahmad, Asad Hayat
   Hussain, Mudassar
   Yusuf, Muhammed Aasim
   Sutton, Chris
TI Proteomics analysis of colon cancer progression
SO CLINICAL PROTEOMICS
LA English
DT Article
DE Colon cancer; iTRAQ proteomics; Orbitrap fusion; Biomarkers
ID COLORECTAL-CANCER; SERUM MATRIX-METALLOPROTEINASE-9; CELL-MIGRATION;
   CAVEOLIN-1; EXPRESSION; CARCINOMA; MECHANISMS; NEOPLASIA; CACHEXIA;
   PREDICTS
AB Background The aim of this pilot study was to identify proteins associated with advancement of colon cancer (CC). Methods A quantitative proteomics approach was used to determine the global changes in the proteome of primary colon cancer from patients with non-cancer normal colon (NC), non-adenomatous colon polyp (NAP), non-metastatic tumor (CC NM) and metastatic tumor (CC M) tissues, to identify up- and down-regulated proteins. Total protein was extracted from each biopsy, trypsin-digested, iTRAQ-labeled and the resulting peptides separated using strong cation exchange (SCX) and reverse-phase (RP) chromatography on-line to electrospray ionization mass spectrometry (ESI-MS). Results Database searching of the MS/MS data resulted in the identification of 2777 proteins which were clustered into groups associated with disease progression. Proteins which were changed in all disease stages including benign, and hence indicative of the earliest molecular perturbations, were strongly associated with spliceosomal activity, cell cycle division, and stromal and cytoskeleton disruption reflecting increased proliferation and expansion into the surrounding healthy tissue. Those proteins changed in cancer stages but not in benign, were linked to inflammation/immune response, loss of cell adhesion, mitochondrial function and autophagy, demonstrating early evidence of cells within the nutrient-poor solid mass either undergoing cell death or adjusting for survival. Caveolin-1, which decreased and Matrix metalloproteinase-9, which increased through the three disease stages compared to normal tissue, was selected to validate the proteomics results, but significant patient-to-patient variation obfuscated interpretation so corroborated the contradictory observations made by others. Conclusion Nevertheless, the study has provided significant insights into CC stage progression for further investigation.
C1 [Saleem, Saira; Tariq, Sahrish; Aleem, Iffat] Shaukat Khanum Mem Canc Hosp & Res Ctr, Bas Sci Res, 7-A Block R-3, Lahore 54000, Pakistan.
   [Shaheed, Sadr-ul; Sutton, Chris] Univ Bradford, Inst Canc Therapeut, Tumbling Hill St, Bradford BD7 1BD, W Yorkshire, England.
   [Tahseen, Muhammad; Atiq, Aribah; Ahmad, Asad Hayat; Hussain, Mudassar] Shaukat Khanum Mem Canc Hosp & Res Ctr, Dept Pathol, 7-A Block R-3, Lahore 54000, Pakistan.
   [Hassan, Sadia] Shaukat Khanum Mem Canc Hosp & Res Ctr, Clin Res Off, 7-A Block R-3, Lahore 54000, Pakistan.
   [Abu Bakar, Muhammad] Shaukat Khanum Mem Canc Hosp & Res Ctr, Canc Registry & Clin Data Management, 7-A Block R-3, Lahore 54000, Pakistan.
   [Khattak, Shahid; Syed, Aamir Ali] Shaukat Khanum Mem Canc Hosp & Res Ctr, Dept Surg Oncol, 7-A Block R-3, Lahore 54000, Pakistan.
   [Yusuf, Muhammed Aasim] Shaukat Khanum Mem Canc Hosp & Res Ctr, Dept Internal Med, 7-A Block R-3, Lahore 54000, Pakistan.
RP Saleem, S (corresponding author), Shaukat Khanum Mem Canc Hosp & Res Ctr, Bas Sci Res, 7-A Block R-3, Lahore 54000, Pakistan.
EM sairas@skm.org.pk
OI Aleem, Iffat/0000-0003-4824-2757
FU Shaukat Khanum Memorial Cancer hospital and Research Center, Pakistan;
   Yorkshire Cancer Research, UK
FX This work was supported by Shaukat Khanum Memorial Cancer hospital and
   Research Center, Pakistan Chris Sutton and Sadr ul Shaheed work is
   supported by Yorkshire Cancer Research, UK. They had no involvement in
   the study design and writing of article.
CR Akhtar F, 2007, ASIAN PAC J CANCER P, V8, P452
   Alvarez-Chaver P, 2014, WORLD J GASTROENTERO, V20, P3804, DOI 10.3748/wjg.v20.i14.3804
   Anwar N, 2008, ANN NY ACAD SCI, V1138, P199, DOI 10.1196/annals.1414.026
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Badar F, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011828
   Bender FC, 2000, CANCER RES, V60, P5870
   Bhurgri Y, 2000, INT J CANCER, V85, P325, DOI 10.1002/(SICI)1097-0215(20000201)85:3&lt;325::AID-IJC5&gt;3.0.CO;2-J
   Bhurgri Yasmin, 2006, J Pak Med Assoc, V56, P124
   Boudjadi S, 2016, ONCOGENE, V35, P1671, DOI 10.1038/onc.2015.231
   Bozzi F, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-016-0475-z
   CHARRASSE S, 1995, EUR J BIOCHEM, V234, P406, DOI 10.1111/j.1432-1033.1995.406_b.x
   Chevalier S, 2014, APPL PHYSIOL NUTR ME, V39, P643, DOI 10.1139/apnm-2013-0369
   Chu DK, 2012, ANN SURG ONCOL, V19, P318, DOI 10.1245/s10434-011-1686-3
   Cristobal A, 2017, CELL REP, V18, P263, DOI 10.1016/j.celrep.2016.12.016
   Deb M, 2016, GENE, V581, P75, DOI 10.1016/j.gene.2016.01.029
   Friedman DB, 2004, PROTEOMICS, V4, P793, DOI 10.1002/pmic.200300635
   Han F, 2010, J SURG RES, V159, P443, DOI 10.1016/j.jss.2009.03.079
   Hartl WH, 1998, ANN SURG, V227, P390, DOI 10.1097/00000658-199803000-00011
   Honeywell RJ, 2018, NUCLEOS NUCLEOT NUCL, V37, P696, DOI 10.1080/15257770.2018.1498516
   Hurst NG, 2007, BRIT J CANCER, V97, P971, DOI 10.1038/sj.bjc.6603958
   Inui A, 1999, CANCER RES, V59, P4493
   Jamal S, 2014, J PAK MED ASSOC, V64, P24
   Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6
   Khan Naveed Ali, 2015, Asian Pac J Cancer Prev, V16, P7967
   Kostova E, 2014, VOJNOSANIT PREGL, V71, P52, DOI 10.2298/VSP121221024K
   Kreutz D, 2017, CHEM-EUR J, V23, P1881, DOI 10.1002/chem.201604516
   Le Tourneau Christophe, 2007, Oncology (Williston Park), V21, P21
   Lian JY, 2015, ONCOTARGET, V6, P29357, DOI 10.18632/oncotarget.4982
   Liao F, 2010, MED ONCOL, V27, P1219, DOI 10.1007/s12032-009-9362-1
   Mancias JD, 2016, J MOL BIOL, V428, P1659, DOI 10.1016/j.jmb.2016.02.027
   Masoudi M, 2011, MOL BIOL REP, V38, P4309, DOI 10.1007/s11033-010-0555-7
   McMahon KM, 2012, J PROTEOME RES, V11, P2863, DOI 10.1021/pr2012472
   Messick CA, 2010, SURGERY, V147, P713, DOI 10.1016/j.surg.2009.10.056
   Mishra P, 2016, J CELL BIOL, V212, P379, DOI 10.1083/jcb.201511036
   Ng SC, 2013, BRIT MED BULL, V105, P29, DOI 10.1093/bmb/lds040
   Ngoka LCM, 2008, PROTEOME SCI, V6, DOI 10.1186/1477-5956-6-30
   Nohata N, 2011, INT J ONCOL, V38, P209, DOI 10.3892/ijo_00000840
   Nunez-Wehinger S, 2014, CURR MOL MED, V14, P255, DOI 10.2174/1566524014666140128112827
   Okayama A, 2007, ASIAN PAC J CANCER P, V8, P191
   Porporato PE, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.3
   Porporato PE, 2018, CELL RES, V28, P265, DOI 10.1038/cr.2017.155
   Quest AFG, 2013, CURR MOL MED, V13, P266
   Ramkumar K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13084
   Roy UKB, 2013, INT J CANCER, V133, P43, DOI 10.1002/ijc.28001
   Shatz M, 2008, INT J RADIAT BIOL, V84, P177, DOI 10.1080/09553000701745293
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   Vyas S, 2016, CELL, V166, P555, DOI 10.1016/j.cell.2016.07.002
   Wang JJ, 2012, ASIAN PAC J CANCER P, V13, P1663, DOI 10.7314/APJCP.2012.13.4.1663
   Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9
   Wilson S, 2012, BRIT J CANCER, V106, P1431, DOI 10.1038/bjc.2012.93
   Ye QR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103298
   Zhang B, 2014, NATURE, V513, P382, DOI 10.1038/nature13438
   Zhao Z, 2015, WORLD J GASTROENTERO, V21, P1140, DOI 10.3748/wjg.v21.i4.1140
NR 53
TC 5
Z9 5
U1 4
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1542-6416
EI 1559-0275
J9 CLIN PROTEOM
JI Clin. Proteom.
PD DEC 28
PY 2019
VL 16
IS 1
AR 44
DI 10.1186/s12014-019-9264-y
PG 17
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA KK2OE
UT WOS:000512586900001
PM 31889941
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Kaleagasioglu, F
   Ali, DM
   Berger, MR
AF Kaleagasioglu, Ferda
   Ali, Doaa M.
   Berger, Martin R.
TI Multiple Facets of Autophagy and the Emerging Role of
   Alkylphosphocholines as Autophagy Modulators
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Review
DE types of autophagy; autophagy as drug target; alkylphosphocholines; Akt;
   mTOR pathway; miltefosine; perifosine; erufosine
ID CHAPERONE-MEDIATED AUTOPHAGY; ADVANCED SOLID TUMORS; PHASE-I TRIAL;
   MYELOGENOUS LEUKEMIA-CELLS; SIGNALING PATHWAYS; COLORECTAL-CANCER;
   ANTITUMOR-ACTIVITY; PANCREATIC-CANCER; DUAL INHIBITION; ERUFOSINE
AB Autophagy is a highly conserved multistep process and functions as passage for degrading and recycling protein aggregates and defective organelles in eukaryotic cells. Based on the nature of these materials, their size and degradation rate, four types of autophagy have been described,i.e.chaperone mediated autophagy, microautophagy, macroautophagy, and selective autophagy. One of the major regulators of this process is mTOR, which inhibits the downstream pathway of autophagy following the activation of its complex 1 (mTORC1). Alkylphosphocholine (APC) derivatives represent a novel class of antineoplastic agents that inhibit the serine-threonine kinase Akt (i.e.protein kinase B), which mediates cell survival and cause cell cycle arrest. They induce autophagy through inhibition of the Akt/mTOR cascade. They interfere with phospholipid turnover and thus modify signaling chains, which start from the cell membrane and modulate PI3K/Akt/mTOR, Ras-Raf-MAPK/ERK and SAPK/JNK pathways. APCs include miltefosine, perifosine, and erufosine, which represent the first-, second- and third generation of this class, respectively. In a high fraction of human cancers, constitutively active oncoprotein Akt1 suppresses autophagyin vitroandin vivo. mTOR is a down-stream target for Akt, the activation of which suppresses autophagy. However, treatment with APC derivatives will lead to dephosphorylation (hence deactivation) of mTOR and thus induces autophagy. Autophagy is a double-edged sword and may result in chemotherapeutic resistance as well as cancer cell death when apoptotic pathways are inactive. APCs display differential autophagy induction capabilities in different cancer cell types. Therefore, autophagy-dependent cellular responses need to be well understood in order to improve the chemotherapeutic outcome.
C1 [Kaleagasioglu, Ferda] Near East Univ, Fac Med, Dept Pharmacol, Mersin, Turkey.
   [Ali, Doaa M.; Berger, Martin R.] German Canc Res Ctr, Toxicol & Chemotherapy Unit, Heidelberg, Germany.
   [Ali, Doaa M.] Alexandria Univ, Med Res Inst, Dept Pharmacol & Expt Therapeut, Alexandria, Egypt.
RP Berger, MR (corresponding author), German Canc Res Ctr, Toxicol & Chemotherapy Unit, Heidelberg, Germany.
EM m.berger@dkfz-heidelberg.de
RI Kaleagasioglu, Ferda/E-9447-2011
OI Kaleagasioglu, Ferda/0000-0003-1511-0432
CR Abdik EA, 2019, ANTI-CANCER DRUG, V30, P383, DOI 10.1097/CAD.0000000000000736
   Agarraberes FA, 2001, J CELL SCI, V114, P2491
   Ali DM, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0206-2
   Alistar A, 2017, LANCET ONCOL, V18, P770, DOI 10.1016/S1470-2045(17)30314-5
   Ansari SS, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0342-2
   Ansari Shariq S, 2018, Oncotarget, V9, P5797, DOI 10.18632/oncotarget.23537
   Ansari SS, 2017, CELL ONCOL, V40, P89, DOI 10.1007/s13402-016-0302-8
   Arnaout A, 2019, BREAST CANCER RES TR, V178, P327, DOI 10.1007/s10549-019-05381-y
   Awde AR, 2013, J NUCL MED, V54, P2125, DOI 10.2967/jnumed.112.118794
   Bagley RG, 2011, CANCER CHEMOTH PHARM, V68, P1537, DOI 10.1007/s00280-011-1658-0
   Bandyopadhyay U, 2008, MOL CELL BIOL, V28, P5747, DOI 10.1128/MCB.02070-07
   Basmaciyan L, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007264
   Bednarczyk Martyna, 2018, Oncotarget, V9, P34413, DOI 10.18632/oncotarget.26126
   Bejarano Eloy, 2010, Proc Am Thorac Soc, V7, P29, DOI 10.1513/pats.200909-102JS
   Berger MD, 2017, EUR J CANCER, V77, P13, DOI 10.1016/j.ejca.2017.02.020
   Berger MR, 2003, ANN NY ACAD SCI, V1010, P307, DOI 10.1196/annals.1299.054
   BERGER MR, 1993, J CANCER RES CLIN, V119, P541, DOI 10.1007/BF01686464
   BERGER MR, 1992, PROG EXP TUMOR RES, V34, P98
   BERGER MR, 1987, CANCER TREAT REV, V14, P307, DOI 10.1016/0305-7372(87)90023-5
   Bhatt AP, 2010, BLOOD, V115, P4455, DOI 10.1182/blood-2009-10-251082
   Bilger A, 2014, STRAHLENTHER ONKOL, V190, P957, DOI 10.1007/s00066-014-0693-2
   Bonkowski MS, 2016, NAT REV MOL CELL BIO, V17, P679, DOI 10.1038/nrm.2016.93
   Boone BA, 2015, ANN SURG ONCOL, V22, P4402, DOI 10.1245/s10434-015-4566-4
   Brana I, 2014, INVEST NEW DRUG, V32, P1269, DOI 10.1007/s10637-014-0159-5
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Chang CM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18050903
   Chi KH, 2015, ONCOTARGET, V6, P16735, DOI 10.18632/oncotarget.3793
   Chi MS, 2015, ONCOTARGET, V6, P29808, DOI 10.18632/oncotarget.5060
   Cirstea D, 2010, MOL CANCER THER, V9, P963, DOI 10.1158/1535-7163.MCT-09-0763
   Cuervo AM, 2014, CELL RES, V24, P92, DOI 10.1038/cr.2013.153
   Deng ZQ, 2017, TRENDS CELL BIOL, V27, P491, DOI 10.1016/j.tcb.2017.01.001
   Dineva IK, 2012, J CANCER RES CLIN, V138, P1909, DOI 10.1007/s00432-012-1271-6
   El-Chemaly S, 2017, CHEST, V151, P1302, DOI 10.1016/j.chest.2017.01.033
   Eldredge HB, 2013, J RADIOL ONCOL, V2, P315, DOI 10.1007/s13566-013-0111-x
   Erdlenbruch B, 1998, ANTICANCER RES, V18, P2551
   Erdlenbruch B, 1999, CANCER CHEMOTH PHARM, V44, P484, DOI 10.1007/s002800051122
   Eskelinen EL, 2008, INT REV CEL MOL BIO, V266, P207, DOI 10.1016/S1937-6448(07)66005-5
   Espina VA, 2017, CANCER RES, V77, DOI 10.1158/1538-7445.AM2017-CT140
   Fang EF, 2014, CELL, V157, P882, DOI 10.1016/j.cell.2014.03.026
   Fang YY, 2015, CELL BIOL INT, V39, P891, DOI 10.1002/cbin.10463
   Fiegl M, 2008, CANCER CHEMOTH PHARM, V62, P321, DOI 10.1007/s00280-007-0612-7
   Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150
   Fu L, 2009, CANCER RES, V69, P8967, DOI 10.1158/0008-5472.CAN-09-2190
   Galluzzi L, 2017, NAT REV DRUG DISCOV, V16, P487, DOI 10.1038/nrd.2017.22
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Gammoh N, 2012, P NATL ACAD SCI USA, V109, P6561, DOI 10.1073/pnas.1204429109
   Georgieva MC, 2002, CANCER LETT, V182, P163, DOI 10.1016/S0304-3835(02)00088-5
   Goldberg SB, 2012, J THORAC ONCOL, V7, P1602, DOI 10.1097/JTO.0b013e318262de4a
   Gomes LR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112351
   Guidetti A, 2012, BRIT J HAEMATOL, V158, P108, DOI 10.1111/j.1365-2141.2012.09139.x
   Haas NB, 2019, CLIN CANCER RES, V25, P2080, DOI 10.1158/1078-0432.CCR-18-2204
   Hailey DW, 2010, CELL, V141, P656, DOI 10.1016/j.cell.2010.04.009
   Hamasaki M, 2013, NATURE, V495, P389, DOI 10.1038/nature11910
   Hansen AR, 2019, ONCOLOGIST, V24, P1188, DOI 10.1634/theoncologist.2018-0621
   Hansen M, 2018, NAT REV MOL CELL BIO, V19, P579, DOI 10.1038/s41580-018-0033-y
   Hayashi-Nishino M, 2009, NAT CELL BIOL, V11, P1433, DOI 10.1038/ncb1991
   Hilgard P, 1997, EUR J CANCER, V33, P442
   HILGARD P, 1988, EUR J CANCER CLIN ON, V24, P1457, DOI 10.1016/0277-5379(88)90336-7
   Huynh KK, 2007, EMBO J, V26, P313, DOI 10.1038/sj.emboj.7601511
   Iacano AJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47610-w
   Jackson MP, 2016, ESSAYS BIOCHEM, V60, P173, DOI 10.1042/EBC20160005
   Janji B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00887
   Jendrossek V, 1999, INT J ONCOL, V14, P15
   Jewell JL, 2013, NAT REV MOL CELL BIO, V14, P133, DOI 10.1038/nrm3522
   Jin MM, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00378
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kaleagasioglu F, 2019, ANTI-CANCER AGENT ME, V19, P66, DOI 10.2174/1871520618666181012093056
   Kaleagasioglu F, 2014, ONCOL REP, V31, P1407, DOI 10.3892/or.2013.2942
   Kao C, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.468
   Kapoor V, 2014, AUTOPHAGY CANC OTHER, V3, P229
   Kapoor V, 2012, CANCER LETT, V319, P39, DOI 10.1016/j.canlet.2011.12.032
   Karasic TB, 2019, JAMA ONCOL, V5, P993, DOI 10.1001/jamaoncol.2019.0684
   Kardideh B, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-019-0327-6
   Kaushik S., 2006, Molecular Aspects of Medicine, V27, P444, DOI 10.1016/j.mam.2006.08.007
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X
   Konigs SK, 2010, LEUKEMIA RES, V34, P1064, DOI 10.1016/j.leukres.2009.12.003
   Kondapuram S.K, 2019, J CANC METASTASIS TR, V5, P32, DOI [10.20517/2394-4722.2018.105, DOI 10.20517/2394-4722.2018.105]
   Konstantinov SM, 1999, CANCER LETT, V144, P153, DOI 10.1016/S0304-3835(99)00219-0
   Kostadinova A, 2015, ADV PROTEIN CHEM STR, V101, P27, DOI 10.1016/bs.apcsb.2015.08.001
   Lamattina AM, 2018, CHEST, V154, P1070, DOI 10.1016/j.chest.2018.08.1029
   Lazova R, 2012, CLIN CANCER RES, V18, P370, DOI 10.1158/1078-0432.CCR-11-1282
   Lee HJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0749-9
   Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li M, 2018, CURR GENE THER, V18, P286, DOI 10.2174/1566523218666181008155039
   Li WW, 2012, CELL MOL LIFE SCI, V69, P1125, DOI 10.1007/s00018-011-0865-5
   Li X, 2018, INT J BIOL SCI, V14, P1291, DOI 10.7150/ijbs.26776
   Li YJ, 2017, CHIN J CANCER, V52, DOI 10.1186/s40880-017-0219-2
   Lippai M, 2017, CELL BIOL TOXICOL, V33, P145, DOI 10.1007/s10565-016-9374-5
   Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926
   Loaiza-Bonilla A, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.3614
   Lou GF, 2020, TRENDS MOL MED, V26, P8, DOI 10.1016/j.molmed.2019.07.002
   Mahalingam D, 2014, AUTOPHAGY, V10, P1403, DOI 10.4161/auto.29231
   Maiuri MC, 2019, CELL DEATH DIFFER, V26, P680, DOI 10.1038/s41418-019-0290-0
   Malhotra Jyoti, 2019, Cancer Treat Res Commun, V21, P100158, DOI 10.1016/j.ctarc.2019.100158
   Mandrioli J, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-028486
   Mandrioli J, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011119
   Mardones P, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf1937
   Marino ML, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.67
   Martelli AM, 2010, LEUKEMIA, V24, P687, DOI 10.1038/leu.2010.32
   Mehnert JM, 2019, CANCER CHEMOTH PHARM, V84, P899, DOI 10.1007/s00280-019-03919-x
   Mijaljica D, 2011, AUTOPHAGY, V7, P673, DOI 10.4161/auto.7.7.14733
   Momota H, 2005, CANCER RES, V65, P7429, DOI 10.1158/0008-5472.CAN-05-1042
   Morel E, 2017, ANNU REV PHARMACOL, V57, P375, DOI 10.1146/annurev-pharmtox-010716-104936
   MUSCHIOL C, 1987, LIPIDS, V22, P930, DOI 10.1007/BF02535558
   Nascimbeni AC, 2017, EMBO J, V36, P2018, DOI 10.15252/embj.201797006
   New M, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00028
   Novita Bernadette Dian, 2019, Indian J Tuberc, V66, P64, DOI 10.1016/j.ijtb.2018.04.003
   Padmapriyadarsini C, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024363
   Patel S, 2016, ONCOTARGET, V7, P59087, DOI 10.18632/oncotarget.10824
   Perez-Hernandez M, 2019, CANCERS, V11, DOI 10.3390/cancers11101599
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Peymani P, 2016, CAN J PHYSIOL PHARM, V94, P613, DOI 10.1139/cjpp-2015-0507
   Philip PA, 2019, FUTURE ONCOL, V15, P3189, DOI 10.2217/fon-2019-0209
   Porta C, 2009, J UROLOGY, V182, P2569, DOI 10.1016/j.juro.2009.08.085
   Puri C, 2018, AUTOPHAGY, V14, P1475, DOI 10.1080/15548627.2018.1482148
   Rabanal-Ruiz Y, 2017, ESSAYS BIOCHEM, V61, P565, DOI 10.1042/EBC20170027
   Rangwala R, 2014, AUTOPHAGY, V10, P1391, DOI 10.4161/auto.29119
   Rangwala R, 2014, AUTOPHAGY, V10, P1369, DOI 10.4161/auto.29118
   Ravikumar B, 2010, NAT CELL BIOL, V12, P747, DOI 10.1038/ncb2078
   Reis-Sobreiro M, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.15
   Rios-Marco P, 2015, BIOCHEM PHARMACOL, V96, P10, DOI 10.1016/j.bcp.2015.04.015
   Rogov V, 2014, MOL CELL, V53, P167, DOI 10.1016/j.molcel.2013.12.014
   Rojas-Puentes LL, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-209
   Rosenfeld MR, 2014, AUTOPHAGY, V10, P1359, DOI 10.4161/auto.28984
   Rudner J, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-108
   Ruiter GA, 2003, ANTI-CANCER DRUG, V14, P167, DOI 10.1097/00001813-200302000-00011
   Sharma Anuj, 2018, F1000Res, V7, P9, DOI 10.12688/f1000research.13242.1
   Sotelo J, 2006, ANN INTERN MED, V144, P337, DOI 10.7326/0003-4819-144-5-200603070-00008
   Stein M, 2010, PROSTATE, V70, P1388, DOI 10.1002/pros.21172
   Stolz A, 2014, NAT CELL BIOL, V16, P495, DOI 10.1038/ncb2979
   Sun SY, 2010, AUTOPHAGY, V6, P184, DOI 10.4161/auto.6.1.10816
   Sun T, 2017, CELL PHYSIOL BIOCHEM, V44, P716, DOI 10.1159/000485285
   Sun WL, 2012, ONCOTARGETS THER, V5, P21, DOI 10.2147/OTT.S14578
   Tang Y, 2019, CHEST, V156, P1137, DOI 10.1016/j.chest.2019.05.038
   Tong Y, 2012, ACTA PHARMACOL SIN, V33, P542, DOI 10.1038/aps.2011.192
   Tooze SA, 2010, NAT CELL BIOL, V12, P831, DOI 10.1038/ncb0910-831
   van Blitterswijk WJ, 2008, CURR PHARM DESIGN, V14, P2061, DOI 10.2174/138161208785294636
   van Blitterswijk WJ, 2013, BBA-MOL CELL BIOL L, V1831, P663, DOI 10.1016/j.bbalip.2012.10.008
   Vogl DT, 2017, CLIN CANCER RES, V23, P3307, DOI 10.1158/1078-0432.CCR-16-2526
   Vogl DT, 2014, AUTOPHAGY, V10, P1380, DOI 10.4161/auto.29264
   Wei X, 2016, ONCOTARGET, V7, P34430, DOI 10.18632/oncotarget.9119
   Wei Y, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/1012789
   Wirth M, 2019, ALZHEIMERS RES THER, V11, DOI 10.1186/s13195-019-0484-1
   Wirth M, 2018, CORTEX, V109, P181, DOI 10.1016/j.cortex.2018.09.014
   Wolpin BM, 2014, ONCOLOGIST, V19, P637, DOI 10.1634/theoncologist.2014-0086
   Yamamoto H, 2012, J CELL BIOL, V198, P219, DOI 10.1083/jcb.201202061
   Yang Y, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.161
   Yee AJ, 2016, LANCET ONCOL, V17, P1569, DOI 10.1016/S1470-2045(16)30375-8
   Yoshida GJ, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0436-9
   Yosifov DY, 2014, LEUKEMIA RES, V38, P49, DOI 10.1016/j.leukres.2013.10.011
   Yosifov DY, 2011, CANCER CHEMOTH PHARM, V67, P13, DOI 10.1007/s00280-010-1273-5
   Yu L, 2018, AUTOPHAGY, V14, P207, DOI 10.1080/15548627.2017.1378838
   Zaharieva MM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100950
   Zaremberg V, 2020, HANDB EXP PHARMACOL, V259, P261, DOI 10.1007/164_2019_222
   Zhang H, 2004, MOL IMAGING CONTRAST
   Zhu F, 2018, NEUROSCI BULL, V34, P283, DOI 10.1007/s12264-017-0165-7
   Zitzmann K, 2012, ENDOCR-RELAT CANCER, V19, P423, DOI 10.1530/ERC-12-0074
NR 159
TC 11
Z9 11
U1 2
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD APR 29
PY 2020
VL 11
AR 547
DI 10.3389/fphar.2020.00547
PG 23
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA MV9AV
UT WOS:000556642300001
PM 32410999
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Peng, Y
   Qiu, L
   Xu, D
   Zhang, L
   Yu, HX
   Ding, YD
   Deng, LL
   Lin, JG
AF Peng, Ying
   Qiu, Ling
   Xu, Dong
   Zhang, Li
   Yu, Huixin
   Ding, Yuedi
   Deng, Lili
   Lin, Jianguo
TI M4IDP, a zoledronic acid derivative, induces G1 arrest, apoptosis and
   autophagy in HCT116 colon carcinoma cells via blocking PI3K/Akt/mTOR
   pathway
SO LIFE SCIENCES
LA English
DT Article
DE Bisphosphonate; Zoledronic acid derivative; Colorectal cancer;
   PI3K/Akt/mTOR; Apoptosis; Autophagy
ID MEDIATED ER STRESS; CANCER CELLS; OXIDATIVE STRESS; INHIBITS GROWTH; BH3
   PROTEINS; IN-VITRO; BISPHOSPHONATES; AKT; DEATH; MECHANISMS
AB Aims: The aim of this work was to examine the antitumor effects and mechanisms of M4IDP, a zoledronic acid derivative, on human colorectal cancer (CRC) HCT116 cells.
   Main methods: The effects of M4IDP on proliferation, cell cycle and ROS production were determined by CCK-8 and flow cytometry assays. Annexin-V-FITC/PI, Hoechst 33258, MDC staining assays and Ad-mCherry-GFP-LC3B fluorescence assay were performed to investigate apoptosis and autophagy. The effects of M4IDP on the induction of ER stress as well as the expression of cell cycle, apoptosis and autophagy-related proteins were analyzed by western blot assay.
   Key findings: M4IDP exhibited strong and sustained inhibitory effect on the growth of HCT116 cells. G1 arrest caused by M4IDP might be attributed to the enhancement of p27 and reduction of cyclin D1 expression. Proper time treatment of M4IDP activated autophagy and promoted autophagic flux, while long-time treatment might inhibit the autophagic degradation and undermine the autophagy. M4IDP-induced apoptosis and autophagy were related to the ROS production and subsequent ER stress. M4IDP treatment increased the expression of PTEN, inhibited the phosphorylation of PDK1, Akt, mTOR, p7056K, and increased the phosphorylation of GSK-3 beta and Bad, suggesting that the inhibition of PI3K/Akt/mTOR pathway might be involved in the antitumor activities of M4IDP.
   Significance: Our study indicates the antitumor properties of M4IDP and its potential clinical use in CRC therapy by blocking PI3K/Akt/mTOR pathway. This study also provides a better understanding of the antitumor effects and the underlying mechanisms of bisphosphonates in the field of CRC therapy.
C1 [Peng, Ying; Qiu, Ling; Xu, Dong; Zhang, Li; Yu, Huixin; Ding, Yuedi; Deng, Lili; Lin, Jianguo] Jiangsu Inst Nucl Med, Jiangsu Key Lab Mol Nucl Med, Minist Hlth, Key Lab Nucl Med, Wuxi 214063, Jiangsu, Peoples R China.
RP Lin, JG (corresponding author), Jiangsu Inst Nucl Med, Jiangsu Key Lab Mol Nucl Med, Minist Hlth, Key Lab Nucl Med, Wuxi 214063, Jiangsu, Peoples R China.
EM linjianguo@jsinm.org
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [21371082, 21501074, 81402214]; Natural
   Science Foundation of Jiangsu ProvinceNatural Science Foundation of
   Jiangsu Province [BK20141102, BK20151118]; 333 Project of Jiangsu
   ProvinceNatural Science Foundation of Jiangsu Province [BRA2016518]; Key
   Youth Medical Talent Project of Jiangsu Province [QNRC20162016626,
   QNRC20162016629]
FX This work was supported by the National Natural Science Foundation of
   China [21371082, 21501074 and 81402214]; the Natural Science Foundation
   of Jiangsu Province [BK20141102 and BK20151118]; the 333 Project of
   Jiangsu Province [BRA2016518], and the Key Youth Medical Talent Project
   of Jiangsu Province [QNRC20162016626 and QNRC20162016629].
CR Agarwal C, 2004, NEOPLASIA, V6, P646, DOI 10.1593/neo.04232
   Almubarak Hussain, 2011, J Carcinog, V10, P2, DOI 10.4103/1477-3163.75723
   Aranovich A, 2012, MOL CELL, V45, P754, DOI 10.1016/j.molcel.2012.01.030
   Blanco-Aparicio C, 2007, CARCINOGENESIS, V28, P1379, DOI 10.1093/carcin/bgm052
   Chagin AS, 2016, CURR OPIN PHARMACOL, V28, P1, DOI 10.1016/j.coph.2016.02.004
   Chan CH, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-59
   Chang S.H., 2017, J DERMATOL SCI, pS0923
   Chen L.P., 2013, NAT SCI EDUC, V12, P465
   Chen WQ, 2016, ONCOTARGET, V7, P16593, DOI 10.18632/oncotarget.7565
   Clezardin P, 2003, CURR MED CHEM, V10, P173, DOI 10.2174/0929867033368529
   Cohen MH, 2002, ONCOLOGIST, V7, P393, DOI 10.1634/theoncologist.7-5-393
   Coleman RE, 2004, ONCOLOGIST, V9, P14, DOI 10.1634/theoncologist.9-90004-14
   Cross FR, 2011, PHILOS T R SOC B, V366, P3532, DOI 10.1098/rstb.2011.0078
   Dai Zhen, 2012, Zhonghua Yu Fang Yi Xue Za Zhi, V46, P598
   Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Gao X, 2015, TUMOR BIOL, V36, P5315, DOI 10.1007/s13277-015-3192-x
   Ge XY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101207
   Han FS, 2016, ASIAN PAC J TROP MED, V9, P164, DOI 10.1016/j.apjtm.2016.01.005
   Heras-Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019
   Heymann D, 2004, TRENDS MOL MED, V10, P337, DOI 10.1016/j.molmed.2004.05.007
   Hill R, 2009, J BIOL CHEM, V284, P11755, DOI 10.1074/jbc.R800071200
   Kahl CR, 2004, J BIOL CHEM, V279, P15411, DOI 10.1074/jbc.M312543200
   Katsuragi Y, 2015, FEBS J, V282, P4672, DOI 10.1111/febs.13540
   Khandelwal VKM, 2014, PHYSIOL RES, V63, pS601, DOI 10.33549/physiolres.932934
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   La XQ, 2017, ONCOTARGET, V8, P20909, DOI 10.18632/oncotarget.14959
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li ZP, 2016, AM J TRANSL RES, V8, P4628
   Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433
   Lin JF, 2011, J UROLOGY, V185, P1490, DOI 10.1016/j.juro.2010.11.045
   Lin JG, 2011, NUCL MED BIOL, V38, P619, DOI 10.1016/j.nucmedbio.2010.12.005
   Liu Q, 2012, CELL CYCLE, V11, P3536, DOI 10.4161/cc.21462
   Liu Q, 2013, CHINESE MED J-PEKING, V126, P1486, DOI 10.3760/cma.j.issn.0366-6999.20122385
   Long JT, 2013, BMC BIOTECHNOL, V13, DOI 10.1186/1472-6750-13-45
   Ma YM, 2016, ACTA PHARMACOL SIN, V37, P1381, DOI 10.1038/aps.2016.61
   Mallampalli RK, 2013, CELL SIGNAL, V25, P2047, DOI 10.1016/j.cellsig.2013.05.012
   Maycotte P., 2014, CANCER BIOL THER, V11, P127
   Nadar RA, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201601119
   Pyo JO, 2012, EXP MOL MED, V44, P73, DOI 10.3858/emm.2012.44.2.029
   Qiu L, 2015, EUR J MED CHEM, V89, P42, DOI 10.1016/j.ejmech.2014.10.028
   Qiu L, 2014, AUST J CHEM, V67, P192, DOI 10.1071/CH13194
   Riechelmann R, 2017, THER ADV MED ONCOL, V9, P106, DOI 10.1177/1758834016676703
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198-007-0540-8
   Saiki S, 2011, AUTOPHAGY, V7, P176, DOI 10.4161/auto.7.2.14074
   Sewing L, 2008, APOPTOSIS, V13, P782, DOI 10.1007/s10495-008-0211-z
   SHINODA H, 1983, CALCIFIED TISSUE INT, V35, P87, DOI 10.1007/BF02405012
   Shinojima N, 2007, AUTOPHAGY, V3, P635, DOI 10.4161/auto.4916
   Sinha K, 2013, ARCH TOXICOL, V87, P1157, DOI 10.1007/s00204-013-1034-4
   Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374
   Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8
   Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986
   Wang IT, 2014, TUMOR BIOL, V35, P11913, DOI 10.1007/s13277-014-2460-5
   Wang R, 2016, SCI REP-UK, V6, DOI 10.1038/srep27071
   Widler L, 2002, J MED CHEM, V45, P3721, DOI 10.1021/jm020819i
   Zeeshan HMA, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030327
   Zhai H.Z., 2010, J ISOT, V23, P225
   Zhang C, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010157
NR 58
TC 26
Z9 28
U1 5
U2 26
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD SEP 15
PY 2017
VL 185
BP 63
EP 72
DI 10.1016/j.lfs.2017.07.024
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA FF2BB
UT WOS:000408701800009
PM 28751160
DA 2022-04-25
ER

PT J
AU Zhong, XL
   Chen, O
   Zhou, TJ
   Lu, MH
   Wan, JY
AF Zhong, Xiaolin
   Chen, Ou
   Zhou, TieJun
   Lu, Muhan
   Wan, Juyi
TI Cytotoxin-Associated Gene A-Positive Helicobacter pylori Promotes
   Autophagy in Colon Cancer Cells by Inhibiting miR-125b-5p
SO CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY
LA English
DT Article
ID INFECTION; STATISTICS; EXPRESSION; DISEASE
AB Objectives. To investigate the effects of cytotoxin-associated gene A- (CagA-) positive Helicobacter pylori on proliferation, invasion, autophagy, and expression of miR-125b-5p in colon cancer cells. Methods. Colon cancer cells were cocultured with H. pylori (CagA+) to analyze the effects of H. pylori on miR-125b-5p and autophagy. Colon cancer cells infected with H. pylori (CagA+) were mimicked by transfection of CagA plasmid. The effects of CagA on the proliferation, invasion, and autophagy of colon cancer cells were analyzed. Cell counting kit-8 (CCK-8), clone formation, and Transwell assays were used to detect cell viability, proliferation, and invasion ability, respectively. Proteins and miRNAs were detected by western blotting and qPCR, respectively. Results. H. pylori (CagA+) inhibited expression of miR-125b-5p and promoted autophagy in colon cancer cells. MiR-125 b-5p was underexpressed in colon cancer cells after CagA overexpression. CagA promoted colon cancer cell proliferation, invasion, and autophagy. Overexpression of miR-125b-5p inhibited the proliferation, invasion, and autophagy of colon cancer cells and reversed the effects of CagA. Conclusion. H. pylori (CagA+) infection may promote the development and invasion of colon cancer by inhibiting miR-125b-5p.
C1 [Zhong, Xiaolin; Lu, Muhan] Southwest Med Univ, Dept Gastroenterol, Affiliated Hosp, Luzhou 646000, Peoples R China.
   [Zhong, Xiaolin; Lu, Muhan] Nucl Med & Mol Imaging Key Lab Sichuan Prov, Luzhou 646000, Peoples R China.
   [Chen, Ou] Yaan Peoples Hosp, Dept Gastroenterol, Yaan 625000, Peoples R China.
   [Zhou, TieJun] Southwest Med Univ, Dept Pathol, Affiliated Hosp, Luzhou 646000, Peoples R China.
   [Wan, Juyi] Southwest Med Univ, Dept Cardiovasc Surg, Affiliated Hosp, Luzhou 646000, Peoples R China.
   [Wan, Juyi] Cardiovasc & Metab Dis Key Lab Luzhou, Luzhou 646000, Peoples R China.
   [Wan, Juyi] Southwest Med Univ, Collaborat Innovat Ctr Prevent Cardiovasc Dis, Key Lab Med Electrophysiol, Inst Cardiovasc Res,Minist Educ, Luzhou 646000, Peoples R China.
   [Wan, Juyi] Southwest Med Univ, Collaborat Innovat Ctr Prevent Cardiovasc Dis, Med Electrophysiol Key Lab Sichuan Prov, Inst Cardiovasc Res, Luzhou 646000, Peoples R China.
RP Wan, JY (corresponding author), Southwest Med Univ, Dept Cardiovasc Surg, Affiliated Hosp, Luzhou 646000, Peoples R China.; Wan, JY (corresponding author), Cardiovasc & Metab Dis Key Lab Luzhou, Luzhou 646000, Peoples R China.; Wan, JY (corresponding author), Southwest Med Univ, Collaborat Innovat Ctr Prevent Cardiovasc Dis, Key Lab Med Electrophysiol, Inst Cardiovasc Res,Minist Educ, Luzhou 646000, Peoples R China.; Wan, JY (corresponding author), Southwest Med Univ, Collaborat Innovat Ctr Prevent Cardiovasc Dis, Med Electrophysiol Key Lab Sichuan Prov, Inst Cardiovasc Res, Luzhou 646000, Peoples R China.
EM wanjuyi@yeah.net
FU Sichuan Province Science and Technology Projects [2020YJ0190,
   2021YFH0148]; Science and Technology Strategic Cooperation Programs of
   Luzhou Municipal People's Government; Southwest Medical University
   [2019LZXNYDJ27, 2019LZXNYDJ30]; Sichuan Science and Technology Grant for
   Overseas Students [19059]; Medical Research Project of Sichuan Province
   [Q16081]
FX This study was supported in part by the following funding sources:
   Sichuan Province Science and Technology Projects (2020YJ0190 and
   2021YFH0148), Science and Technology Strategic Cooperation Programs of
   Luzhou Municipal People's Government and Southwest Medical University
   (2019LZXNYDJ27 and 2019LZXNYDJ30), Sichuan Science and Technology Grant
   for Overseas Students (19059), and Medical Research Project of Sichuan
   Province (Q16081).
CR Amieva M, 2016, GASTROENTEROLOGY, V150, P64, DOI 10.1053/j.gastro.2015.09.004
   Cao WT, 2018, BIOMED PHARMACOTHER, V99, P791, DOI 10.1016/j.biopha.2018.01.119
   Carroll RG, 2013, CANCER CELL, V23, P425, DOI 10.1016/j.ccr.2013.04.001
   Chen SY, 2014, INT J ONCOL, V45, P764, DOI 10.3892/ijo.2014.2444
   Chen WQ, 2012, CHINESE J CANCER RES, V24, P1, DOI 10.1007/s11670-012-0001-6
   Chen WQ, 2015, CHINESE J CANCER RES, V27, P1, DOI 10.3978/j.issn.1000-9604.2015.02.07
   Espinoza JL, 2018, CANCER LETT, V414, P147, DOI 10.1016/j.canlet.2017.11.009
   Horridge DN, 2017, PATHOG DIS, V75, DOI 10.1093/femspd/ftx113
   Hu Y, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00168
   Huang MH, 2020, HEPATOLOGY, V71, P76, DOI 10.1002/hep.30820
   Ibrahim M, 2014, EUR J CONTRACEP REPR, V19, P78, DOI 10.3109/13625187.2013.873399
   Krzysiek-Maczka G, 2018, HELICOBACTER, V23, DOI 10.1111/hel.12538
   Kuo SH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14102-8
   Li M, 2019, ONCOL LETT, V18, P145, DOI 10.3892/ol.2019.10304
   Li NS, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0962-5
   Li R, 2019, HORM CANCER-US, V10, P150, DOI 10.1007/s12672-019-00366-1
   Li YZ, 2018, BIOCHEM BIOPH RES CO, V504, P277, DOI 10.1016/j.bbrc.2018.08.172
   Mei LL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185636
   Mellis D, 2018, BIOCHEM SOC T, V46, P11, DOI 10.1042/BST20170037
   NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604
   Pan ZJ, 1997, J CLIN MICROBIOL, V35, P1344, DOI 10.1128/JCM.35.6.1344-1347.1997
   Park JY, 2018, TOXINS, V10, DOI 10.3390/toxins10040163
   Qu M, 2017, EUR REV MED PHARMACO, V21, P3384
   Ritchie W, 2017, METHODS MOL BIOL, V1513, P193, DOI 10.1007/978-1-4939-6539-7_13
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Teimoorian Fatemeh, 2018, Iran J Pathol, V13, P325
   Weinberg BA, 2017, ONCOLOGY-NY, V31, P381
   Xiao CC, 2018, CIRC RES, V123, P564, DOI 10.1161/CIRCRESAHA.118.312758
   Xie GC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168822
   Xu J, 2019, EXP THER MED, V18, P1458, DOI 10.3892/etm.2019.7689
   Xu LM, 2016, TUMOR BIOL, V37, P8721, DOI 10.1007/s13277-015-4737-8
   Yang D, 2017, SCI REP-UK, V7, DOI 10.1038/srep43109
   You YN, 2015, SURG ONCOL, V24, P61, DOI 10.1016/j.suronc.2015.02.001
   Zhong XL, 2020, CELL MOL GASTROENTER, V10, P341, DOI 10.1016/j.jcmgh.2020.04.005
   Zumkeller N, 2006, HELICOBACTER, V11, P75, DOI 10.1111/j.1523-5378.2006.00381.x
NR 35
TC 2
Z9 2
U1 1
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1712-9532
EI 1918-1493
J9 CAN J INFECT DIS MED
JI Can. J. Infect. Dis. Med. Microbiol.
PD MAR 2
PY 2021
VL 2021
AR 6622092
DI 10.1155/2021/6622092
PG 9
WC Infectious Diseases; Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Infectious Diseases; Microbiology
GA RH5MU
UT WOS:000636263400001
PM 33791049
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhou, WG
   Zhang, SJ
   Li, HB
   Cai, ZY
   Tang, ST
   Chen, LX
   Lang, JY
   Chen, Z
   Chen, XL
AF Zhou, Weige
   Zhang, Shijing
   Li, Hui-biao
   Cai, Zheyou
   Tang, Shuting
   Chen, Li-xia
   Lang, Jian-ying
   Chen, Zheng
   Chen, Xin-lin
TI Development of Prognostic Indicator Based on Autophagy-Related lncRNA
   Analysis in Colon Adenocarcinoma
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID COLORECTAL-CANCER; INACTIVATION; INSIGHTS
AB There were no systematic researches about autophagy-related long noncoding RNA (lncRNA) signatures to predict the survival of patients with colon adenocarcinoma. It was necessary to set up corresponding autophagy-related lncRNA signatures. The expression profiles of lncRNAs which contained 480 colon adenocarcinoma samples were obtained from The Cancer Genome Atlas (TCGA) database. The coexpression network of lncRNAs and autophagy-related genes was utilized to select autophagy-related lncRNAs. The lncRNAs were further screened using univariate Cox regression. In addition, Lasso regression and multivariate Cox regression were used to develop an autophagy-related lncRNA signature. A risk score based on the signature was established, and Cox regression was used to test whether it was an independent prognostic factor. The functional enrichment of autophagy-related lncRNAs was visualized using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes. Ten prognostic autophagy-related lncRNAs (AC027307.2, AC068580.3, AL138756.1, CD27-AS1, EIF3J-DT, LINC01011, LINC01063, LINC02381, AC073896.3, and SNHG16) were identified to be significantly different, which made up an autophagy-related lncRNA signature. The signature divided patients with colon adenocarcinoma into the low-risk group and the high-risk group. A risk score based on the signature was a significantly independent factor for the patients with colon adenocarcinoma (HR=1.088,95%CI=1.057-1.120;P<0.001). Additionally, the ten lncRNAs were significantly enriched in autophagy process, metabolism, and tumor classical pathways. In conclusion, the ten autophagy-related lncRNAs and their signature might be molecular biomarkers and therapeutic targets for the patients with colon adenocarcinoma.
C1 [Zhou, Weige; Zhang, Shijing; Cai, Zheyou; Chen, Li-xia; Lang, Jian-ying; Chen, Xin-lin] Guangzhou Univ Chinese Med, Sch Basic Med Sci, Guangzhou, Peoples R China.
   [Li, Hui-biao] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Peoples R China.
   [Tang, Shuting] Guangzhou Univ Chinese Med, Clin Coll 1, Guangzhou, Peoples R China.
   [Chen, Zheng] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Stomatol, Guangzhou, Peoples R China.
RP Chen, XL (corresponding author), Guangzhou Univ Chinese Med, Sch Basic Med Sci, Guangzhou, Peoples R China.; Chen, Z (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 3, Dept Stomatol, Guangzhou, Peoples R China.
EM 1364569514@qq.com; 386558374@qq.com; gzzyydx2011@163.com;
   838782814@qq.com; 1772338334@qq.com; gzclx@gzucm.edu.cn;
   langjy@gzucm.edu.cn; chenzh68@mail.sysu.edu.cn; chenxlsums@126.com
RI Chen, Xin-lin/AAZ-7287-2021
OI Chen, Xin-lin/0000-0002-2650-8051; chen, zheng/0000-0002-3505-0396
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81774451]; Natural Science Foundation of
   Guangdong ProvinceNational Natural Science Foundation of Guangdong
   Province [2017A030313827]; Science Program for Overseas Scholar (Xinhuo
   plan) of Guangzhou University of Chinese Medicine [XH20190102]
FX This study was funded by the National Natural Science Foundation of
   China (81774451), the Natural Science Foundation of Guangdong Province
   (2017A030313827), and Science Program for Overseas Scholar (Xinhuo plan)
   of Guangzhou University of Chinese Medicine (XH20190102).
CR Amaravadi RK, 2019, CANCER DISCOV, V9, P1167, DOI 10.1158/2159-8290.CD-19-0292
   Barresi V, 2015, HISTOL HISTOPATHOL, V30, P1059, DOI 10.14670/HH-11-633
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Devenport SN, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111349
   Fan S, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.100835
   Gil J, 2018, MED ONCOL, V35, DOI 10.1007/s12032-018-1220-6
   Gu JX, 2019, WORLD J GASTROENTERO, V25, P220, DOI 10.3748/wjg.v25.i2.220
   Guo ZX, 2019, J CLIN LAB ANAL, V33, DOI 10.1002/jcla.22986
   Huang Z, 2019, DOSE-RESPONSE, V17, DOI 10.1177/1559325819894179
   Jafarzadeh M, 2020, BIOCHIMIE, V171, P63, DOI 10.1016/j.biochi.2020.02.009
   Jin KT, 2020, RNA BIOL, V17, P1727, DOI 10.1080/15476286.2020.1737787
   Jing Z, 2020, CANCER MED-US, V9, P4324, DOI 10.1002/cam4.3020
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levine B, 2019, CELL, V176, P11, DOI 10.1016/j.cell.2018.09.048
   Li JQ, 2017, ONCOTARGET, V8, P42664, DOI 10.18632/oncotarget.16844
   Lin YL, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00318
   Liu DS, 2020, J CELL BIOCHEM, V121, P1923, DOI 10.1002/jcb.29427
   Liu Y, 2019, BIOCHEM BIOPH RES CO, V518, P127, DOI 10.1016/j.bbrc.2019.08.019
   Lv J, 2020, J CELL BIOCHEM, V121, P3780, DOI 10.1002/jcb.29518
   MA J, 2018, J INVEST DERMATOL S, V0138, pS 204, DOI DOI 10.1016/j.jid.2018.03.1214
   Mah LY, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008821
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521
   Mo SB, 2019, CARCINOGENESIS, V40, P861, DOI 10.1093/carcin/bgz031
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Patel KD, 2020, EXP MOL PATHOL, V113, DOI 10.1016/j.yexmp.2020.104378
   Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200
   Sakitani K, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1789-5
   Si YR, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658-019-0175-8
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P145, DOI 10.3322/caac.21601
   Son Y, 2019, PHYTOTHER RES, V33, P1689, DOI 10.1002/ptr.6357
   Tsai WT, 2016, J BIOL CHEM, V291, P19299, DOI 10.1074/jbc.M115.686683
   Wang M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1187-4
   Wen Y, 2020, ONCOTARGETS THER, V13, P263, DOI 10.2147/OTT.S226915
   Yang HJ, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00081
   Yang X, 2019, BIOCHEM BIOPH RES CO, V518, P239, DOI 10.1016/j.bbrc.2019.08.039
   Zhang W, 2018, BIOCHIMIE, V144, P21, DOI 10.1016/j.biochi.2017.10.002
NR 39
TC 14
Z9 14
U1 1
U2 4
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD SEP 3
PY 2020
VL 2020
AR 9807918
DI 10.1155/2020/9807918
PG 14
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA NS2CM
UT WOS:000572072700002
PM 32964050
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Petroni, G
   Bagni, G
   Iorio, J
   Duranti, C
   Lottini, T
   Stefanini, M
   Kragol, G
   Becchetti, A
   Arcangeli, A
AF Petroni, Giulia
   Bagni, Giacomo
   Iorio, Jessica
   Duranti, Claudia
   Lottini, Tiziano
   Stefanini, Matteo
   Kragol, Goran
   Becchetti, Andrea
   Arcangeli, Annarosa
TI Clarithromycin inhibits autophagy in colorectal cancer by regulating the
   hERG1 potassium channel interaction with PI3K
SO CELL DEATH & DISEASE
LA English
DT Article
ID COLON-CANCER; CELL-DEATH; MACROLIDE ANTIBIOTICS; INDUCE APOPTOSIS;
   BECLIN 1; 5-FLUOROURACIL; RESISTANCE; EXPRESSION; CHLOROQUINE;
   BORTEZOMIB
AB We have studied how the macrolide antibiotic Clarithromycin (Cla) regulates autophagy, which sustains cell survival and resistance to chemotherapy in cancer. We found Cla to inhibit the growth of human colorectal cancer (CRC) cells, by modulating the autophagic flux and triggering apoptosis. The accumulation of cytosolic autophagosomes accompanied by the modulation of autophagic markers LC3-II and p62/SQSTM1, points to autophagy exhaustion. Because Cla is known to bind human Ether-a-go-go Related Gene 1 (hERG1) K+ channels, we studied if its effects depended on hERG1 and its conformational states. By availing of hERG1 mutants with different gating properties, we found that fluorescently labelled Cla preferentially bound to the closed channels. Furthermore, by sequestering the channel in the closed conformation, Cla inhibited the formation of a macromolecular complex between hERG1 and the p85 subunit of PI3K. This strongly reduced Akt phosphorylation, and stimulated the p53-dependent cell apoptosis, as witnessed by late caspase activation. Finally, Cla enhanced the cytotoxic effect of 5-fluorouracil (5-FU), the main chemotherapeutic agent in CRC, in vitro and in a xenograft CRC model. We conclude that Cla affects the autophagic flux by impairing the signaling pathway linking hERG1 and PI3K. Combining Cla with 5-FU might be a novel therapeutic option in CRC.
C1 [Petroni, Giulia; Bagni, Giacomo; Iorio, Jessica; Duranti, Claudia; Lottini, Tiziano; Stefanini, Matteo; Arcangeli, Annarosa] Univ Firenze, Dept Expt & Clin Med, Viale GB Morgagni 50, I-50134 Florence, Italy.
   [Kragol, Goran] Fidelta Ltd, Prilaz Baruna Filipovica 29, Zagreb 10000, Croatia.
   [Becchetti, Andrea] Univ Milano Bicocca, Dept Biosci & Biotechnol, Piazza Sci 2, I-20126 Milan, Italy.
RP Arcangeli, A (corresponding author), Univ Firenze, Dept Expt & Clin Med, Viale GB Morgagni 50, I-50134 Florence, Italy.
EM annarosa.arcangeli@unifi.it
RI Kragol, Goran/AGJ-3512-2022; Petroni, Giulia/AAR-7219-2020
OI Petroni, Giulia/0000-0002-0558-5322
FU Associazione Italiana per la Ricerca sul CancroFondazione AIRC per la
   ricerca sul cancro [15627, 21510]; PAR FAS-Linea di Azione 1.1-Azione
   1.1.2-Bando FAS Salute 2014 Project OMITERC [DD 4042/2014]; FAR 2018
FX We thank M. Lulli (University of Florence, Italy) for acquiring images
   of immunofluorescence-labeled cells. This work was supported by grants
   from Associazione Italiana per la Ricerca sul Cancro (#15627 and #21510
   to A.A.); PAR FAS-Linea di Azione 1.1-Azione 1.1.2-Bando FAS Salute 2014
   (DD 4042/2014) Project OMITERC to A.A.; FAR 2018 to A.B.
CR Arcangeli A, 2009, CURR MED CHEM, V16, P66, DOI 10.2174/092986709787002835
   Arcangeli Annarosa, 2005, V266, P225
   Aubrey BJ, 2018, CELL DEATH DIFFER, V25, P104, DOI 10.1038/cdd.2017.169
   Becchetti A, 2019, TRENDS CELL BIOL, V29, P298, DOI 10.1016/j.tcb.2018.12.005
   Becchetti A, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aaf3236
   Beer M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01256-8
   Bryant KL, 2019, NAT MED, V25, P628, DOI 10.1038/s41591-019-0368-8
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Cherubini A, 2005, MOL BIOL CELL, V16, P2972, DOI 10.1091/mbc.E04-10-0940
   Choi JH, 2014, GASTROENT RES PRACT, V2014, DOI 10.1155/2014/179586
   Choi JH, 2012, APMIS, V120, P597, DOI 10.1111/j.1600-0463.2012.02876.x
   Comel A, 2014, FEBS LETT, V588, P2600, DOI 10.1016/j.febslet.2014.04.015
   Crociani O, 2013, SCI REP-UK, V3, DOI 10.1038/srep03308
   Du BY, 2017, INT J CLIN EXP PATHO, V10, P6071
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4
   Galluzzi L, 2017, EMBO J, V36, P1811, DOI 10.15252/embj.201796697
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Geng F, 2017, CANCER BIOTHER RADIO, V32, P149, DOI 10.1089/cbr.2017.2210
   Giatromanolaki A, 2010, J CLIN PATHOL, V63, P867, DOI 10.1136/jcp.2010.079525
   Gong J, 2017, ANTICANCER RES, V37, P2831, DOI 10.21873/anticanres.11634
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   Hammond WA, 2016, THER ADV MED ONCOL, V8, P57, DOI 10.1177/1758834015614530
   Hamoya T, 2017, J CLIN BIOCHEM NUTR, V60, P199, DOI 10.3164/jcbn.16-107
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Hirasawa K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164529
   Holck Susanne, 2019, Oncotarget, V10, P1745, DOI 10.18632/oncotarget.26741
   Jehle J, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.77
   Kinsey CG, 2019, NAT MED, V25, P620, DOI 10.1038/s41591-019-0367-9
   Komatsu S, 2013, BIOCHEM BIOPH RES CO, V437, P41, DOI 10.1016/j.bbrc.2013.06.032
   Komatsu S, 2012, INT J ONCOL, V40, P1029, DOI 10.3892/ijo.2011.1317
   Kucharewicz K, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0383-6
   Lastraioli E, 2004, CANCER RES, V64, P606, DOI 10.1158/0008-5472.CAN-03-2360
   Lastraioli E, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/896432
   Lastraioli E, 2015, BBA-BIOMEMBRANES, V1848, P2685, DOI 10.1016/j.bbamem.2014.12.016
   Lastraioli E, 2012, TRANSL ONCOL, V5, P105, DOI 10.1593/tlo.11250
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001
   Masi A, 2005, BRIT J CANCER, V93, P781, DOI 10.1038/sj.bjc.6602775
   Matijasic M, 2012, PHARMACOL RES, V66, P332, DOI 10.1016/j.phrs.2012.06.001
   Mitcheson J, 2015, ION CHANNEL DRUG DIS
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Moriya S, 2013, INT J ONCOL, V42, P1541, DOI 10.3892/ijo.2013.1870
   Mowers EE, 2017, ONCOGENE, V36, P1619, DOI 10.1038/onc.2016.333
   Mukai S, 2016, INT J ONCOL, V48, P45, DOI 10.3892/ijo.2015.3237
   Nakamura M, 2010, INT J ONCOL, V37, P815, DOI 10.3892/ijo_00000731
   Ohara T, 2004, ANTICANCER RES, V24, P3723
   Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954
   Patel BB, 2008, INT J CANCER, V122, P267, DOI 10.1002/ijc.23097
   Petroni G, 2019, DATA BRIEF, V26, DOI 10.1016/j.dib.2019.104406
   Pillozzi S, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.32
   Pillozzi S, 2019, ONCOL REP, V41, P312, DOI 10.3892/or.2018.6808
   Pillozzi S, 2018, BRIT J CANCER, V118, P200, DOI 10.1038/bjc.2017.392
   Pillozzi S, 2011, BLOOD, V117, P902, DOI 10.1182/blood-2010-01-262691
   Qiao XR, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0309-9
   Sasaki K, 2012, ANTI-CANCER DRUG, V23, P675, DOI 10.1097/CAD.0b013e328353f8c7
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Schafranek L, 2013, LEUKEMIA LYMPHOMA, V54, P198, DOI 10.3109/10428194.2012.698737
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/nmeth.2019, 10.1038/NMETH.2019]
   Schmitz KJ, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0946-x
   Schonewolf CA, 2014, WORLD J GASTRO ONCOL, V6, P74, DOI 10.4251/wjgo.v6.i3.74
   Seithel A, 2007, DRUG METAB DISPOS, V35, P779, DOI 10.1124/dmd.106.014407
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Sridharan Savitha, 2011, Cancers (Basel), V3, P2630, DOI 10.3390/cancers3022630
   Stanat SJC, 2003, MOL CELL BIOCHEM, V254, P1, DOI 10.1023/A:1027309703313
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Van der Jeught K, 2018, WORLD J GASTROENTERO, V24, P3834, DOI 10.3748/wjg.v24.i34.3834
   van Nuffel AMT, 2015, ECANCERMEDICALSCIENC, V9, DOI 10.3332/ecancer.2015.513
   Volberg WA, 2002, J PHARMACOL EXP THER, V302, P320, DOI 10.1124/jpet.302.1.320
   Wang L, 2015, CANCER BIOL THER, V16, P383, DOI 10.1080/15384047.2014.1002331
   Wang RC, 2012, SCIENCE, V338, P956, DOI 10.1126/science.1225967
   Wu SH, 2015, INT J CLIN EXP PATHO, V8, P3882
   Yang MP, 2015, ONCOTARGET, V6, P7084, DOI 10.18632/oncotarget.3054
   Yatsunami J, 1997, RES EXP MED, V197, P189, DOI 10.1007/s004330050068
   Zhang M, 2004, J GEN PHYSIOL, V124, P703, DOI 10.1085/jgp.200409119
NR 75
TC 19
Z9 19
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD MAR 2
PY 2020
VL 11
IS 3
AR 161
DI 10.1038/s41419-020-2349-8
PG 18
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA KW1NS
UT WOS:000520938800007
PM 32123164
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Wei, JS
   Ge, XX
   Tang, Y
   Qian, YC
   Lu, W
   Jiang, K
   Fang, YM
   Hwang, M
   Fu, DL
   Xiao, Q
   Ding, KF
AF Wei, Jingsun
   Ge, Xiaoxu
   Tang, Yang
   Qian, Yucheng
   Lu, Wei
   Jiang, Kai
   Fang, Yimin
   Hwang, Maxwell
   Fu, Dongliang
   Xiao, Qian
   Ding, Kefeng
TI An Autophagy-Related Long Noncoding RNA Signature Contributes to Poor
   Prognosis in Colorectal Cancer
SO JOURNAL OF ONCOLOGY
LA English
DT Article
ID CELL APOPTOSIS; STATISTICS; INHIBITION; EXPRESSION; PATHWAY; DEATH
AB Purpose. Colorectal cancer is one of the most common malignant primary tumors, prone to metastasis, and associated with a poor prognosis. As autophagy is closely related to the development and treatment of colorectal cancer, we investigated the potential prognostic value of long noncoding RNA (lncRNA) associated with autophagy in colorectal cancer. Methods. In this study, we acquired information on the expression of lncRNAs in colorectal cancer from the Cancer Genome Atlas (TCGA) database and found that 860 lncRNAs were associated with autophagy-related genes. Subsequently, univariate Cox regression analysis was used to investigate 32 autophagy-related lncRNAs linked to colon cancer prognosis. Subsequently, eight of the 32 autophagy-related lncRNAs (i.e., long intergenic nonprotein coding RNA 1503 [LINC01503], ZEB1 antisense RNA 1 [ZEB1-AS1], AC087481.3, AC008760.1, AC073896.3, AL138756.1, AL022323.1, and TNFRSF10A-AS1) were selected through multivariate Cox regression analysis. Based on these autophagy-related lncRNAs, a risk signature was constructed, and the patients were divided into highand low-risk groups. Results. The high-risk group's overall survival time was significantly shorter than that of the low-risk group (p < 0.0001). Receiver operating characteristic curve analysis was performed to further confirm the validity of the model (area under the curve: 0.689). Moreover, multivariate regression suggested that the risk score was a significant prognostic risk factor in colorectal cancer. Gene set enrichment analysis showed that these gene sets are significantly enriched in cancer-related pathways, such as Kirsten rat sarcoma viral oncogene homolog (KRAS) signaling. Conclusion. (e risk signature of eight autophagy-related lncRNAs has prognostic potential for colorectal cancer. These autophagy-related lncRNAs may play a vital role in the biology of colorectal cancer.
C1 [Wei, Jingsun; Ge, Xiaoxu; Tang, Yang; Qian, Yucheng; Lu, Wei; Jiang, Kai; Fang, Yimin; Hwang, Maxwell; Fu, Dongliang; Xiao, Qian; Ding, Kefeng] Zhejiang Univ Sch Med, Affiliated Hosp 2, Dept Colorectal Surg & Oncol, Key Lab Canc Prevent & Intervent,Minist Educ, Hangzhou, Zhejiang, Peoples R China.
RP Ding, KF (corresponding author), Zhejiang Univ Sch Med, Affiliated Hosp 2, Dept Colorectal Surg & Oncol, Key Lab Canc Prevent & Intervent,Minist Educ, Hangzhou, Zhejiang, Peoples R China.
EM dingkefeng@zju.edu.cn
OI Wei, jingsun/0000-0002-4425-0533
FU National Key R&D Program of China [2017YFC0908200]; Key Technology
   Research and Development Program of Zhejiang Province [2017C03017];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81772545]
FX This study was funded by the National Key R&D Program of China
   (2017YFC0908200) the Key Technology Research and Development Program of
   Zhejiang Province (no. 2017C03017) and the National Natural Science
   Foundation of China (grant no. 81772545).
CR Bertelsen CA, 2011, COLORECTAL DIS, V13, P1123, DOI 10.1111/j.1463-1318.2010.02474.x
   Binefa G, 2014, WORLD J GASTROENTERO, V20, P6786, DOI 10.3748/wjg.v20.i22.6786
   Carroll RG, 2013, CANCER CELL, V23, P425, DOI 10.1016/j.ccr.2013.04.001
   Chen JF, 2018, MOL CANCER, V17, DOI 10.1186/s12943-017-0756-y
   Chen S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.486
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Dai WX, 2018, CARCINOGENESIS, V39, P1235, DOI 10.1093/carcin/bgy087
   Ding J, 2021, DIGEST DIS SCI, V66, P452, DOI 10.1007/s10620-020-06215-4
   Frankel LB, 2017, AUTOPHAGY, V13, P3, DOI 10.1080/15548627.2016.1222992
   Fu XR, 2020, PEERJ, V8, DOI 10.7717/peerj.8877
   Gong HB, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317705336
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004
   Lerebours F, 2013, INT J CANCER, V133, P1614, DOI 10.1002/ijc.28171
   Li JL, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12423
   Li T, 2016, ONCOGENE, V35, P1575, DOI 10.1038/onc.2015.223
   Li YM, 2013, INT J ONCOL, V42, P1417, DOI 10.3892/ijo.2013.1817
   Lin JH, 2017, ONCOTARGET, V8, P24202, DOI 10.18632/oncotarget.15527
   Liu AF, 2016, ADV EXP MED BIOL, V927, P137, DOI 10.1007/978-981-10-1498-7_5
   Liu JL, 2013, BMC VET RES, V9, DOI 10.1186/1746-6148-9-75
   Liu MH, 2018, BIOCHEM BIOPH RES CO, V500, P589, DOI 10.1016/j.bbrc.2018.04.109
   Lu SR, 2018, EXP THER MED, V16, P4879, DOI 10.3892/etm.2018.6775
   Lu XX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117400
   Luo Y, 2014, CANCER RES, V74, P330, DOI 10.1158/0008-5472.CAN-13-1052
   Lv QL, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091431
   Magaji BA, 2014, ASIAN PAC J CANCER P, V15, P6059, DOI 10.7314/APJCP.2014.15.15.6059
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200
   Pandey RR, 2011, PROG MOL SUBCELL BIO, V51, P1, DOI 10.1007/978-3-642-16502-3_1
   Qin Y, 2018, ENDOCRINE, V59, P555, DOI 10.1007/s12020-017-1520-1
   Schmukler E, 2014, ONCOTARGET, V5, P577, DOI 10.18632/oncotarget.1775
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Singh KE, 2014, J ADOLESC YOUNG ADUL, V3, P176, DOI 10.1089/jayao.2014.0006
   Su WJ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0711-y
   Thewes B, 2016, NEW ENGL J MED, V375, P2199, DOI 10.1056/NEJMc1612048
   Thorburn J, 2005, MOL BIOL CELL, V16, P1189, DOI 10.1091/mbc.E04-10-0906
   Tiessen I, 2019, ONCOGENE, V38, P5127, DOI 10.1038/s41388-019-0783-9
   Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020
   Xie JJ, 2018, GASTROENTEROLOGY, V154, P2137, DOI 10.1053/j.gastro.2018.02.018
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yang YX, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1280-8
   Yu X, 2018, CANCER BIOL MED, V15, P228, DOI 10.20892/j.issn.2095-3941.2017.0150
   Yue W, 2013, AUTOPHAGY, V9, P714, DOI 10.4161/auto.23997
   Zhang XP, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225573
   Zhao HK, 2018, J NEURO-ONCOL, V140, P281, DOI 10.1007/s11060-018-2874-9
   Zhou M, 2018, MOL THER-NUCL ACIDS, V12, P518, DOI 10.1016/j.omtn.2018.06.007
NR 49
TC 14
Z9 14
U1 2
U2 8
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687-8450
EI 1687-8469
J9 J ONCOL
JI J. Oncol.
PD OCT 23
PY 2020
VL 2020
AR 4728947
DI 10.1155/2020/4728947
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA OT6JR
UT WOS:000590950900001
PM 33149738
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Biggers, JW
   Nguyen, T
   Di, X
   Gupton, JT
   Henderson, SC
   Emery, SM
   Alotaibi, M
   White, KL
   Brown, R
   Almenara, J
   Gewirtz, DA
AF Biggers, Jonathan W.
   Tuyen Nguyen
   Di, Xu
   Gupton, John T.
   Henderson, Scott C.
   Emery, Sean M.
   Alotaibi, Moureq
   White, Kimber L., Jr.
   Brown, Ronetta
   Almenara, Jorge
   Gewirtz, David A.
TI Autophagy, cell death and sustained senescence arrest in B16/F10
   melanoma cells and HCT-116 colon carcinoma cells in response to the
   novel microtubule poison, JG-03-14
SO CANCER CHEMOTHERAPY AND PHARMACOLOGY
LA English
DT Article
DE Melanoma; Colon cancer; Microtubule poison; Autophagy; Senescence
ID BREAST-TUMOR CELLS; CANCER-CELLS; ACCELERATED SENESCENCE; APOPTOSIS;
   INHIBITION; RADIATION; THERAPY; AGENT; CHEMOTHERAPY; DEGRADATION
AB Previous studies have shown that the novel microtubule poison, JG-03-14, which binds to the colchicine binding site of tubulin, has the capacity to kill breast tumor cells primarily through the promotion of autophagy. The current work was designed to determine whether autophagy was, in fact, the primary mode of action as well as susceptibility to JG-03-14 in two additional tumor cell models, the B16/F10 murine melanoma cell line and the HCT-116 human colon cancer cell line.
   Drug cytotoxicity was monitored based on viable cell number and clonogenic survival. Apoptosis was assessed by DAPI staining, the TUNEL assay and/or FACS analysis. Autophagy was monitored based on staining with acridine orange, redistribution and punctuation of RFP-LC3 and electron microscopy as well as p62 degradation. Senescence was evaluated based on beta-galactosidase staining and alterations in cell morphology. Drug effects were also evaluated in a murine model of B16/F10 cells that localizes to the lungs while peripheral neuropathy was assessed by three complementary behavioral assays.
   Both HCT-116 colon cancer cells and B16/F10 melanoma cells were sensitive to JG-03-14 in that the drug demonstrated tumor cell killing. However, there was minimal induction of apoptosis. In contrast, there was clear evidence for autophagy and autophagic flux while the residual surviving cells appeared to be in a state of irreversible senescence. Inhibition of drug-induced autophagy in either the melanoma cells or the colon carcinoma cells was only slightly protective as the cells instead died by apoptosis. JG-03-14 reduced the size of tumor nodules in mice lungs; furthermore, the drug did not promote peripheral neuropathy.
   Taken together with evidence for its actions as a vascular disrupting agent, these observations support the potential utility of JG-03-14 to effectively treat malignancies that might be resistant to conventional chemotherapy through evasion of apoptosis.
C1 [Biggers, Jonathan W.; Tuyen Nguyen; Di, Xu; Emery, Sean M.; Alotaibi, Moureq; White, Kimber L., Jr.; Brown, Ronetta; Gewirtz, David A.] Virginia Commonwealth Univ, Dept Pharmacol & Pharmacol, Massey Canc Ctr, Richmond, VA 23298 USA.
   [Gupton, John T.] Univ Richmond, Dept Chem, Richmond, VA 23173 USA.
   [Henderson, Scott C.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23173 USA.
   [Almenara, Jorge] Virginia Commonwealth Univ, Dept Anat Pathol, Richmond, VA 23173 USA.
RP Gewirtz, DA (corresponding author), Virginia Commonwealth Univ, Dept Pharmacol & Pharmacol, Massey Canc Ctr, POB 980035, Richmond, VA 23298 USA.
EM gewirtz@vcu.edu
RI Henderson, Scott/AAP-2785-2021
OI Henderson, Scott/0000-0002-1076-3867
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [2R15 CA067236-04, RO1 CA135043-01A1,
   P30CA16059]; NIH-NINDS Center core grant [P30NS047463]; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R01CA135043, R15CA067236, P30CA016059] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS)
   [P30NS047463] Funding Source: NIH RePORTER
FX This work was supported, in part, by NIH Grant # 2R15 CA067236-04 to Dr.
   John Gupton and NIH Grant # RO1 CA135043-01A1 to Dr. David Gewirtz.
   Electron microscopy was performed at the VCU-Department of Neurobiology
   and Anatomy Microscopy Facility, supported, in part, with funding from
   NIH-NINDS Center core grant P30NS047463. We acknowledge the support of
   the Flow cytometry shared resource facility supported in part by NIH
   Grant P30CA16059. We are grateful to the Anatomic Pathology Research
   Services for the histology work. The RFP-LC3 vector was generously
   provided by Dr. Keith Miskimins at the University of South Dakota and
   was originally developed by the laboratory of Dr. A. M. Tolkovsky. We
   are grateful to Dr. Fiorenza Ianzini at the University of Iowa for
   guidance with the assessment of mitotic catastrophe.
CR Alva AS, 2004, CELL DEATH DIFFER, V11, P1046, DOI 10.1038/sj.cdd.4401445
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Arthur CR, 2007, BIOCHEM PHARMACOL, V74, P981, DOI 10.1016/j.bcp.2007.07.003
   Bajetta E, 2002, SEMIN ONCOL, V29, P427, DOI 10.1053/sonc.2002.35238
   Bampton ETW, 2005, AUTOPHAGY, V1, P23, DOI 10.4161/auto.1.1.1495
   Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Callizot N, 2008, CANCER CHEMOTH PHARM, V62, P995, DOI 10.1007/s00280-008-0689-7
   Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233
   Carlson K, 2011, CLIN BREAST CANCER, V11, P73, DOI 10.1016/j.clbc.2011.03.006
   Chao SK, 2011, P NATL ACAD SCI USA, V108, P391, DOI 10.1073/pnas.1016962108
   Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206
   Dalyot-Herman N, 2009, BIOCHEM PHARMACOL, V78, P1167, DOI 10.1016/j.bcp.2009.06.093
   DeMasters G, 2006, MOL CANCER THER, V5, P2786, DOI 10.1158/1535-7163.MCT-06-0316
   El-Emir E, 2005, EUR J CANCER, V41, P799, DOI 10.1016/j.ejca.2005.01.001
   Elmore LW, 2005, CLIN CANCER RES, V11, P2637, DOI 10.1158/1078-0432.CCR-04-1462
   Fulda S, 2009, INT J CANCER, V124, P511, DOI 10.1002/ijc.24064
   Gewirtz DA, 2008, BIOCHEM PHARMACOL, V76, P947, DOI 10.1016/j.bcp.2008.06.024
   Goehe R. W, 2012, J PHARM EXP THER
   Gonzalez-Polo RA, 2007, TOXICOL SCI, V97, P448, DOI 10.1093/toxsci/kfm040
   Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661
   Greene LM, 2012, BIOCHEM PHARMACOL, V84, P612, DOI 10.1016/j.bcp.2012.06.005
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Haugstetter AM, 2010, BRIT J CANCER, V103, P505, DOI 10.1038/sj.bjc.6605784
   Jones KR, 2005, INT J RADIAT BIOL, V81, P445, DOI 10.1080/09553000500168549
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Meschini S, 2008, AUTOPHAGY, V4, P1020, DOI 10.4161/auto.6952
   Mooberry SL, 2007, MOL PHARMACOL, V72, P132, DOI 10.1124/mol.107.034876
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Negoescu A, 1996, J HISTOCHEM CYTOCHEM, V44, P959, DOI 10.1177/44.9.8773561
   Paglin S, 2001, CANCER RES, V61, P439
   Prabhudesai SG, 2007, J SURG ONCOL, V96, P77, DOI 10.1002/jso.20785
   Roberson RS, 2005, CANCER RES, V65, P2795, DOI 10.1158/0008-5472.CAN-04-1270
   Scarlatti F, 2009, CELL DEATH DIFFER, V16, P12, DOI 10.1038/cdd.2008.101
   Schwartz RN, 2008, AM J HEALTH-SYST PH, V65, pS8, DOI 10.2146/ajhp080101
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Shacka JJ, 2006, MOL PHARMACOL, V69, P1125, DOI 10.1124/mol.105.018408
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Sills RC, 2000, TOXICOL PATHOL, V28, P142, DOI 10.1177/019262330002800118
   Song YS, 2005, MECH AGEING DEV, V126, P580, DOI 10.1016/j.mad.2004.11.008
   Sorensen NM, 2008, SCAND J GASTROENTERO, V43, P186, DOI 10.1080/00365520701491355
   Swain Sandra M, 2008, Clin Adv Hematol Oncol, V6, P455
   Tormo D, 2009, CANCER CELL, V16, P103, DOI 10.1016/j.ccr.2009.07.004
   Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P1153, DOI 10.1038/cdd.2008.47
   Wachsberger PR, 2005, CLIN CANCER RES, V11, P835
   Yla-Anttila P, 2009, METHOD ENZYMOL, V452, P143, DOI 10.1016/S0076-6879(08)03610-0
NR 46
TC 24
Z9 24
U1 0
U2 29
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0344-5704
EI 1432-0843
J9 CANCER CHEMOTH PHARM
JI Cancer Chemother. Pharmacol.
PD FEB
PY 2013
VL 71
IS 2
BP 441
EP 455
DI 10.1007/s00280-012-2024-6
PG 15
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 077RC
UT WOS:000314044200019
PM 23178952
DA 2022-04-25
ER

PT J
AU Wang, HF
   Cheng, X
   Zhang, L
   Xu, SC
   Zhang, QX
   Lu, RR
AF Wang, Huifang
   Cheng, Xian
   Zhang, Li
   Xu, Shichen
   Zhang, Qiuxiang
   Lu, Rongrong
TI A surface-layer protein from Lactobacillus acidophilus NCFM induces
   autophagic death in HCT116 cells requiring ROS-mediated modulation of
   mTOR and JNK signaling pathways
SO FOOD & FUNCTION
LA English
DT Article
ID CANCER-CELLS; COLON-CANCER; PROBIOTICS; INDUCTION; PROLIFERATION;
   PI3K/AKT/MTOR; INHIBITION; BACTERIA; ADHESION; STRAINS
AB A surface-layer protein (Slp) derived from Lactobacillus acidophilus NCFM has been reported to possess multiple biological properties, including anti-inflammatory, inhibition of apoptosis in pathogen-invaded HT-29 cells and oxidative stress relief. However, its anti-tumor ability and underlying molecular mechanism are unknown. Here, we report that Slp suppresses cell proliferation and induces autophagic cell death in HCT116 cells. Accumulation of Beclin-1 and microtubule-associated protein 1 light chain 3 from II (LC3-II), and the degradation of p62 were observed when cells were treated with various concentrations of Slp (25, 50, 100 mu g mL(-1)) for 24 h. We also found that the mammalian targets of rapamycin (mTOR) and c-Jun N-terminal kinase (JNK) signaling pathways were crucial mediators regulating Slp-induced autophagic cell death. Additionally, treatment with Slp resulted in the obvious formation of reactive oxygen species (ROS). SP600125, a JNK inhibitor, and N-acetylcysteine (NAC), a ROS inhibitor, attenuated Slp-induced autophagic cell death in HCT116 cells. Furthermore, NAC was found to prevent Slp-induced p70 and JNK phosphorylation. Taken together, our results suggest a novel mechanism of action of Slp induced autophagy, acting simultaneously through the ROS-mediated mTOR and JNK signaling pathways in HCT116 colon cancer cells.
C1 [Wang, Huifang; Zhang, Qiuxiang; Lu, Rongrong] Jiangnan Univ, Sch Food Sci & Technol, 1800 Lihu Ave, Wuxi 214122, Jiangsu, Peoples R China.
   [Cheng, Xian; Zhang, Li; Xu, Shichen] Minist Hlth, Key Lab Nucl Med, Jiangsu Inst Nucl Med, 20 Qian Rong, Wuxi 214063, Jiangsu, Peoples R China.
RP Lu, RR (corresponding author), Jiangnan Univ, Sch Food Sci & Technol, 1800 Lihu Ave, Wuxi 214122, Jiangsu, Peoples R China.
EM lurr@jiangnan.edu.cn
OI Lu, Rongrong/0000-0001-8671-9144
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31471696]
FX This research was supported by the National Natural Science Foundation
   of China (No. 31471696). We would like to appreciate Mr Qingzhu Liu
   (Jiangsu Institute of Nuclear Medicine) for providing the HCT116 cells,
   and Miss Jie Pan and Miss Jiangxia Zheng for their enthusiastic support
   in this work.
CR Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039
   Abedin-Do A, 2015, IMMUNOTHERAPY-UK, V7, P1307, DOI 10.2217/imt.15.92
   Bendali F, 2017, BENEF MICROBES, V8, P271, DOI 10.3920/BM2016.0121
   Cai ZD, 2018, J FUNCT FOODS, V51, P16, DOI 10.1016/j.jff.2018.10.008
   Chalamaiah M, 2018, FOOD CHEM, V245, P205, DOI 10.1016/j.foodchem.2017.10.087
   Chen CC, 2012, BRIT J NUTR, V107, P1623, DOI 10.1017/S0007114511004934
   Choi SS, 2006, LETT APPL MICROBIOL, V42, P452, DOI 10.1111/j.1472-765X.2006.01913.x
   Chung EJ, 2017, EUR J PHARMACOL, V794, P1, DOI 10.1016/j.ejphar.2016.11.012
   Dallal MMS, 2015, ARCH IRAN MED, V18, P167, DOI 0151803/AIM.006
   Di W, 2018, ONCOL LETT, V16, P3577, DOI 10.3892/ol.2018.9129
   El-Deeb NM, 2018, MICROB CELL FACT, V17, DOI 10.1186/s12934-018-0877-z
   Eslami M., 2019, J CELL PHYSL, V3, P1
   Hambright HG, 2015, ONCOTARGET, V6, P7195, DOI 10.18632/oncotarget.3131
   Hashemi A, 2016, FOOD FUNCT, V7, P1752, DOI [10.1039/C5FO01148E, 10.1039/c5fo01148e]
   Hirayama K, 2000, MICROBES INFECT, V2, P681, DOI 10.1016/S1286-4579(00)00357-9
   Hollmann A, 2010, COLLOID SURFACE B, V79, P191, DOI 10.1016/j.colsurfb.2010.03.046
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P384, DOI 10.1038/nrclinonc.2011.82
   Johnson BR, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01185
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Khang YH, 2009, J MICROBIOL BIOTECHN, V19, P511, DOI 10.4014/jmb.0805.325
   Kim JY, 2002, BIOTECHNOL LETT, V24, P1431, DOI 10.1023/A:1019875204323
   Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Lightfoot YL, 2015, EMBO J, V34, P881, DOI 10.15252/embj.201490296
   Maiese K, 2013, TRENDS MOL MED, V19, P51, DOI 10.1016/j.molmed.2012.11.001
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Meng J, 2018, ANN MICROBIOL, V68, P207, DOI 10.1007/s13213-018-1335-1
   Meng J, 2014, INT J BIOL MACROMOL, V65, P110, DOI 10.1016/j.ijbiomac.2014.01.024
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Mobili P, 2009, VIB SPECTROSC, V50, P68, DOI 10.1016/j.vibspec.2008.07.016
   Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200
   Ouyang DY, 2013, FOOD CHEM TOXICOL, V60, P424, DOI 10.1016/j.fct.2013.08.007
   Paglin S, 2001, CANCER RES, V61, P439
   Parvez S, 2006, J APPL MICROBIOL, V100, P1171, DOI 10.1111/j.1365-2672.2006.02963.x
   Perdigon G, 2002, EUR J CLIN NUTR, V56, pS65, DOI 10.1038/sj.ejcn.1601490
   Roninson IB, 2003, CANCER RES, V63, P2705
   Sakatani A, 2016, ANTICANCER RES, V36, P591
   Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009
   Sun ZL, 2013, APPL MICROBIOL BIOT, V97, P1941, DOI 10.1007/s00253-012-4044-x
   Tian PJ, 2015, INT J MOL SCI, V16, P20033, DOI 10.3390/ijms160820033
   Vazquez-Martin A, 2009, CELL CYCLE, V8, P88, DOI 10.4161/cc.8.1.7499
   WALDMAN T, 1995, CANCER RES, V55, P5187
   Wang HF, 2018, J AGR FOOD CHEM, V66, P7655, DOI 10.1021/acs.jafc.8b02012
   Wang SM, 2014, RES MICROBIOL, V165, P202, DOI 10.1016/j.resmic.2014.02.004
   Wang WX, 2017, INT J PHARMACEUT, V529, P227, DOI 10.1016/j.ijpharm.2017.07.006
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   Xu JA, 2017, REDOX BIOL, V12, P198, DOI 10.1016/j.redox.2017.02.017
   Zhang DD, 2017, J SCI FOOD AGR, V97, P4204, DOI 10.1002/jsfa.8294
   Zhao RL, 2015, J CANCER, V6, P623, DOI 10.7150/jca.11291
NR 49
TC 12
Z9 12
U1 3
U2 25
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2042-6496
EI 2042-650X
J9 FOOD FUNCT
JI Food Funct.
PD JUL 1
PY 2019
VL 10
IS 7
BP 4102
EP 4112
DI 10.1039/c9fo00109c
PG 11
WC Biochemistry & Molecular Biology; Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Food Science & Technology
GA IK6GK
UT WOS:000476683600024
PM 31233063
DA 2022-04-25
ER

PT J
AU Lucas, C
   Salesse, L
   Hoang, MHT
   Bonnet, M
   Sauvanet, P
   Larabi, A
   Godfraind, C
   Gagniere, J
   Pezet, D
   Rosenstiel, P
   Barnich, N
   Bonnet, R
   Dalmasso, G
   Nguyen, HTT
AF Lucas, Cecily
   Salesse, Laurene
   My Hanh Thi Hoang
   Bonnet, Mathilde
   Sauvanet, Pierre
   Larabi, Anais
   Godfraind, Catherine
   Gagniere, Johan
   Pezet, Denis
   Rosenstiel, Philip
   Barnich, Nicolas
   Bonnet, Richard
   Dalmasso, Guillaume
   Hang Thi Thu Nguyen
TI Autophagy of Intestinal Epithelial Cells Inhibits Colorectal
   Carcinogenesis Induced by Colibactin-Producing Escherichia coil in
   Apc(Min/+) Mice
SO GASTROENTEROLOGY
LA English
DT Article
DE Microbiome; Pathogenic Bacteria; Toxin; Colon Cancer
ID TUMOR-GROWTH; HUMAN GUT; E. COLI; CANCER; TUMORIGENESIS; COLONIZATION;
   ELIMINATION; INSTABILITY; EXPRESSION; MICROBIOTA
AB BACKGROUND & AIMS: Colibactin-producing Escherichia coli (CoPEC) colonize the colonic mucosa of a higher proportion of patients with vs without colorectal cancer (CRC) and promote colorectal carcinogenesis in susceptible mouse models of CRC. Autophagy degrades cytoplasmic contents, including intracellular pathogens, via lysosomes and regulates intestinal homeostasis. We investigated whether inhibiting autophagy affects colorectal carcinogenesis in susceptible mice infected with CoPEC. METHODS: Human intestinal epithelial cells (IECs) (HCT-116) were infected with a strain of CoPEC (11G5 strain) isolated from a patient or a mutant strain that does not produce colibactin (11G5 Delta clbQ). Levels of ATG5, ATG16L1, and SQSTM1 (also called p62) were knocked down in HCT-116 cells using small interfering RNAs. Apc(Min/+) mice and Apc(Min/+) mice with IEC-specific disruption of Atg1611 (Apc(Min/+)/Atg16l1(Delta IEG)) were infected with 11G5 or 11G5AclbQ. Colonic tissues were collected from mice and analyzed for tumor size and number and by immunohistochemical staining, immunoblot, and quantitative reverse transcription polymerase chain reaction for markers of autophagy, DNA damage, cell proliferation, and inflammation. We analyzed levels of messenger RNAs (mRNAs) encoding proteins involved in autophagy in colonic mucosal tissues from patients with sporadic CRC colonized with vs without CoPEC by quantitative reversetranscription polymerase chain reaction. RESULTS: Patient colonic mucosa with CoPEC colonization had higher levels of mRNAs encoding proteins involved in autophagy than colonic mucosa without these bacteria. Infection of cultured IECs with 11G5 induced autophagy and DNA damage repair, whereas infection with 11G5 Delta clbQ did not. Knockdown of ATG5 in HCT-116 cells increased numbers of intracellular 11G5, secretion of interleukin (IL) 6 and IL8, and markers of DNA double-strand breaks but reduced markers of DNA repair, indicating that autophagy is required for bacteria-induced DNA damage repair. Knockdown of ATG5 in HCT-116 cells increased 11G5-induced senescence, promoting proliferation of uninfected cells. Under uninfected condition, Apc(Min/+)/Atg16l1(Delta IEG) mice developed fewer and smaller colon tumors than Apc(Min/+) mice. However, after infection with 11G5, Apc(Min/+)/Atg16l1(Delta IEG) mice developed more and larger tumors, with a significant increase in mean histologic score, than infected Apc(Min/+) mice. Increased levels of 116, Tnf, and Cxcl/mRNAs, decreased level of 1110 mRNA, and increased markers of DNA double-strand breaks and proliferation were observed in the colonic mucosa of 11G5-infected Apc(Min/+)/Atg16l1(Delta IEG) A1Ec mice vs 11G5-infected Apc(Min/+) mice. CONCLUSION: Infection of IECs and susceptible mice with CoPEC promotes autophagy, which is required to prevent colorectal tumorigenesis. Loss of ATG16L1 from IECs increases markers of inflammation, DNA damage, and cell proliferation and increases colorectal tumorigenesis in 11G5-infected Apc(Min/+) mice. These findings indicate the importance of autophagy in response to CoPEC infection, and strategies to induce autophagy might be developed for patients with CRC and CoPEC colonization.
C1 [Lucas, Cecily; Salesse, Laurene; My Hanh Thi Hoang; Bonnet, Mathilde; Sauvanet, Pierre; Larabi, Anais; Godfraind, Catherine; Gagniere, Johan; Pezet, Denis; Barnich, Nicolas; Bonnet, Richard; Dalmasso, Guillaume; Hang Thi Thu Nguyen] Univ Clermont Auvergne, INSERM, UMR 1071, M2iSH, 28 Pl Henri Dunant, F-63001 Clermont Ferrand, France.
   [My Hanh Thi Hoang] Vietnam Natl Univ, Univ Sci, Fac Biol, Dept Cell Biol, Hanoi, Vietnam.
   [Sauvanet, Pierre; Gagniere, Johan; Pezet, Denis] CHU Clermont Ferrand, Dept Digest & Hepatobiliary Surg, Clermont Ferrand, France.
   [Godfraind, Catherine] CHU Gabriel Montpied, Dept Pathol, Clermont Ferrand, France.
   [Rosenstiel, Philip] Univ Kiel, Inst Clin Mol Biol, Kiel, Germany.
   [Rosenstiel, Philip] Univ Hosp Schleswig Holstein, Kiel, Germany.
   [Bonnet, Richard] CHU Gabriel Montpied, Dept Bacteriol, Clermont Ferrand, France.
RP Nguyen, HTT (corresponding author), Univ Clermont Auvergne, INSERM, UMR 1071, M2iSH, 28 Pl Henri Dunant, F-63001 Clermont Ferrand, France.
EM hang.nguyen@uca.fr
RI Nguyen, Hang/N-2441-2018; Dalmasso, Guillaume/N-2443-2018; Rosenstiel,
   Philip/A-5137-2009; Bonnet, Mathilde/T-2835-2017
OI Nguyen, Hang/0000-0001-7431-5126; Dalmasso,
   Guillaume/0000-0002-3433-870X; Rosenstiel, Philip/0000-0002-9692-8828;
   Lucas, Cecily/0000-0002-4276-723X; Bonnet, Mathilde/0000-0003-3629-7267
FU Ministere de la Recherche et de la Technologie; Inserm (Institut
   national de la sante et de la recherche medicale)Institut National de la
   Sante et de la Recherche Medicale (Inserm) [UMR1071]; INRAE (Institut
   national de recherche en agriculture, alimentation et environnement; USC
   2018); Agence Nationale de la Recherche of the French government through
   the program "Investissements d'Avenir"French National Research Agency
   (ANR) [16-IDEX-0001 CAP 20-25]; European Union FP7 People Marie Curie
   International Incoming Fellowship; DFG (Deutsche
   Forschungsgemeinschaft)German Research Foundation (DFG) [CRC1182]
FX This work was supported by the Ministere de la Recherche et de la
   Technologie, Inserm (Institut national de la sante et de la recherche
   medicale; UMR1071), INRAE (Institut national de recherche en
   agriculture, alimentation et environnement; USC 2018), the Agence
   Nationale de la Recherche of the French government through the program
   "Investissements d'Avenir" (16-IDEX-0001 CAP 20-25) (to Hang Thi Thu
   Nguyen), the European Union FP7 People Marie Curie International
   Incoming Fellowship (to Hang Thi Thu Nguyen) and the DFG (Deutsche
   Forschungsgemeinschaft) ExC Precision Medicine in Chronic Inflammation
   and the CRC1182 project C2 (to Philip Rosenstiel).
CR Adolph TE, 2013, NATURE, V503, P272, DOI 10.1038/nature12599
   Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Arthur JC, 2012, SCIENCE, V338, P120, DOI 10.1126/science.1224820
   Arvelo F, 2015, ECANCERMEDICALSCIENC, V9, DOI 10.3332/ecancer.2015.520
   Bonnet M, 2014, CLIN CANCER RES, V20, P859, DOI 10.1158/1078-0432.CCR-13-1343
   Bretin A, 2016, AUTOPHAGY, V12, P770, DOI 10.1080/15548627.2016.1156823
   Buc E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056964
   Chen ZH, 2013, DIGEST DIS SCI, V58, P2887, DOI 10.1007/s10620-013-2732-8
   Cohen-Kaplan V, 2016, ONCOTARGET, V7, P83833, DOI 10.18632/oncotarget.13805
   Cougnoux A, 2014, GUT, V63, P1932, DOI 10.1136/gutjnl-2013-305257
   Cuevas-Ramos G, 2010, P NATL ACAD SCI USA, V107, P11537, DOI 10.1073/pnas.1001261107
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Gagniere J, 2017, CLIN SCI, V131, P471, DOI 10.1042/CS20160876
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Nguyen HTT, 2014, GASTROENTEROLOGY, V146, P508, DOI 10.1053/j.gastro.2013.10.021
   Nguyen HTT, 2013, J INNATE IMMUN, V5, P434, DOI 10.1159/000345129
   Jo YK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052705
   Kostic AD, 2013, CELL HOST MICROBE, V14, P207, DOI 10.1016/j.chom.2013.07.007
   Lapaquette P, 2010, CELL MICROBIOL, V12, P99, DOI 10.1111/j.1462-5822.2009.01381.x
   Levy J, 2015, NAT CELL BIOL, V17, P1062, DOI 10.1038/ncb3206
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Li YH, 2012, CARCINOGENESIS, V33, P1231, DOI 10.1093/carcin/bgs137
   Lucas C, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061310
   Ma YT, 2013, IMMUNITY, V39, P211, DOI 10.1016/j.immuni.2013.07.017
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Mima K, 2016, GUT, V65, P1973, DOI 10.1136/gutjnl-2015-310101
   Mizushima N, 2018, NAT CELL BIOL, V20, P521, DOI 10.1038/s41556-018-0092-5
   MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722
   Nougayrede JP, 2006, SCIENCE, V313, P848, DOI 10.1126/science.1127059
   Raisch J, 2015, LAB INVEST, V95, P296, DOI 10.1038/labinvest.2014.161
   Raisch J, 2014, WORLD J GASTROENTERO, V20, P6560, DOI 10.3748/wjg.v20.i21.6560
   Singh SS, 2018, ONCOGENE, V37, P1142, DOI 10.1038/s41388-017-0046-6
   Tang B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165701
   Tomkovich S, 2017, CANCER RES, V77, P2620, DOI 10.1158/0008-5472.CAN-16-3472
   Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034
   Wang YN, 2016, MOL CELL, V63, P34, DOI 10.1016/j.molcel.2016.05.027
   Wong SH, 2017, GASTROENTEROLOGY, V153, P1621, DOI 10.1053/j.gastro.2017.08.022
   Yang MP, 2015, ONCOTARGET, V6, P7084, DOI 10.18632/oncotarget.3054
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Zackular JP, 2013, MBIO, V4, DOI 10.1128/mBio.00692-13
   Zheng Hai-yang, 2012, Cancer Biology Medicine, V9, P105, DOI 10.3969/j.issn.2095-3941.2012.02.004
NR 41
TC 21
Z9 23
U1 0
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
EI 1528-0012
J9 GASTROENTEROLOGY
JI Gastroenterology
PD APR
PY 2020
VL 158
IS 5
BP 1373
EP 1388
DI 10.1053/j.gastro.2019.12.026
PG 16
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA KW4IK
UT WOS:000521129300031
PM 31917256
OA hybrid
DA 2022-04-25
ER

PT J
AU Harmse, L
   Dahan-Farkas, N
   Panayides, JL
   van Otterlo, W
   Penny, C
AF Harmse, Leonie
   Dahan-Farkas, Nurit
   Panayides, Jenny-Lee
   van Otterlo, Willem
   Penny, Clement
TI Aberrant Apoptotic Response of Colorectal Cancer Cells to Novel
   Nucleoside Analogues
SO PLOS ONE
LA English
DT Article
ID CYTOCHROME-C RELEASE; COLON-CANCER; DRUG-RESISTANCE; WILD-TYPE;
   MITOCHONDRIA; DEATH; P53; BAX; MECHANISMS; BCL-2
AB Despite the increased understanding of colorectal cancer and the introduction of targeted drug therapy, the metastatic phase of the disease remains refractory to treatment. Since the deregulation of normal apoptosis contributes to the pathogenesis of colorectal cancer, novel nucleoside analogues were synthesized here and evaluated for their ability to induce apoptosis and cause cell death in two colorectal adeno-carcinoma cell lines, Caco-2 and HT-29. Three novel nucleoside analogues assessed here showed cytotoxic activity, as measured by the MTT assay against both cell lines: the IC50 values ranged between 3 and 37 mu M, with Caco-2 cells being more sensitive than HT-29 cells. Compared to camptothecin, the positive control, the nucleoside analogues were significantly less toxic to normal unstimulated leukocytes (p>0.05). Moreover, the nucleosides were able to induce apoptosis as measured by an increase in caspase 8 and caspase 3 activity above that of the control. This was additionally supported by data derived from Annexin V-FITC assays. Despite marginal changes to the mitochondrial membrane potential, all three nucleosides caused a significant increase in cytosolic cytochrome c (p>0.05), with a corresponding decrease in mitochondrial cytochrome c. Morphological analysis of both cell lines showed the rapid appearance of vacuoles following exposure to two of the nucleosides, while a third caused cellular detachment, delayed cytoplasmic vacuolisation and nuclear abnormalities. Preliminary investigations, using the autophagic indicator monodansylcadaverine and chloroquine as positive control, showed that two of the nucleosides induced the formation of autophagic vacuoles. In summary, the novel nucleoside analogues showed selective cytotoxicity towards both cancer cell lines and are effective initiators of an unusual apoptotic response, demonstrating their potential to serve as structural scaffolds for more potent analogues.
C1 [Harmse, Leonie; Dahan-Farkas, Nurit] Univ Witwatersrand, Div Pharmacol, Dept Pharm & Pharmacol, Fac Hlth Sci, ZA-2193 Parktown, South Africa.
   [Panayides, Jenny-Lee; van Otterlo, Willem] Univ Witwatersrand, Inst Mol Sci, Sch Chem, Fac Sci, ZA-2050 Johannesburg, South Africa.
   [van Otterlo, Willem] Univ Stellenbosch, Dept Chem & Polymer Sci, ZA-7602 Matieland, South Africa.
   [Penny, Clement] Univ Witwatersrand, Dept Internal Med, Fac Hlth Sci, ZA-2193 Parktown, South Africa.
RP Harmse, L (corresponding author), Univ Witwatersrand, Div Pharmacol, Dept Pharm & Pharmacol, Fac Hlth Sci, 7 York Rd, ZA-2193 Parktown, South Africa.
EM Leonie.Harmse@wits.ac.za
FU Research Niche Areas Program of the National Research Foundation (NRF)
   of South Africa; University of the Witwatersrand Faculty of Health
   Sciences Research Committee; NRF Scarce Skill Program
FX This work was supported by the Research Niche Areas Program of the
   National Research Foundation (NRF) of South Africa and the University of
   the Witwatersrand Faculty of Health Sciences Research Committee. JLP was
   supported by the NRF Scarce Skill Program for studies towards a Ph.D.
   The funders had no role in study design, data collection, analysis,
   decision to publish or preparation of the manuscript.
CR Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35
   Bampton ETW, 2005, AUTOPHAGY, V1, P23, DOI 10.4161/auto.1.1.1495
   Bedner E, 2000, CYTOMETRY, V41, P83, DOI 10.1002/1097-0320(20001001)41:2<83::AID-CYTO1>3.3.CO;2-I
   Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37
   Carrato A, 2013, J CLIN ONCOL, V31, P1341, DOI 10.1200/JCO.2012.45.1930
   Chabner BA, 2011, GOODMAN GILMANS PHAR, P1695
   Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107
   Denecker G, 2001, CELL MOL LIFE SCI, V58, P356, DOI 10.1007/PL00000863
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   FADOK VA, 1992, J IMMUNOL, V148, P2207
   Feng L, 2000, INT J MOL MED, V5, P597
   Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137
   Galmarini CM, 2001, LEUKEMIA, V15, P875, DOI 10.1038/sj.leu.2402114
   Geng Y, 2010, NEURO-ONCOLOGY, V12, P473, DOI 10.1093/neuonc/nop048
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899
   Hajdo L, 2010, DRUG DEVELOP RES, V71, P383, DOI 10.1002/ddr.20390
   Hatok J, 2009, CLIN EXP MED, V9, P1, DOI 10.1007/s10238-008-0011-3
   HEIDELBERGER C, 1983, ADV ENZYMOL RAMB, V54, P57
   Huerta S, 2006, AM J SURG, V191, P517, DOI 10.1016/j.amjsurg.2005.11.009
   Jeong SY, 2008, BMB REP, V41, P11, DOI 10.1146/annurev-genet-102108-134850
   Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706
   Jimenez C, 2009, J EXP BOT, V60, P815, DOI 10.1093/jxb/ern330
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994
   Lamberti M, 2015, INT J ONCOL, V46, P1893, DOI 10.3892/ijo.2015.2904
   Lazaro-Dieguez F, 2008, J CELL SCI, V121, P1415, DOI 10.1242/jcs.017665
   Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1
   Liu Y, 2006, P NATL ACAD SCI USA, V103, P976, DOI 10.1073/pnas.0510146103
   Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5
   Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762
   Marshman E, 2001, J PATHOL, V195, P285
   Mikhailov V, 2003, J BIOL CHEM, V278, P5367, DOI 10.1074/jbc.M203392200
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Munafo DB, 2001, J CELL SCI, V114, P3619
   O'Connell J, 2000, ANN NY ACAD SCI, V910, P178
   Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476
   Portier BP, 2006, J BIOL CHEM, V281, P40493, DOI 10.1074/jbc.M606181200
   Roucou X, 2002, BIOCHEM J, V368, P915, DOI 10.1042/BJ20020972
   Sampath D, 2003, ONCOGENE, V22, P9063, DOI 10.1038/sj.onc.1207229
   Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321
   SPROAT BS, 1994, J CHEM SOC PERK T 1, P419, DOI 10.1039/p19940000419
   Van Geelen CMM, 2004, DRUG RESIST UPDATE, V7, P345, DOI 10.1016/j.drup.2004.11.002
   van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970
   Wang LM, 2008, CHEM-BIOL INTERACT, V176, P165, DOI 10.1016/j.cbi.2008.07.005
   Wang NS, 2001, J BIOL CHEM, V276, P44117, DOI 10.1074/jbc.M101958200
   Wang Y, 2004, J CELL SCI, V117, P1525, DOI 10.1242/jcs.00994
   Watson AJM, 2004, GUT, V53, P1701, DOI 10.1136/gut.2004.052704
   Wong RSY, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-87
   Xu Y, 2008, ONCOGENE, V27, P3501, DOI 10.1038/sj.onc.1211023
   Yang SY, 2009, TRENDS MOL MED, V15, P225, DOI 10.1016/j.molmed.2009.03.003
   Zaidi AU, 2001, J NEUROPATH EXP NEUR, V60, P937, DOI 10.1093/jnen/60.10.937
   Zhang W, 2005, WORLD J GASTROENTERO, V11, P3632, DOI 10.3748/wjg.v11.i23.3632
   Zhang ZW, 2000, ANTI-CANCER DRUG, V11, P757, DOI 10.1097/00001813-200010000-00013
   Zong D, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.62
NR 55
TC 4
Z9 4
U1 2
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 21
PY 2015
VL 10
IS 9
AR e0138607
DI 10.1371/journal.pone.0138607
PG 31
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CS0ZM
UT WOS:000361791000043
PM 26390405
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Conacci-Sorrell, M
   Ngouenet, C
   Anderson, S
   Brabletz, T
   Eisenman, RN
AF Conacci-Sorrell, Maralice
   Ngouenet, Celine
   Anderson, Sarah
   Brabletz, Thomas
   Eisenman, Robert N.
TI Stress-induced cleavage of Myc promotes cancer cell survival
SO GENES & DEVELOPMENT
LA English
DT Article
DE Myc; Myc-nick; hypoxia; autophagy; motility; fascin
ID C-MYC; COLORECTAL-CANCER; BETA-CATENIN; INVASION FRONT; CYCLE ARREST;
   AUTOPHAGY; APOPTOSIS; HYPOXIA; FASCIN; ACETYLATION
AB Evasion of apoptosis is critical in Myc-induced tumor progression. Here we report that cancer cells evade death under stress by activating calpain-mediated proteolysis of Myc. This generates Myc-nick, a cytoplasmic, transcriptionally inactive cleavage product of Myc. We found conversion of Myc into Myc-nick in cell lines and tissues derived from multiple cancers. In colon cancer, the production of Myc-nick is enhanced under stress conditions such as hypoxia and nutrient deprivation. Under these conditions, ectopic expression of Myc-nick promotes anchorage-independent growth and cell survival at least in part by promoting autophagy. Myc-nick also delays colon cancer cell death after treatment with chemotherapeutic drugs such as etoposide, cisplatin, and imatinib. Furthermore, colon cancer cells expressing a cleavage-resistant form of Myc undergo extensive apoptosis but are rescued by overexpression of Myc-nick. We also found that ectopic expression of Myc-nick results in the induction of the actin-bundling protein fascin, formation of filopodia, and increased cell motility-all mediators of tumor metastasis. Myc-nick-induced survival, autophagy, and motility require Myc box II ( MBII), a region of Myc-nick that recruits acetyltransferases that in turn modify cytoplasmic proteins, including a-tubulin and ATG3. Our results suggest that Myc-nick-induced survival and motility contribute to colon cancer progression and metastasis.
C1 [Conacci-Sorrell, Maralice; Ngouenet, Celine; Anderson, Sarah; Eisenman, Robert N.] Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA.
   [Brabletz, Thomas] Univ Freiburg, Ctr Comprehens Canc, Dept Visceral Surg, D-79095 Freiburg, Germany.
RP Eisenman, RN (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA.
EM eisenman@fhcrc.org
RI Sorrell, Maralice/ABD-6764-2021
FU National Institutes of Health/National Cancer InstituteUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [CA20525]; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R37CA020525, R01CA020525] Funding Source: NIH RePORTER
FX We are grateful to Nao Ikegaki, William Tansey, John Sedivy, Jonathan
   Grim, Bruce Clurman, Markus Welker, Lukas Low, Brian Freie, and Denise
   Galloway for advice, protocols, reagents, and equipment essential for
   this work. We also thank James Olson for mouse medulloblastoma samples,
   and Peter Nelson for prostate cancer xenografts. This work was supported
   by National Institutes of Health/National Cancer Institute grant CA20525
   (to R.N.E.).
CR ADAMS JM, 1985, PROC R SOC SER B-BIO, V226, P59, DOI 10.1098/rspb.1985.0079
   Aratyn YS, 2007, MOL BIOL CELL, V18, P3928, DOI 10.1091/mbc.E07-04-0346
   BAI MK, 1994, ONCOLOGY, V51, P314
   Barcellos KSA, 2013, J BIOL CHEM, V288, P2179, DOI 10.1074/jbc.M112.432716
   Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498
   Calcagno DQ, 2009, ANTICANCER RES, V29, P2479
   Conacci-Sorrell M, 2011, CELL CYCLE, V10, P604, DOI 10.4161/cc.10.4.14794
   Conacci-Sorrell M, 2010, CELL, V142, P480, DOI 10.1016/j.cell.2010.06.037
   Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104
   Dang CV, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014217
   Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003
   Dang CV, 2010, CELL CYCLE, V9, P3884, DOI 10.4161/cc.9.19.13302
   Dang CV, 2011, GENES CANC, V1, P526
   Dey S, 2013, AUTOPHAGY, V9, P612, DOI 10.4161/auto.23486
   Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408
   EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T
   FERNANDEZ JLR, 1993, J CELL BIOL, V122, P1285, DOI 10.1083/jcb.122.6.1285
   Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861
   FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6
   Geeraert C, 2010, J BIOL CHEM, V285, P24184, DOI 10.1074/jbc.M109.091553
   Goode BL, 2000, CURR OPIN CELL BIOL, V12, P63, DOI 10.1016/S0955-0674(99)00058-7
   Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hatton BA, 2006, CANCER RES, V66, P8655, DOI 10.1158/0008-5472.CAN-06-1621
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Heiden MGV, 2010, SCIENCE, V329, P1492, DOI 10.1126/science.1188015
   HERMEKING H, 1995, ONCOGENE, V11, P1409
   Hockel M, 1996, CANCER RES, V56, P4509
   Hongo K, 2013, J SURG RES, V182, P75, DOI 10.1016/j.jss.2012.08.034
   Ji HK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026057
   Jubb AM, 2010, J CELL MOL MED, V14, P18, DOI 10.1111/j.1582-4934.2009.00944.x
   Jung A, 2001, AM J PATHOL, V159, P1613, DOI 10.1016/S0002-9440(10)63007-6
   Kahlert C, 2011, CLIN CANCER RES, V17, P7654, DOI 10.1158/1078-0432.CCR-10-2816
   Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183
   Kim JW, 2004, MOL CELL BIOL, V24, P5923, DOI 10.1128/MCB.24.13.5923-5936.2004
   Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152
   Kodama A, 2004, J CELL BIOL, V167, P203, DOI 10.1083/jcb.200408047
   Li A, 2010, CURR BIOL, V20, P339, DOI 10.1016/j.cub.2009.12.035
   Li HB, 2012, EXP HEMATOL, V40, P548, DOI 10.1016/j.exphem.2012.02.002
   Li Q, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008531
   Machesky Laura M, 2010, Commun Integr Biol, V3, P263
   McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000
   Mucaj V, 2012, INT J HEMATOL, V95, P464, DOI 10.1007/s12185-012-1070-5
   Nagy P, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003664
   Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033
   Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903
   Ozerhan IH, 2010, CLINICS, V65, P157, DOI 10.1590/S1807-59322010000200007
   PIETILAINEN T, 1995, ANTICANCER RES, V15, P959
   Rahl PB, 2010, CELL, V141, P432, DOI 10.1016/j.cell.2010.03.030
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Ruzinova MB, 2010, AM J SURG PATHOL, V34, P882, DOI 10.1097/PAS.0b013e3181db83af
   Saggar JK, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00154
   Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Schober JM, 2007, J CELL SCI, V120, P1235, DOI 10.1242/jcs.003913
   Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511
   Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658
   Shortt J, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a009829
   Sloan Elizabeth J, 2010, Genes Cancer, V1, P587, DOI 10.1177/1947601910377489
   Storr SJ, 2011, NAT REV CANCER, V11, P364, DOI 10.1038/nrc3050
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Toh PPC, 2013, HUM MOL GENET, V22, P5237, DOI 10.1093/hmg/ddt381
   Tredan O, 2007, J NATL CANCER I, V99, P1441, DOI 10.1093/jnci/djm135
   Vignjevic D, 2007, CANCER RES, V67, P6844, DOI 10.1158/0008-5472.CAN-07-0929
   Vignjevic D, 2006, J CELL BIOL, V174, P863, DOI 10.1083/jcb.200603013
   Vinci M, 2012, BMC BIOL, V10, DOI 10.1186/1741-7007-10-29
   WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817
   Wolf E, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3535
   Wong WJ, 2013, MOL CELL BIOL, V33, P3494, DOI 10.1128/MCB.00853-12
   Xie R, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-89
   Xu W, 2013, ONCOGENE
   Yang FC, 2013, J BIOL CHEM, V288, P6227, DOI 10.1074/jbc.M112.431239
   Yang YH, 2013, P NATL ACAD SCI USA, V110, P6841, DOI 10.1073/pnas.1217692110
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yi C, 2012, SCIENCE, V336, P474, DOI 10.1126/science.1216990
   Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099
   Zanet J, 2012, J CELL BIOL, V197, P477, DOI 10.1083/jcb.201110135
   Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424
NR 79
TC 60
Z9 61
U1 0
U2 15
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 0890-9369
EI 1549-5477
J9 GENE DEV
JI Genes Dev.
PD APR 1
PY 2014
VL 28
IS 7
BP 689
EP 707
DI 10.1101/gad.231894.113
PG 19
WC Cell Biology; Developmental Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA AE9UA
UT WOS:000334354700004
PM 24696454
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Panda, PK
   Naik, PP
   Praharaj, PP
   Meher, BR
   Gupta, PK
   Verma, RS
   Maiti, TK
   Shanmugam, MK
   Chinnathambi, A
   Alharbi, SA
   Sethi, G
   Agarwal, R
   Bhutia, SK
AF Panda, Prashanta K.
   Naik, Prajna P.
   Praharaj, Prakash P.
   Meher, Biswa R.
   Gupta, Piyush K.
   Verma, Rama S.
   Maiti, Tapas K.
   Shanmugam, Muthu K.
   Chinnathambi, Arunachalam
   Alharbi, Sulaiman A.
   Sethi, Gautam
   Agarwal, Rajesh
   Bhutia, Sujit K.
TI Abrus agglutinin stimulates BMP-2-dependent differentiation through
   autophagic degradation of -catenin in colon cancer stem cells
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE beta-catenin; Abrus agglutinin; BMP-2; cancer stem cells;
   differentiation; hVps34
ID PROMOTES DIFFERENTIATION; RETINOIC ACID; SELF-RENEWAL; IN-VITRO;
   APOPTOSIS; KINETICS; SURVIVAL; AGENT; ROS
AB Eradicating cancer stem cells (CSCs) in colorectal cancer (CRC) through differentiation therapy is a promising approach for cancer treatment. Our retrospective tumor-specimen analysis elucidated alteration in the expression of bone morphogenetic protein 2 (BMP-2) and -catenin during the colon cancer progression, indicating that their possible intervention through forced differentiation in colon cancer remission. We reveal that Abrus agglutinin (AGG) induces the colon CSCs differentiation, and enhances sensitivity to the anticancer therapeutics. The low dose AGG (max. dose=100ng/mL) decreased the expression of stemness-associated molecules such as CD44 and -catenin in the HT-29 cell derived colonospheres. Further, AGG augmented colonosphere differentiation, as demonstrated by the enhanced CK20/CK7 expression ratio and induced alkaline phosphatase activity. Interestingly, the AGG-induced expression of BMP-2 and the AGG-induced differentiation were demonstrated to be critically dependent on BMP-2 in the colonospheres. Similarly, autophagy-induction by AGG was associated with colonosphere differentiation and the gene silencing of BMP-2 led to the reduced accumulation of LC3-II, suggesting that AGG-induced autophagy is dependent on BMP-2. Furthermore, hVps34 binds strongly to BMP-2, indicating a possible association of BMP-2 with the process of autophagy. Moreover, the reduction in the self-renewal capacity of the colonospheres was associated with AGG-augmented autophagic degradation of -catenin through an interaction with the autophagy adaptor protein p62. In the subcutaneous HT-29 xenograft model, AGG profoundly inhibited the growth of tumors through an increase in BMP-2 expression and LC3-II puncta, and a decrease in -catenin expression, confirming the antitumor potential of AGG through induction of differentiation in colorectal cancer.
C1 [Panda, Prashanta K.; Naik, Prajna P.; Praharaj, Prakash P.; Bhutia, Sujit K.] Natl Inst Technol, Dept Life Sci, Rourkela, India.
   [Meher, Biswa R.] Berhampur Univ, Dept Bot, Berhampur, Orissa, India.
   [Gupta, Piyush K.; Verma, Rama S.] Indian Inst Technol Madras, Dept Biotechnol, Bhupat & Jyoti Mehta Sch Biosci, Madras, Tamil Nadu, India.
   [Maiti, Tapas K.] Indian Inst Technol, Dept Biotechnol, Kharagpur, W Bengal, India.
   [Shanmugam, Muthu K.; Sethi, Gautam] Natl Univ Singapore, Dept Pharmacol, Yong Loo Lin Sch Med, Singapore, Singapore.
   [Chinnathambi, Arunachalam; Alharbi, Sulaiman A.] King Saud Univ, Dept Bot & Microbiol, Coll Sci, Riyadh, Saudi Arabia.
   [Sethi, Gautam] Curtin Univ, Sch Biomed Sci, Curtin Hlth Innovat Res Inst, Perth, WA, Australia.
   [Agarwal, Rajesh] Univ Colorado Denver, Skaggs Sch Pharm & Pharmaceut Sci, Aurora, CO USA.
RP Bhutia, SK (corresponding author), Natl Inst Technol, Dept Life Sci, Rourkela, India.; Bhutia, SK (corresponding author), Natl Inst Technol Rourkela, Dept Life Sci, Rourkela 769008, Odisha, India.
EM sujitb@nitrkl.ac.in
RI Praharaj, Prakash P./J-5515-2018; Sethi, Gautam/F-2372-2011; Naik,
   Prajna Paramita/AAV-8237-2020; GUPTA, Dr PIYUSH KUMAR/H-1588-2015
OI Praharaj, Prakash P./0000-0003-0425-5118; Sethi,
   Gautam/0000-0002-8677-8475; Naik, Prajna Paramita/0000-0002-6086-3022;
   GUPTA, Dr PIYUSH KUMAR/0000-0002-3346-910X; Meher, Biswa
   Ranajn/0000-0003-0519-9074; Chinnathambi,
   Arunachalam/0000-0001-5075-5901; Bhutia, Sujit Kumar/0000-0003-0962-3354
FU Department of Biotechnology, Ministry of Science and Technology
   [BT/PR7791/BRB/10/1187/2013]; Board of Research in Nuclear
   SciencesDepartment of Atomic Energy (DAE)Board of Research in Nuclear
   Sciences (BRNS) [37(1)/14/38/2016-BRNS/37276]; International Scientific
   Partnership Program ISPP at King Saud University [ISPP# 0091]; Science
   and Engineering Research Board [EMR/2016/001246]; National Cancer
   InstituteUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [CA195708]; NATIONAL CANCER INSTITUTEUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [R01CA195708] Funding Source: NIH RePORTER
FX Department of Biotechnology, Ministry of Science and Technology, Grant
   number: BT/PR7791/BRB/10/1187/2013; Board of Research in Nuclear
   Sciences, Grant number: 37(1)/14/38/2016-BRNS/37276; International
   Scientific Partnership Program ISPP at King Saud University, Grant
   number: ISPP# 0091; Science and Engineering Research Board, Grant
   number: EMR/2016/001246; National Cancer Institute, Grant number:
   CA195708
CR Alborzinia H, 2013, J CELL SCI, V126, P117, DOI 10.1242/jcs.109777
   Bagaria A, 2006, J BIOL CHEM, V281, P34465, DOI 10.1074/jbc.M601777200
   Bai ZG, 2010, CELL BIOL INT, V34, P1141, DOI 10.1042/CBI20090481
   Bhutia SK, 2016, INT J CANCER, V139, P457, DOI 10.1002/ijc.30055
   Dasgupta N, 2015, EXP CELL RES, V334, P323, DOI 10.1016/j.yexcr.2015.03.020
   DEGOS L, 1995, BLOOD, V85, P2643, DOI 10.1182/blood.V85.10.2643.bloodjournal85102643
   Dow LE, 2015, CELL, V161, P1539, DOI 10.1016/j.cell.2015.05.033
   Futter CE, 2001, J CELL BIOL, V155, P1251, DOI 10.1083/jcb.200108152
   Groulx JF, 2012, AUTOPHAGY, V8, P893, DOI 10.4161/auto.19738
   Guo L, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/1651325
   He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430
   HEGDE R, 1991, ANAL BIOCHEM, V194, P101, DOI 10.1016/0003-2697(91)90156-N
   Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487
   Kirsch T, 2000, NAT STRUCT BIOL, V7, P492
   Kodach LL, 2008, GASTROENTEROLOGY, V134, P1332, DOI 10.1053/j.gastro.2008.02.059
   Kodach LL, 2011, GUT, V60, P1544, DOI 10.1136/gut.2011.237495
   Kuhn K, 2015, CELL DEATH DISCOV, V1, DOI 10.1038/cddiscovery.2015.31
   Kumar R, 2014, CLIN COLORECTAL CANC, V13, P87, DOI 10.1016/j.clcc.2013.11.008
   Kumar S, 2014, ONCOTARGET, V5, P4972, DOI 10.18632/oncotarget.2068
   Lee G, 2011, DEV BIOL, V356, P588, DOI 10.1016/j.ydbio.2011.06.024
   Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002
   Liu T, 2015, ONCOTARGET, V6, P7992, DOI 10.18632/oncotarget.3505
   Lombardo Y, 2011, GASTROENTEROLOGY, V140, P297, DOI 10.1053/j.gastro.2010.10.005
   Masciarelli S, 2018, LEUKEMIA, V32, P285, DOI 10.1038/leu.2017.231
   Mukhopadhyay S, 2014, ACTA PHARMACOL SIN, V35, P814, DOI 10.1038/aps.2014.15
   Nabissi M, 2015, INT J CANCER, V137, P1855, DOI 10.1002/ijc.29573
   Nagy P, 2017, DEVELOPMENT, V144, P3990, DOI 10.1242/dev.147033
   Naik PP, 2016, ORAL ONCOL, V62, P122, DOI 10.1016/j.oraloncology.2016.10.008
   Obara K, 2008, GENES CELLS, V13, P537, DOI 10.1111/j.1365-2443.2008.01188.x
   Ozeki N, 2016, EXP CELL RES, V347, P24, DOI 10.1016/j.yexcr.2016.07.002
   Panda PK, 2017, MOL CARCINOGEN, V56, P389, DOI 10.1002/mc.22502
   Panda PK, 2015, SEMIN CELL DEV BIOL, V39, P43, DOI 10.1016/j.semcdb.2015.02.013
   Pera MF, 2004, J CELL SCI, V117, P1269, DOI 10.1242/jcs.00970
   Petherick KJ, 2013, EMBO J, V32, P1903, DOI 10.1038/emboj.2013.123
   Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481
   Sell S, 2004, CRIT REV ONCOL HEMAT, V51, P1, DOI 10.1016/j.critrevonc.2004.04.007
   Sinha N, 2017, MOL CARCINOGEN, V56, P2400, DOI 10.1002/mc.22679
   Sinha N, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317701634
   Storm EE, 2016, NATURE, V529, P97, DOI 10.1038/nature16466
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Vermeulen L, 2008, P NATL ACAD SCI USA, V105, P13427, DOI 10.1073/pnas.0805706105
   Wang CR, 2016, J CELL BIOL, V212, P545, DOI 10.1083/jcb.201507023
   Wang CR, 2013, NAT NEUROSCI, V16, P532, DOI 10.1038/nn.3365
   Wang JR, 2008, AUTOPHAGY, V4, P947, DOI 10.4161/auto.6787
   Wielenga MCB, 2015, CELL REP, V13, P489, DOI 10.1016/j.celrep.2015.09.016
   Zhang WV, 2004, CELL COMMUN ADHES, V11, P89, DOI 10.1080/15419060490951790
   Zhang YY, 2014, ONCOL REP, V32, P1013, DOI 10.3892/or.2014.3308
   Zhuang WZ, 2012, CANCER SCI, V103, P684, DOI 10.1111/j.1349-7006.2011.02198.x
NR 48
TC 18
Z9 18
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
EI 1098-2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD MAY
PY 2018
VL 57
IS 5
BP 664
EP 677
DI 10.1002/mc.22791
PG 14
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA GB2MZ
UT WOS:000428888600009
PM 29457276
DA 2022-04-25
ER

PT J
AU Wang, Z
   Zhang, QQ
   Zhou, L
   Liu, G
   Wu, QF
   Chen, CW
AF Wang, Zhang
   Zhang, Qinqin
   Zhou, Ling
   Liu, Gao
   Wu, Quanfeng
   Chen, Changwang
TI Norwogonin flavone suppresses the growth of human colon cancer cells via
   mitochondrial mediated apoptosis, autophagy induction and triggering
   G2/M phase cell cycle arrest
SO JOURNAL OF BUON
LA English
DT Article
DE Colorectal cancer; apoptosis; autophagy; cell cycle arrest; flow
   cytometry
ID CARCINOMA; PATHWAYS; CHEMOTHERAPY; TOXICITY
AB Purpose: Colorectal cancer is one of the deadly malignancies and is one of the top three most common cancers and the third leading cause of cancer-related deaths. The main objective of the study was to investigate the anticancer effects of norwogonin - a naturally occurring plant flavone. We also examined its effects on programmed cell death, autophagy and cell cycle phase distribution.
   Methods: Cell viability of colon cancer cells was evaluated by MTT assay while apoptotic studies were carried out by fluorescence microscopy using acridine orange (AO)/ethidium bromide (EB) and Comet assays. Transmission electron microscopy (TEM) was used to study formation of autophagosomes reminiscent of autophagy. Furthermore, western blot assay was used to study the effects of norwogonin on apoptosis-related protein expressions including Bax, Bcl-2 and autophagy-related proteins. Effects on cell cycle were evaluated by flow cytometry.
   Results: The results showed that norwogonin causes substantial reduction in the viability of the human colorectal carcinoma cells in a dose-dependent manner, exhibiting an IC50 of 15.5 mu M in cancer cells and IC50 of 90 mu M in normal cell lines. The AO/EB staining assay showed that norwogonin suppresses the viability of cancer cells via induction of apoptotic cell death which was associated with increase in Bax and decrease in Bcl-2 levels. Comet assay results also confirmed that norwogonin induces apoptosis. Norwogonin also led to induction of autophagy along with triggering G2/M phase cell cycle arrest.
   Conclusions: In conclusion, the current study shows that norwogonin has a potential to inhibit in vitro colorectal cancer cells growth by triggering apoptosis, autophagy and cell cycle arrest and as such could be developed as a possible anticancer agent.
C1 [Wang, Zhang; Liu, Gao; Wu, Quanfeng; Chen, Changwang] Cent Hosp Enshi Tujia & Miao Autonomous Prefectur, Dept Gastrointestinal Surg, Enshi 445000, Hubei, Peoples R China.
   [Zhang, Qinqin] Hualong Hosp Enshi Tujia & Miao Autonomous Prefec, Dept Digest Med, Enshi 445000, Hubei, Peoples R China.
   [Zhou, Ling] Cent Hosp Enshi Tujia & Miao Autonomous Prefectur, Dept Dermatol, 158 WuYang St, Enshi 445000, Hubei, Peoples R China.
RP Chen, CW (corresponding author), Cent Hosp Enshi Tujia & Miao Autonomous Prefectur, Dept Dermatol, 158 WuYang St, Enshi 445000, Hubei, Peoples R China.
EM LauriSchmittwzc@yahoo.com
CR Abd El-Hafeez AA, 2019, PHARMACOL REP, V71, P289, DOI 10.1016/j.pharep.2019.01.001
   Chow LM, 2008, J CELL BIOCHEM, V103, P1394, DOI 10.1002/jcb.21528
   Compton CC, 2003, MODERN PATHOL, V16, P376, DOI 10.1097/01.MP.0000062859.46942.93
   Dancey J, 1996, BRIT J CANCER, V74, P327, DOI 10.1038/bjc.1996.362
   El-Shami K, 2015, CA-CANCER J CLIN, V65, P427, DOI 10.3322/caac.21286
   Ghobrial IM, 2005, CA-CANCER J CLIN, V55, P178, DOI 10.3322/canjclin.55.3.178
   Haggar Fatima A, 2009, Clin Colon Rectal Surg, V22, P191, DOI 10.1055/s-0029-1242458
   Lakshmi S, 2008, MED CHEM RES, V17, P335, DOI 10.1007/s00044-007-9069-9
   Lavrik IN, 2005, J CLIN INVEST, V115, P2665, DOI 10.1172/JCI26252
   Lee KW, 2011, NAT REV CANCER, V11, P211, DOI 10.1038/nrc3017
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x
   Ping Kwan Yuet, 2013, Asian Pacific Journal of Tropical Biomedicine, V3, P692, DOI 10.1016/S2221-1691(13)60140-9
   Schuell B, 2005, BRIT J CANCER, V93, P744, DOI 10.1038/sj.bjc.6602783
   Sillars-Hardebol AH, 2010, TUMOR BIOL, V31, P89, DOI 10.1007/s13277-009-0012-1
   Valachis A, 2012, J CLIN ONCOL, V30, P1316, DOI 10.1200/JCO.2011.38.6078
   Wiela-Hojenska A, 2015, ADV CLIN EXP MED, V24, P103, DOI 10.17219/acem/38154
NR 17
TC 1
Z9 1
U1 1
U2 3
PU IMPRIMATUR PUBLICATIONS
PI ATHENS
PA 30 DEM POLIORKETES ST, ATHENS, 136 76, GREECE
SN 1107-0625
EI 2241-6293
J9 J BUON
JI J. BUON
PD MAY-JUN
PY 2020
VL 25
IS 3
BP 1449
EP 1454
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA NE1UI
UT WOS:000562382600024
PM 32862589
DA 2022-04-25
ER

PT J
AU Chang, CH
   Lee, CY
   Lu, CC
   Tsai, FJ
   Hsu, YM
   Tsao, JW
   Juan, YN
   Chiu, HY
   Yang, JS
   Wang, CC
AF Chang, Chao-Hsiang
   Lee, Chao-Ying
   Lu, Chi-Cheng
   Tsai, Fuu-Jen
   Hsu, Yuan-Man
   Tsao, Je-Wei
   Juan, Yu-Ning
   Chiu, Hong-Yi
   Yang, Jai-Sing
   Wang, Ching-Chiung
TI Resveratrol-induced autophagy and apoptosis in cisplatin-resistant human
   oral cancer CAR cells: A key role of AMPK and Akt/mTOR signaling
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE resveratrol; autophagic death; apoptosis; AMP-activated protein kinase;
   cisplatin-resistant oral cancer cell
ID HUMAN COLON-CANCER; ENDOPLASMIC-RETICULUM STRESS; MITOCHONDRIAL
   DYSFUNCTION; MEDIATED APOPTOSIS; TUMOR XENOGRAFTS; IN-VITRO; DEATH;
   PATHWAYS; KINASE; PROTEINS
AB Resveratrol is known to be an effective chemopreventive phytochemical against multiple tumor cells. However, the increasing drug resistance avoids the cancer treatment in oral cavity cancer. In this study, we investigated the oral antitumor activity of resveratrol and its mechanism in cisplatin-resistant human oral cancer CAR cells. Our results demonstrated that resveratrol had an extremely low toxicity in normal oral cells and provoked autophagic cell death to form acidic vesicular organelles (AVOs) and autophagic vacuoles in CAR cells by acridine orange (AO) and monodansylcadaverine (MDC) staining. Either DNA fragmentation or DNA condensation occurred in resveratrol-triggered CAR cell apoptosis. These inhibitors of PI3K class III (3-MA) and AMP-activated protein kinase (AMPK) (compound c) suppressed the autophagic vesicle formation, LC3-II protein levels and autophagy induced by resveratrol. The pan-caspase inhibitor Z-VAD-FMK attenuated resveratrol-triggered cleaved caspase-9, cleaved caspase-3 and cell apoptosis. Resveratrol also enhanced phosphorylation of AMPK and regulated autophagy- and pro-apoptosis-related signals in resveratrol-treated CAR cells. Importantly, resveratrol also stimulated the autophagic mRNA gene expression, including Atg5, Atg12, Beclin-1 and LC3-II in CAR cells. Overall, our findings indicate that resveratrol is likely to induce autophagic and apoptotic death in drug-resistant oral cancer cells and might become a new approach for oral cancer treatment in the near future.
C1 [Chang, Chao-Hsiang; Wang, Ching-Chiung] Taipei Med Univ, Sch Pharm, Coll Pharm, Taipei 110, Taiwan.
   [Lee, Chao-Ying] China Med Univ, Sch Pharm, Taichung 404, Taiwan.
   [Lu, Chi-Cheng; Tsao, Je-Wei; Juan, Yu-Ning; Yang, Jai-Sing] China Med Univ, Dept Med Res, China Med Univ Hosp, Taichung 404, Taiwan.
   [Tsai, Fuu-Jen] China Med Univ Hosp, Human Genet Ctr, Taichung 404, Taiwan.
   [Tsai, Fuu-Jen] China Med Univ, Sch Postbaccalaureate Chinese Med, Taichung 404, Taiwan.
   [Hsu, Yuan-Man] China Med Univ, Dept Biol Sci & Technol, Taichung 404, Taiwan.
   [Chiu, Hong-Yi] Buddhist Tzu Chi Gen Hosp, Dept Pharm, Hualien 970, Taiwan.
RP Wang, CC (corresponding author), Taipei Med Univ, Sch Pharm, Coll Pharm, 250 Wu Hsing St, Taipei 11042, Taiwan.; Yang, JS (corresponding author), China Med Univ, Dept Med Res, China Med Univ Hosp, 2 Yuh Der Rd, Taichung 40447, Taiwan.
EM jaisingyang@gmail.com; crystal@tmu.edu.tw
RI Hsu, Yuan-Man/K-7074-2015; Lu, Chi-Cheng/N-7770-2013; Yang, Jai
   Sing/M-1162-2015
OI Hsu, Yuan-Man/0000-0002-4575-7475; Lu, Chi-Cheng/0000-0003-3149-0914;
   Yang, Jai Sing/0000-0001-7302-8248
FU China Medical University Hospital, Taichung, Taiwan [DMR-105-096]
FX This study was supported by the grant from China Medical University
   Hospital, Taichung, Taiwan (DMR-105-096).
CR Adhauliya N, 2016, ORAL ONCOL, V61, P120, DOI 10.1016/j.oraloncology.2016.09.001
   Alayev A, 2015, J CELL BIOCHEM, V116, P450, DOI 10.1002/jcb.24997
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Button RW, 2016, ONCOTARGET, V7, P5157, DOI 10.18632/oncotarget.6986
   Ceyda C, 2014, FREE RADICAL BIO MED, V75, pS27, DOI 10.1016/j.freeradbiomed.2014.10.750
   Chang PY, 2013, INT J ONCOL, V43, P1141, DOI 10.3892/ijo.2013.2050
   Chiang JH, 2013, TOXICOL APPL PHARM, V269, P150, DOI 10.1016/j.taap.2013.03.007
   Dandawate PR, 2016, SEMIN CANCER BIOL, V40-41, P192, DOI 10.1016/j.semcancer.2016.09.001
   de Oliveira MR, 2016, BBA-GEN SUBJECTS, V1860, P727, DOI 10.1016/j.bbagen.2016.01.017
   Din FVN, 2012, GASTROENTEROLOGY, V142, P1504, DOI 10.1053/j.gastro.2012.02.050
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Fu YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102535
   Garcia-Zepeda SP, 2013, EUR J CANCER PREV, V22, P577, DOI 10.1097/CEJ.0b013e328360345f
   Gehm BD, 1997, P NATL ACAD SCI USA, V94, P14138, DOI 10.1073/pnas.94.25.14138
   Gosepath EM, 2008, INT J CANCER, V123, P2013, DOI 10.1002/ijc.23721
   Gwak H, 2016, CANCER LETT, V371, P347, DOI 10.1016/j.canlet.2015.11.032
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Ho TF, 2015, BIOMEDICINE-TAIWAN, V5, P29, DOI 10.7603/s40681-015-0023-8
   Hsieh MT, 2014, INT J ONCOL, V45, P782, DOI 10.3892/ijo.2014.2478
   Huang WW, 2010, MOL NUTR FOOD RES, V54, P1585, DOI 10.1002/mnfr.201000005
   Inoue H, 2014, CELL DEATH DIFFER, V21, P39, DOI 10.1038/cdd.2013.84
   Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218
   Jiang H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161017
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kong B, 2015, ANN NY ACAD SCI, V1350, P1, DOI 10.1111/nyas.12883
   Lai KC, 2010, J AGR FOOD CHEM, V58, P2935, DOI 10.1021/jf9036694
   Lang FF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129196
   Li YC, 2014, CANCER LETT, V344, P239, DOI 10.1016/j.canlet.2013.11.001
   Lin X, 2012, INT J UROL, V19, P757, DOI 10.1111/j.1442-2042.2012.03024.x
   Liu Y, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0031406, 10.1371/journal.pone.0048083]
   Lu CC, 2014, MOL NUTR FOOD RES, V58, P2146, DOI 10.1002/mnfr.201400051
   Lu CC, 2014, BBA-GEN SUBJECTS, V1840, P2310, DOI 10.1016/j.bbagen.2014.02.022
   Ma YS, 2012, FOOD CHEM TOXICOL, V50, P1271, DOI 10.1016/j.fct.2012.01.033
   Mancias JD, 2011, ONCOTARGET, V2, P1302
   Marques FZ, 2009, INT J BIOCHEM CELL B, V41, P2125, DOI 10.1016/j.biocel.2009.06.003
   Miki H, 2012, INT J ONCOL, V40, P1020, DOI 10.3892/ijo.2012.1325
   Pereira DL, 2015, PATHOL ONCOL RES, V21, P103, DOI 10.1007/s12253-014-9794-6
   Plati J, 2011, INTEGR BIOL-UK, V3, P279, DOI 10.1039/c0ib00144a
   Selvaraj S, 2016, MOL CARCINOGEN, V55, P818, DOI 10.1002/mc.22324
   Shen HM, 2011, AUTOPHAGY, V7, P457, DOI 10.4161/auto.7.5.14226
   Shih YP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094812
   Shimizu S, 2014, INT J MOL SCI, V15, P3145, DOI 10.3390/ijms15023145
   Soleas GJ, 1997, CLIN BIOCHEM, V30, P91, DOI 10.1016/S0009-9120(96)00155-5
   Subramanian L, 2010, CLIN CANCER RES, V16, P5942, DOI 10.1158/1078-0432.CCR-10-1486
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Trincheri NF, 2008, CARCINOGENESIS, V29, P381, DOI 10.1093/carcin/bgm271
   Varoni EM, 2016, FRONT NUTR, V3, DOI 10.3389/fnut.2016.00008
   Xiong SB, 2014, PROTEIN CELL, V5, P737, DOI 10.1007/s13238-014-0089-1
   Yang JS, 2009, FOOD CHEM TOXICOL, V47, P171, DOI 10.1016/j.fct.2008.10.032
   Yeh CC, 2016, CLIN ORAL INVEST, V20, P2343, DOI 10.1007/s00784-016-1736-0
   Yuan C.H., 2016, ENVIRON TOXICOL
   Yuan SX, 2016, ONCOL REP, V35, P939, DOI 10.3892/or.2015.4407
   Zhao YY, 2014, DRUG DES DEV THER, V8, P1827, DOI 10.2147/DDDT.S67961
   Zhu LQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084175
   Zhu YS, 2015, SCI REP-UK, V5, DOI 10.1038/srep17730
NR 55
TC 108
Z9 113
U1 0
U2 61
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD MAR
PY 2017
VL 50
IS 3
BP 873
EP 882
DI 10.3892/ijo.2017.3866
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EN7MH
UT WOS:000396186400014
PM 28197628
OA Bronze
DA 2022-04-25
ER

PT J
AU Yang, C
   Deng, SP
AF Yang, Chun
   Deng, Shaoping
TI High level of Helicobacter pylori infection contributes to the survival
   of colon cancer via up-regulating autophagy in vitro
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Helicobacter pylori; survival; colon cancer; beclin1
ID INDUCED APOPTOSIS; COLORECTAL-CANCER; EXPRESSION; PROLIFERATION;
   PATHOGENESIS; INHIBITION; PATHWAY; DISEASE; BECLIN1; RISK
AB Colon cancer (CRC) is one of the most prevalent gastrointestinal malignancies and the fourth leading cause of cancer death in the world. Helicobacter pylori (H. pylori) infection is prevalent in the population and is associated with kinds of digestive system diseases. In this study, we aimed to investigate the effect of H. pylori infection on the survival of colon cancer in vitro. Firstly, the expression of autophagy related protein-beclin1 was found aberrantly overexpressed in the tissue sample from colon cancer patients compared with the healthy control. Further research showed that cell apoptosis rate in SW480 cells was suppressed by H. pylori infection in a dose dependent manner. Western blot analysis showed that the expression of beclin1 was increased by H. pylori infection in dose dependent manner and the microtubule-associated protein 1 light chain 3 (LC3)-II/I ratio was obviously increased and the level of autophagy specific degradation protein p62 was decreased by H. pylori infection at 100 MOI. Moreover, high level of H. pylori infection promoted cell viability and suppressed cell apoptosis in SW480 cells. The expression of proliferation marker (Ki67) and apoptosis suppressing protein Bcl-2 was both up-regulated and the rate of cleaved-caspase-3/caspase-3 and the level of apoptosis promoting protein Bax was both suppressed in H. pylori infected SW480 cells compared with the control group. Moreover, autophagy inhibitor 3-MA counteracted the effect of H. pylori infection on cell viability. Taken together, we revealed that high level of H. pylori infection contributes to the survival of colon cancer in vitro. In consideration of the aberrant expression of beclin1, we speculated that beclin1 mediated the tumor-promoting activity of H. pylori infection.
C1 [Yang, Chun; Deng, Shaoping] Univ Elect Sci & Technol China, Sch Med, Chengdu, Sichuan, Peoples R China.
   [Yang, Chun; Deng, Shaoping] Sichuan Acad Med Sci, Dept Gastrointestinal Surg, Chengdu, Sichuan, Peoples R China.
   [Yang, Chun; Deng, Shaoping] Sichuan Prov Peoples Hosp, Chengdu, Sichuan, Peoples R China.
RP Deng, SP (corresponding author), Univ Elect Sci & Technol China, Sch Med, Chengdu, Sichuan, Peoples R China.; Deng, SP (corresponding author), Sichuan Acad Med Sci, Dept Gastrointestinal Surg, Chengdu, Sichuan, Peoples R China.; Deng, SP (corresponding author), Sichuan Prov Peoples Hosp, Chengdu, Sichuan, Peoples R China.
EM dengshaopingestu@163.com
CR [Anonymous], 1994, IARC Monogr Eval Carcinog Risks Hum, V61, P177
   Cai MB, 2014, INT J MOL SCI, V15, P5292, DOI 10.3390/ijms15045292
   Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78
   Chiozzi V, 2009, J PHYSIOL PHARMACOL, V60, P23
   Cid TP, 2013, HELICOBACTER, V18, P12, DOI 10.1111/hel.12076
   Coker-Gurkan A, 2014, EXP CELL RES, V328, P87, DOI 10.1016/j.yexcr.2014.07.022
   Covacci A, 1999, SCIENCE, V284, P1328, DOI 10.1126/science.284.5418.1328
   DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192
   Fashner J, 2015, AM FAM PHYSICIAN, V91, P236
   GORBACH SL, 1982, INFECTION, V10, P379, DOI 10.1007/BF01642307
   Greenfield LK, 2013, TRENDS MICROBIOL, V21, P602, DOI 10.1016/j.tim.2013.09.004
   Inoue I, 2014, WORLD J GASTROENTERO, V20, P1485, DOI 10.3748/wjg.v20.i6.1485
   Jiang LL, 2014, ONCOL REP, V32, P1931, DOI 10.3892/or.2014.3432
   Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061
   Meng WB, 2015, DISCOV MED, V20, P285
   Mimuro H, 2007, CELL HOST MICROBE, V2, P250, DOI 10.1016/j.chom.2007.09.005
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Murata-Kamiya N, 2007, ONCOGENE, V26, P4617, DOI 10.1038/sj.onc.1210251
   Neu B, 2002, AM J PHYSIOL-GASTR L, V283, pG309, DOI 10.1152/ajpgi.00546.2001
   Pugh SA, 2016, ANN SURG, V263, P1143, DOI 10.1097/SLA.0000000000001351
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Shimizu T, 2015, GASTROENTEROL CLIN N, V44, P625, DOI 10.1016/j.gtc.2015.05.011
   Suzuki M, 2009, CELL HOST MICROBE, V5, P23, DOI 10.1016/j.chom.2008.11.010
   Tenesa A, 2009, NAT REV GENET, V10, P353, DOI 10.1038/nrg2574
   Terebiznik MR, 2009, AUTOPHAGY, V5, P370, DOI 10.4161/auto.5.3.7663
   Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131
   Wan XK, 2016, HELICOBACTER, V21, P554, DOI 10.1111/hel.12311
   Wang F, 2014, CANCER LETT, V345, P196, DOI 10.1016/j.canlet.2013.08.016
   Wang Y, 2013, HEPATOLOGY, V58, P995, DOI 10.1002/hep.26394
   Wang Y, 2014, ONCOL LETT, V8, P1947, DOI 10.3892/ol.2014.2487
   WARREN JR, 1983, LANCET, V1, P1273
   Watanabe T, 2010, J CLIN INVEST, V120, P1645, DOI 10.1172/JCI39481
   Wu SH, 2015, INT J CLIN EXP PATHO, V8, P3882
   Xie JH, 2016, INT IMMUNOPHARMACOL, V35, P43, DOI 10.1016/j.intimp.2016.02.022
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yang ZL, 2015, CLIN RES HEPATOL GAS, V39, P98, DOI 10.1016/j.clinre.2014.06.014
   Ying L, 2013, MOL BIOSYST, V9, P407, DOI 10.1039/c2mb25386k
   Zhai H, 2013, ONCOGENE, V32, P1570, DOI 10.1038/onc.2012.167
   Zhang Y, 2017, DEV COMP IMMUNOL, V73, P46, DOI 10.1016/j.dci.2017.03.010
   Zhao YS, 2008, INT J COLORECTAL DIS, V23, P875, DOI 10.1007/s00384-008-0479-z
   Zheng S, 2017, J MOL NEUROSCI
   Zhou FF, 2011, FEBS J, V278, P403, DOI 10.1111/j.1742-4658.2010.07965.x
NR 42
TC 1
Z9 1
U1 1
U2 7
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2018
VL 11
IS 11
BP 11901
EP 11910
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA HC5SO
UT WOS:000451862900052
DA 2022-04-25
ER

PT J
AU Koom, WS
   Sai, S
   Suzuki, M
   Fujimori, A
   Yamada, S
   Tsujii, H
AF Koom, Woong Sub
   Sai, Sei
   Suzuki, Masao
   Fujimori, Akira
   Yamada, Shigeru
   Tsujii, Hirohiko
TI Superior Effect of the Combination of Carbon-Ion Beam Irradiation and
   5-Fluorouracil on Colorectal Cancer Stem Cells in vitro and in vivo
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE colorectal cancer stem cell; heavy ion radiation; 5-FU
ID COLON-CANCER; ADJUVANT CHEMOTHERAPY; RADIATION-THERAPY; SURVIVAL; 5-FU;
   RADIOSENSITIVITY; MODULATION; PROGNOSIS; CARCINOMA; APOPTOSIS
AB Background: The aim of this study was to investigate whether carbon-ion beam irradiation in combination with 5-fluorouracil (5-FU) is superior to carbon-ion beam irradiation alone in targeting colorectal cancer stem-like cells (CSCs).
   Materials and Methods: Human colorectal cancer (CRC) cells, HCT116 and HT29, were treated with carbon-ion beam irradiation alone or in combination with 5-FU. Cell viability assay, colony and spheroid formation assay, apoptotic assay, and quantitative real-time PCR analysis of apoptosis- and autophagy-related gene expression were performed.
   Results: Carbon-ion beam irradiation dose-dependently decreased CRC cell viability and showed significantly enhanced cell killing effect when combined with 5-FU. Carbon-ion beam irradiation in combination with 5-FU significantly increased the percentage of apoptotic cells. The expression of some apoptotic and autophagy-related genes such as Bax, Bcl2, Beclin1 and ATG7 was significantly induced by carbon-ion beam irradiation alone and was further enhanced when the beam was combined with 5-FU. The spheroid forming capacity of CD133+ cell subpopulations was significantly inhibited by carbon-ion beam in combination with 5-FU. Histopathologically, the combination of carbon-ion beam irradiation and 5-FU destroyed more xenograft tumor cells, and resulted in increased necrosis, cavitation, and fibrosis, compared to carbon-ion beam irradiation alone.
   Conclusion: In conclusion, carbon-ion beam treatment combined with 5-FU has the potential to kill CRC cells including CSCs by inducing increased apoptosis and autophagy.
C1 [Koom, Woong Sub] Yonsei Univ, Dept Radiat Oncol, Coll Med, Yonsei Canc Ctr, Seoul, South Korea.
   [Koom, Woong Sub; Yamada, Shigeru; Tsujii, Hirohiko] QST Hosp, Natl Inst Quantum & Radiol Sci & Technol QST, Chiba, Japan.
   [Sai, Sei; Suzuki, Masao; Fujimori, Akira] Natl Inst Quantum & Radiol Sci & Technol QST, Natl Inst Radiol Sci NIRS, Dept Basic Med Sci Radiat Damages, Chiba, Japan.
RP Sai, S (corresponding author), Natl Inst Quantum & Radiol Sci & Technol QST, Natl Inst Radiol Sci NIRS, Dept Basic Med Sci Radiat Damages, Inage Ku, 4-9-1 Anagawa, Chiba 2638555, Japan.
EM sai.sei@qst.go.jp
OI Koom, Woong Sub/0000-0002-9435-7750
CR Abugomaa A, 2020, EXPERT REV PRECIS ME, V5, P1, DOI 10.1080/23808993.2020.1715794
   Abugomaa A, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010235
   Balart J, 2002, PANCREATOLOGY, V2, P40, DOI 10.1159/000049447
   Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Baumann M, 2008, NAT REV CANCER, V8, P545, DOI 10.1038/nrc2419
   Cui X, 2011, CANCER RES, V71, P3676, DOI 10.1158/0008-5472.CAN-10-2926
   Diehn M, 2006, J NATL CANCER I, V98, P1755, DOI 10.1093/jnci/djj505
   Dingli D, 2006, STEM CELLS, V24, P2603, DOI 10.1634/stemcells.2006-0136
   Elbadawy M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092340
   Farhat W, 2019, WORLD J SURG ONCOL, V17, DOI 10.1186/s12957-019-1718-1
   Fu KK, 1997, SEMIN RADIAT ONCOL, V7, P274, DOI 10.1016/S1053-4296(97)80026-4
   Grothey A, 2018, NEW ENGL J MED, V378, P1177, DOI 10.1056/NEJMoa1713709
   Gustavsson B, 2015, CLIN COLORECTAL CANC, V14, P1, DOI 10.1016/j.clcc.2014.11.002
   Guyot F, 2005, ANN ONCOL, V16, P756, DOI 10.1093/annonc/mdi151
   Hambardzumyan D, 2006, CANCER CELL, V10, P454, DOI 10.1016/j.ccr.2006.11.008
   Harris CA, 2016, ANN SURG, V264, P323, DOI 10.1097/SLA.0000000000001524
   Hashiguchi Y, 2020, INT J CLIN ONCOL, V25, P1, DOI 10.1007/s10147-019-01485-z
   Kim EH, 2020, CANCERS, V12, DOI 10.3390/cancers12030698
   Kornmann M, 2008, EJSO-EUR J SURG ONC, V34, P1316, DOI 10.1016/j.ejso.2008.01.019
   Lips DJ, 2011, BMC SURG, V11, DOI 10.1186/1471-2482-11-11
   Loree JM, 2016, FUTURE ONCOL, V12, P2021, DOI 10.2217/fon-2016-0109
   Neugut AI, 2006, J CLIN ONCOL, V24, P2368, DOI 10.1200/JCO.2005.04.5005
   Nita ME, 1998, BRIT J CANCER, V78, P986, DOI 10.1038/bjc.1998.617
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Oonishi K, 2012, RADIOTHER ONCOL, V105, P258, DOI 10.1016/j.radonc.2012.08.009
   Osaki M, 1997, APOPTOSIS, V2, P221, DOI 10.1023/A:1026476801463
   Renehan AG, 2016, CLIN ONCOL-UK, V28, P103, DOI 10.1016/j.clon.2015.11.006
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Rich JN, 2007, CANCER RES, V67, P8980, DOI 10.1158/0008-5472.CAN-07-0895
   Ryuk JP, 2014, ANN SURG TREAT RES, V86, P143, DOI 10.4174/astr.2014.86.3.143
   Sai S, 2020, AM J CANCER RES, V10, P2371
   Sai Sei, 2018, Oncotarget, V9, P14849, DOI 10.18632/oncotarget.23756
   Sai S, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0429-7
   Sai S, 2015, ONCOTARGET, V6, P5517, DOI 10.18632/oncotarget.3584
   Shiba S, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00702
   Shinoto M, 2019, RADIOTHER ONCOL, V132, P236, DOI 10.1016/j.radonc.2018.10.007
   Short SS, 2012, J SURG ONCOL, V106, P119, DOI 10.1002/jso.23057
   SMALLEY SR, 1991, INT J RADIAT ONCOL, V20, P207, DOI 10.1016/0360-3016(91)90091-H
   Tang JC, 2016, CHINESE MED J-PEKING, V129, P456, DOI 10.4103/0366-6999.176069
   Urick ME, 2011, CLIN CANCER RES, V17, P5038, DOI 10.1158/1078-0432.CCR-11-0358
   Westberg K, 2018, EJSO-EUR J SURG ONC, V44, P100, DOI 10.1016/j.ejso.2017.11.013
   WONG CS, 1991, INT J RADIAT ONCOL, V21, P1291, DOI 10.1016/0360-3016(91)90288-F
   Xiong HY, 2010, CANCER LETT, V288, P68, DOI 10.1016/j.canlet.2009.06.039
   Yamada S, 2016, INT J RADIAT ONCOL, V96, P93, DOI 10.1016/j.ijrobp.2016.04.022
   Yang JW, 2018, J CANCER RES THER, V14, pS1141, DOI 10.4103/0973-1482.204898
NR 45
TC 1
Z9 1
U1 1
U2 2
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2020
VL 13
BP 12625
EP 12635
DI 10.2147/OTT.S276035
PG 11
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA PE8QZ
UT WOS:000598627300005
PM 33335403
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Li, X
   Guo, J
   Ding, AP
   Qi, WW
   Zhang, PH
   Lv, J
   Qiu, WS
   Sun, ZQ
AF Li, Xian
   Guo, Jing
   Ding, Ai-Ping
   Qi, Wei-Wei
   Zhang, Pei-Hua
   Lv, Jing
   Qiu, Wen-Sheng
   Sun, Zhen-Qing
TI Association of Mixed Lineage Kinase Domain-Like Protein Expression With
   Prognosis in Patients With Colon Cancer
SO TECHNOLOGY IN CANCER RESEARCH & TREATMENT
LA English
DT Article
DE MLKL; necroptosis; prognostic value; colon cancer
ID COLORECTAL-CANCER; CELL-DEATH; NECROPTOSIS; CARCINOMA; TUMOR; APOPTOSIS;
   AUTOPHAGY; MECHANISM; MLKL
AB Background: The mixed lineage kinase domain-like protein has recently been identified as a key downstream component of tumor necrosis factor-induced necroptosis, which is an important pathway of cancer cell death. The goal of the current study is to explore the expression of mixed lineage kinase domain-like protein in colon cancer tissues and evaluate the prognostic value in patients with colon cancer. Methods: We collected normal and cancer colon tissues from 135 patients diagnosed with colon cancer after radical operation during July 2007 to April 2009 at The Affiliated Hospital of Qingdao University. Immunohistochemistry analysis was scored using an established scoring system. Kaplan-Meier survival curves were generated for recurrence-free survival and overall survival for all patients and 2 subsets of patients. The relationship between mixed lineage kinase domain-like protein expression and prognosis parameter (recurrence-free survival, overall survival) was analyzed by univariate and multivariate Cox regression analyses. Results: The median age of all patients was 67 years and 56.3% were male. Low expression of mixed lineage kinase domain-like protein was associated with decreased overall survival (78.6 vs 81.2 months; P = .011) in all patients. In the subset of 79 patients who received adjuvant chemotherapy, low expression of mixed lineage kinase domain-like protein was associated with decreased recurrence-free survival 60.4 vs 72.8 months; P = .032) and decreased overall survival ( 66.3 vs 72.9 months; P = .005). Low expression of mixed lineage kinase domain-like protein was associated with decreased overall survival (4.9 vs 79.8 months; P = .006) and recurrence-free survival (69.6 vs 78.8 months; P = .005) among patients with Tumor Node Metastasis (TNM) stage II colon cancer. Conclusions: Low expression of mixed lineage kinase domain-like protein was associated with decreased overall survival in all patient-group with resected colon cancer. It is associated with decreased recurrencefree survival and overall survival in the subset of patients who receive adjuvant chemotherapy and patients who were TNM stage II. Mixed lineage kinase domain-like protein may provide important prognostic information in patients with colon cancer.
C1 [Li, Xian; Sun, Zhen-Qing] Qingdao Univ, Affiliated Hosp, Dept Surg, 59 Haier Rd, Qingdao 266000, Shandong, Peoples R China.
   [Guo, Jing; Ding, Ai-Ping; Qi, Wei-Wei; Zhang, Pei-Hua; Lv, Jing; Qiu, Wen-Sheng] Qingdao Univ, Affiliated Hosp, Dept Oncol, Qingdao, Shandong, Peoples R China.
RP Sun, ZQ (corresponding author), Qingdao Univ, Affiliated Hosp, Dept Surg, 59 Haier Rd, Qingdao 266000, Shandong, Peoples R China.
EM sunzhanqing0532@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81472338]; Project of Shandong Province
   Higher Educational Science and Technology Program [J15LL58]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This
   research was supported by the National Natural Science Foundation of
   China under award numbers 81472338 to Qiu and a Project of Shandong
   Province Higher Educational Science and Technology Program award J15LL58
   to Lv.
CR Casimiro S, 2014, CLIN EXP METASTAS, V31, P689, DOI 10.1007/s10585-014-9659-0
   Colbert LE, 2013, CANCER-AM CANCER SOC, V119, P3148, DOI 10.1002/cncr.28144
   Corin I, 2010, ACTA ONCOL, V49, P63, DOI 10.3109/02841860903268049
   Fulda S, 2013, CANCER BIOL THER, V14, P999, DOI 10.4161/cbt.26428
   Galluzzi L, 2011, INT REV CEL MOL BIO, V289, P1, DOI 10.1016/B978-0-12-386039-2.00001-8
   Ghita C, 2012, ROM J MORPHOL EMBRYO, V53, P549
   He L, 2013, CANCER, V119, P3148
   Killeen S, 2014, COLORECTAL DIS, V16, P577, DOI 10.1111/codi.12616
   Long JS, 2012, ONCOGENE, V31, P5045, DOI 10.1038/onc.2012.7
   Moujalled DM, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.18
   Myklebust MP, 2012, BRIT J CANCER, V107, P1684, DOI 10.1038/bjc.2012.463
   Nehs MA, 2011, SURGERY, V150, P1032, DOI 10.1016/j.surg.2011.09.012
   Shin A, 2013, WORLD J GASTROENTERO, V19, P979, DOI 10.3748/wjg.v19.i7.979
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Song Bi-Wei, 2013, Sheng Li Ke Xue Jin Zhan, V44, P281
   Strater J, 2010, INT J CANCER, V127, P873, DOI 10.1002/ijc.25111
   Su ZY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0321-5
   Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970
   Wu JF, 2013, CELL RES, V23, P994, DOI 10.1038/cr.2013.91
   Wu W, 2012, CRIT REV ONCOL HEMAT, V82, P249, DOI 10.1016/j.critrevonc.2011.08.004
NR 20
TC 35
Z9 38
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1533-0346
EI 1533-0338
J9 TECHNOL CANCER RES T
JI Technol. Cancer Res. Treat.
PD AUG
PY 2017
VL 16
IS 4
BP 428
EP 434
DI 10.1177/1533034616655909
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EZ8TN
UT WOS:000405001000005
PM 27432118
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Pecoraro, A
   Carotenuto, P
   Franco, B
   De Cegli, R
   Russo, G
   Russo, A
AF Pecoraro, Annalisa
   Carotenuto, Pietro
   Franco, Brunella
   De Cegli, Rossella
   Russo, Giulia
   Russo, Annapina
TI Role of uL3 in the Crosstalk between Nucleolar Stress and Autophagy in
   Colon Cancer Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE cancer; chemotherapy; nucleolar stress; nucleolus; p53; ribosomal
   proteins; uL3; autophagy
ID RIBOSOMAL-PROTEINS; GENE-EXPRESSION; HNRNP H1; RPL3; RESISTANCE; RNA
AB The nucleolus is the site of ribosome biogenesis and has been recently described as important sensor for a variety of cellular stressors. In the last two decades, it has been largely demonstrated that many chemotherapeutics act by inhibiting early or late rRNA processing steps with consequent alteration of ribosome biogenesis and activation of nucleolar stress response. The overall result is cell cycle arrest and/or apoptotic cell death of cancer cells. Our previously data demonstrated that ribosomal protein uL3 is a key sensor of nucleolar stress activated by common chemotherapeutic agents in cancer cells lacking p53. We have also demonstrated that uL3 status is associated to chemoresistance; down-regulation of uL3 makes some chemotherapeutic drugs ineffective. Here, we demonstrate that in colon cancer cells, the uL3 status affects rRNA synthesis and processing with consequent activation of uL3-mediated nucleolar stress pathway. Transcriptome analysis of HCT 116(p53-/-) cells expressing uL3 and of a cell sub line stably depleted of uL3 treated with Actinomycin D suggests a new extra-ribosomal role of uL3 in the regulation of autophagic process. By using confocal microscopy and Western blotting experiments, we demonstrated that uL3 acts as inhibitory factor of autophagic process; the absence of uL3 is associated to increase of autophagic flux and to chemoresistance. Furthermore, experiments conducted in presence of chloroquine, a known inhibitor of autophagy, indicate a role of uL3 in chloroquine-mediated inhibition of autophagy. On the basis of these results and our previous findings, we hypothesize that the absence of uL3 in cancer cells might inhibit cancer cell response to drug treatment through the activation of cytoprotective autophagy. The restoration of uL3 could enhance the activity of many drugs thanks to its pro-apoptotic and anti-autophagic activity.
C1 [Pecoraro, Annalisa; Russo, Giulia; Russo, Annapina] Univ Naples Federico II, Dept Pharm, Via Domenico Montesano 49, Naples 80131, Italy.
   [Carotenuto, Pietro; Franco, Brunella; De Cegli, Rossella] Telethon Inst Genet & Med TIGEM, Via Campi Flegrei 34, Naples 80078, Italy.
   [Carotenuto, Pietro] Inst Canc Res, Canc Therapeut Unit, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.
   [Franco, Brunella] Univ Naples Federico II, Dept Translat Med Sci, Med Genet, Via Sergio Pansini 5, Naples 80131, Italy.
RP Russo, A (corresponding author), Univ Naples Federico II, Dept Pharm, Via Domenico Montesano 49, Naples 80131, Italy.
EM annalisa.pecoraro@unina.it; p.carotenuto@tigem.it; franco@tigem.it;
   decegli@tigem.it; giulia.russo@unina.it; annapina.russo@unina.it
RI De Cegli, Rossella/ABA-4372-2020; Pecoraro, Annalisa/AFQ-5507-2022;
   Russo, Annapina/O-7545-2015
OI Carotenuto, Pietro/0000-0002-6622-183X; Russo,
   Annapina/0000-0002-7509-3702
FU Regione Campania-POR FERS 2014/2020 "Combattere la resistenza tumorale:
   piattaforma integrata multidiscilinare per un approccio tecnologico
   innovativo alle oncoterapie-Campania Oncoterapie" [B61G18000470007];
   Fondo di ricerca di base FFABR-2017 Ministero della Universita e della
   ricerca (MIUR)Ministry of Education, Universities and Research (MIUR);
   POR CAMPANIA FESR 2014/2020 "Genomica e Terapia" grant; Italian
   Association for Cancer Research (AIRC)Fondazione AIRC per la ricerca sul
   cancro [IG 17711/2015]; Marie Sklodowska-Curie Career Re-Integration
   Grant from AIRC; European Union's Horizon 2020 research and innovation
   programme under the Marie Sklodowska-Curie grantSKA South Africa
   [800924]
FX Annapina Russo gratefully acknowledge Regione Campania-POR FERS
   2014/2020 "Combattere la resistenza tumorale: piattaforma integrata
   multidiscilinare per un approccio tecnologico innovativo alle
   oncoterapie-Campania Oncoterapie"-PROJECT N: B61G18000470007; Fondo di
   ricerca di base FFABR-2017 Ministero della Universita e della ricerca
   (MIUR) for financial support. Carotenuto P. is supported by POR CAMPANIA
   FESR 2014/2020 "Genomica e Terapia" grant, by the Italian Association
   for Cancer Research (AIRC) (grant n. IG 17711/2015 to B.F.); Carotenuto
   P. is recipient of a Marie Sklodowska-Curie Career Re-Integration Grant
   funding from AIRC and the European Union's Horizon 2020 research and
   innovation programme under the Marie Sklodowska-Curie grant agreement No
   800924.
CR Arruebo Manuel, 2011, Cancers (Basel), V3, P3279, DOI 10.3390/cancers3033279
   Aubert M, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8040123
   Benjamin D, 2011, NAT REV DRUG DISCOV, V10, P868, DOI 10.1038/nrd3531
   Bianca RDD, 2016, SCI REP-UK, V6, DOI 10.1038/srep31491
   Carotenuto P, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091090
   Chen HT, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1030-2
   Chun Y, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7120278
   De Filippis D, 2008, BRIT J PHARMACOL, V154, P1672, DOI 10.1038/bjp.2008.211
   De Filippis D, 2014, EUR J PHARMACOL, V725, P64, DOI 10.1016/j.ejphar.2013.12.021
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Esposito D, 2014, ONCOTARGET, V5, P11737, DOI 10.18632/oncotarget.2591
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Hofman IJF, 2017, HAEMATOLOGICA, V102, pE317, DOI 10.3324/haematol.2016.162198
   Holmberg Olausson Karl, 2012, Cells, V1, P774, DOI 10.3390/cells1040774
   Housman G, 2014, CANCERS, V6, P1769, DOI 10.3390/cancers6031769
   Juli G, 2016, SCI REP-UK, V6, DOI 10.1038/srep35026
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323
   Li XY, 2019, BIOMED PHARMACOTHER, V119, DOI 10.1016/j.biopha.2019.109415
   Li YJ, 2017, CHIN J CANCER, V52, DOI 10.1186/s40880-017-0219-2
   Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   O'Donohue MF, 2010, J CELL BIOL, V190, P853, DOI 10.1083/jcb.201005117
   Pagliara V, 2016, ONCOTARGET, V7, P50333, DOI 10.18632/oncotarget.10385
   Pecoraro A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51723-7
   Pfister AS, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00156
   Pinelli M, 2016, NUCLEIC ACIDS RES, V44, P5773, DOI 10.1093/nar/gkw486
   Pucci C, 2019, ECANCERMEDICALSCIENC, V13, DOI 10.3332/ecancer.2019.961
   Rawla P, 2019, GASTROENTEROL REV, V14, P89, DOI 10.5114/pg.2018.81072
   Ricci MS, 2006, ONCOLOGIST, V11, P342, DOI 10.1634/theoncologist.11-4-342
   Russo A, 2006, BBA-MOL CELL RES, V1763, P833, DOI 10.1016/j.bbamcr.2006.05.010
   Russo A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010140
   Russo A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030547
   Russo A, 2016, ONCOTARGET, V7, P79656, DOI 10.18632/oncotarget.13216
   Russo A, 2016, SCI REP-UK, V6, DOI 10.1038/srep38369
   Russo A, 2016, CELL CYCLE, V15, P41, DOI 10.1080/15384101.2015.1120926
   Russo A, 2013, CELL CYCLE, V12, P76, DOI 10.4161/cc.22963
   Russo A, 2011, NUCLEIC ACIDS RES, V39, P7576, DOI 10.1093/nar/gkr461
   Russo A, 2010, BBA-GENE REGUL MECH, V1799, P419, DOI 10.1016/j.bbagrm.2010.01.008
   Russo A, 2008, BBA-GENE REGUL MECH, V1779, P820, DOI 10.1016/j.bbagrm.2008.08.006
   Sasaki K, 2012, ANTI-CANCER DRUG, V23, P675, DOI 10.1097/CAD.0b013e328353f8c7
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Stepinski D, 2018, HISTOCHEM CELL BIOL, V150, P607, DOI 10.1007/s00418-018-1706-5
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sulima SO, 2017, CANCER DISCOV, V7, P1069, DOI 10.1158/2159-8290.CD-17-0550
   Thorburn A, 2014, MOL PHARMACOL, V85, P830, DOI 10.1124/mol.114.091850
   Weeks SE, 2019, CELL MOL LIFE SCI, V76, P4511, DOI 10.1007/s00018-019-03231-0
   Yang K, 2018, CELL STRESS, V2, P125, DOI 10.15698/cst2018.06.139
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
NR 49
TC 15
Z9 15
U1 3
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR
PY 2020
VL 21
IS 6
AR 2143
DI 10.3390/ijms21062143
PG 21
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA LJ0UU
UT WOS:000529890200239
PM 32244996
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Ziolkowska, B
   Wozniak, M
   Ziolkowski, P
AF Ziolkowska, Barbara
   Wozniak, Marta
   Ziolkowski, Piotr
TI Co-expression of autophagic markers following photodynamic therapy in
   SW620 human colon adenocarcinoma cells
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE photodynamic therapy; autophagy; cell death; cancer; colon cancer cells
ID REGULATES AUTOPHAGY; MACHINERY; APOPTOSIS
AB Photodynamic therapy (PDT) is a minimally invasive cancer treatment. It involves the combination of a photosensitizer and light of a specific wavelength to generate singlet oxygen and other reactive oxygen species that lead to tumor cell death. Autophagy is one of the pathways that tumor cells undergo during photodamage and it is common in photodynamic therapy. The aim of this study was to examine the effect of in vitro PDT on the expression of autophagy-related proteins, autophagy related 7 (Atg7), light chain 3 (LC3) and Beclin-1. Human SW620 colon carcinoma cells were treated with 5-aminolevulinic acid (ALA)-based PDT at a dose of 3 mM. The irradiation was performed using 4.5 J/cm(2) total light and a fluence rate of 60 mW/cm(2). Autophagy was evaluated by immunocytochemistry using specific antibodies to Atg7, Beclin-1 and LC3. The evaluation was repeated at several time points (0, 4, 8 and 24 h) following irradiation. The induction of autophagy was observed directly following the 5-ALA-mediated PDT procedure with the strongest expression of autophagy-related proteins at 4 and 8 h after irradiation as demonstrated using immunocytochemistry. It was characterized by significantly increased expression of Beclin-1, Atg7 and LC3. To the best of our knowledge this is the first study to analyze Beclin-1, Atg7 and LC3 expression in a PDT-related experiment. This study enhances the understanding of the role of autophagy in PDT, which may contribute to better and more effective tumor responses to this therapy.
C1 [Ziolkowska, Barbara; Wozniak, Marta; Ziolkowski, Piotr] Wrocaw Med Univ, Dept Pathol, Ul Marcinkowskiego 1, PL-50368 Wroclaw, Poland.
RP Ziolkowski, P (corresponding author), Wrocaw Med Univ, Dept Pathol, Ul Marcinkowskiego 1, PL-50368 Wroclaw, Poland.
EM ziolkows@interia.pl
RI Wozniak, Marta/ABD-2161-2021; Ziolkowski, Piotr/AAU-2452-2021
OI Wozniak, Marta/0000-0001-7978-6330; Ziolkowska,
   Barbara/0000-0002-3087-8303; Ziolkowski, Piotr/0000-0003-3036-2611
CR Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI 10.1089/ARS.2008.2270
   Brech A, 2009, MOL ONCOL, V3, P366, DOI 10.1016/j.molonc.2009.05.007
   Castano AP, 2005, PHOTODIAGN PHOTODYN, V2, P1, DOI 10.1016/S1572-1000(05)00030-X
   Chen Y, 2009, CELL DEATH DIFFER, V16, P1040, DOI 10.1038/cdd.2009.49
   Dewaele M, 2011, J CELL MOL MED, V15, P1402, DOI 10.1111/j.1582-4934.2010.01118.x
   Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889
   Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724
   Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114
   Itakura E, 2008, MOL BIOL CELL, V19, P5360, DOI 10.1091/mbc.E08-01-0080
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kessel D, 2004, J PORPHYR PHTHALOCYA, V8, P1009, DOI 10.1142/S1088424604000374
   Kessel D, 2007, PHOTOCH PHOTOBIO SCI, V6, P1290, DOI 10.1039/b707953b
   Kessel D, 2007, PHOTOCHEM PHOTOBIOL, V83, P1024, DOI 10.1111/j.1751-1097.2007.00088.x
   Kessel D, 2006, AUTOPHAGY, V2, P289, DOI 10.4161/auto.2792
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Mandelbaum J., 2015, AUTOPHAGY, DOI [10.1080/15548627.2015.1056966., DOI 10.1080/15548627.2015.1056966]
   Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522
   Reiners JJ, 2010, AUTOPHAGY, V6, P7, DOI 10.4161/auto.6.1.10220
   Scherz-Shouval R, 2019, EMBO J, V38, DOI 10.15252/embj.2019101812
   Song J, 2015, EXP NEUROBIOL, V24, P117, DOI 10.5607/en.2015.24.2.117
   Taherbhoy AM, 2011, MOL CELL, V44, P451, DOI 10.1016/j.molcel.2011.08.034
   Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Xue LY, 2001, ONCOGENE, V20, P3420, DOI 10.1038/sj.onc.1204441
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
   Zhong Y, 2009, AUTOPHAGY, V5, P890, DOI 10.4161/auto.9162
NR 36
TC 5
Z9 6
U1 0
U2 10
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD SEP
PY 2016
VL 14
IS 3
BP 2548
EP 2554
DI 10.3892/mmr.2016.5541
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA DU8EF
UT WOS:000382445400088
PM 27485939
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Huang, W
   Zeng, C
   Hu, SB
   Wang, L
   Liu, J
AF Huang, Wei
   Zeng, Chong
   Hu, Shanbiao
   Wang, Lei
   Liu, Jie
TI ATG3, a Target of miR-431-5p, Promotes Proliferation and Invasion of
   Colon Cancer via Promoting Autophagy
SO CANCER MANAGEMENT AND RESEARCH
LA English
DT Article
DE colon cancer; proliferation; invasion; ATG3; miR-431-5p; autophagy
ID GENE-EXPRESSION; UP-REGULATION; BECLIN 1; DEGRADATION; CELLS; APOPTOSIS;
   INTERACTS; BECN1
AB Background: Studies have indicated that ATG3 could mediate the effects of other tumor-related regulators in carcinogenesis. However, the expression, role, and mechanism of ATG3 itself in cancers are rarely revealed. Thus, we explored the expression, function, and mechanism of ATG3 in colon cancer.
   Materials and methods: The expression of ATG3 was detected in colon cancer tissues and cell lines, as well as in adjacent tumor tissues and normal colon epithelial cells. The effects of ATG3 alteration on proliferation and invasion were further analyzed. The expression and role of miR-431-5p, a potential negative regulator of ATG3, were also studied. Eventually, the role of autophagy in ATG3 related effects in colon cancer was checked.
   Results: ATG3 is upregulated in colon cancer tissues and cells demonstrated by qPCR and IHC. ATG3 knockdown significantly suppressed proliferation and invasion of colon cancer cells indicated by plate clone formation and Transwell invasion assays. The expression of miR-431-5p is downregulated and negatively correlates with ATG3 in colon cancer. Furthermore, luciferase report system, plate clone formation and Transwell invasion assays demonstrated that miR-431-5p could prohibit cell proliferation and invasion via directly targeting ATG3 in colon cancer. Eventually, Western blot, plate clone formation and Transwell invasion assays proved that autophagy block could antagonize the promotive functions of ATG3 on proliferation and invasion in cancer suggesting autophagy activation accounts for the promotive role of ATG3 on proliferation and invasion in colon cancer.
   Conclusion: Collectively, ATG3 upregulation, caused by downregulated miR-435-5p, promotes proliferation and invasion via an autophagy-dependent manner in colon cancer suggesting that miR-431-5p/ATG3/autophagy may be a potential therapeutic target in colon cancer.
C1 [Huang, Wei; Liu, Jie] Changsha Cent Hosp, Dept Pathol, 161 Shaoshan South Rd, Changsha 410004, Hunan, Peoples R China.
   [Huang, Wei] Cent S Univ, Xiangya Hosp, Res Ctr Carcinogenesis & Targeted Therapy, Changsha, Hunan, Peoples R China.
   [Zeng, Chong] Hunan Rongjun Hosp, Dept Resp & Neurol, Changsha, Hunan, Peoples R China.
   [Hu, Shanbiao] Cent S Univ, Xiangya Hosp 2, Dept Urol Organ Transplantat, Changsha, Hunan, Peoples R China.
   [Wang, Lei] Cent S Univ, Sch Basic Med Sci, Collaborat Innovat Ctr Canc Med, Canc Res Inst, Changsha, Hunan, Peoples R China.
RP Liu, J (corresponding author), Changsha Cent Hosp, Dept Pathol, 161 Shaoshan South Rd, Changsha 410004, Hunan, Peoples R China.
EM lj511907352@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81702924]; Natural Science Foundation of
   Hunan Province of ChinaNatural Science Foundation of Hunan Province
   [2018JJ3811]
FX The present study was supported by the National Natural Science
   Foundation of China (nos. 81702924) and the Natural Science Foundation
   of Hunan Province of China (nos. 2018JJ3811).
CR Afzal S, 2015, P NATL ACAD SCI USA, V112, P1119, DOI 10.1073/pnas.1423588112
   Cao QH, 2016, AM J TRANSL RES, V8, P3831
   Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002
   Chung SJ, 2017, AUTOPHAGY, V13, P1386, DOI 10.1080/15548627.2017.1332565
   Das CK, 2018, CANCER METAST REV, V37, P749, DOI 10.1007/s10555-018-9727-z
   Dienstmann R, 2015, J CLIN ONCOL, V33, P1787, DOI 10.1200/JCO.2014.60.0213
   Elgendy M, 2015, AUTOPHAGY, V11, P581, DOI 10.1080/15548627.2015.1029836
   Etna MP, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006790
   Feng XL, 2013, INT J ONCOL, V42, P1973, DOI 10.3892/ijo.2013.1885
   Hua L, 2018, CELL BIOL INT, V42, P1240, DOI 10.1002/cbin.10995
   Huber GF, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-217
   Jones B, 2015, NAT REV GENET, V16, DOI 10.1038/nrg3918
   Kim HM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030540
   Kong F, 2019, BIOMED PHARMACOTHER, V109, P716, DOI 10.1016/j.biopha.2018.10.079
   Ku G, 2012, LANCET ONCOL, V13, pE470, DOI 10.1016/S1470-2045(12)70424-2
   Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248
   Li LX, 2018, CELL PHYSIOL BIOCHEM, V48, P1723, DOI 10.1159/000492300
   Li W, 2016, FEBS LETT, V590, P726, DOI 10.1002/1873-3468.12108
   Li YJ, 2017, CHIN J CANCER, V52, DOI 10.1186/s40880-017-0219-2
   Liu H, 2015, J MOL MED, V93, P159, DOI 10.1007/s00109-014-1241-3
   Liu J, 2015, SCI REP-UK, V5, DOI 10.1038/srep11614
   Liu J, 2015, BIOCHEM BIOPH RES CO, V463, P262, DOI 10.1016/j.bbrc.2015.05.042
   Ma K, 2017, AUTOPHAGY, V13, P579, DOI 10.1080/15548627.2016.1272742
   Masuda G, 2016, ANTICANCER RES, V36, P129
   Murrow L, 2015, AUTOPHAGY, V11, P961, DOI 10.1080/15548627.2015.1040976
   Peng Y, 2016, AUTOPHAGY, V12, P2167, DOI 10.1080/15548627.2016.1217380
   Pope SD, 2018, MOL CELL, V71, P389, DOI 10.1016/j.molcel.2018.07.017
   Qu B, 2017, J HUAZHONG U SCI-MED, V37, P37, DOI 10.1007/s11596-017-1691-2
   Russo M, 2018, BIOCHEM PHARMACOL, V153, P51, DOI 10.1016/j.bcp.2018.02.007
   Schaaf MBE, 2016, FASEB J, V30, P3961, DOI 10.1096/fj.201600698R
   Sheng Y, 2018, CELL DEATH DIFFER, V25, P918, DOI 10.1038/s41418-017-0023-1
   Wong NW, 2018, BIOINFORMATICS, V34, P713, DOI 10.1093/bioinformatics/btx627
   Xiao T, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1113-9
   Xiu YL, 2017, ONCOTARGET, V8, P31727, DOI 10.18632/oncotarget.15955
   Xu F, 2017, SCI REP-UK, V7, DOI 10.1038/srep45385
   Yang L, 2019, GENE, V697, P94, DOI 10.1016/j.gene.2019.02.036
   Yang L, 2016, MOL BIOSYST, V12, P2605, DOI 10.1039/c6mb00114a
   Yang ZB, 2018, BIOMED PHARMACOTHER, V97, P248, DOI 10.1016/j.biopha.2017.10.070
   Yoo BH, 2015, AUTOPHAGY, V11, P1230, DOI 10.1080/15548627.2015.1056968
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
NR 40
TC 18
Z9 20
U1 4
U2 7
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1179-1322
J9 CANCER MANAG RES
JI Cancer Manag. Res.
PY 2019
VL 11
BP 10275
EP 10285
DI 10.2147/CMAR.S226828
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA JV3IE
UT WOS:000502259100001
PM 31849517
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Nakayama, S
   Karasawa, H
   Suzuki, T
   Yabuuchi, S
   Takagi, K
   Aizawa, T
   Onodera, Y
   Nakamura, Y
   Watanabe, M
   Fujishima, F
   Yoshida, H
   Morikawa, T
   Sase, T
   Naitoh, T
   Unno, M
   Sasano, H
AF Nakayama, Shun
   Karasawa, Hideaki
   Suzuki, Takashi
   Yabuuchi, Shinichi
   Takagi, Kiyoshi
   Aizawa, Takashi
   Onodera, Yoshiaki
   Nakamura, Yasuhiro
   Watanabe, Mika
   Fujishima, Fumiyoshi
   Yoshida, Hiroshi
   Morikawa, Takanori
   Sase, Tomohiko
   Naitoh, Takeshi
   Unno, Michiaki
   Sasano, Hironobu
TI p62/sequestosome 1 in human colorectal carcinoma as a potent prognostic
   predictor associated with cell proliferation
SO CANCER MEDICINE
LA English
DT Article
DE Cell proliferation; colorectal carcinoma; immunohistochemistry; p62;
   prognosis
ID AUTOPHAGY-DEFICIENT MICE; C COLON-CANCER; HEPATOCELLULAR-CARCINOMA;
   DIGESTIVE-SYSTEM; P62; PROTEIN; P62/SQSTM1; APOPTOSIS; OVEREXPRESSION;
   EXPRESSION
AB p62/sequestosome 1 (p62) is a multi-domain protein that functions as a receptor for ubiquitinated targets in the selective autophagy and serves as a scaffold in various signaling cascades. p62 have been reported to be up-regulated in several human malignancies, but the biological roles and significance of p62 are still poorly understood in colorectal carcinoma. We immunohistochemically evaluated p62 in 118 colorectal adenocarcinoma and 28 colorectal adenoma cases. We used four colon carcinoma cells (HCT8, HT29, COLO320, and SW480) in the in vitro studies. p62 immunoreactivity was detected in 11% of colorectal adenoma cases and 31% of adenocarcinoma cases, while it was negligible in the normal epithelium. The immunohistochemical p62 status was significantly associated with synchronous liver metastasis, and it turned out to be an independent adverse prognostic factor in colorectal cancer patients. Following in vitro studies revealed that HCT8 and HT29 cells transfected with p62-specific siRNA showed significantly decreased cell proliferation activity, whereas COLO320 and SW480 cells transfected with p62 expression plasmid showed significantly increased cell proliferation activity. The p62-mediated cell proliferation was not associated with the autophagy activity. These findings suggest that p62 promotes the cell proliferation mainly as a scaffold protein, and that the p62 status is a potent prognostic factor in colorectal carcinoma patients.
C1 [Nakayama, Shun; Karasawa, Hideaki; Yabuuchi, Shinichi; Aizawa, Takashi; Yoshida, Hiroshi; Morikawa, Takanori; Sase, Tomohiko; Naitoh, Takeshi; Unno, Michiaki] Tohoku Univ, Grad Sch Med, Dept Surg, Sendai, Miyagi, Japan.
   [Nakayama, Shun; Watanabe, Mika; Fujishima, Fumiyoshi; Sasano, Hironobu] Tohoku Univ Hosp, Dept Pathol, Sendai, Miyagi, Japan.
   [Suzuki, Takashi; Takagi, Kiyoshi] Tohoku Univ, Grad Sch Med, Dept Pathol & Histotechnol, Sendai, Miyagi, Japan.
   [Onodera, Yoshiaki; Nakamura, Yasuhiro; Sasano, Hironobu] Tohoku Univ, Grad Sch Med, Dept Anat Pathol, Sendai, Miyagi, Japan.
RP Suzuki, T (corresponding author), Tohoku Univ, Grad Sch Med, Dept Pathol & Histotechnol, Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.
EM t-suzuki@patholo2.med.tohoku.ac.jp
RI Morikawa, Takanori/AAK-6989-2021; Karasawa, Hideaki/AAQ-2771-2021; Unno,
   Michiaki/A-8633-2010; Nakamura, Yasuhiro/AAR-7367-2020; Unno,
   Michiaki/AAX-5246-2020; Naitoh, Takeshi/K-1693-2014
OI Unno, Michiaki/0000-0002-2145-6416; Unno, Michiaki/0000-0002-2145-6416;
   Karasawa, Hideaki/0000-0003-0358-3398; Naitoh,
   Takeshi/0000-0003-4169-6334; Suzuki, Takashi/0000-0003-0195-815X
CR Allegra CJ, 2003, J CLIN ONCOL, V21, P241, DOI 10.1200/JCO.2003.05.044
   American Cancer Society, 2016, CANC FACTS FIG 2016
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Brown DC, 2002, HISTOPATHOLOGY, V40, P2, DOI 10.1046/j.1365-2559.2002.01343.x
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Duchrow M, 2003, HISTOPATHOLOGY, V42, P566, DOI 10.1046/j.1365-2559.2003.01613.x
   Duran A, 2011, MOL CELL, V44, P134, DOI 10.1016/j.molcel.2011.06.038
   Fan WL, 2010, AUTOPHAGY, V6, P614, DOI 10.4161/auto.6.5.12189
   FURTADO JS, 1970, STAIN TECHNOL, V45, P19, DOI 10.3109/10520297009063377
   Galavotti S, 2013, ONCOGENE, V32, P699, DOI 10.1038/onc.2012.111
   Garrity MM, 2004, J CLIN ONCOL, V22, P1572, DOI 10.1200/JCO.2004.10.042
   GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104
   Hilska M, 2005, DIS COLON RECTUM, V48, P2197, DOI 10.1007/s10350-005-0202-x
   Huang SB, 2010, AUTOPHAGY, V6, P256, DOI 10.4161/auto.6.2.11124
   Ichimura Y, 2008, J BIOL CHEM, V283, P22847, DOI 10.1074/jbc.M802182200
   Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031
   Inoue D, 2012, CANCER SCI, V103, P760, DOI 10.1111/j.1349-7006.2012.02216.x
   Kawakami M, 2010, SURG TODAY, V40, P245, DOI 10.1007/s00595-009-4028-3
   Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451
   Kitamura H, 2006, HISTOPATHOLOGY, V48, P157, DOI 10.1111/j.1365-2559.2005.02313.x
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Ling JH, 2012, CANCER CELL, V21, P105, DOI 10.1016/j.ccr.2011.12.006
   Luo Rong-Zhen, 2013, Onco Targets Ther, V6, P883, DOI 10.2147/OTT.S46222
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954
   Porter K, 2013, AUTOPHAGY, V9, P581, DOI 10.4161/auto.23568
   Qian HL, 2005, WORLD J GASTROENTERO, V11, P1788
   Rolland P, 2007, ENDOCR-RELAT CANCER, V14, P73, DOI 10.1677/erc.1.01312
   Stumptner C, 1999, AM J PATHOL, V154, P1701, DOI 10.1016/S0002-9440(10)65426-0
   Su YX, 2005, CLIN IMMUNOL, V116, P118, DOI 10.1016/j.clim.2005.04.004
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Thompson HGR, 2003, ONCOGENE, V22, P2322, DOI 10.1038/sj.onc.1206325
   Valera V, 2005, BRIT J SURG, V92, P1002, DOI 10.1002/bjs.4858
   Wu YC, 2009, BIOCHEM BIOPH RES CO, V382, P451, DOI 10.1016/j.bbrc.2009.03.051
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yu H, 2011, EUR J CANCER, V47, P1585, DOI 10.1016/j.ejca.2011.01.019
NR 37
TC 16
Z9 16
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2045-7634
J9 CANCER MED-US
JI Cancer Med.
PD JUN
PY 2017
VL 6
IS 6
BP 1264
EP 1274
DI 10.1002/cam4.1093
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EX1ZA
UT WOS:000403024100012
PM 28544335
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Shen, H
   Yin, L
   Deng, GL
   Guo, C
   Han, Y
   Li, YY
   Cai, CJ
   Fu, YJ
   Liu, SS
   Zeng, S
AF Shen, Hong
   Yin, Ling
   Deng, Ganlu
   Guo, Cao
   Han, Ying
   Li, Yiyi
   Cai, Changjing
   Fu, Yaojie
   Liu, Shanshan
   Zeng, Shan
TI Knockdown of Beclin-1 impairs epithelial-mesenchymal transition of colon
   cancer cells
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE autophagy; Beclin-1; colon cancer; epithelial-mesenchymal transition
ID HEPATOCELLULAR-CARCINOMA; FAVORABLE PROGNOSIS; PROTEIN EXPRESSION;
   AUTOPHAGY; INVASION; STATISTICS; ACTIVATION; LC3; P62
AB Activation of autophagy significantly affects cancer cell behaviors, such as proliferation, differentiation, and invasiveness. Epithelial-to-mesenchymal transition (EMT) as an initial step of malignant transformation of cancer cells was linked to the activation of autophagy, but the detailed molecular mechanisms are still unknown. The present study investigates the effects of Beclin-1, a key molecule involved in activation of autophagy, on EMT of colon cancer cells. The normal colon epithelia cell line of CCD-18Co and six colon cancer cell lines with different expression levels of Beclin-1 were used in this study. The activation of autophagy and EMT markers of cancer cells were monitored by Western blotting and quantitative real-time PCR assay in the presence or absence of rapamycin (autophagy activator) and 3-MA (autophagy inhibitor). The expression of Beclin-1 in selected cell lines was modulated using small interfering RNA, and consequentially EMT markers, and cancer cell behaviors including migration and invasion, were also explored. Activation or inhibition of autophagy in colon cancer cells had positive or negative impacts on the expression of EMT markers and malignant behaviors such as cell migration and invasion. Knockdown of beclin-1 by siRNA apparently inhibited the activation of autophagy induced by rapamycin, consequentially resulted in suppression of EMT and attenuation of invasiveness of colon cancer cells. The results in this study demonstrated an association between activation of autophagy and EMT in colon cancer cells. The results showed suppression of Beclin-1 expression significantly reduced EMT and invasive behaviors in colon cancer cells.
C1 [Shen, Hong; Yin, Ling; Deng, Ganlu; Guo, Cao; Li, Yiyi; Fu, Yaojie; Liu, Shanshan; Zeng, Shan] Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha 410008, Hunan, Peoples R China.
   [Shen, Hong; Yin, Ling; Deng, Ganlu; Han, Ying; Li, Yiyi; Cai, Changjing; Fu, Yaojie; Liu, Shanshan; Zeng, Shan] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Hunan, Peoples R China.
   [Shen, Hong; Guo, Cao; Han, Ying; Cai, Changjing; Zeng, Shan] Cent South Univ, Xiangya Hosp, Key Lab Mol Radiat Oncol Hunan Prov, Changsha, Hunan, Peoples R China.
RP Zeng, S (corresponding author), Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha 410008, Hunan, Peoples R China.
EM zengshan2000@csu.edu.cn
RI Shen, Hong/N-9734-2019; Yin, Ling/AAD-8990-2022; Cai,
   Changjing/ABA-4542-2021
OI Shen, Hong/0000-0002-6456-8231; Yin, Ling/0000-0003-1606-2620; 
FU National Nature Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81070362, 81172470, 81372629, 81772627];
   Nature Science Foundation of Hunan ProvinceNatural Science Foundation of
   Hunan Province [2015JC3021, 2016JC2037]
FX National Nature Science Foundation of China, Grant numbers: 81070362,
   81172470, 81372629, 81772627; Nature Science Foundation of Hunan
   Province, Grant numbers: 2015JC3021, 2016JC2037
CR Al-Shenawy HA, 2016, APMIS, V124, P229, DOI 10.1111/apm.12498
   Catalano M, 2015, MOL ONCOL, V9, P1612, DOI 10.1016/j.molonc.2015.04.016
   Chen YS, 2009, PATHOL ONCOL RES, V15, P487, DOI 10.1007/s12253-008-9143-8
   Cicchini M, 2014, AUTOPHAGY, V10, P2036, DOI 10.4161/auto.34398
   Deng GL, 2017, SCI REP-UK, V7, DOI 10.1038/srep41616
   Gammoh N, 2016, AUTOPHAGY, V12, P1431, DOI 10.1080/15548627.2016.1190053
   Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189
   Ju LL, 2016, EUR REV MED PHARMACO, V20, P1993
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kim SY, 2014, BIOCHEM PHARMACOL, V88, P178, DOI 10.1016/j.bcp.2014.01.027
   Ko YH, 2013, PANCREAS, V42, P829, DOI 10.1097/MPA.0b013e318279d0dc
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Li J, 2013, CARCINOGENESIS, V34, P1343, DOI 10.1093/carcin/bgt063
   Lin L, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.985913
   Ma J, 2017, BMP4 ENHANCES HEPATO
   Masuda G, 2016, ANTICANCER RES, V36, P129
   Mei Y, 2016, PROTEIN SCI, V25, P1767, DOI 10.1002/pro.2984
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   Nitta T, 2014, INT J CLIN EXP PATHO, V7, P4913
   Park JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100819
   Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Song JR, 2009, AUTOPHAGY, V5, P1131, DOI 10.4161/auto.5.8.9996
   Tan SF, 2016, INT J MOL MED, V37, P1030, DOI 10.3892/ijmm.2016.2492
   Toton E, 2014, J PHYSIOL PHARMACOL, V65, P459
   Winardi D, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/723176
   Won SJ, 2017, AUTOPHAGY MEDIATES C
   Yang SW, 2016, ONCOTARGET, V7, P39279, DOI 10.18632/oncotarget.9827
   Yang ZL, 2015, CLIN RES HEPATOL GAS, V39, P98, DOI 10.1016/j.clinre.2014.06.014
   Yue ZY, 2010, J MOL CELL BIOL, V2, P305, DOI 10.1093/jmcb/mjq028
   Zhang Y, 2015, INT J COLORECTAL DIS, V30, P1173, DOI 10.1007/s00384-015-2273-z
   Zhong Y, 2009, NAT CELL BIOL, V11, P468, DOI 10.1038/ncb1854
   Zhu HT, 2014, ONCOL REP, V32, P935, DOI 10.3892/or.2014.3298
NR 36
TC 25
Z9 27
U1 3
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD AUG
PY 2018
VL 119
IS 8
BP 7022
EP 7031
DI 10.1002/jcb.26912
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA GK9EG
UT WOS:000436542900068
PM 29738069
DA 2022-04-25
ER

PT J
AU Castro, ED
   Mathias, PPM
   Batista, WL
   Sato, AYS
   Toledo, MS
   Almeida, VT
   Curcio, MF
   Costa, PE
   Stern, A
   Monteiro, HP
AF Castro, Eloisa D.
   Mathias, Pedro Paulo M.
   Batista, Wagner L.
   Sato, Alex Yuri S.
   Toledo, Mayte S.
   Almeida, Victor T.
   Curcio, Marli F.
   Costa, Paulo E.
   Stern, Arnold
   Monteiro, Hugo P.
TI Knockdown of the inducible nitric oxide synthase (NOS2) splicing variant
   S3 promotes autophagic cell death from nitrosative stress in SW480 human
   colon cancer cells
SO CELL BIOLOGY INTERNATIONAL
LA English
DT Article
DE alternative splicing; autophagy; colon cancer cells; inducible nitric
   oxide synthase-NOS2; nitric oxide; nitrosative stress
ID INHIBITION; PROTEIN; EXPRESSION; INSIGHTS; BREAST; NITROSYLATION;
   MUTAGENESIS; INDUCTION; PROGRAM; TARGET
AB Low levels of nitric oxide (NO) produced by constitutively expressed inducible NO synthase (NOS2) in tumor cells may be an important factor in their development. NOS2 expression is associated with high mortality rates for various cancers. Alternative splicing of NOS2 down-regulates its enzymatic activity, resulting in decreased intracellular NO concentrations. Specific probes to detect alternative splicing of NOS2 were used in two isogenic human colon cancer cell lines derived either from the primary tumor (SW480) or from a lymph node metastasis (SW620). Splicing variant of NOS2 S3, lacking exons 9, 10, and 11, was overexpressed in SW480 cells. NOS2 S3 was silenced in SW480 cells. Flow-cytometry analysis was used to estimate the intracellular NO levels and to analyze the cell cycle of the studied cell lines. Western blot analysis and quantitative real-time polymerase chain reaction (qRT-PCR) were used to determine apoptosis and autophagy markers. SW480 and SW620 cells expressed NOS2 S3. Overexpression of the NOS2 S3 in SW480 cells downregulated intracellular NO levels. SW480 cells with knocked down NOS2 S3 (referred to as S3C9 cells) had higher intracellular levels of NO compared to the wild-type SW480 cells under serum restriction. Higher NO levels resulted in the loss of viability of S3C9 cells, which was associated with autophagy. Induction of autophagy by elevated intracellular NO levels in S3C9 cells under serum restriction, suggests that autophagy operates as a cytotoxic response to nitrosative stress. The expression of NOS2 S3 plays an important role in regulating intracellular NO production and maintaining viability in SW480 cells under serum restriction. These findings may prove significant in the design of NOS2/NO-based therapies for colon cancer.
C1 [Castro, Eloisa D.; Mathias, Pedro Paulo M.; Toledo, Mayte S.; Almeida, Victor T.; Curcio, Marli F.; Costa, Paulo E.; Monteiro, Hugo P.] Univ Fed Sao Paulo, Ctr Cellular & Mol Therapy CTCMol, Dept Biochem, Rua Mirassol 207, Sao Paulo, SP, Brazil.
   [Batista, Wagner L.] Univ Fed Sao Paulo, Dept Pharmaceut Sci, Sao Paulo, Brazil.
   [Stern, Arnold] NYU, Grossman Sch Med, New York, NY USA.
   [Sato, Alex Yuri S.] Univ Fed Sao Paulo, Dept Morphol & Genet, Sao Paulo, Brazil.
RP Monteiro, HP (corresponding author), Univ Fed Sao Paulo, Ctr Cellular & Mol Therapy CTCMol, Dept Biochem, Rua Mirassol 207, Sao Paulo, SP, Brazil.
EM hugo.monteiro@unifesp.br
RI Batista, Wagner L./C-8204-2012; Sato, Alex Yuri Simões/R-6850-2017
OI Sato, Alex Yuri Simões/0000-0002-4085-2000
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES/Brazil)Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES); Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico, (CNPq)/BrazilConselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPQ) [481154/2013-2]; Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP)/BrazilFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2012/10470-1, 2018/15038-7]
FX Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES/Brazil); Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico, (CNPq)/Brazil, Grant/Award Number: 481154/2013-2; Fundacao
   de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)/Brazil, Grant/Award
   Numbers: 2012/10470-1, 2018/15038-7
CR Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Benson G, 1999, NUCLEIC ACIDS RES, V27, P573, DOI 10.1093/nar/27.2.573
   Chakraborty S, 2019, CELL SIGNAL, V64, DOI 10.1016/j.cellsig.2019.109411
   Chen M, 2009, NAT REV MOL CELL BIO, V10, P741, DOI 10.1038/nrm2777
   Cheng RYS, 2014, NITRIC OXIDE-BIOL CH, V43, P17, DOI 10.1016/j.niox.2014.08.003
   de Oliveira GA, 2017, ANTIOXID REDOX SIGN, V26, P1059, DOI 10.1089/ars.2016.6850
   Eissa NT, 1998, P NATL ACAD SCI USA, V95, P7625, DOI 10.1073/pnas.95.13.7625
   Eissa NT, 1996, J BIOL CHEM, V271, P27184, DOI 10.1074/jbc.271.43.27184
   Eissa NT, 2001, AM J RESP CELL MOL, V24, P616, DOI 10.1165/ajrcmb.24.5.4324
   Fujiwara K, 2008, J BIOL CHEM, V283, P388, DOI 10.1074/jbc.M611043200
   Fukumura D, 2006, NAT REV CANCER, V6, P521, DOI 10.1038/nrc1910
   Heinecke JL, 2014, P NATL ACAD SCI USA, V111, P6323, DOI 10.1073/pnas.1401799111
   HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351
   HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2
   Izuishi K, 2000, CANCER RES, V60, P6201
   Jarry A, 2004, CANCER RES, V64, P4227, DOI 10.1158/0008-5472.CAN-04-0254
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Klionsky DJ, 2008, AUTOPHAGY, V4, P849, DOI 10.4161/auto.6845
   LAVAL F, 1994, CARCINOGENESIS, V15, P443, DOI 10.1093/carcin/15.3.443
   LEE CM, 1995, J BIOL CHEM, V270, P27403, DOI 10.1074/jbc.270.46.27403
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liao WB, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/6304851
   Lim DY, 2005, J CELL PHYSIOL, V205, P107, DOI 10.1002/jcp.20380
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ma Z, 2017, ENVIRON TOXICOL, V32, P2428, DOI 10.1002/tox.22457
   Mauvezin C, 2015, AUTOPHAGY, V11, P1437, DOI 10.1080/15548627.2015.1066957
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Monteiro HP, 2019, NITRIC OXIDE-BIOL CH, V89, P1, DOI 10.1016/j.niox.2019.04.009
   Monteiro HP, 2015, BIOMED J, V38, P380, DOI 10.4103/2319-4170.158624
   Oliveira CJR, 2008, NITRIC OXIDE-BIOL CH, V18, P241, DOI 10.1016/j.niox.2008.02.001
   Pautz A, 2010, NITRIC OXIDE-BIOL CH, V23, P75, DOI 10.1016/j.niox.2010.04.007
   Puschel F, 2020, P NATL ACAD SCI USA, V117, P9932, DOI 10.1073/pnas.1913707117
   Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936
   STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543
   Swart C, 2016, EUR J CELL BIOL, V95, P598, DOI 10.1016/j.ejcb.2016.10.005
   Tiscornia AC, 2004, LEUKEMIA, V18, P48, DOI 10.1038/sj.leu.2403169
   Vannini F, 2015, REDOX BIOL, V6, P334, DOI 10.1016/j.redox.2015.08.009
   Vasudevan D, 2014, VITAM HORM, V96, P265, DOI 10.1016/B978-0-12-800254-4.00011-8
   WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
NR 41
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1065-6995
EI 1095-8355
J9 CELL BIOL INT
JI Cell Biol. Int.
PD JAN
PY 2022
VL 46
IS 1
BP 158
EP 169
DI 10.1002/cbin.11717
EA NOV 2021
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA XV4LP
UT WOS:000715878800001
PM 34719858
DA 2022-04-25
ER

PT J
AU Chen, GY
   Meng, CL
   Lin, KC
   Tuan, HY
   Yang, HJ
   Chen, CL
   Li, KC
   Chiang, CS
   Hu, YC
AF Chen, Guan-Yu
   Meng, Chia-Le
   Lin, Kuan-Chen
   Tuan, Hsing-Yu
   Yang, Hong-Jie
   Chen, Chiu-Ling
   Li, Kuei-Chang
   Chiang, Chi-Shiun
   Hu, Yu-Chen
TI Graphene oxide as a chemosensitizer: Diverted autophagic flux, enhanced
   nuclear import, elevated necrosis and improved antitumor effects
SO BIOMATERIALS
LA English
DT Article
DE Autophagy; Cisplatin; Chemoresistance; Graphene oxide; Nuclear import;
   Necrosis
ID CANCER-CELLS; CISPLATIN RESISTANCE; OVARIAN-CANCER; THERAPY; DEATH;
   CYTOTOXICITY; CARCINOMA; RESPONSES; DNA; INFLAMMATION
AB Graphene oxide (GO) is a nanomaterial that provokes autophagy in CT26 colon cancer cells and confers antitumor effects. Here we demonstrated that both GO and the chemotherapy drug cisplatin (CDDP) induced autophagy but elicited low degrees of CT26 cell death. Strikingly, GO combined with CDDP (GO/COOP) potentiated the CT26 cell killing via necrosis. GO/CDDP not only elicited autophagy, but induced the nuclear import of CDDP and the autophagy marker LC3. The nuclear LC3 did not co-localize with p62 or Lamp-2, neither did blocking autolysosome formation significantly hinder the nuclear import of LC3/CDDP and necrosis, indicating that autophagosome and autolysosome formation was dispensable. Conversely, suppressing phagophore formation and importin-alpha/beta significantly alleviated the nuclear import of LO/CDDP and necrosis. These data suggested that GO/CDDP diverted the LC3 flux in the early phase of autophagy, resulting in LC3 trafficking towards the nucleus in an importin-alpha/beta-dependent manner, which concurred with the CDDP nuclear import and necrosis. Intratumoral injection of GO/CDDP into mice bearing CT26 colon tumors potentiated immune cell infiltration and promoted cell death, autophagy and HMGB1 release, thereby synergistically augmenting the antitumor effects. Altogether, we unveiled a mechanism concerning how nanomaterials chemosensitize cancer cells and demonstrated the potentials of GO as a chemosensitizer. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Chen, Guan-Yu; Meng, Chia-Le; Lin, Kuan-Chen; Tuan, Hsing-Yu; Yang, Hong-Jie; Chen, Chiu-Ling; Li, Kuei-Chang; Hu, Yu-Chen] Natl Tsing Hua Univ, Dept Chem Engn, Hsinchu 300, Taiwan.
   [Lin, Kuan-Chen; Chiang, Chi-Shiun] Natl Tsing Hua Univ, Dept Biomed Engn & Environm Sci, Hsinchu 300, Taiwan.
RP Hu, YC (corresponding author), Natl Tsing Hua Univ, Dept Chem Engn, Hsinchu 300, Taiwan.
EM ychu@mx.nthu.edu.tw
RI Chiang, Chi-Shiun/A-9562-2008
OI Chiang, Chi-Shiun/0000-0002-2581-4129; Tuan,
   Hsing-Yu/0000-0003-2819-2270
FU National Tsing Hua University (Toward World-Class University Project)
   [102N2051E1, 103N2051E1]; National Tsing Hua University (NTHU-CGMH Joint
   Research Program) [103N2758E1]; Ministry of Science and Technology,
   TaiwanMinistry of Science and Technology, Taiwan [NSC
   102-2622-E-007-022-CC1, NSC 102-2221-E-007-023-MY3, MOST
   103-2221-E-007-093-MY3]
FX The authors acknowledge the support from the National Tsing Hua
   University (Toward World-Class University Project 102N2051E1, 103N2051E1
   and NTHU-CGMH Joint Research Program 103N2758E1) and Ministry of Science
   and Technology (NSC 102-2622-E-007-022-CC1, NSC 102-2221-E-007-023-MY3
   and MOST 103-2221-E-007-093-MY3), Taiwan.
CR AKABOSHI M, 1994, JPN J CANCER RES, V85, P106, DOI 10.1111/j.1349-7006.1994.tb02893.x
   Badding MA, 2013, MOL THER, V21, P775, DOI 10.1038/mt.2012.231
   Bampton ETW, 2005, AUTOPHAGY, V1, P23, DOI 10.4161/auto.1.1.1495
   Cepeda V, 2007, ANTI-CANCER AGENT ME, V7, P3, DOI 10.2174/187152007779314044
   Chen GY, 2012, BIOMATERIALS, V33, P418, DOI 10.1016/j.biomaterials.2011.09.071
   Chen GY, 2014, ADV HEALTHC MATER, V3, P1486, DOI 10.1002/adhm.201300591
   Chen GY, 2012, BIOMATERIALS, V33, P6559, DOI 10.1016/j.biomaterials.2012.05.064
   Choi CKK, 2008, CLIN ONCOL-UK, V20, P168, DOI 10.1016/j.clon.2007.11.008
   Cieehomska IA, 2007, AUTOPHAGY, V3, P586, DOI 10.4161/auto.4843
   Cloonan SM, 2011, INT J CANCER, V128, P1712, DOI 10.1002/ijc.25477
   Drake KR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009806
   Eisenberg T, 2009, NAT CELL BIOL, V11, P1305, DOI 10.1038/ncb1975
   Florea Ana-Maria, 2011, Cancers (Basel), V3, P1351, DOI 10.3390/cancers3011351
   Fullgrabe J, 2014, NAT REV MOL CELL BIO, V15, P65, DOI 10.1038/nrm3716
   Galluzzi L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.428
   Garg AD, 2012, EMBO J, V31, P1062, DOI 10.1038/emboj.2011.497
   Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966
   Gonzalez VM, 2001, MOL PHARMACOL, V59, P657, DOI 10.1124/mol.59.4.657
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Kochl R, 2006, TRAFFIC, V7, P129, DOI 10.1111/j.1600-0854.2005.00368.x
   Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380
   Kuma A, 2007, AUTOPHAGY, V3, P323, DOI 10.4161/auto.4012
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Martinez-Lopez N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3799
   Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347
   Peracchio C, 2012, J OVARIAN RES, V5, DOI 10.1186/1757-2215-5-22
   Qu GB, 2013, ACS NANO, V7, P5732, DOI 10.1021/nn402330b
   Raucci A, 2007, AUTOIMMUNITY, V40, P285, DOI 10.1080/08916930701356978
   Ren JH, 2010, CANCER BIOTHER RADIO, V25, P75, DOI 10.1089/cbr.2009.0701
   Safaei R, 2005, MOL CANCER THER, V4, P1595, DOI 10.1158/1535-7163.MCT-05-0102
   Sancho-Martinez SM, 2012, PHARMACOL THERAPEUT, V136, P35, DOI 10.1016/j.pharmthera.2012.07.003
   Tao Y, 2014, BIOMATERIALS, V35, P9963, DOI 10.1016/j.biomaterials.2014.08.036
   Tesniere A, 2010, ONCOGENE, V29, P482, DOI 10.1038/onc.2009.356
   Tournigand C, 2012, J CLIN ONCOL, V30, P3353, DOI 10.1200/JCO.2012.42.5645
   Tyedmers J, 2010, NAT REV MOL CELL BIO, V11, P777, DOI 10.1038/nrm2993
   Uchino H, 2005, BRIT J CANCER, V93, P678, DOI 10.1038/sj.bjc.6602772
   Wagstaff KM, 2012, BIOCHEM J, V443, P851, DOI 10.1042/BJ20120150
   Wan B, 2013, TOXICOL LETT, V221, P118, DOI 10.1016/j.toxlet.2013.06.208
   Wang X, 2012, ANAL METHODS-UK, V4, P360, DOI 10.1039/c2ay05827h
   Yang HN, 2010, P NATL ACAD SCI USA, V107, P12611, DOI 10.1073/pnas.1006542107
   Yang HP, 2013, CARBON, V62, P422, DOI 10.1016/j.carbon.2013.06.027
   Yang K, 2012, BIOMATERIALS, V33, P2206, DOI 10.1016/j.biomaterials.2011.11.064
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yu H, 2011, EUR J CANCER, V47, P1585, DOI 10.1016/j.ejca.2011.01.019
   Yue H, 2012, BIOMATERIALS, V33, P4013, DOI 10.1016/j.biomaterials.2012.02.021
   Zhang H, 2011, CANCER LETT, V308, P62, DOI 10.1016/j.canlet.2011.04.014
   Zhang LM, 2011, SMALL, V7, P460, DOI 10.1002/smll.201001522
   Zhang LM, 2010, SMALL, V6, P537, DOI 10.1002/smll.200901680
   Zhang Q, 2009, AUTOPHAGY, V5, P1107, DOI 10.4161/auto.5.8.9842
   Zong D, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.62
NR 50
TC 63
Z9 65
U1 1
U2 63
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD FEB
PY 2015
VL 40
BP 12
EP 22
DI 10.1016/j.biomaterials.2014.11.034
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA CA5QW
UT WOS:000348963900002
PM 25498801
DA 2022-04-25
ER

PT J
AU Swayden, M
   Bekdash, A
   Fakhoury, I
   El-Atat, O
   Borjac-Natour, J
   El-Sibai, M
   Abi-Habib, RJ
AF Swayden, Mirna
   Bekdash, Amira
   Fakhoury, Isabelle
   El-Atat, Oula
   Borjac-Natour, Jamila
   El-Sibai, Mirvat
   Abi-Habib, Ralph J.
TI Activation of autophagy following [HuArgI (Co)-PEG5000]-induced arginine
   deprivation mediates cell death in colon cancer cells
SO HUMAN CELL
LA English
DT Article
DE [HuArgI (co)-PEG5000]; Colorectal cancer; Arginine auxotrophy; Autophagy
ID RECOMBINANT HUMAN ARGINASE; ARGININOSUCCINATE SYNTHETASE EXPRESSION;
   HUMAN HEPATOCELLULAR-CARCINOMA; ANTHRAX LETHAL TOXIN; I (CO)-PEG5000;
   L-ASPARAGINASE; CYTOTOXICITY; LEUKEMIA; PROLIFERATION; DEPLETION
AB Deregulating cellular energetics by reprogramming metabolic pathways, including arginine metabolism, is critical for cancer cell onset and survival. Drugs that target the specific metabolic requirements of cancer cells have emerged as promising targeted cancer therapeutics. In this study, we investigate the therapeutic potential of targeting colon cancer cells using arginine deprivation induced by a pegylated cobalt-substituted recombinant human Arginase I [HuArgI (Co)-PEG5000]. Four colon cancer cell lines were tested for their sensitivity to [HuArgI (Co)-PEG5000] as well as for their mechanism of cell death following arginine deprivation. All four cell lines were sensitive to arginine deprivation induced by [HuArgI (Co)-PEG5000]. All cells expressed ASS1 and were rescued from arginine deprivation-induced cytotoxicity by the addition of excessl-citrulline, indicating they are partially auxotrophic for arginine. Mechanistically, cells treated with [HuArgI (Co)-PEG5000] were negative for AnnexinV and lacked caspase activation. Further investigation revealed that arginine deprivation leads to a marked and prolonged activation of autophagy in both Caco-2 and T84 cell lines. Finally, we show that [HuArgI (Co)-PEG5000] causes cell death by sustained activation of autophagy as evidenced by the decrease in cell cytotoxicity upon treatment with chloroquine, an autophagy inhibitor. Altogether, these data demonstrate that colon cancer cells are partially auxotrophic for arginine and sensitive to [HuArgI (Co)-PEG5000]-induced arginine deprivation. They also show that the activation of autophagy does not play protective roles but rather, induces cytotoxicity and leads to cell death.
C1 [Bekdash, Amira; Fakhoury, Isabelle; El-Atat, Oula; El-Sibai, Mirvat; Abi-Habib, Ralph J.] Lebanese Amer Univ, Dept Nat Sci, Sch Arts & Sci, Beirut 11022801, Lebanon.
   [Swayden, Mirna; Borjac-Natour, Jamila] Beirut Arab Univ, Dept Biol & Environm Sci, Sch Arts & Sci, Beirut, Lebanon.
RP Abi-Habib, RJ (corresponding author), Lebanese Amer Univ, Dept Nat Sci, Sch Arts & Sci, Beirut 11022801, Lebanon.
EM ralph.abihabib@lau.edu.lb
RI Abi-Habib, Ralph/AAP-2397-2020; atat, oula el/AAH-7689-2019; Abi-Habib,
   Ralph/S-5194-2019
OI atat, oula el/0000-0003-1341-0204; Abi-Habib, Ralph/0000-0002-9587-7758;
   Bekdash, Amira/0000-0002-5065-5131
FU Lebanese American University
FX The authors thank the Lebanese American University for funding and
   support
CR Agrawal V, 2013, PROTEIN PEPTIDE LETT, V20, P392, DOI 10.2174/092986613805290426
   Agrawal V, 2012, ANTI-CANCER DRUG, V23, P51, DOI 10.1097/CAD.0b013e32834ae42b
   Al-Dimasi S, 2016, INT J ONCOL, V48, P1913, DOI 10.3892/ijo.2016.3431
   Al-Koussa H, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236018
   Araghi M, 2019, INT J CANCER, V144, P2992, DOI 10.1002/ijc.32055
   Bean GR, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.232
   Bekdash A, 2015, TRANSL ONCOL, V8, P347, DOI 10.1016/j.tranon.2015.07.001
   Changou CA, 2014, P NATL ACAD SCI USA, V111, P14147, DOI 10.1073/pnas.1404171111
   Cheng PNM, 2007, CANCER RES, V67, P309, DOI 10.1158/0008-5472.CAN-06-1945
   Cloonan SM, 2011, INT J CANCER, V128, P1712, DOI 10.1002/ijc.25477
   Cramer SL, 2017, NAT MED, V23, P120, DOI 10.1038/nm.4232
   Daaboul HE, 2017, CHEM-BIOL INTERACT, V275, P162, DOI 10.1016/j.cbi.2017.08.003
   Davis FF, 1978, ENZYME ENG, P169
   Delage B, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.83
   Delage B, 2010, INT J CANCER, V126, P2762, DOI 10.1002/ijc.25202
   El-Boubbou K, 2017, J BIOMED NANOTECHNOL, V13, P500, DOI 10.1166/jbn.2017.2365
   Glazer ES, 2011, TRANSL ONCOL, V4, P138, DOI 10.1593/tlo.10265
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033
   Hernandez CP, 2010, BLOOD, V115, P5214, DOI 10.1182/blood-2009-12-258822
   Kassab E, 2013, TRANSL ONCOL, V6, P25, DOI 10.1593/tlo.12313
   Khoury O, 2015, J NEURO-ONCOL, V122, P75, DOI 10.1007/s11060-014-1698-5
   Kim RH, 2009, CANCER RES, V69, P700, DOI 10.1158/0008-5472.CAN-08-3157
   Kuo MT, 2010, ONCOTARGET, V1, P246, DOI 10.18632/oncotarget.135
   Lam TL, 2009, CANCER LETT, V277, P91, DOI 10.1016/j.canlet.2008.11.031
   Lin C, 2015, APPL MICROBIOL BIOT, V99, P8487, DOI 10.1007/s00253-015-6565-6
   Macintosh RL, 2012, CELL CYCLE, V11, P2022, DOI 10.4161/cc.20424
   Mauldin JP, 2012, TRANSL ONCOL, V5, P26, DOI 10.1593/tlo.11262
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Morris SM, 2004, J NUTR, V134, p2743S, DOI 10.1093/jn/134.10.2743S
   Muller HJ, 1998, CRIT REV ONCOL HEMAT, V28, P97, DOI 10.1016/S1040-8428(98)00015-8
   Mussai F, 2013, BLOOD, V122, P749, DOI 10.1182/blood-2013-01-480129
   Nasrallah A, 2014, ONCOL REP, V31, P505, DOI 10.3892/or.2013.2861
   Nasreddine G, 2020, INVEST NEW DRUG, V38, P10, DOI 10.1007/s10637-019-00756-w
   Periyasamy-Thandavan S, 2009, AM J PHYSIOL-RENAL, V297, pF244, DOI 10.1152/ajprenal.00033.2009
   Shebaby WN, 2015, J MED FOOD, V18, P745, DOI 10.1089/jmf.2014.3225
   Stone EM, 2010, ACS CHEM BIOL, V5, P333, DOI 10.1021/cb900267j
   Syed N, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.197
   Tanios R, 2013, LEUKEMIA RES, V37, P1565, DOI 10.1016/j.leukres.2013.08.007
   Wang J, 2014, J BIOL CHEM, V289, P17163, DOI 10.1074/jbc.M114.558288
   Wetzler M, 2007, BLOOD, V109, P4164, DOI 10.1182/blood-2006-09-045351
   Yoon CY, 2007, INT J CANCER, V120, P897, DOI 10.1002/ijc.22322
   Zhang N, 2010, AUTOPHAGY, V6, P1157, DOI 10.4161/auto.6.8.13614
NR 43
TC 3
Z9 4
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0914-7470
EI 1749-0774
J9 HUM CELL
JI Hum. Cell
PD JAN
PY 2021
VL 34
IS 1
BP 152
EP 164
DI 10.1007/s13577-020-00437-4
EA SEP 2020
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA PP2RN
UT WOS:000572858600001
PM 32979152
DA 2022-04-25
ER

PT J
AU Jiang, F
   Zhou, JY
   Zhang, D
   Liu, MH
   Chen, YG
AF Jiang, Feng
   Zhou, Jin-Yong
   Zhang, Dan
   Liu, Ming-Hao
   Chen, Yu-Gen
TI Artesunate induces apoptosis and autophagy in HCT116 colon cancer cells,
   and autophagy inhibition enhances the artesunate-induced apoptosis
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE apoptosis; artesunate; autophagy; colon cancer
ID MEDIATED INTRINSIC PATHWAY; COLORECTAL-CANCER; SKM-1 CELLS; EXPRESSION;
   GROWTH; SUPPRESSES; RESISTANCE; STRESS; ATG12
AB The present study assessed the antitumor effect of artesunate (ART) in vitro and in vivo, as well as its underlying mechanism of action in HCT116 colon cancer cells. An MTT assay, DAPI staining, flow cytometry, western blotting, immunohistochemistry, transmission electron microscopy and TUNEL assay were performed to study the molecular mechanism underlying the antitumor effects of ART in HCT116 colon cancer cells. ART was observed to inhibit proliferation by inducing the apoptosis of HCT116 cells both in vitro and in vivo. Flow cytometry analysis demonstrated that treatment with 2 and 4 mu g/ml ART for 48 h induced early apoptosis in 22.7 and 33.8% of cells, respectively. In the xenograft tumors of BALB/c nude mice, TUNEL-positive cells increased in the ART group compared with that in the normal saline group. Furthermore,the associated mitochondrial cleaved-caspase 3, poly-ADP ribose polymerase (PARP), caspase 9 and Bcl-2-associated X protein levels increased while B-cell lymphoma-2 (Bcl-2) decreased both in the cell and animal ART-treated group. ART-treated cells also exhibited autophagy induction, as evidenced by increased protein expression levels of light chain 3 (LC3) and beclin-1, and the presence of autophagosomes. Notably, pharmacological blockade of autophagy activation using hydroxychloroquine markedly enhanced ART-induced apoptosis and increased the protein levels of cleaved caspase 3 and PARP, while decreasing the levels of LC3 and beclin-1. These findings suggested that the ART-induced autophagy may have a cytoprotective effect by suppressing apoptosis. In conclusion, ART may be a potentially clinically useful anticancer drug for human colon cancer. In addition, co-treatment with ART and an autophagy inhibitor may be an effective anticancer therapy.
C1 [Jiang, Feng; Zhang, Dan; Chen, Yu-Gen] Nanjing Univ TCM, Affiliated Hosp, Dept Colorectal Surg, 155 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
   [Jiang, Feng; Zhang, Dan; Liu, Ming-Hao] Nanjing Univ Chinese Med, Clin Med Coll 1, Nanjing 210023, Jiangsu, Peoples R China.
   [Zhou, Jin-Yong] Nanjing Univ TCM, Affiliated Hosp, Dept Cent Lab, Nanjing 210029, Jiangsu, Peoples R China.
RP Chen, YG (corresponding author), Nanjing Univ TCM, Affiliated Hosp, Dept Colorectal Surg, 155 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM chenyg666@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81373645, 81573978]; Priority Academic
   Program Development of Jiangsu Higher Education Institutions; Jiangsu
   Province Special Program of Medical Science [BL2014100]; Peak Academic
   Talents plan of the Jiangsu Province Hospital of TCM (Jiangsu, China)
   [BRA2017536]
FX This study was supported by the National Natural Science Foundation of
   China (grant no. 81373645, 81573978). This study was also supported by
   the Priority Academic Program Development of Jiangsu Higher Education
   Institutions and Jiangsu Province Special Program of Medical Science
   (grant no. BL2014100) and by the Peak Academic Talents plan (grant no.
   BRA2017536) of the Jiangsu Province Hospital of TCM (Jiangsu, China).
CR Chaitanya GV, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-31
   Chen K, 2014, ANTI-CANCER DRUG, V25, P652, DOI 10.1097/CAD.0000000000000089
   Clark RL, 2009, REPROD TOXICOL, V28, P285, DOI 10.1016/j.reprotox.2009.05.002
   Coghlin C, 2015, PROTEOM CLIN APPL, V9, P64, DOI 10.1002/prca.201400082
   Coker-Gurkan A, 2015, ONCOL REP, V33, P2761, DOI 10.3892/or.2015.3918
   Delle Cave D, 2018, J CELL PHYSIOL, V233, P1370, DOI 10.1002/jcp.26015
   Efferth T, 1996, ARZNEIMITTEL-FORSCH, V46, P196
   Efferth T, 2010, CRIT REV TOXICOL, V40, P405, DOI 10.3109/10408441003610571
   Hanada T, 2005, AUTOPHAGY, V1, P110, DOI 10.4161/auto.1.2.1858
   Hseu YC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08659-7
   Huang CC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128045
   Jeong DE, 2015, ONCOTARGET, V6, P33046, DOI 10.18632/oncotarget.5422
   Jung HJ, 2017, J ETHNOPHARMACOL, V208, P253, DOI 10.1016/j.jep.2017.07.020
   Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509
   Kim C, 2015, ONCOTARGET, V6, P4020, DOI 10.18632/oncotarget.3004
   Liu L, 2015, MOL MED REP, V12, P1465, DOI 10.3892/mmr.2015.3517
   Liu L, 2017, ONCOL LETT, V14, P4319, DOI 10.3892/ol.2017.6687
   Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069
   Meng FR, 2017, MOLECULES, V22, DOI 10.3390/molecules22071119
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   O'Donovan TR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134676
   Oh KJ, 2006, J BIOL CHEM, V281, P36999, DOI 10.1074/jbc.M602341200
   Pang YL, 2016, EXP CELL RES, V347, P251, DOI 10.1016/j.yexcr.2016.06.012
   Papanikolaou X, 2014, ONCOTARGET, V5, P4118, DOI 10.18632/oncotarget.1847
   Qin GQ, 2015, EXP CELL RES, V336, P308, DOI 10.1016/j.yexcr.2015.07.004
   Ranjan A, 2016, SCI REP-UK, V6, DOI 10.1038/srep26165
   Roh JL, 2017, REDOX BIOL, V11, P254, DOI 10.1016/j.redox.2016.12.010
   Rosenthal PJ, 2008, NEW ENGL J MED, V358, P1829, DOI 10.1056/NEJMct0709050
   Siddiqui WA, 2015, ARCH TOXICOL, V89, P289, DOI 10.1007/s00204-014-1448-7
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Wang Y, 2014, CHEM-BIOL INTERACT, V219, P28, DOI 10.1016/j.cbi.2014.03.011
   Wang YY, 2018, ONCOL RES, V26, P889, DOI 10.3727/096504017X15009419625178
   Wang ZC, 2017, EUR REV MED PHARMACO, V21, P2238
   Wang ZZ, 2017, BIOL PHARM BULL, V40, P479, DOI 10.1248/bpb.b16-00908
   Won SJ, 2015, J CELL PHYSIOL, V230, P930, DOI 10.1002/jcp.24825
   Xu N, 2015, INT J MED SCI, V12, P524, DOI 10.7150/ijms.11352
   Zhang LX, 2014, CELL BIOL INT, V38, P639, DOI 10.1002/cbin.10244
   Zhang YW, 2017, EXP THER MED, V14, P593, DOI 10.3892/etm.2017.4529
   Zuo W, 2014, INT J MOL SCI, V15, P14298, DOI 10.3390/ijms150814298
NR 39
TC 42
Z9 45
U1 5
U2 20
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD SEP
PY 2018
VL 42
IS 3
BP 1295
EP 1304
DI 10.3892/ijmm.2018.3712
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA GW4IE
UT WOS:000446875200010
PM 29901098
OA Green Published, hybrid, Green Submitted
DA 2022-04-25
ER

PT J
AU Chen, MC
   Lee, NH
   Ho, TJ
   Hsu, HH
   Kuo, CH
   Kuo, WW
   Lin, YM
   Tsai, FJ
   Tsai, CH
   Huang, CY
AF Chen, Ming-Cheng
   Lee, Nien-Hung
   Ho, Tsung-Jung
   Hsu, Hsi-Hsien
   Kuo, Chia-Hua
   Kuo, Wei-Wen
   Lin, Yueh-Min
   Tsai, Fuu-Jen
   Tsai, Chang-Hai
   Huang, Chih-Yang
TI Resistance to irinotecan (CPT-11) activates epidermal growth factor
   receptor/nuclear factor kappa B and increases cellular metastasis and
   autophagy in LoVo colon cancer cells
SO CANCER LETTERS
LA English
DT Article
DE Chemoresistance; CPT-11; NF-kappa B; Metastasis; Autophagy
ID COLORECTAL-CANCER; INDUCIBLE CHEMORESISTANCE; ANTICANCER DRUGS;
   GEFITINIB IRESSA; INHIBITION; CHEMOTHERAPY; MECHANISMS; THERAPY; DEATH;
   5-FLUOROURACIL
AB Chemotherapy is usually applied to treat colon cancer but leads to chemoresistance, and increased metastasis and invasion. The main focus of this study is to observe effects of resistance to irinotecan (CPT-11) on metastasis, invasion and autophagy in CPT-11 resistant (CPT-11-R) LoVo colon cancer cells. CPT-11, a topoisomerase I inhibitor and a first-line chemotherapeutic drug, is used to treat colon cancer. CPT-11-R cells were constructed in a step-wise fashion with increasing CPT-11 doses. The CPT-11-R strain had a significantly lower expression of Wnt/beta-catenin pathway, but induced an EGFR/IKK alpha/beta/NF-kappa B pathway with elevated cell cycle, metastasis and basal autophagy. C) 2014 Elsevier Ireland Ltd. All rights reserved.
C1 [Chen, Ming-Cheng; Lee, Nien-Hung; Huang, Chih-Yang] China Med Univ, Grad Inst Basic Med Sci, Taichung, Taiwan.
   [Chen, Ming-Cheng] Taichung Vet Gen Hosp, Puli Branch, Nantou, Taiwan.
   [Ho, Tsung-Jung] China Med Univ, Beigang Hosp, Chinese Med Dept, Yunlin, Taiwan.
   [Hsu, Hsi-Hsien] Mackay Mem Hosp, Div Colorectal Surg, Taipei, Taiwan.
   [Hsu, Hsi-Hsien] Nursing & Management Coll, Mackay Jr Coll Med, Taipei, Taiwan.
   [Kuo, Chia-Hua] Univ Taipei, Dept Sports Sci, Taipei, Taiwan.
   [Kuo, Wei-Wen] China Med Univ, Dept Biol Sci & Technol, Taichung, Taiwan.
   [Lin, Yueh-Min] Changhua Christian Hosp, Dept Pathol, Changhua, Taiwan.
   [Lin, Yueh-Min] Jen Teh Jr Coll Med, Dept Med Technol, Miaoli, Taiwan.
   [Tsai, Fuu-Jen; Huang, Chih-Yang] China Med Univ, Grad Inst Chinese Med Sci, Taichung, Taiwan.
   [Tsai, Chang-Hai] Asia Univ, Dept Healthcare Adm, Taichung, Taiwan.
   [Huang, Chih-Yang] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung, Taiwan.
RP Huang, CY (corresponding author), China Med Univ & Hosp, Sch Med, Grad Inst Basic Med Sci, 91 Hsueh Shih Rd, Taichung 404, Taiwan.
EM cyhuang@mail.cmu.edu.tw
RI Yuang, Chih-Yang/O-5111-2015; Tsai, Fuu-Jen/J-4140-2015
OI Lee, Nien-Hung/0000-0001-5423-8880; Kuo, Chia-Hua/0000-0002-1731-4984
FU Taiwan Department of Health Clinical Trial and Research Center of
   Excellence [DOH102-TD-B-111-004]
FX This study is supported in part by Taiwan Department of Health Clinical
   Trial and Research Center of Excellence (DOH102-TD-B-111-004).
CR Baldwin AS, 2012, IMMUNOL REV, V246, P327, DOI 10.1111/j.1600-065X.2012.01095.x
   Becouarn Y, 1998, J CLIN ONCOL, V16, P2739, DOI 10.1200/JCO.1998.16.8.2739
   Choi KS, 2012, EXP MOL MED, V44, P109, DOI 10.3858/emm.2012.44.2.033
   Cusack JC, 2000, CANCER RES, V60, P2323
   Cusack JC, 1999, DRUG RESIST UPDATE, V2, P271, DOI 10.1054/drup.1999.0094
   DREWINKO B, 1976, CANCER RES, V36, P467
   Fodde R, 2002, SCIENCE, V298, P761, DOI 10.1126/science.1077707
   Fournier DB, 2000, J CELL BIOCHEM, P97
   Fukuyama R, 2007, MOL CARCINOGEN, V46, P402, DOI 10.1002/mc.20288
   Garg AK, 2005, ANTIOXID REDOX SIGN, V7, P1630, DOI 10.1089/ars.2005.7.1630
   Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405
   Hsu SC, 2013, BIOMEDICINE-TAIWAN, V3, P120, DOI 10.1016/j.biomed.2013.04.008
   Hurley LH, 2002, NAT REV CANCER, V2, P188, DOI 10.1038/nrc749
   Jiang X, 2003, J BIOL CHEM, V278, P919, DOI 10.1074/jbc.M208696200
   Kaminski BM, 2011, CANCER CHEMOTH PHARM, V67, P1167, DOI 10.1007/s00280-010-1413-y
   Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221
   Kenific CM, 2010, CURR OPIN CELL BIOL, V22, P241, DOI 10.1016/j.ceb.2009.10.008
   Kishida O, 2005, CANCER CHEMOTH PHARM, V55, P393, DOI 10.1007/s00280-004-0904-0
   Koizumi F, 2004, INT J CANCER, V108, P464, DOI 10.1002/ijc.11539
   Li F, 2010, BBA-REV CANCER, V1805, P167, DOI 10.1016/j.bbcan.2010.01.002
   Lin Y, 2010, EXPERT OPIN THER TAR, V14, P45, DOI 10.1517/14728220903431069
   Lu Si-Zhao, 2013, World J Biol Chem, V4, P64, DOI 10.4331/wjbc.v4.i3.64
   Luqmani YA, 2005, MED PRIN PRACT, V14, P35, DOI 10.1159/000086183
   Marin JJG, 2012, CURR CANCER DRUG TAR, V12, P402
   Marin JJG, 2012, DRUG METAB REV, V44, P148, DOI 10.3109/03602532.2011.638303
   Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588
   Papazisis KT, 2006, CANCER LETT, V233, P255, DOI 10.1016/j.canlet.2005.03.022
   Park KS, 2011, J GASTROEN HEPATOL, V26, P391, DOI 10.1111/j.1440-1746.2010.06504.x
   Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977
   PUGH S, 1994, GUT, V35, P675, DOI 10.1136/gut.35.5.675
   RIGAS B, 1993, J LAB CLIN MED, V122, P518
   Rothenberg ML, 2001, ONCOLOGIST, V6, P66, DOI 10.1634/theoncologist.6-1-66
   Sansom OJ, 2005, J BIOL CHEM, V280, P28463, DOI 10.1074/jbc.M500191200
   Shimoyama T, 2006, LUNG CANCER, V53, P13, DOI 10.1016/j.lungcan.2006.03.014
   Tang CH, 2012, BIOMEDICINE-TAIWAN, V2, P92, DOI 10.1016/j.biomed.2012.01.001
   Uetsuka H, 2003, EXP CELL RES, V289, P27, DOI 10.1016/S0014-4827(03)00223-4
   Veiby OP, 2004, CLIN CANCER RES, V10, P3262, DOI 10.1158/1078-0432.CCR-04-0703
   Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410
   Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784
   Weekes J, 2009, WORLD J GASTROENTERO, V15, P3597, DOI 10.3748/wjg.15.3597
   Wilson TR, 2006, ANN ONCOL, V17, pX315, DOI 10.1093/annonc/mdl280
   Xu Y, 2002, ANN ONCOL, V13, P1841, DOI 10.1093/annonc/mdf337
   Yim KL, 2011, RECENT RESULTS CANC, V185, P159, DOI 10.1007/978-3-642-03503-6_10
NR 43
TC 22
Z9 24
U1 3
U2 35
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD JUL 10
PY 2014
VL 349
IS 1
BP 51
EP 60
DI 10.1016/j.canlet.2014.03.023
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AI8YW
UT WOS:000337213900007
PM 24726344
DA 2022-04-25
ER

PT J
AU Niklaus, M
   Adams, O
   Berezowska, S
   Zlobec, I
   Graber, F
   Slotta-Huspenina, J
   Nitsche, U
   Rosenberg, R
   Tschan, MP
   Langer, R
AF Niklaus, Monique
   Adams, Olivia
   Berezowska, Sabina
   Zlobec, Inti
   Graber, Franziska
   Slotta-Huspenina, Julia
   Nitsche, Ulrich
   Rosenberg, Robert
   Tschan, Mario P.
   Langer, Rupert
TI Expression analysis of LC3B and p62 indicates intact activated autophagy
   is associated with an unfavorable prognosis in colon cancer
SO ONCOTARGET
LA English
DT Article
DE colon cancer; autophagy; LC3; p62; immunohistochemistry
ID COLORECTAL-CANCER; P62/SEQUESTOSOME 1; CARCINOMA; CELLS; COMBINATION;
   PROGRESSION; INHIBITION; GUIDELINES; THERAPY; IMPACT
AB Autophagy is a lysosomal degradation and recycling process implicated in cancer progression and therapy resistance. We assessed the impact of basal autophagy in colon cancer (CC) in vitro and ex vivo. Functional autophagy was demonstrated in CC cell lines (LoVo; HT-29) showing a dose-dependent increase of the autophagy markers LC3B, p62 and autophagic vesciles upon increasing concentrations of the autophagy inhibitor chloroquine, which was demonstrated by immunoblotting, immunofluorescence and electron microscopy. Next, tissue microarrays with 292 primary resected CC, with cores from different tumor regions, and normal mucosa were analyzed by immunohistochemistry for LC3B and p62. CC tissue showed LC3B dot-like, p62 dot-like, cytoplasmic and nuclear staining in various levels without significant intratumoral heterogeneity. Tumoral LC3B and p62 expression was significantly higher than in normal tissue (p<0.001). No associations between staining patterns and pathological features (e.g. TNM categories; grading) were observed. Both low LC3B dot-like and low p62 dot-like-cytoplasmic staining were associated with worse overall survival (p=0.005 and p=0.002). The best prognostic discrimination, however, was seen for a combination of LC3B dot-like/p62 dot-like-cytoplasmic staining: high expression of both markers, indicative of impaired activated autophagy, was associated with the best overall survival. In contrast, high LC3B dot-like/low p62 dot-like-cytoplasmic expression, indicative of intact activated autophagy, was associated with the worst outcome (p<0.001 in univariate and HR=0.751; CI=0.6070.928; p=0.008 in multivariate analysis). These specific expression patterns of LC3B and p62 pointing to different states of autophagy associated with diverging clinical outcomes highlighte the potential significance of basal autophagy in CC biology.
C1 [Niklaus, Monique; Adams, Olivia; Berezowska, Sabina; Zlobec, Inti; Graber, Franziska; Tschan, Mario P.; Langer, Rupert] Univ Bern, Inst Pathol, CH-3008 Bern, Switzerland.
   [Adams, Olivia; Zlobec, Inti; Tschan, Mario P.] Univ Bern, Grad Sch Cellular & Biomed Sci, CH-3008 Bern, Switzerland.
   [Slotta-Huspenina, Julia] Tech Univ Munich, Inst Pathol, D-81675 Munich, Germany.
   [Nitsche, Ulrich] Tech Univ Munich, Dept Surg, D-81675 Munich, Germany.
   [Rosenberg, Robert] Kantonsspital Liestal, Dept Surg, CH-4410 Liestal, Switzerland.
RP Langer, R (corresponding author), Univ Bern, Inst Pathol, CH-3008 Bern, Switzerland.
EM rupert.langer@pathology.unibe.ch
RI Langer, Rupert/AAU-1174-2021; Berezowska, Sabina/AAJ-4557-2021
OI Langer, Rupert/0000-0001-9491-3609; Berezowska,
   Sabina/0000-0001-5442-9791; Zlobec, Inti/0000-0001-6741-3000
FU Swiss Cancer League [KFS-3083-02-2013]
FX The study has been funded by the Swiss Cancer League (KFS-3083-02-2013).
CR Adams O, 2016, ONCOTARGET, V7, P39241, DOI 10.18632/oncotarget.9649
   Bauer K, 2012, CELL ONCOL, V35, P197, DOI 10.1007/s13402-012-0079-3
   Boone BA, 2015, ANN SURG ONCOL, V22, P4402, DOI 10.1245/s10434-015-4566-4
   Choi JH, 2014, GASTROENT RES PRACT, V2014, DOI 10.1155/2014/179586
   Drecoll E, 2014, INT J COLORECTAL DIS, V29, P663, DOI 10.1007/s00384-014-1857-3
   Duffy A, 2015, CANCER CHEMOTH PHARM, V75, P439, DOI 10.1007/s00280-014-2637-z
   Fitzmaurice C, 2015, JAMA ONCOL, V1, P505, DOI 10.1001/jamaoncol.2015.0735
   Galluzzi L, 2017, NAT REV CLIN ONCOL, V14, P247, DOI 10.1038/nrclinonc.2016.183
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Gewirtz DA, 2016, CANCER RES, V76, P5610, DOI 10.1158/0008-5472.CAN-16-0722
   Groulx JF, 2012, AUTOPHAGY, V8, P893, DOI 10.4161/auto.19738
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   Jiang PD, 2015, METHODS, V75, P13, DOI 10.1016/j.ymeth.2014.11.021
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Liu JL, 2014, BRIT J CANCER, V111, P944, DOI 10.1038/bjc.2014.355
   Mahalingam D, 2014, AUTOPHAGY, V10, P1403, DOI 10.4161/auto.29231
   Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954
   Ren F, 2014, MOL CELL BIOCHEM, V385, P95, DOI 10.1007/s11010-013-1818-0
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Schlafli AM, 2015, EUR J HISTOCHEM, V59, P137, DOI 10.4081/ejh.2015.2481
   Schlafli AM, 2016, ONCOTARGET, V7, P39544, DOI 10.18632/oncotarget.9647
   Schmitz KJ, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0946-x
   Schmoll HJ, 2012, ANN ONCOL, V23, P2479, DOI 10.1093/annonc/mds236
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Wong A, 2014, CLIN GASTROENTEROL H, V12, P139, DOI 10.1016/j.cgh.2013.08.040
   Wu SH, 2015, INT J CLIN EXP PATHO, V8, P3882
   Yang MP, 2015, ONCOTARGET, V6, P7084, DOI 10.18632/oncotarget.3054
   Zhang Y, 2015, CURR MED RES OPIN, V31, P1009, DOI 10.1185/03007995.2015.1025731
   Zheng Hai-yang, 2012, Cancer Biology Medicine, V9, P105, DOI 10.3969/j.issn.2095-3941.2012.02.004
   Zlobec I, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-104
   Zlobec I, 2011, HISTOPATHOLOGY, V59, P482, DOI 10.1111/j.1365-2559.2011.03975.x
NR 33
TC 33
Z9 36
U1 0
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG
PY 2017
VL 8
IS 33
BP 54604
EP 54615
DI 10.18632/oncotarget.17554
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FD9ER
UT WOS:000407826100059
PM 28903368
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Piao, SF
   Ojha, R
   Rebecca, VW
   Samanta, A
   Ma, XH
   Mcafee, Q
   Nicastri, MC
   Buckley, M
   Brown, E
   Winkler, JD
   Gimotty, PA
   Amaravadi, RK
AF Piao, Shengfu
   Ojha, Rani
   Rebecca, Vito W.
   Samanta, Arabinda
   Ma, Xiao-hong
   Mcafee, Quentin
   Nicastri, Michael C.
   Buckley, Meghan
   Brown, Eric
   Winkler, Jeffrey D.
   Gimotty, Phyllis A.
   Amaravadi, Ravi K.
TI ALDH1A1 and HLTF modulate the activity of lysosomal autophagy inhibitors
   in cancer cells
SO AUTOPHAGY
LA English
DT Article
DE ALDH1; autophagy; chloroquine; HLTF; lysosome
ID ADVANCED SOLID TUMORS; PHASE-I TRIAL; RETINOIC ACID; CHROMOSOMAL
   INSTABILITY; COLORECTAL-CANCER; BRAIN-TUMORS; HYDROXYCHLOROQUINE;
   MELANOMA; GROWTH; BRAF(V600E)
AB Lysosomal autophagy inhibitors (LAI) such as hydroxychloroquine (HCQ) have significant activity in a subset of cancer cell lines. LAIs are being evaluated in cancer clinical trials, but genetic determinants of sensitivity to LAIs are unknown, making it difficult to predict which tumors would be most susceptible. Here we characterize differentially expressed genes in HCQ-sensitive (-S) and -resistant (-R) cancer cells. Notably, expression of canonical macroautophagy/autophagy genes was not associated with sensitivity to HCQ. Expression patterns of ALDH1A1 (aldehyde dehydrogenase 1 family member A1) and HLTF (helicase like transcription factor) identified HCQ-S (ALDH1A1(high) HLTFlow; ALDH1A1(low) HLTFlow) and HCQ-R (ALDH1A1(low) HLTFhigh) cells. ALDH1A1 overexpression was found to enhance LAI cell entry and cytotoxicity without directly affecting lysosome function or autophagic flux. Expression of HLTF allows repair of DNA damage caused by LAI-induced reactive oxygen species, leading to HCQ resistance. Sensitivity to HCQ is increased in cells where HLTF is silenced by promoter methylation. HLTF overexpression blunted the antitumor efficacy of chloroquine derivatives in vitro and in vivo. Analysis of tumor RNA sequencing data from >700 patients in the Cancer Genome Atlas identified cancers including colon cancer, renal cell carcinoma, and gastric cancers, that were enriched for the HCQ-S or HCQ-R signature. These results provide mechanistic insights into LAI efficacy, and guidance for LAI clinical development.
C1 [Piao, Shengfu; Ojha, Rani; Rebecca, Vito W.; Samanta, Arabinda; Ma, Xiao-hong; Mcafee, Quentin; Amaravadi, Ravi K.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
   [Nicastri, Michael C.; Winkler, Jeffrey D.] Univ Penn, Dept Chem, Philadelphia, PA 19104 USA.
   [Buckley, Meghan; Gimotty, Phyllis A.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
   [Brown, Eric] Univ Penn, Dept Canc Biol, Philadelphia, PA 19104 USA.
   [Brown, Eric; Winkler, Jeffrey D.; Gimotty, Phyllis A.; Amaravadi, Ravi K.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
RP Amaravadi, RK (corresponding author), Univ Penn, Dept Med, Abramson Canc Ctr, 777 South Tower PCAM 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.; Gimotty, PA (corresponding author), Univ Penn, Dept Biostat & Epidemiol, Abramson Canc Ctr, 631 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM pgimotty@mail.med.upenn.edu; ravi.amaravadi@uphs.upenn.edu
RI Ojha, Rani/ABF-9507-2020
FU SPORE [P50 CA174523]; Pennsylvania Dept of Health;  [R01CA169134];  [P01
   CA114046];  [P30 CA016520];  [1R01CA198015]; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [P01CA114046, P50CA174523, R01CA198015, P30CA016520, R01CA169134]
   Funding Source: NIH RePORTER
FX R01CA169134 (RA; PG); P01 CA114046 (RA, JW); P30 CA016520 (RA); SPORE
   P50 CA174523 (RA); 1R01CA198015 (RA); Pennsylvania Dept of Health (RA)
CR Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Amaravadi RK, 2015, J CLIN INVEST, V125, P1393, DOI 10.1172/JCI81504
   Barnard RA, 2014, AUTOPHAGY, V10, P1415, DOI 10.4161/auto.29165
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Boone BA, 2015, ANN SURG ONCOL, V22, P4402, DOI 10.1245/s10434-015-4566-4
   Carew JS, 2007, BLOOD, V110, P313, DOI 10.1182/blood-2006-10-050260
   Chang DJ, 2009, NAT CHEM BIOL, V5, P82, DOI 10.1038/nchembio.139
   Das S, 2010, CANCER RES, V70, P7874, DOI 10.1158/0008-5472.CAN-10-1534
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Degtyarev M, 2008, J CELL BIOL, V183, P101, DOI 10.1083/jcb.200801099
   Dhont L, 2016, CELL MOL LIFE SCI, V73, P129, DOI 10.1007/s00018-015-2060-6
   Eng CH, 2016, P NATL ACAD SCI USA, V113, P182, DOI 10.1073/pnas.1515617113
   Fazi F, 2005, ONCOGENE, V24, P1820, DOI 10.1038/sj.onc.1208286
   Goulielmaki M, 2016, ONCOTARGET, V7, P9188, DOI 10.18632/oncotarget.6942
   Graves PR, 2002, MOL PHARMACOL, V62, P1364, DOI 10.1124/mol.62.6.1364
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Guo XY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0328-y
   Johansson P, 2007, PIGM CELL RES, V20, P216, DOI 10.1111/j.1600-0749.2007.00375.x
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Laddha SV, 2014, MOL CANCER RES, V12, P485, DOI 10.1158/1541-7786.MCR-13-0614
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levy JMM, 2014, AUTOPHAGY, V10, P2077, DOI 10.4161/auto.36138
   Levy JMM, 2014, CANCER DISCOV, V4, P773, DOI 10.1158/2159-8290.CD-14-0049
   Lin JR, 2011, MOL CELL, V42, P237, DOI 10.1016/j.molcel.2011.02.026
   Liu EY, 2015, P NATL ACAD SCI USA, V112, P773, DOI 10.1073/pnas.1409563112
   Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   Ma XH, 2014, J CLIN INVEST, V124, P1406, DOI 10.1172/JCI70454
   Maclean KH, 2008, J CLIN INVEST, V118, P79, DOI 10.1172/JCI33700
   Mahalingam D, 2014, AUTOPHAGY, V10, P1403, DOI 10.4161/auto.29231
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109
   Morgan MJ, 2014, AUTOPHAGY, V10, P1814, DOI 10.4161/auto.32135
   Park C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7823
   Paulsen RD, 2007, DNA REPAIR, V6, P953, DOI 10.1016/j.dnarep.2007.02.015
   Perera R, 2015, NATURE, V524, P361, DOI 10.1038/nature14587
   Piao SF, 2016, ANN NY ACAD SCI, V1371, P45, DOI 10.1111/nyas.12953
   Rangwala R, 2014, AUTOPHAGY, V10, P1391, DOI 10.4161/auto.29119
   Rangwala R, 2014, AUTOPHAGY, V10, P1369, DOI 10.4161/auto.29118
   Rebecca VW, 2016, ONCOGENE, V35, P1, DOI 10.1038/onc.2015.99
   Rosenfeld MR, 2014, AUTOPHAGY, V10, P1359, DOI 10.4161/auto.28984
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Sheffer M, 2009, P NATL ACAD SCI USA, V106, P7131, DOI 10.1073/pnas.0902232106
   Thorburn A, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001967
   Tomita H, 2016, ONCOTARGET, V7, P11018, DOI 10.18632/oncotarget.6920
   Unk I, 2010, DNA REPAIR, V9, P257, DOI 10.1016/j.dnarep.2009.12.013
   Vogl DT, 2014, AUTOPHAGY, V10, P1380, DOI 10.4161/auto.29264
   Wang YN, 2016, MOL CELL, V63, P34, DOI 10.1016/j.molcel.2016.05.027
   Wei YJ, 2013, CELL, V154, P1269, DOI 10.1016/j.cell.2013.08.015
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Yang A, 2014, AUTOPHAGY, V10, P1683, DOI 10.4161/auto.29961
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Zhang Y, 2014, J CELL BIOCHEM, V115, P1528, DOI 10.1002/jcb.24807
NR 53
TC 14
Z9 16
U1 0
U2 11
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PY 2017
VL 13
IS 12
BP 2056
EP 2071
DI 10.1080/15548627.2017.1377377
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FT5TJ
UT WOS:000423215800005
PM 28981387
OA Bronze, Green Published
DA 2022-04-25
ER

PT J
AU Han, J
   Li, J
   Tang, KJ
   Zhang, HH
   Guo, B
   Hou, N
   Huang, C
AF Han, Jia
   Li, Jie
   Tang, Kaijie
   Zhang, Huahua
   Guo, Bo
   Hou, Ni
   Huang, Chen
TI miR-338-3p confers 5-fluorouracil resistance in p53 mutant colon cancer
   cells by targeting the mammalian target of rapamycin
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE miR-338-3p; 5-FU resistance; Colon cancer cell; p53; mTOR
ID COLORECTAL-CANCER; AUTOPHAGY; CHEMORESISTANCE; MECHANISMS; APOPTOSIS;
   MICRORNA; MTOR
AB Evidence demonstrate that p53 mutations and microRNAs (miRs) are important components of 5-FU resistance in colorectal cancer (CRC). miR-338-3p has been reported associated with cancer prognosis. However whether or not it influences chemotherapy sensitivity and the underlying mechanisms have not been elucidated. Here, three types of human colon cancer cell lines, HT29 (mutant p53), HCT116 (wild-type p53), and HCT116 p53(-/-) (deficient p53), were treated with 5-FU. We showed that expression of miR-338-3p was correlated with apoptosis and 5-FU resistance in colon cancer cells. Ectopic expression of miR-338-3p conferred resistance to 5-FU in HCT116 cells. Further experiments indicated that miR-338-3p mediated 5-FU resistance through down-regulation of mTOR expression. Moreover, inhibition of miR-338-3p in HT29 and HCT116 p53(-/-) cells increased their sensitivity to 5-FU treatment. Furthermore, we detected autophagy changes in our experiment because mTOR was known prominently regulating autophagy and the competition between autophagy and apoptosis in response to 5-FU was a mechanism influencing 5-FU sensitivity. Our results reveal a critical and novel role of miR-338-3p in the correlation of 5-FU resistance with p53 status. Moreover, the miR-338-3p inhibitor has the potential to overcome 5-FU resistance in p53 mutant colon cancer cells.
C1 [Han, Jia; Tang, Kaijie; Zhang, Huahua; Guo, Bo; Hou, Ni; Huang, Chen] Xi An Jiao Tong Univ, Sch Basic Med Sci, Dept Cell Biol & Genet, Hlth Sci Ctr, 76 Western Yanta Rd, Xian 710061, Shaanxi, Peoples R China.
   [Li, Jie] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Gen Surg, Xian, Shaanxi, Peoples R China.
   [Zhang, Huahua] Yanan Univ, Med Coll, Yanan, Peoples R China.
   [Huang, Chen] Xi An Jiao Tong Univ, Coll Stomatol, Key Lab Shaanxi Prov Craniofacial Precis Med Res, Xian, Shaanxi, Peoples R China.
RP Hou, N; Huang, C (corresponding author), Xi An Jiao Tong Univ, Sch Basic Med Sci, Dept Cell Biol & Genet, Hlth Sci Ctr, 76 Western Yanta Rd, Xian 710061, Shaanxi, Peoples R China.
EM houni@mail.xjtu.edu.cn; hchen@mail.xjtu.edu.cn
RI Tang, Kaijie/AAE-8848-2019
OI Tang, Kaijie/0000-0002-8138-0206
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81172358, 31100969]; Scientific Research
   Foundation for Returned Overseas Chinese Scholars, State Education
   MinistryScientific Research Foundation for the Returned Overseas Chinese
   Scholars [2013-09]; Shaanxi Province Scientific Research and Sharing
   Platform Construction Project [2015FWPT-14]
FX We thank Prof. Mian Wu for providing HCT116 p53<SUP>-/-</SUP> cell line.
   This work was supported by the grant from the National Natural Science
   Foundation of China (81172358) to Jie Li, the grants from the National
   Natural Science Foundation of China (31100969) and the Scientific
   Research Foundation for Returned Overseas Chinese Scholars, State
   Education Ministry (2013-09) to Ni Hou, and the grant from the Shaanxi
   Province Scientific Research and Sharing Platform Construction Project
   (2015FWPT-14) to Chen Huang.
CR Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863
   Cecconi F, 2008, DEV CELL, V15, P344, DOI 10.1016/j.devcel.2008.08.012
   Francipane MG, 2014, ONCOTARGET, V5, P49, DOI 10.18632/oncotarget.1548
   Gaedcke J, 2012, CLIN CANCER RES, V18, P4919, DOI 10.1158/1078-0432.CCR-12-0016
   He C, 2017, CHEMOTHERAPY, V62, P43, DOI 10.1159/000446361
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Hou N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114779
   Huang C, 2009, CANCER BIOL THER, V8, P2185, DOI 10.4161/cbt.8.22.10446
   Huang X, 2013, EMBO J, V32, P2204, DOI 10.1038/emboj.2013.133
   Hummel R, 2010, EUR J CANCER, V46, P298, DOI 10.1016/j.ejca.2009.10.027
   Iacopetta B, 2003, HUM MUTAT, V21, P271, DOI 10.1002/humu.10175
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Koehler BC, 2014, WORLD J GASTROENTERO, V20, P1923, DOI 10.3748/wjg.v20.i8.1923
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Li XH, 2010, GUT, V59, P579, DOI 10.1136/gut.2008.175497
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Lorin S, 2013, SEMIN CANCER BIOL, V23, P361, DOI 10.1016/j.semcancer.2013.06.007
   Mohammad RM, 2015, SEMIN CANCER BIOL, V35, pS78, DOI 10.1016/j.semcancer.2015.03.001
   Nikoletopoulou V, 2013, BBA-MOL CELL RES, V1833, P3448, DOI 10.1016/j.bbamcr.2013.06.001
   Petak I, 2000, CLIN CANCER RES, V6, P4432
   Raghunath M, 2000, MOL BRAIN RES, V77, P151, DOI 10.1016/S0169-328X(00)00048-6
   Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865
   Siemens H, 2013, ONCOTARGET, V4, P1399, DOI 10.18632/oncotarget.1202
   Subbarayan PR, 2010, ANTICANCER RES, V30, P1149
   Sui XB, 2014, SCI REP-UK, V4, DOI 10.1038/srep04694
   Tan SF, 2016, INT J MOL MED, V37, P1030, DOI 10.3892/ijmm.2016.2492
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Valeri N, 2010, P NATL ACAD SCI USA, V107, P21098, DOI 10.1073/pnas.1015541107
   Wang Q, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-521
   Wei R., 2016, BIOSCIENCE REP, P36
   Wu WKK, 2011, CARCINOGENESIS, V32, P247, DOI 10.1093/carcin/bgq243
   Yu XF, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0480-4
   Zhao S, 2016, BIOCHEM BIOPH RES CO, V481, P212, DOI 10.1016/j.bbrc.2016.10.104
   Zheng R, 2014, J BUON, V19, P336
NR 34
TC 39
Z9 40
U1 1
U2 13
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD NOV 15
PY 2017
VL 360
IS 2
BP 328
EP 336
DI 10.1016/j.yexcr.2017.09.023
PG 9
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FM3EV
UT WOS:000414888000031
PM 28928082
DA 2022-04-25
ER

PT J
AU Habeeb, BS
   Kitayama, J
   Nagawa, H
AF Habeeb, Baker S.
   Kitayama, Joji
   Nagawa, Hirokazu
TI Adiponectin supports cell survival in glucose deprivation through
   enhancement of autophagic response in colorectal cancer cells
SO CANCER SCIENCE
LA English
DT Article
ID PLASMA ADIPONECTIN; PROSTATE-CANCER; ENDOMETRIAL CANCER; GROWTH;
   ASSOCIATION; RISK; EXPRESSION; RECEPTORS; OBESITY; DEATH
AB Adiponectin is known to have suppressive effects on tumor growth and is thought to be a key molecule in the positive correlation between obesity and cancer. However, the detailed mechanisms regulating tumor cell activity have not been elucidated. In this study, we found that both full-length (f-Ad) and globular adiponectin (g-Ad) inhibited cell growth in colon cancer cell lines in glucose-containing medium, whereas it supported cell survival in glucose-deprived medium, with an increase in AdipoR1 and AdipoR2 expression. The latter effect of adiponectin in glucose deprivation was significantly inhibited by adding autophagy inhibitors, chloroquine, 3-methyl adenine or a combination of pepstatin A and E-64d, suggesting that the effect of supporting cell growth was dependent, at least in part, on the induction of autophagy. The enhancement of autophagy was confirmed morphologically using green fluorescent protein (GFP)-microtubule-associated protein 1 light chain 3 (LC3) fusion proteins under a fluorescence microscope using stably transfected DLD-1 cells expressing GFP-LC3. Western blot analysis revealed that adiponectin increased the expression of LC3-1, LC3-2, phosphorylated AMPK alpha and PPAR alpha but decreased that of phosphorylated mTOR, insulin like growth factor (IGF)-1, phosphorylated serine/threonine kinase (Akt) and phosphorylated phosphatidylinositol 3-kinase (PI3K) in glucose-deprived medium. We conclude that adiponectin supports cell survival in glucose deprivation through enhancement of the autophagic machinery by AMPK alpha and PPAR alpha activation and IGF-1/PI3k/Akt/mTOR pathway inhibition. The bimodal effects of adiponectin are thought to be clinically important in the pathophysiology of tumor development and progression. (Cancer Sci 2011; 102: 999-1006).
C1 [Habeeb, Baker S.; Kitayama, Joji; Nagawa, Hirokazu] Univ Tokyo, Dept Surg Oncol, Tokyo, Japan.
RP Habeeb, BS (corresponding author), Univ Tokyo, Dept Surg Oncol, Tokyo, Japan.
EM bakershalal@gmail.com
OI Habeeb, Baker/0000-0001-8070-8532
FU Ministry of Education, Culture, Sports, Science and Technology of
   JapanMinistry of Education, Culture, Sports, Science and Technology,
   Japan (MEXT) [20591563]; Ministry of Health, Labor and Welfare of
   JapanMinistry of Health, Labour and Welfare, Japan
FX This work was funded by the Ministry of Education, Culture, Sports,
   Science and Technology of Japan (No. 20591563), and the Ministry of
   Health, Labor and Welfare of Japan.
CR Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255
   Avcu F, 2006, INT J HEMATOL, V83, P254, DOI 10.1532/IJH97.NA0411
   Barb D, 2007, ENDOCR-RELAT CANCER, V14, P995, DOI 10.1677/ERC-06-0091
   Brakenhielm E, 2004, P NATL ACAD SCI USA, V101, P2476, DOI 10.1073/pnas.0308671100
   Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423
   Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408
   Cong L, 2007, ENDOCR-RELAT CANCER, V14, P713, DOI 10.1677/ERC-07-0065
   Dal Maso L, 2004, J CLIN ENDOCR METAB, V89, P1160, DOI 10.1210/jc.2003-031716
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Deldicque L, 2005, EUR J APPL PHYSIOL, V94, P1, DOI 10.1007/s00421-004-1255-6
   Dos Santos E, 2008, ONCOL REP, V20, P971, DOI 10.3892/or_00000098
   Fang X, 2005, J MOL ENDOCRINOL, V35, P465, DOI 10.1677/jme.1.01877
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092
   Goktas S, 2005, UROLOGY, V65, P1168, DOI 10.1016/j.urology.2004.12.053
   Grabacka M, 2008, PPAR RES, V2008, DOI 10.1155/2008/930705
   Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038
   Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724
   Housa D, 2006, PHYSIOL RES, V55, P233, DOI 10.33549/physiolres.930848
   Ishikawa M, 2005, CLIN CANCER RES, V11, P466
   Jung TW, 2006, BIOCHEM PHARMACOL, V72, P616, DOI 10.1016/j.bcp.2006.05.013
   Kaaks R, 2000, JNCI-J NATL CANCER I, V92, P1592, DOI 10.1093/jnci/92.19.1592
   Kadowaki T, 2005, ENDOCR REV, V26, P439, DOI 10.1210/er.2005-0005
   Kim AY, 2010, MOL ENDOCRINOL, V24, P1441, DOI 10.1210/me.2009-0498
   Kim EH, 2007, CANCER RES, V67, P6314, DOI 10.1158/0008-5472.CAN-06-4217
   Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Liu BH, 2008, J ANIM SCI, V86, P3377, DOI 10.2527/jas.2008-0971
   Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512
   Luo ZJ, 2005, TRENDS PHARMACOL SCI, V26, P69, DOI 10.1016/j.tips.2004.12.011
   Mantzoros C, 2004, J CLIN ENDOCR METAB, V89, P1102, DOI 10.1210/jc.2003-031804
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Michalakis K, 2007, CANCER EPIDEM BIOMAR, V16, P308, DOI 10.1158/1055-9965.EPI-06-0621
   Miyoshi Y, 2003, CLIN CANCER RES, V9, P5699
   Nakai A, 2007, NAT MED, V13, P619, DOI 10.1038/nm1574
   Nedjic J, 2008, NATURE, V455, P396, DOI 10.1038/nature07208
   OGUNWOBI OO, 2002, REGUL PEPTIDES, V134, P105
   Otake S, 2005, CLIN CANCER RES, V11, P3642, DOI 10.1158/1078-0432.CCR-04-1868
   Ouchi N, 1999, CIRCULATION, V100, P2473, DOI 10.1161/01.CIR.100.25.2473
   Park KJ, 2007, CANCER RES, V67, P7327, DOI 10.1158/0008-5472.CAN-06-4766
   Petridou E, 2006, BRIT J CANCER, V94, P156, DOI 10.1038/sj.bjc.6602896
   Petridou E, 2003, J CLIN ENDOCR METAB, V88, P993, DOI 10.1210/jc.2002-021209
   Pyo JO, 2005, J BIOL CHEM, V280, P20722, DOI 10.1074/jbc.M413934200
   Schmid D, 2007, IMMUNITY, V26, P79, DOI 10.1016/j.immuni.2006.10.018
   Shibata R, 2009, CIRC J, V73, P608, DOI 10.1253/circj.CJ-09-0057
   Soliman PT, 2006, CANCER-AM CANCER SOC, V106, P2376, DOI 10.1002/cncr.21866
   Spyridopoulos TN, 2007, INT J CANCER, V120, P1573, DOI 10.1002/ijc.22526
   Sugiyama M, 2009, INT J ONCOL, V34, P339, DOI 10.3892/ijo_00000156
   Tokunaga C, 2004, BIOCHEM BIOPH RES CO, V313, P443, DOI 10.1016/j.bbrc.2003.07.019
   Tworoger SS, 2007, J CLIN ENDOCR METAB, V92, P1510, DOI 10.1210/jc.2006-1975
   Wang Y, 2005, J BIOL CHEM, V280, P18341, DOI 10.1074/jbc.M501149200
   Wei EK, 2005, JNCI-J NATL CANCER I, V97, P1688, DOI 10.1093/jnci/dji376
   Wolk A, 2001, CANCER CAUSE CONTROL, V12, P13, DOI 10.1023/A:1008995217664
   Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705
   Yen WL, 2008, PHYSIOLOGY, V23, P248, DOI 10.1152/physiol.00013.2008
   Yokota T, 2000, BLOOD, V96, P1723, DOI 10.1182/blood.V96.5.1723
NR 56
TC 46
Z9 47
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1347-9032
EI 1349-7006
J9 CANCER SCI
JI Cancer Sci.
PD MAY
PY 2011
VL 102
IS 5
BP 999
EP 1006
DI 10.1111/j.1349-7006.2011.01902.x
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 751PP
UT WOS:000289630300012
PM 21299716
OA Bronze
DA 2022-04-25
ER

PT J
AU Chen, XP
   Xu, H
   Yu, XH
   Wang, X
   Zhu, XH
   Xu, XF
AF Chen, Xiaping
   Xu, Hang
   Yu, Xinhua
   Wang, Xue
   Zhu, Xiaohu
   Xu, Xiaofeng
TI Apigenin inhibits in vitro and in vivo tumorigenesis in
   cisplatin-resistant colon cancer cells by inducing autophagy, programmed
   cell death and targeting m-TOR/PI3K/Akt signalling pathway
SO JOURNAL OF BUON
LA English
DT Article
DE autophagy; apoptosis; cell cycle; apigenin; colon cancer
ID DIETARY FLAVONOID FISETIN; ANTICANCER ACTIVITY; PI3K/AKT/MTOR;
   APOPTOSIS; QUERCETIN; CURCUMIN; GROWTH
AB Purpose: Colon cancer is one of the deadly malignancies and the second most frequent cancer in the world. The development of drug resistance and dearth of the viable drug options forms an obstacle in the treatment of colon cancer. Herein, the anticancer potential of Apigenin was examined against cisplatin-resistant colon cancer cells.
   Methods: The proliferation rate of the cisplatin-resistant colon cancer cell line HT-29 was assessed by WST-1 assay. Autophagy was detected by electron microscopy. Apoptotic cell death was analysed by propidium iodide (PI) staining. Cell cycle analysis was performed by flow cytometry. Protein expression was determined by immuno blotting. Xenografted mice models were used for in vivo evaluation of Apigenin.
   Results: The results showed that Apigenin could considerably inhibit the proliferation of colon cancer cells. The anticancer activity of Apigenin against the HT-29 colon cancer cells was found to be due to induction of autophagy and apoptosis. The Apigenin-triggered apoptosis and autophagy were also linked with alteration in the apoptosis and autophagy-related protein expression. Furthermore, it was found that Apigenin could inhibit the m-TOR/PI3K/AKT signalling pathway in the cisplatin-resistant colon cancer cells. The effects of Apigenin were also examined in vivo in xenografted mice models and it was revealed that Apigenin inhibited the growth of xenografted tumors.
   Conclusions: Taken together, these results indicate that Apigenin could inhibit the growth of cisplatin-resistant colon cancer cells in vitro and in vivo and may be used for the improvement of therapy of colon cancer.
C1 [Chen, Xiaping] Hubei Univ Med, Taihe Hosp, Dept Sci Res, Shiyan 442000, Hubei, Peoples R China.
   [Xu, Hang] Hubei Univ Med, Taihe Hosp, Dept Phys Examinat Ctr, Shiyan 442000, Hubei, Peoples R China.
   [Yu, Xinhua; Zhu, Xiaohu] Hubei Univ Med, Taihe Hosp, Dept Orthopaed Rehabil Ward, Shiyan 442000, Hubei, Peoples R China.
   [Wang, Xue] Hubei Univ Med, Taihe Hosp, Dept Obstet & Gynaecol, Shiyan 442000, Hubei, Peoples R China.
   [Xu, Xiaofeng] Hubei Univ Med, Renmin Hosp, Dept Pharm, Shiyan 442000, Hubei, Peoples R China.
RP Xu, XF (corresponding author), Hubei Univ Med, Shiyan Renmin Hosp, Dept Pharm, 37 Chaoyang Middle Rd, Shiyan 442000, Hubei, Peoples R China.
EM Alejandrinerhaj@yahoo.com
CR Adhami VM, 2012, BIOCHEM PHARMACOL, V84, P1277, DOI 10.1016/j.bcp.2012.07.012
   Barrett D, 2012, PEDIATR DRUGS, V14, P299, DOI 10.2165/11594740-000000000-00000
   Caltagirone S, 2000, INT J CANCER, V87, P595, DOI 10.1002/1097-0215(20000815)87:4&lt;595::AID-IJC21&gt;3.0.CO;2-5
   Chahar Maheep K, 2011, Pharmacogn Rev, V5, P1, DOI 10.4103/0973-7847.79093
   Choudhury D, 2013, BIOCHIMIE, V95, P1297, DOI 10.1016/j.biochi.2013.02.010
   Del Follo-Martinez A, 2013, NUTR CANCER, V65, P494, DOI 10.1080/01635581.2012.725194
   GOLDWASSER F, 1995, CANCER RES, V55, P2116
   Jayaprakasha GK, 2007, BIOORGAN MED CHEM, V15, P4923, DOI 10.1016/j.bmc.2007.04.044
   Kumar D, 2014, CANCER LETT, V343, P179, DOI 10.1016/j.canlet.2013.10.003
   Liu HL, 2010, RECENT PAT ANTI-CANC, V5, P152, DOI 10.2174/157489210790936261
   Manfredi GI, 2015, ENDOCRINE, V48, P363, DOI 10.1007/s12020-014-0380-1
   Mao F, 2011, MED ONCOL, V28, P121, DOI 10.1007/s12032-009-9415-5
   Ren WY, 2003, MED RES REV, V23, P519, DOI 10.1002/med.10033
   Santhosh RS, 2014, PLANTA MED, V80, P9, DOI 10.1055/s-0033-1350978
   Su CC, 2006, ANTICANCER RES, V26, P4379
   Su ZY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0321-5
   Tapia O, 2014, VIRCHOWS ARCH, V465, P25, DOI 10.1007/s00428-014-1588-4
   Wang F, 2015, DRUG DES DEV THER, V9, P575, DOI 10.2147/DDDT.S75221
   Wang YC, 2013, INT J PHARMACEUT, V441, P728, DOI 10.1016/j.ijpharm.2012.10.021
   Yang PM, 2012, INT J ONCOL, V40, P469, DOI 10.3892/ijo.2011.1203
   Yu FS, 2016, ENVIRON TOXICOL, V31, P395, DOI 10.1002/tox.22053
NR 21
TC 34
Z9 34
U1 2
U2 10
PU IMPRIMATUR PUBLICATIONS
PI ATHENS
PA 30 DEM POLIORKETES ST, ATHENS, 136 76, GREECE
SN 1107-0625
EI 2241-6293
J9 J BUON
JI J. BUON
PD MAR-APR
PY 2019
VL 24
IS 2
BP 488
EP 493
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HT3JW
UT WOS:000464461100011
PM 31127995
DA 2022-04-25
ER

PT J
AU Rikiishi, H
AF Rikiishi, Hidemi
TI Autophagic action of new targeting agents in head and neck oncology
SO CANCER BIOLOGY & THERAPY
LA English
DT Review
DE head and neck squamous cell carcinoma; molecular targeted agents;
   epidermal growth factor; autophagy; autophagic cell death; autophagic
   resistance; apoptosis
ID SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR-RECEPTOR; AND/OR METASTATIC HEAD;
   SIGNAL-TRANSDUCTION PATHWAYS; MAMMALIAN TARGET; CANCER-CELLS; PHASE-II;
   MALIGNANT GLIOMA; ZD1839 IRESSA; TUMOR-CELLS
AB The survival rates of patients with squamous cell carcinoma of the head and neck (HNSCC) have not improved significantly despite multi-modality therapy, including surgery, radiation therapy and chemotherapy. Recently, molecular targeted agents have shown significant improvement in clinical outcomes; for example, in chronic myelogeneous leukemia with imatinib, breast cancer with trastuzumab, colon cancer with bevacizumab and cetuximab, and renal cell cancer with sorafenib and sunitinib. In HNSCC, the epidermal growth factor receptor antibody cetuximab has shown promising results in combination with radiation. Targeted agents including cetuximab induce stresses to activate prosurvival autophagy. Combining autophagy inhibitors with agents that induce autophagy as a prosurvival response may therefore increase their therapeutic efficacy. Whether autophagy contributes to the prosurvival response or to the antitumor effect of chemotherapeutic drugs is largely unknown. This review will discuss the possible role of autophagy as a novel target for anticancer therapy agents in HNSCC.
C1 Tohoku Univ, Grad Sch Dent, Dept Microbiol & Immunol, Sendai, Miyagi 980, Japan.
RP Rikiishi, H (corresponding author), Tohoku Univ, Grad Sch Dent, Dept Microbiol & Immunol, Sendai, Miyagi 980, Japan.
EM riki@dent.tohoku.ac.jp
CR Ahn MY, 2011, ORAL ONCOL, V47, P1032, DOI 10.1016/j.oraloncology.2011.07.027
   Aissat N, 2008, CANCER CHEMOTH PHARM, V62, P305, DOI 10.1007/s00280-007-0609-2
   Ammer Amanda Gatesman, 2009, J Cancer Sci Ther, V1, P52
   Amornphimoltham P, 2005, CANCER RES, V65, P9953, DOI 10.1158/0008-5472.CAN-05-0921
   Amornphimoltham P, 2008, CANCER RES, V68, P1144, DOI 10.1158/0008-5472.CAN-07-1756
   Amrein L, 2011, LEUKEMIA RES, V35, P99, DOI 10.1016/j.leukres.2010.05.029
   Argiris A, 2011, CLIN CANCER RES, V17, P5755, DOI 10.1158/1078-0432.CCR-11-0861
   Bareford MD, 2011, CANCER RES, V71, P4955, DOI 10.1158/0008-5472.CAN-11-0898
   Bozec A, 2011, ORAL ONCOL, V47, P340, DOI 10.1016/j.oraloncology.2011.02.020
   Brandt GEL, 2009, CURR TOP MED CHEM, V9, P1447, DOI 10.2174/156802609789895683
   Brehmer D, 2005, CANCER RES, V65, P379
   Canel M, 2006, CLIN CANCER RES, V12, P3272, DOI 10.1158/1078-0432.CCR-05-1583
   Castedo M, 2002, CELL DEATH DIFFER, V9, P99, DOI 10.1038/sj.cdd.4400978
   Chaachouay H, 2011, RADIOTHER ONCOL, V99, P287, DOI 10.1016/j.radonc.2011.06.002
   Chang HH, 2009, ORAL ONCOL, V45, P610, DOI 10.1016/j.oraloncology.2008.08.011
   Chang KY, 2011, CLIN CANCER RES, V17, P7116, DOI 10.1158/1078-0432.CCR-11-0796
   Chang YM, 2008, ONCOGENE, V27, P6365, DOI 10.1038/onc.2008.250
   Chen SN, 2011, MED HYPOTHESES, V77, P206, DOI 10.1016/j.mehy.2011.04.013
   Cheng Y, 2012, MOL CANCER THER, V11, P154, DOI 10.1158/1535-7163.MCT-11-0606
   Chow LQM, 2007, J CLIN ONCOL, V25, P884, DOI 10.1200/JCO.2006.06.3602
   Chung CH, 2010, ANN ONCOL, V21, P864, DOI 10.1093/annonc/mdp390
   Cohen EEW, 2006, J CLIN ONCOL, V24, P2659, DOI 10.1200/JCO.2005.05.4577
   Cohen SM, 2011, ANN SURG ONCOL
   Copetti T, 2009, AUTOPHAGY, V5, P858, DOI 10.4161/auto.8822
   del Campo JM, 2011, BRIT J CANCER, V105, P618, DOI 10.1038/bjc.2011.237
   Eimer S, 2011, CANCER BIOL THER, V11, P1017, DOI 10.4161/cbt.11.12.15693
   Ekshyyan O, 2009, MOL CANCER THER, V8, P2255, DOI 10.1158/1535-7163.MCT-08-1184
   Erjala K, 2006, CLIN CANCER RES, V12, P4103, DOI 10.1158/1078-0432.CCR-05-2404
   Foon KA, 2004, INT J RADIAT ONCOL, V58, P984, DOI 10.1016/j.ijrobp.2003.09.098
   Fribley A, 2004, MOL CELL BIOL, V24, P9695, DOI 10.1128/MCB.24.22.9695-9704.2004
   Fury MG, 2011, J NATL COMPR CANC NE, V9, P681, DOI 10.6004/jnccn.2011.0056
   Giannopoulou E, 2009, ANTICANCER RES, V29, P5077
   Han JW, 2000, CANCER RES, V60, P6068
   Han WD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018691
   Hegymegi-Barakonyi B, 2009, CURR OPIN MOL THER, V11, P308
   Henson ES, 2006, CELL SIGNAL, V18, P2089, DOI 10.1016/j.cellsig.2006.05.015
   Iglesias-Linares A, 2010, ORAL ONCOL, V46, P323, DOI 10.1016/j.oraloncology.2010.01.009
   Ishii Y, 2007, ANTI-CANCER AGENT ME, V7, P359, DOI 10.2174/187152007780618180
   Iwamaru A, 2007, ONCOGENE, V26, P1840, DOI 10.1038/sj.onc.1209992
   Jiang QA, 2011, MOL BIOL CELL, V22, P1167, DOI 10.1091/mbc.E10-10-0860
   Kamal A, 2004, TRENDS MOL MED, V10, P283, DOI 10.1016/j.molmed.2004.04.006
   Klos KS, 2006, CANCER RES, V66, P2028, DOI 10.1158/0008-5472.CAN-04-4559
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kruser TJ, 2008, INT J RADIAT ONCOL, V72, P534, DOI 10.1016/j.ijrobp.2008.06.1490
   Le XF, 2010, CANCER-AM CANCER SOC, V116, P4980, DOI 10.1002/cncr.25426
   Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982
   Li CY, 2012, CANCER LETT, V314, P102, DOI 10.1016/j.canlet.2011.09.020
   Li CR, 2010, RADIOTHER ONCOL, V97, P330, DOI 10.1016/j.radonc.2010.06.010
   Li XQ, 2010, AUTOPHAGY, V6, P1066, DOI 10.4161/auto.6.8.13366
   Li XQ, 2010, CANCER RES, V70, P5942, DOI 10.1158/0008-5472.CAN-10-0157
   Lin CI, 2010, MOL CANCER RES, V8, P1217, DOI 10.1158/1541-7786.MCR-10-0162
   Liu YL, 2010, AUTOPHAGY, V6, P1057, DOI 10.4161/auto.6.8.13365
   Machiels JPH, 2010, J CLIN ONCOL, V28, P21, DOI 10.1200/JCO.2009.23.8584
   Mehra R, 2011, DRUG RESIST UPDATE, V14, P260, DOI 10.1016/j.drup.2011.08.002
   Milano V, 2009, MOL CANCER THER, V8, P394, DOI 10.1158/1535-7163.MCT-08-0669
   Molinolo AA, 2007, CLIN CANCER RES, V13, P4964, DOI 10.1158/1078-0432.CCR-07-1041
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Nathan CAO, 2007, CANCER RES, V67, P2160, DOI 10.1158/0008-5472.CAN-06-2449
   Orcutt KP, 2011, CANCER RES, V71, P3932, DOI 10.1158/0008-5472.CAN-10-3425
   Park MA, 2010, MOL CANCER THER, V9, P2220, DOI 10.1158/1535-7163.MCT-10-0274
   Patel V, 2011, CANCER RES, V71, P7103, DOI 10.1158/0008-5472.CAN-10-3192
   Pedrero JMG, 2005, INT J CANCER, V114, P242, DOI 10.1002/ijc.20711
   Pernas FG, 2009, CLIN CANCER RES, V15, P2361, DOI 10.1158/1078-0432.CCR-08-1011
   Qian X, 2009, CLIN EXP PHARMACOL P, V36, P487, DOI 10.1111/j.1440-1681.2008.05091.x
   Qing GL, 2007, CELL RES, V17, P520, DOI 10.1038/cr.2007.47
   Ren JH, 2010, CANCER BIOTHER RADIO, V25, P75, DOI 10.1089/cbr.2009.0701
   Saito Y, 2012, AM J PHYSIOL-ENDOC M, V302, pE615, DOI 10.1152/ajpendo.00035.2011
   Shewchuk L, 2000, J MED CHEM, V43, P133, DOI 10.1021/jm990401t
   Shi YH, 2011, AUTOPHAGY, V7, P1159, DOI 10.4161/auto.7.10.16818
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Sirotnak FM, 2000, CLIN CANCER RES, V6, P4885
   Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483
   Summy JM, 2006, CLIN CANCER RES, V12, P1398, DOI 10.1158/1078-0432.CCR-05-2692
   Tanizaki J, 2011, ONCOGENE, V30, P4097, DOI 10.1038/onc.2011.111
   Tejani MA, 2010, BIOL-TARGETS THER, V4, P173
   Trisciuoglio D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011772
   Vergez S, 2010, CLIN CANCER RES, V16, P4434, DOI 10.1158/1078-0432.CCR-09-2795
   Vermorken JB, 2008, NEW ENGL J MED, V359, P1116, DOI 10.1056/NEJMoa0802656
   Wakeling AE, 2002, CANCER RES, V62, P5749
   Weichert W, 2009, CANCER LETT, V280, P168, DOI 10.1016/j.canlet.2008.10.047
   Weihua Z, 2008, CANCER CELL, V13, P385, DOI 10.1016/j.ccr.2008.03.015
   Williamson SK, 2010, J CLIN ONCOL, V28, P3330, DOI 10.1200/JCO.2009.25.6834
   Wu Zhaoju, 2010, Genes Cancer, V1, P40, DOI 10.1177/1947601909358324
   Xie BS, 2011, INT J MOL MED, V27, P599, DOI 10.3892/ijmm.2011.607
   Yazbeck VY, 2008, EXP HEMATOL, V36, P443, DOI 10.1016/j.exphem.2007.12.008
   Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366
   Yin XY, 2005, CLIN CANCER RES, V11, P3889, DOI 10.1158/1078-0432.CCR-04-2272
   Zhang H, 2004, J MOL MED, V82, P488, DOI 10.1007/s00109-004-0549-9
   Zhao YQ, 2010, TOXICOL APPL PHARM, V248, P20, DOI 10.1016/j.taap.2010.07.007
NR 89
TC 15
Z9 16
U1 0
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD SEP
PY 2012
VL 13
IS 11
BP 978
EP 991
DI 10.4161/cbt.21079
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 004PT
UT WOS:000308694300002
PM 22825332
OA hybrid, Green Published
DA 2022-04-25
ER

PT J
AU Dimitrova, EG
   Chaushev, BG
   Conev, NV
   Kashlov, JK
   Zlatarov, AK
   Petrov, DP
   Popov, HB
   Stefanova, NT
   Klisarova, AD
   Bratoeva, KZ
   Donev, IS
AF Dimitrova, Eleonora G.
   Chaushev, Borislav G.
   Conev, Nikolay V.
   Kashlov, Javor K.
   Zlatarov, Aleksandar K.
   Petrov, Dilyan P.
   Popov, Hristo B.
   Stefanova, Nadezhda T.
   Klisarova, Anelia D.
   Bratoeva, Kameliya Z.
   Donev, Ivan S.
TI Role of the pretreatment F-18-fluorodeoxyglucose positron emission
   tomography maximal standardized uptake value in predicting outcomes of
   colon liver metastases and that value's association with Beclin-1
   expression
SO BIOSCIENCE TRENDS
LA English
DT Article
DE Maximum standardized uptake value (SUVmax); Beclin-1; colon cancer
ID CELL LUNG-CANCER; COLORECTAL-CANCER; F-18-FDG PET/CT; FAVORABLE
   PROGNOSIS; CLINICAL-PRACTICE; FDG-PET/CT; CHEMOTHERAPY; AUTOPHAGY;
   ACCUMULATION; MUTATIONS
AB The current study sought to evaluate the predictive and prognostic performance of the maximum standardized uptake value (SUVmax) prior to treatment in 43 patients with colon cancer and unresectable liver metastases. Patients with colon cancer who underwent F-18-FDG-PET/computed tomography (CT) scans for staging before the start of first-line 5-fluorouracil-based chemotherapy were retrospectively analyzed. Expression of Beclin-1 in cancer cells was evaluated in primary tumors using immunohistochemical staining. The pretreatment SUVmax for liver metastases was not able to predict progression-free survival but was significantly associated with poorer overall survival, with a hazard ratio of 2.05 (95 % CI, 1.016-4.155). Moreover, a negative correlation was noted between SUVmax and expression of a marker of autophagy-Beclin-1 (rho=-0.42, p=0.006). This suggests that the pretreatment SUVmax in F-18-FDG PET/CT is a useful tool to help predict survival outcome in patients with colon cancer and unresectable liver metastases and may significantly distinguish between patients with low and high levels of Beclin-1 expression (AUC = 0.809, 95% CI: 0.670-0.948, p = 0.001).
C1 [Dimitrova, Eleonora G.; Conev, Nikolay V.; Donev, Ivan S.] UMHAT St Marina, Clin Med Oncol, Varna, Bulgaria.
   [Dimitrova, Eleonora G.; Conev, Nikolay V.; Kashlov, Javor K.; Donev, Ivan S.] Med Univ Varna, Dept Propedeut Internal Dis, Marin Drinov Str 55, Varna 9000, Bulgaria.
   [Chaushev, Borislav G.; Klisarova, Anelia D.] UMHAT St Marina, Dept Nucl Med, Varna, Bulgaria.
   [Zlatarov, Aleksandar K.; Petrov, Dilyan P.] UMHAT St Marina, Surg Clin, Varna, Bulgaria.
   [Zlatarov, Aleksandar K.; Petrov, Dilyan P.] Med Univ Varna, Dept Gen & Operat Surg, Varna, Bulgaria.
   [Popov, Hristo B.; Stefanova, Nadezhda T.] UMHAT St Marina, Ctr Clin Pathol, Varna, Bulgaria.
   [Bratoeva, Kameliya Z.] Med Univ Varna, Div Pathophysiol, Varna, Bulgaria.
RP Donev, IS (corresponding author), Med Univ Varna, Dept Propedeut Internal Dis, Marin Drinov Str 55, Varna 9000, Bulgaria.
EM ivan_donev75@abv.bg
RI Popov, Hristo/AAS-2552-2020; Donev, Ivan Shterev/AAE-7011-2020
OI Donev, Ivan Shterev/0000-0003-3045-3775; Popov,
   Hristo/0000-0002-5891-1494; Conev, Nikolay/0000-0001-5267-0354; Kashlov,
   Yavor/0000-0002-2465-8734
CR Avallone A, 2012, EUR J NUCL MED MOL I, V39, P1848, DOI 10.1007/s00259-012-2229-2
   De Bruyne S, 2012, BRIT J CANCER, V106, P1926, DOI 10.1038/bjc.2012.184
   de Geus-Oei LF, 2008, ANN ONCOL, V19, P348, DOI 10.1093/annonc/mdm470
   Eberhard DA, 2008, J CLIN ONCOL, V26, P983, DOI 10.1200/JCO.2007.12.9858
   Fendler WP, 2013, J NUCL MED, V54, P1202, DOI 10.2967/jnumed.112.116426
   Goldsmith J, 2014, METHOD ENZYMOL, V542, P25, DOI 10.1016/B978-0-12-416618-9.00002-9
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Han Y., 2014, J ADV SIGNAL PROCESS, V2014, P1, DOI DOI 10.1097/PAT.0000000000000125
   Hendlisz A, 2012, ANN ONCOL, V23, P1687, DOI 10.1093/annonc/mdr554
   Iwamoto M, 2014, J NUCL MED, V55, P2038, DOI 10.2967/jnumed.114.142927
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Juweid ME, 2006, NEW ENGL J MED, V354, P496, DOI 10.1056/NEJMra050276
   Kawada K, 2012, CLIN CANCER RES, V18, P1696, DOI 10.1158/1078-0432.CCR-11-1909
   Kinahan PE, 2010, SEMIN ULTRASOUND CT, V31, P496, DOI 10.1053/j.sult.2010.10.001
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Krikelis D, 2014, ANTICANCER RES, V34, P2571
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Mertens J, 2013, EUR J NUCL MED MOL I, V40, P1214, DOI 10.1007/s00259-013-2421-z
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Moruno Felix, 2012, Cells, V1, P372, DOI 10.3390/cells1030372
   Muralidharan V, 2012, J NUCL MED, V53, P1345, DOI 10.2967/jnumed.112.102749
   Riedl CC, 2007, J NUCL MED, V48, P771, DOI 10.2967/jnumed.106.037291
   Sadahiro S, 2004, CANCER, V100, P590, DOI 10.1002/cncr.11945
   Schmitz KJ, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0946-x
   Tsikitis VL, 2009, J CLIN ONCOL, V27, P3671, DOI 10.1200/JCO.2008.20.7050
   Van Cutsem E, 2014, ANN ONCOL, V25, P1, DOI 10.1093/annonc/mdu260
   Van den Abbeele AD, 2008, ONCOLOGIST, V13, P8, DOI 10.1634/theoncologist.13-S2-8
   Vansteenkiste JF, 1999, J CLIN ONCOL, V17, P3201, DOI 10.1200/JCO.1999.17.10.3201
   Vivanco I, 2014, BRIT J CANCER, V111, P2033, DOI 10.1038/bjc.2014.461
   WEISS L, 1986, J PATHOL, V150, P195, DOI 10.1002/path.1711500308
   Xia Q, 2015, CANCER IMAGING, V15, P1, DOI 10.1186/s40644-015-0055-z
   Yang ZL, 2015, CLIN RES HEPATOL GAS, V39, P98, DOI 10.1016/j.clinre.2014.06.014
   Zerizer I, 2012, EUR J NUCL MED MOL I, V39, P1391, DOI 10.1007/s00259-012-2149-1
NR 34
TC 1
Z9 1
U1 2
U2 5
PU IRCA-BSSA
PI TOKYO
PA PEARL CITY KOISHIKAWA 603, 2-4-5 KASUGA, BUNKYO-KU, TOKYO, 112-0003,
   JAPAN
SN 1881-7815
EI 1881-7823
J9 BIOSCI TRENDS
JI BioSci. Trends
PD APR
PY 2017
VL 11
IS 2
BP 221
EP 228
DI 10.5582/bst.2016.01205
PG 8
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA EY2OD
UT WOS:000403806900016
PM 28250335
OA Bronze
DA 2022-04-25
ER

PT J
AU Tang, JC
   Feng, YL
   Liang, X
   Cai, XJ
AF Tang, Jia-Cheng
   Feng, Yi-Li
   Liang, Xiao
   Cai, Xiu-Jun
TI Autophagy in 5-Fluorouracil Therapy in Gastrointestinal Cancer: Trends
   and Challenges
SO CHINESE MEDICAL JOURNAL
LA English
DT Review
DE 5-Fluorouracil; Autophagy; Gastrointestinal Cancer; Tumor
ID CARCINOMA EC9706 CELLS; HEPATOCELLULAR-CARCINOMA; COLON-CANCER;
   PANCREATIC ADENOCARCINOMA; TARGETING AUTOPHAGY; COLORECTAL-CANCER;
   PHASE-II; IN-VITRO; BECLIN 1; GALLBLADDER CARCINOMA
AB Objective: 5-Fluorouracil (5-FU)-based combination therapies are standard treatments for gastrointestinal cancer, where the modulation of autophagy is becoming increasingly important in offering effective treatment for patients in clinical practice. This review focuses on the role of autophagy in 5-FU-induced tumor suppression and cancer therapy in the digestive system. Data Sources: All articles published in English from 1996 to date those assess the synergistic effect of autophagy and 5-FU in gastrointestinal cancer therapy were identified through a systematic online search by use of PubMed. The search terms were "autophagy" and "5-FU" and ("colorectal cancer" or "hepatocellular carcinoma" or "pancreatic adenocarcinoma" or "esophageal cancer" or "gallbladder carcinoma" or "gastric cancer"). Study Selection: Critical reviews on relevant aspects and original articles reporting in vitro and/or in vivo results regarding the efficiency of autophagy and 5-FU in gastrointestinal cancer therapy were reviewed, analyzed, and summarized. The exclusion criteria for the articles were as follows: (1) new materials (e.g., nanomaterial)-induced autophagy; (2) clinical and experimental studies on diagnostic and/or prognostic biomarkers in digestive system cancers; and (3) immunogenic cell death for anticancer chemotherapy. Results: Most cell and animal experiments showed inhibition of autophagy by either pharmacological approaches or via genetic silencing of autophagy regulatory gene, resulting in a promotion of 5-FU-induced cancer cells death. Meanwhile, autophagy also plays a pro-death role and may mediate cell death in certain cancer cells where apoptosis is defective or difficult to induce. The dual role of autophagy complicates the use of autophagy inhibitor or inducer in cancer chemotherapy and generates inconsistency to an extent in clinic trials. Conclusion: Autophagy might be a therapeutic target that sensitizes the 5-FU treatment in gastrointestinal cancer.
C1 [Tang, Jia-Cheng; Feng, Yi-Li; Liang, Xiao; Cai, Xiu-Jun] Zhejiang Univ, Sir Run Run Shaw Hosp, Zhejiang Prov Key Lab Laparosop Technol, Dept Gen Surg, Hangzhou 310016, Zhejiang, Peoples R China.
RP Cai, XJ (corresponding author), Zhejiang Univ, Sir Run Run Shaw Hosp, Hangzhou 310016, Zhejiang, Peoples R China.
EM cxjzu@hotmail.com
FU Zhejiang Provincial Natural Science Foundation of ChinaNatural Science
   Foundation of Zhejiang Province [LY13H180001]
FX This study was supported by a grant of Zhejiang Provincial Natural
   Science Foundation of China (No. LY13H180001).
CR Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Bhattacharya B, 2014, BRIT J PHARMACOL, V171, P3255, DOI 10.1111/bph.12668
   Billard C, 2013, MOL CANCER THER, V12, P1691, DOI 10.1158/1535-7163.MCT-13-0058
   Boone BA, 2015, ANN SURG ONCOL, V22, P4402, DOI 10.1245/s10434-015-4566-4
   Brech A, 2009, MOL ONCOL, V3, P366, DOI 10.1016/j.molonc.2009.05.007
   Chen LM, 2012, INT J ONCOL, V40, P1066, DOI 10.3892/ijo.2011.1278
   Chen N, 2009, BBA-MOL CELL RES, V1793, P1516, DOI 10.1016/j.bbamcr.2008.12.013
   Chen YG, 2011, HEPATO-GASTROENTEROL, V58, P20
   Choi JH, 2012, APMIS, V120, P597, DOI 10.1111/j.1600-0463.2012.02876.x
   Choi KS, 2012, EXP MOL MED, V44, P109, DOI 10.3858/emm.2012.44.2.033
   Coppola D, 2008, CANCER-AM CANCER SOC, V113, P2665, DOI 10.1002/cncr.23892
   Crazzolara R, 2009, AUTOPHAGY, V5, P727, DOI 10.4161/auto.5.5.8507
   Czyzyk-Krzeska MF, 2012, AUTOPHAGY, V8, P1155, DOI 10.4161/auto.20650
   de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938
   de la Cruz-Morcillo MA, 2012, ONCOGENE, V31, P1073, DOI 10.1038/onc.2011.321
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Ding ZB, 2011, CLIN CANCER RES, V17, P6229, DOI 10.1158/1078-0432.CCR-11-0816
   Feng Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.59
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092
   Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305
   Guo XL, 2014, CANCER LETT, V346, P278, DOI 10.1016/j.canlet.2014.01.011
   Guo XL, 2013, J MOL MED, V91, P473, DOI 10.1007/s00109-012-0966-0
   Guo XL, 2012, CANCER LETT, V320, P171, DOI 10.1016/j.canlet.2012.03.002
   Hamilton SR, 2008, MODERN PATHOL, V21, pS23, DOI 10.1038/modpathol.2008.14
   Hao J, 2011, EUR J PHARMACOL, V670, P29, DOI 10.1016/j.ejphar.2011.08.045
   Hashimoto D, 2014, EUR J CANCER, V50, P1382, DOI 10.1016/j.ejca.2014.01.011
   Hersey P, 2003, J CELL PHYSIOL, V196, P9, DOI 10.1002/jcp.10256
   Hervouet E, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1761-4
   Hu T, 2015, PHYTOMEDICINE, V22, P536, DOI 10.1016/j.phymed.2015.03.010
   Hung JY, 2009, J AGR FOOD CHEM, V57, P9809, DOI 10.1021/jf902315e
   Ju J, 2007, CLIN CANCER RES, V13, P4245, DOI 10.1158/1078-0432.CCR-06-2890
   Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509
   Kenific CM, 2010, CURR OPIN CELL BIOL, V22, P241, DOI 10.1016/j.ceb.2009.10.008
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Kong JP, 2016, MOL CARCINOGEN, V55, P1526, DOI 10.1002/mc.22406
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Li LQ, 2016, TUMOR BIOL, V37, P653, DOI 10.1007/s13277-015-3842-z
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liang X, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-10
   Liu DL, 2015, ONCOL LETT, V9, P2278, DOI 10.3892/ol.2015.3047
   Liu DL, 2011, MED ONCOL, V28, P105, DOI 10.1007/s12032-009-9397-3
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   LoPiccolo J, 2008, DRUG RESIST UPDATE, V11, P32, DOI 10.1016/j.drup.2007.11.003
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Maycotte P, 2011, CANCER BIOL THER, V11, P127, DOI 10.4161/cbt.11.2.14627
   Mijatovic S, 2005, CELL MOL LIFE SCI, V62, P589, DOI 10.1007/s00018-005-4425-8
   Miracco C, 2007, INT J ONCOL, V30, P429
   Mirzoeva OK, 2011, J MOL MED, V89, P877, DOI 10.1007/s00109-011-0774-y
   Mujumdar N, 2010, GASTROENTEROLOGY, V139, P598, DOI 10.1053/j.gastro.2010.04.046
   Notte A, 2011, BIOCHEM PHARMACOL, V82, P427, DOI 10.1016/j.bcp.2011.06.015
   O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066
   Opipari AW, 2004, CANCER RES, V64, P696, DOI 10.1158/0008-5472.CAN-03-2404
   Pal I, 2015, EUR J PHARMACOL, V765, P217, DOI 10.1016/j.ejphar.2015.08.039
   Pan HM, 2014, SCI REP-UK, V4, DOI 10.1038/srep06683
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Phillips PA, 2007, CANCER RES, V67, P9407, DOI 10.1158/0008-5472.CAN-07-1077
   Raza A, 2014, WORLD J GASTROENTERO, V20, P4115, DOI 10.3748/wjg.v20.i15.4115
   Ringborg U, 1996, ACTA ONCOL, V35, P76, DOI 10.3109/02841869609083976
   Sasaki K, 2012, ANTI-CANCER DRUG, V23, P675, DOI 10.1097/CAD.0b013e328353f8c7
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Schonewolf CA, 2014, WORLD J GASTRO ONCOL, V6, P74, DOI 10.4251/wjgo.v6.i3.74
   Shi YH, 2011, AUTOPHAGY, V7, P1159, DOI 10.4161/auto.7.10.16818
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Sohn BS, 2013, TUMORI J, V99, P139, DOI 10.1700/1283.14182
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Sui XB, 2014, SCI REP-UK, V4, DOI 10.1038/srep04694
   Sun RR, 2015, TUMOR BIOL, V36, P1173, DOI 10.1007/s13277-014-2699-x
   Suzuki R, 2014, ANTICANCER RES, V34, P4685
   Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Tanemura M, 2009, TRANSPL P, V41, P334, DOI 10.1016/j.transproceed.2008.10.032
   Tang Jiacheng, 2014, Zhonghua Yi Xue Za Zhi, V94, P612
   Tengchaisri T, 1998, CANCER LETT, V133, P169, DOI 10.1016/S0304-3835(98)00222-5
   Turcotte S, 2010, CURR OPIN CELL BIOL, V22, P246, DOI 10.1016/j.ceb.2009.12.007
   Uhm JE, 2009, CANCER CHEMOTH PHARM, V63, P929, DOI 10.1007/s00280-008-0817-4
   Viola G, 2012, BIOCHEM PHARMACOL, V83, P16, DOI 10.1016/j.bcp.2011.09.017
   Wang BS, 2014, MOL CARCINOGEN, V53, P514, DOI 10.1002/mc.22003
   Wang JR, 2009, J BIOL CHEM, V284, P21412, DOI 10.1074/jbc.M109.026013
   Wang L, 2007, APOPTOSIS, V12, P1489, DOI 10.1007/s10495-007-0073-9
   Wang Samuel J, 2010, AMIA Annu Symp Proc, V2010, P847
   Wolpin BM, 2014, ONCOLOGIST, V19, P637, DOI 10.1634/theoncologist.2014-0086
   Xiong HY, 2010, CANCER LETT, V288, P68, DOI 10.1016/j.canlet.2009.06.039
   Xu R, 2006, HISTOL HISTOPATHOL, V21, P867, DOI 10.14670/HH-21.867
   Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780
   Yang C, 2016, TUMOR BIOL, V37, P15489, DOI 10.1007/s13277-015-3775-6
   Yang J, 2015, INT J MOL SCI, V16, P25744, DOI 10.3390/ijms161025744
   Yang SM, 2003, MOL CANCER THER, V2, P65
   Yang Y, 2016, TUMOR BIOL, V37, P1853, DOI 10.1007/s13277-015-3974-1
   Yang Y, 2014, CHINESE MED J-PEKING, V127, P353, DOI 10.3760/cma.j.issn.0366-6999.20130996
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yen CY, 2014, J ORAL PATHOL MED, V43, P91, DOI 10.1111/jop.12102
   Yousefi S, 2009, RESULTS PROBL CELL D, V49, P183, DOI 10.1007/400_2008_25
   Yu L, 2014, CANCER LETT, V355, P34, DOI 10.1016/j.canlet.2014.09.020
   Zhang YH, 2011, ACTA PHARMACOL SIN, V32, P1266, DOI 10.1038/aps.2011.92
   Zhou XK, 2012, J CANCER RES CLIN, V138, P1081, DOI 10.1007/s00432-012-1181-7
   Zhou Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep05382
   Zhu BS, 2015, MOL MED REP, V11, P1891, DOI 10.3892/mmr.2014.2926
NR 104
TC 32
Z9 33
U1 2
U2 38
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0366-6999
J9 CHINESE MED J-PEKING
JI Chin. Med. J.
PD FEB 20
PY 2016
VL 129
IS 4
BP 456
EP 463
DI 10.4103/0366-6999.176069
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA DF0MC
UT WOS:000371032200012
PM 26879020
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Taniguchi, K
   Sugito, N
   Kumazaki, M
   Shinohara, H
   Yamada, N
   Nakagawa, Y
   Ito, Y
   Otsuki, Y
   Uno, B
   Uchiyama, K
   Akao, Y
AF Taniguchi, Kohei
   Sugito, Nobuhiko
   Kumazaki, Minami
   Shinohara, Haruka
   Yamada, Nami
   Nakagawa, Yoshihito
   Ito, Yuko
   Otsuki, Yoshinori
   Uno, Bunji
   Uchiyama, Kazuhisa
   Akao, Yukihiro
TI MicroRNA-124 inhibits cancer cell growth through PTB1/PKM1/PKM2 feedback
   cascade in colorectal cancer
SO CANCER LETTERS
LA English
DT Article
DE miR-124; PTB1; PKM; Warburg effect; Colorectal cancer
ID PYRUVATE-KINASE; DOWN-REGULATION; MIR-124; EXPRESSION; METABOLISM;
   APOPTOSIS; RCK/P54; PROTEIN; GENE
AB Altered levels and functions of microRNAs (miRs) have been associated with carcinogenesis. In this study, we investigated the role of miR-124 in colorectal adenoma (CRA) and cancer (CRC). The expression levels of miR-124 were decreased in CRA (81.8%) and CRC (57.6%) in 55 clinical samples. The ectopic expression of miR-124 induced apoptosis and autophagy in colon cancer cells. Also, miR-124 targeted polypyrimidine tract-binding protein 1 (PTB1), which is a splicer of pyruvate kinase muscles I and 2 (PKM1 and PKM2) and induced the switching of PKM isoform expression from PKM2 to PKM1. Also, siR-PTB1 induced drastic apoptosis in colon cancer cells. Furthermore, we found that the ectopic expression of miR-124 enhanced oxidative stress and the miR-124/PTB1/PKM1/PKM2 axis constituted a feedback cascade. Finally, we showed that intratumor injection of miR-124 and siR-PTB1 induced a tumor-suppressive effect in xenografted mice. The axis was established by both in vitro and in vivo experiments to function in human colorectal cancer cells. These findings suggest that miR-124 acts as a tumor-suppressor and a modulator of energy metabolism through a PTB1/PKM1/PKM2 feedback cascade in human colorectal tumor cells. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Taniguchi, Kohei; Sugito, Nobuhiko; Kumazaki, Minami; Shinohara, Haruka; Yamada, Nami; Uno, Bunji; Akao, Yukihiro] Gifu Univ, United Grad Sch Drug Discovery & Med Informat Sci, Gifu 5011193, Japan.
   [Taniguchi, Kohei; Uchiyama, Kazuhisa] Osaka Med Coll, Dept Gen & Gastroenterol Surg, Takatsuki, Osaka 5698686, Japan.
   [Nakagawa, Yoshihito] Fujita Hlth Univ, Sch Med, Dept Gastroenterol, Toyoake, Aichi 4701192, Japan.
   [Ito, Yuko; Otsuki, Yoshinori] Osaka Med Coll, Div Life Sci, Dept Anat & Cell Biol, Takatsuki, Osaka 5698686, Japan.
RP Akao, Y (corresponding author), Gifu Univ, United Grad Sch Drug Discovery & Med Informat Sci, 1-1 Yanagido, Gifu 5011193, Japan.
EM yakao@gifu-u.ac.jp
OI Shinohara, Haruka/0000-0001-8326-1203; Taniguchi,
   Kohei/0000-0003-0648-1370; Yamada, Nami/0000-0002-1220-0814
FU Ministry of Education, Science, Sports, and Culture of JapanMinistry of
   Education, Culture, Sports, Science and Technology, Japan (MEXT)
   [YA-24659157]
FX This work was supported by a Grant-in-aid for scientific research from
   the Ministry of Education, Science, Sports, and Culture of Japan
   (YA-24659157).
CR Akao Y, 2010, CANCER GENE THER, V17, P398, DOI 10.1038/cgt.2009.88
   Akao Y, 2006, INT J ONCOL, V29, P41
   Chen M, 2010, CANCER RES, V70, P8977, DOI 10.1158/0008-5472.CAN-10-2513
   Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233
   Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734
   Clower CV, 2010, P NATL ACAD SCI USA, V107, P1894, DOI 10.1073/pnas.0914845107
   David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697
   Furuta M, 2010, CARCINOGENESIS, V31, P766, DOI 10.1093/carcin/bgp250
   Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001
   Goel A, 2012, GASTROENTEROLOGY, V143, P1442, DOI 10.1053/j.gastro.2012.09.032
   Goldberg MS, 2012, J EXP MED, V209, P217, DOI 10.1084/jem.20111487
   Hashimoto K, 2001, CARCINOGENESIS, V22, P1965, DOI 10.1093/carcin/22.12.1965
   Hirota K, 2006, CRIT REV ONCOL HEMAT, V59, P15, DOI 10.1016/j.critrevonc.2005.12.003
   Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021
   Hunt S, 2011, FEBS LETT, V585, P187, DOI 10.1016/j.febslet.2010.11.038
   Lee YS, 2009, ANNU REV PATHOL-MECH, V4, P199, DOI 10.1146/annurev.pathol.4.110807.092222
   Luo WB, 2011, ONCOTARGET, V2, P551
   Maiorano NA, 2010, RNA BIOL, V7, P528, DOI 10.4161/rna.7.5.12262
   Makeyev EV, 2007, MOL CELL, V27, P435, DOI 10.1016/j.molcel.2007.07.015
   Noguchi S, 2013, MOL THER, V21, P1204, DOI 10.1038/mt.2013.70
   NOGUCHI T, 1986, J BIOL CHEM, V261, P3807
   Nugent M, 2011, EJSO-EUR J SURG ONC, V37, P649, DOI 10.1016/j.ejso.2011.05.005
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Sun Y, 2012, ONCOL REP, V28, P1346, DOI 10.3892/or.2012.1958
   Tang YX, 2009, MOL CANCER THER, V8, P458, DOI 10.1158/1535-7163.MCT-08-0885
   Taniguchi K, 2015, SCI REP-UK, V5, DOI 10.1038/srep08647
   Wang DR, 2014, CIRC RES, V114, P67, DOI 10.1161/CIRCRESAHA.114.301633
   Wang MJ, 2013, INT J COLORECTAL DIS, V28, P183, DOI 10.1007/s00384-012-1550-3
   Wang ZX, 2012, J MOL CELL BIOL, V4, P79, DOI 10.1093/jmcb/mjr030
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Xia HP, 2012, J BIOL CHEM, V287, P9962, DOI 10.1074/jbc.M111.332627
   Xia JT, 2012, J PATHOL, V227, P470, DOI 10.1002/path.4030
   Yamada N., 1839, BIOCHIM BIOPHYS ACTA, V2014, P1256
   Yamada N, 2013, CANCER LETT, V335, P332, DOI 10.1016/j.canlet.2013.02.060
   Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Zhang JF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070300
NR 37
TC 116
Z9 123
U1 0
U2 37
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD JUL 10
PY 2015
VL 363
IS 1
BP 17
EP 27
DI 10.1016/j.canlet.2015.03.026
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CJ3AN
UT WOS:000355355900003
PM 25818238
DA 2022-04-25
ER

PT J
AU Qian, J
   Cao, Y
   Zhang, JF
   Li, LC
   Wu, J
   Wei, GL
   Yu, JL
   Huo, JG
AF Qian, Jun
   Cao, Yi
   Zhang, Junfeng
   Li, Lingchang
   Wu, Juan
   Wei, Guoli
   Yu, Jialin
   Huo, Jiege
TI Tanshinone IIA induces autophagy in colon cancer cells through
   MEK/ERK/mTOR pathway
SO TRANSLATIONAL CANCER RESEARCH
LA English
DT Article
DE Tanshinone IIA; autophagy; colon cancer cells; MEK/ERK/mTOR pathway
ID DOWN-REGULATION; APOPTOSIS; GROWTH; ANGIOGENESIS
AB Background: Colon cancer is a common malignancy of the digestive tract. The search for effective drugs to treat colon cancer has become the focus of current researches. Tanshinone IIA (Tan IIA) is a fat-soluble component extracted from tanshinone, a traditional Chinese medicine. Tan IIA can modulate the occurrence and development of tumors, but its effect on autophagy in colon cancer cells has not been reported.
   Methods: Two types of colon cancer cell lines were selected and different concentrations of Tan IIA were used to treat cells at different time points. Cell Counting Kit-8 assay (CCK-8) was used to detect the effect of Tan IIA on cell proliferation; transmission electron microscopy was used to observe the formation of autophagosomes; reverse transcription-polymerase chain reaction (RT-qPCR) and western blot were used to detect the expression of autophagy related genes and proteins. Cell transfection was used to interfere with MEK (mitogen-activated extracellular signal-regulated kinase) expression, and RT-qPCR and western blot were used to detect the expression of MEK/ERK/mTOR pathway-related proteins.
   Results: Tan IIA resulted in a significant reduction in the viability of the two kinds of colon cancer cells. The number of autophagosomes increased significantly after the treatment of Tan IIA into these cells. Addition of autophagy inhibitor 3-MA (3-Methyladenine) improved the increase of autophagosomes in cells induced by Tan IIA. At the same time, Tan IIA induced the expression of autophagy-related proteins in the two colon cancer cell lines. When Tan IIA induced autophagy in colon cancer cells, the expression of MEK/ ERK/mTOR pathway-related proteins increased significantly. After interfering with the expression of MEK, the expression of autophagy decreased significantly, indicating that Tan IIA promoted autophagy of colon cancer cells through MEK/ERK/mTOR pathway.
   Conclusions: Tan IIA stimulates autophagy in colon cancer cells through MEK/ERK/mTOR pathway, hence inhibiting the growth of colon cancer cells.
C1 [Qian, Jun] Nanjing Univ Chinese Med, Sch Chinese Med, Sch Integrated Chinese & Western Med, Dept Diagnost Chinese Med, Nanjing, Peoples R China.
   [Cao, Yi] Nanjing Univ Chinese Med, Inst Literature Chinese Med, Res Off Herbal Literature, Nanjing, Peoples R China.
   [Zhang, Junfeng] Nanjing Univ Chinese Med, Sch Med & Holist Integrat Med, Dept Pathogen & Immunol, Nanjing, Peoples R China.
   [Li, Lingchang; Wei, Guoli; Yu, Jialin; Huo, Jiege] Nanjing Univ Chinese Med, Affiliated Hosp Integrated Tradit Chinese & Weste, Dept Oncol, Nanjing, Peoples R China.
   [Wu, Juan] Nanjing Univ Chinese Med, Sch Med & Holist Integrat Med, Dept Publ Hlth, Nanjing, Peoples R China.
RP Qian, J (corresponding author), 138 Xianlin Rd, Nanjing 210023, Jiangsu, Peoples R China.; Huo, JG (corresponding author), 100 Shizi St, Nanjing 210028, Jiangsu, Peoples R China.
EM junqian_njucm@163.com; huojiege@jsatcm.com
RI Li, Lingchang/AAL-4850-2021
OI Li, Lingchang/0000-0001-5520-7023
FU Project of National Clinical Research Base of Traditional Chinese
   Medicine in Jiangsu Province, China [JD2019SZXYB04]; Priority Academic
   Program Development of Jiangsu Higher Education Institutions
   (Integration of Chinese and Western Medicine); Leading Talents Project
   of Chinese Medicine in Jiangsu Province [SLJ0211]
FX This work was supported by Project of National Clinical Research Base of
   Traditional Chinese Medicine in Jiangsu Province, China (No.
   JD2019SZXYB04); a Project Funded by the Priority Academic Program
   Development of Jiangsu Higher Education Institutions (Integration of
   Chinese and Western Medicine); the Leading Talents Project of Chinese
   Medicine in Jiangsu Province (No. SLJ0211).
CR Benson AB, 2018, J NATL COMPR CANC NE, V16, P359, DOI 10.6004/jnccn.2018.0021
   Gao GY, 2018, BIOMED PHARMACOTHER, V108, P1208, DOI 10.1016/j.biopha.2018.06.172
   Gogiraju R, 2019, CIRC-HEART FAIL, V12, DOI 10.1161/CIRCHEARTFAILURE.118.005622
   Hegedus C, 2020, CANCERS, V12, DOI 10.3390/cancers12010005
   Krishan S, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2019.165657
   Lamark T, 2017, ESSAYS BIOCHEM, V61, P609, DOI 10.1042/EBC20170035
   Li JP, 2020, J CELL BIOCHEM, V121, P3392, DOI 10.1002/jcb.29613
   Li YX, 2020, PHARMACOL REP, V72, P400, DOI 10.1007/s43440-019-00006-z
   Li Z, 2018, EXP THER MED, V15, P1847, DOI 10.3892/etm.2017.5636
   Liang XF, 2020, BIOMED PHARMACOTHER, V126, DOI 10.1016/j.biopha.2020.110065
   Lin T J, 1991, Sheng Li Ke Xue Jin Zhan, V22, P342
   Long R, 2015, LIFE SCI, V142, P8, DOI 10.1016/j.lfs.2015.10.018
   Ma LF, 2019, AGING-US, V11, P9719, DOI 10.18632/aging.102420
   Ma SY, 2018, J BUON, V23, P1337
   Pecoraro A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062143
   Ravanan P, 2017, LIFE SCI, V188, P53, DOI 10.1016/j.lfs.2017.08.029
   Ri-Ge-le A, 2018, EXP CLIN ENDOCR DIAB, V126, P632, DOI 10.1055/s-0044-100722
   Roy B, 2014, CHEM-BIOL INTERACT, V210, P96, DOI 10.1016/j.cbi.2014.01.003
   Shan YF, 2009, ACTA PHARMACOL SIN, V30, P1537, DOI 10.1038/aps.2009.139
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Wang H, 2020, BMC CARDIOVASC DISOR, V20, DOI 10.1186/s12872-019-01289-z
   Wang JR, 2009, J BIOL CHEM, V284, P21412, DOI 10.1074/jbc.M109.026013
   Wang ML, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184459
   Wang R, 2019, ONCOTARGETS THER, V12, P9355, DOI 10.2147/OTT.S221228
   Wang Y, 2018, PHARMAZIE, V73, P396, DOI 10.1691/ph.2018.7509
   Xue JL, 2019, MED SCI MONITOR, V25, P4793, DOI 10.12659/MSM.914446
   Yang AN, 2018, CANCER DISCOV, V8, P276, DOI 10.1158/2159-8290.CD-17-0952
   Zhang LK, 2019, ONCOL LETT, V18, P6554, DOI 10.3892/ol.2019.11032
   Zhang P, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0661-7
   Zhao YL, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201600437
   Zhou LH, 2012, ASIAN PAC J CANCER P, V13, P4453, DOI 10.7314/APJCP.2012.13.9.4453
   Zhu J, 2017, EUR J PHARMACOL, V815, P427, DOI 10.1016/j.ejphar.2017.09.047
NR 32
TC 1
Z9 1
U1 1
U2 8
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2218-676X
EI 2219-6803
J9 TRANSL CANCER RES
JI Transl. Cancer Res.
PD NOV
PY 2020
VL 9
IS 11
BP 6919
EP 6928
DI 10.21037/tcr-20-1963
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA OX4WB
UT WOS:000593565600029
PM 35117300
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Shao, LN
   Zhu, BS
   Xing, CG
   Yang, XD
   Young, W
   Cao, JP
AF Shao, Le-Ning
   Zhu, Bao-Song
   Xing, Chun-Gen
   Yang, Xiao-Dong
   Young, Wu
   Cao, Jian-Ping
TI Effects of autophagy regulation of tumor-associated macrophages on
   radiosensitivity of colorectal cancer cells
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE tumor-associated macrophages; autophagy; colorectal cancer;
   radiosensitivity
ID LYMPH-NODE METASTASIS; INDUCED APOPTOSIS; POOR-PROGNOSIS;
   MICROENVIRONMENT; COLON; PROGRESSION; BIOMARKERS; SURVIVIN; TARGET;
   MODEL
AB Tumor-associated macrophages (TAMs), a major component of the tumor microenvironment, are crucial to the processes of tumor growth, infiltration and metastasis, and contribute to drug resistance. The importance of TAMs in radiation resistance of colorectal cancer remains unclear. To investigate the effects of autophagy regulation of TAMs on the radiosensitivity of colorectal cancer cells, the current study induced TAM formation from THP-1 monocyte cells. Sequential treatment of THP-1 cells with PMA for 72 h and human recombinant interleukin-4 for 24 h was used to stimulate THP-1 differentiation to TAMs. Expression of the cell surface markers CD68, CD204 and CD206, and changes to cell morphology were used to confirm successful differentiation. The TAMs were stimulated to promote or inhibit autophagy during co-culture with LoVo colorectal adenocarcinoma cells. The cells were irradiated, with subsequent measurement of LoVo colony formation and apoptosis. Additionally, the expression of p53, Bcl-2, survivin and Smac proteins was assessed by western blotting. Monodansylcadaverin staining was used to analyze the presence of autophagic vacuoles in TAM, and western blot analysis was used to assess the expression of Beclin-1, LC3B I and II, ATG-3, -5 and -7. The results demonstrated TAM autophagy to be markedly altered by rapamycin and bafilomycin A1 treatment. Following co-culture with TAMs, the colony formation rate and survival fraction of LoVo cells were significantly higher than those in the control group (P<0.05). It was further demonstrated that the regulation of autophagy in TAMs was able to inhibit the colony formation of LoVo colorectal cancer cells. Upregulation of TAM autophagy using rapamycin exhibited more effective inhibition of LoVo colony formation than autophagy downregulation. Notably, apoptosis was significantly increased in LoVo cells when co-cultured with TAMs only, or with rapamycin-mediated autophagy upregulated TAMs, compared with LoVo cells cultured alone (P<0.01). Expression of Bcl-2, survivin and p53 were reduced in LoVo cells co-cultured with TAMs, compared with the control group (P<0.05), whereas Smac expression was increased in the co-culture groups (P<0.01). It was demonstrated that rapamycin-mediated autophagy stimulation in TAMs led to reduced expression levels of survivin and Bcl-2, however, Smac expression was increased. The upregulation of autophagy in TAMs inhibited proliferation and induced apoptosis in colon cancer cells, and altered the expression of radiosensitivity-associated proteins. This data indicated that the radiosensitivity of colorectal cancer cells is associated with autophagy of TAM, and that stimulating TAM autophagy may increase the radiosensitivity of colorectal cancer cells.
C1 [Shao, Le-Ning; Zhu, Bao-Song; Xing, Chun-Gen; Yang, Xiao-Dong; Young, Wu] Soochow Univ, Affiliated Hosp 2, Dept Gen Surg, 1055 Sanxian Rd, Suzhou 215004, Jiangsu, Peoples R China.
   [Cao, Jian-Ping] Soochow Univ, Jiangsu Prov Key Lab Radiat Med & Protect, Suzhou 215123, Jiangsu, Peoples R China.
RP Xing, CG (corresponding author), Soochow Univ, Affiliated Hosp 2, Dept Gen Surg, 1055 Sanxian Rd, Suzhou 215004, Jiangsu, Peoples R China.
EM xingcg@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81172348]; Jiangsu Provincial Key Laboratory
   of Radiation Medicine and Protection [KJS1334]; Suzhou Science and
   Education Guardian Youth Science and Technology Project [2011010]
FX The present study was supported by grants from the National Natural
   Science Foundation of China (no. 81172348), the Jiangsu Provincial Key
   Laboratory of Radiation Medicine and Protection (no. KJS1334) and Suzhou
   Science and Education Guardian Youth Science and Technology Project (no.
   2011010).
CR Akagi T, 2012, INT J CANCER, V131, P1307, DOI 10.1002/ijc.27341
   Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004
   Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Barker HE, 2015, NAT REV CANCER, V15, P409, DOI 10.1038/nrc3958
   Bingle L, 2006, BRIT J CANCER, V94, P101, DOI 10.1038/sj.bjc.6602901
   Canioni D, 2008, J CLIN ONCOL, V26, P440, DOI 10.1200/JCO.2007.12.8298
   Coffelt SB, 1796, BIOCHIM BIOPHYS ACTA, V11, P18
   Essafi-Benkhadir K, 2012, BIOCHEM BIOPH RES CO, V418, P180, DOI 10.1016/j.bbrc.2012.01.003
   Giagkousiklidis S, 2005, CANCER RES, V65, P10502, DOI 10.1158/0008-5472.CAN-05-0866
   Gocheva V, 2010, GENE DEV, V24, P241, DOI 10.1101/gad.1874010
   GUTMAN M, 1995, WORLD J SURG, V19, P226, DOI 10.1007/BF00308631
   Huang ZH, 2010, INT J CANCER, V127, P118, DOI 10.1002/ijc.25007
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Kanematsu S, 2010, ANTICANCER RES, V30, P3381
   Karar J, 2009, CANCER BIOL THER, V8, P1994, DOI 10.4161/cbt.8.21.9988
   Kohli M, 2004, P NATL ACAD SCI USA, V101, P16897, DOI 10.1073/pnas.0403405101
   Kuwahara Y, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.56
   Lin Y, 2009, NEOPLASIA, V11, P864, DOI 10.1593/neo.09542
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Pander J, 2011, CLIN CANCER RES, V17, P5668, DOI 10.1158/1078-0432.CCR-11-0239
   Qin ZY, 2012, ATHEROSCLEROSIS, V221, P2, DOI 10.1016/j.atherosclerosis.2011.09.003
   Rigo A, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-273
   Rodel C, 2003, INT J RADIAT ONCOL, V55, P1341, DOI 10.1016/S0360-3016(02)04618-7
   Sasaki H, 2008, CANCER SCI, V99, P711, DOI 10.1111/j.1349-7006.2008.00725.x
   Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Sleeman JP, 2000, RECENT RESULTS CANC, V157, P55
   Spencer M, 2010, AM J PHYSIOL-ENDOC M, V299, pE1016, DOI 10.1152/ajpendo.00329.2010
   Sreevalsan S, 2009, INT J ONCOL, V35, P1191, DOI 10.3892/ijo_00000436
   Stout RD, 2005, J IMMUNOL, V175, P342, DOI 10.4049/jimmunol.175.1.342
   Tan SH, 2012, J BIOL CHEM, V287, P14364, DOI 10.1074/jbc.M111.294157
   Toiyama Y, 2013, CARCINOGENESIS, V34, P2548, DOI 10.1093/carcin/bgt282
   Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449
   Xu N, 1998, Zhonghua Bing Li Xue Za Zhi, V27, P359
   Yin-Xu Zhang, 2011, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V33, P71, DOI 10.3881/j.issn.1000-503X.2011.01.015
   [余力伟 YU Liwei], 2008, [中华实验外科杂志, Chinese Journal of Experimental Surgery], V25, P291
   Yue ZQ, 2012, CHINESE MED J-PEKING, V125, P3305, DOI 10.3760/cma.j.issn.0366-6999.2012.18.020
   Zheng LD, 2008, CHIN MED J, V8, P226
NR 38
TC 13
Z9 17
U1 0
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD MAR
PY 2016
VL 13
IS 3
BP 2661
EP 2670
DI 10.3892/mmr.2016.4820
PG 10
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA DF8TS
UT WOS:000371633000094
PM 26821367
OA Bronze
DA 2022-04-25
ER

PT J
AU Yu, HY
   Yin, SS
   Zhou, SY
   Shao, YY
   Sun, JC
   Pang, X
   Han, LF
   Zhang, Y
   Gao, XM
   Jin, CY
   Qiu, YL
   Wang, T
AF Yu, Haiyang
   Yin, Shuangshuang
   Zhou, Shiyue
   Shao, Yingying
   Sun, Jiachen
   Pang, Xu
   Han, Lifeng
   Zhang, Yi
   Gao, Xiumei
   Jin, Chengyun
   Qiu, Yuling
   Wang, Tao
TI Magnolin promotes autophagy and cell cycle arrest via blocking
   LIF/Stat3/Mcl-1 axis in human colorectal cancers
SO CELL DEATH & DISEASE
LA English
DT Article
ID SIGNALING PATHWAY; IN-VITRO; PROGRESSION; CARCINOMA; TRANSFORMATION;
   METASTASIS; METABOLISM; ACTIVATION; EXPRESSION; APOPTOSIS
AB Magnolin is a multi-bioactive natural compound that possesses underlying anti-cancer properties. However, the mechanisms underlying remain to be elucidated. Here, we report the role of magnolin in suppressing human colorectal cancer (CRC) cells via activating autophagy and cell cycle arrest in vitro and in vivo. Pre-treatment of cells with specific autophagy inhibitor (3-methyladenine) or knockdown of endogenous LC-3B by siRNA significantly abrogates magnolin-induced cell cycle arrest. Molecular validation mechanistically shows that magnolin-induced autophagy and cell cycle arrest in CRC cells is correlated with decreased transcriptional levels of leukemia inhibitory factor (LIF), and we further find that inhibition of LIF decreases phosphorylation level of Stat3 and represses transcriptional expression of Mcl-1. Furthermore, magnolin-induced autophagy and cell cycle arrest suppress the growth of xenograft colorectal tumors without apparent toxicity. Finally, we evaluate the clinical correlation of LIF/Stat3/Mcl-1 in CRC patient tissues. As expected, LIF, p-Stat3, and Mcl-1 levels are high in CRC tissue but are scarcely found in normal colon tissue. High positive expressions of LIF or Mcl-1 are associated with poor prognosis. Doubly positive cases have shown the worst outcome. Taken together, our results have clarified a novel molecular mechanism whereby magnolin induces autophagy and cell cycle arrest through LIF/Stat3/Mcl-1 pathway in CRCs. Our results also have revealed that magnolin has a promising therapeutic potential in CRCs.
C1 [Yu, Haiyang; Yin, Shuangshuang; Zhou, Shiyue; Shao, Yingying; Sun, Jiachen; Pang, Xu; Han, Lifeng; Zhang, Yi; Gao, Xiumei; Wang, Tao] Tianjin Univ Tradit Chinese Med, Tianjin State Key Lab Modern Chinese Med, Tianjin 300193, Peoples R China.
   [Jin, Chengyun] Zhengzhou Univ, Sch Pharmaceut Sci, Key Lab Henan Prov Drug Qual Control & Evaluat, Key Lab,State Minist Educ, Zhengzhou 450001, Henan, Peoples R China.
   [Qiu, Yuling] Tianjin Med Univ, Sch Pharm, Tianjin 300070, Peoples R China.
RP Wang, T (corresponding author), Tianjin Univ Tradit Chinese Med, Tianjin State Key Lab Modern Chinese Med, Tianjin 300193, Peoples R China.; Jin, CY (corresponding author), Zhengzhou Univ, Sch Pharmaceut Sci, Key Lab Henan Prov Drug Qual Control & Evaluat, Key Lab,State Minist Educ, Zhengzhou 450001, Henan, Peoples R China.; Qiu, YL (corresponding author), Tianjin Med Univ, Sch Pharm, Tianjin 300070, Peoples R China.
EM cyjin@zzu.edu.cn; qiuyuling@tmu.edu.cn; wangt@263.net
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81603253, 21711540293, 81673703, 81602614];
   Natural Science Foundation of Tianjin CityNatural Science Foundation of
   Tianjin [15JCYBJC54900, 15PTCYSY00030]
FX We thank Dr. Yuhong Hu (Hebei Normal University) for her technical
   assistance in electron microscope analysis. This work was supported by
   grants from National Natural Science Foundation of China (Nos. 81603253
   and 21711540293 to H. Yu, No. 81673703 to T. Wang, No. 81602614 to Y.
   Qiu), Natural Science Foundation of Tianjin City (No. 15JCYBJC54900 to
   H. Yu, No. 15PTCYSY00030 to Z. Li).
CR Aarts M, 2013, CURR OPIN PHARMACOL, V13, P529, DOI 10.1016/j.coph.2013.03.012
   Albrengues J, 2014, CELL REP, V7, P1664, DOI 10.1016/j.celrep.2014.04.036
   Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   An ZY, 2014, AUTOPHAGY, V10, P1702, DOI 10.4161/auto.32122
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Asghar U, 2015, NAT REV DRUG DISCOV, V14, P130, DOI 10.1038/nrd4504
   Belmar J, 2015, PHARMACOL THERAPEUT, V145, P76, DOI 10.1016/j.pharmthera.2014.08.003
   Bertoli C, 2013, NAT REV MOL CELL BIO, V14, P518, DOI 10.1038/nrm3629
   Canel M, 2017, CANCER RES, V77, P5301, DOI 10.1158/0008-5472.CAN-17-0418
   Diaz-Moralli S, 2013, PHARMACOL THERAPEUT, V138, P255, DOI 10.1016/j.pharmthera.2013.01.011
   Galluzzi L, 2017, EMBO J, V36, P1811, DOI 10.15252/embj.201796697
   Guo JY, 2013, CELL, V155, P1216, DOI 10.1016/j.cell.2013.11.019
   Huang HS, 2016, AUTOPHAGY, V12, P1687, DOI 10.1080/15548627.2016.1196313
   Huang YQ, 2017, BIOMED PHARMACOTHER, V87, P714, DOI 10.1016/j.biopha.2017.01.010
   Ibarra-Alvarado C, 2010, PHARM BIOL, V48, P732, DOI 10.3109/13880200903271280
   Kenific CM, 2015, TRENDS CELL BIOL, V25, P37, DOI 10.1016/j.tcb.2014.09.001
   Khan K, 2017, GUT, DOI [10.1136/gutjnl-2017-314178., DOI 10.1136/GUTJNL-2017-314178.]
   Kim JY, 2009, BIOORG MED CHEM LETT, V19, P937, DOI 10.1016/j.bmcl.2008.11.103
   Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Lee CJ, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1580-7
   Lee CJ, 2014, CARCINOGENESIS, V35, P432, DOI 10.1093/carcin/bgt306
   Lee HJ, 2014, CANCER CELL, V26, P207, DOI 10.1016/j.ccr.2014.05.019
   Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260
   Li XY, 2014, ONCOTARGET, V5, P788, DOI 10.18632/oncotarget.1772
   Liu SC, 2013, J CLIN INVEST, V123, P5269, DOI 10.1172/JCI63428
   Lorin S, 2013, SEMIN CANCER BIOL, V23, P361, DOI 10.1016/j.semcancer.2013.06.007
   Luo M, 2017, J CELL MOL MED, V21, P46, DOI 10.1111/jcmm.12937
   Macintosh RL, 2013, SEMIN CANCER BIOL, V23, P344, DOI 10.1016/j.semcancer.2013.05.006
   Mathiassen SG, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00051
   Mukhija M, 2014, J ETHNOPHARMACOL, V152, P106, DOI 10.1016/j.jep.2013.12.039
   Pathania AS, 2016, SCI REP-UK, V6, DOI 10.1038/srep33146
   Perciavalle RM, 2013, TRENDS CELL BIOL, V23, P22, DOI 10.1016/j.tcb.2012.08.011
   Salazar-Roa M, 2017, TRENDS CELL BIOL, V27, P69, DOI 10.1016/j.tcb.2016.08.009
   Sarfaty M, 2018, EUR UROL, V73, P628, DOI 10.1016/j.eururo.2017.07.041
   Sendinc E, 2015, CELL, V162, P235, DOI 10.1016/j.cell.2015.06.050
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Siveen K.S, 2014, BIOCHIM BIOPHYS ACTA, V1845, P2136
   Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005
   Valcifahmetoglu-Norberg H, 2015, J CLIN INVEST, V125, P5, DOI 10.1172/JCI73937
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Wang F, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/203458
   Wang JB, 2016, HEPATOLOGY, V64, P1606, DOI 10.1002/hep.28781
   White E, 2015, CLIN CANCER RES, V21, P5037, DOI 10.1158/1078-0432.CCR-15-0490
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Wu LH, 2015, ONCOTARGET, V6, P4406, DOI 10.18632/oncotarget.3017
   Yu HY, 2017, MOL CANCER THER, V16, P2711, DOI 10.1158/1535-7163.MCT-17-0498
   Yu HY, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6218
   Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818
NR 49
TC 19
Z9 20
U1 5
U2 20
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JUN 13
PY 2018
VL 9
AR 702
DI 10.1038/s41419-018-0660-4
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA GK9NV
UT WOS:000436579400007
PM 29899555
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Ou, JJ
   Miao, HM
   Ma, YY
   Guo, F
   Deng, J
   Wei, X
   Zhou, J
   Xie, GF
   Shi, H
   Xue, BZ
   Liang, HJ
   Yu, LQ
AF Ou, Juanjuan
   Miao, Hongming
   Ma, Yinyan
   Guo, Feng
   Deng, Jia
   Wei, Xing
   Zhou, Jie
   Xie, Ganfeng
   Shi, Hang
   Xue, Bingzhong
   Liang, Houjie
   Yu, Liqing
TI Loss of Abhd5 Promotes Colorectal Tumor Development and Progression by
   Inducing Aerobic Glycolysis and Epithelial-Mesenchymal Transition
SO CELL REPORTS
LA English
DT Article
ID ADIPOSE TRIGLYCERIDE LIPASE; ACTIVATED PROTEIN-KINASE; LIPID STORAGE
   DISEASE; GENE-TRANSCRIPTION; ENERGY-METABOLISM; HEPATIC STEATOSIS;
   CANCER; CGI-58; GROWTH; AUTOPHAGY
AB How cancer cells shift metabolism to aerobic glycolysis is largely unknown. Here, we show that deficiency of alpha/beta-hydrolase domain-containing 5 (Abhd5), an intracellular lipolytic activator that is also known as comparative gene identification 58 (CGI- 58), promotes this metabolic shift and enhances malignancies of colorectal carcinomas (CRCs). Silencing of Abhd5 in normal fibroblasts induces malignant transformation. Intestine- specific knockout of Abhd5 in Apc(Min/+) mice robustly increases tumorigenesis and malignant transformation of adenomatous polyps. In colon cancer cells, Abhd5 deficiency induces epithelial-mesenchymal transition by suppressing the AMPK alpha-p53 pathway, which is attributable to increased aerobic glycolysis. In human CRCs, Abhd5 expression falls substantially and correlates negatively with malignant features. Our findings link Abhd5 to CRC pathogenesis and suggest that cancer cells develop aerobic glycolysis by suppressing Abhd5-mediated intracellular lipolysis.
C1 [Ou, Juanjuan; Miao, Hongming; Ma, Yinyan; Wei, Xing; Yu, Liqing] Univ Maryland, Dept Anim & Avian Sci, College Pk, MD 20742 USA.
   [Ou, Juanjuan; Miao, Hongming; Deng, Jia; Wei, Xing; Zhou, Jie; Xie, Ganfeng; Liang, Houjie] Third Mil Med Univ, Southwest Hosp, Dept Oncol, Chongqing 400038, Peoples R China.
   [Ou, Juanjuan; Miao, Hongming; Deng, Jia; Wei, Xing; Zhou, Jie; Xie, Ganfeng; Liang, Houjie] Third Mil Med Univ, Southwest Hosp, Southwest Canc Ctr, Chongqing 400038, Peoples R China.
   [Guo, Feng] Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27157 USA.
   [Shi, Hang; Xue, Bingzhong] Georgia State Univ, Dept Biol, Atlanta, GA 30302 USA.
RP Liang, HJ (corresponding author), Third Mil Med Univ, Southwest Hosp, Dept Oncol, Chongqing 400038, Peoples R China.
EM lianghoujie@sina.com; lyu123@umd.edu
RI miao, hongming/AAV-8561-2020
FU National Institute of Diabetes and Digestive and Kidney DiseasesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK) [R01DK085176, R01DK084172]; National Heart, Lung
   and Blood InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [R01HL107500]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [81370063, 81172115]; China National Natural Science Foundation,
   Oversea, Hong Kong & Macao Scholars Collaborated Research Fund [510025];
   NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [R01HL107500] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND
   KIDNEY DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK085176,
   R01DK084172] Funding Source: NIH RePORTER
FX We thank Jianbing Zhang, Xianfeng Wang, Rongbin Zhou, and Shun Lei for
   technical assistance.This work was supported in part by grants
   R01DK085176 (L.Y.) and R01DK084172 (H.S.) from the National Institute of
   Diabetes and Digestive and Kidney Diseases; grant R01HL107500 (B.X.)
   from the National Heart, Lung and Blood Institute; grants 81370063
   (J.O.) and 81172115 (H.L.) from the National Natural Science Foundation
   of China; and grant 510025 (L.Y.) from the China National Natural
   Science Foundation, Oversea, Hong Kong & Macao Scholars Collaborated
   Research Fund.
CR Accioly MT, 2008, CANCER RES, V68, P1732, DOI 10.1158/0008-5472.CAN-07-1999
   Bozza PT, 2010, PROSTAG LEUKOTR ESS, V82, P243, DOI 10.1016/j.plefa.2010.02.005
   Brown JM, 2007, J LIPID RES, V48, P2295, DOI 10.1194/jlr.M700279-JLR200
   Brown JM, 2010, J LIPID RES, V51, P3306, DOI 10.1194/jlr.M010256
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   CHANARIN I, 1975, BRIT MED J, V1, P553, DOI 10.1136/bmj.1.5957.553
   Das SK, 2011, SCIENCE, V333, P233, DOI 10.1126/science.1198973
   DeBerardinis RJ, 2012, CELL, V148, P1132, DOI 10.1016/j.cell.2012.02.032
   DORFMAN ML, 1974, ARCH DERMATOL, V110, P261, DOI 10.1001/archderm.110.2.261
   Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Fischer J, 2007, NAT GENET, V39, P28, DOI 10.1038/ng1951
   Frezza C, 2011, J MOL MED, V89, P213, DOI 10.1007/s00109-011-0728-4
   Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001
   Guo F, 2013, J LIPID RES, V54, P2109, DOI 10.1194/jlr.M035519
   GUPPY M, 1993, EUR J BIOCHEM, V212, P95, DOI 10.1111/j.1432-1033.1993.tb17637.x
   Haemmerle G, 2006, SCIENCE, V312, P734, DOI 10.1126/science.1123965
   Hahn S, 2013, EMBO J, V32, P3079, DOI 10.1038/emboj.2013.236
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249
   Igal RA, 1997, J PEDIATR GASTR NUTR, V25, P541, DOI 10.1097/00005176-199711000-00011
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI 10.3322/caac.20073
   Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027
   Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Kruse JP, 2006, CELL METAB, V4, P1, DOI 10.1016/j.cmet.2006.06.004
   Lass A, 2006, CELL METAB, V3, P309, DOI 10.1016/j.cmet.2006.03.005
   Lee CH, 2007, EMBO J, V26, P4812, DOI 10.1038/sj.emboj.7601900
   Lefevre C, 2001, AM J HUM GENET, V69, P1002, DOI 10.1086/324121
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Lyssiotis CA, 2012, CELL, V151, P1155, DOI 10.1016/j.cell.2012.11.020
   Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222
   Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642
   Nomura DK, 2010, CELL, V140, P49, DOI 10.1016/j.cell.2009.11.027
   Radner FPW, 2010, J BIOL CHEM, V285, P7300, DOI 10.1074/jbc.M109.081877
   RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518
   Siemens H, 2011, CELL CYCLE, V10, P4256, DOI 10.4161/cc.10.24.18552
   Singh R, 2009, NATURE, V458, P1131, DOI 10.1038/nature07976
   Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437
   Straub BK, 2008, HEPATOLOGY, V47, P1936, DOI 10.1002/hep.22268
   SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108
   Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087
   Vogt PK, 2001, TRENDS MOL MED, V7, P482, DOI 10.1016/S1471-4914(01)02161-X
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Wu JW, 2011, HEPATOLOGY, V54, P122, DOI 10.1002/hep.24338
   Xie P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091652
   Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018
   Yun H, 2005, J BIOL CHEM, V280, P9963, DOI 10.1074/jbc.M412994200
   Zimmermann R, 2004, SCIENCE, V306, P1383, DOI 10.1126/science.1100747
NR 51
TC 64
Z9 68
U1 3
U2 16
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD DEC 11
PY 2014
VL 9
IS 5
BP 1798
EP 1811
DI 10.1016/j.celrep.2014.11.016
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AX3PR
UT WOS:000346851900023
PM 25482557
OA Green Accepted, gold, Green Published
DA 2022-04-25
ER

PT J
AU Symonds, EL
   Konczak, I
   Fenech, M
AF Symonds, Erin L.
   Konczak, Izabela
   Fenech, Michael
TI The Australian fruit Illawarra plum (Podocarpus elatus Endl.,
   Podocarpaceae) inhibits telomerase, increases histone deacetylase
   activity and decreases proliferation of colon cancer cells
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE Colon cancer; Anthocyanins; Autophagy; Histone deacetylase;
   Proliferation
ID ANTHOCYANINS; EXTRACTS; GROWTH; MICRONUCLEUS; ANTIOXIDANTS; EXPRESSION;
   APOPTOSIS; SURVIVAL; SIRT1; LINES
AB Fruit antioxidants have many health benefits including prevention of cancer development. The native Australian bush fruit Illawarra plum (Podocarpus elatus Endl., Podocarpaceae) has a high content of anthocyanin-rich phenolics, with an antioxidant capacity at levels higher than most fruits. In the present study the molecular mechanisms of the anti-proliferative activity of Illawarra plum on colorectal cancer cells were investigated. Non-tumorigenic young adult mouse colonic (YAMC) cells and tumorigenic human colonic (HT-29) cells were treated with a polyphenolic-rich Illawarra plum extract (0-1000 mu g/ml). Illawarra plum had anti-proliferative properties in only the cancer cells, with growth suppressed in a dose- and time-dependent manner. Treatment of HT-29 cells with Illawarra plum extract (500 mu g/ml; 24 h) was also associated with a 2-fold increase in apoptosis, and a cell cycle delay in the S phase (P<0.01). Assessment of biomarkers for DNA damage revealed that plum treatment caused a 93% down-regulation of telomerase activity (P<0.001) and a decrease in telomere length (up to 75 %; P<0.01). Treatment with Illawarra plum extract also induced morphological alterations to HT-29 cells that were suggestive of induction of autophagy, as the formation of cytoplasmic vacuoles was observed in many cells. This could be induced by the increased (6-fold) histone deacetylase (HDAC) activity (P<0.001) and the trend for increased expression of the class III HDAC sirtuin 1. The present study has shown that Illawarra plum extract is able to reduce the proliferation of colon cancer cells by altering the cell cycle, increasing apoptosis and possibly inducing autophagy. The active ingredients in Illawarra plum may provide an alternative chemo-prevention strategy to conventional chemotherapy.
C1 [Symonds, Erin L.; Fenech, Michael] CSIRO Food & Nutr Sci, Adelaide, SA 5000, Australia.
   [Konczak, Izabela] CSIRO Food & Nutr Sci, N Ryde, NSW 1670, Australia.
RP Symonds, EL (corresponding author), CSIRO Food & Nutr Sci, Adelaide, SA 5000, Australia.
EM erinsymonds@yahoo.com
RI Konczak, Izabela/AAF-7476-2021
OI Konczak, Izabela/0000-0002-1712-9754; Symonds, Erin/0000-0003-2451-0358
FU National Health and Medical Research Council of AustraliaNational Health
   and Medical Research Council (NHMRC) of Australia [357702]
FX E. L. S. was supported by a CJ Martin post-doctoral fellowship (salary)
   awarded by the National Health and Medical Research Council of Australia
   (no. 357702). The research project received no specific grant from any
   funding agency in the public, commercial or not-for-profit sectors. E.
   L. S., I. K. and M. F. designed the research; I. K. provided methodology
   and essential reagents; E. L. S. conducted the research; E. L. S. and M.
   F. analysed the data; E. L. S. wrote the paper and had primary
   responsibility for final content. All authors read and approved the
   final manuscript. The authors have no conflicts of interest.
CR Akare S, 2006, INT J CANCER, V119, P2958, DOI 10.1002/ijc.22231
   Australian Institute of Health and Welfare, 2011, AUSTR CANC INC MORT
   Bandyopadhyay D, 2003, EXP GERONTOL, V38, P1299, DOI 10.1016/j.exger.2003.09.009
   BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553
   Boivin D, 2007, ANTICANCER RES, V27, P937
   Boklan J, 2002, CANCER RES, V62, P2104
   Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196
   Darzynkiewicz Z, 2004, CURR PROTOC IMMUNOL, V60, P571
   Di Domenico F, 2012, BBA-MOL BASIS DIS, V1822, P737, DOI 10.1016/j.bbadis.2011.10.005
   Fenech M, 2011, MUTAGENESIS, V26, P125, DOI 10.1093/mutage/geq052
   Fenech M, 2007, NAT PROTOC, V2, P1084, DOI 10.1038/nprot.2007.77
   Fenton JI, 2005, CANCER EPIDEM BIOMAR, V14, P1646, DOI 10.1158/1055-9965.EPI-04-0916
   George J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023395
   Gonzalez-Sarrias A, 2012, PHYTOTHER RES, V26, P995, DOI 10.1002/ptr.3677
   Halliwell B, 2007, CARDIOVASC RES, V73, P341, DOI 10.1016/j.cardiores.2006.10.004
   HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0
   JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096
   Kang SY, 2003, CANCER LETT, V194, P13, DOI 10.1016/S0304-3940(02)00583-9
   Konczak I, 2008, J CLIN BIOCHEM NUTR, V43, P543
   Krick R, 2009, AUTOPHAGY, V5, P270, DOI 10.4161/auto.5.2.7639
   Kundu JK, 2008, CANCER LETT, V269, P243, DOI 10.1016/j.canlet.2008.03.057
   Lant B, 2010, INT J BIOL SCI, V6, P9
   Lazze MC, 2004, CARCINOGENESIS, V25, P1427, DOI 10.1093/carcin/bgh138
   Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105
   Ling YH, 1996, MOL PHARMACOL, V49, P832
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Malik M, 2003, NUTR CANCER, V46, P186, DOI 10.1207/S15327914NC4602_12
   Morselli E, 2011, J CELL BIOL, V192, P615, DOI 10.1083/jcb.201008167
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   NetZel M, 2007, INNOV FOOD SCI EMERG, V8, P339, DOI 10.1016/j.ifset.2007.03.007
   O'Callaghan NJ, 2008, BIOTECHNIQUES, V44, P807, DOI 10.2144/000112761
   Ramachandran C, 2002, CANCER LETT, V184, P1, DOI 10.1016/S0304-3835(02)00192-1
   RiceEvans CA, 1996, FREE RADICAL BIO MED, V20, P933, DOI 10.1016/0891-5849(95)02227-9
   Seeram NP, 2006, J AGR FOOD CHEM, V54, P9329, DOI 10.1021/jf061750g
   Shimizu N, 1996, NAT GENET, V12, P65, DOI 10.1038/ng0196-65
   Shimizu N, 2000, MUTAT RES-FUND MOL M, V448, P81, DOI 10.1016/S0027-5107(00)00003-8
   Stoner GD, 2006, NUTR CANCER, V54, P33, DOI 10.1207/s15327914nc5401_5
   Tan AC, 2011, FOOD RES INT, V44, P2362, DOI 10.1016/j.foodres.2010.12.031
   Terahara N, 2000, PHYTOCHEMISTRY, V54, P919, DOI 10.1016/S0031-9422(00)00099-6
   WHITEHEAD RH, 1993, P NATL ACAD SCI USA, V90, P587, DOI 10.1073/pnas.90.2.587
   Wu QK, 2007, J AGR FOOD CHEM, V55, P1156, DOI 10.1021/jf062320t
   Yi WG, 2005, J AGR FOOD CHEM, V53, P7320, DOI 10.1021/jf051333o
   Zhao C, 2004, J AGR FOOD CHEM, V52, P6122, DOI 10.1021/jf049517a
NR 43
TC 22
Z9 23
U1 1
U2 28
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
EI 1475-2662
J9 BRIT J NUTR
JI Br. J. Nutr.
PD JUN 28
PY 2013
VL 109
IS 12
BP 2117
EP 2125
DI 10.1017/S0007114512004333
PG 9
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 153NF
UT WOS:000319608300001
PM 23069328
OA Bronze
DA 2022-04-25
ER

PT J
AU Giannopoulou, E
   Antonacopoulou, A
   Matsouka, P
   Kalofonos, HP
AF Giannopoulou, Efstathia
   Antonacopoulou, Anna
   Matsouka, Panagiota
   Kalofonos, Haralabos P.
TI Autophagy: Novel Action of Panitumumab in Colon Cancer
SO ANTICANCER RESEARCH
LA English
DT Article
DE Panitumumab; autophagy; redox status
ID METASTATIC COLORECTAL-CANCER; GROWTH-FACTOR RECEPTOR;
   MONOCLONAL-ANTIBODY; SIGNAL-TRANSDUCTION; OXIDATIVE STRESS; EGFR
   INHIBITORS; THERAPY; KRAS; CELLS; PROTEIN
AB Background: Panitumumab, a fully-human monoclonal antibody raised against epidermal growth factor receptor (EGFR), has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) for the treatment of patients with EGFR expressing metastatic colorectal carcinoma (mCRC) after failure of standard chemotherapy. Additionally, the guideline of the EMEA includes the use of panitumumab in patients with wild-type KRAS. The goal of the current study was to evaluate the effect of panitumumab oil colon cancer cells, proliferation, apoptosis, necrosis, cell cycle arrest and autophagy. The effect Of panitumumab oil the redox status of the cells was also studied. Materials and Methods: The cell lines Caco-2, DLD-1 and HT-29 which differ in their expression of EGFR and HER-2 were used. Cell proliferation and apoptosis/necrosis were measured by methyl tetrazolium (MTT) assay and annexin V/propidium iodide assay, respectively. Cell cycle arrest was estimated by propidium iodide assay and autophagy was detected using Western blot analysis. Spectrophotometrical quantification of glutathione (GSH) levels and an analysis, of KRAS sequence were applied. Results: Panitumumab reduced proliferation only in the DLD-1 cells despite the mutated KRAS in this cell line. However, panitumumab did not affect DLD-1 cell apoptosis, necrosis or cell cycle progression. Interestingly, immunoblotting analysis revealed that panitumumab increased protein levels of beclin-1, a marker of autophagy. In addition, an increase in the GSH level was noted following panitumumab treatment reflecting an imbalance in the redox status of the cells. Conclusion: Panitumumab affects colon cancer cell proliferation independently of KRAS mutations and EGFR protein levels, possibly through the induction of autophagy.
C1 [Giannopoulou, Efstathia; Antonacopoulou, Anna; Matsouka, Panagiota; Kalofonos, Haralabos P.] Univ Hosp Patras, Patras Med Sch, Div Oncol, Clin Oncol Lab,Dept Med, Rion 26504, Greece.
RP Kalofonos, HP (corresponding author), Univ Hosp Patras, Patras Med Sch, Div Oncol, Rion 26504, Greece.
EM kalofon@med.upatras.gr
OI Kalofonos, Haralabos/0000-0002-3286-778X
FU Oncological Research Fund (EOGE); Hellenic Cooperative Oncology Group
   (HECOG)
FX This work was supported by the Oncological Research Fund (EOGE) and
   Efstathia Giannopoulou and Anna Antonacopoulou were supported by the
   Hellenic Cooperative Oncology Group (HECOG). We would like to thank
   Amgen Inc. for providing panitumumab and Mr. Kostas Polimenous for study
   support.
CR Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Aizawa S, 2003, CANCER SCI, V94, P886, DOI 10.1111/j.1349-7006.2003.tb01371.x
   Alekshun Todd, 2005, Cancer Control, V12, P105
   Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116
   Behrend L, 2003, BIOCHEM SOC T, V31, P1441
   Blau S, 1999, MOL CELL BIOCHEM, V194, P185, DOI 10.1023/A:1006994800272
   Calonghi N, 2006, BIOCHEM BIOPH RES CO, V342, P585, DOI 10.1016/j.bbrc.2006.02.008
   Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78
   Dutta PR, 2007, CANCER LETT, V254, P165, DOI 10.1016/j.canlet.2007.02.006
   Emlet DR, 2006, BRIT J CANCER, V94, P1144, DOI 10.1038/sj.bjc.6603078
   Freeman DJ, 2008, CLIN COLORECTAL CANC, V7, P184, DOI 10.3816/CCC.2008.n.024
   Ghezzi P, 2005, FREE RADICAL RES, V39, P573, DOI 10.1080/10715760500072172
   Giannopoulou E, 2002, ANTICANCER RES, V22, P2821
   Giannopoulou E, 2009, CANCER CHEMOTH PHARM, V63, P973, DOI 10.1007/s00280-008-0820-9
   Giusti RM, 2007, ONCOLOGIST, V12, P577, DOI 10.1634/theoncologist.12-5-577
   Hecht JR, 2008, AM J HEALTH-SYST PH, V65, pS15, DOI 10.2146/ajhp080102
   HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409
   Jean GW, 2008, PHARMACOTHERAPY, V28, P742, DOI 10.1592/phco.28.6.742
   Keller JW, 2007, J CELL PHYSIOL, V210, P740, DOI 10.1002/jcp.20898
   Kuwada SK, 2004, INT J CANCER, V109, P291, DOI 10.1002/ijc.11686
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Mano M, 2008, NAT CLIN PRACT ONCOL, V5, P415, DOI 10.1038/ncponc1136
   Marmor MD, 2004, INT J RADIAT ONCOL, V58, P903, DOI 10.1016/j.ijrobp.2003.06.002
   Pal SK, 2005, ANTI-CANCER DRUG, V16, P483
   Peeters M, 2008, ALIMENT PHARM THER, V28, P269, DOI 10.1111/j.1365-2036.2008.03717.x
   Plesec TP, 2009, ADV ANAT PATHOL, V16, P196, DOI 10.1097/PAP.0b013e3181a9d4ed
   Prewett MC, 2002, CLIN CANCER RES, V8, P994
   Qadir MA, 2008, BREAST CANCER RES TR, V112, P389, DOI 10.1007/s10549-007-9873-4
   Rainis T, 2007, DIGEST DIS SCI, V52, P526, DOI 10.1007/s10620-006-9177-2
   Raponi M, 2008, CURR OPIN PHARMACOL, V8, P413, DOI 10.1016/j.coph.2008.06.006
   Russo RE, 2005, CONTEMP TOP LAB ANIM, V44, P49
   Schumacker PT, 2006, CANCER CELL, V10, P175, DOI 10.1016/j.ccr.2006.08.015
   Scibior D, 2008, CLIN BIOCHEM, V41, P852, DOI 10.1016/j.clinbiochem.2008.03.005
   Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9
   Spano JP, 2005, ANN ONCOL, V16, P189, DOI 10.1093/annonc/mdi057
   Toffolli G, 2007, INT J BIOL MARKER, V22, pS24
   Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009
   Vallbohmer Daniel, 2005, Clin Colorectal Cancer, V5 Suppl 1, pS19, DOI 10.3816/CCC.2005.s.003
   Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620
   van Krieken JHJM, 2008, VIRCHOWS ARCH, V453, P417, DOI 10.1007/s00428-008-0665-y
   Weihua Z, 2008, CANCER CELL, V13, P385, DOI 10.1016/j.ccr.2008.03.015
   Wu M, 2008, CLIN THER, V30, P14, DOI 10.1016/j.clinthera.2008.01.014
   Yang XD, 2001, CRIT REV ONCOL HEMAT, V38, P17, DOI 10.1016/S1040-8428(00)00134-7
   Zhang W, 2006, ANN MED, V38, P545, DOI 10.1080/09546630601070812
NR 44
TC 46
Z9 47
U1 0
U2 3
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD DEC
PY 2009
VL 29
IS 12
BP 5077
EP 5082
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 540UP
UT WOS:000273365700024
PM 20044619
DA 2022-04-25
ER

PT J
AU Jin, Y
   Hong, Y
   Park, CY
   Hong, Y
AF Jin, Yunho
   Hong, Yunkyung
   Park, Chan Young
   Hong, Yonggeun
TI Molecular Interactions of Autophagy with the Immune System and Cancer
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE autophagy; immune system; cancer; cell death; metabolic homeostasis
ID DOUBLE-EDGED-SWORD; TOLL-LIKE RECEPTORS; CHAPERONE-MEDIATED AUTOPHAGY;
   T-CELL HOMEOSTASIS; COLORECTAL-CANCER; INNATE IMMUNITY; THERAPY; TUMOR;
   GENE; MACROAUTOPHAGY
AB Autophagy is a highly conserved catabolic mechanism that mediates the degradation of damaged cellular components by inducing their fusion with lysosomes. This process provides cells with an alternative source of energy for the synthesis of new proteins and the maintenance of metabolic homeostasis in stressful environments. Autophagy protects against cancer by mediating both innate and adaptive immune responses. Innate immune receptors and lymphocytes (T and B) are modulated by autophagy, which represent innate and adaptive immune responses, respectively. Numerous studies have demonstrated beneficial roles for autophagy induction as well as its suppression of cancer cells. Autophagy may induce either survival or death depending on the cell/tissue type. Radiation therapy is commonly used to treat cancer by inducing autophagy in human cancer cell lines. Additionally, melatonin appears to affect cancer cell death by regulating programmed cell death. In this review, we summarize the current understanding of autophagy and its regulation in cancer.
C1 [Jin, Yunho; Hong, Yonggeun] Inje Univ, Dept Rehabil Sci, Grad Sch, Gimhae 50834, South Korea.
   [Jin, Yunho; Hong, Yunkyung; Hong, Yonggeun] Inje Univ, Ubiquitous Healthcare & Antiaging Res Ctr U HARC, Gimhae 50834, South Korea.
   [Jin, Yunho; Hong, Yunkyung; Hong, Yonggeun] Inje Univ, BPRC, Gimhae 50834, South Korea.
   [Hong, Yunkyung; Hong, Yonggeun] Inje Univ, Dept Phys Therapy, Coll Biomed Sci & Engn, Gimhae 50834, South Korea.
   [Park, Chan Young] UNIST, Dept Life Sci, Ulsan 44919, South Korea.
RP Hong, Y (corresponding author), Inje Univ, Dept Rehabil Sci, Grad Sch, Gimhae 50834, South Korea.; Hong, Y (corresponding author), Inje Univ, Ubiquitous Healthcare & Antiaging Res Ctr U HARC, Gimhae 50834, South Korea.; Hong, Y (corresponding author), Inje Univ, BPRC, Gimhae 50834, South Korea.; Hong, Y (corresponding author), Inje Univ, Dept Phys Therapy, Coll Biomed Sci & Engn, Gimhae 50834, South Korea.; Park, CY (corresponding author), UNIST, Dept Life Sci, Ulsan 44919, South Korea.
EM jynh33@naver.com; dangmoo777@naver.com; cypark@unist.ac.kr;
   yonghong@inje.ac.kr
RI Park, Chan Young/F-5696-2010
OI Park, Chan Young/0000-0002-5183-3665
FU National Research Foundation [2015R1A1A1A05027490,
   NRF-2015R1C1A2A01055691, NRF-2017R1A2A2A01067169]; KRIBB Research
   Initiative Program, Republic of Korea [KGM4611714]; Inje University
FX We thank Sookyoung Park, Jinyoung Won, and Jeonghyun Choi for critically
   reading the manuscript, and Jongwon Kim for critical comments and useful
   suggestions. This work was supported by grants from the National
   Research Foundation (2015R1A1A1A05027490 to Chan Young Park,
   NRF-2015R1C1A2A01055691 to Yunkyung Hong, NRF-2017R1A2A2A01067169 to
   Yonggeun Hong,), and by the KRIBB Research Initiative Program
   (KGM4611714), Republic of Korea. This work was also supported by the
   2016 Creative Research Program of Inje University.
CR Adams JM, 2007, CURR OPIN IMMUNOL, V19, P488, DOI 10.1016/j.coi.2007.05.004
   Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622
   Basith S, 2012, ARCH PHARM RES, V35, P1297, DOI 10.1007/s12272-012-0802-7
   Baskar R, 2017, INT J MED SCI, V14, P13, DOI 10.7150/ijms.17288
   Bassham DC, 2007, CURR OPIN PLANT BIOL, V10, P587, DOI 10.1016/j.pbi.2007.06.006
   Bell CW, 2006, AM J PHYSIOL-CELL PH, V291, pC1318, DOI 10.1152/ajpcell.00616.2005
   Chen R, 2008, ONCOGENE, V27, P225, DOI 10.1038/sj.onc.1210907
   Clarke AJ, 2015, ANN RHEUM DIS, V74, P912, DOI 10.1136/annrheumdis-2013-204343
   Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   de Castro CP, 2012, J IMMUNOL, V189, P4144, DOI 10.4049/jimmunol.1201946
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   English L, 2009, NAT IMMUNOL, V10, P480, DOI 10.1038/ni.1720
   Feng YC, 2014, CELL RES, V24, P24, DOI 10.1038/cr.2013.168
   Franchi L, 2008, CELL MICROBIOL, V10, P1, DOI 10.1111/j.1462-5822.2007.01059.x
   Garg AD, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26260
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Hong Y, 2014, J PINEAL RES, V56, P264, DOI 10.1111/jpi.12119
   Huang B, 2008, ONCOGENE, V27, P218, DOI 10.1038/sj.onc.1210904
   Jia W, 2011, J IMMUNOL, V186, P1564, DOI 10.4049/jimmunol.1001822
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kaushik S, 2008, MOL BIOL CELL, V19, P2179, DOI 10.1091/mbc.E07-11-1155
   Kaushik S, 2012, TRENDS CELL BIOL, V22, P407, DOI 10.1016/j.tcb.2012.05.006
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   Kim BM, 2015, INT J MOL SCI, V16, P26880, DOI 10.3390/ijms161125991
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kos-Kudla B, 2002, NEUROENDOCRINOL LETT, V23, P239
   Kumai T, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.976077
   Kutikhin AG, 2011, HUM IMMUNOL, V72, P955, DOI 10.1016/j.humimm.2011.06.003
   Lei YY, 2017, CANCER LETT, V393, P33, DOI 10.1016/j.canlet.2017.02.012
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594
   Macri C, 2016, PROG INFLAMM RES SER, P155, DOI 10.1007/978-3-319-30079-5_8
   Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Miller BC, 2008, AUTOPHAGY, V4, P309, DOI 10.4161/auto.5474
   Miracco C, 2007, INT J ONCOL, V30, P429
   O'Neill LAJ, 2007, NAT REV IMMUNOL, V7, P353, DOI 10.1038/nri2079
   Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0
   Oh Ji Eun, 2013, Immune Netw, V13, P1, DOI 10.4110/in.2013.13.1.1
   Pan HM, 2016, ONCOTARGET, V7, P21235, DOI 10.18632/oncotarget.6908
   Parekh VV, 2013, J IMMUNOL, V190, P5086, DOI 10.4049/jimmunol.1202071
   Pinto A, 2011, CANCER IMMUNOL IMMUN, V60, P1211, DOI 10.1007/s00262-011-1057-8
   Pua HH, 2009, AUTOPHAGY, V5, P745, DOI 10.4161/auto.5.5.8702
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Schernhammer ES, 2003, JNCI-J NATL CANCER I, V95, P825, DOI 10.1093/jnci/95.11.825
   Shaw MH, 2011, TRENDS IMMUNOL, V32, P73, DOI 10.1016/j.it.2010.12.007
   Shen Y, 2008, AUTOPHAGY, V4, P1067, DOI 10.4161/auto.6827
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Sui XB, 2011, AUTOPHAGY, V7, P565, DOI 10.4161/auto.7.6.14073
   Tang D, 2010, ONCOGENE, V29, P5299, DOI 10.1038/onc.2010.261
   Travassos LH, 2010, NAT IMMUNOL, V11, P55, DOI 10.1038/ni.1823
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Willinger T, 2012, P NATL ACAD SCI USA, V109, P8670, DOI 10.1073/pnas.1205305109
   Xu Yi, 2010, Proc Am Thorac Soc, V7, P22, DOI 10.1513/pats.200909-103JS
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
   Yuan XP, 2015, EXP CELL RES, V330, P267, DOI 10.1016/j.yexcr.2014.09.006
   Zhan ZZ, 2014, AUTOPHAGY, V10, P257, DOI 10.4161/auto.27162
   Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051
   Zhou M, 2015, EXP CELL RES, V331, P320, DOI 10.1016/j.yexcr.2014.10.015
NR 62
TC 19
Z9 20
U1 1
U2 14
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2017
VL 18
IS 8
AR 1694
DI 10.3390/ijms18081694
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA FF4HB
UT WOS:000408897400095
PM 28771183
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Wang, X
   Xu, YM
   Li, T
   Chen, B
   Yang, WQ
AF Wang, Xu
   Xu, Yuanmin
   Li, Ting
   Chen, Bo
   Yang, Wenqi
TI Development of prognosis model for colon cancer based on
   autophagy-related genes
SO WORLD JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Article
DE Autophagy-related genes; Prognosis model; Colon cancer; TCGA
ID COLORECTAL-CANCER; YOUNGER
AB \Background: Autophagy is an orderly catabolic process for degrading and removing unnecessary or dysfunctional cellular components such as proteins and organelles. Although autophagy is known to play an important role in various types of cancer, the effects of autophagy-related genes (ARGs) on colon cancer have not been well studied.
   Methods: Expression profiles from ARGs in 457 colon cancer patients were retrieved from the TCGA database (https://portal.gdc.cancer.gov). Differentially expressed ARGs and ARGs related to overall patient survival were identified. Cox proportional-hazard models were used to investigate the association between ARG expression profiles and patient prognosis.
   Results: Twenty ARGs were significantly associated with the overall survival of colon cancer patients. Five of these ARGs had a mutation rate >= 3%. Patients were divided into high-risk and low-risk groups based on Cox regression analysis of 8 ARGs. Low-risk patients had a significantly longer survival time than high-risk patients (p < 0.001). Univariate and multivariate Cox regression analysis showed that the resulting risk score, which was associated with infiltration depth and metastasis, could be an independent predictor of patient survival. A nomogram was established to predict 1-, 3-, and 5-year survival of colon cancer patients based on 5 independent prognosis factors, including the risk score. The prognostic nomogram with online webserver was more effective and convenient to provide information for researchers and clinicians.
   Conclusion: The 8 ARGs can be used to predict the prognosis of patients and provide information for their individualized treatment.
C1 [Wang, Xu; Xu, Yuanmin; Li, Ting; Chen, Bo; Yang, Wenqi] Anhui Med Univ, Affiliated Hosp 1, Dept Gen Surg, Hefei 230032, Anhui, Peoples R China.
RP Yang, WQ (corresponding author), Anhui Med Univ, Affiliated Hosp 1, Dept Gen Surg, Hefei 230032, Anhui, Peoples R China.
EM doctoryangwenqi@sina.com
FU Key Research and Development Plan Projects of Anhui Province
   [201904a07020055]
FX The Key Research and Development Plan Projects of Anhui Province (No.
   201904a07020055).
CR Balachandran VP, 2015, LANCET ONCOL, V16, pE173, DOI 10.1016/S1470-2045(14)71116-7
   Bhandari A, 2017, J INVEST MED, V65, P311, DOI 10.1136/jim-2016-000229
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   D'Arcangelo D, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/1471682
   Devenport SN, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111349
   Doonan BB, 2017, IN VITRO CELL DEV-AN, V53, P575, DOI 10.1007/s11626-017-0174-x
   Dulak AM, 2013, NAT GENET, V45, P478, DOI 10.1038/ng.2591
   Gil J, 2018, MED ONCOL, V35, DOI 10.1007/s12032-018-1220-6
   Goruppi S, 2017, CELL REP, V20, P2468, DOI 10.1016/j.celrep.2017.08.048
   Hu WW, 2007, NATURE, V450, P721, DOI 10.1038/nature05993
   Iasonos A, 2008, J CLIN ONCOL, V26, P1364, DOI 10.1200/JCO.2007.12.9791
   Kamburov A, 2015, P NATL ACAD SCI USA, V112, pE5486, DOI 10.1073/pnas.1516373112
   Kwon CH, 2015, ONCOTARGET, V6, P20312, DOI 10.18632/oncotarget.3964
   Lee SJ, 2014, ANN SURG ONCOL, V21, pS634, DOI 10.1245/s10434-014-3729-z
   Lenz Heinz-Josef, 2008, Gastrointest Cancer Res, V2, P203
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Russo AG, 2019, CANCER EPIDEMIOL, V60, P134, DOI 10.1016/j.canep.2019.03.015
   Salemi M, 2014, HUM CELL, V27, P172, DOI 10.1007/s13577-013-0076-5
   Schroll MM, 2016, NUTR RES, V36, P1068, DOI 10.1016/j.nutres.2016.08.002
   Tian XQ, 2015, ONCOTARGETS THER, V8, P1691, DOI 10.2147/OTT.S81621
   Yuan WZ, 2019, J MOL MED, V97, P89, DOI 10.1007/s00109-018-1716-8
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
NR 24
TC 4
Z9 4
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477-7819
J9 WORLD J SURG ONCOL
JI World J. Surg. Oncol.
PD OCT 30
PY 2020
VL 18
IS 1
AR 285
DI 10.1186/s12957-020-02061-w
PG 8
WC Oncology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Surgery
GA OP4NN
UT WOS:000588058700003
PM 33126898
OA gold, Green Submitted, Green Published
DA 2022-04-25
ER

PT J
AU Xu, JS
   Dai, SQ
   Yuan, Y
   Xiao, Q
   Ding, KF
AF Xu, Jiasheng
   Dai, Siqi
   Yuan, Ying
   Xiao, Qian
   Ding, Kefeng
TI A Prognostic Model for Colon Cancer Patients Based on Eight Signature
   Autophagy Genes
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE colon cancer; autophagy genes; prognostic model; TCGA; prognostic
   markers
ID COLORECTAL-CANCER; STATISTICS; SURVIVAL; THERAPY; DEATH; CELLS
AB Objective: To screen key autophagy genes in colon cancer and construct an autophagy gene model to predict the prognosis of patients with colon cancer.
   Methods: The colon cancer data from the TCGA were downloaded as the training set, data chip of GSE17536 as the validation set. The differential genes of the training set were obtained and were analyzed for enrichment and protein network. Acquire autophagy genes from Human Autophagy Database . Autophagy genes in differentially expressed genes were extracted using R-packages limma. Using LASSO/Cox regression analysis combined with clinical information to construct the autophagy gene risk scoring model and divide the samples into high and low risk groups according to the risk value. The Nomogram assessment model was used to predict patient outcomes. CIBERSORT was used to calculate the infiltration of immune cells in the samples and study the relationship between high and low risk groups and immune checkpoints.
   Results: Nine hundred seventy-six differentially expressed genes were screened from training set, including five hundred sixty-eight up-regulated genes and four hundred eight down regulated genes. These differentially expressed genes were mainly involved: the regulation of membrane potential, neuroactive ligand-receptor interaction. We identified eight autophagy genes CTSD, ULK3, CDKN2A, NRG1, ATG4B, ULK1, DAPK1, and SERPINA1 as key prognostic genes and constructed the model after extracting the differential autophagy genes in the training set. Survival analysis showed significant differences in sample survival time after grouping according to the model. Nomogram assessment showed that the model had high reliability for predicting the survival of patients with colon cancer in the 1, 3, 5 years. In the high-risk group, the infiltration degrees of nine types of immune cells are different and the samples can be well distinguished according to these nine types of immune cells. Immunological checkpoint correlation results showed that the expression levels of CTLA4, IDO1, LAG3, PDL1, and TIGIT increased in high-risk groups.
   Conclusion: The prognosis prediction model based on autophagy gene has a good evaluation effect on the prognosis of colon cancer patients. Eight key autophagy genes can be used as prognostic markers for colon cancer.
C1 [Xu, Jiasheng; Dai, Siqi; Xiao, Qian; Ding, Kefeng] Zhejiang Univ, Affiliated Hosp 2, Dept Colorectal Surg & Oncol, Minist Educ,Key Lab Canc Prevent & Intervent,Sch, Hangzhou, Peoples R China.
   [Xu, Jiasheng; Dai, Siqi; Yuan, Ying; Xiao, Qian; Ding, Kefeng] Zhejiang Univ, Canc Ctr, Hangzhou, Peoples R China.
   [Yuan, Ying] Zhejiang Univ, Affiliated Hosp 2, Dept Med Oncol, Sch Med, Hangzhou, Peoples R China.
RP Ding, KF (corresponding author), Zhejiang Univ, Affiliated Hosp 2, Dept Colorectal Surg & Oncol, Minist Educ,Key Lab Canc Prevent & Intervent,Sch, Hangzhou, Peoples R China.; Ding, KF (corresponding author), Zhejiang Univ, Canc Ctr, Hangzhou, Peoples R China.
EM dingkefeng@zju.edu.cn
FU National Key R&D Program of China [2017YFC0908200]; Key Technology
   Research and Development Program of Zhejiang Province [2017C03017];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81772545]; Project of the regional diagnosis
   and treatment center of the Health Planning Committee [JBZX-201903]
FX The authors' research was supported by the research fund of the National
   Key R&D Program of China (2017YFC0908200), the Key Technology Research
   and Development Program of Zhejiang Province (No. 2017C03017), Project
   of the regional diagnosis and treatment center of the Health Planning
   Committee (No. JBZX-201903), and National Natural Science Foundation of
   China (No. 81772545).
CR American Cancer Society, 2017, CANC FACTS FIG 2015
   Bhardwaj M, 2018, ONCOTARGET, V9, P3278, DOI 10.18632/oncotarget.22890
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Cheng Y, 2013, PHARMACOL REV, V65, P1162, DOI 10.1124/pr.112.007120
   Edwards BK, 2014, CANCER-AM CANCER SOC, V120, P1290, DOI 10.1002/cncr.28509
   Eskelinen EL, 2011, CURR OPIN PHARMACOL, V11, P294, DOI 10.1016/j.coph.2011.03.009
   Fang C, 2017, CANCER MED-US, V6, P2850, DOI 10.1002/cam4.1241
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Fulda S, 2015, ONCOGENE, V34, P5105, DOI 10.1038/onc.2014.458
   Gade TPF, 2017, RADIOLOGY, V283, P701, DOI 10.1148/radiol.2017160728
   Goruppi S, 2017, CELL REP, V20, P2468, DOI 10.1016/j.celrep.2017.08.048
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Kumar Priyank, 2012, Cells, V1, P558, DOI 10.3390/cells1030558
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li ZL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0518-9
   Liu J, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-1054-0
   Lu WQ, 2017, ONCOTARGET, V8, P44171, DOI 10.18632/oncotarget.17396
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Martinet W, 2009, CIRC RES, V104, P304, DOI 10.1161/CIRCRESAHA.108.188318
   Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Ni ZH, 2018, AUTOPHAGY, V14, P685, DOI 10.1080/15548627.2017.1407887
   Shen SS, 2017, INT J ONCOL, V50, P1289, DOI 10.3892/ijo.2017.3911
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Thongchot S, 2018, MOL CARCINOGEN, V57, P1735, DOI 10.1002/mc.22893
   Yan S, 2014, CANCER GENE THER, V21, P188, DOI 10.1038/cgt.2014.16
   Yan SY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215415
NR 33
TC 12
Z9 12
U1 2
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD NOV 26
PY 2020
VL 8
AR 602174
DI 10.3389/fcell.2020.602174
PG 13
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA PC2RO
UT WOS:000596854500001
PM 33324651
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Wang, R
   Xiao, X
   Wang, PY
   Wang, L
   Guan, QN
   Du, CG
   Wang, XJ
AF Wang, Rong
   Xiao, Xin
   Wang, Peng-Yuan
   Wang, Lin
   Guan, Qiunong
   Du, Caigan
   Wang, Xiao-Juan
TI Stimulation of autophagic activity in human glioma cells by
   anti-proliferative ardipusilloside I isolated from Ardisia pusilla
SO LIFE SCIENCES
LA English
DT Article
DE Ardipusilloside I; Natural compound; Triterpenoid saponin; Ardisia
   pusilla; Human glioblastoma; Autophagy; Apoptosis
ID GLIOBLASTOMA U251MG CELLS; COLON-CANCER CELLS; TRITERPENOID SAPONINS;
   SIGNALING PATHWAYS; APOPTOSIS; DEATH; INHIBITION; MACROAUTOPHAGY;
   PROLIFERATION; MECHANISMS
AB Aims: Ardipusilloside I (ADS-I), a triterpenoid saponin isolated from Ardisia pusilla A. DC (Myrsinaceae), has been recently tested for cancer treatment including brain cancer. However, the mechanism of its action remains elusive. The present study was to investigate the role of autophagy activation in the anti-tumor activities of ADS-I in human glioma cells.
   Main methods: The tetrazolium dye (MTT) colorimetric assay was used for the measurement of cell proliferation in cultured glioma cells, transmission electron microscopy (TEM) for the examination of autophagic activity, flow cytometric analysis for the determination of cell cycle and apoptotic cells, and immunocytochemistry and Western blot for protein expression of microtubule-associated protein light-chain 3 (LC3) and Beclin 1.
   Key findings: ADS-I significantly inhibited the proliferation of both U373 and T98G glioma cells in cultures in a dose-dependent manner. The cytotoxic activity of ADS-I against glioma cell growth was associated not only with the induction of cell cycle arrest at G(2)/M phase and cell apoptosis in flow cytometric analysis, but also with the activation of autophagy, indicated by the formation of autophagosomes and up-regulated expression of both autophagic protein Beclin 1 and LC3 in glioma cells. Additionally, the treatment with chloroquine, an autophagy inhibitor, reduced ADS-1-mediated cell death.
   Significance: These data suggest that the anti-proliferative activity of ADS-I in human glioma cells is associated with the activation of autophagy in addition to cell cycle arrest and apoptosis, and the antagonistic effect of chloroquine suggests an important role of autophagy in ADS-I-mediated cell death against tumor growth. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Wang, Rong; Xiao, Xin; Wang, Peng-Yuan; Wang, Lin; Wang, Xiao-Juan] Fourth Mil Med Univ, Sch Stomatol, Dept Pharm, Xian 710032, Shaanxi, Peoples R China.
   [Wang, Rong] Xi An Jiao Tong Univ, Dept Pharmacol, Coll Med, Xian 710061, Shaanxi, Peoples R China.
   [Guan, Qiunong; Du, Caigan] Univ British Columbia, Dept Urol Sci, Vancouver, BC V6H 3Z6, Canada.
RP Du, CG (corresponding author), Jack Bell Res Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.
EM caigan@mail.ubc.ca; wxjyh231@fmmu.edu.cn
FU National Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [30973623]; Shaanxi Science and Technology Innovation
   project plan as a whole project [2011KTCL03-01]; project of the
   Administration of Traditional Chinese Medicine of Shaanxi [13-ZY041]
FX The authors greatly appreciate the financial support from the National
   Science Foundation of China (grant no. 30973623), Shaanxi Science and
   Technology Innovation project plan as a whole project (grant no.
   2011KTCL03-01) and project of the Administration of Traditional Chinese
   Medicine of Shaanxi (grant no. 13-ZY041).
CR Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Barazzuol L, 2012, RADIAT RES, V177, P651, DOI 10.1667/RR2803.1
   Bommareddy A, 2009, CANCER RES, V69, P3704, DOI 10.1158/0008-5472.CAN-08-4344
   Bursch W, 2000, ANN NY ACAD SCI, V926, P1, DOI 10.1111/j.1749-6632.2000.tb05594.x
   Carew Jennifer S, 2012, Cancer Manag Res, V4, P357, DOI 10.2147/CMAR.S26133
   Chen YQ, 2010, CAN J PHYSIOL PHARM, V88, P285, DOI 10.1139/Y10-010
   [程江雪 Cheng Jiangxue], 2012, [中草药, Chinese Traditional and Herbal Drugs], V43, P1923
   Chu TLH, 2013, INT IMMUNOPHARMACOL, V16, P414, DOI 10.1016/j.intimp.2013.04.031
   DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6
   DERIDDER LI, 1987, ACTA NEUROPATHOL, V72, P207, DOI 10.1007/BF00691091
   Ellington AA, 2006, CARCINOGENESIS, V27, P298, DOI 10.1093/carcin/bgi214
   Ellington AA, 2005, CARCINOGENESIS, V26, P159, DOI 10.1093/carcin/bgh297
   Eskelinen EL, 2011, AUTOPHAGY, V7, P935, DOI 10.4161/auto.7.9.15760
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Liao AJ, 2012, EUR J PHARM SCI, V45, P600, DOI 10.1016/j.ejps.2011.12.014
   Lin H, 2008, APOPTOSIS, V13, P247, DOI 10.1007/s10495-007-0170-9
   Lou LQ, 2012, PHYTOMEDICINE, V19, P603, DOI 10.1016/j.phymed.2012.01.003
   Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005
   Nguan CYC, 2014, AM J PHYSIOL-RENAL, V306, pF724, DOI 10.1152/ajprenal.00410.2013
   Rikiishi Hidemi, 2012, Int J Cell Biol, V2012, P317645, DOI 10.1155/2012/317645
   Schoenherr D, 2013, INT J RADIAT BIOL, V89, P1009, DOI 10.3109/09553002.2013.825061
   STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107
   Tang HF, 2009, CHEM BIODIVERS, V6, P1443, DOI 10.1002/cbdv.200800233
   Tao Xiaojun, 2005, Zhong Yao Cai, V28, P574
   Tasdemir Ezgi, 2008, V445, P29, DOI 10.1007/978-1-59745-157-4_3
   Theron AE, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-87
   Tian Y, 2009, PLANTA MED, V75, P70, DOI 10.1055/s-0028-1088369
   Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777
   Turcotte S, 2010, CURR OPIN CELL BIOL, V22, P246, DOI 10.1016/j.ceb.2009.12.007
   Wang R, 2012, J ASIAN NAT PROD RES, V14, P55, DOI 10.1080/10286020.2011.631182
   Wang SY, 2011, INT J BIOCHEM CELL B, V43, P1263, DOI 10.1016/j.biocel.2011.05.010
   Wei K, 2012, CNS NEUROSCI THER, V18, P879, DOI 10.1111/cns.12005
   Xia YH, 2011, FITOTERAPIA, V82, P1258, DOI 10.1016/j.fitote.2011.08.015
   Xiong J, 2009, ENVIRON TOXICOL PHAR, V27, P264, DOI 10.1016/j.etap.2008.11.008
   Xu XF, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-322
   Xu ZX, 2007, CELL DEATH DIFFER, V14, P1948, DOI 10.1038/sj.cdd.4402207
   Yu XJ, 2012, CANCER LETT, V322, P185, DOI 10.1016/j.canlet.2012.03.004
   Zhang Q H, 1993, Yao Xue Xue Bao, V28, P673
   Zhang YM, 2010, PHYTOMEDICINE, V17, P519, DOI 10.1016/j.phymed.2009.09.001
NR 44
TC 10
Z9 13
U1 2
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD AUG 6
PY 2014
VL 110
IS 1
BP 15
EP 22
DI 10.1016/j.lfs.2014.06.016
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA AL6QS
UT WOS:000339258300003
PM 24984215
DA 2022-04-25
ER

PT J
AU Skarkova, V
   Kralova, V
   Vitovcova, B
   Rudolf, E
AF Skarkova, Veronika
   Kralova, Vera
   Vitovcova, Barbora
   Rudolf, Emil
TI Selected Aspects of Chemoresistance Mechanisms in Colorectal CarcinomaA
   Focus on Epithelial-to-Mesenchymal Transition, Autophagy, and Apoptosis
SO CELLS
LA English
DT Review
DE colorectal carcinoma (CRC); chemoresistance; epithelial-to-mesenchymal
   transition (EMT); autophagy; apoptosis
ID III COLON-CANCER; ABERRANT CRYPT FOCI; DRUG-RESISTANCE; E-CADHERIN;
   PROGNOSTIC-SIGNIFICANCE; SMAC/DIABLO EXPRESSION; PROTEIN EXPRESSION;
   ADJUVANT THERAPY; BETA-CATENIN; TUMOR-GROWTH
AB Chemoresistance has been found in all malignant tumors including colorectal carcinoma (CRC). Nowadays chemoresistance is understood as a major reason for therapy failure, with consequent tumor growth and spreading leading ultimately to the patient's premature death. The chemotherapy-related resistance of malignant colonocytes may be manifested in diverse mechanisms that may exist both prior to the onset of the therapy or after it. The ultimate function of this chemoresistance is to ensure the survival of malignant cells through continuing adaptation within an organism, therefore, the nature and spectrum of cell-survival strategies in CRC represent a highly significant target of scientific inquiry. Among these survival strategies employed by CRC cells, three unique but significantly linked phenomena stand outepithelial-to-mesenchymal transition (EMT), autophagy, and cell death. In this mini-review, current knowledge concerning all three mechanisms including their emergence, timeline, regulation, and mutual relationships will be presented and discussed.
C1 [Skarkova, Veronika; Kralova, Vera; Vitovcova, Barbora; Rudolf, Emil] Charles Univ Prague, Fac Med Hradec Kralove, Dept Med Biol & Genet, Zborovska 2089, Hradec Kralove 50003, Czech Republic.
RP Rudolf, E (corresponding author), Charles Univ Prague, Fac Med Hradec Kralove, Dept Med Biol & Genet, Zborovska 2089, Hradec Kralove 50003, Czech Republic.
EM hanusovav@lfhk.cuni.cz; kralovav@lfhk.cuni.cz; vitovcob@lfhk.cuni.cz;
   rudolf@lfhk.cuni.cz
RI Rudolf, Emil/B-5956-2017; Králová, Věra/B-6608-2017
OI Rudolf, Emil/0000-0002-9526-3174; Králová, Věra/0000-0001-5971-4110
FU  [GACR 17-10331S]
FX This research was funded by the research project GACR 17-10331S.
CR Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Alberts SR, 2012, JAMA-J AM MED ASSOC, V307, P1383, DOI 10.1001/jama.2012.385
   Amaro A, 2016, CANCER METAST REV, V35, P63, DOI 10.1007/s10555-016-9606-4
   Armaghany Tannaz, 2012, Gastrointest Cancer Res, V5, P19
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Bahnassy AA, 2014, HISTOL HISTOPATHOL, V29, P207, DOI 10.14670/HH-29.207
   Bao Y, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0250-9
   Bellam N, 2010, CANCER TREAT RES, V155, P85, DOI 10.1007/978-1-4419-6033-7_5
   Benson AB, 2017, J NATL COMPR CANC NE, V15, P370, DOI 10.6004/jnccn.2017.0036
   Bertrand M, 2015, CELL CYCLE, V14, P364, DOI 10.4161/15384101.2014.987619
   Bhardwaj M, 2018, ONCOTARGET, V9, P3278, DOI 10.18632/oncotarget.22890
   Bhutia SK, 2013, ADV CANCER RES, V118, P61, DOI 10.1016/B978-0-12-407173-5.00003-0
   Blank A, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00234
   Borras E, 2016, CANCER PREV RES, V9, P417, DOI 10.1158/1940-6207.CAPR-16-0081
   Brachtendorf S, 2018, BBA-MOL CELL BIOL L, V1863, P1214, DOI 10.1016/j.bbalip.2018.07.011
   Brule SY, 2015, EUR J CANCER, V51, P1405, DOI 10.1016/j.ejca.2015.03.015
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Busch EL, 2016, CLIN EXP METASTAS, V33, P53, DOI 10.1007/s10585-015-9757-7
   Cai ZR, 2014, ANN SURG ONCOL, V21, P179, DOI 10.1245/s10434-013-3146-8
   Catalano M, 2015, MOL ONCOL, V9, P1612, DOI 10.1016/j.molonc.2015.04.016
   Chen EB, 2018, J ONCOL, V2018, DOI 10.1155/2018/3979135
   Chen J, 2017, SEMIN IMMUNOL, V32, P43, DOI 10.1016/j.smim.2017.09.006
   Cho DH, 2012, ANTICANCER RES, V32, P4091
   Choi JH, 2014, GASTROENT RES PRACT, V2014, DOI 10.1155/2014/179586
   Choi JH, 2012, APMIS, V120, P597, DOI 10.1111/j.1600-0463.2012.02876.x
   Crea F, 2011, DRUG RESIST UPDATE, V14, P280, DOI 10.1016/j.drup.2011.08.001
   Cummings O W, 2000, Semin Gastrointest Dis, V11, P229
   de Krijger I, 2011, J PATHOL, V224, P438, DOI 10.1002/path.2922
   De Mattia E, 2015, DRUG RESIST UPDATE, V20, P39, DOI 10.1016/j.drup.2015.05.003
   De Smedt L, 2017, BRIT J CANCER, V116, P58, DOI 10.1038/bjc.2016.382
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Dziaman T, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0505-0
   Endo K, 2009, ONCOL REP, V21, P351, DOI 10.3892/or_00000229
   Fakih MG, 2015, J CLIN ONCOL, V33, P1809, DOI 10.1200/JCO.2014.59.7633
   Fan F, 2012, CANCER MED-US, V1, P5, DOI 10.1002/cam4.4
   Fanale D, 2016, ADV EXP MED BIOL, V937, P207, DOI 10.1007/978-3-319-42059-2_11
   Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235
   Findlay VJ, 2014, MOL CANCER THER, V13, P2713, DOI 10.1158/1535-7163.MCT-14-0207
   Fujikawa H, 2012, J GASTROENTEROL, V47, P775, DOI 10.1007/s00535-012-0532-0
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Gil J, 2016, BIOMARK MED, V10, P1081, DOI 10.2217/bmm-2016-0083
   Gill S, 2004, J CLIN ONCOL, V22, P1797, DOI 10.1200/JCO.2004.09.059
   Gong C, 2013, ONCOGENE, V32, P2261, DOI 10.1038/onc.2012.252
   Grossi V, 2014, WORLD J GASTROENTERO, V20, P9744, DOI 10.3748/wjg.v20.i29.9744
   Gugnoni M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.415
   Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058
   Haggar Fatima A, 2009, Clin Colon Rectal Surg, V22, P191, DOI 10.1055/s-0029-1242458
   Haller DG, 2011, J CLIN ONCOL, V29, P1465, DOI 10.1200/JCO.2010.33.6297
   Hammond WA, 2016, THER ADV MED ONCOL, V8, P57, DOI 10.1177/1758834015614530
   Han Y, 2014, ASIAN PAC J CANCER P, V15, P4583, DOI 10.7314/APJCP.2014.15.11.4583
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Hu T, 2016, WORLD J GASTROENTERO, V22, P6876, DOI 10.3748/wjg.v22.i30.6876
   Huang CY, 2015, WORLD J GASTROENTERO, V21, P11777, DOI 10.3748/wjg.v21.i41.11777
   Ikeguchi M, 2000, SCAND J GASTROENTERO, V35, P839
   Jensen NF, 2015, MOL ONCOL, V9, P1169, DOI 10.1016/j.molonc.2015.02.008
   John S, 2013, ANTI-CANCER AGENT ME, V13, P811, DOI 10.2174/1871520611313050015
   Joyce T, 2009, CLIN EXP METASTAS, V26, P569, DOI 10.1007/s10585-009-9256-9
   Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626
   Kim AY, 2015, TOX RESEARCH, V31, P151, DOI 10.5487/TR.2015.31.2.151
   Kim MR, 2007, DIGEST DIS SCI, V52, P2751, DOI 10.1007/s10620-007-9799-z
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Klionsky DJ, 2011, AUTOPHAGY, V7, P1273, DOI 10.4161/auto.7.11.17661
   Koehler BC, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1929-y
   Kosuri KV, 2010, BIOCHEM BIOPH RES CO, V391, P1465, DOI 10.1016/j.bbrc.2009.12.095
   Krajewska M, 2005, CLIN CANCER RES, V11, P5451, DOI 10.1158/1078-0432.CCR-05-0094
   Lai K, 2014, J CLIN PATHOL, V67, P854, DOI 10.1136/jclinpath-2014-202529
   Lee DW, 1996, EUR J CANCER, V32A, P945, DOI 10.1016/0959-8049(96)00046-9
   Levy J, 2015, NAT CELL BIOL, V17, P1062, DOI 10.1038/ncb3206
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Li JP, 2015, MOL MED REP, V12, P192, DOI 10.3892/mmr.2015.3356
   Lippert TH, 2011, INT J MED SCI, V8, P245, DOI 10.7150/ijms.8.245
   Lubner SJ, 2017, J GASTROINTEST ONCOL, V8, P499, DOI 10.21037/jgo.2017.01.16
   Lugli A, 2007, HISTOPATHOLOGY, V50, P453, DOI 10.1111/j.1365-2559.2007.02620.x
   Luqmani YA, 2005, MED PRIN PRACT, V14, P35, DOI 10.1159/000086183
   Ma Qiang, 2015, Hepatogastroenterology, V62, P880
   Marcucci F, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00714
   Marmol I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010197
   Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P3515, DOI 10.4161/cc.9.17.12928
   Mathonnet M, 2014, WORLD J GASTROENTERO, V20, P4189, DOI 10.3748/wjg.v20.i15.4189
   Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714
   Miquel C, 2005, AM J CLIN PATHOL, V123, P562, DOI 10.1309/JQ2X3RV3L8F9TGYW
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Moriwaki K, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.16
   Mumenthaler SM, 2015, CANCER INFORM, V14, P19, DOI 10.4137/CIN.S19338
   Mundade Rasika, 2014, Oncoscience, V1, P400
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   O'Neil BH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189848
   Olmeda D, 2007, ONCOGENE, V26, P1862, DOI 10.1038/sj.onc.1209997
   Panda PK, 2015, SEMIN CELL DEV BIOL, V39, P43, DOI 10.1016/j.semcdb.2015.02.013
   Pandurangan AK, 2018, WORLD J GASTRO ONCOL, V10, P244, DOI 10.4251/wjgo.v10.i9.244
   Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026
   Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954
   Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131
   Qian HR, 2017, ONCOTARGET, V8, P62759, DOI 10.18632/oncotarget.18663
   Radtke F, 2006, CURR MOL MED, V6, P275, DOI 10.2174/156652406776894527
   Ren BJ, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010041
   Ren J, 2018, THERANOSTICS, V8, P3932, DOI 10.7150/thno.25541
   Roca F, 2006, J SURG ONCOL, V93, P151, DOI 10.1002/jso.20413
   Roy S, 2010, SEMIN IMMUNOPATHOL, V32, P383, DOI 10.1007/s00281-010-0213-0
   Rustgi AK, 2007, GENE DEV, V21, P2525, DOI 10.1101/gad.1593107
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Schmoll HJ, 2014, NAT REV CLIN ONCOL, V11, P79, DOI 10.1038/nrclinonc.2013.254
   Scopa CD, 2003, DIGEST DIS SCI, V48, P1990, DOI 10.1023/A:1026178506348
   Shan ZZ, 2015, AM J CANCER RES, V5, P344
   Shanmugathasan M, 2000, PATHOL INT, V50, P273, DOI 10.1046/j.1440-1827.2000.01047.x
   Shen H, 2018, J CELL BIOCHEM, V119, P7022, DOI 10.1002/jcb.26912
   Shintani M, 2014, ONCOL LETT, V8, P2581, DOI 10.3892/ol.2014.2598
   Sipos F, 2012, WORLD J GASTROENTERO, V18, P601, DOI 10.3748/wjg.v18.i7.601
   Su ZY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0321-5
   Suehiro Y, 2008, CANCER SCI, V99, P1071, DOI 10.1111/j.1349-7006.2008.00784.x
   Suman S, 2014, MOL CARCINOGEN, V53, pE151, DOI 10.1002/mc.22076
   Takayama T, 1998, NEW ENGL J MED, V339, P1277, DOI 10.1056/NEJM199810293391803
   Tato-Costa J, 2016, CLIN COLORECTAL CANC, V15, P170, DOI 10.1016/j.clcc.2015.09.003
   Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058
   Testa Ugo, 2018, Med Sci (Basel), V6, DOI 10.3390/medsci6020031
   Tiwari N, 2012, SEMIN CANCER BIOL, V22, P194, DOI 10.1016/j.semcancer.2012.02.013
   Tsoumas D, 2018, CANCER GENOM PROTEOM, V15, P127, DOI 10.21873/cgp.20071
   Twelves C, 2012, ANN ONCOL, V23, P1190, DOI 10.1093/annonc/mdr366
   Vachon PH, 2018, METHODS MOL BIOL, V1765, P99, DOI 10.1007/978-1-4939-7765-9_7
   Vaque JP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119946
   Vogel A, 2017, CANCER TREAT REV, V59, P54, DOI 10.1016/j.ctrv.2017.04.007
   Wilson TR, 2006, ANN ONCOL, V17, pX315, DOI 10.1093/annonc/mdl280
   Wilson TR, 2007, CANCER RES, V67, P5754, DOI 10.1158/0008-5472.CAN-06-3585
   Wu SH, 2015, INT J CLIN EXP PATHO, V8, P3882
   Xiang GA, 2009, J SURG ONCOL, V100, P708, DOI 10.1002/jso.21408
   Yamamoto H, 2015, ARCH TOXICOL, V89, P899, DOI 10.1007/s00204-015-1474-0
   Yang AD, 2006, CLIN CANCER RES, V12, P4147, DOI 10.1158/1078-0432.CCR-06-0038
   Yang MP, 2015, ONCOTARGET, V6, P7084, DOI 10.18632/oncotarget.3054
   Yang Y, 2017, INT J ONCOL, V51, P515, DOI 10.3892/ijo.2017.4044
   Ye ZY, 2015, INT J CLIN EXP MED, V8, P3707
   Zhang L, 2013, CURR COLORECT CANC R, V9, P331, DOI 10.1007/s11888-013-0188-z
   Zhang MY, 2019, ONCOL LETT, V17, P2441, DOI 10.3892/ol.2018.9817
   Zhang X, 2016, J CANCER RES CLIN, V142, P453, DOI 10.1007/s00432-015-1997-z
   Zheng HC, 2017, ONCOTARGET, V8, P59950, DOI 10.18632/oncotarget.19048
NR 136
TC 30
Z9 30
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD MAR
PY 2019
VL 8
IS 3
AR 234
DI 10.3390/cells8030234
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA HU9UV
UT WOS:000465640400002
PM 30871055
OA Green Submitted, gold, Green Published
DA 2022-04-25
ER

PT J
AU Zhang, P
   Pan, Y
   Sun, JJ
   Pan, GY
AF Zhang, Peng
   Pan, Yan
   Sun, Jujun
   Pan, Gaiyan
TI Aberrant expression of LncRNA CASC2 mediated the cell viability,
   apoptosis and autophagy of colon cancer cells by sponging miR-19a via
   NF-kappa B signaling pathway
SO INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE apoptosis; autophagy; cell viability; colon cancer; lncRNA CASC2;
   NF&#8208; &#954; B
ID COLORECTAL-CANCER; RNA; PROLIFERATION; PROGRESSION
AB Abnormal and rapid proliferation of colon cancer cells is a severe problem that can be regulated by non-coding RNAs. Thus, our study focused on effects of lncRNA CASC2 and miR-19a on colon cancer cells. Expressions of lncRNA CASC2, miR-19a, Bcl-2, Bax and NF-kappa B/p65 were examined by RT-qPCR. Cell viabilities were detected by CCK-8. A luciferase report assay was used for measuring binding conditions between lncRNA CASC2 and miR-19a. Western blotting was used to evaluate expression of LC3-I, LC3-II and p62 related to autophagy. Expression of lncRNA CASC2 lower in cancer cell lines and the overexpression reduced the cell viability of HT29 and SW480. Furthermore, Bcl-2 was suppressed by overexpressed lncRNA CASC2, while Bax was upregulated. LC3-? and p62 were both inhibited, but LC3-II was promoted. MiR-19a was predicted to bind lncRNA CASC2 and expressed higher in cancer cell lines. Overexpressed miR-19a reduced expression of lncRNA CASC2 and increased cell viability. This was repressed by upregulated lncRNA CASC2. Bcl-2 and Bax expression and proteins implicated in autophagy that are regulated by lncRNA CASC2 upregulation were reversed by miR-19a overexpression. NF-kappa B was upregulated in colon cancer cell lines, while inhibition of NF-kappa B reversed functions of lncRNA CASC2 and magnified roles of miR-19a. Our findings showed that lncRNA CASC2 inhibited cell viability in colon cancer cell lines and miR-19a reversed its functions through the NF-kappa B signalling pathway, suggesting that these could be factors in treating colon cancer in the future.
C1 [Zhang, Peng] Xian Union Hosp, Xian, Shaanxi, Peoples R China.
   [Pan, Yan] Xian Cent Hosp, Xian, Shaanxi, Peoples R China.
   [Sun, Jujun] Xian XD Grp Hosp, Xian, Shaanxi, Peoples R China.
   [Pan, Gaiyan] Shaanxi Univ Chinese Med, Affiliated Hosp, Xian 710000, Shaanxi, Peoples R China.
RP Pan, GY (corresponding author), Shaanxi Univ Chinese Med, Affiliated Hosp, Xian 710000, Shaanxi, Peoples R China.
EM naiikai812984@163.com
CR Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238
   Becker H, 1995, Praxis (Bern 1994), V84, P1371
   Braconi C, 2011, ONCOGENE, V30, P4750, DOI 10.1038/onc.2011.193
   Brosnan CA, 2009, CURR OPIN CELL BIOL, V21, P416, DOI 10.1016/j.ceb.2009.04.001
   Buttner R, 2019, PATHOLOGE, V40, P584, DOI 10.1007/s00292-019-0643-y
   Calin GA, 2007, CANCER CELL, V12, P215, DOI 10.1016/j.ccr.2007.07.027
   Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239
   Ellis BC, 2014, BBA-MOL CELL RES, V1843, P372, DOI 10.1016/j.bbamcr.2013.10.016
   Epinat JC, 1999, ONCOGENE, V18, P6896, DOI 10.1038/sj.onc.1203218
   Graham Lloyd D, 2011, Genes Cancer, V2, P829, DOI 10.1177/1947601911431081
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   He XZ, 2016, TUMOR BIOL, V37, P9503, DOI 10.1007/s13277-016-4787-6
   Huang GL, 2016, SCI REP-UK, V6, DOI 10.1038/srep26524
   Huxley RR, 2009, INT J CANCER, V125, P171, DOI 10.1002/ijc.24343
   Ju BL, 2020, AM J TRANSL RES, V12, P2695
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li YX, 2018, BIOMED PHARMACOTHER, V108, P1775, DOI 10.1016/j.biopha.2018.09.181
   Liu YM, 2018, J CELL BIOCHEM, V119, P358, DOI 10.1002/jcb.26188
   Liu YQ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0625-8
   Liu ZY, 2020, J CELL PHYSIOL, V235, P1494, DOI 10.1002/jcp.29069
   Luo Sheng-lan, 2013, Zhonghua Liu Xing Bing Xue Za Zhi, V34, P1194
   Marques AC, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r124
   Mu P, 2009, GENE DEV, V23, P2806, DOI 10.1101/gad.1872909
   Nissan A, 2012, INT J CANCER, V130, P1598, DOI 10.1002/ijc.26170
   OBRIEN JM, 2000, NEW ENGL J MED, V45, P167
   Olive V, 2009, GENE DEV, V23, P2839, DOI 10.1101/gad.1861409
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Rong L, 2020, BIOMED PHARMACOTHER, V122, DOI 10.1016/j.biopha.2019.109726
   SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Sun K, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-019-0353-4
   Tong JF, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190452
   Tsai HL, 2009, INT J COLORECTAL DIS, V24, P177, DOI 10.1007/s00384-008-0594-x
   Xiao T, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1113-9
   Xu DF, 2020, INT J ONCOL, V56, P494, DOI 10.3892/ijo.2019.4937
   Zhang B, 2019, ONCOL LETT, V17, P414, DOI 10.3892/ol.2018.9592
   Zhang SX, 2018, BIOMED PHARMACOTHER, V102, P302, DOI 10.1016/j.biopha.2018.03.071
   Zhang YK, 2019, ONCOL RES, V27, P371, DOI 10.3727/096504018X15178740729367
   Zhao L, 2018, J CELL PHYSIOL, V233, P6661, DOI 10.1002/jcp.26446
   Zhou JF, 2017, MOL MED REP, V16, P5235, DOI 10.3892/mmr.2017.7233
   Zhou PP, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3829-9
NR 41
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0959-9673
EI 1365-2613
J9 INT J EXP PATHOL
JI Int. J. Exp. Pathol.
PD JUN
PY 2021
VL 102
IS 3
BP 163
EP 171
DI 10.1111/iep.12393
EA MAY 2021
PG 9
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA SF3JV
UT WOS:000649822900001
PM 33983643
DA 2022-04-25
ER

PT J
AU Ouyang, GQ
   Xiong, L
   Liu, ZP
   Lam, B
   Bui, B
   Ma, L
   Chen, X
   Zhou, P
   Wang, KP
   Zhang, ZJ
   Huang, H
   Miao, XY
   Chen, W
   Wen, Y
AF Ouyang, Guoqing
   Xiong, Li
   Liu, Zhipeng
   Lam, Brandon
   Bui, Brian
   Ma, Lun
   Chen, Xiang
   Zhou, Pan
   Wang, Kunpeng
   Zhang, Zijian
   Huang, He
   Miao, Xiongying
   Chen, Wei
   Wen, Yu
TI Inhibition of autophagy potentiates the apoptosis-inducing effects of
   photodynamic therapy on human colon cancer cells
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE Apoptosis; Autophagy; Colorectal cancer; Photodynamic therapy; Porphyrin
   IX
ID COLORECTAL-CANCER; STATISTICS; RESPONSES; BCL-2; PHOTOSENSITIZERS;
   ACCUMULATION; MECHANISMS; RESISTANCE; PATHWAY; DEATH
AB Background: Photodynamic therapy (PDT) has been reported to be a promising therapy for colon cancer because of its substantial safety features and its ability to induce a systematic reaction rather than local effects on the focal lesion in the intestine. Autophagy and apoptosis play important roles in the response to PDT. However, the role of autophagy after PDT treatment has not yet been clarified.
   Methods: In this study, we investigated the relationship between apoptosis and autophagy in porphyrin IX (PpIX)-mediated PDT (PpIX-PDT) in HCT116 colon cancer cells. PpIX-PDT decreased cell viability in a concentration-and light dose-dependent manner.
   Results: PpIX-PDT results in nuclear condensation, increased the expression of Caspase-3, Bax, and PARP, and decreased expression of Bcl-2. PpIX-PDT also induces the double membrane autophagosome, up-regulates LC3B, Atg7, Beclin-1, and Bcl-2 expression and down-regulates P62 expression. Inhibition of autophagy using chloroquine (CQ) or Atg7 knockdown with a shRNA enhances apoptotic cell death. Based on these findings, autophagy plays a self-protective role in HCT116 cells in response to PpIX-PDT treatment.
   Discussion: Both autophagy and apoptosis were induced by PpIX-PDT in HCT116 cells, and the inhibition of autophagy strengthened the proapoptotic effect of PpIX-PDT. Thus, the appropriate modulation of autophagy may be as a potential therapeutic target for colon cancer cells treated with PpIX-PDT.
C1 [Ouyang, Guoqing; Xiong, Li; Liu, Zhipeng; Chen, Xiang; Zhou, Pan; Wang, Kunpeng; Zhang, Zijian; Miao, Xiongying; Wen, Yu] Cent South Univ, Xiangya Hosp 2, Dept Gen Surg, Changsha 410011, Hunan, Peoples R China.
   [Lam, Brandon; Bui, Brian; Ma, Lun; Chen, Wei] Univ Texas Arlington, Dept Phys, Arlington, TX 76019 USA.
   [Lam, Brandon; Bui, Brian; Ma, Lun; Chen, Wei] Univ Texas Arlington, SAVANT Ctr, Arlington, TX 76019 USA.
   [Ouyang, Guoqing] Liuzhou Peoples Hosp, Dept Hepatobiliary Surg, Liuzhou 545000, Guangxi, Peoples R China.
   [Huang, He] Cent South Univ, Xiangya Sch Med, Changsha 410078, Hunan, Peoples R China.
RP Wen, Y (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Gen Surg, Changsha 410011, Hunan, Peoples R China.; Chen, W (corresponding author), Univ Texas Arlington, Dept Phys, Arlington, TX 76019 USA.; Chen, W (corresponding author), Univ Texas Arlington, SAVANT Ctr, Arlington, TX 76019 USA.
EM weichen@uta.edu; wenyu2861@csu.edu.cn
RI wen, yu/AAJ-7482-2021
FU Chinese National Natural Science Foundation of ChinaNational Natural
   Science Foundation of China (NSFC) [81773293]; Keypoint Research and
   Invention Program of Hunan Province [2017DK2010]; Development and Reform
   Commission of Hunan [201583]; Fundamental Research Funds for the Central
   South University [2016zzts537]; Furong Scholarship from Central South
   University; U.S. Army Medical Research Acquisition Activity (USAMRAA)
   [W81XWH-10-1-0279, W81XWH-10-1-0234]
FX This work was supported by the Chinese National Natural Science
   Foundation of China(Grant 81773293), the Keypoint Research and Invention
   Program of Hunan Province (2017DK2010), Development and Reform
   Commission of Hunan (Grant 201583), the Fundamental Research Funds for
   the Central South University (grant 2016zzts537), the Furong Scholarship
   from Central South University, the support from the U.S. Army Medical
   Research Acquisition Activity (USAMRAA) under Contracts of
   W81XWH-10-1-0279 and W81XWH-10-1-0234.
CR Agostinis P, 2011, CA-CANCER J CLIN, V61, P250, DOI 10.3322/caac.20114
   Andrzejak M, 2011, AUTOPHAGY, V7, P979, DOI 10.4161/auto.7.9.15865
   BARR H, 1990, BRIT J SURG, V77, P93, DOI 10.1002/bjs.1800770132
   Bigelow CE, 2001, BRIT J CANCER, V85, P727, DOI 10.1054/bjoc.2001.1977
   Bonora M, 2015, ONCOGENE, V34, P1608, DOI [10.1038/onc.2014.462, 10.1038/onc.2014.96]
   Bugaj AM, 2011, PHOTOCH PHOTOBIO SCI, V10, P1097, DOI 10.1039/c0pp00147c
   Castano AP, 2004, PHOTODIAGN PHOTODYN, V1, P279, DOI 10.1016/S1572-1000(05)00007-4
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Chu X, 2017, ACS BIOMATER SCI ENG, V3, P1836, DOI 10.1021/acsbiomaterials.7b00110
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   De Dosso S, 2009, CANCER TREAT REV, V35, P160, DOI 10.1016/j.ctrv.2008.10.001
   Dlugosz PJ, 2006, EMBO J, V25, P2287, DOI 10.1038/sj.emboj.7601126
   Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071
   Favoriti P, 2016, UPDATES SURG, V68, P7, DOI 10.1007/s13304-016-0359-y
   Fidanzi-Dugas C, 2017, BBA-GEN SUBJECTS, V1861, P1676, DOI 10.1016/j.bbagen.2017.02.003
   Garg AD, 2015, PHOTOCH PHOTOBIO SCI, V14, P1410, DOI 10.1039/c4pp00466c
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Gross A, 2016, BBA-BIOENERGETICS, V1857, P1243, DOI 10.1016/j.bbabio.2016.01.017
   Huang Z, 2005, TECHNOL CANCER RES T, V4, P283, DOI 10.1177/153303460500400308
   Inguscio Valentina, 2012, Cells, V1, P464, DOI 10.3390/cells1030464
   Katayama M, 2007, CELL DEATH DIFFER, V14, P548, DOI 10.1038/sj.cdd.4402030
   Kawczyk-Krupka A, 2015, PHOTODIAGN PHOTODYN, V12, P545, DOI 10.1016/j.pdpdt.2015.04.004
   Kessel DH, 2012, AUTOPHAGY, V8, P1333, DOI 10.4161/auto.20792
   Klionsky DJ, 2014, AUTOPHAGY, V10, P1691, DOI 10.4161/auto.36187
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Lawen A, 2003, BIOESSAYS, V25, P888, DOI 10.1002/bies.10329
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li LH, 2017, PHOTODIAGN PHOTODYN, V19, P5, DOI 10.1016/j.pdpdt.2017.04.001
   Lin CH, 2017, TOXICOL SCI, V157, P196, DOI 10.1093/toxsci/kfx030
   Liu ZX, 2017, SCI REP-UK, V7, DOI 10.1038/srep46033
   Ma L, 2014, J BIOMED NANOTECHNOL, V10, P1501, DOI 10.1166/jbn.2014.1954
   Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005
   Mroz Pawel, 2011, Cancers (Basel), V3, P2516, DOI 10.3390/cancers3022516
   Mulsow J, 2011, BRIT J SURG, V98, P1785, DOI 10.1002/bjs.7653
   Nakamura T, 2003, GASTROINTEST ENDOSC, V57, P266, DOI 10.1067/mge.2003.57
   Robertson CA, 2009, J PHOTOCH PHOTOBIO B, V96, P1, DOI 10.1016/j.jphotobiol.2009.04.001
   Rouschop KMA, 2009, CURR MOL MED, V9, P417, DOI 10.2174/156652409788167131
   Sheridan C, 2010, MITOCHONDRION, V10, P640, DOI 10.1016/j.mito.2010.08.005
   Siboni G, 2003, CANCER LETT, V196, P57, DOI 10.1016/S0304-3835(03)00207-6
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Tanabe F, 2011, AUTOPHAGY, V7, P1462, DOI 10.4161/auto.7.12.17892
   Timmerman RD, 2009, CA-CANCER J CLIN, V59, P145, DOI 10.3322/caac.20013
   Wang CC, 2017, MOLECULES, V22, DOI 10.3390/molecules22050732
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Xiong L, 2017, ONCOTARGET, V8, P6419, DOI 10.18632/oncotarget.14117
   Xue LY, 2010, AUTOPHAGY, V6, P248, DOI 10.4161/auto.6.2.11077
   Xue Q, 2015, PHOTODIAGN PHOTODYN, V12, P84, DOI 10.1016/j.pdpdt.2014.12.001
   Yan L., 2017, BIOMACROMOLECULES, DOI [10.1021/acs.biomac.7b0027, DOI 10.1021/ACS.BIOMAC.7B0027]
   Yao MY, 2016, J BIOMED NANOTECHNOL, V12, P1835, DOI 10.1166/jbn.2016.2322
   Yao Q, 2011, TUMOR BIOL, V32, P1163, DOI 10.1007/s13277-011-0219-9
   Zou XJ, 2014, NANOMEDICINE-UK, V9, P2339, DOI [10.2217/NNM.13.198, 10.2217/nnm.13.198]
NR 53
TC 19
Z9 19
U1 7
U2 24
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD MAR
PY 2018
VL 21
BP 396
EP 403
DI 10.1016/j.pdpdt.2018.01.010
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GD6UP
UT WOS:000430644200063
PM 29355734
DA 2022-04-25
ER

PT J
AU Wang, WH
   Xu, L
   Liu, PY
   Jairam, K
   Yin, YB
   Chen, K
   Sprengers, D
   Peppelenbosch, MP
   Pan, QW
   Smits, R
AF Wang, Wenhui
   Xu, Lei
   Liu, Pengyu
   Jairam, Kiran
   Yin, Yuebang
   Chen, Kan
   Sprengers, Dave
   Peppelenbosch, Maikel P.
   Pan, Qiuwei
   Smits, Ron
TI Blocking Wnt Secretion Reduces Growth of Hepatocellular Carcinoma Cell
   Lines Mostly Independent of beta-Catenin Signaling
SO NEOPLASIA
LA English
DT Article
ID COLON-CANCER CELLS; COLORECTAL-CANCER; GAMMA-CATENIN; ADHERENS
   JUNCTIONS; GENE-EXPRESSION; PATHWAY; KNOCKDOWN; PORCUPINE;
   TUMORIGENESIS; INHIBITORS
AB Aberrant activation of Wnt/beta-catenin signaling plays a key role in the onset and development of hepatocellular carcinomas (HCC), with about half of them acquiring mutations in either CTNNB1 or AXIN1. However, it remains unclear whether these mutations impose sufficient beta-catenin signaling or require upstream Wnt ligand activation for sustaining optimal growth, as previously suggested for colorectal cancers. Using a panel of nine HCC cell lines, we show that siRNA-mediated knockdown of beta-catenin impairs growth of all these lines. Blocking Wnt secretion, by either treatment with the IWP12 porcupine inhibitor or knockdown of WLS, reduces growth of most of the lines. Unexpectedly, interfering with Wnt secretion does not clearly affect the level of beta-catenin signaling in the majority of lines, suggesting that other mechanisms underlie the growth-suppressive effect. However, IWP12 treatment did not induce autophagy or endoplasmic reticulum (ER) stress, which may have resulted from the accumulation of Wnt ligands within the ER. Similar results were observed for colorectal cancer cell lines used for comparison in various assays. These results suggest that most colorectal and liver cancers with mutations in components of the beta-catenin degradation complex do not strongly rely on extracellular Wnt ligand exposure to support optimal growth. In addition, our results also suggest that blocking Wnt secretion may aid in tumor suppression through alternative routes currently unappreciated.
C1 [Wang, Wenhui; Xu, Lei; Liu, Pengyu; Jairam, Kiran; Yin, Yuebang; Chen, Kan; Sprengers, Dave; Peppelenbosch, Maikel P.; Pan, Qiuwei; Smits, Ron] Erasmus MC, Univ Med Ctr, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands.
RP Smits, R (corresponding author), Dept Gastroenterol & Hepatol, S Gravendijkwal 230, NL-3015 CE Rotterdam, Netherlands.
EM m.j.m.smits@erasmusmc.nl
RI Peppelenbosch, Maikel P./U-5304-2019
OI Pan, Qiuwei/0000-0001-9982-6184; Peppelenbosch,
   Maikel/0000-0001-9112-6028; liu, pengyu/0000-0001-6600-6139
FU China Scholarship Council PhD fellowshipChina Scholarship Council
   [201306190123]; Erasmus Trustfonds [III A 97095.78/16.0366/evt]
FX The authors gratefully thank Dr. Francois Helle (Centre Universitaire de
   Recherche en Sante, Amiens, France) for providing the SNU182, SNU398,
   SNU449, and PLC/PRF/5 cell lines. This research is sponsored by a China
   Scholarship Council PhD fellowship (file no. 201306190123) and Erasmus
   Trustfonds travel grant (reference: III A 97095.78/16.0366/evt) to
   Wenhui Wang.
CR Albuquerque C, 2011, BBA-REV CANCER, V1816, P219, DOI 10.1016/j.bbcan.2011.07.005
   Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   Baehs S, 2009, CANCER LETT, V276, P152, DOI 10.1016/j.canlet.2008.11.003
   Bakker ERM, 2013, CARCINOGENESIS, V34, P2629, DOI 10.1093/carcin/bgt215
   Bengochea A, 2008, BRIT J CANCER, V99, P143, DOI 10.1038/sj.bjc.6604422
   Bi LQ, 2014, INT J CLIN EXP PATHO, V7, P987
   Boone JD, 2016, LAB INVEST, V96, P249, DOI 10.1038/labinvest.2015.150
   Brembeck FH, 2006, CURR OPIN GENET DEV, V16, P51, DOI 10.1016/j.gde.2005.12.007
   Chang HW, 2013, CELL SIGNAL, V25, P839, DOI 10.1016/j.cellsig.2012.12.020
   Covey TM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034532
   Dahmani R, 2011, CLIN RES HEPATOL GAS, V35, P709, DOI 10.1016/j.clinre.2011.05.010
   de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847
   de Lau W, 2014, GENE DEV, V28, P305, DOI 10.1101/gad.235473.113
   El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061
   Feng GJ, 2012, GASTROENTEROLOGY, V143, P1650, DOI 10.1053/j.gastro.2012.08.047
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075
   Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0
   Fu YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102535
   Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200
   Fukunaga Y, 2005, CELL STRUCT FUNCT, V30, P25, DOI 10.1247/csf.30.25
   Giannakis M, 2014, NAT GENET, V46, P1264, DOI 10.1038/ng.3127
   Grumolato L, 2010, GENE DEV, V24, P2517, DOI 10.1101/gad.1957710
   Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8
   Hausmann G, 2007, NAT REV MOL CELL BIO, V8, P331, DOI 10.1038/nrm2141
   Ho SY, 2015, BIOORG MED CHEM LETT, V25, P5472, DOI 10.1016/j.bmcl.2015.10.032
   Hoshida Y, 2008, NEW ENGL J MED, V359, P1995, DOI 10.1056/NEJMoa0804525
   Ivanov I, 2007, ONCOGENE, V26, P2873, DOI 10.1038/sj.onc.1210098
   Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389
   Laurent-Puig P, 2006, ONCOGENE, V25, P3778, DOI 10.1038/sj.onc.1209547
   Lee HJ, 2015, ELIFE, V4, DOI 10.7554/eLife.08142
   Llovet JM, 2008, HEPATOLOGY, V48, P1312, DOI 10.1002/hep.22506
   Ma L, 2014, GASTROINTESTINAL CAN, V4, P49
   Madan B, 2015, MOL CANCER THER, V14, P1087, DOI 10.1158/1535-7163.MCT-14-1038
   Monga SP, 2015, GASTROENTEROLOGY, V148, P1294, DOI 10.1053/j.gastro.2015.02.056
   Pez F, 2013, J HEPATOL, V59, P1107, DOI 10.1016/j.jhep.2013.07.001
   Qu B, 2014, ONCOL LETT, V7, P1175, DOI 10.3892/ol.2014.1828
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282
   Shi JL, 2014, J HEPATOCELL CARCINO, V1, P1, DOI 10.2147/JHC.S44537
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339
   van de Wetering M, 2015, CELL, V161, P933, DOI 10.1016/j.cell.2015.03.053
   van Veelen W, 2011, GUT, V60, P1204, DOI 10.1136/gut.2010.233460
   Vilchez V, 2016, WORLD J GASTROENTERO, V22, P823, DOI 10.3748/wjg.v22.i2.823
   Voloshanenko O, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3610
   Wang XL, 2013, J MED CHEM, V56, P2700, DOI 10.1021/jm400159c
   Wang XH, 2010, ONCOL REP, V24, P1093, DOI 10.3892/or_00000960
   Wickline ED, 2013, NEOPLASIA, V15, P421, DOI 10.1593/neo.122098
   Wickline ED, 2011, J HEPATOL, V55, P1256, DOI 10.1016/j.jhep.2011.03.014
   Yuzugullu H, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-90
   Zeng G, 2007, NEOPLASIA, V9, P951, DOI 10.1593/neo.07469
   Zhou JB, 2007, AM J PHYSIOL-HEART C, V292, pH270, DOI 10.1152/ajpheart.00576.2006
   Zucman-Rossi J, 2007, ONCOGENE, V26, P774, DOI 10.1038/sj.onc.1209824
NR 54
TC 28
Z9 30
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1476-5586
J9 NEOPLASIA
JI Neoplasia
PD DEC
PY 2016
VL 18
IS 12
BP 711
EP 723
DI 10.1016/j.neo.2016.10.004
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EJ2RF
UT WOS:000393057700001
PM 27851986
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Chen, JC
   Hsieh, YY
   Lo, HL
   Li, A
   Chou, CJ
   Yang, PM
AF Chen, Jung-Chien
   Hsieh, Yao-Yu
   Lo, Hsiang-Ling
   Li, Albert
   Chou, Chia-Jung
   Yang, Pei-Ming
TI In Vitro and In Silico Mechanistic Insights into miR-21-5p-Mediated
   Topoisomerase Drug Resistance in Human Colorectal Cancer Cells
SO BIOMOLECULES
LA English
DT Article
DE autophagy; colorectal cancer; Connectivity Map; drug resistance;
   microRNA
ID CONNECTIVITY MAP; INHIBITING AUTOPHAGY; THERAPEUTIC TARGET; MICRORNA-21;
   MIR-21; EXPRESSION; ENCYCLOPEDIA; COMBINATION; DOXORUBICIN; SENSITIVITY
AB Although chemotherapy for treating colorectal cancer has had some success, drug resistance and metastasis remain the major causes of death for colorectal cancer patients. MicroRNA-21-5p (hereafter denoted as miR-21) is one of the most abundant miRNAs in human colorectal cancer. A Kaplan-Meier survival analysis found a negative prognostic correlation of miR-21 and metastasis-free survival in colorectal cancer patients (The Cancer Genome Atlas Colon Adenocarcinoma/TCGA-COAD cohort). To explore the role of miR-21 overexpression in drug resistance, a stable miR-21-overexpressing clone in a human DLD-1 colorectal cancer cell line was established. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) cell viability assay found that miR-21 overexpression induced drug resistance to topoisomerase inhibitors (SN-38, doxorubicin, and etoposide/VP-16). Mechanistically, we showed that miR-21 overexpression reduced VP-16-induced apoptosis and concomitantly enhanced pro-survival autophagic flux without the alteration of topoisomerase expression and activity. Bioinformatics analyses suggested that miR-21 overexpression induced genetic reprogramming that mimicked the gene signature of topoisomerase inhibitors and downregulated genes related to the proteasome pathway. Taken together, our results provide a novel insight into the role of miR-21 in the development of drug resistance in colorectal cancer.
C1 [Chen, Jung-Chien; Hsieh, Yao-Yu; Lo, Hsiang-Ling; Li, Albert; Chou, Chia-Jung; Yang, Pei-Ming] Taipei Med Univ, Coll Med Sci & Technol, PhD Program Canc Mol Biol & Drug Discovery, Taipei 111, Taiwan.
   [Chen, Jung-Chien; Hsieh, Yao-Yu; Lo, Hsiang-Ling; Li, Albert; Chou, Chia-Jung; Yang, Pei-Ming] Acad Sinica, Taipei 111, Taiwan.
   [Chen, Jung-Chien] Min Sheng Gen Hosp, Dept Surg, Taoyuan 168, Taiwan.
   [Chen, Jung-Chien] Cent Clin & Hosp, Taipei 106, Taiwan.
   [Hsieh, Yao-Yu] Taipei Med Univ, Shuang Ho Hosp, Div Hematol & Oncol, New Taipei 235, Taiwan.
   [Hsieh, Yao-Yu] Taipei Med Univ, Div Hematol & Oncol, Sch Med, Dept Internal Med,Coll Med, Taipei 111, Taiwan.
   [Lo, Hsiang-Ling; Li, Albert; Chou, Chia-Jung; Yang, Pei-Ming] Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Canc Biol & Drug Discovery, Taipei 111, Taiwan.
   [Li, Albert] Taipei Med Univ, Sch Med, Taipei 111, Taiwan.
   [Yang, Pei-Ming] TMU Res Ctr Canc Translat Med, Taipei 111, Taiwan.
   [Chou, Chia-Jung; Yang, Pei-Ming] Taipei Med Univ, Wan Fang Hosp, Canc Ctr, Taipei 111, Taiwan.
RP Yang, PM (corresponding author), Taipei Med Univ, Coll Med Sci & Technol, PhD Program Canc Mol Biol & Drug Discovery, Taipei 111, Taiwan.; Yang, PM (corresponding author), Acad Sinica, Taipei 111, Taiwan.; Yang, PM (corresponding author), Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Canc Biol & Drug Discovery, Taipei 111, Taiwan.; Yang, PM (corresponding author), TMU Res Ctr Canc Translat Med, Taipei 111, Taiwan.; Yang, PM (corresponding author), Taipei Med Univ, Wan Fang Hosp, Canc Ctr, Taipei 111, Taiwan.
EM yangpm@tmu.edu.tw
RI ; Chen, Jung-Chien/J-5386-2015
OI Li, Albert/0000-0002-4590-3268; Chen, Jung-Chien/0000-0001-8634-1145
FU health and welfare surcharge of tobacco products (WanFang Hospital,
   Chi-Mei Medical Center) [MOHW108-TDU-B-212-124020]; health and welfare
   surcharge of tobacco products (Hualien Tzu-Chi Hospital Joing Cancer
   Center Grant-Focus on Colon Cancer Research) [MOHW108-TDU-B-212-124020];
   Ministry of Science and Technology [MOST103-2320-B-038-052,
   MOST104-2320-B-038-005, MOST105-2320-B-038-002, MOST108-2314-B-038-010];
   Ministry of Education [DP2-108-21121-01-C-03-05]; Taipei Medical
   University [TMU103-AE2-I04-4, TMU104-AE2-I02-4, TMU105-AE2-I03-4,
   TMU105-U-32, TMU106-F-005]; Taipei Medical University - Shuang Ho
   Hospital [108TMU-SHH-19]
FX This research was funded by the health and welfare surcharge of tobacco
   products (WanFang Hospital, Chi-Mei Medical Center, and Hualien Tzu-Chi
   Hospital Joing Cancer Center Grant-Focus on Colon Cancer Research),
   grant number MOHW108-TDU-B-212-124020; the Ministry of Science and
   Technology, grant numbers MOST103-2320-B-038-052,
   MOST104-2320-B-038-005, MOST105-2320-B-038-002, MOST108-2314-B-038-010;
   the Ministry of Education, grant number DP2-108-21121-01-C-03-05; the
   Taipei Medical University, grant numbers TMU103-AE2-I04-4,
   TMU104-AE2-I02-4, TMU105-AE2-I03-4, TMU105-U-32, TMU106-F-005; and the
   Taipei Medical University - Shuang Ho Hospital, grant number
   108TMU-SHH-19.
CR Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Basu A, 2013, CELL, V154, P1151, DOI 10.1016/j.cell.2013.08.003
   Biasoli D, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.283
   Chen C, 2018, ANTI-CANCER DRUG, V29, P1, DOI 10.1097/CAD.0000000000000572
   Chen MC, 2014, CANCER LETT, V349, P51, DOI 10.1016/j.canlet.2014.03.023
   Delgado ME, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.520
   Ding WX, 2007, AM J PATHOL, V171, P513, DOI 10.2353/ajpath.2007.070188
   Goswami CP, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-970
   Goswami Chirayu Pankaj, 2012, J Clin Bioinforma, V2, P23, DOI 10.1186/2043-9113-2-23
   Guo YS, 2017, CANCER BIOMARK, V18, P1, DOI 10.3233/CBM-160650
   He CJ, 2015, ONCOTARGET, V6, P28867, DOI 10.18632/oncotarget.4814
   Hewish M, 2010, NAT REV CLIN ONCOL, V7, P197, DOI 10.1038/nrclinonc.2010.18
   Hong L, 2013, EXPERT OPIN THER TAR, V17, P1073, DOI 10.1517/14728222.2013.819853
   HSIANG YH, 1988, CANCER RES, V48, P1722
   Javanmardi S, 2016, CURR GENE THER, V16, P375, DOI 10.2174/1566523217666170102105119
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kanehisa M, 2019, NUCLEIC ACIDS RES, V47, pD590, DOI 10.1093/nar/gky962
   Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092
   Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Kouzminova N, 2010, NEW ENGL J MED, V362, P1245, DOI 10.1056/NEJMc1000949
   Krichevsky AM, 2009, J CELL MOL MED, V13, px, DOI 10.1111/j.1582-4934.2008.00556.x
   Krishnakumar R, 2010, MOL CELL, V39, P8, DOI 10.1016/j.molcel.2010.06.017
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   Kurokawa K, 2012, J GASTROENTEROL, V47, P883, DOI 10.1007/s00535-012-0547-6
   Lamb J, 2007, NAT REV CANCER, V7, P54, DOI 10.1038/nrc2044
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Liston DR, 2017, CLIN CANCER RES, V23, P3489, DOI 10.1158/1078-0432.CCR-16-3083
   Liu XL, 2016, TOXICOL LETT, V252, P1, DOI 10.1016/j.toxlet.2016.04.015
   Loboda A, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-9
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Meyers M, 2005, J BIOL CHEM, V280, P5516, DOI 10.1074/jbc.M412105200
   Pan XA, 2010, CANCER BIOL THER, V10, P1224, DOI 10.4161/cbt.10.12.14252
   PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266
   Pekow JR, 2012, INFLAMM BOWEL DIS, V18, P187, DOI 10.1002/ibd.21691
   Qu J, 2015, J CELL PHYSIOL, V230, P535, DOI 10.1002/jcp.24366
   Rajapakse VN, 2018, ISCIENCE, V10, P247, DOI 10.1016/j.isci.2018.11.029
   Rees MG, 2016, NAT CHEM BIOL, V12, P109, DOI [10.1038/nchembio.1986, 10.1038/NCHEMBIO.1986]
   Reissfelder C, 2009, ANN SURG ONCOL, V16, P3279, DOI 10.1245/s10434-009-0654-7
   Rothenberg ML, 1996, J CLIN ONCOL, V14, P1128, DOI 10.1200/JCO.1996.14.4.1128
   Schee K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066165
   Seashore-Ludlow B, 2015, CANCER DISCOV, V5, P1210, DOI 10.1158/2159-8290.CD-15-0235
   Selcuklu SD, 2009, BIOCHEM SOC T, V37, P918, DOI 10.1042/BST0370918
   Shimada H, 2009, LANGENBECK ARCH SURG, V394, P973, DOI 10.1007/s00423-009-0530-8
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Song LL, 2016, TUMOR BIOL, V37, P12161, DOI 10.1007/s13277-016-5073-3
   Sparreboom A, 1999, ANTI-CANCER DRUG, V10, P719, DOI 10.1097/00001813-199909000-00005
   Stransky N, 2015, NATURE, V528, P84, DOI 10.1038/nature15736
   Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049
   SUGIMOTO Y, 1990, CANCER RES, V50, P6925
   SUGIMOTO Y, 1990, CANCER RES, V50, P7962
   Sun GH, 2016, ONCOTARGET, V7, P3857, DOI 10.18632/oncotarget.6460
   Tang F, 2017, EXP CELL RES, V359, P374, DOI 10.1016/j.yexcr.2017.08.021
   Valeri N, 2010, P NATL ACAD SCI USA, V107, P21098, DOI 10.1073/pnas.1015541107
   van Zuylen L, 1999, ANTI-CANCER DRUG, V10, P361, DOI 10.1097/00001813-199904000-00003
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Waldner MJ, 2010, MOL ASPECTS MED, V31, P171, DOI 10.1016/j.mam.2010.02.005
   Yu YJ, 2012, CARCINOGENESIS, V33, P68, DOI 10.1093/carcin/bgr246
   Zhao J, 2015, CANCER BIOMARK, V15, P219, DOI 10.3233/CBM-150468
NR 60
TC 13
Z9 13
U1 1
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2218-273X
J9 BIOMOLECULES
JI Biomolecules
PD SEP
PY 2019
VL 9
IS 9
AR 467
DI 10.3390/biom9090467
PG 16
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA JC2JH
UT WOS:000489102800079
PM 31505885
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhu, J
   Zhao, L
   Luo, B
   Sheng, W
AF Zhu, Jing
   Zhao, Lei
   Luo, Bin
   Sheng, Wang
TI Shikonin regulates invasion and autophagy of cultured colon cancer cells
   by inhibiting yes-associated protein
SO ONCOLOGY LETTERS
LA English
DT Article
DE colon cancer; shikonin; autophagy; yes-associated protein
ID DEGRADATION; STATISTICS; YAP/TAZ; PATHWAY; YAP
AB Colon cancer is a common malignancy, and its morbidity and mortality have been increasing in recent years in China. Shikonin (Shi), a naturally occurring naphthoquinone, exhibits anticancer activity. However, the mechanisms of action of Shi remain unclear. The aim of the present study was to investigate the antitumor mechanism of Shi in colon cancer cells. The effects of different Shi concentrations on the viability of colon cancer cells using MTT, colony formation and wound-healing assays were assessed. Western blot analysis was performed to detect the expression of LC3-II, p62. Shi effectively suppressed viability and cell migration, and induced autophagy in colon cancer cells. Yes-associated protein (YAP) increases cell viability, and inhibits cell apoptosis and cell contact. Expression of YAP is downregulated by Shi. The cytotoxic effects of Shi were further investigated on YAP overexpression and on YAP knockout cell lines. The findings revealed that Shi suppressed the viability and induced autophagy of colon cancer cells. Additionally, YAP expression reversed the effects of Shi. The results of the present study suggest that Shi may be a promising anticancer treatment for colon cancer, and YAP may be a potential diagnostic marker for colon cancer.
C1 [Zhu, Jing; Sheng, Wang] Beijing Univ Technol, Coll Life Sci & Bioengn, Canc Lab, 100 Pingleyuan, Beijing 100124, Peoples R China.
   [Zhu, Jing; Luo, Bin] Hubei Univ Med, Dept Basic Med Sci, Shiyan 442000, Hubei, Peoples R China.
   [Zhao, Lei] Hubei Univ Med, Taihe Hosp, Reprod Med Ctr, Shiyan 442000, Hubei, Peoples R China.
RP Zhu, J; Sheng, W (corresponding author), Beijing Univ Technol, Coll Life Sci & Bioengn, Canc Lab, 100 Pingleyuan, Beijing 100124, Peoples R China.
EM jing_Zhu0719@163.com; shengwang@bjut.edu.en
OI Zhu, Jing/0000-0002-2860-3685
FU National Natural Technology Foundation of China (Beijing, China)
   [81428016]; Key Program for Science and Technology Development of
   Beijing (Beijing, China) [Z151100003915073]
FX This study was supported by the National Natural Technology Foundation
   of China (Beijing, China; grant no. 81428016) and the Key Program for
   Science and Technology Development of Beijing (Beijing, China; grant no.
   Z151100003915073).
CR DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235
   Fridlender M, 2015, FRONT PLANT SCI, V6, DOI 10.3389/fpls.2015.00799
   Gao Y, 2014, INT J MOL SCI, V15, P15173, DOI 10.3390/ijms150915173
   He GD, 2016, BIOCHEM BIOPH RES CO, V469, P1075, DOI 10.1016/j.bbrc.2015.12.100
   Jouffret L, 2015, ANZ J SURG, V85, P860, DOI 10.1111/ans.13277
   Kim HJ, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1223-7
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Li YJ, 2017, CHIN J CANCER, V52, DOI 10.1186/s40880-017-0219-2
   Liu ZM, 2017, AM J TRANSL RES, V9, P3212
   Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638
   Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876
   Oku Y, 2015, FEBS OPEN BIO, V5, P542, DOI 10.1016/j.fob.2015.06.007
   Petherick KJ, 2013, EMBO J, V32, P1903, DOI 10.1038/emboj.2013.123
   Qian HR, 2016, ONCOTARGET, V7, P17641, DOI 10.18632/oncotarget.7508
   Shi SQ, 2014, ONCOL LETT, V8, P1087, DOI 10.3892/ol.2014.2293
   Singh KE, 2014, J ADOLESC YOUNG ADUL, V3, P176, DOI 10.1089/jayao.2014.0006
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Wang SP, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.160119
   Wang XD, 2012, EUR J CANCER, V48, P1227, DOI 10.1016/j.ejca.2011.10.001
   Wang YP, 2015, INT J CLIN EXP MED, V8, P1080
   Wang Z, 2017, CANCER RES, V77, P2413, DOI 10.1158/0008-5472.CAN-16-3229
   Wu H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052706
   XU TA, 1995, DEVELOPMENT, V121, P1053
   Zhou W, 2011, BIOMED CHROMATOGR, V25, P1067, DOI 10.1002/bmc.1570
NR 24
TC 8
Z9 10
U1 0
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD DEC
PY 2019
VL 18
IS 6
BP 6117
EP 6125
DI 10.3892/ol.2019.10980
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA KA1RN
UT WOS:000505576300049
PM 31788086
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Chen, L
   Zhang, KZ
   Sun, J
   Tang, JT
   Zhou, JP
AF Chen, Lin
   Zhang, Kunzi
   Sun, Jian
   Tang, Jingtong
   Zhou, Jianping
TI Development and Validation of an Autophagy-Stroma-Based Microenvironment
   Gene Signature for Risk Stratification in Colorectal Cancer
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE autophagy; stroma; tumor microenvironment; colorectal cancer; TNS1;
   TAGLN; SFRP4
ID COLON-CANCER; OXIDATIVE STRESS; TUMOR-STROMA; FIBROBLASTS; INHIBITION;
   METABOLISM; CELLS; HYDROXYCHLOROQUINE; POLYMORPHISM; INSTABILITY
AB Background: Colorectal cancer is the fourth most common cancer and the second leading cause of cancer-related death in the USA. The aim of this study was to establish a tumor gene signature based on tumor stromal cell and autophagy for predicting the risk of recurrence in patients with colorectal cancer.
   Methods: We used "Rtsne" and "xCell" R packages to estimate autophagy and stroma status, respectively. The discovery cohort used microarray gene expression data retrieved from the GSE39582 dataset. The Cox regression model and Least Absolute Shrinkage and Selection Operator (LASSO) were used to identify prognostic genes and to construct an autophagy-stroma-based gene signature. Moreover, external validation was conducted using GSE17538, GSE38832, TCGA database, and patient data obtained from the First Hospital of China Medical University (CMU).
   Results: The LASSO model identified three genes (TNS1, TAGLN, and SFRP4) which were used to develop a risk stratification gene signature. The autophagy-stroma-based gene signature was identified as an independent prognostic factor by multivariate analysis (p=0.0023). The results were validated in GSE17538 (p=0.0062), GSE38832 (p=0.028), TCGA (p=0.046) database, and patient data obtained from the First Hospital of China Medical University (CMU) (p=0.027).
   Conclusion: We have established and verified a feasible prognostic model of colorectal cancer based on autophagy and stromal cell characteristics of patients. The model can be used to evaluate recurrence risk of cancer patients, and the hub genes in the model provide potential targets for targeted colorectal cancer treatment.
C1 [Chen, Lin; Zhang, Kunzi; Sun, Jian; Tang, Jingtong; Zhou, Jianping] China Med Univ, Dept Gastrointestinal Surg, Hosp 1, Shenyang 110001, Peoples R China.
RP Zhou, JP (corresponding author), China Med Univ, Dept Gastrointestinal Surg, Hosp 1, Shenyang 110001, Peoples R China.
EM zjphama@163.com
OI Chen, Lin/0000-0001-5602-7139
FU Department of gastrointestinal surgery of the First Hospital of China
   Medical University
FX We acknowledge the support from the Department of gastrointestinal
   surgery of the First Hospital of China Medical University.
CR Angell HK, 2020, CLIN CANCER RES, V26, P332, DOI 10.1158/1078-0432.CCR-18-1851
   Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chen SG, 2014, J GASTROINTEST SURG, V18, P1040, DOI 10.1007/s11605-014-2497-1
   Cui L, 2016, ONCOL REP, V35, P3639, DOI 10.3892/or.2016.4752
   Danielsen HE, 2018, ANN ONCOL, V29, P616, DOI 10.1093/annonc/mdx794
   Folkerts H, 2019, MED RES REV, V39, P517, DOI 10.1002/med.21531
   Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01
   Hothorn T, 2008, BIOMETRICS, V64, P1263, DOI 10.1111/j.1541-0420.2008.00995.x
   Hu JL, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1019-x
   Huijbers A, 2012, ENDOCR-RELAT CANCER, V19, pL15, DOI 10.1530/ERC-11-0302
   Ishiguro K, 2006, GUT, V55, P695, DOI 10.1136/gut.2005.079459
   Kim BG, 2006, NATURE, V441, P1015, DOI 10.1038/nature04846
   Ko YH, 2011, CANCER BIOL THER, V12, P1085, DOI 10.4161/cbt.12.12.18671
   Lannagan TRM, 2021, CURR OPIN GENET DEV, V66, P50, DOI 10.1016/j.gde.2020.12.003
   Levy J, 2015, NAT CELL BIOL, V17, P1062, DOI 10.1038/ncb3206
   Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248
   Liu J, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-1054-0
   Lucas C, 2020, GASTROENTEROLOGY, V158, P1373, DOI 10.1053/j.gastro.2019.12.026
   Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P3515, DOI 10.4161/cc.9.17.12928
   Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P3256, DOI 10.4161/cc.9.16.12553
   Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Nassour J, 2019, NATURE, V565, P659, DOI 10.1038/s41586-019-0885-0
   New J, 2017, CANCER RES, V77, P6679, DOI 10.1158/0008-5472.CAN-17-1077
   Nicoli ER, 2014, ROM J MORPHOL EMBRYO, V55, P57
   Ouahoud S, 2020, ONCOGENE, V39, P2453, DOI 10.1038/s41388-020-1157-z
   Rangwala R, 2014, AUTOPHAGY, V10, P1391, DOI 10.4161/auto.29119
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Schaaf MB, 2019, CELL DEATH DIFFER, V26, P665, DOI 10.1038/s41418-019-0287-8
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sugiyama Y, 2005, GASTROENTEROLOGY, V128, P480, DOI 10.1053/j.gastro.2004.11.010
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Tauriello DVF, 2017, MOL ONCOL, V11, P97, DOI 10.1002/1878-0261.12018
   Tibshirani R, 1997, STAT MED, V16, P385, DOI 10.1002/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3
   van Pelt GW, 2018, HISTOPATHOLOGY, V73, P197, DOI 10.1111/his.13489
   Vogl DT, 2014, AUTOPHAGY, V10, P1380, DOI 10.4161/auto.29264
   Wang Q, 2016, CELL CYCLE, V15, P1376, DOI 10.1080/15384101.2016.1170269
   Wen YA, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.21
   Wu H, 2019, SENSORS-BASEL, V19, DOI 10.3390/s19235112
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zhang JX, 2013, LANCET ONCOL, V14, P1295, DOI 10.1016/S1470-2045(13)70491-1
   Zhang MH, 2013, INT J ONCOL, V42, P1390, DOI 10.3892/ijo.2013.1810
   Zhou WJ, 2017, CELL CYCLE, V16, P73, DOI 10.1080/15384101.2016.1252882
NR 45
TC 0
Z9 0
U1 0
U2 2
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2021
VL 14
BP 3503
EP 3515
DI 10.2147/OTT.S312003
PG 13
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA SK3UM
UT WOS:000656144200001
PM 34103941
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Kim, JY
   Cho, TJ
   Woo, BH
   Choi, KU
   Lee, CH
   Ryu, MH
   Park, HR
AF Kim, Ji Young
   Cho, Tae Jin
   Woo, Bok Hee
   Choi, Kyung Un
   Lee, Chang Hun
   Ryu, Mi Heon
   Park, Hae Ryoun
TI Curcumin-induced autophagy contributes to the decreased survival of oral
   cancer cells
SO ARCHIVES OF ORAL BIOLOGY
LA English
DT Article
DE Curcumin; Autophagy; Apoptosis; Oral squamous cell carcinoma
ID NF-KAPPA-B; CARCINOMA-CELLS; JURKAT CELLS; COLON-CANCER; APOPTOSIS;
   DEATH; ACTIVATION; INDUCTION; CHEMOPREVENTION; CASPASE-3
AB Curcumin, a major active component of turmeric Curcuma longa, has been shown to have inhibitory effects on cancers. In vitro studies suggest that curcumin inhibits cancer cell growth by activating apoptosis, but the mechanism underlying the anticancer effects of curcumin is unclear. Recently, it has been suggested that autophagy may play an important role in cancer therapy. However, little data are available regarding the role of autophagy in oral cancers. In this study, we have shown that curcumin has anticancer activity against oral squamous cell carcinoma (OSCC). Induction of autophagy, marked by autophagic vacuoles formation, was detected by acridine orange staining and monodansylcadaverine (MDC) dye after exposure to curcumin. Conversion of LC3-I to LC3-II, a marker of active autophagosome formation, was also detectable by Western blot following curcumin treatment We have also observed that curcumin induced reactive oxygen species (ROS) production and autophagic vacuoles formation by curcumin was almost completely blocked in the presence of N-acetylcystein (NAC), an antioxidant. Rescue experiments using an autophagy inhibitor suppressed curcumin-induced cell death in OSCC, confirming that autophagy acts as a pro-death signal. Furthermore, curcumin shows anticancer activity against OSCC via both autophagy and apoptosis. These findings suggest that curcumin may potentially contribute to oral cancer treatment and provide useful information for the development of a new therapeutic agent. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Kim, Ji Young; Cho, Tae Jin; Woo, Bok Hee; Ryu, Mi Heon; Park, Hae Ryoun] Pusan Natl Univ, Sch Dent, Dept Oral Pathol, Yangsan 626870, South Korea.
   [Choi, Kyung Un; Lee, Chang Hun] Pusan Natl Univ, Sch Med, Dept Pathol, Yangsan 626870, South Korea.
RP Park, HR (corresponding author), Pusan Natl Univ, Sch Dent, Dept Oral Pathol, Yangsan 626870, South Korea.
EM parkhr@pusan.ac.kr
OI Park, Hae Ryoun/0000-0003-1908-0824
FU National research Foundation of Korea (NRF)National Research Foundation
   of Korea; Ministry of Education, Science and technologyMinistry of
   Education, Science and Technology, Republic of Korea [2011-0005931,
   2011-0016183]
FX This research was supported by Basic Science Research Program through
   the National research Foundation of Korea (NRF) funded by the Ministry
   of Education, Science and technology (2011-0005931) and by NRF funded by
   MEST (2011-0016183).
CR Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167
   Bursch W, 2000, ANN NY ACAD SCI, V926, P1, DOI 10.1111/j.1749-6632.2000.tb05594.x
   Chang KW, 2010, INT J CANCER, V127, P9, DOI 10.1002/ijc.25220
   Choudhuri T, 2002, FEBS LETT, V512, P334, DOI 10.1016/S0014-5793(02)02292-5
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   Duvoix A, 2003, ANN NY ACAD SCI, V1010, P389, DOI 10.1196/annals.1299.071
   Goel A, 2008, BIOCHEM PHARMACOL, V75, P787, DOI 10.1016/j.bcp.2007.08.016
   Hussain AR, 2008, MOL CANCER THER, V7, P3318, DOI 10.1158/1535-7163.MCT-08-0541
   Johnson JJ, 2007, CANCER LETT, V255, P170, DOI 10.1016/j.canlet.2007.03.005
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Lee EJ, 2005, EXP MOL MED, V37, P379, DOI 10.1038/emm.2005.48
   Lee YJ, 2011, KOREAN J PHYSIOL PHA, V15, P1, DOI 10.4196/kjpp.2011.15.1.1
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Nonaka M, 2006, INT J ORAL MAX SURG, V35, P649, DOI 10.1016/j.ijom.2006.01.011
   O'Sullivan-Coyne G, 2009, BRIT J CANCER, V101, P1585, DOI 10.1038/sj.bjc.6605308
   Paglin S, 2001, CANCER RES, V61, P439
   Piwocka K, 2002, ANN NY ACAD SCI, V973, P250, DOI 10.1111/j.1749-6632.2002.tb04643.x
   Piwocka K, 1999, EXP CELL RES, V249, P299, DOI 10.1006/excr.1999.4480
   Ravindran J, 2009, AAPS J, V11, P495, DOI 10.1208/s12248-009-9128-x
   Reuter S, 2008, BIOCHEM PHARMACOL, V76, P1340, DOI 10.1016/j.bcp.2008.07.031
   Shin HK, 2010, PHYTOTHER RES, V24, P577, DOI 10.1002/ptr.2989
   Sikora E, 2006, MOL CANCER THER, V5, P927, DOI 10.1158/1535-7163.MCT-05-0360
   Singh M, 2009, MOL CELL BIOCHEM, V325, P107, DOI 10.1007/s11010-009-0025-5
   SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995
   Singh Sarvjeet, 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P259, DOI 10.2174/187152006776930918
   Su CC, 2006, ANTICANCER RES, V26, P4379
   Tan TW, 2006, ANTICANCER RES, V26, P4361
   William BM, 2008, HEMATOLOGY, V13, P333, DOI 10.1179/102453308X343437
   Wright TI, 2006, J AM ACAD DERMATOL, V54, P933, DOI 10.1016/j.jaad.2005.08.062
   Yu SW, 2008, MOL CANCER THER, V7, P2609, DOI 10.1158/1535-7163.MCT-07-2400
NR 32
TC 91
Z9 96
U1 2
U2 25
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0003-9969
EI 1879-1506
J9 ARCH ORAL BIOL
JI Arch. Oral Biol.
PD AUG
PY 2012
VL 57
IS 8
BP 1018
EP 1025
DI 10.1016/j.archoralbio.2012.04.005
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 992RO
UT WOS:000307797600003
PM 22554995
DA 2022-04-25
ER

PT J
AU Ryan, D
   Carberry, S
   Murphy, AC
   Lindner, AU
   Fay, J
   Hector, S
   McCawley, N
   Bacon, O
   Concannon, CG
   Kay, EW
   McNamara, DA
   Prehn, JHM
AF Ryan, Deborah
   Carberry, Steven
   Murphy, Aine C.
   Lindner, Andreas U.
   Fay, Joanna
   Hector, Suzanne
   McCawley, Niamh
   Bacon, Orna
   Concannon, Caoimhin G.
   Kay, Elaine W.
   McNamara, Deborah A.
   Prehn, Jochen H. M.
TI Calnexin, an ER-induced protein, is a prognostic marker and potential
   therapeutic target in colorectal cancer
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Colorectal cancer; ER Stress; Calnexin; GRP78; GRP94; UPR (unfolded
   protein response)
ID ENDOPLASMIC-RETICULUM STRESS; ADJUVANT CHEMOTHERAPY; GRP78; PROGRESSION;
   AUTOPHAGY; CELLS; FLUOROURACIL; RESISTANCE; CARCINOMA; APOPTOSIS
AB Background: Colorectal cancer (CRC) is a leading cause of cancer mortality in the Western world and commonly treated with genotoxic chemotherapy. Stress in the endoplasmic reticulum (ER) was implicated to contribute to chemotherapeutic resistance. Hence, ER stress related protein may be of prognostic or therapeutic significance.
   Methods: The expression levels of ER stress proteins calnexin, calreticulin, GRP78 and GRP94 were determined in n = 23 Stage II and III colon cancer fresh frozen tumour and matched normal tissue samples. Data were validated in a cohort of n = 11 rectal cancer patients treated with radiochemotherapy in the neoadjuvant setting. The calnexin gene was silenced using siRNA in HCT116 cells.
   Results: There were no increased levels of ER stress proteins in tumour compared to matched normal tissue samples in Stage II or III CRC. However, increased calnexin protein levels were predictive of poor clinical outcome in the patient cohort. Data were validated in the rectal cancer cohort treated in the neoadjuvant setting. Calnexin gene-silencing significantly reduced cell survival and increased cancer cell susceptibility to 5FU chemotherapy.
   Conclusion: Increased tumour protein levels of calnexin may be of prognostic significance in CRC, and calnexin may represent a potential target for future therapies.
C1 [Ryan, Deborah; Carberry, Steven; Murphy, Aine C.; Lindner, Andreas U.; Hector, Suzanne; McCawley, Niamh; Bacon, Orna; Concannon, Caoimhin G.; Prehn, Jochen H. M.] Royal Coll Surgeons Ireland, Ctr Syst Med, Dept Physiol & Med Phys, 123 St Stephens Green, Dublin 2, Ireland.
   [Ryan, Deborah; McCawley, Niamh; Bacon, Orna; Concannon, Caoimhin G.; McNamara, Deborah A.] Beaumont Hosp, Dept Colorectal Surg, Dublin 9, Ireland.
   [Fay, Joanna; Kay, Elaine W.] Beaumont Hosp, Dept Pathol, Dublin 9, Ireland.
   [Fay, Joanna; Kay, Elaine W.] Royal Coll Surgeons Ireland, Dublin 9, Ireland.
RP Prehn, JHM (corresponding author), Royal Coll Surgeons Ireland, Ctr Syst Med, Dept Physiol & Med Phys, 123 St Stephens Green, Dublin 2, Ireland.
EM prehn@rcsi.ie
RI Prehn, Jochen HM/A-3928-2010
OI Prehn, Jochen HM/0000-0003-3479-7794; Fay, Joanna/0000-0001-6294-2886;
   Lindner, Andreas/0000-0003-1590-3547
FU Health Research Board [TRA/2007/26]; Science Foundation IrelandScience
   Foundation IrelandEuropean Commission [13/IA/1881]; European
   UnionEuropean Commission [306021]
FX This research was supported by grants from the Health Research Board
   (TRA/2007/26), Science Foundation Ireland (13/IA/1881) and the European
   Union (FP7 APO-DECIDE Contract 306021) to JHMP.
CR Arnaudeau S, 2002, J BIOL CHEM, V277, P46696, DOI 10.1074/jbc.M202395200
   Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315
   Corazzari M, 2015, CELL DEATH DIFFER, V22, P946, DOI 10.1038/cdd.2014.183
   de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938
   Delom F, 2007, CELL DEATH DIFFER, V14, P586, DOI 10.1038/sj.cdd.4402012
   Feldman DE, 2005, MOL CANCER RES, V3, P597, DOI 10.1158/1541-7786.MCR-05-0221
   Fernandez PM, 2000, BREAST CANCER RES TR, V59, P15, DOI 10.1023/A:1006332011207
   Figueredo A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005390.pub2
   Fu Y, 2006, CANCER BIOL THER, V5, P741, DOI 10.4161/cbt.5.7.2970
   Gray R, 2007, LANCET, V370, P2020, DOI 10.1016/s0140-6736(07)61866-2
   Hardy B, 2012, CELL ONCOL, V35, P345, DOI 10.1007/s13402-012-0094-4
   Jamora C, 1996, P NATL ACAD SCI USA, V93, P7690, DOI 10.1073/pnas.93.15.7690
   Li XM, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756-8722-4-8
   Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731
   Ni M, 2007, FEBS LETT, V581, P3641, DOI 10.1016/j.febslet.2007.04.045
   PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J
   Ragnhammar P, 2001, ACTA ONCOL, V40, P282, DOI 10.1080/02841860151116367
   Ribic CM, 2003, NEW ENGL J MED, V349, P247, DOI 10.1056/NEJMoa022289
   Schild H, 2000, NAT IMMUNOL, V1, P100, DOI 10.1038/77770
   Schonthal AH, 2009, CANCER LETT, V275, P163, DOI 10.1016/j.canlet.2008.07.005
   Shuda M, 2003, J HEPATOL, V38, P605, DOI 10.1016/S0168-8278(03)00029-1
   Singh-Jasuja H, 2000, EUR J IMMUNOL, V30, P2211, DOI 10.1002/1521-4141(2000)30:18<2211::AID-IMMU2211>3.0.CO;2-H
   Takizawa T, 2004, J BIOCHEM, V136, P399, DOI 10.1093/jb/mvh133
   Tamura Y, 1997, SCIENCE, V278, P117, DOI 10.1126/science.278.5335.117
   Ullman E, 2008, CELL DEATH DIFFER, V15, P422, DOI 10.1038/sj.cdd.4402234
   Wang GH, 2010, AM J TRANSL RES, V2, P65
   Yang SY, 2009, TRENDS MOL MED, V15, P225, DOI 10.1016/j.molmed.2009.03.003
   Zhuang LQ, 2009, HISTOPATHOLOGY, V54, P462, DOI 10.1111/j.1365-2559.2009.03242.x
NR 28
TC 31
Z9 32
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD JUL 1
PY 2016
VL 14
AR 196
DI 10.1186/s12967-016-0948-z
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA DR3MW
UT WOS:000379808300002
PM 27369741
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Tang, Y
   Li, M
   Wang, YL
   Threadgill, MD
   Xiao, M
   Mou, CF
   Song, GL
   Kuang, J
   Yang, X
   Yang, L
   Gao, XJ
   Wang, YP
   Meng, YP
AF Tang, Yi
   Li, Ming
   Wang, Ya-Lan
   Threadgill, Michael D.
   Xiao, Ming
   Mou, Chun-Feng
   Song, Guang-Lin
   Kuang, Jing
   Yang, Xi
   Yang, Li
   Gao, Xing-Jie
   Wang, Ya-Ping
   Meng, Yun-Peng
TI ART1 promotes starvation-induced autophagy: a possible protective role
   in the development of colon carcinoma
SO AMERICAN JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE Autophagy; colon carcinoma; ART1; proliferation; apoptosis
ID ARGININE ADP-RIBOSYLTRANSFERASE; COLORECTAL-CANCER CELLS;
   POLY(ADP-RIBOSE) POLYMERASE-1; INTEGRIN ALPHA-7; DUAL ROLE;
   RIBOSYLATION; INHIBITION; APOPTOSIS; MIGRATION; NECROSIS
AB Autophagy plays a protective role in colorectal carcinoma. Arginine ADP-ribosyltransferase 1 (ART1) is an important mono-ADP-ribose transferase, which has been shown to play a role in biological processes such as proliferation and invasion of cancer cells. Interestingly, the role of ART1 in the regulation of autophagy is still not clear. We examined effects of overexpression or knockdown of ART1 by lentiviral transfection on starvation-induced autophagy of colon carcinoma CT26 cell lines in vivo and in vitro. The formation of autophagosome was detected by electron microscopy, acridine orange staining and expression of LC3 B. The molecular contributions of ART1 in regulation of autophagy were detected by western blotting or by co-immunoprecipitation. Additionally, inhibitors were used to study further the signaling pathway of ART1 in the regulation of autophagy. CCK8 assay, plate cloning assay, soft agar assay, examination of subcutaneous transplanted carcinoma in BALB/c mice, flow cytometry and Hoechst33342 staining were used to assess survival and apoptotic ability when starvation-induced autophagy modulated by ART1 was inhibited by 3-MA. Overexpression of ART1 promoted starvation-induced autophagy, which related to increases in the expression of Rac1, NF-kappa B, PARP-1, LKB1 and p-AMPK and a decrease in the expression of p-P70S6K. Correspondingly, knockdown of ART1 caused the opposite effects. ART1 also interacted with integrin alpha 7. Additionally, changes of protein expressions were further validated following inhibition of Rac1 and PARP-1 in the starvation-induced ART1-GFP CT26 cells. Inhibition of ART1-stimulated starvation-induced autophagy restrained the growth and promoted apoptosis. ART1 is thus relevant in starvation-induced autophagy in colorectal carcinoma and may play essential roles in therapeutic anticancer strategies.
C1 [Tang, Yi; Li, Ming; Wang, Ya-Lan; Xiao, Ming; Song, Guang-Lin; Kuang, Jing; Yang, Xi] Chongqing Med Univ, Mol Med & Canc Res Ctr, Dept Pathol, Chongqing 400016, Peoples R China.
   [Threadgill, Michael D.] Univ Bath, Sch Pharm & Pharmacol, Bath BA2 7AY, Avon, England.
   [Mou, Chun-Feng; Yang, Li] Chongqing Med Univ, Fac Basic Med Sci, Chongqing 400016, Peoples R China.
   [Gao, Xing-Jie; Wang, Ya-Ping; Meng, Yun-Peng] Chongqing Med Univ, Clin Med Coll, Chongqing 400016, Peoples R China.
RP Wang, YL (corresponding author), Chongqing Med Univ, Mol Med & Canc Res Ctr, Dept Pathol, Chongqing 400016, Peoples R China.
EM wangyalan074@126.com
FU Ministry of Education Specialized Research Fund for the Doctoral Program
   of Higher Education [20105503110009]; Science and Technology Program of
   Chongqing Municipal Education Commission [KJ110322]; National Nature
   Science Foundation of China (NSFC)National Natural Science Foundation of
   China (NSFC) [30870946]
FX This study was supported by the Ministry of Education Specialized
   Research Fund for the Doctoral Program of Higher Education (Grant No.
   20105503110009), the Science and Technology Program of Chongqing
   Municipal Education Commission (Grant No. KJ110322) and the National
   Nature Science Foundation of China (NSFC: 30870946).
CR Bartnik A, 2011, ONCOLOGY NEWS, V5, P188
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Eskelinen EL, 2011, CURR OPIN PHARMACOL, V11, P294, DOI 10.1016/j.coph.2011.03.009
   Gastonguay AJ, 2012, CANCER BIOL THER, V13, P647, DOI 10.4161/cbt.20082
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249
   Helleday T, 2005, CELL CYCLE, V4, P1176, DOI 10.4161/cc.4.9.2031
   Huang Q, 2009, CELL DEATH DIFFER, V16, P264, DOI 10.1038/cdd.2008.151
   Huang Q, 2009, AUTOPHAGY, V5, P273, DOI 10.4161/auto.5.2.7640
   Jones EM, 1997, BIOCHEM J, V323, P173, DOI 10.1042/bj3230173
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kuang J, 2014, ONCOL REP, V31, P2335, DOI 10.3892/or.2014.3100
   Laing S, 2011, AMINO ACIDS, V41, P257, DOI 10.1007/s00726-010-0676-2
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Liu DL, 2011, MED ONCOL, V28, P105, DOI 10.1007/s12032-009-9397-3
   Matsuo N, 2003, MOL CELL NEUROSCI, V24, P69, DOI 10.1016/S1044-7431(03)00122-2
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Moss J, 1999, MOL CELL BIOCHEM, V193, P109, DOI 10.1023/A:1006924514074
   Munoz-Gomez JA, 2009, AUTOPHAGY, V5, P61, DOI 10.4161/auto.5.1.7272
   Paone G, 2002, P NATL ACAD SCI USA, V99, P8231, DOI 10.1073/pnas.122238899
   Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Saxty BA, 2001, BRIT J PHARMACOL, V133, P1219, DOI 10.1038/sj.bjp.0704187
   Scherz-Shouval R, 2007, TRENDS CELL BIOL, V17, P422, DOI 10.1016/j.tcb.2007.07.009
   Su Y, 2014, INT J MOL MED, V34, P842, DOI 10.3892/ijmm.2014.1819
   Sui YQ, 2012, CHINESE J CLIN EXPT, V3, P014
   Tang Y, 2013, INT J MOL MED, V32, P130, DOI 10.3892/ijmm.2013.1370
   Xiao M, 2013, CELL PHYSIOL BIOCHEM, V32, P1587, DOI 10.1159/000356595
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Zhao ZF, 2005, BIOCHEM J, V385, P309, DOI 10.1042/BJ20040590
   Zheng Hai-yang, 2012, Cancer Biology Medicine, V9, P105, DOI 10.3969/j.issn.2095-3941.2012.02.004
   Zhou Y, 2007, BIOCHEMISTRY-US, V46, P14907, DOI 10.1021/bi701384k
   ZOLKIEWSKA A, 1993, J BIOL CHEM, V268, P25273
   ZOLKIEWSKA A, 1995, J BIOL CHEM, V270, P9227, DOI 10.1074/jbc.270.16.9227
   ZOLKIEWSKA A, 1992, P NATL ACAD SCI USA, V89, P11352, DOI 10.1073/pnas.89.23.11352
NR 39
TC 13
Z9 14
U1 0
U2 8
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2156-6976
J9 AM J CANCER RES
JI Am. J. Cancer Res.
PY 2015
VL 5
IS 2
BP 498
EP 513
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CF0AL
UT WOS:000352204800003
PM 25973293
DA 2022-04-25
ER

PT J
AU Khandia, R
   Dadar, M
   Munjal, A
   Dhama, K
   Karthik, K
   Tiwari, R
   Yatoo, MI
   Iqbal, HMN
   Singh, KP
   Joshi, SK
   Chaicumpa, W
AF Khandia, Rekha
   Dadar, Maryam
   Munjal, Ashok
   Dhama, Kuldeep
   Karthik, Kumaragurubaran
   Tiwari, Ruchi
   Yatoo, Mohd Iqbal
   Iqbal, Hafiz M. N.
   Singh, Karam Pal
   Joshi, Sunil K.
   Chaicumpa, Wanpen
TI A Comprehensive Review of Autophagy and Its Various Roles in Infectious,
   Non-Infectious, and Lifestyle Diseases: Current Knowledge and Prospects
   for Disease Prevention, Novel Drug Design, and Therapy
SO CELLS
LA English
DT Review
DE autophagy mechanism; autophagy-associated diseases; macroautophagy;
   chaperone-mediated autophagy; apoptosis; necroptosis; necrosis; iron
   homeostasis; autophagy inhibition; AKT/mTOR signaling pathway; autosis
ID HEPATITIS-C VIRUS; CHAPERONE-MEDIATED AUTOPHAGY; ENDOPLASMIC-RETICULUM
   STRESS; STARVATION-INDUCED AUTOPHAGY; ACTIVATED PROTEIN-KINASE;
   COLORECTAL-CANCER CELLS; TUMOR-SUPPRESSOR GENE; X-LINKED MYOPATHY;
   ALPHA-SYNUCLEIN; SELECTIVE AUTOPHAGY
AB Autophagy (self-eating) is a conserved cellular degradation process that plays important roles in maintaining homeostasis and preventing nutritional, metabolic, and infection-mediated stresses. Autophagy dysfunction can have various pathological consequences, including tumor progression, pathogen hyper-virulence, and neurodegeneration. This review describes the mechanisms of autophagy and its associations with other cell death mechanisms, including apoptosis, necrosis, necroptosis, and autosis. Autophagy has both positive and negative roles in infection, cancer, neural development, metabolism, cardiovascular health, immunity, and iron homeostasis. Genetic defects in autophagy can have pathological consequences, such as static childhood encephalopathy with neurodegeneration in adulthood, Crohn's disease, hereditary spastic paraparesis, Danon disease, X-linked myopathy with excessive autophagy, and sporadic inclusion body myositis. Further studies on the process of autophagy in different microbial infections could help to design and develop novel therapeutic strategies against important pathogenic microbes. This review on the progress and prospects of autophagy research describes various activators and suppressors, which could be used to design novel intervention strategies against numerous diseases and develop therapeutic drugs to protect human and animal health.
C1 [Khandia, Rekha; Munjal, Ashok] Barkatullah Univ, Dept Genet, Bhopal 462026, Madhya Pradesh, India.
   [Dadar, Maryam] AREEO, Razi Vaccine & Serum Res Inst, Karaj 31975148, Iran.
   [Dhama, Kuldeep; Singh, Karam Pal] ICAR Indian Vet Res Inst, Div Pathol, Bareilly 243122, Uttar Pradesh, India.
   [Karthik, Kumaragurubaran] Tamil Nadu Vet & Anim Sci Univ, Cent Univ Lab, Chennai 600051, Tamil Nadu, India.
   [Tiwari, Ruchi] UP Pandit Deen Dayal Upadhayay Pashu Chikitsa Vig, Coll Vet Sci, Dept Vet Microbiol & Immunol, Mathura 281001, Uttar Pradesh, India.
   [Yatoo, Mohd Iqbal] Sher E Kashmir Univ Agr Sci & Technol Kashmir, Srinagar 190025, Jammu & Kashmir, India.
   [Iqbal, Hafiz M. N.] Tecnol Monterrey, Sch Engn & Sci, Campus Monterrey,Ave Eugenio Garza Sada 2501, Monterrey 64849, NL, Mexico.
   [Joshi, Sunil K.] Univ Miami, Sch Med, Div Hematol Oncol & Bone Marrow Transplantat, Dept Pediat, Miami, FL 33136 USA.
   [Chaicumpa, Wanpen] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Parasitol,Ctr Res Excellence Therapeut Prot, Bangkok 10700, Thailand.
RP Munjal, A (corresponding author), Barkatullah Univ, Dept Genet, Bhopal 462026, Madhya Pradesh, India.; Dhama, K (corresponding author), ICAR Indian Vet Res Inst, Div Pathol, Bareilly 243122, Uttar Pradesh, India.; Joshi, SK (corresponding author), Univ Miami, Sch Med, Div Hematol Oncol & Bone Marrow Transplantat, Dept Pediat, Miami, FL 33136 USA.
EM ak.munjal@bubhopal.ac.in; kdhama@rediffmail.com;
   sunil.joshi@med.miami.edu
RI Dadar, Maryam/D-3660-2017; Yatoo, Mohd Iqbal/AAT-1624-2020; Khandia,
   Rekha/AAE-6122-2022; Karthik, K/AAN-5411-2020; Kumaragurubaran,
   Karthik/ABF-9301-2021; Dhama, Kuldeep/B-7852-2015; Tiwari,
   Ruchi/ABG-9049-2021; Iqbal, Hafiz M.N./J-5423-2014
OI Dadar, Maryam/0000-0001-5831-801X; Khandia, Rekha/0000-0002-9961-3127;
   Kumaragurubaran, Karthik/0000-0002-9215-6306; Dhama,
   Kuldeep/0000-0001-7469-4752; Tiwari, Ruchi/0000-0001-7763-5547; Iqbal,
   Hafiz M.N./0000-0003-4855-2720; Munjal, Ashok/0000-0001-6294-1584;
   Yatoo, Dr. Mohd. Iqbal/0000-0002-4501-7354
CR Aguib Y, 2009, AUTOPHAGY, V5, P361, DOI 10.4161/auto.5.3.7662
   Ahmad L, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00155
   Ahmed Mahmoud, 2018, Oncotarget, V9, P15526, DOI 10.18632/oncotarget.24506
   Akazawa H, 2004, J BIOL CHEM, V279, P41095, DOI 10.1074/jbc.M313084200
   Alem F, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00050
   Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11
   Alexander A, 2010, P NATL ACAD SCI USA, V107, P4153, DOI 10.1073/pnas.0913860107
   Allison Susan J, 2016, Nat Rev Rheumatol, V12, P311, DOI 10.1038/nrrheum.2016.73
   Amaravadi RK, 2016, Dimeric quinacrine derivatives as autophagy inhibitors for cancer therapy, Patent No. [WO2016168721, 2016168721]
   Anding AL, 2017, DEV CELL, V41, P10, DOI 10.1016/j.devcel.2017.02.016
   Antonioli M, 2017, TRENDS BIOCHEM SCI, V42, P28, DOI 10.1016/j.tibs.2016.09.008
   Arenas F, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00382
   Arnold J, 2016, CELL DEATH DIFFER, V23, P853, DOI 10.1038/cdd.2015.149
   Arsham AM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006068
   Bader CA, 2015, BIOL OPEN, V4, P1345, DOI 10.1242/bio.013979
   Balvers R, 2011, FUTURE VIROL, V6, P1161, DOI 10.2217/FVL.11.93
   Bandyopadhyay U, 2008, MOL CELL BIOL, V28, P5747, DOI 10.1128/MCB.02070-07
   Barboza LA, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414-431X20176299, 10.1590/1414-431x20176299]
   Barnwal B, 2016, J BIOL CHEM, V291, P582, DOI 10.1074/jbc.M115.667436
   Battu S, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2005317
   Baumgart DC, 2012, LANCET, V380, P1590, DOI 10.1016/S0140-6736(12)60026-9
   Becker AC, 2018, MOL CELL PROTEOMICS, V17, P1909, DOI 10.1074/mcp.RA117.000364
   Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204
   Bell BD, 2008, P NATL ACAD SCI USA, V105, P16677, DOI 10.1073/pnas.0808597105
   Benhar M, 2009, NAT REV MOL CELL BIO, V10, P721, DOI 10.1038/nrm2764
   Berndt J. D., 2014, SCI SIGNAL, V7, pec99
   Bhattacharya D, 2018, EXCLI J, V17, P709, DOI 10.17179/excli2018-1353
   Bi XN, 2007, AUTOPHAGY, V3, P646, DOI 10.4161/auto.5074
   Birmingham CL, 2006, AUTOPHAGY, V2, P156, DOI 10.4161/auto.2825
   Boada-Romero E, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11821
   Bonapace L, 2010, J CLIN INVEST, V120, P1310, DOI 10.1172/JCI39987
   Bradner J. E., 2008, Patent WO, Patent No. [2008122038A1, 2008122038]
   Bussi C, 2017, SCI REP-UK, V7, DOI 10.1038/srep43153
   Campbell GR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002689
   Campbell P, 2018, EXPERT OPIN THER TAR, V22, P823, DOI 10.1080/14728222.2018.1517156
   Cao CH, 2017, INT J CLIN EXP MED, V10, P5497
   Cao ZX, 2017, J ETHNOPHARMACOL, V202, P20, DOI 10.1016/j.jep.2016.07.028
   Carew J., 2018, U. S. Patent, Patent No. 9926326
   Cargnello M, 2015, MUTAGENESIS, V30, P169, DOI 10.1093/mutage/geu045
   Caruso Lisa B, 2018, Oncotarget, V9, P10585, DOI 10.18632/oncotarget.24291
   Cerezo M, 2017, AUTOPHAGY, V13, P216, DOI 10.1080/15548627.2016.1246107
   Cesari R, 2003, P NATL ACAD SCI USA, V100, P5956, DOI 10.1073/pnas.0931262100
   Chang TY, 2005, J BIOL CHEM, V280, P20917, DOI 10.1074/jbc.R400040200
   Chatterjee A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095716
   Che Y, 2018, MOL MED REP, V18, P3251, DOI 10.3892/mmr.2018.9301
   Chen HD, 2017, AUTOPHAGY, V13, P371, DOI 10.1080/15548627.2016.1256933
   Chen X, 2016, SCI REP-UK, V6, DOI 10.1038/srep28423
   Chen Yong, 2012, Sci Rep, V2, P808, DOI 10.1038/srep00808
   Chiramel Abhilash I, 2013, Cells, V2, P83, DOI 10.3390/cells2010083
   Chiu HC, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-110
   Chiu HC, 2009, ANTIMICROB AGENTS CH, V53, P5236, DOI 10.1128/AAC.00555-09
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Clarke AJ, 2019, NAT REV IMMUNOL, V19, P170, DOI 10.1038/s41577-018-0095-2
   Comincini S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020391
   Congdon EE, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00372
   Cooper KF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4701275
   Cottam EM, 2011, AUTOPHAGY, V7, P1335, DOI 10.4161/auto.7.11.16642
   Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501
   Cullup T, 2013, NAT GENET, V45, P83, DOI 10.1038/ng.2497
   D'amelio M., 2012, PatentWO, Patent No. 2012076555
   D'souza RS, 2014, CIRC-HEART FAIL, V7, P843, DOI 10.1161/CIRCHEARTFAILURE.114.001105
   Dahmene M, 2017, J BIOL CHEM, V292, P3919, DOI 10.1074/jbc.M116.759373
   Das TK, 2015, ARCH NEUROSCI, V2, DOI 10.5812/archneurosci.20078
   Dash S, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8050150
   Daskalaki I, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00104
   Datan E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.409
   Silva BJD, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006103
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Deng ZQ, 2017, TRENDS CELL BIOL, V27, P491, DOI 10.1016/j.tcb.2017.01.001
   Dent P., 2016, Patent WO, Patent No. 2016069854
   Deretic V, 2013, NAT REV IMMUNOL, V13, P722, DOI 10.1038/nri3532
   Deretic V, 2009, CURR OPIN IMMUNOL, V21, P53, DOI 10.1016/j.coi.2009.02.002
   Dhama K, 2013, INT J CURR RES, V5
   Dhama K, 2016, RECENT PATENTS INFLA, V10, P105, DOI 10.2174/1872213X10666161226162229
   Dhama K, 2015, INT J PHARMACOL, V11, P253, DOI 10.3923/ijp.2015.253.290
   Dhama Kuldeep, 2013, Pak J Biol Sci, V16, P101, DOI 10.3923/pjbs.2013.101.111
   DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8
   Ding WX, 2012, BIOL CHEM, V393, P547, DOI 10.1515/hsz-2012-0119
   Donovan A, 2006, PHYSIOLOGY, V21, P115, DOI 10.1152/physiol.00052.2005
   Dorn BR, 2002, CELL MICROBIOL, V4, P1, DOI 10.1046/j.1462-5822.2002.00164.x
   Dowdle WE, 2014, NAT CELL BIOL, V16, P1069, DOI 10.1038/ncb3053
   Dowling JJ, 2015, ACTA NEUROPATHOL, V129, P383, DOI 10.1007/s00401-015-1393-4
   Ebato C, 2008, CELL METAB, V8, P325, DOI 10.1016/j.cmet.2008.08.009
   Egger D, 2002, J VIROL, V76, P5974, DOI 10.1128/JVI.76.12.5974-5984.2002
   English L, 2009, NAT IMMUNOL, V10, P480, DOI 10.1038/ni.1720
   Fabri M, 2011, CURR OPIN IMMUNOL, V23, P65, DOI 10.1016/j.coi.2010.10.010
   Fan XX, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.489
   Farkas T, 2011, J BIOL CHEM, V286, P38904, DOI 10.1074/jbc.M111.269134
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925
   Fitzwalter BE, 2015, FEBS J, V282, P4279, DOI 10.1111/febs.13515
   Floto RA, 2007, AUTOPHAGY, V3, P620, DOI 10.4161/auto.4898
   Franco LH, 2017, CELL HOST MICROBE, V21, P59, DOI [10.1016/j.chom.2017.08.005, 10.1016/j.chom.2016.11.002]
   Frankel LB, 2017, AUTOPHAGY, V13, P3, DOI 10.1080/15548627.2016.1222992
   Frederick C, 2015, J ALZHEIMERS DIS, V44, P1145, DOI 10.3233/JAD-142097
   Fu Q, 2014, J MICROBIOL, V52, P619, DOI 10.1007/s12275-014-3479-4
   Fujikake N, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00255
   Fujita N, 2009, J BIOL CHEM, V284, P32602, DOI 10.1074/jbc.M109.037671
   Fujiwara Y, 2017, J BIOCHEM, V161, P145, DOI 10.1093/jb/mvw085
   Fukuda T, 2018, MOL CELLS, V41, P35, DOI 10.14348/molcells.2018.2214
   Fullgrabe J, 2016, J CELL SCI, V129, P3059, DOI 10.1242/jcs.188920
   Ganesan R, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006227
   Gannage M, 2009, CELL HOST MICROBE, V6, P367, DOI 10.1016/j.chom.2009.09.005
   Ganz T., 2014, Patent CA, Patent No. [2890040A1, 2890040]
   Gentilella A, 2015, BBA-GENE REGUL MECH, V1849, P812, DOI 10.1016/j.bbagrm.2015.02.005
   Germic N, 2019, CELL DEATH DIFFER, V26, P715, DOI 10.1038/s41418-019-0297-6
   Germic N, 2019, CELL DEATH DIFFER, V26, P703, DOI 10.1038/s41418-019-0295-8
   Gewirtz DA, 2009, AUTOPHAGY, V5, P1232, DOI 10.4161/auto.5.8.9896
   Girault V, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.29
   Gkikas I, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01283
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Goldman SJ, 2011, ANTIOXID REDOX SIGN, V14, P1971, DOI 10.1089/ars.2010.3777
   Goodall ML, 2016, DEV CELL, V37, P337, DOI 10.1016/j.devcel.2016.04.018
   Gorski SM, 2011, Inhibition of autophagy genes in cancer chemotherapy, Patent No. [8076308, US8076308]
   Gozuacik D, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00065
   Gu Y, 2016, ONCOTARGET, V7, P24656, DOI 10.18632/oncotarget.8262
   Gump JM, 2014, AUTOPHAGY, V10, P1327, DOI 10.4161/auto.29394
   Guo B, 2014, EMBO REP, V15, P705, DOI 10.1002/embr.201338310
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Gustafsson AB, 2009, CIRC RES, V104, P150, DOI 10.1161/CIRCRESAHA.108.187427
   Haack TB, 2012, AM J HUM GENET, V91, P1144, DOI 10.1016/j.ajhg.2012.10.019
   Halfon P, 2015, U. S. Patent, Patent No. 8987302
   Hamai A, 2017, M S-MED SCI, V33, P260, DOI 10.1051/medsci/20173303012
   Han BA, 2016, TRENDS PARASITOL, V32, P565, DOI 10.1016/j.pt.2016.04.007
   Hansen MD, 2017, P NATL ACAD SCI USA, V114, pE3462, DOI 10.1073/pnas.1616683114
   Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724
   Hara T, 2009, AUTOPHAGY, V5, P85, DOI 10.4161/auto.5.1.7180
   Harhaji-Trajkovic L, 2012, PHARM RES-DORDR, V29, P2249, DOI 10.1007/s11095-012-0753-1
   Harris J, 2011, J BIOL CHEM, V286, P9587, DOI 10.1074/jbc.M110.202911
   Hassanpour M, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-1060-5
   He Q, 2016, MOL NEUROBIOL, V53, P2258, DOI 10.1007/s12035-015-9173-7
   He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021
   Heckmann BL, 2013, BRIT J PHARMACOL, V168, P163, DOI 10.1111/j.1476-5381.2012.02110.x
   Herb M., 2019, SEMIN CELL DEV BIOL
   Hidenao S., 2017, Patent JPWO, Patent No. 2015037656
   Holland P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13889
   Honma Y, 2018, HEPATOL RES, V48, P94, DOI 10.1111/hepr.12892
   Hsu P, 2017, BBA-MOL CELL BIOL L, V1862, P114, DOI 10.1016/j.bbalip.2016.08.003
   Huang C. C., 2018, U. S. Patent, Patent No. 20180050012
   Huang CQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020975
   Huang F, 2018, WORLD J GASTROENTERO, V24, P4643, DOI 10.3748/wjg.v24.i41.4643
   Huang SB, 2010, AUTOPHAGY, V6, P256, DOI 10.4161/auto.6.2.11124
   Huang XW, 2016, SCI REP-UK, V6, DOI 10.1038/srep22303
   Huang YP, 2011, CELL CYCLE, V10, P3938, DOI 10.4161/cc.10.22.18107
   Huber LA, 2016, CURR OPIN CELL BIOL, V39, P8, DOI 10.1016/j.ceb.2016.01.006
   Hurley JH, 2017, ANNU REV BIOCHEM, V86, P225, DOI 10.1146/annurev-biochem-061516-044820
   Hutchins MU, 1999, J CELL SCI, V112, P4079
   Iida T, 2017, WORLD J GASTROENTERO, V23, P1944, DOI 10.3748/wjg.v23.i11.1944
   Iqbal HMN, 2016, RECENT PATENTS INFLA, V10, P86, DOI 10.2174/1872213X10666161213162823
   Isakson P, 2013, CELL DEATH DIFFER, V20, P12, DOI 10.1038/cdd.2012.66
   Jackson WT, 2005, PLOS BIOL, V3, P861, DOI 10.1371/journal.pbio.0030156
   Jang YJ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020138
   Janji B, 2016, CURR CANCER RES, P117, DOI 10.1007/978-3-319-42740-9_7
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P384, DOI 10.1038/nrclinonc.2011.82
   Ji MM, 2015, AUTOPHAGY, V11, P2160, DOI 10.1080/15548627.2015.1082024
   Jia KL, 2007, AUTOPHAGY, V3, P21, DOI 10.4161/auto.3528
   Jia KL, 2009, P NATL ACAD SCI USA, V106, P14564, DOI 10.1073/pnas.0813319106
   Jiang GM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0944-z
   Jiang H, 2008, AUTOPHAGY, V4, P118, DOI 10.4161/auto.5260
   Jin Juan, 2019, Ren Fail, V41, P294, DOI 10.1080/0886022X.2019.1598432
   Jin SK, 2006, AUTOPHAGY, V2, P80, DOI 10.4161/auto.2.2.2460
   Jing Z, 2015, CANCER LETT, V356, P332, DOI 10.1016/j.canlet.2014.09.039
   Jones KE, 2008, NATURE, V451, P990, DOI 10.1038/nature06536
   Joy S, 2018, CELL DEATH DISCOV, V4, DOI 10.1038/s41420-018-0107-9
   Jung HS, 2008, CELL METAB, V8, P318, DOI 10.1016/j.cmet.2008.08.013
   Jung J. U., 2010, Patent WO, Patent No. 2010011952
   Jung M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116972
   Kamada Y, 2010, MOL CELL BIOL, V30, P1049, DOI 10.1128/MCB.01344-09
   Kanki T, 2009, DEV CELL, V17, P98, DOI 10.1016/j.devcel.2009.06.014
   Karlsson M, 2013, EXP EYE RES, V116, P359, DOI 10.1016/j.exer.2013.10.014
   Kaur J, 2015, NAT REV MOL CELL BIO, V16, P461, DOI 10.1038/nrm4024
   Kaushik S, 2009, METHOD ENZYMOL, V452, P297, DOI 10.1016/S0076-6879(08)03619-7
   Ke PY, 2011, J CLIN INVEST, V121, P37, DOI 10.1172/JCI41474
   Khambu B, 2018, SEMIN LIVER DIS, V38, P308, DOI 10.1055/s-0038-1669939
   Khandia R., 2016, TOPICS ANTICANCER RE, P43
   Khandia R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00597
   Khandia R, 2016, RECENT PATENTS INFLA, V10, P94, DOI 10.2174/1872213X10666161213163301
   Kharaziha P, 2015, ONCOTARGET, V6, P37066, DOI 10.18632/oncotarget.5797
   Kheloufi M, 2015, HEPATOLOGY, V62, P657, DOI 10.1002/hep.27597
   Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5
   Kim HJ, 2010, SEMIN IMMUNOPATHOL, V32, P323, DOI 10.1007/s00281-010-0226-8
   Kim JK, 2017, AUTOPHAGY, V13, P423, DOI 10.1080/15548627.2016.1241922
   Kim YH, 2011, J NEUROSCI RES, V89, P1666, DOI 10.1002/jnr.22700
   Kimmelman A. C., 2015, Patent WO, Patent No. 2015149006
   Kissing S, 2017, AUTOPHAGY, V13, P670, DOI 10.1080/15548627.2017.1280216
   Kissova I, 2007, AUTOPHAGY, V3, P329, DOI 10.4161/auto.4034
   Klein JA, 2017, METHODS MOL BIOL, V1519, P285, DOI 10.1007/978-1-4939-6581-6_19
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   Kovacs T, 2017, SCI REP-UK, V7, DOI 10.1038/srep42014
   Krishan S, 2015, NAGOYA J MED SCI, V77, P1
   Krokowski S, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00017
   Kruger U, 2012, NEUROBIOL AGING, V33, P2291, DOI 10.1016/j.neurobiolaging.2011.11.009
   Kuchitsu Y, 2018, J CELL SCI, V131, DOI 10.1242/jcs.215442
   Kudchodkar SB, 2009, REV MED VIROL, V19, P359, DOI 10.1002/rmv.630
   Kuldeep Dhama, 2014, Research Opinions in Animal and Veterinary Sciences, V4, P353
   Kuldeep Dhama, 2013, Research Opinions in Animal and Veterinary Sciences, V3, P195
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029
   Kumsta C, 2017, AUTOPHAGY, V13, P1076, DOI 10.1080/15548627.2017.1299313
   Kunz JB, 2004, J BIOL CHEM, V279, P9987, DOI 10.1074/jbc.M307905200
   Kurz T, 2011, FREE RADICAL BIO MED, V50, P1647, DOI 10.1016/j.freeradbiomed.2011.03.014
   KVANSAKUL M, 2017, VIRUSES-BASEL, V9, DOI DOI 10.3390/V9100290
   Kyei GB, 2009, J CELL BIOL, V186, P255, DOI 10.1083/jcb.200903070
   Lassen KG, 2017, MUCOSAL IMMUNOL, V10, P589, DOI 10.1038/mi.2017.18
   Law Y. K., 2015, U. S. Patent, Patent No. 9005677
   Lee HK, 2007, SCIENCE, V315, P1398, DOI 10.1126/science.1136880
   Lee IH, 2009, J BIOL CHEM, V284, P6322, DOI 10.1074/jbc.M807135200
   Lee J, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7110198
   Lee MS, 2018, MOL CELLS, V41, P1, DOI 10.14348/molcells.2018.0400
   Lee SH, 2007, APMIS, V115, P1274, DOI 10.1111/j.1600-0643.2007.00795.x
   Lee WS, 2015, J LEUKOCYTE BIOL, V97, P425, DOI 10.1189/jlb.6A0214-097R
   Lee YR, 2008, VIROLOGY, V374, P240, DOI 10.1016/j.virol.2008.02.016
   Lee YR, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18909-3
   Lee YA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07338-z
   Lei YY, 2017, CANCER LETT, V393, P33, DOI 10.1016/j.canlet.2017.02.012
   Levine B. C., 2017, Patent CA, Patent No. [2864145C, 2864145]
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levine B, 2007, NAT REV IMMUNOL, V7, P767, DOI 10.1038/nri2161
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Li C, 2017, FISH SHELLFISH IMMUN, V60, P25, DOI 10.1016/j.fsi.2016.11.037
   Li M., 2016, U. S. Patent, Patent No. 9351946
   Li M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030332
   Li SJ, 2016, ONCOL LETT, V12, P5059, DOI 10.3892/ol.2016.5367
   Li WW, 2012, CELL MOL LIFE SCI, V69, P1125, DOI 10.1007/s00018-011-0865-5
   Li XL, 2015, INT J CLIN EXP MED, V8, P10304
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang QM, 2013, J VIROL, V87, P12499, DOI 10.1128/JVI.01898-13
   Liang QP, 2019, PHYTOMEDICINE, V58, DOI 10.1016/j.phymed.2018.11.029
   Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liao GH, 2007, AM J PATHOL, V171, P962, DOI 10.2353/ajpath.2007.070052
   Liao ZH, 2019, IN VITRO CELL DEV-AN, V55, P341, DOI 10.1007/s11626-019-00342-7
   Lim Y, 2016, BRAIN RES, V1649, P158, DOI 10.1016/j.brainres.2016.02.049
   Lin JF, 2016, DRUG DES DEV THER, V10, P1501, DOI 10.2147/DDDT.S95900
   Lin LT, 2010, VIROLOGY, V402, P1, DOI 10.1016/j.virol.2010.03.026
   Lin MG, 2016, CURR OPIN CELL BIOL, V39, P61, DOI 10.1016/j.ceb.2016.02.010
   Lindsey ARI, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10040141
   Liu D, 2017, AM J NEPHROL, V45, P293, DOI 10.1159/000456039
   Liu HL, 2019, IUBMB LIFE, V71, P1771, DOI 10.1002/iub.2121
   Liu L., 2018, U. S. Patent, Patent No. [9861623B1, 9861623]
   Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143
   Liu Y, 2013, P NATL ACAD SCI USA, V110, P20364, DOI 10.1073/pnas.1319661110
   Lu Q, 2011, DEV CELL, V21, P343, DOI 10.1016/j.devcel.2011.06.024
   Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512
   Luo QH, 2018, ISCIENCE, V3, P87, DOI 10.1016/j.isci.2018.04.010
   Luo T, 2016, AUTOPHAGY, V12, P1355, DOI 10.1080/15548627.2015.1034405
   Ma JJ, 2017, INT IMMUNOPHARMACOL, V46, P70, DOI 10.1016/j.intimp.2017.02.026
   Machiya Y, 2010, J BIOL CHEM, V285, P40732, DOI 10.1074/jbc.M110.141952
   Madeo F, 2015, J CLIN INVEST, V125, P85, DOI 10.1172/JCI73946
   Mahil SK, 2016, J INVEST DERMATOL, V136, P2251, DOI 10.1016/j.jid.2016.06.618
   Mahima, 2012, Pak J Biol Sci, V15, P754, DOI 10.3923/pjbs.2012.754.774
   Maier HJ, 2012, VIRUSES-BASEL, V4, P3440, DOI 10.3390/v4123440
   Majdoul S, 2017, J BIOL CHEM, V292, P18672, DOI 10.1074/jbc.M117.800813
   Majeski AE, 2004, INT J BIOCHEM CELL B, V36, P2435, DOI 10.1016/j.biocel.2004.02.013
   Malik Y. S., 2013, South Asian Journal of Experimental Biology, V3, P207
   Mancias JD, 2016, J MOL BIOL, V428, P1659, DOI 10.1016/j.jmb.2016.02.027
   Mancias JD, 2014, NATURE, V509, P105, DOI 10.1038/nature13148
   Mandhana R, 2018, J INTERF CYTOK RES, V38, P319, DOI 10.1089/jir.2018.0049
   Manjithaya R., 2017, Patent WO, Patent No. [2017098467A1, 2017098467]
   Mardones P, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf1937
   Mari M, 2010, J CELL BIOL, V190, P1005, DOI 10.1083/jcb.200912089
   Marinkovic M, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8023821
   Marino G, 2004, CELL MOL LIFE SCI, V61, P1439, DOI 10.1007/s00018-004-4012-4
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Maron BJ, 2009, JAMA-J AM MED ASSOC, V301, P1253, DOI 10.1001/jama.2009.371
   Martin-Acebes MA, 2015, AUTOPHAGY, V11, P861, DOI 10.1080/15548627.2015.1037062
   Mastaglia F L, 2009, Acta Myol, V28, P66
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Matsui Y, 2007, CIRC RES, V100, P914, DOI 10.1161/01.RES.0000261924.76669.36
   McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109
   McKnight NC, 2012, EMBO J, V31, P1931, DOI 10.1038/emboj.2012.36
   McLean JE, 2011, J BIOL CHEM, V286, P22147, DOI 10.1074/jbc.M110.192500
   Meier JL, 2017, YALE J BIOL MED, V90, P25
   Meng CC, 2012, ARCH VIROL, V157, P1011, DOI 10.1007/s00705-012-1270-6
   Menghini R, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.556
   Menon MB, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00137
   Menzies FM, 2017, NEURON, V93, P1015, DOI 10.1016/j.neuron.2017.01.022
   Mercer TJ, 2018, J BIOL CHEM, V293, P5386, DOI 10.1074/jbc.R117.810366
   Metaxakis A, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7050037
   Middleton R. P., 2016, Patent EP, Patent No. 2717695
   Milne JC, 2008, CURR OPIN CHEM BIOL, V12, P11, DOI 10.1016/j.cbpa.2008.01.019
   Mindell JA, 2012, ANNU REV PHYSIOL, V74, P69, DOI 10.1146/annurev-physiol-012110-142317
   Mitchell G, 2018, P NATL ACAD SCI USA, V115, pE210, DOI 10.1073/pnas.1716055115
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mizushima N, 2010, CURR OPIN CELL BIOL, V22, P132, DOI 10.1016/j.ceb.2009.12.004
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Molino D, 2017, J MOL BIOL, V429, P497, DOI 10.1016/j.jmb.2016.12.013
   Moras M, 2017, FRONT PHYSIOL, V8, DOI [10.3389/FPHYS.2017.01076, 10.3389/fphys.2017.01076]
   Moreau K, 2010, CELL MICROBIOL, V12, P1108, DOI 10.1111/j.1462-5822.2010.01456.x
   Moriwaki K, 2013, GENE DEV, V27, P1640, DOI 10.1101/gad.223321.113
   Moriyasu Y, 2008, METHOD ENZYMOL, V451, P557, DOI 10.1016/S0076-6879(08)03232-1
   Mortensen M, 2010, P NATL ACAD SCI USA, V107, P832, DOI 10.1073/pnas.0913170107
   Motoi Y, 2014, ACS CHEM NEUROSCI, V5, P434, DOI 10.1021/cn500056q
   Moulis M, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7100149
   Mowers EE, 2016, AUTOPHAGY, V12, P1679, DOI 10.1080/15548627.2016.1203487
   Moy RH, 2014, IMMUNITY, V40, P51, DOI 10.1016/j.immuni.2013.10.020
   Mrakovcic M, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8020014
   Munoz-Pinedo C, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.246
   Nagar R, 2017, INDIAN J DERMATOL VE, V83, P290, DOI 10.4103/0378-6323.196320
   Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966
   Nakai A, 2007, NAT MED, V13, P619, DOI 10.1038/nm1574
   Nakajima S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170138
   Nakamoto M, 2012, IMMUNITY, V36, P658, DOI 10.1016/j.immuni.2012.03.003
   Nazarko TY, 2009, MOL BIOL CELL, V20, P3828, DOI 10.1091/mbc.E09-03-0221
   Needs S., 2016, P FRANKF C UB AUT QU
   Nezis IP, 2010, AUTOPHAGY, V6, P1214, DOI 10.4161/auto.6.8.13694
   Ng KM, 2016, CIRCULATION, V134, P1373, DOI 10.1161/CIRCULATIONAHA.115.019847
   Ni HM, 2016, AM J PATHOL, V186, P2623, DOI 10.1016/j.ajpath.2016.06.009
   Nicolas G., 2007, U. S. Patent, Patent No. [7169758B2, 7169758]
   Nikoletopoulou V, 2015, CELL DEATH DIFFER, V22, P398, DOI 10.1038/cdd.2014.204
   Nimmerjahn F, 2003, EUR J IMMUNOL, V33, P1250, DOI 10.1002/eji.200323730
   Nishino I, 2000, NATURE, V406, P906, DOI 10.1038/35022604
   Niu H, 2008, CELL MICROBIOL, V10, P593, DOI 10.1111/j.1462-5822.2007.01068.x
   Niu H, 2012, P NATL ACAD SCI USA, V109, P20800, DOI 10.1073/pnas.1218674109
   Nixon RA, 2008, AUTOPHAGY, V4, P590, DOI 10.4161/auto.6259
   Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232
   Nixon RA, 2006, ALZHEIMER'S DISEASE: A CENTURY OF SCIENTIFIC AND CLINICAL RESEARCH, P277
   Nogalska A, 2010, AM J PATHOL, V177, P1377, DOI 10.2353/ajpath.2010.100050
   Novak I, 2011, AUTOPHAGY, V7, P301, DOI 10.4161/auto.7.3.14509
   Novak I, 2010, EMBO REP, V11, P45, DOI 10.1038/embor.2009.256
   O'Donnell V, 2011, VIROLOGY, V410, P142, DOI 10.1016/j.virol.2010.10.042
   Oami Takehiko, 2017, Crit Care Med, V45, pe77
   OgierDenis E, 1996, J BIOL CHEM, V271, P28593, DOI 10.1074/jbc.271.45.28593
   Okamoto K, 2009, DEV CELL, V17, P87, DOI 10.1016/j.devcel.2009.06.013
   Oot RA, 2017, PROTEIN SCI, V26, P896, DOI 10.1002/pro.3147
   Orvedahl A, 2007, CELL HOST MICROBE, V1, P23, DOI 10.1016/j.chom.2006.12.001
   Orvedahl A, 2010, CELL HOST MICROBE, V7, P115, DOI 10.1016/j.chom.2010.01.007
   Osborn SL, 2010, P NATL ACAD SCI USA, V107, P13034, DOI 10.1073/pnas.1005997107
   Owczarczyk AB, 2015, J IMMUNOL, V195, P1637, DOI 10.4049/jimmunol.1500326
   Oz-Levi D, 2012, AM J HUM GENET, V91, P1065, DOI 10.1016/j.ajhg.2012.09.015
   Ozawa T, 2014, AM J MED GENET A, V164, P2388, DOI 10.1002/ajmg.a.36635
   Pajuelo D, 2018, CELL REP, V24, P429, DOI 10.1016/j.celrep.2018.06.042
   Paolini A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27429-7
   Park HJ, 2011, MOL IMMUNOL, V48, P720, DOI 10.1016/j.molimm.2010.10.020
   Park S, 2016, CELL HOST MICROBE, V19, P91, DOI 10.1016/j.chom.2015.12.010
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Pattison JS, 2011, AUTOPHAGY, V7, P1259, DOI 10.4161/auto.7.10.16882
   Paul P, 2016, ADV VIRUS RES, V95, P149, DOI 10.1016/bs.aivir.2016.02.002
   Paul S, 2012, IMMUNITY, V36, P947, DOI 10.1016/j.immuni.2012.04.008
   Peng HP, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10050259
   Pengo N, 2013, NAT IMMUNOL, V14, P298, DOI 10.1038/ni.2524
   Philpott DJ, 2014, NAT REV IMMUNOL, V14, P9, DOI 10.1038/nri3565
   Pickford F, 2008, J CLIN INVEST, V118, P2190, DOI 10.1172/JCI33585
   Pierzynowska K, 2018, METAB BRAIN DIS, V33, P989, DOI 10.1007/s11011-018-0214-6
   Pietrocola F, 2015, CELL DEATH DIFFER, V22, P509, DOI 10.1038/cdd.2014.215
   Pietrocola F, 2014, CELL CYCLE, V13, P1987, DOI 10.4161/cc.28929
   Pissawong T, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-148
   Pleet ML, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00362
   Polson HEJ, 2010, AUTOPHAGY, V6, P506, DOI 10.4161/auto.6.4.11863
   Pott J, 2018, AUTOPHAGY, V14, P1460, DOI 10.1080/15548627.2018.1450021
   Prentice E, 2004, J BIOL CHEM, V279, P10136, DOI 10.1074/jbc.M306124200
   Puyal J, 2013, PROG NEUROBIOL, V105, P24, DOI 10.1016/j.pneurobio.2013.03.002
   Qian QW, 2018, DIABETES, V67, P193, DOI 10.2337/db17-0223
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Rainsford KD, 2015, INFLAMMOPHARMACOLOGY, V23, P231, DOI 10.1007/s10787-015-0239-y
   Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362
   Redmann M, 2017, REDOX BIOL, V11, P73, DOI 10.1016/j.redox.2016.11.004
   Reggiori F, 2010, CELL HOST MICROBE, V7, P500, DOI 10.1016/j.chom.2010.05.013
   Renna M, 2010, J BIOL CHEM, V285, P11061, DOI 10.1074/jbc.R109.072181
   REZ G, 1973, ACTA BIOL ACAD SCI H, V24, P201
   Richards AL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003046
   Robinson CM, 2017, J VIROL, V91, DOI 10.1128/JVI.02101-16
   Roehrich AD, 2017, J BIOL CHEM, V292, P1705, DOI 10.1074/jbc.M116.746826
   Rossman JS, 2009, CELL HOST MICROBE, V6, P299, DOI 10.1016/j.chom.2009.09.009
   Rothaug M, 2015, ACTA NEUROPATHOL COM, V3, DOI 10.1186/s40478-014-0182-y
   Rothermel BA, 2008, CIRC RES, V103, P1363, DOI 10.1161/CIRCRESAHA.108.186551
   Rowland TJ, 2016, J CELL SCI, V129, P2135, DOI 10.1242/jcs.184770
   Rubinstein AD, 2011, MOL CELL, V44, P698, DOI 10.1016/j.molcel.2011.10.014
   Ruggieri A, 2015, NEUROMUSCULAR DISORD, V25, P207, DOI 10.1016/j.nmd.2014.11.014
   Sahni S, 2014, J CLIN PATHOL, V67, P656, DOI 10.1136/jclinpath-2014-202356
   Sahu R, 2011, DEV CELL, V20, P131, DOI 10.1016/j.devcel.2010.12.003
   Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383
   Saitsu H, 2013, NAT GENET, V45, P445, DOI 10.1038/ng.2562
   Salah FS, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.93
   Sandoval H, 2018, MITOCHONDRION, V41, P58, DOI 10.1016/j.mito.2017.11.005
   Saribas AS, 2015, CELL CYCLE, V14, P2899, DOI 10.1080/15384101.2015.1069927
   Sarkar S, 2005, J CELL BIOL, V170, P1101, DOI 10.1083/jcb.200504035
   Sarkar S, 2009, CELL DEATH DIFFER, V16, P46, DOI 10.1038/cdd.2008.110
   Sarkar S, 2007, J BIOL CHEM, V282, P5641, DOI 10.1074/jbc.M609532200
   Sarkar S, 2013, CELL REP, V5, P1302, DOI 10.1016/j.celrep.2013.10.042
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Schiattarella GG, 2016, J MOL CELL CARDIOL, V95, P86, DOI 10.1016/j.yjmcc.2015.11.019
   Schiebler M, 2015, EMBO MOL MED, V7, P127, DOI 10.15252/emmm.201404137
   Schmid D, 2007, IMMUNITY, V26, P79, DOI 10.1016/j.immuni.2006.10.018
   Schneider SA, 2013, CURR TREAT OPTION NE, V15, P652, DOI 10.1007/s11940-013-0254-5
   Schneider SA, 2012, SEMIN PEDIATR NEUROL, V19, P57, DOI 10.1016/j.spen.2012.03.005
   Schonewolf CA, 2014, WORLD J GASTRO ONCOL, V6, P74, DOI 10.4251/wjgo.v6.i3.74
   Seidel K, 2016, NEUROPATH APPL NEURO, V42, P153, DOI 10.1111/nan.12253
   Shah SZA, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00310
   Sharma V, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00147
   Shelly S, 2009, IMMUNITY, V30, P588, DOI 10.1016/j.immuni.2009.02.009
   Shimizu S, 2018, MOL CELLS, V41, P50, DOI 10.14348/molcells.2018.2215
   Shin HJR, 2016, AUTOPHAGY, V12, P2248, DOI 10.1080/15548627.2016.1214780
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Shirakabe A, 2016, CIRC RES, V118, P1563, DOI 10.1161/CIRCRESAHA.116.307474
   Shoji-Kawata S, 2013, NATURE, V494, P201, DOI 10.1038/nature11866
   Shoji-Kawata S, 2009, BBA-MOL CELL RES, V1793, P1478, DOI 10.1016/j.bbamcr.2009.02.008
   Shrivastava S, 2016, J VIROL, V90, P1387, DOI 10.1128/JVI.02383-15
   Shrivastava S, 2011, HEPATOLOGY, V53, P406, DOI 10.1002/hep.24073
   Shu XM, 2017, MOL MED REP, V16, P1180, DOI 10.3892/mmr.2017.6693
   Simonsen A, 2008, AUTOPHAGY, V4, P176, DOI 10.4161/auto.5269
   Singh RK, 2017, VET QUART, V37, P98, DOI 10.1080/01652176.2017.1309474
   Singh RK, 2016, VET QUART, V36, P150, DOI 10.1080/01652176.2016.1188333
   Singh V, 2017, J BIOL CHEM, V292, P1847, DOI 10.1074/jbc.M116.759456
   Sir D, 2008, HEPATOLOGY, V48, P1054, DOI 10.1002/hep.22464
   Song SL, 2017, J CELL PHYSIOL, V232, P2977, DOI 10.1002/jcp.25785
   Sorbara MT, 2013, IMMUNITY, V39, P858, DOI 10.1016/j.immuni.2013.10.013
   Spencer B, 2009, J NEUROSCI, V29, P13578, DOI 10.1523/JNEUROSCI.4390-09.2009
   Srivastava RAK, 2012, J LIPID RES, V53, P2490, DOI 10.1194/jlr.R025882
   Stanley SA, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003946
   Stappenbeck TS, 2011, AUTOPHAGY, V7, P355, DOI [10.4161/auto.7.4.13074, 10.4161/auto.7.2.13074]
   Starr T, 2012, CELL HOST MICROBE, V11, P33, DOI 10.1016/j.chom.2011.12.002
   Steele S, 2015, FRONT CELL INFECT MI, V5, DOI 10.3389/fcimb.2015.00051
   Stige KE, 2018, CLIN CASE REP, V6, P353, DOI 10.1002/ccr3.1358
   Su MF, 2014, J BIOL CHEM, V289, P8029, DOI 10.1074/jbc.M113.515361
   Su ZL, 2015, IMMUNOBIOLOGY, V220, P539, DOI 10.1016/j.imbio.2014.12.009
   Su ZY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0321-5
   Subudhi BB, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10050235
   Sun K, 2013, CELL BIOSCI, V3, DOI 10.1186/2045-3701-3-35
   Sun L, 2017, J MED CHEM, V60, P6638, DOI 10.1021/acs.jmedchem.7b00592
   Sun T, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7080104
   Sun Y, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2001931
   Sun YJ, 2014, J VIROL, V88, P525, DOI 10.1128/JVI.01849-13
   Surviladze Z, 2013, J VIROL, V87, P2508, DOI 10.1128/JVI.02319-12
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Takemura G, 2006, AUTOPHAGY, V2, P212, DOI 10.4161/auto.2608
   Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299
   Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595
   Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078
   Tang H, 2009, HEPATOLOGY, V49, P60, DOI 10.1002/hep.22581
   Tang YB, 2015, STEM CELLS, V33, P1863, DOI 10.1002/stem.2005
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Tanida I, 2011, MICROBIOL IMMUNOL, V55, P1, DOI 10.1111/j.1348-0421.2010.00271.x
   Tasset I, 2016, FEBS J, V283, P2403, DOI 10.1111/febs.13677
   Tavera-Mendoza LE, 2017, P NATL ACAD SCI USA, V114, pE2186, DOI 10.1073/pnas.1615015114
   Taylor Graham S, 2011, Herpesviridae, V2, P2, DOI 10.1186/2042-4280-2-2
   Taylor MP, 2007, J VIROL, V81, P12543, DOI 10.1128/JVI.00755-07
   Terman A, 2005, CARDIOVASC RES, V68, P355, DOI 10.1016/j.cardiores.2005.08.014
   Thorburn J, 2014, CELL REP, V7, P45, DOI 10.1016/j.celrep.2014.02.036
   Todd AG, 2015, ANN NEUROL, V78, P222, DOI 10.1002/ana.24433
   Tooze SA, 2008, CURR OPIN NEUROBIOL, V18, P504, DOI 10.1016/j.conb.2008.09.015
   Tsai HH, 2017, ONCOTARGET, V8, P13832, DOI 10.18632/oncotarget.14640
   Tsuchihara K, 2009, CANCER LETT, V278, P130, DOI 10.1016/j.canlet.2008.09.040
   Tylichova Z, 2017, J NUTR BIOCHEM, V39, P145, DOI 10.1016/j.jnutbio.2016.09.006
   Ueno T, 2017, NAT REV GASTRO HEPAT, V14, P170, DOI 10.1038/nrgastro.2016.185
   Usategui-Martin R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128984
   Vance JE, 2006, FEBS LETT, V580, P5518, DOI 10.1016/j.febslet.2006.06.008
   Vantaggiato C, 2019, AUTOPHAGY, V15, P34, DOI 10.1080/15548627.2018.1507438
   Vantaggiato C, 2013, BRAIN, V136, P3119, DOI 10.1093/brain/awt227
   Vazquez CL, 2010, CELL DEATH DIFFER, V17, P421, DOI 10.1038/cdd.2009.129
   Vignot S, 2005, ANN ONCOL, V16, P525, DOI 10.1093/annonc/mdi113
   Viscomi MT, 2017, CONTEMP CLIN NEUROSC, P35, DOI 10.1007/978-3-319-52067-4_2
   Vives-Bauza C, 2010, P NATL ACAD SCI USA, V107, P378, DOI 10.1073/pnas.0911187107
   Vogiatzi T, 2008, J BIOL CHEM, V283, P23542, DOI 10.1074/jbc.M801992200
   Wada S, 2015, J ANTIBIOT, V68, P521, DOI 10.1038/ja.2015.23
   Wang C, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1108-6
   Wang FJ, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00252
   Wang L, 2019, EXP CELL RES, V380, P149, DOI 10.1016/j.yexcr.2019.04.014
   Wang YP, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00206
   Watson AS, 2011, CELL CYCLE, V10, P1719, DOI 10.4161/cc.10.11.15673
   Webb JL, 2003, J BIOL CHEM, V278, P25009, DOI 10.1074/jbc.M300227200
   Wen HX, 2017, J NEUROSCI RES, V95, P1993, DOI 10.1002/jnr.24034
   White E, 2010, CURR OPIN CELL BIOL, V22, P212, DOI 10.1016/j.ceb.2009.12.008
   Whitworth AJ, 2017, CURR OPIN GENET DEV, V44, P47, DOI 10.1016/j.gde.2017.01.016
   Wong E, 2010, NAT NEUROSCI, V13, P805, DOI 10.1038/nn.2575
   Wong J, 2008, J VIROL, V82, P9143, DOI 10.1128/JVI.00641-08
   Wong KZ, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10060294
   Wu DJ, 2017, CLIN IMMUNOL, V176, P55, DOI 10.1016/j.clim.2017.01.007
   Wu XT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10533
   Wu YT, 2011, CELL DEATH DIFFER, V18, P26, DOI 10.1038/cdd.2010.72
   Wu YC, 2009, BIOCHEM BIOPH RES CO, V382, P451, DOI 10.1016/j.bbrc.2009.03.051
   Wu YP, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00469
   Xia QH, 2016, ONCOL LETT, V12, P1826, DOI 10.3892/ol.2016.4880
   Xu H., 2016, U. S. Patent, Patent No. 9339488
   Xu PF, 2017, CHEM-EUR J, V23, P1263, DOI 10.1002/chem.201605622
   Yamasaki A, 2017, J MOL BIOL, V429, P531, DOI 10.1016/j.jmb.2017.01.003
   Yang G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02653
   Yang L, 2010, CELL METAB, V11, P467, DOI 10.1016/j.cmet.2010.04.005
   Yang Q, 2009, SCIENCE, V323, P124, DOI 10.1126/science.1166088
   Yang X, 2015, CELL BIOSCI, V5, DOI 10.1186/s13578-015-0005-2
   Yang Z, 2015, EXP MOL PATHOL, V98, P219, DOI 10.1016/j.yexmp.2015.02.003
   Yang Z, 2015, J MOL MED, V93, P707, DOI 10.1007/s00109-015-1297-8
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yano K, 2015, PLANT SIGNAL BEHAV, V10, DOI 10.1080/15592324.2015.1082699
   Yao QM, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/7959707
   Yarana C, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6040075
   Ye JL, 2017, J NEUROCHEM, V142, P215, DOI 10.1111/jnc.14042
   Ye X, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02334
   Yin H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01512
   Yin ZY, 2017, AUTOPHAGY, V13, P779, DOI 10.1080/15548627.2017.1305534
   Yoshii SR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091865
   Yoshikawa Y, 2009, AUTOPHAGY, V5, P1220, DOI 10.4161/auto.5.8.10177
   You LS, 2017, ONCOTARGET, V8, P12374, DOI 10.18632/oncotarget.13583
   Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028
   Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709
   Yu L, 2010, NATURE, V465, P942, DOI 10.1038/nature09076
   Zaupa C., 2016, Patent WO, Patent No. 2016131945
   Yuan N, 2015, HAEMATOLOGICA, V100, P345, DOI 10.3324/haematol.2014.113324
   Yue Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0917-y
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
   Zaffagnini G, 2016, J MOL BIOL, V428, P1714, DOI 10.1016/j.jmb.2016.02.004
   Zhang H, 2019, BIOORG CHEM, V88, DOI 10.1016/j.bioorg.2019.102940
   Zhang KZ, 2018, DIABETES, V67, P180, DOI 10.2337/dbi17-0048
   Zhang L, 2017, BBA-MOL CELL RES, V1864, P613, DOI 10.1016/j.bbamcr.2017.01.003
   Zhao CF, 2016, AM J CARDIOVASC DIS, V6, P163
   Zhao YG, 2013, AUTOPHAGY, V9, P1258, DOI 10.4161/auto.24856
   Zhao Y, 2010, AUTOPHAGY, V6, P988, DOI 10.4161/auto.6.7.13289
   Zhong ZY, 2016, CELL, V164, P896, DOI 10.1016/j.cell.2015.12.057
   Zhou DJ, 2008, AIDS, V22, P695, DOI 10.1097/QAD.0b013e3282f4a836
   Zhou HY, 2017, EXP CELL RES, V351, P68, DOI 10.1016/j.yexcr.2016.12.024
   Zhou XJ, 2012, AUTOPHAGY, V8, P1286, DOI 10.4161/auto.21212
   Zhou Z, 2009, AUTOPHAGY, V5, P321, DOI 10.4161/auto.5.3.7406
   Zhu HX, 2007, J CLIN INVEST, V117, P1782, DOI 10.1172/JCI27523
   Zhu JH, 2007, AM J PATHOL, V170, P75, DOI 10.2353/ajpath.2007.060524
   Zhu ZC, 2018, ONCOGENE, V37, P2936, DOI 10.1038/s41388-018-0180-9
NR 519
TC 84
Z9 88
U1 4
U2 20
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD JUL
PY 2019
VL 8
IS 7
AR 674
DI 10.3390/cells8070674
PG 64
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA IN8AC
UT WOS:000478902000085
PM 31277291
OA gold, Green Submitted, Green Published
DA 2022-04-25
ER

PT J
AU Wang, HW
   Yang, SH
   Huang, GD
   Lin, JK
   Chen, WS
   Jiang, JK
   Lan, YT
   Lin, CC
   Hwang, WL
   Tzeng, CH
   Li, AFY
   Yen, CC
   Teng, HW
AF Wang, Hsei-Wei
   Yang, Shung-Haur
   Huang, Guan-Da
   Lin, Jen-Kou
   Chen, Wei-Shone
   Jiang, Jeng-Kai
   Lan, Yuan-Tzu
   Lin, Chun-Chi
   Hwang, Wei-Lun
   Tzeng, Cheng-Hwai
   Li, Anna Fen-Yau
   Yen, Chueh-Chuan
   Teng, Hao-Wei
TI Temsirolimus enhances the efficacy of cetuximab in colon cancer through
   a CIP2A-dependent mechanism
SO JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
LA English
DT Article
DE utophagy; mTOR; AKT; Erk
ID METASTATIC COLORECTAL-CANCER; SIGNALING PATHWAYS; HUMAN MALIGNANCIES;
   1ST-LINE THERAPY; PROGNOSTIC ROLE; GASTRIC-CANCER; PHOSPHATASE 2A;
   PHASE-III; CIP2A; CHEMOTHERAPY
AB Purpose A dozen clinical trials examining a combination of temsirolimus and cetuximab in treating metastatic colon cancer are currently underway. We investigated the role of cancerous inhibitor of protein phosphatase 2A (CIP2A) in the synergism between temsirolimus and cetuximab in colon cancer.
   Methods Five colon cancer cell lines were used for in vitro studies. Signal transduction pathways were assessed by immunoblotting. The synergism between studied drugs was analyzed with combination indexes. Gene silencing was performed using small interfering RNAs. The efficacies of temsirolimus and cetuximab were tested in nude mice with colon cancer xenografts. Transcriptional activity was assessed using a reporter assay. The inhibitors leupeptin, chloroquine, and MG132 were used to assess protein degradation. The association between CIP2A, clinicopathological parameters, and survival was examined by immunohistochemical staining using a tumor tissue microarray.
   Results Temsirolimus decreased the resistance of cells to cetuximab by both inhibiting transcription of CIP2A and increasing degradation of CIP2A through the lysosomal-autophagy pathway. The mammalian target of rapamycin (mTOR) protein immunoprecipitated along with CIP2A. Temsirolimus decreased expression of phosphorylated extracellular regulated protein kinase (pErk) and phosphorylated v-akt murine thymoma viral oncogene (pAKT) and decreased the interaction of CIP2A and mTOR in cell lines without the K-ras codon 12 mutation. CIP2A was a prognostic marker only in colon cancer patients with weak expression of pErk or pAKT.
   Conclusions Temsirolimus decreases cellular resistance to cetuximab by regulating CIP2A expression in colon cancer cells. Potential biomarkers for CIP2A inhibitors include pErk and pAKT.
C1 [Wang, Hsei-Wei; Yang, Shung-Haur; Lin, Jen-Kou; Chen, Wei-Shone; Jiang, Jeng-Kai; Lan, Yuan-Tzu; Lin, Chun-Chi; Hwang, Wei-Lun; Tzeng, Cheng-Hwai; Li, Anna Fen-Yau; Yen, Chueh-Chuan; Teng, Hao-Wei] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan.
   [Wang, Hsei-Wei; Hwang, Wei-Lun] Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 112, Taiwan.
   [Wang, Hsei-Wei; Hwang, Wei-Lun] Natl Taiwan Univ Hosp, Natl Ctr Excellence Clin Trial & Res, Taipei, Taiwan.
   [Yang, Shung-Haur; Lin, Jen-Kou; Chen, Wei-Shone; Jiang, Jeng-Kai; Lan, Yuan-Tzu; Lin, Chun-Chi] Taipei Vet Gen Hosp, Dept Surg, Div Colon & Rectal Surg, Taipei 112, Taiwan.
   [Huang, Guan-Da; Tzeng, Cheng-Hwai; Yen, Chueh-Chuan; Teng, Hao-Wei] Taipei Vet Gen Hosp, Dept Med, Div Hematol & Oncol, Taipei 112, Taiwan.
   [Tzeng, Cheng-Hwai; Yen, Chueh-Chuan; Teng, Hao-Wei] Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan.
   [Li, Anna Fen-Yau] Gen Hosp, Dept Pathol, Taipei, Taiwan.
RP Teng, HW (corresponding author), Taipei Vet Gen Hosp, Dept Med, Div Hematol & Oncol, 201,Sec 2,Shih Pai Rd, Taipei 112, Taiwan.
EM danny_teng@yahoo.com.tw
OI Hwang, Wei-Lun/0000-0002-8694-877X
FU Division of Experimental Surgery of the Department of Surgery, Taipei
   Veterans General HospitalTaipei Veterans General Hospital; Taipei
   Veterans General Hospital, Taiwan Clinical Oncology Research Foundation,
   Department of Health, Taiwan (Center of Excellence for Cancer Research
   at Taipei Veterans General Hospital [102DHA0100184, 101DHA0100369]
FX This work was supported in part by the Division of Experimental Surgery
   of the Department of Surgery, Taipei Veterans General Hospital, and by
   the Taipei Veterans General Hospital, Taiwan Clinical Oncology Research
   Foundation, Department of Health, Taiwan (Center of Excellence for
   Cancer Research at Taipei Veterans General Hospital (102DHA0100184,
   101DHA0100369).
CR Bockelman C, 2011, BRIT J CANCER, V105, P989, DOI 10.1038/bjc.2011.346
   Bockelman C, 2012, CANCER BIOL THER, V13, P289, DOI [10.4161/cbt.18922, 10.4161/cbt.13.5.18922]
   Bokemeyer C, 2012, EUR J CANCER, V48, P1466, DOI 10.1016/j.ejca.2012.02.057
   Chen KF, 2010, ONCOGENE, DOI [10.1038/onc.2010.357, DOI 10.1038/0NC.2010.357]
   Chen W, 2005, CANCER RES, V65, P8183, DOI 10.1158/0008-5472.CAN-05-1103
   Chen XG, 2010, MOL CARCINOGEN, V49, P603, DOI 10.1002/mc.20628
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Coenen EA, 2011, LEUKEMIA RES, V35, P133, DOI 10.1016/j.leukres.2010.08.017
   Come C, 2009, CLIN CANCER RES, V15, P5092, DOI 10.1158/1078-0432.CCR-08-3283
   Dong QZ, 2011, ANN SURG ONCOL, V18, P857, DOI 10.1245/s10434-010-1313-8
   Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6
   Hess G, 2009, J CLIN ONCOL, V27, P3822, DOI 10.1200/JCO.2008.20.7977
   Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838
   Hui L, 2005, J BIOL CHEM, V280, P35829, DOI 10.1074/jbc.M504192200
   Junttila MR, 2008, CELL CYCLE, V7, P592, DOI 10.4161/cc.7.5.5492
   Junttila MR, 2007, CELL, V130, P51, DOI 10.1016/j.cell.2007.04.044
   Khanna A, 2009, JNCI-J NATL CANCER I, V101, P793, DOI 10.1093/jnci/djp103
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Li WJ, 2008, CLIN CANCER RES, V14, P3722, DOI 10.1158/1078-0432.CCR-07-4137
   McCubrey JA, 2006, ADV ENZYME REGUL, V46, P249, DOI 10.1016/j.advenzreg.2006.01.004
   Migliardi G, 2012, CLIN CANCER RES, V18, P2515, DOI 10.1158/1078-0432.CCR-11-2683
   Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438
   Populo H, 2012, INT J MOL SCI, V13, P1886, DOI 10.3390/ijms13021886
   Qin L, 2010, AUTOPHAGY, V6, P239, DOI 10.4161/auto.6.2.11062
   Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930
   Teng HW, 2012, J SURG ONCOL, V106, P123, DOI 10.1002/jso.23063
   Teng HW, 2012, J GASTROINTEST SURG, V16, P1037, DOI 10.1007/s11605-012-1828-3
   Tseng LM, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3175
   Vaarala MH, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-136
   Wiegering A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075292
   Windsor ACJ, 2008, FUTURE ONCOL, V4, P741, DOI 10.2217/14796694.4.6.741
   Zhao DP, 2010, J MED MICROBIOL, V59, P259, DOI 10.1099/jmm.0.014704-0
NR 33
TC 18
Z9 20
U1 0
U2 22
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171-5216
EI 1432-1335
J9 J CANCER RES CLIN
JI J. Cancer Res. Clin. Oncol.
PD APR
PY 2014
VL 140
IS 4
BP 561
EP 571
DI 10.1007/s00432-014-1596-4
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AC9SW
UT WOS:000332875700004
PM 24493623
DA 2022-04-25
ER

PT J
AU Gandesiri, M
   Chakilam, S
   Ivanovska, J
   Benderska, N
   Ocker, M
   Di Fazio, P
   Feoktistova, M
   Gali-Muhtasib, H
   Rave-Frank, M
   Prante, O
   Christiansen, H
   Leverkus, M
   Hartmann, A
   Schneider-Stock, R
AF Gandesiri, Muktheshwar
   Chakilam, Saritha
   Ivanovska, Jelena
   Benderska, Natalya
   Ocker, Matthias
   Di Fazio, Pietro
   Feoktistova, Maria
   Gali-Muhtasib, Hala
   Rave-Fraenk, Margret
   Prante, Olaf
   Christiansen, Hans
   Leverkus, Martin
   Hartmann, Arndt
   Schneider-Stock, Regine
TI DAPK plays an important role in panobinostat-induced autophagy and
   commits cells to apoptosis under autophagy deficient conditions
SO APOPTOSIS
LA English
DT Article
DE Panobinostat; LBH589; DAPK; Autophagy; Apoptosis; Colon cancer
ID HISTONE DEACETYLASE INHIBITOR; ENDOPLASMIC-RETICULUM STRESS;
   PROTEIN-KINASE DAPK; COLON-CANCER; DNA METHYLATION; TUMOR-CELLS; DEATH;
   LBH589; RESISTANCE; LINES
AB The histone deacetylase inhibitor (HDACi) LBH589 has been verified as an effective anticancer agent. The identification and characterization of new targets for LBH589 action would further enhance our understanding of the molecular mechanisms involved in HDACi therapy. The role of the tumor suppressor death-associated protein kinase (DAPK) in LBH589-induced cytotoxicity has not been investigated to date. Stable DAPK knockdown (shRNA) and DAPK overexpressing (DAPK+++) cell lines were generated from HCT116 wildtype colon cancer cells. LBH589 inhibited cell proliferation, reduced the long-term survival, and up-regulated and activated DAPK in colorectal cancer cells. Moreover, LBH589 significantly suppressed the growth of colon tumor xenografts and in accordance with the in vitro studies, increased DAPK levels were detected immunohistochemically. LBH589 induced a DAPK-dependent autophagy as assessed by punctuate accumulation of LC3-II, the formation of acidic vesicular organelles, and degradation of p62 protein. LBH589-induced autophagy seems to be predominantly caused by DAPK protein interactions than by its kinase activity. Caspase inhibitor zVAD increased autophagosome formation, decreased the cleavage of caspase 3 and PARP but didn't rescue the cells from LBH589-induced cell death in crystal violet staining suggesting both caspase-dependent as well as caspase-independent apoptosis pathways. Pre-treatment with the autophagy inhibitor Bafilomycin A1 caused caspase 3-mediated apoptosis in a DAPK-dependent manner. Altogether our data suggest that DAPK induces autophagy in response to HDACi-treatment. In autophagy deficient cells, DAPK plays an essential role in committing cells to HDACi-induced apoptosis.
C1 [Gandesiri, Muktheshwar; Chakilam, Saritha; Ivanovska, Jelena; Benderska, Natalya; Hartmann, Arndt; Schneider-Stock, Regine] Univ Erlangen Nurnberg, Dept Pathol, D-91054 Erlangen, Germany.
   [Ocker, Matthias; Di Fazio, Pietro] Univ Marburg, Inst Surg Res, Marburg, Germany.
   [Feoktistova, Maria; Leverkus, Martin] Univ Heidelberg, Mol Dermatol Sect, Dept Dermatol Venereol & Allergol, Med Fac Mannheim, Heidelberg, Germany.
   [Gali-Muhtasib, Hala] Amer Univ Beirut, Dept Biol, Beirut, Lebanon.
   [Rave-Fraenk, Margret; Christiansen, Hans] Univ Hosp Gottingen, Dept Radiat Oncol, Gottingen, Germany.
   [Prante, Olaf] Clin Nucl Med, Lab Mol Imaging, Erlangen, Germany.
   [Christiansen, Hans] Med Sch Hanover, Hannover, Germany.
RP Schneider-Stock, R (corresponding author), Univ Erlangen Nurnberg, Dept Pathol, Univ Str 22, D-91054 Erlangen, Germany.
EM regine.schneider-stock@uk-erlangen.de
RI Schneider-Stock, Regine/H-8863-2012; Di Fazio, Pietro/ABC-1524-2020; Di
   Fazio, Pietro/AAU-4575-2020
OI Di Fazio, Pietro/0000-0003-0091-8498; Ocker,
   Matthias/0000-0001-8263-6288
CR Anjum R, 2005, CURR BIOL, V15, P1762, DOI 10.1016/j.cub.2005.08.050
   Atadja P, 2009, CANCER LETT, V280, P233, DOI 10.1016/j.canlet.2009.02.019
   Bajbouj K, 2009, AM J PATHOL, V175, P557, DOI 10.2353/ajpath.2009.080853
   Bialik S, 2006, ANNU REV BIOCHEM, V75, P189, DOI 10.1146/annurev.biochem.75.103004.142615
   Brazelle W, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014335
   Bursch W, 2000, J CELL SCI, V113, P1189
   Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852
   Chen CH, 2005, EMBO J, V24, P294, DOI 10.1038/sj.emboj.7600510
   Cheng Yan, 2011, World J Biol Chem, V2, P226, DOI 10.4331/wjbc.v2.i10.226
   Chuang YT, 2011, BLOOD, V117, P960, DOI 10.1182/blood-2010-08-303115
   Cohen O, 1999, J CELL BIOL, V146, P141
   DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15
   Di Fazio P, 2010, CELL ONCOL, V32, P285, DOI 10.3233/CLO-2010-0511
   Diessenbacher P, 2008, J INVEST DERMATOL, V128, P1134, DOI 10.1038/sj.jid.5701141
   Eisenberg-Lerner A, 2012, CELL DEATH DIFFER, V19, P788, DOI 10.1038/cdd.2011.149
   Eisenberg-Lerner A, 2012, CELL CYCLE, V11, P2051, DOI 10.4161/cc.20538
   Ellis L, 2009, BLOOD, V114, P380, DOI 10.1182/blood-2008-10-182758
   Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024
   Fazzone W, 2009, INT J CANCER, V125, P463, DOI 10.1002/ijc.24403
   Gammoh N, 2012, P NATL ACAD SCI USA, V109, P6561, DOI 10.1073/pnas.1204429109
   Gloesenkamp CR, 2012, INT J ONCOL, V40, P876, DOI 10.3892/ijo.2011.1256
   Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010
   Gozuacik D, 2008, CELL DEATH DIFFER, V15, P1875, DOI 10.1038/cdd.2008.121
   Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1
   HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329
   Harrison B, 2008, J BIOL CHEM, V283, P9999, DOI 10.1074/jbc.M706040200
   Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094
   Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731
   Jin YJ, 2006, J BIOL CHEM, V281, P39033, DOI 10.1074/jbc.M605097200
   Kauh J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010376
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   LaBonte MJ, 2011, CANCER RES, V71, P3635, DOI 10.1158/0008-5472.CAN-10-2430
   LaBonte MJ, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-67
   Lee SC, 2011, ANTICANCER RES, V31, P3385
   Leverkus M, 2003, MOL CELL BIOL, V23, P777, DOI 10.1128/MCB.23.3.777-790.2003
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Lin Y, 2010, FEBS J, V277, P48, DOI 10.1111/j.1742-4658.2009.07411.x
   Mariadason JM, 2008, EPIGENETICS-US, V3, P28, DOI 10.4161/epi.3.1.5736
   Michie AM, 2010, FEBS J, V277, P74, DOI 10.1111/j.1742-4658.2009.07414.x
   Myeku N, 2011, J BIOL CHEM, V286, P22426, DOI 10.1074/jbc.M110.149252
   Neri P, 2012, EXPERT OPIN INV DRUG, V21, P733, DOI 10.1517/13543784.2012.668883
   Newman RA, 2007, INTEGR CANCER THER, V6, P354, DOI 10.1177/1534735407309623
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Ogawa T, 2012, CELL CYCLE, V11, P1656, DOI 10.4161/cc.20120
   Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0
   Okamoto M, 2010, BIOORGAN MED CHEM, V18, P2728, DOI 10.1016/j.bmc.2010.02.018
   Paglin S, 2001, CANCER RES, V61, P439
   Pettazzoni P, 2011, FREE RADICAL BIO MED, V50, P313, DOI 10.1016/j.freeradbiomed.2010.11.011
   Rao R, 2010, CLIN CANCER RES, V16, P4742, DOI 10.1158/1078-0432.CCR-10-0529
   Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117
   Saeki K, 2000, CELL DEATH DIFFER, V7, P1263, DOI 10.1038/sj.cdd.4400759
   Scuto A, 2008, BLOOD, V111, P5093, DOI 10.1182/blood-2007-10-117762
   Shamloo M, 2005, J BIOL CHEM, V280, P42290, DOI 10.1074/jbc.M505804200
   Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102
   Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037
   Wang WJ, 2007, MOL CELL, V27, P701, DOI 10.1016/j.molcel.2007.06.037
   Wu J, 2010, ACTA PHARMACOL SIN, V31, P93, DOI 10.1038/aps.2009.183
   Wu YT, 2008, AUTOPHAGY, V4, P457, DOI 10.4161/auto.5662
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
   Zalckvar E, 2009, AUTOPHAGY, V5, P720, DOI 10.4161/auto.5.5.8625
   Zhang F, 2009, CANCER BIOL THER, V8, P823, DOI 10.4161/cbt.8.9.8143
   Zhang XT, 2006, ONCOL REP, V16, P563
NR 63
TC 47
Z9 49
U1 0
U2 15
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1360-8185
J9 APOPTOSIS
JI Apoptosis
PD DEC
PY 2012
VL 17
IS 12
BP 1300
EP 1315
DI 10.1007/s10495-012-0757-7
PG 16
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 042XG
UT WOS:000311504800006
PM 23011180
DA 2022-04-25
ER

PT J
AU Yang, PY
   Cartwright, C
   Efuet, E
   Hamilton, SR
   Wistuba, II
   Menter, D
   Addington, C
   Shureiqi, I
   Newman, RA
AF Yang, Peiying
   Cartwright, Carrie
   Efuet, Ekem
   Hamilton, Stanley R.
   Wistuba, Ignacio Ivan
   Menter, David
   Addington, Crandell
   Shureiqi, Imad
   Newman, Robert A.
TI Cellular location and expression of Na+, K+-ATPase alpha subunits affect
   the anti-proliferative activity of oleandrin
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE CaCO-2 cells; oleandrin; Na, K-ATPase alpha 3 isoform; colon tissues;
   cardiac glycoside
ID CARDIAC-GLYCOSIDES; 15-LIPOXYGENASE-1 EXPRESSION; CANCER-CELLS;
   BETA-SUBUNIT; SODIUM-PUMP; NA,K-ATPASE; APOPTOSIS; DEATH; THERAPY;
   DIFFERENTIATION
AB The purpose of this study was to investigate whether intracellular distribution of Na+, K+-ATPase alpha 3 subunit, a receptor for cardiac glycosides including oleandrin, is differentially altered in cancer versus normal cells and whether this altered distribution can be therapeutically targeted to inhibit cancer cell survival. The cellular distribution of Na+, K+-ATPase alpha 3 isoform was investigated in paired normal and cancerous mucosa biopsy samples from patients with lung and colorectal cancers by immunohistochemical staining. The effects of oleandrin on alpha 3 subunit intracellular distribution, cell death, proliferation, and EKR phosphorylation were examined in differentiated and undifferentiated human colon cancer CaCO-2 cells. While Na+, K+-ATPase alpha 3 isoform was predominantly located near the cytoplasmic membrane in normal human colon and lung epithelia, the expression of this subunit in their paired cancer epithelia was shifted to a peri-nuclear position in both a qualitative and quantitative manner. Similarly, distribution of alpha 3 isoform was also shifted from a cytoplasmic membrane location in differentiated human colon cancer CaCO-2 cells to a peri-nuclear position in undifferentiated CaCO-2 cells. Intriguingly, oleandrin exerted threefold stronger anti-proliferative activity in undifferentiated CaCO-2 cells (IC50, 8.25 nM) than in differentiated CaCO-2 cells (IC50, >25 nM). Oleandrin (10 to 20 nM) caused an autophagic cell death and altered ERK phosphorylation in undifferentiated but not in differentiated CaCO-2 cells. These data demonstrate that the intracellular location of Na+, K+-ATPase alpha 3 isoform is altered in human cancer versus normal cells. These changes in alpha 3 cellular location and abundance may indicate a potential target of opportunity for cancer therapy. (c) 2012 Wiley Periodicals, Inc.
C1 [Yang, Peiying; Cartwright, Carrie; Efuet, Ekem] Univ Texas MD Anderson Canc Ctr, Dept Gen Oncol, Houston, TX 77030 USA.
   [Yang, Peiying; Menter, David] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA.
   [Hamilton, Stanley R.; Wistuba, Ignacio Ivan] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
   [Addington, Crandell] Phoenix Biotechnol Inc, San Antonio, TX USA.
   [Shureiqi, Imad] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA.
   [Shureiqi, Imad] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA.
   [Newman, Robert A.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA.
RP Newman, RA (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, 112 Whale Rock Lane, Surry, ME 04684 USA.
RI Shureiqi, imad/T-6214-2019
OI Shureiqi, Imad/0000-0003-2019-938X
FU Phoenix Biotechnology, Inc. (San Antonio, TX); NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [P30CA016672, P01CA091844] Funding Source: NIH RePORTER
FX The research work was in part supported by Phoenix Biotechnology, Inc.
   (San Antonio, TX). We thank Kennith Burner Jr. for his expert technical
   support with respect to transmission electron microscopy.
CR Avila J, 1997, ANN NY ACAD SCI, V834, P653, DOI 10.1111/j.1749-6632.1997.tb52341.x
   Benfante R, 2005, BIOCHEM J, V386, P63, DOI 10.1042/BJ20041294
   Blanco G, 2005, SEMIN NEPHROL, V25, P292, DOI 10.1016/j.semnephrol.2005.03.004
   Blanco G, 1998, AM J PHYSIOL-RENAL, V275, pF633, DOI 10.1152/ajprenal.1998.275.5.F633
   Dunbar LA, 2001, J BIOL CHEM, V276, P29617, DOI 10.1074/jbc.R100023200
   Espineda C, 2003, CANCER-AM CANCER SOC, V97, P1859, DOI 10.1002/cncr.11267
   Frese S, 2006, CANCER RES, V66, P5867, DOI 10.1158/0008-5472.CAN-05-3544
   Haux J, 1999, MED HYPOTHESES, V53, P543, DOI 10.1054/mehy.1999.0985
   Juhaszova M, 1997, ANN NY ACAD SCI, V834, P524, DOI 10.1111/j.1749-6632.1997.tb52310.x
   Jung MH, 2000, GENOMICS, V69, P281, DOI 10.1006/geno.2000.6338
   Kaplan Jack H, 2005, Sci STKE, V2005, ppe31, DOI 10.1126/stke.2892005pe31
   Kjeldsen K, 2002, CARDIOVASC RES, V55, P710, DOI 10.1016/S0008-6363(02)00466-2
   Lin Yun, 2008, J Exp Ther Oncol, V7, P195
   MATSUMOTO H, 1990, GASTROENTEROLOGY, V98, P1199, DOI 10.1016/0016-5085(90)90334-W
   McConkey DJ, 2000, CANCER RES, V60, P3807
   Mijatovic T, 2007, J PATHOL, V212, P170, DOI 10.1002/path.2172
   Mijatovic T, 2007, BBA-REV CANCER, V1776, P32, DOI 10.1016/j.bbcan.2007.06.002
   Mobasheri A, 2000, BIOSCIENCE REP, V20, P51, DOI 10.1023/A:1005580332144
   Moussalli MJ, 2011, CANCER PREV RES, V4, P1961, DOI 10.1158/1940-6207.CAPR-10-0280
   Newman RA, 2008, MOL INTERV, V8, P36, DOI 10.1124/mi.8.1.8
   Newman RA, 2007, INTEGR CANCER THER, V6, P354, DOI 10.1177/1534735407309623
   Pathak S, 2000, ANTI-CANCER DRUG, V11, P455, DOI 10.1097/00001813-200007000-00006
   PODEVIN RA, 1989, J PHARMACOL EXP THER, V250, P672
   Raghavendra PB, 2007, MOL IMMUNOL, V44, P2292, DOI 10.1016/j.molimm.2006.11.009
   Raghavendra PB, 2007, APOPTOSIS, V12, P307, DOI 10.1007/s10495-006-0626-3
   Rajasekaran SA, 2005, SEMIN NEPHROL, V25, P328, DOI 10.1016/j.semnephrol.2005.03.008
   Rajasekaran SA, 1999, J UROLOGY, V162, P574, DOI 10.1016/S0022-5347(05)68629-6
   Rajasekaran SA, 2010, MOL CANCER THER, V9, P1515, DOI 10.1158/1535-7163.MCT-09-0832
   Raso MG, 2009, CLIN CANCER RES, V15, P5359, DOI 10.1158/1078-0432.CCR-09-0033
   ROSE AM, 1994, CLIN CHEM, V40, P1674
   SAUMON G, 1989, PFLUG ARCH EUR J PHY, V414, P340, DOI 10.1007/BF00584636
   Shureiqi I, 1999, CARCINOGENESIS, V20, P1985, DOI 10.1093/carcin/20.10.1985
   Smith JA, 2001, BIOCHEM PHARMACOL, V62, P469, DOI 10.1016/S0006-2952(01)00690-6
   Sreenivasan Y, 2006, J CLIN IMMUNOL, V26, P308, DOI 10.1007/s10875-006-9028-0
   Srivastava M, 2004, P NATL ACAD SCI USA, V101, P7693, DOI 10.1073/pnas.0402030101
   Stenkvist B, 1999, ONCOL REP, V6, P493
   SWEADNER KJ, 1985, J BIOL CHEM, V260, P1508
   Turan Nevruz, 2006, J Exp Ther Oncol, V6, P31
   Xie Zijian, 2003, Mol Interv, V3, P157, DOI 10.1124/mi.3.3.157
   Yang PY, 2009, MOL CANCER THER, V8, P2319, DOI 10.1158/1535-7163.MCT-08-1085
   Yang PY, 2004, J LIPID RES, V45, P1030, DOI 10.1194/jlr.M300455-JLR200
   Yang QF, 2005, P NATL ACAD SCI USA, V102, P9631, DOI 10.1073/pnas.0504097102
   Yeh JY, 2001, J UROLOGY, V166, P1937, DOI 10.1016/S0022-5347(05)65724-2
NR 43
TC 22
Z9 22
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
EI 1098-2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD APR
PY 2014
VL 53
IS 4
BP 253
EP 263
DI 10.1002/mc.21968
PG 11
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA AC4LR
UT WOS:000332493300001
PM 23073998
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Wirawan, E
   Berghe, TV
   Lippens, S
   Agostinis, P
   Vandenabeele, P
AF Wirawan, Ellen
   Vanden Berghe, Tom
   Lippens, Saskia
   Agostinis, Patrizia
   Vandenabeele, Peter
TI Autophagy: for better or for worse
SO CELL RESEARCH
LA English
DT Review
DE autophagy; autophagosome; vesicle; degradation; cell death
ID PROGRAMMED CELL-DEATH; BECLIN 1-DEPENDENT AUTOPHAGY; ENDOGENOUS
   VIRAL-ANTIGENS; INNATE IMMUNE-RESPONSE; LIFE-SPAN EXTENSION;
   COLON-CANCER CELLS; MICROSATELLITE INSTABILITY; MITOCHONDRIAL CLEARANCE;
   ENDOPLASMIC-RETICULUM; MEDIATED AUTOPHAGY
AB Autophagy is a lysosomal degradation pathway that degrades damaged or superfluous cell components into basic biomolecules, which are then recycled back into the cytosol. In this respect, autophagy drives a flow of biomolecules in a continuous degradation-regeneration cycle. Autophagy is generally considered a pro-survival mechanism protecting cells under stress or poor nutrient conditions. Current research clearly shows that autophagy fulfills numerous functions in vital biological processes. It is implicated in development, differentiation, innate and adaptive immunity, ageing and cell death. In addition, accumulating evidence demonstrates interesting links between autophagy and several human diseases and tumor development. Therefore, autophagy seems to be an important player in the life and death of cells and organisms. Despite the mounting knowledge about autophagy, the mechanisms through which the autophagic machinery regulates these diverse processes are not entirely understood. In this review, we give a comprehensive overview of the autophagic signaling pathway, its role in general cellular processes and its connection to cell death. In addition, we present a brief overview of the possible contribution of defective autophagic signaling to disease.
C1 [Wirawan, Ellen; Vanden Berghe, Tom; Lippens, Saskia; Vandenabeele, Peter] VIB, Dept Mol Biomed Res, Unit Mol Signaling & Cell Death, B-9052 Ghent, Zwijnaarde, Belgium.
   [Wirawan, Ellen; Vanden Berghe, Tom; Lippens, Saskia; Vandenabeele, Peter] Univ Ghent, Dept Biomed Mol Biol, Unit Mol Signaling & Cell Death, B-9052 Ghent, Belgium.
   [Agostinis, Patrizia] KULeuven, Lab Cell Death & Therapy, Dept Mol & Cell Biol, B-3000 Louvain, Belgium.
RP Vandenabeele, P (corresponding author), VIB, Dept Mol Biomed Res, Unit Mol Signaling & Cell Death, Technol Pk 927, B-9052 Ghent, Zwijnaarde, Belgium.
EM Peter.Vandenabeele@dmbr.vib-UGent.be
RI Vandenabeele, Peter/AAD-5793-2022; Agostinis, Patrizia/AAO-2468-2020;
   Agostinis, Patrizia/ABI-1177-2020; Berghe, Tom Vanden/C-4916-2009;
   Vandenabeele, Peter/C-8597-2009; Berghe, Tom Vanden/N-2902-2019
OI Vandenabeele, Peter/0000-0002-6669-8822; Agostinis,
   Patrizia/0000-0003-1314-2115; Berghe, Tom Vanden/0000-0002-1633-0974;
   Berghe, Tom Vanden/0000-0002-1633-0974; Lippens,
   Saskia/0000-0002-8261-3462
FU Flanders Institute for Biotechnology (VIB); European grants
   [MRTN-CT-035624, FP7-200767]; Belgian grants [IAP 6/18]; Fonds
   Wetenschappelijk Onderzoek VlaanderenFWO [FWO G.0875.11, FWO G.0973.11];
   Ghent UniversityGhent University; Flemish GovernmentEuropean Commission
   [BOF09/01M00709]; Ghent UniversityGhent University [BOF 2001-GOA
   12050502 en BOF 2005-GOA 01GC0205]; Methusalem project [BOF09/01M00709];
   FWOFWO [G.0661.09, G.0728.10]; Catholic University of LeuvenKU Leuven
   [GOA/11/009]
FX This research has been supported by Flanders Institute for Biotechnology
   (VIB), by European grants (FP6 ApopTrain, MRTN-CT-035624; FP7 EC RTD
   Integrated Project, Apo-Sys, FP7-200767; Euregional PACT II), Belgian
   grants (Interuniversity Attraction Poles, IAP 6/18), Flemish grants
   (Fonds Wetenschappelijk Onderzoek Vlaanderen, FWO G.0875.11 and FWO
   G.0973.11), and Ghent University grants (MRP, GROUP-ID). PV is holder of
   a Methusalem grant (BOF09/01M00709) from the Flemish Government. The
   doctoral fellowship of EW has been supported by Ghent University grants
   (BOF 2001-GOA 12050502 en BOF 2005-GOA 01GC0205) and by the Methusalem
   project BOF09/01M00709. SL and TV are postdoctoral fellows with the FWO.
   Research in PA's laboratory is supported by FWO G.0661.09 and G.0728.10,
   the Catholic University of Leuven (GOA/11/009) and the Stichting tegen
   Kanker. We thank Dr Amin Bredan (DMBR-VIB, Ghent) for editing the
   manuscript.
CR Aguado C, 2010, HUM MOL GENET, V19, P2867, DOI 10.1093/hmg/ddq190
   Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Akar U, 2008, AUTOPHAGY, V4, P669, DOI 10.4161/auto.6083
   Akar U, 2007, MOL CANCER RES, V5, P241, DOI 10.1158/1541-7786.MCR-06-0229
   Alvers AL, 2009, AUTOPHAGY, V5, P847, DOI 10.4161/auto.8824
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Andrade RM, 2006, J CLIN INVEST, V116, P2366, DOI 10.1172/JCI28796
   Axe EL, 2008, J CELL BIOL, V182, P685, DOI 10.1083/jcb.200803137
   Baerga R, 2009, AUTOPHAGY, V5, P1118, DOI 10.4161/auto.5.8.9991
   Bell BD, 2008, P NATL ACAD SCI USA, V105, P16677, DOI 10.1073/pnas.0808597105
   Berry DL, 2007, CELL, V131, P1137, DOI 10.1016/j.cell.2007.10.048
   Betin VMS, 2009, J CELL SCI, V122, P2554, DOI 10.1242/jcs.046250
   Birmingham CL, 2006, J BIOL CHEM, V281, P11374, DOI 10.1074/jbc.M509157200
   Bonapace L, 2010, J CLIN INVEST, V120, P1310, DOI 10.1172/JCI39987
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Buytaert E, 2006, AUTOPHAGY, V2, P238, DOI 10.4161/auto.2730
   Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416
   Castino R, 2010, TOXICOL SCI, V117, P152, DOI 10.1093/toxsci/kfq170
   Chano T, 2002, NAT GENET, V31, P285, DOI 10.1038/ng911
   Chaumorcel M, 2008, AUTOPHAGY, V4, P46, DOI 10.4161/auto.5184
   Ciechomska IA, 2009, ONCOGENE, V28, P2128, DOI 10.1038/onc.2009.60
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Crotzer VL, 2010, IMMUNOLOGY, V131, P9, DOI 10.1111/j.1365-2567.2010.03321.x
   Cuervo AM, 2004, MOL CELL BIOCHEM, V263, P55, DOI 10.1023/B:MCBI.0000041848.57020.57
   Cuervo AM, 2005, AUTOPHAGY, V1, P131, DOI 10.4161/auto.1.3.2017
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Deretic V, 2009, CELL HOST MICROBE, V5, P527, DOI 10.1016/j.chom.2009.05.016
   Dewaele M, 2010, AUTOPHAGY, V6, P838, DOI 10.4161/auto.6.7.12113
   Di Bartolomeo S, 2010, J CELL BIOL, V191, P155, DOI 10.1083/jcb.201002100
   Duprez L, 2009, MICROBES INFECT, V11, P1050, DOI 10.1016/j.micinf.2009.08.013
   Eisenberg T, 2009, NAT CELL BIOL, V11, P1305, DOI 10.1038/ncb1975
   English L, 2009, AUTOPHAGY, V5, P1026, DOI 10.4161/auto.5.7.9163
   English L, 2009, NAT IMMUNOL, V10, P480, DOI 10.1038/ni.1720
   Espert L, 2006, J CLIN INVEST, V116, P2161, DOI 10.1172/JCI26185
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925
   Fujita N, 2008, MOL BIOL CELL, V19, P2092, DOI 10.1091/mbc.E07-12-1257
   Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002
   Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092
   Ganley IG, 2009, J BIOL CHEM, V284, P12297, DOI 10.1074/jbc.M900573200
   Gao C, 2010, NAT CELL BIOL, V12, P781, DOI 10.1038/ncb2082
   Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263
   Goldman SJ, 2011, ANTIOXID REDOX SIGN, V14, P1971, DOI 10.1089/ars.2010.3777
   Grumati P, 2010, NAT MED, V16, P1313, DOI 10.1038/nm.2247
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038
   Hailey DW, 2010, CELL, V141, P656, DOI 10.1016/j.cell.2010.04.009
   Hara T, 2008, J CELL BIOL, V181, P497, DOI 10.1083/jcb.200712064
   Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724
   Harris J, 2007, IMMUNITY, V27, P505, DOI 10.1016/j.immuni.2007.07.022
   Harris J, 2011, J BIOL CHEM, V286, P9587, DOI 10.1074/jbc.M110.202911
   Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221
   He CC, 2010, CURR OPIN CELL BIOL, V22, P140, DOI 10.1016/j.ceb.2010.01.001
   Heidari N, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.53
   Hidvegi T, 2010, SCIENCE, V329, P229, DOI 10.1126/science.1190354
   Hosokawa N, 2009, AUTOPHAGY, V5, P973, DOI 10.4161/auto.5.7.9296
   Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248
   Hou W, 2010, AUTOPHAGY, V6, P891, DOI 10.4161/auto.6.7.13038
   Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960
   Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X
   Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178
   Jaeger PA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011102
   Jahreiss L, 2008, TRAFFIC, V9, P574, DOI 10.1111/j.1600-0854.2008.00701.x
   Jeong HS, 2011, BBA-MOL CELL RES, V1813, P80, DOI 10.1016/j.bbamcr.2010.09.016
   Jia KL, 2007, AUTOPHAGY, V3, P21, DOI 10.4161/auto.3528
   Jin ZY, 2009, CELL, V137, P721, DOI 10.1016/j.cell.2009.03.015
   Juhasz G, 2007, GENE DEV, V21, P3061, DOI 10.1101/gad.1600707
   Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249
   Jung HS, 2010, ANN NY ACAD SCI, V1201, P79, DOI 10.1111/j.1749-6632.2010.05614.x
   Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131
   Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kaushik S, 2011, J CELL SCI, V124, P495, DOI 10.1242/jcs.073874
   Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5
   Kim MS, 2008, HUM PATHOL, V39, P1059, DOI 10.1016/j.humpath.2007.11.013
   Kim Y, 2008, BIOCHEM BIOPH RES CO, V377, P975, DOI 10.1016/j.bbrc.2008.10.104
   Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026
   Kirkin V, 2009, MOL CELL, V33, P505, DOI 10.1016/j.molcel.2009.01.020
   Kissova I, 2004, J BIOL CHEM, V279, P39068, DOI 10.1074/jbc.M406960200
   Knaevelsrud H, 2010, AUTOPHAGY, V6, P863, DOI 10.4161/auto.6.7.13033
   Knaevelsrud H, 2010, FEBS LETT, V584, P2635, DOI 10.1016/j.febslet.2010.04.041
   Kochl R, 2006, TRAFFIC, V7, P129, DOI 10.1111/j.1600-0854.2005.00368.x
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   Koneri K, 2007, ANTICANCER RES, V27, P1453
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029
   Kuma A, 2002, J BIOL CHEM, V277, P18619, DOI 10.1074/jbc.M111889200
   Kuma A, 2010, SEMIN CELL DEV BIOL, V21, P683, DOI 10.1016/j.semcdb.2010.03.002
   Kundu M, 2008, BLOOD, V112, P1493, DOI 10.1182/blood-2008-02-137398
   Kyei GB, 2009, J CELL BIOL, V186, P255, DOI 10.1083/jcb.200903070
   Lee CY, 2002, DEV BIOL, V250, P101, DOI 10.1006/dbio.2002.0784
   Lee HK, 2007, SCIENCE, V315, P1398, DOI 10.1126/science.1136880
   Lee HK, 2010, IMMUNITY, V32, P227, DOI 10.1016/j.immuni.2009.12.006
   Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105
   Lee JW, 2007, APMIS, V115, P750, DOI 10.1111/j.1600-0463.2007.apm_640.x
   Lee JS, 2009, NAT CELL BIOL, V11, P1355, DOI 10.1038/ncb1980
   Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li ZD, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-98
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liu Y, 2005, CELL, V121, P567, DOI 10.1016/j.cell.2005.03.007
   Luciani A, 2010, NAT CELL BIOL, V12, P863, DOI 10.1038/ncb2090
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   Madeo F, 2010, NAT CELL BIOL, V12, P842, DOI 10.1038/ncb0910-842
   Mair W, 2003, SCIENCE, V301, P1731, DOI 10.1126/science.1086016
   Malicdan MC, 2008, NEUROMUSCULAR DISORD, V18, P521, DOI 10.1016/j.nmd.2008.04.010
   Marciniak SJ, 2010, NEW ENGL J MED, V363, P1863, DOI 10.1056/NEJMcibr1008007
   Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200
   Martin DN, 2004, DEVELOPMENT, V131, P275, DOI 10.1242/dev.00933
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Matsuda N, 2010, AUTOPHAGY, V6, P952, DOI 10.4161/auto.6.7.13039
   Matsui Y, 2007, CIRC RES, V100, P914, DOI 10.1161/01.RES.0000261924.76669.36
   Maycotte P, 2011, CANCER BIOL THER, V11, P127, DOI 10.4161/cbt.11.2.14627
   Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782
   Mercer CA, 2009, AUTOPHAGY, V5, P649, DOI 10.4161/auto.5.5.8249
   Michiorri S, 2010, CELL DEATH DIFFER, V17, P962, DOI 10.1038/cdd.2009.200
   Miller BC, 2008, AUTOPHAGY, V4, P309, DOI 10.4161/auto.5474
   Mizushima N, 2003, J CELL SCI, V116, P1679, DOI 10.1242/jcs.00381
   Mizushima N, 2010, NAT CELL BIOL, V12, P823, DOI 10.1038/ncb0910-823
   Morselli E, 2010, AUTOPHAGY, V6, P186, DOI 10.4161/auto.6.1.10817
   Morselli E, 2009, AGING-US, V1, P961, DOI 10.18632/aging.100110
   Mortensen M, 2010, AUTOPHAGY, V6, P423, DOI 10.4161/auto.6.3.11528
   Mukaiyama H, 2010, FEBS LETT, V584, P1327, DOI 10.1016/j.febslet.2009.12.037
   Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Nakai A, 2007, NAT MED, V13, P619, DOI 10.1038/nm1574
   Narendra DP, 2011, ANTIOXID REDOX SIGN, V14, P1929, DOI 10.1089/ars.2010.3799
   Nedjic J, 2008, NATURE, V455, P396, DOI 10.1038/nature07208
   Nezis IP, 2010, J CELL BIOL, V190, P523, DOI 10.1083/jcb.201002035
   Nishida K, 2009, CELL DEATH DIFFER, V16, P31, DOI 10.1038/cdd.2008.163
   Nishino I, 2000, NATURE, V406, P906, DOI 10.1038/35022604
   Obara K, 2006, MOL BIOL CELL, V17, P1527, DOI 10.1091/mbc.E05-09-0841
   Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200
   Ogawa M, 2005, SCIENCE, V307, P727, DOI 10.1126/science.1106036
   Orvedahl A, 2007, CELL HOST MICROBE, V1, P23, DOI 10.1016/j.chom.2006.12.001
   Otto GP, 2003, J BIOL CHEM, V278, P17636, DOI 10.1074/jbc.M212467200
   Pandey UB, 2007, NATURE, V447, P859, DOI 10.1038/nature05853
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Park JW, 2007, ONCOL REP, V18, P1269
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Pickford F, 2008, J CLIN INVEST, V118, P2190, DOI 10.1172/JCI33585
   Polson HEJ, 2010, AUTOPHAGY, V6, P506, DOI 10.4161/auto.6.4.11863
   Pua HH, 2007, J EXP MED, V204, P25, DOI 10.1084/jem.20061303
   Pua HH, 2009, J IMMUNOL, V182, P4046, DOI 10.4049/jimmunol.0801143
   Pyo JO, 2005, J BIOL CHEM, V280, P20722, DOI 10.1074/jbc.M413934200
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Qu XP, 2007, CELL, V128, P931, DOI 10.1016/j.cell.2006.12.044
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Radoshevich L, 2010, CELL, V142, P590, DOI 10.1016/j.cell.2010.07.018
   Ravikumar B, 2010, NAT CELL BIOL, V12, P747, DOI 10.1038/ncb2078
   Remijsen Q, 2011, CELL RES, V21, P290, DOI 10.1038/cr.2010.150
   Rohn TT, 2011, NEUROBIOL DIS, V43, P68, DOI 10.1016/j.nbd.2010.11.003
   Roze E, 2010, ADV EXP MED BIOL, V685, P45
   Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383
   Saitoh T, 2009, P NATL ACAD SCI USA, V106, P20842, DOI 10.1073/pnas.0911267106
   Samara C, 2008, CELL DEATH DIFFER, V15, P105, DOI 10.1038/sj.cdd.4402231
   Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044
   Schweers RL, 2007, P NATL ACAD SCI USA, V104, P19500, DOI 10.1073/pnas.0708818104
   Sengupta S, 2010, MOL CELL, V40, P310, DOI 10.1016/j.molcel.2010.09.026
   Shen W, 2009, J CELL BIOL, V187, P71, DOI 10.1083/jcb.200907109
   Shi CS, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000751
   Shi CS, 2008, J BIOL CHEM, V283, P33175, DOI 10.1074/jbc.M804478200
   Shiba K, 2009, BIOCHEM BIOPH RES CO, V383, P331, DOI 10.1016/j.bbrc.2009.04.006
   Shibata M, 2006, J BIOL CHEM, V281, P14474, DOI 10.1074/jbc.M600364200
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Sinha S, 2008, AUTOPHAGY, V4, P989, DOI 10.4161/auto.6803
   Sou Y, 2008, MOL BIOL CELL, V19, P4762, DOI 10.1091/mbc.E08-03-0309
   Spencer B, 2009, J NEUROSCI, V29, P13578, DOI 10.1523/JNEUROSCI.4390-09.2009
   Strappazzon F, 2011, EMBO J, V30, P1195, DOI 10.1038/emboj.2011.49
   Suzuki T, 2007, PLOS PATHOG, V3, P1082, DOI 10.1371/journal.ppat.0030111
   Takacs-Vellai K, 2005, CURR BIOL, V15, P1513, DOI 10.1016/j.cub.2005.07.035
   Tal MC, 2009, P NATL ACAD SCI USA, V106, P2770, DOI 10.1073/pnas.0807694106
   Tal R, 2007, J BIOL CHEM, V282, P5617, DOI 10.1074/jbc.M605940200
   Talloczy Z, 2006, AUTOPHAGY, V2, P24, DOI 10.4161/auto.2176
   Tang HW, 2011, EMBO J, V30, P636, DOI 10.1038/emboj.2010.338
   Tanida I, 2004, J BIOL CHEM, V279, P36268, DOI 10.1074/jbc.M401461200
   Tanida I, 2011, ANTIOXID REDOX SIGN, V14, P2201, DOI 10.1089/ars.2010.3482
   Tasdemir E, 2008, AUTOPHAGY, V4, P810, DOI 10.4161/auto.6486
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Terman A, 1995, GERONTOLOGY, V41, P319
   Thurston TLM, 2009, NAT IMMUNOL, V10, P1215, DOI 10.1038/ni.1800
   Tong JJ, 2010, PROTEIN CELL, V1, P907, DOI 10.1007/s13238-010-0121-z
   Travassos LH, 2010, NAT IMMUNOL, V11, P55, DOI 10.1038/ni.1823
   Tsukamoto S, 2008, SCIENCE, V321, P117, DOI 10.1126/science.1154822
   Uhl M, 2009, CELL DEATH DIFFER, V16, P991, DOI 10.1038/cdd.2009.8
   Ullman E, 2008, CELL DEATH DIFFER, V15, P422, DOI 10.1038/sj.cdd.4402234
   Valentim L, 2006, J MOL CELL CARDIOL, V40, P846, DOI 10.1016/j.yjmcc.2006.03.428
   Vives-Bauza C, 2010, P NATL ACAD SCI USA, V107, P378, DOI 10.1073/pnas.0911187107
   Walls KC, 2010, J BIOL CHEM, V285, P10497, DOI 10.1074/jbc.M110.103747
   Wang K, 2011, AUTOPHAGY, V7, P297, DOI 10.4161/auto.7.3.14502
   Webber JL, 2010, FEBS LETT, V584, P1319, DOI 10.1016/j.febslet.2010.01.020
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Williams A, 2006, CURR TOP DEV BIOL, V76, P89, DOI 10.1016/S0070-2153(06)76003-3
   Wirawan E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.16
   Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789
   Xia HG, 2010, AUTOPHAGY, V6, P61, DOI 10.4161/auto.6.1.10326
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yang ZF, 2006, MOL BIOL CELL, V17, P5094, DOI 10.1091/mbc.E06-06-0479
   Yano T, 2008, NAT IMMUNOL, V9, P908, DOI 10.1038/ni.1634
   Yoo BH, 2010, J BIOL CHEM, V285, P5438, DOI 10.1074/jbc.M109.046789
   Young ARJ, 2006, J CELL SCI, V119, P3888, DOI 10.1242/jcs.03172
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Yu HB, 2009, J BIOL CHEM, V284, P36007, DOI 10.1074/jbc.C109.073627
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
   Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zalckvar E, 2009, AUTOPHAGY, V5, P720, DOI 10.4161/auto.5.5.8625
   Zeng M, 2008, CELL SIGNAL, V20, P659, DOI 10.1016/j.cellsig.2007.11.015
   Zhang Y, 2009, P NATL ACAD SCI USA, V106, P19860, DOI 10.1073/pnas.0906048106
   Zhao YD, 2010, BRAIN RES, V1313, P250, DOI 10.1016/j.brainres.2009.12.004
   Zheng YT, 2009, J IMMUNOL, V183, P5909, DOI 10.4049/jimmunol.0900441
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
NR 221
TC 281
Z9 312
U1 1
U2 67
PU INST BIOCHEMISTRY & CELL BIOLOGY
PI SHANGHAI
PA SIBS, CAS, 319 YUEYANG ROAD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1001-0602
EI 1748-7838
J9 CELL RES
JI Cell Res.
PD JAN
PY 2012
VL 22
IS 1
BP 43
EP 61
DI 10.1038/cr.2011.152
PG 19
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 879EQ
UT WOS:000299312900009
PM 21912435
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Du, BY
   Guo, Y
   Jin, L
   Xiong, MY
   Liu, DD
   Xi, XY
AF Du, Boyu
   Guo, Yang
   Jin, Lan
   Xiong, Mengyuan
   Liu, Dandan
   Xi, Xueyan
TI Targeting autophagy promote the 5-fluorouracil induced apoptosis in
   human colon cancer cells
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Chloroquine; 5-fluorouracil; colon cancer; autophagy; apoptosis
ID DRUG-RESISTANCE; CHLOROQUINE; INHIBITION; CYTOTOXICITY; MECHANISMS;
   CISPLATIN; OVERCOME; STRESS; DEATH
AB Colon cancer is a leading cause of cancer-related death in developed countries. Although 5-fluorouracil (5-FU) has traditionally been studied for its potential to induce apoptosis, its clinical use had been greatly limited as a result of the development of drug resistance in patients. Besides the medicines that could induce apoptosis in cancer cells, several other alternative treatments, which had different mechanisms of action (such as autophagy), had gained more and more attention recently. As for colon cancer, autophagy appeared to have certain protective effects in tumor cells by antagonizing the inhibition caused by chemotherapy and radiotherapy. Therefore, autophagy inhibition seemed to be an effective mean for cancer treatment. In this study, HT29 and SW480 cells were treated with autophagy inhibitors together with/without 5-FU, the proliferation rate, apoptosis and autophagy induction effects were then evaluated. The proliferation rate of cancer cells was analyzed by MTT assay. Apoptosis was quantified by flow-cytometry after the cells were double-stained with Annexin V/PI. Autophagy and apoptosis were both further confirmed by western blot analysis. Finally, to confirm the effects of combinational use of 5-FU with 3-methyladenine (3-MA) and Chloroquine (CQ), the colony formation assay was also performed. Our results demonstrated that 5-FU could induce apoptosis and autophagy in colon cancer cells. Both 3-MA and CQ could enhance the apoptosis induced by 5-FU in colon cancer cells, while CQ had better inhibitory effect against the proliferation of colon cancer cells. Meanwhile, CQ could induce a caspase-dependent apoptosis in colon cancer cells. Cathepins might function in the synergistic interaction between 5-FU and CQ. Based on the above results, we proposed the combinational use of 5-FU and CQ might be a novel therapeutic method for the treatment of colon cancer.
C1 [Du, Boyu; Guo, Yang; Jin, Lan; Xiong, Mengyuan; Liu, Dandan; Xi, Xueyan] Hubei Univ Med, Sch Basic Med Sci, Shiyan, Peoples R China.
RP Xi, XY (corresponding author), Hubei Univ Med, Sch Basic Med Sci, Dept Immunol, 30 Renmin Nanlu, Shiyan 442000, Hubei Province, Peoples R China.
EM xixueyan2001@126.com
FU Science and Technology Research Project of Education Department of Hubei
   Province [D20162104, B2016504]; Faculty Development Grant of Hubei
   University of Medicine [2015QDJZR07, 2015QDJZR10]
FX This work was supported by grants from Science and Technology Research
   Project of Education Department of Hubei Province (D20162104 to Xueyan
   Xi and B2016504 to Dandan Liu) and Faculty Development Grant of Hubei
   University of Medicine (2015QDJZR07 to Xueyan Xi and 2015QDJZR10 to Boyu
   Du).
CR Apel A, 2009, INT J CANCER, V125, P991, DOI 10.1002/ijc.24500
   Bijnsdorp IV, 2010, INT J CANCER, V126, P2457, DOI 10.1002/ijc.24943
   Carew JS, 2007, BLOOD, V110, P313, DOI 10.1182/blood-2006-10-050260
   Carew JS, 2011, J BIOL CHEM, V286, P6602, DOI 10.1074/jbc.M110.151324
   Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003
   Choi JH, 2012, APMIS, V120, P597, DOI 10.1111/j.1600-0463.2012.02876.x
   Dahan L, 2009, BRIT J PHARMACOL, V158, P610, DOI 10.1111/j.1476-5381.2009.00341.x
   Denise C, 2015, ONCOTARGET, V6, P41706, DOI 10.18632/oncotarget.5991
   Golden EB, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.9.FOCUS14504
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738
   Lamparska-Przybysz M, 2005, J Physiol Pharmacol, V56 Suppl 3, P159
   Li CG, 2015, CELL PHYSIOL BIOCHEM, V35, P1303, DOI 10.1159/000373952
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Liu F, 2014, ACTA PHARMACOL SIN, V35, P645, DOI 10.1038/aps.2014.3
   Liu L, 2016, NEOPLASMA, V63, P193, DOI 10.4149/203_150422N214
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Pan XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056679
   Refaat B, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0187-9
   Sasaki K, 2012, ANTI-CANCER DRUG, V23, P675, DOI 10.1097/CAD.0b013e328353f8c7
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Shi SM, 2016, ONCOL REP, V35, P2606, DOI 10.3892/or.2016.4680
   Shi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051076
   Sui XB, 2014, SCI REP-UK, V4, DOI 10.1038/srep04694
   TAMAI M, 1986, J PHARMACOBIO-DYNAM, V9, P672, DOI 10.1248/bpb1978.9.672
   Tang MC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119135
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   UENO T, 1991, BIOMED BIOCHIM ACTA, V50, P365
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Xi X, 2016, PLOS ONE, V8
   Xu R, 2006, HISTOL HISTOPATHOL, V21, P867, DOI 10.14670/HH-21.867
   Xu Y, 2012, CANCER LETT, V314, P232, DOI 10.1016/j.canlet.2011.09.034
   Zeleznik TZ, 2015, BIOCHEM BIOPH RES CO, V465, P213, DOI 10.1016/j.bbrc.2015.07.155
NR 35
TC 3
Z9 3
U1 1
U2 9
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2017
VL 10
IS 5
BP 6071
EP 6081
PG 11
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA EW1UG
UT WOS:000402279600130
DA 2022-04-25
ER

PT J
AU Prasad, AR
   Prasad, S
   Nguyen, H
   Facista, A
   Lewis, C
   Zaitlin, B
   Bernstein, H
   Bernstein, C
AF Prasad, Anil R.
   Prasad, Shilpa
   Nguyen, Huy
   Facista, Alexander
   Lewis, Cristy
   Zaitlin, Beryl
   Bernstein, Harris
   Bernstein, Carol
TI Novel diet-related mouse model of colon cancer parallels human colon
   cancer
SO WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
LA English
DT Article
DE Diet; Deoxycholate; Mouse model; Colon cancer; Histology; Chlorogenic
   acid; 8-OH-dG; Beclin 1; Beta-catenin
AB AIM: To investigate the close parallels between our novel diet-related mouse model of colon cancer and human colon cancer.
   METHODS: Twenty-two wild-type female mice (ages 6-8 wk) were fed the standard control diet (AIN-93G) and an additional 22 female mice (ages 6-8 wk) were fed the control diet supplemented with 0.2% deoxycholic acid [diet + deoxycholic acid (DOC)] for 10 mo. Tumors occurred in the colons of mice fed diet + DOC and showed progression to colon cancer [adenocarcinoma (AC)]. This progression is through the stages of tubular adenoma (TA), TA with high grade dysplasia or adenoma with sessile serrated morphology, intramucosal AC, AC stage T1, and AC stage T2. The mouse tumors were compared to human tumors at the same stages by histopathological analysis. Sections of the small and large intestines of mice and humans were evaluated for glandular architecture, cellular and nuclear morphology including cellular orientation, cellular and nuclear atypia, pleomorphism, mitotic activity, frequency of goblet cells, crypt architecture, ulceration, penetration of crypts through the muscularis mucosa and presence of malignant crypts in the muscularis propria. In addition, preserved colonic tissues from genetically similar male mice, obtained from a prior experiment, were analyzed by immunohistochemistry. The male mice had been fed the control diet or diet + DOC. Four molecular markers were evaluated: 8-OH-dG, DNA repair protein ERCC1, autophagy protein beclin-1 and the nuclear location of beta-catenin in the stem cell region of crypts. Also, male mice fed diet + DOC plus 0.007% chlorogenic acid (diet + DOC + CGA) were evaluated for ERCC1, beclin-1 and nuclear location of beta-catenin.
   RESULTS: Humans with high levels of diet-related DOC in their colons are at a substantially increased risk of developing colon cancer. The mice fed diet + DOC had levels of DOC in their colons comparable to that of humans on a high fat diet. The 22 mice without added DOC in their diet had no colonic tumors while 20 of the 22 mice (91%) fed diet + DOC developed colonic tumors. Furthermore, the tumors in 10 of these mice (45% of mice) included an adenocarcinoma. All mice were free of cancers of the small intestine. Histopathologically, the colonic tumor types in the mice were virtually identical to those in humans. In humans, characteristic aberrant changes in molecular markers can be detected both in field defects surrounding cancers (from which cancers arise) and within cancers. In the colonic tissues of mice fed diet + DOC similar changes in biomarkers appeared to occur. Thus, 8-OH-dG was increased, DNA repair protein ERCC1 was decreased, autophagy protein beclin-1 was increased and, in the stem cell region at the base of crypts there was substantial nuclear localization of beta-catenin as well as increased cytoplasmic beta-catenin. However, in mice fed diet + DOC + CGA (with reduced frequency of cancer) and evaluated for ERCC1, beclin-1, and beta-catenin in the stem cell region of crypts, mouse tissue showed amelioration of the aberrancies, suggesting that chlorogenic acid is protective at the molecular level against colon cancer. This is the first diet-related model of colon cancer that closely parallels human progression to colon cancer, both at the histomorphological level as well as in its molecular profile.
   CONCLUSION: The diet-related mouse model of colon cancer parallels progression to colon cancer in humans, and should be uniquely useful in model studies of prevention and therapeutics. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
C1 [Prasad, Anil R.] Northwest Med Ctr, Dept Pathol, Tucson, AZ 85741 USA.
   [Prasad, Anil R.] Univ Arizona, Coll Med, Dept Pathol, Tucson, AZ 85724 USA.
   [Prasad, Shilpa] Boston Univ, Coll Arts & Sci, Boston, MA USA.
   [Nguyen, Huy; Facista, Alexander; Lewis, Cristy; Bernstein, Harris; Bernstein, Carol] Univ Arizona, Coll Med, Dept Cellular & Mol Med, Tucson, AZ 85724 USA.
   [Zaitlin, Beryl] Matrix Solut Inc, Calgary, AB T2R 0V2, Canada.
RP Bernstein, C (corresponding author), Univ Arizona, Coll Med, Dept Cellular & Mol Med, 2639 E 4th St, Tucson, AZ 85716 USA.
EM bernstein324@yahoo.com
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [5 R01 CA119087];
   Arizona Biomedical Research Commission [0803]; Veterans Affairs Merit
   ReviewUS Department of Veterans Affairs [0142]
FX Supported by National Institutes of Health, No. 5 R01 CA119087; Arizona
   Biomedical Research Commission, No. 0803; and Veterans Affairs Merit
   Review, No. 0142; administered by the Southern Arizona Veterans Affairs
   Health Care System
CR Bernstein C., 2013, NEW RES DIRECTIONS D
   Bernstein C, 2011, ARCH TOXICOL, V85, P863, DOI 10.1007/s00204-011-0648-7
   Bernstein H, 2004, CARCINOGENESIS, V25, P681, DOI 10.1093/carcin/bgh072
   Bernstein H., 2007, NEW RES DNA REPAIR, P99
   Bernstein H, 2009, WORLD J GASTROENTERO, V15, P3329, DOI 10.3748/wjg.15.3329
   Buchner AM, 2010, GASTROENTEROLOGY, V138, P834, DOI 10.1053/j.gastro.2009.10.053
   Campbell CD, 2012, NAT GENET, V44, P1277, DOI 10.1038/ng.2418
   CHEAH PY, 1990, NUTR CANCER, V14, P5, DOI 10.1080/01635589009514073
   Clifford MN, 1999, J SCI FOOD AGR, V79, P362, DOI [10.1002/(SICI)1097-0010(19990301)79:3<362::AID-JSFA256>3.0.CO;2-D, 10.1002/(SICI)1097-0010(19990301)79:3&lt;362::AID-JSFA256&gt;3.0.CO;2-D]
   Corpet DE, 2005, EUR J CANCER, V41, P1911, DOI 10.1016/j.ejca.2005.06.006
   Cortopassi GA, 1996, MECH AGEING DEV, V91, P211, DOI 10.1016/S0047-6374(96)01788-5
   CRAVEN PA, 1986, J CLIN INVEST, V77, P850, DOI 10.1172/JCI112382
   Crowley-Weber CL, 2002, CARCINOGENESIS, V23, P2063, DOI 10.1093/carcin/23.12.2063
   Cuozzo C, 2007, PLOS GENET, V3, P1144, DOI 10.1371/journal.pgen.0030110
   Delaney S, 2012, FREE RADICAL RES, V46, P420, DOI 10.3109/10715762.2011.653968
   Facista Alexander, 2012, Genome Integr, V3, P3, DOI 10.1186/2041-9414-3-3
   Fisher LA, 2011, CHEM RES TOXICOL, V24, P1876, DOI 10.1021/tx200221j
   GARCIA M, 2007, GLOBAL CANC FACTS FI
   Halford S, 2005, GUT, V54, P797, DOI 10.1136/gut.2004.059535
   HILL MJ, 1990, MUTAT RES, V238, P313, DOI 10.1016/0165-1110(90)90023-5
   Hugh TJ, 1999, INT J CANCER, V82, P504, DOI 10.1002/(SICI)1097-0215(19990812)82:4<504::AID-IJC6>3.0.CO;2-6
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Kapiteijn E, 2001, J PATHOL, V195, P171, DOI 10.1002/path.918
   Katsurano M, 2012, ONCOGENE, V31, P342, DOI 10.1038/onc.2011.241
   Kono S, 2004, EUR J CANCER PREV, V13, P127, DOI 10.1097/00008469-200404000-00006
   Kunz BA, 1998, GENETICS, V148, P1491
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Lechner S, 2002, CARCINOGENESIS, V23, P1281, DOI 10.1093/carcin/23.8.1281
   Longpre JM, 2008, APOPTOSIS, V13, P1162, DOI 10.1007/s10495-008-0244-3
   Lorin S, 2013, SEMIN CANCER BIOL, V23, P361, DOI 10.1016/j.semcancer.2013.06.007
   Maskarinec G, 2004, ETHNIC DIS, V14, P431
   Mattila P, 2002, J AGR FOOD CHEM, V50, P3660, DOI 10.1021/jf020028p
   Newmark HL, 2009, CARCINOGENESIS, V30, P88, DOI 10.1093/carcin/bgn229
   Nguyen H, 2010, J VIS EXP
   O'Hagan HM, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000155
   O'Keefe SJD, 1999, AM J GASTROENTEROL, V94, P1373, DOI 10.1111/j.1572-0241.1999.01089.x
   Ou JH, 2012, NUTR CANCER, V64, P34, DOI 10.1080/01635581.2012.630164
   Payne CM, 2007, CARCINOGENESIS, V28, P215, DOI 10.1093/carcin/bgl139
   Payne CM, 2009, J TOXICOL-US, V2009, DOI 10.1155/2009/785907
   Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658
   REDDY BS, 1980, J NUTR, V110, P1880, DOI 10.1093/jn/110.9.1880
   Reddy S, 1998, BRIT J NUTR, V79, P495, DOI 10.1079/BJN19980087
   Roach JC, 2010, SCIENCE, V328, P636, DOI 10.1126/science.1186802
   Rosenberg DW, 2009, CARCINOGENESIS, V30, P183, DOI 10.1093/carcin/bgn267
   Rubin H, 2011, BIOESSAYS, V33, P224, DOI 10.1002/bies.201000067
   Saif MW, 2010, CANCER J, V16, P196, DOI 10.1097/PPO.0b013e3181e076af
   SAMUEL P, 1968, J CLIN INVEST, V47, P2070, DOI 10.1172/JCI105892
   Schmitt MW, 2012, ANN NY ACAD SCI, V1267, P110, DOI 10.1111/j.1749-6632.2012.06590.x
   Scott TL, 2014, ANTIOXID REDOX SIGN, V20, P708, DOI 10.1089/ars.2013.5529
   Shibata H, 1999, BIOSCI BIOTECH BIOCH, V63, P1295, DOI 10.1271/bbb.63.1295
   Stuart GR, 2000, GENETICS, V154, P1291
   Thomas LA, 2001, GUT, V49, P835, DOI 10.1136/gut.49.6.835
   Truninger K, 2005, GASTROENTEROLOGY, V128, P1160, DOI 10.1053/j.gastro.2005.01.056
   Valavanidis A, 2009, J ENVIRON SCI HEAL C, V27, P120, DOI 10.1080/10590500902885684
   Valeri N, 2010, P NATL ACAD SCI USA, V107, P6982, DOI 10.1073/pnas.1002472107
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Yachida S, 2009, AM J SURG PATHOL, V33, P1823, DOI 10.1097/PAS.0b013e3181b6da19
   Yost SE, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks299
NR 58
TC 10
Z9 10
U1 1
U2 2
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1948-5204
J9 WORLD J GASTRO ONCOL
JI World J. Gastrointest. Oncol.
PD JUL 15
PY 2014
VL 6
IS 7
BP 225
EP 243
DI 10.4251/wjgo.v6.i7.225
PG 19
WC Oncology; Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Gastroenterology & Hepatology
GA V9A4H
UT WOS:000422132600003
PM 25024814
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Sipos, F
   Firneisz, G
   Muzes, G
AF Sipos, Ferenc
   Firneisz, Gabor
   Muzes, Gyorgyi
TI Therapeutic aspects of c-MYC signaling in inflammatory and cancerous
   colonic diseases
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Review
DE c-MYC; Therapy; Apoptosis; Autophagy; Colon; Inflammation; Colorectal
   cancer
ID MESENCHYMAL STEM-CELLS; COLORECTAL-CANCER; INDUCED APOPTOSIS;
   BOWEL-DISEASE; TRANSCRIPTION FACTORS; GENE-EXPRESSION;
   SELECTIVE-INHIBITION; INTESTINAL CRYPTS; EPITHELIAL-CELLS; BETA-CATENIN
AB Colonic inflammation is required to heal infections, wounds, and maintain tissue homeostasis. As the seventh hallmark of cancer, however, it may affect all phases of tumor development, including tumor initiation, promotion, invasion and metastatic dissemination, and also evasion immune surveillance. Inflammation acts as a cellular stressor and may trigger DNA damage or genetic instability, and, further, chronic inflammation can provoke genetic mutations and epigenetic mechanisms that promote malignant cell transformation. Both sporadical and colitis-associated colorectal carcinogenesis are multi-step, complex processes arising from the uncontrolled proliferation and spreading of malignantly transformed cell clones with the obvious ability to evade the host's protective immunity. In cells upon DNA damage several protooncogenes, including c-MYC are activated in parelell with the inactivation of tumor suppressor genes. The target genes of the c-MYC protein participate in different cellular functions, including cell cycle, survival, protein synthesis, cell adhesion, and microRNA expression. The transcriptional program regulated by c-MYC is context dependent, therefore the final cellular response to elevated c-MYC levels may range from increased proliferation to augmented apoptosis. Considering physiological intestinal homeostasis, c-MYC displays a fundamental role in the regulation of cell proliferation and crypt cell number. However, c-MYC gene is frequently deregulated in inflammation, and overexpressed in both sporadic and colitis-associated colon adenocarcinomas. Recent results demonstrated that endogenous c-MYC is essential for efficient induction of p53-dependent apoptosis following DNA damage, but c-MYC function is also involved in and regulated by autophagy-related mechanisms, while its expression is affected by DNA-methylation, or histone acetylation. Molecules directly targeting c-MYC, or agents acting on other genes involved in the c-MYC pathway could be selected for combined regiments. However, due to its context-dependent cellular function, it is clinically essential to consider which cytotoxic drugs are used in combination with c-MYC targeted agents in various tissues. Increasing our knowledge about MYC-dependent pathways might provide direction to novel anti-inflammatory and colorectal cancer therapies.
C1 [Sipos, Ferenc; Firneisz, Gabor; Muzes, Gyorgyi] Semmelweis Univ, Dept Internal Med 2, Szentkiralyi St 46, H-1088 Budapest, Hungary.
RP Sipos, F (corresponding author), Semmelweis Univ, Dept Internal Med 2, Szentkiralyi St 46, H-1088 Budapest, Hungary.
EM dr.siposf@gmail.com
RI Mao, Yurong/AAB-6858-2022; Firneisz, Gabor/AAC-9654-2021
OI Firneisz, Gabor/0000-0002-9123-8131
CR Ai GQ, 2016, TUMOR BIOL, V37, P1727, DOI 10.1007/s13277-015-3959-0
   Alexander RJ, 1996, DIGEST DIS SCI, V41, P660, DOI 10.1007/BF02213120
   Axelrad JE, 2016, WORLD J GASTROENTERO, V22, P4794, DOI 10.3748/wjg.v22.i20.4794
   Bajpe PK, 2015, ONCOGENE, V34, P531, DOI 10.1038/onc.2013.588
   Bandukwala HS, 2012, P NATL ACAD SCI USA, V109, P14532, DOI 10.1073/pnas.1212264109
   Basith S, 2012, ARCH PHARM RES, V35, P1297, DOI 10.1007/s12272-012-0802-7
   Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2
   BEAULIEU JF, 1992, J CELL SCI, V102, P427
   Bettess MD, 2005, MOL CELL BIOL, V25, P7868, DOI 10.1128/MCB.25.17.7868-7878.2005
   Bouchard C, 2007, GENE DEV, V21, P2775, DOI 10.1101/gad.453107
   Boudjadi S, 2016, ONCOGENE, V35, P1671, DOI 10.1038/onc.2015.231
   Boudjadi S, 2013, BIOMARK RES, V1, DOI 10.1186/2050-7771-1-16
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Brabletz T, 2000, AM J PATHOL, V156, P865, DOI 10.1016/S0002-9440(10)64955-3
   Brentnall TA, 2009, PROTEOM CLIN APPL, V3, P1326, DOI 10.1002/prca.200900061
   Cannell IG, 2010, P NATL ACAD SCI USA, V107, P5375, DOI 10.1073/pnas.0910015107
   Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982
   Chen BJ, 2014, INT J BIOL SCI, V10, P1084, DOI 10.7150/ijbs.10190
   Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2
   Chen L, 2013, J BIOL CHEM, V288, P14510, DOI 10.1074/jbc.M113.458737
   Chu EC, 2007, ALIMENT PHARM THER, V25, P1443, DOI 10.1111/j.1365-2036.2007.03336.x
   Cianfanelli Valentina, 2015, Nat Cell Biol, V17, P706, DOI 10.1038/ncb3171
   CICLITIRA PJ, 1987, J PATHOL, V151, P293, DOI 10.1002/path.1711510409
   Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014
   Dansen TB, 2006, J BIOL CHEM, V281, P10890, DOI 10.1074/jbc.M513655200
   Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017
   Dydensborg AB, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-223
   Eischen CM, 2001, ONCOGENE, V20, P6983, DOI 10.1038/sj.onc.1204892
   Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001
   ERISMAN MD, 1988, ONCOGENE, V2, P367
   ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969
   EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235
   Felsher Dean W, 2010, Genes Cancer, V1, P597, DOI 10.1177/1947601910377798
   Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504
   Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925
   Giuriato S, 2006, P NATL ACAD SCI USA, V103, P16266, DOI 10.1073/pnas.0608017103
   Groulx JF, 2014, CARCINOGENESIS, V35, P1217, DOI 10.1093/carcin/bgu006
   Grunt TW, 2015, AM J CANCER RES, V5, P560
   Gu Shuo, 2010, Silence, V1, P11, DOI 10.1186/1758-907X-1-11
   Gu W, 2014, J APPL MATH, DOI 10.1155/2014/560567
   Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615
   Hayashi Y, 2008, J PHARMACOL EXP THER, V326, P523, DOI 10.1124/jpet.108.137083
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232
   Hock A, 2010, INT J BIOCHEM CELL B, V42, P1618, DOI 10.1016/j.biocel.2010.06.011
   Hoffman B, 2008, ONCOGENE, V27, P6462, DOI 10.1038/onc.2008.312
   Hoffman B, 1998, ONCOGENE, V17, P3351, DOI 10.1038/sj.onc.1202592
   Huang HL, 2014, CURR PHARM DESIGN, V20, P6543, DOI 10.2174/1381612820666140826153203
   Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305
   Hurley LH, 2006, SEMIN ONCOL, V33, P498, DOI 10.1053/j.seminoncol.2006.04.012
   Hydbring P, 2010, P NATL ACAD SCI USA, V107, P58, DOI 10.1073/pnas.0900121106
   IMASEKI H, 1989, CANCER, V64, P704, DOI 10.1002/1097-0142(19890801)64:3<704::AID-CNCR2820640323>3.0.CO;2-S
   Itzkowitz SH, 2004, AM J PHYSIOL-GASTR L, V287, pG7, DOI 10.1152/ajpgi.00079.2004
   Iyengar RV, 2001, CANCER RES, V61, P3045
   Iyer KS, 2003, MACROMOLECULES, V36, P6519, DOI 10.1021/ma034460z
   Jensen SA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006839
   Jing H, 2016, CANCER CELL, V29, P607, DOI 10.1016/j.ccell.2016.03.011
   Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367
   Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003
   Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382
   Konsavage WM, 2012, MOL CELL BIOL, V32, P3891, DOI 10.1128/MCB.00548-12
   Kress TR, 2011, MOL CELL, V41, P445, DOI 10.1016/j.molcel.2011.01.023
   Larsson LG, 2010, EXP CELL RES, V316, P1429, DOI 10.1016/j.yexcr.2010.03.025
   Laurenti E, 2009, CURR OPIN CELL BIOL, V21, P844, DOI 10.1016/j.ceb.2009.09.006
   Lazebnik L B, 2010, Ter Arkh, V82, P38
   Lazebnik Y, 2010, NAT REV CANCER, V10, P232, DOI 10.1038/nrc2827
   Liu M, 2010, J GENET GENOMICS, V37, P347, DOI 10.1016/S1673-8527(09)60053-9
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Maclean KH, 2003, MOL CELL BIOL, V23, P7256, DOI 10.1128/MCB.23.20.7256-7270.2003
   Mathur A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098515
   Meck MM, 2001, CANCER RES, V61, P5083
   Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108
   Meyer N, 2006, SEMIN CANCER BIOL, V16, P275, DOI 10.1016/j.semcancer.2006.07.011
   Moghimi SM, 2005, MOL THER, V11, P990, DOI 10.1016/j.ymthe.2005.02.010
   MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480
   Muncan V, 2006, MOL CELL BIOL, V26, P8418, DOI 10.1128/MCB.00821-06
   Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018
   Nazio F, 2013, NAT CELL BIOL, V15, P406, DOI 10.1038/ncb2708
   Nemoto Y, 2013, GUT, V62, P1142, DOI 10.1136/gutjnl-2012-302029
   Ni HH, 2005, ONCOGENE, V24, P6820, DOI 10.1038/sj.onc.1208848
   Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261
   Ooi A, 2004, MODERN PATHOL, V17, P895, DOI 10.1038/modpathol.3800137
   Fiorentino FP, 2016, ONCOTARGET, V7, P31014, DOI 10.18632/oncotarget.8826
   Park J, 2016, ONCOTARGET, V7, P28670, DOI 10.18632/oncotarget.8764
   PAVELIC ZP, 1992, ANTICANCER RES, V12, P171
   Peiro-Jordan R, 2012, EUR J CANCER PREV, V21, P413, DOI 10.1097/CEJ.0b013e32834ef16f
   PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x
   Phesse TJ, 2014, CELL DEATH DIFFER, V21, P956, DOI 10.1038/cdd.2014.15
   Poortinga G, 2015, ONCOGENE, V34, P403, DOI 10.1038/onc.2014.13
   Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418
   Raup-Konsavage WM, 2016, DIGEST DIS SCI, V61, P410, DOI 10.1007/s10620-015-3852-0
   Robles AI, 2016, GASTROENTEROLOGY, V150, P931, DOI 10.1053/j.gastro.2015.12.036
   Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989
   Rousseaux C, 2005, J EXP MED, V201, P1205, DOI 10.1084/jem.20041948
   ROUSSEL MF, 1994, ONCOGENE, V9, P405
   Sakamuro D, 1995, ONCOGENE, V11, P2411
   Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674
   Saxena A, 2006, ONCOGENE, V25, P7274, DOI 10.1038/sj.onc.1209714
   Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800
   Semont A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070170
   Shah M, 2015, CELL CYCLE, V14, P323, DOI 10.4161/15384101.2014.980643
   Shi Dingding, 2012, Genes Cancer, V3, P240, DOI 10.1177/1947601912455199
   Shimada T, 2002, GUT, V50, P658, DOI 10.1136/gut.50.5.658
   Slack A, 2005, P NATL ACAD SCI USA, V102, P731, DOI 10.1073/pnas.0405495102
   Sodir NM, 2011, GENE DEV, V25, P907, DOI 10.1101/gad.2038411
   Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260
   Suresh P.K., 2015, INT J DRUG DEV RES, V7, P127
   Tangudu NK, 2015, MOL CANCER THER, V14, P1259, DOI 10.1158/1535-7163.MCT-14-0970
   Togel L, 2016, MOL CANCER THER, V15, P1217, DOI 10.1158/1535-7163.MCT-15-0724
   Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325
   Uddin MJ, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/210563
   UNTAWALE S, 1993, CANCER RES, V53, P1630
   Vadde R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/649263
   van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Vucicevic D, 2016, ONCOTARGET
   Wang HT, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1728-5
   Winkle M, 2015, FASEB J, V29, P2338, DOI 10.1096/fj.14-263889
   Wu CH, 2007, P NATL ACAD SCI USA, V104, P13028, DOI 10.1073/pnas.0701953104
   Wu X, 2012, CANCER EPIDEMIOL, V36, P212, DOI 10.1016/j.canep.2011.08.002
   Xiang JF, 2014, CELL RES, V24, P513, DOI 10.1038/cr.2014.35
   Xing YF, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0092-3
   Yabana T, 2009, J PATHOL, V218, P350, DOI 10.1002/path.2535
   Yaeger R, 2016, GASTROENTEROLOGY, V151, P278, DOI 10.1053/j.gastro.2016.04.001
   Yamakawa-Karakida N, 2002, CELL DEATH DIFFER, V9, P513, DOI 10.1038/sj.cdd.4401000
   Yang F, 2013, J CANCER RES CLIN, V139, P437, DOI 10.1007/s00432-012-1324-x
   Yekkala K, 2007, MOL CANCER RES, V5, P1296, DOI 10.1158/1541-7786.MCR-07-0232
   Yin YW, 2015, GENE EXPRESSION, V16, P187, DOI 10.3727/105221615X14399878166230
   You ZB, 2002, J BIOL CHEM, V277, P36671, DOI 10.1074/jbc.M203213200
   Zhang Huan-Le, 2016, Shengli Xuebao, V68, P171, DOI 10.13294/j.aps.2016.0027
NR 132
TC 47
Z9 49
U1 3
U2 16
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD SEP 21
PY 2016
VL 22
IS 35
BP 7938
EP 7950
DI 10.3748/wjg.v22.i35.7938
PG 13
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA DW9LT
UT WOS:000383981800007
PM 27672289
OA hybrid, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Liu, TT
   Liu, SM
AF Liu, Ting-ting
   Liu, Shu-min
TI Prediction of Prognostic Biomarkers and Construction of an Autophagy
   Prognostic Model for Colorectal Cancer Using Bioinformatics
SO TECHNOLOGY IN CANCER RESEARCH & TREATMENT
LA English
DT Article
DE autophagy; prognostic model; colorectal cancer; bioinformatics; markers
AB Objective:
   The incidence of colorectal cancer is increasing every year, and autophagy may be related closely to the pathogenesis of colorectal cancer. Autophagy is a natural catabolic mechanism that allows the degradation of cellular components in eukaryotic cells. However, autophagy plays a dual role in tumorigenesis. It not only promotes normal cell survival and tumor growth but also induces cell death and suppresses tumors survival. In addition, the pathogenesis of various conditions, including inflammation, neurodegenerative diseases, or tumors, is associated with abnormal autophagy. The present work aimed to examine the significance of autophagy-related genes (ARGs) in prognosis prediction, to construct an autophagy prognostic model, and to identify independent prognostic factors for colorectal cancer (CRC).
   Methods:
   This study discovered a total of 36 ARGs in CRC cases using The Cancer Genome Atlas (TCGA) and Human Autophagy-dedicated (HADd) databases along with functional enrichment analysis. Then, an autophagy prognostic model was constructed using univariate Cox regression analysis, and the key prognostic genes were screened. Finally, independent prognostic markers were determined through independent prognostic analysis and clinical correlation analysis of key genes.
   Results:
   Of the 36 differentially expressed ARGs, 13 were related to prognosis, as determined by univariate Cox regression analysis. A total of 6 key genes were obtained by a multivariate Cox regression analysis. Independent prognostic values were shown by 3 genes, namely, microtubule-associated protein 1 light chain 3 (MAP1LC3C), small GTPase superfamily and Rab family (RAB7A), and WD-repeat domain phosphoinositide-interacting protein 2 (WIPI2) by independent prognostic analysis and clinical correlation.
   Conclusions:
   In this study, molecular bioinformatics technology was employed to determine and construct a prognostic model of autophagy for colon cancer patients, which revealed 3 autophagy-related features, namely, MAP1LC3C, WIPI2, and RAB7A.
C1 [Liu, Ting-ting; Liu, Shu-min] Heilongjiang Univ Chinese Med, Grad Sch, Harbin, Heilongjiang, Peoples R China.
   [Liu, Shu-min] Heilongjiang Univ Chinese Med, Inst Tradit Chinese Med, 24 Heping Rd, Harbin 150040, Heilongjiang, Peoples R China.
RP Liu, SM (corresponding author), Heilongjiang Univ Chinese Med, Inst Tradit Chinese Med, 24 Heping Rd, Harbin 150040, Heilongjiang, Peoples R China.
EM keji-liu@163.com
CR Bakula D, 2013, BIOCHEM SOC T, V41, P962, DOI 10.1042/BST20130039
   Bathe OF, 2014, GENES-BASEL, V5, P536, DOI 10.3390/genes5030536
   Bell ES, 2020, AUTOPHAGY, V16, P959, DOI 10.1080/15548627.2020.1728099
   Brody H, 2015, NATURE, V521, pS1, DOI 10.1038/521S1a
   Chen C, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232832
   Devenport SN, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111349
   Dooley HC, 2014, MOL CELL, V55, P238, DOI 10.1016/j.molcel.2014.05.021
   Dorayappan KDP, 2018, ONCOGENE, V37, P3806, DOI 10.1038/s41388-018-0189-0
   Gafar AA, 2016, PEERJ, V4, DOI 10.7717/peerj.2445
   Gonzalez-Gaitan Marcos, 2003, Cell, V115, P513, DOI 10.1016/S0092-8674(03)00932-2
   Grimmel M, 2015, CELLS-BASEL, V4, P202, DOI 10.3390/cells4020202
   Guerra F, 2019, CANCERS, V11, DOI 10.3390/cancers11081096
   Guerra F, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5030034
   He Y, 2020, BIOSCI BIOTECH BIOCH, V84, P1645, DOI 10.1080/09168451.2020.1760784
   Kuchitsu Y, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7110215
   Liang XH, 2001, CANCER RES, V61, P3443
   Liao CC, 2013, AUTOPHAGY, V9, P5, DOI 10.4161/auto.22379
   Liu PF, 2014, AUTOPHAGY, V10, P1454, DOI 10.4161/auto.29556
   Mo SB, 2019, CARCINOGENESIS, V40, P861, DOI 10.1093/carcin/bgz031
   Mowers EE, 2017, ONCOGENE, V36, P1619, DOI 10.1038/onc.2016.333
   Polson HEJ, 2010, AUTOPHAGY, V6, P506, DOI 10.4161/auto.6.4.11863
   Proikas-Cezanne T, 2004, ONCOGENE, V23, P9314, DOI 10.1038/sj.onc.1208331
   Snider MD, 2003, MOL CELL, V12, P796, DOI 10.1016/S1097-2765(03)00401-5
   Tian S, 2017, ONCOTARGET, V8, P11071, DOI 10.18632/oncotarget.14360
   Towers CG, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201909033
   Towers CG, 2016, EBIOMEDICINE, V14, P15, DOI 10.1016/j.ebiom.2016.10.034
   Weiser MR, 2011, J CLIN ONCOL, V29, P4796, DOI 10.1200/JCO.2011.36.5080
   Yang Z, 2020, INT J ONCOL, V56, P1442, DOI 10.3892/ijo.2020.5027
   Yu J., 2019, MODERN ONCOL MED, V27, P2055
   Zhang CR, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00245
   Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051
   Zhou HY, 2016, CANCER BIOMARK, V17, P1, DOI 10.3233/CBM-160613
NR 32
TC 0
Z9 0
U1 3
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1533-0346
EI 1533-0338
J9 TECHNOL CANCER RES T
JI Technol. Cancer Res. Treat.
PD DEC 24
PY 2020
VL 19
AR 1533033820984177
DI 10.1177/1533033820984177
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA PM1FL
UT WOS:000603554100001
PM 33357130
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhai, H
   Song, B
   Xu, X
   Zhu, W
   Ju, J
AF Zhai, H.
   Song, B.
   Xu, X.
   Zhu, W.
   Ju, J.
TI Inhibition of autophagy and tumor growth in colon cancer by miR-502
SO ONCOGENE
LA English
DT Article
DE miR-502; autophagy; p53; colon cancer
ID CELL-CYCLE; GENE-EXPRESSION; SMALL RNAS; TRANSCRIPTIONAL ACTIVATION;
   P53; MICRORNAS; MIR-34A; PROLIFERATION; CHEMORESISTANCE; 5-FLUOROURACIL
AB Autophagy is a catabolic process that allows cellular macromolecules to be broken down and recycled as metabolic precursors. The influence of non-coding microRNAs in autophagy has not been explored in colon cancer. In this study, we discover a novel mechanism of autophagy regulated by hsa-miR-502-5p (miR-502) by suppression of Rab1B, a critical mediator of autophagy. A number of other miR-502 suppressed mRNA targets (for example, dihydroorotate dehydrogenase) are also identified by microarray analysis. Ectopic expression of miR-502 inhibited autophagy, colon cancer cell growth and cell-cycle progression of colon cancer cells in vitro. miR-502 also inhibited in-vivo colon cancer growth in a mouse tumor xenografts model. In addition, the expression of miR-502 was regulated by p53 via a negative feedback regulatory mechanism. The expression of miR-502 was downregulated in colon cancer patient specimens compared with the paired normal control samples. These results suggest that miR-502 may function as a potential tumor suppressor and therefore be a novel candidate for developing miR-502-based therapeutic strategies. Oncogene (2013) 32, 1570-1579; doi:10.1038/onc.2012.167; published online 14 May 2012
C1 [Zhai, H.; Ju, J.] SUNY Stony Brook, Dept Pathol, Translat Res Lab, Stony Brook, NY 11794 USA.
   [Song, B.] Dalian Med Univ, Dept Pathol, Dalian, Peoples R China.
   [Xu, X.; Zhu, W.] SUNY Stony Brook, Dept Appl Math & Stat, Stony Brook, NY 11794 USA.
RP Ju, J (corresponding author), SUNY Stony Brook, Dept Pathol, Translat Res Lab, BST L9,Room 185, Stony Brook, NY 11794 USA.
EM jingfang.ju@stonybrookmedicine.edu
RI zhai, haiyan/K-4659-2014
OI Ju, Jingfang/0000-0002-4821-7458
FU Stony Brook University Translational Research Laboratory [R01CA155019,
   R33CA147966]; NATIONAL CANCER INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [R01CA155019, R33CA147966] Funding
   Source: NIH RePORTER
FX We appreciate the critical review by Ms Sonya R Lorrain. We thank Dr
   Stella E Tsirka for technical support in animal experiments. This study
   was supported in part by Stony Brook University Translational Research
   Laboratory Start-up Fund (J Ju), R01CA155019 (J Ju) and R33CA147966 (J
   Ju).
CR Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657
   Akao Y, 2010, CANCER GENE THER, V17, P398, DOI 10.1038/cgt.2009.88
   Akao Y, 2007, DNA CELL BIOL, V26, P311, DOI 10.1089/dna.2006.0550
   Akao Y, 2009, LEUKEMIA RES, V33, P1530, DOI 10.1016/j.leukres.2009.04.019
   Alwan A, 2007, DISASTER MED PUBLIC, V1, P7, DOI 10.1097/DMP.0b013e3180676d32
   Baumann P, 2009, MOL CANCER THER, V8, P366, DOI 10.1158/1535-7163.MCT-08-0664
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Braun CJ, 2008, CANCER RES, V68, P10094, DOI 10.1158/0008-5472.CAN-08-1569
   Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9
   Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137
   Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30
   Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010
   Crawford L V, 1984, Mol Biol Med, V2, P261
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   DRESSLER LG, 1988, CANCER, V61, P420, DOI 10.1002/1097-0142(19880201)61:3<420::AID-CNCR2820610303>3.0.CO;2-0
   Eisenberg-Lerner A, 2009, APOPTOSIS, V14, P376, DOI 10.1007/s10495-008-0307-5
   Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x
   Georges SA, 2008, CANCER RES, V68, P10105, DOI 10.1158/0008-5472.CAN-08-1846
   Ghodgaonkar MM, 2009, CELL DEATH DIFFER, V16, P858, DOI 10.1038/cdd.2009.15
   Gunaratne PH, 2010, METHODS MOL BIOL, V667, P297, DOI 10.1007/978-1-60761-811-9_20
   He H, 2002, GENE EXPRESSION, V10, P231, DOI 10.3727/000000002783992406
   He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552
   He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939
   Hegde Sanjay R, 2008, Expert Rev Gastroenterol Hepatol, V2, P135, DOI 10.1586/17474124.2.1.135
   Hirst J, 1999, MOL BIOL CELL, V10, P2787, DOI 10.1091/mbc.10.8.2787
   Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023
   Ibrahim AF, 2011, CANCER RES, V71, P5214, DOI 10.1158/0008-5472.CAN-10-4645
   Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083
   Jung YS, 2010, CELL SIGNAL, V22, P1003, DOI 10.1016/j.cellsig.2010.01.013
   Karaayvaz M, 2011, CLIN COLORECTAL CANC, V10, P340, DOI 10.1016/j.clcc.2011.06.002
   KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Zoppino FCM, 2010, TRAFFIC, V11, P1246, DOI 10.1111/j.1600-0854.2010.01086.x
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Michael MZ, 2003, MOL CANCER RES, V1, P882
   Miller SJ, 2000, MOL CELL BIOL, V20, P8420, DOI 10.1128/MCB.20.22.8420-8431.2000
   Navarro F, 2010, J IMMUNOL, V184, P5939, DOI 10.4049/jimmunol.0902567
   PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31
   Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017
   Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106
   Scherz-Shouval R, 2010, P NATL ACAD SCI USA, V107, P18511, DOI 10.1073/pnas.1006124107
   SCOTT N, 1991, BRIT J CANCER, V63, P317, DOI 10.1038/bjc.1991.74
   Shi B, 2007, J BIOL CHEM, V282, P32582, DOI 10.1074/jbc.M702806200
   Shin S, 2009, INT J ONCOL, V35, P1343, DOI 10.3892/ijo_00000452
   Shin S, 2009, INT J ONCOL, V34, P1645, DOI 10.3892/ijo_00000295
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Slaby O, 2007, ONCOLOGY-BASEL, V72, P397, DOI 10.1159/000113489
   Song B, 2009, ONCOGENE, V28, P4065, DOI 10.1038/onc.2009.274
   Song B, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-96
   Song B, 2008, CLIN CANCER RES, V14, P8080, DOI 10.1158/1078-0432.CCR-08-1422
   Stenmark H, 2009, NAT REV MOL CELL BIO, V10, P513, DOI 10.1038/nrm2728
   Tang FC, 2010, DIFFERENTIATION, V79, P141, DOI 10.1016/j.diff.2009.11.002
   Tang XH, 2004, ONCOGENE, V23, P5759, DOI 10.1038/sj.onc.1207706
   Tasdemir E, 2008, CELL CYCLE, V7, P3006, DOI 10.4161/cc.7.19.6702
   Tasdemir E, 2008, AUTOPHAGY, V4, P810, DOI 10.4161/auto.6486
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104
   Thompson T, 2004, J BIOL CHEM, V279, P53015, DOI 10.1074/jbc.M410233200
   Trang P, 2010, ONCOGENE, V29, P1580, DOI 10.1038/onc.2009.445
   VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901
   Wang XD, 2010, FEBS LETT, V584, P3392, DOI 10.1016/j.febslet.2010.06.033
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   White RM, 2011, NATURE, V471, P518, DOI 10.1038/nature09882
   WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4
   Xi YG, 2006, BIOMARK INSIGHTS, V1, P113
   Xi YG, 2006, CLIN CANCER RES, V12, P2014, DOI 10.1158/1078-0432.CCR-05-1853
   Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105
   Zhao RB, 2000, GENE DEV, V14, P981
   Zhou JF, 2010, ONCOL REP, V23, P121, DOI 10.3892/or_00000613
NR 72
TC 99
Z9 108
U1 0
U2 27
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD MAR 21
PY 2013
VL 32
IS 12
BP 1570
EP 1579
DI 10.1038/onc.2012.167
PG 10
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 110PC
UT WOS:000316456000010
PM 22580605
OA Green Accepted, Bronze
DA 2022-04-25
ER

PT J
AU Zhang, HZ
   Cui, ZH
   Cheng, D
   Du, YY
   Guo, XL
   Gao, R
   Chen, JW
   Sun, WW
   He, RR
   Ma, XJ
   Peng, QW
   Martin, RAL
   Yan, W
   Rong, YG
   Wang, CH
AF Zhang, Huazhi
   Cui, Zhihui
   Cheng, Du
   Du, Yanyun
   Guo, Xiaoli
   Gao, Ru
   Chen, Jianwen
   Sun, Wanwei
   He, Ruirui
   Ma, Xiaojian
   Peng, Qianwen
   Martin, Bradley N.
   Yan, Wei
   Rong, Yueguang
   Wang, Chenhui
TI RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the
   colonic epithelial cells for the maintenance of intestinal homeostasis
SO AUTOPHAGY
LA English
DT Article
DE Autophagy; EPHB2; ephrin B1; RNF186; ulcerative colitis
ID INFLAMMATORY-BOWEL-DISEASE; GENOME-WIDE ASSOCIATION; COLORECTAL-CANCER;
   EPHB RECEPTORS; ULCERATIVE-COLITIS; SUSCEPTIBILITY; PROLIFERATION;
   DEGRADATION; PREVALENCE; EXPRESSION
AB Although genome-wide association studies have identified the gene RNF186 encoding an E3 ubiquitin-protein ligase as conferring susceptibility to ulcerative colitis, the exact function of this protein remains unclear. In the present study, we demonstrate an important role for RNF186 in macroautophagy/autophagy activation in colonic epithelial cells and intestinal homeostasis. Mechanistically, RNF186 acts as an E3 ubiquitin-protein ligase for EPHB2 and regulates the ubiquitination of EPHB2. Upon stimulation by ligand EFNB1 (ephrin B1), EPHB2 is ubiquitinated by RNF186 at Lys892, and further recruits MAP1LC3B for autophagy. Compared to control mice, rnf186(-/-) and ephb2(-/-) mice have a more severe phenotype in the DSS-induced colitis model, which is due to a defect in autophagy in colon epithelial cells. More importantly, treatment with ephrin-B1-Fc recombinant protein effectively relieves DSS-induced mouse colitis, which suggests that ephrin-B1-Fc may be a potential therapy for human inflammatory bowel diseases.
C1 [Zhang, Huazhi; Cui, Zhihui; Du, Yanyun; Guo, Xiaoli; Gao, Ru; Chen, Jianwen; Sun, Wanwei; He, Ruirui; Ma, Xiaojian; Peng, Qianwen; Wang, Chenhui] Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Natl Engn Res Ctr Nanomed, Key Lab Mol Biophys,Minist Educ, 1037th Luoyu Ave, Wuhan 430074, Peoples R China.
   [Cheng, Du] Wuhan Univ, Dept Gastroenterol, Renmin Hosp, Wuhan, Peoples R China.
   [Martin, Bradley N.] Brigham & Womens Hosp, Harvard Med Sch, Dept Med, Boston, MA USA.
   [Yan, Wei] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Gastroenterol, Wuhan, Peoples R China.
   [Rong, Yueguang] Huazhong Univ Sci & Technol, Sch Basic Med, Dept Pathogen Biol, Wuhan, Peoples R China.
   [Wang, Chenhui] Wuhan Inst Biotechnol, Dept Bioinformat, Wuhan, Peoples R China.
RP Wang, CH (corresponding author), Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Natl Engn Res Ctr Nanomed, Key Lab Mol Biophys,Minist Educ, 1037th Luoyu Ave, Wuhan 430074, Peoples R China.; Rong, YG (corresponding author), Huazhong Univ Sci & Technol, Sch Basic Med, Dept Pathogen Biol, Wuhan, Peoples R China.
EM rongyueguang@hust.edu.cn; wangchenhui@hust.edu.cn
OI Martin, Bradley/0000-0002-8902-8805; RONG, YUEGUANG/0000-0001-6661-9664;
   Wang, Chenhui/0000-0002-3186-3066
FU Huazhong University of Science Technology [2017KFYXJJ163]; National
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [81871280]; Junior Thousand Talents Program of China
FX This investigation was supported by the independent innovation grant
   from Huazhong University of Science & Technology [grant 2017KFYXJJ163];
   and the grant from the National Natural Science Foundation of China
   [grants 81871280]; and the Junior Thousand Talents Program of China [to
   C.H.W.].
CR Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295
   Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175
   Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626
   Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2
   Beaudoin M, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003723
   Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416
   Chen JW, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15564-7
   Cho JH, 2008, NAT REV IMMUNOL, V8, P458, DOI 10.1038/nri2340
   Chukkapalli S, 2014, EXP CELL RES, V320, P233, DOI 10.1016/j.yexcr.2013.10.022
   Cohen LJ, 2019, GASTROENTEROLOGY, V156, P2174, DOI 10.1053/j.gastro.2019.03.017
   Cortina C, 2007, NAT GENET, V39, P1376, DOI 10.1038/ng.2007.11
   Dalva MB, 2000, CELL, V103, P945, DOI 10.1016/S0092-8674(00)00197-5
   Din Farhat V N, 2012, Gastroenterology, V142, P1504, DOI 10.1053/j.gastro.2012.02.050
   Fritz T, 2011, GUT, V60, P1580, DOI 10.1136/gut.2009.206466
   Frolkis AD, 2013, GASTROENTEROLOGY, V145, P996, DOI 10.1053/j.gastro.2013.07.041
   Fujimoto K, 2017, MUCOSAL IMMUNOL, V10, P446, DOI 10.1038/mi.2016.58
   Garcia-Navas R, 2012, AUTOPHAGY, V8, P1557, DOI 10.4161/auto.21315
   Genander M, 2009, CELL, V139, P679, DOI 10.1016/j.cell.2009.08.048
   Henckaerts L, 2011, INFLAMM BOWEL DIS, V17, P1392, DOI 10.1002/ibd.21486
   Hendrickson BA, 2002, CLIN MICROBIOL REV, V15, P79, DOI 10.1128/CMR.15.1.79-94.2002
   Henkemeyer M, 2003, J CELL BIOL, V163, P1313, DOI 10.1083/jcb.200306033
   Hidvegi T, 2010, SCIENCE, V329, P229, DOI 10.1126/science.1190354
   Holmberg J, 2006, CELL, V125, P1151, DOI 10.1016/j.cell.2006.04.030
   Homer CR, 2010, GASTROENTEROLOGY, V139, P1630, DOI 10.1053/j.gastro.2010.07.006
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249
   Kandouz M, 2010, CELL CYCLE, V9, P398, DOI 10.4161/cc.9.2.10505
   Kim J.-D., 2012, BMC BIOINFORMATI S11, V13, pS1
   Lassen KG, 2016, IMMUNITY, V44, P1392, DOI 10.1016/j.immuni.2016.05.007
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   McCarroll SA, 2008, NAT GENET, V40, P1107, DOI 10.1038/ng.215
   Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020
   Mimouna S, 2014, AUTOPHAGY, V10, P2333, DOI 10.4161/15548627.2014.984275
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Munkholm P, 2003, ALIMENT PHARM THER, V18, P1, DOI 10.1046/j.1365-2036.18.s2.2.x
   Mutalib M, 2014, J CROHNS COLITIS, V8, P1730, DOI 10.1016/j.crohns.2014.08.014
   Ng SC, 2017, LANCET, V390, P2769, DOI 10.1016/S0140-6736(17)32448-0
   Parkes M, 2007, NAT GENET, V39, P830, DOI 10.1038/ng2061
   Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011
   Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806
   Reinisch W, 2008, AM J GASTROENTEROL, V103, P2284, DOI 10.1111/j.1572-0241.2008.02024.x
   Rivas MA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12869
   Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027
   Roy S, 2018, GASTROENTEROLOGY, V154, P2060, DOI 10.1053/j.gastro.2018.02.026
   Sakaki K, 2008, J BIOL CHEM, V283, P15370, DOI 10.1074/jbc.M710209200
   Schiebler M, 2015, EMBO MOL MED, V7, P127, DOI 10.15252/emmm.201404137
   Song JX, 2016, AUTOPHAGY, V12, P1372, DOI 10.1080/15548627.2016.1179404
   Takagi T, 2011, DIGEST DIS SCI, V56, P1663, DOI 10.1007/s10620-010-1484-y
   Tanabe H, 2011, INT J ONCOL, V39, P33, DOI 10.3892/ijo.2011.1011
   Tremelling M, 2008, GUT, V57, pA150
   Triantafillidis JK, 2009, ANTICANCER RES, V29, P2727
   van Wijk SJL, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.76
   Vucicevic L, 2011, AUTOPHAGY, V7, P40, DOI 10.4161/auto.7.1.13883
   Wang P, 2013, CELL SIGNAL, V25, P2320, DOI 10.1016/j.cellsig.2013.07.016
   Xiao H, 2007, IMMUNITY, V26, P461, DOI 10.1016/j.immuni.2007.02.012
   Yang SK, 2013, INFLAMM BOWEL DIS, V19, P954, DOI 10.1097/MIB.0b013e3182802ab6
   Zhang XY, 2014, J CANCER RES THER, V10, pC108, DOI 10.4103/0973-1482.145811
NR 58
TC 4
Z9 4
U1 3
U2 11
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD OCT 3
PY 2021
VL 17
IS 10
BP 3030
EP 3047
DI 10.1080/15548627.2020.1851496
EA DEC 2020
PG 18
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA WG7FR
UT WOS:000599403300001
PM 33280498
OA Green Published
DA 2022-04-25
ER

PT J
AU Wen, J
   Zhao, YY
   Guo, L
AF Wen, Jing
   Zhao, Yuyan
   Guo, Lei
TI Orexin A induces autophagy in HCT-116 human colon cancer cells through
   the ERK signaling pathway
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE orexin A; autophagy; extracellular signal-regulated kinase signaling
   pathway; HCT-116 human colon cancer cells
ID INHIBITION; BECLIN-1; GROWTH; SUPPRESSES; APOPTOSIS; PROTEIN; GENE;
   MACROAUTOPHAGY; TUMORIGENESIS; ACTIVATION
AB Orexins are a class of peptides which have a potent influence on a broad variety of cancer cells. Autophagy is closely associated with tumors; however, its function is not yet completely understood. In this study, we aimed to determine whether orexin A induces autophagy in HCT-116 human colon cancer cells and to elucidate the molecular mechanisms involved. For this purpose, HCT-116 cells were treated with orexin A, and cell viability was then measured by MTT assay, and apoptosis was determined by flow cytometry. The expression levels of autophagy-related proteins were measured by western blot analysis. Quantitative analysis of autophagy following acridine orange (AO) staining was performed using fluorescence microscopy, and cellular morphology was observed under a transmission electron microscope. In addition, the HCT-116 cells were treated with the extracellular signal-regulated kinase (ERK) inhibitor, U0126, or the autophagy inhibitor, chloroquine, in combination with orexin A in order to examine the activation of ERK. We found that orexin A significantly inhibited the viability of the HCT-116 cells. Both autophagy and apoptosis were activated during the orexin A-induced death of HCT-116 cells. When the HCT-116 cells were treated with orexin A for 24 h, an accumulation of punctate microtubule-associated protein-1 light chain 3 (LC3) and an increase in LC3-II protein levels were also detected, indicating the activation of autophagy. Moreover, orexin A upregulated ERK phosphorylation; however, U0126 or chloroquine abrogated ERK phosphorylation and decreased autophagy, compared to treatment with orexin A alone. Therefore, our findings demonstratedm that orexin A induced autophagy through the ERK pathway in HCT-116 human colon cancer cells. The inhibition of autophagy may thus prove to be an effective strategy for enhancing the antitumor potential of orexin A as a treatment for colon cancer.
C1 [Wen, Jing; Zhao, Yuyan] China Med Univ, Affiliated Hosp 1, Dept Endocrinol, Shenyang 110001, Liaoning, Peoples R China.
   [Guo, Lei] China Med Univ, Affiliated Hosp 1, Dept Orthoped Surg, Shenyang 110001, Liaoning, Peoples R China.
RP Zhao, YY (corresponding author), China Med Univ, Affiliated Hosp 1, Dept Endocrinol, 155 Nanjing North St, Shenyang 110001, Liaoning, Peoples R China.
EM g572@sina.com; 15241818899@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81470998, 81071460, 81271996]; Natural
   Science Foundation of Liaoning ProvinceNatural Science Foundation of
   Liaoning Province [201202292]
FX The authors would like to thank The China Medical University Affiliated
   Hospital Laboratory Center for kindly providing the equipment. This
   study was supported by the National Natural Science Foundation of China
   (grant nos. 81470998, 81071460 and 81271996) and the Natural Science
   Foundation of Liaoning Province (grant no. 201202292).
CR Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Alexandre D, 2014, EUR J CANCER, V50, P2126, DOI 10.1016/j.ejca.2014.05.008
   Ammoun S, 2006, J BIOL CHEM, V281, P834, DOI 10.1074/jbc.M508603200
   Aston-Jones G, 2010, BRAIN RES, V1314, P74, DOI 10.1016/j.brainres.2009.09.106
   Awan MUF, 2014, APPL MICROBIOL BIOT, V98, P5319, DOI 10.1007/s00253-014-5721-8
   Bieganska K, 2012, J MOL NEUROSCI, V48, P706, DOI 10.1007/s12031-012-9799-0
   Choi AMK, 2013, NEW ENGL J MED, V368, P1845, DOI 10.1056/NEJMc1303158
   Dai JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061026
   Ellington AA, 2006, CARCINOGENESIS, V27, P298, DOI 10.1093/carcin/bgi214
   Esmaeili-Mahani S, 2013, NEUROCHEM INT, V63, P719, DOI 10.1016/j.neuint.2013.09.022
   Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623
   Furuya D, 2005, EXP CELL RES, V307, P26, DOI 10.1016/j.yexcr.2005.02.023
   Gestreau C, 2008, CURR OPIN PULM MED, V14, P512, DOI 10.1097/MCP.0b013e32831311d3
   Helgason GV, 2013, ESSAYS BIOCHEM, V55, P133, DOI [10.1042/bse0550133, 10.1042/BSE0550133]
   Hsieh MJ, 2013, ARCH TOXICOL, V87, P1927, DOI 10.1007/s00204-013-1047-z
   Ji RR, 2002, J NEUROSCI, V22, P478, DOI 10.1523/JNEUROSCI.22-02-00478.2002
   Kodadek T, 2010, MOL BIOSYST, V6, P1366, DOI 10.1039/c003468a
   Koneri K, 2007, ANTICANCER RES, V27, P1453
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Li YB, 2013, MOL NEUROBIOL, V47, P1000, DOI 10.1007/s12035-013-8403-0
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Maiuri MC, 2009, CELL DEATH DIFFER, V16, P87, DOI 10.1038/cdd.2008.131
   Martinez-Lopez N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3799
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Miracco C, 2007, INT J ONCOL, V30, P429
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Niso-Santano M, 2012, AUTOPHAGY, V8, P268, DOI 10.4161/auto.8.2.18845
   Quan W, 2012, EXP MOL MED, V44, P81, DOI 10.3858/emm.2012.44.2.030
   Rouet-Benzineb P, 2004, J BIOL CHEM, V279, P45875, DOI 10.1074/jbc.M404136200
   Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272
   Sakurai T, 2010, ANN NY ACAD SCI, V1200, P149, DOI 10.1111/j.1749-6632.2010.05513.x
   Subramaniam S, 2010, FEBS J, V277, P22, DOI 10.1111/j.1742-4658.2009.07367.x
   Taneike M, 2010, AUTOPHAGY, V6, P600, DOI 10.4161/auto.6.5.11947
   Wang ZH, 2007, GYNECOL ONCOL, V107, P107, DOI 10.1016/j.ygyno.2007.05.034
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wong E, 2010, NAT NEUROSCI, V13, P805, DOI 10.1038/nn.2575
   Xie M, 2011, CURR OPIN CARDIOL, V26, P216, DOI 10.1097/HCO.0b013e328345980a
NR 39
TC 12
Z9 15
U1 0
U2 11
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD JAN
PY 2016
VL 37
IS 1
BP 126
EP 132
DI 10.3892/ijmm.2015.2409
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA DA5UB
UT WOS:000367867000015
PM 26572581
OA Bronze
DA 2022-04-25
ER

PT J
AU Shang, YY
   Yao, M
   Zhou, ZW
   Jian-Cui
   Li-Xia
   Hu, RY
   Yu, YY
   Qiong-Gao
   Biao-Yang
   Liu, YX
   Dang, J
   Zhou, SF
   Nan-Yu
AF Shang, Yuan-Yuan
   Yao, Ming
   Zhou, Zhi-Wei
   Jian-Cui
   Li-Xia
   Hu, Rong-Ying
   Yu, Ying-Yao
   Qiong-Gao
   Biao-Yang
   Liu, Yu-Xi
   Dang, Jie
   Zhou, Shu-Feng
   Nan-Yu
TI Alisertib promotes apoptosis and autophagy in melanoma through p38
   MAPK-mediated aurora a signaling
SO ONCOTARGET
LA English
DT Article
DE alisertib; melanoma; AURKA; MAPK
ID PROSTATE-CANCER CELLS; COLON-CANCER; IN-VIVO; KINASE; PATHWAY; THERAPY;
   DEATH; INHIBITOR; CARCINOMA; OVEREXPRESSION
AB We investigated the efficacy of Alisertib (ALS), a selective Aurora kinase A (AURKA) inhibitor, in melanoma. We found that ALS exerts anti-proliferative, proapoptotic, and pro-autophagic effects on A375 and skmel-5 melanoma cells by inhibiting p38 MAPK signaling. SB202190, a p38 MAPK-selective inhibitor, enhanced ALS-induced apoptosis and autophagy in both cell lines. ALS induced cell cycle arrest in melanoma cells through activation of the p53/p21/cyclin B1 pathway. Knockdown of p38 MAPK enhanced ALS-induced apoptosis and reduced ALS-induced autophagy. Inhibition of autophagy sensitized melanoma cells to ALS-induced apoptosis. These data indicate ALS is a potential therapeutic agent for melanoma.
C1 [Shang, Yuan-Yuan; Li-Xia; Hu, Rong-Ying; Yu, Ying-Yao; Qiong-Gao; Biao-Yang; Liu, Yu-Xi; Nan-Yu] NingXia Med Univ, Gen Hosp, Dept Dermatol, Yinchuan, Peoples R China.
   [Shang, Yuan-Yuan; Yao, Ming; Zhou, Zhi-Wei; Zhou, Shu-Feng] Univ S Florida, Dept Pharmaceut Sci, Coll Pharm, Tampa, FL 33620 USA.
   [Yao, Ming] NingXia Med Univ, Dept Burns & Plast Surg, Gen Hosp, Yinchuan, Peoples R China.
   [Jian-Cui] NingXia Med Univ, Gen Hosp, Dept Anesthesia, Yinchuan, Peoples R China.
   [Dang, Jie] Ningxia Med Univ, Dept Med Genet & Cell Biol, Yinchuan, Peoples R China.
RP Nan-Yu (corresponding author), NingXia Med Univ, Gen Hosp, Dept Dermatol, Yinchuan, Peoples R China.; Zhou, SF (corresponding author), Univ S Florida, Dept Pharmaceut Sci, Coll Pharm, Tampa, FL 33620 USA.
EM szhou@health.usf.edu; syy23301@163.com
RI Zhou, Shu-Feng/E-3166-2013
OI Zhou, Shu-Feng/0000-0002-5542-6119
FU General Hospital of NingXia Medical University
FX This work is supported by General Hospital of NingXia Medical
   University.
CR Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Ascierto PA, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-85
   Balch CM, 2009, J CLIN ONCOL, V27, P6199, DOI 10.1200/JCO.2009.23.4799
   Blanke CD, 2008, J CLIN ONCOL, V26, P620, DOI 10.1200/JCO.2007.13.4403
   Chiacchiera F, 2009, CELL DEATH DIFFER, V16, P1203, DOI 10.1038/cdd.2009.36
   Comes F, 2007, CELL DEATH DIFFER, V14, P693, DOI 10.1038/sj.cdd.4402076
   Cuadrado A, 2010, BIOCHEM J, V429, P403, DOI 10.1042/BJ20100323
   Cui Q, 2007, J PHARMACOL SCI, V105, P317, DOI 10.1254/jphs.FP0070336
   Do TV, 2014, ONCOGENE, V33, P539, DOI 10.1038/onc.2012.632
   Engelberg D, 2004, SEMIN CANCER BIOL, V14, P271, DOI 10.1016/j.semcancer.2004.04.006
   Fletcher GC, 2011, MOL CANCER THER, V10, P126, DOI 10.1158/1535-7163.MCT-10-0574
   Gan L, 2011, PROSTATE, V71, P1158, DOI 10.1002/pros.21331
   GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Jeng YM, 2004, CLIN CANCER RES, V10, P2065, DOI 10.1158/1078-0432.CCR-1057-03
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kyriakis JM, 2012, PHYSIOL REV, V92, P689, DOI 10.1152/physrev.00028.2011
   Limami Y, 2012, BIOCHIMIE, V94, P1754, DOI 10.1016/j.biochi.2012.04.006
   Manfredi MG, 2011, CLIN CANCER RES, V17, P7614, DOI 10.1158/1078-0432.CCR-11-1536
   Maycotte P, 2011, CANCER BIOL THER, V11, P127, DOI 10.4161/cbt.11.2.14627
   Monzon JG, 2012, ONCOTARGETS THER, V5, DOI 10.2147/OTT.S21259
   Nikonova AS, 2013, CELL MOL LIFE SCI, V70, P661, DOI 10.1007/s00018-012-1073-7
   Olsen BB, 2012, INT J ONCOL, V41, P1967, DOI 10.3892/ijo.2012.1635
   Olson JM, 2004, TRENDS MOL MED, V10, P125, DOI 10.1016/j.molmed.2004.01.007
   Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6
   Pang H, 2011, CANCER BIOTHER RADIO, V26, P165, DOI 10.1089/cbr.2010.0838
   Sehdev V, 2013, CANCER-AM CANCER SOC, V119, P904, DOI 10.1002/cncr.27801
   Shin DY, 2009, INT J ONCOL, V35, P1499, DOI 10.3892/ijo_00000469
   Simone C, 2007, AUTOPHAGY, V3, P468, DOI 10.4161/auto.4319
   Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019
   Thyagarajan A, 2010, NUTR CANCER, V62, P630, DOI 10.1080/01635580903532390
   Tiwari M, 2006, CARCINOGENESIS, V27, P2047, DOI 10.1093/carcin/bgl051
   Tong T, 2004, CLIN CANCER RES, V10, P7304, DOI 10.1158/1078-0432.CCR-04-0806
   Vader G, 2008, BBA-REV CANCER, V1786, P60, DOI 10.1016/j.bbcan.2008.07.003
   Yang SH, 2013, GENE, V513, P1, DOI 10.1016/j.gene.2012.10.033
   Zhan Y, 2012, FREE RADICAL BIO MED, V53, P532, DOI 10.1016/j.freeradbiomed.2012.05.018
   Zhou CH, 2012, ACTA BIOCH BIOPH SIN, V44, P815, DOI 10.1093/abbs/gms064
NR 37
TC 8
Z9 10
U1 5
U2 15
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD DEC 5
PY 2017
VL 8
IS 63
BP 107076
EP 107088
DI 10.18632/oncotarget.22328
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FS1KO
UT WOS:000419534900090
PM 29291012
OA Green Submitted, gold, Green Published
DA 2022-04-25
ER

PT J
AU Xu, D
   Yang, F
   He, HY
   Hu, J
   Lv, XD
   Ma, DL
   Chen, YY
AF Xu, Dong
   Yang, Fan
   He, Huiying
   Hu, Jia
   Lv, Xiaodong
   Ma, Dalong
   Chen, Ying Yu
TI Expression of TMEM166 Protein in Human Normal and Tumor Tissues
SO APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
LA English
DT Article
DE TMEM166; tissue microarrays; immunohistochemistry; normal human tissues;
   tumor tissues
ID CELL-DEATH; MOLECULAR-MECHANISMS; AUTOPHAGY GENE; SUPPRESSOR; BECLIN-1;
   CANCER; TUMORIGENESIS; APOPTOSIS; UVRAG
AB Transmembrane protein 166 (TMEM166) is a novel human regulator involved in both autophagy and apoptosis. In this study, we generated a specific rabbit polyclonal antibody against human TMEM166 and assessed the expression of this protein in various human normal and tumor tissue samples by tissue microarray-based immunohistochemical analysis. Varying TMEM166 protein levels were expressed in a cell-type and tissue-type-specific manner in detected tissues or organs. Strong TMEM166 expression was shown in the glomerular zona of the adrenal cortex, chromophil cells of the pituitary gland, islet cells, squamous epithelium of the esophagus mucosa, the fundic gland, and hepatocytes. Moderate or weak TMEM166 staining was identified in the parathyroid gland, the testis, vaginal stratified squamous cells, lung macrophages, hematopoietic cells, renal tubular epithelial cells, macrophages in the spleen red pulp, and neuronal cells in the cerebral cortex. Some tissues failed to stain for TMEM166, such as adipose tissue, colon, cerebellum, lymph node, mammary gland, ovary, prostate, rectum, skin, small intestine, thyroid gland, tonsil, and thymus. In comparing human normal and tumor tissues, TMEM166 expression was widely downregulated in the cancer tissues. Our studies provide the basis for future investigations into cell-type-specific functions of this protein in human normal and tumor tissues.
C1 [Xu, Dong; Hu, Jia; Lv, Xiaodong; Ma, Dalong; Chen, Ying Yu] Peking Univ, Minist Hlth, Key Lab Med Immunol, Beijing 100083, Peoples R China.
   [Xu, Dong; Hu, Jia; Ma, Dalong; Chen, Ying Yu] Peking Univ, Ctr Human Dis Genom, Beijing 100083, Peoples R China.
   [Yang, Fan] Peking Univ, Peoples Hosp, Dept Thorac Surg, Beijing 100083, Peoples R China.
   [He, Huiying] Peking Univ, Sch Basic Med Sci, Dept Pathol, Beijing 100083, Peoples R China.
RP Chen, YY (corresponding author), Peking Univ, Ctr Human Dis Genom, 38 Xue Yuan Rd, Beijing 100083, Peoples R China.
EM yingyu_chen@bjmu.edu.cn
OI Yang, Fan/0000-0002-1044-7821
FU National Key Project for Basic Research of China (973)National Basic
   Research Program of China [2011CB910103]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [30771057]
FX Supported by the grants from the National Key Project for Basic Research
   of China (973, 2011CB910103) and the National Natural Science Foundation
   of China (30771057).
CR Ciavarra G, 2011, AUTOPHAGY, V7, P544, DOI 10.4161/auto.7.5.15056
   Coppola D, 2008, CANCER-AM CANCER SOC, V113, P2665, DOI 10.1002/cncr.23892
   Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Gozuacik D, 2006, AUTOPHAGY, V2, P74, DOI 10.4161/auto.2.2.2459
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620
   Levine B, 2005, CELL, V120, P159, DOI 10.1016/j.cell.2005.01.005
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Liang CY, 2008, NAT CELL BIOL, V10, P776, DOI 10.1038/ncb1740
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Maclean KH, 2008, J CLIN INVEST, V118, P79, DOI 10.1172/JCI33700
   Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008
   Pimkina J, 2009, AUTOPHAGY, V5, P397, DOI 10.4161/auto.5.3.7782
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Rashmi R, 2008, ONCOGENE, V27, P1366, DOI 10.1038/sj.onc.1210783
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   Wang L, 2007, APOPTOSIS, V12, P1489, DOI 10.1007/s10495-007-0073-9
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
NR 24
TC 18
Z9 18
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1541-2016
EI 1533-4058
J9 APPL IMMUNOHISTO M M
JI Appl. Immunohistochem.
PD DEC
PY 2013
VL 21
IS 6
BP 543
EP 552
DI 10.1097/PAI.0b013e31824e93d1
PG 10
WC Anatomy & Morphology; Medical Laboratory Technology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Anatomy & Morphology; Medical Laboratory Technology; Pathology
GA 255AR
UT WOS:000327212100011
PM 22495369
DA 2022-04-25
ER

PT J
AU Zhang, N
   Hu, XY
   Du, YN
   Du, J
AF Zhang, Ning
   Hu, Xianyu
   Du, Yinan
   Du, Juan
TI The role of miRNAs in colorectal cancer progression and
   chemoradiotherapy
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Review
DE microRNA; Colorectal cancer; Chemoradiotherapy; Cancer therapy;
   Biomarkers
ID COLON-CANCER; CELL-PROLIFERATION; SIGNALING PATHWAY; DOWN-REGULATION;
   TUMOR-GROWTH; MESENCHYMAL TRANSITION; INHIBITS PROLIFERATION;
   TRANSCRIPTION FACTORS; RADIATION-RESISTANCE; TARGETING ZEB1
AB Colorectal cancer (CRC) is known as the third most common cancer as well as the fourth most deadly cancer worldwide. CRC accounts for approximately 10 % of all new cancer cases globally, remaining the second most frequent cause of cancer-related deaths. MicroRNAs (miRNAs) are a class of small noncoding RNAs that can affect a variety of cellular and molecular targets. Depending on the cell environment in which the information is expressed, miRNAs can serve as a CRC suppressor or promoter and play essential roles in several biological processes. In this review, we summarized the relationship between miRNAs and proliferation, metastasis, angiogenesis, autophagy, apoptosis, and the chemoradiotherapy of CRC, revealing that relevant miRNAs could serve as potential targets for CRC therapy.
C1 [Du, Juan] Chinese Univ Hong Kong, Longgang Dist Peoples Hosp Shenzhen, Shenzhen 518172, Guangdong, Peoples R China.
   [Du, Juan] Chinese Univ Hong Kong, Affiliated Hosp Provis 3, Shenzhen 518172, Guangdong, Peoples R China.
   [Zhang, Ning; Hu, Xianyu; Du, Yinan; Du, Juan] Anhui Med Univ, Sch Basic Med Sci, Hefei 230032, Anhui, Peoples R China.
RP Du, J (corresponding author), Chinese Univ Hong Kong, Longgang Dist Peoples Hosp Shenzhen, Shenzhen 518172, Guangdong, Peoples R China.; Du, J (corresponding author), Chinese Univ Hong Kong, Affiliated Hosp Provis 3, Shenzhen 518172, Guangdong, Peoples R China.; Du, YN (corresponding author), Anhui Med Univ, Sch Basic Med Sci, Hefei 230032, Anhui, Peoples R China.
EM duyinannan@163.com; dujuan@cuhk.edu.cn
OI Du, Yinan/0000-0002-7678-7546; Zhang, Ning/0000-0002-5892-2193
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31701162, 8197102295, U1732157]
FX This work was funded by the National Natural Science Foundation of China
   (No. 31701162, 8197102295 and U1732157).
CR Afshar S, 2018, BIOMED PHARMACOTHER, V106, P763, DOI 10.1016/j.biopha.2018.07.002
   Akiyama T, 2009, MOL CANCER THER, V8, P3173, DOI 10.1158/1535-7163.MCT-09-0685
   Alcantara KMM, 2019, ONCOL REP, V41, P2103, DOI 10.3892/or.2019.7020
   Allen J, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0621-2
   Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850
   Avgeris M, 2015, CARCINOGENESIS, V36, P528, DOI 10.1093/carcin/bgv024
   Besora S, 2018, J CANCER RES CLIN, V144, P1793, DOI 10.1007/s00432-018-2691-8
   Brody H, 2015, NATURE, V521, pS1, DOI 10.1038/521S1a
   Buccafusca G, 2019, CRIT REV ONCOL HEMAT, V136, P20, DOI 10.1016/j.critrevonc.2019.01.023
   Cao L, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0757-8
   Carmeliet P, 2011, NAT REV DRUG DISCOV, V10, P417, DOI 10.1038/nrd3455
   Che J, 2019, MOL CARCINOGEN, V58, P1234, DOI 10.1002/mc.23006
   Chen B, 2019, OPEN BIOL, V9, DOI 10.1098/rsob.180212
   Chen LJ, 2018, MOL MED REP, V18, P2571, DOI 10.3892/mmr.2018.9287
   Chen L, 2018, AM J CANCER RES, V8, P2387
   Chen XX, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1188-3
   Chen Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0453-9
   Chu CA, 2019, EBIOMEDICINE, V43, P270, DOI 10.1016/j.ebiom.2019.04.010
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Dimitrova N, 2016, CANCER DISCOV, V6, P188, DOI 10.1158/2159-8290.CD-15-0854
   Ding JQ, 2018, ACTA BIOCH BIOPH SIN, V50, P597, DOI 10.1093/abbs/gmy040
   Ding XH, 2019, ONCOTARGETS THER, V12, P3255, DOI 10.2147/OTT.S184118
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   Fan TJ, 2005, ACTA BIOCH BIOPH SIN, V37, P719, DOI 10.1111/j.1745-7270.2005.00108.x
   Fang YT, 2019, GENE, V699, P37, DOI 10.1016/j.gene.2019.03.004
   Fasihi A, 2019, GENE, V712, DOI 10.1016/j.gene.2019.143958
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Feng C, 2018, BIOMED PHARMACOTHER, V101, P945, DOI 10.1016/j.biopha.2018.03.028
   Feng ZY, 2017, EUR REV MED PHARMACO, V21, P4844
   Flum M, 2018, J CELL COMMUN SIGNAL, V12, P451, DOI 10.1007/s12079-017-0410-x
   Fu Q, 2016, ONCOL REP, V36, P3682, DOI 10.3892/or.2016.5195
   Fu YX, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658-019-0155-z
   Gaedcke J, 2012, CLIN CANCER RES, V18, P4919, DOI 10.1158/1078-0432.CCR-12-0016
   Ge JX, 2019, J CELL PHYSIOL, V234, P18872, DOI 10.1002/jcp.28525
   Goossens S, 2017, BBA-REV CANCER, V1868, P584, DOI 10.1016/j.bbcan.2017.06.006
   Green DR, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a006080
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Grilo AL, 2019, BIOTECHNOL ADV, V37, P459, DOI 10.1016/j.biotechadv.2019.02.012
   Gu CJ, 2019, ONCOL RES, V27, P515, DOI 10.3727/096504018X15166183598572
   Guo LC, 2019, CANCER SCI, V110, P805, DOI 10.1111/cas.13910
   Guo YS, 2017, CANCER BIOMARK, V18, P1, DOI 10.3233/CBM-160650
   Han SH, 2019, WORLD J GASTROENTERO, V25, P6495, DOI 10.3748/wjg.v25.i44.6495
   Heydari K, 2018, PATHOL ONCOL RES, V24, P145, DOI 10.1007/s12253-017-0222-6
   Hu HY, 2019, INT J BIOL MACROMOL, V132, P470, DOI 10.1016/j.ijbiomac.2019.03.221
   Hu JL, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0028-8
   Hu Y, 2019, FASEB J, V33, P2314, DOI 10.1096/fj.201801390R
   Hu YB, 2017, BIOCHEM BIOPH RES CO, V490, P317, DOI 10.1016/j.bbrc.2017.06.042
   Huang CZ, 2019, CANCER MANAG RES, V11, P3521, DOI 10.2147/CMAR.S191087
   Huang LC, 2019, UNITED EUR GASTROENT, V7, P517, DOI 10.1177/2050640619837440
   Hwang JH, 2019, MICROMACHINES-BASEL, V10, DOI 10.3390/mi10080511
   Jepsen RK, 2018, HUM PATHOL, V80, P231, DOI 10.1016/j.humpath.2018.05.027
   Ji DB, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-86
   Jiang HP, 2017, J BIOCHEM MOL TOXIC, V31, DOI 10.1002/jbt.21888
   Karaayvaz M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.193
   Kasahara Viviani A, 2017, Microrna, V6, P166, DOI 10.2174/2211536606666170724154752
   Keum N, 2019, NAT REV GASTRO HEPAT, V16, P713, DOI 10.1038/s41575-019-0189-8
   Kim CW, 2018, CANCER LETT, V416, P31, DOI 10.1016/j.canlet.2017.12.018
   Knudsen KN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140503
   Kohlan AK, 2019, LIFE SCI, V228, P221, DOI 10.1016/j.lfs.2019.05.005
   Kojima S, 2014, J HUM GENET, V59, P78, DOI 10.1038/jhg.2013.121
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   Li GQ, 2019, PATHOL RES PRACT, V215, P34, DOI 10.1016/j.prp.2018.10.008
   Li JX, 2017, ONCOL LETT, V13, P81, DOI 10.3892/ol.2016.5445
   Li JL, 2018, ARCH BIOCHEM BIOPHYS, V640, P53, DOI 10.1016/j.abb.2018.01.002
   Li LX, 2019, EUR REV MED PHARMACO, V23, P1487, DOI 10.26355/eurrev_201902_17106
   Li P, 2018, BIOMED PHARMACOTHER, V104, P832, DOI 10.1016/j.biopha.2018.03.013
   Li TT, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0879-z
   Li XH, 2012, ONCOL REP, V28, P77, DOI 10.3892/or.2012.1769
   Li YY, 2015, CANCER RES, V75, P2674, DOI 10.1158/0008-5472.CAN-14-2875
   Li Y, 2018, J IMMUNOL RES, V2018, DOI [10.1155/2018/7198514, 10.1155/2018/7498514]
   Liang H, 2019, ONCOTARGETS THER, V12, P9651, DOI 10.2147/OTT.S228995
   Liang LL, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.352
   Liang Z, 2019, BIOCHEM BIOPH RES CO, V514, P699, DOI 10.1016/j.bbrc.2019.05.002
   Liao D, 2018, EXP THER MED, V15, P1712, DOI 10.3892/etm.2017.5522
   Lin MS, 2019, CANCER MANAG RES, V11, P5353, DOI 10.2147/CMAR.S208233
   Liu B, 2017, MOL CARCINOGEN, V56, P2669, DOI 10.1002/mc.22710
   Liu F, 2017, ONCOL RES, V25, P967, DOI 10.3727/096504016X14803476672380
   Liu H, 2019, NEOPLASIA, V21, P765, DOI 10.1016/j.neo.2019.05.007
   Liu L, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15027704
   Liu M, 2011, CANCER LETT, V301, P151, DOI 10.1016/j.canlet.2010.11.009
   Liu T, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0981-7
   Liu ZZ, 2019, CANCER MANAG RES, V11, P5317, DOI 10.2147/CMAR.S197733
   Lu ML, 2019, EXP THER MED, V17, P2807, DOI 10.3892/etm.2019.7260
   Lu TX, 2018, J ALLERGY CLIN IMMUN, V141, P1202, DOI 10.1016/j.jaci.2017.08.034
   Lun WJ, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0575-2
   Lv SM, 2020, CLIN EXP PHARMACOL P, V47, P158, DOI 10.1111/1440-1681.13185
   Ma HB, 2016, CANCER LETT, V376, P293, DOI 10.1016/j.canlet.2016.04.011
   Machackova T., 2019, CANCERS, V11
   Mansoori B, 2020, J CELL PHYSIOL, V235, P920, DOI 10.1002/jcp.29007
   Meng QK, 2018, ONCOL REP, V40, P916, DOI 10.3892/or.2018.6460
   Michael MZ, 2003, MOL CANCER RES, V1, P882
   Mo JS, 2019, CANCERS, V11, DOI 10.3390/cancers11101613
   Mohammad RM, 2015, SEMIN CANCER BIOL, V35, pS78, DOI 10.1016/j.semcancer.2015.03.001
   Moridikia A, 2018, J CELL PHYSIOL, V233, P901, DOI 10.1002/jcp.25801
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Nagel R, 2008, CANCER RES, V68, P5795, DOI 10.1158/0008-5472.CAN-08-0951
   Ng EKO, 2009, BRIT J CANCER, V101, P699, DOI 10.1038/sj.bjc.6605195
   Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054
   Ning XF, 2019, ONCOL RES, V27, P399, DOI 10.3727/096504018X15179675206495
   Pajonk F, 2010, STEM CELLS, V28, P639, DOI 10.1002/stem.318
   Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608
   Park YR, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180664
   Paterson EL, 2013, NEOPLASIA, V15, P180, DOI 10.1593/neo.121828
   Peng H, 2019, BIOMED PHARMACOTHER, V109, P208, DOI 10.1016/j.biopha.2018.10.048
   Przygodzka P, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39200-7
   Qi YX, 2019, EXP MOL PATHOL, V107, P23, DOI 10.1016/j.yexmp.2019.01.008
   Qian X, 2013, CELL CYCLE, V12, P1385, DOI 10.4161/cc.24477
   Qin S, 2014, NEOPLASMA, V61, P27, DOI 10.4149/neo_2014_005
   Qin Y, 2018, CELL PHYSIOL BIOCHEM, V48, P1627, DOI 10.1159/000492284
   Qin Y, 2018, ONCOL LETT, V15, P3197, DOI 10.3892/ol.2017.7715
   Qu J, 2015, J CELL PHYSIOL, V230, P535, DOI 10.1002/jcp.24366
   Radice GL, 2013, PROG MOL BIOL TRANSL, V116, P263, DOI 10.1016/B978-0-12-394311-8.00012-1
   Ramjiawan RR, 2017, ANGIOGENESIS, V20, P185, DOI 10.1007/s10456-017-9552-y
   Reimondez-Troitino S, 2019, EUR J PHARM BIOPHARM, V142, P449, DOI 10.1016/j.ejpb.2019.07.016
   Ren YL, 2017, CANCER LETT, V390, P126, DOI 10.1016/j.canlet.2017.01.009
   Rivankar S, 2014, J CANCER RES THER, V10, P853, DOI 10.4103/0973-1482.139267
   Samadi P, 2019, J CELL PHYSIOL, V234, P10718, DOI 10.1002/jcp.27742
   Sawa M, 2016, EXPERT OPIN THER TAR, V20, P419, DOI 10.1517/14728222.2016.1098619
   Schreuders EH, 2015, GUT, V64, P1637, DOI 10.1136/gutjnl-2014-309086
   Shen XN, 2019, ONCOTARGETS THER, V12, P10799, DOI 10.2147/OTT.S216147
   Shi L, 2019, BIOMED PHARMACOTHER, V109, P902, DOI 10.1016/j.biopha.2018.10.080
   Shi LP, 2018, AM J CANCER RES, V8, P30
   Shirafkan N, 2018, BIOMED PHARMACOTHER, V97, P1319, DOI 10.1016/j.biopha.2017.11.046
   Shuai F, 2018, ONCOL RES, V26, P1295, DOI 10.3727/096504018X15172747209020
   Su C, 2019, ONCOL LETT, V18, P2825, DOI 10.3892/ol.2019.10629
   Su JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114420
   Sun LN, 2019, THERANOSTICS, V9, P8409, DOI 10.7150/thno.36605
   Sun M, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0445-8
   Sun SN, 2019, AM J TRANSL RES, V11, P5338
   Sun XL, 2018, J BIOCHEM MOL TOXIC, V32, DOI 10.1002/jbt.22028
   Sun Y, 2015, INT J ONCOL, V46, P750, DOI 10.3892/ijo.2014.2745
   Tan SF, 2016, INT J MOL MED, V37, P1030, DOI 10.3892/ijmm.2016.2492
   Tang WM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08225-3
   Tauriello DVF, 2017, MOL ONCOL, V11, P97, DOI 10.1002/1878-0261.12018
   Temraz S, 2014, CRIT REV ONCOL HEMAT, V89, P217, DOI 10.1016/j.critrevonc.2013.08.015
   Thanikachalam K, 2019, NUTRIENTS, V11, DOI 10.3390/nu11010164
   Thomas LW, 2010, FEBS LETT, V584, P2981, DOI 10.1016/j.febslet.2010.05.061
   Tian ML, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20181584
   Tian S, 2017, ONCOTARGET, V8, P11071, DOI 10.18632/oncotarget.14360
   Tiwari A, 2018, CURR CANCER DRUG TAR, V18, P266, DOI 10.2174/1568009617666170630142725
   Vu T, 2017, CANCERS, V9, DOI 10.3390/cancers9120171
   Valeri Nicola, 2009, Cancer Genomics & Proteomics, V6, P195
   Vandenbroucke RE, 2014, NAT REV DRUG DISCOV, V13, P904, DOI 10.1038/nrd4390
   Vandewalle C, 2009, CELL MOL LIFE SCI, V66, P773, DOI 10.1007/s00018-008-8465-8
   Wan JE, 2019, YONSEI MED J, V60, P414, DOI 10.3349/ymj.2019.60.5.414
   Wang B, 2018, AM J CANCER RES, V8, P2518
   Wang LQ, 2019, J CELL COMMUN SIGNAL, V13, P549, DOI 10.1007/s12079-019-00522-w
   Wang W., 2016, BIOCH PHARM, V121
   Wang W, 2019, ONCOL LETT, V17, P807, DOI 10.3892/ol.2018.9710
   Wang Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0970-5
   Wang YF, 2013, CURR CANCER DRUG TAR, V13, P963, DOI 10.2174/15680096113136660102
   Wang YB, 2019, AM J PHYSIOL-CELL PH, V316, pC33, DOI 10.1152/ajpcell.00047.2018
   Wang YB, 2018, J CELL BIOCHEM, V119, P1702, DOI 10.1002/jcb.26330
   Wang YF, 2019, ONCOTARGETS THER, V12, P4621, DOI 10.2147/OTT.S196992
   Wei LJ, 2018, CHEM-BIOL INTERACT, V289, P9, DOI 10.1016/j.cbi.2018.04.016
   Wewala NT, 2017, ASIA-PAC J CLIN ONCO, V13, P341, DOI 10.1111/ajco.12744
   Wong SH, 2019, NAT REV GASTRO HEPAT, V16, P690, DOI 10.1038/s41575-019-0209-8
   Wu FX, 2019, INT J ONCOL, V55, P671, DOI 10.3892/ijo.2019.4852
   Wu W, 2019, J CELL MOL MED, V23, P3118, DOI 10.1111/jcmm.14134
   Xiao F, 2015, ONCOGENE, V34, P1968, DOI 10.1038/onc.2014.134
   Xiao JJ, 2017, THERANOSTICS, V7, P1901, DOI 10.7150/thno.19168
   Xie Y, 2019, ARTIF CELL NANOMED B, V47, P1722, DOI 10.1080/21691401.2019.1606006
   Xing YP, 2020, INT J BIOCHEM CELL B, V118, DOI 10.1016/j.biocel.2019.105643
   Xu Y, 2019, J CELL PHYSIOL, V234, P21380, DOI 10.1002/jcp.28747
   Yan LK, 2017, BIOMED PHARMACOTHER, V96, P974, DOI 10.1016/j.biopha.2017.11.138
   Yan SS, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/8128501
   Yang LQ, 2016, CANCER MED-US, V5, P2022, DOI 10.1002/cam4.760
   Yang XD, 2015, AM J CANCER RES, V5, P545
   Yao H, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20180441
   Ye J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060687
   Yu XF, 2017, SCI REP-UK, V7, DOI 10.1038/srep42226
   Zeng ZC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07810-w
   Zhai H, 2013, ONCOGENE, V32, P1570, DOI 10.1038/onc.2012.167
   Zhang HH, 2015, CANCER LETT, V356, P781, DOI 10.1016/j.canlet.2014.10.029
   Zhang LJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-124
   Zhang LL, 2019, J CELL BIOCHEM, V120, P6078, DOI 10.1002/jcb.27894
   Zhang LY, 2019, ONCOL LETT, V18, P4064, DOI 10.3892/ol.2019.10741
   Zhang N, 2016, ONCOL LETT, V12, P4589, DOI 10.3892/ol.2016.5249
   Zhang N, 2008, MOLECULES, V13, P1551, DOI 10.3390/molecules13081551
   Zhang PJ, 2015, CELL CYCLE, V14, P481, DOI 10.1080/15384101.2015.1006048
   Zhang R., 2017, TUMOUR BIOL, V39
   Zhang WJ, 2018, EUR J PHARMACOL, V825, P75, DOI 10.1016/j.ejphar.2018.02.019
   Zhang XM, 2017, ONCOL LETT, V14, P2325, DOI 10.3892/ol.2017.6444
   Zhang YF, 2019, J COASTAL RES, P10, DOI 10.2112/SI97-002.1
   Zhang Y, 2018, MOL CANCER, V17, DOI 10.1186/s12943-017-0753-1
   Zhang Y, 2013, ONCOL REP, V30, P1976, DOI 10.3892/or.2013.2633
   Zhang YQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093917
   Zhang Z, 2019, ONCOL REP, V41, P619, DOI 10.3892/or.2018.6806
   Zhang ZY, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12505
   Zhao C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04172-z
   Zhao J, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0015-4
   Zheng L, 2017, ONCOTARGETS THER, V10, P1027, DOI 10.2147/OTT.S125067
   Zheng L, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0592-z
   Zhou HY, 2016, CANCER BIOMARK, V17, P1, DOI 10.3233/CBM-160613
   Zhou QX, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.306
   Zhu DH, 2018, ONCOL REP, V40, P589, DOI 10.3892/or.2018.6463
   Zhu GF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07998-x
   Zhu MM, 2019, EXP THER MED, V18, P4049, DOI 10.3892/etm.2019.8032
   Zhu Y, 2018, MOL THER, V26, P744, DOI 10.1016/j.ymthe.2017.12.023
   Zou J, 2017, BIOCHEM BIOPH RES CO, V488, P247, DOI 10.1016/j.bbrc.2017.03.162
NR 200
TC 15
Z9 15
U1 5
U2 9
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD FEB
PY 2021
VL 134
AR 111099
DI 10.1016/j.biopha.2020.111099
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA PY7MT
UT WOS:000612226900008
PM 33338745
OA gold
DA 2022-04-25
ER

PT J
AU Wang, QY
   Wang, P
   Xiao, ZG
AF Wang, Qiuyu
   Wang, Peng
   Xiao, Zhigang
TI Resistant starch prevents tumorigenesis of dimethylhydrazine-induced
   colon tumors via regulation of an ER stress-mediated mitochondrial
   apoptosis pathway
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE resistant starch; tumorigenesis; colon tumor; apoptosis; endoplasmic
   reticulum stress
ID COLORECTAL-CANCER; CELL INVASION; UP-REGULATION; EXPRESSION; METASTASIS;
   AUTOPHAGY; METAANALYSIS; ACTIVATION; CARCINOMA; ANTITUMOR
AB Resistant starch is as common soluble fiber that escapes digestion in the small intestine and can regulate intestinal function, metabolism of blood glucose and lipids, and may prevent tumorigenesis of gastrointestinal cancer. Epidemiology and other evidence have suggested that resistant starch may prevent colon cancer development. The aim of the current study was to explore the ameliorative effects and potential mechanisms of resistant starch in the tumorigenesis of colon tumors induced by dimethylhydrazine in C57BL/6 mice. Western blot analysis, ELISA, microscopy, immunofluorescence and immunohistochemistry were used to analyze the efficacy of resistant starch on the metabolic balance in the colon and tumorigenesis of colon tumors. The results demonstrated that a diet containing resistant starch decreased the animal body weight and reduced free ammonia, pH and short chain fatty acids in feces compared with mice that received a standard diet. Resistant starch reduced the incidence of colon tumors and suppressed the expression of carcinogenesis-associated proteins, including heat shock protein 25, protein kinase C-d and gastrointestinal glutathione peroxidase in colon epithelial cells compared with standard starch and control groups. Colon tumor cells proliferation and dedifferentiation were significantly decreased by a resistant starch diet. The results also demonstrated that resistant starch increased the apoptosis of colon tumor cells through regulation of apoptosis-associated gene expression levels in colon tumor cells. Oxidative stress and endoplasmic reticulum stress were upregulated, and elevation eukaryotic translation initiation factor 2 (eIF2), activating transcription factor-4 and secretase- expression levels were increased in the resistant starch diet group. Additionally, the activity of eIF2 and PERK were increased in colon tumor cells from mice that had received resistant starch. Increasing DNA damage-inducible transcript 3 protein (CHOP), binding immunoglobulin protein (BIP) and caspase-12 expression levels upregulated by resistant starch diet may contribute to the resistant starch-induced apoptosis of colon tumor cells induced by 1,2-dimethylhydrazine. In vitro assays demonstrated that knockdown of eIF2 inhibited apoptosis of colon tumor cells isolated from mice fed with resistant starch, which also downregulated CHOP, BIP and caspase-3 expression levels compared with controls. Furthermore, long-term survival of experimental mice was prolonged by the resistant starch diet compared with the standard diet group. In conclusion, the results indicate that resistant starch in the diet may prevent carcinogenesis of colon epithelial cells, mediated by enhancing apoptosis through an endoplasmic reticulum stress-mediated mitochondrial apoptosis pathway.
C1 [Wang, Qiuyu; Wang, Peng; Xiao, Zhigang] Northeast Agr Univ, Coll Food Sci, 59 Mucai St, Harbin 150030, Heilongjiang, Peoples R China.
RP Xiao, ZG (corresponding author), Northeast Agr Univ, Coll Food Sci, 59 Mucai St, Harbin 150030, Heilongjiang, Peoples R China.
EM xiaozhigangprof@163.com
CR Atkins C, 2013, CANCER RES, V73, P1993, DOI 10.1158/0008-5472.CAN-12-3109
   Baskaran R, 2016, BIOMED PHARMACOTHER, V83, P1407, DOI 10.1016/j.biopha.2016.08.063
   Birt DF, 2014, TOXICOL PATHOL, V42, P182, DOI 10.1177/0192623313506791
   Bukurova Iu A, 2010, Mol Biol (Mosk), V44, P375
   Burness CB, 2016, DRUGS, V76, P1393, DOI 10.1007/s40265-016-0633-9
   Chaveroux C, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa0549
   Chibaudel B, 2015, LANCET ONCOL, V16, pE583, DOI 10.1016/S1470-2045(15)00448-9
   Christova I, 2003, INT J IMMUNOPATH PH, V16, P261, DOI 10.1177/039463200301600312
   Crespo I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050407
   Dagistanli FK, 2018, EXP CLIN ENDOCR DIAB, V126, P168, DOI 10.1055/s-0042-107243
   Dronamraju SS, 2009, GUT, V58, P413, DOI 10.1136/gut.2008.162933
   Edagawa M, 2014, J BIOL CHEM, V289, P21544, DOI 10.1074/jbc.M114.558890
   Fan ZY, 2015, ONCOTARGET, V6, P25266, DOI 10.18632/oncotarget.4457
   Guo J, 2016, TUMOR BIOL, V37, P6371, DOI 10.1007/s13277-015-4504-x
   Haigis KM, 2008, NAT GENET, V40, P600, DOI 10.1038/ng.115
   Hawkins P, 2011, LAB ANIM-UK, V45, P1, DOI 10.1258/la.2010.010031
   Hino M, 2012, BIOL PHARM BULL, V35, P2097, DOI 10.1248/bpb.b12-00633
   Hirai HW, 2016, ALIMENT PHARM THER, V43, P755, DOI 10.1111/apt.13556
   Ho Y, 2016, AM J PATHOL, V186, P1939, DOI 10.1016/j.ajpath.2016.03.004
   Jang YM, 2016, FREE RADICAL BIO MED, V95, P190, DOI 10.1016/j.freeradbiomed.2016.03.018
   Jiang N, 2014, TUMOR BIOL, V35, P9429, DOI 10.1007/s13277-014-2258-5
   Khan I, 2016, BIOMED PHARMACOTHER, V84, P789, DOI 10.1016/j.biopha.2016.09.094
   Le Leu RK, 2010, CARCINOGENESIS, V31, P246, DOI 10.1093/carcin/bgp197
   Lee JS, 2012, INT J TOXICOL, V31, P70, DOI 10.1177/1091581811423845
   Liu WL, 2016, INT J MOL MED, V37, P309, DOI 10.3892/ijmm.2015.2425
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lopez NE, 2016, AM J SURG, V212, P700, DOI 10.1016/j.amjsurg.2016.06.019
   Ma Z, 2016, CRIT REV FOOD SCI NU, DOI [10. 1080/10408398. 2016. 1230537 27646607, DOI 10.1080/10408398.2016.123053727646607]
   Marin M, 2000, PARASITOL RES, V86, P431, DOI 10.1007/s004360050690
   Mathers JC, 2012, LANCET ONCOL, V13, P1242, DOI 10.1016/S1470-2045(12)70475-8
   Moilanen JM, 2015, HUM PATHOL, V46, P434, DOI 10.1016/j.humpath.2014.11.020
   Molinari AJ, 2012, RADIAT RES, V177, P59, DOI 10.1667/RR2729.1
   Moriarity A, 2016, THER ADV MED ONCOL, V8, P276, DOI 10.1177/1758834016646734
   Nabizadeh A, 2016, IRAN J CANCER PREV, V9, DOI 10.17795/ijcp-3919
   Ou JH, 2013, AM J CLIN NUTR, V98, P111, DOI 10.3945/ajcn.112.056689
   Raigond P, 2015, J SCI FOOD AGR, V95, P1968, DOI 10.1002/jsfa.6966
   Ridlon JM, 2006, CANCER BIOL THER, V5, P273, DOI 10.4161/cbt.5.3.2728
   Shen DQ, 2017, INT J FOOD SCI NUTR, V68, P149, DOI 10.1080/09637486.2016.1226275
   Stanton MJ, 2013, CANCER RES, V73, P160, DOI 10.1158/0008-5472.CAN-11-3635
   Thompson BA, 2013, HUM MUTAT, V34, P200, DOI 10.1002/humu.22213
   Wali VB, 2009, APOPTOSIS, V14, P1366, DOI 10.1007/s10495-009-0406-y
   Xiao SH, 2016, INT J BIOL MARKER, V31, pE276, DOI 10.5301/jbm.5000199
   Yamaoka Y, 2015, SURG CASE REP, V1, DOI 10.1186/s40792-015-0118-1
   Yuan W, 2017, AM J TRANSL RES, V9, P5662
   Yueh AE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148730
   Zhai H, 2013, ONCOGENE, V32, P1570, DOI 10.1038/onc.2012.167
   Zhang C, 2016, CELL STRESS CHAPERON, V21, P251, DOI 10.1007/s12192-015-0655-3
   Zhang XB, 2016, TUMOR BIOL, V37, P8317, DOI 10.1007/s13277-015-4511-y
NR 48
TC 5
Z9 6
U1 4
U2 22
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD APR
PY 2018
VL 41
IS 4
BP 1887
EP 1898
DI 10.3892/ijmm.2018.3423
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FY9BQ
UT WOS:000427160600010
PM 29393371
OA hybrid, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Wu, YH
   Yao, JL
   Xie, JS
   Liu, Z
   Zhou, YB
   Pan, HM
   Han, WD
AF Wu, Yuhui
   Yao, Junlin
   Xie, Jiansheng
   Liu, Zhen
   Zhou, Yubin
   Pan, Hongming
   Han, Weidong
TI The role of autophagy in colitis-associated colorectal cancer
SO SIGNAL TRANSDUCTION AND TARGETED THERAPY
LA English
DT Review
ID INTESTINAL EPITHELIAL-CELLS; NATURAL-KILLER-CELLS; REGULATORY T-CELLS;
   COLON-CANCER; GENE ATG16L1; STEM-CELLS; IMPAIRED AUTOPHAGY; TUMOR
   ANGIOGENESIS; IMMUNE-RESPONSE; BECLIN 1
AB Autophagy is an evolutionarily conserved catabolic process that eliminates harmful components through lysosomal degradation. In addition to its role in maintaining cellular homeostasis, autophagy is critical to pathological processes, such as inflammation and cancer. Colitis-associated colorectal cancer (CAC) is a specific type of colorectal cancer that develops from long-standing colitis in inflammatory bowel disease (IBD) patients. Accumulating evidence indicates that autophagy of microenvironmental cells plays different but vital roles during tumorigenesis and CAC development. Herein, after summarizing the recent advances in understanding the role of autophagy in regulating the tumor microenvironment during different CAC stages, we draw the following conclusions: autophagy in intestinal epithelial cells inhibits colitis and CAC initiation but promotes CAC progression; autophagy in macrophages inhibits colitis, but its function on CAC is currently unclear; autophagy in neutrophils and cancer-associated fibroblasts (CAFs) promotes both colitis and CAC; autophagy in dendritic cells (DCs) and T cells represses both colitis and CAC; autophagy in natural killer cells (NKs) inhibits colitis, but promotes CAC; and autophagy in endothelial cells plays a controversial role in colitis and CAC. Understanding the role of autophagy in specific compartments of the tumor microenvironment during different stages of CAC may provide insight into malignant transformation, tumor progression, and combination therapy strategies for CAC.
C1 [Wu, Yuhui; Yao, Junlin; Liu, Zhen; Pan, Hongming; Han, Weidong] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Med Oncol, Coll Med, Hangzhou 310016, Zhejiang, Peoples R China.
   [Xie, Jiansheng] Zhejiang Univ, Inst Clin Sci, Sir Run Run Shaw Hosp, Lab Canc Biol,Coll Med, Hangzhou 310016, Zhejiang, Peoples R China.
   [Zhou, Yubin] Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Translat Canc Res, Houston, TX 77030 USA.
RP Pan, HM; Han, WD (corresponding author), Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Med Oncol, Coll Med, Hangzhou 310016, Zhejiang, Peoples R China.
EM panhongming@zju.edu.cn; hanwd@zju.edu.cn
RI Zhou, Yubin/D-4748-2011
OI Zhou, Yubin/0000-0001-7962-0517; Liu, Zhen/0000-0002-8910-9664
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81572361, 81772543, 81572592]; Zhejiang
   Province Preeminence Youth Fund [LR16H160001]; Zhejiang Medical
   Innovative Discipline Construction Project-2016
FX This work was supported by the National Natural Science Foundation of
   China (81572361, 81772543, and 81572592); the Zhejiang Province
   Preeminence Youth Fund (LR16H160001); and the Zhejiang Medical
   Innovative Discipline Construction Project-2016.
CR Abdel-Aziz AK, 2014, CHEM-BIOL INTERACT, V217, P28, DOI 10.1016/j.cbi.2014.04.007
   Abdulrahman BA, 2011, AUTOPHAGY, V7, P1359, DOI 10.4161/auto.7.11.17660
   Allen-Vercoe E, 2014, IMMUNOL LETT, V162, P54, DOI 10.1016/j.imlet.2014.05.014
   Asano J, 2017, CELL REP, V20, P1050, DOI 10.1016/j.celrep.2017.07.019
   Aust DE, 2002, CANCER, V94, P1421, DOI 10.1002/cncr.10334
   Benjamin JL, 2013, CELL HOST MICROBE, V13, P723, DOI 10.1016/j.chom.2013.05.004
   Bernstein CN, 2001, CANCER-AM CANCER SOC, V91, P854, DOI 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z
   Bhardwaj M, 2018, ONCOTARGET, V9, P3278, DOI 10.18632/oncotarget.22890
   Bhattacharya A, 2015, CELL REP, V12, P1731, DOI 10.1016/j.celrep.2015.08.019
   Birmingham CL, 2007, AUTOPHAGY, V3, P442, DOI 10.4161/auto.4450
   Buckley CD, 2003, RHEUMATOLOGY, V42, P1433, DOI 10.1093/rheumatology/keg413
   Bullon P, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-122
   Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416
   Capparelli C, 2012, CELL CYCLE, V11, P2285, DOI 10.4161/cc.20718
   Cemma M, 2011, AUTOPHAGY, V7, P341, DOI 10.4161/auto.7.3.14046
   Chen W, 2012, CANCER RES, V72, P1363, DOI 10.1158/0008-5472.CAN-11-2684
   Chuang SY, 2013, P NATL ACAD SCI USA, V110, P16079, DOI 10.1073/pnas.1306556110
   Doherty J, 2018, NAT CELL BIOL, V20, P1110, DOI 10.1038/s41556-018-0201-5
   Domigan CK, 2015, J CELL SCI, V128, P2236, DOI 10.1242/jcs.163774
   Du JH, 2012, AM J PHYSIOL-CELL PH, V302, pC383, DOI 10.1152/ajpcell.00164.2011
   Fiegl D, 2013, J IMMUNOL, V190, P2791, DOI 10.4049/jimmunol.1202741
   Geremia A, 2014, AUTOIMMUN REV, V13, P3, DOI 10.1016/j.autrev.2013.06.004
   Gong L, 2012, IUBMB LIFE, V64, P740, DOI 10.1002/iub.1070
   Goyal A, 2014, MATRIX BIOL, V34, P46, DOI 10.1016/j.matbio.2013.12.011
   Greene LM, 2013, INT J ONCOL, V43, P927, DOI 10.3892/ijo.2013.1989
   Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001
   Guo WJ, 2014, AUTOPHAGY, V10, P972, DOI 10.4161/auto.28374
   Hall LJ, 2013, MUCOSAL IMMUNOL, V6, P1016, DOI 10.1038/mi.2012.140
   Nguyen HTT, 2014, GASTROENTEROLOGY, V146, P508, DOI 10.1053/j.gastro.2013.10.021
   He G, 2014, TUMOR BIOL, V35, P1003, DOI 10.1007/s13277-013-1134-z
   Henson SM, 2014, J CLIN INVEST, V124, P4004, DOI 10.1172/JCI75051
   Hu JL, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0028-8
   Huang XY, 2010, J EXP MED, V207, P505, DOI 10.1084/jem.20090397
   Hubbard-Lucey VM, 2014, IMMUNITY, V41, P579, DOI 10.1016/j.immuni.2014.09.011
   Huo HZ, 2014, BIOCHEM BIOPH RES CO, V443, P406, DOI 10.1016/j.bbrc.2013.11.099
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094
   Kaneko M, 2014, J CANCER RES CLIN, V140, P769, DOI 10.1007/s00432-014-1628-0
   Kang R, 2013, EXP CELL RES, V319, P556, DOI 10.1016/j.yexcr.2012.11.012
   Kantara C, 2014, CANCER RES, V74, P2487, DOI 10.1158/0008-5472.CAN-13-3536
   Kim Y, 2013, AUTOPHAGY, V9, P2126, DOI 10.4161/auto.26308
   Kumar S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.399
   Lahiri A, 2015, P NATL ACAD SCI USA, V112, P10461, DOI 10.1073/pnas.1501752112
   Lee HY, 2016, AUTOPHAGY, V12, P1390, DOI 10.1080/15548627.2016.1184799
   Lee HK, 2010, IMMUNITY, V32, P227, DOI 10.1016/j.immuni.2009.12.006
   Lee SJ, 2011, AUTOPHAGY, V7, P829, DOI 10.4161/auto.7.8.15598
   Levin AD, 2016, J CROHNS COLITIS, V10, P323, DOI 10.1093/ecco-jcc/jjv174
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levy J, 2015, NAT CELL BIOL, V17, P1062, DOI 10.1038/ncb3206
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Li L., 2018, J CELL COMMUN SIGNAL, DOI [10.1007/s12079-12018-10454-12076, DOI 10.1007/S12079-12018-10454-12076]
   Li XF, 2015, J HEPATOL, V62, P131, DOI 10.1016/j.jhep.2014.08.023
   Li YH, 2012, CARCINOGENESIS, V33, P1231, DOI 10.1093/carcin/bgs137
   Lin H, 2013, HEPATOLOGY, V57, P171, DOI 10.1002/hep.25991
   Liu K, 2015, AUTOPHAGY, V11, P271, DOI 10.1080/15548627.2015.1009787
   Lu CM, 2014, GASTROENTEROLOGY, V146, P188, DOI 10.1053/j.gastro.2013.09.006
   McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109
   Messai Y, 2014, CANCER RES, V74, P6820, DOI 10.1158/0008-5472.CAN-14-0303
   Miki H, 2012, INT J ONCOL, V40, P1020, DOI 10.3892/ijo.2012.1325
   Mimouna S, 2014, AUTOPHAGY, V10, P2333, DOI 10.4161/15548627.2014.984275
   Mineharu Y, 2013, NEUROL MED-CHIR, V53, P741, DOI 10.2176/nmc.ra2013-0234
   Mintern JD, 2015, AUTOPHAGY, V11, P906, DOI 10.1080/15548627.2015.1045178
   Nagasaki T, 2014, BRIT J CANCER, V110, P469, DOI 10.1038/bjc.2013.748
   Neufert C, 2013, J CLIN INVEST, V123, P1428, DOI 10.1172/JCI63748
   Nguyen TMB, 2007, BLOOD, V109, P4793, DOI 10.1182/blood-2006-11-059352
   Nighot PK, 2015, J BIOL CHEM, V290, P7234, DOI 10.1074/jbc.M114.597492
   Ning C, 2015, MUCOSAL IMMUNOL, V8, P1275, DOI 10.1038/mi.2015.18
   Nishikawa T, 2010, ANGIOGENESIS, V13, P227, DOI 10.1007/s10456-010-9180-2
   Ogawa M, 2011, CELL HOST MICROBE, V9, P376, DOI 10.1016/j.chom.2011.04.010
   Olguin JE, 2018, J CANCER, V9, P239, DOI 10.7150/jca.21336
   Packiriswamy N, 2017, WORLD J GASTROENTERO, V23, P3427, DOI 10.3748/wjg.v23.i19.3427
   Pan CC, 2015, J BIOL CHEM, V290, P14884, DOI 10.1074/jbc.M114.630178
   Parekh VV, 2013, J IMMUNOL, V190, P5086, DOI 10.4049/jimmunol.1202071
   Pastille E, 2014, CANCER RES, V74, P4258, DOI 10.1158/0008-5472.CAN-13-3065
   Peiris-Pages M, 2015, ONCOTARGET, V6, P10728, DOI 10.18632/oncotarget.3828
   Pua HH, 2007, J EXP MED, V204, P25, DOI 10.1084/jem.20061303
   Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Raina K, 2013, AUTOPHAGY, V9, P697, DOI 10.4161/auto.23960
   Randow F, 2011, AUTOPHAGY, V7, P304, DOI 10.4161/auto.7.3.14539
   Riffelmacher T, 2017, IMMUNITY, V47, P466, DOI 10.1016/j.immuni.2017.08.005
   Rolny C, 2011, CANCER CELL, V19, P31, DOI 10.1016/j.ccr.2010.11.009
   Saito M, 2012, DIGEST DIS SCI, V57, P2022, DOI 10.1007/s10620-012-2133-4
   Sakitani K, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1789-5
   Sasaki K, 2012, ANTI-CANCER DRUG, V23, P675, DOI 10.1097/CAD.0b013e328353f8c7
   Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Shang K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051848
   Shao LN, 2016, MOL MED REP, V13, P2661, DOI 10.3892/mmr.2016.4820
   Shen WL, 2013, FREE RADICAL BIO MED, V55, P73, DOI 10.1016/j.freeradbiomed.2012.11.011
   Shi CS, 2008, J BIOL CHEM, V283, P33175, DOI 10.1074/jbc.M804478200
   Shibutani ST, 2015, NAT IMMUNOL, V16, P1014, DOI 10.1038/ni.3273
   Strisciuglio C, 2013, J CROHNS COLITIS, V7, P534, DOI 10.1016/j.crohns.2012.08.009
   Sun Y, 2015, INT J ONCOL, V46, P750, DOI 10.3892/ijo.2014.2745
   Tang YL, 2014, VET MICROBIOL, V171, P160, DOI 10.1016/j.vetmic.2014.03.025
   Tattoli I, 2012, AUTOPHAGY, V8, P1848, DOI 10.4161/auto.21863
   Tittarelli A, 2015, J BIOL CHEM, V290, P23670, DOI 10.1074/jbc.M115.651547
   Travassos LH, 2010, NAT IMMUNOL, V11, P55, DOI 10.1038/ni.1823
   Viry E, 2014, AUTOPHAGY, V10, P173, DOI 10.4161/auto.26924
   Wang S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11023
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   Wen YA, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.21
   Willinger T, 2012, P NATL ACAD SCI USA, V109, P8670, DOI 10.1073/pnas.1205305109
   Wu SB, 2013, BIOCHEM BIOPH RES CO, V434, P898, DOI 10.1016/j.bbrc.2013.04.053
   Xiao L, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1319044
   Xie CM, 2014, AUTOPHAGY, V10, P1495, DOI 10.4161/auto.29164
   Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016
   Xu XJ, 2014, NAT IMMUNOL, V15, P1152, DOI 10.1038/ni.3025
   Xu Y, 2007, IMMUNITY, V27, P135, DOI 10.1016/j.immuni.2007.05.022
   Yang M, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-43
   Yang XD, 2016, ONCOTARGET, V7, P79603, DOI 10.18632/oncotarget.12873
   Yoo BH, 2010, J BIOL CHEM, V285, P5438, DOI 10.1074/jbc.M109.046789
   Yoon S, 2010, AUTOPHAGY, V6, P1125, DOI 10.4161/auto.6.8.13547
   Yue CC, 2017, BIOCHEM BIOPH RES CO, V490, P541, DOI 10.1016/j.bbrc.2017.06.075
   Yuk JM, 2010, AUTOPHAGY, V6, P46, DOI 10.4161/auto.6.1.10325
   Zhai ZL, 2014, AUTOPHAGY, V10, P468, DOI 10.4161/auto.27553
   Zhang H, 2017, J IMMUNOL, V198, P2133, DOI 10.4049/jimmunol.1601293
   Zhao J, 2015, INT IMMUNOPHARMACOL, V26, P221, DOI 10.1016/j.intimp.2015.03.033
   Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051
   Zhu XR, 2015, J CLIN INVEST, V125, P1098, DOI 10.1172/JCI76344
NR 120
TC 29
Z9 31
U1 5
U2 17
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2095-9907
EI 2059-3635
J9 SIGNAL TRANSDUCT TAR
JI Signal Transduct. Target. Ther.
PD NOV 30
PY 2018
VL 3
AR 31
DI 10.1038/s41392-018-0031-8
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA HG0EM
UT WOS:000454615200001
PM 30510778
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Yu, R
   Zhang, ZQ
   Wang, B
   Jiang, HX
   Cheng, L
   Shen, LM
AF Yu, Rong
   Zhang, Zhi-qing
   Wang, Bin
   Jiang, Hong-xin
   Cheng, Lei
   Shen, Li-ming
TI Berberine-induced apoptotic and autophagic death of HepG2 cells requires
   AMPK activation
SO CANCER CELL INTERNATIONAL
LA English
DT Article
DE Hepatocellular carcinoma; Berberine; AMPK; Apoptosis; Autophagy and mTOR
ID SKELETAL-MUSCLE CELLS; COLON-CANCER CELLS; PROTEIN-KINASE;
   HEPATOCELLULAR-CARCINOMA; SIGNALING PATHWAY; GROWTH; INHIBITION; MTOR;
   AKT; PHOSPHORYLATION
AB Background: Hepatocellular carcinoma (HCC), the primary liver cancer, is one of the most malignant human tumors with extremely poor prognosis. The aim of this study was to investigate the anti-cancer effect of berberine in a human hepatocellular carcinoma cell line (HepG2), and to study the underlying mechanisms by focusing on the AMP-activated protein kinase (AMPK) signaling cascade.
   Results: We found that berberine induced both apoptotic and autophagic death of HepG2 cells, which was associated with a significant activation of AMPK and an increased expression of the inactive form of acetyl-CoA carboxylase (ACC). Inhibition of AMPK by RNA interference (RNAi) or by its inhibitor compound C suppressed berberine-induced caspase-3 cleavage, apoptosis and autophagy in HepG2 cells, while AICAR, the AMPK activator, possessed strong cytotoxic effects. In HepG2 cells, mammalian target of rapamycin complex 1 (mTORC1) activation was important for cell survival, and berberine inhibited mTORC1 via AMPK activation.
   Conclusions: Together, these results suggested that berberine-induced both apoptotic and autophagic death requires AMPK activation in HepG2 cells.
C1 [Yu, Rong; Wang, Bin; Jiang, Hong-xin] Nanjing Med Univ, Dept Oncol, Suzhou Municipal Hosp, Affiliated Suzhou Hosp, Suzhou 215000, Jiangsu, Peoples R China.
   [Yu, Rong; Cheng, Lei; Shen, Li-ming] Nanjing Med Univ, Dept Intervent Radiol, Suzhou Municipal Hosp, Affiliated Suzhou Hosp, Suzhou 215000, Jiangsu, Peoples R China.
   [Zhang, Zhi-qing] Soochow Univ, Inst Neurosci, Suzhou 215123, Jiangsu, Peoples R China.
RP Cheng, L (corresponding author), Nanjing Med Univ, Dept Intervent Radiol, Suzhou Municipal Hosp, Affiliated Suzhou Hosp, Suzhou 215000, Jiangsu, Peoples R China.
EM 2979701309@qq.com; limingshensz@163.com
FU Soochow University
FX This work is funded by the research start-up funds of Soochow
   University.
CR Altekruse SF, 2009, J CLIN ONCOL, V27, P1485, DOI 10.1200/JCO.2008.20.7753
   Bogachus LD, 2010, AM J PHYSIOL-CELL PH, V299, pC1549, DOI 10.1152/ajpcell.00279.2010
   Cao C, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000118
   Cheng Z, 2006, BBA-GEN SUBJECTS, V1760, P1682, DOI 10.1016/j.bbagen.2006.09.007
   Choudhari SR, 2007, MOL CANCER THER, V6, P112, DOI 10.1158/1535-7163.MCT-06-0561
   Din FVN, 2012, GASTROENTEROLOGY, V142, P1504, DOI 10.1053/j.gastro.2012.02.050
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Hardie DG, 2008, MOL CELL, V30, P263, DOI 10.1016/j.molcel.2008.04.012
   Hardie DG, 2012, CHEM BIOL, V19, P1222, DOI 10.1016/j.chembiol.2012.08.019
   Huo HZ, 2013, MOL CELL BIOCHEM, V378, P171, DOI 10.1007/s11010-013-1608-8
   Hwang JT, 2007, ANN NY ACAD SCI, V1095, P441, DOI 10.1196/annals.1397.047
   Hwang JT, 2007, CANCER LETT, V247, P115, DOI 10.1016/j.canlet.2006.03.030
   Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055
   Inoki K, 2012, ANNU REV PHARMACOL, V52, P381, DOI 10.1146/annurev-pharmtox-010611-134537
   Kim IY, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00175
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim YM, 2007, ANN NY ACAD SCI, V1095, P496, DOI 10.1196/annals.1397.053
   Lee YS, 2006, DIABETES, V55, P2256, DOI 10.2337/db06-0006
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Luo ZJ, 2005, TRENDS PHARMACOL SCI, V26, P69, DOI 10.1016/j.tips.2004.12.011
   Meisse D, 2002, FEBS LETT, V526, P38, DOI 10.1016/S0014-5793(02)03110-1
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Nieminen AI, 2013, P NATL ACAD SCI USA, V110, pE1839, DOI 10.1073/pnas.1208530110
   Niu WY, 2010, AM J PHYSIOL-ENDOC M, V298, pE1058, DOI 10.1152/ajpendo.00773.2009
   Puissant A, 2010, AUTOPHAGY, V6, P655, DOI 10.4161/auto.6.5.12126
   Rocha GZ, 2011, CLIN CANCER RES, V17, P3993, DOI 10.1158/1078-0432.CCR-10-2243
   Spangenberg HC, 2009, NAT REV GASTRO HEPAT, V6, P423, DOI 10.1038/nrgastro.2009.86
   Sun H, 2011, CANCER LETT, V310, P118, DOI 10.1016/j.canlet.2011.06.010
   Sun YY, 2009, ANTI-CANCER DRUG, V20, P757, DOI 10.1097/CAD.0b013e328330d95b
   Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990
   Wu CH, 2012, NANO LETT, V12, P5475, DOI 10.1021/nl301865c
   Yang JD, 2010, NAT REV GASTRO HEPAT, V7, P448, DOI 10.1038/nrgastro.2010.100
   Zhang HH, 2006, MOL CELL, V24, P185, DOI 10.1016/j.molcel.2006.09.019
   Zhang WB, 2010, J BIOL CHEM, V285, P40461, DOI 10.1074/jbc.M110.164046
   Zheng QY, 2012, BIOCHEM BIOPH RES CO, V419, P741, DOI 10.1016/j.bbrc.2012.02.093
NR 37
TC 74
Z9 79
U1 1
U2 26
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2867
J9 CANCER CELL INT
JI Cancer Cell Int.
PD JUN 11
PY 2014
VL 14
AR 49
DI 10.1186/1475-2867-14-49
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AK9YY
UT WOS:000338785700001
PM 24991192
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU D'Onofrio, N
   Martino, E
   Mele, L
   Colloca, A
   Maione, M
   Cautela, D
   Castaldo, D
   Balestrieri, ML
AF D'Onofrio, Nunzia
   Martino, Elisa
   Mele, Luigi
   Colloca, Antonino
   Maione, Martina
   Cautela, Domenico
   Castaldo, Domenico
   Balestrieri, Maria Luisa
TI Colorectal Cancer Apoptosis Induced by Dietary delta-Valerobetaine
   Involves PINK1/Parkin Dependent-Mitophagy and SIRT3
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE colon cancer; mitophagy; mitochondrial dysfunction; PINK1; Parkin
ID PARKIN; MITOCHONDRIA; AUTOPHAGY; CELLS
AB Understanding the mechanisms of colorectal cancer progression is crucial in the setting of strategies for its prevention. delta-Valerobetaine (delta VB) is an emerging dietary metabolite showing cytotoxic activity in colon cancer cells via autophagy and apoptosis. Here, we aimed to deepen current knowledge on the mechanism of delta VB-induced colon cancer cell death by investigating the apoptotic cascade in colorectal adenocarcinoma SW480 and SW620 cells and evaluating the molecular players of mitochondrial dysfunction. Results indicated that delta VB reduced cell viability in a time-dependent manner, reaching IC50 after 72 h of incubation with delta VB 1.5 mM, and caused a G2/M cell cycle arrest with upregulation of cyclin A and cyclin B protein levels. The increased apoptotic cell rate occurred via caspase-3 activation with a concomitant loss in mitochondrial membrane potential and SIRT3 downregulation. Functional studies indicated that delta VB activated mitochondrial apoptosis through PINK1/Parkin pathways, as upregulation of PINK1, Parkin, and LC3B protein levels was observed (p < 0.0001). Together, these findings support a critical role of PINK1/Parkin-mediated mitophagy in mitochondrial dysfunction and apoptosis induced by delta VB in SW480 and SW620 colon cancer cells.
C1 [D'Onofrio, Nunzia; Martino, Elisa; Colloca, Antonino; Maione, Martina; Balestrieri, Maria Luisa] Univ Campania Luigi Vanvitelli, Dept Precis Med, Via L De Crecchio 7, I-80138 Naples, Italy.
   [Mele, Luigi] Univ Campania Luigi Vanvitelli, Dept Expt Med, Via Luciano Armanni 5, I-80138 Naples, Italy.
   [Cautela, Domenico; Castaldo, Domenico] Azienda Speciale CCIAA Reggio Calabria, Stn Sperimentale Ind Essenze & Derivati Dagli Agr, Via G Tommasini 2, I-89125 Reggio Di Calabria, Italy.
   [Castaldo, Domenico] Minist Sviluppo Econ MiSE, Via Molise 2, I-00187 Rome, Italy.
RP D'Onofrio, N (corresponding author), Univ Campania Luigi Vanvitelli, Dept Precis Med, Via L De Crecchio 7, I-80138 Naples, Italy.
EM nunzia.donofrio@unicampania.it; elisa.martino@unicampania.it;
   luigi.mele@unicampania.it; antonino.colloca@studenti.unicampania.it;
   martina.maione@unicampania.it; dcautela@ssea.it; dcastaldo@ssea.it;
   marialuisa.balestrieri@unicampania.it
RI Mele, Luigi/AAC-9887-2019; D'Onofrio, Nunzia/M-2081-2019; Cautela,
   Domenico/J-5235-2013
OI Mele, Luigi/0000-0002-6008-0802; D'Onofrio, Nunzia/0000-0002-5300-9530;
   Balestrieri, Maria Luisa/0000-0001-6001-1789; Cautela,
   Domenico/0000-0003-4894-0299; Martino, Elisa/0000-0003-4070-2894
FU VALERE 2019 Program University of Campania L. Vanvitelli [PON I&C
   2014-2020-TABAREZO-F/200085/01-03/X45]
FX This research was supported by VALERE 2019 Program University of
   Campania L. Vanvitelli and PON I&C
   2014-2020-TABAREZO-F/200085/01-03/X45.
CR Bin-Umer MA, 2014, P NATL ACAD SCI USA, V111, P11798, DOI 10.1073/pnas.1403145111
   Carroll RG, 2014, CELL REP, V9, P1538, DOI 10.1016/j.celrep.2014.10.046
   D'Onofrio N, 2020, CANCERS, V12, DOI 10.3390/cancers12092468
   D'Onofrio N, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65865-6
   D'Onofrio N, 2019, J AGR FOOD CHEM, V67, P1702, DOI 10.1021/acs.jafc.8b07166
   Devenport SN, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.138835
   Doblado L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22083903
   Durcan TM, 2015, GENE DEV, V29, P989, DOI 10.1101/gad.262758.115
   Eiyama A, 2015, CURR OPIN CELL BIOL, V33, P95, DOI 10.1016/j.ceb.2015.01.002
   Fink MA, 2019, CLIN CANCER RES, V25, P2874, DOI 10.1158/1078-0432.CCR-18-2380
   Gao GY, 2018, BIOMED PHARMACOTHER, V108, P1208, DOI 10.1016/j.biopha.2018.06.172
   Grimaldi A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079658
   Hollville E, 2014, MOL CELL, V55, P451, DOI 10.1016/j.molcel.2014.06.001
   Li SA, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6617256
   Lin CS, 2018, ONCOL REP, V39, P316, DOI 10.3892/or.2017.6087
   LIU C, 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/871263
   Nakatogawa H, 2020, NAT REV MOL CELL BIO, V21, P439, DOI 10.1038/s41580-020-0241-0
   Poulogiannis G, 2010, P NATL ACAD SCI USA, V107, P15145, DOI 10.1073/pnas.1009941107
   Ragimbeau R, 2021, FASEB J, V35, DOI 10.1096/fj.202000930R
   Ramesh P, 2020, APOPTOSIS, V25, P305, DOI 10.1007/s10495-020-01601-9
   Sekine S, 2020, J BIOCHEM, V167, P217, DOI 10.1093/jb/mvz069
   Servillo L, 2018, FOOD CHEM, V260, P193, DOI 10.1016/j.foodchem.2018.03.114
   Shirihai OS, 2015, CIRC RES, V116, P1835, DOI 10.1161/CIRCRESAHA.116.306374
   Spinelli JB, 2018, NAT CELL BIOL, V20, P745, DOI 10.1038/s41556-018-0124-1
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tanaka K, 2020, NEUROSCI RES, V159, P9, DOI 10.1016/j.neures.2020.01.006
   Torrens-Mas M, 2019, AM J PHYSIOL-CELL PH, V317, pC398, DOI 10.1152/ajpcell.00112.2019
   Torrens-Mas M, 2018, J CELL PHYSIOL, V233, P6067, DOI 10.1002/jcp.26443
   Torrens-Mas M, 2017, J CELL BIOCHEM, V118, P397, DOI 10.1002/jcb.25653
   Vara-Perez M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050493
   Wan XY, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02825-y
   Wang L, 2018, BBA-GEN SUBJECTS, V1862, P2281, DOI 10.1016/j.bbagen.2018.07.017
   Wang QL, 2019, BIOCHEM BIOPH RES CO, V515, P517, DOI 10.1016/j.bbrc.2019.05.114
   Wang YY, 2018, ONCOL RES, V26, P889, DOI 10.3727/096504017X15009419625178
   Yeo CWS, 2012, CANCER RES, V72, P2543, DOI 10.1158/0008-5472.CAN-11-3060
   Yin KL, 2021, CELL DEATH DIFFER, V28, P2421, DOI 10.1038/s41418-021-00760-9
   Zeng C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115820
   Zhang C, 2011, P NATL ACAD SCI USA, V108, P16259, DOI 10.1073/pnas.1113884108
   Zhang J, 2020, THERANOSTICS, V10, P8315, DOI 10.7150/thno.45922
   Zhou E, 2021, GASTROENTEROL CLIN N, V50, P101, DOI 10.1016/j.gtc.2020.10.012
   Zhu ML, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906-020-02965-w
NR 41
TC 4
Z9 4
U1 6
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2021
VL 22
IS 15
AR 8117
DI 10.3390/ijms22158117
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA TV8IS
UT WOS:000681960700001
PM 34360883
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Liu, M
   Sun, TY
   Li, N
   Peng, JJ
   Fu, D
   Li, W
   Li, L
   Gao, WQ
AF Liu, Min
   Sun, Tongyu
   Li, Ni
   Peng, Junjie
   Fu, Da
   Li, Wei
   Li, Li
   Gao, Wei-Qiang
TI BRG1 attenuates colonic inflammation and tumorigenesis through
   autophagy-dependent oxidative stress sequestration
SO NATURE COMMUNICATIONS
LA English
DT Article
ID ULCERATIVE-COLITIS; CROHN-DISEASE; PANETH CELLS; CANCER; PROMOTES;
   SWI/SNF; GENE; HOMEOSTASIS; IMMUNITY; VARIANTS
AB Autophagy is a central component of integrated stress responses that influences many inflammatory diseases, including inflammatory bowel disease (IBD) and colorectal cancer (CRC). While the core machinery is known, the molecular basis of the epigenetic regulation of autophagy and its role in colon inflammation remain largely undefined. Here, we report that BRG1, an ATPase subunit of the SWI/SNF chromatin remodeling complex, is required for the homeostatic maintenance of intestinal epithelial cells (IECs) to prevent the inflammation and tumorigenesis. BRG1 emerges as a key regulator that directly governs the transcription of Atg16l1, Ambra1, Atg7 and Wipi2, which are important for autophagosome biogenesis. Defective autophagy in BRG1-deficient IECs results in excess reactive oxygen species (ROS), which leads to the defects in barrier integrity. Together, our results establish that BRG1 may represent an autophagy checkpoint that is pathogenetically linked to colitis and is therefore likely a potential therapeutic target for disease intervention.
C1 [Liu, Min; Li, Li; Gao, Wei-Qiang] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Renji Med X Clin Stem Cell Res Ctr, Ren Ji Hosp,Sch Med, Shanghai, Peoples R China.
   [Liu, Min; Li, Li; Gao, Wei-Qiang] Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai, Peoples R China.
   [Liu, Min; Li, Li; Gao, Wei-Qiang] Shanghai Jiao Tong Univ, Med X Res Inst, Shanghai, Peoples R China.
   [Sun, Tongyu; Li, Ni] Univ Chinese Acad Sci, Chinese Acad Sci, CAS Key Lab Tissue Microenvironm & Tumor,Shanghai, CAS Ctr Excellence Mol Cell Sci,Shanghai Inst Nut, Shanghai, Peoples R China.
   [Peng, Junjie] Fudan Univ, Shanghai Canc Ctr, Dept Colorectal Surg, Shanghai, Peoples R China.
   [Fu, Da] Tongji Univ, Sch Med, Cent Lab Med Res, Shanghai Peoples Hosp 10, Shanghai, Peoples R China.
   [Li, Wei] Chinese Acad Sci, Inst Zool, State Key Lab Stem Cell & Reprod Biol, Beijing, Peoples R China.
RP Li, L; Gao, WQ (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Renji Med X Clin Stem Cell Res Ctr, Ren Ji Hosp,Sch Med, Shanghai, Peoples R China.; Li, L; Gao, WQ (corresponding author), Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai, Peoples R China.; Li, L; Gao, WQ (corresponding author), Shanghai Jiao Tong Univ, Med X Res Inst, Shanghai, Peoples R China.
EM lil@sjtu.edu.cn; gao.weiqiang@sjtu.edu.cn
OI Li, Wei/0000-0001-7864-404X; Li, Li/0000-0003-2342-3658
FU Ministry of Science and Technology of the People's Republic of
   ChinaMinistry of Science and Technology, China [2017YFA0102900];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81872406, 81630073, 81772938]; State Key
   Laboratory of Oncogenes and Related Genes [KF01801]; Science and
   Technology Commission of Shanghai MunicipalityScience & Technology
   Commission of Shanghai Municipality (STCSM) [16JC1405700, 18140902700,
   19140905500]; High Peak IV fund from Education Commission of Shanghai
   Municipality on Stem Cell Research; KC Wong foundation; Innovation
   Research Plan from Shanghai Municipal Education Commission [ZXGF082101];
   Shanghai Jiao Tong University Medical Engineering Cross Fund
   [YG2016MS52]; Bio-ID Center, School of Biomedical Engineering, Shanghai
   Jiao Tong University
FX This study was supported by funds from Ministry of Science and
   Technology of the People's Republic of China (2017YFA0102900 to W.Q.G.),
   National Natural Science Foundation of China (81872406 and 81630073 to
   W.Q.G., 81772938 to L.L.), State Key Laboratory of Oncogenes and Related
   Genes (KF01801 to L.L.), Science and Technology Commission of Shanghai
   Municipality (16JC1405700 to W.Q.G., 18140902700 and 19140905500 to
   L.L.), High Peak IV fund from Education Commission of Shanghai
   Municipality on Stem Cell Research (to W.Q.G.), KC Wong foundation (to
   W.Q.G.). L.L. is supported by Innovation Research Plan from Shanghai
   Municipal Education Commission (ZXGF082101), and Shanghai Jiao Tong
   University Medical Engineering Cross Fund (YG2016MS52). The study is
   also supported by Bio-ID Center, School of Biomedical Engineering,
   Shanghai Jiao Tong University.
CR Adolph TE, 2013, NATURE, V503, P272, DOI 10.1038/nature12599
   Alenghat T, 2013, NATURE, V504, P153, DOI 10.1038/nature12687
   Barrett CW, 2015, J CLIN INVEST, V125, P2646, DOI 10.1172/JCI76099
   Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011
   Boivin GP, 2003, GASTROENTEROLOGY, V124, P762, DOI 10.1053/gast.2003.50094
   Bretin A, 2016, AUTOPHAGY, V12, P770, DOI 10.1080/15548627.2016.1156823
   Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416
   Chakrabarty S, 2017, BRIT J CANCER, V117, P136, DOI 10.1038/bjc.2017.148
   Council NR, 2011, GUIDE CARE USE LAB A, V8th
   Davis RB, 2013, DEVELOPMENT, V140, P1272, DOI 10.1242/dev.087379
   Di Bartolomeo S, 2010, J CELL BIOL, V191, P155, DOI 10.1083/jcb.201002100
   Dooley HC, 2015, AUTOPHAGY, V11, P190, DOI 10.1080/15548627.2014.996029
   Dooley HC, 2014, MOL CELL, V55, P238, DOI 10.1016/j.molcel.2014.05.021
   Edelblum KL, 2009, CURR OPIN PHARMACOL, V9, P715, DOI 10.1016/j.coph.2009.06.022
   EKBOM A, 1990, NEW ENGL J MED, V323, P1228, DOI 10.1056/NEJM199011013231802
   El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042
   Fimia GM, 2011, AUTOPHAGY, V7, P115, DOI 10.4161/auto.7.1.14071
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Gunther C, 2013, GUT, V62, P1062, DOI 10.1136/gutjnl-2011-301364
   Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954
   Hang CT, 2010, NATURE, V466, P62, DOI 10.1038/nature09130
   Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724
   Hargreaves DC, 2011, CELL RES, V21, P396, DOI 10.1038/cr.2011.32
   Helming KC, 2014, CANCER CELL, V26, P309, DOI 10.1016/j.ccr.2014.07.018
   Holik AZ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004453
   Holik AZ, 2013, STEM CELLS, V31, P2457, DOI 10.1002/stem.1498
   Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107
   Ireland H, 2005, DEV DYNAM, V233, P1332, DOI 10.1002/dvdy.20446
   Joossens M, 2011, GUT, V60, P631, DOI 10.1136/gut.2010.223263
   Jubierre L, 2016, ONCOGENE, V35, P5179, DOI 10.1038/onc.2016.50
   Li N, 2017, J CLIN INVEST, V127, P1284, DOI 10.1172/JCI91144
   Liu YF, 2017, P NATL ACAD SCI USA, V114, pE3796, DOI 10.1073/pnas.1700909114
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Moreau K, 2011, CELL, V146, P303, DOI 10.1016/j.cell.2011.06.023
   Noubade R, 2014, NATURE, V509, P235, DOI 10.1038/nature13152
   Parkes M, 2007, NAT GENET, V39, P830, DOI 10.1038/ng2061
   Patel KK, 2013, EMBO J, V32, P3130, DOI 10.1038/emboj.2013.233
   Pulendran B, 2015, ANNU REV IMMUNOL, V33, P563, DOI 10.1146/annurev-immunol-020711-075049
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Ravindran R, 2016, NATURE, V531, P523, DOI 10.1038/nature17186
   Reisman DN, 2003, CANCER RES, V63, P560
   Rescigno M, 2011, TRENDS IMMUNOL, V32, P256, DOI 10.1016/j.it.2011.04.003
   Romero OA, 2014, CANCER DISCOV, V4, P292, DOI 10.1158/2159-8290.CD-13-0799
   Roy N, 2015, GENE DEV, V29, P658, DOI 10.1101/gad.256628.114
   Sakamaki JI, 2017, MOL CELL, V66, P517, DOI 10.1016/j.molcel.2017.04.027
   Shadel GS, 2015, CELL, V163, P560, DOI 10.1016/j.cell.2015.10.001
   Shi J, 2013, GENE DEV, V27, P2648, DOI 10.1101/gad.232710.113
   SumiIchinose C, 1997, MOL CELL BIOL, V17, P5976, DOI 10.1128/MCB.17.10.5976
   Takada Y, 2016, DEVELOPMENT, V143, P3532, DOI 10.1242/dev.141549
   Takahashi N, 2014, NATURE, V513, P95, DOI 10.1038/nature13706
   Thachil E, 2012, GASTROENTEROLOGY, V142, P1097, DOI 10.1053/j.gastro.2012.01.031
   Turner JR, 2009, NAT REV IMMUNOL, V9, P799, DOI 10.1038/nri2653
   von Figura G, 2014, NAT CELL BIOL, V16, P255, DOI 10.1038/ncb2916
   Wei FZ, 2015, AUTOPHAGY, V11, P2309, DOI 10.1080/15548627.2015.1117734
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068
   Witkowski L, 2014, NAT GENET, V46, P438, DOI 10.1038/ng.2931
   Wlodarska M, 2014, CELL, V156, P1045, DOI 10.1016/j.cell.2014.01.026
   Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005
   Xiao YC, 2013, NAT MED, V19, P595, DOI 10.1038/nm.3111
   Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051
NR 61
TC 22
Z9 23
U1 4
U2 26
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD OCT 10
PY 2019
VL 10
AR 4614
DI 10.1038/s41467-019-12573-z
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA JC8WW
UT WOS:000489557800007
PM 31601814
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Kao, C
   Chao, A
   Tsai, CL
   Chuang, WC
   Huang, WP
   Chen, GC
   Lin, CY
   Wang, TH
   Wang, HS
   Lai, CH
AF Kao, C.
   Chao, A.
   Tsai, C-L
   Chuang, W-C
   Huang, W-P
   Chen, G-C
   Lin, C-Y
   Wang, T-H
   Wang, H-S
   Lai, C-H
TI Bortezomib enhances cancer cell death by blocking the autophagic flux
   through stimulating ERK phosphorylation
SO CELL DEATH & DISEASE
LA English
DT Article
ID INDUCED PHOSPHOPROTEIN 1; PROTEASOME INHIBITOR; DECREASED EXPRESSION;
   CYSTEINE CATHEPSINS; MATURATION STEP; APOPTOSIS; DEGRADATION; CISPLATIN;
   PATHWAYS; RESISTANCE
AB The antitumor activity of an inhibitor of 26S proteasome bortezomib (Velcade) has been observed in various malignancies, including colon cancer, prostate cancer, breast cancer, and ovarian cancer. Bortezomib has been proposed to stimulate autophagy, but scientific observations did not always support this. Interactions between ERK activity and autophagy are complex and not completely clear. Autophagy proteins have recently been shown to regulate the functions of ERK, and ERK activation has been found to induce autophagy. On the other hand, sustained activation of ERK has also been shown to inhibit the maturation step of the autophagy process. In this study, we sought to identify the mechanism of autophagy regulation in cancer cells treated with bortezomib. Our results indicate that bortezomib blocked the autophagic flux without inhibiting the fusion of the autophagosome and lysosome. In ovarian cancer, as well as endometrial cancer and hepatocellular carcinoma cells, bortezomib inhibited protein degradation in lysosomes by suppressing cathepsins, which requires the participation of ERK phosphorylation, but not JNK or p38. Our findings that ERK phosphorylation reduced cathepsins further explain how ERK phosphorylation inhibits the autophagic flux. In conclusion, bortezomib may induce ERK phosphorylation to suppress cathepsin B and inhibit the catalytic process of autophagy in ovarian cancer and other solid tumors. The inhibition of cisplatin-induced autophagy by bortezomib can enhance chemotherapy efficacy in ovarian cancer. As we also found that bortezomib blocks the autophagic flux in other cancers, the synergistic cytotoxic effect of bortezomib by abolishing chemotherapy-related autophagy may help us develop strategies of combination therapies for multiple cancers.
C1 [Kao, C.; Chao, A.; Tsai, C-L; Chuang, W-C; Lin, C-Y; Wang, T-H; Wang, H-S; Lai, C-H] Chang Gung Mem Hosp, Linkou Med Ctr, Dept Obstet & Gynecol, Taoyuan 333, Guishan, Taiwan.
   [Kao, C.; Chuang, W-C; Wang, T-H] Chang Gung Univ, Coll Med, Grad Inst Biomed Sci, Taoyuan, Taiwan.
   [Huang, W-P] Natl Taiwan Univ, Dept Life Sci, Taipei 10764, Taiwan.
   [Chen, G-C] Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan.
   [Wang, T-H] Chang Gung Mem Hosp, Linkou Med Ctr, Genom Med Res Core Lab, Taoyuan 333, Guishan, Taiwan.
   [Wang, T-H] Chang Gung Univ, Coll Med, Sch Tradit Chinese Med, Taoyuan, Taiwan.
   [Wang, H-S] Chang Gung Univ, Coll Med, Grad Inst Clin Med Sci, Taoyuan, Taiwan.
RP Wang, TH (corresponding author), Chang Gung Mem Hosp, Linkou Med Ctr, 5 Fushin St, Taoyuan 333, Guishan, Taiwan.
EM knoxtn@cgmh.org.tw
RI Lai, Chyong-Huey/AAE-5731-2022
OI HUANG, WEI-PANG/0000-0001-8410-6555; Lai,
   Chyong-Huey/0000-0002-9977-9645
FU [MOHW102-TD-PB-111-NSC106];  [NSC100-2314-B182-016 MY3];  [CMRPG391461
   similar to 4];  [CMRPG3C0281 similar to 3]
FX This work was supported by the grants: MOHW102-TD-PB-111-NSC106 (to T.
   H. Wang), NSC100-2314-B182-016 MY3 (to TH Wang), CMRPG391461 similar to
   4 (to T. H. Wang), and CMRPG3C0281 similar to 3 (to TH Wang). We are
   grateful for the help from Microscope Core Laboratory, CGMH, and
   Molecular Imaging Center, CGMH, and English editing by Dr. Shihyee Mimi
   Wang (Department of Obstetrics and Gynecology, White Memorial Hospital,
   Los Angeles).
CR Armstrong JL, 2011, CLIN CANCER RES, V17, P2216, DOI 10.1158/1078-0432.CCR-10-3003
   Bast R C Jr, 2011, Ann Oncol, V22 Suppl 8, pviii5, DOI 10.1093/annonc/mdr516
   Beckham TH, 2012, INT J CANCER, V131, P2034, DOI 10.1002/ijc.27480
   Befani CD, 2012, J MOL MED, V90, P45, DOI 10.1007/s00109-011-0805-8
   Bengsch F, 2014, ONCOGENE, V33, P4474, DOI 10.1038/onc.2013.395
   Burger RA, 2011, NEW ENGL J MED, V365, P2473, DOI 10.1056/NEJMoa1104390
   Chao A, 2012, ONCOGENE, V31, P764, DOI 10.1038/onc.2011.269
   Chao A, 2010, CANCER LETT, V291, P99, DOI 10.1016/j.canlet.2009.10.005
   Chao Ariana, 2013, Yale J Biol Med, V86, P1
   Chen KF, 2010, ONCOGENE, V29, P6257, DOI 10.1038/onc.2010.357
   Codony-Servat J, 2006, MOL CANCER THER, V5, P665, DOI 10.1158/1535-7163.MCT-05-0147
   Coleman RL, 2013, NAT REV CLIN ONCOL, V10, P211, DOI 10.1038/nrclinonc.2013.5
   Corcelle E, 2007, AUTOPHAGY, V3, P57, DOI 10.4161/auto.3424
   Corcelle E, 2006, CANCER RES, V66, P6861, DOI 10.1158/0008-5472.CAN-05-3557
   Cusack JC, 2001, CANCER RES, V61, P3535
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   de la Cruz-Morcillo MA, 2012, ONCOGENE, V31, P1073, DOI 10.1038/onc.2011.321
   Djavaheri-Mergny M, 2006, J BIOL CHEM, V281, P30373, DOI 10.1074/jbc.M602097200
   Eskelinen EL, 2005, CELL DEATH DIFFER, V12, P1468, DOI 10.1038/sj.cdd.4401721
   Fang J, 2012, BLOOD, V120, P858, DOI 10.1182/blood-2012-02-407999
   Granato M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075965
   Hailey DW, 2010, CELL, V141, P656, DOI 10.1016/j.cell.2010.04.009
   He W, 2014, ONCOGENE, V33, P3004, DOI 10.1038/onc.2013.256
   Hui B, 2012, CANCER-AM CANCER SOC, V118, P5560, DOI 10.1002/cncr.27586
   Kao C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.38
   Katsumata N, 2009, LANCET, V374, P1331, DOI 10.1016/S0140-6736(09)61157-0
   Kaushal GP, 2008, AUTOPHAGY, V4, P710, DOI 10.4161/auto.6309
   Kim SY, 2014, BIOCHEM PHARMACOL, V88, P178, DOI 10.1016/j.bcp.2014.01.027
   Kraft C, 2010, NAT CELL BIOL, V12, P836, DOI 10.1038/ncb0910-836
   Li CY, 2012, CANCER LETT, V314, P102, DOI 10.1016/j.canlet.2011.09.020
   Lin CY, 2014, J MOL MED, V92, P969, DOI 10.1007/s00109-014-1163-0
   Long JS, 2012, ONCOGENE, V31, P5045, DOI 10.1038/onc.2012.7
   Martinez-Lopez N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3799
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Milani M, 2009, CANCER RES, V69, P4415, DOI 10.1158/0008-5472.CAN-08-2839
   Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Mizushima N, 2010, NAT CELL BIOL, V12, P823, DOI 10.1038/ncb0910-823
   Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200
   Periyasamy-Thandavan S, 2010, AUTOPHAGY, V6, P19, DOI 10.4161/auto.6.1.10323
   Perren TJ, 2011, NEW ENGL J MED, V365, P2484, DOI 10.1056/NEJMoa1103799
   Reiser J, 2010, J CLIN INVEST, V120, P3421, DOI 10.1172/JCI42918
   Richardson Paul G, 2003, Clin Adv Hematol Oncol, V1, P596
   Rodriguez A, 2006, CELL METAB, V3, P211, DOI 10.1016/j.cmet.2006.01.011
   Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291
   Selimovic D, 2013, CELL SIGNAL, V25, P308, DOI 10.1016/j.cellsig.2012.10.004
   Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592
   Shen Y, 2008, AUTOPHAGY, V4, P1067, DOI 10.4161/auto.6827
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Spowart JE, 2012, J PATHOL, V228, P437, DOI 10.1002/path.4090
   Tsai CL, 2012, CELL REP, V2, P283, DOI 10.1016/j.celrep.2012.07.002
   Wang TH, 2010, MOL CELL PROTEOMICS, V9, P1873, DOI 10.1074/mcp.M110.000802
   White E, 2012, CANCER DISCOV, V2, P863, DOI 10.1158/2159-8290.CD-ND2012-036
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Yu HC, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0055705, 10.1371/journal.pone.0057111, 10.1371/journal.pone.0066447]
   Yu H, 2011, EUR J CANCER, V47, P1585, DOI 10.1016/j.ejca.2011.01.019
   Zhang N, 2013, INT J ONCOL, V42, P2053, DOI 10.3892/ijo.2013.1906
   Zhang Y, 2012, ONCOGENE, V31, P1055, DOI 10.1038/onc.2011.290
   Zhang Y, 2012, BLOOD, V119, P2895, DOI 10.1182/blood-2011-08-372383
   Zhu Keyi, 2009, Proceedings of the American Association for Cancer Research Annual Meeting, V50, P451, DOI 10.1038/onc.2009.343
NR 63
TC 66
Z9 67
U1 0
U2 12
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD NOV
PY 2014
VL 5
AR e1510
DI 10.1038/cddis.2014.468
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AU5JW
UT WOS:000345643900004
PM 25375375
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Sun, Y
   Xing, X
   Liu, Q
   Wang, Z
   Xin, YH
   Zhang, P
   Hu, CS
   Liu, Y
AF Sun, Yong
   Xing, Xing
   Liu, Qi
   Wang, Zheng
   Xin, Yuhu
   Zhang, Ping
   Hu, Chaosu
   Liu, Yong
TI Hypoxia-induced autophagy reduces. radiosensitivity by the HIF-1
   alpha/miR-210/Bcl-2 pathway in colon cancer cells
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE autophagy; hypoxia; radiosensitivity; colon cancer
ID BREAST-CANCER; IONIZING-RADIATION; INDUCIBLE FACTORS; BCL-2 EXPRESSION;
   APOPTOSIS; RESISTANCE; MIR-210; HIF-1-ALPHA; INHIBITION; PROTEINS
AB Autophagy is an evolutionarily conserved cellular response to conditions of stress such as hypoxia, which induce radioresistance in cancer cells. We studied the mechanism of action of hypoxia on autophagy and radiosensitivity in colon cancer cells. In the human colon cancer cell lines SW480 and SW620, autophagosomes were analyzed to evaluate autophagy by flow cytometry. The expression of hypoxia inducible factor-la (HIF-1 alpha), Bcl-2, and miR-210 was detected by western blotting and quantitative real-time polymerase chain reaction (PCR). HIF-1 alpha and miR-210 inhibition was induced by siRNA transfections. Apoptosis detection and colony assays were performed to determine radiosensitivity. HIF-1 alpha and miR-210 showed a significant increase under hypoxic condition. The inhibition of HIF-1 alpha decreased miR-210 expression and autophagy. Silencing of miR-210 upregulated Bcl-2 expression and reduced the survival fraction of colon cancer cells after radiation treatment. Under hypoxia, HIF-1 alpha induces miRNA-210 which in turn enhances autophagy and reduces radiosensitivity by downregulating Bcl-2 expression in colon cancer cells. Our results imply that autophagy contributes to the reduction of radiosensitivity in hypoxic environment, and the process is mediated through the HIF-1 alpha/miR-210/Bcl-2 pathway in human colon cancer cells.
C1 [Sun, Yong; Liu, Qi; Xin, Yuhu; Zhang, Ping; Liu, Yong] Fudan Univ, Shanghai Canc Ctr, Canc Res Inst, Shanghai 200032, Peoples R China.
   [Xing, Xing; Wang, Zheng; Hu, Chaosu; Liu, Yong] Fudan Univ, Shanghai Canc Ctr, Dept Radiat Oncol, Shanghai 200032, Peoples R China.
   [Sun, Yong; Xing, Xing; Liu, Qi; Wang, Zheng; Xin, Yuhu; Zhang, Ping; Hu, Chaosu; Liu, Yong] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.
RP Liu, Y (corresponding author), Fudan Univ, Shanghai Canc Ctr, Canc Res Inst, 270 Dong An Rd, Shanghai 200032, Peoples R China.
EM hucsu62@yahoo.com; drliuyong@fudan.edu.cn
OI Hu, Chaosu/0000-0002-6503-0951
FU Scientific Research Foundation for the Returned Overseas Chinese
   Scholars from China State Education MinistryScientific Research
   Foundation for the Returned Overseas Chinese Scholars [N130204];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81202148, 31370838]; Foundation of Fudan
   University 985 Project [985IIIYPT06]; Shanghai Pujiang ProgramShanghai
   Pujiang Program [13PJ1401600]; Foundation of Shanghai Committee of
   Science and Technology of China [12DZ2260100]
FX This study was supported by the Scientific Research Foundation for the
   Returned Overseas Chinese Scholars (no. N130204) from China State
   Education Ministry, the National Natural Science Foundation of China
   (nos. 81202148 and 31370838), the Foundation of Fudan University 985
   Project (985IIIYPT06), the Shanghai Pujiang Program (no. 13PJ1401600),
   the Foundation of Shanghai Committee of Science and Technology of China
   (no. 12DZ2260100).
CR Agani F, 2013, CURR CANCER DRUG TAR, V13, P245, DOI 10.2174/1568009611313030003
   Akar U, 2008, AUTOPHAGY, V4, P669, DOI 10.4161/auto.6083
   Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562
   Avivar-Valderas A, 2013, ONCOGENE, V32, P4932, DOI 10.1038/onc.2012.512
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Camps C, 2008, CLIN CANCER RES, V14, P1340, DOI 10.1158/1078-0432.CCR-07-1755
   Chaachouay H, 2011, RADIOTHER ONCOL, V99, P287, DOI 10.1016/j.radonc.2011.06.002
   Chan YC, 2012, MICROCIRCULATION, V19, P215, DOI 10.1111/j.1549-8719.2011.00154.x
   Chio CC, 2013, ARCH TOXICOL, V87, P459, DOI 10.1007/s00204-012-0965-5
   Clara CA, 2014, NEUROPATHOLOGY, V34, P343, DOI 10.1111/neup.12111
   Devlin C, 2011, IUBMB LIFE, V63, P94, DOI [10.1002/iub.00427, 10.1002/iub.427]
   Fasanaro P, 2008, J BIOL CHEM, V283, P15878, DOI 10.1074/jbc.M800731200
   Goda N, 2012, INT J HEMATOL, V95, P457, DOI 10.1007/s12185-012-1069-y
   Grosso S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.71
   He WS, 2012, ONCOL RES, V20, P251, DOI 10.3727/096504013X13589503483012
   Janga SC, 2011, ADV EXP MED BIOL, V722, P59, DOI 10.1007/978-1-4614-0332-6_4
   Kaminskyy VO, 2014, ANTIOXID REDOX SIGN, V21, P86, DOI 10.1089/ars.2013.5746
   KITADA S, 1994, ANTISENSE RES DEV, V4, P71, DOI 10.1089/ard.1994.4.71
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196
   Lin SC, 2014, EXP BIOL MED, V239, P779, DOI 10.1177/1535370214532755
   Liu B, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.422
   Liu Y, 2009, BRAIN RES, V1304, P149, DOI 10.1016/j.brainres.2009.09.083
   Maejima Y, 2013, NAT MED, V19, P1478, DOI 10.1038/nm.3322
   Maiuri MC, 2007, AUTOPHAGY, V3, P374, DOI 10.4161/auto.4237
   Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mukhopadhyay S, 2014, APOPTOSIS, V19, P555, DOI 10.1007/s10495-014-0967-2
   Nakatogawa H, 2009, NAT REV MOL CELL BIO, V10, P458, DOI 10.1038/nrm2708
   Ni ZH, 2014, FREE RADICAL BIO MED, V70, P194, DOI 10.1016/j.freeradbiomed.2014.02.012
   Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Peitzsch C, 2014, INT J RADIAT BIOL, V90, P636, DOI 10.3109/09553002.2014.916841
   Qu AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090952
   Ruan K, 2009, J CELL BIOCHEM, V107, P1053, DOI 10.1002/jcb.22214
   Saito S, 2013, PLACENTA, V34, pS79, DOI 10.1016/j.placenta.2012.11.026
   Sannigrahi MK, 2015, ORAL DIS, V21, P283, DOI 10.1111/odi.12254
   Semenza GL, 2007, CANCER METAST REV, V26, P223, DOI 10.1007/s10555-007-9058-y
   Wang J, 2014, J BIOL CHEM, V289, P17163, DOI 10.1074/jbc.M114.558288
   Wei YJ, 2008, AUTOPHAGY, V4, P949, DOI 10.4161/auto.6788
   Wu SY, 2014, FRONT BIOSCI-LANDMRK, V19, P490, DOI 10.2741/4220
   Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200
   Zhou FF, 2011, FEBS J, V278, P403, DOI 10.1111/j.1742-4658.2010.07965.x
NR 43
TC 69
Z9 74
U1 2
U2 24
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD FEB
PY 2015
VL 46
IS 2
BP 750
EP 756
DI 10.3892/ijo.2014.2745
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AY6IX
UT WOS:000347671200035
PM 25385144
OA Bronze
DA 2022-04-25
ER

PT J
AU Ji, YC
   Liu, C
   Zhang, X
   Zhang, CS
   Wang, D
   Zhang, Y
AF Ji, Yan-Chao
   Liu, Chang
   Zhang, Xia
   Zhang, Cheng-Sen
   Wang, Dong
   Zhang, Yan
TI Intestinal bacterium-derived cyp27a1 prevents colon cancer cell
   apoptosis
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Colon cancer; vitamin D; Cyp27a1; apoptosis
ID INNATE LYMPHOID-CELLS; INDUCE APOPTOSIS; COLORECTAL-CANCER;
   PROSTATE-CANCER; VITAMIN-D; AUTOPHAGY; PROGRESSION; MECHANISMS;
   PROTECTS; SURVIVAL
AB The pathogenesis of metastasis of colon cancer (Cca) is to be further investigated. The dysfunction of apoptotic mechanism plays a role in the cancer cell over growth. This study tests a hypothesis by which intestinal bacterium-derived cyp27a1 prevents apoptosis in colon cancer cells. In this study, the levels of cyp27a1 in human stool samples were assessed by enzyme-linked immunosorbent assay. The apoptosis of Cca cells was observed by flow cytometry. The expression of cyp27a1 was assessed by real time RT-PCR and Western blotting. We observed higher levels of cyp27a1 in the stool samples of Cca patients than that from healthy subjects. Cca colon epithelial biopsy contained high levels of cyp27a1 protein, but not the cyp27a1 mRNA. Cyp27a1 prevented Cca cell apoptosis induced by vitamin D3. In conclusion, intestinal bacterium-derived cyp27a1 facilitates Cca survival by inhibiting Cca cell apoptosis.
C1 [Ji, Yan-Chao; Liu, Chang; Zhang, Xia; Zhang, Cheng-Sen; Wang, Dong; Zhang, Yan] Harbin Med Univ, Affiliated Hosp 4, Dept Gen Surg, 37 Yiyuan St, Harbin 150001, Peoples R China.
RP Liu, C (corresponding author), Harbin Med Univ, Affiliated Hosp 4, Dept Gen Surg, 37 Yiyuan St, Harbin 150001, Peoples R China.
EM changrrliu@sina.com
FU Natural Science Foundation of Heilongjiang ProvinceNatural Science
   Foundation of Heilongjiang Province [H201384]; Harbin medical university
   scientific research innovation fund [2016LCZX26]; Heilongjiang
   provincial health and Family Planning Commission research subject
   [2016128]
FX This study was supported by grants of Natural Science Foundation of
   Heilongjiang Province (H201384); Harbin medical university scientific
   research innovation fund (2016LCZX26) and Heilongjiang provincial health
   and Family Planning Commission research subject (2016128).
CR Adler J, 2015, AM J GASTROENTEROL, V110, P1657, DOI 10.1038/ajg.2015.365
   Ahmed K, 2015, APOPTOSIS, V20, P1411, DOI 10.1007/s10495-015-1168-3
   Banks M, 2015, ANTICANCER RES, V35, P3773
   Ben-Eltriki M, 2016, J STEROID BIOCHEM, V158, P207, DOI 10.1016/j.jsbmb.2015.12.002
   Brzozowa M, 2015, WSPOLCZESNA ONKOL, V19, P265, DOI 10.5114/wo.2014.42173
   Buchheit CL, 2014, NAT REV CANCER, V14, P632, DOI 10.1038/nrc3789
   Chen JF, 2016, AM J TRANSL RES, V8, P2169
   Chu KF, 2014, NAT REV CANCER, V14, P199, DOI 10.1038/nrc3672
   Cotter TG, 2009, NAT REV CANCER, V9, P501, DOI 10.1038/nrc2663
   Di Sabatino A, 2015, AUTOIMMUN REV, V14, P1161, DOI 10.1016/j.autrev.2015.08.004
   Diesing D, 2006, ANTICANCER RES, V26, P2755
   Feldman D, 2014, NAT REV CANCER, V14, P342, DOI 10.1038/nrc3691
   Goc J, 2016, INT IMMUNOL, V28, P43, DOI 10.1093/intimm/dxv056
   Gong X, 2016, AM J TRANSL RES, V8, P2127
   Guo XH, 2015, J CLIN INVEST, V125, P3430, DOI 10.1172/JCI83823
   Janknecht R, 2010, AM J TRANSL RES, V2, P223
   Jones G, 2014, J LIPID RES, V55, P13, DOI 10.1194/jlr.R031534
   Kalady MF, 2015, CLIN COLON RECT SURG, V28, P205, DOI 10.1055/s-0035-1564432
   Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485
   Ma YY, 2016, VITAM HORM, V100, P395, DOI 10.1016/bs.vh.2015.11.003
   Marignol L, 2013, NAT REV UROL, V10, P405, DOI 10.1038/nrurol.2013.110
   Roos WP, 2016, NAT REV CANCER, V16, P20, DOI 10.1038/nrc.2015.2
   Russo E, 2016, THER ADV GASTROENTER, V9, P594, DOI 10.1177/1756283X16635082
   Sharma K, 2014, INT J MOL SCI, V15, P10034, DOI 10.3390/ijms150610034
   Shen C, 2015, APOPTOSIS, V20, P1176, DOI 10.1007/s10495-015-1146-9
   Steele SR, 2015, DIS COLON RECTUM, V58, P713, DOI 10.1097/DCR.0000000000000410
   Szymczak I, 2016, SCAND J IMMUNOL, V83, P83, DOI 10.1111/sji.12403
   Wang XM, 2015, GUT MICROBES, V6, P370, DOI 10.1080/19490976.2015.1103426
   Wierzbicka JM, 2015, INT J ONCOL, V47, P1084, DOI 10.3892/ijo.2015.3088
   Zhang S, 2016, AM J TRANSL RES, V8, P354
NR 30
TC 3
Z9 3
U1 0
U2 5
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2016
VL 8
IS 10
BP 4434
EP 4439
PG 6
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA EB8OI
UT WOS:000387650100040
PM 27830027
DA 2022-04-25
ER

PT J
AU Dai, CP
   Zhang, XN
   Xie, D
   Tang, PP
   Li, CM
   Zuo, Y
   Jiang, BF
   Xue, CP
AF Dai, Cuiping
   Zhang, Xuning
   Xie, Da
   Tang, Peipei
   Li, Chunmei
   Zuo, Yi
   Jiang, Baofei
   Xue, Caiping
TI Targeting PP2A activates AMPK signaling to inhibit colorectal cancer
   cells
SO ONCOTARGET
LA English
DT Article
DE protein phosphatase 2A (PP2A); LB-100; colorectal cancer (CRC);
   AMP-activated protein kinase (AMPK) and mTOR
ID PROTEIN PHOSPHATASE 2A; CARCINOMA CELLS; NONCODING RNA; GROWTH; KINASE;
   MTOR; PHOSPHORYLATION; AUTOPHAGY; PATHWAY; APOPTOSIS
AB LB-100 is a novel PP2A inhibitor. Its activity in human colorectal cancer (CRC) cells was tested. The in vitro studies demonstrated that LB-100 inhibited survival and proliferation of both established CRC cells (HCT-116 and HT-29 lines) and primary human colon cancer cells. Further, LB-100 activated apoptosis and induced G1-S cell cycle arrest in CRC cells. LB-100 inhibited PP2A activity and activated AMPK signaling in CRC cells. AMPKa1 dominant negative mutation, shRNA-mediated knockdown or complete knockout (by CRISPR/Cas9 method) largely attenuated LB-100-induced AMPK activation and HCT-116 cytotoxicity. Notably, microRNA-17-92-mediated silence of PP2A (regulatory B subunit) also activated AMPK and induced HCT-116 cell death. Such effects were again largely attenuated by AMPKa mutation, silence or complete knockout. In vivo studies showed that intraperitoneal injection of LB-100 inhibited HCT-116 xenograft growth in nude mice. Its anti-tumor activity was largely compromised against HCT-116 tumors-derived from AMPKa1-knockout cells. We conclude that targeting PP2A by LB-100 and microRNA-17-92 activates AMPK signaling to inhibit CRC cells.
C1 [Dai, Cuiping] Jiangsu Food & Pharmaceut Sci Coll, Fac Hlth, Huaian, Peoples R China.
   [Zhang, Xuning; Tang, Peipei; Li, Chunmei; Xue, Caiping] Jiangsu Coll Nursing, Huaian Key Lab Gastrointestinal Canc, Huaian, Peoples R China.
   [Xie, Da] Nanjing Med Univ, Affiliated Hosp 2, Oncol Dept, Nanjing, Jiangsu, Peoples R China.
   [Zuo, Yi] Nantong Univ, Dept Med, Xinglin Coll, Nantong, Peoples R China.
   [Jiang, Baofei] First Peoples Hosp Huaian City, Gastrointestinal Surg, Huaian, Peoples R China.
RP Xue, CP (corresponding author), Jiangsu Coll Nursing, Huaian Key Lab Gastrointestinal Canc, Huaian, Peoples R China.; Jiang, BF (corresponding author), First Peoples Hosp Huaian City, Gastrointestinal Surg, Huaian, Peoples R China.
EM slhjliangcq@163.com; xuecplwtg@163.com
FU "533 Talents Project" of Huaian City; Medical Technology Development
   Project of Health Department of Jiangsu Province [J200912]; Social
   Development Fund of Technology Project, in Huaian City, Jiangsu
   Province, China [HAS2009002-3]; Science and Technology Development
   Project, in Huaian City, Jiangsu Province, China [HAS2009002-3,
   HAS201605]
FX This study was supported in part by the "533 Talents Project" research
   project in 2011 of Huaian City (Hygiene category 78), by the Medical
   Technology Development Project of Health Department of Jiangsu Province
   (J200912), by the Social Development Fund of Technology Project, in
   Huaian City, Jiangsu Province, China (HAS2009002-3) and by the Science
   and Technology Development Project, in Huaian City, Jiangsu Province,
   China (HAS201605 and HAS2009002-3).
CR Bai XL, 2014, MOL CANCER THER, V13, P2062, DOI 10.1158/1535-7163.MCT-13-0800
   Bai XL, 2014, CANCER LETT, V355, P281, DOI 10.1016/j.canlet.2014.09.048
   Chang KE, 2015, MOL CANCER THER, V14, P90, DOI 10.1158/1535-7163.MCT-14-0496
   Chen GQ, 2015, ONCOTARGET, V6, P24148, DOI 10.18632/oncotarget.4376
   Chen MB, 2017, ONCOTARGET, V8, P31288, DOI 10.18632/oncotarget.16126
   Chen MB, 2015, CARCINOGENESIS, V36, P1061, DOI 10.1093/carcin/bgv094
   Chen MB, 2014, CELL SIGNAL, V26, P102, DOI 10.1016/j.cellsig.2013.07.017
   Chen MB, 2013, CELL SIGNAL, V25, P1993, DOI 10.1016/j.cellsig.2013.05.026
   Chung V, 2017, CLIN CANCER RES, V23, P3277, DOI 10.1158/1078-0432.CCR-16-2299
   Cunningham CE, 2016, ONCOTARGET, V7, P61544, DOI 10.18632/oncotarget.11399
   Dal Bo M, 2015, ONCOTARGET, V6, P19381
   Deepa SS, 2011, MOL ENDOCRINOL, V25, P1773, DOI 10.1210/me.2011-0082
   Din FVN, 2012, GASTROENTEROLOGY, V142, P1504, DOI 10.1053/j.gastro.2012.02.050
   Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005
   Faubert B, 2015, CANCER LETT, V356, P165, DOI 10.1016/j.canlet.2014.01.018
   Francipane MG, 2014, ONCOTARGET, V5, P49, DOI 10.18632/oncotarget.1548
   Fu QH, 2016, TUMOR BIOL, V37, P7277, DOI 10.1007/s13277-015-4560-2
   Garcia D, 2017, MOL CELL, V66, P789, DOI 10.1016/j.molcel.2017.05.032
   Gong YQ, 2016, ONCOTARGET, V7, P60123, DOI 10.18632/oncotarget.11164
   Gordon IK, 2015, MOL CANCER THER, V14, P1540, DOI 10.1158/1535-7163.MCT-14-0614
   Guo SG, 2017, BIOCHEM BIOPH RES CO, V487, P660, DOI 10.1016/j.bbrc.2017.04.111
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Hardie DG, 2008, MOL CELL, V30, P263, DOI 10.1016/j.molcel.2008.04.012
   Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249
   Hardie DG, 2016, TRENDS CELL BIOL, V26, P190, DOI 10.1016/j.tcb.2015.10.013
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055
   Jablonska E, 2017, EXP HEMATOL, V46, P56, DOI 10.1016/j.exphem.2016.09.011
   Jensen TE, 2007, AM J PHYSIOL-ENDOC M, V292, pE1308, DOI 10.1152/ajpendo.00456.2006
   Jo DH, 2014, ONCOTARGET, V5, P11513, DOI 10.18632/oncotarget.2546
   Jonas S, 2015, NAT REV GENET, V16, P421, DOI 10.1038/nrg3965
   Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027
   Kang MR, 2012, ONCOL REP, V27, P1407, DOI 10.3892/or.2012.1644
   Kaur A, 2016, BIOCHEM SOC T, V44, P1683, DOI 10.1042/BST20160161
   Khanna A, 2013, CANCER RES, V73, P6548, DOI 10.1158/0008-5472.CAN-13-1994
   Kim J, 2013, CELL, V152, P290, DOI 10.1016/j.cell.2012.12.016
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kuipers EJ, 2013, NAT REV CLIN ONCOL, V10, P130, DOI 10.1038/nrclinonc.2013.12
   Lai TY, 2016, ONCOTARGET, V7, P4542, DOI 10.18632/oncotarget.6609
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Lee M, 2003, J BIOL CHEM, V278, P39653, DOI 10.1074/jbc.M306104200
   Li C, 2015, CANCER BIOL THER, V16, P34, DOI 10.4161/15384047.2014.972274
   Li JP, 2016, ONCOTARGET, V7, P77815, DOI 10.18632/oncotarget.12802
   Li KR, 2016, SCI REP-UK, V6, DOI 10.1038/srep25525
   Li Z, 2016, ONCOTARGET
   Lu PH, 2016, ONCOTARGET, V7, P45889, DOI 10.18632/oncotarget.9969
   Lu XS, 2017, ONCOTARGET, V8, P988, DOI 10.18632/oncotarget.13519
   McCarthy N, 2013, NAT REV CANCER, V13, P297, DOI [10.1038/nrc3509, 10.1038/nrc3909]
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   O'Neill LAJ, 2013, NATURE, V493, P346, DOI 10.1038/nature11862
   Pandurangan AK, 2013, ASIAN PAC J CANCER P, V14, P2201, DOI 10.7314/APJCP.2013.14.4.2201
   Pasquinelli AE, 2012, NAT REV GENET, V13, P271, DOI 10.1038/nrg3162
   Perera ND, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090449
   Pineda CT, 2015, AUTOPHAGY, V11, P844, DOI 10.1080/15548627.2015.1034420
   Plews RL, 2015, J CLIN ENDOCR METAB, V100, pE748, DOI 10.1210/jc.2014-1777
   Qin LS, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0174-1
   Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100
   Sujobert P, 2015, CELL REP, V11, P1446, DOI 10.1016/j.celrep.2015.04.063
   Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20
   Vogelsberg-Ragaglia V, 2001, EXP NEUROL, V168, P402, DOI 10.1006/exnr.2001.7630
   Wang L, 2016, ONCOTARGET, V7, P51713, DOI 10.18632/oncotarget.10563
   Wu L, 2015, BIOCHEM BIOPH RES CO, V466, P547, DOI 10.1016/j.bbrc.2015.09.068
   Wu Y, 2007, J BIOL CHEM, V282, P9777, DOI 10.1074/jbc.M608310200
   Zhang WF, 2015, ONCOTARGET, V6, P5253, DOI 10.18632/oncotarget.2867
   Zhao Z, 2017, ONCOTARGET, V8, P18312, DOI 10.18632/oncotarget.15436
   Zhijun H, 2016, TUMOUR BIOL
NR 69
TC 21
Z9 22
U1 0
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD NOV 10
PY 2017
VL 8
IS 56
BP 95810
EP 95823
DI 10.18632/oncotarget.21336
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FM3VP
UT WOS:000414937900062
PM 29221169
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Li, DD
   Sun, T
   Wu, XQ
   Chen, SP
   Deng, R
   Jiang, S
   Feng, GK
   Pan, JX
   Zhang, XS
   Zeng, YX
   Zhu, XF
AF Li, Dan-Dan
   Sun, Ting
   Wu, Xiao-Qi
   Chen, Shu-Peng
   Deng, Rong
   Jiang, Shan
   Feng, Gong-Kan
   Pan, Jing-Xuan
   Zhang, Xiao-Shi
   Zeng, Yi-Xin
   Zhu, Xiao-Feng
TI The Inhibition of Autophagy Sensitises Colon Cancer Cells with Wild-Type
   p53 but Not Mutant p53 to Topotecan Treatment
SO PLOS ONE
LA English
DT Article
ID ACTIVATED PROTEIN-KINASE; DEATH; MECHANISM; APOPTOSIS; SESTRIN2;
   DISEASE; STRESS; PHOSPHORYLATION; UPSTREAM; PATHWAYS
AB Background: Topotecan produces DNA damage that induces autophagy in cancer cells. In this study, sensitising topotecan to colon cancer cells with different P53 status via modulation of autophagy was examined.
   Methodology/Principal Findings: The DNA damage induced by topotecan treatment resulted in cytoprotective autophagy in colon cancer cells with wild-type p53. However, in cells with mutant p53 or p53 knockout, treatment with topotecan induced autophagy-associated cell death. In wild-type p53 colon cancer cells, topotecan treatment activated p53, upregulated the expression of sestrin 2, induced the phosphorylation of the AMPKa subunit at Thr172, and inhibited the mTORC1 pathway. Furthermore, the inhibition of autophagy enhanced the anti-tumour effect of topotecan treatment in wild-type p53 colon cancer cells but alleviated the anti-tumour effect of topotecan treatment in p53 knockout cells in vivo.
   Conclusions/Significance: These results imply that the wild-type p53-dependent induction of cytoprotective autophagy is one of the cellular responses that determines the cellular sensitivity to the DNA-damaging drug topotecan. Therefore, our study provides a potential therapeutic strategy that utilises a combination of DNA-damaging agents and autophagy inhibitors for the treatment of colon cancer with wild-type p53.
C1 [Li, Dan-Dan; Sun, Ting; Wu, Xiao-Qi; Chen, Shu-Peng; Deng, Rong; Jiang, Shan; Feng, Gong-Kan; Zhang, Xiao-Shi; Zeng, Yi-Xin; Zhu, Xiao-Feng] Sun Yat Sen Univ, State Key Lab Oncol S China, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China.
   [Pan, Jing-Xuan] Sun Yat Sen Univ, Dept Pathophysiol, Zhongshan Sch Med, Guangzhou 510275, Guangdong, Peoples R China.
RP Li, DD (corresponding author), Sun Yat Sen Univ, State Key Lab Oncol S China, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China.
EM zhuxfeng@mail.sysu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [30873085, 30972882, 81101670]; Major Science
   and Technology Project of the National Basic Research Program (973
   Program) of ChinaNational Basic Research Program of China
   [2011CB504300]; Natural Science Foundation of Guangdong in China
   [S2011020002759]
FX This work was supported by grants from the National Natural Science
   Foundation of China (30873085, 30972882, 81101670)
   (http://www.nsfc.gov.cn/Portal0/default106.htm), the Major Science and
   Technology Project of the National Basic Research Program (973 Program)
   of China (2011CB504300) and the Natural Science Foundation of Guangdong
   in China (S2011020002759). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Bareford MD, 2011, CANCER RES, V71, P4955, DOI 10.1158/0008-5472.CAN-11-0898
   Bialik S, 2008, ADV EXP MED BIOL, V615, P177, DOI 10.1007/978-1-4020-6554-5_9
   Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028
   Crighton D, 2007, AUTOPHAGY, V3, P72, DOI 10.4161/auto.3438
   D'Amelio M, 2009, CELL CYCLE, V8, P1467
   Facompre M, 2002, MOL PHARMACOL, V62, P1215, DOI 10.1124/mol.62.5.1215
   Florey O, 2011, NAT CELL BIOL
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Grander D, 2010, FUTURE MED CHEM, V2, P285, DOI 10.4155/FMC.09.155
   Green DR, 2011, SCIENCE, V333, P1109, DOI 10.1126/science.1201940
   Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009
   Herrero-Martin G, 2009, EMBO J, V28, P677, DOI 10.1038/emboj.2009.8
   Hoyer-Hansen M, 2007, AUTOPHAGY, V3, P381, DOI 10.4161/auto.4240
   Jiang H, 2007, J NATL CANCER I, V99, P1410, DOI 10.1093/jnci/djm102
   Kim HS, 2008, J BIOL CHEM, V283, P3731, DOI 10.1074/jbc.M704432200
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li DD, 2009, ONCOGENE, V28, P886, DOI 10.1038/onc.2008.441
   Li DD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012176
   Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537
   Liu B, 2010, ACTA PHARMACOL SIN, V31, P1154, DOI 10.1038/aps.2010.118
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Maiuri MC, 2009, CELL CYCLE, V8, P1571, DOI 10.4161/cc.8.10.8498
   Marino ML, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.67
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Mizushima N, 2005, CELL DEATH DIFFER, V12, P1535, DOI 10.1038/sj.cdd.4401728
   Mujumdar N, 2010, AUTOPHAGY, V6, P997, DOI 10.4161/auto.6.7.13334
   Murray-Zmijewski F, 2008, NAT REV MOL CELL BIO, V9, P702, DOI 10.1038/nrm2451
   Nakatogawa H, 2007, CELL, V130, P165, DOI 10.1016/j.cell.2007.05.021
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Sanchez AM, 2011, J CELL BIOCH
   Scherz-Shouval R, P NATL ACAD SCI US, V107, P18511
   Staker BL, 2002, P NATL ACAD SCI USA, V99, P15387, DOI 10.1073/pnas.242259599
   Szigeti A, 2010, J BIOL CHEM, V285, P2140, DOI 10.1074/jbc.M109.015222
   Tang Y, 2012, MOL PHARM
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Todde V, 2009, BBA-MOL BASIS DIS, V1792, P3, DOI 10.1016/j.bbadis.2008.10.016
   Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147
   White EJ, 2011, AM J CANCER RES, V1, P362
   Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005
   Wu JX, 2006, BIOCHEM BIOPH RES CO, V339, P437, DOI 10.1016/j.bbrc.2005.10.211
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Zhou WJ, 2009, MOL CANCER THER, V8, P3203, DOI 10.1158/1535-7163.MCT-09-0244
NR 50
TC 51
Z9 51
U1 3
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 14
PY 2012
VL 7
IS 9
AR e45058
DI 10.1371/journal.pone.0045058
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 007AD
UT WOS:000308860100050
PM 23024792
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Arisan, ED
   Akkoc, Y
   Akyuz, KG
   Kerman, EM
   Obakan, P
   Coker-Gurkan, A
   Unsal, NP
AF Arisan, Elif Damla
   Akkoc, Yunus
   Akyuz, Kaan Gencer
   Kerman, Ezgi Melek
   Obakan, Pinar
   Coker-Gurkan, Ajda
   Unsal, Narcin Palavan
TI Polyamines modulate the roscovitine-induced cell death switch decision
   autophagy vs. apoptosis in MCF-7 and MDA-MB-231 breast cancer cells
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE breast cancer; polyamines; roscovitine; apoptosis; autophagy
ID LYMPHOCYTIC-LEUKEMIA CELLS; COLON-CARCINOMA-CELLS; LIFE-SPAN EXTENSION;
   ORNITHINE-DECARBOXYLASE; CDK INHIBITORS; HISTONE ACETYLTRANSFERASE;
   THERAPEUTIC TARGET; SELICICLIB CYC202; R-ROSCOVITINE; CYCLE ARREST
AB Current clinical strategies against breast cancer mainly involve the use of anti-hormonal agents to decrease estrogen production; however, development of resistance is a major problem. The resistance phenotype depends on the modulation of cell-cycle regulatory proteins, cyclins and cyclin-dependent kinases. Roscovitine, a selective inhibitor of cyclin-dependent kinases, shows high therapeutic potential by causing cell-cycle arrest in various cancer types. Autophagy is a type of cell death characterized by the enzymatic degradation of macromolecules and organelles in double- or multi-membrane autophagic vesicles. This process has important physiological functions, including the degradation of misfolded proteins and organelle turnover. Recently, the switch between autophagy and apoptosis has been proposed to constitute an important regulator of cell death in response to chemotherapeutic drugs. The process is regulated by several proteins, such as the proteins of the Atg family, essential for the initial formation of the autophagosome, and PI3K, important at the early stages of autophagic vesicle formation. Polyamines (PAs) are small aliphatic amines that play major roles in a number of eukaryotic processes, including cell proliferation. The PA levels are regulated by ornithine decarboxylase (ODC), the rate-limiting enzyme in PA biosynthesis. In this study, we aimed to investigate the role of PAs in roscovitine-induced autophagic/apoptotic cell death in estrogen receptor-positive MCF-7 and estrogen receptor-negative MDA-MB-231 breast cancer cells. We show that MDA-MB-231 cells are more resistant to roscovitine than MCF-7 cells. This difference was related to the regulation of autophagic key molecules in MDA-MB-231 cells. In addition, we found that exogenous PAs have a role in the cell death decision between roscovitine-induced apoptosis or autophagy in MCF-7 and MDA-MB-231 breast cancer cells.
C1 [Arisan, Elif Damla; Akkoc, Yunus; Akyuz, Kaan Gencer; Kerman, Ezgi Melek; Obakan, Pinar; Coker-Gurkan, Ajda; Unsal, Narcin Palavan] Istanbul Kultur Univ, Dept Mol Biol & Genet, TR-34156 Istanbul, Turkey.
RP Arisan, ED (corresponding author), Istanbul Kultur Univ, Dept Mol Biol & Genet, Atakoy Campus,E5 Highway Bakirkoy, TR-34156 Istanbul, Turkey.
EM d.arisan@iku.edu.tr
RI Arisan, Elif Damla/W-8682-2019; Arisan, ElifDamla/AAB-1173-2021; AKKOC,
   Yunus/AAK-8853-2020; OBAKAN, PINAR/D-2836-2015
OI Arisan, Elif Damla/0000-0002-4844-6381; AKKOC,
   Yunus/0000-0001-5379-6151; Gurkan, Ajda/0000-0003-1475-2417
CR Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039
   Al-Minawi AZ, 2008, NUCLEIC ACIDS RES, V36, P1, DOI 10.1093/nar/gkm888
   Aldoss IT, 2009, EXPERT OPIN INV DRUG, V18, P1957, DOI 10.1517/13543780903418445
   Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Appleyard MVCL, 2009, INT J CANCER, V124, P465, DOI 10.1002/ijc.23938
   Arisan ED, 2012, AMINO ACIDS, V42, P655, DOI 10.1007/s00726-011-1040-x
   BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804
   Benson C, 2007, BRIT J CANCER, V96, P29, DOI 10.1038/sj.bjc.6603509
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Buzdar AU, 1998, CLIN CANCER RES, V4, P527
   Canizares F, 1999, CLIN CANCER RES, V5, P2035
   Casero RA, 2007, NAT REV DRUG DISCOV, V6, P373, DOI 10.1038/nrd2243
   CELANO P, 1988, J BIOL CHEM, V263, P5491
   CHAROLLAIS RH, 1988, J CELL PHYSIOL, V137, P559, DOI 10.1002/jcp.1041370323
   Cheng Y, 2008, ARCH BIOCHEM BIOPHYS, V475, P148, DOI 10.1016/j.abb.2008.04.027
   Decker T, 2004, BRIT J HAEMATOL, V125, P141, DOI 10.1111/j.1365-2141.2004.04901.x
   Deng WS, 2008, ACTA BIOCH BIOPH SIN, V40, P235, DOI 10.1111/j.1745-7270.2008.00397.x
   Eisenberg T, 2009, NAT CELL BIOL, V11, P1305, DOI 10.1038/ncb1975
   Fischer PM, 2003, EXPERT OPIN INV DRUG, V12, P955, DOI 10.1517/eoid.12.6.955.21792
   Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1
   Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320
   Hahntow IN, 2004, LEUKEMIA, V18, P747, DOI 10.1038/sj.leu.2403295
   HARADA JJ, 1981, MOL CELL BIOL, V1, P594, DOI 10.1128/MCB.1.7.594
   Hobbs CA, 2000, J CELL BIOCHEM, V77, P345, DOI 10.1002/(SICI)1097-4644(20000601)77:3<345::AID-JCB1>3.3.CO;2-G
   Hobbs CA, 2002, CANCER RES, V62, P67
   HOGGARD N, 1986, MOL CELL ENDOCRINOL, V46, P71, DOI 10.1016/0303-7207(86)90071-7
   Hunt T, 2008, CELL CYCLE, V7, P3789, DOI 10.4161/cc.7.24.7515
   JAIYESIMI IA, 1995, J CLIN ONCOL, V13, P513, DOI 10.1200/JCO.1995.13.2.513
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Jia KL, 2007, AUTOPHAGY, V3, P597, DOI 10.4161/auto.4989
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Lambert LA, 2008, CANCER RES, V68, P7966, DOI 10.1158/0008-5472.CAN-08-1333
   LERNER LJ, 1990, CANCER RES, V50, P4177
   Liu B, 2010, BIOCHIMIE, V92, P1934, DOI 10.1016/j.biochi.2010.08.009
   Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522
   Madeo F, 2010, AUTOPHAGY, V6, P160, DOI 10.4161/auto.6.1.10600
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Manni A, 2002, IN VIVO, V16, P493
   Marra M, 2008, BBA-MOL CELL RES, V1783, P2269, DOI 10.1016/j.bbamcr.2008.09.002
   Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x
   Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782
   Moffatt J, 2000, CARCINOGENESIS, V21, P2151, DOI 10.1093/carcin/21.12.2151
   Nair BC, 2008, GENE THER MOL BIOL, V12B, P395
   Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x
   PEGG AE, 1988, CANCER RES, V48, P759
   PERSSON L, 1989, CANCER LETT, V45, P83, DOI 10.1016/0304-3835(89)90140-7
   Ringer L, 2010, CANCER BIOL THER, V10, P320, DOI 10.4161/cbt.10.4.12208
   Rogatsky I, 1999, J BIOL CHEM, V274, P22296, DOI 10.1074/jbc.274.32.22296
   Stefanelli C, 2000, BIOCHEM J, V347, P875, DOI 10.1042/0264-6021:3470875
   Stefanelli C, 1998, FEBS LETT, V437, P233, DOI 10.1016/S0014-5793(98)01239-3
   Sutherland RL, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2454
   Tavernarakis N, 2008, AUTOPHAGY, V4, P870, DOI 10.4161/auto.6730
   Tian ZY, 2009, ORG BIOMOL CHEM, V7, P4651, DOI 10.1039/b912685f
   Trowbridge JM, 1997, P NATL ACAD SCI USA, V94, P10132, DOI 10.1073/pnas.94.19.10132
   Wang YL, 2006, J BIOCHEM, V139, P17, DOI 10.1093/jb/mvj021
   Wesierska-Gadek J, 2005, MOL CANCER THER, V4, P113
   Wesierska-Gadek J, 2008, J CELL BIOCHEM, V105, P1161, DOI 10.1002/jcb.21903
   Wesierska-Gqdek J, 2004, POL J PHARMACOL, V56, P635
   Wojciechowski J, 2003, INT J CANCER, V106, P486, DOI 10.1002/ijc.11290
   Xie XZ, 1997, EXP CELL RES, V230, P386, DOI 10.1006/excr.1996.3442
   Yenugonda VM, 2011, BIOORGAN MED CHEM, V19, P2714, DOI 10.1016/j.bmc.2011.02.052
   Zaletok S, 2004, EXP ONCOL, V26, P221
NR 63
TC 6
Z9 7
U1 0
U2 20
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD JUN
PY 2015
VL 11
IS 6
BP 4532
EP 4540
DI 10.3892/mmr.2015.3303
PG 9
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA CJ4ZL
UT WOS:000355497100076
PM 25650699
OA Bronze
DA 2022-04-25
ER

PT J
AU El Hasasna, H
   Athamneh, K
   Al Samri, H
   Karuvantevida, N
   Al Dhaheri, Y
   Hisaindee, S
   Ramadan, G
   Al Tamimi, N
   AbuQamar, S
   Eid, A
   Iratni, R
AF El Hasasna, Hussain
   Athamneh, Khawlah
   Al Samri, Halima
   Karuvantevida, Noushad
   Al Dhaheri, Yusra
   Hisaindee, Soleiman
   Ramadan, Gaber
   Al Tamimi, Nedaa
   AbuQamar, Synan
   Eid, Ali
   Iratni, Rabah
TI Rhus coriaria induces senescence and autophagic cell death in breast
   cancer cells through a mechanism involving p38 and ERK1/2 activation
SO SCIENTIFIC REPORTS
LA English
DT Article
ID COLON-CANCER; GROWTH ARREST; CYCLE ARREST; DNA-DAMAGE; APOPTOSIS;
   INDUCTION; L.; INHIBITION; THERAPY; G(1)
AB Here, we investigated the anticancer effect of Rhus coriaria on three breast cancer cell lines. We demonstrated that Rhus coriaria ethanolic extract (RCE) inhibits the proliferation of these cell lines in a time-and concentration-dependent manner. RCE induced senescence and cell cycle arrest at G1 phase. These changes were concomitant with upregulation of p21, downregulation of cyclin D1, p27, PCNA, c-myc, phospho-RB and expression of senescence-associated beta-galactosidase activity. No proliferative recovery was detected after RCE removal. Annexin V staining and PARP cleavage analysis revealed a minimal induction of apoptosis in MDA-MB-231 cells. Electron microscopy revealed the presence of autophagic vacuoles in RCE-treated cells. Interestingly, blocking autophagy by 3-methyladenine (3-MA) or chloroquine (CQ) reduced RCE-induced cell death and senescence. RCE was also found to activate p38 and ERK1/2 signaling pathways which coincided with induction of autophagy. Furthermore, we found that while both autophagy inhibitors abolished p38 phosphorylation, only CQ led to significant decrease in pERK1/2. Finally, RCE induced DNA damage and reduced mutant p53, two events that preceded autophagy. Our findings provide strong evidence that R. coriaria possesses strong anti-breast cancer activity through induction of senescence and autophagic cell death, making it a promising alternative or adjunct therapeutic candidate against breast cancer.
C1 [El Hasasna, Hussain; Athamneh, Khawlah; Al Samri, Halima; Karuvantevida, Noushad; Al Dhaheri, Yusra; Ramadan, Gaber; Al Tamimi, Nedaa; AbuQamar, Synan; Iratni, Rabah] United Arab Emirates Univ, Coll Sci, Dept Biol, Al Ain, U Arab Emirates.
   [Hisaindee, Soleiman] United Arab Emirates Univ, Coll Sci, Dept Chem, Al Ain, U Arab Emirates.
   [Eid, Ali] Qatar Univ, Dept Biol & Environm Sci, Coll Arts & Sci, Doha, Qatar.
RP Eid, A (corresponding author), Qatar Univ, Dept Biol & Environm Sci, Coll Arts & Sci, POB 2713, Doha, Qatar.
EM ali.eid@qu.edu.qa; R_iratni@uaeu.ac.ae
RI AbuQamar, Synan/AAV-1229-2021; Eid, Ali Hussein/ABD-6291-2021;
   Hisaindee, Soleiman/AAK-4862-2020
OI AbuQamar, Synan/0000-0002-2129-7689; Eid, Ali
   Hussein/0000-0003-3004-5675; Hisaindee, Soleiman/0000-0003-0084-8362;
   Karuvantevida, Noushad/0000-0002-9836-0316
FU UAEU Program for Advanced Research [31S111-UPAR]; Zayed Center for
   Health Sciences (ZCHS) [31R021]; College of Science Individual Research
   Grant [31S123]
FX This work was supported by UAEU Program for Advanced Research (Grant
   31S111-UPAR) and by the Zayed Center for Health Sciences (ZCHS) research
   grant (grant 31R021) and College of Science Individual Research Grant
   (grant 31S123) to Rabah Iratni. We are thankful to Mr. Tariq Saeed, from
   the college of Medicine and health science, UAEU, for his precious
   technical help in electron microscopy. We also are thankful to Ms. Asma
   Al Rashedi for proofreading this manuscript.
CR Abu-Reidah IM, 2015, FOOD CHEM, V166, P179, DOI 10.1016/j.foodchem.2014.06.011
   Abu-Shanab B., 2005, J ISLAMIC U GAZA, V13, P147
   Aiyer HS, 2012, J AGR FOOD CHEM, V60, P5693, DOI 10.1021/jf204084f
   Al Dhaheri Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109630
   Al Dhaheri Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056649
   Al Dhaheri Y, 2013, BBA-GEN SUBJECTS, V1830, P3121, DOI 10.1016/j.bbagen.2013.01.010
   Anwer T, 2013, ACTA POL PHARM, V70, P861
   Bhui K, 2010, BIOFACTORS, V36, P474, DOI 10.1002/biof.121
   Bossi G, 2006, ONCOGENE, V25, P304, DOI 10.1038/sj.onc.1209026
   Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233
   Chakraborty A, 2009, MUTAT RES-FUND MOL M, V661, P10, DOI 10.1016/j.mrfmmm.2008.10.009
   Choi CH, 2010, MOL PHARMACOL, V78, P114, DOI 10.1124/mol.110.063495
   Corcelle E, 2007, AUTOPHAGY, V3, P57, DOI 10.4161/auto.3424
   Dang CV, 1999, MOL CELL BIOL, V19, P1
   Davis P. H., 1967, FLORA TURKEY AEGEAN, V2
   Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Ellington AA, 2006, CARCINOGENESIS, V27, P298, DOI 10.1093/carcin/bgi214
   Ewald JA, 2010, JNCI-J NATL CANCER I, V102, P1536, DOI 10.1093/jnci/djq364
   Fojo T, 2002, DRUG RESIST UPDATE, V5, P209, DOI 10.1016/S1368-7646(02)00119-X
   Fujiwara K, 2008, J BIOL CHEM, V283, P388, DOI 10.1074/jbc.M611043200
   Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200
   Javier AF, 1997, J CLIN INVEST, V99, P2094, DOI 10.1172/JCI119382
   Jiang Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.200
   Kaczirek K, 2004, J CLIN ENDOCR METAB, V89, P2397, DOI 10.1210/jc.2003-031314
   Kang KB, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-66
   Knizhnik AV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055665
   Kosar M, 2007, FOOD CHEM, V103, P952, DOI 10.1016/j.foodchem.2006.09.049
   Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610
   Larsson O, 2004, CANCER RES, V64, P482, DOI 10.1158/0008-5472.CAN-03-1872
   Lee J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075699
   Liao PC, 2010, J MED FOOD, V13, P1415, DOI 10.1089/jmf.2010.1126
   Mizushima N, 2010, NAT CELL BIOL, V12, P823, DOI 10.1038/ncb0910-823
   Mohammadi S, 2010, DARU, V18, P270
   MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022
   Nardella C, 2011, NAT REV CANCER, V11, P503, DOI 10.1038/nrc3057
   Nasar-Abbas SM, 2004, INT J FOOD MICROBIOL, V97, P63, DOI 10.1016/j.ijfoodmicro.2004.04.009
   Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s
   Panico A, 2009, J MED PLANTS RES, V3, P855
   Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640
   Pourahmad J, 2010, FOOD CHEM TOXICOL, V48, P854, DOI 10.1016/j.fct.2009.12.021
   Qi M, 2013, J PHARMACOL SCI, V121, P200, DOI 10.1254/jphs.12269FP
   Rayne S, 2007, PLANT FOOD HUM NUTR, V62, P165, DOI 10.1007/s11130-007-0058-4
   Reis-Filho JS, 2008, HISTOPATHOLOGY, V52, P108, DOI 10.1111/j.1365-2559.2007.02889.x
   Reuben SC, 2012, MOL NUTR FOOD RES, V56, P14, DOI 10.1002/mnfr.201100619
   Rikiishi Hidemi, 2012, Int J Cell Biol, V2012, P317645, DOI 10.1155/2012/317645
   Rodriguez-Rocha H, 2011, MUTAT RES-FUND MOL M, V711, P158, DOI 10.1016/j.mrfmmm.2011.03.007
   Romanov VS, 2010, CELL CYCLE, V9, P3945, DOI 10.4161/cc.9.19.13160
   Schwarze SR, 2001, ONCOGENE, V20, P8184, DOI 10.1038/sj.onc.1205049
   Selivanova G, 2001, Curr Opin Investig Drugs, V2, P1136
   Shabbir A, 2012, J ANIM PLANT SCI, V22, P505
   Sivaprasad U, 2008, J CELL MOL MED, V12, P1265, DOI 10.1111/j.1582-4934.2008.00282.x
   Sridharan Savitha, 2011, Cancers (Basel), V3, P2630, DOI 10.3390/cancers3022630
   Tan W, 2011, CHIN MED-UK, V6, DOI 10.1186/1749-8546-6-27
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   te Poele RH, 2002, CANCER RES, V62, P1876
   Thyagarajan A, 2010, NUTR CANCER, V62, P630, DOI 10.1080/01635580903532390
   Verdoodt B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044132
   Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675
   Wang XH, 1998, CANCER RES, V58, P5019
   Wang XT, 2011, J MED CHEM, V54, P809, DOI 10.1021/jm101199t
   Wong CH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009996
   Wu CH, 2007, P NATL ACAD SCI USA, V104, P13028, DOI 10.1073/pnas.0701953104
   Xue L, 2001, CURR BIOL, V11, P361, DOI 10.1016/S0960-9822(01)00100-2
   Yen A, 1998, EXP CELL RES, V241, P324, DOI 10.1006/excr.1998.4007
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
   Zargham Hanieh, 2008, Mcgill J Med, V11, P119
   Zhang X, 2012, CELL PROLIFERAT, V45, P466, DOI 10.1111/j.1365-2184.2012.00833.x
NR 68
TC 43
Z9 43
U1 0
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 12
PY 2015
VL 5
AR 13013
DI 10.1038/srep13013
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CO7TV
UT WOS:000359365700001
PM 26263881
OA gold, Green Submitted, Green Published
DA 2022-04-25
ER

PT J
AU Li, J
   Hou, N
   Faried, A
   Tsutsumi, S
   Kuwano, H
AF Li, Jie
   Hou, Ni
   Faried, Ahmad
   Tsutsumi, Soichi
   Kuwano, Hiroyuki
TI Inhibition of autophagy augments 5-fluorouracil chemotherapy in human
   colon cancer in vitro and in vivo model
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE Colon cancer cells; 5-FU; Autophagy; Apoptosis
ID PROGRAMMED CELL-DEATH; ADJUVANT THERAPY; INDUCED CYTOTOXICITY;
   APOPTOSIS; PATHWAY; TARGET; EXPRESSION; RAPAMYCIN; P53
AB Although 5-fluorouracil (5-FU)-based adjuvant chemotherapy is widely used in the treatment of colorectal cancer, novel therapeutic strategies need to be explored. It has been reported that autophagy is extensively implicated in cancer. However, the function of autophagy is not fully understood. In the present study, apoptosis induced by 5-FU in 3 human colon cancer cell lines (HCT116, DLD-1, and DLD-1/5-FU (a specific 5-FU-resistant sub-line)) was measured using MTT assay, DNA fragmentation assay, Hoechst 33342 staining, and caspase-3 immunoblotting. The autophagy activation induced by 5-FU treatment was revealed by microtubule-associated protein 1 light chain 3 (LC3) immunofluorescence and immunoblotting and p62 immunoblotting. Inhibition of autophagy by 3-methyladenine (3-MA) or small interference RNA targeting Atg7 (Atg7 siRNA) significantly augmented 5-FU-induced apoptosis. This synergistic effect of 5-FU and 3-MA was further confirmed in the DLD-1 xenograft tumour model. Tumour growth was suppressed more significantly with combination treatment than 5-FU treatment alone. In conclusion, autophagy was activated as a protective mechanism against 5-FU-induced apoptosis and its inhibition could be a promising strategy for adjuvant chemotherapy in colon cancer. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Li, Jie; Faried, Ahmad; Tsutsumi, Soichi; Kuwano, Hiroyuki] Gunma Univ, Dept Gen Surg Sci, Grad Sch Med, Maebashi, Gunma 3718511, Japan.
   [Hou, Ni] Gunma Univ, Dept Mol Med, Inst Mol & Cellular Regulat, Maebashi, Gunma 3718511, Japan.
   [Faried, Ahmad] Padjadjaran State Univ, Fac Med, Bandung, Indonesia.
RP Li, J (corresponding author), Gunma Univ, Dept Gen Surg Sci, Grad Sch Med, 3-39-22 Showa Machi, Maebashi, Gunma 3718511, Japan.
EM lijie@med.gunma-u.ac.jp
CR ABEDIN MJ, 2006, CELL DEATH DIFFER, V22, P1
   Albert JM, 2006, MOL CANCER THER, V5, P1183, DOI 10.1158/1535-7163.MCT-05-0400
   Bauvy C, 2001, EXP CELL RES, V268, P139, DOI 10.1006/excr.2001.5285
   BRATTAIN MG, 1981, CANCER RES, V41, P1751
   BUYSE M, 1988, JAMA-J AM MED ASSOC, V259, P3571
   Cao C, 2006, CANCER RES, V66, P10040, DOI 10.1158/0008-5472.CAN-06-0802
   Danila DC, 2008, ACTA ENDOCRINOL-BUCH, V4, P75, DOI 10.4183/aeb.2008.75
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Eisenberg-Lerner A, 2009, APOPTOSIS, V14, P376, DOI 10.1007/s10495-008-0307-5
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Herman-Antosiewicz A, 2006, CANCER RES, V66, P5828, DOI 10.1158/0008-5472.CAN-06-0139
   Hippert MM, 2006, CANCER RES, V66, P9349, DOI 10.1158/0008-5472.CAN-06-1597
   Hoyer-Hansen M, 2008, AUTOPHAGY, V4, P574, DOI 10.4161/auto.5921
   Ju J, 2007, CLIN CANCER RES, V13, P4245, DOI 10.1158/1078-0432.CCR-06-2890
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Kim EH, 2007, CANCER RES, V67, P6314, DOI 10.1158/0008-5472.CAN-06-4217
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Komatsu M, 2007, P NATL ACAD SCI USA, V104, P14489, DOI 10.1073/pnas.0701311104
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kondo Y, 2006, AUTOPHAGY, V2, P85, DOI 10.4161/auto.2.2.2463
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002
   Meley D, 2006, J BIOL CHEM, V281, P34870, DOI 10.1074/jbc.M605488200
   Ng G, 2005, MOL CARCINOGEN, V43, P183, DOI 10.1002/mc.20097
   O'Connell MJ, 2009, J CLIN ONCOL, V27, P3082, DOI 10.1200/JCO.2009.22.2919
   OConnell MJ, 1997, J CLIN ONCOL, V15, P246, DOI 10.1200/JCO.1997.15.1.246
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Qadir MA, 2008, BREAST CANCER RES TR, V112, P389, DOI 10.1007/s10549-007-9873-4
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Shingu T, 2009, INT J CANCER, V124, P1060, DOI 10.1002/ijc.24030
   Tolkovsky AM, 2002, BIOCHIMIE, V84, P233, DOI 10.1016/S0300-9084(02)01371-8
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Wolpin BM, 2008, GASTROENTEROLOGY, V134, P1296, DOI 10.1053/j.gastro.2008.02.098
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Yazawa S, 2002, GLYCOBIOLOGY, V12, P545, DOI 10.1093/glycob/cwf070
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
NR 37
TC 225
Z9 239
U1 3
U2 52
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
EI 1879-0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD JUL
PY 2010
VL 46
IS 10
BP 1900
EP 1909
DI 10.1016/j.ejca.2010.02.021
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 627JO
UT WOS:000280035500032
PM 20231086
DA 2022-04-25
ER

PT J
AU He, SS
   Zhao, Z
   Yang, YF
   O'Connell, D
   Zhang, XW
   Oh, S
   Ma, BY
   Lee, JH
   Zhang, T
   Varghese, B
   Yip, J
   Pirooz, SD
   Li, M
   Zhang, Y
   Li, GM
   Martin, SE
   Machida, K
   Liang, CY
AF He, Shanshan
   Zhao, Zhen
   Yang, Yongfei
   O'Connell, Douglas
   Zhang, Xiaowei
   Oh, Soohwan
   Ma, Binyun
   Lee, Joo-Hyung
   Zhang, Tian
   Varghese, Bino
   Yip, Janae
   Pirooz, Sara Dolatshahi
   Li, Ming
   Zhang, Yong
   Li, Guo-Min
   Martin, Sue Ellen
   Machida, Keigo
   Liang, Chengyu
TI Truncating mutation in the autophagy gene UVRAG confers oncogenic
   properties and chemosensitivity in colorectal cancers
SO NATURE COMMUNICATIONS
LA English
DT Article
ID MICROSATELLITE INSTABILITY; COLON-CANCER; CHROMOSOMAL INSTABILITY;
   GASTRIC-CANCER; TARGET GENES; CELL-GROWTH; IN-VITRO; TUMORIGENESIS;
   COMPLEX; PROTEIN
AB Autophagy-related factors are implicated in metabolic adaptation and cancer metastasis. However, the role of autophagy factors in cancer progression and their effect in treatment response remain largely elusive. Recent studies have shown that UVRAG, a key autophagic tumour suppressor, is mutated in common human cancers. Here we demonstrate that the cancer-related UVRAG frameshift (FS), which does not result in a null mutation, is expressed as a truncated UVRAGFS in colorectal cancer (CRC) with microsatellite instability (MSI), and promotes tumorigenesis. UVRAGFS abrogates the normal functions of UVRAG, including autophagy, in a dominant-negative manner. Furthermore, expression of UVRAGFS can trigger CRC metastatic spread through Rac1 activation and epithelial-to-mesenchymal transition, independently of autophagy. Interestingly, UVRAGFS expression renders cells more sensitive to standard chemotherapy regimen due to a DNA repair defect. These results identify UVRAG as a new MSI target gene and provide a mechanism for UVRAG participation in CRC pathogenesis and treatment response.
C1 [He, Shanshan; Zhao, Zhen; Yang, Yongfei; O'Connell, Douglas; Zhang, Xiaowei; Oh, Soohwan; Ma, Binyun; Lee, Joo-Hyung; Zhang, Tian; Yip, Janae; Pirooz, Sara Dolatshahi; Machida, Keigo; Liang, Chengyu] Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA.
   [Varghese, Bino] Univ So Calif, Keck Sch Med, Dept Radiol, Los Angeles, CA 90033 USA.
   [Li, Ming] Peking Univ, Canc Hosp & Inst, Dept Colorectal Surg, Key Lab Carcinogenesis & Translat Res, Beijing 100142, Peoples R China.
   [Zhang, Yong] Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 1, Dept Surg Oncol, Xian 710061, Peoples R China.
   [Li, Guo-Min] Univ Kentucky, Grad Ctr Toxicol, Markey Canc Ctr, Coll Med, Lexington, KY 40506 USA.
   [Martin, Sue Ellen] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
RP Liang, CY (corresponding author), Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA.
EM chengyu.liang@med.usc.edu
RI zhao, zhen/A-2080-2012; Lee, Joo-Hyung/ABB-7759-2021
OI zhao, zhen/0000-0001-8967-5570; Lee, Joo-Hyung/0000-0001-5345-1102;
   Machida, Keigo/0000-0002-9721-8553; Li, Guo-Min/0000-0002-9842-4578;
   yang, yongfei/0000-0002-1135-669X
FU National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [E14TG2a.4];
   Margaret Early Trustee Foundation; American Cancer SocietyAmerican
   Cancer Society [RSG-11-121-01-CCG]; NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA [R01
   CA140964]; NATIONAL CANCER INSTITUTEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [R01CA140964] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK) [P30DK048522] Funding Source: NIH RePORTER
FX The results shown here are in whole or part based on data generated by
   COSMIC (Catalogue of somatic mutations in cancer;
   http://cancer.sanger.ac.uk). We acknowledge the National Institutes of
   Health (NIH)-sponsored Mutant Mouse Regional Resource Center National
   System as the source of mouse embryonic stem cells (E14TG2a.4) for use
   in this study. We thank Victoria Bedell and the Cytogenetics Core of the
   City of Hope (Duarte, CA) for the SKY analysis. We thank Drs. J.U. Jung,
   M. Levine, T. Yoshimori, and Y. Ohsumi for providing reagents. We thank
   all the members of the Liang laboratory for helpful discussion. We thank
   Dr. Martine Torres for her editorial assistance. This work was supported
   by the Margaret Early Trustee Foundation, American Cancer Society
   (RSG-11-121-01-CCG), and NIH grant R01 CA140964 to C. Liang.
CR ALLALUNISTURNER MJ, 1993, RADIAT RES, V134, P349, DOI 10.2307/3578196
   Bekri S, 1997, CYTOGENET CELL GENET, V79, P125, DOI 10.1159/000134699
   Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110
   Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI [10.1053/j.gastro.2009.12.064, 10.1053/j.gastro.2010.04.024]
   Buhard O, 2006, J CLIN ONCOL, V24, P241, DOI 10.1200/JCO.2005.02.7227
   Chamberlain PP, 2014, NAT STRUCT MOL BIOL, V21, P803, DOI 10.1038/nsmb.2874
   Corso G, 2012, HUM PATHOL, V43, P961, DOI 10.1016/j.humpath.2012.01.021
   Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339
   Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Godinho SA, 2014, NATURE, V510, P167, DOI 10.1038/nature13277
   Goi T, 2003, SURG TODAY, V33, P702, DOI 10.1007/s00595-002-2567-y
   Hara T, 2008, J CELL BIOL, V181, P497, DOI 10.1083/jcb.200712064
   Hewish M, 2010, NAT REV CLIN ONCOL, V7, P197, DOI 10.1038/nrclinonc.2010.18
   Huang ZM, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004225
   Iacovoni JS, 2010, EMBO J, V29, P1446, DOI 10.1038/emboj.2010.38
   Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178
   Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509
   Kim MS, 2008, HUM PATHOL, V39, P1059, DOI 10.1016/j.humpath.2007.11.013
   Kim NG, 2002, ONCOGENE, V21, P5081, DOI 10.1038/sj.onc.1205703
   Knaevelsrud H, 2010, AUTOPHAGY, V6, P863, DOI 10.4161/auto.6.7.13033
   Leahy JJJ, 2004, BIOORG MED CHEM LETT, V14, P6083, DOI 10.1016/j.bmcl.2004.09.060
   Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x
   Liang CY, 2008, AUTOPHAGY, V4, P817, DOI 10.4161/auto.6496
   Liang CY, 2008, NAT CELL BIOL, V10, P776, DOI 10.1038/ncb1740
   Liang CY, 2007, AUTOPHAGY, V3, P69, DOI 10.4161/auto.3437
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang CY, 2010, CURR OPIN CELL BIOL, V22, P226, DOI 10.1016/j.ceb.2009.11.003
   Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
   Mack NA, 2011, CELL CYCLE, V10, P1571, DOI 10.4161/cc.10.10.15612
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Matsunaga K, 2009, NAT CELL BIOL, V11, P385, DOI 10.1038/ncb1846
   Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Oh S, 2011, CELL DEATH DIFFER, V18, P452, DOI 10.1038/cdd.2010.116
   Padilla-Nash HM, 2006, NAT PROTOC, V1, P3129, DOI 10.1038/nprot.2006.358
   Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858
   Shoemaker RH, 2006, NAT REV CANCER, V6, P813, DOI 10.1038/nrc1951
   Streit M, 1999, AM J PATHOL, V155, P441, DOI 10.1016/S0002-9440(10)65140-1
   Sun K, 2013, CELL BIOSCI, V3, DOI 10.1186/2045-3701-3-35
   Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634
   Thompson SL, 2010, CURR BIOL, V20, pR285, DOI 10.1016/j.cub.2010.01.034
   Vieira OV, 2001, J CELL BIOL, V155, P19, DOI 10.1083/jcb.200107069
   Wang K, 2014, NAT GENET, V46, P573, DOI 10.1038/ng.2983
   Woerner SM, 2003, ONCOGENE, V22, P2226, DOI 10.1038/sj.onc.1206421
   Wong A. S., NAT CELL BIOL, V13, P568
   Zhao Z, 2012, DEV CELL, V22, P1001, DOI 10.1016/j.devcel.2011.12.027
   Zhong Y, 2009, NAT CELL BIOL, V11, P468, DOI 10.1038/ncb1854
NR 54
TC 48
Z9 50
U1 0
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD AUG
PY 2015
VL 6
AR 7839
DI 10.1038/ncomms8839
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CQ1FO
UT WOS:000360342900001
PM 26234763
OA Green Published, Green Accepted, gold
DA 2022-04-25
ER

PT J
AU Wang, QS
   Shen, SQ
   Sun, HW
   Xing, ZX
   Yang, HL
AF Wang, Qiu-Shuang
   Shen, Shi-Qiang
   Sun, Hua-Wen
   Xing, Zhi-Xiang
   Yang, Hou-Lai
TI Interferon-gamma induces autophagy-associated apoptosis through
   induction of cPLA2-dependent mitochondrial ROS generation in colorectal
   cancer cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Interferon-gamma; Cytosolic phospholipase A2; Reactive oxygen species;
   Autophagy; Apoptosis; Colorectal cancer
ID OXIDATIVE STRESS; TUMOR-GROWTH; COLON; PATHWAY; INHIBITION; ACTIVATION;
   MECHANISM; THERAPY; DEATH
AB Colorectal cancer (CRC) is the second most commonly diagnosed cancer in females and the third in males. In this work, we aim to investigate the possible anti-cancer effects of interferon-gamma (IFN-gamma) in CRC cells. We observed that IFN-gamma induced mitochondria-derived reactive oxygen species (ROS) production in a time-dependent manner in SW480 and HCT116 cell lines. The IFN-gamma-induced mitochondrial ROS generation was dependent on the activation of cytosolic phospholipase A2 (cPLA2). In addition, a mitochondria-targeted antioxidant SS31 and/or cPLA2 inhibitor AACOCF3 abolished the IFN-gamma-induced ROS production and subsequent autophagy and apoptosis. Moreover, suppression of autophagy by CQ was able to reduce IFN-gamma-induced cell apoptosis. Beclin-1 gene silencing resulted in caspase-3 inactivation, decreased Bax/Bcl-2 ratio and less population of apoptotic cells. Collectively, our results suggested that IFN-gamma induces autophagy-associated apoptosis in CRC cells via inducing cPLA2-dependent mitochondrial ROS production. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Wang, Qiu-Shuang; Shen, Shi-Qiang; Sun, Hua-Wen; Xing, Zhi-Xiang; Yang, Hou-Lai] Wuhan Univ, Renmin Hosp, Dept Gen Surg, 99 Zhangzhidong Rd, Wuhan 430060, Hubei, Peoples R China.
RP Shen, SQ (corresponding author), Wuhan Univ, Renmin Hosp, Dept Gen Surg, 99 Zhangzhidong Rd, Wuhan 430060, Hubei, Peoples R China.
EM dr_sqshen@163.com
CR Aiken CT, 2011, MOL CELLULAR PROTEOM, V10, P744
   Alexandre J, 2006, INT J CANCER, V119, P41, DOI 10.1002/ijc.21685
   Bartsch H, 2006, LANGENBECK ARCH SURG, V391, P499, DOI 10.1007/s00423-006-0073-1
   Billiau A, 1998, ANN NY ACAD SCI, V856, P22, DOI 10.1111/j.1749-6632.1998.tb08309.x
   Brieger K, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13659
   Chen PJ, 2017, FREE RADICAL BIO MED, V104, P280, DOI 10.1016/j.freeradbiomed.2017.01.033
   Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233
   Giannopoulos A, 2003, CLIN CANCER RES, V9, P5550
   Gough DJ, 2008, CYTOKINE GROWTH F R, V19, P383, DOI 10.1016/j.cytogfr.2008.08.004
   Hanada T, 2006, J EXP MED, V203, P1391, DOI 10.1084/jem.20060436
   HANNIGAN GE, 1991, SCIENCE, V251, P204, DOI 10.1126/science.1898993
   Kalashnikova I, 2017, NANOSCALE, V9, P10375, DOI 10.1039/c7nr02770b
   Ko CH, 2007, INT J CANCER, V121, P1670, DOI 10.1002/ijc.22910
   LOLLINI PL, 1993, INT J CANCER, V55, P320, DOI 10.1002/ijc.2910550224
   Miki H, 2012, INT J ONCOL, V40, P1020, DOI 10.3892/ijo.2012.1325
   Pearl-Yafe M, 2003, BIOCHEM PHARMACOL, V65, P833, DOI 10.1016/S0006-2952(02)01620-9
   Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604
   PONZONI M, 1992, FEBS LETT, V310, P17, DOI 10.1016/0014-5793(92)81136-A
   Saeidnia S., 2003, TOXICOL APPL PHARM, P49
   Sakitani K, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1789-5
   Sawai N, 1999, INFECT IMMUN, V67, P279, DOI 10.1128/IAI.67.1.279-285.1999
   Slattery ML, 2011, CARCINOGENESIS, V32, P1660, DOI 10.1093/carcin/bgr189
   Sun GY, 2014, MOL NEUROBIOL, V50, P6, DOI 10.1007/s12035-014-8662-4
   Supinski GS, 2016, AM J PHYSIOL-LUNG C, V310, pL975, DOI 10.1152/ajplung.00312.2015
   Tjandra SS, 2007, CANCER RES, V67, P7124, DOI 10.1158/0008-5472.CAN-07-0686
   Wang L, 2015, J INTERF CYTOK RES, V35, P273, DOI 10.1089/jir.2014.0132
   Wang SQ, 2016, ONCOTARGET, V7, P72990, DOI 10.18632/oncotarget.12166
   Watanabe Y, 2003, J CELL BIOCHEM, V89, P244, DOI 10.1002/jcb.10501
   Wen SJ, 2013, FUTURE MED CHEM, V5, P53, DOI 10.4155/fmc.12.190
   WIESENFELD M, 1995, J CLIN ONCOL, V13, P2324, DOI 10.1200/JCO.1995.13.9.2324
   Windbichler GH, 2000, BRIT J CANCER, V82, P1138
   WU T, 1994, J CLIN INVEST, V93, P571, DOI 10.1172/JCI117009
   Xiao MJ, 2009, CANCER RES, V69, P2010, DOI 10.1158/0008-5472.CAN-08-3479
   Yang D, 2007, EXP EYE RES, V85, P462, DOI 10.1016/j.exer.2007.06.013
   Yu HG, 2003, REGUL PEPTIDES, V114, P101, DOI 10.1016/S0167-0115(03)00084-3
   Zhu M, 2017, BIOCHEM BIOPH RES CO, V492, P373, DOI 10.1016/j.bbrc.2017.08.097
   Ziech D, 2011, MUTAT RES-FUND MOL M, V711, P167, DOI 10.1016/j.mrfmmm.2011.02.015
NR 37
TC 14
Z9 14
U1 0
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD APR 15
PY 2018
VL 498
IS 4
BP 1058
EP 1065
DI 10.1016/j.bbrc.2018.03.118
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA GC9ZT
UT WOS:000430158200053
PM 29551681
DA 2022-04-25
ER

PT J
AU Kim, TW
   Lee, SJ
   Kim, JT
   Kim, SJ
   Min, JK
   Bae, KH
   Jung, H
   Kim, BY
   Lim, JS
   Yang, Y
   Yoon, DY
   Choe, YK
   Lee, HG
AF Kim, Tae Woo
   Lee, Seon-Jin
   Kim, Jong-Tae
   Kim, Sun Jung
   Min, Jeong-Ki
   Bae, Kwang-Hee
   Jung, Haiyoung
   Kim, Bo-Yeon
   Lim, Jong-Seok
   Yang, Young
   Yoon, Do-Young
   Choe, Yong-Kyung
   Lee, Hee Gu
TI Kallikrein-related peptidase 6 induces chemotherapeutic resistance by
   attenuating auranofin-induced cell death through activation of autophagy
   in gastric cancer
SO ONCOTARGET
LA English
DT Article
DE kallikrein-related peptidase 6; autophagy; auranofin; cell death;
   chemoresistance
ID CLINICAL-SIGNIFICANCE; BREAST-CANCER; THIOREDOXIN REDUCTASE;
   MULTIDRUG-RESISTANCE; THERAPEUTIC TARGET; COLON-CANCER; APOPTOSIS; P53;
   EXPRESSION; INHIBITION
AB Kallikrein-related peptidase 6 (KLK6) is a biomarker of gastric cancer associated with poor prognosis. Mechanisms by which KLK6 could be exploited for chemotherapeutic use are unclear. We evaluated auranofin (AF), a compound with cytotoxic effects, in KLK6-deficient cells, and we investigated whether KLK6 expression induces autophagy and acquisition of drug resistance in gastric cancer. Using cultured human cells and a mouse xenograft model, we investigated how KLK6 affects antitumor-reagent-induced cell death and autophagy. Expression levels of KLK6, p53, and autophagy marker LC3B were determined in gastric cancer tissues. We analyzed the effects of knockdown/overexpression of KLK6, LC3B, and p53 on AF-induced cell death in cancer cells. Increased KLK6 expression in human gastric cancer tissues and cells inhibited AF-induced cell motility due to increased autophagy and p53 levels. p53 dependent induction of KLK6 expression increased autophagy and drug resistance, whereas KLK6 silencing decreased the autophagy level and increased drug sensitivity. During AF-induced cell death, KLK6 and LC3B colocalized to autophagosomes, associated with p53, and were then trafficked to the cytosol. In the xenograft model of gastric cancer, KLK6 expression decreased AF-induced cell death and KLK6-induced autophagy increased AF resistance. Taken together, the data suggest that the induction of autophagic processes through KLK6 expression may increase acquisition of resistance to AF. Our findings may contribute to a new paradigm for tumor therapeutics.
C1 [Kim, Tae Woo; Lee, Seon-Jin; Kim, Jong-Tae; Jung, Haiyoung; Choe, Yong-Kyung; Lee, Hee Gu] Korea Res Inst Biosci & Biotechnol, Immunotherapy Convergence Res Ctr, Daejeon, South Korea.
   [Kim, Tae Woo; Lee, Seon-Jin; Lee, Hee Gu] Univ Sci & Technol, Dept Biomol Sci, Daejeon, South Korea.
   [Kim, Sun Jung] Dongguk Univ Seoul, Dept Life Sci, Seoul, South Korea.
   [Min, Jeong-Ki] Korea Res Inst Biosci & Biotechnol, Biotherapeut Translat Res Ctr, Daejeon, South Korea.
   [Bae, Kwang-Hee] Korea Res Inst Biosci & Biotechnol, Res Ctr Metab Regulat, Daejeon, South Korea.
   [Kim, Bo-Yeon] Korea Res Inst Biosci & Biotechnol, World Class Inst, Ochang, Cheongwon, South Korea.
   [Lim, Jong-Seok; Yang, Young] Sookmyung Womens Univ, Dept Biol Sci, Seoul, South Korea.
   [Yoon, Do-Young] Konkuk Univ, Dept Biosci & Biotechnol, Seoul, South Korea.
RP Choe, YK; Lee, HG (corresponding author), Korea Res Inst Biosci & Biotechnol, Immunotherapy Convergence Res Ctr, Daejeon, South Korea.; Lee, HG (corresponding author), Univ Sci & Technol, Dept Biomol Sci, Daejeon, South Korea.
EM ykccoruk@kribb.re.kr; hglee@kribb.re.kr
RI Lee, Seon-Jin/AAJ-8258-2020; kim, sun jung/T-1013-2019
OI Bae, Kwang-Hee/0000-0002-5868-2556; Min, Jeong-Ki/0000-0003-4924-8739;
   Yang, Young/0000-0003-4239-0804; Lee, Seon-Jin/0000-0001-7214-7536
CR Chan SN, 2013, MOL MEMBR BIOL, V30, P394, DOI 10.3109/09687688.2013.850178
   Chen S, 2013, CLIN CANCER RES, V19, P6853, DOI 10.1158/1078-0432.CCR-13-1617
   Comel A, 2014, FEBS LETT, V588, P2600, DOI 10.1016/j.febslet.2014.04.015
   Contreras AU, 2013, J CELL BIOL, V201, P427, DOI 10.1083/jcb.201205064
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   Debnath A, 2012, NAT MED, V18, P956, DOI 10.1038/nm.2758
   Drucker KL, 2013, NEURO-ONCOLOGY, V15, P305, DOI 10.1093/neuonc/nos313
   Ehedego H, 2015, CANCER RES, V75, P1144, DOI 10.1158/0008-5472.CAN-14-1356
   Ehrenfeld P, 2014, ANTICANCER RES, V34, P6925
   Fan C, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.132
   Fan KC, 2000, ANTICANCER RES, V20, P4809
   Fiskus W, 2014, CANCER RES, V74, P2520, DOI 10.1158/0008-5472.CAN-13-2033
   Gandin V, 2010, BIOCHEM PHARMACOL, V79, P90, DOI 10.1016/j.bcp.2009.07.023
   Gray-Schopfer VC, 2007, CANCER RES, V67, P122, DOI 10.1158/0008-5472.CAN-06-1880
   Gui YX, 2015, ONCOTARGET, V6, P37043, DOI 10.18632/oncotarget.6158
   Hager KM, 2014, CARCINOGENESIS, V35, P740, DOI 10.1093/carcin/bgt487
   Hanusova V, 2015, CURR CANCER DRUG TAR, V15, P35, DOI 10.2174/1568009615666141229152812
   Ignatenko N, 2008, NEOPLASIA, V10, P140, DOI 10.1593/neo.07817
   Jiang XY, 2013, BIOMATERIALS, V34, P2969, DOI 10.1016/j.biomaterials.2012.12.049
   John S, 2008, CANCER RES, V68, P7855, DOI 10.1158/0008-5472.CAN-07-5875
   Kim JT, 2011, CANCER-AM CANCER SOC, V117, P2608, DOI 10.1002/cncr.25841
   King H, 2014, INT REV CEL MOL BIO, V309, P347, DOI 10.1016/B978-0-12-800255-1.00007-7
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Lee SJ, 2011, AM J RESP CRIT CARE, V183, P649, DOI 10.1164/rccm.201005-0746OC
   Levine B, 2008, NAT CELL BIOL, V10, P637, DOI 10.1038/ncb0608-637
   Li H, 2016, ONCOTARGET, V7, P3548, DOI 10.18632/oncotarget.6516
   Loessner D, 2012, GYNECOL ONCOL, V127, P569, DOI 10.1016/j.ygyno.2012.09.001
   Ludwig JA, 2006, CANCER RES, V66, P4808, DOI 10.1158/0008-5472.CAN-05-3322
   Maiuri MC, 2009, CELL DEATH DIFFER, V16, P87, DOI 10.1038/cdd.2008.131
   Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Marx J, 2006, SCIENCE, V312, P1160, DOI 10.1126/science.312.5777.1160
   Marzano C, 2007, FREE RADICAL BIO MED, V42, P872, DOI 10.1016/j.freeradbiomed.2006.12.021
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Morselli E, 2011, CELL CYCLE, V10, P2763, DOI 10.4161/cc.10.16.16868
   Morselli E, 2009, BBA-MOL CELL RES, V1793, P1524, DOI 10.1016/j.bbamcr.2009.01.006
   Nakaya A, 2011, LEUKEMIA RES, V35, P243, DOI 10.1016/j.leukres.2010.05.011
   Ogawa K, 2005, CLIN CANCER RES, V11, P2889, DOI 10.1158/1078-0432.CCR-04-2281
   Pan BZ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-165
   Park SJ, 2005, BRIT J PHARMACOL, V146, P506, DOI 10.1038/sj.bjp.0706360
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Schrader CH, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0381-6
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Sui XB, 2014, SCI REP-UK, V4, DOI 10.1038/srep04694
   Sui XB, 2011, AUTOPHAGY, V7, P565, DOI 10.4161/auto.7.6.14073
   Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Tatebe H, 2010, NEUROSCI RES, V67, P341, DOI 10.1016/j.neures.2010.04.008
   Thorburn A, 2014, MOL PHARMACOL, V85, P830, DOI 10.1124/mol.114.091850
   Turner R, 2002, NAT MED, V8, P449, DOI 10.1038/nm0502-449
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   White NMA, 2009, BRIT J CANCER, V101, P1107, DOI 10.1038/sj.bjc.6605280
   Wirawan E, 2012, CELL RES, V22, P43, DOI 10.1038/cr.2011.152
   Yang X, 2015, CELL BIOSCI, V5, DOI 10.1186/s13578-015-0005-2
   Zheng Y, 2016, EXP GERONTOL, V75, P64, DOI 10.1016/j.exger.2016.01.004
   Zhou J, 2015, CARCINOGENESIS, V36, P441, DOI 10.1093/carcin/bgv014
   Zou P, 2015, ONCOTARGET, V6, P36505, DOI 10.18632/oncotarget.5364
NR 58
TC 21
Z9 22
U1 0
U2 4
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD DEC 20
PY 2016
VL 7
IS 51
BP 85332
EP 85348
DI 10.18632/oncotarget.13352
PG 17
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EG9BT
UT WOS:000391353200124
PM 27863404
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Nagy, P
   Kovacs, L
   Sandor, GO
   Juhasz, G
AF Nagy, Peter
   Kovacs, Laura
   Sandor, Gyongyver O.
   Juhasz, Gabor
TI Stem-cell-specific endocytic degradation defects lead to intestinal
   dysplasia in Drosophila
SO DISEASE MODELS & MECHANISMS
LA English
DT Article
DE Autophagy; Drosophila; Endocytosis; UVRAG
ID PHOSPHATIDYLINOSITOL 3-KINASE COMPLEXES; HOPS COMPLEX; COLON-CANCER;
   AUTOPHAGY; UVRAG; HOMEOSTASIS; PROLIFERATION; REGENERATION; MAINTENANCE;
   MUTATIONS
AB UV radiation resistance-associated gene (UVRAG) is a tumor suppressor involved in autophagy, endocytosis and DNA damage repair, but how its loss contributes to colorectal cancer is poorly understood. Here, we show that UVRAG deficiency in Drosophila intestinal stem cells leads to uncontrolled proliferation and impaired differentiation without preventing autophagy. As a result, affected animals suffer from gut dysfunction and short lifespan. Dysplasia upon loss of UVRAG is characterized by the accumulation of endocytosed ligands and sustained activation of STAT and JNK signaling, and attenuation of these pathways suppresses stem cell hyperproliferation. Importantly, the inhibition of early (dynamin-dependent) or late (Rab7-dependent) steps of endocytosis in intestinal stem cells also induces hyperproliferation and dysplasia. Our data raise the possibility that endocytic, but not autophagic, defects contribute to UVRAG-deficient colorectal cancer development in humans.
C1 [Nagy, Peter; Kovacs, Laura; Sandor, Gyongyver O.; Juhasz, Gabor] Eotvos Lorand Univ, Dept Anat Cell & Dev Biol, Pazmany S 1-C, H-1117 Budapest, Hungary.
   [Juhasz, Gabor] Hungarian Acad Sci, Biol Res Ctr, Inst Genet, Temesvari Krt 62, H-6726 Szeged, Hungary.
RP Juhasz, G (corresponding author), Eotvos Lorand Univ, Dept Anat Cell & Dev Biol, Pazmany S 1-C, H-1117 Budapest, Hungary.; Juhasz, G (corresponding author), Hungarian Acad Sci, Biol Res Ctr, Inst Genet, Temesvari Krt 62, H-6726 Szeged, Hungary.
EM szmrt@elte.hu
RI Juhasz, Gabor/G-5622-2013
OI Juhasz, Gabor/0000-0001-8548-8874; Nagy, Peter/0000-0002-5053-0646
FU Wellcome TrustWellcome TrustEuropean Commission [087518/Z/08/Z];
   Hungarian Academy of Sciences (Magyar Tudoma'nyos Akade'mia)
   [LP-2014/2]; National Research, Development and Innovation Office
   (NKFIH) [PD115568]; Bolyai Research Scholarship of the Hungarian Academy
   of SciencesHungarian Academy of Sciences; Erdos Junior Research
   Fellowship [TAMOP4.2.4.A/1-11-1-2012-0001]
FX This work was supported by the Wellcome Trust [087518/Z/08/Z to G.J.];
   the Hungarian Academy of Sciences (Magyar Tudoma'nyos Akade'mia) [grant
   number LP-2014/2 to G.J.]; the National Research, Development and
   Innovation Office (NKFIH) [PD115568 to P.N.]; the Bolyai Research
   Scholarship of the Hungarian Academy of Sciences to P.N.; and the Erdos
   Junior Research Fellowship [TAMOP4.2.4.A/1-11-1-2012-0001 to P.N.].
CR Amcheslavsky A, 2014, CELL REP, V9, P32, DOI 10.1016/j.celrep.2014.08.052
   Amcheslavsky A, 2009, CELL STEM CELL, V4, P49, DOI 10.1016/j.stem.2008.10.016
   Beebe K, 2010, DEV BIOL, V338, P28, DOI 10.1016/j.ydbio.2009.10.045
   Biteau B, 2008, CELL STEM CELL, V3, P442, DOI 10.1016/j.stem.2008.07.024
   Biteau B, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001159
   Cherry S, 2013, ELIFE, V2, DOI 10.7554/eLife.01064
   Cordero JB, 2012, EMBO J, V31, P3901, DOI 10.1038/emboj.2012.248
   Garcia-Prat L, 2016, NATURE, V529, P37, DOI 10.1038/nature16187
   He SS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8839
   Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178
   Issman-Zecharya N, 2014, DEV CELL, V31, P461, DOI 10.1016/j.devcel.2014.10.013
   Itakura E, 2008, MOL BIOL CELL, V19, P5360, DOI 10.1091/mbc.E08-01-0080
   Jiang HQ, 2012, CURR OPIN GENET DEV, V22, P354, DOI 10.1016/j.gde.2012.04.002
   Jiang HQ, 2009, CELL, V137, P1343, DOI 10.1016/j.cell.2009.05.014
   Jiang P, 2014, MOL BIOL CELL, V25, P1327, DOI 10.1091/mbc.E13-08-0447
   Juhasz G, 2008, J CELL BIOL, V181, P655, DOI 10.1083/jcb.200712051
   Kapuria S, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003045
   Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519
   Knaevelsrud H, 2010, AUTOPHAGY, V6, P863, DOI 10.4161/auto.6.7.13033
   Kutateladze TG, 2012, CURR TOP MICROBIOL, V362, P111, DOI 10.1007/978-94-007-5025-8_6
   Lee G, 2011, DEV BIOL, V356, P588, DOI 10.1016/j.ydbio.2011.06.024
   Lemaitre B, 2013, ANNU REV GENET, V47, P377, DOI 10.1146/annurev-genet-111212-133343
   Liang CY, 2008, NAT CELL BIOL, V10, P776, DOI 10.1038/ncb1740
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Lin GN, 2008, NATURE, V455, P1119, DOI 10.1038/nature07329
   Lorincz P, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/851349
   Lu H, 2005, NAT CELL BIOL, V7, P1232, DOI 10.1038/ncb1324
   Mauvezin C, 2014, METHODS, V68, P134, DOI 10.1016/j.ymeth.2014.03.014
   Micchelli CA, 2006, NATURE, V439, P475, DOI 10.1038/nature04371
   Moline MM, 1999, DEVELOPMENT, V126, P4375
   Montagne C, 2014, DEVELOPMENT, V141, P2014, DOI 10.1242/dev.104240
   Nagy P, 2015, METHODS, V75, P151, DOI 10.1016/j.ymeth.2014.11.016
   Nagy P, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003664
   Nezis IP, 2008, J CELL BIOL, V180, P1065, DOI 10.1083/jcb.200711108
   Ohlstein B, 2007, SCIENCE, V315, P988, DOI 10.1126/science.1136606
   Osman D, 2012, J CELL SCI, V125, P5944, DOI 10.1242/jcs.113100
   Patel PH, 2015, NAT CELL BIOL, V17, P1182, DOI 10.1038/ncb3214
   Pircs K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044214
   Platta HW, 2011, CURR OPIN CELL BIOL, V23, P393, DOI 10.1016/j.ceb.2011.03.008
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Song ZP, 2014, CARDIOVASC RES, V101, P48, DOI 10.1093/cvr/cvt223
   Stempfle D, 2010, MOL CELL BIOL, V30, P3165, DOI 10.1128/MCB.00030-10
   Takats S, 2014, MOL BIOL CELL, V25, P1338, DOI 10.1091/mbc.E13-08-0449
   Takats S, 2013, J CELL BIOL, V201, P531, DOI 10.1083/jcb.201211160
   Tang HW, 2013, DEV CELL, V27, P489, DOI 10.1016/j.devcel.2013.10.017
   TEITZ T, 1990, GENE, V87, P295, DOI 10.1016/0378-1119(90)90316-J
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zeng XK, 2015, CELL REP, V10, P1226, DOI 10.1016/j.celrep.2015.01.051
   Zhao Z, 2012, DEV CELL, V22, P1001, DOI 10.1016/j.devcel.2011.12.027
NR 49
TC 16
Z9 16
U1 1
U2 7
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 1754-8403
EI 1754-8411
J9 DIS MODEL MECH
JI Dis. Model. Mech.
PD MAY 1
PY 2016
VL 9
IS 5
BP 501
EP 512
DI 10.1242/dmm.023416
PG 12
WC Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Pathology
GA DN5DP
UT WOS:000377086800003
PM 26921396
OA gold, Green Published, Green Accepted
DA 2022-04-25
ER

PT J
AU Cheung, FWK
   Che, CT
   Sakagami, H
   Kochi, M
   Liu, WK
AF Cheung, F. W. K.
   Che, C. T.
   Sakagami, H.
   Kochi, M.
   Liu, W. K.
TI Sodium 5,6-Benzylidene-L-Ascorbate Induces Oxidative Stress, Autophagy,
   and Growth Arrest in Human Colon Cancer HT-29 Cells
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE OXIDATIVE STRESS; GROWTH ARREST; P21 INHIBITOR; AUTOPHAGY
ID HUMAN PROSTATE-CANCER; CYCLE ARREST; MOLECULAR-MECHANISMS;
   LIPID-PEROXIDATION; HACAT CELLS; VITAMIN-C; IN-VITRO; APOPTOSIS;
   ASCORBATE; PHOSPHORYLATION
AB Our previous studies have demonstrated the oxidative stress properties of sodium ascorbate (SAA) and its benzaldehyde derivative (SBA) on cancer cell lines, but the molecular mechanisms mediating their cytotoxicity remain unclear. In this study, we treated human colon cancer HT-29 cells with SAA and SBA, and found a significant exposure time-dependent increase of cytotoxicity in both treatments, with a higher cytotoxicity for 24 h with SAA (IC50 = 5 mM) than SBA (IC50 = 10 mM). A short-term treatment of cells with 10 mM SAA for 2 h revealed a destabilization of the lysosomes and subsequent induction of cell death, whereas 10 mM SBA triggered a remarkable production of reactive oxidative species, phosphorylation of survival kinase AKT, expression of cyclin kinase-dependent inhibitor p21, and induction of transient growth arrest. The crucial role of p21 mediating this cytotoxicity was confirmed by isogenic derivatives of the human colon carcinoma HCT116 cell lines (p21(+/+) and p21(-/-)), and immunoprecipitation studies with p21 antibody. The SAA cytotoxicity was blocked by co-incubation with catalase, whereas the SBA cytotoxicity and its subsequent growth arrest were abolished by N-acetyl-L-cysteine (NAC), but was not affected by PI3K phosphorylation inhibitor LY294002, or catalase, suggesting two separated oxidative stress pathways were mediated by these two ascorbates. In addition, neither active caspase 3 nor apoptotic bodies but autophagic vacuoles associated with increased LC3-II were found in SBA-treated HT-29 cells; implicating that SBA induced AKT phosphorylation-autophagy and p21-growth arrest in colon cancer HT-29 cells through an NAC-inhibitable oxidative stress pathway. J. Cell. Biochem. 111: 412-424, 2010. (C) 2010 Wiley-Liss, Inc.
C1 [Liu, W. K.] Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China.
   [Cheung, F. W. K.; Che, C. T.] Chinese Univ Hong Kong, Sch Chinese Med, Shatin, Hong Kong, Peoples R China.
   [Sakagami, H.] Meikai Univ, Sch Dent, Div Pharmacol, Dept Diagnost & Therapeut Sci, Sakado, Saitama, Japan.
   [Kochi, M.] Ichijokai Hosp, Chiba, Japan.
RP Liu, WK (corresponding author), Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China.
EM ken-liu@cuhk.edu.hk
RI Che, Chun-Tao/AAV-2795-2020
CR Altomare DA, 2004, ONCOGENE, V23, P5853, DOI 10.1038/sj.onc.1207721
   Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315
   Banhegyi G, 2003, BIOFACTORS, V17, P37, DOI 10.1002/biof.5520170105
   Barnouin K, 2002, J BIOL CHEM, V277, P13761, DOI 10.1074/jbc.M111123200
   Broker LE, 2005, CLIN CANCER RES, V11, P3155, DOI 10.1158/1078-0432.CCR-04-2223
   Cerella C, 2009, ANN NY ACAD SCI, V1171, P583, DOI 10.1111/j.1749-6632.2009.04723.x
   Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6
   Chen Q, 2005, P NATL ACAD SCI USA, V102, P13604, DOI 10.1073/pnas.0506390102
   Cheung FWK, 2010, MAR DRUGS, V8, P80, DOI 10.3390/md8010080
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Fiebig HH, 2004, EUR J CANCER, V40, P802, DOI 10.1016/j.ejca.2004.01.009
   Gao N, 2003, BIOCHEM BIOPH RES CO, V310, P1124, DOI 10.1016/j.bbrc.2003.09.132
   Herman-Antosiewicz A, 2006, CANCER RES, V66, P5828, DOI 10.1158/0008-5472.CAN-06-0139
   Kaap S, 2004, BIOCHEM PHARMACOL, V67, P919, DOI 10.1016/j.bcp.2003.10.001
   Keeshan K, 2003, BRIT J HAEMATOL, V123, P34, DOI 10.1046/j.1365-2141.2003.04538.x
   KOCHI M, 1980, CANCER TREAT REP, V64, P21
   KOCHI M, 1988, PROGR CANCER RES THE, V35, P338
   Kontopidis G, 2005, P NATL ACAD SCI USA, V102, P1871, DOI 10.1073/pnas.0406540102
   KONTOPIDIS G, 2007, CELL DEATH DIFFER, V14, P230
   Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984
   Lee JY, 2003, J NEUROSCI RES, V73, P156, DOI 10.1002/jnr.10647
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Li X, 2003, BIOCHEM BIOPH RES CO, V305, P656, DOI 10.1016/S0006-291X(03)00836-2
   Lin SY, 2006, MELANOMA RES, V16, P509, DOI 10.1097/01.cmr.0000232297.99160.9e
   Liu BPL, 2005, BIOCHEM PHARMACOL, V70, P287, DOI 10.1016/j.bcp.2005.04.024
   Liu WK, 2008, J NAT PROD, V71, P842, DOI 10.1021/np8001223
   Lockshin RA, 2004, INT J BIOCHEM CELL B, V36, P2405, DOI 10.1016/j.biocel.2004.04.011
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   MATSUIYUASA I, 1989, BIOCHEM INT, V18, P623
   Olsson ME, 2004, J AGR FOOD CHEM, V52, P7264, DOI 10.1021/jf030479p
   Paglin S, 2001, CANCER RES, V61, P439
   Peterszegi G, 2002, EUR J CLIN INVEST, V32, P372, DOI 10.1046/j.1365-2362.2002.00992.x
   Riviere J, 2006, FREE RADICAL BIO MED, V40, P2071, DOI 10.1016/j.freeradbiomed.2006.02.003
   Sakagami H, 1997, ANTICANCER RES, V17, P4451
   SAKAGAMI H, 1995, ANTICANCER RES, V15, P1269
   Sakagami H, 2000, CELL MOL BIOL, V46, P129
   SAKAGAMI H, 1991, ANTICANCER RES, V11, P1535
   Savini I, 1999, FREE RADICAL BIO MED, V26, P1172, DOI 10.1016/S0891-5849(98)00311-6
   Serbecic N, 2005, CELL TISSUE RES, V320, P465, DOI 10.1007/s00441-004-1030-3
   Shen GX, 2006, CANCER CHEMOTH PHARM, V57, P317, DOI 10.1007/s00280-005-0050-3
   Song JH, 2001, EXP NEUROL, V169, P425, DOI 10.1006/exnr.2001.7680
   Thomas CG, 2005, J CELL PHYSIOL, V205, P310, DOI 10.1002/jcp.20405
   Tse WP, 2006, J ETHNOPHARMACOL, V108, P133, DOI 10.1016/j.jep.2006.04.023
   Wenzel U, 2004, CARCINOGENESIS, V25, P703, DOI 10.1093/carcin/bgh079
   Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200
   Yamamoto M, 2006, MOL CARCINOGEN, V45, P901, DOI 10.1002/mc.20204
   Zafarullah M, 2003, CELL MOL LIFE SCI, V60, P6, DOI 10.1007/s000180300001
NR 47
TC 10
Z9 12
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD OCT 1
PY 2010
VL 111
IS 2
BP 412
EP 424
DI 10.1002/jcb.22717
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 658HZ
UT WOS:000282482400017
PM 20503249
DA 2022-04-25
ER

PT J
AU Qian, K
   Huang, HY
   Jiang, J
   Xu, DH
   Guo, SN
   Cui, Y
   Wang, H
   Wang, LQ
   Li, KN
AF Qian, Kun
   Huang, Huiying
   Jiang, Jing
   Xu, Dahua
   Guo, Shengnan
   Cui, Ying
   Wang, Hao
   Wang, Liqiang
   Li, Kongning
TI Identifying autophagy gene-associated module biomarkers through
   construction and analysis of an autophagy-mediated ceRNA-ceRNA
   interaction network in colorectal cancer
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE autophagy; competing endogenous RNA; interaction network; colorectal
   cancer; prognostic biomarkers
ID B-CELL LYMPHOMA; SURVIVAL PREDICTION; COLON-CANCER; EXPRESSION; TUMOR;
   METASTASIS; SUPPRESSOR; MICROENVIRONMENT; ORGANIZATION; APOPTOSIS
AB Autophagy is crucial in cellular homeostasis and has been implicated in the development of malignant tumors. However, the regulatory function of autophagy in cancer remains to be fully elucidated. In the present study, the autophagy-mediated competing endogenous RNA (ceRNA)-ceRNA interaction networks in colorectal cancer (CRC) were constructed by integrating systematically expression profiles of long non-coding RNAs and mRNAs. It was found that a large proportion of autophagy genes were inclined to target hub nodes, including a fraction of autophagy genes, by comparing with other genes within ceRNA networks, and showed preferential interaction with themselves. The present study also revealed that autophagy genes may be used as prognostic markers for cancer therapy. A risk score model based on multivariable Cox regression analysis was then used to capture novel biomarkers in connection with lncRNA for the prognosis of CRC. These biomarkers were confirmed in the test dataset and an additional independent dataset. Furthermore, the prognostic value of biomarkers is independent of conventional clinical factors. These results provide improved understanding of autophagy-mediated ceRNA regulatory mechanisms in CRC and provide novel potential molecular therapeutic targets for the diagnosis and treatment of CRC.
C1 [Qian, Kun; Huang, Huiying; Xu, Dahua; Guo, Shengnan; Cui, Ying; Wang, Liqiang; Li, Kongning] Harbin Med Univ, Coll Bioinformat Sci & Technol, 157 Baojian Rd, Harbin 150081, Heilongjiang, Peoples R China.
   [Jiang, Jing; Wang, Hao] Harbin Med Univ, Affiliated Hosp 2, Obstet & Gynaecol Dept, Harbin 150001, Heilongjiang, Peoples R China.
RP Wang, LQ; Li, KN (corresponding author), Harbin Med Univ, Coll Bioinformat Sci & Technol, 157 Baojian Rd, Harbin 150081, Heilongjiang, Peoples R China.
EM wangliqiang0619@163.com; likongning@ems.hrbmu.edu.cn
RI ; Li, Kongning/L-6188-2015
OI Wang, Hong/0000-0003-3524-0891; Li, Kongning/0000-0002-4928-6922
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31501075, 31301094]; Natural Science
   Foundation of Heilongjiang ProvinceNatural Science Foundation of
   Heilongjiang Province [B201302]; Education Department Foundation of
   Heilongjiang Province [12531227]; Health Department Foundation of
   Heilongjiang Province [2012-798]; Scientific Research Project of
   Heilongjiang Provincial Education Department [12541565]
FX This study was supported by the National Natural Science Foundation of
   China (grant nos. 31501075 and 31301094), the Natural Science Foundation
   of Heilongjiang Province (grant no. B201302), the Education Department
   Foundation of Heilongjiang Province (grant no. 12531227), the Health
   Department Foundation of Heilongjiang Province (grant no. 2012-798) and
   the Scientific Research Project of Heilongjiang Provincial Education
   Department (grant no. 12541565).
CR Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Alizadeh AA, 2011, BLOOD, V118, P1350, DOI 10.1182/blood-2011-03-345272
   Arntzen MO, 2015, PROTEOMICS, V15, P3765, DOI 10.1002/pmic.201500144
   Blum C, 2008, INT J ONCOL, V33, P579, DOI 10.3892/ijo_00000043
   Chen DT, 2012, J GASTROINTEST SURG, V16, P905, DOI 10.1007/s11605-011-1815-0
   Cheng DT, 2016, ONCOTARGET, V7, P45199, DOI 10.18632/oncotarget.9900
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385
   Christensen LL, 2016, MOL ONCOL, V10, P1266, DOI 10.1016/j.molonc.2016.06.003
   Conte F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171661
   Fang LK, 2014, ONCOTARGET, V5, P2974, DOI 10.18632/oncotarget.1614
   Galluzzi L, 2014, CELL, V159, P1263, DOI 10.1016/j.cell.2014.11.006
   Gu MJ, 2018, BMC CANCER, V18, DOI 10.1186/s12885-017-3968-z
   Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111
   He YQ, 2015, AM J CANCER RES, V5, P1382
   Katheder NS, 2017, AUTOPHAGY, V13, P1241, DOI 10.1080/15548627.2017.1310361
   Li CL, 2015, ONCOTARGETS THER, V8, P3407, DOI 10.2147/OTT.S90057
   Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248
   Li LX, 2006, BIOINFORMATICS, V22, P466, DOI 10.1093/bioinformatics/bti824
   Liu L, 2017, ONCOL LETT, V14, P4319, DOI 10.3892/ol.2017.6687
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Qian HR, 2017, ONCOTARGET, V8, P62759, DOI 10.18632/oncotarget.18663
   Qiang L, 2017, AUTOPHAGY, V13, P2086, DOI 10.1080/15548627.2017.1380757
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Stanel SC, 2017, ESMO OPEN, V2, DOI 10.1136/esmoopen-2017-000190
   Sun J, 2016, SCI REP-UK, V6, DOI 10.1038/srep27842
   Sun M, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0445-8
   Takada T, 2016, J SURG ONCOL, V113, P213, DOI 10.1002/jso.24114
   Wang P, 2015, NUCLEIC ACIDS RES, V43, P3478, DOI 10.1093/nar/gkv233
   Wang SSS, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.18
   Wu D, 2015, AUTOPHAGY, V11, P1917, DOI 10.1080/15548627.2015.1089375
   Wu TY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12795-5
   Xu J, 2012, CELL DEATH DIFFER, V19, P1571, DOI 10.1038/cdd.2012.87
   Yang JJ, 2016, J GINSENG RES, V40, P400, DOI 10.1016/j.jgr.2016.03.007
   Yu L, 2017, ONCOL LETT, V13, P1194, DOI 10.3892/ol.2017.5579
   Zhang HE, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-244
   Zhang W, 2018, BIOCHIMIE, V144, P21, DOI 10.1016/j.biochi.2017.10.002
   Zhang Y, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0261-3
   Zhao ST, 2016, CANCER MED-US, V5, P1950, DOI 10.1002/cam4.714
   Zhao WH, 2018, MOL CARCINOGEN, V57, P193, DOI 10.1002/mc.22746
   Zheng YB, 2016, ONCOL LETT, V12, P2194, DOI 10.3892/ol.2016.4814
NR 40
TC 4
Z9 4
U1 1
U2 8
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD SEP
PY 2018
VL 53
IS 3
BP 1083
EP 1093
DI 10.3892/ijo.2018.4443
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GP1NO
UT WOS:000440583100013
PM 29916526
OA Green Submitted, hybrid, Green Published
DA 2022-04-25
ER

PT J
AU Rodriguez, ME
   Arevalo, DE
   Sanabria, LM
   Carrion, FDC
   Fanelli, MA
   Rivarola, VA
AF Exequiel Rodriguez, Matias
   Elisa Arevalo, Daniela
   Milla Sanabria, Laura
   Cuello Carrion, Fernando Dario
   Andrea Fanelli, Mariel
   Alicia Rivarola, Viviana
TI Heat shock protein 27 modulates autophagy and promotes cell survival
   after photodynamic therapy
SO PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES
LA English
DT Article
ID INDUCED APOPTOSIS; CANCER-CELLS; RESISTANCE; HSP27; INDUCTION; DEATH;
   STRESS; PDT; ACTIVATION; MECHANISMS
AB Photodynamic therapy (PDT) is a clinically approved treatment that exerts a selective cytotoxic activity toward cancer cells. The procedure involves the administration of a photosensitizer drug followed by its activation by visible light. In the presence of oxygen, a series of events lead to tumor cell death. PDT releases different cell signals, some of these lead to death while others can lead to survival. The surviving or resistant cells contribute to the recurrence of tumors after treatment, from which the necessity to understand this molecular response induced by PDT arises. It has been shown that both Heat Shock Proteins (HSPs) and autophagy promote PDT resistance. Moreover, both of them can be stimulated by PDT treatment. However, the molecular interplay between HSPs and autophagy in the photodynamic therapy context is poorly understood. We studied whether PDT induces autophagic activity through HSPs. We demonstrated that PDT promoted HSP27 expression, which in turn triggered autophagic cell survival as well as inhibited apoptosis in colon cancer cells. In addition, an overexpression of the HSP27autophagy axis was observed in skin carcinoma cells resistant to PDT.
C1 [Exequiel Rodriguez, Matias; Elisa Arevalo, Daniela; Milla Sanabria, Laura; Alicia Rivarola, Viviana] Natl Univ Rio Cuarto, Dept Mol Biol, Natl Route 36,Km 601, RA-5800 Rio Cuarto, Cordoba, Argentina.
   [Cuello Carrion, Fernando Dario; Andrea Fanelli, Mariel] IMBECU CRICYT, Inst Expt Med & Biol Cuyo, Oncol Lab, Boulogne Sur Mer 683, RA-5500 Mendoza, Argentina.
RP Rodriguez, ME; Sanabria, LM (corresponding author), Natl Univ Rio Cuarto, Dept Mol Biol, Natl Route 36,Km 601, RA-5800 Rio Cuarto, Cordoba, Argentina.
EM exequiel198803@gmail.com; lmilla@exa.unrc.edu.ar
RI Rodriguez, Matias/Q-4760-2017
OI Rodriguez, Matias/0000-0002-5819-670X; Rivarola, v/0000-0001-7924-1445
FU Consejo Nacional de Investigacion Cientifica y Tecnologica
   (CONICET)Consejo Nacional de Investigaciones Cientificas y Tecnicas
   (CONICET); Secretaria de Ciencia y Tecnica (SeCyT) at the National
   University of Rio Cuarto (UNRC); Agencia FONCYTFONCyT
FX This research was supported by Consejo Nacional de Investigacion
   Cientifica y Tecnologica (CONICET), Secretaria de Ciencia y Tecnica
   (SeCyT) at the National University of Rio Cuarto (UNRC), and Agencia
   FONCYT. Moreover, the authors thank Anca Mihaela Nichifor and Maria
   Julia Urbina.
CR Agostinis P, 2011, CA-CANCER J CLIN, V61, P250, DOI 10.3322/caac.20114
   Andrzejak M, 2011, AUTOPHAGY, V7, P979, DOI 10.4161/auto.7.9.15865
   Arrigo AP, 1998, BIOL CHEM, V379, P19
   Ashrafi G, 2013, CELL DEATH DIFFER, V20, P31, DOI 10.1038/cdd.2012.81
   Buytaert E, 2007, BBA-REV CANCER, V1776, P86, DOI 10.1016/j.bbcan.2007.07.001
   Casas A, 2011, CURR MED CHEM, V18, P2486, DOI 10.2174/092986711795843272
   Chen N, 2009, BBA-MOL CELL RES, V1793, P1516, DOI 10.1016/j.bbamcr.2008.12.013
   Chen R, 2011, FOLIA BIOL-PRAGUE, V57, P87
   Concannon CG, 2003, APOPTOSIS, V8, P61, DOI 10.1023/A:1021601103096
   Costantino VV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053168
   Dewaele M, 2011, J CELL MOL MED, V15, P1402, DOI 10.1111/j.1582-4934.2010.01118.x
   Di Napol M., 2008, UBIQUITIN PROTEASOME, V17, P327
   Francois A, 2011, INT J ONCOL, V39, P1537, DOI 10.3892/ijo.2011.1174
   Gomer CJ, 1996, CANCER RES, V56, P2355
   Hanlon JG, 2001, J PHOTOCH PHOTOBIO B, V64, P55, DOI 10.1016/S1011-1344(01)00189-0
   Havasi A, 2008, J BIOL CHEM, V283, P12305, DOI 10.1074/jbc.M801291200
   Heinrich JC, 2016, ONCOTARGET, V7, P68156, DOI 10.18632/oncotarget.11905
   Jego G, 2013, CANCER LETT, V332, P275, DOI 10.1016/j.canlet.2010.10.014
   Joo JH, 2011, MOL CELL, V43, P572, DOI 10.1016/j.molcel.2011.06.018
   Kang R, 2011, AUTOPHAGY, V7, P1256, DOI 10.4161/auto.7.10.16753
   Kessel DH, 2012, AUTOPHAGY, V8, P1333, DOI 10.4161/auto.20792
   Kim J., 2015, ORAL SURG ORAL MED O, V119, pe167
   Kim J, 2013, J ORAL PATHOL MED, V42, P9, DOI 10.1111/j.1600-0714.2012.01155.x
   Korbelik M., 2005, CANCER, P1018
   Kumano M, 2012, MOL CANCER THER, V11, P1661, DOI 10.1158/1535-7163.MCT-12-0072
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Lin L, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.985913
   Maycotte P, 2012, AUTOPHAGY, V8, P200, DOI 10.4161/auto.8.2.18554
   Mehrpour M., 2012, ATLAS GENET CYTOGENE, V16, P165
   Milla LN, 2011, J CELL BIOCHEM, V112, P2266, DOI 10.1002/jcb.23145
   Sanabria LM, 2013, BBA-REV CANCER, V1835, P36, DOI 10.1016/j.bbcan.2012.10.001
   Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005
   Nowak J, 2009, MOL BIOL CELL, V20, P870, DOI 10.1091/mbc.E08-07-0671
   O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066
   Pandey P, 2000, ONCOGENE, V19, P1975, DOI 10.1038/sj.onc.1203531
   Panzarini E, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.51
   Reiners JJ, 2010, AUTOPHAGY, V6, P7, DOI 10.4161/auto.6.1.10220
   Robertson CA, 2009, J PHOTOCH PHOTOBIO B, V96, P1, DOI 10.1016/j.jphotobiol.2009.04.001
   Rodriguez ME, 2017, PHOTOCH PHOTOBIO SCI, V16, P1631, DOI 10.1039/c7pp00161d
   Rodriguez ME, 2016, PHOTOCH PHOTOBIO SCI, V15, P1090, DOI 10.1039/c6pp00097e
   Takayama S, 2003, ONCOGENE, V22, P9041, DOI 10.1038/sj.onc.1207114
   Tyedmers J, 2010, NAT REV MOL CELL BIO, V11, P777, DOI 10.1038/nrm2993
   Vos MJ, 2011, AUTOPHAGY, V7, P101, DOI 10.4161/auto.7.1.13935
   Vrouenraets MB, 2003, ANTICANCER RES, V23, P505
   Wachowska M, 2011, MOLECULES, V16, P4140, DOI 10.3390/molecules16054140
   Wang HP, 2002, PHOTOCHEM PHOTOBIOL, V76, P98, DOI 10.1562/0031-8655(2002)076<0098:UROHPA>2.0.CO;2
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   Wong E, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a006734
   Xue LY, 2007, PHOTOCHEM PHOTOBIOL, V83, P1016, DOI 10.1111/j.1751-1097.2007.00159.x
   Yang YH, 2013, P NATL ACAD SCI USA, V110, P6841, DOI 10.1073/pnas.1217692110
   Zacal N, 2005, BIOCHEM BIOPH RES CO, V331, P648, DOI 10.1016/j.bbrc.2005.03.213
   Zakeri Z, 2008, METHOD ENZYMOL, V442, P289, DOI 10.1016/S0076-6879(08)01415-8
   Zhang F, 2009, CANCER LETT, V286, P232, DOI 10.1016/j.canlet.2009.05.039
   Ziegler SA, 2007, J ENVIRON PATHOL TOX, V26, P173, DOI 10.1615/JEnvironPatholToxicolOncol.v26.i3.20
NR 54
TC 7
Z9 7
U1 1
U2 12
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1474-905X
EI 1474-9092
J9 PHOTOCH PHOTOBIO SCI
JI Photochem. Photobiol. Sci.
PD FEB 1
PY 2019
VL 18
IS 2
BP 546
EP 554
DI 10.1039/c8pp00536b
PG 9
WC Biochemistry & Molecular Biology; Biophysics; Chemistry, Physical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Chemistry
GA HL2WG
UT WOS:000458569100027
PM 30681107
OA hybrid
DA 2022-04-25
ER

PT J
AU Katona, BW
   Liu, YY
   Ma, AQ
   Jin, J
   Hua, XX
AF Katona, Bryson W.
   Liu, Yuanyuan
   Ma, Anqi
   Jin, Jian
   Hua, Xianxin
TI EZH2 inhibition enhances the efficacy of an EGFR inhibitor in
   suppressing colon cancer cells
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE autophagy; colon cancer; EGFR; epigenetics; EZH2; gefitinib; UNC1999
ID GROWTH-FACTOR RECEPTOR; AUTOPHAGY; CHLOROQUINE; PROGRESSION; MUTATIONS;
   APOPTOSIS; ERLOTINIB; THERAPY
AB Metastatic colon cancer has a 5-year survival of less than 10% despite the use of aggressive chemotherapeutic regimens. As signaling from epidermal growth factor receptor (EGFR) is often enhanced and epigenetic regulation is often altered in colon cancer, it is desirable to enhance the efficacy of EGFR-directed therapy by co-targeting an epigenetic pathway. We showed that the histone methyltransferase EZH2, which catalyzes methylation of histone H3 lysine 27 (H3K27), was upregulated in colon cancers in The Cancer Genome Atlas (TCGA) database. Since co-inhibition of both EGFR and EZH2 has not been studied in colon cancer, we examined the effects of co-inhibition of EGFR and EZH2 on 2 colon cancer cell lines, HT-29 and HCT-15. Co-inhibition of EZH2 and EGFR with the small molecules UNC1999 and gefitinib, led to a significant decrease in cell number and increased apoptosis compared to inhibition of either pathway alone, and similar results were noted after EZH2 shRNA knockdown. Moreover, co-inhibition of EZH2 and EGFR also significantly induced autophagy, indicating that autophagy may play a role in the observed synergy. Together, these findings suggest that inhibition of both EZH2 and EGFR serves as an effective method to increase the efficacy of EGFR inhibitors in suppressing colon cancer cells.
C1 [Katona, Bryson W.] Univ Penn, Div Gastroenterol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Katona, Bryson W.; Liu, Yuanyuan; Hua, Xianxin] Univ Penn, Dept Canc Biol, Perelman Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.
   [Liu, Yuanyuan] Hubei Canc Hosp, Hubei Canc Res Inst, Wuhan, Hubei, Peoples R China.
   [Ma, Anqi; Jin, Jian] Icahn Sch Med Mt Sinai, Dept Struct & Chem Biol, New York, NY 10029 USA.
RP Hua, XX (corresponding author), Univ Penn, Div Gastroenterol, Perelman Sch Med, Philadelphia, PA 19104 USA.
EM huax@mail.med.upenn.edu
OI Katona, Bryson/0000-0001-8186-9119
FU NIH/NIDDKUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [T32-DK007066]; NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [R01-DK085121, R01-GM103893]; Caring for Carcinoid Foundation-AACR
   Grant Care for Carcinoid Foundation [11-60-33]; TRP grant from the
   Leukemia and Lymphoma Society; ITMAT of the University of Pennsylvania;
   Hubei Province's Outstanding Medical Academic Leader Program; NIH/NIDDK
   Center for Molecular Studies in Digestive and Liver DiseasesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK) [P30DK050306]; NATIONAL INSTITUTE OF DIABETES
   AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
   [R01DK085121, P30DK050306] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of General Medical Sciences (NIGMS) [R01GM103893] Funding
   Source: NIH RePORTER
FX We would like to acknowledge the following support: NIH/NIDDK
   T32-DK007066 (BK), NIH R01-DK085121 (XH), NIH R01-GM103893 (JJ), Caring
   for Carcinoid Foundation-AACR Grant Care for Carcinoid Foundation
   11-60-33 (XH), TRP grant from the Leukemia and Lymphoma Society (XH),
   pilot grant from ITMAT of the University of Pennsylvania (XH), Hubei
   Province's Outstanding Medical Academic Leader Program-2013 (YL), and
   NIH/NIDDK Center for Molecular Studies in Digestive and Liver Diseases
   (P30DK050306) and its core facilities.
CR American Cancer Society Cancer, 2014, CANC FACTS FIG 2014
   Azad N, 2013, NAT REV CLIN ONCOL, V10, P256, DOI 10.1038/nrclinonc.2013.42
   Barth S, 2010, J PATHOL, V221, P117, DOI 10.1002/path.2694
   Benoit YD, 2013, EXP CELL RES, V319, P1463, DOI 10.1016/j.yexcr.2013.04.006
   Benoit YD, 2013, J CELL PHYSIOL, V228, P764, DOI 10.1002/jcp.24224
   Bokobza SM, 2014, ONCOTARGET, V5, P4765, DOI 10.18632/oncotarget.2017
   Chen YQ, 2011, J CELL SCI, V124, P161, DOI 10.1242/jcs.064576
   Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Dragowska WH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076503
   Eimer S, 2011, CANCER BIOL THER, V11, P1017, DOI 10.4161/cbt.11.12.15693
   Fussbroich B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021651
   Han CB, 2012, CANCER INVEST, V30, P741, DOI 10.3109/07357907.2012.732159
   Komatsu M, 2012, PHARMACOL RES, V66, P457, DOI 10.1016/j.phrs.2012.07.004
   Konze KD, 2013, ACS CHEM BIOL, V8, P1324, DOI [10.1021/cb400133J, 10.1021/cb400133j]
   Kristensen LS, 2009, EUR J PHARMACOL, V625, P131, DOI 10.1016/j.ejphar.2009.10.011
   Li YY, 2013, LUNG CANCER, V81, P354, DOI 10.1016/j.lungcan.2013.05.012
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   McCabe MT, 2014, EPIGENOMICS-UK, V6, P341, DOI [10.2217/EPI.14.23, 10.2217/epi.14.23]
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Mok TSK, 2014, SEMIN ONCOL, V41, P101, DOI 10.1053/j.seminoncol.2013.12.010
   Morselli E, 2009, BBA-MOL CELL RES, V1793, P1524, DOI 10.1016/j.bbamcr.2009.01.006
   R Core Team, 2014, R LANG ENV STAT COMP
   Remon J, 2014, CANCER TREAT REV, V40, P723, DOI 10.1016/j.ctrv.2014.03.006
   Shen L, 2013, ONCOTARGETS THER, V6, P321, DOI 10.2147/OTT.S42453
   Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Wei YJ, 2013, CELL, V154, P1269, DOI 10.1016/j.cell.2013.08.015
   Xu LB, 2014, J HEPATOL, V60, P590, DOI 10.1016/j.jhep.2013.10.028
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Zou YY, 2013, J THORAC ONCOL, V8, P693, DOI 10.1097/JTO.0b013e31828c7210
NR 32
TC 34
Z9 36
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PY 2014
VL 15
IS 12
BP 1677
EP 1687
DI 10.4161/15384047.2014.972776
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AZ7EP
UT WOS:000348382100012
PM 25535899
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Wang, SM
   Gu, KS
AF Wang, Shuomin
   Gu, Kangsheng
TI Insulin-like growth factor 1 inhibits autophagy of human colorectal
   carcinoma drug-resistant cells via the protein kinase B/mammalian target
   of rapamycin signaling pathway
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE insulin-like growth factor 1; human colorectal carcinoma cells;
   autophagy; protein kinase B; mammalian target of rapamycin
ID REGULATE AUTOPHAGY; CANCER CELLS; APOPTOSIS; EXPRESSION; PROGNOSIS;
   CLEAVAGE; BECLIN-1; RECEPTOR; DEATH
AB Insulin-like growth factor 1 (IGF-1) is reported to inhibit autophagy of human colorectal carcinoma cells (HCT); however, little is known regarding the mechanisms underlying the inhibitory effect of IGF-1 on autophagy in HCT resistant strains. The present study aimed to analyze the inhibitory effect of IGF-1 on the autophagy of HCT resistant strains and its potential underlying mechanisms. The viability and apoptosis of HCT-8 colon cancer cells were analyzed, and expression levels of relevant genes and proteins were investigated using reverse transcription-quantitative polymerase chain reaction and western blot analysis, respectively. Treatment of cells with IGF-1 induced apoptosis. IGF-1 treatment activated protein kinase B (AKT), which may inhibit autophagy via the AKT/mammalian target of rapamycin signaling pathway. Following inhibition of autophagy, drug resistant cells became sensitive to apoptosis induced by 5-fluorouracil.
C1 [Wang, Shuomin; Gu, Kangsheng] Anhui Med Univ, Affiliated Hosp 1, Dept Oncol, 218 Jixi Rd, Hefei 230022, Anhui, Peoples R China.
   [Wang, Shuomin] Anhui Med Univ, Affiliated Hosp 4, Dept Oncol, Hefei 230032, Anhui, Peoples R China.
RP Gu, KS (corresponding author), Anhui Med Univ, Affiliated Hosp 1, Dept Oncol, 218 Jixi Rd, Hefei 230022, Anhui, Peoples R China.
EM kangshenggu11@sina.com
CR Betin VMS, 2009, J CELL SCI, V122, P2554, DOI 10.1242/jcs.046250
   Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4
   Galluzzi L, 2008, BIOCHEM SOC T, V36, P786, DOI 10.1042/BST0360786
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   Hayashi-Nishino M, 2009, NAT CELL BIOL, V11, P1433, DOI 10.1038/ncb1991
   Ikeda H, 2009, J MOL CELL CARDIOL, V47, P664, DOI 10.1016/j.yjmcc.2009.08.028
   Jia GH, 2006, IMMUNOL CELL BIOL, V84, P448, DOI 10.1111/j.1440-1711.2006.01454.x
   Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lin CW, 2015, MOL PHARMACEUT, V12, P2858, DOI 10.1021/acs.molpharmaceut.5b00329
   Liu WJ, 2015, CANCER BIOL THER, V16, P511, DOI 10.1080/15384047.2015.1017691
   Lyu Q, 2015, BIOCHEM BIOPH RES CO, V462, P38, DOI 10.1016/j.bbrc.2015.04.102
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Nikoletopoulou V, 2013, BBA-MOL CELL RES, V1833, P3448, DOI 10.1016/j.bbamcr.2013.06.001
   Oliveira CSF, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.157
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Schwartz-Roberts JL, 2015, CANCER RES, V75, P1046, DOI 10.1158/0008-5472.CAN-14-1851
   Sekharam M, 2003, ANTICANCER RES, V23, P1517
   Sobolewska A, 2009, EUR J CELL BIOL, V88, P117, DOI 10.1016/j.ejcb.2008.09.004
   Troncoso R, 2012, CARDIOVASC RES, V93, P320, DOI 10.1093/cvr/cvr321
   Yang MP, 2015, ONCOTARGET, V6, P7084, DOI 10.18632/oncotarget.3054
   Yao W, 2016, OSTEOPOROSIS INT, V27, P283, DOI 10.1007/s00198-015-3308-6
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Zhou WH, 2012, AUTOPHAGY, V8, P389, DOI 10.4161/auto.18641
NR 25
TC 9
Z9 9
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD FEB
PY 2018
VL 17
IS 2
BP 2952
EP 2956
DI 10.3892/mmr.2017.8272
PG 5
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA FT5WP
UT WOS:000423224300111
PM 29257307
OA Green Published, hybrid, Green Submitted
DA 2022-04-25
ER

PT J
AU Tylichova, Z
   Strakova, N
   Vondracek, J
   Vaculova, AH
   Kozubik, A
   Hofmanova, J
AF Tylichova, Zuzana
   Strakova, Nicol
   Vondracek, Jan
   Vaculova, Alena Hyrslova
   Kozubik, Alois
   Hofmanova, Jirina
TI Activation of autophagy and PPAR gamma protect colon cancer cells
   against apoptosis induced by interactive effects of butyrate and DHA in
   a cell type-dependent manner: The role of cell differentiation
SO JOURNAL OF NUTRITIONAL BIOCHEMISTRY
LA English
DT Article
DE Colon cancer; Butyrate; PPAR gamma; Autophagy; Differentiation;
   Docosahexaenoic acid
ID POLYUNSATURATED FATTY-ACIDS; DOCOSAHEXAENOIC ACID; COLORECTAL-CANCER;
   SODIUM-BUTYRATE; TERMINAL DIFFERENTIATION; DIETARY FIBER; EXPRESSION;
   METABOLISM; DEATH; CARCINOGENESIS
AB The short-chain and n-3 polyunsaturated fatty acids exhibit anticancer properties, and they may mutually interact within the colon. However, the molecular mechanisms of their action in colon cancer cells are still not fully understood. Our study focused on the mechanisms responsible for the diverse effects of sodium butyrate (NaBt), in particular when interacting with docosahexaenoic acid (DHA), in distinct colon cancer cell types, in which NaBt either induces cell differentiation or activates programmed cell death involving mitochondrial pathway. NaBt activated aufophagy both in HT-29 cells, which are sensitive to induction of differentiation, and in nondifferentiating HCT-116 cells. However, autophagy supported cell survival only in HT-29 cells. Combination of NaBt with DHA-promoted cell death, especially in HCT-116 cells and after longer time intervals. The inhibition of autophagy both attenuated differentiation and enhanced apoptosis in HT-29 cells treated with NaBt and DHA, but it had no effect in HCT-116 cells. NaBt, especially in combination with DHA, activated PPAR gamma in both cell types. PPAR gamma silencing decreased differentiation and increased apoptosis only in HT-29 cells, therefore we verified the role of caspases in apoptosis, differentiation and also PPAR gamma activity using a pan-caspase inhibitor. In summary, our data suggest that diverse responses of colon cancer cells to fatty acids may rely on their sensitivity to differentiation, which may in turn depend on distinct engagement of autophagy, caspases and PPAR gamma. These results contribute to understanding of mechanisms underlying differential effects of NaBt, when interacting with other dietary fatty acids, in colon cancer cells. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Tylichova, Zuzana; Strakova, Nicol; Vondracek, Jan; Vaculova, Alena Hyrslova; Kozubik, Alois; Hofmanova, Jirina] Czech Acad Sci, Inst Biophys, Dept Cytokinet, Brno, Czech Republic.
   [Tylichova, Zuzana; Vondracek, Jan; Kozubik, Alois; Hofmanova, Jirina] Masaryk Univ, Dept Expt Biol, Fac Sci, Brno, Czech Republic.
   [Strakova, Nicol] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic.
RP Hofmanova, J (corresponding author), Kralovopolska 135, Brno 61265, Czech Republic.
EM strakova@ibp.cz; hofmanova@ibp.cz
RI Straková, Nicol/E-9685-2019; Tylichova, Zuzana/AAX-9085-2021; Vondracek,
   Jan/J-3037-2012
OI Straková, Nicol/0000-0003-3874-3777; Vondracek, Jan/0000-0003-4071-1969;
   Hyrslova Vaculova, Alena/0000-0002-0445-8807
FU Czech Science FoundationGrant Agency of the Czech Republic [13-09766S];
   Internal Grant Agency of Ministry of Health of the Czech Republic [NT
   11201-5/2010]; National Program of Sustainability II (MEYS CR) [LQ1605];
   project FNUSA-ICRC [CZ.1.05/1.1.00/02.0123]
FX This work was supported by grants No. 13-09766S of the Czech Science
   Foundation, NT 11201-5/2010 from Internal Grant Agency of Ministry of
   Health of the Czech Republic and no. LQ1605 from the National Program of
   Sustainability II (MEYS CR), the project FNUSA-ICRC no.
   CZ.1.05/1.1.00/02.0123 (OP VaVpI).
CR Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35
   Alex S, 2013, MOL CELL BIOL, V33, P1303, DOI 10.1128/MCB.00858-12
   Tran AT, 2015, EUR J NUTR, V54, P265, DOI 10.1007/s00394-014-0707-y
   Bartova E, 2005, J CELL SCI, V118, P5035, DOI 10.1242/jcs.02621
   Belcheva A, 2014, CELL, V158, P288, DOI 10.1016/j.cell.2014.04.051
   Biondo PD, 2008, J NUTR BIOCHEM, V19, P787, DOI 10.1016/j.jnutbio.2008.02.003
   Bordonaro M, 2008, CELL CYCLE, V7, P1178, DOI 10.4161/cc.7.9.5818
   Bultman SJ, 2014, CELL HOST MICROBE, V16, P143, DOI 10.1016/j.chom.2014.07.011
   Cai JY, 2004, ARCH BIOCHEM BIOPHYS, V424, P119, DOI 10.1016/j.abb.2004.02.012
   Calviello G, 2007, CURR MED CHEM, V14, P3059, DOI 10.2174/092986707782793934
   Chapkin RS, 2008, CHEM PHYS LIPIDS, V153, P14, DOI 10.1016/j.chemphyslip.2008.02.011
   Chapkin RS, 2007, CURR OPIN GASTROEN, V23, P48, DOI 10.1097/MOG.0b013e32801145d7
   Chapkin RS, 2002, LIPIDS, V37, P193, DOI 10.1007/s11745-002-0880-8
   Cho YM, 2014, EXP BIOL MED, V239, P302, DOI 10.1177/1535370213514927
   Cortie CH, 2012, INT J MOL SCI, V13, P15447, DOI 10.3390/ijms131115447
   Dai Y, 2010, WORLD J GASTRO ONCOL, V2, P159, DOI 10.4251/wjgo.v2.i3.159
   Donohoe DR, 2012, MOL CELL, V48, P612, DOI 10.1016/j.molcel.2012.08.033
   Donohoe DR, 2012, J CELL PHYSIOL, V227, P3169, DOI 10.1002/jcp.24054
   Eckhart L, 2000, J INVEST DERMATOL, V115, P1148, DOI 10.1046/j.1523-1747.2000.00205.x
   FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0
   Habermann N, 2009, BIOFACTORS, V35, P460, DOI 10.1002/biof.60
   He F, 2008, OBESITY, V16, P1735, DOI 10.1038/oby.2008.269
   Hinnebusch BF, 2002, J NUTR, V132, P1012, DOI 10.1093/jn/132.5.1012
   Hofmanova J, 2005, EUR J NUTR, V44, P40, DOI 10.1007/s00394-004-0490-2
   Hofmanova J, 2017, EUR J NUTR, V56, P1493, DOI 10.1007/s00394-016-1196-y
   Hofmanova J, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/848632
   Hofmanova J, 2013, CURR PHARM BIOTECHNO, V14, P274, DOI 10.2174/1389201011314030004
   Hofmanova J, 2009, MOL NUTR FOOD RES, V53, pS102, DOI 10.1002/mnfr.200800175
   Hossain Z, 2009, NUTR CANCER, V61, P123, DOI 10.1080/01635580802395725
   Huo Yan-qiu, 2013, Zhonghua Zhong Liu Za Zhi, V35, P579
   Jansson EA, 2005, P NATL ACAD SCI USA, V102, P1460, DOI 10.1073/pnas.0405928102
   Jing K, 2011, AUTOPHAGY, V7, P1348, DOI 10.4161/auto.7.11.16658
   Kato M, 2004, J CANCER RES CLIN, V130, P73, DOI 10.1007/s00432-003-0510-2
   Kovarikova M, 2000, EUR J CANCER, V36, P1844, DOI 10.1016/S0959-8049(00)00178-7
   Kraja B, 2015, J NUTR, V145, P1709, DOI 10.3945/jn.114.208462
   Lange K, 2015, MOL NUTR FOOD RES, V59, P1590, DOI 10.1002/mnfr.201400597
   Lazarova Darina L, 2014, BMC Res Notes, V7, P226, DOI 10.1186/1756-0500-7-226
   Leszczyniecka M, 2001, PHARMACOL THERAPEUT, V90, P105, DOI 10.1016/S0163-7258(01)00132-2
   Lupton JR, 2004, J NUTR, V134, P479, DOI 10.1093/jn/134.2.479
   Mahmood DFD, 2011, J BIOL CHEM, V286, P28858, DOI 10.1074/jbc.M111.273292
   Mariadason JM, 2001, CANCER RES, V61, P3465
   Muntener K, 2004, J BIOL CHEM, V279, P41012, DOI 10.1074/jbc.M405333200
   Ng Y, 2005, CARCINOGENESIS, V26, P1914, DOI 10.1093/carcin/bgi163
   Ogino S, 2009, GASTROENTEROLOGY, V136, P1242, DOI 10.1053/j.gastro.2008.12.048
   Ooi CC, 2010, CLIN EXP PHARMACOL P, V37, P905, DOI 10.1111/j.1440-1681.2010.05403.x
   Pajak B, 2007, ADV MED SCI-POLAND, V52, P83
   Pajak B, 2009, APOPTOSIS, V14, P203, DOI 10.1007/s10495-008-0291-9
   Pellerito O, 2014, APOPTOSIS, V19, P1029, DOI 10.1007/s10495-014-0985-0
   Peperzak V, 2013, NAT IMMUNOL, V14, P290, DOI 10.1038/ni.2527
   Peters JM, 2012, NAT REV CANCER, V12, P181, DOI 10.1038/nrc3214
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Rikiishi Hidemi, 2012, Int J Cell Biol, V2012, P317645, DOI 10.1155/2012/317645
   Rovito D, 2013, J CELL PHYSIOL, V228, P1314, DOI 10.1002/jcp.24288
   Roynette CE, 2004, CLIN NUTR, V23, P139, DOI 10.1016/j.clnu.2003.07.005
   Sabatino L, 2014, WORLD J GASTROENTERO, V20, P7137, DOI 10.3748/wjg.v20.i23.7137
   Schwab M, 2006, APOPTOSIS, V11, P1801, DOI 10.1007/s10495-006-9788-2
   Shah MS, 2011, PHYSIOL GENOMICS, V43, P640, DOI 10.1152/physiolgenomics.00213.2010
   Shalini S, 2015, CELL DEATH DIFFER, V22, P526, DOI 10.1038/cdd.2014.216
   Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102
   Shen S, 2011, ONCOGENE, V30, P4544, DOI 10.1038/onc.2011.168
   Shin J, 2014, J BIOL CHEM, V289, P25306, DOI 10.1074/jbc.M114.557546
   Skender B, 2014, BBA-MOL CELL BIOL L, V1841, P1308, DOI 10.1016/j.bbalip.2014.06.005
   Skender B, 2012, BIOMED PAP, V156, P186, DOI 10.5507/bp.2012.093
   Su WD, 2007, PHYSIOL GENOMICS, V30, P342, DOI 10.1152/physiolgenomics.00042.2007
   Tang Y, 2011, CELL DEATH DIFFER, V18, P602, DOI 10.1038/cdd.2010.117
   Thompson EA, 2007, MOL CELLS, V24, P167
   Triff Karen, 2015, Curr Pharmacol Rep, V1, P11
   Tsukahara T, 2012, BIOCHEM BIOPH RES CO, V424, P524, DOI 10.1016/j.bbrc.2012.06.149
   Vaculova A, 2005, CANCER LETT, V229, P43, DOI 10.1016/j.canlet.2004.12.016
   Vara D, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.141
   Wang YJ, 2008, J BIOL CHEM, V283, P4766, DOI 10.1074/jbc.M706666200
   Wu YT, 2008, AUTOPHAGY, V4, P457, DOI 10.4161/auto.5662
   Yang K, 2005, INT J CANCER, V116, P495, DOI 10.1002/ijc.21018
   Youssef J, 2011, BRIT J PHARMACOL, V164, P68, DOI 10.1111/j.1476-5381.2011.01383.x
   Zand H, 2008, MOL CELL BIOCHEM, V317, P113, DOI 10.1007/s11010-008-9838-x
   Zhang JT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147218
   Zhou J, 2009, INT J BIOCHEM CELL B, V41, P2334, DOI 10.1016/j.biocel.2009.06.007
NR 77
TC 29
Z9 30
U1 0
U2 41
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0955-2863
EI 1873-4847
J9 J NUTR BIOCHEM
JI J. Nutr. Biochem.
PD JAN
PY 2017
VL 39
BP 145
EP 155
DI 10.1016/j.jnutbio.2016.09.006
PG 11
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA EE4IT
UT WOS:000389566200017
PM 27840291
DA 2022-04-25
ER

PT J
AU Hu, Q
   Liang, B
   Sun, Y
   Guo, XL
   Bao, YJ
   Xie, DH
   Zhou, M
   Duan, YR
   Yin, PH
   Peng, ZH
AF Hu, Qiang
   Liang, Bo
   Sun, Ying
   Guo, Xiao-Ling
   Bao, Yi-Jie
   Xie, Dong-Hao
   Zhou, Ming
   Duan, You-Rong
   Yin, Pei-Hao
   Peng, Zhi-Hai
TI Preparation of bufalin-loaded pluronic polyetherimide nanoparticles,
   cellular uptake, distribution, and effect on colorectal cancer
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE colon cancer; nanoparticles; tumor target; bufalin
ID APOPTOSIS; CELLS; AUTOPHAGY; DEATH
AB A large number of studies have shown that bufalin can have a significant antitumor effect in a variety of tumors. However, because of toxicity, insolubility in water, fast metabolism, short half-life, and other shortcomings, its application is limited in cancer therapy. In this study, we explored the anti-metastatic role of bufalin-loaded pluronic polyetherimide nanoparticles on HCT116 colon cancer-bearing mice. Nanoparticle size, shape, drug loading, encapsulation efficiency, and in vitro drug release were studied. Also, cellular uptake of nanoparticles, in vivo tumor targeting, and tumor metastasis were studied. The nanoparticles had a particle size of about 60 nm and an encapsulation efficiency of 75.71%, by weight. The in vitro release data showed that free bufalin was released faster than bufalin-loaded pluronic polyetherimide nanoparticles, and almost 80% of free bufalin was released after 32 hours. Nanoparticles had an even size distribution, were stable, and had a slow release and a tumor-targeting effect. Bufalin-loaded pluronic polyetherimide nanoparticles can significantly inhibit the growth and metastasis of colorectal cancer.
C1 [Hu, Qiang; Peng, Zhi-Hai] Shandong Univ, Qianfoshan Hosp, Dept Hepatobiliary Surg, Jinan 250100, Peoples R China.
   [Liang, Bo; Guo, Xiao-Ling; Bao, Yi-Jie; Yin, Pei-Hao] Shanghai Univ Tradit Chinese Med, Dept Gen Surg, Putuo Hosp, Shanghai 200062, Peoples R China.
   [Hu, Qiang; Xie, Dong-Hao; Zhou, Ming] Shanghai Jiao Tong Univ, Dahua Hosp, Dept Gen Surg, Shanghai 200030, Peoples R China.
   [Sun, Ying; Duan, You-Rong] Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai 200030, Peoples R China.
RP Yin, PH (corresponding author), Shanghai Univ Tradit Chinese Med, Dept Gen Surg, Putuo Hosp, 164 Lanxi Rd, Shanghai 200062, Peoples R China.
EM yinpeihao1975@hotmail.com; zhihai.peng@hotmail.com
FU Shanghai Committee of Science and Technology, ChinaShanghai Science &
   Technology Committee [114119b3100]; Putuo District Committee of Science
   and Technology, Shanghai, China [201102]; State Administration of
   Traditional Chinese Medicine of People's Republic of China
FX This project was supported by the Shanghai Committee of Science and
   Technology, China (Number 114119b3100), and by the Putuo District
   Committee of Science and Technology, Shanghai, China (Number 201102).
   This research work was also supported by Construct Program of the Key
   Discipline of State Administration of Traditional Chinese Medicine of
   People's Republic of China. The four affiliations contributed equally to
   this work, thanks for the support of the four units.
CR Amano Y, 2009, J STEROID BIOCHEM, V114, P144, DOI 10.1016/j.jsbmb.2009.01.022
   Chen YY, 2013, ENV TOXICOL
   Cui XY, 2010, BIOL PHARM BULL, V33, P1728, DOI 10.1248/bpb.33.1728
   Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614
   Dykxhoorn DM, 2010, CANCER RES, V70, P6401, DOI 10.1158/0008-5472.CAN-10-1346
   Ferrari M, 2005, NAT REV CANCER, V5, P161, DOI 10.1038/nrc1566
   Figueredo A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005390.pub2
   Gong LL, 2007, FOOD DRUG, V9, P51
   Hunter Kent W, 2008, Breast Cancer Res, V10 Suppl 1, pS2, DOI 10.1186/bcr1988
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Kasemets K, 2009, TOXICOL IN VITRO, V23, P1116, DOI 10.1016/j.tiv.2009.05.015
   Kim SS, 2014, MOL THER, V22, P278, DOI 10.1038/mt.2013.231
   Krenn L, 1998, PHYTOCHEMISTRY, V48, P1, DOI 10.1016/S0031-9422(97)00426-3
   Lee BS, 2010, J CONTROL RELEASE, V147, P253, DOI 10.1016/j.jconrel.2010.07.096
   Li D, 2009, ANTI-CANCER DRUG, V20, P59, DOI 10.1097/CAD.0b013e3283160fd6
   Li F, 2010, DRUG DEV IND PHARM, V36, P508, DOI 10.3109/03639040903264397
   Lu CX, 2008, ANTI-CANCER DRUG, V19, P931, DOI 10.1097/CAD.0b013e3283139100
   Miao Q, 2013, INT J MOL SCI, V14, P1370, DOI 10.3390/ijms14011370
   Patel NR, 2013, ADV DRUG DELIVER REV, V65, P1748, DOI 10.1016/j.addr.2013.08.004
   Qi FH, 2011, INT IMMUNOPHARMACOL, V11, P342, DOI 10.1016/j.intimp.2010.12.007
   Shen SY, 2014, INT J BIOL SCI, V10, P212, DOI 10.7150/ijbs.8056
   Tsai SC, 2012, INT J ONCOL, V41, P1431, DOI 10.3892/ijo.2012.1579
   Venkatasubbu GD, 2012, J NANOPART RES, V14, DOI 10.1007/s11051-012-0819-3
   Xia HM, 2011, BIOMATERIALS, V32, P9888, DOI 10.1016/j.biomaterials.2011.09.004
   Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016
   Yin PH, 2012, INT J NANOMED, V7, P3961, DOI 10.2147/IJN.S32063
NR 26
TC 30
Z9 31
U1 3
U2 31
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2014
VL 9
BP 4035
EP 4041
DI 10.2147/IJN.S64708
PG 7
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA AN5CU
UT WOS:000340607800001
PM 25187707
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Sun, PH
   Zhu, LM
   Qiao, MM
   Zhang, YP
   Jiang, SH
   Wu, YL
   Tu, SP
AF Sun, Ping Hu
   Zhu, Li Ming
   Qiao, Min Min
   Zhang, Yong Ping
   Jiang, Shi Hu
   Wu, Yun Lin
   Tu, Shui Ping
TI The XAF1 tumor suppressor induces autophagic cell death via upregulation
   of Beclin-1 and inhibition of Akt pathway
SO CANCER LETTERS
LA English
DT Article
DE XAF1; Autophagy; Apoptosis; Gastric cancer; Berlin 1
ID XIAP-ASSOCIATED FACTOR-1; HALF LIM PROTEIN-2; SIGNALING PATHWAYS;
   COLON-CANCER; APOPTOSIS; GENE; EXPRESSION; DEGRADATION; ACTIVATION;
   GROWTH
AB Autophagy is designated as type II programmed cell death and may confer a tumor-suppressive function. Our previous studies have shown that XIAP-associated factor 1 (XAF1) induced apoptosis and inhibited tumor growth in gastric cancer cells. In this study, we investigated the effect of XAF1 on the induction of autophagy in gastric cancer cells. We found that adenovirus vector-mediated XAF1 (adeno-XAF1) expression markedly induced autophagy, upregulated the level of Beclin-1 and inhibited phospho-Akt and phospho-p70S6K in gastric cancer cells. The downregulation of Beclin 1 or 3-methyladenine treatment suppressed adeno-XAF1-induced autophagy, but significantly enhanced adeno-XAF1-induced apoptosis. A pan-caspase inhibitor prevented adeno-XAF1-induced apoptosis, but significantly increased adeno-XAF1-induced autophagy. Furthermore, adeno-XAF1 induced autophagy in xenograft tumor and inhibited tumor growth. Our results document that adeno-XAF1 induces autophagy through upregulation of Beclin 1 expression and inhibition of Akt/p70S6K pathway, and reveal a new mechanism of XAF1 tumor suppression. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Sun, Ping Hu; Zhu, Li Ming; Qiao, Min Min; Zhang, Yong Ping; Jiang, Shi Hu; Wu, Yun Lin; Tu, Shui Ping] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Gastroenterol, Shanghai, Peoples R China.
RP Wu, YL (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Gastroenterol, Shanghai, Peoples R China.
EM wuyunlin1951@163.com; tushuiping@yahoo.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [30572142, 30772518]
FX The project was supported by National Natural Science Foundation of
   China (Nos. 30572142, 30772518, S.P. Tu).
CR Abida WM, 2008, CANCER RES, V68, P352, DOI 10.1158/0008-5472.CAN-07-2069
   Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Aoki H, 2008, AUTOPHAGY, V4, P467, DOI 10.4161/auto.5668
   Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200
   Arora V, 2007, J BIOL CHEM, V282, P26202, DOI 10.1074/jbc.M700776200
   Basciani S, 2007, FEBS LETT, V581, P5897, DOI 10.1016/j.febslet.2007.11.069
   BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320
   Byun DS, 2003, CANCER RES, V63, P7068
   Chen N, 2010, FEBS LETT, V584, P1427, DOI 10.1016/j.febslet.2009.12.034
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Fong WG, 2000, GENOMICS, V70, P113, DOI 10.1006/geno.2000.6364
   Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Hoang B, 2009, MOL CANCER THER, V8, P1974, DOI 10.1158/1535-7163.MCT-08-1177
   Huang J, 2010, CANCER SCI, V101, P559, DOI 10.1111/j.1349-7006.2009.01396.x
   Kandouz M, 2010, CELL CYCLE, V9, P398, DOI 10.4161/cc.9.2.10505
   Klionsky DJ, 2007, AUTOPHAGY, V3, P181, DOI 10.4161/auto.3678
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Lee MG, 2006, ONCOGENE, V25, P5807, DOI 10.1038/sj.onc.1209867
   Levine B, 2008, NAT CELL BIOL, V10, P637, DOI 10.1038/ncb0608-637
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li DD, 2009, ONCOGENE, V28, P886, DOI 10.1038/onc.2008.441
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027
   Maclean KH, 2008, J CLIN INVEST, V118, P79, DOI 10.1172/JCI33700
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Paglin S, 2001, CANCER RES, V61, P439
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Qian WB, 2007, LEUKEMIA RES, V31, P329, DOI 10.1016/j.leukres.2006.06.021
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3
   Shigemitsu K, 1999, J BIOL CHEM, V274, P1058, DOI 10.1074/jbc.274.2.1058
   Thorburn J, 2005, MOL BIOL CELL, V16, P1189, DOI 10.1091/mbc.E04-10-0906
   Tu SP, 2010, CANCER-AM CANCER SOC, V116, P1252, DOI 10.1002/cncr.24814
   Tu SP, 2009, INT J CANCER, V125, P688, DOI 10.1002/ijc.24282
   Ueno T, 2008, AUTOPHAGY, V4, P692, DOI 10.4161/auto.6085
   Wang J, 2009, CARCINOGENESIS, V30, P1507, DOI 10.1093/carcin/bgp155
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
   Yu LF, 2007, CANCER-AM CANCER SOC, V109, P1996, DOI 10.1002/cncr.22624
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zeng XH, 2007, CLIN CANCER RES, V13, P1315, DOI 10.1158/1078-0432.CCR-06-1517
   Zhang WJ, 2011, MOL CARCINOGEN, V50, P199, DOI 10.1002/mc.20705
   Zhang WJ, 2011, EUR J CANCER, V47, P121, DOI 10.1016/j.ejca.2010.07.045
   Zou B, 2006, GASTROENTEROLOGY, V131, P1835, DOI 10.1053/j.gastro.2006.09.050
NR 49
TC 28
Z9 31
U1 3
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
J9 CANCER LETT
JI Cancer Lett.
PD NOV 28
PY 2011
VL 310
IS 2
BP 170
EP 180
DI 10.1016/j.canlet.2011.06.037
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 820DA
UT WOS:000294884500006
PM 21788101
DA 2022-04-25
ER

PT J
AU Wu, JN
   Lin, L
   Luo, SB
   Qiu, XZ
   Zhu, LY
   Chen, D
   Wei, ED
   Fu, ZH
   Qin, MB
   Liang, ZH
   Huang, JA
   Liu, SQ
AF Wu, Jiang-Ni
   Lin, Lan
   Luo, Shi-Bo
   Qiu, Xin-Ze
   Zhu, Li-Ye
   Chen, Da
   Wei, Er-Dan
   Fu, Zhen-Hua
   Qin, Meng-Bin
   Liang, Zhi-Hai
   Huang, Jie-An
   Liu, Shi-Quan
TI SphK1-driven autophagy potentiates focal adhesion paxillin-mediated
   metastasis in colorectal cancer
SO CANCER MEDICINE
LA English
DT Article
DE autophagy; colorectal cancer; metastases; paxillin; sphingosine kinase 1
ID CELL-MIGRATION; COLON-CANCER; P-PAXILLIN; EXPRESSION; FAK; TRANSITION;
   PATHWAY
AB Invasion and metastasis are the main causes of colorectal cancer (CRC)-related death. Accumulating evidence suggested that sphingosine kinase 1 (SphK1) promoted the metastasis of CRC and autophagy played an important role in SphK1 promoting the metastasis of malignancy. However, the mechanism by which SphK1-driven autophagy promotes invasion and metastasis in CRC remains to be clarified. In the present study, immunohistochemical detection showed the expression of SphK1 and paxillin was higher in human CRC tissues than those of normal colorectal mucosal tissues, they were both associated with TNM staging, lymphatic, and distance metastasis. In addition, study of in situ tumor transplantation model in nude mice showed that the suppression of SphK1 inhibited the growth of colonic orthotopic implantation tumors and the expression of paxillin, p-paxillin, LC3 in the tumor. So, SphK1 may promote CRC metastasis via inducing the expression of paxillin expression and its phosphorylation, in vivo. Furthermore, results of CCK8 assay, transwell and wound healing assays showed that SphK1 promoted the viability, invasion, and metastasis of CRC cells. Transmission electron microscopy detection showed that SphK1 is the key factor in autophagy induction in CRC cells. Moreover, western blot examination indicated that the expression of LC3II/I, paxillin, p-paxillin, MMP-2, and vimentin was enhanced in SphK1-overexpressed CRC cells and suppressed in SphK1 knockdown CRC cells, meanwhile, the expression of E-cadherin was suppressed in SphK1-overexpressed CRC cells and enhanced in SphK1 knockdown CRC cells. Suppression of autophagy by 3MA reversed the expression of paxillin and its phosphorylation in SphK1-overexpressed CRC cells, indicated that SphK1-driven autophagy induced the expression of paxillin and its phosphorylation in CRC cells. Together, these findings reveal that SphK1-driven autophagy may promote the invasion and metastasis of CRC via promoting the expression of focal adhesion paxillin and its phosphorylation.
C1 [Wu, Jiang-Ni; Lin, Lan; Luo, Shi-Bo; Qiu, Xin-Ze; Zhu, Li-Ye; Chen, Da; Wei, Er-Dan; Fu, Zhen-Hua; Qin, Meng-Bin; Huang, Jie-An; Liu, Shi-Quan] Guangxi Med Univ, Affiliated Hosp 2, Dept Gastroenterol, Nanning 530007, Guangxi, Peoples R China.
   [Liang, Zhi-Hai] Guangxi Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Nanning, Guangxi, Peoples R China.
RP Liu, SQ (corresponding author), Guangxi Med Univ, Affiliated Hosp 2, Dept Gastroenterol, Nanning 530007, Guangxi, Peoples R China.
EM poempower@163.com
OI WU, Jiangni/0000-0001-6514-226X
FU Natural Science Foundation of Guangxi ProvinceNational Natural Science
   Foundation of Guangxi Province [2017GXNSFAA198019, 2020GXNSFAA159056];
   Natural Science Foundation Fostering Science Foundation of the Second
   Affiliated Hospital of Guangxi Medical University [GJPY2018010];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81460380]
FX Natural Science Foundation of Guangxi Province, Grant/Award Number:
   2017GXNSFAA198019 and 2020GXNSFAA159056; Natural Science Foundation
   Fostering Science Foundation of the Second Affiliated Hospital of
   Guangxi Medical University, Grant/Award Number: GJPY2018010; National
   Natural Science Foundation of China, Grant/Award Number: 81460380
CR Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Assar EA, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00733
   Benson AB, 2017, J NATL COMPR CANC NE, V15, P370, DOI 10.6004/jnccn.2017.0036
   Birgisdottir AB, 2013, J CELL SCI, V126, P3237, DOI 10.1242/jcs.126128
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chen GC, 2008, AUTOPHAGY, V4, P37, DOI 10.4161/auto.5141
   Chen HT, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1030-2
   Chen J, 2012, CANCER RES, V72, P4130, DOI 10.1158/0008-5472.CAN-12-0655
   Das J, 2019, EXP CELL RES, V381, P201, DOI 10.1016/j.yexcr.2019.04.037
   Deakin NO, 2008, J CELL SCI, V121, P2435, DOI 10.1242/jcs.018044
   Digman MA, 2008, BIOPHYS J, V94, P2819, DOI 10.1529/biophysj.107.104984
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Guo P, 2019, CANCER BIOL MED, V16, P377, DOI 10.20892/j.issn.2095-3941.2018.0386
   Hong KO, 2019, MOLECULES, V24, DOI 10.3390/molecules24101928
   Kenific CM, 2016, J CELL BIOL, V212, P577, DOI 10.1083/jcb.201503075
   Lee BY, 2015, PHARMACOL THERAPEUT, V146, P132, DOI 10.1016/j.pharmthera.2014.10.001
   Li XH, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1138-4
   Liu H, 2017, AUTOPHAGY, V13, P900, DOI 10.1080/15548627.2017.1291479
   Liu SQ, 2019, INT J ONCOL, V54, P41, DOI 10.3892/ijo.2018.4607
   Maceyka M, 2012, TRENDS CELL BIOL, V22, P50, DOI 10.1016/j.tcb.2011.09.003
   Mantonakis E, 2017, J BUON, V22, P1097
   Lopez-Colome AM, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0418-y
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Pyne Nigel J., 2018, Advances in Biological Regulation, V68, P97, DOI 10.1016/j.jbior.2017.09.006
   Sharifi MN, 2016, CELL REP, V15, P1660, DOI 10.1016/j.celrep.2016.04.065
   Sukocheva OA, 2020, PHARMACOL THERAPEUT, V207, DOI 10.1016/j.pharmthera.2019.107464
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   Theocharis S, 2017, ANTICANCER RES, V37, P1313, DOI 10.21873/anticanres.11449
   Turner CE, 2000, J CELL SCI, V113, P4139
   Wang DP, 2019, BIOSCI BIOTECH BIOCH, V83, P836, DOI 10.1080/09168451.2019.1569496
   Wang XW, 2020, CANCER CONTROL, V27, DOI 10.1177/1073274820976664
   Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97
   Wen L, 2020, ONCOL REP, V44, P1105, DOI 10.3892/or.2020.7687
   Xu CY, 2017, INT J MOL MED, V39, P1277, DOI 10.3892/ijmm.2017.2921
   Xu CY, 2018, ONCOL LETT, V15, P9719, DOI 10.3892/ol.2018.8588
   Yin SC, 2019, CANCER MED-US, V8, P1731, DOI 10.1002/cam4.2041
   Young MM, 2016, CELL REP, V17, P1532, DOI 10.1016/j.celrep.2016.10.019
   Zheng QS, 2018, J CANCER, V9, P959, DOI 10.7150/jca.22787
   Zheng XJ, 2019, PHARMACOL THERAPEUT, V195, P85, DOI 10.1016/j.pharmthera.2018.10.011
NR 39
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2045-7634
J9 CANCER MED-US
JI Cancer Med.
PD SEP
PY 2021
VL 10
IS 17
BP 6010
EP 6021
DI 10.1002/cam4.4129
EA JUL 2021
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA UN2AV
UT WOS:000673964500001
PM 34268882
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Yang, Y
   Bai, LL
   Liao, WT
   Feng, MY
   Zhang, MX
   Wu, QJ
   Zhou, KX
   Wen, F
   Lei, WT
   Zhang, N
   Huang, JX
   Li, Q
AF Yang, Yang
   Bai, LiangLiang
   Liao, Weiting
   Feng, Mingyang
   Zhang, Mengxi
   Wu, Qiuji
   Zhou, Kexun
   Wen, Feng
   Lei, Wanting
   Zhang, Nan
   Huang, Jiaxing
   Li, Qiu
TI The role of non-apoptotic cell death in the treatment and
   drug-resistance of digestive tumors
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Review
DE Digestive tumors; Autophagy; Pyroptosis; Ferroptosis; Treatment;
   Drug-resistance
ID PANCREATIC-CANCER CELLS; ERASTIN-INDUCED FERROPTOSIS; INHIBITS
   AUTOPHAGIC FLUX; COLON-CANCER; CYTOPLASMIC VACUOLATION; OBETICHOLIC
   ACID; CARCINOMA-CELLS; PYROPTOSIS; CISPLATIN; SENSITIVITY
AB Tumor cell apoptosis evasion is one of the main reasons for easy metastasis occurrence, chemotherapy resistance, and the low five-year survival rate of digestive system tumors. Current research has shown that non-apoptotic cell death plays an important role in tumors of the digestive system. Therefore, increasing the proportion of non-apoptotic tumor cells is one of the effective methods of improving therapeutic efficacies for digestive system tumors. Non-apoptotic cell death modes mainly include autophagic cell death, pyroptosis, ferroptosis, in addition to other cell death modes. This review covers a systematic review relating to the research progress made into autophagic cell death, pyroptosis, ferroptosis, and other cell death modes in the treatment of digestive system tumors. It also highlights how treatment is a reasonable prospect based on clinical experience and provides reliable guidance for the further development of digestive system tumor treatments.
C1 [Yang, Yang; Bai, LiangLiang; Liao, Weiting; Feng, Mingyang; Zhang, Mengxi; Wu, Qiuji; Zhou, Kexun; Wen, Feng; Lei, Wanting; Zhang, Nan; Huang, Jiaxing; Li, Qiu] Sichuan Univ, West China Hosp, Canc Ctr, Dept Med Oncol, 37 GuoXue Xiang, Chengdu, Sichuan, Peoples R China.
   [Yang, Yang; Bai, LiangLiang; Liao, Weiting; Feng, Mingyang; Zhang, Mengxi; Wu, Qiuji; Zhou, Kexun; Wen, Feng; Lei, Wanting; Zhang, Nan; Huang, Jiaxing; Li, Qiu] Sichuan Univ, West China Biomed Big Data Ctr, 37 GuoXue Xiang, Chengdu, Sichuan, Peoples R China.
RP Li, Q (corresponding author), Sichuan Univ, West China Hosp, Dept Canc Ctr, Chengdu, Peoples R China.
EM liqiu@scu.edu.cn
CR Ahechu P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02918
   Alnuqaydan AM, 2020, AM J CANCER RES, V10, P799
   Andrade-Tomaz M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9092140
   Arai H, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001714
   Badgley MA, 2020, SCIENCE, V368, P85, DOI 10.1126/science.aaw9872
   Bai T, 2020, J CELL PHYSIOL, V235, P5637, DOI 10.1002/jcp.29496
   Bai T, 2019, J CELL MOL MED, V23, P7349, DOI 10.1111/jcmm.14594
   Bai T, 2017, BIOCHEM BIOPH RES CO, V491, P919, DOI 10.1016/j.bbrc.2017.07.136
   Barber G, 2020, CANCER IMMUNOL IMMUN, V69, P2635, DOI 10.1007/s00262-020-02650-4
   Camidge DR, 2018, NEW ENGL J MED, V379, P2027, DOI 10.1056/NEJMoa1810171
   Carneiro BA, 2020, NAT REV CLIN ONCOL, V17, P395, DOI 10.1038/s41571-020-0341-y
   Chapkin RS, 2020, DIGEST DIS SCI, V65, P840, DOI 10.1007/s10620-020-06106-8
   Chen B, 2013, BIOCHEM BIOPH RES CO, V437, P526, DOI 10.1016/j.bbrc.2013.06.103
   Chen C, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.532
   Chen CH, 2019, CANCERS, V11, DOI 10.3390/cancers11091345
   Chen HZ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1278-9
   Chen HI, 2016, PATHOL ONCOL RES, V22, P699, DOI 10.1007/s12253-016-0051-z
   Chen J, 2020, ANN PALLIAT MED, V9, P1912, DOI 10.21037/apm-20-867
   Chen L, 2020, BIOCHEM BIOPH RES CO, V526, P293, DOI 10.1016/j.bbrc.2020.03.079
   Chen MB, 2018, MOL CANCER THER, V17, P1229, DOI 10.1158/1535-7163.MCT-17-1094
   Chen P, 2020, THERANOSTICS, V10, P5107, DOI 10.7150/thno.44705
   Chen YX, 2020, LANCET GASTROENTEROL, V5, P267, DOI 10.1016/S2468-1253(19)30409-1
   Chen ZH, 2020, ONCOL LETT, V20, P893, DOI 10.3892/ol.2020.11635
   Cheng DM, 2015, J LIPID RES, V56, P1583, DOI 10.1194/jlr.M059733
   Cicconi L, 2020, LEUKEMIA, V34, P914, DOI 10.1038/s41375-019-0589-3
   Cui JJ, 2019, MOL CANCER RES, V17, P1316, DOI 10.1158/1541-7786.MCR-18-0910
   Daher B, 2019, CANCER RES, V79, P3877, DOI 10.1158/0008-5472.CAN-18-3855
   Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711
   Deng BB, 2020, CELL BIOL INT, V44, P1890, DOI 10.1002/cbin.11395
   Derangere V, 2014, CELL DEATH DIFFER, V21, P1914, DOI 10.1038/cdd.2014.117
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Douzandegan Yousef, 2019, Osong Public Health Res Perspect, V10, P246, DOI 10.24171/j.phrp.2019.10.4.08
   Feng J, 2021, ACTA PHARMACOL SIN, V42, P160, DOI 10.1038/s41401-020-0439-x
   Fritsch M, 2019, NATURE, V575, P683, DOI 10.1038/s41586-019-1770-6
   Fucikova J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03221-2
   Fucikova J, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00402
   Galluzzi L, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000337corr1
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4
   Galluzzi L, 2017, NAT REV IMMUNOL, V17, P97, DOI 10.1038/nri.2016.107
   Gao YF, 2020, NAT BIOMED ENG, V4, P743, DOI 10.1038/s41551-020-0583-0
   Geller LT, 2017, SCIENCE, V357, P1156, DOI 10.1126/science.aah5043
   Geng R, 2017, CHIN J CANCER, V36, DOI 10.1186/s40880-017-0228-1
   Hage C, 2019, HEPATOLOGY, V70, P1280, DOI 10.1002/hep.30666
   Hampton T, 2019, JAMA-J AM MED ASSOC, V322, P1244, DOI 10.1001/jama.2019.14766
   Hao SH, 2017, NEOPLASIA, V19, P1022, DOI 10.1016/j.neo.2017.10.005
   He RZ, 2018, TOXICOL APPL PHARM, V356, P159, DOI 10.1016/j.taap.2018.08.003
   Henics T, 1999, BIOL CELL, V91, P485, DOI 10.1016/S0248-4900(00)88205-2
   Hotta M, 2019, BIOCHEM BIOPH RES CO, V519, P824, DOI 10.1016/j.bbrc.2019.09.033
   Hou XY, 2017, BIOMATERIALS, V124, P195, DOI 10.1016/j.biomaterials.2016.12.032
   Hu J, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392-019-0062-9
   Huang HX, 2020, EUR REV MED PHARMACO, V24, P4745, DOI 10.26355/eurrev_202005_21163
   Jennis M, 2016, GENE DEV, V30, P918, DOI 10.1101/gad.275891.115
   Jin MM, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110282
   Kabashima A, 2018, J HEPATOL, V68, P1228, DOI 10.1016/j.jhep.2018.01.026
   Karki N, 2020, CHEM-BIOL INTERACT, V327, DOI 10.1016/j.cbi.2020.109142
   Karki R, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.136720
   Khalil N, 2020, INVEST NEW DRUG, V38, P1236, DOI 10.1007/s10637-019-00883-4
   Kim D, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2618-6
   Kofahi HM, 2016, SCI REP-UK, V6, DOI 10.1038/srep37433
   Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Kumar S, 2018, MICROB PATHOGENESIS, V125, P468, DOI 10.1016/j.micpath.2018.10.012
   Lai HH, 2019, MOL ONCOL, V13, P928, DOI 10.1002/1878-0261.12449
   Lee CS, 2019, P NATL ACAD SCI USA, V116, P4508, DOI 10.1073/pnas.1817494116
   Lee E, 2012, SCIENCE, V337, P967, DOI 10.1126/science.1222077
   Lee HJ, 2018, NUTRIENTS, V10, DOI 10.3390/nu10081043
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li CF, 2021, AUTOPHAGY, V17, P948, DOI [10.1080/15548627.2020.1739447, 10.1145/3421766.3421867]
   Li H, 2019, J CELL BIOCHEM, V120, P2391, DOI 10.1002/jcb.27570
   Li PY, 2012, CANCER LETT, V314, P213, DOI 10.1016/j.canlet.2011.09.031
   Li XM, 2020, INT J BIOL SCI, V16, P61, DOI 10.7150/ijbs.38475
   Li XQ, 2019, CELL DEATH DIFFER, V26, P382, DOI 10.1038/s41418-018-0207-3
   Li YC, 2019, ONCOTARGETS THER, V12, P2649, DOI 10.2147/OTT.S188054
   Liao GY, 2016, SCI REP-UK, V6, DOI 10.1038/srep34564
   Ling Y, 2019, EUR J MED CHEM, V168, P515, DOI 10.1016/j.ejmech.2019.02.054
   Lippmann J, 2020, TRANSL ONCOL, V13, DOI 10.1016/j.tranon.2020.100785
   Liu J, 2020, CANCER GENE THER, V27, P267, DOI 10.1038/s41417-019-0134-6
   Liu SP, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392-019-0087-0
   Liu Y, 2021, CANCER GENE THER, V28, P55, DOI 10.1038/s41417-020-0182-y
   Lorenzato A, 2020, CANCERS, V12, DOI 10.3390/cancers12030685
   Louandre C, 2015, CANCER LETT, V356, P971, DOI 10.1016/j.canlet.2014.11.014
   Lu XH, 2020, INT J BIOL SCI, V16, P1427, DOI 10.7150/ijbs.42962
   Ma J, 2018, EXP CELL RES, V366, P103, DOI 10.1016/j.yexcr.2018.02.037
   Ma YS, 2018, ONCOL REP, V40, P2648, DOI 10.3892/or.2018.6694
   Ma Z, 2017, DIS ESOPHAGUS, V30, DOI 10.1093/dote/dox059
   Malfa GA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112723
   Man SM, 2016, EUR J IMMUNOL, V46, P269, DOI 10.1002/eji.201545839
   McGrail DJ, 2020, CANCER CELL, V37, P371, DOI 10.1016/j.ccell.2020.01.011
   Miyake T, 2016, SCI REP-UK, V6, DOI 10.1038/srep24853
   Nevens F, 2016, NEW ENGL J MED, V375, P631, DOI 10.1056/NEJMoa1509840
   New J, 2019, MOL CARCINOGEN, V58, P1400, DOI 10.1002/mc.23023
   Nishizawa S, 2018, ONCOL LETT, V15, P8735, DOI 10.3892/ol.2018.8447
   Niu Y, 2019, LIFE SCI, V237, DOI 10.1016/j.lfs.2019.116893
   Nyhan MJ, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2123-6
   O'Donovan TR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134676
   Ou WJ, 2017, FREE RADICAL BIO MED, V112, P597, DOI 10.1016/j.freeradbiomed.2017.09.002
   Pachathundikandi SK, 2020, CANCERS, V12, DOI 10.3390/cancers12040803
   Pan HT, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1653-7
   Park HH, 2019, J GINSENG RES, V43, P86, DOI 10.1016/j.jgr.2017.08.006
   Po WW, 2020, BIOMOL THER, V28, P202, DOI 10.4062/biomolther.2019.103
   Qi WC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52837-8
   Raha S, 2020, AM J CHINESE MED, V48, P679, DOI 10.1142/S0192415X20500342
   Ren NS, 2020, AGING-US, V12, P11025, DOI 10.18632/aging.103314
   Ribeiro-Varandas E, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-264
   Shang YX, 2020, CELL SIGNAL, V72, DOI 10.1016/j.cellsig.2020.109633
   Shen LD, 2021, ANAT REC, V304, P313, DOI 10.1002/ar.24378
   Shi CJ, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00139
   Shi JJ, 2017, TRENDS BIOCHEM SCI, V42, P245, DOI 10.1016/j.tibs.2016.10.004
   Shintoku R, 2017, CANCER SCI, V108, P2187, DOI 10.1111/cas.13380
   Sobczuk P, 2020, CANCERS, V12, DOI 10.3390/cancers12113232
   Song XX, 2018, GASTROENTEROLOGY, V154, P1480, DOI 10.1053/j.gastro.2017.12.004
   Song ZW, 2020, ONCOL REP, V43, P516, DOI 10.3892/or.2019.7425
   Sui XB, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01371
   Sun J, 2019, INT J ONCOL, V54, P1601, DOI 10.3892/ijo.2019.4757
   Sun LH, 2017, AUTOPHAGY, V13, P703, DOI 10.1080/15548627.2017.1280217
   Sun XL, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2019.109118
   Sun XF, 2016, HEPATOLOGY, V64, P488, DOI 10.1002/hep.28574
   Sun XF, 2016, HEPATOLOGY, V63, P173, DOI 10.1002/hep.28251
   Tai CJ, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040908
   Tan H, 2019, J BUON, V24, P1143
   Tang HX, 2019, INT J PHARMACEUT, V572, DOI 10.1016/j.ijpharm.2019.118782
   Tian W, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00123
   Towers CG, 2016, EBIOMEDICINE, V14, P15, DOI 10.1016/j.ebiom.2016.10.034
   Tusskorn O, 2019, BIOMED PHARMACOTHER, V111, P109, DOI 10.1016/j.biopha.2018.12.051
   Vallecillo-Hernandez J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21455-1
   van der Pluijm RW, 2020, LANCET, V395, P1345, DOI 10.1016/S0140-6736(20)30552-3
   Wang D, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01238
   Wang F, 2018, INT J CANCER, V142, P1938, DOI 10.1002/ijc.31211
   Wang K, 2019, DRUG DES DEV THER, V13, P2135, DOI 10.2147/DDDT.S199459
   Wang L, 2019, PHYTOMEDICINE, V52, P147, DOI 10.1016/j.phymed.2018.09.221
   Wang L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1063-2
   Wang L, 2019, CANCER LETT, V450, P22, DOI 10.1016/j.canlet.2019.02.014
   Wang YB, 2018, BIOCHEM BIOPH RES CO, V495, P1418, DOI 10.1016/j.bbrc.2017.11.156
   Weh KM, 2016, MOL CARCINOGEN, V55, P1876, DOI 10.1002/mc.22432
   Wei Q, 2019, ONCOL RES, V27, P827, DOI 10.3727/096504018X15462920753012
   Wen XX, 2020, BIOMATERIALS, V250, DOI 10.1016/j.biomaterials.2020.120061
   Werth EG, 2020, PROTEOMICS, V20, DOI 10.1002/pmic.202000006
   Whelan KA, 2017, ONCOGENE, V36, P4843, DOI 10.1038/onc.2017.102
   Xia XJ, 2019, CURR GENE THER, V19, P117, DOI 10.2174/1566523219666190628152137
   Xian ZY, 2020, NEOPLASMA, V67, P1063, DOI 10.4149/neo_2020_191024N1084
   Xie BS, 2020, BIOCHEM BIOPH RES CO, V521, P232, DOI 10.1016/j.bbrc.2019.10.114
   Xie YC, 2017, GASTROENTEROLOGY, V153, P1429, DOI 10.1053/j.gastro.2017.07.036
   Xie YC, 2017, CELL REP, V20, P1692, DOI 10.1016/j.celrep.2017.07.055
   Xie YC, 2016, BIOCHEM BIOPH RES CO, V473, P775, DOI 10.1016/j.bbrc.2016.03.052
   Xu BB, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2016.96
   Xu XT, 2020, EUR J PHARM SCI, V152, DOI 10.1016/j.ejps.2020.105450
   Yamaguchi Y, 2018, INT J ONCOL, V52, P1011, DOI 10.3892/ijo.2018.4259
   Yang Y, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/1242784
   Younossi ZM, 2019, LANCET, V394, P2184, DOI 10.1016/S0140-6736(19)33041-7
   Yu HT, 2017, J CELL MOL MED, V21, P648, DOI 10.1111/jcmm.13008
   Yu JH, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1441-4
   Yuan H, 2016, BIOCHEM BIOPH RES CO, V478, P838, DOI 10.1016/j.bbrc.2016.08.034
   Zhang HY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01168-8
   Zhang L, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1675613
   Zhang WF, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00507
   Zhang XB, 2019, J ADV RES, V20, P9, DOI 10.1016/j.jare.2019.04.006
   Zhang Y, 2020, PHARMACOL REP, V72, P1370, DOI 10.1007/s43440-020-00064-8
   Zhang Z, 2019, THERANOSTICS, V9, P4878, DOI 10.7150/thno.36254
   Zhao XF, 2018, J CELL BIOCHEM, V119, P5538, DOI 10.1002/jcb.26723
   Zhao YC, 2020, ONCOTARGETS THER, V13, P5429, DOI 10.2147/OTT.S254995
   Zheng K, 2020, MOL NUTR FOOD RES, V64, DOI 10.1002/mnfr.201901231
   Zheng K, 2016, J AGR FOOD CHEM, V64, P1702, DOI 10.1021/acs.jafc.5b05668
   Zheng LH, 2020, ANTI-CANCER DRUG, V31, P601, DOI 10.1097/CAD.0000000000000908
   Zhou L, 2019, FASEB J, V33, P5520, DOI 10.1096/fj.201801983R
   Zhou Y, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0898-7
   Zhou Y, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2053-8
   Zhu LY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1585-2
   Zhu S, 2017, CANCER RES, V77, P2064, DOI 10.1158/0008-5472.CAN-16-1979
   Zhu YP, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/5787218
   Zitvogel L, 2018, SCIENCE, V359, P1366, DOI 10.1126/science.aar6918
NR 170
TC 1
Z9 2
U1 6
U2 10
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD AUG 15
PY 2021
VL 405
IS 2
AR 112678
DI 10.1016/j.yexcr.2021.112678
EA JUL 2021
PG 18
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA TS0HE
UT WOS:000679336700002
PM 34171351
DA 2022-04-25
ER

PT J
AU Chen, XL
   Liu, P
   Zhu, WL
   Lou, LG
AF Chen, Xiang-ling
   Liu, Peng
   Zhu, Wei-liang
   Lou, Li-guang
TI DCZ5248, a novel dual inhibitor of Hsp90 and autophagy, exerts antitumor
   activity against colon cancer
SO ACTA PHARMACOLOGICA SINICA
LA English
DT Article
DE DCZ5248; Hsp90; autophagy; lysosomal function; antitumor activity; colon
   cancer
ID PROTEIN 90 INHIBITORS; ADVANCED SOLID TUMORS; PHASE-I TRIAL; INDUCED
   APOPTOSIS; RESISTANCE; MUTANT; HYDROXYCHLOROQUINE; DEGRADATION;
   GANETESPIB; TEMOZOLOMIDE
AB Hsp90 is a potential therapeutic target for tumor, as it maintains the stability of a variety of proteins related to tumor development and progression. Autophagy is a self-degradation process to maintain cellular homeostasis and autophagy inhibitors can suppress tumor growth. In this study, we identified DCZ5248, a triazine derivative, was a dual inhibitor of both Hsp90 and late-autophagy with potent antitumor activity against colon cancer cells in vitro and in vivo. We showed that DCZ5248 (0.1-10 mu M) induced dose-dependent degradation of Hsp90 client proteins (AKT, CDK4, CDK6 and RAF-1) in HCT 116 colon cancer cells through a proteasome-dependent pathway. Meanwhile, DCZ5248 (0.3 mu M) induced cytoplasmic vacuole formation, LC3 II conversion, p62 protein upregulation, and inhibited autophagy at the late stage in the colon cancer cell lines tested. We further revealed that the inhibition of autophagy was achieved by impairing lysosomal functions through induction of lysosomal acidification and attenuation of lysosomal cathepsin activity. The modulation of autophagy by DCZ5248 was independent of Hsp90 inhibition as the autophagy inhibition was not blocked by Hsp90 knockdown. Importantly, inhibition of both Hsp90 function and autophagy by DCZ5248 induced G(1)-phase cell cycle arrest, apoptosis, and exerted potent antitumor activity against colon cancer cells both in vitro and in vivo. These findings demonstrate that DCZ5248 is a novel dual inhibitor of Hsp90 and autophagy with potential for colon cancer therapy.
C1 [Chen, Xiang-ling; Liu, Peng; Zhu, Wei-liang; Lou, Li-guang] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China.
   [Chen, Xiang-ling; Zhu, Wei-liang; Lou, Li-guang] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
RP Lou, LG (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China.; Lou, LG (corresponding author), Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
EM lglou@mail.shcnc.ac.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81273546]; Science and Technology Commission
   of Shanghai MunicipalityScience & Technology Commission of Shanghai
   Municipality (STCSM) [18DZ2293200]; Yunnan Province Sciences and
   Technology plan [2017ZF010]
FX This research was supported by grants from the National Natural Science
   Foundation of China (No. 81273546), the Science and Technology
   Commission of Shanghai Municipality (No. 18DZ2293200) and the Yunnan
   Province Sciences and Technology plan (No. 2017ZF010).
CR Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Carew JS, 2011, J BIOL CHEM, V286, P6602, DOI 10.1074/jbc.M110.151324
   Chen FF, 2018, AM J CANCER RES, V8, P1466
   Chen XL, 2018, CANCER LETT, V434, P70, DOI 10.1016/j.canlet.2018.07.012
   Chen Y, 2017, TRAFFIC, V18, P358, DOI 10.1111/tra.12484
   Chikh A, 2014, J CELL SCI, V127, P3079, DOI 10.1242/jcs.144816
   Dong ZW, 2016, BLOOD REV, V30, P369, DOI 10.1016/j.blre.2016.04.005
   El Zouhairi Majed, 2011, Gastrointest Cancer Res, V4, P15
   Fennell D, 2018, J THORAC ONCOL, V13, pS397, DOI 10.1016/j.jtho.2018.08.415
   Goulielmaki M, 2016, ONCOTARGET, V7, P9188, DOI 10.18632/oncotarget.6942
   He SQ, 2014, INVEST NEW DRUG, V32, P577, DOI 10.1007/s10637-014-0095-4
   He W, 2016, INT J ONCOL, V48, P1710, DOI 10.3892/ijo.2016.3382
   Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1
   Jhaveri K, 2014, EXPERT OPIN INV DRUG, V23, P611, DOI 10.1517/13543784.2014.902442
   Johnson ML, 2015, J CLIN ONCOL, V33, P1666, DOI 10.1200/JCO.2014.59.7328
   Kim DG, 2014, ONCOTARGET, V5, P4438, DOI 10.18632/oncotarget.2034
   Kong A, 2016, ONCOTARGET, V7, P37680, DOI 10.18632/oncotarget.8974
   Li L, 2020, J MED CHEM, V63, P1798, DOI 10.1021/acs.jmedchem.9b00940
   Liu KS, 2012, CANCER LETT, V318, P180, DOI 10.1016/j.canlet.2011.12.015
   Liu P, 2019, CHEMISTRYOPEN, V8, P344, DOI 10.1002/open.201900055
   Mathew R, 2011, CELL, V145, P322, DOI 10.1016/j.cell.2011.03.046
   Menon MB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023054
   Mielczarek-Lewandowska A, 2019, APOPTOSIS, V24, P596, DOI 10.1007/s10495-019-01542-y
   Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Mori M, 2015, INT J ONCOL, V46, P47, DOI 10.3892/ijo.2014.2727
   Nti AA, 2019, RETINA-J RET VIT DIS, V39, P502, DOI 10.1097/IAE.0000000000002027
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Patel HJ, 2011, EXPERT OPIN DRUG DIS, V6, P559, DOI 10.1517/17460441.2011.563296
   Rangwala R, 2014, AUTOPHAGY, V10, P1391, DOI 10.4161/auto.29119
   Rangwala R, 2014, AUTOPHAGY, V10, P1369, DOI 10.4161/auto.29118
   Rao R, 2012, MOL CANCER THER, V11, P973, DOI 10.1158/1535-7163.MCT-11-0979
   Rosenfeld MR, 2014, AUTOPHAGY, V10, P1359, DOI 10.4161/auto.28984
   Shao S, 2014, INT J ONCOL, V44, P1661, DOI 10.3892/ijo.2014.2313
   Shen HM, 2014, TRENDS BIOCHEM SCI, V39, P61, DOI 10.1016/j.tibs.2013.12.001
   Sheng Y, 2014, BRIT J PHARMACOL, V171, P4970, DOI 10.1111/bph.12821
   Smith DL, 2015, TARGET ONCOL, V10, P235, DOI 10.1007/s11523-014-0329-6
   Smyth T, 2014, MOL CANCER THER, V13, P2793, DOI 10.1158/1535-7163.MCT-14-0452
   Taldone T, 2008, CURR OPIN PHARMACOL, V8, P370, DOI 10.1016/j.coph.2008.06.015
   Thorburn A, 2014, MOL PHARMACOL, V85, P830, DOI 10.1124/mol.114.091850
   Vasilevskaya IA, 2005, BIOCHEM PHARMACOL, V70, P580, DOI 10.1016/j.bcp.2005.05.018
   Wang CY, 2016, MOL CANCER THER, V15, P448, DOI 10.1158/1535-7163.MCT-15-0778
   Wang ZH, 2013, CARCINOGENESIS, V34, P128, DOI 10.1093/carcin/bgs295
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zhao XJ, 2015, AUTOPHAGY, V11, P1849, DOI 10.1080/15548627.2015.1017185
   Zhao ZX, 2016, ONCOTARGET, V7, P29648, DOI 10.18632/oncotarget.8818
NR 47
TC 4
Z9 5
U1 2
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1671-4083
EI 1745-7254
J9 ACTA PHARMACOL SIN
JI Acta Pharmacol. Sin.
PD JAN
PY 2021
VL 42
IS 1
BP 132
EP 141
DI 10.1038/s41401-020-0398-2
EA MAY 2020
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA PM9GU
UT WOS:000532622200003
PM 32404982
OA Bronze, Green Published
DA 2022-04-25
ER

PT J
AU Lee, YJ
   Kim, NY
   Suh, YA
   Lee, C
AF Lee, Youn Ju
   Kim, Nam-Yi
   Suh, Young-Ah
   Lee, ChuHee
TI Involvement of ROS in Curcumin-induced Autophagic Cell Death
SO KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY
LA English
DT Article
DE Autophagy; Curcumin; Microtubule-associated protein 1 light chain 3;
   Mitogen-activated protein kinase; Sequestome-1; Reactive oxygen species
ID MALIGNANT GLIOMA-CELLS; COLON-CANCER CELLS; OXIDATIVE STRESS;
   DOWN-REGULATION; APOPTOSIS; LC3; INHIBITION; ANTIOXIDANT; EXPRESSION;
   INDUCTION
AB Many anticancer agents as well as ionizing radiation have been shown to induce autophagy which is originally described as a protein recycling process and recently reported to play a crucial role in various disorders. In HCT116 human colon cancer cells, we found that curcumin, a polyphenolic phytochemical extracted from the plant Curcuma longa, markedly induced the conversion of microtubule-associated protein 1 light chain 3 (LC3)-I to LC3-II and degradation of sequestome-1 (SQSTM1) which is a marker of autophagosome degradation. Moreover, we found that curcumin caused GFP-LC3 formation puncta, a marker of autophagosome, and decrease of GFP-LC3 and SQSTM1 protein level in GFP-LC3 expressing HCT116 cells. It was further confirmed that treatment of cells with hydrogen peroxide induced increase of LC3 conversion and decrease of GFP-LC3 and SQSTM1 levels, but these changes by curcumin were almost completely blocked in the presence of antioxidant, N-acetylcystein (NAC), indicating that curcumin leads to reactive oxygen species (ROS) production, which results in autophagosome development and autolysosomal degradation. In parallel with NAC, SQSTM1 degradation was also diminished by bafilomycin A, a potent inhibitor of autophagosome-lysosome fusion, and cell viability assay was further confirmed that cucurmin-induced cell death was partially blocked by bafilomycin A as well as NAC. We also observed that NAC abolished curcumin-induced activation of extracelluar signal-regulated kinases (ERK) 1/2 and p38 mitogen-activated protein kinases (MAPK), but not Jun N-terminal kinase (JNK). However, the activation of ERK1/2 and p38 MAPK seemed to have no effect on the curcumin-induced autophagy, since both the conversion of LC3 protein and SQSTM1 degradation by curcumin was not changed in the presence of NAC. Taken together, our data suggest that curcumin induced ROS production, which resulted in autophagic activation and concomitant cell death in HCT116 human colon cancer cell. However, ROS-dependent activation of ERK1/2 and p38 MAPK, but not JNK, might not be involved in the curcumin-induced autophagy.
C1 [Kim, Nam-Yi; Lee, ChuHee] Yeungnam Univ, Dept Biochem & Mol Biol, Sch Med, Taegu 705717, South Korea.
   [Lee, Youn Ju] Catholic Univ, Coll Med, Dept Pharmacol, Taegu 705718, South Korea.
   [Suh, Young-Ah] Asan Med Ctr, Inst Innovat Canc Res, Seoul 138736, South Korea.
RP Lee, C (corresponding author), Yeungnam Univ, Dept Biochem & Mol Biol, Sch Med, 317-1 Daemyung 5 Dong, Taegu 705717, South Korea.
EM chlee2@ynu.ac.kr
FU Ministry of Korean Government Education, Science and Technology
   [2010-0007352]
FX This work was supported by Fure-based Technology Development Program
   (Nano Fields, Grant No. 2010-0007352) through the National Research
   Foundation of Korea (NRF) funded by the Ministry of Korean Government
   Education, Science and Technology.
CR Abe Y, 1999, PHARMACOL RES, V39, P41, DOI 10.1006/phrs.1998.0404
   Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Butler R, 2000, CELL GROWTH DIFFER, V11, P49
   Chen QY, 2010, ONCOL REP, V23, P397, DOI 10.3892/or_00000648
   Collett GP, 2004, CARCINOGENESIS, V25, P2183, DOI 10.1093/carcin/bgh233
   Dhillon N, 2008, CLIN CANCER RES, V14, P4491, DOI 10.1158/1078-0432.CCR-08-0024
   Huang WP, 2002, CELL STRUCT FUNCT, V27, P409, DOI 10.1247/csf.27.409
   Ito H, 2005, INT J ONCOL, V26, P1401
   Javvadi P, 2008, MOL PHARMACOL, V73, P1491, DOI 10.1124/mol.107.043554
   Jia YL, 2009, J ASIAN NAT PROD RES, V11, P918, DOI 10.1080/10286020903264077
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Kar R, 2009, ONCOGENE, V28, P2556, DOI 10.1038/onc.2009.118
   Kim KC, 2010, KOREAN J PHYSIOL PHA, V14, P391, DOI 10.4196/kjpp.2010.14.6.391
   Komatsu M, 2006, AUTOPHAGY, V2, P315, DOI 10.4161/auto.2974
   Lee HS, 2010, J ENZYM INHIB MED CH, V25, P720, DOI 10.3109/14756360903555274
   Lee JC, 2010, RADIAT RES, V173, P590, DOI 10.1667/RR1522.1
   MANN SS, 1994, J BIOL CHEM, V269, P11492
   McClung JM, 2010, AM J PHYSIOL-CELL PH, V298, pC542, DOI 10.1152/ajpcell.00192.2009
   Menon VP, 2007, ADV EXP MED BIOL, V595, P105
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Nagano T, 1997, JPN J PHARMACOL, V75, P363, DOI 10.1254/jjp.75.363
   Noda T, 2002, TRENDS CELL BIOL, V12, P231, DOI 10.1016/S0962-8924(02)02278-X
   O'Sullivan-Coyne G, 2009, BRIT J CANCER, V101, P1585, DOI 10.1038/sj.bjc.6605308
   Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522
   Pongrakhananon V, 2010, APOPTOSIS, V15, P574, DOI 10.1007/s10495-010-0461-4
   Ramachandiran S, 2002, CHEM RES TOXICOL, V15, P1635, DOI 10.1021/tx0200663
   Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107
   Scarlatti F, 2004, J BIOL CHEM, V279, P18384, DOI 10.1074/jbc.M313561200
   Sharma RA, 2004, CLIN CANCER RES, V10, P6847, DOI 10.1158/1078-0432.CCR-04-0744
   Tanida I, 2002, BIOCHEM BIOPH RES CO, V296, P1164, DOI 10.1016/S0006-291X(02)02057-0
   Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200
   Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200
   Webb JL, 2003, J BIOL CHEM, V278, P25009, DOI 10.1074/jbc.M300227200
   Woo JH, 2003, CARCINOGENESIS, V24, P1199, DOI 10.1093/carcin/bgg082
   Zhou DJ, 2008, AIDS, V22, P695, DOI 10.1097/QAD.0b013e3282f4a836
NR 37
TC 97
Z9 112
U1 0
U2 29
PU KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY
PI SEOUL
PA C/O EDITORIAL OFFICE, 448-13 SEOKYO-DONG, SEOUL, SOUTH KOREA
SN 1226-4512
EI 2093-3827
J9 KOREAN J PHYSIOL PHA
JI KOREAN J. PHYSIOL. PHARMACOL.
PD FEB
PY 2011
VL 15
IS 1
BP 1
EP 7
DI 10.4196/kjpp.2011.15.1.1
PG 7
WC Pharmacology & Pharmacy; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Physiology
GA 735LQ
UT WOS:000288416400001
PM 21461234
OA Green Published
DA 2022-04-25
ER

PT J
AU Hasan, M
   Reddy, SM
   Das, NK
AF Hasan, Mazen
   Reddy, Sreedhar M.
   Das, Nupur K.
TI Ferritinophagy is not required for colon cancer cell growth
SO CELL BIOLOGY INTERNATIONAL
LA English
DT Article
DE colon cancer; ferritin; ferritinophagy; iron homeostasis
ID COLORECTAL-CANCER; IRON HOMEOSTASIS; FERROPTOSIS; PROGRESSION;
   METABOLISM; MECHANISMS; DEATH; NCOA4
AB Ferritinophagy is a form of selective autophagy responsible for degrading intracellular ferritin, mediated by nuclear receptor coactivator 4 (NCOA4). NCOA4 plays significant roles in systemic iron homeostasis, and its disruption leads to simultaneous anemia and susceptibility to iron overload. The importance of iron colorectal cancer pathogenesis is well studied; however, the role of ferritinophagy in colon cancer cell growth has not been assessed. Disruption of ferritinophagy via NCOA4 knockout leads to only marginal differences in growth under basal and iron-restricted conditions. Moreover, NCOA4 played no significant role in cell death induced by 5-fluorouracil and erastin. Western blotting analysis for ferritin and transferrin receptor 1 found a dose-dependent effect on expression in both proteins in wild-type and NCOA4 knockout cell lines, but further investigation revealed no difference in growth response when treated at both high and low doses. Our data demonstrate a marginal role for ferritinophagy in growth both under normal and cytotoxic conditions in colon cancer cells, as well as a possible compensatory mechanism in colon cancer cells in response to ferroptosis induction.
C1 [Hasan, Mazen; Reddy, Sreedhar M.; Das, Nupur K.] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA.
RP Das, NK (corresponding author), 7703,MS 2,E Catherine St, Ann Arbor, MI 48109 USA.
EM nkdas@umich.edu
RI Das, Nupur/AAK-7877-2020
OI Das, Nupur/0000-0002-5652-1134
FU University of Michigan Centre for Gastrointestinal Research (UMCGR);
   Undergraduate Research Opportunity Program (UROP), University of
   MichiganUniversity of Michigan System
FX The authors acknowledge the support of the University of Michigan Centre
   for Gastrointestinal Research (UMCGR) and the Undergraduate Research
   Opportunity Program (UROP), University of Michigan.
CR Andrews NC, 2008, BLOOD, V112, P219, DOI 10.1182/blood-2007-12-077388
   Bellelli R, 2016, CELL REP, V14, P411, DOI 10.1016/j.celrep.2015.12.065
   Bogaert J, 2014, ANN GASTROENTEROL, V27, P9
   Bogdan AR, 2016, TRENDS BIOCHEM SCI, V41, P274, DOI 10.1016/j.tibs.2015.11.012
   Cao JY, 2016, CELL MOL LIFE SCI, V73, P2195, DOI 10.1007/s00018-016-2194-1
   Chifman J, 2014, ADV EXP MED BIOL, V844, P201, DOI 10.1007/978-1-4939-2095-2_10
   Cui C, 2019, CANCER MANAG RES, V11, P6323, DOI 10.2147/CMAR.S198911
   Ferreira C, 2001, BLOOD, V98, P525, DOI 10.1182/blood.V98.3.525
   Gao GF, 2019, ADV EXP MED BIOL, V1173, P21, DOI 10.1007/978-981-13-9589-5_2
   Gao MH, 2016, CELL RES, V26, P1021, DOI 10.1038/cr.2016.95
   Gao XF, 2017, P NATL ACAD SCI USA, V114, P10107, DOI 10.1073/pnas.1711058114
   Hou W, 2016, AUTOPHAGY, V12, P1425, DOI 10.1080/15548627.2016.1187366
   Kawabata H, 2019, FREE RADICAL BIO MED, V133, P46, DOI 10.1016/j.freeradbiomed.2018.06.037
   Krenn MA, 2015, FREE RADICAL BIO MED, V80, P48, DOI 10.1016/j.freeradbiomed.2014.12.007
   Kurz T, 2011, FREE RADICAL BIO MED, V50, P1647, DOI 10.1016/j.freeradbiomed.2011.03.014
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Mancias JD, 2015, ELIFE, V4, DOI 10.7554/eLife.10308
   Mancias JD, 2014, NATURE, V509, P105, DOI 10.1038/nature13148
   Marley AR, 2016, INT J MOL EPIDEMIOL, V7, P105
   Shah YM, 2009, CELL METAB, V9, P152, DOI 10.1016/j.cmet.2008.12.012
   Shen Y, 2018, AM J CANCER RES, V8, P916
   Xue X, 2016, CELL METAB, V24, P447, DOI 10.1016/j.cmet.2016.07.015
   Xue X, 2013, NUTRIENTS, V5, P2333, DOI 10.3390/nu5072333
   Xue X, 2012, CANCER RES, V72, P2285, DOI 10.1158/0008-5472.CAN-11-3836
NR 24
TC 4
Z9 4
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1065-6995
EI 1095-8355
J9 CELL BIOL INT
JI Cell Biol. Int.
PD NOV
PY 2020
VL 44
IS 11
BP 2307
EP 2314
DI 10.1002/cbin.11439
EA AUG 2020
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA OC2LZ
UT WOS:000559437200001
PM 32767706
DA 2022-04-25
ER

PT J
AU Williams, JA
   Hou, YF
   Ni, HM
   Ding, WX
AF Williams, Jessica A.
   Hou, Yifeng
   Ni, Hong-Min
   Ding, Wen-Xing
TI Role of Intracellular Calcium in Proteasome Inhibitor-Induced
   Endoplasmic Reticulum Stress, Autophagy, and Cell Death
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE autophagy; cell death; ER stress; intracellular calcium; proteasome
   inhibitor
ID TARGETING AUTOPHAGY; FUSION; CA2+; MACROAUTOPHAGY; THAPSIGARGIN;
   HOMEOSTASIS; MATURATION; LYSOSOMES; SURVIVAL; SYSTEM
AB Proteasome inhibition induces endoplasmic reticulum (ER) stress and compensatory autophagy to relieve ER stress. Disturbance of intracellular calcium homeostasis can lead to ER stress and alter the autophagy process. It has been suggested that inhibition of the proteasome disrupts intracellular calcium homeostasis. However, it is unknown if intracellular calcium affects proteasome inhibitor-induced ER stress and autophagy.
   Human colon cancer HCT116 Bax positive and negative cell lines were treated with MG132, a proteasome inhibitor. BAPTA-AM, a cell permeable free calcium chelator, was used to modulate intracellular calcium levels. Autophagy and cell death were determined by fluorescence microscopy and immunoblot analysis.
   MG132 increased intracellular calcium levels in HCT116 cells, which was suppressed by BAPTA-AM. MG132 suppressed proteasome activity independent of Bax and intracellular calcium levels in HCT116 cells. BAPTA-AM inhibited MG132-induced cellular vacuolization and ER stress, but not apoptosis. MG132 induced autophagy with normal autophagosome-lysosome fusion. BAPTA-AM seemed not to affect autophagosome-lysosome fusion in MG132-treated cells but further enhanced MG132-induced LC3-II levels and GFP-LC3 puncta formation, which was likely via impaired lysosome function.
   Blocking intracellular calcium by BAPTA-AM relieved MG132-induced ER stress, but it was unable to rescue MG132-induced apoptosis, which was likely due to impaired autophagic degradation.
C1 [Williams, Jessica A.; Ni, Hong-Min; Ding, Wen-Xing] Univ Kansas, Med Ctr, Dept Pharmacol Toxicol & Therapeut, Kansas City, KS 66160 USA.
   [Hou, Yifeng] Fudan Univ, Canc Hosp, Breast Canc Inst, Dept Breast Surg, Shanghai 200433, Peoples R China.
RP Ding, WX (corresponding author), Univ Kansas, Med Ctr, Dept Pharmacol Toxicol & Therapeut, MS 1018 3901 Rainbow Blvd, Kansas City, KS 66160 USA.
EM wxding@kumc.edu
FU NIAAAUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse
   & Alcoholism (NIAAA) [R01 AA020518-01]; National Center for Research
   ResourcesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [5P20RR021940-07]; National Institute of Environmental
   Health SciencesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Environmental Health Sciences (NIEHS) [5T32 ES007079]; National
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [81072165]; Shanghai Science and Technology
   CommitteeShanghai Science & Technology Committee [09PJ1402700]; NATIONAL
   CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Research Resources (NCRR) [P20RR021940] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Environmental Health Sciences (NIEHS)
   [T32ES007079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON
   ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Alcohol Abuse & Alcoholism (NIAAA) [R37AA020518, R01AA020518] Funding
   Source: NIH RePORTER
FX Jessica A. Williams and Yifeng Hou contribute equally to this work. The
   research work in W. X Ding's lab was supported in part by the NIAAA
   funds R01 AA020518-01 and National Center for Research Resources
   (5P20RR021940-07). J. A. Williams was supported by the "Training Program
   in Environmental Toxicology" [grant 5T32 ES007079] from the National
   Institute of Environmental Health Sciences. Y.F. Hou was supported by
   the National Natural Science Foundation of China (# 81072165) and the
   Shanghai Science and Technology Committee (# 09PJ1402700). The authors
   are indebted to Dr. Bert Vogelstein (Johns Hopkins University) and Lin
   Zhang (University of Pittsburgh) for the HCT116 Bax-positive and
   Bax-negative cell lines.
CR Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5
   Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Avivar-Valderas A, 2011, MOL CELL BIOL, V31, P3616, DOI 10.1128/MCB.05164-11
   Burdakov D, 2005, CELL CALCIUM, V38, P303, DOI 10.1016/j.ceca.2005.06.010
   Chauhan D, 2005, ANNU REV PHARMACOL, V45, P465, DOI 10.1146/annurev.pharmtox.45.120403.100037
   Ding WX, 2007, APOPTOSIS, V12, P2233, DOI 10.1007/s10495-007-0142-0
   Ding WX, 2007, AM J PATHOL, V171, P513, DOI 10.2353/ajpath.2007.070188
   Ding WX, 2007, J BIOL CHEM, V282, P4702, DOI 10.1074/jbc.M609267200
   Ding WX, 2012, J BIOL CHEM, V287, P42379, DOI 10.1074/jbc.M112.413682
   Ding WX, 2009, MOL CANCER THER, V8, P2036, DOI 10.1158/1535-7163.MCT-08-1169
   Eskelinen EL, 2002, MOL BIOL CELL, V13, P3355, DOI 10.1091/mbc.E02-02-0114
   Ganley IG, 2011, MOL CELL, V42, P731, DOI 10.1016/j.molcel.2011.04.024
   Gao WT, 2008, AUTOPHAGY, V4, P754, DOI 10.4161/auto.6360
   GORDON PB, 1993, J BIOL CHEM, V268, P26107
   Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425
   Hoyer-Hansen M, 2007, MOL CELL, V25, P193, DOI 10.1016/j.molcel.2006.12.009
   Itakura E, 2012, CELL, V151, P1256, DOI 10.1016/j.cell.2012.11.001
   Jager S, 2004, J CELL SCI, V117, P4837, DOI 10.1242/jcs.01370
   Kamada Y, 2003, CURR TOP MICROBIOL, V279, P73
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   Korolchuk VI, 2009, MOL CELL, V33, P517, DOI 10.1016/j.molcel.2009.01.021
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Li XP, 2007, NEUROCHEM INT, V50, P959, DOI 10.1016/j.neuint.2007.04.014
   Lloyd-Evans E, 2011, CELL CALCIUM, V50, P200, DOI 10.1016/j.ceca.2011.03.010
   Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660
   Michalak M, 2002, CELL CALCIUM, V32, P269, DOI 10.1016/S0143416002001884
   Mikoshiba K, 2007, J NEUROCHEM, V102, P1426, DOI 10.1111/j.1471-4159.2007.04825.x
   Mitchell BS, 2003, NEW ENGL J MED, V348, P2597, DOI 10.1056/NEJMp030092
   Ni HM, 2012, PHARMACOL RES, V66, P463, DOI 10.1016/j.phrs.2012.07.003
   Ni HM, 2011, AUTOPHAGY, V7, P188, DOI 10.4161/auto.7.2.14181
   Peppiatt CM, 2003, CELL CALCIUM, V34, P97, DOI 10.1016/S0143-4160(03)00026-5
   Pryor PR, 2000, J CELL BIOL, V149, P1053, DOI 10.1083/jcb.149.5.1053
   Rossi D, 2008, TRAFFIC, V9, P1044, DOI 10.1111/j.1600-0854.2008.00717.x
   Rusten TE, 2009, J CELL SCI, V122, P2179, DOI 10.1242/jcs.050021
   Sarkar S, 2009, AUTOPHAGY, V5, P307, DOI 10.4161/auto.5.3.7664
   Starkov AA, 2010, FEBS J, V277, P3652, DOI 10.1111/j.1742-4658.2010.07756.x
   THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466
   Williams A, 2008, NAT CHEM BIOL, V4, P295, DOI 10.1038/nchembio.79
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989
   Zhu K, 2010, ONCOGENE, V29, P451, DOI 10.1038/onc.2009.343
NR 42
TC 41
Z9 43
U1 4
U2 38
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD SEP
PY 2013
VL 30
IS 9
BP 2279
EP 2289
DI 10.1007/s11095-013-1139-8
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 206EG
UT WOS:000323499900011
PM 23893020
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Nishikawa, T
   Tsuno, NH
   Okaji, Y
   Shuno, Y
   Sasaki, K
   Hongo, K
   Sunami, E
   Kitayama, J
   Takahashi, K
   Nagawa, H
AF Nishikawa, Takeshi
   Tsuno, Nelson H.
   Okaji, Yurai
   Shuno, Yasutaka
   Sasaki, Kazuhito
   Hongo, Kumiko
   Sunami, Eiji
   Kitayama, Joji
   Takahashi, Koki
   Nagawa, Hirokazu
TI Inhibition of Autophagy Potentiates Sulforaphane-Induced Apoptosis in
   Human Colon Cancer Cells
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Article
ID CASPASE-MEDIATED APOPTOSIS; CYTOCHROME-C; CYCLE ARREST; G(2)/M ARREST;
   INDUCTION; GROWTH; PHASE; ISOTHIOCYANATES; PROTECTION; ENZYMES
AB Background. Sulforaphane (SUL), an isothiocyanate naturally present in widely consumed vegetables, particularly broccoli, has recently attracted attention due to its inhibitory effects on tumor cell growth by inducing apoptosis. We investigated the ability of SUL to induce autophagy in human colon cancer cells and whether inhibition of autophagy could potentiate the proapoptotic effect of SUL.
   Methods. The proliferation of cells treated with SUL was assessed by MTS assay and colony-forming assay. Apoptosis and caspases activity were investigated by flow cytometry. The formation of acidic vesicular organelles (AVOs) was detected in acridine-orange-stained cells by flow cytometry. Western blotting was used for the detection of light chain 3 (LC3). Localizations of LC3 and cytochrome c were analyzed by immunocytochemistry.
   Results. The proapoptotic effect was observed by treatment of cells with relatively high concentrations of SUL for long periods of time. After 16 h of treatment, evident formation of AVOs and recruitment of LC3 to autophagosomes, features of autophagy, were observed. Treatment of cells with a specific autophagy inhibitor (3-methyladenine) potentiated the proapoptotic effect of SUL, which was dependent on the activation of caspases and the release of cytochrome c to the cytosol.
   Conclusion. The present results demonstrate induction of autophagy in colon cancer cells as a protective reaction against the proapoptotic effect of SUL, and consequently, the potentiation of the proapoptotic effect by autophagy inhibition. These findings provide a premise for use of autophagy inhibitors in combination with chemotherapeutic agents for treatment of colorectal cancer.
C1 [Nishikawa, Takeshi; Tsuno, Nelson H.; Shuno, Yasutaka; Sasaki, Kazuhito; Hongo, Kumiko; Sunami, Eiji; Kitayama, Joji; Nagawa, Hirokazu] Univ Tokyo, Fac Med Sci, Dept Surg Oncol, Tokyo, Japan.
   [Tsuno, Nelson H.; Okaji, Yurai; Takahashi, Koki] Univ Tokyo, Dept Transfus Med, Fac Med Sci, Tokyo, Japan.
RP Nishikawa, T (corresponding author), Univ Tokyo, Fac Med Sci, Dept Surg Oncol, Tokyo, Japan.
EM takn-tky@umin.ac.jp
CR Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Asakage Masahiro, 2006, Angiogenesis, V9, P83, DOI 10.1007/s10456-006-9034-0
   Bonnesen C, 2001, CANCER RES, V61, P6120
   Chiao JW, 2002, INT J ONCOL, V20, P631
   Cho SD, 2005, NUTR CANCER, V52, P213, DOI 10.1207/s15327914nc5202_11
   de Bruin EC, 2008, CANCER TREAT REV, V34, P737, DOI 10.1016/j.ctrv.2008.07.001
   Fahey JW, 1997, P NATL ACAD SCI USA, V94, P10367, DOI 10.1073/pnas.94.19.10367
   Gamet-Payrastre L, 2000, CANCER RES, V60, P1426
   Gao XQ, 2001, P NATL ACAD SCI USA, V98, P15221, DOI 10.1073/pnas.261572998
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Herman-Antosiewicz A, 2007, MOL CANCER THER, V6, P1673, DOI 10.1158/1535-7163.MCT-06-0807
   Herman-Antosiewicz A, 2006, CANCER RES, V66, P5828, DOI 10.1158/0008-5472.CAN-06-0139
   Ito H, 2005, INT J ONCOL, V26, P1401
   Jakubikova J, 2005, BIOCHEM PHARMACOL, V69, P1543, DOI 10.1016/j.bcp.2005.03.015
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998
   Matsuda K, 2002, CANCER RES, V62, P2883
   Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005
   Nishikawa T, 2009, ANN SURG ONCOL, V16, P534, DOI 10.1245/s10434-008-0215-5
   Pappa G, 2007, MOL NUTR FOOD RES, V51, P977, DOI 10.1002/mnfr.200700115
   Pappa G, 2006, MUTAT RES-FUND MOL M, V599, P76, DOI 10.1016/j.mrfmmm.2006.01.007
   Park SY, 2007, ONCOL REP, V18, P181
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Sekine-Suzuki E, 2008, BIOCHEM BIOPH RES CO, V377, P341, DOI 10.1016/j.bbrc.2008.09.150
   Shan Y, 2006, INT J ONCOL, V29, P883
   Shen GX, 2006, CANCER CHEMOTH PHARM, V57, P317, DOI 10.1007/s00280-005-0050-3
   Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959
   Singh AV, 2004, CARCINOGENESIS, V25, P83, DOI 10.1093/carcin/bgg178
   Singh SV, 2004, J BIOL CHEM, V279, P25813, DOI 10.1074/jbc.M313538200
   Singletary K, 2008, CANCER EPIDEM BIOMAR, V17, P1596, DOI 10.1158/1055-9965.EPI-07-2917
   Wang LG, 2004, INT J ONCOL, V24, P187
   Yang YM, 2002, CANCER RES, V62, P2
   ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399
NR 36
TC 66
Z9 66
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2010
VL 17
IS 2
BP 592
EP 602
DI 10.1245/s10434-009-0696-x
PG 11
WC Oncology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Surgery
GA 557SR
UT WOS:000274690900036
PM 19830499
DA 2022-04-25
ER

PT J
AU Zhang, Z
   Shi, JY
   Nice, EC
   Huang, CH
   Shi, Z
AF Zhang, Zhe
   Shi, Jiayan
   Nice, Edouard C.
   Huang, Canhua
   Shi, Zheng
TI The Multifaceted Role of Flavonoids in Cancer Therapy: Leveraging
   Autophagy with a Double-Edged Sword
SO ANTIOXIDANTS
LA English
DT Review
DE flavonoids; autophagy; cancer prevention; cancer therapy; nanotechnology
ID PROGRAMMED CELL-DEATH; PANCREATIC BETA-CELLS; NATURAL-PRODUCTS;
   PROTECTIVE AUTOPHAGY; INDUCED INJURY; COLON-CANCER; LUNG-CANCER; GREEN
   TEA; IN-VITRO; APOPTOSIS
AB Flavonoids are considered as pleiotropic, safe, and readily obtainable molecules. A large number of recent studies have proposed that flavonoids have potential in the treatment of tumors by the modulation of autophagy. In many cases, flavonoids suppress cancer by stimulating excessive autophagy or impairing autophagy flux especially in apoptosis-resistant cancer cells. However, the anti-cancer activity of flavonoids may be attenuated due to the simultaneous induction of protective autophagy. Notably, flavonoids-triggered protective autophagy is becoming a trend for preventing cancer in the clinical setting or for protecting patients from conventional therapeutic side effects in normal tissues. In this review, focusing on the underlying autophagic mechanisms of flavonoids, we hope to provide a new perspective for clinical application of flavonoids in cancer therapy. In addition, we highlight new research ideas for the development of new dosage forms of flavonoids to improve their various pharmacological effects, establishing flavonoids as ideal candidates for cancer prevention and therapy in the clinic.
C1 [Zhang, Zhe; Shi, Jiayan; Huang, Canhua; Shi, Zheng] Chengdu Univ, Clin Med Coll, Chengdu 610106, Peoples R China.
   [Zhang, Zhe; Shi, Jiayan; Huang, Canhua; Shi, Zheng] Chengdu Univ, Affiliated Hosp, Chengdu 610106, Peoples R China.
   [Zhang, Zhe; Shi, Jiayan; Huang, Canhua] Sichuan Univ, Collaborat Innovat Ctr Biotherapy, Canc Ctr, West China Hosp, Chengdu 610041, Peoples R China.
   [Zhang, Zhe; Shi, Jiayan; Huang, Canhua] Sichuan Univ, State Key Lab Biotherapy, West China Hosp, Chengdu 610041, Peoples R China.
   [Zhang, Zhe; Shi, Jiayan; Huang, Canhua] Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Chengdu 610041, Peoples R China.
   [Nice, Edouard C.] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia.
RP Huang, CH; Shi, Z (corresponding author), Chengdu Univ, Clin Med Coll, Chengdu 610106, Peoples R China.; Huang, CH; Shi, Z (corresponding author), Chengdu Univ, Affiliated Hosp, Chengdu 610106, Peoples R China.; Huang, CH (corresponding author), Sichuan Univ, Collaborat Innovat Ctr Biotherapy, Canc Ctr, West China Hosp, Chengdu 610041, Peoples R China.; Huang, CH (corresponding author), Sichuan Univ, State Key Lab Biotherapy, West China Hosp, Chengdu 610041, Peoples R China.; Huang, CH (corresponding author), Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Chengdu 610041, Peoples R China.
EM scuzz@stu.scu.edu.cn; shijiayan@stu.scu.edu.cn; ed.nice@monash.edu;
   hcanhua@scu.edu.cn; shizheng@cdu.edu.cn
OI Nice, Edouard/0000-0001-5480-4715; Zhang, Zhe/0000-0001-7509-6965
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81821002, 81790251]; National Key Research
   and Development Project [2020YFA0509400, 2020YFC2002705]; Guangdong
   Basic and Applied Basic Research Foundation [2019B030302012]
FX This study was supported by grants from the National Natural Science
   Foundation of China (81821002 and 81790251), National Key Research and
   Development Project (2020YFA0509400, 2020YFC2002705), and Guangdong
   Basic and Applied Basic Research Foundation (2019B030302012).
CR Adham AN, 2021, PHYTOMEDICINE, V80, DOI 10.1016/j.phymed.2020.153371
   Aiello P, 2021, SEMIN CANCER BIOL, V69, P150, DOI 10.1016/j.semcancer.2019.08.029
   Almatroodi SA, 2021, MOLECULES, V26, DOI 10.3390/molecules26051315
   Atanasov AG, 2021, NAT REV DRUG DISCOV, V20, P200, DOI 10.1038/s41573-020-00114-z
   Bondonno NP, 2019, NAT COMMUN, V10, DOI [10.1038/s41467-019-11622-X, 10.1038/s41467-019-11622-x]
   Buyel JF, 2018, BIOTECHNOL ADV, V36, P506, DOI 10.1016/j.biotechadv.2018.02.002
   Calderon-Montano JM, 2011, MINI-REV MED CHEM, V11, P298, DOI 10.2174/138955711795305335
   Campbell JE, 2021, NAT REV MOL CELL BIO, V22, P142, DOI 10.1038/s41580-020-00317-7
   Chang CT, 2017, ARCH TOXICOL, V91, P3341, DOI 10.1007/s00204-017-1967-0
   Chen MX, 2016, MOL CELL, V64, P105, DOI 10.1016/j.molcel.2016.08.025
   Chen XP, 2019, J BUON, V24, P488
   Clemens DL, 2002, HEPATOLOGY, V35, P1196, DOI 10.1053/jhep.2002.32668
   Cocco S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21217836
   Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227
   Cragg GM, 2009, CHEM REV, V109, P3012, DOI 10.1021/cr900019j
   Devarajan A, 2021, REDOX BIOL, V38, DOI 10.1016/j.redox.2020.101810
   Diwan A.D., 2016, J NUTR SCI, V5, P47, DOI [10.1017/jns.2016.41, DOI 10.1017/jns.2016.41]
   Dutta S, 2019, FOOD CHEM TOXICOL, V128, P240, DOI 10.1016/j.fct.2019.04.012
   Efferth T, 2020, BIOTECHNOL ADV, V38, DOI 10.1016/j.biotechadv.2019.01.009
   Farha AK, 2022, CRIT REV FOOD SCI, V62, P832, DOI 10.1080/10408398.2020.1829541
   Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Garg AK, 2005, ANTIOXID REDOX SIGN, V7, P1630, DOI 10.1089/ars.2005.7.1630
   Gilardini Montani MS, 2019, CANCERS, V11, DOI 10.3390/cancers11050703
   Gomez-Sierra T, 2020, MOLECULES, V25, DOI 10.3390/molecules25194442
   Granato M, 2017, J NUTR BIOCHEM, V41, P124, DOI 10.1016/j.jnutbio.2016.12.011
   Green DR, 2017, CANCER CELL, V31, P2, DOI 10.1016/j.ccell.2016.12.007
   Ha EJ, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/7989276
   Han B, 2017, ONCOTARGET, V8, P86227, DOI 10.18632/oncotarget.21043
   Han X, 2018, BIOMED PHARMACOTHER, V108, P809, DOI 10.1016/j.biopha.2018.09.087
   Hasima N, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.467
   Havsteen BH, 2002, PHARMACOL THERAPEUT, V96, P67, DOI 10.1016/S0163-7258(02)00298-X
   He H, 2018, FOOD FUNCT, V9, P4404, DOI 10.1039/c8fo00466h
   Huang WW, 2013, INT J ONCOL, V42, P2069, DOI 10.3892/ijo.2013.1909
   Imran M, 2019, MOLECULES, V24, DOI 10.3390/molecules24122277
   Imran M, 2019, PHYTOTHER RES, V33, P263, DOI 10.1002/ptr.6227
   Jin X, 2014, MOL NUTR FOOD RES, V58, P1941, DOI 10.1002/mnfr.201400161
   Johnson R, 2017, MOLECULES, V22, DOI 10.3390/molecules22101589
   Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877
   Kanarek N, 2020, NATURE, V579, P507, DOI 10.1038/s41586-020-2124-0
   Kang CH, 2018, FOOD CHEM TOXICOL, V111, P623, DOI 10.1016/j.fct.2017.12.018
   Khan H, 2021, SEMIN CANCER BIOL, V69, P200, DOI 10.1016/j.semcancer.2019.07.023
   Khan JA, 2018, J CLIN ONCOL, V36, P194, DOI 10.1200/JCO.2017.74.9812
   Khan SA, 2009, PHARMACOL RES, V60, P382, DOI 10.1016/j.phrs.2009.07.007
   Kim CJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010125
   Kim H, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/596496
   Kim SM, 2020, NUTRIENTS, V12, DOI 10.3390/nu12082462
   Kim SM, 2020, J NUTR BIOCHEM, V83, DOI 10.1016/j.jnutbio.2020.108427
   Kim TW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0930-1
   Klimaszewska-Wisniewska A, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0288-3
   Kopustinskiene DM, 2020, NUTRIENTS, V12, DOI 10.3390/nu12020457
   Kovac AL, 2003, DRUG SAFETY, V26, P227, DOI 10.2165/00002018-200326040-00003
   Kumar Rahul, 2015, Curr Pharmacol Rep, V1, P206
   Kumar S, 2013, SCI WORLD J, DOI 10.1155/2013/162750
   Lai DN, 2019, ACTA BIOCH BIOPH SIN, V51, P1242, DOI 10.1093/abbs/gmz126
   Law BYK, 2014, SCI REP-UK, V4, DOI 10.1038/srep05510
   Lecumberri E, 2013, CLIN NUTR, V32, P894, DOI 10.1016/j.clnu.2013.03.008
   Lee DY, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9010083
   Lee DY, 2018, ACTA ORTHOP TRAUMATO, V52, P58, DOI 10.1016/j.aott.2017.11.011
   Li B, 2017, J NAT MED-TOKYO, V71, P433, DOI 10.1007/s11418-017-1076-7
   Li JWH, 2009, SCIENCE, V325, P161, DOI 10.1126/science.1168243
   Li WJ, 2010, J AGR FOOD CHEM, V58, P8977, DOI 10.1021/jf101277t
   Li X, 2020, FOOD CHEM TOXICOL, V146, DOI 10.1016/j.fct.2020.111801
   Li XR, 2019, CELL METAB, V30, P414, DOI 10.1016/j.cmet.2019.08.011
   Li Y, 2019, ENDOCR METAB IMMUNE, V19, P632, DOI 10.2174/1871530319666190207163325
   Li YT, 2020, FOOD FUNCT, V11, P10317, DOI [10.1039/d0fo01562h, 10.1039/D0FO01562H]
   Lin Y, 2008, CURR CANCER DRUG TAR, V8, P634, DOI 10.2174/156800908786241050
   Liu WW, 2013, J PHOTOCH PHOTOBIO B, V123, P23, DOI 10.1016/j.jphotobiol.2013.03.014
   Liu Y, 2017, APOPTOSIS, V22, P544, DOI 10.1007/s10495-016-1334-2
   Liu YM, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12894
   Ma YY, 2017, BBA-MOL BASIS DIS, V1863, P1904, DOI 10.1016/j.bbadis.2016.12.021
   Madunic J, 2018, CANCER LETT, V413, P11, DOI 10.1016/j.canlet.2017.10.041
   Mann J, 2002, NAT REV CANCER, V2, P143, DOI 10.1038/nrc723
   Mao YX, 2015, J CLIN ONCOL, V33, P2120, DOI 10.1200/JCO.2014.60.2896
   Mozaffarian D, 2018, CIRC RES, V122, P369, DOI 10.1161/CIRCRESAHA.117.309008
   Mukund V, 2017, CRIT REV ONCOL HEMAT, V119, P13, DOI 10.1016/j.critrevonc.2017.09.004
   Musial C, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10010123
   Adham AN, 2020, MOLECULES, V25, DOI 10.3390/molecules25215016
   Nwodo JN, 2016, ANTI-CANCER AGENT ME, V16, P108, DOI 10.2174/1871520615666150520143827
   Ojha S, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5724973
   Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412
   Pang XN, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11020135
   Peng Z, 2011, ARCH ORAL BIOL, V56, P738, DOI 10.1016/j.archoralbio.2010.12.009
   Pierzynowska K, 2019, NEUROPHARMACOLOGY, V148, P332, DOI 10.1016/j.neuropharm.2019.01.030
   Prieto-Dominguez N, 2018, CURR MED CHEM, V25, P814, DOI 10.2174/0929867324666170918125155
   Raha S, 2020, AM J CHINESE MED, V48, P679, DOI 10.1142/S0192415X20500342
   Ramos S, 2008, MOL NUTR FOOD RES, V52, P507, DOI 10.1002/mnfr.200700326
   Rengasamy KRR, 2019, PHARMACOL THERAPEUT, V194, P107, DOI 10.1016/j.pharmthera.2018.09.009
   Rezabakhsh A, 2018, J CELL BIOCHEM, V119, P8084, DOI 10.1002/jcb.26735
   Rodrigues T, 2016, NAT CHEM, V8, P531, DOI [10.1038/NCHEM.2479, 10.1038/nchem.2479]
   Rubinsztein DC, 2011, CELL, V146, P682, DOI 10.1016/j.cell.2011.07.030
   Rybstein MD, 2018, NAT CELL BIOL, V20, P243, DOI 10.1038/s41556-018-0042-2
   Sahin K, 2010, LIFE SCI, V87, P240, DOI 10.1016/j.lfs.2010.06.014
   Saitoh T, 2009, P NATL ACAD SCI USA, V106, P20842, DOI 10.1073/pnas.0911267106
   Salehi B, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061305
   Sample A, 2017, PHOTOCHEM PHOTOBIOL, V93, P943, DOI 10.1111/php.12691
   SCHLATTER J, 1990, FOOD CHEM TOXICOL, V28, P205, DOI 10.1016/0278-6915(90)90008-B
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Shoji T, 2021, TRENDS PLANT SCI, V26, P23, DOI 10.1016/j.tplants.2020.07.015
   Simoben CV, 2015, ANTI-CANCER AGENT ME, V15, P1092, DOI 10.2174/1871520615666150113110241
   Song XY, 2021, TOXICOL IN VITRO, V70, DOI 10.1016/j.tiv.2020.105047
   Stocker R, 2004, PHYSIOL REV, V84, P1381, DOI 10.1152/physrev.00047.2003
   Su HM, 2020, J AGR FOOD CHEM, V68, P13025, DOI 10.1021/acs.jafc.9b03338
   Su M, 2021, CANCERS, V13, DOI 10.3390/cancers13112512
   Sui YX, 2017, J MOL MED, V95, P311, DOI 10.1007/s00109-016-1487-z
   Tang CY, 2020, NAT REV NEPHROL, V16, P489, DOI 10.1038/s41581-020-0309-2
   Tang D, 2017, EXPERT OPIN DRUG MET, V13, P323, DOI 10.1080/17425255.2017.1251903
   Tuli HS, 2021, SEMIN CANCER BIOL, V73, P196, DOI 10.1016/j.semcancer.2020.09.014
   Verschoyle RD, 2008, EUR J CANCER, V44, P898, DOI 10.1016/j.ejca.2008.02.020
   Wang K, 2011, AUTOPHAGY, V7, P966, DOI 10.4161/auto.7.9.15863
   Wang QL, 2021, J CLIN TRANSL HEPATO, V9, P90, DOI 10.14218/JCTH.2020.00104
   Wang XN, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109086
   Warshauer JT, 2020, CELL METAB, V31, P46, DOI 10.1016/j.cmet.2019.11.017
   Watson RR, 2015, MINERVA CARDIOANGIOL, V63, P1
   Wei F, 2017, INT J ONCOL, V51, P1383, DOI 10.3892/ijo.2017.4134
   Wen WW, 2020, CURR OPIN PLANT BIOL, V55, P100, DOI 10.1016/j.pbi.2020.04.004
   Wu N, 2021, BIOMED PHARMACOTHER, V136, DOI 10.1016/j.biopha.2021.111227
   Xu HX, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00113
   Yang JL, 2018, BIOMED PHARMACOTHER, V103, P699, DOI 10.1016/j.biopha.2018.04.072
   Yang J, 2018, BIOMED PHARMACOTHER, V102, P344, DOI 10.1016/j.biopha.2018.01.128
   Yao YF, 2017, LIFE SCI, V180, P151, DOI 10.1016/j.lfs.2016.12.004
   Yarmohammadi F, 2021, J BIOCHEM MOL TOXIC, V35, DOI 10.1002/jbt.22683
   Ye J, 2018, CANCER LETT, V420, P210, DOI 10.1016/j.canlet.2018.01.061
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
   Yuhara H, 2011, AM J GASTROENTEROL, V106, P1911, DOI 10.1038/ajg.2011.301
   Zhang L, 2015, FOOD FUNCT, V6, P3464, DOI [10.1039/c5fo00671f, 10.1039/C5FO00671F]
   Zhang Z, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00213-8
   Zhang Z, 2019, THERANOSTICS, V9, P4878, DOI 10.7150/thno.36254
   Zhang Z, 2019, REDOX BIOL, V25, DOI 10.1016/j.redox.2018.11.005
   Zheng HN, 2019, BIOCHEM BIOPH RES CO, V514, P1133, DOI 10.1016/j.bbrc.2019.04.195
NR 130
TC 4
Z9 4
U1 19
U2 20
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD JUL
PY 2021
VL 10
IS 7
AR 1138
DI 10.3390/antiox10071138
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA TN0SU
UT WOS:000675955300001
PM 34356371
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Xuan, Y
   Zhao, S
   Xiao, XJ
   Xiang, LW
   Zheng, HC
AF Xuan, Ying
   Zhao, Shuang
   Xiao, Xingjun
   Xiang, Liwei
   Zheng, Hua-Chuan
TI Inhibition of chaperone-mediated autophagy reduces tumor growth and
   metastasis and promotes drug sensitivity in colorectal cancer
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE chaperone-mediated autophagy; lysosome-associated membrane protein 2A;
   colorectal cancer; drug resistance; NF-&#954; B p65 pathway;
   5-fluorouracil
AB Chaperone-mediated autophagy (CMA) is a selective type of autophagy whereby a specific subset of intracellular proteins is targeted to the lysosome for degradation. The present study investigated the mechanisms underlying the response and resistance to 5-fluorouracil (5-FU) in colorectal cancer (CRC) cell lines. In engineered 5-FU-resistant CRC cell lines, a significant elevation of lysosome-associated membrane protein 2A (LAMP2A), which is the key molecule in the CMA pathway, was identified. High expression of LAMP2A was found to be responsible for 5-FU resistance and to enhance PLD2 expression through the activation of NF-kappa B pathway. Accordingly, loss or gain of function of LAMP2A in 5-FU-resistant CRC cells rendered them sensitive or resistant to 5-FU, respectively. Taken together, the results of the present study suggested that chemoresistance in patients with CRC may be mediated by enhancing CMA. Thus, CMA is a promising predictor of chemosensitivity to 5-FU treatment and anti-CMA therapy may be a novel therapeutic option for patients with CRC.
C1 [Xuan, Ying; Zhao, Shuang; Xiao, Xingjun; Xiang, Liwei; Zheng, Hua-Chuan] China Med Univ, Dept Expt Oncol, Shengjing Hosp, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China.
RP Zheng, HC (corresponding author), China Med Univ, Dept Expt Oncol, Shengjing Hosp, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China.
EM zheng_huachuan@hotmail.com
FU Liaoning BaiQianWan Talents Program; Key Scientific and Technological
   Project of Liaoning Province [2015408001]; National Natural Scientific
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [81472544, 81672700]
FX The present study was supported by Liaoning BaiQianWan Talents Program,
   Award for Liaoning Distinguished Professor, a Key Scientific and
   Technological Project of Liaoning Province (grant no. 2015408001) and
   National Natural Scientific Foundation of China (grant nos. 81472544 and
   81672700).
CR Catarino S, 2017, ESSAYS BIOCHEM, V61, P663, DOI 10.1042/EBC20170057
   Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3
   Cuervo AM, 1998, MOL BIOL CELL, V9, P1995, DOI 10.1091/mbc.9.8.1995
   De Angelis R, 2014, LANCET ONCOL, V15, P23, DOI 10.1016/S1470-2045(13)70546-1
   Diaz-Aragon R, 2019, MOL CELL BIOCHEM, V457, P119, DOI 10.1007/s11010-019-03517-8
   Ding ZB, 2016, INT J ONCOL, V49, P2367, DOI 10.3892/ijo.2016.3754
   Du CZ, 2017, CANCER LETT, V400, P183, DOI 10.1016/j.canlet.2017.04.033
   Dubois A, 2019, LEUKEMIA, V33, P1501, DOI 10.1038/s41375-018-0336-1
   Fiucci G, 2000, INT J CANCER, V85, P882, DOI 10.1002/(SICI)1097-0215(20000315)85:6<882::AID-IJC24>3.0.CO;2-E
   Foster DA, 2003, MOL CANCER RES, V1, P789
   Germano G, 2017, NATURE, V552, P116, DOI 10.1038/nature24673
   HAMMOND SM, 1995, J BIOL CHEM, V270, P29640
   He JL, 2020, INT J CANCER, V146, P1052, DOI 10.1002/ijc.32543
   Henkels KM, 2013, ONCOGENE, V32, P5551, DOI 10.1038/onc.2013.207
   Kaushik S, 2018, NAT REV MOL CELL BIO, V19, P365, DOI 10.1038/s41580-018-0001-6
   Kaushik S, 2012, TRENDS CELL BIOL, V22, P407, DOI 10.1016/j.tcb.2012.05.006
   Kon M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003182
   Kuang YH, 2009, CANCER LETT, V276, P189, DOI 10.1016/j.canlet.2008.11.010
   Li HN, 2015, J MATER CHEM B, V3, P8070, DOI 10.1039/c5tb01210d
   Li L, 2016, ONCOGENE, V35, P4048, DOI 10.1038/onc.2015.476
   Liu MX, 2020, PATHOL ONCOL RES, V26, P281, DOI 10.1007/s12253-018-0429-1
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Nakayama K, 2002, INT J CANCER, V101, P488, DOI 10.1002/ijc.10608
   Peng SL, 2014, ANZ J SURG, V84, P837, DOI 10.1111/ans.12444
   Prados J, 2013, ANTI-CANCER AGENT ME, V13, P1204, DOI 10.2174/18715206113139990325
   Quintavalle C, 2014, J CELL PHYSIOL, V229, P1359, DOI 10.1002/jcp.24569
   Rezasoltani S, 2017, IRAN J MICROBIOL, V9, P55
   Saha T, 2012, AUTOPHAGY, V8, P1643, DOI 10.4161/auto.21654
   Saito M, 2007, ONCOL REP, V18, P1329
   Sciskalska M, 2020, EUR REV MED PHARMACO, V24, P8537, DOI 10.26355/eurrev_202008_22650
   Selvy PE, 2011, CHEM REV, V111, P6064, DOI 10.1021/cr200296t
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P145, DOI 10.3322/caac.21601
   Skarkova V, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8030234
   Suzuki J, 2017, BIOCHEM BIOPH RES CO, V482, P1334, DOI 10.1016/j.bbrc.2016.12.037
   Takayama T, 2006, J GASTROENTEROL, V41, P185, DOI 10.1007/s00535-006-1801-6
   Uchida H, 1999, ANTICANCER RES, V19, P671
   Vakifahmetoglu-Norberg H, 2013, GENE DEV, V27, P1718, DOI 10.1101/gad.220897.113
   Xiao GD, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12473
   Xie W, 2015, AUTOPHAGY, V11, P1623, DOI 10.1080/15548627.2015.1075688
   Yao YF, 2020, BIOL REV, V95, P911, DOI 10.1111/brv.12592
   Zhang Y, 2017, AUTOPHAGY, V13, P538, DOI 10.1080/15548627.2016.1268302
   Zhou JF, 2016, AUTOPHAGY, V12, P515, DOI 10.1080/15548627.2015.1136770
NR 42
TC 3
Z9 3
U1 4
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD MAY
PY 2021
VL 23
IS 5
AR 360
DI 10.3892/mmr.2021.11999
PG 9
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA RA0JS
UT WOS:000631106200001
PM 33760140
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Burada, F
   Nicoli, ER
   Ciurea, ME
   Uscatu, DC
   Ioana, M
   Gheonea, DI
AF Burada, Florin
   Nicoli, Elena Raluca
   Ciurea, Marius Eugen
   Uscatu, Daniel Constantin
   Ioana, Mihai
   Gheonea, Dan Ionut
TI Autophagy in colorectal cancer: An important switch from physiology to
   pathology
SO WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
LA English
DT Article
DE Colorectal cancer; Autophagy; Gene; Protein; Carcinogenesis
ID GENOME-WIDE ASSOCIATION; BECLIN 1 EXPRESSION; COLON-CANCER; CELL-DEATH;
   IN-VITRO; FAVORABLE PROGNOSIS; REGULATES AUTOPHAGY; SELECTIVE AUTOPHAGY;
   SUSCEPTIBILITY LOCI; DOWN-REGULATION
AB Colorectal cancer (CRC) remains a leading cause of cancer death in both men and women worldwide. Among the factors and mechanisms that are involved in the multifactorial etiology of CRC, autophagy is an important transformational switch that occurs when a cell shifts from normal to malignant. In recent years, multiple hypotheses have been considered regarding the autophagy mechanisms that are involved in cancer. The currently accepted hypothesis is that autophagy has dual and contradictory roles in carcinogenesis, but the precise mechanisms leading to autophagy in cancer are not yet fully defined and seem to be context dependent. Autophagy is a surveillance mechanism used by normal cells that protects them from the transformation to malignancy by removing damaged organelles and aggregated proteins and by reducing reactive oxygen species, mitochondrial abnormalities and DNA damage. However, autophagy also supports tumor formation by promoting access to nutrients that are critical to the metabolism and growth of tumor cells and by inhibiting cellular death and increasing drug resistance. Autophagy studies in CRC have focused on several molecules, mainly microtubule-associated protein 1 light chain 3, beclin 1, and autophagy related 5, with conflicting results. Beneficial effects were observed for some agents that modulate autophagy in CRC either alone or, more often, in combination with other agents. More extensive studies are needed in the future to clarify the roles of autophagy-related genes and modulators in colorectal carcinogenesis, and to develop potential beneficial agents for the prognosis and treatment of CRC.
C1 [Burada, Florin; Ciurea, Marius Eugen; Ioana, Mihai; Gheonea, Dan Ionut] Univ Med & Pharm Craiova, Res Ctr Gastroenterol & Hepatol, 1 Mai 66, Craiova 200638, Romania.
   [Nicoli, Elena Raluca] Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England.
   [Nicoli, Elena Raluca; Uscatu, Daniel Constantin] Univ Med & Pharm Craiova, Human Genom Lab, Craiova 200638, Romania.
RP Burada, F (corresponding author), Univ Med & Pharm Craiova, Res Ctr Gastroenterol & Hepatol, 1 Mai 66, Craiova 200638, Romania.
EM buradaflorin@gmail.com
RI Nicoli, Elena-Raluca/F-3968-2011; Gheonea, Dan Ionut/C-3578-2012; Ioana,
   Mihai/N-4923-2016
OI Nicoli, Elena-Raluca/0000-0002-5545-630X; Ioana,
   Mihai/0000-0002-2186-1606
FU European Social Found, Human Resources Development Operational Programme
   [POSDRU/159/1.5/S/133377]
FX Supported by Grant POSDRU/159/1.5/S/133377, from European Social Found,
   Human Resources Development Operational Programme 2007-2013 (to Burada
   F).
CR Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   An CH, 2011, PATHOL RES PRACT, V207, P433, DOI 10.1016/j.prp.2011.05.002
   Anderson CA, 2011, NAT GENET, V43, P246, DOI 10.1038/ng.764
   Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167
   Avalos Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/603980
   Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175
   Bhutia SK, 2013, ADV CANCER RES, V118, P61, DOI 10.1016/B978-0-12-407173-5.00003-0
   Carew JS, 2010, J CELL MOL MED, V14, P2448, DOI 10.1111/j.1582-4934.2009.00832.x
   Chan EY, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.284pe51
   Chen ZH, 2013, DIGEST DIS SCI, V58, P2887, DOI 10.1007/s10620-013-2732-8
   Cho DH, 2012, ANTICANCER RES, V32, P4091
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Choi JH, 2014, GASTROENT RES PRACT, V2014, DOI 10.1155/2014/179586
   Cianfanelli V, 2015, J CELL SCI, V128, P2003, DOI 10.1242/jcs.168153
   Cianfanelli V, 2015, NAT CELL BIOL, V17, P20, DOI 10.1038/ncb3072
   Coppola D, 2008, CANCER-AM CANCER SOC, V113, P2665, DOI 10.1002/cncr.23892
   Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Deretic V, 2013, NAT REV IMMUNOL, V13, P722, DOI 10.1038/nri3532
   Ding WX, 2009, MOL CANCER THER, V8, P2036, DOI 10.1158/1535-7163.MCT-08-1169
   Duffy A, 2015, CANCER CHEMOTH PHARM, V75, P439, DOI 10.1007/s00280-014-2637-z
   Ellington AA, 2005, CARCINOGENESIS, V26, P159, DOI 10.1093/carcin/bgh297
   Fujii S, 2008, CANCER SCI, V99, P1813, DOI 10.1111/j.1349-7006.2008.00893.x
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Gardet A, 2012, CURR OPIN IMMUNOL, V24, P522, DOI 10.1016/j.coi.2012.08.001
   Geng JF, 2008, EMBO REP, V9, P859, DOI 10.1038/embor.2008.163
   Giatromanolaki A, 2010, J CLIN PATHOL, V63, P867, DOI 10.1136/jcp.2010.079525
   Gong C, 2013, ONCOGENE, V32, P2261, DOI 10.1038/onc.2012.252
   Green DR, 2014, CELL, V157, P65, DOI 10.1016/j.cell.2014.02.049
   Green DR, 2011, SCIENCE, V333, P1109, DOI 10.1126/science.1201940
   Grimm WA, 2016, GUT, V65, P456, DOI 10.1136/gutjnl-2014-308735
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954
   Han Y, 2014, ASIAN PAC J CANCER P, V15, P4583, DOI 10.7314/APJCP.2014.15.11.4583
   Hanif R, 1997, J LAB CLIN MED, V130, P576, DOI 10.1016/S0022-2143(97)90107-4
   Hanna RA, 2012, J BIOL CHEM, V287, P19094, DOI 10.1074/jbc.M111.322933
   Huo YY, 2013, CANCER DISCOV, V3, P894, DOI 10.1158/2159-8290.CD-13-0011
   Jiang XJ, 2015, J CLIN INVEST, V125, P47, DOI 10.1172/JCI73942
   Jo YK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052705
   Jounai N, 2007, P NATL ACAD SCI USA, V104, P14050, DOI 10.1073/pnas.0704014104
   Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kaufmann AM, 2007, J PHARM SCI-US, V96, P729, DOI 10.1002/jps.20792
   Kenific CM, 2010, CURR OPIN CELL BIOL, V22, P241, DOI 10.1016/j.ceb.2009.10.008
   Kim MS, 2008, HUM PATHOL, V39, P1059, DOI 10.1016/j.humpath.2007.11.013
   Kimura S, 2008, CELL STRUCT FUNCT, V33, P109, DOI 10.1247/csf.08005
   Klionsky DJ, 2007, AUTOPHAGY, V3, P181, DOI 10.4161/auto.3678
   Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620
   Ko A, 2014, CELL DEATH DIFFER, V21, P92, DOI 10.1038/cdd.2013.124
   Koehler BC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076446
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Koneri K, 2007, ANTICANCER RES, V27, P1453
   Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029
   Laddha SV, 2014, MOL CANCER RES, V12, P485, DOI 10.1158/1541-7786.MCR-13-0614
   Lamb CA, 2013, NAT REV MOL CELL BIO, V14, P759, DOI 10.1038/nrm3696
   Lee YJ, 2011, KOREAN J PHYSIOL PHA, V15, P1, DOI 10.4196/kjpp.2011.15.1.1
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levy JMM, 2014, CANCER DISCOV, V4, P773, DOI 10.1158/2159-8290.CD-14-0049
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Liang CY, 2008, NAT CELL BIOL, V10, P776, DOI 10.1038/ncb1740
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lindqvist LM, 2014, P NATL ACAD SCI USA, V111, P8512, DOI 10.1073/pnas.1406425111
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Ma YT, 2013, IMMUNITY, V39, P211, DOI 10.1016/j.immuni.2013.07.017
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Maycotte P, 2012, AUTOPHAGY, V8, P200, DOI 10.4161/auto.8.2.18554
   Mizushima N, 2003, J CELL SCI, V116, P1679, DOI 10.1242/jcs.00381
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mizushima N, 2010, CURR OPIN CELL BIOL, V22, P132, DOI 10.1016/j.ceb.2009.12.004
   Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966
   Naumov GN, 2009, CLIN EXP METASTAS, V26, P51, DOI 10.1007/s10585-008-9176-0
   Panda PK, 2015, SEMIN CELL DEV BIOL, V39, P43, DOI 10.1016/j.semcdb.2015.02.013
   Park JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100819
   Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954
   Patel BB, 2008, INT J CANCER, V122, P267, DOI 10.1002/ijc.23097
   Pattingre S, 2008, BIOCHIMIE, V90, P313, DOI 10.1016/j.biochi.2007.08.014
   Paul S, 2012, IMMUNITY, V36, P947, DOI 10.1016/j.immuni.2012.04.008
   Psahoulia FH, 2007, CARCINOGENESIS, V28, P1021, DOI 10.1093/carcin/bgl232
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Qu XP, 2007, CELL, V128, P931, DOI 10.1016/j.cell.2006.12.044
   Radogna F, 2015, BIOCHEM PHARMACOL, V94, P1, DOI 10.1016/j.bcp.2014.12.018
   Rello-Varona S, 2012, CELL CYCLE, V11, P170, DOI 10.4161/cc.11.1.18564
   Ren F, 2014, MOL CELL BIOCHEM, V385, P95, DOI 10.1007/s11010-013-1818-0
   Reuter S, 2008, BIOCHEM PHARMACOL, V76, P1340, DOI 10.1016/j.bcp.2008.07.031
   Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032
   Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865
   Rosich L, 2012, CLIN CANCER RES, V18, P5278, DOI 10.1158/1078-0432.CCR-12-0351
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Rutter M, 2004, GASTROENTEROLOGY, V126, P451, DOI 10.1053/j.gastro.2003.11.010
   Sadowska A, 2014, PATHOL RES PRACT, V210, P576, DOI 10.1016/j.prp.2014.04.023
   Sahni S, 2014, J CLIN PATHOL, V67, P656, DOI 10.1136/jclinpath-2014-202356
   Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948
   Sasaki K, 2012, ANTI-CANCER DRUG, V23, P675, DOI 10.1097/CAD.0b013e328353f8c7
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Schonewolf CA, 2014, WORLD J GASTRO ONCOL, V6, P74, DOI 10.4251/wjgo.v6.i3.74
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Shingu T, 2009, INT J CANCER, V124, P1060, DOI 10.1002/ijc.24030
   Sotelo J, 2006, ANN INTERN MED, V144, P337, DOI 10.7326/0003-4819-144-5-200603070-00008
   Strohecker AM, 2013, CANCER DISCOV, V3, P1272, DOI 10.1158/2159-8290.CD-13-0397
   Su ZY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0321-5
   Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Trisciuoglio D, 2013, NEOPLASIA, V15, P315, DOI 10.1593/neo.121392
   Vara D, 2011, CELL DEATH DIFFER, V18, P1099, DOI 10.1038/cdd.2011.32
   Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611
   Vignot S, 2005, ANN ONCOL, V16, P525, DOI 10.1093/annonc/mdi113
   Wang JR, 2008, J BIOL CHEM, V283, P25596, DOI 10.1074/jbc.M801716200
   Wang L, 2015, CANCER BIOL THER, V16, P383, DOI 10.1080/15384047.2014.1002331
   Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wild P, 2014, J CELL SCI, V127, P3, DOI 10.1242/jcs.140426
   Wolf J, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3576
   Wu SB, 2013, BIOCHEM BIOPH RES CO, V434, P898, DOI 10.1016/j.bbrc.2013.04.053
   Wu Zhaoju, 2010, Genes Cancer, V1, P40, DOI 10.1177/1947601909358324
   Xie XQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055096
   Yang A, 2014, CANCER DISCOV, V4, P905, DOI 10.1158/2159-8290.CD-14-0362
   Yang MP, 2015, ONCOTARGET, V6, P7084, DOI 10.18632/oncotarget.3054
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yang ZL, 2015, CLIN RES HEPATOL GAS, V39, P98, DOI 10.1016/j.clinre.2014.06.014
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zaanan A, 2015, INT J CANCER, V137, P1498, DOI 10.1002/ijc.29496
   Zhan Y, 2012, FREE RADICAL BIO MED, V53, P532, DOI 10.1016/j.freeradbiomed.2012.05.018
   Zhang L, 2014, J PATHOL, V233, P103, DOI 10.1002/path.4351
   Zhang MY, 2014, INT J MOL SCI, V15, P14372, DOI 10.3390/ijms150814372
   Zheng Hai-yang, 2012, Cancer Biology Medicine, V9, P105, DOI 10.3969/j.issn.2095-3941.2012.02.004
   Zhi Xiaoyong, 2015, F1000Prime Rep, V7, P18, DOI 10.12703/P7-18
NR 142
TC 88
Z9 92
U1 1
U2 8
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1948-5204
J9 WORLD J GASTRO ONCOL
JI World J. Gastrointest. Oncol.
PD NOV 15
PY 2015
VL 7
IS 11
BP 271
EP 284
DI 10.4251/wjgo.v7.i11.271
PG 14
WC Oncology; Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Gastroenterology & Hepatology
GA V9A6T
UT WOS:000422139000002
PM 26600927
OA hybrid, Green Published
DA 2022-04-25
ER

PT J
AU Khaket, TP
   Singh, MP
   Khan, I
   Bhardwaj, M
   Kang, SC
AF Khaket, Tejinder Pal
   Singh, Mahendra Pal
   Khan, Imran
   Bhardwaj, Monika
   Kang, Sun Chul
TI Targeting of cathepsin C induces autophagic dysregulation that directs
   ER stress mediated cellular cytotoxicity in colorectal cancer cells
SO CELLULAR SIGNALLING
LA English
DT Article
DE Cathepsins; Autophag; Endoplasmic reticulum stress; Apoptosis
ID DIPEPTIDYL PEPTIDASE-I; UNFOLDED PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM
   STRESS; MONITORING AUTOPHAGY; CYSTEINE CATHEPSINS; SERINE PROTEASES;
   DEATH; ACTIVATION; INHIBITION; APOPTOSIS
AB As Autophagy is a pivotal mechanism of cancer cell survival and the development of chemotherapeutic resistance; therefore, new approaches are warranted for its targeting which may be fulfilled by cathepsins regulation. Amongst cathepsins, cathepsin C (CTSC) is highly expressed in various cancers and possesses significant therapeutic potential in autoimmune disorders; however, its role in colorectal cancer has not been explored. Herein, we aimed to investigate the role of CTSC in autophagy regulation mediated colorectal carcinoma cell proliferation. Cathepsin C targeting through inhibitors/siRNA leads to the accumulation of light chain 3 II and p62 without affecting the lysosomal integrity, revealed dysfunctional autolysosomal degradation which is also substantiated by proteolytic studies. Cathepsin C inhibition showed comparable autophagy blockade with E64d and augmented the autophagy blockade mediated by bafilomycin. Loss of CTSC function also induced ER stress mediated JNK phosphorylation accompanied by the translocation of mitochondrial cyt c followed by apoptotic cell death in colorectal carcinoma cells. Taken together, the study reveals that CTSC targeting plays a key role in the regulation of autophagy mediated colorectal cancer cell proliferation. Further investigations are required to determine the functional role of CTSC in other tumors also which may have implications for the therapeutic prevention of cancer in the future.
C1 [Khaket, Tejinder Pal; Singh, Mahendra Pal; Khan, Imran; Bhardwaj, Monika; Kang, Sun Chul] Daegu Univ, Dept Biotechnol, Gyongsan 38453, Gyeongbuk, South Korea.
RP Kang, SC (corresponding author), Daegu Univ, Coll Engn, Dept Biotechnol, Gyongsan 38453, Gyeongbuk, South Korea.
EM sckang@daegu.ac.kr
RI Singh, Mahendra Pal/J-8391-2019; Khaket, Tej/I-6260-2015
FU National Research Foundation of Korea (NRF) through Korea Research
   Fellowship Program [NRF 2016H1D3A1938249, NRF 2017R1D1A1B03036569, NRF
   2016R1A2B4009227]
FX This work was supported by the National Research Foundation of Korea
   (NRF) through Korea Research Fellowship Program (NRF 2016H1D3A1938249,
   NRF 2017R1D1A1B03036569 and NRF 2016R1A2B4009227).
CR Altorjay A, 2005, WORLD J GASTROENTERO, V11, P5751, DOI 10.3748/wjg.v11.i37.5751
   Alva AS, 2004, CELL DEATH DIFFER, V11, P1046, DOI 10.1038/sj.cdd.4401445
   Bjorkoy G, 2006, AUTOPHAGY, V2, P138, DOI 10.4161/auto.2.2.2405
   Chen KL, 2012, CANCER LETT, V317, P89, DOI 10.1016/j.canlet.2011.11.015
   Choi HS, 2006, J IMMUNOASS IMMUNOCH, V27, P31, DOI 10.1080/15321810500403722
   Colella R, 2010, CANCER LETT, V294, P195, DOI 10.1016/j.canlet.2010.01.037
   Felbor U, 2002, P NATL ACAD SCI USA, V99, P7883, DOI 10.1073/pnas.112632299
   Freundt EC, 2007, CELL RES, V17, P956, DOI 10.1038/cr.2007.80
   Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406
   Ha SD, 2010, J BIOL CHEM, V285, P2120, DOI 10.1074/jbc.M109.065813
   Hah YS, 2012, CANCER LETT, V323, P208, DOI 10.1016/j.canlet.2012.04.012
   Han J, 2013, NAT CELL BIOL, V15, P481, DOI 10.1038/ncb2738
   Hsu KF, 2009, AUTOPHAGY, V5, P451, DOI 10.4161/auto.5.4.7666
   Huang CC, 2013, FREE RADICAL BIO MED, V65, P1473, DOI 10.1016/j.freeradbiomed.2013.07.020
   Ikenoue T, 2009, METHOD ENZYMOL, V452, P165, DOI 10.1016/S0076-6879(08)03611-2
   Ishidoh K, 2002, BIOL CHEM, V383, P1827, DOI 10.1515/BC.2002.206
   Joyce JA, 2004, CELL CYCLE, V3, P1516, DOI 10.4161/cc.3.12.1289
   Jung M., 2015, PLOS ONE
   Kaminskyy V, 2012, BBA-PROTEINS PROTEOM, V1824, P44, DOI 10.1016/j.bbapap.2011.05.013
   Khaket TP, 2017, INT J PEPT RES THER, V23, P81, DOI 10.1007/s10989-016-9539-3
   Khaket TP, 2016, PROCESS BIOCHEM, V51, P1015, DOI 10.1016/j.procbio.2016.04.010
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li J, 2008, CELL DEATH DIFFER, V15, P1460, DOI 10.1038/cdd.2008.81
   Lilla JN, 2010, DEV BIOL, V337, P124, DOI 10.1016/j.ydbio.2009.10.021
   Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704
   MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458
   Methot N, 2007, J BIOL CHEM, V282, P20836, DOI 10.1074/jbc.M702615200
   Mikhaylov G, 2011, NAT NANOTECHNOL, V6, P594, DOI [10.1038/nnano.2011.112, 10.1038/NNANO.2011.112]
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Olson OC, 2015, NAT REV CANCER, V15, P712, DOI 10.1038/nrc4027
   Panda PK, 2015, SEMIN CELL DEV BIOL, V39, P43, DOI 10.1016/j.semcdb.2015.02.013
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Periyasamy-Thandavan S, 2010, AUTOPHAGY, V6, P19, DOI 10.4161/auto.6.1.10323
   Pham CTN, 2004, J IMMUNOL, V173, P7277, DOI 10.4049/jimmunol.173.12.7277
   Pham CTN, 1999, P NATL ACAD SCI USA, V96, P8627, DOI 10.1073/pnas.96.15.8627
   Powers JC, 2002, CHEM REV, V102, P4639, DOI 10.1021/cr010182v
   Repnik U, 2017, J CELL SCI, V130, P3124, DOI 10.1242/jcs.204529
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Ruffell B, 2013, GENE DEV, V27, P2086, DOI 10.1101/gad.224899.113
   Sakitani K, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1789-5
   Sheth PD, 2003, BIOCHEM PHARMACOL, V66, P2251, DOI 10.1016/j.bcp.2003.08.002
   Singh MP, 2017, FOOD CHEM TOXICOL, V110, P371, DOI 10.1016/j.fct.2017.10.054
   Singh MP, 2017, BIOMED PHARMACOTHER, V88, P151, DOI 10.1016/j.biopha.2017.01.027
   Soori M, 2016, J PHARMACOL EXP THER, V356, P375, DOI 10.1124/jpet.115.229229
   St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200
   Stahl S, 2007, BBA-PROTEINS PROTEOM, V1774, P1237, DOI 10.1016/j.bbapap.2007.07.004
   Stewart BWKP, 2015, WORLD CANC REPORT 20
   Sudhan DR, 2015, PHARMACOL THERAPEUT, V155, P105, DOI 10.1016/j.pharmthera.2015.08.007
   Sutton VR, 2007, J CELL BIOL, V176, P425, DOI 10.1083/jcb.200609077
   SWALLOW CJ, 1993, J CELL PHYSIOL, V157, P453, DOI 10.1002/jcp.1041570304
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Uchiyama Y, 2001, ARCH HISTOL CYTOL, V64, P233, DOI 10.1679/aohc.64.233
   Wei YJ, 2008, AUTOPHAGY, V4, P949, DOI 10.4161/auto.6788
   Wolters PJ, 2001, J BIOL CHEM, V276, P18551, DOI 10.1074/jbc.M100223200
   Wu J, 2006, CELL DEATH DIFFER, V13, P374, DOI 10.1038/sj.cdd.4401840
   Wu WKK, 2008, BIOCHEM BIOPH RES CO, V374, P258, DOI 10.1016/j.bbrc.2008.07.031
   Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373
   Xu HX, 2015, ANNU REV PHYSIOL, V77, P57, DOI 10.1146/annurev-physiol-021014-071649
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Yang XY, 2016, ONCOL LETT, V12, P102, DOI 10.3892/ol.2016.4590
   Yang YP, 2013, ACTA PHARMACOL SIN, V34, P625, DOI 10.1038/aps.2013.5
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707
   Zhang L, 2014, TOXICOL LETT, V228, P248, DOI 10.1016/j.toxlet.2014.05.015
   Zheng X, 2008, BBA-MOL CELL RES, V1783, P2294, DOI 10.1016/j.bbamcr.2008.07.027
   Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982
NR 69
TC 22
Z9 23
U1 1
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0898-6568
EI 1873-3913
J9 CELL SIGNAL
JI Cell. Signal.
PD JUN
PY 2018
VL 46
BP 92
EP 102
DI 10.1016/j.cellsig.2018.02.017
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA GD8RN
UT WOS:000430779900010
PM 29501728
DA 2022-04-25
ER

PT J
AU Shi, Y
   Han, Y
   Xie, F
   Wang, A
   Feng, XK
   Li, N
   Guo, HL
   Chen, DX
AF Shi, Ying
   Han, Yue
   Xie, Fang
   Wang, Anna
   Feng, Xiaokun
   Li, Ning
   Guo, Hongliang
   Chen, Dexi
TI ASPP2 enhances Oxaliplatin (L-OHP)-induced colorectal cancer cell
   apoptosis in a p53-independent manner by inhibiting cell autophagy
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE ASPP2; colorectal cancer; apoptosis; p53; autophagy
ID P53 GENE-MUTATIONS; TUMOR-SUPPRESSOR; STIMULATING PROTEIN; DNA-DAMAGE;
   EXPRESSION; PATHWAY; DEATH; DYSFUNCTION; DELETIONS; GROWTH
AB Inactivation of p53-mediated cell death pathways is a central component of cancer progression. ASPP2 (apoptosis stimulated protein of p53-2) is a p53 binding protein that specially stimulates pro-apoptosis function of p53. Down-regulation of ASPP2 is observed in many human cancers and is associated with poor prognosis and metastasis. In this study, ASPP2 was found to enhance L-OHP-induced apoptosis in HCT116 p53(-/-) cells in a p53-independent manner. Such apoptosis-promoting effect of ASPP2 was achieved by inhibiting autophagy. Further experiments with ASPP2 RNA interference and autophagy inhibitor (3-methyladenine, 3-MA) confirmed that ASPP2 enhanced HCT116 p53(-/-) cell apoptosis via inhibiting the autophagy. The association of cell death and autophagy was also found in ASPP2(+/-) mice, where colon tissue with reduced ASPP2 expression displayed more autophagy and less cell death. Finally, colorectal tumours and their adjacent normal tissues from 20 colorectal cancer patients were used to examine ASPP2 expression, p53 expression and p53 mutation, to understand their relationships with the patients' outcome. Three site mutations were found in p53 transcripts from 16 of 20 patients. ASPP2 mRNA expressions were higher, and autophagy level was lower in the adjacent normal tissues, compared with the tumour tissues, which was independent of both p53 mutation and expression level. Taken together, ASPP2 increased tumour sensitivity to chemotherapy via inhibiting autophagy in a p53-independent manner, which was associated with the tumour formation, suggesting that both p53 inactivation and ASPP2 expression level were involved in the sensitivity of colorectal cancer to chemotherapy.
C1 [Shi, Ying; Wang, Anna; Li, Ning; Chen, Dexi] Capital Univ Med Sci, Beijing Youan Hosp, Beijing, Peoples R China.
   [Shi, Ying; Xie, Fang; Wang, Anna; Li, Ning; Chen, Dexi] Beijing Inst Hepatol, Beijing, Peoples R China.
   [Han, Yue; Feng, Xiaokun; Guo, Hongliang] Univ Jinan, Shandong Acad Med Sci, Sch Med & Life Sci, Shandong Tumor Hosp, Jinan, Peoples R China.
RP Guo, HL (corresponding author), Univ Jinan, Shandong Acad Med Sci, Sch Med & Life Sci, Shandong Tumor Hosp, Jinan, Peoples R China.
EM hliangbb@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81100288, 81272266, 81361120401]; National
   Key Technology RD ProgramNational Key Technology R&D Program
   [2012BAI15B08]
FX This work was supported by National Natural Science Foundation of China
   (81100288, 81272266, 81361120401). This work is also supported by The
   National Key Technology R&D Program (2012BAI15B08).
CR BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057
   BAKER SJ, 1990, CANCER RES, V50, P7717
   BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981
   Beroud C, 2003, HUM MUTAT, V21, P176, DOI 10.1002/humu.10187
   Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967
   Chen DX, 2006, CANCER RES, V66, P3485, DOI 10.1158/0008-5472.CAN-05-4103
   Cobleigh MA, 2005, CLIN CANCER RES, V11, P8623, DOI 10.1158/1078-0432.CCR-05-0735
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Compton S, 2011, J BIOL CHEM, V286, P20297, DOI 10.1074/jbc.M110.163063
   Crighton D, 2004, BBA-REV CANCER, V1705, P3, DOI 10.1016/j.bbcan.2004.09.001
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Czaja MJ, 2013, AUTOPHAGY, V9, P1131, DOI 10.4161/auto.25063
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840
   Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152
   Kampa KM, 2009, P NATL ACAD SCI USA, V106, P4390, DOI 10.1073/pnas.0809080106
   Kobayashi S, 2005, GENES CELLS, V10, P253, DOI 10.1111/j.1365-2443.2005.00835.x
   Lossos IS, 2002, LEUKEMIA LYMPHOMA, V43, P2309, DOI 10.1080/1042819021000040017
   Mori T, 2000, FEBS LETT, V465, P124, DOI 10.1016/S0014-5793(99)01726-3
   Munro AJ, 2005, BRIT J CANCER, V92, P434, DOI 10.1038/sj.bjc.6602358
   Ozaki Toshinori, 2011, Cancers (Basel), V3, P994, DOI 10.3390/cancers3010994
   PURDIE CA, 1991, AM J PATHOL, V138, P807
   Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7
   Staples OD, 2008, SURG-J R COLL SURG E, V6, P240, DOI 10.1016/S1479-666X(08)80034-0
   Sullivan A, 2007, BRIT J CANCER, V96, P196, DOI 10.1038/sj.bjc.6603525
   Vazquez A, 2008, NAT REV DRUG DISCOV, V7, P979, DOI 10.1038/nrd2656
   Vives V, 2006, GENE DEV, V20, P1262, DOI 10.1101/gad.374006
   VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8
   Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675
   Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864
   Wang Y, 2013, CELL DEATH DIFFER, V20, P525, DOI 10.1038/cdd.2013.3
   Wang YH, 2012, P NATL ACAD SCI USA, V109, P13325, DOI 10.1073/pnas.1120193109
NR 32
TC 26
Z9 33
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD MAR
PY 2015
VL 19
IS 3
BP 535
EP 543
DI 10.1111/jcmm.12435
PG 9
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA CC4UD
UT WOS:000350348500003
PM 25534115
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Shu, W
   Liu, G
   Dai, Y
   Feng, A
   Chen, Z
   Han, J
   Li, X
AF Shu, Weibin
   Liu, Guoqin
   Dai, Yunpeng
   Feng, Alei
   Chen, Zheng
   Han, Junqing
   Li, Xinyu
TI The oncogenic role of NKAP in the growth and invasion of colon cancer
   cells
SO ONCOLOGY REPORTS
LA English
DT Article
DE colon cancer; NKAP; progression; metastasis; Akt; mTOR pathway
ID COLORECTAL-CANCER; SIGNALING PATHWAYS; E-CADHERIN; EXPRESSION;
   APOPTOSIS; STATISTICS; PI3K/AKT; PROTEIN; PROLIFERATION; AUTOPHAGY
AB It has been reported that NF-kappa B activating protein (NKAP) is a transcriptional repressor of the Notch signaling pathway and is involved in the proliferation and survival of hematopoietic stem cells. In the present study, we aimed to investigate the effect of NKAP on the progression and metastasis of colon cancer. The results of immunohistochemical staining and western blot analysis showed that NKAP was upregulated in colon cancer tissues, and its expression was associated with colon cancer stages. CCK-8, colony formation, Transwell, and flow cytometry assays were used to demonstrate that NKAP knockdown significantly suppressed the proliferation and invasion of HCT116 and HT-29 cells, and also induced apoptosis and autophagy. By contrast, NKAP overexpression markedly promoted the proliferation and invasion of HCT-15 cells, and inhibited cell apoptosis and autophagy. Moreover, we observed that NKAP knockdown inhibited the epithelial-mesenchymal transition (EMT) process in HCT116 and HT-29 cells, while NKAP overexpression promoted EMT in HCT-15 cells. Furthermore, NKAP knockdown inhibited activation of the Akt/mTOR signaling pathway by downregulating the phosphorylation of Akt and mTOR, as well as their downstream proteins, whereas NKAP overexpression promoted the Akt/mTOR signaling pathway. Additionally, expression of P65 was downregulated by silencing of NKAP and upregulated by NKAP overexpression. These data suggest that NKAP functions as an oncogene in the growth and invasion of colon cancer in vitro.
C1 [Shu, Weibin; Feng, Alei; Chen, Zheng; Han, Junqing] Shandong Univ, Shandong Prov Hosp, Dept Oncol, 324 Jingwu Rd, Jinan 250021, Shandong, Peoples R China.
   [Liu, Guoqin] Shandong Univ, Jinan Cent Hosp, Dept Gen Surg, Jinan 250021, Shandong, Peoples R China.
   [Dai, Yunpeng; Li, Xinyu] Shandong Univ, Shandong Prov Hosp, Dept Pediat, 324 Jingwu Rd, Jinan 250021, Shandong, Peoples R China.
RP Han, J (corresponding author), Shandong Univ, Shandong Prov Hosp, Dept Oncol, 324 Jingwu Rd, Jinan 250021, Shandong, Peoples R China.; Li, X (corresponding author), Shandong Univ, Shandong Prov Hosp, Dept Pediat, 324 Jingwu Rd, Jinan 250021, Shandong, Peoples R China.
EM hanjq19601960@163.com; lixinyu0627@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81502508, 81600121]; Natural Science
   Foundations of Shandong Province [ZR2016HQ46]
FX This study was supported by National Natural Science Foundation of China
   (nos. 81502508 and 81600121) and Natural Science Foundations of Shandong
   Province (no. ZR2016HQ46).
CR Alao JP, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-24
   Amado NG, 2014, INT J MOL SCI, V15, P12094, DOI 10.3390/ijms150712094
   Burgute BD, 2014, NUCLEIC ACIDS RES, V42, P3177, DOI 10.1093/nar/gkt1311
   Burman C, 2010, SEMIN IMMUNOPATHOL, V32, P397, DOI 10.1007/s00281-010-0222-z
   Chen DY, 2003, BIOCHEM BIOPH RES CO, V310, P720, DOI 10.1016/j.bbrc.2003.09.074
   Cotter TG, 2009, NAT REV CANCER, V9, P501, DOI 10.1038/nrc2663
   Croce CM, 2016, CANCER RES, V76, P5914, DOI 10.1158/0008-5472.CAN-16-1248
   Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736
   Gui DK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039824
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Hsu FC, 2011, J EXP MED, V208, P1291, DOI 10.1084/jem.20101874
   Huang Q, 2017, WORLD J GASTROENTERO, V23, P5018, DOI 10.3748/wjg.v23.i27.5018
   Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776
   Jiang BH, 2013, CURR CANCER DRUG TAR, V13, P233, DOI 10.2174/1568009611313030001
   Jiang QG, 2014, MOL BIOL REP, V41, P3359, DOI 10.1007/s11033-014-3198-2
   Kwak JM, 2007, DIS COLON RECTUM, V50, P1873, DOI 10.1007/s10350-007-9034-1
   Li T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12969
   Liu JT, 2018, CANCER MANAG RES, V10, P5091, DOI 10.2147/CMAR.S178919
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Malinowsky K, 2014, BRIT J CANCER, V110, P2081, DOI 10.1038/bjc.2014.100
   Martinou JC, 2011, DEV CELL, V21, P92, DOI 10.1016/j.devcel.2011.06.017
   Murray L, 2010, ROLE E CADHERIN COLO
   Oguma K, 2008, EMBO J, V27, P1671, DOI 10.1038/emboj.2008.105
   Pajerowski AG, 2010, BLOOD, V116, P2684, DOI 10.1182/blood-2010-02-268391
   Pajerowski AG, 2009, IMMUNITY, V30, P696, DOI 10.1016/j.immuni.2009.02.011
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Parrish Amanda B, 2013, Cold Spring Harb Perspect Biol, V5, DOI 10.1101/cshperspect.a008672
   Saito T, 2004, ONCOL REP, V11, P605
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Tan SF, 2016, INT J MOL MED, V37, P1030, DOI 10.3892/ijmm.2016.2492
   Tang X, 2017, ONCOL REP, V38, P2023, DOI 10.3892/or.2017.5923
   Thapa P, 2016, J IMMUNOL, V196, P4987, DOI 10.4049/jimmunol.1501653
   Thapa P, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2580
   Vatandoust S, 2015, WORLD J GASTROENTERO, V21, P11767, DOI 10.3748/wjg.v21.i41.11767
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wu QB, 2015, WORLD J GASTROENTERO, V21, P6206, DOI 10.3748/wjg.v21.i20.6206
   Wu RD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167052
NR 39
TC 2
Z9 2
U1 2
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD NOV
PY 2019
VL 42
IS 5
BP 2130
EP 2138
DI 10.3892/or.2019.7322
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA JE9BA
UT WOS:000490982300046
PM 31545474
OA Bronze
DA 2022-04-25
ER

PT J
AU Hong, Y
   Won, J
   Lee, Y
   Lee, S
   Park, K
   Chang, KT
   Hong, Y
AF Hong, Yunkyung
   Won, Jinyoung
   Lee, Youngjeon
   Lee, Seunghoon
   Park, Kanghui
   Chang, Kyu-Tae
   Hong, Yonggeun
TI Melatonin treatment induces interplay of apoptosis, autophagy, and
   senescence in human colorectal cancer cells
SO JOURNAL OF PINEAL RESEARCH
LA English
DT Article
DE apoptosis; autophagy; cardiotoxicity; melatonin; senescence
ID HISTONE-DEACETYLASE INHIBITOR; TRICHOSTATIN-A; CYCLE ARREST; CELLULAR
   SENESCENCE; PROLIFERATION; INDUCTION; DEATH; CHEMOTHERAPY; SUPPRESSION;
   DOXORUBICIN
AB In Asia, the incidence of colorectal cancer has been increasing gradually due to a more Westernized lifestyle. The aim of study is to determine the interaction between melatonin-induced cell death and cellular senescence. We treated HCT116 human colorectal adenocarcinoma cells with 10m melatonin and determined the levels of cell death-related proteins and evaluated cell cycle kinetics. The plasma membrane melatonin receptor, MT1, was significantly decreased by melatonin in a time-dependent manner, whereas the nuclear receptor, ROR, was increased only after 12hr treatment. HCT116 cells, which upregulated both pro-apoptotic Bax and anti-apoptotic Bcl-xL in the early response to melatonin treatment, activated autophagic as well as apoptotic machinery within 18hr. Melatonin decreased the S-phase population of the cells to 57% of the control at 48hr, which was concomitant with a reduction in BrdU-positive cells in the melatonin-treated cell population. We found not only marked attenuation of E- and A-type cyclins, but also increased expression of p16 and p-p21. Compared to the cardiotoxicity of Trichostatin A in vitro, single or cumulative melatonin treatment induced insignificant detrimental effects on neonatal cardiomyocytes. We found that 10m melatonin activated cell death programs early and induced G1-phase arrest at the advanced phase. Therefore, we suggest that melatonin is a potential chemotherapeutic agent for treatment of colon cancer, the effects of which are mediated by regulation of both cell death and senescence in cancerous cells with minimized cardiotoxicity.
C1 [Hong, Yunkyung; Won, Jinyoung; Lee, Youngjeon; Lee, Seunghoon; Park, Kanghui; Hong, Yonggeun] Inje Univ, Dept Rehabil Sci, Grad Sch, 197 Inje Ro, Gimhae 621749, Gyeong Nam, South Korea.
   [Hong, Yunkyung; Won, Jinyoung; Lee, Seunghoon; Hong, Yonggeun] Inje Univ, Coll Biomed Sci & Engn, Cardiovasc & Metab Dis Ctr, Gimhae 621749, Gyeong Nam, South Korea.
   [Hong, Yunkyung; Won, Jinyoung; Lee, Seunghoon; Hong, Yonggeun] Inje Univ, Ubiquitous Healthcare Res Ctr, Gimhae 621749, Gyeong Nam, South Korea.
   [Lee, Youngjeon; Chang, Kyu-Tae] KRIBB, NPRC, Ochang 363883, Chung Buk, South Korea.
   [Park, Kanghui] Dongwei Med Ctr, Div Rehabil Med, Pusan, South Korea.
   [Hong, Yonggeun] Inje Univ, Coll Biomed Sci & Engn, Dept Phys Therapy, Gimhae 621749, Gyeong Nam, South Korea.
RP Hong, Y (corresponding author), Inje Univ, Dept Rehabil Sci, Grad Sch, 197 Inje Ro, Gimhae 621749, Gyeong Nam, South Korea.
EM changkt@kribb.re.kr; yonghong@inje.ac.kr
OI Lee, Youngjeon/0000-0002-5387-3441
FU KRIBB Research Initiative Program [KGM4251314]; National Research
   Foundation, Republic of Korea [NRF-2012R1A1A200 5089]
FX This work was supported by grants from the KRIBB Research Initiative
   Program (KGM4251314 to YH) and by the National Research Foundation
   (NRF-2012R1A1A200 5089 to YH), Republic of Korea.
CR Bejarano I, 2009, J PINEAL RES, V46, P392, DOI 10.1111/j.1600-079X.2009.00675.x
   Bertagnolli MM, 2009, CLIN CANCER RES, V15, P2116, DOI 10.1158/1078-0432.CCR-08-2674
   Blask DE, 2011, J PINEAL RES, V51, P259, DOI 10.1111/j.1600-079X.2011.00888.x
   Byeon JS, 2007, GASTROINTEST ENDOSC, V65, P1015, DOI 10.1016/j.gie.2006.12.065
   Cabrera J, 2010, J PINEAL RES, V49, P45, DOI 10.1111/j.1600-079X.2010.00765.x
   Calvo JR, 2013, J PINEAL RES, V55, P103, DOI 10.1111/jpi.12075
   Carew JS, 2008, CANCER LETT, V269, P7, DOI 10.1016/j.canlet.2008.03.037
   Ciechomska IA, 2009, ONCOGENE, V28, P2128, DOI 10.1038/onc.2009.60
   Claustrat B, 2005, SLEEP MED REV, V9, P11, DOI 10.1016/j.smrv.2004.08.001
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Edwards BK, 2005, JNCI-J NATL CANCER I, V97, P1407, DOI 10.1093/jnci/dji289
   Elaut G, 2007, J PHARMACOL EXP THER, V321, P400, DOI 10.1124/jpet.106.116202
   Fujiwara K, 2008, J BIOL CHEM, V283, P388, DOI 10.1074/jbc.M611043200
   Garcia-Santos G, 2006, J PINEAL RES, V41, P130, DOI 10.1111/j.1600-079X.2006.00342.x
   Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611
   Gewirtz DA, 2009, AUTOPHAGY, V5, P1232, DOI 10.4161/auto.5.8.9896
   Habold C, 2008, J CELL MOL MED, V12, P607, DOI 10.1111/j.1582-4934.2007.00136.x
   Half E, 2009, EXPERT OPIN PHARMACO, V10, P211, DOI [10.1517/14656560802560153, 10.1517/14656560802560153 ]
   Herold C, 2002, J HEPATOL, V36, P233, DOI 10.1016/S0168-8278(01)00257-4
   Jetten Anton M, 2009, Nucl Recept Signal, V7, pe003, DOI 10.1621/nrs.07003
   Johnson SM, 2009, ANTICANCER RES, V29, P3185
   Joo SS, 2009, J PINEAL RES, V47, P8, DOI 10.1111/j.1600-079X.2009.00682.x
   Kaeser MD, 2004, J BIOL CHEM, V279, P7598, DOI 10.1074/jbc.M311732200
   Karagiannis TC, 2010, AGING-US, V2, P659, DOI 10.18632/aging.100203
   Karasek M, 2005, J PINEAL RES, V39, P73, DOI 10.1111/j.1600-079X.2005.00221.x
   Kishimoto H, 2011, CELL CYCLE, V10, P2737, DOI 10.4161/cc.10.16.16756
   Korkmaz A, 2009, BREAST CANCER RES TR, V115, P13, DOI 10.1007/s10549-008-0103-5
   Kos-Kudla B, 2002, NEUROENDOCRINOL LETT, V23, P239
   Kosmas C, 2008, J CANCER RES CLIN, V134, P75, DOI 10.1007/s00432-007-0250-9
   Kuninaka S, 2000, BRIT J CANCER, V83, P928, DOI 10.1054/bjoc.2000.1367
   Leon-Blanco MM, 2003, J PINEAL RES, V35, P204, DOI 10.1034/j.1600-079X.2003.00077.x
   LLeonart ME, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-3
   Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307
   Mariotto AB, 2006, CANCER CAUSE CONTROL, V17, P1215, DOI 10.1007/s10552-006-0072-0
   Martin-Renedo J, 2008, J PINEAL RES, V45, P532, DOI 10.1111/j.1600-079X.2008.00641.x
   Mauriz JL, 2013, J PINEAL RES, V54, P1, DOI 10.1111/j.1600-079X.2012.01014.x
   Meijer AJ, 2009, CRIT REV CL LAB SCI, V46, P210, DOI 10.1080/10408360903044068
   Min KJ, 2012, J PINEAL RES, V53, P99, DOI 10.1111/j.1600-079X.2012.00975.x
   Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421
   Nardella C, 2011, NAT REV CANCER, V11, P503, DOI 10.1038/nrc3057
   Narita M, 2006, CELL, V126, P503, DOI 10.1016/j.cell.2006.05.052
   Neganova I, 2008, J ANAT, V213, P30, DOI 10.1111/j.1469-7580.2008.00931.x
   Nemeth C, 2011, J BIOL REG HOMEOS AG, V25, P531
   Pandi-Perumal SR, 2008, PROG NEUROBIOL, V85, P335, DOI 10.1016/j.pneurobio.2008.04.001
   Pizarro JG, 2008, J PINEAL RES, V45, P8, DOI 10.1111/j.1600-079X.2007.00548.x
   Platta CS, 2007, J SURG RES, V142, P219, DOI 10.1016/j.jss.2006.12.555
   Poon AMS, 1996, ENDOCR RES, V22, P77, DOI 10.3109/07435809609030499
   Reiter RJ, 2002, J PHARM PHARMACOL, V54, P1299, DOI 10.1211/002235702760345374
   Renthal W, 2009, SEMIN CELL DEV BIOL, V20, P387, DOI 10.1016/j.semcdb.2009.01.005
   Rigas A, 2002, CANCER INVEST, V20, P657, DOI 10.1081/CNV-120002491
   Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149
   Sainz RM, 2003, CELL MOL LIFE SCI, V60, P1407, DOI 10.1007/s00018-003-2319-1
   Sasaki M, 2010, LAB INVEST, V90, P835, DOI 10.1038/labinvest.2010.56
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Schernhammer ES, 2003, JNCI-J NATL CANCER I, V95, P825, DOI 10.1093/jnci/95.11.825
   Schwartz RN, 2008, AM J HEALTH-SYST PH, V65, pS8, DOI 10.2146/ajhp080101
   Seymour MT, 2007, LANCET, V370, P143, DOI 10.1016/S0140-6736(07)61087-3
   Shin DY, 2009, INT J ONCOL, V35, P1499, DOI 10.3892/ijo_00000469
   Sliwinska MA, 2009, MECH AGEING DEV, V130, P24, DOI 10.1016/j.mad.2008.04.011
   Slominski RM, 2012, MOL CELL ENDOCRINOL, V351, P152, DOI 10.1016/j.mce.2012.01.004
   Sorensen NM, 2008, SCAND J GASTROENTERO, V43, P186, DOI 10.1080/00365520701491355
   Tan ML, 2009, PHARM RES-DORDR, V26, P1547, DOI 10.1007/s11095-009-9895-1
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Toyota N, 2008, CELL STRUCT FUNCT, V33, P193, DOI 10.1247/csf.08010
   Uguz AC, 2012, J PINEAL RES, V53, P91, DOI 10.1111/j.1600-079X.2012.00974.x
   Vicencio JM, 2008, GERONTOLOGY, V54, P92, DOI 10.1159/000129697
   Vigushin DM, 2001, CLIN CANCER RES, V7, P971
   Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032
   Wang JS, 2012, J PINEAL RES, V53, P77, DOI 10.1111/j.1600-079X.2012.00973.x
   Winczyk K, 2002, TUMOR BIOL, V23, P298, DOI 10.1159/000068569
   Won YJ, 2009, CANCER RES TREAT, V41, P122, DOI 10.4143/crt.2009.41.3.122
   Wu ZQ, 2007, CHINESE MED J-PEKING, V120, P2112, DOI 10.1097/00029330-200712010-00009
   Xavier CPR, 2011, CANCER CHEMOTH PHARM, V68, P1449, DOI 10.1007/s00280-011-1641-9
   Yang SY, 2009, TRENDS MOL MED, V15, P225, DOI 10.1016/j.molmed.2009.03.003
   Yeh ETH, 2004, CIRCULATION, V109, P3122, DOI 10.1161/01.CIR.0000133187.74800.B9
   Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709
   Zhang F, 2009, CANCER BIOL THER, V8, P823, DOI 10.4161/cbt.8.9.8143
   Zhang S, 2013, BIOTECH HISTOCHEM, V88, P281, DOI 10.3109/10520295.2013.769633
   Zhuang PW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035636
NR 79
TC 95
Z9 95
U1 0
U2 26
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-3098
EI 1600-079X
J9 J PINEAL RES
JI J. Pineal Res.
PD APR
PY 2014
VL 56
IS 3
BP 264
EP 274
DI 10.1111/jpi.12119
PG 11
WC Endocrinology & Metabolism; Neurosciences; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Neurosciences & Neurology; Physiology
GA AC5YR
UT WOS:000332597400005
PM 24484372
DA 2022-04-25
ER

PT J
AU Wu, JB
   Meng, XM
   Gao, R
   Jia, YB
   Chai, JY
   Zhou, Y
   Wang, J
   Xue, XH
   Dang, T
AF Wu, Jinbao
   Meng, Xianmei
   Gao, Rui
   Jia, Yanbin
   Chai, Jianyuan
   Zhou, Yi
   Wang, Jing
   Xue, Xiaohui
   Dang, Tong
TI Long non-coding RNA LINC00858 inhibits colon cancer cell apoptosis,
   autophagy, and senescence by activating WNK2 promoter methylation
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Long non-coding RNA LINC00858; WNK lysine deficient protein kinase 2;
   Colon cancer; DNA methyltransferase
ID KINASE; GROWTH; PROLIFERATION; EXPRESSION
AB Accumulating evidence shows the involvement of long non-coding RNAs (lncRNAs) in tumorigenesis of many types of human cancers. However, the role of LINC00858 in colon cancer has not been fully elucidated. Therefore, we investigated the involvement of LINC00858 in the progression of colon cancer and identified its downstream targets. After examining the expression of LINC00858 in colon cancer tissues and cell lines, we then identified the possible interaction between LINC00858 and WNK lysine deficient protein kinase 2 (WNK2) by fluorescence in situ hybridization, RNA immunoprecipitation, chromatin immunoprecipitation, and RNA pulldown assays. Next, the role of the LINC00858/WNK2 axis was explored by evaluating the apoptosis, autophagy, and senescence of colon cancer cells in vitro after ectopic expression and depletion experiments in HCT116 cells. Moreover, a mouse xenograft model of HCT116 cells was established to verify the function of the LINC00858/WNK2 axis in vivo. There was high expression of LINC00858 and low expression of WNK2 in colon cancer tissues and cell lines. Silencing of LINC00858 promoted apoptosis, senescence, and autophagy in colon cancer cells. Additionally, the enrichment of WNK2 was promoted when LINC00858 bound to DNA methyltransferases. Furthermore, in vivo assays demonstrated that silencing of LINC00858 resulted in inhibited tumor growth by upregulating WNK2. In summary, LINC00858 acts as a tumor-promoting lncRNA in colon cancer by downregulating WNK2. Our results may provide novel targets for the treatment for colon cancer.
C1 [Wu, Jinbao; Meng, Xianmei; Jia, Yanbin; Chai, Jianyuan; Zhou, Yi; Wang, Jing; Xue, Xiaohui; Dang, Tong] Inner Mongolia Univ Sci & Technol, Affiliated Hosp 2, Inner Mongolia Inst Digest Dis, Baotou Med Coll, Baotou 014030, Peoples R China.
   [Gao, Rui] Inner Mongolia Univ Sci & Technol, Affiliated Hosp 2, Anesthesiol Dept, Baotou Med Coll, Baotou 014030, Peoples R China.
   [Jia, Yanbin] Inner Mongolia Univ Sci & Technol, Baotou Med Coll, Nursing Coll, Baotou 014030, Peoples R China.
RP Dang, T (corresponding author), Inner Mongolia Univ Sci & Technol, Affiliated Hosp 2, Inner Mongolia Inst Digest Dis, Baotou Med Coll, Baotou 014030, Peoples R China.
EM dtong@sina.com
OI Chai, Jianyuan/0000-0001-6975-6867
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81960445, 81550020]; Natural Science
   Foundation of Inner Mongolia Autonomous Region [2020LH08004,
   2020LH08005, 2018LH08081, 2015MS0854]; Science and Technology Project of
   Baotou [2016X1030-11-01, 2017S2001-5-03, 2019Z3011-04, 2019P3078]
FX This study was supported by National Natural Science Foundation of China
   (81960445, 81550020), Natural Science Foundation of Inner Mongolia
   Autonomous Region (2020LH08004, 2020LH08005, 2018LH08081, 2015MS0854),
   and Science and Technology Project of Baotou (2016X1030-11-01,
   2017S2001-5-03, 2019Z3011-04, 2019P3078).
CR Banerjee A, 2017, DRUG DISCOV TODAY, V22, P1224, DOI 10.1016/j.drudis.2017.05.006
   Bouras E, 2019, GENE, V710, P333, DOI 10.1016/j.gene.2019.06.023
   Cao XX, 2011, J BIOL CHEM, V286, P33447, DOI 10.1074/jbc.M111.225565
   Carethers JM, 2014, CLIN GASTROENTEROL H, V12, P377, DOI 10.1016/j.cgh.2013.12.007
   Chen Y, 2019, J THORAC DIS, V11, P3030, DOI 10.21037/jtd.2019.07.46
   Cheng Y, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/7636757
   Costa AM, 2015, ONCOTARGET, V6, P1422
   Dutruel C, 2014, ONCOGENE, V33, P3401, DOI 10.1038/onc.2013.312
   Gu ZH, 2018, BIOCHEM BIOPH RES CO, V503, P1134, DOI 10.1016/j.bbrc.2018.06.131
   Guo L, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00134
   Hong CB, 2007, P NATL ACAD SCI USA, V104, P10974, DOI 10.1073/pnas.0700683104
   Hu WL, 2017, BMC MED GENOMICS, V10, DOI 10.1186/s12920-017-0307-9
   Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815
   Martinez-Useros J., 2019, J CLIN MED, V8
   Merry CR, 2015, HUM MOL GENET, V24, P6240, DOI 10.1093/hmg/ddv343
   Moniz S, 2007, ONCOGENE, V26, P6071, DOI 10.1038/sj.onc.1210706
   Moniz S, 2013, HUM MOL GENET, V22, P84, DOI 10.1093/hmg/dds405
   Sanaei M, 2019, ADV BIOMED RES-INDIA, V8, DOI 10.4103/abr.abr_91_19
   Sha QK, 2019, ARTIF CELL NANOMED B, V47, P1057, DOI 10.1080/21691401.2018.1544143
   Sharaf LK, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4999-9
   Szyniarowski P, 2011, AUTOPHAGY, V7, P892, DOI 10.4161/auto.7.8.15770
   Wu KM, 2018, IUBMB LIFE, V70, P1093, DOI 10.1002/iub.1880
   Xu T, 2020, CELL ONCOL, V43, P297, DOI 10.1007/s13402-019-00490-8
   Yamada A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18407-6
   Zheng QQ, 2018, J CELL MOL MED, V22, P131, DOI 10.1111/jcmm.13301
   Zhou SL, 2019, J HEPATOL, V71, P1152, DOI 10.1016/j.jhep.2019.07.014
   Zhu B, 2014, ONCOGENE, V33, P5348, DOI 10.1038/onc.2013.477
   Zhu SP, 2017, AGING-US, V9, P475, DOI 10.18632/aging.101171
NR 28
TC 2
Z9 3
U1 0
U2 10
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD NOV 1
PY 2020
VL 396
IS 1
AR 112214
DI 10.1016/j.yexcr.2020.112214
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA OF9AO
UT WOS:000581491000020
PM 32768499
DA 2022-04-25
ER

PT J
AU Dong, Y
   Wu, Y
   Zhao, GL
   Ye, ZY
   Xing, CG
   Yang, XD
AF Dong, Y.
   Wu, Y.
   Zhao, G. -L.
   Ye, Z. -Y.
   Xing, C. -G.
   Yang, X. -D.
TI Inhibition of autophagy by 3-MA promotes hypoxia-induced apoptosis in
   human colorectal cancer cells
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Autophagy; Hypoxia; Apoptosis; Colorectal cancer
ID STRESS-INDUCED APOPTOSIS; STATISTICS; INTERPLAY
AB OBJECTIVE: Cell autophagy reduces the sensitivity of cancer cells to therapeutic reagents in various types of human cancer. Therefore, the aim of our study was to use human colorectal cancer HCT116 cells to explore whether inhibition of autophagy by 3-Methyladenine (3-MA, an autophagy inhibitor) is able to enhance hypoxia-induced apoptosis in vitro.
   MATERIALS AND METHODS: HCT116 cells were treated with 3-MA. hypoxia. or 3-MA plus hypoxia. and the autophagy. apoptosis and proliferation of the HCT116 cells were investigated. Western blot analysis was used to detect autophagy specificity protein microtubule-associated protein light chain 3 (LC3) expression. Effects on apoptosis were evaluated by using flow cytometry (JC-1 staining to measure mitochondrial membrane potential) and annexin V-propidium iodide (PI) staining.
   RESULTS: The results showed that the treatment of HCT116 cells in vitro with hypoxia alone increased autophagy as well as apoptosis, whereas combination treatment with 3-MA and hypoxia markedly inhibited hypoxia-induced autophagy. but increased hypoxia-induced cell apoptosis.
   CONCLUSIONS: Autophagy might play a role as a self-defense mechanism in hypoxia-treated colon cancer cells, and its inhibition could be a promising strategy for the adjuvant chemotherapy of colon cancer.
C1 [Dong, Y.; Wu, Y.; Ye, Z. -Y.; Xing, C. -G.; Yang, X. -D.] Soochow Univ, Dept Gen Surg, Affiliated Hosp 2, Suzhou, Peoples R China.
   [Dong, Y.] Nanjing Univ Chinese Med, Dept Pathol, WuXi Hosp, Nanjing, Jiangsu, Peoples R China.
   [Zhao, G. -L.] Peoples Hosp Gaomi, Dept Gen Surg, Gaomi, Peoples R China.
RP Xing, CG; Yang, XD (corresponding author), Soochow Univ, Dept Gen Surg, Affiliated Hosp 2, Suzhou, Peoples R China.
EM xingcg@126.com; wjyxd@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81672970]; Projects of Suzhou Technology
   Bureau [SYS201552, SZS201618, SS201753]; focus of Clinical Disease
   Treatment Technology Special Funds of Suzhou City [LCZX201505]; Second
   Affiliated Hospital of Soochow University Preponderant Clinic Discipline
   Group Project Funding
FX This work was partially supported by the National Natural Science
   Foundation of China (Grant No.: 81672970), the Projects of Suzhou
   Technology Bureau (SYS201552, SZS201618, SS201753) and the focus of
   Clinical Disease Treatment Technology Special Funds of Suzhou City
   (LCZX201505), and the Second Affiliated Hospital of Soochow University
   Preponderant Clinic Discipline Group Project Funding.
CR Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Cui Q, 2007, BIOL PHARM BULL, V30, P859, DOI 10.1248/bpb.30.859
   Cui Q, 2006, J PHARMACOL SCI, V101, P230, DOI 10.1254/jphs.FPJ06003X
   Du HL, 2012, ONCOL REP, V27, P143, DOI 10.3892/or.2011.1464
   Fimia GM, 2010, CELL MOL LIFE SCI, V67, P1581, DOI 10.1007/s00018-010-0284-z
   Jiang RY, 2014, EUR REV MED PHARMACO, V18, P806
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Kumar D, 2014, CANCER LETT, V343, P179, DOI 10.1016/j.canlet.2013.10.003
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li DY, 2017, EUR REV MED PHARMACO, V21, P5548, DOI 10.26355/eurrev_201712_13991
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Li MM, 2015, APOPTOSIS, V20, P769, DOI 10.1007/s10495-015-1110-8
   Liao CS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082497
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Mazure NM, 2010, CURR OPIN CELL BIOL, V22, P177, DOI 10.1016/j.ceb.2009.11.015
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Shen Yang, 2008, Ai Zheng, V27, P595
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Song LL, 2013, ONCOL LETT, V6, P1031, DOI 10.3892/ol.2013.1498
   Ullman E, 2008, CELL DEATH DIFFER, V15, P422, DOI 10.1038/sj.cdd.4402234
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
NR 23
TC 15
Z9 19
U1 2
U2 15
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD FEB
PY 2019
VL 23
IS 3
BP 1047
EP 1054
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA HM0ZX
UT WOS:000459178100020
PM 30779071
DA 2022-04-25
ER

PT J
AU Zhang, WL
   Shi, HS
   Zhang, MM
   Liu, B
   Mao, S
   Li, L
   Tong, F
   Liu, GL
   Yang, SL
   Wang, HH
AF Zhang, Wenliang
   Shi, Hongshun
   Zhang, Mingming
   Liu, Bin
   Mao, Shuai
   Li, Li
   Tong, Fang
   Liu, Guoliang
   Yang, Shulan
   Wang, Haihe
TI Poly C binding protein 1 represses autophagy through downregulation of
   LC3B to promote tumor cell apoptosis in starvation
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE PCBP1; Autophagy; Apoptosis; LOB; Cancer
ID CANCER; CASPASE-8; BINDING-PROTEIN-1; EXPRESSION; CROSSTALK; COMPLEX;
   PCBP1; GENE; P62; RNA
AB Accumulating evidences indicate that poly C binding protein (PCBP1) is downregulated in various carcinomas as a tumor suppressor, but the underlying mechanism in suppression of tumorigenesis still remains elusive. Here, we found that PCBP1 overexpression attenuates tumor cell growth upon serum free starvation. Notably, the autophagic degradation inhibitor, chloroquine, could mimic this suppressive effect in tumor cell growth. Autophagy analyses demonstrated that PCBP1 overexpression blocked autophagic flux of tumor cells under starvation conditions, while PCBP1 downregulation in turn refueled this autophagic flux, protecting cells from death. Mechanistically, PCBP1 overexpression attenuated microtubule-associated protein Light chain 3 (LOB) mRNA stability to repress LC3B expression, resulting in the autophagy inhibition. Consequently, PCBP1 overexpression strongly triggered the caspase 3 and 8-mediated apoptosis of tumor cells and downregulated anti-apoptotic BcI-2 expression upon starvation, which could be further synergized by autophagic inhibitor, indicating that PCBP1 not only inhibits tumor cell autophagy, but also renders them to apoptosis. Taken together, our results uncovered a novel mechanism of PCBP1 in repressing autophagy-mediated cell survival and indicated that inhibition of tumor cell autophagy by PCBP1 upregulation or with autophagic inhibitors could be an effective therapeutical strategy to colon and ovary tumors with low PCBP1 expression. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Zhang, Wenliang; Shi, Hongshun; Zhang, Mingming; Liu, Bin; Li, Li; Tong, Fang; Wang, Haihe] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, CPZN, Guangzhou 510080, Guangdong, Peoples R China.
   [Zhang, Wenliang; Yang, Shulan] Sun Yat Sen Univ, Affiliated Hosp 1, Translat Med Ctr, CPZN, Guangzhou 510080, Guangdong, Peoples R China.
   [Mao, Shuai] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Hepat Surg, CPZN, Guangzhou 510080, Guangdong, Peoples R China.
   [Wang, Haihe] Sun Yat Sen Univ, Ctr Stem Cell Biol & Tissue Engn, CPZN, Guangzhou 510080, Guangdong, Peoples R China.
   [Liu, Guoliang] Jinxian Peoples Hosp Nanchang, Dept Internal Med, CPZN, Nanchang 331700, Jiangxi, Peoples R China.
RP Yang, SL (corresponding author), CPZN, 74 Zhonshan Rd 2nd, Guangzhou 510080, Guangdong, Peoples R China.; Wang, HH (corresponding author), CPZN, 58 Zhonshan Rd 2nd, Guangzhou 510080, Guangdong, Peoples R China.
EM yangshl3@mail.sysu.edu.cn; wanghaih@mail.sysu.edu.cn
RI 张, 文亮/AAM-6021-2020; Haihe, Wang/AAD-4036-2021
OI zhang, wenliang/0000-0003-0454-6935; LIU, BIN/0000-0003-0467-3678; ,
   Haihe/0000-0002-9302-2334
FU National Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [31271481]; Guangzhou Science Technology and Innovation
   Commission [201510010144]
FX We thank our group members for the critical comments on this manuscript.
   This work was supported by National Science Foundation of China (grant
   no. 31271481) to W.H. and Guangzhou Science Technology and Innovation
   Commission (no. 201510010144) to Y.S.
CR Bardag-Gorce F, 2005, LIFE SCI, V77, P2594, DOI 10.1016/j.lfs.2005.04.020
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Chen Q, 2015, CELL PHYSIOL BIOCHEM, V35, P1052, DOI 10.1159/000373931
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Deretic Vojo, 2008, V445, P1, DOI 10.1007/978-1-59745-157-4_1
   Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Giles KM, 2003, J BIOL CHEM, V278, P2937, DOI 10.1074/jbc.M208439200
   Huang SB, 2013, J BIOL CHEM, V288, P33654, DOI 10.1074/jbc.M113.518134
   Huang YH, 2014, AUTOPHAGY, V10, P1787, DOI 10.4161/auto.29989
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Kim JH, 2014, EXP CELL RES, V327, P340, DOI 10.1016/j.yexcr.2014.08.001
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Kruidering M, 2000, IUBMB LIFE, V50, P85, DOI 10.1080/15216540050212088
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Li J, 2008, ONCOGENE, V27, P6194, DOI 10.1038/onc.2008.297
   Liu YF, 2015, INT J CLIN EXP PATHO, V8, P7165
   Lu Z, 2014, AUTOPHAGY, V10, P1071, DOI 10.4161/auto.28577
   Maiuri MC, 2010, EMBO J, V29, P515, DOI 10.1038/emboj.2009.377
   Malik AK, 2006, BRAIN RES, V1112, P33, DOI 10.1016/j.brainres.2006.07.019
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Nishinakamura H, 2007, INT IMMUNOL, V19, P609, DOI 10.1093/intimm/dxm026
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   Rivera-Gines A, 2006, BIOCHEM BIOPH RES CO, V345, P530, DOI 10.1016/j.bbrc.2006.04.117
   Sun K, 2013, CELL BIOSCI, V3, DOI 10.1186/2045-3701-3-35
   Tang Y, 2015, AM J CANCER RES, V5, P498
   Valente G, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/462658
   Wang HH, 2010, CANCER CELL, V18, P52, DOI 10.1016/j.ccr.2010.04.028
   Wu HJ, 2014, INT J BIOL SCI, V10, P1072, DOI 10.7150/ijbs.9719
   Young MM, 2012, J BIOL CHEM, V287, P12455, DOI 10.1074/jbc.M111.309104
   Zhang T, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-72
   Zhao Y, 2014, EURASIP J WIREL COMM, P1, DOI 10.1186/1687-1499-2014-208
NR 34
TC 13
Z9 15
U1 1
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357-2725
EI 1878-5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD APR
PY 2016
VL 73
BP 127
EP 136
DI 10.1016/j.biocel.2016.02.009
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA EL2TI
UT WOS:000394472700012
PM 26880484
OA Bronze
DA 2022-04-25
ER

PT J
AU Ge, Y
   Liu, BL
   Cui, JP
   Li, SQ
AF Ge, Yang
   Liu, Bao-lin
   Cui, Jun-peng
   Li, Shu-qiang
TI Livin Regulates H2A.X-Y142 Phosphorylation and Promotes Autophagy in
   Colon Cancer Cells via a Novel Kinase Activity
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE Livin; autophagy; colon cancer cells; H2A.X; phosphorylation
ID DNA-DAMAGE; HISTONE; INHIBITORS; EXPRESSION
AB Objective: To investigate Livin-mediated regulation of H2A.X-Y142 phosphorylation via a novel kinase activity and its effect on autophagy in colon cancer cells. Methods: The interaction between Livin and H2A.X was tested by immunoprecipitation. H2A.X-/- HCT116 cells were transfected with human influenza hemagglutinin (HA)-tagged WT or Y142F phospho-dead mutantH2A.X plasmids. GST-tagged recombinant Livin protein was used to perform in vitro pull-down experiment and kinase assay. H2A.X-/-Livin+/+ SW480 cells were co-transfected with H2A.X-WT/H2A.X-Y142F plasmid and LC3 EGFP-tagged plasmid to explore whether H2A.X-Y142F was involved in Livin-mediated autophagy induced by starvation in colon cancer cells. Results: Co-immunoprecipitation studies confirmed that Livin interacted with H2A.X and that it was phosphorylation dependent. In vitro kinase assay confirmed that Livin could phosphorylate H2A.X. Knockdown of Livin (Livin-/-) in SW480 cells or HCT116 cells canceled the starvation-induced autophagy in colon cancer cells; H2A.X-/-Livin+/+ SW480 cells transfected with H2A.X-WT activated autophagy induced by starvation while cells transfected with H2A.X-Y142F had no significant difference; Livin-H2A.X-Y142F axis activated autophagy in colon cancer cells through transcriptionally regulating ATG5 and ATG7. Conclusion: Livin promotes autophagy in colon cancer cells via regulating the phosphorylation of H2A.X-Y142.
C1 [Ge, Yang; Liu, Bao-lin; Cui, Jun-peng; Li, Shu-qiang] China Med Univ, Dept Gen Surg 6, Shengjing Hosp, Shenyang, Liaoning, Peoples R China.
RP Li, SQ (corresponding author), China Med Univ, Dept Gen Surg 6, Shengjing Hosp, Shenyang, Liaoning, Peoples R China.
EM lishuqiang_cmu@163.com
CR Beach TA, 2018, INT J RADIAT BIOL, V94, P1104, DOI 10.1080/09553002.2018.1516907
   Castillo Josefa, 2017, Adv Exp Med Biol, V966, P65, DOI 10.1007/5584_2017_58
   Chen SA, 2017, MOL CELL BIOCHEM, V434, P135, DOI 10.1007/s11010-017-3043-8
   Chen YS, 2010, MOL BIOL REP, V37, P2241, DOI 10.1007/s11033-009-9711-3
   Erdel F, 2017, BIOESSAYS, V39, DOI 10.1002/bies.201700053
   Fan J, 2015, ACS CHEM BIOL, V10, P95, DOI 10.1021/cb500846u
   Gimenez-Xavier P, 2008, INT J MOL MED, V22, P781, DOI 10.3892/ijmm_00000085
   Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004
   Kimura T, 2013, CANCER RES, V73, P3, DOI 10.1158/0008-5472.CAN-12-2464
   Kumar D, 2015, TOXICOL LETT, V235, P161, DOI 10.1016/j.toxlet.2015.04.006
   Lawrence M, 2016, TRENDS GENET, V32, P42, DOI 10.1016/j.tig.2015.10.007
   Lee J, 2017, BIOCHEMISTRY-US, V56, P977, DOI 10.1021/acs.biochem.6b01252
   Liu S, 2018, ONCOL LETT, V15, P7707, DOI 10.3892/ol.2018.8282
   Lorkovic ZJ, 2017, CURR BIOL, V27, P1192, DOI 10.1016/j.cub.2017.03.002
   Pacaud R, 2015, THERANOSTICS, V5, P12, DOI 10.7150/thno.8799
   Piquet S, 2018, MOL CELL, V72, P888, DOI 10.1016/j.molcel.2018.09.010
   Rieux-Laucat F, 2017, CURR OPIN IMMUNOL, V49, P79, DOI 10.1016/j.coi.2017.10.001
   Saleem M, 2013, CHEM BIOL DRUG DES, V82, P243, DOI 10.1111/cbdd.12176
   Silke J, 2017, CURR TOP MICROBIOL, V403, P95, DOI 10.1007/82_2016_507
   Silke J, 2014, METHOD ENZYMOL, V545, P35, DOI 10.1016/B978-0-12-801430-1.00002-0
   Singh RK, 2011, EPIGENETICS-US, V6, P153, DOI 10.4161/epi.6.2.13589
   Sofueva S, 2010, MOL CELL BIOL, V30, P4732, DOI 10.1128/MCB.00413-10
   Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446
   Tessarz P, 2014, NAT REV MOL CELL BIO, V15, P703, DOI 10.1038/nrm3890
   Xu M, 2013, EUR J GYNAECOL ONCOL, V34, P152
   Yoon TM, 2017, ONCOL REP, V37, P3667, DOI 10.3892/or.2017.5584
   Zhan L, 2018, BIOCHEM BIOPH RES CO, V495, P60, DOI 10.1016/j.bbrc.2017.10.145
   Zhang LP, 2019, AM J CANCER RES, V9, P406
   Zhao CL, 2018, INT J MOL MED, V41, P2901, DOI 10.3892/ijmm.2018.3475
   Zhuang L, 2015, MOL MED REP, V12, P547, DOI 10.3892/mmr.2015.3372
NR 30
TC 0
Z9 0
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD NOV 14
PY 2019
VL 9
AR 1233
DI 10.3389/fonc.2019.01233
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA JT8RO
UT WOS:000501250900001
PM 31799193
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Song, X
   Kim, SY
   Zhang, L
   Tang, D
   Bartlett, DL
   Kwon, YT
   Lee, YJ
AF Song, X.
   Kim, S-Y
   Zhang, L.
   Tang, D.
   Bartlett, D. L.
   Kwon, Y. T.
   Lee, Y. J.
TI Role of AMP-activated protein kinase in cross-talk between apoptosis and
   autophagy in human colon cancer
SO CELL DEATH & DISEASE
LA English
DT Article
ID CASPASE-MEDIATED CLEAVAGE; BECLIN 1; LIVER METASTASES; MTOR INHIBITORS;
   CELLS; STIMULATION; COMBINATION; INDUCTION; COMPLEXES; RELEASE
AB Unresectable colorectal liver metastases remain a major unresolved issue and more effective novel regimens are urgently needed. While screening synergistic drug combinations for colon cancer therapy, we identified a novel multidrug treatment for colon cancer: chemotherapeutic agent melphalan in combination with proteasome inhibitor bortezomib and mTOR (mammalian target of rapamycin) inhibitor rapamycin. We investigated the mechanisms of synergistic antitumor efficacy during the multidrug treatment. All experiments were performed with highly metastatic human colon cancer CX-1 and HCT116 cells, and selected critical experiments were repeated with human colon cancer stem Tu-22 cells and mouse embryo fibroblast (MEF) cells. We used immunochemical techniques to investigate a cross-talk between apoptosis and autophagy during the multidrug treatment. We observed that melphalan triggered apoptosis, bortezomib induced apoptosis and autophagy, rapamycin caused autophagy and the combinatorial treatment-induced synergistic apoptosis, which was mediated through an increase in caspase activation. We also observed that mitochondrial dysfunction induced by the combination was linked with altered cellular metabolism, which induced adenosine monophosphate-activated protein kinase (AMPK) activation, resulting in Beclin-1 phosphorylated at Ser 93/96. Interestingly, Beclin-1 phosphorylated at Ser 93/96 is sufficient to induce Beclin-1 cleavage by caspase-8, which switches off autophagy to achieve the synergistic induction of apoptosis. Similar results were observed with the essential autophagy gene, autophagy-related protein 7, -deficient MEF cells. The multidrug treatment-induced Beclin-1 cleavage was abolished in Beclin-1 double-mutant (D133A/D146A) knock-in HCT116 cells, restoring the autophagy-promoting function of Beclin-1 and suppressing the apoptosis induced by the combination therapy. These observations identify a novel mechanism for AMPK-induced apoptosis through interplay between autophagy and apoptosis.
C1 [Song, X.; Kim, S-Y; Tang, D.; Bartlett, D. L.; Lee, Y. J.] Univ Pittsburgh, Dept Surg, Hillman Canc Ctr, Pittsburgh, PA 15213 USA.
   [Zhang, L.; Lee, Y. J.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA.
   [Kwon, Y. T.] Seoul Natl Univ, Coll Med, Prot Metab Med Res Ctr, Seoul 110799, South Korea.
   [Kwon, Y. T.] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul 110799, South Korea.
RP Lee, YJ (corresponding author), Univ Pittsburgh, Dept Surg, Hillman Canc Ctr, 497 Scaife Hall, Pittsburgh, PA 15213 USA.
EM leeyj@upmc.edu
RI Zhang, Lin/A-7389-2009; Tang, Daolin/ABD-5062-2021; Tang,
   Daolin/B-2905-2010
OI Zhang, Lin/0000-0003-0018-3903; Tang, Daolin/0000-0002-1903-6180; 
FU NCIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R01CA140554, R01CA106348, R01CA172136, R01CA160417]; National Research
   Foundation of Korea Program [NRF-2013R1A2A2A01014170]; Nobel Laureates
   Invitation Program of Seoul National University;  [P30CA047904];
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R01CA160417, P30CA047904, R01CA140554, R01CA172136,
   R01CA106348] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [R01HL083365] Funding Source: NIH RePORTER
FX This work was supported by the following grants: NCI R01CA140554 (YJL),
   R01CA106348 (LZ), R01CA172136 (LZ) and R01CA160417 (DT); National
   Research Foundation of Korea Program NRF-2013R1A2A2A01014170 (YTK); and
   Nobel Laureates Invitation Program of Seoul National University (YTK).
   This project used the UPCI Core Facility and was supported in part by
   award P30CA047904.
CR Baumann P, 2007, ANTI-CANCER DRUG, V18, P405, DOI 10.1097/CAD.0b013e32801416b6
   Cho DH, 2009, CANCER LETT, V274, P95, DOI 10.1016/j.canlet.2008.09.004
   Cirocchi R, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006317.pub3
   Cummins Jordan M., 2004, Cancer Research, V64, P3006
   Faivre S, 2006, NAT REV DRUG DISCOV, V5, P671, DOI 10.1038/nrd2062
   Fasolo A, 2008, EXPERT OPIN INV DRUG, V17, P1717, DOI [10.1517/13543784.17.11.1717, 10.1517/13543784.17.11.1717 ]
   Fennell DA, 2008, ONCOGENE, V27, P1189, DOI 10.1038/sj.onc.1210744
   Fu D, 2012, NAT REV CANCER, V12, P104, DOI 10.1038/nrc3185
   Garrido C, 2006, CELL CYCLE, V5, P2592, DOI 10.4161/cc.5.22.3448
   Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929
   Green A, 2011, DIX-NEUF, V15, P1, DOI 10.1179/147873111X12973011702121
   Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007
   Habib SL, 2010, EUR J CANCER, V46, P2806, DOI 10.1016/j.ejca.2010.06.117
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hwang JT, 2005, BIOCHEM BIOPH RES CO, V332, P433, DOI 10.1016/j.bbrc.2005.04.143
   Itakura E, 2008, MOL BIOL CELL, V19, P5360, DOI 10.1091/mbc.E08-01-0080
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Jeong SY, 2008, BMB REP, V41, P11, DOI 10.1146/annurev-genet-102108-134850
   Juenemann Katrin, 2012, Int J Cell Biol, V2012, P189794, DOI 10.1155/2012/189794
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kefas BA, 2003, DIABETOLOGIA, V46, P250, DOI 10.1007/s00125-002-1030-3
   Kefas BA, 2003, J MOL ENDOCRINOL, V30, P151, DOI 10.1677/jme.0.0300151
   Kim J, 2013, CELL, V152, P290, DOI 10.1016/j.cell.2012.12.016
   Kwon HJ, 2010, EXP MOL MED, V42, P254, DOI 10.3858/emm.2010.42.4.025
   Lee YJ, 2001, CANCER GENE THER, V8, P397, DOI 10.1038/sj.cgt.7700310
   Li H, 2011, CANCER RES, V71, P3625, DOI 10.1158/0008-5472.CAN-10-4475
   Lucken-Ardjomande S, 2005, J CELL SCI, V118, P473, DOI 10.1242/jcs.01654
   Matsunaga K, 2009, NAT CELL BIOL, V11, P385, DOI 10.1038/ncb1846
   Odoux C, 2008, CANCER RES, V68, P6932, DOI 10.1158/0008-5472.CAN-07-5779
   Padrissa-Altes S, 2012, CLIN SCI, V123, P93, DOI 10.1042/CS20110093
   Poultsides George A, 2011, Ther Adv Med Oncol, V3, P35, DOI 10.1177/1758834010386283
   Reddy SK, 2014, THER ADV MED ONCOL, V6, P180, DOI 10.1177/1758834014529175
   Rocha GZ, 2011, CLIN CANCER RES, V17, P3993, DOI 10.1158/1078-0432.CCR-10-2243
   Ruers T, 2002, EUR J CANCER, V38, P1023, DOI 10.1016/S0959-8049(02)00059-X
   Russell RC, 2013, NAT CELL BIOL, V15, P741, DOI 10.1038/ncb2757
   Saitoh M, 2004, BIOCHEM PHARMACOL, V67, P2005, DOI 10.1016/j.bcp.2004.01.020
   Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100
   Song XX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073654
   Song XX, 2012, MOL CANCER RES, V10, P1567, DOI 10.1158/1541-7786.MCR-12-0209-T
   Song XX, 2012, J CELL BIOCHEM, V113, P1547, DOI 10.1002/jcb.24023
   Souliotis VL, 2003, CLIN CANCER RES, V9, P4465
   Townsend A, 2009, COCHRANE DB SYST REV, V7
   Vogl TJ, 2014, RADIOL MED, V119, P451, DOI 10.1007/s11547-014-0415-y
   Wang RC, 2012, SCIENCE, V338, P956, DOI 10.1126/science.1225967
   Wirawan E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.16
   Xiang XQ, 2004, BIOCHEM BIOPH RES CO, V321, P161, DOI 10.1016/j.bbrc.2004.06.133
   Zalckvar E, 2009, EMBO REP, V10, P285, DOI 10.1038/embor.2008.246
   Zhou Z, 2013, J BIOL CHEM, V288, P18134, DOI 10.1074/jbc.M113.456962
   Zhu Keyi, 2009, Proceedings of the American Association for Cancer Research Annual Meeting, V50, P451, DOI 10.1038/onc.2009.343
   Zhu YS, 2010, PROTEIN CELL, V1, P468, DOI 10.1007/s13238-010-0048-4
NR 50
TC 40
Z9 43
U1 0
U2 16
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD OCT
PY 2014
VL 5
AR e1504
DI 10.1038/cddis.2014.463
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AT5PG
UT WOS:000344994000075
PM 25356873
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Martyna, B
   Malgorzata, MW
   Nikola, Z
   Beniamin, G
   Urszula, M
   Grazyna, J
AF Martyna, Bednarczyk
   Malgorzata, Muc-Wierzgon
   Nikola, Zmarzly
   Beniamin, Grabarek
   Urszula, Mazurek
   Grazyna, Janikowska
TI Expression Profile of Genes Associated with the Proteins Degradation
   Pathways in Colorectal Adenocarcinoma
SO CURRENT PHARMACEUTICAL BIOTECHNOLOGY
LA English
DT Article
DE Autophagy; cancer; ubiquitination; colon; microarrays; lysosome
ID CELL-DEATH; CANCER; SYSTEM; RECRUITMENT; ACTIVATION; PROTEASOME;
   HOMEOSTASIS; OPTINEURIN; MITOPHAGY; CARCINOMA
AB Background: Changes in expression of genes associated with proteins or organelles degradation system in the cell may be a cause or signal to carcinogenesis. Thus, the aim of this study was to assess the profile of gene expression linked to the degradation systems of proteins or organelles in histo-pathologically confirmed colorectal adenocarcinoma in relation to normal colon tissue.
   Methods: Using oligonucleotide microarrays and GeneSpring 13.0, and PANTHER 13.1 software's we characterized 1095 mRNAs linked to the degradation system of proteins and organelles in sections of colorectal cancer from patients at various clinical stages of disease. Subsequent analyses with restrictive assumptions narrowed down the number of genes differentiating cancer, assuming a P-value of less than 0.05.
   Results: We found that most of the significant genes were silenced in the development of colorectal cancer. The FOXO1 had the lowest fold change value in the first clinical stage (CSI) comparing to the control. The HSPA8 was up-regulated in the two early clinical stages (CSI and CUE), and UBB only in the CSI. Only little-known PTPN22 showed increasing expression at all stages.
   Conclusion: In summary, the examined colorectal adenocarcinoma samples were characterized by almost complete silencing of the significant genes associated with the degradation of proteins and mitochondria in transcriptomic level. The FOXO1, HSPA8 and UBB genes may become potential diagnostic and/or therapeutic targets in the early stage of this cancer.
C1 [Martyna, Bednarczyk; Malgorzata, Muc-Wierzgon] Med Univ Silesia, Sch Publ Hlth, Dept & Clin Internal Dis, Katowice, Poland.
   [Nikola, Zmarzly; Beniamin, Grabarek; Urszula, Mazurek] Med Univ Silesia, Sch Pharm, Dept Mol Biol, Katowice, Poland.
   [Nikola, Zmarzly; Beniamin, Grabarek; Urszula, Mazurek; Grazyna, Janikowska] Med Univ Silesia, Div Lab Med, Katowice, Poland.
   [Grazyna, Janikowska] Med Univ Silesia, Dept Analyt Chem, Sch Pharm, Katowice, Poland.
RP Martyna, B (corresponding author), Med Univ Silesia, Sch Publ Hlth, Dept & Clin Internal Dis, Katowice, Poland.
EM martyna.bednarczyk@outlook.com
RI grabarek, beniamin/V-3630-2019
OI grabarek, beniamin/0000-0003-1633-7145; Zmarzly,
   Nikola/0000-0002-7833-6167; Mazurek, Urszula/0000-0003-1181-4934;
   Janikowska, Grazyna/0000-0002-2839-174X; Muc-Wierzgon,
   Malgorzata/0000-0001-6562-7072; Bednarczyk, Martyna/0000-0001-8360-9126
FU Medical University of Silesia [KNW-1-071/N/8/K]
FX The study was funded by the grant from Medical University of Silesia No.
   KNW-1-071/N/8/K.
CR Agesen TH, 2012, GUT, V61, P1560, DOI 10.1136/gutjnl-2011-301179
   Arena G, 2013, CELL DEATH DIFFER, V20, P920, DOI 10.1038/cdd.2013.19
   Azuma K, 2003, BRIT J CANCER, V89, P1079, DOI 10.1038/sj.bjc.6601203
   Behrends C., 2012, INT J CELL BIOL
   Bubko I, 2010, POSTEP HIG MED DOSW, V64, P314
   Chu CT, 2010, BBA-MOL BASIS DIS, V1802, P20, DOI 10.1016/j.bbadis.2009.06.012
   Cichoz-Lach H, 2017, ANN AGR ENV MED, V24, P108, DOI 10.5604/12321966.1227648
   Clark-Langone KM, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-691
   Didkowska J., 2017, NATL CANC REGISTRY
   Farhan M, 2017, INT J BIOL SCI, V13, P815, DOI 10.7150/ijbs.20052
   Fullgrabe J, 2016, J CELL SCI, V129, P3059, DOI 10.1242/jcs.188920
   Gadhave K, 2016, J CELL MOL MED, V20, P1392, DOI 10.1111/jcmm.12817
   Grzmil M, 2003, AM J PATHOL, V163, P543, DOI 10.1016/S0002-9440(10)63682-6
   Hamacher-Brady A, 2016, CELL MOL LIFE SCI, V73, P775, DOI 10.1007/s00018-015-2087-8
   Heo JM, 2015, MOL CELL, V60, P7, DOI 10.1016/j.molcel.2015.08.016
   Hervouet E, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1761-4
   Huang XD, 2016, CELL RES, V26, P484, DOI 10.1038/cr.2016.31
   Kaushik S, 2006, EMBO J, V25, P3921, DOI 10.1038/sj.emboj.7601283
   Kedves AT, 2017, J CLIN INVEST, V127, P4554, DOI 10.1172/JCI92914
   Kubota H, 2010, CELL STRESS CHAPERON, V15, P1003, DOI 10.1007/s12192-010-0211-0
   Kwon YT, 2017, TRENDS BIOCHEM SCI, V42, P873, DOI 10.1016/j.tibs.2017.09.002
   La Spada AR, 2012, AUTOPHAGY, V8, P1845, DOI 10.4161/auto.21862
   Lee H, 2016, BMB REP, V49, P270, DOI 10.5483/BMBRep.2016.49.5.187
   Levin AA, 2017, NEW ENGL J MED, V376, P86, DOI 10.1056/NEJMcibr1613559
   Lisak DA, 2015, BBA-MOL CELL RES, V1853, P2104, DOI 10.1016/j.bbamcr.2015.03.002
   Liu Q, 2017, BBA-MOL CELL RES, V1864, P850, DOI 10.1016/j.bbamcr.2016.12.023
   Loeffler DA, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00178
   Mastropasqua F, 2018, GENES-BASEL, V9, DOI 10.3390/genes9010048
   Moore AS, 2016, P NATL ACAD SCI USA, V113, pE3349, DOI 10.1073/pnas.1523810113
   Nelson DE, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.130131
   Nowakowska DJ, 2016, J IMMUNOL, V196, P2145, DOI 10.4049/jimmunol.1501877
   O'Flanagan CH, 2014, BBA-REV CANCER, V1846, P590, DOI 10.1016/j.bbcan.2014.10.006
   Oh C, 2013, SCI REP-UK, V3, DOI 10.1038/srep02623
   Qian H, 2018, AUTOPHAGY, V14, P563, DOI 10.1080/15548627.2018.1425057
   Radici L., 2013, ADV BIOSCIENCE BIOTE, DOI [DOI 10.4236/ABB.2013.412141, 10.4236/abb.2013.412141]
   Randle SJ, 2015, J PATHOL, V237, P263, DOI 10.1002/path.4571
   Rohatgi RA, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1030539
   Salah FS, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.93
   Shaid S, 2013, CELL DEATH DIFFER, V20, P21, DOI 10.1038/cdd.2012.72
   Shan NC, 2016, ONCOTARGETS THER, V9, P2169, DOI 10.2147/OTT.S97983
   SHOEMAKER C, 2015, ELIFE, P1
   Slowicka K, 2016, EUR J IMMUNOL, V46, P971, DOI 10.1002/eji.201545863
   Spalinger MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072384
   Steffen J, 2017, MOL BIOL CELL, V28, P600, DOI 10.1091/mbc.E16-07-0545
   Sujashvili R, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/4190390
   Sun T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8215
   Tang H, 2015, EBIOMEDICINE, V2, P255, DOI 10.1016/j.ebiom.2015.01.008
   Tian Y, 2018, PHYTOTHER RES, V32, P1320, DOI 10.1002/ptr.6064
   Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010
   Whitehouse CA, 2010, P NATL ACAD SCI USA, V107, P12913, DOI 10.1073/pnas.0913058107
   Wong YC, 2015, AUTOPHAGY, V11, P422, DOI 10.1080/15548627.2015.1009792
   Xiao W, 2017, ONCOTARGET, V8, P94819, DOI 10.18632/oncotarget.21999
   Yang CS, 2014, AUTOPHAGY, V10, P785, DOI 10.4161/auto.28072
   Zatonski WA., 2015, NOWOTWORY J ONCOL, V65, P179, DOI [DOI 10.5603/NJO.2015.0041, 10.5603/NJO.2015.0041]
   Zhang YF, 2017, ONCOL LETT, V13, P731, DOI 10.3892/ol.2016.5480
   Zhao Y, 2013, AUTOPHAGY, V9, P794, DOI 10.4161/auto.23918
   Zhong JL, 2016, WORLD J GASTRO ONCOL, V8, P198, DOI 10.4251/wjgo.v8.i2.198
   Zhou HY, 2016, CANCER BIOMARK, V17, P1, DOI 10.3233/CBM-160613
NR 58
TC 1
Z9 1
U1 1
U2 4
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-2010
EI 1873-4316
J9 CURR PHARM BIOTECHNO
JI Curr. Pharm. Biotechnol.
PY 2019
VL 20
IS 7
BP 551
EP 561
DI 10.2174/1389201020666190516090744
PG 11
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA IP9FV
UT WOS:000480356500003
PM 31096896
DA 2022-04-25
ER

PT J
AU Lee, WY
   Lee, WT
   Cheng, CH
   Chen, KC
   Chou, CM
   Chung, CH
   Sun, MS
   Cheng, HW
   Ho, MN
   Lin, CW
AF Lee, Wen-Ying
   Lee, Wai-Theng
   Cheng, Chia-Hsiung
   Chen, Ku-Chung
   Chou, Chih-Ming
   Chung, Chu-Hung
   Sun, Min-Siou
   Cheng, Hung-Wei
   Ho, Meng-Ni
   Lin, Cheng-Wei
TI Repositioning antipsychotic chlorpromazine for treating colorectal
   cancer by inhibiting sirtuin 1
SO ONCOTARGET
LA English
DT Article
DE chlorpromazine; drug reposition; p53; apoptosis; SIRT1
ID HUMAN BREAST-CANCER; AUTOPHAGIC CELL-DEATH; P53 ACETYLATION;
   GENE-EXPRESSION; IN-VIVO; PROSTATE-CANCER; GLIOMA-CELLS; TUMOR-GROWTH;
   COLON-CANCER; MUTANT P53
AB Investigating existing drugs for repositioning can enable overcoming bottlenecks in the drug development process. Here, we investigated the effect and molecular mechanism of the antipsychotic drug chlorpromazine (CPZ) and identified its potential for treating colorectal cancer (CRC). Human CRC cell lines harboring different p53 statuses were used to investigate the inhibitory mechanism of CPZ. CPZ effectively inhibited tumor growth and induced apoptosis in CRC cells in a p53-dependent manner. Activation of c-jun N-terminal kinase (JNK) was crucial for CPZ-induced p53 expression and the subsequent induction of tumor apoptosis. Induction of p53 acetylation at lysine382 was involved in CPZ-mediated tumor apoptosis, and this induction was attenuated by sirtuin 1 (SIRT1), a class III histone deacetylase. By contrast, knocking down SIRT1 sensitized tumor cells to CPZ treatment. Moreover, CPZ induced the degradation of SIRT1 protein participating downstream of JNK, and JNK suppression abrogated CPZ-mediated SIRT1 downregulation. Clinical analysis revealed a significant association between high SIRT1 expression and poor outcome in CRC patients. These data suggest that SIRT1 is an attractive therapeutic target for CRC and that CPZ is a potential repositioned drug for treating CRC.
C1 [Lee, Wen-Ying] Chi Mei Med Ctr, Dept Pathol, Tainan, Taiwan.
   [Lee, Wen-Ying] Taipei Med Univ, Sch Med, Dept Pathol, Coll Med, Taipei, Taiwan.
   [Lee, Wai-Theng; Cheng, Chia-Hsiung; Chen, Ku-Chung; Chou, Chih-Ming; Cheng, Hung-Wei; Ho, Meng-Ni; Lin, Cheng-Wei] Taipei Med Univ, Sch Med, Dept Biochem & Mol Cell Biol, Coll Med, Taipei, Taiwan.
   [Cheng, Chia-Hsiung; Chen, Ku-Chung; Chou, Chih-Ming; Lin, Cheng-Wei] Taipei Med Univ, Grad Inst Med Sci, Sch Med, Coll Med, Taipei, Taiwan.
   [Chung, Chu-Hung; Sun, Min-Siou] Acad Sinica, Inst Cellular & Organism Biol, Taipei 115, Taiwan.
RP Lin, CW (corresponding author), Taipei Med Univ, Sch Med, Dept Biochem & Mol Cell Biol, Coll Med, Taipei, Taiwan.
EM cwlin@tmu.edu.tw
RI Cheng, Chia-Hsiung/A-6044-2019
OI Cheng, Chia-Hsiung/0000-0003-0307-9650
FU Taipei Medical University [TMU101-AE1-B24, TMUTOP103005-7]; Chi-Mei
   Medical Center [102CM-TMU-09, 103CM-TMU-03]
FX We thank the Zebrafish Core Facility of Taipei Medical University for
   assisting in the zebrafish toxicity test and the National RNAi Core
   Facility of Academia Sinica for providing shRNA clones. We also thank
   Dr. Michael Greenberg for providing the SIRT1 construct. This study was
   supported by grants from Taipei Medical University (TMU101-AE1-B24 and
   TMUTOP103005-7) and Chi-Mei Medical Center (102CM-TMU-09 and
   103CM-TMU-03).
CR Babcook MA, 2014, MOL CANCER THER, V13, P2288, DOI 10.1158/1535-7163.MCT-14-0451
   Blagosklonny MV, 2003, TRENDS BIOTECHNOL, V21, P103, DOI 10.1016/S0167-7799(03)00004-0
   Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637
   Chen MH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027186
   Chen XJ, 2014, SCI REP-UK, V4, DOI 10.1038/srep07481
   Del Barco S, 2011, ONCOTARGET, V2, P896, DOI 10.18632/oncotarget.387
   Elangovan S, 2011, CANCER RES, V71, P6654, DOI 10.1158/0008-5472.CAN-11-1446
   Gao ZG, 2011, J BIOL CHEM, V286, P22227, DOI 10.1074/jbc.M111.228874
   Gritti M, 2014, ONCOTARGET, V5, P11252, DOI 10.18632/oncotarget.2617
   Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008-5472.CAN-09-2994
   Hoffmann G, 2014, J BIOL CHEM, V289, P5208, DOI 10.1074/jbc.M113.487736
   Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616
   Jorissen RN, 2009, CLIN CANCER RES, V15, P7642, DOI 10.1158/1078-0432.CCR-09-1431
   Jung-Hynes B, 2009, J BIOL CHEM, V284, P3823, DOI 10.1074/jbc.M807869200
   Kawano T, 2010, INT J ONCOL, V37, P787, DOI 10.3892/ijo_00000728
   Lain S, 2008, CANCER CELL, V13, P454, DOI 10.1016/j.ccr.2008.03.004
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Lau AW, 2014, AM J CANCER RES, V4, P245
   Lee CW, 2012, CANCER RES, V72, P4394, DOI 10.1158/0008-5472.CAN-12-0429
   Li D, 2011, CELL DEATH DIFFER, V18, P1904, DOI 10.1038/cdd.2011.71
   Li L, 2012, CANCER CELL, V21, P266, DOI 10.1016/j.ccr.2011.12.020
   Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200
   Liang ZX, 2014, MOL CANCER THER, V13, P1860, DOI 10.1158/1535-7163.MCT-13-0942
   Lin CW, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.386235
   Mohammed A, 2015, ONCOTARGET
   Muller BM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-215
   Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021
   Naccarati A, 2012, MUTAGENESIS, V27, P211, DOI 10.1093/mutage/ger067
   Nasrin N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008414
   Peck B, 2010, MOL CANCER THER, V9, P844, DOI 10.1158/1535-7163.MCT-09-0971
   Portmann S, 2013, MOL CANCER THER, V12, P499, DOI 10.1158/1535-7163.MCT-12-0700
   Sasaki T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004020
   Shangary S, 2008, CLIN CANCER RES, V14, P5318, DOI 10.1158/1078-0432.CCR-07-5136
   Shin SY, 2013, CARCINOGENESIS, V34, P2080, DOI 10.1093/carcin/bgt169
   Shin SY, 2010, EXP MOL MED, V42, P395, DOI 10.3858/emm.2010.42.5.041
   Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005
   Stenzinger A, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-450
   Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025
   Vainio P, 2011, ONCOTARGET, V2, P1176
   van Leeuwen IMM, 2013, MOL CANCER THER, V12, P471, DOI 10.1158/1535-7163.MCT-12-0904
   Vazquez-Martin A, 2011, BREAST CANCER RES TR, V126, P355, DOI 10.1007/s10549-010-0924-x
   Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468
   Wang J, 2012, INT J ONCOL, V41, P1101, DOI 10.3892/ijo.2012.1534
   Wu GS, 2004, CANCER BIOL THER, V3, P156, DOI 10.4161/cbt.3.2.614
   Yamaguchi H, 2009, J BIOL CHEM, V284, P11171, DOI 10.1074/jbc.M809268200
   Yang YH, 2007, NAT CELL BIOL, V9, P1253, DOI 10.1038/ncb1645
   Yde CW, 2009, ANTI-CANCER DRUG, V20, P723, DOI 10.1097/CAD.0b013e32832ec041
   Yu Q, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-71
   Zhang Q, 2012, EMBO MOL MED, V4, P298, DOI 10.1002/emmm.201100211
   Zhang Y, 2013, NEOPLASIA, V15, P523, DOI 10.1593/neo.13142
   Zhang YW, 2012, CANCER BIOL THER, V13, P915, DOI 10.4161/cbt.20844
   Zhu Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.103
NR 52
TC 32
Z9 35
U1 0
U2 14
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 29
PY 2015
VL 6
IS 29
BP 27580
EP 27595
DI 10.18632/oncotarget.4768
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CT9UE
UT WOS:000363161300085
PM 26363315
OA gold, Green Submitted, Green Published
DA 2022-04-25
ER

PT J
AU Zhang, P
   Lai, ZL
   Chen, HF
   Zhang, M
   Wang, A
   Jia, T
   Sun, WQ
   Zhu, XM
   Chen, XF
   Zhao, Z
   Zhang, J
AF Zhang, Pan
   Lai, Ze-Lin
   Chen, Hui-Fen
   Zhang, Min
   Wang, An
   Jia, Tao
   Sun, Wen-Qin
   Zhu, Xi-Min
   Chen, Xiao-Feng
   Zhao, Zheng
   Zhang, Jun
TI Curcumin synergizes with 5-fluorouracil by impairing AMPK/ULK1-dependent
   autophagy, AKT activity and enhancing apoptosis in colon cancer cells
   with tumor growth inhibition in xenograft mice
SO JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
LA English
DT Article
DE Curcumin; 5-fluorouracil; Autophagy; Colon cancer; Combination
   chemotherapy
ID STEM-LIKE CELLS; COLORECTAL-CANCER; SIGNALING PATHWAYS; HUMAN BREAST;
   IN-VIVO; TARGETS; ULK1; PHOSPHORYLATION; RESISTANCE; PROMOTES
AB Background: Chemoresistance is a major obstacle that limits the benefits of 5-Fluorouracil (5-Fu)-based chemotherapy for colon cancer patients. Autophagy is an important cellular mechanism underlying chemoresistance. Recent research advances have given new insights into the use of natural bioactive compounds to overcome chemoresistance in colon cancer chemotherapy. As one of the multitargeted and safer phytomedicines, curcumin has been reported to work as cancer-specific chemosensitizer, presumably via induction of autophagic signaling pathways. The precise therapeutic effect of curcumin on autophagy in determining tumorous cells' fate, however, remains unclear. This study was conducted to investigate the differential modulations of the treatments either with 5-Fu alone or 5-Fu combined with curcumin on cellular autophagic responses and viabilities in the human colon cancer cells HCT116 and HT29, and explore molecular signaling transductions underlying the curcumin-mediated autophagic changes and potentiation of 5-Fu's cytotoxicity in vitro and in vivo.
   Methods: Cell proliferation assay and morphology observation were used to identify the cytotoxicity of different combinations of curcumin and 5-Fu in HCT116 and HT29 cells. Cell immunofluorescence assay, Flow cytometry and Western blot were employed to detect changes of autophagy and the autophagy-related signaling pathways in the colon cancer cells and/or xenograft mice.
   Results: Curcumin could significantly augment the cytotoxicity of 5-Fu to the tumorous cells, and the pre-treatment with curcumin followed by 5-Fu (pre-Cur) proved to be the most effective one compared to other two combinations. The chemosensitizing role of curcumin might attribute to the autophagy turnover from being activated in 5-Fu mono-treatment to being inhibited in the pre-Cur treatment as indicated by the changes in expression of beclin-1, p62 and LC3II/LC3I and the intensity of Cyto-ID Green staining. The autophagic alterations appeared to be contributed by down-regulation of not only the phospho-Akt and phospho-mTOR expressions but the phospho-AMPK and phospho-ULK1 levels as well. The cellular activation of AMPK by addition of A-769662 to the pre-Cur combination resulted in reversed changes in expressions of the autophagy protein markers and apoptotic status compared to those of the pre-Cur combination treatment. The findings were validated in the xenograft mice, in which the tumor growth was significantly suppressed in the mice with 25-day combination treatment, and meanwhile expressions of the autophagy markers, P-AMPK and P-ULK1 were all reversely altered in line with those observed in HCT116 cells.
   Conclusion: Pre-treatment with curcumin followed by 5-Fu may mediate autophagy turnover both in vitro and in vivo via AMPK/ULK1-dependent autophagy inhibition and AKT modulation, which may account for the increased susceptibility of the colon cancer cells/xenograft to the cytotoxicity of 5-Fu.
C1 [Zhang, Pan; Lai, Ze-Lin; Zhu, Xi-Min; Zhao, Zheng] East China Normal Univ, Sch Life Sci, Minist Educ, Key Lab Brain Funct Genom, Shanghai 200062, Peoples R China.
   [Chen, Hui-Fen; Sun, Wen-Qin; Zhang, Jun] Tongji Univ, Shanghai Matern & Infant Hosp 1, Dept Clin Lab, Sch Med, Shanghai 201204, Peoples R China.
   [Zhang, Min; Zhang, Jun] Fudan Univ, Dept Clin Lab, Shanghai Publ Hlth Clin Ctr, Shanghai 201508, Peoples R China.
   [Wang, An; Chen, Xiao-Feng] Fudan Univ, Huashan Hosp, Dept Thorac Surg, Shanghai 200040, Peoples R China.
   [Jia, Tao] CNRS, Inst Adv Biosci, INSERM UGA U1209, UMR5309, F-38700 La Tronche, France.
RP Zhao, Z (corresponding author), East China Normal Univ, Sch Life Sci, Minist Educ, Key Lab Brain Funct Genom, Shanghai 200062, Peoples R China.; Zhang, J (corresponding author), Tongji Univ, Shanghai Matern & Infant Hosp 1, Dept Clin Lab, Sch Med, Shanghai 201204, Peoples R China.; Zhang, J (corresponding author), Fudan Univ, Dept Clin Lab, Shanghai Publ Hlth Clin Ctr, Shanghai 201508, Peoples R China.; Chen, XF (corresponding author), Fudan Univ, Huashan Hosp, Dept Thorac Surg, Shanghai 200040, Peoples R China.
EM dr_chenxiaofeng@126.com; zzhao@brain.ecnu.edu.cn; zhangjun@51mch.com
RI JIA, Tao/AAZ-1963-2020; Lai, Zelin/AGP-0626-2022
OI JIA, Tao/0000-0002-8358-6005; Lai, Zelin/0000-0002-5781-4780
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81,470,829, 31,171,019]; Key Laboratory of
   Brain Functional Genomics (ECNU), Ministry of Education
FX This work was supported in part by grants from the National Natural
   Science Foundation of China (81,470,829 to JZ and 31,171,019 to ZZ), and
   an opening grant from Key Laboratory of Brain Functional Genomics
   (ECNU), Ministry of Education (JZ).
CR An ZY, 2014, AUTOPHAGY, V10, P1702, DOI 10.4161/auto.32122
   Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r
   Beretta GD, 2004, SURG ONCOL, V13, P63, DOI 10.1016/j.suronc.2004.09.008
   Boya P, 2013, NAT CELL BIOL, V15, P713, DOI 10.1038/ncb2788
   Chainani-Wu N, 2003, J ALTERN COMPLEM MED, V9, P161, DOI 10.1089/107555303321223035
   Charpentier MS, 2014, CANCER RES, V74, P1250, DOI 10.1158/0008-5472.CAN-13-1778
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Duarte VM, 2010, MOL CANCER THER, V9, P2665, DOI 10.1158/1535-7163.MCT-10-0064
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   El-Khattouti Abdelouahid, 2013, J Cell Death, V6, P37, DOI 10.4137/JCD.S11034
   Gump JM, 2014, NAT CELL BIOL, V16, P47, DOI 10.1038/ncb2886
   Gump JM, 2011, TRENDS CELL BIOL, V21, P387, DOI 10.1016/j.tcb.2011.03.007
   Hector S, 2009, BBA-REV CANCER, V1795, P117, DOI 10.1016/j.bbcan.2008.12.002
   Hoyer-Hansen M, 2008, AUTOPHAGY, V4, P574, DOI 10.4161/auto.5921
   James MI, 2015, CANCER LETT, V364, P135, DOI 10.1016/j.canlet.2015.05.005
   Kang YT, 2016, ONCOTARGETS THER, V9, P7373, DOI 10.2147/OTT.S118272
   Khan MA, 2012, MOL CANCER THER, V11, P1873, DOI 10.1158/1535-7163.MCT-12-0141
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kolinsky K, 2009, MOL CANCER THER, V8, P75, DOI 10.1158/1535-7163.MCT-08-0596
   Kunnumakkara AB, 2008, CLIN CANCER RES, V14, P2128, DOI 10.1158/1078-0432.CCR-07-4722
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Li W, 2017, ONCOL REP, V37, P3459, DOI 10.3892/or.2017.5637
   Lopez-Lazaro M, 2008, MOL NUTR FOOD RES, V52, pS103, DOI 10.1002/mnfr.200700238
   Lozy F, 2012, SEMIN CELL DEV BIOL, V23, P395, DOI 10.1016/j.semcdb.2012.01.005
   Masuelli L, 2017, ONCOTARGET, V8, P34405, DOI 10.18632/oncotarget.14907
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Nazarko VY, 2013, NAT CELL BIOL, V15, P727, DOI 10.1038/ncb2797
   Patel BB, 2008, INT J CANCER, V122, P267, DOI 10.1002/ijc.23097
   Rao S, 2017, SEMIN IMMUNOL, V32, P54, DOI 10.1016/j.smim.2017.08.004
   Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302
   Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282
   Shinojima N, 2007, AUTOPHAGY, V3, P635, DOI 10.4161/auto.4916
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Teiten MH, 2010, TOXINS, V2, P128, DOI 10.3390/toxins2010128
   Toden S, 2015, CARCINOGENESIS, V36, P355, DOI 10.1093/carcin/bgv006
   Vogl DT, 2014, AUTOPHAGY, V10, P1380, DOI 10.4161/auto.29264
   Wang JG, 2016, SCI REP-UK, V6, DOI 10.1038/srep22146
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Yao CW, 2017, BIOMOL THER, V25, P315, DOI 10.4062/biomolther.2016.069
   Yap TA, 2013, J CLIN ONCOL, V31, P1592, DOI 10.1200/JCO.2011.37.6418
   Yu L, 2014, CANCER LETT, V355, P34, DOI 10.1016/j.canlet.2014.09.020
   Zhang HH, 2015, CANCER LETT, V356, P781, DOI 10.1016/j.canlet.2014.10.029
   Zhang YW, 2017, EXP THER MED, V14, P593, DOI 10.3892/etm.2017.4529
   Zhao GM, 2016, ONCOL REP, V35, P1065, DOI 10.3892/or.2015.4413
   Zhao MT, 2011, CELL METAB, V13, P119, DOI 10.1016/j.cmet.2011.01.009
   Zhou QM, 2011, ACTA PHARMACOL SIN, V32, P1402, DOI 10.1038/aps.2011.97
NR 47
TC 61
Z9 63
U1 1
U2 43
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-9966
J9 J EXP CLIN CANC RES
JI J. Exp. Clin. Cancer Res.
PD DEC 22
PY 2017
VL 36
AR 190
DI 10.1186/s13046-017-0661-7
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FR0FJ
UT WOS:000418736500002
PM 29273065
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Classen, F
   Kranz, P
   Riffkin, H
   Pompsch, M
   Wolf, A
   Gopelt, K
   Baumann, M
   Baumann, J
   Brockmeier, U
   Metzen, E
AF Classen, Fabian
   Kranz, Philip
   Riffkin, Helena
   Pompsch, Mosche
   Wolf, Alexandra
   Goepelt, Kirsten
   Baumann, Melanie
   Baumann, Jennifer
   Brockmeier, Ulf
   Metzen, Eric
TI Autophagy induced by ionizing radiation promotes cell death over
   survival in human colorectal cancer cells
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Autophagy; Atg7; Beclin1; Hypoxia; Glutamine starvation
ID TUMOR-CELLS; CHLOROQUINE; RESISTANCE; INHIBITION; MECHANISMS; GROWTH
AB Autophagy is commonly described as a cell survival mechanism and has been implicated in chemo- and radioresistance of cancer cells. Whether ionizing radiation induced autophagy triggers tumor cell survival or cell death still remains unclear. In this study the autophagy related proteins Beclinl and ATG7 were tested as potential targets to sensitize colorectal carcinoma cells to ionizing radiation under normoxic, hypoxic and starvation conditions. Colony formation, apoptosis and cell cycle analysis revealed that knockdown of Beclinl or ATG7 does not enhance radiosensitivity in HCT-116 cells. Furthermore, ATG7 knockdown led to an increased survival fraction under oxygen and glutamine starvation, indicating that ionizing radiation indeed induces autophagy which, however, leads to cell death finally. These results highlight that inhibition of autophagic pathways does not generally increase therapy success but may also lead to an unfavorable outcome especially under amino acid and oxygen restriction.
C1 [Classen, Fabian; Kranz, Philip; Riffkin, Helena; Pompsch, Mosche; Wolf, Alexandra; Goepelt, Kirsten; Baumann, Melanie; Baumann, Jennifer; Brockmeier, Ulf; Metzen, Eric] Univ Duisburg Essen, Inst Physiol, Hufelandstr 55, D-45147 Essen, Germany.
RP Metzen, E (corresponding author), Univ Duisburg Essen, Inst Physiol, Hufelandstr 55, D-45147 Essen, Germany.
EM eric.metzen@uni-due.de
FU Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG)
   [GRK1739]; IFORES program of the University of Duisburg-Essen
FX This study was funded by the research training group GRK1739 of the
   Deutsche Forschungsgemeinschaft and the IFORES program of the University
   of Duisburg-Essen. None of the funding bodies had an active role in the
   design of the study, in the collection, analysis and interpretation of
   data, in the preparation of the manuscript or in the publication
   process.
CR Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562
   Barker HE, 2015, NAT REV CANCER, V15, P409, DOI 10.1038/nrc3958
   Bortnik S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071496
   Briceno Eduardo, 2003, Neurosurg Focus, V14, pe3
   Bryant KL, 2014, TRENDS BIOCHEM SCI, V39, P91, DOI 10.1016/j.tibs.2013.12.004
   Chaachouay H, 2011, RADIOTHER ONCOL, V99, P287, DOI 10.1016/j.radonc.2011.06.002
   Chaurasia M, 2016, FREE RADICAL RES, V50, P273, DOI 10.3109/10715762.2015.1129534
   Chen YS, 2015, MOL MED REP, V12, P1645, DOI 10.3892/mmr.2015.3623
   Chude CI, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061279
   Eng CH, 2016, P NATL ACAD SCI USA, V113, P182, DOI 10.1073/pnas.1515617113
   Feng YC, 2014, CELL RES, V24, P24, DOI 10.1038/cr.2013.168
   Gewirtz DA, 2014, RADIAT RES, V182, P363, DOI 10.1667/RR13774.1
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Hanekamp DW, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.2236.2236
   He YY, 2014, TUMOR BIOL, V35, P7317, DOI 10.1007/s13277-014-2060-4
   Hussmann M, 2015, ONCOTARGET, V6, P39247, DOI 10.18632/oncotarget.5746
   Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114
   Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kaur J, 2015, NAT REV MOL CELL BIO, V16, P461, DOI 10.1038/nrm4024
   Kim BM, 2015, INT J MOL SCI, V16, P26880, DOI 10.3390/ijms161125991
   Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li Y, 2016, THORAC CANCER, V7, P379, DOI 10.1111/1759-7714.12332
   Liang Diana Hwang, 2015, J Nucl Med Radiat Ther, V6
   Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143
   Ma YT, 2013, IMMUNITY, V39, P211, DOI 10.1016/j.immuni.2013.07.017
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Nyfeler B, 2016, AUTOPHAGY, V12, P1206, DOI 10.1080/15548627.2016.1170265
   Palumbo S, 2013, J CELL PHYSIOL, V228, P1, DOI 10.1002/jcp.24118
   Schaaf MBE, 2015, RADIOTHER ONCOL, V114, P406, DOI 10.1016/j.radonc.2015.02.019
   Schonewolf CA, 2014, WORLD J GASTRO ONCOL, V6, P74, DOI 10.4251/wjgo.v6.i3.74
   Solitro AR, 2016, FUTURE MED CHEM, V8, P73, DOI 10.4155/fmc.15.166
   Sotelo J, 2006, ANN INTERN MED, V144, P337, DOI 10.7326/0003-4819-144-5-200603070-00008
   Stolz A, 2014, NAT CELL BIOL, V16, P495, DOI 10.1038/ncb2979
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Tam SY, 2017, RADIAT ONCOL, V12, DOI 10.1186/s13014-017-0795-y
   Wang F, 2018, CELL PHYSIOL BIOCHEM, V45, P54, DOI 10.1159/000486222
   Xu F, 2017, SCI REP-UK, V7, DOI 10.1038/srep45385
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Ye HX, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0700-6
   Yonekawa T, 2013, ESSAYS BIOCHEM, V55, P105, DOI [10.1042/BSE0550105, 10.1042/bse0550105]
NR 43
TC 19
Z9 19
U1 1
U2 5
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD JAN 1
PY 2019
VL 374
IS 1
BP 29
EP 37
DI 10.1016/j.yexcr.2018.11.004
PG 9
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA HI7KY
UT WOS:000456636300004
PM 30412717
OA hybrid
DA 2022-04-25
ER

PT J
AU Chen, SS
   Fang, Y
   Sun, LY
   He, RN
   He, BH
   Zhang, S
AF Chen, Shanshan
   Fang, Yi
   Sun, Lingyu
   He, Ruonan
   He, Beihui
   Zhang, Shuo
TI Long Non-Coding RNA: A Potential Strategy for the Diagnosis and
   Treatment of Colorectal Cancer
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE long non-coding RNA; colorectal cancer; drug resistance; proliferation;
   metastasis; occurrence; invasion
ID EPITHELIAL-MESENCHYMAL-TRANSITION; COLON-CANCER; STEM-CELLS;
   PROGNOSTIC-FACTOR; HIPPO PATHWAY; EXPRESSION; PROMOTES; PROLIFERATION;
   PROTEIN; GROWTH
AB Colorectal cancer (CRC), being one of the most commonly diagnosed cancers worldwide, endangers human health. Because the pathological mechanism of CRC is not fully understood, there are many challenges in the prevention, diagnosis, and treatment of this disease. Long non-coding RNAs (lncRNAs) have recently drawn great attention for their potential roles in the different stages of CRC formation, invasion, and progression, including regulation of molecular signaling pathways, apoptosis, autophagy, angiogenesis, tumor metabolism, immunological responses, cell cycle, and epithelial-mesenchymal transition (EMT). This review aims to discuss the potential mechanisms of several oncogenic lncRNAs, as well as several suppressor lncRNAs, in CRC occurrence and development to aid in the discovery of new methods for CRC diagnosis, treatment, and prognosis assessment.</p>
C1 [Chen, Shanshan; Fang, Yi; Sun, Lingyu; He, Beihui; Zhang, Shuo] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Hangzhou, Peoples R China.
   [Fang, Yi; Sun, Lingyu; He, Ruonan] Zhejiang Chinese Med Univ, Clin Med Coll 1, Hangzhou, Peoples R China.
RP He, BH; Zhang, S (corresponding author), Zhejiang Chinese Med Univ, Affiliated Hosp 1, Hangzhou, Peoples R China.
EM graf303@sina.com; zhangshuotcm@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81973598, 82074186, 82074214]; Medicine and
   Health Science and Technology Plan Projects in Zhejiang province
   [2021KY834]; Research Fund Project of Zhejiang Chinese Medical
   University [2019ZY02, 2020ZG41]
FX Funding This work was supported in part by the National Natural Science
   Foundation of China (81973598, 82074186, 82074214). Funding was also
   provided by the Medicine and Health Science and Technology Plan Projects
   in Zhejiang province (2021KY834), and Research Fund Project of Zhejiang
   Chinese Medical University (2019ZY02, 2020ZG41).
CR Alnabulsi A, 2012, J PATHOL, V228, P471, DOI 10.1002/path.4031
   Bates RC, 2005, CELL CYCLE, V4, P1350, DOI 10.4161/cc.4.10.2053
   Bates RC, 2007, CELLS TISSUES ORGANS, V185, P29, DOI 10.1159/000101300
   Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111
   Bronner C, 2013, BIOCHEM PHARMACOL, V86, P1643, DOI 10.1016/j.bcp.2013.10.002
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156
   Chen BQ, 2020, GASTROENTEROLOGY, V159, P2146, DOI 10.1053/j.gastro.2020.08.018
   Cherry EM, 2015, MOL CANCER, V14, DOI 10.1186/s12943-014-0273-1
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Comet I, 2016, NAT REV CANCER, V16, P803, DOI 10.1038/nrc.2016.83
   Cui MF, 2019, J CELL BIOCHEM, V120, P6926, DOI 10.1002/jcb.27630
   Doherty JR, 2013, J CLIN INVEST, V123, P3685, DOI 10.1172/JCI69741
   El-Deiry WS, 2015, CANCER BIOL THER, V16, P1726, DOI 10.1080/15384047.2015.1113356
   Fountzilas G, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-212
   Furfaro AL, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/1958174
   Gadepalli R, 2013, J BIOL CHEM, V288, P30815, DOI 10.1074/jbc.M113.463414
   Gordon DJ, 2012, NAT REV GENET, V13, P189, DOI 10.1038/nrg3123
   Goruppi S, 1999, ONCOGENE, V18, P4224, DOI 10.1038/sj.onc.1202788
   Graham Lloyd D, 2011, Genes Cancer, V2, P829, DOI 10.1177/1947601911431081
   Grandclement C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020444
   Grommes C, 2008, J NEUROIMMUNE PHARM, V3, P130, DOI 10.1007/s11481-007-9090-2
   Guo JB, 2020, ONCOTARGETS THER, V13, P4169, DOI 10.2147/OTT.S245091
   Han P, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0583-1
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Holland JD, 2013, CURR OPIN CELL BIOL, V25, P254, DOI 10.1016/j.ceb.2013.01.004
   Huang JG, 2016, NUCLEIC ACIDS RES, V44, P3059, DOI 10.1093/nar/gkv1353
   Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827
   Ishiwata T, 2016, PATHOL INT, V66, P601, DOI 10.1111/pin.12447
   Isin M, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00168
   Kawasaki Y, 2019, EMBO REP, V20, DOI 10.15252/embr.201847052
   Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021
   Lan Y, 2018, NUCLEIC ACIDS RES, V46, P5809, DOI 10.1093/nar/gky214
   Lebedeva S, 2011, MOL CELL, V43, P340, DOI 10.1016/j.molcel.2011.06.008
   Li PL, 2017, MOL CANCER THER, V16, P739, DOI 10.1158/1535-7163.MCT-16-0591
   Li TT, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0877-2
   Li XF, 2014, ONCOTARGET, V5, P9498, DOI 10.18632/oncotarget.2411
   Li YS, 2021, THERANOSTICS, V11, P4516, DOI 10.7150/thno.54549
   Lien WH, 2014, GENE DEV, V28, P1517, DOI 10.1101/gad.244772.114
   Liu AH, 2019, J CELL PHYSIOL, V234, P13747, DOI 10.1002/jcp.28054
   Liu CX, 2016, ONCOTARGETS THER, V9, P2865, DOI 10.2147/OTT.S103460
   Liu G, 2021, AGING-US, V13, P9748, DOI 10.18632/aging.202729
   Liu J, 2020, MOL ONCOL, V14, P3211, DOI 10.1002/1878-0261.12819
   Liu Q, 2013, NUCLEIC ACIDS RES, V41, P4976, DOI 10.1093/nar/gkt182
   Luo P, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0223035
   Ma SP, 2018, AGING-US, V10, P2062, DOI 10.18632/aging.101530
   Ma WR, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01150-4
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Marin-Bejar O, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-9-r104
   Masoumi-Moghaddam S, 2014, CANCER METAST REV, V33, P695, DOI 10.1007/s10555-014-9497-1
   Matsumura K, 2017, ONCOGENE, V36, P1191, DOI 10.1038/onc.2016.282
   Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115
   Meseure D, 2016, MOL CANCER RES, V14, P623, DOI 10.1158/1541-7786.MCR-15-0418
   Minn I, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4662
   Miura JT, 2015, CANCER BIOL THER, V16, P764, DOI 10.1080/15384047.2015.1026479
   Mo SB, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2338-y
   Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P
   Na HK, 2014, FREE RADICAL BIO MED, V67, P353, DOI 10.1016/j.freeradbiomed.2013.10.819
   Naemura M, 2016, MOL CELL BIOCHEM, V412, P141, DOI 10.1007/s11010-015-2618-5
   Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200
   Ni X, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12723
   Norimura S, 2018, J CANCER RES THER, V14, P409, DOI 10.4103/jcrt.JCRT_1053_16
   Nygard SB, 2013, SCAND J GASTROENTERO, V48, P1436, DOI 10.3109/00365521.2013.848230
   Ou CL, 2017, CANCER LETT, V399, P53, DOI 10.1016/j.canlet.2017.04.011
   Pei YF, 2018, BBA-MOL BASIS DIS, V1864, P197, DOI 10.1016/j.bbadis.2017.10.019
   Pelletier J, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00018
   Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006
   Punt CJA, 2009, NAT REV CLIN ONCOL, V6, P731, DOI 10.1038/nrclinonc.2009.168
   Ren J, 2018, THERANOSTICS, V8, P3932, DOI 10.7150/thno.25541
   Sase T, 2012, INT J CANCER, V131, P2284, DOI 10.1002/ijc.27525
   Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658
   Shiraiwa K, 2019, THYROID, V29, P674, DOI 10.1089/thy.2018.0212
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P145, DOI 10.3322/caac.21601
   Silva-Fisher JM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15547-8
   Slattery ML, 2011, CARCINOGENESIS, V32, P318, DOI 10.1093/carcin/bgq245
   Sokolenko AP, 2014, INT J CANCER, V134, P2352, DOI 10.1002/ijc.28569
   Soleimani A, 2020, GENE, V726, DOI 10.1016/j.gene.2019.144132
   Sonderstrup IMH, 2015, MOL ONCOL, V9, P1207, DOI 10.1016/j.molonc.2015.02.009
   Song N, 2018, CELL PHYSIOL BIOCHEM, V49, P1060, DOI 10.1159/000493286
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Svoboda M, 2014, CARCINOGENESIS, V35, P1510, DOI 10.1093/carcin/bgu055
   Takahashi K, 2014, MOL CANCER RES, V12, P1377, DOI 10.1158/1541-7786.MCR-13-0636
   Takahashi K, 2014, FEBS OPEN BIO, V4, P458, DOI 10.1016/j.fob.2014.04.007
   Tang JY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11447-8
   Tang Q, 2018, CELL PHYSIOL BIOCHEM, V47, P893, DOI 10.1159/000490131
   Taniue K, 2016, P NATL ACAD SCI USA, V113, P1273, DOI 10.1073/pnas.1500992113
   Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986
   Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20
   Tsai KW, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0821-1
   Tsavaris N, 2009, CANCER CHEMOTH PHARM, V64, P391, DOI 10.1007/s00280-008-0886-4
   Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020
   Wang HJ, 2018, BIOMED PHARMACOTHER, V106, P1607, DOI 10.1016/j.biopha.2018.07.131
   Wang JH, 2020, CANCERS, V12, DOI 10.3390/cancers12113171
   Wang WG, 2005, EMBO REP, V6, P158, DOI 10.1038/sj.embor.7400346
   Wang YB, 2015, J BIOL CHEM, V290, P10395, DOI 10.1074/jbc.M114.631689
   Wen DC, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.110039
   Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716
   Wu XB, 2019, AM J TRANSL RES, V11, P5740
   Xu GR, 2020, J CELL MOL MED, V24, P4136, DOI 10.1111/jcmm.15070
   Xu M, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0894-x
   Xu W, 2020, INT J CANCER, V146, P2901, DOI 10.1002/ijc.32747
   Yang L, 2016, ONCOL REP, V35, P318, DOI 10.3892/or.2015.4364
   Yoon JH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6248
   Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044
   Yu YJ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0725-5
   Yue B, 2018, MOL THER, V26, P1287, DOI 10.1016/j.ymthe.2018.02.024
   Yue B, 2016, MOL THER, V24, P2064, DOI 10.1038/mt.2016.180
   Zhang HX, 2019, ONCOL REP, V41, P3386, DOI 10.3892/or.2019.7106
   Zhang YF, 2020, CANCER MED-US, V9, P1842, DOI 10.1002/cam4.2840
   Zheng YW, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109628
   Zhou R, 2020, J CELL MOL MED, V24, P3229, DOI 10.1111/jcmm.14999
   Zhu JH, 2013, ASIAN PAC J CANCER P, V14, P1017, DOI 10.7314/APJCP.2013.14.2.1017
NR 112
TC 0
Z9 0
U1 3
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD OCT 27
PY 2021
VL 11
AR 762752
DI 10.3389/fonc.2021.762752
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA WW0AI
UT WOS:000717589400001
PM 34778084
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Benhalilou, N
   Alsamri, H
   Atneyadi, A
   Athamneh, K
   Alrashedi, A
   Altamimi, N
   Al Dhaheri, Y
   Eid, AH
   Iratni, R
AF Benhalilou, Nehia
   Alsamri, Halima
   Atneyadi, Aysha
   Athamneh, Khawlah
   Alrashedi, Asma
   Altamimi, Nedaa
   Al Dhaheri, Yusra
   Eid, Ali H.
   Iratni, Rabah
TI Origanum majorana Ethanolic Extract Promotes Colorectal Cancer Cell
   Death by Triggering Abortive Autophagy and Activation of the Extrinsic
   Apoptotic Pathway
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE colon cancer; abortive autophagy; apoptosis; DNA damage; Origanum
   majorana; HPLC-MS
ID SURVIVIN; INHIBITION; ANTIOXIDANT; ANTICANCER; MARJORAM; IDENTIFICATION
AB Colorectal cancer is considered as the third leading cause of cancer death. In the present study, we investigated the potential anticancer effect and the molecular mechanism of Origanum majorana ethanolic extract (OME) against human colorectal cancer cells. We showed that OME exhibited strong anti-proliferative activity in a concentration- and time-dependent manner against two human colorectal cancer cell lines (HT-29 and Caco-2). OME inhibited cell viability, colony growth and induced mitotic arrest of HT-29 cells. Also, OME induced DNA damage, triggered abortive autophagy and activated a caspase 3 and 7-dependent extrinsic apoptotic pathway, most likely through activation of the TNF alpha pathway. Time-course analysis revealed that DNA damage occurred concomitantly with abortive autophagy after 4 h post-OME treatment while apoptosis was activated only 24 h later. Blockade of autophagy initiation, by 3-methyladenine, partially rescued OME-induced cell death. Cell viability arose from 37% in control group to 67% in group pre-treated with 3-MA before addition of OME. Inhibition of apoptosis, however, had a minimal effect on cell viability; it rose from 37% in control group to 43% in group pre-treated with Z-VAD-FMK. We also found that OME downregulated survivin in HT-29 cells. Our findings provide a strong evidence that O. majorana extract possesses strong anti-colon cancer potential, at least, through induction of autophagy and apoptosis. These finding provide the basis for therapeutic potential of O. majorana in the treatment of colon cancer.
C1 [Benhalilou, Nehia; Alsamri, Halima; Atneyadi, Aysha; Athamneh, Khawlah; Alrashedi, Asma; Altamimi, Nedaa; Al Dhaheri, Yusra; Iratni, Rabah] United Arab Emirates Univ, Coll Sci, Dept Biol, Abu Dhabi, U Arab Emirates.
   [Eid, Ali H.] Amer Univ Beirut, Fac Med, Dep Pharmacol & Toxicol, Beirut, Lebanon.
RP Iratni, R (corresponding author), United Arab Emirates Univ, Coll Sci, Dept Biol, Abu Dhabi, U Arab Emirates.
EM R_iratni@uaeu.ac.ae
RI Eid, Ali Hussein/ABD-6291-2021
OI Eid, Ali Hussein/0000-0003-3004-5675; Alneyadi,
   Aysha/0000-0002-6450-4713
FU Al Jalila FoundationAl Jalila Foundation (AJF) [21S102-AJF2018007]
FX This work was supported by Al Jalila Foundation research grant (Grant
   21S102-AJF2018007) to RI.
CR Al Dhaheri Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068808
   Al Dhaheri Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056649
   Al-Howiriny T, 2009, AM J CHINESE MED, V37, P531, DOI 10.1142/S0192415X0900703X
   Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917
   Athamneh K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11202-3
   Attoub S, 2011, EUR J PHARMACOL, V651, P18, DOI 10.1016/j.ejphar.2010.10.063
   Benbrook D. M., 2012, Experimental Oncology, V34, P286
   Bina F, 2017, J EVID-BASED INTEGR, V22, P175, DOI 10.1177/2156587216650793
   Cao ZJ, 2017, CELL PHYSIOL BIOCHEM, V43, P1803, DOI 10.1159/000484066
   Chandele A, 2004, NEOPLASIA, V6, P29, DOI 10.1016/S1476-5586(04)80051-4
   Claerhout S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039400
   Dahham SS, 2015, MOLECULES, V20, P11808, DOI 10.3390/molecules200711808
   Dai DJ, 2012, ONCOL REP, V27, P621, DOI 10.3892/or.2011.1544
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   El Hasasna H, 2015, SCI REP-UK, V5, DOI 10.1038/srep13013
   Erenler R, 2016, J SCI FOOD AGR, V96, P822, DOI 10.1002/jsfa.7155
   Fathy SA, 2016, CELL MOL BIOL, V62, P80, DOI 10.14715/cmb/2016.62.10.13
   Goel P, 2015, PHYTO PHARM REV, V6, P261
   Han YH, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00068
   Hossain MB, 2014, J SEP SCI, V37, P3205, DOI 10.1002/jssc.201400597
   Humphry NJ, 2018, BIOL OPEN, V7, DOI 10.1242/bio.037374
   Leeja L, 2007, J ENVIRON BIOL, V28, P145
   Lu ML, 2008, CLIN CANCER RES, V14, P3168, DOI 10.1158/1078-0432.CCR-07-4362
   Makrane H, 2019, J ETHNOPHARMACOL, V239, DOI 10.1016/j.jep.2018.09.005
   Mizushima N, 2010, NAT CELL BIOL, V12, P823, DOI 10.1038/ncb0910-823
   Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055
   Park SH, 2013, BIOMOL THER, V21, P29, DOI 10.4062/biomolther.2012.088
   Pecorino L., 2012, MOL BIOL CANC MECH T
   Rauf A, 2018, PHYTOTHER RES, V32, P2109, DOI 10.1002/ptr.6155
   Serafini LF, 2018, ACTA HORTIC, V1198, P85, DOI 10.17660/ActaHortic.2018.1198.16
   Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q
   Soliman AM, 2016, NUTRIENTS, V8, DOI 10.3390/nu8050264
   Surova O, 2013, ONCOGENE, V32, P3789, DOI 10.1038/onc.2012.556
   Tamm I, 1998, CANCER RES, V58, P5315
   Tuorkey MJ, 2016, EUR J CANCER PREV, V25, P65, DOI 10.1097/CEJ.0000000000000128
   Verschooten L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048264
   Wang YF, 2014, APOPTOSIS, V19, P748, DOI 10.1007/s10495-013-0960-1
   Wojtkowiak JW, 2011, J PHARMACOL EXP THER, V337, P65, DOI 10.1124/jpet.110.174573
   Xipell E, 2016, ONCOTARGET, V7, P30626, DOI [10.16632/oncotarget.8905, 10.18632/oncotarget.8905]
   Yao F, 2012, MOL MED REP, V5, P84, DOI 10.3892/mmr.2011.590
   Yazdanparast R, 2008, VASC PHARMACOL, V48, P32, DOI 10.1016/j.vph.2007.11.003
   Zhao Y, 2016, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.2016
NR 42
TC 12
Z9 13
U1 1
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD AUG 21
PY 2019
VL 9
AR 795
DI 10.3389/fonc.2019.00795
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA IS2VU
UT WOS:000482012900002
PM 31497536
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Geng, YD
   Zhang, L
   Wang, GY
   Feng, XJ
   Chen, ZL
   Jiang, L
   Shen, AZ
AF Geng, Ya-di
   Zhang, Lei
   Wang, Guo-Yu
   Feng, Xiao-Jun
   Chen, Zhao-Lin
   Jiang, Ling
   Shen, Ai-Zong
TI Xanthatin mediates G(2)/M cell cycle arrest, autophagy and apoptosis via
   ROS/XIAP signaling in human colon cancer cells
SO NATURAL PRODUCT RESEARCH
LA English
DT Article
DE Xanthatin; cell cycle; apoptosis; autophagy; XIAP; colon cancer
ID XIAP; STRESS
AB Xanthatin is a natural plant bicyclic sesquiterpene lactone extracted fromXanthium plants (Asteraceae).In the present study, we demonstrated for the first time that Xanthatin inhibited cell proliferation and mediated G(2)/M phase arrest in human colon cancer cells. Xanthatin also activated caspase and mediated apoptosis in these cells. Concomitantly, Xanthatin triggered cell autophagic response. We found down-regulation of X-linked inhibitor of apoptosis protein (XIAP) contribute to the induction of apoptosis and autophagy. Moreover, reactive oxygen species (ROS) production was triggered upon exposure to Xanthatin in colon cancer cells. ROS inhibitor N-acetylcysteine (NAC) significantly reversed Xanthatin-mediated XIAP down-regulation, G(2)/M phase arrest, apoptosis and autophagosome accumulation. In summary, our findings demonstrated that Xanthatin caused G(2)/M phase arrest and mediated apoptosis and autophagy through ROS/XIAP in human colon cancer cells. We provided molecular bases for developing Xanthatin as a promising antitumor candidate for colon cancer therapy.
C1 [Geng, Ya-di; Zhang, Lei; Wang, Guo-Yu; Feng, Xiao-Jun; Chen, Zhao-Lin; Jiang, Ling; Shen, Ai-Zong] Anhui Med Univ, Anhui Prov Hosp, Dept Pharm, Hefei, Anhui, Peoples R China.
RP Jiang, L; Shen, AZ (corresponding author), Anhui Med Univ, Anhui Prov Hosp, Dept Pharm, Hefei, Anhui, Peoples R China.
EM ahslyyjl@126.com; ahslyysaz@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81603339, 81602344]; Natural Science
   Foundation of Anhui ProvinceNatural Science Foundation of Anhui Province
   [1708085QH175]
FX This work was co-supported by the National Natural Science Foundation of
   China (Program No. 81603339, 81602344) and Natural Science Foundation of
   Anhui Province (Program No. 1708085QH175).
CR Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903
   Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI 10.1089/ARS.2008.2270
   Barni S, 2007, ANN ONCOL, V18, P179, DOI 10.1093/annonc/mdm252
   Crawford S, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00068
   Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795
   Hileman EO, 2004, CANCER CHEMOTH PHARM, V53, P209, DOI 10.1007/s00280-003-0726-5
   Huang X, 2013, EMBO J, V32, P2204, DOI 10.1038/emboj.2013.133
   Jiang H, 2020, NAT PROD RES, V34, P1743, DOI 10.1080/14786419.2018.1530229
   Kim R, 2006, CANCER BIOL THER, V5, P1429, DOI 10.4161/cbt.5.11.3456
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Linsalata M, 2008, NUTRITION, V24, P382, DOI 10.1016/j.nut.2007.12.014
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Mone A., 2013, ISSUES SCREENING SUR
   Olivaro C, 2016, NATURAL PRODUCT RES, V30, P1
   Schile AJ, 2008, GENE DEV, V22, P2256, DOI 10.1101/gad.1663108
   Sharifi-Rad J, 2016, CELL MOL BIOL, V62, P69, DOI 10.14715/cmb/2016.62.9.11
   Shi YS, 2015, J NAT PROD, V78, P1526, DOI 10.1021/np500951s
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696
   Zhang L, 2012, PLANTA MED, V78, P890, DOI 10.1055/s-0031-1298481
NR 21
TC 7
Z9 7
U1 2
U2 23
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1478-6419
EI 1478-6427
J9 NAT PROD RES
JI Nat. Prod. Res.
PD SEP 16
PY 2020
VL 34
IS 18
BP 2616
EP 2620
DI 10.1080/14786419.2018.1544976
PG 5
WC Chemistry, Applied; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA NL1BI
UT WOS:000567158900010
PM 30587055
DA 2022-04-25
ER

PT J
AU Wu, D
   Zhou, WY
   Lin, XT
   Fang, L
   Xie, CM
AF Wu, Di
   Zhou, Wen-Yi
   Lin, Xiao-Tong
   Fang, Lei
   Xie, Chuan-Ming
TI Bufalin induces apoptosis via mitochondrial ROS-mediated caspase-3
   activation in HCT-116 and SW620 human colon cancer cells
SO DRUG AND CHEMICAL TOXICOLOGY
LA English
DT Article
DE Bufalin; apoptosis; ROS; colon cancer
ID DNA-DAMAGE; LEUKEMIA-CELLS; DEATH; AUTOPHAGY; CINOBUFAGIN; GENERATION;
   INHIBITION
AB Objective: Bufalin has been reported to kill various types of cancer including human colorectal cancer. Our previous study demonstrated that bufalin induced cell death via autophagy in HT-29 and Caco-2 colon cancer cells, but the action of bufalin remains unclear. This study was conducted to investigate the role of bufalin in other colon cancer HCT-116 and SW620 cells as well as its potential mechanism. Methods: The effect of bufalin in HCT-116 and SW620 colon cancer cells was detected by assessing cell viability and cell death. Apoptotic cells were analyzed by Western blot and trypan blue dye exclusion assay. Mitochondrial ROS production was analyzed by flow cytometry after DCFDA and DHR-123 staining. The potential mechanism was investigated via pharmacological inhibitors. Results: Bufalin had high potency against HCT-116 and SW620 cells with IC50 values of 12.823 +/- 1.792 nM and 26.303 +/- 2.498 nM in HCT-116 and SW620 cells, respectively. Bufalin decreased cell viability, increased cell death as well as caspase-3 downstream target (cleaved PARP) accumulation, and these actions were significantly blocked by pan-caspase inhibitor zVAD-FMK. Mechanistically, ROS production, but neither the NAD(P)H oxidase, AMPK, ERK nor p38, is responsible for bufalin-induced apoptotic cell death. Moreover, bufalin-induced ROS generation is derived from mitochondria. Conclusion: Bufalin significantly induces apoptosis in HCT-116 and SW620 colon cancer cells via mitochondrial ROS-mediated caspase-3 activation. We believe that our novel findings will greatly alter our current understanding on the anti-cancer mechanism of bufalin in colon cancer cells and will pave the way for further exploiting the clinical application.
C1 [Wu, Di; Lin, Xiao-Tong; Fang, Lei; Xie, Chuan-Ming] Third Mil Med Univ, Inst Hepatobiliary Surg, Southwest Hosp, Army Med Univ, Chongqing, Peoples R China.
   [Zhou, Wen-Yi] Essence Secur Co Ltd, Chongqing, Peoples R China.
RP Xie, CM (corresponding author), Third Mil Med Univ, Inst Hepatobiliary Surg, Southwest Hosp, Army Med Univ, Chongqing, Peoples R China.
EM chuanming506@126.com
RI Xie, Chuan-Ming/AAT-9557-2021
OI Xie, Chuan-Ming/0000-0003-4362-6612
FU Southwest Hospital, Third Military Medical University (Army Medical
   University) [SWH2016JCYB-19]
FX This work was supported by the Direct Grant from Southwest Hospital,
   Third Military Medical University (Army Medical University)
   (SWH2016JCYB-19).
CR Bazhin AV, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4197815
   Chang YW, 2014, TUMOR BIOL, V35, P1075, DOI 10.1007/s13277-013-1143-y
   Degli Esposti M, 1998, FEBS LETT, V430, P338, DOI 10.1016/S0014-5793(98)00688-7
   Dikalov SI, 2014, ANTIOXID REDOX SIGN, V20, P372, DOI 10.1089/ars.2012.4886
   Farah MA, 2016, COLLOID SURFACE B, V141, P158, DOI 10.1016/j.colsurfb.2016.01.027
   Hu T, 2016, WORLD J GASTROENTERO, V22, P6876, DOI 10.3748/wjg.v22.i30.6876
   Jiang YT, 2010, CYTOTECHNOLOGY, V62, P573, DOI 10.1007/s10616-010-9310-0
   Kang XH, 2017, CELL PHYSIOL BIOCHEM, V41, P2067, DOI 10.1159/000475438
   Liu F, 2016, ONCOTARGET, V7, P8896, DOI 10.18632/oncotarget.6840
   Liu X, 2016, J ETHNOPHARMACOL, V193, P538, DOI 10.1016/j.jep.2016.09.047
   Pelicano H, 2003, J BIOL CHEM, V278, P37832, DOI 10.1074/jbc.M301546200
   Qi J, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/312684
   Qiu DZ, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-185
   SCHERZSHOUVAL R, 2007, PROCEEDINGS OF THE N, V107, P18511, DOI DOI 10.1073/PNAS.1006124107
   Sheng X, 2016, INT J ONCOL, V49, P1513, DOI 10.3892/ijo.2016.3667
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Sivaprasad U, 2008, J CELL MOL MED, V12, P1265, DOI 10.1111/j.1582-4934.2008.00282.x
   Tian X, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/546210
   Wang J, 2015, GASTROENT RES PRACT, V2015, DOI 10.1155/2015/457193
   WATABE M, 1957, CANCER RES, V57, P3097
   Wu SH, 2014, AM J CHINESE MED, V42, P729, DOI 10.1142/S0192415X14500475
   Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016
   Yan SC, 2014, ANTI-CANCER DRUG, V25, P683, DOI 10.1097/CAD.0000000000000095
   Yeh JY, 2003, PROSTATE, V54, P112, DOI 10.1002/pros.10172
   Yu CH, 2008, CANCER SCI, V99, P2467, DOI 10.1111/j.1349-7006.2008.00966.x
   ZHAI X, 1934, PAN, V34, P678
   Zhang X, 2017, BIOMED PHARMACOTHER, V94, P627, DOI 10.1016/j.biopha.2017.07.136
   Zhu ZT, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-228
   Zhu ZT, 2012, ACTA HAEMATOL-BASEL, V128, P144, DOI 10.1159/000339424
NR 29
TC 11
Z9 11
U1 2
U2 40
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0148-0545
EI 1525-6014
J9 DRUG CHEM TOXICOL
JI Drug Chem. Toxicol.
PD JUL 4
PY 2019
VL 42
IS 4
BP 444
EP 450
DI 10.1080/01480545.2018.1512611
PG 7
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy; Toxicology
GA HW7FB
UT WOS:000466854400013
PM 30777466
DA 2022-04-25
ER

PT J
AU Lei, C
   Zhao, B
   Liu, L
   Zeng, XY
   Yu, Z
   Wang, XY
AF Lei, Cheng
   Zhao, Bing
   Liu, Lin
   Zeng, Xiangyue
   Yu, Zhen
   Wang, Xiyan
TI Expression and clinical significance of p62 protein in colon cancer
SO MEDICINE
LA English
DT Article
DE colon cancer; immunohistochemistry; indicators; p62 protein
ID AUTOPHAGY; ACTIVATION; PHYSIOLOGY; PREDICTOR; CARCINOMA
AB p62 is a multifunctional protein involved in multiple cellular processes including proliferation, drug sensitivity and autophagy-associated cancer cell growth. However, the role of p62 in colon cancer remains controversial. Here we investigated the expression of p62 protein in colon cancer and its clinical significance. Patients with colon adenocarcinoma who underwent resection at the Third Affiliated Teaching Hospital of Xinjiang Medical University (Affiliated Cancer Hospital) were retrospectively analyzed. The expression of p62 protein in tumor tissues and adjacent normal tissues was detected by immunohistochemistry and western-blotting. Real-time quantitative polymerase chain reaction was used to detect the expression level of p62 messenger ribonucleic acid in specimens. Progression-free survival (PFS) and overall survival (OS) were assessed using Kaplan-Meier method and the log-rank test. A total of 85 colon cancer patients were enrolled, including 55 (64.71%) patients with high p62 expression, and 30 (35.29%) patients with low p62 expression. The transcription and expression level of p62 in colon cancer tissues were higher than those in adjacent normal tissues (P < .01). High expression of p62 was an independent risk factor for the poor prognosis (PFS and OS) of colon cancer. p62 may be a potential indicator of determining the progression and prognosis evaluation of colon cancer.
C1 [Lei, Cheng; Liu, Lin; Zeng, Xiangyue; Yu, Zhen] Xinjiang Med Univ, Dept Gastrointestinal Surg, Affiliated Teaching Hosp 3, Affiliated Canc Hosp, Xinjiang, Peoples R China.
   [Zhao, Bing] Xinjiang Med Univ, Dept Day Oncol Unit, Affiliated Teaching Hosp 3, Affiliated Canc Hosp, Xinjiang, Peoples R China.
   [Wang, Xiyan] Xinjiang Med Univ, Affiliated Teaching Hosp 3, Affiliated Canc Hosp, Urumqi 830011, Xinjiang, Peoples R China.
RP Wang, XY (corresponding author), Xinjiang Med Univ, Affiliated Teaching Hosp 3, Affiliated Canc Hosp, Urumqi 830011, Xinjiang, Peoples R China.
EM wangxiyan2415@163.com
FU Natural Science Foundation of Xinjiang Uygur Autonomous Region
   [2017D01C412]
FX The study was supported by the Natural Science Foundation of Xinjiang
   Uygur Autonomous Region (No. 2017D01C412).
CR Amin MB., 2017, AJCC CANC STAGING MA, V8th ed.
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Burdelski C, 2015, CLIN CANCER RES, V21, P3471, DOI 10.1158/1078-0432.CCR-14-0620
   Charafe-Jaufrret E, 2004, J PATHOL, V202, P265, DOI 10.1002/path.1515
   Chen HY, 2011, CANCER PREV RES, V4, P973, DOI 10.1158/1940-6207.CAPR-10-0387
   De Rosa M, 2015, ONCOL REP, V34, P1087, DOI 10.3892/or.2015.4108
   Eadens MJ, 2011, CURR ONCOL REP, V13, P168, DOI 10.1007/s11912-011-0157-0
   Iwadate R, 2015, AM J PATHOL, V185, P2523, DOI 10.1016/j.ajpath.2015.05.008
   Jin ZY, 2009, CELL, V137, P721, DOI 10.1016/j.cell.2009.03.015
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Komatsu M, 2012, PHARMACOL RES, V66, P457, DOI 10.1016/j.phrs.2012.07.004
   Komatsu M, 2011, AUTOPHAGY, V7, P1088, DOI 10.4161/auto.7.9.16474
   Kongara S, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00171
   Lau A, 2010, MOL CELL BIOL, V30, P3275, DOI 10.1128/MCB.00248-10
   Li SY, 2018, ONCOL LETT, V15, P9572, DOI 10.3892/ol.2018.8482
   Liu JL, 2014, BRIT J CANCER, V111, P944, DOI 10.1038/bjc.2014.355
   Liu WJ, 2016, CELL MOL BIOL LETT, V21, DOI 10.1186/s11658-016-0031-z
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu ML, 2001, AM J PATHOL, V159, P945, DOI 10.1016/S0002-9440(10)61770-1
   Marinkovic M, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8023821
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Mizuno Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18323-9
   Nakayama S, 2017, CANCER MED-US, V6, P1264, DOI 10.1002/cam4.1093
   Niklaus M, 2017, ONCOTARGET, V8, P54604, DOI 10.18632/oncotarget.17554
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Pugsley HR, 2017, JOVE-J VIS EXP, DOI 10.3791/55637
   Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576
   SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Thompson HGR, 2003, ONCOGENE, V22, P2322, DOI 10.1038/sj.onc.1206325
   Wu YH, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0031-8
   Xiang X, 2017, CANCER MED-US, V6, P2357, DOI 10.1002/cam4.1176
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
NR 33
TC 9
Z9 9
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JAN
PY 2020
VL 99
IS 3
AR e18791
DI 10.1097/MD.0000000000018791
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA LB9LQ
UT WOS:000524950700048
PM 32011477
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Lim, MJ
   Ahn, JY
   Han, Y
   Yu, CH
   Kim, MH
   Lee, SLO
   Lim, DS
   Song, JY
AF Lim, Min-Jin
   Ahn, Ji-Yeon
   Han, Youngsoo
   Yu, Chi-ho
   Kim, Mi-Hyoung
   Lee, Sae-lo-oom
   Lim, Dae-Seog
   Song, Jie-Young
TI Acriflavine enhances radiosensitivity of colon cancer cells through
   endoplasmic reticulum stress-mediated apoptosis
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE Acriflavine; Radiosensitivity; p53; ER stress
ID RADIATION-INDUCED AUTOPHAGY; NEGATIVE PROGNOSTIC-FACTOR;
   COLORECTAL-CANCER; CARCINOMA-CELLS; DEATH DECISIONS; LOW BAX; P53;
   PROTEIN; ACTIVATION; GROWTH
AB Radiotherapy (RT) is one of the most effective tools in the clinical treatment of cancer. Because the tumor suppressor p53 plays a central role in radiation-mediated responses, including cell cycle-arrest and apoptosis, a number of studies have suggested that p53 could be a useful therapeutic target of anti-cancer agents. Accordingly, we sought to discover a new agent capable of increasing p53 activity. HCT116 colon cancer cells, containing wild-type p53, were stably transfected with a p53 responsive-luciferase (p53-Luc) reporter gene. A cell-based high-throughput screen of 7920 synthetic small molecules was performed in duplicate. Of the screened compounds, acriflavine (ACF) significantly increased p53-Luc activity in a concentration-dependent manner without causing toxicity. Pretreatment with ACF enhanced the induction of p53 protein expression and phosphorylation on serine 15 by gamma-irradiation. Clonogenic assays showed that ACF pretreatment also potentiated radiation-induced cell death. The combination of irradiation and ACF treatment induced mitochondrial release of cytochrome c and significant activation of caspase-3 with PARP cleavage in colon cancer cells, demonstrating typical apoptotic cell death. Combined treatment with ACF and radiation increased the expression of Bax and Bad, while decreasing expression of Bcl-2. In addition, the ACF/radiation treatment combination induced endoplasmic reticulum (ER) stress responses mediated by IRE1 alpha (inositol-requiring transmembrane kinase and endonuclease 1 alpha), eIF-2 alpha (eukaryotic initiation factor 2 alpha), caspase-2/12, and CHOP (C/EBP homologous protein). The knockdown of IRE1 alpha by siRNA inhibited the apoptotic cell death induced by ACF/radiation treatment. In vivo studies showed that combined treatment with ACF and radiation significantly inhibited the growth of tumors in colorectal cancer xenografted mice. These results indicate that ACF acts through p53-dependent mitochondrial pathways and ER stress signals, and could be a promising radiosensitizer. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Lim, Min-Jin; Ahn, Ji-Yeon; Yu, Chi-ho; Kim, Mi-Hyoung; Lee, Sae-lo-oom; Song, Jie-Young] Korea Inst Radiol & Med Sci, Dept Radiat Canc Sci, Seoul 139706, South Korea.
   [Han, Youngsoo] Sookmyung Womens Univ, Coll Sci, Div Biol Sci, Seoul 140742, South Korea.
   [Lim, Dae-Seog] CHA Univ, Dept Appl Biosci, Songnam 463836, Gyeonggi Do, South Korea.
RP Song, JY (corresponding author), Korea Inst Radiol & Med Sci, Dept Radiat Canc Sci, 215-4 Gongneung Dong, Seoul 139706, South Korea.
EM dslim@cha.ac.kr; immu@kirams.re.kr
RI Song, Jie-Young/AAG-6684-2019; Song, Jie-Young/AAH-1254-2019
OI Song, Jie-Young/0000-0002-5769-3886; Song, Jie-Young/0000-0003-2434-7511
FU Nuclear Research & Development Program of the Korea Science and
   Engineering Foundation (KOSEF)Korea Science and Engineering Foundation;
   Korean Government (MEST)Ministry of Education, Science and Technology,
   Republic of KoreaKorean Government
FX This work was supported by a grant from the Nuclear Research &
   Development Program of the Korea Science and Engineering Foundation
   (KOSEF), funded by the Korean Government (MEST).
CR Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0
   Adamsen BL, 2009, RADIAT RES, V171, P562, DOI 10.1667/RR1524.1
   Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305
   Bernales S, 2006, PLOS BIOL, V4, P2311, DOI 10.1371/journal.pbio.0040423
   Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063
   Brady CA, 2010, J CELL SCI, V123, P2527, DOI 10.1242/jcs.064501
   Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863
   Ding WX, 2007, J BIOL CHEM, V282, P4702, DOI 10.1074/jbc.M609267200
   El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097
   Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677
   Gajkowska B, 2004, J MOL HISTOL, V35, P11
   GOLDIE H, 1959, J NATL CANCER I, V23, P841
   Hassan S, 2011, CANCER SCI, V102, P2206, DOI 10.1111/j.1349-7006.2011.02097.x
   Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015
   Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211
   Lee K, 2009, P NATL ACAD SCI USA, V106, P17910, DOI 10.1073/pnas.0909353106
   Luciani MG, 2007, CARCINOGENESIS, V28, P2207, DOI 10.1093/carcin/bgm101
   Moretti L, 2007, AUTOPHAGY, V3, P142, DOI 10.4161/auto.3607
   Nicholson DW, 2003, SCIENCE, V299, P214, DOI 10.1126/science.1081274
   Obeng EA, 2005, J BIOL CHEM, V280, P29578, DOI 10.1074/jbc.M502685200
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373
   Park MT, 2005, BLOOD, V105, P1724, DOI 10.1182/blood-2004-07-2938
   Rieber M, 2008, CANCER BIOL THER, V7, P1561, DOI 10.4161/cbt.7.10.6540
   Satoh T, 2002, ONCOGENE, V21, P2171, DOI 10.1038/sj.onc.1205279
   Schelwies K, 2002, INT J CANCER, V99, P589, DOI 10.1002/ijc.10380
   Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056
   Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208
   Sturm I, 1999, J CLIN ONCOL, V17, P1364, DOI 10.1200/JCO.1999.17.5.1364
   Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349
   Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779
   Tsuboi Y, 2009, J NEUROSURG, V110, P594, DOI 10.3171/2008.8.JNS17648
   Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656
   Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675
   Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9
   Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5
   Wainwright M, 2001, J ANTIMICROB CHEMOTH, V47, P1, DOI 10.1093/jac/47.1.1
   Wilson GD, 2004, CANCER METAST REV, V23, P209, DOI 10.1023/B:CANC.0000031762.91306.b4
   Yamaguchi H, 2004, J BIOL CHEM, V279, P45495, DOI 10.1074/jbc.M406933200
   Zois CE, 2009, AUTOPHAGY, V5, P442, DOI 10.4161/auto.5.4.7667
NR 40
TC 23
Z9 25
U1 0
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357-2725
EI 1878-5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD AUG
PY 2012
VL 44
IS 8
BP 1214
EP 1222
DI 10.1016/j.biocel.2012.04.022
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 974QE
UT WOS:000306450600002
PM 22564437
DA 2022-04-25
ER

PT J
AU Qi, WC
   Zhou, XT
   Wang, JQ
   Zhang, K
   Zhou, YJ
   Chen, SP
   Nie, SP
   Xie, MY
AF Qi, Wucheng
   Zhou, Xingtao
   Wang, Junqiao
   Zhang, Ke
   Zhou, Yujia
   Chen, Shuping
   Nie, Shaoping
   Xie, Mingyong
TI Cordyceps sinensis polysaccharide inhibits colon cancer cells growth by
   inducing apoptosis and autophagy flux blockage via mTOR signaling
SO CARBOHYDRATE POLYMERS
LA English
DT Article
DE Cordyceps sinensis polysaccharide; Autophagy; Apoptosis; Colon cancer
   cell; mTOR signaling
ID PROTEIN; MODULATION; DEATH
AB Cordyceps sinensis is thought to have anti-cancer effects, but its mechanisms remain elusive. In this study, we aimed to investigate the anti-cancer effect of Cordyceps sinensis polysaccharide (CSP) on human colon cancer cell line (HCT116) and its mechanism. Results indicated that CSP significantly inhibited the proliferation of HCT116 cells, increased autophagy and apoptosis, while blocked autophagy flux and lysosome formation. Further experiments showed that CSP decreased the expression of PI3K and phosphorylation level of AKT and mTOR, increased the expression of AMPKa and phosphorylation level of ULK1. In addition, repression of CSP-induced autophagy by bafilomycin (autophagy inhibitor) enhanced apoptosis and cell death of HCT116 cells. Hence, our findings suggested that CSP inhibited the proliferation of HCT116 cells by inducing apoptosis and autophagy flux blockage, which might be achieved through PI3K-AKT-mTOR and AMPK-mTOR-ULK1 signaling. CSP may be a potential therapeutic agent for colon cancer.
C1 [Qi, Wucheng; Zhou, Xingtao; Wang, Junqiao; Zhang, Ke; Zhou, Yujia; Chen, Shuping; Nie, Shaoping; Xie, Mingyong] Nanchang Univ, State Key Lab Food Sci & Technol, China Canada Joint Lab Food Sci & Technol Nanchan, 235 Nanjing East Rd, Nanchang 330047, Jiangxi, Peoples R China.
   [Xie, Mingyong] Jiangxi Normal Univ, Natl R&D Ctr Freshwater Fish Proc, Nanchang 330022, Jiangxi, Peoples R China.
RP Zhou, XT; Xie, MY (corresponding author), Nanchang Univ, State Key Lab Food Sci & Technol, China Canada Joint Lab Food Sci & Technol Nanchan, 235 Nanjing East Rd, Nanchang 330047, Jiangxi, Peoples R China.
EM 13576019586@163.com; myxie@ncu.edu.cn
RI 周, 兴涛/F-2927-2019
OI 周, 兴涛/0000-0002-1902-9677; Nie, Shao-Ping/0000-0002-2412-4679
FU National Key Research and Development Program of China [2017YFC1600405,
   2017YFD0400705-2]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China (NSFC) [31571826]; Jiangxi
   Provincial Major Program of Research and Development Foundation
   [20165ABC28004]
FX The financial support from the National Key Research and Development
   Program of China (2017YFC1600405); The National Natural Science
   Foundation of China (31571826); The National Key Research and
   Development Program of China (2017YFD0400705-2); Jiangxi Provincial
   Major Program of Research and Development Foundation (Agriculture field)
   (20165ABC28004) are gratefully acknowledged. ptfLC3 was a gift from
   Tamotsu Yoshimori (Addgene plasmid #21074).
CR Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Baxt LA, 2015, GASTROENTEROLOGY, V149, P553, DOI 10.1053/j.gastro.2015.06.046
   Chen JP, 2006, LIFE SCI, V78, P2742, DOI 10.1016/j.lfs.2005.10.047
   Cosin-Roger J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00213-3
   DUBOIS M, 1951, NATURE, V168, P167, DOI 10.1038/168167a0
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Ferreira SS, 2015, CARBOHYD POLYM, V132, P378, DOI 10.1016/j.carbpol.2015.05.079
   Fuchs Y, 2015, NAT REV MOL CELL BIO, V16, P329, DOI 10.1038/nrm3999
   Ha J, 2015, MOL ASPECTS MED, V46, P46, DOI 10.1016/j.mam.2015.08.002
   He ZJ, 2017, FOOD CHEM TOXICOL, V101, P55, DOI 10.1016/j.fct.2017.01.002
   Heras-Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019
   Hidvegi T, 2010, SCIENCE, V329, P229, DOI 10.1126/science.1190354
   Hyun JH, 2009, BIOL PHARM BULL, V32, P1760, DOI 10.1248/bpb.32.1760
   Ji NF, 2011, INTEGR CANCER THER, V10, P359, DOI 10.1177/1534735410392573
   Ji XL, 2018, INT J BIOL MACROMOL, V114, P1127, DOI 10.1016/j.ijbiomac.2018.03.186
   Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Li WY, 2018, J FUNCT FOODS, V45, P75, DOI 10.1016/j.jff.2018.03.024
   Liang J, 2019, PHARMACOL RES, V148, DOI 10.1016/j.phrs.2019.104417
   Liang ZGN, 2014, INT J MOL SCI, V15, P9103, DOI 10.3390/ijms15059103
   Liu YQ, 2016, CARBOHYD POLYM, V151, P474, DOI 10.1016/j.carbpol.2016.05.103
   Luo T., 2017, SCI REPORTS, V7, P1
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Meng Y, 2018, CARBOHYD POLYM, V183, P207, DOI 10.1016/j.carbpol.2017.12.017
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   Netea-Maier RT, 2016, AUTOPHAGY, V12, P245, DOI 10.1080/15548627.2015.1071759
   Pandeirada CO, 2019, CARBOHYD POLYM, V222, DOI 10.1016/j.carbpol.2019.06.001
   Papp D, 2016, AUTOPHAGY, V12, P273, DOI 10.1080/15548627.2015.1082023
   Porter NT, 2017, ANNU REV MICROBIOL, V71, P349, DOI 10.1146/annurev-micro-102215-095316
   Pott J, 2018, CELL HOST MICROBE, V23, P191, DOI 10.1016/j.chom.2017.12.017
   Saffi GT, 2019, TRENDS CELL BIOL, V29, P635, DOI 10.1016/j.tcb.2019.05.003
   Savini M, 2019, TRENDS CELL BIOL, V29, P876, DOI 10.1016/j.tcb.2019.08.008
   SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6
   Song D, 2013, EUR J NUTR, V52, P687, DOI 10.1007/s00394-012-0373-x
   Sun PD, 2017, CARBOHYD POLYM, V167, P90, DOI 10.1016/j.carbpol.2017.03.022
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Wang JQ, 2017, FOOD SCI BIOTECHNOL, V26, P55, DOI 10.1007/s10068-017-0008-3
   Wu YL, 2006, PHYTOTHER RES, V20, P646, DOI 10.1002/ptr.1921
   Yang ZY, 2013, CARBOHYD POLYM, V95, P615, DOI 10.1016/j.carbpol.2013.03.024
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Zhou XT, 2018, J AGR FOOD CHEM, V66, P9719, DOI 10.1021/acs.jafc.8b03340
NR 43
TC 22
Z9 25
U1 17
U2 72
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0144-8617
EI 1879-1344
J9 CARBOHYD POLYM
JI Carbohydr. Polym.
PD JUN 1
PY 2020
VL 237
AR 116113
DI 10.1016/j.carbpol.2020.116113
PG 11
WC Chemistry, Applied; Chemistry, Organic; Polymer Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Polymer Science
GA KY2FV
UT WOS:000522387000013
PM 32241434
DA 2022-04-25
ER

PT J
AU Coker-Gurkan, A
   Arisan, ED
   Obakan, P
   Palavan-Unsal, N
AF Coker-Gurkan, Ajda
   Arisan, Elif Damla
   Obakan, Pinar
   Palavan-Unsal, Narcin
TI Lack of functional p53 renders DENSpm-induced autophagy and apoptosis in
   time dependent manner in colon cancer cells
SO AMINO ACIDS
LA English
DT Article
DE Colon cancer; Apoptosis; Autophagy; Polyamine analogues; DENSpm; p53
ID HUMAN-MELANOMA CELLS; POLYAMINE ANALOG N-1,N-11-DIETHYLNORSPERMINE;
   SPERMIDINE/SPERMINE N-1-ACETYLTRANSFERASE; INHIBITION; INDUCTION; DEATH;
   CATABOLISM; MODULATORS; MECHANISM; CARCINOMA
AB Polyamines (PAs), such as putrescine, spermidine and spermine, are alkyl-amines that are essential for cell growth, proliferation, differentiation and cancer progression in eukaryotic cells. A designed PA analogue; DENSpm, induces cell cycle arrest, inhibits proliferation and induces apoptosis in melanoma, breast, prostate, lung and colon cancer cells. Although the mechanism by which DENSpm induces apoptosis has been examined, the effect of DENSpm on autophagy has not been investigated yet. Therefore, in this study, our objective was to determine the role of p53 in the DENSpm-induced autophagy/apoptotic regulation in a time-dependent manner in colon cancer cells. Exposure of HCT 116 colon cancer cells to DENSpm decreased cell viability in a dose- and time-dependent manner. However, the p53 mutant, SW480, and deficient HCT 116 p53(-/-) cells were more resistant to DENSpm treatment compared to HCT 116 p53(+/+) cells. The resistant profile caused by p53 defect also caused a cell type-specific response to PA pool depletion and SSAT overexpression. In addition to PA depletion, DENSpm induced apoptosis by activating the mitochondria-mediated pathway in a caspase-dependent manner regardless of p53 expression in colon cancer cells. Concomitantly, we determined that DENSpm also affected autophagy in HCT 116 p53(+/+), SW480 and HCT 116 p53(-/-) colon cancer cells for different periods of exposure to DENSpm. Therefore, this study revealed that effect of DENSpm on cell death differs due to p53 protein expression profile. In addition, DENSpm-induced autophagy may be critical in drug resistance in colon cancer cells.
C1 [Coker-Gurkan, Ajda; Arisan, Elif Damla; Obakan, Pinar; Palavan-Unsal, Narcin] Istanbul Kultur Univ, Sci & Literature Fac, Mol Biol & Genet Dept, TR-34156 Istanbul, Turkey.
RP Coker-Gurkan, A (corresponding author), Istanbul Kultur Univ, Sci & Literature Fac, Mol Biol & Genet Dept, Atakoy Campus, TR-34156 Istanbul, Turkey.
EM a.coker@iku.edu.tr
RI OBAKAN, PINAR/D-2836-2015; Arisan, Elif Damla/W-8682-2019
OI Arisan, Elif Damla/0000-0002-4844-6381; Unsal Palavan,
   Narcin/0000-0002-2945-540X; Gurkan, Ajda/0000-0003-1475-2417
FU TUBITAKTurkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)
   [TBAG-212T227]; Istanbul Kultur University Scientific Projects Support
   CenterIstanbul Kultur University
FX This work was supported by the grant from TUBITAK (TBAG-212T227) and
   funded in part by Istanbul Kultur University Scientific Projects Support
   Center.
CR Allen WL, 2007, MOL CANCER THER, V6, P128, DOI 10.1158/1535-7163.MCT-06-0303
   CHANG BK, 1993, J UROLOGY, V150, P1293, DOI 10.1016/S0022-5347(17)35763-4
   Chen Y, 2003, ONCOGENE, V22, P4964, DOI 10.1038/sj.onc.1206725
   Chen Y, 2001, CANCER RES, V61, P6437
   Choi WY, 2005, J BIOL CHEM, V280, P3295, DOI 10.1074/jbc.M409930200
   COHEN SS, 1978, NATURE, V274, P209, DOI 10.1038/274209a0
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557
   Hahm HA, 2002, CLIN CANCER RES, V8, P684
   Hector S, 2004, MOL CANCER THER, V3, P813
   Hegardt C, 2002, EUR J BIOCHEM, V269, P1033, DOI 10.1046/j.0014-2956.2001.02744.x
   Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601
   Kim E, 2009, BIOCHEM PHARMACOL, V77, P11, DOI 10.1016/j.bcp.2008.08.030
   Kramer DL, 1999, CANCER RES, V59, P1278
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   McCloskey DE, 1996, CLIN CANCER RES, V2, P441
   McCloskey DE, 2000, J BIOL CHEM, V275, P28708, DOI 10.1074/jbc.M004120200
   Mizushima N, 2009, CURR TOP MICROBIOL, V335, P71, DOI 10.1007/978-3-642-00302-8_3
   Morselli E, 2008, CELL CYCLE, V7, P3056, DOI 10.4161/cc.7.19.6751
   Morselli E, 2008, CELL RES, V18, P708, DOI 10.1038/cr.2008.77
   Oredsson SM, 2007, BIOCHEM SOC T, V35, P405, DOI 10.1042/BST0350405
   Pattingre S, 2006, CANCER RES, V66, P2885, DOI 10.1158/0008-5472.CAN-05-4412
   PEGG AE, 1988, CANCER RES, V48, P759
   PORTER CW, 1991, CANCER RES, V51, P3715
   SAAB NH, 1993, J MED CHEM, V36, P2998, DOI 10.1021/jm00072a020
   Schipper RG, 2000, PROSTATE, V44, P313, DOI 10.1002/1097-0045(20000901)44:4<313::AID-PROS8>3.0.CO;2-D
   Wolff JC, 2003, CLIN CANCER RES, V9, P5922
   Xu Y, 2012, CANCER LETT, V314, P232, DOI 10.1016/j.canlet.2011.09.034
   Yang ZF, 2009, CURR TOP MICROBIOL, V335, P1, DOI 10.1007/978-3-642-00302-8_1
   Zagaja GP, 1998, CANCER CHEMOTH PHARM, V41, P505, DOI 10.1007/s002800050774
NR 30
TC 6
Z9 7
U1 0
U2 14
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0939-4451
EI 1438-2199
J9 AMINO ACIDS
JI Amino Acids
PD JAN
PY 2015
VL 47
IS 1
BP 87
EP 100
DI 10.1007/s00726-014-1851-7
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AX9UX
UT WOS:000347248500008
PM 25311224
DA 2022-04-25
ER

PT J
AU Zhang, Z
AF Zhang, Zhuo
TI Trefoil factor 3 knock-down prevents autophagy-related gene 12 elevation
   in colon adenocarcinoma
SO JOURNAL OF HISTOTECHNOLOGY
LA English
DT Article
DE TFF3; ATG12; colon adenocarcinoma; autophagy; immunohistochemistry;
   Western blot; siRNA
ID EXPRESSION; PROTEIN; SURVIVAL; YEAST
AB Colon cancer, which is considered a common gastrointestinal cancer, has been the third leading cause of cancer mortality in the United States. Colon cancer has various histological sub-types and 90% of them are adenocarcinoma. In recent years, autophagy, the process by which cells are self-cannibalized, has been implicated in pathophysiology of various diseases including colon adenocarcinoma and thus, has become a strong research focus. This has also been true for trefoil factor 3 (TFF3). TFF3 is a small secreted peptide that is present in almost all mucin-secreting tissues, it is most abundant in goblet cells of the gastrointestinal tract and expressed at high protein levels in colon cancer. The present study analyzed the expression of TFF3 and autophagy-related gene ATG12 in cancerous and normal tissue samples collected from patients with colon adenocarcinoma. The expression of both proteins was shown to be increased in cancerous as compared to adjacent non-cancerous tissues. Furthermore, these proteins were shown to be positively correlated using the Pearson's Correlation test in cancerous tissues. Finally, TFF3 was shown to regulate ATG12 in human colon adenocarcinoma cells in vitro. Thus, the data presented here suggest that both TFF3 and ATG12 may be promising potential therapeutic targets to develop novel treatment strategies for patients with colon adenocarcinoma.
C1 [Zhang, Zhuo] China Med Univ, Coll Basic Med Sci, Dept Cell Biol, Taichung, Taiwan.
RP Zhang, Z (corresponding author), China Med Univ, Coll Basic Med Sci, Dept Cell Biol, Taichung, Taiwan.
EM 549652114@qq.com
FU Key discipline of China Medical University [3110116002]
FX This work was supported by the promotion project funds from Key
   discipline of China Medical University (Project Number: 3110116002).
CR Ahmed ARH, 2012, AM J PATHOL, V180, P904, DOI 10.1016/j.ajpath.2011.11.022
   Aiping D, 2013, PLOS ONE, V8
   BABA M, 1994, J CELL BIOL, V124, P903, DOI 10.1083/jcb.124.6.903
   Cufi S, 2012, ONCOTARGET, V3, P1600
   Dong CY, 2016, ONCOTARGET, V7, P8850, DOI 10.18632/oncotarget.7091
   Gu JC, 2015, TUMOR BIOL, V36, P3001, DOI 10.1007/s13277-014-2933-6
   Kannan N, 2010, NEOPLASIA, V12, P1041, DOI 10.1593/neo.10916
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Maibritt N, 2017, INT J MOL SCI, V18, P1
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506
   Mizushima N, 1999, EMBO J, V18, P3888, DOI 10.1093/emboj/18.14.3888
   Morito K, 2015, INT J ONCOL, V46, P563, DOI 10.3892/ijo.2014.2755
   Pandey V, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0429-3
   Parlato M, 2014, INT J MOL SCI, V15, P9594, DOI 10.3390/ijms15069594
   Regalo G, 2005, CELL MOL LIFE SCI, V62, P2910, DOI 10.1007/s00018-005-5478-4
   Rosenfeldt MT, 2011, CARCINOGENESIS, V32, P955, DOI 10.1093/carcin/bgr031
   Rosenfeldt MT, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001306
   SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509
   Sophie P, 2003, J BIOL CHEM, V275, P39090
   Taheshige K, 1992, J CELL BIOL, V119, P301
   Tamura H, 2010, J HISTOCHEM CYTOCHEM, V58, P443, DOI 10.1369/jhc.2010.955690
   Vestergaard EM, 2010, INT J CANCER, V127, P1857, DOI 10.1002/ijc.25209
   Wilkinson S, 2010, CURR OPIN GENET DEV, V20, P57, DOI 10.1016/j.gde.2009.12.004
   William A, 1994, TRENDS CELL BIOL, V4, P139
   Xu M, 2017, NEOPLASMA, V64, P56, DOI 10.4149/neo_2017_107
   Zhou ST, 2012, CANCER LETT, V323, P115, DOI 10.1016/j.canlet.2012.02.017
NR 27
TC 0
Z9 0
U1 0
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0147-8885
EI 2046-0236
J9 J HISTOTECHNOL
JI J. Histotechnol.
PD OCT 2
PY 2019
VL 42
IS 4
SI SI
BP 169
EP 176
DI 10.1080/01478885.2019.1633088
EA AUG 2019
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA KB3WD
UT WOS:000479371800001
PM 31362594
DA 2022-04-25
ER

PT J
AU Zheng, A
   Li, H
   Wang, X
   Feng, ZH
   Xu, J
   Cao, K
   Zhou, B
   Wu, J
   Liu, JK
AF Zheng, Adi
   Li, Hao
   Wang, Xun
   Feng, Zhihui
   Xu, Jie
   Cao, Ke
   Zhou, Bo
   Wu, Jing
   Liu, Jiankang
TI Anticancer Effect of a Curcumin Derivative B63: ROS Production and
   Mitochondrial Dysfunction
SO CURRENT CANCER DRUG TARGETS
LA English
DT Article
DE Colon cancer cells; curcumin; curcumin derivative; ER stress;
   mitochondrial dysfunction; ROS
ID CANCER-CELLS; APOPTOSIS; BIM; INHIBITION; ACTIVATION; AUTOPHAGY;
   ANALOGS; DEATH; PUMA
AB Curcumin, a polyphenol isolated from the plant Curcuma longa, displays chemotherapeutic and chemo-preventive effects in diverse cancers, including colorectal cancer. A mono-carbonyl analogue B63 was synthesized through several chemical modifications of the basic structure of curcumin to increase its biological activity and bioavailability. In vitro assays showed potent anti-proliferative effects of B63 on colon cancer cells (about 2 fold more effective than curcumin based on IC50). B63 treatment also induced significant necrosis, apoptosis, and S phase cell cycle arrest in SW620 colon cancer cells. The pro-apoptotic proteins Bad and Bim were up-regulated, and cytochrome c release from the mitochondria into the cytosol was enhanced, resulting in pro-caspase-3 and PARP-1 cleavage. Furthermore, the anticancer activity of B63 was dependent on intracellular ROS from damaged mitochondrial function and induced endoplasmic reticulum (ER) stress. In vivo, 50 mg/kg of B63 inhibit tumor growth similarly to 100 mg/kg curcumin in a mouse xenograft model using SW620 cells. These results suggest that the curcumin derivative B63 has a greater anticancer capacity than the parent curcumin in colon cancer cells and that the necrotic and apoptotic effects of B63 are mediated by ROS resulting from ER stress and mitochondrial dysfunction.
C1 [Zheng, Adi; Li, Hao; Wang, Xun; Feng, Zhihui; Xu, Jie; Cao, Ke; Wu, Jing; Liu, Jiankang] Xi An Jiao Tong Univ, Sch Life Sci & Technol, Key Lab Biomed Informat Engn, Ctr Mitochondrial Biol & Med,Minist Educ, Xian 710049, Peoples R China.
   [Zheng, Adi; Li, Hao; Wang, Xun; Feng, Zhihui; Xu, Jie; Cao, Ke; Wu, Jing; Liu, Jiankang] Xi An Jiao Tong Univ, Frontier Inst Life Sci, FIST, Xian 710049, Peoples R China.
   [Zhou, Bo] Lanzhou Univ, State Key Lab Appl Organ Chem, Lanzhou 730000, Gansu, Peoples R China.
RP Wu, J (corresponding author), Xi An Jiao Tong Univ, Sch Life Sci & Technol, Inst Mitochondrial Biol & Med, Xian 710049, Peoples R China.
EM Jing_wu@mail.xjtu.edu.cn; j.liu@mail.xjtu.edu.cn
RI Li, Hao/K-7001-2017; Liu, Jiankang/A-1610-2011; Feng, Zhihui/E-7408-2011
OI Li, Hao/0000-0001-5677-3377; Feng, Zhihui/0000-0002-2448-6565; Wang,
   Xun/0000-0001-5172-0305
FU National Natural Science Foundation of China, Key ProgramNational
   Natural Science Foundation of China (NSFC) [30930105]; National 12-5
   Support Plan Project of the Ministry of Science and Technology of China
   [2012BAH30F03]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China (NSFC) [31070740, 21172101]; Xi'an
   Jiaotong UniversityXi'an Jiaotong University
FX The authors thank Prof. JianJian Li at University of California at Davis
   for his critical reading and ideas to this work. This study was
   partially supported by the National Natural Science Foundation of China,
   Key Program 30930105, National 12-5 Support Plan Project of the Ministry
   of Science and Technology of China (2012BAH30F03), the National Natural
   Science Foundation of China (No. 31070740 and No. 21172101), and the 985
   and 211 Projects of Xi'an Jiaotong University.
CR Adams BK, 2004, BIOORGAN MED CHEM, V12, P3871, DOI 10.1016/j.bmc.2004.05.006
   Anand P, 2008, CANCER LETT, V267, P133, DOI 10.1016/j.canlet.2008.03.025
   Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r
   Bao B, 2012, CANCER RES, V72, P335, DOI 10.1158/0008-5472.CAN-11-2182
   Bill MA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-165
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96
   Galluzzi L, 2009, J MOL CELL BIOL, V1, P8, DOI 10.1093/jmcb/mjp007
   Gupta SC, 2011, NAT PROD REP, V28, P1937, DOI 10.1039/c1np00051a
   Hussain AR, 2006, APOPTOSIS, V11, P245, DOI 10.1007/s10495-006-3392-3
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Johnson JJ, 2007, CANCER LETT, V255, P170, DOI 10.1016/j.canlet.2007.03.005
   Karunagaran D, 2005, CURR CANCER DRUG TAR, V5, P117, DOI 10.2174/1568009053202081
   Kim H, 2009, MOL CELL, V36, P487, DOI 10.1016/j.molcel.2009.09.030
   Kim JY, 2011, APOPTOSIS, V16, P347, DOI 10.1007/s10495-010-0567-8
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   Kudo C, 2011, ANTICANCER RES, V31, P3719
   Luo C., 2013, APOPTOSIS, P1
   Luo C, 2013, CURR CANCER DRUG TAR, V13, P625, DOI 10.2174/15680096113139990035
   McCall K, 2010, CURR OPIN CELL BIOL, V22, P882, DOI 10.1016/j.ceb.2010.09.002
   Morishima N, 2004, J BIOL CHEM, V279, P50375, DOI 10.1074/jbc.M408493200
   Nishikawa K, 2003, CANCER LETT, V201, P51, DOI 10.1016/S0304-3835(03)00462-2
   Orlando RA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031869
   Ravindran J, 2009, AAPS J, V11, P495, DOI 10.1208/s12248-009-9128-x
   Singh S, 2007, CELL, V130, P765, DOI 10.1016/j.cell.2007.08.024
   Sinicrope FA, 2008, CLIN CANCER RES, V14, P5810, DOI 10.1158/1078-0432.CCR-07-5202
   Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005
   Thayyullathil F, 2008, FREE RADICAL BIO MED, V45, P1403, DOI 10.1016/j.freeradbiomed.2008.08.014
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Ullman E, 2008, CELL DEATH DIFFER, V15, P422, DOI 10.1038/sj.cdd.4402234
   Weber WM, 2005, BIOORGAN MED CHEM, V13, P3811, DOI 10.1016/j.bmc.2005.03.035
   Xiao J, 2012, INT J CANCER, V131, P1455, DOI 10.1002/ijc.27406
NR 32
TC 28
Z9 29
U1 1
U2 29
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568-0096
EI 1873-5576
J9 CURR CANCER DRUG TAR
JI Curr. Cancer Drug Targets
PY 2014
VL 14
IS 2
BP 156
EP 166
DI 10.2174/1568009613666131126115444
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AN8UE
UT WOS:000340879400005
PM 24274397
DA 2022-04-25
ER

PT J
AU Dukel, M
   Tavsan, Z
   Erdogan, D
   Gok, DE
   Kayali, HA
AF Dukel, Muzaffer
   Tavsan, Zehra
   Erdogan, Duygu
   Gok, Deniz Erkan
   Kayali, Hulya Ayar
TI Protein kinase C Inhibitors selectively modulate dynamics of cell
   adhesion molecules and cell death in human colon cancer cells
SO CELL ADHESION & MIGRATION
LA English
DT Article
DE Colon cancer; protein kinase C; cell adhesion molecules; reactive oxygen
   species; cell death
ID COLORECTAL-CANCER; EXPRESSION; ALPHA; APOPTOSIS; ACTIVATION; TIGHT;
   BETA; PKC; METASTASIS; INDUCTION
AB During development of colon cancer, Protein Kinase Cs (PKCs) are involved in regulation of many genes controlling several cellular mechanisms. Here, we examined the changes in cell adhesion molecules and PKCs for colorectal cancer progression. We identified that PKCs affected expression of EpCAM, claudins, tetraspanins. Treatment with low concentrations of PKC inhibitors resulted in decreased cell viability. In addition, immunoblotting and qRT-PCR analysis showed that apoptosis was inhibited while autophagy was induced by PKC inhibition in colon cancer cells. Furthermore, we observed decreased levels of intracellular Reactive Oxygen Species (ROS), lipid peroxidation and protein carbonyl, confirming the ROS-induced apoptosis. Taken together, our results reveal that PKC signalling modulates not only cell adhesion dynamics but also cell death-related mechanisms.Abbreviations: PKC: Protein Kinase C; EpCAM: Epithelial cell adhesion molecule; FBS: fetal bovine serum; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide); CAM: cell adhesion molecule; ROS: reactive oxygen species
C1 [Dukel, Muzaffer] Mehmet Akif Ersoy Univ, Fac Art & Sci, Mol Biol & Genet Dept, Burdur, Turkey.
   [Dukel, Muzaffer; Tavsan, Zehra; Gok, Deniz Erkan; Kayali, Hulya Ayar] Izmir Biomed & Genome Ctr, TR-35340 Izmir, Turkey.
   [Erdogan, Duygu] Dokuz Eylul Univ, Izmir Int Biomed & Genome Inst, Izmir, Turkey.
   [Kayali, Hulya Ayar] Dokuz Eylul Univ, Sci Fac, Chem Dept, Biochem Div, Izmir, Turkey.
RP Kayali, HA (corresponding author), Izmir Biomed & Genome Ctr, TR-35340 Izmir, Turkey.
EM hulya.ayarkayali@gmail.com
RI Tavsan, Zehra/AAR-6576-2021
OI Erdogan, Duygu/0000-0002-4930-7017
FU Dokuz Eylul University, Department of Scientific Research ProjectsDokuz
   Eylul University [KB.FEN.001]
FX This work was supported by the Dokuz Eylul University, Department of
   Scientific Research Projects (2016.KB.FEN.001).
CR Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313
   Chen PW, 2004, MOL PHARMACOL, V66, P1625, DOI 10.1124/mol.104.001206
   Datta R, 2000, J BIOL CHEM, V275, P41000, DOI 10.1074/jbc.M009322200
   Detchokul S, 2014, BRIT J PHARMACOL, V171, P5462, DOI 10.1111/bph.12260
   DOI S, 1994, MOL CARCINOGEN, V11, P197, DOI 10.1002/mc.2940110405
   Findley MK, 2009, IUBMB LIFE, V61, P431, DOI 10.1002/iub.175
   Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5
   Hao F, 2011, J BIOL CHEM, V286, P18104, DOI 10.1074/jbc.M110.208488
   Hemler ME, 2014, NAT REV CANCER, V14, P49, DOI 10.1038/nrc3640
   Hu CT, 2011, CLIN EXP METASTAS, V28, P851, DOI 10.1007/s10585-011-9416-6
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kang J.-H., 2014, NEW J SCI, V2014, P1, DOI [10.1155/2014/231418, DOI 10.1155/2014/231418]
   Karihtala P, 2011, HISTOPATHOLOGY, V58, P854, DOI 10.1111/j.1365-2559.2011.03835.x
   Kumar D, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-171
   Leotlela PD, 2007, ONCOGENE, V26, P3846, DOI 10.1038/sj.onc.1210155
   Li PF, 1999, CIRCULATION, V100, P967, DOI 10.1161/01.CIR.100.9.967
   Liu D, 2014, ONCOL LETT, V7, P1544, DOI 10.3892/ol.2014.1907
   Lu G, 2016, WORLD J SURG ONCOL, V14, P1
   Macdonald J, 2018, CANCERS, V10, DOI 10.3390/cancers10010019
   MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194
   Maurer CA, 1999, SURGERY, V126, P869, DOI 10.1016/S0039-6060(99)70028-0
   Mees ST, 2009, INT J COLORECTAL DIS, V24, P361, DOI 10.1007/s00384-009-0653-y
   Mochly-Rosen D, 2012, NAT REV DRUG DISCOV, V11, P937, DOI 10.1038/nrd3871
   Mokhtari Mojhgan, 2017, Adv Biomed Res, V6, P56, DOI 10.4103/2277-9175.205529
   Mori M, 1998, CLIN CANCER RES, V4, P1507
   Morley M, 2010, CELL TISSUE RES, V340, P229, DOI 10.1007/s00441-010-0938-z
   Oster H, 2006, CANCER RES, V66, P6955, DOI 10.1158/0008-5472.CAN-06-0268
   Oufkir T, 2011, PLACENTA, V32, P1033, DOI 10.1016/j.placenta.2011.09.005
   Pajak B, 2008, APOPTOSIS, V13, P509, DOI 10.1007/s10495-008-0194-9
   Palaghia M, 2016, ROM J MORPHOL EMBRYO, V57, P205
   PONGRACZ J, 1995, INT J CANCER, V61, P35, DOI 10.1002/ijc.2910610107
   Pysz MA, 2009, EXP CELL RES, V315, P1415, DOI 10.1016/j.yexcr.2009.02.002
   Qi P, 2016, ONCOL LETT, V12, P4577, DOI 10.3892/ol.2016.5255
   Satoh D, 2014, BIOL PHARM BULL, V37, P534, DOI 10.1248/bpb.b13-00708
   Singh AB, 2010, J ONCOL, V2010, P1, DOI DOI 10.1155/2010/541957
   Sun XA, 2017, ACTA PHARMACOL SIN, V38, P524, DOI 10.1038/aps.2016.171
   Tabaries S, 2017, ONCOGENE, V36, P1176, DOI 10.1038/onc.2016.289
   Tariq K, 2016, CANCER BIOL MED, V13, P120, DOI 10.28092/j.issn.2095-3941.2015.0103
   TOULLEC D, 1991, J BIOL CHEM, V266, P15771
   Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001
   VUILLAUME M, 1987, MUTAT RES, V186, P43, DOI 10.1016/0165-1110(87)90014-5
   Went PT, 2004, HUM PATHOL, V35, P122, DOI 10.1016/j.humpath.2003.08.026
   Wu CJ, 2013, J BIOL CHEM, V288, P12253, DOI 10.1074/jbc.M113.457499
   Wu WS, 2006, MOL CANCER RES, V4, P747, DOI 10.1158/1541-7786.MCR-06-0096
   Yoshida A, 2014, BIOCHEM PHARMACOL, V90, P16, DOI 10.1016/j.bcp.2014.04.002
   Young O, 2010, HEAD NECK-J SCI SPEC, V32, P750, DOI 10.1002/hed.21247
NR 46
TC 5
Z9 5
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
EI 1933-6926
J9 CELL ADHES MIGR
JI Celll Adhes. Migr.
PY 2019
VL 13
IS 1
BP 83
EP 97
DI 10.1080/19336918.2018.1530933
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA IC0SK
UT WOS:000470670000004
PM 30289336
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Wang, L
   Hu, T
   Shen, J
   Zhang, L
   Chan, RLY
   Lu, L
   Li, MX
   Cho, CH
   Wu, WKK
AF Wang, Lin
   Hu, Tao
   Shen, Jing
   Zhang, Lin
   Chan, Ruby Lok-Yi
   Lu, Lan
   Li, Mingxing
   Cho, Chi Hin
   Wu, William. Ka Kei
TI Dihydrotanshinone I induced apoptosis and autophagy through caspase
   dependent pathway in colon cancer
SO PHYTOMEDICINE
LA English
DT Article
DE Dihydrotanshinone I; Apoptosis; Autophagy; Caspase; Mitochondria; Colon
   cancer
ID MITOCHONDRIAL RELEASE; CELL; AIF; DOWNSTREAM
AB Background: Dihydrotanshinone I (DHTS) was previously reported to exhibit the most potent anti-cancer activity among several tanshinones in colon cancer cells. Its cytotoxic action was reactive oxygen species (ROS) dependent but p53 independent.
   Purpose: To further study the anti-cancer activity of DHTS and its molecular mechanisms of action in colon cancer both in vitro and in vivo.
   Methods: Caspase activity was detected by fluorescence assay. Apoptosis was detected by flow cytometry and TUNEL assay. Protein levels were analyzed by western blotting. Knockdown of target gene was achieved by siRNA transfection. Formation of LOB puncta and activation of caspase-3 were detected by confocal fluorescence microscope. In vivo anti-colon cancer activity of DHTS was observed in xenograft tumors in NOD/SCID mice.
   Results: Anti-colon cancer activity of DHTS by inducing apoptosis and autophagy was observed both in vitro and in vivo. Mitochondria mediated caspase dependent pathway was essential in DHTS-induced cytotoxicity. The apoptosis induced by DHTS was suppressed by knockdown of apoptosis inducing factor (AIF), inhibition of caspase-3/9 but was increased after knockdown of caspase-2. Meantime, knockdown of caspase-2, pretreatment with Z-VAD-fmk or NAC (N-Acety-L-Cysteine) efficiently inhibited the autophagy induced by DHTS. A crosstalk between cytochrome c and AIF was also reported.
   Conclusion: DHTS-induced caspase and ROS dependent apoptosis and autophagy were mediated by mitochondria in colon cancer. DHTS could be a promising leading compound for the development of anti-tumor agent or be developed as an adjuvant drug for colon cancer therapy. (C) 2015 Elsevier GmbH. All rights reserved.
C1 [Wang, Lin; Hu, Tao; Shen, Jing; Zhang, Lin; Chan, Ruby Lok-Yi; Lu, Lan; Li, Mingxing; Cho, Chi Hin] Chinese Univ Hong Kong, Lo Kwee Seong Integrated Biomed Sci Bldg, Fac Med, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China.
   [Wu, William. Ka Kei] Chinese Univ Hong Kong, Fac Med, Dept Anaesthesia & Intens Care, Hong Kong, Hong Kong, Peoples R China.
RP Wang, L (corresponding author), Chinese Univ Hong Kong, Lo Kwee Seong Integrated Biomed Sci Bldg, Fac Med, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China.
EM wanglinster@gmail.com
RI Cho, Chi Hin/C-6543-2014; Hu, Tao/O-2570-2014; Wu, William
   K.K./A-3277-2009
OI Cho, Chi Hin/0000-0002-7658-3260; Wu, William K.K./0000-0002-5662-5240;
   WANG, LIN/0000-0001-7883-4900; Hu, Tao/0000-0002-0601-3078; LI,
   Mingxing/0000-0001-5729-3850
FU Innovation and Technology Support Programme; Tier 3/Seed Projects;
   Innovation and Technology Commission, Hong Kong [ITS/212/12]; General
   Research Fund, Hong Kong Research Grant Council, Hong Kong [CUHK463613]
FX This work was supported by Innovation and Technology Support Programme,
   Tier 3/Seed Projects, Innovation and Technology Commission, Hong Kong
   (ITS/212/12) and General Research Fund, Hong Kong Research Grant
   Council, Hong Kong (CUHK463613).
CR Aksenova VI, 2013, MOL BIOL+, V47, P165, DOI 10.1134/S0026893313010020
   Arbel N, 2012, J BIOL CHEM, V287, P23152, DOI 10.1074/jbc.M112.345918
   Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423
   Arnoult D, 2002, J CELL BIOL, V159, P923, DOI 10.1083/jcb.200207071
   Bouchier-Hayes L, 2012, CELL DEATH DIFFER, V19, P51, DOI 10.1038/cdd.2011.157
   Brenner C, 2006, ONCOGENE, V25, P4744, DOI 10.1038/sj.onc.1209609
   Brynychova V, 2013, FUTURE ONCOL, V9, P427, DOI [10.2217/FON.12.200, 10.2217/fon.12.200]
   Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729
   Fan TJ, 2005, ACTA BIOCH BIOPH SIN, V37, P719, DOI 10.1111/j.1745-7270.2005.00108.x
   Han CH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067033
   Iwanaga N, 2005, J LAB CLIN MED, V145, P105, DOI 10.1016/j.lab.2004.11.020
   Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004
   Kuwana T, 2003, CURR OPIN CELL BIOL, V15, P691, DOI 10.1016/j.ceb.2003.10.004
   Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035
   Lamkanfi M, 2010, INT J BIOCHEM CELL B, V42, P21, DOI 10.1016/j.biocel.2009.09.013
   Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527
   Ming L, 2006, J BIOL CHEM, V281, P16034, DOI 10.1074/jbc.M513587200
   Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x
   Pan WR, 2015, MOL CELL BIOCHEM, V400, P77, DOI 10.1007/s11010-014-2264-3
   Puccini J, 2013, CELL DEATH DIFFER, V20, P1133, DOI 10.1038/cdd.2013.87
   Sevrioukova IF, 2011, ANTIOXID REDOX SIGN, V14, P2545, DOI 10.1089/ars.2010.3445
   Singh MH, 2010, NEUROSCI LETT, V469, P179, DOI 10.1016/j.neulet.2009.11.067
   Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952
   Thayyullathil F, 2008, FREE RADICAL BIO MED, V45, P1403, DOI 10.1016/j.freeradbiomed.2008.08.014
   Walsh JG, 2008, P NATL ACAD SCI USA, V105, P12815, DOI 10.1073/pnas.0707715105
   Wang L, 2013, LIFE SCI, V93, P344, DOI 10.1016/j.lfs.2013.07.007
   Woltering EJ, 2010, TRENDS PLANT SCI, V15, P185, DOI 10.1016/j.tplants.2010.02.001
NR 27
TC 45
Z9 46
U1 2
U2 38
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944-7113
EI 1618-095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD NOV 15
PY 2015
VL 22
IS 12
BP 1079
EP 1087
DI 10.1016/j.phymed.2015.08.009
PG 9
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA CX2WG
UT WOS:000365556900003
PM 26547530
DA 2022-04-25
ER

PT J
AU Jeong, HS
   Choi, HY
   Lee, ER
   Kim, JH
   Jeon, K
   Lee, HJ
   Cho, SG
AF Jeong, Hyo-Soon
   Choi, Hye Yeon
   Lee, Eung-Ryoung
   Kim, Jung-Hyun
   Jeon, Kilsoo
   Lee, Hyun-Joo
   Cho, Ssang-Goo
TI Involvement of caspase-9 in autophagy-mediated cell survival pathway
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
LA English
DT Article
DE NSAIDs; Caspase; Apoptosis; Autophagy; MCF-7
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROSTATE-CANCER CELLS;
   BREAST-CANCER; INDUCED APOPTOSIS; COX INHIBITORS; CYTOCHROME-C; DEATH;
   EXPRESSION; MODEL; COLON
AB Nonsteroidal anti-inflammatory drugs (NSAIDs) have been considered for use in the prevention and treatment of cancer malignancy. FR122047 (FR) is known to have an anti-inflammatory effect, but the anticancer activity of the chemical has not yet been identified. In the present study, we could find that treatment of breast cancer MCF-7 cells with FR led to apoptosis accompanying with apparent activation of caspases. Treatment of caspase-specific inhibitors revealed that FR-induced apoptosis was caspase-8-dependent and inhibition of caspase-9 activity resulted in unexpected, marked enhancement of cell death. Knockdown of caspase-9 expression by specific siRNA caused increased susceptibility to FR-induced cell death, consistent with the results obtained with treatment of caspase-9 inhibitor. Inhibition of caspase-9 blocked the autophagic process by modulating lysosomal pH and acid-dependent cathepsin activities and augmented cell death due to blockage of cytoprotective autophagy. MCF-7 cells treated with sulforaphane, an autophagy-inducing drug, also showed marked accumulation of LC3-II, and co-treatment with caspase-9 inhibitor brought about increased susceptibility to sulforaphane-induced cell death. Different from the cases with FR or sulforaphane, etoposide- or doxorubicin-induced cell death was suppressed with co-treatment of caspase-9 inhibitor, and the drugs failed to induce significant autophagy in MCF-7 cells. Taken together, our data originally suggest that inhibition of caspase-9 may block the autophagic flux and enhance cell death due to blockage of cytoprotective autophagy. (c) 2010 Elsevier B.V. All rights reserved.
C1 Konkuk Univ, Dept Anim Biotechnol BK21, Anim Resources Res Ctr, Seoul 143701, South Korea.
   Konkuk Univ, RCTCP, Seoul 143701, South Korea.
RP Cho, SG (corresponding author), Konkuk Univ, Dept Anim Biotechnol, Seoul 143701, South Korea.
EM ssangoo@konkuk.ac.kr
RI Kim, Jung-Hyun/AAK-8795-2021; CHOI, HYEYEON/O-1234-2019; Jeon,
   Kilsoo/D-5187-2011
OI Kim, Jung-Hyun/0000-0001-7176-409X; 
FU Korean government (MEST)Ministry of Education, Science and Technology,
   Republic of KoreaKorean Government [2009-0083694, 2010-0001348];
   Ministry for Health, Welfare, and Family Affairs [A08-4065]; Rural
   Development AdministrationRural Development Administration (RDA)
   [20070501-034-001-009-02-00]; Korea Research Council of Fundamental
   Science Technology; KRIBB Initiative [KGM3110912]; Korean government
   (MEST), Republic of KoreaMinistry of Education, Science and Technology,
   Republic of KoreaKorean Government
FX We thank Dr. T. Yoshimori (Research Institute for Microbial Diseases,
   Osaka University, Japan) for providing the GFP-LC3 plasmid and Dr.
   Seunghwa Park (Konkuk University, South Korea) for helping with the
   transmission electron microscopy. This work was supported in part by the
   National Research Foundation of Korea (NRF) grant funded by the Korean
   government (MEST) (No. 2009-0083694 and No. 2010-0001348) and by a grant
   from Korea Health 21 R&D Project, Ministry for Health, Welfare, and
   Family Affairs (A08-4065), a grant from BioGreen 21 Program, Rural
   Development Administration (Code # 20070501-034-001-009-02-00), and Top
   Brand Project grant from Korea Research Council of Fundamental Science &
   Technology and KRIBB Initiative program (KGM3110912). We acknowledge a
   graduate fellowship provided by the Korean government (MEST) through the
   Brain Korea 21 project, Republic of Korea.
CR Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039
   Abraham MC, 2004, TRENDS CELL BIOL, V14, P184, DOI 10.1016/j.tcb.2004.03.002
   Akdemir F, 2006, DEVELOPMENT, V133, P1457, DOI 10.1242/dev.02332
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Baek SJ, 2006, PROG LIPID RES, V45, P1, DOI 10.1016/j.plipres.2005.10.001
   Baron JA, 2000, ANNU REV MED, V51, P511, DOI 10.1146/annurev.med.51.1.511
   Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852
   Cao C, 2006, INT J RADIAT ONCOL, V66, pS554, DOI 10.1016/j.ijrobp.2006.07.1033
   Cheng I, 2007, BRIT J CANCER, V97, P557, DOI 10.1038/sj.bjc.6603874
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Ferguson HA, 2003, J BIOL CHEM, V278, P45793, DOI 10.1074/jbc.M307979200
   Fernando P, 2005, FASEB J, V19, P1671, DOI 10.1096/fj.04-2981fje
   Gyrd-Hansen M, 2006, MOL CELL BIOL, V26, P7880, DOI 10.1128/MCB.00716-06
   Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5
   Harris RE, 2003, CANCER RES, V63, P6096
   HARRIS RE, 1995, PREV MED, V24, P119, DOI 10.1006/pmed.1995.1022
   Herman-Antosiewicz A, 2006, CANCER RES, V66, P5828, DOI 10.1158/0008-5472.CAN-06-0139
   IVY GO, 1984, SCIENCE, V226, P985, DOI 10.1126/science.6505679
   Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357
   Jia L, 1997, BRIT J HAEMATOL, V98, P673, DOI 10.1046/j.1365-2141.1997.2623081.x
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kern MA, 2006, CANCER RES, V66, P7059, DOI 10.1158/0008-5472.CAN-06-0325
   Kim BW, 2008, CANCER BIOL THER, V7, P1080, DOI 10.4161/cbt.7.7.6164
   Kim SH, 2004, J CANCER RES CLIN, V130, P551, DOI 10.1007/s00432-004-0567-6
   Kundu N, 2002, CANCER RES, V62, P2343
   Lanza-Jacoby S, 2004, MOL CANCER THER, V3, P417
   Lee ER, 2005, J BIOL CHEM, V280, P31498, DOI 10.1074/jbc.M505537200
   Lupulescu A, 1996, PROSTAG LEUKOTR ESS, V54, P83, DOI 10.1016/S0952-3278(96)90064-2
   Mazhar D, 2006, BRIT J CANCER, V94, P346, DOI 10.1038/sj.bjc.6602942
   Ochi T, 2000, EUR J PHARMACOL, V391, P49, DOI 10.1016/S0014-2999(00)00051-0
   Ochi T, 2002, BRIT J PHARMACOL, V135, P782, DOI 10.1038/sj.bjp.0704511
   Ravikumar B, 2006, HUM MOL GENET, V15, P1209, DOI 10.1093/hmg/ddl036
   Sato K, 2003, BRIT J CANCER, V89, P1366, DOI 10.1038/sj.bjc.6601253
   SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138, DOI 10.1097/00001648-199403000-00003
   Shah N, 2004, BLOOD, V104, P2873, DOI 10.1182/blood-2003-10-3720
   Sheng HM, 1998, CANCER RES, V58, P362
   Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323
   Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev
   Thorburn A, 2008, APOPTOSIS, V13, P1, DOI 10.1007/s10495-007-0154-9
   Uchiyama R, 2007, INFECT IMMUN, V75, P2894, DOI 10.1128/IAI.01639-06
   Wang WH, 2003, JNCI-J NATL CANCER I, V95, P1784, DOI 10.1093/jnci/djg106
   Wu YT, 2008, AUTOPHAGY, V4, P457, DOI 10.4161/auto.5662
   Yanagisawa H, 2003, CELL DEATH DIFFER, V10, P798, DOI 10.1038/sj.cdd.4401246
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
NR 44
TC 40
Z9 40
U1 0
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-4889
EI 0006-3002
J9 BBA-MOL CELL RES
JI Biochim. Biophys. Acta-Mol. Cell Res.
PD JAN
PY 2011
VL 1813
IS 1
BP 80
EP 90
DI 10.1016/j.bbamcr.2010.09.016
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 715GC
UT WOS:000286867800008
PM 20888374
OA Bronze
DA 2022-04-25
ER

PT J
AU Nam, TW
   Park, SY
   Lee, JH
   Roh, JI
   Lee, HW
AF Nam, Tae Wool
   Park, Song Yi
   Lee, Jae Hoon
   Roh, Jae Il
   Lee, Han-Woong
TI Effect of EI24 expression on the tumorigenesis of Apc(Min)/+ colorectal
   cancer mouse model
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Colorectal cancer; EI24; Apc(Min/+) mice
ID PROTEIN-KINASE-C; DOWN-REGULATION; BREAST-CANCER; ALPHA; OVEREXPRESSION;
   RESISTANCE; AUTOPHAGY; IGF-1R; GENES
AB Etoposide-induced 2.4 kb transcript (EI24, also known as PIGS) is a p53 target gene involved in cell growth suppression and apoptosis and known to be frequently altered in human cancers. Although EI24 expression is decreased in various cancers and is associated with colorectal cancer progression and metastasis, the physiological function of EI24 in colorectal cancer is yet unclear. We generated an EI24 conditional transgenic (Tg) mouse to study the therapeutic effects of EI24 in vivo and evaluated whether EI24 plays a role of a tumor suppressor using EI24 Tg mouse crossed with Apc(Min/+) mouse, which develops multiple intestinal adenomas. The overexpression of EI24 failed to cause any notable difference in the number of polyps, lengths of the intestine and spleen, and survival rate between Apc(Min/+) and Apc(Min/+) EI24 Tg mice. EI24 plays no significant role in colon cancer caused by the substitutional mutation of Apc in mice. Therefore, our result dismisses the hypothesized direct link between Apc(Min/+) mutation and EI24 expression in colorectal cancer model. (C) 2019 The Authors. Published by Elsevier Inc.
C1 [Nam, Tae Wool; Park, Song Yi; Lee, Jae Hoon; Roh, Jae Il; Lee, Han-Woong] Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biochem, Seoul 03722, South Korea.
RP Lee, HW (corresponding author), Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biochem, Seoul 03722, South Korea.
EM hwl@yonsei.ac.kr
FU National Research Foundation of Korea (NRF)National Research Foundation
   of Korea [2017R1A4A1015328, 2018R1A2A1A05022746]
FX This work was supported by grants from the National Research Foundation
   of Korea (NRF; 2017R1A4A1015328 and 2018R1A2A1A05022746). Both grants
   were supported in managing the mouse and gave funds for studying Ei24.
   The National Research Foundation of Korea was not involved in study
   design, data collection, data analysis, or interpretation of study
   results.
CR Armaghany Tannaz, 2012, Gastrointest Cancer Res, V5, P19
   Beck GR, 2001, CELL GROWTH DIFFER, V12, P61
   Burns TF, 2001, ONCOGENE, V20, P4601, DOI 10.1038/sj.onc.1204484
   Cho A., 2009, CURR PROTOC CELL BIO, V42
   Choi JM, 2015, LUNG CANCER, V90, P175, DOI 10.1016/j.lungcan.2015.08.019
   Choi JM, 2013, ONCOTARGET, V4, P2383, DOI 10.18632/oncotarget.1434
   Devkota S, 2016, AUTOPHAGY, V12, P2038, DOI 10.1080/15548627.2016.1217371
   Devkota S, 2012, INT J BIOCHEM CELL B, V44, P1887, DOI 10.1016/j.biocel.2012.06.034
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Gentile M, 2001, ONCOGENE, V20, P7753, DOI 10.1038/sj.onc.1204993
   Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110
   Gu ZM, 2000, MOL CELL BIOL, V20, P233, DOI 10.1128/MCB.20.1.233-241.2000
   Gwak J, 2009, J CELL MOL MED, V13, P2171, DOI 10.1111/j.1582-4934.2009.00683.x
   Jeong DU, 2017, J CELL PHYSIOL, V232, P78, DOI 10.1002/jcp.25446
   Lee J, 2011, INT J EXP PATHOL, V92, P251, DOI 10.1111/j.1365-2613.2011.00762.x
   MOSER AR, 1995, EUR J CANCER, V31A, P1061, DOI 10.1016/0959-8049(95)00181-H
   O'Gorman S, 1997, P NATL ACAD SCI USA, V94, P14602, DOI 10.1073/pnas.94.26.14602
   Oster H, 2006, CANCER RES, V66, P6955, DOI 10.1158/0008-5472.CAN-06-0268
   Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   Ritland SR, 1999, CARCINOGENESIS, V20, P51, DOI 10.1093/carcin/20.1.51
   RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555
   RONCUCCI L, 1991, CANCER EPIDEM BIOMAR, V1, P57
   SAKANOUE Y, 1991, INT J CANCER, V48, P803, DOI 10.1002/ijc.2910480602
   Schell MJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11743
   Shiratsuchi I, 2011, ANTICANCER RES, V31, P2541
   Skrzypczak M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013091
   Suga K, 1998, BIOCHEM MOL BIOL INT, V44, P523
   Sun YJ, 2009, PROSTATE, V69, P1119, DOI 10.1002/pros.20961
   Weitz J, 2005, LANCET, V365, P153, DOI 10.1016/S0140-6736(05)17706-X
   Zhao XS, 2005, CANCER RES, V65, P2125, DOI 10.1158/0008-5472.CAN-04-3377
   Zhao YG, 2012, J BIOL CHEM, V287, P42053, DOI 10.1074/jbc.M112.415968
NR 32
TC 2
Z9 2
U1 1
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUL 5
PY 2019
VL 514
IS 4
BP 1087
EP 1092
DI 10.1016/j.bbrc.2019.04.186
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA IC8EM
UT WOS:000471209100010
PM 31097220
OA hybrid
DA 2022-04-25
ER

PT J
AU Masui, A
   Hamada, M
   Kameyama, H
   Wakabayashi, K
   Takasu, A
   Imai, T
   Iwai, S
   Yura, Y
AF Masui, Atsushi
   Hamada, Masakazu
   Kameyama, Hiroyasu
   Wakabayashi, Ken
   Takasu, Ayako
   Imai, Tomoaki
   Iwai, Soichi
   Yura, Yoshiaki
TI Autophagy as a Survival Mechanism for Squamous Cell Carcinoma Cells in
   Endonuclease G-Mediated Apoptosis
SO PLOS ONE
LA English
DT Article
ID PROTEIN-KINASE-C; MALIGNANT GLIOMA-CELLS; COLON-CANCER CELLS; INHIBITOR
   SAFINGOL; HUMAN HEAD; INDUCTION; DEATH; MACROAUTOPHAGY; DEGRADATION;
   CISPLATIN
AB Safingol, L-threo-dihydrosphingosine, induces cell death in human oral squamous cell carcinoma (SCC) cells through an endonuclease G (endoG) -mediated pathway. We herein determined whether safingol induced apoptosis and autophagy in oral SCC cells. Safingol induced apoptotic cell death in oral SCC cells in a dose-dependent manner. In safingol-treated cells, microtubule-associated protein 1 light chain 3 (LC3)-I was changed to LC3-II and the cytoplasmic expression of LC3, amount of acidic vesicular organelles (AVOs) stained by acridine orange and autophagic vacuoles were increased, indicating the occurrence of autophagy. An inhibitor of autophagy, 3-methyladenine (3-MA), enhanced the suppressive effects of safingol on cell viability, and this was accompanied by an increase in the number of apoptotic cells and extent of nuclear fragmentation. The nuclear translocation of endoG was minimal at a low concentration of safingol, but markedly increased when combined with 3-MA. The suppressive effects of safingol and 3-MA on cell viability were reduced in endoG siRNA-transfected cells. The scavenging of reactive oxygen species (ROS) prevented cell death induced by the combinational treatment, whereas a pretreatment with a pan-caspase inhibitor z-VAD-fmk did not. These results indicated that safingol induced apoptosis and autophagy in SCC cells and that the suppression of autophagy by 3-MA enhanced apoptosis. Autophagy supports cell survival, but not cell death in the SCC cell system in which apoptosis occurs in an endoG-mediated manner.
C1 [Masui, Atsushi; Hamada, Masakazu; Kameyama, Hiroyasu; Wakabayashi, Ken; Takasu, Ayako; Imai, Tomoaki; Iwai, Soichi; Yura, Yoshiaki] Osaka Univ, Grad Sch Dent, Dept Oral & Maxillofacial Surg, 1-8 Yamadaoka, Suita, Osaka 5650871, Japan.
RP Hamada, M (corresponding author), Osaka Univ, Grad Sch Dent, Dept Oral & Maxillofacial Surg, 1-8 Yamadaoka, Suita, Osaka 5650871, Japan.
EM hmdmskz@dent.osaka-u.ac.jp
RI Imai, Tomoaki/AAY-9065-2020
OI Imai, Tomoaki/0000-0002-1404-8721; Yura, Yoshiaki/0000-0002-9469-5477
FU Japan Society for the Promotion of ScienceMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science [25861929]
FX This work was supported by a Grant-in Aid for Scientific Research from
   the Japan Society for the Promotion of Science (no. 25861929,
   http://www.jsps.go.jp/english/e.grants/index.html). The funder had a
   role in data collection and analysis, as well as in preparing the
   manuscript.; This work was supported by a Grant-in Aid for Scientific
   Research from the Japan Society for the Promotion of Science
   (No.25861929). The funder had a role in data collection and analysis, as
   well as in preparing the manuscript.
CR Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595
   CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615
   Cosway B, 2016, ORAL ONCOL, V54, P1, DOI 10.1016/j.oraloncology.2015.12.007
   Coward J, 2009, AUTOPHAGY, V5, P184, DOI 10.4161/auto.5.2.7361
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   Dickson MA, 2011, CLIN CANCER RES, V17, P2484, DOI 10.1158/1078-0432.CCR-10-2323
   Hamada M, 2006, APOPTOSIS, V11, P47, DOI 10.1007/s10495-005-3348-z
   Hamada M, 2014, INT J MOL SCI, V15, P2660, DOI 10.3390/ijms15022660
   HANNUN YA, 1986, J BIOL CHEM, V261, P2604
   Herman-Antosiewicz A, 2006, CANCER RES, V66, P5828, DOI 10.1158/0008-5472.CAN-06-0139
   Hoffmann TK, 2002, ANTI-CANCER DRUG, V13, P93, DOI 10.1097/00001813-200201000-00011
   Irimie AI, 2015, ONCOTARGETS THER, V8, P461, DOI 10.2147/OTT.S78358
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Kim JS, 2008, INT J CANCER, V122, P672, DOI 10.1002/ijc.23158
   Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kondo Y, 2006, AUTOPHAGY, V2, P85, DOI 10.4161/auto.2.2.2463
   Lavieu G, 2006, J BIOL CHEM, V281, P8518, DOI 10.1074/jbc.M506182200
   Li JC, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0211-0
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Ling LU, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.12
   Ling LU, 2009, INT J ONCOL, V35, P1463, DOI 10.3892/ijo_00000465
   MARTINEZGIMENO C, 1995, HEAD NECK-J SCI SPEC, V17, P516, DOI 10.1002/hed.2880170609
   Maurer BJ, 2000, JNCI-J NATL CANCER I, V92, P1897, DOI 10.1093/jnci/92.23.1897
   Miki H, 2012, INT J ONCOL, V40, P1020, DOI 10.3892/ijo.2012.1325
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571
   Noda T, 2009, APOPTOSIS, V14, P287, DOI 10.1007/s10495-009-0319-9
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   SACHS CW, 1995, J BIOL CHEM, V270, P26639, DOI 10.1074/jbc.270.44.26639
   Scarlatti F, 2004, J BIOL CHEM, V279, P18384, DOI 10.1074/jbc.M313561200
   Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3
   Schwartz GK, 1997, CLIN CANCER RES, V3, P537
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640
   Tang QS, 2013, CANCER LETT, V336, P325, DOI 10.1016/j.canlet.2013.03.023
   Tanida I, 2004, J BIOL CHEM, V279, P47704, DOI 10.1074/jbc.M407016200
   Turcotte S, 2010, CURR OPIN CELL BIOL, V22, P246, DOI 10.1016/j.ceb.2009.12.007
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Yazbeck VY, 2014, ORAL ONCOL, V50, P120, DOI 10.1016/j.oraloncology.2013.10.013
   Zhu LQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084175
   Zhu WY, 2014, INT J MOL SCI, V15, P3336, DOI 10.3390/ijms15023336
NR 44
TC 19
Z9 19
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 22
PY 2016
VL 11
IS 9
AR e0162786
DI 10.1371/journal.pone.0162786
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DW8GO
UT WOS:000383893200033
PM 27658240
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Guo, Y
   Shan, QQ
   Gong, PY
   Wang, SC
AF Guo, Yong
   Shan, Qing Qing
   Gong, Ping Yu
   Wang, Sen Chun
TI The autophagy induced by curcumin via MEK/ERK pathway plays an early
   anti-leukemia role in human Philadelphia chromosome-positive acute
   lymphoblastic leukemia SUP-B15 cells
SO JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
LA English
DT Article
DE Autophagy; curcumin; Philadelphia chromosome-positive acute
   lymphoblastic leukemia; RAF/MEK/ERK
ID CHRONIC MYELOID-LEUKEMIA; COLON-CANCER CELLS; SIGNALING PATHWAYS;
   TYROSINE KINASE; DEATH; APOPTOSIS; INDUCTION; THERAPY; MACROAUTOPHAGY;
   TRANSFORMATION
AB Background: Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is triggered by BCR/ABL tyrosine kinase which activates the downstream signaling pathways, such as Akt/mTOR, RAF/MEK/ERK, and STAT5 pathways. Curcumin has been shown to have inhibitory effects on cancers by inducing apoptosis and autophagy. We demonstrated that curcumin inhibited activation of Akt-mTOR, ABL/STAT5 pathways, inhibited cell proliferation, and induced apoptosis in Ph+ ALL cells. Experiments here, were conducted to determine whether autophagy via MEK/ERK pathway involved in anti-leukemia effect of curcumin in Ph+ ALL.
   Materials and Methods: Ph+ ALL cell line SUP-B15 was treated with curcumin. Cytotoxic activity of curcumin was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide assay. Signaling protein and specific maker of autophagy and conversion of LC3-I to LC3-II were determined by Western blot analysis. Cell apoptosis was determined by flow cytometry.
   Results: Curcumin treatment up-regulated the activation of RAF/MEK/ERK at 4 h and 8 h after curcumin exposure in SUP-B15 cells, curcumin treatment induced autophagy at exactly 4 h and 8 h after curcumin exposure. Curcumin exerted cytotoxic activity against SUP-B15 cells at 4 h and 8 h, which was independent of apoptosis. MEK specific inhibitor U0126 inhibited the occurrence of autophagy, and then blocked curcumin-induced cytotoxicity at 4 h and 8 h.
   Conclusions: Curcumin induce autophagic cell death in SUP-B15 cells via activating RAF/MEK/ERK pathway. These findings suggest that autophagic mechanism contribute to the curcumin-induced early SUP-B15 cell death, and autophagy is another anti-leukemia mechanism of curcumin.
C1 [Guo, Yong; Shan, Qing Qing; Gong, Ping Yu] Sichuan Univ, West China Hosp, Dept Hematol, 37 Guo Xue Xiang, Chengdu 610041, Sichuan, Peoples R China.
   [Guo, Yong; Shan, Qing Qing; Gong, Ping Yu] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, 37 Guo Xue Xiang, Chengdu 610041, Sichuan, Peoples R China.
   [Wang, Sen Chun] Sichuan Prov Peoples Hosp, Dept Hematol, Chengdu 610041, Sichuan, Peoples R China.
RP Gong, PY (corresponding author), Sichuan Univ, West China Hosp, Dept Hematol, 37 Guo Xue Xiang, Chengdu 610041, Sichuan, Peoples R China.; Gong, PY (corresponding author), Sichuan Univ, West China Hosp, State Key Lab Biotherapy, 37 Guo Xue Xiang, Chengdu 610041, Sichuan, Peoples R China.
EM gongyuping@hotmail.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81400123]; Foundation of the Science and
   Technology Department of Sichuan Province [2013SZ0025]
FX National Natural Science Foundation of China (No. 81400123), Foundation
   of the Science and Technology Department of Sichuan Province (No.
   2013SZ0025).
CR Aggarwal BB, 2003, ANTICANCER RES, V23, P363
   Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167
   Dombret H, 2002, BLOOD, V100, P2357, DOI 10.1182/blood-2002-03-0704
   Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402
   Ellington AA, 2006, CARCINOGENESIS, V27, P298, DOI 10.1093/carcin/bgi214
   Eskelinen EL, 2005, CELL DEATH DIFFER, V12, P1468, DOI 10.1038/sj.cdd.4401721
   Faderl S, 2003, CANCER-AM CANCER SOC, V98, P1337, DOI 10.1002/cncr.11664
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Gruber F, 2009, BRIT J HAEMATOL, V145, P581, DOI 10.1111/j.1365-2141.2009.07666.x
   Guillon-Munos A, 2006, AUTOPHAGY, V2, P140, DOI 10.4161/auto.2.2.2443
   Hochhaus A, 2009, LEUKEMIA, V23, P1054, DOI 10.1038/leu.2009.38
   Karunagaran D, 2005, CURR CANCER DRUG TAR, V5, P117, DOI 10.2174/1568009053202081
   Kim JY, 2012, ARCH ORAL BIOL, V57, P1018, DOI 10.1016/j.archoralbio.2012.04.005
   Kunnumakkara AB, 2008, CANCER LETT, V269, P199, DOI 10.1016/j.canlet.2008.03.009
   Lee YJ, 2011, KOREAN J PHYSIOL PHA, V15, P1, DOI 10.4196/kjpp.2011.15.1.1
   Li B, 2013, INT J GYNECOL CANCER, V23, P803, DOI 10.1097/IGC.0b013e31828c9581
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Moorman AV, 2007, BLOOD, V109, P3189, DOI 10.1182/blood-2006-10-051912
   O'Sullivan-Coyne G, 2009, BRIT J CANCER, V101, P1585, DOI 10.1038/sj.bjc.6605308
   Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200
   Ottmann OG, 2002, BLOOD, V100, P1965, DOI 10.1182/blood-2001-12-0181
   Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200
   Piccaluga PP, 2006, EXPERT OPIN BIOL TH, V6, P1011, DOI 10.1517/14712598.6.10.1011
   Pui CH, 2006, NEW ENGL J MED, V354, P166, DOI 10.1056/NEJMra052603
   Sawyers CL, 1997, BAILLIERE CLIN HAEM, V10, P223, DOI 10.1016/S0950-3536(97)80004-2
   Schultz KR, 2009, J CLIN ONCOL, V27, P5175, DOI 10.1200/JCO.2008.21.2514
   Sharma RA, 2005, EUR J CANCER, V41, P1955, DOI 10.1016/j.ejca.2005.05.009
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151
   Wu JC, 2011, MOL NUTR FOOD RES, V55, P1646, DOI 10.1002/mnfr.201100454
   Yamauchi Y, 2012, PHYTOTHER RES, V26, P1779, DOI 10.1002/ptr.4645
NR 32
TC 10
Z9 11
U1 2
U2 8
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0973-1482
EI 1998-4138
J9 J CANCER RES THER
JI J. Canc. Res. Ther.
PY 2018
VL 14
SU 1
BP S125
EP S131
DI 10.4103/0973-1482.172111
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GM1NJ
UT WOS:000437835100021
PM 29578162
OA gold
DA 2022-04-25
ER

PT J
AU Xia, D
   Ji, WL
   Xu, CT
   Lin, X
   Wang, XK
   Xia, Y
   Lv, P
   Song, QS
   Ma, DL
   Chen, YY
AF Xia, Dan
   Ji, Wanli
   Xu, Chentong
   Lin, Xin
   Wang, Xiaokun
   Xia, Yan
   Lv, Ping
   Song, Quansheng
   Ma, Dalong
   Chen, Yingyu
TI Knockout of MARCH2 inhibits the growth of HCT116 colon cancer cells by
   inducing endoplasmic reticulum stress
SO CELL DEATH & DISEASE
LA English
DT Article
ID UNFOLDED PROTEIN RESPONSE; ER STRESS; SIGNALING PATHWAY;
   PROSTATE-CANCER; GRP78; AUTOPHAGY; INVOLVEMENT; RECURRENCE; ACTIVATION;
   MECHANISMS
AB Membrane-associated RING-CH protein 2 (MARCH2), a member of the MARCH family, functions in vesicle trafficking and autophagy regulation. In this study, we established MARCH2 knockout HCT116 cell lines using CRISPR/Cas9-mediated genome editing to evaluate the role of MARCH2 in colon cancer in vitro and in vivo. Knockout of MARCH2 suppressed cell proliferation, and promoted autophagy, apoptosis and G2/M phase cell cycle arrest. These effects were associated with activation of endoplasmic reticulum (ER) stress. In addition, loss of MARCH2 sensitized HCT116 cells to the chemotherapy drugs etoposide and cisplatin. Moreover, we analyzed the clinical significance of MARCH2 in human colon carcinoma (n=100). High MARCH2 expression was significantly associated with advanced clinicopathological features and poorer overall survival in colon carcinoma. MARCH2 expression correlated negatively with expression of the unfolded protein response molecule p-PERK in colon cancer. Collectively, these data reveal a relationship between MARCH2, ER stress and colon cancer, and indicates MARCH2 may have an important role in the development and progression of colon cancer.
C1 [Xia, Dan; Xu, Chentong; Lin, Xin; Wang, Xiaokun; Xia, Yan; Lv, Ping; Song, Quansheng; Ma, Dalong; Chen, Yingyu] Peking Univ, Sch Basic Med Sci, Key Lab Med Immunol, Dept Immunol,Minist Hlth,Hlth Sci Ctr, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
   [Xia, Dan] Shandong Med Coll, Dept Pathol, 6 Jucai Rd, Linyi 276000, Peoples R China.
   [Xia, Dan; Xu, Chentong; Lin, Xin; Wang, Xiaokun; Xia, Yan; Lv, Ping; Song, Quansheng; Ma, Dalong; Chen, Yingyu] Peking Univ, Ctr Human Dis Genom, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
   [Ji, Wanli] Shandong Med Coll, Affiliated Hosp, Dept Pathol, 80 Jintan Rd, Linyi 276000, Peoples R China.
RP Chen, YY (corresponding author), Peking Univ, Sch Basic Med Sci, Dept Immunol, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
EM yingyu_chen@bjmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [3137089, 814201080028, 91430101]; Projects
   of medical and health technology development program in Shandong
   province [2016WS0569]; The science and technology plan project of
   Shandong higher education institutions [J17KA238]
FX This work was supported by grants from the National Natural Science
   Foundation of China (31370898, 81420108002, 91430101), Projects of
   medical and health technology development program in Shandong province
   (2016WS0569), The science and technology plan project of Shandong higher
   education institutions (J17KA238).
CR Ando T, 2001, J BIOL CHEM, V276, P42971, DOI 10.1074/jbc.M106460200
   Ariyasu D, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020382
   Bartee E, 2004, J VIROL, V78, P1109, DOI 10.1128/JVI.78.3.1109-1120.2004
   Boutell C, 2002, J VIROL, V76, P841, DOI 10.1128/JVI.76.2.841-850.2002
   Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197
   Burdelski C, 2015, CLIN CANCER RES, V21, P3471, DOI 10.1158/1078-0432.CCR-14-0620
   Cai Y, 2016, J CELL BIOL, V215, P245, DOI 10.1083/jcb.201605065
   Cao ZF, 2008, CELL SIGNAL, V20, P73, DOI 10.1016/j.cellsig.2007.08.019
   Carroll D, 2014, ANNU REV BIOCHEM, V83, P409, DOI 10.1146/annurev-biochem-060713-035418
   Chen L, 2016, LEUKEMIA RES, V49, P7, DOI 10.1016/j.leukres.2016.07.006
   Cheng J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068001
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Cubillos-Ruiz JR, 2017, CELL, V168, P692, DOI 10.1016/j.cell.2016.12.004
   Daneshmand S, 2007, HUM PATHOL, V38, P1547, DOI 10.1016/j.humpath.2007.03.014
   Ghosh R, 2014, CELL, V158, P534, DOI 10.1016/j.cell.2014.07.002
   Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610
   Guo ML, 2015, AUTOPHAGY, V11, P995, DOI 10.1080/15548627.2015.1052205
   Han SO, 2012, J CELL BIOL, V199, P817, DOI 10.1083/jcb.201208192
   Hiramatsu N, 2015, AM J PATHOL, V185, P1800, DOI 10.1016/j.ajpath.2015.03.009
   Kang BR, 2016, SCI REP-UK, V6, DOI 10.1038/srep34922
   Kugimiya N, 2015, J CELL MOL MED, V19, P1569, DOI 10.1111/jcmm.12531
   Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005
   Moscat J, 2016, CELL, V167, P606, DOI 10.1016/j.cell.2016.09.030
   Nakamura N, 2005, MOL BIOL CELL, V16, P1696, DOI 10.1091/mbc.E04-03-0216
   Nishimura T, 2017, EMBO J, V36, P1719, DOI 10.15252/embj.201695189
   Oakes SA, 2017, AM J PHYSIOL-CELL PH, V312, pC93, DOI 10.1152/ajpcell.00266.2016
   Pytel D, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006518
   Rani S, 2017, MOL CELLS, V40, P66, DOI 10.14348/molcells.2017.2259
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Rozpedek W, 2016, CURR MOL MED, V16, P533, DOI 10.2174/1566524016666160523143937
   Schlafli AM, 2016, ONCOTARGET, V7, P39544, DOI 10.18632/oncotarget.9647
   Senft D, 2015, TRENDS BIOCHEM SCI, V40, P141, DOI 10.1016/j.tibs.2015.01.002
   Shuda M, 2003, J HEPATOL, V38, P605, DOI 10.1016/S0168-8278(03)00029-1
   Tameire F, 2015, SEMIN CANCER BIOL, V33, P3, DOI 10.1016/j.semcancer.2015.04.002
   Wu HM, 2014, HUM PATHOL, V45, P1936, DOI 10.1016/j.humpath.2014.04.023
   Wu XB, 2014, NAT BIOTECHNOL, V32, P670, DOI 10.1038/nbt.2889
   Xia D, 2016, AUTOPHAGY, V12, P1614, DOI 10.1080/15548627.2016.1192752
   Xie YX, 2016, SCI REP-UK, V6, DOI 10.1038/srep38832
   Xue Z, 2011, J BIOL CHEM, V286, P30859, DOI 10.1074/jbc.M111.273714
   Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200
   Zheng HC, 2008, HUM PATHOL, V39, P1042, DOI 10.1016/j.humpath.2007.11.009
NR 41
TC 11
Z9 12
U1 3
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JUL
PY 2017
VL 8
AR e2957
DI 10.1038/cddis.2017.347
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FC5GR
UT WOS:000406870400046
PM 28749466
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Su, ZY
   Yang, ZZ
   Xu, YQ
   Chen, YB
   Yu, Q
AF Su, Zhenyi
   Yang, Zuozhang
   Xu, Yongqing
   Chen, Yongbin
   Yu, Qiang
TI MicroRNAs in apoptosis, autophagy and necroptosis
SO ONCOTARGET
LA English
DT Article
DE microRNA; apoptosis; autophagy; necroptosis; cancer progression
ID HEPATOCELLULAR-CARCINOMA CELLS; SUPPRESSES TUMOR-GROWTH; BREAST-CANCER
   CELLS; BCL-X-L; PROMOTES APOPTOSIS; COLORECTAL-CANCER; DOWN-REGULATION;
   PANCREATIC-CANCER; SIGNALING PATHWAYS; MEDIATED CLEAVAGE
AB MicroRNAs (miRNAs) are endogenous 22 nt non-coding RNAs that target mRNAs for cleavage or translational repression. Numerous miRNAs regulate programmed cell death including apoptosis, autophagy and necroptosis. We summarize how miRNAs regulate apoptotic, autophagic and necroptotic pathways and cancer progression. We also discuss how miRNAs link different types of cell death.
C1 [Su, Zhenyi] Southeast Univ, Sch Med, Dept Biochem & Mol Biol, Nanjing 210009, Jiangsu, Peoples R China.
   [Su, Zhenyi] Harvard Univ, Dept Cell Biol, Sch Med, Boston, MA 02115 USA.
   [Yang, Zuozhang] Kunming Med Univ, Tumor Hosp Yunnan Prov, Bone & Soft Tissue Tumors Res Ctr Yunnan Prov, Dept Orthopaed,Affiliated Hosp 3, Kunming 650118, Yunnan, Peoples R China.
   [Xu, Yongqing] Chengdu Mil Command, Kunming Gen Hosp, Dept Orthopaed, Kunming 650118, Yunnan, Peoples R China.
   [Chen, Yongbin] Chinese Acad Sci, Kunming Inst Zool, Key Lab Anim Models & Human Dis Mech, Kunming 650223, Yunnan, Peoples R China.
   [Yu, Qiang] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China.
RP Yang, ZZ (corresponding author), Kunming Med Univ, Tumor Hosp Yunnan Prov, Bone & Soft Tissue Tumors Res Ctr Yunnan Prov, Dept Orthopaed,Affiliated Hosp 3, Kunming 650118, Yunnan, Peoples R China.
EM yangzuozhang@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81460440, 31300666, 81260322, 81372322];
   Natural Science Foundation of Yunnan ProvinceNatural Science Foundation
   of Yunnan Province [2012FB163]; Joint Special Funds for the Department
   of Science and Technology of Yunnan Province-Kunming Medical University
   [2014FB059]; Specialty Fund of High-level Talents Medical Personnel
   Training of Yunnan Province [D-201242]
FX This research was supported in part by grants from the National Natural
   Science Foundation of China (No. 81460440, No. 31300666, No. 81260322,
   and No. 81372322), the Natural Science Foundation of Yunnan Province
   (No. 2012FB163), the Joint Special Funds for the Department of Science
   and Technology of Yunnan Province-Kunming Medical University (No.
   2014FB059), and the Specialty Fund of High-level Talents Medical
   Personnel Training of Yunnan Province (No. D-201242).
CR Abend JR, 2010, J VIROL, V84, P12139, DOI 10.1128/JVI.00884-10
   Alahari SK., 2013, REGULATION METASTASI, P81
   Alajez NM, 2011, CANCER RES, V71, P2381, DOI 10.1158/0008-5472.CAN-10-2754
   Barlev NA, 2010, CELL DEATH DIFFER, V17, P373, DOI 10.1038/cdd.2009.73
   Behrman S, 2011, J CELL BIOL, V192, P919, DOI 10.1083/jcb.201010055
   Bhutia SK, 2010, CANCER RES, V70, P3667, DOI 10.1158/0008-5472.CAN-09-3647
   Bian K, 2012, FEBS LETT, V586, P804, DOI 10.1016/j.febslet.2012.01.050
   Cai N, 2013, RNA, V19, P85, DOI 10.1261/rna.035295.112
   Cai ZY, 2014, NAT CELL BIOL, V16, P55, DOI 10.1038/ncb2883
   Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035
   Chan FK-M, 2014, PROGRAMMED NECROSIS, P211
   Chang Y, 2012, GASTROENTEROLOGY, V143, P177, DOI 10.1053/j.gastro.2012.04.009
   Chen F, 2010, ONCOL REP, V23, P1457, DOI 10.3892/or_00000784
   Chen HY, 2012, CANCER RES, V72, P3631, DOI 10.1158/0008-5472.CAN-12-0667
   Chen Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.92
   Chitnis NS, 2012, MOL CELL, V48, P353, DOI 10.1016/j.molcel.2012.08.025
   Cimino D, 2013, FASEB J, V27, P1223, DOI 10.1096/fj.12-214692
   Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102
   Comincini S, 2013, CANCER BIOL THER, V14, P574, DOI 10.4161/cbt.24597
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711
   Deng M, 2011, J CELL SCI, V124, P2997, DOI 10.1242/jcs.085050
   Ding J, 2013, HEPATOLOGY, V58, P654, DOI 10.1002/hep.26378
   Dontula R, 2013, GENES CANC
   Donzelli Sara, 2014, Oncoscience, V1, P427
   Fang J, 2012, APOPTOSIS, V17, P410, DOI 10.1007/s10495-011-0683-0
   Favreau AJ., 2013, BLOOD, V122, P3811, DOI [10.1182/blood.V122.21.3811.3811, DOI 10.1182/BLOOD.V122.21.3811.3811]
   Feoktistova M, 2011, MOL CELL, V43, P449, DOI 10.1016/j.molcel.2011.06.011
   Fornari F, 2010, CANCER RES, V70, P5184, DOI 10.1158/0008-5472.CAN-10-0145
   Frankel LB, 2012, CARCINOGENESIS, V33, P2018, DOI 10.1093/carcin/bgs266
   Frankel LB, 2011, EMBO J, V30, P4628, DOI 10.1038/emboj.2011.331
   Fujita N, 2008, MOL BIOL CELL, V19, P2092, DOI 10.1091/mbc.E07-12-1257
   Guennewig B, 2014, RNA, V20, P61, DOI 10.1261/rna.038968.113
   Guo QY, 2013, BLOOD, V121, P4875, DOI 10.1182/blood-2012-08-452425
   Hamada S, 2014, CELL SIGNAL, V26, P179, DOI 10.1016/j.cellsig.2013.11.003
   Hatley ME, 2010, CANCER CELL, V18, P282, DOI 10.1016/j.ccr.2010.08.013
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021
   Hirata H, 2012, CARCINOGENESIS, V33, P41, DOI 10.1093/carcin/bgr239
   Hobbs RG, 2014, INT VACUUM NANOELECT
   Hu WW, 2010, MOL CELL, V38, P689, DOI 10.1016/j.molcel.2010.05.027
   Huang GX, 2012, CANCER RES, V72, P908, DOI 10.1158/0008-5472.CAN-11-1460
   Huang YP, 2012, CELL CYCLE, V11, P1247, DOI 10.4161/cc.11.6.19670
   Huang Y, 2011, J PHYSIOL BIOCHEM, V67, P129, DOI 10.1007/s13105-010-0050-6
   Hudson RS, 2013, ONCOGENE, V32, P4139, DOI 10.1038/onc.2012.424
   Huse JT, 2009, GENE DEV, V23, P1327, DOI 10.1101/gad.1777409
   Hwang-Verslues WW, 2011, ONCOGENE, V30, P2463, DOI 10.1038/onc.2010.618
   Ichimura A, 2010, MOL PHARM
   Ichimura Y, 2010, SEMIN IMMUNOPATHOL, V32, P431, DOI 10.1007/s00281-010-0220-1
   Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023
   Ji F, 2013, BONE, V56, P220, DOI 10.1016/j.bone.2013.05.020
   Jiang LL, 2012, J CLIN INVEST, V122, P33, DOI 10.1172/JCI58849
   Jin L, 2011, P NATL ACAD SCI USA, V108, P15840, DOI 10.1073/pnas.1019312108
   Ju JA, 2013, BIOMARK GENOM MED, V5, P74, DOI 10.1016/j.bgm.2013.07.006
   Kato M, 2009, NAT CELL BIOL, V11, P881, DOI 10.1038/ncb1897
   Keklikoglou I, 2012, ONCOGENE, V31, P4150, DOI 10.1038/onc.2011.571
   Korkmaz G, 2012, AUTOPHAGY, V8, P165, DOI 10.4161/auto.8.2.18351
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843
   Lan SH, 2014, HEPATOLOGY, V59, P505, DOI 10.1002/hep.26659
   Le MTN, 2009, GENE DEV, V23, P862, DOI 10.1101/gad.1767609
   Lee JS, 2009, NAT CELL BIOL, V11, P1355, DOI 10.1038/ncb1980
   Legakis JE, 2007, AUTOPHAGY, V3, P422, DOI 10.4161/auto.4129
   Li Haoran, 2014, Oncoscience, V1, P531
   Li Haoran, 2014, Oncoscience, V1, P3
   Li Jun-cai, 2010, Xibei Zhiwu Xuebao, V30, P30
   Li Q, 2013, SCI REPORTS, P3
   Li ZJ, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1681
   Liao WT, 2014, J PATHOL, V232, P415, DOI 10.1002/path.4309
   Lima RT, 2011, EUR J CANCER, V47, P163, DOI 10.1016/j.ejca.2010.11.005
   Liu J, 2011, J CELL MOL MED, V15, P1474, DOI 10.1111/j.1582-4934.2010.01104.x
   Lorin S, 2013, SEMIN CANCER BIOL, V23, P361, DOI 10.1016/j.semcancer.2013.06.007
   Lu C, 2012, J IMMUNOL, V188, p[172, 141]
   Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001
   Martin Elizabeth C, 2014, Genes Cancer, V5, P353
   Meijer AJ, 2011, CURR BIOL, V21, pR227, DOI 10.1016/j.cub.2011.02.007
   Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022
   Menghini R, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.556
   Mikhaylova O, 2012, CANCER CELL, V21, P532, DOI 10.1016/j.ccr.2012.02.019
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Mouw JK, 2014, NAT MED, V20, P360, DOI 10.1038/nm.3497
   Nakano H, 2010, INT J CANCER, V127, P1072, DOI 10.1002/ijc.25143
   Ninio-Many Lihi, 2014, Oncoscience, V1, P250
   Oberst A, 2011, NATURE, V471, P363, DOI 10.1038/nature09852
   Oneyama C, 2011, ONCOGENE, V30, P3489, DOI 10.1038/onc.2011.63
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Png KJ, 2012, NATURE, V481, P190, DOI 10.1038/nature10661
   Razumilava N, 2012, HEPATOLOGY, V55, P465, DOI 10.1002/hep.24698
   Rossato M, 2012, P NATL ACAD SCI USA, V109, pE3101, DOI 10.1073/pnas.1209100109
   Russell RC, 2014, CELL RES, V24, P42, DOI 10.1038/cr.2013.166
   Sacconi A, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.160
   Sanchez-Diaz Patricia C, 2014, Oncoscience, V1, P599
   Shi Y, 2014, CLIN CANCER RES, V20, P1803, DOI 10.1158/1078-0432.CCR-13-2284
   Siegel C, 2011, P NATL ACAD SCI USA, V108, P11662, DOI 10.1073/pnas.1102635108
   Singh R, 2011, CELL METAB, V13, P495, DOI 10.1016/j.cmet.2011.04.004
   Srivastava N, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2861
   Srivastava R., 2007, APOPTOSIS CELL SIGNA
   Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031
   Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199
   Swarbrick A, 2010, NAT MED, V16, P1134, DOI 10.1038/nm.2227
   Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184
   Tsang WP, 2008, APOPTOSIS, V13, P1215, DOI 10.1007/s10495-008-0256-z
   Tsukamoto Y, 2010, CANCER RES, V70, P2339, DOI 10.1158/0008-5472.CAN-09-2777
   Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047
   Verbrugge I, 2010, CELL, V143, P1192, DOI 10.1016/j.cell.2010.12.004
   Walker JC, 2009, GENE DEV, V23, P1046, DOI 10.1101/gad.1777709
   Wang F, 2013, STEM CELL RES, V11, P657, DOI 10.1016/j.scr.2013.04.005
   Wang HQ, 2011, J PATHOL, V225, P232, DOI 10.1002/path.2931
   Wang JX, 2011, NAT MED, V17, P71, DOI 10.1038/nm.2282
   Wang JL, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003697
   Wang K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.233
   Wang L, 2012, FEBS LETT, V586, P1312, DOI 10.1016/j.febslet.2012.03.035
   Wang P, 2013, GASTROENTEROLOGY, V145, P1133, DOI 10.1053/j.gastro.2013.07.048
   Wang P, 2013, MOL ONCOL, V7, P334, DOI 10.1016/j.molonc.2012.10.011
   Wang SY, 2011, INT J BIOCHEM CELL B, V43, P1263, DOI 10.1016/j.biocel.2011.05.010
   Wang ZG, 2012, CELL, V148, P228, DOI 10.1016/j.cell.2011.11.030
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   Wirawan E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.16
   Wu H, 2012, CELL SIGNAL, V24, P2179, DOI 10.1016/j.cellsig.2012.07.001
   Xie Y, 2013, ONCOGENE, V32, P2442, DOI 10.1038/onc.2012.258
   Xu CQ, 2007, J CELL SCI, V120, P3045, DOI 10.1242/jcs.010728
   Xu CX, 2012, J BIOL CHEM, V287, P34970, DOI 10.1074/jbc.M112.374611
   Yamada N, 2014, BBA-MOL CELL RES, V1843, P590, DOI 10.1016/j.bbamcr.2013.11.022
   Yang G, 2013, ONCOL REP, V30, P877, DOI 10.3892/or.2013.2532
   Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488
   Yang K, 2014, J INFECT DIS, V210, P89, DOI 10.1093/infdis/jiu002
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Ye D, 2012, STEM CELLS, V30, P1645, DOI 10.1002/stem.1149
   Ye HS, 2012, NUCLEIC ACIDS RES, V40, P5201, DOI 10.1093/nar/gks175
   Ying Q, 2011, HEPATOLOGY, V54, P2064, DOI 10.1002/hep.24614
   Yoo J, 2014, CELL DEATH DIFFERENT
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Yu T, 2014, ONCOGENE, V1351, P531
   Yu Y, 2012, AUTOPHAGY, V8, P853, DOI 10.4161/auto.20053
   Zalckvar E, 2009, EMBO REP, V10, P285, DOI 10.1038/embor.2008.246
   Zhang H, 2011, CELL DEATH DIFFER, V18, P1702, DOI 10.1038/cdd.2011.28
   Zhang J, 2010, ONCOL REP, V24, P1217, DOI 10.3892/or_00000975
   Zhang L, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-211
   Zhang Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091546
   Zhao G, 2013, MOL CANCER THER, V12, P83, DOI 10.1158/1535-7163.MCT-12-0534-T
   Zhao N, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-35
   Zhou M, 2010, J BIOL CHEM, V285, P21496, DOI 10.1074/jbc.M109.083337
   Zhou W, 2014, SEMIN CELL DEV BIOL, V35, P14, DOI 10.1016/j.semcdb.2014.07.013
   Zhou W, 2014, CELL, V158, P464, DOI 10.1016/j.cell.2014.06.041
   Zhu H, 2009, AUTOPHAGY, V5, P816, DOI 10.4161/auto.9064
   Zuckerman V, 2009, J PATHOL, V219, P3, DOI 10.1002/path.2584
NR 146
TC 245
Z9 254
U1 6
U2 116
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD APR 20
PY 2015
VL 6
IS 11
BP 8474
EP 8490
DI 10.18632/oncotarget.3523
PG 17
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CN9NB
UT WOS:000358774600005
PM 25893379
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Grossi, V
   Peserico, A
   Tezil, T
   Simone, C
AF Grossi, Valentina
   Peserico, Alessia
   Tezil, Tugsan
   Simone, Cristiano
TI p38 alpha MAPK pathway: A key factor in colorectal cancer therapy and
   chemoresistance
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE p38 mitogen-activated protein kinase; Chemoresistance;
   Molecularly-targeted drugs; Colorectal cancer; Cell death
ID ACTIVATED PROTEIN-KINASE; JUN NH2-TERMINAL KINASE; SIGNAL-REGULATED
   KINASE; AUTOPHAGIC CELL-DEATH; INDUCED APOPTOSIS; OVARIAN-CANCER;
   IN-VITRO; MULTIKINASE INHIBITOR; MAMMARY TUMORIGENESIS; TRANSDUCTION
   PATHWAY
AB Colorectal cancer (CRC) remains one of the most common malignancies in the world. Although surgical resection combined with adjuvant therapy is effective at the early stages of the disease, resistance to conventional therapies is frequently observed in advanced stages, where treatments become ineffective. Resistance to cisplatin, irinotecan and 5-fluorouracil chemotherapy has been shown to involve mitogen-activated protein kinase (MAPK) signaling and recent studies identified p38 alpha MAPK as a mediator of resistance to various agents in CRC patients. Studies published in the last decade showed a dual role for the p38 alpha pathway in mammals. Its role as a negative regulator of proliferation has been reported in both normal (including cardiomyocytes, hepatocytes, fibroblasts, hematopoietic and lung cells) and cancer cells (colon, prostate, breast, lung tumor cells). This function is mediated by the negative regulation of cell cycle progression and the transduction of some apoptotic stimuli. However, despite its anti-proliferative and tumor suppressor activity in some tissues, the p38 alpha pathway may also acquire an oncogenic role involving cancer related-processes such as cell metabolism, invasion, inflammation and angiogenesis. In this review, we summarize current knowledge about the predominant role of the p38 alpha MAPK pathway in CRC development and chemoresistance. In our view, this might help establish the therapeutic potential of the targeted manipulation of this pathway in clinical settings. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
C1 [Grossi, Valentina; Peserico, Alessia; Tezil, Tugsan; Simone, Cristiano] Univ Bari Aldo Moro, Dept Biomed Sci & Human Oncol DIMO, Div Med Genet, I-70124 Bari, Italy.
   [Grossi, Valentina; Peserico, Alessia; Tezil, Tugsan; Simone, Cristiano] IRCCS Oncol Giovanni Paolo II, Natl Canc Inst, I-70124 Bari, Italy.
   [Peserico, Alessia] Fdn Mario Negri Sud, I-66030 Santa Maria Imbaro, CH, Italy.
RP Simone, C (corresponding author), Univ Bari Aldo Moro, Dept Biomed Sci & Human Oncol DIMO, Div Med Genet, Via Nazl 8-A, I-70124 Bari, Italy.
EM simone@negrisud.it
RI tezil, tugsan/P-4053-2019; Simone, Cristiano/K-3452-2018; Tezil,
   Tugsan/A-3909-2013; GROSSI, Valentina/O-6546-2019; Grossi,
   Valentina/K-9821-2016
OI Simone, Cristiano/0000-0002-2628-7658; Tezil,
   Tugsan/0000-0003-0796-3718; GROSSI, Valentina/0000-0003-3843-1618;
   Grossi, Valentina/0000-0003-3843-1618; Peserico,
   Alessia/0000-0003-2025-2419
FU Italian Association for Cancer Research (AIRC) fellowshipFondazione AIRC
   per la ricerca sul cancro; Italian Foundation for Cancer Research (FIRC)
   fellowshipsFondazione AIRC per la ricerca sul cancro; Italian
   Association for Cancer Research (AIRC)Fondazione AIRC per la ricerca sul
   cancro [IG10177]; FIRB "Futuro in Ricerca" from the Italian MIUR
   [RBFR12VP3Q_003]
FX Supported by Italian Association for Cancer Research (AIRC) fellowship
   (to Grossi V); Italian Foundation for Cancer Research (FIRC) fellowships
   (to Peserico A and Tezil T); Investigator Grant 2010 No. IG10177 to
   Simone C from the Italian Association for Cancer Research (AIRC) and by
   FIRB "Futuro in Ricerca" RBFR12VP3Q_003 (to Simone C) from the Italian
   MIUR
CR Adam AP, 2009, CANCER RES, V69, P5664, DOI 10.1158/0008-5472.CAN-08-3820
   Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220
   Alvarado-Kristensson M, 2004, J EXP MED, V199, P449, DOI 10.1084/jem.20031771
   Bakin AV, 2002, J CELL SCI, V115, P3193
   Barancik M, 2001, EUR J PHARM SCI, V14, P29, DOI 10.1016/S0928-0987(01)00139-7
   Benson VS, 2008, INT J CANCER, V122, P1357, DOI 10.1002/ijc.23273
   Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792
   Biondi RM, 2003, BIOCHEM J, V372, P1, DOI 10.1042/BJ20021641
   Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303
   BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220
   Brozovic A, 2007, CANCER LETT, V251, P1, DOI 10.1016/j.canlet.2006.10.007
   Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637
   Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317
   Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894
   Casar B, 2007, EMBO J, V26, P635, DOI 10.1038/sj.emboj.7601523
   Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031
   Chen L, 2009, CANCER RES, V69, P8853, DOI 10.1158/0008-5472.CAN-09-1636
   Chen SS, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0036784, 10.1371/journal.pone.0050456, 10.1371/journal.pone.0045763, 10.1371/journal.pone.0049275]
   Chiacchiera F, 2009, CELL DEATH DIFFER, V16, P1203, DOI 10.1038/cdd.2009.36
   Chiacchiera F, 2008, CANCER LETT, V265, P16, DOI 10.1016/j.canlet.2008.02.061
   Chiacchiera F, 2012, CANCER LETT, V324, P98, DOI 10.1016/j.canlet.2012.05.006
   Chiacchiera F, 2010, CELL CYCLE, V9, P1091, DOI 10.4161/cc.9.6.11035
   Chiacchiera F, 2009, AUTOPHAGY, V5, P1030, DOI 10.4161/auto.5.7.9252
   Ciesielski-Treska J, 2001, J BIOL CHEM, V276, P13113, DOI 10.1074/jbc.M009711200
   Comes F, 2007, CELL DEATH DIFFER, V14, P693, DOI 10.1038/sj.cdd.4402076
   Corcelle E, 2007, AUTOPHAGY, V3, P57, DOI 10.4161/auto.3424
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Cuadrado A, 2010, BIOCHEM J, V429, P403, DOI 10.1042/BJ20100323
   Cuenda A, 2007, BBA-MOL CELL RES, V1773, P1358, DOI 10.1016/j.bbamcr.2007.03.010
   Dal Lago L, 2008, ONCOLOGIST, V13, P845, DOI 10.1634/theoncologist.2007-0233
   De Robertis Mariangela, 2011, J Carcinog, V10, P9, DOI 10.4103/1477-3163.78279
   De Zutter GS, 2001, P NATL ACAD SCI USA, V98, P6168, DOI 10.1073/pnas.111027698
   Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468
   Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5
   Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421
   Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013
   Dolado Ignacio, 2008, V20, P99, DOI 10.1007/4735_2007_0245
   Edlund S, 2003, MOL BIOL CELL, V14, P529, DOI 10.1091/mbc.02-03-0037
   Emerling BM, 2005, MOL CELL BIOL, V25, P4853, DOI 10.1128/MCB.25.12.4853-4862.2005
   Esteva FJ, 2004, CANCER-AM CANCER SOC, V100, P499, DOI 10.1002/cncr.11940
   Ferry KV, 2000, BIOCHEM PHARMACOL, V60, P1305, DOI 10.1016/S0006-2952(00)00441-X
   Filomia F, 2010, BIOORGAN MED CHEM, V18, P6805, DOI 10.1016/j.bmc.2010.07.047
   Germani A, 2014, CANCER LETT, V344, P110, DOI 10.1016/j.canlet.2013.10.035
   Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335
   Gill K, 2013, BBA-GEN SUBJECTS, V1830, P2763, DOI 10.1016/j.bbagen.2012.12.001
   Gout S, 2006, CANCER RES, V66, P9117, DOI 10.1158/0008-5472.CAN-05-4605
   Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014
   Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610
   Grossi V, 2012, J ONCOL, V2012, DOI 10.1155/2012/382159
   Grossi V, 2012, CANCER BIOL THER, V13, P1471, DOI 10.4161/cbt.22254
   Haigis KM, 2008, NAT GENET, V40, P600, DOI 10.1038/ng.115
   Halawani D, 2004, ONCOGENE, V23, P3726, DOI 10.1038/sj.onc.1207422
   Han SJ, 1998, J BIOL CHEM, V273, P369, DOI 10.1074/jbc.273.1.369
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833
   Hawk ET, 2003, PROG EXP TUMOR RES, V37, P210
   Hideshima T, 2004, ONCOGENE, V23, P8766, DOI 10.1038/sj.onc.1208118
   Hsieh YH, 2007, CANCER RES, V67, P4320, DOI 10.1158/0008-5472.CAN-06-2486
   Hui LJ, 2007, NAT GENET, V39, P741, DOI 10.1038/ng2033
   Im JS, 2008, J BIOL CHEM, V283, P25171, DOI 10.1074/jbc.M802851200
   Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Jin SK, 2008, AUTOPHAGY, V4, P563, DOI 10.4161/auto.5830
   Junttila MR, 2007, ONCOGENE, V26, P5267, DOI 10.1038/sj.onc.1210332
   Junttila MR, 2008, FASEB J, V22, P954, DOI 10.1096/fj.06-7859rev
   Katano K, 2002, CANCER RES, V62, P6559
   Keil E, 2013, CELL DEATH DIFFER, V20, P321, DOI 10.1038/cdd.2012.129
   Kemp Z, 2004, HUM MOL GENET, V13, pR177, DOI 10.1093/hmg/ddh247
   Kim MJ, 2008, MOL CANCER RES, V6, P1718, DOI 10.1158/1541-7786.MCR-08-0032
   Kim MS, 2003, CANCER RES, V63, P5454
   Krajewska M, 1996, CANCER RES, V56, P2422
   Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Kufareva I, 2008, J MED CHEM, V51, P7921, DOI 10.1021/jm8010299
   Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807
   Kyriakis JM, 2012, PHYSIOL REV, V92, P689, DOI 10.1152/physrev.00028.2011
   Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751
   LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0
   Lee MR, 2005, CURR MED CHEM, V12, P2979, DOI 10.2174/092986705774462914
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888
   Li SP, 2003, CANCER RES, V63, P3473
   Limami Y, 2011, BIOCHIMIE, V93, P749, DOI 10.1016/j.biochi.2011.01.003
   Lin SP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049605
   Lin SP, 2013, CANCER LETT, V328, P226, DOI 10.1016/j.canlet.2012.08.036
   Mackay K, 1999, J BIOL CHEM, V274, P6272, DOI 10.1074/jbc.274.10.6272
   Madia Federica, 2012, Cells, V1, P535, DOI 10.3390/cells1030535
   Marengo B, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.118
   Marin JJG, 2012, DRUG METAB REV, V44, P148, DOI 10.3109/03602532.2011.638303
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Matrone A, 2010, INT J GYNECOL CANCER, V20, P203, DOI 10.1111/IGC.0b013e3181c8ca12
   Medicherla S, 2008, ANTICANCER RES, V28, P3827
   Minet E, 2001, FREE RADICAL BIO MED, V31, P847, DOI 10.1016/S0891-5849(01)00657-8
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Montagut C, 2009, CANCER LETT, V283, P125, DOI 10.1016/j.canlet.2009.01.022
   Namboodiri HV, 2010, BIOCHEMISTRY-US, V49, P3611, DOI 10.1021/bi100070r
   Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4
   Nelyudova A, 2007, CELL CYCLE, V6, P2171, DOI 10.4161/cc.6.17.4610
   Nicke B, 2005, MOL CELL, V20, P673, DOI 10.1016/j.molcel.2005.10.038
   OZOLS RF, 1991, CANCER TREAT REV, V18, P77, DOI 10.1016/0305-7372(91)90027-W
   Paillas S, 2012, AUTOPHAGY, V8, P1098, DOI 10.4161/auto.20268
   Paillas S, 2011, CANCER RES, V71, P1041, DOI 10.1158/0008-5472.CAN-10-2726
   Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200
   Perdiguero E, 2007, CELL CYCLE, V6, P1298, DOI 10.4161/cc.6.11.4315
   Pereira L, 2013, EMBO MOL MED, V5, P1759, DOI 10.1002/emmm.201302732
   PETRELLI N, 1989, J CLIN ONCOL, V7, P1419, DOI 10.1200/JCO.1989.7.10.1419
   Placzek WJ, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.18
   Porras A, 2004, MOL BIOL CELL, V15, P922, DOI 10.1091/mbc.E03-08-0592
   Qi XM, 2004, J BIOL CHEM, V279, P22138, DOI 10.1074/jbc.M313964200
   Rabik CA, 2007, CANCER TREAT REV, V33, P9, DOI 10.1016/j.ctrv.2006.09.006
   Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967
   Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200
   Ranganathan AC, 2006, CELL CYCLE, V5, P1799, DOI 10.4161/cc.5.16.3109
   Remenyi A, 2005, MOL CELL, V20, P951, DOI 10.1016/j.molcel.2005.10.030
   Ricote M, 2006, J PATHOL, V208, P401, DOI 10.1002/path.1910
   ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1
   Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004
   Salvador JM, 2005, NAT IMMUNOL, V6, P396, DOI 10.1038/ni1176
   Sanz V, 2000, FEBS LETT, V474, P169, DOI 10.1016/S0014-5793(00)01598-2
   Saurin AT, 2000, FASEB J, V14, P2237, DOI 10.1096/fj.99-0671com
   Schindler EM, 2009, CANCER RES, V69, P4648, DOI 10.1158/0008-5472.CAN-08-4455
   Schreiber S, 2006, CLIN GASTROENTEROL H, V4, P325, DOI 10.1016/j.cgh.2005.11.013
   Seifert A, 2009, CELL SIGNAL, V21, P1626, DOI 10.1016/j.cellsig.2009.06.009
   SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0
   Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276
   Simone C, 2007, AUTOPHAGY, V3, P468, DOI 10.4161/auto.4319
   Strumberg D, 2012, BRIT J CANCER, V106, P1722, DOI 10.1038/bjc.2012.153
   Strumberg D, 2012, EXPERT OPIN INV DRUG, V21, P879, DOI 10.1517/13543784.2012.684752
   Suarez-Cuervo C, 2004, CLIN EXP METASTAS, V21, P525, DOI 10.1007/s10585-004-3503-x
   Tront JS, 2006, CANCER RES, V66, P8448, DOI 10.1158/0008-5472.CAN-06-2013
   Vachon PH, 2002, GASTROENTEROLOGY, V123, P1980, DOI 10.1053/gast.2002.37072
   Valladares A, 2000, ENDOCRINOLOGY, V141, P4383, DOI 10.1210/en.141.12.4383
   VENERONI S, 1994, EUR J CANCER, V30A, P1002, DOI 10.1016/0959-8049(94)90132-5
   Ventura JJ, 2007, NAT GENET, V39, P750, DOI 10.1038/ng2037
   Voisset E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078911
   vom Dahl S, 2001, BIOCHEM J, V354, P31, DOI 10.1042/0264-6021:3540031
   Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694
   Wang SN, 2012, EUR J CLIN INVEST, V42, P1295, DOI 10.1111/eci.12003
   Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232
   Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002
   Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161
   Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262
   Webber JL, 2010, EMBO J, V29, P27, DOI 10.1038/emboj.2009.321
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   Wen HC, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001684
   Wen JG, 2010, LEUKEMIA RES, V34, P85, DOI 10.1016/j.leukres.2009.05.024
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   White E, 2009, GENE DEV, V23, P784, DOI 10.1101/gad.1795309
   Wilhelm S, 2006, NAT REV DRUG DISCOV, V5, P835, DOI 10.1038/nrd2130
   Wilhelm SM, 2008, MOL CANCER THER, V7, P3129, DOI 10.1158/1535-7163.MCT-08-0013
   Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443
   Willett CG, 2009, J CLIN ONCOL, V27, P3020, DOI 10.1200/JCO.2008.21.1771
   Wilson KP, 1996, J BIOL CHEM, V271, P27696, DOI 10.1074/jbc.271.44.27696
   Wolfman JC, 2002, MOL CELL BIOL, V22, P1589, DOI 10.1128/MCB.22.5.1589-1606.2002
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Yagasaki Y, 2004, FEBS LETT, V575, P136, DOI 10.1016/j.febslet.2004.08.050
   Yang SY, 2011, INT J ONCOL, V38, P1695, DOI 10.3892/ijo.2011.982
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
   Yu W, 2007, ONCOGENE, V26, P1178, DOI 10.1038/sj.onc.1209899
   Zhang CL, 2010, BIOCHEM BIOPH RES CO, V394, P976, DOI 10.1016/j.bbrc.2010.03.102
   ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0
   ZHANG ZG, 1992, SEMIN ONCOL, V19, P4
   Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200
   Zuluaga S, 2007, CELL SIGNAL, V19, P62, DOI 10.1016/j.cellsig.2006.05.032
NR 164
TC 146
Z9 152
U1 0
U2 27
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD AUG 21
PY 2014
VL 20
IS 29
BP 9744
EP 9758
DI 10.3748/wjg.v20.i29.9744
PG 15
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA AN6TK
UT WOS:000340730300009
PM 25110412
OA hybrid, Green Published
DA 2022-04-25
ER

PT J
AU Ma, YM
   Han, W
   Li, J
   Hu, LH
   Zhou, YB
AF Ma, Yi-ming
   Han, Wei
   Li, Jia
   Hu, Li-hong
   Zhou, Yu-bo
TI Physalin B not only inhibits the ubiquitin-proteasome pathway but also
   induces incomplete autophagic response in human colon cancer cells in
   vitro
SO ACTA PHARMACOLOGICA SINICA
LA English
DT Article
DE physalin B; Physalis angulata L; HCT116 colon cancer cells; autophagy;
   reactive oxygen species; p38 mitogen-activated protein kinases;
   microtubule-associated proteins; apoptosis; ubiquitins;
   N-acetyl-L-cysteine
ID BIOLOGICAL EVALUATION; APOPTOSIS; DIFFERENTIATION; PROTEIN; STRESS;
   DESIGN; FUSION; ARREST; SYSTEM; ROLES
AB Aim: To investigate the effects of physalin B insolated from Physalis divericata on human colon cancer cells in vitro and its anticancer mechanisms.
   Methods: Human HCT116 colon cancer cell line was tested. Cell viability and apoptosis were detected, and relevant proteins were measured using Western blot analyses. Autophagosomes were observed in stable GFP-LC3 HCT116 cells. Localization of autophagosomes and lysosomes was evaluated in GFP-LC3/RFP-LAMP1-co-transfected cells. Microtubules and F-actin microfilaments were observed with confocal microscope. Mitochondrial ROS (mito-ROS) was detected with flow cytometry in the cells stained with MitoSox dye.
   Results: Physalin B inhibited the viability of HCT116 cells with an IC50 value of 1.35 mu mol/L. Treatment of the cells with physalin B (2.5-10 mu mol/L) induced apoptosis and the cleavage of PARP and caspase-3. Meanwhile, physalin B treatment induced autophagosome formation, and accumulation of LC3-II and p62, but decreased Beclin 1 protein level. Marked changes of microtubules and F-actin microfilaments were observed in physalin B-treated cells, which led to the blockage of co-localization of autophagosomes and lysosomes. Physalin B treatment dose-dependently increased the phosphorylation of p38, ERK and JNK in the cells, whereas the p38 inhibitor SB202190, ERK inhibitor U0126 or JNK inhibitor SP600125 could partially reduce physalin B-induced PARP cleavage and p62 accumulation. Moreover, physalin B treatment dose-dependently increased mito-ROS production in the cells, whereas the ROS scavenger NAC could reverse physalin B-induced effects, including incomplete autophagic response, accumulation of ubiquitinated proteins, changes of microtubules and F-actin, activation of p38, ERK and JNK, as well as cell death and apoptosis.
   Conclusion: Physalin B induces mito-ROS, which not only inhibits the ubiquitin-proteasome pathway but also induces incomplete autophagic response in HCT116 cells in vitro.
C1 [Ma, Yi-ming; Han, Wei; Li, Jia; Hu, Li-hong; Zhou, Yu-bo] Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Mat Med, Natl Ctr Drug Screening, Shanghai 201203, Peoples R China.
RP Hu, LH (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Mat Med, Natl Ctr Drug Screening, Shanghai 201203, Peoples R China.
EM lhhu@simm.ac.cn; ybzhou@simm.ac.cn
RI Ma, Yiming/AAG-3479-2019; Li, Jia/F-9116-2011
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81473244, 81270942, 81125023]; National
   Science and Technology Major Projects for "Major New Drugs Innovation
   and Development" [2012ZX09301001-004, 2013ZX09508104]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No 81473244, 81270942, and 81125023), and the
   National Science and Technology Major Projects for "Major New Drugs
   Innovation and Development" (2012ZX09301001-004, 2013ZX09508104).
CR Aiken CT, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.006924
   Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4
   BOLWELL BJ, 1988, LEUKEMIA, V2, P253
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Can G, 2011, HEMATOLOGY, V16, P95, DOI 10.1179/102453311X12902908412039
   Cerella Claudia, 2013, Int J Cell Biol, V2013, P639401, DOI 10.1155/2013/639401
   Chang KH, 2013, ONCOL LETT, V6, P1435, DOI 10.3892/ol.2013.1548
   Cheong H, 2012, NAT BIOTECHNOL, V30, P671, DOI 10.1038/nbt.2285
   da Rocha Adriana B., 2001, Current Opinion in Pharmacology, V1, P364
   Ding WX, 2007, AM J PATHOL, V171, P513, DOI 10.2353/ajpath.2007.070188
   Djavaheri-Mergny M, 2010, ONCOGENE, V29, P1717, DOI 10.1038/onc.2009.519
   Dong QH, 2013, INT J MOL MED, V31, P1305, DOI 10.3892/ijmm.2013.1327
   dos Santos RA, 2008, BIOCELL, V32, P195
   Ge PF, 2009, ACTA PHARMACOL SIN, V30, P1046, DOI 10.1038/aps.2009.71
   Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959-8049(98)00228-7
   He H, 2013, J ETHNOPHARMACOL, V148, P544, DOI 10.1016/j.jep.2013.04.051
   Jahreiss L, 2008, TRAFFIC, V9, P574, DOI 10.1111/j.1600-0854.2008.00701.x
   JORDAN MA, 1985, CANCER RES, V45, P2741
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Lao J, 2013, J DRUG DELIV, V2013, DOI 10.1155/2013/456409
   Lee JY, 2010, EMBO J, V29, P969, DOI 10.1038/emboj.2009.405
   Liu G, 2008, CHEMMEDCHEM, V3, P74, DOI 10.1002/cmdc.200700214
   Ma L, 2007, TETRAHEDRON LETT, V48, P449, DOI 10.1016/j.tetlet.2006.11.081
   Ma YM, 2012, ACTA PHARMACOL SIN, V33, P407, DOI 10.1038/aps.2011.176
   Magalhaes HIF, 2006, J PHARM PHARMACOL, V58, P235, DOI 10.1211/jpp.58.2.0011
   MATSUURA T, 1970, J CHEM SOC C, P664, DOI 10.1039/j39700000664
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Monastyrska I, 2009, BIOL REV, V84, P431, DOI 10.1111/j.1469-185X.2009.00082.x
   Perez LM, 2006, FREE RADICAL BIO MED, V40, P2005, DOI 10.1016/j.freeradbiomed.2006.01.034
   Russell RC, 2014, CELL RES, V24, P42, DOI 10.1038/cr.2013.166
   Scherz-Shouval R, 2007, TRENDS CELL BIOL, V17, P422, DOI 10.1016/j.tcb.2007.07.009
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   SLICHENMYER WJ, 1991, ANTI-CANCER DRUG, V2, P519, DOI 10.1097/00001813-199112000-00002
   Son Yong, 2011, J Signal Transduct, V2011, P792639, DOI 10.1155/2011/792639
   Sterz J, 2008, EXPERT OPIN INV DRUG, V17, P879, DOI [10.1517/13543784.17.6.879, 10.1517/13543784.17.6.879 ]
   Sukumari-Ramesh Sangeetha, 2011, Surg Neurol Int, V2, P22, DOI 10.4103/2152-7806.77029
   Tai WY, 2011, CHEMMEDCHEM, V6, P1555, DOI 10.1002/cmdc.201100164
   Teicher BA, 1999, CLIN CANCER RES, V5, P2638
   Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005
   Vandenberghe I, 2008, BIOCHEM PHARMACOL, V76, P453, DOI 10.1016/j.bcp.2008.05.031
   Webb JL, 2004, INT J BIOCHEM CELL B, V36, P2541, DOI 10.1016/j.biocel.2004.02.003
   Wong CH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009996
   Xu Y, 2002, ANN ONCOL, V13, P1841, DOI 10.1093/annonc/mdf337
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yao Tso-Pang, 2010, Genes Cancer, V1, P779
   Zang Y, 2008, J BIOL CHEM, V283, P6201, DOI 10.1074/jbc.M708619200
   Zang Y, 2009, J BIOL CHEM, V284, P6175, DOI 10.1074/jbc.M806887200
   Zhu K, 2010, ONCOGENE, V29, P451, DOI 10.1038/onc.2009.343
   Zolk O, 2006, CARDIOVASC RES, V70, P410, DOI 10.1016/j.cardiores.2005.12.021
NR 50
TC 21
Z9 25
U1 0
U2 24
PU ACTA PHARMACOLOGICA SINICA
PI SHANGHAI
PA 294 TAI-YUAN RD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1671-4083
EI 1745-7254
J9 ACTA PHARMACOL SIN
JI Acta Pharmacol. Sin.
PD APR
PY 2015
VL 36
IS 4
BP 517
EP 527
DI 10.1038/aps.2014.157
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA CE9ZW
UT WOS:000352203300012
PM 25832431
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Wang, LJ
   Chen, PR
   Hsu, LP
   Hsu, WL
   Liu, DW
   Chang, CH
   Hsu, YC
   Lee, JW
AF Wang, Ling-Jung
   Chen, Peir-Rong
   Hsu, Lee-Ping
   Hsu, Wen-Lin
   Liu, Dai-Wei
   Chang, Chung-Hsing
   Hsu, Yih-Chih
   Lee, Jeng-Woei
TI Concomitant Induction of Apoptosis and Autophagy by Prostate Apoptosis
   Response-4 in Hypopharyngeal Carcinoma Cells
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID TUMOR-SUPPRESSOR PAR-4; COLON-CANCER CELLS; PROTEIN-KINASE; MAMMALIAN
   AUTOPHAGY; INHIBITS AUTOPHAGY; MEDIATED CLEAVAGE; CYCLIN D1; EXPRESSION;
   DEATH; PHOSPHORYLATION
AB The tumor-suppressive activity of prostate apoptosis response-4 (Par-4) has been demonstrated in a variety of human cancers. In this study, for the first time to our knowledge, we demonstrated that a higher intensity of Par-4 was significantly correlated with a better response in patients with hypopharyngeal carcinoma undergoing radiotherapy alone or concurrent chemoradiotherapy. Mechanistically, an elevated expression of Par-4 induced apoptosis of hypopharyngeal carcinoma cells and sensitized cells toward chemotherapeutic agents or X-ray irradiation. Along with apoptotic incitation, intriguingly, autophagic flux also increased on Par-4 stimulation and contributed to cell death. Moreover, the expressions of multiple common regulators involved in apoptosis and autophagy were regulated by Par-4. Taken together, our results suggested a prognostic role of Par-4 in hypopharyngeal carcinoma and showed novel activity of Par-4 in apoptosis and autophagy induction.
C1 [Wang, Ling-Jung; Lee, Jeng-Woei] Tzu Chi Univ, Inst Med Sci, Hualien 97004, Taiwan.
   [Chen, Peir-Rong] Tzu Chi Univ, Dept Otolaryngol, Hualien 97004, Taiwan.
   [Lee, Jeng-Woei] Tzu Chi Univ, Dept Life Sci, Hualien 97004, Taiwan.
   [Hsu, Wen-Lin; Liu, Dai-Wei] Tzu Chi Univ, Sch Med, Hualien 97004, Taiwan.
   [Hsu, Lee-Ping] Buddhist Tzu Chi Gen Hosp, Dept Otorhinolaryngol, Taichung, Taiwan.
   [Hsu, Wen-Lin; Liu, Dai-Wei] Buddhist Tzu Chi Gen Hosp, Dept Radiat Oncol, Hualien, Taiwan.
   [Chang, Chung-Hsing] Kaohsiung Med Univ, Res Ctr Excellence Environm Med, Kaohsiung, Taiwan.
   [Chang, Chung-Hsing] Kaohsiung Med Univ, Dept Dermatol, Kaohsiung, Taiwan.
   [Hsu, Yih-Chih] Chung Yuan Christian Univ, Dept Biosci Technol, Tao Yuan, Taiwan.
   [Hsu, Yih-Chih] Chung Yuan Christian Univ, Ctr Nanotechnol, Tao Yuan, Taiwan.
RP Lee, JW (corresponding author), Tzu Chi Univ, Dept Life Sci, 701 Zhongyang Rd,Sect 3, Hualien 97004, Taiwan.
EM jwlee@mail.tcu.edu.tw
RI Hsu, Yih-Chih/AAV-2616-2020
OI Chang, Chung Hsing/0000-0003-2197-4923
FU Taiwan National Science CouncilMinistry of Science and Technology,
   Taiwan [NSC99-2320-B-320-014-MY2]; Taiwan Department of Health
   [DOH97-TD-I-111-TM017]
FX Supported by the Taiwan National Science Council grant
   NSC99-2320-B-320-014-MY2 and the Taiwan Department of Health grant
   DOH97-TD-I-111-TM017.
CR Barradas M, 1999, EMBO J, V18, P6362, DOI 10.1093/emboj/18.22.6362
   Benbrook DM, 2011, CURR CANCER DRUG TAR, V11, P586
   Betin VM, 2009, J CELL SCI, V122, P2554
   Boehrer S, 2001, Hematol J, V2, P103, DOI 10.1038/sj.thj.6200089
   Burikhanov R, 2009, CELL, V138, P377, DOI 10.1016/j.cell.2009.05.022
   Butler J, 2003, CURR DRUG TARGETS, V4, P223, DOI 10.2174/1389450033491163
   Chang SW, 2002, FEBS LETT, V510, P57, DOI 10.1016/S0014-5793(01)03224-0
   Chaudhry P, 2012, MOL CELL BIOL, V32, P826, DOI 10.1128/MCB.06321-11
   Cook J, 1999, ONCOGENE, V18, P1205, DOI 10.1038/sj.onc.1202416
   Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345
   DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X
   El-Guendy N, 2003, MOL CELL BIOL, V23, P5516, DOI 10.1128/MCB.23.16.5516-5525.2003
   Eskelinen EL, 2011, CURR OPIN PHARMACOL, V11, P294, DOI 10.1016/j.coph.2011.03.009
   FRANK JL, 1994, CANCER-AM CANCER SOC, V73, P181, DOI 10.1002/1097-0142(19940101)73:1<181::AID-CNCR2820730131>3.0.CO;2-3
   Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1
   Garcia-Cao I, 2005, EMBO REP, V6, P577, DOI 10.1038/sj.embor.7400421
   Goswami A, 2005, MOL CELL, V20, P33, DOI 10.1016/j.molcel.2005.08.016
   Goswami A, 2008, CANCER RES, V68, P6190, DOI 10.1158/0008-5472.CAN-08-0831
   Gump JM, 2011, TRENDS CELL BIOL, V21, P387, DOI 10.1016/j.tcb.2011.03.007
   Gurumurthy S, 2005, MOL CELL BIOL, V25, P1146, DOI 10.1128/MCB.25.3.1146-1161.2005
   Hebbar N, 2012, J CELL PHYSIOL, V227, P3715, DOI 10.1002/jcp.24098
   Hughes JP, 2003, J NEUROCHEM, V86, P25, DOI 10.1046/j.1471-4159.2003.01830.x
   Irby RB, 2013, EXPERT OPIN THER TAR, V17, P77, DOI 10.1517/14728222.2013.731047
   Johnstone RW, 1996, MOL CELL BIOL, V16, P6945
   Joshi J, 2008, EMBO J, V27, P2181, DOI 10.1038/emboj.2008.149
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kikkawa N, 2010, BRIT J CANCER, V103, P877
   Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5
   Kogel D, 2001, BRIT J CANCER, V85, P1801, DOI 10.1054/bjoc.2001.2158
   Kohmura T, 1999, ARCH OTOLARYNGOL, V125, P1351, DOI 10.1001/archotol.125.12.1351
   Korolchuk VI, 2011, NAT CELL BIOL, V13, P453, DOI 10.1038/ncb2204
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Lee JW, 2010, HEAD NECK-J SCI SPEC, V32, P877, DOI 10.1002/hed.21282
   Lee JW, 2009, CANCER LETT, V279, P193, DOI 10.1016/j.canlet.2009.01.037
   Lee JW, 2007, CANC LETT, V257, P252
   Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260
   Luo SQ, 2012, MOL CELL, V47, P359, DOI 10.1016/j.molcel.2012.05.040
   Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689
   Masuda M, 1996, CANCER, V78, P390
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   McEwan DG, 2011, TRENDS CELL BIOL, V21, P195, DOI 10.1016/j.tcb.2010.12.006
   Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347
   Mineta H, 1999, ANTICANCER RES, V19, P4407
   MIYAJIMA Y, 1995, ANN OTO RHINOL LARYN, V104, P678, DOI 10.1177/000348949510400902
   Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005
   Mizushima N, 2010, NAT CELL BIOL, V12, P823, DOI 10.1038/ncb0910-823
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Moreno-Bueno G, 2007, CANCER RES, V67, P1927, DOI 10.1158/0008-5472.CAN-06-2687
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Nalca A, 1999, J BIOL CHEM, V274, P29976, DOI 10.1074/jbc.274.42.29976
   Norman JM, 2010, AUTOPHAGY, V6, P1042, DOI 10.4161/auto.6.8.13337
   Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   Ravikumar B, 2009, J CELL SCI, V122, P1707, DOI 10.1242/jcs.031773
   Romeo Y, 2012, BIOCHEM J, V441, P553, DOI 10.1042/BJ20110289
   SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Shimizu S, 2010, ONCOGENE, V29, P2070, DOI 10.1038/onc.2009.487
   Shvets E, 2008, AUTOPHAGY, V4, P621, DOI 10.4161/auto.5939
   Steinhart H, 2001, ONCOL REP, V8, P1229
   Tang GM, 2008, HUM MOL GENET, V17, P1540, DOI 10.1093/hmg/ddn042
   Wang BD, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-98
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   Welkoborsky HJ, 2000, ANN OTO RHINOL LARYN, V109, P401, DOI 10.1177/000348940010900411
   Wirawan E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.16
   XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326
   Xu ZX, 2007, CELL DEATH DIFFER, V14, P1948, DOI 10.1038/sj.cdd.4402207
   Yang W, 2013, EXP CELL RES, V319, P122, DOI 10.1016/j.yexcr.2012.11.014
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
   Yu L, 2012, ONCOL REP, V27, P416, DOI 10.3892/or.2011.1481
   Zhao YM, 2007, CANCER RES, V67, P9276, DOI 10.1158/0008-5472.CAN-07-2124
   Zhao YM, 2011, CANCER BIOL THER, V12, P152, DOI 10.4161/cbt.12.2.15734
NR 74
TC 6
Z9 6
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD FEB
PY 2014
VL 184
IS 2
BP 418
EP 430
DI 10.1016/j.ajpath.2013.10.012
PG 13
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 297LU
UT WOS:000330257700013
PM 24418097
OA Bronze
DA 2022-04-25
ER

PT J
AU Kralova, V
   Benesova, S
   Cervinka, M
   Rudolf, E
AF Kralova, Vera
   Benesova, Sona
   Cervinka, Miroslav
   Rudolf, Emil
TI Selenite-induced apoptosis and autophagy in colon cancer cells
SO TOXICOLOGY IN VITRO
LA English
DT Article
DE Sodium selenite; Colon cancer; Apoptosis; Autophagy
ID SODIUM-SELENITE; COLORECTAL-CANCER; DNA-DAMAGE; P53; ACTIVATION;
   EXPRESSION; DEATH; CHEMOPREVENTION; PATHWAYS; P38
AB Sodium selenite (Se) is known to induce diverse stress responses in malignant cells which may lead to various types of cell death including apoptosis and/or autophagy. In colon cancer cells, Se activates several signaling pathways whose interactions and ultimate endpoints may vary in individual study models. In our previous work we showed differences in Se-dependent growth inhibition, cell cycle alterations and apoptosis in colon cancer cells with functional (HCT-116) and deleted (HCT-116-p53KO) p53. Moreover, detailed morphological and biochemical analyses revealed the presence of autophagy in Se-treated cells. Thus the aim of this study was to investigate in detail mechanisms, relationship and crosstalk between apoptosis and autophagy in Se-treated HCT-116 cancer cells differing in p53 status since p53 has been shown to play a well-known role in apoptosis but dichotomous role in autophagy. We report that the absence of p53 in malignant colonocytes changes patterns of response to Se-induced stress which include differential activation of MAP kinases (p38 - HCT-116 and JNK - HCT-116 p53KO) including their respective roles in the process of apoptosis and autophagy as well as the involvement of mTOR or PI3K signaling. Our results seem to suggest that deletion of p53 inevitably leads to a higher level of instability and delays in an individual cell decision in the face of stress whether to activate apoptosis or autophagy which may consequently occur simultaneously with mutual dichotomous relationship. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Kralova, Vera; Benesova, Sona; Cervinka, Miroslav; Rudolf, Emil] Charles Univ Prague, Fac Med Hradec Kralove, Dept Med Biol & Genet, Hradec Kralove 50038, Czech Republic.
RP Rudolf, E (corresponding author), Charles Univ Prague, Fac Med Hradec Kralove, Dept Med Biol & Genet, Simkova 870, Hradec Kralove 50038, Czech Republic.
EM rudolf@lfhk.cuni.cz
RI Králová, Věra/B-6608-2017; Rudolf, Emil/B-5956-2017; Cervinka,
   Miroslav/R-7387-2016
OI Králová, Věra/0000-0001-5971-4110; Rudolf, Emil/0000-0002-9526-3174;
   Cervinka, Miroslav/0000-0001-8602-4756
FU GAUK [129609]; Ministry of Education of Czech RepublicMinistry of
   Education, Youth & Sports - Czech Republic [MSM 0021620820]
FX This research was supported by GAUK No. 129609 and Ministry of Education
   of Czech Republic Research Project MSM 0021620820.
CR Brenneisen Peter, 2005, Molecular Aspects of Medicine, V26, P256, DOI 10.1016/j.mam.2005.07.004
   Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497
   Corcelle E, 2007, AUTOPHAGY, V3, P57, DOI 10.4161/auto.3424
   Courtney EDJ, 2004, ALIMENT PHARM THER, V19, P1, DOI 10.1046/j.1365-2036.2003.01806.x
   F.A.O. WHO. Organization, HUM VIT MIN REQ REP, P105
   Ghose A, 2001, CANCER RES, V61, P7479
   Hu HB, 2006, MOL CANCER THER, V5, P1873, DOI 10.1158/1535-7163.MCT-06-0063
   Huang F, 2009, FREE RADICAL BIO MED, V46, P1186, DOI 10.1016/j.freeradbiomed.2009.01.026
   Jiang QA, 2011, MOL BIOL CELL, V22, P1167, DOI 10.1091/mbc.E10-10-0860
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kim DH, 2011, MOL CARCINOGEN, V50, P222, DOI 10.1002/mc.20709
   Kim EH, 2007, CANCER RES, V67, P6314, DOI 10.1158/0008-5472.CAN-06-4217
   Kralova V, 2009, TOXICOL IN VITRO, V23, P1497, DOI 10.1016/j.tiv.2009.07.012
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   McClung JM, 2010, AM J PHYSIOL-CELL PH, V298, pC542, DOI 10.1152/ajpcell.00192.2009
   Muecke R, 2010, INTEGR CANCER THER, V9, P136, DOI 10.1177/1534735410367648
   Nilsonne G, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-92
   Portugal J, 2009, TUMORI J, V95, P409
   Puissant A, 2010, CANCER RES, V70, P1042, DOI 10.1158/0008-5472.CAN-09-3537
   Ren Y, 2009, BMB REP, V42, P599, DOI 10.5483/BMBRep.2009.42.9.599
   Sinha R, 2004, CURR CANCER DRUG TAR, V4, P13, DOI 10.2174/1568009043481614
   SPALLHOLZ JE, 1994, FREE RADICAL BIO MED, V17, P45, DOI 10.1016/0891-5849(94)90007-8
   Tasdemir E, 2008, AUTOPHAGY, V4, P810, DOI 10.4161/auto.6486
   UBEZIO P, 1994, FREE RADICAL BIO MED, V16, P509, DOI 10.1016/0891-5849(94)90129-5
   Wang HT, 2003, J INORG BIOCHEM, V97, P221, DOI 10.1016/S0162-0134(03)00284-8
   Zhao R, 2006, CANCER RES, V66, P2296, DOI 10.1158/0008-5472.CAN-05-2216
   Zhivotovsky B, 2005, BIOCHEM BIOPH RES CO, V331, P859, DOI 10.1016/j.bbrc.2005.03.191
   Zou YF, 2008, CANCER BIOL THER, V7, P689, DOI 10.4161/cbt.7.5.5688
NR 29
TC 28
Z9 28
U1 0
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-2333
J9 TOXICOL IN VITRO
JI Toxicol. Vitro
PD MAR
PY 2012
VL 26
IS 2
BP 258
EP 268
DI 10.1016/j.tiv.2011.12.010
PG 11
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA 902DU
UT WOS:000301019600009
PM 22200533
DA 2022-04-25
ER

PT J
AU Baldea, I
   Olteanu, D
   Filip, GA
   Pogacean, F
   Coros, M
   Suciu, M
   Tripon, SC
   Cenariu, M
   Magerusan, L
   Stefan-van Staden, RI
   Pruneanu, S
AF Baldea, Ioana
   Olteanu, Diana
   Filip, Gabriela Adriana
   Pogacean, Florina
   Coros, Maria
   Suciu, Maria
   Tripon, Septimiu Cassian
   Cenariu, Mihai
   Magerusan, Lidia
   Stefan-van Staden, Raluca-Ioana
   Pruneanu, Stela
TI Cytotoxicity mechanisms of nitrogen-doped graphene obtained by
   electrochemical exfoliation of graphite rods, on human endothelial and
   colon cancer cells
SO CARBON
LA English
DT Article
DE Nitrogen-doped graphene; Electrochemical exfoliation of graphite;
   Cytotoxicity; Oxidative stress; Apoptosis; DNA lesions; Autophagy
ID WALLED CARBON NANOTUBES; IN-VITRO; QUANTUM DOTS; SIGNALING PATHWAYS;
   COLORECTAL-CANCER; PROTEIN-KINASE; OXIDE; AUTOPHAGY; TOXICITY;
   NANOMATERIALS
AB Three nitrogen-doped graphene samples were synthesized by electrochemical exfoliation of graphite rods via pulses of current. Depending on the synthesis conditions, the samples had different content of nitrogen (0.79, 2.56 and 2.33 wt%) and were denoted as NGr-1, NGr-2 and NGr-3, respectively. All samples consist in a mixture of graphene oxide, few- and multi-layer graphene. Several biological effects (cytotoxicity, oxidative stress induction, apoptosis, autophagy and DNA lesions) induced by the N-doped graphenes on human endothelial and colon cancer cells were investigated. The in vitro effects of graphenes were different and depended on the type of cell and the amount of nitrogen in the structure. On human endothelial cells, the graphenes showed antioxidant effects and were less toxic than on colon cancer cells, especially the one with low content of nitrogen (NGr-1). In contrast, on colon cancer cells the graphenes induced cell death by various mechanisms: free radicals generation, apoptosis, autophagy and DNA damage. The most severe DNA lesions and ultrastructural changes were produced by graphene with high content of nitrogen (NGr-2 and NGr-3). Our research demonstrates the cytotoxic effect of graphene with high content of nitrogen on colon cancer cells and antioxidant and protective properties on human endothelial cells. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Baldea, Ioana; Olteanu, Diana; Filip, Gabriela Adriana] Iuliu Hatieganu Univ Med & Pharm, Physiol Dept, Cluj Napoca, Romania.
   [Pogacean, Florina; Coros, Maria; Suciu, Maria; Tripon, Septimiu Cassian; Magerusan, Lidia; Pruneanu, Stela] Natl Inst Res & Dev Isotop & Mol Technol, Donat St 67-103, RO-400293 Cluj Napoca, Romania.
   [Suciu, Maria; Tripon, Septimiu Cassian] Babes Bolyai Univ, Biol & Geol Fac, Mol Biol & Biotechnol Dept, 4-7 Clin Str, Cluj Napoca 400007, Romania.
   [Cenariu, Mihai] Univ Agr Sci & Vet Med, Dept Anim Reprod, Cluj Napoca, Romania.
   [Stefan-van Staden, Raluca-Ioana] Natl Inst Res Electrochem & Condensed Matter, Lab Electrochem, 202 Splaiul Independentei St, Bucharest 060021 6, Romania.
   [Stefan-van Staden, Raluca-Ioana] Natl Inst Res Electrochem & Condensed Matter, PATLAB, 202 Splaiul Independentei St, Bucharest 060021 6, Romania.
   [Stefan-van Staden, Raluca-Ioana] Univ Politehn Bucuresti, Fac Appl Chem & Mat Sci, Bucharest, Romania.
RP Filip, GA (corresponding author), Iuliu Hatieganu Univ Med & Pharm, Physiol Dept, Cluj Napoca, Romania.; Pruneanu, S (corresponding author), Natl Inst Res & Dev Isotop & Mol Technol, Donat St 67-103, RO-400293 Cluj Napoca, Romania.
EM adrianafilip33@yahoo.com; gabriela.filip@umfcluj.ro
RI Suciu, Maria/N-7405-2017; Coros, Maria/S-1091-2019; Magerusan,
   Lidia/R-8552-2016; Ioana, Baldea/Y-6129-2019; Adriana, Filip
   Gabriela/AAB-7418-2019; Olteanu, Elena Diana/A-4750-2017; Pogacean,
   Florina/B-7876-2012; Coros, Maria/C-2635-2012; Lidia,
   Magerusan/X-2146-2019; Cenariu, Mihai Cosmin/C-2558-2012; Magerusan,
   Lidia/ABC-7589-2021
OI Suciu, Maria/0000-0001-5449-9108; Coros, Maria/0000-0002-7733-4725;
   Magerusan, Lidia/0000-0002-7998-7754; Adriana, Filip
   Gabriela/0000-0002-7447-4925; Olteanu, Elena Diana/0000-0002-3034-3659;
   Lidia, Magerusan/0000-0002-7998-7754; Cenariu, Mihai
   Cosmin/0000-0001-6501-0128; Baldea, Ioana/0000-0003-4046-7310
FU Ministry of Research and Innovation, CNCS - UEFISCDI, within PNCDI III
   [PN-III-P4-ID-PCCF2016-0006]; Project: Research Center and Advanced
   Technologies for Alternative Energies -CETATEA [POS-CCE 623/11.03.2014]
FX This work was supported by a grant of Ministry of Research and
   Innovation, CNCS - UEFISCDI, project number PN-III-P4-ID-PCCF2016-0006,
   within PNCDI III. TEM measurements were partially supported through the
   infrastructure obtained in the Project: Research Center and Advanced
   Technologies for Alternative Energies -CETATEA - POS-CCE 623/11.03.2014.
   The authors are grateful to PhD student Alexandru Turza for recording
   the XRD measurements, Dr. Emese Gal for Elemental Analysis, Dr. Ioan
   Ovidiu Pana and Dr. Cristian Leostean for recording XPS measurements,
   Dr. Camelia Berghian-Grosan for recording Raman measurements, Dr. Maria
   Perde (Ion Chiricuta Institute of Oncology, Cluj-Napoca, Romania) for
   assistance with the DCFDA assay and Dr. Olga Soritau (Ion Chiricuta
   Institute of Oncology, Cluj-Napoca, Romania) for helpful comments and
   suggestions.
CR Agnoli S, 2016, J MATER CHEM A, V4, P5002, DOI 10.1039/c5ta10599d
   Aryappalli P, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00167
   Baldea I, 2015, J PHOTOCH PHOTOBIO B, V151, P142, DOI 10.1016/j.jphotobiol.2015.07.019
   Banerjee AN, 2018, INTERFACE FOCUS, V8, DOI 10.1098/rsfs.2017.0056
   Bernabo N, 2018, CARBON, V129, P428, DOI 10.1016/j.carbon.2017.12.042
   Bhandari A, 2017, J INVEST MED, V65, P311, DOI 10.1136/jim-2016-000229
   BRADSHAW AM, 1974, J PHYS C SOLID STATE, V7, P4503, DOI 10.1088/0022-3719/7/24/013
   Bundaleska N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30870-3
   Cancado LG, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2196057
   Chaturvedi MM, 2011, ONCOGENE, V30, P1615, DOI 10.1038/onc.2010.566
   Chen FX, 2019, J PHOTOCH PHOTOBIO B, V198, DOI 10.1016/j.jphotobiol.2019.111578
   Chen GY, 2014, ADV HEALTHC MATER, V3, P1486, DOI 10.1002/adhm.201300591
   CONTI M, 1991, CLIN CHEM, V37, P1273
   Cui XJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01746-9
   Deon D, 2001, J IMMUNOL, V167, P5395, DOI 10.4049/jimmunol.167.9.5395
   Dervin S, 2018, APPL SURF SCI, V434, P1274, DOI 10.1016/j.apsusc.2017.11.217
   Dresselhaus MS, 2010, NANO LETT, V10, P751, DOI 10.1021/nl904286r
   Eom HJ, 2009, TOXICOL IN VITRO, V23, P1326, DOI 10.1016/j.tiv.2009.07.010
   Ferrari AC, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.075414
   Ferrari AC, 2013, NAT NANOTECHNOL, V8, P235, DOI 10.1038/nnano.2013.46
   Galluzzi L, 2017, NAT REV DRUG DISCOV, V16, P487, DOI 10.1038/nrd.2017.22
   Garbers C, 2015, CURR OPIN IMMUNOL, V34, P75, DOI 10.1016/j.coi.2015.02.008
   Guo RH, 2013, BIOMATERIALS, V34, P4296, DOI 10.1016/j.biomaterials.2013.02.047
   Hassan HH, 2006, CAN J CARDIOL, V22, p35B, DOI 10.1016/S0828-282X(06)70985-0
   Idan C, 2015, SCI REP-UK, V5, DOI 10.1038/srep14756
   Jaworski S, 2015, INT J NANOMED, V10, P1585, DOI 10.2147/IJN.S77591
   Jin C, 2014, BIOL TRACE ELEM RES, V159, P393, DOI 10.1007/s12011-014-0027-3
   Jun S. C., 2015, GRAPHENE BASED ENERG, P1
   Kitko KE, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03185-0
   Kobayashi N, 2017, J OCCUP HEALTH, V59, P394, DOI 10.1539/joh.17-0089-RA
   Krasteva N, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3738980
   KRIEG AF, 1967, CLIN CHEM, V13, P196
   Kucki M, 2017, J NANOBIOTECHNOL, V15, DOI 10.1186/s12951-017-0280-7
   Lasocka I, 2018, TOXICOL IN VITRO, V48, P276, DOI 10.1016/j.tiv.2018.01.028
   Li SH, 2013, J PHYS CHEM C, V117, P16150, DOI 10.1021/jp405991q
   Li YF, 2013, P NATL ACAD SCI USA, V110, P12295, DOI 10.1073/pnas.1222276110
   Liao CZ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113564
   Liao KH, 2011, ACS APPL MATER INTER, V3, P2607, DOI 10.1021/am200428v
   Lin KC, 2018, THERANOSTICS, V8, P2477, DOI 10.7150/thno.24173
   Linares J, 2014, ACS APPL MATER INTER, V6, P13697, DOI 10.1021/am5031598
   Litmanovich A, 2018, ONCOL THER, V6, P109, DOI 10.1007/s40487-018-0089-z
   Long JM, 2017, J NANOBIOTECHNOL, V15, DOI 10.1186/s12951-017-0318-x
   Luo Y, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00604
   Maddi C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21639-9
   Magerusan L, 2018, ELECTROCHIM ACTA, V283, P578, DOI 10.1016/j.electacta.2018.06.203
   Mari E, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17121995
   Rivera LM, 2019, DIAM RELAT MATER, V97, DOI 10.1016/j.diamond.2019.107447
   Markovic ZM, 2011, BIOMATERIALS, V32, P1121, DOI 10.1016/j.biomaterials.2010.10.030
   Mendes RG, 2015, J MATER CHEM B, V3, P2522, DOI 10.1039/c5tb00180c
   Mu QX, 2012, ACS APPL MATER INTER, V4, P2259, DOI 10.1021/am300253c
   Noda NN, 2015, ANNU REV BIOPHYS, V44, P101, DOI 10.1146/annurev-biophys-060414-034248
   Olteanu D, 2014, J PHOTOCH PHOTOBIO B, V136, P54, DOI 10.1016/j.jphotobiol.2014.04.018
   Olteanu D, 2015, COLLOID SURFACE B, V136, P791, DOI 10.1016/j.colsurfb.2015.10.023
   Pogacean F, 2019, TALANTA, V196, P182, DOI 10.1016/j.talanta.2018.12.051
   Poirier D. M., 1993, Surface Science Spectra, V2, P232, DOI 10.1116/1.1247704
   Poudel K.R., 2018, DEV CELL, V18, DOI 10.1016/j.dev-cel.2018.05.021,738-752.e6
   Qin YR, 2015, TOXICOLOGY, V327, P62, DOI 10.1016/j.tox.2014.10.011
   Rao CNR, 2014, NANO TODAY, V9, P324, DOI 10.1016/j.nantod.2014.04.010
   Rashid M., 2019, GRAPHENE TRIGGERED A, P353, DOI [10.1016/B978-0-12-815889-0.00017-9, DOI 10.1016/B978-0-12-815889-0.00017-9]
   Rastogi SK, 2017, NANO LETT, V17, P3297, DOI 10.1021/acs.nanolett.7b01215
   Rivera L.M., 2019, REDUCTION SIMULTANEO, P1902
   Rosli NF, 2019, LANGMUIR, V35, P3176, DOI 10.1021/acs.langmuir.8b03086
   Roy P, 2015, NANOSCALE, V7, P2504, DOI 10.1039/c4nr07005d
   Roy P, 2014, NEW J CHEM, V38, P4946, DOI 10.1039/c4nj01185f
   Russier J, 2013, NANOSCALE, V5, P11234, DOI 10.1039/c3nr03543c
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Silverstein RM., 2005, SPECTROMETRIC IDENTI, V7th ed
   Susi T, 2015, BEILSTEIN J NANOTECH, V6, P177, DOI 10.3762/bjnano.6.17
   Tabish TA, 2018, REDOX BIOL, V15, P34, DOI 10.1016/j.redox.2017.11.018
   Tang ZB, 2018, INT J NANOMED, V13, P2907, DOI 10.2147/IJN.S159388
   Tsukahara T, 2015, INT J MOL SCI, V16, P40, DOI 10.3390/ijms16010040
   Valentini F, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051316
   Wan B, 2013, TOXICOL LETT, V221, P118, DOI 10.1016/j.toxlet.2013.06.208
   Wang D, 2015, NANOSCALE, V7, P9894, DOI 10.1039/c5nr01734c
   Wang K, 2011, NANOSCALE RES LETT, V6, DOI 10.1007/s11671-010-9751-6
   Warren B.E., 1969, XRAY DIFFRACTION
   Wu JJ, 2016, NANO LETT, V16, P466, DOI 10.1021/acs.nanolett.5b04123
   Zhang B, 2016, ADV DRUG DELIVER REV, V105, P145, DOI 10.1016/j.addr.2016.08.009
   Zhang YB, 2010, ACS NANO, V4, P3181, DOI 10.1021/nn1007176
   Zhao YL, 2016, BIOMATERIALS, V79, P15, DOI 10.1016/j.biomaterials.2015.11.052
   Zhou T, 2014, BIOMATERIALS, V35, P4185, DOI 10.1016/j.biomaterials.2014.01.044
   Zhu YP, 2015, J IMMUNOL, V194, P584, DOI 10.4049/jimmunol.1401024
NR 82
TC 9
Z9 9
U1 5
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0008-6223
EI 1873-3891
J9 CARBON
JI Carbon
PD MAR
PY 2020
VL 158
BP 267
EP 281
DI 10.1016/j.carbon.2019.12.011
PG 15
WC Chemistry, Physical; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Materials Science
GA KK8ON
UT WOS:000512995800028
DA 2022-04-25
ER

PT J
AU Zhao, Y
   Yang, J
   Liao, WJ
   Liu, XY
   Zhang, H
   Wang, S
   Wang, DL
   Feng, JN
   Yu, L
   Zhu, WG
AF Zhao, Ying
   Yang, Jing
   Liao, Wenjuan
   Liu, Xiangyu
   Zhang, Hui
   Wang, Shan
   Wang, Donglai
   Feng, Jingnan
   Yu, Li
   Zhu, Wei-Guo
TI Cytosolic FoxO1 is essential for the induction of autophagy and tumour
   suppressor activity
SO NATURE CELL BIOLOGY
LA English
DT Article
ID TRANSCRIPTION FACTORS; CELL-DEATH; LIFE-SPAN; ACTIVATION; BECLIN-1;
   TARGET; GENE; TUMORIGENESIS; EXPRESSION; PROTEINS
AB Autophagy is characterized by the sequestration of bulk cytoplasm, including damaged proteins and organelles, and delivery of the cargo to lysosomes for degradation. Although the autophagic pathway is also linked to tumour suppression activity, the mechanism is not yet clear. Here we report that cytosolic FoxO1, a forkhead O family protein, is a mediator of autophagy. Endogenous FoxO1 was required for autophagy in human cancer cell lines in response to oxidative stress or serum starvation, but this process was independent of the transcriptional activity of FoxO1. In response to stress, FoxO1 was acetylated by dissociation from sirtuin-2 (SIRT2), a NAD(+)-dependent histone deacetylase, and the acetylated FoxO1 bound to Atg7, an E1-following protein, to influence the autophagic process leading to cell death. This FoxO1-modulated cell death is associated with tumour suppressor activity in human colon tumours and a xenograft mouse model. Our finding links the anti-neoplastic activity of FoxO1 and the process of autophagy.
C1 [Zhao, Ying; Yang, Jing; Liao, Wenjuan; Liu, Xiangyu; Zhang, Hui; Wang, Donglai; Feng, Jingnan; Zhu, Wei-Guo] Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100191, Peoples R China.
   [Zhang, Hui; Wang, Shan] Peking Univ, Hlth Sci Ctr, Dept Surg, Affiliated Hosp 2, Beijing 100044, Peoples R China.
   [Yu, Li] Tsinghua Univ, Dept Biol Sci, Beijing 100084, Peoples R China.
   Peking Univ, Beijing 00142, Peoples R China.
   [Zhu, Wei-Guo] Peking Univ, Hlth Sci Ctr, Sch Oncol, Beijing 00142, Peoples R China.
RP Zhu, WG (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100191, Peoples R China.
EM zhuweiguo@bjmu.edu.cn
RI liu, xiangyu/D-8213-2014; zhu, wei-guo/E-1334-2012
OI Zhu, Wei-Guo/0000-0001-8385-6581
CR Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Al-Mubarak B, 2009, CHANNELS, V3, P233
   Arden KC, 2007, CELL, V128, P235, DOI 10.1016/j.cell.2007.01.009
   Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4
   Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637
   Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8
   Cao Y, 2006, J BIOL CHEM, V281, P40242, DOI 10.1074/jbc.M608116200
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101
   Dryden SC, 2003, MOL CELL BIOL, V23, P3173, DOI 10.1128/MCB.23.9.3173-3185.2003
   Essaghir A, 2009, J BIOL CHEM, V284, P10334, DOI 10.1074/jbc.M808848200
   Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476
   Geng JF, 2008, EMBO REP, V9, P859, DOI 10.1038/embor.2008.163
   Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086
   Huang HJ, 2006, SCIENCE, V314, P294, DOI 10.1126/science.1130512
   Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114
   Jing EX, 2007, CELL METAB, V6, P105, DOI 10.1016/j.cmet.2007.07.003
   Juhasz G, 2007, CELL DEATH DIFFER, V14, P1181, DOI 10.1038/sj.cdd.4402123
   Kalaany NY, 2009, NATURE, V458, P725, DOI 10.1038/nature07782
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kawamori D, 2006, J BIOL CHEM, V281, P1091, DOI 10.1074/jbc.M508510200
   KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0
   Kitamura YI, 2005, CELL METAB, V2, P153, DOI 10.1016/j.cmet.2005.08.004
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029
   Lam EWF, 2006, BIOCHEM SOC T, V34, P722, DOI 10.1042/BST0340722
   Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105
   Lee SS, 2003, SCIENCE, V300, P644, DOI 10.1126/science.1083614
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Liang CY, 2008, NAT CELL BIOL, V10, P776, DOI 10.1038/ncb1740
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319
   Liu P, 2008, CANCER RES, V68, P10290, DOI 10.1158/0008-5472.CAN-08-2038
   Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001
   Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Matsunaga K, 2009, NAT CELL BIOL, V11, P385, DOI 10.1038/ncb1846
   Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6
   North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8
   Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194
   Onodera J, 2005, J BIOL CHEM, V280, P31582, DOI 10.1074/jbc.M506736200
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7
   Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Sou Y, 2006, J BIOL CHEM, V281, P3017, DOI 10.1074/jbc.M505888200
   Sun QM, 2008, P NATL ACAD SCI USA, V105, P19211, DOI 10.1073/pnas.0810452105
   Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634
   van der Horst A, 2007, NAT REV MOL CELL BIO, V8, P440, DOI 10.1038/nrm2190
   Wang F, 2009, MOL BIOL CELL, V20, P801, DOI 10.1091/mbc.E08-06-0647
   Yang Y, 2009, NEOPLASIA, V11, P313, DOI 10.1593/neo.81358
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zhao J, 2007, CELL METAB, V6, P472, DOI 10.1016/j.cmet.2007.11.004
   Zhong Y, 2009, NAT CELL BIOL, V11, P468, DOI 10.1038/ncb1854
NR 65
TC 412
Z9 441
U1 4
U2 88
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1465-7392
EI 1476-4679
J9 NAT CELL BIOL
JI Nat. Cell Biol.
PD JUL
PY 2010
VL 12
IS 7
BP 665
EP U88
DI 10.1038/ncb2069
PG 19
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 618RW
UT WOS:000279374400010
PM 20543840
DA 2022-04-25
ER

PT J
AU Zheng, Z
   He, QS
   Xu, LT
   Cui, WH
   Bai, H
   Zhang, Z
   Rao, J
   Dou, FF
AF Zheng, Zhi
   He, Qinsi
   Xu, Liting
   Cui, Wenhao
   Bai, Hua
   Zhang, Zhe
   Rao, Jun
   Dou, Fangfang
TI The peiminine stimulating autophagy in human colorectal carcinoma cells
   via AMPK pathway by SQSTM1
SO OPEN LIFE SCIENCES
LA English
DT Article
DE peiminine; autophagy; natural product; autophagic cell death; SQTEM1;
   AMPK/mTOC/ULK signaling pathway
ID APOPTOSIS; GROWTH; P62
AB Autophagy is a conserved catabolic process, which functions in maintenance of cellular homeostasis in eukaryotic cells. The self-eating process engulfs cellular long-lived proteins and organelles with double-membrane vesicles, and forms a so-called autophagosome. Degradation of contents via fusion with lysosome provides recycled building blocks for synthesis of new molecules during stress, e.g. starvation. Peiminine is a steroidal alkaloid extracted from Fritillaria thunbergii which is widely used in Traditional Chinese Medicine. Previously, peiminine has been identified to induce autophagy in human colorectal carcinoma cells. In this study, we further investigated whether peiminine could induce autophagic cell death via activating autophagy-related signaling pathway AMPK-mTOR-ULK by promoting SQSTM1(P62). Xenograft tumor growth in vivo suggested that both peiminine and starvation inhibit the growth of tumor size and weight, which was prominently enhanced when peiminine and starvation combined. The therapeutical effect of peiminine in cancer treatment is to be expected.
C1 [Zheng, Zhi; He, Qinsi; Xu, Liting; Rao, Jun; Dou, Fangfang] Nanchang Univ, Grad Sch Med, Nanchang 330029, Jiangxi, Peoples R China.
   [Zheng, Zhi; He, Qinsi; Xu, Liting; Rao, Jun; Dou, Fangfang] Jiangxi Canc Hosp, Jiangxi Canc Ctr, Nanchang 330029, Jiangxi, Peoples R China.
   [Cui, Wenhao] Lavion Life Inc, Life Sci R&D Ctr, Beijing 100020, Peoples R China.
   [Bai, Hua] China Acad Chinese Med Sci, Guanganmen Hosp, South Area, Beijing 102618, Peoples R China.
   [Zhang, Zhe] China Japan Friendship Hosp, Dept TCM Gastroenterol, Beijing 100029, Peoples R China.
RP Dou, FF (corresponding author), Nanchang Univ, Grad Sch Med, Nanchang 330029, Jiangxi, Peoples R China.
EM zheng_sheva@hotmail.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81260592]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81260592). The funding institutes had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11
   Aneja R, 2007, CANCER RES, V67, P3862, DOI 10.1158/0008-5472.CAN-06-4282
   Feng LF, 2014, AUTOPHAGY, V10, P1442, DOI 10.4161/auto.29486
   Ferrandiz N, 2009, DNA REPAIR, V8, P390, DOI 10.1016/j.dnarep.2008.12.001
   Gump JM, 2011, TRENDS CELL BIOL, V21, P387, DOI 10.1016/j.tcb.2011.03.007
   Inoue D, 2012, CANCER SCI, V103, P760, DOI 10.1111/j.1349-7006.2012.02216.x
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim PK, 2008, P NATL ACAD SCI USA, V105, P20567, DOI 10.1073/pnas.0810611105
   Komatsu M, 2011, AUTOPHAGY, V7, P1088, DOI 10.4161/auto.7.9.16474
   Kuo WL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090171
   Liang JY, 2013, CANCER RES, V73, P2929, DOI 10.1158/0008-5472.CAN-12-3876
   Long Z, 2016, TALANTA, V151, P239, DOI 10.1016/j.talanta.2016.01.027
   Lozy F, 2012, SEMIN CELL DEV BIOL, V23, P395, DOI 10.1016/j.semcdb.2012.01.005
   Lyu Q, 2015, BIOCHEM BIOPH RES CO, V462, P38, DOI 10.1016/j.bbrc.2015.04.102
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Neufeld TP, 2012, J CELL SCI, V125, P2359, DOI 10.1242/jcs.103333
   Shimizu S, 2014, INT J MOL SCI, V15, P3145, DOI 10.3390/ijms15023145
   Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777
   Wang DD, 2014, NUTR CANCER, V66, P441, DOI 10.1080/01635581.2013.878737
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Zhang Y, 2013, J MATER CHEM B, V1, P132, DOI 10.1039/c2tb00071g
NR 22
TC 4
Z9 5
U1 2
U2 12
PU SCIENDO
PI WARSAW
PA DE GRUYTER POLAND SP Z O O, BOGUMILA ZUGA 32A STR, 01-811 WARSAW, POLAND
SN 2391-5412
J9 OPEN LIFE SCI
JI Open Life Sci.
PD JAN
PY 2016
VL 11
IS 1
BP 358
EP 366
DI 10.1515/biol-2016-0047
PG 9
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA EI4YH
UT WOS:000392499400011
OA gold
DA 2022-04-25
ER

PT J
AU Xie, CM
   Liu, XY
   Sham, KWY
   Lai, JMY
   Cheng, CHK
AF Xie, Chuan-Ming
   Liu, Xiao-Yu
   Sham, Kathy W. Y.
   Lai, Josie M. Y.
   Cheng, Christopher H. K.
TI Silencing of EEF2K (eukaryotic elongation factor-2 kinase) reveals
   AMPK-ULK1-dependent autophagy in colon cancer cells
SO AUTOPHAGY
LA English
DT Review
DE elongation factor-2 kinase; autophagy; colon cancer; AMPK; ULK1; ATG;
   MTOR; ROS; cancer growth; cell survival
ID PROTEIN-SYNTHESIS; PHOSPHORYLATION; AMPK; GLIOBLASTOMA; TRANSLATION;
   ASSOCIATION; ACTIVATION; RESISTANCE; INDUCTION; APOPTOSIS
AB EEF2K (eukaryotic elongation factor-2 kinase), also known as Ca2+/calmodulin-dependent protein kinase III, functions in downregulating peptide chain elongation through inactivation of EEF2 (eukaryotic translation elongation factor 2). Currently, there is a limited amount of information on the promotion of autophagic survival by EEF2K in breast and glioblastoma cell lines. However, the precise role of EEF2K in carcinogenesis as well as the underlying mechanism involved is still poorly understood. In this study, contrary to the reported autophagy-promoting activity of EEF2K in certain cancer cells, EEF2K is shown to negatively regulate autophagy in human colon cancer cells as indicated by the increase of LC3-II levels, the accumulation of LC3 dots per cell, and the promotion of autophagic flux in EEF2K knockdown cells. EEF2K negatively regulates cell viability, clonogenicity, cell proliferation, and cell size in colon cancer cells. Autophagy induced by EEF2K silencing promotes cell survival and does not potentiate the anticancer efficacy of the AKT inhibitor MK-2206. In addition, autophagy induced by silencing of EEF2K is attributed to induction of protein synthesis and activation of the AMPK-ULK1 pathway, independent of the suppression of MTOR activity and ROS generation. Knockdown of AMPK or ULK1 significantly abrogates EEF2K silencing-induced increase of LC3-II levels, accumulation of LC3 dots per cell as well as cell proliferation in colon cancer cells. In conclusion, silencing of EEF2K promotes autophagic survival via activation of the AMPK-ULK1 pathway in colon cancer cells. This finding suggests that upregulation of EEF2K activity may constitute a novel approach for the treatment of human colon cancer.
C1 [Xie, Chuan-Ming; Liu, Xiao-Yu; Sham, Kathy W. Y.; Lai, Josie M. Y.; Cheng, Christopher H. K.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China.
   [Cheng, Christopher H. K.] Chinese Univ Hong Kong, Ctr Novel Funct Mol, Hong Kong, Hong Kong, Peoples R China.
RP Cheng, CHK (corresponding author), Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China.
EM chkcheng@cuhk.edu.hk
RI CHENG, Ki Christopher/R-9641-2018; Xie, Chuan-Ming/AAT-9557-2021
OI CHENG, Ki Christopher/0000-0001-8970-9048; Xie,
   Chuan-Ming/0000-0003-4362-6612; Sham, Kathy Wai-yan/0000-0002-8883-2551;
   Xiaoyu, LIU/0000-0001-5259-7038
FU Chinese University of Hong KongChinese University of Hong Kong
FX This work was supported by a Strategic Investments Scheme from the
   Chinese University of Hong Kong. We thank the Chinese University of Hong
   Kong for the provision of Direct Grants. We also thank the depositors of
   the Addgene plasmid pDONR223-EEF2K (# 23726), Dr William Hahn and Dr
   David Root of Broad Institute of Harvard and Massachusetts Institute of
   Technology, Massachusetts.
CR Aoki H, 2008, AUTOPHAGY, V4, P467, DOI 10.4161/auto.5668
   Berryman S, 2012, J VIROL, V86, P12940, DOI 10.1128/JVI.00846-12
   Bhutia SK, 2010, P NATL ACAD SCI USA, V107, P22243, DOI 10.1073/pnas.1009479107
   Browne GJ, 2004, MOL CELL BIOL, V24, P2986, DOI 10.1128/MCB.24.7.2986-2997.2004
   Browne GJ, 2004, J BIOL CHEM, V279, P12220, DOI 10.1074/jbc.M309773200
   Browne GJ, 2002, EUR J BIOCHEM, V269, P5360, DOI 10.1046/j.1432-1033.2002.03290.x
   CARLBERG U, 1990, EUR J BIOCHEM, V191, P639, DOI 10.1111/j.1432-1033.1990.tb19169.x
   Chang YY, 2009, BIOCHEM SOC T, V37, P232, DOI 10.1042/BST0370232
   Chen ZH, 2011, J BIOL CHEM, V286, P43951, DOI 10.1074/jbc.M111.301291
   Cheng Y, 2013, AUTOPHAGY, V9, P208, DOI 10.4161/auto.22801
   Cheng Y, 2011, AUTOPHAGY, V7, P660, DOI 10.4161/auto.7.6.15385
   Cheng Y, 2011, CANCER RES, V71, P2654, DOI 10.1158/0008-5472.CAN-10-2889
   Cheng Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009715
   Cheong H, 2012, NAT BIOTECHNOL, V30, P671, DOI 10.1038/nbt.2285
   Diggle TA, 1999, FEBS LETT, V457, P189, DOI 10.1016/S0014-5793(99)01034-0
   Diggle TA, 2001, BIOCHEM J, V353, P621, DOI 10.1042/0264-6021:3530621
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   Ganley IG, 2009, J BIOL CHEM, V284, P12297, DOI 10.1074/jbc.M900573200
   Guo LP, 2013, J IMMUNOL, V190, P3620, DOI 10.4049/jimmunol.1102975
   Hait WN, 2006, AUTOPHAGY, V2, P294, DOI 10.4161/auto.2857
   Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248
   Hovland R, 1999, FEBS LETT, V444, P97, DOI 10.1016/S0014-5793(99)00039-3
   Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Knebel A, 2001, EMBO J, V20, P4360, DOI 10.1093/emboj/20.16.4360
   Leprivier G, 2013, CELL, V153, P1064, DOI 10.1016/j.cell.2013.04.055
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Li L, 2013, CELL SIGNAL, V25, P50, DOI 10.1016/j.cellsig.2012.09.020
   Lipinski MM, 2010, DEV CELL, V18, P1041, DOI 10.1016/j.devcel.2010.05.005
   Liu QQ, 2010, FASEB J, V24, P4229, DOI 10.1096/fj.10-159723
   Mok CF, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/792840
   NAIRN AC, 1985, P NATL ACAD SCI USA, V82, P7939, DOI 10.1073/pnas.82.23.7939
   Nakano A, 2010, NAT CELL BIOL, V12, P583, DOI 10.1038/ncb2060
   Nishida Y, 2009, NATURE, V461, P654, DOI 10.1038/nature08455
   Podrabsky JE, 2000, PHYSIOL BIOCHEM ZOOL, V73, P799, DOI 10.1086/318106
   Py BF, 2009, AUTOPHAGY, V5, P393, DOI 10.4161/auto.5.3.7762
   Rodriguez-Rocha H, 2011, MUTAT RES-FUND MOL M, V711, P158, DOI 10.1016/j.mrfmmm.2011.03.007
   Ryazanov AG, 2002, FEBS LETT, V514, P26, DOI 10.1016/S0014-5793(02)02299-8
   RYAZANOV AG, 1988, NATURE, V334, P170, DOI 10.1038/334170a0
   Skrzypczak M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013091
   Tafani M, 2008, AUTOPHAGY, V4, P1042, DOI 10.4161/auto.7070
   Tekedereli I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041171
   Uchiyama Y, 2008, HISTOCHEM CELL BIOL, V129, P407, DOI 10.1007/s00418-008-0406-y
   Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370
   Wu H, 2006, CANCER RES, V66, P3015, DOI 10.1158/0008-5472.CAN-05-1554
   Wu H, 2009, CANCER RES, V69, P2453, DOI 10.1158/0008-5472.CAN-08-2872
   Wullner U, 2008, CURR CANCER DRUG TAR, V8, P554, DOI 10.2174/156800908786241078
   Xie CM, 2013, CARCINOGENESIS, V34, P1870, DOI 10.1093/carcin/bgt136
   Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016
NR 49
TC 57
Z9 60
U1 1
U2 40
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD SEP
PY 2014
VL 10
IS 9
BP 1495
EP 1508
DI 10.4161/auto.29164
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AO9AH
UT WOS:000341647200003
PM 24955726
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Deng, HM
   Huang, L
   Liao, ZK
   Liu, M
   Li, Q
   Xu, RH
AF Deng, Huiming
   Huang, Ling
   Liao, Zhongkai
   Liu, Mi
   Li, Qiang
   Xu, Ronghua
TI Itraconazole inhibits the Hedgehog signaling pathway thereby inducing
   autophagy-mediated apoptosis of colon cancer cells
SO CELL DEATH & DISEASE
LA English
DT Article
ID PROLIFERATION; CHEMOTHERAPY; ANTIFUNGAL; ACTIVATION; MECHANISMS;
   PROTEINS; SURVIVAL; GROWTH; GLI1
AB Itraconazole is as an antifungal medication used to treat systemic fungal infections. Recently, it has been reported to be effective in suppressing tumor growth by inhibiting the Hedgehog signaling pathway and angiogenesis. In the present study, we investigated whether itraconazole induces autophagy-mediated cell death of colon cancer cells through the Hedgehog signaling pathway. Cell apoptosis and cell cycle distribution of the colon cancer cell lines SW-480 and HCT-116 were detected by flow cytometry and terminal TUNEL assay. Autophagy and signal proteins were detected by western blotting and cell proliferation-associated antigen Ki-67 was measured using immunohistochemistry. The images of autophagy flux and formation of autophagosomes were observed by laser scanning confocal and/or transmission electron microscopy. Colon cancer cell xenograft mouse models were also established. Itraconazole treatment inhibited cell proliferation via G1 cell cycle arrest as well as autophagy-mediated apoptosis of SW-480 and HCT-116 colon cancer cells. In addition, the Hedgehog pathway was found to be involved in activation of itraconazole-mediated autophagy. After using the Hedgehog agonist recombinant human Sonic Hedgehog (rhshh), itraconazole could counteract the activation of rhshh. Moreover, treatment with itraconazole produced significant cancer inhibition in HCT-116-bearing mice. Thus, itraconazole may be a potential and effective therapy for the treatment of colon cancer.
C1 [Deng, Huiming; Xu, Ronghua] Huazhong Univ Sci & Technol, Dept Gastrointestinal Surg, Union Shenzhen Hosp, 89 Taoyuan Rd, Shenzhen 518000, Peoples R China.
   [Deng, Huiming] Zengcheng Dist Peoples Hosp Guangzhou, Dept Gen Surg, 1 Guangming East Rd, Guangzhou 511300, Peoples R China.
   [Huang, Ling; Liu, Mi] Hainan Med Univ, Sch Hainan Prov Drug Safety Evaluat Res Ctr, 3 Xueyuan Rd, Haikou 571199, Hainan, Peoples R China.
   [Huang, Ling] Hainan Med Univ, Key Lab Emergency & Trauma, Minist Educ, 3 Xueyuan Rd, Haikou 571199, Hainan, Peoples R China.
   [Liao, Zhongkai; Li, Qiang] Hainan Med Univ, Dept Gastrointestinal Oncol, Affiliated Hosp 1, 31 Longhua Rd, Haikou 570102, Hainan, Peoples R China.
RP Xu, RH (corresponding author), Huazhong Univ Sci & Technol, Dept Gastrointestinal Surg, Union Shenzhen Hosp, 89 Taoyuan Rd, Shenzhen 518000, Peoples R China.
EM hyfyweichang@163.com
RI Xu, Ronghua/AAE-8353-2021
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81403006, 81760674]; Natural Science
   Foundation of Hainan Province [ZDXM2015080]; Cultivating Foundation of
   Hainan Medical University [HY2018-23]
FX This work was supported by National Natural Science Foundation of China
   [No: 81403006 and 81760674], Natural Science Foundation of Hainan
   Province [No: ZDXM2015080] and Cultivating Foundation of Hainan Medical
   University [No: HY2018-23]. The funder had no role in the study design,
   data collection or analysis, decision to publish or preparation of the
   manuscript.
CR Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Barnfield PC, 2005, DIFFERENTIATION, V73, P397, DOI 10.1111/j.1432-0436.2005.00042.x
   Bigelow RLH, 2004, J BIOL CHEM, V279, P1197, DOI 10.1074/jbc.M310589200
   Birner P, 2000, CANCER RES, V60, P4693
   Buczacki SJA, 2018, J EXP MED, V215, P1891, DOI 10.1084/jem.20171385
   Chen MB, 2018, MOL CANCER THER, V17, P1229, DOI 10.1158/1535-7163.MCT-17-1094
   Deegan S, 2013, CELL MOL LIFE SCI, V70, P2425, DOI 10.1007/s00018-012-1173-4
   Dirix L, 2014, J CLIN ONCOL, V32, P720, DOI 10.1200/JCO.2013.53.7118
   Doring M, 2015, EUR J CLIN MICROBIOL, V34, P1189, DOI 10.1007/s10096-015-2340-y
   Duman-Scheel M, 2002, NATURE, V417, P299, DOI 10.1038/417299a
   Faiao-Flores F, 2017, ONCOGENE, V36, P1849, DOI 10.1038/onc.2016.348
   Fattahi S, 2018, J CELL PHYSIOL, V233, P5726, DOI 10.1002/jcp.26506
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fulda S, 2015, ONCOGENE, V34, P5105, DOI 10.1038/onc.2014.458
   Goh V, 2008, RADIOLOGY, V249, P510, DOI 10.1148/radiol.2492071365
   Gu DS, 2013, MOL CANCER THER, V12, P1038, DOI 10.1158/1535-7163.MCT-12-1030
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Hu Q, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0526-0
   Hui CC, 2011, ANNU REV CELL DEV BI, V27, P513, DOI 10.1146/annurev-cellbio-092910-154048
   Jiang F, 2019, J CELL BIOCHEM, V120, P4333, DOI 10.1002/jcb.27719
   Kim J, 2010, CANCER CELL, V17, P388, DOI 10.1016/j.ccr.2010.02.027
   Lam A, 2015, INT FORUM ALLERGY RH, V5, P477, DOI 10.1002/alr.21454
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Liu R, 2014, AUTOPHAGY, V10, P1241, DOI 10.4161/auto.28912
   Loupakis F, 2016, TARGET ONCOL, V11, P293, DOI 10.1007/s11523-015-0400-y
   Moscat J, 2016, CELL, V167, P606, DOI 10.1016/j.cell.2016.09.030
   National Comprehensive Cancer Network, 2018, NCCN CLIN PRACT GUID
   Odds FC, 2000, ANTIMICROB AGENTS CH, V44, P3180, DOI 10.1128/AAC.44.11.3180-3183.2000
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Pak E, 2016, DEV CELL, V38, P333, DOI 10.1016/j.devcel.2016.07.026
   Pantziarka P, 2015, ECANCERMEDICALSCIENC, V9, DOI 10.3332/ecancer.2015.521
   Rimkus TK, 2016, CANCERS, V8, DOI 10.3390/cancers8020022
   Rush SZ, 2010, NEURO-ONCOLOGY, V12, P790, DOI 10.1093/neuonc/noq026
   Scales SJ, 2009, TRENDS PHARMACOL SCI, V30, P303, DOI 10.1016/j.tips.2009.03.007
   Schaaf MBE, 2016, FASEB J, V30, P3961, DOI 10.1096/fj.201600698R
   Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
   Shi T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013054
   Stecca B, 2010, J MOL CELL BIOL, V2, P84, DOI 10.1093/jmcb/mjp052
   Stewart BWKP, 2015, WORLD CANC REPORT 20
   Sun Y, 2018, THERANOSTICS, V8, P2044, DOI 10.7150/thno.23304
   Tang XL, 2015, EUR J CELL BIOL, V94, P223, DOI 10.1016/j.ejcb.2015.03.003
   Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009
   Tsubamoto H, 2014, ANTICANCER RES, V34, P2481
   Wang Y, 2013, HEPATOLOGY, V58, P995, DOI 10.1002/hep.26394
   Zeng X, 2015, AUTOPHAGY, V11, P355, DOI 10.4161/15548627.2014.994368
   ZHANG L, 2016, OXID MED CELL LONGEV, V2016, DOI DOI 10.1155/2016/3897250
   Zheng Hai-yang, 2012, Cancer Biology Medicine, V9, P105, DOI 10.3969/j.issn.2095-3941.2012.02.004
NR 47
TC 11
Z9 12
U1 7
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JUL 17
PY 2020
VL 11
IS 7
AR 539
DI 10.1038/s41419-020-02742-0
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA MP7NE
UT WOS:000552387300001
PM 32681018
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Marinkovic, M
   Sprung, M
   Buljubasic, M
   Novak, I
AF Marinkovic, Mija
   Sprung, Matilda
   Buljubasic, Maja
   Novak, Ivana
TI Autophagy Modulation in Cancer: Current Knowledge on Action and Therapy
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Review
ID CELL LUNG-CANCER; INHIBITS TUMOR-GROWTH; BECLIN 1 EXPRESSION;
   COLON-CANCER; HEPATOCELLULAR-CARCINOMA; DIRECT PHOSPHORYLATION;
   MOLECULAR-MECHANISMS; FAVORABLE PROGNOSIS; IMMUNE-RESPONSES;
   DOWN-REGULATION
AB In the last two decades, accumulating evidence pointed to the importance of autophagy in various human diseases. As an essential evolutionary catabolic process of cytoplasmatic component digestion, it is generally believed that modulating autophagic activity, through targeting specific regulatory actors in the core autophagy machinery, may impact disease processes. Both autophagy upregulation and downregulation have been found in cancers, suggesting its dual oncogenic and tumor suppressor properties during malignant transformation. Identification of the key autophagy targets is essential for the development of new therapeutic agents. Despite this great potential, no therapies are currently available that specifically focus on autophagy modulation. Although drugs like rapamycin, chloroquine, hydroxychloroquine, and others act as autophagy modulators, they were not originally developed for this purpose. Thus, autophagy may represent a new and promising pharmacologic target for future drug development and therapeutic applications in human diseases. Here, we summarize our current knowledge in regard to the interplay between autophagy and malignancy in the most significant tumor types: pancreatic, breast, hepatocellular, colorectal, and lung cancer, which have been studied in respect to autophagy manipulation as a promising therapeutic strategy. Finally, we present an overview of the most recent advances in therapeutic strategies involving autophagy modulators in cancer.
C1 [Marinkovic, Mija; Buljubasic, Maja; Novak, Ivana] Univ Split, Sch Med, Soltanska 2, Split 21000, Croatia.
   [Sprung, Matilda] Univ Split, Fac Sci, Rudera Boskov 33, Split 21000, Croatia.
RP Novak, I (corresponding author), Univ Split, Sch Med, Soltanska 2, Split 21000, Croatia.
EM ivana.novak@mefst.hr
RI , Matilda/ABD-1905-2020; Buljubasic, Maja/E-1241-2017; Sprung,
   Matilda/D-5067-2017
OI , Matilda/0000-0001-5008-2700; Buljubasic, Maja/0000-0003-2466-2036;
   Sprung, Matilda/0000-0001-5008-2700; Novak, Ivana/0000-0003-0682-7052
FU Croatian Science Foundation [UIP-11-2013-5246]; Transautophagy COST
   Action by the EU COST [CA15138]
FX I.N. laboratory is supported by the Croatian Science Foundation (Grant
   no. UIP-11-2013-5246) and Transautophagy COST Action by the EU COST
   (CA15138).
CR Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703
   Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5
   An CH, 2011, PATHOL RES PRACT, V207, P433, DOI 10.1016/j.prp.2011.05.002
   Anandappa G, 2010, Cancer Manag Res, V2, P61
   Arakawa S, 2017, P JPN ACAD B-PHYS, V93, P378, DOI 10.2183/pjab.93.023
   Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368
   Bareford MD, 2011, CANCER RES, V71, P4955, DOI 10.1158/0008-5472.CAN-11-0898
   Barth S, 2010, J PATHOL, V221, P117, DOI 10.1002/path.2694
   Beau I, 2011, INT J BIOCHEM CELL B, V43, P460, DOI 10.1016/j.biocel.2011.01.006
   Bian JL, 2017, WORLD J GASTROENTERO, V23, P4311, DOI 10.3748/wjg.v23.i23.4311
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Boya P, 2003, ONCOGENE, V22, P3927, DOI 10.1038/sj.onc.1206622
   Cai MB, 2014, INT J MOL SCI, V15, P5292, DOI 10.3390/ijms15045292
   Carew JS, 2010, J CELL MOL MED, V14, P2448, DOI 10.1111/j.1582-4934.2009.00832.x
   Chan E. Y., 2009, SCI SIGNAL, V2, P1
   Chen CL, 2015, BIOMATERIALS, V44, P71, DOI 10.1016/j.biomaterials.2014.12.023
   Chen K, 2016, TUMOR BIOL, V37, P10539, DOI 10.1007/s13277-016-4929-x
   Chen KF, 2011, J PHARMACOL EXP THER, V337, P155, DOI 10.1124/jpet.110.175786
   Chen MB, 2017, ONCOTARGET, V8, P33704, DOI 10.18632/oncotarget.16734
   Chen ZH, 2013, DIGEST DIS SCI, V58, P2887, DOI 10.1007/s10620-013-2732-8
   Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7
   Choi JH, 2014, GASTROENT RES PRACT, V2014, DOI 10.1155/2014/179586
   Cuervo AM, 2014, CELL RES, V24, P92, DOI 10.1038/cr.2013.153
   Decaens T, 2012, DIGEST LIVER DIS, V44, P610, DOI 10.1016/j.dld.2012.02.005
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Deretic V, 2011, IMMUNOL REV, V240, P92, DOI 10.1111/j.1600-065X.2010.00995.x
   Dhillon S, 2013, DRUGS, V73, P475, DOI 10.1007/s40265-013-0034-2
   Diao JJ, 2015, NATURE, V520, P563, DOI 10.1038/nature14147
   Ding WX, 2009, MOL CANCER THER, V8, P2036, DOI 10.1158/1535-7163.MCT-08-1169
   Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001
   Egan DF, 2015, MOL CELL, V59, P285, DOI 10.1016/j.molcel.2015.05.031
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   FUTREAL PA, 1992, CANCER RES, V52, P2624
   Galluzzi L, 2017, NAT REV DRUG DISCOV, V16, P487, DOI 10.1038/nrd.2017.22
   GAO X, 1995, CANCER RES, V55, P1002
   Ge J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110293
   Geng JF, 2008, EMBO REP, V9, P859, DOI 10.1038/embor.2008.163
   Goldberg SB, 2013, ONCOLOGIST, V18, P1214, DOI 10.1634/theoncologist.2013-0168
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Gutierrez MG, 2004, J CELL SCI, V117, P2687, DOI 10.1242/jcs.01114
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
   Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704
   Hayashi-Nishino M, 2009, NAT CELL BIOL, V11, P1433, DOI 10.1038/ncb1991
   Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X
   Huang Shile, 2002, Curr Opin Investig Drugs, V3, P295
   Huang X, 2010, J CLIN NEUROSCI, V17, P1515, DOI 10.1016/j.jocn.2010.03.051
   Huo YY, 2013, CANCER DISCOV, V3, P894, DOI 10.1158/2159-8290.CD-13-0011
   Huynh H, 2009, J CELL MOL MED, V13, P1371, DOI 10.1111/j.1582-4934.2008.00364.x
   Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114
   Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178
   Itakura E, 2012, CELL, V151, P1256, DOI 10.1016/j.cell.2012.11.001
   Itakura E, 2008, MOL BIOL CELL, V19, P5360, DOI 10.1091/mbc.E08-01-0080
   Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183
   Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104
   Jager S, 2004, J CELL SCI, V117, P4837, DOI 10.1242/jcs.01370
   Jiang PD, 2010, BIOMED PHARMACOTHER, V64, P609, DOI 10.1016/j.biopha.2010.06.004
   Jiang P, 2014, MOL BIOL CELL, V25, P1327, DOI 10.1091/mbc.E13-08-0447
   Jiang S, 2011, CANCER SCI, V102, P1568, DOI 10.1111/j.1349-7006.2011.01964.x
   Jo YK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052705
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131
   Kaur A, 2017, INFLAMMOPHARMACOLOGY, V25, P293, DOI 10.1007/s10787-017-0336-1
   Kenific CM, 2015, TRENDS CELL BIOL, V25, P37, DOI 10.1016/j.tcb.2014.09.001
   Khushboo S., 2014, AUTOPHAGY, V10, P2346
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim KH, 2014, NAT REV ENDOCRINOL, V10, P322, DOI 10.1038/nrendo.2014.35
   Kim MS, 2008, HUM PATHOL, V39, P1059, DOI 10.1016/j.humpath.2007.11.013
   Kim MS, 2011, APMIS, V119, P802, DOI 10.1111/j.1600-0463.2011.02812.x
   Kirschey S, 2012, CLIN MED INSIGHTS-ON, V6, DOI 10.4137/CMO.S7327
   KISEN GO, 1993, CARCINOGENESIS, V14, P2501, DOI 10.1093/carcin/14.12.2501
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Koneri K, 2007, ANTICANCER RES, V27, P1453
   Kowalik MA, 2016, ONCOTARGET, V7, P5788, DOI 10.18632/oncotarget.6810
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029
   Kumar R, 2017, CURR OPIN SUPPORT PA, V11, P231, DOI 10.1097/SPC.0000000000000277
   Kwitkowski VE, 2010, ONCOLOGIST, V15, P428, DOI 10.1634/theoncologist.2009-0178
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li WW, 2012, CELL MOL LIFE SCI, V69, P1125, DOI 10.1007/s00018-011-0865-5
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liu G., 2017, INTERNATIONAL JOURNA, V18, P1
   Liu JT, 2015, CLIN LUNG CANCER, V16, pE55, DOI 10.1016/j.cllc.2015.03.006
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x
   Lozy F, 2014, AUTOPHAGY, V10, P662, DOI 10.4161/auto.27867
   Luo ZJ, 2005, TRENDS PHARMACOL SCI, V26, P69, DOI 10.1016/j.tips.2004.12.011
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347
   Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Mizushima N, 2010, NAT CELL BIOL, V12, P823, DOI 10.1038/ncb0910-823
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Negri T, 2010, GENE CHROMOSOME CANC, V49, P901, DOI 10.1002/gcc.20798
   Nicotra G, 2010, MODERN PATHOL, V23, P937, DOI 10.1038/modpathol.2010.80
   NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0
   Nishida Y, 2009, NATURE, V461, P654, DOI 10.1038/nature08455
   Njaria PM, 2015, EXPERT OPIN THER PAT, V25, P1003, DOI 10.1517/13543776.2015.1050791
   Pan HM, 2016, ONCOTARGET, V7, P21235, DOI 10.18632/oncotarget.6908
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954
   Paz MV, 2016, EXPERT OPIN THER TAR, V20, P487, DOI 10.1517/14728222.2016.1101068
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Qiu DM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-327
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Renna M, 2011, J CLIN INVEST, V121, P3554, DOI 10.1172/JCI46095
   RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573
   Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Rubinsztein DC, 2011, CELL, V146, P682, DOI 10.1016/j.cell.2011.07.030
   Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198
   Sasaki K, 2012, ANTI-CANCER DRUG, V23, P675, DOI 10.1097/CAD.0b013e328353f8c7
   Schonewolf CA, 2014, WORLD J GASTRO ONCOL, V6, P74, DOI 10.4251/wjgo.v6.i3.74
   SCHWARZE PE, 1985, EXP CELL RES, V157, P15, DOI 10.1016/0014-4827(85)90148-X
   Seliger C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181089
   Shimizu S, 2012, INT J CANCER, V131, P548, DOI 10.1002/ijc.26374
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Strohecker AM, 2013, CANCER DISCOV, V3, P1272, DOI 10.1158/2159-8290.CD-13-0397
   Sun K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.35
   Suzuki K, 2007, GENES CELLS, V12, P209, DOI 10.1111/j.1365-2443.2007.01050.x
   Tai WT, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.18
   Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Tang J, 2012, INT J MOL SCI, V13, P13414, DOI 10.3390/ijms131013414
   Thomas HE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003923
   Tian Y, 2015, CELL DEATH DIFFER, V22, P1025, DOI 10.1038/cdd.2014.201
   Tooze SA, 2010, NAT CELL BIOL, V12, P831, DOI 10.1038/ncb0910-831
   Torii S, 2016, EMBO REP, V17, P1552, DOI 10.15252/embr.201642565
   Toso C, 2010, HEPATOLOGY, V51, P1237, DOI 10.1002/hep.23437
   TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E
   Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0
   Wei HJ, 2014, GENE DEV, V28, P1204, DOI 10.1101/gad.237354.113
   Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wolpin BM, 2014, ONCOLOGIST, V19, P637, DOI 10.1634/theoncologist.2014-0086
   Wong PM, 2013, AUTOPHAGY, V9, P124, DOI 10.4161/auto.23323
   Wu DH, 2014, TUMOR BIOL, V35, P12225, DOI 10.1007/s13277-014-2531-7
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Xu HT, 2013, INT J CLIN EXP PATHO, V6, P711
   Yang A, 2014, CANCER DISCOV, V4, P905, DOI 10.1158/2159-8290.CD-14-0362
   Yang MP, 2015, ONCOTARGET, V6, P7084, DOI 10.18632/oncotarget.3054
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yang YP, 2013, ACTA PHARMACOL SIN, V34, P625, DOI 10.1038/aps.2013.5
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yang ZL, 2015, CLIN RES HEPATOL GAS, V39, P98, DOI 10.1016/j.clinre.2014.06.014
   Yao JC, 2011, NEW ENGL J MED, V364, P514, DOI 10.1056/NEJMoa1009290
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Yun M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117375
   Zhang MY, 2014, INT J MOL SCI, V15, P14372, DOI 10.3390/ijms150814372
   Zhang XY, 2017, CANCER IMMUNOL RES, V5, P363, DOI 10.1158/2326-6066.CIR-16-0398
   Zhang ZC, 2009, J HUAZHONG U SCI-MED, V29, P737, DOI 10.1007/s11596-009-0613-3
   Zheng Hai-yang, 2012, Cancer Biology Medicine, V9, P105, DOI 10.3969/j.issn.2095-3941.2012.02.004
   Zhu AX, 2014, JAMA-J AM MED ASSOC, V312, P57, DOI 10.1001/jama.2014.7189
   Zhu JL, 2017, MOL THER-NUCL ACIDS, V7, P299, DOI 10.1016/j.omtn.2017.04.012
   Zou YY, 2013, J THORAC ONCOL, V8, P693, DOI 10.1097/JTO.0b013e31828c7210
NR 169
TC 103
Z9 108
U1 3
U2 11
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2018
VL 2018
AR 8023821
DI 10.1155/2018/8023821
PG 18
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FV8CV
UT WOS:000424813400001
PM 29643976
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Wu, M
   Lao, YZ
   Xu, NH
   Wang, XY
   Tan, HS
   Fu, WW
   Lin, ZX
   Xu, HX
AF Wu, Man
   Lao, Yuanzhi
   Xu, Naihan
   Wang, Xiaoyu
   Tan, Hongsheng
   Fu, Wenwei
   Lin, Zhixiu
   Xu, Hongxi
TI Guttiferone K induces autophagy and sensitizes cancer cells to nutrient
   stress-induced cell death
SO PHYTOMEDICINE
LA English
DT Article
DE Apoptosis; Autophagy; Guttiferone K; Natural compound; Starvation
ID COLON-CANCER; APOPTOSIS; COMPOUND; TARGET; JNK; PROLIFERATION;
   INHIBITION; TOLERANCE
AB Background: Medicinal plants have long been an excellent source of pharmaceutical agents. Autophagy, a catabolic degradation process through lysosomes, plays an important role in tumorigenesis and cancer therapy.
   Purpose: Through a screen designed to identify autophagic regulators from a library of natural compounds, we found that Guttiferone K (GUTK) can activate autophagy in several cancer cell lines. The objective of this study is to investigate the mechanism by which GUTK sensitizes cancer cells to cell death in nutrient starvation condition.
   Methods: Cell death analysis was performed by propidium iodide staining with flow cytometry or Annexin V-FITC/PI staining assay. DCFH-DA staining was used for intracellular ROS measurement. Protein levels were analyzed by western blot analysis. Cell viability was measured by MTT assay.
   Results: Exposure to GUTK was observed to markedly induce GFP-LC3 puncta formation and activate the accumulation of LC3-II and the degradation of p62 in HeLa cells, suggesting that GUTK is an autophagy inducer. Importantly, hydroxychloroquine, an autophagy inhibitor, was found to significantly prevent GUTK-induced cell death in nutrient starvation conditions, suggesting that the cell death observed is largely dependent on autophagy. We further provide evidence that GUTK inhibits Akt phosphorylation, thereby inhibiting the mTOR pathway in cancer cells during nutrient starvation. In addition, GUTK causes the accumulation of reactive oxygen species (ROS) and the phosphorylation of JNK in EBSS, which may mediate both autophagy and apoptosis.
   Conclusion: These data indicate that GUTK sensitizes cancer cells to nutrient stress-induced cell death though Akt/mTOR dependent autophagy pathway. (C) 2015 The Authors. Published by Elsevier GmbH.
C1 [Wu, Man; Lao, Yuanzhi; Wang, Xiaoyu; Tan, Hongsheng; Fu, Wenwei; Xu, Hongxi] Shanghai Univ Tradit Chinese Med, Sch Pharm, Shanghai 201203, Peoples R China.
   [Wu, Man; Lao, Yuanzhi; Wang, Xiaoyu; Tan, Hongsheng; Fu, Wenwei; Xu, Hongxi] Engn Res Ctr Shanghai Coll TCM New Drug Discovery, Shanghai 201203, Peoples R China.
   [Xu, Naihan] Tsinghua Univ, Grad Sch Shenzhen, Div Life Sci, Key Lab Hlth Sci & Technol, Shenzhen 518055, Peoples R China.
   [Lin, Zhixiu] Chinese Univ Hong Kong, Sch Chinese Med, Fac Sci, Shatin, Hong Kong, Peoples R China.
RP Xu, HX (corresponding author), Shanghai Univ Tradit Chinese Med, Sch Pharm, Shanghai 201203, Peoples R China.
EM xuhongxi88@gmail.com
RI Xu, Hongxi/AAC-2799-2020; tan, Hongsheng/AAD-5830-2020; wu,
   man/AAD-5877-2020; Xu, Naihan/C-2778-2018; Fu, Wenwei/AAD-6756-2020;
   Lin, Zhi-Xiu/H-2807-2016; , Yuanzhi/D-3936-2015
OI , Yuanzhi/0000-0002-7803-4484; Xu, Hongxi/0000-0001-6238-4511
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81303188, 21272135]; Natural Science
   Foundation of ShanghaiNatural Science Foundation of Shanghai
   [14ZR1441300]
FX We would like to thank Professor Kevin Ryan (Beatson Institute for
   Cancer Research, CRUK) for providing the MEF Bax/Bak<SUP>-/-</SUP> cell
   line. This work was supported by the National Natural Science Foundation
   of China (No. 81303188 and 21272135) and the Natural Science Foundation
   of Shanghai (14ZR1441300).
CR Awale S, 2006, CANCER RES, V66, P1751, DOI 10.1158/0008-5472.CAN-05-3143
   Bartlett BJ, 2011, AUTOPHAGY, V7, P572, DOI 10.4161/auto.7.6.14943
   Beevers CS, 2006, INT J CANCER, V119, P757, DOI 10.1002/ijc.21932
   Chen Y, 2009, CELL DEATH DIFFER, V16, P1040, DOI 10.1038/cdd.2009.49
   Cheng P, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.17
   Fulda S, 2012, AUTOPHAGY, V8, P1250, DOI 10.4161/auto.20669
   Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1
   Green DR, 2014, CELL, V157, P65, DOI 10.1016/j.cell.2014.02.049
   Han QB, 2009, CURR MED CHEM, V16, P3775, DOI 10.2174/092986709789104993
   Izuishi K, 2000, CANCER RES, V60, P6201
   Johnson SM, 2009, ANTICANCER RES, V29, P3185
   Kan WLT, 2013, INT J CANCER, V132, P707, DOI 10.1002/ijc.27694
   Kim AD, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.273
   Lao YZ, 2014, AUTOPHAGY, V10, P736, DOI 10.4161/auto.28034
   Li L, 2012, FREE RADICAL BIO MED, V53, P1399, DOI 10.1016/j.freeradbiomed.2012.07.011
   Maes H, 2013, TRENDS MOL MED, V19, P428, DOI 10.1016/j.molmed.2013.04.005
   Maycotte P, 2012, AUTOPHAGY, V8, P200, DOI 10.4161/auto.8.2.18554
   Moyer MW, 2012, NAT MED, V18, P636, DOI 10.1038/nm0512-636b
   O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Richard JA, 2012, ANGEW CHEM INT EDIT, V51, P4536, DOI 10.1002/anie.201103873
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Saggar JK, 2014, INT J CANCER, V134, P2726, DOI 10.1002/ijc.28595
   Shimizu S, 2010, ONCOGENE, V29, P2070, DOI 10.1038/onc.2009.487
   Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019
   Xu G, 2008, J AGR FOOD CHEM, V56, P11144, DOI 10.1021/jf802690g
   Yang XL, 2014, ONCOTARGETS THER, V7, P1033, DOI 10.2147/OTT.S63145
   Yu SW, 2008, MOL CANCER THER, V7, P2609, DOI 10.1158/1535-7163.MCT-07-2400
   Zhang L, 2014, TOXICOL LETT, V228, P248, DOI 10.1016/j.toxlet.2014.05.015
NR 29
TC 37
Z9 43
U1 1
U2 45
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944-7113
J9 PHYTOMEDICINE
JI Phytomedicine
PD SEP 15
PY 2015
VL 22
IS 10
BP 902
EP 910
DI 10.1016/j.phymed.2015.06.008
PG 9
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA CQ4CH
UT WOS:000360551300004
PM 26321739
OA hybrid
DA 2022-04-25
ER

PT J
AU Coker-Gurkan, A
   Arisart, ED
   Obakan, P
   Guvenir, E
   Unsal, NP
AF Coker-Gurkan, Ajda
   Arisan, Elif Damla
   Obakan, Pinar
   Guvenir, Esin
   Unsal, Narcin Palavan
TI Inhibition of autophagy by 3-MA potentiates purvalanol-induced apoptosis
   in Bax deficient HCT 116 colon cancer cells
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Colon cancer; Apoptosis; Autophagy; CDK inhibitors; Bax
ID IN-VITRO; ROSCOVITINE; DEATH; MACROAUTOPHAGY; OLOMOUCINE; PATHWAY
AB The purine-derived analogs, roscovitine and purvalanol are selective synthetic inhibitors of cyclin-dependent kinases (CDKs) induced cell cycle arrest and lead to apoptotic cell death in various cancer cells. Although a number of studies investigated the molecular mechanism of each CDK inhibitor on apoptotic cell death mechanism with their therapeutic potential, their regulatory role on autophagy is not clarified yet. In this paper, our aim was to investigate molecular mechanism of CDK inhibitors on autophagy and apoptosis in wild type (wt) and Bax deficient HCT 116 cells. Exposure of HCT 116 wt and Bax(-/-) cells to roscovitine or purvalanol for 24 h decreased cell viability in dose-dependent manner. However, Bax deficient HCT 116 cells were found more resistant against purvalanol treatment compared to wt cells. We also established that both CDK inhibitors induced apoptosis through activating mitochondria-mediated pathway in caspase-dependent manner regardless of Bax expression in HCT 116 colon cancer cells. Concomitantly, we determined that purvalanol was also effective on autophagy in HCT 116 colon cancer cells. Inhibition of autophagy by 3-MA treatment enhanced the purvalanol induced apoptotic cell death in HCT 116 Bax(-/-) cells. Our results revealed that mechanistic action of each CDK inhibitor on cell death mechanism differs. While purvalanol treatment activated apoptosis and autophagy in HCT 116 cells, roscovitine was only effective on caspase-dependent apoptotic pathway. Another important difference between two CDK inhibitors, although roscovitine treatment overcame Bax-mediated drug resistance in HCT 116 cells, purvalanol did not exert same effect. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Coker-Gurkan, Ajda; Arisan, Elif Damla; Obakan, Pinar; Guvenir, Esin; Unsal, Narcin Palavan] Istanbul Kultur Univ, Mol Biol & Genet Dept, Sci & Literature Fac, TR-34156 Istanbul, Turkey.
RP Coker-Gurkan, A (corresponding author), Istanbul Kultur Univ, Mol Biol & Genet Dept, Sci & Literature Fac, Atakoy Campus, TR-34156 Istanbul, Turkey.
EM a.coker@iku.edu.tr
RI OBAKAN, PINAR/D-2836-2015; Arisan, Elif Damla/W-8682-2019
OI Arisan, Elif Damla/0000-0002-4844-6381; Gurkan, Ajda/0000-0003-1475-2417
FU Istanbul Kultur University Scientific Projects Support CenterIstanbul
   Kultur University
FX This work was supported by Istanbul Kultur University Scientific
   Projects Support Center.
CR Arisan E.D., 2013, CURR PHARM DES
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Cabon L, 2012, CELL DEATH DIFFER, V19, P245, DOI 10.1038/cdd.2011.91
   Coker A, 2012, MOL MED REP, V5, P1037, DOI 10.3892/mmr.2012.768
   Cui Q, 2007, BIOL PHARM BULL, V30, P859, DOI 10.1248/bpb.30.859
   Cui Q, 2006, J PHARMACOL SCI, V101, P230, DOI 10.1254/jphs.FPJ06003X
   Dorsey FC, 2009, METHOD ENZYMOL, V453, P251, DOI 10.1016/S0076-6879(08)04012-3
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Garrofe-Ochoa X, 2008, MOL CANCER THER, V7, P3800, DOI 10.1158/1535-7163.MCT-08-0655
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Gray N, 1999, CURR MED CHEM, V6, P859
   Gurkan AC, 2013, APOPTOSIS, V18, P1536, DOI 10.1007/s10495-013-0885-8
   Hwang SO, 2008, BIOTECHNOL BIOENG, V99, P678, DOI 10.1002/bit.21589
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Krystof V, 2002, BIOORG MED CHEM LETT, V12, P3283, DOI 10.1016/S0960-894X(02)00693-5
   Ku B, 2008, AUTOPHAGY, V4, P519, DOI 10.4161/auto.5846
   Kumar D, 2014, CANCER LETT, V343, P179, DOI 10.1016/j.canlet.2013.10.003
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Liu DL, 2011, MED ONCOL, V28, P105, DOI 10.1007/s12032-009-9397-3
   Martinet W, 2009, CLIN SCI, V116, P697, DOI 10.1042/CS20080508
   McClue SJ, 2002, INT J CANCER, V102, P463, DOI 10.1002/ijc.10738
   Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x
   Monaco EA, 2004, BIOCHEM PHARMACOL, V67, P1947, DOI 10.1016/j.bcp.2004.02.007
   Notte A, 2011, BIOCHEM PHARMACOL, V82, P427, DOI 10.1016/j.bcp.2011.06.015
   Pan XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056679
   Park JH, 2005, J BIOCHEM MOL BIOL, V38, P619
   Pattingre S, 2006, CANCER RES, V66, P2885, DOI 10.1158/0008-5472.CAN-05-4412
   Senderowicz AM, 2003, CANCER BIOL THER, V2, pS84
   Song LL, 2013, ONCOL LETT, V6, P1031, DOI 10.3892/ol.2013.1498
   Ullman E, 2008, CELL DEATH DIFFER, V15, P422, DOI 10.1038/sj.cdd.4402234
   Wang ZH, 2007, GYNECOL ONCOL, V107, P107, DOI 10.1016/j.ygyno.2007.05.034
   Wesierska-Gadek J, 2008, J CELL BIOCHEM, V105, P1161, DOI 10.1002/jcb.21903
   Wesierska-Gadek J, 2008, BIOCHEM PHARMACOL, V76, P1503, DOI 10.1016/j.bcp.2008.07.040
   Xiong HY, 2010, CANCER LETT, V288, P68, DOI 10.1016/j.canlet.2009.06.039
   Zatloukal M, 2013, EUR J MED CHEM, V61, P61, DOI 10.1016/j.ejmech.2012.06.036
   Zhang T, 2010, ONCOL REP, V23, P239, DOI 10.3892/or_00000629
   Zhou CJ, 2012, J CELL PHYSIOL, V227, P3778, DOI 10.1002/jcp.24086
NR 37
TC 22
Z9 27
U1 0
U2 21
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD OCT 15
PY 2014
VL 328
IS 1
BP 87
EP 98
DI 10.1016/j.yexcr.2014.07.022
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA AQ1KK
UT WOS:000342540100007
PM 25088259
DA 2022-04-25
ER

PT J
AU Yu, L
   Hou, JG
   Li, YF
   Wang, Y
   Hong, M
   Yang, YM
AF Yu, Lei
   Hou, Ji-Guang
   LI, Yun-Feng
   Wang, Yin
   Hong, Ming
   Yang, Yan-Ming
TI Inhibiting endoplasmic reticulum stress mediated-autophagy enhances the
   pro-apoptotic effects of resveratrol derivative in colon cancer cells
SO NEOPLASMA
LA English
DT Article
DE endoplasmic reticulum stress; trans-3; 5; 4'-trimethoxystilbene;
   apoptosis; autophagy; colon cancer
AB Previous studies have demonstrated that endoplasmic reticulum stress (ERS) might play a major role in inducing cellular autophagy and apoptosis in multiple types of cancer. Herein, we observed that trans-3,5,4'-trimethoxystilbene (TMS) exposure facilitated apoptotic cell death and ERS-mediated autophagy in colon cancer SW480 and HCT116 cells. Interestingly, our data demonstrated that ERS was not involved in TMS-induced apoptosis. However, ERS notably induced protective autophagy in SW480 and HCT116 cells. In addition, inhibiting cellular ERS significantly improved the pro-apoptotic effects of TMS. Thus, our results indicated that TMS-mediated autophagy was dependent on ERS, while apoptotic cell death might be induced in the ERS-independent pathway after TMS treatment. Generally, inhibiting ERS-mediated autophagy can enhance the pro-apoptotic effects of TMS. TMS might be a potential therapeutic agent for colon cancer treatment.
C1 [Yu, Lei; Hou, Ji-Guang; LI, Yun-Feng; Wang, Yin; Yang, Yan-Ming] Second Hosp Jilin Univ, Dept Radiotherapy, Changchun, Peoples R China.
   [Hong, Ming] Guangzhou Univ, Inst Adv Diagnost & Clin Med, Zhongshan Peoples Hosp, Zhongshan, Peoples R China.
   [Hong, Ming] Zhongshan Peoples Hosp, Joint Biomed Inst, Zhongshan, Peoples R China.
   [Hong, Ming] Dongguan & Guangzhou Univ Chinese Med, Cooperat Acad Math Engn Chinese Med, Dongguan, Peoples R China.
RP Yang, YM (corresponding author), Second Hosp Jilin Univ, Dept Radiotherapy, Changchun, Peoples R China.; Hong, M (corresponding author), Guangzhou Univ, Inst Adv Diagnost & Clin Med, Zhongshan Peoples Hosp, Zhongshan, Peoples R China.; Hong, M (corresponding author), Zhongshan Peoples Hosp, Joint Biomed Inst, Zhongshan, Peoples R China.; Hong, M (corresponding author), Dongguan & Guangzhou Univ Chinese Med, Cooperat Acad Math Engn Chinese Med, Dongguan, Peoples R China.
EM hongming1986@gzucm.edu.cn; richard8207@126.com
FU projects of science and technology development plan of Jilin province
   [20190201203JC, 20190201214JC]; projects of Guangdong Basic and Applied
   Basic Research Foundation [2019A1515110167]
FX This research was supported by the projects of science and technology
   development plan of Jilin province (20190201203JC, 20190201214JC) and
   the projects of Guangdong Basic and Applied Basic Research Foundation
   (2019A1515110167) .
CR Abdel-Aziz AK, 2016, EXP NEUROL, V283, P129, DOI 10.1016/j.expneurol.2016.06.004
   Abdouh M, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1248-2
   Avila-Galvez MA, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201801239
   Baek SH, 2016, PHYTOMEDICINE, V23, P566, DOI 10.1016/j.phymed.2016.02.011
   Devis-Jauregui L, 2021, AUTOPHAGY, V17, P1077, DOI 10.1080/15548627.2020.1752548
   Fan YM, 2020, INT J ONCOL, V57, P925, DOI 10.3892/ijo.2020.5107
   Fuggetta MP, 2006, J EXP CLIN CANC RES, V25, P189
   Gimenez-Bastida JA, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201900629
   Hashemzaei M, 2017, ONCOL REP, V38, P819, DOI 10.3892/or.2017.5766
   Hashemzaei M, 2016, ENVIRON TOXICOL PHAR, V46, P110, DOI 10.1016/j.etap.2016.07.010
   Hong M, 2020, MOL NUTR FOOD RES, V64, DOI 10.1002/mnfr.201901115
   Hsieh MJ, 2019, PHYTOMEDICINE, V58, DOI 10.1016/j.phymed.2018.12.028
   Krasanakis T, 2019, ONCOL REP, V42, P2228, DOI 10.3892/or.2019.7351
   Kumar D, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-171
   Lee TY, 2021, AUTOPHAGY, V17, P4141, DOI [10.1080/15548627.2021.1904495, 10.6084/m9.figshare.14259880.v3]
   Lin FZ, 2019, PHYTOMEDICINE, V54, P1, DOI 10.1016/j.phymed.2018.09.181
   Lindeman TE, 2011, MUTAGENESIS, V26, P629, DOI 10.1093/mutage/ger024
   de Faria JML, 2016, INVEST OPHTH VIS SCI, V57, P4356, DOI 10.1167/iovs.16-19197
   Ming H, 2020, PHYTOMEDICINE, V68, DOI 10.1016/j.phymed.2020.153174
   Moller F, 2007, PHYTOMEDICINE, V14, P716, DOI 10.1016/j.phymed.2007.09.001
   Pak S, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1342-5
   Qomaladewi NP, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092081
   Yamamoto K, 2020, AUTOPHAGY, V16, P1524, DOI 10.1080/15548627.2020.1769973
   Zhou YX, 2016, MOL CARCINOGEN, V55, P1317, DOI 10.1002/mc.22374
NR 24
TC 0
Z9 0
U1 5
U2 5
PU AEPRESS SRO
PI BRATISLAVA
PA BAJZOVA 7, BRATISLAVA, 821 08, SLOVAKIA
SN 0028-2685
EI 1338-4317
J9 NEOPLASMA
JI Neoplasma
PY 2021
VL 68
IS 6
BP 1236
EP +
DI 10.4149/neo_2021_210422N552
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA XN0II
UT WOS:000729198300001
PM 34648300
DA 2022-04-25
ER

PT J
AU Zhou, YJ
   Zhou, XT
   Huang, XJ
   Hong, T
   Zhang, K
   Qi, WC
   Guo, M
   Nie, SP
AF Zhou, Yujia
   Zhou, Xingtao
   Huang, Xiaojun
   Hong, Tao
   Zhang, Ke
   Qi, Wucheng
   Guo, Mi
   Nie, Shaoping
TI Lysosome-Mediated Cytotoxic Autophagy Contributes to Tea
   Polysaccharide-Induced Colon Cancer Cell Death via mTOR-TFEB Signaling
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE tea polysaccharide; autophagy; lysosome; colon cancer cell; mTOR-TFEB
   signaling
ID RELEASE
AB Targeting autophagy and lysosome may serve as a promising strategy for cancer therapy. Tea polysaccharide (TP) has shown promising antitumor effects. However, its mechanism remains elusive. Here, TP was found to have a significant inhibitory effect on the proliferation of colon cancer line HCT116 cells. RNA-seq analysis showed that TP upregulated autophagy and lysosome signal pathways, which was further confirmed through experiments. Immunofluorescence experiments indicated that TP activated transcription factor EB (TFEB), a key nuclear transcription factor modulating autophagy and lysosome biogenesis. In addition, TP inhibited the activity of mTOR, while it increased the expression of Lamp1. Furthermore, TP ameliorated the lysosomal damage and autophagy flux barrier caused by Baf A1 (lysosome inhibitor). Hence, our data suggested that TP repressed the proliferation of HCT116 cells by targeting lysosome to induce cytotoxic autophagy, which might be achieved through mTOR-TFEB signaling. In summary, TP may be used as a potential drug to overcome colon cancer.
C1 [Zhou, Yujia; Zhou, Xingtao; Huang, Xiaojun; Hong, Tao; Zhang, Ke; Qi, Wucheng; Guo, Mi; Nie, Shaoping] Nanchang Univ, State Key Lab Food Sci & Technol, China Canada Joint Lab Food Sci & Technol Nanchan, Nanchang 330047, Jiangxi, Peoples R China.
RP Zhou, XT; Nie, SP (corresponding author), Nanchang Univ, State Key Lab Food Sci & Technol, China Canada Joint Lab Food Sci & Technol Nanchan, Nanchang 330047, Jiangxi, Peoples R China.
EM zhouxingtao@ncu.edu.cn; spnie@ncu.edu.cn
RI 周, 兴涛/F-2927-2019
OI 周, 兴涛/0000-0002-1902-9677; Nie, Shao-Ping/0000-0002-2412-4679
FU National Natural Science Foundation of China for Distinguished Young
   ScholarsNational Natural Science Foundation of China (NSFC)National
   Science Fund for Distinguished Young Scholars [31825020]; Natural
   Science Foundation of Jiangxi ProvinceNatural Science Foundation of
   Jiangxi Province [20192BAB204024]
FX Grant support is from the National Natural Science Foundation of China
   for Distinguished Young Scholars (31825020) and the Natural Science
   Foundation of Jiangxi Province (20192BAB204024).
CR Bahrami A, 2020, LIFE SCI, V244, DOI 10.1016/j.lfs.2020.117341
   Baxt LA, 2015, GASTROENTEROLOGY, V149, P553, DOI 10.1053/j.gastro.2015.06.046
   Bonam SR, 2019, NAT REV DRUG DISCOV, V18, P923, DOI 10.1038/s41573-019-0036-1
   Cheng LZ, 2018, INT J BIOL MACROMOL, V120, P853, DOI 10.1016/j.ijbiomac.2018.08.154
   Davidson SM, 2017, ANNU REV PHARMACOL, V57, P481, DOI 10.1146/annurev-pharmtox-010715-103101
   Dibble CC, 2013, NAT CELL BIOL, V15, P555, DOI 10.1038/ncb2763
   [丁婧思 Ding Jingsi], 2014, [食品科学, Food Science], V35, P57
   Du LL, 2016, MOLECULES, V21, DOI 10.3390/molecules21111449
   Evans TD, 2018, AUTOPHAGY, V14, P724, DOI 10.1080/15548627.2018.1434373
   Huang GL, 2017, FUTURE MED CHEM, V9, P1931, DOI 10.4155/fmc-2017-0132
   Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451
   Lawrence RE, 2019, NAT CELL BIOL, V21, P133, DOI 10.1038/s41556-018-0244-7
   [李海珊 Li Haishan], 2017, [食品科学, Food Science], V38, P187
   Liu LQ, 2018, J AGR FOOD CHEM, V66, P4384, DOI 10.1021/acs.jafc.8b00710
   Liu LQ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020506
   Luo CC, 2018, J AGR FOOD CHEM, V66, P13041, DOI 10.1021/acs.jafc.8b04508
   Martini-Stoica H, 2016, TRENDS NEUROSCI, V39, P221, DOI 10.1016/j.tins.2016.02.002
   Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565
   Nepal S, 2014, FOOD CHEM TOXICOL, V68, P11, DOI 10.1016/j.fct.2014.02.027
   Nie CZP, 2018, CARBOHYD POLYM, V188, P236, DOI 10.1016/j.carbpol.2018.02.009
   Nnah I. C., 2015, J CELL DEATH, V1, DOI [10.1515/cdth-2015-0001, DOI 10.1515/CDTH-2015-0001]
   Nnah IC, 2019, AUTOPHAGY, V15, P151, DOI 10.1080/15548627.2018.1511504
   Pan HT, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1653-7
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Piao SF, 2016, ANN NY ACAD SCI, V1371, P45, DOI 10.1111/nyas.12953
   Qi WC, 2020, CARBOHYD POLYM, V237, DOI 10.1016/j.carbpol.2020.116113
   Repnik U, 2017, J CELL SCI, V130, P3124, DOI 10.1242/jcs.204529
   Roczniak-Ferguson A, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002790
   Saftig P, 2016, NAT CELL BIOL, V18, P1025, DOI 10.1038/ncb3409
   Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447
   Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32
   Song WS, 2014, ACS NANO, V8, P10328, DOI 10.1021/nn505073u
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Tan YQ, 2017, AUTOPHAGY, V13, P225, DOI 10.1080/15548627.2016.1234563
   Tian H, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108709
   Vega-Rubin-de-Celis S, 2017, AUTOPHAGY, V13, P464, DOI 10.1080/15548627.2016.1271514
   Wang Z, 2015, INT J BIOCHEM CELL B, V64, P126, DOI 10.1016/j.biocel.2015.03.018
   Wu TR, 2019, GUT, V68, P248, DOI 10.1136/gutjnl-2017-315458
   Wu YJ, 2018, INT J BIOL MACROMOL, V107, P1151, DOI 10.1016/j.ijbiomac.2017.09.092
   Yang JJ, 2012, CARBOHYD POLYM, V90, P943, DOI 10.1016/j.carbpol.2012.06.024
   Yang K, 2019, INT J BIOL MACROMOL, V125, P557, DOI 10.1016/j.ijbiomac.2018.12.088
   Yang ZY, 2013, CARBOHYD POLYM, V95, P615, DOI 10.1016/j.carbpol.2013.03.024
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Zhang H, 2015, AUTOPHAGY, V11, P9, DOI 10.1080/15548627.2014.1003478
   Zhang JB, 2016, ONCOTARGET, V7, P75659, DOI 10.18632/oncotarget.12318
   Zhang M, 2019, PROG MOL BIOL TRANSL, V163, P297, DOI 10.1016/bs.pmbts.2019.02.013
   Zheng K, 2017, J AGR FOOD CHEM, V65, P6625, DOI 10.1021/acs.jafc.7b02296
   Zhou XT, 2019, J AGR FOOD CHEM, V67, P9831, DOI 10.1021/acs.jafc.9b03939
NR 48
TC 5
Z9 5
U1 18
U2 66
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
EI 1520-5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD JAN 20
PY 2021
VL 69
IS 2
BP 686
EP 697
DI 10.1021/acs.jafc.0c07166
PG 12
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Agriculture; Chemistry; Food Science & Technology
GA PZ2IO
UT WOS:000612563800007
PM 33369397
DA 2022-04-25
ER

PT J
AU Liu, YX
   Yang, B
   Zhang, LR
   Cong, XL
   Liu, Z
   Hu, Y
   Zhang, J
   Hu, HX
AF Liu, Yuxia
   Yang, Bin
   Zhang, Lirong
   Cong, Xianling
   Liu, Zhen
   Hu, Yu
   Zhang, Jing
   Hu, Haixia
TI Ginkgolic acid induces interplay between apoptosis and autophagy
   regulated by ROS generation in colon cancer
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Colon cancer; Ginkgolic acids; Cell cycle arrest; Apoptosis and
   autophagy; ROS
ID EPITHELIAL-MESENCHYMAL TRANSITION; CELL-CYCLE ARREST; PANCREATIC-CANCER;
   MITOCHONDRIA; GROWTH
AB Presently, developing effective anti-colon cancer drugs still remains to be important. Ginkgolic acids (GA), as a botanical drug extracted from the seed coat of Ginkgo biloba L, possess various bioactive properties. Our findings, for the first time, indicated that GA suppressed colon cancer cell proliferation, migration and invasion. GA led to cell death through G0/G1 phase arrest. In addition, apoptosis was significantly induced by GA treatment. The intrinsic apoptosis pathway was included, proved by the release of cytochrome c (Cyto-c) from the mitochondria into the cytosol. GA-induced autophagy was supported by the dose-dependent increase of LC3BII, autophagy-related gene-5 (ATG-5) and Beclin-1. Notably, silencing ATG-5 further reduced the cell viability and enhanced apoptosis in GA-treated colon cancer cells, indicating that GA-induced apoptosis rather than autophagy contributes to colon cancer cell death. And mammalian target of rapamycin complex 1 (mTORC1) was dose-dependently reduced by GA, evidenced by the reduction of p-mTOR, p-p70 ribosomal S6 kinase (p70s6k) and p-pras40. Moreover, GA markedly resulted in reactive oxygen species (ROS) generation, along with increased H2O2 and O-2(-). However, blocking ROS generation using its scavenger, NAC, significantly recovered GA-induced cells death, supported by the increase of cell viability, and the decrease of apoptosis. The expressions of autophagy- and cell cycle arrest-related molecules, as well as mTORC1 were also reversed by N-acetyl-L-cysteine (NAC) in GA-treated cells. In vivo, GA reduced tumor growth without toxicity to animals. In conclusion, our study illustrated that GA caused G0/G1 phase arrest and triggered intrinsic apoptosis and autophagy modulated by ROS generation in human colon cancer, elucidating that GA might be considered as a potential agent for colon cancer therapy. (C) 2018 Published by Elsevier Inc.
C1 [Liu, Yuxia] Jilin Univ, China Japan Union Hosp, Med Records Room,126 Xiantai Rd, Changchun 130033, Jilin, Peoples R China.
   [Yang, Bin] Jilin Univ, China Japan Union Hosp, Dept Breast Surg, 126 Xiantai Rd, Changchun 130033, Jilin, Peoples R China.
   [Zhang, Lirong; Cong, Xianling; Hu, Yu] Jilin Univ, China Japan Union Hosp, Dept Pathol, 126 Xiantai Rd, Changchun 130033, Jilin, Peoples R China.
   [Liu, Zhen] Tradit Chinese Med Hosp Luhe Dist, Dept TCM Pediat, Nanjing 223300, Jiangsu, Peoples R China.
   [Zhang, Jing] Jilin Univ, Dept Nephrol, China Japan Union Hosp, 126 Xiantai Rd, Changchun 130033, Jilin, Peoples R China.
   [Hu, Haixia] Jilin Univ, Colorectal Surg, China Japan Union Hosp, 126 Xiantai Rd, Changchun 130033, Jilin, Peoples R China.
RP Zhang, J (corresponding author), Jilin Univ, Dept Nephrol, China Japan Union Hosp, 126 Xiantai Rd, Changchun 130033, Jilin, Peoples R China.; Hu, HX (corresponding author), Jilin Univ, Colorectal Surg, China Japan Union Hosp, 126 Xiantai Rd, Changchun 130033, Jilin, Peoples R China.
EM 3322399048@qq.com; huhaixiajl@foxmail.com
CR Brentnall M, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471-2121-14-32
   Chen LH, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2468-x
   Dixon SJ, 2014, NAT CHEM BIOL, V10, P9, DOI 10.1038/nchembio.1416
   Eymin B, 2010, CELL ADHES MIGR, V4, P114, DOI 10.4161/cam.4.1.10977
   Ghavami S, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.61
   Iwatsuki M, 2010, INT J CANCER, V126, P1828, DOI 10.1002/ijc.24879
   Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011
   Lu JM, 2012, MED SCI MONITOR, V18, pBR293
   Ma JG, 2015, ONCOTARGET, V6, P20993, DOI 10.18632/oncotarget.3663
   Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602
   Martinou JC, 2011, DEV CELL, V21, P92, DOI 10.1016/j.devcel.2011.06.017
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Pei Z, 2017, BIOCHEM BIOPH RES CO, V493, P455, DOI 10.1016/j.bbrc.2017.08.170
   Pyo JO, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3300
   Quirke P, 2015, LANCET ONCOL, V16, P121, DOI 10.1016/S1470-2045(14)71223-9
   Relja B, 2010, INT J MOL MED, V26, P733, DOI 10.3892/ijmm_00000520
   Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205
   Saha A, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001275
   Sentelle RD, 2012, NAT CHEM BIOL, V8, P831, DOI 10.1038/NCHEMBIO.1059
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Su ZY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0321-5
   Xiang TX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029783
   Yu J, 2011, ASIAN PAC J CANCER P, V12, P1925
   Zhang JW, 2013, NAT CELL BIOL, V15, P1186, DOI 10.1038/ncb2822
   Zhou CC, 2010, CHEMOTHERAPY, V56, P393, DOI 10.1159/000317750
NR 27
TC 28
Z9 31
U1 6
U2 27
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAR 25
PY 2018
VL 498
IS 1
BP 246
EP 253
DI 10.1016/j.bbrc.2018.01.091
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA GC2SR
UT WOS:000429633400037
PM 29353042
DA 2022-04-25
ER

PT J
AU Kim, KY
   Oh, TW
   Yang, HJ
   Kim, YW
   Ma, JY
   Park, KI
AF Kim, Kwang-Youn
   Oh, Tae-Woo
   Yang, Hye-Jin
   Kim, Young-Woo
   Ma, Jin-Yeul
   Park, Kwang-Il
TI Ethanol extract of Chrysanthemum zawadskii Herbich induces autophagy and
   apoptosis in mouse colon cancer cells through the regulation of reactive
   oxygen species
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
DE Chrysanthemum zawadskii Herbich; Colon cancer; Apoptosis; Autophagy;
   Reactive oxygen species
ID INHIBITION; LINARIN; PATHWAYS; DEATH; P53
AB Background Recent research has suggested that autophagy can provide a better mechanism for inducing cell death than current therapeutic strategies. This study investigated the effects of using an ethanol extract of Chrysanthemum zawadskii Herbich (ECZ) to induce apoptosis and autophagy associated with reliable signal pathways in mouse colon cancer CT-26 cells. Methods Using ECZ on mouse colon cancer CT-26 cells, cell viability, annexin V/propidium iodide staining, acridine orange staining, reactive oxygen species (ROS) and western blotting were assayed. Results ECZ exhibited cytotoxicity in CT-26 cells in a dose-dependent manner. ECZ induced apoptosis was confirmed by caspase-3 activation, poly (ADP-ribose) polymerase cleavage, and increased production of reactive oxygen species (ROS). Furthermore, it was shown that ECZ induced autophagy via the increased conversion of microtubule-associated protein 1 light chain 3II, the degradation of p62, and the formation of acidic vesicular organelles. The inhibition of ROS production by N-Acetyl-L-cysteine resulted in reduced ECZ-induced apoptosis and autophagy. Furthermore, the inhibition of autophagy by 3-methyladenine resulted in enhanced ECZ-induced apoptosis via increased ROS generation. Conclusion These findings confirmed that ECZ induced ROS-mediated autophagy and apoptosis in colon cancer cells. Therefore, ECZ may serve as a novel potential chemotherapeutic candidate for colon cancer.
C1 [Kim, Kwang-Youn; Oh, Tae-Woo; Yang, Hye-Jin; Ma, Jin-Yeul; Park, Kwang-Il] KIOM, Korean Med KM Applicat Ctr, Daegu 41062, South Korea.
   [Kim, Young-Woo] Daegu Haany Univ, Coll Oriental Med, Dept Herbal Formula Med Res Ctr MRC GHF, Gyongsan 38610, South Korea.
RP Park, KI (corresponding author), KIOM, Korean Med KM Applicat Ctr, Daegu 41062, South Korea.
EM kipark@kiom.re.kr
FU Korea Institute of Oriental Medicine - Ministry of Education, Science
   and Technology (MEST), Republic of KoreaMinistry of Education, Science
   and Technology, Republic of Korea [KSN1812102]; National Research
   Foundation of Korea (NRF) - Ministry of Education
   [NRF-2017R1D1A1B03032284]; Ministry of Oceans and Fisheries, Republic of
   Korea [20190055]
FX This work was supported by a grant (No. KSN1812102) from the Korea
   Institute of Oriental Medicine funded by the Ministry of Education,
   Science and Technology (MEST), Republic of Korea. This work was also
   supported by Basic Science Research Program through the National
   Research Foundation of Korea (NRF) funded by the Ministry of Education
   (NRF-2017R1D1A1B03032284) and by grant (No. 20190055) funded by the
   Ministry of Oceans and Fisheries, Republic of Korea.
CR Ben Sassi A, 2008, INDIAN J MED RES, V127, P183
   Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622
   Cheng Y, 2013, PHARMACOL REV, V65, P1162, DOI 10.1124/pr.112.007120
   El-Khattouti Abdelouahid, 2013, J Cell Death, V6, P37, DOI 10.4137/JCD.S11034
   Esteve Juan M, 2011, World J Biol Chem, V2, P232, DOI 10.4331/wjbc.v2.i10.232
   Han S, 2002, ARCH PHARM RES, V25, P170, DOI 10.1007/BF02976559
   Hao WH, 2014, PEERJ, V2, DOI 10.7717/peerj.555
   He JP, 2011, J PLANT PHYSIOL, V168, P687, DOI 10.1016/j.jplph.2010.10.009
   Hu C, 2017, MOLECULES, V22, DOI 10.3390/molecules22040557
   Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437
   Jeong SY, 2008, BMB REP, V41, P11, DOI 10.1146/annurev-genet-102108-134850
   Kim KY, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051088
   Kim KY, 2017, BIOMED PHARMACOTHER, V88, P1016, DOI 10.1016/j.biopha.2017.01.140
   Kim SH, 2016, BIOCHEM BIOPH RES CO, V473, P607, DOI 10.1016/j.bbrc.2016.03.132
   Kim SH, 2015, BIOCHEM BIOPH RES CO, V468, P151, DOI 10.1016/j.bbrc.2015.10.143
   Kim SJ, 2014, EUR J PHARMACOL, V738, P66, DOI 10.1016/j.ejphar.2014.05.024
   Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811
   Kongara S, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00171
   Liu QJ, 2012, COLLOID SURFACE B, V92, P348, DOI 10.1016/j.colsurfb.2011.12.007
   Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143
   Miki H, 2012, INT J ONCOL, V40, P1020, DOI 10.3892/ijo.2012.1325
   Ohsumi Y, 2014, CELL RES, V24, P9, DOI 10.1038/cr.2013.169
   Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x
   Pan XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056679
   Park Min-Jun, 2016, Prev Nutr Food Sci, V21, P227, DOI 10.3746/pnf.2016.21.3.227
   Qin Shan, 2011, Zhongguo Zhong Yao Za Zhi, V36, P1474
   Seo JY, 2010, NUTR RES PRACT, V4, P93, DOI 10.4162/nrp.2010.4.2.93
   Valdor R, 2012, PHARMACOL RES, V66, P475, DOI 10.1016/j.phrs.2012.10.003
   Wu TY, 2011, AAPS J, V13, P1, DOI 10.1208/s12248-010-9239-4
   Yang PF, 2017, J NAT PROD, V80, P1028, DOI 10.1021/acs.jnatprod.6b01026
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yuan L, 2014, J AGR FOOD CHEM, V62, P5390, DOI 10.1021/jf500903g
   Zhan Y, 2012, FREE RADICAL BIO MED, V53, P532, DOI 10.1016/j.freeradbiomed.2012.05.018
   Zhang T, 2012, AUTOPHAGY, V8, P559, DOI 10.4161/auto.18867
   Zhen ZG, 2017, BIOMED PHARMACOTHER, V95, P363, DOI 10.1016/j.biopha.2017.08.023
   Zhou YT, 2016, ACTA BIOCH BIOPH SIN, V48, P60, DOI 10.1093/abbs/gmv119
NR 36
TC 8
Z9 8
U1 1
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1472-6882
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD OCT 21
PY 2019
VL 19
IS 1
AR 274
DI 10.1186/s12906-019-2688-0
PG 10
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA JF4DZ
UT WOS:000491339200003
PM 31638961
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Lampada, A
   O'Prey, J
   Szabadkai, G
   Ryan, KM
   Hochhauser, D
   Salomoni, P
AF Lampada, Aikaterini
   O'Prey, James
   Szabadkai, Gyorgy
   Ryan, Kevin M.
   Hochhauser, Daniel
   Salomoni, Paolo
TI mTORC1-independent autophagy regulates receptor tyrosine kinase
   phosphorylation in colorectal cancer cells via an mTORC2-mediated
   mechanism
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Article
ID GROWTH-FACTOR RECEPTOR; PRIMARY COLON-CANCER; TARGETING AUTOPHAGY; TUMOR
   PROGRESSION; OPEN-LABEL; CETUXIMAB; TUMORIGENESIS; EGFR; RESISTANCE;
   INHIBITION
AB The intracellular autophagic degradative pathway can have a tumour suppressive or tumour-promoting role depending on the stage of tumour development. Upon starvation or targeting of oncogenic receptor tyrosine kinases (RTKs), autophagy is activated owing to the inhibition of PI3K/AKT/mTORC1 signalling pathway and promotes survival, suggesting that autophagy is a relevant therapeutic target in these settings. However, the role of autophagy in cancer cells where the PI3K/AKT/mTORC1 pathway is constitutively active remains partially understood. Here we report a role for mTORC1-independent basal autophagy in regulation of RTK activation and cell migration in colorectal cancer (CRC) cells. PI3K and RAS-mutant CRC cells display basal autophagy levels despite constitutive mTORC1 signalling, but fail to increase autophagic flux upon RTK inhibition. Inhibition of basal autophagy via knockdown of ATG7 or ATG5 leads to decreased phosphorylation of several RTKs, in particular c-MET. Internalised c-MET colocalised with LAMP1-negative, LC3-positive vesicles. Finally, autophagy regulates c-MET phosphorylation via an mTORC2-dependent mechanism. Overall, our findings reveal a previously unappreciated role of autophagy and mTORC2 in regulation of oncogenic RTK activation, with implications for understanding of cancer cell signalling.
C1 [Lampada, Aikaterini; Salomoni, Paolo] UCL Canc Inst, Dept Canc Biol, Paul OGorman Bldg,72 Huntley St, London WC1E 6DD, England.
   [Lampada, Aikaterini; Hochhauser, Daniel] UCL Canc Inst, Dept Oncol, Paul OGorman Bldg,72 Huntley St, London WC1E 6DD, England.
   [O'Prey, James; Ryan, Kevin M.] Beatson Inst, Glasgow, Lanark, Scotland.
   [Szabadkai, Gyorgy] UCL, Dept Cell & Dev Biol, Consortium Mitochondrial Res, London, England.
RP Salomoni, P (corresponding author), UCL Canc Inst, Dept Canc Biol, Paul OGorman Bldg,72 Huntley St, London WC1E 6DD, England.; Hochhauser, D (corresponding author), UCL Canc Inst, Dept Oncol, Paul OGorman Bldg,72 Huntley St, London WC1E 6DD, England.
EM d.hochhauser@ucl.ac.uk; p.salomoni@ucl.ac.uk
OI Szabadkai, Gyorgy/0000-0002-3006-3577; Hochhauser,
   Daniel/0000-0001-5522-9281
FU UCL Grand Challenges; Cancer Research UK Programme GrantCancer Research
   UK [C2259/A16569]; Samantha Dickson Brain Cancer Unit; Cancer Research
   UKCancer Research UK [15816, 22903, 16569, 16463] Funding Source:
   researchfish
FX We thank Dr Pablo Rodriguez-Viciana (University College London, UK), Dr
   Ivana Bjedov (University College London, UK), Professor Bart
   Vanhaesebroeck (University College London, UK), Dr Benoit Bilanges
   (University College London, UK), Professor Clare Futter (University
   College London, UK), Professor Bert Vogelstein (Johns Hopkins
   University, USA), Professor Alberto Bardelli (University of Torino,
   Italy) for reagents. Special thanks also to all members of PS and DH
   laboratories and the CRUK UCL Centre Core Services and the UCL
   Scientific Services. AL was recipient of a PhD studentship award from
   the UCL Grand Challenges. DH was supported by the Cancer Research UK
   Programme Grant (C2259/A16569). PS is head of the Brain Tumour
   Charity-funded Samantha Dickson Brain Cancer Unit.
CR Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Arias E, 2015, MOL CELL, V59, P270, DOI 10.1016/j.molcel.2015.05.030
   Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558
   Barrow-McGee R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11942
   Bellodi C, 2009, J CLIN INVEST, V119, P1109, DOI 10.1172/JCI35660
   Bernard M, 2014, AUTOPHAGY, V10, P2193, DOI 10.4161/15548627.2014.981786
   De Roock W, 2011, LANCET ONCOL, V12, P594, DOI 10.1016/S1470-2045(10)70209-6
   Dragowska WH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076503
   Eimer S, 2011, CANCER BIOL THER, V11, P1017, DOI 10.4161/cbt.11.12.15693
   Feng YC, 2014, CELL RES, V24, P24, DOI 10.1038/cr.2013.168
   Galavotti S, 2013, ONCOGENE, V32, P699, DOI 10.1038/onc.2012.111
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113
   Han WD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018691
   Humbert M, 2013, BIOCHEM BIOPH RES CO, V431, P264, DOI 10.1016/j.bbrc.2012.12.120
   Humphrey SJ, 2013, CELL METAB, V17, P1009, DOI 10.1016/j.cmet.2013.04.010
   Jones S, 2014, J CELL SCI, V127, P994, DOI 10.1242/jcs.136895
   Kammula US, 2007, CANCER LETT, V248, P219, DOI 10.1016/j.canlet.2006.07.007
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kim YM, 2015, MOL CELL, V57, P207, DOI 10.1016/j.molcel.2014.11.013
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Komatsu M, 2012, PHARMACOL RES, V66, P457, DOI 10.1016/j.phrs.2012.07.004
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Levy J, 2015, NAT CELL BIOL, V17, P1062, DOI 10.1038/ncb3206
   Li XQ, 2010, AUTOPHAGY, V6, P1066, DOI 10.4161/auto.6.8.13366
   Li XQ, 2010, CANCER RES, V70, P5942, DOI 10.1158/0008-5472.CAN-10-0157
   Li YY, 2013, LUNG CANCER, V81, P354, DOI 10.1016/j.lungcan.2013.05.012
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liu PD, 2013, NAT CELL BIOL, V15, P1340, DOI 10.1038/ncb2860
   Martinez-Lopez N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3799
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462
   Musiwaro P, 2013, AUTOPHAGY, V9, P1407, DOI 10.4161/auto.25455
   Price TJ, 2014, LANCET ONCOL, V15, P569, DOI 10.1016/S1470-2045(14)70118-4
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   RADINSKY R, 1995, CLIN CANCER RES, V1, P19
   Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056
   Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865
   Russell RC, 2014, CELL RES, V24, P42, DOI 10.1038/cr.2013.166
   Sandilands E, 2012, EMBO REP, V13, P733, DOI 10.1038/embor.2012.92
   Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047
   Sarkar S, 2013, BIOCHEM SOC T, V41, P1103, DOI 10.1042/BST20130134
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Strohecker AM, 2014, AUTOPHAGY, V10, P384, DOI 10.4161/auto.27320
   Strohecker AM, 2013, CANCER DISCOV, V3, P1272, DOI 10.1158/2159-8290.CD-13-0397
   Taieb J, 2014, LANCET ONCOL, V15, P862, DOI 10.1016/S1470-2045(14)70227-X
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Takeuchi H, 2003, CLIN CANCER RES, V9, P1480
   Tan XJ, 2015, CELL, V160, P145, DOI 10.1016/j.cell.2014.12.006
   Tang MC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119135
   Troiani T, 2016, ESMO OPEN, V1, DOI 10.1136/esmoopen-2016-000088
   Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012
   Wang T, 2014, SCIENCE, V343, P80, DOI 10.1126/science.1246981
   Wasan H, 2014, LANCET ONCOL, V15, P631, DOI 10.1016/S1470-2045(14)70106-8
   Wei YJ, 2013, CELL, V154, P1269, DOI 10.1016/j.cell.2013.08.015
   Wiederschain D, 2009, CELL CYCLE, V8, P498, DOI 10.4161/cc.8.3.7701
   Xie J, 2014, TRANSLATION, V2, DOI 10.4161/trla.28174
   Yang A, 2014, CANCER DISCOV, V4, P905, DOI 10.1158/2159-8290.CD-14-0362
   Yin YC, 2016, CELL RES, V26, P46, DOI 10.1038/cr.2015.133
   Zoncu R, 2011, SCIENCE, V334, P678, DOI 10.1126/science.1207056
NR 61
TC 30
Z9 31
U1 0
U2 7
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1350-9047
EI 1476-5403
J9 CELL DEATH DIFFER
JI Cell Death Differ.
PD JUN
PY 2017
VL 24
IS 6
BP 1045
EP 1062
DI 10.1038/cdd.2017.41
PG 18
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA EV4AY
UT WOS:000401701800011
PM 28475179
OA Green Submitted, Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Vizcaino, C
   Rodriguez-Sanchez, MA
   Nunez, LE
   Moris, F
   Portugal, J
AF Vizcaino, Carolina
   Rodriguez-Sanchez, Maria A.
   Nunez, Luz-Elena
   Moris, Francisco
   Portugal, Jose
TI Cytotoxic effects of mithramycin DIG-MSK can depend on the rise of
   autophagy
SO TOXICOLOGY IN VITRO
LA English
DT Article
DE Autophagy; Mithramycin; Cell death; A2780 cells; HCT116 cells
ID CELL-DEATH; PAGETS-DISEASE; CANCER-CELLS; TRANSCRIPTION; APOPTOSIS;
   LUNG; INTERPLAY; BINDING; ANALOG; BASAL
AB DIG-MSK (demycarosil-3D-beta-D-digitoxosyl mithramycin SK; EC-8042), a novel analogue of mithramycin A, induced autophagy in HCT116 human colon carcinoma and, to a lesser extent, in A2780 human ovarian carcinoma cell lines, which was followed by apoptosis and/or necrotic cell death in a time-dependent way. The effects of DIG-MSK included changes in the expression of a set of genes involved in autophagy, the progression of cells through the different phases of cell cycle, and their halting at the checkpoints. Cells treated with the glucose analogue 2-DG (2-deoxy-D-glucose), which induces autophagy because it impairs cell metabolism, or co-treated with 2-DG plus DIG-MSK, also showed altered gene expression and autophagy. In A2780 cells, some genes involved in autophagy were down-regulated by the different treatments, yet the levels of the proteins they encode could be enough to ensure autophagic flux. In HCT116 cells, up-regulation of several pro-autophagic genes resulted in strong autophagic response. Acidic cell organelles and autophagic flux were more evident in HCT116 than in A2780 cells. DIG-MSK was still cytotoxic in cells that underwent autophagy induced by 2-DG. Therefore, we verified that autophagy resulting from a stress response did not protect cells against DIG-MSK, but, instead, autophagy promoted by either 2-DG or the novel mithralogue can enhance the antitumour activity, which depended on the cell type. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Vizcaino, Carolina; Rodriguez-Sanchez, Maria A.; Portugal, Jose] CSIC, Inst Biol Mol Barcelona, E-08028 Barcelona, Spain.
   [Nunez, Luz-Elena; Moris, Francisco] EntreChem SL, Oviedo, Spain.
RP Portugal, J (corresponding author), CSIC, Inst Biol Mol Barcelona, Parc Cient Barcelona 10, E-08028 Barcelona, Spain.
EM jpmbmc@ibmb.csic.es
RI Portugal, José/K-4504-2014
OI Portugal, José/0000-0002-1923-9666
FU Spanish Ministry of Science and InnovationSpanish Government
   [BFU2010-15518]; FEDER program of the European CommunityEuropean
   Commission; JAE-Predoc fellowship (CSIC); European Social FundEuropean
   Social Fund (ESF)
FX This work was partially supported by Grant BFU2010-15518 from the
   Spanish Ministry of Science and Innovation, and the FEDER program of the
   European Community, and it was performed within the framework of the
   "Xarxa de Referencia en Biotecnologia" of the Generalitat de Catalunya.
   Carolina Vizcaino was recipient of a JAE-Predoc2010 fellowship (CSIC),
   co-financed by the European Social Fund.
CR Bincoletto C, 2013, CHEM-BIOL INTERACT, V206, P279, DOI 10.1016/j.cbi.2013.09.018
   BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474
   BROWN JH, 1965, NEW ENGL J MED, V272, P111, DOI 10.1056/NEJM196501212720301
   Criollo A, 2012, CELL CYCLE, V11, P194, DOI 10.4161/cc.11.1.18669
   Fernandez-Guizan A, 2014, CHEM-BIOL INTERACT, V219, P123, DOI 10.1016/j.cbi.2014.05.019
   Gewirtz DA, 2014, BIOCHEM PHARMACOL, V90, P208, DOI 10.1016/j.bcp.2014.05.016
   Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966
   Grohar PJ, 2011, JNCI-J NATL CANCER I, V103, P962, DOI 10.1093/jnci/djr156
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Krick R, 2008, MOL BIOL CELL, V19, P4492, DOI 10.1091/mbc.E08-04-0363
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Layfield R, 2006, BIOCHEM SOC T, V34, P735, DOI 10.1042/BST0340735
   Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260
   Levy JMM, 2011, PHARMACOL THERAPEUT, V131, P130, DOI 10.1016/j.pharmthera.2011.03.009
   Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001
   Mansilla S, 2015, J CELL MOL MED, V19, P786, DOI 10.1111/jcmm.12402
   Mansilla S, 2012, ANTI-CANCER AGENT ME, V12, P226, DOI 10.2174/187152012800228805
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Maschek G, 2004, CANCER RES, V64, P31, DOI 10.1158/0008-5472.CAN-03-3294
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Moscat J, 2012, TRENDS BIOCHEM SCI, V37, P230, DOI 10.1016/j.tibs.2012.02.008
   Notte A, 2011, BIOCHEM PHARMACOL, V82, P427, DOI 10.1016/j.bcp.2011.06.015
   Nunez LE, 2012, J MED CHEM, V55, P5813, DOI 10.1021/jm300234t
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Pietrocola F, 2013, SEMIN CANCER BIOL, V23, P310, DOI 10.1016/j.semcancer.2013.05.008
   Platini F, 2010, CURR PHARM DESIGN, V16, P101, DOI 10.2174/138161210789941810
   Radogna F, 2015, BIOCHEM PHARMACOL, V94, P1, DOI 10.1016/j.bcp.2014.12.018
   Scherz-Shouval R, 2010, P NATL ACAD SCI USA, V107, P18511, DOI 10.1073/pnas.1006124107
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Sharma K, 2014, INT J MOL SCI, V15, P10034, DOI 10.3390/ijms150610034
   Sirichanchuen B, 2012, MOL CELL BIOCHEM, V364, P11, DOI 10.1007/s11010-011-1199-1
   SIRIS ES, 1980, B NEW YORK ACAD MED, V56, P285
   Tasdemir E, 2008, AUTOPHAGY, V4, P810, DOI 10.4161/auto.6486
   Vizcaino C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104687
   Vizcaino C, 2012, BIOCHEM PHARMACOL, V84, P1133, DOI 10.1016/j.bcp.2012.08.003
   Wani WY, 2015, LAB INVEST, V95, P14, DOI 10.1038/labinvest.2014.131
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Xu R, 2007, BIOCHEM BIOPH RES CO, V356, P286, DOI 10.1016/j.bbrc.2007.02.140
   Yin X, 2013, INT J GYNECOL CANCER, V23, P630, DOI 10.1097/IGC.0b013e3182892cee
   Zhang DS, 2014, CANCER LETT, V355, P176, DOI 10.1016/j.canlet.2014.09.003
   Zhang M, 2012, CANCER RES, V72, P4178, DOI 10.1158/0008-5472.CAN-11-3983
NR 42
TC 0
Z9 0
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-2333
J9 TOXICOL IN VITRO
JI Toxicol. Vitro
PD OCT
PY 2015
VL 29
IS 7
BP 1537
EP 1544
DI 10.1016/j.tiv.2015.06.008
PG 8
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA CR3WJ
UT WOS:000361263500026
PM 26079942
OA Green Submitted
DA 2022-04-25
ER

PT J
AU Song, YW
   Shrestha, S
   Gyawali, R
   Lee, DS
   Cho, SK
AF Song, Yeon Woo
   Shrestha, Sabina
   Gyawali, Rajendra
   Lee, Dong-Sun
   Cho, Somi Kim
TI Citrus unshiu leaf extract containing phytol as a major compound induces
   autophagic cell death in human gastric adenocarcinoma AGS cells
SO JOURNAL OF THE KOREAN SOCIETY FOR APPLIED BIOLOGICAL CHEMISTRY
LA English
DT Article
DE AGS human gastric adenocarcinoma cells; Autophagy; Citrus unshiu; Phytol
ID COLON-CANCER CELLS; ANTIPROLIFERATIVE ACTIVITIES; RAT HEPATOCYTES; CYCLE
   ARREST; VITAMIN-E; APOPTOSIS; CARCINOMA; INHIBITION; FLAVONOIDS;
   INDUCTION
AB The pharmaceutical potential of the methanolic extract of Citrus unshiu leaves (MECL) was assessed through analysis of its inhibitory effect on cancer cells. The antiproliferative activities of the leaves were evaluated using several cancer cell lines and considerable cytotoxicity was observed in human gastric adenocarcinoma AGS cells. Inhibition of AGS cell viability was both time-and dose-dependent, and MECL induced non-apoptotic cell death. AGS cells treated with MECL increased the formation of acidic vesicular organelles and GFP-LC3 puncta. Pretreatment with an autophagy inhibitor, 3-methyladenine, inhibited MECL-induced cell death. These results indicated that the mechanism underlying the anticancer effects of MECL in AGS cells could be via the induction of autophagic cell death. The major compounds of MECL were identified as phytol, 4-ethenyl-2-methoxyphenol, hexadecanoic acid, 2,3-dihydro-3,5-dihydroxy-6-methyl-4H-pyran-4-one, and vitamin E using gas chromatography-mass spectrometry. These results indicate that C. unshiu leaves can be exploited for numerous pharmaceutical applications as a source of anticancer ingredients.
C1 [Song, Yeon Woo; Lee, Dong-Sun; Cho, Somi Kim] Jeju Natl Univ, SARI, Fac Biotechnol, Coll Appl Life Sci, Jeju 690756, South Korea.
   [Shrestha, Sabina; Lee, Dong-Sun; Cho, Somi Kim] Jeju Natl Univ, Subtrop Hort Res Inst, Jeju 690756, South Korea.
   [Gyawali, Rajendra] Kathmandu Univ, Dept Pharm, Kavre, Dhulikhel, Nepal.
RP Cho, SK (corresponding author), Jeju Natl Univ, SARI, Fac Biotechnol, Coll Appl Life Sci, Jeju 690756, South Korea.
EM somikim@jejunu.ac.kr
RI Shrestha, Sabina/AAZ-5437-2020
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Education [2014047495]; Ministry of
   Education [2013R1A1A2A10012017]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Education (2014047495) and by the Ministry of Education
   (2013R1A1A2A10012017). This work was done while the author has research
   year Jeju National University in 2013.
CR Adams R. P., 1995, IDENTIFICATION ESSEN
   Araki N, 2006, CELL STRUCT FUNCT, V31, P145, DOI 10.1247/csf.06029
   Arias BA, 2005, J ETHNOPHARMACOL, V97, P89, DOI 10.1016/j.jep.2004.10.019
   Bae JM, 2008, GASTRIC CANCER, V11, P23, DOI 10.1007/s10120-007-0447-2
   Ban JO, 2007, ARCH PHARM RES, V30, P1455, DOI 10.1007/BF02977371
   Beevi SS, 2010, PLANT FOOD HUM NUTR, V65, P200, DOI 10.1007/s11130-010-0178-0
   da Rocha Adriana B., 2001, Current Opinion in Pharmacology, V1, P364
   Harada H, 2002, ANTICANCER RES, V22, P2587
   Herman-Antosiewicz A, 2006, CANCER RES, V66, P5828, DOI 10.1158/0008-5472.CAN-06-0139
   Hosni K, 2013, BIOCHEM SYST ECOL, V50, P65, DOI 10.1016/j.bse.2013.03.035
   Jeong JB, 2010, BIOCHEM BIOPH RES CO, V400, P752, DOI 10.1016/j.bbrc.2010.08.142
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kamei T, 2000, J ALTERN COMPLEM MED, V6, P557, DOI 10.1089/acm.2000.6.557
   KANDASWAMI C, 1991, CANCER LETT, V56, P147, DOI 10.1016/0304-3835(91)90089-Z
   KANDASWAMI C, 1992, ANTI-CANCER DRUG, V3, P525, DOI 10.1097/00001813-199210000-00013
   Karim MR, 2010, BIOCHEM BIOPH RES CO, V394, P981, DOI 10.1016/j.bbrc.2010.03.103
   Kim HG, 2011, FOOD CHEM, V128, P49, DOI 10.1016/j.foodchem.2011.02.075
   Kim H, 2010, FOOD CHEM TOXICOL, V48, P2435, DOI 10.1016/j.fct.2010.06.006
   Kline K, 2007, VITAM HORM, V76, P435, DOI 10.1016/S0083-6729(07)76017-X
   Ko HC, 2010, FOOD CHEM, V123, P484, DOI 10.1016/j.foodchem.2010.04.028
   Lee S, 2011, J ETHNOPHARMACOL, V133, P973, DOI 10.1016/j.jep.2010.07.018
   Li DD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012176
   Lim HK, 2009, FOOD CHEM, V114, P1245, DOI 10.1016/j.foodchem.2008.10.088
   Lota ML, 2001, BIOCHEM SYST ECOL, V29, P77, DOI 10.1016/S0305-1978(00)00029-6
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Manthey JA, 2002, J AGR FOOD CHEM, V50, P5837, DOI 10.1021/jf020121d
   Marino G, 2004, CELL MOL LIFE SCI, V61, P1439, DOI 10.1007/s00018-004-4012-4
   Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002
   Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005
   Moon JY, 2009, J KOREAN SOC APPL BI, V52, P168, DOI 10.3839/jksabc.2009.031
   Morley KL, 2007, CANCER LETT, V251, P168, DOI 10.1016/j.canlet.2006.11.016
   Murakami A, 2000, CANCER RES, V60, P5059
   Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s
   Park HJ, 2008, PHYTOMEDICINE, V15, P147, DOI 10.1016/j.phymed.2007.07.061
   Parka EJ, 2011, CHEM-BIOL INTERACT, V189, P37, DOI 10.1016/j.cbi.2010.10.013
   Patil JR, 2009, FOOD CHEM, V114, P1351, DOI 10.1016/j.foodchem.2008.11.033
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Sun SY, 2004, JNCI-J NATL CANCER I, V96, P662, DOI 10.1093/jnci/djh123
   Yanez J, 2004, NUTR CANCER, V49, P191, DOI 10.1207/s15327914nc4902_11
   Yang EJ, 2009, FOOD SCI BIOTECHNOL, V18, P1063
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yo YT, 2009, J AGR FOOD CHEM, V57, P8266, DOI 10.1021/jf901054c
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
NR 43
TC 4
Z9 5
U1 0
U2 6
PU KOREAN SOC  APPLIED BIOLOGICAL CHEMISTRY
PI KANGNAM-GU
PA RM 803,  KOREA SCIENCE & TECHNOLOGY CENTER, 635-4 YEOGSAM-DONG,
   KANGNAM-GU, SEOUL 135-703, SOUTH KOREA
SN 1738-2203
EI 2234-344X
J9 J KOREAN SOC APPL BI
JI J. Korean Soc. Appl. Biol. Chem.
PD APR
PY 2015
VL 58
IS 2
BP 257
EP 265
DI 10.1007/s13765-015-0026-x
PG 9
WC Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology
GA CH9LH
UT WOS:000354356600014
DA 2022-04-25
ER

PT J
AU Lei, S
   Ding, Y
   Fu, Y
   Wu, S
   Xie, X
   Wang, CC
   Liang, HJ
AF Lei, Shun
   Ding, Yao
   Fu, Yun
   Wu, Shuang
   Xie, Xiong
   Wang, Cancan
   Liang, Houjie
TI The preclinical analysis of TW-37 as a potential anti-colorectal cancer
   cell agent
SO PLOS ONE
LA English
DT Article
ID SMALL-MOLECULE INHIBITOR; AUTOPHAGY; BCL-2; COMBINATIONS; APOPTOSIS;
   PATHWAYS; TARGET; DEATH
AB TW-37 is a novel, potent and non-peptide Bcl-2 small-molecule inhibitor. Its activity in colorectal cancer (CRC) cells is studied. In both HCT-116 cells and primary human colon cancer cells, treatment with TW-37 at only nM concentration efficiently inhibited cell survival and proliferation. TW-37 also induced caspase-3/9 and apoptosis activation in CRC cells. Feedback autophagy activation was observed in TW-37-treated CRC cells. Reversely pharmacological autophagy inhibition or Beclin-1 knockdown by targeted-shRNA potentiated TW-37-induced apoptosis and killing of CRC cells. In vivo, intravenous injection of TW-37 inhibited HCT-116 tumor growth in mice. TW-37's anti-tumor activity was further potentiated against Beclin-1-silenced HCT-116 tumors. Together, targeting Bcl-2 family protein by TW-37 efficiently inhibits CRC cell growth in vitro and in vivo. Inhibition of feedback autophagy activation could further sensitize TW-37.
C1 [Lei, Shun; Ding, Yao; Wu, Shuang; Xie, Xiong; Wang, Cancan; Liang, Houjie] Third Mil Med Univ, Southwest Hosp, Dept Oncol, Chongqing, Peoples R China.
   [Lei, Shun; Ding, Yao; Wu, Shuang; Xie, Xiong; Wang, Cancan; Liang, Houjie] Third Mil Med Univ, Southwest Hosp, Southwest Canc Ctr, Chongqing, Peoples R China.
   [Fu, Yun] Gao Xin Dist Peoples Hosp Chong Qing, Dept Gen Surg, Chongqing, Peoples R China.
RP Liang, HJ (corresponding author), Third Mil Med Univ, Southwest Hosp, Dept Oncol, Chongqing, Peoples R China.; Liang, HJ (corresponding author), Third Mil Med Univ, Southwest Hosp, Southwest Canc Ctr, Chongqing, Peoples R China.
EM lianghoujie@sina.com
FU National Nature Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81702443, 81702929]
FX This study was supported by the grants from National Nature Science
   Foundation of China (Grant No. 81702443 and 81702929). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Al-Katib AM, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-8
   Ashimori N, 2009, MOL CANCER THER, V8, P893, DOI 10.1158/1535-7163.MCT-08-1078
   Bravo-San Pedro JM, 2015, AUTOPHAGY, V11, P452, DOI 10.1080/15548627.2015.1017191
   Brouquet A, 2013, NAT REV GASTRO HEPAT, V10, P266, DOI 10.1038/nrgastro.2013.53
   Chaabane W, 2013, ARCH IMMUNOL THER EX, V61, P43, DOI 10.1007/s00005-012-0205-y
   Chen MB, 2016, ONCOTARGET, V7, P17047, DOI 10.18632/oncotarget.7742
   Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722
   Frankfurt OS, 2001, J IMMUNOL METHODS, V253, P133, DOI 10.1016/S0022-1759(01)00387-8
   Fu LL, 2013, INT J BIOCHEM CELL B, V45, P921, DOI 10.1016/j.biocel.2013.02.007
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Hubbard JM, 2015, NAT REV CLIN ONCOL, V12, P73, DOI 10.1038/nrclinonc.2014.233
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Kang MH, 2009, CLIN CANCER RES, V15, P1126, DOI 10.1158/1078-0432.CCR-08-0144
   Kim KH, 2014, NAT REV ENDOCRINOL, V10, P322, DOI 10.1038/nrendo.2014.35
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kuipers EJ, 2013, NAT REV CLIN ONCOL, V10, P130, DOI 10.1038/nrclinonc.2013.12
   Leake Isobel, 2014, Nat Rev Gastroenterol Hepatol, V11, P270, DOI 10.1038/nrgastro.2014.60
   Li C, 2015, CANCER BIOL THER, V16, P34, DOI 10.4161/15384047.2014.972274
   Li JP, 2016, ONCOTARGET, V7, P77815, DOI 10.18632/oncotarget.12802
   Lu PH, 2016, ONCOTARGET, V7, P45889, DOI 10.18632/oncotarget.9969
   Manne U, 1997, INT J CANCER, V74, P346, DOI 10.1002/(SICI)1097-0215(19970620)74:3<346::AID-IJC19>3.0.CO;2-9
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Mohammad RM, 2007, CLIN CANCER RES, V13, P2226, DOI 10.1158/1078-0432.CCR-06-1574
   Reed JC, 2008, BLOOD, V111, P3322, DOI 10.1182/blood-2007-09-078162
   Reyjal J, 2014, ADV EXP MED BIOL, V772, P167, DOI 10.1007/978-1-4614-5915-6_8
   Schmoll HJ, 2014, NAT REV CLIN ONCOL, V11, P79, DOI 10.1038/nrclinonc.2013.254
   Schonewolf CA, 2014, WORLD J GASTRO ONCOL, V6, P74, DOI 10.4251/wjgo.v6.i3.74
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Wang ZW, 2008, INT J CANCER, V123, P958, DOI 10.1002/ijc.23610
   Yang JY, 2008, LIFE SCI, V82, P1032, DOI 10.1016/j.lfs.2008.03.003
   Yang LF, 2016, AM J CANCER RES, V6, P1345
   Yao X, 2017, TUMOR BIOL, V39, P1, DOI DOI 10.1177/1010428317695965
   Zhen YF, 2016, ONCOTARGET, V7, P79403, DOI 10.18632/oncotarget.12712
NR 34
TC 12
Z9 13
U1 4
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 24
PY 2017
VL 12
IS 10
AR e0184501
DI 10.1371/journal.pone.0184501
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FK5VD
UT WOS:000413568900002
PM 29065135
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Xiong, W
   Dong, JH
   Kong, SJ
AF Xiong, Wei
   Dong, Jianhua
   Kong, Shujia
TI Dentatin exerts anticancer effects on human colon cancer cell lines via
   cell cycle arrest, autophagy, inhibition of cell migration and JAK/STAT
   signalling pathway
SO JOURNAL OF BUON
LA English
DT Article
DE colon cancer; dentatin; autophagy; migration; S-phase arrest
ID NATURAL-PRODUCTS; COUMARINS
AB Purpose: Colon cancer is a malignant disease with significant mortality. In the present study the anticancer effects of a carbazole alkaloid, Dentatin, were examined against colon cancer cells.
   Methods: The colon cancer HT-29 cell line and the normal CCD-18 CO colon cell line were used in the present study. MTT assay was used to check the proliferation rate of the cancer cells. Autophagy was detected by electron microscopy. DNA damage was checked by alkaline comet assay. Cell cycle analysis was performed by flow cytometry. Cell migration was monitored by wound healing assay. Protein expression was checked by western blot analysis.
   Results: The results showed that Dentatin inhibited the growth of HT-29 cancer cells in a concentration-dependent manner and with IC50 of 25 mu M. However, the IC50 of Dentatin against the normal CCD-18CO colon cells was four times higher (ie., 100 mu M). Dentatin inhibited the proliferation of the HT-29 cancer cells by triggering S-phase arrest. This was also accompanied with increase in the expression of cyclin D1 and decrease in the expression of Cyclin A and B1. Moreover, Dentatin also induced autophagy in the HT-29 cells which was associated with upregulation of LC3 II and downregulation of Beclin-1 expression. Comet assay revealed that Dentatin induced DNA damage in the HT-29 cells. Dentatin also significantly inhibited the migration of the HT-29 cells. Finally the effects of Dentatin were examined on the JAK/STAT signalling pathway and it was found that Dentatin inhibited this pathway.
   Conclusion: Dentatin may prove to be an essential lead molecule for the management of colon cancer.
C1 [Xiong, Wei; Dong, Jianhua] Kunming Med Univ, Yunnan Canc Hosp, Dept Colorectal Canc Surg, Kunming 650118, Yunnan, Peoples R China.
   [Kong, Shujia] Kunming Med Univ, Yunnan Canc Hosp, Dept Pharm, Kunming 650118, Yunnan, Peoples R China.
   [Kong, Shujia] Kunming Med Univ, Affiliated Hosp 3, Kunming 650118, Yunnan, Peoples R China.
RP Kong, SJ (corresponding author), Kunming Med Univ, Yunnan Canc Hosp, Dept Pharm, Kunming 650118, Yunnan, Peoples R China.; Kong, SJ (corresponding author), Kunming Med Univ, Affiliated Hosp 3, Kunming 650118, Yunnan, Peoples R China.
EM ShylaFinnecesi@yahoo.com
CR Arbab IA, 2012, EVID-BASED COMPL ALT, V7, P21
   Harvey AL, 2015, NAT REV DRUG DISCOV, V14, P111, DOI 10.1038/nrd4510
   Hua F, 2018, INT J MOL MED, V41, P3485, DOI 10.3892/ijmm.2018.3531
   Karakas HE, 2014, TURK J BIOL, V38, P720, DOI 10.3906/biy-1408-16
   Lawson CD, 2018, J CELL BIOL, V217, P447, DOI 10.1083/jcb.201612069
   Ng RC, 2018, SAINS MALAYS, V47, P1749, DOI 10.17576/jsm-2018-4708-14
   O'Shea JJ, 2015, ANNU REV MED, V66, P311, DOI 10.1146/annurev-med-051113-024537
   Otto T, 2017, NAT REV CANCER, V17, P93, DOI 10.1038/nrc.2016.138
   Petersen GM, 2018, GENETIC EPIDEMIOLOGY, P187
   Reddy B.S., 2018, DIET COLON CANC EVID, P47, DOI DOI 10.1201/9781351071406
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Schlafli AM, 2015, EUR J HISTOCHEM, V59, P137, DOI 10.4081/ejh.2015.2481
   Taha MM, 2013, J ETHNOPHARMACOL, V145, P343
   Thakur A, 2015, EUR J MED CHEM, V101, P476, DOI 10.1016/j.ejmech.2015.07.010
   Thomas SJ, 2015, BRIT J CANCER, V113, P365, DOI 10.1038/bjc.2015.233
   Yarla NS, 2016, SEMIN CANCER BIOL, V40-41, P48, DOI 10.1016/j.semcancer.2016.02.001
NR 16
TC 6
Z9 6
U1 2
U2 5
PU IMPRIMATUR PUBLICATIONS
PI ATHENS
PA 30 DEM POLIORKETES ST, ATHENS, 136 76, GREECE
SN 1107-0625
EI 2241-6293
J9 J BUON
JI J. BUON
PD JUL-AUG
PY 2019
VL 24
IS 4
BP 1488
EP 1493
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA IR7BT
UT WOS:000481595900023
PM 31646796
DA 2022-04-25
ER

PT J
AU Bai, JH
   Xu, J
   Zhao, J
   Zhang, R
AF Bai, Jing Hui
   Xu, Jian
   Zhao, Jian
   Zhang, Rui
TI Ganoderma lucidum Polysaccharide Enzymatic Hydrolysate Suppresses the
   Growth of Human Colon Cancer Cells via Inducing Apoptosis
SO CELL TRANSPLANTATION
LA English
DT Article
DE colon cancer; enzymatically hydrolyzed polysaccharide; Ganoderma lucidum
ID COLORECTAL-CANCER; ANTIOXIDANT ACTIVITY; ANTITUMOR-ACTIVITY; IN-VITRO;
   AUTOPHAGY; PROMOTES
AB Ganoderma lucidum is a popular traditional Chinese medicine used in China to improve health. Previous researches have revealed that the polysaccharide from G. lucidum could exert diversity activities, including immunomodulation, antioxidant, and antitumor effects. However, the effect of enzymatically hydrolyzed G. lucidum polysaccharide (EGLP) in colorectal cancer (CRC) progression remains unknown. The present research aimed to investigate the antitumor mechanism of EGLP in human colon cancer cells. For this purpose, the cytotoxic effects of EGLP were measured by the (3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide (MTT) method. The apoptosis was evoked upon EGLP treatment, which was assayed using flow cytometry. The results indicated that EGLP may induce apoptosis in human colon cancer cell (HCT-116) cells via the upregulation of BCL-2 associated X protein (Bax), phospho-extracellular regulated protein kinases (P-ERK), and cleaved caspase-3 expression and downregulation of B-cell lymphoma-2 (Bcl-2), phospho-serine/threonine kinase 1 (p-Akt1), and cyclo-oxygen-ase (COX-2) expression. The obtained findings indicated EGLP as a new therapeutic agent in fighting CRC.
C1 [Bai, Jing Hui] China Med Univ, Liaoning Canc Hosp & Inst, Dept Internal Med, Canc Hosp, Shenyang, Peoples R China.
   [Xu, Jian; Zhao, Jian; Zhang, Rui] China Med Univ, Liaoning Canc Hosp & Inst, Dept Colorectal Surg, Canc Hosp, Shenyang, Peoples R China.
RP Zhang, R (corresponding author), China Med Univ, Liaoning Canc Hosp & Inst, Canc Hosp, 44 Xiaoheyan Rd, Shenyang 110042, Liaoning, Peoples R China.
EM zhangr190221@163.com
CR Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fleita D, 2015, LWT-FOOD SCI TECHNOL, V63, P1236, DOI 10.1016/j.lwt.2015.04.024
   Fortin O, 2018, NUTR CANCER, V70, P632, DOI 10.1080/01635581.2018.1460672
   Gill CIR, 2002, BRIT J NUTR, V88, pS73, DOI 10.1079/BJN2002632
   Haggar Fatima A, 2009, Clin Colon Rectal Surg, V22, P191, DOI 10.1055/s-0029-1242458
   Hou Y, 2012, CARBOHYD POLYM, V87, P153, DOI 10.1016/j.carbpol.2011.07.031
   Ji J., 2010, INT J BIOL, V3, P74, DOI [10.5539/ijb.v3n1p74, DOI 10.5539/IJB.V3N1P74]
   Jiang YF, 2017, BIOMED PHARMACOTHER, V96, P865, DOI 10.1016/j.biopha.2017.09.060
   Kim YJ, 2015, BIOORG MED CHEM LETT, V25, P2559, DOI 10.1016/j.bmcl.2015.04.054
   Kong M, 2019, INT J IMMUNOPATH PH, V33, DOI 10.1177/2058738419869489
   Li Q, 2013, INT J BIOL MACROMOL, V57, P245, DOI 10.1016/j.ijbiomac.2013.03.034
   Li WJ, 2011, J AGR FOOD CHEM, V59, P3707, DOI 10.1021/jf1049497
   Liu ZJ, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414-431X20187256, 10.1590/1414-431x20187256]
   Luo JM, 2018, J FUNCT FOODS, V47, P127, DOI 10.1016/j.jff.2018.05.041
   Ma R, 2018, BIOMED PHARMACOTHER, V108, P119, DOI 10.1016/j.biopha.2018.08.038
   Pan K, 2013, INT J BIOL MACROMOL, V55, P301, DOI 10.1016/j.ijbiomac.2013.01.022
   Risso A, 2001, AM J PHYSIOL-ENDOC M, V281, pE924, DOI 10.1152/ajpendo.2001.281.5.E924
   Sajadimajd S, 2019, CURR PHARM DESIGN, V25, P1210, DOI 10.2174/1381612825666190425155126
   Shao P, 2015, INT J BIOL MACROMOL, V74, P420, DOI 10.1016/j.ijbiomac.2014.12.021
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Song G, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.01.054
   Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048
   Stevens RG, 2007, CANCER LETT, V252, P171, DOI 10.1016/j.canlet.2006.11.009
   Xin MG, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5935
   Yang GH, 2016, J RECEPT SIG TRANSD, V36, P6, DOI 10.3109/10799893.2014.970275
   Yousef BA, 2018, PHYTOMEDICINE, V40, P140, DOI 10.1016/j.phymed.2018.01.008
   Yu Y, 2018, CARBOHYD POLYM, V183, P91, DOI 10.1016/j.carbpol.2017.12.009
   Zhang RJ, 2019, ONCOTARGETS THER, V12, P4109, DOI 10.2147/OTT.S195615
   Zhang T, 2014, LWT-FOOD SCI TECHNOL, V56, P9, DOI 10.1016/j.lwt.2013.11.010
   Zhou HY, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957-018-1441-3
   Zou P, 2018, CHEM-BIOL INTERACT, V279, P129, DOI 10.1016/j.cbi.2017.11.010
NR 31
TC 2
Z9 3
U1 12
U2 18
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0963-6897
EI 1555-3892
J9 CELL TRANSPLANT
JI Cell Transplant.
PD JAN-DEC
PY 2020
VL 29
AR 0963689720931435
DI 10.1177/0963689720931435
PG 9
WC Cell & Tissue Engineering; Medicine, Research & Experimental;
   Transplantation
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine; Transplantation
GA NU2ER
UT WOS:000573455300077
PM 32495637
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Wang, LB
   Jiang, XL
   Zhang, XG
   Shu, P
AF Wang, Liangbin
   Jiang, Xinlei
   Zhang, Xingguo
   Shu, Peng
TI Prognostic implications of an autophagy-based signature in colorectal
   cancer
SO MEDICINE
LA English
DT Article
DE autophagy; colorectal cancer; prognosis; regulatory network inference;
   subtype
ID CONSENSUS MOLECULAR SUBTYPES; TUMOR GENE-EXPRESSION; III COLON-CANCER;
   STAGE-II; RECURRENCE; SURVIVAL; FLUOROURACIL; PREDICTION; SCORE
AB Background: The heterogeneity of colorectal cancer (CRC) poses a significant challenge to the precise treatment of patients. CRC has been divided into 4 consensus molecular subtypes (CMSs) with distinct biological and clinical characteristics, of which CMS4 has the mesenchymal identity and the highest relapse rate. Autophagy plays a vital role in CRC development and therapeutic response. Methods: The gene expression profiles collected from 6 datasets were applied to this study. Network analysis was applied to integrate the subtype-specific molecular modalities and autophagy signature to establish an autophagy-based prognostic signature for CRC (APSCRC). Results: Network analysis revealed that 6 prognostic autophagy genes (VAMP7, DLC1, FKBP1B, PEA15, PEX14, and DNAJB1) predominantly regulated the mesenchymal modalities of CRC. The APSCRC was constructed by these 6 core genes and applied for risk calculation. Patients were divided into high- and low-risk groups based on APSCRC score in all cohorts. Patients within the high-risk group showed an unfavorable prognosis. In multivariate analysis, the APSCRC remained an independent predictor of prognosis. Moreover, the APSCRC achieved higher prognostic power than commercialized multigene signatures. Conclusions: We proposed and validated an autophagy-based signature, which is a promising prognostic biomarker of CRC patients. Further prospective studies are warranted to test and validate its efficiency for clinical application.
C1 [Wang, Liangbin] Beilun Peoples Hosp, Dept Anorectal Surg, Ningbo, Peoples R China.
   [Jiang, Xinlei] Tianjin Chengjian Univ, Sch Environm & Municipal Engn, Tianjin Key Lab Aquat Sci & Technol, Tianjin, Peoples R China.
   [Zhang, Xingguo; Shu, Peng] Beilun Peoples Hosp, Mol Lab, Ningbo, Peoples R China.
RP Shu, P (corresponding author), Beilun Peoples Hosp, 1288 East Lushan Rd, Ningbo 315800, Peoples R China.
EM m17757498873@163.com
CR Arnold M, 2015, LANCET ONCOL, V16, P36, DOI 10.1016/S1470-2045(14)71123-4
   Barrier A, 2006, J CLIN ONCOL, V24, P4685, DOI 10.1200/JCO.2005.05.0229
   Chang WJ, 2014, GUT, V63, P1457, DOI 10.1136/gutjnl-2013-305475
   de Sousa e Melo F, 2011, CELL STEM CELL, V9, P476, DOI 10.1016/j.stem.2011.10.008
   Devenport SN, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111349
   Dienstmann R, 2017, ANN ONCOL, V28, P1023, DOI 10.1093/annonc/mdx052
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Fletcher MNC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3464
   Funke V, 2013, CANCER LETT, V335, P431, DOI 10.1016/j.canlet.2013.02.053
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Huang Z, 2019, DOSE-RESPONSE, V17, DOI 10.1177/1559325819894179
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Jorissen RN, 2009, CLIN CANCER RES, V15, P7642, DOI 10.1158/1078-0432.CCR-09-1431
   Kon M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003182
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Koustas E, 2019, AM J CLIN ONCOL-CANC, V42, P767, DOI 10.1097/COC.0000000000000592
   Koustas E, 2019, CANCERS, V11, DOI 10.3390/cancers11040533
   Koustas E, 2018, WORLD J GASTRO ONCOL, V10, P367, DOI 10.4251/wjgo.v10.i11.367
   Laibe S, 2012, OMICS, V16, P560, DOI 10.1089/omi.2012.0039
   Margolin AA, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-S1-S7
   Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453
   Mejlvang J, 2018, J CELL BIOL, V217, P3640, DOI 10.1083/jcb.201711002
   Miller JA, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-322
   O'Connell MJ, 2010, J CLIN ONCOL, V28, P3937, DOI 10.1200/JCO.2010.28.9538
   Park SY, 2015, BBA-MOL CELL RES, V1853, P2722, DOI 10.1016/j.bbamcr.2015.07.024
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Roxburgh CSD, 2012, CANCER TREAT REV, V38, P451, DOI 10.1016/j.ctrv.2011.09.001
   Salazar R, 2011, J CLIN ONCOL, V29, P17, DOI 10.1200/JCO.2010.30.1077
   Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sveen A, 2018, CLIN CANCER RES, V24, P794, DOI 10.1158/1078-0432.CCR-17-1234
   Tripathi MK, 2014, CANCER RES, V74, P6947, DOI 10.1158/0008-5472.CAN-14-1592
   Vakifahmetoglu-Norberg H, 2016, GENE DEV, V30, P870, DOI 10.1101/gad.280453.116
   Van Cutsem E, 2006, EUR J CANCER, V42, P2212, DOI 10.1016/j.ejca.2006.04.012
   Wang YX, 2004, J CLIN ONCOL, V22, P1564, DOI 10.1200/JCO.2004.08.186
   Yothers G, 2013, J CLIN ONCOL, V31, P4512, DOI 10.1200/JCO.2012.47.3116
   Zhang GJ, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0189-7
   Zhao M, 2015, SCI REP-UK, V5, DOI 10.1038/srep11459
   Zhu FX, 2019, ONCOL LETT, V18, P5310, DOI 10.3892/ol.2019.10881
NR 41
TC 2
Z9 2
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD APR 2
PY 2021
VL 100
IS 13
AR e25148
DI 10.1097/MD.0000000000025148
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA SO4RD
UT WOS:000658960700031
PM 33787596
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Wang, D
   Ge, SK
   Chen, Z
   Song, YW
AF Wang, Dan
   Ge, Shuke
   Chen, Zhe
   Song, Yongwei
TI Evodiamine exerts anticancer effects via induction of apoptosis and
   autophagy and suppresses the migration and invasion of human colon
   cancer cells
SO JOURNAL OF BUON
LA English
DT Article
DE evodiamine; colon cancer; apoptosis; autophagy; migration
ID IN-VITRO; OVARIAN-CANCER; CARCINOMA; CONSTITUENT; METASTASIS; FRUCTUS
AB Purpose: Colon cancer ranks as the fourth common type of cancer and is responsible for significant morbidity and mortality throughout the world. Late diagnosis and the rarity of potent and safer chemotherapeutic drugs and efficient therapeutic targets create severe obstacle in the treatment of colon cancer. This study was undertaken to examine the anticancer effects of Evodiamine against human colon cancer cells.
   Methods: The proliferation rate of the SW480 colon cancer cells was monitored by MTT assay. Apoptosis was detected by Annexin V/propidium iodide (PI) and acridine orange (AO)/ethidium bromide (EB) staining. Transmission electron microscopy (TEM) was used for detection of autophagy. Cell migration and invasion was detected by wound healing and transwell assays, respectively. Protein expression was determined by western blotting.
   Results: Evodiamine suppressed the proliferation of the SW480 colon cancer cells and exhibited an IC50 of 10 mu M. The cytotoxic effects of Evodiamine were found to be com-paratively lower against the normal CDD-18Co colon cells as evidenced from the IC50 of 100 mu M. AO/EB staining showed that Evodiamine caused apoptosis of the SW480 cells and the percentage of the apoptotic SW480 cells increased with increase in the Evodiamine concentration as indicated by annexin V/PI staining. Evodiamine-induced apoptosis was also accompanied by upregulation of caspase-3 and Bax and suppression of Bcl-2. TEM analysis showed that Evodiamine also activated autophagy in the SW480 cells by enhancing the expression of LC3 II and Beclin 1. The wound assay showed that Evodiamine suppressed the migration of the SW480 cells. Evodiamine also reduced the invasion potential of the SW480 cells as suggested by the transwell assay.
   Conclusion: The findings of the present study suggest that Evodiamine is a potent anticancer agent and may prove beneficial in the development of systemic therapy of colon cancer.
C1 [Wang, Dan; Chen, Zhe; Song, Yongwei] Dalian Med Univ, Peoples Hosp Dalian 3, Dept Gen Surg, 40 QianShan Rd, Dalian 116034, Liaoning, Peoples R China.
   [Ge, Shuke] Dalian Municipal Cent Hosp, Dept Thyroid Surg, Dalian 116021, Liaoning, Peoples R China.
RP Song, YW (corresponding author), Dalian Med Univ, Peoples Hosp Dalian 3, Dept Gen Surg, 40 QianShan Rd, Dalian 116034, Liaoning, Peoples R China.
EM WilburPottszio@yahoo.com
CR Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Chen TC, 2016, PHYTOMEDICINE, V23, P68, DOI 10.1016/j.phymed.2015.12.003
   Cordell GA, 2001, PHYTOTHER RES, V15, P183, DOI 10.1002/ptr.890
   Dienstmann R, 2015, J CLIN ONCOL, V33, P1787, DOI 10.1200/JCO.2014.60.0213
   Fang CS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115204
   Fei XF, 2003, CANCER SCI, V94, P92, DOI 10.1111/j.1349-7006.2003.tb01358.x
   Hong Ji-Young, 2014, J Cancer Prev, V19, P7
   Hu CQ, 2016, MOL MED REP, V14, P413, DOI 10.3892/mmr.2016.5237
   Jiang JL, 2009, MOLECULES, V14, P1852, DOI 10.3390/molecules14051852
   Kan SF, 2004, INT J CANCER, V110, P641, DOI 10.1002/ijc.20138
   Kan SF, 2007, J CELL BIOCHEM, V101, P44, DOI 10.1002/jcb.21036
   Lai XJ, 2018, EUR REV MED PHARMACO, V22, P322, DOI 10.26355/eurrev_201801_14175
   Lee TJ, 2006, MOL CANCER THER, V5, P2398, DOI 10.1158/1535-7163.MCT-06-0167
   Liao CH, 2005, CARCINOGENESIS, V26, P968, DOI 10.1093/carcin/bgi041
   Ogasawara M, 2001, BIOL PHARM BULL, V24, P917, DOI 10.1248/bpb.24.917
   Peng XB, 2015, CANCER CHEMOTH PHARM, V76, P1173, DOI 10.1007/s00280-015-2902-9
   Ping HC, 2003, CHINESE PHARMACOL B, V10
   POTTER JD, 1993, EPIDEMIOL REV, V15, P499, DOI 10.1093/oxfordjournals.epirev.a036132
   Rasul A, 2012, ONCOL REP, V27, P1481, DOI 10.3892/or.2012.1694
   Shi L, 2016, TUMOR BIOL, V37, P12791, DOI 10.1007/s13277-016-5251-3
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Tu YJ, 2013, ONCOL REP, V29, P481, DOI 10.3892/or.2012.2125
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Wang SP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097512
   Zhang T, 2014, INT J MOL SCI, V15, P3154, DOI 10.3390/ijms15023154
   Zhong ZF, 2015, SCI REP-UK, V5, DOI 10.1038/srep16415
NR 26
TC 10
Z9 12
U1 0
U2 1
PU IMPRIMATUR PUBLICATIONS
PI ATHENS
PA 30 DEM POLIORKETES ST, ATHENS, 136 76, GREECE
SN 1107-0625
EI 2241-6293
J9 J BUON
JI J. BUON
PD SEP-OCT
PY 2019
VL 24
IS 5
BP 1824
EP 1829
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA JU6CG
UT WOS:000501762000011
PM 31786843
DA 2022-04-25
ER

PT J
AU Guo, SJ
   Liang, XX
   Guo, M
   Zhang, XL
   Li, ZY
AF Guo, Songjia
   Liang, Xinxin
   Guo, Min
   Zhang, Xiaoli
   Li, Zhuoyu
TI Migration inhibition of water stress proteins from Nostoc commune Vauch.
   via activation of autophagy in DLD-1 cells
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Water stress protein 1; Colon cancer; Migration; Autophagy; EMT
ID EPITHELIAL-MESENCHYMAL TRANSITIONS; BETA-CATENIN; CANCER; EXPRESSION;
   RESISTANCE; WNT; ASSOCIATION; METASTASIS; CARCINOMA; PROMOTE
AB Water stress proteins (WSP1) from Nostoc commune Vauch. had been proven to selectively induce colon cancer cells apoptosis. In this study, the effect of WSP1 on migration of human colon cancer cells was investigated. It showed that WSP1 inhibited DLD-1 cell migration, but with an insignificant effect on normal human colon epithelial cells. The data further indicated that WSP1 activated autophagy through down regulation of PI3K/AKT/mTOR pathway. Meanwhile, beta catenin was degraded by autophagy, which then restrained epithelial-mesenchymal transition (EMT) of DLD-1 cell and its migration was subsequently suppressed significantly. The same changes occurred in xenografted nude mice according to the obtained immunohistochemical results. Consistently, the application of autophagy inhibitor largely reversed the inhibited migration by WSP1 treatment. Taken together, WSP1 could suppress migration of DLD-1 cells by autophagy inhibited EMT. The results suggested that WSP1 possessed the potential as a selective therapeutic agent against metastatic colon cancer. (C) 2018 Published by Elsevier B.V.
C1 [Guo, Songjia] Shanxi Prov Peoples Hosp, Ctr Precis Med, Taiyuan 030006, Shanxi, Peoples R China.
   [Guo, Songjia; Liang, Xinxin; Guo, Min; Zhang, Xiaoli; Li, Zhuoyu] Shanxi Univ, Inst Biotechnol, Key Lab Chem Biol & Mol Engn, Natl Minist Educ, Taiyuan 030006, Shanxi, Peoples R China.
RP Li, ZY (corresponding author), Shanxi Univ, Inst Biotechnol, Key Lab Chem Biol & Mol Engn, Natl Minist Educ, Taiyuan 030006, Shanxi, Peoples R China.
EM lzy@sxu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31770382]; National Natural Science
   Foundation of China for Youths [81603020]; Shanxi Province Science
   Foundation for Youths [201601D021108]
FX This study was supported by the National Natural Science Foundation of
   China (No. 31770382), the National Natural Science Foundation of China
   for Youths (No. 81603020) and Shanxi Province Science Foundation for
   Youths (201601D021108).
CR Berx G, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003129
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Chen N, 2010, FEBS LETT, V584, P1427, DOI 10.1016/j.febslet.2009.12.034
   Chen N, 2009, BBA-MOL CELL RES, V1793, P1516, DOI 10.1016/j.bbamcr.2008.12.013
   Cook KL, 2011, EXPERT REV ANTICANC, V11, P1283, DOI [10.1586/era.11.111, 10.1586/ERA.11.111]
   Eskelinen EL, 2011, CURR OPIN PHARMACOL, V11, P294, DOI 10.1016/j.coph.2011.03.009
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Gao C, 2010, NAT CELL BIOL, V12, P781, DOI 10.1038/ncb2082
   Guo SJ, 2015, J AGR FOOD CHEM, V63, P150, DOI 10.1021/jf503208p
   [郭松佳 Guo Songjia], 2014, [食品科学, Food Science], V35, P151
   Huang CY, 2014, J FUNCT FOODS, V6, P534, DOI 10.1016/j.jff.2013.11.020
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Jia ZQ, 2014, CELL SIGNAL, V26, P2299, DOI 10.1016/j.cellsig.2014.07.028
   Kanavos P, 2006, ANN ONCOL, V17, P15, DOI 10.1093/annonc.mdl983
   Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011
   Lefranc F, 2005, J CLIN ONCOL, V23, P2411, DOI 10.1200/JCO.2005.03.089
   Li JY, 2010, AUTOPHAGY, V6, P711, DOI 10.4161/auto.6.6.12397
   Li ZW, 2013, INT J BIOCHEM CELL B, V45, P987, DOI 10.1016/j.biocel.2013.02.002
   McEwen AE, 2014, MOL BIOL CELL, V25, P2365, DOI 10.1091/mbc.E14-01-0690
   Meng XX, 2012, SCIENCE, V335, P1168, DOI 10.1126/science.335.6073.1168-a
   Morgensztern D, 2005, ANTI-CANCER DRUG, V16, P797, DOI 10.1097/01.cad.0000173476.67239.3b
   Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291
   Nilsson G., 2014, THESIS
   Noda NN, 2010, FEBS LETT, V584, P1379, DOI 10.1016/j.febslet.2010.01.018
   O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925
   Ogura Y, 2011, BIOCHEM BIOPH RES CO, V414, P756, DOI 10.1016/j.bbrc.2011.09.152
   Olaso E, 2002, J BIOL CHEM, V277, P3606, DOI 10.1074/jbc.M107571200
   Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938
   Peng YF, 2013, AUTOPHAGY, V9, P2056, DOI 10.4161/auto.26398
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   Shevde LA, 2006, CLIN EXP METASTAS, V23, P123, DOI 10.1007/s10585-006-9013-2
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Singletary K, 2008, CANCER EPIDEM BIOMAR, V17, P1596, DOI 10.1158/1055-9965.EPI-07-2917
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Stemmer V, 2008, ONCOGENE, V27, P5075, DOI 10.1038/onc.2008.140
   Wu WKK, 2012, ONCOGENE, V31, P939, DOI 10.1038/onc.2011.295
   Wu YT, 2009, AUTOPHAGY, V5, P824, DOI 10.4161/auto.9099
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508
   Zeng R, 2014, ASIAN PAC J CANCER P, V15, P6103, DOI 10.7314/APJCP.2014.15.15.6103
NR 40
TC 9
Z9 9
U1 0
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141-8130
EI 1879-0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD NOV
PY 2018
VL 119
BP 669
EP 676
DI 10.1016/j.ijbiomac.2018.07.188
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA GX4FD
UT WOS:000447682100076
PM 30071226
DA 2022-04-25
ER

PT J
AU Lim, SC
   Kim, SM
   Choi, JE
   Kim, CH
   Duong, HQ
   Han, SI
   Kang, HS
AF Lim, Sung-Chul
   Kim, Sun Mi
   Choi, Jeong Eun
   Kim, Cho Hee
   Duong, Hong-Quan
   Han, Song Iy
   Kang, Ho Sung
TI Sodium salicylate switches glucose depletion-induced necrosis to
   autophagy and inhibits high mobility group box protein 1 release in A549
   lung adenocarcinoma cells
SO ONCOLOGY REPORTS
LA English
DT Article
DE sodium salicylate; necrosis; autophagy; ROS; CuZn superoxide dismutase
ID DRUG-ACTIVATED GENE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; NF-KAPPA-B;
   OXIDATIVE STRESS; APOPTOSIS; CANCER; HMGB1; EXPRESSION; ASPIRIN; GROWTH
AB Sodium salicylate, the active metabolite of aspirin, has been shown to exert anti-inflammatory activities by inhibiting the expression of various pro-inflammatory factors, and has potent anti-cancer effects against a number of human cancers including colon, lung, breast and leukemia. Necrotic cell death is emerging as one of the crucial factors that trigger an inflammatory response since during necrotic death the cell membrane is ruptured and the intracellular constituents including high mobility group box 1 (HMGB1) are released into the extracellular space, thereby activating an inflammatory response. In contrast, autophagic death is regarded as a form of tumour suppressive cell death, as indicated in tumour suppressors such as beclin 1 in autophagic pathways. To better understand the anti-inflammatory properties of sodium salicylate and its effect on necrotic cell death in A549 cells induced by glucose depletion (GD), a common characteristic of the tumour micro-environment, was examined. While GD induced mostly necrotic death in A549 cells, salicylate suppresssed GD-induced necrosis and HMGB 1 release. In addition, salicylate shifted the cell death pattern to autophagy by inhibiting GD-induced Cu/Zn superoxide dismutase release and ROS production. These results indicate that the activity of salicylate to prevent necrotic death may contribute to its anti-inflammatory action and suppress tumour development possibly through switching the cell death mode from tumour-promoting necrotic cell death to tumour-suppressive autophagic cell death.
C1 [Kim, Sun Mi; Kim, Cho Hee; Kang, Ho Sung] Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea.
   [Kim, Sun Mi; Kim, Cho Hee; Kang, Ho Sung] Pusan Natl Univ, Res Inst Genet Engn, Pusan 609735, South Korea.
   [Lim, Sung-Chul; Choi, Jeong Eun; Duong, Hong-Quan; Han, Song Iy] Chosun Univ, Coll Med, Res Ctr Resistant Cells, Kwangju 501759, South Korea.
   [Lim, Sung-Chul] Chosun Univ, Coll Med, Dept Pathol, Kwangju 501759, South Korea.
RP Kang, HS (corresponding author), Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea.
EM sihan@chosun.ac.kr; hspkang@pusan.ac.kr
RI li, tao/B-2402-2008
CR Ahmad IM, 2005, J BIOL CHEM, V280, P4254, DOI 10.1074/jbc.M411662200
   Amann R, 2002, EUR J PHARMACOL, V447, P1, DOI 10.1016/S0014-2999(02)01828-9
   Backer M, 2006, DEUT MED WOCHENSCHR, V131, P1553, DOI 10.1055/s-2006-947797
   Baek SJ, 2002, CARCINOGENESIS, V23, P425, DOI 10.1093/carcin/23.3.425
   Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901
   Battaglia V, 2005, J BIOL CHEM, V280, P33864, DOI 10.1074/jbc.M502391200
   Bellosillo B, 1998, BLOOD, V92, P1406, DOI 10.1182/blood.V92.4.1406.416k17_1406_1414
   Bernales S, 2006, PLOS BIOL, V4, P2311, DOI 10.1371/journal.pbio.0040423
   Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681
   Chen XQ, 2002, INT J HEMATOL, V75, P407, DOI 10.1007/BF02982133
   Chung YM, 2003, FREE RADICAL BIO MED, V34, P434, DOI 10.1016/S0891-5849(02)01301-1
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Ding WX, 2007, J BIOL CHEM, V282, P4702, DOI 10.1074/jbc.M609267200
   Elder DJE, 1996, CANCER RES, V56, P2273
   Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925
   FOSSMANN E, 2007, LANCET, V369, P1603
   Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478
   Golstein P, 2007, TRENDS BIOCHEM SCI, V32, P37, DOI 10.1016/j.tibs.2006.11.001
   Hippert MM, 2006, CANCER RES, V66, P9349, DOI 10.1158/0008-5472.CAN-06-1597
   Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269
   JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322
   Kim CH, 2007, J CELL PHYSIOL, V211, P371, DOI 10.1002/jcp.20941
   Klampfer L, 1999, BLOOD, V93, P2386, DOI 10.1182/blood.V93.7.2386.407k15_2386_2394
   KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854
   Law BK, 2000, J BIOL CHEM, V275, P38261, DOI 10.1074/jbc.M005545200
   Lee EJ, 2003, INT J ONCOL, V23, P503
   Li W, 2007, J IMMUNOL, V178, P3856, DOI 10.4049/jimmunol.178.6.3856
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lim SC, 2007, INT J MOL MED, V20, P187
   Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594
   Marra DE, 2000, CIRCULATION, V102, P2124, DOI 10.1161/01.CIR.102.17.2124
   Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119
   Mates J M, 1999, Front Biosci, V4, pD339
   Newman D, 2003, MOL PHARMACOL, V63, P557, DOI 10.1124/mol.63.3.557
   Raucci A, 2007, AUTOIMMUNITY, V40, P285, DOI 10.1080/08916930701356978
   Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858
   Schlueter C, 2005, AM J PATHOL, V166, P1259, DOI 10.1016/S0002-9440(10)62344-9
   Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869
   Shiff SJ, 1996, EXP CELL RES, V222, P179, DOI 10.1006/excr.1996.0023
   Stark LA, 2007, CARCINOGENESIS, V28, P968, DOI 10.1093/carcin/bgl220
   Syntichaki P, 2003, NAT REV NEUROSCI, V4, P672, DOI 10.1038/nrn1174
   Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626
   Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev
   Ulloa L, 2006, CYTOKINE GROWTH F R, V17, P189, DOI 10.1016/j.cytogfr.2006.01.003
   Ulrich CM, 2006, NAT REV CANCER, V6, P130, DOI 10.1038/nrc1801
   Vakkila J, 2004, NAT REV IMMUNOL, V4, P641, DOI 10.1038/nri1415
   Wilson LC, 2003, INT J CANCER, V105, P747, DOI 10.1002/ijc.11173
   Yang H, 2005, J LEUKOCYTE BIOL, V78, P1, DOI 10.1189/jlb.1104648
   Yorimitsu T, 2006, J BIOL CHEM, V281, P30299, DOI 10.1074/jbc.M607007200
   ZONG WX, 2006, GENE DEV, V20
NR 52
TC 7
Z9 7
U1 0
U2 1
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD MAY
PY 2008
VL 19
IS 5
BP 1165
EP 1171
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 293CI
UT WOS:000255312000013
PM 18425372
DA 2022-04-25
ER

PT J
AU Gurkan, AC
   Arisan, ED
   Yerlikaya, PO
   Ilhan, H
   Unsal, NP
AF Gurkan, Ajda Coker
   Arisan, Elif Damla
   Yerlikaya, Pinar Obakan
   Ilhan, Halime
   Unsal, Narcin Palavan
TI Inhibition of autophagy enhances DENSpm-induced apoptosis in human colon
   cancer cells in a p53 independent manner
SO CELLULAR ONCOLOGY
LA English
DT Article
DE Colon cancer; Apoptosis; Autophagy; Polyamine analogue; DENSpm
ID HUMAN-MELANOMA CELLS; POLYAMINE ANALOG N-1,N-11-DIETHYLNORSPERMINE;
   SPERMIDINE/SPERMINE N-1-ACETYLTRANSFERASE; CARCINOMA-CELLS; INDUCTION;
   RESISTANCE; DEATH; METABOLISM; CATABOLISM; MODULATORS
AB One of the recently developed polyamine (PA) analogues, N (1) ,N (11)-diethylnorspermine (DENSpm), has been found to act as an apoptotic inducer in melanoma, breast, prostate and colon cancer cells. Also, its potential to induce autophagy has been established. Unfolded protein responses and starvation of amino acids are known to trigger autophagy. As yet, however, the molecular mechanism underlying PA deficiency-induced autophagy is not fully clarified. Here, we aimed to determine the apoptotic effect of DENSpm after autophagy inhibition by 3-methyladenine (3-MA) or siRNA-mediated Beclin-1 silencing in colon cancer cells.
   The apoptotic effects of DENSpm after 3-MA treatment or Beclin-1 silencing were determined by PI and AnnexinV/PI staining in conjunction with flow cytometry. Intracellular PA levels were measured by HPLC, whereas autophagy and the expression profiles of PA key players were determined in HCT116, SW480 and HT29 colon cancer cells by Western blotting.
   We found that DENSpm-induced autophagy was inhibited by 3-MA treatment and Beclin-1 silencing, and that apoptotic cell death was increased by PA depletion and spermidine/spermine N (1)-acetyltransferase (SSAT) upregulation. We also found that autophagy inhibition led to DENSpm-induced apoptosis through Atg5 down-regulation, p62 degradation and LC3 lipidation in both HCT116 and SW480 cells. p53 deficiency did not alter the response of the colon cancer cells to DENSpm-induced apoptotic cell death under autophagy suppression conditions.
   From our results we conclude that DENSpm-induced apoptotic cell death is increased when autophagy is inhibited by 3-MA or Beclin-1 siRNA through PA depletion and PA catabolic activation in colon cancer cells, regardless p53 mutation status.
C1 [Gurkan, Ajda Coker; Arisan, Elif Damla; Yerlikaya, Pinar Obakan; Ilhan, Halime; Unsal, Narcin Palavan] Istanbul Kultur Univ, Sci & Letters Fac, Mol Biol & Genet Dept, Atakoy Campus, TR-34156 Istanbul, Turkey.
RP Gurkan, AC (corresponding author), Istanbul Kultur Univ, Sci & Letters Fac, Mol Biol & Genet Dept, Atakoy Campus, TR-34156 Istanbul, Turkey.
EM a.coker@iku.edu.tr
RI Arisan, ElifDamla/AAB-1173-2021; YERLIKAYA, PINAR OBAKAN/AAG-5979-2019;
   Arisan, Elif Damla/W-8682-2019; GURKAN, AJDA/AAG-6669-2019
OI YERLIKAYA, PINAR OBAKAN/0000-0001-7058-955X; Arisan, Elif
   Damla/0000-0002-4844-6381; GURKAN, AJDA/0000-0003-1475-2417; Unsal
   Palavan, Narcin/0000-0002-2945-540X
FU Scientific and Technological Research Council of TURKEY
   [(TUBITAK)]Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)
   [212T227]; Istanbul Kultur University Scientific Projects Support
   CenterIstanbul Kultur University
FX This work was supported by The Scientific and Technological Research
   Council of TURKEY [(TUBITAK), Grant Number; 212T227] and the Istanbul
   Kultur University Scientific Projects Support Center. We are thankful to
   Esin Guvenir, Merve Karatas and Derya Bulut for their technical
   assistance.
CR Akyol Z, 2016, BIOMED PHARMACOTHER, V84, P2029, DOI 10.1016/j.biopha.2016.11.016
   Allen WL, 2007, MOL CANCER THER, V6, P128, DOI 10.1158/1535-7163.MCT-06-0303
   CHANG BK, 1993, J UROLOGY, V150, P1293, DOI 10.1016/S0022-5347(17)35763-4
   Chen Y, 2003, ONCOGENE, V22, P4964, DOI 10.1038/sj.onc.1206725
   Chen Y, 2001, CANCER RES, V61, P6437
   Choi WY, 2005, J BIOL CHEM, V280, P3295, DOI 10.1074/jbc.M409930200
   Coker-Gurkan A, 2015, AMINO ACIDS, V47, P87, DOI 10.1007/s00726-014-1851-7
   Das S, 2017, CELL ONCOL, V40, P593, DOI 10.1007/s13402-017-0347-3
   Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557
   Hahm HA, 2002, CLIN CANCER RES, V8, P684
   Hector S, 2004, MOL CANCER THER, V3, P813
   Hegardt C, 2002, EUR J BIOCHEM, V269, P1033, DOI 10.1046/j.0014-2956.2001.02744.x
   Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601
   Khaodee W, 2017, CELL ONCOL, V40, P579, DOI 10.1007/s13402-017-0349-1
   Kim E, 2009, BIOCHEM PHARMACOL, V77, P11, DOI 10.1016/j.bcp.2008.08.030
   Kramer DL, 1999, CANCER RES, V59, P1278
   McCloskey DE, 1996, CLIN CANCER RES, V2, P441
   McCloskey DE, 2000, J BIOL CHEM, V275, P28708, DOI 10.1074/jbc.M004120200
   Mizushima N, 2009, CURR TOP MICROBIOL, V335, P71, DOI 10.1007/978-3-642-00302-8_3
   Morselli E, 2008, CELL CYCLE, V7, P3056, DOI 10.4161/cc.7.19.6751
   Oredsson SM, 2007, BIOCHEM SOC T, V35, P405, DOI 10.1042/BST0350405
   Pattingre S, 2006, CANCER RES, V66, P2885, DOI 10.1158/0008-5472.CAN-05-4412
   PEGG AE, 1988, CANCER RES, V48, P759
   Pledgie-Tracy A, 2010, CANCER CHEMOTH PHARM, V65, P1067, DOI 10.1007/s00280-009-1112-8
   PORTER CW, 1991, CANCER RES, V51, P3715
   SAAB NH, 1993, J MED CHEM, V36, P2998, DOI 10.1021/jm00072a020
   Schipper RG, 2000, PROSTATE, V44, P313, DOI 10.1002/1097-0045(20000901)44:4<313::AID-PROS8>3.0.CO;2-D
   Sinha S, 2008, ONCOGENE, V27, pS137, DOI 10.1038/onc.2009.51
   Tummala R, 2010, ONCOL REP, V24, P15, DOI 10.3892/or_00000823
   Wallace HM, 2003, BIOCHEM J, V376, P1, DOI 10.1042/BJ20031327
   Wolff JC, 2003, CLIN CANCER RES, V9, P5922
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Yang ZF, 2009, CURR TOP MICROBIOL, V335, P1, DOI 10.1007/978-3-642-00302-8_1
   Zagaja GP, 1998, CANCER CHEMOTH PHARM, V41, P505, DOI 10.1007/s002800050774
NR 34
TC 8
Z9 8
U1 1
U2 12
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 2211-3428
EI 2211-3436
J9 CELL ONCOL
JI Cell. Oncol.
PD JUN
PY 2018
VL 41
IS 3
BP 297
EP 317
DI 10.1007/s13402-017-0369-x
PG 21
WC Oncology; Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology; Pathology
GA GF8KC
UT WOS:000432218500005
PM 29492901
DA 2022-04-25
ER

PT J
AU Mao, MT
   Liu, YM
   Gao, XH
AF Mao, Mintao
   Liu, Yumei
   Gao, Xinhai
TI Feedback autophagy activation as a key resistance factor of Ku-0060648
   in colorectal cancer cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Colorectal cancer; Ku-0060648; Autophagy; DNA-PKcs; PI3K-AKT-mTOR
ID DEPENDENT PROTEIN-KINASE; ACTIVITY IN-VITRO; DNA-PKCS; THERAPEUTIC
   TARGET; STATISTICS; INHIBITOR; PATHWAY; PREVENTION; CHINA
AB The current study evaluated the potential anti-colorectal cancer (CRC) activity by Ku-0060648, a novel DNA-PKcs and PI3K duel inhibitor. In both CRC cell lines (HCT-116 and HT-29) and primary human colon cancer cells, Ku-0060648 exposure at nM concentrations efficiently inhibited cell proliferation. Meanwhile, Ku-0060648 provoked apoptosis in CRC cells. Ku-0060648 was yet ineffective to the normal colon epithelial cells. Ku-0060648 blocked PI3K-AKT-mTOR cascade and in-activated DNA-PKcs in CRC cells. Intriguingly, Ku-0060648 treatment induced feedback autophagy activation in HCT-116 cells. On the other hand, pharmacological autophagy inhibitors (3-methyladenine or chloroquine) or silencing key autophagy proteins (Beclin-1 or ATG-7) dramatically potentiated Ku-0060648-induced HCT-116 cell apoptosis. Together, these results suggest that feedback autophagy activation is a key resistance factor of Ku-0060648 in CRC cells, and autophagy inhibition sensitizes Ku-0060648-induced anti-CRC activity. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Mao, Mintao; Liu, Yumei; Gao, Xinhai] Shanghai Jiao Tong Univ, Sch Med, Tongren Hosp, Emergency Ctr, 1111 Xianxia St, Shanghai 200336, Peoples R China.
RP Gao, XH (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Tongren Hosp, Emergency Ctr, 1111 Xianxia St, Shanghai 200336, Peoples R China.
EM yishenggxhsh@163.com
CR Amaravadi RK, 2007, CLIN CANCER RES, V13, P7271, DOI 10.1158/1078-0432.CCR-07-1595
   Banerjee Hirendra Nath, 2012, J Cancer Sci Ther, V4, P12
   Bouchaert P, 2012, INT J RADIAT ONCOL, V84, P1179, DOI 10.1016/j.ijrobp.2012.02.014
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Brouquet A, 2013, NAT REV GASTRO HEPAT, V10, P266, DOI 10.1038/nrgastro.2013.53
   Chen MB, 2016, ONCOTARGET, V7, P17047, DOI 10.18632/oncotarget.7742
   Chen MB, 2015, BIOCHEM BIOPH RES CO, V463, P954, DOI 10.1016/j.bbrc.2015.06.041
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Chen WQ, 2015, CHINESE J CANCER RES, V27, P1, DOI 10.3978/j.issn.1000-9604.2015.02.07
   Dungl DA, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00240
   Eriksson A, 2002, ANTICANCER RES, V22, P1787
   Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442
   Francipane MG, 2014, ONCOTARGET, V5, P49, DOI 10.18632/oncotarget.1548
   Fu LL, 2013, INT J BIOCHEM CELL B, V45, P921, DOI 10.1016/j.biocel.2013.02.007
   Furukawa T, 2008, J GASTROENTEROL, V43, P905, DOI 10.1007/s00535-008-2226-1
   Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902
   Hosoi Y, 2004, INT J ONCOL, V25, P461
   Hubbard JM, 2015, NAT REV CLIN ONCOL, V12, P73, DOI 10.1038/nrclinonc.2014.233
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249
   Kerr D, 2003, NAT REV CANCER, V3, P615, DOI 10.1038/nrc1147
   Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kuipers EJ, 2013, NAT REV CLIN ONCOL, V10, P130, DOI 10.1038/nrclinonc.2013.12
   Leake Isobel, 2014, Nat Rev Gastroenterol Hepatol, V11, P270, DOI 10.1038/nrgastro.2014.60
   Li JP, 2016, ONCOTARGET, V7, P77815, DOI 10.18632/oncotarget.12802
   Li YM, 2012, AM J MED SCI, V343, P155, DOI 10.1097/MAJ.0b013e31821f978d
   Lu PH, 2016, ONCOTARGET, V7, P45889, DOI 10.18632/oncotarget.9969
   Lu XS, 2017, ONCOTARGET, V8, P988, DOI 10.18632/oncotarget.13519
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   McCoy F, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.86
   Moscat J, 2011, CELL, V147, P724, DOI 10.1016/j.cell.2011.10.021
   Munck JM, 2012, MOL CANCER THER, V11, P1789, DOI 10.1158/1535-7163.MCT-11-0535
   Nezis IP, 2012, ANTIOXID REDOX SIGN, V17, P786, DOI 10.1089/ars.2011.4394
   Palta M, 2014, NAT REV CLIN ONCOL, V11, P182, DOI 10.1038/nrclinonc.2014.43
   Pandurangan AK, 2013, ASIAN PAC J CANCER P, V14, P2201, DOI 10.7314/APJCP.2013.14.4.2201
   Pascale RM, 2016, DNA REPAIR, V47, P12, DOI 10.1016/j.dnarep.2016.10.004
   Robert F, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0215-6
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Schmoll HJ, 2014, NAT REV CLIN ONCOL, V11, P79, DOI 10.1038/nrclinonc.2013.254
   Schonewolf CA, 2014, WORLD J GASTRO ONCOL, V6, P74, DOI 10.4251/wjgo.v6.i3.74
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Separovic D, 2010, ARCH BIOCHEM BIOPHYS, V494, P101, DOI 10.1016/j.abb.2009.11.023
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Ullal AJ, 2014, CLIN IMMUNOL, V154, P178, DOI 10.1016/j.clim.2014.05.007
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   Wrighton KH, 2013, NAT REV MOL CELL BIO, V14, P1, DOI 10.1038/nrm3499
   Wu L, 2015, BIOCHEM BIOPH RES CO, V466, P547, DOI 10.1016/j.bbrc.2015.09.068
   Yu R, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-49
   Zhai L, 2015, BIOCHEM BIOPH RES CO, V468, P274, DOI 10.1016/j.bbrc.2015.10.113
   Zhang Q, 2016, BIOCHEM BIOPH RES CO, V480, P334, DOI 10.1016/j.bbrc.2016.10.043
   Zhao Z, 2017, ONCOTARGET, V8, P18312, DOI 10.18632/oncotarget.15436
   Zhu YR, 2014, BIOCHEM BIOPH RES CO, V451, P112, DOI 10.1016/j.bbrc.2014.07.077
NR 56
TC 5
Z9 5
U1 0
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 2
PY 2017
VL 490
IS 4
BP 1244
EP 1249
DI 10.1016/j.bbrc.2017.07.002
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA FD4UX
UT WOS:000407528800018
PM 28676397
DA 2022-04-25
ER

PT J
AU Choi, JB
   Kim, JH
   Lee, H
   Pak, JN
   Shim, BS
   Kim, SH
AF Choi, Jhin-Baek
   Kim, Ju-Ha
   Lee, Hyemin
   Pak, Ji-Na
   Shim, Bum Sang
   Kim, Sung-Hoon
TI Reactive Oxygen Species and p53 Mediated Activation of p38 and Caspases
   is Critically Involved in Kaempferol Induced Apoptosis in Colorectal
   Cancer Cells
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE Kaempferol; apoptosis; ROS; p53; p38 MAPK
ID HEPATOCELLULAR-CARCINOMA CELLS; COLON-CANCER; OXIDATIVE STRESS;
   HUMAN-DISEASES; PATHWAY; MAPK; AUTOPHAGY; DEATH; JNK; STATISTICS
AB Here the molecular mechanisms of Kaempferol were examined in colorectal cancers (CRCs). Kaempferol significantly exerted antiproliferative and cytotoxic effect in HCT116, HCT15, and SW480 cells. Also, Kaempferol increased sub G1 population, G2/M arrest, and the numbers of TUNEL cells in HCT116 colorectal cancer cells. Also, Kaempferol increased the PARP cleavages and activation of caspase-8, -9, and -3, phospho-p38 MAPK, p53, and p21 in HCT116 and HCT15 cells. Of note, Kaempferol generated reactive oxygen species (ROS) (43.7 +/- 0.56 vs 25.8 +/- 0.43, P < 0.01) in HCT116 cells and reversely ROS inhibitor NAC obstructed the effects of Kaempferol to cleave PARP and caspase-3 and activate phosphorylation of p38 MAPK in HCT116 colorectal cancer cells. Likewise, pancaspase inhibitor z-vad-fmk, p38 MAPK inhibitor SB203580, and p53 depletion blocked PARP and caspase-3 in Kaempferol treated HCT116 colorectal cancer cells. Therefore, these findings provide novel insight that ROS and p53 signalings mediate p38 phosphorylation and caspase activation in Kaempferol stimulated apoptosis in CRCs.
C1 [Choi, Jhin-Baek; Kim, Ju-Ha; Lee, Hyemin; Shim, Bum Sang; Kim, Sung-Hoon] Kyung Hee Univ, Coll Korean Med, Seoul 02447, South Korea.
   [Pak, Ji-Na] Grad Sch East West Med Sci, Dept East West Med Sci, Yongin 17104, South Korea.
RP Kim, SH (corresponding author), Kyung Hee Univ, Canc Mol Targeted Herbal Res Lab, 26 Kyungheedae Ro, Seoul 02447, South Korea.
EM sungkim7@khu.ac.kr
RI Shim, Bum-sang/AAH-9081-2020
OI kim, sunghoon/0000-0003-2423-1973
FU National Research Foundation of Korea (NRF)National Research Foundation
   of Korea [2017R1A2A1A17069297]
FX This study was financially supported by the National Research Foundation
   of Korea (NRF) (no. 2017R1A2A1A17069297).
CR Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Banerjee K, 2015, REDOX BIOL, V5, P153, DOI 10.1016/j.redox.2015.04.009
   Calderon-Montano JM, 2011, MINI-REV MED CHEM, V11, P298, DOI 10.2174/138955711795305335
   Chai RF, 2017, MOL MED REP, V16, P8037, DOI 10.3892/mmr.2017.7612
   Cuenda A, 2007, BBA-MOL CELL RES, V1773, P1358, DOI 10.1016/j.bbamcr.2007.03.010
   Ibrahim A, 2008, CHEM PHARM BULL, V56, P1253, DOI 10.1248/cpb.56.1253
   Jimenez-Del-Rio M, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/163913
   Jung MH, 2009, CARCINOGENESIS, V30, P655, DOI 10.1093/carcin/bgp039
   Kang JW, 2010, PHYTOTHER RES, V24, pS77, DOI 10.1002/ptr.2913
   Kim DH, 2016, MOL CARCINOGEN, V55, P1096, DOI 10.1002/mc.22353
   Kim EK, 2015, ARCH TOXICOL, V89, P867, DOI 10.1007/s00204-015-1472-2
   Kim GT, 2016, INT J ONCOL, V49, P1088, DOI 10.3892/ijo.2016.3578
   Kim JH, 2017, EXPERT OPIN THER TAR, V21, P911, DOI 10.1080/14728222.2017.1369044
   Kwon HY, 2018, ARCH TOXICOL, V92, P241, DOI 10.1007/s00204-017-2021-y
   Lee HS, 2014, INT J MOL SCI, V15, P2722, DOI 10.3390/ijms15022722
   Lee SY, 2016, J AGR FOOD CHEM, V64, P5508, DOI 10.1021/acs.jafc.6b01945
   Li W, 2009, CHEM-BIOL INTERACT, V177, P121, DOI 10.1016/j.cbi.2008.10.048
   Liu T, 2016, J BIOCHEM, V160, P315, DOI 10.1093/jb/mvw040
   McCreath S.B., 2017, PHARMACOGNOSY FUNDAM
   Millimouno FM, 2014, CANCER PREV RES, V7, P1081, DOI 10.1158/1940-6207.CAPR-14-0136
   Mou SF, 2017, ONCOL LETT, V14, P4937, DOI 10.3892/ol.2017.6739
   Okayama S, 2014, J BIOL CHEM, V289, P6513, DOI 10.1074/jbc.M113.532523
   Park YS, 2015, ASIA-PAC J CLIN ONCO, V11, P334, DOI 10.1111/ajco.12409
   Raza MH, 2017, J CANCER RES CLIN, V143, P1789, DOI 10.1007/s00432-017-2464-9
   Sak Katrin, 2014, Pharmacogn Rev, V8, P122, DOI 10.4103/0973-7847.134247
   Sharma V, 2007, MOL CANCER THER, V6, P2544, DOI 10.1158/1535-7163.MCT-06-0788
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   van Zutphen M, 2017, CURR COLORECT CANC R, V13, P370, DOI 10.1007/s11888-017-0386-1
   Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694
   Wang L, 2016, LIFE SCI, V151, P224, DOI 10.1016/j.lfs.2016.02.083
   Weinberg R. A, 2013, BIOL CANC
   Xavier CPR, 2013, J NUTR BIOCHEM, V24, P706, DOI 10.1016/j.jnutbio.2012.04.004
   Yang N, 2017, MOL MED REP, V15, P929, DOI 10.3892/mmr.2016.6081
   Yoshida T, 2008, BIOCHEM BIOPH RES CO, V375, P129, DOI 10.1016/j.bbrc.2008.07.131
   Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308
   Zhang Q, 2015, FOOD FUNCT, V6, P1518, DOI [10.1039/C5FO00142K, 10.1039/c5fo00142k]
NR 37
TC 28
Z9 31
U1 2
U2 27
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
EI 1520-5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD SEP 26
PY 2018
VL 66
IS 38
BP 9960
EP 9967
DI 10.1021/acs.jafc.8b02656
PG 8
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Agriculture; Chemistry; Food Science & Technology
GA GV5LE
UT WOS:000446142800011
PM 30211553
DA 2022-04-25
ER

PT J
AU Ha, TK
   Kim, ME
   Yoon, JH
   Bae, SJ
   Yeom, J
   Lee, JS
AF Ha, Tae Kwun
   Kim, Mi Eun
   Yoon, Ju Hwa
   Bae, Sung Jin
   Yeom, Jihye
   Lee, Jun Sik
TI Galangin induces human colon cancer cell death via the mitochondrial
   dysfunction and caspase-dependent pathway
SO EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Human colon cancer; galangin; apoptosis; caspase activation; chromatin
   condensation
ID APOPTOSIS; AUTOPHAGY
AB Galangin is a member of flavonols and found in Alpinia officinarum, galangal root, and propolis. Previous studies have demonstrated that galangin has anti-cancer effects on several cancers, including melanoma, hepatoma, and leukaemia cells. However, anti-cancer activity of galangin on human colon cancer has not been established yet. In this study, we investigated the anti-cancer effects of galangin on two types of human colon cancer cells (HCT-15 and HT-29). We found that galangin induced apoptosis and DNA condensation of human colon cancer cells in a dose-dependent manner. We also determined that galangin increased the activation of caspase-3 and -9, and release of apoptosis inducing factor from the mitochondria into the cytoplasm by Western blot analysis. In addition, galangin induced human colon cancer cell death through the alteration of mitochondria membrane potential and dysfunction. These results suggest that galangin induces apoptosis of HCT-15 and HT-29 human colon cancer cells and may prove useful in the development of therapeutic agents for human colon cancer.
C1 [Ha, Tae Kwun] Inje Univ, Coll Med, Busan Paik Hosp, Dept Surg, Pusan 633165, South Korea.
   [Kim, Mi Eun; Yoon, Ju Hwa; Yeom, Jihye; Lee, Jun Sik] Chosun Univ, Coll Nat Sci, Dept Biol, Kwangju 501759, South Korea.
   [Bae, Sung Jin] Pusan Natl Univ, Coll Pharm, Pusan 609735, South Korea.
RP Lee, JS (corresponding author), Chosun Univ, Coll Nat Sci, Dept Biol, Kwangju 501759, South Korea.
EM junsiklee@chosun.ac.kr
FU Inje University
FX This work was supported by the 2013 Inje University research grant.
CR Chaabane W, 2013, ARCH IMMUNOL THER EX, V61, P43, DOI 10.1007/s00005-012-0205-y
   Fujimoto N, 2008, DRUG METAB PHARMACOK, V23, P216, DOI 10.2133/dmpk.23.216
   Gwak J, 2011, MOL PHARMACOL, V79, P1014, DOI 10.1124/mol.110.069591
   Jin CH, 2012, TOXICOL LETT, V211, P45, DOI 10.1016/j.toxlet.2012.02.020
   Kim DA, 2012, FOOD CHEM TOXICOL, V50, P684, DOI 10.1016/j.fct.2011.11.039
   Kwon CH, 2008, TOXICOLOGY, V244, P13, DOI 10.1016/j.tox.2007.10.019
   Leonard E, 2006, METAB ENG, V8, P172, DOI 10.1016/j.ymben.2005.11.001
   Seelinger G, 2008, MOLECULES, V13, P2628, DOI 10.3390/molecules13102628
   Sivakumar AS, 2011, CHEM-BIOL INTERACT, V193, P141, DOI 10.1016/j.cbi.2011.06.003
   Tolomeo M, 2008, CANCER LETT, V265, P289, DOI 10.1016/j.canlet.2008.02.025
   Wang L, 2009, AM J CLIN NUTR, V89, P905, DOI 10.3945/ajcn.2008.26913
   Watson AJM, 2011, DIGEST DIS, V29, P222, DOI 10.1159/000323926
   Wen M, 2012, PHARMACOLOGY, V89, P247, DOI 10.1159/000337041
   Xie CH, 2012, J NUTR BIOCHEM, V23, P1184, DOI 10.1016/j.jnutbio.2011.06.013
   Zhang HT, 2010, WORLD J GASTROENTERO, V16, P3377, DOI 10.3748/wjg.v16.i27.3377
   Zhang WJ, 2013, J CELL BIOCHEM, V114, P152, DOI 10.1002/jcb.24312
NR 16
TC 42
Z9 47
U1 0
U2 17
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1535-3702
EI 1535-3699
J9 EXP BIOL MED
JI Exp. Biol. Med.
PD SEP
PY 2013
VL 238
IS 9
BP 1047
EP 1054
DI 10.1177/1535370213497882
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 220LA
UT WOS:000324584000008
PM 23925650
DA 2022-04-25
ER

PT J
AU Rudolf, E
   Kralova, V
   Rudolf, K
   John, S
AF Rudolf, E.
   Kralova, V.
   Rudolf, K.
   John, S.
TI The role of p38 in irinotecan-induced DNA damage and apoptosis of colon
   cancer cells
SO MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
LA English
DT Article
DE Colon cancer; Irinotecan; p38; Apoptosis; DNA damage
ID ACTIVATED PROTEIN-KINASE; COLORECTAL-CANCER; MAP KINASE;
   7-ETHYL-10-HYDROXYCAMPTOTHECIN SN-38; PATHWAY; CHEMOTHERAPY; AUTOPHAGY;
   P38-ALPHA; PHOSPHORYLATION; CHECKPOINT
AB The role of p38 in irinotecan (CPT-11)-induced damage and cell death in colon cancer cell line SW620 was investigated. We demonstrate that CPT-11 treatment activates p38 in exposed cells, however with concentration dependent dynamics and differing consequences. Higher CPT-11 concentrations induce a massive early but relatively short-lasting p38 activity leading to apoptosis mediated by mitochondria and caspases. Pharmacological or siRNA inhibition of p38 then significantly prevents CPT-11-dependent cell death. Conversely, lower CPT-11 concentrations activate p38 in a delayed, however sustained manner, with apoptosis occurring only in a fraction of cells and in the absence of significant autophagy. Blocking p38 in thus treated cells increases their sensitivity toward CPT-11 and increases cell death. In summary, our results confirm the involvement of p38 in colon cancer cells response to CPT-11 while indicating a varying role of p38 in the final biological response. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Rudolf, E.; Kralova, V.; Rudolf, K.; John, S.] Charles Univ Prague, Fac Med Hradec Kralove, Dept Med Biol & Genet, Hradec Kralove 50038, Czech Republic.
RP Rudolf, E (corresponding author), Charles Univ Prague, Fac Med Hradec Kralove, Dept Med Biol & Genet, Simkova 870, Hradec Kralove 50038, Czech Republic.
EM rudolf@lfhk.cuni.cz
RI Rudolf, Kamil/B-8060-2017; Rudolf, Emil/B-5956-2017; Králová,
   Věra/B-6608-2017
OI Rudolf, Kamil/0000-0003-1704-132X; Rudolf, Emil/0000-0002-9526-3174;
   Králová, Věra/0000-0001-5971-4110
FU program PRVOUK [P37/01]
FX This work was supported by the program PRVOUK P37/01.
CR Ashwell JD, 2006, NAT REV IMMUNOL, V6, P532, DOI 10.1038/nri1865
   Bulavin DV, 2004, ADV CANCER RES, V92, P95, DOI 10.1016/S0065-230X(04)92005-2
   Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845
   Chiu SJ, 2008, TOXICOL LETT, V179, P63, DOI 10.1016/j.toxlet.2008.04.004
   Comes F, 2007, CELL DEATH DIFFER, V14, P693, DOI 10.1038/sj.cdd.4402076
   Cuadrado A, 2007, EMBO J, V26, P2115, DOI 10.1038/sj.emboj.7601657
   Cuenda A, 2007, BBA-MOL CELL RES, V1773, P1358, DOI 10.1016/j.bbamcr.2007.03.010
   Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013
   Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741
   Ettlinger DE, 2006, ANTICANCER RES, V26, P1337
   Fiorentini G, 2003, TUMORI J, V89, P382, DOI 10.1177/030089160308900406
   Gagne JF, 2002, MOL PHARMACOL, V62, P608, DOI 10.1124/mol.62.3.608
   Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335
   Han JH, 2007, TRENDS BIOCHEM SCI, V32, P364, DOI 10.1016/j.tibs.2007.06.007
   Hofmann C, 2005, ANTICANCER RES, V25, P795
   Hsu SC, 1999, J BIOL CHEM, V274, P25769, DOI 10.1074/jbc.274.36.25769
   Kim MJ, 2008, MOL CANCER RES, V6, P1718, DOI 10.1158/1541-7786.MCR-08-0032
   LAUGHTON C, 1984, ANAL BIOCHEM, V140, P417, DOI 10.1016/0003-2697(84)90187-8
   Li H, 2011, CANCER RES, V71, P3625, DOI 10.1158/0008-5472.CAN-10-4475
   Ling X, 2009, AM J TRANSL RES, V1, P393
   Nakatomi K, 2001, BIOCHEM BIOPH RES CO, V288, P827, DOI 10.1006/bbrc.2001.5850
   Paillas S, 2011, CANCER RES, V71, P1041, DOI 10.1158/0008-5472.CAN-10-2726
   Phong MS, 2010, MOL CELL BIOL, V30, P3816, DOI 10.1128/MCB.00949-09
   Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977
   Sanchez-Prieto R, 2000, CANCER RES, V60, P2464
   Shi Y, 2002, BIOL CHEM, V383, P1519, DOI 10.1515/BC.2002.173
   Simone C, 2007, AUTOPHAGY, V3, P468, DOI 10.4161/auto.4319
   Tanaka Y, 2003, J BIOL CHEM, V278, P33753, DOI 10.1074/jbc.M303313200
   Tourian L, 2004, J CELL SCI, V117, P6459, DOI 10.1242/jcs.01573
   Vanhoefer U, 2001, J CLIN ONCOL, V19, P1501, DOI 10.1200/JCO.2001.19.5.1501
   Wen JG, 2010, LEUKEMIA RES, V34, P85, DOI 10.1016/j.leukres.2009.05.024
   Wu CC, 2010, PROTEIN CELL, V1, P573, DOI 10.1007/s13238-010-0075-1
   Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257
   Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200
NR 34
TC 20
Z9 20
U1 5
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0027-5107
J9 MUTAT RES-FUND MOL M
JI Mutat. Res.-Fundam. Mol. Mech. Mutagen.
PD JAN-FEB
PY 2013
VL 741
BP 27
EP 34
DI 10.1016/j.mrfmmm.2013.02.002
PG 8
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
GA 137RZ
UT WOS:000318456400004
PM 23422270
DA 2022-04-25
ER

PT J
AU Sameri, S
   Mohammadi, C
   Mehrabani, M
   Najafi, R
AF Sameri, Saba
   Mohammadi, Chiman
   Mehrabani, Mehrnaz
   Najafi, Rezvan
TI Targeting the hallmarks of cancer: the effects of silibinin on
   proliferation, cell death, angiogenesis, and migration in colorectal
   cancer
SO BMC COMPLEMENTARY MEDICINE AND THERAPIES
LA English
DT Article
DE Colorectal cancer; Silibinin; Angiogenesis; Autophagy; Apoptosis;
   Migration
ID ENDOTHELIAL-CELLS; CARCINOMA-CELLS; CYCLE ARREST; HYPOXIA; EXPRESSION;
   GROWTH; APOPTOSIS; AUTOPHAGY; ACTIVATION; INDUCTION
AB Background Silibinin, as a chemopreventive agent, has shown anti-cancer efficacy against different types of cancers. In the present study, we investigated the anti-cancer activities of silibinin on CT26 mouse colon cell line. Methods CT26 cells were treated with different concentrations of silibinin. To examine the cytotoxic effect of silibinin on proliferation, apoptosis, autophagy, angiogenesis, and migration, MTT, colony-forming assay, Annexin V/PI flow cytometry, RT-qPCR, and Scratch assay were used. Results Silibinin was found to significantly reduce CT26 cells survival. Furthermore, silibinin strongly induced apoptosis and autophagy by up-regulating the expression of Bax, Caspase-3, Atg5, Atg7 and BECN1 and down-regulating Bcl-2. Silibinin considerably down-regulated the expression of COX-2, HIF-1 alpha, VEGF, Ang-2, and Ang-4 as well as the expression of MMP-2, MMP-9, CCR-2 and CXCR-4. Conclusions The present study revealed that silibinin shows anticancer activities by targeting proliferation, cell survival, angiogenesis, and migration of CT26 cells.
C1 [Sameri, Saba; Mohammadi, Chiman; Najafi, Rezvan] Hamadan Univ Med Sci, Res Ctr Mol Med, Hamadan, Iran.
   [Mehrabani, Mehrnaz] Kerman Univ Med Sci, Inst Neuropharmacol, Physiol Res Ctr, Kerman, Iran.
RP Najafi, R (corresponding author), Hamadan Univ Med Sci, Res Ctr Mol Med, Hamadan, Iran.
EM re.najafi@umsha.ac.ir
FU Hamadan University of Medical Sciences [9811158675]
FX This study was funded by Hamadan University of Medical Sciences under
   Grant numbers 9811158675.
CR Bai ZL, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/6165192
   Balachandran C, 2014, CHEM-BIOL INTERACT, V224, P24, DOI 10.1016/j.cbi.2014.09.019
   Bayram D, 2017, HUM EXP TOXICOL, V36, P573, DOI 10.1177/0960327116658105
   Byun HJ, 2017, ONCOL REP, V37, P3270, DOI 10.3892/or.2017.5588
   Chen PN, 2005, CHEM-BIOL INTERACT, V156, P141, DOI 10.1016/j.cbi.2005.08.005
   Duan WJ, 2010, J PHARMACOL SCI, V113, P48, DOI 10.1254/jphs.09315FP
   Fan SM, 2012, FREE RADICAL RES, V46, P310, DOI 10.3109/10715762.2012.655244
   Folkman J, 2006, ANNU REV MED, V57, P1, DOI 10.1146/annurev.med.57.121304.131306
   Forghani P, 2014, CANCER MED-US, V3, P215, DOI 10.1002/cam4.186
   Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200
   Gu M, 2007, CANCER RES, V67, P3483, DOI 10.1158/0008-5472.CAN-06-3955
   Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481
   Half E, 2009, EXPERT OPIN PHARMACO, V10, P211, DOI [10.1517/14656560802560153, 10.1517/14656560802560153 ]
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Jahanafrooz Z, 2018, LIFE SCI, V213, P236, DOI 10.1016/j.lfs.2018.10.009
   Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131
   Kaur M, 2009, MOL CANCER THER, V8, P2366, DOI 10.1158/1535-7163.MCT-09-0304
   Kim S, 2009, J ETHNOPHARMACOL, V126, P252, DOI 10.1016/j.jep.2009.08.032
   Kondo Y, 2006, AUTOPHAGY, V2, P85, DOI 10.4161/auto.2.2.2463
   Kurzejamska E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030686
   Kwan YP, 2016, PHARM BIOL, V54, P1223, DOI 10.3109/13880209.2015.1064451
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lopez-Lazaro M, 2006, CANCER EPIDEM BIOMAR, V15, P2332, DOI 10.1158/1055-9965.EPI-06-0369
   Lv X, 2017, GENES DIS, V4, P19, DOI 10.1016/j.gendis.2016.11.003
   Mathonnet M, 2014, WORLD J GASTROENTERO, V20, P4189, DOI 10.3748/wjg.v20.i15.4189
   Montgomery A, 2016, J CANCER, V7, P1250, DOI 10.7150/jca.15690
   Moradi M, 2019, CELL BIOL TOXICOL, V35, P373, DOI 10.1007/s10565-018-09455-3
   Oh SJ, 2013, ONCOL REP, V29, P1343, DOI 10.3892/or.2013.2252
   Oh YS, 2012, ONCOL REP, V28, P2239, DOI 10.3892/or.2012.2063
   Olaru OT, 2015, ONCOL LETT, V10, P1323, DOI 10.3892/ol.2015.3453
   Prasad NR, 2016, CANCERS, V8, DOI 10.3390/cancers8030032
   Raina K, 2013, AUTOPHAGY, V9, P697, DOI 10.4161/auto.23960
   Rybstein MD, 2018, NAT CELL BIOL, V20, P243, DOI 10.1038/s41556-018-0042-2
   Sameri S, 2021, NUTR CANCER, V73, P1389, DOI 10.1080/01635581.2020.1800764
   Simon MP, 2008, J CELL PHYSIOL, V217, P809, DOI 10.1002/jcp.21558
   Singh RP, 2008, CANCER RES, V68, P2043, DOI 10.1158/0008-5472.CAN-07-6247
   Singh RP, 2006, J NATL CANCER I, V98, P846, DOI 10.1093/jnci/djj231
   Singh RP, 2002, CANCER RES, V62, P3063
   Tang CH, 2008, CARCINOGENESIS, V29, P35, DOI 10.1093/carcin/bgm220
   Thorburn A, 2008, APOPTOSIS, V13, P1, DOI 10.1007/s10495-007-0154-9
   Tyagi A, 2004, CARCINOGENESIS, V25, P1711, DOI 10.1093/carcin/bgh180
   Tyagi A, 2006, CARCINOGENESIS, V27, P2269, DOI 10.1093/carcin/bgl098
   Wang Y, 2014, PHYTOMEDICINE, V21, P1310, DOI 10.1016/j.phymed.2014.06.018
   Webb AH, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3418-y
   Yamakawa M, 2004, AM J PHYSIOL-RENAL, V287, pF649, DOI 10.1152/ajprenal.00028.2004
   Yamakawa M, 2003, CIRC RES, V93, P664, DOI 10.1161/01.RES.0000093984.48643.D7
   Yuan J, 2003, NEURON, V40, P401, DOI 10.1016/S0896-6273(03)00601-9
   Zhang RH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023831
   Zhang XK, 2018, ONCOL LETT, V15, P9868, DOI 10.3892/ol.2018.8541
   Zheng N, 2017, ACTA PHARMACOL SIN, V38, P277, DOI 10.1038/aps.2016.117
NR 50
TC 1
Z9 2
U1 4
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2662-7671
J9 BMC COMPLEMENT MED
JI BMC Complement. Med. Ther.
PD MAY 31
PY 2021
VL 21
IS 1
AR 160
DI 10.1186/s12906-021-03330-1
PG 9
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA SK8EY
UT WOS:000656449800001
PM 34059044
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Chen, L
   He, M
   Zhang, M
   Sun, Q
   Zeng, S
   Zhao, H
   Yang, H
   Liu, ML
   Ren, S
   Meng, XL
   Xu, HB
AF Chen, Li
   He, Man
   Zhang, Meng
   Sun, Qiang
   Zeng, Sha
   Zhao, Hui
   Yang, Han
   Liu, Maolun
   Ren, Shan
   Meng, Xianli
   Xu, Haibo
TI The Role of non-coding RNAs in colorectal cancer, with a focus on its
   autophagy
SO PHARMACOLOGY & THERAPEUTICS
LA English
DT Review
DE Colorectal cancer; ncRNA; miRNA; lncRNA; circRNA; Autophagy
ID EPITHELIAL-MESENCHYMAL TRANSITION; COLON-CANCER; CELL-PROLIFERATION;
   SIGNALING PATHWAY; PROMOTES ANGIOGENESIS; ATTENUATES AUTOPHAGY; INDUCED
   APOPTOSIS; METASTASIS; EMT; SUPPRESSES
AB Colorectal cancer (CRC) is one of malignant afflictions burdening people worldwide, mainly caused by shortages of effective medical intervention and poorly mechanistic understanding of the pathogenesis of CRC. Non-coding RNAs (ncRNAs) are a type of heterogeneous transcripts without the capability of coding protein, but have the po-tency of regulating protein-coding gene expression. Autophagy is an evolutionarily conserved catabolic process in which cytoplasmic contents are delivered to cellular lysosomes for degradation, resulting in the turnover of cellular components and producing energy for cell functions. A growing body of evidence reveals that ncRNAs, autophagy, and the crosstalks of ncRNAs and autophagy play intricate roles in the initiation, progression, metas-tasis, recurrence and therapeutic resistance of CRC, which confer ncRNAs and autophagy to serve as clinical bio-markers and therapeutic targets for CRC. In this review, we sought to delineate the complicated roles of ncRNAs, mainly including miRNAs, lncRNAs and circRNAs, in the pathogenesis of CRC, particularly focus on the regulatory role of ncRNAs in CRC-related autophagy, attempting to shed light on the complex pathological mechanisms, in-volving ncRNAs and autophagy, responsible for CRC tumorigenesis and development, so as to underpin the ncRNAs-and autophagy-based therapeutic strategies for CRC in clinical setting. (c) 2021 Elsevier Inc. All rights reserved.
C1 [Chen, Li; He, Man; Zhang, Meng; Sun, Qiang; Zeng, Sha; Zhao, Hui; Yang, Han; Liu, Maolun; Ren, Shan; Meng, Xianli; Xu, Haibo] Chengdu Univ Tradit Chinese Med, State Key Lab Southwestern Chinese Med Resources, Chengdu 611137, Peoples R China.
   [Chen, Li; He, Man; Zhang, Meng; Sun, Qiang; Zeng, Sha; Zhao, Hui; Yang, Han; Liu, Maolun; Ren, Shan; Xu, Haibo] Chengdu Univ Tradit Chinese Med, Sch Pharm, Dept Pharmacol, 1166 Liutai Ave, Chengdu 611137, Peoples R China.
   [Meng, Xianli] Chengdu Univ Tradit Chinese Med, Innovat Inst Chinese Med & Pharm, 1166 Liutai Ave, Chengdu 611137, Peoples R China.
RP Xu, HB (corresponding author), Chengdu Univ Tradit Chinese Med, Sch Pharm, Dept Pharmacol, 1166 Liutai Ave, Chengdu 611137, Peoples R China.; Meng, XL (corresponding author), Chengdu Univ Tradit Chinese Med, Innovat Inst Chinese Med & Pharm, 1166 Liutai Ave, Chengdu 611137, Peoples R China.
EM xlm999@cdutcm.edu.cn; haibo.xu@cdutcm.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81573813, 81173598]; Excellent Talent
   Program of Chengdu University of Traditional Chinese Medicine of China
   [YXRC2019002, ZRYY1917]; Fund of Scientific Research Innovation Team
   Construction in Sichuan Provincial University of China [18TD0017]; Open
   Research Fund of State Key Laboratory of Southwestern Chinese Medicine
   Resources of China [2020 XSGG006]
FX This work was sponsored by the National Natural Science Foundation of
   China (Nos. 81573813 and 81173598), the Excellent Talent Program of
   Chengdu University of Traditional Chinese Medicine of China (Nos.
   YXRC2019002 and ZRYY1917), the Fund of Scientific Research Innovation
   Team Construction in Sichuan Provincial University of China (No.
   18TD0017), and Open Research Fund of State Key Laboratory of
   Southwestern Chinese Medicine Resources of China (No. 2020 XSGG006).
CR Abdollahzadeh R, 2019, J CELL PHYSIOL, V234, P10080, DOI 10.1002/jcp.27941
   Agrawal N, 2003, MICROBIOL MOL BIOL R, V67, P657, DOI 10.1128/MMBR.67.4.657-685.2003
   Ai XH, 2019, ONCOL REP, V41, P483, DOI 10.3892/or.2018.6834
   Alers S, 2011, AUTOPHAGY, V7, P1424, DOI 10.4161/auto.7.12.18027
   Aquila S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071725
   Arif KMT, 2020, CANCERS, V12, DOI 10.3390/cancers12102922
   Bai J, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.568738
   Barault L, 2018, GUT, V67, P1995, DOI 10.1136/gutjnl-2016-313372
   Bardaji HR, 2018, EUR J CELL BIOL, V97, P279, DOI 10.1016/j.ejcb.2018.04.004
   Bednarczyk M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9124020
   Beg MS, 2017, INVEST NEW DRUG, V35, P180, DOI 10.1007/s10637-016-0407-y
   Beggs AD, 2019, EBIOMEDICINE, V39, P265, DOI 10.1016/j.ebiom.2018.11.034
   Bose S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061451
   Bugter JM, 2021, NAT REV CANCER, V21, P5, DOI 10.1038/s41568-020-00307-z
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Cai Y, 2021, HUM EXP TOXICOL, V40, P1463, DOI 10.1177/0960327121997976
   Cao P. G, 2021, TRANSL ONCOL, V14
   Carlsson SR, 2015, J CELL SCI, V128, P193, DOI 10.1242/jcs.141036
   Chen C, 2021, THERANOSTICS, V11, P4298, DOI 10.7150/thno.51342
   Chen DL, 2017, THERANOSTICS, V7, P4836, DOI 10.7150/thno.20942
   Chen LL, 2015, RNA BIOL, V12, P381, DOI 10.1080/15476286.2015.1020271
   Chen YY, 2016, ONCOTARGET, V7, P41306, DOI 10.18632/oncotarget.9320
   CHEN Z, 2021, ONCOL REP, V45
   Chen ZH, 2013, DIGEST DIS SCI, V58, P2887, DOI 10.1007/s10620-013-2732-8
   Cheng L, 2021, INT J MED SCI, V18, P88, DOI 10.7150/ijms.49449
   Cheng WC, 2019, INT J CANCER, V145, P2209, DOI 10.1002/ijc.32338
   Cheng X, 2018, CANCER LETT, V431, P105, DOI 10.1016/j.canlet.2018.05.046
   Cho DH, 2012, ANTICANCER RES, V32, P4091
   Chu CA, 2019, EBIOMEDICINE, V43, P270, DOI 10.1016/j.ebiom.2019.04.010
   Chu YM, 2017, J DIGEST DIS, V18, P169, DOI 10.1111/1751-2980.12463
   Cui Zhi, 2021, J Gene Med, pe3327, DOI 10.1002/jgm.3327
   Deng H, 2021, CELL BIOCHEM BIOPHYS, V79, P387, DOI 10.1007/s12013-021-00976-z
   Dong XM, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005669
   Dou J, 2016, AM J TRANSL RES, V8, P98
   Du GH, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.634596
   Eluard B, 2020, TRENDS CANCER, V6, P677, DOI 10.1016/j.trecan.2020.04.003
   Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074
   Fanale D, 2016, ADV EXP MED BIOL, V937, P93, DOI 10.1007/978-3-319-42059-2_5
   Ferretti, 2020, PHARMACOL THERAPEUT, V107708
   Forterre A, 2020, CANCERS, V12, DOI 10.3390/cancers12071852
   Frias-Lasserre D, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02483
   Fu Q, 2016, ONCOL REP, V36, P3682, DOI 10.3892/or.2016.5195
   Fu YY, 2019, AUTOPHAGY, V15, P295, DOI 10.1080/15548627.2018.1517073
   Fusco N, 2020, GENES-BASEL, V11, DOI 10.3390/genes11070719
   Galluzzi L, 2017, EMBO J, V36, P1811, DOI 10.15252/embj.201796697
   Gao TY, 2020, AGING-US, V12, P21236, DOI 10.18632/aging.103837
   Gao TY, 2020, ARTIF CELL NANOMED B, V48, P664, DOI 10.1080/21691401.2020.1727491
   Ghazanchaei A, 2019, J CELL PHYSIOL, V234, P769, DOI 10.1002/jcp.26891
   Gil J, 2018, MED ONCOL, V35, DOI 10.1007/s12032-018-1220-6
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Guo GF, 2019, WORLD J GASTROENTERO, V25, P1840, DOI 10.3748/wjg.v25.i15.1840
   Han P, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0583-1
   Han QR, 2019, ONCOGENE, V38, P3019, DOI 10.1038/s41388-018-0614-4
   Han Y, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109580
   Hao HB, 2017, MED MOL MORPHOL, V50, P76, DOI 10.1007/s00795-016-0150-7
   He SS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8839
   Hinshaw DC, 2019, CANCER RES, V79, P4557, DOI 10.1158/0008-5472.CAN-18-3962
   Hombach S, 2016, ADV EXP MED BIOL, V937, P3, DOI 10.1007/978-3-319-42059-2_1
   Hou PF, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01857-2
   Huang LX, 2017, CANCER SCI, V108, P1985, DOI 10.1111/cas.13338
   Itatani Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235822
   Javanmard AR, 2020, J CANCER RES CLIN, V146, P1205, DOI 10.1007/s00432-020-03145-6
   Javed Z, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01412-7
   Jia GQ, 2018, J CELL BIOCHEM, V119, P7091, DOI 10.1002/jcb.27031
   Jiang L, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1428-0
   Jiang SX, 2019, J CELL MOL MED, V23, P630, DOI 10.1111/jcmm.13968
   Jin P, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1844-2
   Jing XM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1089-9
   Jing YM, 2020, CELL BIOL TOXICOL, V36, P517, DOI 10.1007/s10565-020-09553-1
   Jo YK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052705
   Ju BL, 2020, AM J TRANSL RES, V12, P2695
   Karimzadeh MR, 2020, CANCER GENE THER, V27, P739, DOI 10.1038/s41417-020-0172-0
   Kita Y, 2017, J HUM GENET, V62, P41, DOI 10.1038/jhg.2016.66
   Koustas E, 2019, AM J CLIN ONCOL-CANC, V42, P767, DOI 10.1097/COC.0000000000000592
   Kyriazi AA, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186658
   Lai HH, 2018, J CLIN INVEST, V128, P625, DOI 10.1172/JCI89212
   Li HW, 2021, J CELL PHYSIOL, V236, P5875, DOI 10.1002/jcp.30271
   Li J, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1150-y
   Li M, 2019, LIFE SCI, V233, DOI 10.1016/j.lfs.2019.04.066
   Li X, 2018, MOL CELL, V71, P428, DOI 10.1016/j.molcel.2018.06.034
   Li Y, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0632-2
   Li Y, 2018, ONCOL REP, V39, P1619, DOI 10.3892/or.2018.6260
   Liang CY, 2010, CURR OPIN CELL BIOL, V22, P226, DOI 10.1016/j.ceb.2009.11.003
   Lin JG, 2018, BIOMED PHARMACOTHER, V98, P433, DOI 10.1016/j.biopha.2017.12.058
   Liu B, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1468-5
   Liu F, 2020, CANCER MED-US, V9, P1079, DOI 10.1002/cam4.2746
   Liu HJ, 2020, HUM CELL, V33, P386, DOI 10.1007/s13577-019-00301-0
   Liu L, 2019, MOL THER-NUCL ACIDS, V17, P644, DOI 10.1016/j.omtn.2019.06.009
   Liu RJ, 2021, WORLD J SURG ONCOL, V19, DOI 10.1186/s12957-021-02164-y
   Liu Y, 2020, CANCER MANAG RES, V12, P13501, DOI 10.2147/CMAR.S285254
   Liu YQ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2268-8
   Long JL, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12900
   Lu B, 2020, CANCERS BASEL, V12
   Lu S, 2018, ONCOL LETT, V15, P1861, DOI 10.3892/ol.2017.7520
   Luan N, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.638244
   Lv ZB, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1357-7
   Ma WQ, 2018, BIOMED PHARMACOTHER, V105, P670, DOI 10.1016/j.biopha.2018.06.025
   Ma YL, 2016, GUT, V65, P1494, DOI 10.1136/gutjnl-2014-308392
   Matsui M, 2017, NAT REV DRUG DISCOV, V16, P167, DOI 10.1038/nrd.2016.117
   Matsuyama H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010132
   Milane L, 2015, J CONTROL RELEASE, V219, P278, DOI 10.1016/j.jconrel.2015.06.029
   Mizushima N, 2020, NEW ENGL J MED, V383, P1564, DOI 10.1056/NEJMra2022774
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Mrozek D, 2020, COMPUT BIOL CHEM, V88, DOI 10.1016/j.compbiolchem.2020.107365
   Nie XB, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01341
   Nunez-Olvera SI, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67550-0
   O'Brien SJ, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00427-x
   Ogunwobi OO, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00834
   Pan SM, 2019, BBA-MOL CELL RES, V1866, P750, DOI 10.1016/j.bbamcr.2019.02.004
   Park YR, 2017, J CANCER RES CLIN, V143, P1915, DOI 10.1007/s00432-017-2440-4
   Parsons R, 2020, CSH PERSPECT MED, V10, DOI 10.1101/cshperspect.a036129
   Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371
   Pentimalli F, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1419-2
   Perera R, 2015, NATURE, V524, P361, DOI 10.1038/nature14587
   Pidikova P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134633
   Qiao PF, 2020, ONCOL REP, V43, P1053, DOI 10.3892/or.2020.7494
   Rajagopal T, 2020, CLIN CHIM ACTA, V503, P1, DOI 10.1016/j.cca.2019.12.028
   Ravanan P, 2017, LIFE SCI, V188, P53, DOI 10.1016/j.lfs.2017.08.029
   Razig K, 2020, BIOMED PHARMACOTHER, V130, DOI 10.1016/j.biopha.2020.110570
   Ren F, 2014, MOL CELL BIOCHEM, V385, P95, DOI 10.1007/s11010-013-1818-0
   Ren JY, 2021, EUR J CANCER PREV, V30, P143, DOI 10.1097/CEJ.0000000000000608
   Salas A, 2020, NAT REV GASTRO HEPAT, V17, P323, DOI 10.1038/s41575-020-0273-0
   Salgado-Garcia R, 2021, GENES-BASEL, V12, DOI 10.3390/genes12020245
   Samadani AA, 2020, CLIN CHIM ACTA, V510, P581, DOI [10.1016/j.caa.2020.08.016, 10.1016/j.cca.2020.08.016]
   Santana-Codina N, 2017, ANNU REV CANC BIOL, V1, P19, DOI 10.1146/annurev-cancerbio-041816-122338
   Sathyanarayanan A, 2018, J CELL BIOCHEM, V119, P2022, DOI 10.1002/jcb.26365
   Schaaf MBE, 2016, FASEB J, V30, P3961, DOI 10.1096/fj.201600698R
   Scherr AL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21031099
   Seto AG, 2018, BRIT J HAEMATOL, V183, P428, DOI 10.1111/bjh.15547
   Shaker F, 2020, COMPUT BIOL MED, V127, DOI 10.1016/j.compbiomed.2020.104060
   Shan TD, 2016, ONCOTARGET, V7, P961, DOI 10.18632/oncotarget.5830
   Shan YJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0759-7
   Shen H, 2018, J CELL BIOCHEM, V119, P7022, DOI 10.1002/jcb.26912
   Shen Y, 2018, GENE, V666, P64, DOI 10.1016/j.gene.2018.05.001
   Shen ZT, 2017, CELL DEATH DIS, V8, DOI 10.1038/s41419-017-0048-x
   Shi ZL, 2021, BIOENGINEERED, V12, P627, DOI 10.1080/21655979.2021.1882164
   Shiratori H, 2019, ONCOL REP, V42, P377, DOI 10.3892/or.2019.7134
   Si YR, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658-019-0175-8
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P145, DOI 10.3322/caac.21601
   Smillie CL, 2018, CRIT REV BIOCHEM MOL, V53, P231, DOI 10.1080/10409238.2018.1447542
   Soleimani A, 2020, GENE, V726, DOI 10.1016/j.gene.2019.144132
   Sun C, 2017, WORLD J GASTROENTERO, V23, P1816, DOI 10.3748/wjg.v23.i10.1816
   Sun JF, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0771-x
   Sun W, 2020, THERANOSTICS, V10, P1981, DOI 10.7150/thno.37621
   Sun W, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0490-4
   Sun XC, 2021, MOL THER-NUCL ACIDS, V24, P164, DOI 10.1016/j.omtn.2021.02.022
   Sun YJ, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8753413
   Sundaram P, 2011, CANCER RES, V71, P7490, DOI 10.1158/0008-5472.CAN-11-1124
   Sung BH, 2017, CELL ADHES MIGR, V11, P187, DOI 10.1080/19336918.2016.1273307
   Tampellini M, 2016, EXPERT OPIN INV DRUG, V25, P507, DOI 10.1517/13543784.2016.1161754
   Tao YM, 2017, ONCOTARGET, V8, P36410, DOI 10.18632/oncotarget.16850
   Vu T, 2017, CANCERS, V9, DOI 10.3390/cancers9120171
   van Zandwijk N, 2017, LANCET ONCOL, V18, P1386, DOI 10.1016/S1470-2045(17)30621-6
   Vicinus B, 2013, ONCOL REP, V30, P1285, DOI 10.3892/or.2013.2580
   Wang CX, 2020, CANCER MANAG RES, V12, P12185, DOI 10.2147/CMAR.S278566
   Wang G, 2018, BIOSCIENCE REP, V38
   Wang H, 2017, BIOCHEM BIOPH RES CO, V485, P181, DOI 10.1016/j.bbrc.2017.02.049
   Wang JY, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109627
   Wang J, 2015, ONCOTARGET, V6, P37852, DOI 10.18632/oncotarget.5635
   Wang LY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225758
   Wang LQ, 2018, MOL ONCOL, V12, P1949, DOI 10.1002/1878-0261.12376
   Wang M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1187-4
   Wang QY, 2019, CANCER LETT, V451, P68, DOI 10.1016/j.canlet.2019.02.041
   Wang XK, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0951-6
   Wang XK, 2019, INT J MED SCI, V16, P51, DOI 10.7150/ijms.27359
   Wang Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1105-0
   Wei JW, 2017, ONCOL REP, V37, P3, DOI 10.3892/or.2016.5236
   Wei L, 2020, ONCOTARGETS THER, V13, P2459, DOI 10.2147/OTT.S238348
   Wu JB, 2020, EXP CELL RES, V396, DOI 10.1016/j.yexcr.2020.112214
   Wu KM, 2017, CELL CYCLE, V16, P1295, DOI 10.1080/15384101.2017.1317416
   Wu SH, 2015, HUM PATHOL, V46, P1752, DOI 10.1016/j.humpath.2015.07.016
   Wu WB, 2021, CURR PHARM BIOTECHNO, V22, P1129, DOI 10.2174/1389201021666201002155955
   Wu XL, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00812
   Xian ZY, 2020, ONCOTARGETS THER, V13, P7571, DOI 10.2147/OTT.S258727
   Xiao CH, 2018, ONCOL LETT, V16, P5317, DOI 10.3892/ol.2018.9259
   Xie L, 2021, BIOENGINEERED, V12, P886, DOI 10.1080/21655979.2021.1889130
   Xin H, 2019, BMC CANCER, V19, DOI 10.1186/s12885-018-5245-1
   Xiong G, 2021, MOL MED REP, V23, DOI 10.3892/mmr.2021.11963
   Xu M, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1063-6
   Xu M, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-018-0690-5
   Xue JF, 2018, CANCER BIOMARK, V21, P849, DOI 10.3233/CBM-170780
   Xue L, 2018, J BUON, V23, P1633
   Yan L, 2018, AGING-US, V10, P3774, DOI 10.18632/aging.101671
   Yan SS, 2018, J CELL PHYSIOL, V233, P6660, DOI 10.1002/jcp.26316
   Yang CG, 2021, MOL THER, V29, P2088, DOI 10.1016/j.ymthe.2021.02.006
   Yang LQ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0110-5
   Yang X, 2017, EUR REV MED PHARMACO, V21, P3586
   Yang Y, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.582040
   Yao Jie, 2015, Onco Targets Ther, V8, P3467, DOI 10.2147/OTT.S81393
   Yarani R, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0188-9
   Yu JT, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0896-y
   Yu XF, 2017, SCI REP-UK, V7, DOI 10.1038/srep42226
   Yuan ZX, 2016, INT J ONCOL, V48, P2675, DOI 10.3892/ijo.2016.3447
   Yue M, 2021, RNA BIOL, V18, P1981, DOI 10.1080/15476286.2021.1885232
   Zeng KX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0454-8
   Zeng ZL, 2021, CANCER MED-US, V10, P2423, DOI 10.1002/cam4.3777
   Zeng ZC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07810-w
   Zhai HY, 2015, ONCOTARGET, V6, P19735, DOI 10.18632/oncotarget.3771
   Zhang HX, 2019, ONCOL REP, V41, P3386, DOI 10.3892/or.2019.7106
   Zhang J, 2021, CANCER GENE THER, V28, P1269, DOI 10.1038/s41417-020-00276-3
   Zhang M, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0656-7
   Zhang T, 2019, J GASTROINTEST CANC, V50, P35, DOI 10.1007/s12029-017-0024-9
   Zhang W, 2018, BIOCHIMIE, V144, P21, DOI 10.1016/j.biochi.2017.10.002
   Zhang YL, 2019, EBIOMEDICINE, V48, P277, DOI 10.1016/j.ebiom.2019.09.051
   Zhang YY, 2020, AGING-US, V12, P6191, DOI 10.18632/aging.103016
   Zhang YH, 2016, AM J TRANSL RES, V8, P5286
   Zhao H, 2017, ONCOTARGET, V8, P59058, DOI 10.18632/oncotarget.19939
   Zhao SL, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0585-z
   Zhao YC, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1375-9
   Zheng S, 2019, J BIOSCIENCES, V44, DOI 10.1007/s12038-019-9918-y
   Zheng YS, 2019, J CELL BIOCHEM, V120, P3922, DOI 10.1002/jcb.27676
   Zhou H, 2020, J CELL BIOCHEM, V121, P2510, DOI 10.1002/jcb.29473
NR 212
TC 21
Z9 22
U1 15
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0163-7258
EI 1879-016X
J9 PHARMACOL THERAPEUT
JI Pharmacol. Ther.
PD OCT
PY 2021
VL 226
AR 107868
DI 10.1016/j.pharmthera.2021.107868
EA APR 2021
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA TF7GY
UT WOS:000670887200001
PM 33901505
DA 2022-04-25
ER

PT J
AU Cernigliaro, C
   D'Anneo, A
   Carlisi, D
   Giuliano, M
   Gammazza, AM
   Barone, R
   Longhitano, L
   Cappello, F
   Emanuele, S
   Distefano, A
   Campanella, C
   Calvaruso, G
   Lauricella, M
AF Cernigliaro, Cesare
   D'Anneo, Antonella
   Carlisi, Daniela
   Giuliano, Michela
   Gammazza, Antonella Marino
   Barone, Rosario
   Longhitano, Lucia
   Cappello, Francesco
   Emanuele, Sonia
   Distefano, Alfio
   Campanella, Claudia
   Calvaruso, Giuseppe
   Lauricella, Marianna
TI Ethanol-Mediated Stress Promotes Autophagic Survival and Aggressiveness
   of Colon Cancer Cells via Activation of Nrf2/HO-1 Pathway
SO CANCERS
LA English
DT Article
DE colon cancer cells; ethanol; Nrf2; HO-1; ER stress; autophagy; MMPs
ID ENDOPLASMIC-RETICULUM STRESS; COLORECTAL-CANCER; OXIDATIVE STRESS;
   POSSIBLE MECHANISMS; HUMAN OSTEOSARCOMA; ALCOHOL INTAKE; NRF2;
   EXPRESSION; RECEPTOR; PARTHENOLIDE
AB Epidemiological studies suggest that chronic alcohol consumption is a lifestyle risk factor strongly associated with colorectal cancer development and progression. The aim of the present study was to examine the effect of ethanol (EtOH) on survival and progression of three different colon cancer cell lines (HCT116, HT29, and Caco-2). Our data showed that EtOH induces oxidative and endoplasmic reticulum (ER) stress, as demonstrated by reactive oxygen species (ROS) and ER stress markers Grp78, ATF6, PERK and, CHOP increase. Moreover, EtOH triggers an autophagic response which is accompanied by the upregulation of beclin, LC3-II, ATG7, and p62 proteins. The addition of the antioxidant N-acetylcysteine significantly prevents autophagy, suggesting that autophagy is triggered by oxidative stress as a prosurvival response. EtOH treatment also upregulates the antioxidant enzymes SOD, catalase, and heme oxygenase (HO-1) and promotes the nuclear translocation of both Nrf2 and HO-1. Interestingly, EtOH also upregulates the levels of matrix metalloproteases (MMP2 and MMP9) and VEGF. Nrf2 silencing or preventing HO-1 nuclear translocation by the protease inhibitor E64d abrogates the EtOH-induced increase in the antioxidant enzyme levels as well as the migration markers. Taken together, our results suggest that EtOH mediates both the activation of Nrf2 and HO-1 to sustain colon cancer cell survival, thus leading to the acquisition of a more aggressive phenotype.
C1 [Cernigliaro, Cesare; Carlisi, Daniela; Emanuele, Sonia; Lauricella, Marianna] Univ Palermo, Inst Biochem, Dept Biomed Neurosci & Adv Diagnost BIND, I-90127 Palermo, Italy.
   [D'Anneo, Antonella; Giuliano, Michela; Calvaruso, Giuseppe] Univ Palermo, Lab Biochem, Dept Biol Chem & Pharmaceut Sci & Technol STEBICE, I-90127 Palermo, Italy.
   [Gammazza, Antonella Marino; Barone, Rosario; Cappello, Francesco; Campanella, Claudia] Univ Palermo, Inst Human Anat, Dept Biomed Neurosci & Adv Diagnost BIND, I-90127 Palermo, Italy.
   [Gammazza, Antonella Marino; Barone, Rosario; Cappello, Francesco; Campanella, Claudia] Euromediterranean Inst Sci & Technol, I-90100 Palermo, Italy.
   [Longhitano, Lucia; Distefano, Alfio] Univ Catania, Dept Biomed & Biotechnol Sci, I-95123 Catania, Italy.
RP Lauricella, M (corresponding author), Univ Palermo, Inst Biochem, Dept Biomed Neurosci & Adv Diagnost BIND, I-90127 Palermo, Italy.
EM cesare.cernigliaro@unipa.it; antonella.danneo@unipa.it;
   daniela.carlisi@unipa.it; michela.giuliano@unipa.it;
   antonella.marino@hotmail.it; rosario.barone@unipa.it;
   lucia.longhitano@unict.it; francapp@hotmail.com;
   sonia.emanuele@unipa.it; distalfio@gmail.com; claudiettacam@hotmail.com;
   giuseppe.calvaruso@unipa.it; marianna.lauricella@unipa.it
RI Lauricella, Marianna/ABD-1263-2020; Gammazza, Antonella
   Marino/AAV-3123-2020; D’Anneo, Antonella/P-1064-2019; Barone,
   Rosario/ABD-8488-2020; barone, rosario/ABA-6758-2021; Cappello,
   Francesco/F-9153-2012
OI D’Anneo, Antonella/0000-0002-1785-8236; CERNIGLIARO,
   Cesare/0000-0002-0264-4921; GIULIANO, Michela/0000-0002-5114-6267;
   LAURICELLA, Marianna/0000-0002-0157-3834; barone,
   rosario/0000-0002-8240-1240; Cappello, Francesco/0000-0001-9288-1148
FU Gruppo Azione Locale (GAL) of Golfo di Castellammare, Italy [17/2015];
   Italian National Operational Programme (PON) "Imprese e Competitivita"
   2014-2020 FESR - Italian Ministry of Economic Development
   [F/090012/01-02/X36]
FX This work has been carried out with the financial support from Gruppo
   Azione Locale (GAL) of Golfo di Castellammare, Italy (Progetto Operativo
   n. 17/2015, misura 313B). Part of this work was funded by the Italian
   National Operational Programme (PON) "Imprese e Competitivita" 2014-2020
   FESR, grant awarded by the Italian Ministry of Economic Development to
   the project titled "Gestione di un servizio integrato multi centrico di
   diagnostica e terapia personalizzata in oncologia" (Project code:
   F/090012/01-02/X36).
CR Ahmed SMU, 2017, BBA-MOL BASIS DIS, V1863, P585, DOI 10.1016/j.bbadis.2016.11.005
   Baan R, 2007, LANCET ONCOL, V8, P292, DOI 10.1016/S1470-2045(07)70099-2
   Bajpai VK, 2017, SCI REP-UK, V7, DOI 10.1038/srep46035
   Barone R, 2016, SCI REP-UK, V6, DOI 10.1038/srep19781
   Bartolome A, 2012, AUTOPHAGY, V8, P1757, DOI 10.4161/auto.21994
   Berberat PO, 2005, CLIN CANCER RES, V11, P3790, DOI 10.1158/1078-0432.CCR-04-2159
   Bishehsari F, 2014, WORLD J GASTROENTERO, V20, P6055, DOI 10.3748/wjg.v20.i20.6055
   Biswas C, 2014, J BIOL CHEM, V289, P26882, DOI 10.1074/jbc.M114.567685
   Blanco AM, 2004, NEUROREPORT, V15, P681, DOI 10.1097/00001756-200403220-00021
   Cai SW, 2014, ECOTOXICOLOGY, V23, P76, DOI 10.1007/s10646-013-1153-y
   Campanella C, 2016, ONCOTARGET, V7, P28849, DOI 10.18632/oncotarget.6680
   Cao SS, 2014, ANTIOXID REDOX SIGN, V21, P396, DOI 10.1089/ars.2014.5851
   Cappello F, 2014, EXPERT OPIN THER TAR, V18, P185, DOI 10.1517/14728222.2014.856417
   Carlisi D, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.78
   Carlisi D, 2015, J CELL PHYSIOL, V230, P1276, DOI 10.1002/jcp.24863
   Chen C, 2014, GENET TEST MOL BIOMA, V18, P187, DOI 10.1089/gtmb.2013.0425
   Chiang SK, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010039
   Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003
   D'Anneo A, 2013, INT J ONCOL, V43, P1895, DOI 10.3892/ijo.2013.2137
   D'Anneo A, 2013, J CELL PHYSIOL, V228, P952, DOI 10.1002/jcp.24131
   Dodson M, 2015, BIOCHEM J, V469, P347, DOI 10.1042/BJ20150568
   Emanuele S, 2018, NUTRIENTS, V10, DOI 10.3390/nu10101490
   Emanuele S, 2018, REND LINCEI-SCI FIS, V29, P397, DOI 10.1007/s12210-018-0704-9
   Emanuele S, 2018, CHEM RES TOXICOL, V31, P201, DOI 10.1021/acs.chemrestox.7b00311
   Furfaro AL, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/1958174
   Gammazza AM, 2017, CANCER LETT, V385, P75, DOI 10.1016/j.canlet.2016.10.045
   Gonzalez-Donquiles C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177549
   Haggar Fatima A, 2009, Clin Colon Rectal Surg, V22, P191, DOI 10.1055/s-0029-1242458
   Haorah J, 2008, FREE RADICAL BIO MED, V45, P1542, DOI 10.1016/j.freeradbiomed.2008.08.030
   Homann N, 2009, ALCOHOL CLIN EXP RES, V33, P551, DOI 10.1111/j.1530-0277.2008.00868.x
   Hu JI, 2010, NEOPLASMA, V57, P86, DOI 10.4149/neo_2010_01_086
   Ji C, 2012, BIOCHEM RES INT, V2012, DOI 10.1155/2012/216450
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kaspar JW, 2009, FREE RADICAL BIO MED, V47, P1304, DOI 10.1016/j.freeradbiomed.2009.07.035
   Kawaratani H, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/495156
   Kim J, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2746457
   Kim S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085984
   Kitamura H, 2018, CANCER SCI, V109, P900, DOI 10.1111/cas.13537
   Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097
   Koehler BC, 2016, ALCOHOL CLIN EXP RES, V40, P2094, DOI 10.1111/acer.13180
   Kou X., 2013, FOOD SCI HUM WELL, V2, P22
   Lamichhane TN, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14356-2
   Lauricella M, 2017, NUTRIENTS, V9, DOI 10.3390/nu9050525
   Lauricella M, 2016, INT J ONCOL, V49, P352, DOI 10.3892/ijo.2016.3495
   Linhart K, 2014, REDOX BIOL, V3, P56, DOI 10.1016/j.redox.2014.08.009
   Liu S, 2018, FOOD FUNCT, V9, P4184, DOI 10.1039/c8fo00650d
   Lucas C, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061310
   Luo J, 2014, AUTOPHAGY, V10, P2099, DOI 10.4161/15548627.2014.981916
   Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320
   Miyata Y, 2014, TRANSL RES, V164, P468, DOI 10.1016/j.trsl.2014.06.010
   Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003
   Nieminen MT, 2018, CANCERS, V10, DOI 10.3390/cancers10010011
   Nitti M, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6020029
   Pugsley HR, 2017, JOVE-J VIS EXP, DOI 10.3791/55637
   Raffa D, 2019, BIOORG CHEM, V83, P367, DOI 10.1016/j.bioorg.2018.10.055
   Rossi M, 2018, CANCERS, V10, DOI 10.3390/cancers10020038
   Sadeghi MR, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317705510
   Sakaki K, 2008, AUTOPHAGY, V4, P841, DOI 10.4161/auto.6607
   Seitz HK, 2005, DIGEST DIS, V23, P297, DOI 10.1159/000090177
   Shimodaira Y, 2014, BIOCHEM BIOPH RES CO, V445, P524, DOI 10.1016/j.bbrc.2014.02.054
   Singletary KW, 2001, CANCER LETT, V165, P131, DOI 10.1016/S0304-3835(01)00419-0
   Song SL, 2018, J CELL PHYSIOL, V233, P3867, DOI 10.1002/jcp.26137
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Thygesen LC, 2008, EPIDEMIOLOGY, V19, P258, DOI 10.1097/EDE.0b013e31816339e0
   Tibullo D, 2016, ONCOTARGET, V7, P28868, DOI 10.18632/oncotarget.7563
   Tibullo D, 2013, CURR PHARM DESIGN, V19, P2765, DOI 10.2174/1381612811319150012
   Tomasello G, 2011, EUR J HISTOCHEM, V55, P210, DOI 10.4081/ejh.2011.e38
   Tsuruya A, 2016, ALCOHOL ALCOHOLISM, V51, P395, DOI 10.1093/alcalc/agv135
   Tuan J, 2016, GASTROINTEST TUMORS, V3, P17, DOI 10.1159/000442831
   van Engeland M, 2003, CANCER RES, V63, P3133
   Vanella L, 2016, ONCOTARGET, V7, P69075, DOI 10.18632/oncotarget.11923
   Vignesh RC, 2006, TOXICOLOGY, V220, P63, DOI 10.1016/j.tox.2005.11.026
   Wang ZG, 2014, HEPATOLOGY, V59, P1381, DOI 10.1002/hep.26912
   Xiong JH, 2015, PROTEIN CELL, V6, P722, DOI 10.1007/s13238-015-0195-8
   Yang CX, 2005, WORLD J GASTROENTERO, V11, P2531, DOI 10.3748/wjg.v11.i17.2531
   Yeo EJ, 2000, EXP MOL MED, V32, P161, DOI 10.1038/emm.2000.27
   Zhang Z, 2019, REDOX BIOL, V25, DOI 10.1016/j.redox.2018.11.005
   Zhao HD, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26856-w
   Zhou SN, 2012, CRIT REV EUKAR GENE, V22, P149, DOI 10.1615/CritRevEukarGeneExpr.v22.i2.60
NR 79
TC 23
Z9 23
U1 1
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD APR
PY 2019
VL 11
IS 4
AR 505
DI 10.3390/cancers11040505
PG 21
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HY0BE
UT WOS:000467773400073
PM 30974805
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Yoo, HS
   Won, SB
   Kwon, YH
AF Yoo, Ho Soo
   Won, Sae Bom
   Kwon, Young Hye
TI Luteolin Induces Apoptosis and Autophagy in HCT116 Colon Cancer Cells
   via p53-Dependent Pathway
SO NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
LA English
DT Article
AB Although a dietary phytochemical luteolin has been shown to regulate various anticancer mechanisms, a role of luteolin in autophagy regulation is mostly unidentified. Here, we investigated whether luteolin exhibits its anticancer effects by induction of apoptosis and autophagy in a p53-dependent manner in colon cancer cells. Cell viability was determined using trypan blue exclusion test. The expressions of proteins and mRNAs were measured by immunoblotting and reverse transcription polymerase chain reaction, respectively. Luteolin at 10 - 20 mu M induced cytotoxicity in p53 wild-type HCT116 colon cancer cells but not in p53 mutant HT-29 cells and normal colon cells. Luteolin exhibited its anticancer effect by increasing p53 phosphorylation and p53 target gene expression, leading to apoptosis and cell cycle arrest in HCT116 cells. We identified that luteolin can induce autophagy in p53 wild-type cells but not in p53 mutant cells, suggesting that luteolin-induced autophagy is p53-dependent; however, chloroquine-mediated inhibition of autophagy did not alter cytotoxicity and apoptosis of cells treated with luteolin. In conclusion, the present data showed that luteolin inhibits the growth of HCT116 colon cancer cells through p53-dependent regulation of apoptosis and cell cycle arrest regardless of the induction of autophagy.
C1 [Yoo, Ho Soo; Kwon, Young Hye] Seoul Natl Univ, Dept Food & Nutr, Seoul, South Korea.
   [Won, Sae Bom] Chungwoon Univ, Dept Human Nutr & Food Sci, Hongseong, Chungnam, South Korea.
   [Kwon, Young Hye] Seoul Natl Univ, Res Inst Human Ecol, Seoul, South Korea.
RP Kwon, YH (corresponding author), 1 Gwanak Ro, Seoul 08826, South Korea.
EM hye0414@snu.ac.kr
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Science, ICT and Future PlanningNational
   Research Foundation of Korea [NRF-2017R1A2B4011432]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Science, ICT and Future Planning (no. NRF-2017R1A2B4011432).
CR Barth S, 2010, J PATHOL, V221, P117, DOI 10.1002/path.2694
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Cao J, 2010, BRIT J NUTR, V103, P249, DOI 10.1017/S000711450999170X
   Cao ZJ, 2017, CELL PHYSIOL BIOCHEM, V43, P1803, DOI 10.1159/000484066
   Chalet C, 2019, XENOBIOTICA, V49, P945, DOI 10.1080/00498254.2018.1509246
   Del Bo' C, 2019, NUTRIENTS, V11, DOI 10.3390/nu11061355
   Fass E, 2006, J BIOL CHEM, V281, P36303, DOI 10.1074/jbc.M607031200
   Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116
   Guan JJ, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.546
   Hao Q, 2020, ONCOL REP, V43, P1067, DOI 10.3892/or.2020.7495
   Jang CH, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040770
   Kang Kyoung Ah, 2019, Exp Mol Med, V51, P1, DOI 10.1038/s12276-019-0238-y
   Kim J, 2011, BRAIN RES, V1418, P42, DOI 10.1016/j.brainres.2011.08.059
   Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   Lee Y, 2019, BIOCHEM BIOPH RES CO, V517, P617, DOI 10.1016/j.bbrc.2019.07.073
   Lim DY, 2007, AM J PHYSIOL-GASTR L, V292, pG66, DOI 10.1152/ajpgi.00248.2006
   Lim DY, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-9
   Liu M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079172
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mrakovcic M, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8020014
   Nakayama M, 2019, J MOL CELL BIOL, V11, P267, DOI 10.1093/jmcb/mjy075
   Nikoletopoulou V, 2013, BBA-MOL CELL RES, V1833, P3448, DOI 10.1016/j.bbamcr.2013.06.001
   Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107
   Park SH, 2013, FOOD CHEM TOXICOL, V56, P100, DOI 10.1016/j.fct.2013.02.022
   Perkins S, 2002, CANCER EPIDEM BIOMAR, V11, P535
   Scalbert A, 2000, J NUTR, V130, p2073S, DOI 10.1093/jn/130.8.2073S
   Seelinger G, 2008, MOLECULES, V13, P2628, DOI 10.3390/molecules13102628
   Selvendiran K, 2006, CANCER RES, V66, P4826, DOI 10.1158/0008-5472.CAN-05-4062
   Shi RX, 2007, MOL CANCER THER, V6, P1338, DOI 10.1158/1535-7163.MCT-06-0638
   Taliou A, 2013, CLIN THER, V35, P592, DOI 10.1016/j.clinthera.2013.04.006
   Tan BS, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.191
   Theoharides TC, 2012, INT J IMMUNOPATH PH, V25, P317, DOI 10.1177/039463201202500201
   Tuorkey MJ, 2016, EUR J CANCER PREV, V25, P65, DOI 10.1097/CEJ.0000000000000128
   Verschooten L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048264
   Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147
   Wittemer SM, 2005, PHYTOMEDICINE, V12, P28, DOI 10.1016/j.phymed.2003.11.002
   Yoshizumi M, 2002, BIOCHEM BIOPH RES CO, V293, P1458, DOI 10.1016/S0006-291X(02)00407-2
   Zhao H, 2017, ONCOTARGET, V8, P59058, DOI 10.18632/oncotarget.19939
NR 39
TC 3
Z9 3
U1 1
U2 7
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0163-5581
EI 1532-7914
J9 NUTR CANCER
JI Nutr. Cancer
PD FEB 7
PY 2022
VL 74
IS 2
BP 677
EP 686
DI 10.1080/01635581.2021.1903947
EA MAR 2021
PG 10
WC Oncology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Nutrition & Dietetics
GA ZG0RC
UT WOS:000632285400001
PM 33757400
DA 2022-04-25
ER

PT J
AU Bijnsdorp, IV
   Peters, GJ
   Temmink, OH
   Fukushima, M
   Kruyt, FA
AF Bijnsdorp, Irene V.
   Peters, Godefridus J.
   Temmink, Olaf H.
   Fukushima, Masakazu
   Kruyt, Frank A.
TI Differential activation of cell death and autophagy results in an
   increased cytotoxic potential for trifluorothymidine compared to
   5-fluorouracil in colon cancer cells
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE cell death; caspase; trifluorothymidine; 5-fluorouracil; cathepsin B;
   autophagy
ID THYMIDYLATE SYNTHASE INHIBITION; CYSTEINE CATHEPSINS; APOPTOSIS;
   TAS-102; PATHWAYS; ANTIMETABOLITE; SENSITIVITY; METABOLISM; MECHANISMS;
   RESISTANCE
AB Trifluorothymidine (TFT) is part of the oral drug formulation TAS-102. Both 5-fluorouracil (5-FU) and TFT can inhibit thymidylate synthase and be incorporated into DNA. TFT shows only moderate cross-resistance to 5-FU. Therefore, we examined whether mechanistic differences in cell death could underlie their different modes of action in colorectal cancer cell lines (WiDR, Lovo92 and Colo320). Drug cytotoxicity was determined by SRB- and clonogenic assays, cell death by flow cytometry (PI and annexin V), caspase cleavage by Western blotting and activity assays and in vivo activity in the hollow fiber assay. The IC50 values of TFT were 1-6 fold lower than for 5-FU, and clonogenic survival was less than 0.9% at 3 mu M TFT, while 2-20% of the cells still survived after 20 mu M 5-FU. In general, TFT was a more potent inducer of apoptosis than 5-FU, although the contribution of caspases varied between the used cell lines and necrosis-like cell death was detected. Accordingly, both drugs induced caspase (Z-VAD) independent cell death and lysosomal cathepsin B was involved. Activation of autophagy recovery mechanisms was only triggered by 5-FU, but not by TFT as determined by LC3B expression and cleavage. Inhibition of autophagy by 3-MA in 5-FU exposed cells reduced cell survival. Also, in vivo TFT (as TAS-102) caused more cell death than a 5-FU formulation. We conclude that TFT and 5-FU induce cell death via both caspase-dependent and independent mechanisms. The TFT was more potent than 5-FU, because it induces higher levels of cell death and does not elicit an autophagic survival response in the cancer cell lines. This provides a strong molecular basis for further application of TFT in cancer therapy.
C1 [Bijnsdorp, Irene V.; Peters, Godefridus J.; Temmink, Olaf H.; Kruyt, Frank A.] Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, NL-1007 MB Amsterdam, Netherlands.
   [Fukushima, Masakazu] Taiho Pharmaceut Co Ltd, Tokushima Res Ctr, Tokushima, Japan.
   [Kruyt, Frank A.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, NL-9713 AV Groningen, Netherlands.
RP Peters, GJ (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, POB 7057, NL-1007 MB Amsterdam, Netherlands.
EM gj.peters@vumc.nl
RI Peters, Godefridus J/C-7562-2013
OI Peters, Godefridus J/0000-0002-5447-2877; Kruyt,
   Frank/0000-0002-2445-9380
FU Taiho Pharmaceuticals, Co., Ltd
FX Grant sponsor: This study was financially supported by Taiho
   Pharmaceuticals, Co., Ltd
CR Ackland SP, 2006, UPDATE CANC THERAPEU, V1, P403
   Backus HHJ, 2003, EUR J CANCER, V39, P1310, DOI 10.1016/S0959-8049(03)00204-1
   Bijnsdorp IV, 2008, CANCER SCI, V99, P2302, DOI 10.1111/j.1349-7006.2008.00963.x
   Bijnsdorp IV, 2008, NUCLEOS NUCLEOT NUCL, V27, P699, DOI 10.1080/15257770802145017
   Bijnsdorp IV, 2007, J NEURO-ONCOL, V85, P25, DOI 10.1007/s11060-007-9385-4
   Broker LE, 2004, CANCER RES, V64, P27, DOI 10.1158/0008-5472.CAN-03-3060
   Broker LE, 2002, CANCER RES, V62, P4081
   Broker LE, 2005, CLIN CANCER RES, V11, P3155, DOI 10.1158/1078-0432.CCR-04-2223
   Bruin M De, 2006, CANC THER, V4, P99
   Carew JS, 2008, CANCER LETT, V269, P7, DOI 10.1016/j.canlet.2008.03.037
   Carew JS, 2007, AUTOPHAGY, V3, P464, DOI 10.4161/auto.4311
   Droga-Mazovec G, 2008, J BIOL CHEM, V283, P19140, DOI 10.1074/jbc.M802513200
   ECKSTEIN JW, 1994, BIOCHEMISTRY-US, V33, P15086, DOI 10.1021/bi00254a018
   Emura T, 2004, INT J MOL MED, V13, P545
   Emura T, 2004, INT J MOL MED, V13, P249
   Fazi B, 2008, AUTOPHAGY, V4, P435, DOI 10.4161/auto.5669
   Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085
   Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999
   Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608
   Giovannetti E, 2007, BRIT J CANCER, V96, P769, DOI 10.1038/sj.bjc.6603639
   KEEPERS YP, 1991, EUR J CANCER, V27, P897, DOI 10.1016/0277-5379(91)90142-Z
   Kruyt FAE, 2008, CANCER LETT, V263, P14, DOI 10.1016/j.canlet.2008.02.003
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Matsuhashi N, 2004, ONCOL REP, V12, P357
   Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200
   Murakami Y, 2000, INT J ONCOL, V17, P277
   OConnor PM, 1997, CANCER RES, V57, P4285
   Overman MJ, 2008, INVEST NEW DRUG, V26, P445, DOI 10.1007/s10637-008-9142-3
   Peters GJ, 2002, BBA-MOL BASIS DIS, V1587, P194, DOI 10.1016/S0925-4439(02)00082-0
   Peters GJ, 1999, CANC DRUG DISC DEV, P101
   PIEDBOIS P, 1992, J CLIN ONCOL, V10, P896
   PINEDO HM, 1988, J CLIN ONCOL, V6, P1653, DOI 10.1200/JCO.1988.6.10.1653
   Rossi D, 2003, HAEMATOLOGICA, V88, P212
   SANTI DV, 1971, BIOCHEMISTRY-US, V10, P3598, DOI 10.1021/bi00795a018
   Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102
   Stoka V, 2007, BIOL CHEM, V388, P555, DOI 10.1515/BC.2007.064
   Temmink OH, 2007, BRIT J CANCER, V96, P61, DOI 10.1038/sj.bjc.6603507
   Temmink OH, 2007, BRIT J CANCER, V96, P231, DOI 10.1038/sj.bjc.6603549
   Temmink OH, 2005, ANTI-CANCER DRUG, V16, P285, DOI 10.1097/00001813-200503000-00007
   Temmink OH, 2004, NUCLEOS NUCLEOT NUCL, V23, P1491, DOI 10.1081/NCN-200027707
   Temmink OH, 2007, CANCER SCI, V98, P779, DOI 10.1111/j.1349-7006.2007.00477.x
   Tillman DM, 1999, CLIN CANCER RES, V5, P425
   Turk B, 2007, FEBS LETT, V581, P2761, DOI 10.1016/j.febslet.2007.05.038
   Voortman J, 2007, MOL CANCER THER, V6, P1046, DOI 10.1158/1535-7163.MCT-06-0577
   Wilson TR, 2007, CANCER RES, V67, P5754, DOI 10.1158/0008-5472.CAN-06-3585
NR 48
TC 64
Z9 68
U1 1
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD MAY 15
PY 2010
VL 126
IS 10
BP 2457
EP 2468
DI 10.1002/ijc.24943
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 586RF
UT WOS:000276928700019
PM 19816940
OA Bronze
DA 2022-04-25
ER

PT J
AU Mariani, F
   Sena, P
   Roncucci, L
AF Mariani, Francesco
   Sena, Paola
   Roncucci, Luca
TI Inflammatory pathways in the early steps of colorectal cancer
   development
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Myeloperoxidase; Colorectal carcinogenesis; Inflammation; Aberrant crypt
   foci; Autophagy; Hypoxia; Apoptosis
ID HYPOXIA-INDUCIBLE FACTOR; NF-KAPPA-B; COLON-CANCER; TRANSCRIPTION
   FACTOR; NITRIC-OXIDE; DNA-DAMAGE; OXIDATIVE STRESS; MYOFIBROBLAST
   DIFFERENTIATION; INTESTINAL TUMORIGENESIS; GASTROINTESTINAL-TRACT
AB Colorectal cancer is a major cause of cancer-related death in many countries. Colorectal carcinogenesis is a stepwise process which, from normal mucosa leads to malignancy. Many factors have been shown to influence this process, however, at present, several points remain obscure. In recent years some hypotheses have been considered on the mechanisms involved in cancer development, expecially in its early stages. Tissue injury resulting from infectious, mechanical, or chemical agents may elicit a chronic immune response resulting in cellular proliferation and regeneration. Chronic inflammation of the large bowel (as in inflammatory bowel diseases), has been associated with the subsequent development of colorectal cancer. In this review we examine the inflammatory pathways involved in the early steps of carcinogenesis, with particular emphasis on colorectal. Firstly, we describe cells and proteins recently suggested as central in the mechanism leading to tumor development. Macrophages and neutrophils are among the cells mostly involved in these processes and proteins, as cyclooxygenases and resolvins, are crucial in these inflammatory pathways. Indeed, the activation of these pathways establishes an oxidative and anaerobic microenvironment with DNA damage to epithelial cells, and shifting from an aerobic to an anaerobic metabolism. Many cellular mechanisms, such as proliferation, apoptosis, and autophagy are altered causing failure to control normal mucosa repair and renewal. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
C1 [Mariani, Francesco; Roncucci, Luca] Univ Modena & Reggio Emilia, Dept Diagnost Clin & Publ Hlth Med, I-41124 Modena, Italy.
   [Sena, Paola] Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, Sect Human Morphol, I-41124 Modena, Italy.
RP Roncucci, L (corresponding author), Univ Modena & Reggio Emilia, Dept Diagnost Clin & Publ Hlth Med, Via Univ 4, I-41124 Modena, Italy.
EM luca.roncucci@unimore.it
RI Roncucci, Luca/L-1392-2016; Sena, Paola/G-9394-2016
OI Roncucci, Luca/0000-0002-0410-1760; Sena, Paola/0000-0003-4724-8786
FU Fondazione Umberto Veronesi (FUV)Fondazione Umberto Veronesi;
   Associazione Ricerca Tumori Intestinali (ARTI) of Modena
FX Supported by The Fondazione Umberto Veronesi (FUV) and the Associazione
   Ricerca Tumori Intestinali (ARTI) of Modena
CR Asano T, 2008, J SURG RES, V146, P32, DOI 10.1016/j.jss.2007.02.011
   Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100
   Berdowska I, 2004, CLIN CHIM ACTA, V342, P41, DOI 10.1016/j.cccn.2003.12.016
   Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972
   Bharti AC, 2002, ANN NY ACAD SCI, V973, P392, DOI 10.1111/j.1749-6632.2002.tb04671.x
   Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7
   Biswas SK, 2008, J IMMUNOL, V180, P2011, DOI 10.4049/jimmunol.180.4.2011
   Bortuzzo C, 1996, BBA-LIPID LIPID MET, V1300, P240, DOI 10.1016/0005-2760(96)00003-3
   Botti J, 2006, AUTOPHAGY, V2, P67, DOI 10.4161/auto.2.2.2458
   Brenmoehl J, 2009, WORLD J GASTROENTERO, V15, P1431, DOI 10.3748/wjg.15.1431
   Brown SL, 2007, J CLIN INVEST, V117, P258, DOI 10.1172/JCI29159
   Castellone MD, 2006, CANCER RES, V66, P11085, DOI 10.1158/0008-5472.CAN-06-2233
   Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731
   Cheung KL, 2014, MOL CARCINOGEN, V53, P77, DOI 10.1002/mc.21950
   Chi JT, 2006, PLOS MED, V3, P395, DOI 10.1371/journal.pmed.0030047
   Crocker PR, 2007, NAT REV IMMUNOL, V7, P255, DOI 10.1038/nri2056
   Cui XL, 2010, CANCER PREV RES, V3, P549, DOI 10.1158/1940-6207.CAPR-09-0117
   Curran JN, 2006, WOUND REPAIR REGEN, V14, P376, DOI 10.1111/j.1743-6109.2006.00151.x
   DalleDonne I, 1995, BIOPHYS J, V69, P2710, DOI 10.1016/S0006-3495(95)80142-6
   Dang DT, 2006, CANCER RES, V66, P1684, DOI 10.1158/0008-5472.CAN-05-2887
   DVORAK HF, 1986, NEW ENGL J MED, V315, P1650
   Egeblad M, 2010, CURR OPIN CELL BIOL, V22, P697, DOI 10.1016/j.ceb.2010.08.015
   El Kebir D, 2009, AM J RESP CRIT CARE, V180, P311, DOI 10.1164/rccm.200810-1601OC
   Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169
   Erwig LP, 2007, AM J PATHOL, V171, P2, DOI 10.2353/ajpath.2007.070135
   Evans MD, 2004, MUTAT RES-REV MUTAT, V567, P1, DOI 10.1016/j.mrrev.2003.11.001
   Faraonio R, 2006, J BIOL CHEM, V281, P39776, DOI 10.1074/jbc.M605707200
   Ferguson LR, 2010, MUTAT RES-FUND MOL M, V690, P3, DOI 10.1016/j.mrfmmm.2010.03.007
   Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020
   Ford J, 2005, CANCER RES, V65, P10457, DOI 10.1158/0008-5472.CAN-05-1923
   Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047
   Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871
   Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427
   Ganster RW, 2001, P NATL ACAD SCI USA, V98, P8638, DOI 10.1073/pnas.151239498
   Gill SE, 2008, INT J BIOCHEM CELL B, V40, P1334, DOI 10.1016/j.biocel.2007.10.024
   Ginis I, 1997, AM J PHYSIOL-CELL PH, V272, pC295, DOI 10.1152/ajpcell.1997.272.1.C295
   Giudice A, 2006, BIOESSAYS, V28, P169, DOI 10.1002/bies.20359
   Glebov OK, 2006, CANCER EPIDEM BIOMAR, V15, P2253, DOI 10.1158/1055-9965.EPI-05-0694
   Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978
   Gungor N, 2007, FASEB J, V21, P2359, DOI 10.1096/fj.07-8163com
   Haddow A, 1972, Adv Cancer Res, V16, P181
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Holloway KR, 2010, P NATL ACAD SCI USA, V107, P9216, DOI 10.1073/pnas.0911325107
   Huber S, 2012, NATURE, V491, P259, DOI 10.1038/nature11535
   Jung-Hynes B, 2010, J PINEAL RES, V48, P9, DOI 10.1111/j.1600-079X.2009.00729.x
   Kabra N, 2009, J BIOL CHEM, V284, P18210, DOI 10.1074/jbc.M109.000034
   Kaidi A, 2006, CANCER RES, V66, P6683, DOI 10.1158/0008-5472.CAN-06-0425
   Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877
   Kapsoritakis AN, 2008, BMC GASTROENTEROL, V8, DOI 10.1186/1471-230X-8-55
   Kawamura YI, 2008, GASTROENTEROLOGY, V135, P142, DOI 10.1053/j.gastro.2008.03.031
   Kettritz R, 1999, KIDNEY INT, V55, P562, DOI 10.1046/j.1523-1755.1999.00280.x
   Kikuchi N, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-31
   Kim HS, 2010, CANCER CELL, V17, P41, DOI 10.1016/j.ccr.2009.11.023
   Klebanoff SJ, 2005, J LEUKOCYTE BIOL, V77, P598, DOI 10.1189/jlb.1204697
   Knaapen AM, 2006, MUTAGENESIS, V21, P225, DOI 10.1093/mutage/gel032
   Koh TJ, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411001943
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   Kwak JM, 2010, WORLD J GASTROENTERO, V16, P3897, DOI 10.3748/wjg.v16.i31.3897
   Lakatos G, 2012, DIGEST DIS, V30, P289, DOI 10.1159/000336995
   Lamagna C, 2006, J LEUKOCYTE BIOL, V80, P705, DOI 10.1189/jlb.1105656
   Lau D, 2005, P NATL ACAD SCI USA, V102, P431, DOI 10.1073/pnas.0405193102
   Lawrence T, 2002, NAT REV IMMUNOL, V2, P787, DOI 10.1038/nri915
   Leitch AE, 2008, MUCOSAL IMMUNOL, V1, P350, DOI 10.1038/mi.2008.31
   Li C, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/849054
   Lonkar P, 2011, INT J CANCER, V128, P1999, DOI 10.1002/ijc.25815
   Lopez-Lazaro M, 2006, FASEB J, V20, P828, DOI 10.1096/fj.05-5168hyp
   Lum JJ, 2007, GENE DEV, V21, P1037, DOI 10.1101/gad.1529107
   Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322
   Maloberti PM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015540
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5
   Mariani F, 2009, CANCER LETT, V279, P221, DOI 10.1016/j.canlet.2009.02.001
   Martin MJ, 2001, CURR PHARM DESIGN, V7, P881, DOI 10.2174/1381612013397645
   McKenzie BS, 2006, TRENDS IMMUNOL, V27, P17, DOI 10.1016/j.it.2005.10.003
   McMahon B, 2001, TRENDS PHARMACOL SCI, V22, P391, DOI 10.1016/S0165-6147(00)01771-5
   Meira LB, 2008, J CLIN INVEST, V118, P2516, DOI 10.1172/JCI35073
   Melstrom LG, 2008, CLIN CANCER RES, V14, P6525, DOI 10.1158/1078-0432.CCR-07-4631
   Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140
   Lopez-Novoa JM, 2009, EMBO MOL MED, V1, P303, DOI 10.1002/emmm.200900043
   Miyazaki K, 2004, CANCER RES, V64, P4498, DOI 10.1158/0008-5472.CAN-03-3614
   Miyazaki K, 2012, J IMMUNOL, V188, P4690, DOI 10.4049/jimmunol.1100605
   Morselli E, 2009, BBA-MOL CELL RES, V1793, P1524, DOI 10.1016/j.bbamcr.2009.01.006
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Motilva V, 2011, J PINEAL RES, V51, P44, DOI 10.1111/j.1600-079X.2011.00915.x
   Moussalli MJ, 2011, CANCER PREV RES, V4, P1961, DOI 10.1158/1940-6207.CAPR-10-0280
   Munder M, 1998, J IMMUNOL, V160, P5347
   Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073
   Mutoh M, 2002, CANCER RES, V62, P28
   Nakayama Y, 2012, ONCOL REP, V27, P1325, DOI 10.3892/or.2012.1640
   NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815
   Nishikawa M, 2005, BRIT J CANCER, V93, P331, DOI 10.1038/sj.bjc.6602664
   Nixon JB, 2004, PROSTAG LEUKOTR ESS, V70, P7, DOI 10.1016/j.plefa.2003.06.001
   Nosho K, 2009, MODERN PATHOL, V22, P922, DOI 10.1038/modpathol.2009.49
   Ohd JF, 2003, GASTROENTEROLOGY, V124, P57, DOI 10.1053/gast.2003.50011
   Okamoto R, 2004, J GASTROENTEROL, V39, P1, DOI 10.1007/s00535-003-1259-8
   Orlando UD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040794
   Othman EM, 2013, MUTAT RES-FUND MOL M, V745, P34, DOI 10.1016/j.mrfmmm.2013.03.006
   Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924
   Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103
   Provenzano PP, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-38
   Qiu XL, 2010, CELL METAB, V12, P662, DOI 10.1016/j.cmet.2010.11.015
   Ramalho-Santos M, 2000, DEVELOPMENT, V127, P2763
   Rankin EB, 2008, CELL DEATH DIFFER, V15, P678, DOI 10.1038/cdd.2008.21
   Ravichandran KS, 2011, IMMUNITY, V35, P445, DOI 10.1016/j.immuni.2011.09.004
   Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006
   Richmond A, 2002, NAT REV IMMUNOL, V2, P664, DOI 10.1038/nri887
   Roncucci L, 2008, CANCER EPIDEM BIOMAR, V17, P2291, DOI 10.1158/1055-9965.EPI-08-0224
   Rubino SJ, 2012, TRENDS IMMUNOL, V33, P112, DOI 10.1016/j.it.2012.01.003
   Saunders LR, 2007, ONCOGENE, V26, P5489, DOI 10.1038/sj.onc.1210616
   Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957
   SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970
   SEMENZA GL, 1994, J BIOL CHEM, V269, P23757
   Sena P, 2010, CANCER EPIDEM BIOMAR, V19, P351, DOI 10.1158/1055-9965.EPI-09-0438
   Serhan CN, 2007, ANNU REV IMMUNOL, V25, P101, DOI 10.1146/annurev.immunol.25.022106.141647
   Seril DN, 2007, MOL CARCINOGEN, V46, P341, DOI 10.1002/mc.20282
   Shelton P, 2013, FASEB J, V27, P414, DOI 10.1096/fj.12-217257
   Shen H, 2013, CRIT REV EUKAR GENE, V23, P37, DOI 10.1615/CritRevEukarGeneExpr.2013006288
   Shureiqi I, 2001, CANCER RES, V61, P6307
   Simon HU, 2003, IMMUNOL REV, V193, P101, DOI 10.1034/j.1600-065X.2003.00038.x
   Singh UP, 2010, J PHARMACOL EXP THER, V332, P829, DOI 10.1124/jpet.109.160838
   Sinicrope FA, 2004, CANCER METAST REV, V23, P63, DOI 10.1023/A:1025863029529
   Soehnlein O, 2010, NAT REV IMMUNOL, V10, P427, DOI 10.1038/nri2779
   Solinas G, 2009, J LEUKOCYTE BIOL, V86, P1065, DOI 10.1189/jlb.0609385
   Stark MA, 2005, IMMUNITY, V22, P285, DOI 10.1016/j.immuni.2005.01.011
   Stenson WF, 2007, CURR OPIN GASTROEN, V23, P107, DOI 10.1097/MOG.0b013e3280143cb6
   Sui GP, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-73
   Sylvia C J, 2003, J Wound Care, V12, P13
   Talieri M, 2004, CANCER LETT, V205, P97, DOI 10.1016/j.canlet.2003.09.033
   Tilley SL, 2001, J CLIN INVEST, V108, P15, DOI 10.1172/JCI200113416
   Toullec A, 2010, EMBO MOL MED, V2, P211, DOI 10.1002/emmm.201000073
   Tsujino T, 2007, CLIN CANCER RES, V13, P2082, DOI 10.1158/1078-0432.CCR-06-2191
   Ullah MS, 2006, J BIOL CHEM, V281, P9030, DOI 10.1074/jbc.M511397200
   Vellai T, 2009, TRENDS CELL BIOL, V19, P487, DOI 10.1016/j.tcb.2009.07.007
   Wasilewicz MP, 2010, INT J COLORECTAL DIS, V25, P1079, DOI 10.1007/s00384-010-0980-z
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Winterbourn CC, 2002, TOXICOLOGY, V181, P223, DOI 10.1016/S0300-483X(02)00286-X
   Woo DK, 2012, AM J PATHOL, V180, P24, DOI 10.1016/j.ajpath.2011.10.003
   Wynn Thomas A, 2011, Curr Protoc Immunol, VChapter 14, DOI 10.1002/0471142735.im1422s93
   Wynn TA, 2010, SEMIN LIVER DIS, V30, P245, DOI 10.1055/s-0030-1255354
   Xouri G, 2010, SEMIN CELL DEV BIOL, V21, P40, DOI 10.1016/j.semcdb.2009.11.017
   Yu LX, 2006, WORLD J GASTROENTERO, V12, P4660, DOI 10.3748/wjg.v12.i29.4660
   Zhang LM, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-66
   Zhang T, 2010, BBA-PROTEINS PROTEOM, V1804, P1666, DOI 10.1016/j.bbapap.2009.10.022
   Zindl CL, 2013, P NATL ACAD SCI USA, V110, P12768, DOI 10.1073/pnas.1300318110
NR 144
TC 88
Z9 94
U1 1
U2 12
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD AUG 21
PY 2014
VL 20
IS 29
BP 9716
EP 9731
DI 10.3748/wjg.v20.i29.9716
PG 16
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA AN6TK
UT WOS:000340730300007
PM 25110410
OA hybrid, Green Published
DA 2022-04-25
ER

PT J
AU Thongchot, S
   Singsuksawat, E
   Sumransub, N
   Pongpaibul, A
   Trakarnsanga, A
   Thuwajit, P
   Thuwajit, C
AF Thongchot, Suyanee
   Singsuksawat, Ekapot
   Sumransub, Nuttavut
   Pongpaibul, Ananya
   Trakarnsanga, Attaporn
   Thuwajit, Peti
   Thuwajit, Chanitra
TI Periostin regulates autophagy through integrin alpha 5 beta 1 or alpha 6
   beta 4 and an AKT-dependent pathway in colorectal cancer cell migration
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE autophagy; cancer-associated fibroblast; colorectal cancer; integrin;
   periostin
ID EPITHELIAL-MESENCHYMAL TRANSITION; COLON-CANCER; FIBROBLASTS;
   EXPRESSION; CARCINOMA; INVASION
AB Colorectal cancer (CRC) is one of the most fatal cancers with highly invasive properties. The progression of CRC is determined by the driving force of periostin (PN) from cancer-associated fibroblasts (CAFs) in the tumour microenvironment. This present work aims to investigate autophagy-mediated CRC invasion via the receptor integrin (ITG) by PN. The level of PN in 410 clinical CRC tissues was found increased and was an independent poor prognosis marker (HR = 2.578, 95% CI = 1.218-5.457,P-value = .013) with a significant correlation with overall survival time (P-value < .001). PN activated proliferation, migration and invasion of CRC cells, but with reduced autophagy. Interestingly, the reduction of LC3 autophagic protein corresponded to the increased ability of CRC cell migration. The siITG alpha 5-treated HT-29 and siITG beta 4-treated HCT-116 CRC cells attenuated epithelial-to-mesenchymal transitions (EMT)-related genes and pAKT compared with those in siITG-untreated cells. The reduction of pAKT by a PI3K inhibitor significantly restored autophagy in CRC cells. These evidences confirmed the effect of PN through either ITG alpha 5 beta 1 or ITG alpha 6 beta 4 and the AKT-dependent pathway to control autophagy-regulated cell migration. In conclusion, these results exhibited the impact of PN activation of ITG alpha 5 beta 1 or ITG alpha 6 beta 4 through pAKT in autophagy-mediated EMT and migration in CRC cells.
C1 [Thongchot, Suyanee; Singsuksawat, Ekapot; Sumransub, Nuttavut; Thuwajit, Peti; Thuwajit, Chanitra] Mahidol Univ, Siriraj Hosp, Dept Immunol, Fac Med, 2 Wang Lang Rd, Bangkok 10700, Thailand.
   [Thongchot, Suyanee] Mahidol Univ, Siriraj Hosp, Siriraj Ctr Res Excellence Canc Immunotherapy, Fac Med, Bangkok, Thailand.
   [Pongpaibul, Ananya] Mahidol Univ, Siriraj Hosp, Dept Pathol, Fac Med, Bangkok, Thailand.
   [Trakarnsanga, Attaporn] Mahidol Univ, Siriraj Hosp, Dept Surg, Fac Med, Bangkok, Thailand.
RP Thuwajit, C (corresponding author), Mahidol Univ, Siriraj Hosp, Dept Immunol, Fac Med, 2 Wang Lang Rd, Bangkok 10700, Thailand.
EM cthuwajit@yahoo.com
RI Thuwajit, Peti/AAD-1014-2021; Thuwajit, Chanitra/AAT-7933-2021
OI Sumransub, Nuttavut/0000-0001-7456-0623; Thuwajit,
   Chanitra/0000-0001-9506-6405
FU National Science and Technology Development Agency of Thailand
   [P-15-50267]; Faculty of Medicine Siriraj Hospital, Mahidol University
   [R016033015]
FX This work was financially supported by National Science and Technology
   Development Agency of Thailand, Grant no. P-15-50267 and the Research
   Grant, Faculty of Medicine Siriraj Hospital, Mahidol University, Grant
   no. R016033015 to CT.
CR Bao SD, 2004, CANCER CELL, V5, P329, DOI 10.1016/S1535-6108(04)00081-9
   Barczyk M, 2010, CELL TISSUE RES, V339, P269, DOI 10.1007/s00441-009-0834-6
   Baril P, 2007, ONCOGENE, V26, P2082, DOI 10.1038/sj.onc.1210009
   Ben QW, 2009, INT J ONCOL, V34, P821, DOI 10.3892/ijo_00000208
   Boudjadi S, 2017, CANCERS, V9, DOI 10.3390/cancers9080096
   Choi KS, 2012, EXP MOL MED, V44, P109, DOI 10.3858/emm.2012.44.2.033
   Devenport SN, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111349
   Ferlay J, 2018, EUR J CANCER, V103, P356, DOI 10.1016/j.ejca.2018.07.005
   Ferraresi A, 2017, MOL CARCINOGEN, V56, P1164, DOI 10.1002/mc.22582
   Goertzen C, 2019, BIOL PROCED ONLINE, V21, DOI 10.1186/s12575-019-0100-6
   Gong YZ, 2019, ONCOL REP, V42, P923, DOI 10.3892/or.2019.7216
   Kikuchi Y, 2008, J HISTOCHEM CYTOCHEM, V56, P753, DOI 10.1369/jhc.2008.951061
   Kudo Y, 2007, HISTOL HISTOPATHOL, V22, P1167, DOI 10.14670/HH-22.1167
   Li ZW, 2015, INT J MOL SCI, V16, P12108, DOI 10.3390/ijms160612108
   Lv YJ, 2017, ONCOL LETT, V14, P376, DOI 10.3892/ol.2017.6124
   Moniuszko T, 2016, ONCOL LETT, V12, P783, DOI 10.3892/ol.2016.4692
   Morra L, 2011, VIRCHOWS ARCH, V459, P465, DOI 10.1007/s00428-011-1151-5
   Oh HJ, 2017, J PATHOL TRANSL MED, V51, P306, DOI 10.4132/jptm.2017.01.19
   Puppa G, 2010, ARCH PATHOL LAB MED, V134, P837, DOI 10.1043/1543-2165-134.6.837
   Qin H, 2019, CELL REPROGRAM, V21, P122, DOI 10.1089/cell.2018.0051
   Ratajczak-Wielgomas K, 2015, FOLIA HISTOCHEM CYTO, V53, P120, DOI 10.5603/FHC.a2015.0014
   Ruan K, 2009, CELL MOL LIFE SCI, V66, P2219, DOI 10.1007/s00018-009-0013-7
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Thongchot S, 2018, CANCER LETT, V430, P160, DOI 10.1016/j.canlet.2018.05.031
   Thuwajit C, 2017, ONCOL LETT, V14, P623, DOI 10.3892/ol.2017.6250
   Underwood TJ, 2015, J PATHOL, V235, P466, DOI 10.1002/path.4467
   Utispan K, 2012, INT J ONCOL, V41, P1110, DOI 10.3892/ijo.2012.1530
   Utispan K, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-13
   Xiao ZM, 2015, BIOTECHNOL APPL BIOC, V62, P401, DOI 10.1002/bab.1193
   Xu XW, 2016, ONCOTARGET, V7, P798, DOI 10.18632/oncotarget.5985
   Zhang H, 2014, CELL PHYSIOL BIOCHEM, V33, P991, DOI 10.1159/000358670
NR 31
TC 5
Z9 5
U1 2
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-1838
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD NOV
PY 2020
VL 24
IS 21
BP 12421
EP 12432
DI 10.1111/jcmm.15756
EA SEP 2020
PG 12
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA OV1EP
UT WOS:000573376700001
PM 32990415
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Yin, KL
   Lee, J
   Liu, ZL
   Kim, H
   Martin, DR
   Wu, DD
   Liu, ML
   Xue, X
AF Yin, Kunlun
   Lee, Jordan
   Liu, Zhaoli
   Kim, Hyeoncheol
   Martin, David R.
   Wu, Dandan
   Liu, Meilian
   Xue, Xiang
TI Mitophagy protein PINK1 suppresses colon tumor growth by metabolic
   reprogramming via p53 activation and reducing acetyl-CoA production
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Article
AB Colorectal cancer (CRC) is the third leading cause of cancer-related deaths in the US. Understanding the mechanisms of CRC progression is essential to improve treatment. Mitochondria is the powerhouse for healthy cells. However, in tumor cells, less energy is produced by the mitochondria and metabolic reprogramming is an early hallmark of cancer. The metabolic differences between normal and cancer cells are being interrogated to uncover new therapeutic approaches. Mitochondria targeting PTEN-induced kinase 1 (PINK1) is a key regulator of mitophagy, the selective elimination of damaged mitochondria by autophagy. Defective mitophagy is increasingly associated with various diseases including CRC. However, a significant gap exists in our understanding of how PINK1-dependent mitophagy participates in the metabolic regulation of CRC. By mining Oncomine, we found that PINK1 expression was downregulated in human CRC tissues compared to normal colons. Moreover, disruption of PINK1 increased colon tumorigenesis in two colitis-associated CRC mouse models, suggesting that PINK1 functions as a tumor suppressor in CRC. PINK1 overexpression in murine colon tumor cells promoted mitophagy, decreased glycolysis and increased mitochondrial respiration potentially via activation of p53 signaling pathways. In contrast, PINK1 deletion decreased apoptosis, increased glycolysis, and reduced mitochondrial respiration and p53 signaling. Interestingly, PINK1 overexpression in vivo increased apoptotic cell death and suppressed colon tumor xenograft growth. Metabolomic analysis revealed that acetyl-CoA was significantly reduced in tumors with PINK1 overexpression, which was partly due to activation of the HIF-1 alpha-pyruvate dehydrogenase (PDH) kinase 1 (PDHK1)-PDHE1 alpha axis. Strikingly, treating mice with acetate increased acetyl-CoA levels and rescued PINK1-suppressed tumor growth. Importantly, PINK1 disruption simultaneously increased xenografted tumor growth and acetyl-CoA production. In conclusion, mitophagy protein PINK1 suppresses colon tumor growth by metabolic reprogramming and reducing acetyl-CoA production.
C1 [Yin, Kunlun; Lee, Jordan; Liu, Zhaoli; Kim, Hyeoncheol; Wu, Dandan; Liu, Meilian; Xue, Xiang] Univ New Mexico, Dept Biochem & Mol Biol, Albuquerque, NM 87131 USA.
   [Martin, David R.] Univ New Mexico, Dept Pathol, Albuquerque, NM 87131 USA.
RP Xue, X (corresponding author), Univ New Mexico, Dept Biochem & Mol Biol, Albuquerque, NM 87131 USA.
EM xxue@salud.unm.edu
RI ; Xue, Xiang/P-9071-2014
OI Wu, Dandan/0000-0003-2073-5998; Xue, Xiang/0000-0003-4704-1814; Martin,
   David/0000-0002-2196-5851; Liu, ZHAOLI/0000-0001-6609-0203; Liu,
   Meilian/0000-0003-1639-262X
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [P20 GM130422,
   K01DK114390]; American Cancer SocietyAmerican Cancer Society
   [RSG-18-050-01-NEC]; University of New Mexico [P42 ES025589]; Shared
   Resources Pilot Project Award from UNM comprehensive cancer center;
   Research Program Support Pilot Project Award from UNM comprehensive
   cancer center [P30CA118100]; Dedicated Health Research Funds at the
   University of New Mexico School of Medicine; Core Utilization Voucher
   Program award; Metabolomic Studies Voucher Award from the Autophagy,
   Inflammation and Metabolism (AIM) Center of Biomedical Research
   Excellence [P20GM121176]; Core Utilization Voucher Program award from
   the Autophagy, Inflammation and Metabolism (AIM) Center of Biomedical
   Research Excellence
FX This research was supported in part by the National Institutes of Health
   (P20 GM130422, K01DK114390), a Research Scholar Grant from the American
   Cancer Society (RSG-18-050-01-NEC), a Research Pilot Project Grant from
   University of New Mexico Environmental Health Signature Program and
   Superfund (P42 ES025589), a Shared Resources Pilot Project Award and a
   Research Program Support Pilot Project Award from UNM comprehensive
   cancer center (P30CA118100), a new investigator award from the Dedicated
   Health Research Funds at the University of New Mexico School of
   Medicine, and a Core Utilization Voucher Program award and a Metabolomic
   Studies Voucher Award from the Autophagy, Inflammation and Metabolism
   (AIM) Center of Biomedical Research Excellence (P20GM121176). We thank
   Dr. Jim Liu for providing us access to the SpectraMax M2 Microplate
   Reader, Dr. Laurie Hudson for providing us access to the microtome, Dr.
   Michael Paffett from the UNMCC Fluorescence Microscopy Core facility for
   helping with confocal imaging, Dr. Sharina P Desai from Scientific Cores
   off AIM center for helping with ImageStream analysis, and Dr. Jesse L
   Denson for proofreading the manuscript.
CR Agnihotri S, 2016, CANCER RES, V76, P4708, DOI 10.1158/0008-5472.CAN-15-3079
   Ahn CS, 2015, CANCER METAB, V3, DOI 10.1186/s40170-015-0128-2
   Arduini A, 2017, MAGN RESON MED, V77, P11, DOI 10.1002/mrm.26492
   Bae JM, 2017, MODERN PATHOL, V30, P267, DOI 10.1038/modpathol.2016.172
   Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036
   Cai L, 2011, MOL CELL, V42, P426, DOI 10.1016/j.molcel.2011.05.004
   Chen L, 2020, GASTROENTEROLOGY, V158, P985, DOI 10.1053/j.gastro.2019.11.031
   Cheung EC, 2013, DEV CELL, V25, P463, DOI 10.1016/j.devcel.2013.05.001
   Comerford SA, 2014, CELL, V159, P1591, DOI 10.1016/j.cell.2014.11.020
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Dagda RK, 2009, J BIOL CHEM, V284, P13843, DOI 10.1074/jbc.M808515200
   Dang CV, 2011, J MOL MED, V89, P205, DOI 10.1007/s00109-011-0730-x
   Frost G, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4611
   Ganapathy V, 2008, AAPS J, V10, P193, DOI 10.1208/s12248-008-9022-y
   Gartel AL, 2002, MOL CANCER THER, V1, P639
   Green DR, 2006, CELL, V126, P30, DOI 10.1016/j.cell.2006.06.032
   Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281
   Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015
   Kaldma A, 2014, INT J BIOCHEM CELL B, V55, P171, DOI 10.1016/j.biocel.2014.09.004
   Kang R, 2016, AUTOPHAGY, V12, P2374, DOI 10.1080/15548627.2016.1239678
   Kim H, 2019, TOXICOL APPL PHARM, V374, P77, DOI 10.1016/j.taap.2019.04.025
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002
   Li CF, 2018, DEV CELL, V46, P441, DOI 10.1016/j.devcel.2018.07.012
   Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001
   Liu K, 2017, MOL CELL, V68, P281, DOI 10.1016/j.molcel.2017.09.022
   Louis P, 2014, NAT REV MICROBIOL, V12, P661, DOI 10.1038/nrmicro3344
   Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863
   Mouton-Liger F, 2018, GLIA, V66, P1736, DOI 10.1002/glia.23337
   Pan QF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00057-3
   Requejo-Aguilar R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5514
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   Riviere L, 2009, P NATL ACAD SCI USA, V106, P12694, DOI 10.1073/pnas.0903355106
   Rojansky R, 2016, ELIFE, V5, DOI 10.7554/eLife.17896
   Satoh K, 2017, P NATL ACAD SCI USA, V114, pE7697, DOI 10.1073/pnas.1710366114
   Schug ZT, 2015, CANCER CELL, V27, P57, DOI 10.1016/j.ccell.2014.12.002
   Shirihai OS, 2015, CIRC RES, V116, P1835, DOI 10.1161/CIRCRESAHA.116.306374
   Shubitowski TB, 2019, PHYSIOL REP, V7, DOI 10.14814/phy2.14005
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Sliter DA, 2018, NATURE, V561, P258, DOI 10.1038/s41586-018-0448-9
   Sp N, 2020, EXP THER MED, V19, P214, DOI 10.3892/etm.2019.8196
   Spinelli JB, 2018, NAT CELL BIOL, V20, P745, DOI 10.1038/s41556-018-0124-1
   Stine RR, 2019, CELL STEM CELL, V25, P830, DOI 10.1016/j.stem.2019.08.017
   Um JH, 2017, BMB REP, V50, P299, DOI 10.5483/BMBRep.2017.50.6.056
   Walker AW, 2005, APPL ENVIRON MICROB, V71, P3692, DOI 10.1128/AEM.71.7.3692-3700.2005
   Wang K, 2011, AUTOPHAGY, V7, P297, DOI 10.4161/auto.7.3.14502
   Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014
   WEAVER GA, 1988, GUT, V29, P1539, DOI 10.1136/gut.29.11.1539
   Weber JD, 2003, CELL DEATH DIFFER, V10, P409, DOI 10.1038/sj.cdd.4401226
   Xue X, 2017, P NATL ACAD SCI USA, V114, pE9608, DOI 10.1073/pnas.1712946114
   Xue X, 2016, CELL METAB, V24, P447, DOI 10.1016/j.cmet.2016.07.015
   Youle RJ, 2019, SCIENCE, V365, P655, DOI 10.1126/science.aaw9855
   Zhang Y, 2014, J IMMUNOL, V192, P5296, DOI 10.4049/jimmunol.1400653
   Ziegler PK, 2018, CELL, V174, P88, DOI 10.1016/j.cell.2018.05.028
NR 53
TC 6
Z9 6
U1 3
U2 17
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1350-9047
EI 1476-5403
J9 CELL DEATH DIFFER
JI Cell Death Differ.
PD AUG
PY 2021
VL 28
IS 8
BP 2421
EP 2435
DI 10.1038/s41418-021-00760-9
EA MAR 2021
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA TT8JU
UT WOS:000629091500003
PM 33723373
DA 2022-04-25
ER

PT J
AU Zhou, J
   Zhang, W
   Liang, B
   Casimiro, MC
   Whitaker-Menezes, D
   Wang, M
   Lisanti, MP
   Lanza-Jacoby, S
   Pestell, RG
   Wang, CG
AF Zhou, Jie
   Zhang, Wei
   Liang, Bing
   Casimiro, Mathew C.
   Whitaker-Menezes, Diana
   Wang, Min
   Lisanti, Michael P.
   Lanza-Jacoby, Susan
   Pestell, Richard G.
   Wang, Chenguang
TI PPAR gamma activation induces autophagy in breast cancer cells
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE PPAR gamma; Autophagy; Breast cancer; HIF1 alpha; BNIP3
ID DMBA-INDUCED MAMMARY; RECEPTOR-GAMMA; CYCLIN D1; GENE-EXPRESSION;
   COLON-CANCER; APOPTOSIS; LIGAND; GROWTH; DEATH; DIFFERENTIATION
AB It has been previously shown that PPAR gamma ligands induce apoptotic cell death in a variety of cancer cells Given the evidence that these ligands have a receptor-independent function, we further examined the specific role of PPAR gamma activation in this biological process. Surprisingly, we failed to demonstrate that MDA-MB-231 breast cancer cells undergo apoptosis when treated with sub-saturation doses of troglitazone and rosightazone, which are synthetic PPAR gamma ligands. Acridine orange (AO) staining showed acidic vesicular formation within ligand-treated cells, indicative of autophagic activity. This was confirmed by autophagosome formation as indicated by redistribution of LC3, an autophagy-specific protein, and the appearance of double-membrane autophagic vacuoles by electron microscopy following exposure to ligand. To determine the mechanism by which PPAR gamma, induces autophagy, we transduced primary mammary epithelial cells with a constitutively active mutant of PPAR gamma and screened gene expression associated with PPAR gamma activation by genome-wide array analysis. HIF1 alpha and BNIP3 were among 42 genes up-regulated by active PPAR gamma. Activation of PPAR gamma induced HIF1 alpha and BNIP3 protein and mRNA abundance. HIF1 alpha knockdown by shRNA abolished the autophagosome formation induced by PPAR gamma activation. In summary, our data shows a specific induction of autophagy by PPAR gamma activation in breast cancer cells providing an understanding of distinct roles of PPAR gamma in tumorigenesis. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Zhou, Jie; Zhang, Wei; Liang, Bing; Casimiro, Mathew C.; Whitaker-Menezes, Diana; Wang, Min; Lisanti, Michael P.; Pestell, Richard G.; Wang, Chenguang] Thomas Jefferson Univ, Dept Canc Biol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA.
   [Lisanti, Michael P.; Pestell, Richard G.; Wang, Chenguang] Thomas Jefferson Univ, Ctr Stem Cell Biol, Philadelphia, PA 19107 USA.
   [Lisanti, Michael P.; Pestell, Richard G.; Wang, Chenguang] Thomas Jefferson Univ, Regenerat Med Ctr, Philadelphia, PA 19107 USA.
   [Lanza-Jacoby, Susan] Thomas Jefferson Univ, Dept Surg, Philadelphia, PA 19107 USA.
   [Zhang, Wei] Beijing Normal Univ, Coll Life Sci, Key Lab Cell Proliferat & Regulat Biol, Minist Educ, Beijing 100875, Peoples R China.
   [Liang, Bing] Natl Ctr Biomed Anal, Inst Basic Med Sci, Beijing, Peoples R China.
RP Wang, CG (corresponding author), Thomas Jefferson Univ, Dept Canc Biol, Kimmel Canc Ctr, Bluemle Life Sci Bldg,Room 1032,233 S 10th St, Philadelphia, PA 19107 USA.
RI Lisanti, Michael P/C-6866-2013; Lisanti, Michael P/B-6131-2018
FU Susan Komen Breast Cancer FoundationSusan G. Komen Breast Cancer
   Foundation [BCTR0504227, R01CA70896, R01CA75503, R01CA86072,
   R01CA86071]; DOD Synergistic Idea Award; National Natural Science
   FundsNational Natural Science Foundation of China (NSFC) [30300173];
   National High Technology Research and Development Program of
   ChinaNational High Technology Research and Development Program of China
   [2006AA02Z4A6]; NIH Cancer Center CoreUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USA [P30CA56036];
   Pennsylvania Department of Health; NATIONAL CANCER INSTITUTEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA056036,
   R01CA070896, R01CA075503, R01CA086072] Funding Source: NIH RePORTER
FX This work was supported in part by awards from the Susan Komen Breast
   Cancer Foundation BCTR0504227 (C.W ) R01CA70896, R01CA75503, R01CA86072,
   R01CA86071 (R.G.P.), DOD Synergistic Idea Award (M.P.L.), National
   Natural Science Funds (grant no.: 30300173 (WZ)), National High
   Technology Research and Development Program of China (863, grant no.
   2006AA02Z4A6 (WZ)). Work conducted at the Kimmel Cancer Center was
   supported by the NIH Cancer Center Core grant (P30CA56036 (R.G.P.)).
   This project is funded in part by the Pennsylvania Department of Health
   grant (to C W.. R.G.P.).
CR Aiello A, 2006, ENDOCRINOLOGY, V147, P4463, DOI 10.1210/en.2005-1610
   Azad MB, 2008, AUTOPHAGY, V4, P195, DOI 10.4161/auto.5278
   Bacon AL, 2004, ANN MED, V36, P530, DOI 10.1080/07853890410018231
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Boutros PC, 2004, BIOCHEM BIOPH RES CO, V321, P707, DOI 10.1016/j.bbrc.2004.06.177
   Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016-5085(98)70072-1
   Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5
   Carew JS, 2007, BLOOD, V110, P313, DOI 10.1182/blood-2006-10-050260
   Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336
   Chen JH, 2002, MAGNET RESON MED, V48, P602, DOI 10.1002/mrm.10256
   Clay CE, 1999, CARCINOGENESIS, V20, P1905, DOI 10.1093/carcin/20.10.1905
   Clay CE, 2002, J LIPID RES, V43, P1818, DOI 10.1194/jlr.M200224-JLR200
   Cosse JP, 2008, ANTI-CANCER AGENT ME, V8, P790, DOI 10.2174/187152008785914798
   Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806
   Girnun GD, 2008, CLIN CANCER RES, V14, P6478, DOI 10.1158/1078-0432.CCR-08-1128
   Girnun GD, 2007, CANCER CELL, V11, P395, DOI 10.1016/j.ccr.2007.02.025
   Hippert MM, 2006, CANCER RES, V66, P9349, DOI 10.1158/0008-5472.CAN-06-1597
   Hirota K, 2004, J BIOL CHEM, V279, P41521, DOI 10.1074/jbc.M405164200
   Hoyer-Hansen M, 2005, CELL DEATH DIFFER, V12, P1297, DOI 10.1038/sj.cdd.4401651
   Hrzenjak A, 2008, J PATHOL, V216, P495, DOI 10.1002/path.2434
   Ishida M, 2007, WORLD J GASTROENTERO, V13, P4593, DOI 10.3748/wjg.v13.i34.4593
   Kato M, 2002, JPN J CANCER RES, V93, P660, DOI 10.1111/j.1349-7006.2002.tb01304.x
   Lang SA, 2007, CLIN CANCER RES, V13, P6459, DOI 10.1158/1078-0432.CCR-07-1104
   Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341
   Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036
   Lu J, 2005, CANCER RES, V65, P4769, DOI 10.1158/0008-5472.CAN-04-2293
   Martelli ML, 2002, J CLIN ENDOCR METAB, V87, P4728, DOI 10.1210/jc.2001-012054
   Matthiessen MW, 2005, SCAND J GASTROENTERO, V40, P198, DOI 10.1080/00365520410009573
   Mehta RG, 2000, J NATL CANCER I, V92, P418, DOI 10.1093/jnci/92.5.418
   Mody M, 2007, ENDOCR-RELAT CANCER, V14, P305, DOI 10.1677/ERC-06-0003
   Morote-Garcia JC, 2008, BLOOD, V111, P5571, DOI 10.1182/blood-2007-11-126763
   Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7
   Neumeister P, 2003, MOL BIOL CELL, V14, P2005, DOI 10.1091/mbc.02-07-0102
   Nicol CJ, 2004, CARCINOGENESIS, V25, P1747, DOI 10.1093/carcin/bgh160
   Nwankwo JO, 2001, PROSTAG LEUKOTR ESS, V64, P241, DOI 10.1054/plef.2001.0266
   Peraza MA, 2006, TOXICOL SCI, V90, P269, DOI 10.1093/toxsci/kfj062
   Pighetti GM, 2001, ANTICANCER RES, V21, P825
   Pignatelli M, 2001, J CELL SCI, V114, P4117
   Renn SCP, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-42
   Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614
   Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200
   Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042
   Saez E, 2004, GENE DEV, V18, P528, DOI 10.1101/gad.1167804
   Samaddar JS, 2008, MOL CANCER THER, V7, P2977, DOI 10.1158/1535-7163.MCT-08-0447
   Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030
   Sato T, 1968, J Electron Microsc (Tokyo), V17, P158
   Shimada T, 2002, GUT, V50, P658, DOI 10.1136/gut.50.5.658
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Suh N, 1999, CANCER RES, V59, P5671
   TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X
   Toyoda M, 2002, GUT, V50, P563, DOI 10.1136/gut.50.4.563
   Wang CG, 2003, MOL CELL BIOL, V23, P6159, DOI 10.1128/MCB.23.17.6159-6173.2003
   Wang CG, 2001, MOL CELL BIOL, V21, P3057, DOI 10.1128/MCB.21.9.3057-3070.2001
   Wang YL, 2002, J BIOL CHEM, V277, P31781, DOI 10.1074/jbc.M204279200
   Yoshizawa K, 2002, CANCER-AM CANCER SOC, V95, P2243, DOI 10.1002/cncr.10906
   Yu HN, 2008, CELL BIOL INT, V32, P906, DOI 10.1016/j.cellbi.2008.04.011
   Yu ST, 2003, J BIOL CHEM, V278, P498, DOI 10.1074/jbc.M210062200
NR 57
TC 82
Z9 83
U1 1
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357-2725
EI 1878-5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD NOV
PY 2009
VL 41
IS 11
BP 2334
EP 2342
DI 10.1016/j.biocel.2009.06.007
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 510WR
UT WOS:000271124700030
PM 19563910
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Han, CZ
   Xing, GZ
   Zhang, MY
   Zhong, M
   Han, Z
   He, CY
   Liu, XP
AF Han, Chengzheng
   Xing, Guozheng
   Zhang, Mengying
   Zhong, Min
   Han, Zhen
   He, Chiyi
   Liu, Xiaoping
TI Wogonoside inhibits cell growth and induces mitochondrial-mediated
   autophagy-related apoptosis in human colon cancer cells through the
   PI3K/AKT/mTOR/p70S6K signaling pathway
SO ONCOLOGY LETTERS
LA English
DT Article
DE wogonoside; human colon cancer cells; phosphatidylinositol 3 kinase;
   RAC-alpha serine/threonine-protein kinase; mechanistic target of
   rapamycin; p70 S6 kinase
ID ACTIVATION; EXPRESSION; ANGIOGENESIS; BAICALIN; EXTRACT; TARGETS; DEATH
AB Wogonoside, the main effective constituent of traditional Chinese medicine Scutellaria, belongs to the glucuronide family, with various functions, including detoxification, anti-inflammation and nourishing gallbladder, lowering blood pressure, diuresis and anti-allergic reactions. However, the effects of wogonoside on human colon cancer cells remain unclear. The present study aimed to investigate the anticancer effect of wogonoside on human colon cancer cells in vitro and its anticancer mechanisms. The results demonstrated that wogonoside significantly inhibited cell growth, induced apoptosis and mitochondrial-mediated autophagy of colon cancer cells. Furthermore, the results revealed that wogonoside significantly increased caspase-3 and caspase-9 expression levels, induced apoptosis regulator Bax/Bcl-2 and microtubule-associated protein 1A/1B-light chain 3 protein expression, suppressed the phosphatidylinositol 3 kinase (PI3K)/RAC-alpha serine/threonine-protein kinase (Akt)/mechanistic target of rapamycin (mTOR)/p70 S6 kinase (p70S6K) signaling pathway and induced p62 protein expression in colon cancer cells. In conclusion, these results demonstrated that wogonoside inhibits cell growth and induces mitochondrial mediated autophagy-related apoptosis in human colon cancer cells through modulation of the PI3K/Akt/mTOR/p70S6K signaling pathway.
C1 [Han, Chengzheng] Wannan Med Coll, Affiliated Hosp 1, Clin Integrated Tradit Chinese & Western Med, Wuhu 241001, Anhui, Peoples R China.
   [Xing, Guozheng] Anhui Univ Technol, Sch Management Sci & Engn, 59 Hudong Rd, Maanshan 243032, Anhui, Peoples R China.
   [Zhang, Mengying; Zhong, Min] Wannan Med Coll, Affiliated Hosp 1, Dept Cent Lab, Wuhu 241001, Anhui, Peoples R China.
   [Han, Zhen; He, Chiyi] Wannan Med Coll, Affiliated Hosp 1, Dept Gastroenterol, Wuhu 241001, Anhui, Peoples R China.
   [Liu, Xiaoping] Wannan Med Coll, Coll Pharm, Wuhu 241001, Anhui, Peoples R China.
RP Xing, GZ (corresponding author), Anhui Univ Technol, Sch Management Sci & Engn, 59 Hudong Rd, Maanshan 243032, Anhui, Peoples R China.
EM hlhugzaea8711@126.com
FU Natural Science Foundation of the Institutions of Higher Education from
   the Education Department of Anhui Province [KJ2017A261]; Natural Science
   Foundation of Wannan Medical College [WK2016F08]
FX The present study was supported by the Natural Science Foundation of the
   Institutions of Higher Education from the Education Department of Anhui
   Province (grant no. KJ2017A261) and Natural Science Foundation of Wannan
   Medical College (grant no. WK2016F08).
CR Buchser WJ, 2012, CANCER RES, V72, P2970, DOI 10.1158/0008-5472.CAN-11-3396
   Cai Y, 2016, J CHROMATOGR B, V1026, P124, DOI 10.1016/j.jchromb.2015.11.049
   Cao ZX, 2017, J ETHNOPHARMACOL, V202, P20, DOI 10.1016/j.jep.2016.07.028
   Chen WK, 2015, INT J COLORECTAL DIS, V30, P475, DOI 10.1007/s00384-014-2098-1
   Coker-Gurkan A, 2015, ONCOL REP, V33, P2761, DOI 10.3892/or.2015.3918
   Declercq J, 2015, BIOMED RES INT, V2015
   Gu SC, 2013, CELL SIGNAL, V25, P66, DOI 10.1016/j.cellsig.2012.08.005
   Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058
   Hestetun KE, 2015, ACTA ONCOL, V54, P470, DOI 10.3109/0284186X.2014.952386
   Huang YJ, 2016, MOL CARCINOGEN, V55, P1598, DOI 10.1002/mc.22412
   Kumar A, 2016, CELL BIOCHEM FUNCT, V34, P69, DOI 10.1002/cbf.3166
   Kwatra D, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/702869
   Liu CY, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/871263
   Meng Y, 2015, AM J CHINESE MED, V43, P1471, DOI 10.1142/S0192415X15500834
   Pal I, 2012, ACTA PHARMACOL SIN, V33, P1441, DOI 10.1038/aps.2012.72
   Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954
   Pigna E, 2016, SCI REP-UK, V6, DOI 10.1038/srep26991
   Qazi AK, 2015, CANCER LETT, V359, P47, DOI 10.1016/j.canlet.2014.12.034
   Sun YJ, 2013, FOOD CHEM TOXICOL, V51, P53, DOI 10.1016/j.fct.2012.09.012
   Sun Y, 2016, ONCOTARGET, V7, P34300, DOI 10.18632/oncotarget.8815
   Tahir AA, 2015, NUTR J, V14, DOI 10.1186/s12937-015-0015-2
   Wang ZG, 2015, SCI REP-UK, V5, DOI 10.1038/srep09287
   Wu SB, 2013, BIOCHEM BIOPH RES CO, V434, P898, DOI 10.1016/j.bbrc.2013.04.053
   Xiong HY, 2010, CANCER LETT, V288, P68, DOI 10.1016/j.canlet.2009.06.039
   Xu Q, 2012, NUCLEIC ACIDS RES, V40, P761, DOI 10.1093/nar/gkr730
   Yang YZ, 2013, J ETHNOPHARMACOL, V148, P271, DOI 10.1016/j.jep.2013.04.025
   Yu CH, 2013, ONCOL REP, V30, P2411, DOI 10.3892/or.2013.2726
   Zhang L, 2014, ONCOL REP, V32, P1179, DOI 10.3892/or.2014.3294
   Zhang LL, 2015, J BIOL CHEM, V290, P15018, DOI 10.1074/jbc.M115.641407
   Zhu L, 2014, CANCER LETT, V354, P355, DOI 10.1016/j.canlet.2014.08.038
   Zou H, 2016, INT J NANOMED, V11, P1947, DOI 10.2147/IJN.S100744
NR 31
TC 22
Z9 26
U1 7
U2 16
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD APR
PY 2018
VL 15
IS 4
BP 4463
EP 4470
DI 10.3892/ol.2018.7852
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GD9HA
UT WOS:000430822500057
PM 29541215
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Sharma, S
   Evans, A
   Hemers, E
AF Sharma, Sikander
   Evans, Andrew
   Hemers, Elaine
TI Mesenchymal-epithelial signalling in tumour microenvironment: role of
   high-mobility group Box 1
SO CELL AND TISSUE RESEARCH
LA English
DT Article
DE HMGB1; Myofibroblasts; Invasion; Glucose deprivation; Tumour
   microenvironment
ID INFLAMMATORY MYOFIBROBLASTIC TUMOR; GLYCATION END-PRODUCTS; DENDRITIC
   CELLS; COLORECTAL-CANCER; HMGB1 RELEASE; ACTIVATION; PROLIFERATION;
   MIGRATION; AUTOPHAGY; GROWTH
AB Glucose deprivation, hypoxia and acidosis are characteristic features of the central core of most solid tumours. Myofibroblasts are stromal cells present in many such solid tumours, including those of the colon, and are known to be involved in all stages of tumour progression. HMGB1 is a nuclear protein with an important role in nucleosome stabilisation and gene transcription; it is also released from immune cells and is involved in the inflammatory process. We report that the microenvironmental condition of glucose deprivation is responsible for the active release of HMGB1 from various types of cancer cell lines (HT-29, MCF-7 and A549) under normoxic conditions. Recombinant HMGB1 (10 ng/ml) triggered proliferation in myofibroblast cells via activation of PI3K and MEK1/2. Conditioned medium collected from glucose-deprived HT-29 colon cancer cells stimulated the migration and invasion of colonic myofibroblasts, and these processes were significantly inhibited by immunoneutralising antibodies to HMGB1, RAGE and TLR4, together with specific inhibitors of PI3K and MEK1/2. Our data suggest that HMGB1 released from cancer cells under glucose deprivation is involved in stimulating colonic myofibroblast migration and invasion and that this occurs through the activation of RAGE and TLR4, resulting in the activation of the MAPK and PI3K signalling pathways. Thus, HMGB1 might be released by cancer cells in areas of low glucose in solid tumours with the resulting activation of myofibroblasts and is a potential therapeutic target to inhibit solid tumour growth.
C1 [Sharma, Sikander; Evans, Andrew; Hemers, Elaine] Liverpool John Moores Univ, Sch Pharm & Bimol Sci, Biomol Sci, Liverpool L3 3AF, Merseyside, England.
RP Hemers, E (corresponding author), Liverpool John Moores Univ, Sch Pharm & Bimol Sci, Biomol Sci, Liverpool L3 3AF, Merseyside, England.
EM a.r.evans@ljmu.ac.uk
CR BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G
   Chen PN, 2005, CHEM-BIOL INTERACT, V156, P141, DOI 10.1016/j.cbi.2005.08.005
   Chien MH, 2013, EXPERT OPIN THER TAR, V17, P203, DOI 10.1517/14728222.2013.740012
   Chitanuwat A, 2013, J ORAL SCI, V55, P45, DOI 10.2334/josnusd.55.45
   Curtin JF, 2009, PLOS MED, V6, P83, DOI 10.1371/journal.pmed.1000010
   Dabiri S, 2013, ARCH IRAN MED, V16, P93, DOI 013162/AIM.008
   De Wever O, 2008, INT J CANCER, V123, P2229, DOI 10.1002/ijc.23925
   Downs-Kelly E, 2013, M DAWSONS GASTROINT, V5, P223
   Duckworth CA, 2013, GASTROENTEROLOGY, V145, P197, DOI 10.1053/j.gastro.2013.03.012
   Dumitriu IE, 2005, J IMMUNOL, V174, P7506, DOI 10.4049/jimmunol.174.12.7506
   Dumitriu IE, 2007, J LEUKOCYTE BIOL, V81, P84, DOI 10.1189/jlb.0306171
   Evans A, 2008, CANCER CHEMOTH PHARM, V61, P377, DOI 10.1007/s00280-007-0480-1
   Gardella S, 2002, EMBO REP, V3, P995, DOI 10.1093/embo-reports/kvf198
   Guan HJ, 2015, HISTOPATHOLOGY, V66, P781, DOI 10.1111/his.12519
   Hamada N, 2008, AM J RESP CELL MOL, V39, P440, DOI 10.1165/rcmb.2007-0330OC
   Hemers E, 2005, CANCER RES, V65, P7363, DOI 10.1158/0008-5472.CAN-05-0157
   Hinz B, 2007, AM J PATHOL, V170, P1807, DOI 10.2353/ajpath.2007.070112
   Holmberg C, 2013, J PROTEOME RES, V12, P3413, DOI 10.1021/pr400270q
   Hu M, 2008, CANCER CELL, V13, P394, DOI 10.1016/j.ccr.2008.03.007
   Jang A, 1997, CLIN EXP METASTAS, V15, P469, DOI 10.1023/A:1018470709523
   Kang R, 2014, ONCOGENE, V33, P567, DOI 10.1038/onc.2012.631
   Kim S, 2013, MOL MED, V19, P88, DOI 10.2119/molmed.2012.00306
   Kokkola R, 2005, SCAND J IMMUNOL, V61, P1, DOI 10.1111/j.0300-9475.2005.01534.x
   Lange SS, 2008, P NATL ACAD SCI USA, V105, P10320, DOI 10.1073/pnas.0803181105
   Lee C-C, 2015, EVID-BASED COMPL ALT, V2015, P1, DOI DOI 10.1371/J0URNAL.P0NE.0116393
   Li G, 2013, FRONT IMMUNOL, V4, P1
   Li L, 2013, CELL SIGNAL, V25, P50, DOI 10.1016/j.cellsig.2012.09.020
   Li W, 2015, LAB INVEST, V95, P635, DOI 10.1038/labinvest.2015.44
   Liu YY, 2010, ATHEROSCLEROSIS, V208, P34, DOI 10.1016/j.atherosclerosis.2009.06.007
   Luca M, 1997, AM J PATHOL, V151, P1105
   Mahajan N, 2013, INT J CARDIOL, V168, P1788, DOI 10.1016/j.ijcard.2013.05.013
   Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002
   Mareel M, 2009, VIRCHOWS ARCH, V454, P599, DOI 10.1007/s00428-009-0784-0
   Nagarajan S, 2013, J PEDIATR GASTR NUTR, V57, P277, DOI 10.1097/MPG.0b013e31829e0b3b
   Pena C, 2013, CANCER RES, V73, P1287, DOI 10.1158/0008-5472.CAN-12-1875
   Ranzato E, 2010, CELL BIOCHEM BIOPHYS, V57, P9, DOI 10.1007/s12013-010-9077-0
   Ranzato E, 2009, MOL CELL BIOCHEM, V332, P199, DOI 10.1007/s11010-009-0192-4
   Riuzzi F, 2006, J BIOL CHEM, V281, P8242, DOI 10.1074/jbc.M509436200
   Rojas A, 2010, CARCINOGENESIS, V31, P334, DOI 10.1093/carcin/bgp322
   Tang DL, 2007, J LEUKOCYTE BIOL, V81, P741, DOI 10.1189/jlb.0806540
   Tang D, 2013, INT J CANCER, V132, P993, DOI 10.1002/ijc.27715
   Thorburn J, 2009, CELL DEATH DIFFER, V16, P175, DOI 10.1038/cdd.2008.143
   Thorburn J, 2009, AUTOPHAGY, V5, P247, DOI 10.4161/auto.5.2.7552
   Tripathi M, 2012, CELL ADHES MIGR, V6, P231, DOI 10.4161/cam.20419
   Vaughan MB, 2000, EXP CELL RES, V257, P180, DOI 10.1006/excr.2000.4869
   Wang FP, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0061792, 10.1371/journal.pone.0069284, 10.1371/journal.pone.0062988, 10.1371/journal.pone.0064373, 10.1371/journal.pone.0080480, 10.1371/journal.pone.0078025]
   Werner S, 2007, J INVEST DERMATOL, V127, P998, DOI 10.1038/sj.jid.5700786
   Yang D, 2007, J LEUKOCYTE BIOL, V81, P59, DOI 10.1189/jlb.0306180
   Yang X, 2015, CELL BIOSCI, V5, DOI 10.1186/s13578-015-0005-2
   Yeung TM, 2013, BRIT J CANCER, V108, P2106, DOI 10.1038/bjc.2013.209
   Yoshida A, 2013, HISTOPATHOLOGY, V63, P881, DOI 10.1111/his.12218
NR 51
TC 11
Z9 11
U1 0
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0302-766X
EI 1432-0878
J9 CELL TISSUE RES
JI Cell Tissue Res.
PD AUG
PY 2016
VL 365
IS 2
BP 357
EP 366
DI 10.1007/s00441-016-2389-7
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA DR6WN
UT WOS:000380042100012
PM 26979829
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Chen, ST
   Lee, TY
   Tsai, TH
   Huang, YC
   Lin, YC
   Lin, CP
   Shieh, HR
   Hsu, ML
   Chi, CW
   Lee, MC
   Chang, HH
   Chen, YJ
AF Chen, Shun-Ting
   Lee, Tzung-Yan
   Tsai, Tung-Hu
   Huang, Yu-Chuen
   Lin, Yin-Cheng
   Lin, Chin-Ping
   Shieh, Hui-Ru
   Hsu, Ming-Ling
   Chi, Chih-Wen
   Lee, Ming-Cheng
   Chang, Hen-Hong
   Chen, Yu-Jen
TI Traditional Chinese medicine Danggui Buxue Tang inhibits colorectal
   cancer growth through induction of autophagic cell death
SO ONCOTARGET
LA English
DT Article
DE Danggui Buxue Tang; colorectal cancer; autophagy; traditional Chinese
   medicine; mammalian target of rapamycin (mTOR)
ID HERBAL DECOCTION; RADIX-ASTRAGALI; MTOR INHIBITORS; MAMMALIAN TARGET;
   STATISTICS; CARCINOMA; MODEL; MCF-7
AB Purpose: The induction of autophagic cell death is an important process in the development of anticancer therapeutics. We aimed to evaluate the activity of the ancient Chinese decoction Danggui Buxue Tang (DBT) against colorectal cancer (CRC) and the associated autophagy-related mechanism.
   Materials and methods: CT26 CRC cells were implanted into syngeneic BALB/c mice for the tumor growth assay. DBT extracts and DBT-PD (polysaccharide-depleted) fractions were orally administered. The toxicity profiles of the extracts were analyzed using measurements of body weight, hemogram, and biochemical parameters. The morphology of tissue sections was observed using light and transmission electron microscopy. Western blotting and small interference RNA assays were used to determine the mechanism.
   Results: DBT-PD and DBT, which contained an equal amount of DBT-PD, inhibited CT26 syngeneic tumor growth. In the tumor specimen, the expression of microtubule-associated proteins 1A/1B light chain 3B (LC3B) was upregulated by DBT-PD and DBT. The development of autophagosomes was observed via transmission electron microscopy in tumors treated with DBT-PD and DBT. In vitro experiments for mechanism clarification demonstrated that DBT-PD could induce autophagic death in CT26 cells accompanied by LC3B lipidation, downregulation of phospho-p70(s6k), and upregulation of Atg7. RNA interference of Atg7, but not Atg5, partially reversed the effect of DBT-PD on LC3B lipidation and expression of phospho-p70(s6k) and Atg7. The changes in ultrastructural morphology and LC3B expression induced by DBT-PD were also partially blocked by the knockdown of Atg7 mRNA.
   Conclusion: DBT induced autophagic death of colorectal cancer cells through the upregulation of Atg7 and modulation of the mTOR/p70(s6k) signaling pathway.
C1 [Chen, Shun-Ting] Buddhist Tzu Chi Med Fdn, Taipei Buddhist Tzu Chi Hosp, Dept Chinese Med, New Taipei 23142, Taiwan.
   [Chen, Shun-Ting; Lee, Tzung-Yan] Chang Gung Univ, Coll Med, Sch Chinese Med, Grad Inst Tradit Chinese Med, Taoyuan 33302, Taiwan.
   [Chen, Shun-Ting] Chang Gung Univ, Coll Med, Grad Inst Clin Med Sci, Taoyuan 33302, Taiwan.
   [Tsai, Tung-Hu] Natl Yang Ming Univ, Sch Med, Inst Tradit Med, Taipei 11221, Taiwan.
   [Huang, Yu-Chuen] China Med Univ, Sch Chinese Med, Taichung 40402, Taiwan.
   [Huang, Yu-Chuen; Chen, Yu-Jen] China Med Univ Hosp, Dept Med Res, Taichung 40402, Taiwan.
   [Lin, Yin-Cheng; Lin, Chin-Ping; Shieh, Hui-Ru; Hsu, Ming-Ling; Chi, Chih-Wen; Chen, Yu-Jen] Mackay Mem Hosp, Dept Med Res, New Taipei 25160, Taiwan.
   [Lee, Ming-Cheng] Buddhist Tzu Chi Med Fdn, Taipei Buddhist Tzu Chi Hosp, Dept Res, New Taipei 23141, Taiwan.
   [Chang, Hen-Hong] China Med Univ, Sch Postbaccalaureate Chinese Med, Coll Chinese Med, Taichung 40402, Taiwan.
   [Chang, Hen-Hong] China Med Univ, Res Ctr Chinese Med & Acupuncture, Taichung 40402, Taiwan.
   [Chang, Hen-Hong] China Med Univ Hosp, Dept Chinese Med, Taichung 40402, Taiwan.
   [Chen, Yu-Jen] Mackay Mem Hosp, Dept Radiat Oncol, Taipei 10449, Taiwan.
   [Tsai, Tung-Hu] Natl United Univ, Dept Chem Engn, Miaoli 36003, Taiwan.
RP Chen, YJ (corresponding author), China Med Univ Hosp, Dept Med Res, Taichung 40402, Taiwan.; Chen, YJ (corresponding author), Mackay Mem Hosp, Dept Med Res, New Taipei 25160, Taiwan.; Chang, HH (corresponding author), China Med Univ, Sch Postbaccalaureate Chinese Med, Coll Chinese Med, Taichung 40402, Taiwan.; Chang, HH (corresponding author), China Med Univ, Res Ctr Chinese Med & Acupuncture, Taichung 40402, Taiwan.; Chang, HH (corresponding author), China Med Univ Hosp, Dept Chinese Med, Taichung 40402, Taiwan.; Chen, YJ (corresponding author), Mackay Mem Hosp, Dept Radiat Oncol, Taipei 10449, Taiwan.
EM tcmchh55@mail.cmu.edu.tw; chenmdphd@gmail.com
RI Tsai, Tung-Hu/AAG-4558-2021
OI Tsai, Tung-Hu/0000-0002-9007-2547
FU Ministry of Science Technology [MOST 103-2314-B-195-013-MY3]; Mackay
   Memorial Hospital of Taiwan [MMH-E-105-13, MMH-E-106-13]
FX This study was supported by Ministry of Science Technology (grant number
   MOST 103-2314-B-195-013-MY3) and Mackay Memorial Hospital (grant numbers
   MMH-E-105-13 and MMH-E-106-13) of Taiwan.
CR Bellmunt J, 2008, ANN ONCOL, V19, P1387, DOI 10.1093/annonc/mdn066
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595
   Center MM, 2009, CA-CANCER J CLIN, V59, P366, DOI 10.3322/caac.20038
   Chen ST, 2016, MOLECULES, V21, DOI 10.3390/molecules21121677
   Chen Y, 2009, CHIN J INTEGR MED, V15, P435, DOI 10.1007/s11655-009-0435-y
   Choi RCY, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nen085
   Choueiri TK, 2013, ANN ONCOL, V24, P2092, DOI 10.1093/annonc/mdt155
   Easton JB, 2006, ONCOGENE, V25, P6436, DOI 10.1038/sj.onc.1209886
   EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373
   Efeyan A, 2015, NATURE, V517, P302, DOI 10.1038/nature14190
   Gao J, 2011, J ETHNOPHARMACOL, V136, P21, DOI 10.1016/j.jep.2011.03.013
   Gao QT, 2008, PLANTA MED, V74, P392, DOI 10.1055/s-2008-1034322
   Gao QT, 2007, FEBS LETT, V581, P233, DOI 10.1016/j.febslet.2006.12.018
   Gao QT, 2006, PLANTA MED, V72, P1227, DOI 10.1055/s-2006-947186
   Hammond WA, 2016, THER ADV MED ONCOL, V8, P57, DOI 10.1177/1758834015614530
   Huang ZB, 2015, FUTURE ONCOL, V11, P1687, DOI 10.2217/fon.15.70
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Kim KW, 2008, AUTOPHAGY, V4, P659, DOI 10.4161/auto.6058
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Lee SY, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/7590245
   Lv J, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/284963
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976-0105.177703
   O'Connell JB, 2004, JNCI-J NATL CANCER I, V96, P1420, DOI 10.1093/jnci/djh275
   Pyo JO, 2012, EXP MOL MED, V44, P73, DOI 10.3858/emm.2012.44.2.029
   Qiao LW, 2014, INT J CLIN EXP MED, V7, P3333
   Rikiishi Hidemi, 2012, Int J Cell Biol, V2012, P317645, DOI 10.1155/2012/317645
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Sou Y, 2008, MOL BIOL CELL, V19, P4762, DOI 10.1091/mbc.E08-03-0309
   Steelman LS, 2016, BRIT J CLIN PHARMACO, V82, P1189, DOI 10.1111/bcp.12958
   Su MF, 2013, J ONCOL, V2013, DOI 10.1155/2013/102735
   Su YC, 2014, INT J MOL MED, V34, P1417, DOI 10.3892/ijmm.2014.1927
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Wang CC, 2013, MENOPAUSE, V20, P223, DOI 10.1097/gme.0b013e318267f64e
   Wang W, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/518609
   Xiong JH, 2015, PROTEIN CELL, V6, P722, DOI 10.1007/s13238-015-0195-8
   Yang M, 2009, J ETHNOPHARMACOL, V124, P87, DOI 10.1016/j.jep.2009.04.007
   Zhang WL, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/483286
NR 39
TC 10
Z9 12
U1 1
U2 27
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 24
PY 2017
VL 8
IS 51
BP 88563
EP 88574
DI 10.18632/oncotarget.19902
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FK6AP
UT WOS:000413585600029
PM 29179457
OA Green Submitted, gold, Green Published
DA 2022-04-25
ER

PT J
AU Zhang, WL
   Zhang, SY
   Guan, W
   Huang, ZC
   Kong, JQ
   Huang, CL
   Wang, HH
   Yang, SL
AF Zhang, Wenliang
   Zhang, Shaoyang
   Guan, Wen
   Huang, Zhicong
   Kong, Jianqiu
   Huang, Chunlong
   Wang, Haihe
   Yang, Shulan
TI Poly C Binding Protein 1 Regulates p62/SQSTM1 mRNA Stability and
   Autophagic Degradation to Repress Tumor Progression
SO FRONTIERS IN GENETICS
LA English
DT Article
DE PCBP1; p62; SQSTM1; autophagy; apoptosis; ovary cancer; colon cancer;
   caspase-8
ID APOPTOSIS; CASPASE-8; EXPRESSION; PCBP1; TRANSLATION; CROSSTALK;
   COMPLEX; P62
AB Accumulating evidence show that Poly C Binding Protein 1 (PCBP1) is deleted in distinct types of tumors as a novel tumor suppressor, but its tumor suppression mechanism remains elusive. Here, we firstly describe that downregulation of PCBP1 is significantly associated with clinical ovarian tumor progression. Mechanistically, PCBP1 overexpression affects various autophagy-related genes expression at various expression levels to attenuate the intrinsic cell autophagy, including the autophagy-initiating ULK, ATG12, ATG7 as well as the bona fide marker of autophagosome, LC3B. Accordingly, knockdown of the endogenous PCBP1 in turn enhances autophagy and less cell death. Meanwhile, PCBP1 upregulates p62/SQSTM1 via inhibition p62/SQSTM1 autophagolysome and proteasome degradation as well as its mRNA stability, consequently accompanying with the caspase 3 or 8 activation for tumor cell apoptosis. Importantly, clinical ovary cancer sample analysis consistently validates the relevance of PCBP1 expression to both p62/SQSTM1 and caspase-8 to overall survival, and indicates PCBP1 may be a master player to repress tumor initiation. Taken together, our results uncover the tumorigenic mechanism of PCBP1 depletion and suggest that inhibition of tumor cell autophagy with autophagic inhibitors could be an effective therapeutical strategy for PCBP1-deficient tumor.
C1 [Zhang, Wenliang; Yang, Shulan] Sun Yat Sen Univ, Affiliated Hosp 1, Translat Med Ctr, Guangzhou, Peoples R China.
   [Zhang, Wenliang; Zhang, Shaoyang; Guan, Wen; Huang, Zhicong; Kong, Jianqiu; Wang, Haihe] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou, Peoples R China.
   [Huang, Chunlong] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Guangzhou, Peoples R China.
   [Wang, Haihe] Sun Yat Sen Univ, Ctr Stem Cell Biol & Tissue Engn, Guangzhou, Peoples R China.
   [Yang, Shulan] Sun Yat Sen Univ, Guangdong Engn & Technol Res Ctr Dis Model Anim, Guangzhou, Peoples R China.
RP Yang, SL (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Translat Med Ctr, Guangzhou, Peoples R China.; Wang, HH (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou, Peoples R China.; Wang, HH (corresponding author), Sun Yat Sen Univ, Ctr Stem Cell Biol & Tissue Engn, Guangzhou, Peoples R China.; Yang, SL (corresponding author), Sun Yat Sen Univ, Guangdong Engn & Technol Res Ctr Dis Model Anim, Guangzhou, Peoples R China.
EM wanghaih@mail.sysu.edu.cn; yangshl3@mail.sysu.edu.cn
RI Haihe, Wang/AAD-4036-2021; 张, 文亮/AAM-6021-2020
OI , Haihe/0000-0002-9302-2334; zhang, wenliang/0000-0003-0454-6935
FU National Key R&D Program of China [2018YFA0801005]; National Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [31271481, 81472730]
FX This work was supported by the National Key R&D Program of China (No.
   2018YFA0801005 to SY) and National Science Foundation of China (Nos.
   31271481 and 81472730 to HW).
CR Bardag-Gorce F, 2005, LIFE SCI, V77, P2594, DOI 10.1016/j.lfs.2005.04.020
   Bialik S, 2018, J CELL SCI, V131, DOI 10.1242/jcs.215152
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   D'Arcy MS, 2019, CELL BIOL INT, V43, P582, DOI 10.1002/cbin.11137
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Giles KM, 2003, J BIOL CHEM, V278, P2937, DOI 10.1074/jbc.M208439200
   Guo JN, 2017, ONCOTARGET, V8, P13312, DOI 10.18632/oncotarget.14516
   Guo JH, 2019, J CELL PHYSIOL, V234, P33, DOI 10.1002/jcp.26873
   Huang SB, 2013, J BIOL CHEM, V288, P33654, DOI 10.1074/jbc.M113.518134
   Huang YH, 2014, AUTOPHAGY, V10, P1787, DOI 10.4161/auto.29989
   Ishii T, 2018, P NATL ACAD SCI USA, V115, P6715, DOI 10.1073/pnas.1806912115
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   JI F, 2017, SCI REP-UK, V7, DOI DOI 10.1038/s41598-017-15448-15449
   Jin ZY, 2009, CELL, V137, P721, DOI 10.1016/j.cell.2009.03.015
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Kruidering M, 2000, IUBMB LIFE, V50, P85, DOI 10.1080/15216540050212088
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Li J, 2008, ONCOGENE, V27, P6194, DOI 10.1038/onc.2008.297
   Lu Z, 2014, AUTOPHAGY, V10, P1071, DOI 10.4161/auto.28577
   Maiuri MC, 2010, EMBO J, V29, P515, DOI 10.1038/emboj.2009.377
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Nishinakamura H, 2007, INT IMMUNOL, V19, P609, DOI 10.1093/intimm/dxm026
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   SHI H, 2018, J EXP CLIN CANC RES, V37, DOI DOI 10.1186/s13046-018-0840-841
   Singh SS, 2018, ONCOGENE, V37, P1142, DOI 10.1038/s41388-017-0046-6
   Tang Y, 2015, AM J CANCER RES, V5, P498
   Tao MM, 2020, EUR J MED CHEM, V193, DOI 10.1016/j.ejmech.2020.112231
   Tripathi V, 2016, MOL CELL, V64, P549, DOI 10.1016/j.molcel.2016.09.013
   Valente G, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/462658
   Villa E, 2017, CELL REP, V20, P2846, DOI 10.1016/j.celrep.2017.08.087
   Wang HH, 2010, CANCER CELL, V18, P52, DOI 10.1016/j.ccr.2010.04.028
   Wang XL, 2019, INT J BIOL SCI, V15, P1177, DOI 10.7150/ijbs.33103
   Wang ZZ, 2018, IMMUNITY, V49, P80, DOI 10.1016/j.immuni.2018.05.008
   Wu HJ, 2014, INT J BIOL SCI, V10, P1072, DOI 10.7150/ijbs.9719
   Yan XY, 2019, J CELL MOL MED, V23, P4030, DOI 10.1111/jcmm.14288
   Young MM, 2012, J BIOL CHEM, V287, P12455, DOI 10.1074/jbc.M111.309104
   Zhang MP, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20170114
   Zhang MP, 2017, AM J TRANSL RES, V9, P708
   Zhang T, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-72
   Zhang WL, 2016, INT J BIOCHEM CELL B, V73, P127, DOI 10.1016/j.biocel.2016.02.009
   Zhao L, 2019, IUBMB LIFE, V71, P177, DOI 10.1002/iub.1948
   Zhao Y, 2014, TUMOR BIOL, V35, P1955, DOI 10.1007/s13277-013-1261-6
   Zheng K, 2019, THERANOSTICS, V9, P104, DOI 10.7150/thno.30308
NR 47
TC 3
Z9 3
U1 5
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD AUG 14
PY 2020
VL 11
AR 930
DI 10.3389/fgene.2020.00930
PG 16
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA NJ7KI
UT WOS:000566221700001
PM 32922440
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Bonfili, L
   Cuccioloni, M
   Cecarini, V
   Mozzicafreddo, M
   Palermo, FA
   Cocci, P
   Angeletti, M
   Eleuteri, AM
AF Bonfili, Laura
   Cuccioloni, Massimiliano
   Cecarini, Valentina
   Mozzicafreddo, Matteo
   Palermo, Francesco Alessandro
   Cocci, Paolo
   Angeletti, Mauro
   Eleuteri, Anna Maria
TI Ghrelin induces apoptosis in colon adenocarcinoma cells via proteasome
   inhibition and autophagy induction
SO APOPTOSIS
LA English
DT Article
DE Ghrelin; Apoptosis; Proteasome; Autophagy; Colon adenocarcinoma cells
ID MULTICATALYTIC PROTEINASE COMPLEX; DES-ACYL GHRELIN; HORMONE
   SECRETAGOGUE RECEPTOR; CANCER-CELLS; IN-VIVO; BIOLOGICAL-ACTIVITY;
   OCTANOYL GHRELIN; GH SECRETAGOGUES; SKELETAL-MUSCLE; NATURAL GHRELIN
AB Ghrelin is a metabolism-regulating hormone recently investigated for its role in cancer survival and progression. Controversially, ghrelin may act as either anti-apoptotic or pro-apoptotic factor in different cancer cells, suggesting that the effects are cell type dependent. Limited data are currently available on the effects exerted by ghrelin on intracellular proteolytic pathways in cancer. Both the lysosomal and the proteasomal systems are fundamental in cellular proliferation and apoptosis regulation. With the aim of exploring if the proteasome and autophagy may be possible targets of ghrelin in cancer, we exposed human colorectal adenocarcinoma cells to ghrelin. Preliminary in vitro fluorimetric assays evidenced for the first time a direct inhibition of 20S proteasomes by ghrelin, particularly evident for the trypsin-like activity. Moreover, 1 mu M ghrelin induced apoptosis in colorectal adenocarcinoma cells by inhibiting the ubiquitin-proteasome system and by activating autophagy, with p53 having an "interactive" role.
C1 [Bonfili, Laura; Cuccioloni, Massimiliano; Cecarini, Valentina; Mozzicafreddo, Matteo; Palermo, Francesco Alessandro; Cocci, Paolo; Angeletti, Mauro; Eleuteri, Anna Maria] Univ Camerino, Sch Biosci & Biotechnol, I-62032 Camerino, Macerata, Italy.
RP Bonfili, L (corresponding author), Univ Camerino, Sch Biosci & Biotechnol, Via Gentile 3 Varano, I-62032 Camerino, Macerata, Italy.
EM laura.bonfili@unicam.it
RI Palermo, Francesco A/D-7732-2018; Angeletti, Mauro/C-2960-2014;
   Mozzicafreddo, Matteo/AAW-2816-2021; Cuccioloni,
   Massimiliano/X-7188-2019; Angeletti, Mauro/AAC-5597-2019; Cecarini,
   Valentina/AAU-9749-2021; Cocci, Paolo/AAL-2599-2021
OI Palermo, Francesco A/0000-0001-7804-7149; Angeletti,
   Mauro/0000-0001-6719-5517; Mozzicafreddo, Matteo/0000-0001-9835-8446;
   Angeletti, Mauro/0000-0001-6719-5517; Cocci, Paolo/0000-0001-6890-9796;
   Cuccioloni, Massimiliano/0000-0002-6025-1990; Eleuteri, Anna
   Maria/0000-0003-0461-1346; Cecarini, Valentina/0000-0001-9315-9747;
   Bonfili, Laura/0000-0002-9542-4310
CR Affar EB, 2001, J BIOL CHEM, V276, P2935, DOI 10.1074/jbc.M007269200
   Amici M, 2008, BIOCHIMIE, V90, P790, DOI 10.1016/j.biochi.2007.12.001
   Amici M, 2003, FREE RADICAL BIO MED, V34, P987, DOI 10.1016/S0891-5849(02)01369-2
   Ammori JB, 2008, SURGERY, V144, P159, DOI 10.1016/j.surg.2008.03.008
   Andreis PG, 2003, FEBS LETT, V536, P173, DOI 10.1016/S0014-5793(03)00051-6
   Balasubramaniam A, 2009, AM J PHYSIOL-REG I, V296, pR893, DOI 10.1152/ajpregu.00015.2008
   Baldanzi G, 2002, J CELL BIOL, V159, P1029, DOI 10.1083/jcb.200207165
   Bedendi I, 2003, EUR J PHARMACOL, V476, P87, DOI 10.1016/S0014-2999(03)02083-1
   BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3
   Bonfili L, 2009, BIOCHIMIE, V91, P1131, DOI 10.1016/j.biochi.2009.06.001
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Buonanno F, 2008, CHEM-BIOL INTERACT, V176, P151, DOI 10.1016/j.cbi.2008.07.007
   Cassoni P, 2004, EUR J ENDOCRINOL, V150, P173, DOI 10.1530/eje.0.1500173
   Cassoni P, 2001, J CLIN ENDOCR METAB, V86, P1738, DOI 10.1210/jc.86.4.1738
   Cecarini V, 2011, CURR CANCER DRUG TAR, V11, P307, DOI 10.2174/156800911794519815
   Cecarini V, 2012, BBA-MOL BASIS DIS, V1822, P1741, DOI 10.1016/j.bbadis.2012.07.015
   Chopin L, 2011, MOL CELL ENDOCRINOL, V340, P65, DOI 10.1016/j.mce.2011.04.013
   Ciechanover A, 2005, CELL DEATH DIFFER, V12, P1178, DOI 10.1038/sj.cdd.4401692
   Ciechanover A, 2000, J CELL BIOCHEM, P40
   Du YL, 2009, AUTOPHAGY, V5, P663, DOI 10.4161/auto.5.5.8377
   Duxbury MS, 2003, BIOCHEM BIOPH RES CO, V309, P464, DOI 10.1016/j.bbrc.2003.08.024
   Ekeblad S, 2007, CLIN ENDOCRINOL, V66, P115, DOI 10.1111/j.1365-2265.2006.02695.x
   Eleuteri AM, 1997, J BIOL CHEM, V272, P11824, DOI 10.1074/jbc.272.18.11824
   Eleuteri AM, 2000, PROTEIN EXPRES PURIF, V18, P160, DOI 10.1006/prep.1999.1187
   Fujishima Y, 2011, ARCH BIOCHEM BIOPHYS, V506, P223, DOI 10.1016/j.abb.2010.12.009
   Fung Jenny N. T., 2010, Hormones & Cancer, V1, P245, DOI 10.1007/s12672-010-0047-1
   Garber K, 2006, SCIENCE, V312, P1158, DOI 10.1126/science.312.5777.1158
   Ghe C, 2002, ENDOCRINOLOGY, V143, P484, DOI 10.1210/en.143.2.484
   Gnanapavan S, 2002, J CLIN ENDOCR METAB, V87, P2988, DOI 10.1210/jc.87.6.2988
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Granado M, 2005, AM J PHYSIOL-ENDOC M, V289, pE1007, DOI 10.1152/ajpendo.00109.2005
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hosoda H, 2004, CLIN CHEM, V50, P1077, DOI 10.1373/clinchem.2003.025841
   Hosoda H, 2000, BIOCHEM BIOPH RES CO, V279, P909, DOI 10.1006/bbrc.2000.4039
   Itakura E, 2011, J CELL BIOL, V192, P17, DOI 10.1083/jcb.201009067
   Jeffery PL, 2005, ENDOCR-RELAT CANCER, V12, P839, DOI 10.1677/erc.1.00984
   Jeffery PL, 2002, J ENDOCRINOL, V172, pR7, DOI 10.1677/joe.0.172R007
   Jeffery PL, 2003, CYTOKINE GROWTH F R, V14, P113, DOI 10.1016/S1359-6101(02)00089-8
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X
   Kloetzel PM, 1999, BIOL CHEM, V380, P293, DOI 10.1515/BC.1999.040
   Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230
   Kojima M, 2005, PHYSIOL REV, V85, P495, DOI 10.1152/physrev.00012.2004
   Korbonits M, 2001, J CLIN ENDOCR METAB, V86, P881, DOI 10.1210/jc.86.2.881
   Korolchuk VI, 2009, AUTOPHAGY, V5, P862, DOI 10.4161/auto.8840
   Lawnicka H, 2012, PHARMACOL REP, V64, P951
   LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Maccarinelli G, 2005, J ENDOCRINOL, V184, P249, DOI 10.1677/joe.1.05837
   McCray BA, 2008, NEUROSIGNALS, V16, P75, DOI 10.1159/000109761
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Nanzer AM, 2004, EUR J ENDOCRINOL, V151, P233, DOI 10.1530/eje.0.1510233
   Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0
   ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001
   ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022
   PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798
   Paglin S, 2001, CANCER RES, V61, P439
   Pettersson I, 2002, J ENDOCRINOL, V175, P201, DOI 10.1677/joe.0.1750201
   Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476
   Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002
   Rikiishi H., 2012, INT J CELL BIOL
   Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844
   Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Sirotkin AV, 2006, MOL CELL ENDOCRINOL, V257-8, P15, DOI 10.1016/j.mce.2006.06.004
   Soares JB, 2008, PEPTIDES, V29, P1255, DOI 10.1016/j.peptides.2008.02.018
   Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968
   Steele RJC, 1998, BRIT J SURG, V85, P1460
   Sun JZ, 2001, CANCER RES, V61, P1280
   Thompson NM, 2004, ENDOCRINOLOGY, V145, P234, DOI 10.1210/en.2003-0899
   Tian PY, 2012, J DIGEST DIS, V13, P453, DOI 10.1111/j.1751-2980.2012.00616.x
   Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090
   Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040
   Wang DH, 2009, ENDOCRINE, V35, P112, DOI 10.1007/s12020-008-9117-3
   Waseem T, 2008, PEPTIDES, V29, P1369, DOI 10.1016/j.peptides.2008.03.020
   Xia Q, 2004, REGUL PEPTIDES, V122, P173, DOI 10.1016/j.regpep.2004.06.016
   Yogalingam G, 2008, J BIOL CHEM, V283, P35941, DOI 10.1074/jbc.M804543200
   Yu L, 2010, NATURE, V465, P942, DOI 10.1038/nature09076
   Zheng Qingwen, 2009, Int J Physiol Pathophysiol Pharmacol, V1, P127
   Zhu BS, 2011, WORLD J GASTROENTERO, V17, P478, DOI 10.3748/wjg.v17.i4.478
NR 80
TC 32
Z9 35
U1 0
U2 17
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1360-8185
J9 APOPTOSIS
JI Apoptosis
PD OCT
PY 2013
VL 18
IS 10
BP 1188
EP 1200
DI 10.1007/s10495-013-0856-0
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 219EX
UT WOS:000324490000005
PM 23632965
DA 2022-04-25
ER

PT J
AU Perez-Hernandez, M
   Arias, A
   Martinez-Garcia, D
   Perez-Tomas, R
   Quesada, R
   Soto-Cerrato, V
AF Perez-Hernandez, Marta
   Arias, Alain
   Martinez-Garcia, David
   Perez-Tomas, Ricardo
   Quesada, Roberto
   Soto-Cerrato, Vanessa
TI Targeting Autophagy for Cancer Treatment and Tumor Chemosensitization
SO CANCERS
LA English
DT Review
DE autophagy; anticancer therapy; autophagy inhibitors; autophagic cell
   death; chemoresistance; chemosensitization
ID ADVANCED SOLID TUMORS; LYSOSOMAL PROTEIN-DEGRADATION; RADIATION-INDUCED
   AUTOPHAGY; RENAL-CELL CARCINOMA; PHASE-II TRIAL; COLON-CANCER; IN-VITRO;
   SELECTIVE INHIBITOR; MAMMALIAN TARGET; BINDING-PROTEIN
AB Autophagy is a tightly regulated catabolic process that facilitates nutrient recycling from damaged organelles and other cellular components through lysosomal degradation. Deregulation of this process has been associated with the development of several pathophysiological processes, such as cancer and neurodegenerative diseases. In cancer, autophagy has opposing roles, being either cytoprotective or cytotoxic. Thus, deciphering the role of autophagy in each tumor context is crucial. Moreover, autophagy has been shown to contribute to chemoresistance in some patients. In this regard, autophagy modulation has recently emerged as a promising therapeutic strategy for the treatment and chemosensitization of tumors, and has already demonstrated positive clinical results in patients. In this review, the dual role of autophagy during carcinogenesis is discussed and current therapeutic strategies aimed at targeting autophagy for the treatment of cancer, both under preclinical and clinical development, are presented. The use of autophagy modulators in combination therapies, in order to overcome drug resistance during cancer treatment, is also discussed as well as the potential challenges and limitations for the use of these novel therapeutic strategies in the clinic.
C1 [Perez-Hernandez, Marta; Arias, Alain; Martinez-Garcia, David; Perez-Tomas, Ricardo; Soto-Cerrato, Vanessa] Univ Barcelona, Fac Med & Hlth Sci, Dept Pathol & Expt Therapeut, Barcelona 08905, Spain.
   [Perez-Hernandez, Marta; Martinez-Garcia, David; Perez-Tomas, Ricardo; Soto-Cerrato, Vanessa] Hosp Llobregat, Oncobell Program, Inst Invest Biomed Bellvitge IDIBELL, Barcelona 08908, Spain.
   [Arias, Alain] Univ La Frontera, Res Ctr Dent Sci CICO, Dept Integral Adult Dent, Temuco 4811230, Chile.
   [Arias, Alain] Univ Adventista Chile, Fac Hlth Sci, Res Grp Hlth Sci, Chillan 3780000, Chile.
   [Quesada, Roberto] Univ Burgos, Dept Chem, Burgos 09001, Spain.
RP Soto-Cerrato, V (corresponding author), Univ Barcelona, Fac Med & Hlth Sci, Dept Pathol & Expt Therapeut, Barcelona 08905, Spain.; Soto-Cerrato, V (corresponding author), Hosp Llobregat, Oncobell Program, Inst Invest Biomed Bellvitge IDIBELL, Barcelona 08908, Spain.
EM martaperezh@ub.edu; alain.arias@ufrontera.cl; david.martinez@ub.edu;
   rperez@ub.edu; rquesada@ubu.es; vsoto@ub.edu
RI Quesada, Roberto/C-6965-2008; quesada, roberto/AAX-8833-2021;
   Pérez-Hernández, Marta/K-8778-2014; Soto-Cerrato, Vanessa/AAB-4392-2020;
   Garcia, David Martinez/P-2461-2016
OI Quesada, Roberto/0000-0003-2764-7157; quesada,
   roberto/0000-0003-2764-7157; Pérez-Hernández, Marta/0000-0003-1331-5493;
   Soto-Cerrato, Vanessa/0000-0001-5835-3595; Garcia, David
   Martinez/0000-0001-7731-2107; ARIAS, ALAIN/0000-0002-1107-9426;
   Perez-Tomas, Ricardo/0000-0003-3226-1240
FU Instituto de Salud Carlos III (European Regional Development Fund. ERDF,
   a way to build Europe) [PI18/00441]
FX This research has been partially supported by Instituto de Salud Carlos
   III (Grant PI18/00441) (Co-funded by European Regional Development Fund.
   ERDF, a way to build Europe).
CR Akin D, 2014, AUTOPHAGY, V10, P2021, DOI 10.4161/auto.32229
   Armstrong JL, 2015, J INVEST DERMATOL, V135, P1629, DOI 10.1038/jid.2015.45
   Avniel-Polak S, 2018, ENDOCR-RELAT CANCER, V25, P677, DOI 10.1530/ERC-18-0121
   Bago R, 2014, BIOCHEM J, V463, P413, DOI 10.1042/BJ20140889
   Balic A, 2014, MOL CANCER THER, V13, P1758, DOI 10.1158/1535-7163.MCT-13-0948
   Baquero P, 2019, LEUKEMIA, V33, P981, DOI 10.1038/s41375-018-0252-4
   Basit F, 2013, CELL DEATH DIFFER, V20, P1161, DOI 10.1038/cdd.2013.45
   Bei SH, 2019, BIOCHEM BIOPH RES CO, V511, P13, DOI 10.1016/j.bbrc.2019.02.032
   Benjamin D, 2011, NAT REV DRUG DISCOV, V10, P868, DOI 10.1038/nrd3531
   Benvenuto M, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01269
   Benvenuto M, 2017, INT J FOOD SCI NUTR, V68, P298, DOI 10.1080/09637486.2016.1236077
   Bhat P, 2018, BIOCHEM PHARMACOL, V147, P170, DOI 10.1016/j.bcp.2017.11.021
   Bilger A, 2014, STRAHLENTHER ONKOL, V190, P957, DOI 10.1007/s00066-014-0693-2
   Bonapace L, 2010, J CLIN INVEST, V120, P1310, DOI 10.1172/JCI39987
   Bongiorno-Borbone L, 2015, ONCOTARGET, V6, P16926, DOI 10.18632/oncotarget.4700
   Boone BA, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4584-2
   Boone BA, 2015, ANN SURG ONCOL, V22, P4402, DOI 10.1245/s10434-015-4566-4
   Bortnik S, 2016, ONCOTARGET, V7, P66970, DOI 10.18632/oncotarget.11408
   Bosc D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29900-x
   BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Briceno Eduardo, 2003, Neurosurg Focus, V14, pe3
   Bristol ML, 2013, J PHARMACOL EXP THER, V344, P544, DOI 10.1124/jpet.112.199802
   Busschaert N, 2017, NAT CHEM, V9, P667, DOI [10.1038/nchem.2706, 10.1038/NCHEM.2706]
   Carew JS, 2007, BLOOD, V110, P313, DOI 10.1182/blood-2006-10-050260
   Carew JS, 2011, TARGET ONCOL, V6, P17, DOI 10.1007/s11523-011-0167-8
   Carew JS, 2010, J CELL MOL MED, V14, P2448, DOI 10.1111/j.1582-4934.2009.00832.x
   Chaikuad A, 2019, BIOCHEM J, V476, P875, DOI 10.1042/BCJ20190038
   Chakradeo S, 2015, MOL PHARMACOL, V87, P803, DOI 10.1124/mol.114.095273
   Chen G, 2019, AM J PHYSIOL-CELL PH, V317, pC244, DOI 10.1152/ajpcell.00390.2018
   Chen N, 2015, INT J BIOL SCI, V11, P833, DOI 10.7150/ijbs.10564
   Chen P, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1234-8
   Chen S, 2016, GENE DEV, V30, P856, DOI 10.1101/gad.276428.115
   Chen YJ, 2016, ONCOTARGETS THER, V9, P4453, DOI 10.2147/OTT.S105664
   Chen YJ, 2014, ONCOTARGET, V5, P4845, DOI 10.18632/oncotarget.2045
   Chen Y, 2018, ANTICANCER RES, V38, P1445, DOI 10.21873/anticanres.12369
   Cheng SJ, 2015, INTEGR CANCER THER, V14, P249, DOI 10.1177/1534735414568721
   Chi KH, 2015, ONCOTARGET, V6, P16735, DOI 10.18632/oncotarget.3793
   Chi MS, 2015, ONCOTARGET, V6, P29808, DOI 10.18632/oncotarget.5060
   Chiarini F, 2019, BBA-MOL CELL RES, V1866, P1322, DOI 10.1016/j.bbamcr.2019.03.013
   Chiu HW, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0531-5
   Choi JH, 2012, APMIS, V120, P597, DOI 10.1111/j.1600-0463.2012.02876.x
   Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751
   Chu JQ, 2018, ARCH BIOCHEM BIOPHYS, V644, P29, DOI 10.1016/j.abb.2018.03.001
   Chude CI, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061279
   Costa L, 2016, PROSTAG OTH LIPID M, V122, P54, DOI 10.1016/j.prostaglandins.2015.12.006
   Costedoat-Chalumeau N, 2007, CARDIOLOGY, V107, P73, DOI 10.1159/000094079
   Cufi S, 2013, SCI REP-UK, V3, DOI 10.1038/srep02469
   Cui ZF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06749-2
   Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722
   Daido S, 2005, CANCER RES, V65, P4368, DOI 10.1158/0008-5472.CAN-04-4202
   De U, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092743
   Degtyarev M, 2008, J CELL BIOL, V183, P101, DOI 10.1083/jcb.200801099
   Deng Q, 2018, EUR J PHARMACOL, V826, P24, DOI 10.1016/j.ejphar.2018.02.038
   Denton D, 2019, CELL DEATH DIFFER, V26, P605, DOI 10.1038/s41418-018-0252-y
   DETER RL, 1967, J CELL BIOL, V35, pC11, DOI 10.1083/jcb.35.2.C11
   Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4
   Dite TA, 2018, J BIOL CHEM, V293, P8874, DOI 10.1074/jbc.RA118.003547
   Donohue E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114964
   Donohue E, 2013, J CANCER, V4, P585, DOI 10.7150/jca.7030
   Donohue E, 2011, J BIOL CHEM, V286, P7290, DOI 10.1074/jbc.M110.139915
   Dowdle WE, 2014, NAT CELL BIOL, V16, P1069, DOI 10.1038/ncb3053
   Dower CM, 2018, MOL CANCER THER, V17, P2365, DOI 10.1158/1535-7163.MCT-18-0176
   Egan DF, 2015, MOL CELL, V59, P285, DOI 10.1016/j.molcel.2015.05.031
   El-Chemaly S, 2017, CHEST, V151, P1302, DOI 10.1016/j.chest.2017.01.033
   Eldredge Harriet Belding, 2013, J Radiat Oncol, V2, DOI 10.1007/s13566-013-0111-x
   Eng CH, 2016, P NATL ACAD SCI USA, V113, P182, DOI 10.1073/pnas.1515617113
   Enzenmuller S, 2013, ANTI-CANCER DRUG, V24, P14, DOI 10.1097/CAD.0b013e32835a36db
   Farkas T, 2011, J BIOL CHEM, V286, P38904, DOI 10.1074/jbc.M111.269134
   Feng QH, 2019, ACS APPL MATER INTER, V11, P32729, DOI 10.1021/acsami.9b10948
   Fennelly C, 2017, METHODS MOL BIOL, V1594, P293, DOI 10.1007/978-1-4939-6934-0_19
   Follo C, 2019, MOL CARCINOGEN, V58, P1754, DOI 10.1002/mc.23050
   Fontana F, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12576
   Fu YY, 2019, CANCERS, V11, DOI 10.3390/cancers11050649
   Fu YY, 2019, AUTOPHAGY, V15, P295, DOI 10.1080/15548627.2018.1517073
   Fu YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102535
   Fulda S, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00128
   Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002
   Galluzzi L, 2017, EMBO J, V36, P1811, DOI 10.15252/embj.201796697
   Gammoh N, 2016, AUTOPHAGY, V12, P1431, DOI 10.1080/15548627.2016.1190053
   Garlich JR, 2008, CANCER RES, V68, P206, DOI 10.1158/0008-5472.CAN-07-0669
   Ginet V, 2014, AUTOPHAGY, V10, P603, DOI 10.4161/auto.27722
   Goldberg SB, 2012, J THORAC ONCOL, V7, P1602, DOI 10.1097/JTO.0b013e318262de4a
   Goncalves RM, 2019, BIOCHEM PHARMACOL, V163, P440, DOI 10.1016/j.bcp.2019.03.015
   Goodall ML, 2014, AUTOPHAGY, V10, P1120, DOI 10.4161/auto.28594
   GRINDE B, 1983, EXP CELL RES, V149, P27, DOI 10.1016/0014-4827(83)90377-4
   Guo JY, 2013, CELL, V155, P1216, DOI 10.1016/j.cell.2013.11.019
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Hamasaki M, 2013, NATURE, V495, P389, DOI 10.1038/nature11910
   Han H, 2017, ONCOTARGET, V8, P53352, DOI 10.18632/oncotarget.18410
   Hernandez-Tiedra S, 2016, AUTOPHAGY, V12, P2213, DOI 10.1080/15548627.2016.1213927
   Hori YS, 2015, J NEURO-ONCOL, V122, P11, DOI 10.1007/s11060-014-1686-9
   Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248
   Hu M, 2014, ONCOL REP, V31, P649, DOI 10.3892/or.2013.2890
   Hua H, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0754-1
   Huang TZ, 2017, CANCER CELL, V32, P840, DOI 10.1016/j.ccell.2017.11.005
   Hubert V, 2016, BIOL OPEN, V5, P1516, DOI 10.1242/bio.018648
   Itakura E, 2012, CELL, V151, P1256, DOI 10.1016/j.cell.2012.11.001
   Jiang GM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0944-z
   Jiang RY, 2014, EUR REV MED PHARMACO, V18, P806
   Jiang S, 2011, CANCER SCI, V102, P1568, DOI 10.1111/j.1349-7006.2011.01964.x
   Jin SK, 2008, AUTOPHAGY, V4, P563, DOI 10.4161/auto.5830
   Kaneko M, 2014, J CANCER RES CLIN, V140, P769, DOI 10.1007/s00432-014-1628-0
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kaushik S, 2012, TRENDS CELL BIOL, V22, P407, DOI 10.1016/j.tcb.2012.05.006
   Keshmiri-Neghab H, 2014, GEN PHYSIOL BIOPHYS, V33, P433, DOI 10.4149/gpb_2014017
   Kim EJ, 2013, J CELL BIOCHEM, V114, P1248, DOI 10.1002/jcb.24465
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim KW, 2008, AUTOPHAGY, V4, P659, DOI 10.4161/auto.6058
   Ko A, 2014, CELL DEATH DIFFER, V21, P92, DOI 10.1038/cdd.2013.124
   Kocaturk NM, 2019, EUR J PHARM SCI, V134, P116, DOI 10.1016/j.ejps.2019.04.011
   Koehler BC, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1929-y
   Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738
   Kurdi A, 2017, BIOCHEM PHARMACOL, V138, P150, DOI 10.1016/j.bcp.2017.06.119
   KWAKYEBERKO F, 1989, MOL BIOCHEM PARASIT, V35, P51, DOI 10.1016/0166-6851(89)90141-2
   Lamattina AM, 2018, CHEST, V154, P1070, DOI 10.1016/j.chest.2018.08.1029
   Lan L, 2015, MOL ONCOL, V9, P1406, DOI 10.1016/j.molonc.2015.03.014
   Lazarus MB, 2015, ACS CHEM BIOL, V10, P257, DOI 10.1021/cb500835z
   Lee EJ, 2011, AUTOPHAGY, V7, P689, DOI 10.4161/auto.7.7.15450
   Leontieva OV, 2016, AGING-US, V8, P3535, DOI 10.18632/aging.101155
   Levy JMM, 2017, ELIFE, V6, DOI 10.7554/eLife.19671
   Levy JMM, 2014, CANCER DISCOV, V4, P773, DOI 10.1158/2159-8290.CD-14-0049
   Li WW, 2012, CELL MOL LIFE SCI, V69, P1125, DOI 10.1007/s00018-011-0865-5
   Liang LZ, 2015, ORAL DIS, V21, P470, DOI 10.1111/odi.12305
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   LIBBY P, 1978, SCIENCE, V199, P534, DOI 10.1126/science.622552
   Lin XK, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20181822
   Lindmo K, 2006, J CELL SCI, V119, P605, DOI 10.1242/jcs.02855
   Liu DL, 2011, MED ONCOL, V28, P105, DOI 10.1007/s12032-009-9397-3
   Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037
   Liu PF, 2018, THERANOSTICS, V8, P830, DOI 10.7150/thno.22012
   Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926
   Liu WL, 2014, PATHOL RES PRACT, V210, P764, DOI 10.1016/j.prp.2014.03.008
   Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112
   Loehberg CR, 2012, BIOCHEM PHARMACOL, V83, P480, DOI 10.1016/j.bcp.2011.11.022
   Lu J, 2018, EBIOMEDICINE, V34, P85, DOI 10.1016/j.ebiom.2018.07.034
   Lu YY, 2014, AUTOPHAGY, V10, P1895, DOI 10.4161/auto.32200
   Lui A, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2490-z
   Lui JW, 2019, J CANCER, V10, P1, DOI 10.7150/jca.27472
   Lv TT, 2018, ACTA BIOMATER, V76, P257, DOI 10.1016/j.actbio.2018.06.034
   Lystad AH, 2019, NAT CELL BIOL, V21, P372, DOI 10.1038/s41556-019-0274-9
   Ma XH, 2014, J CLIN INVEST, V124, P1406, DOI 10.1172/JCI70454
   Ma XW, 2011, ACS NANO, V5, P8629, DOI 10.1021/nn202155y
   Maes H, 2014, CANCER CELL, V26, P190, DOI 10.1016/j.ccr.2014.06.025
   Mahalingam D, 2014, AUTOPHAGY, V10, P1403, DOI 10.4161/auto.29231
   Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247
   Mao BB, 2017, EUR J MED CHEM, V129, P135, DOI 10.1016/j.ejmech.2017.02.015
   Margolin K, 2005, CANCER-AM CANCER SOC, V104, P1045, DOI 10.1002/cncr.21265
   Marmor MF, 2016, OPHTHALMOLOGY, V123, P1386, DOI 10.1016/j.ophtha.2016.01.058
   Martin KR, 2018, ISCIENCE, V8, P74, DOI 10.1016/j.isci.2018.09.012
   Mauvezin C, 2015, AUTOPHAGY, V11, P1437, DOI 10.1080/15548627.2015.1066957
   Maycotte P, 2012, AUTOPHAGY, V8, P200, DOI 10.4161/auto.8.2.18554
   McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109
   Melles RB, 2014, JAMA OPHTHALMOL, V132, P1453, DOI 10.1001/jamaophthalmol.2014.3459
   Mercer CA, 2009, AUTOPHAGY, V5, P649, DOI 10.4161/auto.5.5.8249
   Merino D, 2018, CANCER CELL, V34, P879, DOI 10.1016/j.ccell.2018.11.004
   Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347
   Miller-Ocuin JL, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1605822
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Morgan MJ, 2018, P NATL ACAD SCI USA, V115, pE8479, DOI 10.1073/pnas.1706526115
   Mrakovcic M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123952
   Mrakovcic M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091883
   Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156
   Nascimbeni AC, 2017, EMBO J, V36, P2018, DOI 10.15252/embj.201797006
   Newbold A, 2016, FEBS J, V283, P4032, DOI 10.1111/febs.13746
   Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963
   Noda T, 2011, AUTOPHAGY, V7, P438, DOI 10.4161/auto.7.4.14679
   Opydo-Chanek M, 2017, BIOCHEM PHARMACOL, V136, P12, DOI 10.1016/j.bcp.2017.03.006
   Ota M, 2008, DEVELOPMENT, V135, P4059, DOI 10.1242/dev.027151
   Pan HT, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1653-7
   Pasquier B, 2015, AUTOPHAGY, V11, P725, DOI 10.1080/15548627.2015.1033601
   Pasquier B, 2015, J MED CHEM, V58, P376, DOI 10.1021/jm5013352
   Pattingre S, 2008, BIOCHIMIE, V90, P313, DOI 10.1016/j.biochi.2007.08.014
   Petherick KJ, 2015, J BIOL CHEM, V290, P11376, DOI [10.1074/jbc.C114.627778, 10.1074/jbc.A114.627778]
   Piao SF, 2017, AUTOPHAGY, V13, P2056, DOI 10.1080/15548627.2017.1377377
   Pinto-Leite R, 2014, UROL ONCOL-SEMIN ORI, V32, DOI 10.1016/j.urolonc.2013.04.012
   POOLE B, 1981, J CELL BIOL, V90, P665, DOI 10.1083/jcb.90.3.665
   POWIS G, 1994, CANCER RES, V54, P2419
   Qin An-Cheng, 2019, Cell Physiol Biochem, V52, P758, DOI 10.33594/000000053
   Qin L, 2016, DRUG DES DEV THER, V10, P1035, DOI 10.2147/DDDT.S101701
   Qiu ZX, 2016, ACS MED CHEM LETT, V7, P802, DOI 10.1021/acsmedchemlett.6b00208
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Rangwala R, 2014, AUTOPHAGY, V10, P1391, DOI 10.4161/auto.29119
   Rangwala R, 2014, AUTOPHAGY, V10, P1369, DOI 10.4161/auto.29118
   Rebecca VW, 2017, CANCER DISCOV, V7, P1266, DOI 10.1158/2159-8290.CD-17-0741
   Ren XQ, 2018, ACS APPL MATER INTER, V10, P27701, DOI 10.1021/acsami.8b10167
   Rodilla AM, 2017, BIOCHEM PHARMACOL, V126, P23, DOI 10.1016/j.bcp.2016.11.022
   Rojas-Puentes LL, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-209
   Ronan B, 2014, NAT CHEM BIOL, V10, P1013, DOI 10.1038/nchembio.1681
   Rosenfeld MR, 2014, AUTOPHAGY, V10, P1359, DOI 10.4161/auto.28984
   Rossi M, 2009, J CELL SCI, V122, P3330, DOI 10.1242/jcs.048181
   Sahu R, 2011, DEV CELL, V20, P131, DOI 10.1016/j.devcel.2010.12.003
   Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948
   Saleh T, 2016, BBA-GEN SUBJECTS, V1860, P2130, DOI 10.1016/j.bbagen.2016.06.012
   Schelman WR, 2014, INVEST NEW DRUG, V32, P295, DOI 10.1007/s10637-013-9999-7
   Scott AJ, 2018, MOL CANCER THER, V17, P2112, DOI 10.1158/1535-7163.MCT-17-0131
   Scott KA, 2014, MOL CANCER THER, V13, P2955, DOI 10.1158/1535-7163.MCT-14-0402
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   SEHGAL SN, 1975, J ANTIBIOT, V28, P727, DOI 10.7164/antibiotics.28.727
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Sharma G, 2019, AUTOPHAGY, V15, P1694, DOI 10.1080/15548627.2019.1586257
   Sharma N, 2012, CANCER LETT, V326, P143, DOI 10.1016/j.canlet.2012.07.029
   Shi HB, 2019, J CANCER RES THER, V15, P398, DOI 10.4103/jcrt.JCRT_639_18
   Shi TT, 2017, CANCER CHEMOTH PHARM, V79, P287, DOI 10.1007/s00280-016-3197-1
   Shimizu S., 2015, INNOVATIVE MED BASIC, P219
   Shingu T, 2009, INT J CANCER, V124, P1060, DOI 10.1002/ijc.24030
   Singh K, 2012, AUTOPHAGY, V8, P236, DOI 10.4161/auto.8.2.18600
   Singla M, 2017, BIOMED PHARMACOTHER, V94, P332, DOI 10.1016/j.biopha.2017.07.070
   Skah Seham, 2018, Oncotarget, V9, P30434, DOI 10.18632/oncotarget.25758
   Sledzinski P, 2018, CANCER MED-US, V7, P765, DOI 10.1002/cam4.1312
   Solomon VR, 2009, EUR J PHARMACOL, V625, P220, DOI 10.1016/j.ejphar.2009.06.063
   Sotelo J, 2006, ANN INTERN MED, V144, P337, DOI 10.7326/0003-4819-144-5-200603070-00008
   Stein MN, 2016, CLIN GENITOURIN CANC, V14, P22, DOI 10.1016/j.clgc.2015.09.010
   Stern ST, 2012, PART FIBRE TOXICOL, V9, DOI 10.1186/1743-8977-9-20
   Sulkshane P, 2017, ONCOTARGET, V8, P60060, DOI 10.18632/oncotarget.11085
   Swiecicki PL, 2016, INVEST NEW DRUG, V34, P481, DOI 10.1007/s10637-016-0364-5
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Tang F, 2017, ONCOL REP, V37, P3449, DOI 10.3892/or.2017.5635
   Tang Y, 2019, CHEST, V156, P1137, DOI 10.1016/j.chest.2019.05.038
   Tanida I, 2004, J BIOL CHEM, V279, P36268, DOI 10.1074/jbc.M401461200
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Nguyen TN, 2016, J CELL BIOL, V215, P857, DOI 10.1083/jcb.201607039
   THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960
   Tran E, 2013, BIOCHEM BIOPH RES CO, V441, P726, DOI 10.1016/j.bbrc.2013.10.117
   TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E
   Uhlman A, 2017, CANCER MICROENVIRON, V10, P49, DOI 10.1007/s12307-017-0196-7
   Valet C, 2017, BLOOD, V130, P2032, DOI 10.1182/blood-2017-04-781641
   Vara D, 2011, CELL DEATH DIFFER, V18, P1099, DOI 10.1038/cdd.2011.32
   Vera-Ramirez L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04070-6
   Verbaanderd C, 2017, ECANCERMEDICALSCIENC, V11, DOI 10.3332/ecancer.2017.781
   VEZINA C, 1975, J ANTIBIOT, V28, P721, DOI 10.7164/antibiotics.28.721
   VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241
   Vogl DT, 2014, AUTOPHAGY, V10, P1380, DOI 10.4161/auto.29264
   Voss V, 2010, MOL CANCER RES, V8, P1002, DOI 10.1158/1541-7786.MCR-09-0562
   Wang F, 2018, CELL PHYSIOL BIOCHEM, V45, P54, DOI 10.1159/000486222
   Wang HW, 2014, J CANCER RES CLIN, V140, P561, DOI 10.1007/s00432-014-1596-4
   Wang JB, 2019, BIOCHEM J, V476, P535, DOI 10.1042/BCJ20180385
   Wang Peng, 2018, Genes Cancer, V9, P190, DOI 10.18632/genesandcancer.181
   Wang XH, 2018, INT J PHARMACEUT, V536, P1, DOI 10.1016/j.ijpharm.2017.09.007
   Wang Y, 2016, AUTOPHAGY, V12, P949, DOI 10.1080/15548627.2016.1162930
   Wei HL, 2017, CANCER SCI, V108, P478, DOI 10.1111/cas.13138
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Wolfram J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14221-2
   Wolpin BM, 2014, ONCOLOGIST, V19, P637, DOI 10.1634/theoncologist.2014-0086
   Wu KK, 2018, INT J ONCOL, V53, P2356, DOI 10.3892/ijo.2018.4578
   Wu YY, 2013, AUTOPHAGY, V9, P595, DOI 10.4161/auto.23641
   Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796
   Xie J, 2017, ONCOTARGET, V8, P50814, DOI 10.18632/oncotarget.15135
   Xie XQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055096
   Xie ZG, 2013, ONCOL LETT, V6, P1465, DOI 10.3892/ol.2013.1531
   Xu DQ, 2017, SLAS DISCOV, V22, P338, DOI 10.1177/1087057116639202
   Xu HM, 2022, ARCH PHYSIOL BIOCHEM, V128, P281, DOI 10.1080/13813455.2019.1675714
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yao XX, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317695965
   Yi HL, 2019, TRANSL ONCOL, V12, P1221, DOI 10.1016/j.tranon.2019.06.001
   Yu ZQ, 2012, AUTOPHAGY, V8, P883, DOI 10.4161/auto.19652
   Yun M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117375
   Zachari M, 2017, ESSAYS BIOCHEM, V61, P585, DOI 10.1042/EBC20170021
   Zhang HB, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aac5418
   Zhang HJ, 2019, ACS APPL MATER INTER, V11, P29641, DOI 10.1021/acsami.9b10578
   Zhang JF, 2019, ONCOL REP, V41, P819, DOI 10.3892/or.2018.6879
   Zhang XD, 2014, THERANOSTICS, V4, P1085, DOI 10.7150/thno.9933
   Zhang XD, 2014, BIOMATERIALS, V35, P1932, DOI 10.1016/j.biomaterials.2013.10.034
   Zhang XD, 2014, MOL CELL BIOCHEM, V385, P265, DOI 10.1007/s11010-013-1835-z
   Zheng L, 2017, ONCOTARGET, V8, P98964, DOI 10.18632/oncotarget.22147
   Zhou H, 2017, ONCOTARGET, V8, P80770, DOI 10.18632/oncotarget.20415
   Zhou PT, 2018, CELL CYCLE, V17, P997, DOI 10.1080/15384101.2018.1467677
   Zhou ZJ, 2017, BIOMATERIALS, V141, P116, DOI 10.1016/j.biomaterials.2017.06.030
   Zou YF, 2015, ONCOL LETT, V10, P1583, DOI 10.3892/ol.2015.3417
   Zou ZY, 2014, J DRUG TARGET, V22, P839, DOI [10.3109/1061186X.2014.936870, 10.13695/j.cnki.12-1222/o3.2014.06.026]
NR 272
TC 80
Z9 81
U1 15
U2 29
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD OCT
PY 2019
VL 11
IS 10
AR 1599
DI 10.3390/cancers11101599
PG 47
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA JQ3CF
UT WOS:000498826000196
PM 31635099
OA gold, Green Published
HC Y
HP N
DA 2022-04-25
ER

PT J
AU Talero, E
   Alcaide, A
   Avila-Roman, J
   Garcia-Maurino, S
   Vendramini-Costa, D
   Motilva, V
AF Talero, Elena
   Alcaide, Antonio
   Avila-Roman, Javier
   Garcia-Maurino, Sofia
   Vendramini-Costa, Debora
   Motilva, Virginia
TI Expression patterns of sirtuin 1-AMPK-autophagy pathway in chronic
   colitis and inflammation-associated colon neoplasia in IL-10-deficient
   mice
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Chronic inflammation; Colon carcinogenesis; IL-10-deficient mice; SIRT1;
   Autophagy
ID SODIUM-INDUCED COLITIS; ULCERATIVE-COLITIS; BOWEL-DISEASE;
   COLORECTAL-CANCER; KAPPA-B; AUTOPHAGY; CARCINOGENESIS; ADENOCARCINOMA;
   ACTIVATION; PROLIFERATION
AB Background: Interleukin-10-deficient (IL-10 (-/-)) mice spontaneously develop chronic colitis and adenocarcinoma through the dysplasia sequence. Autophagy malfunction is associated to inflammatory bowel disease (IBD) and colorectal cancer (CRC) pathogenesis. Autophagy is regulated by silent information regulator-1 (SIRT1), a NAD+-dependent histone deacetylase. Our aim was to investigate the expression changes of SIRT1-AMPK-autophagy pathway in the progression from chronic colitis to CRC.
   Methods: We studied C57BL/6-IL-10-deficient mice between 6 and 18 weeks of age. Macroscopic and histological analysis, and characterization of inflammatory and tumor biomarkers were performed.
   Results: IL-10-deficient mice developed colitis from the age of 6 weeks onward. The severity of inflammation and dysplasia, and the proliferative activity increased gradually with age. IL-10 (-/-) mice were characterized by improved levels of TNF-alpha and decreased expression of SIRT1. Moreover, our findings show an increase in p-AMPK expression and an activation of the autophagy in IL-10 (-/-) mice from all stages, evidenced by the accumulation of LC3-II protein, the increase in Beclin 1 expression and the reduction in Bcl-2 levels.
   Conclusions: SIRT1-AMPK-autophagy pathway may be involved in the maintenance of chronic inflammation and dysplasia development in the IL-10-deficient mice model. Modulation of this pathway could be a novel strategy for IBD and CRC treatment. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Talero, Elena; Alcaide, Antonio; Avila-Roman, Javier; Motilva, Virginia] Univ Seville, Sch Pharm, Dept Pharmacol, Seville, Spain.
   [Garcia-Maurino, Sofia] Univ Seville, Fac Biol, Dept Plant Biol & Ecol, Seville, Spain.
   [Vendramini-Costa, Debora] Univ Estadual Campinas, Inst Chem, Dept Organ Chem, Campinas, SP, Brazil.
RP Talero, E (corresponding author), Univ Seville, Dept Pharmacol, Sch Pharm, Profesor Garcia Gonzalez 2, Seville 41012, Spain.
EM etalero@us.es
RI Vendramini-Costa, Debora Barbosa/G-1287-2012; García-Mauriño,
   Sofía/E-6707-2010; Avila-Roman, Javier/B-5337-2017; Talero,
   Elena/I-2613-2015
OI Vendramini-Costa, Debora Barbosa/0000-0001-7617-4945; García-Mauriño,
   Sofía/0000-0002-7698-5112; Avila-Roman, Francisco
   Javier/0000-0001-9766-8178
FU Consejeria de Innovacion, Ciencia y Empresa-Junta de Andalucia
   (Polfanat) [P09-AGR-5185]
FX This work was supported by Consejeria de Innovacion, Ciencia y
   Empresa-Junta de Andalucia (P09-AGR-5185, Polfanat). We thank "Centro de
   Investigacion, Tecnologia e Innovation (CITIUS)" of the University of
   Seville for providing technical assistance.
CR Baxt LA, 2015, GASTROENTEROLOGY, V149, P553, DOI 10.1053/j.gastro.2015.06.046
   Berg DJ, 1996, J CLIN INVEST, V98, P1010, DOI 10.1172/JCI118861
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Craven B, 2015, INFLAMM BOWEL DIS, V21, P485, DOI 10.1097/MIB.0000000000000303
   Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020
   Francescone R, 2015, INFLAMM BOWEL DIS, V21, P409, DOI 10.1097/MIB.0000000000000236
   Garcia-Maurino S, 2012, CURR PHARM DESIGN, V18, P3853, DOI 10.2174/138161212802083653
   Ghosh HS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009199
   Giatromanolaki A, 2013, COLORECTAL DIS, V15, pE223, DOI 10.1111/codi.12147
   Habeeb BS, 2011, CANCER SCI, V102, P999, DOI 10.1111/j.1349-7006.2011.01902.x
   Hale LP, 2010, INFLAMM BOWEL DIS, V16, P2012, DOI 10.1002/ibd.21320
   Hegazi RAF, 2006, NUTRITION, V22, P275, DOI 10.1016/j.nut.2005.06.006
   Herszenyi L, 2015, DIGEST DIS, V33, P52, DOI 10.1159/000368447
   Ierardi E, 2001, DIGEST DIS SCI, V46, P1083, DOI 10.1023/A:1010774331331
   Jang SH, 2012, J CLIN PATHOL, V65, P735, DOI 10.1136/jclinpath-2012-200685
   Kabra N, 2009, J BIOL CHEM, V284, P18210, DOI 10.1074/jbc.M109.000034
   Kim YJ, 2010, CANCER PREV RES, V3, P1314, DOI 10.1158/1940-6207.CAPR-09-0272
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Lan F, 2008, J BIOL CHEM, V283, P27628, DOI 10.1074/jbc.M805711200
   Lu JJ, 2014, INT J CLIN EXP MED, V7, P5050
   Luo S, 2010, CELL DEATH DIFFER, V17, P268, DOI 10.1038/cdd.2009.121
   Lv L, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0965-9
   Ng F, 2013, J CELL PHYSIOL, V228, P2262, DOI 10.1002/jcp.24399
   Okayasu I, 2002, J GASTROEN HEPATOL, V17, P1078, DOI 10.1046/j.1440-1746.2002.02853.x
   Olmos Y, 2011, DRUG RESIST UPDATE, V14, P35, DOI 10.1016/j.drup.2010.12.001
   Qasim BJ, 2012, SAUDI J GASTROENTERO, V18, P268, DOI 10.4103/1319-3767.98435
   RIDDELL RH, 1983, HUM PATHOL, V14, P931, DOI 10.1016/S0046-8177(83)80175-0
   Satoh A, 2013, CELL METAB, V18, P416, DOI 10.1016/j.cmet.2013.07.013
   Schmitt EG, 2012, J IMMUNOL, V189, P5638, DOI 10.4049/jimmunol.1200936
   Shen F, 2011, J CELL BIOCHEM, V112, P756, DOI 10.1002/jcb.23002
   Shin DH, 2014, CANCER RES, V74, P298, DOI 10.1158/0008-5472.CAN-13-2620
   Singh UP, 2010, J PHARMACOL EXP THER, V332, P829, DOI 10.1124/jpet.109.160838
   Talero E, 2011, INFLAMM BOWEL DIS, V17, P696, DOI 10.1002/ibd.21420
   Talero E, 2015, INFLAMM BOWEL DIS, V21, P1027, DOI 10.1097/MIB.0000000000000346
   Tanaka T, 2012, CURR DRUG TARGETS, V13, P1689, DOI 10.2174/138945012804545452
   Tsuboi K, 2015, J BIOL CHEM, V290, P20511, DOI 10.1074/jbc.M114.632257
   Wu SH, 2015, HUM PATHOL, V46, P1752, DOI 10.1016/j.humpath.2015.07.016
   Yang HH, 2012, SCI WORLD J, P1, DOI 10.1100/2012/149132
   Yeo M, 2006, PROTEOMICS, V6, P1158, DOI 10.1002/pmic.200500390
   Zadra G, 2015, MOL CANCER RES, V13, P1059, DOI 10.1158/1541-7786.MCR-15-0068
   Zhang R, 2010, J BIOL CHEM, V285, P7097, DOI 10.1074/jbc.M109.038604
   Zhang R, 2007, CARCINOGENESIS, V28, P1122, DOI 10.1093/carcin/bgl224
   Zheng HH, 2016, EUR J GASTROEN HEPAT, V28, P383, DOI 10.1097/MEG.0000000000000576
NR 43
TC 26
Z9 28
U1 0
U2 28
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD JUN
PY 2016
VL 35
BP 248
EP 256
DI 10.1016/j.intimp.2016.03.046
PG 9
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA DM2XX
UT WOS:000376212500030
PM 27085036
DA 2022-04-25
ER

PT J
AU Ju, BL
   Liu, ZL
   Nai, C
   Zhu, XY
AF Ju, Banglv
   Liu, Zhilan
   Nai, Chao
   Zhu, Xinyong
TI Long non-coding RNA CASC2 induces apoptosis and autophagy in human colon
   cancer cells via modulation of TRIM16 expression
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Colon cancer; CASC2; apoptosis; autophagy
ID POOR-PROGNOSIS; LNCRNA CASC2; PROLIFERATION; SUPPRESSES; MIGRATION
AB Long non-coding RNAs (LncRNAs) have been shown to be involved in diverse cellular and physiological processes. Recent studies have proved their potential as the prospective therapeutic targets for cancer treatment. Herein, we examined the role of LncRNA CASC2 in human colon cancer. The gene expression analysis showed that LncRNA CASC2 is significantly suppressed in colon cancer tissues and cell lines. The immunohistochemistry also showed considerable increase of the Ki67 in colon cancer tissues suggestive of their aggressiveness. Overexpression of CASC2 inhibited the growth of HT-29 cells. The inhibition of HT-29 growth was due to the induction of apoptosis which was accompanied by upsurge of Bax, depletion of Bcl-2 and activation of caspase-3 cleavage. Electron microscopic analysis showed CASC2 overexpression also induced autophagy in the HT-29 cells which was associated with increase in LC3B II and Beclin 1 expression. Bioinformatic approaches and dual luciferase assay showed that CASC2 controls the TRIM16 via microRNA-214 axis. TRIM16 was found to be overexpressed in all the colon cancer tissues and cell lines. Overexpression of CASC2 caused significant inhibition of TRIM16. Additionally, silencing of TRIM16 resulted in the inhibition of HT-29 cell growth similar to that of CASC2 overexpression. Taken together, CASC2 may prove to be an important therapeutic target for colon cancer treatment.
C1 [Ju, Banglv; Nai, Chao] Chinese Peoples Liberat Army Gen Hosp, Dept Hepatobiliary Surg, Med Ctr 7, Beijing 100700, Peoples R China.
   [Liu, Zhilan] Qinghai Prov Peoples Hosp, Dept Gastroenterol, Xining 810007, Qinghai, Peoples R China.
   [Zhu, Xinyong] Peoples Liberat Army Gen Hosp, Med Ctr 4, Dept Gen Surg, Beijing 100048, Peoples R China.
RP Zhu, XY (corresponding author), Peoples Liberat Army Gen Hosp, Med Ctr 4, Dept Gen Surg, Beijing 100048, Peoples R China.
EM zxy304@126.com
CR Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Ba ZW, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12409
   Cao YJ, 2016, MOL MED REP, V14, P1019, DOI 10.3892/mmr.2016.5337
   Evans JR, 2016, J CLIN INVEST, V126, P2775, DOI 10.1172/JCI84421
   Fan JC, 2018, J CELL BIOCHEM, V119, P6391, DOI 10.1002/jcb.26479
   Feng YQ, 2017, ARCH BIOCHEM BIOPHYS, V623, P20, DOI 10.1016/j.abb.2017.05.001
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   He XZ, 2016, TUMOR BIOL, V37, P9503, DOI 10.1007/s13277-016-4787-6
   Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981
   Li P, 2016, AM J TRANSL RES, V8, P3522
   Li Q, 2018, RSC ADV, V8, P40846, DOI 10.1039/c8ra09573f
   Pei Z, 2017, ONCOTARGET, V8, P18145, DOI 10.18632/oncotarget.15210
   POTTER JD, 1993, EPIDEMIOL REV, V15, P499, DOI 10.1093/oxfordjournals.epirev.a036132
   Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Sutton SK, 2014, ONCOTARGET, V5, P10127, DOI 10.18632/oncotarget.2466
   Tan HW, 2017, ONCOL RES, V25, P551, DOI 10.3727/096504016X14758370595285
   Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492
   Wang P, 2015, CELL SIGNAL, V27, P275, DOI 10.1016/j.cellsig.2014.11.011
   Xiong XQ, 2017, BIOMED PHARMACOTHER, V93, P391, DOI 10.1016/j.biopha.2017.06.063
   Yao JT, 2016, ONCOL REP, V35, P1204, DOI 10.3892/or.2015.4437
   Zhang H, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-37
   Zhang R, 2016, ONCOL LETT, V12, P1233, DOI 10.3892/ol.2016.4770
   Zhang Y, 2019, ONCOL RES, V27, P379, DOI 10.3727/096504018X15199531937158
NR 24
TC 4
Z9 4
U1 0
U2 1
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2020
VL 12
IS 6
BP 2695
EP 2702
PG 8
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA MJ7DE
UT WOS:000548246400008
PM 32655801
DA 2022-04-25
ER

PT J
AU Comes, F
   Matrone, A
   Lastella, P
   Nico, B
   Susca, FC
   Bagnulo, R
   Ingravallo, G
   Modica, S
   Lo Sasso, G
   Moschetta, A
   Guanti, G
   Simone, C
AF Comes, F.
   Matrone, A.
   Lastella, P.
   Nico, B.
   Susca, F. C.
   Bagnulo, R.
   Ingravallo, G.
   Modica, S.
   Lo Sasso, G.
   Moschetta, A.
   Guanti, G.
   Simone, C.
TI A novel cell type-specific role of p38 alpha in the control of autophagy
   and cell death in colorectal cancer cells
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Article
DE colorectal cancer; p38 alpha; autophagic cell death; apoptosis; SB202190
ID ACTIVATED PROTEIN-KINASE; MALIGNANT GLIOMA-CELLS; SIGNALING PATHWAYS;
   P38; DIFFERENTIATION; SURVIVAL; MAPK; INHIBITION; ISOFORMS; COMPLEX
AB Cancer develops when molecular pathways that control the fine balance between proliferation, differentiation, autophagy and cell death undergo genetic deregulation. The prospects for further substantial advances in the management of colorectal cancer reside in a systematic genetic and functional dissection of these pathways in tumor cells. In an effort to evaluate the impact of p38 signaling on colorectal cancer cell fate, we treated HT29, Caco2, Hct116, LS174T and SW480 cell lines with the inhibitor SB202190 specific for p38 alpha/beta kinases. We report that p38 alpha is required for colorectal cancer cell homeostasis as the inhibition of its kinase function by pharmacological blockade or genetic inactivation causes cell cycle arrest, autophagy and cell death in a cell type- specific manner. Deficiency of p38 alpha activity induces a tissue- restricted upregulation of the GABARAP gene, an essential component of autophagic vacuoles and autophagosomes, whereas simultaneous inhibition of autophagy significantly increases cell death by triggering apoptosis. These data identify p38 alpha as a central mediator of colorectal cancer cell homeostasis and establish a rationale for the evaluation of the pharmacological manipulation of the p38 alpha pathway in the treatment of colorectal cancer.
C1 Univ Bari, Div Med Genet, Dept Biomed Childhood, Bari, Italy.
   Univ Bari, Dept Human Anat & Histol, Bari, Italy.
   Univ Bari, Dept Pathol Anat, Bari, Italy.
   Univ Bari, Consorzio Mario Negri Sud, Santa Maria Imbaro Ch, Bari, Italy.
   Univ Bari, Clin Med Mum, Dept Internal Med, Bari, Italy.
   Temple Univ, Sbarro Inst Canc Res & Mol Med, Ctr Biotechnol, Coll Sci & Technol, Philadelphia, PA 19122 USA.
RP Guanti, G (corresponding author), Univ Bari, Div Med Genet, Dept Biomed Childhood, Bari, Italy.
EM guanti@medgene.uniba.it; csimone@temple.edu
RI Ingravallo, Giuseppe/Q-1477-2016; Moschetta, Antonio/AAC-5295-2022;
   Moschetta, Antonio/K-6211-2016; INGRAVALLO, Giuseppe/N-2466-2019;
   Simone, Cristiano/K-3452-2018
OI Ingravallo, Giuseppe/0000-0002-4792-3545; INGRAVALLO,
   Giuseppe/0000-0002-4792-3545; Simone, Cristiano/0000-0002-2628-7658;
   Susca, Francesco Claudio/0000-0002-9899-8301; Moschetta,
   Antonio/0000-0003-2123-6074
CR ABEDIN MJ, 2006, CELL DEATH DIFFER
   Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025
   Archer SY, 2005, AM J PHYSIOL-GASTR L, V289, pG696, DOI 10.1152/ajpgi.00575.2004
   Bakin AV, 2002, J CELL SCI, V115, P3193
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Corin I, 2006, CANCER BIOL THER, V5, P198, DOI 10.4161/cbt.5.2.2356
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   DEMIDOV ON, 2006, ONCOGENE
   Faust D, 2005, ONCOGENE, V24, P7941, DOI 10.1038/sj.onc.1208948
   Gout S, 2006, CANCER RES, V66, P9117, DOI 10.1158/0008-5472.CAN-05-4605
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Halawani D, 2004, ONCOGENE, V23, P3726, DOI 10.1038/sj.onc.1207422
   Herman-Antosiewicz A, 2006, CANCER RES, V66, P5828, DOI 10.1158/0008-5472.CAN-06-0139
   Hiramoto T, 1999, ONCOGENE, V18, P3422, DOI 10.1038/sj.onc.1202691
   Houde M, 2001, J BIOL CHEM, V276, P21885, DOI 10.1074/jbc.M100236200
   Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   KATAYAMA M, 2006, CELL DEATH DIFF 0901
   Laprise P, 2002, J BIOL CHEM, V277, P8226, DOI 10.1074/jbc.M110235200
   Luongo D, 2002, MOL CELL BIOCHEM, V231, P43, DOI 10.1023/A:1014476706382
   Marx J, 2006, SCIENCE, V312, P1160, DOI 10.1126/science.312.5777.1160
   McGartland Laura P, 2004, Clin Adv Hematol Oncol, V2, P806
   Medina V, 1998, JPEN-PARENTER ENTER, V22, P14, DOI 10.1177/014860719802200114
   Orchel A, 2005, DIGEST DIS SCI, V50, P490, DOI 10.1007/s10620-005-2463-6
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Prakash J, 2006, J PHARMACOL EXP THER, V319, P8, DOI 10.1124/jpet.106.106054
   Prick T, 2006, BIOCHEM J, V394, P153, DOI 10.1042/BJ20051243
   Samoha S, 2005, ONCOLOGY-BASEL, V69, P33, DOI 10.1159/000086630
   Schwab M, 2006, APOPTOSIS, V11, P1801, DOI 10.1007/s10495-006-9788-2
   Simone C, 2006, J CELL PHYSIOL, V207, P309, DOI 10.1002/jcp.20514
   Simone C, 2004, NAT GENET, V36, P738, DOI 10.1038/ng1378
   Suarez-Cuervo C, 2004, CLIN EXP METASTAS, V21, P525, DOI 10.1007/s10585-004-3503-x
   Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640
   Tassa A, 2003, BIOCHEM J, V376, P577, DOI 10.1042/BJ20030826
   ten Hove T, 2002, GUT, V50, P507, DOI 10.1136/gut.50.4.507
   Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777
   Vachon PH, 2002, GASTROENTEROLOGY, V123, P1980, DOI 10.1053/gast.2002.37072
   van den Brink GR, 2004, NAT GENET, V36, P277, DOI 10.1038/ng1304
   vom Dahl S, 2001, BIOCHEM J, V354, P31, DOI 10.1042/0264-6021:3540031
NR 40
TC 99
Z9 103
U1 1
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1350-9047
EI 1476-5403
J9 CELL DEATH DIFFER
JI Cell Death Differ.
PD APR
PY 2007
VL 14
IS 4
BP 693
EP 702
DI 10.1038/sj.cdd.4402076
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 148UV
UT WOS:000245102900006
PM 17159917
OA Bronze
DA 2022-04-25
ER

PT J
AU Park, GB
   Jin, DH
   Kim, D
AF Park, Ga-Bin
   Jin, Dong-Hoon
   Kim, Daejin
TI Sequential treatment with celecoxib and bortezomib enhances the ER
   stress-mediated autophagy-associated cell death of colon cancer cells
SO ONCOLOGY LETTERS
LA English
DT Article
DE celecoxib; bortezomib; endoplasmic reticulum stress; autophagy; colon
   cancer; p53
ID ENDOPLASMIC-RETICULUM STRESS; INDUCED APOPTOSIS; INHIBITION; SURVIVAL;
   RECEPTOR; BAX; P53
AB Treatment with celecoxib and bortezomib as single chemotherapeutic agents reduces the viability and proliferation of colorectal cancer cells. The use of these agents in combination with other chemotherapeutic agents is usually associated with adverse effects. In the present study, a combination of celecoxib and bortezomib was investigated for potential synergistic effects in colon cancer cells. The sequential exposure to celecoxib with bortezomib synergistically induced apoptotic death in human colon cancer cells compared with groups treated with a single drug or other drug combinations. c-Jun N-terminal kinase/p38-mitogen-activated protein kinase-induced endoplasmic reticulum (ER) stress through serial exposure to celecoxib and bortezomib may have induced the intracellular Ca2+ release, leading to the generation of autophagosomes in p53-expressing HCT-116 cells. Targeted inhibition of p53 activity or ER stress or treatment with the Ca2+-chelating agent BAPTA-AM suppressed the ER stress-mediated Ca2+ release and apoptosis. Although p53(-/-) HCT-116 cells were less sensitive to sequential treatment with celecoxib and bortezomib, co-localization of autophagosomes was detected in the absence of CCAAT-enhancer-binding protein homologous protein expression. Treatment of p53(-/-) HCT-116 cells with BAPTA-AM did not inhibit apoptosis following serial treatment with celecoxib and bortezomib. These results suggest that the order of drug administration is important in treating cancer and that the sequential treatment with celecoxib and bortezomib enhances the ER stress-mediated autophagy-associated cell death of colon cancer cells, regardless of p53 expression.
C1 [Park, Ga-Bin] Kosin Univ, Coll Med, Dept Biochem, Busan 49267, South Korea.
   [Jin, Dong-Hoon] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Convergence, Seoul 05505, South Korea.
   [Jin, Dong-Hoon] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul 05505, South Korea.
   [Kim, Daejin] Inje Univ, Coll Med, Dept Anat, 75 Bokji St, Busan 47392, South Korea.
RP Kim, D (corresponding author), Inje Univ, Coll Med, Dept Anat, 75 Bokji St, Busan 47392, South Korea.
EM kimdj@inje.ac.kr
FU 2016 Inje University research grant [20170021]
FX The present study was supported by a 2016 Inje University research grant
   (grant no. 20170021).
CR Altorki NK, 2003, J CLIN ONCOL, V21, P2645, DOI 10.1200/JCO.2003.07.127
   Arico S, 2002, J BIOL CHEM, V277, P27613, DOI 10.1074/jbc.M201119200
   Boyce M, 2006, CELL DEATH DIFFER, V13, P363, DOI 10.1038/sj.cdd.4401817
   Cho HY, 2009, CANCER LETT, V282, P87, DOI 10.1016/j.canlet.2009.03.007
   Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002
   Deniaud A, 2008, ONCOGENE, V27, P285, DOI 10.1038/sj.onc.1210638
   Edagawa M, 2014, J BIOL CHEM, V289, P21544, DOI 10.1074/jbc.M114.558890
   Giorgi C, 2015, P NATL ACAD SCI USA, V112, P1779, DOI 10.1073/pnas.1410723112
   Huang SB, 2010, AUTOPHAGY, V6, P256, DOI 10.4161/auto.6.2.11124
   Kao C, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.468
   Kardosh A, 2008, CANCER RES, V68, P843, DOI 10.1158/0008-5472.CAN-07-5555
   Kim JE, 2014, ONCOL REP, V31, P2429, DOI 10.3892/or.2014.3082
   Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260
   Li JZ, 2006, J BIOL CHEM, V281, P7260, DOI 10.1074/jbc.M509868200
   Ludwig H, 2005, CANCER-AM CANCER SOC, V104, P1794, DOI 10.1002/cncr.21414
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   Lynch PM, 2010, AM J GASTROENTEROL, V105, P1437, DOI 10.1038/ajg.2009.758
   Masferrer JL, 2000, CANCER RES, V60, P1306
   Milani M, 2009, CANCER RES, V69, P4415, DOI 10.1158/0008-5472.CAN-08-2839
   Nawrocki ST, 2005, CANCER RES, V65, P11658, DOI 10.1158/0008-5472.CAN-05-2370
   Oakes SA, 2005, P NATL ACAD SCI USA, V102, P105, DOI 10.1073/pnas.0408352102
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Pinton P, 2011, CELL DEATH DIFFER, V18, P1450, DOI 10.1038/cdd.2011.31
   Sacchetti A, 2013, J CELL BIOCHEM, V114, P1434, DOI 10.1002/jcb.24485
   Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405
   Tsutsumi S, 2006, ONCOGENE, V25, P1018, DOI 10.1038/sj.onc.1209139
   Tsutsumi S, 2004, CELL DEATH DIFFER, V11, P1009, DOI 10.1038/sj.cdd.4401436
   Wu Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038402
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yu J, 2003, CANCER BIOL THER, V2, P694
NR 30
TC 8
Z9 8
U1 1
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD OCT
PY 2018
VL 16
IS 4
BP 4526
EP 4536
DI 10.3892/ol.2018.9233
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GU1BU
UT WOS:000444990700057
PM 30214587
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Zhan, Y
   Kong, SX
   Fan, L
   Jiang, J
AF Zhan, Yan
   Kong, Shuangxi
   Fan, Liang
   Jiang, Jun
TI Irigenin exhibits anticancer activity against human colon cancer cells
   via autophagy, inhibition of cell migration and invasion, and targeting
   of ERK/MAPK signal pathway
SO TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH
LA English
DT Article
DE Colon cancer; Isoflavonoids; Irigenin; Autophagy; Cell migration; Cell
   invasion
AB Purpose: To study the anticancer effect of naturally-occurring irigenin isoflavonoid on colon cancer, and to determine the mechanism involved.
   Methods: The effect of irigenin on viability of normal and cancerous colon cells was assessed by MTT assay, while clonogenic assay was used to measure colony generation. Autophagy was examined by transmission electron microscopy (TEM) and western blotting. Transwell chamber assay was used to determine the influence of irigenin isoflavonoid on cell migration and invasion. The expression levels of ERK/MAPK signal pathway-associated proteins were assayed using Western blotting.
   Results: Irigenin significantly decreased the viability of Caco-2 colon cancer cells, in contrast to normal CCD841 colon cells, and produced concentration-dependent anti-proliferative effects (p < 0.05). The number of cell colonies in control group decreased significantly (p < 0.05) upon exposure to irigenin. Results from TEM revealed that irigenin caused dose-dependent formation of autophagosomes, and dose-based up-regulation of the expressions of Beclin-1, LC3-I and LC3-II (p < 0.05). Moreover, irigenin markedly suppressed the migration and invasion of Coca-2 cells. Furthermore, irigenin exposure dose-dependently blocked the expressions of proteins associated with ERK/MAPK signal pathway in Coca-2 cells.
   Conclusion: These results indicate that irigenin exerts potent inhibitory effect on the growth and migration of colon cancer cells. Furthermore, irigenin induces autophagy, inhibits cell migration and invasion, and targets ERK/MAPK survival signal pathway. Therefore, irigenin may be a lead candidate drug for colon cancer treatment. However, there is need for further in vivo and clinical studies to validate these findings.
C1 [Zhan, Yan; Kong, Shuangxi; Fan, Liang; Jiang, Jun] Huazhong Univ Sci & Technol, Dept Oncol, Cent Hosp Wuhan, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China.
RP Jiang, J (corresponding author), Huazhong Univ Sci & Technol, Dept Oncol, Cent Hosp Wuhan, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China.
EM hardyjiangjun77730@yahoo.com
CR Afshari K, 2019, J CELL PHYSIOL, V234, P21519, DOI 10.1002/jcp.28777
   Birt DF, 2001, PHARMACOL THERAPEUT, V90, P157, DOI 10.1016/S0163-7258(01)00137-1
   Caraballo Alejandro, 2004, Rev. Soc. Bras. Med. Trop., V37, P186, DOI 10.1590/S0037-86822004000200016
   Dahanukar S. A., 2000, Indian Journal of Pharmacology, V32, pS81
   EMIM JAD, 1994, J PHARM PHARMACOL, V46, P118, DOI 10.1111/j.2042-7158.1994.tb03753.x
   Engstrom PF, 2009, J NATL COMPR CANC NE, V7, P778, DOI 10.6004/jnccn.2009.0056
   Garcia A, 2012, EUR J MED CHEM, V49, P1, DOI 10.1016/j.ejmech.2011.12.029
   Gonzalez MN, 2017, SKELET MUSCLE, V7, DOI 10.1186/s13395-017-0138-6
   Hampel H, 2018, SURG ONCOL CLIN N AM, V27, P319, DOI 10.1016/j.soc.2017.11.006
   Heo DN, 2020, INT J BIOL MACROMOL, V146, P922, DOI 10.1016/j.ijbiomac.2019.09.215
   Hutton SR, 2017, J NEUROSCI, V37, P8102, DOI 10.1523/JNEUROSCI.0473-17.2017
   Leow CC, 2004, CANCER RES, V64, P6050, DOI 10.1158/0008-5472.CAN-04-0290
   Li WY, 2018, J FUNCT FOODS, V45, P75, DOI 10.1016/j.jff.2018.03.024
   Patwardhan B, 2005, EVID-BASED COMPL ALT, V2, P465, DOI 10.1093/ecam/neh140
   Qin MJ, 2005, J INTEGR PLANT BIOL, V47, P1404, DOI 10.1111/j.1744-7909.2005.00142.x
   Tahtamouni L, 2019, ANAL CELL PATHOL, V2019, DOI 10.1155/2019/1356508
   Tan HD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01504
   Van Blarigan E, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.10006
   WON SW, 1993, PHYTOCHEMISTRY, V33, P939
   Xu Y, 2018, BIOCHEM BIOPH RES CO, V496, P998, DOI 10.1016/j.bbrc.2018.01.003
   Zhang L, 2016, J ETHNOPHARMACOL, V186, P1, DOI 10.1016/j.jep.2016.03.046
NR 21
TC 0
Z9 0
U1 6
U2 7
PU PHARMACOTHERAPY GROUP
PI BENIN CITY
PA UNIV BENIN, FACULTY PHARMACY, BENIN CITY, 00000, NIGERIA
SN 1596-5996
J9 TROP J PHARM RES
JI Trop. J. Pharm. Res.
PD JUL
PY 2021
VL 20
IS 7
BP 1357
EP 1363
DI 10.4314/tjpr.v20i7.6
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA TS0VN
UT WOS:000679375500006
OA gold
DA 2022-04-25
ER

PT J
AU Sundarraj, K
   Raghunath, A
   Perumal, E
AF Sundarraj, Kiruthika
   Raghunath, Azhwar
   Perumal, Ekambaram
TI A review on the chemotherapeutic potential of fisetin: In vitro
   evidences
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Review
DE Apoptosis; Autophagic cell death; Cancer; Chemotherapeutic agent;
   Combination therapy; Fisetin
ID DIETARY FLAVONOID FISETIN; CELL-CYCLE ARREST; COLON-CANCER CELLS;
   PROSTATE-CANCER; INDUCED APOPTOSIS; BREAST-CANCER; LUNG-CANCER;
   MESENCHYMAL TRANSITION; PI3K/AKT/MTOR PATHWAY; INDUCED CYTOTOXICITY
AB During the past five decades, cancer cell lines are being successfully used as an in vitro model to discover the anticancer potential of plant secondary metabolites. Fisetin-the most popular polyphenol from fruits and vegetables, exhibits a repertoire of promising pharmacological features. Such versatile properties make fisetin an excellent anticancer agent and its efficacy as a chemotherapeutic agent against tumor heterogeneity from in vitro studies are encouraging. Fisetin is like a Pandora's box, as more research studies are being carried out, it reveals its new molecules within the cancer cells as therapeutic targets. These molecular targets orchestrate processes such as apoptosis, autophagic cell death, cell cycle, invasion, metastasis and angiogenesis in cancer cells. Besides apoptotic elicitation, fisetin's ability to induce autophagic cell death in cancer cells has been reported. This review examines the various molecular mechanisms of action elicited by fisetin leading to apoptosis and autophagic cell death as evidenced from cancer cell lines. In addition, the increased bioavailability and sustained release of fisetin improved through conjugation and enhanced effect of fisetin through synergism on various cancers are also highlighted.
C1 [Sundarraj, Kiruthika; Raghunath, Azhwar; Perumal, Ekambaram] Bharathiar Univ, Dept Biotechnol, Mol Toxicol Lab, Coimbatore 641046, Tamil Nadu, India.
RP Perumal, E (corresponding author), Bharathiar Univ, Dept Biotechnol, Mol Toxicol Lab, Coimbatore 641046, Tamil Nadu, India.
EM ekas2009@buc.edu.in
RI Perumal, Ekambaram/R-9319-2018; Raghunath, Azhwar/E-2720-2012;
   Sundarraj, Kiruthika/AAL-5777-2020
OI Raghunath, Azhwar/0000-0001-5217-0341; Sundarraj,
   Kiruthika/0000-0003-4068-4534; Perumal, Ekambaram/0000-0003-2159-8198
FU Department of Science and Technology, Science and Engineering Research
   Board, New Delhi, under the scheme Empowerment and Equity Opportunities
   for Excellence in ScienceDepartment of Science & Technology
   (India)Department of Science & Technology (DOST), Philippines
   [SB/EMEQ-246/2014]; University Grants Commission - Basic Scientific
   Research Senior Research Fellowship (UGC-BSR-SRF) - UGC-BSR, New Delhi,
   India [F.7-25/2007]; UGC-SAP DRS, New Delhi, India [II:F-3-30/2013];
   UGC-SAP DST, New Delhi, India [FIST:SR/FST/LSI-618/2014]
FX This work was supported by the Department of Science and Technology,
   Science and Engineering Research Board, New Delhi, under the scheme
   Empowerment and Equity Opportunities for Excellence in Science
   (SB/EMEQ-246/2014). Azhwar Raghunath is the recipient of a University
   Grants Commission - Basic Scientific Research Senior Research Fellowship
   (UGC-BSR-SRF - No. F.7-25/2007) funded by UGC-BSR, New Delhi, India. The
   authors also thank the UGC-SAP DRS II:F-3-30/2013 and DST
   FIST:SR/FST/LSI-618/2014, New Delhi, India for their partial financial
   assistance.
CR Adan A, 2015, TUMOR BIOL, V36, P8973, DOI 10.1007/s13277-015-3597-6
   Adhami VM, 2012, BIOCHEM PHARMACOL, V84, P1277, DOI 10.1016/j.bcp.2012.07.012
   Amaravadi RK, 2007, CLIN CANCER RES, V13, P7271, DOI 10.1158/1078-0432.CCR-07-1595
   Arai Y, 2000, J NUTR, V130, P2243
   Bandele OJ, 2007, BIOCHEMISTRY-US, V46, P6097, DOI 10.1021/bi7000664
   Becker MS, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.528
   Bhat TA, 2012, CARCINOGENESIS, V33, P385, DOI 10.1093/carcin/bgr282
   Bohl M, 2007, BIOPHYS J, V93, P2767, DOI 10.1529/biophysj.107.107813
   Bothiraja C, 2014, EXPERT OPIN DRUG DEL, V11, P17, DOI 10.1517/17425247.2013.860131
   Chen YC, 2002, ARCH TOXICOL, V76, P351, DOI 10.1007/s00204-002-0346-6
   Chen YS, 2015, ACS APPL MATER INTER, V7, P534, DOI 10.1021/am5066893
   Chien CS, 2010, MOL CELL BIOCHEM, V333, P169, DOI 10.1007/s11010-009-0217-z
   Chou RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071983
   De Sousa RRR, 2007, J ENZYM INHIB MED CH, V22, P439, DOI 10.1080/14756360601162063
   Ghayad SE, 2010, RECENT PAT ANTI-CANC, V5, P29, DOI 10.2174/157489210789702208
   Gupta S, 2001, BIOCHEM BIOPH RES CO, V287, P914, DOI 10.1006/bbrc.2001.5672
   Haddad AQ, 2010, NUTR CANCER, V62, P668, DOI 10.1080/01635581003605524
   Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704
   Huang WY, 2010, NUTR CANCER, V62, P1, DOI 10.1080/01635580903191585
   Hudis CA, 2011, ONCOLOGIST, V16, P1, DOI 10.1634/theoncologist.2011-S1-01
   Jang KY, 2012, CANCER LETT, V319, P197, DOI 10.1016/j.canlet.2012.01.008
   Jeong D, 2013, CARBOHYD POLYM, V97, P196, DOI 10.1016/j.carbpol.2013.04.066
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kadari A, 2017, DRUG DELIV, V24, P224, DOI 10.1080/10717544.2016.1245366
   Kang KA, 2016, TUMOR BIOL, V37, P9615, DOI 10.1007/s13277-016-4864-x
   Kang KA, 2015, IN VITRO CELL DEV-AN, V51, P300, DOI 10.1007/s11626-014-9830-6
   Khan MI, 2014, ONCOTARGET, V5, P2462, DOI 10.18632/oncotarget.1790
   Khan N, 2008, CANCER RES, V68, P8555, DOI 10.1158/0008-5472.CAN-08-0240
   Khan N, 2008, CARCINOGENESIS, V29, P1049, DOI 10.1093/carcin/bgn078
   Khan N, 2012, INT J CANCER, V130, P1695, DOI 10.1002/ijc.26178
   Kim JA, 2015, CARCINOGENESIS, V36, P696, DOI 10.1093/carcin/bgv045
   Kim JY, 2010, FOOD CHEM TOXICOL, V48, P2259, DOI 10.1016/j.fct.2010.05.058
   Kimira M, 1998, J Epidemiol, V8, P168
   Klimaszewska-Wisniewska A, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0288-3
   Lall RK, 2016, MOL NUTR FOOD RES, V60, P1396, DOI 10.1002/mnfr.201600025
   LAUGHTON MJ, 1991, BIOCHEM PHARMACOL, V42, P1673, DOI 10.1016/0006-2952(91)90501-U
   Lee WR, 2002, BIOCHEM PHARMACOL, V63, P225, DOI 10.1016/S0006-2952(01)00876-0
   Li JM, 2015, BANGL J PHARMACOL, V10, P820, DOI 10.3329/bjp.v10i4.23039
   Li J, 2011, BASIC CLIN PHARMACOL, V108, P84, DOI 10.1111/j.1742-7843.2010.00613.x
   Li R, 2014, MOL MED REP, V9, P413, DOI 10.3892/mmr.2013.1836
   Liao YC, 2009, J AGR FOOD CHEM, V57, P8933, DOI 10.1021/jf902630w
   Lim DY, 2009, AM J PHYSIOL-GASTR L, V296, pG1060, DOI 10.1152/ajpgi.90490.2008
   Liu XF, 2017, ONCOL REP, V38, P53, DOI 10.3892/or.2017.5676
   LoPiccolo J, 2008, DRUG RESIST UPDATE, V11, P32, DOI 10.1016/j.drup.2007.11.003
   Lu XH, 2005, J NUTR, V135, P2884, DOI 10.1093/jn/135.12.2884
   MACGREGOR JT, 1978, MUTAT RES, V54, P297, DOI 10.1016/0165-1161(78)90020-1
   Maher P, 2006, P NATL ACAD SCI USA, V103, P16568, DOI 10.1073/pnas.0607822103
   Markovic ZS, 2009, J PHYS CHEM A, V113, P14170, DOI 10.1021/jp907071v
   Memmott RM, 2009, CELL SIGNAL, V21, P656, DOI 10.1016/j.cellsig.2009.01.004
   Min KJ, 2017, MOLECULES, V22, DOI 10.3390/molecules22081285
   Mohammad RM, 2006, CANCER-AM CANCER SOC, V106, P1260, DOI 10.1002/cncr.21731
   Monasterio A, 2004, NUTR CANCER, V50, P90, DOI 10.1207/s15327914nc5001_12
   Morley KL, 2007, CANCER LETT, V251, P168, DOI 10.1016/j.canlet.2006.11.016
   Mukhtar E, 2016, MOL CANCER THER, V15, P2863, DOI 10.1158/1535-7163.MCT-16-0515
   Mukhtar E, 2015, CANCER LETT, V367, P173, DOI 10.1016/j.canlet.2015.07.030
   Murtaza I, 2009, INT J CANCER, V125, P2465, DOI 10.1002/ijc.24628
   MYARA I, 1993, J PHARMACOL TOXICOL, V30, P69, DOI 10.1016/1056-8719(93)90009-4
   Pal HC, 2013, EXP DERMATOL, V22, P470, DOI 10.1111/exd.12181
   Pal HC, 2015, ONCOTARGET, V6, P28296, DOI 10.18632/oncotarget.5064
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Ramalingam Srinivasan, 2016, Free Radicals and Antioxidants, V6, P145, DOI 10.5530/fra.2016.2.3
   Sabarwal A, 2017, MOL CARCINOGEN, V56, P499, DOI 10.1002/mc.22512
   Salmela AL, 2009, CARCINOGENESIS, V30, P1032, DOI 10.1093/carcin/bgp101
   Seguin J, 2013, INT J PHARMACEUT, V444, P146, DOI 10.1016/j.ijpharm.2013.01.050
   Sengupta B, 2004, FEBS LETT, V570, P77, DOI 10.1016/j.febslet.2004.06.027
   Shi B, 2017, INT J ONCOL, V50, P2123, DOI 10.3892/ijo.2017.3970
   Smith ML, 2016, J CELL BIOCHEM, V117, P1913, DOI 10.1002/jcb.25490
   Stuckey DW, 2013, TRENDS MOL MED, V19, P685, DOI 10.1016/j.molmed.2013.08.007
   Su CH, 2017, ENVIRON TOXICOL, V32, P1725, DOI 10.1002/tox.22396
   Suh Y, 2010, CARCINOGENESIS, V31, P1424, DOI 10.1093/carcin/bgq115
   Suh Y, 2009, CARCINOGENESIS, V30, P300, DOI 10.1093/carcin/bgn269
   SUN Y, 1990, FREE RADICAL BIO MED, V8, P583, DOI 10.1016/0891-5849(90)90156-D
   Syed DN, 2008, CANCER LETT, V265, P167, DOI 10.1016/j.canlet.2008.02.050
   Syed DN, 2014, ARCH BIOCHEM BIOPHYS, V563, P108, DOI 10.1016/j.abb.2014.06.034
   Syed DN, 2011, J INVEST DERMATOL, V131, P1291, DOI 10.1038/jid.2011.6
   Szliszka E, 2011, INT J ONCOL, V39, P771, DOI 10.3892/ijo.2011.1116
   TORDERA M, 1994, Z NATURFORSCH C, V49, P235
   Touil YS, 2011, CANCER CHEMOTH PHARM, V68, P445, DOI 10.1007/s00280-010-1505-8
   Tripathi R, 2011, MOL CANCER THER, V10, P255, DOI 10.1158/1535-7163.MCT-10-0606
   Vinas P, 2011, J CHROMATOGR A, V1218, P639, DOI 10.1016/j.chroma.2010.12.026
   Wu MS, 2014, MOL CARCINOGEN, V53, pE119, DOI 10.1002/mc.22053
   Wu MS, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/987612
   Yang PM, 2012, INT J ONCOL, V40, P469, DOI 10.3892/ijo.2011.1203
   Yang Q, 2014, J BIOMED NANOTECHNOL, V10, P580, DOI 10.1166/jbn.2014.1746
   Yi CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099943
   Ying TH, 2012, ARCH TOXICOL, V86, P263, DOI 10.1007/s00204-011-0754-6
   Youns M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169335
   Yu SH, 2011, CANCER LETT, V300, P96, DOI 10.1016/j.canlet.2010.09.015
   Zhang L, 2016, AM J TRANSL RES, V8, P4857
   Zhang L, 2011, J AGR FOOD CHEM, V59, P12361, DOI 10.1021/jf203146e
   Zhang XJ, 2016, BIOMED PHARMACOTHER, V83, P1164, DOI 10.1016/j.biopha.2016.08.035
   Zhao XP, 2012, FOOD CHEM TOXICOL, V50, P3166, DOI 10.1016/j.fct.2012.05.039
   Zhu XJ, 2004, BIOCHEM BIOPH RES CO, V321, P623, DOI 10.1016/j.bbrc.2004.05.229
   Zhuo WL, 2015, AM J TRANSL RES, V7, P2045
NR 94
TC 39
Z9 40
U1 4
U2 33
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD JAN
PY 2018
VL 97
BP 928
EP 940
DI 10.1016/j.biopha.2017.10.164
PG 13
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA FR4NC
UT WOS:000419041300112
PM 29136771
DA 2022-04-25
ER

PT J
AU Choi, JH
   Yoon, JS
   Won, YW
   Park, BB
   Lee, YY
AF Choi, Jung-Hye
   Yoon, Jin Sun
   Won, Young-Woong
   Park, Byeong-Bae
   Lee, Young Yiul
TI Chloroquine enhances the chemotherapeutic activity of 5-fluorouracil in
   a colon cancer cell line via cell cycle alteration
SO APMIS
LA English
DT Article
DE Chloroquine; colon cancer; autophagy; 5-fluorouracil; cell cycle
ID AUTOPHAGY; P53; EXPRESSION; THERAPY; BIOLOGY; ASSAY
AB Autophagy is a conserved catabolic process that degrades cytoplasmic proteins and organelles for recycling. The role of autophagy in tumorigenesis is controversial because autophagy can be either protective or damaging to tumor cells, and its effects may change during tumor progression. A number of cancer cell lines have been exposed to chloroquine, an anti-malarial drug, with the aim of inhibiting cell growth and inducing cell death. In addition, chloroquine inhibits a late phase of autophagy. This study was conducted to investigate the anti-cancer effect of autophagy inhibition, using chloroquine together with 5-fluorouracil (5-FU) in a colon cancer cell line. Human colon cancer DLD-1 cells were treated with 5-FU (10 mu) or chloroquine (100 mu), or a combination of both. Autophagy was evaluated by western blot analysis of microtubule-associated protein light chain3 (LC3). Proliferative activity, alterations of the cell cycle, and apoptosis were measured by MTT assays, flow cytometry, and western blotting. LC3-II protein increased after treatment with 5-FU, and chloroquine potentiated the cytotoxicity of 5-FU. MTT assays showed that 5-FU inhibited proliferation of the DLD-1 cells and that chloroquine enhanced this inhibitory effect of 5-FU. The combination of 5-FU and chloroquine induced G1 arrest, up-regulation of p27 and p53, and down-regulation of CDK2 and cyclin D1. These results suggest that chloroquine may potentiate the anti-cancer effect of 5-FU via cell cycle inhibition. Chloroquine potentiates the anti-cancer effect of 5-FU in colon cancer cells. Supplementation of conventional chemotherapy with chloroquine may provide a new cancer therapy modality.
C1 [Choi, Jung-Hye; Won, Young-Woong; Park, Byeong-Bae; Lee, Young Yiul] Hanyang Univ, Coll Med, Dept Internal Med, Seoul 133792, South Korea.
   [Yoon, Jin Sun; Lee, Young Yiul] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea.
RP Lee, YY (corresponding author), Hanyang Univ, Coll Med, Dept Internal Med, 222 Wangsimni Ro Seongdong Gu, Seoul 133792, South Korea.
EM leeyy@hanyang.ac.kr
RI Park, Byeong-Bae/D-2137-2015; Park, Byeong Bae/P-4827-2015; Won,
   Young-Woong/C-9794-2015
OI Won, Young-Woong/0000-0001-6209-8339
FU research fund of Hanyang University [HY-2009-MC]
FX This work was supported by the research fund of Hanyang University
   (HY-2009-MC).
CR Aizu W, 2006, BIOCHEM PHARMACOL, V72, P981, DOI 10.1016/j.bcp.2006.07.009
   CAMPLING BG, 1988, LEUKEMIA RES, V12, P823, DOI 10.1016/0145-2126(88)90036-7
   Endo S, 2011, CANCER SCI, V102, P605, DOI 10.1111/j.1349-7006.2010.01821.x
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Ju J, 2007, CLIN CANCER RES, V13, P4245, DOI 10.1158/1078-0432.CCR-06-2890
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Loehberg CR, 2007, CANCER RES, V67, P12026, DOI 10.1158/0008-5472.CAN-07-3058
   Meric-Bernstam F, 2009, J CLIN ONCOL, V27, P2278, DOI 10.1200/JCO.2008.20.0766
   Pistollato F, 2010, BIOCHEM PHARMACOL, V80, P1517, DOI 10.1016/j.bcp.2010.08.003
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Solomon VR, 2009, EUR J PHARMACOL, V625, P220, DOI 10.1016/j.ejphar.2009.06.063
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
NR 20
TC 34
Z9 39
U1 1
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0903-4641
J9 APMIS
JI APMIS
PD JUL
PY 2012
VL 120
IS 7
BP 597
EP 604
DI 10.1111/j.1600-0463.2012.02876.x
PG 8
WC Immunology; Microbiology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Microbiology; Pathology
GA 961ZA
UT WOS:000305507000009
PM 22716215
OA Bronze
DA 2022-04-25
ER

PT J
AU Trivedi, PP
   Jena, GB
   Tikoo, KB
   Kumar, V
AF Trivedi, P. P.
   Jena, G. B.
   Tikoo, K. B.
   Kumar, V.
TI Melatonin modulated autophagy and Nrf2 signaling pathways in mice with
   colitis-associated colon carcinogenesis
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE colitis-associated colon carcinogenesis; autophagy; Nrf2; inflammation;
   oxidative stress; melatonin
ID NF-KAPPA-B; ERYTHROID 2-RELATED FACTOR-2; INDUCED ULCERATIVE-COLITIS;
   UNPHOSPHORYLATED STAT3; OXIDATIVE STRESS; COLORECTAL-CANCER; RAT;
   INHIBITION; 1,2-DIMETHYLHYDRAZINE; TRANSCRIPTION
AB Colon carcinogenesis is long known to be associated with ulcerative colitis (UC), a chronic gastrointestinal disorder. Various pre-clinical and clinical studies have shown that melatonin (MEL) has beneficial effects in cancer. However, elucidation of the detailed molecular mechanisms involved in MEL-mediated protection against the colon carcinogenesis deserves further investigation. The present study was aimed at deciphering the effect of MEL on autophagy and Nrf2 signaling pathways in a mouse model of colitis-associated colon carcinogenesis (CACC). For the induction of CACC, male Swiss Albino mice were administered a single ip injection of 20mg 1, 2-dimethylhydrazine dihydrochloride (DMH)/kg bw, followed by 3 cycles of 3% w/v dextran sulfate sodium (DSS) in drinking water treatment initiated 1wk after DMH injection. One week after the initiation of DSS treatment, MEL was administered at the dose of 1mg/kg, bw, po for 8 and 18 wk. Mice were sacrificed at 10 and 20wk after DMH injection. MEL treatment decreased the progression of CACC by down regulating the process of autophagy as revealed by the expression pattern of various autophagy markers such as Beclin-1, LC3B-II/LC3B-I ratio and p62. These findings were accompanied with the increased expression of Nrf2 and the associated antioxidant enzymes, NAD(P)H:quinone oxidoreductase (NQO-1) and heme oxygenase-1 (HO-1) in the colon of mice with CACC. MEL intervention reduced autophagy by ameliorating inflammation and oxidative stress in the colon of mice with CACC. We conclude that MEL treatment attenuates the progression of CACC in mice by modulating autophagy and Nrf2 signaling pathways. (c) 2015 Wiley Periodicals, Inc.
C1 [Trivedi, P. P.; Jena, G. B.] Natl Inst Pharmaceut Educ & Res, Dept Pharmacol & Toxicol, Facil Risk Assessment & Intervent Studies, Mohali, Punjab, India.
   [Tikoo, K. B.] Natl Inst Pharmaceut Educ & Res, Dept Pharmacol & Toxicol, Lab Chromatin Biol, Mohali, Punjab, India.
   [Kumar, V.] Icon Analyt Equipment Pvt Ltd, Delhi, India.
RP Jena, GB (corresponding author), Natl Inst Pharmaceut Educ & Res, Dept Pharmacol & Toxicol, Sect 67, Sas Nagar 160062, Punjab, India.
OI Tikoo, Kulbhushan/0000-0003-3061-9739
FU National Institute of Pharmaceutical Education and Research (NIPER),
   Mohali
FX We wish to acknowledge the financial assistance received from the
   National Institute of Pharmaceutical Education and Research (NIPER),
   Mohali to undertake the present study.
CR Anisimov VN, 2000, EXP TOXICOL PATHOL, V52, P71, DOI 10.1016/S0940-2993(00)80022-6
   Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI 10.1089/ARS.2008.2270
   BIRD RP, 1987, CANCER LETT, V37, P147, DOI 10.1016/0304-3835(87)90157-1
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Bonnefont-Rousselot D, 2011, J PINEAL RES, V50, P328, DOI 10.1111/j.1600-079X.2010.00847.x
   Bubenik GA, 2002, DIGEST DIS SCI, V47, P2336, DOI 10.1023/A:1020107915919
   Chang CF, 2012, J PINEAL RES, V52, P312, DOI 10.1111/j.1600-079X.2011.00945.x
   Chuang JI, 1996, CELL BIOL INT, V20, P687, DOI 10.1006/cbir.1996.0091
   Coto-Montes A, 2006, AUTOPHAGY, V2, P126, DOI 10.4161/auto.2.2.2351
   Crespo I, 2010, J PINEAL RES, V49, P193, DOI 10.1111/j.1600-079X.2010.00787.x
   DE DUVE CHRISTIAN, 1963, SCI AMER, V208, P64
   De Filippis D, 2008, J PINEAL RES, V44, P45, DOI 10.1111/j.1600-079X.2007.00526.x
   de Luxan-Delgado B, 2013, J PINEAL RE IN PRESS
   Dong WG, 2003, WORLD J GASTROENTERO, V9, P1307, DOI 10.3748/wjg.v9.i6.1307
   Esrefoglu M, 2006, J PINEAL RES, V40, P92, DOI 10.1111/j.1600-079X.2005.00288.x
   Galano A, 2011, J PINEAL RES, V51, P1, DOI 10.1111/j.1600-079X.2011.00916.x
   Garcia-Navarro A, 2007, J PINEAL RES, V43, P195, DOI 10.1111/j.1600-079X.2007.00463.x
   Gitto E, 2001, J PHARM PHARMACOL, V53, P1393, DOI 10.1211/0022357011777747
   Izuishi K, 2000, CANCER RES, V60, P6201
   Javanmard SH, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/676829
   Jena G, 2014, INFLAMM BOWEL DIS, V20, P553, DOI 10.1097/01.MIB.0000436962.32164.6e
   Jess T, 2012, CLIN GASTROENTEROL H, V10, P639, DOI 10.1016/j.cgh.2012.01.010
   Jung KH, 2010, J PINEAL RES, V48, P239, DOI 10.1111/j.1600-079X.2010.00748.x
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kang JW, 2014, CELL PHYSIOL BIOCHEM, V33, P23, DOI 10.1159/000356647
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   Leon J, 2014, J PINEAL RES, V56, P415, DOI 10.1111/jpi.12131
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Lin NY, 2013, AUTOPHAGY, V9, P1253, DOI 10.4161/auto.25467
   Lu HT, 2006, MOL CANCER RES, V4, P221, DOI 10.1158/1541-7786.MCR-05-0261
   Marchetti C, 2011, J PINEAL RES, V51, P286, DOI 10.1111/j.1600-079X.2011.00889.x
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Moore MN, 2007, AQUAT TOXICOL, V84, P80, DOI 10.1016/j.aquatox.2007.06.007
   MORON MS, 1979, BIOCHIM BIOPHYS ACTA, V582, P67, DOI 10.1016/0304-4165(79)90289-7
   Nopparat C, 2010, J PINEAL RES, V49, P382, DOI 10.1111/j.1600-079X.2010.00805.x
   OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Pattingre S, 2008, BIOCHIMIE, V90, P313, DOI 10.1016/j.biochi.2007.08.014
   Saleh M, 2011, NAT REV IMMUNOL, V11, P9, DOI 10.1038/nri2891
   San-Miguel B, 2014, J PINEAL RES, V56, P313, DOI 10.1111/jpi.12124
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Tan Dun-Xian, 2002, Current Topics in Medicinal Chemistry, V2, P181, DOI 10.2174/1568026023394443
   Tanaka T, 2009, CHEM-BIOL INTERACT, V177, P128, DOI 10.1016/j.cbi.2008.10.047
   Timofeeva OA, 2012, J BIOL CHEM, V287, P14192, DOI 10.1074/jbc.M111.323899
   TOTH B, 1976, AM J PATHOL, V84, P69
   Tripathi DN, 2010, J PINEAL RES, V48, P324, DOI 10.1111/j.1600-079X.2010.00756.x
   Trivedi PP, 2013, DIGEST DIS SCI, V58, P3460, DOI 10.1007/s10620-013-2831-6
   Trivedi PP, 2013, FOOD CHEM TOXICOL, V59, P339, DOI 10.1016/j.fct.2013.06.019
   Trivedi PP, 2012, MUTAT RES-GEN TOX EN, V744, P172, DOI 10.1016/j.mrgentox.2012.03.001
   Wang Z, 2012, J PINEAL RES, V53, P129, DOI 10.1111/j.1600-079X.2012.00978.x
   Wu HH, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-19
   Yang J, 2005, CANCER RES, V65, P939
   Yang JB, 2007, GENE DEV, V21, P1396, DOI 10.1101/gad.1553707
   Yoo YM, 2010, J PINEAL RES, V48, P204, DOI 10.1111/j.1600-079X.2010.00744.x
   Zeng M, 2013, BIOCHEM BIOPH RES CO, V436, P180, DOI 10.1016/j.bbrc.2013.05.070
   Zhang HY, 2009, TOXICOL SCI, V110, P376, DOI 10.1093/toxsci/kfp101
   Zheng YQ, 2014, J PHARMACOL SCI, V124, P354, DOI 10.1254/jphs.13220FP
   Zhou HY, 2012, J PINEAL RES, V52, P120, DOI 10.1111/j.1600-079X.2011.00926.x
   Zoghbi S, 2007, INT J ONCOL, V30, P489
NR 60
TC 65
Z9 67
U1 0
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
EI 1098-2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD MAR
PY 2016
VL 55
IS 3
BP 255
EP 267
DI 10.1002/mc.22274
PG 13
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA DD2BN
UT WOS:000369727500003
PM 25598500
DA 2022-04-25
ER

PT J
AU Motilva, V
   Garcia-Maurino, S
   Talero, E
   Illanes, M
AF Motilva, Virginia
   Garcia-Maurino, Sofia
   Talero, Elena
   Illanes, Matilde
TI New paradigms in chronic intestinal inflammation and colon cancer: role
   of melatonin
SO JOURNAL OF PINEAL RESEARCH
LA English
DT Review
DE autophagy; chronic inflammation; colitis; colon cancer; inflammatory
   bowel disease; melatonin; sirtuins
ID NF-KAPPA-B; ACID-INDUCED COLITIS; RESVERATROL SUPPRESSES COLITIS;
   CERULEIN-INDUCED PANCREATITIS; ENDOPLASMIC-RETICULUM STRESS; MURINE
   SENESCENCE MODEL; GENOME-WIDE ASSOCIATION; CLOCK GENE-EXPRESSION;
   TNBS-INDUCED COLITIS; BOWEL-DISEASE
AB In intestinal bowel disease (IBD), immune-mediated conditions exert their effects through various cells and proinflammatory mediators. Recent data support a participation of the endoplasmic reticulum stress and mitochondrial dysfunctions in IBD. Moreover, it is evident that chronic degenerative pathologies, including IBD, share comparable disease mechanisms with alteration in the autophagy mechanisms. Chronic inflammation in IBD exposes these patients to a number of signals known to have tumorigenic effects. This circuitry of inflammation and cancer modifies apoptosis and autophagy, and promotes cellular cycle progression, invasion, and angiogenesis. Melatonin has been shown as a specific antioxidant reducing oxidative damage in both lipid and aqueous cell environments. However, several studies provide further insight into the molecular mechanisms of melatonin action in the colon. In this line, recent data suggest that melatonin modulates autophagy and sirtuin activity. An anti-autophagic property of melatonin has been demonstrated, and it could contribute to its anti-oncogenic activity. Nevertheless, there is no information about whether antitumoral effects of melatonin on colon cancer are dependent on autophagy. Sirtuins have pleiotropic effects on cancer development, being reported both as facilitator and as suppressor of colon cancer development. Sirtuins and melatonin are connected through the circadian clock machinery, and melatonin seems able to correct the alterations in sirtuin activity associated with several pathological conditions. Autophagy and sirtuin activities are linked through 5'AMP-activated protein kinase (AMPK) activation, which switches on autophagy and increases sirtuin. The effect of melatonin on AMPK and the impact of this effect on IBD and colon cancer remain an open question.
C1 [Motilva, Virginia] Univ Seville, Dept Pharmacol, Sch Pharm, E-41012 Seville, Spain.
   [Garcia-Maurino, Sofia] Univ Seville, Dept Vegetal Physiol & Ecol, E-41012 Seville, Spain.
   [Illanes, Matilde] Univ Seville, Dept Pathol Anat, E-41012 Seville, Spain.
RP Motilva, V (corresponding author), Univ Seville, Dept Pharmacol, Sch Pharm, C Prof Garcia Gonzalez 2, E-41012 Seville, Spain.
EM motilva@us.es
RI García-Mauriño, Sofía/E-6707-2010; Talero, Elena/I-2613-2015
OI García-Mauriño, Sofía/0000-0002-7698-5112; Motilva Sanchez,
   Virginia/0000-0001-5674-6969; Talero Barrientos/0000-0001-9955-801X
CR Abreu Maria T, 2002, Curr Gastroenterol Rep, V4, P481, DOI 10.1007/s11894-002-0024-0
   Aggarwal BB, 2006, BIOCHEM PHARMACOL, V72, P1605, DOI 10.1016/j.bcp.2006.06.029
   Anisimov VN, 1997, CARCINOGENESIS, V18, P1549, DOI 10.1093/carcin/18.8.1549
   Anisimov VN, 2000, EXP TOXICOL PATHOL, V52, P71, DOI 10.1016/S0940-2993(00)80022-6
   Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI 10.1089/ARS.2008.2270
   Back SH, 2006, J BIOL CHEM, V281, P18691, DOI 10.1074/jbc.M602030200
   Balaburski GM, 2010, TRENDS CELL BIOL, V20, P363, DOI 10.1016/j.tcb.2010.02.007
   BANG J, 2010, RHEUMATOL INT
   BARLOWWALDEN LR, 1995, NEUROCHEM INT, V26, P497, DOI 10.1016/0197-0186(94)00154-M
   Bartsch C, 1999, ADV EXP MED BIOL, V467, P247
   Bassaganya-Riera J, 2004, GASTROENTEROLOGY, V127, P777, DOI 10.1053/j.gastro.2004.06.049
   Bassaganya-Riera J, 2006, CLIN NUTR, V25, P454, DOI 10.1016/j.clnu.2005.12.008
   Bassaganya-Riera J, 2010, CURR OPIN CLIN NUTR, V13, P569, DOI 10.1097/MCO.0b013e32833b648e
   Bauvy C, 2001, EXP CELL RES, V268, P139, DOI 10.1006/excr.2001.5285
   Bharti AC, 2002, ANN NY ACAD SCI, V973, P392, DOI 10.1111/j.1749-6632.2002.tb04671.x
   Bird RP, 2000, TOXICOL LETT, V112, P395, DOI 10.1016/S0378-4274(99)00261-1
   Bonnefont-Rousselot D, 2010, TOXICOLOGY, V278, P55, DOI 10.1016/j.tox.2010.04.008
   Brant SR, 2004, INFLAMM BOWEL DIS, V10, P300, DOI 10.1097/00054725-200405000-00019
   Bubenik GA, 2008, J PHYSIOL PHARMACOL, V59, P33
   Caballero B, 2009, MECH AGEING DEV, V130, P722, DOI 10.1016/j.mad.2009.09.001
   Cabrera J, 2010, J PINEAL RES, V49, P45, DOI 10.1111/j.1600-079X.2010.00765.x
   Calvo JR, 2002, J PINEAL RES, V32, P277
   Campisi J, 2009, AGING CELL, V8, P221, DOI 10.1111/j.1474-9726.2009.00475.x
   Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813
   Cario E, 2008, CURR OPIN GASTROEN, V24, P725, DOI 10.1097/MOG.0b013e32830c4341
   Carrillo-Vico A, 2005, ENDOCRINE, V27, P189, DOI 10.1385/ENDO:27:2:189
   Chang HM, 2009, J PINEAL RES, V47, P211, DOI 10.1111/j.1600-079X.2009.00704.x
   Chapkin RS, 2007, J NUTR, V137, p200S, DOI 10.1093/jn/137.1.200S
   Chuang JI, 1996, CELL BIOL INT, V20, P687, DOI 10.1006/cbir.1996.0091
   Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635
   Cooney R, 2010, NAT MED, V16, P90, DOI 10.1038/nm.2069
   Cooper HS, 2000, CARCINOGENESIS, V21, P757, DOI 10.1093/carcin/21.4.757
   Coto-Montes A, 2006, AUTOPHAGY, V2, P126, DOI 10.4161/auto.2.2.2351
   Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002
   Cui XL, 2010, CANCER PREV RES, V3, P549, DOI 10.1158/1940-6207.CAPR-09-0117
   Cuzzocrea S, 1998, EUR J PHARMACOL, V342, P67, DOI 10.1016/S0014-2999(97)01417-9
   Cuzzocrea S, 2001, J PINEAL RES, V30, P1, DOI 10.1034/j.1600-079X.2001.300101.x
   Das A, 2010, J PINEAL RES, V48, P157, DOI 10.1111/j.1600-079X.2009.00739.x
   Dominguez-Rodriguez A, 2010, J PINEAL RES, V49, P14, DOI 10.1111/j.1600-079X.2010.00773.x
   Dominy JE, 2010, BBA-PROTEINS PROTEOM, V1804, P1676, DOI 10.1016/j.bbapap.2009.11.023
   Dong WG, 2003, WORLD J GASTROENTERO, V9, P1307, DOI 10.3748/wjg.v9.i6.1307
   Erren TC, 2008, NEUROENDOCRINOL LETT, V29, P815
   Esposito E, 2008, J PINEAL RES, V45, P166, DOI 10.1111/j.1600-079X.2008.00572.x
   Esrefoglu M, 2006, J PINEAL RES, V40, P92, DOI 10.1111/j.1600-079X.2005.00288.x
   Farriol M, 2000, J APPL TOXICOL, V20, P21, DOI 10.1002/(SICI)1099-1263(200001/02)20:1<21::AID-JAT623>3.0.CO;2-M
   Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020
   Ford J, 2005, CANCER RES, V65, P10457, DOI 10.1158/0008-5472.CAN-05-1923
   Fritz JH, 2005, EUR J IMMUNOL, V35, P2459, DOI 10.1002/eji.200526286
   Fukata M, 2006, GASTROENTEROLOGY, V131, P862, DOI 10.1053/j.gastro.2006.06.017
   Ganguly K, 2010, J PINEAL RES, V49, P130, DOI 10.1111/j.1600-079X.2010.00776.x
   Garcia-Navarro A, 2007, J PINEAL RES, V43, P195, DOI 10.1111/j.1600-079X.2007.00463.x
   Garcia-Santos G, 2006, J PINEAL RES, V41, P130, DOI 10.1111/j.1600-079X.2006.00342.x
   Ge XJ, 2009, MOL BIOL CELL, V20, P419, DOI 10.1091/mbc.E08-08-0792
   Gonzalez-Puga C, 2005, J PINEAL RES, V39, P243, DOI 10.1111/j.1600-079X.2005.00239.x
   Greenstein AJ, 2000, MT SINAI J MED, V67, P227
   Guo YC, 2010, J HUAZHONG U SCI-MED, V30, P1, DOI 10.1007/s11596-010-0101-9
   Guri AJ, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-60
   Gutierrez O, 2002, J BIOL CHEM, V277, P41701, DOI 10.1074/jbc.M206473200
   Gutierrez-Cuesta J, 2008, J PINEAL RES, V45, P497, DOI 10.1111/j.1600-079X.2008.00626.x
   Haller D, 2006, NEUROGASTROENT MOTIL, V18, P184, DOI 10.1111/j.1365-2982.2006.00762.x
   Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954
   Han J, 2008, J BIOL CHEM, V283, P19665, DOI 10.1074/jbc.M710169200
   Hanauer SB, 2006, INFLAMM BOWEL DIS, V12, pS3, DOI 10.1097/01.MIB.0000195385.19268.68
   Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221
   HINTON JM, 1966, GUT, V7, P427, DOI 10.1136/gut.7.5.427
   Hofseth LJ, 2010, AGING-US, V2, P183, DOI 10.18632/aging.100143
   Holloway KR, 2010, P NATL ACAD SCI USA, V107, P9216, DOI 10.1073/pnas.0911325107
   Huang J, 2011, ANTIOXID REDOX SIGN, V14, P2215, DOI 10.1089/ars.2010.3554
   Huett A, 2010, CURR OPIN GASTROEN, V26, P302, DOI 10.1097/MOG.0b013e32833ae2ed
   Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107
   Imai SI, 2010, BBA-PROTEINS PROTEOM, V1804, P1584, DOI 10.1016/j.bbapap.2009.10.024
   Itzkowitz SH, 2004, AM J PHYSIOL-GASTR L, V287, pG7, DOI 10.1152/ajpgi.00079.2004
   Itzkowitz SH, 2006, GASTROENTEROL CLIN N, V35, P553, DOI 10.1016/j.gtc.2006.07.002
   Jaworek J, 2005, J PINEAL RES, V38, P73, DOI 10.1111/j.1600-079X.2004.00179.x
   Jou MJ, 2010, J PINEAL RES, V48, P20, DOI 10.1111/j.1600-079X.2009.00721.x
   Jung KH, 2010, J PINEAL RES, V48, P239, DOI 10.1111/j.1600-079X.2010.00748.x
   Jung-Hynes B, 2011, J PINEAL RES, V50, P140, DOI 10.1111/j.1600-079X.2010.00823.x
   Jung-Hynes B, 2010, J PINEAL RES, V49, P60, DOI 10.1111/j.1600-079X.2010.00767.x
   Jung-Hynes B, 2010, J PINEAL RES, V48, P9, DOI 10.1111/j.1600-079X.2009.00729.x
   Jung-Hynes B, 2009, FASEB J, V23, P2803, DOI 10.1096/fj.09-129148
   Kabra N, 2009, J BIOL CHEM, V284, P18210, DOI 10.1074/jbc.M109.000034
   Kaeberlein M, 2010, BIOESSAYS, V32, P96, DOI 10.1002/bies.200900171
   Karasek M, 1999, BIOL SIGNAL RECEPT, V8, P75
   Karasek M., 1998, NEUROENDOCRINOL LETT, V19, P71
   Kaser A, 2010, MUCOSAL IMMUNOL, V3, P11, DOI 10.1038/mi.2009.122
   Kaser A, 2010, CURR OPIN GASTROEN, V26, P318, DOI 10.1097/MOG.0b013e32833a9ff1
   Kaser A, 2010, ANNU REV IMMUNOL, V28, P573, DOI 10.1146/annurev-immunol-030409-101225
   Katsman A, 2009, CURR PHARM DESIGN, V15, P792, DOI 10.2174/138161209787582156
   Kaur J, 2010, EUR J CANCER PREV, V19, P319, DOI 10.1097/CEJ.0b013e32833ad385
   Kennedy BK, 2007, CELL MOL LIFE SCI, V64, P1323, DOI 10.1007/s00018-007-6470-y
   Kimball SR, 2008, J PINEAL RES, V44, P379, DOI 10.1111/j.1600-079X.2007.00539.x
   Koh PO, 2008, NEUROSCI LETT, V444, P74, DOI 10.1016/j.neulet.2008.08.024
   Kongsuphol P, 2009, J PINEAL RES, V46, P199, DOI 10.1111/j.1600-079X.2008.00648.x
   Kos-Kudla B, 2002, NEUROENDOCRINOL LETT, V23, P239
   Kossoy G, 2000, ONCOL REP, V7, P1401
   Lahiri S, 2009, J PINEAL RES, V46, P207, DOI 10.1111/j.1600-079X.2008.00650.x
   Lala S, 2003, GASTROENTEROLOGY, V125, P47, DOI 10.1016/S0016-5085(03)00661-9
   Latella G, 2010, J CROHNS COLITIS, V4, P690, DOI 10.1016/j.crohns.2010.08.002
   Lea MA, 2010, FUTURE ONCOL, V6, P993, DOI 10.2217/FON.10.53
   Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105
   Lee JW, 2010, MOL CELLS, V30, P545, DOI 10.1007/s10059-010-0161-5
   Lee YD, 2009, J PINEAL RES, V46, P53, DOI 10.1111/j.1600-079X.2008.00621.x
   Leja-Szpak A, 2010, J PINEAL RES, V49, P248, DOI 10.1111/j.1600-079X.2010.00789.x
   Lewis JD, 2008, GASTROENTEROLOGY, V134, P688, DOI 10.1053/j.gastro.2007.12.012
   Li JH, 2005, MEDIAT INFLAMM, P185, DOI 10.1155/MI.2005.185
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Lu SP, 2010, BBA-PROTEINS PROTEOM, V1804, P1567, DOI 10.1016/j.bbapap.2009.09.030
   Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322
   Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001
   Maldonado MD, 2008, J PINEAL RES, V45, P339, DOI 10.1111/j.1600-079X.2008.00584.x
   Mann S, 2003, AM J GASTROENTEROL, V98, P232
   Marquez E, 2006, J PINEAL RES, V40, P48, DOI 10.1111/j.1600-079X.2005.00275.x
   Martin B, 2009, IMMUNITY, V31, P321, DOI 10.1016/j.immuni.2009.06.020
   Martin H, 2009, MUTAT RES-FUND MOL M, V669, P1, DOI 10.1016/j.mrfmmm.2009.06.009
   Martin MJ, 2001, CURR PHARM DESIGN, V7, P881, DOI 10.2174/1381612013397645
   Martin-Renedo J, 2008, J PINEAL RES, V45, P532, DOI 10.1111/j.1600-079X.2008.00641.x
   Mazzon E, 2006, J PINEAL RES, V41, P363, DOI 10.1111/j.1600-079X.2006.00378.x
   Mediavilla MD, 2010, CURR MED CHEM, V17, P4462, DOI 10.2174/092986710794183015
   Mei Q, 2005, POSTGRAD MED J, V81, P667, DOI 10.1136/pgmj.2004.030817
   Mei Q, 2002, ACTA PHARMACOL SIN, V23, P882
   Meira LB, 2008, J CLIN INVEST, V118, P2516, DOI 10.1172/JCI35073
   Melen-Mucha G, 1998, ANTICANCER RES, V18, P3615
   Meley D, 2006, J BIOL CHEM, V281, P34870, DOI 10.1074/jbc.M605488200
   Miller SC, 2006, INT J EXP PATHOL, V87, P81, DOI 10.1111/j.0959-9673.2006.00474.x
   Montgomery SM, 2002, CURR OPIN GASTROEN, V18, P416, DOI 10.1097/00001574-200207000-00004
   Morselli E, 2010, AUTOPHAGY, V6, P186, DOI 10.4161/auto.6.1.10817
   MOTORAJAN M, 1995, BIOCHEM MOL BIOL INT, V37, P1063
   Nakamura T, 2010, CELL, V140, P338, DOI 10.1016/j.cell.2010.01.001
   Necefli A, 2006, DIGEST DIS SCI, V51, P1538, DOI 10.1007/s10620-005-9047-3
   Neurath MF, 2002, J EXP MED, V195, P1129, DOI 10.1084/jem.20011956
   Nishikawa T, 2010, ANN SURG ONCOL, V17, P592, DOI 10.1245/s10434-009-0696-x
   Nopparat C, 2010, J PINEAL RES, V49, P382, DOI 10.1111/j.1600-079X.2010.00805.x
   Nosal'ova V, 2007, J PINEAL RES, V42, P364, DOI 10.1111/j.1600-079X.2007.00428.x
   Nosho K, 2009, MODERN PATHOL, V22, P922, DOI 10.1038/modpathol.2009.49
   O'Connor PM, 2010, INFLAMM BOWEL DIS, V16, P1411, DOI 10.1002/ibd.21217
   Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114
   Pablos MI, 1995, J PINEAL RES, V19, P111, DOI 10.1111/j.1600-079X.1995.tb00178.x
   Padillo FJ, 2010, J PINEAL RES, V49, P264, DOI 10.1111/j.1600-079X.2010.00791.x
   Paradies G, 2010, J PINEAL RES, V48, P297, DOI 10.1111/j.1600-079X.2010.00759.x
   Pasare C, 2004, SEMIN IMMUNOL, V16, P23, DOI 10.1016/j.smim.2003.10.006
   PASCAL RR, 1994, HUM PATHOL, V25, P1160, DOI 10.1016/0046-8177(94)90032-9
   Pasparakis M, 2009, NAT REV IMMUNOL, V9, P778, DOI 10.1038/nri2655
   PENTNEY PT, 1995, J PINEAL RES, V19, P31, DOI 10.1111/j.1600-079X.1995.tb00168.x
   Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647
   Polakis P, 2000, GENE DEV, V14, P1837
   Poon AMS, 1996, ENDOCR RES, V22, P77, DOI 10.3109/07435809609030499
   Radogna F, 2010, BIOCHEM PHARMACOL, V80, P1844, DOI 10.1016/j.bcp.2010.07.041
   Rakhimova O Iu, 2010, Klin Med (Mosk), V88, P56
   Rato AG, 1999, FASEB J, V13, P857, DOI 10.1096/fasebj.13.8.857
   Reiter RJ, 2000, NEWS PHYSIOL SCI, V15, P246
   Reiter RJ, 2010, PROG BRAIN RES, V181, P127, DOI 10.1016/S0079-6123(08)81008-4
   Reiter RJ, 2009, CRIT REV BIOCHEM MOL, V44, P175, DOI 10.1080/10409230903044914
   Reiter Russel J., 2007, Critical Reviews in Oncogenesis, V13, P303
   Richmond A, 2002, NAT REV IMMUNOL, V2, P664, DOI 10.1038/nri887
   RIDDELL RH, 1983, HUM PATHOL, V14, P931, DOI 10.1016/S0046-8177(83)80175-0
   Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032
   Rodriguez C, 2004, J PINEAL RES, V36, P1, DOI 10.1046/j.1600-079X.2003.00092.x
   Rosenstein RE, 2010, J PINEAL RES, V49, P1, DOI 10.1111/j.1600-079X.2010.00764.x
   Sahar S, 2009, NAT REV CANCER, V9, P886, DOI 10.1038/nrc2747
   Sainz RM, 2003, CELL MOL LIFE SCI, V60, P1407, DOI 10.1007/s00018-003-2319-1
   Salminen A, 2008, CELL MOL LIFE SCI, V65, P2979, DOI 10.1007/s00018-008-8103-5
   Sanchez-Barcelo EJ, 2010, CURR MED CHEM, V17, P2070, DOI 10.2174/092986710791233689
   Sarra M, 2010, INFLAMM BOWEL DIS, V16, P1332, DOI 10.1002/ibd.21238
   Sartor RB, 2005, MUCOSAL IMMUNOLOGY, 3RD EDITION, P681, DOI 10.1016/B978-012491543-5/50039-5
   Sartor RB, 2006, NAT CLIN PRACT GASTR, V3, P390, DOI 10.1038/ncpgasthep0528
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Schernhammer ES, 2003, JNCI-J NATL CANCER I, V95, P825, DOI 10.1093/jnci/95.11.825
   Scherz-Shouval R, 2010, P NATL ACAD SCI USA, V107, P18511, DOI 10.1073/pnas.1006124107
   Schmidt MV, 2010, THESCIENTIFICWORLDJO, V10, P2181, DOI 10.1100/tsw.2010.213
   Seril DN, 2007, MOL CARCINOGEN, V46, P341, DOI 10.1002/mc.20282
   Singh UP, 2010, J PHARMACOL EXP THER, V332, P829, DOI 10.1124/jpet.109.160838
   Stappenbeck TS, 2010, AUTOPHAGY
   Stehle JH, 2003, J NEUROENDOCRINOL, V15, P383, DOI 10.1046/j.1365-2826.2003.01001.x
   Strober W, 2011, GASTROENTEROLOGY, V140, P1756, DOI 10.1053/j.gastro.2011.02.016
   Stuenkel Walter, 2007, Biotechnology Journal, V2, P1360, DOI 10.1002/biot.200700087
   Sun Y, 2009, CARCINOGENESIS, V30, P93, DOI 10.1093/carcin/bgn242
   Swanson GR, 2011, EXPERT REV CLIN IMMU, V7, P29, DOI [10.1586/eci.10.83, 10.1586/ECI.10.83]
   Tahan G, 2011, DIGEST DIS SCI, V56, P715, DOI 10.1007/s10620-010-1364-5
   Tajes M, 2009, J PINEAL RES, V47, P228, DOI 10.1111/j.1600-079X.2009.00706.x
   Takemoto K, 2011, NEUROCHEM INT, V58, P880, DOI 10.1016/j.neuint.2011.02.015
   Talero E, 2011, INFLAMM BOWEL DIS, V17, P696, DOI 10.1002/ibd.21420
   Tan DX, 1998, BIOCHEM BIOPH RES CO, V253, P614, DOI 10.1006/bbrc.1998.9826
   Tanaka T, 2009, CHEM-BIOL INTERACT, V177, P128, DOI 10.1016/j.cbi.2008.10.047
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Tergaonkar V, 2006, INT J BIOCHEM CELL B, V38, P1647, DOI 10.1016/j.biocel.2006.03.023
   Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Torres-Farfan C, 2006, ENDOCRINOLOGY, V147, P4618, DOI 10.1210/en.2006-0628
   Travassos LH, 2010, NAT IMMUNOL, V11, P55, DOI 10.1038/ni.1823
   Von Gall C, 2005, ANN NY ACAD SCI, V1040, P508, DOI 10.1196/annals.1327.105
   Wang SL, 2009, CELL MOL IMMUNOL, V6, P327, DOI 10.1038/cmi.2009.43
   Wenzel U, 2005, INT J CANCER, V116, P236, DOI 10.1002/ijc.20837
   Winczyk K, 2002, TUMOR BIOL, V23, P298, DOI 10.1159/000068569
   Winczyk K, 2001, J PINEAL RES, V31, P179, DOI 10.1034/j.1600-079x.2001.310213.x
   Wirawan E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.16
   Wood PA, 2008, MOL CANCER RES, V6, P1786, DOI 10.1158/1541-7786.MCR-08-0196
   Wullaert A, 2010, INT J MED MICROBIOL, V300, P49, DOI 10.1016/j.ijmm.2009.08.007
   Yang QH, 2007, J PINEAL RES, V42, P172, DOI 10.1111/j.1600-079X.2006.00403.x
   Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244
   Yi JJ, 2010, BBA-PROTEINS PROTEOM, V1804, P1684, DOI 10.1016/j.bbapap.2010.05.002
   Yoo YM, 2010, J PINEAL RES, V48, P204, DOI 10.1111/j.1600-079X.2010.00744.x
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Yu QN, 2000, J PINEAL RES, V29, P86, DOI 10.1034/j.1600-079X.2000.290204.x
   Zhang SZ, 2006, CELL MOL IMMUNOL, V3, P35
   Zhang T, 2010, BBA-PROTEINS PROTEOM, V1804, P1666, DOI 10.1016/j.bbapap.2009.10.022
NR 205
TC 91
Z9 91
U1 2
U2 31
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-3098
EI 1600-079X
J9 J PINEAL RES
JI J. Pineal Res.
PD AUG
PY 2011
VL 51
IS 1
BP 44
EP 60
DI 10.1111/j.1600-079X.2011.00915.x
PG 17
WC Endocrinology & Metabolism; Neurosciences; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Neurosciences & Neurology; Physiology
GA 791VA
UT WOS:000292693700003
PM 21752096
OA Bronze
DA 2022-04-25
ER

PT J
AU Shi, YS
   Wang, JQ
   Liu, JY
   Lin, G
   Xie, FF
   Pang, X
   Pei, YH
   Cheng, Y
   Zhang, Y
   Lin, ZN
   Yin, ZY
   Wang, XM
   Niu, G
   Chen, XY
   Liu, G
AF Shi, Yesi
   Wang, Junqing
   Liu, Jingyi
   Lin, Gan
   Xie, Fengfei
   Pang, Xin
   Pei, Yihua
   Cheng, Yi
   Zhang, Yang
   Lin, Zhongning
   Yin, Zhengyu
   Wang, Xiaomin
   Niu, Gang
   Chen, Xiaoyuan
   Liu, Gang
TI Oxidative stress-driven DR5 upregulation restores TRAIL/Apo2L
   sensitivity induced by iron oxide nanoparticles in colorectal cancer
SO BIOMATERIALS
LA English
DT Article
DE TRAIL/Apo2L; Iron oxide nanoparticle; ROS; Autophagy; DR5; Colorectal
   cancer
ID TRAIL-INDUCED APOPTOSIS; DEATH RECEPTOR 5; COLON-CANCER;
   MONOCLONAL-ANTIBODY; MEDIATED APOPTOSIS; PHASE-II; COMBINATION; LIGAND;
   RESISTANCE; CELLS
AB There exists an emergency clinical demand to overcome TRAIL/Apo2L (tumor necrosis factor-related apoptosis-inducing ligand) resistance, which is a major obstacle attributed to insufficient level or mutation of TRAIL receptors. Here, we developed an iron oxide cluster-based nanoplatform for both sensitization and MR image-guided evaluation to improve TRAIL/Apo2L efficacy in colorectal cancer, which has an inadequate response to TRAIL/Apo2L or chemotherapy. Specifically, NanoTRAIL (TRAIL/Apo2L-iron oxide nanoparticles) generated ROS (reactive oxygen species)-triggered JNK (c-Jun N-terminal kinase) activation and induced subsequent autophagy-assisted DR5 upregulation, resulting in a significant enhanced antitumor efficacy of TRAIL/Apo2L, which confirmed in both TRAIL-resistant HT-29, intermediately resistant SW-480 and sensitive HCT-116 cells. Furthermore, in a subcutaneous colorectal cancer mouse model, the in vivo tumor retention of NanoTRAIL can be demonstrated by MR T-2 weighted contrast imaging, and NanoTRAIL significantly suppressed tumor growth and prolonged the survival time without observable adverse effects compared with control and TRAIL/Apo2L monotherapy. Importantly, in the study of colorectal cancer patient-derived xenograft models, we found that the NanoTRAIL treatment could significantly improve the survival outcome with consistent ROS-dependent autophagy-assisted DR5 upregulation and tumor apoptosis. Our results describe a transformative design that can be applied clinically to sensitize Apo2L/TRAIL-resistant patients using FDA-approved iron oxide nanoparticles.
C1 [Shi, Yesi; Wang, Junqing; Liu, Jingyi; Lin, Gan; Xie, Fengfei; Pang, Xin; Cheng, Yi; Zhang, Yang; Lin, Zhongning; Liu, Gang] Xiamen Univ, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen 361102, Peoples R China.
   [Shi, Yesi; Wang, Junqing; Liu, Jingyi; Lin, Gan; Xie, Fengfei; Pang, Xin; Cheng, Yi; Zhang, Yang; Lin, Zhongning; Liu, Gang] Xiamen Univ, Sch Publ Hlth, Ctr Mol Imaging & Translat Med, Xiamen 361102, Peoples R China.
   [Liu, Jingyi; Pei, Yihua; Yin, Zhengyu; Wang, Xiaomin] Xiamen Univ, Sch Med, Xiamen 361105, Peoples R China.
   [Pei, Yihua; Yin, Zhengyu; Wang, Xiaomin] Xiamen Univ, Zhongshan Hosp, Dept Gastroenterol, Xiamen 361004, Peoples R China.
   [Niu, Gang; Chen, Xiaoyuan] Natl Inst Biomed Imaging & Bioengn, Lab Mol Imaging & Nanomed, NIH, Bethesda, MD 20892 USA.
   [Liu, Gang] Xiamen Univ, Sch Life Sci, Innovat Ctr Cell Biol, State Key Lab Cellular Stress Biol, Xiamen 361102, Peoples R China.
   [Wang, Junqing] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510275, Peoples R China.
RP Liu, G (corresponding author), Xiamen Univ, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen 361102, Peoples R China.; Liu, G (corresponding author), Xiamen Univ, Sch Publ Hlth, Ctr Mol Imaging & Translat Med, Xiamen 361102, Peoples R China.
EM gangliu.cmitm@xmu.edu.cn
RI Liu, Gang/AAC-4177-2020
OI Liu, Gang/0000-0003-2613-7286
FU Major State Basic Research Development Program of ChinaNational Basic
   Research Program of China [2017YFA0205201]; National Natural Science
   Foundation of China (NSFC)National Natural Science Foundation of China
   (NSFC) [81422023, 81925019, 81371596, 51273165, U1705281, U1505221];
   Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [20720190088]; Natural
   Science Foundation of Fujian Province of ChinaNatural Science Foundation
   of Fujian Province [2018J05144]; Program for New Century Excellent
   Talents in University, ChinaProgram for New Century Excellent Talents in
   University (NCET) [NCET-13-0502]
FX Y.S., J.W., and J. L. contributed equally to this work. This work was
   supported by the Major State Basic Research Development Program of China
   (Grant No. 2017YFA0205201), the National Natural Science Foundation of
   China (NSFC) (Grant Nos. 81422023, 81925019, 81371596, 51273165,
   U1705281, and U1505221), the Fundamental Research Funds for the Central
   Universities (Grant No. 20720190088), Natural Science Foundation of
   Fujian Province of China (Grant No. 2018J05144), the Program for New
   Century Excellent Talents in University, China (NCET-13-0502).
CR Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926
   Behbakht K, 2007, CANCER RES, V67, P3036, DOI 10.1158/0008-5472.CAN-06-3755
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chen L, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.234
   Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046
   Dimberg LY, 2013, ONCOGENE, V32, P1341, DOI 10.1038/onc.2012.164
   Favaloro B, 2012, AGING-US, V4, P330, DOI 10.18632/aging.100459
   Forero-Torres A, 2013, CANCER MED-US, V2, P925, DOI 10.1002/cam4.137
   Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116
   Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258
   Ganten TM, 2006, CLIN CANCER RES, V12, P2640, DOI 10.1158/1078-0432.CCR-05-2635
   Ghobrial IM, 2005, CA-CANCER J CLIN, V55, P178, DOI 10.3322/canjclin.55.3.178
   Goel A, 2003, CANCER RES, V63, P1608
   Guimaraes PPG, 2018, ACS NANO, V12, P912, DOI 10.1021/acsnano.7b05876
   Gura T, 1997, SCIENCE, V277, P768, DOI 10.1126/science.277.5327.768
   Hammond WA, 2016, THER ADV MED ONCOL, V8, P57, DOI 10.1177/1758834015614530
   He CY, 2016, BIOMATERIALS, V83, P102, DOI 10.1016/j.biomaterials.2016.01.010
   Herbst RS, 2010, J CLIN ONCOL, V28, P2839, DOI 10.1200/JCO.2009.25.1991
   Holland PM, 2013, CANCER LETT, V332, P156, DOI 10.1016/j.canlet.2010.11.001
   Horak P, 2005, MOL CANCER RES, V3, P335, DOI 10.1158/1541-7786.MCR-04-0136
   Huang G, 2013, THERANOSTICS, V3, P116, DOI 10.7150/thno.5411
   Izeradjene K, 2005, CANCER RES, V65, P7436, DOI 10.1158/0008-5472.CAN-04-2628
   Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6
   Kang CH, 2018, FOOD CHEM TOXICOL, V111, P623, DOI 10.1016/j.fct.2017.12.018
   Kannappan R, 2010, MOL CANCER THER, V9, P2196, DOI 10.1158/1535-7163.MCT-10-0277
   Kelley SK, 2001, J PHARMACOL EXP THER, V299, P31
   Kim J, 2016, BRIT J PHARMACOL, V173, P1033, DOI 10.1111/bph.13408
   Lao VV, 2011, NAT REV GASTRO HEPAT, V8, P686, DOI 10.1038/nrgastro.2011.173
   Lim B, 2013, CANCER BIOL THER, V14, P711, DOI 10.4161/cbt.25310
   Lin G, 2018, BIOMATERIALS, V176, P60, DOI 10.1016/j.biomaterials.2018.05.036
   Liu MD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06556-9
   Merchant MS, 2012, J CLIN ONCOL, V30, P4141, DOI 10.1200/JCO.2012.44.1055
   Na YJ, 2017, INT J BIOCHEM CELL B, V89, P147, DOI 10.1016/j.biocel.2017.06.010
   Papadopoulos KP, 2015, CANCER CHEMOTH PHARM, V75, P887, DOI 10.1007/s00280-015-2712-0
   Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687
   Prabhudesai SG, 2007, J SURG ONCOL, V96, P77, DOI 10.1002/jso.20785
   Sharma S, 2014, INVEST NEW DRUG, V32, P135, DOI 10.1007/s10637-013-9952-9
   Soria JC, 2011, J CLIN ONCOL, V29, P4442, DOI 10.1200/JCO.2011.37.2623
   Sung B, 2012, FREE RADICAL BIO MED, V53, P1977, DOI 10.1016/j.freeradbiomed.2012.08.012
   Tang SY, 2013, ONCOL REP, V29, P474, DOI 10.3892/or.2012.2127
   von Karstedt S, 2017, NAT REV CANCER, V17, P352, DOI 10.1038/nrc.2017.28
   von Pawel J, 2014, CLIN LUNG CANCER, V15, P188, DOI 10.1016/j.cllc.2013.12.005
   Wainberg ZA, 2013, CLIN COLORECTAL CANC, V12, P248, DOI 10.1016/j.clcc.2013.06.002
   Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517
   Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232
   Watson AJM, 2004, GUT, V53, P1701, DOI 10.1136/gut.2004.052704
   Yang JK, 2008, YONSEI MED J, V49, P19, DOI 10.3349/ymj.2008.49.1.19
   Yodkeeree S, 2009, CANCER RES, V69, P6581, DOI 10.1158/0008-5472.CAN-09-1161
   Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792
   Zhu J, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201904056
NR 51
TC 18
Z9 18
U1 7
U2 55
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD MAR
PY 2020
VL 233
AR 119753
DI 10.1016/j.biomaterials.2019.119753
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA KM6NC
UT WOS:000514253800008
PM 31923762
DA 2022-04-25
ER

PT J
AU Coppola, D
   Khalil, F
   Eschrich, SA
   Boulware, D
   Yeatman, T
   Wang, HG
AF Coppola, Domenico
   Khalil, Farah
   Eschrich, Steven A.
   Boulware, David
   Yeatman, Timothy
   Wang, Hong-Gang
TI Down-regulation of Bax-interacting Factor-1 in Colorectal Adenocarcinoma
SO CANCER
LA English
DT Article
DE Bif-1; colon adenocarcinoma; microarray; immunohistochemistry
ID CONFORMATIONAL-CHANGE; COLON-CANCER; CELL-DEATH; AUTOPHAGY; PROTEIN;
   BIF-1; REGION; HETEROZYGOSITY; NEUROBLASTOMA; DYSFUNCTION
AB BACKGROUND. Bax-interacting factor-1 (Bif-1) protein is a member of the endophilin B family that plays a critical role in apoptosis, autophagy, and mitochondrial morphology. Loss of Bif-1 suppresses programmed cell death and promotes tumorigenesis. The connection of Bif-1 to colorectal cancer remains to be evaluated.
   METHODS. To determine Bif-1 expression in human colorectal adenocarcinoma (CRC), the authors performed immunohistochemistry using stage-oriented cancer tissue microarrays containing 102 CRC samples of different stages and 38 samples of normal colorectal mucosa (NR). Formalin-fixed, paraffin-embedded core sections on the tissue array were immunostained using the avidin-biotin-peroxidase method and the anti-Bif-1 murine monoclonal antibody Bif-1 staining was scored by 2 independent observers. To examine Bif-1 mRNA levels, the authors performed DNA microarray analysis of 205 CRC and 10 NR samples.
   RESULTS. Bif-1 expression was negative in 22.5% (23 of 102) of CRCs. Moderateto strong Bif-1 staining was identified in 36.3% (37 of 102) of the tumors, and weak staining was noted in 41.2% (42 of 102). Twenty-six of 38 (68.4%) NR samples exhibited moderate to strong Bif-1 immunoreactivity, and none of them was negative. In 12 (31.6%) cases NR demonstrated weak Bif-1 stain. The mean (median) scores for CRCs and NR differed significantly: 3.2 (3.0) and 5.2 (6.0), respectively (P = .0003). The percentage of cases with negative expression also differed significantly between NR and CRC (P = .002). Decreased Bif-1 expression in CRCs was confirmed at the mRNA level by microarray analysis.
   CONCLUSIONS. The authors report the down-regulation of Bif-1 during the transition from NR to CRC, a novel finding in agreement with the tumor suppressor function of Bif-1. Cancer 2008;113:2665-70. (C) 2008American Cancer Society.
C1 [Coppola, Domenico; Khalil, Farah] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Div Anat Pathol, Tampa, FL 33612 USA.
   [Coppola, Domenico; Yeatman, Timothy] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Expt Therapeut, Tampa, FL 33612 USA.
   [Coppola, Domenico; Yeatman, Timothy] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Gastrointestinal Programs, Tampa, FL 33612 USA.
   [Eschrich, Steven A.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Div Biostat, Tampa, FL 33612 USA.
   [Wang, Hong-Gang] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Drug Discovery Programs, Tampa, FL 33612 USA.
RP Coppola, D (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Div Anat Pathol, 12902 Magnolia Dr, Tampa, FL 33612 USA.
EM Domenico.Coppola@moffitt.org
RI Eschrich, Steven/K-6848-2013; Wang, Hong-Gang/A-3018-2015
OI Eschrich, Steven/0000-0002-9833-2788; Wang,
   Hong-Gang/0000-0003-0551-0571
FU American Cancer SocietyAmerican Cancer Society [RSG-05-244-01-CCG];
   National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [CA82197]; NATIONAL
   CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R01CA082197] Funding Source: NIH RePORTER
FX Supported in part by grants from American Cancer Society
   (RSG-05-244-01-CCG) and National Institutes of Health (CA82197) to
   H.-G.W.
CR Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Balakrishnan A, 2006, GENE CHROMOSOME CANC, V45, P883, DOI 10.1002/gcc.20352
   Bello MJ, 2000, CANCER GENET CYTOGEN, V120, P30, DOI 10.1016/S0165-4608(99)00249-6
   Bonner AE, 2004, ONCOGENE, V23, P1166, DOI 10.1038/sj.onc.1207234
   Cuddeback SM, 2001, J BIOL CHEM, V276, P20559, DOI 10.1074/jbc.M101527200
   Emi, 1997, Breast Cancer, V4, P243, DOI 10.1007/BF02966514
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6
   Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7
   Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Kakinuma H, 2001, CANCER GENET CYTOGEN, V126, P134, DOI 10.1016/S0165-4608(00)00405-2
   Karbowski M, 2004, J CELL BIOL, V166, P1027, DOI 10.1083/jcb.200407046
   Knosel T, 2002, VIRCHOWS ARCH, V440, P187, DOI 10.1007/s004280100493
   Lee JW, 2006, PATHOLOGY, V38, P312, DOI 10.1080/00313020600820880
   Lee WC, 1996, CANCER RES, V56, P4297
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Mathew R, 2007, AUTOPHAGY, V3, P502, DOI 10.4161/auto.4605
   Ming L, 2006, J BIOL CHEM, V281, P16034, DOI 10.1074/jbc.M513587200
   Mora J, 2000, J MOL DIAGN, V2, P37, DOI 10.1016/S1525-1578(10)60613-7
   Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265
   NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563
   Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522
   Pierrat B, 2001, GENOMICS, V71, P222, DOI 10.1006/geno.2000.6378
   RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0
   Reed J C, 1996, Behring Inst Mitt, P72
   Roberts T, 1998, CANCER GENET CYTOGEN, V100, P10, DOI 10.1016/S0165-4608(97)00013-7
   Rupnarain C, 2004, BIOL CHEM, V385, P449, DOI 10.1515/BC.2004.053
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Takahashi Y, 2005, MOL CELL BIOL, V25, P9369, DOI 10.1128/MCB.25.21.9369-9382.2005
   Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634
   Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4
   Walker GJ, 2004, GENE CHROMOSOME CANC, V41, P56, DOI 10.1002/gcc.20056
   Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108
   Yamaguchi H, 2002, CANCER RES, V62, P466
NR 37
TC 68
Z9 74
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD NOV 15
PY 2008
VL 113
IS 10
BP 2665
EP 2670
DI 10.1002/cncr.23892
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 372PV
UT WOS:000260914400007
PM 18833585
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Du, C
   Wang, X
   Zhang, JL
   Liu, XZ
   Zhu, J
   Liu, YC
AF Du, Chuang
   Wang, Xin
   Zhang, Junling
   Liu, Xiangzheng
   Zhu, Jing
   Liu, Yucun
TI Paxillin is positively correlated with the clinicopathological factors
   of colorectal cancer, and knockdown of Paxillin improves sensitivity to
   cetuximab in colorectal cancer cells
SO ONCOLOGY REPORTS
LA English
DT Article
DE paxillin; colorectal cancer; p-Erk; apoptosis; cetuximab resistance;
   clinicopathological factors
ID COLON-CANCER; EPITHELIAL MORPHOGENESIS; MOLECULAR-MECHANISMS;
   MONOCLONAL-ANTIBODY; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; GROWTH;
   AUTOPHAGY; KRAS; PHOSPHORYLATION
AB Paxillin (PXN) encodes a 68-kDa focal adhesion-associated protein and plays an important role in signal transduction, regulation of cell morphology, migration, proliferation and apoptosis. The aim of the present study was to evaluate the relationship between PXN and clinicopathological factors in colorectal cancer, the role of PXN in cetuximab resistance, and whether knockdown of PXN expression could improve the sensitivity to cetuximab in colorectal cancer cells. In the present study, immunohistochemical staining in 148 colorectal carcinoma and 126 normal adjacent tissues was performed, which showed that the positive rate of PXN was significantly higher in the colorectal adenocarcinoma samples than that in the normal colorectal mucosa samples (P<0.001). Moreover, PXN presence was also positively correlated with TNM stage (P=0.023), distant metastasis (P=0.014), recurrence (P=0.032) and reduced survival (P=0.004). In vitro, PXN expression was positively correlated with the proliferation rate in colorectal cells insensitive to cetuximab. Inhibition of PXN expression by PXN-siRNA clearly increased apoptosis by downregulating the phosphorylation of extracellular signal regulated kinase (p-Erk) level, and overexpression of PXN by PXN-cDNA decreased apoptosis by upregulating the p-Erk level. This suggests that overexpression of PXN could be one of the reasons for cetuximab resistance, and downregulation of PXN plays an important role in improving sensitivity to cetuximab by suppressing the activitation of p-Erk in colorectal cancer cells. Above all, knockdown of PXN could represent a rational therapeutic strategy for increasing the sensitivity or overcoming cetuximab-resistance in patients with colorectal cancer.
C1 [Du, Chuang; Wang, Xin; Zhang, Junling; Zhu, Jing; Liu, Yucun] Peking Univ, Hosp 1, Dept Gen Surg, Beijing 100034, Peoples R China.
   [Liu, Xiangzheng] Peking Univ, Hosp 1, Dept Thorac Surg, Beijing 100034, Peoples R China.
RP Wang, X (corresponding author), Peking Univ, Hosp 1, Dept Gen Surg, 8 Xishiku St, Beijing 100034, Peoples R China.
EM wangxin_guo@126.com
RI liu, xiangzheng/AAC-4183-2019
CR Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116
   Brand TM, 2011, CANCER BIOL THER, V11, P777, DOI 10.4161/cbt.11.9.15050
   Chen DL, 2013, CARCINOGENESIS, V34, P803, DOI 10.1093/carcin/bgs400
   Chen MC, 2013, NEOPLASMA, V60, P561, DOI 10.4149/neo_2013_073
   Coker-Gurkan A, 2015, AMINO ACIDS, V47, P87, DOI 10.1007/s00726-014-1851-7
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Galizia G, 2007, ONCOGENE, V26, P3654, DOI 10.1038/sj.onc.1210381
   Guller MC, 2009, MOL CARCINOGEN, V48, P532, DOI 10.1002/mc.20492
   Ishibe S, 2004, MOL CELL, V16, P257, DOI 10.1016/j.molcel.2004.10.006
   Ishibe S, 2003, MOL CELL, V12, P1275, DOI 10.1016/S1097-2765(03)00406-4
   Kumar Shalini Sree, 2014, Gastrointest Cancer Res, V7, P23
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Munshi N, 2000, J IMMUNOL, V164, P1169, DOI 10.4049/jimmunol.164.3.1169
   Nishikawa T, 2010, ANN SURG ONCOL, V17, P592, DOI 10.1245/s10434-009-0696-x
   Qin J, 2011, HEPATO-GASTROENTEROL, V58, P1951, DOI 10.5754/hge11352
   Sen A, 2010, J BIOL CHEM, V285, P28787, DOI 10.1074/jbc.M110.134064
   Shigeta K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066302
   Sui XB, 2014, SCI REP-UK, V4, DOI 10.1038/srep04694
   Teranishi S, 2009, INVEST OPHTH VIS SCI, V50, P5646, DOI 10.1167/iovs.08-2534
   Therkildsen C, 2014, ACTA ONCOL, V53, P852, DOI 10.3109/0284186X.2014.895036
   Troiani T, 2013, CLIN CANCER RES, V19, P6751, DOI 10.1158/1078-0432.CCR-13-0423
   Turner CE, 2000, J CELL SCI, V113, P4139
   Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091
   Wu DW, 2014, ONCOGENE, V33, P4385, DOI 10.1038/onc.2013.389
   Xiao LJ, 2014, ONCOL LETT, V7, P189
   Yin HF, 2014, CHINESE MED J-PEKING, V127, P423, DOI 10.3760/cma.j.issn.0366-6999.20121360
   Zhai H, 2013, ONCOGENE, V32, P1570, DOI 10.1038/onc.2012.167
NR 28
TC 10
Z9 10
U1 0
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD JAN
PY 2016
VL 35
IS 1
BP 409
EP 417
DI 10.3892/or.2015.4352
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CY0BZ
UT WOS:000366072500049
PM 26530439
OA Bronze
DA 2022-04-25
ER

PT J
AU Zhu, SJ
   Wu, Q
   Zhang, B
   Wei, HG
   Li, B
   Shi, W
   Fang, M
   Zhu, SZ
   Wang, L
   Zhou, YL
   Dong, YL
AF Zhu, Shajun
   Wu, Qiong
   Zhang, Bo
   Wei, Huagen
   Li, Ben
   Shi, Wei
   Fang, Miao
   Zhu, Shengze
   Wang, Lei
   Zhou, You Lang
   Dong, Yulin
TI Autophagy-related gene expression classification defines three molecular
   subtypes with distinct clinical and microenvironment cell infiltration
   characteristics in colon cancer
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Autophagy; Molecular subtypes; Tumor microenvironment; Immunotherapy;
   Colon cancer
ID EXCLUSION; SURVIVAL; IMMUNITY; THERAPY
AB Background: Multiple molecular subtypes with distinct clinical outcomes in colon cancer have been identified in recent years. Nonetheless, the autophagy-related molecular subtypes as well as its mediated tumor microenvironment (TME) cell infiltration characteristics have not been fully understood.
   Methods: Based on the seven colon cancer cohorts with 1580 samples, we performed a comprehensive genomic analysis to explore the molecular subtypes mediated by autophagy-related genes. The single-sample gene-set enrichment analysis (ssGSEA) was used to quantify the relative abundance of each cell infiltration in the TME. Unsupervised methods were used to perform autophagy subtype clustering. Least absolute shrinkage and selection operator regression (LASSO) was used to construct autophagy characterization score (APCS) signature.
   Results: We determined three distinct autophagy-related molecular subtypes in colon cancer. The three autophagy subtypes presented significant survival differences. Microenvironment analyses revealed the heterogeneous TME immune cell infiltration characterization between three subtypes. Cluster 1 autophagy subtype was characterized by abundant innate and adaptive immune cell infiltration. This subtype exhibited an enhanced stromal activity including activated pathways of epithelial-mesenchymal transition, TGF-beta and angiogenesis, and an increased infiltration of fibroblasts and endothelial cells. The expression of immune checkpoint molecules was also significantly up-regulated, which may mediate immune escape in Cluster 1 subtype. Cluster 2 subtype was characterized by relatively lower TME immune cell infiltration and enhanced DNA damage repair pathways. Cluster 3 subtype was characterized by the suppression of immunity. Patients with high APCS, with poorer survival, presented a significantly positive correlation with TME stromal activity. Low APCS, relevant to activated damage repair pathways, showed enhanced responses to anti-PD-1/PD-L1 immunotherapy. Two immunotherapy cohorts confirmed patients with low APCS exhibited prominently enhanced clinical response and treatment advantages.
   Conclusions: This study may help understand the molecular characterization of autophagy-related subtypes. We demonstrated the autophagy genes in colon cancer could drive the heterogeneity of TME immune cell infiltration. Our study represented a step toward personalized immunotherapy in colon cancer.
C1 [Zhu, Shajun; Wei, Huagen; Fang, Miao; Zhu, Shengze; Dong, Yulin] Nantong Univ, Med Sch, Nantong 226001, Jiangsu, Peoples R China.
   [Zhu, Shajun] Nantong Univ, Affiliated Hosp, Dept Hepatobiliary & Pancreat Surg, Nantong 226001, Peoples R China.
   [Wu, Qiong; Zhang, Bo; Shi, Wei; Zhou, You Lang] Nantong Univ, Affiliated Hosp, Res Ctr Clin Med, Nantong 226001, Jiangsu, Peoples R China.
   [Li, Ben] Nantong Univ, Affiliated Hosp, Dept Cardiothorac Surg, Nantong 226001, Jiangsu, Peoples R China.
   [Wang, Lei] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Shanghai 200025, Peoples R China.
RP Dong, YL (corresponding author), Nantong Univ, Med Sch, Nantong 226001, Jiangsu, Peoples R China.; Zhou, YL (corresponding author), Nantong Univ, Affiliated Hosp, Res Ctr Clin Med, Nantong 226001, Jiangsu, Peoples R China.; Wang, L (corresponding author), Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Shanghai 200025, Peoples R China.
EM dyldyl@ntu.edu.cn
CR Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460
   Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935
   Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Fitzwalter BE, 2018, DEV CELL, V44, P555, DOI 10.1016/j.devcel.2018.02.014
   Gafar AA, 2016, PEERJ, V4, DOI 10.7717/peerj.2445
   Gao JB, 2010, NEURAL NETWORKS, V23, P257, DOI 10.1016/j.neunet.2009.07.001
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Gurkan AC, 2018, CELL ONCOL, V41, P297, DOI 10.1007/s13402-017-0369-x
   Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7
   Hartigan J. A., 1979, Applied Statistics, V28, P100, DOI 10.2307/2346830
   Hazra A, 2016, INDIAN J DERMATOL, V61, P251, DOI 10.4103/0019-5154.182416
   Hegde PS, 2016, CLIN CANCER RES, V22, P1865, DOI 10.1158/1078-0432.CCR-15-1507
   Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011
   Hothorn T, 2015, MAXSTAT MAXIMALLY SE
   Hu H., 2011, SEMIN ONCOL, V38
   Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065
   Jiang F, 2018, INT J MOL MED, V42, P1295, DOI 10.3892/ijmm.2018.3712
   Joyce JA, 2015, SCIENCE, V348, P74, DOI 10.1126/science.aaa6204
   Katheder NS, 2017, NATURE, V541, P417, DOI 10.1038/nature20815
   Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501
   Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453
   Monti S., CONSENSUS CLUSTERING, V52, P91
   Peng DJ, 2015, NATURE, V527, P249, DOI 10.1038/nature15520
   Punt CJA, 2017, NAT REV CLIN ONCOL, V14, P235, DOI 10.1038/nrclinonc.2016.171
   Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002
   Salmon H, 2012, J CLIN INVEST, V122, P899, DOI 10.1172/JCI45817
   Shajani-Yi Z, 2018, NEOPLASIA, V20, P256, DOI 10.1016/j.neo.2017.12.005
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Snaebjornsson P, 2014, INT J CANCER, V135, P467, DOI 10.1002/ijc.28676
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sveen A, 2018, CLIN CANCER RES, V24, P794, DOI 10.1158/1078-0432.CCR-17-1234
   Tarazona N, 2019, ANN ONCOL, V30, P1804, DOI 10.1093/annonc/mdz390
   Tauriello DVF, 2018, NATURE, P1476
   Wen YA, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.21
   White E, 2015, CLIN CANCER RES, V21, P5037, DOI 10.1158/1078-0432.CCR-15-0490
   Xiao T, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1113-9
   Xiao Y, 2019, CLIN CANCER RES, V25, P5002, DOI 10.1158/1078-0432.CCR-18-3524
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhang R, 2017, TUMOR BIOL, V39, P1, DOI 10.1177/1010428317703984
   Zhang Y, 2017, CANCER CELL, V32, P377, DOI 10.1016/j.ccell.2017.08.004
NR 42
TC 3
Z9 3
U1 4
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD OCT
PY 2020
VL 87
AR 106757
DI 10.1016/j.intimp.2020.106757
PG 12
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA NU3QG
UT WOS:000573556600004
PM 32769067
DA 2022-04-25
ER

PT J
AU Tan, SS
   Peng, XC
   Peng, W
   Zhao, YL
   Wei, YQ
AF Tan, Shisheng
   Peng, Xingchen
   Peng, Wen
   Zhao, Yinglan
   Wei, Yuquan
TI Enhancement of oxaliplatin-induced cell apoptosis and tumor suppression
   by 3-methyladenine in colon cancer
SO ONCOLOGY LETTERS
LA English
DT Article
DE colon cancer; autophagy; apoptosis; chemotherapy; mouse; combination
ID STAGE-II; AUTOPHAGY; FLUOROURACIL; LEUCOVORIN; INHIBITION;
   5-FLUOROURACIL; PATTERNS; MODEL
AB Oxaliplatin (OX) has been widely used in adjuvant and palliative treatments of advanced colon cancer; however, cancer cells ultimately become resistant in the majority of cases. Therefore, the development of a novel strategy to overcome this resistance is important for the effective treatment of colon cancer; Cell autophagy reduces the sensitivity of cancer cells to therapeutic reagents in various types of human cancer; therefore, the present study used murine CT26 colon carcinoma cells to explore whether inhibition of autophagy by 3-methyladenine (3-MA) is able to enhance OX-induced apoptosis in vitro and OX-suppressed tumor growth in vivo. CT26 cells were treated with 3-MA, OX, or 3-MA plus OX, and the autophagy, apoptosis and proliferation of the CT26 cells was investigated. Additionally, the therapeutic efficiency of the combination of 3-MA and OX treatment was evaluated in vivo by determining the survival time of the tumor-bearing mice and, thus, tumor growth rate. The treatment of CT26 cells in vitro with OX alone increased autophagy as well as apoptosis, whereas treatment with 3-MA plus OX markedly inhibited OX-induced autophagy, but increased OX-induced cell apoptosis. Furthermore, the combination of OX and 3-MA treatment significantly suppressed tumor growth in vivo and prolonged mouse survival time when compared with OX treatment alone. Similarly, 3-MA increased OX-induced cell apoptosis and decreased autophagy in xenograft tumor tissues. Thus, the administration of 3-MA may increase tumor cell sensitivity to OX by reducing its autophagic effects and enhancing its apoptotic effects. Data obtained in the present study indicates that the clinical combination of an autophagy inhibitor with OX may increase the therapeutic effect of OX and improve the clinical outcome of patients with colon cancer.
C1 [Tan, Shisheng; Peng, Xingchen; Zhao, Yinglan; Wei, Yuquan] Sichuan Univ, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China.
   [Tan, Shisheng; Peng, Xingchen; Zhao, Yinglan; Wei, Yuquan] Sichuan Univ, West China Hosp, West China Med Sch, Ctr Canc, Chengdu 610041, Sichuan, Peoples R China.
   [Tan, Shisheng; Peng, Wen] Guizhou Prov Peoples Hosp, Dept Oncol, Guiyang 550002, Guizhou, Peoples R China.
RP Zhao, YL (corresponding author), Sichuan Univ, State Key Lab Biotherapy, 17 Renmin Rd, Chengdu 610041, Sichuan, Peoples R China.
EM yinglanzhao1@sina.com; yuquanwei1@sina.com
OI Peng, Xingchen/0000-0001-7042-718X
CR Alcindor T, 2011, CURR ONCOL, V18, P18
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Andre T, 2009, J CLIN ONCOL, V27, P3109, DOI 10.1200/JCO.2008.20.6771
   Bijnsdorp IV, 2010, INT J CANCER, V126, P2457, DOI 10.1002/ijc.24943
   Bleiberg H, 1998, BRIT J CANCER, V77, P1, DOI 10.1038/bjc.1998.427
   Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003
   Dahan L, 2009, BRIT J PHARMACOL, V158, P610, DOI 10.1111/j.1476-5381.2009.00341.x
   de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938
   Giatromanolaki A, 2013, COLORECTAL DIS, V15, pE223, DOI 10.1111/codi.12147
   Giatromanolaki A, 2010, J CLIN PATHOL, V63, P867, DOI 10.1136/jcp.2010.079525
   He G, 2014, TUMOR BIOL, V35, P1003, DOI 10.1007/s13277-013-1134-z
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Howells LM, 2011, INT J CANCER, V129, P476, DOI 10.1002/ijc.25670
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Kuebler JP, 2007, J CLIN ONCOL, V25, P2198, DOI 10.1200/JCO.2006.08.2974
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Romano S, 2010, CELL DEATH DIFFER, V17, P145, DOI 10.1038/cdd.2009.115
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Shi W, 2009, J MOL MED, V87, P493, DOI 10.1007/s00109-009-0444-5
   Shi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051076
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Torre LA, 2015, CA CANC J CLIN
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Xu Y, 2012, CANCER LETT, V314, P232, DOI 10.1016/j.canlet.2011.09.034
NR 25
TC 27
Z9 30
U1 0
U2 10
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD MAY
PY 2015
VL 9
IS 5
BP 2056
EP 2062
DI 10.3892/ol.2015.2996
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CH2IW
UT WOS:000353849900014
PM 26137012
OA Green Submitted, gold, Green Published
DA 2022-04-25
ER

PT J
AU Bhardwaj, M
   Paul, S
   Jakhar, R
   Khan, I
   Kang, JI
   Kim, HM
   Yun, JW
   Lee, SJ
   Cho, HJ
   Lee, HG
   Kang, SC
AF Bhardwaj, Monika
   Paul, Souren
   Jakhar, Rekha
   Khan, Imran
   Kang, Ji In
   Kim, Ho Min
   Yun, Jong Won
   Lee, Seon-Jin
   Cho, Hee Jun
   Lee, Hee Gu
   Kang, Sun Chul
TI Vitexin confers HSF-1 mediated autophagic cell death by activating JNK
   and ApoL1 in colorectal carcinoma cells
SO ONCOTARGET
LA English
DT Article
DE vitexin; HSF-1; ApoL1; autophagic cell death; colorectal carcinoma
ID HEAT-SHOCK FACTOR-1; TRANSCRIPTION FACTOR-1; SIGNALING PATHWAY;
   DNA-BINDING; ANTIOXIDANT ACTIVITIES; POTENTIAL ROLE; TUMOR-GROWTH;
   APOPTOSIS; PHOSPHORYLATION; PROTEIN
AB Heat shock transcription factor-1 (HSF-1) guards the cancerous cells proteome against the alterations in protein homeostasis generated by their hostile tumor microenvironment. Contrasting with the classical induction of heat shock proteins, the pro-oncogenic activities of HSF-1 remains to be explored. Therefore, cancer's fragile proteostatic pathway governed by HSF-1 could be a potential therapeutic target and novel biomarker by natural compounds. Vitexin, a natural flavonoid has been documented as a potent anti-tumor agent on various cell lines. However, in the present study, when human colorectal carcinoma HCT-116 cells were exposed to vitexin, the induction of HSF-1 downstream target proteins, such as heat shock proteins were suppressed. We identified HSF-1 as a potential molecular target of vitexin that interact with DNA-binding domain of HSF-1, which inhibited HSF-1 oligomerization and activation (in silico). Consequently, HSF-1 hyperphosphorylation mediated by JNK operation causes transcriptional inactivation of HSF-1, and supported ROS-mediated autophagy induction. Interestingly, in HSF-1 immunoprecipitated and silenced HCT-116 cells, co-expression of apolipoprotein 1 (ApoL1) and JNK was observed which promoted the caspase independent autophagic cell death accompanied by p62 downregulation and increased LC3-I to LC3-II conversion. Finally, in vivo findings confirmed that vitexin suppressed tumor growth through activation of autophagic cascade in HCT-116 xenograft model. Taken together, our study insights a probable novel association between HSF-1 and ApoL-1 was established in this study, which supports HSF-1 as a potential target of vitexin to improve treatment outcome in colorectal cancer.
C1 [Bhardwaj, Monika; Paul, Souren; Jakhar, Rekha; Khan, Imran; Yun, Jong Won; Kang, Sun Chul] Daegu Univ, Dept Biotechnol, Kyongsan, Kyoungbook, South Korea.
   [Kang, Ji In; Kim, Ho Min] Korea Adv Inst Sci & Technol, GSMSE, Dis Mol Biochem Lab, Daejeon, South Korea.
   [Lee, Seon-Jin; Cho, Hee Jun; Lee, Hee Gu] Korea Res Inst Biosci & Biotechnol, Immunotherapy Convergence Res Ctr, Daejeon, South Korea.
   [Lee, Seon-Jin; Lee, Hee Gu] UST, Dept Biomol Sci, Daejeon, South Korea.
RP Kang, SC (corresponding author), Daegu Univ, Dept Biotechnol, Kyongsan, Kyoungbook, South Korea.; Lee, HG (corresponding author), Korea Res Inst Biosci & Biotechnol, Immunotherapy Convergence Res Ctr, Daejeon, South Korea.; Lee, HG (corresponding author), UST, Dept Biomol Sci, Daejeon, South Korea.
EM hglee@kribb.re.kr; sckang@daegu.ac.kr
RI Kim, Ho Min/G-2712-2011; Lee, Seon-Jin/AAJ-8258-2020
OI Lee, Seon-Jin/0000-0001-7214-7536
FU NRF (National Research Foundation of South Korea) [2016R1A2B4009227,
   2017R1A2B2005629]
FX This research was funded by NRF (National Research Foundation of South
   Korea)-2016R1A2B4009227 and 2017R1A2B2005629.
CR Aggarwal BB, 2009, EXP BIOL MED, V234, P825, DOI 10.3181/0902-MR-78
   Bhardwaj M, 2015, LIFE SCI, V142, P36, DOI 10.1016/j.lfs.2015.10.012
   Chang L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.415
   Cotto JJ, 1997, J CELL SCI, V110, P2925
   Cotto JJ, 1996, J BIOL CHEM, V271, P3355
   Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020
   Dai RJ, 2000, J BIOL CHEM, V275, P18210, DOI 10.1074/jbc.M000958200
   Desai S, 2013, J BIOL CHEM, V288, P9165, DOI 10.1074/jbc.M112.422071
   Dokladny K, 2013, J BIOL CHEM, V288, P14959, DOI 10.1074/jbc.M113.462408
   Hippert MM, 2006, CANCER RES, V66, P9349, DOI 10.1158/0008-5472.CAN-06-1597
   Hoang AT, 2000, AM J PATHOL, V156, P857, DOI 10.1016/S0002-9440(10)64954-1
   Holmberg CI, 2001, EMBO J, V20, P3800, DOI 10.1093/emboj/20.14.3800
   Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2
   Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+
   Jin XJ, 2011, CELL METAB, V14, P91, DOI 10.1016/j.cmet.2011.03.025
   Khan N, 2008, ANTIOXID REDOX SIGN, V10, P475, DOI 10.1089/ars.2007.1740
   Kim EH, 2009, CANCER RES, V69, P9404, DOI 10.1158/0008-5472.CAN-09-1411
   Kim JH, 2005, ARCH PHARM RES, V28, P195, DOI 10.1007/BF02977715
   Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Lan XQ, 2014, AM J PHYSIOL-RENAL, V307, pF326, DOI 10.1152/ajprenal.00647.2013
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Lee CY, 2012, ONCOL REP, V28, P1883, DOI 10.3892/or.2012.2000
   Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260
   Li HY, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.543
   Li HL, 2009, J AM SOC MASS SPECTR, V20, P1496, DOI 10.1016/j.jasms.2009.04.003
   Ma K, 2016, ONCOL REP, V36, P90, DOI 10.3892/or.2016.4782
   McCollum AK, 2008, MOL CANCER THER, V7, P3256, DOI 10.1158/1535-7163.MCT-08-0157
   Nakatogawa H, 2009, NAT REV MOL CELL BIO, V10, P458, DOI 10.1038/nrm2708
   Neudegger T, 2016, NAT STRUCT MOL BIOL, V23, P140, DOI 10.1038/nsmb.3149
   Olabisi OA, 2016, P NATL ACAD SCI USA, V113, P830, DOI 10.1073/pnas.1522913113
   Park MA, 2008, MOL PHARMACOL, V73, P1168, DOI 10.1124/mol.107.042697
   Pattaramanon N, 2007, BIOCHEMISTRY-US, V46, P3405, DOI 10.1021/bi061124c
   Qin L, 2010, AUTOPHAGY, V6, P239, DOI 10.4161/auto.6.2.11062
   RABINDRAN SK, 1994, MOL CELL BIOL, V14, P6552, DOI 10.1128/MCB.14.10.6552
   Raychaudhuri S, 2014, CELL, V156, P975, DOI 10.1016/j.cell.2014.01.055
   Samarasinghe B, 2014, BIOCHEM PHARMACOL, V87, P445, DOI 10.1016/j.bcp.2013.11.014
   Shen HM, 2006, FREE RADICAL BIO MED, V40, P928, DOI 10.1016/j.freeradbiomed.2005.10.056
   Tan ZH, 2012, INT J GYNECOL CANCER, V22, P360, DOI 10.1097/IGC.0b013e31823de844
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tsai JC, 2011, AFR J PHARM PHARMACO, V5, P468, DOI 10.5897/AJPP11.059
   Vilaboa NE, 2000, J BIOL CHEM, V275, P24970, DOI 10.1074/jbc.M909136199
   Vinay R, 2011, INT RES J BIOCH BIOI, V1, P95
   Wan GH, 2008, J BIOL CHEM, V283, P21540, DOI 10.1074/jbc.M800214200
   Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716
   Wu M, 2015, PHYTOMEDICINE, V22, P902, DOI 10.1016/j.phymed.2015.06.008
   Wu N, 2009, MOLECULES, V14, P1032, DOI 10.3390/molecules14031032
   Xavier IJ, 2000, J BIOL CHEM, V275, P29147, DOI 10.1074/jbc.M002169200
   Xia WL, 1997, J BIOL CHEM, V272, P4094, DOI 10.1074/jbc.272.7.4094
   Xu Y, 2006, J BIOL CHEM, V281, P19179, DOI 10.1074/jbc.M513377200
   Yoon YJ, 2011, J BIOL CHEM, V286, P1737, DOI 10.1074/jbc.M110.179440
   Zhou J, 2013, ANTI-CANCER DRUG, V24, P928, DOI 10.1097/CAD.0b013e328364e8d3
   Zhou YJ, 2009, CLIN CANCER RES, V15, P5161, DOI 10.1158/1078-0432.CCR-09-0661
   Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3
NR 55
TC 13
Z9 14
U1 1
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD DEC 22
PY 2017
VL 8
IS 68
BP 112426
EP 112441
DI 10.18632/oncotarget.20113
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FS1WP
UT WOS:000419569800023
PM 29348836
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Talero, E
   Avila-Roman, J
   Motilva, V
AF Talero, Elena
   Avila-Roman, Javier
   Motilva, Virginia
TI Chemoprevention with Phytonutrients and Microalgae Products in Chronic
   Inflammation and Colon Cancer
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE Gut; immunology; chronic inflammation; colon cancer; inflammatory bowel
   disease; chemoprevention; phytonutrients; microalgae
ID NF-KAPPA-B; ABERRANT CRYPT FOCI; DEXTRAN SULFATE SODIUM; POLYUNSATURATED
   FATTY-ACIDS; ACTIVATED RECEPTOR-GAMMA; INDUCED COLORECTAL
   CARCINOGENESIS; RESVERATROL SUPPRESSES COLITIS; EPITHELIAL-CELL
   PROLIFERATION; ENDOPLASMIC-RETICULUM STRESS; CURCUMIN-INDUCED APOPTOSIS
AB Inflammatory bowel disease (IBD) is a chronic inflammatory disorder caused by deregulated immune responses in a genetically predisposed individual. This is a complex process mediated by cytokines, chemokines, adhesion molecules, cytoplasm nuclear receptors, among others. Recent data support a participation of the endoplasmic reticulum (ER) stress and mitochondrial dysfunctions in IBD. Moreover, now it is evident that chronic degenerative pathologies, including IBD, share comparable disease mechanisms at the cellular level with alteration of the autophagy mechanisms.
   Mounting evidence suggests that the risk of developing colorectal cancer (CRC) is dramatically increased in patients with chronic inflammatory disease. Chronic inflammation in IBD exposes these patients to a number of signals known to have tumorigenic effects including nuclear factor kappa B (NF-kappa B) activation, proinflammatory cytokines and prostaglandins release and reactive oxygen species (ROS) production.
   Chemoprevention consists in the use of drugs, vitamins, or nutritional supplements to reduce the risk of developing, or having a recurrence of cancer. Numerous in vitro and animal studies have established the potential colon cancer chemopreventive properties of phytochemicals derived from both plants (curcumin, resveratrol, epigallocatechin gallate, quercetin or genistein) and substances from marine environment, including microalgae species and their products. This review summarizes the mechanisms by which these naturally occurring compounds may mediate chemopreventive effects on cancer. These actions include induction of cell cycle arrest and apoptosis, inhibition of cell proliferation, stimulation of antimetastatic and antiangiogenic responses and increased antioxidant and anti-inflammatory activity.
C1 [Talero, Elena; Avila-Roman, Javier; Motilva, Virginia] Univ Seville, Sch Pharm, Dept Pharmacol, E-41012 Seville, Spain.
RP Talero, E (corresponding author), Univ Seville, Sch Pharm, Dept Pharmacol, C Prof Garcia Gonzalez 2, E-41012 Seville, Spain.
EM etalero@us.es
RI Talero, Elena/I-2613-2015; Avila-Roman, Javier/B-5337-2017
OI Motilva Sanchez, Virginia/0000-0001-5674-6969; Avila-Roman, Francisco
   Javier/0000-0001-9766-8178; Talero Barrientos/0000-0001-9955-801X
CR Abboud PA, 2008, EUR J PHARMACOL, V579, P411, DOI 10.1016/j.ejphar.2007.10.053
   Abd El-Baky HH, 2010, J SCI FOOD AGR, V90, P299, DOI 10.1002/jsfa.3815
   Abreu Maria T, 2002, Curr Gastroenterol Rep, V4, P481, DOI 10.1007/s11894-002-0024-0
   Adachi S, 2007, CANCER RES, V67, P6493, DOI 10.1158/0008-5472.CAN-07-0411
   Adams KF, 2005, AM J CLIN NUTR, V82, P620, DOI 10.1093/ajcn/82.3.620
   Aggarwal BB, 2006, BIOCHEM PHARMACOL, V72, P1605, DOI 10.1016/j.bcp.2006.06.029
   Agullo G, 1996, CANCER LETT, V105, P61, DOI 10.1016/0304-3835(96)04262-0
   Allred CD, 2008, J NUTR, V138, P250, DOI 10.1093/jn/138.2.250
   Almushatat ASK, 2006, INT J CANCER, V118, P1051, DOI 10.1002/ijc.21451
   Arafa HMM, 2009, FOOD CHEM TOXICOL, V47, P1311, DOI 10.1016/j.fct.2009.03.003
   Ariazi EA, 2006, CURR TOP MED CHEM, V6, P203, DOI 10.2174/1568026610606030203
   Athar M, 2009, ARCH BIOCHEM BIOPHYS, V486, P95, DOI 10.1016/j.abb.2009.01.018
   Augustsson K, 2003, CANCER EPIDEM BIOMAR, V12, P64
   Roman FA, 2011, SHOCK, V36, P8
   Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI 10.1089/ARS.2008.2270
   Back SH, 2006, J BIOL CHEM, V281, P18691, DOI 10.1074/jbc.M602030200
   Balaburski GM, 2010, TRENDS CELL BIOL, V20, P363, DOI 10.1016/j.tcb.2010.02.007
   Balachandran P, 2006, INT IMMUNOPHARMACOL, V6, P1808, DOI 10.1016/j.intimp.2006.08.001
   Barnes PJ, 1997, INT J BIOCHEM CELL B, V29, P867, DOI 10.1016/S1357-2725(96)00159-8
   Baron JA, 2010, CANCER PREV RES, V3, P573, DOI 10.1158/1940-6207.CAPR-10-0050
   Bassaganya-Riera J, 2004, GASTROENTEROLOGY, V127, P777, DOI 10.1053/j.gastro.2004.06.049
   Bassaganya-Riera J, 2006, CLIN NUTR, V25, P454, DOI 10.1016/j.clnu.2005.12.008
   Bassaganya-Riera J, 2010, CURR OPIN CLIN NUTR, V13, P569, DOI 10.1097/MCO.0b013e32833b648e
   Bauvy C, 2001, EXP CELL RES, V268, P139, DOI 10.1006/excr.2001.5285
   Belluzzi A, 1996, NEW ENGL J MED, V334, P1557, DOI 10.1056/NEJM199606133342401
   Bharti AC, 2002, ANN NY ACAD SCI, V973, P392, DOI 10.1111/j.1749-6632.2002.tb04671.x
   Biel RK, 2011, PUBLIC HEALTH NUTR, V14, P1
   Bielecki A, 2011, NUTR CANCER, V63, P139, DOI 10.1080/01635581.2010.516867
   Binion DG, 2008, GUT, V57, P1509, DOI 10.1136/gut.2008.152496
   Bird P.R., 2000, TOXICOL LETT, V112-113, P295
   BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201
   Bobe G, 2010, CANCER PREV RES, V3, P764, DOI 10.1158/1940-6207.CAPR-09-0161
   Boeckaert C, 2008, J DAIRY SCI, V91, P4714, DOI 10.3168/jds.2008-1178
   Boopathy NS, 2010, J ONCOL, V2010, DOI 10.1155/2010/214186
   Booth C, 1999, BRIT J CANCER, V80, P1550, DOI 10.1038/sj.bjc.6690559
   Brant SR, 2004, INFLAMM BOWEL DIS, V10, P300, DOI 10.1097/00054725-200405000-00019
   Brower V, 2011, NATURE, V471, pS19, DOI 10.1038/471S19a
   Buchner FL, 2010, CANCER CAUSE CONTROL, V21, P357, DOI 10.1007/s10552-009-9468-y
   Burns J, 2002, J AGR FOOD CHEM, V50, P3337, DOI 10.1021/jf0112973
   Calviello G, 2004, CARCINOGENESIS, V25, P2303, DOI 10.1093/carcin/bgh265
   Camacho-Barquero L, 2007, INT IMMUNOPHARMACOL, V7, P333, DOI 10.1016/j.intimp.2006.11.006
   Campisi J, 2009, AGING CELL, V8, P221, DOI 10.1111/j.1474-9726.2009.00475.x
   Camuesco D, 2006, CLIN NUTR, V25, P466, DOI 10.1016/j.clnu.2005.12.009
   Camuesco D, 2005, J NUTR, V135, P687, DOI 10.1093/jn/135.4.687
   Camuesco D, 2004, BRIT J PHARMACOL, V143, P908, DOI 10.1038/sj.bjp.0705941
   Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813
   Cario E, 2008, CURR OPIN GASTROEN, V24, P725, DOI 10.1097/MOG.0b013e32830c4341
   Carroll RE, 2011, CANCER PREV RES, V4, P354, DOI 10.1158/1940-6207.CAPR-10-0098
   Carter O, 2007, NUTR CANCER, V58, P60, DOI 10.1080/01635580701308182
   Ceron MC, 2007, APPL MICROBIOL BIOT, V74, P1112, DOI 10.1007/s00253-006-0743-5
   Cha KH, 2008, J AGR FOOD CHEM, V56, P10521, DOI 10.1021/jf802111x
   Cha TS, 2011, J MICROBIOL METH, V84, P430, DOI 10.1016/j.mimet.2011.01.005
   Chan JY, 2008, CANCER BIOL THER, V7, P1305, DOI 10.4161/cbt.7.8.6302
   Chapkin RS, 2007, J NUTR, V137, p200S, DOI 10.1093/jn/137.1.200S
   CHEESEMAN KH, 1993, BRIT MED BULL, V49, P481, DOI 10.1093/oxfordjournals.bmb.a072625
   Chen AP, 2005, AM J PHYSIOL-GASTR L, V288, pG447, DOI 10.1152/ajpgi.00209.2004
   Cheng AL, 2001, ANTICANCER RES, V21, P2895
   Cheng JL, 2003, CANCER LETT, V193, P17, DOI 10.1016/S0304383502007176
   Chew BP, 2011, VET IMMUNOL IMMUNOP, V140, P199, DOI 10.1016/j.vetimm.2010.12.004
   Chiaiese P, 2011, ENZYME MICROB TECH, V49, P540, DOI 10.1016/j.enzmictec.2011.06.002
   Chiou YS, 2010, J AGR FOOD CHEM, V58, P8833, DOI 10.1021/jf101571z
   Chirumbolo Salvatore, 2010, Inflammation & Allergy Drug Targets, V9, P263
   Cho JY, 2011, MOL NUTR FOOD RES, V55, P239, DOI 10.1002/mnfr.201000070
   Choi SY, 2006, BIOFACTORS, V27, P137, DOI 10.1002/biof.5520270112
   Chondrogianni N, 2010, EXP GERONTOL, V45, P763, DOI 10.1016/j.exger.2010.07.001
   Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635
   Comalada M, 2005, EUR J IMMUNOL, V35, P584, DOI 10.1002/eji.200425778
   Cooney JM, 2012, J PROTEOME RES, V11, P1065, DOI 10.1021/pr200807p
   Cooney R, 2010, NAT MED, V16, P90, DOI 10.1038/nm.2069
   Cooper HS, 2000, CARCINOGENESIS, V21, P757, DOI 10.1093/carcin/21.4.757
   Cordero BF, 2011, APPL MICROBIOL BIOT, V91, P341, DOI 10.1007/s00253-011-3262-y
   Cosan DT, 2010, CANCER BIOTHER RADIO, V25, P577, DOI 10.1089/cbr.2010.0799
   Courtney ED, 2007, INT J COLORECTAL DIS, V22, P765, DOI 10.1007/s00384-006-0240-4
   Cragg GM, 2002, TRENDS PHARMACOL SCI, V23, P404, DOI 10.1016/S0165-6147(02)02099-0
   Cragg GM, 2009, CHEM REV, V109, P3012, DOI 10.1021/cr900019j
   Cruz-Correa M, 2006, CLIN GASTROENTEROL H, V4, P1035, DOI 10.1016/j.cgh.2006.03.020
   Cui XL, 2010, CANCER PREV RES, V3, P549, DOI 10.1158/1940-6207.CAPR-09-0117
   Dadhaniya P, 2011, FOOD CHEM TOXICOL, V49, P1834, DOI 10.1016/j.fct.2011.05.001
   De Flora S, 2005, MUTAT RES-FUND MOL M, V591, P8, DOI 10.1016/j.mrfmmm.2005.02.029
   de la Vega M, 2011, BIOTECHNOL PROGR, V27, P1535, DOI 10.1002/btpr.686
   de Medina FS, 2002, LIFE SCI, V70, P3097, DOI 10.1016/S0024-3205(02)01568-0
   de Mejia EG, 2009, BRAIN BEHAV IMMUN, V23, P721, DOI 10.1016/j.bbi.2009.02.013
   Deguchi Y, 2007, DIGEST DIS SCI, V52, P2993, DOI 10.1007/s10620-006-9138-9
   Del Campo JA, 2007, APPL MICROBIOL BIOT, V74, P1163, DOI 10.1007/s00253-007-0844-9
   DeMedina FS, 1996, J PHARMACOL EXP THER, V278, P771
   Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064
   DESCHNER EE, 1991, CARCINOGENESIS, V12, P1193, DOI 10.1093/carcin/12.7.1193
   Desreumaux P, 2001, J EXP MED, V193, P827, DOI 10.1084/jem.193.7.827
   Deweerdt S, 2011, NATURE, V471, pS22, DOI 10.1038/471S22a
   Dhillon N, 2008, CLIN CANCER RES, V14, P4491, DOI 10.1158/1078-0432.CCR-08-0024
   Di Leo A, 2008, DIGEST LIVER DIS, V40, P260, DOI 10.1016/j.dld.2007.10.018
   Dihal AA, 2006, J NUTR, V136, P2862, DOI 10.1093/jn/136.11.2862
   Dominy JE, 2010, BIOPHYS ACTA, V1804, P1684
   Dommels YEM, 2003, CARCINOGENESIS, V24, P385, DOI 10.1093/carcin/24.3.385
   Du BY, 2006, CHEMOTHERAPY, V52, P23, DOI 10.1159/000090238
   Durai R, 2005, INT J COLORECTAL DIS, V20, P203, DOI 10.1007/s00384-004-0675-4
   Duthie SJ, 1999, EUR J NUTR, V38, P28, DOI 10.1007/s003940050043
   Dwyer JH, 2001, CIRCULATION, V103, P2922, DOI 10.1161/01.CIR.103.24.2922
   Juan ME, 2008, J AGR FOOD CHEM, V56, P4813, DOI 10.1021/jf800175a
   Estrada JEP, 2001, FARMACO, V56, P497
   Fabregas J, 1999, ANTIVIR RES, V44, P67, DOI 10.1016/S0166-3542(99)00049-2
   Fassett RG, 2011, MAR DRUGS, V9, P447, DOI 10.3390/md9030447
   Fattah EAA, 2010, GEN PHYSIOL BIOPHYS, V29, P85, DOI 10.4149/gpb_2010_01_85
   Feagan BG, 2008, JAMA-J AM MED ASSOC, V299, P1690, DOI 10.1001/jama.299.14.1690
   Fernandez-Sevilla JM, 2010, APPL MICROBIOL BIOT, V86, P27, DOI 10.1007/s00253-009-2420-y
   Fini L, 2010, CLIN CANCER RES, V16, P5703, DOI 10.1158/1078-0432.CCR-10-1990
   Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020
   Ford J, 2005, CANCER RES, V65, P10457, DOI 10.1158/0008-5472.CAN-05-1923
   Fritz JH, 2005, EUR J IMMUNOL, V35, P2459, DOI 10.1002/eji.200526286
   Fukata M, 2006, GASTROENTEROLOGY, V131, P862, DOI 10.1053/j.gastro.2006.06.017
   Fukunaga K, 2008, NUTR RES, V28, P635, DOI 10.1016/j.nutres.2008.05.005
   Ge XJ, 2009, MOL BIOL CELL, V20, P419, DOI 10.1091/mbc.E08-08-0792
   Geresh S, 2002, J BIOCHEM BIOPH METH, V50, P179, DOI 10.1016/S0165-022X(01)00185-3
   Gescher AJ, 2008, PLANTA MED, V74, P1523, DOI [10.1055/s-0028-1088305, 10.1055/s-0028-1088300]
   Glick AB, 2004, CANCER BIOL THER, V3, P276, DOI 10.4161/cbt.3.3.849
   Goel A, 2001, CANCER LETT, V172, P111, DOI 10.1016/S0304-3835(01)00655-3
   GOTTLICHER M, 1993, BIOCHEM PHARMACOL, V46, P2177, DOI 10.1016/0006-2952(93)90607-X
   Gravitz L, 2011, NATURE, V471, pS5, DOI 10.1038/471S5a
   Greenstein AJ, 2000, MT SINAI J MED, V67, P227
   Guedes AC, 2011, MAR DRUGS, V9, P625, DOI 10.3390/md9040625
   Guerin M, 2003, TRENDS BIOTECHNOL, V21, P210, DOI 10.1016/S0167-7799(03)00078-7
   Guil-Guerrero JL, 2000, BIOSEPARATION, V9, P299, DOI 10.1023/A:1011124624001
   Guo JY, 2004, J NUTR, V134, P179, DOI 10.1093/jn/134.1.179
   Gupta SC, 2011, EXP BIOL MED, V236, P658, DOI 10.1258/ebm.2011.011028
   Guri AJ, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-60
   Gutierrez O, 2002, J BIOL CHEM, V277, P41701, DOI 10.1074/jbc.M206473200
   Haines DD, 2011, PHYTOTHER RES, V25, P128, DOI 10.1002/ptr.3160
   Haller D, 2006, NEUROGASTROENT MOTIL, V18, P184, DOI 10.1111/j.1365-2982.2006.00762.x
   Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954
   Han J, 2008, J BIOL CHEM, V283, P19665, DOI 10.1074/jbc.M710169200
   Hanai H, 2006, CLIN GASTROENTEROL H, V4, P1502, DOI 10.1016/j.cgh.2006.08.008
   Hanauer SB, 2006, INFLAMM BOWEL DIS, V12, pS3, DOI 10.1097/01.MIB.0000195385.19268.68
   Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221
   Hassan A, 2010, J NUTR, V140, P1714, DOI 10.3945/jn.109.119768
   Hatcher H, 2008, CELL MOL LIFE SCI, V65, P1631, DOI 10.1007/s00018-008-7452-4
   He ZY, 2011, CANCER INVEST, V29, P208, DOI 10.3109/07357907.2010.550592
   Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902
   Herrero M, 2006, J FOOD PROTECT, V69, P2471, DOI 10.4315/0362-028X-69.10.2471
   HINTON JM, 1966, GUT, V7, P427, DOI 10.1136/gut.7.5.427
   Hoensch H, 2008, WORLD J GASTROENTERO, V14, P2187, DOI 10.3748/wjg.14.2187
   Hofseth LJ, 2010, AGING-US, V2, P183, DOI 10.18632/aging.100143
   Hollman PCH, 1999, FOOD CHEM TOXICOL, V37, P937, DOI 10.1016/S0278-6915(99)00079-4
   Holloway KR, 2010, P NATL ACAD SCI USA, V107, P9216, DOI 10.1073/pnas.0911325107
   Holt PR, 2005, DIGEST DIS SCI, V50, P2191, DOI 10.1007/s10620-005-3032-8
   Hontecillas R, 2002, J NUTR, V132, P2019, DOI 10.1093/jn/132.7.2019
   Hope C, 2008, MOL NUTR FOOD RES, V52, pS52, DOI 10.1002/mnfr.200700448
   Hossain Z, 2009, NUTR CANCER, V61, P123, DOI 10.1080/01635580802395725
   Hu FL, 2012, BREAST CANCER RES TR, V131, P239, DOI 10.1007/s10549-011-1723-8
   Jiang H, 2006, WORLD J GASTROENTERO, V12, P3848, DOI 10.3748/wjg.v12.i24.3848
   Huang J, 2011, ANTIOXID REDOX SIGNA
   Huett A, 2010, CURR OPIN GASTROEN, V26, P302, DOI 10.1097/MOG.0b013e32833ae2ed
   Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107
   Hwang JT, 2007, CANCER LETT, V247, P115, DOI 10.1016/j.canlet.2006.03.030
   Hwang JT, 2005, BIOCHEM BIOPH RES CO, V332, P433, DOI 10.1016/j.bbrc.2005.04.143
   Imai SI, 2010, BBA-PROTEINS PROTEOM, V1804, P1584, DOI 10.1016/j.bbapap.2009.10.024
   Itzkowitz SH, 2004, AM J PHYSIOL-GASTR L, V287, pG7, DOI 10.1152/ajpgi.00079.2004
   Itzkowitz SH, 2006, GASTROENTEROL CLIN N, V35, P553, DOI 10.1016/j.gtc.2006.07.002
   Jaiswal AS, 2002, ONCOGENE, V21, P8414, DOI 10.1038/sj.onc.1205947
   Jian YT, 2005, WORLD J GASTROENTERO, V11, P1747, DOI 10.3748/wjg.v11.i12.1747
   Jobin C, 1999, J IMMUNOL, V163, P3474
   John S, 2010, EUR J GASTROEN HEPAT, V22, P602, DOI 10.1097/MEG.0b013e3283352d05
   Johnson E A, 1996, Adv Biochem Eng Biotechnol, V53, P119
   Ju J, 2005, CANCER RES, V65, P10623, DOI 10.1158/0008-5472.CAN-05-1949
   Kabra N, 2009, J BIOL CHEM, V284, P18210, DOI 10.1074/jbc.M109.000034
   Kameoka S, 1999, CANCER LETT, V146, P161, DOI 10.1016/S0304-3835(99)00253-0
   Kanai M, 2012, CANCER CHEMOTH PHARM, V69, P65, DOI 10.1007/s00280-011-1673-1
   Kaser A, 2010, MUCOSAL IMMUNOL, V3, P11, DOI 10.1038/mi.2009.122
   Kaser A, 2010, CURR OPIN GASTROEN, V26, P318, DOI 10.1097/MOG.0b013e32833a9ff1
   Kaser A, 2010, ANNU REV IMMUNOL, V28, P573, DOI 10.1146/annurev-immunol-030409-101225
   Kato T, 2007, NUTR CANCER, V58, P178, DOI 10.1080/01635580701328362
   Katsman A, 2009, CURR PHARM DESIGN, V15, P792, DOI 10.2174/138161209787582156
   Kaur J, 2010, EUR J CANCER PREV, V19, P319, DOI 10.1097/CEJ.0b013e32833ad385
   Kawamori T, 1999, CANCER RES, V59, P597
   Kelloff GJ, 2000, J NUTR, V130, p467S, DOI 10.1093/jn/130.2.467S
   KENNEDY AR, 1995, J NUTR, V125, pS733, DOI 10.1093/jn/125.3_Suppl.733S
   Kennedy BK, 2007, CELL MOL LIFE SCI, V64, P1323, DOI 10.1007/s00018-007-6470-y
   Khachik F, 1997, ANAL CHEM, V69, P1873, DOI 10.1021/ac961085i
   Khan SK, 2010, THROMB RES, V126, P299, DOI 10.1016/j.thromres.2010.07.003
   Kim EJ, 2005, J MED FOOD, V8, P431, DOI 10.1089/jmf.2005.8.431
   Kim HJ, 2010, J AGR FOOD CHEM, V58, P8643, DOI 10.1021/jf101510z
   Kim WK, 2005, J NUTR BIOCHEM, V16, P155, DOI 10.1016/j.jnutbio.2004.10.010
   Kim Y, 2011, J NUTR SCI VITAMINOL, V57, P216, DOI 10.3177/jnsv.57.216
   Kimura Y, 2008, CANCER SCI, V99, P2083, DOI 10.1111/j.1349-7006.2008.00948.x
   King-Batoon A, 2008, ENVIRON MOL MUTAGEN, V49, P36, DOI 10.1002/em.20363
   Klaunig JE, 2004, ANNU REV PHARMACOL, V44, P239, DOI 10.1146/annurev.pharmtox.44.101802.121851
   Klein CB, 2007, TOXICOL APPL PHARM, V224, P1, DOI 10.1016/j.taap.2007.06.022
   KONO S, 1993, JPN J CANCER RES, V84, P13, DOI 10.1111/j.1349-7006.1993.tb02777.x
   Kostadinova R, 2005, CURR MED CHEM, V12, P2995, DOI 10.2174/092986705774462905
   Kousidou OC, 2006, MINI-REV MED CHEM, V6, P331, DOI 10.2174/138955706776073420
   KRINSKY NI, 1979, PURE APPL CHEM, V51, P649, DOI 10.1351/pac197951030649
   Krishnaswamy R, 2010, FREE RADICAL BIO MED, V49, P50, DOI 10.1016/j.freeradbiomed.2010.03.016
   Kroon PA, 2010, CURR MED CHEM, V17, P2442
   KU HH, 1993, FREE RADICAL BIO MED, V15, P621, DOI 10.1016/0891-5849(93)90165-Q
   Kuo SM, 1996, CANCER LETT, V110, P41, DOI 10.1016/S0304-3835(96)04458-8
   Kurzawa-Zegota M, 2012, FOOD CHEM TOXICOL, V50, P124, DOI 10.1016/j.fct.2011.08.020
   Kwon KH, 2005, BIOCHEM PHARMACOL, V69, P395, DOI 10.1016/j.bcp.2004.10.015
   Lala S, 2003, GASTROENTEROLOGY, V125, P47, DOI 10.1016/S0016-5085(03)00661-9
   Lambert JD, 2008, CARCINOGENESIS, V29, P2019, DOI 10.1093/carcin/bgn182
   Lambert JD, 2010, ARCH BIOCHEM BIOPHYS, V501, P65, DOI 10.1016/j.abb.2010.06.013
   Larrosa M, 2009, J AGR FOOD CHEM, V57, P2211, DOI 10.1021/jf803638d
   Latella G, 2010, J CROHNS COLITIS, V4, P690, DOI 10.1016/j.crohns.2010.08.002
   Latham P, 1999, CARCINOGENESIS, V20, P645, DOI 10.1093/carcin/20.4.645
   Lea MA, 2010, FUTURE ONCOL, V6, P993, DOI 10.2217/FON.10.53
   Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105
   Lee JW, 2010, MOL CELLS, V30, P545, DOI 10.1007/s10059-010-0161-5
   Lee SC, 2006, PROTEOMICS, V6, P2386, DOI 10.1002/pmic.200500366
   Lee YK, 2009, ANN NY ACAD SCI, V1171, P489, DOI 10.1111/j.1749-6632.2009.04699.x
   Lee YK, 2009, EXP MOL MED, V41, P201, DOI 10.3858/emm.2009.41.3.023
   Lev-Ari S, 2005, CLIN CANCER RES, V11, P6738, DOI 10.1158/1078-0432.CCR-05-0171
   Levy-Ontman O, 2011, J BIOL CHEM, V286, P21340, DOI 10.1074/jbc.M110.175042
   Lewis JD, 2008, GASTROENTEROLOGY, V134, P688, DOI 10.1053/j.gastro.2007.12.012
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li L, 2007, MOL CANCER THER, V6, P1276, DOI 10.1158/1535-7163.MCT-06-0556
   Li Q, 2011, EPIGENETICS-US, V6, P849, DOI 10.4161/epi.6.7.16314
   Loft S, 1996, J MOL MED, V74, P297, DOI 10.1007/s001090050031
   LOTAN R, 1995, J NATL CANCER I, V87, P1655, DOI 10.1093/jnci/87.22.1655
   Lu SP, 2010, BBA-PROTEINS PROTEOM, V1804, P1567, DOI 10.1016/j.bbapap.2009.09.030
   Lubbad A, 2009, MOL CELL BIOCHEM, V322, P127, DOI 10.1007/s11010-008-9949-4
   Lucchi L, 2005, ARTIF ORGANS, V29, P67, DOI 10.1111/j.1525-1594.2004.29011.x
   Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322
   Mahmoud NN, 2000, CARCINOGENESIS, V21, P921, DOI 10.1093/carcin/21.5.921
   Mahyar-Roemer M, 2001, INT J CANCER, V94, P615, DOI 10.1002/ijc.1516
   Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001
   Majid S, 2009, CARCINOGENESIS, V30, P662, DOI 10.1093/carcin/bgp042
   Majumdar APN, 2009, NUTR CANCER, V61, P544, DOI 10.1080/01635580902752262
   Malhotra Samir, 2006, BMC Pulm Med, V6, P2, DOI 10.1186/1471-2466-6-2
   Marini H, 2007, ANN INTERN MED, V146, P839, DOI 10.7326/0003-4819-146-12-200706190-00005
   Marques FZ, 2009, INT J BIOCHEM CELL B, V41, P2125, DOI 10.1016/j.biocel.2009.06.003
   Martin AR, 2004, BIOCHEM PHARMACOL, V67, P1399, DOI 10.1016/j.bcp.2003.12.024
   Martin B, 2009, IMMUNITY, V31, P321, DOI 10.1016/j.immuni.2009.06.020
   Martin D, 2009, J BIOL CHEM, V284, P6038, DOI 10.1074/jbc.C800207200
   Martin H, 2009, MUTAT RES-FUND MOL M, V669, P1, DOI 10.1016/j.mrfmmm.2009.06.009
   Martin MJ, 2001, CURR PHARM DESIGN, V7, P881, DOI 10.2174/1381612013397645
   Mathy-Hartert M, 2009, INFLAMM RES, V58, P899, DOI 10.1007/s00011-009-0063-1
   Matsukawa Y, 1997, ONCOLOGY-BASEL, V54, P118
   Mayne ST, 1996, FASEB J, V10, P690, DOI 10.1096/fasebj.10.7.8635686
   Meira LB, 2008, J CLIN INVEST, V118, P2516, DOI 10.1172/JCI35073
   Meley D, 2006, J BIOL CHEM, V281, P34870, DOI 10.1074/jbc.M605488200
   MENDES RL, 1995, FOOD CHEM, V53, P99, DOI 10.1016/0308-8146(95)95794-7
   Mendes RL, 2003, INORG CHIM ACTA, V356, P328, DOI 10.1016/S0020-1693(03)00363-3
   Mendiola JA, 2007, FOOD CHEM, V102, P1357, DOI 10.1016/j.foodchem.2006.06.068
   Mendiola JA, 2008, J SUPERCRIT FLUID, V43, P484, DOI 10.1016/j.supflu.2007.07.021
   Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174
   Milacic V, 2008, CANCER RES, V68, P7283, DOI 10.1158/0008-5472.CAN-07-6246
   Min WK, 2010, J MED FOOD, V13, P495, DOI 10.1089/jmf.2009.1208
   Ming ME, 2011, J INVEST DERMATOL, V131, P1835
   Mochizuki M, 2010, PHYTOTHER RES, V24, pS120, DOI 10.1002/ptr.2862
   Mohan J, 2006, J BIOL CHEM, V281, P17599, DOI 10.1074/jbc.M602641200
   Montgomery SM, 2002, CURR OPIN GASTROEN, V18, P416, DOI 10.1097/00001574-200207000-00004
   Morselli E, 2010, AUTOPHAGY, V6, P186, DOI 10.4161/auto.6.1.10817
   Murakami A, 2008, CANCER LETT, V269, P315, DOI 10.1016/j.canlet.2008.03.046
   Murphy EA, 2011, NUTR CANCER, V63, P421, DOI 10.1080/01635581.2011.535954
   Murphy EA, 2011, J INTERF CYTOK RES, V31, P219, DOI 10.1089/jir.2010.0051
   Murtaugh MA, 2005, CANCER EPIDEM BIOMAR, V14, P1224, DOI 10.1158/1055-9965.EPI-04-0681
   Mutoh M, 2000, CARCINOGENESIS, V21, P959, DOI 10.1093/carcin/21.5.959
   Nagendraprabhu P, 2011, INVEST NEW DRUG, V29, P207, DOI 10.1007/s10637-009-9342-5
   Nakamura T, 2010, CELL, V140, P338, DOI 10.1016/j.cell.2010.01.001
   Nakamura Y, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-100
   Navarro-Peran E, 2008, INFLAMM RES, V57, P472, DOI 10.1007/s00011-008-8013-x
   Neurath MF, 2002, J EXP MED, V195, P1129, DOI 10.1084/jem.20011956
   Nguyen Anthony V, 2009, Cancer Manag Res, V1, P25
   Nishikawa T, 2010, ANN SURG ONCOL, V17, P592, DOI 10.1245/s10434-009-0696-x
   Niu YF, 2011, GENET MOL RES, V10, P3427, DOI 10.4238/2011.October.21.1
   Nobre B, 2006, EUR FOOD RES TECHNOL, V223, P787, DOI 10.1007/s00217-006-0270-8
   Nosho K, 2009, MODERN PATHOL, V22, P922, DOI 10.1038/modpathol.2009.49
   O'Connor PM, 2010, INFLAMM BOWEL DIS, V16, P1411, DOI 10.1002/ibd.21217
   Ogasawara M, 2007, BIOL PHARM BULL, V30, P200, DOI 10.1248/bpb.30.200
   Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114
   Ohtsuka Y, 2011, J PEDIATR SURG, V46, P489, DOI 10.1016/j.jpedsurg.2010.07.032
   Olmedilla B, 2003, NUTRITION, V19, P21, DOI 10.1016/S0899-9007(02)00861-4
   Ovesna Z, 2005, NEOPLASMA, V52, P450
   Palozza P, 2005, J NUTR, V135, P129, DOI 10.1093/jn/135.1.129
   Palozza P, 2009, CANCER LETT, V283, P108, DOI 10.1016/j.canlet.2009.03.031
   Park IJ, 2009, ANN NY ACAD SCI, V1171, P538, DOI 10.1111/j.1749-6632.2009.04698.x
   Park JS, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-18
   Park JW, 2007, ONCOL REP, V18, P1269
   Pasare C, 2004, SEMIN IMMUNOL, V16, P23, DOI 10.1016/j.smim.2003.10.006
   PASCAL RR, 1994, HUM PATHOL, V25, P1160, DOI 10.1016/0046-8177(94)90032-9
   Pasparakis M, 2009, NAT REV IMMUNOL, V9, P778, DOI 10.1038/nri2655
   Pasquet V, 2011, MAR DRUGS, V9, P819, DOI 10.3390/md9050819
   Patel BB, 2008, INT J CANCER, V122, P267, DOI 10.1002/ijc.23097
   Patel KR, 2010, CANCER RES, V70, P7392, DOI 10.1158/0008-5472.CAN-10-2027
   Paul S, 2010, CARCINOGENESIS, V31, P1272, DOI 10.1093/carcin/bgq004
   Peng G, 2006, MOL CARCINOGEN, V45, P309, DOI 10.1002/mc.20166
   Perkins S, 2002, CANCER EPIDEM BIOMAR, V11, P535
   Perse M, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/473964
   PIETTE M, 1970, ANN PHARM FR, V28, P529
   Plaza M, 2010, J PHARMACEUT BIOMED, V51, P450, DOI 10.1016/j.jpba.2009.03.016
   Plaza M, 2009, J AGR FOOD CHEM, V57, P7159, DOI 10.1021/jf901070g
   Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980
   Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647
   Polakis P, 2000, GENE DEV, V14, P1837
   Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007
   Pollak M, 2010, CANCER PREV RES, V3, P1060, DOI 10.1158/1940-6207.CAPR-10-0175
   Porath D, 2005, J PHARMACOL EXP THER, V315, P1172, DOI 10.1124/jpet.105.090167
   Proksch P, 2002, APPL MICROBIOL BIOT, V59, P125, DOI 10.1007/s00253-002-1006-8
   Pugh N, 2001, PLANTA MED, V67, P737, DOI 10.1055/s-2001-18358
   Raju J, 2005, INT J CANCER, V113, P798, DOI 10.1002/ijc.20640
   Ramos AL, 2010, NUTR CANCER, V62, P1170, DOI 10.1080/01635581.2010.513801
   Ran ZH, 2008, BIOMED PHARMACOTHER, V62, P189, DOI 10.1016/j.biopha.2008.02.002
   RAO CV, 1995, CANCER RES, V55, P259
   Rasala BA, 2010, PLANT BIOTECHNOL J, V8, P719, DOI 10.1111/j.1467-7652.2010.00503.x
   Reynoso-Camacho R, 2011, NUTR CANCER, V63, P39, DOI 10.1080/01635581.2010.516477
   Richmond A, 2002, NAT REV IMMUNOL, V2, P664, DOI 10.1038/nri887
   Richter M, 1999, NUTR CANCER, V34, P88, DOI 10.1207/S15327914NC340113
   RIDDELL RH, 1983, HUM PATHOL, V14, P931, DOI 10.1016/S0046-8177(83)80175-0
   Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032
   Salminen A, 2008, CELL MOL LIFE SCI, V65, P2979, DOI 10.1007/s00018-008-8103-5
   Sanchez JF, 2008, PROCESS BIOCHEM, V43, P398, DOI 10.1016/j.procbio.2008.01.004
   Sanchez-Fidalgo S, 2010, EUR J PHARMACOL, V633, P78, DOI 10.1016/j.ejphar.2010.01.025
   Sanghvi Avani M, 2010, Recent Pat Food Nutr Agric, V2, P187, DOI 10.2174/1876142911002030187
   Sarra M, 2010, INFLAMM BOWEL DIS, V16, P1332, DOI 10.1002/ibd.21238
   Sartor RB, 2005, MUCOSAL IMMUNOLOGY, 3RD EDITION, P681, DOI 10.1016/B978-012491543-5/50039-5
   Sartor RB, 2006, NAT CLIN PRACT GASTR, V3, P390, DOI 10.1038/ncpgasthep0528
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Saubermann LJ, 2002, INFLAMM BOWEL DIS, V8, P330, DOI 10.1097/00054725-200209000-00004
   Scherz-Shouval R, 2010, P NATL ACAD SCI USA, V107, P18511, DOI 10.1073/pnas.1006124107
   Schmidt MV, 2010, THESCIENTIFICWORLDJO, V10, P2181, DOI 10.1100/tsw.2010.213
   Schneider Y, 2001, NUTR CANCER, V39, P102, DOI 10.1207/S15327914nc391_14
   Seibel J, 2009, EUR J NUTR, V48, P213, DOI 10.1007/s00394-009-0004-3
   Selvaraj RK, 2010, COMP BIOCHEM PHYS A, V157, P198, DOI 10.1016/j.cbpa.2010.06.172
   Senda T, 2007, MED MOL MORPHOL, V40, P68, DOI 10.1007/s00795-006-0352-5
   Sengottuvelan M, 2006, CARCINOGENESIS, V27, P1038, DOI 10.1093/carcin/bgi286
   Sengottuvelan M, 2006, BRIT J NUTR, V96, P145, DOI 10.1079/BJN20061789
   Sengottuvelan M, 2009, NUTRITION, V25, P1169, DOI 10.1016/j.nut.2009.03.009
   Seril DN, 2007, MOL CARCINOGEN, V46, P341, DOI 10.1002/mc.20282
   Serpeloni JM, 2012, TOXICOL IN VITRO, V26, P288, DOI 10.1016/j.tiv.2011.11.011
   Setchell KDR, 1999, J NUTR, V129, p758S, DOI 10.1093/jn/129.3.758S
   Shan BE, 2009, CANCER INVEST, V27, P604, DOI 10.1080/07357900802337191
   Sharma RA, 2004, CLIN CANCER RES, V10, P6847, DOI 10.1158/1078-0432.CCR-04-0744
   Shehzad A, 2011, EUR J NUTR, V50, P151, DOI 10.1007/s00394-011-0188-1
   Shibata S, 2007, BIOSCI BIOTECH BIOCH, V71, P916, DOI 10.1271/bbb.60566
   Shimizu M, 2005, CLIN CANCER RES, V11, P2735, DOI 10.1158/1078-0432.CCR-04-2014
   Shimizu M, 2005, J EXP THER ONCOL, V5, P69
   Shimizu M, 2008, CANCER PREV RES, V1, P298, DOI 10.1158/1940-6207.CAPR-08-0045
   Shirakami Y, 2008, MOL MED REP, V1, P355
   Shpitz B, 2006, DIGESTION, V74, P140, DOI 10.1159/000098655
   Shukla Y, 2011, ANN NY ACAD SCI, V1229, P162, DOI 10.1111/j.1749-6632.2011.06104.x
   Si HW, 2007, CURR MED CHEM, V14, P2581, DOI 10.2174/092986707782023325
   Sijtsma L, 2004, APPL MICROBIOL BIOT, V64, P146, DOI 10.1007/s00253-003-1525-y
   Singh UP, 2012, BRAIN BEHAV IMMUN, V26, P72, DOI 10.1016/j.bbi.2011.07.236
   Singh UP, 2010, J PHARMACOL EXP THER, V332, P829, DOI 10.1124/jpet.109.160838
   Slimestad R, 2007, J AGR FOOD CHEM, V55, P10067, DOI 10.1021/jf0712503
   Smelcerovic A, 2008, CURR PHARM DESIGN, V14, P3168, DOI 10.2174/138161208786404254
   Smith W, 2005, CRIT REV ONCOL HEMAT, V55, P143, DOI 10.1016/j.critrevonc.2005.02.003
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Sorensen IK, 1998, CANCER LETT, V130, P217, DOI 10.1016/S0304-3835(98)00139-6
   Specht E, 2010, BIOTECHNOL LETT, V32, P1373, DOI 10.1007/s10529-010-0326-5
   Sporn MB, 2011, NATURE, V471, pS10, DOI 10.1038/471S10a
   Srivastava RM, 2011, INT IMMUNOPHARMACOL, V11, P331, DOI 10.1016/j.intimp.2010.08.014
   Stappenbeck TS, 2010, AUTOPHAGY
   Steinmetz KA, 1996, J AM DIET ASSOC, V96, P1027, DOI 10.1016/S0002-8223(96)00273-8
   Stuenkel Walter, 2007, Biotechnology Journal, V2, P1360, DOI 10.1002/biot.200700087
   Su CC, 2006, ANTICANCER RES, V26, P1281
   Su CC, 2006, ANTICANCER RES, V26, P4379
   Suh N, 2007, CLIN CANCER RES, V13, P350, DOI 10.1158/1078-0432.CCR-06-1528
   Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5
   Sun Y, 2009, CARCINOGENESIS, V30, P93, DOI 10.1093/carcin/bgn242
   Swanson GR, 2011, EXPERT REV CLIN IMMU, V7, P29, DOI [10.1586/eci.10.83, 10.1586/ECI.10.83]
   Szkudelska K, 2007, J STEROID BIOCHEM, V105, P37, DOI 10.1016/j.jsbmb.2007.01.005
   Takahashi M, 1997, CARCINOGENESIS, V18, P1337, DOI 10.1093/carcin/18.7.1337
   Takemoto K, 2011, NEUROCHEM INT
   Talero E, 2011, INFLAMM BOWEL DIS, V17, P696, DOI 10.1002/ibd.21420
   Tan XL, 2011, CANCER PREV RES, V4, P1835, DOI 10.1158/1940-6207.CAPR-11-0146
   Tanaka T, 2001, CANCER RES, V61, P2424
   Tang FY, 2009, J NUTR BIOCHEM, V20, P426, DOI 10.1016/j.jnutbio.2008.05.001
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Tergaonkar V, 2006, INT J BIOCHEM CELL B, V38, P1647, DOI 10.1016/j.biocel.2006.03.023
   Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058
   Tessitore L, 2000, CARCINOGENESIS, V21, P1619, DOI 10.1093/carcin/21.8.1619
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Tonon T, 2002, PHYTOCHEMISTRY, V61, P15, DOI 10.1016/S0031-9422(02)00201-7
   Travassos LH, 2010, NAT IMMUNOL, V11, P55, DOI 10.1038/ni.1823
   Tunstall RG, 2006, EUR J CANCER, V42, P415, DOI 10.1016/j.ejca.2005.10.024
   Ukil A, 2003, BRIT J PHARMACOL, V139, P209, DOI 10.1038/sj.bjp.0705241
   Ulrich S, 2006, CANCER RES, V66, P7348, DOI 10.1158/0008-5472.CAN-05-2777
   Undeger U, 2004, TOXICOL LETT, V151, P143, DOI 10.1016/j.toxlet.2003.12.071
   Ung VYL, 2010, DIGEST DIS SCI, V55, P1272, DOI 10.1007/s10620-009-0843-z
   Urso ML, 2003, TOXICOLOGY, V189, P41, DOI 10.1016/S0300-483X(03)00151-3
   van Beelen VA, 2007, FOOD CHEM TOXICOL, V45, P716, DOI 10.1016/j.fct.2006.10.017
   van Beelen VA, 2009, FOOD CHEM TOXICOL, V47, P316, DOI 10.1016/j.fct.2008.11.014
   Vanamala J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-238
   Varnalidis I, 2011, REV ESP ENFERM DIG, V103, P511, DOI 10.4321/s1130-01082011001000003
   Villa FA, 2010, IMMUNOPHARM IMMUNOT, V32, P228, DOI 10.3109/08923970903296136
   Villegas I, 2008, MOL NUTR FOOD RES, V52, P1040, DOI 10.1002/mnfr.200700280
   Villegas I, 2011, MOL NUTR FOOD RES, V55, P259, DOI 10.1002/mnfr.201000225
   Volate SR, 2005, CARCINOGENESIS, V26, P1450, DOI 10.1093/carcin/bgi089
   Wach A, 2007, FOOD CHEM, V100, P699, DOI 10.1016/j.foodchem.2005.10.028
   Wang Jayson, 2012, J Gastrointest Cancer, V43, P444, DOI 10.1007/s12029-011-9330-9
   Wang JB, 2009, WORLD J GASTROENTERO, V15, P1346, DOI 10.3748/wjg.15.1346
   Wang SL, 2009, CELL MOL IMMUNOL, V6, P327, DOI 10.1038/cmi.2009.43
   Wang XF, 2006, CLIN CANCER RES, V12, P5346, DOI 10.1158/1078-0432.CCR-06-0968
   Wang ZG, 2010, ANTICANCER RES, V30, P4537
   Warren CA, 2009, J NUTR, V139, P101, DOI 10.3945/jn.108.096271
   Waterman M, 2011, INFLAMM BOWEL DIS, V17, P1936, DOI 10.1002/ibd.21579
   Waters DJ, 2007, CANCER EPIDEM BIOMAR, V16, P1906, DOI 10.1158/1055-9965.EPI-07-0034
   Watson JL, 2010, CANCER LETT, V297, P1, DOI 10.1016/j.canlet.2010.04.018
   West NJ, 2010, GUT, V59, P918, DOI 10.1136/gut.2009.200642
   Wirawan E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.16
   Witte JS, 1996, AM J EPIDEMIOL, V144, P1015, DOI 10.1093/oxfordjournals.aje.a008872
   Wu HZ, 2008, BIOMED PHARMACOTHER, V62, P613, DOI 10.1016/j.biopha.2008.06.036
   Xu G, 2010, FOOD CHEM TOXICOL, V48, P390, DOI 10.1016/j.fct.2009.10.027
   Xue CH, 2002, FOOD CHEM, V77, P9, DOI 10.1016/S0308-8146(01)00315-6
   Yang CS, 2011, MOL NUTR FOOD RES, V55, P819, DOI 10.1002/mnfr.201100036
   Yang K, 2000, CARCINOGENESIS, V21, P1655, DOI 10.1093/carcin/21.9.1655
   Yao J, 2010, ARCH MED RES, V41, P288, DOI 10.1016/j.arcmed.2010.05.002
   Yasui Y, 2011, CHEM-BIOL INTERACT, V193, P79, DOI 10.1016/j.cbi.2011.05.006
   Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244
   Youn J, 2009, NUTR CANCER, V61, P847, DOI 10.1080/01635580903285072
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Yu ZL, 2005, BIOCHEM BIOPH RES CO, V333, P827, DOI 10.1016/j.bbrc.2005.05.177
   Yu ZL, 2004, CANCER LETT, V215, P159, DOI 10.1016/j.canlet.2004.06.010
   Yuan JP, 2011, MOL NUTR FOOD RES, V55, P150, DOI 10.1002/mnfr.201000414
   Yuan JH, 2008, MOL MED, V14, P590, DOI 10.2119/2007-00050.Yuan
   Yuan ZP, 2006, CLIN CANCER RES, V12, P3193, DOI 10.1158/1078-0432.CCR-05-2365
   Zhang F, 1999, CARCINOGENESIS, V20, P445, DOI 10.1093/carcin/20.3.445
   Zhang L, 2010, NATURE, V464, P1058, DOI 10.1038/nature08871
   Zhang M, 2006, ACTA PHARMACOL SIN, V27, P1071, DOI 10.1111/j.1745-7254.2006.00322.x
   Zhang M, 2006, INT IMMUNOPHARMACOL, V6, P1233, DOI 10.1016/j.intimp.2006.02.013
   Zhang SZ, 2006, CELL MOL IMMUNOL, V3, P35
   Zhang T, 2010, BBA-PROTEINS PROTEOM, V1804, P1666, DOI 10.1016/j.bbapap.2009.10.022
   Zhu QL, 2002, NUTR CANCER, V42, P131, DOI 10.1207/S15327914NC421_18
   Zykova TA, 2008, MOL CARCINOGEN, V47, P797, DOI 10.1002/mc.20437
NR 423
TC 35
Z9 40
U1 4
U2 64
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD SEP
PY 2012
VL 18
IS 26
BP 3939
EP 3965
DI 10.2174/138161212802083725
PG 27
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 993OV
UT WOS:000307870100008
PM 22632755
DA 2022-04-25
ER

PT J
AU Yang, HL
   Liu, HW
   Shrestha, S
   Thiyagarajan, V
   Huang, HC
   Hseu, YC
AF Yang, Hsin-Ling
   Liu, Hui-Wen
   Shrestha, Sirjana
   Thiyagarajan, Varadharajan
   Huang, Hui-Chi
   Hseu, You-Cheng
TI Antrodia salmonea induces apoptosis and enhances cytoprotective
   autophagy in colon cancer cells
SO AGING-US
LA English
DT Article
DE Antrodia salmonea; colon cancer; apoptosis; autophagy; ROS
ID OXYGEN SPECIES ROS; CYCLE ARREST; IN-VITRO; MECHANISMS; INHIBITION;
   ACTIVATION; 5-FLUOROURACIL; AZOXYMETHANE; PROGRESSION; INDUCTION
AB A traditional Chinese medicinal fungus, Antrodia salmonea (AS), with antioxidant properties is familiar in Taiwan but anti-cancer activity of AS in human colon cancer is ambiguous. Hence, we explored the anti-cancer activity of AS in colon cancer cells. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay revealed that AS showed a remarkable effect on cell viability in colon cancer cells; SW620, HCT116, and HT29. Annexin V/propidium iodide (PI) stained cells indicated that AS induced both early/late apoptosis in SW620 cells. Additionally, cells treated with AS induced caspase-3 activation, poly (ADP-ribose) polymerase (PARP) cleavage, mitochondrial dysfunction, and Bcl-2 associated X (Bax)/B-cell lymphoma (Bcl-2) dysregulation. Microtubule- associated protein 1A/1B-light chain 3B (LC3-II) accumulation, sequestosome 1 (p62/SQSTM1) activation, autophagy related 4B cysteine peptidase (ATG4B) inactivation, acidic vesicular organelles (AVOs) formation, and Beclin-1/Bcl-2 dysregulation revealed that AS-induced autophagy. Interestingly, cells pretreated with 3-methyladenine (3-MA) strengthened AS-induced caspase-3/apoptosis. Suppression of apoptosis by z-Val-Ala-Asp fluoromethyl ketone (Z-VAD-FMK) did not however block AS-induced autophagy, suggesting that autophagy was not attenuated by the AS-induced apoptosis. Application of N-acetylcysteine (NAC) prevented AS-induced cell death, caspase-3 activation, LC3-II accumulation, and AVOs formation, indicating that AS-induced apoptosis and autophagy was mediated by reactive oxygen species (ROS). Furthermore, AS-induced cytoprotective autophagy and apoptosis through extracellular signal-regulated kinase (ERK) signaling cascades. Moreover, in vivo data disclosed that AS inhibited colitis-associated tumorigenesis in azoxymethane (AOM)-dextran sodium sulphate (DSS)-treated mice. For the first time, we report the anti-cancer properties of this potentially advantageous mushroom for the treatment of human colon cancer.
C1 [Yang, Hsin-Ling; Liu, Hui-Wen; Shrestha, Sirjana] China Med Univ, Coll Hlth Care, Inst Nutr, Taichung 40402, Taiwan.
   [Huang, Hui-Chi] China Med Univ, Coll Chinese Med, Dept Chinese Pharmaceut Sci & Chinese Med Resourc, Taichung 40402, Taiwan.
   [Thiyagarajan, Varadharajan; Hseu, You-Cheng] China Med Univ, Coll Pharm, Dept Cosmeceut, Taichung 40402, Taiwan.
   [Hseu, You-Cheng] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung 41354, Taiwan.
   [Hseu, You-Cheng] China Med Univ, Chinese Med Res Ctr, Taichung 40402, Taiwan.
RP Hseu, YC (corresponding author), China Med Univ, Coll Pharm, Dept Cosmeceut, Taichung 40402, Taiwan.; Hseu, YC (corresponding author), Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung 41354, Taiwan.; Hseu, YC (corresponding author), China Med Univ, Chinese Med Res Ctr, Taichung 40402, Taiwan.
EM ychseu@mail.qmu.edu.tw
RI K.J., Senthil Kumar/F-5309-2011
FU Ministry of Science and Technology [MOST-109-2320-B-039-057-MY3,
   MOST-107-2320-B-039-013-MY3]; China Medical University, TaiwanChina
   Medical University [CMU107-TU-12, CMU108MF-19, CMU108-MF-80]; Taiwan and
   Chinese Medicine Research Center, China Medical University from the
   "Featured Areas Research Center Program" within the Ministry of
   Education (MOE) [CMRC-CHM-1]; Asia University
FX This research is funded by Ministry of Science and Technology
   (MOST-109-2320-B-039-057-MY3 and MOST-107-2320-B-039-013-MY3), Asia
   University, China Medical University (CMU107-TU-12, CMU108MF-19 and
   CMU108-MF-80), Taiwan and Chinese Medicine Research Center, China
   Medical University from the "Featured Areas Research Center Program"
   within the framework of the Higher Education Sprout Project by the
   Ministry of Education (MOE) funded this study (CMRC-CHM-1).
CR Alfarouk KO, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0221-1
   Aung TN, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030656
   Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI 10.1089/ARS.2008.2270
   Azeem Salman, 2015, Asian Pac J Cancer Prev, V16, P5389
   Bitto A, 2014, AGE, V36, P1123, DOI 10.1007/s11357-014-9626-3
   Caesar LK, 2019, NAT PROD REP, V36, P869, DOI 10.1039/c9np00011a
   Campbell KJ, 2018, OPEN BIOL, V8, DOI 10.1098/rsob.180002
   Chang CT, 2017, FOOD CHEM TOXICOL, V103, P1, DOI 10.1016/j.fct.2017.02.019
   Chang CT, 2017, J ETHNOPHARMACOL, V196, P9, DOI 10.1016/j.jep.2016.12.018
   Chen Y, 2020, J MED CHEM, V63, P10135, DOI 10.1021/acs.jmedchem.9b02038
   Chung KS, 2018, NUTRIENTS, V10, DOI 10.3390/nu10020202
   Chung Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1229-y
   CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615
   De Robertis Mariangela, 2011, J Carcinog, V10, P9, DOI 10.4103/1477-3163.78279
   Dossou AS, 2019, CANCERS, V11, DOI 10.3390/cancers11101422
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Fakih M, 2010, CURR ONCOL, V17, pS18
   Fu YY, 2019, CANCERS, V11, DOI 10.3390/cancers11050649
   Garcia-Foncillas J, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00849
   Gerl R, 2005, CARCINOGENESIS, V26, P263, DOI 10.1093/carcin/bgh283
   Green DR, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a006080
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710
   Hill BG, 2012, BIOL CHEM, V393, P1485, DOI 10.1515/hsz-2012-0198
   Hseu YC, 2019, FREE RADICAL BIO MED, V143, P397, DOI 10.1016/j.freeradbiomed.2019.08.015
   Hseu YC, 2019, FOOD CHEM TOXICOL, V124, P219, DOI 10.1016/j.fct.2018.12.009
   Hseu YC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08659-7
   Hseu YC, 2014, J ETHNOPHARMACOL, V153, P499, DOI 10.1016/j.jep.2014.03.012
   Hseu YC, 2014, FOOD CHEM TOXICOL, V66, P150, DOI 10.1016/j.fct.2014.01.035
   Ichimura Y, 2008, J BIOL CHEM, V283, P22847, DOI 10.1074/jbc.M802182200
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Khan N, 2010, ENDOCR-RELAT CANCER, V17, pR39, DOI 10.1677/ERC-09-0262
   Li B, 2017, BIOCHEM BIOPH RES CO, V491, P98, DOI 10.1016/j.bbrc.2017.07.052
   Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1
   Lin SR, 2020, BRIT J PHARMACOL, V177, P1409, DOI 10.1111/bph.14816
   Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Los M, 2002, MOL BIOL CELL, V13, P978, DOI 10.1091/mbc.01-05-0272
   Low D, 2014, INFLAMM BOWEL DIS, V20, P2115, DOI 10.1097/MIB.0000000000000094
   Malik A, 2005, P NATL ACAD SCI USA, V102, P14813, DOI 10.1073/pnas.0505870102
   Markowitz SD, 2002, CANCER CELL, V1, P233, DOI 10.1016/S1535-6108(02)00053-3
   Marquez RT, 2012, AM J CANCER RES, V2, P214
   Mohammad RM, 2015, SEMIN CANCER BIOL, V35, pS78, DOI 10.1016/j.semcancer.2015.03.001
   Munshi Anupama, 2013, Genes Cancer, V4, P401, DOI 10.1177/1947601913485414
   OKAYASU I, 1990, GASTROENTEROLOGY, V98, P694, DOI 10.1016/0016-5085(90)90290-H
   Parveen A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8030350
   Presley AD, 2003, J CHROMATOGR B, V793, P141, DOI 10.1016/S1570-0232(03)00371-4
   Ravichandran K, 2010, CLIN CANCER RES, V16, P4595, DOI 10.1158/1078-0432.CCR-10-1213
   Rawla P, 2019, GASTROENTEROL REV, V14, P89, DOI 10.5114/pg.2018.81072
   Saraste A, 2000, CARDIOVASC RES, V45, P528, DOI 10.1016/S0008-6363(99)00384-3
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034
   Shamas-Din A, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008714
   Shaul YD, 2007, BBA-MOL CELL RES, V1773, P1213, DOI 10.1016/j.bbamcr.2006.10.005
   Shen CC, 2006, PLANTA MED, V72, P199, DOI 10.1055/s-2005-916175
   Shen CC, 2008, J CHIN CHEM SOC-TAIP, V55, P854, DOI 10.1002/jccs.200800127
   Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3
   Sohn OS, 2001, CANCER RES, V61, P8435
   Storz P, 2005, FRONT BIOSCI-LANDMRK, V10, P1881, DOI 10.2741/1667
   Tanida I, 2010, METHODS MOL BIOL, V648, P193, DOI 10.1007/978-1-60761-756-3_13
   Thanikachalam K, 2019, NUTRIENTS, V11, DOI 10.3390/nu11010164
   Thiyagarajan V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141285
   VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I
   Wang H, 2012, ANTI-CANCER AGENT ME, V12, P1281, DOI 10.2174/187152012803833026
   Wang RA, 2013, J CELL MOL MED, V17, P205, DOI 10.1111/j.1582-4934.2012.01663.x
   Wilhelm M, 2016, CLIN COLORECTAL CANC, V15, P381, DOI 10.1016/j.clcc.2016.04.001
   Wlodkowic D, 2011, METHOD CELL BIOL, V103, P55, DOI 10.1016/B978-0-12-385493-3.00004-8
   Wong RSY, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-87
   Yang HL, 2019, J CELL PHYSIOL, V234, P10747, DOI 10.1002/jcp.27749
   Yang HL, 2019, J CELL PHYSIOL, V234, P3029, DOI 10.1002/jcp.27123
   Yang HL, 2014, J ETHNOPHARMACOL, V151, P394, DOI 10.1016/j.jep.2013.10.052
   Yin ZY, 2016, MICROB CELL, V3, P457, DOI 10.15698/mic2016.12.546
   Yoshii SR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091865
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
   Zorov DB, 2014, PHYSIOL REV, V94, P909, DOI 10.1152/physrev.00026.2013
NR 75
TC 2
Z9 4
U1 2
U2 3
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD JUN 30
PY 2021
VL 13
IS 12
BP 15964
EP 15989
PG 26
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA TD0LM
UT WOS:000669027700014
PM 34031264
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Lian, GH
   Li, FJ
   Yin, YN
   Chen, LL
   Yang, JW
AF Lian, Guanghui
   Li, Fujun
   Yin, Yani
   Chen, Linlin
   Yang, Junwen
TI Herbal extract of Artemisia vulgaris (mugwort) induces antitumor effects
   in HCT-15 human colon cancer cells via autophagy induction, cell
   migration suppression and loss of mitochondrial membrane potential
SO JOURNAL OF BUON
LA English
DT Article
DE Artemisia vulgaris; autophagy; colon cancer; ROS
ID APOPTOSIS
AB Purpose: Artemisia vulgaris (A. vulgaris) belonging to family Compositae, commonly known as mugwort, has been used as a medicinal herb in Chinese traditional medicine for treatment of diseases. Studies have reported a diversity of activities for this plant which include antiseptic, antispasmodic, antigastric, anticancer and nervous system diseases. However, the anticancer activity of A. vulgaris in HCT-15 human colon cancer cells has not been scientifically validated. Therefore the present study aimed at evaluating the anticancer activity of methanolic extract of A. vulgaris against HCT-15 human colon cancer cell line.
   Methods: Cell cytotoxicity effects of the extract were evaluated by MTT cell viability assay, while clonogenic assay assessed the effects on cancer cell colony formation. Effects on reactive oxygen species (ROS) production and mitochondrial membrane potential (MMP) were evaluated by flow cytometry. In vitro wound healing assay was used to evaluate the effects on cell migration. To confirm autophagy, we evaluated the expression of several autophagy-associated proteins using Western blot assay.
   Results: Results indicated that the methanolic extract of A. vulgaris exhibited an IC50 value of 50 mu g/ml and exerted its cytotoxic effects in a dose-dependent manner. Moreover, it was observed that the extract inhibits colony formation and induces autophagy dose-dependently. The underlying mechanism for the induction of autophagy was found to be ROS-mediated MMP and significant inhibition of cell migration potential of colon cancer cells at the IC50 was observed.
   Conclusion: These results strongly stress that the methanolic extract may prove a source for the isolation of novel anticancer lead molecules for the management of colon cancer.
C1 [Lian, Guanghui; Li, Fujun; Yin, Yani; Chen, Linlin; Yang, Junwen] Cent S Univ, Xiangya Hosp, Dept Gastroenterol, Changsha 410008, Hunan, Peoples R China.
RP Yang, JW (corresponding author), Cent S Univ, Xiangya Hosp, Dept Gastroenterol, Changsha 410008, Hunan, Peoples R China.
EM junwenyang999@yahoo.com
OI Chen, Linlin/0000-0001-6560-126X
CR Azuma M, 2003, ORAL ONCOL, V39, P282, DOI 10.1016/S1368-8375(02)00116-1
   Baba SA, 2015, S AFR J BOT, V99, P80, DOI 10.1016/j.sajb.2015.03.194
   Bora KS, 2011, PHARM BIOL, V49, P101, DOI 10.3109/13880209.2010.497815
   Chopra RN, 1956, GLOSSARY INDIAN MED, V26, P2
   Ding HM, 2009, NUTR CANCER, V61, P348, DOI 10.1080/01635580802567158
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2
   Husain A., 2016, ADV BIOMED PHARM, V3, P227, DOI DOI 10.19046/ABP.V03I04.07
   Khursheed A, 2016, ADV BIOMED PHARM, V3, P245, DOI [10.19046/abp.v03i04.08, DOI 10.19046/abp.v03i04.08, 10.19046/ abp.v03i04.08, DOI 10.19046/ABP.V03I04.08]
   Kowaltowski AJ, 2009, FREE RADICAL BIO MED, V47, P333, DOI 10.1016/j.freeradbiomed.2009.05.004
   Narwaria A, 1994, EXPT STUDIES ARTEMIS, V14, P10
   Rejiya CS, 2009, TOXICOL IN VITRO, V23, P1034, DOI 10.1016/j.tiv.2009.06.010
   Shoemaker RH, 2006, NAT REV CANCER, V6, P813, DOI 10.1038/nrc1951
   Sreelatha S, 2011, FOOD CHEM TOXICOL, V49, P1270, DOI 10.1016/j.fct.2011.03.006
   Yadav J. P., 2010, International Journal of Green Pharmacy, V4, P140
NR 16
TC 14
Z9 14
U1 0
U2 2
PU IMPRIMATUR PUBLICATIONS
PI ATHENS
PA 30 DEM POLIORKETES ST, ATHENS, 136 76, GREECE
SN 1107-0625
EI 2241-6293
J9 J BUON
JI J. BUON
PD JAN-FEB
PY 2018
VL 23
IS 1
BP 73
EP 78
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GB0TZ
UT WOS:000428762100013
PM 29552763
DA 2022-04-25
ER

PT J
AU Qased, A
   Yi, HQ
   Liang, N
   Ma, SM
   Qiao, SX
   Liu, XD
AF Qased, Abu Baker
   Yi, Heqing
   Liang, Nan
   Ma, Shumei
   Qiao, Shixing
   Liu, Xiaodong
TI MicroRNA-18a upregulates autophagy and ataxia telangiectasia mutated
   gene expression in HCT116 colon cancer cells
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE ataxia telangiectasia mutated; miR-18a; autophagy; ionizing radiation;
   colon cancer
ID MIR-17-92 CLUSTER; ATM; TARGET; DAMAGE; MIR-21
AB Autophagy is an evolutionarily conserved, multi-step lysosomal degradation process in which a cell degrades its own long-lived proteins and damaged organelles. Ataxia telangiectasia mutated (ATM) has recently been shown to upregulate the process of autophagy. Previous studies showed that certain microRNAs, including miR-18a, potentially regulate ATM in cancer cells. However, the mechanisms behind the modulation of ATM by miR-18a remain to be elucidated in colon cancer cells. In the present study, we explored the impact of miR-18a on the autophagy process and ATM expression in HCT116 colon cancer cells. To determine whether a preliminary link exists between autophagy and miR-18a, HCT116 cells were irradiated and quantitative (q) PCR was performed to measure miR-18a expression. HCT116 cells were transfected with an miR-18a mimic to study its impact on indicators of autophagy. Western blotting and luciferase assays were implemented to explore the impact of miR-18a on ATM gene expression in HCT116 cells. The results showed that miR-18a expression was strongly stimulated by radiation. Ectopic overexpression of miR-18a in HCT116 cell lines potently enhanced autophagy and ionizing radiation-induced autophagy. Moreover, miR-18a overexpression led to the upregulation of ATM expression and suppression of mTORC1 activity. Results of the present study pertaining to the role of miR-18a in regulating autophagy and ATM gene expression in colon cancer cells revealed a novel function for miR-18a in a critical cellular event and on a crucial gene with significant impacts in cancer development, progression, treatment and in other diseases.
C1 [Qased, Abu Baker; Qiao, Shixing] Jilin Univ, Dept Surg, Hosp 2, Changchun 130041, Jilin, Peoples R China.
   [Yi, Heqing; Liang, Nan; Ma, Shumei; Liu, Xiaodong] Jilin Univ, Key Lab Radiobiol, Minist Hlth, Sch Publ Hlth, Changchun 130021, Jilin, Peoples R China.
   [Qased, Abu Baker] Univ Mosul, Dept Surg, Coll Med, Mosul, Iraq.
RP Qiao, SX (corresponding author), Jilin Univ, Dept Surg, Hosp 2, 218 Ziqiang St, Changchun 130041, Jilin, Peoples R China.
EM shixingqiaojdey@yahoo.com; liuxiaod@jlu.edu.cn
RI Liu, Xiaodong/R-5861-2019
FU NSFCNational Natural Science Foundation of China (NSFC) [30770649,
   30970682]; Research Fund for the Doctoral Program of Higher Education of
   ChinaResearch Fund for the Doctoral Program of Higher Education of China
   (RFDP)Specialized Research Fund for the Doctoral Program of Higher
   Education (SRFDP) [20100061110070]
FX The authors would like to thank Dr Yin-Yuan Mo (Department of Medical
   Microbiology, Immunology and Cell Biology, Southern Illinois University
   School of Medicine, Springfield, IL, USA) for providing them with a
   (pCDHCMV-MCS-EF1-copGFP) lenti-vector. They are also grateful to Mr.
   Song Zhiheng for his technical assistance. This study was sponsored by
   an NSFC grant (30770649, 30970682) and the Research Fund for the
   Doctoral Program of Higher Education of China (20100061110070).
CR Alexander A, 2011, FEBS LETT, V585, P952, DOI 10.1016/j.febslet.2011.03.010
   Alexander A, 2010, P NATL ACAD SCI USA, V107, P4153, DOI 10.1073/pnas.0913860107
   Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881
   Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482
   Chaachouay H, 2011, RADIOTHER ONCOL, V99, P287, DOI 10.1016/j.radonc.2011.06.002
   Corradetti MN, 2006, ONCOGENE, V25, P6347, DOI 10.1038/sj.onc.1209885
   Derheimer FA, 2010, FEBS LETT, V584, P3675, DOI 10.1016/j.febslet.2010.05.031
   Dong J, 2011, ARCH MED RES, V42, P8, DOI 10.1016/j.arcmed.2011.01.006
   Frankel LB, 2011, EMBO J, V30, P4628, DOI 10.1038/emboj.2011.331
   Fu LL, 2012, INT J BIOCHEM CELL B, V44, P733, DOI 10.1016/j.biocel.2012.02.004
   Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   Hermsen M, 2002, GASTROENTEROLOGY, V123, P1109, DOI 10.1053/gast.2002.36051
   Hoyer-Hansen M, 2008, AUTOPHAGY, V4, P574, DOI 10.4161/auto.5921
   Hu HL, 2010, P NATL ACAD SCI USA, V107, P1506, DOI 10.1073/pnas.0907763107
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Ko H, 2011, J CELL BIOCHEM, V112, P2471, DOI 10.1002/jcb.23171
   Korkmaz G, 2012, AUTOPHAGY, V8, P165, DOI 10.4161/auto.8.2.18351
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Ng WL, 2010, DNA REPAIR, V9, P1170, DOI 10.1016/j.dnarep.2010.08.007
   Ota A, 2004, CANCER RES, V64, P3087, DOI 10.1158/0008-5472.CAN-03-3773
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011
   Song LB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025454
   Tsuchida A, 2011, CANCER SCI, V102, P2264, DOI 10.1111/j.1349-7006.2011.02081.x
   van Haaften G, 2010, GENE DEV, V24, P1, DOI 10.1101/gad.1887110
   Vasudevan S, 2008, CELL CYCLE, V7, P1545, DOI 10.4161/cc.7.11.6018
   Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460
   Wickramasinghe NS, 2009, NUCLEIC ACIDS RES, V37, P2584, DOI 10.1093/nar/gkp117
   Wu WKK, 2012, ONCOGENE, V31, P939, DOI 10.1038/onc.2011.295
   Xiao JA, 2011, INT J CARDIOL, V148, P110, DOI 10.1016/j.ijcard.2011.01.029
   Yan D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011397
   Yuk JM, 2010, AUTOPHAGY, V6, P46, DOI 10.4161/auto.6.1.10325
   Zhou WJ, 2009, MOL CANCER THER, V8, P3203, DOI 10.1158/1535-7163.MCT-09-0244
   Zhu H, 2009, AUTOPHAGY, V5, P816, DOI 10.4161/auto.9064
NR 37
TC 34
Z9 41
U1 0
U2 16
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD FEB
PY 2013
VL 7
IS 2
BP 559
EP 564
DI 10.3892/mmr.2012.1214
PG 6
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA 073TB
UT WOS:000313764300037
PM 23229340
OA Bronze
DA 2022-04-25
ER

PT J
AU Li, SY
   Yang, G
   Zhu, XS
   Cheng, L
   Sun, YY
   Zhao, ZX
AF Li, Siying
   Yang, Guang
   Zhu, Xiaosong
   Cheng, Lin
   Sun, Yueyue
   Zhao, Zhongxi
TI Combination of rapamycin and garlic-derived S-allylmercaptocysteine
   induces colon cancer cell apoptosis and suppresses tumor growth in
   xenograft nude mice through autophagy/p62/Nrf2 pathway
SO ONCOLOGY REPORTS
LA English
DT Article
DE rapamycin; S-allylmercaptocysteine; autophagy; Nrf2; colorectal cancer;
   p62
ID SIGNALING PATHWAY; MAMMALIAN TARGET; DUAL ROLES; L-CYSTEINE; MTOR; NRF2;
   RESISTANCE
AB The natural plant-derived product S-allylmercaptocysteine (SAMC) has been studied in cancer therapy as a single and combination chemotherapeutic agent. The present study was employed to verify the combination use of SAMC and rapamycin that is the mTOR inhibitor with anticancer ability but has limited efficacy due to drug resistance, and to explore the underlying mechanisms. We combined rapamycin and SAMC for colorectal cancer treatment in the HCT-116 cancer cells and a xenograft murine model. The in vivo study was established by xenografting HCT-116 cells in BALB/c nude mice. It was found that the combination therapy had enhanced tumor-suppressing ability with the upregulation of the Bax/Bcl-2 ratio as a consequence of activated apoptosis, inhibition of autophagic activity and prevention of Akt phosphorylation. The rapamycin and SAMC combination activated antioxidant transcription expressions of Nrf2 and downstream gene NQO1. Concomitantly, autophagosome cargo p62 was downregulated, indicating that the p62 played a negative-regulatory role between Nrf2 and autophagy. Our results show that the combination of SAMC and rapamycin enhanced the anticancer ability, which could be used for the treatment of colorectal cancer. The underling mechanism of autophagy/p62/Nrf2 pathway discovered may provide a new direction for drug development, especially for traditional Chinese medicines.
C1 [Li, Siying; Zhu, Xiaosong; Sun, Yueyue; Zhao, Zhongxi] Shandong Univ, Sch Pharmaceut Sci, 44 West Wenhua Rd, Jinan 250012, Shandong, Peoples R China.
   [Yang, Guang] Shandong Univ, Dept Joint Surg, Shandong Prov Hosp, Jinan 250021, Shandong, Peoples R China.
   [Cheng, Lin] Heze Municipal Hosp, Dept Endocrinol, Heze 274000, Shandong, Peoples R China.
RP Zhao, ZX (corresponding author), Shandong Univ, Sch Pharmaceut Sci, 44 West Wenhua Rd, Jinan 250012, Shandong, Peoples R China.
EM zxzhao@sdu.edu.cn
FU National 'Major Science and Technology Project-Prevention and Treatment
   of AIDS, Viral Hepatitis, and Other Major Infectious Diseases'
   [2013ZX10005004]; Major Project of Science and Technology of Shandong
   Province [2015ZDJS04001]; Science and Technology Enterprise Technology
   Innovation Fund of Jiangsu Province [BC2014172]; Small and Medium
   Enterprise Technology Innovation Project of Lianyungang City [CK1333]
FX This study was supported by the funds from National 'Major Science and
   Technology Project-Prevention and Treatment of AIDS, Viral Hepatitis,
   and Other Major Infectious Diseases' (grant no. 2013ZX10005004), Major
   Project of Science and Technology of Shandong Province (grant no.
   2015ZDJS04001), Science and Technology Enterprise Technology Innovation
   Fund of Jiangsu Province (grant no. BC2014172), Small and Medium
   Enterprise Technology Innovation Project of Lianyungang City (grant no.
   CK1333).
CR Abraham RT, 2007, CLIN CANCER RES, V13, P3109, DOI 10.1158/1078-0432.CCR-06-2798
   Alayev A, 2015, J CELL BIOCHEM, V116, P450, DOI 10.1002/jcb.24997
   Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Chen N, 2015, INT J BIOL SCI, V11, P833, DOI 10.7150/ijbs.10564
   Cigremis Y, 2009, MOL CELL BIOCHEM, V323, P31, DOI 10.1007/s11010-008-9961-8
   Feldman ME, 2011, CURR TOP MICROBIOL, V347, P241, DOI 10.1007/82_2010_64
   Hiramatsu K, 2016, NUTR RES, V36, P143, DOI 10.1016/j.nutres.2015.09.018
   Howard EW, 2007, CLIN CANCER RES, V13, P1847, DOI 10.1158/1078-0432.CCR-06-2074
   Hu H, 2011, MOL MED REP, V4, P9, DOI 10.3892/mmr.2010.380
   Hu YL, 2012, CANCER RES, V72, P4294, DOI 10.1158/0008-5472.CAN-12-1076
   Jiang BH, 2008, DRUG RESIST UPDATE, V11, P63, DOI 10.1016/j.drup.2008.03.001
   Jiang T, 2015, FREE RADICAL BIO MED, V88, P199, DOI 10.1016/j.freeradbiomed.2015.06.014
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   Lee Y, 2008, INT J MOL MED, V21, P765
   Lee Y, 2011, BIOL PHARM BULL, V34, P677, DOI 10.1248/bpb.34.677
   Leinonen HM, 2014, ADV CANCER RES, V122, P281, DOI 10.1016/B978-0-12-420117-0.00008-6
   Liang DS, 2011, CANCER LETT, V310, P69, DOI 10.1016/j.canlet.2011.06.019
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   McGuire S, 2016, ADV NUTR, V7, P418, DOI 10.3945/an.116.012211
   Menegon S, 2016, TRENDS MOL MED, V22, P578, DOI 10.1016/j.molmed.2016.05.002
   Mita MM, 2003, CANCER BIOL THER, V2, pS169
   Moon EJ, 2015, FREE RADICAL BIO MED, V79, P292, DOI 10.1016/j.freeradbiomed.2014.11.009
   Ouakrim DA, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4970
   Padiya R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094228
   Rahman K, 2006, J NUTR, V136, p736S, DOI 10.1093/jn/136.3.736S
   Shirin H, 2001, CANCER RES, V61, P725
   Starkenmann C, 2011, J AGR FOOD CHEM, V59, P9457, DOI 10.1021/jf202082f
   Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Thomson M, 2003, CURR CANCER DRUG TAR, V3, P67, DOI 10.2174/1568009033333736
   Viry E, 2014, BIOCHEM PHARMACOL, V92, P31, DOI 10.1016/j.bcp.2014.07.006
   Wang XW, 1999, ANTICANCER RES, V19, P4759
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Willems L, 2012, CURR ONCOL REP, V14, P129, DOI 10.1007/s11912-012-0227-y
   Xiao J, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/642920
   Xiao J, 2012, EUR J NUTR, V51, P323, DOI 10.1007/s00394-011-0217-0
   Xu K, 2014, BBA-REV CANCER, V1846, P638, DOI 10.1016/j.bbcan.2014.10.007
   Xu XH, 2015, BRAIN RES, V1614, P38, DOI 10.1016/j.brainres.2015.04.014
   ZHANG L, 2016, OXID MED CELL LONGEV, V2016, DOI DOI 10.1155/2016/3897250
   Zhang Y, 2014, ONCOL LETT, V8, P2591, DOI 10.3892/ol.2014.2579
NR 42
TC 27
Z9 27
U1 1
U2 38
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD SEP
PY 2017
VL 38
IS 3
BP 1637
EP 1644
DI 10.3892/or.2017.5849
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FB7CM
UT WOS:000406298700034
PM 28737825
OA Bronze
DA 2022-04-25
ER

PT J
AU Fujiya, M
   Konishi, H
   Kamel, MKM
   Ueno, N
   Inaba, Y
   Moriichi, K
   Tanabe, H
   Ikuta, K
   Ohtake, T
   Kohgo, Y
AF Fujiya, M.
   Konishi, H.
   Kamel, M. K. Mohamed
   Ueno, N.
   Inaba, Y.
   Moriichi, K.
   Tanabe, H.
   Ikuta, K.
   Ohtake, T.
   Kohgo, Y.
TI microRNA-18a induces apoptosis in colon cancer cells via the
   autophagolysosomal degradation of oncogenic heterogeneous nuclear
   ribonucleoprotein A1
SO ONCOGENE
LA English
DT Article
DE microRNAs; heterogeneous nuclear ribonucleoproteins; colon cancer;
   apoptosis; autophagy; ubiquitin
ID POSTTRANSCRIPTIONAL REGULATION; COLORECTAL-CANCER; NONCODING RNAS;
   C-ELEGANS; GENE; MUTATIONS; RAS; EXPRESSION; PROLIFERATION;
   TUMORIGENESIS
AB It is well known that microRNAs (miRs) are abnormally expressed in various cancers and target the messenger RNAs (mRNAs) of cancer-associated genes. While (miRs) are abnormally expressed in various cancers, whether miRs directly target oncogenic proteins is unknown. The present study investigated the inhibitory effects of miR-18a on colon cancer progression, which was considered to be mediated through its direct binding and degradation of heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1). An MTT assay and xenograft model demonstrated that the transfection of miR-18a induced apoptosis in SW620 cells. A binding assay revealed direct binding between miR-18a and hnRNP A1 in the cytoplasm of SW620 cells, which inhibited the oncogenic functions of hnRNP A1. A competitor RNA, which included the complementary sequence of the region of the miR-18a-hnRNP A1 binding site, repressed the effects of miR-18a on the induction of cancer cell apoptosis. In vitro single and in vivo double isotope assays demonstrated that miR-18a induced the degradation of hnRNP A1. An immunocytochemical study of hnRNP A1 and LC3-II and the inhibition of autophagy by 3-methyladenine and ATG7, p62 and BAG3 siRNA showed that miR-18a and hnRNP A1 formed a complex that was degraded through the autophagolysosomal pathway. This is the first report showing a novel function of a miR in the autophagolysosomal degradation of an oncogenic protein resulting from the creation of a complex consisting of the miR and a RNA-binding protein, which suppressed cancer progression.
C1 [Fujiya, M.; Konishi, H.; Kamel, M. K. Mohamed; Ueno, N.; Inaba, Y.; Moriichi, K.; Tanabe, H.; Ikuta, K.; Ohtake, T.; Kohgo, Y.] Asahikawa Med Coll, Dept Med, Div Gastroenterol & Hematol Oncol, Asahikawa, Hokkaido 0788510, Japan.
RP Fujiya, M (corresponding author), Asahikawa Med Coll, Dept Med, Div Gastroenterol & Hematol Oncol, 2-1 Midorigaoka Higashi, Asahikawa, Hokkaido 0788510, Japan.
EM fjym@asahikawa-med.ac.jp
RI Kohgo, Yutaka/AAN-4863-2020
OI Tanabe, Hiroki/0000-0001-9029-5081
FU Grants-in-Aid for Scientific ResearchMinistry of Education, Culture,
   Sports, Science and Technology, Japan (MEXT)Japan Society for the
   Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)
   [24790671] Funding Source: KAKEN
CR Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0
   Eiring AM, 2010, CELL, V140, P652, DOI 10.1016/j.cell.2010.01.007
   Eulalio A, 2008, CELL, V132, P9, DOI 10.1016/j.cell.2007.12.024
   Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290
   FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0
   Guan RJ, 1999, GASTROENTEROLOGY, V116, P1063, DOI 10.1016/S0016-5085(99)70009-0
   Guil S, 2007, NAT STRUCT MOL BIOL, V14, P591, DOI 10.1038/nsmb1250
   He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552
   Hope NR, 2011, HUM PATHOL, V42, P393, DOI 10.1016/j.humpath.2010.08.006
   Jo OD, 2008, J BIOL CHEM, V283, P23274, DOI 10.1074/jbc.M801185200
   Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014
   Kettern N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016398
   Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Liu WH, 2009, GASTROENTEROLOGY, V136, P683, DOI 10.1053/j.gastro.2008.10.029
   Mattick JS, 2001, MOL BIOL EVOL, V18, P1611, DOI 10.1093/oxfordjournals.molbev.a003951
   Michlewski G, 2008, MOL CELL, V32, P383, DOI 10.1016/j.molcel.2008.10.013
   Motoyama K, 2009, INT J ONCOL, V34, P1069, DOI 10.3892/ijo_00000233
   NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0
   POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0
   Qased A, 2013, MOL MED REP, V7, P559, DOI 10.3892/mmr.2012.1214
   Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462
   Taft RJ, 2010, J PATHOL, V220, P126, DOI 10.1002/path.2638
   Tao J, 2012, MOL MED REP, V5, P167, DOI 10.3892/mmr.2011.591
   Thiele BJ, 2004, CIRC RES, V95, P1058, DOI 10.1161/01.RES.0000149166.33833.08
   Tsuchiya N, 2011, CANCER RES, V71, P4628, DOI 10.1158/0008-5472.CAN-10-2475
   Ushigome M, 2005, INT J ONCOL, V26, P635
   Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019
   Wienholds E, 2005, SCIENCE, V309, P310, DOI 10.1126/science.1114519
   WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4
   Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228
   Wu JM, 2012, CARCINOGENESIS, V33, P519, DOI 10.1093/carcin/bgr304
   Yamakuchi M, 2010, P NATL ACAD SCI USA, V107, P6334, DOI 10.1073/pnas.0911082107
   Yu YJ, 2012, CARCINOGENESIS, V33, P68, DOI 10.1093/carcin/bgr246
   Zhang Y, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-23
   Zhao YC, 2011, BREAST CANCER RES TR, V127, P69, DOI 10.1007/s10549-010-0972-2
NR 38
TC 43
Z9 43
U1 0
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD OCT 2
PY 2014
VL 33
IS 40
BP 4847
EP 4856
DI 10.1038/onc.2013.429
PG 10
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA AR0EH
UT WOS:000343240100006
PM 24166503
DA 2022-04-25
ER

PT J
AU Won, SJ
   Yen, CH
   Liu, HS
   Wu, SY
   Lan, SH
   Jiang-Shieh, YF
   Lin, CN
   Su, CL
AF Won, Shen-Jeu
   Yen, Cheng-Hsin
   Liu, Hsiao-Sheng
   Wu, Shan-Ying
   Lan, Sheng-Hui
   Jiang-Shieh, Ya-Fen
   Lin, Chun-Nan
   Su, Chun-Li
TI Justicidin A-Induced Autophagy Flux Enhances Apoptosis of Human
   Colorectal Cancer Cells via Class III PI3K and Atg5 Pathway
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID HUMAN HEPATOMA-CELLS; MONITORING AUTOPHAGY; KAPPA-B; DEATH; THERAPY;
   EXPRESSION; PROTEIN; INHIBITION; PROCUMBENS; LIGNANS
AB Our previous reports showed that justicidin A (JA), a novel and pure arylnaphthalide lignan isolated from Justicia procumbens, induces apoptosis of human colorectal cancer cells and hepatocellular carcinoma cells, leading to the suppression of both tumor cell growth in NOD-SCID mice. Here, we reveal that JA induces autophagy in human colorectal cancer HT-29 cells by conversion of autophagic marker LC3-I to LC3-II. Furthermore, LC3 puncta and autophagic vesicle formation, and SQSTM1/p62 suppression were observed. Administration of autophagy inhibitor (bafilomycin A1 and chloroquine) and transfection of a tandem fluorescent-tagged LC3 (mRFP-GFP) reporter plasmid (ptfLC3) demonstrated that JA induces autophagy flux in HT-29 cells. Expression of LC3, SQSTM1, Beclin 1, and nuclear DNA double-strand breaks (representing apoptosis) were also detected in the tumor tissue of HT-29 cells transplanted into NOD-SCID mice orally administrated with JA. In addition, the expression of autophagy signaling pathway-related molecules p-PDK1, p-mTOR, p-p70S6k/p-RPS6KB2 was decreased, whereas that of class III PI3K, Beclin 1, Atg5-Atg12, and mitochondrial BNIP3 was increased in response to JA. Pre-treatment of the cells with class III PI3K inhibitor 3-methyladenine or Atg5 shRNA attenuated JA-induced LC3-II expression and LC3 puncta formation, indicating the involvement of class III PI3K and Atg5. A novel mechanism was demonstrated in the anticancer compound JA; pre-treatment with 3-methyladenine or Atg5 shRNA blocked JA-induced suppression in cell growth and colony formation, respectively, via inhibition of apoptosis. In contrast, administration of apoptosis inhibitor Z-VAD did not affect JA-induced autophagy. Our data suggest the chemotherapeutic potential of JA for treatment of human colorectal cancer. (C) 2014 Wiley Periodicals, Inc.
C1 [Won, Shen-Jeu; Liu, Hsiao-Sheng; Wu, Shan-Ying; Lan, Sheng-Hui] Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan 70101, Taiwan.
   [Yen, Cheng-Hsin] Chang Jung Christian Univ, Dept Nursing, Tainan, Taiwan.
   [Yen, Cheng-Hsin; Su, Chun-Li] Natl Taiwan Normal Univ, Dept Human Dev & Family Studies, Taipei 10610, Taiwan.
   [Liu, Hsiao-Sheng] Natl Cheng Kung Univ, Coll Med, Ctr Infect Dis, Tainan 70101, Taiwan.
   [Liu, Hsiao-Sheng] Natl Cheng Kung Univ, Coll Med, Signaling Res Ctr, Tainan 70101, Taiwan.
   [Jiang-Shieh, Ya-Fen] Natl Cheng Kung Univ, Coll Med, Dept Anat, Tainan 70101, Taiwan.
   [Lin, Chun-Nan] Kaohsiung Med Univ, Sch Pharm, Kaohsiung, Taiwan.
RP Su, CL (corresponding author), Natl Taiwan Normal Univ, Dept Human Dev & Family Studies, 162,Sec 1,He Ping East Rd, Taipei 10610, Taiwan.
EM chunlisu@ntnu.edu.tw
RI Lan, Sheng-Hui/AAV-1662-2021
OI Wu, Shan-Ying/0000-0003-2380-5760; Liu, Hsiao-Sheng/0000-0003-0576-7203
FU National Science CouncilMinistry of Science and Technology, Taiwan [NSC
   96-2313-B-309-001-MY2, 98-2313-B-003-002-MY3, 101-2313-B-003-002-MY3];
   Ministry of Economic Affairs [100-EC-17-A-17-S1-152]; National Taiwan
   Normal University [99-D, 100NTNU-D-06]
FX Contract grant sponsor: National Science Council;; Contract grant
   numbers: NSC 96-2313-B-309-001-MY2, 98-2313-B-003-002-MY3,
   101-2313-B-003-002-MY3.; Contract grant sponsor: The Ministry of
   Economic Affairs;; Contract grant number: 100-EC-17-A-17-S1-152.;
   Contract grant sponsor: National Taiwan Normal University;; Contract
   grant number: 99-D, 100NTNU-D-06.
CR Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   An CH, 2011, PATHOL RES PRACT, V207, P433, DOI 10.1016/j.prp.2011.05.002
   Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167
   Bocharov EV, 2007, J BIOL CHEM, V282, P16256, DOI 10.1074/jbc.M701745200
   Burton TR, 2009, CELL DEATH DIFFER, V16, P515, DOI 10.1038/cdd.2008.185
   Byun JY, 2009, CARCINOGENESIS, V30, P1880, DOI 10.1093/carcin/bgp235
   Carew JS, 2010, J CELL MOL MED, V14, P2448, DOI 10.1111/j.1582-4934.2009.00832.x
   Chang YP, 2010, J BIOL CHEM, V285, P28715, DOI 10.1074/jbc.M110.133355
   Chen S, 2011, BIOCHIM BIOPHYS ACTA, V1806, P220
   Codogno P, 2006, NAT CELL BIOL, V8, P1045, DOI 10.1038/ncb1006-1045
   Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2
   Day SH, 2002, J NAT PROD, V65, P379, DOI 10.1021/np0101651
   Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014
   FUKAMIYA N, 1986, J NAT PROD, V49, P348, DOI 10.1021/np50044a030
   Guo XZ, 2005, ONCOL REP, V14, P59
   Hector S, 2009, BBA-REV CANCER, V1795, P117, DOI 10.1016/j.bbcan.2008.12.002
   Huang SB, 2011, J BIOL CHEM, V286, P40002, DOI 10.1074/jbc.M111.297432
   Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI 10.3322/caac.20073
   KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J
   Kimura N, 2007, PATHOBIOLOGY, V74, P169, DOI 10.1159/000103376
   Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451
   Klionsky DJ, 2007, AUTOPHAGY, V3, P181, DOI 10.4161/auto.3678
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kondo Y, 2006, AUTOPHAGY, V2, P85, DOI 10.4161/auto.2.2.2463
   Lawson EL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029606
   Lee JC, 2005, CARCINOGENESIS, V26, P1716, DOI 10.1093/carcin/bgi133
   Lee YR, 2008, VIROLOGY, V374, P240, DOI 10.1016/j.virol.2008.02.016
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liu B, 2010, ACTA PHARMACOL SIN, V31, P1154, DOI 10.1038/aps.2010.118
   Liu HS, 2011, MOL PHARMACOL, V80, P638, DOI 10.1124/mol.111.072512
   Liu JJ, 2011, CANCER LETT, V300, P105, DOI 10.1016/j.canlet.2010.10.001
   Lotze MT, 2012, AUTOPHAGY, V8, P1264, DOI 10.4161/auto.20752
   Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005
   Moretti L, 2007, DRUG RESIST UPDATE, V10, P135, DOI 10.1016/j.drup.2007.05.001
   Nagata S, 2000, EXP CELL RES, V256, P12, DOI 10.1006/excr.2000.4834
   Nawrocki ST, 2007, CANCER RES, V67, P6987, DOI 10.1158/0008-5472.CAN-07-0812
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Papandreou I, 2008, CELL DEATH DIFFER, V15, P1572, DOI 10.1038/cdd.2008.84
   Saarinen NM, 2007, MOL NUTR FOOD RES, V51, P857, DOI 10.1002/mnfr.200600240
   Su CL, 2007, FEBS J, V274, P3633, DOI 10.1111/j.1742-4658.2007.05896.x
   Su CL, 2006, FEBS LETT, V580, P3185, DOI 10.1016/j.febslet.2006.04.085
   Su CL, 2011, FOOD CHEM TOXICOL, V49, P17, DOI 10.1016/j.fct.2010.08.017
   Tan ML, 2009, PHARM RES-DORDR, V26, P1547, DOI 10.1007/s11095-009-9895-1
   Virk-Baker MK, 2010, PLANTA MED, V76, P1132, DOI 10.1055/s-0030-1250074
   Wang LN, 2011, J SEP SCI, V34, P667, DOI 10.1002/jssc.201000781
   Wickman G, 2012, CELL DEATH DIFFER, V19, P735, DOI 10.1038/cdd.2012.25
   Wlodkowic D., 2012, Experimental Oncology, V34, P255
   Wu SY, 2011, NEOPLASIA, V13, P1171, DOI 10.1593/neo.11888
   Xiao GT, 2007, CYTOKINE GROWTH F R, V18, P233, DOI 10.1016/j.cytogfr.2007.04.006
   Yang DQ, 2007, BIOCHEM PHARMACOL, V73, P1665, DOI 10.1016/j.bcp.2007.01.020
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Zhang J, 2011, GASTROENTEROLOGY, V141, P50, DOI 10.1053/j.gastro.2011.05.010
NR 55
TC 30
Z9 32
U1 1
U2 53
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD APR
PY 2015
VL 230
IS 4
BP 930
EP 946
DI 10.1002/jcp.24825
PG 17
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA AX4QP
UT WOS:000346916900022
PM 25216025
DA 2022-04-25
ER

PT J
AU Mo, SB
   Dai, WX
   Xiang, WQ
   Li, YQ
   Feng, Y
   Zhang, L
   Li, QG
   Cai, GX
AF Mo, Shaobo
   Dai, Weixing
   Xiang, Wenqiang
   Li, Yaqi
   Feng, Yang
   Zhang, Long
   Li, Qingguo
   Cai, Guoxiang
TI Prognostic and predictive value of an autophagy-related signature for
   early relapse in stages I-III colon cancer
SO CARCINOGENESIS
LA English
DT Article
ID COLORECTAL-CANCER; CURATIVE RESECTION; RECURRENCE; SURVIVAL; PROTEIN;
   EXPRESSION; BREAST; P53; DISEASE; LEVEL
AB We postulated that expression differences of autophagy-related genes are instrumental in stratifying the risk of early relapse after surgery and evaluating the prognosis of patients with stages I-III colon cancer. Therefore, propensity score matching analysis was performed between patients in early relapse group and long-term survival group from GSE39582 test series and internal validation series. Using Cox regression model, a nine-autophagy-related signature (CAPN2, ATG16L2, TP63, SIRT1, RPS6KB1, PEX3, ATG5, UVRAG, NAF1) was established to classify patients into those at high risk of early relapse (high-risk group), and those at low risk of early relapse (low-risk group). Relapse-free survival (RFS) was significantly different between the two groups in test [hazard ratio (HR): 2.019, 95% confidence interval (CI): 1.362-2.992, P < 0.001], internal validation (HR: 2.464, 95% CI: 1.196-5.079, P < 0.001) and another two external validation series (GSE14333-HR: 2.250, 95% CI: 1.227-4.126, P = 0.007; GSE33113-HR: 5.552, 95% CI: 2.098-14.693, P < 0.001). Then, based on RFS, we developed a nomogram, integrating the nine-autophagy-related classifier and four clinicopathological risk factors to evaluate prognosis of stages I-III colon cancer patients. Time-dependent receiver operating curve at 2 years showed that the integrated signature (area under curve = 0.758) had better prognostic accuracy than American Joint Committee on Cancer TNM stage (area under curve = 0.620). In conclusion, we identified and built a nine-autophagy-related signature, a credible approach to early relapse prediction in stages I-III colon cancer patients, which can assist physicians in devising more efficient therapeutic strategies.
C1 [Mo, Shaobo; Dai, Weixing; Xiang, Wenqiang; Li, Yaqi; Feng, Yang; Zhang, Long; Li, Qingguo; Cai, Guoxiang] Fudan Univ, Dept Colorectal Surg, Shanghai Canc Ctr, Shanghai 200032, Peoples R China.
   [Mo, Shaobo; Dai, Weixing; Xiang, Wenqiang; Li, Yaqi; Feng, Yang; Li, Qingguo; Cai, Guoxiang] Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai 200032, Peoples R China.
   [Zhang, Long] Fudan Univ, Shanghai Canc Ctr, Canc Inst, Shanghai 200032, Peoples R China.
RP Li, QG; Cai, GX (corresponding author), Fudan Univ, Dept Colorectal Surg, Shanghai Canc Ctr, Shanghai 200032, Peoples R China.; Li, QG; Cai, GX (corresponding author), Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai 200032, Peoples R China.
EM oncosurgeonli@sohu.com; gxcaifuscc@163.com
FU National Key R&D Program of China [2016YFC0905300, 2016YFC0905301];
   Grant of Science and Technology Commission of Shanghai
   MunicipalityScience & Technology Commission of Shanghai Municipality
   (STCSM) [16401970502]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81572351];
   Shanghai Shenkang Program [SHDC12014206]
FX the National Key R&D Program of China (No. 2016YFC0905300 and
   2016YFC0905301); the Grant of Science and Technology Commission of
   Shanghai Municipality (No. 16401970502); the Grant of National Natural
   Science Foundation of China (No. 81572351) and Shanghai Shenkang Program
   (No. SHDC12014206).
CR Allegra CJ, 2003, J CLIN ONCOL, V21, P241, DOI 10.1200/JCO.2003.05.044
   Bathe OF, 2014, GENES-BASEL, V5, P536, DOI 10.3390/genes5030536
   Bekri S, 1997, CYTOGENET CELL GENET, V79, P125, DOI 10.1159/000134699
   Chen B, 2013, CELL BIOL INT, V37, P643, DOI 10.1002/cbin.10062
   Cho DH, 2012, ANTICANCER RES, V32, P4091
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Gil J, 2016, BIOMARK MED, V10, P1081, DOI 10.2217/bmm-2016-0083
   Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002
   Grizzle WE, 2002, INT J CANCER, V97, P403, DOI 10.1002/ijc.1617
   Hammond EM, 1998, FEBS LETT, V425, P391, DOI 10.1016/S0014-5793(98)00266-X
   Hwang CC, 2011, ANN SURG ONCOL, V18, P139, DOI 10.1245/s10434-010-1209-7
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Kobayashi H, 2007, SURGERY, V141, P67, DOI 10.1016/j.surg.2006.07.020
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Lai K, 2014, J CLIN PATHOL, V67, P854, DOI 10.1136/jclinpath-2014-202529
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 2001, CANCER RES, V61, P3443
   Liu PF, 2014, AUTOPHAGY, V10, P1454, DOI 10.4161/auto.29556
   Lu CY, 2011, BRIT J CANCER, V104, P1178, DOI 10.1038/bjc.2011.40
   Lv L, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0965-9
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Massion PP, 2003, CANCER RES, V63, P7113
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Murray-Zmijewski F, 2006, CELL DEATH DIFFER, V13, P962, DOI 10.1038/sj.cdd.4401914
   O'Connell MJ, 2008, J CLIN ONCOL, V26, P2336, DOI 10.1200/JCO.2007.15.8261
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Reis JS, 2003, VIRCHOWS ARCH, V443, P122, DOI 10.1007/s00428-003-0859-2
   Sargent DJ, 2005, J CLIN ONCOL, V23, P8664, DOI 10.1200/JCO.2005.01.6071
   Smolle MA, 2015, PHARMACOGENOMICS, V16, P1313, DOI 10.2217/pgs.15.83
   Song HW, 2015, AUTOPHAGY, V11, P1308, DOI 10.1080/15548627.2015.1060386
   Storr SJ, 2012, ANN ONCOL, V23, P2289, DOI 10.1093/annonc/mds176
   Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459
   Tanida I, 2002, J BIOL CHEM, V277, P13739, DOI 10.1074/jbc.M200385200
   Tasdemir E, 2008, AUTOPHAGY, V4, P810, DOI 10.4161/auto.6486
   Tjandra JJ, 2007, DIS COLON RECTUM, V50, P1783, DOI 10.1007/s10350-007-9030-5
   Tsai HL, 2016, WORLD J SURG, V40, P1002, DOI 10.1007/s00268-015-3331-y
   Walker AS, 2014, J CANCER, V5, P272, DOI 10.7150/jca.8871
   Weiser MR, 2011, J CLIN ONCOL, V29, P4796, DOI 10.1200/JCO.2011.36.5080
   White E, 2015, CLIN CANCER RES, V21, P5037, DOI 10.1158/1078-0432.CCR-15-0490
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Yu J, 2015, GUT, V64, P636, DOI 10.1136/gutjnl-2013-306620
   Zhou HY, 2016, CANCER BIOMARK, V17, P1, DOI 10.3233/CBM-160613
   Zhou W, 2002, LANCET, V359, P219, DOI 10.1016/S0140-6736(02)07448-2
NR 46
TC 43
Z9 43
U1 1
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD JUL
PY 2019
VL 40
IS 7
BP 861
EP 870
DI 10.1093/carcin/bgz031
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA JH8US
UT WOS:000493043700005
PM 30933267
DA 2022-04-25
ER

PT J
AU Sui, XB
   Kong, N
   Ye, L
   Han, WD
   Zhou, JC
   Zhang, Q
   He, C
   Pan, HM
AF Sui, Xinbing
   Kong, Na
   Ye, Li
   Han, Weidong
   Zhou, Jichun
   Zhang, Qin
   He, Chao
   Pan, Hongming
TI p38 and JNK MAPK pathways control the balance of apoptosis and autophagy
   in response to chemotherapeutic agents
SO CANCER LETTERS
LA English
DT Review
DE P38; JNK; Autophagy; Apoptosis; Chemoresistance
ID ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; SIGNAL-TRANSDUCTION
   PATHWAYS; COLORECTAL-CANCER GROWTH; CELL-DEATH; C-JUN; OXIDATIVE STRESS;
   UP-REGULATION; COLON-CANCER; REGULATES AUTOPHAGY
AB The Mitogen Activated Protein Kinase (MAPK) signaling plays a critical role in the outcome and the sensitivity to anticancer therapies. Activated MAPK can transmit extracellular signals to regulate cell growth, proliferation, differentiation, migration, apoptosis and so on. Apoptosis as well as macroautophagy (hereafter referred to as autophagy) can be induced by extracellular stimuli such the treatment of chemotherapeutic agents, resulting in different cell response to these drugs. However, the molecular mechanisms mediating these two cellular processes remain largely unknown. Recently, several studies provide new insights into p38 and JNK MAPK pathways function in the control of the balance of autophagy and apoptosis in response to genotoxic stress. Our increased understanding of the role of p38 and JNK MAPK pathways in regulating the balance of autophagy and apoptosis will hopefully provide prospective strategies for cancer therapy. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Sui, Xinbing; Kong, Na; Han, Weidong; Pan, Hongming] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Med Oncol, Hangzhou 310003, Zhejiang, Peoples R China.
   [Sui, Xinbing; Kong, Na; Han, Weidong; He, Chao; Pan, Hongming] Biomed Res Ctr, Hangzhou, Zhejiang, Peoples R China.
   [Sui, Xinbing; Kong, Na; Han, Weidong; He, Chao; Pan, Hongming] Key Lab Biotherapy Zhejiang Prov, Hangzhou, Zhejiang, Peoples R China.
   [Ye, Li] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Gen Med, Hangzhou 310003, Zhejiang, Peoples R China.
   [He, Chao] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Colorectal Surg, Hangzhou 310003, Zhejiang, Peoples R China.
   [Zhou, Jichun] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Surg Oncol, Hangzhou 310003, Zhejiang, Peoples R China.
   [Zhang, Qin] Zhejiang Prov Peoples Hosp, Dept Gastrointestinal Surg, Hangzhou 310016, Zhejiang, Peoples R China.
RP Zhang, Q (corresponding author), Zhejiang Prov Peoples Hosp, Dept Gastrointestinal Surg, Hangzhou 310016, Zhejiang, Peoples R China.
EM hz166cn@163.com; drhechao@yahoo.com.cn; hzzju@zju.edu.cn
RI Zhou, Jichun/Q-8646-2019
OI Zhou, Jichun/0000-0002-0727-4034
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81301891, 81272593]; Zhejiang Provincial
   Natural Science Foundation of ChinaNatural Science Foundation of
   Zhejiang Province [LQ13H160008]
FX This study is supported by grants from National Natural Science
   Foundation of China (Grant Nos. 81301891 and 81272593) and Zhejiang
   Provincial Natural Science Foundation of China (Grant No. LQ13H160008).
CR Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303
   Chen SS, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0036784, 10.1371/journal.pone.0050456, 10.1371/journal.pone.0045763, 10.1371/journal.pone.0049275]
   Chiacchiera F, 2009, CELL DEATH DIFFER, V16, P1203, DOI 10.1038/cdd.2009.36
   Chiacchiera F, 2012, CANCER LETT, V324, P98, DOI 10.1016/j.canlet.2012.05.006
   Chiu SJ, 2008, TOXICOL LETT, V179, P63, DOI 10.1016/j.toxlet.2008.04.004
   Choi CH, 2012, BIOCHEM BIOPH RES CO, V418, P759, DOI 10.1016/j.bbrc.2012.01.095
   Comes F, 2007, CELL DEATH DIFFER, V14, P693, DOI 10.1038/sj.cdd.4402076
   Cuadrado A, 2010, BIOCHEM J, V429, P403, DOI 10.1042/BJ20100323
   Cuenda A, 2007, BBA-MOL CELL RES, V1773, P1358, DOI 10.1016/j.bbamcr.2007.03.010
   Cui J, 2007, ACTA PHARMACOL SIN, V28, P601, DOI 10.1111/j.1745-7254.2007.00579.x
   Cui Q, 2007, J PHARMACOL SCI, V105, P317, DOI 10.1254/jphs.FP0070336
   de la Cruz-Morcillo MA, 2012, ONCOGENE, V31, P1073, DOI 10.1038/onc.2011.321
   de la Cruz-Morcillo MA, 2012, AUTOPHAGY, V8, P135, DOI 10.4161/auto.8.1.18275
   Deacon K, 2003, MOL BIOL CELL, V14, P2071, DOI 10.1091/mbc.E02-10-0653
   Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013
   Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6
   Fleming Y, 2000, BIOCHEM J, V352, P145, DOI 10.1042/0264-6021:3520145
   Gan L, 2011, PROSTATE, V71, P1158, DOI 10.1002/pros.21331
   Haberzettl P, 2013, REDOX BIOL, V1, P56, DOI 10.1016/j.redox.2012.10.003
   Hallahan AR, 2003, NAT MED, V9, P1033, DOI 10.1038/nm904
   HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033
   Hommes DW, 2003, GUT, V52, P144, DOI 10.1136/gut.52.1.144
   Hu C, 2012, TOXICOL LETT, V210, P78, DOI 10.1016/j.toxlet.2012.01.019
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Jia L, 2008, PROSTATE, V68, P427, DOI 10.1002/pros.20716
   Johnson GL, 2007, BBA-MOL CELL RES, V1773, P1341, DOI 10.1016/j.bbamcr.2006.12.009
   Jung KH, 2012, HEPATOLOGY, V56, P644, DOI 10.1002/hep.25699
   Keil E, 2013, CELL DEATH DIFFER, V20, P321, DOI 10.1038/cdd.2012.129
   Kelkel M, 2012, CARCINOGENESIS, V33, P2162, DOI 10.1093/carcin/bgs240
   Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7
   Khavari TA, 2007, CELL CYCLE, V6, P2928, DOI 10.4161/cc.6.23.4998
   Kim DS, 2010, BIOL PHARM BULL, V33, P545, DOI 10.1248/bpb.33.545
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kralova V, 2012, TOXICOL IN VITRO, V26, P258, DOI 10.1016/j.tiv.2011.12.010
   KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0
   Kyriakis JM, 2012, PHYSIOL REV, V92, P689, DOI 10.1152/physrev.00028.2011
   Li CY, 2012, CANCER LETT, V314, P102, DOI 10.1016/j.canlet.2011.09.020
   Li DD, 2009, ONCOGENE, V28, P886, DOI 10.1038/onc.2008.441
   Li YC, 2012, TOXICOL APPL PHARM, V263, P21, DOI 10.1016/j.taap.2012.05.018
   Li YL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044254
   Lim JH, 2012, CHEM-BIOL INTERACT, V197, P1, DOI 10.1016/j.cbi.2012.02.003
   Limami Y, 2012, BIOCHIMIE, V94, P1754, DOI 10.1016/j.biochi.2012.04.006
   Loesch M, 2008, FRONT BIOSCI-LANDMRK, V13, P3581, DOI 10.2741/2951
   Lorin S, 2010, AUTOPHAGY, V6, P153, DOI 10.4161/auto.6.1.10537
   Lorin S, 2009, CANCER RES, V69, P6924, DOI 10.1158/0008-5472.CAN-09-1270
   Lou XQ, 2009, MOL CANCER THER, V8, P1126, DOI 10.1158/1535-7163.MCT-08-0904
   Luo SQ, 2013, AUTOPHAGY, V9, P104, DOI 10.4161/auto.22399
   Luo SQ, 2012, MOL CELL, V47, P359, DOI 10.1016/j.molcel.2012.05.040
   Lv XC, 2012, CAN J PHYSIOL PHARM, V90, P655, DOI [10.1139/Y2012-051, 10.1139/y2012-051]
   Malilas W, 2013, CANCER GENE THER, V20, P125, DOI 10.1038/cgt.2012.96
   Malki A, 2012, J CHEMOTHERAPY, V24, P268, DOI 10.1179/1973947812Y.0000000035
   Mansouri A, 2003, J BIOL CHEM, V278, P19245, DOI 10.1074/jbc.M208134200
   Maycotte P, 2011, CANCER BIOL THER, V11, P127, DOI 10.4161/cbt.11.2.14627
   Olsen BB, 2012, INT J ONCOL, V41, P1967, DOI 10.3892/ijo.2012.1635
   Olson JM, 2004, TRENDS MOL MED, V10, P125, DOI 10.1016/j.molmed.2004.01.007
   Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6
   Paillas S, 2012, AUTOPHAGY, V8, P1098, DOI 10.4161/auto.20268
   Paillas S, 2011, CANCER RES, V71, P1041, DOI 10.1158/0008-5472.CAN-10-2726
   Pang H, 2011, CANCER BIOTHER RADIO, V26, P165, DOI 10.1089/cbr.2010.0838
   PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0
   Rosenfeldt MT, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001306
   Sabapathy K, 2012, PROG MOL BIOL TRANSL, V106, P145, DOI 10.1016/B978-0-12-396456-4.00013-4
   Salim H, 2012, BRIT J CANCER, V107, P1361, DOI 10.1038/bjc.2012.382
   Sau A, 2012, MOL BIOSYST, V8, P994, DOI 10.1039/c1mb05295k
   Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435
   Shajahan AN, 2012, J BIOL CHEM, V287, P17682, DOI 10.1074/jbc.M111.304022
   Shimizu S, 2010, ONCOGENE, V29, P2070, DOI 10.1038/onc.2009.487
   Shin DY, 2009, INT J ONCOL, V35, P1499, DOI 10.3892/ijo_00000469
   Simone C, 2007, AUTOPHAGY, V3, P468, DOI 10.4161/auto.4319
   Song HW, 2012, J BIOL CHEM, V287, P5528, DOI 10.1074/jbc.M111.285114
   Song IS, 2012, GASTROENTEROLOGY, V143, P1341, DOI 10.1053/j.gastro.2012.07.103
   Song XX, 2012, MOL CANCER RES, V10, P1567, DOI 10.1158/1541-7786.MCR-12-0209-T
   Sun T, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-161
   Tang RX, 2012, WORLD J GASTROENTERO, V18, P1485, DOI 10.3748/wjg.v18.i13.1485
   Thyagarajan A, 2010, NUTR CANCER, V62, P630, DOI 10.1080/01635580903532390
   Tiwari M, 2008, CARCINOGENESIS, V29, P600, DOI 10.1093/carcin/bgm264
   Tiwari M, 2006, CARCINOGENESIS, V27, P2047, DOI 10.1093/carcin/bgl051
   Wang YJ, 2010, HEPATOLOGY, V52, P266, DOI 10.1002/hep.23645
   Webber JL, 2010, AUTOPHAGY, V6, P292, DOI 10.4161/auto.6.2.11128
   Webber JL, 2010, EMBO J, V29, P27, DOI 10.1038/emboj.2009.321
   Wei YJ, 2008, AUTOPHAGY, V4, P949, DOI 10.4161/auto.6788
   West RJH, 2012, AUTOPHAGY, V8, P284, DOI 10.4161/auto.8.2.18981
   Wyrsch P, 2012, MOL CELL BIOL, V32, P3541, DOI 10.1128/MCB.00437-12
   Xiao F, 2012, WORLD J GASTROENTERO, V18, P7348, DOI 10.3748/wjg.v18.i48.7348
   Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899
   Yang SH, 2013, GENE, V513, P1, DOI 10.1016/j.gene.2012.10.033
   Ye YC, 2011, J PHARMACOL SCI, V117, P160, DOI 10.1254/jphs.11105FP
   Zhan Y, 2012, FREE RADICAL BIO MED, V53, P532, DOI 10.1016/j.freeradbiomed.2012.05.018
   Zhang XY, 2013, CELL SIGNAL, V25, P150, DOI 10.1016/j.cellsig.2012.09.004
   Zhao MY, 2011, BMB REP, V44, P601, DOI 10.5483/BMBRep.2011.44.9.601
   Zhou CH, 2012, ACTA BIOCH BIOPH SIN, V44, P815, DOI 10.1093/abbs/gms064
   Zhou FF, 2011, FEBS J, V278, P403, DOI 10.1111/j.1742-4658.2010.07965.x
   Zhu BY, 2013, INT J CANCER, V132, P2270, DOI 10.1002/ijc.27927
NR 93
TC 558
Z9 601
U1 17
U2 277
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD MAR 28
PY 2014
VL 344
IS 2
BP 174
EP 179
DI 10.1016/j.canlet.2013.11.019
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AB3EC
UT WOS:000331673100004
PM 24333738
HC Y
HP N
DA 2022-04-25
ER

PT J
AU Ortiz, LMG
   Croce, AL
   Aredia, F
   Sapienza, S
   Fiorillo, G
   Syeda, TM
   Buzzetti, F
   Lombardi, P
   Scovassi, AI
AF Ortiz, Luis Miguel Guaman
   Croce, Anna Leta
   Aredia, Francesca
   Sapienza, Simone
   Fiorillo, Gaetano
   Syeda, Tanjia Monir
   Buzzetti, Franco
   Lombardi, Paolo
   Scovassi, Anna Ivana
TI Effect of new berberine derivatives on colon cancer cells
SO ACTA BIOCHIMICA ET BIOPHYSICA SINICA
LA English
DT Article
DE apoptosis; autophagy; berberine; colon cancer; fluorescence
ID AUTOPHAGY; AMPLIFICATION; MECHANISMS; APOPTOSIS; DEATH
AB The natural alkaloid berberine has been recently described as a promising anticancer drug. In order to improve its efficacy and bioavailability, several derivatives have been designed and synthesized and found to be even more potent than the lead compound. Among the series of berberine derivatives we have produced, five compounds were identified to be able to heavily affect the proliferation of human HCT116 and SW613-B3 colon carcinoma cell lines. Remarkably, these active compounds exhibit high fluorescence emission property and ability to induce autophagy.
C1 [Ortiz, Luis Miguel Guaman; Croce, Anna Leta; Aredia, Francesca; Sapienza, Simone; Scovassi, Anna Ivana] CNR, Ist Genet Mol, I-27100 Pavia, Italy.
   [Ortiz, Luis Miguel Guaman] Univ Tecn Particular Loja, Dept Ciencias Salud, Loja, Ecuador.
   [Aredia, Francesca] Univ Pavia, Dipartimento Biol & Biotecnol L Spallanzani, I-27100 Pavia, Italy.
   [Fiorillo, Gaetano; Syeda, Tanjia Monir; Buzzetti, Franco; Lombardi, Paolo] Naxospharma Srl, Novate Milanese, Italy.
RP Scovassi, AI (corresponding author), CNR, Ist Genet Mol, I-27100 Pavia, Italy.
EM scovassi@igm.cnr.it
RI Ortiz, Luis Miguel Guaman/X-9496-2019
OI Ortiz, Luis Miguel Guaman/0000-0003-2919-4905; Lombardi,
   Paolo/0000-0002-7971-7404; Scovassi, Anna Ivana/0000-0003-3484-9881
FU Regione Lombardia, Italy (Project Plant Cell)Regione Lombardia
   [13810040]; Regione Lombardia, Italy (Naxospharma)
FX The work was supported by a grant from Regione Lombardia, Italy (Project
   Plant Cell, grant No. 13810040 to A.I.S. and Naxospharma).
CR Aredia F, 2013, APOPTOSIS, V18, P1586, DOI 10.1007/s10495-013-0898-3
   Aredia Francesca, 2012, Cells, V1, P520, DOI 10.3390/cells1030520
   Aredia F, 2013, FUTURE MED CHEM, V5, P1009, DOI 10.4155/fmc.13.85
   Bhowmik D, 2012, J PHYS CHEM B, V116, P2314, DOI 10.1021/jp210072a
   Bottone MG, 2003, EXP CELL RES, V290, P49, DOI 10.1016/S0014-4827(03)00312-4
   Donzelli M, 1999, ONCOGENE, V18, P439, DOI 10.1038/sj.onc.1202309
   Fan XD, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0450-z
   Fatokun AA, 2014, BRIT J PHARMACOL, V171, P2000, DOI 10.1111/bph.12416
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Giansanti V, 2013, J CELL MOL MED, V17, P103, DOI 10.1111/j.1582-4934.2012.01652.x
   Gorrini C, 2003, INT J MOL MED, V11, P737
   Guaman-Ortiz L.M., 2014, BIOMED RES INT, V2014
   Hou Q, 2011, CANCER SCI, V102, P1287, DOI 10.1111/j.1349-7006.2011.01933.x
   Hu XJ, 2014, MOL MED REP, V9, P1883, DOI 10.3892/mmr.2014.1999
   Iwasa K, 1997, PLANTA MED, V63, P196, DOI 10.1055/s-2006-957651
   Lee KH, 2014, SCI REP-UK, V4, DOI 10.1038/srep06394
   Liu ZJ, 2009, MUTAT RES-FUND MOL M, V662, P75, DOI 10.1016/j.mrfmmm.2008.12.009
   Ortiz LMG, 2014, MOLECULES, V19, P12349, DOI 10.3390/molecules190812349
   Peng PL, 2008, INT J RADIAT ONCOL, V70, P529, DOI 10.1016/j.ijrobp.2007.08.034
   Pierpaoli E, 2013, BIOFACTORS, V39, P672, DOI 10.1002/biof.1131
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Singh IP, 2013, EXPERT OPIN THER PAT, V23, P215, DOI 10.1517/13543776.2013.746314
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Tillhon M, 2012, BIOCHEM PHARMACOL, V84, P1260, DOI 10.1016/j.bcp.2012.07.018
   Uzasci S, 2014, J CHROMATOGR A, V1338, P184, DOI 10.1016/j.chroma.2014.02.068
   Wang N, 2010, J CELL BIOCHEM, V111, P1426, DOI 10.1002/jcb.22869
   Wang Y, 2012, MUTAT RES-FUND MOL M, V734, P20, DOI 10.1016/j.mrfmmm.2012.04.005
   Waters ML, 2002, CURR OPIN CHEM BIOL, V6, P736, DOI 10.1016/S1367-5931(02)00359-9
   Zhu Y, 2014, MOL MED REP, V10, P1734, DOI 10.3892/mmr.2014.2405
NR 29
TC 33
Z9 35
U1 1
U2 20
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1672-9145
EI 1745-7270
J9 ACTA BIOCH BIOPH SIN
JI Acta Biochim. Biophys. Sin.
PD OCT
PY 2015
VL 47
IS 10
BP 824
EP 833
DI 10.1093/abbs/gmv077
PG 10
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA CS3VQ
UT WOS:000362003700008
PM 26341980
OA Bronze
DA 2022-04-25
ER

PT J
AU Wu, QX
   Yuan, SX
   Ren, CM
   Yu, Y
   Sun, WJ
   He, BC
   Wu, K
AF Wu, Qiu-Xiang
   Yuan, Shuang-Xue
   Ren, Chun-Mei
   Yu, Yu
   Sun, Wen-Juan
   He, Bai-Cheng
   Wu, Ke
TI Oridonin upregulates PTEN through activating p38 MAPK and inhibits
   proliferation in human colon cancer cells
SO ONCOLOGY REPORTS
LA English
DT Article
DE oridonin; colon cancer; proliferation inhibition; PTEN; p38 MAPK
ID COLORECTAL-CANCER; PANCREATIC-CANCER; GROWTH-INHIBITION; IN-VITRO;
   APOPTOSIS; EXPRESSION; AUTOPHAGY; PATHWAY; TETRANDRINE; SENESCENCE
AB Oridonin (ORI) has been reported as an antiproliferation and apoptosis-inducing natural product in various cancer cells. However, the exact molecular mechanism underlying these effects remains unclear. In the present study, we demonstrated the antiproliferation effect of ORI in HCT116 cells, and analyzed the possible molecular mechanism which mediates this effect. We found that ORI inhibits proliferation, induces cell cycle arrest and apoptosis in HCT116 cells, thus also tumor growth. Mechanically, we found that ORI has no substantial effect on mRNA expression of phosphatase and tensin homologue (PTEN), but increases the total protein level of PTEN and markedly reduces the phosphorylation of PTEN; Exogenous expression of PTEN potentiates the anticancer effect of ORI, while knockdown of PTEN attenuates it. ORI also increases the phosphorylation of p38 MAPK, and p38 MAPK-specific inhibitor reduces the antiproliferation effect ORI in HCT116 cells. Moreover, inhibition of p38 MAPK increases the phosphorylation of PTEN, and reverses ORI-induced decrease of PTEN phosphorylation. Our findings suggested that ORI may be a potential anticancer drug for colon cancer, this effect may be mediated by enhancing the function of PTEN through reducing its phosphorylation, which may be resulted from the ORI-induced activation of p38 MAPK.
C1 [Wu, Qiu-Xiang; Yuan, Shuang-Xue; Ren, Chun-Mei; Yu, Yu; Sun, Wen-Juan; He, Bai-Cheng; Wu, Ke] Chongqing Med Univ, Sch Pharm, Chongqing Municipal Key Lab Higher Educ Inst Bioc, Chongqing 400016, Peoples R China.
   [Wu, Qiu-Xiang; Yuan, Shuang-Xue; Ren, Chun-Mei; Sun, Wen-Juan; He, Bai-Cheng; Wu, Ke] Chongqing Med Univ, Sch Pharm, Dept Pharmacol, 1 Yixueyuan Rd, Chongqing 400016, Peoples R China.
   [Yu, Yu] Chongqing Med Univ, Sch Pharm, Dept Chem, Chongqing 400016, Peoples R China.
RP He, BC; Wu, K (corresponding author), Chongqing Med Univ, Sch Pharm, Dept Pharmacol, 1 Yixueyuan Rd, Chongqing 400016, Peoples R China.
EM hebaicheng99@yahoo.com; wukecqmu@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [NSFC 81372120, 81572226]
FX We thank Professor Tong-Chuan He of the University of Chicago Medical
   Center (Chicago, IL, USA) for his kind provision of the recombinant
   adenoviruses. The present study was supported by the Research Grant from
   the National Natural Science Foundation of China (grant nos. NSFC
   81372120 and 81572226 to Bai-Cheng He).
CR [Anonymous], 2010, Prescrire Int, V19, P219
   Banjerdpongchai R, 2009, ASIAN PAC J CANCER P, V10, P1137
   Binefa G, 2014, WORLD J GASTROENTERO, V20, P6786, DOI 10.3748/wjg.v20.i22.6786
   Bu HQ, 2014, ONCOL REP, V31, P975, DOI 10.3892/or.2013.2888
   Carnero A, 2008, CURR CANCER DRUG TAR, V8, P187, DOI 10.2174/156800908784293659
   Cheng Y, 2009, ARCH BIOCHEM BIOPHYS, V490, P70, DOI 10.1016/j.abb.2009.08.011
   Cui Q, 2007, BIOL PHARM BULL, V30, P859, DOI 10.1248/bpb.30.859
   Cui Q, 2007, J PHARMACOL SCI, V105, P317, DOI 10.1254/jphs.FP0070336
   Feng FF, 2011, DRUG DELIV, V18, P265, DOI 10.3109/10717544.2010.536271
   Feng QY, 2014, WORLD J GASTROENTERO, V20, P4263, DOI 10.3748/wjg.v20.i15.4263
   Gao FH, 2012, INT J MOL MED, V29, P649, DOI 10.3892/ijmm.2012.895
   Gao FH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-610
   Gao SY, 2014, ASIAN PAC J CANCER P, V15, P6437, DOI 10.7314/APJCP.2014.15.15.6437
   He BC, 2011, MOL PHARMACOL, V79, P211, DOI 10.1124/mol.110.068668
   Hsieh TC, 2005, BIOCHEM BIOPH RES CO, V337, P224, DOI 10.1016/j.bbrc.2005.09.040
   Hsu CP, 2011, EJSO-EUR J SURG ONC, V37, P140, DOI 10.1016/j.ejso.2010.12.003
   Hu HZ, 2007, ACTA PHARMACOL SIN, V28, P1819, DOI 10.1111/j.1745-7254.2007.00667.x
   Huang HL, 2012, MOL CANCER THER, V11, P1155, DOI 10.1158/1535-7163.MCT-12-0066
   Huang J, 2014, BIOMATERIALS, V35, P9649, DOI 10.1016/j.biomaterials.2014.08.016
   Li D, 2008, J ASIAN NAT PROD RES, V10, P77, DOI 10.1080/10286020701273866
   Li X, 2012, INT J BIOL SCI, V8, P901, DOI 10.7150/ijbs.4554
   Liu DL, 2014, MOL MED REP, V10, P3027, DOI 10.3892/mmr.2014.2584
   Liu YQ, 2006, BIOL PHARM BULL, V29, P1873, DOI 10.1248/bpb.29.1873
   Liu Y, 2013, J PHARM PHARMACOL, V65, P1622, DOI 10.1111/jphp.12140
   Luo J, 2007, NAT PROTOC, V2, P1236, DOI 10.1038/nprot.2007.135
   Milella M, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00024
   Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd
   Owona BA, 2015, DRUGS R&D, V15, P233, DOI 10.1007/s40268-015-0102-z
   Polivka J, 2014, PHARMACOL THERAPEUT, V142, P164, DOI 10.1016/j.pharmthera.2013.12.004
   Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330
   Tormos AM, 2013, FREE RADICAL RES, V47, P905, DOI 10.3109/10715762.2013.821200
   Tran NH, 2015, THER ADV MED ONCOL, V7, P252, DOI 10.1177/1758834015591952
   Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007
   Wang SP, 2013, AM J CHINESE MED, V41, P177, DOI 10.1142/S0192415X13500134
   Waniczek D, 2013, POL J PATHOL, V64, P15, DOI 10.5114/PJP.2013.34598
   Weaver BA, 2014, MOL BIOL CELL, V25, P2677, DOI 10.1091/mbc.E14-04-0916
   Wu K, 2015, INT J ONCOL, V46, P1205, DOI 10.3892/ijo.2014.2800
   Zhou GB, 2007, BLOOD, V109, P3441, DOI 10.1182/blood-2006-06-032250
   Zhu Y, 2007, PHARMAZIE, V62, P439, DOI 10.1691/ph.2007.6.6691
NR 39
TC 28
Z9 29
U1 2
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD JUN
PY 2016
VL 35
IS 6
BP 3341
EP 3348
DI 10.3892/or.2016.4735
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DM7OT
UT WOS:000376550600024
PM 27108927
OA Bronze
DA 2022-04-25
ER

PT J
AU Yoshimoto, T
   Morine, Y
   Takasu, C
   Feng, R
   Ikemoto, T
   Yoshikawa, K
   Iwahashi, S
   Saito, Y
   Kashihara, H
   Akutagawa, M
   Emoto, T
   Kinouchi, Y
   Shimada, M
AF Yoshimoto, Toshiaki
   Morine, Yuji
   Takasu, Chie
   Feng, Rui
   Ikemoto, Tetsuya
   Yoshikawa, Kozo
   Iwahashi, Syuichi
   Saito, Yu
   Kashihara, Hideya
   Akutagawa, Masatake
   Emoto, Takahiro
   Kinouchi, Yosuke
   Shimada, Mitsuo
TI Blue light-emitting diodes induce autophagy in colon cancer cells by
   Opsin 3
SO ANNALS OF GASTROENTEROLOGICAL SURGERY
LA English
DT Article
DE autophagy; blue light-emitting diode; colorectal cancer; Opsin 3;
   photoreceptor
ID APOPTOSIS; MITOCHONDRIA; IRRADIATION; MELANOMA; NECROSIS; SYSTEM
AB Background: Light emitting-diodes (LED) have various effects on living organisms and recent studies have shown the efficacy of visible light irradiation from LED for anticancer therapies. However, the mechanism of LED's effects on cancer cells remains unclear. The aim of the present study was to investigate the effects of LED on colon cancer cell lines and the role of photoreceptor Opsin 3 (Opn3) on LED irradiation in vitro.
   Methods: Human colon cancer cells (HT-29 or HCT-116) were seeded onto laboratory dishes and irradiated with 465-nm LED at 30 mW/cm(2) for 30 minutes. Cell Counting Kit-8 was used to measure cell viability, and apoptosis and caspase 3/8 expression were evaluated by AnnexinV/PI and reverse transcription-polymerase chain reaction (RT-PCR), respectively. Autophagy and expression of LC-3 and beclin-1 were also evaluated by autophagy assays, RT-PCR and Western blotting. We further tested Opn3 knockdown by Opn3 siRNA and the G(i/o) G-protein inhibitor NF023 in these assays.
   Results: Viability of HT-29 and HCT-116 cells was lower in 465-nm LED-irradiated cultures than in control cultures. LC-3 and beclin-1 expressions were significantly higher in LED-irradiated cultures, and autophagosomes were detected in irradiated cells. The reductive effect of cancer cell viability following blue LED irradiation was reversed by Opn3 knockdown or NF023 treatment. Furthermore, increased LC-3 and beclin-1 expression that resulted from blue LED irradiation was suppressed by Opn3 knockdown or NF023 treatment.
   Conclusion: Blue LED irradiation suppressed the growth of colon cancer cells and Opn3 may play an important role as a photoreceptor.
C1 [Yoshimoto, Toshiaki; Morine, Yuji; Takasu, Chie; Feng, Rui; Ikemoto, Tetsuya; Yoshikawa, Kozo; Iwahashi, Syuichi; Saito, Yu; Kashihara, Hideya; Shimada, Mitsuo] Tokushima Univ, Dept Surg, Grad Sch, Tokushima, Japan.
   [Akutagawa, Masatake; Emoto, Takahiro] Tokushima Univ, Grad Sch Technol Ind & Social Sci, Tokushima, Japan.
   [Kinouchi, Yosuke] Tokushima Univ, Ctr Res Adm & Collaborat, Tokushima, Japan.
RP Morine, Y (corresponding author), Tokushima Univ, Dept Surg, Grad Sch, Tokushima, Japan.
EM ymorine@tokushima-u.ac.jp
CR Barolet D, 2008, SEMIN CUTAN MED SURG, V27, P227, DOI 10.1016/j.sder.2008.08.003
   Canu N, 2005, J NEUROCHEM, V92, P1228, DOI 10.1111/j.1471-4159.2004.02956.x
   de Assis LVM, 2016, BBA-MOL CELL RES, V1863, P1119, DOI 10.1016/j.bbamcr.2016.03.001
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   del Olmo-Aguado S, 2016, NEUROCHEM RES, V41, P2324, DOI 10.1007/s11064-016-1946-5
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kim S, 2013, PHOTOMED LASER SURG, V31, P554, DOI 10.1089/pho.2012.3343
   Koyanagi M, 2014, BBA-BIOENERGETICS, V1837, P710, DOI 10.1016/j.bbabio.2013.09.003
   Koyanagi M, 2013, P NATL ACAD SCI USA, V110, P4998, DOI 10.1073/pnas.1219416110
   Kuse Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep05223
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Matsumoto N, 2014, ANTICANCER RES, V34, P4709
   Nikoletopoulou V, 2013, BBA-MOL CELL RES, V1833, P3448, DOI 10.1016/j.bbamcr.2013.06.001
   Oh PS, 2016, INT J BIOCHEM CELL B, V70, P13, DOI 10.1016/j.biocel.2015.11.004
   Oh PS, 2015, J PHOTOCH PHOTOBIO B, V142, P197, DOI 10.1016/j.jphotobiol.2014.12.006
   Park JY, 2016, BIOCHEM BIOPH RES CO, V470, P336, DOI 10.1016/j.bbrc.2016.01.049
   Sakai K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141238
   Sparsa A, 2010, ANTICANCER RES, V30, P143
   Terakita A, 2014, ZOOL SCI, V31, P653, DOI 10.2108/zs140094
   Vinck E, 2006, LASER MED SCI, V21, P11, DOI 10.1007/s10103-005-0366-6
   Yamashita T, 2010, P NATL ACAD SCI USA, V107, P22084, DOI 10.1073/pnas.1012498107
   Yang F, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.425
   Yoshida A, 2013, J PHOTOCH PHOTOBIO B, V129, P1, DOI 10.1016/j.jphotobiol.2013.09.003
   Zhou HY, 2016, CANCER BIOMARK, V17, P1, DOI 10.3233/CBM-160613
NR 25
TC 18
Z9 19
U1 2
U2 7
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 2475-0328
J9 ANN GASTROENT SURG
JI Ann. Gastroent. Surg.
PD MAR
PY 2018
VL 2
IS 2
BP 154
EP 161
DI 10.1002/ags3.12055
PG 8
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA GX0HT
UT WOS:000447391700009
PM 29863164
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhang, ZH
   Xu, M
   Sun, X
   Guo, X
AF Zhang, Zhihang
   Xu, Meng
   Sun, Xu
   Guo, Xu
TI Naturally occurring glycyrrhizin triterpene exerts anticancer effects on
   colorectal cancer cells via induction of apoptosis and autophagy and
   suppression of cell migration and invasion by targeting MMP-9 and MMP-2
   expression
SO JOURNAL OF BUON
LA English
DT Article
DE glycyrrhizin; colorectal cancer; apoptosis; autophagy; cell invasion
ID ACID; HEREDITARY; CYCLE
AB Purpose: The main aim of the current study was to investi-gate the anticancer properties of naturally occurring triter-pene - glycyrrhizin - against human colorectal carcinoma cells along with evaluation of its effects on cells apoptosis, autophagy and cell migration and invasion.
   Methods: Cell viability was evaluated by CellTiter95 (R) Aqueous One Solution cell viability assay, while the effects on cell apoptosis were observed by fluorescence microscopy using DAPI staining. Effects on autophagy were detected by transmission electron microscopy (TEM) along with western blot method. Transwell assay was performed to monitor the effects on cell migration and invasion.
   Results: Glycyrrhizin induced selective and dose-dependent inhibition of cell growth in SW48 human colorectal carcinoma cells with lesser cytotoxicity in normal colon cells (CCD-18Co). Glycyrrhizin also led to cell apoptotic effects manifested by chromatin condensation and nuclear fragmentation as evidenced by brighter fluorescence. Apoptosis was confirmed by western blot which showed increase in Bax expression and decrease in Bcl-2 expression. TEM analysis showed that glycyrrhizin-treated cells at 12 mu M showed autophagosomes indicating onset of autophagy. Western blot assay confirmed the autophagy results which showed glycyrrhizin-treated cells indicated increased expression of Beclin-1, LC3B-I and LC3B-II in a dose-dependent manner. Glycyrrhizin treatment also led to inhibition of both cell migration and invasion.
   Conclusion: The results of this study reveal that glycyrrhi-zin can be developed as a potent anticancer agent against colorectal cancer provided further studied are performed, especially on its toxicity to humans.
C1 [Zhang, Zhihang; Xu, Meng; Sun, Xu; Guo, Xu] Dalian Cent Hosp, Dept Anorectal Surg, Southwest Rd 826, Dalian 116000, Peoples R China.
RP Zhang, ZH (corresponding author), Dalian Cent Hosp, Dept Anorectal Surg, Southwest Rd 826, Dalian 116000, Peoples R China.
EM zhangzhihang7279@126.com
CR Asl MN, 2008, PHYTOTHER RES, V22, P709, DOI 10.1002/ptr.2362
   Brenner H, 2011, ANN INTERN MED, V154, P22, DOI 10.7326/0003-4819-154-1-201101040-00004
   Burt RW, 2000, GASTROENTEROLOGY, V119, P837, DOI 10.1053/gast.2000.16508
   Canada CCSNCIo, 2008, CAN CANC STAT 2008
   Cappell M S, 2007, Minerva Gastroenterol Dietol, V53, P351
   Center MM, 2009, CA-CANCER J CLIN, V59, P366, DOI 10.3322/caac.20038
   Farooqui A, 2018, BIOMED PHARMACOTHER, V97, P752, DOI 10.1016/j.biopha.2017.10.147
   Haghshenas V, 2014, ADV PHARM BULL, V4, P437, DOI 10.5681/apb.2014.064
   Humphries A, 2008, NAT REV CANCER, V8, P415, DOI 10.1038/nrc2392
   Jasperson KW, 2010, GASTROENTEROLOGY, V138, P2044, DOI 10.1053/j.gastro.2010.01.054
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Jeong HG, 2002, PHARMACOL RES, V46, P221, DOI 10.1016/S1043-6618(02)00121-4
   Khan R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056020
   Lin SC, 2018, ONCOL REP, V39, P703, DOI 10.3892/or.2017.6123
   Meng YQ, 2012, CHEM RES CHINESE U, V28, P214
   Moh Saudi, 2013, HLTH AWARENESS CTR C
   Rahmani M, 2018, CANCER RES, V78, P3075, DOI 10.1158/0008-5472.CAN-17-3024
   Rhodes JM, 2002, TRENDS MOL MED, V8, P10, DOI 10.1016/S1471-4914(01)02194-3
   Rossi T, 2005, IN VIVO, V19, P319
   Rustgi AK, 2007, GENE DEV, V21, P2525, DOI 10.1101/gad.1593107
   Lopez PJT, 2014, CLIN MED INSIGHTS-GA, V7, P33, DOI 10.4137/CGast.S14039
   Thirugnanam S, 2008, ONCOL REP, V20, P1387, DOI 10.3892/or_00000157
   Tsoi KKF, 2009, CLIN GASTROENTEROL H, V7, P682, DOI 10.1016/j.cgh.2009.02.016
   Vasen HFA, 2008, GUT, V57, DOI 10.1136/gut.2007.136127
   Wan XY, 2009, CHEM-BIOL INTERACT, V181, P15, DOI 10.1016/j.cbi.2009.04.013
   Whitlock EP, 2008, 080505124EF1 AG HEAL
   Wu X, 2018, BIOMED RES INT, V7, P5
   Zhang Z, 2019, ARCH MED SCI, V15, P174, DOI 10.5114/aoms.2018.79429
NR 28
TC 1
Z9 1
U1 1
U2 2
PU IMPRIMATUR PUBLICATIONS
PI ATHENS
PA 30 DEM POLIORKETES ST, ATHENS, 136 76, GREECE
SN 1107-0625
EI 2241-6293
J9 J BUON
JI J. BUON
PD JAN-FEB
PY 2020
VL 25
IS 1
BP 188
EP 193
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA KQ7HD
UT WOS:000517089300024
PM 32277631
DA 2022-04-25
ER

PT J
AU Dent, P
   Booth, L
   Roberts, JL
   Poklepovic, A
   Cridebring, D
   Reiman, EM
AF Dent, Paul
   Booth, Laurence
   Roberts, Jane L.
   Poklepovic, Andrew
   Cridebring, Derek
   Reiman, Eric M.
TI Inhibition of heat shock proteins increases autophagosome formation, and
   reduces the expression of APP, Tau, SOD1 G93A and TDP-43
SO AGING-US
LA English
DT Article
DE Alzheimer's; chaperone; GRP78; autophagy; neratinib
ID ENDOPLASMIC-RETICULUM STRESS; OSU-03012; ACTIVATION; CHAPERONES;
   CARCINOMA; TOXICITY; BINDING; KINASE; TARGET; MUTANT
AB Aberrant expression and denaturation of Tau, amyloid-beta and TDP-43 can lead to cell death and is a major component of pathologies such as Alzheimer's Disease (AD). AD neurons exhibit a reduced ability to form autophagosomes and degrade proteins via autophagy. Using genetically manipulated colon cancer cells we determined whether drugs that directly inhibit the chaperone ATPase activity or cause chaperone degradation and endoplasmic reticulum stress signaling leading to macroautophagy could reduce the levels of these proteins. The antiviral chaperone ATPase inhibitor AR12 reduced the ATPase activities and total expression of GRP78, HSP90, and HSP70, and of Tau, Tau 301L, APP, APP692, APP715, SOD1 G93A and TDP-43. In parallel, it increased the phosphorylation of ATG13 S318 and eIF2A S51 and caused eIF2A-dependent autophagosome formation and autophagic flux. Knock down of Beclin1 or ATG5 prevented chaperone, APP and Tau degradation. Neratinib, used to treat HER2+ breast cancer, reduced chaperone levels and expression of Tau and APP via macroautophagy, and neratinib interacted with AR12 to cause further reductions in protein levels. The autophagy-regulatory protein ATG16L1 is expressed as two isoforms, T300 or A300: Africans trend to express T300 and Europeans A300. We observed higher basal expression of Tau in T300 cells when compared to isogenic A300 cells. ATG16L1 isoform expression did not alter basal levels of HSP90, HSP70 or HSP27, however, basal levels of GRP78 were reduced in A300 cells. The abilities of both AR12 and neratinib to stimulate ATG13 S318 and eIF2A S51 phosphorylation and autophagic flux was also reduced in A300 cells. Our data support further evaluation of AR12 and neratinib in neuronal cells as repurposed treatments for AD.
C1 [Dent, Paul; Booth, Laurence] Dept Biochem & Mol Biol, Richmond, VA 23298 USA.
   [Roberts, Jane L.] Dept Pharmacol & Toxicol, Richmond, VA 23298 USA.
   [Poklepovic, Andrew] Virginia Commonwealth Univ, Dept Med, Richmond, VA 23298 USA.
   [Cridebring, Derek; Reiman, Eric M.] Translat Genom Res Inst TGEN, Phoenix, AZ 85004 USA.
   [Reiman, Eric M.] Banner Alzheimers Inst, Phoenix, AZ 85006 USA.
RP Dent, P (corresponding author), Dept Biochem & Mol Biol, Richmond, VA 23298 USA.
EM paul.dent@vcuhealth.org
FU Puma Biotechnology; Commonwealth Health Research Board of Virginia;
   Massey Cancer Center; Universal Chair in Signal Transduction; National
   Institute on AgingUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Aging (NIA) [P30 AG019610]
FX The Dent laboratory received financial support from Puma Biotechnology
   for these studies. The Dent laboratory received financial support from
   the Commonwealth Health Research Board of Virginia. Studies were also in
   part funded by Massey Cancer Center and the Universal Chair in Signal
   Transduction. Dr. Reiman received financial support from National
   Institute on Aging grant P30 AG019610, for which he is the PI.
CR Sastre AA, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176312
   Banerjee M, 2021, PHARMACOL THERAPEUT, V221, DOI 10.1016/j.pharmthera.2020.107747
   Booth L., 2016, J CLIN CELL IMMUNOL, V7, P454
   Booth L, 2019, CANCER BIOL THER, V20, P700, DOI 10.1080/15384047.2018.1551747
   Booth L, 2019, J CELL PHYSIOL, V234, P4874, DOI 10.1002/jcp.27276
   Booth L, 2018, CANCER BIOL THER, V19, P525, DOI 10.1080/15384047.2018.1436024
   Booth Laurence, 2018, Oncotarget, V9, P6062, DOI 10.18632/oncotarget.23681
   Booth L, 2017, ONCOTARGET, V8, P90262, DOI 10.18632/oncotarget.21660
   Booth L, 2016, J CELL PHYSIOL, V231, P2286, DOI 10.1002/jcp.25431
   Booth L, 2016, ONCOTARGET, V7, P12975, DOI 10.18632/oncotarget.7349
   Booth L, 2015, J CELL PHYSIOL, V230, P1982, DOI 10.1002/jcp.24977
   Booth L, 2015, J CELL PHYSIOL, V230, P1661, DOI 10.1002/jcp.24919
   Booth L, 2015, DNA CELL BIOL, V34, P153, DOI 10.1089/dna.2015.2808
   Booth L, 2014, CANCER BIOL THER, V15, P1646, DOI 10.4161/15384047.2014.967992
   Booth L, 2014, MOL CANCER THER, V13, P2384, DOI 10.1158/1535-7163.MCT-14-0172
   Booth L, 2012, CANCER BIOL THER, V13, P224, DOI 10.4161/cbt.13.4.18877
   Cha-Molstad H, 2015, NAT CELL BIOL, V17, P917, DOI 10.1038/ncb3177
   Chambraud B, 2021, AUTOPHAGY, V17, P3491, DOI [10.1080/15548627.2021.1875611, 10.6084/m9.figshare.13603263.v3]
   Chen HH, 2017, ANTIVIR RES, V142, P158, DOI 10.1016/j.antiviral.2017.02.015
   Chen WJ, 2018, EXP CELL RES, V362, P83, DOI 10.1016/j.yexcr.2017.11.005
   Cheng YF, 2021, TRANSL NEURODEGENER, V10, DOI 10.1186/s40035-020-00228-9
   DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789
   DENT P, 1995, MOL CELL BIOL, V15, P4125
   Dent P, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00022
   Dent P, 2020, J CELL PHYSIOL, V235, P7889, DOI 10.1002/jcp.29443
   Dent P, 2019, ONCOGENE, V38, P5890, DOI 10.1038/s41388-019-0849-8
   Elfiky AA, 2020, LIFE SCI, V260, DOI 10.1016/j.lfs.2020.118317
   Giovedi S, 2020, FRONT CELL NEUROSCI, V14, DOI 10.3389/fncel.2020.602116
   Gordon SW, 2019, AM J CLIN ONCOL-CANC, V42, P649, DOI 10.1097/COC.0000000000000567
   Goswami P, 2020, BRAIN RES BULL, V165, P108, DOI 10.1016/j.brainresbull.2020.09.022
   Grimm WA, 2016, GUT, V65, P456, DOI 10.1136/gutjnl-2014-308735
   Gu JL, 2020, CURR MED SCI, V40, P1009, DOI 10.1007/s11596-020-2282-1
   Gunawardana CG, 2015, MOL CELL PROTEOMICS, V14, P3000, DOI 10.1074/mcp.M115.050724
   Hassandarvish P, 2017, J ANTIMICROB CHEMOTH, V72, P2438, DOI 10.1093/jac/dkx191
   Hegde RN, 2020, EMBO J, V39, DOI 10.15252/embj.2020104671
   Hooten KG, 2015, NEUROTHERAPEUTICS, V12, P364, DOI 10.1007/s13311-014-0329-3
   Humeau J, 2020, MOL CELL ONCOL, V7, DOI 10.1080/23723556.2020.1776570
   Ibrahim IM, 2020, J INFECTION, V80, P554, DOI 10.1016/j.jinf.2020.02.026
   Irwin M, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00117
   Jellinger KA, 2021, DEMENT GERIATR COGN, V49, P321, DOI 10.1159/000508625
   Kakimura J, 2001, BIOCHEM BIOPH RES CO, V281, P6, DOI 10.1006/bbrc.2001.4299
   Komar AA, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062054
   Kumar S, 2021, MOL NEURODEGENER, V16, DOI 10.1186/s13024-020-00420-5
   Lahue Robert S, 2020, Neuronal Signal, V4, pNS20200010, DOI 10.1042/NS20200010
   Li L, 2021, EXPERT OPIN THER PAT, V31, P67, DOI 10.1080/13543776.2021.1829595
   Liao Y, 2016, J GEN VIROL, V97, P867, DOI 10.1099/jgv.0.000426
   Lima-Junior JR, 2021, HUM IMMUNOL, V82, P155, DOI 10.1016/j.humimm.2021.01.017
   Lin YG, 2015, ONCOGENE, V34, P5418, DOI 10.1038/onc.2015.4
   Madruga E, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020740
   Mao KM, 2021, FEBS J, DOI 10.1111/febs.15716
   Masnata M, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.580732
   Mclaughlin M, 2020, MOL THER-ONCOLYTICS, V16, P238, DOI 10.1016/j.omto.2020.01.001
   Migneault F, 2021, MATRIX BIOL
   Moreno JA, 2015, NEUROCHEM RES, V40, P329, DOI 10.1007/s11064-014-1405-0
   Pang XC, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9084507
   Portz B, 2021, TRENDS BIOCHEM SCI, V46, P550, DOI 10.1016/j.tibs.2020.12.005
   Rayner JO, 2020, BIOCHEM PHARMACOL, V182, DOI 10.1016/j.bcp.2020.114227
   Shafer D, 2020, NEUROONCOL ADV, V2
   Wang BJ, 2017, P NATL ACAD SCI USA, V114, pE3129, DOI 10.1073/pnas.1618804114
   Wang ZJ, 2019, J ALZHEIMERS DIS, V72, P1217, DOI 10.3233/JAD-190796
   Wani A, 2021, AUTOPHAGY, V17, P3813, DOI 10.1080/15548627.2021.1872187
   Yacoub A, 2006, MOL PHARMACOL, V70, P589, DOI 10.1124/mol.106.025007
   Yuan CL, 2019, BBA-MOL BASIS DIS, V1865, P161, DOI 10.1016/j.bbadis.2018.10.028
   Zhao Z, 2003, MOL CELL NEUROSCI, V24, P367, DOI 10.1016/S1044-7431(03)00175-1
   Zhou B, 2019, INT J BIOL SCI, V15, P1905, DOI 10.7150/ijbs.32550
NR 65
TC 1
Z9 1
U1 1
U2 3
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD JUL 15
PY 2021
VL 13
IS 13
BP 17097
EP 17117
PG 21
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA TP3KG
UT WOS:000677491700013
PM 34252884
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Li, XX
   Huang, LY
   Peng, JJ
   Liang, L
   Shi, DB
   Zheng, HT
   Cai, SJ
AF Li, Xin-Xiang
   Huang, Li-Yong
   Peng, Jun-Jie
   Liang, Lei
   Shi, De-Bing
   Zheng, Hong-Tu
   Cai, San-Jun
TI Klotho suppresses growth and invasion of colon cancer cells through
   inhibition of IGF1R-mediated PI3K/AKT pathway
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE klotho; colon cancer; growth; invasion
ID EXPRESSION INDUCES APOPTOSIS; LUNG-CANCER; TUMOR PROGRESSION;
   PROLIFERATION; RESTORATION; AUTOPHAGY
AB Klotho (KL) was originally characterized as an aging suppressor gene, and has been identified as a tumor suppressor gene in a variety of cancers including colon cancer. However, the potential role and molecular events for KL in colon cancer remain unclear. The present study aimed to investigate the expression of KL in human colon cancer by immunohistochemistry, and to analyze the correlation between KL expression and clinicopathological characteristics of patients with colon cancer. Functional analysis after lentivirus-mediated gain of KL expression was used to assess the tumor growth and invasion in colon cancer cells in vitro and in vivo. The rate of KL expression was significantly decreased in cancer tissues compared with that in adjacent non-cancer tissues (ANCT) (60.3 vs.77.9%, P=0.022), and KL expression was negatively associated with Dukes staging (P=0.034) and depth of tumor invasion (P=0.008). Overexpression of KL in vitro inhibited cell proliferative activities and invasive potential in colon cancer cells, companied with decreased expression of p-IGF1R, p-PI3K, p-AKT, PCNA and MMP-2. In addition, the tumor volumes in the HT-29 subcutaneous tumor model treated with lentivirus-mediated KL vector (Lv-KL) was significantly smaller than those of the negative control (NC) group (P<0.01). Taken together, our findings indicate that the expression of KL is downregulated in human colon caner and correlates with tumor invasion and Dukes staging, while overexpression of KL suppresses growth and invasion through inhibition of IGF1R-mediated PI3K/AKT pathway in colon cancer cells, suggesting that KL may serve as a potential therapeutic target for the treatment of colon cancer.
C1 [Li, Xin-Xiang] Fudan Univ, Shanghai Canc Ctr, Dept Colorectal Surg, Shanghai 200032, Peoples R China.
   [Li, Xin-Xiang] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.
RP Li, XX (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Colorectal Surg, 270 Dongan Rd, Shanghai 200032, Peoples R China.
EM lixinxiang2014@163.com
CR Abramovitz L, 2011, CLIN CANCER RES, V17, P4254, DOI 10.1158/1078-0432.CCR-10-2749
   Antonic V, 2013, J CANCER, V4, P227, DOI 10.7150/jca.5835
   Camilli TC, 2011, PIGM CELL MELANOMA R, V24, P175, DOI 10.1111/j.1755-148X.2010.00792.x
   Chang B, 2012, ONCOL REP, V28, P1022, DOI 10.3892/or.2012.1865
   Chen B, 2012, CANCER BIOL THER, V13, P1221, DOI 10.4161/cbt.21420
   Chen B, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-99
   Chen L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053949
   Dermaku-Sopjani M, 2013, MOL MEMBR BIOL, V30, P369, DOI 10.3109/09687688.2013.837518
   Doi S, 2011, J BIOL CHEM, V286, P8655, DOI 10.1074/jbc.M110.174037
   Fu YC, 2009, CANCER BIOL THER, V8, P1002, DOI 10.4161/cbt.8.11.8285
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Kuro-O M, 2008, BIOL CHEM, V389, P233, DOI 10.1515/BC.2008.028
   Kuro-O M, 2012, CURR OPIN NEPHROL HY, V21, P362, DOI 10.1097/MNH.0b013e32835422ad
   Liabakk NB, 1996, CANCER RES, V56, P190
   Lim DY, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-9
   Lu L, 2008, CANCER INVEST, V26, P185, DOI 10.1080/07357900701638343
   Pan J, 2011, TUMOR BIOL, V32, P729, DOI 10.1007/s13277-011-0174-5
   Poh WJ, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-14
   RISIO M, 1992, J CELL BIOCHEM, P79
   Rubinek T, 2012, BREAST CANCER RES TR, V133, P649, DOI 10.1007/s10549-011-1824-4
   Shu GS, 2013, CELL ONCOL, V36, P121, DOI 10.1007/s13402-012-0118-0
   Usuda J, 2011, LUNG CANCER, V74, P332, DOI 10.1016/j.lungcan.2011.03.004
   Usuda J, 2011, LUNG CANCER, V72, P355, DOI 10.1016/j.lungcan.2010.10.008
   Wang LJ, 2011, AM J CANCER RES, V1, P111
   Wang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057391
   Xie B, 2013, PATHOL ONCOL RES, V19, P611, DOI 10.1007/s12253-013-9663-8
   Xie BA, 2013, HUM PATHOL, V44, P795, DOI 10.1016/j.humpath.2012.07.023
   Xie B, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-18
   Yahata K, 2000, J MOL MED, V78, P389, DOI 10.1007/s001090000131
   Ye XM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055615
   Young PE, 2013, J CANCER, V4, P217, DOI 10.7150/jca.5829
   Zhu Y, 2013, CANCER SCI, V104, P663, DOI 10.1111/cas.12134
NR 32
TC 38
Z9 40
U1 1
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD AUG
PY 2014
VL 45
IS 2
BP 611
EP 618
DI 10.3892/ijo.2014.2430
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AK5RR
UT WOS:000338484600017
PM 24818842
OA Bronze
DA 2022-04-25
ER

PT J
AU Tsai, CH
   Hung, AC
   Chen, YY
   Chiu, YW
   Hsieh, PW
   Lee, YC
   Su, YH
   Chang, PC
   Hu, SCS
   Yuan, SSF
AF Tsai, Chun-Hao
   Hung, Amos C.
   Chen, Yuan-Yin
   Chiu, Ya-Wen
   Hsieh, Pei-Wen
   Lee, Yi-Chen
   Su, Yu-Han
   Chang, Po-Chih
   Hu, Stephen Chu-Sung
   Yuan, Shyng-Shiou F.
TI 3 '-hydroxy-4 '-methoxy-beta-methyl-beta-nitrostyrene inhibits
   tumorigenesis in colorectal cancer cells through ROS-mediated DNA damage
   and mitochondrial dysfunction
SO ONCOTARGET
LA English
DT Article
DE beta-nitrostyrene; cell cycle; ROS; colorectal cancer; DNA damage
ID BETA-NITROSTYRENE DERIVATIVES; COLON-CANCER; OXIDATIVE STRESS;
   APOPTOSIS; ACTIVATION; AUTOPHAGY; MECHANISMS; GENERATION; INDUCTION;
   GROWTH
AB The beta-nitrostyrene family has been shown to suppress cell proliferation and induce apoptosis in types of various cancers. However, the mechanisms underlying the anticancer effects of beta-nitrostyrenes in colorectal cancer remain poorly understood. In this study, we synthesized a beta-nitrostyrene derivative, CYT-Rx20 (3'-hydroxy-4'-methoxy- beta-methyl-beta-nitrostyrene), and investigated its anticancer activities in human colorectal cancer cells both in vitro and in vivo. Our findings showed that treatment with CYT-Rx20 reduced cell viability and induced DNA damage in colorectal cancer cells. In addition, CYT-Rx20 induced cell cycle arrest of colorectal cancer cells at the G2/M phase and upregulated the protein expression of phospho-ERK, cyclin B1, phospho-cdc2 (Tyr15), aurora A, and aurora B, while it downregulated the expression of cdc25A and cdc25C. Furthermore, we found that CYT-Rx20 caused accumulation of intracellular reactive oxygen species (ROS) and reduction of mitochondrial membrane potential. The effects of CYT-Rx20 on cell viability, DNA damage, and mitochondrial membrane potential were reversed by pretreatment with the thiol antioxidant N-acetyl-L-cysteine (NAC), suggesting that ROS-mediated DNA damage and mitochondrial dysregulation play a critical role in these events. Finally, the nude mice xenograft study showed that CYT-Rx20 significantly reduced tumor growth of implanted colorectal cancer cells accompanied by elevated protein expression of aurora A, aurora B, gamma H2AX, phosphor-ERK, and MDA in the tumor tissues. Taken together, these results suggest that CYT-Rx20 may potentially be developed as a novel beta-nitrostyrene-based anticancer agent for colorectal cancer.
C1 [Tsai, Chun-Hao; Hung, Amos C.; Chen, Yuan-Yin; Chiu, Ya-Wen; Lee, Yi-Chen; Su, Yu-Han; Yuan, Shyng-Shiou F.] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Translat Res Ctr, Kaohsiung, Taiwan.
   [Tsai, Chun-Hao; Yuan, Shyng-Shiou F.] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung, Taiwan.
   [Hsieh, Pei-Wen] Chang Gung Univ, Coll Med, Sch Tradit Chinese Med, Grad Inst Nat Prod, Taoyuan, Taiwan.
   [Hsieh, Pei-Wen] Chang Gung Univ, Coll Med, Grad Inst Biomed Sci, Taoyuan, Taiwan.
   [Lee, Yi-Chen] Kaohsiung Med Univ, Coll Med, Sch Med, Dept Anat, Kaohsiung, Taiwan.
   [Chang, Po-Chih] I Shou Univ, E Da Hospital, Dept Surg, Divis Gen Surg, Kaohsiung, Taiwan.
   [Hu, Stephen Chu-Sung] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Dermatol, Kaohsiung, Taiwan.
   [Hu, Stephen Chu-Sung] Kaohsiung Med Univ, Coll Med, Dept Dermatol, Kaohsiung, Taiwan.
   [Yuan, Shyng-Shiou F.] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Obstet & Gynecol, Kaohsiung, Taiwan.
RP Yuan, SSF (corresponding author), Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Translat Res Ctr, Kaohsiung, Taiwan.; Yuan, SSF (corresponding author), Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung, Taiwan.; Yuan, SSF (corresponding author), Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Obstet & Gynecol, Kaohsiung, Taiwan.
EM yuanssf@ms33.hinet.net
OI Hung, Amos/0000-0001-7572-8897; Hu, Stephen
   Chu-Sung/0000-0002-1832-4471; yuan, shyng-shiou/0000-0002-4753-788X
FU Kaohsiung Medical University Hospital [KMUH103-3R28, KMUH102-2T07,
   KMUH102-2R25]; Kaohsiung Medical University [KMU-DT103010,
   KMU-TP103D18]; National Health Research InstitutesNational Health
   Research Institutes, Japan [NHRI-EX104-10212BI]; E-Da Hospital/I-Shou
   University [EDAHP102024]; Ministry of Health and Welfare of Taiwan
   [MOHW104-TDU-B-212-124-003]
FX The work was supported by grants from Kaohsiung Medical University
   Hospital (KMUH103-3R28, KMUH102-2T07, KMUH102-2R25), Kaohsiung Medical
   University (Aim for the Top Journals Grant, KMU-DT103010, KMU-TP103D18),
   National Health Research Institutes (NHRI-EX104-10212BI), E-Da
   Hospital/I-Shou University (EDAHP102024), and Ministry of Health and
   Welfare (MOHW104-TDU-B-212-124-003, Health and welfare surcharge of
   tobacco products) of Taiwan.
CR Calgarotto AK, 2012, EUR J PHARMACOL, V678, P6, DOI 10.1016/j.ejphar.2011.12.031
   Chae IG, 2014, FREE RADICAL RES, V48, P1311, DOI 10.3109/10715762.2014.951838
   Chambard JC, 2007, BBA-MOL CELL RES, V1773, P1299, DOI 10.1016/j.bbamcr.2006.11.010
   Chen HM, 2011, FREE RADICAL BIO MED, V50, P1151, DOI 10.1016/j.freeradbiomed.2011.01.015
   Chen IH, 2015, BIOCHIMIE, V110, P81, DOI 10.1016/j.biochi.2015.01.006
   Chen YJ, 2013, LIFE SCI, V92, P1081, DOI 10.1016/j.lfs.2013.04.007
   Chen YJ, 2012, CANCER LETT, V319, P223, DOI 10.1016/j.canlet.2012.01.017
   Chong SJF, 2014, MITOCHONDRION, V19, P39, DOI 10.1016/j.mito.2014.06.002
   Dickinson BC, 2011, NAT CHEM BIOL, V7, P504, DOI [10.1038/NCHEMBIO.607, 10.1038/nchembio.607]
   Dong LW, 2015, INT J MOL SCI, V16, P14655, DOI 10.3390/ijms160714655
   Ferruzza S, 2012, TOXICOL IN VITRO, V26, P1252, DOI 10.1016/j.tiv.2012.01.008
   Grek CL, 2010, CURR OPIN PHARMACOL, V10, P362, DOI 10.1016/j.coph.2010.05.003
   Haller DG, 2015, ANN ONCOL, V26, P715, DOI 10.1093/annonc/mdv003
   He Y, 2014, J BIOL CHEM, V289, P1142, DOI 10.1074/jbc.M113.515080
   Holmstrom KM, 2014, NAT REV MOL CELL BIO, V15, P411, DOI 10.1038/nrm3801
   Hsieh PW, 2010, BIOORGAN MED CHEM, V18, P7621, DOI 10.1016/j.bmc.2010.08.039
   Hung AC, 2016, CANCER LETT, V371, P251, DOI 10.1016/j.canlet.2015.11.035
   Kaidar-Person O, 2015, ANTI-CANCER DRUG, V26, P363, DOI 10.1097/CAD.0000000000000201
   Karna P, 2011, CELL DEATH DIFFER, V18, P632, DOI 10.1038/cdd.2010.133
   Kim AD, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.273
   Kim B, 2015, EXPERT OPIN THER TAR, V19, P113, DOI 10.1517/14728222.2014.961425
   Kim JA, 2008, CIRC RES, V102, P401, DOI 10.1161/CIRCRESAHA.107.165472
   MacCorkle RA, 2005, CELL BIOCHEM BIOPHYS, V43, P451, DOI 10.1385/CBB:43:3:451
   Marin JJG, 2012, DRUG METAB REV, V44, P148, DOI 10.3109/03602532.2011.638303
   McNamara YM, 2011, BIOORGAN MED CHEM, V19, P1328, DOI 10.1016/j.bmc.2010.11.054
   Natarajan N, 2006, SURG CLIN N AM, V86, P1023, DOI 10.1016/j.suc.2006.06.002
   Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5
   Ott M, 2007, APOPTOSIS, V12, P913, DOI 10.1007/s10495-007-0756-2
   Park J, 2004, BIOCHEMISTRY-US, V43, P15014, DOI 10.1021/bi0486233
   Rahmani-Nezhad S, 2014, EUR J MED CHEM, V86, P562, DOI 10.1016/j.ejmech.2014.09.017
   Roy RV, 2013, J NAT PROD, V76, P1909, DOI 10.1021/np400441f
   Rushworth GF, 2014, PHARMACOL THERAPEUT, V141, P150, DOI 10.1016/j.pharmthera.2013.09.006
   Shalini S, 2015, CELL DEATH DIFFER, V22, P526, DOI 10.1038/cdd.2014.216
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Sosa V, 2013, AGEING RES REV, V12, P376, DOI 10.1016/j.arr.2012.10.004
   Stoian M, 2014, J Med Life, V7, P160
   Stoyianni A, 2012, ANTICANCER RES, V32, P1273
   Van Cutsem E, 1999, HEPATO-GASTROENTEROL, V46, P709
   Verschoor ML, 2010, CAN J PHYSIOL PHARM, V88, P204, DOI 10.1139/Y09-135
   Wang WY, 2007, BIOCHEM PHARMACOL, V74, P601, DOI 10.1016/j.bcp.2007.06.001
   Weiderhold KN, 2006, INT J CANCER, V118, P1032, DOI 10.1002/ijc.21424
   Wong S, 2014, LIFE SCI, V107, P32, DOI 10.1016/j.lfs.2014.04.031
   Zorov DB, 2014, PHYSIOL REV, V94, P909, DOI 10.1152/physrev.00026.2013
NR 43
TC 9
Z9 9
U1 1
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAR 14
PY 2017
VL 8
IS 11
BP 18106
EP 18117
DI 10.18632/oncotarget.14996
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EO7NN
UT WOS:000396877500057
PM 28178649
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Guaman-Ortiz, LM
   Bailon-Moscoso, N
   Morocho, V
   Vega-Ojeda, D
   Gordillo, F
   Suarez, AI
AF Guaman-Ortiz, Luis Miguel
   Bailon-Moscoso, Natalia
   Morocho, Vladimir
   Vega-Ojeda, Daisy
   Gordillo, Fernando
   Suarez, Alirica I.
TI Onoseriolide, from Hedyosmum racemosum, induces cytotoxicity and
   apoptosis in human colon cancer cells
SO NATURAL PRODUCT RESEARCH
LA English
DT Article
DE Hedyosmum racemosum; onoseriolide; colon cancer; cytotoxicity;
   apoptosis; autophagy
ID CHEMICAL-CONSTITUENTS; SESQUITERPENES; AUTOPHAGY; PLANTS
AB The number of colon cancer patients is increasing, and new alternatives for treatment are important. We focused on the sesquiterpene lactone onoseriolide from Hedyosmum racemosum, which is widely used in traditional medicine. This compound was evaluated to determine its cytotoxic effect and the mechanism of cell death that is induced in the human colon cancer cell line RKO. A dose-dependent decrease in cell viability was observed. p53 expression increased followed by an increase in p21 expression, which is involved in cell cycle arrest in the G(2)/M phase. Caspase-3 activation and PARP-1 cleavage, which are apoptotic markers, were also monitored. Autophagy markers were also studied, and Beclin 1 was downregulated, while LC-3II increased in a dose-dependent manner. There were no changes in SQSTM1/p62 regulation. Onoseriolide exerts cytotoxic and cytostatic effects, activating the autophagy pathway as a protective mechanism and apoptosis as the cell death pathway.
C1 [Guaman-Ortiz, Luis Miguel; Bailon-Moscoso, Natalia; Vega-Ojeda, Daisy] Univ Tecn Particular Loja, Dept Ciencias Salud, Loja, Ecuador.
   [Morocho, Vladimir; Gordillo, Fernando; Suarez, Alirica I.] Univ Tecn Particular Loja, Dept Quim & Ciencias Exactas, Loja, Ecuador.
   [Suarez, Alirica I.] Cent Univ Venezuela, Fac Farm, Caracas, Venezuela.
RP Guaman-Ortiz, LM (corresponding author), Univ Tecn Particular Loja, Dept Ciencias Salud, Loja, Ecuador.
EM lmguaman@utpl.edu.ec
RI Bailon-Moscoso, Natalia/Z-1548-2019; Morocho, Vladimir/Z-2544-2019
OI Morocho, Vladimir/0000-0001-5156-0700
FU Universidad Tecnica Particular de Loja (UTPL), Loja, Ecuador
   [PROY_QUI_1144]
FX This work was supported by Universidad Tecnica Particular de Loja
   (UTPL), Loja, Ecuador. PROY_QUI_1144.
CR Acebey L, 2010, PLANTA MED, V76, P365, DOI 10.1055/s-0029-1186192
   Babaei G, 2018, BIOMED PHARMACOTHER, V106, P239, DOI 10.1016/j.biopha.2018.06.131
   Cao CM, 2008, CHEM BIODIVERS, V5, P219, DOI 10.1002/cbdv.200890020
   Chino H, 2019, MOL CELL, V74, P909, DOI 10.1016/j.molcel.2019.03.033
   Chiu WJ, 2018, J CLIN MED, V7, DOI 10.3390/jcm7100321
   Diaz-Villasenor A, 2008, TOXICOL APPL PHARM, V231, P291, DOI 10.1016/j.taap.2008.05.018
   Fernandez AF, 2018, NATURE, V558, P136, DOI 10.1038/s41586-018-0162-7
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4
   Geng YD, 2020, NAT PROD RES, V34, P2616, DOI 10.1080/14786419.2018.1544976
   Gordy C, 2012, PROTEIN CELL, V3, P17, DOI 10.1007/s13238-011-1127-x
   Hu M, 2018, GENE, V678, P261, DOI 10.1016/j.gene.2018.08.048
   KAWABATA J, 1981, AGR BIOL CHEM TOKYO, V45, P1447, DOI 10.1080/00021369.1981.10864706
   Li JN, 2001, CANCER RES, V61, P1493
   Liu R, 2019, MOLECULES, V24, DOI 10.3390/molecules24101908
   Radice M, 2019, J ETHNOPHARMACOL, V244, DOI 10.1016/j.jep.2019.111932
   Shoaib M, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-016-1517-y
   Su KM, 2014, BOT STUD, V55, DOI 10.1186/1999-3110-55-21
   Teng A, 2019, CANCER-AM CANCER SOC, V125, P3749, DOI 10.1002/cncr.32325
   Todzia Carol A., 1993, Novon, V3, P81, DOI 10.2307/3391430
   Wang YS, 2017, CASE REP INFECT DIS, V2017, P1, DOI 10.1155/2017/7052908
NR 20
TC 2
Z9 2
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1478-6419
EI 1478-6427
J9 NAT PROD RES
JI Nat. Prod. Res.
PD SEP 17
PY 2021
VL 35
IS 18
BP 3151
EP 3155
DI 10.1080/14786419.2019.1690485
EA NOV 2019
PG 5
WC Chemistry, Applied; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA UP6GB
UT WOS:000497019400001
PM 31736362
DA 2022-04-25
ER

PT J
AU Guo, WJ
   Sun, Y
   Liu, W
   Wu, XX
   Guo, LL
   Cai, PF
   Wu, XF
   Wu, XD
   Shen, Y
   Shu, YQ
   Gu, YH
   Xu, Q
AF Guo, Wenjie
   Sun, Yang
   Liu, Wen
   Wu, Xingxin
   Guo, Lele
   Cai, Peifen
   Wu, Xuefeng
   Wu, Xudong
   Shen, Yan
   Shu, Yongqian
   Gu, Yanhong
   Xu, Qiang
TI Small molecule-driven mitophagy-mediated NLRP3 inflammasome inhibition
   is responsible for the prevention of colitis-associated cancer
SO AUTOPHAGY
LA English
DT Article
DE mitophagy; inflammasome; inflammation-associated cancer; colitis;
   andrographolide
ID DEXTRAN SULFATE SODIUM; AUTOPHAGIC CELL-DEATH; BOWEL-DISEASE;
   ULCERATIVE-COLITIS; COLORECTAL-CANCER; MITOCHONDRIAL-DNA; MURINE
   COLITIS; T-CELLS; INTERLEUKIN-1; ANDROGRAPHOLIDE
AB Nonresolving inflammation in the intestine predisposes individuals to the development of colitis-associated cancer (CAC). Inflammasomes are thought to mediate intestinal homeostasis, and their dysregulation contributes to inflammatory bowel diseases and CAC. However, few agents have been reported to reduce CAC by targeting inflammasomes. Here we show that the small molecule andrographolide (Andro) protects mice against azoxymethane/dextran sulfate sodium-induced colon carcinogenesis through inhibiting the NLRP3 inflammasome. Administration of Andro significantly attenuated colitis progression and tumor burden. Andro also inhibited NLRP3 inflammasome activation in macrophages both in vivo and in vitro, as indicated by reduced expression of cleaved CASP1, disruption of NLRP3-PYCARD-CASP1 complex assembly, and lower IL1B secretion. Importantly, Andro was found to trigger mitophagy in macrophages, leading to a reversed mitochondrial membrane potential collapse, which in turn inactivated the NLRP3 inflammasome. Moreover, downregulation of the PIK3CA-AKT1-MTOR-RPS6KB1 pathway accounted for Andro-induced autophagy. Finally, Andro-driven inhibition of the NLRP3 inflammasome and amelioration of murine models for colitis and CAC were significantly blocked by BECN1 knockdown, or by various autophagy inhibitors. Taken together, our findings demonstrate that mitophagy-mediated NLRP3 inflammasome inhibition by Andro is responsible for the prevention of CAC. Our data may help guide decisions regarding the use of Andro in patients with inflammatory bowel diseases, which ultimately reduces the risk of CAC.
C1 [Guo, Wenjie; Sun, Yang; Liu, Wen; Wu, Xingxin; Guo, Lele; Wu, Xuefeng; Wu, Xudong; Shen, Yan; Xu, Qiang] Nanjing Univ, State Key Lab Pharmaceut Biotechnol, Sch Life Sci, Nanjing 210008, Jiangsu, Peoples R China.
   [Guo, Wenjie] Jiangsu Univ, Sch Pharm, Zhenjiang, Peoples R China.
   [Cai, Peifen; Shu, Yongqian; Gu, Yanhong] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing, Peoples R China.
RP Sun, Y (corresponding author), Nanjing Univ, State Key Lab Pharmaceut Biotechnol, Sch Life Sci, Nanjing 210008, Jiangsu, Peoples R China.
EM yangsun@nju.edu.cn; guyhphd@163.com; molpharm@163.com
RI Wu, xingxin/A-3595-2009; Guo, Wenjie/AAQ-7553-2020; Shu,
   Yongqian/ABD-5698-2021
FU Science Fund for Creative Research Groups of NSFCScience Fund for
   Creative Research Groups [81121062]; National Natural Science Foundation
   of ChinaNational Natural Science Foundation of China (NSFC) [91229109,
   81330079, 90913023, 91129728]; National Science and Technology Major
   Project [2012ZX09304-001]; Jiangsu Province Clinical Science and
   Technology Project (Clinical Research Center) [BL2012008]
FX This work was supported by Science Fund for Creative Research Groups of
   NSFC (No. 81121062), National Natural Science Foundation of China (Nos.
   91229109, 81330079, 90913023, 91129728), National Science and Technology
   Major Project (No. 2012ZX09304-001), and Jiangsu Province Clinical
   Science and Technology Project (Clinical Research Center, BL2012008).
CR Abu-Ghefreh AA, 2009, INT IMMUNOPHARMACOL, V9, P313, DOI 10.1016/j.intimp.2008.12.002
   Allen IC, 2010, J EXP MED, V207, P1045, DOI 10.1084/jem.20100050
   Arai Y, 1998, CYTOKINE, V10, P890, DOI 10.1006/cyto.1998.0355
   Bauer C, 2007, DIGEST DIS SCI, V52, P1642, DOI 10.1007/s10620-007-9802-8
   Bauer C, 2012, DIGEST DIS, V30, P82, DOI 10.1159/000341681
   Bauer C, 2010, GUT, V59, P1192, DOI 10.1136/gut.2009.197822
   Ben-Sasson SZ, 2009, P NATL ACAD SCI USA, V106, P7119, DOI 10.1073/pnas.0902745106
   Bernstein CN, 2001, CANCER-AM CANCER SOC, V91, P854, DOI 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z
   Chan SJ, 2010, BRIT J PHARMACOL, V161, P668, DOI 10.1111/j.1476-5381.2010.00906.x
   Chen W, 2012, CARCINOGENESIS, V33, P2190, DOI 10.1093/carcin/bgs264
   Coccia M, 2012, J EXP MED, V209, P1595, DOI 10.1084/jem.20111453
   Coll RC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029539
   Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127
   Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095
   Ding WX, 2012, BIOL CHEM, V393, P547, DOI 10.1515/hsz-2012-0119
   Fantini MC, 2008, CURR DRUG TARGETS, V9, P375, DOI 10.2174/138945008784221206
   Farrell RJ, 2002, LANCET, V359, P331, DOI 10.1016/S0140-6736(02)07499-8
   Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235
   GIONCHETTI P, 1991, GUT, V32, P338, DOI 10.1136/gut.32.3.338-a
   Grivennikov SI, 2013, SEMIN IMMUNOPATHOL, V35, P229, DOI 10.1007/s00281-012-0352-6
   Gross O, 2011, IMMUNOL REV, V243, P136, DOI 10.1111/j.1600-065X.2011.01046.x
   Guo WJ, 2013, AUTOPHAGY, V9, P996, DOI 10.4161/auto.24407
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hsieh CY, 2011, J BIOL CHEM, V286, P5942, DOI 10.1074/jbc.M110.123968
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Jobin C, 2000, INFLAMM BOWEL DIS, V6, P206, DOI 10.1097/00054725-200008000-00007
   Kepp O, 2011, NAT IMMUNOL, V12, P199, DOI 10.1038/ni0311-199
   Lee KC, 2011, J ETHNOPHARMACOL, V135, P678, DOI 10.1016/j.jep.2011.03.068
   LIGUMSKY M, 1990, GUT, V31, P686, DOI 10.1136/gut.31.6.686
   Loher F, 2004, J PHARMACOL EXP THER, V308, P583, DOI 10.1124/jpet.103.057059
   Lupfer C, 2013, NAT IMMUNOL, V14, P480, DOI 10.1038/ni.2563
   Malik M, 2012, P NATL ACAD SCI USA, V109, P6130, DOI 10.1073/pnas.1201351109
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3
   Martinon F, 2012, IMMUNITY, V36, P313, DOI 10.1016/j.immuni.2012.03.005
   McAlindon ME, 1998, GUT, V42, P214, DOI 10.1136/gut.42.2.214
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029
   Nunes T, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/654963
   Pancione Massimo, 2012, Patholog Res Int, V2012, P509348, DOI 10.1155/2012/509348
   Rajagopal Sriram, 2003, J Exp Ther Oncol, V3, P147, DOI 10.1046/j.1359-4117.2003.01090.x
   REINECKER HC, 1993, CLIN EXP IMMUNOL, V94, P174
   Ricciotti E, 2011, ARTERIOSCL THROM VAS, V31, P986, DOI 10.1161/ATVBAHA.110.207449
   Rogler G, 2012, DIGEST DIS, V30, P48, DOI 10.1159/000341893
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
   Shimada K, 2012, IMMUNITY, V36, P401, DOI 10.1016/j.immuni.2012.01.009
   Siegmund B, 2001, P NATL ACAD SCI USA, V98, P13249, DOI 10.1073/pnas.231473998
   Siegmund B, 2001, AM J PHYSIOL-REG I, V281, pR1264, DOI 10.1152/ajpregu.2001.281.4.R1264
   Sivakumar PV, 2002, GUT, V50, P812, DOI 10.1136/gut.50.6.812
   Sutton C, 2006, J EXP MED, V203, P1685, DOI 10.1084/jem.20060285
   Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058
   THOMAS TK, 1991, AGENTS ACTIONS, V34, P187, DOI 10.1007/BF01993274
   Triantafillidis JK, 2009, ANTICANCER RES, V29, P2727
   Weir HK, 2003, JNCI-J NATL CANCER I, V95, P1276, DOI 10.1093/jnci/djg040
   Wiart C, 2005, PHYTOTHER RES, V19, P1069, DOI 10.1002/ptr.1765
   Wirtz S, 2007, NAT PROTOC, V2, P541, DOI 10.1038/nprot.2007.41
   Zaki MH, 2010, IMMUNITY, V32, P379, DOI 10.1016/j.immuni.2010.03.003
   Zhou J, 2012, AUTOPHAGY, V8, P338, DOI 10.4161/auto.18721
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
NR 58
TC 162
Z9 169
U1 6
U2 76
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD JUN
PY 2014
VL 10
IS 6
BP 972
EP 985
DI 10.4161/auto.28374
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AI6GT
UT WOS:000336970800003
PM 24879148
OA Bronze, Green Published
DA 2022-04-25
ER

PT J
AU Hirayama, A
   Kami, K
   Sugimoto, M
   Sugawara, M
   Toki, N
   Onozuka, H
   Kinoshita, T
   Saito, N
   Ochiai, A
   Tomita, M
   Esumi, H
   Soga, T
AF Hirayama, Akiyoshi
   Kami, Kenjiro
   Sugimoto, Masahiro
   Sugawara, Maki
   Toki, Naoko
   Onozuka, Hiroko
   Kinoshita, Taira
   Saito, Norio
   Ochiai, Atsushi
   Tomita, Masaru
   Esumi, Hiroyasu
   Soga, Tomoyoshi
TI Quantitative Metabolome Profiling of Colon and Stomach Cancer
   Microenvironment by Capillary Electrophoresis Time-of-Flight Mass
   Spectrometry
SO CANCER RESEARCH
LA English
DT Article
ID ADENYLATE ENERGY-CHARGE; COLORECTAL-CANCER; AUTOPHAGY; HYPOXIA; CELLS;
   ACID; PATHWAYS; GROWTH; MITOCHONDRIA; NUCLEOTIDES
AB Most cancer cells predominantly produce energy by glycolysis rather than oxidative phosphorylation via the tricarboxylic acid (TCA) cycle, even in the presence of an adequate oxygen supply (Warburg effect). However, little has been reported regarding the direct measurements of global metabolites in clinical tumor tissues. Here, we applied capillary electrophoresis time-of-flight mass spectrometry, which enables comprehensive and quantitative analysis of charged metabolites, to simultaneously measure their levels in tumor and grossly normal tissues obtained from 16 colon and 12 stomach cancer patients. Quantification of 94 metabolites in colon and 95 metabolites in stomach involved in glycolysis, the pentose phosphate pathway, the TCA and urea cycles, and amino acid and nucleotide metabolisms resulted in the identification of several cancer-specific metabolic traits. Extremely low glucose and high lactate and glycolytic intermediate concentrations were found in both colon and stomach tumor tissues, which indicated enhanced glycolysis and thus confirmed the Warburg effect. Significant accumulation of all amino acids except glutamine in the tumors implied autophagic degradation of proteins and active glutamine breakdown for energy production, i.e., glutaminolysis. In addition, significant organ-specific differences were found in the levels of TCA cycle intermediates, which reflected the dependency of each tissue on aerobic respiration according to oxygen availability. The results uncovered unexpectedly poor nutritional conditions in the actual tumor microenvironment and showed that capillary electrophoresis coupled to mass spectrometry-based metabolomics, which is capable of quantifying the levels of energy metabolites in tissues, could be a powerful tool for the development of novel anticancer agents that target cancer-specific metabolism. [Cancer Res 2009;69(11):4918-25]
C1 [Hirayama, Akiyoshi; Kami, Kenjiro; Sugimoto, Masahiro; Sugawara, Maki; Toki, Naoko; Tomita, Masaru; Soga, Tomoyoshi] Keio Univ, Inst Adv Biosci, Yamagata 9970052, Japan.
   [Onozuka, Hiroko; Kinoshita, Taira; Saito, Norio; Ochiai, Atsushi; Esumi, Hiroyasu] Natl Canc Ctr Hosp E, Chiba, Japan.
RP Soga, T (corresponding author), Keio Univ, Inst Adv Biosci, Yamagata 9970052, Japan.
EM soga@sfc.keio.ac.jp
RI Sugimoto, Masahiro/B-7391-2014; Soga, Tomoyoshi/B-8105-2014
OI Soga, Tomoyoshi/0000-0001-9502-2509; Sugimoto,
   Masahiro/0000-0003-3316-2543
FU Ministry of Health, Labour and WelfareMinistry of Health, Labour and
   Welfare, Japan; Global COE ProgramMinistry of Education, Culture,
   Sports, Science and Technology, Japan (MEXT); Ministry of Education,
   Culture, Sports, Science and Technology of JapanMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT); City of Tsuruoka
FX Grant support: Third Term Comprehensive 10-year Strategy for Cancer
   Control from the Ministry of Health, Labour and Welfare and a grant from
   the Global COE Program entitled, "Human Metabolomic Systems Biology."
   This work was also supported by KAKENHI (Grant-in-Aid for Scientific
   Research) on Priority Areas "Systems Genomes" and on "Lifesurveyor" from
   the Ministry of Education, Culture, Sports, Science and Technology of
   Japan as well as research foods from the Yamagata prefectural government
   and the City of Tsuruoka.
CR ARGILES JM, 1988, MOL CELL BIOCHEM, V81, P3
   Baran R, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-530
   Brahimi-Horn MC, 2007, CURR OPIN CELL BIOL, V19, P223, DOI 10.1016/j.ceb.2007.02.003
   Buckstein MH, 2008, J BACTERIOL, V190, P718, DOI 10.1128/JB.01020-07
   Chan ECY, 2009, J PROTEOME RES, V8, P352, DOI 10.1021/pr8006232
   CHAPMAN AG, 1971, J BACTERIOL, V108, P1072, DOI 10.1128/JB.108.3.1072-1086.1971
   CHAPMAN AG, 1973, J BIOL CHEM, V248, P8309
   Chen Y, 2007, PACIFIC SYMPOSIUM ON BIOCOMPUTING 2007, P181
   Chen Z, 2007, J BIOENERG BIOMEMBR, V39, P267, DOI 10.1007/s10863-007-9086-x
   Denkert C, 2006, CANCER RES, V66, P10795, DOI 10.1158/0008-5472.CAN-06-0755
   Denkert C, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-72
   Droge W, 2004, MECH AGEING DEV, V125, P161, DOI 10.1016/j.mad.2003.12.003
   Fujii S, 2008, CANCER SCI, V99, P1813, DOI 10.1111/j.1349-7006.2008.00893.x
   Gatenby RA, 2007, BRIT J CANCER, V97, P646, DOI 10.1038/sj.bjc.6603922
   HISANAGA K, 1986, J NEUROCHEM, V47, P1344, DOI 10.1111/j.1471-4159.1986.tb00763.x
   Kita K, 2002, BBA-BIOENERGETICS, V1553, P123, DOI 10.1016/S0005-2728(01)00237-7
   Kondoh H, 2008, EXP CELL RES, V314, P1923, DOI 10.1016/j.yexcr.2008.03.007
   Koukourakis MI, 2006, CANCER SCI, V97, P1056, DOI 10.1111/j.1349-7006.2006.00298.x
   Koukourakis MI, 2006, CANCER SCI, V97, P582, DOI 10.1111/j.1349-7006.2006.00220.x
   Lu J, 2004, CANCER SCI, V95, P547, DOI 10.1111/j.1349-7006.2004.tb03247.x
   Mazzanti R, 2006, AM J PHYSIOL-GASTR L, V290, pG1329, DOI 10.1152/ajpgi.00563.2005
   MEDINA MA, 1992, MOL CELL BIOCHEM, V113, P1
   Mizushima N, 2007, ANNU REV NUTR, V27, P19, DOI 10.1146/annurev.nutr.27.061406.093749
   MOREADITH RW, 1984, J BIOL CHEM, V259, P6215
   Opstad KS, 2008, NMR BIOMED, V21, P1138, DOI 10.1002/nbm.1296
   Pan James G, 2007, Sci STKE, V2007, ppe14
   Pedersen PL, 2002, BBA-BIOENERGETICS, V1555, P14, DOI 10.1016/S0005-2728(02)00248-7
   Phang JM, 2008, AMINO ACIDS, V35, P681, DOI 10.1007/s00726-008-0063-4
   Plumb R, 2003, ANALYST, V128, P819, DOI 10.1039/b304296k
   Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Sato S, 2004, PLANT J, V40, P151, DOI 10.1111/j.1365-313X.2004.02187.x
   Schauer N, 2006, NAT BIOTECHNOL, V24, P447, DOI 10.1038/nbt1192
   Shakoori A, 2005, BIOCHEM BIOPH RES CO, V334, P1365, DOI 10.1016/j.bbrc.2005.07.041
   Smith CA, 2006, ANAL CHEM, V78, P779, DOI 10.1021/ac051437y
   Soga T, 2002, ANAL CHEM, V74, P2233, DOI 10.1021/ac020064n
   Soga T, 2003, J PROTEOME RES, V2, P488, DOI 10.1021/pr034020m
   Soga T, 2000, ANAL CHEM, V72, P1236, DOI 10.1021/ac990976y
   Soga T, 2007, J CHROMATOGR A, V1159, P125, DOI 10.1016/j.chroma.2007.05.054
   Soga T, 2006, J BIOL CHEM, V281, P16768, DOI 10.1074/jbc.M601876200
   Ullmann R, 2000, J BACTERIOL, V182, P5757, DOI 10.1128/JB.182.20.5757-5764.2000
   Vaupel P, 2003, INT J ONCOL, V22, P795
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   WIESNER RJ, 1988, BIOCHIM BIOPHYS ACTA, V936, P114, DOI 10.1016/0005-2728(88)90258-7
NR 44
TC 668
Z9 684
U1 10
U2 201
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUN 1
PY 2009
VL 69
IS 11
BP 4918
EP 4925
DI 10.1158/0008-5472.CAN-08-4806
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 455JL
UT WOS:000266755000047
PM 19458066
DA 2022-04-25
ER

PT J
AU Zhang, HB
   Ramakrishnan, SK
   Triner, D
   Centofanti, B
   Maitra, D
   Gyorffy, B
   Sebolt-Leopold, JS
   Dame, MK
   Varani, J
   Brenner, DE
   Fearon, ER
   Omary, MB
   Shah, YM
AF Zhang, Huabing
   Ramakrishnan, Sadeesh K.
   Triner, Daniel
   Centofanti, Brook
   Maitra, Dhiman
   Gyorffy, Balazs
   Sebolt-Leopold, Judith S.
   Dame, Michael K.
   Varani, James
   Brenner, Dean E.
   Fearon, Eric R.
   Omary, M. Bishr
   Shah, Yatrik M.
TI Tumor-selective proteotoxicity of verteporfin inhibits colon cancer
   progression independently of YAP1
SO SCIENCE SIGNALING
LA English
DT Article
ID PHOTODYNAMIC THERAPY; CHOROIDAL NEOVASCULARIZATION; MACULAR
   DEGENERATION; CELL-PROLIFERATION; TEAD/TEF FAMILY; HIPPO; SURVIVAL;
   PATHWAY; GROWTH; ACTIVATION
AB Yes-associated protein 1 (YAP1) is a transcriptional coactivator in the Hippo signaling pathway. Increased YAP1 activity promotes the growth of tumors, including that of colorectal cancer (CRC). Verteporfin, a drug that enhances phototherapy to treat neovascular macular degeneration, is an inhibitor of YAP1. We found that verteporfin inhibited tumor growth independently of its effects on YAP1 or the related protein TAZ in genetically or chemically induced mouse models of CRC, in patient-derived xenografts, and in enteroid models of CRC. Instead, verteporfin exhibited in vivo selectivity for killing tumor cells in part by impairing the global clearance of high-molecular weight oligomerized proteins, particularly p62 (a sequestrome involved in autophagy) and STAT3 (signal transducer and activator of transcription 3; a transcription factor). Verteporfin inhibited cytokine-induced STAT3 activity and cell proliferation and reduced the viability of cultured CRC cells. Although verteporfin accumulated to a greater extent in normal cells than in tumor cells in vivo, experiments with cultured cells indicated that the normal cells efficiently cleared verteporfin-induced protein oligomers through autophagic and proteasomal pathways. Culturing CRC cells under hypoxic or nutrient-deprived conditions (modeling a typical CRC microenvironment) impaired the clearance of protein oligomers and resulted in cell death, whereas culturing cells under normoxic or glucose-replete conditions protected cell viability and proliferation in the presence of verteporfin. Furthermore, verteporfin suppressed the proliferation of other cancer cell lines even in the absence of YAP1, suggesting that verteporfin may be effective against multiple types of solid cancers.
C1 [Zhang, Huabing; Ramakrishnan, Sadeesh K.; Triner, Daniel; Centofanti, Brook; Maitra, Dhiman; Omary, M. Bishr; Shah, Yatrik M.] Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA.
   [Gyorffy, Balazs] Semmelweis Univ, Dept Pediat 2, MTA SE Pediat & Nephrol Res Grp, MTA TTK Lendulet Canc Biomarker Res Grp, H-1117 Budapest, Hungary.
   [Sebolt-Leopold, Judith S.] Univ Michigan, Sch Med, Dept Radiol, Ann Arbor, MI 48109 USA.
   [Dame, Michael K.; Varani, James; Brenner, Dean E.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.
   [Fearon, Eric R.] Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA.
   [Fearon, Eric R.; Omary, M. Bishr; Shah, Yatrik M.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA.
   [Omary, M. Bishr] Dept Vet Affairs Ann Arbor Hlth Care Syst, Ann Arbor, MI 48105 USA.
RP Shah, YM (corresponding author), Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA.
EM shahy@umich.edu
RI Gyorffy, Balazs/AAA-9135-2021
OI Omary, Bishr/0000-0002-8624-2347; zhang, huabing/0000-0001-8402-7830; ,
   dhiman/0000-0002-8775-2963; Gyorffy, Balazs/0000-0002-5772-3766; Dame,
   Michael K/0000-0003-3760-1654
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [CA148828, DK095201, CA181855-01,
   CA046592-26S3, DK52951]; University of Michigan Gastrointestinal Peptide
   Research Center grant [DK034933]; GI SPORE [CA130810]; OTKA (Hungarian
   Scientific Research Fund) grantOrszagos Tudomanyos Kutatasi
   Alapprogramok (OTKA) [K108655]; American Heart AssociationAmerican Heart
   Association [15POST22650034]; NATIONAL CANCER INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [P30CA046592, R21CA181855,
   R01CA148828, P50CA130810] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Diabetes & Digestive & Kidney Diseases
   (NIDDK) [R01DK052951, P30DK034933, R56DK052951, K01DK091415,
   R01DK095201, P30DK020572] Funding Source: NIH RePORTER
FX This work was supported by NIH grants CA148828 and DK095201 to Y.M.S;
   CA181855-01 and CA046592-26S3 to J.V.; and DK52951 to M.B.O.; University
   of Michigan Gastrointestinal Peptide Research Center grant DK034933; GI
   SPORE CA130810. B.G. was supported by OTKA (Hungarian Scientific
   Research Fund) grant K108655. S.K.R was supported by a postdoctoral
   fellowship from the American Heart Association (15POST22650034).
CR Avruch J, 2012, CELL CYCLE, V11, P1090, DOI 10.4161/cc.11.6.19453
   Azab M, 2004, RETINA-J RET VIT DIS, V24, P1
   Azzolin L, 2014, CELL, V158, P157, DOI 10.1016/j.cell.2014.06.013
   Azzolin L, 2012, CELL, V151, P1443, DOI 10.1016/j.cell.2012.11.027
   Barakat MR, 2009, EXPERT OPIN INV DRUG, V18, P637, DOI [10.1517/13543780902855316, 10.1517/13543780902855316 ]
   Barry ER, 2013, NATURE, V493, P106, DOI 10.1038/nature11693
   Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002
   Brodowska K, 2014, EXP EYE RES, V124, P67, DOI 10.1016/j.exer.2014.04.011
   Cai J, 2010, GENE DEV, V24, P2383, DOI 10.1101/gad.1978810
   Dame MK, 2014, LAB INVEST, V94, P222, DOI 10.1038/labinvest.2013.145
   Dame MK, 2010, IN VITRO CELL DEV-AN, V46, P114, DOI 10.1007/s11626-009-9247-9
   Donohue E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114964
   Donohue E, 2011, J BIOL CHEM, V286, P7290, DOI 10.1074/jbc.M110.139915
   Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235
   Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016
   Feng Y, 2013, AM J PATHOL, V183, P493, DOI 10.1016/j.ajpath.2013.04.013
   Goulev Y, 2008, CURR BIOL, V18, P435, DOI 10.1016/j.cub.2008.02.034
   Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001
   Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241
   Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9
   Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831
   Huggett MT, 2014, BRIT J CANCER, V110, P1698, DOI 10.1038/bjc.2014.95
   Itzkowitz SH, 2004, AM J PHYSIOL-GASTR L, V287, pG7, DOI 10.1152/ajpgi.00079.2004
   Jiang N, 2015, ONCOGENE, V34, P2764, DOI 10.1038/onc.2014.206
   Lamark Trond, 2012, Int J Cell Biol, V2012, P736905, DOI 10.1155/2012/736905
   Li VSW, 2013, CURR BIOL, V23, pR110, DOI 10.1016/j.cub.2012.12.021
   Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112
   Mani A, 2005, J CLIN ONCOL, V23, P4776, DOI 10.1200/JCO.2005.05.081
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Ozcan U, 2006, SCIENCE, V313, P1137, DOI 10.1126/science.1128294
   Perra A, 2014, J HEPATOL, V61, P1088, DOI 10.1016/j.jhep.2014.06.033
   Rosenbluh J, 2012, CELL, V151, P1457, DOI 10.1016/j.cell.2012.11.026
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Singla A, 2013, J CELL SCI, V126, P3105, DOI 10.1242/jcs.123026
   Singla A, 2012, HEPATOLOGY, V56, P322, DOI 10.1002/hep.25664
   Song SM, 2014, CANCER RES, V74, P4170, DOI 10.1158/0008-5472.CAN-13-3569
   Taniguchi K, 2015, NATURE, V519, P57, DOI 10.1038/nature14228
   Vizcaino JA, 2014, NAT BIOTECHNOL, V32, P223, DOI 10.1038/nbt.2839
   Wu S, 2008, DEV CELL, V14, P388, DOI 10.1016/j.devcel.2008.01.007
   Xue X, 2013, GASTROENTEROLOGY, V145, P831, DOI 10.1053/j.gastro.2013.07.010
   Yu FX, 2014, CANCER CELL, V25, P822, DOI 10.1016/j.ccr.2014.04.017
   Zhang L, 2008, DEV CELL, V14, P377, DOI 10.1016/j.devcel.2008.01.006
   Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907
   Zhou DW, 2011, P NATL ACAD SCI USA, V108, pE1312, DOI 10.1073/pnas.1110428108
   Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026
   Ziemssen F, 2012, EXPERT OPIN DRUG MET, V8, P1023, DOI 10.1517/17425255.2012.701617
NR 47
TC 114
Z9 116
U1 1
U2 26
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1945-0877
EI 1937-9145
J9 SCI SIGNAL
JI Sci. Signal.
PD OCT 6
PY 2015
VL 8
IS 397
AR ra98
DI 10.1126/scisignal.aac5418
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA CU1YU
UT WOS:000363319100001
PM 26443705
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Wang, Z
   Yang, X
   Liu, C
   Li, X
   Zhang, BY
   Wang, B
   Zhang, Y
   Song, C
   Zhang, TZ
   Liu, MH
   Liu, BY
   Ren, MM
   Jiang, HP
   Zou, JH
   Liu, XY
   Zhang, HQ
   Zhu, WG
   Yin, YX
   Zhang, Z
   Gu, W
   Luo, JY
AF Wang, Zhe
   Yang, Xin
   Liu, Cheng
   Li, Xin
   Zhang, Buyu
   Wang, Bo
   Zhang, Yu
   Song, Chen
   Zhang, Tianzhuo
   Liu, Minghui
   Liu, Boya
   Ren, Mengmeng
   Jiang, Hongpeng
   Zou, Junhua
   Liu, Xiaoyun
   Zhang, Hongquan
   Zhu, Wei-Guo
   Yin, Yuxin
   Zhang, Zhang
   Gu, Wei
   Luo, Jianyuan
TI Acetylation of PHF5A Modulates Stress Responses and Colorectal
   Carcinogenesis through Alternative Splicing-Mediated Upregulation of
   KDM3A
SO MOLECULAR CELL
LA English
DT Article
ID GENE-EXPRESSION; CANCER; AUTOPHAGY; JMJD1A; REQUIREMENT; METABOLISM;
   MECHANISMS; GROWTH; JHDM2A
AB Alternative pre-mRNA-splicing-induced post-transcriptional gene expression regulation is one of the pathways for tumors maintaining proliferation rates accompanying the malignant phenotype under stress. Here, we uncover a list of hyperacetylated proteins in the context of acutely reduced Acetyl-CoA levels under nutrient starvation. PHF5A, a component of U2 snRNPs, can be acetylated at lysine 29 in response to multiple cellular stresses, which is dependent on p300. PHF5A acetylation strengthens the interaction among U2 snRNPs and affects global pre-mRNA splicing pattern and extensive gene expression. PHF5A hyperacetylation-induced alternative splicing stabilizes KDM3A mRNA and promotes its protein expression. Pathologically, PHF5A K29 hyperacetylation and KDM3A upregulation axis are correlated with poor prognosis of colon cancer. Our findings uncover a mechanism of an anti-stress pathway through which acetylation on PHF5A promotes the cancer cells' capacity for stress resistance and consequently contributes to colon carcinogenesis.
C1 [Wang, Zhe; Yang, Xin; Zhang, Yu; Song, Chen; Zhang, Tianzhuo; Liu, Minghui; Liu, Boya; Ren, Mengmeng; Zou, Junhua; Luo, Jianyuan] Peking Univ, Hlth Sci Ctr, Ctr Med Genet, Dept Med Genet, Beijing 100191, Peoples R China.
   [Liu, Cheng; Zhang, Hongquan] Peking Univ, Hlth Sci Ctr, Dept Anat Histol & Embryol, Beijing 100191, Peoples R China.
   [Li, Xin] Peking Union Med Coll Hosp, Dept Allergy, Beijing 100730, Peoples R China.
   [Zhang, Buyu; Liu, Xiaoyun] Peking Univ, Hlth Sci Ctr, Dept Microbiol, Beijing 100191, Peoples R China.
   [Wang, Bo; Jiang, Hongpeng] Peking Univ, Peoples Hosp, Dept Gastroenterol Surg, Beijing 100044, Peoples R China.
   [Zhu, Wei-Guo] Shenzhen Univ, Sch Med, Dept Biochem & Mol Biol, Shenzhen 518060, Peoples R China.
   [Yin, Yuxin] Peking Univ, Hlth Sci Ctr, Inst Syst Biomed, Beijing 100191, Peoples R China.
   [Zhang, Zhang] Jingjie PTM Biolab Hangzhou Co Ltd, Hangzhou 310018, Zhejiang, Peoples R China.
   [Gu, Wei] Columbia Univ, Inst Canc Genet, New York, NY 10032 USA.
   [Luo, Jianyuan] Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing Key Lab Prot Posttranslat Modificat & Cel, Beijing 100191, Peoples R China.
RP Luo, JY (corresponding author), Peking Univ, Hlth Sci Ctr, Ctr Med Genet, Dept Med Genet, Beijing 100191, Peoples R China.; Luo, JY (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing Key Lab Prot Posttranslat Modificat & Cel, Beijing 100191, Peoples R China.
EM luojianyuan@bjmu.edu.cn
RI Luo, Jianyuan/ABI-7585-2020
OI Luo, Jianyuan/0000-0001-6057-2914; Yang, Xin/0000-0003-0222-5839; Zhu,
   Wei-Guo/0000-0001-8385-6581
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81874147, 81671389, 81471405, 81621063,
   81720108027]; Innovative Fund for Doctoral Students of Peking University
   Health Science Center (2018)
FX We thank John Luo and Ruizhi Li (Cornell University) for editorial
   assistance. We thank Peng Zhang (Northwest A&F University) for RNA
   sequencing analysis assistance. This work was supported by National
   Natural Science Foundation of China (81874147, 81671389, 81471405,
   81621063, and 81720108027), and Innovative Fund for Doctoral Students of
   Peking University Health Science Center (2018).
CR Beyer S, 2008, J BIOL CHEM, V283, P36542, DOI 10.1074/jbc.M804578200
   Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7
   Chang YF, 2007, ANNU REV BIOCHEM, V76, P51, DOI 10.1146/annurev.biochem.76.050106.093909
   Cretu C, 2016, MOL CELL, V64, P307, DOI 10.1016/j.molcel.2016.08.036
   Edmond V, 2011, EMBO J, V30, P510, DOI 10.1038/emboj.2010.333
   Falletta P, 2017, GENE DEV, V31, P18, DOI 10.1101/gad.290940.116
   Fan W, 2010, MOL CELL, V39, P247, DOI 10.1016/j.molcel.2010.07.006
   Geeraert C, 2010, J BIOL CHEM, V285, P24184, DOI 10.1074/jbc.M109.091553
   Hoskins AA, 2012, TRENDS BIOCHEM SCI, V37, P179, DOI 10.1016/j.tibs.2012.02.009
   Hu M, 2014, J PROTEOMICS, V109, P16, DOI 10.1016/j.jprot.2014.06.017
   Hubert CG, 2013, GENE DEV, V27, P1032, DOI 10.1101/gad.212548.112
   Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026
   Li J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15146
   Li YI, 2018, NAT GENET, V50, P151, DOI 10.1038/s41588-017-0004-9
   Lin SY, 2012, SCIENCE, V336, P477, DOI 10.1126/science.1217032
   Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126
   Marino G, 2014, MOL CELL, V53, P710, DOI 10.1016/j.molcel.2014.01.016
   Nilsen TW, 2010, NATURE, V463, P457, DOI 10.1038/nature08909
   Ohguchi H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10258
   Osawa T, 2013, CANCER RES, V73, P3019, DOI 10.1158/0008-5472.CAN-12-3231
   PAIK WK, 1970, BIOCHIM BIOPHYS ACTA, V213, P513, DOI 10.1016/0005-2787(70)90058-4
   Peng KS, 2018, J BIOL CHEM, V293, P10606, DOI 10.1074/jbc.RA118.001730
   Pertea M, 2016, NAT PROTOC, V11, P1650, DOI 10.1038/nprot.2016.095
   Sebti S, 2014, P NATL ACAD SCI USA, V111, P4115, DOI 10.1073/pnas.1313618111
   Shi L, 2015, CURR OPIN CELL BIOL, V33, P125, DOI 10.1016/j.ceb.2015.02.003
   Son SM, 2019, CELL METAB, V29, P192, DOI 10.1016/j.cmet.2018.08.013
   Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042
   Strikoudis A, 2016, NAT CELL BIOL, V18, P1127, DOI 10.1038/ncb3424
   Tani H, 2012, RNA BIOL, V9, P1233, DOI 10.4161/rna.22036
   Tateishi K, 2009, NATURE, V458, P757, DOI 10.1038/nature07777
   Teng T, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15522
   Trappe R, 2002, BIOCHEM BIOPH RES CO, V293, P816, DOI 10.1016/S0006-291X(02)00277-2
   Weake VM, 2010, NAT REV GENET, V11, P426, DOI 10.1038/nrg2781
   Will CL, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003707
   Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027
   Yang X, 2018, CANCER RES, V78, P372, DOI 10.1158/0008-5472.CAN-17-1912
   Yang Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0736-0
   Yang YZ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7428
   Zhang J, 2013, CANCER DISCOV, V3, P1228, DOI 10.1158/2159-8290.CD-13-0253
   Zhao SM, 2010, SCIENCE, V327, P1000, DOI 10.1126/science.1179689
   Zheng YZ, 2018, CANCER RES, V78, P3190, DOI 10.1158/0008-5472.CAN-17-3514
NR 41
TC 22
Z9 23
U1 4
U2 30
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1097-2765
EI 1097-4164
J9 MOL CELL
JI Mol. Cell
PD JUN 20
PY 2019
VL 74
IS 6
BP 1250
EP +
DI 10.1016/j.molcel.2019.04.009
PG 20
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA IE2RL
UT WOS:000472231600015
PM 31054974
OA Bronze
DA 2022-04-25
ER

PT J
AU Lin, KC
   Lin, MW
   Hsu, MN
   Guan, YC
   Chao, YC
   Tuan, HY
   Chiang, CS
   Hu, YC
AF Lin, Kuan-Chen
   Lin, Mei-Wei
   Hsu, Mu-Nung
   Guan Yu-Chen
   Chao, Yu-Chan
   Tuan, Hsing-Yu
   Chiang, Chi-Shiun
   Hu, Yu-Chen
TI Graphene oxide sensitizes cancer cells to chemotherapeutics by inducing
   early autophagy events, promoting nuclear trafficking and necrosis
SO THERANOSTICS
LA English
DT Article
DE graphene oxide; autophagy; cisplatin; chemoresistance; nuclear import;
   LC3
ID CISPLATIN RESISTANCE; PHOTOTHERMAL THERAPY; SIGNALING PATHWAYS;
   EPIGENETIC CONTROL; IN-SITU; COMPLEXES; MEMBRANE; AGENTS; ACETYLATION;
   MACROPHAGES
AB Rationale: Cisplatin (CDDP) is a broad-spectrum anticancer drug but chemoresistance to CDDP impedes its wide use for cancer therapy. Autophagy is an event occurring in the cytoplasm and cytoplasmic LC3 puncta formation is a hallmark of autophagy. Graphene oxide (GO) is a nanomaterial that provokes autophagy in CT26 colon cancer cells and confers antitumor effects. Here we aimed to evaluate whether combined use of GO with CDDP (GO/CDDP) overcomes chemoresistance in different cancer cells and uncover the underlying mechanism.
   Methods: We treated different cancer cells with GO/CDDP and evaluated the cytotoxicity, death mechanism, autophagy induction and nuclear entry of CDDP. We further knocked down genes essential for autophagic flux and deciphered which step is critical to nuclear import and cell death. Finally, we performed immunoprecipitation, mass spectrometry and immunofluorescence labeling to evaluate the association of LC3 and CDDP.
   Results: We uncovered that combination of GO and CDDP (GO/CDDP) promoted the killing of not only CT26 cells, but also ovarian, cervical and prostate cancer cells. In the highly chemosensitized Skov-3 cells, GO/CDDP significantly enhanced concurrent nuclear import of CDDP and autophagy marker LC3 and elevated cell necrosis, which required autophagy initiation and progression but did not necessitate late autophagy events (e.g., autophagosome completion and autolysosome formation). The GO/CDDP-elicited nuclear trafficking and cell death also required importin alpha/beta, and LC3 also co-migrated with CDDP and histone H1/H4 into the nucleus. In particular, GO/CDDP triggered histone H4 acetylation in the nucleus, which could decondense the chromosome and enable CDDP to more effectively access chromosomal DNA to trigger cell death.
   Conclusion: These findings shed light on the mechanisms of GO/CDDP-induced chemosensitization and implicate the potential applications of GO/CDDP to treat multiple cancers.
C1 [Lin, Kuan-Chen; Lin, Mei-Wei; Hsu, Mu-Nung; Tuan, Hsing-Yu; Hu, Yu-Chen] Natl Tsing Hua Univ, Dept Chem Engn, Hsinchu 30013, Taiwan.
   [Lin, Mei-Wei] Ind Technol Res Inst, Biomed Technol & Device Res Labs, Hsinchu 31057, Taiwan.
   [Guan Yu-Chen] Natl Chiao Tung Univ, Inst Biomed Engn, Hsinchu 30010, Taiwan.
   [Guan Yu-Chen] Natl Chiao Tung Univ, Dept Biol Sci & Technol, Hsinchu 30010, Taiwan.
   [Chao, Yu-Chan] Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan.
   [Chiang, Chi-Shiun] Natl Tsing Hua Univ, Dept Biomed Engn & Environm Sci, Hsinchu 30013, Taiwan.
   [Hu, Yu-Chen] Natl Tsing Hua Univ, Frontier Res Ctr Fundamental & Appl Sci Matters, Hsinchu 30013, Taiwan.
RP Hu, YC (corresponding author), Natl Tsing Hua Univ, Dept Chem Engn, Hsinchu 30013, Taiwan.; Hu, YC (corresponding author), Natl Tsing Hua Univ, Frontier Res Ctr Fundamental & Appl Sci Matters, Hsinchu 30013, Taiwan.
EM yuchen@che.nthu.edu.tw
RI Chao, Yu-Chan/ABF-6571-2021; Chiang, Chi-Shiun/A-9562-2008
OI Chao, Yu-Chan/0000-0002-9528-8806; Chiang,
   Chi-Shiun/0000-0002-2581-4129; Tuan, Hsing-Yu/0000-0003-2819-2270
FU National Tsing Hua University (Toward World-Class University Project)
   [106N526CE1, 105N526CE1, 104N2050E1]; Ministry of Science and
   TechnologyMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT) [MOST 103-2221-E-007-093-MY3]
FX The authors acknowledge the support from the National Tsing Hua
   University (Toward World-Class University Project 106N526CE1,
   105N526CE1, 104N2050E1) and Ministry of Science and Technology (MOST
   103-2221-E-007-093-MY3).
CR Badding MA, 2013, MOL THER, V21, P775, DOI 10.1038/mt.2012.231
   Baek SH, 2017, MOL CELL, V65, P781, DOI 10.1016/j.molcel.2016.12.027
   Cepeda V, 2007, ANTI-CANCER AGENT ME, V7, P3, DOI 10.2174/187152007779314044
   Chen GY, 2012, BIOMATERIALS, V33, P418, DOI 10.1016/j.biomaterials.2011.09.071
   Chen GY, 2015, BIOMATERIALS, V40, P12, DOI 10.1016/j.biomaterials.2014.11.034
   Chen GY, 2014, ADV HEALTHC MATER, V3, P1486, DOI 10.1002/adhm.201300591
   Chen GY, 2012, BIOMATERIALS, V33, P6559, DOI 10.1016/j.biomaterials.2012.05.064
   Chook YM, 2011, BBA-MOL CELL RES, V1813, P1593, DOI 10.1016/j.bbamcr.2010.10.014
   Dou ZX, 2015, NATURE, V527, P105, DOI 10.1038/nature15548
   Drake KR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009806
   Fujita N, 2008, MOL BIOL CELL, V19, P2092, DOI 10.1091/mbc.E07-12-1257
   Fullgrabe J, 2014, AUTOPHAGY, V10, P556, DOI 10.4161/auto.27280
   Fullgrabe J, 2014, NAT REV MOL CELL BIO, V15, P65, DOI 10.1038/nrm3716
   Fullgrabe J, 2013, NATURE, V500, P468, DOI 10.1038/nature12313
   Furuta S, 2002, ONCOGENE, V21, P7060, DOI 10.1038/sj.onc.1205790
   Galluzzi L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.428
   Goenka S, 2014, J CONTROL RELEASE, V173, P75, DOI 10.1016/j.jconrel.2013.10.017
   Gonzalez VM, 2001, MOL PHARMACOL, V59, P657, DOI 10.1124/mol.59.4.657
   Hajji N, 2010, ONCOGENE, V29, P2192, DOI 10.1038/onc.2009.505
   Hu SH, 2012, ADV MATER, V24, P1748, DOI 10.1002/adma.201104070
   Huang R, 2015, MOL CELL, V57, P456, DOI 10.1016/j.molcel.2014.12.013
   Ishiguro K, 2011, J IMMUNOL, V186, P2710, DOI 10.4049/jimmunol.1003322
   Itakura E, 2012, CELL, V151, P1256, DOI 10.1016/j.cell.2012.11.001
   Keck KM, 2012, BBA-GENE REGUL MECH, V1819, P277, DOI 10.1016/j.bbagrm.2011.09.007
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Kraft LJ, 2016, TRAFFIC, V17, P369, DOI 10.1111/tra.12372
   Kraft LJ, 2014, AUTOPHAGY, V10, P861, DOI 10.4161/auto.28175
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Levy JMM, 2011, PHARMACOL THERAPEUT, V131, P130, DOI 10.1016/j.pharmthera.2011.03.009
   Mahipal A, 2016, PHARMACOL THERAPEUT, V164, P135, DOI 10.1016/j.pharmthera.2016.03.020
   Martinez-Lopez N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3799
   Meisenberg C, 2017, NUCLEIC ACIDS RES, V45, P1159, DOI 10.1093/nar/gkw1026
   Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347
   Morelli E, 2014, AUTOPHAGY, V10, P2251, DOI 10.4161/15548627.2014.981913
   Mottamal M, 2015, MOLECULES, V20, P3898, DOI 10.3390/molecules20033898
   Nikoletopoulou V, 2013, BBA-MOL CELL RES, V1833, P3448, DOI 10.1016/j.bbamcr.2013.06.001
   Nowak J, 2009, MOL BIOL CELL, V20, P870, DOI 10.1091/mbc.E08-07-0671
   Qu GB, 2013, ACS NANO, V7, P5732, DOI 10.1021/nn402330b
   Shen DW, 2012, PHARMACOL REV, V64, P706, DOI 10.1124/pr.111.005637
   Tao Y, 2014, BIOMATERIALS, V35, P9963, DOI 10.1016/j.biomaterials.2014.08.036
   Wang J, 2014, J BIOL CHEM, V289, P17163, DOI 10.1074/jbc.M114.558288
   Wang Y, 2010, J AM CHEM SOC, V132, P9274, DOI 10.1021/ja103169v
   Wilting RH, 2012, DRUG RESIST UPDATE, V15, P21, DOI 10.1016/j.drup.2012.01.008
   Yang K, 2012, BIOMATERIALS, V33, P2206, DOI 10.1016/j.biomaterials.2011.11.064
   Zhang LM, 2011, SMALL, V7, P460, DOI 10.1002/smll.201001522
   Zhang LM, 2010, SMALL, V6, P537, DOI 10.1002/smll.200901680
   Zhou HJ, 2012, BIOMATERIALS, V33, P6933, DOI 10.1016/j.biomaterials.2012.06.064
   Zhu JQ, 2017, ACS NANO, V11, P2637, DOI 10.1021/acsnano.6b07311
NR 48
TC 26
Z9 27
U1 2
U2 16
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838-7640
J9 THERANOSTICS
JI Theranostics
PY 2018
VL 8
IS 9
BP 2477
EP 2487
DI 10.7150/thno.24173
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA GC6DN
UT WOS:000429880400004
PM 29721093
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Nagappan, A
   Lee, WS
   Yun, JW
   Lu, JN
   Chang, SH
   Jeong, JH
   Kim, GS
   Jung, JM
   Hong, SC
AF Nagappan, Arulkumar
   Lee, Won Sup
   Yun, Jeong Won
   Lu, Jing Nan
   Chang, Seong-Hwan
   Jeong, Jae-Hoon
   Kim, Gon Sup
   Jung, Jin-Myung
   Hong, Soon Chan
TI Tetraarsenic hexoxide induces G2/M arrest, apoptosis, and autophagy via
   PI3K/Akt suppression and p38 MAPK activation in SW620 human colon cancer
   cells
SO PLOS ONE
LA English
DT Article
ID ARSENIC TRIOXIDE; POLY(ADP-RIBOSE) POLYMERASE; CYCLE PROGRESSION;
   DOWN-REGULATION; UP-REGULATION; DEATH; PATHWAY; BCL-2; MODULATION;
   INDUCTION
AB Tetraarsenic hexoxide (As4O6) has been used in Korean folk medicines for the treatment of cancer, however its anti-cancer mechanisms remain obscured. Here, this study investigated the anti-cancer effect of As4O6 on SW620 human colon cancer cells. As4O6 has showed a dose-dependent inhibition of SW620 cells proliferation. As4O6 significantly increased the sub-G1 and G2/M phase population, and Annexin V-positive cells in a dose-dependent manner. G2/M arrest was concomitant with augment of p21 and reduction in cyclin B1, cell division cycle 2 (cdc 2) expressions. Nuclear condensation, cleaved nuclei and poly (adenosine diphosphate-ribose) polymerase (PARP) activation were also observed in As(4)O(6)treated SW620 cells. As4O6 induced depolarization of mitochondrial membrane potential (MMP, Delta psi m) but not reactive oxygen species (ROS) generation. Further, As4O6 increased death receptor 5 (DR5), not DR4 and suppressed the B-cell lymphoma-2 (Bcl-2) and Xlinked inhibitor of apoptosis protein (XIAP) family proteins. As4O6 increased the formation of AVOs (lysosomes and autophagolysosomes) and promoted the conversion of microtubuleassociated protein 1A/1B-light chain 3 (LC3)-I to LC3-II in a dose-and time-dependent manner. Interestingly, a specific phosphoinositide 3-kinase (PI3K)/Akt inhibitor (LY294002) augmented the As4O6 induced cell death; whereas p38 mitogen-activated protein kinases (p38 MAPK) inhibitor (SB203580) abrogated the cell death. Thus, the present study provides the first evidence that As4O6 induced G2/M arrest, apoptosis and autophagic cell death through PI3K/Akt and p38 MAPK pathways alteration in SW620 cells.
C1 [Nagappan, Arulkumar; Lee, Won Sup; Yun, Jeong Won; Lu, Jing Nan] Gyeongsang Natl Univ, Sch Med, Dept Internal Med, Inst Hlth Sci, 90 Chilam Dong, Jinju, South Korea.
   [Chang, Seong-Hwan] Konkuk Univ, Sch Med, Dept Surg, Seoul, South Korea.
   [Jeong, Jae-Hoon] Korea Inst Radiol & Med Sci, Res Ctr Radiotherapy, Seoul, South Korea.
   [Kim, Gon Sup] Gyeongsang Natl Univ, Res Inst Life Sci, 900 Gajwadong, Jinju, South Korea.
   [Kim, Gon Sup] Gyeongsang Natl Univ, Coll Vet Med, 900 Gajwadong, Jinju, South Korea.
   [Jung, Jin-Myung] Gyeongsang Natl Univ, Sch Med, Dept Neurosurg, Inst Hlth Sci, 90 Chilam Dong, Jinju, South Korea.
   [Hong, Soon Chan] Gyeongsang Natl Univ, Sch Med, Inst Hlth Sci, Dept Surg, 90 Chilam Dong, Jinju, South Korea.
   [Lu, Jing Nan] Fifth Hosp Shijiazhuang, Shijiazhuang, Peoples R China.
RP Lee, WS (corresponding author), Gyeongsang Natl Univ, Sch Med, Dept Internal Med, Inst Hlth Sci, 90 Chilam Dong, Jinju, South Korea.
EM lwshmo@hanmail.net
OI Chang, Seong-Hwan/0000-0002-0419-4418; Hong,
   Soon-Chan/0000-0003-4499-8741
FU National Research Foundation of Korea (NRF) - Korea government
   (MEST)Ministry of Education, Science and Technology, Republic of
   KoreaNational Research Foundation of KoreaKorean Government
   [20120002631]; National R&D Program for Cancer Control, Ministry for
   Health, Welfare and Family Affairs, Republic of KoreaMinistry of Health
   & Welfare, Republic of Korea [0820050]
FX The present study was supported by a grant from the National Research
   Foundation of Korea (NRF) funded by the Korea government (MEST) (no.
   20120002631), in part by a grant of the National R&D Program for Cancer
   Control, Ministry for Health, Welfare and Family Affairs, Republic of
   Korea (0820050).
CR Ai ZL, 2006, BIOCHEM BIOPH RES CO, V348, P1075, DOI 10.1016/j.bbrc.2006.07.181
   Aksamitiene E, 2012, BIOCHEM SOC T, V40, P139, DOI 10.1042/BST20110609
   Aranda A, 2013, TOXICOL IN VITRO, V27, P954, DOI 10.1016/j.tiv.2013.01.016
   Boonstra J, 2004, GENE, V337, P1, DOI 10.1016/j.gene.2004.04.032
   Borutaite V, 2010, ENVIRON MOL MUTAGEN, V51, P406, DOI 10.1002/em.20564
   Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824
   Chang HS, 2007, INT J ONCOL, V30, P1129
   Chen GQ, 1996, BLOOD, V88, P1052
   Chiruvella KK, 2008, FEBS LETT, V582, P4066, DOI 10.1016/j.febslet.2008.11.001
   De Castro LFP, 2002, J MOL RECOGNIT, V15, P209, DOI 10.1002/jmr.581
   Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421
   Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887
   Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115
   Freimoser FM, 1999, APPL ENVIRON MICROB, V65, P3727
   Gobeil S, 2001, CELL DEATH DIFFER, V8, P588, DOI 10.1038/sj.cdd.4400851
   Goussetis DJ, 2010, J BIOL CHEM, V285, P29989, DOI 10.1074/jbc.M109.090530
   Han MH, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/201414
   Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710
   Jeong JW, 2015, PHYTOTHER RES, V29, P1516, DOI 10.1002/ptr.5402
   Kang YH, 2004, CANCER RES, V64, P8960, DOI 10.1158/0008-5472.CAN-04-1830
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Kim JJ, 2010, CELL DEATH DIFFER, V17, P1420, DOI 10.1038/cdd.2010.19
   Lee WS, 2015, ONCOL REP, V33, P2940, DOI 10.3892/or.2015.3890
   Liu J, 2008, J PHARMACOL EXP THER, V326, P363, DOI 10.1124/jpet.108.139543
   Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032
   Miyajima A, 1997, BRIT J CANCER, V76, P206, DOI 10.1038/bjc.1997.363
   Munoz-Gomez JA, 2009, AUTOPHAGY, V5, P61, DOI 10.4161/auto.5.1.7272
   Nikoletopoulou V, 2013, BBA-MOL CELL RES, V1833, P3448, DOI 10.1016/j.bbamcr.2013.06.001
   Nutt LK, 2005, CANCER BIOL THER, V4, P459
   Park JW, 2001, BIOCHEM BIOPH RES CO, V286, P726, DOI 10.1006/bbrc.2001.5416
   Qian WB, 2007, LEUKEMIA RES, V31, P329, DOI 10.1016/j.leukres.2006.06.021
   Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392
   Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0
   Shah GM, 1996, BIOCHEM BIOPH RES CO, V229, P838, DOI 10.1006/bbrc.1996.1889
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Smith DM, 2010, CELL DEATH DIFFER, V17, P1867, DOI 10.1038/cdd.2010.53
   Srivastava S, 2016, SCI REP-UK, V6, DOI 10.1038/srep24049
   Thorburn A, 2008, APOPTOSIS, V13, P1, DOI 10.1007/s10495-007-0154-9
   Van Cutsem E, 2014, ANN ONCOL, V25, P1, DOI 10.1093/annonc/mdu260
   Wang R, 2016, SCI REP-UK, V6, DOI 10.1038/srep27071
   Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232
   Wong WWL, 2008, IUBMB LIFE, V60, P390, DOI 10.1002/iub.51
   Yang YP, 2008, ACTA PHARMACOL SIN, V29, P123, DOI 10.1111/j.1745-7254.2008.00732.x
   Zhang XY, 2012, J CELL BIOCHEM, V113, P3528, DOI 10.1002/jcb.24230
NR 44
TC 35
Z9 36
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 29
PY 2017
VL 12
IS 3
AR e0174591
DI 10.1371/journal.pone.0174591
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA ER9VG
UT WOS:000399174600068
PM 28355296
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Torricelli, C
   Daveri, E
   Salvadori, S
   Valacchi, G
   Ietta, F
   Muscettola, M
   Carlucci, F
   Maioli, E
AF Torricelli, C.
   Daveri, E.
   Salvadori, S.
   Valacchi, G.
   Ietta, F.
   Muscettola, M.
   Carlucci, F.
   Maioli, E.
TI Phosphorylation-independent mTORC1 inhibition by the autophagy inducer
   Rottlerin
SO CANCER LETTERS
LA English
DT Article
DE Rottlerin; AMPK; mTOR; Raptor; Autophagy
ID KINASE-C-DELTA; COLON-CARCINOMA CELLS; MAMMALIAN TARGET; HUMAN PROSTATE;
   S6 KINASE; PROTEIN; CANCER; AMPK; ULK1; MIGRATION
AB We recently found that Rottlerin not only inhibits proliferation but also causes Bcl-2- and Beclin 1-independent autophagic death in apoptosis-resistant breast adenocarcinoma MCF-7 cells. Having excluded a role for canonical signaling pathways, the current study was aimed to investigate the contribution of the AMPK/mTOR axis in autophagy induction and to search for the upstream signaling molecules potentially targeted by Rottlerin. Using several enzyme inhibitors, Western blotting analysis, mTOR siRNA and pull down assay, we demonstrate that the Rottlerin-triggered autophagy is mediated by inhibition of mTORC1 activity through a novel AMPK and mTORC1 phosphorylation-independent mechanism, likely mediated by the direct interaction between Rottlerin and mTOR. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Torricelli, C.; Daveri, E.; Salvadori, S.; Ietta, F.; Maioli, E.] Univ Siena, Dept Life Sci, I-53100 Siena 7, Italy.
   [Valacchi, G.] Univ Ferrara, Dept Biol & Evolut, I-44100 Ferrara, Italy.
   [Valacchi, G.] Kyung Hee Univ, Dept Food & Nutr, Seoul 130701, South Korea.
   [Muscettola, M.] Univ Siena, Dept Med Surg & Neurosci, I-53100 Siena 4, Italy.
   [Carlucci, F.] Univ Siena, Dept Med Biotechnol, I-53100 Siena 4, Italy.
RP Maioli, E (corresponding author), Univ Siena, Dept Life Sci, Via Aldo Moro, I-53100 Siena 7, Italy.
EM emanuela.maioli@unisi.it
RI Daveri, Elena/C-6910-2019
OI Daveri, Elena/0000-0001-8351-2762; MAIOLI, Emanuela/0000-0002-0701-1445;
   Ietta, Francesca/0000-0002-2160-8790
FU Istituto Toscano Tumori
FX This work has received financial support from the Istituto Toscano
   Tumori (grant 2010).
CR Balgi AD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007124
   Beevers CS, 2009, CANCER RES, V69, P1000, DOI 10.1158/0008-5472.CAN-08-2367
   Bennasser Y, 2002, FASEB J, V16, P546, DOI 10.1096/fj.01-0775com
   Brenner W, 2008, INT J ONCOL, V32, P1125
   Carew JS, 2011, TARGET ONCOL, V6, P17, DOI 10.1007/s11523-011-0167-8
   Carriere A, 2008, CURR BIOL, V18, P1269, DOI 10.1016/j.cub.2008.07.078
   Chen YQ, 2011, J CELL SCI, V124, P161, DOI 10.1242/jcs.064576
   Cheng SWY, 2004, J BIOL CHEM, V279, P15719, DOI 10.1074/jbc.C300534200
   De-Xing H., 2010, ANTIOXID REDOX SIGN, V13, P691
   Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683
   Egan DF, 2011, AUTOPHAGY, V7, P645, DOI 10.4161/auto.7.6.15123
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839
   Jung SK, 2008, CANCER RES, V68, P6021, DOI 10.1158/0008-5472.CAN-08-0899
   Kharait S, 2006, BIOCHEM BIOPH RES CO, V343, P848, DOI 10.1016/j.bbrc.2006.03.044
   Kim J, 2011, CELL CYCLE, V10, P1337, DOI 10.4161/cc.10.9.15291
   Kojima K, 2008, BIOCHEM BIOPH RES CO, V376, P434, DOI 10.1016/j.bbrc.2008.09.007
   Kumar D, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-171
   Kwon KY, 2011, BIOCHEM BIOPH RES CO, V416, P343, DOI 10.1016/j.bbrc.2011.11.038
   Lee E, 2013, TOXICOL APPL PHARM, V272, P12, DOI 10.1016/j.taap.2013.04.030
   Lee SJ, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-44
   Lim JH, 2008, APOPTOSIS, V13, P1378, DOI 10.1007/s10495-008-0264-z
   Lim JH, 2012, CHEM-BIOL INTERACT, V197, P1, DOI 10.1016/j.cbi.2012.02.003
   Lin CJ, 2010, J CELL BIOCHEM, V110, P428, DOI 10.1002/jcb.22555
   Maioli E, 2012, SCI WORLD J, DOI 10.1100/2012/350826
   Maioli E, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/742936
   Maioli E, 2009, BIOL PROCED ONLINE, V11, P227, DOI 10.1007/s12575-009-9020-1
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Pattingre S, 2008, BIOCHIMIE, V90, P313, DOI 10.1016/j.biochi.2007.08.014
   Pena-Llopis S, 2011, EMBO J, V30, P3242, DOI 10.1038/emboj.2011.257
   Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438
   Pyo JO, 2012, EXP MOL MED, V44, P73, DOI 10.3858/emm.2012.44.2.029
   Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101
   Seon MR, 2012, J NUTR BIOCHEM, V23, P85, DOI 10.1016/j.jnutbio.2010.11.010
   Shim JH, 2010, CANCER PREV RES, V3, P670, DOI 10.1158/1940-6207.CAPR-09-0185
   Singh BN, 2012, BIOCHEM PHARMACOL, V84, P1154, DOI 10.1016/j.bcp.2012.08.007
   Soltoff SP, 2004, J BIOL CHEM, V279, P10910, DOI 10.1074/jbc.M305396200
   Song KS, 2008, AUTOPHAGY, V4, P650, DOI 10.4161/auto.6057
   Tillman DM, 2003, CANCER RES, V63, P5118
   Torricelli C, 2008, LIFE SCI, V82, P638, DOI 10.1016/j.lfs.2007.12.020
   Torricelli C, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/980658
   Tran PLCHB, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-276
   Valacchi G, 2011, CHEM BIOL DRUG DES, V77, P460, DOI 10.1111/j.1747-0285.2011.01121.x
   Wilkinson S, 2010, CURR OPIN GENET DEV, V20, P57, DOI 10.1016/j.gde.2009.12.004
   Xie H, 2012, CARCINOGENESIS, V33, P1814, DOI 10.1093/carcin/bgs234
   Zhao MT, 2011, CELL METAB, V13, P119, DOI 10.1016/j.cmet.2011.01.009
NR 49
TC 17
Z9 18
U1 0
U2 14
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD APR 28
PY 2015
VL 360
IS 1
BP 17
EP 27
DI 10.1016/j.canlet.2015.01.040
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CE6UO
UT WOS:000351973900003
PM 25661734
DA 2022-04-25
ER

PT J
AU Pourhanifeh, MH
   Mehrzadi, S
   Kamali, M
   Hosseinzadeh, A
AF Pourhanifeh, Mohammad Hossein
   Mehrzadi, Saeed
   Kamali, Mahboobeh
   Hosseinzadeh, Azam
TI Melatonin and gastrointestinal cancers: Current evidence based on
   underlying signaling pathways
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Review
DE Melatonin; Oral cancer; Esophageal cancer; Gastric cancer; Liver cancer;
   Hepatocellular carcinoma; Cholangiocarcinoma; Colon cancer; Colorectal
   cancer; Pancreatic cancer; Angiogenesis; Apoptosis; Autophagy;
   Inflammation; Oxidative stress; Proliferation; Metastasis; Invasion;
   Signaling pathway; Gastrointestinal cancers; Resistance
ID HUMAN HEPATOCELLULAR-CARCINOMA; ENDOPLASMIC-RETICULUM STRESS; APOPTOTIC
   CELL-DEATH; INFLAMMATORY-BOWEL-DISEASE; ENDOTHELIAL GROWTH-FACTOR;
   PINEAL HORMONE MELATONIN; FACTOR-KAPPA-B; COLORECTAL-CANCER;
   INTRAHEPATIC CHOLANGIOCARCINOMA; IN-VITRO
AB Gastrointestinal (GI) cancers, leading causes of cancer-related deaths, have been serious challenging human diseases up to now. Because of high rates of mortality, late-stage diagnosis, metastasis to distant locations, and low effectiveness and adverse events of routine standard therapies, the quality of life and survival time are low in patients with GI cancers. Hence, many efforts need to be done to explore and find novel efficient treatments. Beneficial effects of melatonin have been reported in a wide variety of human diseases. Melatonin has antioxidant, anti-inflammatory, antimicrobial, and anticancer effects. Various studies have showed the regulatory effects of melatonin on apoptotsis, autophagy and angiogenesis; these properties result in the inhibition of invasion, migration, and proliferation of GI cancer cells in vivo and in vitro. Together, this review suggests that melatonin in combination with anticancer agents may improve the efficacy of routine medicine and survival rate of patients with cancer.
C1 [Mehrzadi, Saeed; Hosseinzadeh, Azam] Iran Univ Med Sci, Razi Drug Res Ctr, Tehran, Iran.
   [Kamali, Mahboobeh] Iran Univ Med Sci, Tehran, Iran.
   [Pourhanifeh, Mohammad Hossein] Kashan Univ Med Sci, Res Ctr Biochem & Nutr Metab Dis, Kashan, Iran.
RP Hosseinzadeh, A (corresponding author), Iran Univ Med Sci, Razi Drug Res Ctr, Tehran, Iran.
EM hosseinzadeazam@gmail.com
RI kamali, mahboobeh/AAM-3404-2021; Mehrzadi, Saeed/AAY-8389-2020;
   Hosseinzadeh, Azam/AAN-6886-2021; kamali, mahboobeh/S-3735-2018
OI Mehrzadi, Saeed/0000-0001-6619-2330; Hosseinzadeh,
   Azam/0000-0001-6379-5769; kamali, mahboobeh/0000-0003-4419-9560;
   Pourhanifeh, Mohammad Hossein/0000-0002-6752-2765
CR Abadi SHMH, 2018, CURR MOL PHARMACOL, V11, P326, DOI 10.2174/1874467211666180830150154
   Abraham C, 2011, GASTROENTEROLOGY, V140, P1729, DOI 10.1053/j.gastro.2011.02.012
   Akbarzadeh M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16940-y
   ALDEGHI R, 1994, EUR J CANCER, V30A, P167, DOI 10.1016/0959-8049(94)90080-9
   Amini P, 2020, ENVIRON TOXICOL, V35, P815, DOI 10.1002/tox.22917
   Cid MA, 2012, CELL PHYSIOL BIOCHEM, V30, P1502, DOI 10.1159/000343338
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Arthur JC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5724
   Bahrami N, 2018, BIOMED PHARMACOTHER, V108, P515, DOI 10.1016/j.biopha.2018.09.044
   Banales JM, 2016, NAT REV GASTRO HEPAT, V13, P261, DOI 10.1038/nrgastro.2016.51
   Bartsch C., 1999, MELATONIN CANC PATIE, P247
   Batista APC, 2014, MICRON, V59, P17, DOI 10.1016/j.micron.2013.12.003
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Brzozowska I, 2014, CURR PHARM DESIGN, V20, P4807
   Bu LJ, 2017, WORLD J GASTROENTERO, V23, P986, DOI 10.3748/wjg.v23.i6.986
   Calastretti A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051505
   Calvo JR, 2013, J PINEAL RES, V55, P103, DOI 10.1111/jpi.12075
   Capote-Moreno A, 2019, CANCERS, V11, DOI 10.3390/cancers11111712
   Carbajo-Pescador S, 2013, BRIT J CANCER, V109, P83, DOI 10.1038/bjc.2013.285
   Carbajo-Pescador S, 2013, BRIT J CANCER, V108, P442, DOI 10.1038/bjc.2012.563
   Carlberg C, 2000, ANN NY ACAD SCI, V917, P387
   Carretero M, 2009, J PINEAL RES, V47, P192, DOI 10.1111/j.1600-079X.2009.00700.x
   Celinski K, 2011, J PHYSIOL PHARMACOL, V62, P521
   Cerea G, 2003, ANTICANCER RES, V23, P1951
   Chao CC, 2019, CLIN SCI, V133, P709, DOI 10.1042/CS20180945
   Chen YN, 2016, CELL PHYSIOL BIOCHEM, V40, P1094, DOI 10.1159/000453164
   Cheng J, 2019, INT J MOL MED, V43, P945, DOI 10.3892/ijmm.2018.4021
   Chojnacki C, 2011, J PHYSIOL PHARMACOL, V62, P327
   Chojnacki C, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/845032
   Chok KC, 2019, HORM MOL BIOL CLIN I, V39, DOI 10.1515/hmbci-2019-0001
   Chovancova B, 2017, CELL PHYSIOL BIOCHEM, V44, P763, DOI 10.1159/000485290
   Codenotti S, 2015, ONCOL REP, V34, P279, DOI 10.3892/or.2015.3987
   Coleman HG, 2018, GASTROENTEROLOGY, V154, P390, DOI 10.1053/j.gastro.2017.07.046
   Colombo J, 2018, ANTI-CANCER AGENT ME, V18, P1688, DOI 10.2174/1871520618666180131112304
   Colombo J, 2016, ONCOL LETT, V12, P231, DOI 10.3892/ol.2016.4605
   Crespo I, 2016, J PINEAL RES, V61, P168, DOI 10.1111/jpi.12335
   Cui PL, 2012, J PINEAL RES, V52, P236, DOI 10.1111/j.1600-079X.2011.00933.x
   Cutando A, 2007, J PERIODONTOL, V78, P1094, DOI 10.1902/jop.2007.060396
   Cutando A, 2014, ONCOL LETT, V7, P923, DOI 10.3892/ol.2014.1813
   Daryani A, 2018, BIOMED PHARMACOTHER, V97, P948, DOI 10.1016/j.biopha.2017.11.007
   Dehdashtian E, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3336
   Dehdashtian E, 2018, LIFE SCI, V193, P20, DOI 10.1016/j.lfs.2017.12.001
   Dodda BR, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00525
   Edwards BK, 2010, CANCER-AM CANCER SOC, V116, P544, DOI 10.1002/cncr.24760
   El-Magd MA, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108732
   Elsabagh HH, 2020, ORAL DIS, V26, P566, DOI 10.1111/odi.13265
   Escames G, 2003, FASEB J, V17, P932, DOI 10.1096/fj.02-0692fje
   Everhart JE, 2009, GASTROENTEROLOGY, V136, P1134, DOI 10.1053/j.gastro.2009.02.038
   Fan LL, 2013, J PINEAL RES, V55, P184, DOI 10.1111/jpi.12061
   Fan LL, 2013, J PINEAL RES, V55, P174, DOI 10.1111/jpi.12060
   Fan TF, 2018, J PINEAL RES, V64, DOI 10.1111/jpi.12457
   Fang Z, 2018, CELL PHYSIOL BIOCHEM, V47, P1751, DOI 10.1159/000491058
   Farriol M, 2000, J APPL TOXICOL, V20, P21, DOI 10.1002/(SICI)1099-1263(200001/02)20:1<21::AID-JAT623>3.0.CO;2-M
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fernandez-Gil BI, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/7187128
   Fic M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071396
   Filatova N A, 2011, Tsitologiia, V53, P404
   Franke AJ, 2019, JNCI-J NATL CANCER I, V111, P1131, DOI 10.1093/jnci/djz093
   Garborg K, 2013, ANN ONCOL, V24, P1963, DOI 10.1093/annonc/mdt157
   Giovannucci E, 2002, GASTROENTEROL CLIN N, V31, P925, DOI 10.1016/S0889-8553(02)00057-2
   Goncalves ND, 2014, ANTI-CANCER AGENT ME, V14, P1302, DOI 10.2174/1871520614666140812110246
   Gonzalez A, 2011, J PINEAL RES, V50, P250, DOI 10.1111/j.1600-079X.2010.00834.x
   Gu CJ, 2020, CANCER LETT, V476, P34, DOI 10.1016/j.canlet.2020.02.009
   Guneri P, 2014, ORAL ONCOL, V50, P1131, DOI 10.1016/j.oraloncology.2014.09.005
   Haddad RI, 2008, NEW ENGL J MED, V359, P1143, DOI 10.1056/NEJMra0707975
   Han YY, 2011, AM J PHYSIOL-GASTR L, V301, pG623, DOI 10.1152/ajpgi.00118.2011
   Hardeland R, 2012, AGING DIS, V3, P194
   Hemati K, 2021, FUND CLIN PHARMACOL, V35, P25, DOI 10.1111/fcp.12566
   Hemati K, 2020, COMPLEMENT THER CLIN, V38, DOI 10.1016/j.ctcp.2019.101072
   Ho HY, 2016, J PINEAL RES, V61, P479, DOI 10.1111/jpi.12365
   Hong Y, 2014, J PINEAL RES, V56, P264, DOI 10.1111/jpi.12119
   Hosseinzadeh A, 2019, CURR DRUG TARGETS, V20, P1112, DOI 10.2174/1389450120666190319162147
   Hosseinzadeh A, 2018, EXPERT OPIN THER TAR, V22, P1049, DOI 10.1080/14728222.2018.1541318
   Hosseinzadeh A, 2018, LIFE SCI, V201, P17, DOI 10.1016/j.lfs.2018.03.032
   Hosseinzadeh A, 2016, J PINEAL RES, V61, P411, DOI 10.1111/jpi.12362
   Hsieh MJ, 2020, MOL THER-NUCL ACIDS, V19, P877, DOI 10.1016/j.omtn.2019.12.022
   Hu CX, 2019, J CELL MOL MED, V23, P7151, DOI 10.1111/jcmm.14634
   Hu ZP, 2013, J PINEAL RES, V55, P388, DOI 10.1111/jpi.12085
   Hui M., 2003, J XIAN, V31
   Hunsaker M., 2019, DENT J, V7
   Iravani S, 2020, J GASTROINTEST CANC, V51, P748, DOI 10.1007/s12029-019-00336-4
   Jaworek J., 2014, MELATONIN INFLUENCES
   Jaworek J, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051014
   Jiang W, 2011, ANN ONCOL, V22, P1644, DOI 10.1093/annonc/mdq650
   Ju HQ, 2016, J PINEAL RES, V60, P27, DOI 10.1111/jpi.12285
   Juybari KB, 2019, CURR PHARM DESIGN, V25, P3057, DOI 10.2174/1381612825666190829151314
   Juybari KB, 2020, VIRUS RES, V287, DOI 10.1016/j.virusres.2020.198108
   Kamisawa T, 2016, LANCET, V388, P73, DOI 10.1016/S0140-6736(16)00141-0
   Kang JW, 2016, J PINEAL RES, V60, P383, DOI 10.1111/jpi.12319
   Kleeff J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.22
   Kleszczynski K, 2019, J PINEAL RES, V67, DOI 10.1111/jpi.12610
   Kostoglou-Athanassiou I, 2013, THER ADV ENDOCRINOL, V4, P13, DOI 10.1177/2042018813476084
   Kouhi Habibi N, 2019, CLIN TRANSL ONCOL, V21, P745, DOI 10.1007/s12094-018-1977-2
   Kowalski LP, 2000, HEAD NECK-J SCI SPEC, V22, P207, DOI 10.1002/(SICI)1097-0347(200005)22:3<207::AID-HED1>3.3.CO;2-0
   Kumari R, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317705758
   Lagergren J, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c6280
   Laothong U, 2015, ONCOL REP, V33, P1443, DOI 10.3892/or.2015.3738
   Laothong U, 2013, J PINEAL RES, V55, P257, DOI 10.1111/jpi.12068
   Laothong U, 2010, J PINEAL RES, V49, P271, DOI 10.1111/j.1600-079X.2010.00792.x
   Lee JH, 2018, J PINEAL RES, V65, DOI 10.1111/jpi.12519
   Leja-Szpak A, 2007, J PHYSIOL PHARMACOL, V58, P177
   Leja-Szpak A., 2018, PHARM REP, VPR 70, P1079
   Leja-Szpak A, 2018, PHARMACOL REP, V70, P1079, DOI 10.1016/j.pharep.2018.05.007
   Leja-Szpak A, 2010, J PINEAL RES, V49, P248, DOI 10.1111/j.1600-079X.2010.00789.x
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li WM, 2016, ONCOL REP, V36, P2861, DOI 10.3892/or.2016.5100
   Li WM, 2015, CELL PHYSIOL BIOCHEM, V37, P2323, DOI 10.1159/000438587
   Li Y, 2017, ONCOTARGET, V8, P39896, DOI 10.18632/oncotarget.16379
   Liew ZH, 2019, DIGEST DIS SCI, V64, P585, DOI 10.1007/s10620-018-5331-x
   Lin M, 2019, J INT MED RES, DOI 10.1177/0300060519892388
   Lin S, 2017, 2017 INTERNATIONAL CONFERENCE ON DIGITAL IMAGE COMPUTING - TECHNIQUES AND APPLICATIONS (DICTA), P628
   Lin ZY, 2010, BIOMED PHARMACOTHER, V64, P659, DOI 10.1016/j.biopha.2010.09.006
   LISSONI P, 1993, TUMORI J, V79, P401, DOI 10.1177/030089169307900606
   Liu C, 2012, INT IMMUNOPHARMACOL, V12, P394, DOI 10.1016/j.intimp.2011.12.012
   Liu H, 2019, ONCOL REP, V42, P753, DOI 10.3892/or.2019.7190
   Liu R, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/3510970
   Liu SW, 2017, FEBS OPEN BIO, V7, P798, DOI 10.1002/2211-5463.12223
   Liu VWS, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061130
   Liu Z, 2017, MOL MED REP, V16, P9383, DOI 10.3892/mmr.2017.7836
   Lu YX, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.330
   Luo JH, 2018, INT IMMUNOPHARMACOL, V64, P116, DOI 10.1016/j.intimp.2018.08.034
   Lv D, 2012, CHINESE J CANCER RES, V24, P310, DOI [10.3978/j.issn.1000-9604.2012.09.03, 10.1007/s11670-012-0269-6]
   Lv JW, 2019, J PINEAL RES, V66, DOI 10.1111/jpi.12557
   M'Koma AE, 2013, CLIN MED INSIGHTS-GA, V6, P33, DOI 10.4137/CGast.S12731
   Mancebo A, 2018, J GASTROEN HEPATOL, V33, P1524, DOI 10.1111/jgh.14108
   Mayo J.C., 2017, J PINEAL RES, V62
   Mehrzadi S, 2020, EXPERT OPIN THER TAR, V24, P359, DOI 10.1080/14728222.2020.1737015
   Mehrzadi S, 2017, CAN J PHYSIOL PHARM, V95, P773, DOI 10.1139/cjpp-2016-0409
   Mirza-Aghazadeh-Attari M, 2020, J CELL PHYSIOL, V235, P804, DOI 10.1002/jcp.29049
   Mittal S, 2013, J CLIN GASTROENTEROL, V47, pS2, DOI 10.1097/MCG.0b013e3182872f29
   Mizushima N, 2010, CURR OPIN CELL BIOL, V22, P132, DOI 10.1016/j.ceb.2009.12.004
   Mohamed Y, 2019, BIOMEDICINE-TAIWAN, V9, P23, DOI 10.1051/bmdcn/2019090424
   Moneim AEA, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051003
   Onseng K, 2017, J ALTERN COMPLEM MED, V23, P957, DOI 10.1089/acm.2017.0081
   Ordonez R, 2015, J PINEAL RES, V59, P178, DOI 10.1111/jpi.12249
   Ordonez R, 2014, J PINEAL RES, V56, P20, DOI 10.1111/jpi.12092
   Ortiz F, 2015, J PINEAL RES, V58, P34, DOI 10.1111/jpi.12191
   Padillo FJ, 2010, J PINEAL RES, V49, P264, DOI 10.1111/j.1600-079X.2010.00791.x
   Pandi-Perumal SR, 2008, PROG NEUROBIOL, V85, P335, DOI 10.1016/j.pneurobio.2008.04.001
   Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370
   Pariente R, 2018, MOL CELL BIOCHEM, V440, P43, DOI 10.1007/s11010-017-3154-2
   Pariente R, 2017, CANCER CHEMOTH PHARM, V80, P985, DOI 10.1007/s00280-017-3441-3
   Park EJ, 2014, J PINEAL RES, V56, P97, DOI 10.1111/jpi.12102
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Plaimee P, 2015, CELL PROLIFERAT, V48, P67, DOI 10.1111/cpr.12158
   Pourhanifeh MH, 2020, DIABETOL METAB SYNDR, V12, DOI 10.1186/s13098-020-00537-z
   Prieto-Dominguez N, 2017, ONCOTARGET, V8, P91402, DOI 10.18632/oncotarget.20592
   Prieto-Dominguez N, 2016, J PINEAL RES, V61, P396, DOI 10.1111/jpi.12358
   Quintana C, 2016, J PINEAL RES, V61, P381, DOI 10.1111/jpi.12356
   Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155
   Razumilava N, 2014, LANCET, V383, P2168, DOI 10.1016/S0140-6736(13)61903-0
   Reiter RJ, 2015, J PERIODONTAL RES, V50, P9, DOI 10.1111/jre.12176
   Reiter RJ, 2000, ANN NY ACAD SCI, V917, P376
   Reiter RJ, 2016, J PINEAL RES, V61, P253, DOI 10.1111/jpi.12360
   Reiter RJ, 2013, MINI-REV MED CHEM, V13, P373
   Riabykh T P, 2000, Vestn Ross Akad Med Nauk, P30
   Ribero D, 2012, ARCH SURG-CHICAGO, V147, P1107, DOI 10.1001/archsurg.2012.1962
   Rizvi S, 2013, GASTROENTEROLOGY, V145, P1215, DOI 10.1053/j.gastro.2013.10.013
   Ruiz-Rabelo J, 2011, PANCREAS, V40, P410, DOI 10.1097/MPA.0b013e318201ca4f
   Saffo S, 2019, DIGEST DIS SCI, V64, P1016, DOI 10.1007/s10620-019-05582-x
   Sainz RM, 2003, CELL MOL LIFE SCI, V60, P1407, DOI 10.1007/s00018-003-2319-1
   Sargazi F, 2018, NEUROENDOCRINOL LETT, V39, P111
   Sargent D, 2009, J CLIN ONCOL, V27, P872, DOI 10.1200/JCO.2008.19.5362
   Schmidt TM, 2018, ANTICANCER RES, V38, P4027, DOI 10.21873/anticanres.12691
   Shen YQ, 2018, J PINEAL RES, V64, DOI 10.1111/jpi.12461
   Shield KD, 2017, CA-CANCER J CLIN, V67, P51, DOI 10.3322/caac.21384
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Song J, 2018, ONCOL REP, V39, P1975, DOI 10.3892/or.2018.6282
   Soreide K, 2018, GASTROENTEROLOGY, V155, P265, DOI 10.1053/j.gastro.2018.06.054
   Srinivasan V, 2008, INTEGR CANCER THER, V7, P189, DOI 10.1177/1534735408322846
   Sung GJ, 2019, J PINEAL RES, V66, DOI 10.1111/jpi.12556
   Tan DX, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122124
   Tang YL, 2019, CANCER LETT, V443, P167, DOI 10.1016/j.canlet.2018.11.037
   Thrumurthy SG, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6367
   Triantafillidis A, 2009, ANN GASTROENTEROL, V22, P10
   Trivedi PP, 2016, MOL CARCINOGEN, V55, P255, DOI 10.1002/mc.22274
   Uguz AC, 2012, J PINEAL RES, V53, P91, DOI 10.1111/j.1600-079X.2012.00974.x
   Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3
   Vennin C, 2018, GASTROENTEROLOGY, V154, P820, DOI 10.1053/j.gastro.2017.11.280
   Verma D, 2014, J CANCER RES THER, V10, P1040, DOI 10.4103/0973-1482.138227
   Wang QL, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030849
   Wang RX, 2016, ONCOL LETT, V12, P897, DOI 10.3892/ol.2016.4729
   Wang TH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092687
   Wang TH, 2017, ONCOTARGET, V8, P82280, DOI 10.18632/oncotarget.19316
   Wang X.T., 2019, NEOPLASMA
   Wang Ya-peng, 2015, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V37, P215, DOI 10.3881/j.issn.1000-503X.2015.02.013
   Wang Y, 2018, ONCOTARGETS THER, V11, P7895, DOI 10.2147/OTT.S174100
   Wang YZ, 2013, J CLIN ONCOL, V31, P1188, DOI 10.1200/JCO.2012.41.5984
   Wei DM, 2019, INT J ONCOL, V54, P600, DOI 10.3892/ijo.2018.4660
   Wei JY, 2015, J PINEAL RES, V58, P429, DOI 10.1111/jpi.12226
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064
   Wongsena W, 2018, PHARMACOL REP, V70, P98, DOI 10.1016/j.pharep.2017.07.017
   Xiao W, 2019, J PINEAL RES, V67, DOI 10.1111/jpi.12607
   Xing J, 2019, CELL STRESS CHAPERON, V24, P621, DOI 10.1007/s12192-019-00994-0
   Xu CF, 2013, BIOMED PHARMACOTHER, V67, P133, DOI 10.1016/j.biopha.2012.10.005
   Xu F, 2020, J PINEAL RES, V68, DOI 10.1111/jpi.12631
   Xu Li, 2014, Shengli Xuebao, V66, P723
   Xu L, 2013, ANAT REC, V296, P914, DOI 10.1002/ar.22689
   Yan Jian-Jun, 2002, Hepatobiliary Pancreat Dis Int, V1, P183
   Yang CY, 2017, ONCOTARGET, V8, P33756, DOI 10.18632/oncotarget.16808
   Ye LN, 2013, SCI WORLD J, DOI 10.1155/2013/296470
   Yeh CM, 2016, ONCOTARGET, V7, P21952, DOI 10.18632/oncotarget.8009
   Yun CW, 2018, ANTICANCER RES, V38, P3951, DOI 10.21873/anticanres.12681
   Zare H, 2019, J OVARIAN RES, V12, DOI 10.1186/s13048-019-0502-8
   Zha LX, 2012, J PINEAL RES, V52, P322, DOI 10.1111/j.1600-079X.2011.00946.x
   Zhang HM, 2014, J PINEAL RES, V57, P131, DOI 10.1111/jpi.12162
   Zhang S, 2013, BIOTECH HISTOCHEM, V88, P281, DOI 10.3109/10520295.2013.769633
   Zhao Q, 2018, PANCREAS, V47, P884, DOI 10.1097/MPA.0000000000001082
   Zhao QH, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0777-2
   Zheng YS, 2019, ONCOTARGETS THER, V12, P10187, DOI 10.2147/OTT.S226140
   Zhiqin W, 2014, INTEST RES, V12, P194, DOI 10.5217/ir.2014.12.3.194
   Zhou B, 2019, J CELL MOL MED, V23, P5246, DOI 10.1111/jcmm.14399
   Zhou H., 2018, J PINEAL RES, V64
   Zhou N, 2019, BMC NEUROSCI, V20, DOI 10.1186/s12868-019-0545-1
   Zhu CY, 2018, DNA CELL BIOL, V37, P244, DOI 10.1089/dna.2017.4040
   Zou Duo-Bing, 2015, Asian Pac J Cancer Prev, V16, P5835
   Zou ZW, 2018, REDOX BIOL, V16, P226, DOI 10.1016/j.redox.2018.02.025
NR 220
TC 11
Z9 11
U1 1
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD NOV 5
PY 2020
VL 886
AR 173471
DI 10.1016/j.ejphar.2020.173471
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA OE6JJ
UT WOS:000580634600022
PM 32877658
DA 2022-04-25
ER

PT J
AU Moura, AF
   Lima, KSB
   Sousa, TS
   Marinho, JDB
   Pessoa, C
   Silveira, ER
   Pessoa, ODL
   Costa-Lotufo, LV
   Moraes, MO
   Araujo, AJ
AF Moura, A. F.
   Lima, K. S. B.
   Sousa, T. S.
   Marinho-Filho, J. D. B.
   Pessoa, C.
   Silveira, E. R.
   Pessoa, O. D. L.
   Costa-Lotufo, L. V.
   Moraes, M. O.
   Araujo, A. J.
TI In vitro antitumor effect of a lignan isolated from Combretum
   fruticosum, trachelogenin, in HCT-116 human colon cancer cells
SO TOXICOLOGY IN VITRO
LA English
DT Article
DE Lignans; Combretum fruticosum; Autophagy; Anticancer
ID COLORIMETRIC ASSAY; SIGNALING PATHWAY; GLIOMA-CELLS; AUTOPHAGY; DEATH;
   ACCUMULATION; HYDROLYSIS; INDUCTION; FRUIT
AB The use of natural products in therapeutics has been growing over the years. Lignans are compounds with large pharmaceutical use, which has aroused interest in the search for new drugs to treat diseases. The present study evaluated the cytotoxicity of (-)-trachelogenin, a dibenzylbutyrolactone type lignan isolated from Combretum fruticosum, against several tumor and non-tumor cell lines using the MTT assay and its possible mechanism of action. (-)-Trachelogenin showed IC50 values ranging of 0.8-32.4 mu M in SF-295 and HL-60 cell lines, respectively and IC50 values > 64 mu M in non-tumor cell lines. (-)-trachelogenin persistently induced autophagic cell death, with cytoplasmic vacuolization and formation of autophagosomes mediated by increasing LC3 activation and altering the expression levels of Beclin-1.
C1 [Moura, A. F.; Marinho-Filho, J. D. B.; Pessoa, C.; Costa-Lotufo, L. V.; Moraes, M. O.; Araujo, A. J.] Univ Fed Ceara, Dept Fisiol & Farmacol, BR-60430270 Fortaleza, Ceara, Brazil.
   [Lima, K. S. B.; Silveira, E. R.; Pessoa, O. D. L.] Univ Fed Ceara, Dept Quim Organ & Inorgan, BR-60451970 Fortaleza, Ceara, Brazil.
   [Lima, K. S. B.; Sousa, T. S.; Silveira, E. R.; Pessoa, O. D. L.] Univ Fed Ceara, Dept Quim Organ & Inorgan, BR-60021940 Fortaleza, Ceara, Brazil.
   [Lima, K. S. B.] Univ Estadual Ceara, Dept Quim, BR-60714903 Fortaleza, Ceara, Brazil.
   [Sousa, T. S.] Inst Fed Educ Ciencia & Tecnol Piaui, BR-6460000 Picos, PI, Brazil.
   [Marinho-Filho, J. D. B.; Araujo, A. J.] Univ Fed Piaui, Curso Med, BR-64200500 Parnaiba, PI, Brazil.
   [Costa-Lotufo, L. V.] Univ Sao Paulo, Dept Farmacol, BR-05508900 Sao Paulo, SP, Brazil.
RP Moura, AF (corresponding author), NPDM, Coronel Nunes Melo 1000, BR-60430270 Fortaleza, Ceara, Brazil.
EM andreafmoura@gmail.com; edil@ufc.br; odorico@ufc.br
RI Pessoa, Otilia DL/L-8863-2016; Araújo, Ana Jersia/D-1049-2019;
   Marinho-Filho, José Delano Barreto/D-1232-2019; Costa-Lotufo, Leticia
   V/D-4998-2014; Costa-Lotufo, Leticia/ABC-5742-2021
OI Pessoa, Otilia DL/0000-0002-1617-7586; Araújo, Ana
   Jersia/0000-0001-7182-7097; Marinho-Filho, José Delano
   Barreto/0000-0002-2493-6159; Costa-Lotufo, Leticia
   V/0000-0003-1861-5153; Costa-Lotufo, Leticia/0000-0003-1861-5153
CR American Cancer Society, 2016, KEY STAT COL CANC
   Bardhan Kankana, 2013, Cancers (Basel), V5, P676, DOI 10.3390/cancers5020676
   BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3
   Braga FC, 2007, FITOTERAPIA, V78, P353, DOI [10.1016/j.fitote.2007.02.007, 10.1016/J.fitote.2007.02.007]
   Chifenti Barbara, 2013, Clin Exp Reprod Med, V40, P33, DOI 10.5653/cerm.2013.40.1.33
   DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802
   Lima GRD, 2012, MOLECULES, V17, P9142, DOI 10.3390/molecules17089142
   Eloff JN, 2008, J ETHNOPHARMACOL, V119, P686, DOI 10.1016/j.jep.2008.07.051
   Geng Y, 2010, NEURO-ONCOLOGY, V12, P473, DOI 10.1093/neuonc/nop048
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Haeri Mohammad, 2012, J Ophthalmic Vis Res, V7, P45
   ICHIKAWA K, 1986, CHEM PHARM BULL, V34, P3514
   Institute Nacional do Cancer (INCA), 2016, EST CANC BRAS
   Isoda H, 2014, CHEM-BIOL INTERACT, V220, P269, DOI 10.1016/j.cbi.2014.07.006
   IWAKAMI S, 1992, CHEM PHARM BULL, V40, P1196, DOI 10.1248/cpb.40.1196
   JOHN LMD, 1992, J NAT PROD, V55, P1313, DOI 10.1021/np50087a022
   Kang K, 2007, BIOL PHARM BULL, V30, P2352, DOI 10.1248/bpb.30.2352
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Lee Kuo-Hsiung, 2003, Phytochemistry Reviews, V2, P341, DOI 10.1023/B:PHYT.0000045495.59732.58
   Lee W, 2015, SCI REP-UK, V5, DOI 10.1038/srep09701
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MACRAE WD, 1984, PHYTOCHEMISTRY, V23, P1207, DOI 10.1016/S0031-9422(00)80428-8
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   MELO JG, 2007, ACTA BOT BRAS, V21, P27
   Mervai Z, 2015, FITOTERAPIA, V100, P19, DOI 10.1016/j.fitote.2014.10.017
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Nascimento S.C., 1985, REV I ANTIBIOT U FED, V22, P19
   Paglin S, 2001, CANCER RES, V61, P439
   Paska C., 1996, TOXICOL LETT, V88, P104
   Qian XJ, 2016, J GEN VIROL, V97, P1134, DOI 10.1099/jgv.0.000432
   Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028
   SCHRODER HC, 1990, Z NATURFORSCH C, V45, P1215
   Serra CP, 2005, PHYTOMEDICINE, V12, P424, DOI 10.1016/j.phymed.2004.07.002
   Shin HS, 2015, BIOL PHARM BULL, V38, P1707, DOI 10.1248/bpb.b15-00332
   Solyomvary A, 2017, MINI-REV MED CHEM, V17, P1053, DOI 10.2174/1389557516666160614005828
   Solyomvary A, 2015, PROCESS BIOCHEM, V50, P2281, DOI 10.1016/j.procbio.2015.09.011
   Solyomvary A, 2014, NAT PROD RES, V28, P732, DOI 10.1080/14786419.2013.879473
   TRUMM S, 1989, Planta Medica, V55, P658, DOI 10.1055/s-2006-962248
   Umezawa Toshiaki, 2003, Wood Research, P27
   VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I
   Vijayakurup V, 2014, MOL BIOL REP, V41, P85, DOI 10.1007/s11033-013-2840-8
   Xia PY, 2013, EMBO J, V32, P2685, DOI 10.1038/emboj.2013.189
   Zhu CC, 2013, ACTA PHARM SIN B, V3, P109, DOI 10.1016/j.apsb.2013.02.004
NR 44
TC 11
Z9 11
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-2333
J9 TOXICOL IN VITRO
JI Toxicol. Vitro
PD MAR
PY 2018
VL 47
BP 129
EP 136
DI 10.1016/j.tiv.2017.11.014
PG 8
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA FX9HO
UT WOS:000426409400014
PM 29174024
DA 2022-04-25
ER

PT J
AU Hsuan, SW
   Chyau, CC
   Hung, HY
   Chen, JH
   Chou, FP
AF Hsuan, Shu-Wen
   Chyau, Charng-Cherng
   Hung, Hsiao-Yu
   Chen, Jing-Hsien
   Chou, Fen-Pi
TI The induction of apoptosis and autophagy by Wasabia japonica extract in
   colon cancer
SO EUROPEAN JOURNAL OF NUTRITION
LA English
DT Article
DE Apoptosis; Autophagy; Colon cancer; RAD001; Wasabia japonica
ID CELL-DEATH; IN-VITRO; PATHWAY; ISOTHIOCYANATE; EVEROLIMUS;
   IDENTIFICATION; COMBINATION; INHIBITION; EXPRESSION; TARGET
AB Wasabia japonica (wasabi) has been shown to exhibit properties of detoxification, anti-inflammation and the induction of apoptosis in cancer cells. This study aimed to investigate the molecular mechanism of the cytotoxicity of wasabi extract (WE) in colon cancer cells to evaluate the potential of wasabi as a functional food for chemoprevention.
   Colo 205 cells were treated with different doses of WE, and the cytotoxicity was analyzed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide. Apoptosis and autophagy were detected by 4',6-diamidino-2-phenylindole, 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethyl-imidacarbo-yanine iodide and staining for acidic vascular organelles (AVOs), along with Western blotting.
   The results demonstrated that WE induced the extrinsic pathway and mitochondrial death machinery through the activation of TNF-alpha, Fas-L, caspases, truncated Bid and cytochrome C. WE also induced autophagy by decreasing the phosphorylation of Akt and mTOR and promoting the expression of microtubule-associated protein 1 light chain 3-II and AVO formation. An in vivo xenograft model verified that tumor growth was delayed by WE treatment.
   Our studies revealed that WE exhibits anti-colon cancer properties through the induction of apoptosis and autophagy. These results provide support for the application of WE as a chemopreventive functional food and as a prospective treatment of colon cancer.
C1 [Hsuan, Shu-Wen; Hung, Hsiao-Yu; Chou, Fen-Pi] Chung Shan Med Univ, Coll Med, Inst Biochem & Biotechnol, Taichung 402, Taiwan.
   [Chyau, Charng-Cherng] Hung Kuang Univ, Biotechnol Res Inst, Taichung, Taiwan.
   [Chen, Jing-Hsien] Chung Shan Med Univ, Sch Nutr, Taichung 402, Taiwan.
   [Chen, Jing-Hsien; Chou, Fen-Pi] Chung Shan Med Univ, 110,Sec 1,Jiangou N Rd, Taichung 402, Taiwan.
   [Chou, Fen-Pi] Chung Shan Med Univ Hosp, Clin Lab, Taichung 40201, Taiwan.
RP Chen, JH; Chou, FP (corresponding author), Chung Shan Med Univ, 110,Sec 1,Jiangou N Rd, Taichung 402, Taiwan.
EM cjh0828@csmu.edu.tw; fpchou@csmu.edu.tw
FU National Science Council of TaiwanMinistry of Science and Technology,
   Taiwan [NSC 99-2632-B-040-001-MY3, NSC100-2313-B-040-002-MY3]
FX This study was supported by the Grants from the National Science Council
   of Taiwan (NSC 99-2632-B-040-001-MY3 and NSC100-2313-B-040-002-MY3).
CR Albert JM, 2006, MOL CANCER THER, V5, P1183, DOI 10.1158/1535-7163.MCT-05-0400
   Anto RJ, 2002, CARCINOGENESIS, V23, P143, DOI 10.1093/carcin/23.1.143
   Beretta GD, 2001, EUR J SURG ONCOL, V27, P595, DOI 10.1053/ejso.2001.1128
   Blazevic I, 2011, CHEM BIODIVERS, V8, P2310, DOI 10.1002/cbdv.201100169
   Bursch W, 2000, J CELL SCI, V113, P1189
   Chang YT, 2011, EUR J CLIN INVEST, V41, P84, DOI 10.1111/j.1365-2362.2010.02383.x
   Danovi D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011774
   Giannopoulou E, 2009, ANTICANCER RES, V29, P5077
   Hoyer-Hansen M, 2008, AUTOPHAGY, V4, P574, DOI 10.4161/auto.5921
   Jaeger PA, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-16
   Kelekar A, 2005, ANN NY ACAD SCI, V1066, P259, DOI 10.1196/annals.1363.015
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Lee YS, 2010, EVID-BASED COMPL ALT, V7, P459, DOI 10.1093/ecam/nen038
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Lin HH, 2007, CHEM-BIOL INTERACT, V165, P59, DOI 10.1016/j.cbi.2006.10.011
   Lin HM, 2007, J AGR FOOD CHEM, V55, P3620, DOI 10.1021/jf062406m
   Lin LT, 2010, VIROLOGY, V402, P1, DOI 10.1016/j.virol.2010.03.026
   Liu N, 2012, ENDOCR-RELAT CANCER, V19, P711, DOI 10.1530/ERC-12-0150
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   O'Reilly T, 2011, ANTI-CANCER DRUG, V22, P58, DOI 10.1097/CAD.0b013e3283400a20
   Pajak B, 2012, PHARMACOL REP, V64, P991
   Pajak Beata, 2004, Postepy Hig Med Dosw (Online), V58, P428
   Pedras MSC, 1998, PHYTOCHEMISTRY, V49, P1959, DOI 10.1016/S0031-9422(98)00424-5
   Rose P, 2000, CARCINOGENESIS, V21, P1983, DOI 10.1093/carcin/21.11.1983
   Shingu T, 2009, INT J CANCER, V124, P1060, DOI 10.1002/ijc.24030
   Singletary K, 2008, CANCER EPIDEM BIOMAR, V17, P1596, DOI 10.1158/1055-9965.EPI-07-2917
   SPIERS DE, 1984, J APPL PHYSIOL, V56, P240, DOI 10.1152/jappl.1984.56.1.240
   Stoner GD, 1997, ENVIRON HEALTH PERSP, V105, P945, DOI 10.2307/3433309
   Tai S, 2012, MOL CANCER THER, V11, P1320, DOI 10.1158/1535-7163.MCT-11-0954
   Tajima H, 1998, BIOSCI BIOTECH BIOCH, V62, P491, DOI 10.1271/bbb.62.491
   TRAGANOS F, 1994, METHOD CELL BIOL, V41, P185
   Uto T, 2005, BIOCHEM PHARMACOL, V70, P1211, DOI 10.1016/j.bcp.2005.07.011
   Wang JR, 2009, J BIOL CHEM, V284, P21412, DOI 10.1074/jbc.M109.026013
   Wang N, 2010, J CELL BIOCHEM, V111, P1426, DOI 10.1002/jcb.22869
   Watanabe M, 2003, PHYTOCHEMISTRY, V62, P733, DOI 10.1016/S0031-9422(02)00613-1
   Weil MJ, 2005, J AGR FOOD CHEM, V53, P1440, DOI 10.1021/jf048264i
   Weil MJ, 2004, NUTR CANCER, V48, P207, DOI 10.1207/s15327914nc4802_11
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Wu C.H., 2007, J CANC MOL, V3, P15
   Yano T, 2000, CANCER LETT, V155, P115, DOI 10.1016/S0304-3835(00)00364-5
   Zimmermann NS, 2007, MOL NUTR FOOD RES, V51, P1537, DOI 10.1002/mnfr.200700103
NR 43
TC 14
Z9 14
U1 1
U2 22
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1436-6207
EI 1436-6215
J9 EUR J NUTR
JI Eur. J. Nutr.
PD MAR
PY 2016
VL 55
IS 2
BP 491
EP 503
DI 10.1007/s00394-015-0866-5
PG 13
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA DF3RD
UT WOS:000371262400006
PM 25720497
DA 2022-04-25
ER

PT J
AU Lee, HY
   Chung, KJ
   Hwang, IH
   Gwak, J
   Park, S
   Ju, BG
   Yun, E
   Kim, DE
   Chung, YH
   Na, M
   Song, GY
   Oh, S
AF Lee, Hyun-Young
   Chung, Kyu Jin
   Hwang, In Hyun
   Gwak, Jungsuk
   Park, Seoyoung
   Ju, Bong Gun
   Yun, Eunju
   Kim, Dong-Eun
   Chung, Young-Hwa
   Na, MinKyun
   Song, Gyu-Yong
   Oh, Sangtaek
TI Activation of p53 with Ilimaquinone and Ethylsmenoquinone, Marine Sponge
   Metabolites, Induces Apoptosis and Autophagy in Colon Cancer Cells
SO MARINE DRUGS
LA English
DT Article
DE ilimaquinone; ethylsmenoquinone; p53; colon cancer; apoptosis; autophagy
ID BETA-CATENIN DEGRADATION; IN-VITRO; PATHWAY; PHOSPHORYLATION;
   PROLIFERATION; INDUCTION; COMPLEX; SUPPRESS; BINDING; ARREST
AB The tumor suppressor, p53, plays an essential role in the cellular response to stress through regulating the expression of genes involved in cell cycle arrest, apoptosis and autophagy. Here, we used a cell-based reporter system for the detection of p53 response transcription to identify the marine sponge metabolites, ilimaquinone and ethylsmenoquinone, as activators of the p53 pathway. We demonstrated that ilimaquinone and ethylsmenoquinone efficiently stabilize the p53 protein through promotion of p53 phosphorylation at Ser15 in both HCT116 and RKO colon cancer cells. Moreover, both compounds upregulate the expression of p21(WAF1/CIP1), a p53-dependent gene, and suppress proliferation of colon cancer cells. In addition, ilimaquinone and ethylsmenoquinone induced G(2)/M cell cycle arrest and increased caspase-3 cleavage and the population of cells that positively stained with Annexin V-FITC, both of which are typical biochemical markers of apoptosis. Furthermore, autophagy was elicited by both compounds, as indicated by microtubule-associated protein 1 light chain 3 (LC3) puncta formations and LC3-II turnover in HCT116 cells. Our findings suggest that ilimaquinone and ethylsmenoquinone exert their anti-cancer activity by activation of the p53 pathway and may have significant potential as chemo-preventive and therapeutic agents for human colon cancer.
C1 [Lee, Hyun-Young; Park, Seoyoung; Oh, Sangtaek] Kookmin Univ, Dept Bio & Fermentat Convergence Technol, Seoul 136702, South Korea.
   [Chung, Kyu Jin; Yun, Eunju; Na, MinKyun; Song, Gyu-Yong] Chungnam Natl Univ, Coll Pharm, Taejon 305764, South Korea.
   [Hwang, In Hyun] Univ Iowa, Dept Chem, Iowa City, IA 52242 USA.
   [Gwak, Jungsuk; Ju, Bong Gun] Sogang Univ, Dept Life Sci, Seoul 121742, South Korea.
   [Kim, Dong-Eun] Konkuk Univ, Dept Biosci & Biotechnol, Seoul 143701, South Korea.
   [Chung, Young-Hwa] Pusan Natl Univ, Dept Cognomechatron Engn, BK21, Pusan 609735, South Korea.
RP Na, M (corresponding author), Chungnam Natl Univ, Coll Pharm, Taejon 305764, South Korea.
EM IHyunYoungg@gmail.com; doccap@naver.com; inhyun-hwang@uiowa.edu;
   dmulder@dreamwiz.com; qkr092@nate.com; bgju@sogang.ac.kr;
   yunej@cnu.ac.kr; kimde@konkuk.ac.kr; younghc@pusan.ac.kr;
   mkna@cnu.ac.kr; gysong@cnu.ac.kr; ohsa@kookmin.ac.kr
OI Na, MinKyun/0000-0002-4865-6506; Song, Gyu Yong/0000-0001-6058-5790;
   Kim, Dong-Eun/0000-0001-6545-8387
FU Basic Science Research Program [2013062764, 2014R1A2A2A01006793];
   Fundamental Technology Program through the National Research Foundation
   of Korea (NRF) - Ministry of Education, Science and Technology
   [2012M3A9B2028335]
FX This work was supported by the Basic Science Research Program
   (2013062764; 2014R1A2A2A01006793) and the Fundamental Technology Program
   (2012M3A9B2028335) through the National Research Foundation of Korea
   (NRF) funded by the Ministry of Education, Science and Technology.
CR Altman BJ, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008763
   Amado NG, 2014, J BIOL CHEM, V289, P35456, DOI 10.1074/jbc.M114.621599
   Anderson CNG, 1999, J NEUROSCI, V19, P664
   Bae SK, 2011, BIOCHEM BIOPH RES CO, V409, P75, DOI 10.1016/j.bbrc.2011.04.108
   Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303
   Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6
   Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543
   Chiu SC, 2013, PROSTATE CANCER P D, V16, P315, DOI 10.1038/pcan.2013.38
   Do MT, 2014, FOOD CHEM TOXICOL, V71, P51, DOI 10.1016/j.fct.2014.06.001
   Du L, 2013, J NAT PROD, V76, P1175, DOI 10.1021/np400320r
   Fukuda R, 2013, J BIOL CHEM, V288, P16117, DOI 10.1074/jbc.M112.442442
   Gump JM, 2011, TRENDS CELL BIOL, V21, P387, DOI 10.1016/j.tcb.2011.03.007
   Haggar Fatima A, 2009, Clin Colon Rectal Surg, V22, P191, DOI 10.1055/s-0029-1242458
   Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615
   Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723
   Jaamaa S, 2010, CANCER RES, V70, P8630, DOI 10.1158/0008-5472.CAN-10-0937
   Jackson CL, 2009, J CELL SCI, V122, P443, DOI 10.1242/jcs.032581
   Kim JH, 2014, FOOD CHEM TOXICOL, V67, P87, DOI 10.1016/j.fct.2014.02.019
   Kim TD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034618
   Kochanowska AJ, 2008, J NAT PROD, V71, P186, DOI 10.1021/np070371u
   Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784
   Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723
   Livesey KM, 2012, CANCER RES, V72, P1996, DOI 10.1158/0008-5472.CAN-11-2291
   Loughery J, 2014, NUCLEIC ACIDS RES, V42, P7664, DOI 10.1093/nar/gku501
   McLeland CB, 2011, METHODS MOL BIOL, V697, P199, DOI 10.1007/978-1-60327-198-1_21
   Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8
   Moos PJ, 2000, P NATL ACAD SCI USA, V97, P9215, DOI 10.1073/pnas.160241897
   Nieminen AI, 2013, P NATL ACAD SCI USA, V110, pE1839, DOI 10.1073/pnas.1208530110
   Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532
   Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412
   Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107
   Park S, 2006, MOL PHARMACOL, V70, P960, DOI 10.1124/mol.106.024729
   Park S, 2014, MAR DRUGS, V12, P3231, DOI 10.3390/md12063231
   Roura S, 2003, BIOCHEM BIOPH RES CO, V309, P830, DOI 10.1016/j.bbrc.2003.08.075
   Speidel D, 2010, TRENDS CELL BIOL, V20, P14, DOI 10.1016/j.tcb.2009.10.002
   Sun Xiao-Xin, 2014, World J Biol Chem, V5, P75, DOI 10.4331/wjbc.v5.i2.75
   Thanendrarajan S, 2011, Leuk Res Treatment, V2011, P329572, DOI 10.4061/2011/329572
   Tzifi Flora, 2012, Adv Hematol, V2012, P524308, DOI 10.1155/2012/524308
   Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037
   Yang J, 2003, CARCINOGENESIS, V24, P1571, DOI 10.1093/carcin/bgg137
NR 40
TC 32
Z9 32
U1 0
U2 10
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1660-3397
J9 MAR DRUGS
JI Mar. Drugs
PD JAN
PY 2015
VL 13
IS 1
BP 543
EP 557
DI 10.3390/md13010543
PG 15
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AZ7MO
UT WOS:000348403200030
PM 25603347
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Francipane, MG
   Lagasse, E
AF Francipane, Maria Giovanna
   Lagasse, Eric
TI Selective targeting of human colon cancer stem-like cells by the mTOR
   inhibitor Torin-1
SO ONCOTARGET
LA English
DT Article
DE colorectal cancer; cancer stem cells; mTOR; apoptosis
ID EXTENDS LIFE-SPAN; MAMMALIAN TARGET; RAPAMYCIN MTOR; LYMPH-NODE;
   PHOSPHORYLATION; ACTIVATION; EXPRESSION; PATHWAY; KINASE; RICTOR
AB Metastatic colorectal cancer (CRC) is incurable for most patients. Since mammalian target of rapamycin (mTOR) has been suggested as a crucial modulator of tumor biology, we aimed at evaluating the effectiveness of mTOR targeting for CRC therapy. To this purpose, we analyzed mTOR expression and the effect of mTOR inhibition in cancer stem-like cells isolated from three human metastatic CRCs (CoCSCs).
   CoCSCs exhibited a strong mTOR complex 2 (mTORC2) expression, and a rare expression of mTOR complex 1 (mTORC1). This latter correlated with differentiation, being expressed in CoCSC-derived xenografts. We indicate Serum/glucocorticoid-regulated kinase 1 (SGK1) as the possible main mTORC2 effector in CoCSCs, as highlighted by the negative effect on cancer properties following its knockdown. mTOR inhibitors affected CoCSCs differently, resulting in proliferation, autophagy as well as apoptosis induction. The apoptosis-inducing mTOR inhibitor Torin-1 hindered growth, motility, invasion, and survival of CoCSCs in vitro, and suppressed tumor growth in vivo with a concomitant reduction in vessel formation. Torin-1 also affected the expression of markers for cell proliferation, angio-/lympho-genesis, and stemness in vivo, including Ki67, DLL1, DLL4, Notch, Lgr5, and CD44. Importantly, Torin-1 did not affect the survival of normal colon stem cells in vivo, suggesting its selectivity towards cancer cells. Thus, we propose Torin-1 as a powerful drug candidate for metastatic CRC therapy.
C1 [Francipane, Maria Giovanna; Lagasse, Eric] Univ Pittsburgh, Sch Med, McGowan Inst Regenerat Med, Pittsburgh, PA 15260 USA.
   [Francipane, Maria Giovanna; Lagasse, Eric] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA.
   [Francipane, Maria Giovanna] RiMed Fdn, Palermo, Italy.
RP Lagasse, E (corresponding author), Univ Pittsburgh, Sch Med, McGowan Inst Regenerat Med, Pittsburgh, PA 15260 USA.
EM Lagasse@pitt.edu
RI Francipane, Maria Giovanna/D-6537-2014
OI Francipane, Maria Giovanna/0000-0002-7194-7918
FU Ri.MED foundation
FX This work was supported by Ri.MED foundation (MGF). The authors thank
   Lynda Guzik for help with cell cycle analysis and cell sorting, and for
   English editing, and Julie Chandler for providing qRT-PCR primers and
   human fetal intestinal epithelial cells.
CR Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265
   Asao T, 2000, DIS COLON RECTUM, V43, P1250, DOI 10.1007/BF02237430
   Baba Y, 2011, CANCER-AM CANCER SOC, V117, P1399, DOI 10.1002/cncr.25630
   Battelli Chiara, 2011, Therapy, V8, P359
   Blaser B, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-86
   Cai Z, 2013, ANN SURG ONCOLOGY
   Carlson CJ, 2004, BIOCHEM BIOPH RES CO, V316, P533, DOI 10.1016/j.bbrc.2004.02.082
   Castilho RM, 2009, CELL STEM CELL, V5, P279, DOI 10.1016/j.stem.2009.06.017
   Comas M, 2012, AGING-US, V4, P715, DOI 10.18632/aging.100496
   Cybulski N, 2009, TRENDS BIOCHEM SCI, V34, P620, DOI 10.1016/j.tibs.2009.09.004
   Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104
   Day FL, 2013, CLIN CANCER RES, V19, P3285, DOI 10.1158/1078-0432.CCR-12-3614
   Easley CA, 2010, CELL REPROGRAM, V12, P263, DOI 10.1089/cell.2010.0011
   Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802
   Foster KG, 2010, J BIOL CHEM, V285, P14071, DOI 10.1074/jbc.R109.094003
   Francipane Maria Giovanna, 2013, Curr Pathobiol Rep, V1, P111
   Francipane MG, 2013, CANC TARGETED DRUG D
   Fujishita T, 2008, P NATL ACAD SCI USA, V105, P13544, DOI 10.1073/pnas.0800041105
   Galandiuk S, 2000, DIS COLON RECTUM, V43, P1254, DOI 10.1007/BF02237431
   Garcia-Martinez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668
   Garrett JT, 2011, ONCOTARGET, V2, P1314
   Gulhati P, 2009, CLIN CANCER RES, V15, P7207, DOI 10.1158/1078-0432.CCR-09-1249
   Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI 10.3322/caac.20073
   Julien LA, 2010, MOL CELL BIOL, V30, P908, DOI 10.1128/MCB.00601-09
   Komarova EA, 2012, AGING-US, V4, P709, DOI 10.18632/aging.100498
   Komori J, 2012, NAT BIOTECHNOL, V30, P976, DOI 10.1038/nbt.2379
   Liu QS, 2011, J MED CHEM, V54, P1473, DOI 10.1021/jm101520v
   Liu QS, 2010, J MED CHEM, V53, P7146, DOI 10.1021/jm101144f
   Maetzel D, 2009, NAT CELL BIOL, V11, P162, DOI 10.1038/ncb1824
   Martelli AM, 2012, ONCOTARGET, V3, P371, DOI 10.18632/oncotarget.477
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Odoux C, 2008, CANCER RES, V68, P6932, DOI 10.1158/0008-5472.CAN-07-5779
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Roper J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025132
   Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054
   Shao JY, 2004, CANCER RES, V64, P229, DOI 10.1158/0008-5472.CAN-03-1859
   Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401
   Tyler WA, 2009, J NEUROSCI, V29, P6367, DOI 10.1523/JNEUROSCI.0234-09.2009
   Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012
   Visvader JE, 2006, CANCER RES, V66, P9798, DOI 10.1158/0008-5472.CAN-06-2254
   Wang YH, 2008, J BIOL CHEM, V283, P9454, DOI 10.1074/jbc.M707962200
   Winter MJ, 2003, EXP CELL RES, V285, P50, DOI 10.1016/S0014-4827(02)00045-9
   Yan MH, 2011, VASC CELL, V3, DOI 10.1186/2045-824X-3-17
   Yang ZJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028405
   Yu YH, 2011, SCIENCE, V332, P1322, DOI 10.1126/science.1199484
   Zhang YJ, 2009, ANN SURG ONCOL, V16, P2617, DOI 10.1245/s10434-009-0555-9
   Zhang YJ, 2012, CELL CYCLE, V11, P594, DOI 10.4161/cc.11.3.19096
   Zhou HY, 2010, ANTI-CANCER AGENT ME, V10, P571, DOI 10.2174/187152010793498663
NR 51
TC 66
Z9 69
U1 0
U2 12
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD NOV
PY 2013
VL 4
IS 11
BP 1948
EP 1962
DI 10.18632/oncotarget.1310
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA 261KW
UT WOS:000327664900012
PM 24185040
OA Green Published, Green Submitted, hybrid
DA 2022-04-25
ER

PT J
AU Yang, WL
   Perillo, W
   Liou, D
   Marambaud, P
   Wang, P
AF Yang, Weng-Lang
   Perillo, William
   Liou, Deanna
   Marambaud, Philippe
   Wang, Ping
TI AMPK inhibitor compound C suppresses cell proliferation by induction of
   apoptosis and autophagy in human colorectal cancer cells
SO JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Article
DE AMPK; compound C; apoptosis; autophagy; colorectal cancer
ID ACTIVATED PROTEIN-KINASE; DOWN-REGULATION; IN-VITRO;
   FLUOROURACIL-LEUCOVORIN; SURVIVIN; GROWTH; METFORMIN; P53; CARCINOMA;
   MECHANISM
AB Background and Objectives AMP-activated protein kinase (AMPK) is a main regulator of energy metabolism through the inhibition of biosynthetic pathways and enhancement of ATP-generating pathways. However, targeting AMPK as anti-tumor therapy remains controversial. In this study, we examined the effect of compound C, a small molecule inhibitor of AMPK, on the proliferation of several human colorectal cancer cell lines with diverse characteristics. Methods Four human colorectal cancer cell lines (HCT116, DLD-1, SW480, and KM12C) were treated with compound C. Cell viability was determined by MTS assay. Cell cycle prolife was analyzed by flow cytometry. Acidic vesicular organelles were detected by acridine orange staining. Protein levels were measured by western blotting. Results Compound C inhibited the growth of four cell lines in a dose-dependent manner and caused G2/M arrest. Compound C increased sub-G1 cell population and induced chromatin condensation and cleavage of PARP in HCT116 and KM12C cells, while it induced acidic vesicular formation and conversion of LC3-I to autophagosome-associated LC3-II in DLD-1 and SW480 cells. Survivin, an anti-apoptotic protein, was down-regulated in all cell lines treated with compound C. Conclusions Compound C induces apoptotic or autophagic death in colorectal cancer cells and the preferred death mode is cell type-dependent. J. Surg. Oncol. 2012; 106:680688. (c) 2012 Wiley Periodicals, Inc.
C1 [Yang, Weng-Lang] Feinstein Inst Med Res, Dept Surg, Surg Res Lab, Manhasset, NY 11030 USA.
   [Yang, Weng-Lang; Perillo, William; Liou, Deanna; Wang, Ping] N Shore Univ Hosp, Dept Surg, Manhasset, NY USA.
   [Yang, Weng-Lang; Perillo, William; Liou, Deanna; Wang, Ping] Long Isl Jewish Med Ctr, Manhasset, NY USA.
   [Marambaud, Philippe] Feinstein Inst Med Res, Litwin Zuker Res Ctr Study Alzheimers Dis, Manhasset, NY 11030 USA.
RP Yang, WL (corresponding author), Feinstein Inst Med Res, Dept Surg, Surg Res Lab, 350 Community Dr, Manhasset, NY 11030 USA.
EM wlyang@nshs.edu
OI Marambaud, Philippe/0000-0002-8983-1497; Wang, Ping/0000-0002-1557-0394
FU Faculty Practice Plan Research Fund of North Shore-Long Island Jewish
   Health System; National Institutes of HealthUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [GM057468]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of General Medical Sciences (NIGMS)
   [R01GM057468] Funding Source: NIH RePORTER
FX Grant sponsor: Faculty Practice Plan Research Fund of North Shore-Long
   Island Jewish Health System; Grant sponsor: National Institutes of
   Health grant; Grant number: GM057468.
CR Ahn HJ, 2004, J CELL BIOCHEM, V91, P1043, DOI 10.1002/jcb.20006
   Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917
   Baselga J, 2001, EUR J CANCER, V37, pS16
   Baumann P, 2007, ANTI-CANCER DRUG, V18, P405, DOI 10.1097/CAD.0b013e32801416b6
   Ben Sahra I, 2008, ONCOGENE, V27, P3576, DOI 10.1038/sj.onc.1211024
   Bowker SL, 2006, DIABETES CARE, V29, P254, DOI 10.2337/diacare.29.02.06.dc05-1558
   Buzzai M, 2007, CANCER RES, V67, P6745, DOI 10.1158/0008-5472.CAN-06-4447
   Cheung CHA, 2011, FRONT BIOSCI-LANDMRK, V16, P952, DOI 10.2741/3728
   Chiou SK, 2011, BIOCHEM PHARMACOL, V81, P1317, DOI 10.1016/j.bcp.2011.03.019
   CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x
   Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7
   Fong YM, 1999, SEMIN ONCOL, V26, P514
   Fujiwara K, 2008, J BIOL CHEM, V283, P388, DOI 10.1074/jbc.M611043200
   Galluzzi L, 2008, CURR MOL MED, V8, P78
   Giacchetti S, 2000, J CLIN ONCOL, V18, P136, DOI 10.1200/JCO.2000.18.1.136
   Grothey A, 2004, J CLIN ONCOL, V22, P1209, DOI 10.1200/JCO.2004.11.037
   Grothey A, 2006, CANCER J, V14, P170
   Guo DL, 2009, P NATL ACAD SCI USA, V106, P12932, DOI 10.1073/pnas.0906606106
   HA J, 1994, J BIOL CHEM, V269, P22162
   Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540
   Jang JH, 2010, EXP CELL RES, V316, P2194, DOI 10.1016/j.yexcr.2010.04.028
   Jin JF, 2009, J LIPID RES, V50, P2389, DOI 10.1194/jlr.M900119-JLR200
   Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295
   Jung SN, 2009, EXP CELL RES, V315, P2433, DOI 10.1016/j.yexcr.2009.05.018
   Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1
   Kim HS, 2008, J BIOL CHEM, V283, P3731, DOI 10.1074/jbc.M704432200
   Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005
   Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06
   Lechler P, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-120
   Lens SMA, 2006, CURR OPIN CELL BIOL, V18, P616, DOI 10.1016/j.ceb.2006.08.016
   Liu ZH, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-20
   Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Morselli E, 2008, CELL CYCLE, V7, P3056, DOI 10.4161/cc.7.19.6751
   Paglin S, 2001, CANCER RES, V61, P439
   Park HU, 2009, MOL CANCER THER, V8, P733, DOI 10.1158/1535-7163.MCT-08-0631
   Robert G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007889
   Roca H, 2008, J BIOL CHEM, V283, P25057, DOI 10.1074/jbc.M801073200
   Rochette PJ, 2005, J MOL BIOL, V352, P44, DOI 10.1016/j.jmb.2005.06.033
   Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302
   Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676
   SULLIVAN JE, 1994, FEBS LETT, V353, P33, DOI 10.1016/0014-5793(94)01006-4
   Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147
   Vucicevic L, 2011, AUTOPHAGY, V7, P40, DOI 10.4161/auto.7.1.13883
   Vucicevic L, 2009, BIOCHEM PHARMACOL, V77, P1684, DOI 10.1016/j.bcp.2009.03.005
   Wang W, 2009, ACTA PHYSIOL, V196, P55, DOI 10.1111/j.1748-1716.2009.01980.x
   Warburg O, 1923, BIOCHEM Z, V142, P317
   White E, 2008, AUTOPHAGY, V4, P399, DOI 10.4161/auto.5907
   Woodard J, 2010, CANCER BIOL THER, V10, P1169, DOI 10.4161/cbt.10.11.13629
   Yang XD, 1999, CANCER RES, V59, P1236
   Zakikhani M, 2006, CANCER RES, V66, P10269, DOI 10.1158/0008-5472.CAN-06-1500
   Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505
NR 53
TC 46
Z9 48
U1 0
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-4790
EI 1096-9098
J9 J SURG ONCOL
JI J. Surg. Oncol.
PD NOV
PY 2012
VL 106
IS 6
BP 680
EP 688
DI 10.1002/jso.23184
PG 9
WC Oncology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Surgery
GA 026CJ
UT WOS:000310249900006
PM 22674626
DA 2022-04-25
ER

PT J
AU Chiacchiera, F
   Grossi, V
   Cappellari, M
   Peserico, A
   Simonatto, M
   Germani, A
   Russo, S
   Moyer, MP
   Resta, N
   Murzilli, S
   Simone, C
AF Chiacchiera, Fulvio
   Grossi, Valentina
   Cappellari, Marianna
   Peserico, Alessia
   Simonatto, Marta
   Germani, Aldo
   Russo, Silvana
   Moyer, Mary P.
   Resta, Nicoletta
   Murzilli, Stefania
   Simone, Cristiano
TI Blocking p38/ERK crosstalk affects colorectal cancer growth by inducing
   apoptosis in vitro and in preclinical mouse models
SO CANCER LETTERS
LA English
DT Article
DE Colorectal cancer; Cell death; p38; ERK; Animal models
ID ACTIVATED PROTEIN-KINASE; MAPK SIGNALING PATHWAYS; DEPENDENT REGULATION;
   CELL PROLIFERATION; AMPK-FOXO3A AXIS; HUMAN BREAST; P38-ALPHA; COLON;
   INHIBITORS; MUTATIONS
AB We recently demonstrated that p38 alpha is required to maintain colorectal cancer (CRC) metabolism, as its inhibition leads to FoxO3A activation, autophagy, cell death, and tumor growth reduction both in vitro and in vivo. Here we show that inhibition of p38 alpha is followed by TRAIL-mediated activation of caspase-8 and FoxO3A-dependent HER3 upregulation with consequent overactivation of the MEK-ERK1/2 survival pathway. p38 alpha and MEK combined inhibition specifically induces apoptosis by enabling TRAIL signaling propagation through t-Bid and caspase-3, and fosters cell death in CRC cells and preclinical mouse models. Current MEK1-directed pharmacological strategies could thus be exploited, in combination with p38 alpha inhibition, to develop new approaches for CRC treatment. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Chiacchiera, Fulvio; Grossi, Valentina; Cappellari, Marianna; Peserico, Alessia; Germani, Aldo; Simone, Cristiano] Consorzio Mario Negri Sud, Dept Translat Pharmacol, Lab Signal Dependent Transcript, I-66030 Santa Maria Imbaro, CH, Italy.
   [Simonatto, Marta] IRCCS Fdn Santa Lucia, Dulbecco Telethon Inst, I-00143 Rome, Italy.
   [Simonatto, Marta] European Brain Res Inst, I-00143 Rome, Italy.
   [Russo, Silvana] Univ Bari, Dept Pathol Anat, I-70124 Bari, Italy.
   [Moyer, Mary P.] INCELL Corp, San Antonio, TX 78249 USA.
   [Resta, Nicoletta; Simone, Cristiano] Univ Bari, DIM, Div Med Genet, I-70124 Bari, Italy.
   [Murzilli, Stefania] Consorzio Mario Negri Sud, Dept Translat Pharmacol, Lab Lipid Metab & Canc, I-66030 Santa Maria Imbaro, CH, Italy.
   [Murzilli, Stefania] Consorzio Mario Negri Sud, Dept Translat Pharmacol, Anim Care Facil, I-66030 Santa Maria Imbaro, CH, Italy.
RP Chiacchiera, F (corresponding author), Consorzio Mario Negri Sud, Dept Translat Pharmacol, Lab Signal Dependent Transcript, Via Nazl 8-A, I-66030 Santa Maria Imbaro, CH, Italy.
EM fulvio.chiacchiera@ieo.eu; simone@negrisud.it
RI GROSSI, Valentina/O-6546-2019; Chiacchiera, Fulvio/ABD-6137-2020;
   Simone, Cristiano/K-3452-2018; Simonatto, Marta/AAW-3042-2020;
   Chiacchiera, Fulvio/K-6740-2016; Grossi, Valentina/K-9821-2016; Resta,
   Nicoletta/I-8424-2018
OI GROSSI, Valentina/0000-0003-3843-1618; Simone,
   Cristiano/0000-0002-2628-7658; Chiacchiera, Fulvio/0000-0003-3830-2090;
   Grossi, Valentina/0000-0003-3843-1618; Resta,
   Nicoletta/0000-0001-8640-5532; Simonatto, Marta/0000-0002-3617-4278;
   Peserico, Alessia/0000-0003-2025-2419
FU FIRC fellowshipFondazione AIRC per la ricerca sul cancro; 'Fondazione
   Negri Sud' fellowship; Italian Association for Cancer Research
   AIRCFondazione AIRC per la ricerca sul cancro [IG10177]
FX We thank Dr. Francesco Paolo Jori for his helpful discussion and
   editorial assistance, Prof. Bert Vogelstein for kindly providing Hct-116
   wt and Bax null cells, Dr. Francesca De Marchi for the anti-LC3
   antibody, MT Ciencioni and Dr. Giovanna Forte for technical assistance.
   Dr. Chiacchiera is supported by a FIRC fellowship, Dr. Grossi by a
   'Fondazione Negri Sud' fellowship. This work was partially supported by
   a 'My First Grant 2007' and an 'Investigator Grant 2010' (IG10177) (to
   Dr. Simone) from the Italian Association for Cancer Research AIRC.
CR Adam AP, 2009, CANCER RES, V69, P5664, DOI 10.1158/0008-5472.CAN-08-3820
   Bakin AV, 2002, J CELL SCI, V115, P3193
   Balmanno K, 2009, CELL DEATH DIFFER, V16, P368, DOI 10.1038/cdd.2008.148
   Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637
   Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031
   Chiacchiera F, 2009, CELL DEATH DIFFER, V16, P1203, DOI 10.1038/cdd.2009.36
   Chiacchiera F, 2008, CANCER LETT, V265, P16, DOI 10.1016/j.canlet.2008.02.061
   Chiacchiera F, 2010, CELL CYCLE, V9, P1091, DOI 10.4161/cc.9.6.11035
   Chiacchiera F, 2009, AUTOPHAGY, V5, P1030, DOI 10.4161/auto.5.7.9252
   Comes F, 2007, CELL DEATH DIFFER, V14, P693, DOI 10.1038/sj.cdd.4402076
   Cuadrado A, 2010, BIOCHEM J, V429, P403, DOI 10.1042/BJ20100323
   De Robertis Mariangela, 2011, J Carcinog, V10, P9, DOI 10.4103/1477-3163.78279
   Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5
   Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013
   Emerling BM, 2005, MOL CELL BIOL, V25, P4853, DOI 10.1128/MCB.25.12.4853-4862.2005
   Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6
   Halawani D, 2004, ONCOGENE, V23, P3726, DOI 10.1038/sj.onc.1207422
   Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833
   Hsieh YH, 2007, CANCER RES, V67, P4320, DOI 10.1158/0008-5472.CAN-06-2486
   Hui LJ, 2007, NAT GENET, V39, P741, DOI 10.1038/ng2033
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Junttila MR, 2007, ONCOGENE, V26, P5267, DOI 10.1038/sj.onc.1210332
   Junttila MR, 2008, FASEB J, V22, P954, DOI 10.1096/fj.06-7859rev
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Kim MS, 2003, CANCER RES, V63, P5454
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1
   Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006
   Lee MR, 2005, CURR MED CHEM, V12, P2979, DOI 10.2174/092986705774462914
   Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013
   Paillas S, 2011, CANCER RES, V71, P1041, DOI 10.1158/0008-5472.CAN-10-2726
   Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200
   Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902
   Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967
   Rinehart J, 2004, J CLIN ONCOL, V22, P4456, DOI 10.1200/JCO.2004.01.185
   Rustgi AK, 2007, GENE DEV, V21, P2525, DOI 10.1101/gad.1593107
   Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533
   Segal NH, 2009, ANNU REV MED, V60, P207, DOI 10.1146/annurev.med.60.041807.132435
   Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304
   Son JK, 2010, CELL DEATH DIFFER, V17, P1288, DOI 10.1038/cdd.2010.9
   Thompson N, 2005, CURR OPIN PHARMACOL, V5, P350, DOI 10.1016/j.coph.2005.04.007
   Ventura JJ, 2007, NAT GENET, V39, P750, DOI 10.1038/ng2037
   Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694
   Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232
   Wen HC, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001684
   Wickenden JA, 2008, ONCOGENE, V27, P7150, DOI 10.1038/onc.2008.335
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Yang SY, 2011, INT J ONCOL, V38, P1695, DOI 10.3892/ijo.2011.982
   Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989
NR 48
TC 35
Z9 37
U1 0
U2 20
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD NOV 1
PY 2012
VL 324
IS 1
BP 98
EP 108
DI 10.1016/j.canlet.2012.05.006
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 987MC
UT WOS:000307420200011
PM 22579651
DA 2022-04-25
ER

PT J
AU Deng, MZ
   Zhang, WZ
   Yuan, LL
   Tan, JQ
   Chen, ZH
AF Deng, Minzi
   Zhang, Weizhi
   Yuan, Lingling
   Tan, Jieqiong
   Chen, Zhihong
TI HIF-1a regulates hypoxia-induced autophagy via translocation of ANKRD37
   in colon cancer
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Colon cancer; Autophagy; ANKRD37; HIF-1a; Hypoxia
ID CELL-SURVIVAL; GENE; PROTEINS; UBIQUITINATION; BECLIN-1; REPEATS; ZNF76
AB Autophagy is a basic catabolic response that eukaryotic cells use to degrade unnecessary or dysfunctional cellular components in an orderly and regulated manner. It plays important roles in maintaining cellular homeostasis, energy homeostasis, response to environmental stimuli, and the development of cancer. In solid tumors, hypoxia induces an increased HIF-1a that activates autophagy. However, the exact mechanism by which induced HIF-1a stimulates autophagy in cancer cells remains elusive. In the present study, we confirmed that ANKRD37 is upregulated in colon cancer tissue. Moreover, the higher expression level of ANKRD37 is related to a poorer survival rate. Using RNA interference, immunoblot, and immunofluorescence, we discovered that in cancer cell line RKO, hypoxia-induced HIF-1a regulates autophagy activity by increasing ANKRD37 level. In addition, intranuclear ANKRD37 played an important role in the regulation of hypoxia-induced autophagy. The translocation of ANKRD37 into cell nuclear is required for promoting cell growth and HIF-1a induced autophagy. These findings provide new insights to understand the hypoxia regulation mechanisms and the role of autophagy in cancer development.
C1 [Deng, Minzi] Cent South Univ, Xiangya Hosp 3, Dept Gastroenterol, Changsha, Hunan, Peoples R China.
   [Deng, Minzi] Hunan Key Lab Nonresolving Inflammat & Canc, Changsha, Hunan, Peoples R China.
   [Zhang, Weizhi] CentralSouth Univ, Xiangya Hosp 2, Dept Cardiovasc Surg, Changsha, Hunan, Peoples R China.
   [Yuan, Lingling] Hubei Univ Med, Taihe Hosp, Shiyan 442000, Hubei, Peoples R China.
   [Tan, Jieqiong] Cent South Univ, Ctr Med Genet, Sch Life Sci, Changsha, Hunan, Peoples R China.
   [Chen, Zhihong] Hunan Normal Univ, Hunan Prov Peoples Hosp, Affiliated Hosp 1, Dept Pathol, Changsha, Hunan, Peoples R China.
RP Chen, ZH (corresponding author), Peoples Hosp Hunan Prov, Dept Pathol, 61 Jiefangxi Rd, Changsha, Hunan, Peoples R China.
EM zhchen1997@hunnu.edu.cn
FU Medical Scientific Research Foundation of Hunan Province [B2015-93];
   Science and Technology Planning Project of Hunan Province [2015JC3116,
   2018JJ2225]; Chinese National Natural Science Foundation Youth Fund
   [81502111]; Third Xiangya Hospital of Central South University
   [JY201604]
FX This work was supported by grants from the Medical Scientific Research
   Foundation of Hunan Province (B2015-93); the Science and Technology
   Planning Project of Hunan Province (2015JC3116, 2018JJ2225); Chinese
   National Natural Science Foundation Youth Fund (81502111); the Third
   Xiangya Hospital of Central South University (JY201604).
CR Alva AS, 2004, CELL DEATH DIFFER, V11, P1046, DOI 10.1038/sj.cdd.4401445
   Benita Y, 2009, NUCLEIC ACIDS RES, V37, P4587, DOI 10.1093/nar/gkp425
   BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405
   Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002
   Che XQ, 2015, INT J NEUROSCI, V125, P390, DOI 10.3109/00207454.2014.940585
   Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128
   Cockman ME, 2006, P NATL ACAD SCI USA, V103, P14767, DOI 10.1073/pnas.0606877103
   Daskalaki I, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00104
   Dreyfus DH, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-12
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831
   Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0
   Kamath A., 2019, BIORXIV, V6, P326470
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377
   Lee YH, 2010, CANCER RES, V70, P8264, DOI 10.1158/0008-5472.CAN-10-0749
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Li JN, 2006, BIOCHEMISTRY-US, V45, P15168, DOI 10.1021/bi062188q
   Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910
   Liu XW, 2014, AUTOPHAGY, V10, P111, DOI 10.4161/auto.26838
   Muz B, 2015, HYPOXIA, V3, P83, DOI 10.2147/HP.S93413
   Myslinski E, 1998, J BIOL CHEM, V273, P21998, DOI 10.1074/jbc.273.34.21998
   NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0
   Peng CH, 2018, TRANSPLANTATION, V102, pS683, DOI 10.1097/01.tp.0000543629.86556.c5
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Shi YQ, 2011, GENE, V485, P153, DOI 10.1016/j.gene.2011.06.025
   Shintani M., 2013, NAT REV CANCER, V7, P961, DOI [10.5772/55315, DOI 10.5772/55315, 10.5772/55315.]
   Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009
   Wang XJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086276
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200
   Zheng G, 2004, J BIOL CHEM, V279, P42410, DOI 10.1074/jbc.M407287200
NR 33
TC 10
Z9 12
U1 2
U2 7
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD OCT 1
PY 2020
VL 395
IS 1
AR 112175
DI 10.1016/j.yexcr.2020.112175
PG 8
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA NN5TN
UT WOS:000568850900006
PM 32679233
DA 2022-04-25
ER

PT J
AU Liu, XY
   Zhang, P
   Xie, CM
   Sham, KWY
   Ng, SSM
   Chen, YC
   Cheng, CHK
AF Liu, Xiaoyu
   Zhang, Peng
   Xie, Chuanming
   Sham, Kathy W. Y.
   Ng, Simon S. M.
   Chen, Yangchao
   Cheng, Christopher H. K.
TI Activation of PTEN by inhibition of TRPV4 suppresses colon cancer
   development
SO CELL DEATH & DISEASE
LA English
DT Article
ID CELL-CYCLE PROGRESSION; HEPATOCELLULAR-CARCINOMA; NUCLEAR PTEN;
   ION-CHANNEL; RECEPTOR; MTOR; AUTOPHAGY; GROWTH; PROLIFERATION;
   TRANSITION
AB Transient receptor potential vanilloid type 4 (TRPV4) is a Ca2+-permeable cation channel that is known to be an osmosensor and thermosensor. Currently, limited evidence shows that TRPV4 plays opposite roles in either promoting or inhibiting cancer development in different cancer types. Furthermore, the precise biological functions and the underlying mechanisms of TRPV4 in carcinogenesis are still poorly understood. In this study, we demonstrated that TRPV4 is upregulated in colon cancer and associated with poor prognosis. Contrary to the reported cell death-promoting activity of TRPV4 in certain cancer cells, TRPV4 positively regulates cell survival in human colon cancer in vitro and in vivo. Inhibition of TRPV4 affects the cell cycle progression from the G1 to S phase through modulating the protein expression of D-type cyclins. Apoptosis and autophagy induced by TRPV4 silencing attenuate cell survival and potentiate the anticancer efficacy of chemotherapeutics against colon cancer cells. In addition, PTEN is activated by inhibition of TRPV4 as indicated by the dephosphorylation and increased nuclear localization. Knockdown of PTEN significantly abrogates TRPV4 silencing induced growth inhibition and recovers the capability of clonogenicity, as well as reduced apoptosis in colon cancer cells. Thus, PTEN regulates the antigrowth effects induced by TRPV4 inhibition through both phosphatase-dependent and independent mechanisms. In conclusion, inhibition of TRPV4 suppresses colon cancer development via activation of PTEN pathway. This finding suggests that downregulation of TPRV4 expression or activity would conceivably constitute a novel approach for the treatment of human colon cancer.
C1 [Liu, Xiaoyu; Zhang, Peng] Longgang ENT Hosp, Shenzhen, Peoples R China.
   [Liu, Xiaoyu; Zhang, Peng] Inst ENT, Shenzhen Key Lab ENT, Shenzhen, Peoples R China.
   [Liu, Xiaoyu; Sham, Kathy W. Y.; Chen, Yangchao; Cheng, Christopher H. K.] Chinese Univ Hong Kong, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China.
   [Xie, Chuanming] Third Mil Med Univ, Southwest Hosp, Inst Hepatobiliary Surg, Army Med Univ, Chongqing, Peoples R China.
   [Ng, Simon S. M.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Shatin, Hong Kong, Peoples R China.
RP Cheng, CHK (corresponding author), Chinese Univ Hong Kong, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China.
EM chkcheng@cuhk.edu.hk
RI Ng, Simon S. M./M-1219-2018; Xie, Chuan-Ming/AAT-9557-2021; CHENG, Ki
   Christopher/R-9641-2018; Chen, Yangchao/AAG-2127-2019; Zhang,
   Peng/ABB-7193-2020
OI Ng, Simon S. M./0000-0002-5389-9297; Xie,
   Chuan-Ming/0000-0003-4362-6612; CHENG, Ki
   Christopher/0000-0001-8970-9048; Chen, Yangchao/0000-0002-0249-3414;
   Xiaoyu, LIU/0000-0001-5259-7038; Zhang, Peng/0000-0002-4598-0300; Sham,
   Kathy Wai-yan/0000-0002-8883-2551
FU Chinese University of Hong KongChinese University of Hong Kong
   [4054212];  [81700437]
FX This work was supported by a Direct Grant (#4054212) (to C.C.) and a
   graduate studentship (to X.L.) from the Chinese University of Hong Kong;
   and the National Natural Science Foundation of China (81700437) (to
   P.Z.).
CR Adapala RK, 2016, ONCOGENE, V35, P314, DOI 10.1038/onc.2015.83
   Averous J, 2008, ONCOGENE, V27, P1106, DOI 10.1038/sj.onc.1210715
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812
   Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016
   Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155
   Butenko O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039959
   Ding X, 2010, JNCI-J NATL CANCER I, V102, P1052, DOI 10.1093/jnci/djq217
   Everaerts W, 2010, P NATL ACAD SCI USA, V107, P19084, DOI 10.1073/pnas.1005333107
   Fang Y, 2018, BIOMED PHARMACOTHER, V101, P910, DOI 10.1016/j.biopha.2018.03.014
   Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004
   Fusi C, 2014, J INVEST DERMATOL, V134, P2408, DOI 10.1038/jid.2014.145
   Gao N, 2004, AM J PHYSIOL-CELL PH, V287, pC281, DOI 10.1152/ajpcell.00422.2003
   Gradilone SA, 2010, GASTROENTEROLOGY, V139, P304, DOI 10.1053/j.gastro.2010.04.010
   Hall DP, 2014, CANCER CELL, V26, P738, DOI 10.1016/j.ccell.2014.09.015
   Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008
   Jie P, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.146
   Kim SJ, 2016, ONCOGENE, V35, P251, DOI 10.1038/onc.2015.80
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Liu XY, 2018, BBA-MOL BASIS DIS, V1864, P975, DOI 10.1016/j.bbadis.2018.01.003
   Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672
   Minaguchi T, 2006, CANCER RES, V66, P11677, DOI 10.1158/0008-5472.CAN-06-2240
   Monteith GR, 2017, NAT REV CANCER, V17, P367, DOI 10.1038/nrc.2017.18
   Moran MM, 2011, NAT REV DRUG DISCOV, V10, P601, DOI 10.1038/nrd3456
   Nilius B, 2013, EMBO REP, V14, P152, DOI 10.1038/embor.2012.219
   Olah A, 2014, J CLIN INVEST, V124, P3713, DOI 10.1172/JCI64628
   Olivan-Viguera A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190307
   Patel R, 2013, J CLIN INVEST, V123, P1157, DOI 10.1172/JCI63672
   Peters AA, 2017, ONCOGENE, V36, P6490, DOI 10.1038/onc.2017.234
   Pla AF, 2012, ONCOGENE, V31, P200, DOI 10.1038/onc.2011.231
   Roderick HL, 2008, NAT REV CANCER, V8, P361, DOI 10.1038/nrc2374
   Rodrigues T, 2016, CHEM SOC REV, V45, P6130, DOI 10.1039/c5cs00916b
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042
   Shi Y, 2009, GUT, V58, P1443, DOI 10.1136/gut.2009.181735
   Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330
   Song MS, 2011, CELL, V144, P187, DOI 10.1016/j.cell.2010.12.020
   Stewart BWKP, 2015, WORLD CANC REPORT 20
   Sukumaran P, 2016, CELL CALCIUM, V60, P123, DOI 10.1016/j.ceca.2016.02.012
   Thoppil RJ, 2016, ONCOTARGET, V7, P25849, DOI 10.18632/oncotarget.8405
   Thoppil RJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep14257
   Thorneloe KS, 2008, J PHARMACOL EXP THER, V326, P432, DOI 10.1124/jpet.108.139295
   Tian YJ, 2017, MOL NEUROBIOL, V54, P5768, DOI 10.1007/s12035-016-0113-y
   Vasaikar SV, 2018, NUCLEIC ACIDS RES, V46, pD956, DOI 10.1093/nar/gkx1090
   Wang Q, 2016, AUTOPHAGY, V12, P1340, DOI 10.1080/15548627.2016.1187365
   Wen L, 2016, SCI REP-UK, V6, DOI 10.1038/srep23269
   White JPM, 2016, PHYSIOL REV, V96, P911, DOI 10.1152/physrev.00016.2015
   Worby CA, 2014, ANNU REV BIOCHEM, V83, P641, DOI 10.1146/annurev-biochem-082411-113907
   Xie CM, 2014, AUTOPHAGY, V10, P1495, DOI 10.4161/auto.29164
   Xie R, 2017, CANCER RES, V77, P6499, DOI 10.1158/0008-5472.CAN-17-0360
   Yang SL, 2009, ONCOGENE, V28, P1320, DOI 10.1038/onc.2008.475
   Zhan L, 2015, MOL CELL BIOCHEM, V402, P9, DOI 10.1007/s11010-014-2298-6
   Zhang P, 2018, HYPERTENSION, V71, P134, DOI 10.1161/HYPERTENSIONAHA.117.09767
   Zhang P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03230-w
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
NR 55
TC 21
Z9 22
U1 2
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JUN 12
PY 2019
VL 10
AR 460
DI 10.1038/s41419-019-1700-4
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA IE5RW
UT WOS:000472436300003
PM 31189890
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Guaman-Ortiz, LM
   Orellana, MIR
   Ratovitski, EA
AF Miguel Guaman-Ortiz, Luis
   Ramirez Orellana, Maria Isabel
   Ratovitski, Edward A.
TI Natural Compounds As Modulators of Non-apoptotic Cell Death in Cancer
   Cells
SO CURRENT GENOMICS
LA English
DT Review
DE Cancer; Autophagy; Necroptosis; Paraptosis; Natural compounds
ID NF-KAPPA-B; RESVERATROL INDUCES APOPTOSIS; ORIDONIN-INDUCED APOPTOSIS;
   INHIBITS AUTOPHAGIC FLUX; MULTIPLE-MYELOMA CELLS; LOW-DOSE EXPOSURES;
   MOLECULAR-MECHANISMS; COLON-CANCER; BETULINIC ACID; LUNG-CANCER
AB Cell death is an innate capability of cells to be removed from microenvironment, if and when they are damaged by multiple stresses. Cell death is often regulated by multiple molecular pathways and mechanism, including apoptosis, autophagy, and necroptosis. The molecular network underlying these processes is often intertwined and one pathway can dynamically shift to another one acquiring certain protein components, in particular upon treatment with various drugs. The strategy to treat human cancer ultimately relies on the ability of anticancer therapeutics to induce tumor-specific cell death, while leaving normal adjacent cells undamaged. However, tumor cells often develop the resistance to the drug-induced cell death, thus representing a great challenge for the anticancer approaches. Numerous compounds originated from the natural sources and biopharmaceutical industries are applied today in clinics showing advantageous results. However, some exhibit serious toxic side effects. Thus, novel effective therapeutic approaches in treating cancers are continued to be developed. Natural compounds with anticancer activity have gained a great interest among researchers and clinicians alike since they have shown more favorable safety and efficacy then the synthetic marketed drugs. Numerous studies in vitro and in vivo have found that several natural compounds display promising anticancer potentials. This review underlines certain information regarding the role of natural compounds from plants, microorganisms and sea life forms, which are able to induce non-apoptotic cell death in tumor cells, namely autophagy and necroptosis.
C1 [Miguel Guaman-Ortiz, Luis; Ramirez Orellana, Maria Isabel] Univ Tecn Particular Loja, Dept Ciencias Salud, Loja, Ecuador.
   [Ratovitski, Edward A.] Johns Hopkins Univ, Sch Med, Head & Neck Canc Res Div, Baltimore, MD USA.
RP Guaman-Ortiz, LM; Ratovitski, EA (corresponding author), UTPL, Calle Paris, Loja, Ecuador.
EM lmguaman@utpl.edu.ec; eratovi1@jhmi.edu
RI Ortiz, Luis Miguel Guaman/X-9496-2019
OI Ortiz, Luis Miguel Guaman/0000-0003-2919-4905
CR Akkoc Y, 2015, BIOMED PHARMACOTHER, V71, P161, DOI 10.1016/j.biopha.2015.02.029
   Alexander A, 2010, P NATL ACAD SCI USA, V107, P4153, DOI 10.1073/pnas.0913860107
   Altonsy MO, 2011, NUTR CANCER, V63, P1104, DOI 10.1080/01635581.2011.601846
   Amagase H, 2006, J NUTR, V136, p716S, DOI 10.1093/jn/136.3.716S
   Andrabi SA, 2014, P NATL ACAD SCI USA, V111, P10209, DOI 10.1073/pnas.1405158111
   Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167
   Aras A, 2014, ASIAN PAC J CANCER P, V15, P3865, DOI 10.7314/APJCP.2014.15.9.3865
   Aredia F, 2014, BIOCHEM PHARMACOL, V92, P157, DOI 10.1016/j.bcp.2014.06.021
   Aredia Francesca, 2014, Front Biosci (Elite Ed), V6, P308
   Aredia Francesca, 2012, Cells, V1, P520, DOI 10.3390/cells1030520
   Armstrong JL, 2015, J INVEST DERMATOL, V135, P1629, DOI 10.1038/jid.2015.45
   Arthur CR, 2007, BIOCHEM PHARMACOL, V74, P981, DOI 10.1016/j.bcp.2007.07.003
   Azarenko O, 2008, CARCINOGENESIS, V29, P2360, DOI 10.1093/carcin/bgn241
   Balunas MJ, 2005, LIFE SCI, V78, P431, DOI 10.1016/j.lfs.2005.09.012
   Banjerdpongchai R, 2013, ASIAN PAC J CANCER P, V14, P7537, DOI 10.7314/APJCP.2013.14.12.7537
   Barrera LN, 2012, P NUTR SOC, V71, P237, DOI 10.1017/S002966511200016X
   Basello DA, 2015, MITOCHONDRION, V24, P56, DOI 10.1016/j.mito.2015.07.005
   Basit F, 2013, CELL DEATH DIFFER, V20, P1161, DOI 10.1038/cdd.2013.45
   Belaid A, 2015, CURR CANCER DRUG TAR, V15, P684, DOI 10.2174/156800961508151001102452
   Biggers JW, 2013, CANCER CHEMOTH PHARM, V71, P441, DOI 10.1007/s00280-012-2024-6
   Bonapace L, 2010, J CLIN INVEST, V120, P1310, DOI 10.1172/JCI39987
   Boridy S, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.182
   Borst P, 2008, CELL CYCLE, V7, P1353, DOI 10.4161/cc.7.10.5930
   Boyanapalli Sarandeep S S, 2015, Curr Pharmacol Rep, V1, P129
   Broz DK, 2013, AUTOPHAGY, V9, P1440, DOI 10.4161/auto.25833
   Broz DK, 2013, GENE DEV, V27, P1016, DOI 10.1101/gad.212282.112
   Cai ZY, 2014, NAT CELL BIOL, V16, P55, DOI 10.1038/ncb2883
   Carnero A, 2015, CARCINOGENESIS, V36, pS19, DOI 10.1093/carcin/bgv029
   Carvalho FC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027892
   Casey SC, 2015, CARCINOGENESIS, V36, pS160, DOI 10.1093/carcin/bgv035
   Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528
   Cerella C, 2011, ANTI-CANCER AGENT ME, V11, P267, DOI 10.2174/187152011795347522
   Chang Yuan S, 2003, Integr Cancer Ther, V2, P13, DOI 10.1177/1534735403251167
   Chen CA, 2013, J MED FOOD, V16, P869, DOI 10.1089/jmf.2012.2617
   Chen GZ, 2015, APOPTOSIS, V20, P92, DOI 10.1007/s10495-014-1058-0
   Chen L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085771
   Chen LM, 2012, INT J ONCOL, V40, P1066, DOI 10.3892/ijo.2011.1278
   Chen MC, 2015, J AGR FOOD CHEM, V63, P1540, DOI 10.1021/jf5054063
   Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622
   Chen N, 2009, BBA-MOL CELL RES, V1793, P1516, DOI 10.1016/j.bbamcr.2008.12.013
   Chen YJ, 2009, TOXICOL IN VITRO, V23, P418, DOI 10.1016/j.tiv.2009.01.011
   Cheng Y, 2008, ARCH BIOCHEM BIOPHYS, V475, P148, DOI 10.1016/j.abb.2008.04.027
   Cheng Y, 2009, AUTOPHAGY, V5, P430, DOI 10.4161/auto.5.3.7896
   Cheng Y, 2009, FEBS J, V276, P1291, DOI 10.1111/j.1742-4658.2008.06864.x
   Chiu CT, 2015, J FOOD SCI, V80, pH649, DOI 10.1111/1750-3841.12790
   Cho YS, 2014, BIOMOL THER, V22, P167, DOI 10.4062/biomolther.2014.046
   Choi JS, 2013, INT J MOL MED, V32, P1227, DOI 10.3892/ijmm.2013.1519
   Chow JPH, 2010, CONTEMP CANCER RES, P79, DOI 10.1007/978-1-4419-1770-6_5
   Christofferson DE, 2014, ANNU REV PHYSIOL, V76, P129, DOI 10.1146/annurev-physiol-021113-170259
   Chu YL, 2013, J AGR FOOD CHEM, V61, P9839, DOI 10.1021/jf403241s
   Chu YL, 2012, J AGR FOOD CHEM, V60, P8363, DOI 10.1021/jf301298y
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Coupienne I, 2011, BIOCHEM PHARMACOL, V81, P606, DOI 10.1016/j.bcp.2010.12.015
   Crighton D, 2007, CELL DEATH DIFFER, V14, P1071, DOI 10.1038/sj.cdd.4402108
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Cui Q, 2006, J PHARMACOL SCI, V101, P230, DOI 10.1254/jphs.FPJ06003X
   D'Anneo A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.415
   Dannappel M, 2014, NATURE, V513, P90, DOI 10.1038/nature13608
   Dashzeveg N, 2015, CANCER LETT, V367, P108, DOI 10.1016/j.canlet.2015.07.019
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Delmas D, 2011, CURR MED CHEM, V18, P1100, DOI 10.2174/092986711795029708
   Deng BY, 2015, TUMOR BIOL, V36, P9311, DOI 10.1007/s13277-015-3662-1
   Doleckova I, 2012, FITOTERAPIA, V83, P1000, DOI 10.1016/j.fitote.2012.06.002
   Dunai ZA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041945
   Dyshlovoy SA, 2015, ONCOTARGET, V6, P17328, DOI 10.18632/oncotarget.4175
   Eby KG, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-95
   Engstrom W, 2015, CARCINOGENESIS, V36, pS38, DOI 10.1093/carcin/bgv030
   Fahey JW, 1999, FOOD CHEM TOXICOL, V37, P973, DOI 10.1016/S0278-6915(99)00082-4
   Fatokun AA, 2014, BRIT J PHARMACOL, V171, P2000, DOI 10.1111/bph.12416
   Feng C, 2012, INT J CANCER, V131, P1445, DOI 10.1002/ijc.27365
   Frankel LB, 2012, CARCINOGENESIS, V33, P2018, DOI 10.1093/carcin/bgs266
   Fu YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102535
   Fu ZZ, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-580
   Fuchs Y, 2015, NAT REV MOL CELL BIO, V16, P329, DOI 10.1038/nrm3999
   Fulda S, 2008, INT J MOL SCI, V9, P1096, DOI 10.3390/ijms9061096
   Fulda S, 2014, SEMIN CELL DEV BIOL, V35, P51, DOI 10.1016/j.semcdb.2014.07.002
   Fulda S, 2013, CANCER BIOL THER, V14, P999, DOI 10.4161/cbt.26428
   Fulda S, 2010, PLANTA MED, V76, P1075, DOI 10.1055/s-0030-1249961
   Gali-Muhtasib H, 2015, APOPTOSIS, V20, P1531, DOI 10.1007/s10495-015-1169-2
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Galluzzi L, 2014, SEMIN CELL DEV BIOL, V35, P24, DOI 10.1016/j.semcdb.2014.02.006
   Galluzzi L, 2014, CELL RES, V24, P139, DOI 10.1038/cr.2014.8
   Galluzzi L, 2011, FRONT ONCOL, V1, DOI 10.3389/fonc.2011.00005
   Garcia-Zepeda SP, 2013, EUR J CANCER PREV, V22, P577, DOI 10.1097/CEJ.0b013e328360345f
   Ge J, 2013, BIOMED ENVIRON SCI, V26, P902, DOI 10.3967/bes2013.019
   Ghantous A, 2013, DRUG DISCOV TODAY, V18, P894, DOI 10.1016/j.drudis.2013.05.005
   Ghantous A, 2010, DRUG DISCOV TODAY, V15, P668, DOI 10.1016/j.drudis.2010.06.002
   Gheorgheosu D, 2014, ANTI-CANCER AGENT ME, V14, P936, DOI 10.2174/1871520614666140223192148
   Gonzalez P, 2012, CELL DEATH DIFFER, V19, P1337, DOI 10.1038/cdd.2012.10
   Goodson WH, 2015, CARCINOGENESIS, V36, pS254, DOI 10.1093/carcin/bgv039
   Guaman-Ortiz L.M., 2014, BIOMED RES INT, V2014
   Guerrero-Preston R., MOL MECH, P251
   Guo JQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140745
   Guo WJ, 2010, J X-RAY SCI TECHNOL, V18, P293, DOI 10.3233/XST-2010-0261
   Hahm ER, 2014, PROSTATE, V74, P1209, DOI 10.1002/pros.22837
   Han B, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1133-0
   Han WD, 2007, MOL CANCER THER, V6, P1641, DOI 10.1158/1535-7163.MCT-06-0511
   Han WD, 2012, INT J MOL SCI, V13, P7212, DOI 10.3390/ijms13067212
   Han WD, 2009, APOPTOSIS, V14, P674, DOI 10.1007/s10495-009-0334-x
   Han XQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100380
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Harhaji-Trajkovic L, 2009, J CELL MOL MED, V13, P3644, DOI 10.1111/j.1582-4934.2009.00663.x
   Hasima N, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.467
   Hematulin A, 2014, ASIAN PAC J CANCER P, V15, P1871, DOI 10.7314/APJCP.2014.15.4.1871
   Herman-Antosiewicz A, 2006, CANCER RES, V66, P5828, DOI 10.1158/0008-5472.CAN-06-0139
   Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462
   Hou Y, 2006, YAKUGAKU ZASSHI, V126, P1383, DOI 10.1248/yakushi.126.1383
   Hu F, 2015, J PHARMACOL SCI, V128, P27, DOI 10.1016/j.jphs.2015.04.003
   Hu T, 2015, PHYTOMEDICINE, V22, P536, DOI 10.1016/j.phymed.2015.03.010
   Hu X, 2008, CANCER LETT, V259, P127, DOI 10.1016/j.canlet.2007.11.007
   Hu X, 2007, AUTOPHAGY, V3, P490, DOI 10.4161/auto.4592
   Hu ZW, 2015, CARCINOGENESIS, V36, pS184, DOI 10.1093/carcin/bgv036
   Huang CJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066326
   Huang J, 2011, CURR DRUG TARGETS, V12, P1925, DOI 10.2174/138945011798184155
   Huang J, 2012, AUTOPHAGY, V8, P275, DOI 10.4161/auto.8.2.18940
   Huang M, 2012, EXPERT OPIN INV DRUG, V21, P1801, DOI 10.1517/13543784.2012.727395
   Huang Y, 2015, AM J CANCER RES, V5, P2361
   Huang YP, 2012, CELL CYCLE, V11, P1247, DOI 10.4161/cc.11.6.19670
   Huang YP, 2010, AGING-US, V2, P959, DOI 10.18632/aging.100249
   Irimie AI, 2015, ONCOTARGETS THER, V8, P461, DOI 10.2147/OTT.S78358
   Jackson SJT, 2004, J NUTR, V134, P2229, DOI 10.1093/jn/134.9.2229
   Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218
   Jang SY, 2014, ONCOL REP, V31, P2827, DOI 10.3892/or.2014.3159
   Jia LT, 2015, CANCER LETT, V357, P75, DOI 10.1016/j.canlet.2014.11.048
   Jia YL, 2009, J ASIAN NAT PROD RES, V11, P918, DOI 10.1080/10286020903264077
   Juncker T, 2009, BIOCHEM PHARMACOL, V78, P1, DOI 10.1016/j.bcp.2009.01.018
   Kaczmarek A, 2013, IMMUNITY, V38, P209, DOI 10.1016/j.immuni.2013.02.003
   Kaewpiboon C, 2014, INT J ONCOL, V44, P1233, DOI 10.3892/ijo.2014.2297
   Kainz KP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065745
   Kaushal GP, 2008, AUTOPHAGY, V4, P710, DOI 10.4161/auto.6309
   Khalfan WA, 2002, CURR OPIN CELL BIOL, V14, P468, DOI 10.1016/S0955-0674(02)00343-5
   Kim AD, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.273
   Kim DG, 2014, ONCOTARGET, V5, P4438, DOI 10.18632/oncotarget.2034
   Kim JY, 2012, ARCH ORAL BIOL, V57, P1018, DOI 10.1016/j.archoralbio.2012.04.005
   Kim Jinwoong, 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P485
   Kim SM, 2010, EUR J PHARMACOL, V631, P1, DOI 10.1016/j.ejphar.2009.12.018
   Kim YJ, 2015, BIOORG MED CHEM LETT, V25, P2559, DOI 10.1016/j.bmcl.2015.04.054
   Kinghorn AD, 2009, PURE APPL CHEM, V81, P1051, DOI 10.1351/PAC-CON-08-10-16
   Kinghorn AD, 2009, IDRUGS, V12, P189
   Kiraly-Veghely Z, 1998, ACTA BIOL HUNG, V49, P281
   Ko H, 2009, BIOSCI BIOTECH BIOCH, V73, P2183, DOI 10.1271/bbb.90250
   Kong FC, 2015, J HUAZHONG U SCI-MED, V35, P343, DOI 10.1007/s11596-015-1435-0
   Kravchenko J, 2015, CARCINOGENESIS, V36, pS111, DOI 10.1093/carcin/bgv033
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Krosch TCK, 2013, AM J SURG, V205, P387, DOI 10.1016/j.amjsurg.2013.01.008
   Krysko DV, 2011, TRENDS IMMUNOL, V32, P157, DOI 10.1016/j.it.2011.01.005
   Kumar B, 2015, BIOCHIMIE
   Kusama Y, 2009, APOPTOSIS, V14, P1165, DOI 10.1007/s10495-009-0390-2
   Laddha SV, 2014, MOL CANCER RES, V12, P485, DOI 10.1158/1541-7786.MCR-13-0614
   Lalaoui N, 2015, SEMIN CELL DEV BIOL, V39, P63, DOI 10.1016/j.semcdb.2015.02.003
   Lan B, 2015, BIOCHEM BIOPH RES CO, V456, P434, DOI 10.1016/j.bbrc.2014.11.102
   Lang FF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129196
   Langie SAS, 2015, CARCINOGENESIS, V36, pS61, DOI 10.1093/carcin/bgv031
   Lao CD, 2006, EXPERT REV ANTICANC, V6, P1559, DOI 10.1586/14737140.6.11.1559
   Lao Feng-xue, 2009, Chinese Journal of Biologicals, V22, P654
   Lao YZ, 2014, AUTOPHAGY, V10, P736, DOI 10.4161/auto.28034
   Larocque K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087064
   Lee HW, 2014, BMB REP, V47, P697, DOI 10.5483/BMBRep.2014.47.12.069
   Lee KH, 2014, SCI REP-UK, V4, DOI 10.1038/srep06394
   Lee YJ, 2011, KOREAN J PHYSIOL PHA, V15, P1, DOI 10.4196/kjpp.2011.15.1.1
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li B, 2013, INT J GYNECOL CANCER, V23, P803, DOI 10.1097/IGC.0b013e31828c9581
   Li BH, 2011, CANCER LETT, V301, P185, DOI 10.1016/j.canlet.2010.11.015
   Li CY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101526
   Li GM, 2013, CANCER PREV RES, V6, P27, DOI 10.1158/1940-6207.CAPR-12-0349
   Li HY, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.543
   Li JX, 2013, ADV IMMUNOL, V119, P135, DOI 10.1016/B978-0-12-407707-2.00005-9
   Li S, 2015, CURR TOP MED CHEM, V15, P720, DOI 10.2174/1568026615666150302105343
   Li WJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094079
   Li XJY, 2014, J ETHNOPHARMACOL, V155, P67, DOI 10.1016/j.jep.2014.06.006
   Lin WP, 2014, TUMOR BIOL, V35, P8065, DOI 10.1007/s13277-014-2064-0
   Liu B, 2009, CANCER LETT, V275, P54, DOI 10.1016/j.canlet.2008.09.042
   Liu B, 2009, AUTOPHAGY, V5, P253, DOI 10.4161/auto.5.2.7561
   Liu P, 2012, LEUKEMIA, V26, P1293, DOI 10.1038/leu.2011.357
   Liu YN, 2015, TOXICON, V95, P30, DOI 10.1016/j.toxicon.2014.12.014
   Long JS, 2012, ONCOGENE, V31, P5045, DOI 10.1038/onc.2012.7
   Longato GB, 2015, TOXICOL IN VITRO, V29, P1026, DOI 10.1016/j.tiv.2015.04.002
   Lotze MT, 2007, CLIN IMMUNOL, V124, P1, DOI 10.1016/j.clim.2007.02.006
   Lu C, 2014, ACTA PHARMACOL SIN, V35, P929, DOI 10.1038/aps.2014.31
   Lu J, 2014, J PHARMACOL SCI, V125, P74, DOI 10.1254/jphs.14013FP
   Luo XJ, 2015, ONCOL REP, V34, P547, DOI 10.3892/or.2015.4029
   Lyu Q, 2015, BIOCHEM BIOPH RES CO, V462, P38, DOI 10.1016/j.bbrc.2015.04.102
   Ma J, 2014, ONCOL REP, V32, P235, DOI 10.3892/or.2014.3211
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Maiuri MC, 2010, EMBO J, V29, P515, DOI 10.1038/emboj.2009.377
   Maiuri MC, 2009, CELL CYCLE, V8, P1571, DOI 10.4161/cc.8.10.8498
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Mathis BJ, 2015, CURR DRUG TARGETS, V16, P284, DOI 10.2174/1389450115666141024152421
   Mc Gee MM, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/146282
   Meiyanto E, 2012, ASIAN PAC J CANCER P, V13, P427, DOI 10.7314/APJCP.2012.13.2.427
   Melo-Lima S, 2015, PHARMACOL RES, V95-96, P2, DOI 10.1016/j.phrs.2015.02.007
   Melo-Lima Sara, 2014, Oncoscience, V1, P649
   Mena S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044524
   Merfort I, 2011, CURR DRUG TARGETS, V12, P1560, DOI 10.2174/138945011798109437
   Mi LX, 2008, J BIOL CHEM, V283, P22136, DOI 10.1074/jbc.M802330200
   Miki H, 2012, INT J ONCOL, V40, P1020, DOI 10.3892/ijo.2012.1325
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Mizushima N, 2010, CURR OPIN CELL BIOL, V22, P132, DOI 10.1016/j.ceb.2009.12.004
   Mohler H, 2014, INT J ONCOL, V45, P1329, DOI 10.3892/ijo.2014.2566
   Mohammad RM, 2015, SEMIN CANCER BIOL, V35, pS78, DOI 10.1016/j.semcancer.2015.03.001
   Moriwaki K, 2013, GENE DEV, V27, P1640, DOI 10.1101/gad.223321.113
   Mujumdar N, 2014, AM J PHYSIOL-GASTR L, V306, pG1011, DOI 10.1152/ajpgi.00466.2013
   Mujumdar N, 2010, GASTROENTEROLOGY, V139, P598, DOI 10.1053/j.gastro.2010.04.046
   Mukhtar E, 2012, CURR DRUG TARGETS, V13, P1831, DOI 10.2174/138945012804545489
   Nag SA, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00025
   Nahta R, 2015, CARCINOGENESIS, V36, pS2, DOI 10.1093/carcin/bgv028
   Narayanan KB, 2015, CARCINOGENESIS, V36, pS89, DOI 10.1093/carcin/bgv032
   Newton K, 2015, TRENDS CELL BIOL, V25, P347, DOI 10.1016/j.tcb.2015.01.001
   Nikoletopoulou V, 2013, BBA-MOL CELL RES, V1833, P3448, DOI 10.1016/j.bbamcr.2013.06.001
   Nomura M, 2014, CANCER RES, V74, P1056, DOI 10.1158/0008-5472.CAN-13-1283
   Nugues AL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.347
   O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066
   Ochieng J, 2015, CARCINOGENESIS, V36, pS128, DOI 10.1093/carcin/bgv034
   Opipari AW, 2004, CANCER RES, V64, P696, DOI 10.1158/0008-5472.CAN-03-2404
   Kreuger MRO, 2012, ANTI-CANCER DRUG, V23, P883, DOI 10.1097/CAD.0b013e328356cad9
   Ortiz LMG, 2015, ACTA BIOCH BIOPH SIN, V47, P824, DOI 10.1093/abbs/gmv077
   Ortiz LMG, 2014, MOLECULES, V19, P12349, DOI 10.3390/molecules190812349
   Ouyang L, 2014, PHYTOMEDICINE, V21, P1658, DOI 10.1016/j.phymed.2014.08.002
   Panda PK, 2015, SEMIN CELL DEV BIOL, V39, P43, DOI 10.1016/j.semcdb.2015.02.013
   Pandey S, 2012, ASIAN PAC J CANCER P, V13, P4867, DOI 10.7314/APJCP.2012.13.10.4867
   Parnaud G, 2004, NUTR CANCER, V48, P198, DOI 10.1207/s15327914nc4802_10
   Pathak S, 2003, INT J ONCOL, V23, P975
   Pawlik A, 2013, EUR J NUTR, V52, P1949, DOI 10.1007/s00394-013-0499-5
   Peng PL, 2008, INT J RADIAT ONCOL, V70, P529, DOI 10.1016/j.ijrobp.2007.08.034
   Piacentini M, 2015, INT J DEV BIOL, V59, P5, DOI 10.1387/ijdb.150167mp
   Piao JL, 2013, CHEM-BIOL INTERACT, V205, P119, DOI 10.1016/j.cbi.2013.06.011
   Potze L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.139
   Pozarowski P, 2003, CYTOM PART A, V54A, P118, DOI 10.1002/cyto.a.10057
   Pozarowski P, 2003, CELL CYCLE, V2, P377, DOI 10.4161/cc.2.4.420
   Pratt J, 2014, CELL SIGNAL, V26, P917, DOI 10.1016/j.cellsig.2014.01.012
   Puissant A, 2010, AUTOPHAGY, V6, P655, DOI 10.4161/auto.6.5.12126
   Qian HR, 2011, EUR J PHARM SCI, V43, P125, DOI 10.1016/j.ejps.2011.04.002
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Radogna F, 2015, BIOCHEM PHARMACOL, V94, P1, DOI 10.1016/j.bcp.2014.12.018
   Ramirez-Orellana M.I., 2014, KEYST S MOL CELL BIO, P86
   Reyjal J, 2014, ADV EXP MED BIOL, V772, P167, DOI 10.1007/978-1-4614-5915-6_8
   Rikiishi H, 2012, CANCER BIOL THER, V13, P978, DOI 10.4161/cbt.21079
   Robey RB, 2015, CARCINOGENESIS, V36, pS203, DOI 10.1093/carcin/bgv037
   Romanov J, 2012, EMBO J, V31, P4304, DOI 10.1038/emboj.2012.278
   Rosenbluth JM, 2009, AUTOPHAGY, V5, P114, DOI 10.4161/auto.5.1.7294
   Ryan KM, 2011, EUR J CANCER, V47, P44, DOI 10.1016/j.ejca.2010.10.020
   Sarkar FH, 2009, CANCER TREAT REV, V35, P597, DOI 10.1016/j.ctrv.2009.07.001
   Satoh M, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-19
   Satoo K, 2009, EMBO J, V28, P1341, DOI 10.1038/emboj.2009.80
   Scarlatti F, 2008, CELL DEATH DIFFER, V15, P1318, DOI 10.1038/cdd.2008.51
   Scarlatti F, 2008, AUTOPHAGY, V4, P1083, DOI 10.4161/auto.7068
   Schmidt SV, 2015, ONCOTARGET, V6, P8635, DOI 10.18632/oncotarget.3249
   Schneider-Stock R, 2012, FRONT BIOSCI-LANDMRK, V17, P129, DOI 10.2741/3919
   Selvaraj S., 2015, MOL CARCINOG
   Shammas MA, 2006, BLOOD, V108, P2804, DOI 10.1182/blood-2006-05-022814
   Shen M, 2012, ANTI-CANCER AGENT ME, V12, P891, DOI 10.2174/187152012802649978
   Shi L., 2015, ENDOCRINE
   Shinojima N, 2007, AUTOPHAGY, V3, P635, DOI 10.4161/auto.4916
   Siddiqui IA, 2008, ONCOGENE, V27, P2055, DOI 10.1038/sj.onc.1210840
   Siedlecka-Kroplewska K, 2013, J PHYSIOL PHARMACOL, V64, P545
   Sosna J, 2014, CELL MOL LIFE SCI, V71, P331, DOI 10.1007/s00018-013-1381-6
   Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376
   Sperandio S, 2010, J CELL BIOCHEM, V111, P1401, DOI 10.1002/jcb.22870
   Su CC, 2015, MOL MED REP, V11, P3160, DOI 10.3892/mmr.2014.3090
   Su ZY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0321-5
   Sui XB, 2011, AUTOPHAGY, V7, P565, DOI 10.4161/auto.7.6.14073
   Sun H, 2013, ANTI-CANCER AGENT ME, V13, P1048, DOI 10.2174/18715206113139990130
   Sun J, 2014, ASIAN PAC J CANCER P, V15, P4897, DOI 10.7314/APJCP.2014.15.12.4897
   Szende B, 2000, EXP MOL MED, V32, P88, DOI 10.1038/emm.2000.16
   Tait SWG, 2014, J CELL SCI, V127, P2135, DOI 10.1242/jcs.093575
   Tang JJ, 2015, CANCER LETT, V363, P101, DOI 10.1016/j.canlet.2015.04.014
   Tang Su-Ni, 2010, J Mol Signal, V5, P14, DOI 10.1186/1750-2187-5-14
   Tang ZH, 2014, J AGR FOOD CHEM, V62, P11910, DOI 10.1021/jf503968k
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Tedesco I, 2013, FOOD CHEM TOXICOL, V60, P377, DOI 10.1016/j.fct.2013.07.078
   Thompson PA, 2015, CARCINOGENESIS, V36, pS232, DOI 10.1093/carcin/bgv038
   Thongrakard V, 2014, PHYTOTHER RES, V28, P1761, DOI 10.1002/ptr.5196
   Tillhon M, 2012, BIOCHEM PHARMACOL, V84, P1260, DOI 10.1016/j.bcp.2012.07.018
   Mai TT, 2012, CANCER LETT, V321, P144, DOI 10.1016/j.canlet.2012.01.045
   Trzoss L, 2014, P NATL ACAD SCI USA, V111, P14687, DOI 10.1073/pnas.1410932111
   Tyihak E, 2011, NAT PROD COMMUN, V6, P631
   Urtishak KA, 2013, BLOOD, V121, P2689, DOI 10.1182/blood-2012-04-425033
   Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P1153, DOI 10.1038/cdd.2008.47
   Vanden Berghe T, 2014, NAT REV MOL CELL BIO, V15, P134, DOI 10.1038/nrm3737
   Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970
   Wada N, 2015, INT J ONCOL, V46, P963, DOI 10.3892/ijo.2014.2804
   Wallach D, 2014, CYTOKINE GROWTH F R, V25, P157, DOI 10.1016/j.cytogfr.2013.12.001
   Wang HY, 2014, MOL CELL, V54, P133, DOI 10.1016/j.molcel.2014.03.003
   Wang M, 2014, NUTR CANCER, V66, P435, DOI 10.1080/01635581.2013.878738
   Wang N, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/934207
   Wang N, 2011, BRIT J PHARMACOL, V164, P731, DOI 10.1111/j.1476-5381.2011.01349.x
   Wang N, 2010, J CELL BIOCHEM, V111, P1426, DOI 10.1002/jcb.22869
   Wang SY, 2011, BIOCHEM BIOPH RES CO, V406, P497, DOI 10.1016/j.bbrc.2011.02.049
   Wang Steven, 2010, Curr Drug Discov Technol, V7, P67
   Wang WB, 2012, J CELL PHYSIOL, V227, P2196, DOI 10.1002/jcp.22956
   Wang XY, 2015, SCI REP-UK, V5, DOI 10.1038/srep10293
   Wang XuanBin, 2014, BioMed Research International, V2014, P530342
   Wang Y, 2013, BIOCHEM BIOPH RES CO, V430, P876, DOI 10.1016/j.bbrc.2012.12.063
   Wang YF, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2000902
   Wang YX, 2015, TOXINS, V7, P3030, DOI 10.3390/toxins7083030
   Wesselborg S, 2015, CELL MOL LIFE SCI, V72, P4721, DOI 10.1007/s00018-015-2034-8
   Wong AST, 2015, NAT PROD REP, V32, P256, DOI 10.1039/c4np00080c
   Wu JC, 2011, MOL NUTR FOOD RES, V55, P1646, DOI 10.1002/mnfr.201100454
   Wu P.F., 2015, EXP DERMATOL
   Wyrsch P, 2012, MOL CELL BIOL, V32, P3541, DOI 10.1128/MCB.00437-12
   Xiao K, 2013, J PHARMACOL SCI, V123, P102, DOI 10.1254/jphs.13085FP
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Xu DQ, 2015, PLANTA MED, V81, P79, DOI 10.1055/s-0034-1383356
   Xu MY, 2014, J NAT PROD, V77, P370, DOI 10.1021/np401022g
   Xuan YY, 2009, CANCER LETT, V274, P233, DOI 10.1016/j.canlet.2008.09.029
   Yamamoto M, 2010, ONCOL LETT, V1, P489, DOI 10.3892/ol_00000086
   Yamauchi Y, 2012, PHYTOTHER RES, V26, P1779, DOI 10.1002/ptr.4645
   Yang HJ, 2006, CANCER RES, V66, P4758, DOI 10.1158/0008-5472.CAN-05-4529
   Yang HJ, 2010, CURR DRUG TARGETS, V11, P733, DOI 10.2174/138945010791170842
   Yang LJ, 2012, ACTA PHARMACOL SIN, V33, P1542, DOI 10.1038/aps.2012.102
   Yang SM, 2003, MOL CANCER THER, V2, P65
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yao Y, 2010, BREAST CANCER RES TR, V121, P233, DOI 10.1007/s10549-009-0547-2
   Ye YC, 2012, ACTA PHARMACOL SIN, V33, P1055, DOI 10.1038/aps.2012.53
   Yoon MJ, 2014, ONCOTARGET, V5, P6816, DOI 10.18632/oncotarget.2256
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
   Yu R, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-49
   Yumnam S., 2015, J CELL PHYSL
   Yun TK, 2001, J KOREAN MED SCI, V16, pS6, DOI 10.3346/jkms.2001.16.S.S6
   Zamaraev AV, 2015, CELL MOL LIFE SCI, V72, P505, DOI 10.1007/s00018-014-1757-2
   Zhang CZ, 2015, INVEST NEW DRUG, V33, P1, DOI 10.1007/s10637-014-0156-8
   Zhang D, 2015, CANCER BIOL THER, V16, P1005, DOI 10.1080/15384047.2015.1046022
   Zhang JS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057779
   Zhang J, 2015, ONCOTARGET, V6, P789, DOI 10.18632/oncotarget.2733
   Zhang L, 2014, BIOCHEM BIOPH RES CO, V450, P247, DOI 10.1016/j.bbrc.2014.05.101
   Zhang L, 2015, ACTA PHARMACOL SIN, V36, P1256, DOI 10.1038/aps.2015.46
   Zhang M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127386
   Zhang SF, 2014, ASIAN PAC J CANCER P, V15, P10557, DOI 10.7314/APJCP.2014.15.24.10557
   Zhang X, 2012, CELL PROLIFERAT, V45, P466, DOI 10.1111/j.1365-2184.2012.00833.x
   Zhang Y, 2012, ONCOGENE, V31, P1055, DOI 10.1038/onc.2011.290
   Zhang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046749
   Zhao N, 2015, ONCOTARGET, V6, P18445, DOI 10.18632/oncotarget.4315
   Zhao QL, 2015, INT J CANCER, V137, P1446, DOI 10.1002/ijc.29483
   Zhou DY, 2014, MOL MED REP, V10, P1315, DOI 10.3892/mmr.2014.2380
   Zhou JY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092828
   Zhou M, 2013, CHEMMEDCHEM, V8, P694, DOI 10.1002/cmdc.201200560
   Zhou W, 2014, SEMIN CELL DEV BIOL, V35, P14, DOI 10.1016/j.semcdb.2014.07.013
   Zhuang WZ, 2012, CANCER SCI, V103, P684, DOI 10.1111/j.1349-7006.2011.02198.x
NR 339
TC 23
Z9 23
U1 1
U2 28
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-2029
EI 1875-5488
J9 CURR GENOMICS
JI Curr. Genomics
PY 2017
VL 18
IS 2
BP 132
EP 155
DI 10.2174/1389202917666160803150639
PG 24
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA EU0FD
UT WOS:000400683600003
PM 28367073
OA Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Lee, Y
   Sung, B
   Kang, YJ
   Kim, DH
   Jang, JY
   Hwang, SY
   Kim, M
   Lim, HS
   Yoon, JH
   Chung, HY
   Kim, ND
AF Lee, Yujin
   Sung, Bokyung
   Kang, Yong Jung
   Kim, Dong Hwan
   Jang, Jung-Yoon
   Hwang, Seong Yeon
   Kim, Minjung
   Lim, Hyun Sook
   Yoon, Jeong-Hyun
   Chung, Hae Young
   Kim, Nam Deuk
TI Apigenin-induced apoptosis is enhanced by inhibition of autophagy
   formation in HCT116 human colon cancer cells
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE apigenin; colon cancer cells; cell cycle; apoptosis; autophagy;
   3-methyladenine
ID CYCLE ARREST; IN-VITRO; CARCINOMA; EXPRESSION; PATHWAY; PHOSPHORYLATION;
   5-FLUOROURACIL; ACTIVATION; GUIDELINES; ASSAYS
AB Apigenin (4',5,7-trihydroxyflavone) is a natural flavonoid, shown to have chemopreventive and/or anticancer properties in a variety of human cancer cells. The involvement of autophagy in apigenin-induced apoptotic cell death of HCT116 human colon cancer cells was investigated. Apigenin induced suppression of cell growth in a concentration-dependent manner in HCT116 cells. Flow cytometric analyses indicated that apigenin resulted in G2/M phase arrest. This flavone also suppressed the expression of both cyclin B1 and its activating partners, Cdc2 and Cdc25c, whereas the expression of cell cycle inhibitors, such as p53 and p53-dependent p21(CIP1/WAF1), was increased after apigenin treatment. Apigenin induced poly (ADP-ribose) polymerase (PARP) cleavage and decreased the levels of procaspase-8, -9 and -3. In addition, the apigenin-treated cells exhibited autophagy, as characterized by the appearance of autophagosomes under fluorescence microscopy and the accumulation of acidic vesicular organelles by flow cytometry. Furthermore, the results of the western blot analysis revealed that the levels of LC3-II, the processed form of LC3-I, was increased by apigenin. Treatment with the autophagy inhibitor 3-methyladenine (3-MA) significantly enhanced the apoptosis induced by apigenin, which was accompanied by an increase in the levels of PARP cleavage. These results indicate that apigenin has apoptosis-and autophagy-inducing effects in HCT116 colon cancer cells. Autophagy plays a cytoprotective role in apigenin-induced apoptosis, and the combination of apigenin and an autophagy inhibitor may be a promising strategy for colon cancer control.
C1 [Lee, Yujin; Sung, Bokyung; Kang, Yong Jung; Kim, Dong Hwan; Jang, Jung-Yoon; Hwang, Seong Yeon; Kim, Minjung; Lim, Hyun Sook; Yoon, Jeong-Hyun; Chung, Hae Young; Kim, Nam Deuk] Pusan Natl Univ, Coll Pharm, Div Pharm, Mol Inflammat Res Ctr Aging Intervent MRCA, Pusan 609735, South Korea.
RP Kim, ND (corresponding author), Pusan Natl Univ, Coll Pharm, Div Pharm, Pusan 609735, South Korea.
EM nadkim@pusan.ac.kr
RI Sung, Bokyung/AAX-5697-2021
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Korea government (MSIP) [NRF-2009-0071649]; National
   Research Foundation of Korea (NRF) - Korea government (MSIP)
   [2009-0083538]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Korea
   government (MSIP) (NRF-2009-0071649). This study was also financially
   supported by the National Research Foundation of Korea (NRF) grant
   funded by the Korea government (MSIP) (no. 2009-0083538). We thank Aging
   Tissue Bank for providing research information. The authors thank Mr.
   Kyoung-Pil Lee (Pusan National University) for helping with confocal
   microscopy.
CR Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220
   Cao XC, 2013, CHINESE J CANCER RES, V25, P212, DOI 10.3978/j.issn.1000-9604.2013.04.01
   Carew JS, 2007, AUTOPHAGY, V3, P464, DOI 10.4161/auto.4311
   Chan LP, 2012, BBA-GEN SUBJECTS, V1820, P1081, DOI 10.1016/j.bbagen.2012.04.013
   Cheng P, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.17
   Das S, 2012, EXP BIOL MED, V237, P1433, DOI 10.1258/ebm.2012.012148
   Fang J, 2005, FASEB J, V19, P342, DOI 10.1096/fj.04-2175com
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Harhaji-Trajkovic L, 2009, J CELL MOL MED, V13, P3644, DOI 10.1111/j.1582-4934.2009.00663.x
   Horinaka M, 2006, MOL CANCER THER, V5, P945, DOI 10.1158/1535-7163.MCT-05-0431
   Huerta S, 2006, AM J SURG, V191, P517, DOI 10.1016/j.amjsurg.2005.11.009
   Jayasooriya RGPT, 2012, FOOD CHEM TOXICOL, V50, P2605, DOI 10.1016/j.fct.2012.05.024
   Jung KW, 2012, CANCER RES TREAT, V44, P11, DOI 10.4143/crt.2012.44.1.11
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim SH, 2013, MOL CELL ENDOCRINOL, V369, P130, DOI 10.1016/j.mce.2013.01.012
   King JC, 2012, BBA-MOL CELL RES, V1823, P593, DOI 10.1016/j.bbamcr.2011.12.008
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Kundu M, 2008, ANNU REV PATHOL-MECH, V3, P427, DOI 10.1146/annurev.pathmechdis.2.010506.091842
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lin JF, 2013, CARCINOGENESIS, V34, P406, DOI 10.1093/carcin/bgs359
   Maggioni D, 2013, INT J ONCOL, V43, P1675, DOI 10.3892/ijo.2013.2072
   McVean M, 2002, MOL CARCINOGEN, V33, P36, DOI 10.1002/mc.10016
   Mirzoeva S, 2008, MOL CARCINOGEN, V47, P686, DOI 10.1002/mc.20421
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Ng G, 2005, MOL CARCINOGEN, V43, P183, DOI 10.1002/mc.20097
   Nishikawa T, 2010, ANN SURG ONCOL, V17, P592, DOI 10.1245/s10434-009-0696-x
   Paglin S, 2001, CANCER RES, V61, P439
   Shao HJ, 2013, MOL CANCER THER, V12, P2640, DOI 10.1158/1535-7163.MCT-13-0066
   Shin A, 2012, CANCER RES TREAT, V44, P219, DOI 10.4143/crt.2012.44.4.219
   Shingu T, 2009, INT J CANCER, V124, P1060, DOI 10.1002/ijc.24030
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Shukla S, 2007, CELL CYCLE, V6, P1102, DOI 10.4161/cc.6.9.4146
   Van Dross RT, 2005, MOL CARCINOGEN, V44, P83, DOI 10.1002/mc.20123
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   Wang WQ, 2000, MOL CARCINOGEN, V28, P102
   Wu DG, 2014, TOXICOL LETT, V224, P157, DOI 10.1016/j.toxlet.2013.10.007
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Xu YM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029169
   Zhu Y, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-54
NR 43
TC 75
Z9 82
U1 1
U2 24
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD MAY
PY 2014
VL 44
IS 5
BP 1599
EP 1606
DI 10.3892/ijo.2014.2339
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AJ8IV
UT WOS:000337947600020
PM 24626522
OA Bronze
DA 2022-04-25
ER

PT J
AU Kohli, L
   Kaza, N
   Coric, T
   Byer, SJ
   Brossier, NM
   Klocke, BJ
   Bjornsti, MA
   Carroll, SL
   Roth, KA
AF Kohli, Latika
   Kaza, Niroop
   Coric, Tatjana
   Byer, Stephanie J.
   Brossier, Nicole M.
   Klocke, Barbara J.
   Bjornsti, Mary-Ann
   Carroll, Steven L.
   Roth, Kevin A.
TI 4-Hydroxytamoxifen Induces Autophagic Death through K-Ras Degradation
SO CANCER RESEARCH
LA English
DT Article
ID BREAST-CANCER CELLS; PROTEIN-KINASE-C; NERVE SHEATH TUMORS;
   TAMOXIFEN-INDUCED APOPTOSIS; ACTIVATION; CALMODULIN; BINDING;
   INHIBITION; EXPRESSION; PROLIFERATION
AB Tamoxifen is widely used to treat estrogen receptor-positive breast cancer. Recent findings that tamoxifen and its derivative 4-hydroxytamoxifen (OHT) can exert estrogen receptor-independent cytotoxic effects have prompted the initiation of clinical trials to evaluate its use in estrogen receptor-negative malignancies. For example, tamoxifen and OHT exert cytotoxic effects in malignant peripheral nerve sheath tumors (MPNST) where estrogen is not involved. In this study, we gained insights into the estrogen receptor-independent cytotoxic effects of OHT by studying how it kills MPNST cells. Although caspases were activated following OHT treatment, caspase inhibition provided no protection from OHT-induced death. Rather, OHT-induced death in MPNST cells was associated with autophagic induction and attenuated by genetic inhibition of autophagic vacuole formation. Mechanistic investigations revealed that OHT stimulated autophagic degradation of K-Ras, which is critical for survival of MPNST cells. Similarly, we found that OHT induced K-Ras degradation in breast, colon, glioma, and pancreatic cancer cells. Our findings describe a novel mechanism of autophagic death triggered by OHT in tumor cells that may be more broadly useful clinically in cancer treatment. (C) 2013 AACR.
C1 [Kohli, Latika; Kaza, Niroop; Byer, Stephanie J.; Klocke, Barbara J.; Carroll, Steven L.; Roth, Kevin A.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   [Kohli, Latika; Brossier, Nicole M.] Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA.
   [Coric, Tatjana; Bjornsti, Mary-Ann] Univ Alabama Birmingham, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA.
   [Brossier, Nicole M.] Univ Alabama Birmingham, Dept Med Scientist Training Program, Birmingham, AL 35294 USA.
RP Roth, KA (corresponding author), Univ Alabama Birmingham, WP P210 619 South 19th St, Birmingham, AL 35294 USA.
EM karoth@uab.edu
RI Brossier, Nicole/AAP-2852-2020
OI Brossier, Nicole/0000-0002-4197-6283; Roth, Kevin/0000-0002-0643-995X;
   Kaza, Niroop/0000-0002-7584-1379; Carroll, Steven/0000-0001-6714-4373
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01 NS041962, R01 CA134773, R01
   CA122804, F30 NS063626, P50CA890919]; Department of DefenseUnited States
   Department of Defense [X81XWH-09-1-0086, X81XWH-12-1-0164]; NATIONAL
   CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R01CA122804, R01CA134773, R01CA058755] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND
   STROKEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [F30NS063626, R01NS041962] Funding Source:
   NIH RePORTER
FX This work was supported by NIH grants R01 NS041962 (K.A. Roth), R01
   CA134773 (K.A. Roth. and S.L. Carroll), R01 CA122804 (S.L. Carroll), F30
   NS063626 (N.M. Brossier), and P50CA890919 (T. Coric and M.A. Bjornsti);
   and Department of Defense Grants X81XWH-09-1-0086 and X81XWH-12-1-0164
   (S.L. Carroll).
CR Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Avgeropoulos N G, 1999, Oncologist, V4, P209
   Barnhart BC, 2008, CANCER BIOL THER, V7, P1443
   Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595
   Byer SJ, 2011, NEURO-ONCOLOGY, V13, P28, DOI 10.1093/neuonc/noq146
   Cabot MC, 1997, INT J CANCER, V70, P567, DOI 10.1002/(SICI)1097-0215(19970304)70:5<567::AID-IJC13>3.0.CO;2-A
   Cocconi G, 2003, MELANOMA RES, V13, P73, DOI 10.1097/00008390-200302000-00012
   COULDWELL WT, 1993, NEUROSURGERY, V32, P485, DOI 10.1227/00006123-199303000-00034
   Criscitiello C, 2011, ONCOTARGETS THER, V4, P1, DOI 10.2147/OTT.S10155
   Ferner RE, 2002, CANCER RES, V62, P1573
   Gelmann EP, 1996, J NATL CANCER I, V88, P224, DOI 10.1093/jnci/88.5.224
   Geng Y, 2010, NEURO-ONCOLOGY, V12, P473, DOI 10.1093/neuonc/nop048
   Gonzalez-Malerva L, 2011, P NATL ACAD SCI USA, V108, P2058, DOI 10.1073/pnas.1018157108
   Gundimeda U, 1996, J BIOL CHEM, V271, P13504, DOI 10.1074/jbc.271.23.13504
   GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658
   HAJDU SI, 1993, CANCER-AM CANCER SOC, V72, P3549, DOI 10.1002/1097-0142(19931215)72:12<3549::AID-CNCR2820721202>3.0.CO;2-Y
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Klionsky DJ, 2008, AUTOPHAGY, V4, P849, DOI 10.4161/auto.6845
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   LAM HYP, 1984, BIOCHEM BIOPH RES CO, V118, P27, DOI 10.1016/0006-291X(84)91062-3
   LOPES MCF, 1990, CANCER RES, V50, P2753
   Lopez G, 2011, AUTOPHAGY, V7, P440, DOI 10.4161/auto.7.4.14680
   Lu A, 2009, J CELL BIOL, V184, P863, DOI 10.1083/jcb.200807186
   Mandlekar S, 2000, CANCER RES, V60, P6601
   Mandlekar S, 2000, CANCER RES, V60, P5995
   Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881
   MCCAGUE R, 1994, BIOCHEM PHARMACOL, V48, P1355, DOI 10.1016/0006-2952(94)90557-6
   McGlynn LM, 2009, CLIN CANCER RES, V15, P1487, DOI 10.1158/1078-0432.CCR-07-4967
   Mendes-Pereira AM, 2012, P NATL ACAD SCI USA, V109, P2730, DOI 10.1073/pnas.1018872108
   Meschini S, 2011, CURR CANCER DRUG TAR, V11, P357, DOI 10.2174/156800911794519707
   Mishima Y, 2008, CANCER SCI, V99, P2200, DOI 10.1111/j.1349-7006.2008.00932.x
   Moya varez- B, 2011, SMALL GTPASES, V2, P99
   OBRIAN CA, 1988, CANCER RES, V48, P3626
   OBRIAN CA, 1990, BIOPOLYMERS, V29, P97, DOI 10.1002/bip.360290114
   PERRY RR, 1995, ANN SURG ONCOL, V2, P238, DOI 10.1007/BF02307030
   Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205
   Beguerie JR, 2010, INT J DERMATOL, V49, P1194, DOI 10.1111/j.1365-4632.2010.04529.x
   Sasaki AT, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001518
   Shacka JJ, 2006, MOL PHARMACOL, V69, P1125, DOI 10.1124/mol.105.018408
   Shin KJ, 2006, P NATL ACAD SCI USA, V103, P13759, DOI 10.1073/pnas.0606179103
   Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657
   Stonecypher MS, 2005, ONCOGENE, V24, P5589, DOI 10.1038/sj.onc.1208730
   Walls KC, 2010, J BIOL CHEM, V285, P10497, DOI 10.1074/jbc.M110.103747
   Williams VC, 2009, PEDIATRICS, V123, P124, DOI 10.1542/peds.2007-3204
   Wu Zhaoju, 2010, Genes Cancer, V1, P40, DOI 10.1177/1947601909358324
   Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103
   Zhang W, 2000, CANCER RES, V60, P5395
NR 47
TC 47
Z9 49
U1 1
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD JUL 15
PY 2013
VL 73
IS 14
BP 4395
EP 4405
DI 10.1158/0008-5472.CAN-12-3765
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 183NR
UT WOS:000321823600022
PM 23722551
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Sipos, F
   Szekely, H
   Kis, ID
   Tulassay, Z
   Muzes, G
AF Sipos, Ferenc
   Szekely, Hajnal
   Kis, Imre Daniel
   Tulassay, Zsolt
   Muzes, Gyorgyi
TI Relation of the IGF/IGF1R system to autophagy in colitis and colorectal
   cancer
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Review
DE Insulin-like growth factor; IGF1R; Autophagy; Colitis; Colorectal
   cancer; Metabolic syndrome
ID GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTOR; CELL-DEATH;
   INSULIN-RESISTANCE; THERAPEUTIC TARGET; KAPPA-B; IGF-I; COLON;
   APOPTOSIS; EXPRESSION
AB Metabolic syndrome (MetS), as a chronic inflammatory disorder has a potential role in the development of inflammatory and cancerous complications of the colonic tissue. The interaction of DNA damage and inflammation is affected by the insulin-like growth factor 1 receptor (IGF1R) signaling pathway. The IGF1R pathway has been reported to regulate autophagy, as well, but sometimes through a bidirectional context. Targeting the IGF1R-autophagy crosstalk could represent a promising strategy for the development of new antiinflammatory and anticancer therapies, and may help for subjects suffering from MetS who are at increased risk of colorectal cancer. However, therapeutic responses to targeted therapies are often shortlived, since a signaling crosstalk of IGF1R with other receptor tyrosine kinases or autophagy exists, leading to acquired cellular resistance to therapy. From a pharmacological point of view, it is attractive to speculate that synergistic benefits could be achieved by inhibition of one of the key effectors of the IGF1R pathway, in parallel with the pharmacological stimulation of the autophagy machinery, but cautiousness is also required, because pharmacologic IGF1R modulation can initiate additional, sometimes unfavorable biologic effects.
C1 [Sipos, Ferenc; Szekely, Hajnal; Muzes, Gyorgyi] Semmelweis Univ, Dept Internal Med 2, H-1088 Budapest, Hungary.
   [Kis, Imre Daniel] Semmelweis Univ, Fac Med, H-1088 Budapest, Hungary.
   [Tulassay, Zsolt] Hungarian Acad Sci, Mol Med Res Grp, H-1088 Budapest, Hungary.
RP Sipos, F (corresponding author), Semmelweis Univ, Dept Internal Med 2, Immunol & Med, Szentkiralyi St 46, H-1088 Budapest, Hungary.
EM dr.siposf@gmail.com
FU Hungarian Scientific Research FundOrszagos Tudomanyos Kutatasi
   Alapprogramok (OTKA) [OTKA-K111743]
FX Supported by the Hungarian Scientific Research Fund (No. OTKA-K111743)
   to Tulassay Z. The funders had no role in data collection, decision to
   publish, or preparation of the manuscript.
CR Aleman JO, 2014, GASTROENTEROLOGY, V146, P357, DOI 10.1053/j.gastro.2013.11.051
   Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200
   Bartke A, 2004, CURR TOP DEV BIOL, V63, P189, DOI 10.1016/S0070-2153(04)63006-7
   Bastard JP, 2006, EUR CYTOKINE NETW, V17, P4
   Belfiore A, 2009, ENDOCR REV, V30, P586, DOI 10.1210/er.2008-0047
   Brahmkhatri VP, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/538019
   Brestoff JR, 2015, CELL, V161, P146, DOI 10.1016/j.cell.2015.02.022
   Byles V, 2010, INT J BIOL SCI, V6, P599
   Cadwell K, 2009, AUTOPHAGY, V5, P250, DOI 10.4161/auto.5.2.7560
   Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408
   Chang CK, 2003, DIABETOLOGIA, V46, P595, DOI 10.1007/s00125-003-1109-5
   Chen Z, 2016, AM J TRANSL RES, V8, P1190
   Chitikova ZV, 2014, CELL CYCLE, V13, P1424, DOI 10.4161/cc.28402
   Cho DH, 2012, ANTICANCER RES, V32, P4091
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Chu E, 2011, ONCOLOGY WILLISTON P, V25, P543
   Chu E, 2011, ONCOLOGY-NY, V25, P538
   Clovel T, 2007, INFLAMM BOWEL DIS, V13, P1153, DOI 10.1002/ibd.20174
   D'Mello S, 2012, INFLAMM BOWEL DIS, V18, P236, DOI 10.1002/ibd.21689
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   De Benedetti F, 2001, ENDOCRINOLOGY, V142, P4818, DOI 10.1210/en.142.11.4818
   Degtyarev M, 2008, J CELL BIOL, V183, P101, DOI 10.1083/jcb.200801099
   Durai R, 2005, INT J COLORECTAL DIS, V20, P203, DOI 10.1007/s00384-004-0675-4
   Ekyalongo RC, 2013, INVEST NEW DRUG, V31, P293, DOI 10.1007/s10637-012-9855-1
   El Yafi F, 2005, CLIN EXP IMMUNOL, V139, P526, DOI 10.1111/j.1365-2249.2004.02724.x
   Eskelinen EL, 2002, TRAFFIC, V3, P878, DOI 10.1034/j.1600-0854.2002.31204.x
   Feng Y, 2016, ONCOTARGET, V7, P81402, DOI 10.18632/oncotarget.13233
   Frezza EE, 2006, GUT, V55, P285, DOI 10.1136/gut.2005.073163
   Ge RT, 2015, SCI REP-UK, V5, DOI 10.1038/srep07735
   Ghosh A, 2017, BIOCHEM BIOPH RES CO, V488, P562, DOI 10.1016/j.bbrc.2017.05.089
   Govannucci E, 2007, GASTROENTEROLOGY, V132, P2208, DOI 10.1053/j.gastro.2007.03.050
   Guo YJ, 2012, J CELL SCI, V125, P1706, DOI 10.1242/jcs.093203
   Hagiwara A, 2012, J CELL PHYSIOL, V227, P2097, DOI 10.1002/jcp.22941
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hopfner M, 2006, WORLD J GASTROENTERO, V12, P5635
   Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485
   Hu T, 2015, PHYTOMEDICINE, V22, P536, DOI 10.1016/j.phymed.2015.03.010
   Hua F, 2015, AUTOPHAGY, V11, P1929, DOI 10.1080/15548627.2015.1084458
   Hua F, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8951
   Huang SB, 2010, AUTOPHAGY, V6, P256, DOI 10.4161/auto.6.2.11124
   Iams WT, 2015, CLIN CANCER RES, V21, P4270, DOI 10.1158/1078-0432.CCR-14-2518
   Iwasa J, 2010, CANCER SCI, V101, P460, DOI 10.1111/j.1349-7006.2009.01402.x
   Karrasch T, 2014, HORM METAB RES, V46, P445, DOI 10.1055/s-0034-1374587
   Kasprzak A, 2017, MUTAT RES-REV MUTAT, V772, P78, DOI 10.1016/j.mrrev.2016.08.007
   Kaulfuss S, 2009, MOL CANCER THER, V8, P821, DOI 10.1158/1535-7163.MCT-09-0058
   Kawaguchi T, 2008, INT J MOL MED, V22, P105
   Kawanishi S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081808
   Kenyon CJ, 2010, NATURE, V464, P504, DOI 10.1038/nature08980
   Korkmaz H, 2014, EUR J GASTROEN HEPAT, V26, P725, DOI 10.1097/MEG.0000000000000104
   Koustas E, 2017, CANCER LETT, V396, P94, DOI 10.1016/j.canlet.2017.03.023
   Kuemmerle JF, 2012, ENDOCRIN METAB CLIN, V41, P409, DOI 10.1016/j.ecl.2012.04.018
   Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levine B, 2007, NAT REV IMMUNOL, V7, P767, DOI 10.1038/nri2161
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Li P, 2014, WORLD J GASTROENTERO, V20, P4648, DOI 10.3748/wjg.v20.i16.4648
   Liu JJ, 2006, BRIT J PHARMACOL, V148, P1099, DOI 10.1038/sj.bjp.0706817
   Liu JJ, 2002, CARCINOGENESIS, V23, P2087, DOI 10.1093/carcin/23.12.2087
   Liu Q, 2017, MOL MED REP, V15, P2136, DOI 10.3892/mmr.2017.6265
   Lopez-Candales Angel, 2017, J Nat Sci, V3
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   Mariani F, 2014, WORLD J GASTROENTERO, V20, P9716, DOI 10.3748/wjg.v20.i29.9716
   Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200
   Massoner P, 2010, BRIT J CANCER, V103, P1479, DOI 10.1038/sj.bjc.6605932
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mohan S, 2002, J ENDOCRINOL, V175, P19, DOI 10.1677/joe.0.1750019
   Monkkonen T, 2018, AUTOPHAGY, V14, P190, DOI 10.1080/15548627.2017.1345412
   Muzes G, 2014, CURR DRUG TARGETS, V15, P743, DOI 10.2174/1389450115666140522120427
   Oberthur R, 2017, CANCER LETT, V407, P93, DOI 10.1016/j.canlet.2017.08.009
   Ouban A, 2003, HUM PATHOL, V34, P803, DOI 10.1016/S0046-8177(03)00291-0
   Oyri SF, 2015, COMP IMMUNOL MICROB, V43, P36, DOI 10.1016/j.cimid.2015.10.005
   Pal S, 2017, ANTI-CANCER AGENT ME, V17, P115, DOI 10.2174/1871520616666160624091519
   Pandini G, 1999, CLIN CANCER RES, V5, P1935
   Pandini G, 2002, J BIOL CHEM, V277, P39684, DOI 10.1074/jbc.M202766200
   Park D, 2016, SCI REP-UK, V6, DOI 10.1038/srep21772
   Pathania AS, 2016, SCI REP-UK, V6, DOI 10.1038/srep33146
   Pillai VB, 2014, CIRC RES, V114, P368, DOI 10.1161/CIRCRESAHA.113.300536
   Rath E, 2011, EUR J NUTR, V50, P219, DOI 10.1007/s00394-011-0197-0
   Renna M, 2013, HUM MOL GENET, V22, P4528, DOI 10.1093/hmg/ddt300
   Reverchon M, 2016, BIOL REPROD, V94, DOI 10.1095/biolreprod.115.134650
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   SALMON WD, 1957, J LAB CLIN MED, V49, P825
   Sanderson MP, 2017, MOL CANCER THER, V16, P2223, DOI 10.1158/1535-7163.MCT-17-0336
   Sansone L, 2013, J CELL PHYSIOL, V228, P1754, DOI 10.1002/jcp.24334
   Schakman O, 2012, AM J PHYSIOL-ENDOC M, V303, pE729, DOI 10.1152/ajpendo.00060.2012
   Schwarzer R, 2006, CELL SIGNAL, V18, P899, DOI 10.1016/j.cellsig.2005.08.002
   Schwer B, 2010, P NATL ACAD SCI USA, V107, P21790, DOI 10.1073/pnas.1016306107
   Shimizu M, 2009, CLIN CANCER RES, V15, P3068, DOI 10.1158/1078-0432.CCR-08-2093
   Sipos F, 2008, SCAND J GASTROENTERO, V43, P289, DOI 10.1080/00365520701714434
   Soori M, 2016, J PHARMACOL EXP THER, V356, P375, DOI 10.1124/jpet.115.229229
   Stanton MJ, 2013, AUTOPHAGY, V9, P789, DOI 10.4161/auto.23783
   Takahashi M, 2012, CARCINOGENESIS, V33, P2441, DOI 10.1093/carcin/bgs286
   Tran TT, 1996, CANCER EPIDEM BIOMAR, V5, P1013
   Valentini L, 2009, NUTRITION, V25, P172, DOI 10.1016/j.nut.2008.07.020
   Wang RC, 2012, SCIENCE, V338, P956, DOI 10.1126/science.1225967
   Wang Y, 2013, INVEST OPHTH VIS SCI, V54, P3806, DOI 10.1167/iovs.13-12091
   Wu WB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169229
   Wubetu GY, 2014, ANTICANCER RES, V34, P4789
   Xiao GT, 2007, CYTOKINE GROWTH F R, V18, P233, DOI 10.1016/j.cytogfr.2007.04.006
   Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016
   Yang JH, 2017, J DIABETES COMPLICAT, V31, P1228, DOI 10.1016/j.jdiacomp.2017.04.012
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yoshiji H, 2009, J GASTROENTEROL, V44, P483, DOI 10.1007/s00535-009-0031-0
   Zietek T, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00154
NR 105
TC 14
Z9 15
U1 0
U2 5
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD DEC 14
PY 2017
VL 23
IS 46
BP 8109
EP 8119
DI 10.3748/wjg.v23.i46.8109
PG 11
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA FP8XL
UT WOS:000417929300001
PM 29290648
OA Green Published, Green Submitted, hybrid
DA 2022-04-25
ER

PT J
AU Garcia-Maurino, S
   Alcaide, A
   Dominguez, C
AF Garcia-Maurino, Sofia
   Alcaide, Antonio
   Dominguez, Cecilia
TI Pharmacological Control of Autophagy: Therapeutic Perspectives in
   Inflammatory Bowel Disease and Colorectal Cancer
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE AMP-dependent kinase; autophagy; colorectal cancer; Endoplasmic
   Reticulum stress; inflammatory bowel disease; mammalian target of
   rapamycin
ID ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; HUMAN
   COLON-CANCER; ADVANCED SOLID TUMORS; FACTOR-KAPPA-B; HISTONE DEACETYLASE
   INHIBITORS; ISOLATED RAT HEPATOCYTES; AIRWAY EPITHELIAL-CELLS;
   INTESTINAL PANETH CELLS; CLASS-II PRESENTATION
AB Autophagy, an intracellular process involved in removing and recycling cellular components, plays a major role in growth, development, and responses to stress and pathogens. Autophagy is compromised in many human diseases, including inflammatory bowel disease (IBD) and colorectal cancer (CRC). Autophagy malfunction is associated to an alteration of both innate and adaptative immune responses, defects in bacterial clearance, and malfunction of goblet and Paneth cells; all these perturbations are related to IBD and CRC pathogenesis. Preclinical data show that both inhibition and induction of autophagy have significant potential to be translated into the clinic. Inhibitors of TORC1 (rapamycin and rapalogs) have proven to be effective in IBD and in many models for CRCs; however, their clinical use has produced only modest success. Second generations of mTOR inhibitors, which target its kinase domain, have been more effective. Optimal antitumor efficacy is achieved by combination of agents with different molecular targets, such as proteasome or histone deacetylase inhibitors combined with autophagy inhibitors (hydroxychloroquine) or activators (everolimus). Clinical trials in course are assaying the effect of these compounds in combination with standard treatments of CRC. This review summarizes current knowledge about the autophagic machinery and its regulation, then it explores the relevance and impact of the malfunction of autophagy on the pathogenesis of IBD and CRC, and, finally, it discusses the therapeutic potential of molecules that regulate autophagy and their use for the treatment of these two diseases.
C1 [Garcia-Maurino, Sofia] Univ Seville, Fac Biol, Dept Plant Biol & Ecol, E-41012 Seville, Spain.
   [Alcaide, Antonio; Dominguez, Cecilia] Univ Seville, Dept Pharmacol, Seville, Spain.
RP Garcia-Maurino, S (corresponding author), Univ Seville, Fac Biol, Dept Plant Biol & Ecol, Ave Reina Mercedes 6, E-41012 Seville, Spain.
EM sgarma@us.es
RI García-Mauriño, Sofía/E-6707-2010
OI García-Mauriño, Sofía/0000-0002-7698-5112
FU Junta de Andalucia, SpainJunta de Andalucia [CTS658, BIO298]
FX This work was supported by the Junta de Andalucia (PAI groups CTS658 and
   BIO298). A. Alcaide was in receipt of a FPI fellowship from the Junta de
   Andalucia, Spain.
CR Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   Aljada A, 2012, PHARMACOL THERAPEUT, V133, P108, DOI 10.1016/j.pharmthera.2011.09.004
   Amaravadi RK, 2011, CLIN CANCER RES, V15, P54
   Andresen L, 2005, GUT, V54, P503, DOI 10.1136/gut.2003.034165
   Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265
   Baba Y, 2010, BRIT J CANCER, V103, P1025, DOI 10.1038/sj.bjc.6605846
   Back JH, 2011, J BIOL CHEM, V286, P19100, DOI 10.1074/jbc.M111.240598
   Baehrecke EH, 2003, CELL DEATH DIFFER, V10, P940, DOI 10.1038/sj.cdd.4401280
   Bafica A, 2007, J IMMUNOL, V179, P5514, DOI 10.4049/jimmunol.179.8.5514
   Balaburski GM, 2010, TRENDS CELL BIOL, V20, P363, DOI 10.1016/j.tcb.2010.02.007
   Barre B, 2010, MOL CELL, V38, P524, DOI 10.1016/j.molcel.2010.03.018
   Bassham DC, 2009, BBA-MOL CELL RES, V1793, P1397, DOI 10.1016/j.bbamcr.2009.01.001
   Bauvy C, 2001, EXP CELL RES, V268, P139, DOI 10.1006/excr.2001.5285
   Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204
   Bekpen C, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000403
   Ben Sahra I, 2008, ONCOGENE, V27, P3576, DOI 10.1038/sj.onc.1211024
   Bernales S, 2006, PLOS BIOL, V4, P2311, DOI 10.1371/journal.pbio.0040423
   Bertolotti A, 2001, J CLIN INVEST, V107, P585, DOI 10.1172/JCI11476
   Bhagwat SV, 2011, MOL CANCER THER, V10, P1394, DOI 10.1158/1535-7163.MCT-10-1099
   Bianco R, 2008, BRIT J CANCER, V98, P923, DOI 10.1038/sj.bjc.6604269
   Bijnsdorp IV, 2010, INT J CANCER, V126, P2457, DOI 10.1002/ijc.24943
   Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x
   Bowker SL, 2006, DIABETES CARE, V29, P254, DOI 10.2337/diacare.29.02.06.dc05-1558
   Brest P, 2010, CURR MOL MED, V10, P486, DOI 10.2174/156652410791608252
   Bruserud O, 2007, CURR PHARM BIOTECHNO, V8, P388, DOI 10.2174/138920107783018417
   Buzzai M, 2007, CANCER RES, V67, P6745, DOI 10.1158/0008-5472.CAN-06-4447
   Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416
   Cadwell K, 2009, AUTOPHAGY, V5, P250, DOI 10.4161/auto.5.2.7560
   Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a
   Canals D, 2011, BRIT J PHARMACOL, V163, P694, DOI 10.1111/j.1476-5381.2011.01279.x
   Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813
   Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78
   Carew JS, 2010, J CELL MOL MED, V14, P2448, DOI 10.1111/j.1582-4934.2009.00832.x
   Cario E, 2005, GUT, V54, P1182, DOI 10.1136/gut.2004.062794
   Chen N, 2010, FEBS LETT, V584, P1427, DOI 10.1016/j.febslet.2009.12.034
   Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622
   Chen Q, 2008, BLOOD, V111, P4690, DOI 10.1182/blood-2007-09-112904
   Cheung ZH, 2011, J NEUROCHEM, V118, P317, DOI 10.1111/j.1471-4159.2011.07314.x
   Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751
   Chung HJ, 2011, CHEM-BIOL INTERACT, V193, P43, DOI 10.1016/j.cbi.2011.05.002
   Cooney R, 2010, NAT MED, V16, P90, DOI 10.1038/nm.2069
   Crighton D, 2007, CELL DEATH DIFFER, V14, P1071, DOI 10.1038/sj.cdd.4402108
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Crisan TO, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018666
   Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002
   Cummings JRF, 2007, INFLAMM BOWEL DIS, V13, P941, DOI 10.1002/ibd.20162
   Currie CJ, 2009, DIABETOLOGIA, V52, P1766, DOI 10.1007/s00125-009-1440-6
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   Debnath J, 2011, J MAMMARY GLAND BIOL, V16, P173, DOI 10.1007/s10911-011-9223-3
   Delgado MA, 2008, EMBO J, V27, P1110, DOI 10.1038/emboj.2008.31
   Deng J, 2004, MOL CELL BIOL, V24, P10161, DOI 10.1128/MCB.24.23.10161-10168.2004
   Deng L, 2010, AM J PATHOL, V176, P952, DOI 10.2353/ajpath.2010.090622
   Dengjel J, 2005, P NATL ACAD SCI USA, V102, P7922, DOI 10.1073/pnas.0501190102
   Deretic V, 2009, CELL HOST MICROBE, V5, P527, DOI 10.1016/j.chom.2009.05.016
   Deretic V, 2009, CURR OPIN IMMUNOL, V21, P53, DOI 10.1016/j.coi.2009.02.002
   Ding WX, 2007, AM J PATHOL, V171, P513, DOI 10.2353/ajpath.2007.070188
   Ding WX, 2007, J BIOL CHEM, V282, P4702, DOI 10.1074/jbc.M609267200
   Ding WX, 2009, MOL CANCER THER, V8, P2036, DOI 10.1158/1535-7163.MCT-08-1169
   Dohrman A, 1998, BBA-MOL BASIS DIS, V1406, P251, DOI 10.1016/S0925-4439(98)00010-6
   Don ASA, 2011, REV RECENT CLIN TRIA, V6, P24, DOI 10.2174/157488711793980147
   Dowling RJO, 2012, J MOL ENDOCRINOL, V48, pR31, DOI 10.1530/JME-12-0007
   Dowling RJO, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-33
   Dubuquoy L, 2003, GASTROENTEROLOGY, V124, P1265, DOI 10.1016/S0016-5085(03)00271-3
   Dufour Marc, 2011, Cancers (Basel), V3, P2478, DOI 10.3390/cancers3022478
   EKBOM A, 1990, LANCET, V336, P357, DOI 10.1016/0140-6736(90)91889-I
   Ekstrand AI, 2010, FAM CANCER, V9, P125, DOI 10.1007/s10689-009-9293-1
   El Homsi M, 2007, AM J PHYSIOL-GASTR L, V293, pG365, DOI 10.1152/ajpgi.00091.2007
   Ellington AA, 2005, CARCINOGENESIS, V26, P159, DOI 10.1093/carcin/bgh297
   Enss ML, 2000, INFLAMM RES, V49, P162, DOI 10.1007/s000110050576
   Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Fels DR, 2008, CANCER RES, V68, P9323, DOI 10.1158/0008-5472.CAN-08-2873
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Fimia GM, 2010, CELL MOL LIFE SCI, V67, P1581, DOI 10.1007/s00018-010-0284-z
   Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020
   Fleming A, 2011, NAT CHEM BIOL, V7, P9, DOI 10.1038/NCHEMBIO.500
   Franchi L, 2009, NAT IMMUNOL, V10, P241, DOI 10.1038/ni.1703
   Fribley A, 2004, MOL CELL BIOL, V24, P9695, DOI 10.1128/MCB.24.22.9695-9704.2004
   Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200
   Fujisaka Y, 2010, JPN J CLIN ONCOL, V40, P732, DOI 10.1093/jjco/hyq047
   Fujishita T, 2008, P NATL ACAD SCI USA, V105, P13544, DOI 10.1073/pnas.0800041105
   Fujita N, 2008, MOL BIOL CELL, V19, P2092, DOI 10.1091/mbc.E07-12-1257
   Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002
   Ganz T, 2000, NAT IMMUNOL, V1, P99, DOI 10.1038/77884
   Gaudier E, 2004, AM J PHYSIOL-GASTR L, V287, pG1168, DOI 10.1152/ajpgi.00219.2004
   Ge XJ, 2009, MOL BIOL CELL, V20, P419, DOI 10.1091/mbc.E08-08-0792
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058
   Gulhati P, 2009, CLIN CANCER RES, V15, P7207, DOI 10.1158/1078-0432.CCR-09-1249
   Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Habeeb BS, 2011, CANCER SCI, V102, P999, DOI 10.1111/j.1349-7006.2011.01902.x
   Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954
   Han D, 2009, CELL, V138, P562, DOI 10.1016/j.cell.2009.07.017
   Han J, 2008, J BIOL CHEM, V283, P19665, DOI 10.1074/jbc.M710169200
   Hanada T, 2007, J BIOL CHEM, V282, P37298, DOI 10.1074/jbc.C700195200
   Hanauer SB, 2006, INFLAMM BOWEL DIS, V12, pS3, DOI 10.1097/01.MIB.0000195385.19268.68
   Harada M, 2008, HEPATOLOGY, V47, P2026, DOI 10.1002/hep.22294
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Heath-Engel HM, 2008, ONCOGENE, V27, P6419, DOI 10.1038/onc.2008.309
   Heazlewood CK, 2008, PLOS MED, V5, P440, DOI 10.1371/journal.pmed.0050054
   Herrero-Martin G, 2009, EMBO J, V28, P677, DOI 10.1038/emboj.2009.8
   Hetz C, 2008, TRENDS CELL BIOL, V18, P38, DOI 10.1016/j.tcb.2007.10.003
   Hetz C, 2009, MOL CELL, V35, P551, DOI 10.1016/j.molcel.2009.08.021
   Hetz Claudio, 2008, Current Immunology Reviews, V4, P1
   Hetz CA, 2007, ANTIOXID REDOX SIGN, V9, P2345, DOI 10.1089/ars.2007.1793
   Higdon JV, 2007, PHARMACOL RES, V55, P224, DOI 10.1016/j.phrs.2007.01.009
   Hippert MM, 2006, CANCER RES, V66, P9349, DOI 10.1158/0008-5472.CAN-06-1597
   Hokari R, 2005, AM J PHYSIOL-GASTR L, V289, pG949, DOI 10.1152/ajpgi.00142.2005
   Hollien J, 2006, SCIENCE, V313, P104, DOI 10.1126/science.1129631
   Holloway KR, 2010, P NATL ACAD SCI USA, V107, P9216, DOI 10.1073/pnas.0911325107
   Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248
   Hosono K, 2010, CANCER PREV RES, V3, P1077, DOI 10.1158/1940-6207.CAPR-10-0186
   Hosono K, 2010, MOL CARCINOGEN, V49, P662, DOI 10.1002/mc.20637
   Hoyer-Hansen M, 2007, CELL DEATH DIFFER, V14, P1576, DOI 10.1038/sj.cdd.4402200
   Hoyer-Hansen M, 2008, AUTOPHAGY, V4, P574, DOI 10.4161/auto.5921
   Hoyer-Hansen M, 2007, MOL CELL, V25, P193, DOI 10.1016/j.molcel.2006.12.009
   Hu P, 2006, MOL CELL BIOL, V26, P3071, DOI 10.1128/MCB.26.8.3071-3084.2006
   Huang WP, 2002, CELL STRUCT FUNCT, V27, P409, DOI 10.1247/csf.27.409
   Huett A, 2010, CURR OPIN GASTROEN, V26, P302, DOI 10.1097/MOG.0b013e32833ae2ed
   Hwang JT, 2007, CANCER LETT, V247, P115, DOI 10.1016/j.canlet.2006.03.030
   Hwang JT, 2006, CANCER RES, V66, P10057, DOI 10.1158/0008-5472.CAN-06-1814
   Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114
   Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839
   Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055
   Ishihara S, 2009, J GASTROENTEROL, V44, P1097, DOI 10.1007/s00535-009-0141-8
   Itakura E, 2010, AUTOPHAGY, V6, P764, DOI 10.4161/auto.6.6.12709
   Iwashita J, 2003, IMMUNOL CELL BIOL, V81, P275, DOI 10.1046/j.1440-1711.2003.t01-1-01163.x
   Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183
   Johnson SM, 2010, J AM COLL SURGEONS, V210, P767, DOI 10.1016/j.jamcollsurg.2009.12.008
   Johnson SM, 2009, ANTICANCER RES, V29, P3185
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kabra N, 2009, J BIOL CHEM, V284, P18210, DOI 10.1074/jbc.M109.000034
   Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507
   Kaser A, 2010, MUCOSAL IMMUNOL, V3, P11, DOI 10.1038/mi.2009.122
   Kaser A, 2008, CELL, V134, P743, DOI 10.1016/j.cell.2008.07.021
   Kaser A, 2011, GASTROENTEROLOGY, V140, P1738, DOI 10.1053/j.gastro.2011.02.048
   Kaser A, 2010, CURR OPIN GASTROEN, V26, P318, DOI 10.1097/MOG.0b013e32833a9ff1
   Kaser A, 2009, SEMIN IMMUNOL, V21, P156, DOI 10.1016/j.smim.2009.01.001
   Kelly D, 2004, NAT IMMUNOL, V5, P104, DOI 10.1038/ni1018
   Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303
   Kim KW, 2010, ONCOGENE, V29, P3241, DOI 10.1038/onc.2010.74
   Kim Y, 2010, LETT APPL MICROBIOL, V51, P123, DOI 10.1111/j.1472-765X.2010.02859.x
   Kim YD, 2002, J KOREAN MED SCI, V17, P765, DOI 10.3346/jkms.2002.17.6.765
   Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435
   Kirkegaard K, 2004, NAT REV MICROBIOL, V2, P301, DOI 10.1038/nrmicro865
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Klionsky DJ, 2010, AUTOPHAGY, V6, P438, DOI 10.4161/auto.6.4.12244
   Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X
   Kokame K, 2001, J BIOL CHEM, V276, P9199, DOI 10.1074/jbc.M010486200
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kuma A, 2002, J BIOL CHEM, V277, P18619, DOI 10.1074/jbc.M111889200
   Lan F, 2008, J BIOL CHEM, V283, P27628, DOI 10.1074/jbc.M805711200
   Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003
   Lee AH, 2003, P NATL ACAD SCI USA, V100, P9946, DOI 10.1073/pnas.1334037100
   Lee HK, 2007, SCIENCE, V315, P1398, DOI 10.1126/science.1136880
   Lee HK, 2010, IMMUNITY, V32, P227, DOI 10.1016/j.immuni.2009.12.006
   Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105
   Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702
   Lee MS, 2011, PHYTOTHER RES, V25, P833, DOI 10.1002/ptr.3323
   Lee SY, 2008, CELL MICROBIOL, V10, P770, DOI 10.1111/j.1462-5822.2007.01083.x
   Lee YK, 2010, ONCOL REP, V24, P1471, DOI 10.3892/or_00001007
   Legakis JE, 2007, AUTOPHAGY, V3, P422, DOI 10.4161/auto.4129
   Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41
   Leverve XM, 2003, DIABETES METAB, V29, pS88
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   LEVINE SJ, 1995, AM J RESP CELL MOL, V12, P196, DOI 10.1165/ajrcmb.12.2.7865217
   Levy JMM, 2011, PHARMACOL THERAPEUT, V131, P130, DOI 10.1016/j.pharmthera.2011.03.009
   Li JD, 1997, P NATL ACAD SCI USA, V94, P967, DOI 10.1073/pnas.94.3.967
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Libby G, 2009, DIABETES CARE, V32, P1620, DOI 10.2337/dc08-2175
   Linden SK, 2008, MUCOSAL IMMUNOL, V1, P183, DOI 10.1038/mi.2008.5
   Liu B, 2010, ACTA PHARMACOL SIN, V31, P1154, DOI 10.1038/aps.2010.118
   Liu JJ, 2011, CANCER LETT, V300, P105, DOI 10.1016/j.canlet.2010.10.001
   Louahed J, 2000, AM J RESP CELL MOL, V22, P649, DOI 10.1165/ajrcmb.22.6.3927
   Lu SP, 2010, BBA-PROTEINS PROTEOM, V1804, P1567, DOI 10.1016/j.bbapap.2009.09.030
   Lynn A, 2006, P NUTR SOC, V65, P135, DOI 10.1079/PNS2005486
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001
   Maloy KJ, 2011, NATURE, V474, P298, DOI 10.1038/nature10208
   MANN SS, 1994, J BIOL CHEM, V269, P11492
   Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532
   Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P4297, DOI 10.4161/cc.9.21.13817
   Massey DCO, 2008, GUT, V57, P1294, DOI 10.1136/gut.2008.157297
   Massey DCO, 2007, AUTOPHAGY, V3, P649, DOI 10.4161/auto.5075
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   McCarroll SA, 2008, NAT GENET, V40, P1107, DOI 10.1038/ng.215
   McGuckin MA, 2010, AM J PHYSIOL-GASTR L, V298, pG820, DOI 10.1152/ajpgi.00063.2010
   McPhee CK, 2009, BBA-MOL CELL RES, V1793, P1452, DOI 10.1016/j.bbamcr.2009.02.009
   Mcvay LD, 2006, J CLIN INVEST, V116, P2914, DOI 10.1172/JCI28121
   Mercer CA, 2009, AUTOPHAGY, V5, P649, DOI 10.4161/auto.5.5.8249
   Meschini S, 2011, CURR CANCER DRUG TAR, V11, P357, DOI 10.2174/156800911794519707
   Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704
   Mizushima N, 2003, J CELL SCI, V116, P1679, DOI 10.1242/jcs.00381
   Mizushima N, 1998, J BIOL CHEM, V273, P33889, DOI 10.1074/jbc.273.51.33889
   Mizushima N, 2010, CURR OPIN CELL BIOL, V22, P132, DOI 10.1016/j.ceb.2009.12.004
   Morselli E, 2008, CELL CYCLE, V7, P3056, DOI 10.4161/cc.7.19.6751
   Morselli E, 2009, BBA-MOL CELL RES, V1793, P1524, DOI 10.1016/j.bbamcr.2009.01.006
   Nakamura Y, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-100
   Navarro SL, 2011, FOOD FUNCT, V2, P579, DOI 10.1039/c1fo10114e
   Nemoto S, 2009, J BIOL CHEM, V284, P10422, DOI 10.1074/jbc.M900735200
   Nishikawa T, 2010, ANN SURG ONCOL, V17, P592, DOI 10.1245/s10434-009-0696-x
   Nishino Ichizo, 2003, Curr Neurol Neurosci Rep, V3, P64, DOI 10.1007/s11910-003-0040-y
   Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302
   Nosho K, 2009, MODERN PATHOL, V22, P922, DOI 10.1038/modpathol.2009.49
   O'Connor PM, 2010, INFLAMM BOWEL DIS, V16, P1411, DOI 10.1002/ibd.21217
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522
   Okamoto I, 2010, JPN J CLIN ONCOL, V40, P17, DOI 10.1093/jjco/hyp120
   Ouellette AJ, 1997, GASTROENTEROLOGY, V113, P1779, DOI 10.1053/gast.1997.v113.pm9352884
   Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160
   PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x
   Papandreou I, 2008, CELL DEATH DIFFER, V15, P1572, DOI 10.1038/cdd.2008.84
   Payne CM, 2009, J TOXICOL-US, V2009, DOI 10.1155/2009/785907
   Perrais M, 2002, J BIOL CHEM, V277, P32258, DOI 10.1074/jbc.M204862200
   Pitts TM, 2009, MOL CANCER THER, V8, P342, DOI 10.1158/1535-7163.MCT-08-0534
   PODOLSKY DK, 1991, NEW ENGL J MED, V325, P928, DOI 10.1056/NEJM199109263251306
   Pyrko P, 2007, CANCER RES, V67, P10920, DOI 10.1158/0008-5472.CAN-07-0796
   Radtke F, 2005, SCIENCE, V307, P1904, DOI 10.1126/science.1104815
   Ramjeet M, 2010, GUT MICROBES, V1, P307, DOI 10.4161/gmic.1.5.13295
   Rath E, 2011, EUR J NUTR, V50, P219, DOI 10.1007/s00394-011-0197-0
   REDDY BS, 1977, CANCER RES, V37, P3238
   RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555
   Rodriguez-Gonzalez A, 2008, CANCER RES, V68, P2557, DOI 10.1158/0008-5472.CAN-07-5989
   Rogler G, 1998, GASTROENTEROLOGY, V115, P357, DOI 10.1016/S0016-5085(98)70202-1
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Roulin D, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-57
   SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815
   Saif MW, 2010, CANCER J, V16, P196, DOI 10.1097/PPO.0b013e3181e076af
   Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383
   Sakaki K, 2008, J BIOL CHEM, V283, P15370, DOI 10.1074/jbc.M710209200
   Saleh M, 2011, IMMUNOL REV, V243, P235, DOI 10.1111/j.1600-065X.2011.01045.x
   Salzman NH, 2010, NAT IMMUNOL, V11, P76, DOI 10.1038/ni.1825
   Sanjuan MA, 2007, NATURE, V450, P1253, DOI 10.1038/nature06421
   Sarkar S, 2009, METHOD ENZYMOL, V453, P83, DOI 10.1016/S0076-6879(08)04005-6
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Schenk M, 2008, BEST PRACT RES CL GA, V22, P391, DOI 10.1016/j.bpg.2007.11.002
   Scherz-Shouval R, 2010, P NATL ACAD SCI USA, V107, P18511, DOI 10.1073/pnas.1006124107
   Schleicher SM, 2010, DRUG RESIST UPDATE, V13, P79, DOI 10.1016/j.drup.2010.04.002
   Schmid D, 2007, IMMUNITY, V27, P11, DOI 10.1016/j.immuni.2007.07.004
   Schmid D, 2007, IMMUNITY, V26, P79, DOI 10.1016/j.immuni.2006.10.018
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
   Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Selsted ME, 2005, NAT IMMUNOL, V6, P551, DOI 10.1038/ni1206
   Selzner M, 2001, CANCER RES, V61, P1233
   Shacka JJ, 2006, AUTOPHAGY, V2, P228, DOI 10.4161/auto.2703
   Shang LB, 2011, AUTOPHAGY, V7, P924, DOI 10.4161/auto.7.8.15860
   Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102
   Shaw RJ, 2009, ACTA PHYSIOL, V196, P65, DOI 10.1111/j.1748-1716.2009.01972.x
   Shih David Q, 2008, Curr Gastroenterol Rep, V10, P568, DOI 10.1007/s11894-008-0104-x
   Shkoda A, 2007, GASTROENTEROLOGY, V132, P190, DOI 10.1053/j.gastro.2006.10.030
   Sigmond T, 2008, METHOD ENZYMOL, V451, P521, DOI 10.1016/S0076-6879(08)03230-8
   Singh SB, 2006, SCIENCE, V313, P1438, DOI 10.1126/science.1129577
   Slattery ML, 2010, CARCINOGENESIS, V31, P1604, DOI 10.1093/carcin/bgq142
   Stappenbeck TS, 2011, AUTOPHAGY, V7, P355, DOI [10.4161/auto.7.4.13074, 10.4161/auto.7.2.13074]
   Stephenson LM, 2009, AUTOPHAGY, V5, P625, DOI 10.4161/auto.5.5.8133
   Stuenkel Walter, 2007, Biotechnology Journal, V2, P1360, DOI 10.1002/biot.200700087
   Sui XB, 2011, AUTOPHAGY, V7, P565, DOI 10.4161/auto.7.6.14073
   Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971
   Tabernero J, 2008, J CLIN ONCOL, V26, P1603, DOI 10.1200/JCO.2007.14.5482
   TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301
   Tal MC, 2009, P NATL ACAD SCI USA, V106, P2770, DOI 10.1073/pnas.0807694106
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200
   Thyagarajan A, 2010, NUTR CANCER, V62, P630, DOI 10.1080/01635580903532390
   Tian Y, 2010, CELL, V141, P1042, DOI 10.1016/j.cell.2010.04.034
   Todd DJ, 2008, NAT REV IMMUNOL, V8, P663, DOI 10.1038/nri2359
   Todde V, 2009, BBA-MOL BASIS DIS, V1792, P3, DOI 10.1016/j.bbadis.2008.10.016
   Tomimoto A, 2008, CANCER SCI, V99, P2136, DOI 10.1111/j.1349-7006.2008.00933.x
   Travassos LH, 2010, NAT IMMUNOL, V11, P55, DOI 10.1038/ni.1823
   Turcotte S, 2010, CURR OPIN CELL BIOL, V22, P246, DOI 10.1016/j.ceb.2009.12.007
   Uchiyama Y, 2008, HISTOCHEM CELL BIOL, V129, P407, DOI 10.1007/s00418-008-0406-y
   Ullman TA, 2011, GASTROENTEROLOGY, V140, P1807, DOI 10.1053/j.gastro.2011.01.057
   Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664
   Ustundag Y, 2007, WORLD J GASTROENTERO, V13, P851, DOI 10.3748/wjg.v13.i6.851
   Vaishnava S, 2008, P NATL ACAD SCI USA, V105, P20858, DOI 10.1073/pnas.0808723105
   Wagner M, 2009, J GASTROINTEST SURG, V13, P1781, DOI 10.1007/s11605-009-0948-x
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Wu L, 2011, CURR MED CHEM, V18, P1866, DOI 10.2174/092986711795496773
   Wu YC, 2009, BIOCHEM BIOPH RES CO, V382, P451, DOI 10.1016/j.bbrc.2009.03.051
   Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016
   Xiong HY, 2010, CANCER LETT, V288, P68, DOI 10.1016/j.canlet.2009.06.039
   Xu Y, 2007, IMMUNITY, V27, P135, DOI 10.1016/j.immuni.2007.05.022
   Xue X, 2005, J BIOL CHEM, V280, P33917, DOI 10.1074/jbc.M505818200
   Yamamoto K, 2007, DEV CELL, V13, P365, DOI 10.1016/j.devcel.2007.07.018
   Yang Q, 2007, CELL RES, V17, P666, DOI 10.1038/cr.2007.64
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yang ZF, 2009, CURR TOP MICROBIOL, V335, P1, DOI 10.1007/978-3-642-00302-8_1
   Yang ZNJ, 2011, CANCER BIOL THER, V11, P169, DOI 10.4161/cbt.11.2.14663
   Yorimitsu T, 2007, AUTOPHAGY, V3, P160, DOI 10.4161/auto.3653
   Yorimitsu T, 2006, J BIOL CHEM, V281, P30299, DOI 10.1074/jbc.M607007200
   Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0
   Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741
   Yoshimoto K, 2010, FEBS LETT, V584, P1350, DOI 10.1016/j.febslet.2010.01.007
   Yuk JM, 2010, AUTOPHAGY, V6, P46, DOI 10.4161/auto.6.1.10325
   Zakikhani M, 2008, CANCER PREV RES, V1, P369, DOI 10.1158/1940-6207.CAPR-08-0081
   Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203
   Zhang T, 2010, BBA-PROTEINS PROTEOM, V1804, P1666, DOI 10.1016/j.bbapap.2009.10.022
   Zhang YJ, 2011, DRUG DISCOV TODAY, V16, P325, DOI 10.1016/j.drudis.2011.02.008
   Zhang YJ, 2009, ANN SURG ONCOL, V16, P2617, DOI 10.1245/s10434-009-0555-9
   Zhang YJ, 2009, INT J COLORECTAL DIS, V24, P629, DOI 10.1007/s00384-009-0664-8
   Zhao F, 2010, DEV BIOL, V338, P268, DOI 10.1016/j.ydbio.2009.12.008
   Zheng YZ, 2009, CANCER INVEST, V27, P286, DOI 10.1080/07357900802427927
   Zhou DL, 2005, IMMUNITY, V22, P571, DOI 10.1016/j.immuni.2005.03.009
NR 316
TC 27
Z9 27
U1 0
U2 28
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD SEP
PY 2012
VL 18
IS 26
BP 3853
EP 3873
DI 10.2174/138161212802083653
PG 21
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 993OV
UT WOS:000307870100004
PM 22632751
DA 2022-04-25
ER

PT J
AU Tang, SN
   Cai, SN
   Ji, S
   Yan, XJ
   Zhang, WJ
   Qiao, X
   Zhang, HQ
   Ye, M
   Yu, SW
AF Tang, Shunan
   Cai, Sina
   Ji, Shuai
   Yan, Xiaojin
   Zhang, Weijia
   Qiao, Xue
   Zhang, Hongquan
   Ye, Min
   Yu, Siwang
TI Isoangustone A induces autophagic cell death in colorectal cancer cells
   by activating AMPK signaling
SO FITOTERAPIA
LA English
DT Article
DE Prenylated flavonoids; Isoangustone A; Autophagy; Apoptosis; AMPK
ID BIOLOGICAL-ACTIVITIES; ADENOCARCINOMA CELLS; DUAL ROLE; MTOR;
   INHIBITION; MODULATION; FLAVONOIDS; APOPTOSIS; PROTEIN; TARGET
AB Phytochemicals, especially flavonoids, have been widely investigated for their diversified pharmacological activities including anticancer activities. Previously we identified isoangustone A from licorice-derived compounds as a potent inducer of cell death. In the present study, the exact mechanism by which isoangustone A induced cell death was further investigated, with autophagy as an indispensible part of this process. Isoangustone A treatment activated autophagic signaling and induced a complete autophagic flux in colorectal cancer cells. Knockdown of ATG5 or pre-treatment with autophagy inhibitors significantly reversed isoangustone A-induced apoptotic signaling and loss of cell viability, suggesting autophagy plays an important role in isoangustone A-induced cell death. Isoangustone A inhibited Akt/mTOR signaling, and overexpressing of a constitutively activated Akt mildly suppressed isoangustone A-induced cell death. More importantly, isoangustone A inhibited cellular ATP level and activated AMPK, and pre-treatment with AMPK inhibitor or overexpression of dominant negative AMPK alpha 2 significantly reversed isoangustone A-induced autophagy and cell death. Further study shows isoangustone A dose-dependently inhibited mitochondrial respiration, which could be responsible for isoangustone A-induced activation of AMPK. Finally, isoangustone A at a dosage of 10 mg/kg potently activated AMPK and autophagic signaling in and inhibited the growth of SW480 human colorectal xenograft in vivo. Taken together, induction of autophagy through activation of AMPK is an important mechanism by which isoangustone A inhibits tumor growth, and isoangustone A deserves further investigation as a promising anti-cancer agent.
C1 [Tang, Shunan; Cai, Sina; Ji, Shuai; Yan, Xiaojin; Zhang, Weijia; Qiao, Xue; Zhang, Hongquan; Ye, Min; Yu, Siwang] Peking Univ, State Key Lab Nat & Biomimet Drugs, Sch Pharmaceut Sci, Beijing 100191, Peoples R China.
   [Tang, Shunan; Cai, Sina; Yan, Xiaojin; Zhang, Weijia; Yu, Siwang] Peking Univ, Dept Mol & Cellular Pharmacol, Sch Pharmaceut Sci, Beijing 100191, Peoples R China.
   [Ji, Shuai; Qiao, Xue; Ye, Min] Peking Univ, Dept Nat Med, Sch Pharmaceut Sci, Beijing 100191, Peoples R China.
   [Zhang, Hongquan] Peking Univ, Dept Anat Histol & Embryol, Sch Basic Med Sci, Beijing, Peoples R China.
RP Ye, M; Yu, SW (corresponding author), Peking Univ, State Key Lab Nat & Biomimet Drugs, Sch Pharmaceut Sci, Beijing 100191, Peoples R China.
EM yemin@bjmu.edu.cn; swang_yu@hsc.pku.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81472657, 81891011, 81730071]
FX This research was supported by the National Natural Science Foundation
   of China (81472657, 81891011 and 81730071) , and the funding source has
   not been involved in the study design, the collection,
   analysisFitoterapia (2021) and interpretation of data, or in the writing
   of the report. The authors thank Dr. AhNg Tony Kong at Rutgers, the
   State University of New Jersey for providing necessary plasmids, and all
   the members of Yu's group for technical assistance and critical
   discussions.
CR Abotaleb M, 2019, CANCERS, V11, DOI 10.3390/cancers11010028
   Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11
   Asl MN, 2008, PHYTOTHER RES, V22, P709, DOI 10.1002/ptr.2362
   Banh RS, 2016, NAT CELL BIOL, V18, P803, DOI 10.1038/ncb3376
   Boozari M, 2019, PHYTOTHER RES, V33, P546, DOI 10.1002/ptr.6265
   Botta B, 2009, CURR MED CHEM, V16, P3414, DOI 10.2174/092986709789057662
   Chen HY, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102025
   Chen X, 2014, PHARM BIOL, V52, P655, DOI 10.3109/13880209.2013.853809
   Gaballah HH, 2017, TOXICOL APPL PHARM, V316, P27, DOI 10.1016/j.taap.2016.12.012
   Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966
   Hasima N, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.467
   Hsieh MJ, 2014, BRIT J PHARMACOL, V171, P3037, DOI 10.1111/bph.12626
   Huang W, 2014, FITOTERAPIA, V94, P36, DOI 10.1016/j.fitote.2014.01.016
   Hui S., 2013, ANTI-CANCER AGENT ME, V13, DOI [10.2174/18715206113139990130, DOI 10.2174/18715206113139990130]
   Ji S, 2017, TOXICOL APPL PHARM, V326, P25, DOI 10.1016/j.taap.2017.04.015
   Ji S, 2016, J NAT PROD, V79, P281, DOI 10.1021/acs.jnatprod.5b00877
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Lam W, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001270
   Lee E, 2013, TOXICOL APPL PHARM, V272, P12, DOI 10.1016/j.taap.2013.04.030
   Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143
   Lorin S, 2013, SEMIN CANCER BIOL, V23, P361, DOI 10.1016/j.semcancer.2013.06.007
   Luzio JP, 2007, NAT REV MOL CELL BIO, V8, P622, DOI 10.1038/nrm2217
   Marinangeli C, 2018, METHODS MOL BIOL, V1732, P289, DOI 10.1007/978-1-4939-7598-3_19
   Munson MJ, 2015, AUTOPHAGY, V11, P2375, DOI 10.1080/15548627.2015.1106668
   Ohno H, 2013, ANTICANCER RES, V33, P3061
   Seon MR, 2012, J NUTR BIOCHEM, V23, P85, DOI 10.1016/j.jnutbio.2010.11.010
   Seon MR, 2010, MOL NUTR FOOD RES, V54, P1329, DOI 10.1002/mnfr.200900260
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Singh SS, 2018, ONCOGENE, V37, P1142, DOI 10.1038/s41388-017-0046-6
   Song NR, 2013, CANCER PREV RES, V6, P1293, DOI 10.1158/1940-6207.CAPR-13-0134
   Song XH, 2016, ONCOTARGET, V7, P65732, DOI 10.18632/oncotarget.11610
   Suh Y, 2010, CARCINOGENESIS, V31, P1424, DOI 10.1093/carcin/bgq115
   Tang ShuNan, 2016, Journal of Chinese Pharmaceutical Sciences, V25, P23
   Venturelli S, 2016, NUTRITION, V32, P1171, DOI 10.1016/j.nut.2016.03.020
   Wang ZY, 2001, NUTR CANCER, V39, P1, DOI 10.1207/S15327914nc391_1
   Wu CH, 2016, ONCOTARGET, V7, P73432, DOI 10.18632/oncotarget.12369
   Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796
   Xiao XY, 2011, CANCER LETT, V302, P69, DOI 10.1016/j.canlet.2010.12.016
   Yo YT, 2009, J AGR FOOD CHEM, V57, P8266, DOI 10.1021/jf901054c
   Yu SW, 2008, MOL CANCER THER, V7, P2609, DOI 10.1158/1535-7163.MCT-07-2400
NR 43
TC 1
Z9 1
U1 11
U2 14
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0367-326X
EI 1873-6971
J9 FITOTERAPIA
JI Fitoterapia
PD JUL
PY 2021
VL 152
AR 104935
DI 10.1016/j.fitote.2021.104935
EA MAY 2021
PG 12
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA SV4YZ
UT WOS:000663829000002
PM 34004245
DA 2022-04-25
ER

PT J
AU Wu, JC
   Lai, CS
   Badmaev, V
   Nagabhushanam, K
   Ho, CT
   Pan, MH
AF Wu, Jia-Ching
   Lai, Ching-Shu
   Badmaev, Vladimir
   Nagabhushanam, Kalyanam
   Ho, Chi-Tang
   Pan, Min-Hsiung
TI Tetrahydrocurcumin, a major metabolite of curcumin, induced autophagic
   cell death through coordinative modulation of PI3K/Akt-mTOR and MAPK
   signaling pathways in human leukemia HL-60 cells
SO MOLECULAR NUTRITION & FOOD RESEARCH
LA English
DT Article
DE Autophagy; Curcumin; Tetrahydrocurcumin
ID MALIGNANT GLIOMA-CELLS; CANCER; RADIATION; APOPTOSIS; AKT
AB Scope: Autophagy (type II programmed cell death) is crucial for maintaining cellular homeostasis. Several autophagy-deficient or knockout studies indicate that autophagy is a tumor suppressor. Tetrahydrocurcumin (THC), a major metabolite of curcumin, has been demonstrated with anti-colon carcinogenesis and antioxidation in vivo.
   Methods and results: In the present study, we found that treatment with THC induced autophagic cell death in human HL-60 promyelocytic leukemia cells by increasing autophage marker acidic vascular organelle (AVO) formation. Flow cytometry also confirmed that THC treatment did not increase sub-G1 cell population whereas curcumin did with strong apoptosis-inducing activity. At the molecular levels, the results from Western blot analysis showed that THC significantly down-regulated phosphatidylinositol 3-kinase/protein kinase B and mitogen-activated protein kinase signalings including decreasing the phosphorylation of mammalian target of rapamycin, glycogen synthase kinase 3 beta and p70 ribosomal protein S6 kinase. Further molecular analysis exhibited that the pretreatment of 3-methyladenine (an autophagy inhibitor) also significantly reduced acidic vascular organelle production in THC-treated cells.
   Conclusion: Taken together, these results demonstrated the anticancer efficacy of THC by inducing autophagy as well as provided a potential application for the prevention of human leukemia.
C1 [Wu, Jia-Ching; Lai, Ching-Shu; Pan, Min-Hsiung] Natl Kaohsiung Marine Univ, Dept Seafood Sci, Kaohsiung 81143, Taiwan.
   [Badmaev, Vladimir] Lab Appl Pharmacol, Staten Isl, NY USA.
   [Nagabhushanam, Kalyanam] Sabinsa Corp, E Windsor, NJ USA.
   [Ho, Chi-Tang] Rutgers State Univ, Dept Food Sci, New Brunswick, NJ 08903 USA.
RP Pan, MH (corresponding author), Natl Kaohsiung Marine Univ, Dept Seafood Sci, 142 Haijhuan Rd, Kaohsiung 81143, Taiwan.
EM mhpan@mail.nkmu.edu.tw
RI Pan, Min-Hsiung/AAT-8865-2021
OI Pan, Min-Hsiung/0000-0002-5188-7030
FU National Science Council NSCMinistry of Science and Technology, Taiwan
   [98-2313-B-022-002-MY3, 98-2321-B-022-001, 100-2918-I-022-005]
FX This study was supported by the National Science Council NSC
   98-2313-B-022-002-MY3, 98-2321-B-022-001, and 100-2918-I-022-005.
CR Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200
   Blommaart EF, 1997, HISTOCHEM J, V290, P1717
   Boylan JM, 2001, J BIOL CHEM, V276, P44457, DOI 10.1074/jbc.M103457200
   Cecconi F, 2008, DEV CELL, V15, P344, DOI 10.1016/j.devcel.2008.08.012
   Chen RJ, 2010, MOL NUTR FOOD RES, V54, P1819, DOI 10.1002/mnfr.201000067
   Cheng AL, 2001, ANTICANCER RES, V21, P2895
   Chiu HW, 2009, AUTOPHAGY, V5, P472, DOI 10.4161/auto.5.4.7759
   Coward J, 2009, AUTOPHAGY, V5, P184, DOI 10.4161/auto.5.2.7361
   Cui Q, 2007, J PHARMACOL SCI, V105, P317, DOI 10.1254/jphs.FP0070336
   DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923
   Easton JB, 2006, ONCOGENE, V25, P6436, DOI 10.1038/sj.onc.1209886
   FENGSRUD M, 1995, EXP CELL RES, V221, P504, DOI 10.1006/excr.1995.1402
   Fujiwara K, 2007, INT J ONCOL, V31, P753
   Gao M, 2008, CANCER RES, V68, P9348, DOI 10.1158/0008-5472.CAN-08-1642
   Hoehle SI, 2006, J AGR FOOD CHEM, V54, P756, DOI 10.1021/jf058146a
   HOLDER GM, 1978, XENOBIOTICA, V8, P761, DOI 10.3109/00498257809069589
   Hung JY, 2009, J AGR FOOD CHEM, V57, P9809, DOI 10.1021/jf902315e
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Kelekar A, 2008, AUTOPHAGY, V4, P555, DOI 10.4161/auto.6396
   Kim EH, 2007, CANCER RES, V67, P6314, DOI 10.1158/0008-5472.CAN-06-4217
   Kim JM, 1998, CARCINOGENESIS, V19, P81, DOI 10.1093/carcin/19.1.81
   Lefranc F, 2007, ONCOLOGIST, V12, P1395, DOI 10.1634/theoncologist.12-12-1395
   Lin CC, 2007, J CELL PHYSIOL, V211, P771, DOI 10.1002/jcp.20987
   Lin JK, 2000, BIOFACTORS, V13, P153, DOI 10.1002/biof.5520130125
   Luo J, 2009, CANCER LETT, V273, P194, DOI 10.1016/j.canlet.2008.05.045
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Naito Michitaka, 2002, J Atheroscler Thromb, V9, P243
   Okada K, 2001, J NUTR, V131, P2090, DOI 10.1093/jn/131.8.2090
   Paglin S, 2001, CANCER RES, V61, P439
   Pan MH, 1999, DRUG METAB DISPOS, V27, P486
   Pan MH, 2009, J AGR FOOD CHEM, V57, P4467, DOI 10.1021/jf900612n
   Pari L, 2004, PHARMACOL RES, V49, P481, DOI 10.1016/j.phrs.2003.11.005
   Peng PL, 2008, INT J RADIAT ONCOL, V70, P529, DOI 10.1016/j.ijrobp.2007.08.034
   Rusten TE, 2004, DEV CELL, V7, P179, DOI 10.1016/j.devcel.2004.07.005
   Sandur SK, 2007, CARCINOGENESIS, V28, P1765, DOI 10.1093/carcin/bgm123
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Yap TA, 2008, CURR OPIN PHARMACOL, V8, P393, DOI 10.1016/j.coph.2008.08.004
   Yodkeeree S, 2008, ACTA PHARMACOL SIN, V29, P853, DOI 10.1111/j.1745-7254.2008.00792.x
   Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103
NR 40
TC 85
Z9 89
U1 1
U2 39
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1613-4125
EI 1613-4133
J9 MOL NUTR FOOD RES
JI Mol. Nutr. Food Res.
PD NOV
PY 2011
VL 55
IS 11
BP 1646
EP 1654
DI 10.1002/mnfr.201100454
PG 9
WC Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology
GA 855RI
UT WOS:000297581500005
PM 21928294
DA 2022-04-25
ER

PT J
AU Wu, YC
   Wang, XJ
   Yu, L
   Chan, FKL
   Cheng, ASL
   Yu, J
   Sung, JJY
   Wu, WKK
   Cho, CH
AF Wu, Ya C.
   Wang, Xiao J.
   Yu, Le
   Chan, Francis K. L.
   Cheng, Alfred S. L.
   Yu, Jun
   Sung, Joseph J. Y.
   Wu, William K. K.
   Cho, Chi H.
TI Hydrogen Sulfide Lowers Proliferation and Induces Protective Autophagy
   in Colon Epithelial Cells
SO PLOS ONE
LA English
DT Article
ID ULCERATIVE-COLITIS; IN-VITRO; CANCER; PROTEIN; HUMANS
AB Hydrogen sulfide (H2S) is a gaseous bacterial metabolite that reaches high levels in the large intestine. In the present study, the effect of H2S on the proliferation of normal and cancerous colon epithelial cells was investigated. An immortalized colon epithelial cell line (YAMC) and a panel of colon cancer cell lines (HT-29, SW1116, HCT116) were exposed to H2S at concentrations similar to those found in the human colon. H2S inhibited normal and cancerous colon epithelial cell proliferation as measured by MTT assay. The anti-mitogenic effect of H2S was accompanied by G(1)-phase cell cycle arrest and the induction of the cyclin-dependent kinase inhibitor p21(Cip). Moreover, exposure to H2S led to features characteristic of autophagy, including increased formation of LC3B(+) autophagic vacuoles and acidic vesicular organelles as determined by immunofluorescence and acridine orange staining, respectively. Abolition of autophagy by RNA interference targeting Vps34 or Atg7 enhanced the anti-proliferative effect of H2S. Further mechanistic investigation revealed that H2S stimulated the phosphorylation of AMP-activated protein kinase (AMPK) and inhibited the phosphorylation of mammalian target of rapamycin (mTOR) and S6 kinase. Inhibition of AMPK significantly reversed H2S-induced autophagy and inhibition of cell proliferation. Collectively, we demonstrate that H2S inhibits colon epithelial cell proliferation and induces protective autophagy via the AMPK pathway.
C1 [Wu, Ya C.; Yu, Le; Cho, Chi H.] Chinese Univ Hong Kong, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China.
   [Wang, Xiao J.; Chan, Francis K. L.; Cheng, Alfred S. L.; Yu, Jun; Sung, Joseph J. Y.; Wu, William K. K.] Chinese Univ Hong Kong, Inst Digest Dis, LKS Inst Hlth Sci, Shatin, Hong Kong, Peoples R China.
   [Wang, Xiao J.; Chan, Francis K. L.; Cheng, Alfred S. L.; Yu, Jun; Sung, Joseph J. Y.; Wu, William K. K.] Chinese Univ Hong Kong, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China.
RP Wu, YC (corresponding author), Chinese Univ Hong Kong, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China.
EM wukakei@cuhk.edu.hk
RI Wu, William K.K./A-3277-2009; Cho, Chi Hin/C-6543-2014; Chan, Francis K.
   L./F-4851-2010; Cheng, Alfred SL/C-3327-2014; Sung, Joseph J.
   Y./R-3203-2018; Yu, Jun/D-8569-2015
OI Wu, William K.K./0000-0002-5662-5240; Cho, Chi Hin/0000-0002-7658-3260;
   Chan, Francis K. L./0000-0001-7388-2436; Cheng, Alfred
   SL/0000-0003-2345-6951; Sung, Joseph J. Y./0000-0003-3125-5199; Yu,
   Jun/0000-0001-5008-2153
CR Bian JS, 2006, J PHARMACOL EXP THER, V316, P670, DOI 10.1124/jpet.105.092023
   Diaz-Troya S, 2008, AUTOPHAGY, V4, P851, DOI 10.4161/auto.6555
   Fiorucci S, 2007, BRIT J PHARMACOL, V150, P996, DOI 10.1038/sj.bjp.0707193
   FLORIN T, 1991, GUT, V32, P766, DOI 10.1136/gut.32.7.766
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Kawabata A, 2007, PAIN, V132, P74, DOI 10.1016/j.pain.2007.01.026
   Kimura Y, 2004, FASEB J, V18, P1165, DOI 10.1096/fj.04-1815fje
   Levine J, 1998, AM J GASTROENTEROL, V93, P83, DOI 10.1111/j.1572-0241.1998.083_c.x
   MACFARLANE GT, 1992, J APPL BACTERIOL, V72, P57, DOI 10.1111/j.1365-2672.1992.tb05187.x
   Magee EA, 2000, AM J CLIN NUTR, V72, P1488
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Meijer AJ, 2007, AUTOPHAGY, V3, P238, DOI 10.4161/auto.3710
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Picton R, 2007, DIGEST DIS SCI, V52, P373, DOI 10.1007/s10620-006-9529-y
   Ramasamy S, 2006, AM J PHYSIOL-GASTR L, V291, pG288, DOI 10.1152/ajpgi.00324.2005
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Schicho R, 2006, GASTROENTEROLOGY, V131, P1542, DOI 10.1053/j.gastro.2006.08.035
   Teague B, 2002, BRIT J PHARMACOL, V137, P139, DOI 10.1038/sj.bjp.0704858
   Tripatara P, 2008, LAB INVEST, V88, P1038, DOI 10.1038/labinvest.2008.73
   Turk HF, 2011, INT J CANCER, V128, P63, DOI 10.1002/ijc.25323
   Wallace JL, 2007, FASEB J, V21, P4070, DOI 10.1096/fj.07-8669com
   Wallace JL, 2007, TRENDS PHARMACOL SCI, V28, P501, DOI 10.1016/j.tips.2007.09.003
   Wu WKK, 2012, ONCOGENE, V31, P939, DOI 10.1038/onc.2011.295
NR 24
TC 74
Z9 81
U1 1
U2 25
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 29
PY 2012
VL 7
IS 5
AR e37572
DI 10.1371/journal.pone.0037572
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 959WT
UT WOS:000305349600021
PM 22679478
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Lin, XT
   Wu, QN
   Qin, S
   Fan, DJ
   Lv, MY
   Chen, X
   Cai, JW
   Weng, JR
   Zou, YF
   Rong, YM
   Gao, F
AF Lin, Xu-tao
   Wu, Qiu-ning
   Qin, Si
   Fan, De-jun
   Lv, Min-yi
   Chen, Xi
   Cai, Jia-wei
   Weng, Jing-rong
   Zou, Yi-feng
   Rong, Yu-ming
   Gao, Feng
TI Identification of an Autophagy-Related Gene Signature for the Prediction
   of Prognosis in Early-Stage Colorectal Cancer
SO FRONTIERS IN GENETICS
LA English
DT Article
DE colorectal cancer; prognosis; early stage; disease-free survival;
   autophagy-related gene
ID II COLON-CANCER; ADJUVANT CHEMOTHERAPY; IMMUNE-RESPONSES; ALPHA; TUMOR;
   INTERFERON; VALIDATION; STAT3
AB Purpose: A certain number of early-stage colorectal cancer (CRC) patients suffer tumor recurrence after initial curative resection. In this context, an effective prognostic biomarker model is constantly in need. Autophagy exhibits a dual role in tumorigenesis. Our study aims to develop an autophagy-related gene (ATG) signature-based on high-throughput data analysis for disease-free survival (DFS) prognosis of patients with stage I/II CRC.Methods: Gene expression profiles and clinical information of CRC patients extracted from four public datasets were distributed to discovery and training cohort (GSE39582), validation cohort (TCGA CRC, n = 624), and meta-validation cohort (GSE37892 and GSE14333, n = 420). Autophagy genes significantly associated with prognosis were identified.Results: Among 655 autophagy-related genes, a 10-gene ATG signature, which was significantly associated with DFS in the training cohort (HR, 2.76[1.56-4.82]; p = 2.06 x 10-4), was constructed. The ATG signature, stratifying patients into high and low autophagy risk groups, was validated in the validation (HR, 2.29[1.15-4.55]; p = 1.5 x 10-2) and meta-validation cohorts (HR, 2.5[1.03-6.06]; p = 3.63 x 10-2) and proved to be prognostic in a multivariate analysis. Functional analysis revealed enrichment of several immune/inflammatory pathways in the high autophagy risk group, where increased infiltration of T regulatory cells (Tregs) and decreased infiltration of M1 macrophages were observed.Conclusion: Our study established a prognostic ATG signature that effectively predicted DFS for early-stage CRC patients. Meanwhile, the study also revealed the possible relationship among autophagy process, immune/inflammatory response, and tumorigenesis.
C1 [Lin, Xu-tao; Wu, Qiu-ning; Fan, De-jun] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Gastrointestinal Endoscopy, Guangzhou, Peoples R China.
   [Lin, Xu-tao; Wu, Qiu-ning; Qin, Si; Fan, De-jun; Lv, Min-yi; Chen, Xi; Cai, Jia-wei; Weng, Jing-rong; Zou, Yi-feng; Gao, Feng] Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Prov Key Lab Colorectal & Pelv Floor Di, Guangdong Inst Gastroenterol, Guangzhou, Peoples R China.
   [Qin, Si] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Med Ultrason, Guangzhou, Peoples R China.
   [Lv, Min-yi; Chen, Xi; Cai, Jia-wei; Weng, Jing-rong; Zou, Yi-feng; Gao, Feng] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, Guangzhou, Peoples R China.
   [Rong, Yu-ming] Sun Yat Sen Univ, Ctr Canc, Dept VIP Reg, Guangzhou, Peoples R China.
RP Gao, F (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Prov Key Lab Colorectal & Pelv Floor Di, Guangdong Inst Gastroenterol, Guangzhou, Peoples R China.; Gao, F (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, Guangzhou, Peoples R China.; Rong, YM (corresponding author), Sun Yat Sen Univ, Ctr Canc, Dept VIP Reg, Guangzhou, Peoples R China.
EM rongym@sysucc.org.cn; gaof57@mail.sysu.edu.cn
FU National Key Clinical Discipline; "5010 Clinical Research Program" of
   Sun Yat-sen University [2010012]; Natural Science Foundation of
   Guangdong Province, ChinaNational Natural Science Foundation of
   Guangdong Province [2020A1515010428]; Medical Science Research Grant
   from the Health Department of Guangdong Province [A2018007]
FX This work was supported by National Key Clinical Discipline; and "5010
   Clinical Research Program" of Sun Yat-sen University (grant number
   2010012); and Natural Science Foundation of Guangdong Province, China
   (grant number 2020A1515010428); and Medical Science Research Grant from
   the Health Department of Guangdong Province (grant number A2018007).
CR Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Carroll RG, 2013, CANCER CELL, V23, P425, DOI 10.1016/j.ccr.2013.04.001
   Chen MC, 2019, CANCERS, V11, DOI 10.3390/cancers11101617
   Chen PW, 2014, AUTOPHAGY, V10, P192, DOI 10.4161/auto.26927
   Cheng L, 2021, INT J MED SCI, V18, P88, DOI 10.7150/ijms.49449
   De Simone V, 2015, ONCOGENE, V34, P3493, DOI 10.1038/onc.2014.286
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Edin S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047045
   Eguchi J, 2003, CANCER IMMUNOL IMMUN, V52, P378, DOI 10.1007/s00262-002-0367-2
   Giordano G, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-018-1019-5
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Hu FQ, 2018, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1260-z
   Huang Z, 2019, DOSE-RESPONSE, V17, DOI 10.1177/1559325819894179
   Kannarkatt J, 2017, J ONCOL PRACT, V13, P233, DOI 10.1200/JOP.2016.017210
   Kim SK, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0319-y
   Kongara S, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00171
   Koustas E, 2019, CANCERS, V11, DOI 10.3390/cancers11040533
   Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004
   Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260
   Markle B, 2010, CANCER METAST REV, V29, P395, DOI 10.1007/s10555-010-9234-3
   Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]
   NICHOLS PH, 1994, BRIT J CANCER, V70, P946, DOI 10.1038/bjc.1994.426
   O'Connor Erin S, 2011, J Clin Oncol, V29, P3381, DOI 10.1200/JCO.2010.34.3426
   Park JH, 2017, CLIN CANCER RES, V23, P1698, DOI 10.1158/1078-0432.CCR-16-1416
   Rosich L, 2013, AUTOPHAGY, V9, P115, DOI 10.4161/auto.22483
   Shapouri-Moghaddam A, 2018, J CELL PHYSIOL, V233, P6425, DOI 10.1002/jcp.26429
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   van der Stok EP, 2017, NAT REV CLIN ONCOL, V14, P297, DOI 10.1038/nrclinonc.2016.199
   White E, 2015, CLIN CANCER RES, V21, P5037, DOI 10.1158/1078-0432.CCR-15-0490
   Wing K, 2010, NAT IMMUNOL, V11, P7, DOI 10.1038/ni.1818
   Yang HD, 2019, HEPATOLOGY, V70, P1262, DOI 10.1002/hep.30657
   Zhang LL, 2017, EUR J PHARMACOL, V797, P1, DOI 10.1016/j.ejphar.2017.01.008
   Zhao HB, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.595099
   Zhao Y, 2010, NAT CELL BIOL, V12, P665, DOI 10.1038/ncb2069
   Zhi XY, 2018, CELL MOL LIFE SCI, V75, P815, DOI 10.1007/s00018-017-2657-z
   Zhou Z, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00878
NR 38
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD NOV 25
PY 2021
VL 12
AR 755789
DI 10.3389/fgene.2021.755789
PG 14
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA XM7CJ
UT WOS:000728980000001
PM 34899841
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Dukel, M
   Tavsan, Z
   Kayali, HA
AF Dukel, Muzaffer
   Tavsan, Zehra
   Kayali, Hulya Ayar
TI Flavonoids regulate cell death-related cellular signaling via ROS in
   human colon cancer cells
SO PROCESS BIOCHEMISTRY
LA English
DT Article
DE Colon cancer; Flavonoid; ROS; CAM; PKC; Cell death
AB Although several studies investigated effects of flavonoids on proliferation and apoptosis, yet no study has correlated the cellular damage caused by reactive oxygen species (ROS) production, cell death related pathways and cell adhesion molecules (CAM) expression with cell survival. Here, we investigate cytotoxic effect of catechin, epicatechin and naringenin on colon cancer cells. While especially naringenin demonstrated most significant inhibition of colon cancer cell viability, high concentrations treatment did not exhibit more pronounced effect in colon epithelial cells. In addition, these flavonoids caused excessive ROS generation resulting in the impairment of lipid and protein, followed by the induction of apoptosis and autophagy. In details, mechanism studies revealed that elevated ROS production leads to caspase activation and pretreated NAC, an antioxidant, blocks catechins and naringenin induced apoptosis and autophagy. PKC activity assay data also showed that catechin and naringenin treatment decreases PKC activity that leads to cell death. Moreover, studied flavonoids, especially naringenin, induced G2/M cell cycle arrest in a ROS-independent manner. Furthermore, the studied flavonoids suppressed or decreased the expression of the cancer progression and metastasis-related cell adhesion molecules. Taken together, our results indicate that studied flavonoids suppress colon cancer cell growth via inducing cell death in ROS dependent manner.
C1 [Dukel, Muzaffer] Mehmet Akif Ersoy Univ, Fac Art & Sci, Mol Biol & Genet Dept, TR-15100 Burdur, Turkey.
   [Dukel, Muzaffer; Tavsan, Zehra; Kayali, Hulya Ayar] Izmir Biomed & Genome Ctr, TR-35340 Izmir, Turkey.
   [Kayali, Hulya Ayar] Dokuz Eylul Univ, Sci Fac, Chem Dept, Biochem Div, TR-35390 Izmir, Turkey.
RP Kayali, HA (corresponding author), Izmir Biomed & Genome Ctr, TR-35340 Izmir, Turkey.
EM hulya.ayarkayali@ibg.edu.tr
RI Tavsan, Zehra/AAR-6576-2021
FU Dokuz Eylul University, Department of Scientific Research ProjectsDokuz
   Eylul University [KB.FEN.001]
FX This work was supported by the Dokuz Eylul University, Department of
   Scientific Research Projects (2016.KB.FEN.001). We thank to Technician
   Birgul Kehlibar who helps MTT analysis. Elcin Ca.gatay carried out the
   cell culture experiments of Annexin-V and cell cycle analysis. Duygu
   Erdo.gan helped in revising the manuscript. The authors declare that
   they have no competing interests.
CR Abotaleb M, 2019, CANCERS, V11, DOI 10.3390/cancers11010028
   Ahamad MS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110003
   Androutsopoulos VP, 2010, PHARMACOL THERAPEUT, V126, P9, DOI 10.1016/j.pharmthera.2010.01.009
   Bigelow RLH, 2006, ONCOGENE, V25, P1922, DOI 10.1038/sj.onc.1209227
   Boonstra J, 2004, GENE, V337, P1, DOI 10.1016/j.gene.2004.04.032
   BRACKE M, 1991, CLIN EXP METASTAS, V9, P13, DOI 10.1007/BF01831706
   Brady SC, 2005, MOL CELL BIOL, V25, P10543, DOI 10.1128/MCB.25.23.10543-10555.2005
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Chakrabarti M, 2016, APOPTOSIS, V21, P312, DOI 10.1007/s10495-015-1198-x
   Chen CC, 2004, MOL PHARMACOL, V66, P683
   Chen D, 2005, BIOCHEM PHARMACOL, V69, P1421, DOI 10.1016/j.bcp.2005.02.022
   Chiang CH, 2019, ANTICANCER RES, V39, P3641, DOI 10.21873/anticanres.13512
   Csupor-Loffler B, 2009, PHYTOTHER RES, V23, P672, DOI 10.1002/ptr.2697
   Cusimano A, 2017, INT J ONCOL, V51, P533, DOI 10.3892/ijo.2017.4049
   Czyz J, 2005, INT J CANCER, V114, P12, DOI 10.1002/ijc.20620
   DelCarlo M., AM J PHYSL CELL PHYS, V290
   Dukel M, 2019, CELL ADHES MIGR, V13, P83, DOI 10.1080/19336918.2018.1530933
   Dumontet V, 2004, J NAT PROD, V67, P858, DOI 10.1021/np030510h
   Farhan M, 2016, TOXINS, V8, DOI 10.3390/toxins8020037
   Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608
   George VC, 2017, J NUTR BIOCHEM, V45, P1, DOI 10.1016/j.jnutbio.2016.11.007
   Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5
   Han KY, 2018, ANTICANCER RES, V38, P6753, DOI 10.21873/anticanres.13045
   Hasima N, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.467
   Irimie AI, 2015, ONCOTARGETS THER, V8, P461, DOI 10.2147/OTT.S78358
   Jeong JC, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-44
   Jin H, 2013, ONCOL REP, V30, P2336, DOI 10.3892/or.2013.2711
   Jomova K, 2019, MOLECULES, V24, DOI 10.3390/molecules24234335
   Kato K, 2009, AM J PHYSIOL-HEART C, V297, pH2253, DOI 10.1152/ajpheart.00274.2009
   Kaul S, 2003, EUR J NEUROSCI, V18, P1387, DOI 10.1046/j.1460-9568.2003.02864.x
   Kim D, 2012, ANTICANCER RES, V32, P5353
   Kim SY, 2008, BIOCHEM BIOPH RES CO, V366, P493, DOI 10.1016/j.bbrc.2007.11.178
   Kim TK, 2015, BIOCHEM BIOPH RES CO, V468, P774, DOI 10.1016/j.bbrc.2015.11.031
   Papademetrio DL, 2013, REV BRAS FARMACOGN, V23, P455, DOI [10.1590/S0102-695X2013005000025, 10.1590/S0102-695X2013000300009]
   Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451
   Lee J, 2019, PHYTOMEDICINE, V58, DOI 10.1016/j.phymed.2018.11.022
   Li GX, 2010, CARCINOGENESIS, V31, P902, DOI 10.1093/carcin/bgq039
   Li RF, 2015, EXP THER MED, V9, P697, DOI 10.3892/etm.2015.2185
   Lim W, 2017, J CELL BIOCHEM, V118, P1118, DOI 10.1002/jcb.25729
   Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lolli G, 2012, BIOCHEMISTRY-US, V51, P6097, DOI 10.1021/bi300531c
   Maurya AK, 2015, TUMOR BIOL, V36, P8913, DOI 10.1007/s13277-015-3634-5
   Neilson AP, 2010, NUTR RES, V30, P327, DOI 10.1016/j.nutres.2010.05.006
   Okegawa T, 2004, ACTA BIOCHIM POL, V51, P445
   Patel K, 2018, CHIN J INTEGR MED, V24, P551, DOI 10.1007/s11655-014-1960-x
   Perez-Vizcaino F, 2009, PHARMACOL REP, V61, P67, DOI 10.1016/S1734-1140(09)70008-8
   Pericleous M, 2013, J GASTROINTEST ONCOL, V4, P409, DOI 10.3978/j.issn.2078-6891.2013.003
   Plaumann B, 1996, ONCOGENE, V13, P1605
   Prochazkova D, 2011, FITOTERAPIA, V82, P513, DOI 10.1016/j.fitote.2011.01.018
   Rabik CA, 2007, CANCER TREAT REV, V33, P9, DOI 10.1016/j.ctrv.2006.09.006
   Ravindranath MH, 2006, EVID-BASED COMPL ALT, V3, P237, DOI 10.1093/ecam/nel003
   Reyland ME, 2016, PHARMACOL THERAPEUT, V165, P1, DOI 10.1016/j.pharmthera.2016.05.001
   Rhouma HE, 2021, NAT PROD RES, V35, P1836, DOI 10.1080/14786419.2019.1637867
   Ryan-Harshman M, 2007, CAN FAM PHYSICIAN, V53, P1913
   Saralamma VVG, 2017, ONCOL LETT, V14, P607, DOI 10.3892/ol.2017.6184
   Shao JW, 2016, SCI REP-UK, V6, DOI 10.1038/srep30549
   Shi Q, 2017, AAPS J, V19, P1779, DOI 10.1208/s12248-017-0134-0
   Singh MP, 2018, ANTI-CANCER AGENT ME, V18, P428, DOI 10.2174/1871520617666171026170009
   Slivova V, 2005, NUTR CANCER, V52, P66, DOI 10.1207/s15327914nc5201_9
   Tamura N, 2011, CELL CYCLE, V10, P135, DOI 10.4161/cc.10.1.14448
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Yan W, 2019, J ADV RES, V20, P117, DOI 10.1016/j.jare.2019.06.002
   Yang GY, 1998, CARCINOGENESIS, V19, P611, DOI 10.1093/carcin/19.4.611
   Zhang L, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0075-3
   Zhang SY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10400-3
   Zhao YL, 2016, EUR J CANCER, V68, P38, DOI 10.1016/j.ejca.2016.09.001
   Zhao ZJ, 2019, INFLAMMOPHARMACOLOGY, V27, P1021, DOI 10.1007/s10787-018-00556-3
   Zhu T, 2010, ONCOGENE, V29, P1050, DOI 10.1038/onc.2009.344
   Zohreh B, 2019, ANTI-CANCER AGENT ME, V19, P1535, DOI 10.2174/1871520619666190704102708
NR 71
TC 5
Z9 5
U1 2
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-5113
EI 1873-3298
J9 PROCESS BIOCHEM
JI Process Biochem.
PD FEB
PY 2021
VL 101
BP 11
EP 25
DI 10.1016/j.procbio.2020.10.002
PG 15
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Engineering, Chemical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Engineering
GA QE1MW
UT WOS:000615974400002
DA 2022-04-25
ER

PT J
AU Mesas, C
   Martinez, R
   Ortiz, R
   Galisteo, M
   Lopez-Jurado, M
   Cabeza, L
   Perazzoli, G
   Melguizo, C
   Porres, JM
   Prados, J
AF Mesas, Cristina
   Martinez, Rosario
   Ortiz, Raul
   Galisteo, Milagros
   Lopez-Jurado, Maria
   Cabeza, Laura
   Perazzoli, Gloria
   Melguizo, Consolacion
   Porres, Jesus M.
   Prados, Jose
TI Antitumor Effect of the Ethanolic Extract from Seeds of Euphorbia
   lathyris in Colorectal Cancer
SO NUTRIENTS
LA English
DT Article
DE colon cancer; Euphorbia lathyris; ethanolic extract; apoptosis;
   antiangiogenic effect; cancer stem cells
AB The seeds of Euphorbia lathyris have been used in traditional medicine to treat various medical conditions. However, neither all of their active biocompounds nor the molecular mechanisms underlying their therapeutic effects have been described. A new ethanolic extract of defatted flour from mature seeds of Euphorbia lathyris showed a high total polyphenol content and significant antioxidant activity. Chromatographic analysis showed that esculetin, euphorbetin, gaultherin, and kaempferol-3-rutinoside were the most abundant polyphenolic bioactive compounds. Antiproliferative assays showed a high and selective antitumor activity against colon cancer cell lines (T84 and HCT-15). In addition, a significant antiproliferative activity against glioblastoma multiforme cells was also demonstrated. Its mechanism of action to induce cell death was mediated by the overexpression of caspases 9, 3, and 8, and by activation of autophagy. Interestingly, a reduction in the migration capacity of colon cancer cells and a significant antiangiogenic effect on human umbilical vein endothelial cells were also demonstrated. Finally, the extract significantly reduced the subpopulations of cancer stem cells. This extract could be the basis to develop new therapeutic strategies for the treatment of colon cancer, although further experiments will be necessary to determine its in vivo effects.
C1 [Mesas, Cristina; Ortiz, Raul; Cabeza, Laura; Perazzoli, Gloria; Melguizo, Consolacion; Prados, Jose] Univ Granada, Ctr Biomed Res CIBM, Inst Biopathol & Regenerat Med IBIMER, Granada 18100, Spain.
   [Mesas, Cristina; Ortiz, Raul; Cabeza, Laura; Perazzoli, Gloria; Melguizo, Consolacion; Prados, Jose] Univ Granada, Fac Med, Dept Anat & Embryol, Granada 18071, Spain.
   [Mesas, Cristina; Ortiz, Raul; Cabeza, Laura; Perazzoli, Gloria; Melguizo, Consolacion; Prados, Jose] Inst Biosanitario Granada Ibs GRANADA, Granada 18014, Spain.
   [Martinez, Rosario; Lopez-Jurado, Maria; Porres, Jesus M.] Univ Granada, Biomed Res Ctr CIBM, Inst Nutr & Food Technol INyTA, Dept Physiol, Granada 18100, Spain.
   [Galisteo, Milagros] Univ Granada, Sch Pharm, Dept Pharmacol, Granada 18071, Spain.
RP Melguizo, C (corresponding author), Univ Granada, Ctr Biomed Res CIBM, Inst Biopathol & Regenerat Med IBIMER, Granada 18100, Spain.; Melguizo, C (corresponding author), Univ Granada, Fac Med, Dept Anat & Embryol, Granada 18071, Spain.; Melguizo, C (corresponding author), Inst Biosanitario Granada Ibs GRANADA, Granada 18014, Spain.
EM cristinam@correo.ugr.es; rosariomz@ugr.es; roquesa@ugr.es;
   mgalist@ugr.es; mlopezj@ugr.es; lautea@ugr.es; gperazzoli@ugr.es;
   melguizo@ugr.es; jmporres@ugr.es; jcprados@ugr.es
RI Mesas, Cristina/AAO-3126-2021; Ortiz Quesada, Raul/J-7256-2017; Prados,
   Jose/J-7116-2017; Porres Foulquie, Jesus Maria/B-6442-2018; Melguizo
   Alonso, Consolacion/E-9842-2016
OI Ortiz Quesada, Raul/0000-0001-8409-5235; Prados,
   Jose/0000-0003-4303-7746; Porres Foulquie, Jesus
   Maria/0000-0001-5657-0764; Mesas, Cristina/0000-0001-6369-5485; Melguizo
   Alonso, Consolacion/0000-0003-3990-806X
FU Granada University [PSE/17/002]; Ministerio de Ciencia e
   InnovacionInstituto de Salud Carlos IIISpanish GovernmentEuropean
   Commission [RTC-2017-6540-1]; CTS-107 Group; AGR145 Group
FX This research was funded by the Granada University (project PSE/17/002),
   Ministerio de Ciencia e Innovacion (project RTC-2017-6540-1) and by the
   CTS-107 and AGR145 Groups.
CR [Anonymous], 2018, LANCET, V392, P985, DOI 10.1016/S0140-6736(18)32252-9
   Arora R, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0550-2
   Bicchi C, 2001, PHYTOCHEM ANALYSIS, V12, P255, DOI 10.1002/pca.592
   Chang HT, 2016, TUMOR BIOL, V37, P4665, DOI 10.1007/s13277-015-4286-1
   Choi YJ, 2019, ENVIRON TOXICOL, V34, P1129, DOI 10.1002/tox.22815
   Cruz LS, 2018, PHYTOMEDICINE, V47, P105, DOI 10.1016/j.phymed.2018.04.055
   de Oliveira TL, 2021, J ETHNOPHARMACOL, V265, DOI 10.1016/j.jep.2020.113348
   Duan FeiPeng, 2014, Journal of Chemical and Pharmaceutical Research, V6, P745
   Duh PD, 1999, FOOD SCI TECHNOL-LEB, V32, P269
   Ernst M, 2016, SCI REP-UK, V6, DOI 10.1038/srep30531
   Ernst M, 2015, J ETHNOPHARMACOL, V176, P90, DOI 10.1016/j.jep.2015.10.025
   Fan L, 2019, PHYTOMEDICINE, V62, DOI 10.1016/j.phymed.2019.152931
   Montes AF, 2019, CANCER MED-US, V8, P882, DOI 10.1002/cam4.1903
   Fu ZY, 2016, WORLD J GASTROENTERO, V22, P3564, DOI 10.3748/wjg.v22.i13.3564
   Goyal S, 2017, CURR TOP MED CHEM, V17, P96, DOI 10.2174/1568026616666160530154407
   Grada A, 2017, J INVEST DERMATOL, V137, pE11, DOI 10.1016/j.jid.2016.11.020
   Guo Xianli, 2018, Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, V35, P244, DOI 10.7507/1001-5515.201609009
   Hirata A, 2019, ADV EXP MED BIOL, V1139, P115, DOI 10.1007/978-3-030-14366-4_7
   Iu IH, 2012, IRAN J PHARM RES, V11, P241
   Jiao Wei, 2010, Zhongcaoyao = Chinese Traditional and Herbal Drugs, V41, P181
   Kapravelou G, 2015, J SCI FOOD AGR, V95, P1207, DOI 10.1002/jsfa.6809
   Kim AD, 2015, ENVIRON TOXICOL PHAR, V39, P982, DOI 10.1016/j.etap.2015.03.003
   Koklesova L, 2020, EPMA J, V11, P261, DOI 10.1007/s13167-020-00210-5
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   Lee JW, 2016, J NAT PROD, V79, P126, DOI 10.1021/acs.jnatprod.5b00789
   Liao SG, 2005, ORG LETT, V7, P1379, DOI 10.1021/ol050206a
   Liu ZG, 2014, J NAT PROD, V77, P792, DOI 10.1021/np400873v
   Lu J, 2014, PHYTOCHEMISTRY, V104, P79, DOI 10.1016/j.phytochem.2014.04.020
   Martins CG, 2020, J ETHNOPHARMACOL, V255, DOI 10.1016/j.jep.2020.112722
   Nam KyungAe, 2000, Natural Product Sciences, V6, P183
   Neto S, 2019, PHYTOCHEM ANALYSIS, V30, P498, DOI 10.1002/pca.2841
   Silva VAO, 2018, EXP THER MED, V16, P557, DOI 10.3892/etm.2018.6244
   Ortiz R, 2009, J MOL MED, V87, P899, DOI 10.1007/s00109-009-0493-9
   Park SL, 2016, AM J CHINESE MED, V44, P61, DOI 10.1142/S0192415X1650004X
   Park SS, 2011, ONCOL REP, V25, P223, DOI 10.3892/or_00001064
   Ramalho SD, 2018, PLANTA MED, V84, DOI 10.1055/s-0043-122604
   Reddy Bonam Srinivasa, 2017, Afr J Tradit Complement Altern Med, V14, P105, DOI 10.21010/ajtcam.v14i3.11
   Remy S, 2019, MOLECULES, V24, DOI 10.3390/molecules24122336
   Ricigliano VA, 2020, PHYTOCHEMISTRY, V179, DOI 10.1016/j.phytochem.2020.112504
   Shi QW, 2008, CHEM REV, V108, P4295, DOI 10.1021/cr078350s
   Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442
   Teng YN, 2018, PHYTOMEDICINE, V41, P62, DOI 10.1016/j.phymed.2018.02.001
   Turkekul K, 2018, J CANCER PREV, V23, P10, DOI 10.15430/JCP.2018.23.1.10
   Vaghari-Tabari M, 2020, LIFE SCI, V259, DOI 10.1016/j.lfs.2020.118255
   Vasas A, 2014, CHEM REV, V114, P8579, DOI 10.1021/cr400541j
   Wang CJ, 2002, CANCER LETT, V183, P163, DOI 10.1016/S0304-3835(02)00031-9
   Wang HP, 2016, J ETHNOPHARMACOL, V194, P1, DOI 10.1016/j.jep.2016.08.041
   Wang Q, 2018, CHEM BIODIVERS, V15, DOI 10.1002/cbdv.201800386
   Wang XD, 2019, J BUON, V24, P1686
   Wang YW, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/3618941
   Zhang LZ, 2017, MOLECULES, V22, DOI 10.3390/molecules22081335
   Zheng XX, 2021, CANCER LETT, V497, P190, DOI 10.1016/j.canlet.2020.10.009
   Zhou B, 2016, J NAT PROD, V79, P1952, DOI 10.1021/acs.jnatprod.6b00205
   Zhou M, 2021, J ASIAN NAT PROD RES, V23, P731, DOI 10.1080/10286020.2020.1769611
   Zhou Yujuan, 2018, Oncotarget, V9, P33403, DOI 10.18632/oncotarget.23607
   Zhu A, 2018, J ETHNOPHARMACOL, V227, P41, DOI 10.1016/j.jep.2018.08.024
NR 56
TC 2
Z9 2
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD FEB
PY 2021
VL 13
IS 2
AR 566
DI 10.3390/nu13020566
PG 17
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA QO1PW
UT WOS:000622919900001
PM 33572111
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Xu, MY
   Kim, YS
AF Xu, Mei-Ying
   Kim, Yeong Shik
TI Antitumor activity of glycyrol via induction of cell cycle arrest,
   apoptosis and defective autophagy
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
DE Glycyrol; Apoptosis; Cell cycle arrest; Defective autophagy; JNK; AMPK
ID COLON-CANCER CELLS; BREAST-CANCER; MAPK PATHWAYS; PHASE ARREST;
   DNA-DAMAGE; DEATH; INHIBITION; GROWTH; JNK; ACTIVATION
AB Glycyrol is a coumestan isolated from Glycyrrhiza uralensis and synthesized to use. In this study, the antitumor activity and the underlying mechanism of glycyrol were evaluated in vitro and in vivo. It was shown that glycyrol induced cell death associated with apoptosis and autophagy as evidenced by morphological changes in AGS and HCT 116 cells. The apoptosis-inducing effect was characterized by increase in ratio of sub-G1 phase, poly (ADP-ribose) polymerase-1 (PARP-1) cleavage and caspase-3 activation. Mechanistic studies showed that glycyrol induced G0/G1 phase cell cycle arrest as indicated by increase in p21. Furthermore, c-Jun N-terminal kinase (JNK)/p38 mitogen-activated protein kinases (MAPKs) activation induced caspase-dependent apoptosis accompanied by adenosine monophosphate-activated protein kinase (AMPK) activation. Defective autophagy was triggered, which stopped the autophagic flux by the slowing of lysosomal degradation. In addition, glycyrol suppressed tumor growth in a nude mouse tumor xenograft model bearing HCT 116 cells. Taken together, glycyrol is demonstrated to have antitumor activity, and might potentially serve as potential candidate for cancer therapy. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Xu, Mei-Ying; Kim, Yeong Shik] Seoul Natl Univ, Coll Pharm, Nat Prod Res Inst, Seoul 151742, South Korea.
RP Kim, YS (corresponding author), Seoul Natl Univ, Coll Pharm, Nat Prod Res Inst, 1 Gwanak Ro, Seoul 151742, South Korea.
EM kims@snu.ac.kr
FU MRC - Korean Government (NRF) [2009-93146]
FX This work was supported by an MRC grant funded by the Korean Government
   (NRF, No. 2009-93146).
CR Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657
   Asl MN, 2008, PHYTOTHER RES, V22, P709, DOI 10.1002/ptr.2362
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7
   Choi SH, 2010, BIOCHEM PHARMACOL, V79, P1352, DOI 10.1016/j.bcp.2009.12.011
   Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301
   Eastman A, 2004, J CELL BIOCHEM, V91, P223, DOI 10.1002/jcb.10699
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   FENG Y, 2014, CELL DEATH DIS
   Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608
   Guo DL, 2009, P NATL ACAD SCI USA, V106, P12932, DOI 10.1073/pnas.0906606106
   Hsu YL, 2005, LIFE SCI, V77, P279, DOI 10.1016/j.lfs.2004.09.047
   Hu YL, 2012, CANCER RES, V72, P4294, DOI 10.1158/0008-5472.CAN-12-1076
   Jin YL, 2008, TETRAHEDRON LETT, V49, P6835, DOI 10.1016/j.tetlet.2008.09.070
   Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097
   Kim HS, 2008, J BIOL CHEM, V283, P3731, DOI 10.1074/jbc.M704432200
   Kimura T, 2013, CANCER RES, V73, P3, DOI 10.1158/0008-5472.CAN-12-2464
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Lee KH, 2011, J BIOL CHEM, V286, P39247, DOI 10.1074/jbc.M111.264598
   Lee YS, 2013, J NAT PROD, V76, P2195, DOI 10.1021/np4005135
   Li SG, 2010, CANCER LETT, V298, P222, DOI 10.1016/j.canlet.2010.07.009
   Li Y, 2013, TOXICOL APPL PHARM, V272, P37, DOI 10.1016/j.taap.2013.05.031
   Lockshin RA, 2002, CURR OPIN CELL BIOL, V14, P727, DOI 10.1016/S0955-0674(02)00383-6
   Mansouri A, 2003, J BIOL CHEM, V278, P19245, DOI 10.1074/jbc.M208134200
   Maycotte P, 2011, CANCER BIOL THER, V11, P127, DOI 10.4161/cbt.11.2.14627
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Mukhtar E, 2012, CURR DRUG TARGETS, V13, P1831, DOI 10.2174/138945012804545489
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Park I, 2009, CANCER LETT, V277, P174, DOI 10.1016/j.canlet.2008.12.005
   Puissant A, 2010, CANCER RES, V70, P1042, DOI 10.1158/0008-5472.CAN-09-3537
   Reinhardt HC, 2013, NAT REV MOL CELL BIO, V14, P563, DOI 10.1038/nrm3640
   Roy RV, 2013, J NAT PROD, V76, P1909, DOI 10.1021/np400441f
   Sarkar FH, 2009, CELL SIGNAL, V21, P1541, DOI 10.1016/j.cellsig.2009.03.009
   Shin EM, 2008, INT IMMUNOPHARMACOL, V8, P1524, DOI 10.1016/j.intimp.2008.06.008
   Shin EM, 2011, PLANTA MED, V77, P242, DOI 10.1055/s-0030-1250260
   Shin SY, 2011, TOXICOL APPL PHARM, V254, P288, DOI 10.1016/j.taap.2011.05.003
   Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556
   Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694
   XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326
   Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Yang PM, 2010, CANCER RES, V70, P7699, DOI 10.1158/0008-5472.CAN-10-1626
   Yun H, 2009, CARCINOGENESIS, V30, P529, DOI 10.1093/carcin/bgn259
NR 43
TC 22
Z9 23
U1 1
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278-6915
EI 1873-6351
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD DEC
PY 2014
VL 74
BP 311
EP 319
DI 10.1016/j.fct.2014.10.023
PG 9
WC Food Science & Technology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Toxicology
GA AY0GD
UT WOS:000347274600048
PM 25445757
DA 2022-04-25
ER

PT J
AU Das, S
   Nayak, A
   Siddharth, S
   Nayak, D
   Narayan, S
   Kundu, CN
AF Das, Sarita
   Nayak, Anmada
   Siddharth, Sumit
   Nayak, Deepika
   Narayan, Satya
   Kundu, Chanakya Nath
TI TRAIL enhances quinacrine-mediated apoptosis in breast cancer cells
   through induction of autophagy via modulation of p21 and DR5
   interactions
SO CELLULAR ONCOLOGY
LA English
DT Article
DE QC; TRAIL; p21; DR5; Autophagy; Apoptosis; Breast cancer
ID LIPID RAFTS; DEATH RECEPTORS; TUMOR-CELLS; RESISTANCE; INHIBITION;
   CARCINOMA; CASCADE; SENSITIVITY; ACTIVATION; EXPRESSION
AB Previously, we reported that quinacrine (QC) may cause apoptosis in breast and colon cancer cells by activating the death receptor 5 (DR5), resulting in autophagic cell death through p21 modulation. Here, we systematically evaluated the combined role of p21 and DR5 and their crosstalk in QC-mediated autophagy and apoptosis in breast cancer cells using in vitro and in vivo models.
   Multiple breast cancer-derived cell lines (MCF-7, ZR-75-1, T47D, MDA-MB-231 and MCF-10A-Tr) and a mouse xenograft model were used. Also, multiple assays, including Western blotting, immunoprecipitation, staining for autophagy and apoptosis, gene silencing, hematoxylin and eosin staining, immunohistochemistry, cell viability assessment, fluorescence imaging and cell sorting were used.
   We found that QC activates p21 and DR5 in combination with the apoptosis inducer TRAIL in the breast cancer-derived cells tested. Combined TRAIL and QC treatment increased autophagy and apoptosis by increasing the interaction between, and co-localization of, p21 and DR5 in the death-inducing signaling complex (DISC). We found that this combination also inhibited the mTOR/PI3K/AKT signaling cascade and modulated reactive oxygen species (ROS) and nitric oxide (NO) production. Reductions in autophagy and apoptosis in DR5-knockout cells and a lack of change in p21-DR5-silenced cells were noted after TRAIL + QC treatment. This result explains dependence of the death (autophagy and apoptosis) cascade on these two key regulatory proteins. In addition, we found in an in vivo mouse xenograft model that increased expression and enhanced co-localization of p21 and DR5 after TRAIL + QC treatment supported a joint regulatory role of these proteins in the co-prevalence of autophagy and apoptosis.
   Our data suggest that a combined treatment of TRAIL and QC causes cell death in breast cancer-derived cells via autophagy and apoptosis by increasing the interaction of p21 and DR5, as indicated by both in vitro and in vivo studies.
C1 [Das, Sarita; Nayak, Anmada; Siddharth, Sumit; Nayak, Deepika; Kundu, Chanakya Nath] KIIT Univ, KIIT Sch Biotechnol, Div Canc Biol, Campus 11, Bhubaneswar 751024, Orissa, India.
   [Narayan, Satya] Univ Florida, Dept Anat & Cell Biol, Coll Med, Gainesville, FL 32610 USA.
RP Kundu, CN (corresponding author), KIIT Univ, KIIT Sch Biotechnol, Div Canc Biol, Campus 11, Bhubaneswar 751024, Orissa, India.
EM cnkundu@gmail.com
RI Siddharth, Sumit/AFL-4204-2022
OI Kundu, Chanakya/0000-0003-0297-1030
FU Department of Science and Technology (DST)Department of Science &
   Technology (India); Indian Council of Medical Research (ICMR),
   Government of IndiaIndian Council of Medical Research (ICMR)
FX We sincerely acknowledge the Department of Science and Technology (DST)
   and the Indian Council of Medical Research (ICMR), Government of India,
   for providing fellowships to SD, AN and SS, respectively. In addition,
   we sincerely thank Mark Zakshevsky, Department of Anatomy and Cell
   Biology, University of Florida, Gainesville, Florida, USA, for
   proofreading the manuscript.
CR Cai YL, 2014, CHINESE J CANCER RES, V26, P564, DOI 10.3978/j.issn.1000-9604.2014.08.20
   Chang JL, 2017, ENVIRON TOXICOL, V32, P1857, DOI 10.1002/tox.22408
   Das D, 2015, CANCER CHEMOTH PHARM, V76, P471, DOI 10.1007/s00280-015-2794-8
   Das S, 2017, ONCOTARGET, V8, P248, DOI 10.18632/oncotarget.11335
   Di X, 2013, ONCOTARGET, V4, P1349, DOI 10.18632/oncotarget.1174
   Ehsanian R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-13
   Ge J, 2013, BIOMED ENVIRON SCI, V26, P902, DOI 10.3967/bes2013.019
   Guo C, 2009, ONCOGENE, V28, P1151, DOI 10.1038/onc.2008.460
   Han J, 2008, J BIOL CHEM, V283, P19665, DOI 10.1074/jbc.M710169200
   He WY, 2012, AUTOPHAGY, V8, P1811, DOI 10.4161/auto.22145
   Herrero-Martin G, 2009, EMBO J, V28, P677, DOI 10.1038/emboj.2009.8
   Hou W, 2010, AUTOPHAGY, V6, P891, DOI 10.4161/auto.6.7.13038
   Jani TS, 2010, J BIOL CHEM, V285, P19162, DOI 10.1074/jbc.M109.091645
   Li X, 2012, INT J BIOL SCI, V8, P901, DOI 10.7150/ijbs.4554
   Li X, 2017, SCI REP-UK, V7, DOI 10.1038/srep42748
   Lin L, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.985913
   Liu H, 2017, ONCOTARGETS THER, V10, P2865, DOI 10.2147/OTT.S95267
   Liu S, 2017, ONCOTARGET, V8, P31901, DOI 10.18632/oncotarget.16650
   Lobo MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114110
   Marklein D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052898
   Mohapatra P, 2014, TOXICOL APPL PHARM, V274, P168, DOI 10.1016/j.taap.2013.09.028
   Mohapatra P, 2012, ONCOL RES, V20, P81, DOI 10.3727/096504012X13473664562628
   Mpoke SS, 1997, J HISTOCHEM CYTOCHEM, V45, P675, DOI 10.1177/002215549704500505
   Nagappan A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174591
   Ouyang W, 2011, INT J ONCOL, V39, P1577, DOI 10.3892/ijo.2011.1129
   Poh TW, 2007, CELL DEATH DIFFER, V14, P1813, DOI 10.1038/sj.cdd.4402177
   Preet R, 2016, BIOCHEM PHARMACOL, V105, P23, DOI 10.1016/j.bcp.2016.01.017
   Preet R, 2013, CARCINOGENESIS, V34, P277, DOI 10.1093/carcin/bgs351
   Preet R, 2012, INT J CANCER, V130, P1660, DOI 10.1002/ijc.26158
   Satapathy SR, 2015, PATHOL ONCOL RES, V21, P405, DOI 10.1007/s12253-014-9835-1
   Thorburn A, 2008, APOPTOSIS, V13, P1, DOI 10.1007/s10495-007-0154-9
   Tong Y, 2014, ONCOL REP, V31, P1581, DOI 10.3892/or.2014.3020
   Twomey JD, 2015, DRUG RESIST UPDATE, V19, P13, DOI 10.1016/j.drup.2015.02.001
   Wang WG, 2011, CANCER BIOL THER, V12, P229, DOI 10.4161/cbt.12.3.17033
   Wolczyk D, 2016, CELL ONCOL, V39, P353, DOI 10.1007/s13402-016-0280-x
   Xu L, 2013, BIOCHEM BIOPH RES CO, V439, P285, DOI 10.1016/j.bbrc.2013.08.040
   Yang PM, 2011, AUTOPHAGY, V7, P107, DOI 10.4161/auto.7.1.13988
   Yonekawa T, 2013, ESSAYS BIOCHEM, V55, P105, DOI [10.1042/BSE0550105, 10.1042/bse0550105]
NR 38
TC 12
Z9 13
U1 0
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 2211-3428
EI 2211-3436
J9 CELL ONCOL
JI Cell. Oncol.
PD DEC
PY 2017
VL 40
IS 6
BP 593
EP 607
DI 10.1007/s13402-017-0347-3
PG 15
WC Oncology; Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology; Pathology
GA FO0RK
UT WOS:000416454200005
PM 28936683
DA 2022-04-25
ER

PT J
AU Son, Y
   An, Y
   Jung, J
   Shin, S
   Park, I
   Gwak, J
   Ju, BG
   Chung, YH
   Na, M
   Oh, S
AF Son, Younglim
   An, Younju
   Jung, Jaeyeon
   Shin, Sora
   Park, InWha
   Gwak, Jungsug
   Ju, Bong Gun
   Chung, Young-Hwa
   Na, MinKyun
   Oh, Sangtaek
TI Protopine isolated from Nandina domestica induces apoptosis and
   autophagy in colon cancer cells by stabilizing p53
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE apoptosis; autophagy; colon cancer; Nandina domestica; p53 signaling;
   protopine
ID PHOSPHORYLATION; ACTIVATION; FUMARIA; DEATH
AB The tumor suppressor p53 plays essential roles in cellular protection mechanisms against a variety of stress stimuli and its activation induces apoptosis or autophagy in certain cancer cells. Here, we identified protopine, an isoquinoline alkaloid isolated from Nandina domestica, as an activator of the p53 pathway from cell-based natural compound screening based on p53-responsive transcription. Protopine increased the p53-mediated transcriptional activity and promoted p53 phosphorylation at the Ser15 residue, resulting in stabilization of p53 protein. Moreover, protopine up-regulated the expression of p21(WAF1/CIP1) and BAX, downstream genes of p53, and inhibited the proliferation of HCT116 colon cancer cells. Apoptosis was elicited by protopine as indicated by caspase-3/7 activation, poly ADP ribose polymerase cleavage, and increased population of Annexin V-FITC-positive cells. Furthermore, protopine induced the formation of microtubule-associated protein 1 light chain 3 (LC3) puncta and LC3-II turnover, typical biochemical markers of autophagy, in HCT116 cells. Our findings suggest that protopine exerts its antiproliferative activity by stimulating the p53 pathway and may have potential as a chemopreventive agent for human colon cancer.
C1 [Son, Younglim; An, Younju; Jung, Jaeyeon; Shin, Sora; Oh, Sangtaek] Kookmin Univ, Dept Bio & Fermentat Convergence Technol, BK21 PLUS Program, Seoul, South Korea.
   [Park, InWha; Na, MinKyun] Chungnam Natl Univ, Coll Pharm, Daejeon 34134, South Korea.
   [Gwak, Jungsug; Ju, Bong Gun] Sogang Univ, Dept Life Sci, Seoul, South Korea.
   [Chung, Young-Hwa] Pusan Natl Univ, Dept Cognomechatron Engn, BK21, Busan, South Korea.
RP Na, M (corresponding author), Chungnam Natl Univ, Coll Pharm, Daejeon 34134, South Korea.; Oh, S (corresponding author), Kookmin Univ, Dept Bio & Fermentat Convergence Technol, Seoul 02707, South Korea.
EM mkna@cnu.ac.kr; ohsa@kookmin.ac.kr
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Korean government [NRF-2018R1D1A1B07048208,
   NRF-2017R1A2A2A05001340]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Korean
   government (NRF-2018R1D1A1B07048208, NRF-2017R1A2A2A05001340).
CR Altman BJ, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008763
   Bae DS, 2012, BMB REP, V45, P108, DOI 10.5483/BMBRep.2012.45.2.108
   Bae SK, 2011, BIOCHEM BIOPH RES CO, V409, P75, DOI 10.1016/j.bbrc.2011.04.108
   Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6
   Broz P, 2013, NAT REV IMMUNOL, V13, P551, DOI 10.1038/nri3479
   Chen CH, 2012, CANCER LETT, V315, P1, DOI 10.1016/j.canlet.2011.09.042
   CordonCardo C, 1997, CANCER RES, V57, P1217
   DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539
   Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C
   Gump JM, 2011, TRENDS CELL BIOL, V21, P387, DOI 10.1016/j.tcb.2011.03.007
   Haberlein H, 1996, PLANTA MED, V62, P227, DOI 10.1055/s-2006-957865
   Haggar Fatima A, 2009, Clin Colon Rectal Surg, V22, P191, DOI 10.1055/s-0029-1242458
   He K, 2014, AFR J TRADIT COMPLEM, V11, P415, DOI 10.4314/ajtcam.v11i2.28
   Jiang B, 2004, EUR J PHARMACOL, V506, P93, DOI 10.1016/j.ejphar.2004.11.004
   Kim BJ, 2006, J BIOL CHEM, V281, P21256, DOI 10.1074/jbc.M510644200
   Kim SR, 1999, PLANTA MED, V65, P218, DOI 10.1055/s-1999-13983
   Lee HY, 2015, MAR DRUGS, V13, P543, DOI 10.3390/md13010543
   LEVINE AJ, 1994, J LAB CLIN MED, V123, P817
   Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723
   Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412
   Orhan I, 2007, Z NATURFORSCH C, V62, P19
   Park S, 2006, MOL PHARMACOL, V70, P960, DOI 10.1124/mol.106.024729
   Rathi A, 2008, PHYTOMEDICINE, V15, P470, DOI 10.1016/j.phymed.2007.11.010
   Saeed SA, 1997, PHARMACOL RES, V36, P1, DOI 10.1006/phrs.1997.0195
   Speidel D, 2010, TRENDS CELL BIOL, V20, P14, DOI 10.1016/j.tcb.2009.10.002
   Tzifi Flora, 2012, Adv Hematol, V2012, P524308, DOI 10.1155/2012/524308
   Xiao XH, 2007, BASIC CLIN PHARMACOL, V101, P85, DOI 10.1111/j.1742-7843.2007.00075.x
NR 27
TC 15
Z9 17
U1 2
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-418X
EI 1099-1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD JUN
PY 2019
VL 33
IS 6
BP 1689
EP 1696
DI 10.1002/ptr.6357
PG 8
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA ID7ZJ
UT WOS:000471901200010
PM 30932278
DA 2022-04-25
ER

PT J
AU Lu, XY
   Wei, HB
   Zhang, XJ
   Zheng, WX
   Chang, C
   Gu, JY
AF Lu, Xueying
   Wei, Haibo
   Zhang, Xiaojin
   Zheng, Wenxin
   Chang, Cheng
   Gu, Jinyu
TI Rapamycin synergizes with low-dose oxaliplatin in the HCT116 colon
   cancer cell line by inducing enhanced apoptosis
SO ONCOLOGY LETTERS
LA English
DT Article
DE rapamycin; oxaliplatin; colon cancer; apoptosis; autophagy
ID CHEMOTHERAPY-INDUCED CYTOTOXICITY; MAMMALIAN TARGET; MTOR INHIBITOR;
   COLORECTAL-CANCER; MULTIPLE-MYELOMA; COMBINATION; AUTOPHAGY;
   NEUROTOXICITY; PACLITAXEL; RADIATION
AB The present study aimed to examine the combined effects of oxaliplatin (L-OHP) and rapamycin (RAPA) in the HCT116 colon cancer cell line. The growth inhibitory effect was evaluated by MTT assay as a monotherapy or combination therapy. IC50 values were determined using CalcuSyn 2.0 software. To determine the interaction of the drugs, the combination index (CI) was calculated using the Chou-Talalay method. Apoptosis was investigated using flow cytometry and Western blotting. Acridine orange staining was employed to observe morphological changes. The results showed the IC50 values of L-OHP and RAPA to be 8.35 +/- 0.78 mu M (r=0.99) and 223.44 +/- 38.10 nM (r=0.94), respectively. Cl was when L-OHP was used at doses ranging from 1 to 5 mu M plus RAPA at a dose of 10 nM, suggesting synergistic or additive effects. CI was >= 1 when 100 nM RAPA was used in combination with low-dose L-OHP, showing additive to antagonistic effects. The combination of L-OHP (1 mu M) and RAPA (10 nM) induced 19.76% Annexin V-positive cells, which was found to be higher than L-OHP (11.45%, p < 0.01) or RAPA (6.89%, p < 0.01) alone. The cleaved PARP protein expression levels were highest after 48 h of combination treatment. Acridine orange staining showed typical bright red Acidic vesicular organdies in the RAPA group, whereas the green condensed chromatin in the apoptotic bodies was found in both the L-OHP and combination groups. In conclusion, at a cytostatic concentration, RAPA was found to potentiate the anti-tumor effects of low-dose L-OHP in the HCT116 colon cancer cell by inducing enhanced apoptosis.
C1 [Chang, Cheng; Gu, Jinyu] Harbin Med Univ, Dept Gen Surg, Affiliated Hosp 2, Harbin 150086, Heilongjiang, Peoples R China.
   [Lu, Xueying; Wei, Haibo; Zhang, Xiaojin; Zheng, Wenxin] Harbin Med Univ, Dept Immunol, Basic Med Sci Coll, Harbin 150081, Heilongjiang, Peoples R China.
RP Gu, JY (corresponding author), Harbin Med Univ, Dept Gen Surg, Affiliated Hosp 2, 246 Baojian Rd, Harbin 150086, Heilongjiang, Peoples R China.
EM gujinyu@hotmail.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [30700997]; Heilongjiang overseas fund
   [LC06C27]
FX This study was funded by grants from the National Natural Science
   Foundation of China (No. 30700997) to Dr Xueying Lu and from the
   Heilongjiang overseas fund (No. LC06C27) to Dr Jinyu Gu.
CR Bae-Jump VL, 2009, CANCER-AM CANCER SOC, V115, P3887, DOI 10.1002/cncr.24431
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Francis LK, 2006, CLIN CANCER RES, V12, P6826, DOI 10.1158/1078-0432.CCR-06-1331
   Fung AS, 2009, CLIN CANCER RES, V15, P5389, DOI 10.1158/1078-0432.CCR-08-3007
   Gerber DE, 2010, CANCER METAST REV, V29, P171, DOI 10.1007/s10555-010-9215-6
   Gu JY, 2006, DIGESTION, V74, P19, DOI 10.1159/000095826
   Houghton PJ, 2010, MOL CANCER THER, V9, P101, DOI 10.1158/1535-7163.MCT-09-0952
   Johnson SM, 2010, J AM COLL SURGEONS, V210, P767, DOI 10.1016/j.jamcollsurg.2009.12.008
   Kondo Y, 2006, AUTOPHAGY, V2, P85, DOI 10.4161/auto.2.2.2463
   McWhinney SR, 2009, MOL CANCER THER, V8, P10, DOI 10.1158/1535-7163.MCT-08-0840
   Merimsky O, 2007, INT J ONCOL, V31, P225
   Mondesire WH, 2004, CLIN CANCER RES, V10, P7031, DOI 10.1158/1078-0432.CCR-04-0361
   Nagata Y, 2010, INT J ONCOL, V37, P1001, DOI 10.3892/ijo_00000751
   Paglin S, 2001, CANCER RES, V61, P439
   Park SB, 2009, J CLIN ONCOL, V27, P1243, DOI 10.1200/JCO.2008.19.3425
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Pencreach E, 2009, CLIN CANCER RES, V15, P1297, DOI 10.1158/1078-0432.CCR-08-0889
   Perotti A, 2010, J CLIN ONCOL, V28, P4554, DOI 10.1200/JCO.2009.27.5867
   Raje N, 2004, BLOOD, V104, P4188, DOI 10.1182/blood-2004-06-2281
   Rodriguez J, 2007, WORLD J GASTROENTERO, V13, P5867, DOI 10.3748/wjg.v13.i44.5867
   Shafer A, 2010, INT J CANCER, V126, P1144, DOI 10.1002/ijc.24837
   Shigematsu H, 2010, INT J CANCER, V126, P2716, DOI 10.1002/ijc.24990
   Silvestris N, 2009, ONCOLOGY-BASEL, V77, P69, DOI 10.1159/000258498
   Wadlow RC, 2010, CANCER-AM CANCER SOC, V116, P3537, DOI 10.1002/cncr.25155
NR 24
TC 7
Z9 8
U1 1
U2 9
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD JUL-AUG
PY 2011
VL 2
IS 4
BP 643
EP 647
DI 10.3892/ol.2011.299
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 775ZD
UT WOS:000291503300011
PM 22848242
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Wiener, Z
   Hogstrom, J
   Hyvonen, V
   Band, AM
   Kallio, P
   Holopainen, T
   Dufva, O
   Haglund, C
   Kruuna, O
   Oliver, G
   Ben-Neriah, Y
   Alitalo, K
AF Wiener, Zoltan
   Hogstrom, Jenny
   Hyvonen, Ville
   Band, Arja M.
   Kallio, Pauliina
   Holopainen, Tanja
   Dufva, Olli
   Haglund, Caj
   Kruuna, Olli
   Oliver, Guillermo
   Ben-Neriah, Yinon
   Alitalo, Kari
TI Prox1 Promotes Expansion of the Colorectal Cancer Stem Cell Population
   to Fuel Tumor Growth and Ischemia Resistance
SO CELL REPORTS
LA English
DT Article
ID INTESTINAL EPITHELIUM; BETA-CATENIN; COLON; IDENTIFICATION; AUTOPHAGY;
   ORIGIN
AB Colorectal cancer (CRC) initiation and growth is often attributed to stem cells, yet little is known about the regulation of these cells. We show here that a sub-population of Prox1-transcription-factor-expressing cells have stem cell activity in intestinal adenomas, but not in the normal intestine. Using in vivo models and 3D ex vivo organoid cultures of mouse adenomas and human CRC, we found that Prox1 deletion reduced the number of stem cells and cell proliferation and decreased intestinal tumor growth via induction of annexin A1 and reduction of the actin-binding protein filamin A, which has been implicated as a prognostic marker in CRC. Loss of Prox1 also decreased autophagy and the survival of hypoxic tumor cells in tumor transplants. Thus, Prox1 is essential for the expansion of the stem cell pool in intestinal adenomas and CRC without being critical for the normal functions of the gut.
C1 [Wiener, Zoltan; Hogstrom, Jenny; Hyvonen, Ville; Band, Arja M.; Kallio, Pauliina; Holopainen, Tanja; Dufva, Olli; Alitalo, Kari] Univ Helsinki, Translat Canc Biol Program, FIN-00014 Helsinki, Finland.
   [Alitalo, Kari] Biomedicum Helsinki, Wihuri Res Inst, Helsinki 00014, Finland.
   [Haglund, Caj; Kruuna, Olli] Univ Helsinki, Cent Hosp, Dept Surg, Helsinki 00029, Finland.
   [Oliver, Guillermo] St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38105 USA.
   [Ben-Neriah, Yinon] Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Immunol, IL-91120 Jerusalem, Israel.
RP Alitalo, K (corresponding author), Univ Helsinki, Translat Canc Biol Program, FIN-00014 Helsinki, Finland.
EM kari.alitalo@helsinki.fi
RI Dufva, Olli/X-7225-2019; Haglund, Caj/N-1240-2019; Ben-Neriah,
   Yinon/L-6285-2019; Alitalo, Kari K/J-5013-2014
OI Alitalo, Kari K/0000-0002-7331-0902; Kallio,
   Pauliina/0000-0001-6374-6203; Dufva, Olli/0000-0002-8084-0282
FU Sigrid Juselius FoundationSigrid Juselius Foundation; Finnish Cancer
   Organizations; Academy of FinlandAcademy of Finland [262976];
   Marie-Curie Intra-European FellowshipEuropean Commission
   [PIEF-GA-2009-236695]
FX We thank Dr. Leif Andersson for the consultations on histopathology, Dr.
   Taija Ma kinen for the Prox1-Cre<SUP>ER</SUP> mice, Dr. Darren Tyson for
   the ANXA1-modulating constructs, Dr. David Calderwood for the FLNA
   antibody, Dr. Meenhard Herlyn (Wistar Institute) for the SW1222 cell
   line, Dr. Tatiana Petrova for discussions of PROX1 functions in CRC, Dr.
   Pekka Katajisto, Dr. Tuomas Tammela, and Dr. Timo Otonkoski for comments
   on the manuscript, and Lari Pyoria , Kirsi Lintula, Katja Salo, Laura
   Raitanen, and Tapio Tainola for their help with the experiments. The
   Biomedicum Imaging Unit is acknowledged for microscopy services. This
   work was funded by the Sigrid Juselius Foundation, the Finnish Cancer
   Organizations, and the Academy of Finland (262976). Z.W. was supported
   by the Sigrid Juselius Foundation and by the Marie-Curie Intra-European
   Fellowship (PIEF-GA-2009-236695).
CR Ashley N, 2013, CANCER RES, V73, P5798, DOI 10.1158/0008-5472.CAN-13-0454
   Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196
   Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602
   Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2
   Bazigou E, 2011, J CLIN INVEST, V121, P2984, DOI 10.1172/JCI58050
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Cristante E, 2013, P NATL ACAD SCI USA, V110, P832, DOI 10.1073/pnas.1209362110
   de Sousa e Melo F, 2011, CELL STEM CELL, V9, P476, DOI 10.1016/j.stem.2011.10.008
   Ehrlicher AJ, 2011, NATURE, V478, P260, DOI 10.1038/nature10430
   Elsir T, 2012, CANCER METAST REV, V31, P793, DOI 10.1007/s10555-012-9390-8
   Elyada E, 2011, NATURE, V470, P409, DOI 10.1038/nature09673
   Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235
   Fodde R, 2001, TRENDS MOL MED, V7, P369, DOI 10.1016/S1471-4914(01)02050-0
   Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405
   Harvey NL, 2005, NAT GENET, V37, P1072, DOI 10.1038/ng1642
   Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831
   Kemper K, 2012, STEM CELLS, V30, P2378, DOI 10.1002/stem.1233
   Kozar S, 2013, CELL STEM CELL, V13, P626, DOI 10.1016/j.stem.2013.08.001
   Maschler S, 2010, EMBO MOL MED, V2, P401, DOI 10.1002/emmm.201000095
   Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020
   Metcalfe C, 2014, CELL STEM CELL, V14, P149, DOI 10.1016/j.stem.2013.11.008
   Myant KB, 2013, CELL STEM CELL, V12, P761, DOI 10.1016/j.stem.2013.04.006
   Parente L, 2004, INFLAMM RES, V53, P125, DOI 10.1007/s00011-003-1235-z
   Petrova TV, 2008, CANCER CELL, V13, P407, DOI 10.1016/j.ccr.2008.02.020
   Ragusa S, 2014, CELL REP, V8, P1957, DOI 10.1016/j.celrep.2014.08.041
   Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175
   Sampieri K, 2012, SEMIN CANCER BIOL, V22, P187, DOI 10.1016/j.semcancer.2012.03.002
   Sansom OJ, 2005, J BIOL CHEM, V280, P28463, DOI 10.1074/jbc.M500191200
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050
   Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935
   Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012
   Srinivasan RS, 2007, GENE DEV, V21, P2422, DOI 10.1101/gad.1588407
   Surrel F, 2009, MOL PHARMACOL, V76, P778, DOI 10.1124/mol.108.053371
   Van Der Flier LG, 2007, GASTROENTEROLOGY, V132, P628, DOI 10.1053/j.gastro.2006.08.039
   Wiener Z, 2014, P NATL ACAD SCI USA, V111, pE2229, DOI 10.1073/pnas.1406444111
   Yeung TM, 2010, P NATL ACAD SCI USA, V107, P3722, DOI 10.1073/pnas.0915135107
   Zheng XW, 2014, P NATL ACAD SCI USA, V111, P2560, DOI 10.1073/pnas.1320815111
   Zhou AX, 2010, TRENDS CELL BIOL, V20, P113, DOI 10.1016/j.tcb.2009.12.001
NR 39
TC 41
Z9 43
U1 0
U2 17
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD SEP 25
PY 2014
VL 8
IS 6
BP 1943
EP 1956
DI 10.1016/j.celrep.2014.08.034
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AR9BZ
UT WOS:000343867400032
PM 25242330
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Liu, YQ
   Cheng, X
   Guo, LX
   Mao, C
   Chen, YJ
   Liu, HX
   Xiao, QC
   Jiang, S
   Yao, ZJ
   Zhou, GB
AF Liu, Yong-Qiang
   Cheng, Xin
   Guo, Liang-Xia
   Mao, Chan
   Chen, Yi-Jie
   Liu, Hai-Xia
   Xiao, Qi-Cai
   Jiang, Sheng
   Yao, Zhu-Jun
   Zhou, Guang-Biao
TI Identification of an Annonaceous Acetogenin Mimetic, AA005, as an AMPK
   Activator and Autophagy Inducer in Colon Cancer Cells
SO PLOS ONE
LA English
DT Article
ID PROTEIN-KINASE; MAMMALIAN TARGET; RAT-LIVER; METFORMIN; ANTICANCER;
   INHIBITION; METABOLISM; PHOSPHORYLATION; 2-DEOXYGLUCOSE; MITOCHONDRIA
AB Annonaceous acetogenins, a large family of naturally occurring polyketides isolated from various species of the plant genus Annonaceae, have been found to exhibit significant cytotoxicity against a variety of cancer cells. Previous studies showed that these compounds could act on the mitochondria complex-I and block the corresponding electron transport chain and terminate ATP production. However, more details of the mechanisms of action remain ambiguous. In this study we tested the effects of a set of mimetics of annonaceous acetogenin on some cancer cell lines, and report that among them AA005 exhibits the most potent antitumor activity. AA005 depletes ATP, activates AMP-activated protein kinase (AMPK) and inhibits mTOR complex 1 (mTORC1) signal pathway, leading to growth inhibition and autophagy of colon cancer cells. AMPK inhibitors compound C and inosine repress, while AMPK activator AICAR enhances, AA005-caused proliferation suppression and subsequent autophagy of colon cancer cells. AA005 enhances the ATP depletion and AMPK activation caused by 2-deoxyglucose, an inhibitor of mitochondrial respiration and glycolysis. AA005 also inhibits chemotherapeutic agent cisplatin-triggered up-regulation of mTOR and synergizes with this drug in suppression of proliferation and induction of apoptosis of colon cancer cells. These data indicate that AA005 is a new metabolic inhibitor which exhibits therapeutic potentials in colon cancer.
C1 [Mao, Chan; Chen, Yi-Jie; Liu, Hai-Xia; Yao, Zhu-Jun] Nanjing Univ, State Key Lab Coordinat Chem, Nanjing Natl Lab Microstruct, Sch Chem & Chem Engn, Nanjing, Jiangsu, Peoples R China.
   [Xiao, Qi-Cai; Jiang, Sheng] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Guangzhou, Guangdong, Peoples R China.
   [Liu, Yong-Qiang; Cheng, Xin; Guo, Liang-Xia; Zhou, Guang-Biao] Chinese Acad Sci, Inst Zool, State Key Lab Biomembrane & Membrane Biotechnol, Div Mol Carcinogenesis & Targeted Therapy Canc, Beijing, Peoples R China.
   [Liu, Yong-Qiang] Chinese Acad Sci, Grad Univ, Beijing, Peoples R China.
RP Yao, ZJ (corresponding author), Nanjing Univ, State Key Lab Coordinat Chem, Nanjing Natl Lab Microstruct, Sch Chem & Chem Engn, Nanjing, Jiangsu, Peoples R China.
EM yaoz@nju.edu.cn; gbzhou@ioz.ac.cn
RI Zhou, Guang-Biao/ABG-5795-2021; Yao, Zhu-Jun/E-7635-2015
OI Xiao, Qicai/0000-0001-9383-4052; Zhou, Guang-Biao/0000-0001-6778-7133;
   Zhou, Guang-Biao/0000-0002-6327-2316
FU National Key Program for Basic ResearchNational Basic Research Program
   of China [2012CB910800, 2010CB833200, 2009CB940900]; National Natural
   Science FoundationNational Natural Science Foundation of China (NSFC)
   [81071930, 81171925, 20972160, 21172220]; Special Foundation of
   President; Key Project of Knowledge Innovation Program of the Chinese
   Academy of SciencesChinese Academy of Sciences [KSCX1-YW-R-26,
   KSCX2-YW-R-235]; National Major Scientific and Technological Program for
   Drug Discovery [2009ZX09103-101]
FX This work was supported in part by the National Key Program for Basic
   Research (2012CB910800, 2010CB833200 and 2009CB940900), the National
   Natural Science Foundation (No. 81071930, 81171925, 20972160 and
   21172220), the Special Foundation of President and the Key Project of
   Knowledge Innovation Program of the Chinese Academy of Sciences
   (KSCX1-YW-R-26 and KSCX2-YW-R-235), and the National Major Scientific
   and Technological Program for Drug Discovery (2009ZX09103-101). No
   additional external funding received for this study. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045
   Ben Sahra I, 2008, ONCOGENE, V27, P3576, DOI 10.1038/sj.onc.1211024
   Ben Sahra I, 2010, CANCER RES, V70, P2465, DOI 10.1158/0008-5472.CAN-09-2782
   Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200
   Bowker SL, 2006, DIABETES CARE, V29, P254, DOI 10.2337/diacare.29.02.06.dc05-1558
   Buzzai M, 2007, CANCER RES, V67, P6745, DOI 10.1158/0008-5472.CAN-06-4447
   Carling D, 2011, NAT CHEM BIOL, V7, P512, DOI [10.1038/NCHEMBIO.610, 10.1038/nchembio.610]
   CHOU TC, 1981, EUR J BIOCHEM, V115, P207, DOI 10.1111/j.1432-1033.1981.tb06218.x
   Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518
   Dowling RJO, 2007, CANCER RES, V67, P10804, DOI 10.1158/0008-5472.CAN-07-2310
   Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7
   Fang HT, 2012, P NATL ACAD SCI USA, V109, P2521, DOI 10.1073/pnas.1121341109
   Fath MA, 2009, CANCER BIOL THER, V8, P1228, DOI 10.4161/cbt.8.13.8631
   Gogvadze V, 2008, TRENDS CELL BIOL, V18, P165, DOI 10.1016/j.tcb.2008.01.006
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111
   Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003-0982
   Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879
   Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1
   Hu Z, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006257
   Imamura K, 2001, BIOCHEM BIOPH RES CO, V287, P562, DOI 10.1006/bbrc.2001.5627
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Inoki K, 2012, ANNU REV PHARMACOL, V52, P381, DOI 10.1146/annurev-pharmtox-010611-134537
   Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030
   Jiang S, 2002, J ORG CHEM, V67, P3404, DOI 10.1021/jo016396u
   Jiang S, 2004, ANGEW CHEM INT EDIT, V43, P329, DOI 10.1002/anie.200352681
   Kang HT, 2006, LIFE SCI, V78, P1392, DOI 10.1016/j.lfs.2005.07.001
   LANDOLT JL, 1995, CHEM-BIOL INTERACT, V98, P1, DOI 10.1016/0009-2797(95)03628-Y
   Liu H, 2007, INT J PRECIS ENG MAN, V8, P8
   Liu Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021930
   Ma L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020159
   Moreno-Sanchez R, 2007, FEBS J, V274, P1393, DOI 10.1111/j.1742-4658.2007.05686.x
   Nakanishi S, 2011, BBA-BIOENERGETICS, V1807, P1170, DOI 10.1016/j.bbabio.2011.05.012
   Neuzil J, 2007, J BIOENERG BIOMEMBR, V39, P65, DOI 10.1007/s10863-006-9060-z
   Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597
   Peng DJ, 2010, BIOCHEM BIOPH RES CO, V394, P600, DOI 10.1016/j.bbrc.2010.03.029
   Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100
   Tang YC, 2011, CELL, V144, P499, DOI 10.1016/j.cell.2011.01.017
   Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504
   Xiao QC, 2011, BIOORG MED CHEM LETT, V21, P3613, DOI 10.1016/j.bmcl.2011.04.095
   Xiao QC, 2011, J MED CHEM, V54, P525, DOI 10.1021/jm101053k
   YAO ZJ, 1995, J ORG CHEM, V60, P1170, DOI 10.1021/jo00110a019
   Yu XJ, 2012, CANCER LETT, V322, P185, DOI 10.1016/j.canlet.2012.03.004
   Zafra-Polo MC, 1998, PHYTOCHEMISTRY, V48, P1087, DOI 10.1016/S0031-9422(97)00917-5
   ZafraPolo MC, 1996, PHYTOCHEMISTRY, V42, P253, DOI 10.1016/0031-9422(95)00836-5
   Zakikhani M, 2006, CANCER RES, V66, P10269, DOI 10.1158/0008-5472.CAN-06-1500
   Zhou GB, 2007, BLOOD, V109, P3441, DOI 10.1182/blood-2006-06-032250
NR 47
TC 28
Z9 30
U1 1
U2 33
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 8
PY 2012
VL 7
IS 10
AR e47049
DI 10.1371/journal.pone.0047049
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 020RP
UT WOS:000309831500128
PM 23056575
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Long, JL
   He, QL
   Yin, YT
   Lei, X
   Li, ZQ
   Zhu, W
AF Long, Jiali
   He, Qinglian
   Yin, Yuting
   Lei, Xue
   Li, Ziqi
   Zhu, Wei
TI The effect of miRNA and autophagy on colorectal cancer
SO CELL PROLIFERATION
LA English
DT Review
DE autophagy; colorectal cancer; microRNA; therapy
ID CONFERS 5-FLUOROURACIL RESISTANCE; INFLAMMATORY-BOWEL-DISEASE;
   NF-KAPPA-B; COLON-CANCER; STEM-CELLS; REGULATES AUTOPHAGY; INHIBIT
   AUTOPHAGY; MAMMALIAN TARGET; EPITHELIAL-CELLS; DRUG-RESISTANCE
AB Colorectal cancer (CRC) has become a concern because of its high recurrence rate and metastasis rate, low early diagnosis rate and poor therapeutic effect. At present, various studies have shown that autophagy is closely connected with the occurrence and progression of CRC. Autophagy is a highly cytosolic catabolic process involved in lysosomes in biological evolution. Cells degrade proteins and damaged organelles by autophagy to achieve material circulation and maintain cell homeostasis. Moreover, microRNAs are key regulators of autophagy, and their mediated regulation of transcriptional and post-transcriptional levels plays an important role in autophagy in CRC cells. This review focuses on the recent research advances of how autophagy and related microRNAs are involved in affecting occurrence and progression of CRC and provides a new perspective for the study of CRC treatment strategies.
C1 [Long, Jiali; He, Qinglian; Yin, Yuting; Lei, Xue; Li, Ziqi; Zhu, Wei] Guangdong Med Univ, Dept Pathol, 1 Xincheng Rd, Dongguan 523808, Guangdong, Peoples R China.
   [Long, Jiali] Sun Yat Sen Univ, Affiliated Hosp 8, Dept Pathol, Shenzhen, Peoples R China.
RP Zhu, W (corresponding author), Guangdong Med Univ, Dept Pathol, 1 Xincheng Rd, Dongguan 523808, Guangdong, Peoples R China.
EM zhuwei@gdmu.edu.cn
OI Zhu, Wei/0000-0002-1217-1718
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81472275]; Guangdong Basic and Applied Basic
   Research Foundation [2020A151501303, 2014A030313542]
FX This work was supported by National Natural Science Foundation of China
   (81472275), Guangdong Basic and Applied Basic Research Foundation
   (2020A151501303, 2014A030313542).
CR Adami HO, 2016, GUT, V65, P889, DOI 10.1136/gutjnl-2015-311003
   Adekola K, 2012, CURR OPIN ONCOL, V24, P650, DOI 10.1097/CCO.0b013e328356da72
   Arroyo DS, 2014, INT IMMUNOPHARMACOL, V18, P55, DOI 10.1016/j.intimp.2013.11.001
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Becouarn Y, 1998, J CLIN ONCOL, V16, P2739, DOI 10.1200/JCO.1998.16.8.2739
   Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013
   Calvet CY, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28131
   Chaachouay H, 2011, RADIOTHER ONCOL, V99, P287, DOI 10.1016/j.radonc.2011.06.002
   Che J, 2019, MOL CARCINOGEN, V58, P1234, DOI 10.1002/mc.23006
   Chen J., 2016, BIO PROTOC, V6, pe2079
   Chen M, 2010, CANCER RES, V70, P8977, DOI 10.1158/0008-5472.CAN-10-2513
   Chu CA, 2019, EBIOMEDICINE, V43, P270, DOI 10.1016/j.ebiom.2019.04.010
   Cojoc Monica, 2013, Onco Targets Ther, V6, P1347, DOI 10.2147/OTT.S36109
   Colangelo T, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.29
   El-Khider F, 2016, DIGEST DIS, V34, P27, DOI 10.1159/000442921
   El-kott AF, 2019, CLIN EXP PHARMACOL P, V46, P944, DOI 10.1111/1440-1681.13133
   Elgendy M, 2011, MOL CELL, V42, P23, DOI 10.1016/j.molcel.2011.02.009
   Fasseu M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013160
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Fu LL, 2012, INT J BIOCHEM CELL B, V44, P733, DOI 10.1016/j.biocel.2012.02.004
   Fujishima Y, 2011, ARCH BIOCHEM BIOPHYS, V506, P223, DOI 10.1016/j.abb.2010.12.009
   Fujiya M, 2014, ONCOGENE, V33, P4847, DOI 10.1038/onc.2013.429
   Galluzzi L, 2017, NAT REV DRUG DISCOV, V16, P487, DOI 10.1038/nrd.2017.22
   Gao X, 2018, TECHNOL CANCER RES T, V17, DOI 10.1177/1533033818790508
   Gibbings D, 2013, AUTOPHAGY, V9, P781, DOI 10.4161/auto.23694
   Gibbings D, 2012, NAT CELL BIOL, V14, P1314, DOI 10.1038/ncb2611
   Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954
   Gugnoni M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.415
   Guil S, 2007, NAT STRUCT MOL BIOL, V14, P591, DOI 10.1038/nsmb1250
   Gulhati P, 2009, CLIN CANCER RES, V15, P7207, DOI 10.1158/1078-0432.CCR-09-1249
   Gustavsson B, 2015, CLIN COLORECTAL CANC, V14, P1, DOI 10.1016/j.clcc.2014.11.002
   Halama N, 2011, CANCER RES, V71, P5670, DOI 10.1158/0008-5472.CAN-11-0268
   Han J, 2017, EXP CELL RES, V360, P328, DOI 10.1016/j.yexcr.2017.09.023
   Nguyen HTT, 2014, GASTROENTEROLOGY, V146, P508, DOI 10.1053/j.gastro.2013.10.021
   He C, 2017, CHEMOTHERAPY, V62, P43, DOI 10.1159/000446361
   Hou W, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.493
   Hu JL, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0028-8
   Hua XH, 2018, CANCER LETT, V436, P38, DOI 10.1016/j.canlet.2018.08.013
   Iacopetta B, 2003, HUM MUTAT, V21, P271, DOI 10.1002/humu.10175
   Jin GY, 2019, CANCER CHEMOTH PHARM, V84, P315, DOI 10.1007/s00280-019-03867-6
   Jin KT, 2020, RNA BIOL, V17, P1727, DOI 10.1080/15476286.2020.1737787
   Jones MF, 2015, P NATL ACAD SCI USA, V112, pE1550, DOI 10.1073/pnas.1503370112
   Kaminskyy VO, 2014, ANTIOXID REDOX SIGN, V21, P86, DOI 10.1089/ars.2013.5746
   Kapral M, 2019, MOLECULES, V24, DOI 10.3390/molecules24224153
   Kim J, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0121-4
   Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811
   Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038
   Kovaleva V, 2012, CANCER RES, V72, P1763, DOI 10.1158/0008-5472.CAN-11-3671
   Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380
   Lan SH, 2014, HEPATOLOGY, V59, P505, DOI 10.1002/hep.26659
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li WQ, 2020, J BIOL REGUL HOMEOST, V34
   Li YC, 2019, ONCOTARGETS THER, V12, P2649, DOI 10.2147/OTT.S188054
   Liang Y, 2019, J CANCER, V10, P6037, DOI 10.7150/jca.34650
   Liao D, 2018, EXP THER MED, V15, P1712, DOI 10.3892/etm.2017.5522
   Lin SC, 2014, EXP BIOL MED, V239, P779, DOI 10.1177/1535370214532755
   Lin XT, 2018, INFLAMM BOWEL DIS, V24, P781, DOI 10.1093/ibd/izx075
   Liu ZY, 2020, J CELL PHYSIOL, V235, P1494, DOI 10.1002/jcp.29069
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Lu CM, 2014, GASTROENTEROLOGY, V146, P188, DOI 10.1053/j.gastro.2013.09.006
   Lubner SJ, 2010, CLIN COLORECTAL CANC, V9, P157, DOI 10.3816/CCC.2010.n.021
   Luo M, 2017, BREAST CANCER-TOKYO, V24, P673, DOI 10.1007/s12282-017-0756-1
   Ma LJ, 2019, ANTI-CANCER DRUG, V30, P1031, DOI 10.1097/CAD.0000000000000816
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Maycotte P, 2012, AUTOPHAGY, V8, P200, DOI 10.4161/auto.8.2.18554
   Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Mohammad RM, 2015, SEMIN CANCER BIOL, V35, pS78, DOI 10.1016/j.semcancer.2015.03.001
   Mohammadi A, 2018, J CROHNS COLITIS, V12, P568, DOI 10.1093/ecco-jcc/jjy010
   Mukhopadhya I, 2012, NAT REV GASTRO HEPAT, V9, P219, DOI 10.1038/nrgastro.2012.14
   Nassar D, 2016, ANNU REV PATHOL-MECH, V11, P47, DOI 10.1146/annurev-pathol-012615-044438
   Ng WK, 2016, INTEST RES, V14, P111, DOI 10.5217/ir.2016.14.2.111
   Nishida K, 2020, CANCERS, V12, DOI 10.3390/cancers12010174
   O'Connell J, 2000, ANN NY ACAD SCI, V910, P178
   Park EY, 2014, CANCER RES, V74, P7573, DOI 10.1158/0008-5472.CAN-14-1140
   Park YL, 2019, INT J CANCER, V144, P389, DOI 10.1002/ijc.31662
   Peitzsch C, 2014, INT J RADIAT BIOL, V90, P636, DOI 10.3109/09553002.2014.916841
   Petak I, 2000, CLIN CANCER RES, V6, P4432
   Punt CJA, 2017, NAT REV CLIN ONCOL, V14, P235, DOI 10.1038/nrclinonc.2016.171
   Pyo JO, 2012, EXP MOL MED, V44, P73, DOI 10.3858/emm.2012.44.2.029
   Qased A, 2013, MOL MED REP, V7, P559, DOI 10.3892/mmr.2012.1214
   Qiang L, 2014, P NATL ACAD SCI USA, V111, P9241, DOI 10.1073/pnas.1322913111
   Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865
   ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x
   Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246
   Salim H, 2012, BRIT J CANCER, V107, P1361, DOI 10.1038/bjc.2012.382
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Sibony M, 2015, INFLAMM BOWEL DIS, V21, P2778, DOI 10.1097/MIB.0000000000000553
   Stein J, 2010, NAT REV GASTRO HEPAT, V7, P599, DOI 10.1038/nrgastro.2010.151
   Sui XB, 2014, SCI REP-UK, V4, DOI 10.1038/srep04694
   Sun J, 2017, MOL CARCINOGEN, V56, P250, DOI 10.1002/mc.22489
   Sun W, 2020, THERANOSTICS, V10, P1981, DOI 10.7150/thno.37621
   Sun Y, 2015, INT J ONCOL, V46, P750, DOI 10.3892/ijo.2014.2745
   Sung JJY, 2015, GUT, V64, P121, DOI 10.1136/gutjnl-2013-306503
   Tagscherer KE, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0321-6
   Tan SF, 2016, INT J MOL MED, V37, P1030, DOI 10.3892/ijmm.2016.2492
   Tandon M, 2018, J CELL PHYSIOL, V233, P559, DOI 10.1002/jcp.25916
   Tang DX, 2019, CELL SIGNAL, V57, P21, DOI 10.1016/j.cellsig.2019.01.013
   Taniguchi K, 2015, CANCER LETT, V363, P17, DOI 10.1016/j.canlet.2015.03.026
   Tesniere A, 2008, CELL DEATH DIFFER, V15, P3, DOI 10.1038/sj.cdd.4402269
   Theodoratou E, 2017, ANNU REV NUTR, V37, P293, DOI 10.1146/annurev-nutr-071715-051004
   Tommelein J, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00063
   Touil Y, 2014, CLIN CANCER RES, V20, P837, DOI 10.1158/1078-0432.CCR-13-1854
   Vaupel P, 2004, ONCOLOGIST, V9, P4, DOI 10.1634/theoncologist.9-90005-4
   Wampfler J, 2015, J LEUKOCYTE BIOL, V98, P357, DOI 10.1189/jlb.1AB0514-258R
   Wang GF, 2012, CHINESE MED J-PEKING, V125, P2405, DOI 10.3760/cma.j.issn.0366-6999.2012.14.001
   Wang HX, 2020, J BIOL REGUL HOMEOST, V34
   Wang M, 2018, MYCOKEYS, P1, DOI 10.3897/mycokeys.34.24221
   Wang W, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12448
   Wang XY, 2021, ENVIRON TECHNOL, V42, P2021, DOI 10.1080/09593330.2019.1687588
   Wang YF, 2019, ONCOTARGETS THER, V12, P4621, DOI 10.2147/OTT.S196992
   Wei YJ, 2008, AUTOPHAGY, V4, P949, DOI 10.4161/auto.6788
   WEISSMANSHOMER P, 1975, MECH AGEING DEV, V4, P159, DOI 10.1016/0047-6374(75)90017-2
   Wongfieng W, 2017, GENES-BASEL, V8, DOI 10.3390/genes8090213
   Wu SB, 2013, BIOCHEM BIOPH RES CO, V434, P898, DOI 10.1016/j.bbrc.2013.04.053
   Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005
   Xie JJ, 2019, J BIOL REG HOMEOS AG, V33, P331
   Yang HZ, 2015, CANCER LETT, V361, P128, DOI 10.1016/j.canlet.2015.02.045
   Yang XD, 2016, ONCOTARGET, V7, P79603, DOI 10.18632/oncotarget.12873
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yao Z, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.35
   Yu Q, 2020, J BIOL REG HOMEOS AG, V34, P101, DOI 10.23812/19-567-A
   Yu XF, 2017, SCI REP-UK, V7, DOI 10.1038/srep42226
   Zeelenberg IS, 2003, CANCER RES, V63, P3833
   Zeng W, 2015, CANCER LETT, V356, P263, DOI 10.1016/j.canlet.2014.01.032
   Zhai H, 2013, ONCOGENE, V32, P1570, DOI 10.1038/onc.2012.167
   Zhai HY, 2015, ONCOTARGET, V6, P19735, DOI 10.18632/oncotarget.3771
   Zhai ZL, 2014, AUTOPHAGY, V10, P468, DOI 10.4161/auto.27553
   Zhang HH, 2015, CANCER LETT, V356, P781, DOI 10.1016/j.canlet.2014.10.029
   Zhang PP, 2013, EMBO REP, V14, P568, DOI 10.1038/embor.2013.53
   Zhang YL, 2019, EBIOMEDICINE, V48, P277, DOI 10.1016/j.ebiom.2019.09.051
   Zheng S, 2019, J BIOSCIENCES, V44, DOI 10.1007/s12038-019-9918-y
   Zhou HY, 2016, CANCER BIOMARK, V17, P1, DOI 10.3233/CBM-160613
   Zhou WJ, 2017, CELL CYCLE, V16, P73, DOI 10.1080/15384101.2016.1252882
   Zhu RX, 2016, MOL MED REP, V14, P2846, DOI 10.3892/mmr.2016.5579
   Zitvogel L, 2008, NAT REV IMMUNOL, V8, P59, DOI 10.1038/nri2216
   Zou ZZ, 2012, AUTOPHAGY, V8, P1798, DOI 10.4161/auto.22110
NR 138
TC 18
Z9 18
U1 2
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0960-7722
EI 1365-2184
J9 CELL PROLIFERAT
JI Cell Prolif.
PD OCT
PY 2020
VL 53
IS 10
AR e12900
DI 10.1111/cpr.12900
EA SEP 2020
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA OI6MM
UT WOS:000568854000001
PM 32914514
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Campos, T
   Ziehe, J
   Palma, M
   Escobar, D
   Tapia, JC
   Pincheira, R
   Castro, AF
AF Campos, Tania
   Ziehe, Javiera
   Palma, Mario
   Escobar, David
   Tapia, Julio C.
   Pincheira, Roxana
   Castro, Ariel F.
TI Rheb Promotes Cancer Cell Survival Through p27Kip1-Dependent Activation
   of Autophagy
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE Rheb GTPase; N-terminal of p27; mTORC1-independent
ID MAMMALIAN TARGET; COMPLEX; INHIBITION; APOPTOSIS; P27(KIP1); MTORC1;
   P27; PHOSPHORYLATION; PROLIFERATION; MECHANISMS
AB We previously found that the small GTPase Rheb regulates the cell-cycle inhibitor p27KIP1 (p27) in colon cancer cells by a mTORC1-independent mechanism. However, the biological function of the Rheb/p27 axis in cancer cells remains unknown. Here, we show that siRNA-mediated depletion of Rheb decreases survival of human colon cancer cells under serum deprivation. As autophagy can support cell survival, we analyzed the effect of Rheb on this process by detecting the modification of the autophagy marker protein LC3 by western blot and imunofluorescence. We found that Rheb promotes autophagy in several human cancer cell lines under serum deprivation. Accordingly, blocking autophagy inhibited the pro-survival effect of Rheb in colon cancer cells. We then analyzed whether p27 was involved in the biological effect of Rheb. Depletion of p27 inhibited colon cancer cell survival, and Rheb induction of autophagy. These results suggest that p27 has an essential role in the effect of Rheb in response to serum deprivation. In addition, we demonstrated that the role of p27 in autophagy stands on the N-terminal portion of the protein, where the CDK-inhibitory domain is located. Our results indicate that a Rheb/p27 axis accounts for the activation of autophagy that supports cancer cell survival. Our work therefore highlights a biological function of Rheb and prompts the need for future studies to address whether the mTORC1-independent Rheb/p27 axis could contribute to tumorigenesis and/or resistance to mTOR inhibitors. (C) 2015 Wiley Periodicals, Inc.
C1 [Campos, Tania; Ziehe, Javiera; Palma, Mario; Escobar, David; Pincheira, Roxana; Castro, Ariel F.] Univ Concepcion, Fac Ciencias Biol, Lab Transducc Senales & Canc, Dept Bioquim & Biol Mol, Concepcion, Chile.
   [Tapia, Julio C.] Univ Chile, ICBM, Fac Med, Lab Transformac Celular, Santiago, Chile.
RP Castro, AF (corresponding author), Univ Concepcion, Fac Ciencias Biol, Dept Bioquim & Biol Mol, Barrio Univ S-N, Concepcion 4030000, Region Bio Bio, Chile.
RI Tapia, Julio/A-7436-2012
OI Pincheira, Roxana/0000-0003-4277-5245
FU Universidad de Concepcion [DIUC 210.037.011-1.0];
   CONICYT/FONDECYTComision Nacional de Investigacion Cientifica y
   Tecnologica (CONICYT)CONICYT FONDECYT [Regular 1120923, Regular 1120132,
   Regular 1110821]; CONICYTComision Nacional de Investigacion Cientifica y
   Tecnologica (CONICYT)
FX Grant sponsor: Universidad de Concepcion; Grant number: DIUC
   210.037.011-1.0; Grant sponsor: CONICYT/FONDECYT; Grant number: Regular
   1120923; Grant sponsor: CONICYT/FONDECYT; Grant number: Regular 1120132;
   Grant sponsor: CONICYT/FONDECYT; Grant number: Regular 1110821; Grant
   sponsor: CONICYT
CR Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Barth S, 2010, J PATHOL, V221, P117, DOI 10.1002/path.2694
   Borriello A, 2007, CELL CYCLE, V6, P1053, DOI 10.4161/cc.6.9.4142
   Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200
   Chen N, 2010, FEBS LETT, V584, P1427, DOI 10.1016/j.febslet.2009.12.034
   Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105
   Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347
   Criollo A, 2010, EMBO J, V29, P619, DOI 10.1038/emboj.2009.364
   Ducker GS, 2014, ONCOGENE, V33, P1590, DOI 10.1038/onc.2013.92
   Furuya T, 2010, MOL CELL, V38, P500, DOI 10.1016/j.molcel.2010.05.009
   Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X
   Giansanti V, 2011, APOPTOSIS, V16, P321, DOI 10.1007/s10495-011-0589-x
   Gordy C, 2012, PROTEIN CELL, V3, P17, DOI 10.1007/s13238-011-1127-x
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hippert MM, 2006, CANCER RES, V66, P9349, DOI 10.1158/0008-5472.CAN-06-1597
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281
   Kelsey I, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004632
   Kim JH, 2011, AUTOPHAGY, V7, P1187, DOI 10.4161/auto.7.10.16643
   Komata T, 2003, BRIT J CANCER, V88, P1277, DOI 10.1038/sj.bjc.6600862
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Lacher MD, 2010, ONCOGENE, V29, P6543, DOI 10.1038/onc.2010.393
   Lacher Markus D, 2011, Small GTPases, V2, P211
   Larrea MD, 2009, CELL CYCLE, V8, P3455, DOI 10.4161/cc.8.21.9789
   Lee J, 2009, EXP MOL MED, V41, P765, DOI 10.3858/emm.2009.41.11.102
   Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537
   Lu KH, 2008, CLIN CANCER RES, V14, P2543, DOI 10.1158/1078-0432.CCR-07-0321
   Mathew R, 2011, COLD SH Q B, V76, P389, DOI 10.1101/sqb.2012.76.011015
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mavrakis KJ, 2008, GENE DEV, V22, P2178, DOI 10.1101/gad.1690808
   Melser S, 2013, CELL METAB, V17, P719, DOI 10.1016/j.cmet.2013.03.014
   Nardella C, 2008, GENE DEV, V22, P2172, DOI 10.1101/gad.1699608
   Neuman NA, 2011, EMBO MOL MED, V3, P189, DOI 10.1002/emmm.201100131
   Rubinsztein DC, 2012, CURR BIOL, V22, pR29, DOI 10.1016/j.cub.2011.11.034
   Saito K, 2005, J BIOCHEM, V137, P423, DOI 10.1093/jb/mvi046
   Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024
   Short JD, 2010, MOL CARCINOG, V49, P14
   Short JD, 2008, CANCER RES, V68, P6496, DOI 10.1158/0008-5472.CAN-07-5756
   Sun XT, 2014, J BIOL CHEM, V289, P16924, DOI 10.1074/jbc.M113.542795
   Tapia JC, 2004, J CELL BIOCHEM, V91, P865, DOI 10.1002/jcb.20027
   Wong PM, 2013, AUTOPHAGY, V9, P124, DOI 10.4161/auto.23323
   Wu YC, 2009, BIOCHEM BIOPH RES CO, V382, P451, DOI 10.1016/j.bbrc.2009.03.051
NR 43
TC 22
Z9 23
U1 1
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
EI 1098-2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD FEB
PY 2016
VL 55
IS 2
BP 220
EP 229
DI 10.1002/mc.22272
PG 10
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA DB9BT
UT WOS:000368811700009
PM 25594310
DA 2022-04-25
ER

PT J
AU Wang, WK
   Lin, ST
   Chang, WW
   Liu, LW
   Li, TYT
   Kuo, CY
   Hsieh, JL
   Lee, CH
AF Wang, Wei-Kuang
   Lin, Song-Tao
   Chang, Wen-Wei
   Liu, Li-Wen
   Li, Tom Yu-Tung
   Kuo, Chun-Yu
   Hsieh, Jeng-Long
   Lee, Che-Hsin
TI Hinokitiol induces autophagy in murine breast and colorectal cancer
   cells
SO ENVIRONMENTAL TOXICOLOGY
LA English
DT Article
DE hinokitiol; antitumor; autophagy
ID APOPTOSIS; DEATH; INDUCTION; PATHWAY; INHIBITION; CARCINOMA
AB Hinokitiol is found in the heartwood of cupressaceous plants and possesses several biological activities. Hinokitiol may play an important role in anti-inflammation and antioxidant processes, making it potentially useful in therapies for inflammatory-mediated disease. Previously, the suppression of tumor growth by hinokitiol has been shown to occur through apoptosis. Programmed cell death can also occur through autophagy, but the mechanism of hinokitiol-induced autophagy in tumor cells is poorly defined. We used an autophagy inhibitor (3-methyladenine) to demonstrate that hinokitiol can induce cell death via an autophagic pathway. Further, we suggest that hinokitiol induces autophagy in a dose-dependent manner. Markers of autophagy were increased after tumor cells were treated with hinokitiol. In addition, immunoblotting revealed that the levels of phosphoprotein kinase B (P-AKT), phosphomammalian target of rapamycin (P-mTOR), and phospho-p70 ribosomal s6 kinase (P-p70S6K) in tumor cells were decreased after hinokitiol treatment. In conclusion, our results indicate that hinokitiol induces the autophagic signaling pathway via downregulation of the AKT/mTOR pathway. Therefore, our findings show that hinokitiol may control tumor growth by inducing autophagic signaling. (c) 2014 Wiley Periodicals, Inc. Environ Toxicol 31: 77-84, 2016.
C1 [Wang, Wei-Kuang] Feng Chia Univ, Dept Environm Engn & Sci, Taichung 40724, Taiwan.
   [Lin, Song-Tao; Kuo, Chun-Yu; Lee, Che-Hsin] China Med Univ, Sch Med, Dept Microbiol, Taichung, Taiwan.
   [Chang, Wen-Wei] Chung Shan Med Univ, Coll Med Sci & Technol, Dept Biomed Sci, Taichung, Taiwan.
   [Chang, Wen-Wei] Chung Shan Med Univ Hosp, Dept Med Res, Taichung 40201, Taiwan.
   [Liu, Li-Wen; Li, Tom Yu-Tung] Osaka Univ, Grad Sch Med, Div Gene Therapy Sci, Osaka, Japan.
   [Hsieh, Jeng-Long] Chung Hwa Univ Med Technol, Dept Nursing, Tainan, Taiwan.
RP Lee, CH (corresponding author), China Med Univ, Sch Med, Dept Microbiol, Taichung, Taiwan.
EM chlee@mail.cmu.edu.tw
RI Wang, Wei-Kuang/Q-3662-2018
OI Chang, Wen-Wei/0000-0003-2283-1377; Li, Yu-Tung/0000-0002-0718-7344
FU National Science Council, TaiwanMinistry of Science and Technology,
   Taiwan; Taiwan Ministry of Health and Welfare Clinical Trial and
   Research Center of Excellence [NSC 101-2320-B-039-012-MY3,
   DOH102-TD-B-111-004]
FX Contract grant sponsors: National Science Council, Taiwan; Taiwan
   Ministry of Health and Welfare Clinical Trial and Research Center of
   Excellence.; Contract grant numbers: NSC 101-2320-B-039-012-MY3;
   DOH102-TD-B-111-004
CR Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Castle JC, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-190
   Chen YL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.159
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Ido Y, 1999, CELL PROLIFERAT, V32, P63, DOI 10.1046/j.1365-2184.1999.00133.x
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Lee CH, 2014, GENE THER, V21, P309, DOI 10.1038/gt.2013.86
   Lee YR, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-65
   Lee YS, 2013, J NAT PROD, V76, P2195, DOI 10.1021/np4005135
   Liu WS, 2013, MAR DRUGS, V11, P1899, DOI 10.3390/md11061899
   Lockshin RA, 2004, INT J BIOCHEM CELL B, V36, P2405, DOI 10.1016/j.biocel.2004.04.011
   Lu CH, 2012, BIOMED PHARMACOTHER, V66, P642, DOI 10.1016/j.biopha.2012.08.001
   Pattingre S, 2006, CANCER RES, V66, P2885, DOI 10.1158/0008-5472.CAN-05-4412
   Shiau AL, 2014, ENVIRON TOXICOL, V29, P363, DOI 10.1002/tox.21763
   Shih YH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094941
   Sun PH, 2011, CANCER LETT, V310, P170, DOI 10.1016/j.canlet.2011.06.037
   Yo YT, 2009, J AGR FOOD CHEM, V57, P8266, DOI 10.1021/jf901054c
   Zhang HY, 2009, TOXICOL SCI, V110, P376, DOI 10.1093/toxsci/kfp101
   Zhu WY, 2014, INT J MOL SCI, V15, P3336, DOI 10.3390/ijms15023336
NR 19
TC 17
Z9 19
U1 0
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1520-4081
EI 1522-7278
J9 ENVIRON TOXICOL
JI Environ. Toxicol.
PD JAN
PY 2016
VL 31
IS 1
BP 77
EP 84
DI 10.1002/tox.22023
PG 8
WC Environmental Sciences; Toxicology; Water Resources
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Toxicology; Water Resources
GA CY7JT
UT WOS:000366585300007
PM 25044443
DA 2022-04-25
ER

PT J
AU Fujiwara, K
   Daido, S
   Yamamoto, A
   Kobayashi, R
   Yokoyama, T
   Aoki, H
   Iwado, E
   Shinojima, N
   Kondo, Y
   Kondo, S
AF Fujiwara, Keishi
   Daido, Shigeru
   Yamamoto, Akitsugu
   Kobayashi, Ryuji
   Yokoyama, Tomohisa
   Aoki, Hiroshi
   Iwado, Eiji
   Shinojima, Naoki
   Kondo, Yasuko
   Kondo, Seiji
TI Pivotal role of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) in
   apoptosis and autophagy
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID PROGRAMMED CELL-DEATH; MALIGNANT GLIOMA-CELLS; HUMAN COLON-CANCER;
   CARCINOMA CELLS; P21 WAF1/CIP1; CERAMIDE; P53; BCL-2; MACROAUTOPHAGY;
   CAMPTOTHECIN
AB Programmed cell death (PCD) is involved in a variety of biologic events. Based on the morphologic appearance of the cells, there are two types of PCD as follows: apoptotic(type I) and autophagic(type II). However, the molecular machinery that determines the type of PCD is poorly defined. The purpose of this study was to show whether the presence of the cyclin-dependent kinase (CDK) inhibitor p21(WAF1/CIP1), a modulator of apoptosis, determines which type of PCD the cell undergoes. Treatment with C-2-ceramide was associated with both the cleavage of caspase-3 and poly(ADP- ribose) polymerase and the degradation of autophagy-related Beclin 1 and Atg5 proteins, without a change in the cyclin-CDK activity, which culminated in apoptosis in p21(+/+) mouse embryonic fibroblasts (MEFs). On the other hand, C-2-ceramide did not cleave caspase-3 or poly(ADP- ribose) polymerase and kept Beclin 1 and Atg5 proteins stable in p21(+/+) MEFs, events that this time culminated in autophagy. When expression of the p21 protein was inhibited by small interfering RNA or when the overexpression of Beclin 1 or Atg5 was induced, autophagy rather than apoptosis was initiated in the p21(+/+) MEFs treated with C-2-ceramide. In contrast, the exogenous expression of p21 or the silencing of Beclin 1 and Atg5 with small interfering RNA increased the number of apoptotic cells and decreased the number of autophagic cells among C-2-ceramide-treated p21(+/+) MEFs. gamma-Irradiation, which endogenously generates ceramide, induced a similar tendency in these MEFs. These results suggest that p21 plays an essential role in determining the type of cell death, positively for apoptosis and negatively for autophagy.
C1 [Fujiwara, Keishi; Daido, Shigeru; Yokoyama, Tomohisa; Aoki, Hiroshi; Iwado, Eiji; Shinojima, Naoki; Kondo, Yasuko; Kondo, Seiji] Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA.
   [Yamamoto, Akitsugu] Nagahama Inst Biosci & Technol, Dept Cell Biol & Biosci, Shiga 5260829, Japan.
   [Kobayashi, Ryuji] Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA.
   [Kondo, Seiji] Univ Texas, Grad Sch Biomed Sci, Houston, TX 77030 USA.
   [Kondo, Seiji] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
RP Kondo, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, 1515 Holcombe Blvd,Unit BSRB 1004, Houston, TX 77030 USA.
EM seikondo@mdanderson.org
RI Shinojima, Naoki/AAW-3038-2021
OI Shinojima, Naoki/0000-0003-3352-7936
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA
   16672] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [P30CA016672] Funding Source:
   NIH RePORTER
CR Bursch W, 2000, ANN NY ACAD SCI, V926, P1, DOI 10.1111/j.1749-6632.2000.tb05594.x
   Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571
   Chopin V, 2004, EXP CELL RES, V298, P560, DOI 10.1016/j.yexcr.2004.04.038
   CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547
   Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0
   Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002
   Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084
   Daido S, 2005, CANCER RES, V65, P4368, DOI 10.1158/0008-5472.CAN-04-4202
   Detjen KM, 2003, EXP CELL RES, V282, P78, DOI 10.1016/S0014-4827(02)00011-3
   ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P
   Gartel AL, 2002, MOL CANCER THER, V1, P639
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978
   Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200
   HARPER JW, 1993, CELL, V75, P805
   Ito H, 2005, HUM GENE THER, V16, P685, DOI 10.1089/hum.2005.16.685
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kang KH, 1999, EXP CELL RES, V253, P403, DOI 10.1006/excr.1999.4644
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X
   Kondo S, 1996, ONCOGENE, V13, P1279
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lockshin RA, 2002, CURR OPIN CELL BIOL, V14, P727, DOI 10.1016/S0955-0674(02)00383-6
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   Mahyar-Roemer M, 2001, ONCOGENE, V20, P3387, DOI 10.1038/sj.onc.1204440
   Mengubas K, 1999, ONCOGENE, V18, P2499, DOI 10.1038/sj.onc.1202622
   Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506
   Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657
   Noda T, 2002, TRENDS CELL BIOL, V12, P231, DOI 10.1016/S0962-8924(02)02278-X
   OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305
   Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411
   Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1
   Pua HH, 2007, J EXP MED, V204, P25, DOI 10.1084/jem.20061303
   Qiao L, 2002, HEPATOLOGY, V36, P39, DOI 10.1053/jhep.2002.33899
   Scarlatti F, 2004, J BIOL CHEM, V279, P18384, DOI 10.1074/jbc.M313561200
   Scovassi AI, 2004, BIOCHEM PHARMACOL, V68, P1041, DOI 10.1016/j.bcp.2004.04.023
   SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149
   Shibata MA, 2001, CANCER GENE THER, V8, P23, DOI 10.1038/sj.cgt.7700275
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299
   Tian H, 2000, CANCER RES, V60, P679
   Tsao YP, 1999, J VIROL, V73, P4983, DOI 10.1128/JVI.73.6.4983-4990.1999
   Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777
   Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0
   WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0
   Weiss RH, 2003, CANCER CELL, V4, P425, DOI 10.1016/S1535-6108(03)00308-8
   XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0
   Xu Y, 2006, J BIOL CHEM, V281, P19179, DOI 10.1074/jbc.M513377200
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
   Zeng XH, 2006, J CELL SCI, V119, P259, DOI 10.1242/jcs.02735
   Zhang YK, 1999, INT J CANCER, V83, P790, DOI 10.1002/(SICI)1097-0215(19991210)83:6<790::AID-IJC15>3.3.CO;2-Y
NR 55
TC 88
Z9 94
U1 2
U2 5
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 4
PY 2008
VL 283
IS 1
BP 388
EP 397
DI 10.1074/jbc.M611043200
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 245MV
UT WOS:000251940300043
PM 17959603
OA hybrid
DA 2022-04-25
ER

PT J
AU Li, JQ
   Song, P
   Zhu, LY
   Aziz, N
   Zhou, QY
   Zhang, YL
   Xu, WX
   Feng, LF
   Chen, DW
   Wang, X
   Jin, HC
AF Li, Jiaqiu
   Song, Ping
   Zhu, Liyuan
   Aziz, Neelum
   Zhou, Qiyin
   Zhang, Yulong
   Xu, Wenxia
   Feng, Lifeng
   Chen, Dingwei
   Wang, Xian
   Jin, Hongchuan
TI Synthetic lethality of glutaminolysis inhibition, autophagy inactivation
   and asparagine depletion in colon cancer
SO ONCOTARGET
LA English
DT Article
DE colorectal cancer; glutaminolysis; glutamine; synthetic lethality
ID COLORECTAL-CANCER; ANTITUMOR-ACTIVITY; METABOLISM; CELLS; PROLIFERATION;
   MUTATIONS; ADDICTION; XENOGRAFT; SURVIVAL; EFFICACY
AB Cancer cells reprogram metabolism to coordinate their rapid growth. They addict on glutamine metabolism for adenosine triphosphate generation and macromolecule biosynthesis. In this study, we report that glutamine deprivation retarded cell growth and induced prosurvival autophagy. Autophagy inhibition by chloroquine significantly enhanced glutamine starvation induced growth inhibition and apoptosis activation. Asparagine deprivation by L-asparaginase exacerbated growth inhibition induced by glutamine starvation and autophagy blockage. Similar to glutamine starvation, inhibition of glutamine metabolism with a chemical inhibitor currently under clinical evaluation was synthetically lethal with chloroquine and L-asparaginase, drugs approved for the treatment of malaria and leukemia, respectively. In conclusion, inhibiting glutaminolysis was synthetically lethal with autophagy inhibition and asparagine depletion. Therefore, targeting glutaminolysis could be a promising approach for colorectal cancer treatment.
C1 [Li, Jiaqiu; Song, Ping; Aziz, Neelum; Zhou, Qiyin; Wang, Xian] Zhejiang Univ, Med Sch, Dept Med Oncol, Sir Runrun Shaw Hosp, Hangzhou, Zhejiang, Peoples R China.
   [Li, Jiaqiu; Zhu, Liyuan; Zhang, Yulong; Xu, Wenxia; Feng, Lifeng; Jin, Hongchuan] Zhejiang Univ, Sir Runrun Shaw Hosp, Key Lab Biotherapy Zhejiang, Lab Canc Biol,Med Sch, Hangzhou, Zhejiang, Peoples R China.
   [Chen, Dingwei] Zhejiang Univ, Sir Runrun Shaw Hosp, Dept Surg, Med Sch, Hangzhou, Zhejiang, Peoples R China.
RP Wang, X (corresponding author), Zhejiang Univ, Med Sch, Dept Med Oncol, Sir Runrun Shaw Hosp, Hangzhou, Zhejiang, Peoples R China.; Jin, HC (corresponding author), Zhejiang Univ, Sir Runrun Shaw Hosp, Key Lab Biotherapy Zhejiang, Lab Canc Biol,Med Sch, Hangzhou, Zhejiang, Peoples R China.; Chen, DW (corresponding author), Zhejiang Univ, Sir Runrun Shaw Hosp, Dept Surg, Med Sch, Hangzhou, Zhejiang, Peoples R China.
EM dwyf@hotmail.com; wangxzju@163.com; jinhc@zju.edu.cn
RI Jin, Hongchuan/C-3686-2009
OI Jin, Hongchuan/0000-0002-6697-3097
FU High Level Talents Program from the Department of Health, Natural
   Science foundation of Zhejiang [LZ17H160003]; Natural Science foundation
   of ChinaNational Natural Science Foundation of China (NSFC) [81672723,
   81672360]; Department of Health in Zhejiang Province [WKJ-ZJ-1520,
   WKJ-ZJ-1720]
FX This work was supported by High Level Talents Program from the
   Department of Health, Natural Science foundation of Zhejiang
   (LZ17H160003), Natural Science foundation of China (81672723; 81672360),
   and the Department of Health in Zhejiang Province (WKJ-ZJ-1520;
   WKJ-ZJ-1720).
CR AHLUWALIA GS, 1990, PHARMACOL THERAPEUT, V46, P243, DOI 10.1016/0163-7258(90)90094-I
   Balasubramanian MN, 2013, AM J PHYSIOL-ENDOC M, V304, pE789, DOI 10.1152/ajpendo.00015.2013
   Chen DW, 2015, ONCOTARGET, V6, P40815, DOI 10.18632/oncotarget.5886
   DeBerardinis RJ, 2010, ONCOGENE, V29, P313, DOI 10.1038/onc.2009.358
   Dey A, 2016, AUTOPHAGY, V12, P659, DOI 10.1080/15548627.2016.1147670
   EAGLE HARRY, 1955, JOUR BIOL CHEM, V214, P839
   Eng CH, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000911
   Feng LF, 2014, AUTOPHAGY, V10, P1442, DOI 10.4161/auto.29486
   Gross MI, 2014, MOL CANCER THER, V13, P890, DOI 10.1158/1535-7163.MCT-13-0870
   Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021
   Ikematsu H, 2013, GASTROENTEROLOGY, V144, P551, DOI 10.1053/j.gastro.2012.12.003
   Katt WP, 2012, MOL CANCER THER, V11, P1269, DOI 10.1158/1535-7163.MCT-11-0942
   Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811
   Ktistakis NT, 2016, TRENDS CELL BIOL, V26, P624, DOI 10.1016/j.tcb.2016.03.006
   KVAMME E, 1960, BIOCHIM BIOPHYS ACTA, V42, P187, DOI 10.1016/0006-3002(60)90779-4
   Le A, 2012, CELL METAB, V15, P110, DOI 10.1016/j.cmet.2011.12.009
   Linardou H, 2008, LANCET ONCOL, V9, P962, DOI 10.1016/S1470-2045(08)70206-7
   Maschek G, 2004, CANCER RES, V64, P31, DOI 10.1158/0008-5472.CAN-03-3294
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Mizushima N, 2011, COLD SH Q B, V76, P397, DOI 10.1101/sqb.2011.76.011023
   Ortlund E, 2000, BIOCHEMISTRY-US, V39, P1199, DOI 10.1021/bi991797d
   OVEJERA AA, 1979, CANCER RES, V39, P3220
   Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006
   Prasanna VK, 2009, J CANCER RES THER, V5, P44, DOI 10.4103/0973-1482.55141
   Pritsa AA, 2001, ANTI-CANCER DRUG, V12, P137, DOI 10.1097/00001813-200102000-00007
   Pusapati RV, 2016, CANCER CELL, V29, P548, DOI 10.1016/j.ccell.2016.02.018
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Seo JW, 2016, SCI REP-UK, V6, DOI 10.1038/srep37594
   Shanware NP, 2011, J MOL MED, V89, P229, DOI 10.1007/s00109-011-0731-9
   Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Venneti S, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa1009
   Wang JB, 2010, CANCER CELL, V18, P207, DOI 10.1016/j.ccr.2010.08.009
   Wengrod JC, 2015, CELL CYCLE, V14, P2571, DOI 10.1080/15384101.2015.1056947
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wirawan E, 2012, CELL RES, V22, P43, DOI 10.1038/cr.2011.152
   Wise DR, 2010, TRENDS BIOCHEM SCI, V35, P427, DOI 10.1016/j.tibs.2010.05.003
   Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105
   Wong CC, 2016, GASTROENTEROLOGY, V151, P945, DOI 10.1053/j.gastro.2016.07.011
   Xu J, 2007, ANN SURG, V245, P583, DOI 10.1097/01.sla.0000250453.34507.d3
   Zhu Yuhua, 2015, Amino Acids, V47, P2185, DOI 10.1007/s00726-014-1785-0
NR 41
TC 25
Z9 25
U1 1
U2 14
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUN 27
PY 2017
VL 8
IS 26
BP 42664
EP 42672
DI 10.18632/oncotarget.16844
PG 9
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FA5OQ
UT WOS:000405493400075
PM 28424408
OA gold, Green Submitted, Green Published
DA 2022-04-25
ER

PT J
AU Chang, CT
   Hseu, YC
   Thiyagarajan, V
   Lin, KY
   Way, TD
   Korivi, M
   Liao, JW
   Yang, HL
AF Chang, Chia-Ting
   Hseu, You-Cheng
   Thiyagarajan, Varadharajan
   Lin, Kai-Yuan
   Way, Tzong-Der
   Korivi, Mallikarjuna
   Liao, Jiuun-Wang
   Yang, Hsin-Ling
TI Chalcone flavokawain B induces autophagic-cell death via reactive oxygen
   species-mediated signaling pathways in human gastric carcinoma and
   suppresses tumor growth in nude mice
SO ARCHIVES OF TOXICOLOGY
LA English
DT Article
DE Flavokawain B; AGS cells; Autophagy; ROS; ATG4B
ID COLON-CANCER CELLS; KAVA EXTRACT; DOWN-REGULATION; ROS GENERATION;
   BREAST-CANCER; CYCLE ARREST; P38 MAPK; IN-VIVO; APOPTOSIS; RATS
AB Flavokawain B (FKB), a naturally occurring chalcone in kava extracts, has been reported to possess anticancer activity. However, the effect of FKB on gastric cancer remains unclear. We examined the in vitro and in vivo anticancer activity and autophagy involvement of FKB and determined the underlying molecular mechanisms. FKB is potently cytotoxic to human gastric cancer cells (AGS/NCI-N87/KATO-III/TSGH9201) and mildly toxic towards normal (Hs738) cells and primary mouse hepatocytes. FKB-induced AGS cell death was characterized by autophagy, not apoptosis, as evidenced by increased LC3-II accumulation, GFP-LC3 puncta and acidic vesicular organelles (AVOs) formation, without resulting procaspase-3/PARP cleavage. FKB further caused p62/SQSTM1 activation, mTOR downregulation, ATG4B inhibition, and Beclin-1/Bcl-2 dysregulation. Silencing autophagy inhibitors CQ/3-MA and LC3 (shRNA) significantly reversed the FKB-induced cell death of AGS cells. FKB-triggered ROS generation and ROS inhibition by NAC pre-treatment diminished FKB-induced cell death, LC3 conversion, AVO formation, p62/SQSTM1 activation, ATG4B inhibition and Beclin-1/Bcl-2 dysregulation, which indicated ROS-mediated autophagy in AGS cells. Furthermore, FKB induces G(2)/M arrest and alters cell-cycle proteins through ROS-JNK signaling. Interestingly, FKB-induced autophagy is associated with the suppression of HER-2 and PI3K/AKT/mTOR signaling cascades. FKB inhibits apoptotic Bax expression, and Bax-transfected AGS cells exhibit both apoptosis and autophagy; thus, FKB-inactivated Bax results in apoptosis inhibition. In vivo data demonstrated that FKB effectively inhibited tumor growth, prolonged the survival rate, and induced autophagy in AGS-xenografted mice. Notably, silencing of LC3 attenuated FKB-induced autophagy in AGS-xenografted tumors. FKB may be a potential chemopreventive agent in the activation of ROS-mediated autophagy of gastric cancer cells.
C1 [Chang, Chia-Ting; Korivi, Mallikarjuna; Yang, Hsin-Ling] China Med Univ, Coll Biopharmaceut & Food Sci, Inst Nutr, 91 Hsueh Shih Rd, Taichung 40402, Taiwan.
   [Hseu, You-Cheng; Thiyagarajan, Varadharajan] China Med Univ, Coll Biopharmaceut & Food Sci, Dept Cosmeceut, 91 Hsueh Shih Rd, Taichung 40402, Taiwan.
   [Hseu, You-Cheng] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung 41354, Taiwan.
   [Lin, Kai-Yuan] Chi Mei Med Ctr, Dept Med Res, Tainan 710, Taiwan.
   [Way, Tzong-Der] China Med Univ, Coll Biopharmaceut & Food Sci, Dept Life Sci, Taichung 40402, Taiwan.
   [Liao, Jiuun-Wang] Natl Chung Hsing Univ, Grad Inst Vet Pathol, Taichung 402, Taiwan.
RP Yang, HL (corresponding author), China Med Univ, Coll Biopharmaceut & Food Sci, Inst Nutr, 91 Hsueh Shih Rd, Taichung 40402, Taiwan.; Hseu, YC (corresponding author), China Med Univ, Coll Biopharmaceut & Food Sci, Dept Cosmeceut, 91 Hsueh Shih Rd, Taichung 40402, Taiwan.; Hseu, YC (corresponding author), Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung 41354, Taiwan.
EM ychseu@mail.cmu.edu.tw; hlyang@mail.cmu.edu.tw
RI Korivi, Mallikarjuna/C-7952-2012
OI Korivi, Mallikarjuna/0000-0002-4038-1368; Liao,
   Jiunn-Wang/0000-0001-7374-1203
FU Ministry of Science and TechnologyMinistry of Education, Culture,
   Sports, Science and Technology, Japan (MEXT)
   [MOST-104-2320-B-039-040-MY3, MOST-103-2320-B-039-038 -MY3,
   NSC-103-2622-B-039-001-CC2, CMU103-ASIA-12, CMU 103-ASIA-09]; Asia
   University; China Medical University, TaiwanChina Medical University;
   China Medical University under the Aim for Top University Plan of the
   Ministry of Education, Taiwan [CHM106-5-3]
FX This work was supported by Grants MOST-104-2320-B-039-040-MY3,
   MOST-103-2320-B-039-038 -MY3, NSC-103-2622-B-039-001-CC2,
   CMU103-ASIA-12, and CMU 103-ASIA-09 from the Ministry of Science and
   Technology, Asia University, and China Medical University, Taiwan to Dr.
   Hsin-Ling Yang and Dr. You-Cheng Hseu. This study was supported by China
   Medical University under the Aim for Top University Plan of the Ministry
   of Education, Taiwan (CHM106-5-3).
CR Abu N, 2015, DRUG DES DEV THER, V9, P1401, DOI 10.2147/DDDT.S67976
   Abu N, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-102
   Carren OI LE, 2014, PERSPECTIVES, V13, P2
   Choi KS, 2012, EXP MOL MED, V44, P109, DOI 10.3858/emm.2012.44.2.033
   Clayton NP, 2007, EXP TOXICOL PATHOL, V58, P223, DOI 10.1016/j.etp.2006.08.002
   DiSilvestro RA, 2007, FOOD CHEM TOXICOL, V45, P1293, DOI 10.1016/j.fct.2007.01.015
   Hale AN, 2013, AUTOPHAGY, V9, P951, DOI 10.4161/auto.24273
   Hasima N, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.467
   Hseu YC, 2012, J AGR FOOD CHEM, V60, P2385, DOI 10.1021/jf205053r
   Hsin IL, 2010, MUTAT RES-FUND MOL M, V688, P72, DOI 10.1016/j.mrfmmm.2010.03.011
   Huang CC, 2007, PSYCHO-ONCOL, V16, P945, DOI 10.1002/pon.1158
   Jain K, 2013, AM J CANCER RES, V3, P251
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Karna P, 2010, J BIOL CHEM, V285, P18737, DOI 10.1074/jbc.M109.091694
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Komoto M, 2009, CANCER SCI, V100, P1243, DOI 10.1111/j.1349-7006.2009.01176.x
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Lin E, 2012, J NUTR BIOCHEM, V23, P368, DOI 10.1016/j.jnutbio.2011.01.002
   Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027
   Mingo-Sion AM, 2004, ONCOGENE, V23, P596, DOI 10.1038/sj.onc.1207147
   Mohan N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078958
   Munshi Anupama, 2013, Genes Cancer, V4, P401, DOI 10.1177/1947601913485414
   Narayanapillai SC, 2014, CHEM RES TOXICOL, V27, P1871, DOI 10.1021/tx5003194
   Nowakowska Z, 2007, EUR J MED CHEM, V42, P125, DOI 10.1016/j.ejmech.2006.09.019
   Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522
   OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O
   Ozpolat B., 2012, NATURAL COMPOUNDS IN, P237
   Pan MH, 2008, CHEM SOC REV, V37, P2558, DOI 10.1039/b801558a
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004
   Qiao SX, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8014
   Rothe K, 2014, BLOOD, V123, P3622, DOI 10.1182/blood-2013-07-516807
   Singh YN, 2003, PLANTA MED, V69, P496, DOI 10.1055/s-2003-40658
   Sorrentino L, 2006, PHYTOMEDICINE, V13, P542, DOI 10.1016/j.phymed.2006.01.006
   Steiner G G, 2000, Hawaii Med J, V59, P420
   Sukawa Y, 2014, DIGESTION, V89, P12, DOI 10.1159/000356201
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   Teschke R, 2010, ANN HEPATOL, V9, P251, DOI 10.1016/S1665-2681(19)31634-5
   Thiyagarajan V, 2016, ENVIRON TOXICOL PHAR, V45, P202, DOI 10.1016/j.etap.2016.06.005
   Thiyagarajan V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141285
   Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694
   Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016
   Zhang H, 2014, PHYTOMEDICINE, V21, P348, DOI 10.1016/j.phymed.2013.09.007
   Zhang X, 2012, CELL PROLIFERAT, V45, P466, DOI 10.1111/j.1365-2184.2012.00833.x
   Zhang Z, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.182
   Zhao Y, 2013, CANCER SCI, V104, P1062, DOI 10.1111/cas.12182
   Zhou HY, 2014, ONCOTARGET, V5, P10140, DOI 10.18632/oncotarget.2471
   Zhou P, 2010, FASEB J, V24, P4722, DOI 10.1096/fj.10-163311
   Zi XL, 2005, CANCER RES, V65, P3479, DOI 10.1158/0008-5472.CAN-04-3803
NR 49
TC 32
Z9 32
U1 1
U2 32
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5761
EI 1432-0738
J9 ARCH TOXICOL
JI Arch. Toxicol.
PD OCT
PY 2017
VL 91
IS 10
BP 3341
EP 3364
DI 10.1007/s00204-017-1967-0
PG 24
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA FH7QR
UT WOS:000411386000013
PM 28374157
DA 2022-04-25
ER

EF